<SEC-DOCUMENT>0001628280-23-005061.txt : 20230224
<SEC-HEADER>0001628280-23-005061.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224162230
ACCESSION NUMBER:		0001628280-23-005061
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		165
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06571
		FILM NUMBER:		23667723

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrk-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:6a80835e-3d33-418a-be61-33ea02b302af,g:f2b57eeb-4f2d-41ff-83c8-1b4e9f7a4523,d:a384118d157240e09e39541b90e2080f--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:mrk="http://www.merck.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrk-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF80LTEtMS0xLTcxMzMw_45baff7f-969e-433d-9ded-5bb4f99af31a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF81LTEtMS0xLTcxMzMw_992b99c9-a253-4e99-bede-e9f5952deb60">2022</ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF82LTEtMS0xLTcxMzMw_ccff7cf2-82ee-4f3b-b73f-e745d43c5777">FY</ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF85LTEtMS0xLTcxMzMw_ae9ecd62-dce1-4a07-86f2-26e93039780c">0000310158</ix:nonNumeric><ix:nonNumeric contextRef="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b">P3M</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ib8d0002590484feda2fc8325dc655c8b_D20210602-20210602" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTQvZnJhZzo0ZTg0Yjg5MTUzZGM0ZTJmYjIzNTY1MmEzNDIxMTUwMi90ZXh0cmVnaW9uOjRlODRiODkxNTNkYzRlMmZiMjM1NjUyYTM0MjExNTAyXzI3_ecf67a0f-fd01-4e2d-821d-cdcd958e21f9">0.1</ix:nonFraction><ix:nonNumeric contextRef="id85c300cf38349adb26180577979e5c2_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i3592e3674e13431aaf91bd67cef2a754_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i7552297483f94fa5b4160dc0db014d06_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i4eb748e33a7a454fac71c562342ce760_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ic45c2b8530f9432f800bd21578f8e217_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i0b231d9fdbfd40ae8d6fe71ed37de345_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i30469f7c418b4bd2a85fcc554df58178_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ia817beebd6444eea99db772afc066555_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i864a963e97a44b5f8189640f9cb94d43_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="ib79c6477e2f646dd83409e81121b5a29_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i3e1e5bec9c0340748f3a3782a3f7fd23_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i804346c2237043e084b1afb341655a9f_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="id3b44b6cfd4f4a8b99ef33bcc3c06df7_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="ib7d722d97d3e436e80d290bc86ab1496_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i2335ada88a2240b6bd6252e8fa8510a4_D20220101-20221231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i015fe5f90bbd4e93a29ffe724e90bfd0_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="ib3c3521eff5d4d78bed2d56d42e3789f_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="ibc8bfe07436149a2b63950679699d1df_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i2c693f6dd72a403f89d6d2355a3b1c83_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="ia7cd884e75e9428f87dc9ff260d2f3ee_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ibaa6d39939da4e91b837b366cdef3966_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i975b430806c14e4dac19b89356167bc0_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="iba21ed671f2448ceb380d10aa9f40bd6_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ibc1ca9c45f2f4c0d8e7d64701e4cb36d_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i0562404e8e0e4465a752940a1235ee59_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i16a86b0a2eb94ae1872813f8188edae8_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i54629a1dafcf430fb0b2f74327fdd6df_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i8d9a9c572051413cbcbfc3a23280168d_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="ice7363f8460840bb83ffb6ca99594560_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i1decc07eadc24124bed0dd2deaff444a_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="ibedf7a5f7ef7456586ec0f021a1d0f3d_D20210101-20211231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i3327a1e7655544f3a7d9953a5234e2fb_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i1b6eb5443eb44c5f83120bd0907e38cb_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i1e08ad749ea24620a73bf3de13d4ba83_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i97f4ba5c710647b8a25a7267abdd6754_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="i51f9f13e5ade4b49abc89a6dd9a5b2b4_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ia78f45a1853841d69480601600ad30b6_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i1b6c21a42378451b9dab85a8423576f3_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i98c6fc33bcf040b88cd4cce4a3bd53e4_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i720ba97855924cd9b21a8b29de3ba988_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i94d6a7f93e314fc384e0b1149d0ae9eb_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i8bdcd5cba5f543dbb50dea0289f3ab2c_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i4983cbf854e94eceae83083147be86a2_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i972eba5067f8445596ed5ff359126657_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i88144043844d4f7eb9f8cde0124c59f9_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i8a80bcbbfa39470ab7a14b86c6fa70a3_D20200101-20201231" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505">http://fasb.org/us-gaap/2022#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="i20cd4c7fd5f14851a86d5a655db5663c_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i50be94d522084d82a3e96d121db4b2c5_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1afdd113c40545adb3ae03acc9c4e126_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i782b995c5324440982290223b2cdddac_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2677274a350445afa69443c36f4a89da_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia2c912a0937747a8a1ae5182d756b260_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i350a79055507478fabc61583f11e2080_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ifc29185c1fed4990966cf824e4597298_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="icdbb1216db6a47e88141c7169ea7875f_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6226dc468d5e40ba93e5e688a3b0e650_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjg_e7b500cc-8996-45e1-8231-cde2ddbd2b59">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjk_b1192ef4-ec86-4241-a5a3-3f1beac17af0">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODcvZnJhZzo1ZTcwOTY4YzFiOWY0N2E1ODM1MWJlYTUyMjQ3MWQzYS90YWJsZTpjODQyYzdhNmM4MmU0ZjU2YWRjNzdhOTIyNjhlYWI2OS90YWJsZXJhbmdlOmM4NDJjN2E2YzgyZTRmNTZhZGM3N2E5MjI2OGVhYjY5XzEtMS0xLTEtNzEzMzA_c5ccadad-0faf-40c3-a645-e49b5ec24cc5">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrk-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48140e5f2c345cd8c115278efdfc4d5_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i988d9636bde7433d8e2793b8bbe786ff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if0af637dd40e445c8087ffbd9b3638e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e30d57aa7714c7c991d4956adf482da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870984a7a0814cf9a460c7a4b331c37f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c3eef0e8e84d89b879da53d7b2eea5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8390537a2d14419183a1bd3184b81223_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9bf241be3f43c8aac25c903996f2e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3278c06a03cc4b83ad0c695bac71a99b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfa7328e43b745528acea4fb982c4641_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a206ace8ff4b2b880a7d891b6470c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia197d01df12640948153fd9f84a852ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb557eb99a549468966b5c77bdf145c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757e7f21bc85496da119ddd7169fc883_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca83e510fb04e31bb09eba119b9f8c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76fa2929d2f845298f21dbaee7f2ef16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e85ab6516bc49b78971f2a3b5bdf41b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8308747617614e9eab0ac29c4014c53b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a03badfaf044d5abe8434be9cfeda8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bd86cfed75419480323eb478cad36f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f49f49133634761b181692557d66dda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77dda1a9a6f4400c931bc6647f046197_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e06bfa03d5c48d190290cd1a81579c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21cb44e6556045cc99f6b8f0af62b975_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5efd7e6396194280b6782fba989ef826_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33db89af09b04ff88b03f0b7993e3646_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32922e48a4134ee0925f14bd1c083d4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i542103e76e6741a6805402bb88262b54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170384be3a654d119874ff6b7ed2eb92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8637c5e12649be98c7fe608718e069_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba91acdcb37e4a5d8335bd645c29a624_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7edbd57c4cf745c49a7f15beff700c5b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15342adbb5e246fdaf6be1f7d6f161e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074f335e3eb646d3a641ffed1cc54d29_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326e10191d3348dd83075e847b9e3840_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e37f8c9ec504794ac6b72298c935735_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5bb04f307f47dcb79f92a26d5a4eb1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1e6ddf39c24d7f843d5f7b097b9c69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if945586aba2d4519bdf8f10667672306_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf11a2d764284028938a06f7df969c24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e6bbb5f87c44047960024c6b0517fd6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2af1368f91147fab0b3d00e67b4afa4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152d7547c40c49cfa09fdd72d4292d05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2d859521db4ed99e9f6f0c3c55169a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90ed8021173448b0b3372bcb951af216_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6acc5aab0ca4602b1c723258ab0abe5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3dd256716df46d1b2aef36eb21dc58a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b53a8f47684df2aa5a27b6be330095_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0248176f895b46cfac11e4d46217846a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24801838a2c42948246ef5a5409d8e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b39a79d65a4ca691a37dcfe4922939_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc952f1b2f2496fb3e7cb831f0dbcc7_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ee48b166b44fbaa88adeaa6cccbcca_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91a08ec51d834fb4b5ee3a778a3ddf08_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b56448c76a44d38b534e9b53205ce6_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eb2867b2dcb413caf68f19d0cff8a38_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe247952fa8f40f48f9d542a2f0c75b2_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e03ea81b4d43bc833a87aaff997b7c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id47f3aaa34b04200b41ca2809b9e4542_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18668b15f364b13be1b1dcc95030f0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa6366e1ebc4503ba80ecd66a39f955_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d0002590484feda2fc8325dc655c8b_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie7668e0129294bdcbf2855d7d0ee191d_D20230201-20230224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib17138b844f348b1a50f35c8ae1978e5_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74aa3e82c01b42c6a7419c59ba514f25_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrk:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44db6d09190041e18d6b1b29eb14bb9b_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ModernaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db175a81b9f43c1b0e8d6bbfc9cad3d_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53196e6917242ea85419903828dbab2_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if640c54f5da1491792d044ba5742c097_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fffd33d73024f8cae603f326b7f1104_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad647dc2d4aa4b91a0013d32ad01912d_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70dba7305144817a9064998df5667d1_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrionCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a30e3c742444082976808cee5c16655_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic774cbcb70554e169b26550e484a0585_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6296f4bad6634365be938b368f535a4e_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8672dcf41ce4577b1f1b821640eae58_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b90cfcdde044b7a79d4c12ce3af129_D20220501-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68d62a9a6db4df3bf89fc5ddf7583e1_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0cf91de3d1d4c32ad48e6066885e0f2_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:FirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1eeae45b61446697e00a09ff97862e_D20220501-20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7073d5a9d7f24a98995d80fe479f8283_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf26d356d3946f4a878afd16a2a4024_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785539df716f4bce95f1ef45066b0e36_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f1de3723354ed1af5631e0fd919013_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if030a4536a8047a1a585275c17092ed8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic10f48c8ad804e3ab3fb873838f81931_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd86187433f44eaeacfe4a3eb6a5201f_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfdc0787087a47d68adfea5ef5195bef_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d43b0dc8d742539a81797aad2c7dac_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e02de6be3a44268b77d9db477d3905_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1df4caa295436598a3f45d73add47c_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaad804e1a1445199d9e01dd42edfc61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd421f3e24b48ab92de4b4ccbc4ffe1_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralAndInjectableFormulationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralFormulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InjectableFormulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="research_program"><xbrli:measure>mrk:research_program</xbrli:measure></xbrli:unit><xbrli:unit id="collaboration_target"><xbrli:measure>mrk:collaboration_target</xbrli:measure></xbrli:unit><xbrli:context id="i8d99c64b435b4e87a51ff910dece08c8_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id251d0d82d7944d495c9d8d8fce4e269_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f4e389e77641b6b46442285a84c3f4_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f065c4f1db344d4862bd79ea44a07a9_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a517b30e874a00bab97ff6980aab5c_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied63ffc9cee949b990458159c3946f6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf1056dbb7047808e6072640db0a6d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24d4378188a4e47a19056c597f67512_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7e45260eac48ce932cb909af8a62bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3283ebb19c47db98e2743d3caf9d25_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7357cac30444434ad7267d089052bf5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a994069745948e3b6a58225dd2dcb81_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb16d00cf524ce297989b91888f968a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib083b0720a7641e5b2ed5b897cb5a1da_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if015b711a0c1463280f53a5f53f0095c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i283a4724505a457e8167cdc1100bb0e8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4da143af2cbc4550b7cd444b2d54ff99_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie84d4260b7474298a9608482089dbef7_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic456a004e9b54fa88ffab861b40c8472_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31c7604e87594ef485dd05502812fe51_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c949b3574474579a0c233dda2bb577b_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic69078b53a814524aeaac691b26539ee_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9049cb40e504958ac9e397e60d37fb6_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i4ef894740f0b49e788276233080a4067_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b6e4139824b4eefae9cfeae92fb9040_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59c3148ee024ea4afbac1489fd25b72_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6e2e88bfbbc44c8886ee11658c63510_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bb7eeadd574ca5b21e9826619b23af_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad0f525031d46d9be68d02f33cb1b6e_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id02a0b579904410ba96e69084e79c5b6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i803562aa74fa4ea3891ea730ee3b8ff2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b0c88b077dc43d395324479284c52e5_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fae9f157404c948f717699cc8b6041_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2616ccfb4c414f9da26e3832020bb2_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b8f860929044a7877bf8a6ed4c2c2c_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44bffe9a3144afd88ce155275642a73_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5431df1071454ba96911ea2466090d_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i611105bf33cb4418b7e1bae1d7e7ea5f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bdf7308172b42feb5eb31dfaf5c1b15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd932eaa95a4c7e99fe3e6f21d65b0c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i259bbbafc4fc42dcac9e345225999d94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i101468e37b9d4cf382b7335393246678_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7aac3504dc4b288b6ecdf3ff0688b9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8deae556e5124fc0a386203ac8730e23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a9b57f7713451ab3d958cb0b3c227c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4bb57af17fa46da951221280cae2d61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd326598790045f6bcc0f44c24e3b67f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29b92e874b140df8ddfc7bb19c76d76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf71a18afeee4bdfa2f728eb5087abcb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a13a1700a349c494acb5ee8a7c314a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01cb97bb488247dca17be49d7a0fb045_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b3ed6377c5412fbd503a5deff1c930_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ebd2bf240ad4502a0f8eb75120c4db4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8026cfa395c34fc78f7ffb4639e7cfd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89fa20a8d8c344b79257be206a940dc8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3721b0ead6be47bd8aaa1248657e3dc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife46a1fcf6064f56a383f3b0d9487ba3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a887176a9241c998829941def3e75f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c243b4cafd413ba234033925c3b3cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce2f27604dc40d8b3dc414670f4a61f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c8a34670be4d2f852e82ad0329e859_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ab1b65fec2429e9e9fb8b77ca7676c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8073582f227c469789fa05dbe73664e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0cbe6f30ebf448ca8dd317840d491e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f186ca6621243c0b67606ff25b17513_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a6baf80c0d6487ba768a3bf8d2eb9d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i477ac519583c49c4a85dfaec2d9aeeb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a011afad64440c8c568e59dfd355ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9171e04635a4e7ca60a79f50cda5a90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2370a20f6b9477d9190b59f039b3caf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86f8b6b06284e30a88d0cfda2123b04_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia743de15853e41f3b910d4cf1122df64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35980e373bed42f38371f148fe8ecf3e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d51996c5b14f1cb72dad54b7d4d76b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1775ff52a4f4c97a6d68baca5ddf177_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab1b0334084476e98316729e3a8c112_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc3245aba5546e0b11f27c281841fce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c7f305f94d485faf5c727853db7751_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c533dce277413ebf7c86906b5c8f94_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a865d1c00d4bf6b87ba7cfb8872940_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ccee6352d064f868e634387f9b6defb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2ef9288be849db9f064efef46fecd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaba9c09c27c48bab00412147d7b1bd5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7660095e034c4216aa9276e5feedb36c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b2184ceafa474a9e19170e8fb42f5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a750360d1484fdfbcaf406737a1903c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i164d9fadd4974909b666bfa2279e3149_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28b73d8d0524599afa19cadb0b0e70a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6ca606083fe4ddabb3985078aa79999_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ab13a91e6d41409f02aa3644bb33d5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09bd2e76e1e742df96a5837cbb96ed58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3ec7d905d742d7a5ff17c57e5fcbf2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30cb0bc5ac844767be8fb1d138e6664b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846e3e5062424fcb9eb3c09ff655d70c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7065d7527cac47058269d8ba6fac070e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie657eb0222df4887b09402876cce71d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3416ec93d1a492fa1f433c26d04679c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5de854d06ac4eeca3f033f63ac8cf18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd89ab9867a451bb7d8f5e7dd23cfa9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5bfe141a54941c1ae25d64fbabae891_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855e5afb6533435a88463827fb0e2179_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d25852fad3a41db9c665d20c687a9bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f6db34c320474f93fc442eab2cae85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib730f07be57a4e6abbd8c475c9858a84_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba49d74de774a7da3dd6fe57759ddd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83aee4fe2eb49e79b304d069fa8ad26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i732d1a8cd545457bb9404f007a3ddbbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8bafd4db40a4019a8844632901e67e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a3942c4b5040c183b0a32bce8ccfc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379f2e061e03444ab72ac31156ba6076_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i890188202bc349308f5fddb70d1ac474_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d323bb0936465fa024e1457a0783f9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9134617e9894461384c3736c75213497_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cca313b49524b8880414378a9bd58a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465e0e2b26a34a65a2ceff807a69c161_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ceb7081ad348a5b332291f5eac99f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d83c83f0aaa41bab160e17f7828a23c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4211db3a27fa41ce9ef8afb548f9103d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1754d2b50304b08aa2cc44626f808d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2440fcb0b354debb320abddbe888325_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864756958f464b8baebe379049606e29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i601ee311bfa347d0b5dcc37af824a720_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd816c120f854e69b9a2159aeed10f3e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie947e36c8b7f43249d8241cd508c5350_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ac66950463401192d572c40841d4cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f9b197fc4714188b0f988ab63603db4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157fad50a46146f7862f955f23ac964b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70782495edd949faa59537a7ff4fad68_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e2939d44e74e1299e632f622332de7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c327eb0afa44aaa8b041180a9931985_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4c5d96e848446187e39b06993aa908_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb42b703c354447eacb3e957b27d7ec1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67875c460a8c4de69af3791511d877db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d4b8387cc44522a4d608929cf3f19d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2f8008c6984b9c8973be53aa0971ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7e27beb28f433687f6a328ad49420e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e6787b2f43c4435bb7b7e0c9b5c5a48_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d8391ce634476c8543dbb3f18f43dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3969c4d6864a2da3a1f1ed7fc44512_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4460340464041e0b1e1151e1bdec68e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb510662b9e944c6a56938d27b6835b2_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85c300cf38349adb26180577979e5c2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3592e3674e13431aaf91bd67cef2a754_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7552297483f94fa5b4160dc0db014d06_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb748e33a7a454fac71c562342ce760_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45c2b8530f9432f800bd21578f8e217_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b231d9fdbfd40ae8d6fe71ed37de345_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30469f7c418b4bd2a85fcc554df58178_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia817beebd6444eea99db772afc066555_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864a963e97a44b5f8189640f9cb94d43_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79c6477e2f646dd83409e81121b5a29_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1e5bec9c0340748f3a3782a3f7fd23_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i804346c2237043e084b1afb341655a9f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b44b6cfd4f4a8b99ef33bcc3c06df7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d722d97d3e436e80d290bc86ab1496_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2335ada88a2240b6bd6252e8fa8510a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib615d69119594f11b401cf972b449c5d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706e14a3fa394260932acb94f50053ee_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015fe5f90bbd4e93a29ffe724e90bfd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c3521eff5d4d78bed2d56d42e3789f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8bfe07436149a2b63950679699d1df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c693f6dd72a403f89d6d2355a3b1c83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7cd884e75e9428f87dc9ff260d2f3ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa6d39939da4e91b837b366cdef3966_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975b430806c14e4dac19b89356167bc0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba21ed671f2448ceb380d10aa9f40bd6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1ca9c45f2f4c0d8e7d64701e4cb36d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0562404e8e0e4465a752940a1235ee59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a86b0a2eb94ae1872813f8188edae8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54629a1dafcf430fb0b2f74327fdd6df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d9a9c572051413cbcbfc3a23280168d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice7363f8460840bb83ffb6ca99594560_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1decc07eadc24124bed0dd2deaff444a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibedf7a5f7ef7456586ec0f021a1d0f3d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3327a1e7655544f3a7d9953a5234e2fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b6eb5443eb44c5f83120bd0907e38cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e08ad749ea24620a73bf3de13d4ba83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97f4ba5c710647b8a25a7267abdd6754_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f9f13e5ade4b49abc89a6dd9a5b2b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia78f45a1853841d69480601600ad30b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b6c21a42378451b9dab85a8423576f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c6fc33bcf040b88cd4cce4a3bd53e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720ba97855924cd9b21a8b29de3ba988_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d6a7f93e314fc384e0b1149d0ae9eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bdcd5cba5f543dbb50dea0289f3ab2c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4983cbf854e94eceae83083147be86a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972eba5067f8445596ed5ff359126657_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88144043844d4f7eb9f8cde0124c59f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a80bcbbfa39470ab7a14b86c6fa70a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8adcbd8025954472931113ef2fd8a95c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0aa3f0a78454591b3695e1829428150_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074bc4aaa1734fa79f0b7f5045ab90d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b319f5a70d43988516fed4f52eb15d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c66f3b052f74fd3a26dc81f448660a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3861723ccf964ba380c10a13117f1a30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235bd559e79d45cebeb01c3aa68198fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5164087f50654464a6032ddfbb33b657_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a75ee9f06394ac58129ef3c07183626_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id196364c06404f1e93dce678dce64cec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i446658f48ca64a5595891b7cc6692950_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bca802b14ca406fa68447bf048b3c14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f49dfec5954846bc22018691bd0081_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5838f63c0490478eae7fa5bddaafa36d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieead02c0663c47e4a289f16813bc7306_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5160bc069bcb4a1386bf4185147cc88d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140d4ac54a9b4fafb92531ca8b76c69e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dfc74fe5a384595a4c97c4a0eabb454_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702a5a6064884c78964fb0c841f02433_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37bec909d9be4e24b3a7a85153c4ce18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4af38eda5034b1d8ed205026267630f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf14eee6b5fa4782a433bc13f07577f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c95ec70187e405ba677c24678202bd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="ia218fcd1db1141ed905f718a91fc9422_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa89acddce894ac08beedd53e127e143_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07e7539f63d64ce1a5c2568c9999a584_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20cd4c7fd5f14851a86d5a655db5663c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50be94d522084d82a3e96d121db4b2c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1afdd113c40545adb3ae03acc9c4e126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782b995c5324440982290223b2cdddac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2677274a350445afa69443c36f4a89da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c912a0937747a8a1ae5182d756b260_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350a79055507478fabc61583f11e2080_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc29185c1fed4990966cf824e4597298_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdbb1216db6a47e88141c7169ea7875f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6226dc468d5e40ba93e5e688a3b0e650_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a0380fe0b24b768f534f7027ad8b63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90271718d0194ea79773a039096567de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie96270cdbd7b4606af8ee569a6ed934f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b986dd8de2458386abddf2a2a64bfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c9b82f66ad4f6498c0bd7bc43fd253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8101d6016e644c484984a91964cd5fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f69e11c219486faa68b50184be96c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1579987fd245a6b9ae265038125773_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i948c5f8c4b584db887310340bf216160_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90fcefa805241de9e12f2aebc441fc2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51bfda27ae2b4cc3b94f9a7440352c5e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a279e868ca477a849941852602f9df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7a1215a0c049cab8f08a9594ad42b1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68492993011c48bbab8080844004db56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3510a74c551e449094abce6bec887425_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60f9472b85e42f18f616225451c542f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i917d2ebe84824a7586c16f24fea495cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fc358415004cc2a37dd74e64f8d2aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581c1be0a6984114bfd52dffb52aa7b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb0ff4d140346c8963217923368c0ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35cfc0da81f545a398181fa07b3382da_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c40b5faace4195ac18bb1e51000e7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759f47c95ce6483d905aaf752e1639ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9644f4dc6e546f19f3bdc2c69c7d465_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b9830a106f140a087b9c78bbfbfeec5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idedfb451ef964827840ce24bbd35a732_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486c2ecbdf8a41108c15e0a511be9082_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa72455647c4823a7fc65aabb141a7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ceb209deb764a8782b3ad355afef10c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3107fb4932bc4642aad4cb642bf31a32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7649d0b0708041d7bd6500bc0db7bc79_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2236bd4b78d4c168553c865384cc010_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e23e28964b402e8ac69b9bf7d33084_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if90327fad224463b8fddba51b5516717_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3fb85e46d14551bb0ef34fe80bda15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c48d4b8b6ca4bb9aaba77abc6391c4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc33cb4b50d4093aaf63905d920b1dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43420ce5f064a3fa05fa2e2380d5539_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b0d4e6828342e7a26da27a695dcde1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57a4692f6adb46a1a2793a6f353cad90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ac1d9076f34481aea8771778d0d812_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4aa8f87dfa5498d867f4797c0697444_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74466407315d4f298256e0ad5a5af77f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3b3087926f41c1a474ada3d5d72501_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459db40bfb714e7ca275d3cd836dbbbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic518fb07b7674674ba2208e212142086_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3452cdca4b2f46d194438c26b62c02fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieccc452488d6486c8350f571676063d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05de9c17c11d43bf908b28fd7f8aa30d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie80636fc2f0a4f8a946fb3e439e28f9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86dc918aa0f64dcebee5f10eb3e80c7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa3f2dea94cb406697c29216f2be9c81_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i193fc51da4a7485394ab28fa7fa5e658_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c7da7d4a5749148765d47894aacd5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4015a3ff1e184474b72f68389cc87127_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e96a196d04943a1ab350c5e9d0cae4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic62406c431da439e8e81a3791303ddb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4177637bb44c09bd64388d2df9d922_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0220a923758c4bbd97582689f870643e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba235620efd64c3b8e1fc94776a989c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ccb5ece8414e37a06261c0cde991d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2601263e66d45e19c1438f48a9f0aee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d8e82b21924b988d762ffa1a17dd8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7899bb44630417a973d878c81948748_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e8c59227254e75bd6682c05eec4d10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae7d7fb2e5a4743961396935e496534_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc30062b2684131ae471612e9872ee9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5dad97abcda4f9fb9cdfaae3938ec50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d91b9f5ded401face6465d1b7b9508_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440ab66872cb40a6b47d2221be7afb0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563ada8aba96419d844e481095ea53b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445a31ac64064f36b804f06383d1bfe0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746270f61b8f444fbc5e79bbfa2f5d0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd8a5476f7e4f6bb0e3488f27974234_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc25519774c84d2b8046b1745b6979f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78bb2725e97d486ba1ea5b683ff9e12a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1027036535d44087b6a7e473c3fdfc32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85671c3d685a45d797f772c5f3312b8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a21b3709dd42128d8264f2a5257c18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d6a9e2a4e04b1bb46f7d1cbcc4e416_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150ff06d48a9497eafdf58dc03d8e518_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b040b0e94924f0291cc48a435447245_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae251a0ecc04d6b9054f018ef917ce8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief83301bd6734273beb742bcd0fd8b21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10131b7117eb4770b663e21fa15b98c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0a0f8c7fc64e1ab6f955a741b7f056_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd64d4dc46a44fca8aa2e2d65f22ec14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94a54e6f42254f4a80ac3cbfedbeda25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1291079726f54d9482e915764e3a28f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9feab63c1b64ebb859b0a44c8c0fe14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4cdff6731374404ac0a075ce6ab9b79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a379c20670240a9b25634d9750efe8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaaa3375ce0c4bcfa1287f588b3077dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34968f94170b4606b1bd3134b883f9fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac658e91c1524deea0992c47f1872ea4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db832513f3d41efa179eca26a0e6899_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b330f981b284955bf6356724ac55d7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c20eb419e3840d885552c3057349c91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19edb02be5e746299724e213abfcaada_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd18b2833711484dbc7ffca9c326cd7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24345a0ff484deb98e10e4105afa5bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36627656f09a4021bfe46b0d8181fb2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4296dad71f474d0fa88ccb38226b4f44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd71198dffc74a99b2e0c368d96a14ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8b5a245d4f455da78fcffb96a7508c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba9f35c12c54ef98f07fea573c78bd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6da2f157b824f52851dd9e978b0eeff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c08e07575e9490cb5a8f9cf49bbd641_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib444129703be4af2a20054714bf0ecec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56c0f796a90447b8097ae8d7be632fe_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567c0acaaf20420daa3260e2b7668e47_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022aa53b13d84e14a5eedc763cefd54e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925bfec8ab2743348c69f615eb5a44fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61807d83368439782aa2842af89525a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ba9b9962fd485ea74e2d2c10d17307_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc9093833ea43efa72b1bc502bed4da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a4d286567e47718bed1dc0ec61c06d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a53de261014635b46dff37511f8a28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ab8ac0847f4ea2aec591d7ec276bb9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c3ea6a6aab40a686a75e01c429aed9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34571e3bf0a24f04a885f828cb94cfd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5bf7773e95f40eeb049ba5fec44f5e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0140812b0eab469a965b4b15301949bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94cf60618c5e4aaca021c753bff1b8a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57473094cd042cca3f71ebfab8a12ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2e09c593c942af8e3407a887af82d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be0c233ffc9447ebd088af22f69de87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie233154d86a14b82a3feeae38dd79d18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6138bf37696649a6bd6e971b74356d51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i213276daa7804281bc7394485ab71d33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460644d8e3e54a79b686e69c684cec5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibace400774984c3dbc9f9ea52b1e0e6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47add64e2cd40f998158d2c98eb4042_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fbb5dd4448e485981b74dc5719bdbc0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7debb2fba50146bebb232e6e8e26d1e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323a82a0676e447aa0ee30bbd32c0379_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4629f93a6cb342d7a2adcf465132267d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice62906f5f13486296cfddb3eecc61f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a998c05c25e45d897132264cd7393b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2eb0aca1931486da121627e2b099a6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SotaterceptMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf54a72af67e45fda2e3769dc2ee1bbb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GefapixantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0ae54ef35294062adb30816c2eba9da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie57ef40fb83d43d0b204010eab10ace2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3518262d4c349ecb316b3c7dec9767f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc70591306cb403fbd97773b449e9870_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc9e424e32fb43b8855afaaf0a1576b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DerazantinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0e372671334e94bc77b2dfc17299c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21861da46868461288c97e4ab76ae0fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fda3b4d09eb4fa583ba37378f5415c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bb0b8ac7a6746a7b99550c3290a6912_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a963f7bb7df4286b00142ee3a4b4163_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b81622562e043619ce4097e5de6538d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd526ebaff749a5b3eafa6e57a81046_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a1b935714646a28acc02e8da2af399_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f6217a86d54e6b955c5c6727e00fbc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233cd0a66f3a4e1293ee7180976a6a9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33401fab91ba450bad968abb1f3afcb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff1742d1bcca4273b22d4c2ec6e6d4d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf0e9d91b9c4abf8d628b3c4bebc216_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09e345560f6497791f50eb94308c444_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb3e5f968ec4dd8825fd0c8bb6ad4aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcfc6075c6a4565a9f8554b61999abe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739a3710a3de4d7ebb81ef763fccbdea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib470cd6f92154bc78779d5a55eb10d70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c794da2c364cef883126c44ac0eadf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i822efa59fe3745939a910b1611d44288_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92399f31232247e0b6bbcf5a6a089235_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b551b1b91d472893ca0398491a7cce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5713c49e1e844949024ca754f258c89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ac8327b23a4313b04a011b58ea1d2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a36c48450a4259b629f674ef5433a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff19b2f06b94d72a4c24b4eea59c7d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f4a58945df459196d4289980f7f9f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0bcb5b5a434f51bab2f5d76da43e3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a8b5ffe89f474aaa717071531eb373_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298d3bf22286484c845cea75b0818c0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ca7a1f2cbc41178098a0d44729387d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400c4310ee744a12bbb7413c21f7cac2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e87abb2aae4b75ba3cbbada4ba4c18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e5590941b574c9c837595f0aace5727_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7aac49ddf54d1c84c0298cedae4e0d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bfb5c52b3d044d7b880a56872ae93e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i224209bee44647d1890dfbfe59b6f186_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa89611a5164af6b8cccaea01b34c43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd075f7f4f1d41c190d492328b684c9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f2e241750c47b19940f1f7920f4c9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i620b959fd9e146b0bd7d17c8f78e14de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6eac77276524db589b7a8df253bdb8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97601a3d96de4a38be031a08c94ba40b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24293f6fd55415d9560fd27185731e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie629738e7a1a43b4844c99c144e93473_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83a7f94ec0b4f15a760d11fa20711ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82da477c35664e5e9a498ca0e106941a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb2ca9915d3447a9524c55e37e9fef7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c0f5eccf7f542f78f0a069e1e0441a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ba76bbfef44f90b331caf152aedf4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92331b59f2ca4a2cb806ae55ee55125f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8c58e35b90f44c7b85f122be398e01b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d334e27c8974586a1e136fdef62aea3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icded3aad9e2b4fa5bcc6bbe73f7bd27d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c09fe213ba245e79cdc9b37441d663c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bccfb63cc84447d9f2fdc7082467dbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45478d0ad35e4c2d8be4c0a65f047423_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75f8a178ed8f450eabe1b16459124dcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dfca1e518a440e79e02408f4fe0efb6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8f6b68af8b9428d91b0377f34290f43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3af20c7a3814238b67e841a07acf4cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a75657caa24185aa254c6f8bac7779_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91242e71ad3045608d2523c26d489ee5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1e9b9048084ef786463cd80bb97477_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5179a79bc0fb422a93c77860d39e3e5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4ff66345424bd1af13776a97cc3571_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18dfd3b19f344509849614fd0c8c7ae6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047a9aa409af47a39aec099d05eb850f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31d717109e794d52a04995b9284f4213_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f477cad38324ad7a03c8f6e78a1056c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd61b5e13024c6d821da5de889797bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mrk:case</xbrli:measure></xbrli:unit><xbrli:context id="ie2746565f1354a23af85f4f99207c98b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894c84a8a53146d0996d343ee95c4d6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1982ad1e3245b8821c7a9045cfbf7f_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrk:claim</xbrli:measure></xbrli:unit><xbrli:context id="ib81588e6e7c24f96af260cda2030da9b_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d2016a9f564132a989caf8220b8a3d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39a2a021f974911b1ac6fafab48dfb4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>mrk:Plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="id7972a4598aa47ccbf40c79991ea05ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a61ea22950f47828b95fed44e6413c2_D20221219-20221219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706bfb75e173464c95cb81cf1f960b6b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i225a64a3f7814a45b055a29ef0ca80d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b134a981f8749cfa64471811826b386_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa23748b8b24ab09e6d4660601d9eb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02fa96876a7745d29042dd0d714d3299_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i591ce0aef96f4308b1211d94ac08b222_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac458cf9779e41db953d53fb8f7b2fb3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619a10076fc241c5bba81067acbe0104_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied7d80ed2ab14e968047a6b71fb4fea8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85a36eaa81c4367aeafea1a95984d7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05aa65f0a24d4c608a963845531c19d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f05e64cc234f2facc385938bb0d4e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29556b6857e2444296df1ce227fcb0df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cb6182a68904c0fa3a216d4c959472b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i047b115329a54c42a89e9abfb277e348_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1539f9d21d0436d90ee19b2d83cb5bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac41e3734b14c5880a3e1babce1d967_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d66e8191e3489da8b88251530ce552_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb1a8351aa841838361b44de4c7bef0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c3c2b238964beeb4fe2cc7ee98547f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574b9cef0b2d4bfba6872a7e1206e397_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a26a46ae4f5482dab104697c724f404_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d9eb5934f114a0ea5d847b51acea3e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01435fa53a734b81a8a042035680737d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3d2094305840f097c63ebbc04cedc4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d52da3a5a0c45c3bc80f202edf4ac2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db1b4d2bd9c40969669b8308c8c2bfc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8022a250b1054e89b99021d780f54e3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6232b3f5be49b195d9d3ebc647e54f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic44da905f6234e16bc83498f4aa76788_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df1024a4cf24b4aaee26f266a7f5311_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56ae559c54a246ed8624ac3c291db4ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848f3f6ab9414064b3b30f280304bf53_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2c0a82ed5be4adf90a87892aa7ff607_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f277519eb246b7ad1d130d25ceadd5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic872792688f1452c879827ccb8b53f29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828d9b689a9a4998aeab58dcb22c19af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied44e32a46c642a681ff4b0c0b6653d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71639f6c7cbe47e6a0f521ccb6b05b3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf01f0ea26c74696a3c2fc263ac75d7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82fec81188f1404dad80d2b60480bcf3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd533fe7f6474d57ac75249e0844aeff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b6b2c158a945fbbbdf1d5fa0e98e1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc462ae433d483c8e93d9298f863a55_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac89e1f592aa4c2dbd20dfdbdfc094c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica85b54a9c6148748a002d6f700af7b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1299e9fb62e24c01a38fa23973dc4b86_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780a5fe64af9456ea212e3e1f7b5e699_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i413442eca9f64a4e80a2e82ca894c2d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbc781fa4b494ad0a981a37fc93215ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ee2b762b6b42f9bcb9883b482b84e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ab820615b2409ca822a8463ecc1b8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8e535c106149f6a29ce6dfa87a1b16_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb5a0ac36a4541debd3bd1591b829d44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae76956543ea4116b33a51d411999395_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f688bf2c244f1f8c8c8453882fdc19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a283bca60094770a190b7b2501d36af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80e040b356d6468cacda7ff0c18e4591_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6e50be712242db98c4f2730d77ff37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i219e6bd79d244a7aa455084fdf94ea31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13af1fe3667346629b41c84114948a2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5ed95b785743b59085bf03f11a8494_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i581419defa34403898493f6ba2fb9935_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a561dd7e3cd44c686766ee939d51f32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia697527e9ee9479b91cf4b0aa0f597a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68566a927ade4b2496958500664255bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e4c057f83442c6859610dc3378cae9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e5e29c38c04370a51a4e41907f7cb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i094e594db1c34ab39387886a26d20ef2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie604b32af7dc41e2a7c47c6f522d23cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i973d00b66e0c460bb172e8acfe0e30e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf57448d49a348f296cd544807eec041_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1def8f4c268e4881aac2d1b076b727ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic55010634a68440fbcb5037b4995212f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a80b04cb6e043ad80ede6971d9cb2fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacbcb5d3d18240d6abf33c438338c41e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbdefef8716e469f866e5bdb3ad97823_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368338736b594e6d8a76278bb806f294_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2074c0c51149d29db8c27132c778b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2d07ba578d453a9b330ea183531e7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e296686a26b46e991479d3824a63f4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i884f9a28b2df4b68bb8abbdc76ca1ecf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3c3527b06a4e589f09f08ceb1e72ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4a61f86932408aa31104c0df81ca3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3d036d559f54833a22c6bca2390859a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84db46bf07e44ef4b3a8a839cbf0f428_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df28cf4387a4d8783f18cf6ddeef882_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ab2d575b2449d08e6ad76e2f9283f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef55351ff9e48e89c15fd31549ae893_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e42ced466d047bf95c8e1543dc8863a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f0c6fe869446d9a36fa7dbefe7fb88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i572499192bfe479396365f275d94e763_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9fc972b25f4585bf6789b43ca0f28a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i408e755f4b8346248d1b01996e6dda61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d015a29c7d47dfa305d0b880483f37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d5d96ce993e4d57bafec31c8f3709be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea35cf15d4343148d21525946bb5556_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id02a5d1a28e148448be5e2748d591f32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0d465701b24fabb785a43c5d0b22a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35e62b283ac416e801a76b2e9fcba1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7da8f4d50a2c49a585bbb716acb0701e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02763a738b84f0f957e97e34d95f28c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6945f7ef76e445392d96e1e24babbc7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e222b032b0148bbbecabb38a15019c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b6676439afb4baa89166d48a1c80d4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9bb0806cf1747e39ed7c1afcb91fcab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab187b6caab4fde8baaa89614f937d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcdb915e70724220b3edab3c2cf16e13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if18d5994096f4b6e8384cad8cc87790b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d94212fbb084b18a3e0d07785229801_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c5eb30d21af404795b2b73f609cadb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14271cdd75a40bd9db2047fa6eebb56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b45cf02542b4df1a1557fc79ecf4d7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac839fbba234105bdce0c3639ea1f65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2884cebbeb4349cbbd54902567b98f99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3419a800d84e95847c4ea6b6573ef9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec63912400cc4143bca10be161105b2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c9d46acf005430da76b238da3400312_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1b3faf898a4df1b8da83fc0342315d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc3922262e347318e148317d58cd00a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeea740fa5b6439494e7da959619e151_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i222c3f84c00f4528b3b117910de864f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b957e5e1bb40e48f22b7266013e6b5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8117fc38d2c448f4957b803029d27a29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e3be79b32040aea41c8fa4c833cfe8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157a12054ba44b08a715faa3db64912a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf31aaab8564b709a2447727d50c0f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18725820f3894e1888c310bc183d1281_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75548de2a3824999a1caa66dd0cbddd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2f0d1c8a7964938a5f4ca7b0fa2b293_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d7c3d7dc05473f9e300744f303a60c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib326ce09514b4493be47a196b35b9582_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd8330fb14d4d3c81eb6e836222ed54_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8077994810984b39938b2aa1928d7cf5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1de47dc04136455bbae3a9a127f6e0b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1375d29c86944eb696207a9446cdb738_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64de9cd521724bc0abcd5e2f16a38d97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1c7dcf2922c4017968e8f899598a7fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b426282e3524c13bbfad8775bd40381_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia564f2a19eab4fd992df2ff0405138c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6582d2efd0054414b352812e2b962b7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63145f7e3f1b41fdb8abebc2998c2d19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f04d31c0704d299ee261c7b15963d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607173f7a74747529e546f2f09ffa3eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1211698fdc9d4fe4b5bfb05d555dd4dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d81a32ba3204600bc00f943bd7244b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee60ebe97eef4e579466f9b404815248_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i690c9d1b13044a0b8c56110bdcdd1656_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8bff79d9b44c1e809568cd8f8ea9dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9495ef8ea329494482b31a7316e5c091_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc0b8c867d2b407bb7a590e2865c3daa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5630976df72c476e8f334a3899a205aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b0851bdc7b8443086939d63202a6a2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7986a9f3720e473ab5b5f32f521a73ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if44e31b11f2140fcab839b2f25edc3a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0de70c29ff2e41c3a2cc1406100028c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d0ac7c4da141c8a4d4240d67ebfa08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674529c9196143a7a4d48e89efa7d6dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1146171a1f32494fb878dd8a8dd84f7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf091cd60ecc46999362e8ca49e4429a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad887cf23134b0d82635fe324756cb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdcb20a992b94779aab076cc55de3e6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e76f4f8aabc405e8b026bc6b713eaf3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9208e7f8ceab4fdda68258420c992acd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0892e4eb2bf447490676f226fec365b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847b880d005a4f7e86c4d63096d9f2fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11fc421c59ce461fa247d668f9e0221e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69d7f997d164052a95715c97dc7fc49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ea705e6e4e4f58ab5537473f2b8015_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23786efd39504e7cbf7f9927055b6962_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7821d4f79dda401db43e25763b2a2bff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5325b943b7c84934a25bbb141bac26e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c2a54b17b24f0c93b411c2e4ad8e00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4438b86aa5244c2818db9db11a86fec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874116ca095e4632ac107ccefe0dd09d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide1a603e4a3f4ea6a050c80f3be11e9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2570383925d24316b345fb6a6f82400b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632724ebfd9a4a49807cc6f4c47e6534_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35977504bb0a4d55a4b76850394ec55d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e90de4ed4f463996171254297798a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29673509c9a4010bcd22958c0959847_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i665dd2b6cb854b829b803fff15542e78_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42e54cf9d54b4adc809169913679112d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9246f8fd405044e7a1e70d29a4549ea1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15e5ad8e04634fc58a8bf8264d2ef413_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd5163788694a7393d6ef6c3f78716e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358c1248155b4206a0b0e8e6b96f4f5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43019cb2131f4efb95c47d2d7a4beaa4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb68c4cc84fa49ccb20a1ed79caa36ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b4b0f9f50a40e5b9e1a1acbbae1af0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32bef4bc7a3846e78b7f7ec8d18a4c04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22d02a4139c468ab28d1f7187278f7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef6b8011f814ceea9fcdf1de32c0ce4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a0ffc04beb4fbfb3aa513e65b14e42_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02aeb26424c437e890d0d17de1ecffc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i468fbb9f8f4c4000adb9871b4f1e127f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3000327cc74724b46322105f078001_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd903913036435f9d3f677c2aead426_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1fe0dac3c04016a05d83b48841886b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105aa835a75742bf940d91e90318d5cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6533c9582744312a8b885531846a690_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d3e011897140d2a236f7bbd70e8013_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i069baeccce9b4520a111bdee9431129f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb99c5b079ae4247a981dba6a8503c3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee39b49b33a847d487e04603c75762fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad821c2d4149482a8d9a5902ea95e485_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4018090676e1474786e1971f3ec5c780_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7809219dc2c546249334a05ed0fb7c04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib828317235f34a7c933d9c8403e3746e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d036f34012427e97ebac833cef5892_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i537bba5b6e244ca494ec109af70bb702_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5679535497fa4788b52666e4cf70d170_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib56d072311c84277b36632d5a803fd7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512bb771659642bd8da429add2af7ece_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia60b0d81c82b44b2a9fb4a6fbdc1f05f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f4a71103804c5c990a5e460fe9febc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8491a5785cf2462fa234d89c89950509_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c94abeafb1473a8d323ca363297440_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980c20ea27d44058855c0549523b629e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f51ec0ea3d34dddab95685e90d307b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia486b0610beb4dedb992b7d0a70d8173_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b084b871a324422ae5462c19f697ce4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01600af18ed54eaa90e40505a5ebe18a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7727910cc59d4a4d84eb330b2e6c98e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3255f205337471b9de00d03043da0b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3cfd0494654287bce631815c2f48fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38cc140712f549368583bb21f0c9ad6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5af5903c6944bc8992989ed8fe54eb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85d88e511504c9f8addf47ea0c5c8c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd750cc2ed934cf198a8e5af0722e734_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bab51d3da9c40bd9dab9219b12b6477_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18fab0cd3eb5497c95c9598936cc5f60_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d226b317f604d05847b7f6e28dc4596_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f30f26103a4bb09be1f8df2ba5a0cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61ce603ee97843dab7cd57610eefcff7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff8b9d77acb419cadc79b2388cf8aea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia49b3ac0859944108a2886b9ffe70668_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e7988a858549c6831c3fc177094480_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6082ce67ffaf4296a00a661b69d5e2fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b08b0d47a644db7b10259546dfb010c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a15f6641e7489e8bec87d0c0d09275_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf55b6630574907879c5690efda4aac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e9d5863fab44dbe8edafd532df689cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274a84d55dbe43f0909b3b9ea5a73369_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8144400fac414d76bbf83fa31a181ee9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7e9a4146a347b6b61274dd7dc190a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib416e715279d4c49acf44bd176c0e993_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2279fdb171bf475ea5bbaf850cf969d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide944573e70e4c3a941f811b9ae4fc69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a3d2cafcaf747a081a5bb4742d24ffd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc86d76a34274e1c9ffa42afa18a0501_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73a0658e8094bba8381b0c5aa3afa6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb05cb659f145bc9934cb7f8611cab9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69eb54ad43994b288d84c18edf6e95b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6da8c122d974d1f937fe4c99ef076c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5733f7bba54d42aaa43b121a730f82fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf522bd9fa148caa6b5eed555edc571_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d449dd9dde74791bf4aaeb9a684a535_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca87f79abc048f6a89896b3f649a822_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d655338ad14d529fd86da3f800ac76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41b6862ec6b49808939615624817c34_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8c892d473c4518b1b24faf48003494_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1567e8cd88db4e33937d223c023e86a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ffff716f5884ae9a3c95e17da117a8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica01a70e35a14ac7b9ab80bb54bbcd37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dcf8778d6694d0b8a4abf0e7cf5ab5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e73b7ddb0346da916527922a567950_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f078b74a4254907b6f6bfa3674d200b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f3f57f040b7479f99574732ff1ae8b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b52200a65f14226a303e0b59890c740_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4975d29336746c9aa345d496769bdb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2c66956557e4be194a774c381c9da86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0551986dd6aa44a8a13162962abcebe3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740356c629584008ad4233ee4ddba3e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391d62977ce249c595df8b51fff32129_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icedae49afe70492a8921f596e854194f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a215a4d92941e58289c363ae043414_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i196e5beea93a4b41b938b075dbb6919f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22de86a0013c4258b4c507ce158eb4e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75398dcffd9046fa9a38d8247cf75272_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25e5ffd30d9c4ef599c56ecbaaf44659_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d52c4001584a19bb8951cddf85e6d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43740d47c36d4df0968fd590a094a8dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f395a8003a04bc1bc87026e0744fb1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb33c38937d499487bba962e0672886_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if954f770736b43af9be4de4254082a5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eec32cd86894cbcbc60de256176e451_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d8c9312ccf47048b5a4a7d309afce1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbbf0cf596c64dd0988a11364164dcad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0855ec477af54d6c9e617a29197d7847_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcc62c4863b4fd5965bad472ce89f84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f98c489cc64681a483c72df528f6e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7203e778ea74a408a9fa5899876be16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723ef648281046feb09a5a0b71329ea6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c611c813754eab88e05244b68c044b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ab2616ba0d4b4cb6674640617b0f57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9381a63fc854eb5922d6264e132c65f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic78ebf602989410196340e3c5dcc143f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb96f837754f4435950d58e7ac6948d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77861343b2ad4e85b03f9edee1fd484a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a9cf06ce114e07b7471b2af3056851_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d33c007f854d6686e954a4cfa0d98e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b3b5be37054468ab22fe27ee8df713_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3aeeacc677f42a5a7d9c47033789337_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4352166d754870a7bd84cb271c20c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic779d812947244a493bd0e236b71c768_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c0625b0b6345e8a53a2d538fa4f71c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6e499506a74f4eb80bc1d6dcb6eb92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9249f1c9bb4890a527687499ad8b1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97fba52804d74a09b2d6f5991fe15088_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a9f1e2ac854460d80e3d43cf0117001_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib24ff29c998a499e98829ddd938859af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i880f66c107f0451ab68cb5731877e3f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0e0627cafe4467a18c0746b1b2cb31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d48bd88a7544ca9f12cbe3c8d542e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i581fc4c408a34c2b823593ff34f1bb45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice88c13053694b56b1bbb9845b06064e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018e647cc2bc4aee9902c487f5cc618d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff115c544a4247a9bebf28565714478f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25beda17672d4e7b927a143d69ecbcf9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b3d9bc36e8470ea10fce95680f1e68_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480b0e7376cc4bf192c2b8defec32548_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e52fe255fa64668b45ea3f63c0ec370_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3df3939a70427b944df35cdc081c04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8b60bea50f4819980218f7402e7751_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id979bf377b1c4fa49c254ea8c1bf378c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1635544067c487894b39dde19771e15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0194124ad9d04baf9e149becd0219b96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5299a986957347d28938ccdaf51e78fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3ebf994c704c56a8470a4394936128_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib520139920004af9959a218c4bc47d91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i627a57072a524b84b539c7ae028c9972_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i913b5f5f9ed74e87afbc473b332d0abc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b96c6aee77c4665b7d0f0f1c63ae176_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b5a437c2054f779c773692231f8df3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2a4b136e3240bbb703440f5d3e6850_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe65bc4981604870be12a703c9e2575e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4945633529e43d2802b597e5521836b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b67d5c167014b2182a1ef46a48101ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f74ddf524274e6fad860cb8fd17fe7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32c0f7bc74d34dfcab9c341a70dce9ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cedd5ed62c843f4a46823653d960a3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae98f337e3924c8fb5cf7830c2920bcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c86d54c41ad43afb4205c1d54aaebd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf0e72b4d76455c823ebeace0a9683c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b61c9047804b46affa899a8994e404_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife91ab3ff9224a8887d6fc6c9327342e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i893c7b0fee694fc39725e06248904f34_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a6cce590324043bd914a90ea6fc3c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i449c16f5e60d47029b762e1c47644d98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6adae9ebb2144625a68e34d2e532d6d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb26e9094cc24bb49df536a196047854_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72091fefb0c4f5eba7ad4a943ab6bcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba55f68908c47baad1db7eed4abbd32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc82d08170a947b081f642de831e03f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5dd78bf53984767890f793f585b726d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4daa1ffee7c443d69903ce6fc8dedd2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45784d2a67054e4aa4806ae5f92c6849_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f3b6b407264debb979379641cba1b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fb8860eec2457bbef07d977cc5fbf0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a1edbf368048fba661bb380d38af5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia405f11b3d1a404a8fbfee06d703b855_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce1c8735b2e427cbfa6b1c2d907a6d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7a12aafcc6847b89509b7ae957e4d23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i369b80c6e5c64b4488babbdd01f641d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e297e9db7d4cca8668e1a16be22d72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924ed285bc1d45b996c203cd7bd05c25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7383c74280514a6eb812d7f52ac9def8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3cf34ce5394b47a3b70ab7ba21f07c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie728cd5943f143eda362306c2e64188a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6010bc5ccc09432a9350066c737cebcb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1c226f8e9b4d3589285259cf838b6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c81130363941eabcbe047788cc8ac0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad865b817d2e4f2eb417e13f1b94cdea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0623f98779b4a1f9deb8c5985cebccc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f2b5e073ef435584f2836b3a9c7e62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8502a68f6c4572816d41762470ddad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795f5a645a9b4b7ca40fb6b7556a8459_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a45fefd7c93443aae003ae9986384cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766d1fb2733a4f39a4b6c0c5a672f068_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd9a236b87e45e38116d6ad65882768_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba509df50d7d4c6a8ad7c22884e1628a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02f69b3633a347ecb320f84b5f266212_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9604e1478cf43bf91e60a2fe7f8e4e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a749daf21de4a6f862d6f87b5c3ec41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd49f7a962454bec93ed6ef6e39f5d9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4de48dbad544b2ac8a8ad5bfb3ffa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic252bec7fec546e7af106a451f9b665f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c314bb744ef4c0dbbd31c567c5f81af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if944cd16f6074744b8d053e0926af6bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c1f9774a89a4460b8b9fcf596fab680_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50e936239a449409453997e9da0fdbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675b5277bd1b4865ac978e2a5444457b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d27b886acce4aba86858f24529ae547_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc364573597419f9c326fddd7d8610d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b12891dbba4474da8538f68cfe990b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2ece4e28dc4d3a8d51b0b78cbadf8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a61546d8dd040dfa6713efca302e7de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1cb9718cd4a44578e0ac990325f2f60_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da749426fbb44f2999732f3b38a24f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i351c42adbb0a4ccdb08af0c3e1a68785_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0352f2158524b81942eb49ff2876ee1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DefinedBenefitPlanCashandOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5495cc09a654440a149148e4e68ccd3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c54d6e8143424db472e467e5653785_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia358ddcd5cd64c81874827bf799c7cbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c9e567da174a86ad13d7332a5ceace_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3d23b42991496e8be8317108cbd31b_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie41dca853a9a42358f40da6cbd07030c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e60950b557f4677846291e08c9270f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:IncomeTaxesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44fa248a36c14567824971ef9f972e05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5705ed276147c49ca285310c722e6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf27171f8c7f483b8f695370dd8fed99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i540b17b98c5447ca8f7d0de2174e6403_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799b8472304c4a24aa87481dc87bcefb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09a86e8c1434a81b69233805423f1e7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0b703f3bba444fa6d4622ccfa960f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74765aa20bbc4bdd99d6913c1418a345_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f82e1279454361b6876985ee31a5f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4630f56a7e0a427882ad898683404c6e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ce7859bb6640678ff3056905b8d464_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f36c5d17d7f4ad793c7d79ff96b69c6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc09dc5008b41e08065acb6f23ea811_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia160115328384ec0a210cc9247afaacf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712fa8b98e5e4ccab42eee70db45d412_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1639bac565704b8db1b75f669f2f8d20_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35687940c55f4162a974c6fba1256951_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d2ea2a866e477993f83cbe1be3386e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78fe5701f56444a87f6705cef245749_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780c56afcbfb4d95a44ba74fad92b717_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10df6e4d4fef4be191cf9f09fe3b0e69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4f7ce11e074645a9ba948f88f64501_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2100c8d9763e4e2aa3d44e5ab5e6f3ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb4671bf8a444d7784d46176642a8000_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia053f4e630254ab8bd394403714172dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i913f7d5516324116a41cb3fd560183ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e9678f0bde4535890e00b607c39661_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief7889eac2c64545bb3064c36a62e54c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3213007d978d4f60ad986031900fb73a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i633b278a9073462da9b159814994a35a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f13a2378f44c6bac00f3c347b5d737_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fec19785aa54818a2736cc335cd0740_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaee5000881d4ca39ed66d7be4ecd22b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98661ac7371d4fd4b9c2f6c95474a731_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f4a1d4687e4f92b7cea51e261e5084_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9544cabffb54d55968d75c6c7d1efed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01173ed3d18241a0a998253f0b59e277_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376ce6e940de4569b4fddf8c906fe3c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6758445e91bf414bb1e7540b3c5e6998_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia91e2c24c996468b982a1dc76e03f861_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9731d40c6ab449cb60589aa31b26a73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i055b33b897694fecaa100eb09d061cc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ceb00afac54256a4f7d60880c98740_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a3ddbfa55a431d93af3aa9f262e6f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i021a82cd1a4140339a5639441d8b47f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i469a9a4b8f4d4ca3ac6924d254ddf426_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd610e2349614dcfb3c65f5ed1df8bd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1932046958463fad5e8a483638872c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d05e5c857ab4caf84ea5087f3cb2a5f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5745637e84f64e87b8c42fd884e6b4cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85cca07e668f4fb582cffbfc5b2aa7b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ad82bfee384b30ac43e9a17ca1089e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4d358834924f50a81f5fafd726b128_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4823df2547cf46b8875abd9cf558f5ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c17734546b947998281488d9a6ec98a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2afc6a3ad1a4eacbe19b964577a66dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cae1b53fac2493694141969a8253308_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7db9326a224e2ba5066b84103c543a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida28401748b24f92b416cd0833611fd1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0bd8d6774e74f7bb3b1974282e31ba0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386ded0f805747da8de2d6ff8fb385c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc73f7080d9b496c8de0c1ab17b2c074_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7022852951b641658ce5d9c243dac44c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i962d004cfae84806a1690091e3ae9d53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b05e5faabb4aa8822babd60bc90181_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e8b2707de1407695f9bbb06e69dc0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5c22c83dbc43948fa3d2fcba8c2036_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983e74feb34f4218b9743956866ea60b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe79fe1f7c2f4216adf7ef2d4c9e7785_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6630bb637394adca02acfc9eeedf615_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec24a942c8b4c0a8fc6fdaf544a83e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110ea0b902704bc5be59e310b57c93a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie88453b113924c5589f84f11706642fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d1c52b6d904599af1561feb5d9d169_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07fa681a6a3f4803ac978bc4430cb16f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644651c9869647669ec353da52f990d9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ab722f2e32a4c6683c5a3c36bc74c42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcbfd454bf4b4f66a38aeb71bd572837_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da2a3204d4e412fb81a43cc22c0763a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e0f2f8901b420ea1bc6e4977b34b1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23153be3d78a4b25841635d342d31f02_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df9cf0c885b47bb915bcac974671884_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f7b5010d8b4521aba879ed86a464bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia33e8904188b4076969981d84d6398e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb0222df25c4f04995c870d2c8857d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e74080b44234734ace0dedce547e587_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda8cdb993f6413fba844f94a33ca058_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea178521e12f47089370df87334ff7b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7077f41ca14446182bb6e9b4d27b1b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b007cc3680b447fb3c5201bf94aad44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0c7519eadd4f2cb22aa9f1248dd720_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b4a4a5f68b41c48bd3a0fcfc84a504_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6fa89df609474b9bb96eaafe8ebbf1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e07e4f949d474eb749d0ba3fb1b4d7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ba2d46833f40a295ab92101c6ea29e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c671ce13ae432fba6dcaad37ca8570_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6d0c174afc46489b7ddef3c33543ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib169bea2441d4f30ae99b18bf17d4fde_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8c832c3c4b4e4eb34256d6efbbd10f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e6f28f13f14ac490531d72573bcbaf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56cb5b6040ce4ad9ac372cec6d2cca04_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ef3a8f82f04dfe83a51cfd751ae411_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04f7472ddd5484b8c9216a9fffd29ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ac39abc88b48dfae3f97f17cd94587_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd57f79d2d0e41c3b93e0ea8a1fa225d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a2e2a2eb9c43d4b2d533d346a44334_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80ca468315e4aae943a5b9df597243d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99df6a07597644d285a92793c5d8e7ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a49a4371bb94327920efa9b894769ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d68a994755427bbfccdd19f9ad6ee0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ee8738806c47fdbfa08983e60c6b39_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74b581cfc6d488fba45c7674c3dfe6d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1f993fee094825a8fff330454f6f81_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380654ff24e1418b9128e9fb90b05595_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2d28f16c5374e7f83b2e84bbe26110e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83690f4cdc6b473bbc907e1481854b3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id86b5383dbf64f898217d2bc2c3fa325_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c50b2fa3e364cbb801d4ba254d494c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e206a2ffcc45d1bb510c4187e62a29_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1603f10ef8494fa56655543909b4c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045d0c50e54f4c0db0bce141309e9adf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b4d13befb54158b149f2d9f6063ff9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11490c3b30c40b1a23a28951f1e180a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1c6fb66e744cdbac35155a426b3d6c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c68bc52927041289397d599a9612eff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f47bdad3162408c9b0f25ac776b4bfa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86224d1130564bcd9c3939e4e0d87dda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66955337b2e7472982d44f7d7785e83f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66f7da2549bc46508c0eb51f336b6e15_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa717dbb9c014d55a5428a202d0f8635_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1348a3599a104ba6a35f574703cd74e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bea3c67785843179ba5a14d3faedac4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696096e4ab134aecb6a7f9a41513fb2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1a741e5ac843f0b62b174581b00278_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f9720b066543308e337df0f16afce7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438e2ece521548b282bf2388b2b7bb93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f274e7070274a88949b99aeff4a315a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c33f54fbf848d3b95f8a9426848007_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6aaafda79ee404ba309fdcef5eb6abb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44ad729c19c4e508c4d35a83785a3b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5118866f4f4421a29aecc0b9d07410_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25c060bf8b740dabb223a13c1a73ff6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i502953fc972e41468a767f66ce4c9cba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9a656842a84362b57aeb885a898b92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f5e15ad16b4a99a824425bbe60d470_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b71549b3e14a12b8973697db00d8a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5077564ac8bc42e3a13c994eadfd523e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265d917b453a46658f7507d16b56613e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i849cac43efbf4becaea56c79b6c78fd9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1370ce5e87458b818b4352ac61a828_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefb64688266941e4a497a73d06448942_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296b1fd777794c17891e11e10a141300_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09f99ef9d1b74fcabeb55184c85dc86f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if880d0df286f426ebb17d41d1f490635_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e66e074cc0484bb09293c2d0e5387e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51deec1b5b1a4ffbadb9e0abc2bf9307_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7480c05016014e139e36eb2b979873e3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a12590988ac4caeaf1fbdb0caf12c50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b87c87bafd747c68f3308bdf2b646b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5634d11ca74ea5af6b94a23678fe55_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a1ed4e577d4643b2128afb0f146b35_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197589a15f2e48f3bd5253b3634b8a2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6db360f0cd94810bf55adb667501e93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8953ddf05c074e5f87682037915661be_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77531b3a80ec4e3db6cebfc5913221da_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681c4e2421fb4a899d60ff0568080be8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ec68701cc14e0f8f6ef79be8cba10e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30d45a724314df6954c76e688a98335_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54a4ca20a1f484298d307aee478cb00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida70ce761b0a4a9abdcb51468b1da149_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03261902b5dc4073ae6a6577c04bb346_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ed6b5c044b44be8ffdeed43f3cb411_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e744f26fdbd4b499f10d72b19177ab2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d4ad8a15ed48bcb33632d14c4c6264_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be72db3712d4da0b435716421f1fbf7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe4fcb8c9074698941c54291c494471_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80bf4c2fae84eec92800503e7eb93b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26309d6272d64a7fba7afe8b3b07827b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1515bf37fb46d2b516dba8cd589e89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c291d86eea247ea9a5865cade31456c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbfca06b90041849cfc691d6f2cdcdd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebeaf99e4a1d4bceb36a747c6b3e139b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bcd1287d5c2475cb24e77ab4fa0658a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0c448b7df4944588d513ed2e91cc958_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea1073cf01244476bfda2869a55121f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7698a3afbd87428f86f0f8054fe5e279_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i617770866c9d4c829c27635c3e97c236_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505e0a1800cb4556b5eb673f1dfc4a33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8af54e95f4451d8430cc22433b5edf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a9406845944bb7a2fd7d973f3a9d1f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd312c6ba714cecbedcc9a7366b852d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f649bf31fa46b39e37b5bbdb7840aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60682002d9fe4c8a8fd6083bda3281ed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice356b14a6ad46418365ea9bb55cb102_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f6d8c5bfbe43ea902f7cce7547af44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f8ca3795ab84ff48b77c6fa70f7cffc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if482bee327734fda9fa6f722e7d953b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2e22a11988949b88c13fe1e17f2b78a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0794dfa269ce44c7890d47b9989dd683_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b258a143a242c6b252146d74dbac1d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a98ae870914b948c565659e918f453_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefba66a377874ba2b44b702df3e1d749_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec35638b37649b895fe6f1af825d879_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f1ca9ec329841abb944f3c69f76e638_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife5efa30ffc24b3ca056dde5eb034cf2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a448ec43a2749f1bb446aa74a3bed8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10456cbffc5448993342502159c294a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bdaeae1c70b40aaa1e3b158b17ef808_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedbc88ea95514451917cf053f720e3ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f58bf19d1640f8a24c1ab656bd7e18_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae8c44fbfd54215a8cb3d32bf50788d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc958ec611e402d89f8dba65cf34f21_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide81cf5396514fa28192d55d76c92ed8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeda3b83cc1345dab64a83c66a84ee67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d25683f4f6841718c7e93350d0d5a67_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629bc23e5a69421a92ee3560e059c642_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e77126574f42bb96d0bb8e53774cd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613d1486fc28474c8acbd3dda55239ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fe4630cc947444b83450d5ccf9a3062_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293647d3e306407ebf8717a4faa018af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc9b30cdb6f46cf84ff8676fca96daf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49136d6485e4f27b3b68f218f591205_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3c8d57174c4ba09a7ae459144cccc8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd8810addb24069affe76f94ec0a5be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c464d5e9ce4a76ba55304fc35bee88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e30185203174bacaee8e9bba03bd862_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib909438afce24a8780c7df58861bb88f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib609b96d8c4c45d1a0af8c7f1afebe6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99e22750ba14129b0cd8b6a97dad49c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f10dba5ec404300bd6208a5fc3914aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec7cb4b83004d9a983d8127e07e2b2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5eeb8fa10948649d5874f868693a1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd6baf002c54d9a9da34f801bd78e3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338443af5bd847189e38c92ac1ec921e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5884d63fe366495081e710da8a78d315_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6da244d9d94c518f93764d97f2d35a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9b9cf8c9aa4481bb00fc5b21378b37_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc50a7e8a028404c9337837900c373c8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51698f086f24b71b9570d9313720f9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc622e652dab409a966bb1005b97fb12_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8283275c2880459b937b5ba98b866084_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2cf47d7044f4adba5964039483ad7f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f0ead2a04c463ebca54852c312306b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4466289ff2147e2b0ad5ba8dad1504d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3e907a5d5f345568c0c95ad777ef996_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08fdb9e60bb54154be013bfb3b99ed37_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552cf9a2dba34015bca9ef712e555836_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc13214640dd49aea3a6f573732950f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i183853257a9744bda89e18492b5adce3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ff9b6d884c4cd4ad827974b7a04cac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38ff4e18c854e00bd319922ef36c8fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e83011764347d1b6364b08e35f618b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c361862132d4c12a3df559d1247ce11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa9b80b3f7d4f2ca54fe62d484ad6ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic322d64f24e846d9afd0e3dba16e24cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ae64bb8a33446faaac7873a35016cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91629c66e76841e49ac8fdbce3d95883_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea2621b38e949de95e267f3fa6822d5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa77411ccf241218037cc5cd351cba4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf36505cfcb544e6bc2016ef576a5a96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40150bacb004b09aa1761eea6e209fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fcc4830492c4d41b40fdd59f5359d79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79561000ee344c4bc43f4af90649a06_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0761d7789524bce842b332f0db014bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8bed311c094329b4d745c12c4a5cc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a1ca67f428141cebc70732cebff9521_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e6f6f6fd524dd69fe636e2947bdfa1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c259a7a44a4b05a2c75e4dbb68b616_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d6f7b78017c4b1aae8ad926d48e6a38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i990a4dc4b81240de8e34aeaaf52eb1ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3d395096a04f008b6ad61b7397f8a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4387d3b03f47fb943aef0ec03b900b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7753d0b2864abf84b4f0352e03b254_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a96ab2adc74657a7fc0400faed593c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f891fe0d78a4c3bbd5bda2518e4ea4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cfe13e7da014c61bc807c8e56ec5f0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b3d413326442638d0877fd2e9e29a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bed06c5b34b488ea2f844c3779949d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86879f1d260a48b2b3fc2ba0929452ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe4eeaab037443a9c7ca2df4c70ad71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc3747831fa47ea8edcca64589a2d04_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b0483a589fe4ef9a10b6defdb741d26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i180972d620b04773bac120852a0a31db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20844159d5914e56aaeb01e98bfffaad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic398861a5e604978a3c98fc5841e68cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531ac966525143049c09ffd864bcbafa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8ac6036c8646999d891c258acab031_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbc57c3e1584457acadc54ca8ee0f09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a777627607f4c4abb9584a4411dbf0d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i890f308e305745e993afb171875461d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56526eb7b6df403d980ccad23c43f766_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d93056d1c2487eb95a4a49fc8d01a3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4894c9df276a4645b9f3fd98b62ebacb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c8a2d41e93427ab955bd22bcf78ae0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2119c2582b0b42a289d1ca7e693a7795_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74dc6f5dabd64668b9cecba5fe18fa39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6688637b104f45498e4d1adcc1dff8f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d257fa44324b53a1ef7ca1720ac517_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2554a55ac3e445b4b77f581e924fa49e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5f83c1f72f44e1be95132b049ae22c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i963120dbdfdb4d71a1491aa18697e865_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c6c6b918224b0b9941f8fdd4403701_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e5c6c625744b5397f0c31a5173824d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb094efcfafa4c4b90bf422d01d01cf6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218fada0b11b421db5b8600c0019d4f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c439560c469498ca75bab3229912fed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id26f89beeaae4c7f931c5d4d81ab0bc1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337d955832ba4199a0df850ea23b5676_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0fa7b9aa8d4e40bc457315bc042e44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd8a7e5fe48142d5a2a4a1449d7e5fd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a2c421146a4685b24d4d63dc874137_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31df7669833c47408aded7bcb0d91766_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2ea2b06d674eb997a7ca0ea9ee4f84_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ff1d1758224e68b457056f4c1aa244_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71007b7779374d738c052de5ee0be00c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ada1ec00a9474b86440d7e3fe85a61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if194957d47c14626990ac7579d8a2860_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if379b668eb4a408d857cc08dbfb7cda2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343efbd897d7479798adb44173aabdef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba066b9bf1844c0e995daa549acba43e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4556e60ce4f74c22ad0cb51ba398629d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb44034bd361427c89ea4308da4aa6cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4158ddf9b78a40c0b069dad583f960ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51d2c4b860046aaae61f55468059f18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7f372308b340f7ba087719099057d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4aab7a7520412f993065e092f416c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3e56752d724c438792f86d2f774c4c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f295cd4f0de410cbcd6deb71260cc77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96716f25cfcd4ea78877e455aa3addec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb33bfd647d4010a30f8e7417dfba4c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec693e2b56e5450795dee9a8f5b1fd7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd89273ea4c4e4086ce9cefe2ab8a36_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4713191775b44625bd8480c87097307a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7771fa9d00e456f945808f5b1350a86_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840fe2106741497387f3e41d6c0fbd82_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad74c169614459ebd6a2feba9923acc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i923e47ae0d0a44b59c583a5e9fa3fa54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0e54bbc4e1406baa90d17d42691c90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b2e025a9ae49f6b693fe2b2b301a7f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5bcd741098644d6bdebda5470bbbf63_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia689dc2ff1e4458792332eba5e96c16b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884402da04444fdfa741b60ec14e6df6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22a7046c70e4bfb87b82cb904893496_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i886f7113739342fe9e0a88000b89520c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc938ddcd1a435c9cf8105a8ddbd1d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998005d150c24a6bb8ccdcd6c0251302_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b79a3305ac435cb2d4da9934529da6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0045db94c49d4a67a671551c92f63b4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied160c449f26454885073f7135732aeb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8284319e3a8f41c5bf0824118bcb2446_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1e166e6f2f4a579b637ff0e714bbbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id876bec63a044a438106d7fc364c0be2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047342a7dd6a464e8f2c160368b133c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8cb013593b44a96a79cd5ac26f510cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3e683e533014f74b1427b3564e847c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad4d8d7f0ad4e40bc7dda4d86aae1fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c971a16db240a29a2f4b213472c027_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f1ccd890df4f68b103d447a8e62b07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269ce30010de4d15b4e17a5aedff6cd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8211b4d2d96b4d6e924cc16fb296c131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fcf7b65ffe347b797e561991df21993_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ccffe7157345caa23575cf77dbeed0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1820461e7a084ed6a964f1b3b8d8d802_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0faa095bd4a45aba5e98f155fde2079_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5bba0a77af4a8783702f2047952acc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fae4d6107f488b8909bcca3be91c69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c06014407b8411a91506d49df92a824_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic251c7f3bb4e47e08296afcc17172e83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e3b8649d7640388a5c9c721c08642e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d9802536b44e179a60195bfc87b3da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123ba3f4a40d493d9ae8d39e4a5ef78f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c691cc03ca947218df95a3a774da470_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd56b99f7e44e7ab521fd0a98e8b8c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6d999cecc9424eaed8887c265ddf14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ee703bcc3304d2199a268dbca3b2a98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id490c58a5ad24c1ea00c4115bb016c7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a8eb31fe5a4c7e8d7672a9f0861b87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525155431d7c4ed0a672cb8897ee553b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa316713ea647e5a80b2ef8e8cc5435_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia384118d157240e09e39541b90e2080f_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As filed with the Securities and Exchange Commission on February&#160;24, 2023 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.985%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">WASHINGTON, D. C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:700;line-height:120%">_________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjUz_61990af7-6ce9-40f4-9474-7a19cc6c4ea6">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(MARK ONE)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.550%"><tr><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6YTcyMTIyNTdlZTFjNDk2MDhlMDcxZWZiMjdkNzBkNGMvdGFibGVyYW5nZTphNzIxMjI1N2VlMWM0OTYwOGUwNzFlZmIyN2Q3MGQ0Y18wLTEtMS0xLTcxMzMw_382b9996-bccd-4ed8-ba68-e733b9972af2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Annual Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="padding-left:144pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yMjU_2bd1c9d4-fb35-4bed-b58e-8dd1c218e01b"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yMjU_fc375326-af69-454b-81d5-a36e72fe6826">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.550%"><tr><td style="width:0.1%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6MzY0YzNkYzc1MzBjNDUwYWEzMzAxZTQ1MzNmOTA1YjAvdGFibGVyYW5nZTozNjRjM2RjNzUzMGM0NTBhYTMzMDFlNDUzM2Y5MDViMF8wLTEtMS0xLTcxMzMw_c229c0f3-90a2-4f63-af33-49e3aad47512">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="padding-left:144pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU0_f490895b-a474-445b-bb8d-e530e902a82a">1-6571</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><img src="mrk-20221231_g1.jpg" alt="mrk-20221231_g1.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:110px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU5_bc0a1e2e-ea8c-4f6e-9856-7242d97447ab">Merck&#160;&amp; Co., Inc.</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.637%"><tr><td style="width:1.0%"></td><td style="width:20.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18wLTAtMS0xLTcxMzMw_e98dfca4-1fa5-4399-b4d8-6837193636c4">126 East Lincoln Avenue</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18xLTAtMS0xLTcxMzMw_59afaf19-02dc-40a1-a56b-555715dd0306">Rahway</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18xLTItMS0xLTcxMzMw_63c11685-461f-48cd-aed9-53be48546ef3">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18xLTMtMS0xLTcxMzMw_194a4b3d-82a1-4b27-ae7d-f21f76cf4dc3">07065</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU1_416a8c5c-2f29-4fd1-a39c-ded74b3e418e">908</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjYw_12d3ce63-76cd-4d39-9be5-28bda02fe93e">740-4000</ix:nonNumeric> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:48.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6MmUwMzVhNDBkM2E2NGZhYTg3NmIwZWJlN2I1NTIzNzYvdGFibGVyYW5nZToyZTAzNWE0MGQzYTY0ZmFhODc2YjBlYmU3YjU1MjM3Nl8wLTAtMS0xLTcxMzMw_3718d436-3b8c-448e-862a-731ffb9f7077">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6MmUwMzVhNDBkM2E2NGZhYTg3NmIwZWJlN2I1NTIzNzYvdGFibGVyYW5nZToyZTAzNWE0MGQzYTY0ZmFhODc2YjBlYmU3YjU1MjM3Nl8wLTEtMS0xLTcxMzMw_2b232619-6695-4ff5-9325-2819add2e7db">22-1918501</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(I.R.S Employer Identification No.)</span></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:35.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of Each Exchange on which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8yLTAtMS0xLTcxMzMw_f637ec7a-955b-4477-a642-adcffae15c7f">Common Stock ($0.50&#160;par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8yLTEtMS0xLTcxMzMw_3d25a962-c133-4f7f-b70e-504937bcbe27">MRK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8yLTItMS0xLTcxMzMw_f5dd7a6e-196b-4357-8536-5489c508e5c6">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8zLTAtMS0xLTcxMzMw_45617156-244b-4516-bd1f-cc4dcaf17be4">0.500% Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8zLTEtMS0xLTcxMzMw_daeb3fcf-3b18-4761-931a-dcb2585749c2">MRK 24</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8zLTItMS0xLTcxMzMw_bf0ffb16-0eb8-4e50-acad-ac0670073763">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF80LTAtMS0xLTcxMzMw_11aa1a32-83c0-4d79-a637-fd4db052f90c">1.875% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF80LTEtMS0xLTcxMzMw_e0d3933d-687c-49f6-a869-e0cec883eb74">MRK/26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF80LTItMS0xLTcxMzMw_0e1512be-be9d-4789-8a50-d90884bad251">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF81LTAtMS0xLTcxMzMw_4b553c17-09ad-47f7-a4b1-2257e3fff758">2.500% Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF81LTEtMS0xLTcxMzMw_37f6bf8f-ea20-4a76-ad12-cd800b4c4629">MRK/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF81LTItMS0xLTcxMzMw_d21df653-9c7a-421a-b28e-49167db7dfdd">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF82LTAtMS0xLTcxMzMw_782671a8-3db7-40b1-b8de-e7794b0e84d7">1.375% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF82LTEtMS0xLTcxMzMw_56fe9c65-49ae-4fcf-8b3e-7c49e0cf5ee0">MRK 36A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF82LTItMS0xLTcxMzMw_0a5f6490-6015-4d43-99a6-eb5b9f3644b8">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">   &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU4_16ac8bb4-c48f-4968-bbb4-c45a26a78b63">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">No </span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Yes </span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU2_e80dac77-5ed7-460b-9ab7-778eb40fc8ad">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjUx_cea1903a-69c4-44c5-91d2-28eaf71fbcff">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">No</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjYx_fce71f24-cf96-4f78-b9bc-2d6b8d2f2464">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">No</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check One):</span></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.289%"><tr><td style="width:1.0%"></td><td style="width:20.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWE0Njc1ZjJlYzE3NDE4YzlkNTA5NTgwMTVmODdjOWIvdGFibGVyYW5nZTo5YTQ2NzVmMmVjMTc0MThjOWQ1MDk1ODAxNWY4N2M5Yl8wLTAtMS0xLTcxMzMw_66f40c1b-cc09-4ba6-9f04-41f232345725">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWE0Njc1ZjJlYzE3NDE4YzlkNTA5NTgwMTVmODdjOWIvdGFibGVyYW5nZTo5YTQ2NzVmMmVjMTc0MThjOWQ1MDk1ODAxNWY4N2M5Yl8xLTMtMS0xLTcxMzMw_00d3fd55-fb4b-42bf-8e38-535d6e8727db">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWE0Njc1ZjJlYzE3NDE4YzlkNTA5NTgwMTVmODdjOWIvdGFibGVyYW5nZTo5YTQ2NzVmMmVjMTc0MThjOWQ1MDk1ODAxNWY4N2M5Yl8yLTMtMS0xLTcxMzMw_aac6ec11-642c-4ffe-9846-11090b176293">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744; </span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjYy_ab8eca54-9136-48be-863d-046eb3d29044">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  &#9744; </span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#167;240.10D-1(b).  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Yes&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> &#160;No&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjUy_6ed5301b-f4e2-4377-aa96-9f68c3ab6e49">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of shares of Common Stock ($0.50&#160;par value) outstanding as of January&#160;31, 2023: <ix:nonFraction unitRef="shares" contextRef="ic48140e5f2c345cd8c115278efdfc4d5_I20230131" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8xMDk5NTExNjM5NTg1_5089beba-9fde-4d7b-bd99-04a8d19704d9">2,538,592,467</ix:nonFraction>.</span></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Aggregate market value of Common Stock ($0.50&#160;par value) held by non-affiliates on June&#160;30, 2022 based on the closing price on June&#160;30, 2022: $<ix:nonFraction unitRef="usd" contextRef="i988d9636bde7433d8e2793b8bbe786ff_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8xMDk5NTExNjM5NzA5_35ce4d2b-4c9b-4481-bb48-0351c220ba7a">230,820,000,000</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.574%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Documents Incorporated by Reference:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Part of Form 10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6YzliZjVhYjcxNGNiNDM3ZTg5NWFhOGEzNDY0MDJlZDAvdGFibGVyYW5nZTpjOWJmNWFiNzE0Y2I0MzdlODk1YWE4YTM0NjQwMmVkMF8yLTAtMS0xLTcxMzMw_a22d0a7c-2a21-4d19-bc55-dc70698eae23" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023, to be filed with the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report</span></div></ix:nonNumeric></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Part&#160;III</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_10">Part&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_52">24</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_55">Cautionary Factors that May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_55">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_58">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_58">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_61">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_61">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_64">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_64">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_67">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_67">39</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_70">Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_70">40</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_73">Part&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_76">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_76">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6. </span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_2209">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_2209">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_79">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_121">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_124">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_124">71</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_127">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_127">71</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_142">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_142">75</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_208">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_208">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_214">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_214">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_217">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_217">130</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_220">Management&#8217;s Report</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_220">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_223">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_223">131</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_226">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_226">131</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_223">Part&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_232">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_232">132</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_235">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_235">132</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_238">Security Ownership of Certain Beneficial Owners and Management and Related</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_238"><br/></a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_238">Stockholder&#160;Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_238">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_241">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_241">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_244">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_244">133</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_247">Part&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_250">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_250">134</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#3030ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3030ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_262">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_262">138</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_265">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia384118d157240e09e39541b90e2080f_265">139</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ia384118d157240e09e39541b90e2080f_13"></div><div style="padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.51pt">Business.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company&#8217;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off (the Spin-Off) of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or services marks are those of their respective owners.</span></div><div id="ia384118d157240e09e39541b90e2080f_19"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Company sales, including sales of the Company&#8217;s top pharmaceutical products, as well as sales of animal health products, were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,897</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,550</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt">Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt">Other revenues are primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceutical</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. Certain of the products within the Company&#8217;s franchises are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Oncology</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab), the Company&#8217;s anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors), including MSI-H/dMMR colorectal cancer (CRC), MSI-H/dMMR advanced endometrial carcinoma, primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and non-squamous NSCLC, in combination with chemotherapy for HNSCC, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with platinum-and fluoropyrimidine-based chemotherapy for esophageal or GEJ carcinoma, in combination with chemotherapy, with or without bevacizumab, for advanced cervical cancer, in combination with chemotherapy for locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), and in combination with axitinib for advanced renal cell carcinoma (RCC). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also approved for certain patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also approved as a monotherapy for the adjuvant treatment of certain patients with RCC, for certain patients with completely resected stage IIB, IIC or III melanoma, and for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a &#8805;4 cm), II, or IIIA NSCLC. In addition, the Company recognizes alliance revenue related to sales of Lynparza (olaparib), an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor, for certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic, and metastatic castration-resistant prostate cancers; alliance revenue related to sales of Lenvima (lenvatinib), an oral receptor tyrosine kinase inhibitor, for certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for certain patients with advanced endometrial carcinoma or advanced RCC; and alliance revenue related to Reblozyl (luspatercept-aamt) for the treatment of certain types of anemia.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Vaccines</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to help prevent certain diseases caused by certain types of human papillomavirus (HPV);</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> ProQuad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M&#8722;M&#8722;R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaqta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (hepatitis A vaccine, inactivated) indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Hospital Acute Care</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection, a medication for the reversal of two types of neuromuscular blocking agents used during surgery; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(letermovir) for the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Dificid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fidaxomicin) for the treatment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">C. difficile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">-associated diarrhea; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Primaxin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (imipenem and cilastatin) for injection, an antibiotic for the treatment of certain bacterial infections; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (posaconazole), an antifungal agent for the prevention of certain invasive fungal infections; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Invanz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ertapenem) for injection, an antibiotic for the treatment of certain bacterial infections; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cancidas</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (caspofungin acetate) for injection, an anti-fungal agent for the treatment of certain fungal infections; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Cardiovascular</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adempas (riociguat), a cardiovascular drug for the treatment of chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension in certain patients; Verquvo (vericiguat), a medicine to reduce the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in certain adults with symptomatic chronic heart failure and reduced ejection fraction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Virology</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, an investigational oral antiviral COVID-19 medicine available in the U.S. under Emergency Use Authorization (EUA);</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Neuroscience</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Belsomra </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(suvorexant), an orexin receptor antagonist, indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Immunology</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (infliximab), a treatment for inflammatory diseases, both of which the Company markets in Europe, Russia and T&#252;rkiye.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Diabetes</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin/metformin HCl) for the treatment of type 2 diabetes.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Animal Health</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as an extensive suite of digitally connected identification, traceability and monitoring products. Principal products in this segment include:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Livestock Products</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Nuflor</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Florfenicol) antibiotic range for use in cattle and swine; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bovilis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vista</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> vaccine lines for infectious diseases in cattle; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Banamine</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Flunixin meglumine) bovine and swine anti-inflammatory; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Estrumate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (cloprostenol sodium) for the treatment of fertility disorders in cattle; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Matrix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (altrenogest) fertility management for swine; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Resflor</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (florfenicol and flunixin meglumine)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a combination broad-spectrum antibiotic and non-steroidal anti-inflammatory drug for bovine respiratory disease; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zuprevo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Tildipirosin) for bovine respiratory disease; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zilmax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (zilpaterol hydrochloride) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revalor</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (trenbolone acetate and estradiol) to improve production efficiencies in beef cattle; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Safe-Guard</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fenbendazole) de-wormer for cattle; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M+Pac&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mycoplasma Hyopneumoniae Bacterin) swine pneumonia vaccine; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Porcilis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Lawsonia intracellularis baterin) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Circumvent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Porcine Circovirus Vaccine, Type&#160;2, Killed Baculovirus Vector) vaccine lines for infectious diseases in swine; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Nobilis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Innovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Live Marek&#8217;s Disease Vector)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> vaccine lines for poultry; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Paracox</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Coccivac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> coccidiosis vaccines; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Exzolt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a systemic treatment for poultry red mite infestations; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Slice</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Emamectin benzoate) parasiticide for sea lice in salmon; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Aquavac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Avirulent Live Culture)/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Norvax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> vaccines against bacterial and viral disease in fish; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compact PD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> vaccine for salmon; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Aquaflor</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Florfenicol) antibiotic for farm-raised fish; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Allflex Livestock Intelligence</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> solutions for animal identification, monitoring and traceability.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Companion Animal Products</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a line of oral and topical parasitic control products, including the original </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner) products for dogs and cats that last up to 12 weeks; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(fluralaner)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> One-Month</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a monthly product for dogs, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Plus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner/moxidectin), a two-month product for cats; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sentinel,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> a line of oral parasitic products for dogs including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sentinel Spectrum</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (milbemycin oxime, lufenuron, and praziquantel) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sentinel Flavor Tabs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (milbemycin oxime, lufenuron); </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Optimmune </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(cyclosporine), an ophthalmic ointment;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Nobivac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> vaccine lines for flexible dog and cat vaccination; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Otomax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Gentamicin sulfate, USP; Betamethasone valerate USP; and Clotrimazole USP ointment)/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Mometamax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Gentamicin sulfate, USP, Mometasone Furoate Monohydrate and Clotrimazole, USP, Otic Suspension)/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Posatex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Orbifloxacin, Mometasone Furoate Monohydrate and Posaconazole, Suspension) ear ointments for acute and chronic otitis; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Caninsulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vetsulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (porcine insulin zinc suspension) diabetes mellitus treatment for dogs and cats; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Panacur</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fenbendazole)/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Safeguard</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fenbendazole) broad-spectrum anthelmintic (de-wormer) for use in many animals; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Regumate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (altrenogest) fertility management for horses; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prestige</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> vaccine line for horses; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Scalibor</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Deltamethrin)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">/Exspot</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for protecting against bites from fleas, ticks, mosquitoes and sandflies; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sure Petcare</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> products for companion animal identification and well-being, including the microchip and pet recovery system </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Home Again</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For a further discussion of sales of the Company&#8217;s products, see Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; below.</span></div><div id="ia384118d157240e09e39541b90e2080f_22"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022 Product Approvals</span></div><div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Set forth below is a summary of significant product approvals received by the Company in 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approval</span></td></tr><tr style="height:45pt"><td colspan="3" rowspan="7" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">European Commission (EC) approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Japan&#8217;s Ministry of Health, Labor and Welfare (MHLW) approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> plus Lenvima for radically unresectable or metastatic RCC.</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MHLW approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care).</span></div></td></tr><tr style="height:54pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">U.S. Food and Drug Administration (FDA) approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. </span></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1.</span></div></td></tr><tr style="height:45pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> as monotherapy for the treatment of certain patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial carcinoma.</span></div></td></tr><tr style="height:44pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence.</span></div></td></tr><tr style="height:74pt"><td colspan="3" rowspan="7" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2022<br/></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection. Additionally, EC approved expanded indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.</span></div></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022<br/></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> as monotherapy for the adjuvant treatment of certain patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.</span></div></td></tr><tr style="height:44pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and HER2-negative breast cancer at high risk of recurrence.</span></div></td></tr><tr style="height:44pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022<br/></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment.</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> as monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection.</span></div></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2022</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">China&#8217;s National Medical Products Administration (NMPA) approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Keytruda </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">as monotherapy for the treatment of patients with HCC who have been previously treated with sorafenib or oxaliplatin-based chemotherapy.</span></div></td></tr><tr style="height:45pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NMPA approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> for the treatment of patients with high-risk early-stage TNBC whose tumors express PD-L1, in combination with chemotherapy as neoadjuvant treatment, and then continued as a monotherapy as adjuvant treatment after surgery.</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-bottom:3pt;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">NMPA granted emergency conditional approval for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19.</span></div></td></tr><tr style="height:45pt"><td colspan="3" rowspan="5" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">FDA approved Lynparza for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. </span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approved Lynparza for the adjuvant treatment for patients with</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-mutated, HER2-negative high recurrent risk breast cancer.</span></div></td></tr><tr style="height:45pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approved Lynparza as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. </span></td></tr><tr style="height:63pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">NMPA approved Lynparza as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.</span></td></tr><tr style="height:45pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approved Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. </span></td></tr><tr style="height:65pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance<br/></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2022</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">FDA approved an expanded indication for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through 17 years of age. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. </span></div></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Vaxneuvance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">for prevention of infections caused by Streptococcus pneumoniae in the elderly or adults who are considered at increased risk for disease caused by Streptococcus pneumoniae.</span></div></td></tr><tr style="height:44pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approved an expanded indication for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Vaxneuvance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.</span></div></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Being jointly developed in collaboration with Ridgeback Biotherapeutics LP.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Being jointly developed and commercialized in a worldwide collaboration with </span><span style="color:#1a1a1a;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div id="ia384118d157240e09e39541b90e2080f_25"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Competition and the Health Care Environment</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The markets in which the Company conducts its business and the pharmaceutical industry in general are highly competitive and highly regulated. The Company&#8217;s competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers, and animal health care companies. The Company&#8217;s operations may be adversely affected by generic and biosimilar competition as the Company&#8217;s products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors&#8217; branded products, and new information from clinical trials of marketed products or post-marketing surveillance. In addition, patent rights are increasingly being challenged by competitors, and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical competition involves a rigorous search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well-positioned to compete in the search for technological innovations. The Company is active in acquiring and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">marketing products through external alliances, such as licensing arrangements and collaborations and has been refining its sales and marketing efforts to address changing industry conditions. However, the introduction of new products and processes by competitors may result in price reductions and product displacements, even for products protected by patents. For example, the number of compounds available to treat a particular disease typically increases over time and can result in slowed sales growth or reduced sales for the Company&#8217;s products in that therapeutic category.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The highly competitive animal health business is affected by several factors including regulatory and legislative issues, scientific and technological advances, product innovation, the quality and price of the Company&#8217;s products as well as competitors&#8217; products, effective promotional efforts and the frequent introduction of generic products by competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Health Care Environment and Government Regulation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access. Changes to the U.S. health care system as part of health care reform enacted in prior years, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s sales performance in 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect sales and profits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company faces increasing pricing pressure from managed care organizations, government agencies and programs that could negatively affect the Company&#8217;s sales and profit margins, including, through (i) practices of managed care organizations, federal and state exchanges, and institutional and governmental purchasers, and (ii) federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the Patient Protection and Affordable Care Act of 2010 (ACA), the American Rescue Plan Act of 2021 (American Rescue Plan Act), and the Inflation Reduction Act of 2022 (Inflation Reduction Act).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., federal and state governments for many years have pursued methods to reduce the cost of drugs and vaccines for which they pay. For example, federal and state laws require the Company to pay specified rebates for medicines reimbursed by Medicaid and to provide discounts for medicines purchased by certain state and federal entities such as the Department of Defense, Veterans Affairs, Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally in the U.S., consolidation and integration among health care providers is a major factor in the competitive marketplace for pharmaceutical products. Health plans and pharmacy benefit managers (PBMs) have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, employ formularies to control costs by negotiating discounted prices in exchange for formulary inclusion. Failure to obtain timely or adequate pricing or formulary placement for Merck&#8217;s products or obtaining such placement at unfavorable pricing could adversely affect revenue. In addition to formulary tier co-pay differentials, private health insurance companies and self-insured employers have been increasing the cost-sharing required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. Private health insurance companies also are increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. These same management tools are also used in treatment areas in which the payor has taken the position that multiple branded products are therapeutically comparable. As the U.S. payor market concentrates further, the Company may face greater pricing pressure from private third-party payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to provide information about the Company&#8217;s pricing practices, the Company annually posts on its website its Pricing Transparency Report for the U.S. The report provides the Company&#8217;s average annual list price, net price increases, and average discounts across the Company&#8217;s U.S. portfolio dating back to 2010. In 2022, the Company&#8217;s gross U.S. sales were reduced by 39.7% as a result of rebates, discounts and returns. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Legislative Changes</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The long-term implications of the Inflation Reduction Act remain uncertain and subject to various factors, including the manner in which U.S. Department of Health and Human Services decides to implement the statute. Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time. Merck is working to mitigate the potentially harmful effects that the law could have on innovation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, in 2021, Congress passed the American Rescue Plan Act, which included a provision that eliminates the statutory c</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, beginning in 2024, it is possible that manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change could present a risk to Merck in the future for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also faces increasing pricing pressure in the states, which are looking to exert greater influence over the price of prescription drugs. A number of states have passed pharmaceutical price and cost transparency laws. These laws typically require manufacturers to report certain product price information or other financial data to the state. Some laws also require manufacturers to provide advance notification of price increases. The Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price control tools such as Prescription Drug Affordability Boards that have the authority to conduct affordability reviews and establish upper payment limits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Changes</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2020, the Department of Health and Human Services Office of Inspector General issued a Final Rule that would have, effective January 1, 2023, eliminated the Anti-Kickback Statute safe harbor for rebates paid to Medicare Part D plans or to PBMs on behalf of such plans. Congress has delayed implementation of this Final Rule until January 1, 2026 and pending federal legislation would repeal it entirely. While the Company cannot anticipate the effects of this change to the way it currently contracts, this new framework could significantly alter the way it does business with Part D Plan Sponsors and PBMs on behalf of such plans. This rulemaking also established, effective January 1, 2021, a new safe harbor for point of sale discounts at the pharmacy counter and a new safe harbor for certain service arrangements between pharmaceutical manufacturers and PBMs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The pharmaceutical industry also could be considered a potential source of savings via other legislative and administrative proposals that have been debated but not enacted. These types of revenue generating or cost saving proposals include additional direct price controls. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">European Union</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Efforts toward health care cost containment remain intense in the European Union (EU). The Company faces competitive pricing pressure resulting from generic and biosimilar drugs. In addition, a majority of countries in the EU attempt to contain drug costs by engaging in reference pricing in which authorities examine pre-determined markets for published prices of drugs. Reference pricing may either compare a product&#8217;s prices in other markets (external reference pricing), or compare a product&#8217;s price with those of other products in a national class (internal reference pricing). The authorities then use the price data to set new local prices for brand-name drugs, including the Company&#8217;s drugs. Guidelines for examining reference pricing are usually set in local markets and can be changed pursuant to local regulations. Some EU Member States have established free-pricing systems, but regulate the pricing for drugs through profit control plans. Others seek to negotiate or set prices based on the cost-effectiveness of a product or an assessment of whether it offers a therapeutic benefit over other products in the relevant class. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In some EU Member States, cross-border imports from low-priced markets also exert competitive pressure that may reduce pricing within an EU Member State.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, EU Member States have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement. In the EU, pricing and reimbursement plans vary widely from Member State to Member State. Some EU Member States provide that drug products may be marketed only after a reimbursement price has been agreed. Some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to already available therapies or so-called health technology assessments (HTA), in order to obtain reimbursement or pricing approval. The HTA of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">most EU Member States. The HTA process, which is governed by the national laws of these countries, involves the assessment of the cost-effectiveness, public health impact, therapeutic impact and/or the economic and social impact of use of a given pharmaceutical product in the national health care system of the individual country in which it is conducted. Ultimately, HTA measures the added value of a new health technology compared to existing ones. The outcome of HTAs regarding specific pharmaceutical products will often influence the pricing and reimbursement status granted to these pharmaceutical products by the regulatory authorities of individual EU Member States. A negative HTA of one of the Company&#8217;s products may mean that the product is not reimbursable or may force the Company to reduce its reimbursement price or offer discounts or rebates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A negative HTA by a leading and recognized HTA body could also undermine the Company&#8217;s ability to obtain reimbursement for the relevant product outside a jurisdiction. For example, EU Member States that have not yet developed HTA mechanisms may rely to some extent on the HTA performed in other countries with a developed HTA framework, to inform their pricing and reimbursement decisions. HTA procedures require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some EU Member States, the Company may be required to conduct studies that compare the cost-effectiveness of the Company&#8217;s product candidates to other therapies that are considered the local standard of care. There can be no assurance that any EU Member State will allow favorable pricing, reimbursement and market access conditions for any of the Company&#8217;s products, or that it will be feasible to conduct additional cost-effectiveness studies, if required.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Japan</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricings for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. In addition, if a Merck product has the same medical action or composition of another product that is subject to market expansion re-pricing, the Merck product could also be subject to re-pricing unless it meets exception criteria. The next government-mandated price reduction will occur in April 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">China</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s business in China has grown rapidly in the past few years, and the importance of China to the Company&#8217;s overall pharmaceutical and vaccines business has increased accordingly. Continued growth of the Company&#8217;s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company&#8217;s current in-line products, and the absence of trade impediments or adverse pricing controls. In recent years, the Chinese government has introduced and implemented a number of structural reforms to accelerate the shift to innovative products and reduce costs. Since 2017, there have been multiple new policies introduced by the government to improve access to new innovation, reduce the complexity of regulatory filings, and accelerate the review and approval process. This has led to a significant increase in the number of new products being approved each year. While the mechanism for drugs being added to the government&#8217;s National Reimbursement Drug List (NRDL) evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2021, drugs were added to the NRDL with an average of more than 60% price reductions. A new NRDL was recently completed in which new entries averaged 60% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through volume based procurement (VBP). In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Emerging Markets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and measures impacting intellectual property, including in exceptional cases, threats of compulsory licenses, that aim to put pressure on the price of innovative pharmaceuticals or result in constrained market access to innovative medicine. The Company anticipates that pricing pressures and market access challenges will continue in the future to varying degrees in the emerging markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beyond pricing and market access challenges, other conditions in emerging market countries can affect the Company&#8217;s efforts to continue to grow in these markets, including potential political instability, changes in trade sanctions and embargoes, significant currency fluctuation and controls, financial crises, limited or changing availability of funding for health care, credit worthiness of health care partners, such as hospitals, and other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">developments that may adversely impact the business environment for the Company. Further, the Company may engage third-party agents to assist in operating in emerging market countries, which may affect its ability to realize continued growth and may also increase the Company&#8217;s risk exposure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addressing global cost containment pressures, the Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care. The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. In markets with historically low rates of health care spending, the Company encourages those governments to increase their investments and adopt market reforms in order to improve their citizens&#8217; access to appropriate health care, including medicines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Although no one can predict the effect of these and other factors on the Company&#8217;s business, the Company continually takes measures to evaluate, adapt and improve the organization and its business practices to better meet customer needs and believes that it is well-positioned to respond to the evolving health care environment and market forces.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Regulation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The pharmaceutical industry is also subject to regulation by regional, country, state and local agencies around the world focused on standards and processes for determining drug safety and effectiveness, as well as conditions for sale or reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Of particular importance is the FDA in the U.S., which administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling, and marketing of prescription pharmaceuticals. In some cases, the FDA requirements and practices have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. At the same time, the FDA has committed to expediting the development and review of products bearing the &#8220;breakthrough therapy&#8221; designation, which has accelerated the regulatory review process for medicines with this designation. The FDA has also undertaken efforts to bring generic competition to market more efficiently and in a more timely manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The EU has adopted directives and other legislation concerning the classification, approval for marketing, labeling, advertising, manufacturing, wholesale distribution, integrity of the supply chain, pharmacovigilance and safety monitoring of medicinal products for human use. These provide mandatory standards throughout the EU, which may be supplemented or implemented with additional regulations by the EU Member States. In particular, EU regulators may approve products subject to a number of post-authorization conditions. Examples of typical post-authorization commitments include additional pharmacovigilance, the conduct of clinical trials, the establishment of patient registries, physician or patient education and controlled distribution and prescribing arrangements. Non-compliance with post-authorization conditions, pharmacovigilance and other obligations can lead to regulatory action, including the variation, suspension or withdrawal of the marketing authorizations, or other enforcement or regulatory actions, including the imposition of financial penalties. The Company&#8217;s policies and procedures are already consistent with the substance of these directives; consequently, it is believed that they will not have any material effect on the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company believes that it will continue to be able to conduct its operations, including launching new drugs, in this regulatory environment. (See &#8220;Research and Development&#8221; below for a discussion of the regulatory approval process.)</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Access to Medicines</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a global health care company, Merck&#8217;s primary role is to discover and develop innovative medicines and vaccines. The Company also recognizes that, in collaboration with key stakeholders, it has a role to play in helping to ensure that its science advances health care, and its products are accessible and affordable. The Company is committed to ensuring a reliable, safe global supply of its quality medicines and vaccines, and to developing, testing and implementing innovative solutions that address barriers to access and affordability of its medicines and vaccines. The Company&#8217;s approach is designed to enable it to serve the greatest number of patients today, while meeting the needs of patients in the future. The Company&#8217;s efforts in this regard are wide-ranging and include a set of principles that the Company strives to embed into its operations and business strategies to guide the Company&#8217;s worldwide approach to expanding access to health care. The Company systematically evaluates its pipeline candidates to identify potential to address significant public health burden and unmet medical needs in underserved health care settings. Products continue to be evaluated for their potential throughout their life cycle to account for changes in the external environment. The Company also collaborates with different stakeholders, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">including private, governmental, multilateral and non-profit organizations, to design and deliver sustainable solutions to help address access challenges at the payer, provider and patient levels. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, through innovative social investments, including philanthropic programs and impact investing, Merck is helping to strengthen health systems and build capacity, particularly in under-resourced communities. The Merck Patient Assistance Program provides certain medicines and adult vaccines for free to people in the U.S. who do not have prescription drug or health insurance coverage and who, without the Company&#8217;s assistance, cannot afford their Merck medicines and vaccines. Globally, Merck has made substantial contributions to access to health through key initiatives, including product donations for humanitarian assistance in low-income countries through the Medical Outreach Program. The Mectizan Donation Program, the longest running disease-specific drug donation program of its kind, supports the elimination of two neglected tropical diseases &#8211; onchocerciasis and lymphatic filariasis. Additionally, through Merck for Mothers the Company provides funding, and scientific and business acumen to help global health partners end preventable deaths from complications of pregnancy and childbirth. Merck has also provided funds to the Merck Foundation, an independent grantmaking organization, which supports a variety of organizations dedicated to addressing systemic barriers to health equity.</span></div><div id="ia384118d157240e09e39541b90e2080f_28"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Privacy and Data Protection</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to a significant number of privacy and data protection laws and regulations globally, many of which place restrictions on the Company&#8217;s ability to transfer, access and use personal data across its business. The legislative and regulatory landscape for privacy and data protection continues to evolve. There has been increased attention to privacy and data protection issues in both developed and emerging markets with the potential to affect directly the Company&#8217;s business, including the EU General Data Protection Regulation (GDPR), which imposes penalties of up to 4% of global revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The GDPR and related implementing laws in individual EU Member States govern the collection and use of personal health data and other personal data in the EU. The GDPR increased responsibility and liability in relation to personal data that the Company processes. It also imposes a number of strict obligations and restrictions on the ability to process (which includes collection, analysis and transfer of) personal data, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities, and the security and confidentiality of the personal data. Further, the GDPR prohibits the transfer of personal data to countries outside of the EU that are not considered by the EC to provide an adequate level of data protection, including to the U.S., except if the data controller meets very specific requirements. Following the Schrems II decision of the Court of Justice of the EU in 2020, there is considerable uncertainty as to the permissibility of international data transfers under the GDPR. In light of the implications of this decision, the Company may face difficulties regarding the transfer of personal data from the EU to third countries. Since then, the Company diligently entered into the EU-approved Standard Contractual Clauses with its vendors, suppliers, collaboration partners and clinical trial sites in order to facilitate the lawful transfer of personal data from the EU to the U.S. In addition, President Biden issued an Executive Order on October 7, 2022 to address the data privacy concerns raised in the Schrems II decision through introducing, among other measures, further safeguards and oversight of personal data collection by U.S. signals intelligence activities and providing individuals with a redress mechanism in the U.S. for their data protection concerns. Further certainty for the international transfer of personal data from the EU via the EU-U.S. Data Privacy Framework (successor to the invalidated EU-U.S. Privacy Shield) may come by way of a new EU Adequacy Decision, issued in draft form by the EU Commission on December 13, 2022 and expected to come into force in mid-2023. However, it remains likely that such a new Adequacy Decision will be contested by privacy advocates and be subject to legal review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines and other administrative penalties as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices is often updated or otherwise revised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against the Company, harm to its reputation, and adversely impact its business and operating results. The uncertainty regarding the interplay between </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">different regulatory frameworks further adds to the complexity that the Company faces with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2021, China passed the Personal Information Protection Law (PIPL) that aims to standardize the handling of personal information in China which became effective in November 2021. The PIPL currently applies to the processing of personal information of natural persons in China, the processing of personal information outside China where the purpose is to provide products and services in China, and to analyze the activities of individuals in China. While similar to the GDPR, the PIPL contains unique requirements not found in the GDPR.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has developed and implemented comprehensive plans to ensure compliance with the PIPL, with those relating to data localization and cross-border transfers yet to be completed pending forthcoming guidance from the Cyberspace Administration of China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional laws and regulations enacted in the U.S. (such as comprehensive data protection acts in California, Virginia, Colorado, Utah and Connecticut), Canada, Europe, Asia, and Latin America, have increased enforcement and litigation activity in the U.S. and other developed markets, as well as increased regulatory cooperation among privacy authorities globally. The Company has adopted a comprehensive global privacy program to manage these evolving requirements and risks and to facilitate the transfer of personal information across international borders.</span></div><div id="ia384118d157240e09e39541b90e2080f_31"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Distribution</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, PBMs and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, physician distributors and government entities. The Company&#8217;s professional representatives communicate the effectiveness, safety and value of the Company&#8217;s pharmaceutical and vaccine products to health care professionals in private practice, group practices, hospitals and managed care organizations. The Company sells its animal health products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div id="ia384118d157240e09e39541b90e2080f_34"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patents, Trademarks and Licenses</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patent protection is considered, in the aggregate, to be of material importance to the Company&#8217;s marketing of its products in the U.S. and in most major foreign markets. Patents may cover products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">per se</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, pharmaceutical formulations, processes for, or intermediates useful in, the manufacture of products, or the uses of products. Protection for individual products extends for varying periods in accordance with the legal life of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent and its scope of coverage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Food and Drug Administration Modernization Act includes a Pediatric Exclusivity Provision that may provide an additional six months of market exclusivity in the U.S. for indications of new or currently marketed drugs if certain agreed upon pediatric studies are completed by the applicant. Current U.S. patent law provides additional patent term for periods when the patented product was under regulatory review by the FDA. The EU also provides an additional six months of pediatric market exclusivity attached to a product&#8217;s Supplementary Protection Certificate (SPC). Japan provides the additional term for pediatric studies attached to market exclusivity unrelated to patent term.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patent portfolios developed for products introduced by the Company normally provide market exclusivity. The Company has the following key patent protection in the U.S., the EU, Japan and China (including the potential for patent term extensions (PTE) and SPCs where indicated) for the following marketed products:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year of Expiration (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year of Expiration (EU)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year of Expiration (Japan)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year of Expiration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(China)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025-2026</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Janumet XR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Isentress</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023-2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Bravecto</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 (patents), 2029 (SPCs)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Gardasil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 (patents)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> 2030</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032-2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (patents), 2029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028-2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (patents), 2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (SPCs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adempas</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> (with pending PTE)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 (patents), 2029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(SPCs)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Verquvo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2035 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Vaxneuvance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No Patent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No Patent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Delstrigo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031 (patents), 2033 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Pifeltro</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031 (patents), 2033 (SPCs)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Recarbrio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(with pending PTE)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029 (patents), 2034 (SPCs)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034 (with pending PTE)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2035 (with pending PTE)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note:&#160;&#160;&#160;&#160;Compound patent unless otherwise noted.&#160;Certain of the products listed may be the subject of patent litigation. See Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221; below.</span></div><div style="margin-top:2pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">N/A:&#160;&#160;&#160;&#160;Currently no marketing approval.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">The EU date represents the expiration date for the following four countries: France, Germany, Italy, and Spain (Major EU Markets). If SPC applications have been filed but have not been granted in all Major EU Markets, both the patent expiry date and the SPC expiry date are listed.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">The PTE system in Japan allows for a patent to be extended more than once provided the later approval is directed to a different indication from that of the previous approval. This may result in multiple PTE approvals for a given patent, each with its own expiration date.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">As a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. before the end of 2023, and it is likely that exclusivity will extend through May 2026.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">Expiry date reflects the approved product and includes granted PTE for the 600 mg tablet in Japan.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">The Company has no marketing rights in the U.S., Japan or China.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">The distribution agreement with Janssen Pharmaceuticals, Inc. expires on October 1, 2024.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">Part of a global strategic oncology collaboration with Eisai Co., Ltd.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">Eligible for 6 months Pediatric Exclusivity.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.95pt">Part of a global strategic oncology collaboration with AstraZeneca.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.42pt">Being commercialized in a worldwide collaboration with Bayer AG.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.42pt">The Company has no marketing rights in the U.S.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(12)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.42pt">The Company has no marketing rights in the EU, Japan or China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has the following key U.S. patent protection for drug candidates under review in the U.S. by the FDA. Additional patent term may be provided for these pipeline candidates based on Patent Term Restoration and Pediatric Exclusivity.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Under Review in the U.S. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currently Anticipated<br/>Year of Expiration (in the U.S.)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MK-7264 (gefapixant)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also has the following key U.S. patent protection for drug candidates in Phase 3 development:&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 3 Drug Candidate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currently Anticipated<br/>Year of Expiration (in the U.S.)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MK-7962 (sotatercept)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MK-8591A (doravirine + islatravir)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2032 (pending PTE for doravirine)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MK-1308A (quavonlimab + pembrolizumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MK-7684A (vibostolimab + pembrolizumab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2035</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MK-4280A (favezelimab + pembrolizumab)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2035</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MK-1654 (clesrovimab)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MK-4482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">V-116 (pneumococcal vaccine)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:110%">MK-3475A (pembrolizumab + hyaluronidase subcutaneous)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2039</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt">As a biologic product, sotatercept will be eligible for 12 years of data exclusivity upon approval in the U.S. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt">Received Emergency Use Authorization from the FDA for the treatment of high-risk adults with mild to moderate COVID-19. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise noted, the patents in the above charts are compound patents. Each patent may be subject to a future patent term restoration of up to five years and six month pediatric market exclusivity, either or both of which may be available. In addition, depending on the circumstances surrounding any final regulatory approval of the compound, there may be other listed patents or patent applications pending that could have relevance to the product as finally approved; the relevance of any such application would depend upon the claims that ultimately may be granted and the nature of the final regulatory approval of the product. Also, regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a compound&#8217;s patent estate. In the U.S., the data protection generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication and 12 years from first marketing approval of a biological product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the expiration of a compound patent normally results in a loss of market exclusivity for the covered pharmaceutical product, commercial benefits may continue to be derived from: (i)&#160;later-expiring patents on processes and intermediates related to the most economical method of manufacture of the active ingredient of such product; (ii)&#160;patents relating to the use of such product; (iii)&#160;patents relating to novel compositions and formulations; and (iv)&#160;in the U.S. and certain other countries, market exclusivity that may be available under relevant law. The effect of product patent expiration on pharmaceutical products also depends upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions to market exclusivity are sought in the U.S. and other countries through all relevant laws, including laws increasing patent life. Some of the benefits of increases in patent life have been partially offset by an increase in the number of incentives for and use of generic products. Additionally, improvements in intellectual property laws are sought in the U.S. and other countries through reform of patent and other relevant laws and implementation of international treaties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For further information with respect to the Company&#8217;s patents, see Item&#160;1A. &#8220;Risk Factors&#8221; and Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide, all of the Company&#8217;s important products are sold under trademarks that are considered in the aggregate to be of material importance. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registration is for fixed terms and can be renewed indefinitely.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Royalty income in 2022 on patent and know-how licenses and other rights amounted to $537 million. Merck also incurred royalty expenses amounting to $3.0 billion in 2022 under patent and know-how licenses it holds.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s business is characterized by the introduction of new products or new uses for existing products through a strong research and development program. At December 31, 2022, approximately 19,200 people were employed in the Company&#8217;s research activities. The Company prioritizes its research and development efforts and focuses on candidates that it believes represent breakthrough science for unmet medical needs that will make a difference for patients and payers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a number of long-term exploratory and fundamental research programs in biology and chemistry as well as research programs directed toward product development. The Company&#8217;s research and development model is designed to increase productivity and improve the probability of success by prioritizing the Company&#8217;s research and development resources on candidates the Company believes are capable of providing unambiguous, promotable advantages to patients and payers and delivering the maximum value of its approved medicines and vaccines through new indications and new formulations. Merck is pursuing emerging product opportunities independent of therapeutic area or modality (small molecule, biologics and vaccines) and is building its biologics capabilities. The Company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, with a focus on supplementing its internal research through acquisitions as well as a licensing and external alliance strategy focused on the entire spectrum of collaborations from early research to late-stage compounds, as well as access to new technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s clinical pipeline includes candidates in multiple disease areas, including cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, respiratory diseases, and vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the development of human health products, industry practice and government regulations in the U.S. and most foreign countries provide for the determination of effectiveness and safety of new chemical compounds through preclinical tests and controlled clinical evaluation. Before a new drug or vaccine may be marketed in the U.S., recorded data on preclinical and clinical experience are included in the New Drug Application (NDA) for a drug or the Biologics License Application (BLA) for a vaccine or biologic submitted to the FDA for the required approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Once the Company&#8217;s scientists discover a new small molecule compound or biologic that they believe has promise to treat a medical condition, the Company commences preclinical testing with that compound. Preclinical testing includes laboratory testing and animal safety studies to gather data on chemistry, pharmacology, immunogenicity and toxicology. Pending acceptable preclinical data, the Company will initiate clinical testing in accordance with established regulatory requirements. The clinical testing begins with Phase 1 studies, which are designed to assess safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic activity of the compound in humans. If favorable, additional, larger Phase&#160;2 studies are initiated to determine the efficacy of the compound in the affected population, define appropriate dosing for the compound, as well as identify any adverse effects that could limit the compound&#8217;s usefulness. In some situations, the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspects of the ongoing clinical study as it continues, without undermining the validity and integrity of the trial. One type of adaptive clinical trial is an adaptive Phase 2a/2b trial design, a two-stage trial design consisting of a Phase 2a proof-of-concept stage and a Phase 2b dose-optimization finding stage. If data from the Phase&#160;2 trials are satisfactory, the Company commences large-scale Phase&#160;3 trials to confirm the compound&#8217;s efficacy and safety. Another type of adaptive clinical trial is an adaptive Phase 2/3 trial design, a study that includes an interim analysis and an adaptation that changes the trial from having features common in a Phase 2 study (e.g., multiple dose groups) to a design similar to a Phase 3 trial. An adaptive Phase 2/3 trial design reduces timelines by eliminating activities which would be required to start a separate study. Upon completion of Phase 3 trials, if satisfactory, the Company submits regulatory filings with the appropriate regulatory agencies around the world to have the product candidate approved for marketing. There can be no assurance that a compound that is the result of any particular program will obtain the regulatory approvals necessary for it to be marketed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vaccine development follows the same general pathway as for drugs. Preclinical testing focuses on the vaccine&#8217;s safety and ability to elicit a protective immune response (immunogenicity). Pre-marketing vaccine clinical trials are typically done in three phases. Initial Phase 1 clinical studies are conducted in normal subjects to evaluate the safety, tolerability and immunogenicity of the vaccine candidate. Phase&#160;2 studies are dose-ranging studies and provide additional data on safety, immunogenicity and/or effectiveness. Finally, Phase&#160;3 trials are conducted in the intended population for licensure and provide data on immunogenicity and/or effectiveness, as well as safety, to support applications for regulatory approvals. If successful, the Company submits regulatory filings with the appropriate regulatory agencies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the FDA review process begins once a complete NDA or BLA is submitted, received and accepted for review by the agency. Within 60 days after receipt, the FDA determines if the application is sufficiently complete to permit a substantive review. The FDA also assesses, at that time, whether the application will be granted </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a priority review or standard review. Pursuant to the Prescription Drug User Fee Act V (PDUFA), the FDA review period target for NDAs or original BLAs is either six months, for priority review, or ten months, for a standard review, from the time the application is deemed sufficiently complete. Once the review timelines are determined, the FDA will generally act upon the application within those timelines, unless a major amendment has been submitted (either at the Company&#8217;s own initiative or the FDA&#8217;s request) to the pending application. If this occurs, the FDA may extend the review period to allow for review of the new information, but by no more than three months. Extensions to the review period are communicated to the Company. The FDA can act on an application either by issuing an approval letter or by issuing a Complete Response Letter (CRL) stating that the application will not be approved in its present form and describing all deficiencies that the FDA has identified. Should the Company wish to pursue an application after receiving a CRL, it can resubmit the application with information that addresses the questions or issues identified by the FDA in order to support approval. Resubmissions are subject to review period targets, which vary depending on the underlying submission type and the content of the resubmission.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The FDA has four program designations &#8212; Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review &#8212; to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions. The Fast Track designation provides pharmaceutical manufacturers with opportunities for frequent interactions with FDA reviewers during the product&#8217;s development and the ability for the manufacturer to do a rolling submission of the NDA/BLA. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The Breakthrough Therapy designation provides manufacturers with all of the features of the Fast Track designation as well as intensive guidance on implementing an efficient development program for the product and a commitment by the FDA to involve senior managers and experienced staff in the review. The Accelerated Approval designation allows the FDA to approve a product based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict a product&#8217;s clinical benefit and generally requires the manufacturer to conduct required post-approval confirmatory trials to verify the clinical benefit. The Priority Review designation means that the FDA&#8217;s goal is to take action on the NDA/BLA within six months, compared to ten months under standard review. More than one of these special designations can be granted for a given application (i.e., a product designated as a Breakthrough Therapy may also be eligible for Priority Review).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the COVID-19 public health crisis, the U.S. Secretary of Health and Human Services has exercised statutory authority to determine that a public health emergency exists, and declared these circumstances justify the emergency use of drugs and biological products as authorized by the FDA. While in effect, this declaration enables the FDA to issue Emergency Use Authorizations (EUAs) permitting distribution and use of specific medical products absent NDA/BLA submission or approval, including products to treat or prevent diseases or conditions caused by the SARS-CoV-2 virus, subject to the terms of any such EUAs. The FDA must make certain findings to grant an EUA, including that it is reasonable to believe based on the totality of evidence that the drug or biologic may be effective, and that known or potential benefits when used under the terms of the EUA outweigh known or potential risks. Additionally, the FDA must find that there is no adequate, approved and available alternative to the emergency use of the authorized drug or biologic. The FDA may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary method the Company uses to obtain marketing authorization of pharmaceutical products in the EU is through the &#8220;centralized procedure.&#8221; This procedure is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA). After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA. It is also possible for new chemical products to obtain marketing authorization in the EU through a &#8220;mutual recognition procedure&#8221; in which an application is made to a single member state and, if the member state approves the pharmaceutical product under a national procedure, the applicant may submit that approval to the mutual recognition procedure of some or all other EU Member States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S. and the EU, the Company submits marketing applications to national regulatory authorities. Examples of such are the Ministry of Health, Labour and Welfare in Japan, the National Medical Products Administration in China, Health Canada, Ag&#234;ncia Nacional de Vigil&#226;ncia Sanat&#225;ria in Brazil, Korea Food and Drug Administration in South Korea, and the Therapeutic Goods Administration in Australia. Each country has a separate and independent review process and timeline. In many markets, approval times can be longer as the regulatory authority requires approval in a major market, such as the U.S. or the EU, and issuance of a Certificate of Pharmaceutical Product from that market before initiating their local review process.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Update</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally or in late-stage clinical development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-4482, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in collaboration with Ridgeback Biotherapeutics LP (Ridgeback). The FDA granted Emergency Use Authorization (EUA) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in December 2021; last issued in February 2023, to authorize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for the treatment of adults with a current diagnosis of mild-to-moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. In November 2021, the EMA issued a positive scientific opinion for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which is intended to support national decision-making on the possible use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> prior to marketing authorization. In October 2021, the EMA initiated a rolling review for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for the treatment of COVID-19 in adults. On February 24, 2023, Merck and Ridgeback announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended the refusal of the marketing authorization for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP&#8217;s opinion. Applications to other regulatory bodies worldwide are underway. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2022, Merck provided an update on new clinical and non-clinical studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. A preliminary analysis of the University of Oxford&#8217;s PANORAMIC study, conducted in the UK in highly-vaccinated adults mostly over 65 years of age, showed no evidence of a difference between </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> added to usual care compared to usual care alone for the reduction of hospitalizations and deaths through Day 28 (primary endpoint was not met); the incidence of hospitalizations and death through Day 28 was very low overall. The main secondary endpoint (time to first self-reported recovery) in the PANORAMIC study was 6 days shorter with the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> group compared to the usual care group; in addition, the use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> also was associated with earlier recovery across a wide range of other symptom measures, as compared to the usual care group. Additionally, an analysis of real-world data from a separate study conducted by investigators in Israel (known as the Clalit study) showed that in a cohort of non-hospitalized, high-risk patients, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> reduced hospitalizations and mortality due to COVID-19 in patients 65 years and above; no evidence of benefit was found in younger adults ages 40 to 64 years. Also, Merck reported results from a separate, non-clinical 6-month carcinogenicity study in transgenic mice, which demonstrated that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was not carcinogenic at any dose tested.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA and the EMA. The marketing applications for gefapixant are based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck&#8217;s NDA for gefapixant. In the CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. The CRL was not related to the safety of gefapixant. The Company is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023 in response to the CRL. The review period in the EU has been extended pending the receipt of additional information from the Company. Merck plans to submit the information to the EMA in the first half of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-3475, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,650 clinical trials, including more than 1,200 trials that combine </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> with other cancer treatments. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA&#8217;s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under priority review by the FDA for use in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of certain patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy. The FDA set a PDUFA date of April 21, 2023 for the supplemental BLAs </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Pedcev. The combination regimen was granted Breakthrough Therapy designation by the FDA in February 2020. The applications are supported by efficacy and safety data from the Phase 1b/2 EV-103 trial (also known as KEYNOTE-869) Dose Escalation/Cohort A and Cohort K. Results from Dose Escalation/Cohort A were published in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Journal of Clinical Oncology</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Results from Cohort K were presented in a late-breaking session at the 2022 European Society for Medical Oncology Congress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also under review by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. This submission is based on data from the Phase 3 KEYNOTE-913 trial. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA&#8217;s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This submission is based on data from the Phase 2 KEYNOTE-158 trial along with supportive data from the KEYNOTE-164 and KEYNOTE-051 trials. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA&#8217;s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review in the EU for the adjuvant treatment of patients with stage IB (&#8805;4 cm), II or IIIA NSCLC following complete surgical resection. The submission is based on data from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 &#8211; PEARLS.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review in Japan for the treatment of patients with relapsed or refractory PMBLC. This submission is based on data from the Phase 2 KEYNOTE-170 study and the Phase 1 KEYNOTE-A33 study. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck announced that it will stop the Phase 3 KEYNOTE-991 trial investigating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer. Merck is discontinuing the study based on the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from a planned interim analysis. At the interim analysis, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in combination with enzalutamide and ADT did not demonstrate an improvement in overall survival or radiographic progression-free survival, the trial&#8217;s dual primary endpoints, compared to placebo plus enzalutamide and ADT. Data from this study will be presented at an upcoming medical meeting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7339, Lynparza, is an oral PARP inhibitor currently approved for certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca PLC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2022, the FDA granted priority review for a supplemental NDA for Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC. The supplemental NDA was based on results from the Phase 3 PROpel trial, which were presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium and later published in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">NEJM Evidence</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The FDA initially set a PDUFA date in the fourth quarter of 2022, but in December 2022 the FDA extended the PDUFA date by three months to provide further time for the full review of the submission. Lynparza is also under review in Japan for the treatment of certain patients with mCRPC based on the PROpel trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai). Merck and Eisai are studying the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program that includes studies across 13 different tumor types (biliary cancer, CRC, endometrial carcinoma, esophageal cancer, gastric cancer, HCC, HNSCC, melanoma, pancreatic cancer, prostate cancer, NSCLC, small-cell-lung cancer (SCLC) and RCC).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also has several other programs in Phase 3 clinical development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-1308A is the coformulation of quavonlimab, Merck&#8217;s novel investigational anti-CTLA-4 antibody, with pembrolizumab being evaluated for the treatment of RCC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subcutaneous MK-3475, pembrolizumab, is being evaluated for comparability with the intravenous formulation of pembrolizumab in NSCLC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subcutaneous MK-3475A, the coformulation of pembrolizumab with hyaluronidase, is being evaluated for comparability with the intravenous formulation of pembrolizumab in NSCLC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-4280A is the coformulation of favezelimab, Merck&#8217;s novel investigational anti-LAG3 therapy, with pembrolizumab, being evaluated for the treatment of CRC and hematological malignancies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-6482, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (belzutifan), is a hypoxia-inducible factor-2&#945; (HIF-2&#945;) inhibitor being evaluated for a supplemental indication for the treatment of patients with RCC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7119, Tukysa (tucatinib), is a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers in development for the treatment of breast cancer and colorectal cancer. In September 2020, Seagen granted Merck an exclusive license and entered into a co-development agreement with Merck to accelerate the global reach of Tukysa. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7684A is the coformulation of vibostolimab, an anti-TIGIT therapy, with pembrolizumab being evaluated for the treatment of melanoma, NSCLC and SCLC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2021, Merck announced that the FDA had placed clinical holds on the investigational new drug applications for islatravir (MK-8591) programs that were in development for the treatment and prevention of HIV-1 infection. The FDA&#8217;s clinical hold was based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced it will initiate a new doravirine/islatravir (MK-8591A) Phase 3 clinical program for the treatment of people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir in previously untreated adults and as a switch in antiretroviral therapy in virologically suppressed adults with HIV-1 infection. The Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead Sciences&#8217; lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational NDA for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for PrEP. The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism. A Phase 1b study in adults with HIV-1 infection assessing MK-8527, a novel NRTTI candidate, will commence shortly. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) for treatment of pneumococcal infection in adults. In June 2022, Merck announced the presentation of positive results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of V116 in pneumococcal vaccine-na&#239;ve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). In both populations, V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23 across age groups. In April 2022, Merck announced that V116 received Breakthrough Therapy designation from the FDA for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. Phase 3 trials evaluating V116 are ongoing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7962, sotatercept, is an investigational activin receptor type IIA-Fc fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension (PAH). Sotatercept was obtained in connection with Merck&#8217;s acquisition of Acceleron Pharma Inc. in 2021. In October 2022, Merck announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept for the treatment of PAH (World Health Organization [WHO] Group 1). The trial met its primary efficacy outcome measure, demonstrating a statistically significant and clinically meaningful improvement in 6-minute walk distance (6MWD, which measures how far patients can walk in 6 minutes). Eight of nine secondary efficacy outcome measures achieved statistical significance, including the outcome measure of proportion of participants achieving multicomponent improvement (defined as improvement in 6MWD, improvement in N-terminal pro-B-type natriuretic peptide level, and either improvement in WHO Functional Class [FC] or maintenance of WHO FC II), and the outcome measure of time to death or the first occurrence of a clinical worsening event. The Cognitive/Emotional Impacts domain score of PAH-SYMPACT, which was assessed as the ninth and final secondary outcome measure, did not achieve statistical significance. Results will be presented at the upcoming American College of Cardiology Annual Scientific Session. The Company anticipates filing sotatercept with regulatory authorities in 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-1654, clesrovimab, is a respiratory syncytial virus (RSV) monoclonal antibody that is being evaluated for the prevention of RSV medically attended lower respiratory tract infection in infants and certain children over 1 year of age. Two Phase 3 trials are currently enrolling.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50&#160;million to co-fund Merck&#8217;s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375&#160;million for the Phase 3 trial. If </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The charts below reflect the Company&#8217;s research pipeline as of February&#160;17, 2023. Candidates shown in Phase&#160;3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase&#160;2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase&#160;1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-0482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1026 (nemtabrutinib)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Hematological Malignancies</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2140 (zilovertamab vedotin)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2870</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Neoplasm Malignant</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3543 (bomedemstat)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Myeloproliferative Disorders</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280 (favezelimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Esophageal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4830</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Esophageal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Melanoma</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-5684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-5890 (boserolimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">MK-6482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Rare cancers</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Von Hippel-Lindau Disease-Associated Tumors (EU)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cervical</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cervical</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V940</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Dengue Fever Virus Vaccine</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V181</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591B (islatravir+MK-8507)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591D (islatravir+lenacapavir)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(5)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Hypercholesterolemia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-0616</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Nonalcoholic Steatohepatitis (NASH)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-6024 (efinopegdutide)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Overgrowth Syndrome</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7075 (miransertib)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-5475</span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Hypertension Due To Left Heart Disease</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7962 (sotatercept)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Thrombosis</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2060</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Treatment Resistant Depression</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1942</span></div><div style="text-indent:9pt"><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:201pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (U.S.) (May 2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(7)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell (April 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary (September 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric (May 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 (pembrolizumab subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (August 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475A (pembrolizumab+hyaluronidase subcutaneous)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (February 2023)</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal (November 2021)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies (October 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-6482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal (August 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (December 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma (January 2023)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (March 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal (July 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric (December 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma (March 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591A (doravirine+islatravir) (February 2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V116 (July 2022)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7962 (sotatercept) (January 2021)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1654 (clesrovimab) (November 2021)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">New Molecular Entities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (EU)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (U.S.)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Certain Supplemental Filings</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Second-Line Hepatocellular Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-394) (U.S.)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    First-Line Locally Advanced Or Metastatic Urothelial Carcinoma </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-869) (U.S.)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Locally Advanced Or Metastatic Merkel Cell Carcinoma </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-913) (U.S.)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Adjuvant Non-Small-Cell Lung Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-091) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Relapsed Or Refractory Primary Mediastinal B-Cell Lymphoma </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-170/KEYNOTE-A33) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    First-Line Metastatic Prostate Cancer </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(PROpel) (U.S.) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></td></tr><tr style="height:201pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Being developed in a collaboration.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Being developed in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Being developed as monotherapy and/or in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  On FDA clinical hold.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  On FDA partial clinical hold for higher doses than those used in current clinical trials.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Phase 2b development costs are being co-funded.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Available in the U.S. under Emergency Use Authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="ia384118d157240e09e39541b90e2080f_40"></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately 69,000 employees worldwide, with approximately 28,000 employed in the U.S., including Puerto Rico, and, additionally, approximately 15,000 third-party contractors globally.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Approximately 67,000 of the Company&#8217;s employees are full-time employees. Globally, women comprise 50% of employees, and in the U.S. individuals from underrepresented ethnic groups comprise 34% of its workforce (the Company defines workforce as its employees). Women comprise 46% of the members of the Board of Directors. Additionally, the Company&#8217;s senior management team is made up of 34% women. Approximately 22% of the Company&#8217;s employees are represented by various collective bargaining groups. The Company&#8217;s voluntary turnover rate was approximately 8.5% and 8.8%, respectively, in 2022 and 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that its employees are critical to meet the needs of its patients and customers and that its ability to excel depends on the integrity, skill, and diversity of its employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Third party contractors include the Company&#8217;s temporary workers, independent contractors, and freelancers who are viewed as full-time equivalent employees. They exclude outsourced service providers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Talent Acquisition</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses a comprehensive approach to ensure recruiting, retention and leadership development goals are systematically executed throughout the Company and that it hires talented leaders to achieve improved gender parity and representation across all dimensions of diversity. The Company provides training to its </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">managers and external recruiting organizations on strategies to mitigate unconscious bias in the candidate selection and hiring process. In addition, the Company utilizes a comprehensive communications strategy, employee branding and marketing outreach, social media and strategic alliance partnerships to reach a broad pool of talent in its critical business areas. In 2022, the Company hired approximately 8,900 employees across the globe through various channels including the Company&#8217;s external career site, direct passive candidate sourcing, diversity partnerships, employee referrals, universities and other external sources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Global Diversity and Inclusion</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diversity and inclusion are fundamental to the Company&#8217;s success and core to future innovation. The Company fosters a globally diverse and inclusive workforce for its employees by creating an environment of belonging, engagement, equity, and empowerment. The Company is proactive and intentional about diversity hiring and development programs to advance talent. The Company creates competitive advantages by leveraging diversity and inclusion to accelerate business performance. This includes fostering global supplier diversity, integrating diversity and inclusion into the Company&#8217;s commercialization strategies and leveraging employee insights to improve performance. In addition to these efforts, the Company has ten Employee Business Resource Groups that provide opportunities for employees to take an active part in contributing to the Company&#8217;s inclusive culture through their work in talent acquisition and development, business and customer insights and social and community outreach.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s diversity goals include increasing representation in senior management roles (defined as an individual holding either a Vice President or Senior Vice President title) by 2024 of (i) women globally to 40%, up from 31% in 2020, (ii) Black/African Americans in the U.S. to 10%, up from 3% in 2020, and (iii) Hispanics/Latinos in the U.S. to 10%, up from 5% in 2020. As of December 31, 2022, representation in senior management roles at the Company for (i) women globally was 34%, (ii) Black/African Americans in the U.S. was 6%, and (iii) Hispanics/Latinos in the U.S. was 8%. In addition, by 2025, the Company seeks to maintain or exceed both its current inclusion index score and its current employee engagement index score based on employee surveys.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gender and Ethnicity Data</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women on the Board of Directors</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">46%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">46%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women in senior management roles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">36%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">31%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women in management roles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">44%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">42%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Women in the workforce</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">50%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">New hires that were women</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">52%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">53%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups on the Board of Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in senior management roles (U.S.)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">20%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in management roles (U.S.)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">27%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">26%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Members of underrepresented ethnic groups in the workforce (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">34%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">32%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">New hires that were members of underrepresented ethnic groups (U.S.)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">47%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">46%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">40%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">As of 12/31. As self-identified to the Company.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2020 data has not been restated to adjust for the Organon Spin-Off in 2021.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Senior management role&#8221; is defined as an individual holding either a Vice President or Senior Vice President title.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Management role&#8221; is defined as all managers with direct reports other than individuals holding an Executive Vice President title.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides a valuable suite of compensation and benefits programs that reflect its commitment to attract, retain and motivate its talent, and support its employees and their families in every stage of life. The Company continuously monitors and adjusts its compensation and benefit programs to ensure they are competitive, contemporary, helpful and engaging, and that they support strategic imperatives such as diversity and inclusion, equity, flexibility, quality, security and affordability. For example, the Company regularly monitors and evaluates its pay practices and policies to ensure that it is paying employees equitably across all genders, races and ethnicities. The Company offers a personal health care concierge service to assist U.S. employees participating in the Company medical plan with their health care needs. Aligned with its business and in support of its cancer care strategy, the Company provides enhanced cancer screening benefits with cash incentives, immediate access to a leading cancer center of excellence for U.S. employees and high value cancer support resources (e.g., caregiving and mental health) for employees and their families. Globally, the Company implemented a minimum standard of 12 weeks of paid parental leave, which inclusively applies to all parents. In the U.S., the Company&#8217;s benefits rank in the top quartile of Fortune 100 companies under the Aon 2022 Benefits Index. The Company has been included in the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Seramount (previously the Working Mother) 100 Best Companies ranking for 36 consecutive years and was named a top ten Best Company for Moms in 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Employee Well-being</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is committed to helping its employees and their families improve their own health and well-being, whether physical, mental, financial, or social. The Company&#8217;s programs ensure quality, competitive value, protection from significant financial hardship and access to tools and resources to support employees and their families in all stages of their career and their lives, winning the Company awards such as the Best Employers Excellence in Health &amp; Well-being from the Business Group on Health 2022. The Company fosters an array of flexible work arrangements that includes flextime, summer hours, remote work, telework, job sharing and part-time work to help employees succeed personally as well as professionally. As part of the Company&#8217;s overall culture of well-being, it also offers onsite services so employees can thrive. For example, in the U.S., these include onsite health care professionals at many major sites, cafeterias committed to healthy menu offerings, onsite childcare, onsite gyms, and the convenient option to bank through its two employee credit unions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Response</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that it has a unique responsibility to help in response to the COVID-19 pandemic and is committed to supporting and protecting its employees and their families, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral approaches and supporting its health care providers and the communities in which they serve. The Company continues to provide employees with easy and regular access to information, including guidance around hygiene measures and travel and how to best collaborate via the Company&#8217;s hybrid work model. Examples of pandemic support resources and programs available to the Company&#8217;s employees include pay continuation for workers who have been sick or exposed, an updated policy that enables employees with medical backgrounds to volunteer in SARS-CoV-2-related activities, resources to prioritize physical and mental wellness, adjustments to medical plans to cover 100% of a COVID-19-related diagnosis, testing and treatment, childcare resources and more.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Engaging Employees</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company strives to foster employee engagement by promoting a safe, positive, diverse, and inclusive work environment that provides numerous opportunities for two-way communication with employees. Some of the Company&#8217;s key programs and initiatives include promoting global employee engagement surveys, ongoing pulse checks to the organization for interim feedback on specific topics, fostering professional networking and collaboration, identifying and providing opportunities for volunteering and establishing positive, cooperative business relations with designated employee representatives. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Talent Management and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As the Company pursues its goal of becoming the world&#8217;s premier research-based biopharmaceutical company, there is a consistent focus on the importance of continuously developing its diverse and talented people. The Company is committed to talent growth for all, allowing its employees to move more fluidly across the organization, unlocking an environment that allows them to shape their career pathways via non-linear and inclusive opportunities and experience. Merck&#8217;s current talent management system supports company-wide performance management, leadership development, talent reviews and succession planning. Annual performance reviews help further the professional development of the Company&#8217;s employees and ensure that the Company&#8217;s workforce is aligned with the Company&#8217;s objectives. The Company seeks to continuously build the skills and capabilities of its workforce to accelerate talent, improve performance and mitigate risk through relevant continuous learning experiences. This includes, but is not limited to, building leadership and management skills, as well as providing technical and functional training to all employees.</span></div><div id="ia384118d157240e09e39541b90e2080f_43"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Environmental Sustainability</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company strives to be a strong environmental steward, and realizes that its strategy and efforts need to continuously evolve in the face of a changing climate. The Company&#8217;s environmental sustainability strategy has three focus areas:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Driving operational efficiency;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Designing new products to minimize environmental impact; and</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Reducing any impacts in the Company&#8217;s upstream and downstream value chain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A primary focus of the Company in each of these areas is on climate action. Merck believes that climate change could present risks to its business, as discussed in further detail in Item 1A. &#8220;Risk Factors&#8221; under the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">headings &#8220;Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company&#8217;s business, results of operations, cash flows and prospects&#8221; and &#8220;Environmental, social and governance (ESG) matters may impact the Company&#8217;s business and reputation.&#8221; Some of the potential impacts of climate change to the Company&#8217;s business include increased operating costs due to additional regulatory requirements, physical risks to the Company&#8217;s facilities, water limitations and disruptions to its supply chain. These potential risks are integrated into the Company&#8217;s business planning, including investment in reducing energy usage, water use and greenhouse gas emissions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, the Company&#8217;s Scope 1, 2 and 3, reduction targets were verified by the Science-Based Targets initiative (SBTi). The Company has made progress toward its climate goals and aspires to meet and exceed the evolving expectations of its stakeholders and employees. These goals include achieving carbon neutrality for greenhouse gas emissions across operations (Scopes 1 and 2) by 2025, reducing Scope 1 and 2 operational greenhouse gas emissions 46% by 2030 (from a 2019 baseline), reducing Scope 3 greenhouse gas emissions by 30% by 2030 (from a 2019 baseline), and sourcing 100% of its purchased electricity from renewables by 2025. Other environmental sustainability initiatives of the Company include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">Low Carbon Transition Playbook</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In 2021, the Company launched its Low Carbon Transition Playbook, a tool intended to help create a site strategy by identifying gaps, uncovering opportunities and creating a common platform for assessment of levers and resource deployment across a range of sustainability initiatives. It also details how employees and stakeholders can accelerate the Company&#8217;s environmental work, along with explanations of the collective benefits of these actions for the business and for stakeholders. Functions across the Company are expected to take advantage of this document to strategize and develop new ways to meet many of the Company&#8217;s broader sustainability goals and streamline the Company&#8217;s tracking and reporting of specific metrics and categories.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">Waste Diversion Playbook</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In 2022, the Company created its Waste Diversion Playbook, which is a tool, similar to the Low Carbon Transition Playbook, to help sites self-assess and develop their waste diversion strategies to achieve the Company&#8217;s corporate waste goals. The objectives are to identify and prioritize the most effective and least resource intensive actions, improve tracking and reporting and generate knowledge sharing between sites.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">Partnering for progress across the Company&#8217;s value chain</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company is a signatory to Schneider Electric&#8217;s Energize program, a pioneering collaboration to help pharmaceutical and health care suppliers address their own operational Scope 2 greenhouse gas emissions through green power procurement, which in turn is intended to help the signatories reduce their Scope 3 emissions.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:14.85pt">Product stewardship and green and sustainable science.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company&#8217;s product stewardship program focuses on identifying and either preventing or minimizing potential safety and environmental hazards throughout a product&#8217;s life cycle. The Company is also committed to understanding, managing and reducing the environmental impacts of its products and the materials associated with discovering and producing them. The Company&#8217;s green and sustainable science program uses a &#8220;green-by-design&#8221; approach. By using more efficient and innovative processing methods and technologies, the Company is reducing the amount of energy, water and raw materials the Company uses to make the Company&#8217;s products, thereby reducing the amount of waste the Company generates and lowering the Company&#8217;s production costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Company&#8217;s financial condition, results of operations, liquidity or capital resources for any year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Environmental Regulation and Remediation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites. Expenditures for remediation and environmental liabilities were $4 million in 2022 and are estimated to be $23 million in the aggregate for the years 2023 through 2027. These amounts do not consider potential recoveries from other parties. The Company has taken an active role in identifying and accruing for these costs and, in management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December&#160;31, 2022 and 2021, respectively. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should have a material adverse effect on the Company&#8217;s financial condition, results of operations, liquidity or capital resources for any year.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Geographic Area Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s operations outside the U.S. are conducted primarily through subsidiaries. Sales worldwide by subsidiaries outside the U.S. as a percentage of total Company sales was 54% in both 2022 and 2021 and 53% in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s worldwide business is subject to risks of currency fluctuations, governmental actions and other governmental proceedings abroad. The Company does not regard these risks as a deterrent to further expansion of its operations abroad. However, the Company closely reviews its methods of operations and adopts strategies responsive to changing economic and political conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has operations in countries located in Latin America, the Middle East, Africa, Eastern Europe and Asia Pacific. Business in these developing areas, while sometimes less stable, offers important opportunities for growth over time.</span></div><div id="ia384118d157240e09e39541b90e2080f_49"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Internet website address is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">merck.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company will make available, free of charge at the &#8220;Investors&#8221; portion of its website, its Annual Report on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, and all amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The address of that website is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">sec.gov</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company will provide without charge a copy of its Annual Report on Form 10-K, including financial statements and schedules, upon the written request of any shareholder to the Office of the Secretary, Merck &amp; Co., Inc., 126&#160;East Lincoln Avenue, Rahway, NJ 07065 U.S.A.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s corporate governance guidelines and the charters of the Board of Directors&#8217; four standing committees are available on the Company&#8217;s website at https://www.merck.com/company-overview/leadership/board-of-directors/ and all such information is available in print to any shareholder who requests it from the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s 2021/2022 Environmental, Social &amp; Governance (ESG) Progress Report, which provides enhanced ESG disclosures, is available on the Company&#8217;s website at https://www.merck.com/company-overview/esg/esg-resources/. Information in the Company&#8217;s ESG Progress Report is not incorporated by reference into this Form 10-K.</span></div><div id="ia384118d157240e09e39541b90e2080f_52"></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:10.02pt">Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Summary Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to a number of risks that if realized could materially adversely affect its business, results of operations, cash flow, financial condition or prospects. The following is a summary of the principal risk factors facing the Company:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">As the Company&#8217;s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Key products generate a significant amount of the Company&#8217;s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company&#8217;s results of operations and financial condition. The Company expects that sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which were $5.7 billion in 2022, will decline significantly to approximately $1.0 billion in 2023.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company&#8217;s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company&#8217;s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company faces continued pricing pressure with respect to its products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company&#8217;s operating results.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company faces intense competition from lower cost generic products.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company faces intense competition from competitors&#8217; products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">COVID-19-related disruptions have had an adverse impact on the Company&#8217;s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company&#8217;s business, results of operations, cash flows and prospects.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Environmental, social and governance (ESG) matters may impact the Company&#8217;s business and reputation.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Failure to attract and retain highly qualified personnel could affect the Company&#8217;s ability to successfully develop and commercialize products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company may not be able to realize the expected benefits of its investments in emerging markets.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company&#8217;s business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Pharmaceutical products can develop unexpected safety or efficacy concerns.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company&#8217;s business.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company&#8217;s future results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company&#8217;s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Developments following regulatory approval may adversely affect sales of the Company&#8217;s products.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company is subject to a variety of U.S. and international laws and regulations.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Adverse outcomes in current or future legal matters could negatively affect Merck&#8217;s business.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Product liability insurance for products may be limited, cost prohibitive or unavailable.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The Company is increasingly dependent on sophisticated software applications and computing infrastructure. The Company could be a target of future cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Social media and mobile messaging platforms present risks and challenges.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The above list is not exhaustive, and the Company faces additional challenges and risks. Investors should carefully consider all of the information set forth in this Form 10-K, including the following risk factors, before deciding to invest in any of the Company&#8217;s securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The risks below are not the only ones the Company faces. Additional risks not currently known to the Company or that the Company presently deems immaterial may also impair its business operations. The Company&#8217;s business, financial condition, results of operations, cash flow or prospects could be materially adversely affected by any of these risks. This Form&#160;10-K also contains forward-looking statements that involve risks and uncertainties. The Company&#8217;s results could materially differ from those anticipated in these forward-looking statements as a result of certain factors, including the risks it faces described below and elsewhere. See &#8220;Cautionary Factors that May Affect Future Results&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Company&#8217;s Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patent protection is considered, in the aggregate, to be of material importance to the Company&#8217;s marketing of human health and animal health products in the U.S. and in most major foreign markets. Patents covering products that it has introduced normally provide market exclusivity, which is important for the successful marketing and sale of its products. The Company seeks patents covering each of its products in each of the markets where it intends to sell the products and where meaningful patent protection is available.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if the Company succeeds in obtaining patents covering its products, third parties or government authorities may challenge or seek to invalidate or circumvent its patents and patent applications. It is important for the Company&#8217;s business to successfully assert and defend the patent rights that provide market exclusivity for its products. The Company is often involved in patent disputes relating to challenges to its patents or claims by third parties of infringement against the Company. The Company asserts and defends its patents both within and outside the U.S., including by filing claims of infringement against other parties. See Item&#160;8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221; below. In particular, manufacturers of generic or biosimilar pharmaceutical products from time to time file abbreviated NDAs or BLAs with the FDA seeking to market generic/biosimilar forms of the Company&#8217;s products prior to the expiration of relevant patents owned or licensed by the Company. The Company normally responds by asserting one or more of its patents with a lawsuit alleging patent infringement. Patent litigation and other challenges to the Company&#8217;s patents are costly and unpredictable and may deprive the Company of market exclusivity for a patented product or, in some cases, third-party patents may prevent the Company from marketing and selling a product in a particular geographic area.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies or in other circumstances, which could diminish or eliminate sales and profits from those regions and negatively affect the Company&#8217;s results of operations. Further, court decisions relating to other companies&#8217; patents, potential legislation in both the U.S. and certain foreign markets relating to patents, as well as regulatory initiatives may result in a more general weakening of intellectual property protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If one or more important products lose patent protection in profitable markets, sales of those products are likely to decline significantly as a result of generic versions of those products becoming available. The Company&#8217;s results of operations may be adversely affected by the lost sales unless and until the Company has launched commercially successful products that replace the lost sales. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively affect product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A chart listing the patent protection for certain of the Company&#8217;s marketed products, and U.S. patent protection for candidates in Phase 3 clinical development is set forth above in Item&#160;1. &#8220;Business &#8212; Patents, Trademarks and Licenses.&#8221;</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As the Company&#8217;s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company depends upon patents to provide it with exclusive marketing rights for its products for some period of time. Loss of patent protection for one of the Company&#8217;s products typically leads to a significant and rapid loss of sales for that product as lower priced generic versions of that drug become available. In the case of products that contribute significantly to the Company&#8217;s sales, the loss of market exclusivity can have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects. While the key U.S. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">patent for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity in the U.S. toward the end of 2023. The Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in all of the EU and for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in some European countries in September 2022. Merck expects that exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be lost in other European countries in April 2023. While the Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in China in 2022 with the approval of a generic equivalent product, the impact on sales in 2023 is expected to be modest. It is anticipated that a generic equivalent of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be approved in China in the first quarter of 2023, but the impact to sales in 2023 is also expected to be modest. As these products lose exclusivity, the Company anticipates that sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will decline substantially.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Key products generate a significant amount of the Company&#8217;s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company&#8217;s results of operations and financial condition. The Company expects that sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">, which were $5.7 billion in 2022, will decline significantly to approximately $1.0 billion in 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s ability to generate profits and operating cash flow depends largely upon the continued profitability of the Company&#8217;s key products, such as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9, Lynparza, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. As a result of the Company&#8217;s dependence on key products, any event that adversely affects any of these products or the markets for any of these products could have a significant adverse impact on results of operations and financial condition. These events could include loss of patent protection, increased costs associated with manufacturing, generic or over-the-counter availability of the Company&#8217;s product or a competitive product, the discovery of previously unknown side effects, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of the product for any reason. Such events could have a material adverse effect on the sales of any such products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In particular, in 2022, sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which were $5.7 billion, represented a substantial portion of the Company&#8217;s revenue and profit growth. The Company expects that sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will decline significantly to approximately $1.0 billion in 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company&#8217;s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to remain competitive, the Company, like other major pharmaceutical companies, must continue to launch new products. Expected declines in sales of products after the loss of market exclusivity mean that the Company&#8217;s future success is dependent on its pipeline of new products, including new products that it may develop through collaborations and joint ventures and products that it is able to obtain through license or acquisition. To accomplish this, the Company commits substantial effort, funds and other resources to research and development, both through its own dedicated resources and through various collaborations with third parties. There is a high rate of failure inherent in the research and development process for new drugs and vaccines. As a result, there is a high risk that funds invested by the Company in research programs will not generate financial returns. This risk profile is compounded by the fact that this research has a long investment cycle. To bring a pharmaceutical compound from the discovery phase to market may take a decade or more and failure can occur at any point in the process, including later in the process after significant funds have been invested.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For a description of the research and development process, see Item&#160;1. &#8220;Business &#8212; Research and Development&#8221; above. Each phase of testing is highly regulated and during each phase there is a substantial risk that the Company will encounter serious obstacles or will not achieve its goals. Therefore, the Company may abandon a product in which it has invested substantial amounts of time and resources. Some of the risks encountered in the research and development process include the following: preclinical testing of a new compound may yield disappointing results; competing products from other manufacturers may reach the market first; clinical trials of a new drug may not be successful; a new drug may not be effective or may have harmful side effects; a new drug may not be approved by the regulators for its intended use; it may not be possible to obtain a patent for a new drug; payers may refuse to cover or reimburse the new product; or sales of a new product may be disappointing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot state with certainty when or whether any of its products now under development will be approved or launched; whether it will be able to develop, license or otherwise acquire compounds, product candidates or products; or whether any products, once launched, will be commercially successful. The Company must maintain a continuous flow of successful new products and successful new indications for existing products </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sufficient both to cover its substantial research and development costs and to replace sales that are lost as profitable products lose market exclusivity or are displaced by competing products or therapies. Failure to do so in the short term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company&#8217;s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Products that appear promising in development may fail to reach the market or fail to succeed for numerous reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">findings of ineffectiveness, superior safety or efficacy of competing products, or harmful side effects in clinical or preclinical testing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">failure to receive the necessary regulatory approvals, including delays in the approval of new products and new indications, or the anticipated labeling, and uncertainties about the time required to obtain regulatory approvals and the benefit/risk standards applied by regulatory agencies in determining whether to grant approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">failure in certain markets to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">lack of economic feasibility due to manufacturing costs or other factors; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">preclusion from commercialization by the proprietary rights of others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the future, if certain pipeline programs are cancelled or if the Company believes that their commercial prospects have been reduced, the Company may recognize material non-cash impairment charges for those programs that were measured at fair value and capitalized in connection with acquisitions or certain collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Failure to successfully develop and market new products in the short term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company faces continued pricing pressure with respect to its products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company faces continued pricing pressure globally and, particularly in mature markets, from managed care organizations, government agencies and programs that could negatively affect the Company&#8217;s sales and profit margins. In the U.S., these include (i)&#160;practices of managed care groups and institutional and governmental purchasers, (ii)&#160;U.S. federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug Improvement and Modernization Act of 2003, the ACA, the Inflation Reduction Act, and (iii) state activities aimed at increasing price transparency, including new laws as noted above in Item 1. &#8220;Competition and the Health Care Environment.&#8221; Changes to the health care system enacted as part of health care reform in the U.S., as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, could result in further pricing pressures. In addition, in the U.S., larger customers have received higher rebates on drugs in certain highly competitive categories. The Company must also compete to be placed on formularies of managed care organizations. Exclusion of a product from a formulary can lead to reduced usage in the managed care organization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to provide information about the Company&#8217;s pricing practices, the Company annually posts on its website&#160;its Pricing Transparency Report for the U.S. The report provides the Company&#8217;s average annual list price and net price increases across the Company&#8217;s U.S. portfolio dating back to 2010. In 2022, the Company&#8217;s gross U.S. sales were reduced by 39.7% as a result of rebates, discounts and returns.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside the U.S., numerous major markets, including the EU, Japan and China have pervasive government involvement in funding health care and, in that regard, fix the pricing and reimbursement of pharmaceutical and vaccine products. Consequently, in those markets, the Company is subject to government decision making and budgetary actions with respect to its products. In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricing for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expects pricing pressures to continue in the future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company&#8217;s operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s business may be adversely affected by local and global economic conditions, including with respect to inflation, interest rates, and costs of raw materials and packaging. Uncertainty in global economic and geopolitical conditions may result in a slowdown to the global economy that could affect the Company&#8217;s business by reducing the prices that drug wholesalers and retailers, hospitals, government agencies and managed health care providers may be able or willing to pay for the Company&#8217;s products or by reducing the demand for the Company&#8217;s products, which could in turn negatively impact the Company&#8217;s sales and result in a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As discussed above in &#8220;Competition and the Health Care Environment,&#8221; global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s sales performance in 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. The Company anticipates all of these actions, and additional actions in the future, will negatively affect sales and profits.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If credit and economic conditions worsen, the resulting economic and currency impacts in the affected markets and globally could have a material adverse effect on the Company&#8217;s results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of global macroeconomic conditions, the Company is experiencing some minor disruption and volatility in its global supply chain network. These disruptions could increase in the future and cause delays in shipments of raw materials and packaging, as well as related cost inflation. Any such disruptions, delays or costs may result in the Company&#8217;s inability to meet demand for the Company&#8217;s products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company faces intense competition from lower cost generic products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In general, the Company faces increasing competition from lower-cost generic products. The patent rights that protect its products are of varying strengths and durations. In addition, in some countries, patent protection is significantly weaker than in the U.S. or in the EU. In the U.S. and the EU, political pressure to reduce spending on prescription drugs has led to legislation and other measures that encourage the use of generic and biosimilar products. Although it is the Company&#8217;s policy to actively protect its patent rights, generic challenges to the Company&#8217;s products can arise at any time, and the Company&#8217;s patents may not prevent the emergence of generic competition for its products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss of patent protection for a product typically is followed promptly by generic substitutes, reducing the Company&#8217;s sales of that product. Availability of generic substitutes for the Company&#8217;s drugs may adversely affect its results of operations and cash flow. In addition, proposals emerge from time to time in the U.S. and other countries for legislation to further encourage the early and rapid approval of generic drugs. Any such proposal that is enacted into law could worsen this substantial negative effect on the Company&#8217;s sales, business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company faces intense competition from competitors&#8217; products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s products face intense competition from competitors&#8217; products. This competition may increase as new products enter the market. In such an event, the competitors&#8217; products may be safer or more effective, more convenient to use, have better insurance coverage or reimbursement levels or be more effectively marketed and sold than the Company&#8217;s products. Alternatively, in the case of generic competition, including the generic availability of competitors&#8217; branded products, they may be equally safe and effective products that are sold at a substantially lower price than the Company&#8217;s products. As a result, if the Company fails to maintain its competitive position, this could have a material adverse effect on its business, cash flow, results of operations, financial condition and prospects. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively impact product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19-related disruptions have had an adverse impact on the Company&#8217;s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s business and financial results have been negatively impacted by COVID-19-related disruptions since the start of the pandemic. Merck believes that global health systems and patients have largely adapted to the impacts of COVID-19, however, a substantial portion of Merck&#8217;s Pharmaceutical segment revenue is comprised of physician-administered products which could be adversely affected by the pandemic if it continues. The continued duration and severity of the COVID-19 pandemic is uncertain and difficult to predict. The degree to which COVID-19-related disruptions impact the Company&#8217;s results in 2023 will depend on future developments, beyond the Company&#8217;s knowledge or control, including governmental and third-party actions taken to contain or prevent the spread and treatment of the virus and mitigate its public health and economic effects. In addition, any future pandemic, epidemic or similar public health threat could present similar risks to the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company&#8217;s results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The extent of the Company&#8217;s operations outside the U.S. is significant. Risks inherent in conducting a global business include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">changes in medical reimbursement policies and programs and pricing restrictions in key markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">multiple regulatory requirements that could restrict the Company&#8217;s ability to manufacture and sell its products in key markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">trade protection measures and import or export licensing requirements, including the imposition of trade sanctions or similar restrictions by the U.S. or other governments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">foreign exchange fluctuations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">diminished protection of intellectual property in some countries; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">possible nationalization and expropriation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, there may be changes to the Company&#8217;s business and political position if there is instability, disruption or destruction in a significant geographic region, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest; and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease. Events like these could result in material adverse effects on macroeconomic conditions, currency exchange rates and financial markets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company&#8217;s business, results of operations, cash flows and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company believes that climate change has the potential to negatively affect its business and results of operations, cash flows and prospects. The Company is exposed to physical risks (such as extreme weather conditions or rising sea levels), risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in technology, market risk and reputational risk) and social and human effects (such as population dislocations and harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The adverse impacts of climate change include increased frequency and severity of natural disasters and extreme weather events such as hurricanes, tornados, wildfires (exacerbated by drought), flooding, and extreme heat. Extreme weather and sea-level rise pose physical risks to the Company&#8217;s facilities as well as those of its suppliers. Such risks include losses incurred as a result of physical damage to facilities, loss or spoilage of inventory, and business interruption caused by such natural disasters and extreme weather events. Other potential physical impacts due to climate change include reduced access to high-quality water in certain regions and the loss of biodiversity, which could impact future product development. These risks could disrupt the Company&#8217;s operations and its supply chain, which may result in increased costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New legal or regulatory requirements may be enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could result in the Company being subject to new or expanded carbon pricing or taxes, increased compliance costs, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, investments in data gathering and reporting systems, upgrades of facilities to meet new building codes, and the redesign of utility systems, which could increase the Company&#8217;s operating costs, including the cost of electricity and energy used by the Company. The Company&#8217;s supply chain would likely be subject to these same transitional risks and would likely pass along any increased costs to the Company, all of which may affect the Company&#8217;s ability to procure raw materials or other supplies required for the operation of the Company&#8217;s business at the quantities and levels we require.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Environmental, social and governance (ESG) matters may impact the Company&#8217;s business and reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Governmental authorities, non-governmental organizations, customers, investors, external stakeholders and employees are increasingly sensitive to ESG concerns, such as diversity and inclusion, climate change, water use, recyclability or recoverability of packaging, and plastic waste. This focus on ESG concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing the Company&#8217;s products. The Company&#8217;s ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for more environmentally friendly products, packaging or supplier practices, or by failure to meet such customer expectations or demand. While the Company strives to improve its ESG performance and has set certain ESG goals and initiatives, the Company risks negative stockholder reaction, including from proxy advisory services, as well as damage to its brand and reputation, if the Company fails to meet its goals and initiatives or otherwise does not act responsibly, or if the Company is perceived to not be acting responsibly, in key ESG areas, including equitable access to medicines and vaccines, product quality and safety, diversity and inclusion, environmental stewardship, support for local communities, corporate governance and transparency, and addressing human capital factors in the Company&#8217;s operations. Responding to these ESG considerations and implementation of the Company&#8217;s ESG goals and initiatives involves risks and uncertainties, requires investments, and depends in part on third-party performance or data that is outside of the Company&#8217;s control. In addition, some stakeholders may disagree with the Company&#8217;s ESG goals and initiatives. If the Company does not meet the evolving and varied ESG expectations of its investors, customers and other stakeholders, the Company could experience reduced demand for its products, loss of customers, and other negative impacts on the Company&#8217;s business and results of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Failure to attract and retain highly qualified personnel could affect the Company&#8217;s ability to successfully develop and commercialize products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s success is largely dependent on its continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical research and development, governmental regulation and commercialization. Competition for qualified personnel in the pharmaceutical industry, both in the U.S. and internationally, is intense. The Company cannot be sure that it will be able to attract and retain quality personnel or that the costs of doing so will not materially increase.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has, in the past, experienced difficulties in manufacturing certain of its products, including vaccines. For example, in 2020 the Company issued a product recall for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following the identification of product sterility issues. The Company may, in the future, experience other difficulties and delays in manufacturing its products, such as (i)&#160;failure of the Company or any of its vendors or suppliers to comply with Current Good Manufacturing Practices and other applicable regulations and quality assurance guidelines that could lead to manufacturing shutdowns, product shortages and delays in product manufacturing; (ii)&#160;delays related to the construction of new facilities or the expansion of existing facilities, including those intended to support future demand for the Company&#8217;s products; and (iii)&#160;other manufacturing or distribution problems including supply chain delays, shortages in raw materials, changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in types of products produced, or physical limitations that could impact continuous supply. As previously disclosed, the Company is working to reduce the level of nitrosamines in its sitagliptin-containing medicines such as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Difficulties in reducing those levels, or achieving timely regulatory approvals for required changes, could result in product shortages. In addition, the Company could experience difficulties or delays in manufacturing its products caused by natural disasters, such as hurricanes. Manufacturing difficulties can result in product shortages, leading to lost sales and reputational harm to the Company.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company may not be able to realize the expected benefits of its investments in emerging markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has been taking steps to increase its sales in emerging markets. However, there is no guarantee that the Company&#8217;s efforts to expand sales in these markets will succeed. Some countries within emerging markets may be especially vulnerable to periods of global financial instability or may have very limited resources to spend on health care. In order for the Company to successfully implement its emerging markets strategy, it must attract and retain qualified personnel. The Company may also be required to increase its reliance on third-party agents within less developed markets, which may affect its ability to realize continued growth and may also increase the Company&#8217;s risk exposure. In addition, many of these countries have currencies that fluctuate substantially and, if such currencies devalue and the Company cannot offset the devaluations, the Company&#8217;s financial performance within such countries could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s business in China has grown rapidly in the past few years, and the importance of China to the Company&#8217;s overall pharmaceutical and vaccines business outside the U.S. has increased accordingly. In addition to its commercial operations, the Company has significant research and manufacturing operations in China. If geopolitical tensions were to increase and disrupt the Company&#8217;s operations in China, such disruption could result in a material adverse effect on the Company&#8217;s product development, sales, business, cash flow, results of operations, financial condition and prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also, continued growth of the Company&#8217;s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company&#8217;s currently marketed products, and the absence of trade impediments or adverse pricing controls. As noted above in &#8220;Competition and the Health Care Environment,&#8221; pricing pressure in China has increased as the Chinese government has been taking steps to reduce costs, including implementing health care reform that has led to the acceleration of generic substitution, where available. While the mechanism for drugs being added to the NRDL evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2021, drugs were added to the NRDL with an average of more than 60% price reductions. A new NRDL was recently completed in which new entries averaged 60% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through the government&#8217;s VBP program. In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For all these reasons, sales within emerging markets carry significant risks. However, at the same time, macro economic growth of selected emerging markets is expected to outpace Europe and even the U.S., leading to significant increased health care spending in those countries and access to innovative medicines for patients. A failure to maintain the Company&#8217;s presence in emerging markets could therefore have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company&#8217;s business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing war between Russia and Ukraine, and the financial and economic sanctions imposed by the U.S., the EU and other countries in response, are having pervasive direct and indirect effects on the global economy, and may adversely affect the Company&#8217;s business, results of operations and financial condition. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck&#8217;s supply chain, operations and clinical trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with international sanctions. Merck is donating profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial impacts of the war between Russia and Ukraine were immaterial to the Company&#8217;s consolidated financial statements in 2022. However, the degree to which the war and related disruptions will impact the Company&#8217;s results in the future is difficult to predict and will depend on developments outside of the Company&#8217;s control, including, but not limited to, the duration and severity of the war, ongoing and additional financial and economic sanctions imposed by governments in response, restrictions on travel, regional instability, geopolitical </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">shifts, and adverse effects on fuel and energy costs, supply chains, macroeconomic conditions, currency exchange rates and financial markets. Such developments may negatively impact the Company directly or indirectly as well as the parties with which the Company conducts business. In addition, the effects of the war between Russia and Ukraine could heighten other risks disclosed herein, which could materially adversely affect the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company operates in multiple jurisdictions and virtually all sales are denominated in currencies of the local jurisdiction. Additionally, the Company has entered and will enter into business development transactions, borrowings or other financial transactions that may give rise to currency and interest rate exposure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since the Company cannot, with certainty, foresee and mitigate against such adverse fluctuations, fluctuations in currency exchange rates, interest rates and inflation could negatively affect the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to mitigate against the adverse impact of these market fluctuations, the Company will from time to time enter into hedging agreements. While hedging agreements, such as currency options and forwards and interest rate swaps, may limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks may be costly and not always successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> A portion of Merck&#8217;s indebtedness bears interest at variable interest rates, primarily based on the London Interbank Offered Rate (LIBOR). LIBOR is the subject of national, international and other regulatory guidance and proposals for reform, which will cause LIBOR to cease to exist entirely in the future. While the Company has begun to implement alternative reference rates as alternatives to LIBOR, the Company cannot predict the consequences and timing of any additional or unexpected developments, which could include an increase in interest expense.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pharmaceutical products can develop unexpected safety or efficacy concerns.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unexpected safety or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, or declining sales, as well as product liability, consumer fraud and/or other claims, including potential civil or criminal governmental actions.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company depends on third parties, including suppliers, alliances with other pharmaceutical and biotechnology companies, and third-party service providers, for key aspects of its business including development, manufacture and commercialization of its products and support for its information technology (IT) systems. Failure of these third parties to meet their contractual, regulatory and other obligations to the Company or the development of factors that materially disrupt the relationships between the Company and these third parties could have a material adverse effect on the Company&#8217;s business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future sales of key animal health products could be adversely affected by a number of risk factors including certain risks that are specific to the animal health business. For example, the outbreak of disease carried by animals, such as African Swine Fever, could lead to their widespread death and precautionary destruction as well as the reduced consumption and demand for animals, which could adversely affect the Company&#8217;s results of operations. Also, the outbreak of any highly contagious diseases near the Company&#8217;s main production sites could require the Company to immediately halt the manufacture of its animal health products at such sites or force the Company to incur substantial expenses in procuring raw materials or products elsewhere. Other risks specific to animal health include epidemics and pandemics, government procurement and pricing practices, weather and global agribusiness economic events. In addition, in 2022, sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $1.0 billion, which represented approximately 19% of the Company&#8217;s Animal Health segment sales. Any negative event with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> could have a material adverse effect on the Company&#8217;s Animal Health sales. If the Animal Health segment of the Company&#8217;s business becomes more significant, the impact of any such events on future results of operations could also become more significant.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company&#8217;s future results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The successful development, testing, manufacturing and commercialization of biologics and vaccines, particularly human and animal health vaccines, is a long, complex, expensive and uncertain process. There are unique risks and uncertainties related to biologics and vaccines, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">There may be limited access to, and supply of, normal and diseased tissue samples, cell lines, pathogens, bacteria, viral strains and other biological materials. In addition, government regulations in multiple jurisdictions, such as the U.S. and the EU, could result in restricted access to, or transport or use of, such materials. If the Company loses access to sufficient sources of such materials, or if tighter restrictions are imposed on the use of such materials, the Company may not be able to conduct research activities as planned and may incur additional development costs.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The development, manufacturing and marketing of biologics and vaccines are subject to regulation by the FDA, the EMA and other regulatory bodies. These regulations are often more complex and extensive than the regulations applicable to other pharmaceutical products. For example, in the U.S., a BLA, including both preclinical and clinical trial data and extensive data regarding the manufacturing procedures, is required for human vaccine candidates, and FDA approval is generally required for the release of each manufactured commercial human vaccine lot.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Manufacturing biologics and vaccines, especially in large quantities, is often complex and may require the use of innovative technologies to handle living micro-organisms. Each lot of an approved biologic and vaccine must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, the Company may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Biologics and vaccines are frequently costly to manufacture because production ingredients are derived from living animal or plant material, and most biologics and vaccines cannot be made synthetically. In particular, keeping up with the demand for vaccines may be difficult due to the complexity of producing vaccines.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The use of biologically derived ingredients can lead to variability in the manufacturing process and could lead to allegations of harm, including infections or allergic reactions, which allegations would be reviewed through a standard investigation process that could lead to closure of product facilities due to possible contamination. Any of these events could result in substantial costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Government Regulation and Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As discussed above in &#8220;Competition and the Health Care Environment,&#8221; the Company believes that the health care industry will continue to be subject to increasing regulation as well as political and legal action, as future proposals to reform the health care system are considered by the Executive branch, Congress and state legislatures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, in 2021, Congress passed the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">American Rescue Plan Act, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, beginning in 2024, it is possible that manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change could present a risk to Merck in the future for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company cannot predict what additional future changes in the health care industry in general, or the pharmaceutical industry in particular, will occur; however, any changes could have a material adverse effect on the Company&#8217;s business, cash flow, results of operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company&#8217;s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s activities, including research, preclinical testing, clinical trials and the manufacturing and marketing of its products, are subject to extensive regulation by numerous federal, state and local governmental authorities in the U.S., including the FDA, and by foreign regulatory authorities, including in the EU, Japan and China. In the U.S., the FDA administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling and marketing of prescription pharmaceuticals and vaccines. In some cases, the FDA requirements have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. Regulation outside the U.S. also is primarily focused on drug safety and effectiveness and, in many cases, reduction in the cost of drugs. The FDA and foreign regulatory authorities, including in the EU, Japan and China, have substantial discretion to require additional testing, to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of a product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if the Company is successful in developing new products, it will not be able to market any of those products unless and until it has obtained all required regulatory approvals in each jurisdiction where it proposes to market the new products. Once obtained, the Company must maintain approval as long as it plans to market its new products in each jurisdiction where approval is required. The Company&#8217;s failure to obtain approval, significant delays in the approval process, or its failure to maintain approval in any jurisdiction will prevent it from selling the products in that jurisdiction. The Company would not be able to realize revenues for those new products in any jurisdiction where it does not have approval.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Developments following regulatory approval may adversely affect sales of the Company&#8217;s products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even after a product reaches the market, certain developments following regulatory approval may decrease demand for the Company&#8217;s products, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">results in post-approval Phase 4 trials or other studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the re-review of products that are already marketed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the recall or loss of marketing approval of products that are already marketed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">changing government standards or public expectations regarding safety, efficacy, quality or labeling changes;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">scrutiny of advertising and promotion; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the withdrawal of indications granted pursuant to accelerated approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the past, clinical trials and post-marketing surveillance of certain marketed drugs of the Company and of competitors within the industry have raised concerns that have led to recalls, withdrawals or adverse labeling of marketed products. Clinical trials and post-marketing surveillance of certain marketed drugs also have raised concerns among some prescribers and patients relating to the safety or efficacy of pharmaceutical products in general that have negatively affected the sales of such products. In addition, increased scrutiny of the outcomes of clinical trials has led to increased volatility in market reaction. Further, these matters often attract litigation and, even where the basis for the litigation is groundless, considerable resources may be needed to respond.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, following in the wake of product withdrawals and other significant safety issues, health authorities such as the FDA, the EMA, Japan&#8217;s PMDA and China&#8217;s NMPA have increased their focus on safety when assessing the benefit/risk balance of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products or indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of the Company&#8217;s products, it could significantly reduce demand for the product or require the Company to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes. Further, in the current environment in which all pharmaceutical companies operate, the Company is at risk for product liability and consumer protection claims and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">civil and criminal governmental actions related to its products, research and/or marketing activities. In addition, dissemination of promotional materials through evolving digital channels serves to increase visibility and scrutiny in the marketplace.</span></div><div style="margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company is subject to a variety of U.S. and international laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is currently subject to a number of government laws and regulations and, in the future, could become subject to new government laws and regulations. The costs of compliance with such laws and regulations, or the negative results of non-compliance, could adversely affect the business, cash flow, results of operations, financial condition and prospects of the Company; these laws and regulations include (i) additional health care reform initiatives in the U.S. or in other countries, including additional mandatory discounts or fees;  (ii) the U.S. Foreign Corrupt Practices Act (FCPA) or other anti-bribery and corruption laws; (iii) new laws, regulations and judicial or other governmental decisions affecting pricing, drug reimbursement, and access or marketing within or across jurisdictions; (iv) changes in intellectual property laws; (v) changes in accounting standards; (vi) new and increasing data privacy regulations and enforcement, particularly in the EU, the U.S., and China; (vii) legislative mandates or preferences for local manufacturing of pharmaceutical or vaccine products; (viii) emerging and new global regulatory requirements for reporting payments and other value transfers to health care professionals; (ix) environmental regulations; and (x) the potential impact of importation restrictions, embargoes, trade sanctions and legislative and/or other regulatory changes.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to evolving and complex tax laws in the jurisdictions in which it operates. Significant judgment is required for determining the Company&#8217;s tax liabilities, and the Company&#8217;s tax returns are routinely examined by various tax authorities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the Organization for Economic Cooperation and Development (OECD) Base Erosion and Profit Shifting project, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company believes that its accrual for tax contingencies is adequate for all open years based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of tax contingencies, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. In addition, the Company may be negatively affected by changes in tax laws, or new tax laws, affecting, for example, tax rates, and/or revised tax law interpretations in domestic or foreign jurisdictions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">including, among others, any potential changes to the existing U.S. tax law by the current U.S. Presidential administration and Congress, as well as any changes in tax law resulting from the implementation of the OECD&#8217;s two-pillar solution to reform the international tax landscape</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has taken the position, based on the opinions of tax counsel, that its distribution of Organon common stock in connection with the 2021 Spin-Off qualifies as a transaction that is tax-free for U.S. federal income tax purposes. If any facts, assumptions, representations, and undertakings from the Company and Organon regarding the past and future conduct of their respective businesses and other matters are incorrect or not otherwise satisfied, the Spin-Off may not qualify for tax-free treatment, which could result in significant U.S. federal income tax liabilities for the Company and its shareholders.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Adverse outcomes in current or future legal matters could negatively affect Merck&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current or future litigation, claims, proceedings and government investigations could preclude or delay the commercialization of Merck&#8217;s products or could adversely affect Merck&#8217;s business, results of operations, cash flow, prospects and financial condition. Such legal matters may include, but are not limited to: (i) intellectual property disputes; (ii) adverse decisions in litigation, including product safety and liability, consumer protection and commercial cases; (iii) anti-bribery regulations, such as the FCPA, including compliance with ongoing reporting obligations to the government resulting from any settlements; (iv) recalls or withdrawals of pharmaceutical products or forced closings of manufacturing plants; (v) product pricing and promotional matters; (vi) lawsuits, claims and administrative proceedings asserting, or investigations into, violations of securities, antitrust, Federal and state pricing, consumer protection, data privacy and other laws and regulations; (vii) environmental, health, safety and sustainability matters, including regulatory actions in response to climate change; and (viii) tax liabilities resulting from assessments from tax authorities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, along with certain subsidiaries, are defendants in a number of lawsuits filed starting in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The lawsuits filed on behalf of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">twenty-five direct purchasers, eight retailers, and a class of indirect purchasers are scheduled to proceed to trial on April 17, 2023. In these cases, plaintiffs seek up to a maximum of $12.7 billion in damages after trebling.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11, &#8220;Contingencies and Environmental Liabilities&#8221; for more information on the Company&#8217;s legal matters.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product liability insurance for products may be limited, cost prohibitive or unavailable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of a number of factors, product liability insurance has become less available while the cost of such insurance has increased significantly. The Company is subject to a substantial number of product liability claims. See Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221; below for more information on the Company&#8217;s current product liability litigation. With respect to product liability, the Company self-insures substantially all of its risk, as the availability of commercial insurance has become more restrictive. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities. The Company will continually assess the most efficient means to address its risk; however, there can be no guarantee that insurance coverage will be obtained or, if obtained, will be sufficient to fully cover product liabilities that may arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Technology</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Company is increasingly dependent on sophisticated software applications and computing infrastructure. The Company could be a target of future cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is increasingly dependent on sophisticated software applications, complex information technology systems, computing infrastructure, and cloud service providers (collectively, IT systems) to conduct critical operations. Certain of these systems are managed, hosted, provided or used by third parties to assist in conducting the Company&#8217;s business. Disruption, degradation, or manipulation of these IT systems through intentional or accidental means by the Company&#8217;s employees, third parties with authorized access or unauthorized third parties could adversely affect key business processes. Cyber-attacks against the Company&#8217;s IT systems or third-party providers&#8217; IT systems, such as cloud-based systems, could result in exposure of confidential information, the modification of critical data, and/or the failure of critical operations. Misuse of any of these IT systems could result in the disclosure of sensitive personal information or the theft of trade secrets, intellectual property, or other confidential business information. The Company continues to leverage new and innovative technologies across the enterprise to replace outmoded technology and improve the efficacy and efficiency of its business processes, including data acquisition; the use of which can create new risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks and network disruptions on the Company&#8217;s operations and financial condition has not been material to date, the Company continues to be a target of events of this nature and expects them to continue. The Company monitors its data, information technology and personnel usage of Company IT systems to reduce these risks and continues to do so on an ongoing basis for any current or potential threats. There can be no assurance that the Company&#8217;s efforts to protect its data and IT systems or the efforts of third-party providers to protect their IT systems will be successful in preventing disruptions to the Company&#8217;s operations, including its manufacturing, research and sales operations. Such disruptions have in the past and could in the future result in loss of revenue, or the loss of critical or sensitive information from the Company&#8217;s or the Company&#8217;s third-party providers&#8217; databases or IT systems and have in the past and could in the future also result in financial, legal, business or reputational harm to the Company and substantial remediation costs.</span></div><div style="margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Social media and mobile messaging platforms present risks and challenges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The inappropriate and/or unauthorized use of certain social media and mobile messaging channels could cause brand damage or information leakage or could lead to legal implications, including from the improper collection and/or dissemination of personally identifiable information. In addition, negative or inaccurate posts or comments about the Company or its products on any social networking platforms could damage the Company&#8217;s reputation, brand image and goodwill. Further, the disclosure of non-public Company-sensitive information by the Company&#8217;s workforce or others through external media channels could lead to information loss. Although there are internal Company Social Media and Mobile Messaging Policies that guide employees on appropriate personal and professional use of these platforms for communication about the Company, the processes in place may not completely secure and protect information. Identifying new points of entry as new communication tools expand also presents new challenges.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cautionary Factors that May Affect Future Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Cautionary Statements Under the Private Securities Litigation Reform Act of 1995)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. The Company cautions you not to place undue reliance on these forward-looking statements. Although it is not possible to predict or identify all such factors, they may include the following:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Competition from generic and/or biosimilar products as the Company&#8217;s products lose patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Increased &#8220;brand&#8221; competition in therapeutic areas important to the Company&#8217;s long-term business performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">The difficulties and uncertainties inherent in new product development. The outcome of the lengthy and complex process of new product development is inherently uncertain. A drug candidate can fail at any stage of the process and one or more late-stage product candidates could fail to receive regulatory approval. New product candidates may appear promising in development but fail to reach the market because of efficacy or safety concerns, the inability to obtain necessary regulatory approvals, the difficulty or excessive cost to manufacture and/or the infringement of patents or intellectual property rights of others. Furthermore, the sales of new products may prove to be disappointing and fail to reach anticipated levels.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Pricing pressures, both in the U.S. and abroad, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">The impact of the global COVID-19 pandemic and any future pandemic, epidemic, or similar public health threat, on the Company&#8217;s business, operations, financial performance and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Changes in government laws and regulations, including laws governing intellectual property, and the enforcement thereof affecting the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Efficacy or safety concerns with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Cyber-attacks on the Company&#8217;s or third-party providers&#8217; information technology systems, which could disrupt the Company&#8217;s operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Lost market opportunity resulting from delays and uncertainties in the approval process of the FDA and foreign regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Increased focus on privacy issues in countries around the world, including the U.S., the EU, and China. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect directly the Company&#8217;s business, including laws in a majority of states in the U.S. requiring security breach notification.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Changes in tax laws including changes related to the taxation of foreign earnings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Changes in accounting pronouncements promulgated by standard-setting or regulatory bodies, including the Financial Accounting Standards Board and the SEC, that are adverse to the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:23.85pt">Economic factors over which the Company has no control, including changes in inflation, interest rates and foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This list should not be considered an exhaustive statement of all potential risks and uncertainties. See &#8220;Risk Factors&#8221; above.</span></div><div id="ia384118d157240e09e39541b90e2080f_58"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:10.02pt">Unresolved Staff Comments.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div id="ia384118d157240e09e39541b90e2080f_61"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.51pt">Properties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s corporate headquarters is currently located in Kenilworth, New Jersey. The Company has previously announced that it intends to consolidate its New Jersey campuses into a single corporate headquarters location in Rahway, New Jersey by the end of 2023. The Company also maintains operational or divisional headquarters in Kenilworth, New Jersey; Madison, New Jersey and Upper Gwynedd, Pennsylvania. Principal U.S. research facilities are located in Rahway and Kenilworth, New Jersey; West Point, Pennsylvania; Boston and Cambridge, Massachusetts; South San Francisco, California; and Elkhorn, Nebraska (Animal Health). Principal research facilities outside the U.S. are located in the United Kingdom, Switzerland and China. Merck&#8217;s manufacturing operations are currently headquartered in Rahway, New Jersey. The Company also has production facilities for human health products at seven locations in the U.S. and Puerto Rico. Outside the U.S., through subsidiaries, the Company owns or has an interest in manufacturing plants or other properties in Japan, Singapore, South Africa, and other countries in Western Europe, Central and South America, and Asia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and its subsidiaries own their principal facilities and manufacturing plants under titles that they consider to be satisfactory. The Company believes that its properties are in good operating condition and that its machinery and equipment have been well maintained. The Company believes that its plants for the manufacture of products are suitable for their intended purposes and have capacities and projected capacities, including previously disclosed capital expansion projects, that will be adequate for current and projected needs for existing Company products. Some capacity of the plants is being converted, with any needed modification, to the requirements of newly introduced and future products.</span></div><div id="ia384118d157240e09e39541b90e2080f_64"></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.51pt">Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;11. &#8220;Contingencies and Environmental Liabilities&#8221;.</span></div><div id="ia384118d157240e09e39541b90e2080f_67"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.51pt">Mine Safety Disclosures.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:5pt;text-indent:45pt"><span><br/></span></div><div id="ia384118d157240e09e39541b90e2080f_70"></div><div style="text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Officers of the Registrant (ages as of February&#160;1, 2023)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All officers listed below serve at the pleasure of the Board of Directors. None of these officers was elected pursuant to any arrangement or understanding between the officer and any other person(s).</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Offices and Business Experience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Robert M. Davis</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chairman, President and Chief Executive Officer (since December 2022); Chief Executive Officer and President (July 2021-December 2022); Executive Vice President, Global Services, and Chief Financial Officer (April 2016-July 2021)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sanat Chattopadhyay</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and President, Merck Manufacturing Division (since March 2016)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard R. DeLuca, Jr.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and President, Merck Animal Health (since September 2011)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cristal Downing </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and Chief Communications &amp; Public Affairs Officer (since August 2021); Vice President Medical Devices, Global Communications and Public Affairs Johnson &amp; Johnson (December 2020-August 2021); Vice President Financial Communication, Johnson &amp; Johnson (January 2018-December 2020); Prior to that, Senior Director Communications at Johnson &amp; Johnson</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chirfi Guindo</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022); Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation, Biogen Inc. (November 2017-June 2018)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rita A. Karachun</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller (since March 2014)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael A. Klobuchar</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Executive Vice President, Chief Strategy Officer (since July 2021); Senior Vice President, CFO of Merck R&amp;D and Head of Global Portfolio and Alliance Management (January 2019-June 2021); Senior Vice President of Corporate Strategy and Planning and President of Emerging Businesses (December 2017-January 2019)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lisa LeCointe-Cephas</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Senior Vice President, Chief Ethics and Compliance Officer (since April 2021); Executive Director, Head of Global Investigations (February 2018-April 2021); Prior to that, Senior Counsel, Litigation and Government Investigations, Bristol-Myers Squibb Company</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dean Li</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021); Vice President, Translational Medicine (March 2017-November 2017)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caroline Litchfield</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Executive Vice President and Chief Financial Officer (since April 2021); Senior Vice President, Corporate Treasurer (January 2018-March 2021) </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steven C. Mizell<br/></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Chief Human Resources Officer (since October 2018); Prior to that, Executive Vice President, Human Resources, Monsanto Company</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johannes J. Oosthuizen</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Joseph Romanelli</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President and President MSD International Human Health (since July 2022); Chief Executive Officer JiXing Pharmaceuticals (July 2021-July 2022); President MSD China (December 2016-July 2021) </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David M. Williams</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Executive Vice President, Chief Information and Digital Officer (since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020); Vice President and Chief Information Officer, Merck Animal Health (May 2017-December 2019)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary (since January 2020); Executive Vice President and General Counsel (April 2018-January 2020); Prior to that, Partner, Covington &amp; Burling LLP</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-indent:45pt"><span><br/></span></div><div id="ia384118d157240e09e39541b90e2080f_73"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ia384118d157240e09e39541b90e2080f_76"></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.51pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal market for trading of the Company&#8217;s Common Stock is the New York Stock Exchange (NYSE) under the symbol MRK. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of January&#160;31, 2023, there were approximately 95,850 shareholders of record of the Company&#8217;s Common Stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended December&#160;31, 2022 were as follows:</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.065%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">($&#160;in&#160;millions)</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of Shares</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average&#160;Price<br/>Paid Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Approximate&#160;Dollar&#160;Value&#160;of&#160;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the Plans or Programs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 1 &#8212; October 31</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 1 &#8212; November 30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1 &#8212; December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The Company did not purchase any shares during the three months ended December 31, 2022 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion in Merck shares for its treasury.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="text-align:center"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graph assumes a $100 investment on December&#160;31, 2017, and reinvestment of all dividends, in each of the Company&#8217;s Common Stock, the S&amp;P 500 Index, and a composite peer group of major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Johnson&#160;&amp; Johnson, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Comparison of Five-Year Cumulative Total Return</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc., Composite Peer Group and S&amp;P 500 Index</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of<br/>Period&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022/2017<br/>CAGR*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MERCK</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$242</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PEER GROUP**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9%</span></td></tr></table></div><div style="text-align:center"><img src="mrk-20221231_g2.jpg" alt="mrk-20221231_g2.jpg" style="height:280px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.641%"><tr><td style="width:1.0%"></td><td style="width:27.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MERCK</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140.0</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.2</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158.8</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.7</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PEER GROUP</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125.7</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164.8</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125.7</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.8</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156.8</span></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Compound Annual Growth Rate</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Peer group average was calculated on a market cap weighted basis as of December 31, 2017. </span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Performance Graph will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference. In addition, the Performance Graph will not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC or subject to Regulation 14A or 14C, other than as provided in Regulation S-K, or to the liabilities of section 18 of the Securities Exchange Act of 1934, except to the extent that the Company specifically requests that such information be treated as soliciting material or specifically incorporates it by reference into a filing under the Securities Act or the Exchange Act.</span></div><div id="ia384118d157240e09e39541b90e2080f_2209"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6. &#160;&#160;&#160;&#160;[Reserved]</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.51pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following section of this Form 10-K generally discusses 2022 and 2021 results and year-to-year comparisons between 2022 and 2021. Discussion of 2020 results and year-to-year comparisons between 2021 and 2020 that are not included in this Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed on February 25, 2022</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">.</span></div><div id="ia384118d157240e09e39541b90e2080f_82"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Description of Merck&#8217;s Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company&#8217;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners. </span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note&#160;3 to the consolidated financial statements).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div id="ia384118d157240e09e39541b90e2080f_85"></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Overview</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution from Continuing Operations Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7.48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.37&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* &gt; 100% </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs, gains and losses from investments in equity securities, and certain other items from Merck&#8217;s results prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). In 2022, the Company changed the treatment of certain items for purposes of its non-GAAP reporting. Prior periods have been recast to conform to the current presentation. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS, see &#8220;Non-GAAP Income and Non-GAAP EPS from Continuing Operations&#8221; below</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#8217;s 2022 results reflect sustained strong demand for the Company&#8217;s innovative product portfolio benefiting patients globally, enabled by strong operational and commercial execution, the completion of business development transactions to support its science-led strategy, as well as progress in its pipeline across therapeutic areas, modalities and stage of development. </span></div><div style="margin-top:3pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:45pt"><img src="mrk-20221231_g3.jpg" alt="mrk-20221231_g3.jpg" style="height:175px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales were $59.3 billion in 2022, an increase of 22% compared with 2021, or 26% excluding the unfavorable effect of foreign exchange. The sales increase was primarily due to growth in virology (driven by the benefit of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales), oncology, vaccines and hospital acute care. Sales within the Animal Health business were consistent with prior year. As discussed below, COVID-19-related disruptions negatively affected sales in 2022, but to a lesser extent than in 2021, which benefited year-over-year sales growth. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck continues to execute strategic business development opportunities to augment its robust internal pipeline with compelling external science. Highlights of 2022 activity include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Exercised an option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 under an existing collaboration and license agreement with Moderna, Inc. (Moderna).</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Entered into a collaboration with Orna Therapeutics (Orna), a company pioneering a new investigational class of engineered circular RNA therapies, to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Entered into a global co-development and co-commercialization agreement for Orion Corporation&#8217;s (Orion) investigational candidate ODM-208 (MK-5684) currently being evaluated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Entered into a license and collaboration agreement with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Exercised an option to obtain an exclusive license (outside of Chinese mainland, Hong Kong, Macau and Taiwan) for the development, manufacture and commercialization of Kelun-Biotech&#8217;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound SKB-264 (MK-2870). </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Entered into a license and collaboration agreement expanding the Company&#8217;s relationship with Kelun-Biotech pursuant to which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs for the treatment of cancer (Kelun-Biotech retained rights for certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau); the transaction closed in February 2023. </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Entered into agreement to acquire Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases; the acquisition closed in January 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During 2022, the Company received numerous regulatory approvals within oncology. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of biliary, colorectal, endometrial, gastric, melanoma, small intestine and renal cell cancers, as well as in combination with chemotherapy in the therapeutic areas of breast and cervical cancers. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was also approved in combination with Lenvima in Japan for the treatment of certain adult patients with radically unresectable or metastatic renal cell carcinoma (RCC). Lenvima is being developed in collaboration with Eisai Co., Ltd. (Eisai). Lynparza, which is being developed in collaboration with AstraZeneca PLC (AstraZeneca), received approval in the U.S., the European Union (EU) and Japan for the adjuvant treatment of certain adult patients with high-risk early breast cancer and in the EU for the treatment of certain patients with mCRPC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a vaccine to help prevent pneumococcal disease, was approved for expanded indications in the U.S. and the EU to include use in infants, adolescents and children. Additionally in 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lyfnua</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (gefapixant) was approved in Japan for adults with refractory or unexplained chronic cough. In addition, in 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which is being developed in a collaboration with Ridgeback Biotherapeutics LP (Ridgeback), received emergency conditional approval in China for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the recent regulatory approvals discussed above, the Company advanced its late-stage pipeline with several regulatory submissions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review in the U.S. and/or internationally for supplemental indications for the treatment of certain patients with hepatocellular, Merkel cell, non-small-cell lung and urothelial cancers, as well as primary mediastinal B-cell lymphoma (PMBCL). Lynparza is under review for supplemental indications in the U.S. and Japan for the treatment of certain patients with mCRPC. MK-4482, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, an investigational oral antiviral COVID-19 medicine, is under a rolling review by the European Medicines Agency (EMA); the Committee for Medicinal Products for Human Use of the EMA has recommended the refusal of the marketing authorization, which Merck and Ridgeback intend to appeal. MK-7264, gefapixant, a selective, non-narcotic, orally-administered, investigational P2X3-receptor antagonist being developed for the treatment of refractory, chronic cough is under review in the U.S. and the EU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Phase 3 oncology programs include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.85pt">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the therapeutic areas of biliary, cutaneous squamous cell, gastric, hepatocellular, mesothelioma, ovarian, prostate and small-cell lung cancers; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Lynparza in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for non-small-cell lung and small-cell lung cancers; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Lenvima in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for colorectal, esophageal, gastric, head and neck, melanoma and non-small-cell lung cancers; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-1308A, the coformulation of quavonlimab, Merck&#8217;s novel investigational anti-CTLA-4 antibody, and pembrolizumab for RCC; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-3475, subcutaneous pembrolizumab for non-small-cell lung cancer (NSCLC);</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-3475A, the subcutaneous coformulation of pembrolizumab with hyaluronidase, for NSCLC;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-4280A, the coformulation of favezelimab, Merck&#8217;s novel investigational anti-LAG3 therapy, and pembrolizumab for colorectal cancer and hematological malignancies; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.85pt">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for RCC; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-7119, Tukysa (tucatinib), which is being developed in collaboration with Seagen Inc. (Seagen), for breast and colorectal cancers; and </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-7684A, the coformulation of vibostolimab, an anti-TIGIT therapy, and pembrolizumab for melanoma, non-small-cell and small-cell lung cancers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, the Company currently has candidates in Phase 3 clinical development in several other therapeutic areas including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">V116, an investigational 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-7962, sotatercept, for the treatment of pulmonary arterial hypertension (PAH); </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-1654, clesrovimab, for the prevention of respiratory syncytial virus; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-8591A, islatravir in combination with doravirine for the treatment of HIV-1 infection (which is on partial clinical hold for higher doses than those used in current clinical trials); and </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">MK-4482, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which is reflected in Phase 3 development in the U.S. as it remains investigational following Emergency Use Authorization in 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#8217;s capital allocation priorities are to make investments in its business to drive near- and long-term growth, including investing in opportunities to address important unmet medical needs and supporting the Company&#8217;s commercial opportunities. In addition, Merck remains committed to its dividend and will continue to pursue the most compelling external science through value-enhancing business development transactions. Research and development expenses in 2022 reflect higher clinical development spending particularly in the therapeutic areas of oncology, cardiovascular, infectious diseases and vaccines.</span></div><div style="margin-top:6pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:45pt"><img src="mrk-20221231_g4.jpg" alt="mrk-20221231_g4.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2022, Merck&#8217;s Board of Directors approved an increase to the Company&#8217;s quarterly dividend, raising it to $0.73 per share from $0.69 per share on the Company&#8217;s outstanding common stock. During 2022, the Company returned $7.0 billion to shareholders through dividends.</span></div><div style="text-align:center;text-indent:45pt"><img src="mrk-20221231_g5.jpg" alt="mrk-20221231_g5.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="mrk-20221231_g6.jpg" alt="mrk-20221231_g6.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">GAAP and Non-GAAP EPS were negatively affected in 2022, 2021 and 2020 by $0.22, $0.65, and $1.56, respectively, of charges for certain upfront and pre-approval milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">War in Ukraine</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. The Company&#8217;s primary concerns are the safety and well-being of its employees and ensuring patients and customers have continued access to medicines and vaccines needed for patient and public health. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck&#8217;s supply chain, operations and clinical trials. For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with international sanctions. Merck is donating profits </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products. The financial impacts of the war were immaterial to the Company&#8217;s consolidated financial statements for 2022. Sales to Russia were approximately 1% of total Merck consolidated sales for 2022 and are expected to decline in future periods. The Company is unable to determine at this time the future direct or indirect impacts of this war on the Company&#8217;s business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although COVID-19-related disruptions had some negative effect on sales in 2022, Merck continues to believe that global health systems and patients have largely adapted to the impacts of the COVID-19 pandemic. Merck&#8217;s revenue in 2022 benefited from sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which were $5.7 billion. Merck expects sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will decline significantly in 2023 to approximately $1.0 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, COVID-19-related disruptions resulted in an estimated negative impact to Pharmaceutical segment sales of approximately $1.3 billion because a substantial portion of Pharmaceutical segment revenue is comprised of physician-administered products, which were unfavorably affected by social distancing measures and fewer well visits. Sales in 2021 benefited from $952 million of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, Merck announced it was discontinuing the development of MK-7110 for the treatment of hospitalized patients with COVID-19, which was obtained as part of Merck&#8217;s acquisition of OncoImmune (see Note&#160;4 to the consolidated financial statements). This decision resulted in charges of $207&#160;million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Operating expenses in 2021 reflect a minor positive effect as investments in COVID-19-related research largely offset the favorable impact of lower spending in other areas due to the COVID-19 pandemic. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, provided Merck with $102 million of funding in the first quarter of 2022 to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. The funding was recognized as a reduction to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the expected production period, offsetting the depreciation expense related to the amounts that were capitalized in connection with the modification of the manufacturing facilities. Merck and Johnson &amp; Johnson have commenced an arbitration regarding a dispute concerning two agreements pursuant to which Merck was supporting the manufacturing and supply of Johnson &amp; Johnson&#8217;s SARS-CoV-2/COVID-19 vaccine and vaccine drug product. The amounts included in the consolidated financial statements for these agreements were immaterial in 2022. Merck does not believe the outcome of the arbitration will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pricing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s sales performance in 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In 2022, the U.S. Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supply Chain</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of global macroeconomic conditions, the Company is experiencing some minor disruption and volatility in its global supply chain network. These disruptions could increase in the future and cause delays in shipments of raw materials and packaging, as well as related cost inflation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Sales</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32,077</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales grew 22% in 2022 attributable in part to higher sales in the virology franchise driven by </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Also contributing to revenue growth were higher sales in the oncology franchise largely due to strong growth of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and increased alliance revenue from Lenvima and Lynparza, as well as higher sales in the vaccines franchise, primarily attributable to growth in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9 and the launch of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for pediatric use. Higher sales of hospital acute care products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Dificid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, as well as higher revenue related to third-party manufacturing arrangements also drove revenue growth in 2022. As discussed above, COVID-19-related disruptions had some negative effects on sales in 2022, but to a lesser extent than in 2021, which benefited year-over-year sales growth. Sales growth in 2022 was partially offset by lower sales of diabetes products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 vaccine, and virology products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales in the U.S. grew 21% in 2022 primarily driven by higher sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil 9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, as well as increased alliance revenue from Lenvima and Reblozyl (obtained as part of the Acceleron Pharma Inc. (Acceleron) acquisition in November 2021), and the launch of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for pediatric use</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Higher sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Dificid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, as well as increased revenue from third-party manufacturing arrangements also contributed to U.S. sales growth in 2022. Lower sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> partially offset revenue growth in the U.S. in 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International sales grew 22% in 2022 primarily due to higher sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, as well as increased revenue from third-party manufacturing arrangements, partially offset by lower sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Remicade</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23. International sales represented 54% of total sales in both 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note&#160;19 to the consolidated financial statements for details on sales of the Company&#8217;s products. A discussion of performance for select products in the franchises follows.</span></div><div id="ia384118d157240e09e39541b90e2080f_91"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* &gt; 100%</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;5 to the consolidated financial statements).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&#160;5 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), NSCLC, melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, MSI-H/dMMR advanced endometrial carcinoma, PMBCL, tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer. Additionally, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved as monotherapy for the adjuvant treatment of certain patients with RCC at intermediate-high or high risk of recurrence and for certain patients with completely resected stage IIB, IIC or III melanoma, and for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a &#8805;4 cm), II, or IIIA NSCLC. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy, with or without bevacizumab for advanced cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for locally recurrent unresectable or metastatic TNBC, in combination with axitinib for advanced RCC, and in combination with Lenvima for certain patients with advanced endometrial carcinoma or advanced RCC. The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> grew 22% in 2022 primarily driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> with multiple new indications globally. Sales in the U.S. continue to build across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, HNSCC, and MSI-H cancers. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales growth in the U.S. also benefited from increased uptake across recent launches in earlier-stage indications including in high-risk early stage TNBC, as well as certain types of RCC and melanoma. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales growth in international markets reflects continued uptake predominately for the NSCLC, HNSCC and RCC indications, particularly in Europe.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> recently received numerous regulatory approvals summarized below.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approval</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Japan&#8217;s Ministry of Health, Labor and Welfare (MHLW) approval of the combination of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> plus Lenvima for radically unresectable or metastatic RCC, based on the CLEAR (Study 307)/KEYNOTE-581 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care), based on the KEYNOTE-158 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation, based on the KEYNOTE-158 trial (Cohorts D &amp; K). </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1, based on the KEYNOTE-826 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approval as monotherapy for the treatment of certain adult patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial carcinoma, based on the KEYNOTE-164 and KEYNOTE-158 trials.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence, based on the KEYNOTE-522 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approval as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection, based on the KEYNOTE-716 trial. EC approval expanding the indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approval as monotherapy for the adjuvant treatment of certain patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and HER2-negative breast cancer at high risk of recurrence, based on the KEYNOTE-522 trial.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approval in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment, based on the KEYNOTE-826 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approval as monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection, based on the KEYNOTE-716 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">China&#8217;s National Medical Products Administration (NMPA) approval as monotherapy for the treatment of patients with HCC who have been previously treated with sorafenib or oxaliplatin-based chemotherapy, based on the KEYNOTE-394 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2022</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NMPA approval for the treatment of patients with high-risk early-stage TNBC whose tumors express PD-L1, in combination with chemotherapy as neoadjuvant treatment, and then continued as a monotherapy as adjuvant treatment after surgery, based on the KEYNOTE-522 trial.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a &#8805;4 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial. </span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Under the terms of the more significant of these agreements, Merck pays a royalty of 6.5% on worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> through December 2023 to one third party; this royalty will decline to 2.5% for 2024 through 2026 and will terminate thereafter. The Company pays an additional 2% royalty on worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to another third party, the termination date of which varies by country; this royalty will expire in the U.S. in September 2024 and on varying dates in major European markets in the second half of 2025. The royalties are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca (see Note&#160;5 to the consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza grew 13% in 2022 largely due to higher demand globally across the multiple approved indications, particularly in the U.S. largely attributable to uptake in the earlier-stage breast cancer indication following approval by the FDA in March 2022. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lynparza received several regulatory approvals in 2022 summarized below.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approval</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">FDA approval for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, based on the OlympiA trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">MHLW approval for the adjuvant treatment of patients with</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">-mutated, HER2-negative high recurrent risk breast cancer, based on the OlympiA trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">EC approval as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1/2-mutations who have HER2-negative, high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy, based on the OlympiA trial. </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">NMPA approval as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status, based on the PAOLA-1 trial.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EC approval in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated, based on the PROpel trial. </span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai (see Note&#160;5 to the consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to Lenvima grew 24% in 2022 reflecting uptake in the advanced RCC and advanced endometrial carcinoma indications, particularly in the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#8217;s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (see Note&#160;5 to the consolidated financial statements). Reblozyl is approved for the treatment of certain types of anemia. Merck recorded alliance revenue of $166 million in 2022, which includes </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">royalties of $146&#160;million, as well as the receipt of a regulatory approval milestone payment of $20&#160;million, compared with alliance revenue of $17 million in 2021. </span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,897</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">839</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">991</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">602</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Combined worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 22% in 2022 driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from increased supply. Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 in the U.S. increased due to public sector buying patterns and higher pricing, partially offset by lower demand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, China&#8217;s NMPA expanded the use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 for use in girls and women ages 9 to 45. The vaccine was previously approved for use in girls and women ages 16 to 26. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 to one third party (which expires in December 2023) and an additional 7% royalty on sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 in the U.S. to another third party (which expires in December 2028). The royalties are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, grew 9% in 2022 primarily due to higher pricing in the U.S. and higher demand in Europe.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II, a vaccine to help protect against measles, mumps and rubella, grew 5% in 2022 primarily due to higher pricing in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Varivax,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> a vaccine to help prevent chickenpox (varicella), grew 2% in 2022 primarily reflecting higher pricing in the U.S., partially offset by lower tenders in Latin America. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23, a vaccine to help prevent pneumococcal disease, declined 33% in 2022 primarily reflecting lower demand in the U.S. as the market continues to shift toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention&#8217;s (CDC&#8217;s) Advisory Committee on Immunization Practices (ACIP) in 2021. The Company expects the decline in U.S. sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 to continue. Lower demand in Europe also contributed to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 sales decline in 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2022, the FDA approved an expanded indication for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to include use in individuals 6 weeks of age and older. The FDA&#8217;s approval was based on data from seven randomized, double-blind clinical studies assessing safety, tolerability and immunogenicity of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in infants and children. Also in June 2022, the CDC&#8217;s ACIP unanimously voted to include </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as a recommended option for vaccination in infants and children, including routine use in children under 2 years of age. These recommendations subsequently were adopted by the director of the CDC and the U.S. Department of Health and Human Services, and published in the CDC&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Morbidity and Mortality Weekly Report</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">MMWR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). The ACIP also unanimously voted to include </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the Vaccines for Children program. In October 2022, the EC approved an expanded indication for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to include use in infants, children and adolescents from 6 weeks to less than 18 years of age. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was previously approved for use in the U.S. and the EU in 2021 for individuals 18 years of age and older. In September 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was approved in Japan for use in adult patients. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> remains under review in Japan for use in pediatric patients. Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $170 million in 2022, largely due to inventory stocking in the U.S. Merck is party to a third-party licensing agreement pursuant to which the Company pays a royalty of 7.25% on net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> through 2026; this royalty will decline to 2.5% on net sales from 2027 through 2035. The royalties are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* Calculation not meaningful.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">** &gt;100%</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 10% in 2022 due to higher demand globally, particularly in the U.S., largely attributable to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8217;s growing share among neuromuscular blockade reversal agents and an increase in surgical procedures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will lose market exclusivity in the EU in July 2023 and the Company anticipates sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in these markets will decline thereafter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 16% in 2022 due to higher demand globally, particularly in the U.S. and Europe. In February 2023, the FDA granted priority review for a supplemental New Drug Application for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (D+/R-); the Prescription Drug User Fee Act (PDUFA), or target action, date is June 5, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Dificid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for the treatment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">C. difficile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">-associated diarrhea, grew 50% in 2022 due to higher demand in the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. As a result, the Company recorded an intangible asset impairment charge in 2020 related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note&#160;9 to the consolidated financial statements). The phased resupply of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> that was initiated in the fourth quarter of 2021 was completed in 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for the treatment of certain adult patients with von Hippel-Lindau disease-associated RCC, increased to $123 million in 2022 due to continued uptake in the U.S. following launch in 2021.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;5 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adempas and Verquvo are part of a worldwide collaboration with Bayer to market and develop soluble guanylate cyclase (sGC) modulators (see Note&#160;5 to the consolidated financial statements). Adempas is approved for the treatment of certain types of PAH and chronic thromboembolic pulmonary hypertension. Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Alliance revenue from the collaboration was essentially flat in 2022 compared with 2021 reflecting higher profit share related to Adempas that was partially offset by lower profit share for Verquvo reflecting higher launch costs. Revenue also includes sales of Adempas and Verquvo in Merck&#8217;s marketing territories. Sales of Adempas in Merck&#8217;s marketing territories declined 6% in 2022; excluding the unfavorable effect of foreign exchange, sales grew 7% primarily reflecting higher demand in Japan.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Virology</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">633</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* &gt; 100%</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note&#160;5 to the consolidated financial statements). Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide. The increase in sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in 2022 primarily reflects higher sales in the UK, Japan and the U.S., as well as the launch in Australia. In December 2022, China&#8217;s NMPA granted emergency conditional approval for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19. Merck expects sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will decline significantly in 2023 to approximately $1.0 billion reflecting in part the waning impact of the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 18% in 2022 due to lower global demand, reflecting in part competitive pressure particularly in Europe, Latin America and the U.S. The Company expects competitive pressure for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to continue. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will lose market exclusivity in the EU in July 2023 and the Company anticipates sales declines of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in these markets will accelerate thereafter.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:-4.5pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,288&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 15% in 2022 primarily reflecting the loss of exclusivity in several markets in Europe and the Asia Pacific region, as well as lower demand in the U.S. The sales decline was partially offset by increased demand in Latin America reflecting in part higher government tenders. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the key U.S. patent for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note&#160;11 to the consolidated financial statements), the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity in the U.S. toward the end of 2023. As a result of competitive pressures, the Company anticipates pricing and volume declines for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the U.S. in 2023 and thereafter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in all of the EU and for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in some European countries in September 2022. Merck expects that exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be lost in other European countries in April 2023. While the Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in China in 2022 with the approval of a generic equivalent product, the impact on sales in 2023 is expected to be modest. It is anticipated that a generic equivalent of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be approved in China in the first quarter of 2023, but the impact to sales in 2023 is also expected to be modest. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in Europe, China and the U.S. represented 19%, 11% and 36%, respectively, of total combined </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In response to a request from a regulatory authority, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug&#8217;s manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities&#8217; interim acceptable NTTP limits for continuing distribution of product to the market. The Company is making progress in its efforts to reduce the level </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of nitrosamines in its sitagliptin-containing medicines. However, difficulties in reducing those levels, or achieving timely regulatory approvals for required changes, could result in product shortages. </span></div><div id="ia384118d157240e09e39541b90e2080f_94"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of livestock products were essentially flat in 2022 primarily due to the unfavorable effect of foreign exchange, offset by higher pricing, as well as increased demand for ruminant and poultry products. Sales of companion animal products declined 1% in 2022 reflecting the unfavorable effect of foreign exchange and supply constraints for certain vaccines, largely offset by higher pricing in the portfolio, as well as higher demand for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> line of products, which had sales of $1.0 billion in 2022.</span></div><div id="ia384118d157240e09e39541b90e2080f_97"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,411</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,042</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">337</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42,839</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,655&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* Calculation not meaningful.</span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales was $17.4 billion in 2022 and $13.6 billion in 2021. Cost of sales includes $3.0 billion and $502 million in 2022 and 2021, respectively, related to the collaboration with Ridgeback for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note&#160;5 to the consolidated financial statements). Cost of sales also includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $2.0 billion in 2022 and $1.6 billion in 2021. Amortization expense in 2022 and 2021 includes $250&#160;million and $153 million, respectively, of cumulative catch-up amortization related to Merck&#8217;s collaborations with AstraZeneca and Bayer, respectively (see Note&#160;5 to the consolidated financial statements). Additionally, costs in 2021 include charges of $225 million related to the discontinuation of COVID-19 development programs (see Note&#160;4 to the consolidated financial statements). Also included in cost of sales are expenses associated with restructuring activities, which amounted to $205 million in 2022 and $160 million in 2021, primarily reflecting accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross margin was 70.6% in 2022 compared with 72.0% in 2021. The gross margin decline primarily reflects the unfavorable impacts of higher amortization of intangible assets (noted above), as well as higher sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and revenue from third-party manufacturing arrangements, both of which have lower gross margins. The gross margin decline was partially offset by the favorable effects of product mix, foreign exchange and charges in 2021 related to the discontinuation of COVID-19 development programs (noted above). </span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses were $10.0 billion in 2022, an increase of 4% compared with 2021. The increase was primarily due to higher administrative costs, as well as higher promotional spending and selling costs, partially offset by the favorable effects of foreign exchange and lower acquisition-related costs. </span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses were $13.5 billion in 2022, an increase of 11% compared with 2021 primarily due to higher intangible asset impairment charges (largely related to nemtabrutinib), higher charges for upfront and option payments related to collaborations and licensing arrangements, higher compensation </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and benefit costs reflecting in part increased headcount to support expanded clinical development activity, and increased clinical development spending. The increase in R&amp;D expenses was partially offset by a charge in 2021 for the acquisition of Pandion Therapeutics, Inc. (Pandion).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company&#8217;s research and development division that focuses on human health-related activities, which were $7.7 billion in 2022 and $7.1 billion in 2021. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were $4.1 billion in 2022 and $4.7 billion in 2021. The decrease in these expenses in 2022 largely reflects a $1.7 billion charge in 2021 for the acquisition of Pandion, partially offset by $690 million of upfront and option payments in the aggregate for collaboration and licensing agreements with Moderna, Orna and Orion. See Note&#160;4 to the consolidated financial statements for additional information related to these business development transactions. R&amp;D expenses also include impairment charges of $1.7 billion and $275 million in 2022 and 2021, respectively, largely related to nemtabrutinib (see Note&#160;9 to the consolidated financial statements). The Company may recognize additional impairment charges in the future related to the cancellation or delay of other pipeline programs that were measured at fair value and capitalized in connection with business combinations and such charges could be material. R&amp;D expenses also include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business combinations. The Company recorded a net reduction in expenses of $75 million in 2022 compared with $35 million of expenses in 2021 related to changes in these estimates.</span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. Merck expects to record charges of approximately $400 million in 2023 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in cumulative annual net cost savings of approximately $900 million by the end of 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $337 million in 2022 and $661 million in 2021. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional costs associated with the Company&#8217;s restructuring activities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">costs. The Company recorded aggregate pretax costs of $666 million in 2022 and $868 million in 2021 related to restructuring program activities (see Note&#160;6 to the consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, was $1.5 billion of expense in 2022 compared with $1.3 billion of income in 2021 primarily due to net unrealized losses from investments in equity securities in 2022 compared with net realized and unrealized gains from investments in equity securities recorded in 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For details on the components of Other (income) expense, net, see Note&#160;15 to the consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-reportable segment profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(22,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A and R&amp;D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&amp;D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in &#8220;Other&#8221; in the above table. Also included in &#8220;Other&#8221; are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits grew 19% in 2022 primarily due to higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of foreign exchange. Animal Health segment profits grew 1% in 2022 reflecting lower manufacturing costs, partially offset by higher selling and administrative costs and the unfavorable effect of foreign exchange. </span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Taxes on Income</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were 11.7% in 2022 and 11.0% in 2021. The tax rate from continuing operations in 2022 and 2021 reflect a favorable mix of income and expense. The tax rate from continuing operations in 2022 also reflects the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. These items reduced domestic pretax income by approximately $2.9&#160;billion in 2022. The tax rate from continuing operations in 2021 also reflects higher foreign tax credits from ordinary business operations that the Company was able to credit, the beneficial impact of the settlement of a foreign tax matter, as well as a net tax benefit of $207&#160;million related to the settlement of certain federal income tax matters (see Note&#160;16 to the consolidated financial statements). Additionally, the tax rate from continuing operations in 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized. </span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-GAAP Income and Non-GAAP EPS from Continuing Operations</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are alternative views of the Company&#8217;s performance that Merck is providing because management believes this information enhances investors&#8217; understanding of the Company&#8217;s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items. These excluded items are significant components in understanding and assessing financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP&#160;EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management&#8217;s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP&#160;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&#160;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with GAAP. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, the Company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck&#8217;s non-GAAP results excluded expenses for upfront and pre-approval milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the Company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Merck&#8217;s non-GAAP results no longer exclude charges related to these items. Prior periods have been recast to conform to the current presentation.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures (from continuing operations) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from continuing operations before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges for the discontinuation of COVID-19 development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP income from continuing operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22,162</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes on income from continuing operations as reported under GAAP</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated tax benefit on excluded items </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net tax benefit from the settlement of certain federal income tax matters</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP taxes on income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,932&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,012</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests as reported under GAAP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS assuming dilution from continuing operations as reported under GAAP</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.37&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.97&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt">Amounts in 2022, 2021 and 2020 include $1.7 billion, $302 million and $1.7 billion, respectively, of intangible asset impairment charges. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments. </span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisition and Divestiture-Related Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude costs related to restructuring actions (see Note&#160;6 to the consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income and Losses from Investments in Equity Securities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS are charges related to the discontinuation of COVID-19 development programs (see Note&#160;4 to the consolidated financial statements), as well as a net tax benefit related to the settlement of certain federal income tax matters (see Note&#160;16 to the consolidated financial statements), and an adjustment to tax benefits recorded in conjunction with the 2015 acquisition of Cubist Pharmaceuticals, Inc. </span></div><div id="ia384118d157240e09e39541b90e2080f_100"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research Pipeline</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally, as well as in late-stage clinical development. A chart reflecting the Company&#8217;s current research pipeline as of February&#160;17, 2023 and related discussion is set forth in Item&#160;1. &#8220;Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Research and Development&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, Research Collaborations and Licensing Agreements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck continues to remain focused on pursuing opportunities that have the potential to drive both near- and long-term growth. Certain recent transactions are summarized below; additional details are included in Note&#160;4 to the consolidated financial statements. Merck actively monitors the landscape for growth opportunities that meet the Company&#8217;s strategic criteria.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $175&#160;million, which will be recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100&#160;million in Kelun-Biotech&#8217;s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago, a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60&#160;million of transaction costs. Imago&#8217;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $200 million and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.2 billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, which resulted in a $250&#160;million charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. In February 2023, Merck and Moderna announced that mRNA-4157/V940 was granted Breakthrough Therapy Designation by the FDA for the adjuvant treatment of patients with high-risk melanoma following complete resection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. In addition, Orna is eligible to receive future contingent </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">development-related payments, as well as royalties on any approved products derived from the collaboration. Merck also invested $100&#160;million in Orna&#8217;s Series B preferred shares in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion announced a global co-development and co-commercialization agreement for Orion&#8217;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with mCRPC. Merck made an upfront payment to Orion of $290&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments, as well as tiered royalties on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech&#8217;s TROP2-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for advanced solid tumors. Upon option exercise, Merck made a payment of $30&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022, and agreed to make additional payments upon completion of specified project activities, technology transfer, as well as payments to fund Kelun-Biotech&#8217;s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent developmental and sales-based milestone payments and royalties on future net sales.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with business combinations, the Company has recorded the fair value of in-process research projects which, at the time of acquisition, had not yet reached technological feasibility. At December&#160;31, 2022, the balance of IPR&amp;D was $7.7 billion, primarily consisting of MK-7962 (sotatercept), $6.4 billion; MK-7264 (gefapixant), $832 million; and MK-1026 (nemtabrutinib), $418 million. Sotatercept is in Phase 3 clinical development and the Company anticipates filing sotatercept with regulatory authorities in 2023. Gefapixant is under review in the U.S. and the EU. Nemtabrutinib is in Phase 2 clinical development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates. The time periods to receive approvals from the FDA and other regulatory agencies are subject to uncertainty. Significant delays in the approval process, or the Company&#8217;s failure to obtain approval at all, would delay or prevent the Company from realizing revenues from these products. Additionally, if the IPR&amp;D programs require additional clinical trial data than previously anticipated, or if the programs fail or are abandoned during development, then the Company will not recover the fair value of the IPR&amp;D recorded as an asset as of the acquisition date. If such circumstances were to occur, the Company&#8217;s future operating results could be adversely affected and the Company may recognize impairment charges, which could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, 2021, and 2020 the Company recorded IPR&amp;D impairment charges within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.6&#160;billion, $275 million and $90 million, respectively (see Note&#160;9 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional research and development will be required before any of the remaining programs reach technological feasibility. The costs to complete the research projects will depend on whether the projects are brought to their final stages of development and are ultimately submitted to the FDA or other regulatory agencies for approval. </span></div><div id="ia384118d157240e09e39541b90e2080f_103"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures were $4.4 billion in 2022, $4.4 billion in 2021 and $4.4 billion in 2020. Expenditures in the U.S. were $2.7 billion in 2022, $2.8 billion in 2021 and $2.6 billion in 2020. The Company plans to invest approximately $20 billion in capital projects from 2021-2025, approximately half of which relates to investments in the U.S., including expanding manufacturing capacity for oncology, vaccine and animal health products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense was $1.8 billion in 2022, $1.6 billion in 2021 and $1.7 billion in 2020, of which $1.3 billion in 2022, $1.1 billion in 2021 and $1.2 billion in 2020, related to locations in the U.S. Total depreciation expense in 2022, 2021 and 2020 included accelerated depreciation of $120 million, $91 million and $268 million, respectively, associated with restructuring activities (see Note&#160;6 to the consolidated financial statements).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#8217;s strong financial profile enables it to fund research and development, focus on external alliances, support in-line products and maximize upcoming launches while providing significant cash returns to shareholders.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0c2340;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Selected Data</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,483</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by operating activities of continuing operations to total debt</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.6:1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4:1</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2:1</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in working capital in 2022 compared with 2021 is primarily due to increased cash and investments reflecting strong operating performance. The increase in working capital in 2021 compared with 2020 is primarily related to decreased short-term debt. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash provided by operating activities of continuing operations was $19.1 billion in 2022 compared with $13.1 billion in 2021. The increase in cash provided by operating activities of continuing operations reflects stronger operating performance. Cash provided by operating activities of continuing operations was reduced by milestone and option payments related to certain collaborations of $2.0 billion in 2022 and $435 million in 2021. Cash provided by operating activities of continuing operations continues to be the Company&#8217;s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases. The mandatory change in R&amp;D capitalization rules that became effective for tax years beginning after December 31, 2021 (related to the Tax Cuts and Jobs Act of 2017 (TCJA)), increased the amount of taxes the Company pays in the U.S. beginning in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash used in investing activities of continuing operations was $5.0 billion in 2022 compared with $16.4 billion in 2021. The lower use of cash in investing activities of continuing operations was primarily due to lower cash used for acquisitions, partially offset by higher purchases of securities and other investments coupled with lower proceeds from sales of securities and other investments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash used in financing activities of continuing operations was $9.1 billion in 2022 compared with cash provided by financing activities of continuing operations of $3.1 billion in 2021. The change was primarily driven by the cash distribution received in 2021 from Organon in connection with the spin-off (see Note&#160;3 to the consolidated financial statements), proceeds from the issuance of debt in 2021 compared with no such proceeds in 2022, and higher dividends paid to stockholders in 2022, partially offset by net repayments of short-term borrowings and treasury stock purchases in 2021 that did not occur in 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2021, the Company issued $8.0&#160;billion principal amount of senior unsecured notes consisting of $1.5&#160;billion of 1.70% notes due 2027, $1.0&#160;billion of 1.90% notes due 2028, $2.0&#160;billion of 2.15% notes due 2031, $2.0&#160;billion of 2.75% notes due 2051 and $1.5&#160;billion of 2.90% notes due 2061. Merck used the net proceeds from the offering of the 2027 notes, the 2031 notes, the 2051 notes and the 2061 notes for general corporate purposes, including the repayment of outstanding commercial paper borrowings (including commercial paper borrowings in connection with Merck&#8217;s acquisition of Acceleron), and other indebtedness. Merck has committed to allocate an amount equal to the net proceeds of the offering of the notes due in 2028 to finance or refinance, in whole or in part, projects and partnerships in the Company&#8217;s priority environmental, social and governance (ESG) areas.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2020, the Company issued $4.5&#160;billion principal amount of senior unsecured notes consisting of $1.0&#160;billion of 0.75% notes due 2026, $1.25&#160;billion of 1.45% notes due 2030, $1.0&#160;billion of 2.35% notes due 2040 and $1.25&#160;billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including the repayment of outstanding commercial paper borrowings and other indebtedness.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, the Company&#8217;s $1.25 billion, 2.35% notes and the Company&#8217;s $1.0&#160;billion, 2.40% notes matured in accordance with their terms and were repaid. In 2021, the Company&#8217;s $1.15 billion, 3.875% notes and the Company&#8217;s &#8364;1.0 billion, 1.125% notes matured in accordance with their terms and were repaid. In 2020, the Company&#8217;s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were repaid.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expects foreseeable liquidity and capital resource requirements to be met through existing cash and cash equivalents and anticipated cash flows from operations, as well as commercial paper borrowings and long-term borrowings if needed. Merck believes that its sources of financing will be adequate to meet its future requirements. The Company&#8217;s material cash requirements arising in the normal course of business primarily include:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt Obligations and Interest Payments &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See Note&#160;10 to the consolidated financial statements for further detail of the Company&#8217;s debt obligations and the timing of expected future principal and interest payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Tax Liabilities &#8212; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the enactment of the TCJA, the Company is required to pay a one-time transition tax, which the Company has elected to pay over a period of eight years through 2025 as permitted under the TCJA. Additionally, the Company has liabilities for unrecognized tax benefits, including interest and penalties. See Note&#160;16 to the consolidated financial statements for further information pertaining to the transition tax and liabilities for unrecognized tax benefits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases &#8212; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note&#160;10 to consolidated financial statements for further details of the Company&#8217;s lease obligations and the timing of expected future lease payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Milestone Payments &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company has an accrued liability for a contingent sales-based milestone payment related to a collaboration with AstraZeneca where payment has been deemed probable by the Company but remains subject to the achievement of the related sales-based milestone. See Note&#160;5 to the consolidated financial statements for additional information related to this sales-based milestone.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Purchase Obligations &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Purchase obligations are enforceable and legally binding obligations for purchases of goods and services including minimum inventory contracts, research and development and advertising. Purchase obligations also include future inventory purchases the Company has committed to in connection with certain divestitures. As of December&#160;31, 2022, the Company had total purchase obligations of $6.0&#160;billion, of which $1.7&#160;billion is estimated to be payable in 2023.</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a securities registration statement with the U.S. Securities and Exchange Commission (SEC) under the automatic shelf registration process available to &#8220;well-known seasoned issuers&#8221; which is effective for three years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company believes it maintains a conservative financial profile. The Company places its cash and investments in instruments that meet high credit quality standards, as specified in its investment policy guidelines. These guidelines also limit the amount of credit exposure to any one issuer. The Company does not participate in any off-balance sheet arrangements involving unconsolidated subsidiaries that provide financing or potentially expose the Company to unrecorded financial obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2022, Merck&#8217;s Board of Directors increased the quarterly dividend, declaring a quarterly dividend of $0.73 per share on the Company&#8217;s outstanding common stock for the first quarter of 2023 that was paid in January 2023. In January 2023, the Board of Directors declared a quarterly dividend of $0.73 per share on the Company&#8217;s outstanding common stock for the second quarter of 2023 payable in April 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2018, Merck&#8217;s Board of Directors authorized purchases of up to $10 billion of Merck&#8217;s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions, on or off an exchange, or in privately negotiated transactions. The Company did not purchase any shares of its common stock for its treasury during 2022 under this program. As of&#160;December&#160;31, 2022, the Company&#8217;s remaining share repurchase authorization was $5.0 billion. The Company anticipates making modest share repurchases under this program in 2023. The Company purchased $840 million and $1.3 billion of its common stock during 2021 and 2020, respectively, under authorized share repurchase programs.</span></div><div id="ia384118d157240e09e39541b90e2080f_109"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Instruments Market Risk Disclosures</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management, and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income (Loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because Merck principally sells foreign currency in its revenue hedging program, a uniform weakening of the U.S. dollar would yield the largest overall potential loss in the market value of these hedge instruments. The market value of Merck&#8217;s hedges would have declined by an estimated $647 million and $648 million at December&#160;31, 2022 and 2021, respectively, from a uniform 10% weakening of the U.S.&#160;dollar. The market value was determined using a foreign exchange option pricing model and holding all factors except exchange rates constant. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck&#8217;s major foreign currency exposures relative to the U.S.&#160;dollar. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A sensitivity analysis to changes in the value of the U.S.&#160;dollar on foreign currency denominated derivatives, investments and monetary assets and liabilities indicated that if the U.S.&#160;dollar uniformly weakened by 10% against all currency exposures of the Company at December&#160;31, 2022 and 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> would have declined by approximately $190 million and $125 million in 2022 and 2021, respectively. Because the Company was in a net short (payable) position relative to its major foreign currencies after consideration of forward contracts, a uniform weakening of the U.S. dollar will yield the largest overall potential net loss in earnings due to exchange. This measurement assumes that a change in one foreign currency relative to the U.S.&#160;dollar would not affect other foreign currencies relative to the U.S.&#160;dollar. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck&#8217;s major foreign </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">currency exposures relative to the U.S.&#160;dollar. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The economy of T&#252;rkiye was determined to be hyperinflationary in 2022. Consequently, in accordance with U.S. GAAP, the Company began remeasuring the monetary assets and liabilities of those operations in earnings beginning in the second quarter of 2022. The impact to the Company&#8217;s results is immaterial. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. The Company is not currently a party to any interest rate swaps.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s investment portfolio includes cash equivalents and short-term investments, the market values of which are not significantly affected by changes in interest rates. The market value of the Company&#8217;s medium- to long-term fixed-rate investments is modestly affected by changes in U.S.&#160;interest rates. Changes in medium- to long-term U.S.&#160;interest rates have a more significant impact on the market value of the Company&#8217;s fixed-rate borrowings, which generally have longer maturities. A sensitivity analysis to measure potential changes in the market value of Merck&#8217;s investments and debt from a change in interest rates indicated that a one percentage point increase in interest rates at December&#160;31, 2022 and 2021 would have positively affected the net aggregate market value of these instruments by $2.0 billion and $3.2 billion, respectively. A one percentage point decrease at December&#160;31, 2022 and 2021 would have negatively affected the net aggregate market value by $2.4 billion and $3.9 billion, respectively. The fair value of Merck&#8217;s debt was determined using pricing models reflecting one percentage point shifts in the appropriate yield curves. The fair values of Merck&#8217;s investments were determined using a combination of pricing and duration models.</span></div><div id="ia384118d157240e09e39541b90e2080f_112"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements are prepared in conformity with GAAP and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates. Application of the following accounting policies result in accounting estimates having the potential for the most significant impact on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Dispositions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To determine whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses, the Company makes certain judgments, which include assessment of the inputs, processes, and outputs associated with the acquired set of activities. If the Company determines that substantially all of the fair value of gross </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">assets included in a transaction is concentrated in a single asset (or a group of similar assets), the assets would not represent a business. To be considered a business, the assets in a transaction need to include an input and a substantive process that together significantly contribute to the ability to create outputs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. The fair values of intangible assets are determined utilizing information available near the acquisition date based on expectations and assumptions that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company&#8217;s results of operations.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an income approach through which fair value is estimated based on each asset&#8217;s discounted projected net cash flows. The Company&#8217;s estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry and therapeutic area growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain additional marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company&#8217;s competitors; and the life of each asset&#8217;s underlying patent and related patent term extension, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of identifiable intangible assets related to IPR&amp;D are also determined using an income approach, through which fair value is estimated based on each asset&#8217;s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate. Amounts allocated to acquired IPR&amp;D are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s business combinations involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Changes in any of the inputs may result in a significantly different fair value adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company determines the transaction will not be accounted for as an acquisition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired IPR&amp;D with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Sales-Based Milestones</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The terms of certain collaborative arrangements require the Company to make payments contingent upon the achievement of sales-based milestones. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized over its remaining useful life, subject to impairment testing.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covers chargebacks and rebates. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. See Note&#160;11 to the consolidated financial statements for information regarding 340B legal proceedings.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continually monitors its provision for aggregate customer discounts. There were no material adjustments to estimates associated with the aggregate customer discount provision in 2022, 2021 or 2020.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about changes in the aggregate customer discount accrual related to U.S. sales is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,844</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12,179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals for chargebacks are reflected as a direct reduction to accounts receivable and accruals for rebates as current liabilities. The accrued balances relative to these provisions included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $178 million and $2.7 billion, respectively, at December&#160;31, 2022 and were $207 million and $2.6 billion, respectively, at December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. The product returns provision for U.S. pharmaceutical sales as a percentage of U.S. net pharmaceutical sales was 1.1% in 2022, 0.9% in 2021 and 0.5% in 2020. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Through its distribution programs with U.S.&#160;wholesalers, the Company encourages wholesalers to align purchases with underlying demand and maintain inventories below specified levels. The terms of the programs allow the wholesalers to earn fees upon providing visibility into their inventory levels, as well as by achieving certain performance parameters such as inventory management, customer service levels, reducing shortage claims and reducing product returns. Information provided through the wholesaler distribution programs includes items such as sales trends, inventory on-hand, on-order quantity and product returns.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories Produced in Preparation for Product Launches</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory does not begin until the related product candidates are in Phase&#160;3 clinical trials and regulatory approval is considered by the Company to be probable. The Company monitors the status of each respective product within the regulatory approval process; however, the Company generally does not disclose specific timing for regulatory approval. If the Company is aware of any specific risks or contingencies other than the normal regulatory approval process or if there are any specific issues identified during the research process relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized. Expiry dates of the inventory are affected by the stage of completion. The Company manages the levels of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issues. For inventories that are capitalized, anticipated future sales and shelf lives support the realization of the inventory value as the inventory shelf life is sufficient to meet initial product launch requirements. Inventories produced in preparation for product launches capitalized at December&#160;31, 2022 and 2021 were $516 million and $256 million, respectively.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Environmental Liabilities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property and commercial litigation, as well as certain additional matters including governmental and environmental matters (see Note&#160;11 to the consolidated financial statements). The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2022 and 2021 of approximately $230 million represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. When a legitimate claim for contribution is asserted, a liability is initially accrued based upon the estimated transaction costs to manage the site. Accruals are adjusted as site investigations, feasibility studies and related cost assessments of remedial techniques are completed, and as the extent to which other potentially responsible parties who may be jointly and severally liable can be expected to contribute is determined.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites and takes an active role in identifying and accruing for these costs. In the past, Merck performed a worldwide survey to assess all sites for potential contamination resulting from past industrial activities. Where assessment indicated that physical investigation was warranted, such investigation was performed, providing a better evaluation of the need for remedial action. Where such need was identified, remedial action was then initiated. As definitive information became available during the course of investigations and/or remedial efforts at each site, estimates were refined and accruals were established or adjusted accordingly. These estimates and related accruals continue to be refined annually.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. Expenditures for remediation and environmental liabilities were $4 million in 2022 and are estimated to be $23 million in the aggregate for the years 2023 through 2027. In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December&#160;31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, including grants of stock options, over the requisite service period based on the grant date fair value of the awards. The Company determines the fair value of certain share-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. Total pretax share-based compensation expense from continuing operations was $541 million in 2022, $479 million in 2021 and $441 million in 2020. At December&#160;31, 2022, there was $813 million of total pretax unrecognized compensation expense related to nonvested stock option, restricted stock unit and performance share unit awards which will be recognized over a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">weighted-average period of 1.9&#160;years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pensions and Other Postretirement Benefit Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost for pension plans totaled $554 million in 2022, $748 million in 2021 and $450 million in 2020. Net periodic benefit credit for other postretirement benefit plans was $93 million in 2022, $83 million in 2021 and $59 million in 2020. Pension and other postretirement benefit plan information for financial reporting purposes is calculated using actuarial assumptions including a discount rate for plan benefit obligations and an expected rate of return on plan assets. The changes in net periodic benefit cost year over year for pension plans are primarily attributable to changes in the discount rates. Additionally, net periodic benefit costs in 2022 and 2021 reflect higher settlement charges incurred by certain plans compared with 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The discount rates for the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans ranged from 5.50% to 5.90% at December&#160;31, 2022, compared with a range of 2.60% to 3.10% at December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, the Company considers long-term compound annualized returns of historical market data, current market conditions and actual returns on the Company&#8217;s plan assets. Using this reference information, the Company develops forward-looking return expectations for each asset category and a weighted-average expected long-term rate of return for a target portfolio allocated across these investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will be 7.00% compared to 6.70% in 2022. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated 25% to 40% in U.S.&#160;equities, 10% to 20% in international equities, 35% to 45% in fixed-income investments, and up to 8% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 10%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial assumptions are based upon management&#8217;s best estimates and judgment. A reasonably possible change of plus (minus) 25&#160;basis points in the discount rate assumption, with other assumptions held constant, would have had an estimated $81 million favorable (unfavorable) impact on the Company&#8217;s net periodic benefit cost in 2022. A reasonably possible change of plus (minus) 25&#160;basis points in the expected rate of return assumption, with other assumptions held constant, would have had an estimated $59&#160;million favorable (unfavorable) impact on Merck&#8217;s net periodic benefit cost in 2022. Required funding obligations for 2023 relating to the Company&#8217;s pension and other postretirement benefit plans are not expected to be material. The preceding hypothetical changes in the discount rate and expected rate of return assumptions would not impact the Company&#8217;s funding requirements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain/loss amounts, which primarily reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions, are recorded as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Expected returns for pension plans are based on a calculated market-related value of assets. Net gain/loss amounts in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. </span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring costs have been recorded in connection with restructuring programs designed to streamline the Company&#8217;s cost structure. As a result, the Company has made estimates and judgments regarding its future plans, including future termination benefits to be incurred in conjunction with involuntary separations when such separations are probable and estimable. When accruing termination costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">estimate than any other amount, the Company recognizes the minimum amount within the range. In connection with these actions, management also assesses the recoverability of long-lived assets employed in the business. In certain instances, asset lives have been shortened based on changes in the expected useful lives of the affected assets. Severance and other related costs are reflected within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Asset-related charges are reflected within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses depending upon the nature of the asset.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairments of Long-Lived Assets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assesses changes in economic, regulatory and legal conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company&#8217;s property, plant and equipment, goodwill and other intangible assets.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its long-lived assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows approach.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the factors considered in the assessment include general macroeconomic conditions, conditions specific to the industry and market, cost factors which could have a significant effect on earnings or cash flows, the overall financial performance of the reporting unit, and whether there have been sustained declines in the Company&#8217;s share price. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangible assets (excluding IPR&amp;D) are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. When events or circumstances warrant a review, the Company will assess recoverability from future operations using pretax undiscounted cash flows derived from the lowest appropriate asset groupings. Impairments are recognized in operating results to the extent that the carrying value of the intangible asset exceeds its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist (such as unfavorable clinical trial data, changes in the commercial landscape or delays in the clinical development program and related regulatory filing and approval timelines), by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. For impairment testing purposes, the Company may combine separately recorded IPR&amp;D intangible assets into one unit of account based on the relevant facts and circumstances. Generally, the Company will combine IPR&amp;D intangible assets for testing purposes if they operate as a single asset and are essentially inseparable. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The judgments made in evaluating impairment of long-lived intangibles can materially affect the Company&#8217;s results of operations.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate is based on pretax income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. An estimated effective tax rate for a year is applied to the Company&#8217;s quarterly operating results. In the event that there is a significant unusual or one-time item recognized, or expected to be recognized, in the Company&#8217;s quarterly operating results, the tax attributable to that item would be separately calculated and recorded at the same time as the unusual or one-time item. The Company considers the resolution of prior year tax matters to be such items. Significant judgment is required in determining the Company&#8217;s tax provision and in evaluating its tax positions. The recognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at the reporting date. The Company evaluates tax positions to determine whether the benefits of tax positions are more </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. If the more likely than not threshold is not met in the period for which a tax position is taken, the Company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled, the statute of limitations expires, or if the more likely than not threshold is met in a subsequent period (see Note&#160;16 to the consolidated financial statements).</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax regulations require items to be included in the tax return at different times than the items are reflected in the financial statements. Timing differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in the tax return in future years for which the Company has already recorded the tax benefit in the financial statements. The Company establishes valuation allowances for its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense recognized in the financial statements for which payment has been deferred or expense for which the Company has already taken a deduction on the tax return, but has not yet recognized as expense in the financial statements. </span></div><div id="ia384118d157240e09e39541b90e2080f_115"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note&#160;2 to the consolidated financial statements.</span></div><div id="ia384118d157240e09e39541b90e2080f_118"></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cautionary Factors That May Affect Future Results</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company&#8217;s filings with the Securities and Exchange Commission, especially on this Form&#160;10-K and Forms 10-Q and 8-K. In Item&#160;1A. &#8220;Risk Factors&#8221; of this annual report on Form&#160;10-K the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.&#160;</span></div><div id="ia384118d157240e09e39541b90e2080f_121"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:10.02pt">Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the discussion under &#8220;Financial Instruments Market Risk Disclosures&#8221; in Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.51pt">Financial Statements and Supplementary Data.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div id="ia384118d157240e09e39541b90e2080f_127"></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:16.02pt">Financial Statements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated balance sheet of Merck&#160;&amp; Co., Inc. and subsidiaries as of December&#160;31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December&#160;31, 2022, the notes to consolidated financial statements, and the report dated February&#160;24, 2023 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:</span></div><div id="ia384118d157240e09e39541b90e2080f_130"></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statement of Income</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEtMS0xLTEtNzEzMzA_84464a4e-99d7-4fb7-bfcd-260e14260db9">59,283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEtMy0xLTEtNzEzMzA_c2ae8312-81e5-4d6b-ab5a-28c547f0a482">48,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEtNS0xLTEtNzEzMzA_94c2f89f-559a-4b42-9c66-233f6b193f69">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzMtMS0xLTEtNzEzMzA_b5bba2b5-f4be-47d5-a3b6-eaf3d6b55c8f">17,411</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzMtMy0xLTEtNzEzMzA_0f8adcb4-d621-47b5-80f2-937536b4fcdc">13,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzMtNS0xLTEtNzEzMzA_b62b4008-7a0e-4d20-b101-140783d14111">13,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzQtMS0xLTEtNzEzMzA_e1d12365-bbcf-44d9-8568-d158ea4bcd2c">10,042</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzQtMy0xLTEtNzEzMzA_75658cbe-d604-42b0-a0f1-4da9350b1f76">9,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzQtNS0xLTEtNzEzMzA_6457cf1e-d4f8-4343-823e-fbf96f07bb1d">8,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzUtMS0xLTEtNzEzMzA_5dc4b231-9603-4413-b8a6-b770c4fef5f0">13,548</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzUtMy0xLTEtNzEzMzA_52cbf22a-ac41-420b-abf0-6e6cbdcb0697">12,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzUtNS0xLTEtNzEzMzA_cd258fff-3c7c-41ed-a706-22d42e0c1ec9">13,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzYtMS0xLTEtNzEzMzA_aaff87b2-59b1-421f-a88f-e5335f59fbbd">337</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzYtMy0xLTEtNzEzMzA_bd675427-a67e-46b4-85b9-7fcdb8b1b74b">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzYtNS0xLTEtNzEzMzA_9aac8d86-755a-48c4-9af5-6e842d96bfc4">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzctMS0xLTEtNzEzMzA_1feb55b5-e7c3-4801-b9f2-d049d6984574">1,501</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzctMy0xLTEtNzEzMzA_7c94603c-737d-4eb3-aeef-d3f050dd8271">1,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzctNS0xLTEtNzEzMzA_084e8321-b481-419f-a636-9b21ab0bc7f4">890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzgtMS0xLTEtNzEzMzA_e14760fb-3df6-466c-8126-f7b2bd39c499">42,839</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzgtMy0xLTEtNzEzMzA_517b89db-095c-4d06-823d-4910e8cd5367">34,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzgtNS0xLTEtNzEzMzA_c99dae0f-04d7-4c10-9c61-e6e615db9b7c">35,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzktMS0xLTEtNzEzMzA_75051f30-cfe0-48a8-a47f-d39f65070c03">16,444</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzktMy0xLTEtNzEzMzA_0161d1cf-01e0-4e19-b3c0-e02aca24f352">13,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzktNS0xLTEtNzEzMzA_3459bdf5-e0e5-4916-b159-d56497145bb3">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on Income from Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEwLTEtMS0xLTcxMzMw_0f89ea8c-8f18-4b7e-9ebb-00a1e5829098">1,918</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEwLTMtMS0xLTcxMzMw_471e445d-6a88-4eb9-b71b-2ca14c46a6fd">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEwLTUtMS0xLTcxMzMw_88363dd4-65d8-4d1d-81ec-dc534b12d45e">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income from Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzExLTEtMS0xLTcxMzMw_255e78f3-0bd4-40c4-b60e-945b0dab26be">14,526</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzExLTMtMS0xLTcxMzMw_34b3f821-efcd-4020-ac28-3037cf20a156">12,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzExLTUtMS0xLTcxMzMw_68ae5589-d783-40c4-8294-e5779c69ab0c">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net Income Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEyLTEtMS0xLTcxMzMw_36653a2a-76d7-420e-9083-02c0b93470b4">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEyLTMtMS0xLTcxMzMw_f2eedd16-7c2f-4b23-b26f-05bbf13eccac">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEyLTUtMS0xLTcxMzMw_c0a2e39a-c686-4489-ba38-24674be9f660">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEzLTEtMS0xLTcxMzMw_1b70d929-1a3b-4655-aa36-d2dc61d7f4ea">14,519</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEzLTMtMS0xLTcxMzMw_da45f28c-7db8-446b-aa65-9d41b3b012b2">12,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEzLTUtMS0xLTcxMzMw_ebcd046a-ba15-4265-af90-1c19504ca184">4,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE0LTEtMS0xLTcxMzMw_3a6516d5-f5bf-4b31-b8a1-54e37bbf7965">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE0LTMtMS0xLTcxMzMw_5bd776a4-030d-4d30-bead-0f3ee7a39088">704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE0LTUtMS0xLTcxMzMw_c5f88b80-0016-495d-a0b1-e249d45a32f3">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE1LTEtMS0xLTcxMzMw_0e2a22e7-f670-43d8-8085-38d9f0d82f2d">14,519</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE1LTMtMS0xLTcxMzMw_e421d46a-979c-432d-8e8e-1b5c77818a7a">13,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE1LTUtMS0xLTcxMzMw_30175bd6-90bf-4acd-ba56-8a742c300bec">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE3LTEtMS0xLTcxMzMw_2d41252d-e082-4224-a958-d648991530c7">5.73</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE3LTMtMS0xLTcxMzMw_b0a1f449-66c3-427f-90cf-f4986ed111a5">4.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE3LTUtMS0xLTcxMzMw_b9a2a8c9-91c7-43c6-8b5c-c52f54a95885">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE4LTEtMS0xLTcxMzMw_c6a48c20-f624-448b-b54b-e28d092e5f45">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE4LTMtMS0xLTcxMzMw_b7e2a7de-4f33-4d5c-9b38-d2b3614f1202">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE4LTUtMS0xLTcxMzMw_f3cbc6b6-a1d3-4735-ba91-254c4e6b5c71">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE5LTEtMS0xLTcxMzMw_1d901e36-21cf-4d8f-8104-5bb253a70a0a">5.73</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE5LTMtMS0xLTcxMzMw_5d231a59-bec9-4487-908d-322055d6cf7f">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE5LTUtMS0xLTcxMzMw_c9db3706-a7b3-4ffe-87cd-52f5e3f29227">2.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIxLTEtMS0xLTcxMzMw_28d7a2df-d855-46f8-86d1-69b7434b0cad">5.71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIxLTMtMS0xLTcxMzMw_5dfa1e8d-4d12-40e1-b0e8-8faaeb3328aa">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIxLTUtMS0xLTcxMzMw_5fe6be47-2d66-4577-8580-ab64270cc042">1.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIyLTEtMS0xLTcxMzMw_d1ba3229-2983-4e8f-b2c8-ebf61c4e254c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIyLTMtMS0xLTcxMzMw_dde1c795-da31-4679-829a-380b374aa0bf">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIyLTUtMS0xLTcxMzMw_f4aab314-7632-4a8d-94f9-4933d657f04a">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIzLTEtMS0xLTcxMzMw_5a1c9517-7cc1-4c30-9fa4-40477d23948d">5.71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIzLTMtMS0xLTcxMzMw_3b5d8d6e-9c5b-4fde-95d5-5edc898bf576">5.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIzLTUtMS0xLTcxMzMw_e391ba98-f6a1-4135-90bd-f884053cf687">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statement of Comprehensive Income</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">($ in millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzEtMS0xLTEtNzEzMzA_234f6839-404f-499e-8929-a6e87d510f4e">14,519</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzEtMy0xLTEtNzEzMzA_ade326cf-0e42-41e1-a50f-6df857c63027">13,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzEtNS0xLTEtNzEzMzA_68c89a68-e8e3-46f3-9a83-4aa8fe3eb3e7">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Comprehensive (Loss) Income Net of Taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzMtMS0xLTEtNzEzMzA_1a5b821d-536c-4d15-b47c-d2650479338d">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzMtMy0xLTEtNzEzMzA_98a02523-59d6-47ed-8692-15f0d2e97468">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzMtNS0xLTEtNzEzMzA_45b7ae06-6ed2-4c24-8c29-1c02c3d469f7">297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on investments, net of reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzQtMS0xLTEtNzEzMzA_6c2f8bf0-6a77-4218-9214-a332f7072d52">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzQtMy0xLTEtNzEzMzA_1c868bf2-7dee-4396-a47b-5665e0d33aac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzQtNS0xLTEtNzEzMzA_02fde83b-ea46-4652-98ab-507266766a42">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit plan net gain (loss) and prior service credit (cost), net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzUtMS0xLTEtNzEzMzA_e18515c7-ac8c-4aef-9c47-273110e5e6bc">335</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzUtMy0xLTEtNzEzMzA_6e194b3b-54d9-437f-abee-e2558a82ed53">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzUtNS0xLTEtNzEzMzA_74c45fa8-4600-47ea-9fca-4f2bfb570605">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzYtMS0xLTEtNzEzMzA_e30a78af-9fe6-4aa1-a090-b57629337918">603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzYtMy0xLTEtNzEzMzA_3a3e28f6-6b6d-49af-be53-582803e981bd">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzYtNS0xLTEtNzEzMzA_4cc1bc32-1157-41ce-9fff-cd1c7016d764">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzctMS0xLTEtNzEzMzA_26ecb0ca-cb51-4963-aeb6-69b7c3584930">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzctMy0xLTEtNzEzMzA_79fa0c07-4e1a-431e-93bc-13f36b6f4e63">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzctNS0xLTEtNzEzMzA_fd44bafd-a38a-46c3-9555-e6c8d917cbac">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzgtMS0xLTEtNzEzMzA_8d8c9982-6fde-4e17-9f66-bd1a614e9896">14,180</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzgtMy0xLTEtNzEzMzA_7759562d-820c-4877-beef-d9508dac73f3">14,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzgtNS0xLTEtNzEzMzA_d0b15607-632d-42fa-98cd-e41e800dfabe">6,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Balance Sheet</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December&#160;31</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMtMS0xLTEtNzEzMzA_6790cb0b-f271-4728-ac24-77e0697fc375">12,694</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMtMy0xLTEtNzEzMzA_ffa09e1d-969a-4567-be68-5cf7cb8cb970">8,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMS0xLTEtMTIxNzg3_99e6a31e-97df-4002-977f-042bfa5804ba">498</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMy0xLTEtMTIxNzg3_87e88920-0573-42d9-8358-8f46b82148b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo1MmQ2MGY4ZTdhYzU0YmM1YjhkNWY3MWVhNGUxNTE5NF82Nw_650e1333-87af-43e9-b123-e63973eae7b0">72</ix:nonFraction> in 2022 </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo1MmQ2MGY4ZTdhYzU0YmM1YjhkNWY3MWVhNGUxNTE5NF84MQ_48510082-e8a2-4723-89d7-9688186fdffc">62</ix:nonFraction> in 2021) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMS0xLTEtNzEzMzA_cc41fb1b-877d-495f-8afb-d562f4fc34dc">9,450</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMy0xLTEtNzEzMzA_8c6c2923-6fec-47af-9aa9-7b0d943d9c59">9,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo2MjdmYzg1NTRjMmE0NDNjODIxMGU3ZDM5YjFjOWU1MV80MQ_5ba6612c-0333-4ea7-8a5b-bb3bb4870dca">2,938</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo2MjdmYzg1NTRjMmE0NDNjODIxMGU3ZDM5YjFjOWU1MV81NA_f59f2822-0803-4a15-b7fb-b1ddb1a62188">2,194</ix:nonFraction> in 2021</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">classified in Other assets - see Note&#160;8)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMS0xLTEtNzEzMzA_7bd1f409-e49e-4776-b820-5c9667624279">5,911</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMy0xLTEtNzEzMzA_9dcb14d7-811c-4c4d-a21d-89d75d6f1afa">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzYtMS0xLTEtNzEzMzA_2b510771-ddf0-40bf-b78d-93debc2cf550">7,169</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzYtMy0xLTEtNzEzMzA_ea2010ff-2c60-4bcf-9539-eb397699f7ee">6,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzgtMS0xLTEtNzEzMzA_2f364fbf-99f0-4f63-9f80-e7038f8b9207">35,722</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzgtMy0xLTEtNzEzMzA_13cccb2c-17a4-45b2-af3e-46c98fbdf124">30,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzktMS0xLTEtNzEzMzA_255ac470-494b-4f5e-9a70-c33b669678e8">1,015</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzktMy0xLTEtNzEzMzA_5d9017e9-7a94-4e75-89ba-fbd2515a67f9">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, Plant and Equipment (at cost)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzExLTEtMS0xLTcxMzMw_8805c834-7708-49e4-bfea-bc8666fd55fa">295</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzExLTMtMS0xLTcxMzMw_f674d695-d9f9-4f1a-91c7-f00b2c5353c6">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEyLTEtMS0xLTcxMzMw_019dcc75-23ca-485c-97fe-30d2bfddfbf8">13,166</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEyLTMtMS0xLTcxMzMw_d78c9ac8-39fe-4d4c-b695-2fc4cb95338c">12,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery, equipment and office furnishings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEzLTEtMS0xLTcxMzMw_6c56ed53-2a3b-432f-8efb-f1d9a342e58d">16,760</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEzLTMtMS0xLTcxMzMw_7e078623-3e21-4f24-87e6-8b184edb8082">16,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE0LTEtMS0xLTcxMzMw_c6874fa5-d752-42b2-8020-c166e4e706b2">9,186</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE0LTMtMS0xLTcxMzMw_1de3b35e-e160-4cf8-b52f-8c89f055006b">8,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE1LTEtMS0xLTcxMzMw_e64cdd76-7c31-4465-b3a1-f8c29b4f8791">39,407</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE1LTMtMS0xLTcxMzMw_74d3bd62-7e0d-434d-bf70-f45b379565ba">37,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE2LTEtMS0xLTcxMzMw_0904f36b-2e3f-43f8-ba88-e2c818c6f4a9">17,985</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE2LTMtMS0xLTcxMzMw_0081df0d-8e9d-4ce4-a11c-0f3f961199ef">18,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE3LTEtMS0xLTcxMzMw_8045b332-9491-47ad-8946-8406bc396e99">21,422</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE3LTMtMS0xLTcxMzMw_f8ab8f28-7de9-460e-b4e6-b19671b4704a">19,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE4LTEtMS0xLTcxMzMw_7b05b389-faa3-428f-bbd1-21c69cbde30c">21,204</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE4LTMtMS0xLTcxMzMw_1b86838a-6f7d-4fb3-82c0-950ec10a7919">21,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE5LTEtMS0xLTcxMzMw_f3767371-dc08-41db-a6fd-f6d90443cdb6">20,269</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE5LTMtMS0xLTcxMzMw_67192ac1-0a1c-49eb-870f-ed1ab0eb9af4">22,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIwLTEtMS0xLTcxMzMw_57afa5b9-2759-4ed0-bc08-ba0444459acc">9,528</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIwLTMtMS0xLTcxMzMw_c40c8d14-83e5-4f06-9207-3fd8209fb3d3">11,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIyLTEtMS0xLTcxMzMw_2bee8908-a557-4011-8e38-0cffb7c5927a">109,160</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIyLTMtMS0xLTcxMzMw_6695dcc2-0d0f-4891-9ac2-fa6fb6e8cc45">105,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI1LTEtMS0xLTcxMzMw_36ff02ec-de56-407e-890e-fb0f06a8e19c">1,946</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI1LTMtMS0xLTcxMzMw_0e938f20-8eb9-4d72-a9a3-e8719a255ea0">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI2LTEtMS0xLTcxMzMw_505f09a7-adbe-4b49-8565-56ea4fb4c5c6">4,264</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI2LTMtMS0xLTcxMzMw_eee9484b-f844-4a29-8cac-7a88d7f3acd9">4,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI3LTEtMS0xLTcxMzMw_738c31c6-af1a-46d1-aa60-c05542f0aa7d">14,159</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI3LTMtMS0xLTcxMzMw_4edc2ce7-b88e-49b2-9a00-da1aeada57ec">13,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI4LTEtMS0xLTcxMzMw_dfe2f4e0-26f3-49fa-8f23-6700c63d3e91">1,986</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI4LTMtMS0xLTcxMzMw_9bc60d08-aac9-4e3f-824c-e990600f1cfe">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI5LTEtMS0xLTcxMzMw_d9e24dbe-f330-4556-90d9-70b72e82334e">1,884</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI5LTMtMS0xLTcxMzMw_6012abe8-ace3-4116-9381-83af6278662b">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMxLTEtMS0xLTcxMzMw_2b4501e2-8c5b-4121-b129-1da9c4d8a447">24,239</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMxLTMtMS0xLTcxMzMw_545ed769-b0ec-41ed-9be9-e3aadc1e294d">23,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMyLTEtMS0xLTcxMzMw_44f0f4e8-6fbb-433c-9985-5f884a817cdd">28,745</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMyLTMtMS0xLTcxMzMw_cc4a6c7a-a4cc-4167-8579-b4f66139329b">30,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMzLTEtMS0xLTcxMzMw_3943c167-a587-4fde-bef3-0ca280414442">1,795</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMzLTMtMS0xLTcxMzMw_0f1ef707-d0c6-4e89-a1c7-9d2314b5ff5c">3,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM0LTEtMS0xLTcxMzMw_b5bc24f5-dab3-4ca7-8ba7-c427f5eb1f4b">8,323</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM0LTMtMS0xLTcxMzMw_d42bcf5c-0975-40af-bf30-da4a28e641a0">9,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfMTk_2eecb14e-ee56-421a-86ea-8980278c747d"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfMTk_c0992fe8-b8db-4b69-ac04-b5075db5a030">0.50</ix:nonFraction></ix:nonFraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized - <ix:nonFraction unitRef="shares" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNDU_c41ecf73-1b37-4a70-af1a-465d95d38e0c"><ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNDU_f7627945-fb21-4674-a7dc-ab2f93d75c6e">6,500,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issued - <ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNjQ_2aec779b-4ca2-4f50-9a3e-c1e2daf1b023"><ix:nonFraction unitRef="shares" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNjQ_b9512a8b-4948-49ab-be2d-e887e5c048d4">3,577,103,522</ix:nonFraction></ix:nonFraction> shares in 2022 and 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTEtMS0xLTcxMzMw_19c35809-b44c-42bf-ac9d-1c805187702a">1,788</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTMtMS0xLTcxMzMw_1093e3b6-3ffb-47fd-878e-5dd48375cffa">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM4LTEtMS0xLTcxMzMw_bd9cceb2-8cd5-487b-9caa-881e63e2f63c">44,379</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM4LTMtMS0xLTcxMzMw_cf5c2ed3-09a3-44be-99d4-84d43360bd72">44,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM5LTEtMS0xLTcxMzMw_180772c0-a57a-45d2-836f-0bd95caf3a38">61,081</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM5LTMtMS0xLTcxMzMw_3bcd84d4-f560-48b8-85e2-00d901333b46">53,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQwLTEtMS0xLTcxMzMw_1a3ff7c0-de93-42a3-9315-90c9fcae2790">4,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQwLTMtMS0xLTcxMzMw_afb1581c-fd08-4c18-bc4e-943130ca69bd">4,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQxLTEtMS0xLTcxMzMw_11b8fd32-48f7-42a5-b5f6-72472d9c5648">102,480</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQxLTMtMS0xLTcxMzMw_d191f150-a679-4912-bc0c-80cbc4c6c329">95,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less treasury stock, at cost:  <ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDMzZGM3ODhmNTZjNGQzNDhhYjUwOWQ1YWZiZDgxNjVfMzU_c72e5feb-8134-467a-8d39-f00fc4287053">1,039,269,638</ix:nonFraction> shares in 2022 and <ix:nonFraction unitRef="shares" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDMzZGM3ODhmNTZjNGQzNDhhYjUwOWQ1YWZiZDgxNjVfNTU_9bebb2e7-b4d2-466a-9e3a-45011f95454c">1,049,499,023</ix:nonFraction> shares in 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTEtMS0xLTcxMzMw_bee83ad0-9a10-4122-8958-ce7550b70ffd">56,489</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTMtMS0xLTcxMzMw_bfcb72a1-1eda-41aa-bae5-869e10a13768">57,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQzLTEtMS0xLTcxMzMw_de47589e-d3d1-46b0-87dc-735b806129a3">45,991</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQzLTMtMS0xLTcxMzMw_a9ddb402-d39d-4e03-a72f-9b502f2e9254">38,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ0LTEtMS0xLTcxMzMw_94aaa095-a91a-4401-8d1c-fdde5231b505">67</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ0LTMtMS0xLTcxMzMw_c14a07b2-ae57-466b-aa7c-5fbfa52806a9">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ1LTEtMS0xLTcxMzMw_0ffc5bfc-1674-4a40-b254-4015fa496e88">46,058</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ1LTMtMS0xLTcxMzMw_a81b8719-0088-4ffd-9be1-f29251197360">38,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ2LTEtMS0xLTcxMzMw_6cb3ed93-4a8d-4162-b119-e0672da378a5">109,160</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ2LTMtMS0xLTcxMzMw_5bb1257c-312e-435c-b9dd-36f60ac888aa">105,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statement of Equity</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Balance January&#160;1, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870984a7a0814cf9a460c7a4b331c37f_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMS0xLTEtNzEzMzA_f35e2045-d86b-415f-bfb9-88270bced672">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c3eef0e8e84d89b879da53d7b2eea5_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMy0xLTEtNzEzMzA_4a85bdd7-0cae-4a99-b1c9-51dddb048feb">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8390537a2d14419183a1bd3184b81223_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtNS0xLTEtNzEzMzA_6996d4f2-e9a6-4a86-a0c2-d8f561ac137c">46,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief9bf241be3f43c8aac25c903996f2e3_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtNy0xLTEtNzEzMzA_f3a68377-4a71-43b0-add6-aae3d19b25ac">6,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3278c06a03cc4b83ad0c695bac71a99b_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtOS0xLTEtNzEzMzA_e048aefa-5f0d-4687-b807-f6f523c3368b">55,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa7328e43b745528acea4fb982c4641_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMTEtMS0xLTcxMzMw_0fea4c1d-20f2-4485-bb50-9f9ff6530ed4">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMTMtMS0xLTcxMzMw_460c69c4-84a6-438e-8cb2-a2da6b346594">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia197d01df12640948153fd9f84a852ed_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzItNS0xLTEtNzEzMzA_2c0da7df-58ad-4441-9a50-a7e2d04eeaad">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzItMTMtMS0xLTcxMzMw_8c9f035f-6e03-4b58-a3f9-c56420de853b">7,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bb557eb99a549468966b5c77bdf145c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzMtNy0xLTEtNzEzMzA_f8502dbc-4293-4700-b5c0-5c2e34049bdc">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzMtMTMtMS0xLTcxMzMw_afd90809-b2ac-414c-8311-28158855a0c5">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo1YTc3ZGFmZTM0M2E0OTc1OGU0NjRkZWVhZWM4NzRhM180NQ_5d71f305-c6f4-4163-a015-3dcb3707dcbd">2.48</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia197d01df12640948153fd9f84a852ed_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzQtNS0xLTEtNzEzMzA_70d7d1b4-7ebf-4832-9980-b938bfbbce49">6,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzQtMTMtMS0xLTcxMzMw_23cf0669-ab30-43cc-8ca8-17d5886e93fd">6,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzUtOS0xLTEtNzEzMzA_a40e43ff-4e59-409e-842a-c66bc6a7e0ac">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzUtMTMtMS0xLTcxMzMw_98949b63-480b-4c21-aac8-da41d4bf84b1">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757e7f21bc85496da119ddd7169fc883_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzYtMTEtMS0xLTcxMzMw_b29a008b-c8a9-40b6-97ed-293f11c83309">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzYtMTMtMS0xLTcxMzMw_122cd331-8e3e-4e42-a5c2-34bb904b1250">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i757e7f21bc85496da119ddd7169fc883_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzctMTEtMS0xLTcxMzMw_d83b976b-9079-4f2d-8d59-ec69657fa2dd">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzctMTMtMS0xLTcxMzMw_2f69b250-c190-498f-a7dd-e9ef030a99c8">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieca83e510fb04e31bb09eba119b9f8c4_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzgtMy0xLTEtNzEzMzA_baf9bd80-848b-46dd-9014-9776d03ad856">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzgtOS0xLTEtNzEzMzA_53a7d5b4-6ae2-49d5-95f5-8beac00b1210">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzgtMTMtMS0xLTcxMzMw_262ef44e-2440-4cd0-aebf-653b8424c6a9">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Balance December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMS0xLTEtNzEzMzA_cc303c93-c8a9-41ea-99d9-dd269e04f44c">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fa2929d2f845298f21dbaee7f2ef16_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMy0xLTEtNzEzMzA_c91645d1-2cc2-44b8-8a4a-ceeb1f996058">39,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85ab6516bc49b78971f2a3b5bdf41b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktNS0xLTEtNzEzMzA_24b335de-d832-4ba6-a267-096375d07b94">47,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8308747617614e9eab0ac29c4014c53b_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktNy0xLTEtNzEzMzA_cd0b14c9-b4cc-49b8-a362-ed51313d8ee2">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06a03badfaf044d5abe8434be9cfeda8_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktOS0xLTEtNzEzMzA_84996f0d-f630-4483-ad00-546022de7c2a">56,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bd86cfed75419480323eb478cad36f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMTEtMS0xLTcxMzMw_f194f57e-b01c-4ce1-a887-59c9da47584e">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMTMtMS0xLTcxMzMw_e24fd1e2-eac5-4270-b0b8-407b92f0239c">25,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77dda1a9a6f4400c931bc6647f046197_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEwLTUtMS0xLTcxMzMw_ebe9ad6e-98db-43b7-850a-c23746f03585">13,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEwLTEzLTEtMS03MTMzMA_5eddfbd3-e5a5-4031-a715-f20040b117f4">13,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e06bfa03d5c48d190290cd1a81579c6_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzExLTctMS0xLTcxMzMw_128be2e8-d2c8-42e9-854b-7fa77a95600e">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzExLTEzLTEtMS03MTMzMA_e217a2ff-7280-43f6-8135-887f8af8e9a4">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246NmM3YjM5MDNkYjAwNDhiNWI0Y2Q2OTZmNWY0OGIxZWJfNDU_5dee3389-92f2-4505-b322-34c5f800ab3a">2.64</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77dda1a9a6f4400c931bc6647f046197_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEyLTUtMS0xLTcxMzMw_cd0a86c1-3409-4faa-8c46-dfcf6d5f68ef">6,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEyLTEzLTEtMS03MTMzMA_a09c2647-7ac1-4bca-9978-e966a59f141d">6,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEzLTktMS0xLTcxMzMw_55da466c-745a-48a3-a373-ef8c642aee43">840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEzLTEzLTEtMS03MTMzMA_d2ed3bf9-1d24-473e-8e0f-0eb300091282">840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Spin-off of Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cb44e6556045cc99f6b8f0af62b975_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTMtMS0xLTcyMzA5_6b8d72a0-2080-43fd-8546-f8e06c261fa1">4,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e06bfa03d5c48d190290cd1a81579c6_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTctMS0xLTcyMzA5_38db9289-b5a2-426f-9127-b1880fed9e1d">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5efd7e6396194280b6782fba989ef826_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTExLTEtMS03MjMwOQ_4922572a-74f7-4b4b-bf0d-d2c916eff1e0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTEzLTEtMS03MjMwOQ_1181fd55-1fa5-4caa-a7d7-e9c9bd86d35e">5,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efd7e6396194280b6782fba989ef826_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTExLTEtMS03MTMzMA_8676382f-54fd-485d-900b-aa08c9151d12">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTEzLTEtMS03MTMzMA_06e71a17-5ba1-4815-a868-2bb6d34448ca">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5efd7e6396194280b6782fba989ef826_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE1LTExLTEtMS03MTMzMA_7c6e0c55-ba52-4b50-9366-b11318852d16">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE1LTEzLTEtMS03MTMzMA_0f8ecfb3-32ef-4527-8880-5db70f4f9e61">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cb44e6556045cc99f6b8f0af62b975_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE2LTMtMS0xLTcxMzMw_9c012ec8-734b-4789-a2e3-6fe70b77f8c2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE2LTktMS0xLTcxMzMw_b724e3a1-e4ca-447b-90df-8db703725379">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE2LTEzLTEtMS03MTMzMA_48a9ca44-eb9b-4922-beed-29bb199af029">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTEtMS0xLTcxMzMw_0c354e54-e47a-4dec-a0eb-86127d2d6944">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33db89af09b04ff88b03f0b7993e3646_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTMtMS0xLTcxMzMw_4361f733-9375-49de-ba43-41e65f78e8b0">44,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32922e48a4134ee0925f14bd1c083d4c_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTUtMS0xLTcxMzMw_b9fb08d0-d70e-40a3-8f1e-5b537946aa93">53,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i542103e76e6741a6805402bb88262b54_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTctMS0xLTcxMzMw_59195142-2c1a-406e-ba62-ed84aff196bb">4,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i170384be3a654d119874ff6b7ed2eb92_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTktMS0xLTcxMzMw_7d9ad4ab-e36b-440b-9242-028d95bf445e">57,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8637c5e12649be98c7fe608718e069_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTExLTEtMS03MTMzMA_455317a9-c26d-4405-ad45-89b014112d3c">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTEzLTEtMS03MTMzMA_41a5bfae-745a-423e-95c4-9d66fcb03c51">38,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba91acdcb37e4a5d8335bd645c29a624_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE4LTUtMS0xLTcxMzMw_66e28ecb-539f-4810-8f1e-660600559037">14,519</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE4LTEzLTEtMS03MTMzMA_e1c033a1-ea85-45df-89df-f73ed522dbca">14,519</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7edbd57c4cf745c49a7f15beff700c5b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE5LTctMS0xLTcxMzMw_b2401fdb-f313-46ec-ba17-27434779deff">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE5LTEzLTEtMS03MTMzMA_118111f5-f2a6-4a57-bf74-ddc7fb223e5a">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIwLTAtMS0xLTcxMzMwL3RleHRyZWdpb246YzI0ZjVlN2MzYWQ0NGE2OGI0YjRmMWRiNmRlMzZkMDdfNDU_30b19d4d-243e-456c-bbb3-5b32a1300e33">2.80</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba91acdcb37e4a5d8335bd645c29a624_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIwLTUtMS0xLTcxMzMw_0135a64c-2199-421b-864d-205d207336fd">7,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIwLTEzLTEtMS03MTMzMA_0ec32e82-6fdd-437a-a593-4cb2a6ff8d27">7,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15342adbb5e246fdaf6be1f7d6f161e2_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIzLTExLTEtMS03MTMzMA_426fdbda-05af-46bc-894e-1ba0c0b24bcb">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIzLTEzLTEtMS03MTMzMA_e139f137-2e9e-4b71-86e2-e7a874b649dd">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15342adbb5e246fdaf6be1f7d6f161e2_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI0LTExLTEtMS03MTMzMA_383a4f31-3685-44bd-9f4d-59f3cf96eec0">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI0LTEzLTEtMS03MTMzMA_940f89b8-f37e-47c5-95b3-273fed7a280b">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074f335e3eb646d3a641ffed1cc54d29_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI1LTMtMS0xLTcxMzMw_03d4ade1-b6f7-421a-8110-0125c5ecdda7">141</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI1LTktMS0xLTcxMzMw_15981058-25ba-4481-a961-a6f76d658ab1">620</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI1LTEzLTEtMS03MTMzMA_94331761-5a0b-43d5-acb9-38cb18532da5">761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326e10191d3348dd83075e847b9e3840_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTEtMS0xLTcxMzMw_efdadf20-4589-47ba-963e-ef6116c614f3">1,788</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e37f8c9ec504794ac6b72298c935735_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTMtMS0xLTcxMzMw_b7953fe5-24bc-47e2-8d8e-ff41e1db9183">44,379</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5bb04f307f47dcb79f92a26d5a4eb1_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTUtMS0xLTcxMzMw_5223e722-cafc-4b63-adfe-b50f777a91ac">61,081</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1e6ddf39c24d7f843d5f7b097b9c69_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTctMS0xLTcxMzMw_c6df57c8-1d02-40fe-a985-8f8866102c30">4,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if945586aba2d4519bdf8f10667672306_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTktMS0xLTcxMzMw_c87f7e39-0771-4c72-ba3d-07558845a7f2">56,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf11a2d764284028938a06f7df969c24_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTExLTEtMS03MTMzMA_49b76dae-7c91-45f2-8fea-682464dff27c">67</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTEzLTEtMS03MTMzMA_89e6de8a-ed92-4fd6-b3d2-b894d20e845a">46,058</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.75pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">($ in millions)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:69.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzItMS0xLTEtNzEzMzA_b278bfee-1b78-408d-aba1-01a966321c63">14,526</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzItMy0xLTEtNzEzMzA_23e78cfc-02b5-498f-806c-acb4a01dd09f">12,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzItNS0xLTEtNzEzMzA_4bf122c6-5199-4d9b-9a52-ea66cb0b2dc4">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQtMS0xLTEtNzEzMzA_eceb3848-a26f-41fe-889d-55b0ee12e0d2">2,085</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQtMy0xLTEtNzEzMzA_bdfab4e7-e909-48c0-b07f-532126ca6f06">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQtNS0xLTEtNzEzMzA_439d3535-4850-46a6-88c4-819a696ae17e">1,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUtMS0xLTEtNzEzMzA_5ad71459-c7ca-4dab-ab24-d8954739169e">1,824</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUtMy0xLTEtNzEzMzA_8dff6263-26e3-48e1-8b0b-11fdea8b1264">1,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUtNS0xLTEtNzEzMzA_89ba8277-4c74-416c-a859-88b67e16c1b2">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzYtMS0xLTEtNzEzMzA_eae46e82-29de-4552-8f1f-569668fab962">1,749</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzYtMy0xLTEtNzEzMzA_4527ffe8-6319-4f82-a226-aa3ccc0fdd6e">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzYtNS0xLTEtNzEzMzA_6fdc451b-6908-4f9c-bfbf-c9cf068b9b9b">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzctMS0xLTEtNzEzMzA_5b8691ec-3637-481d-8b1b-c7711cbacb79">1,419</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzctMy0xLTEtNzEzMzA_fe8c30b4-6cb9-43f9-81b2-4b258596bbb8">1,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzctNS0xLTEtNzEzMzA_74ae74db-6238-452b-9b3d-8a361c965535">1,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Charge for the acquisition of Pandion Therapeutics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzgtMS0xLTEtNzEzMzA_c5291fb5-00bb-4388-883e-8dd977a1af73">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzgtMy0xLTEtNzEzMzA_aa923c9f-965e-4c9a-ac1a-83b772cde24a">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzgtNS0xLTEtNzEzMzA_7634a9b0-6571-425f-8160-894733ab4238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Charge for the acquisition of VelosBio Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzktMS0xLTEtNzEzMzA_c614d138-c3ed-4ae7-a3fc-3b3352fec2eb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzktMy0xLTEtNzEzMzA_eb33de6b-8b30-4c96-8a6b-2ade40d29bff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzktNS0xLTEtNzEzMzA_712ea38b-9c86-4b36-8d8b-52346269f3e7">2,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzExLTEtMS0xLTcxMzMw_afd58960-4548-47ed-a2ff-d1dccb619dec">1,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzExLTMtMS0xLTcxMzMw_65a7fbd3-0a8b-453e-8510-bba13f7cb00c">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzExLTUtMS0xLTcxMzMw_198aa43e-b9dd-4446-ae6e-e3cd21b92eab">566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEyLTEtMS0xLTcxMzMw_e3e628be-02d5-4cbd-8476-0c3aab4727e2">541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEyLTMtMS0xLTcxMzMw_76552702-adff-4385-9fef-e10c52db738b">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEyLTUtMS0xLTcxMzMw_1126f63a-9050-467c-939c-6e3d726a8de6">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEzLTEtMS0xLTcxMzMw_8b303f01-5077-4e06-987e-c7d0a186f8df">1,301</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEzLTMtMS0xLTcxMzMw_a8c42328-fcb9-45fe-ba45-3f38fbda5103">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEzLTUtMS0xLTcxMzMw_afd64402-4394-46a1-9da9-a03db27272b7">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE1LTEtMS0xLTcxMzMw_0320923b-a11f-486c-8067-b49e860af06c">644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE1LTMtMS0xLTcxMzMw_29398d8d-fa01-4e6b-8182-26fbc71b557d">2,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE1LTUtMS0xLTcxMzMw_b7fda32e-e758-40c2-910a-236c740b22df">1,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE2LTEtMS0xLTcxMzMw_d590fc16-f04e-4d6f-9816-7f6f832112ef">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE2LTMtMS0xLTcxMzMw_ce807011-c38b-47bf-8633-8437a550bb7b">674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE2LTUtMS0xLTcxMzMw_6bde3779-1a9a-4a05-bb77-c91bfe728376">895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE3LTEtMS0xLTcxMzMw_83a1c416-df20-4efe-abfe-16b5cfaa9fd9">289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE3LTMtMS0xLTcxMzMw_901aa08b-86d9-4340-a85d-4c717452a1dc">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE3LTUtMS0xLTcxMzMw_e9ed3862-97fd-4248-865c-b3ad4f0fab91">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE4LTEtMS0xLTcxMzMw_2c636e56-a627-42c2-8a10-48912a2a392a">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE4LTMtMS0xLTcxMzMw_e25ff4d6-95dc-4b53-bf2a-67ea4b569475">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE4LTUtMS0xLTcxMzMw_8b6fe7bd-3887-495d-842a-3109f82dbbdb">1,152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE5LTEtMS0xLTcxMzMw_b4faeac3-254f-410a-97b4-951d857cf7b8">380</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE5LTMtMS0xLTcxMzMw_329e9c3d-26b5-4fda-8af2-bc2127c61630">540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE5LTUtMS0xLTcxMzMw_a2b527d2-bad0-46ef-9538-80c01fd80c1c">814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIwLTEtMS0xLTcxMzMw_b91944d7-e1af-4c84-8fbb-e43633fa23df">545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIwLTMtMS0xLTcxMzMw_2c4d0fc8-2382-4428-8bf5-e357b4a3672d">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIwLTUtMS0xLTcxMzMw_118b3060-8267-4d1c-b9fc-7c7f61fec907">617</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIxLTEtMS0xLTcxMzMw_68a765a0-4710-4570-bac1-57ea83423636">1,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIxLTMtMS0xLTcxMzMw_437ac6c5-8284-4963-90c4-d19638c7837c">1,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIxLTUtMS0xLTcxMzMw_005105b9-1077-4060-80f8-b81e6be07515">2,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIyLTEtMS0xLTcxMzMw_27b8d3a9-7d74-483c-a973-ec6033fc6726">19,095</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIyLTMtMS0xLTcxMzMw_69eff714-055b-48a0-87b7-ebca0f1d2f52">13,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIyLTUtMS0xLTcxMzMw_41964ca1-5d46-4707-94a4-f711fb40e010">7,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI0LTEtMS0xLTcxMzMw_0bf5f681-2f9e-43eb-b798-ceedceb33226">4,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI0LTMtMS0xLTcxMzMw_77338c3e-871c-484e-9d5b-b205a0d11a5f">4,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI0LTUtMS0xLTcxMzMw_a64937f6-19ab-41a1-ab96-234c4d5741fa">4,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Purchase of Seagen Inc. common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI1LTEtMS0xLTcxMzMw_a602afb2-fada-412f-b305-1a6256ebc66c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI1LTMtMS0xLTcxMzMw_641e775e-d991-4e4f-9e22-f0564fe8d5de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI1LTUtMS0xLTcxMzMw_753bd690-d0ca-464b-8a39-ae6db346d4ce">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI2LTEtMS0xLTcxMzMw_b2dce2f5-2ed0-421e-9a41-81e052d2751d">1,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI2LTMtMS0xLTcxMzMw_7cdfde1a-9551-41e2-9fa7-79c9ce88e220">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI2LTUtMS0xLTcxMzMw_63e6f359-bf94-4718-ae57-505f5cf8e5a7">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI3LTEtMS0xLTcxMzMw_69d7eee5-73c0-40a3-9317-08e26fc42417">721</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI3LTMtMS0xLTcxMzMw_9e76bf7d-547c-40cb-b1c7-29c06e5c3574">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI3LTUtMS0xLTcxMzMw_25a27a1e-29d3-4cb3-b044-d68c80df50df">2,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Acquisition of Acceleron Pharma Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI4LTEtMS0xLTcxMzMw_4a8c27e3-96c6-43d6-b42e-f9db769ed6dc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI4LTMtMS0xLTcxMzMw_c4c1762c-a52c-4617-ab6e-451ddda4f517">11,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI4LTUtMS0xLTcxMzMw_cfc18851-e86a-4659-a446-5416d4c72701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI5LTEtMS0xLTcxMzMw_b21c9a7b-4aec-47e6-bff3-fb844d80598c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI5LTMtMS0xLTcxMzMw_0971585e-eddd-425f-b392-cd2d55408313">1,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI5LTUtMS0xLTcxMzMw_61b00852-0923-4dac-9b16-3209cd1b747f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Acquisition of VelosBio Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMwLTEtMS0xLTcxMzMw_cee32440-2180-4474-996a-2417b252d444">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMwLTMtMS0xLTcxMzMw_64c0cd47-a71c-4ecc-ad25-25446a90cfc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMwLTUtMS0xLTcxMzMw_0dd0b5c6-0d98-4e16-8d98-d7ff0d0c77ef">2,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Acquisition of ArQule, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMxLTEtMS0xLTcxMzMw_383e617b-3f9f-4fd6-bdeb-dc3755c1892d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMxLTMtMS0xLTcxMzMw_db44b39d-237f-4384-931d-3c05bdce4067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMxLTUtMS0xLTcxMzMw_fd03f093-5c8b-4464-aa33-d0f1f6b8f6da">2,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM0LTEtMS0xLTcxMzMw_9ec82f21-016c-4f0c-b9f6-f59f82e0c10f">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM0LTMtMS0xLTcxMzMw_3240032f-2803-42f5-b80f-7ad4ec6a9973">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM0LTUtMS0xLTcxMzMw_7ce666ef-335d-4d91-947a-163d244c618a">1,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM1LTEtMS0xLTcxMzMw_9f9cba4e-981b-496f-a460-fbf0e8175519">32</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM1LTMtMS0xLTcxMzMw_4439b58e-479d-498b-a130-46542ddd934f">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM1LTUtMS0xLTcxMzMw_008bac54-d8cc-4c21-922b-e0624e8dfedc">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM2LTEtMS0xLTcxMzMw_b53ad816-1f07-4e0e-9529-c395ed7bc377">4,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM2LTMtMS0xLTcxMzMw_387b323f-9f51-434b-82b7-fc2996aad78d">16,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM2LTUtMS0xLTcxMzMw_64ab559c-d808-46c2-aed8-1063d69838a7">9,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM4LTEtMS0xLTcxMzMw_f5c90ece-82a4-4b7d-bf01-004f43cd66f5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM4LTMtMS0xLTcxMzMw_14c97b67-6bff-4ce5-a67e-6b7f123a9edd">3,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM4LTUtMS0xLTcxMzMw_c0a54419-399f-4c25-9bf2-6cb3f3b8cc92">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM5LTEtMS0xLTcxMzMw_b84a61a7-c3ec-4e93-a5c3-fead6fd5dc5f">2,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM5LTMtMS0xLTcxMzMw_812bfc17-83cb-42ea-b4d2-82042abc425a">2,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM5LTUtMS0xLTcxMzMw_8db2987d-0b48-41d3-9f68-36ae88ee8597">1,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQwLTEtMS0xLTcxMzMw_8a3bafc7-4ff3-4cb4-aaf9-3816cf5ce98e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQwLTMtMS0xLTcxMzMw_88b42412-24eb-4129-a708-60fa72e863b4">7,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQwLTUtMS0xLTcxMzMw_e106a46c-1095-4417-9aa4-74c076228c28">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Distribution from Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQxLTEtMS0xLTcxMzMw_c78c31a1-0c06-493e-9d37-62789ddc259c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQxLTMtMS0xLTcxMzMw_b0bee3cd-fabb-4899-8e5f-4e80fe3ea713">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQxLTUtMS0xLTcxMzMw_9d580f20-31fd-421f-9fac-4c8def2eb697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQyLTEtMS0xLTcxMzMw_51095e79-970d-4d6a-888f-596d725ac6f2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQyLTMtMS0xLTcxMzMw_87a205ab-370c-4e4a-827a-d7c4ab510665">840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQyLTUtMS0xLTcxMzMw_f3bc2e2f-c04b-4499-bce0-6e6171b008f4">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQzLTEtMS0xLTcxMzMw_c1552533-892a-48b7-bdcf-700d5de6845d">7,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQzLTMtMS0xLTcxMzMw_0c4e936b-06a0-4999-b2cd-fe1c9b51375d">6,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQzLTUtMS0xLTcxMzMw_8230424a-d6bd-4f72-a94e-808c5ac5e985">6,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ0LTEtMS0xLTcxMzMw_c4d13e19-f4bc-4b4a-a2ae-fbd972396926">384</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ0LTMtMS0xLTcxMzMw_4c2cc0c8-86ef-4c93-9e80-256d97dece83">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ0LTUtMS0xLTcxMzMw_bdb46407-b97b-4161-868f-7ad38f066a58">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ1LTEtMS0xLTcxMzMw_89576a58-8923-4241-bff0-b3593bc82813">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ1LTMtMS0xLTcxMzMw_aefc0b1d-8899-416e-91c2-c391ba82d024">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ1LTUtMS0xLTcxMzMw_1fb9717b-74e7-4e94-b572-7c48ae40c298">436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net Cash (Used in) Provided by Financing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ2LTEtMS0xLTcxMzMw_474dab5a-e3ac-4ecc-8c8d-471d282229d7">9,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ2LTMtMS0xLTcxMzMw_cf5685ab-2a63-41e6-bd1d-11fcc964172b">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ2LTUtMS0xLTcxMzMw_45ef4892-0fcd-402f-ab72-ae8c06f9db6d">2,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Cash Flows from Discontinued Operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ4LTEtMS0xLTcxMzMw_ca7674d9-adf2-4e1b-88a8-4fd8f55eb796">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ4LTMtMS0xLTcxMzMw_03ef6fdd-99ed-4dc1-beea-5c789ae01588">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ4LTUtMS0xLTcxMzMw_fa394b36-13b1-4e6b-a098-53dcbb68cfb3">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ5LTEtMS0xLTcxMzMw_eb5878d1-2d3c-4fe9-bdc3-1df1b2ac45ba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ5LTMtMS0xLTcxMzMw_4db03dae-5cca-4061-b4f0-af2a370092cf">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ5LTUtMS0xLTcxMzMw_7c99c49f-8b7f-4f89-82dd-78c65c6f3de6">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUwLTEtMS0xLTcxMzMw_7d5342fb-7792-4226-841c-767ff8b9e405">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUwLTMtMS0xLTcxMzMw_8ca9d1b1-42d0-488c-af69-13f1981456f7">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUwLTUtMS0xLTcxMzMw_0a8de96c-4af9-4802-ba76-5a61e49b0f1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net Cash Flows Provided by Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUxLTEtMS0xLTcxMzMw_931cb971-0a50-45ea-a261-5961fe099659">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUxLTMtMS0xLTcxMzMw_372142e8-411d-4924-a2af-dbbfa04daf2a">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUxLTUtMS0xLTcxMzMw_570e77e9-1366-44a1-89a6-01716f79bddd">2,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUyLTEtMS0xLTcxMzMw_8e14ba4b-b478-4789-b220-ad391cfcbf6b">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUyLTMtMS0xLTcxMzMw_66bc7c85-138a-4cc1-a83b-df15330574e9">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUyLTUtMS0xLTcxMzMw_2bfffbda-cbd5-467b-a451-19567ba91b75">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUzLTEtMS0xLTcxMzMw_34f990c5-532b-4f55-b24c-29841e16a828">4,606</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUzLTMtMS0xLTcxMzMw_dba9976b-de7c-4878-9bb7-3463cde825e8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUzLTUtMS0xLTcxMzMw_6aacb0ed-dd1e-41e0-aad2-808332fb1c53">1,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246OWQyOTJmMTQ2NGFjNDc0NmE2ODc1YWQ5NzhhNDIzMDFfMzg0ODI5MDY5NzYwMg_86a1f5ed-5322-4903-8d45-773c0306d1f4">71</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246OWQyOTJmMTQ2NGFjNDc0NmE2ODc1YWQ5NzhhNDIzMDFfMzg0ODI5MDY5NzcwOQ_569a1b03-4818-4ba5-b532-c8c15bdb956b">103</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246OWQyOTJmMTQ2NGFjNDc0NmE2ODc1YWQ5NzhhNDIzMDFfMzg0ODI5MDY5NzYxNg_8327f452-20ad-48b6-b09d-c4b982e79eeb">258</ix:nonFraction> of restricted cash at January 1, 2022, 2021 and 2020 included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTEtMS0xLTcxMzMw_5d20d430-72ce-4337-8527-9717cbe7957f">8,167</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTMtMS0xLTcxMzMw_98aaae91-583d-4cdb-a99f-f5bc84903730">8,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTUtMS0xLTcxMzMw_8f5e6a51-b0aa-4e9e-baab-36870a41bc4c">9,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Less: Cash and cash equivalents related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU1LTEtMS0xLTcxMzMw_fab9a20c-0d01-437c-844a-eb8b4702e91a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU1LTMtMS0xLTcxMzMw_6e2edd84-f0c3-4582-a4b0-e7285d957246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU1LTUtMS0xLTcxMzMw_1482b103-39dc-4cdf-aa7b-05cf89612fa8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzE1MDIyMWVjZWJjNGZlOGJhYjA5NWUxMTgxZWNmMzdfMTA5OTUxMTYyODU3OA_a56d9069-c45e-44f9-96a1-7eb4df9bf514">79</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzE1MDIyMWVjZWJjNGZlOGJhYjA5NWUxMTgxZWNmMzdfMzg0ODI5MDY5NzY5MQ_6751b4c8-35cb-4704-94e9-c04ef027506d">71</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzE1MDIyMWVjZWJjNGZlOGJhYjA5NWUxMTgxZWNmMzdfMzg0ODI5MDY5NzU5OQ_60b7a4e6-10a1-4118-a176-1e99fad957e3">103</ix:nonFraction> of restricted cash at December 31, 2022, 2021 and 2020 included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTEtMS0xLTcxMzMw_793ea5f2-3fce-4484-b318-e7d8992a81f3">12,773</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTMtMS0xLTcxMzMw_803fcb0b-5c0c-4d01-9a83-bcb5e84908cf">8,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTUtMS0xLTcxMzMw_6f1f22d2-1f7d-4096-a5b1-54c59168fa2b">8,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of this consolidated financial statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">($ in millions except per share amounts)</span></div><div id="ia384118d157240e09e39541b90e2080f_145"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDUvZnJhZzpjZGVmYmJkNzllMWM0ZTA5YjQyNDFlMmNkMGYzNGZjNS90ZXh0cmVnaW9uOmNkZWZiYmQ3OWUxYzRlMDliNDI0MWUyY2QwZjM0ZmM1XzI5ODk_a4957c21-f8eb-4b56-b110-fe20c4608997" continuedAt="id12141b57802438a9ad86cbf2c683f8d" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="id12141b57802438a9ad86cbf2c683f8d"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company&#8217;s operations are principally managed on a product basis and include <ix:nonFraction unitRef="segment" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDUvZnJhZzpjZGVmYmJkNzllMWM0ZTA5YjQyNDFlMmNkMGYzNGZjNS90ZXh0cmVnaW9uOmNkZWZiYmQ3OWUxYzRlMDliNDI0MWUyY2QwZjM0ZmM1XzMyMQ_b6a0c045-b597-4b96-91d0-2f31c820f1bc">two</ix:nonFraction> operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners. </span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note&#160;3).</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_148"></div><div style="margin-bottom:6pt;margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTE1_8f8d0703-c6e1-476d-a2e3-18c9106711e0" continuedAt="ia3608feccf464e61a5fb6720ada99237" escape="true">Summary of Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia3608feccf464e61a5fb6720ada99237" continuedAt="ic4349d738b0c438d89b8b5160961ffc0"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjY1_2656ed77-2f5f-4e5f-98d1-6c605f1aaaa5" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjMy_0febcc3c-cb07-4024-a989-2048739e2682" continuedAt="i30b04e83cd5f44fc90294019abe0b224" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="ic4349d738b0c438d89b8b5160961ffc0" continuedAt="i5ab81c3dc7f244419a5937e7be2c8909"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i30b04e83cd5f44fc90294019abe0b224">goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</ix:continuation></span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjUy_9b4f0653-c9be-4ec1-a4a4-437741a17745" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMDk4_44a64358-de43-4197-98ae-6b3320af7c34" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTIw_8281d274-7ee3-458e-9354-29caeb420ea6" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTk0_5417136f-28f5-41f4-aef4-34eea0a26f5b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTUx_f1c7d18a-7115-417f-8c23-9f44c37892d7" continuedAt="if07f0f6f45ef46168c97b94f2e44a922" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i5ab81c3dc7f244419a5937e7be2c8909" continuedAt="ia067a1e6bb424e61821348d7d3f9df98"><ix:continuation id="if07f0f6f45ef46168c97b94f2e44a922"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#8217;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwNTQx_7a784aee-38c9-4272-b7e8-e3e2a057c2de">12.3</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwNTUx_9456667a-d292-4a65-bbc6-e0120a136eb3">12.3</ix:nonFraction> billion in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwNTY0_44631ac5-946d-42d1-a02e-2bd1f651bcb8">11.4</ix:nonFraction> billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:AccrualForChargebacks" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMjk1_e768f80c-19e2-43fc-8123-f21544edd94f">178</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="mrk:AccrualForRebates" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMzAy_f27f36eb-ada4-477b-90be-e67bd7d23d98">2.7</ix:nonFraction> billion, respectively, at December&#160;31, 2022 and were $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="mrk:AccrualForChargebacks" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMzM1_0eb5a902-3feb-4aef-954b-b474b50b8443">207</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-8" name="mrk:AccrualForRebates" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMzQy_2c9677ff-9b48-4c41-a726-6c447e0cb8d6">2.6</ix:nonFraction> billion, respectively, at December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b">three</span> to <ix:nonNumeric contextRef="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjU4_f90662af-f5a4-4512-b3a9-c75b586bfb0a">six months</ix:nonNumeric> before and <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjcy_0ce8b2b0-cd6c-4426-9482-ae555d57c303">12</ix:nonNumeric> months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically <ix:nonNumeric contextRef="i6e6bbb5f87c44047960024c6b0517fd6_D20220101-20221231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzODc4_c73efcc4-8cef-4cac-ac27-8af4592d84b0">36</ix:nonNumeric> days from receipt of invoice and for U.S. animal health customers are typically <ix:nonNumeric contextRef="ia2af1368f91147fab0b3d00e67b4afa4_D20220101-20221231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzOTYx_b53a0846-941c-4ca2-ac33-2ec35ccf3214">30</ix:nonNumeric> days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to <ix:nonNumeric contextRef="i152d7547c40c49cfa09fdd72d4292d05_D20220101-20221231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0MDky_cf4c8517-df91-4aec-94ef-46531966a839">90</ix:nonNumeric> days. Outside of the U.S., payment terms are typically <ix:nonNumeric contextRef="i7a2d859521db4ed99e9f6f0c3c55169a_D20220101-20221231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0MTUw_6f70c856-9a00-4084-8c73-288bc8e0367e">30</ix:nonNumeric> days to <ix:nonNumeric contextRef="i90ed8021173448b0b3372bcb951af216_D20220101-20221231" name="mrk:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0MTYx_fc3e3ee2-6d45-46e0-9599-270300414faa">90</ix:nonNumeric> days, although certain markets have longer payment terms.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note&#160;19 for disaggregated revenue disclosures.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="ia067a1e6bb424e61821348d7d3f9df98" continuedAt="i55d24cced2fc4776b60762b2cb66635c"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTM4_966b1887-f832-4c31-8203-f241efaa9b13" continuedAt="ic24390bd3f124f52ab8c7a4c22734d51" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from <ix:nonNumeric contextRef="ib6acc5aab0ca4602b1c723258ab0abe5_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTA0_27251059-574b-436f-b5e9-d8d5d5177864">25</ix:nonNumeric> to <ix:nonNumeric contextRef="ie3dd256716df46d1b2aef36eb21dc58a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTEw_75b841fd-256b-4e1e-abb6-327cf8999376">40</ix:nonNumeric>&#160;years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and from <ix:nonNumeric contextRef="i88b53a8f47684df2aa5a27b6be330095_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTQz_5a056703-4ff1-4247-ba7e-52e2ecc797a4">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i0248176f895b46cfac11e4d46217846a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTQ5_d32ba6e9-81ec-4fab-8d4e-4a23e0332d86">15</ix:nonNumeric>&#160;years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span></ix:nonNumeric><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ic24390bd3f124f52ab8c7a4c22734d51">.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NjMy_39082eb7-0fb6-440b-bdf3-095ff099a9e1">1.8</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NjQy_6d277e5e-04d7-4f8d-bceb-c261f34fe44f">1.6</ix:nonFraction> billion in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-8" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NjU1_f48146d6-a712-4282-91d3-ba9623d64de3">1.7</ix:nonFraction> billion in 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTg5_11cb5bfc-cf40-4c88-b7c3-f03715375983" continuedAt="ieafd6db13329419292c3f7cec966de3f" escape="true">Advertising and Promotion Costs &#8212;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ieafd6db13329419292c3f7cec966de3f"> Advertising and promotion costs are expensed as incurred.</ix:continuation> The Company recorded advertising and promotion expenses of $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0ODE2_08a04ea2-e09c-4be8-b31a-5693dfdb1709">2.2</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0ODI2_77c5aff6-2373-4f47-a3c1-13edaf3269e7">2.0</ix:nonFraction> billion in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0ODM5_8cdafd75-21f6-4df1-8cb4-bc9bb9bd443c">1.8</ix:nonFraction> billion in 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjA2_daa4b95a-3fe0-4cc1-b1f8-8cb3ff4e94c8" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from <ix:nonNumeric contextRef="ie24801838a2c42948246ef5a5409d8e6_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE1NDM3_29e775e0-d853-428a-8762-049d77aea97e">3</ix:nonNumeric> to <ix:nonNumeric contextRef="id9b39a79d65a4ca691a37dcfe4922939_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE1NDQz_de675f3a-3d9c-4540-85f3-0d36fad3b2c3">10</ix:nonNumeric>&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTU0_10f04039-a272-4757-b215-398f3f6fad6f" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjYw_5662fa03-c12d-471e-afc4-9fd55a2c6ca4" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from <ix:nonNumeric contextRef="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE2ODA1_81f0bd68-2b28-430d-b9d6-94a066fef03d">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE2ODEx_0aa706fe-16a4-4c40-a81d-412f594351bb">24</ix:nonNumeric>&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTc3_1c9fb9ac-5ce7-4b23-ad99-778bf8b2e80a" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:ContingentConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTUy_cc686c0a-8377-4827-90e4-14abd165fe0a" continuedAt="if7e9c6b17d8c4ea083f4e78471bc3964" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span></ix:nonNumeric><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="if7e9c6b17d8c4ea083f4e78471bc3964">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjE1_cea5cd28-2733-4e75-9f14-6eef63406456" continuedAt="ib73b58f3b7b0456993796290f1cbb311" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i55d24cced2fc4776b60762b2cb66635c" continuedAt="i637371705b6646b0b03dadf93032341c"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ib73b58f3b7b0456993796290f1cbb311">expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.</ix:continuation> </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTIz_2d6886ef-42dc-479a-8b0b-3491ad81c322" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjY2_1560f27a-832e-4217-be83-408903c9e317" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjY0_c2ba03f8-60e9-4efc-be9a-513a7ea8d008" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjE0_b3de152a-fa78-4e6c-8cce-95553a6e15fe" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></ix:nonNumeric></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTg2_104ca5db-3e5c-4381-a119-3a4ecd9d11c9" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company&#8217;s policy for releasing disproportionate income tax effects from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is to utilize the item-by-item approach.</span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i637371705b6646b0b03dadf93032341c" continuedAt="i503f7039635440d9ba546a8337bcb323"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwOTk1MTE2Nzg3NjE_0de94d7b-bc0c-40ea-a8b1-617e5db1975e" continuedAt="ie2067b02b5734b9ea9f3aac68e44dadb" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></ix:nonNumeric><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ie2067b02b5734b9ea9f3aac68e44dadb">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjg4_50943af9-d229-4b83-bd39-506848cd6e58" escape="true"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTYw_73c6dcc4-94bc-401f-87fa-46222d2e8af4" continuedAt="i364ca2db4b4243d79ae639ba30a770de" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#8217;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><ix:continuation id="i503f7039635440d9ba546a8337bcb323" continuedAt="if33b0b1ef59542fca01eaf58fdd53503"><ix:continuation id="i364ca2db4b4243d79ae639ba30a770de" continuedAt="id7967e6d112a4ad7929d64c865682c24"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard&#160;Not Yet Adopted &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="if33b0b1ef59542fca01eaf58fdd53503"><ix:continuation id="id7967e6d112a4ad7929d64c865682c24">In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div id="ia384118d157240e09e39541b90e2080f_151"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Spin-Off of Organon &amp; Co.</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzU4NDc_544d0054-54da-41e9-8fb5-d13c96158c11" continuedAt="icbd7ad64e07c4f4b8838f7fb0fdf965b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon&#8217;s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $<ix:nonFraction unitRef="usd" contextRef="i4cc952f1b2f2496fb3e7cb831f0dbcc7_I20210602" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzUwOQ_de4479fa-b562-427e-8b99-de151b5423a9">9.5</ix:nonFraction>&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i05ee48b166b44fbaa88adeaa6cccbcca_I20210602" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzc0Mw_232957d5-3b52-4675-82bc-607d890b0cf6">9.0</ix:nonFraction>&#160;billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within <ix:nonNumeric contextRef="i91a08ec51d834fb4b5ee3a778a3ddf08_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzE1NDA_7bb494a6-5378-4eb6-915a-7b33a094613c">25</ix:nonNumeric> months following the spin-off; however, the provision of certain services has been extended to <ix:nonNumeric contextRef="if7b56448c76a44d38b534e9b53205ce6_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzkzNDU4NDg4NDQ3MjI_a43ae40f-89ac-45a5-b840-cf84cb35053e">35</ix:nonNumeric> months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from <ix:nonNumeric contextRef="i3eb2867b2dcb413caf68f19d0cff8a38_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzI4OTk_6af422c6-a75b-4350-9ca9-e43155fc0117">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="ibe247952fa8f40f48f9d542a2f0c75b2_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzI5MDU_43065d33-ef53-4208-89d4-0d7afd9ab5a7">ten years</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts included in the consolidated statement of income for the above MSAs include sales of $<ix:nonFraction unitRef="usd" contextRef="id0e03ea81b4d43bc833a87aaff997b7c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzQwMjc_8bd3a764-c7ad-489a-9b0b-12952a14e5d2">383</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id47f3aaa34b04200b41ca2809b9e4542_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMwMDI_8b54e55c-7e85-4f04-816f-b61ddefef32b">219</ix:nonFraction>&#160;million in 2022 and 2021, respectively, and related cost of sales of $<ix:nonFraction unitRef="usd" contextRef="id0e03ea81b4d43bc833a87aaff997b7c_D20220101-20221231" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzQxMTg_e6edfe34-679e-42db-9386-17958dfc7a4a">404</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id47f3aaa34b04200b41ca2809b9e4542_D20210101-20211231" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMwMzQ_19593666-8f83-4182-9686-b75f59212401">195</ix:nonFraction>&#160;million in 2022 and 2021, respectively. Amounts included in the consolidated statement of income for the TSAs were immaterial in 2022 and 2021. The amounts due from Organon under all of the above agreements were $<ix:nonFraction unitRef="usd" contextRef="ic18668b15f364b13be1b1dcc95030f0c_I20221231" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzM2ODE_2b210b63-cffc-4cfa-bde7-aee39c293776">511</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idfa6366e1ebc4503ba80ecd66a39f955_I20211231" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMxOTk_5de9ca8f-d095-4273-832a-f6d40b5ae1dd">964</ix:nonFraction>&#160;million at December&#160;31, 2022 and 2021, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $<ix:nonFraction unitRef="usd" contextRef="ic18668b15f364b13be1b1dcc95030f0c_I20221231" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzM3NTU_86d3772c-3762-4309-a751-029a85880de5">345</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idfa6366e1ebc4503ba80ecd66a39f955_I20211231" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMzMDM_0fbd6e37-7016-41a8-b02b-11e5d73cdc17">400</ix:nonFraction>&#160;million at December&#160;31, 2022 and 2021, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The results of the women&#8217;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#8217;s consolidated statement of income as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzQwMDY_76621ae6-0a5d-42b2-9032-ecbf1ca41b88">556</ix:nonFraction>&#160;million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzQwMjE_9e2bae43-e8c5-48aa-9a87-692a06d067f9">743</ix:nonFraction>&#160;million in 2020 related to the spin-off of Organon, which are also included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="icbd7ad64e07c4f4b8838f7fb0fdf965b"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzU4NDg_32673393-2142-4551-8225-604820a2bc81" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEtMS0xLTEtNzEzMzA_9f16c735-8cc8-4545-8beb-d9e553f7a93a">2,512</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEtMy0xLTEtNzEzMzA_872eea21-0801-4dbf-8831-e5e1ad76156c">6,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzMtMS0xLTEtNzEzMzA_7b2cbbb8-4028-4ef1-ab98-23db784d8e44">789</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzMtMy0xLTEtNzEzMzA_59a554e4-e25a-40eb-bff7-188153edc58c">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzQtMS0xLTEtNzEzMzA_9267543d-30f4-45b6-ba64-97089255cf1f">877</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzQtMy0xLTEtNzEzMzA_d7704efb-1246-4dff-ac4e-dd53a9849b44">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzUtMS0xLTEtNzEzMzA_b660a826-9710-4527-ad65-bdc283144616">103</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzUtMy0xLTEtNzEzMzA_0b59d5d6-5302-445e-9563-3f637a5ac566">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzYtMS0xLTEtNzEzMzA_b8e819e0-443f-43e8-9131-597e1dc614eb">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzYtMy0xLTEtNzEzMzA_20518a49-b0d2-4f62-afeb-a32bbe97d825">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzctMS0xLTEtNzEzMzA_47955967-f74c-4311-b13a-a14647568f6e">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzctMy0xLTEtNzEzMzA_45369cf2-100c-481e-891b-2965b2c4fcf7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzgtMS0xLTEtNzEzMzA_a74d6740-6009-4373-88ef-c76f81f14f59">1,755</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzgtMy0xLTEtNzEzMzA_9f706bcb-b87e-4d66-87c4-34b6f8d3a9c6">3,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzktMS0xLTEtNzEzMzA_a2b0a4db-16ad-4459-b565-1c735fd9e9c9">757</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzktMy0xLTEtNzEzMzA_96ce65b9-30a8-496d-863b-01a9345b5ce5">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEwLTEtMS0xLTcxMzMw_1d5a3b10-ad1a-439c-9a4f-e0a5dd006339">50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEwLTMtMS0xLTcxMzMw_8449757b-e46d-4806-a087-091088ff1c72">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzExLTEtMS0xLTcxMzMw_e88903a8-a78c-4ede-8811-e42cbd32006d">707</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzExLTMtMS0xLTcxMzMw_717a22d4-2d0d-42fe-a84b-4ed6c1898057">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEyLTEtMS0xLTcxMzMw_b17d1242-db34-49c4-8f37-c8e1a726dd3a">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEyLTMtMS0xLTcxMzMw_65e1666a-ff9b-4b9f-9296-ec8f4369b641">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEzLTEtMS0xLTcxMzMw_ff49adaf-5ae7-4d3a-8ed8-e5582122dfa2">704</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEzLTMtMS0xLTcxMzMw_f4088dfa-5fe9-4b32-8dc2-d3468d7d0cdf">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div></ix:nonNumeric></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_157"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI0MjE3_89334139-61f3-464e-b3e4-7428fd3b14cf" continuedAt="ie34e894ac8d149f9b6fe3f383fbf9877" escape="true">Acquisitions, Research Collaborations and Licensing Agreements</ix:nonNumeric></span></div><ix:continuation id="ie34e894ac8d149f9b6fe3f383fbf9877" continuedAt="i2f2acc33bc1747f6bee3812ee907fdee"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recently Completed Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie7668e0129294bdcbf2855d7d0ee191d_D20230201-20230224" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4NjI_975b0570-f236-4b26-bc4f-c6cc531c1148">175</ix:nonFraction>&#160;million, which will be recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4Njk_bdabb8ff-a833-4789-8887-c71dd6a74c6a">1.0</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4NzY_b5dcb250-f295-4c07-8fd4-1a3955f022d0">2.8</ix:nonFraction>&#160;billion in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4ODM_87d43ccb-2df5-4057-850b-6bc25dea109f">5.5</ix:nonFraction>&#160;billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $<ix:nonFraction unitRef="usd" contextRef="ib17138b844f348b1a50f35c8ae1978e5_I20230131" decimals="-6" name="mrk:CollaborativeArrangementPreferredStockInvestmentInCounterparty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA5MDY_cb728e24-5475-4ccd-b350-43015e354694">100</ix:nonFraction>&#160;million in Kelun-Biotech&#8217;s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $<ix:nonFraction unitRef="usd" contextRef="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131" decimals="-7" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTE4ODA_929254e3-c307-4dfa-93bd-ce6174aac9b2">1.35</ix:nonFraction> billion (including payments to settle share-based equity awards) and also incurred approximately $<ix:nonFraction unitRef="usd" contextRef="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTE5NTU_08baeb18-bca2-4b53-9254-80c39f3e237c">60</ix:nonFraction>&#160;million of transaction costs. Imago&#8217;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $<ix:nonFraction unitRef="usd" contextRef="i74aa3e82c01b42c6a7419c59ba514f25_I20230131" decimals="-6" name="mrk:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTI0MTg_26bbfaef-7505-4fc0-b235-f9ff201dbc13">200</ix:nonFraction> million and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTI0NjM_f98ae9b7-5931-4eac-b5e4-58cb31416c94">1.2</ix:nonFraction> billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i2f2acc33bc1747f6bee3812ee907fdee" continuedAt="i4aad89eab85e4eddbe37613742b61137"><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $<ix:nonFraction unitRef="usd" contextRef="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031" decimals="-6" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExOTI_30f72b08-4dcb-401a-804c-77348293157d">50</ix:nonFraction> million to co-fund Merck&#8217;s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. As Royalty Pharma is sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received is being recognized by Merck as a reduction to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses ratably over the estimated Phase 2b research period. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of <ix:nonFraction unitRef="number" contextRef="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031" decimals="2" name="mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExNjI_7ad1ae55-67da-421a-afa3-b0dce45a088b">50</ix:nonFraction>% of the development costs up to $<ix:nonFraction unitRef="usd" contextRef="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031" decimals="-6" name="mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExNjc_e780fca8-f862-4802-ba22-3bce4f322d3d">375</ix:nonFraction>&#160;million. Royalty Pharma is eligible to receive royalties on future sales. If Royalty Pharma elects to provide the additional funding noted above, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as a higher royalty rate. Merck will record the milestone payments as an expense within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> upon receipt of the related approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $<ix:nonFraction unitRef="usd" contextRef="i44db6d09190041e18d6b1b29eb14bb9b_D20220901-20220930" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyMDc_8e89a628-18d0-48bf-a0b2-59435742eb6a">250</ix:nonFraction> million charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $<ix:nonFraction unitRef="usd" contextRef="i5db175a81b9f43c1b0e8d6bbfc9cad3d_D20220801-20220831" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyMjQ_e55dc7e2-c6f9-42de-b415-8c7c96849ab0">150</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="ie53196e6917242ea85419903828dbab2_D20220801-20220831" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyNDI_d6145411-8b8c-4868-923f-216d50f050d5">440</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="if640c54f5da1491792d044ba5742c097_D20220801-20220831" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyNjA_c79e0189-e872-4a8d-96b9-462ea5444f99">675</ix:nonFraction>&#160;million in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="i4fffd33d73024f8cae603f326b7f1104_D20220801-20220831" decimals="-8" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyNzg_983e478e-3afd-4fda-b918-5428a18403b2">2.4</ix:nonFraction>&#160;billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $<ix:nonFraction unitRef="usd" contextRef="iad647dc2d4aa4b91a0013d32ad01912d_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyOTY_4493b622-5b7b-43e9-9f1e-647869e5136f">100</ix:nonFraction>&#160;million in Orna&#8217;s Series B preferred shares in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion&#8217;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $<ix:nonFraction unitRef="usd" contextRef="id70dba7305144817a9064998df5667d1_D20220701-20220731" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzMTQ_bbfc181a-84b2-4bd7-a671-b873f933ba25">290</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of MK-5684. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of MK-5684, as well as tiered double-digit royalties on sales if the product is approved. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0a30e3c742444082976808cee5c16655_D20220701-20220731" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzMzE_215aaa61-d39f-4c17-a9dc-b41426acc4e6">35</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="ic774cbcb70554e169b26550e484a0585_D20220701-20220731" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzNDg_d3a4109e-12f7-4314-8877-41fa41a1a334">82</ix:nonFraction>&#160;million in developmental milestones, $<ix:nonFraction unitRef="usd" contextRef="i6296f4bad6634365be938b368f535a4e_D20220701-20220731" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzNjY_362b01fd-a3a7-4c94-a04f-9e2392044813">334</ix:nonFraction>&#160;million in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="id8672dcf41ce4577b1f1b821640eae58_D20220701-20220731" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzODQ_4de33cbd-0af1-40d4-bdf8-a7f3279cb697">485</ix:nonFraction>&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech&#8217;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for advanced solid tumors. Upon option </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i4aad89eab85e4eddbe37613742b61137" continuedAt="i7cffc90b407942279f71a17234421404"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">exercise, Merck made a payment of $<ix:nonFraction unitRef="usd" contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0MzA_7f3d7aad-df23-4a35-95eb-bd1a7e0452bc">30</ix:nonFraction>&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022, and agreed to make additional payments of $<ix:nonFraction unitRef="usd" contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1MDE_8c06b9c4-4d0e-4191-ad40-af75e99d9b19">30</ix:nonFraction>&#160;million upon completion of specified project activities and $<ix:nonFraction unitRef="usd" contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531" decimals="-6" name="mrk:MilestonePaymentToBeMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1MTg_b191530c-5884-42a8-baff-1576f6eb146f">25</ix:nonFraction>&#160;million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531" decimals="-6" name="mrk:ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1MzU_5a2e8712-742a-4bde-9bf6-1cb981002d3f">111</ix:nonFraction>&#160;million to fund Kelun-Biotech&#8217;s ongoing research and development activities, of which $<ix:nonFraction unitRef="usd" contextRef="i82b90cfcdde044b7a79d4c12ce3af129_D20220501-20221231" decimals="-6" name="mrk:ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1NTM_1990f16c-e943-48c5-bf3f-c6c4a4131286">51</ix:nonFraction>&#160;million was paid in 2022. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $<ix:nonFraction unitRef="usd" contextRef="ic68d62a9a6db4df3bf89fc5ddf7583e1_D20220501-20220531" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0NDg_ef91ca38-5881-41c3-95a0-d67576638620">90</ix:nonFraction>&#160;million in developmental milestones, $<ix:nonFraction unitRef="usd" contextRef="ic0cf91de3d1d4c32ad48e6066885e0f2_D20220501-20220531" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0NjY_4a227e19-e92b-41d7-b330-d5d734f4ca0d">290</ix:nonFraction>&#160;million in first commercial sale milestones, and $<ix:nonFraction unitRef="usd" contextRef="ifb1eeae45b61446697e00a09ff97862e_D20220501-20220531" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0ODQ_a0221355-db54-440a-b458-06f7410f3f44">780</ix:nonFraction>&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i7073d5a9d7f24a98995d80fe479f8283_D20211101-20211130" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEwMzE_41b1e151-2514-4f80-99ff-89fdbe499c97">11.5</ix:nonFraction> billion. Acceleron&#8217;s development work focused on evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron&#8217;s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay <ix:nonFraction unitRef="number" contextRef="ifcf26d356d3946f4a878afd16a2a4024_D20211101-20211130" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzIwODA_0871d8d0-1f92-44f1-8de6-dd26b66239f4">22</ix:nonFraction>% royalties on future sales of sotatercept in the PH field to BMS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to sotatercept, Acceleron&#8217;s portfolio includes Reblozyl (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. Reblozyl is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a <ix:nonFraction unitRef="number" contextRef="i785539df716f4bce95f1ef45066b0e36_D20211101-20211130" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI2ODA_214e0637-e693-43cb-a50d-a1eab0bee7db">20</ix:nonFraction>% sales royalty from BMS which could increase to a maximum of <ix:nonFraction unitRef="number" contextRef="ic1f1de3723354ed1af5631e0fd919013_D20211101-20211130" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI3NDM_1474cca9-7c07-4f91-b33e-cd901f7a59f2">24</ix:nonFraction>% based on sales levels. This royalty will be reduced by <ix:nonFraction unitRef="number" contextRef="ifcf26d356d3946f4a878afd16a2a4024_D20211101-20211130" decimals="2" name="mrk:RoyaltyRateDeductionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI4MDE_fa2433b3-ca8b-4fb5-9040-47907afa23eb">50</ix:nonFraction>% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck received a contingent regulatory milestone payment of $<ix:nonFraction unitRef="usd" contextRef="if030a4536a8047a1a585275c17092ed8_D20220101-20221231" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI5OTA_794cbd6a-db33-4816-a1fc-2afba993e16c">20</ix:nonFraction>&#160;million in 2022 and remains eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ic10f48c8ad804e3ab3fb873838f81931_D20220101-20221231" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzMwMjg_21590007-882b-4f97-892f-2b1caa0bc89b">80</ix:nonFraction>&#160;million in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The transaction was accounted for as a business combination. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="ifd86187433f44eaeacfe4a3eb6a5201f_I20211130" decimals="-6" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzMxNDE_7773e197-8918-4a13-b712-6b932ed93ebd">280</ix:nonFraction>&#160;million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs in 2021. </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI0MjI4_b7166421-3a8e-428d-b313-6a4760fdf1f1" continuedAt="i9683f4c19dcd4a789229c463c1f03f89" escape="true"><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzEtMi0xLTEtNzEzMzA_5ac1345d-5d83-426d-b434-8b915d1d18e1">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzItMi0xLTEtNzEzMzA_5bffd854-84d6-4454-83ef-32980a4aa4d9">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzQtMi0xLTEtNzEzMzA_395fb031-8138-4fc7-8c8c-054534881eb8">6,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights - Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="i7073d5a9d7f24a98995d80fe479f8283_D20211101-20211130" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzUtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpiYzZkOTMwMThiOGY0MjQyYjRhZDZjZGU0NzU0NmFlMV80NA_097b80ec-4dcf-4418-8741-23400de8cfdd">12</ix:nonNumeric> year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzUtMi0xLTEtNzEzMzA_15aed1d9-f0bb-41ac-b988-c19638d507af">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzYtMi0xLTEtNzEzMzA_54a9a664-dbd0-43bd-b989-43fe7b91b95d">1,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzctMi0xLTEtNzEzMzA_2633eff1-71cf-454e-a535-f217502a9618">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzgtMi0xLTEtNzEzMzA_81cdefdc-2228-4721-9364-6e7add4c12cb">9,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzktMi0xLTEtNzEzMzA_bd8d8381-2790-4d1f-b98c-332738000826">2,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzEwLTItMS0xLTcxMzMw_c7554ca4-09e0-4237-9a35-a6d81cd1857a">11,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="i53d43b0dc8d742539a81797aad2c7dac_I20211119" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM5MjI_74446c4d-ab53-45e0-b381-249e812343f9">7.5</ix:nonFraction>% for sotatercept and <ix:nonFraction unitRef="number" contextRef="i53d43b0dc8d742539a81797aad2c7dac_I20211119" decimals="3" name="mrk:IntangibleAssetProductsAndProductRightsMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM5NDU_bf5fa0c2-eafc-43f6-bb83-ae5aadaa2768">6.0</ix:nonFraction>% for Reblozyl. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion&#8217;s development work focused on advancing a pipeline of precision immune modulators targeting </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i7cffc90b407942279f71a17234421404" continuedAt="i583e2e23459b40fd9f9c0be252007774"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">critical immune control nodes. Total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="i49e02de6be3a44268b77d9db477d3905_D20210401-20210430" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ1OTM_457e51fa-f127-45e3-ad6d-28fb9cf4805b">1.9</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="i49e02de6be3a44268b77d9db477d3905_D20210401-20210430" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ2MDU_d1714b5a-d97c-4139-bbb3-023b061bcd2c">147</ix:nonFraction>&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="ifb1df4caa295436598a3f45d73add47c_I20210430" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ3OTM_e971c4e3-b32f-4645-8585-6ef5c6299d49">156</ix:nonFraction> million (primarily cash) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="icaad804e1a1445199d9e01dd42edfc61_D20210101-20211231" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ4NTQ_9426da76-4ba6-4251-9202-79f7ff9f91d4">1.7</ix:nonFraction> billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead&#8217;s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared <ix:nonFraction unitRef="number" contextRef="i7dd421f3e24b48ab92de4b4ccbc4ffe1_D20210301-20210331" decimals="2" name="mrk:ProfitShareCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzU4MzQ_e1e2a32e-d9b1-4f22-bc55-e352738189ae">60</ix:nonFraction>% Gilead and <ix:nonFraction unitRef="number" contextRef="i7dd421f3e24b48ab92de4b4ccbc4ffe1_D20210301-20210331" decimals="2" name="mrk:ProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzU4NDg_9d587cc2-bd6a-4cb9-86c7-bc1fa3bd33d4">40</ix:nonFraction>% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331" decimals="-8" name="mrk:SalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY0NTQ_d4ba32aa-c7be-4b08-af7a-148ae84194fe">2.0</ix:nonFraction>&#160;billion a year in net product sales for the oral combination, the revenue split will adjust to <ix:nonFraction unitRef="number" contextRef="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331" decimals="2" name="mrk:ProfitShareCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY1NDQ_2d5e25cf-2fcd-42fe-b161-4ac60bcf44ec">65</ix:nonFraction>% Gilead and <ix:nonFraction unitRef="number" contextRef="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331" decimals="2" name="mrk:ProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY1NTg_9091a568-d9c6-41fa-abba-5e817a4337c7">35</ix:nonFraction>% Merck for any revenues above the threshold. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331" decimals="-8" name="mrk:SalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY2MTg_04d30ef3-9dfe-41a3-81e9-d7ef6462326c">3.5</ix:nonFraction>&#160;billion a year in net product sales for the injectable combination, the revenue split will adjust to <ix:nonFraction unitRef="number" contextRef="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331" decimals="2" name="mrk:ProfitShareCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY3MTQ_0d6d804e-319f-408c-b638-312e674c67ca">65</ix:nonFraction>% Gilead and <ix:nonFraction unitRef="number" contextRef="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331" decimals="2" name="mrk:ProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY3Mjg_2a836f27-0dcd-4dd9-b4ca-290bd8e4fa9e">35</ix:nonFraction>% Merck for any revenues above the threshold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced the Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP). The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#8217;s proprietary platform. Merck and Artiva agreed to engage in up to <ix:nonFraction unitRef="research_program" contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131" decimals="0" name="mrk:CollaborativeArrangementNumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwNDQ1MzYwNTE0NzE3_e036430c-e1f7-48ba-94e4-daa47e19e605">three</ix:nonFraction> different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131" decimals="-6" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEwNTg_3031c0a1-d3f9-48e9-8c45-9168486eac57">30</ix:nonFraction>&#160;million, which was included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzkwOTI_0c56e650-1d5c-43cc-9597-9d22f4966d63">15</ix:nonFraction>&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all <ix:nonFraction unitRef="collaboration_target" contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131" decimals="0" name="mrk:CollaborativeArrangementNumberOfCollaborationTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwNDQ1MzYwNTE0NzI3_0507797c-3675-45e0-8ca3-e9f81c590c01">three</ix:nonFraction> collaboration targets), aggregating up to $<ix:nonFraction unitRef="usd" contextRef="i8d99c64b435b4e87a51ff910dece08c8_D20210101-20210131" decimals="-5" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEwOTM_084ca266-59d7-4e51-b75c-f51af4d9b20f">217.5</ix:nonFraction>&#160;million in developmental milestones, $<ix:nonFraction unitRef="usd" contextRef="id251d0d82d7944d495c9d8d8fce4e269_D20210101-20210131" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMDE_fd03ef6b-f200-4ebd-952a-10436d111cfd">570</ix:nonFraction>&#160;million in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="i88f4e389e77641b6b46442285a84c3f4_D20210101-20210131" decimals="-7" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMDg_961eb1ab-807d-49c2-b8fe-b53a55355c7d">1.05</ix:nonFraction>&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i3f065c4f1db344d4862bd79ea44a07a9_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzk1MjY_880997e6-93b3-4adf-8e99-e6a2c718d6b8"><ix:nonFraction unitRef="number" contextRef="i3f065c4f1db344d4862bd79ea44a07a9_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzk1MjY_96744b31-cde9-4fb3-9ec9-ba55fc372537">7</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i12a517b30e874a00bab97ff6980aab5c_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzk1MzI_00cab969-7da1-4700-9620-bf68f1f29940">14</ix:nonFraction>% on future sales.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i583e2e23459b40fd9f9c0be252007774" continuedAt="i8ae4b14558634d72997c26e51513dd70"><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMTQ_ee346759-f359-4a67-91d0-dee28b4eb0a4">423</ix:nonFraction> million. OncoImmune&#8217;s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $<ix:nonFraction unitRef="usd" contextRef="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMTc0_be70d6ea-1e1b-4e3d-bfb9-75a55215708c">50</ix:nonFraction>&#160;million for a <ix:nonFraction unitRef="number" contextRef="ied63ffc9cee949b990458159c3946f6c_I20201231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMTgz_6d79e8b7-5e67-480d-bbfa-df99bdf288c1">20</ix:nonFraction>% ownership interest in the new entity, which was valued at $<ix:nonFraction unitRef="usd" contextRef="iabf1056dbb7047808e6072640db0a6d7_I20201231" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMjQ0_35b1d478-54e0-46c3-858a-8edbd8a1cfe1">33</ix:nonFraction>&#160;million resulting in a $<ix:nonFraction unitRef="usd" contextRef="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231" decimals="-6" name="mrk:PremiumOnSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMjYy_58b28f17-1b6c-469a-adc7-d547a0254386">17</ix:nonFraction>&#160;million premium. Merck also recognized other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="iabf1056dbb7047808e6072640db0a6d7_I20201231" decimals="-6" sign="-" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMzIx_fd679417-0fac-47c5-9e47-304f62329311">22</ix:nonFraction>&#160;million. The Company recorded </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="if24d4378188a4e47a19056c597f67512_D20200101-20201231" decimals="-6" name="mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMjA_cfcffa45-0047-4272-96f9-d2f9e629eae2">462</ix:nonFraction>&#160;million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#8217;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $<ix:nonFraction unitRef="usd" contextRef="i0d7e45260eac48ce932cb909af8a62bd_D20210101-20211231" decimals="-6" name="mrk:ChargesRelatedToProgramDiscontinuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExMTIx_e91e0b01-1f92-4b8f-8bb3-7f9e7a960063">207</ix:nonFraction>&#160;million in 2021, which are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $<ix:nonFraction unitRef="usd" contextRef="i1a3283ebb19c47db98e2743d3caf9d25_D20201201-20201231" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExNDIw_a773f560-7ace-4a34-9ecc-5026d79627c3">2.8</ix:nonFraction> billion. VelosBio&#8217;s lead investigational candidate, zilovertamab vedotin (MK-2140), is an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="ic7357cac30444434ad7267d089052bf5_I20201231" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExNzk5_64b832fe-8e3a-4e4a-9ff4-13193d2f41fd">180</ix:nonFraction>&#160;million (primarily cash) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i3a994069745948e3b6a58225dd2dcb81_D20200101-20201231" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExODYw_3b970efb-a951-4b66-aca7-a5624191f328">2.7</ix:nonFraction> billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i0cb16d00cf524ce297989b91888f968a_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyMDMy_0d523682-d5cb-4cef-b454-335244d73f80">43</ix:nonFraction>&#160;million, an increase to total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="ib083b0720a7641e5b2ed5b897cb5a1da_D20211201-20211231" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyMDc5_3bb90bce-7d27-44f4-bd9c-fb7ff542d725">47</ix:nonFraction>&#160;million, and an increase to net assets recorded of $<ix:nonFraction unitRef="usd" contextRef="if015b711a0c1463280f53a5f53f0095c_I20211231" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyMTI1_0cbc4801-f541-4fe4-b072-10e72f546bb5">90</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational ADC targeting LIV-1, which is currently in Phase 2 clinical trials. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930" decimals="-6" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyNzk4_b247aada-3355-4a1f-b0eb-9e0a8c90966b">600</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930" decimals="-8" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyODA3_123c96b7-4d57-40fe-84fe-e7c5a98a1e90">1.0</ix:nonFraction>&#160;billion equity investment in <ix:nonFraction unitRef="shares" contextRef="i283a4724505a457e8167cdc1100bb0e8_I20200930" decimals="-6" name="us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyODMx_8e59ce35-0453-4845-868a-f94d7b41dbfc">5</ix:nonFraction>&#160;million shares of Seagen common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i283a4724505a457e8167cdc1100bb0e8_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyODc4_f3677ee4-bcc7-4302-99fe-92fb9d370f4c">200</ix:nonFraction> per share. Merck recorded $<ix:nonFraction unitRef="usd" contextRef="i4da143af2cbc4550b7cd444b2d54ff99_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyOTA3_d78f1479-5ab0-4aae-8cd5-0355a8ad2cb1">616</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction reflecting the upfront payment as well as a $<ix:nonFraction unitRef="usd" contextRef="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231" decimals="-6" name="mrk:PremiumOnSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMDI3_7cf1fd43-7faa-4054-bf59-119ad6c27e54">16</ix:nonFraction>&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930" decimals="-8" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMjEy_85b15842-98d9-4dc6-9898-f88a608bf6ec">2.6</ix:nonFraction>&#160;billion, including $<ix:nonFraction unitRef="usd" contextRef="ie84d4260b7474298a9608482089dbef7_D20200901-20200930" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMjI2_85d6ab70-33ec-412c-b2e9-431d51bfde2c">850</ix:nonFraction>&#160;million in development milestones and $<ix:nonFraction unitRef="usd" contextRef="ic456a004e9b54fa88ffab861b40c8472_D20200901-20200930" decimals="-7" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMjU5_136c1987-d202-4edd-bf1e-bff6e3a629ad">1.75</ix:nonFraction>&#160;billion in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $<ix:nonFraction unitRef="usd" contextRef="i31c7604e87594ef485dd05502812fe51_D20200901-20200930" decimals="-6" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0Mjc4_7442f0cb-3ea9-49f5-9a2c-a4cc67f162b5">210</ix:nonFraction>&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i6c949b3574474579a0c233dda2bb577b_D20200901-20200930" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NDQx_3c347c7a-c2fa-4615-9695-79383d35d6c9">65</ix:nonFraction>&#160;million and is receiving tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="ic69078b53a814524aeaac691b26539ee_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NDkx_8ecdb2ff-20e5-45d2-9939-956a7ab3265c">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id9049cb40e504958ac9e397e60d37fb6_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NDk3_239752f6-f128-4f89-a5b8-5aa56c219456">33</ix:nonFraction>% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;<ix:nonFraction unitRef="eur" contextRef="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NzIx_77f149b4-4fbe-4b93-be73-957ff6d1283d">256</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NzI1_3b9b87ca-34a0-4ec4-ab0e-7b2a7ee84ac0">302</ix:nonFraction>&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0ODQz_1a3d7c40-ca42-4157-93ce-0fe0a0060dfe">289</ix:nonFraction>&#160;million and other net assets of $<ix:nonFraction unitRef="usd" contextRef="i4ef894740f0b49e788276233080a4067_I20200930" decimals="-6" name="mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0ODcw_a2898ce2-73c9-42e2-b31e-4c434e0971df">13</ix:nonFraction>&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $<ix:nonFraction unitRef="usd" contextRef="i0b6e4139824b4eefae9cfeae92fb9040_D20200701-20200731" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1MDcy_db62b686-6e1b-4f2d-8851-3a7db2a3714b">410</ix:nonFraction>&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ic59c3148ee024ea4afbac1489fd25b72_D20200701-20200731" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1MjUw_15940d99-3fad-4eb6-ae18-d9be05db4820">401</ix:nonFraction>&#160;million related to currently marketed products and inventory of $<ix:nonFraction unitRef="usd" contextRef="if6e2e88bfbbc44c8886ee11658c63510_I20200731" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1MzA5_0027437d-6fa3-4e24-941c-0fa133ccfe9e">9</ix:nonFraction>&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products are being amortized over their estimated useful lives of <ix:nonNumeric contextRef="i81bb7eeadd574ca5b21e9826619b23af_D20200701-20200731" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1NjYz_2f591c49-7b49-4664-9075-68e9ee4a3a34">15</ix:nonNumeric> years. There are no future contingent payments associated with the acquisition.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i8ae4b14558634d72997c26e51513dd70" continuedAt="i8df4f13cee1b4b43a2140a92f84103fe"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational oral antiviral COVID-19 medicine. See Note&#160;5 for additional information related to this collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $<ix:nonFraction unitRef="usd" contextRef="icad0f525031d46d9be68d02f33cb1b6e_D20200601-20200630" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2MzIx_e7d8fd9c-4ce3-42cc-aa11-9b99b20cdf75">366</ix:nonFraction> million. The acquisition originally provided for Merck to make additional contingent payments. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2NTU4_f0f7ebbe-f2ba-4341-b162-fa4ada7d6f35">85</ix:nonFraction>&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2Nzkw_de9f6b9b-b365-4c1c-83dc-4e20793bb703">113</ix:nonFraction>&#160;million, cash of $<ix:nonFraction unitRef="usd" contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2ODAy_e10c7b3d-0127-406c-bacc-1262f14b386a">59</ix:nonFraction>&#160;million, deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2ODI5_802b596f-3de5-4828-b5e0-21cc4f861848">72</ix:nonFraction>&#160;million and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630" decimals="-6" sign="-" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2ODYx_9ed682d5-7fb2-4fce-bf4e-22549f457d85">32</ix:nonFraction>&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2OTU1_5c043e87-c645-4c3d-93cf-0f5115413073">239</ix:nonFraction>&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i803562aa74fa4ea3891ea730ee3b8ff2_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE3NDIz_52e7e32e-5801-46d0-99f7-0b6bb88b403c">90</ix:nonFraction>&#160;million within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. The Company also recorded a reduction in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses resulting from a decrease in the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i803562aa74fa4ea3891ea730ee3b8ff2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE3NjI2_3349ffb4-38db-48ca-b93a-10dce63ebc45">45</ix:nonFraction>&#160;million. In 2022, the Company wrote off the remaining IPR&amp;D intangible asset and related contingent consideration liability; the net impact to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses was immaterial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $<ix:nonFraction unitRef="usd" contextRef="i0b0c88b077dc43d395324479284c52e5_D20200501-20200531" decimals="-5" name="mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE4MjI3_8b88b744-9349-48db-bfe2-528eafd0689f">6.5</ix:nonFraction>&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231" decimals="-6" name="mrk:ChargesRelatedToProgramDiscontinuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5MTk5_08d36057-1d54-41a0-8bff-8389e72c3f33">305</ix:nonFraction>&#160;million in 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231" decimals="-6" name="us-gaap:ProductionRelatedImpairmentsOrCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5MjIw_58461052-90ab-499d-a364-43e579e8ec49">260</ix:nonFraction>&#160;million was reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The remaining $<ix:nonFraction unitRef="usd" contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5Mzkx_3bdd1542-0dec-49d4-a522-ffc260bce812">45</ix:nonFraction>&#160;million of costs were reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="icd2616ccfb4c414f9da26e3832020bb2_D20200101-20200131" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5ODgz_84aa0c42-bc9e-48e8-8cb1-770aff84b984">2.7</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="ia4b8f860929044a7877bf8a6ed4c2c2c_I20200131" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5ODk1_3bc5780d-6814-4367-91eb-65dbb43ce0d7">138</ix:nonFraction>&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="ia4b8f860929044a7877bf8a6ed4c2c2c_I20200131" decimals="-6" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzIwMDc2_a8668243-fd63-4258-9af4-723cf38dba28">95</ix:nonFraction>&#160;million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020. ArQule&#8217;s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i8df4f13cee1b4b43a2140a92f84103fe"><ix:continuation id="i9683f4c19dcd4a789229c463c1f03f89"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzEtMS0xLTEtNzEzMzA_e0b53380-a163-4e33-af53-5d89c286cb0e">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzItMS0xLTEtNzEzMzA_3ce02ca2-944c-45aa-8a42-aab5c0a03575">2,280</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing arrangement for derazantinib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzMtMS0xLTEtNzEzMzA_fc42f3eb-07e2-4371-a92c-3a420020a2c1">80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzQtMS0xLTEtNzEzMzA_6b39d2b5-0b61-47c9-a8a3-870184ab240f">361</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzUtMS0xLTEtNzEzMzA_3e544fe0-bbb8-4d4f-8672-0c063c2dda6f">34</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzYtMS0xLTEtNzEzMzA_a3ec3948-5fa3-471c-ade3-a069556bd7ca">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzctMS0xLTEtNzEzMzA_0dd1f82f-cb7a-4ca9-aab0-19f4a270a9a1">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzgtMS0xLTEtNzEzMzA_b89bb522-744d-47a9-bd0f-7f742538a212">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="ifa5431df1071454ba96911ea2466090d_I20200116" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzIwOTA0_75bafcb7-c174-4ba7-91f7-652880d217f0">12.5</ix:nonFraction>%. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck recorded intangible asset impairment charges in 2022 and 2021 related to nemtabrutinib and in 2022 related to derazantinib (see Note&#160;9).</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_160"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEyMjkw_84679e68-cab3-4e36-9aaa-b3b894b963f2" continuedAt="i8ae451eab60d4fe29d6bced663ca4de3" escape="true">Collaborative Arrangements</ix:nonNumeric></span></div><ix:continuation id="i8ae451eab60d4fe29d6bced663ca4de3" continuedAt="i82621df924f24b22a9e09f67445bdf05"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $<ix:nonFraction unitRef="usd" contextRef="i611105bf33cb4418b7e1bae1d7e7ea5f_D20220101-20221231" decimals="-6" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDg4NjY_26a1eeeb-98c9-4d62-9ee5-bb65f1409516">600</ix:nonFraction>&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $<ix:nonFraction unitRef="usd" contextRef="i8bdf7308172b42feb5eb31dfaf5c1b15_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDg4ODA_3b6ebf31-8bc2-4fbe-94fb-29e16f5c770a">600</ix:nonFraction>&#160;million liability (which remained accrued at December&#160;31, 2022) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $<ix:nonFraction unitRef="usd" contextRef="i9cd932eaa95a4c7e99fe3e6f21d65b0c_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDg4OTQ_04c61994-1ac2-4632-92be-e6a3730ba73b">250</ix:nonFraction>&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Merck made sales-based milestone payments to AstraZeneca aggregating $<ix:nonFraction unitRef="usd" contextRef="i611105bf33cb4418b7e1bae1d7e7ea5f_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzIxNDk_fb5039d7-8181-4d77-a432-ff3c9b92de81">400</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i259bbbafc4fc42dcac9e345225999d94_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzIxNTY_7dd41480-ac11-4727-9abd-51a68d76489e">550</ix:nonFraction> million in 2022 and 2020, respectively. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i101468e37b9d4cf382b7335393246678_I20221231" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzIzMjA_f15a8031-c11d-4112-9cc8-d2d0b024a86b">2.1</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022 and 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i4c7aac3504dc4b288b6ecdf3ff0688b9_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI1MTg_3f2bb204-0ed9-4404-abe7-b8c85202077e">250</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8deae556e5124fc0a386203ac8730e23_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI1MjU_c0a8646c-5697-4c23-a74e-359ccd87122b">160</ix:nonFraction> million, respectively, from Merck to AstraZeneca. A regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="i101468e37b9d4cf382b7335393246678_I20221231" decimals="-6" name="mrk:CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzM4NDgyOTA3MjA5MDQ_6b9af8a4-1629-44da-a948-63023e7dfec7">105</ix:nonFraction>&#160;million that was accrued at December&#160;31, 2022 was paid in January 2023. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i101468e37b9d4cf382b7335393246678_I20221231" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsRegulatory" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI2Mzc_677993fc-a40b-463b-93b0-c452b1d17abb">1.1</ix:nonFraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i46a9b57f7713451ab3d958cb0b3c227c_I20221231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI3OTY_ed8d6e65-0d76-476e-83a4-8bbaa4d21fa0">1.6</ix:nonFraction> billion at December&#160;31, 2022 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i82621df924f24b22a9e09f67445bdf05" continuedAt="i09eb13c7a0fb49eaa982329c69054c92"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEyMzAw_3eae4646-0e9f-476c-93bd-2c223120e7e3" continuedAt="ie2a2230098954382b068f270745549ba" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4bb57af17fa46da951221280cae2d61_D20220101-20221231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEtMS0xLTEtNzEzMzA_51a8172e-d40d-422f-8e92-a34f1f5d0610">1,116</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd326598790045f6bcc0f44c24e3b67f_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEtMy0xLTEtNzEzMzA_d09e3307-728d-4163-ad7b-fb25b6a011f4">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29b92e874b140df8ddfc7bb19c76d76_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEtNS0xLTEtNzEzMzA_ee65aacb-a415-4526-80d1-2f331d23984c">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf71a18afeee4bdfa2f728eb5087abcb_D20220101-20221231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzItMS0xLTEtNzEzMzA_e7f2bd24-3389-4e2a-9cfe-57676a82965a">54</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a13a1700a349c494acb5ee8a7c314a_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzItMy0xLTEtNzEzMzA_8c9c1980-64c2-43c4-b4de-d49b5b2e5784">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cb97bb488247dca17be49d7a0fb045_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzItNS0xLTEtNzEzMzA_20ebfbeb-644f-4621-a78a-6378d0766d14">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b3ed6377c5412fbd503a5deff1c930_D20220101-20221231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzMtMS0xLTEtNzEzMzA_84d92fcf-3880-4195-b245-eeda382ab073">1,170</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebd2bf240ad4502a0f8eb75120c4db4_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzMtMy0xLTEtNzEzMzA_3db0b0c5-2448-41ac-8d5f-4f93ff615ee4">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8026cfa395c34fc78f7ffb4639e7cfd5_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzMtNS0xLTEtNzEzMzA_9e0267c2-4c2d-4282-8302-71953ae13b9f">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fa20a8d8c344b79257be206a940dc8_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzUtMS0xLTEtNzEzMzA_2c2a93c2-ed31-44bf-a696-77d66f1d69ef">492</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3721b0ead6be47bd8aaa1248657e3dc6_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzUtMy0xLTEtNzEzMzA_770f15dc-61bd-4e85-87ec-c6d11b93b518">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife46a1fcf6064f56a383f3b0d9487ba3_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzUtNS0xLTEtNzEzMzA_775249b8-3e34-44ca-b6cd-e9d51628fc5d">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a887176a9241c998829941def3e75f_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzYtMS0xLTEtNzEzMzA_f2b67647-5617-4a35-8226-75cc5176856f">185</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c243b4cafd413ba234033925c3b3cb_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzYtMy0xLTEtNzEzMzA_7574e9dc-9f50-48e9-a807-4a98d350f34e">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce2f27604dc40d8b3dc414670f4a61f_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzYtNS0xLTEtNzEzMzA_9d250213-8b6d-4cff-a80f-db84ca6a49c1">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23c8a34670be4d2f852e82ad0329e859_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzctMS0xLTEtNzEzMzA_d1bf56ba-126d-4e9d-9886-3da62cc39d71">106</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ab1b65fec2429e9e9fb8b77ca7676c_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzctMy0xLTEtNzEzMzA_729e4267-1ab3-4921-8e3a-fd17f716f55d">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8073582f227c469789fa05dbe73664e4_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzctNS0xLTEtNzEzMzA_10e5f15f-94ad-44d3-8d92-65c51aeb3ceb">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0cbe6f30ebf448ca8dd317840d491e8_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEwLTEtMS0xLTcxMzMw_296b7db1-1fc6-4201-8fb7-f0a74ad39e32">303</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f186ca6621243c0b67606ff25b17513_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEwLTMtMS0xLTcxMzMw_aa65e547-f904-4c12-8a30-21078924c0f0">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6baf80c0d6487ba768a3bf8d2eb9d1_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzExLTEtMS0xLTcxMzMw_c940bd43-7815-4f4e-883c-a927f1143eb1">123</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477ac519583c49c4a85dfaec2d9aeeb8_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzExLTMtMS0xLTcxMzMw_f2074e62-a3f2-4055-8caf-a535971dce05">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a011afad64440c8c568e59dfd355ce_I20221231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEyLTEtMS0xLTExMDA0Nw_4c259a33-480d-4420-bf4c-008e1937be7a">600</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9171e04635a4e7ca60a79f50cda5a90_I20211231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEyLTMtMS0xLTExMDA0Nw_e288dbe7-784f-4f2f-a6ae-bc40f527d426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $<ix:nonFraction unitRef="usd" contextRef="i9cd932eaa95a4c7e99fe3e6f21d65b0c_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDkyMTQ_04c61994-1ac2-4632-92be-e6a3730ba73b">250</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if2370a20f6b9477d9190b59f039b3caf_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NTk5NDg_45ee1c72-8ce4-4ad2-9287-f1d22979c7df">106</ix:nonFraction>&#160;million, respectively, of cumulative amortization catch-up expense.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $<ix:nonFraction unitRef="usd" contextRef="ie86f8b6b06284e30a88d0cfda2123b04_D20210301-20210331" decimals="-6" name="mrk:LicenseOptionPaymentRelatedToCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQzODk_8bc4df59-fff1-425e-90f0-cae00ad4cc96">125</ix:nonFraction> million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck made sales-based milestone payments to Eisai aggregating $<ix:nonFraction unitRef="usd" contextRef="ia743de15853e41f3b910d4cf1122df64_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ2NTU_eeeb4ab6-23dc-445e-b38b-8d5addaf5543">600</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i35980e373bed42f38371f148fe8ecf3e_D20210101-20211231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ2NTk_203ea3c9-5926-4d01-8b21-749b458fb431">200</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09d51996c5b14f1cb72dad54b7d4d76b_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ2NjY_b8e44d53-ae92-4de1-bdf4-9d457a3b0262">500</ix:nonFraction> million&#160;in 2022, 2021 and 2020, respectively. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ib1775ff52a4f4c97a6d68baca5ddf177_I20221231" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ4MzY_13261e19-eb91-4b5c-90aa-f27ee529b2e6">2.6</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i3ab1b0334084476e98316729e3a8c112_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDAxNzE_dd32d3bd-cf3f-40a3-9584-5e13dce9cf69">50</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibfc3245aba5546e0b11f27c281841fce_D20210101-20211231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzUwMzM_22ad2899-ad0e-4455-a0a9-c3f6772cee18">75</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if4c7f305f94d485faf5c727853db7751_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzUwNDA_da673d78-a0d4-4578-8be8-1a71aec7b2bc">10</ix:nonFraction>&#160;million, respectively, from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="ia9c533dce277413ebf7c86906b5c8f94_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzUzNzM_07976841-cdde-4cf6-b77a-14ee077c3d30">814</ix:nonFraction> million at December&#160;31, 2022 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i09eb13c7a0fb49eaa982329c69054c92" continuedAt="iac2c6d966028499da4d6fd1720a3637a"><ix:continuation id="ie2a2230098954382b068f270745549ba" continuedAt="ie96337ada8c24908870dfff268614fdc"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a865d1c00d4bf6b87ba7cfb8872940_D20220101-20221231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzEtMS0xLTEtNzEzMzA_7d4f45b7-24eb-4da7-a2a8-2969a73d9321">876</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccee6352d064f868e634387f9b6defb_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzEtMy0xLTEtNzEzMzA_d668c9e7-db8a-4dcb-a156-ced7deafd7fb">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2ef9288be849db9f064efef46fecd2_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzEtNS0xLTEtNzEzMzA_49edc0a5-995f-4247-8b1a-93748d47eef1">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaba9c09c27c48bab00412147d7b1bd5_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzMtMS0xLTEtNzEzMzA_306f16b6-3fbb-4f0f-b4db-7741d0889fda">212</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7660095e034c4216aa9276e5feedb36c_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzMtMy0xLTEtNzEzMzA_deda6fe2-0162-464f-a480-d59bf2b17ff7">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b2184ceafa474a9e19170e8fb42f5c_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzMtNS0xLTEtNzEzMzA_6bd95b59-5488-4997-b6b0-3376bcb0f506">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a750360d1484fdfbcaf406737a1903c_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzQtMS0xLTEtNzEzMzA_7453fbb5-9d0a-496f-91c0-a43dfd555c4c">158</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i164d9fadd4974909b666bfa2279e3149_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzQtMy0xLTEtNzEzMzA_9e705935-72a8-4545-a852-7dc84d6c4012">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28b73d8d0524599afa19cadb0b0e70a_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzQtNS0xLTEtNzEzMzA_0c581a1d-d659-45a1-92bb-07ec352c1c96">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ca606083fe4ddabb3985078aa79999_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzUtMS0xLTEtNzEzMzA_6779202e-63a6-4e72-8bcb-3ac975fb60a1">136</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ab13a91e6d41409f02aa3644bb33d5_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzUtMy0xLTEtNzEzMzA_18bb6d7a-1fa8-4abe-ac0f-c6036bd58e6e">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bd2e76e1e742df96a5837cbb96ed58_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzUtNS0xLTEtNzEzMzA_012042af-c45a-47c1-8571-a8f7c0b9dc25">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3ec7d905d742d7a5ff17c57e5fcbf2_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzgtMS0xLTEtNzEzMzA_e2b61035-5630-4787-8c26-b2aee67115d4">214</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb0bc5ac844767be8fb1d138e6664b_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzgtMy0xLTEtNzEzMzA_8b82314e-f293-4def-8c5b-b2b0c9c5889f">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846e3e5062424fcb9eb3c09ff655d70c_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzktMS0xLTEtNzEzMzA_bc99c52d-de94-4b9c-9c42-cdaba15be97c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7065d7527cac47058269d8ba6fac070e_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzktMy0xLTEtNzEzMzA_ecee86c7-cc76-4527-aadb-241a6ea309b5">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payments.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made sales-based milestone payments to Bayer of $<ix:nonFraction unitRef="usd" contextRef="ie657eb0222df4887b09402876cce71d3_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDExNjE_0e84159e-bf40-4212-ac53-b8deb359ebbe">400</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id3416ec93d1a492fa1f433c26d04679c_D20200101-20201231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzcxNjk_54af91a4-b729-4478-811f-1982a446d614">375</ix:nonFraction>&#160;million in 2022 and 2020, respectively. There are no sales-based milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $<ix:nonFraction unitRef="usd" contextRef="id5de854d06ac4eeca3f033f63ac8cf18_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzgwNDQ_c9e9026b-b5b2-474f-864f-86f018ef51d5">633</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bd89ab9867a451bb7d8f5e7dd23cfa9_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzgwNTE_1c6d12f6-5d84-4f30-9bca-74bb750dd76b">57</ix:nonFraction> million, respectively, at December&#160;31, 2022 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.</span></div><ix:continuation id="ie96337ada8c24908870dfff268614fdc" continuedAt="ia9c85ead01e74a5e835aa1de038a99f6"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bfe141a54941c1ae25d64fbabae891_D20220101-20221231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEtMS0xLTEtNzEzMzA_376667f9-e389-471c-b416-8ebe3c95fe93">341</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855e5afb6533435a88463827fb0e2179_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEtMy0xLTEtNzEzMzA_4568caaa-9234-4375-b1ad-25ef5fc3b7f5">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d25852fad3a41db9c665d20c687a9bd_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEtNS0xLTEtNzEzMzA_96d637f7-86eb-4b83-9b89-1bbbc8f164de">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f6db34c320474f93fc442eab2cae85_D20220101-20221231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzItMS0xLTEtNzEzMzA_2b60b64f-457b-4791-afa2-b05109564bd2">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib730f07be57a4e6abbd8c475c9858a84_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzItMy0xLTEtNzEzMzA_a968463f-721a-4cfc-ab51-39d283a4b0bb">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba49d74de774a7da3dd6fe57759ddd7_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzItNS0xLTEtNzEzMzA_6328400b-1555-4bd6-a006-d3b4ce8e8580">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83aee4fe2eb49e79b304d069fa8ad26_D20220101-20221231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzMtMS0xLTEtNzEzMzA_b8306aeb-2b21-4691-9d3b-2362316abc22">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i732d1a8cd545457bb9404f007a3ddbbb_D20210101-20211231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzMtMy0xLTEtNzEzMzA_0a33c465-6df3-490d-8aa6-77fa0ae3fe68">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bafd4db40a4019a8844632901e67e2_D20200101-20201231" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzMtNS0xLTEtNzEzMzA_e9db287d-91a9-4881-83af-465d03fa1c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5bfe141a54941c1ae25d64fbabae891_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzQtMS0xLTEtNzEzMzA_fc92c8ac-71bf-4a80-b48f-526af4b71054">601</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855e5afb6533435a88463827fb0e2179_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzQtMy0xLTEtNzEzMzA_a9370b3b-1b46-4a2b-bdd7-591046c93977">601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d25852fad3a41db9c665d20c687a9bd_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzQtNS0xLTEtNzEzMzA_8ee3af4d-0f6a-409c-a531-9c90d00bfb25">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a3942c4b5040c183b0a32bce8ccfc0_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzYtMS0xLTEtNzEzMzA_9be8f615-dc88-4f79-9f2b-1c20c34edb33">210</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379f2e061e03444ab72ac31156ba6076_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzYtMy0xLTEtNzEzMzA_35488a7b-f321-487b-9c6f-3a9d2d347995">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890188202bc349308f5fddb70d1ac474_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzYtNS0xLTEtNzEzMzA_115557ef-cba6-4d78-aba5-c2f5d4bfd790">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d323bb0936465fa024e1457a0783f9_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzctMS0xLTEtNzEzMzA_604f180a-add5-43ab-86ec-ebeba760a89e">153</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9134617e9894461384c3736c75213497_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzctMy0xLTEtNzEzMzA_dad3cf64-f6f7-461a-ad0e-b277b1ba394e">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cca313b49524b8880414378a9bd58a7_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzctNS0xLTEtNzEzMzA_aa614336-7a87-4ea2-9f2a-de9ef7fc5079">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465e0e2b26a34a65a2ceff807a69c161_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzgtMS0xLTEtNzEzMzA_e2a8edb6-4304-4f95-92c0-cb11d1a565af">75</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ceb7081ad348a5b332291f5eac99f6_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzgtMy0xLTEtNzEzMzA_41a71d89-94ee-48ac-be47-2602e2ed1b61">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d83c83f0aaa41bab160e17f7828a23c_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzgtNS0xLTEtNzEzMzA_5f376929-a7b5-492f-a009-3bb1531214b3">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4211db3a27fa41ce9ef8afb548f9103d_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzExLTEtMS0xLTcxMzMw_94a60a6b-757e-4165-bc3f-8c533e2bd6f7">143</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1754d2b50304b08aa2cc44626f808d3_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzExLTMtMS0xLTcxMzMw_e7ecbdb1-ab8d-444c-94f3-4d049c0b9db1">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2440fcb0b354debb320abddbe888325_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEyLTEtMS0xLTcxMzMw_3d94bde3-e78a-4361-aea1-7b8f6cf2c880">80</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864756958f464b8baebe379049606e29_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEyLTMtMS0xLTcxMzMw_9416433f-745f-4692-8620-497b469f6b60">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. Amount in 2021 includes $<ix:nonFraction unitRef="usd" contextRef="i379f2e061e03444ab72ac31156ba6076_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0Xzg0Njk_42f64e73-c5e4-4b22-8381-ed775347309c">153</ix:nonFraction> million of cumulative amortization catch-up expense. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payment.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="iac2c6d966028499da4d6fd1720a3637a"><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><ix:continuation id="ia9c85ead01e74a5e835aa1de038a99f6"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601ee311bfa347d0b5dcc37af824a720_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzEtMS0xLTEtNzEzMzA_73e5e142-ffb3-470e-8899-3e805e982adc">5,684</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd816c120f854e69b9a2159aeed10f3e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzEtMy0xLTEtNzEzMzA_f4ed3727-d1b7-4725-a3b8-028b0e5e8a91">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie947e36c8b7f43249d8241cd508c5350_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzEtNS0xLTEtODU5OTQ_99782429-55ee-4875-830a-ed0f459bfe1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ac66950463401192d572c40841d4cf_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzMtMS0xLTEtNzEzMzA_b074b6e2-56ac-43bb-8d83-ce1324be2324">3,038</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9b197fc4714188b0f988ab63603db4_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzMtMy0xLTEtNzEzMzA_1d8b23d5-07f3-4816-a9ce-fd831753d3d7">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157fad50a46146f7862f955f23ac964b_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzMtNS0xLTEtODU5NzE_7c6f14cf-c120-4afe-a900-c41250c01a01">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70782495edd949faa59537a7ff4fad68_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzQtMS0xLTEtNzEzMzA_be6a87b2-77a5-4534-91f9-ad43fa73f8fc">147</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e2939d44e74e1299e632f622332de7_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzQtMy0xLTEtNzEzMzA_e1acae2a-e524-40d9-bec2-c18e424408c7">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c327eb0afa44aaa8b041180a9931985_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzQtNS0xLTEtODU5NzE_bfe2a38b-173f-4aa9-bf0c-b4a9e0bcfc69">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4c5d96e848446187e39b06993aa908_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzUtMS0xLTEtNzEzMzA_29293f6d-6440-4f20-872c-71f1778107e0">88</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb42b703c354447eacb3e957b27d7ec1_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzUtMy0xLTEtNzEzMzA_b274d4eb-bedc-407c-b9c1-82b9d83ec083">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67875c460a8c4de69af3791511d877db_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzUtNS0xLTEtODU5NzE_c5874c78-7f58-48a2-9261-8bb8f2894a2d">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d4b8387cc44522a4d608929cf3f19d_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzgtMS0xLTEtNzEzMzA_c20e5b9b-c5b5-4fc7-9f40-3750e400a4a1">348</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2f8008c6984b9c8973be53aa0971ea_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzgtMy0xLTEtNzEzMzA_9d28d853-67c6-41e0-8a8f-8a1bd9abb863">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses in all periods now include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalty and milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#8217;s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a <ix:nonFraction unitRef="number" contextRef="iac7e27beb28f433687f6a328ad49420e_D20220101-20221231" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzODI_6a6e52f6-a8b8-43ac-b377-903c323c7a79">20</ix:nonFraction>% sales royalty from BMS which could increase to a maximum of <ix:nonFraction unitRef="number" contextRef="i4e6787b2f43c4435bb7b7e0c9b5c5a48_D20220101-20221231" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzODc_ed94036f-6e14-45f3-b607-ec10acf10a0e">24</ix:nonFraction>% based on sales levels. This royalty will be reduced by <ix:nonFraction unitRef="number" contextRef="ib1d8391ce634476c8543dbb3f18f43dd_D20220101-20221231" decimals="2" name="mrk:RoyaltyRateDeductionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzOTI_e40cffbe-c3e1-4645-be78-17b741e5756f">50</ix:nonFraction>% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic10f48c8ad804e3ab3fb873838f81931_D20220101-20221231" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzOTc_3fb85fac-ea67-427f-abd5-f429e3aa8dae">80</ix:nonFraction>&#160;million. Merck recorded alliance revenue of $<ix:nonFraction unitRef="usd" contextRef="ifc3969c4d6864a2da3a1f1ed7fc44512_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDk2Mzc_1882bef5-18fe-40ab-9a14-0e9ccda4fdd3">166</ix:nonFraction> million in 2022, which includes royalties of $<ix:nonFraction unitRef="usd" contextRef="ib1d8391ce634476c8543dbb3f18f43dd_D20220101-20221231" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDgyOTM_b744e5b8-1b3b-4dd2-aed9-e2509c3b196d">146</ix:nonFraction>&#160;million and the receipt of a regulatory approval milestone payment of $<ix:nonFraction unitRef="usd" contextRef="if030a4536a8047a1a585275c17092ed8_D20220101-20221231" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDgyNTg_ce26075a-fc3b-4115-b59b-4f0c9e7460bf">20</ix:nonFraction>&#160;million, compared with alliance revenue of $<ix:nonFraction unitRef="usd" contextRef="ic4460340464041e0b1e1151e1bdec68e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NTE5NTg_baaf28fa-81ce-4fe7-aa41-af612a5239d7">17</ix:nonFraction> million in 2021.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_163"></div><div style="margin-top:15pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzMyMTY_5ae2c0ac-6035-42fe-bd71-b58cf444e7c1" continuedAt="i55eef8bcb9d9465199aa2d595ae41a9e" escape="true">Restructuring</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i55eef8bcb9d9465199aa2d595ae41a9e" continuedAt="i0e47387eaf4b4a749f74208f053fc35d">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzYzMg_90486846-2dc5-4946-983c-d6d44a7750da">3.7</ix:nonFraction> billion. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzY3Nw_a4e32772-9c46-4bc8-9d7b-18a495222c4e">70</ix:nonFraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzgzMw_d07dfc72-bc24-46b2-8909-ce8e3afa6b86">30</ix:nonFraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i0e47387eaf4b4a749f74208f053fc35d" continuedAt="i30336ed9a27546d387020e86d4be98d3"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEwMjA_9304c229-cc3c-4c1d-9217-25bd5d1e7b3e">666</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEwMzA_e1cb969c-0bfc-4347-aca9-b66286521256">868</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEwNDM_efac51bf-8578-4b85-b375-8135f6c09041">880</ix:nonFraction> million in 2020 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2022, Merck has recorded total pretax accumulated costs of approximately $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEyMjE_f9c17b4e-8fc3-4686-9d8d-530b4f05b69e">3.3</ix:nonFraction> billion. The Company expects to record charges of approximately $<ix:nonFraction unitRef="usd" contextRef="idb510662b9e944c6a56938d27b6835b2_I20231231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEyODA_f2c19d7c-d55f-4545-8af3-02ab067d9a24">400</ix:nonFraction> million in 2023 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzMyMTk_19f8cba3-38b4-4608-a835-b734e34193db" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7552297483f94fa5b4160dc0db014d06_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMS0xLTEtNzEzMzA_96a86990-8951-49bc-8027-c6c76a0b4266">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85c300cf38349adb26180577979e5c2_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMy0xLTEtNzEzMzA_eacee259-baa7-48a8-8684-27d2e56e7387">72</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3592e3674e13431aaf91bd67cef2a754_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItNS0xLTEtNzEzMzA_777ab1a6-133d-46ae-a82d-7f90f6e36c57">133</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItNy0xLTEtNzEzMzA_32a06521-c64a-4828-a38b-bfc39c3318dd">205</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30469f7c418b4bd2a85fcc554df58178_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMS0xLTEtNzEzMzA_fbd9e6c1-49fa-413d-8c4a-38e6f5bebdb2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45c2b8530f9432f800bd21578f8e217_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMy0xLTEtNzEzMzA_edbf6ba3-aef0-454d-aacb-0e243a970410">19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb748e33a7a454fac71c562342ce760_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtNS0xLTEtNzEzMzA_7a4d5707-8db2-4257-a42a-a86163939f35">75</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b231d9fdbfd40ae8d6fe71ed37de345_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtNy0xLTEtNzEzMzA_12fbaed8-7a34-40ea-9c37-6f60e1f5394e">94</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79c6477e2f646dd83409e81121b5a29_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMS0xLTEtNzEzMzA_d1dc663e-652d-4d6c-b9ed-9860614ce070">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864a963e97a44b5f8189640f9cb94d43_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMy0xLTEtNzEzMzA_5b2dec5b-3a70-4d8f-bf6f-df4f237f0d1c">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia817beebd6444eea99db772afc066555_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtNS0xLTEtNzEzMzA_3734034d-a25a-4684-8ea5-2675df2db61e">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1e5bec9c0340748f3a3782a3f7fd23_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtNy0xLTEtNzEzMzA_b1af5a79-c8fa-4144-bc9f-a6d1ecd70d93">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d722d97d3e436e80d290bc86ab1496_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMS0xLTEtNzEzMzA_ca19a99f-8995-4d80-9cba-29926e0842c7">212</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2335ada88a2240b6bd6252e8fa8510a4_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMy0xLTEtNzEzMzA_c1ba1409-8bdf-4cf5-a428-40a674294f62">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b44b6cfd4f4a8b99ef33bcc3c06df7_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtNS0xLTEtNzEzMzA_b12466f5-e75e-4b57-88bd-aeb056ba20fe">125</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804346c2237043e084b1afb341655a9f_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtNy0xLTEtNzEzMzA_0da363fc-0009-4556-ba09-2e70d24bb0be">337</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtMS0xLTEtNzEzMzA_227ffed7-7417-41b1-9449-c7701e239b12">212</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtMy0xLTEtNzEzMzA_fe15cad1-ae77-4f8a-83bf-3fcddb8a541e">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtNS0xLTEtNzEzMzA_be86a6e4-5adc-4cad-bdd5-a082af3ff21b">334</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtNy0xLTEtNzEzMzA_7e3f717f-0522-4279-9c90-e02299f4be6f">666</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c693f6dd72a403f89d6d2355a3b1c83_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMS0xLTEtNzEzMzA_847fa464-601a-47ae-92ac-bdf5b42928a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c3521eff5d4d78bed2d56d42e3789f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMy0xLTEtNzEzMzA_e4c69143-c438-460c-abd0-0fab2d8237d0">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015fe5f90bbd4e93a29ffe724e90bfd0_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtNS0xLTEtNzEzMzA_067a1411-4a1e-4834-9c94-5d3676f44e6b">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8bfe07436149a2b63950679699d1df_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtNy0xLTEtNzEzMzA_301b50eb-1324-495d-9721-9f97ba51b894">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba21ed671f2448ceb380d10aa9f40bd6_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMS0xLTEtNzEzMzA_5163a037-61a4-4d1d-b956-1def12694801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7cd884e75e9428f87dc9ff260d2f3ee_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMy0xLTEtNzEzMzA_993b3066-f923-4477-8967-38b5640d695e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa6d39939da4e91b837b366cdef3966_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktNS0xLTEtNzEzMzA_16644881-8cbd-4e74-9d2c-3479fb8ce2fe">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975b430806c14e4dac19b89356167bc0_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktNy0xLTEtNzEzMzA_09c7beb7-ba79-4b88-8cd8-cc59f512a435">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a86b0a2eb94ae1872813f8188edae8_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTEtMS0xLTcxMzMw_3bcf136d-fb85-46bf-a990-9b814e2c0ace">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1ca9c45f2f4c0d8e7d64701e4cb36d_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTMtMS0xLTcxMzMw_ef6d5120-24ac-46a3-8267-1641ff3e82e5">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54629a1dafcf430fb0b2f74327fdd6df_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTUtMS0xLTcxMzMw_597db157-5e66-4167-8ee8-b242f48ed435">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0562404e8e0e4465a752940a1235ee59_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTctMS0xLTcxMzMw_af50fc17-73f0-4407-a512-bf2315fc5ab2">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9a9c572051413cbcbfc3a23280168d_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTEtMS0xLTcxMzMw_9affa3f9-25da-4bc7-8f26-b9b0133dee85">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1decc07eadc24124bed0dd2deaff444a_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTMtMS0xLTcxMzMw_9ced923c-f35c-46f0-89a3-ee2dce0b04b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice7363f8460840bb83ffb6ca99594560_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTUtMS0xLTcxMzMw_be730f5b-73da-4ef3-a6cc-19792df8f5d9">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedf7a5f7ef7456586ec0f021a1d0f3d_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTctMS0xLTcxMzMw_72aa172a-a6be-4aad-8462-94f852403c2c">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTEtMS0xLTcxMzMw_767b651a-c4b4-4436-81d9-b4f3c0a31456">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTMtMS0xLTcxMzMw_8a064a81-42fd-433d-b05b-ec726b58e365">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTUtMS0xLTcxMzMw_344f0d32-690a-41bc-9f51-d5aec27209d2">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTctMS0xLTcxMzMw_2f61f43d-6675-48ca-b7d3-1e323d95d106">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e08ad749ea24620a73bf3de13d4ba83_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTEtMS0xLTcxMzMw_047f047e-7b83-463f-95c0-7346d3aed6bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f4ba5c710647b8a25a7267abdd6754_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTMtMS0xLTcxMzMw_79f7fbf1-09df-498e-950d-1f1e76485698">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6eb5443eb44c5f83120bd0907e38cb_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTUtMS0xLTcxMzMw_d2e258cd-199d-42c5-bde3-0c9eff33cf4a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3327a1e7655544f3a7d9953a5234e2fb_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTctMS0xLTcxMzMw_b806ffba-b53d-4a07-9238-0a4daf83b831">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f9f13e5ade4b49abc89a6dd9a5b2b4_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTEtMS0xLTcxMzMw_f7f6dea6-0d2f-48d9-ba32-cd454345a7c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia78f45a1853841d69480601600ad30b6_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTMtMS0xLTcxMzMw_ad092adc-6814-425f-b3a5-6561e8e67591">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6c21a42378451b9dab85a8423576f3_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTUtMS0xLTcxMzMw_5ba817f3-b78d-467d-b4ad-33b507b3fc8e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c6fc33bcf040b88cd4cce4a3bd53e4_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTctMS0xLTcxMzMw_6c68a1e9-e771-414c-aa02-dacc5420d935">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i720ba97855924cd9b21a8b29de3ba988_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTEtMS0xLTcxMzMw_19d908d0-89a5-4ce0-911d-9f31e7790e8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdcd5cba5f543dbb50dea0289f3ab2c_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTMtMS0xLTcxMzMw_d4032432-a464-4c9f-bfea-1254419bafae">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d6a7f93e314fc384e0b1149d0ae9eb_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTUtMS0xLTcxMzMw_9b1987b5-bf5d-44b9-bcf3-0dd50abe712a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTctMS0xLTcxMzMw_07af9678-0b02-483b-aafb-c691d8512ca4">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88144043844d4f7eb9f8cde0124c59f9_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTEtMS0xLTcxMzMw_c237d98e-9d9b-4223-98b4-a216edcafe72">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4983cbf854e94eceae83083147be86a2_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTMtMS0xLTcxMzMw_6d8d550f-3545-48a6-96bc-995ddda7093c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972eba5067f8445596ed5ff359126657_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTUtMS0xLTcxMzMw_71d3229f-deb8-49d0-a8ad-fba667b87afb">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a80bcbbfa39470ab7a14b86c6fa70a3_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTctMS0xLTcxMzMw_82de2388-3fe1-47e2-af41-1f0cb5def7fc">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8adcbd8025954472931113ef2fd8a95c_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTEtMS0xLTcxMzMw_0fffd6a8-050a-48d3-ace3-eb241e764c95">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0aa3f0a78454591b3695e1829428150_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTMtMS0xLTcxMzMw_ad910ff7-b7f8-4319-a90f-2fbc352c607b">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074bc4aaa1734fa79f0b7f5045ab90d0_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTUtMS0xLTcxMzMw_c1142f73-2cf2-43cb-afef-bbd3aa8909cd">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTctMS0xLTcxMzMw_b6f01712-76b8-4e1d-9006-82a8b578459d">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other activity in 2022, 2021 and 2020 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;14) and share-based compensation. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i30336ed9a27546d387020e86d4be98d3" continuedAt="i21363965db8e450788877e39e05cd9f7"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzMyMzY_98dc61cf-c061-448e-bc66-255c59fc3e51" continuedAt="i31ebb06385394f76b9fe4b3e7374210d" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:45.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b319f5a70d43988516fed4f52eb15d_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtMS0xLTEtNzEzMzA_a91ae273-c5fc-45a1-99e4-89585b8398ba">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c66f3b052f74fd3a26dc81f448660a5_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtMy0xLTEtNzEzMzA_2d976227-9b39-4256-84fa-a52b2eccc8c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3861723ccf964ba380c10a13117f1a30_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtNS0xLTEtNzEzMzA_b01ccd38-0e65-49af-9a23-97a54b63ef76">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtNy0xLTEtNzEzMzA_ce74f481-de13-412b-be65-f90b43663751">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItMS0xLTEtNzEzMzA_632ca6c2-4513-46e6-a12b-5467747791cc">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItMy0xLTEtNzEzMzA_0b317749-2427-4345-a11f-f5006b1d179b">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItNS0xLTEtNzEzMzA_b64bc58f-8fd3-4257-8465-727228448ba5">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItNy0xLTEtNzEzMzA_6e976700-750f-44e4-9eb5-a927c592d176">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtMS0xLTEtNzEzMzA_2b4718e6-f035-4ba3-84b0-6e0e4c9f6400">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtMy0xLTEtNzEzMzA_1cae39b6-a379-4cc5-a03a-2015ff453375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtNS0xLTEtNzEzMzA_17e1bc79-996e-4f88-b31b-32ff34fe6501">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtNy0xLTEtNzEzMzA_0480fe91-f88a-4796-b3e9-771736d808f2">608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtMS0xLTEtNzEzMzA_d944a834-1aa4-464a-96de-b0f1a9ce4b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtMy0xLTEtNzEzMzA_45ef82c5-7f07-4854-b010-fc49d838086c">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtNS0xLTEtNzEzMzA_be3c766a-d3d2-48c3-97b4-52beca44634c">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtNy0xLTEtNzEzMzA_0e606b37-4862-4e98-8a3e-ec329465f743">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235bd559e79d45cebeb01c3aa68198fe_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtMS0xLTEtNzEzMzA_a2767141-ef05-439b-89d9-99757ff4d147">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5164087f50654464a6032ddfbb33b657_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtMy0xLTEtNzEzMzA_1bce874b-7ec8-483d-bae9-d05ee710d5a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a75ee9f06394ac58129ef3c07183626_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtNS0xLTEtNzEzMzA_b6bf2e5f-9acb-4680-8141-c900056751a9">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtNy0xLTEtNzEzMzA_ae3accfb-8127-4c4f-8780-0d85fe819645">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtMS0xLTEtNzEzMzA_b1870c6c-2e64-4acc-b3ad-c46898adf8be">212</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtMy0xLTEtNzEzMzA_aaf71ba8-a338-4425-9f46-75ecbfbbf92d">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtNS0xLTEtNzEzMzA_90a81f5b-0387-43a5-914a-6260815d6690">334</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtNy0xLTEtNzEzMzA_3a15e887-f587-4be3-8600-d18473d1bea3">666</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctMS0xLTEtNzEzMzA_c9ca4b7e-0a9f-4be7-8cd2-0ca07f998b61">329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctMy0xLTEtNzEzMzA_6de40079-6045-4034-aa9a-d1e0218d0a71">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctNS0xLTEtNzEzMzA_9e7228b0-2de1-4546-a5be-76af5c2fd3c6">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctNy0xLTEtNzEzMzA_4786b3f2-e7a3-49e3-86de-384c228acf4e">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtMS0xLTEtNzEzMzA_abcd26f4-74d9-4730-947e-5ac4dcc2505c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtMy0xLTEtNzEzMzA_383dbc0e-3f3f-4024-9597-3f981ac79e0c">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtNS0xLTEtNzEzMzA_23e40735-793f-4b47-a4a8-241ef9242f17">221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtNy0xLTEtNzEzMzA_82e4ce66-0ba1-4632-9539-4280c5b0210e">341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id196364c06404f1e93dce678dce64cec_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktMS0xLTEtNzEzMzA_aa3ef4ca-8d3e-4c30-a6cc-961ff0a6dd58">479</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i446658f48ca64a5595891b7cc6692950_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktMy0xLTEtNzEzMzA_167894be-d46d-4096-bd37-766c0bb016e3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca802b14ca406fa68447bf048b3c14_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktNS0xLTEtNzEzMzA_18918b1c-f3e2-43b7-95b0-d22a93b55a07">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktNy0xLTEtNzEzMzA_44dc569c-d6b0-4b0c-9111-45d2af547ba6">513</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i21363965db8e450788877e39e05cd9f7" continuedAt="i28675336ee4c483099c75b782971a549"><ix:continuation id="i31ebb06385394f76b9fe4b3e7374210d" continuedAt="i224ae4ee303345e38e8698657f5b1e68">(1)&#160;&#160;&#160;&#160;</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i28675336ee4c483099c75b782971a549"><ix:continuation id="i224ae4ee303345e38e8698657f5b1e68">The remaining cash outlays are expected to be largely completed by the end of 2025.</ix:continuation></ix:continuation> </span></div><div id="ia384118d157240e09e39541b90e2080f_166"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTY0_c0b31242-8ccc-477f-b5bd-d39f0fc1922b" continuedAt="i026560bb84314c3db05ebd338f061a9b" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i026560bb84314c3db05ebd338f061a9b" continuedAt="i6eddb0f01d3e4b95a1bd86130d756ae5"><div style="margin-top:5pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonNumeric contextRef="i37f49dfec5954846bc22018691bd0081_D20220101-20221231" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0ODg_abccdb68-64c1-479b-8368-6ec6d4d2f402">two years</ix:nonNumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i6eddb0f01d3e4b95a1bd86130d756ae5" continuedAt="i6e1e202642e94aab8434a57321453fd8"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonNumeric contextRef="i5838f63c0490478eae7fa5bddaafa36d_D20220101-20221231" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzQ5ODY_a9ed1c17-8c38-49ec-a2a5-8b2f877cb035">six months</ix:nonNumeric>. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTcx_e8207759-201e-4fa7-bcaa-3c88125f20cd" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtMS0xLTEtNzEzMzA_b611d852-59ec-4a08-ba25-b4cad93ece28">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtMy0xLTEtNzEzMzA_e4b036fc-bd9e-451a-a501-1364be01ed0a">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtNS0xLTEtNzEzMzA_25eccb06-d795-4578-900a-32c0f56abc3d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieead02c0663c47e4a289f16813bc7306_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtNy0xLTEtNzEzMzA_65ff30d2-8d8c-4913-b548-497c971c5574">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5160bc069bcb4a1386bf4185147cc88d_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtOS0xLTEtNzEzMzA_adb980bf-1154-4ec4-9024-d385aaa14779">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140d4ac54a9b4fafb92531ca8b76c69e_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtMTEtMS0xLTcxMzMw_ba95c7f5-c764-4356-b26f-eebe6e7d26e7">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dfc74fe5a384595a4c97c4a0eabb454_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtMS0xLTEtNzEzMzA_7d0746af-7967-4cde-9ffd-d169543e554d">162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i702a5a6064884c78964fb0c841f02433_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtMy0xLTEtNzEzMzA_2d5906b0-2781-4529-8f97-cf129da17d0e">296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bec909d9be4e24b3a7a85153c4ce18_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtNS0xLTEtNzEzMzA_8f398536-f872-477c-a3ce-bdbbc03b1249">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4af38eda5034b1d8ed205026267630f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtNy0xLTEtNzEzMzA_2d4bc24d-a6b7-4699-b5e2-6588fb073978">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf14eee6b5fa4782a433bc13f07577f2_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtOS0xLTEtNzEzMzA_f62f5d00-9e00-4e9d-9f27-9f1001909848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c95ec70187e405ba677c24678202bd5_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtMTEtMS0xLTcxMzMw_9aa5458f-9c85-49f6-bc8d-11c8b0fefe8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022,&#160;<ix:nonFraction unitRef="interest_rate_swap" contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231" decimals="INF" name="mrk:NumberOfInterestRateDerivativesMatured" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcwNTM_232a44ae-514c-4f1b-8b4a-a3b3bd0a8395">nine</ix:nonFraction> interest rate swap contracts with a total notional amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231" decimals="-7" name="mrk:DerivativeNotionalAmountMatured" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcxMDg_bd7203e9-13b7-4fc4-81aa-ddf30bc53337">2.25</ix:nonFraction>&#160;billion&#160;matured. These swaps effectively converted the Company&#8217;s&#160;$<ix:nonFraction unitRef="usd" contextRef="ia218fcd1db1141ed905f718a91fc9422_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcxNjg_d0a11a17-6d52-41cf-b160-7552506b1c7b">1.0</ix:nonFraction>&#160;billion,&#160;<ix:nonFraction unitRef="number" contextRef="ia218fcd1db1141ed905f718a91fc9422_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcxNzI_182320e2-0de8-43fb-ba4f-3f62fdbcca45">2.4</ix:nonFraction>%&#160;fixed-rate notes and $<ix:nonFraction unitRef="usd" contextRef="ifa89acddce894ac08beedd53e127e143_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDc2MzE_a3ab79fc-461f-4946-af36-64d1ee6e177b">1.25</ix:nonFraction>&#160;billion, <ix:nonFraction unitRef="number" contextRef="ifa89acddce894ac08beedd53e127e143_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDc2NDY_c779cd7d-9d8b-4c20-8dbf-5263d2f9e743">2.35</ix:nonFraction>% fixed-rate notes due 2022 to variable rate debt. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i6e1e202642e94aab8434a57321453fd8" continuedAt="i735f6b882cb84592aa6ce1b4ea3d243f"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTUw_63a4da67-273e-4f81-828e-632f312d59ae" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:45.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtMS0xLTEtNzEzMzA_b00213b4-bb72-439d-8a46-c05a11380ace">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e7539f63d64ce1a5c2568c9999a584_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtMy0xLTEtNzEzMzA_3db19cf6-69be-479e-bc75-2da31c0fcaef">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtNS0xLTEtNzEzMzA_1cf2093d-5eda-44c4-b519-ebb0bdf71360">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e7539f63d64ce1a5c2568c9999a584_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtNy0xLTEtNzEzMzA_be640a9e-d97c-4d4c-ba9c-0a1c12fb0c29">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTQz_1fc99f2b-47c9-4da4-8ff6-49ebba74847f" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a">Other current assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cd4c7fd5f14851a86d5a655db5663c_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMy0xLTEtNzEzMzA_cf5af43e-0390-4839-a396-f8c747ba7515">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cd4c7fd5f14851a86d5a655db5663c_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtNy0xLTEtNzEzMzA_c52edef4-44f7-4587-8b4c-5d41aab2bc05">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be94d522084d82a3e96d121db4b2c5_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtOS0xLTEtNzEzMzA_b88a8d16-c732-4ab9-a3b9-a8e7568efdad">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50be94d522084d82a3e96d121db4b2c5_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMTMtMS0xLTcxMzMw_3847e608-95fe-47f4-acc8-f14e8ccf3ee3">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782b995c5324440982290223b2cdddac_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMy0xLTEtNzEzMzA_408c8d3b-2f87-4657-b975-93ee43cfdac9">220</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782b995c5324440982290223b2cdddac_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtNy0xLTEtNzEzMzA_2d9ac8b4-5974-43c1-8126-6e5ec38197aa">4,824</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afdd113c40545adb3ae03acc9c4e126_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtOS0xLTEtNzEzMzA_44fec3c0-cb7e-418a-ac29-13e07da57515">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afdd113c40545adb3ae03acc9c4e126_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMTMtMS0xLTcxMzMw_fe496814-a12e-464a-8411-2f56dffb4772">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597">Other Assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c912a0937747a8a1ae5182d756b260_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMy0xLTEtNzEzMzA_6c89a4a1-3097-4952-8f1a-dfaac99dbcea">27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c912a0937747a8a1ae5182d756b260_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctNy0xLTEtNzEzMzA_450415a6-bf65-47e3-bd19-068bb3671810">1,609</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2677274a350445afa69443c36f4a89da_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctOS0xLTEtNzEzMzA_f53cc746-ac17-49f9-96b3-b39627522359">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2677274a350445afa69443c36f4a89da_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMTMtMS0xLTcxMzMw_2ff709b9-1221-48fc-a312-c3eeb4088cf5">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350a79055507478fabc61583f11e2080_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtNS0xLTEtNzEzMzA_e330bd73-4cb6-427b-ab8f-2521617dd801">101</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350a79055507478fabc61583f11e2080_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtNy0xLTEtNzEzMzA_3e8c8ed1-350f-4401-8dc3-820abb372586">2,691</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc29185c1fed4990966cf824e4597298_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMTEtMS0xLTcxMzMw_cb4f5b55-8305-48cc-8515-642264b29b5b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc29185c1fed4990966cf824e4597298_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMTMtMS0xLTcxMzMw_48083bb7-5434-4274-bd58-6a0caaee8e37">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786">Other Noncurrent Liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbb1216db6a47e88141c7169ea7875f_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktNS0xLTEtNzEzMzA_ea5aefe3-262a-4635-a2bf-0ed50b230744">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbb1216db6a47e88141c7169ea7875f_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktNy0xLTEtNzEzMzA_918f8972-d1d1-4ddd-b36e-7bfe6bbf6787">91</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6226dc468d5e40ba93e5e688a3b0e650_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMTEtMS0xLTcxMzMw_20a4ede1-3a76-449f-9126-86c10ffaab85">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6226dc468d5e40ba93e5e688a3b0e650_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMTMtMS0xLTcxMzMw_ead6aa2f-34d3-43ce-9b43-f77102a03068">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a0380fe0b24b768f534f7027ad8b63_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTMtMS0xLTcxMzMw_18f9a254-92e3-4a00-978e-7f792d7a9aff">247</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a0380fe0b24b768f534f7027ad8b63_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTUtMS0xLTcxMzMw_83ec15cf-a581-4656-9880-5a13d89ac07f">102</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a0380fe0b24b768f534f7027ad8b63_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTctMS0xLTcxMzMw_db59d710-599f-4370-b89d-fb6ec390a217">9,215</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90271718d0194ea79773a039096567de_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTktMS0xLTcxMzMw_eef692af-73e7-46b3-b54a-12af28b328db">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90271718d0194ea79773a039096567de_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTExLTEtMS03MTMzMA_699dd8da-451a-4f1d-8a3a-c25a773f437c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90271718d0194ea79773a039096567de_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTEzLTEtMS03MTMzMA_ce9c9fb4-7f4c-4ff5-b5e7-6d81f16333f1">12,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTMtMS0xLTcxMzMw_66fbc809-3a45-4960-94f1-91e7ea0c0bef">186</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b986dd8de2458386abddf2a2a64bfe_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTctMS0xLTcxMzMw_301ae8bc-5327-4d23-9111-e76a585d840c">8,540</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTktMS0xLTcxMzMw_8e7d1c27-5999-4448-8afd-01b44b802ad4">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c9b82f66ad4f6498c0bd7bc43fd253_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEzLTEtMS03MTMzMA_424c7eea-b727-45a3-a0cf-5170f8bbc0cc">10,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTUtMS0xLTcxMzMw_2a53e0b3-e7dd-40bb-83c5-a6523602383a">307</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8101d6016e644c484984a91964cd5fa_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTctMS0xLTcxMzMw_29e60cd7-7c66-4aba-99b2-47c1fc385a43">10,926</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTExLTEtMS03MTMzMA_8b1958dd-092e-424e-9fcf-9c76e94993b7">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f69e11c219486faa68b50184be96c3_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEzLTEtMS03MTMzMA_750b4035-28f0-47b0-84e1-16d11f0951c9">10,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1579987fd245a6b9ae265038125773_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTMtMS0xLTcxMzMw_969c26ca-dcf0-46ab-b292-8b14cef83eac">186</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1579987fd245a6b9ae265038125773_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTUtMS0xLTcxMzMw_f4bacc03-456b-4da4-968e-79a1f774bd64">307</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1579987fd245a6b9ae265038125773_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTctMS0xLTcxMzMw_56fb387e-8355-4ed1-be1b-20158ecbabb7">19,466</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948c5f8c4b584db887310340bf216160_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTktMS0xLTcxMzMw_542c9b58-51d3-438f-8c1a-be0d43ad9734">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948c5f8c4b584db887310340bf216160_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTExLTEtMS03MTMzMA_5edacb51-0297-4dfc-949e-ebb4b6c1cb5e">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948c5f8c4b584db887310340bf216160_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTEzLTEtMS03MTMzMA_d8ff3ad9-bfd7-4fef-9b21-d74af421cd3e">20,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTMtMS0xLTcxMzMw_638f1bdd-4e11-41d1-8bd5-1d2a7d6e04e6">433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTUtMS0xLTcxMzMw_e4f66911-1262-4adc-9bc4-cef170cd8612">409</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTctMS0xLTcxMzMw_76d9c859-a7dd-4da1-8212-339915565af3">28,681</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTktMS0xLTcxMzMw_6e73fcb8-277d-48c6-9c08-86a4ed7f7e22">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTExLTEtMS03MTMzMA_cfb8d5bd-aa01-40b8-93c2-ded85e4310b0">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTEzLTEtMS03MTMzMA_f20871d9-e105-4f49-8750-6a22466eb3f4">32,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTgz_e31dfc28-626f-42cc-95eb-ee1efcea37e8" continuedAt="i19f9f704143644be8c396bb7a8ba2f23" escape="true">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><ix:continuation id="i19f9f704143644be8c396bb7a8ba2f23"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:59.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItMS0xLTEtNzEzMzA_da56418c-31f9-4bc8-be5e-335e0f2693f1">433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItMy0xLTEtNzEzMzA_6d55e846-9bc4-4ed1-ad4e-7541fe90fa06">409</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItNS0xLTEtNzEzMzA_7f531f8a-5a76-4565-a6d1-09951e7b9895">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItNy0xLTEtNzEzMzA_65840b34-467d-4203-ab41-ee5fcd6b63e4">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtMS0xLTEtNzEzMzA_1fa929b6-0e67-4d02-b1c7-5222aabb0bd5">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtMy0xLTEtNzEzMzA_f78372d4-85b1-444e-bd2e-9123174230f9">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtNS0xLTEtNzEzMzA_987d0337-7779-43ec-8ff8-56ea58f180df">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtNy0xLTEtNzEzMzA_507095fb-920b-42ae-8136-8c93a0dbf95b">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtMS0xLTEtNzEzMzA_8f86f105-cc8e-4d80-896b-06df2bb41ccd">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtMy0xLTEtNzEzMzA_06597588-be38-460a-884b-ea19f28c4d88">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtNS0xLTEtNzEzMzA_d0e3e97a-c132-4f4e-8139-0312798e0574">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtNy0xLTEtNzEzMzA_d051c4b0-cc46-471c-9aa5-e5720207d2c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtMS0xLTEtNzEzMzA_9656a18f-0031-41b4-b24d-28a87dfa119b">147</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtMy0xLTEtNzEzMzA_64db48d4-7d5a-4cd0-8572-baffd259eee9">170</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtNS0xLTEtNzEzMzA_25fde904-8ce6-4cf5-88d7-919b81356346">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtNy0xLTEtNzEzMzA_ce84603f-5183-4322-96d6-4eb2c2ae7dea">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i735f6b882cb84592aa6ce1b4ea3d243f" continuedAt="iea2a1ee934c64487a0872df876b3cc53"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTI5_31c27e70-782d-424c-8d2b-b3725070fe39" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMS0xLTEtNzEzMzA_84464a4e-99d7-4fb7-bfcd-260e14260db9">59,283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMy0xLTEtNzEzMzA_c2ae8312-81e5-4d6b-ab5a-28c547f0a482">48,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItNS0xLTEtNzEzMzA_94c2f89f-559a-4b42-9c66-233f6b193f69">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItNy0xLTEtNzEzMzA_1feb55b5-e7c3-4801-b9f2-d049d6984574">1,501</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItOS0xLTEtNzEzMzA_7c94603c-737d-4eb3-aeef-d3f050dd8271">1,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTEtMS0xLTcxMzMw_084e8321-b481-419f-a636-9b21ab0bc7f4">890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTMtMS0xLTcxMzMw_b40f965e-c1a4-4f28-b1d5-9004387293b4">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTUtMS0xLTcxMzMw_d7e4638b-5cd0-418c-9537-3a6288705151">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTctMS0xLTcxMzMw_76662fec-5bac-4adc-830d-0f3c49a771ce">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib90fcefa805241de9e12f2aebc441fc2_D20220101-20221231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzUtNy0xLTEtNzEzMzA_3ee9a354-a510-45eb-8c3d-8192c2ebdbe9">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51bfda27ae2b4cc3b94f9a7440352c5e_D20210101-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzUtOS0xLTEtNzEzMzA_da270f93-989c-4dd2-901b-dae378eb4e75">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a279e868ca477a849941852602f9df_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzUtMTEtMS0xLTcxMzMw_281896ce-6a92-4d68-a182-87832815426d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90fcefa805241de9e12f2aebc441fc2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzYtNy0xLTEtNzEzMzA_80182dc6-36af-48d0-b2fe-878dde8f226f">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51bfda27ae2b4cc3b94f9a7440352c5e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzYtOS0xLTEtNzEzMzA_92862ba1-a694-4bed-b00f-74a7f49b27c1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a279e868ca477a849941852602f9df_D20200101-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzYtMTEtMS0xLTcxMzMw_033ad2a3-5ca1-4192-969c-7ff71ce8f4b9">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzktMTMtMS0xLTcxMzMw_4c31411e-9ff7-48c9-af2f-dff79a703f14">684</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzktMTUtMS0xLTcxMzMw_b28eb147-967e-4eca-9c56-db8a994dbebe">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzktMTctMS0xLTcxMzMw_015f6175-55bb-46a8-bf07-4f8ec5286d84">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7a1215a0c049cab8f08a9594ad42b1_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTEtMS0xLTcxMzMw_f0779d09-6622-4078-b960-cb51e6777a6b">773</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68492993011c48bbab8080844004db56_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTMtMS0xLTcxMzMw_d8f1beff-614a-416e-9166-e8c5cd9bb049">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3510a74c551e449094abce6bec887425_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTUtMS0xLTcxMzMw_a3df18e5-936a-4b8b-9b87-1fee80fdcf3a">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTEzLTEtMS03MTMzMA_9d90c131-69d5-4158-878a-a382021103be">773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTE1LTEtMS03MTMzMA_a55a206d-c530-4929-b9ad-6d29bc8c80c6">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTE3LTEtMS03MTMzMA_9cfc6dab-e480-44a8-84ea-7bb3dc34d59a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTctMS0xLTcxMzMw_52533e3d-b5a3-4344-9695-37c5c1b0bb34">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id60f9472b85e42f18f616225451c542f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTktMS0xLTcxMzMw_fa9ac6d7-99b6-48d2-bcde-9ed4c524d9c6">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917d2ebe84824a7586c16f24fea495cb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTExLTEtMS03MTMzMA_7a5c0eae-6132-4902-a648-aad36e5a4b55">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEzLTEzLTEtMS03MTMzMA_43c143b1-39e1-400c-b8fd-ae228e1a0f4d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id60f9472b85e42f18f616225451c542f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEzLTE1LTEtMS03MTMzMA_35a6a8b1-2e15-4fbc-af3d-0248130962c7">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917d2ebe84824a7586c16f24fea495cb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEzLTE3LTEtMS03MTMzMA_d39f73aa-fe91-44c1-8a97-5f8879f85fc1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTcy_a387dc8d-e64a-4731-80e3-a0f39b173062" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieead02c0663c47e4a289f16813bc7306_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzMtMy0xLTEtNzEzMzA_b66c459f-3692-4ac7-b9b0-ebe90e80db00">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5160bc069bcb4a1386bf4185147cc88d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzMtNS0xLTEtNzEzMzA_2e213b1d-f87d-4834-9459-3a96b68b71b5">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140d4ac54a9b4fafb92531ca8b76c69e_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzMtNy0xLTEtNzEzMzA_b5b0c652-8a2d-4ce8-8d7c-1e4b5e809dc2">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28fc358415004cc2a37dd74e64f8d2aa_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzQtMy0xLTEtNzEzMzA_303c13aa-f802-435e-ac49-af5624dc90a1">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581c1be0a6984114bfd52dffb52aa7b6_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzQtNS0xLTEtNzEzMzA_2dbdf6ff-b6bf-443a-8e01-539d4a14f0e6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb0ff4d140346c8963217923368c0ef_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzQtNy0xLTEtNzEzMzA_ab522ecc-d18b-4efc-a2dc-0527a7282c94">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35cfc0da81f545a398181fa07b3382da_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzUtMy0xLTEtNzEzMzA_e873e3f1-60f8-437e-8348-47a92f700e01">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c40b5faace4195ac18bb1e51000e7e_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzUtNS0xLTEtNzEzMzA_34b6cf14-5d81-4897-bdac-8896682aaa44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i759f47c95ce6483d905aaf752e1639ce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzUtNy0xLTEtNzEzMzA_fdcf99a1-ca0f-4894-b32f-ce7acbc868ee">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9644f4dc6e546f19f3bdc2c69c7d465_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzYtMy0xLTEtNzEzMzA_76dc16b2-8858-4c72-b699-2ca2abcdcde6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9830a106f140a087b9c78bbfbfeec5_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzYtNS0xLTEtNzEzMzA_d79f664d-a236-4fc3-925c-36bf2ed0659a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedfb451ef964827840ce24bbd35a732_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzYtNy0xLTEtNzEzMzA_d7e9dc0e-b90e-4f53-87e7-fa8aee116a53">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges against rising treasury rates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company estimates $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzk5NjA_5995ee88-f7dd-41dd-a1c9-fdb6d4e1fb3d">104</ix:nonFraction> million of pretax net unrealized gains on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="iea2a1ee934c64487a0872df876b3cc53" continuedAt="i0f868611af254a919a0596acbf21ca4a"><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTc2_534867dc-a03c-4481-9ad7-409dbbd1b033" escape="true"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:27.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMS0xLTEtMTE3NDk5_06d5fbe7-b895-4e78-af14-9cb31cc2549a">498</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMy0xLTEtMTE3NDk5_e0774d93-9cae-4711-af1c-671859024762">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNS0xLTEtMTE3NDk5_67000ec2-7df8-47f3-9498-f3610eb5d27b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNy0xLTEtMTE3NDk5_3c5ad3a0-bf9f-465b-8a2d-c030056c886b">498</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtOS0xLTEtMTE3NDk5_18c21859-d64b-4e1a-8c1d-8a70abc6dc95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTEtMS0xLTExNzQ5OQ_e881d671-92d8-4e32-87bc-ff941b714df1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTMtMS0xLTExNzQ5OQ_c507ebe6-77f8-49af-9f0b-f8c2fd2f2fe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTUtMS0xLTExNzQ5OQ_a2a1cc7d-b33f-44de-a76b-c65c34b6a9ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMS0xLTEtNzEzMzA_62be3cd2-d3ce-47ad-a6f8-e32d4cb06e69">68</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMy0xLTEtNzEzMzA_598a3426-bb39-4ebe-ac21-ebfb49908f58">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNS0xLTEtNzEzMzA_99c3f790-1cc3-4bb3-910b-1c4cd7d97c52">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNy0xLTEtNzEzMzA_7a948c3b-92ab-4308-b1e1-f8f6f84b3d1e">68</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtOS0xLTEtNzEzMzA_57322ed3-4492-477b-a94b-924c2fe49259">80</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTEtMS0xLTcxMzMw_29ea27b8-664d-4819-a0d8-bb30775a99a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTMtMS0xLTcxMzMw_681c59cc-01b2-42c5-bfbe-6283d0581685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTUtMS0xLTcxMzMw_7cde3cc1-de94-4c85-a250-47f86559c573">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMS0xLTEtMTI4NjM1_826147b1-9766-485c-8e55-6caaed2bb580">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMy0xLTEtMTI4NjM1_b64b52c1-d9cc-4f79-bff3-adcc89cb30f6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtNS0xLTEtMTI4NjM1_c008c06f-8ce8-4eaf-9f81-228f3be61e8f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtNy0xLTEtMTI4NjM1_bb1831a5-70ae-4bae-b7ca-76a6c776babf">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtOS0xLTEtMTI4NjM1_561f9802-cd6d-4205-ba1a-884b86428d9c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMTEtMS0xLTEyODYzNQ_e292a791-76e7-4ff2-a521-d2ba6839663e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMTMtMS0xLTEyODYzNQ_45300913-181a-409b-8da1-4c04aef0350f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMTUtMS0xLTEyODYzNQ_1876fcc7-c86e-40d2-b234-13f8179acc80">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMS0xLTEtNzEzMzA_8ce47a02-1bf6-408b-b6ed-0db4dfd4122a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMy0xLTEtNzEzMzA_f4ad4a6a-8fbf-473f-87c0-54ee9dae0e6c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtNS0xLTEtNzEzMzA_10766b0b-3cff-4f98-be33-53fcea8cf0de">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtNy0xLTEtNzEzMzA_c1b224ba-4727-4c8d-8d88-15a2aa963837">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtOS0xLTEtNzEzMzA_3f3e2982-081a-4710-9353-bbb90fc65649">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMTEtMS0xLTcxMzMw_613f8d19-03db-464e-93c4-13ad0405b61c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMTMtMS0xLTcxMzMw_8adea116-dadd-44a2-b59e-b4957c61ec43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMTUtMS0xLTcxMzMw_3479efee-f58c-43c3-a78b-1e03a91b92ae">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMS0xLTEtNzEzMzA_ae90183f-be21-4358-8c1b-7ce034105ed5">569</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMy0xLTEtNzEzMzA_cacbed65-8e39-45e1-8a1e-a5532d30c36e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtNS0xLTEtNzEzMzA_7be9667a-fc18-4b37-a5eb-ce3ee5d9a1fa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtNy0xLTEtNzEzMzA_422d7adb-ef6e-4573-81df-8e556e59cbf3">569</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtOS0xLTEtNzEzMzA_9353bbc9-c100-4234-ba72-8dbdc00fc834">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMTEtMS0xLTcxMzMw_d6382d7a-9ee0-486c-96a3-d9340aea90c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMTMtMS0xLTcxMzMw_4754cdcc-e21f-43ec-a59b-86f2021ce5e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMTUtMS0xLTcxMzMw_54fb0d21-cd4b-4195-add4-30a701c6ee19">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzctNy0xLTEtNzEzMzA_8fbaa6f8-e532-4b32-9110-e5d5a8002013">1,284</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzctMTUtMS0xLTcxMzMw_687101c9-cc18-4d9e-8f54-662bd346fd41">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzgtNy0xLTEtNzEzMzA_73ec5d48-da66-4f20-822c-638b3f32810c">1,853</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzgtMTUtMS0xLTcxMzMw_1eef2cd4-f06c-49d2-8fd9-449302d6db77">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDk4NDI_32470d64-2f1d-4aba-920d-65c02e922c0c">462</ix:nonFraction> million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2022 on equity securities still held at December&#160;31, 2022. Unrealized net losses of $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDk4ODU_d129bf50-7257-48d6-9b66-42586341fe48">232</ix:nonFraction> million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2021 on equity securities still held at December&#160;31, 2021.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company also had $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwNzQz_2e6dc1f1-2a43-47a5-86f9-e3fde411a264">832</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwNzUw_e47bed94-0206-43d3-ad95-ca195a2f0700">596</ix:nonFraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During 2022, the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMjE1_365b6e1b-cea3-40f3-a6da-2785dfc51fb9">56</ix:nonFraction> million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMjQz_00c53152-ad31-48b5-98d7-08688b2b8969">12</ix:nonFraction> million related to certain of these equity investments still held at December&#160;31, 2022. During 2021, the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMzYz_d4483e37-5442-4f1c-bf0e-ec37dd22500f">110</ix:nonFraction> million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMzkx_2dc84668-552a-4aef-bf1e-7ba209d9ac99">1</ix:nonFraction> million related to certain of these investments still held at December&#160;31, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNjQ4_5492c48f-9b05-4b5d-9950-dd40c1070b8b">289</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNjU1_45bed4ef-954f-42b1-b564-dadafccd2c21">19</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022, 2021 and 2020, the Company also had $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNzI1_3fcd1192-f338-4540-97d6-b5a48c03a14e">598</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-8" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNzMy_10422c5e-89c8-4c97-912a-31a13e8b1be2">1.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzM4NDgyOTA3MjIyOTc_78af1c4c-f53c-44f2-81f1-78f366081905">800</ix:nonFraction>&#160;million, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-8" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExOTQ2_b5b64a63-97a8-42b6-99f6-f4d9865f595f">1.0</ix:nonFraction>&#160;billion, $(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-8" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExOTUw_7560a943-d111-4ef1-bb97-17a95654038c">1.4</ix:nonFraction>)&#160;billion and $(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExOTU3_33e84c7c-2d68-4094-8907-7fbf09b8b53d">583</ix:nonFraction>)&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i0f868611af254a919a0596acbf21ca4a" continuedAt="ia811518ca0b042a6a56f3f5b69d12bff"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTYy_19af6c58-3f6f-46b5-bd64-196b75b30626" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e23e28964b402e8ac69b9bf7d33084_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMS0xLTEtMTE3MjMy_12ef1936-489a-4f69-8e32-5e6821dd1a0d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if90327fad224463b8fddba51b5516717_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMy0xLTEtMTE3MjMy_6d45c3d6-9e88-44a7-bfc3-21d0bbe40ec7">498</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3fb85e46d14551bb0ef34fe80bda15_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNS0xLTEtMTE3MjMy_cf40bb9f-6d49-413a-b7c9-e24a8acde8fd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c48d4b8b6ca4bb9aaba77abc6391c4b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNy0xLTEtMTE3MjMy_129a2066-84a7-418c-8732-4938b9bcdc62">498</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc33cb4b50d4093aaf63905d920b1dd_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtOS0xLTEtMTE3MjMy_d5e6f200-f4e5-430c-95c7-1f86ce801e58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43420ce5f064a3fa05fa2e2380d5539_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTEtMS0xLTExNzIzMg_a3e2a513-ec19-4dbb-9e61-7c458807d746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b0d4e6828342e7a26da27a695dcde1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTMtMS0xLTExNzIzMg_373bd1c9-d0d4-4ca2-85b5-86c7918057cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a4692f6adb46a1a2793a6f353cad90_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTUtMS0xLTExNzIzMg_f2e97177-c7b7-424d-b300-1e164005655d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ac1d9076f34481aea8771778d0d812_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMS0xLTEtNzEzMzA_e97c9082-86f6-4a18-9d37-af6d0dd3dd12">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4aa8f87dfa5498d867f4797c0697444_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMy0xLTEtNzEzMzA_26ca397c-08b0-4442-892b-c804409b31c3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74466407315d4f298256e0ad5a5af77f_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNS0xLTEtNzEzMzA_ff826398-1f51-43b2-93b1-72fe770d264b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb3b3087926f41c1a474ada3d5d72501_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNy0xLTEtNzEzMzA_7ca108a7-5446-44cb-95ca-20ef9e570fc5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i459db40bfb714e7ca275d3cd836dbbbe_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtOS0xLTEtNzEzMzA_d215b074-6696-43d1-9758-22be8f8ee726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic518fb07b7674674ba2208e212142086_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTEtMS0xLTcxMzMw_d35e8313-bfd9-4f61-a90e-e0652037e6a0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3452cdca4b2f46d194438c26b62c02fe_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTMtMS0xLTcxMzMw_9f11e9dd-a411-491f-aa5b-0d472ccc14a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieccc452488d6486c8350f571676063d6_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTUtMS0xLTcxMzMw_bb9e84d0-225c-440b-80f4-2b334e8a3057">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05de9c17c11d43bf908b28fd7f8aa30d_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMS0xLTEtNzEzMzA_37356123-5e9d-4d8a-b3f9-04f8fa7d2d46">1,015</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80636fc2f0a4f8a946fb3e439e28f9b_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMy0xLTEtNzEzMzA_a3ff721f-a16d-45b5-866a-831c7958d055">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86dc918aa0f64dcebee5f10eb3e80c7b_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtNS0xLTEtNzEzMzA_1fb56100-1a6a-44b2-b553-ecb918de4172">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3f2dea94cb406697c29216f2be9c81_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtNy0xLTEtNzEzMzA_3dbb1712-41b3-4986-b1b1-145a0ab7ba97">1,015</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193fc51da4a7485394ab28fa7fa5e658_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtOS0xLTEtNzEzMzA_09b79a71-e97c-4115-9ac4-0e63dcbd057b">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c7da7d4a5749148765d47894aacd5d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMTEtMS0xLTcxMzMw_9a723451-20c8-40bc-bc88-fe3ce0f8ee5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4015a3ff1e184474b72f68389cc87127_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMTMtMS0xLTcxMzMw_e6377287-840d-43e7-8428-8e5503018a6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e96a196d04943a1ab350c5e9d0cae4b_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMTUtMS0xLTcxMzMw_5ffdb69a-0896-4bfa-a7dd-51b3f0901c07">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMS0xLTEtNzEzMzA_bef0357c-221b-4903-8684-439000725f61">1,015</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMy0xLTEtNzEzMzA_53a023e5-acd8-4c02-a957-755190b069a3">498</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0220a923758c4bbd97582689f870643e_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctNS0xLTEtNzEzMzA_928b32b6-286d-4f83-bb0c-85f51c262d0e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctNy0xLTEtNzEzMzA_be9d3889-c82b-4937-b85a-0785eb30e334">1,513</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctOS0xLTEtNzEzMzA_fccb4417-0eb6-4713-b450-1e3991056497">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMTEtMS0xLTcxMzMw_3348d036-d29d-493d-bd24-8b171aa6f00c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMTMtMS0xLTcxMzMw_a0951172-2a73-4143-95e7-d117c7d6d4d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMTUtMS0xLTcxMzMw_1ab2b5d8-21a3-44a8-b799-3cb6fe5c627f">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d8e82b21924b988d762ffa1a17dd8c_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMS0xLTEtNzEzMzA_35f70306-7ad4-4ccb-985d-e99e43304c4e">68</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7899bb44630417a973d878c81948748_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMy0xLTEtNzEzMzA_8a11d7ad-82c3-4df2-917c-a974d1b8051f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e8c59227254e75bd6682c05eec4d10_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktNS0xLTEtNzEzMzA_e360461d-7e4f-45ad-b701-3bea5be72493">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae7d7fb2e5a4743961396935e496534_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktNy0xLTEtNzEzMzA_1fd178c7-a912-42fd-ae3f-c4eb2d3aa471">68</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc30062b2684131ae471612e9872ee9_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktOS0xLTEtNzEzMzA_0e8671b3-5886-48fe-968d-8f8ab27ab272">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5dad97abcda4f9fb9cdfaae3938ec50_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMTEtMS0xLTcxMzMw_cbb63a2b-d84f-414b-8ee7-58be67fa45c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d91b9f5ded401face6465d1b7b9508_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMTMtMS0xLTcxMzMw_e40fdf7f-b0ff-4315-8d9b-ec8350291355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440ab66872cb40a6b47d2221be7afb0b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMTUtMS0xLTcxMzMw_02c7260d-371e-4fd5-9dfa-36c47d102280">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563ada8aba96419d844e481095ea53b3_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTEtMS0xLTcxMzMw_613b789e-f490-4a27-9d0f-5df99280947b">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445a31ac64064f36b804f06383d1bfe0_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTMtMS0xLTcxMzMw_d72130fc-ccb0-476b-8647-5e8703aa2a54">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746270f61b8f444fbc5e79bbfa2f5d0a_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTUtMS0xLTcxMzMw_fe8a82d6-c50b-42d4-9645-41fdeadacbb7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd8a5476f7e4f6bb0e3488f27974234_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTctMS0xLTcxMzMw_deb4758c-4212-49a7-a606-f0fb7c094b7b">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc25519774c84d2b8046b1745b6979f6_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTktMS0xLTcxMzMw_ff55b379-eb95-4742-83b2-ff108c8155bc">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78bb2725e97d486ba1ea5b683ff9e12a_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTExLTEtMS03MTMzMA_c8da6363-9def-4021-9ae3-f48cccca11e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1027036535d44087b6a7e473c3fdfc32_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTEzLTEtMS03MTMzMA_381f5066-6af8-4ee0-8ae1-d3e75cde226b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85671c3d685a45d797f772c5f3312b8b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTE1LTEtMS03MTMzMA_87efbf60-2dfb-42fc-8701-80655b5dbd58">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05de9c17c11d43bf908b28fd7f8aa30d_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTEtMS0xLTcxMzMw_bed0cbbe-e44d-4e37-9375-7cba3fe92c18">269</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80636fc2f0a4f8a946fb3e439e28f9b_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTMtMS0xLTcxMzMw_0a29160f-3d66-4ced-a09c-cf50d7589b68">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86dc918aa0f64dcebee5f10eb3e80c7b_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTUtMS0xLTcxMzMw_83d51c27-8776-4884-bf79-b59336ff7679">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3f2dea94cb406697c29216f2be9c81_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTctMS0xLTcxMzMw_96b88659-e481-461a-84d9-e6f24fcb52b6">269</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193fc51da4a7485394ab28fa7fa5e658_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTktMS0xLTcxMzMw_65e95fea-7988-483e-8ace-ab6352ab31db">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c7da7d4a5749148765d47894aacd5d_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTExLTEtMS03MTMzMA_9d5fba30-c9c2-43f1-b0be-1bad909d5e37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4015a3ff1e184474b72f68389cc87127_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTEzLTEtMS03MTMzMA_d5334e4c-ce33-4e65-94dd-ae998115218e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e96a196d04943a1ab350c5e9d0cae4b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTE1LTEtMS03MTMzMA_a8d305df-7055-45bb-897d-095ac6aab6fc">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTEtMS0xLTcxMzMw_286c95ee-fde0-4c91-a0ca-a980fb665b28">340</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTMtMS0xLTcxMzMw_7b68208b-b481-4866-973d-caee2eb915fd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0220a923758c4bbd97582689f870643e_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTUtMS0xLTcxMzMw_ea2ad6a0-9eae-4bc9-9fac-803439570126">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTctMS0xLTcxMzMw_2ae159f9-a0c9-4ac6-8857-00342dca1efb">340</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTktMS0xLTcxMzMw_f288337c-2fe0-4b2e-9853-235e4a166b39">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTExLTEtMS03MTMzMA_52ec84b7-f08e-4793-a154-4add995b6f0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTEzLTEtMS03MTMzMA_cf93aedf-0b77-4878-acbb-e69bb7085040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTE1LTEtMS03MTMzMA_05f242f1-0ac6-4518-ab53-582d29cffa74">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a21b3709dd42128d8264f2a5257c18_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTEtMS0xLTcxMzMw_6c69a050-64dc-451e-a312-7fe6b9e62c59">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d6a9e2a4e04b1bb46f7d1cbcc4e416_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTMtMS0xLTcxMzMw_96fa9249-2eca-417b-a3d5-520b513414ce">218</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150ff06d48a9497eafdf58dc03d8e518_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTUtMS0xLTcxMzMw_68507e4d-d091-497c-9b33-f1acb956ab60">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b040b0e94924f0291cc48a435447245_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTctMS0xLTcxMzMw_31378fe9-3d35-4139-bc6f-86e9658bae77">218</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae251a0ecc04d6b9054f018ef917ce8_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTktMS0xLTcxMzMw_53addd25-f798-45c7-9931-34477afcb0e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief83301bd6734273beb742bcd0fd8b21_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTExLTEtMS03MTMzMA_ad8dea12-b9ff-4a5c-b49c-f9630dab1453">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10131b7117eb4770b663e21fa15b98c6_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTEzLTEtMS03MTMzMA_81975ef6-974e-4494-81ac-54c44496efc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0a0f8c7fc64e1ab6f955a741b7f056_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTE1LTEtMS03MTMzMA_2926ee8b-02cc-40cf-b7d4-f3d217c265c7">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd64d4dc46a44fca8aa2e2d65f22ec14_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTEtMS0xLTcxMzMw_46ac279a-18be-4a20-b5c6-a4b6b70d4665">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a54e6f42254f4a80ac3cbfedbeda25_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTMtMS0xLTcxMzMw_a82c5b74-9aec-4dd4-b636-d343a358b0f0">215</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1291079726f54d9482e915764e3a28f8_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTUtMS0xLTcxMzMw_ca1dbca0-f13d-43c3-8844-cfdd64065176">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9feab63c1b64ebb859b0a44c8c0fe14_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTctMS0xLTcxMzMw_97e83962-2e82-40ae-94e9-23b16ac39d0e">215</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cdff6731374404ac0a075ce6ab9b79_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTktMS0xLTcxMzMw_2308d764-ed8e-4cee-b074-0c5f1d2afa77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a379c20670240a9b25634d9750efe8b_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTExLTEtMS03MTMzMA_bc8a49c1-8aec-498c-b119-7d92690076a2">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaaa3375ce0c4bcfa1287f588b3077dd_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTEzLTEtMS03MTMzMA_c8570663-d8a5-441d-9b10-2368fd5db6f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34968f94170b4606b1bd3134b883f9fb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTE1LTEtMS03MTMzMA_a8e2c1c4-2631-4826-be75-1e08efe69d31">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac658e91c1524deea0992c47f1872ea4_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTEtMS0xLTcxMzMw_7fdaea26-4358-4c64-af8e-c74eba7c55e9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db832513f3d41efa179eca26a0e6899_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTMtMS0xLTcxMzMw_ad95ed7e-c9f8-4500-8ecb-414400ba7933">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b330f981b284955bf6356724ac55d7b_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTUtMS0xLTcxMzMw_c5384f57-5b62-483d-bc4d-66760974b294">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c20eb419e3840d885552c3057349c91_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTctMS0xLTcxMzMw_aee98b5a-7a40-4b17-996e-09ebedc442e3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19edb02be5e746299724e213abfcaada_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTktMS0xLTcxMzMw_31a75fb3-4a93-4b19-a4f2-4ccc2611f2cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd18b2833711484dbc7ffca9c326cd7d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTExLTEtMS03MTMzMA_eb57787d-6a54-409b-9da4-f911f23efe8e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24345a0ff484deb98e10e4105afa5bb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTEzLTEtMS03MTMzMA_c33f6b3a-5ce0-457b-82f3-5c8d1d6fe3f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36627656f09a4021bfe46b0d8181fb2f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTE1LTEtMS03MTMzMA_dd3f260b-bade-4259-9c5c-32ade1b89c2b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTEtMS0xLTcxMzMw_7e79266e-d6fc-4d1a-82f0-15febd8f2a1e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTMtMS0xLTcxMzMw_8a089dec-c0ef-4d59-bfea-d5f0081c2b29">433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0220a923758c4bbd97582689f870643e_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTUtMS0xLTcxMzMw_d9761468-bb1c-4cec-aad7-8bab6045b017">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTctMS0xLTcxMzMw_e15668dd-943a-48a3-8020-db5fd334e9e0">433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTktMS0xLTcxMzMw_b6f5b873-8a00-4d9e-99ef-81d323097237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTExLTEtMS03MTMzMA_f99588b6-fca7-4486-8c69-e00ae2ae2229">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTEzLTEtMS03MTMzMA_6d41b5dd-dda9-4e5a-b663-1eef5f903d87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTE1LTEtMS03MTMzMA_0e96a975-b1a9-4069-83dc-b165df4929dd">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTEtMS0xLTcxMzMw_fc799e74-89d8-437b-b1ea-456d4dc681e7">1,355</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTMtMS0xLTcxMzMw_ff25605b-d7c3-4926-adf7-a3383aa5aa80">931</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0220a923758c4bbd97582689f870643e_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTUtMS0xLTcxMzMw_f7f5a5da-d3b9-4395-9089-4d187c19ad41">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTctMS0xLTcxMzMw_f596650f-de73-4a81-891b-6d88d20d4af0">2,286</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTktMS0xLTcxMzMw_92bd9c43-f18d-4303-ad61-6f6854028e04">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTExLTEtMS03MTMzMA_4f49e35a-005e-4586-8b0c-6220e5735e12">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTEzLTEtMS03MTMzMA_c53a0145-d9c4-4814-8507-367c248bbb2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTE1LTEtMS03MTMzMA_19b12dd1-6ed2-4aa6-a5c7-4510e12e48a9">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTEtMS0xLTcxMzMw_3969ab56-e42b-4139-a6cc-85821bdcd4b5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTMtMS0xLTcxMzMw_bfdec829-24ca-4e10-9457-70913bc79f95">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0220a923758c4bbd97582689f870643e_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTUtMS0xLTcxMzMw_f57d0244-1da1-47cf-9587-9afbbbef323d">456</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTctMS0xLTcxMzMw_47898a7d-43f6-4607-a002-314d61764771">456</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTktMS0xLTcxMzMw_56c89434-70fa-4209-95cf-bf87385588c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTExLTEtMS03MTMzMA_a67d9a27-b14f-4f07-80cc-8ac7d39e1d80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTEzLTEtMS03MTMzMA_2e91b108-df64-4ec1-9c4b-5f1f8e4e1d4c">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTE1LTEtMS03MTMzMA_d5823a19-3e8d-4d7c-a3b9-34bf8e34daa7">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a21b3709dd42128d8264f2a5257c18_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTEtMS0xLTcxMzMw_2e00fab2-172b-44df-92e6-3094a57847c3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d6a9e2a4e04b1bb46f7d1cbcc4e416_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTMtMS0xLTcxMzMw_c12108d2-d728-4947-91ca-65e9202e0e61">402</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150ff06d48a9497eafdf58dc03d8e518_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTUtMS0xLTcxMzMw_ce874b88-f123-4246-8072-3fe2624ae40e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b040b0e94924f0291cc48a435447245_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTctMS0xLTcxMzMw_a8332920-e193-4f6a-9a87-ebb2acef6cdf">402</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae251a0ecc04d6b9054f018ef917ce8_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTktMS0xLTcxMzMw_6ad62bea-3458-4f17-a10a-d186ec917752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief83301bd6734273beb742bcd0fd8b21_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTExLTEtMS03MTMzMA_c03c7ebb-c6d1-46b7-90b5-ef8c8ea90c6b">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10131b7117eb4770b663e21fa15b98c6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTEzLTEtMS03MTMzMA_fdb290f1-64c3-4620-8320-c1534675af32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0a0f8c7fc64e1ab6f955a741b7f056_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTE1LTEtMS03MTMzMA_2f6fd26b-3f90-44ac-8888-193a3ac18203">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd64d4dc46a44fca8aa2e2d65f22ec14_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTEtMS0xLTcxMzMw_454fcd4e-e61f-456e-8fa1-7f92606d089b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a54e6f42254f4a80ac3cbfedbeda25_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTMtMS0xLTcxMzMw_d07934f9-ef76-4ba7-9f6d-75dae1b66237">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1291079726f54d9482e915764e3a28f8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTUtMS0xLTcxMzMw_51a0ca91-70f3-4a76-9aed-740c15d3ae4d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9feab63c1b64ebb859b0a44c8c0fe14_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTctMS0xLTcxMzMw_7c13e69e-1eab-48c1-91ad-e3b81bffb85d">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cdff6731374404ac0a075ce6ab9b79_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTktMS0xLTcxMzMw_6936742b-2f72-42e0-a375-0965b26b396e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a379c20670240a9b25634d9750efe8b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTExLTEtMS03MTMzMA_3a0e35f1-0df8-4750-8b9e-954f9b822613">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaaa3375ce0c4bcfa1287f588b3077dd_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTEzLTEtMS03MTMzMA_6d9edbc8-5248-4de9-a4c8-a297a3c2704e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34968f94170b4606b1bd3134b883f9fb_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTE1LTEtMS03MTMzMA_a838e484-2c2d-439c-a6cd-36973f0c7a7e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTEtMS0xLTcxMzMw_ddc09f00-f8bc-4998-afd5-4a52fce2cc86">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTMtMS0xLTcxMzMw_b89df21a-2e03-45e5-9a8d-bec8521b4540">409</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0220a923758c4bbd97582689f870643e_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTUtMS0xLTcxMzMw_20ff773c-efec-417a-8d9b-ac45fcb27716">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTctMS0xLTcxMzMw_84b2ab7a-2b4f-4f6f-a832-be781d7d74fe">409</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTktMS0xLTcxMzMw_3c43061c-4a01-4aa0-9782-837595db5991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTExLTEtMS03MTMzMA_01d30acb-fcca-4f34-adc0-c5c98df30e03">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTEzLTEtMS03MTMzMA_045e2344-fe40-44ec-820b-204e9878bea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTE1LTEtMS03MTMzMA_1aeec72d-7138-4e84-a22e-ab07917c9a6f">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTEtMS0xLTcxMzMw_294c6d14-b56e-49fe-a6f3-1924ee3e84ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTMtMS0xLTcxMzMw_5190d102-b55d-40b9-bf96-6501d4013c9c">409</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0220a923758c4bbd97582689f870643e_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTUtMS0xLTcxMzMw_9e1ead78-83b1-4764-a7c7-150994f5657d">456</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTctMS0xLTcxMzMw_91149dbf-b420-4220-8f71-d5789bce840c">865</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTktMS0xLTcxMzMw_17ad03a9-681a-444b-b4c3-b3d7e775f5ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTExLTEtMS03MTMzMA_1ac3713b-4f4e-4e9c-acb0-3447442e99f4">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTEzLTEtMS03MTMzMA_651a65df-be80-4b52-914e-c76354f15d5c">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTE1LTEtMS03MTMzMA_845fe781-ef64-4ab0-b89d-4ffaee7d16c8">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $<ix:nonFraction unitRef="usd" contextRef="i4296dad71f474d0fa88ccb38226b4f44_I20221231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0MTg3_9bff5fcf-b8e1-4dd7-a0b9-0c146f757e3c">11.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ifd71198dffc74a99b2e0c368d96a14ab_I20211231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDc1MTQ_a2e44749-61cf-4b92-b079-fef9a186f768">6.8</ix:nonFraction>&#160;billion of cash equivalents, respectively, (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTYz_9c364c8f-f9b2-4a5d-8ce4-72f19e9239df" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzEtMS0xLTEtNzEzMzA_d6b42505-f8e6-4d0e-99da-03b9a9920c6e">777</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzEtMy0xLTEtNzEzMzA_848a6b3e-8cee-4641-8082-537be9693cb1">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzMtMS0xLTEtNzEzMzA_9a9b031b-d1b2-4a42-b84b-9707f07de34f">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzMtMy0xLTEtNzEzMzA_113bb28d-dccf-408f-9dd7-f58fd17f38f4">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzQtMS0xLTEtNzEzMzA_1e51e344-f4bf-4581-ad9d-71c7bce0d005">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzQtMy0xLTEtNzEzMzA_e76a1187-493d-41b5-ab1e-cbb7d04cd34b">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzUtMS0xLTEtNzEzMzA_a36e6ebe-1c1e-4945-a095-71d3ecbe6a3e">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzUtMy0xLTEtNzEzMzA_2b1ae038-0c2c-4708-b411-ed8b507c442d">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzYtMS0xLTEtNzEzMzA_cd218c1d-914b-40ec-b55d-d88a46e008ef">456</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzYtMy0xLTEtNzEzMzA_dec6f6db-7b3a-400b-9e6f-d3cfc0e17048">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="iaa8b5a245d4f455da78fcffb96a7508c_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0NzIz_a77a100c-d672-403b-a75e-37952509de7a">368</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1ba9f35c12c54ef98f07fea573c78bd3_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0NzMw_b44fcba7-e538-4412-8ba5-f5c2fe070cf2">620</ix:nonFraction> million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonFraction unitRef="number" contextRef="iaa8b5a245d4f455da78fcffb96a7508c_I20221231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0OTM5_9743ae2c-b85a-48f4-829d-bd37185fa1c6">11.5</ix:nonFraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December&#160;31, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NTAxMzE_d65ab4cc-a8f0-43da-a0fd-8ba7d4952d61">122</ix:nonFraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="ia811518ca0b042a6a56f3f5b69d12bff" continuedAt="i304e4660fc194d0c8f3e0efee2ecc7a1"><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2022, was $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1ODEw_050bd8c5-ca9b-4d29-9b8b-762705483d5c">26.7</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1ODQ3_565af5e7-d397-4b72-8748-89f741095cdf">30.7</ix:nonFraction> billion and at December&#160;31, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1ODY1_5626a560-0428-4b0e-a683-4935276c8ecd">35.7</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1OTAy_a0fdb662-55a9-426c-a288-be8643498031">33.1</ix:nonFraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately <ix:nonFraction unitRef="number" contextRef="ia6da2f157b824f52851dd9e978b0eeff_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3MzI0_ab3a10f7-3e37-40e5-8ab9-d53a676cfa5e">21</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i9c08e07575e9490cb5a8f9cf49bbd641_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3MzI4_a3307ee1-9e77-4813-8d64-ba1236ae5eef">20</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib444129703be4af2a20054714bf0ecec_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3MzM1_e54e6f71-2767-4129-a4f3-155414ca9e1f">13</ix:nonFraction>%, respectively, of total accounts receivable at December&#160;31, 2022. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonFraction unitRef="usd" contextRef="ie56c0f796a90447b8097ae8d7be632fe_D20221001-20221231" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3Nzkx_4a467e19-706a-4a73-95ae-4320d64bf108">2.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i567c0acaaf20420daa3260e2b7668e47_D20211001-20211231" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3Nzk4_8d253155-c4ff-49f7-b37e-bb8a2586c945">2.8</ix:nonFraction> billion of accounts receivable as of December&#160;31, 2022 and 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2022 and 2021, the Company had collected $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE4MzE3_ee756dab-e776-4a2e-b163-384ceff1f54c">67</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE4MzI0_1bd0d35c-24c7-4284-94c3-1851f021cc0f">62</ix:nonFraction>&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in January 2023 and 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><ix:continuation id="i304e4660fc194d0c8f3e0efee2ecc7a1" continuedAt="iaf599e43f208458f88de8292420204b0"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to various counterparties was $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzM4NDgyOTA3MjIzNzk_604e659c-8b85-46d0-8a27-42059acc3c8b">19</ix:nonFraction> million at December&#160;31, 2022. Cash collateral received by the Company from various counterparties was $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDgzMTE_97d36d09-2d65-428d-882a-75d5b010a01e">66</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDgzMDQ_9b9886fc-656b-4177-8dd6-437eb89ae322">164</ix:nonFraction> million at December&#160;31, 2022 and 2021, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="iaf599e43f208458f88de8292420204b0">.</ix:continuation> </span></div><div id="ia384118d157240e09e39541b90e2080f_169"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzU0OQ_59f42800-5d82-4efa-97e0-01307aa95f66" continuedAt="ifaf48dd3154c40838da62e3fef141dc5" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ifaf48dd3154c40838da62e3fef141dc5"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzUzNg_4c068fed-2d02-4555-a6c1-ca2b3d3b0149" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzEtMS0xLTEtNzEzMzA_32ed038c-6e65-4bee-8a80-8f55818633fc">1,841</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzEtMy0xLTEtNzEzMzA_c8dd097d-38b6-4f84-a8a4-f0fe6d5f196d">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzItMS0xLTEtNzEzMzA_94a5e92e-b8c3-4cbe-b3c2-aa13b2db5d13">7,063</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzItMy0xLTEtNzEzMzA_6a82c151-2b79-47eb-bcc3-f0202a4f23d5">6,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzMtMS0xLTEtNzEzMzA_63231493-52e1-4515-bb0e-20bd699098c8">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzMtMy0xLTEtNzEzMzA_cd00f1fd-b52a-48c8-bc7f-e3715aa351d5">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzQtMS0xLTEtNzEzMzA_26052e10-7fd6-462b-a6ea-8377ba800b06">9,142</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzQtMy0xLTEtNzEzMzA_0f5fb99f-b611-419a-afbb-3cdb8d88bc33">8,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzUtMS0xLTEtNzEzMzA_f3764028-ed7f-4223-83db-77e493dd12f1">293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzUtMy0xLTEtNzEzMzA_cd462540-4800-440b-a6b0-f1858f81b900">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzYtMS0xLTEtNzEzMzA_87ed1445-8c18-4cf4-943e-46d690a9e4d5">8,849</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzYtMy0xLTEtNzEzMzA_0d1ad7fa-adaf-4a89-bff3-ad937944d8b0">8,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzgtMS0xLTEtNzEzMzA_081187c5-b9f0-44e5-b554-0b47a9027156">5,911</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzgtMy0xLTEtNzEzMzA_808e26f8-2d16-425c-b1b3-37d7f46ab646">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzktMS0xLTEtNzEzMzA_6c414cc9-713f-492b-8bc0-2a3bff16fa9e">2,938</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzktMy0xLTEtNzEzMzA_98a177a1-e357-46b8-83f0-897d6fcd01c1">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzEzMQ_65d019fc-91db-40d5-a3af-7e4a25e73b26">3.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-8" name="us-gaap:LIFOInventoryAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzEzOA_7503762b-c445-4f79-9ffc-6de9ea53e228">3.3</ix:nonFraction> billion at December&#160;31, 2022 and 2021, respectively. Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2022 and 2021, these amounts included $<ix:nonFraction unitRef="usd" contextRef="i022aa53b13d84e14a5eedc763cefd54e_I20221231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzMyMQ_45d5d139-49ce-458f-8f40-64c037dc6a15">2.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i925bfec8ab2743348c69f615eb5a44fa_I20211231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzMyOA_47fdf36c-2fa0-4110-8d81-4499cb678a42">1.9</ix:nonFraction> billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $<ix:nonFraction unitRef="usd" contextRef="if61807d83368439782aa2842af89525a_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzQzOA_a26d5b96-c713-49e2-b2c3-540f173fc545">516</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i99ba9b9962fd485ea74e2d2c10d17307_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzQ0NQ_4d83e8c0-b2f4-4a06-ae46-a1a23f9e2f29">256</ix:nonFraction> million at December&#160;31, 2022 and 2021, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_172"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyNTQ_e5e5881e-b21e-4df9-9a50-b4adb759022f" continuedAt="i084baf82df6545c5b08654e6fd7d0bc3" escape="true">Goodwill and Other Intangibles</ix:nonNumeric></span></div><ix:continuation id="i084baf82df6545c5b08654e6fd7d0bc3" continuedAt="i415b6f7024d147f38550ef0e039768ee"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyNDM_b20eaeae-40c5-455b-8b65-f8746e029f45" continuedAt="i97344e221a9e4f70a1a44bda55106b30" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc9093833ea43efa72b1bc502bed4da_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzEtMS0xLTEtNzEzMzA_22cd6dfa-d489-48c6-a27b-a2aa556475ed">15,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a4d286567e47718bed1dc0ec61c06d_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzEtMy0xLTEtNzEzMzA_af40e233-7649-4b91-b7b9-9193475fb78c">3,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzEtNy0xLTEtNzEzMzA_8db9a4e4-be6f-4879-a892-6a563c6f867f">18,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a53de261014635b46dff37511f8a28_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzItMS0xLTEtNzEzMzA_10376b3d-4bb3-4ac5-a491-fadfd8e6054e">2,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ab8ac0847f4ea2aec591d7ec276bb9_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzItMy0xLTEtNzEzMzA_b551ac51-0f67-48d4-8684-9670cd59b53a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzItNy0xLTEtNzEzMzA_10f44543-6146-4023-ad5f-f24ce76f69c9">2,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9a53de261014635b46dff37511f8a28_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzQtMS0xLTEtNzEzMzA_905b02a7-644e-41ac-9ae0-f245d365e69f">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8ab8ac0847f4ea2aec591d7ec276bb9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzQtMy0xLTEtNzEzMzA_8f08f1d0-31a3-4b98-a9ae-da16dac9fa83">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzQtNy0xLTEtNzEzMzA_d5ee9880-41e2-4df1-9bd3-ba8f1686a520">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31, 2021 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c3ea6a6aab40a686a75e01c429aed9_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzUtMS0xLTEtNzEzMzA_07b213f0-b7e6-4766-81c3-bf2ad8ad3276">17,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34571e3bf0a24f04a885f828cb94cfd0_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzUtMy0xLTEtNzEzMzA_c2f8ecb4-642b-44f7-b933-06d337a36ea6">3,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzUtNy0xLTEtNzEzMzA_f0618509-2a1c-418c-8f7b-cb5e876d7a13">21,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5bf7773e95f40eeb049ba5fec44f5e6_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzctMS0xLTEtNzEzMzA_87614e31-1129-41ae-90e6-44a9a4a0e3d9">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0140812b0eab469a965b4b15301949bf_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzctMy0xLTEtNzEzMzA_de6ce1c2-d3d3-471f-9f13-7ea6c9f2f112">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzctNy0xLTEtNzEzMzA_c84d44c8-f009-4405-bb7f-461cf3b62518">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December&#160;31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cf60618c5e4aaca021c753bff1b8a8_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzgtMS0xLTEtNzEzMzA_4ca0a345-7625-4d72-abb9-d394456bb0df">17,936</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57473094cd042cca3f71ebfab8a12ed_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzgtMy0xLTEtNzEzMzA_3d300668-b58a-49f0-893b-631928c24258">3,268</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzgtNy0xLTEtNzEzMzA_ba37ae4e-62d5-41ea-8121-4b6a8f105314">21,204</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i97344e221a9e4f70a1a44bda55106b30" continuedAt="i52ba87623e5e4209a0da74b75a9a8b8e">(2)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i52ba87623e5e4209a0da74b75a9a8b8e">Accumulated goodwill impairment losses were $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzIyNQ_0d7703f1-a41a-49d6-ad3a-d4a4404ef671"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzIyNQ_7dca2832-8a03-44d1-80dd-b8848c9cdddd">531</ix:nonFraction></ix:nonFraction> million at both December&#160;31, 2022 and 2021.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron (see Note&#160;4). </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyNTI_3cbd8f2c-8781-4006-a7ca-b5bd41987682" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItMS0xLTEtNzEzMzA_28c59d94-f087-4acd-b340-0a1f7dce65db">23,555</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItMy0xLTEtNzEzMzA_19132fa4-5f28-4fcc-ba6f-ca87fa63cc63">16,745</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItNS0xLTEtNzEzMzA_443632f3-555d-4f92-9c28-f02aadc02576">6,810</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2e09c593c942af8e3407a887af82d4_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItNy0xLTEtNzEzMzA_fa2320e6-29a5-4f01-a17d-4b3aa0f78bd3">23,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2e09c593c942af8e3407a887af82d4_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItOS0xLTEtNzEzMzA_6fb5438b-1731-4d93-8df4-5653fa027983">15,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2e09c593c942af8e3407a887af82d4_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItMTEtMS0xLTcxMzMw_abf211e6-27a9-4a8d-8259-b7d33c094856">7,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be0c233ffc9447ebd088af22f69de87_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtMS0xLTEtNzEzMzA_9ca3a4aa-dcdd-4edc-930f-76ba87217e69">7,661</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be0c233ffc9447ebd088af22f69de87_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtNS0xLTEtNzEzMzA_e026f9d3-2ec3-4df3-92f7-4532560850e3">7,661</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie233154d86a14b82a3feeae38dd79d18_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtNy0xLTEtNzEzMzA_9c047f62-a4ef-4fb7-9486-7aa53f1901e6">9,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie233154d86a14b82a3feeae38dd79d18_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtMTEtMS0xLTcxMzMw_6a06191f-c63d-4d99-8a34-574948e29eaf">9,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6138bf37696649a6bd6e971b74356d51_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtMS0xLTEtNzEzMzA_d0aedef2-1471-4e38-ab25-c796405f73f9">2,879</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6138bf37696649a6bd6e971b74356d51_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtMy0xLTEtNzEzMzA_13c37a17-a6be-46c2-84af-ed272ff98fbb">635</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6138bf37696649a6bd6e971b74356d51_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtNS0xLTEtNzEzMzA_5e30d6cb-6d8c-40a7-af34-5613e1267e64">2,244</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213276daa7804281bc7394485ab71d33_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtNy0xLTEtNzEzMzA_6ddcee28-fd22-42e5-a00e-cb14384c66d2">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213276daa7804281bc7394485ab71d33_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtOS0xLTEtNzEzMzA_7a11865a-2ca3-4eeb-8e67-761c796d0a2b">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213276daa7804281bc7394485ab71d33_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtMTEtMS0xLTcxMzMw_c6bcc8fd-6af9-4ae8-b8be-aab1829fbe27">2,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtMS0xLTEtNzEzMzA_bf95f5f4-e2b0-45d7-ac12-5470d072340c">7,651</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtMy0xLTEtNzEzMzA_761b5fef-08fd-4c0f-aa00-4d07102eb636">4,097</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtNS0xLTEtNzEzMzA_54309a62-f00b-453c-9b4d-1c908cc1088d">3,554</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460644d8e3e54a79b686e69c684cec5a_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtNy0xLTEtNzEzMzA_b776c86d-6ff1-4dd8-9d8a-77a2f4f2e5ac">6,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460644d8e3e54a79b686e69c684cec5a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtOS0xLTEtNzEzMzA_bae69dd1-aa16-48b1-be1d-cc33b1533e60">3,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460644d8e3e54a79b686e69c684cec5a_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtMTEtMS0xLTcxMzMw_b233aadf-b7f3-4eed-8f72-351e74e30ec1">3,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtMS0xLTEtNzEzMzA_59079f7a-b4df-4573-a2e2-91316e0fd95f">41,746</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtMy0xLTEtNzEzMzA_3517190e-81bb-4d62-a9d2-86ebdd35020a">21,477</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtNS0xLTEtNzEzMzA_ddd9c76a-3a18-4402-9f0e-073e3861c550">20,269</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtNy0xLTEtNzEzMzA_1547eb34-541e-44b9-b283-4e105168e0a2">42,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtOS0xLTEtNzEzMzA_23e12afb-7bef-4ca7-a596-87b74f264504">19,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtMTEtMS0xLTcxMzMw_ace62c5d-6a15-458e-882d-00911b5943f4">22,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the more significant acquired intangibles included in products and product rights, on a net basis, related to human health marketed products at December&#160;31, 2022 were Reblozyl, $<ix:nonFraction unitRef="usd" contextRef="ibace400774984c3dbc9f9ea52b1e0e6a_I20221231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwNjY_4d9cbf3c-4850-4b2f-8046-7ff6aef82d37">3.5</ix:nonFraction> billion; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="ie47add64e2cd40f998158d2c98eb4042_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwNzk_2d4fb32c-cd6a-4092-a6b0-d946d91a879e">406</ix:nonFraction> million;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Sivextro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i5fbb5dd4448e485981b74dc5719bdbc0_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NTE5MzY_d3596946-979d-4d28-9261-c7a936f63274">122</ix:nonFraction> million; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, $<ix:nonFraction unitRef="usd" contextRef="i7debb2fba50146bebb232e6e8e26d1e1_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzExMDQ_b594f44d-0e4f-483b-b409-3a6ea12f64a6">120</ix:nonFraction> million; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i323a82a0676e447aa0ee30bbd32c0379_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzExMTc_184c7f4f-5b99-44f2-9ea6-1a88a4abb0f2">97</ix:nonFraction> million. Additionally, the Company had $<ix:nonFraction unitRef="usd" contextRef="i4629f93a6cb342d7a2adcf465132267d_I20221231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzExOTU_8d3959c8-42a8-46e0-853d-d8f4b4ef26ef">4.6</ix:nonFraction> billion of net acquired intangibles related to animal health at December&#160;31, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="ice62906f5f13486296cfddb3eecc61f6_I20221231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE2NDkyNjc0NjcyMDI_27c12087-9a54-4f1c-a5b4-ddca0825c8d8">2.3</ix:nonFraction>&#160;billion related to products and product rights and $<ix:nonFraction unitRef="usd" contextRef="i4a998c05c25e45d897132264cd7393b5_I20221231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE2NDkyNjc0NjcyMTY_c33a5426-6e63-40bd-9b49-f31e4f6fe08f">2.2</ix:nonFraction>&#160;billion was attributable to trade names, primarily related to Allflex. At December&#160;31, 2022, IPR&amp;D primarily relates to MK-7962 (sotatercept), $<ix:nonFraction unitRef="usd" contextRef="id2eb0aca1931486da121627e2b099a6e_I20221231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE0NDE_15d3b7c0-8a25-4104-84e5-5190445c96fc">6.4</ix:nonFraction> billion, obtained through the acquisition of Acceleron in 2021 (see Note&#160;4); MK-7264 (gefapixant), $<ix:nonFraction unitRef="usd" contextRef="ibf54a72af67e45fda2e3769dc2ee1bbb_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE2NDI_75858ffe-e586-434c-8df2-29d69dd418b7">832</ix:nonFraction> million, obtained through the acquisition of Afferent Pharmaceuticals in 2016; and MK-1026 (nemtabrutinib), $<ix:nonFraction unitRef="usd" contextRef="id0ae54ef35294062adb30816c2eba9da_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDMxNjM_178533cd-eace-4cc4-89d5-fb4017c7db5b">418</ix:nonFraction> million, obtained through the acquisition of ArQule in </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i415b6f7024d147f38550ef0e039768ee" continuedAt="i34e1203c7134454ab095008d29ea95f1"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 (see below and Note&#160;4). Some of the more significant net intangible assets included in licenses and other above at December&#160;31, 2022 include Lynparza, $<ix:nonFraction unitRef="usd" contextRef="i46a9b57f7713451ab3d958cb0b3c227c_I20221231" decimals="-8" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE4Mjg_ed8d6e65-0d76-476e-83a4-8bbaa4d21fa0">1.6</ix:nonFraction> billion, related to a collaboration with AstraZeneca; Lenvima, $<ix:nonFraction unitRef="usd" contextRef="ia9c533dce277413ebf7c86906b5c8f94_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE4ODY_07976841-cdde-4cf6-b77a-14ee077c3d30">814</ix:nonFraction> million, related to a collaboration with Eisai; and Adempas, $<ix:nonFraction unitRef="usd" contextRef="id5de854d06ac4eeca3f033f63ac8cf18_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE5Mzg_c9e9026b-b5b2-474f-864f-86f018ef51d5">633</ix:nonFraction> million, related to a collaboration with Bayer. See Note&#160;5 for additional information related to the intangible assets associated with these collaborations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzIyMDU_d12f0a3e-03fd-4853-ae6e-0f9626a511c2">1.6</ix:nonFraction>&#160;billion within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjg_e7b500cc-8996-45e1-8231-cde2ddbd2b59">Cost of sales</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> intangible asset for impairment. The Company revised its cash flow forecasts for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $<ix:nonFraction unitRef="usd" contextRef="i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231" decimals="-6" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzMyODM_264c4faa-8de3-43fc-a358-c0bdddd7cc53">120</ix:nonFraction>&#160;million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in 2020 related to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> recall. A phased resupply of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was initiated in the fourth quarter of 2021 and completed during 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2Mzk2Mjk_02660e96-e096-4101-80a8-dad645c49fd1">1.7</ix:nonFraction> billion of intangible impairment charges within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjk_b1192ef4-ec86-4241-a5a3-3f1beac17af0">Research and development</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses, of which $<ix:nonFraction unitRef="usd" contextRef="ie57ef40fb83d43d0b204010eab10ace2_D20220101-20221231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2Mzk2OTY_c8a144e9-9cec-408a-9cd8-91021a988ffd">1.6</ix:nonFraction>&#160;billion represents IPR&amp;D impairment charges related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies that was obtained through the 2020 acquisition of ArQule (see Note&#160;4). Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $<ix:nonFraction unitRef="usd" contextRef="if3518262d4c349ecb316b3c7dec9767f_D20220701-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDU1NzI_71530e35-1809-440b-92e7-4c9c6d5da6dc">807</ix:nonFraction>&#160;million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which is expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated current fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $<ix:nonFraction unitRef="usd" contextRef="ibc70591306cb403fbd97773b449e9870_D20221201-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDU1NTg_5598233b-554a-4671-a68e-23743a3585d6">780</ix:nonFraction>&#160;million impairment charge. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $<ix:nonFraction unitRef="usd" contextRef="id0ae54ef35294062adb30816c2eba9da_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2Mzk3MDQ_178533cd-eace-4cc4-89d5-fb4017c7db5b">418</ix:nonFraction> million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $<ix:nonFraction unitRef="usd" contextRef="icc9e424e32fb43b8855afaaf0a1576b3_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDE5MTI_c3207acb-f45d-48db-89e3-1f7ce7c6d63d">80</ix:nonFraction>&#160;million intangible asset impairment charge related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i0d0e372671334e94bc77b2dfc17299c3_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2MzYxNjM_6bced37d-0e16-48f4-bd96-ccdc0c816089">275</ix:nonFraction>&#160;million IPR&amp;D impairment charge related to nemtabrutinib. As part of Merck&#8217;s annual impairment assessment of IPR&amp;D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to <ix:nonFraction unitRef="number" contextRef="i21861da46868461288c97e4ab76ae0fc_I20211231" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzU4Nzc_4834c83d-2fc9-4385-9de6-3cb9d85d0180">8.5</ix:nonFraction>% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i34e1203c7134454ab095008d29ea95f1"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2MzYxNzM_2c74fb19-e8db-4617-af9b-cd5dc34f0d4d">90</ix:nonFraction>&#160;million IPR&amp;D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#8217;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzcwMzE_aa684689-f975-423d-b21a-325c74147ecf">45</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgwNjQ_0575a875-f430-428b-a743-61fa2d9ec1d7">2.1</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgwNzQ_b04f481c-c128-408f-882e-ab1b28de4283">1.6</ix:nonFraction> billion in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgwODc_d4a78d66-eed6-48c2-a6ea-6de8a9c1a1c6">1.8</ix:nonFraction> billion in 2020. The estimated aggregate amortization expense for each of the next five years is as follows: 2023, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgxOTM_bb6157fb-cdaf-4130-9acc-4b2ba7e2744d">1.8</ix:nonFraction> billion; 2024, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMDE_8a04903f-ee7f-4fd1-b7b9-101c8df89ec0">1.7</ix:nonFraction> billion; 2025, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMDk_146829a1-85d1-4ef1-9f24-adde32827207">1.6</ix:nonFraction> billion; 2026, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMTc_ed183d65-8382-4e20-840f-1a9ce0d8ce26">1.5</ix:nonFraction> billion; 2027, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMjU_0c4186b7-8647-4964-ad1a-5defa1e86e69">1.3</ix:nonFraction> billion.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_175"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNjA_71647304-a3f3-4d00-a2f1-17beef4baa5e" continuedAt="i9e71ef04d9d243b5890f19be0ae90d0e" escape="true">Loans Payable, Long-Term Debt and Leases</ix:nonNumeric></span></div><ix:continuation id="i9e71ef04d9d243b5890f19be0ae90d0e" continuedAt="i1942eec1a7b14442ad360510ce8b5da1"><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loans payable at December&#160;31, 2022 included $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0Xzk2_c156dd29-4881-4dee-b15f-9e9a96ed0c7c">1.7</ix:nonFraction> billion of notes due in 2023 and $<ix:nonFraction unitRef="usd" contextRef="i7fda3b4d09eb4fa583ba37378f5415c1_I20221231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzEyMg_43220df5-7ea3-4ef7-bb20-8368b02b6ac0">197</ix:nonFraction> million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2021 included $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-8" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNA_0ccaa489-ccd4-4d5d-99d5-b133d0156f62">2.3</ix:nonFraction> billion of notes due in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i2bb0b8ac7a6746a7b99550c3290a6912_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI5NQ_f8c56615-3c9a-4853-8764-6b7e862b4bbc">149</ix:nonFraction> million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was <ix:nonFraction unitRef="number" contextRef="i8a963f7bb7df4286b00142ee3a4b4163_I20221231" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzQ0OA_2e97ffb6-bf46-4370-8a09-94f1b533fe07">0.65</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9b81622562e043619ce4097e5de6538d_I20211231" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzQ1NQ_b5821c25-02b4-4077-8c77-31de8482be5b">0.08</ix:nonFraction>% for the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i1942eec1a7b14442ad360510ce8b5da1" continuedAt="i53106584f1fd4c0e90688cc633829cf9"><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNTY_1949e94c-0b76-4134-9920-09f9ff33a3d4" escape="true"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedd526ebaff749a5b3eafa6e57a81046_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo3OGNlMzU0OGU4Zjc0NmFiYTc1MWYxYjI2Nzg3NzZjNV80_5618ff97-e307-48e9-896c-f715f27c93c9">2.75</ix:nonFraction>% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd526ebaff749a5b3eafa6e57a81046_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEtMS0xLTEtNzEzMzA_3d6a5d6d-4ab7-4e92-ac8b-4609a8ec3b72">2,496</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a1b935714646a28acc02e8da2af399_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEtMy0xLTEtNzEzMzA_0349b57a-9f07-4969-a35c-f9e02a08def2">2,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78f6217a86d54e6b955c5c6727e00fbc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzItMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpkNjU2MDllZWE4MWQ0ZDVhYjViOTlhOWI1MDgzNTgwZF80_67d3857b-4d4c-4872-b019-62d38faad99c">2.15</ix:nonFraction>% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f6217a86d54e6b955c5c6727e00fbc_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzItMS0xLTEtNzEzMzA_76203d8c-1359-4065-bf83-b6bc18139fcc">1,986</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233cd0a66f3a4e1293ee7180976a6a9c_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzItMy0xLTEtNzEzMzA_66407772-ac69-4736-8cf3-da89c17d1747">1,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33401fab91ba450bad968abb1f3afcb4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo5ZDY2MDBhYmI2NDU0N2JhOTQ4OGVjNmFlOTkwNTk2Ml80_058b2d66-daf2-4648-b795-20ac60dda642">2.75</ix:nonFraction>% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33401fab91ba450bad968abb1f3afcb4_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMtMS0xLTEtNzEzMzA_ef25031e-5423-47ea-9dce-c81b336f0ac9">1,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1742d1bcca4273b22d4c2ec6e6d4d7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMtMy0xLTEtNzEzMzA_45692c95-2f6f-4bf9-8bc7-d55da8245301">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaaf0e9d91b9c4abf8d628b3c4bebc216_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo5ZjU5NGI3ZmNhNzg0MmQwOWUyMjQyMWZmMTUwNTBjNV80_46a7f87b-31ae-4439-9cc8-747bd33eafa9">3.70</ix:nonFraction>% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf0e9d91b9c4abf8d628b3c4bebc216_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzQtMS0xLTEtNzEzMzA_d2609527-bd0c-4b89-b9e7-a91a55308e2b">1,978</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09e345560f6497791f50eb94308c444_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzQtMy0xLTEtNzEzMzA_6829825b-c19a-46d7-8f22-aed4a5e2216f">1,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fb3e5f968ec4dd8825fd0c8bb6ad4aa_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzYtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo0MTljNWUxMjFjMDA0YzNkYjVjNDljYzhmYmViN2FhOF80_85d9ef4d-d298-4b8c-8eab-748001f25215">3.40</ix:nonFraction>% notes due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb3e5f968ec4dd8825fd0c8bb6ad4aa_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzYtMS0xLTEtNzEzMzA_4e5d15f7-7539-4f6f-a9d9-c379ec7acc72">1,738</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dcfc6075c6a4565a9f8554b61999abe_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzYtMy0xLTEtNzEzMzA_af02951b-8138-48cb-ad30-a57689305586">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i739a3710a3de4d7ebb81ef763fccbdea_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzctMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjplN2EwNzM0NDg1MTA0MmQ1YjY4ZTFlYjBlYmVjOGI5M180_1f286601-ef90-465a-b2dc-abb60f6308c4">1.70</ix:nonFraction>% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739a3710a3de4d7ebb81ef763fccbdea_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzctMS0xLTEtNzEzMzA_8b962f50-2399-4732-adfa-56e473f36193">1,494</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib470cd6f92154bc78779d5a55eb10d70_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzctMy0xLTEtNzEzMzA_2bf07b8e-55a3-4745-b4bf-2cb3c1e4423e">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1c794da2c364cef883126c44ac0eadf_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzgtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpjNWZkOTExNTA5Y2Y0M2I5YTMwYmFjYzc5ZGIzMzg0N180_5bef9f9a-8c33-41b1-add7-ea6acf5c98ba">2.90</ix:nonFraction>% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c794da2c364cef883126c44ac0eadf_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzgtMS0xLTEtNzEzMzA_cedceaf0-1664-4a08-9b72-d15b8aa160db">1,483</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822efa59fe3745939a910b1611d44288_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzgtMy0xLTEtNzEzMzA_21c24260-e4b6-4200-baec-109184096aba">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92399f31232247e0b6bbcf5a6a089235_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzktMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpkN2FmNzExZTViMDk0M2Y4YTIxY2IxNDYwZDFiYzBmYl80_9247307f-7348-4f1b-a51e-866bd0e7a55a">4.00</ix:nonFraction>% notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92399f31232247e0b6bbcf5a6a089235_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzktMS0xLTEtNzEzMzA_9f60fe9b-85da-4a32-a70e-4e0a4370b7c2">1,471</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b551b1b91d472893ca0398491a7cce_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzktMy0xLTEtNzEzMzA_ad0e3409-d70d-4e39-b608-44991ee7e967">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5713c49e1e844949024ca754f258c89_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEwLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MWYxMmNjMjA3ZDkxNDlhYjk4ZDRhOTUzOTgxN2E3N2JfNA_eff6eef1-7a92-41d3-be13-f8efb0a64918">4.15</ix:nonFraction>% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5713c49e1e844949024ca754f258c89_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEwLTEtMS0xLTcxMzMw_14640b08-4d84-4a74-b6d4-d78d78839cf3">1,239</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ac8327b23a4313b04a011b58ea1d2d_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEwLTMtMS0xLTcxMzMw_cdbf300e-76b4-4fcb-9e3d-c0aba953d687">1,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49a36c48450a4259b629f674ef5433a0_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzExLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MmIwZjVhYmM0MDk3NDY3ODk5NzM1NjZlMmNlMzI0NDVfNA_6574fc48-c2f9-41b2-a1ab-cc2cd4071b95">1.45</ix:nonFraction>% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a36c48450a4259b629f674ef5433a0_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzExLTEtMS0xLTcxMzMw_847b275f-1b9c-4158-b830-6ba7b0c27558">1,237</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff19b2f06b94d72a4c24b4eea59c7d6_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzExLTMtMS0xLTcxMzMw_caa04319-10d9-435e-ba33-d6f28f9de552">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11f4a58945df459196d4289980f7f9f6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246OTQ4YTQyNzhjYzZjNGUzYWI5YjNjN2M4OWFlM2MxMmVfNA_7d1bb9b4-2817-44e0-a761-35f1136cbf58">2.45</ix:nonFraction>% notes due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f4a58945df459196d4289980f7f9f6_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEyLTEtMS0xLTcxMzMw_4e38608c-4c8c-4087-8c9e-dbd28a229219">1,213</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0bcb5b5a434f51bab2f5d76da43e3e_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEyLTMtMS0xLTcxMzMw_75aa32de-cb65-45c7-810e-789530859cee">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2a8b5ffe89f474aaa717071531eb373_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MTJhYjk2MDk0ZjA1NGUxZDllYTg2OGRkYzJiOTk2OGJfNA_92794d72-172d-4473-85ae-5863dde111dc">1.875</ix:nonFraction>% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a8b5ffe89f474aaa717071531eb373_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTEtMS0xLTcxMzMw_2b5da613-dab3-40b6-8bd2-94ae2f9cbc59">1,060</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298d3bf22286484c845cea75b0818c0a_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTMtMS0xLTcxMzMw_17d91df4-9ea0-4090-9ad9-b276fc0a0782">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77ca7a1f2cbc41178098a0d44729387d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTAtMS0xLTExNzU1MS90ZXh0cmVnaW9uOjVhNzM4NGZjMDhmYjRmN2VhZjQzYTgyOTI0OWQyODU1XzQ_0a65176a-8dc6-4fe7-8b2d-868f3d410e61">0.75</ix:nonFraction>% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ca7a1f2cbc41178098a0d44729387d_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTEtMS0xLTExNzU1MQ_a8a10c70-79b3-402d-9d76-a57b7cfbe39f">995</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400c4310ee744a12bbb7413c21f7cac2_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTMtMS0xLTExNzU1MQ_17536860-3ec3-408f-95eb-df91533ce6f4">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58e87abb2aae4b75ba3cbbada4ba4c18_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246YmEyNjJmZmE2ODYyNDU3MDg4Y2M1MWU2NDc0NDdjN2NfNA_44b613a7-10d5-42e1-91f1-b4e664c4abcc">1.90</ix:nonFraction>% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e87abb2aae4b75ba3cbbada4ba4c18_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE0LTEtMS0xLTcxMzMw_0ad60f1e-0298-4043-87cb-1d34446cd798">994</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5590941b574c9c837595f0aace5727_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE0LTMtMS0xLTcxMzMw_8b55a35e-3ec9-4918-b5cd-a6da191a7bde">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f7aac49ddf54d1c84c0298cedae4e0d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246Mzk0Mzc0NzBkMGZlNDIwM2ExYmMzYTE2MThiYjFhMWJfNA_a549fda5-468f-45e5-9145-b014a69a1d15">3.90</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f7aac49ddf54d1c84c0298cedae4e0d_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE2LTEtMS0xLTcxMzMw_a07d99d8-9202-4f7a-bd38-6cfe1163b9ad">985</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bfb5c52b3d044d7b880a56872ae93e0_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE2LTMtMS0xLTcxMzMw_7c52ab4f-6c6a-43c1-8762-31fdad7f5399">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i224209bee44647d1890dfbfe59b6f186_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDA1YzYwYzNkNjM4NDQ1Y2JkZGE1YjMyMjBmOGQyYTJfNA_41877166-afc3-4b8c-b815-4bd66f47897e">2.35</ix:nonFraction>% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224209bee44647d1890dfbfe59b6f186_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE3LTEtMS0xLTcxMzMw_023c48af-0ffd-4bc5-823a-7c0f0863dfc3">984</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa89611a5164af6b8cccaea01b34c43_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE3LTMtMS0xLTcxMzMw_fb2e50cc-f324-4d9f-ac20-b0722878dff8">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd075f7f4f1d41c190d492328b684c9b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE4LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NTdjOTdhNTBjYWJjNGZmZWEzNjdmY2RjZGViNGU4YTdfNA_d94d6ee9-24a2-4122-ab3f-c32fd4640732">2.90</ix:nonFraction>% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd075f7f4f1d41c190d492328b684c9b_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE4LTEtMS0xLTcxMzMw_04078aa5-29de-48b6-8ae0-dc9cae472fcd">749</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f2e241750c47b19940f1f7920f4c9d_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE4LTMtMS0xLTcxMzMw_24014270-da14-4f90-9a9c-8e69b913ef32">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i620b959fd9e146b0bd7d17c8f78e14de_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE5LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NmViOWFjNjVkNDY3NGQxZWExZGI4ZmUwZGZlMWZiNTRfNA_6fff636e-c6af-4660-a69e-77eab11d5173">6.50</ix:nonFraction>% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620b959fd9e146b0bd7d17c8f78e14de_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE5LTEtMS0xLTcxMzMw_d2d60b81-a517-4ecb-a44c-028d740730f0">711</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6eac77276524db589b7a8df253bdb8f_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE5LTMtMS0xLTcxMzMw_bfb0c23f-8acc-4ea3-9dcf-a7d99654fc74">715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97601a3d96de4a38be031a08c94ba40b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIwLTAtMS0xLTcxMzMwL3RleHRyZWdpb246ODUxODdkOGQzZjllNDQzZmIxN2VjYjkwNDNhMGIxMmJfNA_a6602f32-ed50-4ca1-ab69-26e6c4bfbb01">0.50</ix:nonFraction>% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97601a3d96de4a38be031a08c94ba40b_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIwLTEtMS0xLTcxMzMw_eea3070a-55c3-41a7-969d-cfd3fb065867">531</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24293f6fd55415d9560fd27185731e7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIwLTMtMS0xLTcxMzMw_36e7f894-3c74-4699-8c03-442c3e545cb2">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie629738e7a1a43b4844c99c144e93473_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIxLTAtMS0xLTcxMzMwL3RleHRyZWdpb246OTRjOWY0ZmFhZDA5NGRlZjllMmMyYzkwN2Q2OWNlYmFfNA_2a6a5294-8a64-435d-9bce-6da11ec3928b">1.375</ix:nonFraction>% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie629738e7a1a43b4844c99c144e93473_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIxLTEtMS0xLTcxMzMw_82e14e09-8982-42bd-952f-0a16daa034db">527</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83a7f94ec0b4f15a760d11fa20711ed_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIxLTMtMS0xLTcxMzMw_35aa582b-b1dc-48aa-8f6c-7d1eda5bfa78">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82da477c35664e5e9a498ca0e106941a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246NjM0YTU1ZTM0Mzk0NGZmN2FmYzJkZjZhOTllMzMzYmZfNA_07b8e0cc-02cf-47be-9f02-f3e223971dac">2.50</ix:nonFraction>% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82da477c35664e5e9a498ca0e106941a_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIyLTEtMS0xLTcxMzMw_574f8ebe-f240-4c53-a01c-be5a3e19f245">526</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb2ca9915d3447a9524c55e37e9fef7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIyLTMtMS0xLTcxMzMw_56a97e51-f30d-477a-88b8-d86d8500fab1">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c0f5eccf7f542f78f0a069e1e0441a0_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIzLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MWU4MDBmNmMwNDFmNGM5NGFlMzdjOWZlMzM5NTk3ODFfNA_75cd355b-620d-4a54-83e1-ea72952c1cf1">3.60</ix:nonFraction>% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c0f5eccf7f542f78f0a069e1e0441a0_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIzLTEtMS0xLTcxMzMw_eb2ac65a-1b68-4f79-a4ff-3b782a602653">492</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ba76bbfef44f90b331caf152aedf4f_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIzLTMtMS0xLTcxMzMw_6ee21873-e4cb-4f23-8e2a-fdbacabccdfa">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92331b59f2ca4a2cb806ae55ee55125f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MGNiZmMyZWQ5MWUzNDE3NmI1NzU1MDJkMzY1MjhjZThfNA_86cb5562-13f2-4b59-8d67-23bfa3824da3">6.55</ix:nonFraction>% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92331b59f2ca4a2cb806ae55ee55125f_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI0LTEtMS0xLTcxMzMw_5e68cf6a-ca1c-4efc-b884-aade243c7872">408</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c58e35b90f44c7b85f122be398e01b_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI0LTMtMS0xLTcxMzMw_a32c8ccf-0376-4c25-98ec-23f8a78ada24">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d334e27c8974586a1e136fdef62aea3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI1LTAtMS0xLTcxMzMwL3RleHRyZWdpb246ZDgzZWI5ZGNmY2UwNDlkNjkzMGNkMzk2ZTFiY2U4ZGRfNA_1551e53a-9270-4b7a-b939-8d9b0e7a4d19">5.75</ix:nonFraction>% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d334e27c8974586a1e136fdef62aea3_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI1LTEtMS0xLTcxMzMw_dbe86c36-f239-4192-b99b-39924507a7db">339</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icded3aad9e2b4fa5bcc6bbe73f7bd27d_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI1LTMtMS0xLTcxMzMw_acd99ac6-124d-447d-a760-cf412c933abf">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c09fe213ba245e79cdc9b37441d663c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246ZTI3ODY1NGU3NDQwNDNjNzk2MDQ0OTNmNGUwZmI0NGNfNA_2d1ad4e4-bf07-451d-b3f0-8bec62464575">5.95</ix:nonFraction>% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c09fe213ba245e79cdc9b37441d663c_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI2LTEtMS0xLTcxMzMw_6bf70f50-4dda-49d7-ad2b-eb57cb20ee4e">307</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bccfb63cc84447d9f2fdc7082467dbf_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI2LTMtMS0xLTcxMzMw_5472d6b7-8bf1-4cd3-af9c-ef206a7afd2e">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45478d0ad35e4c2d8be4c0a65f047423_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246YjIyMjE1NjM4ZGRlNDFiMWFiMzVhNjE2YTljZDExMDBfNA_a8859656-ad5b-4201-bac9-cae9e6c80a0d">5.85</ix:nonFraction>% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45478d0ad35e4c2d8be4c0a65f047423_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI3LTEtMS0xLTcxMzMw_48c0ddab-5722-4199-b6e9-c4a826a8876f">271</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f8a178ed8f450eabe1b16459124dcf_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI3LTMtMS0xLTcxMzMw_be7737bd-ce4d-43a7-8131-ee3010c34e2b">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8dfca1e518a440e79e02408f4fe0efb6_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI4LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MWQyYTI4OGU2ZWVkNGU5ZWE4NWJiNTJiZWMzOGI4OGJfNA_dfa5210c-9a12-48f4-a695-6a344f7d0cdb">6.40</ix:nonFraction>% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfca1e518a440e79e02408f4fe0efb6_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI4LTEtMS0xLTcxMzMw_d98467c7-b326-4269-bc56-5477c238f917">250</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8f6b68af8b9428d91b0377f34290f43_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI4LTMtMS0xLTcxMzMw_002ba80d-64c3-4a4a-bb86-3b01007a48ca">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3af20c7a3814238b67e841a07acf4cf_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI5LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzM4M2IyOWVmZjhmNDIwZDhlYWNiNTg0YjU2YTEwYTVfNA_e7074fb4-9da1-4948-a452-909677437ab6">6.30</ix:nonFraction>% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3af20c7a3814238b67e841a07acf4cf_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI5LTEtMS0xLTcxMzMw_b1dad3d0-df70-4dee-a9f5-a2e8105dc2c6">135</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a75657caa24185aa254c6f8bac7779_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI5LTMtMS0xLTcxMzMw_31611d9b-b85a-40f7-8766-c3ec45060f88">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91242e71ad3045608d2523c26d489ee5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMwLTAtMS0xLTg0MjY2L3RleHRyZWdpb246YWJiNjYzMTA0OTk4NDRiYzg5MDRkNDU4NThkZTJmYTNfNA_d3081c1e-9e08-4598-b05d-f6e45138104e">2.80</ix:nonFraction>% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91242e71ad3045608d2523c26d489ee5_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMwLTEtMS0xLTg0MjY2_b7de78d3-57c8-4b15-89f4-e57228f61e8a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1e9b9048084ef786463cd80bb97477_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMwLTMtMS0xLTg0MjY2_09b6813f-effd-4ff7-8afb-a99c2e653c71">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5179a79bc0fb422a93c77860d39e3e5c_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMyLTEtMS0xLTcxMzMw_7d522791-b659-47eb-a245-0222bcd18fa5">167</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4ff66345424bd1af13776a97cc3571_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMyLTMtMS0xLTcxMzMw_7e0c68e8-0d6e-4dc2-af4e-86f30c1225ab">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMzLTEtMS0xLTcxMzMw_e33046c2-a3c8-4263-9136-6856a66f0f1b">28,745</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMzLTMtMS0xLTcxMzMw_3924ca31-beb4-4568-a8ff-1e1b17fed912">30,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of <ix:nonFraction unitRef="number" contextRef="i18dfd3b19f344509849614fd0c8c7ae6_I20221231" decimals="5" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzY4OQ_b9127c79-fea8-4087-af61-a56b36d3292d">1.40</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i047a9aa409af47a39aec099d05eb850f_I20211231" decimals="4" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzY5Ng_2cadef57-82f6-4f94-99bf-9f1ed66411ec">zero</ix:nonFraction> for 2022 and 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With the exception of the <ix:nonFraction unitRef="number" contextRef="if3af20c7a3814238b67e841a07acf4cf_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0Xzc1NQ_1fe74492-5a45-4c00-b4c2-d78c37ff3e32">6.30</ix:nonFraction>% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#8217;s option at any time, at varying redemption prices. Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s borrowings require that Merck comply with covenants and, at December&#160;31, 2022, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2023, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNTY_624c506c-4ccf-428f-9605-0eef3afa201e">1.7</ix:nonFraction> billion; 2024, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNjQ_a47b80c9-b05e-48f9-ba49-f765f0ab48f7">1.3</ix:nonFraction> billion; 2025, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNzI_2ae85acf-587e-4e2c-affd-89921ce5a688">2.5</ix:nonFraction> billion; 2026, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzODA_80933a22-5eab-4e08-bcf7-92d1122f100f">2.2</ix:nonFraction> billion; 2027, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzODg_1759c0f8-6d37-4b74-b38f-591aefcc1da7">1.5</ix:nonFraction> billion. Interest payments related to these debt obligations are as follows: 2023, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0NjQ_7cc6ee6a-311d-4ac6-8942-464add49d450">882</ix:nonFraction> million; 2024, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0NzI_d69c9b11-72cc-4875-b3a7-d8552b3c0602">845</ix:nonFraction> million; 2025, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0ODA_e0e2f468-9cae-4e82-8159-5c52968b64a7">778</ix:nonFraction> million; 2026, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0ODg_65d68940-2a26-4913-a372-f1339f3d3371">751</ix:nonFraction> million; 2027, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:LongTermDebtInterestPayableYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0OTY_73ee2751-671d-40a4-9456-42050ef3ef9e">720</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI1MTg_d70e979d-e364-436c-9e9b-43b31ec46105">6.0</ix:nonFraction> billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i53106584f1fd4c0e90688cc633829cf9" continuedAt="i58bf586059464b809fcba7b2ec9b7370"><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of <ix:nonNumeric contextRef="i31d717109e794d52a04995b9284f4213_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzM1MjM_bf47c9da-e8cb-461a-8c2b-19049c52e36b">seven years</ix:nonNumeric>, which include options to extend the leases for up to <ix:nonNumeric contextRef="i31d717109e794d52a04995b9284f4213_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzM1ODA_635f91bb-6132-4595-bd49-9846c3473043">four years</ix:nonNumeric> where applicable. Vehicle leases are generally in effect for <ix:nonNumeric contextRef="i3f477cad38324ad7a03c8f6e78a1056c_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzM2NDQ_acfc4736-5244-464c-9bf0-472f33a60f4b">four years</ix:nonNumeric>. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#8217;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost was $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU1MTk_fd0a1a4c-304b-4070-b309-9a3ecfe44d38">334</ix:nonFraction>&#160;million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU1Mjk_8019e1a6-e6ed-4069-a2c0-efb77453c765">343</ix:nonFraction>&#160;million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU1NDI_d52a2774-871d-40f9-a672-d488ca7b8a64">340</ix:nonFraction>&#160;million in 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU2Mzc_44680aca-f84c-4c61-baed-0391066f64cc">335</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU2NDc_34655c34-1025-47f8-8ebe-91224729a792">340</ix:nonFraction>&#160;million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU2NjA_d0ece100-732f-4ad2-948b-03795b53f7fc">334</ix:nonFraction>&#160;million in 2020. Operating lease assets obtained in exchange for lease obligations were $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU3NDE_e57210cf-60da-4643-bb74-31653f5a07e6">57</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU3NTE_6b1e5a05-19b4-437f-aa8f-8737e454ac48">117</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU3NjQ_a0e7cb84-27f8-4acb-bf70-dbb44640e810">473</ix:nonFraction> million in 2020. </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:AssetsandLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNDY_ecbe6d35-9de7-4efe-b9c6-3b473ba0f186" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMS0xLTEtNzEzMzA_2e678756-ded3-44eb-8a67-d5f34e905908">1,346</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMy0xLTEtNzEzMzA_5b7bd4b5-9872-4699-9753-6af28115f336">1,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMS0xLTEtNzEzMzA_cfa7409e-dfbe-4ff2-ac46-c7f7d129c9d4">281</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMy0xLTEtNzEzMzA_6f195d42-9dd4-4450-802a-bfbd608147ea">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMS0xLTEtNzEzMzA_68bec5df-ac44-40bd-9024-e257dda2cc95">1,013</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMy0xLTEtNzEzMzA_9d1d4aee-89de-4fdd-9231-c0bd02daa689">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzYtMS0xLTEtNzEzMzA_4de5df65-5da2-4146-a1f0-dfecf9e56fac">1,294</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzYtMy0xLTEtNzEzMzA_d5fc55b7-d3ed-4492-b005-25e794c18f9b">1,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzctMS0xLTEtNzEzMzA_32c13533-f673-41fd-b399-949ba4bbc185">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzctMy0xLTEtNzEzMzA_02c71627-0f98-4c06-b409-ab06a6d768c8">7.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzgtMS0xLTEtNzEzMzA_bc4156b3-aead-45fb-8b58-c311119a5385">3.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzgtMy0xLTEtNzEzMzA_ee32d3dd-3c40-4de8-8175-437c02ac6fc7">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i58bf586059464b809fcba7b2ec9b7370"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNTc_72fbca43-9220-4662-a77a-6965c6fc9dea" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzAtMS0xLTEtNzEzMzA_155868e6-12d5-4873-ae6b-5384669c6fb4">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzEtMS0xLTEtNzEzMzA_ce5e6ded-e155-4d55-8b43-c1287b532a16">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzItMS0xLTEtNzEzMzA_191500ce-cb47-410c-bcf7-915d606a89da">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzMtMS0xLTEtNzEzMzA_70a09504-ed48-4e08-bcd6-f57114364a6e">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzQtMS0xLTEtNzEzMzA_1d6cde87-87ff-4560-91e1-e40d71409d4b">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzUtMS0xLTEtNzEzMzA_cc293797-828d-4995-94e1-9b45db4cd858">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzYtMS0xLTEtNzEzMzA_1920fadd-9327-41d4-881d-0590aa973481">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzctMS0xLTEtNzEzMzA_ff4ebe90-ae36-448b-bf24-3849f1ac2083">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzgtMS0xLTEtNzEzMzA_f2d77c58-fd62-40b9-a819-0aaecf0cc302">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNDM_13784c16-6332-4833-bbd7-eeaa13a4d0ba">232</ix:nonFraction> million.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_178"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMzMTg3_0d4ea578-5892-4be6-a684-aee11f6b2ef5" continuedAt="i7b568d2222074cd0990af479556d64e0" escape="true">Contingencies and Environmental Liabilities </ix:nonNumeric></span></div><ix:continuation id="i7b568d2222074cd0990af479556d64e0" continuedAt="i3f45b65ae6cc48bda8621ce9ad29d1f1"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December&#160;31, 2022, approximately <ix:nonFraction unitRef="case" contextRef="icbd61b5e13024c6d821da5de889797bd_I20221231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzEwOTk1MTE2ODk0ODE_9f02ffbd-7ec0-4edf-b5f6-0e3f171da95e">70</ix:nonFraction> cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than <ix:nonFraction unitRef="case" contextRef="ie2746565f1354a23af85f4f99207c98b_I20221231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzEwOTk1MTE2ODk0ODU_1f8a3ead-72dc-4c98-81ca-b755b5d72305">15</ix:nonFraction> product liability cases pending outside the U.S., including <ix:nonFraction unitRef="case" contextRef="i894c84a8a53146d0996d343ee95c4d6e_I20221231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzEwOTk1MTE2ODk0OTM_d2753c35-f6e2-453a-93dd-b1fc98cb2e16">one</ix:nonFraction> purported class action in Colombia.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#8217;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i3f45b65ae6cc48bda8621ce9ad29d1f1" continuedAt="i29df62d694d44d9aafc01f0d5c83726b"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#8217;s information request by seeking information relating to Merck&#8217;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#8217;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#8217;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#8217;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#8217;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#8217;s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company&#8217;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of <ix:nonFraction unitRef="claim" contextRef="i2b1982ad1e3245b8821c7a9045cfbf7f_I20200831" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3MjI_5cde3972-b069-443b-9f46-5c4947d89813">35</ix:nonFraction> direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#8217; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i29df62d694d44d9aafc01f0d5c83726b" continuedAt="ia86c3909cae043dbb04f9873f6abd44a"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other Zetia MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, <ix:nonFraction unitRef="claim" contextRef="ib81588e6e7c24f96af260cda2030da9b_D20220630-20220630" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzM4NDgyOTA3NTg5OTA_b0a9e942-6e0a-4efb-b7e7-db79880e8679">23</ix:nonFraction> new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 10, 2023, the district court denied the Merck Defendants&#8217; and Glenmark defendants&#8217; motions for summary judgment. In the cases filed by direct purchaser plaintiffs, retailer plaintiffs, and indirect purchaser plaintiffs, plaintiffs seek up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="ic3d2016a9f564132a989caf8220b8a3d_D20220101-20221231" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzM4NDgyOTA3NzA1ODQ_6ee485f1-fbed-40c9-9d89-d55cc723cc84">12.7</ix:nonFraction>&#160;billion in damages after trebling. The court has scheduled trial for these plaintiffs (all plaintiffs other than the Insurer Plaintiffs) for April 17, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">340B Program Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck&#8217;s 340B Program integrity initiative. HRSA&#8217;s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA&#8217;s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck&#8217;s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company&#8217;s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit&#8217;s ruling in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharmaceuticals Corp. v. Johnson </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> United Therapeutics Corp. v. Johnson</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by <ix:nonFraction unitRef="plaintiff" contextRef="ic39a2a021f974911b1ac6fafab48dfb4_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzE4ODEy_dbcf58ec-fb92-4a33-b292-c18a3815e3ce">two</ix:nonFraction> former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The <ix:nonFraction unitRef="plaintiff" contextRef="ic39a2a021f974911b1ac6fafab48dfb4_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzE5MjY0_dbcf58ec-fb92-4a33-b292-c18a3815e3ce">two</ix:nonFraction> former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, <ix:nonFraction unitRef="case" contextRef="id7972a4598aa47ccbf40c79991ea05ad_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzE5Mzk1_5657ba60-64b9-4f01-9d9f-f903cfc8da3a">two</ix:nonFraction> putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#8217;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name &#8220;Merck&#8221; in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="ia86c3909cae043dbb04f9873f6abd44a" continuedAt="i5d99ffec5c0a48c3b17d2221b2d6587c"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties&#8217; coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a <ix:nonNumeric contextRef="i7a61ea22950f47828b95fed44e6413c2_D20221219-20221219" name="mrk:LossContingencyTrialPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3NTQ_1ce19472-2a54-4a12-a2a2-83227c294f3c">one-day</ix:nonNumeric> trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments on February 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has settled with <ix:nonFraction unitRef="case" contextRef="i706bfb75e173464c95cb81cf1f960b6b_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3Mzc_b6a2b854-c2ef-40ce-96ca-540c8ab2c4fd">five</ix:nonFraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against <ix:nonFraction unitRef="case" contextRef="i225a64a3f7814a45b055a29ef0ca80d6_I20221231" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3NDY_bd78aa22-24d7-4d49-acc4-4296e5216dfe">two</ix:nonFraction> generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCl), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i5d99ffec5c0a48c3b17d2221b2d6587c" continuedAt="if5d46bc626cc4708a88b4c8a7a5942f4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Court for the Northern District of West Virginia issued a decision in the Company&#8217;s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In total, the Company has settled with <ix:nonFraction unitRef="case" contextRef="i3b134a981f8749cfa64471811826b386_D20220101-20221231" decimals="0" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzI2NTk2_6076f529-5855-4436-9d3e-f54386603dde">22</ix:nonFraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company&#8217;s favor, upholding the USPTO&#8217;s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity toward the end of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in Europe, for which there will be an oral hearing on March 8, 2023. In first instance decisions, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPC has been found invalid in Germany and Romania, and has been upheld in Czech Republic and Sweden. Appeals are pending in Germany, Czech Republic and Sweden. The Company has filed for injunctive relief in Belgium, Czech Republic, Finland, France, Greece, Hungary, Ireland, Portugal, Switzerland and Slovakia. An </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> preliminary injunction was granted in Finland, which has been subsequently maintained in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter-partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> proceedings, Czech Republic and Switzerland, and an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter-partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> preliminary injunction has been granted in Ireland. A preliminary injunction was granted in France and the validity of the SPC and the associated patent were held to be </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">prima facie</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> valid. Preliminary injunctions have been refused in Portugal, Greece, Belgium and Hungary. In Belgium, the Company has filed a main infringement action against generic companies and a request for preliminary measures in that action has been refused.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="if5d46bc626cc4708a88b4c8a7a5942f4"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2022 and 2021 of approximately $<ix:nonFraction unitRef="usd" contextRef="i8fa23748b8b24ab09e6d4660601d9eb9_I20211231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzI5ODc5_194b3e4a-0204-4bb2-9575-aec039e4a3d7"><ix:nonFraction unitRef="usd" contextRef="i02fa96876a7745d29042dd0d714d3299_I20221231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzI5ODc5_7b1a648c-4ab7-444d-af47-e20e6edc61ef">230</ix:nonFraction></ix:nonFraction> million represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#8217;s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc4NjU_63f4c92f-06f1-4c0d-b1a3-1b23f298527b">liabilities</ix:nonNumeric> for all environmental matters that are probable and reasonably estimable have been accrued and totaled $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:AccrualForEnvironmentalLossContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyNDI1_1d4c4cca-2723-4b6c-aba1-d610fe5e5eb9">39</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:AccrualForEnvironmentalLossContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyNDMy_401e583c-fe78-440e-8d3f-16de0acb7609">40</ix:nonFraction> million at December&#160;31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:TermForPayingOffEnvironmentalLiabilities" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyNjg2_91d891fe-d49b-4d8a-8496-584c6c99a8c9">15</ix:nonNumeric>&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyOTc0_486c1f3b-d66a-45f9-8249-9de3e0857cdf">35</ix:nonFraction> million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_181"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1XzMzMQ_c3bc3a4f-e234-49eb-8160-4cb54038e792" continuedAt="ib7974fa4ea5745d2a960e61ec99da917" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="ib7974fa4ea5745d2a960e61ec99da917"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1XzY5_75b3b34b-433a-4cc3-b579-2d4d63af5575">6,500,000,000</ix:nonFraction>&#160;shares of common stock and <ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1Xzk5_6c939479-063c-4f84-816a-9e862f14e0a1">20,000,000</ix:nonFraction>&#160;shares of preferred stock.</span></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capital Stock</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1XzMzNw_d1bc4147-fa3f-479c-ae66-00617db7f219" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItMS0xLTEtNzEzMzA_e11e080f-a086-4ec2-ba5d-824868123964">3,577</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i170384be3a654d119874ff6b7ed2eb92_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItMy0xLTEtNzEzMzA_6eb027e9-d0b8-4f09-b0de-33c6c273daec">1,049</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItNS0xLTEtNzEzMzA_1648b27b-b470-4f45-943c-6e28ace61ce5">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06a03badfaf044d5abe8434be9cfeda8_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItNy0xLTEtNzEzMzA_28368bbf-a139-4bca-b441-f90594e738d6">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i870984a7a0814cf9a460c7a4b331c37f_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItOS0xLTEtNzEzMzA_76745deb-52c6-40fe-8c9c-99f5844c149e">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3278c06a03cc4b83ad0c695bac71a99b_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItMTEtMS0xLTcxMzMw_d12f3f9e-3adb-4222-94a8-0d7686cd8d9d">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i591ce0aef96f4308b1211d94ac08b222_D20220101-20221231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtMS0xLTEtNzEzMzA_0f802255-a8be-44e8-99c4-67b0863491e7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtMy0xLTEtNzEzMzA_941de4d3-a6bf-4e74-88f6-e6080daeccbf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac458cf9779e41db953d53fb8f7b2fb3_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtNS0xLTEtNzEzMzA_0cfeca5d-ae64-46e1-bbcc-948bc8d63527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtNy0xLTEtNzEzMzA_b9571697-1b26-473f-aa88-96b523383abc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i619a10076fc241c5bba81067acbe0104_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtOS0xLTEtNzEzMzA_6e3774c0-928f-42b2-875c-82b42a74ed73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtMTEtMS0xLTcxMzMw_e955a040-e951-4fe8-b8f1-ca81947d995f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i591ce0aef96f4308b1211d94ac08b222_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtMS0xLTEtNzEzMzA_a80cdd68-eed8-42cf-9893-9bae8ff9ecba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtMy0xLTEtNzEzMzA_0304a366-ead3-4c7b-91c6-cf515297a973">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac458cf9779e41db953d53fb8f7b2fb3_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtNS0xLTEtNzEzMzA_cac5650e-be6e-402b-afa7-da727fbc5192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtNy0xLTEtNzEzMzA_3e2ab652-9f3a-47eb-96ab-e9c2f0900d7a">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i619a10076fc241c5bba81067acbe0104_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtOS0xLTEtNzEzMzA_991c771f-389a-456b-ad61-a5a3e5c54f38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtMTEtMS0xLTcxMzMw_e2fe839d-0d05-4548-bac7-888a1e65c744">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i326e10191d3348dd83075e847b9e3840_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtMS0xLTEtNzEzMzA_5fdae441-c930-450f-af0b-d7755454f0c8">3,577</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if945586aba2d4519bdf8f10667672306_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtMy0xLTEtNzEzMzA_7e89c224-9624-4bf2-a15f-a6f7e1adf183">1,039</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtNS0xLTEtNzEzMzA_6296af43-9514-46af-b659-344c797cb0cd">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i170384be3a654d119874ff6b7ed2eb92_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtNy0xLTEtNzEzMzA_e0c841f9-38cd-4f5f-865e-d5e8a9b116ce">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtOS0xLTEtNzEzMzA_9115d0e9-5b3c-40b7-a4be-00024e667226">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06a03badfaf044d5abe8434be9cfeda8_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtMTEtMS0xLTcxMzMw_65657038-5e84-4209-b174-dafbf20a9f44">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div></ix:nonNumeric></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_184"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMjM_f52cae6c-6d8d-411c-a855-72826296b8b1" continuedAt="i51e45204e0284b43bf9ef1760e5b5125" escape="true">Share-Based Compensation Plans</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i51e45204e0284b43bf9ef1760e5b5125" continuedAt="ic4775328923448f89480e223429829c8">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees </ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="ic4775328923448f89480e223429829c8" continuedAt="iabc7a1bb21364402ae45dbc9cc310c2e"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#8217;s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzQ1Mg_27d05d9f-e19c-434c-85cc-185c5b5fdf02">87</ix:nonFraction> million shares collectively were authorized for future grants under the Company&#8217;s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwODQ_9e0bc1fb-f16c-46d6-92e2-f1b19f5731fe">three-year</ix:nonNumeric> period, with a contractual term of <ix:nonNumeric contextRef="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzgyNA_15b68497-b833-46db-99fc-71dbccef2c27">7</ix:nonNumeric>-<ix:nonNumeric contextRef="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzgyNw_b758c9aa-2583-4cf8-a41f-62d4f0fb40d9">10</ix:nonNumeric>&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#8217;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#8217;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#8217;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMDk_a50eec56-4780-425d-abf3-1b52be40053e">three years</ix:nonNumeric>. RSU awards generally vest one-third each year over a <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMTA_c18399d4-da25-448f-b780-c78808bd8d71">three-year</ix:nonNumeric> period.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzEwOTk1MTE2MzUwNDE_11474f9d-7d52-4934-bc4f-aaeec4c09665">541</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIwODA_1b09a12c-fefd-4bc9-b0f2-e5055bb89de2">498</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIwODc_c4c3872b-1e7a-4759-9682-1641660f9424">475</ix:nonFraction>&#160;million, respectively. The amounts in 2021 and 2020 include $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIxMTk_3a4a606f-05d9-4851-bed3-b169b31dd9d2">479</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIxMjY_b89d799f-e424-4f18-a4d0-693f6e643cdf">441</ix:nonFraction> million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIyNjg_9ac8fc3c-0e1f-4112-b3c7-728a1f979f60">78</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIyNzI_cc4d0ff0-269b-44c6-9151-f08d9d8c7f5e">69</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIyNzk_c09db61e-1bb0-48c3-be4a-33f3c36618dc">65</ix:nonFraction> million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#8217;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzMzODc_40c6de3a-0b0c-4a13-ba79-8b0b35c0216a">87.10</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzMzOTE_feb84944-5beb-499e-b4d4-e3c88d24ce94">75.99</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzMzOTg_d2649ba4-fa06-49c6-b7c7-4bb25ca0f3f0">77.67</ix:nonFraction> per option, respectively. <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwODY_631eb90a-ba2f-4ba5-8ea7-fa10b75cb7ae" continuedAt="ia4ad89e34a3345988150b18714567970" escape="true">The weighted average fair value of options granted in 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzM0OTk_ded7bb7e-9148-4c26-b0b2-805b099cff5c">15.45</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzM1MDM_29cf4a3b-65e1-441d-b011-5872d830de9e">9.80</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzM1MTA_33d0e732-af7a-45c2-8953-8116d73c53a3">9.93</ix:nonFraction> per option, respectively, and were determined using the following assumptions:</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><ix:continuation id="ia4ad89e34a3345988150b18714567970"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzEtMS0xLTEtNzEzMzA_e96bde16-00d8-4e02-9935-5b9d8c9df96f">3.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzEtMy0xLTEtNzEzMzA_33a77a4b-82c4-4053-8cd5-cf068f762374">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzEtNS0xLTEtNzEzMzA_a0e2a53d-c495-47dc-af40-9d6af709aed5">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzItMS0xLTEtNzEzMzA_5000f161-8972-4015-b081-85ad7a2b7673">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzItMy0xLTEtNzEzMzA_3aa1d18b-933d-4c48-9a45-e60ecb9448e3">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzItNS0xLTEtNzEzMzA_d754fc9a-e9de-4ea9-ae3a-937e0cfab25a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzMtMS0xLTEtNzEzMzA_d57fe01a-4397-4b7c-a7d0-d83d139afa43">22.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzMtMy0xLTEtNzEzMzA_2727d3ee-28f5-42cd-b186-42c401635cad">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzMtNS0xLTEtNzEzMzA_21acc4d6-310b-45db-8130-de0e68b9851b">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzQtMS0xLTEtNzEzMzA_a17c150a-d959-4b29-9605-24351b6b7545">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzQtMy0xLTEtNzEzMzA_0a9ebe4b-8cc9-4c28-961f-234e36c23de5">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzQtNS0xLTEtNzEzMzA_f251f31a-53f9-4142-bd95-44693f812856">5.8</ix:nonNumeric></span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMDU_2666522a-c988-4ec4-a03b-ace4351d1efa" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzEtMS0xLTEtNzEzMzA_793dd456-be58-450d-a736-16b40606f8de">18,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzEtMy0xLTEtNzEzMzA_a31fcb3b-77d9-4cf6-bd7b-bd23bc615764">65.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzItMS0xLTEtNzEzMzA_70038516-08a8-4dca-9e9e-73004fc46a06">2,326</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzItMy0xLTEtNzEzMzA_965ef1ae-6968-4100-b220-2e46b8a96e70">87.10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzMtMS0xLTEtNzEzMzA_9bf47b74-9d15-46d8-aecf-404992fe64ed">6,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzMtMy0xLTEtNzEzMzA_ec7b45ca-310d-41ea-b406-0b4b93714635">60.77</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzQtMS0xLTEtNzEzMzA_d5499a1a-e6dc-4874-953a-d7f60df02c26">862</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzQtMy0xLTEtNzEzMzA_58beffdc-0ee2-4553-9f21-4ac11176caef">73.11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctMS0xLTEtNzEzMzA_f89635bf-041f-4c32-beda-f5aaeaf9c3f6">13,719</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctMy0xLTEtNzEzMzA_e4ce61b5-3a3f-4480-9b8a-0221507b8e0c">70.55</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctNS0xLTEtNzEzMzA_91f73d66-f160-40dc-8d47-c0c2b4e99151">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctNy0xLTEtNzEzMzA_d38012c7-9f0a-4748-b4b8-d7ccee90ccfe">554</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtMS0xLTEtNzEzMzA_bd6c7830-ad03-473a-8d7c-1ddc663bd8da">13,199</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtMy0xLTEtNzEzMzA_eb81a693-a754-4062-8b45-d011db54aa67">70.09</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtNS0xLTEtNzEzMzA_284bc489-2de0-4983-bd1d-4fb087eae603">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtNy0xLTEtNzEzMzA_6db9fc09-9905-42f2-8e3b-6c4cc36ef859">539</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktMS0xLTEtNzEzMzA_fe518bba-31db-4581-a09e-dd6e5b0b7330">8,730</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktMy0xLTEtNzEzMzA_c60c4735-e16e-4e01-ba9c-74590f3d87a2">65.24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktNS0xLTEtNzEzMzA_1df8aa50-f6a7-4bb3-9449-ba270e8efcb9">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktNy0xLTEtNzEzMzA_a7b01bd2-a971-4934-85c6-543af2365674">399</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="iabc7a1bb21364402ae45dbc9cc310c2e"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwODk_aa81b7de-0146-4f1c-baca-386ec5b87115" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzEtMS0xLTEtNzEzMzA_cbf7aa4a-5d42-4adb-a03a-8a8797b3b3f8">225</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzEtMy0xLTEtNzEzMzA_e7d4d1d3-ff70-4cf3-86c2-91114861dc81">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzEtNS0xLTEtNzEzMzA_b7d2fb38-2d24-40e5-b447-d94c9117ddcc">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzItMS0xLTEtNzEzMzA_5282a629-f1f8-4efe-b1ee-edb20debd0ea">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzItMy0xLTEtNzEzMzA_23398896-66bb-47f9-8190-71ecf0127534">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzItNS0xLTEtNzEzMzA_37fb3617-c5b6-4709-875b-0c5f97f34451">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzMtMS0xLTEtNzEzMzA_1dd1578f-35d0-4d2c-b63f-200325be05a0">384</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzMtMy0xLTEtNzEzMzA_e94ed1e8-ef95-4eff-857b-022a5aba5e9c">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzMtNS0xLTEtNzEzMzA_18df39cc-0141-4759-ad1c-4b900c466a40">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwOTA_28663f6d-724b-41bb-9b54-87e17723f008" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonvested January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied7d80ed2ab14e968047a6b71fb4fea8_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItMi0xLTEtNzEzMzA_af3e041f-1338-45b2-8fc6-5c097bd895cc">11,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied7d80ed2ab14e968047a6b71fb4fea8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItNC0xLTEtNzEzMzA_2d5cf224-11e5-4316-9261-3bc4edfc6c66">74.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if85a36eaa81c4367aeafea1a95984d7c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItNi0xLTEtNzEzMzA_41bf4976-ddab-4d11-a5f2-939439e972cb">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if85a36eaa81c4367aeafea1a95984d7c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItOC0xLTEtNzEzMzA_b00c799e-2385-4405-94e2-52c6a54ce062">77.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtMi0xLTEtNzEzMzA_1e009671-494e-40a9-aa8b-5deaa74d3ac6">7,170</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtNC0xLTEtNzEzMzA_fb2b9b96-42c1-4880-a3f8-4e526da92d63">87.12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtNi0xLTEtNzEzMzA_d2890675-7d58-469a-ae74-90a13611d2cc">951</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtOC0xLTEtNzEzMzA_3591c04f-79cf-4b8a-85b5-49786bcc7fdd">88.52</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtMi0xLTEtNzEzMzA_8da7925d-d1c4-40ab-ac98-3bec7d731d98">5,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtNC0xLTEtNzEzMzA_deb49693-2f64-4c3e-a3a0-1f865133941b">75.40</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtNi0xLTEtNzEzMzA_a736fe22-833c-4888-a242-a0fca3f9953b">725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtOC0xLTEtNzEzMzA_e0a8afde-fb7a-464d-b0ec-be314a11d030">87.87</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtMi0xLTEtNzEzMzA_f50b4868-ed78-43f7-ba80-017b01c61911">1,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtNC0xLTEtNzEzMzA_ccbfae23-d1a0-4ad5-b435-4a23706a1c24">78.65</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtNi0xLTEtNzEzMzA_9fba08eb-7a80-42eb-9efe-15915d471156">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtOC0xLTEtNzEzMzA_2882a042-a3dc-4a12-8827-ca6d37bd7405">77.58</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nonvested December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtMi0xLTEtNzEzMzA_df12cf21-d884-4444-a146-a722c105ae10">12,700</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtNC0xLTEtNzEzMzA_95e580c5-552d-49c3-903e-9538d220688d">81.25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtNi0xLTEtNzEzMzA_2c921a98-fb95-4442-b657-be092812c470">2,021</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtOC0xLTEtNzEzMzA_9b5e9384-2330-4eb7-9e87-7e36ddedbf29">78.60</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected to vest December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktMi0xLTEtNzEzMzA_e62e86b9-ad26-4b35-af9b-86a44ec38acc">11,254</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktNC0xLTEtNzEzMzA_03a75c40-bdf0-4dab-997b-6ece74cf5b92">80.96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231" decimals="-3" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktNi0xLTEtNzEzMzA_56775421-abf7-4c27-8c9e-804b43fc59d0">1,895</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231" decimals="2" name="mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktOC0xLTEtNzEzMzA_e68609f8-873d-4e35-b659-a3cda59ac0e9">78.26</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzQ4MjE_f3819b0f-ee4a-40bf-87f0-47764c2741f8">813</ix:nonFraction> million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzQ5ODg_e599ccf9-c4e3-4319-b4e1-371fddcc903e">1.9</ix:nonNumeric> years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_190"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzk0MTA_91f5b8d3-d4ad-4972-ba5c-5d649813cec6" continuedAt="id7e26aa9f24b4e8fbac5f65021649e2a" escape="true">Pension and Other Postretirement Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="id7e26aa9f24b4e8fbac5f65021649e2a" continuedAt="i20b0da27bca04509ab9a43bbd9f3869a"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Periodic Benefit Cost</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNjI_1fa5578b-528e-43d8-84d3-7b7ad0268586" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:27.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMS0xLTEtNzEzMzA_2be52c05-07ef-4d14-8aa0-0c3df83bd460">372</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMy0xLTEtNzEzMzA_77941cb8-e5cf-47bb-8560-fff0ebdc5d61">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtNS0xLTEtNzEzMzA_a0af8945-fdfa-41a8-888c-c26d13891e66">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtNy0xLTEtNzEzMzA_921890dd-5811-4df2-bc86-6739ca75f14f">283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtOS0xLTEtNzEzMzA_f55dce62-bf95-4292-b846-0cd88994187b">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTEtMS0xLTcxMzMw_fddb3fdb-74cb-4ec4-9df5-6ad15e858290">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTMtMS0xLTcxMzMw_b17993b2-a4f9-4643-b23a-004f6101250c">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTUtMS0xLTcxMzMw_acb5c3ec-97f0-4c96-aefe-abf95adf35c6">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTctMS0xLTcxMzMw_0576b0b5-4a52-41f6-9000-f09b92f7cf56">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMS0xLTEtNzEzMzA_02c633aa-e079-4a68-b906-757ad23b2069">457</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMy0xLTEtNzEzMzA_c68eb6ee-5849-4f60-9b29-58fdd82af6db">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtNS0xLTEtNzEzMzA_4edba5fc-5e53-46cf-b897-e6ac25b5f805">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtNy0xLTEtNzEzMzA_fd6dc5bf-d9d5-45fd-ab28-4e12c4312d1a">145</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtOS0xLTEtNzEzMzA_22346e5c-2862-40b3-b19a-7339f61b549f">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTEtMS0xLTcxMzMw_ca4216d6-c276-4cb3-a5aa-067e26b574ec">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTMtMS0xLTcxMzMw_5f67eb89-0ef8-4d59-94c3-b889696ab062">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTUtMS0xLTcxMzMw_c44e4753-3a54-4f66-a6c6-a23cc348173a">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTctMS0xLTcxMzMw_90d4ef4d-e3db-4bb0-931a-881fb840197b">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMS0xLTEtNzEzMzA_34ca24c5-1d17-49df-83fd-605e5da74d34">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMy0xLTEtNzEzMzA_1b8aef5b-3a88-49da-b1bb-bc5f3c5d6962">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtNS0xLTEtNzEzMzA_c0e57edc-8782-489e-9123-bc5c62101ad6">774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtNy0xLTEtNzEzMzA_80e11aab-0ae6-4a42-aaa7-3852b5681953">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtOS0xLTEtNzEzMzA_31633eb2-ce0b-4c49-b9f9-ad861d08afbf">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTEtMS0xLTcxMzMw_f478cb27-1bfd-45ec-800b-d6a72e3bc4d1">414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTMtMS0xLTcxMzMw_8fb236b8-c1c5-4a90-955f-e6c9531edfed">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTUtMS0xLTcxMzMw_9aa8b645-53c7-436e-b495-553030450219">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTctMS0xLTcxMzMw_d357d8c1-6860-41f2-9598-9fed8676f327">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMS0xLTEtNzEzMzA_a477c02b-4eb6-46ad-b978-5513c53609dd">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMy0xLTEtNzEzMzA_15129830-89c1-474b-b0c8-b366c169c18d">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtNS0xLTEtNzEzMzA_2f9d638b-34ac-449d-b3a9-ad3b533f094a">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtNy0xLTEtNzEzMzA_0e0fa606-769a-45b0-a3dd-d579a9c3f230">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtOS0xLTEtNzEzMzA_9f7f4411-bfb8-4ad9-a985-3bcc8c1874af">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTEtMS0xLTcxMzMw_5a1f5219-dc76-406a-8d39-5dfbd4602c30">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTMtMS0xLTcxMzMw_979214d5-e21f-4146-b3b1-db6d67c029dd">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTUtMS0xLTcxMzMw_b4042ad5-808a-4f17-93be-da6066ae1a5a">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTctMS0xLTcxMzMw_bdd8165c-8012-4437-b565-0ce26ebc7dac">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMS0xLTEtNzEzMzA_d26c777d-d45e-4fac-a057-b85a116f94b7">128</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMy0xLTEtNzEzMzA_62808269-fe11-4850-9adc-6040e942bb3f">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctNS0xLTEtNzEzMzA_2d51042a-3fc2-41d5-9650-6f9c9797fd83">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctNy0xLTEtNzEzMzA_75bb3f35-404e-4fbd-9fac-c5a07477a435">96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctOS0xLTEtNzEzMzA_cdd85c21-249e-4a7f-8f00-39a3f31ae7bc">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTEtMS0xLTcxMzMw_79ff4027-b853-4308-b494-5241c4e538c1">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTMtMS0xLTcxMzMw_2a2b49f6-bc1f-4080-9dc9-2b28b540ce06">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTUtMS0xLTcxMzMw_7b0fd182-64d3-4137-851e-763398a3640d">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTctMS0xLTcxMzMw_b51dfd16-f945-4978-ab60-979e09623a68">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMS0xLTEtNzEzMzA_71e2b92c-10e1-489f-aaf3-438f671d0c33">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMy0xLTEtNzEzMzA_6e4f3906-1e51-4e98-b15c-e9aec547d483">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtNS0xLTEtNzEzMzA_bea5a9a1-16e9-4d72-9803-2920b2bd9faa">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtNy0xLTEtNzEzMzA_b98c366c-a857-4839-9d19-fba1cb19caea">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtOS0xLTEtNzEzMzA_466ff940-ddf9-4dac-ba06-b7cf509e9aab">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTEtMS0xLTcxMzMw_f78f9a74-ce2c-47bf-8315-9ffcfe9dbe0e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTMtMS0xLTcxMzMw_6b48ac4c-f03c-40a0-bcb4-04c9a8aabcc8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTUtMS0xLTcxMzMw_cf54d69d-a03c-45e3-b87e-a620f9e3a400">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTctMS0xLTcxMzMw_1ed5e225-2c1b-4f1d-a92f-f39329e06f9c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMS0xLTEtNzEzMzA_a81c61e7-495b-43db-8373-789889fe816e">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMy0xLTEtNzEzMzA_7b229305-b571-4665-bb43-334c49e00e86">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktNS0xLTEtNzEzMzA_66bccd26-29b8-4eda-92b9-a17580732568">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktNy0xLTEtNzEzMzA_91405f57-e53d-478a-b0f7-6f774ea19302">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktOS0xLTEtNzEzMzA_f9e0bb2a-4b13-4f6a-968b-e03e19c9b7e9">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTEtMS0xLTcxMzMw_8d31c4ed-9b22-441d-898d-b617f8555fd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTMtMS0xLTcxMzMw_3c4e2ebc-f5ee-4ba0-bf9f-3f9d845447d5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTUtMS0xLTcxMzMw_e3b4a4ee-537a-45d3-ac94-915a215669b9">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTctMS0xLTcxMzMw_91271b80-f21d-4584-b9da-b254b6b647b0">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTEtMS0xLTcxMzMw_c9adfcef-5b6f-4e52-8c29-65c072f6b42d">239</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTMtMS0xLTcxMzMw_a25c39a7-dcae-423a-86b2-ebebe46b0cbd">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTUtMS0xLTcxMzMw_8e472a46-a087-48c8-992c-a5614b10522f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTctMS0xLTcxMzMw_ad7a5875-b4f9-448d-8f10-a856c05ce480">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTktMS0xLTcxMzMw_6f9480a3-502b-4561-9a69-1654a88d5c7f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTExLTEtMS03MTMzMA_f0eb6b2f-bcb9-4757-81e3-eb3ec5c033ad">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTEzLTEtMS03MTMzMA_08a545c5-82bd-460c-8d6c-80ada50d4380">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTE1LTEtMS03MTMzMA_e167698e-8e95-4fe7-8485-8186ef9e2ccc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTE3LTEtMS03MTMzMA_238ca565-1bb7-4e41-a376-79502761c3a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTEtMS0xLTcxMzMw_b50dc571-9545-487e-ad93-bd2dc6a3d88c">425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTMtMS0xLTcxMzMw_b2dc2722-f84b-46c5-b13d-c52e10096f5f">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTUtMS0xLTcxMzMw_6d4ecc5c-0148-4c6a-be93-6197114b1e7d">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTctMS0xLTcxMzMw_1b7c1d29-8130-4e7e-91cb-9728cd9e819d">129</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTktMS0xLTcxMzMw_962f01d9-1879-4335-8ff6-f95e734560a2">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTExLTEtMS03MTMzMA_88688c76-62d6-4977-a163-0b46e067d590">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTEzLTEtMS03MTMzMA_dd3ba924-619f-46e2-925a-835b1b9897b2">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTE1LTEtMS03MTMzMA_195bbddf-4bff-4f00-b146-315bcc346318">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTE3LTEtMS03MTMzMA_84d1b144-7c44-4e09-8abb-99af19c78eb2">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;6), termination charges were recorded in 2022, 2021 and 2020 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2022 and 2021.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i20b0da27bca04509ab9a43bbd9f3869a" continuedAt="i1017f49a3484429e8c6c9f614a836926"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note&#160;15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obligations and Funded Status</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNDk_6be1fbdf-f6ee-4615-b7c8-6d81f918be17" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:43.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtMS0xLTEtNzEzMzA_9957a551-908c-4f8a-8616-377ca374a1aa">13,067</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cb6182a68904c0fa3a216d4c959472b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtMy0xLTEtNzEzMzA_45127265-af47-453c-a3e3-df71b21bffa7">12,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtNS0xLTEtNzEzMzA_e5bc78db-f4a4-482b-bfcf-b0ca0c8fdc9d">12,195</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtNy0xLTEtNzEzMzA_f70a29a2-88c2-423d-967a-81cb002dd816">12,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtOS0xLTEtNzEzMzA_ea8b5084-aef2-4683-8a32-b72c41caa022">1,292</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1539f9d21d0436d90ee19b2d83cb5bf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtMTEtMS0xLTcxMzMw_9435488e-cf71-4385-a55d-69093121afaf">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtMS0xLTEtNzEzMzA_2163fa9e-ff0a-451a-b00f-ee09119fd90b">3,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtMy0xLTEtNzEzMzA_cbd4fa89-96de-4a75-b6ad-f28860aecb15">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtNS0xLTEtNzEzMzA_78053e4f-e642-4625-b6b5-ec6b9f17cf58">2,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtNy0xLTEtNzEzMzA_9a522687-0b9c-46d8-b2b8-1bbc2b38cabf">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtOS0xLTEtNzEzMzA_fbafd2d0-af19-4d2d-8004-72b88cf40528">306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtMTEtMS0xLTcxMzMw_fa26d348-0244-4387-9cbe-21d32f1ef282">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtMS0xLTEtNzEzMzA_8411c0b5-acd1-4bb7-8b1a-65cc7fbb5add">293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtMy0xLTEtNzEzMzA_d6b7aa64-18e8-4cb5-be75-4903e157cd71">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtNS0xLTEtNzEzMzA_5e48b8ef-d823-4ce0-b4ca-b8c71304e838">155</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtNy0xLTEtNzEzMzA_54585e32-24c5-4e27-8d14-ceb6f674a3f0">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtOS0xLTEtNzEzMzA_55389831-fc9b-42e7-9b78-481d61c92c42">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtMTEtMS0xLTcxMzMw_bfe86202-9a7c-4ae5-8975-1e0c9bf24632">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtMS0xLTEtNzEzMzA_fab97af9-8772-4332-8781-dc6f13175a3b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtMy0xLTEtNzEzMzA_03fab23e-0583-48b9-8770-16549cb80afd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtNS0xLTEtNzEzMzA_893d00a5-88ae-4369-82c7-844c6613241e">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtNy0xLTEtNzEzMzA_7e594469-aaf1-4565-bcd3-5044d8e4e74e">671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtOS0xLTEtNzEzMzA_0ce28b5b-0bd3-49cd-8a66-006211b88854">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtMTEtMS0xLTcxMzMw_1bba62a2-df59-49d7-aaca-c6fce7d3753d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctMS0xLTEtNzEzMzA_4e8b87ea-710a-4a87-be65-c031a2db83c7">219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctMy0xLTEtNzEzMzA_2ecbfdc8-92b8-48af-8637-9b44bd5c66b4">219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctNS0xLTEtNzEzMzA_84c29e59-2eec-4517-b19e-346145bb87a0">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctNy0xLTEtNzEzMzA_dbb4e5c7-140b-4135-831a-651667e82873">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctOS0xLTEtNzEzMzA_3961136a-393c-48bd-9ebe-1fc38cc16790">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctMTEtMS0xLTcxMzMw_7052e4c1-6219-4433-ac33-a4de5b529eba">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtMS0xLTEtNzEzMzA_942b2c3d-bace-41cf-8d26-0f56d4030e48">918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtMy0xLTEtNzEzMzA_f4cbecde-c157-4ffa-b6db-31b62adcb9a9">941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtNS0xLTEtNzEzMzA_55c0cf4f-f948-4139-97aa-90cac28acd85">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtNy0xLTEtNzEzMzA_51b250b7-50e1-4f25-9158-b4dc1f0a713f">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtOS0xLTEtNzEzMzA_45bef811-3156-45ae-ab04-e8f0bb37930a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtMTEtMS0xLTcxMzMw_2b3d0367-3039-4839-92af-605218e6fdb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktMS0xLTEtNzEzMzA_e786ff96-9d65-440c-97d3-4bd61d976cde">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktMy0xLTEtNzEzMzA_2897498c-9abb-4db7-a400-884a8bd4fcf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktNS0xLTEtNzEzMzA_b8671166-aa98-4ce9-9bc7-081ab99049c9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktNy0xLTEtNzEzMzA_f58c3702-ec6c-446e-8949-82e8a8023abe">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktOS0xLTEtNzEzMzA_c99c500c-2af8-45d5-bcf5-90b6726862f7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktMTEtMS0xLTcxMzMw_7636ecd5-66d1-4785-a7fd-76615c7e5d58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTEtMS0xLTcxMzMw_8fb485b3-ef70-4600-a704-aa9969770b41">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTMtMS0xLTcxMzMw_432fe325-b03c-4c33-b282-b726ad737ca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTUtMS0xLTcxMzMw_20d282c5-321c-4d4d-9c1b-3b3d435f472d">30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTctMS0xLTcxMzMw_f25d536c-2942-43ab-a9cd-3113be68ba61">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTktMS0xLTcxMzMw_4b32c5e0-675b-4ddc-a164-e56cb5052a3c">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="mrk:DefinedBenefitPlanOtherChangesPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTExLTEtMS03MTMzMA_5f51c5ea-5399-435a-a791-09ffb6dddce7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTEtMS0xLTcxMzMw_7676cb40-4767-4ffd-a4c6-5ac6363665a3">9,094</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTMtMS0xLTcxMzMw_e2a7c87e-2e0a-419e-a922-2c1811cc6900">13,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTUtMS0xLTcxMzMw_3da60748-38b2-45fe-8a9c-c0556ae95fc4">8,473</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTctMS0xLTcxMzMw_090c75c9-7caa-456b-95a9-70e98d9ecf31">12,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTktMS0xLTcxMzMw_06e84b3c-c51a-45a0-aa9a-139c98e52bb1">947</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTExLTEtMS03MTMzMA_00262865-d24f-4b17-bfe2-1a220c258656">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTEtMS0xLTcxMzMw_be466ec3-4852-4aeb-b108-80c134a93613">13,999</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cb6182a68904c0fa3a216d4c959472b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTMtMS0xLTcxMzMw_6f3aa9a8-b85a-47a7-8184-726ca45f76bd">14,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTUtMS0xLTcxMzMw_44d65e06-0da8-4169-92f6-a43c06518530">11,575</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTctMS0xLTcxMzMw_938dc850-8d43-404f-a388-9e4359c2af25">12,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTktMS0xLTcxMzMw_0f522619-5f51-4846-9bc9-864d10ba5d5f">1,541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1539f9d21d0436d90ee19b2d83cb5bf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTExLTEtMS03MTMzMA_bb3e2303-1883-4a4a-9685-1409db6bac52">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTEtMS0xLTcxMzMw_b0eeeb16-f820-4f3c-9dc8-8a7843755d1b">372</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTMtMS0xLTcxMzMw_c1c0c224-1b07-4a33-960d-4e9046626b00">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTUtMS0xLTcxMzMw_e2d9ddb3-1573-4fa6-b5ad-898656bf9d53">283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTctMS0xLTcxMzMw_b55fb00f-d20c-40fa-ab4a-f299e583b656">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTktMS0xLTcxMzMw_d6c08c62-36de-4601-8d3a-7054f739bd98">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTExLTEtMS03MTMzMA_e53ab960-23e1-48a2-92b9-b4ab3e0075f4">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTEtMS0xLTcxMzMw_430f55df-b3f8-4f8e-bb2d-9278db777416">457</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTMtMS0xLTcxMzMw_a3348644-c8f7-4cfc-9b78-3d2b7af25973">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTUtMS0xLTcxMzMw_d158f123-9d99-4338-aef9-b34cbb5c8109">145</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTctMS0xLTcxMzMw_45de84df-935f-4db6-ad13-88ec258dd80b">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTktMS0xLTcxMzMw_ba873bf4-9075-4dbb-9430-1eda96f2eb12">46</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTExLTEtMS03MTMzMA_f32fab1b-e150-4b80-8276-5a9f46dd7dd3">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTEtMS0xLTcxMzMw_2da189b9-a810-48a0-aab3-e5b24fe5341d">3,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTMtMS0xLTcxMzMw_1b014fce-4c90-4c55-b280-999f228f708c">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTUtMS0xLTcxMzMw_29c91a60-d00c-4a3c-b1d2-8cbfa2c3e535">3,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTctMS0xLTcxMzMw_eed92ea1-4d55-4f81-92df-933c249f5028">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTktMS0xLTcxMzMw_3da90748-5330-45fd-a33c-426ce987f8b3">392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTExLTEtMS03MTMzMA_c72102ef-3962-41f5-bbd0-0fc8d29ee4c2">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTEtMS0xLTcxMzMw_3c15f740-8619-462f-846e-faa84f1349d3">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTMtMS0xLTcxMzMw_16abfcfb-d188-4a20-9e19-f972fef56388">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTUtMS0xLTcxMzMw_751e4ffa-0842-4f64-bbe8-5bf608046951">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTctMS0xLTcxMzMw_aee7b597-6be0-4d5d-aef8-81cdbc2cde10">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTktMS0xLTcxMzMw_6f67d07b-840a-4f94-b6f9-970962cee613">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTExLTEtMS03MTMzMA_168fe9b7-1dd0-4599-b902-50f78a2f2ed5">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTEtMS0xLTcxMzMw_c5bc5043-ffe0-4013-874c-50cc4372115a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTMtMS0xLTcxMzMw_2d1fd7ed-4e55-4440-bb77-0c700c31d4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTUtMS0xLTcxMzMw_0e49ab55-e2be-4e8e-a62e-96b56f53096a">732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTctMS0xLTcxMzMw_22b34944-e980-4e92-b69a-bc80ee9bde7a">678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTktMS0xLTcxMzMw_532c966f-2f8b-490d-9445-db7904c444e5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTExLTEtMS03MTMzMA_d138993f-f4bb-4225-afad-12195ddc67b4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTEtMS0xLTcxMzMw_c3245b6d-d9c9-42fc-b646-0d4f98f38599">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTMtMS0xLTcxMzMw_5505bdb8-da3e-4139-94b7-fc0e86492ac3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTUtMS0xLTcxMzMw_13c393be-f80f-4477-b08e-166f9e36055c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTctMS0xLTcxMzMw_d501d9c1-4c9b-43ad-9976-66ee5098e14e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTktMS0xLTcxMzMw_76e5fbef-f70e-4f6a-81e9-06e3b52fb3d5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTExLTEtMS03MTMzMA_5b34764d-b970-4db3-8a5a-0c5010cbce20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTEtMS0xLTcxMzMw_ca0dd1f3-623c-4c75-87d6-4ee4225d77da">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTMtMS0xLTcxMzMw_9163215d-fe08-4e72-ade0-b396318e517e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTUtMS0xLTcxMzMw_6ceb475f-a5c5-4ebd-8c00-773c947ff162">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTctMS0xLTcxMzMw_cfc3fcb7-25c1-4e2b-be8b-2382915e5882">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTktMS0xLTcxMzMw_7dfa2c96-45d7-47fd-97ae-78f370a0533f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTExLTEtMS03MTMzMA_1467b4ba-4778-4256-9926-d5fa3a6b4831">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTEtMS0xLTcxMzMw_e3f82055-0f79-4786-bd0c-8546d4f513f9">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTMtMS0xLTcxMzMw_ca543329-0de3-4d95-8f2b-62c602ef59fd">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTUtMS0xLTcxMzMw_405c1079-5984-4ce7-8326-5a7049dc6929">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTctMS0xLTcxMzMw_2fbf674c-2445-40d1-8f25-364d6fb98309">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTktMS0xLTcxMzMw_71b61770-beb3-4086-98e8-2094d8ff0326">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTExLTEtMS03MTMzMA_2d292f8d-2f38-4f85-a43f-dd6737e48c96">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTEtMS0xLTcxMzMw_ff1dae80-825d-4392-961e-459f22e50b8e">918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTMtMS0xLTcxMzMw_8bccffc1-5adc-44c8-b4c5-c6b7f978a4b6">941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTUtMS0xLTcxMzMw_736edc51-7e73-4eb4-87be-445d48f435d6">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTctMS0xLTcxMzMw_32aba912-3720-4845-88dd-394d1fc582d5">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTktMS0xLTcxMzMw_d548b7bb-e0c9-4059-b4ff-d207ab268418">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTExLTEtMS03MTMzMA_16ba2687-2c16-4014-84fe-ecca92853c25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTEtMS0xLTcxMzMw_8fa0f0a1-96a1-4fe7-9f4c-14b6718d4e75">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTMtMS0xLTcxMzMw_62805226-2f61-4db0-93e5-b47de599f0b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTUtMS0xLTcxMzMw_154a90d7-e14e-4ea3-a21d-ec33a5ebcafa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTctMS0xLTcxMzMw_ab8350af-999b-4eae-ad5b-68206e4a1d9f">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTktMS0xLTcxMzMw_83cd71ec-c48e-4f3e-a8c1-912329f33b9f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTExLTEtMS03MTMzMA_7f91b570-c44f-479b-86a7-7866ea98b825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTEtMS0xLTcxMzMw_8afd656d-cd08-48fe-9d8b-4fc5aa59ce88">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTMtMS0xLTcxMzMw_ab57df4f-c517-4c00-9c1a-ca6f5bb9938e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTUtMS0xLTcxMzMw_c231eb07-e32c-4733-ba8d-becc34488f21">28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTctMS0xLTcxMzMw_4e6c4b1f-bc97-45a7-9523-f43dd95657aa">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTktMS0xLTcxMzMw_77f5cf63-a3c9-4a97-b8d9-382b516ca992">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherChanges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTExLTEtMS03MTMzMA_1a84a0c6-9299-43ef-bd34-f2c1f9f0ea65">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTEtMS0xLTcxMzMw_f275f865-0004-4e95-87b6-efe82210597d">9,854</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTMtMS0xLTcxMzMw_701c2312-0441-454c-b728-fc056a8066ac">13,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTUtMS0xLTcxMzMw_2a9bd0a9-8238-43e7-8de2-cc0d04ae7ee9">7,755</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTctMS0xLTcxMzMw_93984e12-fca3-4a19-aac9-a958bf87604d">11,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTktMS0xLTcxMzMw_3d31e20e-3fca-4f75-8a36-9e72dedc5753">1,157</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTExLTEtMS03MTMzMA_205f10bb-b619-442f-bd50-165c8a23ab2c">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTEtMS0xLTcxMzMw_66957e31-3d61-41f5-a657-523cfec2c8a2">760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTMtMS0xLTcxMzMw_ed1258ae-06e6-440d-a519-52773f0a089c">932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTUtMS0xLTcxMzMw_67cc71fc-30ce-4bee-8614-98582ed19438">718</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTctMS0xLTcxMzMw_db9e9228-c566-4756-be3e-5153a41de866">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTktMS0xLTcxMzMw_6ed40216-b6d2-41df-927f-a9381ba426d3">210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTExLTEtMS03MTMzMA_598c5e11-f3d6-4591-a983-d029c942c920">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTEtMS0xLTcxMzMw_a4ae4dfe-197c-45af-851f-0d65144ecdae">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTMtMS0xLTcxMzMw_312f9d12-1c1a-4122-bd3c-eb6fa7790ac0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTUtMS0xLTcxMzMw_0a3171ed-2a4f-4b46-9231-b99fb736c362">1,052</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTctMS0xLTcxMzMw_1a750a33-7994-4a98-985d-37a18b95d47f">1,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTktMS0xLTcxMzMw_4e068e06-ad6b-4ea1-ad0a-d61012ffc1f9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTExLTEtMS03MTMzMA_a44b642b-1fb1-40c6-b577-bc211929d736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTEtMS0xLTcxMzMw_0a20f050-e78e-4b3c-9ced-f3946fde123f">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTMtMS0xLTcxMzMw_3625e945-b4c7-4c73-8a4c-f5c9de4a1eab">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTUtMS0xLTcxMzMw_e40032f5-3212-428f-b031-fe7f19d34bfd">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTctMS0xLTcxMzMw_75009d9a-25d0-481e-9e51-59daef551271">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTktMS0xLTcxMzMw_52d3d213-0557-4834-8841-3cbc245accda">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTExLTEtMS03MTMzMA_28761a73-a977-4ee7-8c0e-727ebf59112c">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTEtMS0xLTcxMzMw_15ab90c5-6aee-4415-9b64-1efb83d88d6e">706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTMtMS0xLTcxMzMw_100f1d36-1b71-464d-acc5-258036d4cb35">877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTUtMS0xLTcxMzMw_e60603de-6085-4216-bb33-5cde88301920">315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTctMS0xLTcxMzMw_1c5c8563-bf9b-4247-ad96-e1ca9f0eb0b3">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTktMS0xLTcxMzMw_9dc2caf1-9b4c-48d6-8726-36713a022072">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTExLTEtMS03MTMzMA_e606e376-0a08-480c-86fa-267e1dc57f63">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Actuarial (gains) losses primarily reflect changes in discount rates.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the accumulated benefit obligation was $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzMjE_380cf9e1-0df0-4b8e-a650-b73128bab2a5">17.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzMjg_8a45a749-7cb5-41e4-b7b6-26f3e6dc6e4a">24.9</ix:nonFraction> billion, respectively, for all pension plans, of which $<ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzNzg_664b1e4e-6497-4a1e-b2e8-2c0fa593ee1e">9.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzODU_062faa8e-7f2c-42b4-a97e-1a9296e398fc">13.8</ix:nonFraction> billion, respectively, related to U.S. pension plans.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i1017f49a3484429e8c6c9f614a836926" continuedAt="i289c2101c7504aa9a98107f0c2087a24"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMzA_15b35339-da5c-436d-9cdb-6ae9ce0733ef" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtMS0xLTEtNzEzMzA_7ed9d6c8-4da4-4147-97a1-b1fb3f9e09e5">9,186</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtMy0xLTEtNzEzMzA_39b1d065-4016-4866-82df-8dcf6f1279dd">13,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtNS0xLTEtNzEzMzA_dcb6df0e-e3b2-4e14-9963-bfce2bb6be54">2,779</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtNy0xLTEtNzEzMzA_61742318-3dca-49ba-9d6d-fd1adb2940e2">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtMS0xLTEtNzEzMzA_28d5b32c-e11a-4ff0-baf3-82d011c84188">8,421</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtMy0xLTEtNzEzMzA_8e10f35a-c428-4b60-8602-7db800390568">12,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtNS0xLTEtNzEzMzA_a2c66be3-0f21-45c3-b178-9a5e92d6bcea">2,445</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtNy0xLTEtNzEzMzA_a83fb6f4-72d7-48a4-9d4b-c77bfc4e4cbf">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtMS0xLTEtNzEzMzA_69d532de-976b-49eb-bf68-ae11ef89fa84">9,081</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtMy0xLTEtNzEzMzA_9f2e9ecb-98b2-4ebc-916d-563f95e84b4b">12,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtNS0xLTEtNzEzMzA_4e184796-0ce6-45d6-9d46-0e5d68410cc6">1,226</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtNy0xLTEtNzEzMzA_5a32afde-1c8c-40b4-884a-3a74b78cc5cd">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctMS0xLTEtNzEzMzA_7ddee3a6-82a1-42d6-8fd1-b5f8eb75aefd">8,421</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctMy0xLTEtNzEzMzA_3565f4a6-07d7-456e-b045-7ebdf1aef705">12,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctNS0xLTEtNzEzMzA_e9d077bd-83a3-46f3-94aa-41b8d45aa141">948</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctNy0xLTEtNzEzMzA_b7551cb4-9408-4e3a-b0ed-9947b1f937ad">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Plan Assets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="iebb1a8351aa841838361b44de4c7bef0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM1ODA_4b10bf70-5d95-4cb9-ac0d-9b1b05bacb48">765</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if1c3c2b238964beeb4fe2cc7ee98547f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM1ODc_eed9a2e2-cba9-4461-925d-a743cf70c88d">943</ix:nonFraction> million, respectively, or approximately <ix:nonFraction unitRef="number" contextRef="i574b9cef0b2d4bfba6872a7e1206e397_I20221231" decimals="2" name="mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM2MjI_ba8ddf3c-c251-4952-9f2b-a552916bb1db"><ix:nonFraction unitRef="number" contextRef="i6a26a46ae4f5482dab104697c724f404_I20211231" decimals="2" name="mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM2MjI_f1d117a5-1ea2-4bd2-9435-0ad6f8ef821f">4</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s pension investments were categorized as Level&#160;3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i289c2101c7504aa9a98107f0c2087a24" continuedAt="i90de126d2dc545d399dc6efbfff5ce3c"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNTY_cd0566ad-e268-401e-9903-f708ec9afaa6" continuedAt="i184f8c17dd144018806122e636970299" escape="true"><div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d9eb5934f114a0ea5d847b51acea3e8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMS0xLTEtNzEzMzA_915fed4a-4917-42b4-a413-f3cf74e56928">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01435fa53a734b81a8a042035680737d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMy0xLTEtNzEzMzA_7c0ce4bc-f6a3-4645-b381-370543596ed5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3d2094305840f097c63ebbc04cedc4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtNS0xLTEtNzEzMzA_b4a15646-dac9-480c-85cf-1458e7b71e61">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d52da3a5a0c45c3bc80f202edf4ac2b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtNy0xLTEtNzEzMzA_c51d9f8b-83cc-4c88-8a75-f9c48741e45d">98</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db1b4d2bd9c40969669b8308c8c2bfc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtOS0xLTEtNzEzMzA_a16e0e93-322c-48e8-9731-df7d34e690c3">147</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8022a250b1054e89b99021d780f54e3a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTEtMS0xLTcxMzMw_3efa3263-5cb9-4b7a-b804-51e557e20776">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6232b3f5be49b195d9d3ebc647e54f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTMtMS0xLTcxMzMw_bf19c3c2-04aa-427b-8eef-1bea9c8b0825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44da905f6234e16bc83498f4aa76788_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTUtMS0xLTcxMzMw_075da3a8-0c88-4b1e-baf3-65d3bd5aae38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df1024a4cf24b4aaee26f266a7f5311_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTctMS0xLTcxMzMw_84cac3ed-1a47-4ac3-97e4-6ab2b07472aa">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ae559c54a246ed8624ac3c291db4ce_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTktMS0xLTcxMzMw_56099d35-f326-4cad-a0be-f161e71c4b1a">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848f3f6ab9414064b3b30f280304bf53_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMS0xLTEtNzEzMzA_13d969d7-1705-4c7a-8413-afab588f2886">211</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c0a82ed5be4adf90a87892aa7ff607_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMy0xLTEtNzEzMzA_a88ac49d-ada3-4e24-a284-f241432fbde7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f277519eb246b7ad1d130d25ceadd5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtNS0xLTEtNzEzMzA_ca702dd6-f341-4b11-8051-df0153b2c535">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic872792688f1452c879827ccb8b53f29_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtNy0xLTEtNzEzMzA_ea16fd30-9ebf-4c2b-8864-8a768484c64a">2,443</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i828d9b689a9a4998aeab58dcb22c19af_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtOS0xLTEtNzEzMzA_aa7fd9d8-1d4a-4895-bc85-9bdcb141b537">2,654</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied44e32a46c642a681ff4b0c0b6653d5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTEtMS0xLTcxMzMw_0c683bb0-248e-42de-8bb7-1043cbfdbf94">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71639f6c7cbe47e6a0f521ccb6b05b3f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTMtMS0xLTcxMzMw_959765b6-5630-4f9b-b9dd-03f76bb1746e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf01f0ea26c74696a3c2fc263ac75d7a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTUtMS0xLTcxMzMw_afdb7436-1f6c-4cad-a43b-04fc51454116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82fec81188f1404dad80d2b60480bcf3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTctMS0xLTcxMzMw_f759f687-af5f-4ae9-a371-58e725dad9e9">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd533fe7f6474d57ac75249e0844aeff_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTktMS0xLTcxMzMw_dc679a7f-7e2e-4116-bf97-2bf020c9c9b8">4,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97b6b2c158a945fbbbdf1d5fa0e98e1c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMS0xLTEtNzEzMzA_6a8fb172-6457-4b0f-bbba-b6f2956003aa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc462ae433d483c8e93d9298f863a55_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMy0xLTEtNzEzMzA_665d2366-ac83-44ff-9fd3-e6506cf4e915">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac89e1f592aa4c2dbd20dfdbdfc094c3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctNS0xLTEtNzEzMzA_f711b172-1a5b-460a-a1ff-ecf06c04dddc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica85b54a9c6148748a002d6f700af7b9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctNy0xLTEtNzEzMzA_80c1edc6-19ec-4af7-a356-fae18ec6608b">707</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1299e9fb62e24c01a38fa23973dc4b86_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctOS0xLTEtNzEzMzA_34f18318-4084-4da4-ba92-ad7d2cd056ee">707</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780a5fe64af9456ea212e3e1f7b5e699_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTEtMS0xLTcxMzMw_7367c52c-29e4-453c-ba1d-805f43e540a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413442eca9f64a4e80a2e82ca894c2d0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTMtMS0xLTcxMzMw_a510baf7-a085-4b91-9282-e202aebe97a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc781fa4b494ad0a981a37fc93215ec_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTUtMS0xLTcxMzMw_d9b19f44-cbf1-421e-b074-3787bc608bec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ee2b762b6b42f9bcb9883b482b84e2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTctMS0xLTcxMzMw_f7858f54-cf8f-4cc9-9cf4-e8ace29a5551">919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ab820615b2409ca822a8463ecc1b8a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTktMS0xLTcxMzMw_718aac0e-14be-400f-a142-8f209e135e5d">919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b8e535c106149f6a29ce6dfa87a1b16_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMS0xLTEtNzEzMzA_bb9e8a57-71eb-458b-93a0-5a642acfd300">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5a0ac36a4541debd3bd1591b829d44_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMy0xLTEtNzEzMzA_77664087-0b29-4d97-9b9d-55a9b1c77d1c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae76956543ea4116b33a51d411999395_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtNS0xLTEtNzEzMzA_c0b3df81-4b09-4def-9f0f-d3266d520915">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f688bf2c244f1f8c8c8453882fdc19_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtNy0xLTEtNzEzMzA_d7d51c2e-f6e6-4c2f-93d8-f61896128f08">131</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a283bca60094770a190b7b2501d36af_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtOS0xLTEtNzEzMzA_b7d16f1f-fff1-4263-92e5-ce283cef1ee4">131</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e040b356d6468cacda7ff0c18e4591_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTEtMS0xLTcxMzMw_784f4662-e889-40cb-968e-4bf5ebd79402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6e50be712242db98c4f2730d77ff37_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTMtMS0xLTcxMzMw_7002a31f-96a6-4207-9917-9f87689667ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219e6bd79d244a7aa455084fdf94ea31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTUtMS0xLTcxMzMw_2c30a843-6c8d-4876-8329-1f08332f91fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13af1fe3667346629b41c84114948a2f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTctMS0xLTcxMzMw_57dbabff-fcb4-48e4-a4d3-d1cf816ce85b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5ed95b785743b59085bf03f11a8494_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTktMS0xLTcxMzMw_ca6e83b6-edd5-43a4-a4e7-78c39a60da57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581419defa34403898493f6ba2fb9935_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTEtMS0xLTcxMzMw_df4c8300-97fd-4221-9bce-dc4593382d76">1,956</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a561dd7e3cd44c686766ee939d51f32_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTMtMS0xLTcxMzMw_3616ab3c-e1ee-4941-8cac-e1b0be5af88a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia697527e9ee9479b91cf4b0aa0f597a3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTUtMS0xLTcxMzMw_ea565ced-319f-49e2-b6d1-945c02e053e2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68566a927ade4b2496958500664255bc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTctMS0xLTcxMzMw_1c99f163-5315-48f0-93b7-5cacb7865850">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e4c057f83442c6859610dc3378cae9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTktMS0xLTcxMzMw_1f4499aa-31e0-4024-b43a-271fef223da5">1,956</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e5e29c38c04370a51a4e41907f7cb9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTExLTEtMS03MTMzMA_866ca418-39d5-494b-a520-7296d0a48289">2,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094e594db1c34ab39387886a26d20ef2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTEzLTEtMS03MTMzMA_155e7ecb-3bac-44b6-9b47-dacaf4d24c4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie604b32af7dc41e2a7c47c6f522d23cf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTE1LTEtMS03MTMzMA_a391c21c-09b1-426c-8e97-5300fdf50b57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973d00b66e0c460bb172e8acfe0e30e8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTE3LTEtMS03MTMzMA_b97cac9f-e5d8-494e-9cdb-84e9080658c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf57448d49a348f296cd544807eec041_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTE5LTEtMS03MTMzMA_201dd42c-93ab-4928-977d-4159dc659488">2,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1def8f4c268e4881aac2d1b076b727ae_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTEtMS0xLTcxMzMw_7567cdd5-dbfd-4e8b-963c-1ecbe0a99714">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55010634a68440fbcb5037b4995212f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTMtMS0xLTcxMzMw_225a06d9-7653-4c24-8b6c-da6727485903">1,934</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a80b04cb6e043ad80ede6971d9cb2fc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTUtMS0xLTcxMzMw_08064791-53ad-46b8-8dda-378d10e91416">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbcb5d3d18240d6abf33c438338c41e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTctMS0xLTcxMzMw_54d24585-0a3c-46b0-bf2c-79bdbffcfe27">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdefef8716e469f866e5bdb3ad97823_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTktMS0xLTcxMzMw_55145d9b-14f5-4527-b160-08bd5eac5e1d">1,934</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368338736b594e6d8a76278bb806f294_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTExLTEtMS03MTMzMA_b1dea009-4b5c-4c05-ab3c-b3833718f74c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2074c0c51149d29db8c27132c778b8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTEzLTEtMS03MTMzMA_c6c18deb-e2e3-48d8-a32b-94b652f05895">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2d07ba578d453a9b330ea183531e7d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTE1LTEtMS03MTMzMA_2a7b2c4b-e2d9-40cb-bbf5-a6df3e9bed5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e296686a26b46e991479d3824a63f4c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTE3LTEtMS03MTMzMA_e7e5719b-ffc5-44f0-9803-9d8402ccf0f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884f9a28b2df4b68bb8abbdc76ca1ecf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTE5LTEtMS03MTMzMA_5feb93e3-fed2-4f56-b7ae-e22044203b42">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3c3527b06a4e589f09f08ceb1e72ef_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTEtMS0xLTcxMzMw_ebd13df8-9daa-43da-a6ba-e3c4e42870c0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4a61f86932408aa31104c0df81ca3d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTMtMS0xLTcxMzMw_06085c2c-d7af-4dad-86c1-cfc5e6fe5856">1,438</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d036d559f54833a22c6bca2390859a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTUtMS0xLTcxMzMw_0ab748a4-5f06-4e88-a5e6-c00b29c8d40d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84db46bf07e44ef4b3a8a839cbf0f428_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTctMS0xLTcxMzMw_9e6165cd-6bf3-41b2-94e1-4b733c627f8f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df28cf4387a4d8783f18cf6ddeef882_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTktMS0xLTcxMzMw_8881b048-9873-4e94-8426-d24fa9f1b7ed">1,438</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ab2d575b2449d08e6ad76e2f9283f6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTExLTEtMS03MTMzMA_f54fad86-35cd-487f-b61f-56757dea4138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef55351ff9e48e89c15fd31549ae893_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTEzLTEtMS03MTMzMA_8744247d-43f4-4100-a9c5-ce2cea7e19ab">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e42ced466d047bf95c8e1543dc8863a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTE1LTEtMS03MTMzMA_85bbd4c9-5779-4f20-8136-0070cb53b4e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f0c6fe869446d9a36fa7dbefe7fb88_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTE3LTEtMS03MTMzMA_5872a21f-3750-432a-860b-00c2a9bb3434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i572499192bfe479396365f275d94e763_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTE5LTEtMS03MTMzMA_8172fc24-d57e-45d9-ac93-47a5ed62e246">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9fc972b25f4585bf6789b43ca0f28a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTEtMS0xLTcxMzMw_96942c0d-b5de-4565-9dca-ccea13dcade7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i408e755f4b8346248d1b01996e6dda61_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTMtMS0xLTcxMzMw_c1c56305-966f-4771-8180-57a848ecd4e4">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d015a29c7d47dfa305d0b880483f37_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTUtMS0xLTcxMzMw_fbfd0e21-0a87-419f-9713-0ed6c5a52e8d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d96ce993e4d57bafec31c8f3709be_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTctMS0xLTcxMzMw_267bdd5d-a62a-4922-ac4f-f358b372a2e9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea35cf15d4343148d21525946bb5556_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTktMS0xLTcxMzMw_00ca3eed-1cb2-4f71-a469-9ff3da109cf0">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id02a5d1a28e148448be5e2748d591f32_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTExLTEtMS03MTMzMA_17436f02-99fc-47d9-afbd-7a426c322eb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0d465701b24fabb785a43c5d0b22a4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTEzLTEtMS03MTMzMA_1b7ea34e-7afe-4c4b-bc82-191d017f96a3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35e62b283ac416e801a76b2e9fcba1f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTE1LTEtMS03MTMzMA_15e11b76-472b-42f8-aba6-58740064cf3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7da8f4d50a2c49a585bbb716acb0701e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTE3LTEtMS03MTMzMA_df251780-0d7d-4867-8f15-6ac8ee98dc16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02763a738b84f0f957e97e34d95f28c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTE5LTEtMS03MTMzMA_07d23d69-9b90-4352-ba0c-07f3b8aa292d">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6945f7ef76e445392d96e1e24babbc7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTEtMS0xLTEyMTQ1Ng_e842821a-a355-4572-b574-701b202394fc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e222b032b0148bbbecabb38a15019c5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTMtMS0xLTEyMTQ1Ng_eac50e9a-26ea-4492-be83-d18f2dee158d">101</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b6676439afb4baa89166d48a1c80d4f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTUtMS0xLTEyMTQ1Ng_51d1b563-bc96-436f-bef0-752683f4087b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9bb0806cf1747e39ed7c1afcb91fcab_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTctMS0xLTEyMTQ1Ng_f968e08c-287a-46d1-b513-dfbf582de387">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab187b6caab4fde8baaa89614f937d8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTktMS0xLTEyMTQ1Ng_d67f040a-1c4b-4f8b-b1c6-c8e415b3555f">101</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcdb915e70724220b3edab3c2cf16e13_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTExLTEtMS0xMjY5NTI_0af520cc-cff1-4f15-81db-c4456c8d5bd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5994096f4b6e8384cad8cc87790b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTEzLTEtMS0xMjY5NTI_658bbdec-af04-4390-bcb8-1bef0c1bfda5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d94212fbb084b18a3e0d07785229801_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTE1LTEtMS0xMjY5NTI_94d34ae1-6a0b-4293-b4f4-915e3f169551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5eb30d21af404795b2b73f609cadb1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTE3LTEtMS0xMjY5NTI_ae7198fb-0458-430e-9324-c4251583974b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14271cdd75a40bd9db2047fa6eebb56_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTE5LTEtMS0xMjIwOTU_ef37aea3-e99d-4c2e-9a3b-8ccf59670e6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b45cf02542b4df1a1557fc79ecf4d7b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEtMS0xLTEyMTQ1Ng_15aa9e18-7b69-44b5-b2b2-1b874da30b00">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac839fbba234105bdce0c3639ea1f65_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTMtMS0xLTEyMTQ1Ng_c54c607d-6acc-49c5-9c34-3e9df64e9df5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2884cebbeb4349cbbd54902567b98f99_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTUtMS0xLTEyMTQ1Ng_33eee17c-7465-4460-be86-3492a50fb60f">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3419a800d84e95847c4ea6b6573ef9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTctMS0xLTEyMTQ1Ng_7a9548bc-3f2c-4987-b919-87bf35b7343a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec63912400cc4143bca10be161105b2d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTktMS0xLTEyMTQ1Ng_5afc3e5f-ac4f-4232-b297-052aa7e76513">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9d46acf005430da76b238da3400312_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTExLTEtMS0xMjE0NTY_c618c460-8743-4b29-8d98-92f99fe7b775">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1b3faf898a4df1b8da83fc0342315d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEzLTEtMS0xMjE0NTY_c56e41aa-c19f-43bf-a4ad-e8c381a38f9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc3922262e347318e148317d58cd00a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE1LTEtMS0xMjE0NTY_31f22945-3ecf-4263-8811-4ff5308ada3b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeea740fa5b6439494e7da959619e151_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE3LTEtMS0xMjE0NTY_23fb8b2d-32fe-48f9-b843-3aa85cf2f94a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i222c3f84c00f4528b3b117910de864f1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE5LTEtMS0xMjE0NTY_1a132f4c-acbc-4700-9790-8ab7d470446a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b957e5e1bb40e48f22b7266013e6b5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEtMS0xLTcxMzMw_7e6fb2d5-67cc-4c2e-9928-11652eafe070">2,216</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8117fc38d2c448f4957b803029d27a29_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTMtMS0xLTcxMzMw_b05b94aa-28bd-44b7-a925-abcb1009f863">3,495</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e3be79b32040aea41c8fa4c833cfe8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTUtMS0xLTcxMzMw_08abddb8-55b0-417d-9ee3-899a0ca4291f">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157a12054ba44b08a715faa3db64912a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTctMS0xLTcxMzMw_6c1617fa-d449-488b-814e-320fea96125c">3,379</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTktMS0xLTcxMzMw_de15b823-099e-4fd9-a3f0-f7a408358d14">9,094</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf31aaab8564b709a2447727d50c0f2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTExLTEtMS03MTMzMA_7e8c8087-b1aa-4863-9181-e5289924dbac">3,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18725820f3894e1888c310bc183d1281_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEzLTEtMS03MTMzMA_a7be4a4e-b854-4b73-b07d-f01d63bbbc0e">4,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75548de2a3824999a1caa66dd0cbddd4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE1LTEtMS03MTMzMA_8c666a03-7c65-4f6d-ae47-0b47a5b10af9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f0d1c8a7964938a5f4ca7b0fa2b293_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE3LTEtMS03MTMzMA_b048d3b4-6318-43fb-84b1-69ceb603e79a">5,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE5LTEtMS03MTMzMA_45897f2d-3c15-48c2-be35-3c221539bdcd">13,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d7c3d7dc05473f9e300744f303a60c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTEtMS0xLTcxMzMw_c8e763a6-e3ca-4fac-928b-40f2f4efec08">57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib326ce09514b4493be47a196b35b9582_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTMtMS0xLTcxMzMw_47e2c210-ca03-4066-918f-5987b3a5f252">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd8330fb14d4d3c81eb6e836222ed54_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTUtMS0xLTcxMzMw_1572a3d0-b260-49a9-afb5-0059804f8339">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8077994810984b39938b2aa1928d7cf5_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTctMS0xLTcxMzMw_71fb1780-c924-4b7a-a309-d0114218b53a">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de47dc04136455bbae3a9a127f6e0b4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTktMS0xLTcxMzMw_4b79a230-a8e4-4e06-b241-6f0f9d841e9a">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1375d29c86944eb696207a9446cdb738_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTExLTEtMS03MTMzMA_17c64731-eb23-4b21-ae55-f31b7216e0a4">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64de9cd521724bc0abcd5e2f16a38d97_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTEzLTEtMS03MTMzMA_cc434ed1-e0d8-4a00-9b8f-0d1a8cbbe7bb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c7dcf2922c4017968e8f899598a7fb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTE1LTEtMS03MTMzMA_827b6071-d742-426b-974f-7e3ca6c918ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b426282e3524c13bbfad8775bd40381_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTE3LTEtMS03MTMzMA_318b8a2e-d0fa-4b55-a0d5-202f0ccc30e6">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia564f2a19eab4fd992df2ff0405138c5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTE5LTEtMS03MTMzMA_7e98cb72-2bc1-4213-be99-06417cc5a866">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6582d2efd0054414b352812e2b962b7f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTEtMS0xLTcxMzMw_b5e4ba48-c39d-4f4d-83ae-ee6142b50303">375</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63145f7e3f1b41fdb8abebc2998c2d19_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTMtMS0xLTcxMzMw_27836e3f-bf95-4fc6-b465-217c49799265">2,957</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f04d31c0704d299ee261c7b15963d7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTUtMS0xLTcxMzMw_48b8137c-fbe6-45c5-be45-91720a5ac124">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607173f7a74747529e546f2f09ffa3eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTctMS0xLTcxMzMw_d44be777-e089-48f5-8f77-a91508034a9c">90</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1211698fdc9d4fe4b5bfb05d555dd4dd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTktMS0xLTcxMzMw_75a1223f-6a86-408a-832d-5802b2d1c794">3,422</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d81a32ba3204600bc00f943bd7244b0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTExLTEtMS03MTMzMA_c8c2b09e-3c0d-4b1b-bf3c-4a19fb2c95c1">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee60ebe97eef4e579466f9b404815248_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTEzLTEtMS03MTMzMA_ed015e11-e202-4539-bb4c-bcd128df19b2">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690c9d1b13044a0b8c56110bdcdd1656_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTE1LTEtMS03MTMzMA_b08e058c-52a2-41f4-b86b-810afe2a3f29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8bff79d9b44c1e809568cd8f8ea9dc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTE3LTEtMS03MTMzMA_3fb8bf44-3eb9-4a40-843f-c28beb7921c7">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9495ef8ea329494482b31a7316e5c091_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTE5LTEtMS03MTMzMA_2cb26961-91e6-49de-b761-2e1166cab89b">4,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0b8c867d2b407bb7a590e2865c3daa_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTEtMS0xLTcxMzMw_d4befd65-9ee7-4244-9acc-74303ca783e4">177</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5630976df72c476e8f334a3899a205aa_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTMtMS0xLTcxMzMw_421aeb0d-0536-44d1-aa42-35260e4f0851">2,656</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0851bdc7b8443086939d63202a6a2e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTUtMS0xLTcxMzMw_cbd4b42c-09e7-426e-a70f-08f87539d73b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7986a9f3720e473ab5b5f32f521a73ce_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTctMS0xLTcxMzMw_d5f2da6e-28e4-496a-a9d9-7059390f7af3">130</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if44e31b11f2140fcab839b2f25edc3a6_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTktMS0xLTcxMzMw_b46e8d2c-e8a2-45ed-9bb5-2184d8f3d8dd">2,963</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de70c29ff2e41c3a2cc1406100028c5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTExLTEtMS03MTMzMA_0bc4ae67-2073-4b64-b7dd-16439b49c698">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d0ac7c4da141c8a4d4240d67ebfa08_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTEzLTEtMS03MTMzMA_2c24c6ba-9e40-4cc0-8b05-09b20a269549">4,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674529c9196143a7a4d48e89efa7d6dc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTE1LTEtMS03MTMzMA_875fc7e0-451c-4030-8c52-5dd9a3391624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1146171a1f32494fb878dd8a8dd84f7e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTE3LTEtMS03MTMzMA_fd7ba174-7f41-44c8-a45b-8f3b90707bce">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf091cd60ecc46999362e8ca49e4429a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTE5LTEtMS03MTMzMA_c0ca064e-19ff-40a1-a962-25b4edd076e4">4,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaad887cf23134b0d82635fe324756cb9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTEtMS0xLTcxMzMw_5c75ca9f-6516-41f5-9786-b40bd20dcdb3">52</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdcb20a992b94779aab076cc55de3e6f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTMtMS0xLTcxMzMw_c6cce020-f72f-4b4e-a51c-3efc6327eb32">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e76f4f8aabc405e8b026bc6b713eaf3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTUtMS0xLTcxMzMw_c9a64af3-aa49-43e6-a1ab-7c72ba09dd1b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9208e7f8ceab4fdda68258420c992acd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTctMS0xLTcxMzMw_4a26b636-aedc-443a-8366-e28b59000cdf">59</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0892e4eb2bf447490676f226fec365b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTktMS0xLTcxMzMw_3c9ab1ea-85c4-4f75-9b38-4f330ebebd3f">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847b880d005a4f7e86c4d63096d9f2fb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTExLTEtMS03MTMzMA_8fadcef8-7db7-440a-94d7-faa26db1c038">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fc421c59ce461fa247d668f9e0221e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTEzLTEtMS03MTMzMA_e4cbc463-06f7-44d2-80c8-37eac1fc0076">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69d7f997d164052a95715c97dc7fc49_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTE1LTEtMS03MTMzMA_c7b46cb0-6ba3-4022-86a9-791dc595574f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ea705e6e4e4f58ab5537473f2b8015_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTE3LTEtMS03MTMzMA_20b094bf-e1f2-44f6-8fb2-d2a4b3cbbde1">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23786efd39504e7cbf7f9927055b6962_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTE5LTEtMS03MTMzMA_89797728-dda1-4dbe-b524-a13c40c6e927">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7821d4f79dda401db43e25763b2a2bff_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTEtMS0xLTcxMzMw_90777d82-9351-4b47-b39a-729f1e9e2e4e">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5325b943b7c84934a25bbb141bac26e9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTMtMS0xLTcxMzMw_89f023aa-9e97-4e86-b7f2-23ee2381a807">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c2a54b17b24f0c93b411c2e4ad8e00_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTUtMS0xLTcxMzMw_3cfe8dce-fca4-48a2-850b-de700358c99a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4438b86aa5244c2818db9db11a86fec_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTctMS0xLTcxMzMw_53f91e47-1a25-47f0-99d2-fe8b5cdc8ddf">129</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874116ca095e4632ac107ccefe0dd09d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTktMS0xLTcxMzMw_2d44914e-f439-473d-9c43-83b93968196e">146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1a603e4a3f4ea6a050c80f3be11e9b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTExLTEtMS03MTMzMA_67f4b613-a31d-41bf-8733-26739b77a244">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2570383925d24316b345fb6a6f82400b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTEzLTEtMS03MTMzMA_3929ba61-b319-47a0-b5d5-1ef059cc2261">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632724ebfd9a4a49807cc6f4c47e6534_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTE1LTEtMS03MTMzMA_4b10ab55-c6a5-4ab7-888e-a05c4296776c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35977504bb0a4d55a4b76850394ec55d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTE3LTEtMS03MTMzMA_b6cb90a9-8b9c-40ed-8101-6fba8d14cc32">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e90de4ed4f463996171254297798a1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTE5LTEtMS03MTMzMA_d2fd88c1-6e82-4b01-995e-11a8147ebbe9">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia29673509c9a4010bcd22958c0959847_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTEtMS0xLTcxMzMw_56372ba8-78a9-4e52-9b82-7f660675b98f">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665dd2b6cb854b829b803fff15542e78_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTMtMS0xLTcxMzMw_97d46c59-0c14-470a-b162-1c76021f7386">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e54cf9d54b4adc809169913679112d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTUtMS0xLTcxMzMw_c7248f11-1fbd-43e9-91dd-b2df96cb2915">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9246f8fd405044e7a1e70d29a4549ea1_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTctMS0xLTcxMzMw_a1e74b5e-b4e6-4ada-a8c4-88504197c98f">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e5ad8e04634fc58a8bf8264d2ef413_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTktMS0xLTcxMzMw_4f4087e8-ce4a-4032-817d-efed44e2b4d6">21</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd5163788694a7393d6ef6c3f78716e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTExLTEtMS03MTMzMA_a87e43da-ca03-4a36-8b88-6ab656dbdaf9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358c1248155b4206a0b0e8e6b96f4f5b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTEzLTEtMS03MTMzMA_5cadd2c9-c945-4e4e-9462-2e5ba0b8d886">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43019cb2131f4efb95c47d2d7a4beaa4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTE1LTEtMS03MTMzMA_c2c78080-7d29-457e-8b98-61ce6cf6b2e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb68c4cc84fa49ccb20a1ed79caa36ef_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTE3LTEtMS03MTMzMA_e02fc348-ac75-451b-84dc-f699476e58a8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b4b0f9f50a40e5b9e1a1acbbae1af0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTE5LTEtMS03MTMzMA_e98afa11-7991-4ecf-aa9f-94b69c59e00a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bef4bc7a3846e78b7f7ec8d18a4c04_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTEtMS0xLTcxMzMw_1f473465-8dd9-40c3-8d81-0dc20d5b844c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie22d02a4139c468ab28d1f7187278f7d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTMtMS0xLTcxMzMw_afd6ab40-e740-4d37-bda8-65126d654edf">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef6b8011f814ceea9fcdf1de32c0ce4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTUtMS0xLTcxMzMw_209de169-2ff3-41e5-99a9-a5f7377a76ad">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a0ffc04beb4fbfb3aa513e65b14e42_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTctMS0xLTcxMzMw_fbd3eb9b-3497-4396-93de-326dc967c094">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02aeb26424c437e890d0d17de1ecffc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTktMS0xLTcxMzMw_1a397fd0-f6a3-4314-9a54-8017a6c194c9">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468fbb9f8f4c4000adb9871b4f1e127f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTExLTEtMS03MTMzMA_1021f283-c61d-41af-8a5a-1481450bddb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3000327cc74724b46322105f078001_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTEzLTEtMS03MTMzMA_4e7e927e-cfe3-40c6-9b92-1ab3f2d31218">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd903913036435f9d3f677c2aead426_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTE1LTEtMS03MTMzMA_0a017427-70ea-42c1-b50a-c6c64a5f5be0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1fe0dac3c04016a05d83b48841886b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTE3LTEtMS03MTMzMA_d61c1045-bcf5-49e7-96ab-5222783ad418">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105aa835a75742bf940d91e90318d5cc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTE5LTEtMS03MTMzMA_0b467558-1ecb-4d90-b0e4-fe40dffc82a4">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6533c9582744312a8b885531846a690_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTEtMS0xLTcxMzMw_7fa3e446-073a-4921-aad3-24239625c7cc">263</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d3e011897140d2a236f7bbd70e8013_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTMtMS0xLTcxMzMw_9dfb48ba-abed-4f61-95bc-5534e9a3e3ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069baeccce9b4520a111bdee9431129f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTUtMS0xLTcxMzMw_ffb3e58a-e9bc-4fda-93ec-98b63374d526">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb99c5b079ae4247a981dba6a8503c3c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTctMS0xLTcxMzMw_3e5f788f-c977-4e51-9fec-46e8479ce51d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee39b49b33a847d487e04603c75762fe_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTktMS0xLTcxMzMw_7eb0aee3-5955-4246-a35b-2407444a0f26">263</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad821c2d4149482a8d9a5902ea95e485_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTExLTEtMS03MTMzMA_faa2c671-9bb2-4fc2-b6c6-ee8ae52e09a3">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4018090676e1474786e1971f3ec5c780_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTEzLTEtMS03MTMzMA_05302244-a1dd-4c50-bd96-3788449a3ca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7809219dc2c546249334a05ed0fb7c04_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTE1LTEtMS03MTMzMA_92407385-227a-4731-bb83-43b6d4958a3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib828317235f34a7c933d9c8403e3746e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTE3LTEtMS03MTMzMA_6f2116a0-af2e-4c29-aeb6-763eca72349b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d036f34012427e97ebac833cef5892_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTE5LTEtMS03MTMzMA_e08c5327-8b96-4e2f-8df0-6af67156ac0b">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537bba5b6e244ca494ec109af70bb702_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTEtMS0xLTcxMzMw_0958d7d7-2f1c-4def-9701-01a0ccaa5373">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5679535497fa4788b52666e4cf70d170_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTMtMS0xLTcxMzMw_8391881e-579a-40d0-8371-8591f204648d">448</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56d072311c84277b36632d5a803fd7b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTUtMS0xLTcxMzMw_47733929-d175-40ed-9df4-7a24a1e5142f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512bb771659642bd8da429add2af7ece_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTctMS0xLTcxMzMw_e06a3558-3663-465d-8066-68a665bd1574">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60b0d81c82b44b2a9fb4a6fbdc1f05f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTktMS0xLTcxMzMw_d0faaa3a-d284-43f6-83da-eea30b911765">448</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f4a71103804c5c990a5e460fe9febc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTExLTEtMS03MTMzMA_f53952c5-2bf6-4122-9544-6b6afc49dd7e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8491a5785cf2462fa234d89c89950509_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTEzLTEtMS03MTMzMA_3fd302c1-e052-4630-95ce-6e9af83878c2">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c94abeafb1473a8d323ca363297440_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTE1LTEtMS03MTMzMA_ae933184-a11f-42fa-92a2-22cc92733be1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980c20ea27d44058855c0549523b629e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTE3LTEtMS03MTMzMA_b578d9ab-f54e-4358-9aca-12b0f4b85787">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f51ec0ea3d34dddab95685e90d307b3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTE5LTEtMS03MTMzMA_60ba7d7b-d9b3-414f-a784-13cb5f1c85f3">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia486b0610beb4dedb992b7d0a70d8173_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTEtMS0xLTcxMzMw_e89d5aac-fc6a-4510-a69d-2f3457f3665d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b084b871a324422ae5462c19f697ce4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTMtMS0xLTcxMzMw_621f6584-616f-460e-9539-615c2a1f53b5">157</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01600af18ed54eaa90e40505a5ebe18a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTUtMS0xLTcxMzMw_0c445be1-689f-4a20-9dea-145cdff95b0d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7727910cc59d4a4d84eb330b2e6c98e1_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTctMS0xLTcxMzMw_7fdcea46-7326-4811-bf00-3098822504bd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3255f205337471b9de00d03043da0b7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTktMS0xLTcxMzMw_6e471894-b630-415d-be46-51d865539f22">157</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d3cfd0494654287bce631815c2f48fc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTExLTEtMS03MTMzMA_dcba64fd-d196-4c29-a0ff-ca7cef1644e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38cc140712f549368583bb21f0c9ad6a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTEzLTEtMS03MTMzMA_132fd5f6-ea0b-4f8d-be75-0c730eece276">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5af5903c6944bc8992989ed8fe54eb1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTE1LTEtMS03MTMzMA_5881742e-8f4d-43d6-a798-1969a63dc104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85d88e511504c9f8addf47ea0c5c8c5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTE3LTEtMS03MTMzMA_3e1f065f-a558-4f62-9558-53718edca9f6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd750cc2ed934cf198a8e5af0722e734_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTE5LTEtMS03MTMzMA_18f10fd0-0a92-4728-99e6-1c3c5278e540">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bab51d3da9c40bd9dab9219b12b6477_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTEtMS0xLTcxMzMw_8dd423af-b8d2-4b3e-97d4-0a9a7aa23233">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fab0cd3eb5497c95c9598936cc5f60_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTMtMS0xLTcxMzMw_e27996ec-8838-4a52-b081-878cad651680">69</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d226b317f604d05847b7f6e28dc4596_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTUtMS0xLTcxMzMw_71d8a5a2-c8d9-486e-8c78-e80d421d9574">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f30f26103a4bb09be1f8df2ba5a0cb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTctMS0xLTcxMzMw_3b753777-6911-4af5-a755-aa35a29b2f6b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ce603ee97843dab7cd57610eefcff7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTktMS0xLTcxMzMw_1c478bcf-f43c-47ee-ac8d-161d3e5dfe96">69</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff8b9d77acb419cadc79b2388cf8aea_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTExLTEtMS03MTMzMA_32955114-072c-4d5e-90c3-839d9e3bd466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49b3ac0859944108a2886b9ffe70668_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTEzLTEtMS03MTMzMA_040c0567-6b8d-4ef3-8525-fec6bb5c7f25">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7988a858549c6831c3fc177094480_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTE1LTEtMS03MTMzMA_d4f5add0-30ca-46ec-b7da-38616efedd50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6082ce67ffaf4296a00a661b69d5e2fb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTE3LTEtMS03MTMzMA_b47994cd-30e8-454c-82ac-1abcf8e0e3df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b08b0d47a644db7b10259546dfb010c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTE5LTEtMS03MTMzMA_af4b4252-15b8-49a3-819c-66d640761cf5">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a15f6641e7489e8bec87d0c0d09275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTEtMS0xLTcxMzMw_e5223f1e-ec1e-4cbc-9798-3280eca06eb9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf55b6630574907879c5690efda4aac_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTMtMS0xLTcxMzMw_bb880d82-913f-4c7f-8c63-9792ab05e8d6">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e9d5863fab44dbe8edafd532df689cd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTUtMS0xLTcxMzMw_e008cd30-2bae-4cba-90be-a41d307c4fdb">761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274a84d55dbe43f0909b3b9ea5a73369_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTctMS0xLTcxMzMw_72834b85-e60a-4e3c-a9a6-fdcce3f9122a">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8144400fac414d76bbf83fa31a181ee9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTktMS0xLTcxMzMw_5774c6ca-ef42-4b1a-b9a0-d5cdbc9b4d9b">780</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7e9a4146a347b6b61274dd7dc190a6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTExLTEtMS03MTMzMA_6308c07a-e0c5-4d2c-bc53-838964261742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib416e715279d4c49acf44bd176c0e993_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTEzLTEtMS03MTMzMA_921f5af7-2bce-4d0f-b449-6282f7aa00d8">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2279fdb171bf475ea5bbaf850cf969d6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTE1LTEtMS03MTMzMA_18f5afba-d907-4559-97f7-e1cc07195803">937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide944573e70e4c3a941f811b9ae4fc69_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTE3LTEtMS03MTMzMA_12d62c52-729a-41ce-b226-19c5935e0f20">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3d2cafcaf747a081a5bb4742d24ffd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTE5LTEtMS03MTMzMA_40193381-0634-43fc-b0ff-cdb145519cea">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc86d76a34274e1c9ffa42afa18a0501_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTEtMS0xLTcxMzMw_c3a6212d-a414-4ba6-a523-96d501ac66fa">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73a0658e8094bba8381b0c5aa3afa6c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTMtMS0xLTcxMzMw_b6401f03-11d3-4867-910d-57eef4c74edc">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb05cb659f145bc9934cb7f8611cab9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTUtMS0xLTcxMzMw_8f81e8c6-e3c9-4a56-9be0-ba330004219d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69eb54ad43994b288d84c18edf6e95b8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTctMS0xLTcxMzMw_878d28a4-6288-4ea1-95bc-2d75231a6397">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6da8c122d974d1f937fe4c99ef076c3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTktMS0xLTcxMzMw_2f475638-4516-4eb5-ab0c-423235eb0f5c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5733f7bba54d42aaa43b121a730f82fe_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTExLTEtMS03MTMzMA_3be0a560-f92d-421f-940d-f989c6153b8f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf522bd9fa148caa6b5eed555edc571_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTEzLTEtMS03MTMzMA_1816fd2e-e7e3-4ad7-a2bb-ffb4004336f1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d449dd9dde74791bf4aaeb9a684a535_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTE1LTEtMS03MTMzMA_eb781eee-6f30-4339-9a88-d801c974d260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca87f79abc048f6a89896b3f649a822_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTE3LTEtMS03MTMzMA_78610e2e-e4ba-4375-8aec-e13b2e9c7cca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d655338ad14d529fd86da3f800ac76_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTE5LTEtMS03MTMzMA_33deae9a-f194-4b6d-a1b8-e1bab45a1e4b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41b6862ec6b49808939615624817c34_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTEtMS0xLTcxMzMw_3466075e-83a0-4095-ae7d-ffe24ad65e04">943</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8c892d473c4518b1b24faf48003494_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTMtMS0xLTcxMzMw_fad7d3e1-807a-45f4-b093-ef99bc16b0d2">6,333</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1567e8cd88db4e33937d223c023e86a6_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTUtMS0xLTcxMzMw_c2164378-39dc-45f1-9b6c-727202219756">761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ffff716f5884ae9a3c95e17da117a8c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTctMS0xLTcxMzMw_6c0d604a-af1e-40cd-8476-b45dc0d3434f">436</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTktMS0xLTcxMzMw_fc86c84c-eda1-4cb2-8c5a-b62f11717ef7">8,473</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica01a70e35a14ac7b9ab80bb54bbcd37_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTExLTEtMS03MTMzMA_b2237613-37bb-4552-a58c-78af965f3310">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcf8778d6694d0b8a4abf0e7cf5ab5e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTEzLTEtMS03MTMzMA_83336d8b-4e6b-4831-8bd8-a8f213383424">9,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e73b7ddb0346da916527922a567950_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTE1LTEtMS03MTMzMA_8aaa75ec-a3cd-4ee3-9068-1f37e6cd620b">937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f078b74a4254907b6f6bfa3674d200b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTE3LTEtMS03MTMzMA_48eebe99-9f9a-4d7a-8262-2254867737d5">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTE5LTEtMS03MTMzMA_35df6270-b74e-40f9-a18e-9746cbbfcf82">12,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i90de126d2dc545d399dc6efbfff5ce3c" continuedAt="i4027a5f742e84e089bbd0cc93153380a"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzOTI_20291f54-8ee7-449e-ad86-da9ee6287b3b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3f57f040b7479f99574732ff1ae8b5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMS0xLTEtNzEzMzA_7736b8d4-dac4-4cf6-b7fd-10a8551fd320">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b52200a65f14226a303e0b59890c740_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMy0xLTEtNzEzMzA_5fe866b9-34b1-4a61-a878-d1ee5fa10ead">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc3922262e347318e148317d58cd00a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtNS0xLTEtNzEzMzA_7b5ba2fc-a2f8-4e1c-bb5e-d30e678cd6f2">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75548de2a3824999a1caa66dd0cbddd4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtNy0xLTEtNzEzMzA_a027b7df-1c46-4403-8cf8-1046218f14bb">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4975d29336746c9aa345d496769bdb8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtOS0xLTEtNzEzMzA_01066532-7bdd-4d2e-ab71-82ee62a0bce4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c66956557e4be194a774c381c9da86_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMTEtMS0xLTcxMzMw_b04daf81-9630-48d2-86ae-abd7ef4b16d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0551986dd6aa44a8a13162962abcebe3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMTMtMS0xLTcxMzMw_ac58b41f-4118-4895-a4a1-458ce572608e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740356c629584008ad4233ee4ddba3e9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMTUtMS0xLTcxMzMw_509f0750-6e9c-4df9-9c02-fa5aa00f2447">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMS0xLTEtNzEzMzA_31b974b6-f61d-443e-ae54-df7c875f703b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391d62977ce249c595df8b51fff32129_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMy0xLTEtNzEzMzA_82151d35-3fec-4318-b0c0-4f7763db0738">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtNS0xLTEtNzEzMzA_61e8e842-e7b3-4f6e-a44d-f6d78ebacbf1">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icedae49afe70492a8921f596e854194f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtNy0xLTEtNzEzMzA_f77ecaf2-502e-4466-bb8a-9bfd4bfabce4">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtOS0xLTEtNzEzMzA_c2b282ee-e600-43b3-836a-f9fc1e56f33d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMTEtMS0xLTcxMzMw_91d2c364-0aae-4ea2-aa7d-d05d943333e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8a215a4d92941e58289c363ae043414_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMTMtMS0xLTcxMzMw_21f90245-fe69-45fd-9d8f-d9af98fabb36">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMTUtMS0xLTcxMzMw_840cb681-7d5a-49d5-aa1d-b425695b2658">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMS0xLTEtNzEzMzA_f8fb17d4-4abd-42d0-8fca-8d1e79cfdf92">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391d62977ce249c595df8b51fff32129_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMy0xLTEtNzEzMzA_2664d890-8145-46e1-a559-017ac6188bea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtNS0xLTEtNzEzMzA_0f49030f-afd0-46bc-950b-25279eff2cd8">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icedae49afe70492a8921f596e854194f_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtNy0xLTEtNzEzMzA_5456bcc9-b87e-4bdc-81e0-47dd9bf82b9d">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtOS0xLTEtNzEzMzA_8571e4ba-5cca-4bac-a79b-f91790eca2e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMTEtMS0xLTcxMzMw_a147b24b-48e1-41dc-bffd-44367cdb4be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a215a4d92941e58289c363ae043414_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMTMtMS0xLTcxMzMw_42447a80-da22-49cd-9d39-7be09aef55e6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMTUtMS0xLTcxMzMw_cbc70176-56c9-476e-9720-cdbfc97d4fa7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMS0xLTEtNzEzMzA_a51affa8-a45f-4681-8941-2fad8c58e337">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391d62977ce249c595df8b51fff32129_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMy0xLTEtNzEzMzA_1a66b8d0-c924-4d04-bf58-34ebb41560ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctNS0xLTEtNzEzMzA_b13e3ee5-8e27-41c8-8095-45b99c6cf372">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icedae49afe70492a8921f596e854194f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctNy0xLTEtNzEzMzA_e835bf1d-f561-453b-b804-8428ae2f1f1a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctOS0xLTEtNzEzMzA_809f160e-edc1-4660-94c2-9328b9e123a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMTEtMS0xLTcxMzMw_20da45c0-c919-47b0-80b1-bd70011f73cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8a215a4d92941e58289c363ae043414_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMTMtMS0xLTcxMzMw_d87dfa60-b00a-4f74-a90f-f502ad2ec566">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMTUtMS0xLTcxMzMw_fe2b0a79-26c2-46aa-a90d-70cc7050e8ae">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i196e5beea93a4b41b938b075dbb6919f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMS0xLTEtNzEzMzA_895f5af6-3538-4613-910c-10adc8022872">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de86a0013c4258b4c507ce158eb4e4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMy0xLTEtNzEzMzA_8ae58330-9cf3-4f99-b607-ae2177d8ab8d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2884cebbeb4349cbbd54902567b98f99_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtNS0xLTEtNzEzMzA_e1751a40-b9ea-4ed0-a89c-7ef3f428d5cf">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e3be79b32040aea41c8fa4c833cfe8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtNy0xLTEtNzEzMzA_0e8255ad-1bf7-4f9f-a4a3-c69e97c7b85e">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3f57f040b7479f99574732ff1ae8b5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtOS0xLTEtNzEzMzA_7f241616-aef4-4ff4-88c5-9c7c04dad791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b52200a65f14226a303e0b59890c740_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMTEtMS0xLTcxMzMw_546a500e-231e-4270-b3de-c7296ac6a4f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc3922262e347318e148317d58cd00a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMTMtMS0xLTcxMzMw_31a3e334-0328-4a2b-94ae-490172bda6e5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75548de2a3824999a1caa66dd0cbddd4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMTUtMS0xLTcxMzMw_7eed2470-76e2-4fcc-baf7-85bb9112256e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2279fdb171bf475ea5bbaf850cf969d6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTEtMS0xLTcxMzMw_93b0d36c-051f-4a08-80bc-43e5d185bc41">937</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75398dcffd9046fa9a38d8247cf75272_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTMtMS0xLTcxMzMw_239f9f1b-0629-4acf-a3db-e6212c03ff57">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d449dd9dde74791bf4aaeb9a684a535_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTUtMS0xLTcxMzMw_fb562051-15ac-4ac1-b48b-5192cca1b6ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e73b7ddb0346da916527922a567950_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTctMS0xLTcxMzMw_f76c96bc-9c4e-49d7-8110-408848f74859">937</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e5ffd30d9c4ef599c56ecbaaf44659_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTktMS0xLTcxMzMw_fc0236ab-cfce-44f6-b71a-2ca42c5b3418">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d52c4001584a19bb8951cddf85e6d0_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTExLTEtMS03MTMzMA_f19f896f-f276-4424-9213-2e28e9c00791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43740d47c36d4df0968fd590a094a8dd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTEzLTEtMS03MTMzMA_4c4a6661-ca31-42cc-989d-78754f7aad6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f395a8003a04bc1bc87026e0744fb1c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTE1LTEtMS03MTMzMA_627db4cd-2a96-429d-a052-e6f24f2decc0">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTEtMS0xLTcxMzMw_8d49db86-c7c9-4d1b-9a36-ce183b2603d7">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTMtMS0xLTcxMzMw_bae901df-6d82-4b05-9993-0c75ce007218">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb33c38937d499487bba962e0672886_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTUtMS0xLTcxMzMw_d825860e-a7a3-4f4b-9348-55cf33c103b2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTctMS0xLTcxMzMw_9ace524c-5546-444e-a6bd-5954281ed2e2">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTktMS0xLTcxMzMw_d6ea1a79-0753-4197-bf09-355385f4948f">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTExLTEtMS03MTMzMA_ad015538-2d38-455d-b9b0-e40763f824da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTEzLTEtMS03MTMzMA_7890cb33-f83e-4e83-b09b-fe5f7581f400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if954f770736b43af9be4de4254082a5f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTE1LTEtMS03MTMzMA_21a7ee11-8284-42d9-b07f-455c6f093b85">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTEtMS0xLTcxMzMw_9a42e1ae-fbfb-4928-8de0-07b0b490ac7d">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTMtMS0xLTcxMzMw_c603d8c1-3900-4cc0-bdec-98d7a3a6eef0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icdb33c38937d499487bba962e0672886_D20220101-20221231" xsi:nil="true" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTUtMS0xLTcxMzMw_2db8ec13-5edd-4031-acdb-a1035c540deb"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTctMS0xLTcxMzMw_acdc4834-f71a-4159-967d-45ee003a615c">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTktMS0xLTcxMzMw_7e9c00d0-e4b2-47d3-9a08-751b9a489785">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTExLTEtMS03MTMzMA_abdae816-606b-4f59-bac4-72e280490ccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTEzLTEtMS03MTMzMA_6873c377-6fdc-4f58-9c4c-a4b4b97c77e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if954f770736b43af9be4de4254082a5f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTE1LTEtMS03MTMzMA_76485a38-b890-40d6-afed-a218dc90a4dd">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTEtMS0xLTcxMzMw_790314dc-9b45-4ec7-b73b-496627e30cc8">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTMtMS0xLTcxMzMw_f9a738aa-d73b-409f-a9f6-580a7ef976ef">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="icdb33c38937d499487bba962e0672886_D20220101-20221231" xsi:nil="true" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTUtMS0xLTcxMzMw_40e45922-1412-4006-ac4f-923dddb29fa3"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTctMS0xLTcxMzMw_dd7cea92-661e-4ed8-bd91-775413d1c85a">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTktMS0xLTcxMzMw_a39673c6-abd9-430c-b633-4064495411ae">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTExLTEtMS03MTMzMA_077e438f-0c35-45d0-a156-7ca6d3942885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTEzLTEtMS03MTMzMA_2447ceb5-e25b-42a4-ab22-52ea48e2e3ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if954f770736b43af9be4de4254082a5f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTE1LTEtMS03MTMzMA_9e3eb6d5-40bf-4064-84f9-5eb28500e038">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e9d5863fab44dbe8edafd532df689cd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTEtMS0xLTcxMzMw_39cca5f6-efc7-4efe-9041-8f342327b1de">761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eec32cd86894cbcbc60de256176e451_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTMtMS0xLTcxMzMw_558e4052-b666-41e4-a83d-cf2e54f10bfb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb05cb659f145bc9934cb7f8611cab9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTUtMS0xLTcxMzMw_91afc880-b0c6-49c4-8eeb-386260251de8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1567e8cd88db4e33937d223c023e86a6_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTctMS0xLTcxMzMw_4da6959f-7db5-4daa-95a3-8c54ccabb779">761</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2279fdb171bf475ea5bbaf850cf969d6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTktMS0xLTcxMzMw_16e22ab4-ba30-42b5-b3fc-fe71061ea30b">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75398dcffd9046fa9a38d8247cf75272_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTExLTEtMS03MTMzMA_fffc2226-8d55-4d12-b942-c836014e2d9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d449dd9dde74791bf4aaeb9a684a535_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTEzLTEtMS03MTMzMA_7bcbc8ac-3c75-4463-8bec-6f36cb70ebf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e73b7ddb0346da916527922a567950_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTE1LTEtMS03MTMzMA_9254aaf5-184f-4c67-af91-50f30553dc5e">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i184f8c17dd144018806122e636970299"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d8c9312ccf47048b5a4a7d309afce1_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMS0xLTEtNzEzMzA_68c90f63-c08c-4ff7-a381-91b9075264aa">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbf0cf596c64dd0988a11364164dcad_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMy0xLTEtNzEzMzA_c947a224-dac5-4abe-9e36-6ff10f941b04">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0855ec477af54d6c9e617a29197d7847_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtNS0xLTEtNzEzMzA_43b1a0c0-90cc-4940-967e-05b2f7b7e0ed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dcc62c4863b4fd5965bad472ce89f84_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtNy0xLTEtNzEzMzA_c3f41a41-7ebb-4a6b-a141-ad3c2117814d">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f98c489cc64681a483c72df528f6e3_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtOS0xLTEtNzEzMzA_7fcad72b-2ebe-4e42-8533-286aeafafaf0">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7203e778ea74a408a9fa5899876be16_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTEtMS0xLTcxMzMw_3c0c3c32-a966-46e1-9dea-278beae068b8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723ef648281046feb09a5a0b71329ea6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTMtMS0xLTcxMzMw_d9cbdc93-b404-4e76-882e-b202f1f9142d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c611c813754eab88e05244b68c044b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTUtMS0xLTcxMzMw_4d5b282a-2960-4599-9cce-c423d1c46174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ab2616ba0d4b4cb6674640617b0f57_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTctMS0xLTcxMzMw_2943d112-0f7d-476b-b8b9-d4b3948ae358">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9381a63fc854eb5922d6264e132c65f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTktMS0xLTcxMzMw_cdfc734a-94fe-462b-8749-b1f50e537bb5">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78ebf602989410196340e3c5dcc143f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMS0xLTEtNzEzMzA_79b54635-b92a-40e1-b33a-10cc4e9130dd">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb96f837754f4435950d58e7ac6948d4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMy0xLTEtNzEzMzA_377cb8dd-1d09-419f-a236-31b9095225c7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77861343b2ad4e85b03f9edee1fd484a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtNS0xLTEtNzEzMzA_f815ea49-6141-42b9-991d-a27ab0698dae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a9cf06ce114e07b7471b2af3056851_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtNy0xLTEtNzEzMzA_52966408-ce44-412d-818c-197734df2d8b">257</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d33c007f854d6686e954a4cfa0d98e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtOS0xLTEtNzEzMzA_61614e39-05f4-4aeb-a999-aca7c9d82d0b">279</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b3b5be37054468ab22fe27ee8df713_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTEtMS0xLTcxMzMw_bd317b8f-1eb7-4091-adda-6ffa54750ba5">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3aeeacc677f42a5a7d9c47033789337_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTMtMS0xLTcxMzMw_c7c76384-8358-44c2-b72d-61d6a51bece7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4352166d754870a7bd84cb271c20c4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTUtMS0xLTcxMzMw_5f214a72-ce3a-4759-856b-15f72c5cc616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic779d812947244a493bd0e236b71c768_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTctMS0xLTcxMzMw_47ea61ac-dadd-4e85-bf07-700d9f470b0b">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c0625b0b6345e8a53a2d538fa4f71c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTktMS0xLTcxMzMw_67fec2c8-a82e-45c6-97f4-0d385eea6a0f">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6e499506a74f4eb80bc1d6dcb6eb92_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMS0xLTEtNzEzMzA_55bf4092-8c7a-44fe-bcb1-009c91efc501">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea9249f1c9bb4890a527687499ad8b1e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMy0xLTEtNzEzMzA_e0ac5dd9-e840-46e1-aa48-ab04f968acff">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fba52804d74a09b2d6f5991fe15088_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtNS0xLTEtNzEzMzA_19295b02-ba45-47a2-8dc1-91c891636f89">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9f1e2ac854460d80e3d43cf0117001_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtNy0xLTEtNzEzMzA_529e813b-31f8-4922-ab7c-d5ee1ca8a904">74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24ff29c998a499e98829ddd938859af_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtOS0xLTEtNzEzMzA_a289f6e3-9016-4c20-a397-5151492f7338">74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880f66c107f0451ab68cb5731877e3f1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTEtMS0xLTcxMzMw_b7e40467-b52a-4e68-b29e-1d63d86f4b0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0e0627cafe4467a18c0746b1b2cb31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTMtMS0xLTcxMzMw_4d6ada7f-1087-4ce4-b4f3-28d3a4a7bc61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d48bd88a7544ca9f12cbe3c8d542e7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTUtMS0xLTcxMzMw_387fcaa5-f85f-4fcc-80fc-e5b30af9a71f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581fc4c408a34c2b823593ff34f1bb45_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTctMS0xLTcxMzMw_925e62e8-54b1-47fa-98d3-27d6de56c5ac">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice88c13053694b56b1bbb9845b06064e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTktMS0xLTcxMzMw_93382b1d-541f-42b3-985a-d40400fc7a8d">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018e647cc2bc4aee9902c487f5cc618d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMS0xLTEtMTI5NTEx_eb97558a-22d5-448e-8cf8-be81c7e448ca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff115c544a4247a9bebf28565714478f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMy0xLTEtMTI5NTEx_dc2d4bab-3a53-409e-b8ff-4f5d002deb6f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25beda17672d4e7b927a143d69ecbcf9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNS0xLTEtMTI5NTEx_c3dc0b7b-6cc6-4256-bf0f-f6eb19a66728">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b3d9bc36e8470ea10fce95680f1e68_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNy0xLTEtMTI5NTEx_9666eeae-2c1d-4a14-a134-4137c0185ad0">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480b0e7376cc4bf192c2b8defec32548_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctOS0xLTEtMTI5NTEx_bc8d0ff9-6391-4d2c-b3da-0dc4918635b9">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e52fe255fa64668b45ea3f63c0ec370_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTEtMS0xLTEyOTUxMQ_b14ae0e4-2140-43b5-b1ce-089a2e8c6f65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3df3939a70427b944df35cdc081c04_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTMtMS0xLTEyOTUxMQ_1b92e8ef-1760-4ad9-8f8b-c83c3693a2e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8b60bea50f4819980218f7402e7751_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTUtMS0xLTEyOTUxMQ_af2a87eb-d1ac-42d6-843c-27fbfe10df2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id979bf377b1c4fa49c254ea8c1bf378c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTctMS0xLTEyOTUxMQ_8f3dd74a-0e80-4138-b09c-97268e6e56a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1635544067c487894b39dde19771e15_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTktMS0xLTEyOTUxMQ_b9279f03-b7b1-4151-a7fc-185ab6a532e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0194124ad9d04baf9e149becd0219b96_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMS0xLTEtNzEzMzA_ad3ad392-2d26-42d4-93b5-a83e65250679">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5299a986957347d28938ccdaf51e78fc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMy0xLTEtNzEzMzA_b4aa1afb-51c0-4ada-a7f4-ec6eb147ad66">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3ebf994c704c56a8470a4394936128_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNS0xLTEtNzEzMzA_351dbae5-1d7e-4878-8d6e-dd1acb690924">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib520139920004af9959a218c4bc47d91_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNy0xLTEtNzEzMzA_1e331647-5360-4338-bdda-de36079851a9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627a57072a524b84b539c7ae028c9972_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctOS0xLTEtNzEzMzA_28c1b9a1-b009-4976-8074-c1ad93b13377">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913b5f5f9ed74e87afbc473b332d0abc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTEtMS0xLTcxMzMw_86b86929-a35f-4af2-9497-f3d561644cf1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b96c6aee77c4665b7d0f0f1c63ae176_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTMtMS0xLTcxMzMw_5d06194a-9dcb-4760-8771-f14b4456898e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b5a437c2054f779c773692231f8df3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTUtMS0xLTcxMzMw_65498027-cd32-4e15-a727-399fbbc54526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc2a4b136e3240bbb703440f5d3e6850_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTctMS0xLTcxMzMw_0a15b65f-cfc6-444d-b404-325e3254cfac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe65bc4981604870be12a703c9e2575e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTktMS0xLTcxMzMw_39c89eff-63cf-4fe5-a976-f5670e7be295">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4945633529e43d2802b597e5521836b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTEtMS0xLTcxMzMw_3e4cf725-5472-452b-847d-694cb2706e46">206</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b67d5c167014b2182a1ef46a48101ef_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTMtMS0xLTcxMzMw_959d056a-b2d2-4178-85e0-ee88f300c2da">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f74ddf524274e6fad860cb8fd17fe7b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTUtMS0xLTcxMzMw_dff371dd-fe42-43e5-a86d-01dbeb796ef4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c0f7bc74d34dfcab9c341a70dce9ff_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTctMS0xLTcxMzMw_3f7d9e1f-a318-4425-aa4d-2b831b67b026">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cedd5ed62c843f4a46823653d960a3c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTktMS0xLTcxMzMw_176b68c8-cf47-428a-b56b-88847f88a8fa">206</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae98f337e3924c8fb5cf7830c2920bcb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTExLTEtMS03MTMzMA_e06d391f-857b-4c51-bb8a-8305a65724fa">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c86d54c41ad43afb4205c1d54aaebd6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTEzLTEtMS03MTMzMA_ec9f4e4a-85d8-46d1-bccb-f445896e7fad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf0e72b4d76455c823ebeace0a9683c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTE1LTEtMS03MTMzMA_f1d5857e-3073-4db2-aa86-8a01d124f7ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b61c9047804b46affa899a8994e404_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTE3LTEtMS03MTMzMA_ff633afb-c955-4b3b-b888-c7c4dbe4cd14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife91ab3ff9224a8887d6fc6c9327342e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTE5LTEtMS03MTMzMA_667b4e5f-9acc-444e-8882-b63adc0a28ef">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893c7b0fee694fc39725e06248904f34_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTEtMS0xLTcxMzMw_8021c173-6479-462d-abce-41bf684f33df">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a6cce590324043bd914a90ea6fc3c4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTMtMS0xLTcxMzMw_92ff3382-0ed7-49a3-a453-57f9d317113e">212</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449c16f5e60d47029b762e1c47644d98_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTUtMS0xLTcxMzMw_28be139e-0a8b-4f14-999a-ad32e611f806">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6adae9ebb2144625a68e34d2e532d6d0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTctMS0xLTcxMzMw_973109dd-bc81-450f-8ca8-cb38add453df">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb26e9094cc24bb49df536a196047854_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTktMS0xLTcxMzMw_78119c72-93ce-4939-a23e-91ff4025b284">212</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72091fefb0c4f5eba7ad4a943ab6bcc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTExLTEtMS03MTMzMA_c6cd731d-79ec-4949-9404-502a213d89c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba55f68908c47baad1db7eed4abbd32_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTEzLTEtMS03MTMzMA_1625bfe9-d23a-4009-8dd9-65fb161dc33a">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc82d08170a947b081f642de831e03f0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTE1LTEtMS03MTMzMA_bae626f3-d6e7-4804-81f5-20812241d44d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5dd78bf53984767890f793f585b726d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTE3LTEtMS03MTMzMA_5507bf31-8453-45c6-9190-41312bea1a3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4daa1ffee7c443d69903ce6fc8dedd2b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTE5LTEtMS03MTMzMA_2d1cb7d6-314d-4215-bfc8-fcd1ef0340c0">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45784d2a67054e4aa4806ae5f92c6849_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTEtMS0xLTcxMzMw_1f544491-3782-4580-a7d6-60eb396b310b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f3b6b407264debb979379641cba1b0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTMtMS0xLTcxMzMw_ec0ee2e4-479a-4678-98b4-eef972062302">137</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fb8860eec2457bbef07d977cc5fbf0_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTUtMS0xLTcxMzMw_9f0754d7-6baa-490b-a837-0b90e4347265">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a1edbf368048fba661bb380d38af5e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTctMS0xLTcxMzMw_9de665eb-fb81-4639-8fde-46cf4c3f49af">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia405f11b3d1a404a8fbfee06d703b855_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTktMS0xLTcxMzMw_e75b2943-5ea4-45ad-aeb3-81040219c69e">137</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce1c8735b2e427cbfa6b1c2d907a6d1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTExLTEtMS03MTMzMA_a622d7f2-b472-4e27-b7f4-49e92b700680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a12aafcc6847b89509b7ae957e4d23_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTEzLTEtMS03MTMzMA_98ef4acb-f8b1-413d-a86f-4e661b71abc6">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369b80c6e5c64b4488babbdd01f641d4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTE1LTEtMS03MTMzMA_c5e33882-87b9-430f-b08c-1f1047d67fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e297e9db7d4cca8668e1a16be22d72_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTE3LTEtMS03MTMzMA_e0d9eaef-7dd0-4da5-a430-d84e3e8f5d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924ed285bc1d45b996c203cd7bd05c25_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTE5LTEtMS03MTMzMA_78b0bada-11a7-481b-ac35-d20d9893a8a2">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7383c74280514a6eb812d7f52ac9def8_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTEtMS0xLTcxMzMw_58e96eb2-1888-481f-8ab1-9b011491a2df">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3cf34ce5394b47a3b70ab7ba21f07c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTMtMS0xLTcxMzMw_edac090b-d69e-4c48-9a0d-6c3b64c33ed7">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie728cd5943f143eda362306c2e64188a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTUtMS0xLTcxMzMw_d195ea2b-2cb3-445f-a238-ae378a6f1f2f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6010bc5ccc09432a9350066c737cebcb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTctMS0xLTcxMzMw_1ba62e9e-7b06-47ed-a8e7-26f0fc792960">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1c226f8e9b4d3589285259cf838b6d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTktMS0xLTcxMzMw_c72c4757-b667-4c2e-ab84-ad71166ebcb0">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c81130363941eabcbe047788cc8ac0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTExLTEtMS03MTMzMA_b03a4b13-cb93-4837-8450-60e4874a3579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad865b817d2e4f2eb417e13f1b94cdea_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTEzLTEtMS03MTMzMA_f4ae2440-00c2-49e5-b53d-fec707f252d5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0623f98779b4a1f9deb8c5985cebccc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTE1LTEtMS03MTMzMA_e13e7b11-0ee2-4bde-ab1e-3c879942ac13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f2b5e073ef435584f2836b3a9c7e62_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTE3LTEtMS03MTMzMA_03605438-efbe-48b1-8b39-5ccac511e9e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8502a68f6c4572816d41762470ddad_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTE5LTEtMS03MTMzMA_d02b464b-ceed-47f7-add4-3baa7e819861">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795f5a645a9b4b7ca40fb6b7556a8459_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTEtMS0xLTEyMTQ4OA_4d9ec049-e10c-434c-bc34-3933f35147fe">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a45fefd7c93443aae003ae9986384cc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTMtMS0xLTEyMTQ4OA_c98d360f-f112-4742-8c92-bb97a32e97e9">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766d1fb2733a4f39a4b6c0c5a672f068_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTUtMS0xLTEyMTQ4OA_ebfbf428-119a-4ff0-ba45-4e55fc6273a5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd9a236b87e45e38116d6ad65882768_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTctMS0xLTEyMTQ4OA_5fc124c7-3dbe-4d4a-9420-d286732509cb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba509df50d7d4c6a8ad7c22884e1628a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTktMS0xLTEyMTQ4OA_39623339-bb80-4494-ae42-1c6f4a24f691">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f69b3633a347ecb320f84b5f266212_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTExLTEtMS0xMjE0ODg_7c801bd9-a919-44c2-97e9-77165fb4844a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9604e1478cf43bf91e60a2fe7f8e4e4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTEzLTEtMS0xMjE0ODg_9fc97fac-8d86-4103-8e38-49102e7c6ad5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a749daf21de4a6f862d6f87b5c3ec41_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTE1LTEtMS0xMjE0ODg_7fe34018-3866-45f4-9999-b511395d752b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd49f7a962454bec93ed6ef6e39f5d9b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTE3LTEtMS0xMjE0ODg_5ff8942d-f74a-4615-883c-e8b3c13dbca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4de48dbad544b2ac8a8ad5bfb3ffa0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTE5LTEtMS0xMjE0ODg_1e24ab70-e99c-44b8-a52a-99a293546cfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic252bec7fec546e7af106a451f9b665f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTEtMS0xLTcxMzMw_694dd943-ce93-42fa-a543-7747b2d7fba2">231</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c314bb744ef4c0dbbd31c567c5f81af_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTMtMS0xLTcxMzMw_ba2ffe7f-afb8-4ef5-b3b8-4708e06c3792">363</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if944cd16f6074744b8d053e0926af6bd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTUtMS0xLTcxMzMw_3ecf1648-d54b-4390-8090-8582588560bc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c1f9774a89a4460b8b9fcf596fab680_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTctMS0xLTcxMzMw_f7eed6bb-db03-4339-ad50-c47569594110">353</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTktMS0xLTcxMzMw_127228b9-ffbd-4704-be80-8300c9c08893">947</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50e936239a449409453997e9da0fdbe_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTExLTEtMS03MTMzMA_e5ef828a-5d34-4330-9bc0-672d76f8b1ab">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675b5277bd1b4865ac978e2a5444457b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTEzLTEtMS03MTMzMA_6a947b0f-7915-44b4-b23a-8eb7563894ef">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d27b886acce4aba86858f24529ae547_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTE1LTEtMS03MTMzMA_f9f38759-5b73-45d3-a71a-0b3d0f383b90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc364573597419f9c326fddd7d8610d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTE3LTEtMS03MTMzMA_1a8b1d50-990b-41d8-8e47-ea408ef31e13">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTE5LTEtMS03MTMzMA_7fdb46d8-5e6d-4bd5-b72d-c8d411668646">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated <ix:nonFraction unitRef="number" contextRef="i6b12891dbba4474da8538f68cfe990b2_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU2ODE_e950987a-2a22-4c49-8c61-af5b0c0a5d21">25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iec2ece4e28dc4d3a8d51b0b78cbadf8b_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU2ODc_2c6625ce-0a21-4dfd-98d6-85ca30edf0e9">40</ix:nonFraction>% in U.S.&#160;equities, <ix:nonFraction unitRef="number" contextRef="i2a61546d8dd040dfa6713efca302e7de_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3MDg_d23f0227-2235-4097-af13-232254c246f5">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia1cb9718cd4a44578e0ac990325f2f60_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3MTQ_a68bf9a8-318f-46af-994c-85601ae2e90b">20</ix:nonFraction>% in international equities, <ix:nonFraction unitRef="number" contextRef="i6da749426fbb44f2999732f3b38a24f1_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3NDQ_d454ecd6-173b-4407-a074-1c5d41719a12">35</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i351c42adbb0a4ccdb08af0c3e1a68785_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3NTA_2b255a64-536d-4b03-bc78-b7ddb37cde32">45</ix:nonFraction>% in fixed-income investments, and up to <ix:nonFraction unitRef="number" contextRef="id0352f2158524b81942eb49ff2876ee1_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3OTI_76955b6f-1ac5-4f1d-95c0-b7448efaf606">8</ix:nonFraction>% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i4027a5f742e84e089bbd0cc93153380a" continuedAt="iaffa2e97c20c491b990430c7f3c9fd4c"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">returns of the target portfolio, which approximates <ix:nonFraction unitRef="number" contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231" decimals="2" name="mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzYwMjg_0d5a13fc-e31f-45bc-a8b6-27c07603e0ac">10</ix:nonFraction>%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contributions during 2023 are expected to be approximately $<ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzY1OTQ_0272d5f6-87b7-448a-99ae-b0cccde5f70f">270</ix:nonFraction> million for U.S. pension plans, approximately $<ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzY2MzU_3216c463-3a26-4333-9690-81962c9cc88c">150</ix:nonFraction> million for international pension plans and approximately $<ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzY2ODg_fd082bec-0a85-4ed3-a1f4-4275c3b6990a">20</ix:nonFraction> million for other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Benefit Payments</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMzk_99c87649-dc0c-43b8-a170-5065e84cddeb" escape="true"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzEtMS0xLTEtNzEzMzA_8e866678-00c8-40ca-b292-35549f22ab5b">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzEtMy0xLTEtNzEzMzA_d27d8442-2285-4eda-ab1b-44bd21fba56d">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzEtNS0xLTEtNzEzMzA_adf05dc7-2df2-4447-94da-ad1e14c38862">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzItMS0xLTEtNzEzMzA_d67619ff-5968-4441-b268-fe21236bcead">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzItMy0xLTEtNzEzMzA_34cca3f1-a779-47c1-a210-0be5d8d196f1">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzItNS0xLTEtNzEzMzA_95b1e1ee-5d81-49d2-91bb-42dab5faf4c4">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzMtMS0xLTEtNzEzMzA_d2bc3df6-5391-44d5-b1b6-dd8d5ef1b70b">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzMtMy0xLTEtNzEzMzA_ea1d6772-3e6f-4238-8e8e-26b72e09b2e9">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzMtNS0xLTEtNzEzMzA_d28c9cc8-dc9b-4809-987d-3980ce77b825">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzQtMS0xLTEtNzEzMzA_33b29542-704d-47c1-9afc-562b29ccbb8a">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzQtMy0xLTEtNzEzMzA_b0a99f8a-09d5-4b85-8750-60be5d689f3a">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzQtNS0xLTEtNzEzMzA_561f7ecc-cf91-43d4-b8c6-6ac7b3531158">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzUtMS0xLTEtNzEzMzA_602365cd-774c-4595-ba12-c3b861df9feb">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzUtMy0xLTEtNzEzMzA_0dfd8568-1229-489b-9104-49765397aa88">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzUtNS0xLTEtNzEzMzA_927aa621-180f-4596-bae8-b9d8089e10b4">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028&#160;&#8212;&#160;2032</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzYtMS0xLTEtNzEzMzA_fe5a829b-4588-4b50-ab3b-004d6608a57f">3,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzYtMy0xLTEtNzEzMzA_cf84a27c-1cee-4433-be7d-f1a4546f252a">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzYtNS0xLTEtNzEzMzA_912380f4-9e7a-4e01-986f-3da14d79b0ff">474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Other Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNDg_2ef2c5c7-d887-44b0-a2d2-d1da40bc5645" continuedAt="ib204197ad4a04165b8339b06196e421f" escape="true">The following amounts were reflected as components of </ix:nonNumeric></span><ix:continuation id="ib204197ad4a04165b8339b06196e421f" continuedAt="i39c8efb8c27f4b3bb55a14db33f96364"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></ix:continuation></div><div style="margin-bottom:1pt"><ix:continuation id="i39c8efb8c27f4b3bb55a14db33f96364"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:28.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMS0xLTEtNzEzMzA_7341ab96-8b73-4170-b613-6381acb784e6">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMy0xLTEtNzEzMzA_b73ee734-ac1a-4888-b59f-80ba6c4a0a72">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtNS0xLTEtNzEzMzA_02f0bad9-dc37-446f-81fc-fbf5c687ddca">472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtNy0xLTEtNzEzMzA_30af10ea-38a9-44fc-b6be-1dbd26bb6fde">116</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtOS0xLTEtNzEzMzA_e16b0b3b-7118-4a4e-8adf-0e9f9ad0ecb4">772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTEtMS0xLTcxMzMw_7a2b60ed-1c13-46ac-94a6-78f57343a5db">424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTMtMS0xLTcxMzMw_78a3fb5b-0737-44ce-ae3a-6274349fb86d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTUtMS0xLTcxMzMw_62a6e5fe-d804-4447-b709-d5e68e024e2e">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTctMS0xLTcxMzMw_65acdce6-768a-4188-a946-da1db77571ec">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMS0xLTEtNzEzMzA_070a6ea9-1f7d-4c5d-9f80-99418b2cfba3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMy0xLTEtNzEzMzA_6cb7a105-68c3-4224-941e-ec8c049c3476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtNS0xLTEtNzEzMzA_8079b9c4-92e1-40ff-b7d3-60d90194538f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtNy0xLTEtNzEzMzA_9951b6be-6f0c-4415-901d-8254c1915f96">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtOS0xLTEtNzEzMzA_ebf868a2-0437-4b89-b6d5-9768fe88cbec">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTEtMS0xLTcxMzMw_ff625f15-83e8-4d00-8776-7f844d45e968">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTMtMS0xLTcxMzMw_4dd7ab5a-94e8-4044-883f-33196342733b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTUtMS0xLTcxMzMw_0b7cecca-71c1-45b2-878e-cb615194f39b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTctMS0xLTcxMzMw_825470b0-c47e-44b1-8685-af11321c883c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMS0xLTEtNzEzMzA_cc397ab9-bc40-4029-a80b-7ef7a09deb01">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMy0xLTEtNzEzMzA_ced7083e-d6c9-4d96-94db-1ce2adec6c90">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtNS0xLTEtNzEzMzA_da9894cc-67e2-4197-b736-aa8478a684ac">472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtNy0xLTEtNzEzMzA_9526d649-7b58-48bf-9bac-807c444900d6">112</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtOS0xLTEtNzEzMzA_8fd0db8e-c2bd-4734-b8c9-5ea4011ec2db">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTEtMS0xLTcxMzMw_bd3030af-543c-4a28-ab51-deb3fa2bc335">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTMtMS0xLTcxMzMw_7aefee40-dcd7-4acd-8f80-94d789e625bd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTUtMS0xLTcxMzMw_b372d697-a87e-422f-a009-2a4c5599a7ec">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTctMS0xLTcxMzMw_b096b5d5-6322-4972-bcf2-b475da139dcd">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMS0xLTEtNzEzMzA_7573dd99-a039-4448-bfda-a7a643b4afb5">128</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMy0xLTEtNzEzMzA_ae3dbfbb-81e7-43a1-aad1-366761e574a6">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtNS0xLTEtNzEzMzA_e9937d38-1193-49db-bc59-692d0d001484">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtNy0xLTEtNzEzMzA_6702faaa-7dec-4a68-848c-7a265cda3b59">96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtOS0xLTEtNzEzMzA_65f835ec-2d77-4c5c-9d09-a0db8de6282d">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTEtMS0xLTcxMzMw_c4770866-3fcf-4f08-b848-4246121c2c63">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTMtMS0xLTcxMzMw_bb9813cb-d113-465b-994c-b05804b59772">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTUtMS0xLTcxMzMw_a5a7263c-1c3e-4e03-9f2d-7b82fd1abcb1">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTctMS0xLTcxMzMw_60f9cd76-c45b-4f3d-bc2c-dcc0ba919619">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMS0xLTEtNzEzMzA_1c162905-c423-4dd2-ab40-5a9053a0c012">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMy0xLTEtNzEzMzA_d302d759-dac0-4568-be5b-f4644b0ee535">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctNS0xLTEtNzEzMzA_af15ecc7-9233-4422-8add-ab72b2f463ea">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctNy0xLTEtNzEzMzA_6e9ce20f-1731-44ad-8f91-58b903f29baf">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctOS0xLTEtNzEzMzA_ae7e8439-82da-4800-8f84-bcff433b6521">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTEtMS0xLTcxMzMw_9a4c6aaf-0888-4250-bf74-f6393a886ec0">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTMtMS0xLTcxMzMw_f724a25d-f378-4519-a933-f331c16a41f9">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTUtMS0xLTcxMzMw_620dc2ab-c69f-4d9a-b46c-04c320e4f01e">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTctMS0xLTcxMzMw_be65e6be-4f8e-458c-9515-7af1b79a7f94">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements and curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMS0xLTEtMTMwMDAx_505c776b-e36c-401f-a670-edc5ae8e4a4f">251</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMy0xLTEtMTMwMDAx_61290977-dddc-4536-ade9-5f873e3fca5e">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNS0xLTEtMTMwMDAx_6580cee8-f8cf-4f1c-9db1-d50710830c98">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNy0xLTEtMTMwMDAx_441758a2-a7c5-482c-8038-9d18a89bba2d">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" sign="-" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtOS0xLTEtMTMwMDAx_2a7b3fb2-7e02-48fa-9f15-aa6a75be696b">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTEtMS0xLTEzMDAwMQ_aedcf657-602b-4bb5-ab92-b7ceb6bce926">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" sign="-" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTMtMS0xLTEzMDAwMQ_2ab61774-ed63-43e2-8690-16a1b4030fbc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" sign="-" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTUtMS0xLTEzMDAwMQ_daa0937d-4fa4-4f48-87ab-970d021117c8">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" sign="-" name="mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTctMS0xLTEzMDAwMQ_3ac0c45b-9579-445d-a6c6-c6802376a3df">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMS0xLTEtNzEzMzA_60173a39-7ab1-4a53-a756-3028e27831e9">347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMy0xLTEtNzEzMzA_bf035354-ed6d-4532-a3cc-deb7fbbee31d">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNS0xLTEtNzEzMzA_558875f5-bb04-42eb-9755-45d186579cbf">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNy0xLTEtNzEzMzA_24d22d18-97fb-4ebb-9a4d-82db92b44e71">83</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtOS0xLTEtNzEzMzA_1d55d243-52eb-48e5-bb20-1ea2ea882d32">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTEtMS0xLTcxMzMw_4f44a063-494c-448e-b7b8-7a3b3734ee34">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTMtMS0xLTcxMzMw_0e1e6eff-1d6a-4712-9f02-47ae2e666743">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTUtMS0xLTcxMzMw_7165e777-2e42-4146-baa9-a8be4e6201dc">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTctMS0xLTcxMzMw_aa33cea3-afa4-4b38-a27b-6814f4cc46c7">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="iaffa2e97c20c491b990430c7f3c9fd4c"><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Actuarial Assumptions</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNTE_ac6ea9c3-ec7a-43b8-9285-e6ad8bf5ceab" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:33.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtMS0xLTEtNzEzMzA_13998342-0f5f-4863-a587-13ca9e77d576">3.00</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtMy0xLTEtNzEzMzA_03c40f5a-368b-48be-b827-665aede1bf52">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtNS0xLTEtNzEzMzA_3ac0c61c-18cc-4ad9-9310-8248cbb27710">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtNy0xLTEtNzEzMzA_4382ba7d-71f9-4616-abf1-857ed25402ab">1.50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtOS0xLTEtNzEzMzA_300896f4-117a-4149-8c77-d10e0004cc4e">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtMTEtMS0xLTcxMzMw_58e16abf-fbbe-4f81-8b29-a1adf823bd42">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtMS0xLTEtNzEzMzA_9ff6c1a0-79bb-43bb-9f89-269ae156b532">6.70</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtMy0xLTEtNzEzMzA_1757b659-daa3-4a52-8b25-2a2c7edc0a0c">6.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtNS0xLTEtNzEzMzA_6196e709-a697-43ff-9f5a-4960b7ad13c4">7.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtNy0xLTEtNzEzMzA_415d9f74-9e91-4b8e-b000-dcb6a42992c5">3.70</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtOS0xLTEtNzEzMzA_7d3ef875-f055-4979-9519-a78cf2b590d7">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtMTEtMS0xLTcxMzMw_c640caf0-39af-4344-8405-517ac652bdb3">4.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtMS0xLTEtNzEzMzA_23a69ed7-29fc-4f68-b26c-3e2990e37620">4.60</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtMy0xLTEtNzEzMzA_1be9e3f1-49b3-4b2b-8575-cf728d2fe8b8">4.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtNS0xLTEtNzEzMzA_c3f4bbc4-fe5f-46ac-870d-a4641e8d3210">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtNy0xLTEtNzEzMzA_ab21dc96-3d0d-47b0-a90e-c760c799ecef">2.90</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtOS0xLTEtNzEzMzA_f8bc60da-9c19-423e-b70b-1b38531df22b">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtMTEtMS0xLTcxMzMw_ba0522c1-4528-47a0-8ab7-e15c27c4b439">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtMS0xLTEtNzEzMzA_2b3c3129-492a-4e07-9df5-f578fb3001e9">5.00</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtMy0xLTEtNzEzMzA_39d4028b-8e4b-4359-a37c-4aa3b8044fa1">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtNS0xLTEtNzEzMzA_f7bf8538-f8aa-4a9a-a02b-2956ef335449">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtNy0xLTEtNzEzMzA_2b974006-ba58-4ea0-bdc2-a0bd2531cd93">3.00</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtOS0xLTEtNzEzMzA_94ab29b9-ca79-45f0-b878-c6ee1e016774">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtMTEtMS0xLTcxMzMw_24e03794-bb2a-406c-89d2-59216d6466db">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtMS0xLTEtNzEzMzA_c3696ee9-6fb3-4845-af5e-bac797058243">5.50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia358ddcd5cd64c81874827bf799c7cbb_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtMy0xLTEtNzEzMzA_90067ecc-038a-49a6-a833-ca8afb3402d1">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69c9e567da174a86ad13d7332a5ceace_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtNS0xLTEtNzEzMzA_cab327fb-214a-4362-b86d-a96b494d7b30">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtNy0xLTEtNzEzMzA_369a33e9-34a7-433e-be62-3823a71f29cd">3.90</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtOS0xLTEtNzEzMzA_34b62e2c-a845-4659-971c-8e2a8c185057">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtMTEtMS0xLTcxMzMw_7a5fbf36-8993-48ef-add2-849a41c6c8c1">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktMS0xLTEtNzEzMzA_9a897332-aaf0-493b-99a9-01440548d06a">4.60</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia358ddcd5cd64c81874827bf799c7cbb_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktMy0xLTEtNzEzMzA_9ecd1145-cd86-4b2a-942c-36fa711f1816">4.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69c9e567da174a86ad13d7332a5ceace_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktNS0xLTEtNzEzMzA_14eb529b-9dad-4e51-8727-887287f4a437">4.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktNy0xLTEtNzEzMzA_6737f2d0-e8fd-442a-84ba-760b9338e04a">3.20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktOS0xLTEtNzEzMzA_063e19bd-2e2e-4af0-abbf-f8dbfc789422">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktMTEtMS0xLTcxMzMw_87fb493f-dc26-4bda-be7a-681136e9e2ac">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTEtMS0xLTcxMzMw_2c553902-3b82-4aca-84e6-e6f8e0b6df46">5.30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia358ddcd5cd64c81874827bf799c7cbb_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTMtMS0xLTcxMzMw_48136255-14ea-434c-bbff-5c105df62ac6">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69c9e567da174a86ad13d7332a5ceace_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTUtMS0xLTcxMzMw_33f0be74-3051-478a-83a7-b91486928276">4.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTctMS0xLTcxMzMw_e0762e8c-1735-4239-8f7f-773b1322cee9">3.30</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTktMS0xLTcxMzMw_36c6f252-31b0-4ae8-bbc4-c8667d3915d4">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTExLTEtMS03MTMzMA_756c8366-6cb2-4c36-9a6b-344220dff12f">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#8217;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will be <ix:nonFraction unitRef="number" contextRef="icd3d23b42991496e8be8317108cbd31b_D20230101-20231231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzg4NDk_59703844-ec16-4647-b8b0-bc6857a5df02">7.00</ix:nonFraction>%, as compared to <ix:nonFraction unitRef="number" contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzg4Nzk_dd503120-53af-46d2-a87d-2910a0c3cf74">6.70</ix:nonFraction>% in 2022. </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNjE_5a5da785-5898-4400-a1ac-0443f8bb9149" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzEtMS0xLTEtNzEzMzA_5497411d-1622-4bca-baf2-eb535f551e92">7.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzEtMy0xLTEtNzEzMzA_24eb3825-096e-40af-9f6f-fc64afa9caec">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26d66e8191e3489da8b88251530ce552_I20221231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzItMS0xLTEtNzEzMzA_78efc0fc-11f8-43cd-97f4-dd23758aaa67">4.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i047b115329a54c42a89e9abfb277e348_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzItMy0xLTEtNzEzMzA_fe3c93e2-0950-4b61-8a8e-d41b1ac84f33">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkyOTc_b1ad66e5-d6b2-4c7f-b8f8-b9a639bf003f">175</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMDE_1ef571af-c980-464e-8e5d-8fbd1cbee6d6">158</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMDg_e003a200-7745-4cb5-b314-b97e2aef4122">158</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_193"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;Other (Income) Expense, Net</span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg5Nw_1d662b78-95af-40a3-b443-9533f3d91c2f" escape="true"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg5OQ_9667e50e-55b1-4c50-a3e5-40baada8aa5c" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzEtMS0xLTEtNzEzMzA_3289cd64-0e6c-40d7-ac4e-71e107fffe5f">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzEtMy0xLTEtNzEzMzA_09e4294c-1a84-4375-9cad-df82c7730ba1">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzEtNS0xLTEtNzEzMzA_1243dfe7-de9e-4309-9143-797014d1d190">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzItMS0xLTEtNzEzMzA_3354405d-9ad6-4717-9071-22a5cd75f3e5">962</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzItMy0xLTEtNzEzMzA_9a070c0a-8625-4d4b-8b93-0e6b207be272">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzItNS0xLTEtNzEzMzA_d20bdd11-1329-4159-9ff3-078265e9960a">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzMtMS0xLTEtNzEzMzA_64f446cd-be36-4518-8d7e-52108e4f5cd2">237</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzMtMy0xLTEtNzEzMzA_82d4fd92-643e-461f-a37e-30b2f6ecabdd">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzMtNS0xLTEtNzEzMzA_efc6b2d0-61b3-43cd-8847-103e57b0fe28">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzQtMS0xLTEtNzEzMzA_80372a46-f6aa-49f7-a4fc-2597d3f83af7">1,419</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzQtMy0xLTEtNzEzMzA_3bc2d4a6-f044-4475-b484-701af3551567">1,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzQtNS0xLTEtNzEzMzA_ebf0450e-a91b-461c-b48c-3d0bc1b80fad">1,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzUtMS0xLTEtNzEzMzA_c73ab68c-f7b7-46ab-9278-428078ae565a">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzUtMy0xLTEtNzEzMzA_da851cb9-4f25-4881-8a52-c9caa994e2b7">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzUtNS0xLTEtNzEzMzA_2a796b00-b376-421b-8e0a-dfb50badabe2">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzYtMS0xLTEtNzEzMzA_33fbfe20-e0d4-4166-95dd-d0f866c0457a">681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzYtMy0xLTEtNzEzMzA_e1a780e2-8782-47e3-b87f-5fe965fa60e9">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzYtNS0xLTEtNzEzMzA_2b68c7ff-d5fd-4800-82c3-79c12bfed5cd">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzctMS0xLTEtNzEzMzA_9b635efd-9654-49d8-ba30-9569211ced22">1,501</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzctMy0xLTEtNzEzMzA_8d08a3cb-b7b5-4b68-be54-f85c0109d38b">1,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzctNS0xLTEtNzEzMzA_a35dc228-7605-4ab4-b165-d523b7ce57d3">890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $<ix:nonFraction unitRef="usd" contextRef="ie41dca853a9a42358f40da6cbd07030c_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzE2NDkyNjc0NDQ4NzA_efd7c1dd-c5f6-4d82-9585-209bd66f41bb">140</ix:nonFraction>&#160;million will be recorded in the first quarter of 2023 from ownership interests in investment funds.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid was $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg2Mg_eae1c7a5-6d0c-4728-a128-0b766a3f0099">937</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg3Mg_737f5399-d8fd-4457-8c13-ce85bc19a73f">779</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg4NQ_0491a4ef-8edd-4345-8be8-8347050e66f7">822</ix:nonFraction> million in 2020.</span></div></ix:nonNumeric><div id="ia384118d157240e09e39541b90e2080f_196"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYzMDM_318d8734-038e-4b80-bdc5-da1d58b26f33" continuedAt="id2451183106b41069b5b41ae83ba2743" escape="true">Taxes on Income</ix:nonNumeric></span></div><ix:continuation id="id2451183106b41069b5b41ae83ba2743" continuedAt="ie7198936f2254bb8a0542cab2d07365a"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNzI_2a75b337-693c-401e-81b6-9c0090184e8f" continuedAt="if22b3b2f3008485eb2e93b66d2459446" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:35.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItMS0xLTEtNzEzMzA_17e40a1b-85c5-4d27-99ae-7b4fadf3b9fd">3,453</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItMy0xLTEtNzEzMzA_82846773-45fc-43c4-be30-31f752a94d58">21.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItNS0xLTEtNzEzMzA_c08f8b7d-b202-4d8a-9467-49342b274773">2,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItNy0xLTEtNzEzMzA_f941973f-c597-463b-ba9a-6426b0c1e798">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItOS0xLTEtNzEzMzA_ca785e07-5e99-43bf-bee9-bb476022f278">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItMTEtMS0xLTcxMzMw_ee4f1c29-b1e0-4dbf-8a08-a420e2fa6b2a">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtMS0xLTEtNzEzMzA_b6682281-30aa-4354-b6ff-3dcd3de0c89d">1,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtMy0xLTEtNzEzMzA_e2488e67-5f36-487e-9f12-a8356c00ac18">11.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtNS0xLTEtNzEzMzA_3302d963-5a87-44f0-a36a-5bcf018da33d">1,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtNy0xLTEtNzEzMzA_73987fe5-bce2-4b64-9865-e22eaf4db002">10.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtOS0xLTEtNzEzMzA_807c1884-ed3e-40ed-bc87-7959734527f8">965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtMTEtMS0xLTcxMzMw_dd99e533-e40f-4d91-83d7-75d8f214cc36">16.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtMS0xLTEtNzEzMzA_1be07e88-a2b9-4c0d-9696-f62d8817c6cf">462</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtMy0xLTEtNzEzMzA_57af7fac-4c5d-4c86-b369-9cb042533ed1">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtNS0xLTEtNzEzMzA_aec0c509-61cb-44e0-9a0b-8251218f4d79">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtNy0xLTEtNzEzMzA_8b20ba14-d46b-4280-9dde-70de8e36c041">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtOS0xLTEtNzEzMzA_3dbb0b09-57b4-40d9-86eb-9e3d29afc363">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtMTEtMS0xLTcxMzMw_444e7c8d-f419-41a9-8f68-015cf5f0377d">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMS0xLTEtMTIzNzk3_adc661c8-2d38-475b-9dd1-5511432466cf">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMy0xLTEtMTIzNzk3_89702a9a-ddaf-4c24-b8f9-bd27c0ebc4dd">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNS0xLTEtMTIzNzk3_b1e89406-ee53-4250-9a30-a8adbe7dd18b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNy0xLTEtMTIzNzk3_a70b3da2-1576-472f-8f24-5722b86b5eaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtOS0xLTEtMTIzNzk3_7983b95b-b95a-4af1-98f7-4392b46e5235">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMTEtMS0xLTEyMzc5Nw_482970d0-2e63-4d09-be0e-5b01b2350d95">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctMS0xLTEtMTIzODA3_36b95bec-7461-4948-bee2-a4dcc425c31b">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctMy0xLTEtMTIzODA3_d38750d7-c595-4966-b75c-34445395a120">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctNS0xLTEtMTIzODA3_a65567d4-dfd9-46b3-86d5-57fbd8629be5">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctNy0xLTEtMTIzODA3_a1e3b209-69a8-4a11-941b-89b1931e9c58">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctOS0xLTEtMTIzODA3_968d9234-7ecb-4851-9b4f-15db5d444a70">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctMTEtMS0xLTEyMzgwNw_4bdecf03-c286-4930-85a4-40c102d3dce6">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMS0xLTEtNzEzMzA_6cb9cf55-3e92-494a-899f-adba5a78e44c">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMy0xLTEtNzEzMzA_783ba022-0ad8-4c77-8f23-de428dd3181f">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNS0xLTEtNzEzMzA_6a195574-c748-47f1-92c1-a8a970082bb2">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNy0xLTEtNzEzMzA_903bd7bb-5344-47df-9182-7818620c4723">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtOS0xLTEtNzEzMzA_6fdb2136-7738-4362-8f23-62cfb4180766">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMTEtMS0xLTcxMzMw_d410a99c-1945-4dea-acf2-c2eb3029baee">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTEtMS0xLTcxMzMw_34769b2a-4ffc-48bc-9c31-85f303a85b4f">108</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTMtMS0xLTcxMzMw_d4b461aa-58cf-46f6-bd67-21ad22c2fa0b">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTUtMS0xLTcxMzMw_1e0d1823-3ed3-41d5-ab17-b57aff7cef19">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTctMS0xLTcxMzMw_d9a2ebce-cb84-46cb-ad55-473103fc44a4">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTktMS0xLTcxMzMw_7b22d6c7-76a3-4de9-9c37-0a3d78589765">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTExLTEtMS03MTMzMA_409eea46-519b-43c5-b7e2-809dfa2cbe64">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTEtMS0xLTcxMzMw_6987e744-ff0f-47f9-82de-6ade404523d8">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTMtMS0xLTcxMzMw_988ca006-723d-49ea-851c-78eabfe1e1a5">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTUtMS0xLTcxMzMw_0adcb43d-7d18-4488-97c6-9a9610cd7d04">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTctMS0xLTcxMzMw_4f835376-26ab-41f4-9c8c-fca77a3991b7">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTktMS0xLTcxMzMw_aa9f0a3c-5023-46df-8db8-f599e736b4d8">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTExLTEtMS03MTMzMA_ec14c66c-6e5d-46e3-ab64-53c362e64243">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:IncomeTaxRateReconciliationAssetAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTEtMS0xLTEyMzgzNg_04919408-b9ed-4b7f-b406-b3be92d51a70">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTMtMS0xLTEyMzgzNg_c612e160-13dd-466c-ab73-bc11d02855e6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="mrk:IncomeTaxRateReconciliationAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTUtMS0xLTEyMzgzNg_12dce822-a57c-4c00-a678-5a08c0518eb2">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" sign="-" name="mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTctMS0xLTEyMzgzNg_a111ba13-eaa0-4ba0-bd23-f6d5c860355f">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:IncomeTaxRateReconciliationAssetAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTktMS0xLTEyMzgzNg_03aaccff-8905-41d2-bfee-c06a0e61313c">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTExLTEtMS0xMjM4MzY_6f8622f7-71fb-42ef-bd9d-c520281d9186">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTEtMS0xLTEyMzgzNg_4a392d4e-e12a-4381-9227-b60087f129b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTMtMS0xLTEyMzgzNg_7343733c-ecf1-463b-aea2-e524509c0280">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTUtMS0xLTEyMzgzNg_459a04d6-22b4-4ce0-8aa2-93a2aed3ba04">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTctMS0xLTEyMzgzNg_4fd7374e-39e3-4cc5-a600-a5c9deb7557e">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTktMS0xLTEyMzgzNg_0446b7c5-b092-4eb1-8490-75fcfc39e955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTExLTEtMS0xMjM4MzY_050b7dc4-b8b4-4a89-883e-c6fa1a9dc648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTEtMS0xLTcxMzMw_0997f7ef-a922-4b1a-99cb-2b9ac1e4f637">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTMtMS0xLTcxMzMw_7a4639cf-f46c-4952-8a01-1f569afb2640">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTUtMS0xLTcxMzMw_8378f853-4dfb-41fe-ac7f-43e2a48167af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTctMS0xLTcxMzMw_3d1d8aba-a71a-417a-8388-727fa76538fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTktMS0xLTcxMzMw_fd6e4266-edcb-4a30-a21d-07ae1cebd616">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTExLTEtMS03MTMzMA_83648576-2a6f-435f-b326-7c6d6b718fd2">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTEtMS0xLTcxMzMw_66e08514-b123-45de-b3ad-19fd3a07e1e7">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTMtMS0xLTcxMzMw_90f9154d-50c2-409f-a665-316298e19414">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTUtMS0xLTcxMzMw_bdffcf71-211b-4f09-ac95-f4a78eb52cb6">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTctMS0xLTcxMzMw_2de0c979-bf2a-43bc-a912-6ffaab17b5bf">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTktMS0xLTcxMzMw_bec549aa-0a35-4e18-a4ab-4fd52f86d07e">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTExLTEtMS03MTMzMA_40bde485-00b2-456c-9c60-6da814e55ba4">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTEtMS0xLTcxMzMw_e5830928-e46a-4d89-97d9-d4e33aa5830f">1,918</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTMtMS0xLTcxMzMw_67e5cfd3-f693-48c7-ba3c-85dd90b67faa">11.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTUtMS0xLTcxMzMw_c6a37df6-f1d4-4c6e-bb05-328a281c9bcd">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTctMS0xLTcxMzMw_789d4054-437b-41a1-be3a-40f5d7882721">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTktMS0xLTcxMzMw_6603544c-0e26-42b1-bc87-11900bae87aa">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTExLTEtMS03MTMzMA_b8195201-0f3b-4ef9-88cc-7eb2cdc26cac">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="if22b3b2f3008485eb2e93b66d2459446">Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the utilization of foreign tax credits, was $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzczNQ_42d26ca7-6d09-43b2-b9e9-cda2d575b156">2.2</ix:nonFraction> billion at December&#160;31, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="i6e60950b557f4677846291e08c9270f0_I20221231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5Xzc1NA_f00ccc48-f4f2-4fbb-93c2-aabe47aaa643">732</ix:nonFraction> million is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the remainder of $<ix:nonFraction unitRef="usd" contextRef="i44fa248a36c14567824971ef9f972e05_I20221231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzgxNA_dac4cf12-47b2-454b-b91b-4d003780680e">1.5</ix:nonFraction> billion is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="ie7198936f2254bb8a0542cab2d07365a" continuedAt="i0e2830a21db34ce0a95356daf48485ac"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNjU_a337858c-55cd-4025-8d62-f6fde591a80a" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzEtMS0xLTEtNzEzMzA_5790d42f-347a-4e4b-922a-d0b83448bd3c">1,011</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzEtMy0xLTEtNzEzMzA_290161cf-49ba-4451-9212-6bc57bbd745f">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzEtNS0xLTEtNzEzMzA_8b2e1b3d-27c4-4f8a-af88-fe2b30b7e923">3,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzItMS0xLTEtNzEzMzA_464763b0-e7ee-40e6-90c7-93ca5b9443fa">15,433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzItMy0xLTEtNzEzMzA_43efff40-b55a-40f0-9db4-bcd5a51f469c">12,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzItNS0xLTEtNzEzMzA_307f429c-8e9d-4a1c-af8a-53e595291945">9,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzMtMS0xLTEtNzEzMzA_3e968f39-76f7-4dc1-bd9b-f5140f0c45d1">16,444</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzMtMy0xLTEtNzEzMzA_dac9b709-c769-46d8-80c8-20940cbc3b49">13,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzMtNS0xLTEtNzEzMzA_36972307-1ebb-439a-b04a-29bfc2e3cdb1">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYzMTg_b227dd8c-f687-478e-a087-d8c9fc7a2036" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzItMS0xLTEtNzEzMzA_2c8faded-ca8d-4b2c-9deb-cbee49459882">2,265</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzItMy0xLTEtNzEzMzA_9c4f99aa-f5d7-4fda-a37e-32a2b14decbf">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzItNS0xLTEtNzEzMzA_7cac91a7-76af-442f-87ca-6140f7d0d023">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzMtMS0xLTEtNzEzMzA_9c9143de-a873-4dc0-8af6-2226bf0e1297">1,164</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzMtMy0xLTEtNzEzMzA_8b5a4642-38f6-4b99-9231-fc91cc6d756f">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzMtNS0xLTEtNzEzMzA_bf125e95-4cc9-474d-91d4-59eba704f123">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzQtMS0xLTEtNzEzMzA_31026992-c1f3-41c2-b66f-a25b238a611e">57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzQtMy0xLTEtNzEzMzA_7086be82-f6a7-4c76-925d-1dc784ff7e75">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzQtNS0xLTEtNzEzMzA_e306b544-4715-4a30-8477-579241731eb5">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzUtMS0xLTEtNzEzMzA_b410f373-8e5c-40c5-bcd6-b9387edc930f">3,486</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzUtMy0xLTEtNzEzMzA_22f2c00a-5c55-40f7-8783-250eaa3fb016">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzUtNS0xLTEtNzEzMzA_a1aaee12-b27e-477f-a2d2-c086170ffbea">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzctMS0xLTEtNzEzMzA_d4ca7519-e933-41e3-9ec9-cd349cf0af2d">1,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzctMy0xLTEtNzEzMzA_00c3942d-f893-4657-a900-c1017515a1c6">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzctNS0xLTEtNzEzMzA_27742abb-48c8-4c30-a7d4-9d765229ed5e">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzgtMS0xLTEtNzEzMzA_59db07d5-1d5c-4dab-9278-f97cd0135e0b">71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzgtMy0xLTEtNzEzMzA_10dcca18-8e56-4844-887c-dc5c7b012368">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzgtNS0xLTEtNzEzMzA_ed8fa6b8-5751-4469-95fd-bd90bcb01ee8">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzktMS0xLTEtNzEzMzA_762ceb38-f20b-4568-a4a6-341d756e1ddd">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzktMy0xLTEtNzEzMzA_9fd7cf6d-bade-4385-9cf6-52d4203e3b54">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzktNS0xLTEtNzEzMzA_0193065b-9fc6-4067-83a1-525ceb1f9ec6">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzEwLTEtMS0xLTcxMzMw_d1330683-0e3e-43fc-ad02-7f4cff09c1b4">1,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzEwLTMtMS0xLTcxMzMw_f0ae5aa2-e413-4d8c-8c8d-ad06af883b95">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzEwLTUtMS0xLTcxMzMw_7a227a4f-ff8f-4f5e-8692-08510506fd9e">566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzExLTEtMS0xLTcxMzMw_bc4c5401-0584-4dba-b3c6-1922209be9eb">1,918</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzExLTMtMS0xLTcxMzMw_8be0a966-795f-4ace-bdd8-08e86072c914">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzExLTUtMS0xLTcxMzMw_b053ec8b-8929-488b-bf8c-85a3811581f0">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNzM_b7293eb6-96a5-4d10-9cd3-de9a82326ac8" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItMS0xLTEtNzEzMzA_8467ad79-b102-4b37-afc9-b627755ccdbf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItMy0xLTEtNzEzMzA_74bf220e-ae8c-480f-9b78-561b4c441288">2,575</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItNS0xLTEtNzEzMzA_bddf9a3d-3212-4f3d-bc67-25f215f7bd19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItNy0xLTEtNzEzMzA_21dead6b-3e00-4b2f-ba4f-51bdd795bc41">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtMS0xLTEtMTI0MDQz_97bf41d9-ea22-48bb-9da3-899b3283989d">1,341</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtNS0xLTEtMTI0MDQz_61a8befd-9422-4271-907c-5ea822be0e28">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtMS0xLTEtNzEzMzA_16850aa0-db4e-4e83-9fd0-cc3fb98a226e">43</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtMy0xLTEtNzEzMzA_031facab-f66d-47b5-8e47-95b181fb33ff">423</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtNS0xLTEtNzEzMzA_5c3e6516-7a8b-4893-92df-927e8a904848">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtNy0xLTEtNzEzMzA_cb235eba-9f43-4c57-949f-cc1879cef6f0">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtMS0xLTEtNzEzMzA_9045aae0-6899-4463-951a-645fc4991c95">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtMy0xLTEtNzEzMzA_65a28b50-7aba-482f-955f-d1b111486eff">657</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtNS0xLTEtNzEzMzA_7b83526e-ad9d-4b34-b94d-bb6b58d0e9e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtNy0xLTEtNzEzMzA_f7a0d58b-8771-4726-a284-085e3508031a">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtMS0xLTEtNzEzMzA_678ecccb-8d52-449e-8049-5d08072eb4b2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:DeferredTaxLiabilitiesEquityMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtMy0xLTEtNzEzMzA_c9ca9178-fae2-4b2b-a242-219524858f03">92</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtNS0xLTEtNzEzMzA_91d12b1e-8cef-4de8-8bb2-8883d52c72d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="mrk:DeferredTaxLiabilitiesEquityMethodInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtNy0xLTEtNzEzMzA_5f7c0966-593c-462c-811d-cf37f4040a61">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtMS0xLTEtNzEzMzA_7051acd5-89be-4ecb-b08e-16fd71e78b16">372</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtMy0xLTEtNzEzMzA_a8985e36-ba62-49d5-ae0e-fb145f6209db">284</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtNS0xLTEtNzEzMzA_c4e42e88-2fad-42af-8c25-7c07d39d9a85">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtNy0xLTEtNzEzMzA_827eb3e7-09a2-44dc-acfb-4893974d0220">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzctMS0xLTEtNzEzMzA_11ac0d57-3bc5-4d80-acb2-ea16f60e5169">335</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzctNS0xLTEtNzEzMzA_28d23045-a6c6-4418-80fa-64ca976985db">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:DeferredTaxAssetsUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzgtMS0xLTEtNzEzMzA_f2594d95-c586-4c83-8855-9b64e226309c">91</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="mrk:DeferredTaxAssetsUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzgtNS0xLTEtNzEzMzA_ad625103-33cc-4ac3-9add-81704af9cdd2">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzktMS0xLTEtNzEzMzA_57428060-4d5e-4d06-ba99-a1d9334844fb">912</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzktNS0xLTEtNzEzMzA_60fac604-54a9-4818-a493-93acbf1396b3">867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTEtMS0xLTcxMzMw_0503ffed-df02-4444-9983-057fa7a513a1">511</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTMtMS0xLTcxMzMw_99466100-f016-40b5-93c9-4074d4fecede">267</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTUtMS0xLTcxMzMw_21a7608a-1e96-49a0-8d24-072c9e39c63d">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTctMS0xLTcxMzMw_d8ff38fd-0d3f-479d-92c8-285fbf39ef8d">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTEtMS0xLTcxMzMw_31f594af-3bc7-44d1-917d-684772dab6bb">3,605</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTMtMS0xLTcxMzMw_b366fcb3-4ad7-44a3-8110-8db0fd330bef">4,298</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTUtMS0xLTcxMzMw_a6282203-41c4-4ea2-a6a7-af925d15f040">2,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTctMS0xLTcxMzMw_8b3320ca-2f20-4a4e-838a-96a3ed56a3b7">5,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEyLTEtMS0xLTcxMzMw_bcb73859-5b7f-4790-b5fc-8b672103cc38">599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEyLTUtMS0xLTcxMzMw_99d9ae99-51e6-4138-b697-7b8c9f67d66a">287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTEtMS0xLTcxMzMw_a6f17a1b-e54d-4135-9f59-2cc8915833c8">3,006</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTMtMS0xLTcxMzMw_b5767008-8d6b-463a-aad6-a9dbc092f84c">4,298</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTUtMS0xLTcxMzMw_0262b55a-96c3-461f-9274-791f99cfc7b7">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTctMS0xLTcxMzMw_c55c2e8e-8bb2-478e-821d-6d8d1bc99dc1">5,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE0LTMtMS0xLTcxMzMw_e59a7bfc-5424-47ea-a23b-ea4d8e671c5d">1,292</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE0LTctMS0xLTcxMzMw_ef35db07-e69b-47c8-8ab1-729993f54472">2,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5705ed276147c49ca285310c722e6a_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE2LTEtMS0xLTcxMzMw_513b94dd-62bd-45ac-861d-eb9e20168966">503</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf27171f8c7f483b8f695370dd8fed99_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE2LTUtMS0xLTcxMzMw_3216744d-ef10-472a-8521-030d03ecf5e8">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE3LTMtMS0xLTcxMzMw_d0bd5f2f-e07e-4363-9f73-b6db66292bee">1,795</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE3LTctMS0xLTcxMzMw_e9469ef1-eb5e-454c-8892-bcdc1e8dbe72">3,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzIyNDY_a71d3f19-1ad8-422d-ac7c-159afa2d3724">349</ix:nonFraction> million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="i540b17b98c5447ca8f7d0de2174e6403_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzIzNTA_7b9ddafa-0bda-4d8e-a9ed-86457638e55c">345</ix:nonFraction> million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI0Nzg_1684349c-0bfa-44d7-90c9-87b4a6884fba">563</ix:nonFraction> million of deferred tax assets relating to various U.S. tax credit carryforwards and </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i0e2830a21db34ce0a95356daf48485ac"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NOL carryforwards. Valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="i799b8472304c4a24aa87481dc87bcefb_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI2MDE_7550a4e7-2809-412c-82d3-c7eaeb1c796d">247</ix:nonFraction>&#160;million have been established on these U.S. tax credit carryforwards and NOL carryforwards. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid in 2022, 2021 and 2020 (including amounts attributable to discontinued operations in 2021 and 2020) were $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI3ODk_f242e315-cdb6-432e-ad08-2c2b5b567bd3">3.2</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI3OTM_56f9c994-e3ff-412d-91e9-da71b0c91913">2.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-8" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4MDA_f24f13b7-3997-4e75-9fb6-5d77700a69f8">2.7</ix:nonFraction> billion, respectively. <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="mrk:ScheduleOfIncomeTaxesPaidTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzM4NDgyOTA3MDg5MzY_34f1b9df-2f7f-420c-a258-02b32088b9c0" continuedAt="i59fe321dbf3244ec86fa7b9e32ebd9c1" escape="true">Income taxes paid consisted of:</ix:nonNumeric></span></div><ix:continuation id="i59fe321dbf3244ec86fa7b9e32ebd9c1"><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09a86e8c1434a81b69233805423f1e7_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzEtMS0xLTEtMTMwNDQz_0f77a23e-d324-42cf-9c3d-c64ed6d4d090">1,891</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0b703f3bba444fa6d4622ccfa960f7_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzEtMy0xLTEtMTMwNDQz_eddd1125-67b8-4af1-908d-0d282d171d00">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74765aa20bbc4bdd99d6913c1418a345_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzEtNS0xLTEtMTMwNDQz_45351ad4-e002-420e-bfc8-ddf592058737">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f82e1279454361b6876985ee31a5f1_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzItMS0xLTEtMTMwNDQz_d31f6eb5-4920-4d38-b614-c29b7bd566be">1,348</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4630f56a7e0a427882ad898683404c6e_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzItMy0xLTEtMTMwNDQz_df170b38-5a6c-45e5-9003-47b44d6fbd14">1,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ce7859bb6640678ff3056905b8d464_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzItNS0xLTEtMTMwNDQz_84bfa761-7ac0-49d6-8ef1-c3cf5e758c0a">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzMtMS0xLTEtMTMwNDQz_8657f5bf-c22c-4937-a649-ff70b181ed40">3,239</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzMtMy0xLTEtMTMwNDQz_18dccf76-4a62-4ab7-8405-8c402e634c2c">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzMtNS0xLTEtMTMwNDQz_7e884013-dab5-4cd2-bdb8-b31c16163b44">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes TCJA transition tax payments.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits relating to stock option exercises were $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4NzE_6ac1cf63-5910-40e6-bd6a-30a539ea456d">45</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4ODE_1a32c92a-4c10-4fd3-be62-957a2b694e15">21</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4OTQ_cc174fac-651e-4abd-ac3f-95cfe0c05795">12</ix:nonFraction> million in 2020. </span></div><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNzk_f792156e-1ec3-4fe1-8418-f7cd876590f0" continuedAt="i29eda247348b4cdf864ee3651b352c66" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzEtMS0xLTEtNzEzMzA_7c0d33ef-d30c-469f-9a5b-cfa06e945839">1,529</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzEtMy0xLTEtNzEzMzA_4051c830-c58b-4d75-a391-616a6e73a355">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzEtNS0xLTEtNzEzMzA_05336a04-4d72-4ef7-b029-b1c2740b5266">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzItMS0xLTEtNzEzMzA_dc1c3725-cb22-40b7-9425-9c0a148234f2">344</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzItMy0xLTEtNzEzMzA_2c8b8de6-1db1-4447-8c83-1027b6b97bc1">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzItNS0xLTEtNzEzMzA_dfc454ca-29b5-4474-89e0-8099dc2da54f">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzMtMS0xLTEtNzEzMzA_c01a0736-7bec-4873-85ef-f4368e89d8f4">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzMtMy0xLTEtNzEzMzA_8cbfaa9e-da22-4f0e-ba47-1d15f24085fe">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzMtNS0xLTEtNzEzMzA_c103b706-0828-4aa0-94d1-458f6d9d070c">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzQtMS0xLTEtNzEzMzA_33308061-d416-4b0d-bda0-df482a4077cc">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzQtMy0xLTEtNzEzMzA_6d930ce9-29b3-4d3a-8460-24361f2e18d6">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzQtNS0xLTEtNzEzMzA_c188dc46-923d-4c1e-9e59-7567f20904af">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzUtMS0xLTEtNzEzMzA_813ef534-9587-41d7-9e87-11491af79262">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzUtMy0xLTEtNzEzMzA_8b9fad93-77d7-475d-8c87-6bb82b3f4a04">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzUtNS0xLTEtNzEzMzA_4f19f31b-b1ea-4b7d-bdb8-17a1c3b85f0c">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzYtMS0xLTEtNzEzMzA_3a999127-4368-49fa-a8d5-18d5fa9a3611">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzYtMy0xLTEtNzEzMzA_30d9893f-dc2c-4108-9b71-843283e45635">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzYtNS0xLTEtNzEzMzA_a45616e7-38a3-46d6-83fe-15e2be01b089">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzctMS0xLTEtNzEzMzA_5814863e-a9a7-4862-a487-2ad430323886">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzctMy0xLTEtNzEzMzA_7425dbf6-3dab-46ca-9393-03d167a828fe">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzctNS0xLTEtNzEzMzA_deac34ca-f59c-40e0-8170-210a198db5a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzgtMS0xLTEtNzEzMzA_5b1d9050-d514-4a41-b816-6f4bf5c9c944">1,835</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzgtMy0xLTEtNzEzMzA_048f737c-9c32-459d-89de-59a5452384ff">1,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzgtNS0xLTEtNzEzMzA_1cf04f33-5906-41be-a9a7-7cf7dce86ace">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i29eda247348b4cdf864ee3651b352c66" continuedAt="id1124bd4632f44b98b45c21a5ccdec9a">(1)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="id1124bd4632f44b98b45c21a5ccdec9a">Amount in 2021 reflects a settlement with the IRS discussed below.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzMyNTE_20475311-8b41-4578-a936-35b6eba5d614">1.8</ix:nonFraction> billion at December&#160;31, 2022, the income tax provision would reflect a favorable net impact of $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzMzMjY_a13fdf16-11cd-4a98-9017-cafcc00ed2f0">1.8</ix:nonFraction> billion.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2022 could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzM1NzY_27ad9c2e-d827-42c3-99bc-4138b3ae9122">31</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#8217;s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQxNjI_9f04edb5-481b-45ea-a733-fd2fa886a560">54</ix:nonFraction> million in 2022, $(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQxNzI_934cc28a-1c96-4398-88f3-07e11dbe2542">37</ix:nonFraction>) million in 2021 and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQxODU_cc9ace09-96b5-4bf0-80ba-32338a8b82fa">16</ix:nonFraction> million in 2020. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $<ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQzNjM_5233288d-15db-4648-9d8b-601417aeed64">256</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQzNzA_7cbd996d-e09e-4080-b66a-beee9fe6d60c">192</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $<ix:nonFraction unitRef="usd" contextRef="i9f36c5d17d7f4ad793c7d79ff96b69c6_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ1ODg_96d0a382-9ecc-47f7-a7e1-b9c81581c7ef">190</ix:nonFraction>&#160;million (of which $<ix:nonFraction unitRef="usd" contextRef="i1fc09dc5008b41e08065acb6f23ea811_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ2MDE_a2e01dd2-dc33-412e-9a4e-314942001253">172</ix:nonFraction>&#160;million related to continuing operations and $<ix:nonFraction unitRef="usd" contextRef="ia160115328384ec0a210cc9247afaacf_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ2NDE_eb6d7719-0a96-4bd8-8546-86e9230e0c67">18</ix:nonFraction>&#160;million related to discontinued operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i9f36c5d17d7f4ad793c7d79ff96b69c6_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ4NjQ_317e61ec-b7c8-4775-a94f-3334384147f2">236</ix:nonFraction>&#160;million net tax benefit in 2021 (of which $<ix:nonFraction unitRef="usd" contextRef="i1fc09dc5008b41e08065acb6f23ea811_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ5MDE_36d4b521-fbb7-4197-81f8-5c666a497f91">207</ix:nonFraction>&#160;million related to continuing operations and $<ix:nonFraction unitRef="usd" contextRef="ia160115328384ec0a210cc9247afaacf_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ5NDE_68d0393d-21a5-4ea3-8bc3-8fd5b6fba06d">29</ix:nonFraction>&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IRS is currently conducting examinations of the Company&#8217;s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#8217;s income tax returns are open for examination for the period 2003 through 2022.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_199"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzQyOA_d4c8754f-e8f3-4a60-a335-ac367f63fb68" continuedAt="i7d3d2ab1050b4b7fa31ca6e2bc962329" escape="true">Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="i7d3d2ab1050b4b7fa31ca6e2bc962329"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzQyMQ_bdc7a18b-27db-4c92-925a-3c54e1dc9a5b" escape="true"><div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEtMS0xLTEtNzEzMzA_a0e1b605-d839-4933-b90e-00d9d5b969e7">14,519</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEtMy0xLTEtNzEzMzA_a5ee9495-d8d5-4d24-a6a7-28f60afa32c8">12,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEtNS0xLTEtNzEzMzA_1a4098ae-6759-464b-a207-d743e905fc1a">4,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzItMS0xLTEtNzEzMzA_e04a69e4-8ca8-4685-9b76-74087c9f0608">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzItMy0xLTEtNzEzMzA_7a55213c-865a-4948-a671-ce8081a1155e">704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzItNS0xLTEtNzEzMzA_57081eaf-1f88-44c9-8d01-c2e29d9e4efe">2,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMS0xLTEtNzEzMzA_448ecea6-0777-4863-9254-248eda20140b"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMS0xLTEtNzEzMzA_f4b794d0-b7fe-42b2-812e-8353c5209296">14,519</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMy0xLTEtNzEzMzA_84256e6e-76fa-4c0c-bca0-74b2a323bf1d"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMy0xLTEtNzEzMzA_85cb0b66-268d-4eb3-8d7f-37ba5f4c90c5">13,049</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtNS0xLTEtNzEzMzA_c6b2c670-725e-4459-acd5-39b7472be7d9"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtNS0xLTEtNzEzMzA_e60f0af1-905d-4860-8b1c-709c1972f46d">7,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzQtMS0xLTEtNzEzMzA_7aa3499b-24b1-42df-a7d2-1fce1c373957">2,532</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzQtMy0xLTEtNzEzMzA_4c4b6fcc-b1e0-4fc8-805f-cb8a85d7f01c">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzQtNS0xLTEtNzEzMzA_e4cd699b-3f1e-4de3-99c3-9cfa7be4d6c1">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzUtMS0xLTEtNzEzMzA_1f7d34ab-a9cd-4ede-b206-709163eba3e7">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzUtMy0xLTEtNzEzMzA_f6c0f96a-c22d-43d2-bdec-86b5fe9697f9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzUtNS0xLTEtNzEzMzA_7a30abd2-41c6-49c8-b29f-325627427bdf">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzYtMS0xLTEtNzEzMzA_9179da2a-e732-41fa-be4a-ed54892b2431">2,542</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzYtMy0xLTEtNzEzMzA_1ba8277a-2a09-4a46-a2c7-c270aeb5e7a6">2,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzYtNS0xLTEtNzEzMzA_edda18b7-f23a-4365-a35c-d91588c85c30">2,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzgtMS0xLTEtNzEzMzA_38ce9fe3-dddb-4256-acc2-86339f67c1f6">5.73</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzgtMy0xLTEtNzEzMzA_d078da01-07b9-4ed6-9a58-23077eba3926">4.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzgtNS0xLTEtNzEzMzA_d7df58d8-11cd-4788-a1da-5b8f7fc4b72b">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzktMS0xLTEtNzEzMzA_6c4ab11e-f54d-4ab0-be99-3786bbb7b81b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzktMy0xLTEtNzEzMzA_f106b890-9ab5-4df2-a214-b9ef2fb03e90">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzktNS0xLTEtNzEzMzA_9130e8d3-b758-48f5-8e37-b45b48199889">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEwLTEtMS0xLTcxMzMw_d31b7fdd-7a87-4a53-8aaf-ca6b6e5c4911">5.73</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEwLTMtMS0xLTcxMzMw_f7cfb750-a75b-4834-ba96-a786bb39cfcf">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEwLTUtMS0xLTcxMzMw_52af3c19-7df4-4e03-b19f-cec15c73e628">2.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEyLTEtMS0xLTcxMzMw_d5ae8368-7d57-4990-8905-147235f1815a">5.71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEyLTMtMS0xLTcxMzMw_dd3ecab5-6c29-4dc3-a9bd-a1c450d89ec0">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEyLTUtMS0xLTcxMzMw_2903af07-4adb-4231-8964-5b2f81489e2e">1.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEzLTEtMS0xLTcxMzMw_77f51d89-17cb-4344-a342-2815790145c2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEzLTMtMS0xLTcxMzMw_02072bf6-6a7b-464d-8ebe-3f5e6c8277ba">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEzLTUtMS0xLTcxMzMw_ec31b9bc-eb9f-4d62-93d2-be8abf61c39c">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzE0LTEtMS0xLTcxMzMw_85f84639-d65e-464e-85c9-7e4794082f03">5.71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzE0LTMtMS0xLTcxMzMw_85bf6f2f-cfd5-4e74-82f2-904a1f69d63a">5.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzE0LTUtMS0xLTcxMzMw_4c03e16c-f89a-4ac9-8853-48d49098720d">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, <ix:nonFraction unitRef="shares" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzE4OQ_03872f21-98c8-4c76-9f03-5c622f001bde">2</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzE5Mw_76fe2ab9-1921-4ca5-93d3-ab573a7dfb79">9</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzIwMA_f70f8138-269b-4fea-82be-678b5a68bd60">5</ix:nonFraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</span></div></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_202"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzkxOQ_cd51e341-b186-4545-86ae-2ec9b9575ec1" continuedAt="i2b88a3bfba1a4bdd8200a9bbf6e44e6c" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="i2b88a3bfba1a4bdd8200a9bbf6e44e6c"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzkzNDU4NDg4MzcxMzI_b066a821-3fc3-4bcf-a53f-64d08a1c3c93" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712fa8b98e5e4ccab42eee70db45d412_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtMS0xLTEtNzEzMzA_63c24ad5-32aa-4a98-85bc-cdd59ff8c135">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1639bac565704b8db1b75f669f2f8d20_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtMy0xLTEtNzEzMzA_11d350c6-57d6-4899-bab0-8a86a710d03e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35687940c55f4162a974c6fba1256951_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtNS0xLTEtNzEzMzA_8048ef14-7af6-4e25-98f8-3bc0393668a1">4,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98d2ea2a866e477993f83cbe1be3386e_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtNy0xLTEtNzEzMzA_c6838640-5bff-4650-b99c-4ecbe301bb70">1,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief9bf241be3f43c8aac25c903996f2e3_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtOS0xLTEtNzEzMzA_0a32c639-2360-4ea4-87e8-f8582a3808e8">6,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItMS0xLTEtNzEzMzA_f8a4a63f-23ac-4100-87f0-f683a0d8c0f2">383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItMy0xLTEtNzEzMzA_f5b55c16-a116-46d3-acab-f2ad3415cd76">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItNS0xLTEtNzEzMzA_cab3ecca-0458-4a39-aceb-2502bc5e9296">633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItNy0xLTEtNzEzMzA_0b914949-b53f-4a12-a921-ca0107641817">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItOS0xLTEtNzEzMzA_ea464807-a185-4b4c-be40-1ad03a0f212f">949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtMS0xLTEtNzEzMzA_a3291903-2d00-4b3d-99f6-de8fa0e66bd3">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtMy0xLTEtNzEzMzA_e033edee-0322-4853-8122-42b7b1fc5fad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtNS0xLTEtNzEzMzA_df971b4d-2291-4658-afa5-ccd56a636da6">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtNy0xLTEtNzEzMzA_d1bb41f5-344e-4b2b-b89f-5d80b6d0de52">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtOS0xLTEtNzEzMzA_6c517b57-2f0d-4c86-af11-87e36cbdd2e6">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtMS0xLTEtNzEzMzA_98514cfc-bada-4315-bbab-03876fe84df9">299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtMy0xLTEtNzEzMzA_1c6e48b0-8f5d-4e4d-ae09-d3a0692a4876">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtNS0xLTEtNzEzMzA_7042c2a5-4e16-4bdb-acd9-06002ff59a88">513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtNy0xLTEtNzEzMzA_42e5f49c-7717-47af-a530-aae55214e68b">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtOS0xLTEtNzEzMzA_aab453a0-f859-441c-bf0c-82586369ebc6">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtMS0xLTEtNzEzMzA_0409650c-8bcb-4927-938e-ed7e8426f743">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtMy0xLTEtNzEzMzA_c9c93cae-9006-41f3-8ef5-03bb17ae3114">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtNS0xLTEtNzEzMzA_55eec6f5-4520-4489-bb8f-5b36a01f731d">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtNy0xLTEtNzEzMzA_446ee64c-78d0-4685-9ecc-6ddffd0d382e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtOS0xLTEtNzEzMzA_6ba3709f-5b07-4e21-b29b-b712cfb056b2">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtMS0xLTEtNzEzMzA_f8d6c157-3338-4bc2-b6e2-55f8f23f1fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtMy0xLTEtNzEzMzA_de6a6055-1165-44e2-8ad9-a689d53e895c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtNS0xLTEtNzEzMzA_0aed6829-442f-4ee8-80b5-1879440751bd">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtNy0xLTEtNzEzMzA_a7455a32-ee89-4daa-ab45-6091f343f037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtOS0xLTEtNzEzMzA_1ffbb2a4-4bdb-4480-9647-6618e866bff8">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctMS0xLTEtNzEzMzA_b57f1f9a-5e96-4d52-9984-5256e415f2f6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctMy0xLTEtNzEzMzA_54f12b5f-dd99-4ce8-ae9b-b8172f876f4d">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctNS0xLTEtNzEzMzA_aec196a9-86c9-4fad-a440-f158083a331e">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctNy0xLTEtNzEzMzA_04859a07-9e5f-40bc-a89c-1c9567c4667c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctOS0xLTEtNzEzMzA_e11fcf4c-d552-4084-88c8-236bc3eb2ccf">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtMS0xLTEtNzEzMzA_be47cbdb-969d-4d03-b5aa-67228729e6db">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtMy0xLTEtNzEzMzA_c7c8ae78-62aa-42f5-b635-19ff6644e0a4">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtNS0xLTEtNzEzMzA_5a025a78-0317-459f-92fb-662bff8e3296">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtNy0xLTEtNzEzMzA_0257a248-e8f1-47d9-9db2-4da175fca3a6">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtOS0xLTEtNzEzMzA_7eefb35f-a972-431c-884a-5a4d1ca6c44d">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i780c56afcbfb4d95a44ba74fad92b717_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktMS0xLTEtNzEzMzA_0506ad6e-893d-4b4c-a6e3-2f0e4a82c49b">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10df6e4d4fef4be191cf9f09fe3b0e69_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktMy0xLTEtNzEzMzA_67d51b49-09a1-46bc-a44a-ac7fae511d5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b4f7ce11e074645a9ba948f88f64501_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktNS0xLTEtNzEzMzA_b36581b2-6f17-418e-92e6-60b5587bca26">4,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2100c8d9763e4e2aa3d44e5ab5e6f3ca_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktNy0xLTEtNzEzMzA_42e54493-7e5d-42f9-a731-dc4cf1bd302e">1,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8308747617614e9eab0ac29c4014c53b_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktOS0xLTEtNzEzMzA_d8a0965e-d81a-49ba-9b33-81e1938cffc2">6,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTEtMS0xLTcxMzMw_ab7817e6-5601-4ff0-be45-f37d44ca08f0">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTMtMS0xLTcxMzMw_f59b17bb-5ea1-4633-ac1c-fc58366bc0f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTUtMS0xLTcxMzMw_800eba1e-849f-41e2-9711-8320d04b40ee">1,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTctMS0xLTcxMzMw_016dcdcb-e91c-41da-ba4f-5fd9ac21da2a">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTktMS0xLTcxMzMw_e010f1c7-11be-4235-a498-a9b153cf3a7a">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTEtMS0xLTcxMzMw_5f3e0af8-754b-4005-8e02-bba86cc2b493">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTMtMS0xLTcxMzMw_158783b6-7ecc-455b-8182-7db2c7da32b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTUtMS0xLTcxMzMw_b67d0a7a-c75b-44b9-a546-2661ec9a0acc">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTctMS0xLTcxMzMw_a9eb7e30-16e7-4f70-a2ad-5e2c58706836">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTktMS0xLTcxMzMw_0aab5586-b367-4b6b-8e7e-33ec2247a935">526</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTEtMS0xLTcxMzMw_919ac1d3-84e8-4032-97c7-c4b7eec7a4ca">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTMtMS0xLTcxMzMw_b13728f4-3efc-41a9-ae09-6bf761b33d22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTUtMS0xLTcxMzMw_f8b551e0-2a3b-4bde-a081-3559ad51ae17">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTctMS0xLTcxMzMw_daa30d38-976e-49d5-9833-b2fed28ec755">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTktMS0xLTcxMzMw_026e8b33-6f30-4608-b22c-566ba02b793d">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTEtMS0xLTcxMzMw_31db5481-4162-49f8-aff3-eb1453538d8d">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTMtMS0xLTcxMzMw_148560cd-320b-47e8-887e-559f95af3c38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTUtMS0xLTcxMzMw_d172132e-7d31-46fb-863f-0719a1fcccdf">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTctMS0xLTcxMzMw_69bed09c-963e-4582-b33c-2449859a501d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTktMS0xLTcxMzMw_71d2cf38-07f5-4b38-acb8-9e3bd783e10f">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTEtMS0xLTcxMzMw_cd09aaf8-fed9-4ea8-808d-f5a1db40da70">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTMtMS0xLTcxMzMw_0162d672-58ee-4459-b414-3882837e3574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTUtMS0xLTcxMzMw_8f322412-1f5e-46e4-99a8-c11e619e78fe">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTctMS0xLTcxMzMw_b00c9f60-7ec7-431d-90c7-df94518fb20a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTktMS0xLTcxMzMw_8941f3ec-c073-429b-9cf2-801b29f30b04">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTEtMS0xLTcxMzMw_1169eae4-074f-40d9-9173-701af417c38c">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTMtMS0xLTcxMzMw_3b159be6-1961-40f7-af0e-fe6aac197376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTUtMS0xLTcxMzMw_afb35b8c-e777-4e72-81eb-1f0fd0d376e2">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTctMS0xLTcxMzMw_542c0272-8c09-4642-afa6-7afe73740bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTktMS0xLTcxMzMw_8fbbc6d3-8c78-4879-af83-c8db879c893b">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTEtMS0xLTcxMzMw_db8a23b4-1cdb-49e8-b4a9-e1656b1a019c">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTMtMS0xLTcxMzMw_73b89f1a-2d91-4452-ab82-bec83250bd67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTUtMS0xLTcxMzMw_0d9b9615-fe1c-4277-a5e6-e95ac3f4b08d">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTctMS0xLTcxMzMw_d9ea8c3b-8a1c-4db7-a570-e35e4285be5c">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTktMS0xLTcxMzMw_1d957535-0ad7-49c5-a50f-42e7b296b42e">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note&#160;3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTEtMS0xLTg0MTE1_caf6bbee-8596-49b7-baa2-979634de6a58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTMtMS0xLTg0MTE1_b468c05b-2e1c-4191-8552-df1ea83e665e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTUtMS0xLTg0MTE1_2ad00254-4ce0-49c7-9f95-df5ad44a9186">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTctMS0xLTg0MTE1_fc561335-6c69-44a9-bee7-bee35bc6ce3c">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7edbd57c4cf745c49a7f15beff700c5b_D20220101-20221231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTktMS0xLTg0MTE1_d4424168-0d7f-4147-bfb9-b4e14819f336">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4671bf8a444d7784d46176642a8000_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTEtMS0xLTcxMzMw_5694b9fd-bbc8-487c-a668-c61f3012eb27">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia053f4e630254ab8bd394403714172dc_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTMtMS0xLTcxMzMw_7c46900f-2844-4ca5-b939-31d215bf979f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i913f7d5516324116a41cb3fd560183ff_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTUtMS0xLTcxMzMw_57e3a00b-8f1d-4e20-9b34-1b192df17f44">2,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49e9678f0bde4535890e00b607c39661_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTctMS0xLTcxMzMw_ff30ade6-e5ad-4751-93b6-af63f45865c4">1,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i542103e76e6741a6805402bb88262b54_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTktMS0xLTcxMzMw_d78e3edd-9408-4ea7-816c-b4d0c4ae7d7c">4,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTEtMS0xLTcxMzMw_60c30750-ae46-4400-aa18-2f9e6ce7bf8b">684</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTMtMS0xLTcxMzMw_9c4f5388-f06a-4368-9448-892de5c6f40c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTUtMS0xLTcxMzMw_a642e4b2-0af8-4d11-b22e-0af8d4f9de5e">70</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTctMS0xLTcxMzMw_fb2d67a0-b330-42fc-84df-17ec06d86948">584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTktMS0xLTcxMzMw_56352165-4ba7-42b0-b0f2-b19054c4dc13">170</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTEtMS0xLTcxMzMw_30ba7d5d-f479-4dd7-ae59-b3ca51d697ee">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTMtMS0xLTcxMzMw_32fbca85-2884-4f34-81d4-082953fc33ae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTUtMS0xLTcxMzMw_b7e8176e-83aa-4c72-87f1-e37b94169114">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTctMS0xLTcxMzMw_8b08e043-5657-4dac-8686-26fec9674a9b">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTktMS0xLTcxMzMw_83b2d5db-a57b-4bfc-a573-43c011c89b13">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTEtMS0xLTcxMzMw_a1ac23ea-a591-473c-9c69-c30db87772db">541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTMtMS0xLTcxMzMw_a4421e8e-3347-4f18-a16d-d8b5c758b213">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTUtMS0xLTcxMzMw_9808d9c1-b681-4edd-8141-9a35728e56ce">82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTctMS0xLTcxMzMw_6508a604-61d5-4c96-93c8-10f361d48920">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTktMS0xLTcxMzMw_428b4dab-2fd1-4e70-a14f-8ea4a787e4f0">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTEtMS0xLTcxMzMw_2bba5f19-0ceb-471f-9b06-1431cd5bcccd">775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTMtMS0xLTcxMzMw_c996c871-7f7f-4005-8de1-0d63fdba4d30">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTUtMS0xLTcxMzMw_df560e86-82a9-4816-87a0-1515e9c361c9">329</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTctMS0xLTcxMzMw_ea933a38-2f58-4d88-ade2-c82175f574d6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTktMS0xLTcxMzMw_a5aad262-9b25-4e6c-9ecb-f69f26a27ea0">446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTEtMS0xLTcxMzMw_20eade2b-5919-4104-8f85-9b0797ddfe6a">163</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTMtMS0xLTcxMzMw_d32a519d-7a5d-44cf-ac4a-53308ded78ed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTUtMS0xLTcxMzMw_9f521202-8595-498c-b087-b7cf0f872c6e">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTctMS0xLTcxMzMw_ac13b9ac-3f92-42f1-8799-c79bbd8e106c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTktMS0xLTcxMzMw_3621b8e8-3146-4a98-b6df-6c85683b6dc8">87</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTEtMS0xLTcxMzMw_08193909-71e1-4623-b256-ca01dc1d1ede">612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTMtMS0xLTcxMzMw_469b0675-6c10-40d2-8dc1-67dfbe88d810">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTUtMS0xLTcxMzMw_17d5086f-d557-48f3-96c0-474f1b91d618">253</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTctMS0xLTcxMzMw_8dbe74a5-0897-4078-9146-065e4e94def3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTktMS0xLTcxMzMw_9ec12ddf-dac5-4989-822e-b58a8f80170c">359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTEtMS0xLTcxMzMw_ca6c471c-32fc-44bd-a4ec-2ad6adb4a214">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTMtMS0xLTcxMzMw_65fa7f15-1f56-4db0-9577-0b94977e5886">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTUtMS0xLTcxMzMw_f1b3393a-65dc-4103-8dcd-f4651397b45a">335</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTctMS0xLTcxMzMw_0f1e551a-3f78-4ac1-8e54-c1d8442e0e5b">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTktMS0xLTcxMzMw_14f44918-357e-4300-84d8-42343448a4c7">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7889eac2c64545bb3064c36a62e54c_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTEtMS0xLTcxMzMw_74fdee56-0358-428c-ad62-9998939c9ad4">73</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3213007d978d4f60ad986031900fb73a_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTMtMS0xLTcxMzMw_84696f9e-f0bd-4df9-a22e-79d077a1e3ee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i633b278a9073462da9b159814994a35a_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTUtMS0xLTcxMzMw_6b99cc8b-c6d6-4044-84f6-0001c1e7ad60">2,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5f13a2378f44c6bac00f3c347b5d737_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTctMS0xLTcxMzMw_794ab04b-4591-4400-9730-af43c35ec0b0">2,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1e6ddf39c24d7f843d5f7b097b9c69_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTktMS0xLTcxMzMw_21c2d271-0740-447e-afea-760296efb156">4,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $<ix:nonFraction unitRef="usd" contextRef="i3fec19785aa54818a2736cc335cd0740_I20221231" decimals="-8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzU1MQ_666ca1c2-3b3c-4c7a-82bb-81ea1c3f46e6">3.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iaaee5000881d4ca39ed66d7be4ecd22b_I20211231" decimals="-8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzU1OA_fa768fd2-3180-4f64-a49a-5a80161b7dee">3.6</ix:nonFraction> billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $<ix:nonFraction unitRef="usd" contextRef="i98661ac7371d4fd4b9c2f6c95474a731_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzY1Mg_9ef83800-65eb-42df-9b7e-717689732c82">446</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic0f4a1d4687e4f92b7cea51e261e5084_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzY1OQ_def9d190-fec3-4a53-a754-d00944bec2d4">473</ix:nonFraction> million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $<ix:nonFraction unitRef="usd" contextRef="ib9544cabffb54d55968d75c6c7d1efed_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzc1MQ_bb2ed551-a3ed-4ea6-84ef-df9a2a06d424">152</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01173ed3d18241a0a998253f0b59e277_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzc1OA_82222c67-8da9-4b29-98e1-eb691c6e00aa">190</ix:nonFraction> million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $<ix:nonFraction unitRef="usd" contextRef="i376ce6e940de4569b4fddf8c906fe3c0_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzg2NA_db70edbd-f4b5-4b05-a2e1-cee09974abc5">135</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6758445e91bf414bb1e7540b3c5e6998_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzg3MQ_d71936e0-6ce5-49a3-a2fa-c63a052c4db7">181</ix:nonFraction> million at December 31, 2022 and 2021, respectively.</span></div></ix:nonNumeric></ix:continuation><div id="ia384118d157240e09e39541b90e2080f_205"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3MTU_cbbc8a29-5ed7-4678-ab0b-2a6796df8db3" continuedAt="i0eef08c10caa429ea15333e8d9e00f2a" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="i0eef08c10caa429ea15333e8d9e00f2a" continuedAt="i8ac99e0e02d14031935108b77d55d1e3"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a product basis and include <ix:nonFraction unitRef="segment" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzExMg_b6a0c045-b597-4b96-91d0-2f31c820f1bc">two</ix:nonFraction> operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i8ac99e0e02d14031935108b77d55d1e3" continuedAt="i1bd77493b0b9492f91977a5233a5247b"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3NDg_059e306b-bab2-4c0d-8557-b137bbe66a4f" continuedAt="i4045680eaeef4c4a9f02105c4c64a54a" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:30.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91e2c24c996468b982a1dc76e03f861_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMS0xLTEtNzEzMzA_611088dc-4271-4092-822b-a5e69e3a7cdc">12,686</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9731d40c6ab449cb60589aa31b26a73_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMy0xLTEtNzEzMzA_10c66783-16a4-45b4-af3d-ca87f6699778">8,251</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i055b33b897694fecaa100eb09d061cc0_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtNS0xLTEtNzEzMzA_29e5920f-23a4-4c42-bb6d-56ddfafefc40">20,937</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ceb00afac54256a4f7d60880c98740_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtNy0xLTEtNzEzMzA_225a37c7-853a-4a07-b79a-a8eb5bce7519">9,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a3ddbfa55a431d93af3aa9f262e6f5_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtOS0xLTEtNzEzMzA_d5a78258-d75a-4091-815e-fb9d25e108b4">7,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021a82cd1a4140339a5639441d8b47f3_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTEtMS0xLTcxMzMw_fec05268-4f0a-4850-bc7a-f093d0556926">17,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i469a9a4b8f4d4ca3ac6924d254ddf426_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTMtMS0xLTcxMzMw_f4635048-265b-4770-80ee-df5639cb553e">8,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd610e2349614dcfb3c65f5ed1df8bd7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTUtMS0xLTcxMzMw_f2bcaf8f-1074-471b-99ec-e0fbef2b3886">6,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1932046958463fad5e8a483638872c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTctMS0xLTcxMzMw_d77e5b8f-1fb9-46f2-beaf-96ec8503ea36">14,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d05e5c857ab4caf84ea5087f3cb2a5f_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMS0xLTEtNzEzMzA_fbf5ea50-ca76-4cb8-93ff-1e5189936313">584</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5745637e84f64e87b8c42fd884e6b4cc_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMy0xLTEtNzEzMzA_b84b83a9-eb17-49d1-981d-bf316b3e8c03">532</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cca07e668f4fb582cffbfc5b2aa7b5_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtNS0xLTEtNzEzMzA_b79847af-c415-4a81-8574-dd9c7c94f4f4">1,116</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ad82bfee384b30ac43e9a17ca1089e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtNy0xLTEtNzEzMzA_b6af5f62-5cf6-46ee-98bc-2fe249b80146">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4d358834924f50a81f5fafd726b128_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtOS0xLTEtNzEzMzA_ba0385fe-2680-4451-a60f-be5a50b84181">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4823df2547cf46b8875abd9cf558f5ab_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTEtMS0xLTcxMzMw_1fd6e296-dafd-4230-8875-5777b03fe344">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c17734546b947998281488d9a6ec98a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTMtMS0xLTcxMzMw_5c0286a5-c016-4bf9-9dea-4feaa57fd7a4">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2afc6a3ad1a4eacbe19b964577a66dd_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTUtMS0xLTcxMzMw_00d75e36-7f7d-4ff2-bf53-4105618c7876">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cae1b53fac2493694141969a8253308_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTctMS0xLTcxMzMw_d3ec8124-9663-4417-8ef5-b9ffdb9e7607">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7db9326a224e2ba5066b84103c543a_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMS0xLTEtNzEzMzA_f747e60b-26b4-4c17-a6c3-9004a2fc4928">579</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida28401748b24f92b416cd0833611fd1_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMy0xLTEtNzEzMzA_c62ffaeb-52e7-444c-ac12-31401bd4917b">297</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0bd8d6774e74f7bb3b1974282e31ba0_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtNS0xLTEtNzEzMzA_50b3dda5-b8c5-4f90-8214-0e839da5d6dd">876</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386ded0f805747da8de2d6ff8fb385c2_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtNy0xLTEtNzEzMzA_16d8192f-c430-4db3-8b84-bc2861e429f0">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc73f7080d9b496c8de0c1ab17b2c074_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtOS0xLTEtNzEzMzA_46c4fbf5-3560-4a5b-b210-b4c15f53da0a">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7022852951b641658ce5d9c243dac44c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTEtMS0xLTcxMzMw_61d0b17c-9c51-43d3-b276-faf4492504e4">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962d004cfae84806a1690091e3ae9d53_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTMtMS0xLTcxMzMw_e3657e36-51f8-4725-8cc7-7f2fac1a7417">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b05e5faabb4aa8822babd60bc90181_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTUtMS0xLTcxMzMw_02970148-83f4-4415-9f9f-3af879ed21ce">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e8b2707de1407695f9bbb06e69dc0f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTctMS0xLTcxMzMw_293f8063-a3ba-4024-b1c0-a9a51a156bfa">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5c22c83dbc43948fa3d2fcba8c2036_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMS0xLTEtMTAwNTU2_9b48648e-a495-43ce-a87d-8755f7433001">123</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983e74feb34f4218b9743956866ea60b_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMy0xLTEtMTAwNTU2_1c41c8d9-4c75-42d7-86a6-4eea09c7c842">43</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3969c4d6864a2da3a1f1ed7fc44512_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctNS0xLTEtMTAwNTU2_1882bef5-18fe-40ab-9a14-0e9ccda4fdd3">166</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe79fe1f7c2f4216adf7ef2d4c9e7785_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctNy0xLTEtMTAwNTU2_a69bb700-c623-4889-b588-77ce62a459de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6630bb637394adca02acfc9eeedf615_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctOS0xLTEtMTAwNTU2_aa075f98-ae8d-4b53-9913-f572e50940ea">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4460340464041e0b1e1151e1bdec68e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTEtMS0xLTEwMDU1Ng_baaf28fa-81ce-4fe7-aa41-af612a5239d7">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec24a942c8b4c0a8fc6fdaf544a83e0_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTMtMS0xLTEwMDU1Ng_b1fd249c-2118-42dd-8153-732a0db93cf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110ea0b902704bc5be59e310b57c93a3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTUtMS0xLTEwMDU1Ng_f20cd35b-268f-4c0c-be61-b3a334d87696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88453b113924c5589f84f11706642fa_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTctMS0xLTEwMDU1Ng_8a2c822a-996b-4b87-8eb8-94c6b48aa30d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d1c52b6d904599af1561feb5d9d169_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMS0xLTEtNzEzMzA_7aa9d047-0cb2-44da-8c7f-e642f758298a">2,065</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07fa681a6a3f4803ac978bc4430cb16f_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMy0xLTEtNzEzMzA_eab868be-5816-493b-bb05-adbda7931f6c">4,832</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644651c9869647669ec353da52f990d9_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtNS0xLTEtNzEzMzA_51bb6287-7320-4a6e-9d08-c60ddccc7549">6,897</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab722f2e32a4c6683c5a3c36bc74c42_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtNy0xLTEtNzEzMzA_d529ba4f-d8b9-4911-bbf7-05d803dbbacd">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcbfd454bf4b4f66a38aeb71bd572837_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtOS0xLTEtNzEzMzA_cfa81578-ea41-423d-83d2-9d17dcd43455">3,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da2a3204d4e412fb81a43cc22c0763a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTEtMS0xLTcxMzMw_d2916f0e-e456-4b86-8d42-745793dfe591">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e0f2f8901b420ea1bc6e4977b34b1d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTMtMS0xLTcxMzMw_6ee8aec7-cfb9-4114-8621-ea2689bda6fe">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23153be3d78a4b25841635d342d31f02_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTUtMS0xLTcxMzMw_035b4fc0-455d-4c00-b166-8616daa79322">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df9cf0c885b47bb915bcac974671884_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTctMS0xLTcxMzMw_a1e71be1-4bad-4c0b-9ef8-fd7e1bd162d9">3,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f7b5010d8b4521aba879ed86a464bd_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMS0xLTEtNzEzMzA_073ceeaf-829d-4826-8e6c-74290c99fbad">1,724</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33e8904188b4076969981d84d6398e2_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMy0xLTEtNzEzMzA_aafbbfd2-1fce-43e7-85fa-e20570ce0103">518</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb0222df25c4f04995c870d2c8857d4_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktNS0xLTEtNzEzMzA_f7149e56-9643-444e-8b91-e76fbeed98b6">2,241</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e74080b44234734ace0dedce547e587_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktNy0xLTEtNzEzMzA_149b19c9-ef61-4a08-8d37-15675aa43098">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda8cdb993f6413fba844f94a33ca058_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktOS0xLTEtNzEzMzA_9b46bd51-4a05-4fc7-8ccb-9818063bf19b">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea178521e12f47089370df87334ff7b0_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTEtMS0xLTcxMzMw_7dcfc683-c6bf-436d-a8fd-ceb6d8a66952">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7077f41ca14446182bb6e9b4d27b1b9_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTMtMS0xLTcxMzMw_d1c1cf14-6a2b-43b3-8bb6-76b0053b9e51">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b007cc3680b447fb3c5201bf94aad44_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTUtMS0xLTcxMzMw_c72c7f49-457e-4a4e-95cd-058cbc666566">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0c7519eadd4f2cb22aa9f1248dd720_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTctMS0xLTcxMzMw_747f6aee-c966-48f9-b9f9-67960232c28b">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b4a4a5f68b41c48bd3a0fcfc84a504_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTEtMS0xLTExNjI0Mw_cb113858-2a4f-4119-9e92-2fdeda06a09d">508</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6fa89df609474b9bb96eaafe8ebbf1_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTMtMS0xLTExNjI0Mw_133e8479-e75b-4f34-863f-5484dafc53a3">275</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e07e4f949d474eb749d0ba3fb1b4d7_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTUtMS0xLTExNjI0Mw_5ea4c678-9e15-4184-a225-9dfa28c0001d">783</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ba2d46833f40a295ab92101c6ea29e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTctMS0xLTExNjI0Mw_eda88385-35df-4f19-8537-13c903703b9b">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c671ce13ae432fba6dcaad37ca8570_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTktMS0xLTExNjI0Mw_61d7cafa-f818-4338-a766-32780079e1e7">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6d0c174afc46489b7ddef3c33543ed_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTExLTEtMS0xMTYyNDM_387a20ab-74ba-4681-8a49-3aed55d03683">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib169bea2441d4f30ae99b18bf17d4fde_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTEzLTEtMS0xMTYyNDM_9f7ebf68-54b7-405b-9d38-0506f96bf8a1">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8c832c3c4b4e4eb34256d6efbbd10f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTE1LTEtMS0xMTYyNDM_58f16c9c-c328-4d25-b66b-8be5c0eef234">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e6f28f13f14ac490531d72573bcbaf_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTE3LTEtMS0xMTYyNDM_54e7bb50-b2fa-40dc-97e6-1f7d5e4845ce">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56cb5b6040ce4ad9ac372cec6d2cca04_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTEtMS0xLTcxMzMw_0f82926f-e6d7-4756-8797-3c32fb28d0ca">346</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ef3a8f82f04dfe83a51cfd751ae411_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTMtMS0xLTcxMzMw_93b8a394-f47f-40af-be7c-864c85d7d6b0">256</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04f7472ddd5484b8c9216a9fffd29ef_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTUtMS0xLTcxMzMw_6b178cf3-c1b6-492f-b18e-3b90304eaa5e">602</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ac39abc88b48dfae3f97f17cd94587_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTctMS0xLTcxMzMw_f044965b-46fe-40a6-b9a7-1350db91fa86">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd57f79d2d0e41c3b93e0ea8a1fa225d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTktMS0xLTcxMzMw_f5278043-bd91-4571-9991-605e824aaeb8">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a2e2a2eb9c43d4b2d533d346a44334_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTExLTEtMS03MTMzMA_b9ec3a61-478d-4976-9fce-53745501e746">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80ca468315e4aae943a5b9df597243d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTEzLTEtMS03MTMzMA_0e9eefd9-c2c1-4860-a6f1-08487eefb77d">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99df6a07597644d285a92793c5d8e7ca_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTE1LTEtMS03MTMzMA_3da9a22a-0f87-4e10-8c6f-43c96daecc64">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a49a4371bb94327920efa9b894769ea_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTE3LTEtMS03MTMzMA_875be54a-be2c-4bce-87c6-fe770d6de15c">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d68a994755427bbfccdd19f9ad6ee0_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTEtMS0xLTcxMzMw_99256aac-2fbd-430d-93a1-90c9b6faf267">95</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ee8738806c47fdbfa08983e60c6b39_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTMtMS0xLTcxMzMw_f76959b8-31a7-48d9-a394-889e1064910a">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74b581cfc6d488fba45c7674c3dfe6d_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTUtMS0xLTcxMzMw_a1028e64-f55c-4dbc-9e61-b9d555b473e3">173</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1f993fee094825a8fff330454f6f81_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTctMS0xLTcxMzMw_3b3e546e-dedc-438d-bbe1-c63e5686f68c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380654ff24e1418b9128e9fb90b05595_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTktMS0xLTcxMzMw_df3cf5d5-ded1-41ea-bd51-4c635df9cb08">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d28f16c5374e7f83b2e84bbe26110e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTExLTEtMS03MTMzMA_67cef9ac-a449-406e-9c48-2884250dd378">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83690f4cdc6b473bbc907e1481854b3e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTEzLTEtMS03MTMzMA_c8255a01-bcb6-402e-a960-2d9abe0c8211">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86b5383dbf64f898217d2bc2c3fa325_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTE1LTEtMS03MTMzMA_3cdfb148-4dca-4ab0-b7dd-713b342c76e4">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c50b2fa3e364cbb801d4ba254d494c8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTE3LTEtMS03MTMzMA_0010a5a2-b948-4cf1-b0b2-f6234d711207">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e206a2ffcc45d1bb510c4187e62a29_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTEtMS0xLTcxMzMw_79cf21ab-677e-4dbe-95fe-dae3f4fe2947">922</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1603f10ef8494fa56655543909b4c7_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTMtMS0xLTcxMzMw_b21a8557-99ec-462c-bbee-ed81bccd173b">762</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045d0c50e54f4c0db0bce141309e9adf_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTUtMS0xLTcxMzMw_ce9083eb-5ec2-47c7-9d98-f612034c70d0">1,685</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b4d13befb54158b149f2d9f6063ff9_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTctMS0xLTcxMzMw_7fba8a80-b4f9-4095-839b-bf0910bb9553">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11490c3b30c40b1a23a28951f1e180a_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTktMS0xLTcxMzMw_75e5f455-c3c8-4f95-9647-0c01853785aa">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1c6fb66e744cdbac35155a426b3d6c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTExLTEtMS03MTMzMA_4d0ac33f-e69f-4a5e-a816-2f47a377d651">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c68bc52927041289397d599a9612eff_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTEzLTEtMS03MTMzMA_1a6455e7-87fc-4528-9a85-f34841684ce9">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f47bdad3162408c9b0f25ac776b4bfa_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTE1LTEtMS03MTMzMA_6059a63d-174f-4491-956a-a1dcae6d070d">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86224d1130564bcd9c3939e4e0d87dda_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTE3LTEtMS03MTMzMA_f6285ac1-6552-43b8-8394-4ca63391fd4e">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66955337b2e7472982d44f7d7785e83f_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTEtMS0xLTcxMzMw_61e05cc1-e7f0-4000-8a77-73df11b6f508">188</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f7da2549bc46508c0eb51f336b6e15_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTMtMS0xLTcxMzMw_db2b6164-fe7d-4553-abf4-694cea877781">240</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa717dbb9c014d55a5428a202d0f8635_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTUtMS0xLTcxMzMw_492cd9ae-a403-4a40-9a44-addf5aba040a">428</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1348a3599a104ba6a35f574703cd74e3_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTctMS0xLTcxMzMw_30085d9b-3554-40b6-851d-65147dcb0fa4">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bea3c67785843179ba5a14d3faedac4_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTktMS0xLTcxMzMw_b9bdd7f4-58d1-48e2-bed8-9eab889adaf0">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696096e4ab134aecb6a7f9a41513fb2f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTExLTEtMS03MTMzMA_d4c7bdb1-a746-4938-87c5-d71cbc2b992a">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1a741e5ac843f0b62b174581b00278_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTEzLTEtMS03MTMzMA_781faf67-7e5e-48e3-9511-cdad23e74937">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f9720b066543308e337df0f16afce7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTE1LTEtMS03MTMzMA_ffb7fa48-af18-4c0c-a655-a1da8d0ffb71">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438e2ece521548b282bf2388b2b7bb93_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTE3LTEtMS03MTMzMA_5e36cb39-5bf5-4aa6-b021-51f70d84f9c1">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f274e7070274a88949b99aeff4a315a_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEtMS0xLTExNjI3Mw_cc553594-15fa-4b33-89a6-62c3b8f11550">241</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c33f54fbf848d3b95f8a9426848007_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTMtMS0xLTExNjI3Mw_d5a69a42-63f2-4868-8406-ec0a734cd669">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6aaafda79ee404ba309fdcef5eb6abb_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTUtMS0xLTExNjI3Mw_87fff8e1-3f3c-4dcc-8a34-d2d75464618e">263</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44ad729c19c4e508c4d35a83785a3b7_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTctMS0xLTExNjI3Mw_29839975-b9ec-43b9-9fbe-2c7554ae73cd">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5118866f4f4421a29aecc0b9d07410_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTktMS0xLTExNjI3Mw_8f477619-8cdd-4182-bb98-2759f4e476f4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25c060bf8b740dabb223a13c1a73ff6_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTExLTEtMS0xMTYyNzM_b803a5a9-edd3-4b76-bd58-3a088100c6e4">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502953fc972e41468a767f66ce4c9cba_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEzLTEtMS0xMTYyNzM_03a4a7e8-a96f-4053-b245-989ff6214b80">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9a656842a84362b57aeb885a898b92_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE1LTEtMS0xMTYyNzM_372b1460-cfde-4ed2-bddb-96d778402938">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f5e15ad16b4a99a824425bbe60d470_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE3LTEtMS0xMTYyNzM_f72001eb-588f-4a88-a0ec-17e8305dc008">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b71549b3e14a12b8973697db00d8a4_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTEtMS0xLTcxMzMw_cc6b8f05-1289-44c5-8ef2-b19cd8880b8f">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5077564ac8bc42e3a13c994eadfd523e_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTMtMS0xLTcxMzMw_e44e59a6-a34b-4c20-b378-3e85dd67017b">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265d917b453a46658f7507d16b56613e_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTUtMS0xLTcxMzMw_312c2af9-1a7b-4aee-a257-773c86fcec2c">239</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849cac43efbf4becaea56c79b6c78fd9_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTctMS0xLTcxMzMw_679eed1a-e497-497f-abe2-c9b25a3fc8b4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1370ce5e87458b818b4352ac61a828_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTktMS0xLTcxMzMw_d5a02080-5749-4db7-b55b-b6c8bf4c04d7">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb64688266941e4a497a73d06448942_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTExLTEtMS03MTMzMA_88f9829b-eab4-40dd-9dae-c8ec7402b517">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296b1fd777794c17891e11e10a141300_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTEzLTEtMS03MTMzMA_f07888d4-c3cb-465a-bf41-d01d41795998">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f99ef9d1b74fcabeb55184c85dc86f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTE1LTEtMS03MTMzMA_0f8d2c56-77f0-4b4d-8449-81b042347360">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if880d0df286f426ebb17d41d1f490635_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTE3LTEtMS03MTMzMA_aea3f526-6879-4294-baf6-794ac6794c8a">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e66e074cc0484bb09293c2d0e5387e_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEtMS0xLTcxMzMw_c3f85816-aadb-45e5-8946-4ed31c6997d7">51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51deec1b5b1a4ffbadb9e0abc2bf9307_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTMtMS0xLTcxMzMw_f3912628-ad73-47af-bfbc-99acc23d5301">187</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7480c05016014e139e36eb2b979873e3_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTUtMS0xLTcxMzMw_d87131ab-e950-4cff-af90-60db4ce9fe6c">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a12590988ac4caeaf1fbdb0caf12c50_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTctMS0xLTcxMzMw_7aae2e6e-a65a-443e-bbb8-483cc795d7e6">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b87c87bafd747c68f3308bdf2b646b3_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTktMS0xLTcxMzMw_c7710e43-8c68-45cc-8c74-d6804824e585">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5634d11ca74ea5af6b94a23678fe55_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTExLTEtMS03MTMzMA_2010c707-9e15-480f-a789-bc822e79c281">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a1ed4e577d4643b2128afb0f146b35_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEzLTEtMS03MTMzMA_2d0819a9-ad7c-457b-9011-5d5fc599ab75">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197589a15f2e48f3bd5253b3634b8a2b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE1LTEtMS03MTMzMA_a3e2a434-21cd-41d1-8150-78860f18c951">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6db360f0cd94810bf55adb667501e93_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE3LTEtMS03MTMzMA_03f6a002-489e-492f-8b71-c69d6ce16790">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8953ddf05c074e5f87682037915661be_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEtMS0xLTExNjI4Ng_056f1676-3308-4d55-bc70-6b410ea97153">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77531b3a80ec4e3db6cebfc5913221da_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTMtMS0xLTExNjI4Ng_11043ee6-da72-492d-a5c2-4a347d7a9d22">185</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681c4e2421fb4a899d60ff0568080be8_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTUtMS0xLTExNjI4Ng_6fe70d59-7f75-4941-87b4-93730e5ea868">189</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57ec68701cc14e0f8f6ef79be8cba10e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTctMS0xLTExNjI4Ng_b5bc201e-838e-4a71-a716-b977ee8835f7">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30d45a724314df6954c76e688a98335_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTktMS0xLTExNjI4Ng_7e00c54b-9728-4daa-a9ae-c185fd67da07">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54a4ca20a1f484298d307aee478cb00_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTExLTEtMS0xMTYyODY_f2122e14-fc67-465f-83a0-6688dca16e81">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida70ce761b0a4a9abdcb51468b1da149_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEzLTEtMS0xMTYyODY_56969d15-d817-4978-a535-7ac94f0fd49b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03261902b5dc4073ae6a6577c04bb346_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE1LTEtMS0xMTYyODY_91dc638c-0492-4b2a-ad32-4bb72a15d346">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ed6b5c044b44be8ffdeed43f3cb411_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE3LTEtMS0xMTYyODY_b66998a4-c6d8-4917-a7d9-4fae91dab703">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e744f26fdbd4b499f10d72b19177ab2_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTEtMS0xLTcxMzMw_89205288-c47e-4a7a-866c-658f7b67f10a">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d4ad8a15ed48bcb33632d14c4c6264_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTMtMS0xLTcxMzMw_662649b3-f4a1-4933-949c-f2abf5eeb2dd">168</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be72db3712d4da0b435716421f1fbf7_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTUtMS0xLTcxMzMw_db9675e6-040c-4049-9b96-7ac62477a40d">174</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe4fcb8c9074698941c54291c494471_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTctMS0xLTcxMzMw_c8e71905-ce14-416f-834c-3f2ecdde2f38">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80bf4c2fae84eec92800503e7eb93b9_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTktMS0xLTcxMzMw_67fb314d-978a-4ec1-b316-453766b9eeb1">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26309d6272d64a7fba7afe8b3b07827b_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTExLTEtMS03MTMzMA_5873b7e0-597c-4382-807b-21898d98082b">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1515bf37fb46d2b516dba8cd589e89_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTEzLTEtMS03MTMzMA_91143bc2-cb7b-4030-b3ea-7120bf4dfed6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c291d86eea247ea9a5865cade31456c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTE1LTEtMS03MTMzMA_54d5d894-82cb-44d0-a892-23ce09b9c4d8">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccbfca06b90041849cfc691d6f2cdcdd_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTE3LTEtMS03MTMzMA_f151c163-f2fe-4ac0-b498-7c90164c4db4">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebeaf99e4a1d4bceb36a747c6b3e139b_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEtMS0xLTcxMzMw_728eb4d4-4e95-4820-98b7-386088dfc8b7">89</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bcd1287d5c2475cb24e77ab4fa0658a_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTMtMS0xLTcxMzMw_51451fc6-e936-4367-8b23-0c2fb568de8f">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c448b7df4944588d513ed2e91cc958_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTUtMS0xLTcxMzMw_88ed2a1a-daaf-446f-bd27-2e3f9615cc15">169</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1073cf01244476bfda2869a55121f1_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTctMS0xLTcxMzMw_4dfe9519-b220-445d-b853-8870cbeac095">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7698a3afbd87428f86f0f8054fe5e279_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTktMS0xLTcxMzMw_85ab6c2f-8000-4191-919e-9194a79c87f3">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i617770866c9d4c829c27635c3e97c236_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTExLTEtMS03MTMzMA_16481992-d6b5-4880-9701-8a77ae33fda5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505e0a1800cb4556b5eb673f1dfc4a33_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEzLTEtMS03MTMzMA_d9b781b3-ad4b-4971-82e1-5a4625ce5c67">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8af54e95f4451d8430cc22433b5edf_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE1LTEtMS03MTMzMA_653ea07d-615e-49e8-9799-99f600e53c67">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a9406845944bb7a2fd7d973f3a9d1f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE3LTEtMS03MTMzMA_efd808ec-792b-4660-a23a-7e4f46b1657f">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd312c6ba714cecbedcc9a7366b852d_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEtMS0xLTEwMDQ5NA_a2752605-b14e-45a2-92e4-82a0f3e706aa">329</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f649bf31fa46b39e37b5bbdb7840aa_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTMtMS0xLTEwMDQ5NA_c2c19a3f-7b0e-4c89-887f-fa96ead83109">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60682002d9fe4c8a8fd6083bda3281ed_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTUtMS0xLTEwMDQ5NA_b1845053-0881-45b7-8d10-d7c1b4f5d7da">341</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice356b14a6ad46418365ea9bb55cb102_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTctMS0xLTEwMDQ5NA_d5af3ece-e6e8-41ce-9f26-fa06c1a018f2">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8f6d8c5bfbe43ea902f7cce7547af44_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTktMS0xLTEwMDQ5NA_0255c776-aeb9-4fa9-a630-fd7e7275e5d7">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8ca3795ab84ff48b77c6fa70f7cffc_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTExLTEtMS0xMDA0OTQ_86502356-3519-45c5-88e1-fee8d3789a86">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if482bee327734fda9fa6f722e7d953b2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEzLTEtMS0xMDA0OTQ_62b46812-7c1d-4997-80a7-ff049fea30f8">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e22a11988949b88c13fe1e17f2b78a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE1LTEtMS0xMDA0OTQ_999105ff-c39b-4198-b507-d28a1b869043">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0794dfa269ce44c7890d47b9989dd683_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE3LTEtMS0xMDA0OTQ_356ee5ed-4897-4968-9c77-270c11bec6b0">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b258a143a242c6b252146d74dbac1d_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTEtMS0xLTEwMDQ5NA_79ae79dc-67a7-434b-a810-ed806832031d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a98ae870914b948c565659e918f453_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTMtMS0xLTEwMDQ5NA_ea40c51b-2b83-49de-b165-de69279c1887">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefba66a377874ba2b44b702df3e1d749_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTUtMS0xLTEwMDQ5NA_4bc3daaf-acce-4f3a-8139-d28a5607cc78">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec35638b37649b895fe6f1af825d879_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTctMS0xLTEwMDQ5NA_1f184f7a-d9fa-4a6f-961a-00a338e39e31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1ca9ec329841abb944f3c69f76e638_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTktMS0xLTEwMDQ5NA_d61e15d5-2faf-4a3a-b5f6-3670b3f6514c">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5efa30ffc24b3ca056dde5eb034cf2_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTExLTEtMS0xMDA0OTQ_1572191f-f349-4be0-8099-ffb15f525e35">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a448ec43a2749f1bb446aa74a3bed8c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTEzLTEtMS0xMDA0OTQ_201fe930-aae3-446f-8a08-376f50964e66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10456cbffc5448993342502159c294a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTE1LTEtMS0xMDA0OTQ_24e0f12a-84bd-4245-9e56-103e02308a57">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bdaeae1c70b40aaa1e3b158b17ef808_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTE3LTEtMS0xMDA0OTQ_1325b8c6-cfd9-4286-8ab2-946d4dc61f94">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedbc88ea95514451917cf053f720e3ff_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTEtMS0xLTEwMDUwMw_d671b9f4-2532-4d45-8a66-b9eb71a755dd">1,523</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f58bf19d1640f8a24c1ab656bd7e18_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTMtMS0xLTEwMDUwMw_518d402b-3dab-4527-b380-3d4fc90d5332">4,161</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae8c44fbfd54215a8cb3d32bf50788d_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTUtMS0xLTEwMDUwMw_ee4f78eb-6d03-4568-9c77-2ca56d5637a3">5,684</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc958ec611e402d89f8dba65cf34f21_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTctMS0xLTEwMDUwMw_18a117f5-28ec-499c-b7b4-36b3358b3049">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide81cf5396514fa28192d55d76c92ed8_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTktMS0xLTEwMDUwMw_a7e45b72-4e12-46da-9dae-0aa5f3519476">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeda3b83cc1345dab64a83c66a84ee67_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTExLTEtMS0xMDA1MDM_3ac86eb0-ef65-4928-bccd-93846dc2e5ac">952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d25683f4f6841718c7e93350d0d5a67_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTEzLTEtMS0xMDA1MDM_8aa14443-ffc8-4406-be65-11fe7eb043a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629bc23e5a69421a92ee3560e059c642_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTE1LTEtMS0xMDA1MDM_8d9f2701-893e-4832-ad80-3356a7735d78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e77126574f42bb96d0bb8e53774cd5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTE3LTEtMS0xMDA1MDM_e095f450-a3b9-480e-8dde-5bdc3967cc95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613d1486fc28474c8acbd3dda55239ac_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTEtMS0xLTEwMDUwMw_10d0183f-68a8-4fa3-97b1-38b56784907d">274</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe4630cc947444b83450d5ccf9a3062_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTMtMS0xLTEwMDUwMw_0cb5e6b2-c433-403f-90fa-b9f7c35ba865">359</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293647d3e306407ebf8717a4faa018af_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTUtMS0xLTEwMDUwMw_f2b07ca3-cbe1-4b45-9556-a5d37f9aacc2">633</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc9b30cdb6f46cf84ff8676fca96daf_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTctMS0xLTEwMDUwMw_5f6a3adb-7341-456b-9b3d-b4b293779216">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49136d6485e4f27b3b68f218f591205_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTktMS0xLTEwMDUwMw_ad7cb621-adcc-4b5e-b0e7-ce2329df2745">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d3c8d57174c4ba09a7ae459144cccc8_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTExLTEtMS0xMDA1MDM_4f6b7061-c292-456c-955c-c3843d5d576b">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd8810addb24069affe76f94ec0a5be_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTEzLTEtMS0xMDA1MDM_aee42ccb-b8d3-4ff7-86ed-6b150cabb267">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c464d5e9ce4a76ba55304fc35bee88_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTE1LTEtMS0xMDA1MDM_60ca8899-7f7d-4092-963e-19d4acbb9451">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e30185203174bacaee8e9bba03bd862_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTE3LTEtMS0xMDA1MDM_586d596b-df11-4537-8877-b481079aa396">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib909438afce24a8780c7df58861bb88f_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTEtMS0xLTEwMDUxOA_e3465769-16ad-4a5f-bf11-b8d8b776cb0f">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib609b96d8c4c45d1a0af8c7f1afebe6c_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTMtMS0xLTEwMDUxOA_94b05485-df2f-4d58-8b5c-aae4e2e423a3">179</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99e22750ba14129b0cd8b6a97dad49c_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTUtMS0xLTEwMDUxOA_11a813f3-b2eb-4962-b1ac-fbc95e7eae71">258</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f10dba5ec404300bd6208a5fc3914aa_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTctMS0xLTEwMDUxOA_fb80d7d1-ed75-4197-9298-acb73fd62be6">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec7cb4b83004d9a983d8127e07e2b2f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTktMS0xLTEwMDUxOA_99e53506-ffaa-463c-bf03-0578cfa25d74">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5eeb8fa10948649d5874f868693a1b_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTExLTEtMS0xMDA1MTg_dde34ec4-17cf-459b-80ac-f4c05fdf817c">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd6baf002c54d9a9da34f801bd78e3b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTEzLTEtMS0xMDA1MTg_b6807d37-106e-42cf-bda4-020a7b2e7e9e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338443af5bd847189e38c92ac1ec921e_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTE1LTEtMS0xMDA1MTg_beda8de6-c7aa-4c09-aa0a-47a52ea9ae47">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5884d63fe366495081e710da8a78d315_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTE3LTEtMS0xMDA1MTg_2dce0e49-c231-4b13-979b-8daccc18f875">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6da244d9d94c518f93764d97f2d35a_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTEtMS0xLTcxMzMw_4241bb4c-7ef0-4f33-8a51-d1479799d229">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9b9cf8c9aa4481bb00fc5b21378b37_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTMtMS0xLTcxMzMw_17af83e7-8940-4dbe-a87b-51473e117b99">706</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc50a7e8a028404c9337837900c373c8_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTUtMS0xLTcxMzMw_9fcf10b3-0487-4142-bc1c-23f32b28b40b">706</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51698f086f24b71b9570d9313720f9d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTctMS0xLTcxMzMw_d5efdf40-37d0-483c-b14c-cfd25fd5af65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc622e652dab409a966bb1005b97fb12_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTktMS0xLTcxMzMw_8d20b7fa-3ff6-4740-beb7-b49c3c099a16">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8283275c2880459b937b5ba98b866084_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTExLTEtMS03MTMzMA_10547a70-dd1e-4a75-b8bb-22b2698be21e">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2cf47d7044f4adba5964039483ad7f8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTEzLTEtMS03MTMzMA_4d6aa718-b0f3-458e-babd-e590edaafd04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f0ead2a04c463ebca54852c312306b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTE1LTEtMS03MTMzMA_ba6d990b-3056-4fda-aa31-20a0ef23f3c5">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4466289ff2147e2b0ad5ba8dad1504d_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTE3LTEtMS03MTMzMA_14eec417-7636-46bb-ac06-12c6d7d6f4f3">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e907a5d5f345568c0c95ad777ef996_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEtMS0xLTcxMzMw_9834b705-bf9c-4b71-b12a-71b8d3d5af6f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fdb9e60bb54154be013bfb3b99ed37_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTMtMS0xLTcxMzMw_82bf0893-4fbf-4f74-8d64-e6fe8eff8579">207</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552cf9a2dba34015bca9ef712e555836_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTUtMS0xLTcxMzMw_d6713388-fa96-4975-b1fe-94d38c803691">207</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc13214640dd49aea3a6f573732950f6_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTctMS0xLTcxMzMw_48166bdb-1642-4b7c-a63a-9dea7ffe024d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i183853257a9744bda89e18492b5adce3_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTktMS0xLTcxMzMw_cde26af1-734b-4f83-be1a-925075ced80b">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ff9b6d884c4cd4ad827974b7a04cac_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTExLTEtMS03MTMzMA_2d87cc70-0bb0-4025-90b8-45f89394a427">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38ff4e18c854e00bd319922ef36c8fb_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEzLTEtMS03MTMzMA_d75e4e68-0e67-44e7-a2ed-88b75f45662a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e83011764347d1b6364b08e35f618b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE1LTEtMS03MTMzMA_d287db4d-f57d-4538-994f-bcf80cb508cc">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c361862132d4c12a3df559d1247ce11_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE3LTEtMS03MTMzMA_15f0abf5-e1c2-4a9a-8da2-5da6c7a17817">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa9b80b3f7d4f2ca54fe62d484ad6ff_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTEtMS0xLTcxMzMw_af99ed92-2807-4925-94e1-46c44e1c0fac">1,248</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic322d64f24e846d9afd0e3dba16e24cf_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTMtMS0xLTcxMzMw_40dc5f78-a7f9-474f-a0a9-3048ae27a43a">1,565</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ae64bb8a33446faaac7873a35016cb_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTUtMS0xLTcxMzMw_356a7a05-d4c4-4301-9182-e8ced5967649">2,813</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91629c66e76841e49ac8fdbce3d95883_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTctMS0xLTcxMzMw_70d77d96-5df8-409c-b989-5152a1f485af">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea2621b38e949de95e267f3fa6822d5_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTktMS0xLTcxMzMw_61f690c5-ee98-4035-a783-fb4e71a7d87e">1,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa77411ccf241218037cc5cd351cba4_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTExLTEtMS03MTMzMA_29427f2b-55f0-47c5-931b-7bc41c251f44">3,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf36505cfcb544e6bc2016ef576a5a96_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTEzLTEtMS03MTMzMA_51eda136-4e71-40f4-8e82-3bfc9d65fccb">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40150bacb004b09aa1761eea6e209fa_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTE1LTEtMS03MTMzMA_00eaa1d3-d598-48fb-8002-7f4ebe809f12">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fcc4830492c4d41b40fdd59f5359d79_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTE3LTEtMS03MTMzMA_5330473b-c4a7-43e6-85bf-cebd3b9d87ca">3,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79561000ee344c4bc43f4af90649a06_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTEtMS0xLTcxMzMw_b9474f49-5bba-4cef-9029-329640fbd51b">355</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0761d7789524bce842b332f0db014bd_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTMtMS0xLTcxMzMw_cdd13767-c5fa-4c2a-8a09-b4da0baaa81c">1,344</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab8bed311c094329b4d745c12c4a5cc0_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTUtMS0xLTcxMzMw_7c602a6a-6c44-40fa-a170-dd140e663b5f">1,700</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1ca67f428141cebc70732cebff9521_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTctMS0xLTcxMzMw_a620c9cc-6f5d-4a47-8f35-d0d9ca71af7e">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e6f6f6fd524dd69fe636e2947bdfa1_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTktMS0xLTcxMzMw_6cfa7187-563a-46eb-a5d8-2646e5f662db">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c259a7a44a4b05a2c75e4dbb68b616_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTExLTEtMS03MTMzMA_3ad8664f-2e6d-4fa2-bc87-8f37d8d83321">1,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6f7b78017c4b1aae8ad926d48e6a38_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTEzLTEtMS03MTMzMA_ed94df26-5029-4234-90d6-5a27a95dbf81">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i990a4dc4b81240de8e34aeaaf52eb1ad_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTE1LTEtMS03MTMzMA_d58cd1ab-23d2-497d-9683-156f8c330278">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3d395096a04f008b6ad61b7397f8a8_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTE3LTEtMS03MTMzMA_44abf9a6-d343-482c-a6bd-55f6a491fbe0">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4387d3b03f47fb943aef0ec03b900b_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTEtMS0xLTcxMzMw_034e5154-b4aa-4499-8aeb-5e012ea78eea">969</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7753d0b2864abf84b4f0352e03b254_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTMtMS0xLTcxMzMw_27f85c3f-03ec-47e2-8492-987a49742c22">1,282</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a96ab2adc74657a7fc0400faed593c_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTUtMS0xLTcxMzMw_44a3ef9e-e5a7-49b2-8ee6-cc98c988fda6">2,249</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f891fe0d78a4c3bbd5bda2518e4ea4e_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTctMS0xLTcxMzMw_28b49930-b938-43d0-892d-c44e0bc97734">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfe13e7da014c61bc807c8e56ec5f0c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTktMS0xLTcxMzMw_a2ec4aa4-03dc-4769-a46c-e31566a4d899">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b3d413326442638d0877fd2e9e29a2_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTExLTEtMS03MTMzMA_39d2e056-f5e6-403f-bb05-54bf591d8fa2">2,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bed06c5b34b488ea2f844c3779949d6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTEzLTEtMS03MTMzMA_7cca13f8-0672-4b31-bc10-fc85c22f9584">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86879f1d260a48b2b3fc2ba0929452ad_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTE1LTEtMS03MTMzMA_764afca4-abe5-4184-8b6d-874d63e969fb">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe4eeaab037443a9c7ca2df4c70ad71_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTE3LTEtMS03MTMzMA_43f76de3-9b42-45d3-a462-b4b08da0c723">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc3747831fa47ea8edcca64589a2d04_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTEtMS0xLTcxMzMw_f09696b6-6f86-4f47-9e22-b9614183189e">24,989</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0483a589fe4ef9a10b6defdb741d26_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTMtMS0xLTcxMzMw_0478c6be-48b5-40ce-a3bf-8d36cc2d96b2">27,016</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTUtMS0xLTcxMzMw_90a4dc24-61b6-446c-979e-328cee114c0e">52,005</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20844159d5914e56aaeb01e98bfffaad_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTctMS0xLTcxMzMw_de48b5a6-c198-427f-92ee-728a5e1ee78c">20,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic398861a5e604978a3c98fc5841e68cf_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTktMS0xLTcxMzMw_e455943a-926b-4bf0-a0a8-29ac885db674">22,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTExLTEtMS03MTMzMA_52add7d4-d151-44c5-be36-2654be7b2e1e">42,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8ac6036c8646999d891c258acab031_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTEzLTEtMS03MTMzMA_2f48d1fe-4e2c-4cde-a7b3-5d3721891ef2">18,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbc57c3e1584457acadc54ca8ee0f09_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTE1LTEtMS03MTMzMA_1b027687-6b72-4ecc-92d3-09eac14ed171">18,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTE3LTEtMS03MTMzMA_eb067c50-51bf-4ae1-80a9-282e00cfb60b">36,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a777627607f4c4abb9584a4411dbf0d_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTEtMS0xLTcxMzMw_443438a5-3e92-4299-911c-aa2b925b368f">710</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i890f308e305745e993afb171875461d3_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTMtMS0xLTcxMzMw_651032ca-b7e7-48c4-95d2-ce360b9b2ec6">2,590</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56526eb7b6df403d980ccad23c43f766_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTUtMS0xLTcxMzMw_9decf053-8adc-4718-9e62-b1d0d992c8ee">3,300</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d93056d1c2487eb95a4a49fc8d01a3_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTctMS0xLTcxMzMw_2df1142e-197a-4108-934c-cca930a6d8da">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4894c9df276a4645b9f3fd98b62ebacb_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTktMS0xLTcxMzMw_03425b74-d1c8-4e0a-983e-0a39db95476f">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c8a2d41e93427ab955bd22bcf78ae0_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTExLTEtMS03MTMzMA_b3d169d0-c945-4434-848e-8c8d0c0454fa">3,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2119c2582b0b42a289d1ca7e693a7795_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTEzLTEtMS03MTMzMA_8cd399e2-c1bb-46a8-a8b0-872e0ea570e1">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74dc6f5dabd64668b9cecba5fe18fa39_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTE1LTEtMS03MTMzMA_0a0d9363-a5ad-404a-8f12-875849d934e2">2,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6688637b104f45498e4d1adcc1dff8f4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTE3LTEtMS03MTMzMA_94c85f5b-45f2-4154-9971-7a1d5d77034f">2,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73d257fa44324b53a1ef7ca1720ac517_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTEtMS0xLTcxMzMw_90594ba2-2f6b-4b29-8c68-b2f8bf86b614">1,112</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2554a55ac3e445b4b77f581e924fa49e_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTMtMS0xLTcxMzMw_067b99de-cb84-47da-8076-eb37f982308c">1,138</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e5f83c1f72f44e1be95132b049ae22c_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTUtMS0xLTcxMzMw_244c32f0-4742-41b4-88a4-39ba4a57ebbc">2,250</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963120dbdfdb4d71a1491aa18697e865_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTctMS0xLTcxMzMw_cf4e98a1-66ef-4f47-a5dc-28a53c261131">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c6c6b918224b0b9941f8fdd4403701_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTktMS0xLTcxMzMw_da98a3d8-bf52-4d33-997a-5769453e3abc">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e5c6c625744b5397f0c31a5173824d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTExLTEtMS03MTMzMA_9510227d-db66-4694-b920-948ec0afe723">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb094efcfafa4c4b90bf422d01d01cf6_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTEzLTEtMS03MTMzMA_6c409e26-6951-4ee3-b5d6-2f4e4165ebeb">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218fada0b11b421db5b8600c0019d4f1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTE1LTEtMS03MTMzMA_af3fba38-93c9-4fc5-adda-103c31a2cc4b">892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c439560c469498ca75bab3229912fed_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTE3LTEtMS03MTMzMA_54bf86ab-4a23-41b3-99ba-3e41c174acaa">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26f89beeaae4c7f931c5d4d81ab0bc1_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTEtMS0xLTcxMzMw_b20fb9de-5653-4fb0-b626-613487e7943a">1,822</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337d955832ba4199a0df850ea23b5676_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTMtMS0xLTcxMzMw_af55b3ad-eb0f-41ff-8a70-7d0d7f6bb899">3,728</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTUtMS0xLTcxMzMw_172d18d5-9093-4557-9bb5-fd8f92cc988b">5,550</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0fa7b9aa8d4e40bc457315bc042e44_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTctMS0xLTcxMzMw_5bc1b703-4b36-43c3-a4b7-895d24cbcae6">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8a7e5fe48142d5a2a4a1449d7e5fd3_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTktMS0xLTcxMzMw_ac435137-95be-41dc-81a2-f29f812e10fb">3,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTExLTEtMS03MTMzMA_427e15e7-b021-4871-8eb3-16d8002b357d">5,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a2c421146a4685b24d4d63dc874137_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTEzLTEtMS03MTMzMA_a425a0fc-ddfa-42e7-9bb6-5926ad443b51">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31df7669833c47408aded7bcb0d91766_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTE1LTEtMS03MTMzMA_0d44340f-d452-4304-869c-9d7c8539b7a5">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTE3LTEtMS03MTMzMA_20f19ae9-777d-42a7-8c4e-a03f8306d121">4,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2ea2b06d674eb997a7ca0ea9ee4f84_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTEtMS0xLTcxMzMw_46e1d163-898c-4365-b4a7-ba8e46914093">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ff1d1758224e68b457056f4c1aa244_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTMtMS0xLTcxMzMw_57e5f4a8-d0e8-4396-87e2-9c62b15abfa6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTUtMS0xLTcxMzMw_b01632c9-ba9f-4db8-b38e-85bdedbc9fcc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71007b7779374d738c052de5ee0be00c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTctMS0xLTcxMzMw_4e025eac-26cf-422f-8981-5c1bdd631e2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ada1ec00a9474b86440d7e3fe85a61_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTktMS0xLTcxMzMw_db06ddb8-a09d-4068-947e-d398be996c13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTExLTEtMS03MTMzMA_c79dd211-2f16-45a9-95be-e7db506c9fac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if379b668eb4a408d857cc08dbfb7cda2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTEzLTEtMS03MTMzMA_797a4cd1-dc01-4416-8eb2-f6dea5f26eef">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343efbd897d7479798adb44173aabdef_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTE1LTEtMS03MTMzMA_33caf423-6b8b-48da-b934-bd702f4aa6c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTE3LTEtMS03MTMzMA_58c20470-e8bb-44f9-9505-ac414da33f88">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba066b9bf1844c0e995daa549acba43e_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTEtMS0xLTcxMzMw_014d4972-8e00-4ecd-b498-3303488c6eeb">26,811</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4556e60ce4f74c22ad0cb51ba398629d_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTMtMS0xLTcxMzMw_a818212b-99d4-434b-b8d6-25c80af19317">30,744</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTUtMS0xLTcxMzMw_d5fecd6c-7445-482b-89f0-3d3366d00b18">57,555</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb44034bd361427c89ea4308da4aa6cb_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTctMS0xLTcxMzMw_e6ee5e6f-f540-4ed3-af71-27f0995c3891">22,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4158ddf9b78a40c0b069dad583f960ec_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTktMS0xLTcxMzMw_c7cdaf6c-9de7-41c1-8dd3-2a194e965505">26,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTExLTEtMS03MTMzMA_a6495dae-aa8f-406a-9cb6-e1c04a08dcd1">48,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51d2c4b860046aaae61f55468059f18_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTEzLTEtMS03MTMzMA_fb078907-e109-4e8c-911b-d19a91f34fa5">19,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7f372308b340f7ba087719099057d4_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTE1LTEtMS03MTMzMA_fc3b1ae3-b6a7-42bc-b8f8-25ee0b1542d8">21,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTE3LTEtMS03MTMzMA_05799423-57b8-4c1e-bcd9-2d027f32e914">41,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4aab7a7520412f993065e092f416c4_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTEtMS0xLTcxMzMw_925358b1-a119-4fa9-a1e9-c8f8592a9030">395</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3e56752d724c438792f86d2f774c4c_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTMtMS0xLTcxMzMw_c23f6d58-e1f9-49f9-80a1-9726afebfff6">1,333</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f295cd4f0de410cbcd6deb71260cc77_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTUtMS0xLTcxMzMw_b155b3a1-78cc-4fae-9950-62ccacaae1aa">1,728</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96716f25cfcd4ea78877e455aa3addec_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTctMS0xLTcxMzMw_9b02127a-137f-4a5e-aedf-4d072a844667">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb33bfd647d4010a30f8e7417dfba4c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTktMS0xLTcxMzMw_0546f804-5751-4f12-aa1a-59c7735f00d4">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec693e2b56e5450795dee9a8f5b1fd7c_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTExLTEtMS03MTMzMA_7c7f1194-55b9-4ff5-87b9-65b79cf0cf4d">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdd89273ea4c4e4086ce9cefe2ab8a36_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTEzLTEtMS03MTMzMA_41949fe1-c48a-460f-85e6-738c08726bac">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4713191775b44625bd8480c87097307a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTE1LTEtMS03MTMzMA_03b91046-d7bb-4006-8992-c5d62da903ce">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7771fa9d00e456f945808f5b1350a86_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTE3LTEtMS03MTMzMA_6506430c-a076-4bd9-8171-b15064032015">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840fe2106741497387f3e41d6c0fbd82_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTEtMS0xLTcxMzMw_7a02a4e8-d0e5-4e26-86ad-ece94b46dd56">27,206</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad74c169614459ebd6a2feba9923acc_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTMtMS0xLTcxMzMw_f3060815-eb5c-4f63-b9bc-d1a3301dbd8f">32,077</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTUtMS0xLTcxMzMw_fc60f346-54fe-4ffd-ac4f-289bb26626d0">59,283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923e47ae0d0a44b59c583a5e9fa3fa54_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTctMS0xLTcxMzMw_8daad395-4a6e-46ef-a78a-1f77c810cb49">22,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0e54bbc4e1406baa90d17d42691c90_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTktMS0xLTcxMzMw_fe1b8b20-c1a5-40a2-9926-77ebd1337cd3">26,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTExLTEtMS03MTMzMA_0cca8c22-41fa-41ec-83eb-0c77751b63c6">48,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b2e025a9ae49f6b693fe2b2b301a7f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTEzLTEtMS03MTMzMA_afe62413-2cc2-4559-9134-201e4b129058">19,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bcd741098644d6bdebda5470bbbf63_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTE1LTEtMS03MTMzMA_6558ff0e-ab2d-4857-b217-2a46419885b0">21,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTE3LTEtMS03MTMzMA_f5c1fb57-ffaf-4eb2-97ea-93265da03df5">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"><ix:continuation id="i4045680eaeef4c4a9f02105c4c64a54a" continuedAt="i49bd361601ea4527a5d635b898213865">(6)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i49bd361601ea4527a5d635b898213865">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="mrk:IncreaseDecreaseInHedgeRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzIxOTkwMjMyNzAwNzM_e956abe5-9798-47db-8ac1-198a0eb6390c">810</ix:nonFraction> million, $(<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" sign="-" name="mrk:IncreaseDecreaseInHedgeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzIxOTkwMjMyNzAwODA_d7c86e92-1be4-4e8f-9d62-292ff508a882">203</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" sign="-" name="mrk:IncreaseDecreaseInHedgeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzIxOTkwMjMyNzAwODk_de516629-0e41-48a6-a818-8c8f301f4481">19</ix:nonFraction>) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $<ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzEwOTk1MTE2MzM5Nzg_9ed5e2f2-8ab8-4c0b-8a13-732891a69ffa">165</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzMzNTc_7904cc74-78d5-4480-9f90-43d6b3018233">218</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzEwOTk1MTE2MzQ3MTk_7bf39a9c-1230-41e1-ab84-db4becfb7e2e">54</ix:nonFraction>&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i1bd77493b0b9492f91977a5233a5247b" continuedAt="i12ebdcb260f44d10808d4220e305908b"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3NTQ_8f885af9-9f0c-42c9-9d5f-5548b62e5e10" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840fe2106741497387f3e41d6c0fbd82_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzEtMS0xLTEtNzEzMzA_24f9bd6d-003f-44c0-bdc4-f1fba0d5a11e">27,206</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923e47ae0d0a44b59c583a5e9fa3fa54_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzEtMy0xLTEtNzEzMzA_31f9105e-b2dd-4f01-9d00-8d91dcb47242">22,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b2e025a9ae49f6b693fe2b2b301a7f_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzEtNS0xLTEtNzEzMzA_b18f18b2-85e5-4849-917c-746d8e121e2d">19,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia689dc2ff1e4458792332eba5e96c16b_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzItMS0xLTEtNzEzMzA_7dad17fc-b965-4e9a-b967-60923580ff5b">14,493</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884402da04444fdfa741b60ec14e6df6_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzItMy0xLTEtNzEzMzA_693abc05-6d24-46ec-84fc-a857315383ba">13,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22a7046c70e4bfb87b82cb904893496_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzItNS0xLTEtNzEzMzA_812e1236-47f4-48cc-b547-d84db52892bb">11,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886f7113739342fe9e0a88000b89520c_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzMtMS0xLTEtNzEzMzA_92243b43-f80a-4fc2-a934-6e3473f7501b">5,191</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc938ddcd1a435c9cf8105a8ddbd1d8_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzMtMy0xLTEtNzEzMzA_d754ed2b-4b07-46a3-ac5a-245f59e34a34">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i998005d150c24a6bb8ccdcd6c0251302_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzMtNS0xLTEtNzEzMzA_9ca17a17-9bdc-4f09-acc6-65fb5da22b9f">2,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b79a3305ac435cb2d4da9934529da6_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzQtMS0xLTEtNzEzMzA_c7c8d396-efdc-4850-b89b-d939789e845f">3,629</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0045db94c49d4a67a671551c92f63b4d_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzQtMy0xLTEtNzEzMzA_674c5d29-a22b-453c-b375-e88f1954405d">2,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied160c449f26454885073f7135732aeb_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzQtNS0xLTEtNzEzMzA_25c1f0cc-252b-47f6-b7d7-57099b1624d7">2,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8284319e3a8f41c5bf0824118bcb2446_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzUtMS0xLTEtNzEzMzA_c7c354b5-0560-46a2-b86d-fe50b0ff4fb9">3,614</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1e166e6f2f4a579b637ff0e714bbbd_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzUtMy0xLTEtNzEzMzA_d24662d9-6e87-436d-a774-a02f7dec15ed">2,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id876bec63a044a438106d7fc364c0be2_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzUtNS0xLTEtNzEzMzA_60a88759-aa7b-4abc-a34a-d4f94f3b95b6">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047342a7dd6a464e8f2c160368b133c3_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzYtMS0xLTEtNzEzMzA_58f12b6e-09e6-4c70-8ac7-ce81dc4a5a6e">2,582</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8cb013593b44a96a79cd5ac26f510cc_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzYtMy0xLTEtNzEzMzA_c5312e16-3373-4f43-93f2-436f3608e19a">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e683e533014f74b1427b3564e847c7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzYtNS0xLTEtNzEzMzA_4a46efbb-73ac-4b2a-aa96-67cc9f681b0c">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad4d8d7f0ad4e40bc7dda4d86aae1fe_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzctMS0xLTEtNzEzMzA_9d4433cf-70cf-44f9-bb84-5b96527cae75">2,568</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c971a16db240a29a2f4b213472c027_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzctMy0xLTEtNzEzMzA_c7a9e246-7923-4c53-bbe5-35c470c4af26">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f1ccd890df4f68b103d447a8e62b07_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzctNS0xLTEtNzEzMzA_fe26bb0b-9212-4241-a5aa-9cfd8514eebc">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzgtMS0xLTEtNzEzMzA_3c855f78-8480-4d5c-9989-758cdfff1826">59,283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzgtMy0xLTEtNzEzMzA_248f0f0f-8cb0-4b73-902e-f596215a0383">48,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzgtNS0xLTEtNzEzMzA_ed6b5f36-53e6-4542-b171-21d024f5c2f9">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3NDI_975f205d-fcd1-4df2-94e0-cf1615062e45" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzItMS0xLTEtNzEzMzA_1859d701-3aae-475f-8df3-c7b658c85567">36,852</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzItMy0xLTEtNzEzMzA_049901bd-a981-4c81-baf8-5e40542b7044">30,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzItNS0xLTEtNzEzMzA_0742a87d-6554-4469-9fae-86f3ae58ef31">26,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzMtMS0xLTEtNzEzMzA_cca83044-aee6-4353-beb8-28fc75b14b05">1,963</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzMtMy0xLTEtNzEzMzA_8516c8d5-49b8-4d57-9225-090fc884e30d">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzMtNS0xLTEtNzEzMzA_2e35d218-2484-447e-b39e-7300902c7356">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzQtMS0xLTEtNzEzMzA_f9653a3a-e215-41c7-b5cd-74daf36de111">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzQtMy0xLTEtNzEzMzA_38fddafb-8dc1-4e48-88ba-29c053d9b901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzQtNS0xLTEtNzEzMzA_2c9709e0-ec28-4f5c-b472-d4d159794684">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzUtMS0xLTEtNzEzMzA_66b47840-5c10-4b46-9ff5-a04de37847d8">38,815</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzUtMy0xLTEtNzEzMzA_2f2c58cd-79a8-4cb7-9789-9beb890694c6">32,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzUtNS0xLTEtNzEzMzA_fd7af41b-e289-4408-9be2-dc828e00b1c8">27,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f295cd4f0de410cbcd6deb71260cc77_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzYtMS0xLTEtNzEzMzA_8ff40155-a1de-481a-a126-5d440dc91a3a">1,160</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec693e2b56e5450795dee9a8f5b1fd7c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzYtMy0xLTEtNzEzMzA_9a49e1ef-6807-49be-863b-679633b7da9e">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7771fa9d00e456f945808f5b1350a86_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzYtNS0xLTEtNzEzMzA_2110bae9-12c1-4e1f-bca8-5e2fa3401153">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzgtMS0xLTEtNzEzMzA_1313c1c6-ec9c-40e3-85f0-e507c6df036e">157</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzgtMy0xLTEtNzEzMzA_8dd26018-872c-415b-b51b-d7d1a5dc6908">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzgtNS0xLTEtNzEzMzA_34eee3cb-84f8-4fee-bdb0-2457dec6f0a9">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzktMS0xLTEtNzEzMzA_184a20c2-19c8-4d24-a253-8c7caaee09fa">962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzktMy0xLTEtNzEzMzA_f4827c92-b8dc-48a3-976d-da5847b8df40">806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzktNS0xLTEtNzEzMzA_9bfc5acd-3635-4c4f-8d1d-e8b52b378b5c">831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEwLTEtMS0xLTcxMzMw_550b558c-e282-4c58-bd07-836490ebb334">2,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEwLTMtMS0xLTcxMzMw_ebca5307-8d9b-4f01-8c4f-7589ac9c6059">1,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEwLTUtMS0xLTcxMzMw_4fa8e2e4-1cd0-4d10-b434-a4541e32b91e">1,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzExLTEtMS0xLTcxMzMw_438c85d4-9955-44e5-9db5-7105ac83bf56">1,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzExLTMtMS0xLTcxMzMw_b037b902-ce2c-48c6-bddd-1dd3ddf126ac">1,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzExLTUtMS0xLTcxMzMw_7e3c8e2a-5aea-4b76-81c0-1d3401ff2e1a">1,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEyLTEtMS0xLTcxMzMw_aee09390-b36c-4d55-9a81-8e82a7f64579">13,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEyLTMtMS0xLTcxMzMw_c8e21266-c973-436d-9b76-4edcbff60106">11,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEyLTUtMS0xLTcxMzMw_e65f80af-676a-4d6b-9f6b-60405292bb11">12,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEzLTEtMS0xLTcxMzMw_39911ce1-ad6f-40c5-967e-3908fc0124c9">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEzLTMtMS0xLTcxMzMw_55754650-cc98-4d60-9342-c4fbeaa60629">661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEzLTUtMS0xLTcxMzMw_b9d358f2-df02-4753-9dcc-9e91fef96ba9">575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE0LTEtMS0xLTcxMzMw_445c97b7-dac9-4e6f-a224-9f615f56970f">5,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE0LTMtMS0xLTcxMzMw_10aa8cc3-925d-4e2f-88a4-08cfb9557cd7">3,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE0LTUtMS0xLTcxMzMw_be40de60-34d6-472c-ae07-b2d7df866fa0">4,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE1LTEtMS0xLTcxMzMw_1c3c41db-9f4a-41c4-9484-d8b92d2554dd">16,444</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE1LTMtMS0xLTcxMzMw_bdb1feca-7c3a-44f1-b418-c2aba50fbcef">13,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE1LTUtMS0xLTcxMzMw_b575d78f-62b9-49a7-9aef-100d0641bb4f">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><ix:continuation id="i12ebdcb260f44d10808d4220e305908b"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3MDQ_c4fb149c-072d-4c47-a46e-f7f323f6dfe1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity income/loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtMS0xLTEtNzEzMzA_fa49ddec-4171-4b68-b0f5-33fcc37c713d">39</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtMy0xLTEtNzEzMzA_776264c9-3c7f-4d8d-9ecc-9619374add47">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtNS0xLTEtNzEzMzA_7b53dd83-dd93-472d-9aaa-e956604ac7de">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtNy0xLTEtNzEzMzA_2c30a4ce-fdcf-4ade-8fa2-b966444a0c88">39</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtMS0xLTEtNzEzMzA_c7502af9-de4f-4b4b-8830-893432349286">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtMy0xLTEtNzEzMzA_f538abc0-846c-4d82-824e-d9d253146294">177</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtNS0xLTEtNzEzMzA_53265f88-f1ef-4aa3-a1e8-f372c1edd4a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtNy0xLTEtNzEzMzA_a0c6c9b8-f0ca-40df-b2ca-b478414f79ad">182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctMS0xLTEtNzEzMzA_33c9e78d-1f28-48b5-acc3-8f3e48de2821">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctMy0xLTEtNzEzMzA_47066e6f-d758-4126-8a43-e3432545b171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctNS0xLTEtNzEzMzA_daa1267e-90c8-4f7a-aaa0-5600116f46a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctNy0xLTEtNzEzMzA_0c4893ff-c19f-407c-a4d1-dd491915b625">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtMS0xLTEtNzEzMzA_de5b1fb9-b89d-41bb-a1e4-650438b273a3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtMy0xLTEtNzEzMzA_fcfff96b-ba16-4f28-a20f-148fa09d6ad2">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtNS0xLTEtNzEzMzA_3773e63e-aa5a-4199-ab20-2ef467838048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtNy0xLTEtNzEzMzA_57f96b9b-e679-4f73-a9e7-439e67443b5d">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTEtMS0xLTcxMzMw_e6dbaa5f-c5d5-4b87-b9ca-55aea75d7a3d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTMtMS0xLTcxMzMw_cefff989-cd7e-4f87-a457-d79147e4aa53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTUtMS0xLTcxMzMw_91bb981b-4140-4017-b865-7445cfc1919d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTctMS0xLTcxMzMw_f84977b2-57ad-43fb-87b5-a0637c860f71">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTEtMS0xLTcxMzMw_379ff501-3315-4e6c-8999-92b7997ac968">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTMtMS0xLTcxMzMw_0f2370f1-0917-4054-a2b7-56d98a65e553">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTUtMS0xLTcxMzMw_0d2e94f4-7bb6-47ab-950c-2ff87ca1e943">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTctMS0xLTcxMzMw_7c75af75-b5f8-4e81-afc8-8643c67dfda1">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3Mjc_78707551-a0e4-4909-a48b-38d4697714bd" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269ce30010de4d15b4e17a5aedff6cd6_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzEtMS0xLTEtNzEzMzA_166f3185-b737-4109-8a19-669a7fb73a57">12,891</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8211b4d2d96b4d6e924cc16fb296c131_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzEtMy0xLTEtNzEzMzA_31d2abcc-88d1-4766-8829-90fc98727426">11,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcf7b65ffe347b797e561991df21993_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzEtNS0xLTEtNzEzMzA_a85801a7-cfdd-4d2c-89f4-8d466db998b5">10,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ccffe7157345caa23575cf77dbeed0_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzItMS0xLTEtNzEzMzA_fd61f973-6b05-4b95-8434-6e6873646d67">6,993</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1820461e7a084ed6a964f1b3b8d8d802_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzItMy0xLTEtNzEzMzA_29c37957-c9bb-4173-b4c5-3abf8d1d4269">6,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0faa095bd4a45aba5e98f155fde2079_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzItNS0xLTEtNzEzMzA_4c0486a7-8f37-4e32-8892-7ef961afa15a">5,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5bba0a77af4a8783702f2047952acc_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzMtMS0xLTEtNzEzMzA_5770afce-70cb-44f0-8b35-60bfb44815d7">966</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fae4d6107f488b8909bcca3be91c69_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzMtMy0xLTEtNzEzMzA_48726817-4dfa-42f7-b932-7ffd15442cb2">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c06014407b8411a91506d49df92a824_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzMtNS0xLTEtNzEzMzA_e2cc08fb-62a7-4777-ae19-0a7b6316216b">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic251c7f3bb4e47e08296afcc17172e83_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMS0xLTEtMTI3NjAy_51cad966-f707-48a8-9311-fdf676813e04">225</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e3b8649d7640388a5c9c721c08642e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMy0xLTEtMTI3NjAy_361c3acf-2f1c-4974-9d3e-4d7d7bea5ec0">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d9802536b44e179a60195bfc87b3da_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtNS0xLTEtMTI3NjAy_cf5b4461-7535-4099-b986-27ad1e275c84">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123ba3f4a40d493d9ae8d39e4a5ef78f_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMS0xLTEtNzEzMzA_cf5bbbc0-b323-429a-8a97-4eab4e6e47eb">207</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c691cc03ca947218df95a3a774da470_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMy0xLTEtNzEzMzA_4aaa20bc-3d6d-4c8f-87ef-27204dea59a6">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd56b99f7e44e7ab521fd0a98e8b8c2_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtNS0xLTEtNzEzMzA_fe645393-5aa2-4c14-a7f0-43791c2d4bd6">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6d999cecc9424eaed8887c265ddf14_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzYtMS0xLTEtNzEzMzA_aee67e7b-96b6-4611-915f-05663e49b0c1">135</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee703bcc3304d2199a268dbca3b2a98_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzYtMy0xLTEtNzEzMzA_706940f2-8e21-4e4b-a920-27f9400883fe">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id490c58a5ad24c1ea00c4115bb016c7d_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzYtNS0xLTEtNzEzMzA_6806fc6d-065a-4f86-b5f7-32d909ef5629">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a8eb31fe5a4c7e8d7672a9f0861b87_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzctMS0xLTEtNzEzMzA_3e4e2215-42d3-4d54-af3a-5167547c897d">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525155431d7c4ed0a672cb8897ee553b_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzctMy0xLTEtNzEzMzA_df4e8f80-cd75-4cac-87d5-f212d6b8e83c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa316713ea647e5a80b2ef8e8cc5435_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzctNS0xLTEtNzEzMzA_012b3e70-190f-436e-ab68-062886f221a7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzgtMS0xLTEtNzEzMzA_bf9bf4a3-e39f-4293-acfe-6c507d963795">21,422</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzgtMy0xLTEtNzEzMzA_2313a4df-fa74-4ab8-b66f-3f1e553a28ad">19,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f49f49133634761b181692557d66dda_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzgtNS0xLTEtNzEzMzA_113b7406-9d64-4969-98ca-6cc141b75c0f">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_208"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Merck &amp; Co., Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Merck &amp; Co., Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">U.S. Rebate Accruals - Medicaid, Managed Care and Medicare Part D </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the Company records certain variable consideration including discounts, which are estimated at the time of sale generally using the expected value method. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Certain of these discounts representing a portion of the accrual take the form of rebates, which are amounts owed based upon definitive contractual agreements or legal requirements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. Management uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. The accrued balance relative to the provision for rebates included in accrued and other current liabilities was $2.7 billion as of December 31, 2022, of which the majority relates to U.S. rebate accruals &#8211; Medicaid, Managed Care and Medicare Part D.  </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to U.S. rebate accruals - Medicaid, Managed Care and Medicare Part D is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the rebate accruals, as the accruals are based on assumptions developed using pricing information and historical customer segment utilization mix, and a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating evidence related to these assumptions.  </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to U.S. rebate accruals - Medicaid, Managed Care and Medicare Part D, including management&#8217;s controls over the assumptions used to estimate the corresponding rebate accruals. These procedures also included, among others (i) developing an independent estimate of the rebate accruals by utilizing third party data on historical customer segment utilization mix in the U.S., pricing information, the terms of the specific rebate programs, and the historical trend of actual rebate claims paid, (ii) comparing the independent estimate to the rebate accruals recorded by management, and (iii) testing rebate claims paid, including evaluating those claims for consistency with the contractual terms of the Company&#8217;s rebate agreements.</span></div><div style="text-align:justify"><img src="mrk-20221231_g7.gif" alt="mrk-20221231_g7.gif" style="height:51px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDgvZnJhZzpkNmI5MGY1YWRmZTc0N2I1OGMxODRiODc0NjkwYWIxOS90ZXh0cmVnaW9uOmQ2YjkwZjVhZGZlNzQ3YjU4YzE4NGI4NzQ2OTBhYjE5Xzk0NzE_3dd32aa7-bac4-47ed-8029-4218a75b3e4a">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDgvZnJhZzpkNmI5MGY1YWRmZTc0N2I1OGMxODRiODc0NjkwYWIxOS90ZXh0cmVnaW9uOmQ2YjkwZjVhZGZlNzQ3YjU4YzE4NGI4NzQ2OTBhYjE5Xzk0NzI_dc95c1d7-5540-4860-8d9e-826fc3681946">Florham Park, New Jersey</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February&#160;24, 2023</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2002.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_214"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia384118d157240e09e39541b90e2080f_217"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures. Based on their evaluation, as of the end of the period covered by this Form&#160;10-K, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Act)) are effective. For the fourth quarter of 2022, there have been no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Act. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated Framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December&#160;31, 2022. PricewaterhouseCoopers LLP, an independent registered public accounting firm, has performed its own assessment of the effectiveness of the Company&#8217;s internal control over financial reporting and its attestation report is included in this Form 10-K filing.</span></div><div id="ia384118d157240e09e39541b90e2080f_220"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Management&#8217;s Report</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Responsibility for Financial Statements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Responsibility for the integrity and objectivity of the Company&#8217;s financial statements rests with management. The financial statements report on management&#8217;s stewardship of Company assets. These statements are prepared in conformity with generally accepted accounting principles and, accordingly, include amounts that are based on management&#8217;s best estimates and judgments. Nonfinancial information included in the Annual Report on Form&#160;10-K has also been prepared by management and is consistent with the financial statements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To assure that financial information is reliable and assets are safeguarded, management maintains an effective system of internal controls and procedures, important elements of which include: careful selection, training and development of operating and financial managers; an organization that provides appropriate division of responsibility; and communications aimed at assuring that Company policies and procedures are understood throughout the organization. A staff of internal auditors regularly monitors the adequacy and application of internal controls on a worldwide basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To ensure that personnel continue to understand the system of internal controls and procedures, and policies concerning good and prudent business practices, annually all employees of the Company are required to complete Code of Conduct training. This training reinforces the importance and understanding of internal controls by reviewing key corporate policies, procedures and systems. In addition, the Company has compliance programs, including an ethical business practices program to reinforce the Company&#8217;s long-standing commitment to high ethical standards in the conduct of its business.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial statements and other financial information included in the Annual Report on Form&#160;10-K fairly present, in all material respects, the Company&#8217;s financial condition, results of operations and cash flows. Our formal certification to the Securities and Exchange Commission is included in this Form&#160;10-K filing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212;&#160;Integrated Framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December&#160;31, 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" rowspan="3" style="padding:0 1pt"><div><img src="mrk-20221231_g8.jpg" alt="mrk-20221231_g8.jpg" style="height:78px;margin-bottom:5pt;vertical-align:text-bottom;width:258px"/></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:69pt"><td colspan="3" style="padding:0 1pt"><div><img src="mrk-20221231_g9.jpg" alt="mrk-20221231_g9.jpg" style="height:78px;margin-bottom:5pt;vertical-align:text-bottom;width:258px"/></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Robert M. Davis</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caroline Litchfield</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chairman, President and Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div id="ia384118d157240e09e39541b90e2080f_223"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div id="ia384118d157240e09e39541b90e2080f_226"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:9pt;padding-left:81pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_229"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ia384118d157240e09e39541b90e2080f_232"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:11.51pt">Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The required information on directors and nominees is incorporated by reference from the discussion under Proposal&#160;1. Election of Directors of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023. Information on executive officers is set forth in Part&#160;I of this document on page </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_70">40</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The required information on compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, if applicable, is incorporated by reference from the discussion under the heading &#8220;Stock Ownership Information&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a Code of Conduct &#8212; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Our Values and Standards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> applicable to all employees, including the principal executive officer, principal financial officer, principal accounting officer and Controller. The Code of Conduct is available on the Company&#8217;s website at merck.com/company-overview/culture-and-values/code-of-conduct/values-and-standards. The Company intends to disclose future amendments to certain provisions of the Code of Conduct, and waivers of the Code of Conduct granted to executive officers and directors, if any, on the website within four business days following the date of any amendment or waiver. Every Merck employee is responsible for adhering to business practices that are in accordance with the law and with ethical principles that reflect the highest standards of corporate and individual behavior.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading &#8220;Board Meetings and Committees&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div id="ia384118d157240e09e39541b90e2080f_235"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:11.51pt">Executive Compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required on executive compensation is incorporated by reference from the discussion under the headings &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;All Other Compensation&#8221; table, &#8220;CEO Pay Ratio,&#8221; &#8220;Pay vs. Performance&#8221; table, &#8220;Grants of Plan-Based Awards&#8221; table, &#8220;Outstanding Equity Awards&#8221; table, &#8220;Option Exercises and Stock Vested&#8221; table, &#8220;Pension Benefits&#8221; table, &#8220;Nonqualified Deferred Compensation&#8221; table, and &#8220;Potential Payments Upon Termination or a Change in Control&#8221;, including the discussion under the subheadings &#8220;Separation&#8221; and &#8220;Change in Control,&#8221; as well as all footnote information to the various tables, of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The required information on director compensation is incorporated by reference from the discussion under the heading &#8220;Director Compensation&#8221; and related &#8220;2022 Schedule of Director Fees&#8221; table and &#8220;2022 Director Compensation&#8221; table of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The required information under the headings &#8220;Compensation and Management Development Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation and Management Development Committee Report&#8221; is incorporated by reference from the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:11.51pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information with respect to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading &#8220;Stock Ownership Information&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes information about the options, warrants and rights and other equity compensation under the Company&#8217;s equity compensation plans as of the close of business on December&#160;31, 2022. The table does not include information about tax qualified plans such as the Merck U.S. Savings Plan.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>securities&#160;to&#160;be<br/>issued upon<br/>exercise of<br/>outstanding<br/>options,&#160;warrants<br/>and rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-average<br/>exercise price of<br/>outstanding<br/>options, warrants<br/>and rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>securities&#160;remaining<br/>available&#160;for&#160;future<br/>issuance&#160;under&#160;equity<br/>compensation plans<br/>(excluding<br/>securities<br/>reflected&#160;in&#160;column&#160;(a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,719,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,776,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,719,333&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.55&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,776,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt">Includes options to purchase shares of Company Common Stock and other rights under the following shareholder-approved plans: the Merck &amp; Co., Inc. 2010 and 2019 Incentive Stock Plans, and the Merck&#160;&amp; Co., Inc. 2010 Non-Employee Directors Stock Option Plan.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt">Excludes approximately 12,700,042&#160;shares of restricted stock units and 1,980,608 performance share units (assuming maximum payouts) under the Merck Sharp&#160;&amp; Dohme 2010 and 2019 Incentive Stock Plans. Also excludes 182,601 shares of phantom stock deferred under the MSD Employee Deferral Program and 487,534 shares of phantom stock deferred under the Merck &amp; Co., Inc. Plan for Deferred Payment of Directors&#8217; Compensation.</span></div><div id="ia384118d157240e09e39541b90e2080f_241"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:20.51pt">Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The required information on transactions with related persons is incorporated by reference from the discussion under the heading &#8220;Related Person Transactions&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The required information on director independence is incorporated by reference from the discussion under the heading &#8220;Independence of Directors&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div id="ia384118d157240e09e39541b90e2080f_244"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:11.51pt">Principal Accountant Fees and Services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information required for this item is incorporated by reference from the discussion under Proposal 4. Ratification of Appointment of Independent Registered Public Accounting Firm for 2023 beginning with the caption &#8220;Pre-Approval Policy for Services of Independent Registered Public Accounting Firm&#8221; through &#8220;Fees for Services Provided by the Independent Registered Public Accounting Firm&#8221; of the Company&#8217;s Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_247"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ia384118d157240e09e39541b90e2080f_250"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:11.51pt">Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The following documents are filed as part of this Form&#160;10-K</span></div><div id="ia384118d157240e09e39541b90e2080f_253"></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated statement of income for the years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated statement of comprehensive income for the years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated balance sheet as of December&#160;31, 2022 and 2021 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated statement of equity for the years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated statement of cash flows for the years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="margin-top:6pt;padding-left:81pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes to consolidated financial statements</span></div><div style="margin-top:6pt;padding-left:81pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Report of PricewaterhouseCoopers LLP, independent registered public accounting firm (PCAOB ID <ix:nonNumeric contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yNTMvZnJhZzo1MzMyM2UxMzI0YjM0MjkyYjljY2JlNWYyNjRiZjFhZi90ZXh0cmVnaW9uOjUzMzIzZTEzMjRiMzQyOTJiOWNjYmU1ZjI2NGJmMWFmXzUwMA_58faedc5-88d7-45e2-ba81-06f9543e182f">238</ix:nonNumeric>)</span></div><div id="ia384118d157240e09e39541b90e2080f_256"></div><div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:81pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Schedules are omitted because they are either not required or not applicable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial statements of affiliates carried on the equity basis have been omitted because, considered individually or in the aggregate, such affiliates do not constitute a significant subsidiary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_259"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;text-indent:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">By-Laws of Merck &amp; Co., Inc. (effective </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm"> 22, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">2022)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm"> &#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">March 25, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm"> (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indenture, dated as of April 1, 1991, between Merck Sharp &amp; Dohme Corp. (f/k/a Schering Corporation) and U.S. Bank Trust National Association (as successor to Morgan Guaranty Trust Company of New York), as Trustee (the 1991 Indenture)&#160;&#8212;&#160;Incorporated by reference to Exhibit&#160;4 to MSD&#8217;s Registration Statement on Form S-3 (No. 33-39349)</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64978/0000950123-97-008101.txt">First Supplemental Indenture to the 1991 Indenture, dated as of October 1, 1997&#160;&#8212;&#160;Incorporated by reference to Exhibit 4(b) to MSD&#8217;s Registration Statement on Form S-3 filed September 25, 1997 (No.&#160;333-36383)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex43.htm">Second Supplemental Indenture to the 1991 Indenture, dated November 3, 2009&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.3 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No.1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512216683/d318209dex41.htm">Third Supplemental Indenture to the 1991 Indenture, dated May 1, 2012&#160;&#8212; Incorporated by reference to Exhibit 4.1 to Merck &amp; Co., Inc.&#8217;s Form 10-Q Quarterly Report for the period ended March&#160;31, 2012 (No.&#160;1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012303013260/y92128exv4w1.txt">Indenture, dated November 26, 2003, between Merck &amp; Co., Inc. (f/k/a Schering-Plough Corporation) and The Bank of New York as Trustee (the 2003 Indenture)&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Schering-Plough&#8217;s Current Report on Form&#160;8&#8209;K filed November&#160;28, 2003 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012303013260/y92128exv4w3.txt">Second Supplemental Indenture to the 2003 Indenture (including Form of Note), dated November&#160;26, 2003&#160;&#8212; Incorporated by reference to Exhibit 4.3 to Schering-Plough&#8217;s Current Report on Form&#160;8&#8209;K filed November 28, 2003 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012307012711/y39738exv4w1.htm">Third Supplemental Indenture to the 2003 Indenture (including Form of Note), dated September 17, 2007&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Schering-Plough&#8217;s Current Report on Form 8&#8209;K filed September 17, 2007 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex44.htm">Fifth Supplemental Indenture to the 2003 Indenture, dated November 3, 2009&#160;&#8212;&#160;Incorporated by reference to Exhibit&#160;4.4 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed November 4, 2009 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312510278450/dex41.htm">Indenture, dated as of January 6, 2010, between Merck &amp; Co., Inc. and U.S. Bank Trust National Association, as Trustee&#160;&#8212;&#160;Incorporated by reference to Exhibit 4.1 to Merck &amp; Co., Inc.&#8217;s Current Report on Form 8-K filed December 10, 2010 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/exhibit410-merckdescriptio.htm">Description of the Registrant&#8217;s Common Stock - Incorporated by reference to Exhibit 4.10 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/exhibit411-merckdescriptio.htm">Description of the Registrant&#8217;s 1.125% Notes due 2021, 1.875% Notes due 2026, and 2.500% Notes due 2034 - Incorporated by reference to Exhibit 4.11 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/exhibit412-merckdescriptio.htm">Description of the Registrant&#8217;s 0.500% Notes due 2024 and 1.375% Notes due 2036 - Incorporated by reference to Exhibit 4.12 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000130817915000131/lmrk2015_def14a.htm">Merck &amp; Co., Inc. Executive Incentive Plan (as amended and restated effective June 1, 2015)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 13, 2015 (No.&#160;1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015820000005/ex102deferralprograme.htm">Merck &amp; Co., Inc. Deferral Program Including the Base Salary Deferral Plan (Amended and Restated effective December 1, 2019) - Incorporated by reference to Exhibit 10.2 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2019 filed February 26, 2020 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000130817915000131/lmrk2015_def14a.htm">Merck &amp; Co., Inc. 2010 Incentive Stock Plan (as amended and restated June 1, 2015)&#160;&#8212;&#160;Incorporated by reference to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 13, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312513084618/d438975dex1019.htm">Form of stock option terms for 2013 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2012 filed February&#160;28, 2013 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015815000005/ex1018stockoptiontermsfor2.htm">Form of stock option terms for 2014 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.18 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December&#160;31, 2014 filed February&#160;27, 2015 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015816000063/ex10202015nqsograntsunderm.htm">Form of stock option terms for 2015 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.20 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December&#160;31, 2015 filed February&#160;26, 2016 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107-2017annualnqsot.htm">Form of stock option terms for 2017 annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan - Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108-2019annualnqsot.htm">Form of stock option terms for 2019 annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan - Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000005/ex1012_2018nqsogranttermsu.htm">Form of stock option terms for 2018 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212; Incorporated by referen</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000005/ex1012_2018nqsogranttermsu.htm">c</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">e</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015818000005/ex1012_2018nqsogranttermsu.htm"> to Exhibit 10.12 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2017 filed February 27, 2018 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015817000010/ex10192016nqsograntsunderm.htm">Form of stock option terms for 2016 quarterly and annual non-qualified option grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan &#8212;&#160;Incorporated by reference to Exhibit 10.19 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2016 filed February&#160;28, 2017 (No. 1-6571)</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000114036119006720/mrk-def14a_052819.htm">Merck &amp; Co., Inc. 2019 Incentive Stock Plan - Incorporated by reference to Appendix C to Merck &amp; Co., Inc.&#8217;s Schedule 14A filed April 8, 2019 (No. 1-6571)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000110465919045319/a19-16979_1s8.htm">to the Registration Statement on Form S-8 filed August 12, 2019 to register 111,000,000 shares under the 2019 Incentive Stock</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000110465919045319/a19-16979_1s8.htm"> Plan (File No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/310158/000110465919045319/a19-16979_1s8.htm">333-233226)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312512485851/d445500dex101.htm">Merck &amp; Co., Inc. Change in Control Separation Benefits Plan (effective as amended and restated, as of January 1, 2013)&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.1 to Merck&#160;&amp; Co., Inc.&#8217;s Current Report on Form&#160;8&#8209;K filed November 29, 2012 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1013-plansepmrk2019.htm">Merck &amp; Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) as further amended by Amendments 2019-1 (as of December 19, 2019), 2020-1 (as of February 25, 2020), 2020-2 (as of December 10, 2020), 2021-1 (as of March 31, 2021), 2021-2 (as of December 16, 2021), 2022-1 (as of December 14, 2022) and 2022-2 (as of December 13, 2021) - Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/64978/0000950123-96-004374.txt">Retirement Plan for the Directors of Merck &amp; Co., Inc. (amended and restated June 21, 1996)&#160;&#8212;Incorporated by reference to Exhibit 10.C to MSD&#8217;s Form 10-Q Quarterly Report for the period ended June&#160;30, 1996 filed August 13, 1996 (No. 1-3305)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1017-planfordeferre.htm">Merck &amp; Co., Inc. Plan for Deferred Payment of Directors&#8217; Compensation (Amended and Restated effective as of January 1, 2022)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1017-planfordeferre.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1017-planfordeferre.htm">- Incorporated by reference to Exhibit 10.17 to Merck &amp; Co., Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1017-planfordeferre.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1017-planfordeferre.htm">s Form 10-K Annual Report for the fiscal year ended December 31, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1017-planfordeferre.htm"> filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1017-planfordeferre.htm">February 25, 2022 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012304005617/y96428exv10wu.txt">Distribution agreement between Schering-Plough and Centocor, Inc., dated April 3, 1998&#160;&#8212;&#160;Incorporated by reference to Exhibit 10(u) to Schering-Plough&#8217;s Amended 10-K for the year ended December 31, 2003 filed May 3, 2004 (No. 1-6571)&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000095012307016977/y45185exv10w1.htm">Amendment Agreement to the Distribution Agreement between Centocor, Inc., CAN Development, LLC, and Schering-Plough (Ireland) Company&#160;&#8212;&#160;Incorporated by reference to Exhibit 10.1 to Schering-Plough&#8217;s Current Report on Form 8-K filed December 21, 2007 (No. 1-6571)&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015819000014/a2018form10-k_ex1028xoffer.htm">Offer Letter between Merck &amp; Co., Inc. and Jennifer Zachary, dated March 16, 2018 - Incorporated by reference to Exhibit 10.28 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2018 filed February 27, 2019 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm">Form of stock option terms for 2021 annual non-qualified option grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan - </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex1023-2021annualnqsoterms.htm">Incorporated by reference to Exhibit 10.23 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm">Form of restricted stock unit terms for 2021 annual grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan - </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015821000004/ex10-24x2021annualrsuterms.htm">Incorporated by reference to Exhibit 10.24 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2020 filed February 25, 2021 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1024-2022annualnqso.htm">Form of stock option terms for 2022 annual non-qualified option grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1024-2022annualnqso.htm"> - Incorporated by reference to Exhibit 10.24 to Merck &amp; Co., Inc.&#8217;s Form 10-K Annual Report for the fiscal year ended December 31, 2021 filed February 25, 2022 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1025-2022annualrsut.htm">Form of restricted stock unit terms for 2022 annual grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1025-2022annualrsut.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1025-2022annualrsut.htm">- Incorporated by reference to Exhibit 10.25 to Merck &amp; Co., Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1025-2022annualrsut.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000003/exhibit1025-2022annualrsut.htm">s Form 10-K Annual Report for the fiscal year ended December 31, 2021 filed February 25, 2022 (No. 1-6571)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1023-2019annualceon.htm">2019 terms for CEO annual non-qualified option grant under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan - Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024-2019annualrsut.htm">Form of restricted stock unit terms for 2019 annual grants under the Merck &amp; Co., Inc. 2010 Incentive Stock Plan - Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1025-2020annualnqso.htm">Form of stock option terms for 2020 annual non-qualified option grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1026-2020annualceon.htm">2020 terms for CEO annual non-qualified option grant under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1027-2020annualrsut.htm">Form of restricted stock unit terms for 2020 annual grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan - Filed herewith </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1028-2020psutermsan.htm">2020 Performance Share Unit terms for grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith </a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1029-2020annualceop.htm">2020 CEO Performance Share Unit terms for grant under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1030-2021annualceon.htm">2021 CEO annual non-qualified option terms for grant under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1031-2021annualpsut.htm">2021 Performance Share Unit terms for grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1032-2021annualceop.htm">2021 CEO Performance Share Unit terms for grant under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1033-2021specialret.htm">Terms for Restricted Stock Unit Grants under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan - Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1034restrictedstock.htm">Restricted stock unit terms for May 3, 2022 and August 3, 2022 grants to Executive Chairman under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan &#8212; Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1035-2022annualrsut.htm">Restricted stock unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan - Filed herewith </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1036-2022annualpsut.htm">Performance share unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck &amp; Co., Inc. 2019 Incentive Stock Plan - Filed herewith </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1037-mrkchirfiguind.htm">Offer Letter between Merck &amp; Co., Inc. and Chirfi Guindo, dated June 8, 2022  - Filed herewith</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21-clean2x22x23.htm">Subsidiaries of Merck &amp; Co., Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23-consentofindependentr.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex241-powerofattorney11.htm">Power of Attorney</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex242-certificationofboard.htm">Certified Resolution of Board of Directors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311-rule13ax14a15dx14ace.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312-rule13ax14a15dx14ace.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321-section1350certifica.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322-section1350certifica.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Certain portions of the exhibit have been omitted pursuant to a request for confidential treatment. The non-public information has been filed separately with the Securities and Exchange Commission pursuant to rule&#160;24b-2 under the Securities Exchange Act of 1934, as amended.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of Merck &amp; Co., Inc.&#8217;s total consolidated assets are not filed as exhibits to this report. Merck &amp; Co., Inc. will furnish a copy of these agreements to the Securities and Exchange Commission on request.</span></td></tr></table></div><div><span><br/></span></div><div id="ia384118d157240e09e39541b90e2080f_262"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="ia384118d157240e09e39541b90e2080f_265"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">Table</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7">of</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia384118d157240e09e39541b90e2080f_7"> Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dated:&#160;&#160;&#160;&#160;February&#160;24, 2023</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.801%"><tr><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MERCK&#160;&amp; CO., INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROBERT M. DAVIS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Chairman, Chief Executive Officer and President)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Attorney-in-Fact)</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:28.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, Chief Executive Officer and President;</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial </span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officer; Principal Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance-Global Controller;</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DOUGLAS M. BAKER, JR.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MARY ELLEN COE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAMELA J. CRAIG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THOMAS H. GLOCER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISA J. LAVIZZO-MOUREY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STEPHEN L. MAYO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAUL B. ROTHMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PATRICIA F. RUSSO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHRISTINE E. SEIDMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INGE G. THULIN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KATHY J. WARDEN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PETER C. WENDELL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2023</span></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Jennifer Zachary, by signing her name hereto, does hereby sign this document pursuant to powers of attorney duly executed by the persons named, filed with the Securities and Exchange Commission as an exhibit to this document, on behalf of such persons, all in the capacities and on the date stated, such persons including a majority of the directors of the Company.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.371%"><tr><td style="width:1.0%"></td><td style="width:14.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/S/ JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Attorney-in-Fact)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">139</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>exhibit107-2017annualnqsot.htm
<DESCRIPTION>EXHIBIT-10.7 2017 ANNUAL NQSO TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ieed18c439c4c439a9f31f339898507ca_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.7</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TERMS FOR </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2010 INCENTIVE STOCK PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. </font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.666%"><div style="padding-left:3.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.511%"><tr><td style="width:1.0%"></td><td style="width:47.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQSO </font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Price&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$63.97</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 5, 2017</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 4, 2027</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Vesting Date</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 5, 2018</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 5, 2019</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 5, 2020</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">I. GENERAL INFORMATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the accompanying box. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eligibility&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Eligibility for grants is determined under the Merck &#38; Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Subject to Recoupment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58; For employees in Band 600 and above, this Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">II. TERMINATION OF EMPLOYMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">A. General Rule.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the same day of the third month (&#8220;Within Three Months&#8221;) after the date of the termination (but in no event after the expiration of the Option Period).  Close of Business for any day on which the New York Stock Exchange is not open means the close of business </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">prior</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> to that date when the Exchange is open.  Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later day (e.g., November 28, 29 and 30 all correspond to February 28 in non leap years).  If you are rehired by the Company or JV, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">B. Retirement. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If you retire from service with the Company the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately.  Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its </font></div></div><div style="display:inline-block;max-width:6.666%;min-width:5.666%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.668%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">original Expiration Date.  For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">C. Involuntary Termination.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> If your employment is terminated by the Company and the Company determines that such termination was involuntary, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs B or D through H, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">D. Sale. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of this stock option award will vest and become exercisable immediately upon such termination&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee  may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this option, and&#47;or in the option price of such option. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">E. Misconduct. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F. Death. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the first anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of </font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.666%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in  paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">G. Disability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">H. Change in Control. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B, D, E, F and G above or termination prior to a change in control. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A &#34;change in control&#34; has the same meaning that it has under the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">I. Joint Venture. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a &#8220;JV&#8221;) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through H above apply to this stock option while the option holder is employed by the JV. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">III. TRANSFERABILITY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IV. ADMINISTRATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant.  Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute </font></div></div><div style="display:inline-block;max-width:6.666%;min-width:5.666%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.668%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">V. GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law.  The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">This stock option is subject to the provisions of the 2010 Incentive Stock Plan.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via http&#58;&#47;&#47;onemerck.com  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unless you notify the Company in writing that you wish to refuse this grant within 60 days of the Grant Date, you will be deemed to acknowledge that you have read, understood and agree to all of the terms, conditions and provisions of this document and the Merck &#38; Co., Inc. 2010 Incentive Stock Plan.  If you wish to reject this grant, you must send your written notice of rejection to the Company at&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Attention&#58; Global Executive Compensation and Benefits</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Merck &#38; Co., Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2000 Galloping Hill Road, Building K-1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Kenilworth, New Jersey, U.S.A. 07033</font></div><div><font><br></font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violations</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.666%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Policy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the  Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Definitions</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1. &#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2. A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3. An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4. &#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Procedures</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1. The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2. The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3. If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:6.666%;min-width:5.666%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.668%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4. In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law.  Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.</font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:94px"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>exhibit108-2019annualnqsot.htm
<DESCRIPTION>EXHIBIT-10.8 2019 ANNUAL NQSO TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie2e89d9acc3a4c5d9207cc5313066aea_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TERMS FOR</font></div><div style="margin-top:0.2pt;padding-left:123.72pt;padding-right:123.72pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:118%">2019 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK &#38; CO., INC. 2010 INCENTIVE STOCK PLAN</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:24.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:117%">This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.276%"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">  </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.334%"><tr><td style="width:1.0%"></td><td style="width:47.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Grant Type&#58;</td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NQSO &#8211; Annual </font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Price&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$77.62</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 3, 2019</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2, 2029</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Vesting Date</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 3, 2020</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 3, 2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 3, 2022</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance</font></td></tr></table><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:0.05pt"><font><br></font></div><div style="padding-left:16.05pt;text-indent:-10.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.05pt"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GENERAL INFORMATION</font></div><div style="text-indent:7.95pt"><font><br></font></div><div style="padding-left:3.6pt;padding-right:3.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.95pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at </font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in Forfeiture of the stock option.</font></div></td></tr></table></div><div style="padding-right:3.65pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:3.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the accompanying box. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:2.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Eligibility&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eligibility for grants is determined under the Merck &#38; Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Subject to Recoupment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58; For employees in Band 600 and above, this Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16.05pt;text-indent:-10.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:2.55pt">TERMINATION OF EMPLOYMENT</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:116%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:116%;padding-left:21.01pt">General Rule. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:116%">If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the same day of the third month (&#8220;Within Three Months&#8221;) after the date of the termination (but in no event after the expiration of the Option Period). Close of Business for any day on which the New York Stock Exchange is not open means the close of business </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:116%">prior </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:116%">to that date when the Exchange is open. Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later day (e.g., November 28, 29 and 30 all correspond to February 28 in </font></div></div><div style="display:inline-block;max-width:5.446%;min-width:4.446%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.278%"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:116%">non leap years). If you are rehired by the Company or JV, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:21.01pt">Retirement. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If you retire from service with the Company the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately.  Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its original Expiration Date.  For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6pt;padding-right:6.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:21.01pt">Involuntary Termination. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment is terminated by the Company and the Company determines that such termination was involuntary, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs B or D through H, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:21.01pt">Sale. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of this stock option award will vest and become exercisable immediately upon such termination&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a  termination of employment, and may make adjustments, if any, as it deems appropriate, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this option, and&#47;or in the option price of such option. If your employment is terminated as described in this paragraph and  you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie2e89d9acc3a4c5d9207cc5313066aea_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.146%"><div style="margin-top:3.2pt;padding-left:5pt;padding-right:1.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.5pt">Misconduct. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:23.01pt">Death. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this  stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that                remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in  paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:1.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:21.5pt">Disability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:22.01pt">Change in Control. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B, D, E, F and G above or termination prior to a change in control. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A &#34;change in control&#34; has the same meaning that it has under the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:20.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:26pt">Joint Venture. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a &#8220;JV&#8221;) is not considered termination of employment for purposes of this</font></div><div style="margin-top:2.95pt;padding-left:5pt;padding-right:4.95pt"><font><br></font></div></div><div style="display:inline-block;max-width:5.706%;min-width:4.706%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.148%"><div style="padding-left:5pt;padding-right:4.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">stock option. If you transfer employment from the Company to  a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through H above apply to this stock option while the option holder is employed by the JV.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:17.55pt;text-indent:-12.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:2.55pt">TRANSFERABILITY</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.</font></div><div style="padding-left:0.05pt;padding-right:9.2pt"><font><br></font></div><div style="padding-left:18.55pt;text-indent:-13.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:2.55pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:5.95pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:18.55pt"><font><br></font></div><div style="padding-left:18.55pt;text-indent:-13.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:5.05pt">ADMINISTRATION</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant.  Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:16pt;text-indent:-11pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">VI. GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law.  The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:4.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:117%">This stock option is subject to the provisions of the 2010 Incentive Stock Plan. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:117%">For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via http&#58;&#47;&#47;one.merck.com  </font></div><div style="margin-top:0.05pt"><font><br></font></div></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie2e89d9acc3a4c5d9207cc5313066aea_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.507%"><div><font><br></font></div></div><div style="display:inline-block;max-width:0.985%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.508%"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violations</font></div><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font><br></font></div><div id="ie2e89d9acc3a4c5d9207cc5313066aea_10"></div><div style="margin-top:0.25pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.507%"><div style="padding-left:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div></div><div style="display:inline-block;max-width:0.985%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.508%"></div></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.287%"><div style="margin-top:3.85pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Policy</font></div><div style="margin-top:0.1pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee  will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Definitions</font></div><div style="margin-top:0.1pt;padding-left:6pt;padding-right:2.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:1.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.1pt;padding-left:6pt;padding-right:2.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to</font></div><div style="margin-top:0.15pt"><font><br></font></div></div><div style="display:inline-block;max-width:5.425%;min-width:4.425%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.288%"><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:6.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:8.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:8.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:6.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:119%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:5.95pt;padding-right:8.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-top:0.1pt;padding-left:5.95pt;padding-right:10.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="margin-top:0.1pt;padding-left:5.95pt;padding-right:9.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law.  Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:477.4pt;text-align:right"><img alt="image_1b.jpg" src="image_1b.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:86px"></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>exhibit1013-plansepmrk2019.htm
<DESCRIPTION>EXHIBIT-10.13 US SEPARATION BENEFITS PLAN AS OF 1/1/19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3fd694a9ca9c42b69eb8c45035645669_1"></div><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.13</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.15pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:22.3pt;padding-right:22.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO. INC. U.S. SEPARATION BENEFITS PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:21.12pt;padding-right:21.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amended and Restated as of January 1, 2019</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_4"></div><hr style="page-break-after:always"><div style="min-height:46.08pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:57.2pt;padding-right:57.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC., U.S. SEPARATION BENEFITS PLAN</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:238.97pt;padding-right:238.97pt;text-align:center;text-indent:-1.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 1 </font></div><div style="padding-left:118.52pt;padding-right:118.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PREAMBLE</font></div><div style="margin-top:11.5pt;padding-left:19.35pt;padding-right:21.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Corp. established the MSD Separation Benefits Plan (the &#34;MSD Plan&#34;), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp &#38; Dohme Corp. or a participating wholly owned subsidiary (collectively, &#34;MSD&#34;) was terminated under certain circumstances at the initiative of MSD.</font></div><div><font><br></font></div><div style="padding-left:19.4pt;padding-right:19.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schering-Plough Corporation established the Schering-Plough Separation Benefits Plan (the &#34;Schering Plan&#34;), as amended from time to time, for the purpose of providing severance benefits to eligible union and non-union employees whose employment with Schering Corporation and certain of its U.S. affiliated companies was terminated under certain circumstances.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:19.4pt;padding-right:25.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2012, the Schering Plan merged into the MSD Plan with the MSD Plan being renamed the Merck &#38; Co., Inc. U.S. Separation Benefits Plan (the &#34;Plan&#34;). The Plan was amended and restated in its entirety at that time. Effective January 1, 2013, September 1, 2013, October 1, 2013, November 15, 2014 and January 1, 2017, the Plan was reinstated in its entirety. Effective January 1, 2019, the Plan is again being amended and restated in its entirety as set forth herein.</font></div><div><font><br></font></div><div style="padding-left:19.4pt;padding-right:16.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The purpose of the Plan is to provide benefits to eligible employees whose employment with an Employer is terminated at the initiative of the Employer for reasons described below. This Plan is part of the MSD Separation Allowance Plan (Plan No. 514).</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_7"></div><hr style="page-break-after:always"><div style="min-height:46.08pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:233.3pt;padding-right:233.3pt;text-align:center;text-indent:3.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 2 </font></div><div style="padding-left:116.13pt;padding-right:116.13pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEFINITIONS</font></div><div><font><br></font></div><div style="padding-left:68.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the purposes of this Plan, the following terms shall have the following meanings&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Annual Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:55.4pt;padding-right:17.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">With respect to a Participant who is exempt as of his or her Separation Date, his or her annual base salary in effect as of his or her Separation Date, according to the Employer&#8217;s payroll records, without reduction for any contributions to Employer-sponsored benefit plans. For the avoidance of doubt, (i) with respect to a Participant who is exempt and regularly scheduled to work less than full-time as of his or her Separation Date, Annual Base Salary is the reduced annual base salary in effect on his or her Separation Date applicable to the less than full time position, according to the Employer&#8217;s payroll records, without reduction for any contributions to the Employer-sponsored benefit plans and (ii) no adjustment is made to Annual Base Salary if the Participant&#8217;s annual base salary in effect during any period prior to his or her Separation Date is higher or lower (for any reason, including promotion&#47;demotion or a move to or from full-time or part-time status) than his or her annual base salary in effect as of his or her Separation Date, according to the Employer&#8217;s payroll records.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:25.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">With respect to a Participant who is non-exempt as of his or her Separation Date, the hourly rate according to the Employer&#8217;s payroll records in effect as of his or her Separation Date multiplied by the number of hours the Eligible Employee is regularly scheduled to work as of his or her Separation Date (up to a maximum of 2080 hours)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:25.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual Base Salary does not include bonuses, commissions, overtime pay, shift pay, premium pay, lump sum merit increases, cost of living allowances, income from stock options or other incentives under an Incentive Stock Plan of the Employer (or the Parent or any of its subsidiaries), stock grants or other incentives, or other pay not specifically included above.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.35pt;padding-right:24.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For example, a Participant who is regularly scheduled to work less than full-time on his Separation Date has 10 Complete Years of Continuous Service (9 at full-time and 1 at less than full-time), had an annual base salary of $100,000 as a full-time employee but on his Separation Date has an annual base salary of $50,000 according to the Employer&#8217;s payroll records because it was reduced as applicable for the less than full-time position. The Participant&#8217;s Separation Pay will be calculated using 10 Complete Years of Continuous Service and an Annual Base Salary of</font></div><div style="padding-left:55.35pt;padding-right:25.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$50,000. There is no adjustment in Annual Base Salary for prior years of higher annual base salary due to full-time service.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Base Pay Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">With respect to an Eligible Employee who is exempt, his&#47;her annual base pay according to the Employer&#8217;s payroll records in effect as of the date the Eligible Employee is offered a Qualified Alternative Position or a Negotiated Job Offer. For an Eligible Employee who is regularly scheduled to work less than full-time, annual base pay is the reduced annual base pay to the less than full-time position.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:49.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">With respect to an Eligible Employee who is non-exempt, the hourly rate according to the Employer&#8217;s payroll records in effect as of the date the Eligible Employee is</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_10"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:55.4pt;padding-right:36.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">offered a Qualified Alternative Position or a Negotiated Job Offer multiplied by the number of hours the Eligible Employee is regularly scheduled to work (up to a maximum of 2080 hours).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:55.35pt;padding-right:19.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Base Pay Rate is calculated without reduction for any contributions to Employer-sponsored benefit plans. Base Pay Rate includes applicable shift pay and premium pay but does not include bonuses, commissions, overtime pay, lump sum merit increases, cost of living allowances, income from awards granted under an Incentive Stock Plan of the Employer (or the Parent or its subsidiaries), or other pay not specifically included above</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:20.45pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Basic Life Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means life insurance provided to an Eligible Employee under a plan sponsored by Parent or a subsidiary of Parent equal to 1x &#34;base pay&#34; as defined under the life insurance plan in which the Eligible Employee participates, as it may be amended from time to time.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:16.75pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Benefits Continuation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the period of time, as set forth on Schedule B-2, during which a Participant is eligible to receive Separation Benefits, provided, however that the Participant may elect to end the period earlier than indicated on Schedule B-2 by notifying the Employer's health and insurance plan administrator (i) within the later of thirty (30) days from the Participant's Separation Date or the date by which the Participant is provided to review the Separation Letter so that the Benefit Continuation Period ends on the date it would have otherwise begun, or (ii) during the Employer's annual open enrollment period for health and insurance benefits so that the Benefit Continuation Period ends the following January 1 (provided that date is not beyond the period set forth on Schedule B-2), or (iii) mid-year with a qualified status change that otherwise permits the Participant to make a change to the Participant's healthcare coverage in accordance with the terms of the Employer's healthcare plan so that the Benefits Continuation Period ends on the date the mid-year change would otherwise be effective under the terms of the Employer's healthcare plan (provided that date is not beyond the period set forth on Schedule B- 2).</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:18.9pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the meaning set forth in the CIC Plan (and, for avoidance of doubt, a valid amendment of that definition under the CIC Plan shall constitute an amendment of this Plan without further action).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:23.6pt;text-indent:1.62pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.98pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CIC Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan, as amended and restated effective January 1, 2013 and as it may be further amended from time to time, and any successor thereto.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:32pt;text-indent:1.44pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:0.16pt">           &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Claims Reviewer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Merck &#38; Co., Inc. Employee Benefits Committee (or its delegate) whose members are appointed by the Parent's Executive Vice President of Human Resources or his or her delegate&#59; provided, however, for Section 16 Officers, Claims Reviewer means the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:55.15pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder.</font></div><div style="padding-left:19.4pt;padding-right:55.15pt;text-indent:18pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:55.15pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Complete Years of Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (d) for a Non-Legacy Company Employee, from the Participant&#8217;s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.</font></div><div style="padding-left:19.4pt;padding-right:55.15pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:55.15pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:55.4pt;padding-right:55.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Separation Date as reflected on the Employer&#8217;s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, and (d) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from &#8220;Continuous Service.&#8221; Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as &#34;Continuous Service&#34;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:22.2pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.8pt">           &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) any regular full-time or regular part-time employee of an Employer who is on the Employer's normal U.S. payroll and as to whom the terms and conditions of employment are not covered by a collective bargaining agreement unless the collective bargaining agreement specifically provides for coverage under the Plan&#59; or (b) a U.S. Expatriate on an Employer's normal U.S. payroll.</font></div><div style="margin-top:6.05pt;padding-left:55.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The term &#8220;Eligible Employee&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">shall not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> include&#58;</font></div><div style="margin-top:6pt;padding-left:73.4pt;padding-right:16.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.29pt">an employee (x) who is a party to an employment agreement with the Employer or with the Parent (or any of its subsidiaries) or (y) who is entitled, upon termination of employment with the Employer, to separation, severance, termination or other similar payments (1) under another plan or program sponsored by the Employer or Parent (or any of its subsidiaries)&#59; or</font></div><div style="padding-left:73.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) pursuant to a separate agreement with the Employer or Parent (or any of its subsidiaries) or</font></div><div style="padding-left:73.4pt;padding-right:20.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z) who is a party to an agreement with the Employer or Parent (or any of its subsidiaries) that provides that no payment or benefits are due to the employee in connection with his or her termination of employment&#59; provided, however, in each case under the foregoing clauses (x),</font></div><div style="padding-left:73.4pt;padding-right:33.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) and (z) unless the plan, program or agreement expressly provides for benefits under this Plan&#59;</font></div><div><font><br></font></div><div style="padding-left:73.4pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.96pt">a participant in the CIC Plan (but this clause shall only apply during the Protection Period (as defined in Section 8.1))&#59;</font></div><div><font><br></font></div><div style="padding-left:73.4pt;padding-right:28.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.63pt">temporary employees (including college coops, summer employees, high school coops, flexible workforce employees, post-doctorate research fellows and any other such temporary classifications ) and&#47;or employees called by the Employer at any time for employment in the</font></div><div style="padding-left:73.35pt;padding-right:53.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">U.S. on a non-scheduled and non-recurring basis, and who becomes an employee of the Employer only after reporting to work for the period of time during which the person is working&#59;</font></div><div style="padding-left:73.35pt;padding-right:53.05pt;text-align:justify"><font><br></font></div><div style="margin-top:3.75pt;padding-left:93.65pt;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.94pt">an Excluded Person&#59;</font></div><div><font><br></font></div><div style="padding-left:73.4pt;padding-right:31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.62pt">employees of a non-US subsidiary of an Employer (or who are dual employees of a non- US subsidiary of an Employer) who are on assignment in the US&#59;</font></div><div><font><br></font></div><div style="padding-left:73.4pt;padding-right:58.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.29pt">employees whose employment ends for any reason while on unapproved leaves of absence&#59;</font></div><div><font><br></font></div><div style="padding-left:73.4pt;padding-right:25.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.96pt">employees whose employment ends for any reason while on approved leaves of absence for a period equal to or more than six continuous months regardless of the reason(s) for the leave excluding the following approved leaves of absence&#58; medical disability leaves, military leaves and family medical leaves under federal or state family medical leave laws&#59;</font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:73.4pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.63pt">employees whose employment ends for any reason while on approved leaves of absence for medical disability for a period equal to or more than one year&#59;</font></div><div><font><br></font></div><div style="padding-left:73.4pt;padding-right:16.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.29pt">employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.</font></div><div style="margin-top:11.5pt;padding-left:73.35pt;padding-right:27.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of the foregoing clauses (vii) and (viii), a series of leaves of absence is considered one continuous leave for purposes of calculating the six-month or one-year requirement if the employee does not return to active employment for any reason, including but not limited to because the employee&#8217;s former position is unavailable and the employee is unable to secure a new position.</font></div><div style="margin-top:11.55pt;padding-left:55.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whether an individual is an Eligible Employee or not is determined as of the date of his&#47;her Termination due to Workforce Restructuring or for Rebadged Employees as of the date of his&#47;her termination of employment due to an outsource transaction.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:37.95pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.12&#160;&#160;&#160;&#160;   &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means individually and collectively, the entities identified on Schedule A attached hereto.</font></div><div style="padding-left:0.55pt;padding-right:37.95pt"><font><br></font></div><div style="padding-left:54pt;padding-right:37.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.13&#160;&#160;&#160;&#160;   &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</font></div><div><font><br></font></div><div style="padding-left:50.9pt;padding-right:22.05pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:34.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Excluded Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a person who (i) is an independent contractor, or agrees or has agreed that he&#47;she is an independent contractor, or (ii) has any agreement or understanding with the Employer, or any of its affiliates that he&#47;she is not an employee or an Eligible Employee, or (iii) is employed by a temporary or other employment agency, regardless of the amount of control, supervision or training provided by the Employer or its affiliates, or (iv) is a &#8220;leased employee&#8221; as defined under Section 414(n) of the Internal Revenue Code of 1986, as amended, or (v) is not treated by the Employer as an employee for purposes of withholding federal income taxes, regardless of any contrary Internal Revenue Service, governmental or judicial determination relating to such employment status or tax withholding. An Excluded Person is not eligible to participate in the Plan even if a court, agency or other authority rules that he&#47;she is a common-law employee of the Employer or its affiliates.</font></div><div><font><br></font></div><div style="margin-top:3.75pt;padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Intentionally Omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="margin-top:3.75pt;padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Intentionally Omitted.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:39.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">IAM Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a collective bargaining agreement between Merck Sharp &#38; Dohme Corp. and District 15, Lodge 315 of the International Association of Machinists and Aerospace Workers.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Legacy Inspire Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his&#47;her Separation Date or is rehired or transferred to such entity after December 31, 2012, and (b) as of his&#47;her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent as S6 (Legacy Inspire) under infotype 35, and (iii) not covered by a collective bargaining agreement.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Legacy Merck Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his&#47;her Separation Date or is rehired or transferred to such entity after December 31, 2012, and (b) as of his&#47;her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent with a blank indicator under infotype 35, and (iii) not covered by a collective bargaining agreement, other than one of the IAM Agreements. For the avoidance of doubt, &#8220;Legacy Merck Employee&#8221; excludes employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.</font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:55.4pt;padding-right:23.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Legacy Merck Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for the period prior to November 4, 2009, Old Merck and its direct or indirect wholly owned subsidiaries and (b) for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:21.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Legacy Schering Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his&#47;her Separation Date or is rehired by or transferred to such entity after December 31, 2012, and</font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:19.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) as of his&#47;her Separation Date is (i) employed by an Employer, (ii) coded in the employee data base of Parent as S1 (Legacy Organon), S2 (Legacy Intervet) or S5 (Legacy Schering-Plough) under infotype 35, and (iii) not covered by a collective bargaining agreement other than one of the IAM Agreements or an agreement that specifically provides for benefits under this Plan. For the avoidance of doubt, &#8220;Legacy Schering Employee&#8221; excludes employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Legacy Schering Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for the period prior to November 4, 2009, Schering- Plough Corporation and its direct or indirect wholly owned subsidiaries and (b) for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:31.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Merck Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:17.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Merck Retiree Medical Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the retiree medical plan sponsored by Merck Sharp &#38; Dohme which includes the following components&#58; (i) the Merck Group Retiree Medical Plan which provides group retiree medical and prescription drug benefits to eligible retirees and their eligible dependents, in each case who are under age 65 or not Medicare-eligible as more fully described in the Merck Group Retiree Medical Plan SPD, and (ii) the Merck Retiree HRA which provides reimbursement benefits to eligible retirees and their eligible dependents who are eligible for subsidized retiree medical benefits and, in each case ,who are age 65 or older and Medicare- eligible as more fully described in the Merck Retiree Health Reimbursement Account SPD.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Misconduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means conduct which includes (a) falsification of an Employer's or Parent's records&#47;misrepresentation&#59; (b) theft&#59; (c) acts or threats of violence&#59; (d) refusal to carry out assigned work&#59; (e) unauthorized possession of alcohol or illegal drugs on an Employer's or Parent's premises&#59; (f) being under the influence of alcohol or illegal drugs during work hours&#59; (g) willful intent to damage or destroy an Employer's or Parent's property&#59; (h) violation of the Parent's &#34;Our Values and Standards&#34;&#59; (i) acts of discrimination&#47;harassment&#59; (j) conduct jeopardizing the integrity of the products of an Employer, Parent or one or more of its subsidiaries&#59; (k) violation of rules, policies, and&#47;or practices of an Employer or Parent&#59; or (l) other conduct considered to be detrimental to an Employer, the Parent or one or more of its subsidiaries.</font></div><div style="padding-left:55.4pt;padding-right:17.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Most Recent Hire Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer&#8217;s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer&#8217;s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, and (d) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of September 3, 2010, is his or her most recent hire date on the Employer&#8217;s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT. For the avoidance of doubt, the most recent hire date at an acquired entity may occur before the date the entity was acquired by a Legacy Schering Entity, Legacy Merck Entity or Merck Entity, provided such date is reflected on the Employer&#8217;s employee data system.</font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:16.15pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:32.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt;text-decoration:underline">&#34;Negotiated Job Offer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an offer of employment (or an offer of continued employment) with a successor employer or outsource vendor the terms and conditions of which are negotiated by an Employer, Parent or one of its subsidiaries or affiliates and may include, among other things, a reduction in Base Pay Rate.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:78.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">New Merck</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means Merck &#38; Co., Inc. (formerly known as Schering-Plough Corporation) on and after November 4, 2009.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:17.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Legacy Company Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an Eligible Employee who (a) is first hired by a Merck Entity on or after January 1, 2013, and (b) as of his&#47;her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent with a blank indicator under infotype 35, and (iii) not covered by a collective bargaining agreement. For purposes of determining whether an Eligible Employee is a &#8220;Non-Legacy Company Employee&#8221; only, an Eligible Employee who was an employee of an entity on the date that it was acquired by a Merck Entity is considered to be first hired by a Merck Entity on the date the entity became a wholly owned subsidiary of New Merck or one of its wholly owned subsidiaries</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Offer Outside Geographic Parameters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (A) for an Eligible Employee who </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">is not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eligible to participate in the Company&#8217;s sales incentive plan and who </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">does not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">qualify as other field-based personnel, a Negotiated Job Offer that results in the relocation of the Eligible Employee's principal business location to a new principal business location (x) where the distance between the Eligible Employee&#8217;s residence immediately prior to the extension of the Negotiated Job Offer and his&#47;her new principal business location is more than 50 miles greater than the distance between the Eligible Employee's residence and his&#47;her principal business location at the time the Negotiated Job Offer is extended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time, and (B) for an Eligible Employee who </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eligible to participate in the Company&#8217;s sales incentive plan or who qualifies as other field-based personnel, a Negotiated Job Offer that results in the relocation of the Eligible Employee's geographic workload center location to a new geographic workload center location (x) where the distance between the Eligible Employee&#8217;s residence immediately prior to the extension of the Negotiated Job Offer and his&#47;her new geographic workload center location is more than 50 miles greater than the distance between the Eligible Employee's residence and his&#47;her geographic workload center location at the time the Negotiated Job Offer is extended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time.</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:17.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Employer, in its sole and absolute discretion, will determine (i) whether an Eligible Employee qualifies as other field-based personnel, (ii) distance using a nationally recognized mapping service, (iii) principal business location, and (iv) the geographic workload center.</font></div><div style="margin-top:6.05pt;padding-left:55.35pt;padding-right:30.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whether a position is an Offer Outside Geographic Parameters shall be determined at the time a Negotiated Job Offer is offered or communicated to the Eligible Employee by the Employer.</font></div><div style="margin-top:6.05pt;padding-right:30.45pt"><font><br></font></div><div style="padding-left:91.4pt;padding-right:26.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Old Merck</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means Merck &#38; Co., Inc. prior to November 4, 2009 (subsequently known as Merck Sharp &#38; Dohme Corp).</font></div><div><font><br></font></div><div style="padding-left:91.4pt;padding-right:26.1pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Outplacement Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means benefits for outplacement counseling or other outplacement services made available to a Participant as provided pursuant to Section 4.4 of this Plan.</font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means New Merck.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:55.4pt;padding-right:21.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an Eligible Employee who has experienced a Termination due to Workforce Restructuring and who has signed, and, if a revocation period is applicable, not revoked, a Release of Claims in a form that is satisfactory to the Employer in its sole and absolute discretion.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:21.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The term &#34;Participant&#34; shall also include, where and as applicable a Rebadged Employee who has signed and, if a revocation period is applicable, not revoked a Release of Claims in a form that is satisfactory to the Employer in its sole and absolute discretion.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:17.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Merck &#38; Co., Inc., U.S. Separation Benefits Plan as set forth herein, and as may be amended from time to time.</font></div><div style="padding-right:17.1pt;text-indent:18pt"><font><br></font></div><div style="padding-left:54pt;padding-right:17.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Parent or its delegate.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:54pt;padding-right:51.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Plan Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the calendar year January 1 through December 31 on which the records of the Plan are kept.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:54pt;padding-right:16.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Qualified Alternative Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a position with an Employer, the Parent or any of its subsidiaries which does not result in either of the following&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">a reduction in the Eligible Employee's Base Pay Rate&#59; or</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:76.5pt;padding-right:16.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.86pt">(A) for an Eligible Employee who </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">is not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eligible to participate in the Company&#8217;s sales incentive plan, relocation of the Eligible Employee's principal business location to a new principal business location (x) where the distance between the Eligible Employee&#8217;s residence immediately prior to the relocation and his&#47;her new principal business location is more than 50 miles greater than the distance between the the Eligible Employee's residence and his&#47;her principal business location immediately prior to the relocation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) that is more than 75 miles from the Eligible Employee's residence immediately prior to the relocation and not closer to the Eligible Employee's residence at that time, and (B) for an Eligible Employee who </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eligible to participate in the Company&#8217;s sales incentive plan or who qualifies as other field- based personnel, relocation of the Eligible Employee's geographic workload center location to a new geographic workload center location (x) where the distance between the Eligible Employee&#8217;s residence immediately prior to the relocation and his&#47;her new geographic workload center location is more than 50 miles greater than the distance between the Eligible Employee's residence and his&#47;her geographic workload center location immediately prior to the relocation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time.</font></div><div style="margin-top:6pt;padding-left:76.5pt;padding-right:26.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Employer, in its sole and absolute discretion, will determine (i) whether an Eligible Employee qualifies as other field-based personnel, (ii) distance using a nationally recognized mapping service, (iii) principal business location, and (iv) the geographic workload center.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:76.5pt;padding-right:56.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whether a position is a Qualified Alternative Position shall be determined at the time such position is offered or communicated to the Eligible Employee by his&#47;her manager.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:54pt;padding-right:45.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Rebadged Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an Eligible Employee whose employment with the Employer is terminated by the Employer in connection with the outsourcing of work by the Employer in a transaction with a third-party vendor where the Eligible Employee is offered a Negotiated Job Offer and&#58;</font></div><div><font><br></font></div><div style="padding-left:76.5pt;padding-right:20.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">(i) accepts the Negotiated Job Offer&#59; or (ii) declines the Negotiated Job Offer, provided the Negotiated Job Offer is not an Offer Outside Geographic Parameters&#59; and</font></div><div><font><br></font></div><div style="padding-left:76.5pt;padding-right:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">remains employed with the Employer through the date established by the Employer as the employee's Separation Date unless the Employer expressly waives this provision.</font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:76.5pt;padding-right:22.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whether an Eligible Employee is a Rebadged Employee shall be determined by the Employer or Parent in its sole discretion. An Eligible Employee shall not be considered to be a Rebadged Employee if his or her employment with the Employer (i) does not end as set forth in this Section 2.38 (ii) ends due to the declination of a Negotiated Job Offer that is an Offer Outside Geographic Parameters, or (iii) ends as a result of any of the events described in Section 3.1(e).</font></div><div style="padding-right:22.7pt"><font><br></font></div><div style="margin-top:3.95pt;padding-left:55.35pt;padding-right:26.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, a Rebadged Employee shall not be considered to have experienced a Termination due to Workforce Restructuring for purposes of the Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:22.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the agreement that an Eligible Employee must execute in order to become a Participant and to receive Separation Plan Benefits, which shall be prepared by the Employer or the Parent and shall contain such terms and conditions as determined by the Employer or the Parent, including but not limited to a general release of claims, known or unknown, that the Eligible Employee may have against the Employer (and the Parent and any of its subsidiaries and&#47;or affiliates), including claims related to the employment and termination of employment of the Eligible Employee&#59; such Release of Claims may also contain, in the Employer&#8217;s or the Parent's discretion, other terms and conditions including, without limitation, cooperation in litigation, non-disclosure, confidentiality, non-disparagement, non-solicitation and&#47;or non-competition provisions.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 16 Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an &#8220;officer&#8221; as such term is defined in Rule 16(a)-1(f) of the Securities Exchange Act of 1934 of the Parent who is also an Eligible Employee of an Employer.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:35.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the benefits provided pursuant to Sections 4.2 and 4.3 of this Plan.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:26pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Eligible Employee&#8217;s last day of employment with the Employer due to a Termination due to Workforce Restructuring or, in the case of a Rebadged Employee, due to the outsourcing transaction. The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his&#47;her date of death.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:24.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the cash benefit payable under this Plan pursuant to Section 4.1 or to a Rebadged Employee pursuant to Section 4.5.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation Plan Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, collectively, Separation Pay, Separation Benefits and Outplacement Benefits.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:18.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt;text-decoration:underline">&#34;Termination Due to Non-Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a termination of an Eligible Employee's employment as determined and caused by the Employer due to the Eligible Employee's failure to perform his or her job assignments in a satisfactory manner.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:29.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination due to Workforce Restructuring</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> &#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the termination of an Eligible Employee's employment as determined and caused by the Employer due to&#58;</font></div><div style="margin-top:6pt;padding-left:127.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the elimination of an Eligible Employee's job&#59;</font></div><div style="margin-top:6pt;padding-left:127.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">organizational changes&#59; or</font></div><div style="margin-top:6pt;padding-left:127.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">a general reduction of the workforce.</font></div><div style="margin-top:6pt;padding-left:55.35pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Whether an Eligible Employee's job is eliminated is determined by the Employer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">but excludes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the maintenance of the position with the elimination of a part-time or job share arrangement or other flexible work arrangement.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Organizational changes are determined by the Employer and include the following actions&#58; discontinuance of operations, location closings, corporate restructuring </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">but exclude</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a reduction in job title, grade or band level, Base Pay Rate, short term incentive opportunity (e.g., cash bonuses under any bonus or incentive plan or program of the Parent), long-term incentive compensation</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_22"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:55.35pt;padding-right:16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">opportunity, equity compensation opportunity and&#47;or other forms of remuneration of an Eligible Employee with or without a change in the Eligible Employee's job duties where such reduction is due to (i) a general change in the Employer&#8217;s or the Parent&#8217;s compensation framework as it applies to similarly situated Eligible Employees (e.g., a change in the general compensation framework applicable to similar jobs with the Employer, or an identifiable segment of the Employer such as a subsidiary, division or department)&#59; (ii) an action to align the Eligible Employee with the Employer's or the Parent's compensation and career framework as it applies to similarly situated Eligible Employees&#59; or (iii) a demotion or other action taken as a result of the Eligible Employee's performance or behaviors.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:17.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An Eligible Employee shall not be considered to have incurred a Termination due to Workforce Restructuring if his or her employment with the Employer (i) does not end due to this Section 2.46 (a), (b) or (c) or (ii) ends as a result of any of the events described in Section 3.1(d).</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:16.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt with respect to outsourcing transactions, (x) an Eligible Employee whose employment with the Employer is terminated by the Employer in connection with the outsourcing of work by the Employer in a transaction with a third-party vendor where the individual is offered a Negotiated Job Offer and declines the Negotiated Job Offer because it is an Offer Outside Geographic Parameters, is considered to have incurred a Termination due to Workforce Restructuring provided his or her employment with the Employer does not end as a result of any of the events described in Section 3.1 (d), and (y) a Rebadged Employee shall not be considered to have experienced a Termination due to Workforce Restructuring for purposes the Plan.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:18.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">U.S. Expatriate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a U.S. citizen or individual with U.S. Permanent Resident status who is employed by the Employer and on assignment outside the U.S. and who is not an Excluded Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_25"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:189.3pt;padding-right:189.3pt;text-align:center;text-indent:47.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 3 </font></div><div style="padding-left:94.15pt;padding-right:94.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ELIGIBILITY FOR BENEFITS</font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt;padding-left:81pt;padding-right:22.3pt;text-align:justify;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:19.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he&#47;she experiences a Termination due to Workforce Restructuring&#59; provided, however, that a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring on or after May 17, 2013.&#160;&#160;&#160;&#160;Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring only if the Eligible Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.</font></div><div><font><br></font></div><div style="margin-top:10.4pt;padding-left:55.4pt;padding-right:19.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">A Rebadged Employee will be eligible for Separation Pay described in Section 4.5&#59; provided, however, that a Rebadged Employee who is a Legacy Inspire Employee will be eligible for Separation Pay described in Section 4.5 only if his&#47;her employment with an Employer is terminated by the Employer in connection with the outsourcing of work on or after May 17, 2013. Separation Pay shall be provided under this Plan to a Rebadged Employee only if the Rebadged Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. A Rebadged Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant. A Rebadged Employee is not eligible for Separation Benefits or Outplacement Benefits.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:16.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">An Eligible Employee will also be entitled to receive those pension benefits set forth in Schedule D (Change in Control&#47;Pension) and retiree medical benefits set forth in Schedule E (Change in Control&#47;Retiree Medical) if (i) a Change in Control has occurred and (ii) within two years thereafter, the Eligible Employee&#8217;s employment with the Employer (or successor employer) is terminated by the Employer (or successor employer) for any reason other than for Misconduct, death or &#34;Permanent Disability&#34; (as such term is defined in the CIC Plan), and (iii) the Eligible Employee signs and returns the release of claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:19.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">Notwithstanding anything herein to the contrary, an Eligible Employee shall not be considered to have incurred a Termination due to Workforce Restructuring under the Plan if his or her employment ends as a result of any of the following events&#58;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:32.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.29pt">a divestiture of a subsidiary, division or other identifiable segment of the Employer or Parent or a transfer of the Eligible Employee to a joint venture or other business entity in which the Employer or the Parent directly or indirectly will own some outstanding voting or other ownership interest, in each case where either</font></div><div style="margin-top:6pt;padding-left:163.4pt;padding-right:63.4pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.07pt">the Eligible Employee is offered and accepts, or continues in, a Negotiated Job Offer&#59; or</font></div><div style="margin-top:6pt;padding-left:163.4pt;padding-right:21.55pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.07pt">the Eligible Employee is offered and declines a Negotiated Job Offer, unless the Negotiated Job Offer is an Offer Outside Geographic Parameters with the acquiring entity or vendor&#59;</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_28"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:91.4pt;padding-right:17.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.96pt">the Employer's decision to outsource work to a third-party vendor where the Eligible Employee is a Rebadged Employee&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:17.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.63pt">the Eligible Employee's voluntary resignation for any reason including after reaching early or normal retirement age under the retirement plan applicable to the Eligible Employee&#59;</font></div><div style="margin-top:6pt;padding-left:163.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">a termination for Misconduct&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:18.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">death (unless the Eligible Employee dies after he&#47;she has been notified of his&#47;her scheduled Separation Date but before the Separation Date occurs and a valid Release of Claims is executed by the Eligible Employee's estate) in which case the Eligible Employee's Separation Date shall be deemed to have occurred on the day before his&#47;her date of death&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:20.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.29pt">the Eligible Employee terminating employment with the Employer prior to the date identified as the date the employee would experience a Termination due to Workforce Restructuring unless the Employer expressly agreed to waive this provision&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:25.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.96pt">failure by the Eligible Employee to return to work at the Employer (or the Parent or any of its subsidiaries) for any reason, including, but not limited to the Eligible Employee&#8217;s failure to secure a position at the Employer (or the Parent or any of its subsidiaries) upon a return from a leave of absence for any reason&#59; or</font></div><div style="margin-top:6pt;padding-left:163.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12.03pt;text-decoration:underline">Intentionally Omitted&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:17.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.29pt">the Eligible Employee's decision to decline a Qualified Alternative Position for any reason (including, but not limited to because the employee is a part-time employee and is offered a full-time position, is a shift-worker and the position offered is on a different shift or has a job share or other flexible work arrangement and the position offered is not a job share or does not include a flexible work arrangement) that is offered to the Eligible Employee prior to the Eligible Employee's Separation Date&#59; or</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:38.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">the Eligible Employee's decision to accept an alternate position with the Employer, Parent or any of its subsidiaries (whether or not the position is a Qualified Alternative Position) and to later decline it&#59; or</font></div><div style="margin-top:6pt;padding-left:163.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Termination Due to Non-Performance.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:18.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Notwithstanding anything herein to the contrary, an Eligible Employee shall not be considered to be a Rebadged Employee under the Plan if his or her employment ends as a result of any of the following events&#58;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:32.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.29pt">a divestiture of a subsidiary, division or other identifiable segment of the Employer or Parent or a transfer of the Eligible Employee to a joint venture or other business entity in which the Employer or the Parent directly or indirectly will own some outstanding voting or other ownership interest&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:17.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.96pt">the Employer's decision to outsource work to a third-party vendor where the Eligible Employee is offered a Negotiated Job Offer and declines it because it is an Offer Outside Geographic Parameters&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:17.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.63pt">the Eligible Employee's voluntary resignation for any reason including after reaching early or normal retirement age under the retirement plan applicable to the Eligible Employee&#59;</font></div><div style="margin-top:6pt;padding-left:163.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">a termination for Misconduct&#59;</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_31"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:91.4pt;padding-right:18.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">death (unless the Eligible Employee dies after he&#47;she has been notified of his&#47;her scheduled Separation Date but before the Separation Date occurs and a valid Release of Claims is executed by the Eligible Employee's estate) in which case the Eligible Employee's Separation Date shall be deemed to have occurred on the day before his&#47;her date of death&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:20.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.29pt">the Eligible Employee terminating employment with the Employer prior to the date identified by the Employer as the Separation Date unless the Employer expressly agreed to waive this provision&#59;</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:25.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.96pt">failure by the Eligible Employee to return to work at the Employer (or the Parent or any of its subsidiaries) for any reason, including, but not limited to the Eligible Employee&#8217;s failure to secure a position at the Employer (or the Parent or any of its subsidiaries) upon a return from a leave of absence for any reason&#59; or</font></div><div style="margin-top:6pt;padding-left:127.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Intentionally Omitted</font></div><div style="margin-top:6pt;padding-left:163.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">Termination Due to Non-Performance.</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:91.4pt;padding-right:38.15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Termination of Eligibility for Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A Participant shall cease to participate in the Plan, and all Separation Plan Benefits shall cease upon the occurrence of the earliest of&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;padding-right:31.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.7pt">Termination of the Plan prior to, or more than two years following, a Change in Control&#59;</font></div><div style="margin-top:6pt;padding-left:130.5pt;text-indent:-17.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.52pt">Inability of the Employer to pay Separation Plan Benefits when due&#59;</font></div><div style="margin-top:6pt;padding-left:77pt;padding-right:48.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.7pt">Completion of payment to the Participant of the Separation Plan Benefits for which the Participant is eligible&#59; and</font></div><div style="margin-top:6pt;padding-left:77pt;padding-right:19.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.02pt">The Claims Reviewer's determination, in its sole discretion, of the occurrence of the Eligible Employee&#8217;s Misconduct, regardless of whether such determination occurs before or after the Eligible Employee&#8217;s Separation Date, unless the Claims Reviewer determines in its sole discretion that Misconduct shall not cause the cessation of Separation Plan Benefits in a particular case.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_34"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:243.3pt;padding-right:243.3pt;text-align:center;text-indent:-6.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 4</font></div><div style="padding-left:121.15pt;padding-right:121.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BENEFITS</font></div><div><font><br></font></div><div style="margin-top:10.35pt;padding-left:55.4pt;padding-right:30.2pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Separation Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Separation Pay shall be payable under this Plan to a Participant who is not a Rebadged Employee as set forth on Schedule B-1. The terms of Schedule B-1 are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan. For Separation Pay payable under this Plan to a Rebadged Employee, see Section 4.5 of this Plan.</font></div><div><font><br></font></div><div style="padding-left:55.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">A Participant who is covered under any of the Employer's group employee medical and dental plans as of his or her Separation Date will be provided the opportunity to continue such employee coverage during his or her Benefits Continuation Period, as determined in accordance with Schedule B-2 of this SPD. as such coverage may be amended from time to time, in accordance with the terms and conditions of such plans, provided the Participant timely pays the required contribution to continue coverage. The required contribution is calculated at active employee rates, as the same may be changed from time to time, during his or her Benefits Continuation Period.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:37.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">A Participant who, prior to his or her Separation Date, had elected no employee medical or dental coverage under the applicable employee medical or dental plan will not be permitted to change from no medical and&#47;or dental coverage to coverage as a result of a Termination due to Workforce Restructuring.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:16.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Employee medical and dental continuation coverage, as it may be amended from time to time, at active rates shall continue during the Benefits Continuation Period. The Benefits Continuation Period begins on the first day of the month following the Participant's Separation Date and shall end on the last day of the month in which the Benefits Continuation Period ends as determined in accordance with Schedule B-2 of this SPD, provided the Participant pays the required contributions for coverage in the time and manner required. If the Participant fails to pay the required contributions for coverage in the time and manner required, or the Participant elects to terminate active medical and&#47;or dental coverage, coverage will end as of the last day of the month for which the contribution was paid and it will not be reinstated during the Benefits Continuation Period. If the Participant has medical and&#47;or dental coverage on the last day of the Benefits Continuation Period, the Participant may be eligible to continue coverage in effect at the end of the Benefits Continuation Period in accordance with COBRA by timely electing and paying the full COBRA premium.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">If, as of his or her Separation Date, a Participant is eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then he or she (i) shall be eligible to continue employee medical and dental benefits in accordance with this Section 4.2 and, (ii) following the completion of the Benefits Continuation Period, shall be eligible for retiree medical benefits at subsidized rates under the Merck Retiree Medical Plan, as it may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan. If a Participant is not eligible to continue active medical coverage during the Benefits Continuation Period (i.e., because the Participant had no employee coverage on his&#47;her Separation) or the Participant's employee medical coverage ends during the Benefits Continuation Period (for any</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_37"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:55.35pt;padding-right:20.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reason, including non-payment), the Participant cannot enroll for medical coverage as a retiree until the end of the Benefits Continuation Period. If the Participant elects to end the Benefits Continuation Period earlier than the period set forth on Schedule B-2 as permitted in Section 2.4, all employee medical and&#47;or dental benefit coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation Period will be permanently and irrevocably forfeited. A Participant cannot be covered as an employee and as a retiree (even under the retiree no coverage option, if available) in a medical plan of an Employer (or Parent) during the same period&#59; provided, however, that a Participant may be covered through COBRA at full COBRA rates for dental coverage even if during that period the Participant is also covered as a retiree for medical coverage.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:34.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Rebadged Employees are not eligible for continuation of employee medical and dental benefits at active contribution rates during the Benefits Continuation Period described in this Section 4.2.</font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Life Insurance Benefits</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:55.4pt;padding-right:17.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">A Participant shall be eligible to continue Basic Life Insurance coverage at no cost to the Participant during his or her Benefits Continuation Period, as determined in accordance with Schedule B-2, subject to and in accordance with the terms of the applicable life insurance plan as they may be amended from time to time. The Participant is responsible for paying applicable tax on imputed income, if any, for Basic Life Insurance coverage during his or her Benefits Continuation Period. The terms of such Schedule B-2 are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">Basic Life Insurance coverage shall end on the last day of the month in which the Benefits Continuation Period ends. If the Participant elects to end the Benefits Continuation Period earlier than the period set forth on Schedule B-2 as permitted in Section 2.4, all Basic Life Insurance coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation Period will be permanently and irrevocably forfeited.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:35.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Rebadged Employees are not eligible for the life insurance benefits described in this Section 4.3.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:27.95pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Outplacement Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Benefits for outplacement counseling or other outplacement services, as set forth in Schedule C, will be made available to a Participant. The terms of such Schedule C are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan. Outplacement benefits shall be provided in kind&#59; cash shall not be paid in lieu of outplacement benefits nor will Separation Pay be increased if a Participant declines or does not use the outplacement benefits. Rebadged Employees are not eligible for outplacement benefits described in this Section 4.4.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:27.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation Pay for Rebadged Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. A Rebadged Employee who is a Participant shall be eligible for Separation Pay under this Plan in an amount equal to 50% of the Separation Pay that would be payable had he or she experienced a Termination due to Workforce Restructuring.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:34.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, a Rebadged Employee shall not be eligible for any Separation Plan Benefits other than the Separation Pay described in this Section 4.5.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_40"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:55.4pt;padding-right:32.85pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Reduction of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything in this Plan to the contrary, a Participant's Separation Pay (including Separation Pay described in Section 4.5) and Separation Benefits, if applicable, shall be reduced by&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:24.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">any amount the Plan Administrator reasonably concludes the Participant owes the Employer (or the Parent or any subsidiary or affiliate of the Parent) including, without limitation, unpaid bills under the corporate credit card program, and for vacation used, but not earned&#59;</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:33.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">any severance or severance type benefits that the Employer (or the Parent or any subsidiary or affiliate of the Parent) must pay to a Participant under applicable law&#59;</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:20.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">where permitted by law, any payments received by the Participant pursuant to state workers compensation laws&#59;</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:22.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">short-term disability benefits where state law does not permit Separation Pay to be offset from short-term disability benefits (or where the Employer in its sole and absolute discretion determines it is administratively easier for the Employer to reduce Separation Pay by short-term disability benefits in lieu of reducing short-term disability benefits by Separation Pay)&#59;</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:16.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">For Participants whose employment ends on or after January 1, 2017 who experienced one or more one-way transfers from a non-U.S. subsidiary to another non-U.S. subsidiary and&#47;or to a U.S. subsidiary, any severance or severance type benefits paid by the Parent or any subsidiary or affiliate of the Parent to the Participant as a result of such transfer(s), provided such amount is determined using the exchange rate on the date(s) of the one-way transfer(s) or the Separation Date, whichever provides the lowest amount.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:18.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in the Plan to the contrary, a Participant&#8217;s Separation Pay (including Separation Pay described in Section 4.5) and Separation Benefits are not meant to duplicate pay and benefits provided by the Employer (or the Parent or any of its subsidiaries) in connection with any Participant's Termination due to Workforce Restructuring or in connection with a Participant's termination due to the outsourcing of work to a third-party vendor, including pay and benefits under the federal Worker Adjustment Retraining and Notification Act and any state or local equivalent (collectively, the &#34;WARN Act&#34;). If the Plan Administrator determines that a Participant is entitled to WARN Act damages or WARN Act notice, the Plan Administrator in its sole and absolute discretion may reduce the Participant's Separation Pay and Separation Benefits under the Plan by the WARN Act damages or pay and benefits after receiving WARN Act notice, but not below $500, with the remaining Separation Pay and Separation Benefits provided to the Participant in accordance with the terms of the Plan in satisfaction of the Participant's WARN Act notice rights or damages. In all other cases, Separation Pay paid under the Plan in excess of $500 will be treated as having been paid to satisfy any WARN Act damages, if applicable.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_43"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:22.42pt;padding-right:22.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 5</font></div><div style="padding-left:131.87pt;padding-right:131.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FORM AND TIMING OF BENEFITS&#59; FORFEITURE AND REPAYMENT OF BENEFITS</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Form and Time of Payment</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:55.4pt;padding-right:22.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Except as otherwise provided in subsection (b), Separation Pay, less taxes and applicable deductions shall be paid in a lump sum as soon as practicable after the Participant's Termination due to Workforce Restructuring (or in the case of a Rebadged Employee, after termination of employment due to the outsourcing transaction) and the expiration of any period during which the Participant may consider, sign and, if a revocation period is applicable, revoke the Release of Claims, but in no event later than March 15 of the calendar year following the year of a Participant's Separation Date.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:23.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">If it is determined by the Employer or Parent in its discretion, that (i) the Participant is, as of his or her Separation Date, a &#34;specified employee&#34; (as such term is defined in Section 409A(2)(B) of the Code)&#59; and (ii) the Separation Pay payable pursuant to the terms of the Plan constitutes nonqualified deferred compensation that would subject the Participant to &#8220;additional tax&#8221; under Section 409A(a)(1)(B) of the Code (the &#34;409A Tax&#34;), then the payment of Separation Pay will be postponed to the first business day of the seventh month following the Separation Date or, if earlier, the date of the Participant's death.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:47.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Separation Pay payable under this Plan shall be subject to the withholding of appropriate federal, state and local taxes.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything in this Plan to the contrary, the Employer or Parent will take such actions as it deems necessary, in its sole and absolute discretion, to avoid the imposition of a 409A Tax at such time and in such manner as permitted under Section 409A of the Code, including, but not limited to, reducing or eliminating benefits and changing the time or form of payment of benefits.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:17.4pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Forfeiture of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Employer reserves the right, in its sole and absolute discretion, to cancel all Separation Plan Benefits and seek the return of Separation Pay in the event a Participant engages in any activity that the Employer considers detrimental to its interests (or the interests of the Parent or any of its subsidiaries) as determined by the Parent&#8217;s Executive Vice President and General Counsel and the Parent&#8217;s Executive Vice President, Human Resources. Activities that the Employer considers detrimental to its interest (or the interests of the Parent or any of its subsidiaries) include, but are not limited to&#58;</font></div><div style="margin-top:6pt;padding-left:127.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">breach of any obligations of the Participant's terms and conditions of employment&#59;</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:21.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">making false or misleading statements about the Employer, the Parent or any of its subsidiaries or their products, officers or employees to competitors, customers, potential customers of the Employer, the Parent or any of its subsidiaries or to current or former employees of the Employer, the Parent or any of its subsidiaries&#59; and</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:38.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">breaching any terms of the Release of Claims, including any non-solicitation or non-competition provisions, if applicable.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_46"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:55.4pt;padding-right:23.1pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Cessation of Separation Pay and Separation Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Separation Pay, Outplacement Benefits and Separation Benefits shall cease in the event a Participant is rehired by the Employer, the Parent or one of its subsidiaries or affiliates.</font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Return of Separation Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon the occurrence of an event described in Section 5.3 or</font></div><div style="padding-left:55.35pt;padding-right:26.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4 of this Plan, the Participant shall repay to the Employer that portion of the lump sum amount that would not have been paid had the Separation Pay been paid in weekly installments from the Participant's Separation Date. If the Participant receives short-term disability benefits from the Employer after his or her Separation Date, the Employer reserves the right to seek repayment by the Participant of that portion of the Separation Pay that would not have been paid in accordance with Section 4.6 had the Separation Pay been paid in installments.</font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Death of Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:55.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Participants Who Die Before January 1, 2017&#58;</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:50.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Participant dies before January 1, 2017 following his or her Separation Date and a valid Release of Claims was signed by the Participant or is signed by the Participant's estate then</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:107.6pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.9pt">any unpaid Separation Pay will be paid to the Participant's estate&#59; and</font></div><div style="margin-top:3pt;padding-left:55.4pt;padding-right:16.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">if the Participant was eligible to continue medical and&#47;or dental coverage during the Benefits Continuation Period on the Participant's date of death and the Participant&#8217;s surviving dependents were covered under the Participant's medical and dental coverages (other than coverages applicable to retirees and their dependents) on that date, they may continue such employee coverage for the balance of the Benefits Continuation Period, provided they continue to remain eligible dependents and they pay the applicable contributions at active employee rates, as they may change from time to time, to continue coverage. Thereafter, if, as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan, or</font></div><div style="margin-top:0.05pt;padding-left:55.35pt;padding-right:17.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) was eligible to participate in the Merck Retiree Medical Plan at unsubsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation Period for the remaining COBRA period, if any, in accordance with COBRA by paying the full COBRA premium and thereafter may be eligible for retiree medical benefits at unsubsidized rates under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare- eligible will not be eligible to participate in the Merck Retiree Medical Plan or (iii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation Period for the remaining COBRA period, if any, in accordance with COBRA by paying the full COBRA premium, or (iv) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates but had at least 25 years of service as of his&#47;her date of death, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for medical benefits at subsidized rates under the terms of medical plan that would have been applicable to such Participant if he&#47;she had been eligible for long term disability benefits, as may be amended from time to time&#59; and</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_49"></div><hr style="page-break-after:always"><div style="min-height:46.08pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:55.4pt;padding-right:16.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">if the if the Participant was eligible to continue medical coverage during the Benefits Continuation Period on the Participant's date of death and the Participant&#8217;s surviving dependents were not covered under the Participant's medical coverage at the time of the Participant&#8217;s death or if the Participant was not eligible to continue medical coverage during the Benefits Continuation Period and, in either case, if as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant&#8217;s medical coverage shall be eligible to enroll for retiree medical benefits at the subsidized or unsubsidized rates, as applicable, under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan and will only be eligible for such coverage if they are eligible for subsidized coverage (dependents eligible for unsubsidized coverage are not eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan), or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates but had at least 25 years of service as of his&#47;her date of death, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant&#8217;s medical coverage shall be eligible to enroll for medical benefits at subsidized rates under the terms of medical plan that would have been applicable to such Participant if he&#47;she had been eligible for long term disability benefits, as may be amended from time to time.</font></div><div><font><br></font></div><div style="padding-left:55.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Medical and dental coverage under this Section 5.6 shall be subject to and in accordance with the terms of the applicable plans as they may be amended from time to time.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his&#47;her date of death.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Participants Who Die On or After January 1, 2017&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:55.35pt;padding-right:31.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a Participant dies on or after January 1, 2017 following his or her Separation Date and a valid Release of Claims was signed by the Participant or is signed by the Participant's estate then</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.3pt">any unpaid Separation Pay will be paid to the Participant's estate&#59; and</font></div><div style="margin-top:3pt;padding-left:55.4pt;padding-right:18.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">if the Participant was eligible to continue medical and&#47;or dental coverage during the Benefits Continuation Period on the Participant's date of death and the Participant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">surviving dependents were covered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the Participant's medical and dental coverages at the time of the Participant&#8217;s death, they may continue such employee coverage for the balance of the Benefits Continuation Period, provided they continue to remain eligible dependents and they pay the applicable contributions at active employee rates, as they may change from time to time, to continue coverage. Thereafter, if, as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan, or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_52"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:55.35pt;padding-right:19.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Period in accordance with COBRA by timely electing COBRA coverage and paying the full COBRA premium&#59; or (iii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates but had at least 25 years of service as of his&#47;her Separation Date, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan&#59; and</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:16.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">if the Participant was eligible to continue medical coverage during the Benefits Continuation Period on the Participant's date of death and the Participant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">surviving dependents were not covered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the Participant's medical coverage at the time of the Participant&#8217;s death or if the Participant was not eligible to continue medical coverage during the Benefits Continuation Period and, in either case, if as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant&#8217;s medical coverage shall be eligible to enroll for retiree medical benefits at subsidized rates under the terms of Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan&#59; or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates but had at least 25 years of service as of his&#47;her Separation Date, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant&#8217;s medical coverage shall be eligible to enroll for medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:23.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Medical and dental coverage under this Section 5.6 shall be subject to and in accordance with the terms of the applicable plans as they may be amended from time to time.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.35pt;padding-right:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his&#47;her date of death.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_55"></div><hr style="page-break-after:always"><div style="min-height:46.08pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:22.42pt;padding-right:22.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 6</font></div><div><font><br></font></div><div style="padding-left:22.37pt;padding-right:22.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PLAN ADMINISTRATION</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:46.35pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parent or its delegate is the Plan Administrator for purposes of ERISA.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:17.1pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Powers and Duties of Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan Administrator or its delegate shall have the full discretionary power and authority to&#58; (i) construe and interpret the Plan (including, without limitation, supplying omissions from, correcting deficiencies in, or resolving inconsistencies or ambiguities in, the language of the Plan)&#59; (ii) determine all questions of fact arising under the Plan, including questions as to eligibility for and the amount of benefits&#59; (iii) establish such rules and regulations (consistent with the terms of the Plan) as it deems necessary or appropriate for administration of the Plan&#59; (iv) delegate responsibilities to others to assist in administering the Plan&#59; and (v) perform all other acts it believes reasonable and proper in connection with the administration of the Plan. The Plan Administrator or its delegate shall be entitled to rely on the records of the Employer in determining any Participant's entitlement to and the amount of benefits payable under the Plan. Any determination of the Plan Administrator or its delegate, including interpretations of the Plan and determinations of questions of fact, shall be final and binding on all parties.</font></div><div><font><br></font></div><div style="padding-left:55.35pt;padding-right:15.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With respect to determining claims and appeals for benefits under this Plan, the Claims Reviewer (and its delegate) shall be deemed to be the delegate of the Plan Administrator and shall have all of the powers and duties of the Plan Administrator described above.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:20pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Additional Discretionary Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan Administrator may, upon written approval of the Parent&#8217;s Executive Vice President, Human Resources (written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:31.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">grant some, all or any portion of the benefits under this Plan to an employee who would not otherwise be eligible for such benefits under Section 3 above&#59;</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:27.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">waive the requirement set forth in Section 3 for any individual Eligible Employee or group of Eligible Employees to execute a Release of Claims&#59; and</font></div><div style="margin-top:6pt;padding-left:127.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">grant additional Separation Plan Benefits to a Participant.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_58"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:22.42pt;padding-right:22.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 7</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:22.4pt;padding-right:22.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CLAIMS AND APPEALS PROCEDURES</font></div><div><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:23.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Any request or claim for benefits under the Plan must be filed by a claimant or the claimant&#8217;s authorized representative within 60 days after the date claimant&#8217;s employment with an Employer ends&#59; provided, however, for claims under Section 5.3, claims must be filed within 60 days after the date Separation Plan Benefits are cancelled.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:19pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">Any request or claim for benefits under the Plan shall be deemed to be filed when a written request made by the claimant or the claimant's authorized representative addressed to the Claims Reviewer at the address below is received by the Claims Reviewer.</font></div><div><font><br></font></div><div style="padding-left:127.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Claims Reviewer for the Separation Benefits Plan</font></div><div style="padding-left:127.35pt;padding-right:83.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c&#47;o Secretary of the Merck &#38; Co., Inc. Employee Benefits Committee Merck &#38; Co., Inc.</font></div><div style="padding-left:127.35pt;padding-right:293.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2000 Galloping Hill Road Mailstop K-1 3029</font></div><div style="padding-left:127.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Kenilworth, NJ 07033</font></div><div style="padding-left:55.35pt;padding-right:33.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The claim for benefits shall be reviewed by, and a determination shall be made by, the Claims Reviewer, within the timeframe required for notice of adverse benefit determinations described below.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:16.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">The Claims Reviewer shall provide written or electronic notification to the claimant or the claimant&#8217;s authorized representative of any &#8220;adverse benefit determination.&#8221; Such notice shall be provided within a reasonable time but not later than 90 days after the receipt by the Claims Reviewer of the claimant's claim, unless the Claims Reviewer determines that special circumstances require an extension of time for processing the claim. If the Claims Reviewer determines that an extension of time for processing is required, written notice of the extension shall be furnished to the claimant before the expiration of the initial 90-day period indicating the special circumstances requiring an extension and the date by which the Claims Reviewer expects to render the benefit determination. No extension can exceed 90 days from the end of the initial 90-day period (i.e., 180 days from the receipt of the claim by the Claims Reviewer) without the consent of the claimant or the claimant&#8217;s authorized representative.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:23.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">An &#8220;adverse benefit determination&#8221; is a denial, reduction, or termination of, or a failure to provide or make payment (in whole or part) for a benefit, including one that is based on a determination of a claimant&#8217;s eligibility to participate in the Plan.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:21.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">The notice of adverse benefit determination shall be written in a manner calculated to be understood by the claimant and shall&#58;</font></div><div style="padding-left:55.4pt;padding-right:21.6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.29pt">set forth the specific reasons for the adverse benefit determination&#59;</font></div><div style="padding-left:19.4pt;padding-right:21.6pt;text-indent:72pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:21.6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.96pt">contain specific references to Plan provisions on which the determination is based&#59;</font></div><div style="padding-left:55.4pt;padding-right:21.6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.13pt">describe any material or information necessary for the claim for benefits to be allowed and an explanation of why such information is necessary&#59; and</font></div><div style="padding-left:19.4pt;padding-right:21.6pt;text-indent:72pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:21.6pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.29pt">describe the Plan&#8217;s appeal procedures and the time limits applicable to such procedures, including a statement of the claimant&#8217;s right to bring a civil action under section 502(a) of ERISA following an adverse benefit determination on review.</font></div><div id="i3fd694a9ca9c42b69eb8c45035645669_64"></div><div style="padding-left:55.4pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Appeals of Adverse Benefit Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:55.4pt;padding-right:17.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Any request to review the Claims Reviewer&#8217;s adverse benefit determination under the Plan must be filed by a claimant or the claimant&#8217;s authorized representative in writing within 60 days after receipt by the claimant of written notification of adverse benefit determination by the </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:55.4pt;padding-right:17.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Claims Reviewer. If the claimant or the claimant&#8217;s authorized representative fails to file a request for review of the Claims Reviewer&#8217;s adverse benefit determination in writing within 60 days after receipt by the claimant of written notification of adverse benefit determination, the Claims Reviewer&#8217;s determination shall become final and conclusive.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:22.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">Any request to review an adverse benefit determination under the Plan shall be deemed to be filed when a written request is made by the claimant or the claimant's authorized representative addressed to the Employee Benefits Committee at the address below is received by the Secretary of the Employee Benefits Committee.</font></div><div style="margin-top:6pt;padding-left:127.4pt;padding-right:179.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Merck &#38; Co., Inc. Employee Benefits Committee c&#47;o Secretary Employee Benefits Committee Merck &#38; Co., Inc.</font></div><div style="padding-left:127.4pt;padding-right:293.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2000 Galloping Hill Road Mailstop K-1 3029</font></div><div style="padding-left:127.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Kenilworth, NJ 07033</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:17.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">If the claimant or the claimant&#8217;s authorized representative timely files a request for review of the Claims Reviewer&#8217;s adverse benefit determination as specified in this Section 7.2, the Employee Benefits Committee shall re-examine all issues relevant to the original adverse benefit determination taking into account all comments, documents, records, and other information submitted by the claimant or the claimant&#8217;s authorized representative relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. Any such claimant or his or her duly authorized representative may&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:91.4pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.29pt">upon request and free of charge have reasonable access to, and copies of, all documents, records, and other information relevant to the claimant&#8217;s claim for benefits&#59; whether an item is relevant shall be determined by the Employee Benefits Committee in accordance with 29 CFR 2560.503-1 (m)(8)&#59; and</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:18.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.96pt">submit in writing any comments, documents, records, and other information relating to the claim for benefits.</font></div><div style="margin-top:6pt;padding-left:55.4pt;padding-right:20.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">The Claims Reviewer shall provide written or electronic notice to the claimant or the claimant&#8217;s authorized representative of its benefit determination on review. Such notice shall be provided within a reasonable time but not later than 60 days after the receipt by the Claims Reviewer of the claimant's request for review, unless the Claims Reviewer determines that special circumstances require an extension of time for processing the request for review. If the Claims Reviewer determines that an extension of time for processing is required, written notice of the extension shall be furnished to the claimant before the expiration of the initial 60-day period indicating the special circumstances requiring an extension and the date by which the Claims Reviewer expects to render the benefit determination. No extension can exceed 60 days from the end of the initial 60-day period (i.e., 120 days from the date the request for review is received by the Claims Reviewer) without the consent of the claimant or the claimant&#8217;s authorized representative.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:33.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">If the claimant&#8217;s appeal is denied, the notice of adverse benefit determination on review shall be written in a manner calculated to be understood by the claimant and shall&#58;</font></div><div style="padding-left:91.4pt;padding-right:33.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.29pt"> &#160;&#160;&#160;&#160;set forth the specific reasons for the adverse benefit determination on</font></div><div style="padding-left:91.4pt;padding-right:33.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.96pt"> &#160;&#160;&#160;&#160;contain specific references to Plan provisions on which the benefit determination is based&#59;</font></div><div style="padding-left:91.4pt;padding-right:33.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.63pt">contain a statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claimant&#8217;s claim for benefits&#59; whether an item is relevant shall be determined by the Claims Reviewer in accordance with 29 CFR 2560.503-1 (m)(8)&#59; and</font></div><div style="padding-left:91.4pt;padding-right:33.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:35.29pt">include a statement of the claimant&#8217;s right to bring a civil action under section 502(a) of ERISA.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_73"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:171.97pt;padding-right:171.97pt;text-align:center;text-indent:69.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">SECTION 8 </font></div><div style="padding-left:85.45pt;padding-right:85.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT AND TERMINATION</font></div><div style="padding-left:55.4pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:91.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:55.4pt;padding-right:16.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.3pt">Except as otherwise set forth in subsection (b) below, Parent or its delegate has the right to amend, suspend or terminate the Plan at any time without prior notice to or the consent of any employee&#59; provided, however, that amendments that apply only to Section 16 Officers must also be approved by the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate. No such amendment shall give the Employer or Parent the right to recover any amount paid to a Participant prior to the date of such amendment. Any such amendment, however, may cause the cessation and discontinuance of payments of Separation Plan Benefits to any person or persons under the Plan. Parent may delegate the authority to amend, suspend or terminate the Plan to the person, entity or committee selected by the Chief Executive Officer and as set forth in the applicable written corporate grant signed by the Chief Executive Officer (the &#8220;Corporate Grant&#8221;). Such Corporate Grant shall allow for the delegation of the authority to an individual, entity or committee&#59; provided the financial impact of such amendment, suspension or termination does not exceed certain predetermined thresholds identified in the applicable Corporate Grant. The person, entity or committee provide with the authority to amend, suspend or terminate the Plan by the Corporate Grant, may further delegate the authority to amend, suspend or terminate the Plan to an individual, entity or committee, in accordance with the appropriate corporate action. Amendments to the Plan must be in writing and approved in accordance with the Corporate Grant.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:32.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.62pt">Except to the extent required by applicable law, for the entirety of the Protection Period, the material terms of the Plan, including this Section 8.1, shall not be modified in any manner that is materially adverse to a Qualifying Participant.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:20.55pt;text-indent:39pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.3pt">Parent or any such successor to Parent, shall pay all legal fees and related expenses (including the costs of experts, evidence and counsel) reasonably and in good faith incurred by a Qualifying Participant if the Qualifying Participant prevails on at least one material item of his or her claim for relief in an action (x) by the Qualifying Participant claiming that the provisions of this Section 8.1 have been violated (but, for the avoidance of doubt, excluding claims for plan benefits in the ordinary course) and (y) if applicable, by the Employer, Parent or its successor to enforce post-termination covenants against the Qualifying Participant.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:127.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Section 8.1&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:91.4pt;padding-right:46pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.29pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Protection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the period beginning on the date of the Change in Control and ending on the second anniversary of the date of the Change in Control&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:91.4pt;padding-right:49.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.96pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an individual who is an Eligible Employee or a Participant as of the date immediately prior to the Change in Control.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_76"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:204.47pt;padding-right:204.47pt;text-align:center;text-indent:36.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">SECTION 9 </font></div><div style="padding-left:101.7pt;padding-right:101.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GENERAL PROVISIONS</font></div><div style="padding-left:101.7pt;padding-right:101.7pt;text-align:center"><font><br></font></div><div style="padding-left:55.4pt;padding-right:22.75pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Unfunded Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Separation Plan Benefits provided under this Plan shall constitute an unfunded obligation of the Employer. Payments shall be made, as due, from the general funds of the Employer. This Plan shall constitute solely an unsecured promise by the Employer to pay such benefits to Participants to the extent provided herein.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.1pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. It is intended that the Plan be an &#34;employee welfare benefit plan&#34; within the meaning of Section 3(1) of ERISA, and the Plan shall be administered in a manner consistent with such intent. The Plan and all rights thereunder shall be governed and construed in accordance with ERISA and, to the extent not preempted by federal law, with the laws of the state of New Jersey, wherein venue shall lie for any dispute arising hereunder.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:30.35pt;text-align:justify;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any provision of this Plan shall be held illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining parts of this Plan, but this Plan shall be construed and enforced as if said illegal or invalid provision had never been included herein.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:26.7pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Nothing contained in this Plan shall give an employee the right to be retained in the employment of the Employer or shall otherwise modify the employee's at will employment relationship with the Employer. This Plan is not a contract of employment between the Employer and any employee.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:22.9pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Heirs, Assigns, and Personal Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan shall be binding upon the heirs, executors, administrators, successors, and assigns of the parties, including each Participant, present and future.</font></div><div><font><br></font></div><div style="padding-left:55.4pt;padding-right:23.6pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Payments to Incompetent Persons, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any benefit payable to or for the benefit of a minor, an incompetent person or other person incapable of receipting therefore shall be deemed paid when paid to such person&#8217;s guardian or to the party providing or reasonably appearing to provide for the care of such person, and such payment shall fully discharge the Employer, Parent, the Plan Administrator, the Claims Administrator and all other parties with respect thereto.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:17.35pt;text-indent:1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:35.8pt;text-decoration:underline">Lost Payees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Benefits shall be deemed forfeited if the Plan Administrator is unable to locate a Participant to whom Separation Plan Benefits are due. Such Separation Plan Benefits shall be reinstated if application is made by the Participant for the forfeited Separation Plan Benefits within one year of the Participant&#8217;s Separation Date and while the Plan is in operation.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_79"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:22.32pt;padding-right:22.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SCHEDULE A</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:22.37pt;padding-right:22.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">List of participating Employers&#58;</font></div><div><font><br></font></div><div style="padding-left:55.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">All U.S. direct and indirect wholly owned subsidiaries of Merck &#38; Co. Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">excluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">the following and their subsidiaries, successors and assigns&#58;</font></div><div style="padding-left:55.4pt"><font><br></font></div><div style="padding-left:73.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.8pt">Comsort, Inc.</font></div><div style="padding-left:55.4pt"><font><br></font></div><div style="padding-left:73.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.8pt">Merck Global Health Innovation Fund, LLC</font></div><div style="padding-left:73.4pt"><font><br></font></div><div style="padding-left:73.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.8pt">HMR Weight Management Services Corp.</font></div><div style="padding-left:73.4pt"><font><br></font></div><div style="padding-left:73.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.8pt">ILUM Health Solutions, LLC (formerly known as Healthcare Services and Solutions, LLC)</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_82"></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:22.32pt;padding-right:22.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SCHEDULE B-1</font></div><div style="margin-top:0.1pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:132.17pt;padding-right:132.17pt;text-align:center;text-indent:42.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation Pay for Participants with a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation Date Occurring on or after January 1, 2013</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4.55pt;padding-left:56.12pt;padding-right:56.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Amount of Separation Pay in weeks (Annual Base Salary divided by 52)</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.1pt;padding-left:5.32pt;padding-right:5.32pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.983%"><tr><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.190%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.5pt;padding-right:6.5pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Complete Years of Continuous Service at Separation</font></div><div style="padding-left:20.22pt;padding-right:20.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Date</font></div></td><td colspan="18" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.8pt;padding-left:200.35pt;padding-right:200.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BAND LEVEL</font></div></td></tr><tr style="height:47pt"><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.65pt;padding-right:8.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Band 200</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.65pt;padding-right:8.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Band 300</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.65pt;padding-right:8.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Band 400</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.65pt;padding-right:8.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Band 500</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.57pt;padding-right:8.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Band 600</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.67pt;padding-right:8.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Band 700&#47;800</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">26</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">26</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">5</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">14</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">20</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">26</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">34</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">42</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">14</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">16</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">22</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">28</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">36</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">44</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">16</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">30</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">38</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">46</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">20</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">26</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">48</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.15pt;padding-right:0.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">9</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">20</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">22</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">28</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">34</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">42</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">50</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">10</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">22</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">30</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">36</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">44</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">52</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">11</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">26</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">38</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">46</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">54</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">26</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">28</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">34</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">48</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">56</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">13</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">28</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">30</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">36</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">42</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">50</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">58</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">14</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">30</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">38</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">44</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">52</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">60</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">15</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">34</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">46</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">54</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">62</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">16</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">34</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">36</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">42</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">48</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">56</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">64</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">17</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">36</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">38</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">44</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">50</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">66</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">18</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">38</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">46</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">52</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">60</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">68</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">19</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">40</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">42</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">48</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">54</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">62</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">70</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">20</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">42</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">44</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">50</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.6pt;padding-right:8.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">56</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">64</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">72</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">21</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">44</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">46</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">52</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">66</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">74</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">22</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">46</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">48</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">54</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">60</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">68</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">76</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">23</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">48</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">50</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">56</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">62</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">70</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">50</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">52</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">64</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">72</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">25</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">52</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">54</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">60</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">66</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">74</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">26</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">54</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">56</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">62</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">68</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">76</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">27</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">56</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">64</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">70</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">28</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">58</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">60</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">66</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">72</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">29</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">60</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">62</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">68</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">74</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">30</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">62</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">64</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">70</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">76</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">31</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">64</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">66</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">72</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">32</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">66</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">68</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">74</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">33</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">68</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">70</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">76</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">34</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">70</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">72</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">35</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">72</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">74</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">36</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">74</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">76</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.17pt;padding-right:20.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">37</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">76</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.2pt;padding-right:20.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">38+</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.62pt;padding-right:8.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">78</font></div></td></tr></table></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_85"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:22.32pt;padding-right:22.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SCHEDULE B-2</font></div><div style="margin-top:0.1pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:49.77pt;padding-right:49.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MEDICAL &#47; DENTAL AND LIFE INSURANCE CONTINUATION</font></div><div style="margin-top:0.05pt;text-align:center"><font><br></font></div><div style="padding-left:26.8pt;padding-right:26.8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.962%"><tr><td style="width:1.0%"></td><td style="width:46.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:25.57pt;padding-right:25.57pt;text-align:center;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">COMPLETE YEARS OF CONTINUOUS SERVICE AT SEPARATION DATE</font></div></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12.05pt;padding-right:12.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BENEFITS CONTINUATION PERIOD</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.5pt;padding-left:93.87pt;padding-right:93.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#60; 5</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.5pt;padding-left:12pt;padding-right:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26 weeks</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:40.7pt;padding-right:40.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5 &#8211; 9.9</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:2.85pt;padding-right:2.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39 weeks*</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:37.7pt;padding-right:37.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10 &#8211; 19.9</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:2.85pt;padding-right:2.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52 weeks*</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:93.92pt;padding-right:93.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">20+</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:12pt;padding-right:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">78 weeks*</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:19.4pt;padding-right:16.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">*For Participants who are eligible for subsidized retiree medical benefits under the Merck Retiree Medical Plan on their Separation Date, the Benefits Continuation Period shall continue to the last day of the month in which the number of weeks set forth above occurs.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_88"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:9.7pt;padding-right:9.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCHEDULE C</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:22.3pt;padding-right:22.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OUTPLACEMENT BENEFITS</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:3.05pt;padding-right:3.05pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.445%"><tr><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:34.15pt;padding-right:34.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BAND LEVEL</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:50.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BENEFIT</font></div></td><td colspan="3" style="background-color:#cccccc;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="padding-left:48.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DURATION</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:34pt;padding-right:34pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Band 200</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">Quick Start Plus</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">3 Months</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:34pt;padding-right:34pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Band 300</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.35pt;padding-right:46.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">Professional--Career Assistance</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">3 Months</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:34pt;padding-right:34pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Band 400</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.35pt;padding-right:46.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Professional--Career Transition</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">6 Months</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:34pt;padding-right:34pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Band 600&#47;500</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">Executive</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">12 Months</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:34pt;padding-right:34pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Band 800&#47;700</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">Executive Premium</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:87%">12 Months</font></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:19.35pt;padding-right:21.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Outplacement Benefits are provided through a third party vendor. The vendor and&#47;or the programs may change from time to time.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_91"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:146.62pt;padding-right:146.62pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULE D (Change in Control&#47;Pension)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:63.55pt;padding-right:63.55pt;text-align:center"><font><br></font></div><div style="padding-left:63.55pt;padding-right:63.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Description of Change-in-Control Benefits under the Pension Plan</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.35pt;padding-right:17.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Schedule describes benefits under the Pension Plan and the Supplemental Plan (as each is defined below) provided to an Eligible Employee under the Plan if such Eligible Employee signs and returns the Release of Claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:24.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.61pt">If an Eligible Employee&#8217;s employment is terminated in circumstances entitling him or her to the benefits provided in Section 3.1 (c) of the Plan&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:91.4pt;padding-right:20.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.6pt">For an Eligible Employee who participates in the Retirement Plan for Salaried Employees of MSD or its successor (the &#8220;MSD Pension Plan) and on his or her Separation Date is not at least age 55 with at least ten years of Credited Service under the MSD Pension Plan but would attain at least age 50 and have at least ten years of Credited Service under the MSD Pension Plan within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for a subsidized early retirement benefit on his &#8220;Prior Plan Formula&#8221; (as defined in the MSD Pension Plan) under the MSD Pension Plan commencing in accordance with the terms of the MSD Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:91.4pt;padding-right:18.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.6pt">For an Eligible Employee who participates in the MSD Pension Plan or the Legacy Schering Retirement Plan, or their successors (collectively the &#8220;Pension Plan&#8221;) and on his or her Separation Date is not at least age 65 but would attain at least age 65 within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for a Prior Plan Formula benefit unreduced for early commencement under the Pension Plan commencing in accordance with the terms of the Pension Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:91.4pt;padding-right:18.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.6pt">For an Eligible Employee who participates in the MSD Pension Plan and on his or her Separation Date is not eligible for the &#8220;Rule of 85 Transition Benefit&#8221; (as such term is defined in the MSD Pension Plan) but would have been eligible for the Rule of 85 Transition Benefit within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for the Rule of 85 Transition Benefit upon commencement of his or her pension benefit under the MSD Pension Plan.</font></div><div style="margin-top:6pt;padding-left:91.4pt;padding-right:19.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4,&#160;&#160;&#160;&#160;For an Eligible Employee who participates in the Pension Plan on his or her Separation Date who is not vested in his or her accrued benefit under the Pension Plan, he or she shall be vested in his accrued benefit under the Pension Plan on his or her Separation Date.</font></div><div><font><br></font></div><div style="margin-top:8.45pt;padding-left:55.4pt;padding-right:18.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.62pt">The benefits described in this Schedule D shall be payable from the Pension Plan and, to the extent that such benefits cannot be paid from the Pension Plan the Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law and to preserve grandfathered status of arrangements subject to Section 409A of the Code), cause such benefits to be paid under a Supplemental Retirement Plan of MSD or the Legacy Schering Benefits Excess Plan, as applicable and any successors thereto (collectively, the &#8220;Supplemental Plan&#8221;) or under new arrangements or from the Employer's general assets.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_94"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:83.25pt;padding-right:83.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SCHEDULE E (Change in Control&#47;Retiree Medical)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:72.67pt;padding-right:72.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Description of Change-in-Control Benefits under Health Plan</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.35pt;padding-right:21.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Schedule describes benefits under the Health Plan provided to an Eligible Employee under the Plan if such Eligible Employee signs and returns the Release of Claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.4pt;padding-right:24.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.61pt">If an Eligible Employee&#8217;s employment is terminated in circumstances entitling him or her to the benefits provided in Section 3.1 (c) of the Plan&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:55.35pt;padding-right:17.5pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Eligible Employee is eligible to participate in the Health Plan and on his or her Separation Date is not at least age 55 with the requisite amount of service with an Employer to satisfy the requirements to be considered a retiree eligible for subsidized retiree medical benefits under the Health Plan but would attain at least age 50 and meet the service requirements to be considered a retiree eligible for subsidized retiree medical benefits under the Health Plan within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be eligible for subsidized retiree medical benefits under the Health Plan on the date his or her Benefits Continuation Period Ends on the same terms and conditions applicable to salaried U.S.- based employees of the Employer whose employment terminated the last day of the month prior to the Eligible Employee&#8217;s Separation Date who were treated as retirees eligible for subsidized retiree medical benefits under the Health Plan as of that date.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:55.4pt;padding-right:18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.62pt">The Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law and to preserve grandfathered status of arrangements subject to Section 409A of the Code), cause the benefits set forth in this Schedule E to be provided from insured arrangements, or pursuant to new arrangements, individual arrangements or otherwise. Further, notwithstanding anything to the contrary, to the extent any benefits to which an Eligible Employee is entitled under this Schedule E would reasonably be likely to constitute a discriminatory benefit under Section 105(h) of the Code or a similar law or regulation at the time the benefit is to be provided to the Eligible Employee, as determined in the sole discretion of the Parent, the Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law), modify the benefit so that the benefit would no longer constitute a discriminatory benefit under Section 105(h) of the Code or such similar law, including, but not limited to, eliminating all subsidy from the Parent or the Employer, requiring that the Eligible Employee pay for participation in the benefit program with after-tax funds or causing the full employer and employee portions of the cost of the benefit to be imputed as gross income to the Eligible Employee.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:55.4pt;padding-right:19.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.63pt">For purposes of this Schedule E, &#8220;Health Plan&#8221; means one or more plans sponsored by the Parent or one of its subsidiaries that provide medical benefits to Eligible Employees and to former Eligible Employees who are considered retirees thereunder and to the eligible dependents of each of the foregoing.</font></div><div style="padding-right:19.85pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_97"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:80.87pt;padding-right:80.87pt;text-align:center;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT 2019-1</font></div><div style="margin-top:0.05pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:100pt;padding-right:100pt;text-align:center;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC. U.S. SEPARATION BENEFITS PLAN</font></div><div style="margin-top:1.05pt;padding-left:99.85pt;padding-right:99.85pt;text-align:center;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(as Amended and Restated as of January 1, 2019)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:6.35pt;padding-right:44.7pt;text-align:justify;text-indent:35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Merck, Sharp </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#38; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Dohme Corp. (the &#34;Company&#34;), a subsidiary of Merck </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#38; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Co., Inc. (&#34;Merck&#34;), sponsors the Merck &#38; Co., Inc. U.S. Separation Benefits Plan (as Amended and Restated as of January 1, 2019) (the &#34;Plan&#34;)&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6.2pt;padding-right:44.7pt;text-align:justify;text-indent:35.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.1pt;padding-right:43.7pt;text-align:justify;text-indent:35.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">pursuant to the grant of authority of Merck's Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck &#38; Co., Inc. Executive Oversight Committee (the &#34;Executive Committee&#34;) in accordance with its charter&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.4pt;padding-right:43.7pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">in accordance with its charter the Executive Committee has delegated to the Merck &#38; Co., Inc. Oversight Committee (the &#34;Committee&#34;&#125; the authority to make certain amendments to the Plan in accordance with the charter of the Committee&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:44.35pt;text-align:justify;text-indent:35.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">the Committee desires to ratify and adopt the amendment to the Plan described herein.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:44.7pt;text-align:justify;text-indent:35.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:46.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:9.38pt">Section 2.7 of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:54pt;text-indent:35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;2.7&#160;&#160;&#160;&#160;&#34;Claims Reviewer&#34; means the Merck &#38; Co., Inc. Employee Benefits Committee (or its delegate)&#59; provided, however, for Section 16 Officers, Claims Reviewer means the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate.&#34;</font></div><div style="margin-top:2.15pt;padding-left:46.25pt;padding-right:60.65pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:223%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:223%;padding-left:9.38pt">The first paragraph of Section 5.3 is hereby amended and restated to read as follows&#58;</font></div><div style="padding-left:10.25pt;padding-right:60.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#34;5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Forfeiture of Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> The Employer reserves the right, in its sole and absolute discretion, to cancel all Separation Plan Benefits and seek the return of Separation Pay in the event a Participant engages in any activity that the Employer considers detrimental to its interests (or the interests of the Parent or any of its subsidiaries) as determined by the Parent's Executive Vice President and General Counsel and the Parent's Executive Vice President &#38; Chief Human Resources Officer or by such other individual who acts as the successor or equivalent thereto of either of the aforementioned positions. Activities that the Employer considers detrimental to its interest (or the interests of the Parent or any of its subsidiaries) include, but are not limited to&#58;&#34;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:46.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:9.38pt">The first paragraph of Section 6.3 is hereby amended to read as follows&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.15pt;padding-right:54pt;text-indent:35.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;text-decoration:underline">Additional Discretionary Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%"> The Plan Administrator may, upon written approval of the Parent's Executive Vice President &#38; Chief Human Resources Officer, or by such other individual who acts as the successor or equivalent thereto of such position, (written </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font></div><div style="padding-left:5.15pt;padding-right:54pt;text-indent:35.2pt"><font><br></font></div><div style="padding-left:46.25pt;text-indent:-18pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:9.38pt">Schedule A of the Plan is hereby updated to read as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:86.62pt;padding-right:86.62pt;text-align:center"><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#34;SCHEDULE </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">A</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:87.25pt;padding-right:87.25pt;text-align:center"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">List of Participating Employers</font><font style="color:#505050;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9.5pt;padding-right:54pt;text-indent:0.55pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">All U. S</font><font style="color:#505050;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">direct and indirect wholly owned subsidiaries of Merck </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#38; </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Co., Inc. excluding the following and their subsidiaries&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:64.05pt;text-indent:-18.05pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:14.03pt">Comsort, Inc. (and its subsidiaries)</font></div><div style="margin-top:1.45pt;padding-left:63.8pt;text-indent:-17.8pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.78pt">Merck Global Health Innovation Fund LLC (and its subsidiaries)</font></div><div style="margin-top:1.45pt;padding-left:63.8pt;text-indent:-17.8pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.78pt">HMR Weight Management Services Corp</font><font style="color:#606060;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(and its subsidiaries)</font></div><div style="margin-top:1.45pt;padding-left:64.2pt;text-indent:-18.2pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:14.18pt">ILUM Health Solutions, LLC </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(and </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">its subsidiaries)</font></div><div style="margin-top:1.45pt;padding-left:64.05pt;padding-right:40.45pt;text-indent:-18pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.98pt">Peloton Therapeutics, Inc</font><font style="color:#606060;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc</font><font style="color:#505050;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">became a subsidiary of the Company and before January 1, 2020</font></div><div style="margin-top:1.1pt;padding-left:64.15pt;padding-right:62.45pt;text-indent:-18.1pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">&#8226;</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:14.08pt">Tilos Therapeutics (and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">its </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">subsidiaries) for the period of time after the date Tilos Therapeutics became a subsidiary of the Company and before January 1, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">2020</font></div><div style="margin-top:0.55pt;padding-left:64.25pt;padding-right:58.15pt;text-indent:-18.25pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:14.23pt">Antelliq Corporation (and its subsidiaries) for the period of time after the date Antelliq Corporation became a subsidiary of the Company and before such date in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">2020 </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">as of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">which </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">the Plan </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Administrator </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">determines Antelliq Corporation shall become an Employer.&#34;</font></div><div><font><br></font></div><div style="margin-top:11.15pt;padding-left:9.95pt;padding-right:52.55pt;text-indent:36.45pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:123%">IN WITNESS WHEREOF, </font><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">the Committee has caused this Amendment 2019-1 to the Plan to be executed by the undersigned on this 19th day of December, 2019</font><font style="color:#505050;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:263.1pt;padding-right:4.95pt;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;text-decoration:underline">&#47;s&#47; Michael Arseneault                                    </font></div><div style="margin-top:4.55pt;padding-left:263.1pt;padding-right:4.95pt;text-indent:0.2pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">Michael Arseneault</font></div><div style="margin-top:0.8pt;padding-left:260.6pt;padding-right:86.6pt;text-indent:-0.35pt"><font style="color:#1d1d1d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Executive Director, Managing Counsel Global Compensation and Benefit</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">s</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:33.92pt;padding-right:33.92pt;text-align:center"><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_100"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:90.05pt;padding-right:90.05pt;text-align:center"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">AMENDMENT 2020-1</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:115.02pt;padding-right:115.02pt;text-align:center"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC. U.S. SEPARATION BENEFITS PLAN</font></div><div style="margin-top:0.45pt;padding-left:114.72pt;padding-right:114.72pt;text-align:center"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">(as Amended and Restated as of January 1, 2019)</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6.3pt;padding-right:74.5pt;text-align:justify;text-indent:35.6pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">WHEREAS</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Merck</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Sharp </font><font style="color:#2f2d2d;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#38; </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Dohme Corp</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">(the </font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Company</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">)</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">a subsidiary of Merck </font><font style="color:#2f2d2d;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:122%">&#38; </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Co.</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Inc</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">(</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Merck</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">), sponsors the Merck &#38; Co</font><font style="color:#797979;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">.</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Inc</font><font style="color:#696969;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">U.S</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Separation Benefits Plan (as Amended and Restated as of January 1, 2019) (the </font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Plan&#34;)</font><font style="color:#5b5b5b;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6.6pt;padding-right:74.75pt;text-align:justify;text-indent:34.8pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">pursuant to Article 8</font><font style="color:#696969;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">1 of the Plan</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">the Company (or its duly authorized representati</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">v</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">e) has reserved the right to amend or terminate the Plan at any time</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6.25pt;padding-right:73.8pt;text-align:justify;text-indent:35.15pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">WHEREAS</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">pursuant to the grant of authority of Merck</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">'</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">s Chief E</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">x</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">ecutive Officer</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">the Company has delegated the authority to amend the Plan to the Merck &#38; Co.</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Inc</font><font style="color:#5b5b5b;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Executive Oversight Committee (the </font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">E</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">x</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">ecutive Committee</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">) in accordance with its charter</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.8pt;padding-right:73.75pt;text-align:justify;text-indent:35.6pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">WHEREAS, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">in accordance with its charter the Executive Committee has delegated to the Merck &#38; Co</font><font style="color:#5b5b5b;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">.</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, Inc</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Oversight Committee (the &#34;Committee</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">) the authority to make certain amendments to the Plan in accordance with the charter of the Committee</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#59; </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6.05pt;padding-right:74.6pt;text-align:justify;text-indent:35.35pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">the Committee desires to ratify and adopt the amendment to the Plan described herein</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6.05pt;padding-right:74.75pt;text-align:justify;text-indent:35.05pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">NOW</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">THEREFORE</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows</font><font style="color:#696969;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.85pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The first paragraph of Section 6</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3 is hereby amended to read as follows</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.6pt;padding-right:80.1pt;text-indent:34.9pt"><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">&#34;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">6</font><font style="color:#797979;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">.</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">3&#160;&#160;&#160;&#160;</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;text-decoration:underline">Additional Discretionary Authority</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">. </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">The Plan Administrator may</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">upon written approval of the Parent's E</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">x</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">ecutive Vice President &#38; Chief Human Resources Officer (or his or her delegate)</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">or by such other individual who acts as the successor or equivalent thereto of such position (or his or her delegate)</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">(written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan&#58;&#34;</font></div><div style="margin-top:11.65pt;padding-left:5.55pt;padding-right:74.05pt;text-indent:35.25pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">IN WITNESS WHEREOF, </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">the Committee has caused this Amendment 2020-1 to the Plan to be executed by the undersigned on this </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;text-decoration:underline">25th</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%"> day of </font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;text-decoration:underline">February.</font><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%"> 2020</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:10.65pt;padding-left:256.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Arseneault                                    </font></div><div style="margin-top:10.65pt;padding-left:256.4pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Michael Arseneault</font></div><div style="margin-top:0.7pt;padding-left:256.45pt;padding-right:74.05pt;text-indent:-0.1pt"><font style="color:#2f2d2d;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Executive Director, Managing Counsel Global Compensation and Benefits</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:66.25pt"><font><br></font></div><div style="padding-right:66.25pt"><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:66.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">U.S. SEPARATION BENEFITS PLAN CHANGE</font></div><div style="margin-top:6pt;padding-right:66.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, that effective as of January 1, 2020, Amendment 2020-1 to the Merck &#38; Co., Inc. U.S. Separation Benefits Plan as Amended and Restated as of January 1, 2019 (the &#8220;Plan&#8221;) be and hereby is adopted, in substantially the same form as attached hereto as Appendix A&#59;</font></div><div style="margin-top:6pt;padding-right:66.25pt"><font><br></font></div><div style="margin-top:6pt;padding-right:66.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">FURTHER RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, that Michael Arseneault, Exec. Dir., Managing Counsel Global Compensation &#38; Employee Benefits&#47;Merck Office of General Counsel is provided with the authority to make such changes as necessary and proper to the terms of the Plan the intent of the Resolutions and to ensure that such documents comply with the Resolutions described herein and to prepare such other documents as are necessary to implement the Resolutions described herein, applicable law and the administration of applicable plans.</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_103"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:97.37pt;padding-right:97.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT 2020-2</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:111.6pt;padding-right:111.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO. INC. U.S. SEPARATION BENEFITS PLAN</font></div><div style="padding-left:110.1pt;padding-right:110.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(Amended and Restated as of January 1, 2019)</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Merck &#38; Co, Inc. (the &#8220;Company&#8221;), a subsidiary of Merck &#38; Co., Inc. (&#8220;Merck&#8221;), sponsors the Merck &#38; Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the &#8220;Plan&#8221;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:11.95pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to the grant of authority of Merck&#8217;s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck &#38; Co., Inc. Executive Oversight Committee (the &#8220;Executive Committee&#8221;) in accordance with its charter&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:11.95pt;padding-right:71.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in accordance with its charter the Executive Committee has delegated to the Merck &#38; Co., Inc. Oversight Committee (the &#8220;Committee&#8221;) the authority to make certain amendments to the Plan in accordance with the charter of the Committee&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:11.95pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Committee desires to ratify and adopt the amendment to the Plan described herein.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:11.95pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:11.95pt;padding-right:71.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.05pt">A new definition of Legacy Quantified Ag, Antelliq Corporation, or ArQule, Inc. Employee is hereby added to the Plan&#8217;s Article II in the correct alphabetical order to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:47.95pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who was formerly an employee of Quantified Ag, Antelliq Corporation, or ArQule, Inc. respectively who became an employee of Merck &#38; Co, Inc. or one of its subsidiaries in 2019 or 2020 and continues to be employed by such entity until his&#47;her Separation Date, and as of his&#47;her Separation Date is employed by an Employer.&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:73.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.9 &#8220;Complete Years of Continuous Service&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:48pt;padding-right:71.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.9 &#8220;Complete Years of Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_106"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:48pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (e) for a Non-Legacy Company Employee, from the Participant&#8217;s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.&#8221;</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:71.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.10 &#8220;Continuous Service&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:48pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10 &#8220;Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, and (e) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from &#8220;Continuous Service.&#8221; Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as &#34;Continuous Service&#34;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.24 &#8220;Most Recent Hire Date&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:47.95pt;padding-right:71.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.24 Most Recent Hire Date&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer&#8217;s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer&#8217;s employee data system,</font></div><div style="padding-left:47.95pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.75pt">for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system,</font></div><div style="padding-left:47.95pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.07pt">for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system. Notwithstanding the foregoing, the</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_109"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:48pt;padding-right:71.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer&#8217;s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.&#8221;</font></div><div><font><br></font></div><div style="padding-left:48pt;padding-right:79.35pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:27pt">Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows&#58; </font></div><div style="padding-left:12pt;padding-right:79.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;3.1(a) Eligibility.</font></div><div style="padding-left:0.55pt;padding-right:79.35pt;text-align:justify"><font><br></font></div><div style="padding-left:48pt;padding-right:71.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)  An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he&#47;she experiences a Termination due to Workforce Restructuring&#59; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring on or after May 17, 2013 and</font></div><div style="margin-top:0.05pt;padding-left:48pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annul Base Salary. A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:48pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt">Schedule A of the Plan is hereby updated to read as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.37pt;padding-right:97.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;SCHEDULE A</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97.37pt;padding-right:97.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">List of participating Employers&#58;</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_112"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:12pt;padding-right:86.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All U. S. direct and indirect wholly owned subsidiaries of Merck &#38; Co. Inc. excluding the following and their subsidiaries&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:66pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.85pt">Comsort, Inc. (and its subsidiaries)</font></div><div style="padding-left:66pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.85pt">Merck Global Health Innovation Fund LLC (and its subsidiaries)</font></div><div style="padding-left:66pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.85pt">HMR Weight Management Services Corp. (and its subsidiaries)</font></div><div style="padding-left:66pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.85pt">ILUM Health Solutions, LLC (and its subsidiaries)</font></div><div style="padding-left:66pt;padding-right:73pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.85pt">Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020</font></div><div style="padding-left:66pt;padding-right:82.35pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.85pt">Effective for the period between June 17, 2020 through October 1, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.</font></div><div style="padding-left:66pt;padding-right:78.25pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.85pt">Effective for the period between April 1, 2019, through July 1, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.</font></div><div style="padding-left:66pt;padding-right:80.75pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.85pt">Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.&#8221;</font></div><div><font><br></font></div><div style="margin-top:10.65pt;padding-left:12pt;padding-right:74.45pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Merck &#38; Co, Inc. Oversight Committee has caused this Amendment 2020-2 of the Merck &#38; Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the &#8220;Plan&#8221;)&#59; to be executed as of the 10th day of December, 2020.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:264pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Michael Arseneault                                    </font></div><div style="padding-left:263.75pt"><font><br></font></div><div style="padding-left:264pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael Arseneault</font></div><div style="padding-left:264pt;padding-right:74.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exec. Dir., Managing Counsel Global Compensation &#38; Employee Benefits&#47;Merck Office of General Counsel</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_115"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:216.75pt;padding-right:216.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT 2021-1 TO THE</font></div><div style="padding-left:111.6pt;padding-right:111.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC., U.S. SEPARATION BENEFITS PLAN</font></div><div style="padding-left:45.7pt;padding-right:45.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(Amended and Restated as of January 1, 2019)</font></div><div style="padding-left:12pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Merck &#38; Co, Inc. (the &#8220;Company&#8221;), a subsidiary of Merck &#38; Co., Inc. (&#8220;Merck&#8221;), sponsors the Merck &#38; Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the &#8220;Plan&#8221;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to the grant of authority of Merck&#8217;s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck &#38; Co., Inc. Executive Oversight Committee (the &#8220;Executive Committee&#8221;) in accordance with its charter&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in accordance with its charter the Executive Committee has delegated to the Merck &#38; Co., Inc. Oversight Committee (the &#8220;Committee&#8221;) the authority to make certain amendments to the Plan in accordance with the charter of the Committee&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Committee desires to ratify and adopt the amendment to the Plan described herein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">A new definition of Legacy Pandion Employee is hereby added to the Plan&#8217;s Article II in the correct alphabetical order to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:48pt;padding-right:71.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Legacy Pandion Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who was formerly an employee of Pandion Therapeutics, Inc. who became an employee of Merck &#38; Co, Inc. or one of its subsidiaries in 2021 and continues to be employed by such entity until his&#47;her Separation Date, and as of his&#47;her Separation Date is employed by an Employer.&#8221;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:73.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.9 &#8220;Complete Years of Continuous Service&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:48pt;padding-right:71.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.9 &#8220;Complete Years of Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (e) for a Legacy Pandion Employee a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_118"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:48pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from each anniversary to the next, and (f) for a Non-Legacy Company Employee, from the Participant&#8217;s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.&#8221;</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:71.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.10 &#8220;Continuous Service&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:48pt;padding-right:71.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10 &#8220;Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (d) for a Legacy Pandion Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, and (f) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from &#8220;Continuous Service.&#8221; Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as &#34;Continuous Service.&#34;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:12pt;padding-right:71.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.27 &#8220;Most Recent Hire Date&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:47.95pt;padding-right:71.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.27 Most Recent Hire Date&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer&#8217;s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer&#8217;s employee data system,</font></div><div style="padding-left:47.95pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system,</font></div><div style="padding-left:47.95pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_121"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:48pt;padding-right:71.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the Employer&#8217;s employee data system, (d) for a Legacy Pandion Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer&#8217;s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.&#8221;</font></div><div><font><br></font></div><div style="padding-left:48pt;padding-right:79.35pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:27pt">Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows&#58; &#8220;3.1(a) Eligibility.</font></div><div style="margin-top:0.05pt;padding-left:48pt;padding-right:71.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt">An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he&#47;she experiences a Termination due to Workforce Restructuring&#59; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, and (3) a Legacy Pandion Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp &#38; Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees.  A Grandfathered Legacy Schering Employee will be eligible for</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_124"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:47.95pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.&#8221;</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:78.9pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.05pt">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Merck &#38; Co, Inc. Oversight Committee has caused this Amendment 2021-1 of the Merck &#38; Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the &#8220;Plan&#8221;)&#59; to be executed as of the 31st day of March, 2021.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:264pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Michael Arseneault                                    </font></div><div><font><br></font></div><div style="padding-left:264pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael Arseneault</font></div><div style="padding-left:264pt;padding-right:74.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exec. Dir., Managing Counsel Global Compensation &#38; Employee Benefits&#47;Merck Office of General Counsel</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:42pt;padding-right:42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_127"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:155.35pt;padding-right:155.35pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT 2021-2 TO THE</font></div><div style="padding-left:41.72pt;padding-right:41.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC., U.S. SEPARATION BENEFITS PLAN</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(Amended and Restated as of January 1, 2019)</font></div><div style="padding-right:27.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Merck &#38; Co, Inc. (the &#8220;Company&#8221;), a subsidiary of Merck &#38; Co., Inc. (&#8220;Merck&#8221;), sponsors the Merck &#38; Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the &#8220;Plan&#8221;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:27.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:27.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to the grant of authority of Merck&#8217;s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck &#38; Co., Inc. Executive Oversight Committee (the &#8220;Executive Committee&#8221;) in accordance with its charter&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:27.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in accordance with its charter the Executive Committee has delegated to the Merck &#38; Co., Inc. Oversight Committee (the &#8220;Committee&#8221;) the authority to make certain amendments to the Plan in accordance with the charter of the Committee&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:27.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Committee desires to ratify and adopt the amendment to the Plan described herein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-right:27.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12pt;padding-right:29.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">A new definition of Legacy Pandion Employee is hereby added to the Plan&#8217;s Article II in the correct alphabetical order to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-right:27.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Legacy IdentiGEN Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who was formerly an employee of IdentiGEN who became an employee of Merck &#38; Co, Inc. or one of its subsidiaries in 2020 and continues to be employed by such entity until his&#47;her Separation Date, and as of his&#47;her Separation Date is employed by an Employer.&#8221;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.9 &#8220;Complete Years of Continuous Service&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:27.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.9 &#8220;Complete Years of Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (e) for a Legacy Pandion Employee a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_130"></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.05pt;padding-right:27.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from each anniversary to the next, (f) for a Legacy IdentiGEN Employee a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (g) for a Non-Legacy Company Employee, from the Participant&#8217;s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.&#8221;</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.10 &#8220;Continuous Service&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-right:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10 &#8220;Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (d) for a Legacy Pandion Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (e) for a Legacy IdentiGEN Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, and (f) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from &#8220;Continuous Service.&#8221; Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as &#34;Continuous Service.&#34;</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:29pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Section 2.27 &#8220;Most Recent Hire Date&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-right:27.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.27 Most Recent Hire Date&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer&#8217;s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer&#8217;s employee data system, (c)or a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, (d) for a Legacy Pandion Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, (e) for a Legacy IdentiGEN Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system and (f) for a Non-Legacy Company Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998,remained continuously employed by Merial through the </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="padding-right:27.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer&#8217;s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.&#8221;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:48pt;padding-right:35.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:27pt">Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows&#58; &#8220;3.1(a) Eligibility.</font></div><div style="padding-right:27.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he&#47;she experiences a Termination due to Workforce Restructuring&#59; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, (3) a Legacy Pandion Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp &#38; Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees, and (4) a Legacy IdentiGEN Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.&#8221;</font></div><div><font><br></font></div><div style="padding-left:48pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.05pt">Schedule A of the Plan is hereby updated to read as follows&#58;</font></div><div style="margin-top:0.35pt;padding-left:11.95pt"><font><br></font></div><div style="padding-left:110.92pt;padding-right:110.92pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SCHEDULE A</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41.72pt;padding-right:41.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">List of participating Employers&#58;</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:18.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All U. S. direct and indirect wholly owned subsidiaries of Merck &#38; Co. Inc. excluding the following and their subsidiaries&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.85pt">Antimicrobial Stewardship, LLC</font></div><div style="padding-left:60pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.85pt">Merck Global Health Innovation Fund LLC (and its subsidiaries)</font></div><div style="padding-left:59.95pt;padding-right:8.6pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020</font></div><div style="padding-left:60pt;padding-right:5.1pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between June 17, 2020 through September 30, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.</font></div><div style="padding-left:60pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between April 1, 2019, through June 30, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.</font></div><div style="padding-left:60pt;padding-right:21.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.</font></div><div style="padding-left:60pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.8pt">Effective February 25, 2021, Pandion, Inc. became an employer under the Plan</font></div><div style="padding-left:59.95pt;padding-right:19.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between August 5, 2020, through December 31, 2021 IdentiGEN Effective as of January 1, 2022, IdentiGEN, Inc. became an employer under the Plan&#8221;</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_136"></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-right:10.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Merck &#38; Co, Inc. Oversight Committee has caused this Amendment 2021-2 of the Merck &#38; Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019)(the &#8220;Plan&#8221;)&#59; to be executed as of the 16th day of December, 2021.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:11.15pt;text-indent:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Michael Arseneault                                   </font></div><div style="padding-left:243pt;text-indent:243pt"><font><br></font></div><div style="padding-left:243pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael Arseneault</font></div><div style="padding-left:243pt;padding-right:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exec. Dir., Managing Counsel Global Compensation &#38; Employee Benefits&#47;Merck Office of General Counsel</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_139"></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:2.15pt;padding-left:90.95pt;padding-right:90.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">AMENDMENT NUMBER 2022-1 TO</font></div><div style="margin-top:0.5pt;text-align:center"><font><br></font></div><div style="padding-left:91.45pt;padding-right:91.45pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">MERCK &#38; CO. INC. U.S. SEPARATION BENEFITS PLAN</font></div><div style="margin-top:0.25pt;text-align:center"><font><br></font></div><div style="padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">As Amended and Restated effective January 1, 2013</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.1pt;padding-right:89.15pt;text-indent:0.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">The Merck &#38; Co., Inc. U.S. Separation Benefits Plan (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:129%">) is hereby amended effective as of May 1, 2022, as follows&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:48.25pt;padding-right:96.05pt;text-indent:-36.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:27.68pt">The Preamble of the Plan is hereby amended to insert the following new paragraph after the 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> paragraph to read as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:46.5pt;padding-right:86.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:128%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:128%">On May 1, 2022, Merck Sharp &#38; Dohme Corp. converted to a limited liability company named Merck Sharp &#38; Dohme LLC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:128%">&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:47.75pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:27.33pt">Section 2.16 of the Plan is amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:42pt;padding-right:86.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;&#8217;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">IAM Agreement&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> means a collective bargaining agreement between Merck Sharp &#38; Dohme LLC or Merck Sharp &#38; Dohme Corp., and District 15, Lodge 315 of the International Association of Machinists and Aerospace Workers.&#8221;</font></div><div><font><br></font></div><div style="margin-top:7pt;padding-left:48.2pt;text-indent:-36.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:27.58pt">Section 2.26 of the Plan is amended to add </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">after the words </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:48.25pt;text-indent:-36.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:27.73pt">Section 2. 33 of the Plan is amended in its entirety to read as follows&#58;</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:46.5pt;padding-right:74.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;Old Merck&#8221; means Merck &#38; Co., Inc. prior to November 4, 2009 (subsequently known on and after November 4, 2009 and prior to May 1, 2022 as Merck Sharp &#38; Dohme Corp., and on and after May 1, 2022 as Merck Sharp &#38; Dohme LLC).&#8221;</font></div><div><font><br></font></div><div style="padding-left:48.25pt;text-indent:-36.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:27.73pt">Section 3.1 Paragraph #4 of the Plan is amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:51pt;padding-right:74.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;#4. notwithstanding the foregoing sub-clause (A), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp &#38; Dohme LLC, Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under Schedule B-1 of the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees&#59; and&#8221;</font></div><div><font><br></font></div><div style="padding-left:48.25pt;text-indent:-36.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:27.73pt">Schedule A of the Plan is amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:42pt;padding-right:86.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;All U. S. direct and indirect wholly owned subsidiaries of Merck &#38; Co., Inc. excluding the following and their subsidiaries&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:127%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:127%;padding-left:14.03pt">Comsort Inc. (and its subsidiaries)</font></div><div style="padding-left:60pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:14.03pt">Merck Global Health Innovation Fund LLC (and its subsidiaries)</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_142"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:60pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:14.03pt">Antimicrobrial Stewardship LLC (and its subsidiaries)</font></div><div style="margin-top:0.05pt;padding-left:60pt;padding-right:92.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.98pt">Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020</font></div><div style="padding-left:60pt;padding-right:114.3pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.98pt">Tilos Therapeutics (and its subsidiaries) for the period of time after the date Tilos Therapeutics became a subsidiary of the Company and before January 1, 2020</font></div><div style="padding-left:60pt;padding-right:68.45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:13.98pt">Antelliq Corporation (and its subsidiaries) for the period of time after the date Antelliq Corporation became a subsidiary of the Company and before such date in 2020 as of which the Plan Administrator determines Antelliq Corporation shall become an Employer.&#8221;</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:67.85pt;text-align:justify;text-indent:27.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Director, Global Compensation &#38; Employee Benefits, Merck Office of General Counsel on behalf of the Merck &#38; Co, Inc. Oversight Committee has caused this Amendment 2022- 1 of the Plan to be executed as of this 14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of December, 2022.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:258pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Arseneault                                    </font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.95pt;padding-left:258pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Michael Arseneault</font></div><div style="padding-left:258pt;padding-right:74.45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dir., Global Compensation &#38; Employee Benefits Merck Office of General Counsel</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3fd694a9ca9c42b69eb8c45035645669_145"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3pt;padding-left:152.85pt;padding-right:152.85pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT 2022-2 </font></div><div style="margin-top:3pt;padding-left:152.85pt;padding-right:152.85pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE</font></div><div style="padding-left:39pt;padding-right:39pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC., U.S. SEPARATION BENEFITS PLAN</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(Amended and Restated as of January 1, 2019)</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:22.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Merck &#38; Co, Inc. (the &#8220;Company&#8221;), a subsidiary of Merck &#38; Co., Inc. (&#8220;Merck&#8221;), sponsors the Merck &#38; Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the &#8220;Plan&#8221;)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:22.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:22.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to the grant of authority of Merck&#8217;s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck &#38; Co., Inc. Executive Oversight Committee (the &#8220;Executive Committee&#8221;) in accordance with its charter&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:22.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in accordance with its charter the Executive Committee has delegated to the Merck &#38; Co., Inc. Oversight Committee (the &#8220;Committee&#8221;) the authority to make certain amendments to the Plan in accordance with the charter of the Committee&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-right:22.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Committee desires to ratify and adopt the amendment to the Plan described herein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-right:22.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:22.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">A new definition of Acceleron Pharma Inc. Employee and Vence employee is hereby</font></div><div style="padding-left:6pt;padding-right:22.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">added to the Plan&#8217;s Article II in    the correct alphabetical order to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-right:22.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acceleron Pharma Inc. Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who was formerly an employee of Acceleron Pharma Inc. who became an employee of Merck &#38; Co, Inc. or    one of its subsidiaries in 2021 and continues to be employed by such entity until his&#47;her Separation Date, and as of his&#47;her Separation Date is employed by an Employer.&#8221;</font></div><div style="padding-right:22.85pt;text-align:justify"><font><br></font></div><div style="padding-right:22.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vence Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who was formerly an employee of Vence who became an employee of Merck &#38; Co, Inc. or    one of its subsidiaries in 2022 and continues to be employed by such entity until his&#47;her Separation Date, and as of his&#47;her Separation Date is employed by an Employer.&#8221;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:24.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Section 2.10 &#8220;Complete Years of Continuous Service&#8221; of the Plan is hereby amended </font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:24.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In its    entirety to read as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:22.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.10 &#8220;Complete Years of Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant&#8217;s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation, ArQule, Inc., Pandion Employee, IdentiGEN, Acceleron Pharma Inc. or Vence from the   Participant&#8217;s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next and (e) for a Non-Legacy Company Employee, from the  Participant&#8217;s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.&#8221;</font></div><div><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.5pt;padding-right:14.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:0.55pt;padding-right:22.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Section 2.11 &#8220;Continuous Service&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-right:22.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.11 &#8220;Continuous Service&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation, ArQule, Inc., Pandion, IdentiGEN, Acceleron Pharma or Vence Employee,  the period of a Participant's continuous employment with a Legacy and Merck Entity commencing on  the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation  Date as reflected on the Employer&#8217;s employee database, and (e) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer&#8217;s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from &#8220;Continuous Service.&#8221; Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as &#34;Continuous Service.&#34;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:0.55pt;padding-right:22.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Section 2.29 &#8220;Most Recent Hire Date&#8221; of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div><font><br></font></div><div style="padding-right:22.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;2.29 Most Recent Hire Date&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer&#8217;s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer&#8217;s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n the Employer&#8217;s employee data system, (d) for a Legacy Pandion, IdentiGEN, Acceleron Pharma, Inc. or Vence Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer&#8217;s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck  Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer&#8217;s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.&#8221;</font></div><div><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.5pt;padding-right:14.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:0.55pt;padding-right:30.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows&#58;</font></div><div style="padding-left:0.55pt;padding-right:30.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;3.1(a) Eligibility.</font></div><div style="padding-left:0.55pt;padding-right:30.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:22.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he&#47;she experiences a Termination due to Workforce Restructuring&#59; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, (3) a Legacy Pandion, IdentiGEN, Acceleron or Vence Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp &#38; Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees, and (4) a Legacy IdentiGEN Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he&#47;she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he&#47;she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.&#8221;</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:30.35pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:27pt">Schedule A of the Plan is hereby updated to read as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;SCHEDULE A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">List of participating Employers&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All U. S. direct and indirect wholly owned subsidiaries of Merck &#38; Co. Inc. excluding the following and their subsidiaries&#58;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Antimicrobial Stewardship, LLC</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Merck Global Health Innovation Fund LLC (and its subsidiaries)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020</font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.5pt;padding-right:14.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between June 17, 2020 through September 30, 2020, Quantified Ag.  Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between April 1, 2019, through June 30, 2020 Antelliq Corporation.  Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc.  Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective February 25, 2021, Pandion, Inc. became an employer under the Plan</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective for the period between August 5, 2020, through December 31, 2021 IdentiGEN  Effective as of January 1, 2022, IdentiGEN, Inc. became an employer under the Plan</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective as of November 19, 2022, Acceleron Pharma Inc. became an employer under the Plan</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Effective January 1, 2023, Vence shall become and employer under the Plan&#8221;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Merck &#38; Co, Inc. Oversight Committee has caused this Amendment 2022-2 of the Merck &#38; Co., Inc. U.S. Separation Benefits Plan  (Amended and Restated as of January 1, 2019)(the &#8220;Plan&#8221;)&#59; to be executed as of the 13th day of December, 2021</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                                                                                      </font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Michael Arseneault                                    </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael Arseneault</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Counsel, Global Compensation &#38; Employee Benefits&#47;Merck Office of General Counsel</font></div><div style="padding-right:48.85pt;text-align:right"><font><br></font></div><div style="padding-right:19.85pt"><font><br></font></div><div style="height:61.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:14.5pt;padding-right:14.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>5
<FILENAME>exhibit1023-2019annualceon.htm
<DESCRIPTION>EXHIBIT-10.23 2019 ANNUAL CEO NQSO TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i806af1dcd2c34a6eb7cc198413974657_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.23</font></div><div style="text-align:right"><font><br></font></div><div style="padding-left:64.47pt;padding-right:64.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TERMS FOR</font></div><div style="margin-top:0.15pt;padding-left:128.77pt;padding-right:128.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">2019 STOCK OPTION CEO GRANT</font></div><div style="margin-top:0.15pt;padding-left:128.77pt;padding-right:128.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">UNDER THE </font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">MERCK &#38; CO., INC. 2010 INCENTIVE STOCK PLAN</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:117%">This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CEO Grant</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Exercisable Date</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Portion Becoming Exercisable</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Option Price&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$77.62</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 3, 2020</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">First&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 3, 2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 3, 2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Second&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Expiration Date&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">November 30, 2027</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 3, 2022</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Balance</font></td></tr></table></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:13.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.44pt">GENERAL INFORMATION</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">IMPORTANT NOTICE</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#58; This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing- equity&#47;managing-your-existing-awards&#47;accepting-awards- grants&#47;) to accept the grant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in forfeiture of the stock option.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div></td></tr></table></div><div style="margin-bottom:0.06pt"><font><br></font></div><div style="margin-bottom:0.06pt;padding-right:2.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II. The vesting and exercisability of this option is also subject to the Restrictive Covenants set forth in Appendix B.</font></div><div><font><br></font></div><div style="padding-right:2.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eligibility&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eligibility for grants is determined under the Merck &#38; Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div><font><br></font></div><div style="padding-right:6.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subject to Recoupment, Forfeiture and Clawback</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; This Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time). </font></div><div style="padding-right:6.85pt"><font><br></font></div><div style="padding-left:13.7pt;text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:2.36pt">VESTING&#59; EXERCISE&#59; EMPLOYMENT TERMINATION</font></div><div><font><br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Vesting&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This option will vest in its entirety if your employment continues through December 31, 2019, or immediately if you die before then. <br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Exercisability.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This option will become exercisable in equal installments (subject to a rounding process) on the Exercisable Dates indicated in the accompanying box above. <br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.81pt">Termination</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any portion of this option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the fifth anniversary of the date your employment terminates </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">due to your retirement </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#8220;Termination Date&#8221;) but in no event after the Expiration Date. Close of Business for any day on which the New York Stock Exchange is not open means the close of business </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">prior </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to that date when the Exchange is open. <br></font></div><div style="padding-right:3.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.81pt">Misconduct. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div><font><br></font></div><div style="padding-right:1.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Death. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. you die while any portion of this stock option remains outstanding, but after your employment terminates, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-right:1.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph C (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div><font><br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.72pt">Change in Control. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination under Paragraph C. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A &#34;change in control&#34; has the same meaning that it has under the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div><font><br></font></div><div style="padding-right:12.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.34pt">Joint Venture. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a &#8220;JV&#8221;) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through F above apply to this stock option while the option holder is employed by the JV.</font></div><div style="padding-right:12.4pt"><font><br></font></div><div style="padding-left:13.7pt;text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:0.08pt"> TRANSFERABILITY</font></div><div style="margin-bottom:6pt;margin-top:0.05pt;padding-left:11pt;padding-right:15.3pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.</font></div><div style="padding-left:13.5pt;text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:21.68pt">ELECTRONIC ACCEPTANCE</font></div><div style="margin-bottom:6pt;padding-left:11.95pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:13.7pt;text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:1.46pt">ADMINISTRATION</font></div><div style="margin-bottom:6pt;padding-left:11pt;padding-right:13.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="padding-left:13.7pt;text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:21.48pt">GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div style="margin-bottom:6pt;padding-left:11pt;padding-right:18.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:11pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">This stock option is subject to the provisions of the 2010 Incentive Stock Plan, including but not limited to choice of law. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:118%">For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via http&#58;&#47;&#47;one.merck.com.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.6pt"><font><br></font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">APPENDIX A</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">RECOUPMENT OF COMPENSATION FOR COMPLIANCE VIOLATIONS</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font><br></font></div><div style="padding-right:5.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">POLICIES AND PROCEDURES</font></div><div style="padding-left:10.8pt;padding-right:5.75pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:11pt;padding-right:1.9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:11pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.16pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:1.9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="margin-bottom:6pt;margin-top:0.4pt;padding-right:11.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek recoupment pursuant to this delegation.</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-bottom:6pt;margin-top:0.3pt;padding-right:12.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="margin-bottom:6pt;margin-top:0.3pt;padding-right:19.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.</font></div><div style="padding-right:1.9pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-right:5.6pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTIVE COVENANTS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You agree that to the extent permitted by law, during your employment with the Company and&#47;or one of its affiliates and until this Award is fully exercisable (the &#8220;Restricted Period&#8221;) you will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that compete</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> with or upon commercialization will compete with any (a) product, technology&#160; or service developed,&#160; marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by you to be in development by the Company or any of its Affiliates .&#160; Nothing herein will prohibit you from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the Restricted Period, you will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture. If the Company determines that you have violated the restrictive covenants set forth in this Appendix B, then you agree and covenant that any Unexercisable portion of this Award will be immediately forfeited. This remedy is not the Company&#8217;s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>6
<FILENAME>exhibit1024-2019annualrsut.htm
<DESCRIPTION>EXHIBIT-10.24 2019 ANNUAL RSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0db25e5e672f409383bfe31e4c98d639_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.24</font></div><div style="padding-left:66.38pt;padding-right:66.38pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TERMS FOR</font></div><div style="padding-left:131.95pt;padding-right:131.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2019 RESTRICTED STOCK UNIT GRANTS</font></div><div style="padding-left:131.95pt;padding-right:131.95pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2010 INCENTIVE STOCK PLAN</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:42.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards.</font></div><div style="padding-right:42.85pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.190%"><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.949%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">RSU</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 3, 2019</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;text-decoration:underline">Vesting Date</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 3, 2020</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">First&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 3, 2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Second&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 3, 2022</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balance</font></td></tr></table></div><div style="padding-left:0.06pt;padding-right:2.9pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Eligibility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#58; Eligibility for grants is determined under the Merck &#38; Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div style="padding-left:6pt;padding-right:2.9pt"><font><br></font></div><div style="padding-left:12.95pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:2.48pt">GENERAL INFORMATION</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.834%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.95pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at </font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RS Award.</font></div></td></tr></table></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:4.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">Restricted Period. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Restricted Period is the period during which this RSU Award is restricted and subject to forfeiture. The Restricted Period ends with respect to one-third of this RSU Award on each of the First, Second and Third anniversaries of the Grant Date as shown in the box above, unless ended earlier under Article II below. No voting rights apply to this RSU Award. No fractional shares will be awarded&#58; all calculations are subject to rounding.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:2.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">Dividend Equivalents. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">During the Restricted Period, dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the time of distribution. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations. </font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">Distribution. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Upon the expiration of the Restricted Period if you are then employed, you will be entitled to receive a number of  shares of Merck common stock equal to the number of RSUs that have become unrestricted and the dividend equivalents that accrued on that portion. Prior to distribution, you must deliver to the Company an amount the Company determines to be sufficient to satisfy any amount required to be withheld, including applicable taxes. The Company may, in its sole discretion, withhold from the RSU Award distribution a number of shares to pay applicable withholding (including taxes).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">409A Compliance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Internal Revenue Code or any successor thereto. Specifically, distributions made due to a separation from service (as defined in Section 409A) to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or </font></div></div><div style="display:inline-block;max-width:5.619%;min-width:4.619%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.191%"><div style="padding-left:6pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">any successor thereto, to the extent required by Section 409A of the Code will not be made until administratively feasible following the first day of the sixth month following the separation from service, in the same form as they  would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:4.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.98pt">Subject to Recoupment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. For employees in Band 600 and above, this RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="padding-left:6pt;padding-right:4.45pt"><font><br></font></div><div style="padding-left:15.35pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:2.27pt">TERMINATION OF EMPLOYMENT</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment with the Company is terminated during the Restricted Period, your right to this RSU Award will be determined according to the terms in this Section II.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">General Rule. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">Sale. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. The remainder will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">Involuntary Termination. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If the company determines that your employment is involuntarily terminated during the Restricted Period but on or after the First Anniversary , a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of RSUs that have vested pursuant to Paragraph&#160;A. The remainder and any accrued dividends will be forfeited on the date your employment ends. An &#8220;involuntary termination&#8221; includes termination of your employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs B, or D through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.85pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.52pt">Retirement. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) </font></div></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.190%"><div style="padding-left:6pt;padding-right:10.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:3.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.98pt">Death. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment terminates due to your death during the Restricted Period, all of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death. If you die during the Restricted Period  but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the remaining, non-forfeited portion of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:9.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:22.45pt">Misconduct. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:3.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.03pt">Disability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this RSU Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:3.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:21.51pt">Change in Control. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary after the closing of any change in control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award. If this RSU does not remain outstanding following the change in control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck common stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire. Change in control is defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control), but if RSUs are considered &#8220;deferred compensation&#8221; under Section 409A of the Internal Revenue Code, the definition of change in control will be modified to the extent necessary to comply with Section 409A.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:1.05pt;text-indent:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:25.28pt">Joint Venture. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employment with a joint venture or other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-H above apply to this RSU Award while you are employed by the joint venture or other entity.</font></div><div><font><br></font></div><div style="padding-left:17.8pt;text-indent:-11.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:113%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:113%;padding-left:2.41pt">TRANSFERABILITY</font></div><div style="padding-left:6pt;padding-right:8pt"><font><br></font></div><div style="padding-left:6pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This RSU Award is not transferable and may not be assigned or otherwise transferred.</font></div><div><font><br></font></div><div style="padding-left:17.8pt;text-indent:-11.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:113%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:113%;padding-left:1.47pt"> ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:5.95pt;padding-right:8pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or </font></div></div><div style="display:inline-block;max-width:5.619%;min-width:4.619%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.191%"><div style="padding-left:5.95pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:18.75pt;text-indent:-12.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:4.78pt">ADMINISTRATION</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16.35pt;text-indent:-10.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:0.02pt"> GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:6.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">This RSU Award is subject to the provisions of the 2010 Incentive Stock Plan. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via http&#58;&#47;&#47;one.merck.com</font></div><div style="margin-top:0.45pt"><font><br></font></div></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0db25e5e672f409383bfe31e4c98d639_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.786%"><div><font><br></font></div></div><div style="display:inline-block;max-width:2.426%;min-width:1.426%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.788%"><div><font><br></font></div></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violations</font></div><div id="i0db25e5e672f409383bfe31e4c98d639_7"></div><div style="margin-top:0.1pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.786%"><div style="margin-top:5.85pt;padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div></div><div style="display:inline-block;max-width:2.426%;min-width:1.426%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.788%"></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.170%"><div><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment  of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take  into account any considerations determined by the Committee to be relevant.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:9.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:0.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:15.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an</font></div><div style="margin-top:0.55pt"><font><br></font></div></div><div style="display:inline-block;max-width:5.658%;min-width:4.658%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.172%"><div><font><br></font></div><div style="padding-left:5pt;padding-right:9.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:11.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:23.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:9.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs Upon Significant Restatement of Finan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">cial Results.</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:476.4pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:94px"></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>7
<FILENAME>exhibit1025-2020annualnqso.htm
<DESCRIPTION>EXHIBIT-10.25 2020 ANNUAL NQSO TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icce6cfc3666a45fb9774cc457b23d35e_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.25</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">TERMS FOR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">2020 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:125%">This is a summary of the terms applicable to the stock option specified in this document.  Different terms may apply to any prior or future stock option.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">NQSO &#8211; Annual </font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Option Price&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">$77.67</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2020</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Expiration Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">April 31, 2030</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Vesting Dates</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">First&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2022</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Second&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2023</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Third&#58; Balance</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:31.28pt">GENERAL INFORMATION</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">IMPORTANT NOTICE&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">This grant requires you to affirmatively accept it.  You </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> log onto the Morgan Stanley website at&#58; </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days.  Failure to accept the terms and conditions of your stock option within 90 days may result in Forfeiture of the stock option.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the accompanying box. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Eligibility&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> Eligibility for grants is determined under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Subject to Recoupment&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> For employees in Band 600 and above, this Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:28.92pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:9.98pt">General Rule.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">  If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the same day of the third month (&#8220;Within Three Months&#8221;) after the date of the termination (but in no event after the expiration of the Option Period).  Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open.  Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later date (e.g., November 28, 29 and 30 all correspond to February 28 in non-leap years).  If you are rehired by the Company or JV, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">  </font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:9.98pt">Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> If you retire from service with the Company the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately.  Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its original Expiration Date.  For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:9.51pt">Involuntary Termination.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">  If your employment is terminated by the Company and the Company determines that such termination was involuntary, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs B or D through H, the portion of this stock option that is unvested will expire on the date your employment ends&#59; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:9.51pt">Sale.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of this stock option award will vest and become exercisable immediately upon such termination&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a  termination of employment, and may make adjustments, if any, as it deems appropriate, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this option, and&#47;or in the option price of such option. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:9.98pt">Misconduct.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:10.45pt">Death.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this  stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in  paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:9.03pt">Disability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:9.51pt">Change in Control.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B through G above or termination prior to a change in control. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A &#34;change in control&#34; has the same meaning that it has under the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div style="padding-left:90pt"><font><br></font></div><div style="padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:13.28pt">Joint Venture.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a &#8220;JV&#8221;) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through H above apply to this stock option while the option holder is employed by the JV.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:26.56pt">TRANSFERABILITY</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:25.62pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:27.98pt">ADMINISTRATION</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant.  Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;padding-left:25.62pt">GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law.  The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">This stock option is subject to the provisions of the 2019 Incentive Stock Plan. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For further information regarding Merck&#8217;s LTI program and your stock options, visit the </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Long-Term Incentives</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> page on Sync &#62; HR portal.</font></div><div style="margin-bottom:8pt;padding-left:54pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:125%">Recoupment of Compensation for Compliance Violations</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">POLICIES AND PROCEDURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Policy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee  will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Definitions</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Procedures</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;padding-left:10.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Miscellaneous</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law.  Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>8
<FILENAME>exhibit1026-2020annualceon.htm
<DESCRIPTION>EXHIBIT-10.26 2020 ANNUAL CEO NQSO TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i88fc5c2fd8404cc79833746473554bf9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.26</font></div><div style="padding-left:64.47pt;padding-right:64.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TERMS FOR</font></div><div style="margin-top:0.15pt;padding-left:128.77pt;padding-right:128.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">2020 STOCK OPTION CEO GRANT</font></div><div style="margin-top:0.15pt;padding-left:128.77pt;padding-right:128.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">UNDER THE </font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:117%">This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CEO Grant</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Exercisable Date</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Portion Becoming Exercisable</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Option Price&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$75.36</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 1, 2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">First&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 1, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 1, 2022</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Second&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Expiration Date&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">November 30, 2027</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 1, 2023</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Balance</font></td></tr></table></div><div style="margin-top:0.15pt"><font><br></font></div><div style="text-indent:-9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.44pt">GENERAL INFORMATION</font></div><div style="margin-top:0.02pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing- equity&#47;managing-your-existing-awards&#47;accepting-awards- grants&#47;) to accept the grant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in forfeiture of the stock option.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="padding-right:2.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II. The vesting and exercisability of this option is also subject to the Restrictive Covenants set forth in Appendix B.</font></div><div><font><br></font></div><div style="padding-right:2.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eligibility&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eligibility for grants is determined under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div><font><br></font></div><div style="padding-right:6.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subject to Recoupment, Forfeiture and Clawback</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; This Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time). </font></div><div style="padding-right:6.85pt"><font><br></font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:2.36pt">VESTING&#59; EXERCISE&#59; EMPLOYMENT TERMINATION</font></div><div><font><br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Vesting&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This option will vest in its entirety if your employment continues through December 31, 2020, or immediately if you die before then. <br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Exercisability.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This option will become exercisable in equal installments (subject to a rounding process) on the Exercisable Dates indicated in the accompanying box above. <br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.81pt">Termination</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any portion of this option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the fifth anniversary of the date your employment terminates </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">due to your retirement </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#8220;Termination Date&#8221;) but in no event after the Expiration Date. Close of Business for any day on which the New York Stock Exchange is not open means the close of business </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">prior </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to that date when the Exchange is open. <br></font></div><div style="padding-right:3.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.81pt">Misconduct. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div><font><br></font></div><div style="padding-right:1.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Death. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. you die while any portion of this stock option remains outstanding, but after your employment terminates, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:1.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph C (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div><font><br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.72pt">Change in Control. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination under Paragraph C. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A &#34;change in control&#34; has the same meaning that it has under the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div><font><br></font></div><div style="padding-right:12.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.34pt">Joint Venture. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a &#8220;JV&#8221;) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through F above apply to this stock option while the option holder is employed by the JV.</font></div><div style="padding-right:12.4pt"><font><br></font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:0.08pt">TRANSFERABILITY</font></div><div style="margin-bottom:6pt;margin-top:0.05pt;padding-left:11pt;padding-right:15.3pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.</font></div><div style="text-indent:-9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:34.98pt">ELECTRONIC ACCEPTANCE</font></div><div style="margin-bottom:6pt;padding-left:11.95pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="text-indent:-9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:1.26pt">ADMINISTRATION</font></div><div style="margin-bottom:6pt;padding-left:11pt;padding-right:13.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:35.18pt">GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div style="margin-bottom:6pt;padding-left:11pt;padding-right:18.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:11pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">This stock option is subject to the provisions of the 2019 Incentive Stock Plan, including but not limited to choice of law. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:118%">For further information regarding Merck&#8217;s LTI program and your stock options, visit the </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:118%">Long-Term Incentives</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:118%"> page on</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:118%"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:118%">Sync &#62; HR portal</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:118%">.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.6pt"><font><br></font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">APPENDIX A</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">RECOUPMENT OF COMPENSATION FOR COMPLIANCE VIOLATIONS</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font><br></font></div><div style="padding-right:5.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">POLICIES AND PROCEDURES</font></div><div style="padding-left:10.8pt;padding-right:5.75pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:11pt;padding-right:1.9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:11pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.16pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:1.9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="margin-bottom:6pt;margin-top:0.4pt;padding-right:11.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek recoupment pursuant to this delegation.</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-bottom:6pt;margin-top:0.3pt;padding-right:12.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="margin-bottom:6pt;margin-top:0.3pt;padding-right:19.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.</font></div><div style="padding-right:1.9pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:5.6pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTIVE COVENANTS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You agree that to the extent permitted by law, during your employment with the Company and&#47;or one of its affiliates and until this Award is fully exercisable (the &#8220;Restricted Period&#8221;) you will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that compete</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> with or upon commercialization will compete with any (a) product, technology&#160; or service developed,&#160; marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by you to be in development by the Company or any of its Affiliates .&#160; Nothing herein will prohibit you from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the Restricted Period, you will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture. If the Company determines that you have violated the restrictive covenants set forth in this Appendix B, then you agree and covenant that any Unexercisable portion of this Award will be immediately forfeited. This remedy is not the Company&#8217;s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>9
<FILENAME>exhibit1027-2020annualrsut.htm
<DESCRIPTION>EXHIBIT-10.27 2020 ANNUAL RSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id3b2ede8b6724e04846d5896158f9966_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.27</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TERMS FOR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2020 RESTRICTED STOCK UNIT GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., 2019 INCENTIVE STOCK PLAN</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document.  </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Different terms may apply to any prior or future RSU Awards.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.861%"><tr><td style="width:1.0%"></td><td style="width:36.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">RSU - Annual</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2020</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Vesting Dates</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Portion that Vests</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">First&#58; 33.333%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Second&#58; 33.333%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 1, 2023</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Third&#58; Balance</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Eligibility&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Eligibility for grants is determined under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:31.28pt">GENERAL INFORMATION</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">  This grant requires you to affirmatively accept it.  You MUST log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.  </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days.  Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Restricted Period.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">  The Restricted is the period during which this RSU Award is restricted and subject to forfeiture.  The Restricted Period ends with respect to one-third of this RSU Award on each of the First, Second, and Third anniversaries of the Grant Date as shown in the box above, unless ended earlier under Article II below.  No voting rights apply to this RSU Award.  No fractional shares will be awarded&#58;  all calculations are subject to rounding.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">  During the Restricted Period, dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock.  Payment of such dividends will be made, without interest or earnings, at the time of distribution.  If any portion of this RSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion.  Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Distribution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> Upon the expiration of the Restricted Period if you are then employed, you will be entitled to receive a number of shares of Merck common stock equal to the number of RSUs that have become unrestricted and the dividend equivalents that accrued on that portion. Prior to distribution, you must deliver to the Company an amount the Company determines to be sufficient to satisfy any amount required to be withheld, including applicable taxes. The Company may, in its sole discretion, withhold from the RSU Award distribution a number of shares to pay applicable withholding (including taxes).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">409A Compliance.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Internal Revenue Code or any successor thereto. Specifically, distributions made due to a separation from service (as defined in Section 409A) to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will not be made until administratively feasible following the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Subject to Recoupment. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:28.92pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment with the Company is terminated during the Restricted Period, your right to the RSU Award will be determined according to the terms in this Section II.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">General Rule</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Sale.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. The remainder will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Involuntary Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. If the company determines that your employment is involuntarily terminated during the Restricted Period but on or after the First Anniversary, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. An &#8220;involuntary termination&#8221; includes termination of your employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs B, or D through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Death.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment terminates due to your death during the Restricted Period, all of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the remaining, non-forfeited portion of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:10.45pt">Misconduct.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.03pt">Disability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this RSU Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. If the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary after the closing of any change in control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award. If this RSU does not remain outstanding following the change in control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck common stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire. Change in control is defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control), but if RSUs are considered &#8220;deferred compensation&#8221; under Section 409A of the Internal Revenue Code, the definition of change in control will be modified to the extent necessary to comply with Section 409A.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:13.28pt">Joint Venture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. Employment with a joint venture or other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-H above apply to this RSU Award while you are employed by the joint venture or other entity.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:26.56pt">TRANSFERABILITY</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This RSU Award is not transferable and may not be assigned or otherwise transferred.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:25.62pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:27.98pt">ADMINISTRATION</font></div><div><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="padding-left:54pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:25.62pt">GRANTS NOT PART OF THE EMPLOYMENT CONTRACT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via http&#58;&#47;&#47;one.merck.com</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violations</font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment  of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>10
<FILENAME>exhibit1028-2020psutermsan.htm
<DESCRIPTION>EXHIBIT-10.28 2020 ANNUAL PSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i282105b3fd1e4698b4ce1a25aa46d09b_1"></div><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font><br></font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2020 PERFORMANCE SHARE </font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNIT AWARD TERMS</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNDER THE</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC. 2019 STOCK INCENTIVE PLAN</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.240%"><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.97pt">GENERAL. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These Performance Share Units (&#8220;PSUs&#8221;) are granted under and subject to the following Award Terms and the Merck &#38; Co., Inc. 2019 Stock Incentive Plan (the &#34;Merck ISP&#34;). The Company has announced its intention to spin-off (the &#8220;Spin-Off&#8221;) certain products into a new, yet-to-be-named, independent, publicly traded company (&#8220;NewCo&#8221;) during the first half of 2021 (&#8220;Spin-Date&#8221;). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the &#8220;Company.&#8221;</font></div><div style="margin-top:0.5pt"><font><br></font></div></div><div style="display:inline-block;max-width:7.518%;min-width:6.518%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.242%"><div style="margin-top:0.5pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PSU - Annual</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2020</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Award Period&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jan. 1, 2020 &#8211;</font></div><div style="margin-top:0.05pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Dec. 31, 2022</font></div></td></tr></table></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div></div></div><div style="margin-top:0.05pt;padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.</font></div></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.64pt">DEFINITIONS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the purpose of these Award Terms&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Award Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three-year period commencing on January 1, 2020 and ending on December 31, 2022.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986 or any successor thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:22.85pt;text-indent:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings Per Share or EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:26.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates&#59; (2) the impact of significant unplanned acquisitions and&#47;or divestitures, extraordinary items and other unusual or non-recurring charges and&#47;or events&#59; (3) an event either not directly related to Company operations or not reasonably within the control of Company management&#59; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes&#59; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s EPS goal as determined under paragraph C of Section III.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Final Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of the Target described in Section III hereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date as of which a Performance Share Unit is granted.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Healthcare Companies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34; are the healthcare companies used by the Committee in evaluating the Company&#8217;s TSR Performance for the entire Award Period. For 2020 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.983%"><tr><td style="width:1.0%"></td><td style="width:29.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AbbVie</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Eli Lilly</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novartis</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen</font></td><td colspan="3" style="padding:2px 1pt 2px 18.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GlaxoSmithKline</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pfizer</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Astra Zeneca</font></div><div style="margin-top:0.85pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Roche</font></div><div style="margin-top:0.85pt;padding-left:17.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sanofi-Aventis</font></td></tr></table></div><div style="margin-top:3.55pt;padding-left:10.8pt;padding-right:17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.</font></div><div><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights&#59; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Unit Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an eligible employee who receives a Performance Share Unit.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an award of Performance Shares as described in these Award Terms.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as &#8220;target&#8221; for the entire Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the change in value of one share of a company&#8217;s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s TSR Performance as determined under paragraph B of Section III.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (&#8220;Termination of Employment&#8221;).</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:19.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.31pt">Performance Metrics. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.</font></div><div><font><br></font></div><div style="margin-top:2.85pt;padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.92pt">TSR Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The TSR Performance Payout shall be determined as follows&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Company&#8217;s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%&#59; provided, however, that if the Company&#8217;s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.</font></div><div><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For example, if the Company&#8217;s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% &#91;100% + ((25% - 20%) x 5%)&#93;.</font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Company&#8217;s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points&#59; provided, however, that if such median exceeds the Company&#8217;s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">EPS Performance Payout. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The EPS Performance Payout shall be determined in accordance with the following performance schedule&#58;</font></div><div style="padding-left:6pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 OriginalCo EPS </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.571%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt;text-indent:15.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $5.18</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$5.18 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$5.69 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6.03</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$6.38 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 through 2022 for OriginalCo and RemainCo </font></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.981%"><tr><td style="width:1.0%"></td><td style="width:62.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt;text-indent:15.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $17.11</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$17.11 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$18.80 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$19.93</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$21.05 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:42pt;padding-right:90.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.31pt">The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a &#8220;RemainCo Grantee&#8221;) or NewCo (a &#8220;NewCo Grantee&#8221;) on the Spin-Date and is subject to Article IX except as noted below.</font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:right"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Spin-Date is after January 1, 2020 and before December 31, 2021, </font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2020 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33&#160;percent.</font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;For NewCo Grantees, the Final Award will equal 100&#160;percent Target Shares.</font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50&#160;percent and (y) 2020 through 2022 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50&#160;percent. </font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Maximum Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">DIVIDENDS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.26pt">TERMINATION OF EMPLOYMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">General Rule. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated during the Award Period for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Involuntary Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment terminates during the Award Period and the Company determines that employment was involuntarily terminated on or after the first anniversary of the first day of the Award Period, a pro rata portion (based on the number of completed months held during the Award Period prior to the date employment terminated) of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on actual performance during the Award Period as determined in accordance with Section III. The remainder will be forfeited on the date employment ends. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36. An &#8220;involuntary termination&#8221; includes termination of employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of duties and the reasons listed under paragraphs C through G of this section.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Sale. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated during the Award Period and the Company determines that such termination resulted from the sale of his or her subsidiary, division or joint venture, the following portion of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on the Final Award&#58; one third if employment terminates on or after the Grant Date but before the first anniversary of the Award Period thereof&#59; and all if employment terminates on or after the first anniversary of the first day of the Award Period. The remainder will be forfeited on the date a Grantee&#8217;s employment ends.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Retirement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee terminates employment during the Award Period by retirement (including early and disability retirement), then this PSU Award will continue and be distributable on a pro rata basis at the time active Grantees receive such distributions with respect to that Award Period based   on the Final Award. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36.  For Grantees who  are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other Grantees, &#8220;retirement&#8221; is determined by the Company.</font></div><div style="padding-left:6pt;padding-right:5.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Death. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If a Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B, C, D or G of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.</font></div><div style="padding-left:6pt;padding-right:18.15pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.54pt">Misconduct. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee&#8217;s receipt of notice of such termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.7pt">Disability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then   this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.7pt">Joint Venture Service. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A transfer of a Grantee&#8217;s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-G above apply to this PSU Award while a Grantee is employed by the joint venture or other entity.</font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">DISTRIBUTION OF PERFORMANCE SHARES</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">General Rule. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from   a Performance Share Unit before it is denominated in actual shares of Common Stock.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Death. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the case of distribution on account of a Grantee&#8217;s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee&#8217;s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">TRANSFERABILITY</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following a Grantee&#8217;s death.</font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:41.75pt;padding-right:12.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:6pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:44.75pt;text-indent:-38.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.78pt">ADMINISTRATIVE POWERS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to the Committee&#8217;s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:42pt;padding-right:22.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.31pt">CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND CERTAIN COMPLIANCE VIOLATIONS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">PSUs Subject to Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs,  and any proceeds therefrom, are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.75pt">The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below)&#59; and</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt">The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.97pt">&#8220;Executive&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.36pt">&#8220;Fault&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.36pt">Exclusions from Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.97pt">Compliance Violations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">Change-in-Control</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon the occurrence of a change-in-control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Company terminates a Grantee&#8217;s employment except as described in Section V(F), (1) during the Award Period and (2) within two years following a change-in-control, the Final Award will be 100% and will be distributed when distributed to active Grantees.</font></div><div><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.7pt">SECTION 409A COMPLIANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.</font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i282105b3fd1e4698b4ce1a25aa46d09b_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violation</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:9.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:11.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div><font><br></font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:12.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;padding-right:9.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>11
<FILENAME>exhibit1029-2020annualceop.htm
<DESCRIPTION>EXHIBIT-10.29 2020 ANNUAL CEO PSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ida2e4236b5fa4018a27581f374991eec_1"></div><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.29</font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font><br></font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2020 CEO PERFORMANCE SHARE UNIT AWARD TERMS</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC. 2019 STOCK INCENTIVE PLAN</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.240%"><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt;padding-left:13.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:4pt">GENERAL.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> These Performance Share Units (&#8220;PSUs&#8221;) are granted under and subject to the following Award Terms and the Merck &#38; Co., Inc. 2019 Stock Incentive Plan (the &#34;Merck ISP&#34;). The Company has announced its intention to spin-off (the &#8220;Spin-Off&#8221;) certain products into a new, yet-to-be-named, independent, publicly traded company (&#8220;NewCo&#8221;) during the first half of 2021 (&#8220;Spin-Date&#8221;). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the &#8220;Company.&#8221;</font></div></div><div style="display:inline-block;max-width:7.518%;min-width:6.518%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.242%"><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:102%">PSU &#8211;  CEO</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58; Award</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2020</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Period&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jan. 1, 2020 &#8211; Dec. 31, 2022</font></div></td></tr></table></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div></div></div><div style="margin-top:0.5pt"><font><br></font></div><div id="ida2e4236b5fa4018a27581f374991eec_4"></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.</font></div></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:28.45pt">DEFINITIONS. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the purpose of these Award Terms&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Award Period</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three-year period commencing on January 1, 2020 and ending on December 31, 2022.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986 or any successor thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:22.85pt;text-indent:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings Per Share or EPS</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:26.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates&#59; (2) the impact of significant unplanned acquisitions and&#47;or divestitures, extraordinary items and other unusual or non-recurring charges and&#47;or events&#59; (3) an event either not directly related to Company operations or not reasonably within the control of Company management&#59; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes&#59; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Performance Payout</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s EPS goal as determined under paragraph C of Section III.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Final Award</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of the Target described in Section III hereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date as of which a Performance Share Unit is granted.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Healthcare Companies</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34; are the healthcare companies used by the Committee in evaluating the Company&#8217;s TSR Performance for the entire Award Period. For 2020 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.</font></div><div style="padding-left:0.06pt;padding-right:22.85pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.983%"><tr><td style="width:1.0%"></td><td style="width:29.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AbbVie</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Eli Lilly</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novartis</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen</font></td><td colspan="3" style="padding:2px 1pt 2px 18.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GlaxoSmithKline</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pfizer</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Astra Zeneca</font></div><div style="margin-top:0.85pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:17.45pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Roche</font></div><div style="margin-top:0.85pt;padding-left:17.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sanofi-Aventis</font></td></tr></table></div><div style="margin-top:3.55pt;padding-left:10.8pt;padding-right:17.3pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.</font></div><div><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights&#59; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Unit Grantee</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grantee</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an eligible employee who receives a Performance Share Unit.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share Unit</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an award of Performance Shares as described in these Award Terms.</font></div><div style="padding-left:11pt;padding-right:17.25pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Appendix B.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Shares</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as &#8220;target&#8221; for the entire Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the change in value of one share of a company&#8217;s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR Performance Payout</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s TSR Performance as determined under paragraph B of Section III.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26pt">CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (&#8220;Termination of Employment&#8221;).</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:19.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Performance Metrics. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.</font></div><div><font><br></font></div><div style="margin-top:2.85pt;padding-left:49.5pt;text-indent:-38.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.7pt">TSR Performance Payout</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The TSR Performance Payout shall be determined as follows&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Company&#8217;s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%&#59; provided, however, that if the Company&#8217;s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.</font></div><div><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For example, if the Company&#8217;s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% &#91;100% + ((25% - 20%) x 5%)&#93;.</font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Company&#8217;s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points&#59; provided, however, that if such median exceeds the Company&#8217;s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">EPS Performance Payout. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The EPS Performance Payout shall be determined in accordance with the following performance schedule&#58;</font></div><div style="padding-left:6pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="padding-left:0.06pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="padding-left:0.06pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="padding-left:0.06pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 OriginalCo EPS </font></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.571%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt;text-indent:15.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $5.18</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$5.18 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$5.69 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6.03</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$6.38 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2020 through 2022 for OriginalCo and RemainCo </font></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.571%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt;text-indent:15.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $17.11</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$17.11 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$18.80 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$19.93</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$21.05 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:42pt;padding-right:90.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt">The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a &#8220;RemainCo Grantee&#8221;) or NewCo (a &#8220;NewCo Grantee&#8221;) on the Spin-Date and is subject to Article IX except as noted below.</font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:right"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Spin-Date is after January 1, 2020 and before December 31, 2021, </font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2020 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33&#160;percent.</font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;For NewCo Grantees, the Final Award will equal 100&#160;percent Target Shares.</font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50&#160;percent and (y) 2020 through 2022 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50&#160;percent. </font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.49pt">Maximum Award</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.99pt">DIVIDENDS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.44pt">TERMINATION OF EMPLOYMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">General Rule. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment is terminated during the Award Period before January 1, 2021 for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.</font></div><div style="padding-left:6pt;padding-right:13.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Retirement or Other Reason.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If the Grantee&#8217;s employment terminates for retirement or any other reason not specified in this Article V on or after January 1, 2021, then this PSU Award will continue and be distributable in </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">full at the time active Grantees receive distributions with respect to the Award Period based on the Final Award as if employment had continued.  </font></div><div style="padding-right:13.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Death. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If the Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B or E of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.</font></div><div style="padding-left:6pt;padding-right:18.15pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Misconduct. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee&#8217;s receipt of notice of such termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Disability. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.54pt">Joint Venture Service. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A transfer of the Grantee&#8217;s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-E above apply to this PSU Award while the Grantee is employed by the joint venture or other entity.</font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.99pt">DISTRIBUTION OF PERFORMANCE SHARES</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">General Rule. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from a Performance Share Unit before it is denominated in actual shares of Common Stock.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">Death. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the case of distribution on account of the Grantee&#8217;s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee&#8217;s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">Violation of Restrictive Covenants.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If the Grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.49pt">TRANSFERABILITY</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following the Grantee&#8217;s death.</font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:41.75pt;padding-right:12.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.99pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:6pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:44.75pt;text-indent:-38.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.74pt">ADMINISTRATIVE POWERS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to the Committee&#8217;s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:42pt;padding-right:22.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.49pt">CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS AND CERTAIN COMPLIANCE VIOLATIONS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">PSUs Subject to Clawback. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs, and any proceeds therefrom, are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.49pt">The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below)&#59; and</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.54pt">The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.05pt">&#8220;Executive&#8221; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.05pt">&#8220;Fault&#8221; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.05pt">Exclusions from Clawback. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.54pt">Compliance Violations. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div><font><br></font></div><div style="padding-left:41.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.99pt">CHANGE-IN-CONTROL</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon the occurrence of a Change-in-Control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Company terminates the Grantee&#8217;s employment for any reason other than Misconduct, as provided above (1) during the Award Period and (2) within two years following a Change-in-Control, the Final Award will be 100% and will be distributed when distributed to active Grantees.</font></div><div><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XII.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.44pt">SECTION 409A COMPLIANCE</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.</font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ida2e4236b5fa4018a27581f374991eec_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violation</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:0.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:9.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:11.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div><font><br></font></div><div style="padding-left:6pt;padding-right:12.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;padding-right:9.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback</font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Policy for PSUs Upon Significant Restatement of Financial Results.</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restrictive Covenants</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Compete.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee agrees that to the extent permitted by law, during his employment with the Company and&#47;or one of its affiliates and until December 31, 2022 (the &#8220;Restricted Period&#8221;) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that compete</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> with or upon commercialization will compete with any (a) product, technology&#160; or service developed,&#160; marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.&#160; Nothing herein will prohibit the Grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Solicit.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the Restricted Period, the Grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeiture</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Company determines that the Grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company&#8217;s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>12
<FILENAME>exhibit1030-2021annualceon.htm
<DESCRIPTION>EXHIBIT-10.30 2021 ANNUAL CEO NQSO TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5bd91874985b4aa3a33f86c8a85c2250_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.30</font></div><div style="text-align:right"><font><br></font></div><div style="padding-left:64.47pt;padding-right:64.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TERMS FOR</font></div><div style="margin-top:0.15pt;padding-left:128.77pt;padding-right:128.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">2021 STOCK OPTION CEO GRANT</font></div><div style="margin-top:0.15pt;padding-left:128.77pt;padding-right:128.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">UNDER THE </font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="margin-top:0.15pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-top:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:117%">This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CEO Grant</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Exercisable Date</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">Portion Becoming Exercisable</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Option Price&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$73.73</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 4, 2022</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">First&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 4, 2023</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Second&#58; 33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Expiration Date&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">November 30, 2027</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">May 4, 2024</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Balance</font></td></tr></table></div><div style="margin-top:0.15pt"><font><br></font></div><div style="text-indent:-9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.44pt">GENERAL INFORMATION</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:125%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards- grants&#47;) to accept the grant.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in forfeiture of the stock option.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div></td></tr></table></div><div style="padding-right:2.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II. The vesting and exercisability of this option is also subject to the Restrictive Covenants set forth in Appendix B.</font></div><div><font><br></font></div><div style="padding-right:2.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eligibility&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eligibility for grants is determined under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div><font><br></font></div><div style="padding-right:6.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subject to Recoupment, Forfeiture and Clawback</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; This Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time). </font></div><div style="padding-right:6.85pt"><font><br></font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:2.36pt">VESTING&#59; EXERCISE&#59; EMPLOYMENT TERMINATION</font></div><div><font><br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Vesting&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This option will vest in its entirety if your employment continues through September 30, 2021, or immediately if you die before then. <br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Exercisability.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This option will become exercisable in equal installments (subject to a rounding process) on the Exercisable Dates indicated in the accompanying box above. <br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.81pt">Termination</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any portion of this option that is vested will expire unless exercised before the New York Stock Exchange closes (the &#8220;Close of Business&#8221;) on the day before the fifth anniversary of the date your employment terminates </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">due to your retirement </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#8220;Termination Date&#8221;) but in no event after the Expiration Date. Close of Business for any day on which the New York Stock Exchange is not open means the close of business </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">prior </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to that date when the Exchange is open. <br></font></div><div style="padding-right:3.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.81pt">Misconduct. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.</font></div><div><font><br></font></div><div style="padding-right:1.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.26pt">Death. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. you die while any portion of this stock option remains outstanding, but after your employment terminates, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:1.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph C (and at least a year from your death in those jurisdictions where such extension is required by law).</font></div><div><font><br></font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.72pt">Change in Control. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination under Paragraph C. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A &#34;change in control&#34; has the same meaning that it has under the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div><font><br></font></div><div style="padding-right:12.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.34pt">Joint Venture. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a &#8220;JV&#8221;) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through F above apply to this stock option while the option holder is employed by the JV.</font></div><div style="padding-right:12.4pt"><font><br></font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:0.08pt"> TRANSFERABILITY</font></div><div style="margin-bottom:6pt;margin-top:0.05pt;padding-left:11pt;padding-right:15.3pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.</font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:35.18pt">ELECTRONIC ACCEPTANCE</font></div><div style="margin-bottom:6pt;padding-left:11.95pt;padding-right:5.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:1.46pt"> ADMINISTRATION</font></div><div style="margin-bottom:6pt;padding-left:11pt;padding-right:13.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="text-indent:-9.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:35.18pt">GRANTS NOT PART OF EMPLOYMENT CONTRACT</font></div><div style="margin-bottom:6pt;padding-left:11pt;padding-right:18.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:11pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">This stock option is subject to the provisions of the 2019 Incentive Stock Plan, including but not limited to choice of law. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:118%">For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.6pt"><font><br></font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">APPENDIX A</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">RECOUPMENT OF COMPENSATION FOR COMPLIANCE VIOLATIONS</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font><br></font></div><div style="padding-right:5.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:118%">POLICIES AND PROCEDURES</font></div><div style="padding-left:10.8pt;padding-right:5.75pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-right:1.9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:11pt;padding-right:1.9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:11pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:36pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:20.16pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:45.35pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-26.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.81pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:1.9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="margin-bottom:6pt;margin-top:0.4pt;padding-right:11.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek recoupment pursuant to this delegation.</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-bottom:6pt;margin-top:0.3pt;padding-right:12.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="margin-bottom:6pt;margin-top:0.3pt;padding-right:19.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.</font></div><div style="padding-right:1.9pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-right:5.6pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTIVE COVENANTS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You agree that to the extent permitted by law, during your employment with the Company and&#47;or one of its affiliates and until this Award is fully exercisable (the &#8220;Restricted Period&#8221;) you will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that compete</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> with or upon commercialization will compete with any (a) product, technology&#160; or service developed,&#160; marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by you to be in development by the Company or any of its Affiliates .&#160; Nothing herein will prohibit you from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the Restricted Period, you will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture. If the Company determines that you have violated the restrictive covenants set forth in this Appendix B, then you agree and covenant that any Unexercisable portion of this Award will be immediately forfeited. This remedy is not the Company&#8217;s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.</font></div><div style="padding-left:8.3pt;padding-right:8.3pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>13
<FILENAME>exhibit1031-2021annualpsut.htm
<DESCRIPTION>EXHIBIT-10.31 2021 ANNUAL PSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iba74a295f76f4f67a63f7f9d09353a41_1"></div><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.31</font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font><br></font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font><br></font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2021 PERFORMANCE SHARE UNIT AWARD TERMS</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNDER THE</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC. 2019 STOCK INCENTIVE PLAN</font></div><div style="padding-left:35.15pt;padding-right:35.15pt;text-align:center"><font><br></font></div><div style="padding-left:35.15pt;padding-right:35.15pt;text-align:center"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.240%"><div style="margin-top:0.5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.3pt">GENERAL. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These Performance Share Units (&#8220;PSUs&#8221;) are granted under and subject to the following Award Terms and the Merck &#38; Co., Inc. 2019 Stock Incentive Plan (the &#34;Merck ISP&#34;). The Company has announced its intention to spin-off (the &#8220;Spin-Off&#8221;) certain products into a new, independent, publicly traded company, Organon &#38; Co. (&#8220;NewCo&#8221;) during the first half of 2021 (&#8220;Spin-Date&#8221;). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the &#8220;Company.&#8221;</font></div></div><div style="display:inline-block;max-width:7.518%;min-width:6.518%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.242%"><div style="margin-top:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">PSU &#8211; Annual</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">March 31, 2021</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Award Period&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Jan. 1, 2021 &#8211; Dec. 31, 2023</font></td></tr></table></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div id="iba74a295f76f4f67a63f7f9d09353a41_4"></div></div></div><div style="margin-top:0.05pt;padding-left:5.4pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.</font></div></td></tr></table></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.64pt">DEFINITIONS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the purpose of these Award Terms&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Award Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three-year period commencing on January 1, 2021 and ending on December 31, 2023.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986 or any successor thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:22.85pt;text-indent:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings Per Share or EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:26.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates&#59; (2) the impact of significant unplanned acquisitions and&#47;or divestitures, extraordinary items and other unusual or non-recurring charges and&#47;or events&#59; (3) an event either not directly related to Company operations or not reasonably within the control of Company management&#59; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes&#59; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s EPS goal as determined under paragraph C of Section III.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Final Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of the Target described in Section III hereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date as of which a Performance Share Unit is granted.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:4.5pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Healthcare Companies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34; are the healthcare companies used by the Committee in evaluating the Company&#8217;s TSR Performance for the entire Award Period. For 2021 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.</font></div><div style="padding-left:0.06pt;padding-right:22.85pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.092%"><tr><td style="width:1.0%"></td><td style="width:26.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AbbVie</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Eli Lilly</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novartis</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen</font></td><td colspan="3" style="padding:2px 1pt 2px 18.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GlaxoSmithKline</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pfizer</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Astra Zeneca</font></div><div style="margin-top:0.85pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:17.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Roche</font></div><div style="margin-top:0.85pt;padding-left:17.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sanofi-Aventis</font></td></tr></table></div><div style="margin-top:3.55pt;padding-left:10.8pt;padding-right:17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.</font></div><div><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights&#59; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Unit Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an eligible employee who receives a Performance Share Unit.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an award of Performance Shares as described in these Award Terms.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as &#8220;target&#8221; for the entire Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the change in value of one share of a company&#8217;s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s TSR Performance as determined under paragraph B of Section III.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (&#8220;Termination of Employment&#8221;).</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:19.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.31pt">Performance Metrics. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.</font></div><div><font><br></font></div><div style="margin-top:2.85pt;padding-left:49.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.92pt">TSR Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The TSR Performance Payout shall be determined as follows&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Company&#8217;s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%&#59; provided, however, that if the Company&#8217;s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.</font></div><div><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For example, if the Company&#8217;s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% &#91;100% + ((25% - 20%) x 5%)&#93;.</font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Company&#8217;s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points&#59; provided, however, that if such median exceeds the Company&#8217;s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">EPS Performance Payout. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The EPS Performance Payout shall be determined in accordance with the following performance schedule&#58;</font></div><div style="padding-left:6pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="padding-left:0.06pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="padding-left:0.06pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021 OriginalCo EPS </font></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.667%"><tr><td style="width:1.0%"></td><td style="width:62.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.37pt;padding-right:18.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $5.98</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$5.98 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$6.58 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6.97</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$7.36 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021 through 2023 for OriginalCo and RemainCo </font></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.667%"><tr><td style="width:1.0%"></td><td style="width:62.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $20.66</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$20.66 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$22.70 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$24.06</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$25.42 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:42pt;padding-right:90.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.31pt">The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a &#8220;RemainCo Grantee&#8221;) or NewCo (a &#8220;NewCo Grantee&#8221;) on the Spin-Date and is subject to Article IX except as noted below.</font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:right"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Spin-Date is during 2021, </font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2021 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33&#160;percent.</font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;For NewCo Grantees, the Final Award will equal 100&#160;percent Target Shares.</font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50&#160;percent and (y) 2021 through 2023 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50&#160;percent. </font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Maximum Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">DIVIDENDS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.26pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-right:13.1pt;text-indent:18pt"><font><br></font></div><div style="padding-left:6pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">General Rule. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated during the Award Period for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Involuntary Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment terminates during the Award Period and the Company determines that employment was involuntarily terminated on or after the first anniversary of the first day of the Award Period, a pro rata portion (based on the number of completed months held during the Award Period prior to the date employment terminated) of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on actual performance during the Award Period as determined in accordance with Section III. The remainder will be forfeited on the date employment ends. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36. An &#8220;involuntary termination&#8221; includes termination of employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of duties and the reasons listed under paragraphs C through G of this section.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Sale. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated during the Award Period and the Company determines that such termination resulted from the sale of his or her subsidiary, division or joint venture, the following portion of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on the Final Award&#58; one third if employment terminates on or after the Grant Date but before the first anniversary of the Award Period thereof&#59; and all if employment terminates on or after the first anniversary of the first day of the Award Period. The remainder will be forfeited on the date a Grantee&#8217;s employment ends.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Retirement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee terminates employment during the Award Period by retirement (including early and disability retirement), then this PSU Award will continue and be distributable on a pro rata basis at the time active Grantees receive such distributions with respect to that Award Period based   on the Final Award. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36.  For Grantees who  are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other Grantees, &#8220;retirement&#8221; is determined by the Company.</font></div><div style="padding-left:6pt;padding-right:5.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Death. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If a Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B, C, D or G of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.</font></div><div style="padding-left:6pt;padding-right:18.15pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.54pt">Misconduct. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee&#8217;s receipt of notice of such termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.7pt">Disability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Grantee&#8217;s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then   this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.</font></div><div style="padding-right:12.55pt;text-indent:18pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.7pt">Joint Venture Service. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A transfer of a Grantee&#8217;s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-G above apply to this PSU Award while a Grantee is employed by the joint venture or other entity.</font></div><div style="padding-left:0.06pt;padding-right:12.55pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">DISTRIBUTION OF PERFORMANCE SHARES</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">General Rule. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from   a Performance Share Unit before it is denominated in actual shares of Common Stock.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Death. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the case of distribution on account of a Grantee&#8217;s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee&#8217;s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">TRANSFERABILITY</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following a Grantee&#8217;s death.</font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:41.75pt;padding-right:12.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:6pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:44.75pt;text-indent:-38.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.78pt">ADMINISTRATIVE POWERS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to the Committee&#8217;s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:42pt;padding-right:22.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.31pt">CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND CERTAIN COMPLIANCE VIOLATIONS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">PSUs Subject to Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs,  and any proceeds therefrom, are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.75pt">The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below)&#59; and</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt">The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.97pt">&#8220;Executive&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.36pt">&#8220;Fault&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.36pt">Exclusions from Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.97pt">Compliance Violations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">Change-in-Control</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon the occurrence of a change-in-control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Company terminates a Grantee&#8217;s employment except as described in Section V(F), (1) during the Award Period and (2) within two years following a change-in-control, the Final Award will be 100% and will be distributed when distributed to active Grantees.</font></div><div><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.7pt">SECTION 409A COMPLIANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.</font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iba74a295f76f4f67a63f7f9d09353a41_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violation</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:9.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:11.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div><font><br></font></div><div style="padding-left:6pt;padding-right:12.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;padding-right:9.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>14
<FILENAME>exhibit1032-2021annualceop.htm
<DESCRIPTION>EXHIBIT-10.32 2021 ANNUAL CEO PSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idb7d1d0753d4418dac9bc5282f6630c0_1"></div><div style="min-height:33.12pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.32</font></div></div><div style="padding-left:76.72pt;padding-right:76.72pt;text-align:center"><font><br></font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font><br></font></div><div style="padding-left:77.01pt;padding-right:77.01pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2021 CEO PERFORMANCE SHARE UNIT AWARD TERMS</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MERCK &#38; CO., INC. 2019 STOCK INCENTIVE PLAN</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.240%"><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt;padding-left:13.5pt;text-indent:-9.01pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:4.01pt">GENERAL. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These Performance Share Units (&#8220;PSUs&#8221;) are granted under and subject to the following Award Terms and the Merck &#38; Co., Inc. 2019 Stock Incentive Plan (the &#34;Merck ISP&#34;). The Company has announced its intention to spin-off (the &#8220;Spin-Off&#8221;) certain products into a new, independent, publicly traded company, Organon &#38; Co. (&#8220;NewCo&#8221;) during the first half of 2021 (&#8220;Spin-Date&#8221;). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the &#8220;Company.&#8221;</font></div></div><div style="display:inline-block;max-width:7.518%;min-width:6.518%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.242%"><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:102%">PSU &#8211;  CEO</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58; Award</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2021</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Period&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jan. 1, 2021 &#8211; Dec. 31, 2023</font></div></td></tr></table></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div id="idb7d1d0753d4418dac9bc5282f6630c0_4"></div></div></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.</font></div></td></tr></table></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:28.45pt">DEFINITIONS. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the purpose of these Award Terms&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Award Period</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three-year period commencing on January 1, 2021 and ending on December 31, 2023.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986 or any successor thereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:22.85pt;text-indent:2.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings Per Share or EPS</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:26.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates&#59; (2) the impact of significant unplanned acquisitions and&#47;or divestitures, extraordinary items and other unusual or non-recurring charges and&#47;or events&#59; (3) an event either not directly related to Company operations or not reasonably within the control of Company management&#59; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes&#59; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Performance Payout</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s EPS goal as determined under paragraph C of Section III.</font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Final Award</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of the Target described in Section III hereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date as of which a Performance Share Unit is granted.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:22.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Healthcare Companies</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34; are the healthcare companies used by the Committee in evaluating the Company&#8217;s TSR Performance for the entire Award Period. For 2021 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.</font></div><div style="padding-left:0.06pt;padding-right:22.85pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:22.85pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.983%"><tr><td style="width:1.0%"></td><td style="width:29.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AbbVie</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Eli Lilly</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pfizer</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 6.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amgen</font></td><td colspan="3" style="padding:2px 1pt 2px 18.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GlaxoSmithKline</font></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Roche</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Astra Zeneca</font></div><div style="margin-top:0.85pt;padding-left:5.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.85pt;padding-left:17.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></div><div style="margin-top:0.85pt;padding-left:17.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novartis</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:2px 1pt 2px 14.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sanofi-Aventis</font></td></tr></table></div><div style="margin-top:3.55pt;padding-left:10.8pt;padding-right:17.3pt"><font><br></font></div><div style="margin-top:3.55pt;padding-left:10.8pt;padding-right:17.3pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.</font></div><div><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights&#59; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Unit Grantee</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grantee</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an eligible employee who receives a Performance Share Unit.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share Unit</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an award of Performance Shares as described in these Award Terms.</font></div><div style="padding-left:11pt;padding-right:17.25pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Appendix B.</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Shares</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as &#8220;target&#8221; for the entire Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the change in value of one share of a company&#8217;s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR Performance Payout</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage of Target Shares to be paid out based upon the Company&#8217;s TSR Performance as determined under paragraph B of Section III.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:47pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:26pt">CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (&#8220;Termination of Employment&#8221;).</font></div><div><font><br></font></div><div style="padding-left:11pt;padding-right:19.85pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16pt">Performance Metrics. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.</font></div><div><font><br></font></div><div style="margin-top:2.85pt;padding-left:49.5pt;text-indent:-38.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.7pt">TSR Performance Payout</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The TSR Performance Payout shall be determined as follows&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Company&#8217;s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%&#59; provided, however, that if the Company&#8217;s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.</font></div><div><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For example, if the Company&#8217;s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% &#91;100% + ((25% - 20%) x 5%)&#93;.</font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Company&#8217;s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points&#59; provided, however, that if such median exceeds the Company&#8217;s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">EPS Performance Payout. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The EPS Performance Payout shall be determined in accordance with the following performance schedule&#58;</font></div><div style="padding-left:6pt;padding-right:25.5pt;text-align:right"><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021 OriginalCo EPS </font></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.571%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $5.98</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$5.98 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$6.58 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6.97</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$7.36 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2021 through 2023 for OriginalCo and RemainCo </font></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.571%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $20.66</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$20.66 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$22.70 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$24.06</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$25.42 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:3.55pt;padding-left:42pt;padding-right:90.8pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt">The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a &#8220;RemainCo Grantee&#8221;) or NewCo (a &#8220;NewCo Grantee&#8221;) on the Spin-Date and is subject to Article IX except as noted below.</font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:right"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Spin-Date is during 2021, </font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2021 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33&#160;percent.</font></div><div style="padding-left:15.5pt;padding-right:2pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;For NewCo Grantees, the Final Award will equal 100&#160;percent Target Shares.</font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:15.5pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50&#160;percent and (y) 2021 through 2023 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50&#160;percent. </font></div><div style="padding-left:15.5pt;padding-right:422.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.49pt">Maximum Award</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.99pt">DIVIDENDS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.44pt">TERMINATION OF EMPLOYMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">General Rule. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment is terminated during the Award Period before September 30, 2021 for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.</font></div><div style="padding-left:6pt;padding-right:13.1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Retirement or Other Reason.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If the Grantee&#8217;s employment terminates for retirement or any other reason not specified in this Article V on or after September 30, 2021, then this PSU Award will continue and be distributable in full at the time active Grantees receive distributions with respect to the Award Period based on the Final Award as if employment had continued.  </font></div><div style="padding-right:13.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Death. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If the Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B or E of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.</font></div><div style="padding-left:6pt;padding-right:18.15pt"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Misconduct. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee&#8217;s receipt of notice of such termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Disability. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Grantee&#8217;s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.54pt">Joint Venture Service. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A transfer of the Grantee&#8217;s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-E above apply to this PSU Award while the Grantee is employed by the joint venture or other entity.</font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.99pt">DISTRIBUTION OF PERFORMANCE SHARES</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">General Rule. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from a Performance Share Unit before it is denominated in actual shares of Common Stock.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">Death. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the case of distribution on account of the Grantee&#8217;s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee&#8217;s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">Violation of Restrictive Covenants.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If the Grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:42pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.49pt">TRANSFERABILITY</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following the Grantee&#8217;s death.</font></div><div style="padding-left:0.06pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:41.75pt;padding-right:12.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.99pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:6pt;padding-right:12.7pt"><font><br></font></div><div style="padding-left:6pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:44.75pt;text-indent:-38.75pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.74pt">ADMINISTRATIVE POWERS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to the Committee&#8217;s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:42pt;padding-right:22.6pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.49pt">CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS AND CERTAIN COMPLIANCE VIOLATIONS</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">PSUs Subject to Clawback. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs, and any proceeds therefrom, are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.49pt">The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below)&#59; and</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.54pt">The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.05pt">&#8220;Executive&#8221; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.05pt">&#8220;Fault&#8221; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:25.5pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.05pt">Exclusions from Clawback. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.54pt">Compliance Violations. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.99pt">CHANGE-IN-CONTROL</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon the occurrence of a Change-in-Control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Company terminates the Grantee&#8217;s employment for any reason other than Misconduct, as provided above (1) during the Award Period and (2) within two years following a Change-in-Control, the Final Award will be 100% and will be distributed when distributed to active Grantees.</font></div><div><font><br></font></div><div style="padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XII.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.44pt">SECTION 409A COMPLIANCE</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.65pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.</font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idb7d1d0753d4418dac9bc5282f6630c0_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violation</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-right:0.35pt"><font><br></font></div><div style="padding-right:0.35pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:9.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:11.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div><font><br></font></div><div style="padding-left:6pt;padding-right:12.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:22.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:10.05pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;padding-right:9.15pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback</font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Policy for PSUs Upon Significant Restatement of Financial Results.</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restrictive Covenants</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Compete.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee agrees that to the extent permitted by law, during his employment with the Company and&#47;or one of its affiliates and until December 31, 2022 (the &#8220;Restricted Period&#8221;) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that compete</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> with or upon commercialization will compete with any (a) product, technology&#160; or service developed,&#160; marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.&#160; Nothing herein will prohibit the Grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Solicit.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the Restricted Period, the Grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Forfeiture</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Company determines that the Grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company&#8217;s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>15
<FILENAME>exhibit1033-2021specialret.htm
<DESCRIPTION>EXHIBIT-10.33 2021 SPECIAL RETENTION RSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ieff43f642300406daa812c8f21c1ae06_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.33</font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TERMS FOR</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021 RETENTION RESTRICTED STOCK UNIT GRANTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., 2019 INCENTIVE STOCK PLAN</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document.  </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Different terms may apply to any prior or future RSU Awards.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.444%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">RSU </font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 4, 2021</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Vesting Date</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">May 4, 2024</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">100%</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Eligibility&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Eligibility for grants is determined under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck&#8217;s Board of Directors, or its delegate (the &#8220;Committee&#8221;).</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:31.28pt">GENERAL INFORMATION</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">  This grant requires you to affirmatively accept it.  You </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.  </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days.  Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Restricted Period.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">  The Restricted is the period during which this RSU Award is restricted and subject to forfeiture.  The Restricted Period begins on the Grant Date and ends on the third anniversary of the Grant Date unless ended earlier under Article II below.  No voting rights apply to this RSU Award.  No fractional shares will be awarded&#58;  all calculations are subject to rounding.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">  During the Restricted Period, dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock.  Payment of such dividends will be made, without interest or earnings, at the end of the Restricted Period.  If any portion of this RSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion.  Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Distribution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> Upon the expiration of the Restricted Period if you are then employed, you will be entitled to receive a number of shares of Merck common stock equal to the number of RSUs that have become unrestricted and the dividend equivalents that accrued on that portion. Prior to distribution, you must deliver to the Company an amount the Company determines to be sufficient to satisfy any amount required to be withheld, including applicable taxes. The Company may, in its sole discretion, withhold from the RSU Award distribution a number of shares to pay applicable withholding (including taxes).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">409A Compliance.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Internal Revenue Code or any successor thereto. Specifically, distributions made due to a separation from service (as defined in Section 409A) to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will not be made until administratively feasible following the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Subject to Recoupment. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">For employees in Band 600 and above, this RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:28.92pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">If your employment with the Company is terminated during the Restricted Period, your right to the RSU Award will be determined according to the terms in this Section II.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">General Rule</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Sale.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date. The remainder will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Involuntary Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. If the company determines that your employment is involuntarily terminated during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36. The remainder and any accrued dividends will be forfeited on the date your employment ends. An &#8220;involuntary termination&#8221; includes termination of your employment by the Company as the result of a restructuring or job </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">elimination, but excludes non-performance of your duties and the reasons listed under paragraphs B, or D through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment terminates by retirement during the Restricted Period, the unvested portion of this RSU Award and any accrued dividend equivalents will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.98pt">Death.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment terminates due to your death during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death. The pro rata portion will equal the full amount of this RSU Award times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36. The remainder and any accrued dividends will be forfeited on the date of your death.. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, G or H of this section, the remaining, non-forfeited portion of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:10.45pt">Misconduct.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.03pt">Disability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36. The remainder and any accrued dividends will be forfeited on the date your employment ends..</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:9.51pt">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. If the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary after the closing of any change in control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award. If this RSU does not remain outstanding following the change in control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck common stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire. Change in control is defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control), but if RSUs are considered &#8220;deferred compensation&#8221; under Section 409A of the Internal Revenue Code, the definition of change in control will be modified to the extent necessary to comply with Section 409A.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:13.28pt">Joint Venture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. Employment with a joint venture or other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-H above apply to this RSU Award while you are employed by the joint venture or other entity.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:26.56pt">TRANSFERABILITY</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This RSU Award is not transferable and may not be assigned or otherwise transferred.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:25.62pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:27.98pt">ADMINISTRATION</font></div><div><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%;padding-left:25.62pt">GRANTS NOT PART OF THE EMPLOYMENT CONTRACT</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program</font><font style="color:#0563c2;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Appendix</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Recoupment of Compensation for Compliance Violations</font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">POLICIES AND PROCEDURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Benefits Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment  of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products&#59; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">A &#8220;Material Policy Violation&#8221; is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:10.92pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and&#47;or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>16
<FILENAME>exhibit1034restrictedstock.htm
<DESCRIPTION>EXHIBIT-10.34 2022 EXECUTIVE CHAIRMAN RSU TERMS AND CONDITIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia01bc794a42546b0b8f47debd5209347_1"></div><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.34</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022 EXECUTIVE CHAIRMAN RESTRICTED STOCK UNIT GRANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.438%"><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:28.98pt">GENERAL.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Merck &#38; Co., Inc. (the &#8220;Company&#8221;) has granted to you the Restricted Stock Unit (&#8220;RSU&#8221;) award specified in this document (&#8220;RSU Award&#8221;) pursuant to the Merck &#38; Co., Inc. 2019 Incentive Stock Plan (the &#8220;Plan&#8221;).  This RSU Award is subject to the terms and conditions of the Plan and these Terms and Conditions (the &#8220;Terms&#8221;).  Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:7.122%;min-width:6.122%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.440%"><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.693%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">RSU - Annual</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">May 3, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">Vesting Date</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">May 3, 2023</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">100%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div style="padding-left:0.36pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.031%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  This grant requires you to affirmatively accept it.  You MUST log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.  </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days.  Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div></td></tr></table></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Restricted (Vesting) Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest.  The RSU Award will vest on May 3, 2023 as shown in the box above, except as otherwise provided in Article II below.  No voting rights apply to this RSU Award.  No fractional shares will be issued upon settlement of the RSU Award&#59; all calculations are subject to rounding.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock.  Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs.  If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion.  Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Distribution (Settlement of RSU Award).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion&#59; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a &#8220;change in control event&#8221; within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">409A Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a &#8220;separation from service (as defined in Section 409A)&#8221; and any such payment to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Subject to Recoupment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;padding-right:5.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.33pt">Violation of Restrictive Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If the grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.69pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (&#8220;JV&#8221;) of the Company by which you are employed (the &#8220;Employer&#8221;) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Retirement or Other Reason.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates by retirement or any other reason not specified in this Article II prior to July 1, 2022, the RSU Award will vest on the Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award (whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on January 1, 2022 and ending on the date employment terminates, and the denominator of which is 6. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. If your employment terminates by retirement or any other reason not specified in this Article II on or after July 1, 2022 and prior to the Vesting Date, the RSU Award will vest in full on the Vesting Date following your termination. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, or E, the RSU Award will immediately vest and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, or E of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Misconduct.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Date set forth in paragraph I(A) and dividend equivalents that have accrued through the corresponding Vesting Date.  If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">TRANSFERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">TAX WITHHOLDING</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regardless of any action the Company and&#47;or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (&#8220;Tax-Related Items&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and&#47;or the Employer, if any. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and&#47;or dividend equivalents&#59; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and&#47;or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and&#47;or any subsidiary, affiliate or JV of the Company&#59; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period&#59; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and&#47;or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">DATA PRIVACY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company&#8217;s data processing practices and declare your consent. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company&#8217;s legal basis for the processing of your personal data would be your consent.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company&#8217;s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company&#8217;s legal basis for the transfer of your personal data is your consent.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee&#59; you would merely forfeit the opportunities associated with the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.54pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and&#47;or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn&#58; Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.14pt">The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company&#8217;s Global Privacy and Data Protection Policy.  You also understand that the Company may, in the future, request you to provide another data privacy consent.&#160; If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.&#160; You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and&#47;or the Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you agree with the data processing practices described in this Article, you will declare your consent by clicking to &#34;Accept&#34; these Terms on the Morgan Stanley website.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">GOVERNING LAW</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">SEVERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">WAIVER</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">ADMINISTRATION</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia01bc794a42546b0b8f47debd5209347_7"></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="padding-left:74.45pt;padding-right:74.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Management Development Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company&#59; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">In addition, awards under the Executive Incentive Plan (&#8220;EIP&#8221;) and Performance Share Units (&#8220;PSU&#8221;) under the Merck &#38; Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company&#8217;s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">A &#8220;Material Violation&#8221; is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company&#8217;s overall goodwill or reputation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Executive&#8221; means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Fault&#8221; means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">For Compliance Violations</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">Chief Executive Officer.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking </font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">For EIP Awards and PSUs Upon Significant Restatement of Financial Results </font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EIP Awards and PSUs for Executives are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above)&#59; and</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the </font></div></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee shall have sole discretion to make all determinations under this policy.  Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the &#8220;Applicable Rules&#8221;).  To the extent the Applicable Rules require recovery of any bonus and&#47;or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.</font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia01bc794a42546b0b8f47debd5209347_16"></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restrictive Covenants</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Non-Compete.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The grantee agrees that to the extent permitted by law, during his employment with the Company and&#47;or one of its affiliates and until May 3, 2023 (the &#8220;Restricted Period&#8221;) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that compete</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> with or upon commercialization will compete with any (a) product, technology&#160; or service developed,&#160; marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.&#160; Nothing herein will prohibit the grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Non-Solicit.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">During the Restricted Period, the grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Forfeiture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">.  If the Company determines that the grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company&#8217;s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.</font></div><div><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia01bc794a42546b0b8f47debd5209347_19"></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TERMS AND CONDITIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022 EXECUTIVE CHAIRMAN RESTRICTED STOCK UNIT GRANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.438%"><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:28.98pt">GENERAL. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Merck &#38; Co., Inc. (the &#8220;Company&#8221;) has granted to you the Restricted Stock Unit (&#8220;RSU&#8221;) award specified in this document (&#8220;RSU Award&#8221;) pursuant to the Merck &#38; Co., Inc. 2019 Incentive Stock Plan (the &#8220;Plan&#8221;).  This RSU Award is subject to the terms and conditions of the Plan and these Terms and Conditions (the &#8220;Terms&#8221;).  Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.</font></div><div style="text-indent:-18.01pt"><font><br></font></div></div><div style="display:inline-block;max-width:7.122%;min-width:6.122%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.440%"><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">RSU - Annual</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">August 3, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Vesting Date</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">August 3, 2023</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:13.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">100%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.031%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">  This grant requires you to affirmatively accept it.  You MUST log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days.  Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div></td></tr></table></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Restricted (Vesting) Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest.  The RSU Award will vest on August 3, 2023 as shown in the box above, except as otherwise provided in Article II below.  No voting rights apply to this RSU Award.  No fractional shares will be issued upon settlement of the RSU Award&#59; all calculations are subject to rounding.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock.  Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs.  If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion.  Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Distribution (Settlement of RSU Award).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion&#59; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a &#8220;change in control event&#8221; within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">409A Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a &#8220;separation from service (as defined in Section 409A)&#8221; and any such payment to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Subject to Recoupment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;padding-right:5.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.33pt">Violation of Restrictive Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If the grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.69pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (&#8220;JV&#8221;) of the Company by which you are employed (the &#8220;Employer&#8221;) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Retirement or Other Reason.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates by retirement or any other reason not specified in this Article II prior to January 1, 2023, the RSU Award will vest on the Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award (whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on July 1, 2022 and ending on the date employment terminates, and the denominator of which is 6. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. If your employment terminates by retirement or any other reason not specified in this Article II on or after January 1, 2023 and prior to the Vesting Date, the RSU Award will vest in full on the Vesting Date following your termination. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, or E, the RSU Award will immediately vest and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, or E of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Misconduct.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Date set forth in paragraph I(A) and dividend equivalents that have accrued through the corresponding Vesting Date.  If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">TRANSFERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">TAX WITHHOLDING</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regardless of any action the Company and&#47;or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (&#8220;Tax-Related Items&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and&#47;or the Employer, if any. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and&#47;or dividend equivalents&#59; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and&#47;or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and&#47;or any subsidiary, affiliate or JV of the Company&#59; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period&#59; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and&#47;or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">DATA PRIVACY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company&#8217;s data processing practices and declare your consent. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.14pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company&#8217;s legal basis for the processing of your personal data would be your consent.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company&#8217;s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company&#8217;s legal basis for the transfer of your personal data is your consent.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee&#59; you would merely forfeit the opportunities associated with the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and&#47;or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn&#58; Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.54pt">The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company&#8217;s Global Privacy and Data Protection Policy.  You also understand that the Company may, in the future, request you to provide another data privacy consent.&#160; If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.&#160; You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and&#47;or the Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you agree with the data processing practices described in this Article, you will declare your consent by clicking to &#34;Accept&#34; these Terms on the Morgan Stanley website.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">GOVERNING LAW</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">SEVERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">WAIVER</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">ADMINISTRATION</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program </font></div><div style="margin-bottom:0.12pt;padding-left:5.95pt;text-indent:36pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia01bc794a42546b0b8f47debd5209347_25"></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="padding-left:74.45pt;padding-right:74.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Management Development Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company&#59; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">In addition, awards under the Executive Incentive Plan (&#8220;EIP&#8221;) and Performance Share Units (&#8220;PSU&#8221;) under the Merck &#38; Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company&#8217;s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">A &#8220;Material Violation&#8221; is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company&#8217;s overall goodwill or reputation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Executive&#8221; means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Fault&#8221; means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">For Compliance Violations</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its </font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">For EIP Awards and PSUs Upon Significant Restatement of Financial Results </font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EIP Awards and PSUs for Executives are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above)&#59; and</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy </font></div></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee shall have sole discretion to make all determinations under this policy.  Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the &#8220;Applicable Rules&#8221;).  To the extent the Applicable Rules require recovery of any bonus and&#47;or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.</font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia01bc794a42546b0b8f47debd5209347_34"></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restrictive Covenants</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Non-Compete.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The grantee agrees that to the extent permitted by law, during his employment with the Company and&#47;or one of its affiliates and until August 3, 2023 (the &#8220;Restricted Period&#8221;) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that compete</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> with or upon commercialization will compete with any (a) product, technology&#160; or service developed,&#160; marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.&#160; Nothing herein will prohibit the grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Non-Solicit.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">During the Restricted Period, the grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Forfeiture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">.  If the Company determines that the grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company&#8217;s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>17
<FILENAME>exhibit1035-2022annualrsut.htm
<DESCRIPTION>EXHIBIT-10.35 2022 ANNUAL RSU TERMS AND CONDITIONS (GUINDO)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib9ed136e185147f8944f69ff6ebf51e3_1"></div><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.35</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLOBAL TERMS AND CONDITIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022 RESTRICTED STOCK UNIT GRANT FOR CHIRFI GUINDO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.438%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:28.98pt">GENERAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Merck &#38; Co., Inc. (the &#8220;Company&#8221;) has granted to you the Restricted Stock Unit (&#8220;RSU&#8221;) award specified in this document (&#8220;RSU Award&#8221;) pursuant to the Merck &#38; Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the &#8220;Plan&#8221;).  This RSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the &#8220;Terms&#8221;).  Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.</font></div></div><div style="display:inline-block;max-width:7.122%;min-width:6.122%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.440%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.693%"><tr><td style="width:1.0%"></td><td style="width:40.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Grant Type&#58;</font></td><td colspan="3" style="border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">RSU - Annual</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Grant Date&#58;</font></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">August 3, 2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">Vesting Dates</font></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">Portion that Vests</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">August 3, 2023</font></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">First&#58;  33.333%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">August 3, 2024</font></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Second&#58;  33.333%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">August 3, 2025</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Third&#58;  Balance</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div style="padding-left:54pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.992%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This grant requires you to affirmatively accept it.  You MUST log onto the Morgan Stanley website at (http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.  </font></div><div style="padding-left:56.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:-0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days.  Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.</font></div></td></tr></table></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Restricted (Vesting) Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest.  The RSU Award will vest with respect to one-third of this RSUs subject to the RSU Award on each of the First, Second, and Third anniversaries of the Grant Date (each a &#8220;Vesting Date&#8221;) as shown in the box above, except as otherwise provided in Article II below.  No voting rights apply to this RSU Award.  No fractional shares will be issued upon settlement of the RSU Award&#59; all calculations are subject to rounding.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (&#8220;you&#8221;) if and to the extent dividends are paid by the Company on Merck Common Stock.  Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs.  If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion.  Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Distribution (Settlement of RSU Award).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion&#59; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a &#8220;change in control event&#8221; within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">409A Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a &#8220;separation from service (as defined in Section 409A)&#8221; and any </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such payment to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Subject to Recoupment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.69pt">TERMINATION OF EMPLOYMENT</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (&#8220;JV&#8221;) of the Company by which you are employed (the &#8220;Employer&#8221;) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II and for grantees outside the United States, also in paragraph 12 of Section A (&#8220;Nature of Grant&#8221;) of Appendix B, Part I.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Involuntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If the Company determines that your employment is involuntarily terminated during the Restricted Period, the RSU Award, any any accrued dividends, will continue to vest on the following original Vesting Date(s), as set forth in paragraph I(A), provided you sign and refraining from revoking a severance agreement in a format prescribed by the Company, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as the Company provides. If the Company determines that your employment is involuntarily terminated during the Restricted Period and you do not sign and refrain from revoking a severance agreement as outlined above, and you are involuntarily terminated on or after the first anniversary of the Grant Date, the RSU Award will vest on the next subsequent Vesting Date following your employment termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to the RSU Award (whether or not vested), multiplied by (ii) a fraction, numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion, if any, of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. An &#8220;involuntary termination&#8221; includes termination of your employment by the Company or the Employer, as applicable, as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs C through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Sale.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the RSU Award, and any accrued dividends, will continue to vest on the following original Vesting Date(s) set forth in paragraph I(A). Notwithstanding the foregoing, the Committee may determine, for purposes of this RSU Award, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this RSU Award.  .</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Retirement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates by retirement during the Restricted Period, the RSU Award will vest on the next subsequent Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending on the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.54pt">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, C, D, G or H, the RSU Award will immediately vest with respect to any portion of this RSU Award that has not vested as of your death and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.14pt">Misconduct.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date.  If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If this RSU Award is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Restricted Period without Cause before the second anniversary of the closing of the Change in Control, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of the RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If this RSU Award does not remain outstanding following the Change in Control and is not converted into a successor RSU, then the RSU Award will immediately vest with respect to the portion of the RSU Award that is unvested as of the Change in Control and dividend equivalents that have accrued though such date and, at the election of the Company, you will be entitled to receive cash for such portion of this RSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. &#8220;Cause&#8221; and &#8220;Change in Control&#8221; are defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.59pt">Transfer of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the &#8220;Company Group&#8221;) is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this RSU Award following a transfer of employment accordance with this section.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.97pt">Good Reason. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment is terminated for Good Reason, the RSU Award, and any accrued dividends, will continue to vest on the following original Vesting Date(s), as set forth in paragraph I(A), provided you sign and refraining from revoking a severance agreement in a format prescribed by the Company, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as the Company provides. &#8220;Good Reason&#8221; is defined to include the following&#58;  a) a material reduction in base salary without your consent, unless such reduction is part of an across-the-board reduction </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">affecting other Executive Team members in like proportions, b) your involuntary reassignment to any position other than a position on the Executive Team reporting to the Company&#8217;s Chief Executive Officer within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, or c) a material breach of this letter, provided that you deliver written notice of a claim of Good Reason to the Company&#8217;s Chief Executive Officer within thirty (30) days of the facts giving rise to such Good Reason, MSD fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after MSD&#8217;s failure to cure.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">TRANSFERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">TAX WITHHOLDING</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regardless of any action the Company and&#47;or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (&#8220;Tax-Related Items&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and&#47;or the Employer, if any. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and&#47;or dividend equivalents&#59; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and&#47;or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and&#47;or any subsidiary, affiliate or JV of the Company&#59; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period&#59; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and&#47;or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">DATA PRIVACY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company&#8217;s data processing practices and declare your consent. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company&#8217;s legal basis for the processing of your personal data would be your consent.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company&#8217;s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company&#8217;s legal basis for the transfer of your personal data is your consent.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee&#59; you would merely forfeit the opportunities associated with the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.54pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and&#47;or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn&#58; Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.14pt">The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company&#8217;s Global Privacy and Data Protection Policy.  You also understand that the Company may, in the future, request you to provide another data privacy consent.&#160; If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.&#160; You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and&#47;or the Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you agree with the data processing practices described in this Article, you will declare your consent by clicking to &#34;Accept&#34; these Terms on the Morgan Stanley website.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">GOVERNING LAW</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">SEVERABILITY</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">WAIVER</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">COUNTY-SPECIFIC APPENDIX</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The RSU Award shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of the RSU Award, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">ADMINISTRATION</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program </font></div><div style="margin-bottom:0.12pt;padding-left:5.95pt;text-indent:36pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib9ed136e185147f8944f69ff6ebf51e3_7"></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="padding-left:74.45pt;padding-right:74.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Management Development Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company&#59; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">In addition, awards under the Executive Incentive Plan (&#8220;EIP&#8221;) and Performance Share Units (&#8220;PSU&#8221;) under the Merck &#38; Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company&#8217;s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">A &#8220;Material Violation&#8221; is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company&#8217;s overall goodwill or reputation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Executive&#8221; means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Fault&#8221; means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">For Compliance Violations</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its </font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">For EIP Awards and PSUs Upon Significant Restatement of Financial Results </font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EIP Awards and PSUs for Executives are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above)&#59; and</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy </font></div></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee shall have sole discretion to make all determinations under this policy.  Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the &#8220;Applicable Rules&#8221;).  To the extent the Applicable Rules require recovery of any bonus and&#47;or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion</font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib9ed136e185147f8944f69ff6ebf51e3_16"></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS FOR GRANTEES OUTSIDE THE U.S.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix, which is part of the Global Terms and Conditions for 2022 Restricted Stock Unit Grants under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan, contains additional &#8220;terms and conditions&#8221; that will apply to you if you reside outside the United States.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The terms and conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Part I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> of this Appendix apply to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">grantees who reside outside the United States.  The additional terms and conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Part II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> of this Appendix will also apply to you if you reside in one of the countries referenced in Part II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The information in this Appendix is based on the laws in effect in the respective countries as of March 1, 2022.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the information in this Appendix&#160;B as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that the Restricted Period lapses and shares of Common Stock are issued to you or you sell shares of Common Stock acquired under the Plan.  </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the information contained in this Appendix is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finally, if you are a citizen or resident of a country, or are considered a resident of a country, other than that in which you are currently working, or transfer residence and&#47;or employment after the Grant Date, the information contained herein may not apply to you in the same manner.  The Company shall, in its sole discretion, determine to what extent the terms and conditions included herein will apply under these circumstances.</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX B - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PART I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; ADDITIONAL TERMS AND CONDITIONS FOR ALL COUNTRIES OUTSIDE OF THE UNITED STATES</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following additional terms and conditions will apply to you if you reside in any country outside the United States.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Nature of Grant</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accepting the RSU Award, you acknowledge and agree that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended, or terminated by the Company at any time&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the grant of the RSU Award is exceptional, voluntary, and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">all decisions with respect to future RSU grants, if any, will be at the sole discretion of the Company&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">your participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">your participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company and shall not interfere with the ability of the Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the RSU Award and any shares of Common Stock acquired under the Plan, and income from and value of same, are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Employer, the Company, or any subsidiary, affiliate or JV of the Company, and that are outside the scope of your employment or service contract, if any&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">unless otherwise agreed with the Company in writing, the RSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of a subsidiary, affiliate or JV of the Company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the RSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the RSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any subsidiary, affiliate or JV of the Company&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">the future value of the shares of Common Stock underlying the RSU is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">no claim or entitlement to compensation or damages shall arise from termination of the RSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">for purposes of the RSU Award, your employment relationship will be considered terminated as of the date you are no longer providing services to the Employer or the Company or any subsidiary, affiliate or JV (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in the Terms, your right to vest in the RSU under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period or any period of &#8220;garden leave&#8221; or similar period mandated under local law&#59; the Committee shall have the exclusive discretion to determine when you are no longer providing services for purposes of the </font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">grant (including whether you may still be considered to be providing services while on a leave of absence)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">the RSU Award and the benefits under the Plan, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">the Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendation regarding your participation in the Plan, or the acquisition or sale of underlying shares&#59; you should consult with your personal tax, legal and financial advisors regarding the decision to participate in the Plan and before taking any action related to the Plan&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">neither the Employer, nor the Company or any subsidiary, affiliate or JV shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the RSU Award or any amounts due to you pursuant to the vesting of the RSU Award, the subsequent sale of shares acquired under the Plan or the receipt of any dividends and&#47;or dividend equivalents.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Insider Trading&#47;Market Abuse Laws</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that, depending on your or your broker&#8217;s country of residence or where shares of Common Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., RSUs) or rights linked to the value of shares of Common Stock under the Plan during such times that you are considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws or regulations in the applicable jurisdictions or your country).  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. You should keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You understand you are responsible for ensuring compliance with any restrictions and should consult with your personal legal advisor on this matter.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Foreign Asset&#47;Account, Exchange Control and Tax Obligations</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that, depending on your country, you may be subject to foreign asset&#47;account, exchange control and&#47;or tax reporting requirements as the result of the acquisition of shares of Common Stock or cash (including dividend equivalents, dividends, and the proceeds of the sale of shares of Common Stock) derived from your participation in the Plan, in, to and&#47;or from a brokerage&#47;bank account or legal entity located outside your country. The applicable laws of your country may require that you report such accounts, assets, the balances therein, the value thereof and&#47;or the transactions related thereto to the applicable authorities in your country. You may also be required to repatriate cash received from participating in the Plan to your country within a certain time after receipt. You acknowledge that you are responsible for ensuring compliance with any applicable foreign asset&#47;account, exchange control and tax reporting requirements and should consult your personal tax, legal and&#47;or financial advisors regarding the same.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.31pt">Language</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that you are proficient in the English language or have consulted with an advisor who is sufficiently proficient, to allow you to understand the terms and conditions of this document. If you have received this document, or any other document related to the RSU Award and&#47;or the Plan translated into a language other than English, and if the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:7.92pt">Imposition of Other Requirements and Issuance of Shares</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company reserves the right to impose other requirements on this RSU Award and the shares of Common Stock acquired pursuant to the RSU Award, to the extent the Company determines it is necessary or advisable to comply with local laws or facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In particular, if advisable due to local law requirements, the Committee, in its sole and absolute discretion, may require the immediate forced sale of the shares of Common Stock issuable upon vesting of the RSUs.  Alternatively, unless otherwise set forth in this Appendix, the Committee, in its sole and absolute discretion, may determine to pay out the RSUs in cash equal to the fair market value of the shares of Common Stock underlying the RSUs.</font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX B - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PART II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; COUNTRY-SPECIFIC ADDITIONAL TERMS AND CONDITIONS AND NOTIFICATIONS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Country</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Additional Terms and Conditions and Notifications</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Algeria</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Argentina</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neither the Award nor the underlying shares of Common Stock are publicly offered, listed on any stock exchange in Argentina or registered with the Argentine Securities Commission (Comisi&#243;n Nacional de Valores).  </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgement</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision supplements the &#8220;Nature of Grant&#8221; section in Part I of this Appendix B&#58;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accepting the grant of the RSU Award, you acknowledge and agree that the grant of the RSU Award is made by the Company, not the Employer, in its sole discretion and the value of any RSU Award and shares of Common Stock acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law, including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, or (ii) any termination or severance indemnities. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If, notwithstanding the foregoing, any benefits under the Plan are considered as salary or wages for any purpose under Argentine labor law, you acknowledge and agree that such benefits shall not accrue more frequently than on an annual basis.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Australian Offer Document</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer document sets out information regarding the offer to participate in the Plan for Australian resident grantees of the Company and its subsidiaries, affiliates and JVs.  This information is provided by the Company to ensure compliance of the offer with Australian Securities and Investments Commission (&#8220;ASIC&#8221;) Class Order 14&#47;1000, ASIC Regulatory Guide 49 and relevant provisions of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Corporations Act 2001</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to the information set out in this Appendix B, you are also being provided with copies of the following documents&#58; </font></div><div style="padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the Plan&#59;</font></div><div style="padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the Plan Prospectus (which contains a summary of the Plan)&#59; </font></div><div style="padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;the Terms&#59;</font></div><div style="padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;LTI Program Overview&#59; and</font></div><div style="margin-bottom:12pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the summary of tax consequences of participation in the Plan for Australia, which is accessible by logging into your account at Morgan Stanley</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(collectively, the &#8220;Additional Documents&#8221;).</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Additional Documents provide further information to help you make an informed investment decision about participating in the Plan.  Neither the Plan nor the Plan Prospectus is a prospectus for the purposes of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Corporations Act 2001</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You should not rely upon any oral statements made in relation to this offer. You should rely only upon the statements contained in this Appendix B and the Additional Documents when considering participation in the Plan.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">General Information Only</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The information herein is general information only. It is not advice or information that takes into account your objectives, financial situation and needs.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You should consider obtaining your own financial product advice from a person who is licensed by ASIC to give such advice.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Risks of Participation in the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Investment in shares of Common Stock involves a degree of risk.  If you elect to participate in the Plan, you should monitor your participation and consider all risk factors relevant to the vesting or issuance of shares of Common Stock under the Plan as set forth below and in the Additional Documents</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You should have regard to risk factors relevant to investment in securities generally and, in particular, to holding shares of Common Stock of the Company.  For example, the value at which an individual share of Common Stock is quoted on the New York Stock Exchange (&#8220;NYSE&#8221;) may increase or decrease due to a number of factors.  There is no guarantee that the value of a share of Common Stock will increase.  Factors that may affect the value of an individual share of Common Stock include fluctuations in the domestic and international market for listed stocks, general economic conditions, including interest rates, inflation rates, commodity and oil prices, changes to government fiscal, monetary or regulatory policies, legislation or regulation, the nature of the markets in which the Company operates and general operational and business risks.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">More information about potential factors that could affect the Company&#8217;s business and financial results will be included in the Company&#8217;s most recent Annual Report on Form 10-K and the Company&#8217;s Quarterly Report on Form 10-Q.  Copies of these reports are available at http&#58;&#47;&#47;www.sec.gov&#47;, on the Company&#8217;s &#8220;Investor Relations&#8221; page at https&#58;&#47;&#47;investors.merck.com&#47;home&#47;default.aspx, and upon request to the Company.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, you should be aware that the Australian dollar (&#8220;AUD&#8221;) value of any shares of Common Stock acquired under the Plan will be affected by the USD&#47;AUD exchange rate.  Participation in the Plan involves certain risks related to fluctuations in this rate of exchange.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock in a U.S. Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Common stock of a U.S. corporation is analogous to ordinary shares of an Australian corporation.  Each holder of a share of Common Stock is entitled to one vote.  Further, shares of Common Stock are not liable to any further calls for payment of capital or for other assessment by the Company and have no sinking fund provisions, pre-emptive rights, conversion rights or redemption provisions.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ascertaining the Market Value of Shares of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You may ascertain the current market value of an individual share of Common Stock as traded on the NYSE under the symbol &#8220;MRK&#8221; at&#58; https&#58;&#47;&#47;www.nyse.com&#47;quote&#47;XNYS&#58;MRK.  The AUD equivalent of that value can be obtained at&#58; https&#58;&#47;&#47;www.rba.gov.au&#47;statistics&#47;frequency&#47;exchange-rates.html. </font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">This will not be a prediction of the market value of an individual share of Common Stock when the RSU Award vests or shares of Common Stock are issued under the Plan or of the applicable exchange rate on the vesting date or the date the shares of Common Stock are issued.</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Information</font></div><div style="margin-bottom:6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;Tax Assessment Act&#8221;) applies (subject to the conditions in the Tax Assessment Act).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Austria</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Belgium</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Bermuda</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan and the Terms, including this Appendix B, are not subject to, and have not received approval from either the Bermuda Monetary Authority or the Registrar of Companies in Bermuda and no statement to the contrary, explicit or implicit, is authorized to be made in this regard.  If any shares of Common Stock acquired under the Plan are offered or sold in Bermuda, the offer or sale must comply with the provisions of the Investment Business Act 2003 of Bermuda.  Alternatively, the shares may be sold on the New York Stock Exchange on which they are listed.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance with Law</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the expiration of the Restricted Period, the sale of shares obtained pursuant to the expiration of the Restricted Period, and the receipt of any dividends or dividend equivalents.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgment </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you agree that you are (i) making an investment decision and (ii) the value of the underlying shares of Common Stock is not fixed and may increase or decrease in value over the Restricted Period without compensation to you.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Further, you acknowledge and agree that, for all legal purposes, (i) any benefits provided to you under the Plan are unrelated to your employment or service&#59; (ii) the Plan is not a part of the terms and conditions of your employment or service&#59; and (iii) the income from your participation in the Plan, if any, is not part of your remuneration from employment or service.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Bulgaria</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination of Employment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision replaces paragraph (9) of the &#8220;Nature of Grant&#8221; section in Part I of this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except to the extent explicitly required under local employment standards legislation, the RSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any parent, subsidiary, affiliate or JV of the Company&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision replaces paragraph (11) of the &#8220;Nature of Grant&#8221; section in Part I of this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except to the extent explicitly required under local employment standards legislation, no claim or entitlement to compensation or damages shall arise from termination of the RSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision replaces paragraph (12) of the &#8220;Nature of Grant&#8221; section in Part I of this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of the RSU Award, except to the extent expressly provided in your Terms or expressly required by applicable legislation, your employment relationship will be considered terminated (regardless of the reason for such termination) and your right to vest in the RSU Award under the Plan, if any, will terminate as of the date that is the earliest of (a) the date you are no longer employed or providing services to the Company or any parent, subsidiary, affiliate or JV, (b) the date you receive written notice of termination of employment, or (c) the date written notice of termination is delivered to your last known address (together, the &#8220;Termination Date&#8221;).  Except to the extent explicitly required by applicable legislation, the Termination Date will exclude any notice period or period of pay in lieu of such notice required under statute, contract, common&#47;civil law or otherwise. You will not earn, or be entitled to earn, any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. In case of any dispute as to whether termination of employment has occurred that cannot be reasonably determined under your Terms and the Plan, the Committee shall have the sole discretion, subject to applicable legislation, to determine whether such termination of employment has occurred and the effective date of such termination. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the RSU Award under the Plan, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You are permitted to sell shares of Common Stock acquired through the Plan through the broker designated by the Company under the Plan, if any, provided the resale of shares of Common Stock acquired under the Plan takes place outside of Canada through the facilities of a stock exchange on which the shares of Common Stock are listed.  The shares are currently listed on the New York Stock Exchange.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of Common Stock only. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The following provisions will apply to you if you are a resident of Quebec&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Consent</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that the Terms, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de la convention, ainsi que de tous documents ex&#233;cut&#233;s, avis donn&#233;s et proc&#233;dures judiciaries intent&#233;es, directement ou indirectement, relativement &#224; ou suite &#224; la pr&#233;sente convention.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Privacy</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision supplements the &#8220;Data Privacy&#8221; section in the Terms&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, and its subsidiaries, affiliates or JVs and Morgan Stanley Smith Barney and any other stock plan service provider that may be selected by the Company to assist with the Plan to disclose and discuss the Plan with their respective advisors.  You further authorize the Company and its subsidiaries, affiliates and JVs to record such information and to keep such information in your employee file.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Chile</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE OFFER OF THE RSU AWARD CONSTITUTES A PRIVATE OFFERING OF SECURITIES IN CHILE EFFECTIVE AS OF THE GRANT DATE.  THE OFFER OF THE RSU AWARD IS MADE SUBJECT TO GENERAL RULING N&#176; 336 OF THE CHILEAN COMMISSION OF THE FINANCIAL MARKET (&#8220;CMF&#8221;).  THE OFFER REFERS TO SECURITIES NOT REGISTERED AT THE SECURITIES REGISTRY OR AT THE FOREIGN SECURITIES REGISTRY OF THE CMF, AND, THEREFORE, SUCH SECURITIES ARE NOT SUBJECT TO OVERSIGHT OF THE CMF.  GIVEN THAT THE RSU AWARD IS NOT REGISTERED IN CHILE, THE COMPANY IS NOT REQUIRED TO PROVIDE PUBLIC INFORMATION ABOUT THE RSU AWARD OR SHARES OF COMMON STOCK IN CHILE.  UNLESS THE RSU AWARD AND&#47;OR THE SHARES OF COMMON STOCK ARE REGISTERED WITH THE CMF, A PUBLIC OFFERING OF SUCH SECURITIES CANNOT BE MADE IN CHILE.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">The People's Republic of China</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The following terms and conditions apply only to grantees who are citizens of the PRC or are otherwise determined to be subject to the requirements imposed by the State Administration of Foreign Exchange (&#8220;SAFE&#8221;) as determined by the Company.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">The following terms and conditions apply only if you are classified as Band 600 and higher on the Grant Date. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award and Termination of Employment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be permitted to hold shares of Common Stock issued to you at the end of the Restricted Period.  Notwithstanding anything to the contrary in the Plan or Terms, due to exchange control laws in China, you agree that any shares of Common Stock acquired under the Plan and held by you at the time of your termination of employment with the Company or the Employer will be sold on your behalf, pursuant to this authorization, as soon as administratively practicable following the termination of your employment, but no later than six-months following termination of employment.  The Company is under no obligation to arrange for such sale at any particular price.  You will receive the sale proceeds, less any broker&#8217;s fees or commissions and subject to satisfaction of any Tax-Related Items.  If the Terms provide that all or a portion of your outstanding RSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and be sold on your behalf as described above.  Any other portion of your RSU Award that is not vested as described above will expire immediately upon your termination of employment.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Due to local regulatory requirements, you agree that the Company may force the sale of any shares of Common Stock issued under the Plan.  The sale may occur (i) immediately upon vesting or (ii) within any other time frame as the Company determines to be necessary or advisable for legal or administrative reasons.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Broker Account</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any shares of Common Stock issued to you at expiration of the Restricted Period must be maintained in an account with Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future until the shares of Common Stock are sold through that broker.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exchange Control Compliance</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand and agree that, to comply with exchange control laws in the PRC, any cash dividends, dividend equivalents and the proceeds from the sale of the shares of Common Stock will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you.  The funds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and&#47;or the Company so that the funds may be deposited into this account.  In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China.  You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">The following terms and conditions apply only if you are classified as below Band 600 on the Grant Date. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To facilitate compliance with exchange control laws in China, any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at expiration of the Restricted Period, less any broker&#8217;s fees or commissions and Tax-Related Items, which will be remitted to you in accordance with applicable exchange control laws and regulations.  You will not be permitted to hold shares of Common Stock after vesting.  The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exchange Control Compliance</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand and agree that, to comply with exchange control laws in the PRC, the cash payable to you at expiration of the Restricted Period will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you.  The funds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and&#47;or the Company so that the funds may be deposited into this account.  In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China.  You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination of Employment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any terms or conditions of the Plan or the &#8220;Termination of Employment&#8221; section of the Terms to the contrary, the cash equivalent of any shares of Common Stock that vest upon termination of your employment will be distributed to you no later than six months from the date of termination of your employment, as determined by the Company in accordance with the Terms, or within any other such timeframe as may be required by SAFE.  If the Terms provide that all or a portion of your outstanding RSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and become distributable immediately upon your termination of employment as described above.  Any other portion of your RSU Award that is not vested as described above will expire immediately upon your termination of employment.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Colombia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ecurities Law Information.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The shares of Common Stock are not and will not be registered with the Colombian registry of publicly traded securities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(Registro Nacional de Valores y Emisores)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and therefore the shares of Common Stock may not be offered to the public in Colombia.  Nothing in this Appendix B should be construed as the making of a public offer of securities in Colombia.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision supplements the &#8220;Nature of Grant&#8221; section in Pat I of this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that pursuant to Article 128 of the Colombian Labor Code, the Plan, the RSU Award and any income realized under the Plan do not constitute a component of your &#8220;salary&#8221;.  Therefore, they will not be included and&#47;or considered for purposes of calculating any and all labor benefits, such as legal&#47;fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and&#47;or any other labor-related amount which may be payable.  </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Costa Rica</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Croatia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Cyprus</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Czech Republic</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Denmark</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision supplements the &#8220;Nature of Grant&#8221; section in this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you understand and agree that this grant relates to future services to be performed and is not a bonus or compensation for past services.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stock Option Act</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that you received the Employer Statement (attached as Appendix C below) which summarizes select terms of your RSUs.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As set forth in Section 1 of the Stock Option Act, the Stock Option Act only applies to &#8220;employees&#8221; as that term is defined in Section 2 of the Stock Option Act and to the extent you are subject to Danish law.  If you are a member of the registered management of the Company's subsidiary, affiliate or JV in Denmark or otherwise do not satisfy the definition of employee or are not subject to Danish law, you will not be subject to the Stock Option Act and the Employer Statement will not apply to you.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Please note the Stock Option Act was revised as of January 1, 2019. The standard termination provisions in the Terms will apply for any grants made under the Plan. The relevant termination provisions are detailed in the &#8220;Termination of Employment&#8221; section in your Terms.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Ecuador</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Egypt</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Estonia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Consent</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the grant of the RSU Award, you confirm having read and understood the documents related to the grant (the Terms and the Plan), which were provided in the English language, and that you do not need the translation thereof into the Estonian language.  You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">V&#245;ttes vastu Award-de pakkumise kinnitad, et oled ingliskeelsena esitatud pakkumisega seotud dokumendid (Tingimused ja Plaan) l&#228;bi lugenud ja nendest aru saanud ning et ei vaja nende t&#245;lkimist eesti keelde. Sellest tulenevalt n&#245;ustud viidatud dokumentide tingimustega</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Finland</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">France</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your RSU Award is not intended to be French tax-qualified.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Consent </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you confirm having read and understood the Plan and your Terms, which were provided in the English language.  You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan de travail et vos conditions g&#233;n&#233;rales et dispositions, qui ont &#233;t&#233; transmis en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Germany</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Greece</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Guatemala</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Consent to Receive Information in English</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By participating in the Plan, you acknowledge that you have reviewed the Terms and are sufficiently proficient in English, or, alternatively, you will seek appropriate assistance, to understand the terms and conditions of this RSU Award. </font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Warning&#58;  The contents of this document have not been reviewed by any regulatory authority in Hong Kong.  You should exercise caution in relation to the offer.  If you are in any doubt about any of the contents of the Plan and the Terms, including this Appendix B, you should obtain independent professional advice.  The RSU Award and any shares of Common Stock issued pursuant to the RSU Award do not constitute a public offering of securities under Hong Kong law and are available only to Eligible Employees of the Company or its subsidiaries, affiliates and JVs.  The Terms, including this Appendix B, the Plan and other incidental communication materials distributed in connection with the RSU Award (i) have not been prepared in accordance with and are not intended to constitute a &#8220;prospectus&#8221; for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each Eligible Employee of the Employer, the Company or its subsidiaries, affiliates and JVs and may not be distributed to any other person.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of Common Stock only. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sale of Shares</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shares of Common Stock received at vesting are accepted as a personal investment.  In the event the Restricted Period on your RSU Award expires within six months of the Grant Date and shares of Common Stock are issued to you, you agree that you will not offer to the public or otherwise dispose of the shares of Common Stock prior to the six-month anniversary of the Grant Date.  </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Hungary</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">India</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Indonesia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A translation of the documents relating to this grant into Bahasa Indonesia can be provided to you upon request to mellisa.riana.dewi&#64;merck.com.  By accepting the RSU Award, you (i) confirm having read and understood the documents relating to this grant (i.e., your Terms, including this Appendix B, and the Plan) which were provided in the English language, (ii) accept the terms of these documents accordingly, and (iii) agree not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Persetujuan dan Pemberitahuan Bahasa.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Terjemahan dari dokumen-dokumen terkait dengan pemberian ini  ke Bahasa Indonesia dapat disediakan untuk anda berdasarkan permintaan kepada mellisa.riana.dewi&#64;merck.com.  Dengan menerima Penghargaan ini, anda (i) mengkonfirmasi bahwa telah membaca dan memahami dokumen-dokumen berkaitan dengan pemberian ini (yaitu, Syarat-syarat anda, termasuk suplemen ini dan Program) yang disediakan dalam Bahasa Inggris, (ii) menerima persyaratan di dalam dokumen-dokumen tersebut, dan (iii) setuju untuk tidak mengajukan keberatan atas keberlakuan dari dokumen ini berdasarkan Undang-Undang No. 24 Tahun 2009 tentang Bendera, Bahasa dan Lambang Negara serta Lagu Kebangsaan ataupun Peraturan Presiden sebagai pelaksanaannya (ketika diterbitkan).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Ireland</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Israel</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The grant of the RSU Award under the Plan is being made pursuant to an exemption from the requirement to file and publish a prospectus in Israel regarding the Plan obtained from the Israeli Securities Authority.  Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission will be sent to you, at no charge, on written request being mailed to Investor Relations at Merck &#38; Co., Inc., 2000 Galloping Hill Road, Kennilworth, NJ 07033, U.S.A. The telephone number at the executive offices is 1-908-740-4000. Alternatively, copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by searching the Company&#8217;s filings on the following web site&#58; http&#58;&#47;&#47;www.sec.gov&#47;edgar&#47;searchedgar&#47;companysearch.html.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trust Arrangement</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand and agree that the RSU Award is offered subject to and in accordance with the terms of the Plan, the Addendum A - Israel to the Plan (the &#8220;Israeli Sub-Plan&#8221;), the Trust Agreement (the &#8220;Trust Agreement&#8221;) between the Company and the Company&#8217;s trustee appointed by the Company or its subsidiary or affiliate in Israel, currently ESOP Management and Trust Services Ltd. (the &#8220;Trustee&#8221;), and the Terms.  In the event of any inconsistencies between the Israeli Sub-Plan, the Terms and&#47;or the Plan, the Israeli Sub-Plan will govern the RSU Award granted to you in Israel. Capitalized terms used but not defined in this Appendix B for Israel, the Plan or the Terms have the meanings set forth in the Israeli Sub-Plan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Requirement to Return Signed Confirmation Letter</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You are required to execute the Confirmation Letter - Trustee 102 Awards (&#8220;Confirmation Letter&#8221;) provided to you in connection with Awards granted to you under the Israeli Sub-Plan.  In particular, you must print, sign and deliver a signed copy of the Confirmation Letter to the Trustee within thirty (30) days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, for the RSU Award to qualify for preferential tax treatment.  By accepting this RSU Award, you acknowledge and agree that the terms and conditions of the Confirmation Letter are hereby incorporated by reference into the Terms and shall apply to shares of Common Stock acquired upon expiration of the Restricted Period of the RSU Award. If the Trustee does not receive the signed Confirmation Letter within 30 days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, the RSU Award may not qualify for favorable tax treatment.  For more details, please contact Daphna Ben-Ari at daphna.ben-ari&#64;merck.com or +972 9533306.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confirmation of Section 102 Capital Gains Award Terms</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The RSU Award is intended to be Capital Gain Awards that qualify for the tax treatment for Approved 102 Awards that are designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance. Notwithstanding the foregoing, by accepting the RSU Award, you acknowledge that the Company cannot guarantee that the Capital Gain Award tax treatment will apply to the Awards granted to you.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you&#58; (a) acknowledge receipt of and represent that you have read and understand the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms&#59; (b) accept the RSU Award subject to all of the terms and conditions of the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms&#59; and (c) agree that the shares of Common Stock issued to upon expiration of the Restricted Period of the RSU Award will be issued to and deposited with the Trustee and shall be held in trust for your benefit as required by the Ordinance, the Israeli Sub-Plan and any approval by the Israeli Tax Authority pursuant to the terms of the Ordinance, the Israeli Sub-Plan and the Trust Agreement.  Furthermore, by accepting the RSU Award, you confirm that you understand  the terms and provisions of Section 102 of the Ordinance, particularly the capital gains track described in subsection (b)(2) and (b)(3) thereof, and agree that you will not require the Trustee to release the shares of Common Stock acquired upon expiration of the Restricted Period of the RSU Award to you or sell the shares of Common Stock to a third party, during the Holding Period, unless permitted to do so by the Ordinance or the Israeli Sub-Plan.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Italy</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan Document Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you further acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms in their entirety and fully understand and accept all provisions of the Plan and the Terms&#59; in particular, you acknowledge that you have read and specifically and expressly approve the following provisions in the Plan and the Terms&#58; (a) your RSU Award cannot be transferred other than by will or the laws of descent and distribution&#59; (b) in the event of involuntary termination of your employment, your right to receive Awards and to receive distributions from Awards, if any, will terminate as of the date that you are no longer actively employed by the Employer, unless otherwise expressly provided in the Terms&#59; (c) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time&#59; (d) you are responsible for all Tax-Related Items&#59; (e) if a reorganization, recapitalization, reclassification or other corporate event that results in an adjustment of the shares of Common Stock described in the Plan occurs, your RSU Award may be adjusted&#59; (f) if a Change in Control, as described in the Plan, occurs, your RSU Award may immediately vest&#59; (g) all decisions with respect to future grants will be at the sole discretion of the Company&#59; and (h) the &#8220;Data Privacy&#8221; section of your Terms.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Jordan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Lebanon</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The grant of Awards and distribution of the Plan and the Terms, including this Appendix B, to Eligible Employees does not constitute the marketing or offering of securities to the public in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law.  Offers under the Plan are being made only to Eligible Employees of the Employer or the Company or any other subsidiary, affiliate or JV of the Company.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Lithuania</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Malaysia</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Director Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you are a director of the Company&#8217;s Malaysian subsidiary, affiliate or JV, you are subject to certain notification requirements under the Malaysian Companies Act.  Among these requirements is an obligation to notify the Malaysian subsidiary, affiliate or JV in writing when you receive or dispose of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, RSU Awards or shares of Common Stock) in the Company or any related company.  Such notifications must be made within 14 days of receiving or disposing of any interest in the Company or any related company.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Privacy</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision replaces the &#8220;Data Privacy&#8221; section in your Terms&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in the Terms and any other grant materials by and among, as applicable, the Employer, the Company and its subsidiaries, affiliates and JVs for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">You understand that the Company and the Employer may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, details of all Awards or any other entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Data is supplied by the Employer and also by you through information collected in connection with the Terms and the Plan.   </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">You understand that Data will be transferred to Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative at kon.li.yoong&#64;merck.com.  You authorize the Company, Morgan Stanley Smith Barney and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke your consent, your employment status or service with the Employer will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing your consent is that the Company would not be able to grant RSU Awards to the you or administer or maintain such RSU Awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Privasi Data</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Peruntukan ini menggantikan bahagian &#8220;Privasi Data&#8221; dalam Terma-terma anda&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Terma-terma atau apa-apa bahan geran oleh dan di antara, seperti mana yang terpakai, Majikan, Syarikat dan mana-mana anak syarikat, syarikat sekutu atau usahasamanya untuk tujuan ekslusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda dalam Pelan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Syarikat dan Majikan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa saham atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir tentang semua Anugerah atau apa-apa hak lain untuk saham biasa yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedah anda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut (&#34;&#8220;Data&#34;&#8221;). Data tersebut dibekalkan oleh Majikan dan juga oleh anda melalui maklumat yang dikumpul berkenaan dengan Terma-terma dan Pelan.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Anda memahami bahawa Data ini akan dipindahkan kepada Morgan Stanley Smith Barney atau pembekal perkhidmatan pelan saham lain yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau di tempat lain, dan bahawa negara penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa anda boleh meminta satu senarai yang mengandungi nama dan alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan di kon.li.yoong&#64;merck.com. Anda memberi kuasa kepada Syarikat, Morgan Stanley Smith Barney dan mana-mana penerima lain yang mungkin membantu Syarikat (pada masa kini atau masa depan) untuk melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, semata-mata dengan tujuan untuk melaksanakan, mentadbir dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa Data hanya akan disimpan untuk tempoh yang perlu bagi melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa anda boleh, pada bila-bila masa, melihat data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela. Jika anda tidak bersetuju, atau jika anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan anda dengan Majikan tidak akan terjejas&#59; satu-satunya akibat buruk jika anda tidak bersetuju atau menarik balik persetujuan anda adalah bahawa Syarikat tidak akan dapat memberikan Anugerah kepada anda atau mentadbir atau mengekalkan anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lanjut mengenai akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Mexico</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award offered under the Plan and the shares of Common Stock underlying the RSU Award have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico.  In addition, the Plan and any other document relating to any Award may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and its subsidiaries, affiliates and JVs and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present Employees of the Company or one of its subsidiaries, affiliates and JVs, made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgement</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">These provisions supplement the &#8220;Nature of Grant&#8221; section in your Terms&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you understand and agree that&#58; (i) the RSU Award is not related to the salary and other contractual benefits granted to you by the Employer and (ii) any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Policy Statement</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The invitation the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability to you.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company, with registered offices at 2000 Galloping Hill Road, Kenilworth, NJ 07033, U.S.A., is solely responsible for the administration of the Plan and your participation in the Plan and the acquisition of shares of Common Stock does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis.  Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participating in the Plan do not establish any rights between you and the Employer and do not form part of the employment conditions and&#47;or benefits provided by the Employer, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against the Company for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to the Company, its subsidiaries, affiliates, JVs, branches, representation offices, shareholders, officers, agents or legal representatives, with respect to any claim that may arise.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan Document Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms, including this Appendix B, in their entirety and fully understand and accept all provisions of the Plan and the Terms.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, by accepting the benefits under this grant, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the &#8220;Nature of Grant&#8221; section of the Terms, in which the following is clearly described and established&#58; (i) your participation in the Plan does not constitute an acquired right&#59; (ii) the Plan and your participation in the Plan is offered by the Company on a wholly discretionary basis&#59; (iii) your participation in the Plan is voluntary&#59; and (iv) the Company and its subsidiaries, affiliates and JVs are not responsible for any decrease in the value of the shares of Common Stock underlying your RSU Award.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Morocco</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  The Company reserves the right to settle the RSU Award in shares of commons stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.  </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Netherlands</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">WARNING&#58;  This is an offer of rights to receive shares of Common Stock upon vesting of the RSU Award subject to the terms of the Plan and the Terms.  The RSU Award gives you a stake in the ownership of the Company.  You may receive a return if dividends are paid on the shares of Common Stock.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">If the Company runs into financial difficulties and is wound up, you will be paid only after all creditors have been paid.  You may lose some or all of your investment.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">New Zealand law normally requires people who offer financial products to give information to investors before they invest.  This information is designed to help investors to make an informed decision.  The usual rules do not apply to this offer because it is made under an employee share purchase scheme.  As a result, you may not be given all the information usually required.  You will also have fewer other legal protections for this investment. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">You should ask questions, read all documents carefully, and seek independent financial advice before committing to participate in the Plan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, you are hereby notified that the documents listed below are available for review at http&#58;&#47;&#47;one.merck.com&#47;sites&#47;hr&#47;Lists&#47;ChannelContent&#47;CustDispForm.aspx&#63;ID&#61;63&#38;Channel&#61;Money.  Filings made with the U.S. SEC can also be found at www.sec.gov.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;this Appendix B which together with the Terms and the Plan sets forth the terms and conditions of your participation in the Plan&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a copy of the Company&#8217;s most recent annual report (i.e., Form 10-K)&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii) &#160;&#160;&#160;&#160;a copy of the Company&#8217;s most recent published financial statements&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;a copy of the Plan&#59; and</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;a copy of the Plan Prospectus.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A copy of the above documents will be sent to you free of charge on written request being mailed to Investor Relations at Merck &#38; Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, U.S.A.  The telephone number at the executive offices is 1-908-740-4000.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As noted above, you are advised to carefully read the materials provided before making a decision whether to participate in the Plan.  You are also encouraged to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Norway</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Panama</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your RSU Award is granted pursuant to the Plan and the shares of Common Stock which may be issued on the expiration of the Restricted Period are offered in a private transaction.  This is not an offer to the public and the offer is not subject to the protections established by Panamanian securities laws, nor registration requirements.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Peru</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The offering of the RSU Award is considered a private offering in Peru&#59; therefore, neither the grant of the RSU Award, nor the issuance of shares at the expiration of the Restricted Period, is subject to securities registration in Peru.  For more information concerning this offer, please refer to the Plan, the Terms, the Plan Prospectus and any other grant documents made available to you by the Company.  For more information regarding the Company, please refer to the Company&#8217;s most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov, as well as the Company&#8217;s &#8220;Investor Relations&#8221; website at http&#58;&#47;&#47;investors.merck.com.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Philippines</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Poland</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Portugal</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Consent</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accept and agree with the terms and conditions established in the Plan and the Terms.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Conhecimento da Lingua.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">O Contratado, pelo presente instrumento, declara expressamente que tem pleno conhecimento da l&#237;ngua inglesa e que leu, compreendeu e livremente aceitou e concordou com os termos e condi&#231;&#245;es estabelecidas no Plano e no Acordo de Atribui&#231;&#227;o (Terms em ingl&#234;s).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Puerto Rico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Romania</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Consent  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you acknowledge that you are proficient in reading and understanding English or have consulted with an advisor who is sufficiently proficient in English as to allow you to fully understood the terms of the documents related to the grant (the Terms, including this Appendix B and the Plan), which were provided in the English language.  You accept the terms of these documents accordingly.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Consimtamant cu privire la limba</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Prin acceptarea de aceasta Acordare, confirmati ca aveti un nivel adecvat de cunoastere in ce priveste cititirea si intelegerea limbii engleze sau ati consultat un consultant care este suficient de competent in limba engleza pentru a va permite sa intelegeti pe deplin termenii documentelor referitoare la acordare (anuntul, Acordul si Planul), care au fost furnizate in limba engleza. Acceptati termenii acestor documente in consecinta.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Russia</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Company in its sole discretion determines that the issuance of shares of Common Stock pursuant to this RSU Award would not comply with applicable laws, rules and regulations and&#47;or that the approval of a governmental agency that it deems necessary or appropriate has not been obtained or has lapsed for whatever reason by the relevant Vesting Date, the Company will settle this RSU Award in cash only.  Alternatively, the Company may permit this RSU Award to vest on the Vesting Date but delay settlement of this RSU Award until such time as it determines it is permissible to issuance shares of Common Stock as determined in accordance with Section 23 of the Plan.  In the event that this RSU Award is settled in cash, upon settlement of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Terms, the Plan and all other materials that may be distributed regarding participation in the Plan do not constitute advertising or an offering of securities in Russia.  Any securities issued under the Plan have not and will not be registered in Russia, nor will they be admitted for listing on any Russian exchange for trading within Russia.  Thus, the securities described in the Terms, the Plan and all other materials that may be distributed regarding participation in the Plan may not be used for an offering or private or public circulation in Russia.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Under the default rule applicable prior to March 1, 2022 and at least temporarily not applicable for the reasons described below, any shares of Common Stock issued pursuant to the RSU Award shall be delivered into a U.S. brokerage account&#59; in no event will any shares of Common Stock issued to you pursuant to the RSU Award be delivered to you in Russia.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective March 1, 2022, a set of temporary counter-measures introduced by the Russian President in Decree 79 dated February 28, 2022, and Decree 81 dated March 1, 2022 impact the ability of Russian residents to transact in securities of a foreign company. Under these rules, Russian residents (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Russian citizens and foreign citizens living in Russia on the basis of a residency permit) may not acquire foreign securities (including the shares of Common Stock) and may not receive any cash amounts in their non-Russian bank accounts and&#47;or broker accounts. Until the restrictions are lifted, the Company is prohibited from issuing shares of Common Stock to you at vesting of this RSU Award and reserves the right to settle the RSU Award in cash or alternatively, to delay the settlement of the RSU Award, as described under &#8220;Payment of Award&#8221; above.  </font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Saudi Arabia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Serbia</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The RSU Award is not subject to the regulations concerning public offers and private placements under the Law on Capital Market.  As set forth in the Terms, the RSU Award is subject to the laws of the State of New Jersey, U.S.A. (without regard to its conflict of law provisions). </font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Singapore</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You hereby agree that any shares of Common Stock acquired pursuant to the RSU Award will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the RSU Award, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;SFA&#8221;) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The RSU Award is being granted to you pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the RSU Award being subsequently offered for sale to any other party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Director Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or JV of the Company, you are subject to certain notification requirements under the Singapore Companies Act.  Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or JV in writing when you receive an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, RSU Awards, shares of Common Stock) in the Company or any related companies.  In addition, you must notify the Singaporean subsidiary, affiliate or JV when you sell shares of the Company&#8217;s Common Stock or any related company (including when you sell shares of Common Stock acquired upon the expiration of the Restricted Period).  These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company.  In addition, a notification must be made of your interests in the Company or any related company within two days of .either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information&#58; equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A &#8220;family member&#8221; means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Slovak Republic</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Slovenia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Consent</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the grant of the RSU Award, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (this Appendix B, the Terms and the Plan), which were provided in the English language.  You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Soglasje za Uporabo Angle&#353;kega Jezika</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">S sprejetjem dodelitve Nagrade (the RSU Award) potrjujete in priznavate, da ste sposobni brati in razumeti angle&#353;ki jezik ter da v celoti razumete dolo&#269;ila dokumentov, povezanih z dodelitvijo (ta dodatek, Dolo&#269;ila (the Terms) in Na&#269;rt (the Plan)), ki so bili posredovani v angle&#353;kem jeziku. Skladno s tem sprejemate dolo&#269;ila teh dokumentov. </font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">South Africa</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the RSU Award, you agree to notify your Employer of the amount of any gain you realize upon the expiration of the Restricted Period.  If you fail to advise your Employer of the gain realized upon expiration of the Restricted Period, you may be liable for a fine.  You will be responsible for paying any difference between the actual tax liability and the amount withheld.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In compliance with South African Securities Law, you acknowledge that you have been notified that the documents listed below are available for your review on the Company intranet site at the web addresses listed below&#58;</font></div><div style="margin-bottom:6pt;padding-left:33.55pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. the Company&#8217;s most recent Annual Report (Form 10-K) &#8211; http&#58;&#47;&#47;investors.merck.com&#47;investors&#47;financial-reports&#47;quarterly-financials&#47;default.aspx</font></div><div style="margin-bottom:6pt;padding-left:33.55pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2. the Company&#8217;s most recent Plan Prospectus  - http&#58;&#47;&#47;one.merck.com&#47;sites&#47;hr&#47;Lists&#47;ChannelContent&#47;CustDispForm.aspx&#63;ID&#61;63&#38;Channel&#61;Money</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Investor Relations at Merck &#38; Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, U.S.A.  The telephone number at the executive offices is 1-908-740-4000.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Spain</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision supplements the &#8220;Nature of Grant&#8221; section in Part I of this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting this RSU Award, you acknowledge that you understand and agree that you consent to participation in the Plan and that you have received a copy of the Plan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand that the Company, in its sole discretion, has unilaterally and gratuitously decided to distribute Awards under the Plan to individuals who may be employees of the Company or its subsidiaries, affiliates or JVs throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its subsidiaries, affiliates or JVs over and above the specific terms of the Plan on an ongoing basis.  Consequently, you understand that any RSU Award is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its subsidiaries, affiliates or JVs) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary Award since the future value of the RSU Award and shares of Common Stock is unknown and unpredictable.  In addition, you understand that the RSU Award would not be made to you but for the assumptions and conditions referred to above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any RSU Award shall be null and void.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You also understand and agree that, as a condition of the grant of the RSU Award, the termination of your employment for any reason (including the reasons listed below), the RSU Award will cease vesting immediately effective on the date you are no longer providing services to the Employer or the Company or any of its subsidiaries, affiliates or JVs (unless otherwise specifically provided in the Terms).  In particular, you understand and agree that the RSU Award will be forfeited without entitlement to the underlying shares of Common Stock or to any amount as indemnification in the event of a termination of your employment as described in the Terms prior to expiration of the Restricted Period by reason of, including but not limited to, resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, subject to &#8220;despido improcednte&#8221;), individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article 40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the RSU Award.  The Plan and the Terms have not been nor will they be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and do not constitute a public offering prospectus.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Sweden</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authorization to Withhold</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following provision supplements the &#8220;Tax Withholding&#8221; section of the Terms&#58; </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the &#8220;Tax Withholding&#8221; section of the Terms, in accepting the RSU Award, you authorize the Company and&#47;or the Employer to withhold shares of Common Stock or to sell shares of Common Stock otherwise deliverable to you upon vesting to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Switzerland</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The offering of participation in the Plan is considered a private offering in Switzerland&#59; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Taiwan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The RSU Award and the shares of Common Stock to be issued pursuant to the Plan are available only to Eligible Employees of the Company and its subsidiaries, affiliates and JVs.  The grant of the RSU Award and offer of participation in the Plan does not constitute a public offer of securities by a Taiwanese company. </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Thailand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Turkey</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Under Turkish law, you are not permitted to sell shares of the Company&#8217;s Common Stock in Turkey&#59; instead, the sale must take place outside Turkey, which will be the case if the shares of Common Stock are sold on the New York Stock Exchange on which the shares are currently listed.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You may be required to engage a Turkish financial intermediary to assist with the sale of shares of Common Stock acquired under the Plan.  While you should not need to engage a Turkish financial intermediary with respect to the acquisition of such shares of Common Stock (as no consideration is paid for the RSU Award or underlying shares of Common Stock), this is less certain.  In light of this uncertainty, you should consult your personal legal advisor prior to the expiration of the Restricted Period or any sale of shares of Common Stock to ensure compliance with the financial intermediary requirements.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Ukraine</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.  </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">United Arab Emirates</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan is only being offered to Eligible Employees of the Company and its subsidiaries, affiliates and JVs and is in the nature of an &#8220;exempt personal offer&#8221; of equity incentives to Eligible Employees of the Company&#8217;s subsidiary in the United Arab Emirates.  The Plan, the Terms and any other grant documents you may receive from the Company are intended for distribution only to such Eligible Employees and must not be delivered to, or relied on by, any other person.  Prospective recipients of the securities offered (i.e., shares of the Company&#8217;s Common Stock) should conduct their own due diligence on the securities.  If you do not understand the contents of the Plan and the Terms, you should consult an authorized financial adviser. The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan.  The Ministry of Economy, the Dubai Department of Economic Development, Emirates Securities and Commodities Authority, Central Bank and the Dubai Financial Services Authority, as applicable depending on your Employer&#8217;s location in the United Arab Emirates, have not approved the Plan or the Terms or taken steps to verify the information set out therein, and have no responsibility for such documents.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">United Kingdom</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company or, if different, your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HRMC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and, if different, your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the amount of any income tax not collected from or paid by you within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Items occurs may constitute a benefit to you on which additional income tax and National Insurance contributions may be payable.  You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and&#47;or the Employer (as appropriate) the amount of any employee National Insurance contributions due on this additional benefit, which may also be recovered from you through any means set forth in the &#8220;Tax Withholding&#8221; section of the Terms.</font></div></td></tr></table></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:94.32pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Uruguay</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Vietnam</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any RSU Award granted to you will be settled in cash only.  This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker&#8217;s fees or commissions, which will be remitted to you via local payroll.  The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.</font></div></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib9ed136e185147f8944f69ff6ebf51e3_19"></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX C</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MERCK &#38; CO., INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SPECIAL NOTICE FOR EMPLOYEES IN DENMARK</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARBEJDSGIVERERKL&#198;RING&#47;EMPLOYER STATEMENT</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I henhold til &#167; 3, stk. 1, i lov om brug af k&#248;beret eller tegningsret til aktier m.v. i ans&#230;ttelsesforhold som &#230;ndret pr. 1 . januar 2019 (&#34;Aktieoptionsloven&#34;) er du berettiget til i en s&#230;rskilt skriftlig erkl&#230;ring at modtage f&#248;lgende oplysninger om betingede aktieenheder (&#34;Tildeling&#34;) tildelt dig af Merck &#38; Co., Inc. (&#34;Selskabet&#34;) i henhold til Selskabets 2019 Incentive Stock Plan (&#8220;Planen&#8221;).</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Denne erkl&#230;ring indeholder kun de oplysninger, der er n&#230;vnt i Aktieoptionsloven.&#160; De fuldst&#230;ndige vilk&#229;r og betingelser, der g&#230;lder for din Tildeling, fremg&#229;r af Planen, vilk&#229;rene for 2019 tildeling af betingede aktieenheder for ikke-amerikanske medarbejdere (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Global</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) (&#8220;Vilk&#229;rene&#8221;) og af landetill&#230;gget, som alle er udleveret til dig.&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I tilf&#230;lde af uoverensstemmelse mellem indholdet af denne erkl&#230;ring og Planen, Vilk&#229;rene, har Planen of Vilk&#229;rene forrang.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to Section 3(1) of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships as amended with effect from 1 January 2019 (the &#8220;Stock Option Act&#8221;), you are entitled to receive the following information regarding restricted stock units (the &#8220;Award&#8221;) granted to you by Merck &#38; Co., Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;Company&#8221;) under its 2019 Incentive Stock Plan (the &#8220;Plan&#8221;) in a separate written statement.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This statement contains only the information mentioned in the Stock Option Act.&#160; The terms and conditions of your Award are set forth in their entirety in the Plan and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Global Terms and Conditions including Appendix B thereto (the &#8220;Terms&#8221;), which have been made available to you.&#160; </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of any inconsistency between the contents of this statement and the Plan and the Terms, the terms and conditions of the Plan and the Terms will prevail.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.  Tidspunkt for tildeling af den vederlagsfri ret til at modtage ordin&#230;re aktier mod opfyldelse af visse betingelser</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tildelingstidspunktet er den dato, hvor Vederlagsudvalget under Selskabets Bestyrelse eller et underudvalg under samme, eller et eventuelt andet bestyrelsesudvalg, der m&#229;tte efterf&#248;lge dette, (&#34;Udvalget&#34;) godkendte tildeling til dig og besluttede, at denne skulle tr&#230;de i kraft som anf&#248;rt i Vilk&#229;rene.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.  Date of grant of unfunded right to receive shares of Common Stock upon satisfying certain conditions</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Grant Date of your Award is the date that the Compensation and Benefits Committee of the Board of Directors of the Company or subcommittee thereof, or such other successor committee of the Board of Directors (the &#8220;Committee&#8221;) approved a grant for you and determined it would be effective, which is set forth in the Terms.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.  Vilk&#229;r for tildeling af ret til at modtage ordin&#230;re aktier mod opfyldelse af visse betingelser</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tildelinger i henhold til Planen sker alene efter Udvalgets eget frie sk&#248;n.&#160; Selskabet har meget vide bef&#248;jelser til at bestemme, hvem der kan modtage Tildelinger og hvorn&#229;r, og til at fasts&#230;tte betingelserne for Tildelingerne.&#160; Selskabet kan efter dets eget frie sk&#248;n v&#230;lge fremover ikke at give Tildelinger. &#160; I henhold til bestemmelserne i Planen og Vilk&#229;rene har du ikke nogen ret til eller noget krav p&#229; fremtidige tildelinger i henhold til Planen.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.  Terms or conditions for grant of a right to receive shares of Common Stock upon satisfying certain conditions</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The grant of Awards under the Plan is made at the sole discretion of the Committee.&#160; The Company has very broad powers to determine who will receive Awards and when, and to set the terms of the Awards.&#160; The Company may decide, in its sole discretion, not to make any grants of Awards in the future.&#160; Under the terms of the Plan and the Terms, you have no entitlement or claim to receive future grants under the Plan.</font></div></td></tr></table></div><div style="height:38.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.  Modningstidspunkt eller -periode</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Din Tildeling modnes med 33,333 % p&#229; hhv. 1-, 2- og 3-&#229;rsdagen for tildelingstidspunktet, medmindre den af de i Vilk&#229;rene anf&#248;rte &#229;rsager inden da er modnet eller oph&#248;rt.&#160; P&#229; modningstidspunktet konverteres din Tildeling til et tilsvarende antal ordin&#230;re aktier i Selskabet.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.  Vesting date or period</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your Award shall vest 33.333% on each of the first, second and third anniversary of the Grant Date, unless vested or terminated earlier for the reasons set forth in the Terms.&#160; Your Award shall be converted into an equivalent number of Company shares of Common Stock upon vesting of the Award.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.  Udnyttelseskurs</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Der betales ingen udnyttelseskurs i forbindelse med modning af din Tildeling eller Selskabets udstedelse af ordin&#230;re aktier til dig i overensstemmelse med den ovenfor beskrevne modningstidsplan.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.  Exercise price</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No exercise price is payable upon the vesting of your Award or the issuance of shares of the Company&#8217;s Common Stock to you in accordance with the vesting schedule described above.</font></div></td></tr></table></div><div style="height:38.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.  Din retsstilling i forbindelse med fratr&#230;den</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ved din fratr&#230;den vil din Tildeling blive behandlet i overensstemmelse med bestemmelsen &#8220;Ans&#230;ttelsesforholdets oph&#248;r&#8221; (defineret som </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  i Vilk&#229;rene), hvilken bestemmelse er opsummeret umiddelbart nedenfor.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.  Generel regel.  Hvis dit ans&#230;ttelsesforhold inden for den Betingede Periode (defineret som </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> i Vilk&#229;rene) oph&#248;rer af nogen anden &#229;rsag end de nedenfor anf&#248;rte, fortabes din Tildeling (og eventuelt optjent udbyttemodv&#230;rdi) p&#229; tidspunktet for oph&#248;ret af dit ans&#230;ttelsesforhold.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.  Ufrivilligt oph&#248;r af ans&#230;ttelsesforholdet.  Hvis Selskabet vurderer, at dit ans&#230;ttelsesforhold er oph&#248;rt ufrivilligt inden for den Betingede Periode, men p&#229; eller efter 1-&#229;rsdagen for Tildelingen, vil en forholdsm&#230;ssig andel af din umodnede Tildeling og eventuelt optjent udbyttemodv&#230;rdi blive udbetalt til dig p&#229; det tidspunkt, hvor s&#229;dan udbetaling ville v&#230;re sket, hvis dit ans&#230;ttelsesforhold ikke var oph&#248;rt. Denne forholdsm&#230;ssige andel vil v&#230;re svarende til Tildelingens fulde bel&#248;b (uanset om Tildelingen er modnet eller ej) gange antal fuldt forl&#248;bne m&#229;neder inden for den Betingede Periode og forud for tidspunktet for ans&#230;ttelsesforholdets oph&#248;r, delt med 36&#59; reduceret med antal modnede betingede aktieenheder. Resten, inklusive eventuelt optjent udbyttemodv&#230;rdi, fortabes p&#229; tidspunktet for ans&#230;ttelsesforholdets oph&#248;r.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.  Salg.  Hvis dit ans&#230;ttelsesforhold inden for den Betingede Periode (som defineret i Vilk&#229;rene) oph&#248;rer, og Selskabet vurderer, at oph&#248;ret skyldes et salg af dit datterselskab, afdeling eller joint venture, vil f&#248;lgende del af din Tildeling og eventuelt optjent udbyttemodv&#230;rdi blive udbetalt til dig p&#229; det tidspunkt, hvor s&#229;dan udbetaling ville v&#230;re sket, hvis dit ans&#230;ttelsesforhold ikke var oph&#248;rt&#58; En tredjedel, hvis ans&#230;ttelsesforholdet oph&#248;rer p&#229; eller efter Tildelingstidspunktet, men f&#248;r 1-&#229;rsdagen for tildelingen&#59; og hele Tildelingen, hvis ans&#230;ttelsesforholdet oph&#248;rer p&#229; eller efter 1-&#229;rsdagen for tildelingen.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.  Pensionering.  Hvis dit ans&#230;ttelsesforhold inden for den Betingede Periode oph&#248;rer som f&#248;lge af pensionering, vil en forholdsm&#230;ssig andel af din umodnede Tildeling og eventuelt optjent udbyttemodv&#230;rdi blive udbetalt til dig p&#229; det tidspunkt, hvor s&#229;dan udbetaling ville v&#230;re sket, hvis dit ans&#230;ttelsesforhold ikke var oph&#248;rt. Denne forholdsm&#230;ssige andel vil v&#230;re svarende til Tildelingens fulde bel&#248;b (uanset om Tildelingen er modnet eller ej) gange antal fuldt forl&#248;bne m&#229;neder inden for den Betingede Periode og forud for tidspunktet for ans&#230;ttelsesforholdets oph&#248;r, delt med 36&#59; reduceret med antal modnede betingede aktieenheder. Resten, inklusive eventuelt optjent udbyttemodv&#230;rdi, fortabes p&#229; tidspunktet for ans&#230;ttelsesforholdets oph&#248;r.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.  D&#248;dsfald.  D&#248;d. Hvis din ans&#230;ttelse opsiges p&#229; grund af din d&#248;d i den begr&#230;nsede periode, men forud for en ans&#230;ttelsesopsigelse, som er p&#229;t&#230;nkt i B, C, D, G eller H, vil hele denne tildeling og optjente udbytte&#230;kvivalenter straks optjenes. Hvis du d&#248;r i den begr&#230;nsede periode, men efter at dit ans&#230;ttelsesforhold oph&#248;rer af de &#229;rsager, der er anf&#248;rt i B, C, D, G eller H, vil den resterende, ikke-fortabte del af denne Award og optjente udbytte&#230;kvivalenter straks optjenes.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.  Uredelighed eller pligtfors&#248;mmelse.  Hvis dit ans&#230;ttelsesforhold oph&#248;rer som f&#248;lge af bevidst uredelighed eller fors&#230;tlig eller grov pligtfors&#248;mmelse fra din side, fortabes denne Tildeling og eventuelt optjent udbyttemodv&#230;rdi samtidig med din modtagelse af meddelelse om ans&#230;ttelsesforholdets oph&#248;r.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G. Uarbejdsdygtighed.  Hvis dit ans&#230;ttelsesforhold inden for den Betingede Periode oph&#248;rer, og Selskabet vurderer, at oph&#248;ret skyldes din manglende evne til at opfylde de forpligtelser, der p&#229;hviler dig i kraft af din stilling, som f&#248;lge af fysisk eller mental svagelighed, der forventes at ville vare ved i mindst 6 m&#229;neder eller medf&#248;re din d&#248;d, vil - uanset, om du m&#229;tte v&#230;re berettiget til invaliditetsydelser fra nogen invaliditetsordning - denne Tildeling forblive i kraft og kvalificeret til udbetaling i overensstemmelse med Vilk&#229;rene p&#229; samme m&#229;de, som hvis ans&#230;ttelsesforholdet ikke var oph&#248;rt, idet udbetaling i s&#229; fald vil ske samtidig med tilsvarende udbetalinger til aktive medarbejdere.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H. Kontrolskifte.  Hvis Selskabet eller noget moderselskabs, datterselskabs, tilknyttet parts eller joint venture af Selskabet inden for den Betingede Periode uden Berettigelse (defineret som </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> i Planen) bringer dit ans&#230;ttelsesforhold til ufrivillig opsigelse, vil denne Tildeling forblive i kraft i overensstemmelse med Vilk&#229;rene p&#229; samme m&#229;de, som hvis ans&#230;ttelsesforholdet ikke var oph&#248;rt, idet udbetaling i s&#229; fald vil ske samtidig med tilsvarende udbetalinger til aktive medarbejdere. Hvis denne Tildeling efter et kontrolskifte ikke l&#230;ngere er udest&#229;ende og heller ikke er konverteret til en anden Tildeling, vil du v&#230;re berettiget til for denne Tildeling at modtage kontant betaling med et bel&#248;b svarende fair markedsv&#230;rdi af det vederlag, kapitalejerne i Selskabet modtog i forbindelse med kontrolskiftet til udbetaling senest 30 dage fra kontrolskiftets gennemf&#248;relse. Dette afsnit bortfalder, n&#229;r der er g&#229;et 2 &#229;r fra kontrolskiftets gennemf&#248;relse.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.  Joint Venture.  Ans&#230;ttelse i et joint venture, herunder enhver anden enhed, som Selskabet har en betydelig forretningsinteresse eller ejerandel i, anses i forhold til denne Tildeling ikke for oph&#248;r af ans&#230;ttelsesforholdet.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.  Your rights upon termination of employment</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The treatment of your Award upon termination of employment will be determined in accordance with the &#8220;Termination of Employment&#8221; section of the Terms summarized immediately below.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.  General Rule.  If your employment is terminated during the Restricted Period (as defined in the Terms), for any reason other than those specified in the following paragraphs, your Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.  Involuntary Termination.  If the Company determines that your employment is involuntarily terminated during the Restricted Period but on or after the first anniversary, a pro rata portion of your unvested Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of the Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of restricted stock units that have vested. The remainder and any accrued dividend equivalents will be forfeited on the date your employment ends.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.  Sale.  If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or joint venture, the following portion of your Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued&#58; one-third if employment terminates on or after the Grant Date but before the first anniversary thereof&#59; and all if employment terminates on or after the first anniversary of the Grant Date.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.  Retirement.  If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of the Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36&#59; reduced by the number of restricted stock units that have vested. The remainder and any accrued dividend equivalents will be forfeited on the date your employment ends.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.  Death.  If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated in B, C, D, G or H, all of this Award and accrued dividend equivalents will immediately vest. If you die during the Restricted Period but after your employment terminates for the reasons contemplated in B, C, D, G or H, the remaining, non-forfeited portion of this Award and accrued dividend equivalents will immediately vest.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.  Misconduct.  If your employment is terminated as a result of your deliberate, willful or gross misconduct, this Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G.  Disability.  If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active employees receive distributions with respect to this Award.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H.  Change in Control.  If the Company or a parent, subsidiary, affiliate or joint venture of the Company involuntarily terminates your employment during the Restricted Period without Cause (as defined by the Plan) before the second anniversary of the closing of any change in control, then this Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active employees receive distributions with respect to this Award. If this Award does not remain outstanding following the change in control and is not converted into a successor Award, then you will be entitled to receive cash for this Award in an amount equal to the fair market value of the consideration paid to Company stockholders for a share of Company Common Stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I.  Joint Venture.  Employment with a joint venture including any other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this Award.</font></div></td></tr></table></div><div style="height:38.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.  &#216;konomiske aspekter ved deltagelse i Planen</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tildelingen har ingen umiddelbare &#248;konomiske konsekvenser for dig.&#160; Det er f&#248;rst ved modning af Tildelingen og det efterf&#248;lgende salg af de modtagne ordin&#230;re aktier ved modning, at du vil kunne realisere nogen indt&#230;gt under Planen.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">V&#230;rdien af Tildelingen indg&#229;r ikke i beregningen af feriepenge, pensionsbidrag, fratr&#230;delsesgodtg&#248;relse, godtg&#248;relser eller andre lovpligtige, vederlagsafh&#230;ngige ydelser.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investering i aktier er ikke uden &#248;konomisk risiko.&#160; V&#230;rdien af aktierne p&#229; modningstidspunkterne afh&#230;nger ikke kun af Selskabets &#248;konomiske udvikling, men ogs&#229; af den generelle udvikling p&#229; aktiemarkedet.&#160; Der kan derfor ikke gives nogen garanti for, at en investering i aktier vil v&#230;re overskudsgivende.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Denne erkl&#230;ring ber&#248;rer ikke de skattem&#230;ssige konsekvenser af deltagelse i Planen, modtagelse af eventuelt udbytte eller et efterf&#248;lgende salg af de i medf&#248;r af Planen erhvervede ordin&#230;re aktier.&#160; Du anbefales at dr&#248;fte dette med din personlige &#248;konomiske r&#229;dgiver eller skatter&#229;dgiver.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.  Financial aspects of participating in the Plan</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The grant of the Award has no immediate financial consequences for you.&#160; It is not until vesting of the Award and the subsequent sale of shares of Common Stock acquired at vesting that you may realize any income under the Plan.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The value of the Award is not taken into account when calculating holiday allowances, pension contributions, severance pay, statutory allowance, compensation or other statutory remuneration calculated on the basis of salary.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investing in shares of Common Stock involves some financial risk.&#160; The value of the shares at the time of vesting and sale will not only be dependent on the Company's financial development, but also on the general development on the stock market.&#160; Consequently, there is no guarantee that investment in shares of Common Stock will yield a profit.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This statement does not address the tax consequences of participating in the Plan, the receipt of any dividends or the subsequent sale of any shares of Common Stock acquired under the Plan.&#160; You are encouraged to discuss this matter with your personal financial or tax advisor.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MERCK &#38; CO., INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2000 Galloping Hill Road</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kenilworth, New Jersey</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S.A. 07033</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MERCK &#38; CO., INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2000 Galloping Hill Road</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kenilworth, New Jersey</font></div><div style="padding-left:50.95pt;padding-right:2.75pt;text-align:justify;text-indent:-48.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S.A. 07033</font></div></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:38.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>18
<FILENAME>exhibit1036-2022annualpsut.htm
<DESCRIPTION>EXHIBIT-10.36 2022 ANNUAL PSU TERMS AND CONDITIONS (GUINDO)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id5dea9796cbd434cb5b219c77c0527b1_1"></div><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.36</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLOBAL TERMS AND CONDITIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022 SIGN-ON EQUITY GRANT OF PERFORMANCE SHARE UNITS FOR CHIRFI GUINDO</font></div><div style="padding-left:63.82pt;padding-right:63.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE MERCK &#38; CO., INC. 2019 INCENTIVE STOCK PLAN</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.234%"><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:31.5pt;text-indent:-22.51pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:15.48pt">GENERAL. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Merck &#38; Co., Inc. (the &#8220;Company&#8221;) has granted to you the award of Performance Share Units (&#8220;PSUs&#8221;) specified in this document (&#8220;PSU Award&#8221; or &#8220;Sign-On Equity&#8221;) pursuant to the Merck &#38; Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the &#8220;Plan&#8221;).  This PSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix&#160;B (the &#8220;Terms&#8221;).  Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></div><div style="display:inline-block;max-width:7.530%;min-width:6.530%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.236%"><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Type&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PSU - Annual</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jan. 1, 2022</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Award Period&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jan. 1, 2022 &#8211;</font></div><div style="margin-top:0.5pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dec. 31, 2024</font></div></td></tr></table></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div></div></div><div style="margin-top:0.05pt;padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IMPORTANT NOTICE&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This grant requires you to affirmatively accept it. You </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">MUST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> log onto the Morgan Stanley website at </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(http&#58;&#47;&#47;www.morganstanley.com&#47;spc&#47;knowledge&#47;managing-equity&#47;managing-your-existing-awards&#47;accepting-awards-grants&#47;) to accept the grant.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.</font></div></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:47pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.69pt">DEFINITIONS. For the purpose of these Terms&#58;</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Award Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three-year period commencing on January 1, 2022 and ending on December 31, 2024.</font></div><div style="padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings Per Share or EPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.</font></div><div style="padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) restructurings, discontinued operations, purchase accounting items, merger-related costs, the impact of significant acquisitions and&#47; or divestitures, extraordinary items and other unusual or non-recurring charges and&#47; or events&#59; (2) an event either not directly related to Company operations or not reasonably within the control of Company management&#59; (3) fluctuations in foreign exchange versus Plan rates&#59; (4) the impact of Share Repurchases above or below planned levels&#59; and (5) the effects of accounting changes in accordance with U.S. generally accepted accounting principles, or other significant legislative changes. </font></div><div style="padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage reflecting the attainment level of the Company&#8217;s EPS goal as determined under paragraph C of Section III.</font></div><div style="padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Final Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the number of PSUs that become eligible to vest based on the attainment level of the goals for each performance metric, as calculated in accordance with Section III hereof.</font></div><div style="margin-top:0.5pt;padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date as of which a Performance Share Unit is granted.</font></div><div style="margin-top:0.4pt;padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Peer Healthcare Companies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are the healthcare companies used by the Committee in evaluating the Company&#8217;s TSR performance for the entire Award Period. For 2022 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.</font></div><div style="margin-top:3.55pt;padding-left:6pt;padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.105%"><tr><td style="width:1.0%"></td><td style="width:29.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.1pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">AbbVie</font></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.4pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Eli Lilly</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.15pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Novartis</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.1pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Amgen</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.35pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">GlaxoSmithKline</font></div></td><td colspan="3" style="border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.15pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Pfizer</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.1pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Astra Zeneca</font></div><div style="margin-top:0.85pt;padding-left:5.1pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:17.45pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Roche</font></div><div style="margin-top:0.85pt;padding-left:17.4pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-right:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:13.15pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sanofi-Aventis</font></div><div style="margin-top:0.45pt;padding-left:13.15pt;padding-right:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead Sciences</font></div></td></tr></table></div><div style="margin-top:3.55pt;padding-left:10.8pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee intends that the list of Peer Healthcare Companies may be subject to such adjustment as may be necessary to reflect a merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.</font></div><div style="padding-right:10.5pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Share Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an award representing the right to vest in shares of Common Stock based upon the attainment level of the performance metrics in accordance with Section III and as otherwise described in these Terms. Until distributed pursuant to Section VI, these PSUs shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights&#59; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the number of shares of Common Stock that would become eligible to vest if the performance metrics set forth in Section &#160;III are each achieved at the level identified as &#8220;target&#8221; for the entire Award Period.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="margin-top:0.55pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Total Shareholder Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the change in value of one share of a company&#8217;s common stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">TSR Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the percentage reflecting the attainment level of Company&#8217;s TSR performance as determined under paragraph B of Section III.</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="padding-left:47pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.41pt">CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:10.95pt;padding-right:13.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (&#8220;Termination of Employment&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:19.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14.31pt">Performance Metrics. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:2.85pt;padding-left:49.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.92pt">TSR Performance Payout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The TSR Performance Payout shall be determined as follows&#58;</font></div><div style="margin-top:0.25pt;text-align:justify"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;If the Company&#8217;s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%&#59; provided, however, that if the Company&#8217;s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For example, if the Company&#8217;s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% &#91;100% + ((25% - 20%) x 5%)&#93;.</font></div><div style="padding-left:15.5pt;padding-right:22.6pt;text-align:justify"><font><br></font></div><div style="padding-left:15.5pt;padding-right:22.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Company&#8217;s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points&#59; provided, however, that if such median exceeds the Company&#8217;s annualized TSR by more than 10 percentage points, then the TSR Performance Payout will be 0%.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:25.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">EPS Performance Payout. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The EPS Performance Payout shall be determined in accordance with the following performance schedule&#58;</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41.7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.377%"><tr><td style="width:1.0%"></td><td style="width:61.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.15pt;padding-right:43.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Earnings Per Share Goals</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.4pt;padding-right:18.35pt;text-indent:9.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payout Percentage</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Less than $19.53</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">0%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$19.53 (Threshold)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:48.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$21.46 (Target)</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 49.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$22.75</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%150</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">$24.04 (Stretch)</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr></table></div><div style="margin-top:0.3pt;text-align:justify"><font><br></font></div><div style="margin-top:3.55pt;padding-left:42pt;padding-right:90.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.31pt">The Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50&#160;percent and (y) EPS Payout Percentage TIMES Target Shares TIMES 50&#160;percent. </font></div><div style="padding-left:15.5pt;padding-right:422.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Maximum Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Anything in these Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award, valued based on the closing price of the Common Stock as of the date the Final Award is determined, may not exceed four times the value of the Target Shares, valued based on the closing price of the Common Stock as of the Grant Date.</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">DIVIDEND EQUIVALENTS</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt;text-align:justify;text-indent:-1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Award Period, dividend equivalents will be accrued on the PSUs if and to the extent dividends are paid by the Company in the Common Stock. Payment of such dividend equivalents will be made, without interest or earnings, at the same time that the Final Award is paid. Such dividend equivalents shall be paid as additional shares in an amount equal to the sum of the dividends paid during the period between the Grant Date and the date immediately prior to the date the PSU Award is settled in accordance with Section VI divided by the price of a share of Common Stock on the date the Final Award is determined. If any portion of this PSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with Section&#160;X.</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="padding-left:41.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.26pt">TERMINATION OF EMPLOYMENT</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.5pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (&#8220;JV&#8221;) of the Company by which you are employed (the &#8220;Employer&#8221;) is terminated during the Award Period, your right to the PSU Award, where references to the Final Award in this section include any accrued dividend equivalents, will be determined according to the terms in this Section V and for grantees outside the United States, also in paragraph 12 of Section A (&#8220;Nature of Grant&#8221;) of Appendix B, Part I.</font></div><div style="margin-top:0.5pt;padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">General Rule. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment is terminated during the Award Period for any reason other than those specified in the following paragraphs, this PSU Award will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Involuntary Termination. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment terminates during the Award Period and the Company determines that employment was involuntarily terminated the Final Award will become eligible to vest when the Final Award is determined, provided you sign and refrain from revoking a severance agreement in a format prescribed by Merck Sharp &#38; Dohme LLC (&#8220;MSD&#8221;), which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. If your employment terminates during the Award Period, the Company determines that employment was involuntarily terminated on or after the first anniversary of the first day of the Award Period and you do not sign and refrain from revoking a severance agreement as outlined above, a pro rata portion of the Final Award will become eligible to vest when the Final Award is determined. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which you were employed by the Company or the Employer, as applicable, and the denominator of which is 36. The right to the remaining PSUs will be forfeited on the date your employment terminates.  An &#8220;involuntary termination&#8221; includes termination of employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of duties and </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:5.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the reasons listed under paragraphs C through G of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this PSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Sale. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment is terminated during the Award Period and the Company determines that such termination resulted from the sale of the subsidiary, affiliate, division or JV that employed you, the Final Award will become eligible to vest on the date the Final Award is determined, provided you sign and refrain from revoking a severance agreement in a format prescribed by MSD, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. Notwithstanding the foregoing, the Committee may determine, for purposes of this PSU Award, whether employment with an entity that is established from the Company&#8217;s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and&#47;or number of shares subject to this PSU Award.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.31pt">Retirement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you terminate employment during the Award Period by retirement (including early and disability retirement), a pro rata portion of the Final Award will become eligible to vest on the date the Final Award is determined. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which you were employed by the Company or the Employer, as applicable, and the denominator of which is 36.  For grantees who are employed in the U.S., &#8220;retirement&#8221; means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.  For other grantees, &#8220;retirement&#8221; is determined by the Company.  The right to the remaining PSUs underlying the Final Award will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="padding-left:6pt;padding-right:5.4pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:5.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.92pt">Death. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment terminates due to death during the Award Period but prior to the date of an employment termination contemplated under paragraphs B, C, D, G or H the Final Award will become eligible to vest on the date the Final Award is determined.  If you die during the Award Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, any portion of the Final Award that remains outstanding at your death will become eligible to vest on the date the Final Award is determined.</font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:18.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.54pt">Cause. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment is terminated for Cause, this PSU Award will be forfeited immediately upon your receipt of notice of such termination.  For purposes of this paragraph, &#8220;Cause&#8221; is as defined in your offer letter from MSD as an act or omission by you, which constitutes&#58; (i) a deliberate (and not justified and appropriate in the performance of your duties) or reckless disclosure of proprietary or other confidential information relating to the Company, MSD or one of their subsidiaries (each a &#8220;Merck Entity&#8221;), its personnel, research or business&#59; (ii) embezzlement, theft or other misappropriation of the assets of a Merck Entity&#59; (iii) deliberate or reckless falsification of records or reports&#59; (iv) deliberate bad faith or reckless action that causes actual or potential significant injury or loss to a Merck Entity and&#47;or its and&#47;or their employees&#59; (v) insubordination (meaning the repeated refusal to carry out work assignments and&#47;or direction)&#59; (vi) willful or repeated failure to perform assigned job duties&#59; (vii) an illegal act on the property of a Merck Entity or in representing a Merck Entity&#59; (viii) a material violation of a Company policy relating to the research, development, manufacturing, sales or marketing of Company products or the overall goodwill or reputation of the Company&#59; (ix) any action that would trigger the claw back provisions of any Bonus or Long-Term Incentive Plans applicable to you&#59; or a (x) breach by you of your representations as set forth in your offer letter from MSD.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.7pt">Disability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then the Final Award will become eligible to vest on the date the Final Award is determined. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this PSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:12.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.7pt">Change in Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Upon the occurrence of a Change in Control (as such term is defined in the Plan), the Final Award shall mean a number of PSUs equal to the Target Shares. If this PSU Award is </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:6pt;padding-right:12.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Award Period without Cause before the second anniversary of the closing of the Change in Control, then this PSU Award and dividend equivalents that have accrued through the end of the Award Period will continue to vest at the end of the original Award Period. If this PSU Award does not remain outstanding following the Change in Control and is not assumed, converted, or otherwise remains outstanding, then the PSU Award and dividend equivalents that have accrued through such date will immediately vest and, at the election of the Company, you will be entitled to receive cash for such portion of this PSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. &#8220;Cause&#8221; and &#8220;Change in Control&#8221; are defined in the Merck &#38; Co., Inc. Change in Control Separation Benefits Plan (excluding MSD Change in Control).</font></div><div><font><br></font></div><div style="padding-left:6pt;text-align:justify;text-indent:-1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:24.47pt">Good Reason. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you terminate employment for Good Reason, the RSU Award, and any accrued dividends, will continue to vest on the following original Vesting Date(s) set forth in paragraph I(A), provided you sign and refrain from revoking a severance agreement in a format prescribed by MSD, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. &#8220;Good Reason&#8221; is as defined in your offer letter from MSD and includes the following&#58;  a) a material reduction in base salary without your consent, unless such reduction is part of an across-the-board reduction affecting other Executive Team members in like proportions, b) your involuntary reassignment to any position other than a position on the Executive Team reporting to MSD&#8217;s Chief Executive Officer within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, or c) a material breach of your offer letter from MSD, provided that you deliver written notice of a claim of Good Reason to MSD&#8217;s Chief Executive Officer within thirty (30) days of the facts giving rise to such Good Reason, MSD fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after MSD&#8217;s failure to cure.</font></div><div style="padding-left:6pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify;text-indent:-1.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.25pt">Transfer of Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the &#8220;Company Group&#8221;) is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this PSU Award following a transfer of employment accordance with this section.</font></div><div style="padding-left:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">DISTRIBUTION OF SHARES</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following the end of the Award Period, you (or your estate, in the case of PSUs that vest pursuant to Section V(E)) shall be entitled to receive a number of shares of Common Stock equal to the Final Award (as modified to the extent provided under Section V and subject to Section X) plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible following the last day of the Award Period, but in no event later than the end of the calendar year immediately following the Award Period. </font></div><div style="padding-right:7.45pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">SECTION 409A COMPLIANCE</font></div><div style="padding-right:7.45pt;text-align:justify"><font><br></font></div><div style="padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anything in the Plan or these Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a &#8220;separation from service (as defined in Section 409A of the Code)&#8221; and any such payment to a &#8220;Specified Employee&#8221; as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied&#59; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.</font></div><div style="padding-right:7.45pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12.47pt">SUBJECT TO RECOUPMENT</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This PSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company&#8217;s Policies and Procedures for Recoupment of Compensation for </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">TRANSFERABILITY</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to distribution pursuant to Section VI, the PSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.</font></div><div style="padding-left:5.95pt;padding-right:12.7pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.31pt">TAX WITHHOLDING</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regardless of any action the Company and&#47;or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (&#8220;Tax-Related Items&#8221;), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and&#47;or the Employer, if any. You further acknowledge that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the PSU, the subsequent sale of shares of Common Stock acquired upon the expiration of the Award Period and the receipt of any dividends and&#47;or dividend equivalents&#59; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the PSU to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="padding-left:0.06pt;padding-right:18.15pt;text-align:justify"><font><br></font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and&#47;or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following&#58; (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and&#47;or any subsidiary, affiliate or JV of the Company&#59; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at expiration of the Award Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization)&#59; or (iii) withholding in shares of Common Stock to be issued upon expiration of the Award Period&#59; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the PSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and&#47;or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested PSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="padding-left:41.75pt;padding-right:12.95pt;text-align:right"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.03pt">DATA PRIVACY</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company&#8217;s data processing practices and declare your consent. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company&#8217;s legal basis for the processing of your personal data would be your consent.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company&#8217;s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.92pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company&#8217;s legal basis for the transfer of your personal data is your consent.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.31pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee&#59; you would merely forfeit the opportunities associated with the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.54pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and&#47;or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn&#58; Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.14pt">The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company&#8217;s Global Privacy and Data Protection Policy.  You also understand that the Company may, in the future, request you to provide another data privacy consent.&#160; If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and&#47;or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.&#160; You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and&#47;or the Employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you agree with the data processing practices described in this Section, you will declare your consent by clicking to &#34;Accept&#34; these Terms on the Morgan Stanley website.</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">GOVERNING LAW</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.47pt">SEVERABILITY</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.09pt">WAIVER</font></div><div style="padding-left:5.75pt;padding-right:12.95pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.</font></div><div style="padding-right:12.95pt"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:17.37pt">ELECTRONIC ACCEPTANCE</font></div><div style="padding-left:6pt;padding-right:12.7pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:12.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XVI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.09pt">COUNTRY-SPECIFIC APPENDIX</font></div><div style="padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The PSU Award shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of the PSU Award, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan. </font></div><div style="padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">XVII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.81pt">ADMINISTRATION</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Committee is responsible for construing and interpreting this PSU Award, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this PSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among Eligible Employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.</font></div><div style="padding-left:5.95pt;padding-right:12.7pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to the Committee&#8217;s powers set forth in the Plan, anything in these Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.</font></div><div style="padding-left:9pt;padding-right:7.65pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:8.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This PSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your PSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync &#62; HR &#62; Money &#62; Long-Term Incentive Program </font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:0.06pt;padding-right:18.15pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id5dea9796cbd434cb5b219c77c0527b1_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-top:2.5pt;padding-left:74.4pt;padding-right:74.4pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="padding-left:74.45pt;padding-right:74.45pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Policy</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">It is the policy of the Compensation and Management Development Committee of the Board of Directors (the &#8220;Committee&#8221;) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and&#47;or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that&#58; a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company&#59; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee&#8217;s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.</font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">In addition, awards under the Executive Incentive Plan (&#8220;EIP&#8221;) and Performance Share Units (&#8220;PSU&#8221;) under the Merck &#38; Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company&#8217;s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Definitions</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Recoupment&#8221; is defined to include any and all of the following actions to the extent permitted by law&#58; (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and&#47;or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">A &#8220;Material Violation&#8221; is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company&#8217;s overall goodwill or reputation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">An &#8220;Affected Employee&#8221; is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation&#59; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Executive&#8221; means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Fault&#8221; means fraud or willful misconduct. &#34;Willful misconduct&#34; is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally&#59; something more than negligence.  If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.</font></div><div style="padding-left:6pt;padding-right:11.15pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">&#8220;Significant Harm&#8221; means a significant negative impact on the Company&#8217;s financial operating results or reputation.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">For Compliance Violations</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The Committee, acting in consultation with the Audit Committee, shall administer this policy and have</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify;text-indent:-9.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;padding-left:2.37pt">In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">For EIP Awards and PSUs Upon </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Significant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"> Restatement of Financial Results </font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EIP Awards and PSUs for Executives are subject to the Company&#8217;s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement&#8212;that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above)&#59; and</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results&#59; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.</font></div><div style="padding-right:11.15pt;text-align:justify"><font><br></font></div></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.268%"><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (&#8220;GAAP&#8221;) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Delegation to Management for Certain Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Disclosure of Recoupment Decisions</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nothing in this policy shall limit or otherwise affect any of the following&#58; 1) management&#8217;s ability to take any disciplinary action with respect to any Affected Employee&#59; 2) the Committee&#8217;s ability </font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div></div><div style="display:inline-block;max-width:5.463%;min-width:4.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.269%"><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">to use its negative discretion with respect to any incentive compensation performance target at any time&#59; or 3) the Committee&#8217;s or management&#8217;s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</font></div><div style="padding-left:6pt;padding-right:14.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Committee shall have sole discretion to make all determinations under this policy.  Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the &#8220;Applicable Rules&#8221;).  To the extent the Applicable Rules require recovery of any bonus and&#47;or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.</font></div><div style="padding-left:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.</font></div></div></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id5dea9796cbd434cb5b219c77c0527b1_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDITIONAL TERMS AND CONDITIONS FOR GRANTEES OUTSIDE THE U.S.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix, which is part of the Global Terms and Conditions for 2022 Performance Share Unit Grants under the Merck &#38; Co., Inc. 2019 Incentive Stock Plan, contains additional &#8220;terms and conditions&#8221; that will apply to you if you reside outside the United States.  </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The terms and conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Part I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> of this Appendix apply to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> grantees who reside outside the United States.  The additional terms and conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Part II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> of this Appendix will also apply to you if you reside in one of the countries referenced in Part II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The information in this Appendix is based on the laws in effect in the respective countries as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">April 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the information in this Appendix as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that the Award Period expires and shares of Common Stock are issued to you or you sells shares of Common Stock acquired under the Plan.  </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the information contained in this Appendix is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result.  Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finally, if you are a citizen or resident of a country, or are considered a resident of a country, other than that in which you are currently working, or transfer residence and&#47;or employment after the Grant Date, the information contained herein may not apply to you in the same manner.  The Company shall, in its sole discretion, determine to what extent the terms and conditions included herein will apply under these circumstances.  </font></div><div><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX B - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PART I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; ADDITIONAL TERMS AND CONDITIONS FOR ALL COUNTRIES OUTSIDE OF THE UNITED STATES</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:4.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following additional terms and conditions will apply to you if you reside in any country outside the United States.   </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:2.81pt">Nature of Grant</font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In accepting the PSU Award, you acknowledge and agree that&#58;</font></div><div style="padding-left:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended, or terminated by the Company at any time&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the grant of the PSU Award is exceptional, voluntary, and occasional and does not create any contractual or other right to receive future grants of PSUs, or benefits in lieu of PSUs, even if PSUs have been granted in the past&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">all decisions with respect to future PSU grants, if any, will be at the sole discretion of the Company&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">your participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">your participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company and shall not interfere with the ability of the Employer to terminate your employment or service relationship (if any) at any time&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the PSU Award and any shares of Common Stock acquired under the Plan, and income from and value of same, are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Employer, the Company, or any subsidiary, affiliate, or JV of the Company, and that are outside the scope of your employment or service contract, if any&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">unless otherwise agreed with the Company in writing, the PSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of a subsidiary, affiliate, or JV of the Company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the PSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the PSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any parent, subsidiary, affiliate or JV of the Company&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">the future value of the shares of Common Stock underlying the PSUs is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">no claim or entitlement to compensation or damages shall arise from termination of the PSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">for purposes of the PSU Award, your employment relationship will be considered terminated as of the date you are no longer providing services to the Employer or the Company or any subsidiary, affiliate or JV (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this document, your right to vest in the PSUs under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period or any period of &#8220;garden leave&#8221; or similar period mandated under local law&#59; the Committee shall have the exclusive discretion to determine when you are no longer providing services for purposes </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the grant (including whether you may still be considered to be providing services while on a leave of absence)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">the PSU Award and the benefits under the Plan, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">the Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendation regarding your participation in the Plan, or the acquisition or sale of underlying shares&#59; you should consult with your personal tax, legal and financial advisors regarding the decision to participate in the Plan and before taking any action related to the Plan&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt">neither the Employer, nor the Company or any subsidiary, affiliate or JV shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the PSU Award or any amounts due to you pursuant to the vesting of the PSU Award, the subsequent sale of shares acquired under the Plan or the receipt of any dividends and&#47;or dividend equivalents.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:3.42pt">Insider Trading&#47;Market Abuse Laws</font></div><div style="margin-bottom:9pt;padding-left:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that, depending on your or your broker&#8217;s country of residence or where shares of Common Stock are listed, you may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., PSUs) or rights linked to the value of shares of Common Stock under the Plan during such times that you are considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws or regulations in the applicable jurisdictions or your country).  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. You should keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  You understand you are responsible for ensuring compliance with any restrictions and should consult with your personal legal advisor on this matter.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:2.81pt">Foreign Asset&#47;Account, Exchange Control and Tax Obligations</font></div><div style="margin-bottom:9pt;padding-left:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that, depending on your country, you may be subject to foreign asset&#47;account, exchange control and&#47;or tax reporting requirements as the result of the acquisition of shares of Common Stock or cash (including dividend equivalents, dividends, and the proceeds of the sale of shares of Common Stock) derived from your participation in the Plan, in, to and&#47;or from a brokerage&#47;bank account or legal entity located outside your country. The applicable laws of your country may require that you report such accounts, assets, the balances therein, the value thereof and&#47;or the transactions related thereto to the applicable authorities in your country. You may also be required to repatriate cash received from participating in the Plan to your country within a certain time after receipt. You acknowledge that you are responsible for ensuring compliance with any applicable foreign asset&#47;account, exchange control and tax reporting requirements and should consult your personal tax, legal and&#47;or financial advisors regarding the same.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:2.81pt">Language</font></div><div style="margin-bottom:9pt;padding-left:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You acknowledge that you are proficient in the English language or have consulted with an advisor who is sufficiently proficient, to allow you to understand the terms and conditions of this document. If you have received this document, or any other document related to the PSU Award and&#47;or the Plan translated into a language other than English, and if the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:3.42pt">Imposition of Other Requirements and Issuance of Shares</font></div><div style="margin-bottom:9pt;padding-left:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company reserves the right to impose other requirements on the PSUs and the shares of Common Stock acquired pursuant to the PSU Award, to the extent the Company determines it is necessary or advisable in order to comply with local laws or facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:9pt;padding-left:4.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In particular, if advisable due to local law requirements, the Committee, in its sole and absolute discretion, may require the immediate forced sale of the shares of Common Stock issuable upon settlement of the PSUs.  </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:4.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alternatively, unless otherwise set forth in this Appendix, the Committee, in its sole and absolute discretion, may determine to pay out the PSUs in cash equal to the fair market value of the shares of Common Stock underlying the PSUs.</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX B - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">PART II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; COUNTRY-SPECIFIC ADDITIONAL TERMS AND CONDITIONS AND NOTIFICATIONS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Country</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Terms and Conditions and Notifications</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Australia</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Australian Offer Document</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer document sets out information regarding the offer to participate in the Plan for Australian resident grantees of the Company and its subsidiaries, affiliates and JVs.  This information is provided by the Company to ensure compliance of the offer with Australian Securities and Investments Commission (&#8220;ASIC&#8221;) Class Order 14&#47;1000, ASIC Regulatory Guide 49 and relevant provisions of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Corporations Act 2001</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to the information set out in this Appendix B, you are also being provided with copies of the following documents&#58; </font></div><div style="padding-left:57.75pt;padding-right:2.75pt;text-align:justify;text-indent:-27.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the Plan&#59;</font></div><div style="padding-left:57.75pt;padding-right:2.75pt;text-align:justify;text-indent:-27.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the Plan Prospectus (which contains a summary of the Plan)&#59; </font></div><div style="padding-left:57.75pt;padding-right:2.75pt;text-align:justify;text-indent:-27.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;the Terms&#59;</font></div><div style="padding-left:57.75pt;padding-right:2.75pt;text-align:justify;text-indent:-27.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;LTI Program Overview&#59; and</font></div><div style="margin-bottom:12pt;padding-left:57.75pt;padding-right:2.75pt;text-align:justify;text-indent:-27.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the summary of tax consequences of participation in the Plan for Australia, which is accessible by logging into your account at Morgan Stanley</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(collectively, the &#8220;Additional Documents&#8221;).</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Additional Documents provide further information to help you make an informed investment decision about participating in the Plan.  Neither the Plan nor the Plan Prospectus is a prospectus for the purposes of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Corporations Act 2001</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You should not rely upon any oral statements made in relation to this offer. You should rely only upon the statements contained in this Appendix B and the Additional Documents when considering participation in the Plan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">General Information Only</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The information herein is general information only. It is not advice or information that takes into account your objectives, financial situation and needs.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You should consider obtaining your own financial product advice from a person who is licensed by ASIC to give such advice.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Risks of Participation in the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Investment in shares of Common Stock involves a degree of risk.  If you elect to participate in the Plan, you should monitor your participation and consider all risk factors relevant to the vesting or issuance of shares of Common Stock under the Plan as set forth below and in the Additional Documents.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You should have regard to risk factors relevant to investment in securities generally and, in particular, to holding shares of Common Stock of the Company.  For example, the value at which an individual share of Common Stock is quoted on the New York Stock Exchange (&#8220;NYSE&#8221;) may increase or decrease due to a number of factors.  There is no guarantee that the value of a share of Common Stock will increase.  Factors that may affect the value of an individual share of Common Stock include fluctuations in the domestic and international market for listed stocks, general economic conditions, including interest rates, inflation rates, commodity and oil prices, changes to government fiscal, monetary or regulatory policies, legislation or regulation, the nature of the markets in which the Company operates and general operational and business risks.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">More information about potential factors that could affect the Company&#8217;s business and financial results will be included in the Company&#8217;s most recent Annual Report on Form 10-K and the Company&#8217;s Quarterly Report on Form 10-Q.  Copies of these reports are available at http&#58;&#47;&#47;www.sec.gov&#47;, on the Company&#8217;s &#8220;Investor Relations&#8221; page at https&#58;&#47;&#47;investors.merck.com&#47;home&#47;default.aspx, and upon request to the Company.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, you should be aware that the Australian dollar (&#8220;AUD&#8221;) value of any shares of Common Stock acquired under the Plan will be affected by the USD&#47;AUD exchange rate.  Participation in the Plan involves certain risks related to fluctuations in this rate of exchange.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock in a U.S. Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Common stock of a U.S. corporation is analogous to ordinary shares of an Australian corporation.  Each holder of a share of Common Stock is entitled to one vote.  Further, shares of Common Stock are not liable to any further calls for payment of capital or for other assessment by the Company and have no sinking fund provisions, pre-emptive rights, conversion rights or redemption provisions.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ascertaining the Market Value of Shares of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You may ascertain the current market value of an individual share of Common Stock as traded on the NYSE under the symbol &#8220;MRK&#8221; at&#58; https&#58;&#47;&#47;www.nyse.com&#47;quote&#47;XNYS&#58;MRK.  The AUD equivalent of that value can be obtained at&#58; https&#58;&#47;&#47;www.rba.gov.au&#47;statistics&#47;frequency&#47;exchange-rates.html. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">This will not be a prediction of the market value of an individual share of Common Stock when the Award vests or shares of Common Stock are issued under the Plan or of the applicable exchange rate on the vesting date or the date the shares of Common Stock are issued.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the &#8220;Tax Assessment Act&#8221;) applies (subject to the conditions in the Tax Assessment Act).</font></div></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Austria</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Belgium</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance with Law</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the PSU Award, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the settlement of the PSU Award, the sale of shares obtained pursuant to the PSU Award, and the receipt of any dividends or dividend equivalents.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgment </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the PSU Award, you agree that you are (i) making an investment decision and (ii) the value of the underlying shares of Common Stock is not fixed and may increase or decrease in value over the Award Period without compensation to you.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Further, you acknowledge and agree that, for all legal purposes, (i) any benefits provided to you under the Plan are unrelated to your employment or service&#59; (ii) the Plan is not a part of the terms and conditions of your employment or service&#59; and (iii) the income from your participation in the Plan, if any, is not part of your remuneration from employment or service.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The People's Republic of China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The following terms and conditions apply only to grantees who are citizens of the PRC or are otherwise determined to be subject to the requirements imposed by the State Administration of Foreign Exchange (&#8220;SAFE&#8221;) as determined by the Company.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">The following terms and conditions apply only if you are classified as Band 600 and higher on the Grant Date. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award and Termination of Employment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be permitted to hold shares of Common Stock issued to you at the end of the Award Period.  Notwithstanding anything to the contrary in the Plan or Terms, due to exchange control laws in China, you agree that any shares of Common Stock acquired under the Plan and held by you at the time of your termination of employment with the Company or the Employer will be sold on your behalf, pursuant to this authorization, as soon as administratively practicable following the termination of your employment, but no later than six-months following termination of employment.  The Company is under no obligation to arrange for such sale at any particular price.  You will receive the sale proceeds, less any broker&#8217;s fees or commissions and subject to satisfaction of any Tax-Related Items.  If the Terms provide that all or a portion of your outstanding PSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and be sold on your behalf as described above.  Any other portion of your PSU Award that is not vested as described above will expire immediately upon your termination of employment.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Due to local regulatory requirements, you agree that the Company may force the sale of any shares of Common Stock issued under the Plan.  The sale may occur (i) immediately upon vesting or (ii) within any other time frame as the Company determines to be necessary or advisable for legal or administrative reasons.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Broker Account</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any shares of Common Stock issued to you at expiration of the Award Period must be maintained in an account with Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future until the shares of Common Stock are sold through that broker.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exchange Control Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand and agree that, to comply with exchange control laws in the PRC, any cash dividends, dividend equivalents and the proceeds from the sale of the shares of Common Stock will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you.  The funds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and&#47;or the Company so that the funds may be deposited into this account.  In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China.  You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">The following terms and conditions apply only if you are classified as below Band 600 on the Grant Date. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment of Award </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To facilitate compliance with exchange control laws in China, any PSU Award granted to you will be settled in cash only.  This means that upon vesting of your PSU Award, you will receive in cash the value of the underlying shares of Common Stock at expiration of the Award Period, less any broker&#8217;s fees or commissions and Tax-Related Items, which will be remitted to you in accordance with applicable exchange control laws and regulations.  You will not be permitted to hold shares of Common Stock after vesting.  The Company reserves the right to settle the PSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exchange Control Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand and agree that, to comply with exchange control laws in the PRC, the cash payable to you at expiration of the Award Period will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you.  The funds may be paid to you in U.S. dollars or local currency at the Company&#8217;s discretion.  To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and&#47;or the Company so that the funds may be deposited into this account.  In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China.  You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination of Employment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any terms or conditions of the Plan or the &#8220;Termination of Employment&#8221; section of the Terms to the contrary, the cash equivalent of any shares of Common Stock that vest upon termination of your employment will be distributed to you no later than six months from the date of termination of your employment, as determined by the Company in accordance with the Terms, or within any other such timeframe as may be required by SAFE.  If the Terms provide that all or a portion of your outstanding PSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and become distributable immediately upon your termination of employment as described above.  Any other portion of your PSU Award that is not vested as described above will expire immediately upon your termination of employment.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Denmark</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision supplements the &#8220;Nature of Grant&#8221; section of this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the PSU Award, you understand and agree that this grant relates to future services to be performed and is not a bonus or compensation for past services.</font></div></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">France</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your PSU Award is not intended to be French tax-qualified.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Language Consent </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the PSU Award, you confirm having read and understood the Plan and your Terms, which were provided in the English language.  You accept the terms of those documents accordingly.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">En acceptant l&#8217;attribution, vous confirmez avoir lu et compris le Plan de travail et vos conditions g&#233;n&#233;rales et dispositions, qui ont &#233;t&#233; transmis en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Germany</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ireland</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The grant of the PSU Award under the Plan is being made pursuant to an exemption from the requirement to file and publish a prospectus in Israel regarding the Plan obtained from the Israeli Securities Authority.  Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission will be sent to you, at no charge, on written request being mailed to Investor Relations at Merck &#38; Co., Inc., 2000 Galloping Hill Road, Kennilworth, NJ 07033, U.S.A. The telephone number at the executive offices is 1-908-740-4000. Alternatively, copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by searching the Company&#8217;s filings on the following web site&#58; http&#58;&#47;&#47;www.sec.gov&#47;edgar&#47;searchedgar&#47;companysearch.html.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trust Arrangement</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand and agree that the PSU Award are offered subject to and in accordance with the terms of the Plan, the Addendum A - Israel to the Plan (the &#8220;Israeli Sub-Plan&#8221;), the Trust Agreement (the &#8220;Trust Agreement&#8221;) between the Company and the Company&#8217;s trustee appointed by the Company or its subsidiary or affiliate in Israel, currently ESOP Management and Trust Services Ltd. (the &#8220;Trustee&#8221;), and the Terms.  In the event of any inconsistencies between the Israeli Sub-Plan, the Terms and&#47;or the Plan, the Israeli Sub-Plan will govern the PSU Award granted to you in Israel. Capitalized terms used but not defined in this Appendix B for Israel, the Plan or the Terms have the meanings set forth in the Israeli Sub-Plan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Requirement to Return Signed Confirmation Letter</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You are required to execute the Confirmation Letter - Trustee 102 Awards (&#8220;Confirmation Letter&#8221;) provided to you in connection with the Awards granted to you under the Israeli Sub-Plan.  In particular, you must print, sign and deliver a signed copy of the Confirmation Letter to the Trustee within thirty (30) days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, for the PSU Award to qualify for preferential tax treatment.  By accepting this PSU Award, you acknowledge and agree that the terms and conditions of the Confirmation Letter are hereby incorporated by reference into the Terms and shall apply to shares of Common Stock acquired upon expiration of the Award Period of the PSU Award. If the Trustee does not receive the signed Confirmation Letter within 30 days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, the PSU Award may not qualify for favorable tax treatment.  For more details, please contact Daphna Ben-Ari at daphna.ben-ari&#64;merck.com or +972 9533306.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confirmation of Section 102 Capital Gains Award Terms</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The PSU Award is intended to be Capital Gain Awards that qualify for the tax treatment for Approved 102 Awards that are designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance. Notwithstanding the foregoing, by accepting the PSU Award, you acknowledge that the Company cannot guarantee that the Capital Gain Award tax treatment will apply to the PSU Award granted to you.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the PSU Award, you&#58; (a) acknowledge receipt of and represent that you have read and understand the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms&#59; (b) accept the PSU Award subject to all of the terms and conditions of the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms&#59; and (c) agree that the shares of Common Stock issued to upon expiration of the Award Period of the PSU Award will be issued to and deposited with the Trustee and shall be held in trust for your benefit as required by the Ordinance, the Israeli Sub-Plan and any approval by the Israeli Tax Authority pursuant to the terms of the Ordinance, the Israeli Sub-Plan and the Trust Agreement.  Furthermore, by accepting the PSU Award, you confirm that you understand  the terms and provisions of Section 102 of the Ordinance, particularly the capital gains track described in subsection (b)(2) and (b)(3) thereof, and agree that you will not require the Trustee to release the shares of Common Stock acquired upon expiration of the Award Period of the PSU Award to you or sell the shares of Common Stock to a third party, during the Holding Period, unless permitted to do so by the Ordinance or the Israeli Sub-Plan.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Italy</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan Document Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting the PSU Award, you further acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms in their entirety and fully understand and accept all provisions of the Plan and the Terms&#59; in particular, you acknowledge that you have read and specifically and expressly approve the following provisions in the Plan and the Terms&#58; (a) your PSU Award cannot be transferred other than by will or the laws of descent and distribution&#59; (b) in the event of involuntary termination of your employment, your right to receive Awards and to receive distributions from Awards, if any, will terminate as of the date that you are no longer actively employed by the Employer, unless otherwise expressly provided in the Terms&#59; (c) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time&#59; (d) you are responsible for all Tax-Related Items&#59; (e) if a reorganization, recapitalization, reclassification or other corporate event that results in an adjustment of the shares of Common Stock described in the Plan occurs, your PSU Award may be adjusted&#59; (f) if a Change in Control, as described in the Plan, occurs, your PSU Award may immediately vest&#59; (g) all decisions with respect to future grants will be at the sole discretion of the Company&#59; and (h) the &#8220;Data Privacy&#8221; section of your Terms.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Netherlands</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restriction on Sale and Transferability</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You hereby agree that any shares of Common Stock acquired pursuant to the PSU Award will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the PSU Award, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (&#8220;SFA&#8221;) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The PSU Award is being granted to you pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the PSU Award being subsequently offered for sale to any other party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Director Notification</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or JV of the Company, you are subject to certain notification requirements under the Singapore Companies Act.  Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or JV in writing when you receive an interest (e.g., PSU Awards, shares of Common Stock) in the Company or any related companies.  In addition, you must notify the Singaporean subsidiary, affiliate or JV when you sell shares of the Company&#8217;s common stock or any related company (including when you sell shares of Common Stock acquired upon the expiration of the Award Period).  These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company.  In addition, a notification must be made of your interests in the Company or any related company within two days of either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information&#58; equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A &#8220;family member&#8221; means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Spain</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Labor Law Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This provision supplements the &#8220;Nature of Grant&#8221; section of this Appendix B&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By accepting this PSU Award, you acknowledge that you understand and agree that you consent to participation in the Plan and that you have received a copy of the Plan.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You understand that the Company, in its sole discretion, has unilaterally and gratuitously decided to distribute Awards under the Plan to individuals who may be employees of the Company or its subsidiaries, affiliates or JVs throughout the world.  The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its subsidiaries, affiliates or JVs over and above the specific terms of the Plan on an ongoing basis.  Consequently, you understand that any PSU Award is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its subsidiaries, affiliates or JVs) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.  Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary Award since the future value of the PSU Award and shares of Common Stock is unknown and unpredictable.  In addition, you understand that the PSU Award would not be made to you but for the assumptions and conditions referred to above&#59; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any PSU Award shall be null and void.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You also understand and agree that, as a condition of the grant of the PSU Award, the termination of your employment for any reason (including the reasons listed below), the PSU Award will cease vesting immediately effective on the date you are no longer providing services to the Employer or the Company or any of its subsidiaries, affiliates or JVs (unless otherwise specifically provided in the Terms).  In particular, you understand and agree that the PSU Award will be forfeited without entitlement to the underlying shares of Common Stock or to any amount as indemnification in the event of a termination of your employment as described in the Terms prior to expiration of the Award Period by reason of, including but not limited to, resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, subject to &#8220;despido improcednte&#8221;), individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers&#8217; Statute, relocation under Article 40 of the Workers&#8217; Statute, Article 50 of the Workers&#8217; Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382&#47;1985.  </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No &#8220;offer of securities to the public,&#8221; as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the PSU Award.  The Plan and the Terms have not been nor will they be registered with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Comisi&#243;n Nacional del Mercado de Valores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and do not constitute a public offering prospectus.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sweden</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authorization to Withhold</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following provision supplements the &#8220;Tax Withholding&#8221; section of the Terms&#58; </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Without limiting the Company&#8217;s and the Employer&#8217;s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the &#8220;Tax Withholding&#8221; section of the Terms, in accepting the PSU Award, you authorize the Company and&#47;or the Employer to withhold shares of Common Stock or to sell shares of Common Stock otherwise deliverable to you upon settlement to satisfy Tax-Related Items, regardless of whether the Company and&#47;or the Employer have an obligation to withhold such Tax-Related Items.</font></div></td></tr></table></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Switzerland</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Law Information</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The offering of participation in the Plan is considered a private offering in Switzerland&#59; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax Acknowledgment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company or, if different, your Employer or by Her Majesty&#8217;s Revenue and Customs (&#8220;HRMC&#8221;) (or any other tax authority or any other relevant authority).  You also agree to indemnify and keep indemnified the Company and, if different, your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the amount of any income tax not collected from or paid by you within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Items occurs may constitute a benefit to you on which additional income tax and National Insurance contributions may be payable.  You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and&#47;or the Employer (as appropriate) the amount of any employee National Insurance contributions due on this additional benefit, which may also be recovered from you through any means set forth in the &#8220;Tax Withholding&#8221; section of the Terms.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>19
<FILENAME>exhibit1037-mrkchirfiguind.htm
<DESCRIPTION>EXHIBIT-10.37 OFFER LETTER (GUINDO)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i25f89d50594d41ceb0aa6740772f43c2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.37</font></div></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="mercklogotoprightcornera.jpg" src="mercklogotoprightcornera.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div><div><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 8, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chirfi Guindo</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Chirfi,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is my pleasure to offer you a position with Merck Sharp &#38; Dohme LLC (&#8220;MSD&#8221; or the &#8220;Company&#8221;), a wholly-owned subsidiary of Merck &#38; Co., Inc. (&#8220;Merck&#8221;), as its Chief Marketing Officer (the &#8220;Position&#8221;) on the terms and conditions set forth in this offer letter (&#8220;letter&#8221; or &#8220;offer letter&#8221;).  We see ourselves as a company inspired to invent, and determined to discover, develop, and deliver medicines and vaccines that will improve the lives of more people in more places around the world. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity and teamwork of people like you.&#160; We strive to create an environment of mutual respect, encouragement and teamwork that enables our employees to achieve our mission.&#160; As part of our global team, you'll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your offer of employment in the Position is subject to the approval of your appointment by the Board of Directors of Merck.&#160;&#160;If approved, you will be a member of the Executive Team (formerly known as the &#8220;Executive Committee&#8221;), an Officer of Merck (as defined in Section 16 of the Securities Exchange Act of 1934) and will report to me (or my successor as Chief Executive Officer).&#160;&#160;The Position will initially be based at our offices in Kenilworth, NJ.  In 2023, with the move of our corporate headquarters, the Position will be based in Rahway, NJ.  We have advised you not to alter your current employment status until all the contingencies have been satisfied.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Our offer includes the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Total Compensation</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Base Salary&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#160;You will be paid a gross annual salary of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$700,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This will be paid (bi-weekly) at a rate of approximately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$26,923</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> per pay period. You will be eligible for consideration for a salary increase on an annual basis.  Your base salary will be subject to applicable payroll deductions and withholdings.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:18.45pt;padding-right:8.95pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">Executive Incentive Plan (EIP)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">You will be eligible to participate in the Executive Incentive Plan (EIP) as it applies to similarly situated employees, subject to the terms of the plan. The target bonus for performance year 2022 for the Position is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%">80% </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">of your annual base salary. The bonus is discretionary and the amount of the bonus, if any, will be determined based on Merck performance. To be eligible for an EIP award, you must be actively employed on or before October 1 and remain actively employed through December 31 of the plan year. Your EIP award, if any, will be pro-rated based on the time you were in an EIP-eligible position during that plan year. Bonuses, if any, for the current performance year will be paid in or about March of the following year.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                                                                                                                                </font></div><div style="padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">        Chirfi Guindo </font></div><div style="padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">         Page 1 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div style="padding-left:18pt;padding-right:7.2pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Long-Term Incentive (LTI) Program&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be eligible for consideration for annual grants of stockbased incentives under the Incentive Stock Plan beginning in the annual cycle following the year you begin employment and, for as long as you remain employed, for each annual cycle thereafter. For Executive Team members, annual grants generally include a mix of non-qualified stock options and performance share units (PSUs), with the number and proportion of shares covered by such incentives determined by the Compensation and Management Development Committee of the Board of Directors of Merck (the &#34;Committee&#34;). The current annual grant value for the Position is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">$2,500,000, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">comprised of 70% PSUs and 30% non-qualified stock options. The exact number of shares granted will be determined based on the value of Merck stock on the date of grant.  Currently, annual grants of Merck </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#38; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Co., Inc. stock options vest in equal installments over three years and PSUs are subject to a 3-year performance period. </font></div><div style="padding-left:18pt;padding-right:7.2pt;text-align:justify;text-indent:0.45pt"><font><br></font></div><div style="padding-left:18.45pt;padding-right:7.4pt;text-align:justify;text-indent:0.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Distribution of shares in connection with PSUs and stock options is dependent on continued employment with Merck, MSD or one of Merck or MSD's subsidiaries (&#34;Merck Entity&#34;)&#59; additionally, the level of PSU payout is contingent on Merck performance. Please note that the value and terms and conditions of any future grants may change from time to time. The specific terms and conditions of your grant(s) will be provided to you shortly after the grant(s) are made.</font></div><div style="padding-left:18.45pt;padding-right:7.4pt;text-align:justify;text-indent:0.15pt"><font><br></font></div><div style="padding-left:18.6pt;padding-right:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be subject to our stock ownership guidelines. The guidelines are intended to reinforce our philosophy concerning &#34;ownership&#34; and, in a concrete way, quantify our expectations concerning ownership of Merck. The guidelines provide that you should acquire Merck stock, over time, equal in value to three times your annual base salary. Importantly, the LTI program - and retention of shares earned in connection therewith - is intended to facilitate the acquisition of shares. Also, there is no required time frame under which you will be required to achieve your stock ownership requirement, however, you will be subject to a 75% retention requirement until you achieve the required base salary multiple.</font></div><div style="padding-left:18.45pt;padding-right:7.4pt;text-align:justify;text-indent:0.15pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Sign-On Incentives</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sign-On Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; You will receive a cash sign-on bonus in the aggregate amount of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$530,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, less applicable payroll deductions and withholdings, payable within thirty days of your start date.  Your right to retain the sign-on bonus is conditioned upon your continued employment with a Merck Entity for two years.  By your signature below, you agree that, if prior to completing two years of employment, you voluntarily terminate your employment with a Merck Entity without Good Reason, as defined below, or if a Merck Entity terminates your employment for Cause, as defined below, you will reimburse the full amount of the sign-on bonus (&#34;Repayment Obligation&#34;).&#160; You further authorize the Company to withhold any and all monies otherwise owed to you, to the extent permitted by law, as payment against such Repayment Obligation.&#160; In such case, such monies will be credited towards the Repayment Obligation, but will not relieve you of your obligation to pay the balance of any Repayment Obligation. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;Cause&#34;  as used in this offer letter means an act or omission by you, which constitutes&#58; (i) a deliberate (and not justified and appropriate in the performance of your duties) or reckless disclosure of proprietary or other confidential information relating to a Merck Entity, its personnel, research or business&#59; (ii) embezzlement, theft or other misappropriation of the assets of  a Merck Entity&#59; (iii) deliberate or reckless falsification of records or reports&#59; (iv) deliberate bad faith or reckless action that causes actual or potential significant injury or loss to a Merck Entity and&#47;or its and&#47;or their employees&#59; (v) insubordination (meaning the repeated refusal to carry out work assignments and&#47;or direction)&#59; (vi) willful or repeated failure to perform assigned job duties&#59; (vii) an illegal act on the property of a Merck Entity or in representing a Merck Entity&#59; (viii) a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company&#59; (ix) any action that would trigger the claw back provisions of any Bonus or Long-Term Incentive Plans applicable to you&#59; or a (x) breach by you of your representations as set forth in this letter.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Good Reason&#8221; is defined to include the following&#58;  a) a material reduction in base salary without your consent, unless such reduction is part of an across-the-board reduction affecting other Executive Team members in like proportions,  b) your involuntary reassignment to any position other than a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                                                                                                                                </font></div><div style="padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">        Chirfi Guindo </font></div><div style="padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">         Page 2 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">position on the Executive Team reporting to the Company&#8217;s Chief Executive Officer  within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, or c) a material breach of this letter, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that you deliver written notice of a claim of Good Reason to the Company&#8217;s  Chief Executive Officer within thirty (30) days of the facts giving rise to such Good Reason, MSD fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after MSD&#8217;s failure to cure.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sign-On Equity&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will receive sign-on equity incentives valued at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$12,200,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, $2,500,000 in the form of Performance Share Units and $9,700,000 in the form of restricted stock units (RSUs).  Merck &#38; Co., Inc. RSU grants are currently scheduled to be made shortly after the release of company earnings each quarter.  The date of your sign-on PSU and RSU grants will be the quarterly grant immediately following your start date (the next quarterly grant date is scheduled for August 2, 2022).  Subject to its terms, this PSU grant is subject to a 3-year performance period and this RSU grant will vest one-third on each anniversary of the grant date.  Both grants will be eligible for continued vesting as provided under the Severance section of this letter below.  A summary of terms and conditions associated with this PSU and RSU grant will be provided to you shortly after the grants are made.  Under current equity terms, should you die while actively employed, the terms of Merck&#8217;s PSU grants provide for vesting on the date the final award is determined and RSU grants provide for immediate vesting plus dividend equivalents accrued through your date of death. Should you become disabled and your employment is terminated as a result, the terms of Merck&#8217;s PSU grants provide for vesting on the date the final award is determined and RSU grants provide for continued vesting on the original vesting dates and dividend equivalents through such corresponding vesting dates.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Benefits</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Health and Insurance Benefits Program&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  You will be eligible to participate in the Health and Insurance Benefits Program, which automatically provides you with basic life insurance and short-term disability coverage. It also allows you to choose from various options including medical, dental, vision, voluntary and dependent life insurance, long-term disability and flexible spending accounts. For most benefits, participation begins on your date of hire.  The Benefits Service Center at Fidelity will mail a Benefits New Hire Package to you within 2 weeks of your hire date. This Package provides important information and instructions for enrolling in your benefits.  You will have 30 days from the date Fidelity mails your benefits information to enroll.  If you do not enroll by the date indicated in the Package, you automatically will be enrolled in medical coverage for you only in the Horizon BlueCross BlueShield PPO plan option (which includes prescription drug coverage), dental coverage for you only, company-provided basic life insurance and short-term and long-term disability coverage.  If you enroll dependents under your medical coverage, you will receive an e-mail and&#47;or letter from HMS Employer Solutions (an independent third-party vendor designated to conduct dependent eligibility verifications) requesting documentation to verify your dependent eligibility.  Failure to respond or provide required documentation within the required timeframe will result in the removal of your dependent(s) from benefits coverage.  In addition, your eligibility for retiree medical coverage will be determined based on Plan rules in effect, using your age and total years of service, at that time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pension Plan&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be eligible to participate in the tax-qualified and non-qualified U.S. Pension Plan, which is a defined benefit pension plan that uses a cash balance formula to calculate your benefit. Your benefit is expressed as a notional account balance that grows with annual Pay Credits ranging from 4.5% to 10.0% of your total pay (based on age and service) and Interest Credits of 3% plus the annual rate of change in the Consumer Price Index (not less than 3.3%).  In addition, your prior pension plan benefit will be restored and the value of your benefit will be determined based on Plan rules in effect, using your age and years of service at that time. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">401(k)&#47;Savings Plan&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be eligible to participate in the U.S. Savings Plan (&#8220;Savings Plan&#8221;).  Within 2 weeks following your date of hire, the Benefits Service Center at Fidelity will mail to you a separate enrollment package for the Savings Plan.  You may contribute to the Savings Plan on a before-tax, Roth, and after-tax basis. The Savings Plan provides a 75% match of the first 6% of total pay (4.5% </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                                                                                                                                </font></div><div style="padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">        Chirfi Guindo </font></div><div style="padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">         Page 3 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of total pay) that you contribute per pay period (subject to plan limits and IRS limits).  If you do not make an active election within 60 days of your hire date, you automatically will be enrolled to contribute 6% base pay and 6% EIP on a before-tax basis, with an annual increase of 1% until you reach a contribution rate of 10%. To maximize the company match, you must contribute at least 6% of your base pay and 6% of your EIP.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deferral Program&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Beginning in 2023, you will be eligible to defer (1) a portion of your base salary and&#47;or (2) all or part of your EIP bonus, if any. You will receive detailed information just prior to the annual enrollment period in December 2022.  In addition, the company will contribute 4.5% of your eligible pay exceeding the Internal Revenue Code pay limit ($305,000 for 2022) to an account established on your behalf. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Planning&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160; You will be eligible to participate in the executive financial planning program, which provides an annual cash allowance of $10,000 payable in&#160;December of each calendar year.&#160; If your start date is on or before October 1 of this calendar year, you will be eligible to commence this benefit in the same calendar year.  If you start after October 1, you will be eligible to commence the benefit in the subsequent calendar year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vacation and Paid Holiday Policy&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> You will be eligible for 30 vacation days per year in accordance with Company policy, as well as 12 company paid holidays and 4 year-end shutdown days between the Christmas and New Year&#8217;s Day holidays.  The number of vacation days for which you are eligible in your first year of employment is dependent upon your date of hire.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Military Reservists&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Merck is a Military Friendly Employer and we proudly offer a generous military leave policy for those that are eligible. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Workplace Accommodations&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">We support employees of all abilities. The Company&#8217;s Workplace EnABLEment program offers employees the resources they need to contribute at the highest level and to advance the business goals of the Company.  If you need an accommodation, contact the Workplace Accommodation Team via email at workacc&#64;merck.com or by phone at 1-866-675-4748.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Relocation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160; You will be eligible for benefits under our Domestic Relocation Policy. As part of our standard domestic relocation benefits, MSD will pay or reimburse you for certain expenses in accordance with this Policy. A global mobility representative will be assigned to you and will be available to explain your specific benefits as well as address any questions you may have.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severance&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> As an employee of MSD, you will be an employee at-will. This means that either you or MSD may terminate the employment relationship at any time for any lawful reason or for no reason. In order to accommodate any concerns you may have in joining MSD, MSD agrees that in the event MSD terminates your employment for a reason other than Cause (as defined above) or you terminate your employment for Good Reason (as defined above) prior to such time when all of your Sign-On Equity is fully vested, then you will be entitled to continue to vest in the Sign-On Equity granted to you (&#8220;Severance Benefit&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that your right to receive the Severance Benefit would be conditioned upon your signing and refraining from revoking a Severance Agreement in a format prescribed by MSD, which Agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides.  This Severance Benefit would be in addition to any other severance or separation pay that you may be entitled to under any applicable plan or policy of MSD or Merck.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the avoidance of doubt, you will be credited for your prior service with the Company eligible in accordance with the terms and conditions on Company plans and policies as those plans and policies apply generally to other Company employees. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change in Control</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Merck has adopted a &#8220;Change in Control&#8221; (CIC) Program.  The Merck CIC Program specifies the types of compensation and benefits-related protections to be provided to eligible Merck employees in the event of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                                                                                                                                </font></div><div style="padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">        Chirfi Guindo </font></div><div style="padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">         Page 4 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a change in control of Merck &#38; Co., Inc.  You will participate as an Executive Team member at the band level applicable under the program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Right to Amend or Terminate Plans, Programs and Policies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The compensation and benefits described in this letter are provided under and subject to the terms and conditions of the applicable plans, programs and policies of MSD, Merck and&#47;or the applicable Merck Entity. &#160;Nothing in this letter in any way limits the right of Merck &#38; Co., Inc. and&#47;or a Merck Entity to amend or terminate those plans, programs or policies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 409A</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer letter shall be interpreted to comply with section 409A of the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder (&#8220;section 409A&#8221;) or an exemption thereto.  Notwithstanding anything in this offer letter to the contrary, payments made pursuant to the offer letter may only be made in a manner and upon an event permitted by section 409A, and all payments to be paid to you upon termination of employment may only be made upon a &#8220;separation from service&#8221; as defined under section 409A.  If section 409A applies to payments under this offer letter, this offer letter shall be administered in accordance with section 409A, including the six-month delay for &#8220;specified employees,&#8221; if applicable.  Each payment under this offer letter, that is part of a series of installment payments, shall be treated as a separate payment for purposed of section 409A.  In no event may you, directly or indirectly, designate the calendar year of any payment.  You are solely responsible for any taxes under this offer letter and in no event will Merck have any liability with respect to any tax, interest or other penalty imposed under section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit under this offer letter (or otherwise referenced herein) is determined to be subject to (and not exempt from) section 409A, the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year will not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other calendar year, in no event will any expenses be reimbursed after the last day of the calendar year following the calendar year in which you incurred such expenses, and in no event will any right to reimbursement or the provision of any in-kind benefit be subjected to  liquidation or exchange for another benefit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Representations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer is made to you based upon your representations that (i) your employment with Merck will not conflict with, or result in the breach of, or violation of, any other agreement, instrument, order, judgment or decree to which you are a party or by which you are bound, and (ii) you are not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity that would restrict your employment with Merck and not provided to Merck for its independent review.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By your signature below, you affirm that these representations are true.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to Board approval, this offer is contingent upon your successful completion of a pre-placement drug screen, satisfactory verification of your employment, education, criminal check, satisfactory references and background check results and, if applicable, proof of your eligibility to work in the United States.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(A List of Acceptable Documents that establishes your eligibility to work in the U.S., which you are required to bring with you on your first day of work, will be forwarded to you upon your acceptance of the offer). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Your employment with Merck is at-will (meaning that you and the Company remain free to end the employment relationship at any time, for any lawful reason, either with or without prior notice) and additionally will be subject to certain terms and conditions of employment, which have been provided to you with this offer.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">We advise you not to alter your current employment status until all of the contingencies have been satisfied.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing herein shall be construed as creating a contract for a specific duration between you and the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Please call </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Steve Mizell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> upon receipt of this letter to acknowledge your acceptance of this offer and to begin your &#8220;on boarding&#8221; process for employment.  Beth Perrone will be your initial point of contact </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                                                                                                                                </font></div><div style="padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">        Chirfi Guindo </font></div><div style="padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">         Page 5 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">throughout the on boarding process and will confirm your start date upon successful completion of the above contingencies.&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">In addition, please print, sign, scan and return this offer letter via email to Steve.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With your abilities and experience, I know you will be able to contribute to the Company and benefit from its growth.  I believe this position offers an outstanding career opportunity and look forward to your acceptance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert Davis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">___________</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Robert Davis</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I accept the employment offer and its terms contained in this letter.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Chirfi Guindo             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">June 9, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Chirfi Guindo&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                                                                                                                                                </font></div><div style="padding-left:360pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">        Chirfi Guindo </font></div><div style="padding-left:396pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">         Page 6 of 6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>20
<FILENAME>exhibit21-clean2x22x23.htm
<DESCRIPTION>EXHIBIT-21 SUBSIDIARY LIST
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i06fed1754efe4f6ca62ddcc28d24a3b2_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 21 - MERCK &#38; CO., INC. SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">changes as of 12&#47;31&#47;2022</font></div><div style="margin-bottom:21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The following is a list of subsidiaries of the Company, doing business under the name stated.</font></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Country or State</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Incorporation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7728026 Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abmaxis Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acceleron Pharma Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afferent Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agrident GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agro Verhen B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aleis Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Argentina S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Australia Pty. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex dan-mark ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Europe Holdings 1 B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:0.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Europe Holdings 2 B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Europe Holdings 3 B.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Netherlands</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Europe S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Group Germany GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Holdings 1 Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Holdings 2 Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Holdings 3 Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex India Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex International do Brasil Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Maroc S.A.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex New Zealand Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Polska Spolka z ograniczona odpowiedzialnoscia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex SCR Vostok</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belarus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex Services S.A.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex UK Group Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allflex USA, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antelliq Finance, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antelliq Holdings France S.A.S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antimicrobial Stewardship LLC</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ArQule, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Allflex Plastic Products Co. Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Protection Science &#38; Technology Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biomark  LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idaho</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRC Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burgwedel Biotech GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calporta Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge Resonant Technologies Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canji, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cCam Biotherapeutics Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cherokee Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chevillot S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controladora MSD Mexicana Sociedad de Responsabilidad Limitada de Capital Variable</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cooper Veterinary Products (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporation Allflex, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cosmas B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cubist Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialstat Trading 91 Pty Ltd T&#47;A Allflex SA</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digital Angel S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diosynth France S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diosynth Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diosynth Produtos Farmo-quimicos Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drovers ID Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DSD Holding ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elastec S.R.L</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Essex Pharmaceuticals, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Essexfarm, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecuador</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmacox - Companhia Farmaceutica, Lda </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmasix-Produtos Farmaceuticos, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financiere MSD</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fontelabor-Produtos Farmaceuticos, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frosst Laboratories, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frosst Portuguesa - Produtos Farmaceuticos, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Farm S.A. </font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GlycoFi, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hangzhou MSD Pharmaceutical Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harrisvaccines LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hawk and Falcon L.L.C.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Services and Solutions, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heptafarma Companhia Farmaceutica, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hydrochemie GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idenix GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Canada Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Deutschland GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN North America Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IdentiGEN Switzerland AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="background-color:#f3f1f1;color:#555555;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune Design Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Indemnity Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Ireland) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Israel) Ltd.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (M) Sdn. Bhd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet (Thailand) Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet AB</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Agencies B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Animal Health Taiwan Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Argentina S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Australia Pty Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Canada Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Central America S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Deutschland GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Ecuador S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecuador</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Egypt for Animal Health SAE</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet GesmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Hellas A.E.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Holdings France SAS</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Hungaria &#201;rt&#233;kes&#237;t&#337; Kft</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet India Pvt Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet International B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet International GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet International Sarl</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Maroc S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Mexico S.A. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Middle East Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyprus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Nederland B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Philippines, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Productions S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Productions S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Romania SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet SAS</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Schering-Plough Animal Health Pty. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet South Africa (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Sp. z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet UK Production Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Venezolana S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Veterinaria Chile Ltda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet Veteriner Ilaclari Pazarlama ve Ticaret Ltd. Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intervet, s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interveterinaria SA de CV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IOmet Pharma Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratoires Merck Sharp &#38; Dohme</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Abello, S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Quimico-Farmaceuticos Chibret, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lemifar S. A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matsuken Yakuhin Kogyo K.K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maya Tibbi &#220;r&#252;nler Ticaret Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MCM Vaccine B.V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck and Company LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Capital Ventures, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Frosst Canada &#38; Co.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Frosst Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Global Health Innovation Fund, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Global Health Innovation, Private Equity, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck HDAC Research, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Holdings II Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Holdings IV Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Holdings LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck International Holdings Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Lumira Biosciences Fund L.P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Registry Holdings, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Research Investments LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Research Laboratories Massachusetts, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Argentina) LLC</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Asia) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Australia) Pty. Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Chile) Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (China) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Enterprises) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Europe) Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Holdings) Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (I.A.) LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (International) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Israel - 1996) Company Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Malaysia) SDN. BHD.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (New Zealand) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Sweden) A.B.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (Switzerland) GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme (UK) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Animal Health, S.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Asia Pacific Services Pte. Ltd.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme BH d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Bulgaria EOOD</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Colombia S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Comercializadora, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Cyprus Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyprus</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme d.o.o. Belgrade</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme de Espana SAU</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Farmaceutica Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Finance Europe Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Gesellschaft m.b.H.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Holdings Corp.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme IDEA GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme inovativna zdravila d.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme International Services B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Ireland (Human Health) Ltd</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Latvija</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latvia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bolivia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Manufacturing Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme OU</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estonia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Peru SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:21.35pt;padding-right:2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Pharmaceutical Industrial and Commercial Societe Anonyme</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Research GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Romania SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Morocco</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Salud Animal Colombia S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Saude Animal Ltda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Singapore Trading Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme Tunisie SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunisia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme, Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme, S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp &#38; Dohme, s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Sharp Dohme Ilaclari Limited Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck Teknika LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merko Acquisition S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merko Dalton B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merko N.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ML Holdings (Canada) Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRL San Francisco, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MRL Ventures Fund LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (I.A.) B.V. </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (L-SP) Unterst&#252;tzungskasse GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Ningbo) Animal Health Technology Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Nippon Holdings) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Norge) AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Proprietary) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Shanghai) Pharmaceuticals Consultancy Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD (Thailand) Ltd.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Agencies B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health UK Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:0.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health (Phils.), Inc</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health (Shanghai) Trading Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health A&#47;S</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Danube Biotech GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health FZ-LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Holdings BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Innovation SAS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health K.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Korea Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Norge AS</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Oy</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Pension Trustee Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health Vietnam Co. Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Animal Health, Lda.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Argentina Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Argentina SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Asia Holdings Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Belgium BV &#8211; SRL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Biotech B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Brazil Investments B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Central America Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD China (Investments) B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD China B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD China Holding Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Cubist Holdings BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Cubist Holdings Unlimited Company</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Czech Republic s.r.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Danmark ApS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Egypt LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD EIC Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Eurofinance</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Europe Belgium BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Farmaceutica C.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD FI BV</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Finance B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Finance Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Finland Oy</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD France</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Global Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD HH Vietnam Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Holdings 2 G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Human Health Holding B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Human Health Holding II B.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD IDEA Algerie SPA</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Algeria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD IDEA Pharmaceuticals Nigeria Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD IDEA Tunisie SARL</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunisia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Innovation &#38; Development GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Business GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Finance B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Finance LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD International Manufacturing GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Italia s.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Japan Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Japan Holdings GK</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD K.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD KSA GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Korea Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Laboratories India LLC</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Latin America Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Latin America Services S. de R.L. de C.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Luxembourg S.a.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Merck Sharp &#38; Dohme AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD NL 4 B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Panama International Services S. de R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Participations B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharma (Singapore) Pte. Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharma GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharma Hungary Korlatolt Felelossegu Tarsasag</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Investments 1 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Investments 3 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Ireland Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russian Federation</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Pharmaceuticals Private Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Polska Dystrybucja Sp. z.o.o.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Polska Sp.z.o.o.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD R&#38;D (China) Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD R&#38;D Innovation Centre Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD RDC Costa Rica Sociedad de Responsabilidad Limitada</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Rica</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Registry Holdings, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Shared Business Services EMEA Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4pt;padding-left:3.25pt;padding-right:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Sharp &#38; Dohme Gesellschaft mit beschr&#228;nkter Haftung</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4pt;padding-left:3.25pt;padding-right:2.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Switzerland Investments 1 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Switzerland Investments 4 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Switzerland Investments 5 Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Ukraine Limited Liability Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Unterstutzungskasse GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vaccines Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vaccins</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vaccins Holdings</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Venezuela Holding GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Verwaltungs GmbH</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vietnam Company Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSD Vietnam Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSDIG Holdings Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSDRG LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSP Singapore Company, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSP Vaccine Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multilan AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nanjing Organon Pharmaceutical Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nihon MSD G.K.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nourifarma - Produtos Quimicos e Farmaceuticos, Sociedade Uniperssoal, Lda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O.PI.VI S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OBS Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncoethix GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OncoImmune, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon China B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Egypt Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Latin America S.A.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organon Middle East S.A.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS ID AS</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS ID Hellas M.I.K.E</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P.T. Merck Sharp &#38; Dohme Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pandion Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pandion Operations, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peloton Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polnet ID Spolka z ograniczona odpowiedzialnoscia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PrognostiX-Poultry Limited </font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prondil Sociedad An&#243;nima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Intervet Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Organon Indonesia</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Putexin Investments Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigontec GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rosetta Inpharmatics LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S.C. Allflex Romania S.R.L.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S.C.R. (Engineers) Limited</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough, S.A.S.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough (Ireland) Unlimited Company</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Animal Health Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Corporation</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Corporation, U.S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough del Peru S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough Holdings Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paraguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schering-Plough S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uruguay</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCR Allflex Management, Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sentipharm AG</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Servicios Veternarios Servet, Sociedad An&#243;nima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costa Rica</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai MSD Pharmaceutical Trading Co., Ltd.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Siren Merger Sub Inc.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sistemas de Identificacao Animal Ltda</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SmartCells, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SOL Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stallmastaren AB</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureFlap (NZ) Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SureFlap Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag ID Investments, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Themis Bio Holdings LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Themis Bio Holdings B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Themis BioScience GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Theriak B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tilos Therapeutics, Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB Merck Sharp &#38; Dohme</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaki Aquaculture Systems ehf.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iceland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VelosBio Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VelosBio Canada Inc.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vence Corp</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.394%"><tr><td style="width:1.0%"></td><td style="width:76.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vence Corp AU Pty Ltd</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venco Farmaceutica S.A.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venezuela</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venco Holding GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vet Pharma Friesoythe GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veterinaria Premium, Sociedad Anonima</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guatemala</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VetInvent, LLC</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vetrex B.V.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vetrex Egypt L.L.C.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilsan Veteriner Ilaclari Ticaret ve Sanayi Anonim Sirketi</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viralytics Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vocaltag Limited</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vree Health Italia S.r.l.</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Werthenstein Biopharma GmbH</font></div></td><td colspan="3" style="border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zo&#246;pharm B.V.</font></div></td><td colspan="3" style="border-bottom:1pt solid #00000a;border-left:1pt solid #00000a;border-right:1pt solid #00000a;border-top:1pt solid #00000a;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:3.35pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:201%">___________</font></div><div style="padding-right:50.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:201%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:201%"> own less than 100%</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:167%">24</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>21
<FILENAME>ex23-consentofindependentr.htm
<DESCRIPTION>EXHIBIT-23 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i08ae51f46ae14354924db40a9395d8e0_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form&#160;S-3 (Nos.&#160;333-254700 and 333-254703) and on Form&#160;S-8 (Nos. 333-173025, 333-173024, 333-162883, 333-162884, 333-162885, 333-162886, 333-121089, and 333-233226) of Merck&#160;&#38; Co., Inc. of our report dated February&#160;24, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form&#160;10-K.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>22
<FILENAME>ex241-powerofattorney11.htm
<DESCRIPTION>EXHIBIT-24.1 POWER OF ATTORNEY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id89b9ce1dc15455085bb0122c383a7c4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 24.1 </font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;text-decoration:underline">POWER OF ATTORNEY </font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Each of the undersigned does hereby appoint JENNIFER ZACHARY as his&#47;her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck&#160;&#38; Co., Inc. for the fiscal year ended December&#160;31, 2022 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith. </font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">IN WITNESS WHEREOF, this instrument has been duly executed as of the 24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:138%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> day of February 2023. </font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">MERCK&#160;&#38; CO., Inc. </font></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:24.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert M. Davis</font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer&#59; Director)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:24.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline Litchfield </font></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rita A. Karachun</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance&#8212;Global Controller</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rita A. Karachun</font></div></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</font></td></tr></table></div><div style="margin-top:13pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">DIRECTORS </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:42.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Douglas M. Baker, Jr.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul B. Rothman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas M. Baker, Jr.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul B. Rothman</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mary Ellen Coe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Patricia F. Russo</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mary Ellen Coe</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia F. Russo</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Pamela J. Craig</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christine E. Seidman</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pamela J. Craig</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine E. Seidman</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas H. Glocer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Inge G. Thulin</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas H. Glocer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inge G. Thulin</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Risa J. Lavizzo-Mourey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathy J. Warden</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risa J. Lavizzo-Mourey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathy J. Warden</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Stephen L. Mayo</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter C. Wendell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen L. Mayo</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter C. Wendell</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.2
<SEQUENCE>23
<FILENAME>ex242-certificationofboard.htm
<DESCRIPTION>EXHIBIT-24.2 CERTIFICATION OF BOARD RESOLUTION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5e8f51cb65bd44068d87ef6b6d422376_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 24.2 </font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">I, Kelly Grez, Corporate Secretary of Merck &#38; Co., Inc. (the &#8220;Company&#8221;), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 24, 2023 in accordance with the provisions of the By-Laws of the Company&#58; </font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%;text-decoration:underline">&#8220;Special Resolution No. &#91;13&#93; &#8211; 2023</font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">RESOLVED, that the proposed form of the Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2022, attached hereto, is hereby approved with such changes as the proper officers of the Company, with the advice of counsel, deem appropriate&#59; </font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">FURTHER RESOLVED, that each officer and director who may be required to execute the aforesaid Annual Report on Form 10-K or any amendments thereto (whether on behalf of the Company or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) is hereby authorized to execute a power of attorney appointing Jennifer Zachary as his&#47;her true and lawful attorney to execute in his&#47;her name, place and stead (in any such capacity) such Annual Report on Form&#160;10&#8209;K and any and all amendments thereto and any and all exhibits and other documents necessary or incidental in connection therewith and to file the same with the Securities and Exchange Commission, the attorney to have power to act and to have full power and authority to do and perform in the name and on behalf of each of said officers and directors, or both, as the case may be, every act whatsoever necessary or advisable to be done in the premises as fully and to all intents and purposes as any such officer or director might or could do in person&#59; and</font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">FURTHER RESOLVED that an executed copy of the Action by Unanimous Written Consent be filed with the minutes of the meetings of the Board of Directors of the Company.&#34;</font></div><div style="padding-left:42.75pt;padding-right:42.75pt;text-align:justify;text-indent:49.5pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%">IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 24</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:138%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:138%"> day of February 2023. </font></div><div style="text-indent:24.75pt"><font><br></font></div><div style="text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:48.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.612%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Corporate Seal&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly Grez</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly Grez<br>Corporate Secretary</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>24
<FILENAME>ex311-rule13ax14a15dx14ace.htm
<DESCRIPTION>EXHIBIT-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1a324ad36fc3420696d0280fcf49a42e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert M. Davis, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2023 </font></div><div style="margin-top:15pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.321%"><tr><td style="width:1.0%"></td><td style="width:9.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Chairman, President and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>25
<FILENAME>ex312-rule13ax14a15dx14ace.htm
<DESCRIPTION>EXHIBIT-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0370312175714fc3b6fb15a877420003_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Caroline Litchfield, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;February&#160;24, 2023 </font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.514%"><tr><td style="width:1.0%"></td><td style="width:9.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>26
<FILENAME>ex321-section1350certifica.htm
<DESCRIPTION>EXHIBIT-32.1 SECTION 1350 CERTIFICATION OF CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1ba52dd240904977800f1cd1b5b3023c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  February 24, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;   ROBERT M. DAVIS</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;     Chairman, President and Chief&#160;Executive&#160;Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>27
<FILENAME>ex322-section1350certifica.htm
<DESCRIPTION>EXHIBIT-32.2 SECTION 1350 CERTIFICATION OF CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5030e6dc84844c30977896ed99b1e544_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  February 24, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-45pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;    CAROLINE LITCHFIELD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;      Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>mrk-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6a80835e-3d33-418a-be61-33ea02b302af,g:f2b57eeb-4f2d-41ff-83c8-1b4e9f7a4523-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrk="http://www.merck.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merck.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.merck.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.merck.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofIncome" roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome">
        <link:definition>0000003 - Statement - Consolidated Statement of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofComprehensiveIncome" roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statement of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheet" roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet">
        <link:definition>0000005 - Statement - Consolidated Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetParenthetical" roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheet (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofEquity" roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity">
        <link:definition>0000007 - Statement - Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofEquityParenthetical" roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statement of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlowsParenthetical" roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical">
        <link:definition>0000010 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://www.merck.com/role/NatureofOperations">
        <link:definition>0000011 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPolicies" roleURI="http://www.merck.com/role/SummaryofAccountingPolicies">
        <link:definition>0000012 - Disclosure - Summary of Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCo" roleURI="http://www.merck.com/role/SpinOffofOrganonCo">
        <link:definition>0000013 - Disclosure - Spin-Off of Organon &amp; Co.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicensingAgreements" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements">
        <link:definition>0000014 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangements" roleURI="http://www.merck.com/role/CollaborativeArrangements">
        <link:definition>0000015 - Disclosure - Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.merck.com/role/Restructuring">
        <link:definition>0000016 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.merck.com/role/FinancialInstruments">
        <link:definition>0000017 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.merck.com/role/Inventories">
        <link:definition>0000018 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibles" roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles">
        <link:definition>0000019 - Disclosure - Goodwill and Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeases" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases">
        <link:definition>0000020 - Disclosure - Loans Payable, Long-Term Debt and Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilities" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities">
        <link:definition>0000021 - Disclosure - Contingencies and Environmental Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.merck.com/role/Equity">
        <link:definition>0000022 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlans" roleURI="http://www.merck.com/role/ShareBasedCompensationPlans">
        <link:definition>0000023 - Disclosure - Share-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlans" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans">
        <link:definition>0000024 - Disclosure - Pension and Other Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNet" roleURI="http://www.merck.com/role/OtherIncomeExpenseNet">
        <link:definition>0000025 - Disclosure - Other (Income) Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncome" roleURI="http://www.merck.com/role/TaxesonIncome">
        <link:definition>0000026 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.merck.com/role/EarningsperShare">
        <link:definition>0000027 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>0000028 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.merck.com/role/SegmentReporting">
        <link:definition>0000029 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPoliciesPolicies" roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies">
        <link:definition>0000030 - Disclosure - Summary of Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoTables" roleURI="http://www.merck.com/role/SpinOffofOrganonCoTables">
        <link:definition>0000031 - Disclosure - Spin-Off of Organon &amp; Co. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicensingAgreementsTables" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables">
        <link:definition>0000032 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsTables" roleURI="http://www.merck.com/role/CollaborativeArrangementsTables">
        <link:definition>0000033 - Disclosure - Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.merck.com/role/RestructuringTables">
        <link:definition>0000034 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.merck.com/role/FinancialInstrumentsTables">
        <link:definition>0000035 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.merck.com/role/InventoriesTables">
        <link:definition>0000036 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesTables" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables">
        <link:definition>0000037 - Disclosure - Goodwill and Other Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesTables" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables">
        <link:definition>0000038 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.merck.com/role/EquityTables">
        <link:definition>0000039 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansTables" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables">
        <link:definition>0000040 - Disclosure - Share-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansTables" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables">
        <link:definition>0000041 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetTables" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables">
        <link:definition>0000042 - Disclosure - Other (Income) Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeTables" roleURI="http://www.merck.com/role/TaxesonIncomeTables">
        <link:definition>0000043 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.merck.com/role/EarningsperShareTables">
        <link:definition>0000044 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>0000045 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.merck.com/role/SegmentReportingTables">
        <link:definition>0000046 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsDetails" roleURI="http://www.merck.com/role/NatureofOperationsDetails">
        <link:definition>0000047 - Disclosure - Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofAccountingPoliciesDetails" roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails">
        <link:definition>0000048 - Disclosure - Summary of Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoNarrativeDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails">
        <link:definition>0000049 - Disclosure - Spin-Off of Organon &amp; Co. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails">
        <link:definition>0000050 - Disclosure - Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails">
        <link:definition>0000051 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000052 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsNarrativeDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails">
        <link:definition>0000053 - Disclosure - Collaborative Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsFinancialInformationDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails">
        <link:definition>0000054 - Disclosure - Collaborative Arrangements - Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.merck.com/role/RestructuringNarrativeDetails">
        <link:definition>0000055 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesActivitiesbyTypeofCostDetails" roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails">
        <link:definition>0000056 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesbyProgramDetails" roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails">
        <link:definition>0000057 - Disclosure - Restructuring - Activities by Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000058 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofNetInvestmentHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
        <link:definition>0000059 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails">
        <link:definition>0000060 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000061 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails">
        <link:definition>0000062 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails">
        <link:definition>0000063 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000064 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails">
        <link:definition>0000065 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000066 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
        <link:definition>0000067 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesDetails" roleURI="http://www.merck.com/role/InventoriesInventoriesDetails">
        <link:definition>0000068 - Disclosure - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesDetails_1" roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1">
        <link:definition>0000068 - Disclosure - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.merck.com/role/InventoriesNarrativeDetails">
        <link:definition>0000069 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails">
        <link:definition>0000070 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesNarrativeDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails">
        <link:definition>0000071 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangiblesOtherIntangiblesDetails" roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails">
        <link:definition>0000072 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesNarrativeDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails">
        <link:definition>0000073 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesLongTermDebtDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails">
        <link:definition>0000074 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails">
        <link:definition>0000075 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails">
        <link:definition>0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1">
        <link:definition>0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandEnvironmentalLiabilitiesDetails" roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails">
        <link:definition>0000077 - Disclosure - Contingencies and Environmental Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.merck.com/role/EquityNarrativeDetails">
        <link:definition>0000078 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityShareholdersEquityDetails" roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails">
        <link:definition>0000079 - Disclosure - Equity - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansNarrativeDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails">
        <link:definition>0000080 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails">
        <link:definition>0000081 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails">
        <link:definition>0000082 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails">
        <link:definition>0000083 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails">
        <link:definition>0000084 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansNarrativeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails">
        <link:definition>0000085 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000086 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails">
        <link:definition>0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1">
        <link:definition>0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails">
        <link:definition>0000088 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails">
        <link:definition>0000089 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails">
        <link:definition>0000090 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails">
        <link:definition>0000091 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails">
        <link:definition>0000092 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails">
        <link:definition>0000093 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails">
        <link:definition>0000094 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails">
        <link:definition>0000095 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails">
        <link:definition>0000096 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetNarrativeDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails">
        <link:definition>0000097 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails">
        <link:definition>0000098 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeNarrativeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails">
        <link:definition>0000099 - Disclosure - Taxes on Income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeIncomeBeforeTaxesDetails" roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails">
        <link:definition>0000100 - Disclosure - Taxes on Income - Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeTaxesonIncomeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails">
        <link:definition>0000101 - Disclosure - Taxes on Income - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeDeferredIncomeTaxesDetails" roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails">
        <link:definition>0000102 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeIncomeTaxAuthorityDetails" roleURI="http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails">
        <link:definition>0000103 - Disclosure - Taxes on Income - Income Tax Authority (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeUnrecognizedTaxBenefitsDetails" roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails">
        <link:definition>0000104 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareCalculationsofEarningsPerShareDetails" roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails">
        <link:definition>0000105 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>0000106 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossDetails" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails">
        <link:definition>0000107 - Disclosure - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails">
        <link:definition>0000108 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSalesofCompanysProductsDetails" roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails">
        <link:definition>0000109 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails">
        <link:definition>0000110 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails">
        <link:definition>0000111 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" roleURI="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails">
        <link:definition>0000112 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails">
        <link:definition>0000113 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" abstract="false" name="ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" abstract="true" name="FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" abstract="true" name="SichuanKelunBiotechBiopharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProfitShare" abstract="false" name="ProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_DebtSecuritiesandEquitySecuritiesFVNI" abstract="false" name="DebtSecuritiesandEquitySecuritiesFVNI" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_InventoriesProducedinPreparationforProductLaunchesMember" abstract="true" name="InventoriesProducedinPreparationforProductLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IncomeTaxesPayableMember" abstract="true" name="IncomeTaxesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DevelopedMarketsEquitySecuritiesMember" abstract="true" name="DevelopedMarketsEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A170NotesDue2027Member" abstract="true" name="A170NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PrevymisMember" abstract="true" name="PrevymisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearFive" abstract="false" name="LongTermDebtInterestPayableYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" abstract="false" name="DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" abstract="false" name="CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A0.500Notesdue2024Member" abstract="true" name="A0.500Notesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" abstract="false" name="ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_VerquvoMember" abstract="true" name="VerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CommercialandOtherLitigationMember" abstract="true" name="CommercialandOtherLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CancidasMember" abstract="true" name="CancidasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.90NotesDue2024Member" abstract="true" name="A2.90NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PremiumOnSharesAcquired" abstract="false" name="PremiumOnSharesAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ThemisMember" abstract="true" name="ThemisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AdempasMember" abstract="true" name="AdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VaqtaMember" abstract="true" name="VaqtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.75NotesDue2025Member" abstract="true" name="A2.75NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" abstract="false" name="OffsettingAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_A280NotesDue2023Member" abstract="true" name="A280NotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" abstract="false" name="LicenseOptionPaymentRelatedToCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ManufacturingAndSupplyAgreementsMember" abstract="true" name="ManufacturingAndSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrk_CorporateObligationsFixedIncomeSecuritiesMember" abstract="true" name="CorporateObligationsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SegmentReportingUnallocatedOtherExpensesNet" abstract="false" name="SegmentReportingUnallocatedOtherExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LivestockMember" abstract="true" name="LivestockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" abstract="false" name="RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_A1.875Notesdue2026Member" abstract="true" name="A1.875Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LegalDefenseCostsMember" abstract="true" name="LegalDefenseCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillBeNoncash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_JanumetMember" abstract="true" name="JanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" abstract="false" name="DeferredTaxAssetsUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IntangibleAssetsExcludingGoodwillLineItems" abstract="true" name="IntangibleAssetsExcludingGoodwillLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotyetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DunboyneMember" abstract="true" name="DunboyneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_KeytrudaMember" abstract="true" name="KeytrudaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VelosBioMember" abstract="true" name="VelosBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OrnaTherapeuticsMember" abstract="true" name="OrnaTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" abstract="false" name="RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" abstract="false" name="IntangibleAssetProductsAndProductRightsMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearThree" abstract="false" name="LongTermDebtInterestPayableYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PensionPlanNetLossMember" abstract="true" name="PensionPlanNetLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" abstract="false" name="AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" abstract="true" name="NotesSubjectToRepaymentAtOptionOfHolderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" abstract="true" name="FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A0.50eurodenominatednotesdue2024Member" abstract="true" name="A0.50eurodenominatednotesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementNumberOfResearchPrograms" abstract="false" name="CollaborativeArrangementNumberOfResearchPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearTwo" abstract="false" name="LongTermDebtInterestPayableYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" abstract="false" name="AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearOne" abstract="false" name="LongTermDebtInterestPayableYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SimponiMember" abstract="true" name="SimponiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_Pneumovax23Member" abstract="true" name="Pneumovax23Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CompanionAnimalsMember" abstract="true" name="CompanionAnimalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProbableContingentPaymentsCollaborativeArrangement" abstract="false" name="ProbableContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsSalesBased" abstract="false" name="PotentialFutureMilestonePaymentsSalesBased" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ChargesRelatedToProgramDiscontinuation" abstract="false" name="ChargesRelatedToProgramDiscontinuation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A3.40NotesDue2029Member" abstract="true" name="A3.40NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AcceleratedDepreciationMember" abstract="true" name="AcceleratedDepreciationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A145NotesDue2030Member" abstract="true" name="A145NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_SotaterceptMember" abstract="true" name="SotaterceptMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A290NotesDue2061Member" abstract="true" name="A290NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CorporateObligationsInvestmentFundsMember" abstract="true" name="CorporateObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ZerbaxaMember" abstract="true" name="ZerbaxaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AccrualForRebates" abstract="false" name="AccrualForRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_NoxafilMember" abstract="true" name="NoxafilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ScheduleOfIncomeTaxesPaidTableTextBlock" abstract="false" name="ScheduleOfIncomeTaxesPaidTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" abstract="true" name="GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsRegulatory" abstract="false" name="PotentialFutureMilestonePaymentsRegulatory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OralAndInjectableFormulationsMember" abstract="true" name="OralAndInjectableFormulationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" abstract="false" name="ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="mrk_MovementinCommonStockandTreasuryStockRollForward" abstract="true" name="MovementinCommonStockandTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_RevenuePerformanceObligationPaymentTerms" abstract="false" name="RevenuePerformanceObligationPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_A63DebenturesDue2026Member" abstract="true" name="A63DebenturesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" abstract="false" name="CollaborativeArrangementPreferredStockInvestmentInCounterparty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SivextroMember" abstract="true" name="SivextroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" abstract="false" name="DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DerivativeNotionalAmountMatured" abstract="false" name="DerivativeNotionalAmountMatured" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" abstract="true" name="EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_AcceleronPharmaIncMember" abstract="true" name="AcceleronPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FirstCommercialSaleMilestonesMember" abstract="true" name="FirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ContingentPaymentsCollaborativeArrangement" abstract="false" name="ContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_GileadSciencesMember" abstract="true" name="GileadSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" abstract="false" name="ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" abstract="true" name="EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_InjectableFormulationMember" abstract="true" name="InjectableFormulationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A4.00NotesDue2049Member" abstract="true" name="A4.00NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LenvimaMember" abstract="true" name="LenvimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EmergingMarketsEquitiesInvestmentFundsMember" abstract="true" name="EmergingMarketsEquitiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LynparzaMember" abstract="true" name="LynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsMadetoCollaborativePartner" abstract="false" name="MilestonePaymentsMadetoCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A1.375Notesdue2036Member" abstract="true" name="A1.375Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" abstract="true" name="FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SalesDiscounts" abstract="false" name="SalesDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OrionCorporationMember" abstract="true" name="OrionCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_A190NotesDue2028Member" abstract="true" name="A190NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_NumberOfInterestRateDerivativesMatured" abstract="false" name="NumberOfInterestRateDerivativesMatured" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_BridionMember" abstract="true" name="BridionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A415NotesDue2043Member" abstract="true" name="A415NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SeagenMember" abstract="true" name="SeagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" abstract="true" name="ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OrganonCoMember" abstract="true" name="OrganonCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProfitShareCounterparty" abstract="false" name="ProfitShareCounterparty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_OtherPostretirementBenefitPlanNetLossMember" abstract="true" name="OtherPostretirementBenefitPlanNetLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EurodominatedNotesMember" abstract="true" name="EurodominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PharmaceuticalsegmentMember" abstract="true" name="PharmaceuticalsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ArtivaBiotherapeuticsIncMember" abstract="true" name="ArtivaBiotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.5EuroNotesDue2034Member" abstract="true" name="A2.5EuroNotesDue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RidgebackBiotherapeuticsLPMember" abstract="true" name="RidgebackBiotherapeuticsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementSalesNet" abstract="false" name="CollaborativeArrangementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A1.375eurodenominatednotesdue2036Member" abstract="true" name="A1.375eurodenominatednotesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.40NotesDue2022Member" abstract="true" name="A2.40NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RotateqMember" abstract="true" name="RotateqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryTable" abstract="true" name="InventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_RecognizedAsAbstract" abstract="true" name="RecognizedAsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_ImagoBioSciencesIncMember" abstract="true" name="ImagoBioSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherPharmaceuticalMember" abstract="true" name="OtherPharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.35NotesDue2022Member" abstract="true" name="A2.35NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" abstract="true" name="DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AnimalHealthMember" abstract="true" name="AnimalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RealEstateInvestmentFundsMember" abstract="true" name="RealEstateInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementNumberOfCollaborationTargets" abstract="false" name="CollaborativeArrangementNumberOfCollaborationTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessFourNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AssetsandLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsandLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" abstract="false" name="UpfrontPaymentsMadeToLicenseOrCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" abstract="true" name="SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DificidMember" abstract="true" name="DificidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" abstract="true" name="GovernmentAndAgencyObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A3.70NotesDue2045Member" abstract="true" name="A3.70NotesDue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PrimaxinMember" abstract="true" name="PrimaxinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DevelopedMarketsEquitiesInvestmentFundsMember" abstract="true" name="DevelopedMarketsEquitiesInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" abstract="false" name="RestructuringReserveIncreaseDecreaseNoncashActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ReblozylMember" abstract="true" name="ReblozylMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PensionPlanPriorServiceCostMember" abstract="true" name="PensionPlanPriorServiceCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IsentressIsentressHDMember" abstract="true" name="IsentressIsentressHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.500Notesdue2034Member" abstract="true" name="A2.500Notesdue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ModernaMember" abstract="true" name="ModernaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DefinedBenefitPlanOtherChangesPlanAssets" abstract="false" name="DefinedBenefitPlanOtherChangesPlanAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AlliancerevenueLynparzaMember" abstract="true" name="AlliancerevenueLynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OralFormulationMember" abstract="true" name="OralFormulationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_GardasilGardasil9Member" abstract="true" name="GardasilGardasil9Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AllianceRevenueAdempasVerquvoMember" abstract="true" name="AllianceRevenueAdempasVerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" abstract="false" name="AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_TermForPayingOffEnvironmentalLiabilities" abstract="false" name="TermForPayingOffEnvironmentalLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" abstract="true" name="InventoryNotExpectedtobeSoldWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InvanzMember" abstract="true" name="InvanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherNonoperatingIncomeExpenseOther" abstract="false" name="OtherNonoperatingIncomeExpenseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AccrualForChargebacks" abstract="false" name="AccrualForChargebacks" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A075NotesDue2026Member" abstract="true" name="A075NotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" abstract="true" name="DefinedBenefitPlanCashandOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IncreaseDecreaseInHedgeRevenue" abstract="false" name="IncreaseDecreaseInHedgeRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A215NotesDue2031Member" abstract="true" name="A215NotesDue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RoyaltyPharmaMember" abstract="true" name="RoyaltyPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" abstract="true" name="SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PatentlitigationMember" abstract="true" name="PatentlitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IncomeTaxRateReconciliationAssetAcquisition" abstract="false" name="IncomeTaxRateReconciliationAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" abstract="true" name="DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CollaborativeArrangementProfitSharing" abstract="false" name="CollaborativeArrangementProfitSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_InsuranceContractsOtherInvestmentsMember" abstract="true" name="InsuranceContractsOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OtherVariableRateDebtMember" abstract="true" name="OtherVariableRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_NemtabrutinibMember" abstract="true" name="NemtabrutinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentToBeMadeToCollaborativePartner" abstract="false" name="MilestonePaymentToBeMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" abstract="true" name="MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" abstract="true" name="OtherPostretirementBenefitPlanPriorServiceCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AnimalHealthsegmentMember" abstract="true" name="AnimalHealthsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" abstract="false" name="UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_JanuviaMember" abstract="true" name="JanuviaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SanofiPasteurMember" abstract="true" name="SanofiPasteurMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" abstract="false" name="CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DerazantinibMember" abstract="true" name="DerazantinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProQuadMMRIIVarivaxMember" abstract="true" name="ProQuadMMRIIVarivaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_OncoImmuneMember" abstract="true" name="OncoImmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredTaxLiabilitiesEquityMethodInvestment" abstract="false" name="DeferredTaxLiabilitiesEquityMethodInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_TukysaMember" abstract="true" name="TukysaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IAVIMember" abstract="true" name="IAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RoyaltyRateDeductionPercentage" abstract="false" name="RoyaltyRateDeductionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_A235NotesDue2040Member" abstract="true" name="A235NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AllianceRevenueKoselugoMember" abstract="true" name="AllianceRevenueKoselugoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A275NotesDue2051Member" abstract="true" name="A275NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SentinelMember" abstract="true" name="SentinelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LagevrioMember" abstract="true" name="LagevrioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ArQuleMember" abstract="true" name="ArQuleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RoyaltyRatePercentage" abstract="false" name="RoyaltyRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A3.90NotesDue2039Member" abstract="true" name="A3.90NotesDue2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_A1.875EuroNotesDue2026Member" abstract="true" name="A1.875EuroNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ZetiaantitrustlitigationMember" abstract="true" name="ZetiaantitrustlitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LossContingencyTrialPeriod" abstract="false" name="LossContingencyTrialPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_PandionTherapeuticsMember" abstract="true" name="PandionTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessFiveNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_FixedIncomeObligationsInvestmentFundsMember" abstract="true" name="FixedIncomeObligationsInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SalesThreshold" abstract="false" name="SalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" abstract="false" name="ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ScheduleOfOtherIntangiblesTable" abstract="true" name="ScheduleOfOtherIntangiblesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_GefapixantMember" abstract="true" name="GefapixantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BelsomraMember" abstract="true" name="BelsomraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" abstract="true" name="SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LongTermDebtInterestPayableYearFour" abstract="false" name="LongTermDebtInterestPayableYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CostsExpensesAndOther" abstract="false" name="CostsExpensesAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_TransitionServicesAgreementMember" abstract="true" name="TransitionServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A245NotesDue2050Member" abstract="true" name="A245NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>mrk-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6a80835e-3d33-418a-be61-33ea02b302af,g:f2b57eeb-4f2d-41ff-83c8-1b4e9f7a4523-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4ae6746a-827a-46b5-93bd-5cd5998f8dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a13d4a13-aa98-4802-ab03-1cff1f58865a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_4ae6746a-827a-46b5-93bd-5cd5998f8dd0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a13d4a13-aa98-4802-ab03-1cff1f58865a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3ad2fdf3-5395-4571-b50f-947aa0c6694b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_4ae6746a-827a-46b5-93bd-5cd5998f8dd0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3ad2fdf3-5395-4571-b50f-947aa0c6694b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1ddeb674-3dde-4b1e-b7c4-a868c704062c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_a0140e2d-be5e-466a-8809-cc7b2be15025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_1ddeb674-3dde-4b1e-b7c4-a868c704062c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_a0140e2d-be5e-466a-8809-cc7b2be15025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_776e94f3-1797-4467-9ed8-adf8f7c3dd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_1ddeb674-3dde-4b1e-b7c4-a868c704062c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_776e94f3-1797-4467-9ed8-adf8f7c3dd37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_922a51a6-236b-4c21-9fbd-35227857680a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_c400a86f-2224-44a5-86bf-5e8783de1966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_922a51a6-236b-4c21-9fbd-35227857680a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_c400a86f-2224-44a5-86bf-5e8783de1966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_eff6317f-a8b0-40bc-925b-c2cb44b3d128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_922a51a6-236b-4c21-9fbd-35227857680a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_eff6317f-a8b0-40bc-925b-c2cb44b3d128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_7c15012a-8797-4a1d-962b-863f1500fae9" xlink:href="mrk-20221231.xsd#mrk_CostsExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_64fa1167-fbf8-454e-ab5a-8ed61ab0bf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_7c15012a-8797-4a1d-962b-863f1500fae9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_64fa1167-fbf8-454e-ab5a-8ed61ab0bf6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0e9ef36b-c15a-4496-94e7-ca998706c898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_7c15012a-8797-4a1d-962b-863f1500fae9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0e9ef36b-c15a-4496-94e7-ca998706c898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_669cc7ea-8570-4580-a7f2-70980337c5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_7c15012a-8797-4a1d-962b-863f1500fae9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_669cc7ea-8570-4580-a7f2-70980337c5c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2dbe2d6c-445a-4c9b-ab4c-6b943f371da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_7c15012a-8797-4a1d-962b-863f1500fae9" xlink:to="loc_us-gaap_RestructuringCharges_2dbe2d6c-445a-4c9b-ab4c-6b943f371da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_079d51c7-9ab6-4e35-93b9-29f2bd290561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_7c15012a-8797-4a1d-962b-863f1500fae9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_079d51c7-9ab6-4e35-93b9-29f2bd290561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_5af10681-f1a6-4c8d-b4ef-0e202efeb323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_5a710761-27e1-4a27-ad22-29e8d666379a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_5af10681-f1a6-4c8d-b4ef-0e202efeb323" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_5a710761-27e1-4a27-ad22-29e8d666379a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a11f80b4-8a97-4459-9040-13c46b19e108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_5af10681-f1a6-4c8d-b4ef-0e202efeb323" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a11f80b4-8a97-4459-9040-13c46b19e108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c90685ab-ebb4-4a9c-95e4-fb489449f595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6bf9afe7-830a-4c5e-be87-3dc5cf7a670c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c90685ab-ebb4-4a9c-95e4-fb489449f595" xlink:to="loc_us-gaap_Revenues_6bf9afe7-830a-4c5e-be87-3dc5cf7a670c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_e9b675ad-3d99-4b8d-a675-d4360a392e2e" xlink:href="mrk-20221231.xsd#mrk_CostsExpensesAndOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c90685ab-ebb4-4a9c-95e4-fb489449f595" xlink:to="loc_mrk_CostsExpensesAndOther_e9b675ad-3d99-4b8d-a675-d4360a392e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_383ce2a6-36f1-4955-b5fd-71c1f4c2a82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5fd0ce91-9d86-4d56-b7aa-5d58578b1d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_383ce2a6-36f1-4955-b5fd-71c1f4c2a82d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5fd0ce91-9d86-4d56-b7aa-5d58578b1d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4be41a8d-51db-4a70-b410-fe069ac2776c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_383ce2a6-36f1-4955-b5fd-71c1f4c2a82d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4be41a8d-51db-4a70-b410-fe069ac2776c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddab6e48-4e29-4e09-89e2-23ce99cf9894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_85008c95-0cad-4465-8b2a-339697228c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddab6e48-4e29-4e09-89e2-23ce99cf9894" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_85008c95-0cad-4465-8b2a-339697228c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ea9cd233-318c-424d-bde1-de6af97a2c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddab6e48-4e29-4e09-89e2-23ce99cf9894" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ea9cd233-318c-424d-bde1-de6af97a2c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1afe0610-79e5-41bf-b8ba-8bf0e8eada18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddab6e48-4e29-4e09-89e2-23ce99cf9894" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1afe0610-79e5-41bf-b8ba-8bf0e8eada18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_62447618-7095-48d8-8d09-e7990fb9b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddab6e48-4e29-4e09-89e2-23ce99cf9894" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_62447618-7095-48d8-8d09-e7990fb9b00b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d875531c-e6e7-4046-a3ab-caaa706cc150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f89abc8a-541c-47b0-aedb-6c8ee7c89dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d875531c-e6e7-4046-a3ab-caaa706cc150" xlink:to="loc_us-gaap_NetIncomeLoss_f89abc8a-541c-47b0-aedb-6c8ee7c89dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f01a0100-e736-4de6-ade6-ac4f427d1479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d875531c-e6e7-4046-a3ab-caaa706cc150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f01a0100-e736-4de6-ade6-ac4f427d1479" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedBalanceSheet"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85c6eaf7-cf05-43ee-9d97-486d312b697a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45f8e6ac-d12e-420f-b15b-79740dc7ae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85c6eaf7-cf05-43ee-9d97-486d312b697a" xlink:to="loc_us-gaap_StockholdersEquity_45f8e6ac-d12e-420f-b15b-79740dc7ae2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c3ea62ce-b155-4035-8ebc-14742802697d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85c6eaf7-cf05-43ee-9d97-486d312b697a" xlink:to="loc_us-gaap_MinorityInterest_c3ea62ce-b155-4035-8ebc-14742802697d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c2bf0ddd-e1d1-4025-a155-2054ce8ce8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6f66691b-e6ee-4fbc-a91d-5d8ec8725b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c2bf0ddd-e1d1-4025-a155-2054ce8ce8c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6f66691b-e6ee-4fbc-a91d-5d8ec8725b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1c03c385-66f5-43a7-b19a-a54775590c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c2bf0ddd-e1d1-4025-a155-2054ce8ce8c9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1c03c385-66f5-43a7-b19a-a54775590c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3570d899-7448-4f88-b590-120469ec737e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05fed2f7-51f5-4f06-a432-f7c4aa21e0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3570d899-7448-4f88-b590-120469ec737e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05fed2f7-51f5-4f06-a432-f7c4aa21e0df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_4d5eb9b5-dff5-4b12-9ac5-a8bfc6ad22bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3570d899-7448-4f88-b590-120469ec737e" xlink:to="loc_us-gaap_ShortTermInvestments_4d5eb9b5-dff5-4b12-9ac5-a8bfc6ad22bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_81bc202f-2d61-45b5-ae66-caf7fa4a486b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3570d899-7448-4f88-b590-120469ec737e" xlink:to="loc_us-gaap_OtherAssetsCurrent_81bc202f-2d61-45b5-ae66-caf7fa4a486b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bcf180b8-3b09-4ea3-8bb2-2a8f07518e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3570d899-7448-4f88-b590-120469ec737e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bcf180b8-3b09-4ea3-8bb2-2a8f07518e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6eec4fa2-9497-4f2a-b9b8-8c1fb4fd42d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3570d899-7448-4f88-b590-120469ec737e" xlink:to="loc_us-gaap_InventoryNet_6eec4fa2-9497-4f2a-b9b8-8c1fb4fd42d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_ff2a5ee0-fe53-4534-b1fd-470bf44c8bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_09957adf-6e03-4616-9279-66fa841a994a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_ff2a5ee0-fe53-4534-b1fd-470bf44c8bd7" xlink:to="loc_us-gaap_CommonStockValue_09957adf-6e03-4616-9279-66fa841a994a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e912be55-b175-4b63-9703-750496f60f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_ff2a5ee0-fe53-4534-b1fd-470bf44c8bd7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e912be55-b175-4b63-9703-750496f60f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5ad5efb-5678-4163-97aa-1a27e1e15699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_ff2a5ee0-fe53-4534-b1fd-470bf44c8bd7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5ad5efb-5678-4163-97aa-1a27e1e15699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c04f2441-8173-4570-ad2f-629bcd187216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_ff2a5ee0-fe53-4534-b1fd-470bf44c8bd7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c04f2441-8173-4570-ad2f-629bcd187216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f7f11879-9e45-445f-89f6-b59f32c9cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_68bfa7ee-7235-4a21-b881-6387f7a951a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f7f11879-9e45-445f-89f6-b59f32c9cd84" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_68bfa7ee-7235-4a21-b881-6387f7a951a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_66220b15-abb2-4e70-aaa4-fa691def9c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f7f11879-9e45-445f-89f6-b59f32c9cd84" xlink:to="loc_us-gaap_TreasuryStockCommonValue_66220b15-abb2-4e70-aaa4-fa691def9c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_32674a75-215d-4072-8c04-0968c8133e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_a15c10a1-cc9e-4c5d-9ff2-9d1936687324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_32674a75-215d-4072-8c04-0968c8133e03" xlink:to="loc_us-gaap_Land_a15c10a1-cc9e-4c5d-9ff2-9d1936687324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_3c3a8f37-aec3-4a86-a7c1-4aecd03de0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_32674a75-215d-4072-8c04-0968c8133e03" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_3c3a8f37-aec3-4a86-a7c1-4aecd03de0b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_f230a683-0b74-4918-b6b4-2e24b97d855c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_32674a75-215d-4072-8c04-0968c8133e03" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_f230a683-0b74-4918-b6b4-2e24b97d855c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_908c9c4f-4610-4253-836e-9a2ffdb4b7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_32674a75-215d-4072-8c04-0968c8133e03" xlink:to="loc_us-gaap_ConstructionInProgressGross_908c9c4f-4610-4253-836e-9a2ffdb4b7ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ba871b42-673d-463a-ae0b-31e3a8a686e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_dc3d124a-9517-455a-aac9-83c4e8c221c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba871b42-673d-463a-ae0b-31e3a8a686e2" xlink:to="loc_us-gaap_DebtCurrent_dc3d124a-9517-455a-aac9-83c4e8c221c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d20a0ed9-d4b9-4c7b-a3e5-070f13b6ec68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba871b42-673d-463a-ae0b-31e3a8a686e2" xlink:to="loc_us-gaap_AccountsPayableCurrent_d20a0ed9-d4b9-4c7b-a3e5-070f13b6ec68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c9bff0cf-6ef2-4f45-8ff4-3ec894dacb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba871b42-673d-463a-ae0b-31e3a8a686e2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c9bff0cf-6ef2-4f45-8ff4-3ec894dacb56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_fc704d13-db3f-476d-809b-2560ebd458b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba871b42-673d-463a-ae0b-31e3a8a686e2" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_fc704d13-db3f-476d-809b-2560ebd458b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_bd0e3f4b-826b-4cd4-86c1-9df283f8752a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba871b42-673d-463a-ae0b-31e3a8a686e2" xlink:to="loc_us-gaap_DividendsPayableCurrent_bd0e3f4b-826b-4cd4-86c1-9df283f8752a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_59130b55-51c5-4da1-a50d-40c7aaf887a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_feecb34b-440b-461b-b54a-8f8830f501f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59130b55-51c5-4da1-a50d-40c7aaf887a7" xlink:to="loc_us-gaap_AssetsCurrent_feecb34b-440b-461b-b54a-8f8830f501f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1fadb059-3b07-4d00-a33d-4a730994468c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59130b55-51c5-4da1-a50d-40c7aaf887a7" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_1fadb059-3b07-4d00-a33d-4a730994468c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7fbba9c8-84bf-4050-a06b-8729b7a671dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59130b55-51c5-4da1-a50d-40c7aaf887a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7fbba9c8-84bf-4050-a06b-8729b7a671dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b9f91e3-2517-4013-81b4-45eddb52969a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59130b55-51c5-4da1-a50d-40c7aaf887a7" xlink:to="loc_us-gaap_Goodwill_7b9f91e3-2517-4013-81b4-45eddb52969a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64f7a856-28a4-435a-b3ee-c4376cb0f3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59130b55-51c5-4da1-a50d-40c7aaf887a7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64f7a856-28a4-435a-b3ee-c4376cb0f3c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_7d309929-1ad5-4a7e-ba6c-6921eb94b6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59130b55-51c5-4da1-a50d-40c7aaf887a7" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_7d309929-1ad5-4a7e-ba6c-6921eb94b6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5ee41c8-346a-47cd-b365-7989d46bdd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c89b94b6-39b8-4111-ae0a-91f1484e0138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5ee41c8-346a-47cd-b365-7989d46bdd05" xlink:to="loc_us-gaap_LiabilitiesCurrent_c89b94b6-39b8-4111-ae0a-91f1484e0138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ee4c38d7-b867-45b5-a87e-f776cbd1c283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5ee41c8-346a-47cd-b365-7989d46bdd05" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ee4c38d7-b867-45b5-a87e-f776cbd1c283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c1d14207-ef0c-4492-8c1c-e85d9bc0471b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5ee41c8-346a-47cd-b365-7989d46bdd05" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c1d14207-ef0c-4492-8c1c-e85d9bc0471b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45adb0a3-157d-4be8-b100-bf332ba68c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5ee41c8-346a-47cd-b365-7989d46bdd05" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45adb0a3-157d-4be8-b100-bf332ba68c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8273a0ea-cfac-4cdd-84f2-854efb5d424c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5ee41c8-346a-47cd-b365-7989d46bdd05" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8273a0ea-cfac-4cdd-84f2-854efb5d424c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b1dce061-8399-49a5-89f4-74ba1f65b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b1dce061-8399-49a5-89f4-74ba1f65b81b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cddcc136-d282-48ad-bb41-bf974a83dff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cddcc136-d282-48ad-bb41-bf974a83dff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6b368125-5603-4b3e-b395-8aa696293b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_ShareBasedCompensation_6b368125-5603-4b3e-b395-8aa696293b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ed98f63-7a6c-4dcc-be51-dd34e4de5241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ed98f63-7a6c-4dcc-be51-dd34e4de5241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8f745ae2-7f30-4303-8e31-14839e80ac52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_8f745ae2-7f30-4303-8e31-14839e80ac52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dc4906d8-4c40-4f3f-8b21-5de6dce4c0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dc4906d8-4c40-4f3f-8b21-5de6dce4c0ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_a97ab811-50e7-4ebf-9321-ac9a7c1b2895" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_a97ab811-50e7-4ebf-9321-ac9a7c1b2895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c823da42-607c-4251-bd05-62e803a37aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c823da42-607c-4251-bd05-62e803a37aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c662bfe8-614f-4da3-b7d7-49fd7853f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c662bfe8-614f-4da3-b7d7-49fd7853f52b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d2c7cb90-935a-4092-8f94-f69bd802d358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d2c7cb90-935a-4092-8f94-f69bd802d358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_038993c0-73d8-4e90-9b6f-ab0d95ad372c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_AdjustmentForAmortization_038993c0-73d8-4e90-9b6f-ab0d95ad372c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_febf5a9b-b9fd-4fd5-9ea2-13c5bf19b1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_febf5a9b-b9fd-4fd5-9ea2-13c5bf19b1be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c3523fab-dbff-4e78-aea5-18b49348d7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c3523fab-dbff-4e78-aea5-18b49348d7e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_4ea6993c-876c-4e02-a16e-a015af4274fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_4ea6993c-876c-4e02-a16e-a015af4274fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_44237deb-7e1f-4be9-899e-c63421cb33ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_Depreciation_44237deb-7e1f-4be9-899e-c63421cb33ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_54545b78-d2d5-4833-8a1a-587730e5933e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_54545b78-d2d5-4833-8a1a-587730e5933e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a3957132-17ea-48d3-832c-0da9b5dbabb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_b488178b-a458-40a3-b8dd-cc92863cbfde" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a3957132-17ea-48d3-832c-0da9b5dbabb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e136c80b-cdaa-49f9-bf56-a875d858ea2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c26015ab-696f-4c2f-b2a0-89de9865731b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e136c80b-cdaa-49f9-bf56-a875d858ea2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_c26015ab-696f-4c2f-b2a0-89de9865731b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_e88d55ae-a62d-4143-82cd-ada10443b6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e136c80b-cdaa-49f9-bf56-a875d858ea2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_e88d55ae-a62d-4143-82cd-ada10443b6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1d5aa99a-954c-46f2-8d5b-ded3c9e0330a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e136c80b-cdaa-49f9-bf56-a875d858ea2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1d5aa99a-954c-46f2-8d5b-ded3c9e0330a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34cc4954-c068-47bb-922a-74a9a17416d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e136c80b-cdaa-49f9-bf56-a875d858ea2c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34cc4954-c068-47bb-922a-74a9a17416d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_de9372c4-09d6-4060-9068-d528293ce652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e136c80b-cdaa-49f9-bf56-a875d858ea2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_de9372c4-09d6-4060-9068-d528293ce652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_09601d7a-44ac-4a01-8cdf-67dabf2219b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_09601d7a-44ac-4a01-8cdf-67dabf2219b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_772971f2-66b0-42c4-9024-4c14dba1ada8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_772971f2-66b0-42c4-9024-4c14dba1ada8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_779022f7-817c-4e47-97e3-6185f5ba337d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_779022f7-817c-4e47-97e3-6185f5ba337d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a588821-4b94-40c7-a54f-d4fa9071e24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a588821-4b94-40c7-a54f-d4fa9071e24d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_a8ceab3e-9344-490b-b044-ad7dc871a9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_a8ceab3e-9344-490b-b044-ad7dc871a9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4188137e-9be3-4a16-95ed-c1fc63b43deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4188137e-9be3-4a16-95ed-c1fc63b43deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d8dde98a-aacf-4a15-9114-bd290b2e9a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d8dde98a-aacf-4a15-9114-bd290b2e9a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_f3973ffa-c6b5-4084-ad6f-e1532546834b" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_3c362d05-ea62-4bb7-af65-eaf0eac68559" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_f3973ffa-c6b5-4084-ad6f-e1532546834b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_20005c1f-3267-4502-a719-e6c566844fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_20005c1f-3267-4502-a719-e6c566844fc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_bb06daf4-2073-4c4e-98c3-2e393cc2b2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_bb06daf4-2073-4c4e-98c3-2e393cc2b2a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_49a3684d-cb34-4ad3-ad1f-3592816410de" xlink:href="mrk-20221231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_49a3684d-cb34-4ad3-ad1f-3592816410de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ea2572c6-2ab6-414d-a521-fa9a06a9deba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ea2572c6-2ab6-414d-a521-fa9a06a9deba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_6363c6b2-99bf-4dd9-a9cb-53e2c8cdc56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_6363c6b2-99bf-4dd9-a9cb-53e2c8cdc56e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_232f5720-5b09-4f42-84e9-c71042fb12a9" xlink:href="mrk-20221231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_232f5720-5b09-4f42-84e9-c71042fb12a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ebe3857e-0e14-410a-b68d-e47a62dcbfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ebe3857e-0e14-410a-b68d-e47a62dcbfc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_15121de2-58f7-4338-b3ba-ca1a4f668bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_15121de2-58f7-4338-b3ba-ca1a4f668bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_d6adef9f-5a82-4551-bbe2-c60b65f50f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_d6adef9f-5a82-4551-bbe2-c60b65f50f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_fdf5d255-0226-4eeb-9366-791bb40f87b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_567fe3cd-be87-435e-bd1a-09fe0867d980" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_fdf5d255-0226-4eeb-9366-791bb40f87b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4b309c1-e4c3-4fed-88b0-ced491a68f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_90cfd49f-f9c7-4602-9b3e-2dce78c5ff32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4b309c1-e4c3-4fed-88b0-ced491a68f95" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_90cfd49f-f9c7-4602-9b3e-2dce78c5ff32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5ce45236-e08f-462c-81a6-ccb912a5dcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4b309c1-e4c3-4fed-88b0-ced491a68f95" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5ce45236-e08f-462c-81a6-ccb912a5dcd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_ac5ca4ea-6616-4bbd-b8c0-ee91d766ef35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_b4b309c1-e4c3-4fed-88b0-ced491a68f95" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_ac5ca4ea-6616-4bbd-b8c0-ee91d766ef35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fabe4676-cceb-4bc3-8957-ab94a69b8a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_90b90cc8-62e2-46fa-9473-041c7283d085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fabe4676-cceb-4bc3-8957-ab94a69b8a1e" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_90b90cc8-62e2-46fa-9473-041c7283d085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_75ab449f-fb86-44a2-a563-7a47f15a0ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fabe4676-cceb-4bc3-8957-ab94a69b8a1e" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_75ab449f-fb86-44a2-a563-7a47f15a0ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_a1597710-fa1b-40b0-8d98-2ce54dcef588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_856de855-03f4-4b69-8331-1ae6c5409798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_a1597710-fa1b-40b0-8d98-2ce54dcef588" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_856de855-03f4-4b69-8331-1ae6c5409798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_e4d706a7-f95d-4891-af33-58482ac4a128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_a1597710-fa1b-40b0-8d98-2ce54dcef588" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_e4d706a7-f95d-4891-af33-58482ac4a128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2912b5d5-351b-4f0b-bb2f-8646fcbcc9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e2c50e49-fc30-411c-9752-76b96b6cef00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2912b5d5-351b-4f0b-bb2f-8646fcbcc9f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e2c50e49-fc30-411c-9752-76b96b6cef00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_3fecddfb-d921-46de-8131-53d72e117571" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2912b5d5-351b-4f0b-bb2f-8646fcbcc9f1" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_3fecddfb-d921-46de-8131-53d72e117571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_b63cd2f2-71c4-4dc0-8a66-8b0f566db9f2" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2912b5d5-351b-4f0b-bb2f-8646fcbcc9f1" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_b63cd2f2-71c4-4dc0-8a66-8b0f566db9f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_6cc90a4d-7e1c-48f8-9598-114c6899b992" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2912b5d5-351b-4f0b-bb2f-8646fcbcc9f1" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_6cc90a4d-7e1c-48f8-9598-114c6899b992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_60f3fae9-60e7-4e7c-8aac-6a56db10c557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2912b5d5-351b-4f0b-bb2f-8646fcbcc9f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_60f3fae9-60e7-4e7c-8aac-6a56db10c557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_f7ad1623-aa8a-4e91-aa5a-8b481fc93ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_597f34b6-3c8f-485c-8efb-18b12684456c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_f7ad1623-aa8a-4e91-aa5a-8b481fc93ab5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_597f34b6-3c8f-485c-8efb-18b12684456c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f31eff5b-0a78-4916-a832-218ff4eee44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_f7ad1623-aa8a-4e91-aa5a-8b481fc93ab5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f31eff5b-0a78-4916-a832-218ff4eee44a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_175d0cec-f11b-4d86-b813-182a72a088ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_175d0cec-f11b-4d86-b813-182a72a088ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4ae486cb-841d-4f3d-858b-3568b2fc59de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4ae486cb-841d-4f3d-858b-3568b2fc59de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18e402f4-76aa-4342-ad17-5e81632276c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18e402f4-76aa-4342-ad17-5e81632276c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_89470d46-4601-4cc9-9afd-aaaf6a3bd0d9" xlink:href="mrk-20221231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_89470d46-4601-4cc9-9afd-aaaf6a3bd0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_c437bca5-0d1f-44f9-928b-a9f2e8124447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_c437bca5-0d1f-44f9-928b-a9f2e8124447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_bc83a0c1-fbbb-459f-a9c4-0aae929d2b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_bc83a0c1-fbbb-459f-a9c4-0aae929d2b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85be20e6-bc83-4516-bfc5-35054f51cf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4d7469b0-383d-4701-93d8-c7c703e40ba7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85be20e6-bc83-4516-bfc5-35054f51cf6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ec30a959-17e1-42e0-b2aa-f69fb4012126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e75bfcc-d8bf-4a3b-b6f8-629cb165e002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ec30a959-17e1-42e0-b2aa-f69fb4012126" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e75bfcc-d8bf-4a3b-b6f8-629cb165e002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_881524c2-010c-40c6-bf45-49092f7a7578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ec30a959-17e1-42e0-b2aa-f69fb4012126" xlink:to="loc_us-gaap_Goodwill_881524c2-010c-40c6-bf45-49092f7a7578" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_88523532-3c00-4cca-9d4d-6cc15b6d9678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_e4b34fc1-c659-4378-9217-7c04c5b46a64" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_88523532-3c00-4cca-9d4d-6cc15b6d9678" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_e4b34fc1-c659-4378-9217-7c04c5b46a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_a675cabc-f006-43f1-8e94-0a528cac2625" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_88523532-3c00-4cca-9d4d-6cc15b6d9678" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_a675cabc-f006-43f1-8e94-0a528cac2625" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a304b645-3097-4f58-a01f-a103d3d1c4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8ddf4cae-e8b8-4103-9c33-0413474d7f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a304b645-3097-4f58-a01f-a103d3d1c4be" xlink:to="loc_us-gaap_DerivativeLiabilities_8ddf4cae-e8b8-4103-9c33-0413474d7f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_f7f4fbf2-9e15-46ba-8a3a-60d75d986388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a304b645-3097-4f58-a01f-a103d3d1c4be" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_f7f4fbf2-9e15-46ba-8a3a-60d75d986388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_27e32771-9089-40e1-bd3a-64bff2976c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a304b645-3097-4f58-a01f-a103d3d1c4be" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_27e32771-9089-40e1-bd3a-64bff2976c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_cea42143-fa7a-4bfc-a767-ba8cebe08076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_58b30639-dea7-46d4-b2fe-806264252395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_cea42143-fa7a-4bfc-a767-ba8cebe08076" xlink:to="loc_us-gaap_DerivativeAssets_58b30639-dea7-46d4-b2fe-806264252395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_9d8ad76f-7892-4907-a6a3-e7a31c807a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_cea42143-fa7a-4bfc-a767-ba8cebe08076" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_9d8ad76f-7892-4907-a6a3-e7a31c807a86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_c829976f-4965-4376-89e9-14e4c2e29492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_cea42143-fa7a-4bfc-a767-ba8cebe08076" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_c829976f-4965-4376-89e9-14e4c2e29492" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_5cd98452-f3d0-4a45-91ca-2782c5535aad" xlink:href="mrk-20221231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e850cd28-89b2-4413-9fcd-fe7f4c569ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_5cd98452-f3d0-4a45-91ca-2782c5535aad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e850cd28-89b2-4413-9fcd-fe7f4c569ba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8b387f06-58cc-4d2a-b860-5bdea6d119c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_5cd98452-f3d0-4a45-91ca-2782c5535aad" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8b387f06-58cc-4d2a-b860-5bdea6d119c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b75a2a8b-e948-457f-b67c-9fcf81f60baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60da60d4-bb61-404a-90e0-ab5a697272bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b75a2a8b-e948-457f-b67c-9fcf81f60baa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60da60d4-bb61-404a-90e0-ab5a697272bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_385644bb-4f9e-407d-b464-377ae2a1d983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b75a2a8b-e948-457f-b67c-9fcf81f60baa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_385644bb-4f9e-407d-b464-377ae2a1d983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f5e299fc-db94-48fd-b4eb-1dfe706f0540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b75a2a8b-e948-457f-b67c-9fcf81f60baa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f5e299fc-db94-48fd-b4eb-1dfe706f0540" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_831b0e0b-d1b2-47f3-9cb3-5f1551b09faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62feeb79-0038-4d96-ad0d-5597022c29de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_831b0e0b-d1b2-47f3-9cb3-5f1551b09faa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62feeb79-0038-4d96-ad0d-5597022c29de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d825a443-beeb-4e04-92bd-4af4959ff55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_831b0e0b-d1b2-47f3-9cb3-5f1551b09faa" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d825a443-beeb-4e04-92bd-4af4959ff55d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a45c89d5-71e5-4d29-9d60-c54b177b7c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ae5a5d5e-f72a-43eb-8979-fccd955c10b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a45c89d5-71e5-4d29-9d60-c54b177b7c4f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ae5a5d5e-f72a-43eb-8979-fccd955c10b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_25ac10fa-d5de-47c0-a517-196991749a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a45c89d5-71e5-4d29-9d60-c54b177b7c4f" xlink:to="loc_us-gaap_DerivativeLiabilities_25ac10fa-d5de-47c0-a517-196991749a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3830ba4e-ad55-42b7-bbd5-c566a5a00277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_82155a76-12d4-421b-938a-60cb44545ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3830ba4e-ad55-42b7-bbd5-c566a5a00277" xlink:to="loc_us-gaap_TradingSecurities_82155a76-12d4-421b-938a-60cb44545ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_91e16bff-5dac-4aad-befe-b74a5d10ed90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3830ba4e-ad55-42b7-bbd5-c566a5a00277" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_91e16bff-5dac-4aad-befe-b74a5d10ed90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_81258b23-a90b-402a-b565-771bb4646603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3830ba4e-ad55-42b7-bbd5-c566a5a00277" xlink:to="loc_us-gaap_DerivativeAssets_81258b23-a90b-402a-b565-771bb4646603" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#InventoriesInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_5f7b0986-4e99-40b5-b64b-4580403cc8a1" xlink:href="mrk-20221231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_8a3819f3-6091-4d96-91f5-6554f9d7259e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_5f7b0986-4e99-40b5-b64b-4580403cc8a1" xlink:to="loc_us-gaap_InventoryLIFOReserve_8a3819f3-6091-4d96-91f5-6554f9d7259e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d4c1f8e2-3afd-4c9f-bb84-549846daa704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_5f7b0986-4e99-40b5-b64b-4580403cc8a1" xlink:to="loc_us-gaap_InventoryGross_d4c1f8e2-3afd-4c9f-bb84-549846daa704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d7e2e89b-62bd-42cc-9d8d-2ccfe65705fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2f6ae1c2-1e69-4197-b4c6-aa1bacfe3485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d7e2e89b-62bd-42cc-9d8d-2ccfe65705fe" xlink:to="loc_us-gaap_InventoryFinishedGoods_2f6ae1c2-1e69-4197-b4c6-aa1bacfe3485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_26f55fbf-c631-4fba-a700-8b908eefb63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d7e2e89b-62bd-42cc-9d8d-2ccfe65705fe" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_26f55fbf-c631-4fba-a700-8b908eefb63e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_ef2ff07b-9870-4311-b664-a7454ed18307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d7e2e89b-62bd-42cc-9d8d-2ccfe65705fe" xlink:to="loc_us-gaap_OtherInventorySupplies_ef2ff07b-9870-4311-b664-a7454ed18307" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20221231.xsd#InventoriesInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_e244f905-021c-405c-afb9-b5c5a68cd0ae" xlink:href="mrk-20221231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_80ec7f6a-e8dc-48c8-bc4c-c970d819d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_e244f905-021c-405c-afb9-b5c5a68cd0ae" xlink:to="loc_us-gaap_InventoryNet_80ec7f6a-e8dc-48c8-bc4c-c970d819d87d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e45648b2-3ee5-4e65-b2b1-b79b310f90ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_e244f905-021c-405c-afb9-b5c5a68cd0ae" xlink:to="loc_us-gaap_InventoryNoncurrent_e45648b2-3ee5-4e65-b2b1-b79b310f90ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a5724cb5-0f20-4910-ac94-5be7c7c75c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c73919be-1b83-470c-945b-4d4cae387277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a5724cb5-0f20-4910-ac94-5be7c7c75c27" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c73919be-1b83-470c-945b-4d4cae387277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b31626ad-ac7b-4cb2-b271-f7c2d531997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a5724cb5-0f20-4910-ac94-5be7c7c75c27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b31626ad-ac7b-4cb2-b271-f7c2d531997c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a411df03-4e4f-41ca-b224-91de6076c53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ccd4ef9e-5f17-4e6e-9640-604e19a8cc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a411df03-4e4f-41ca-b224-91de6076c53c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ccd4ef9e-5f17-4e6e-9640-604e19a8cc7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2140ffed-e9b9-4edc-b2f2-0c14d7239544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a411df03-4e4f-41ca-b224-91de6076c53c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2140ffed-e9b9-4edc-b2f2-0c14d7239544" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c584ae1-607f-4df2-ad40-cee9f3bfb150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_649258de-528d-45be-850f-9afe235ac1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c584ae1-607f-4df2-ad40-cee9f3bfb150" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_649258de-528d-45be-850f-9afe235ac1b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b22e3006-7dd9-4f26-bf5c-cec247034159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c584ae1-607f-4df2-ad40-cee9f3bfb150" xlink:to="loc_us-gaap_OperatingLeaseLiability_b22e3006-7dd9-4f26-bf5c-cec247034159" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3f50e6d-4807-43a4-a35a-b777646a6aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8cfa1f3c-e1c6-4d51-a0fd-88ba8737fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3f50e6d-4807-43a4-a35a-b777646a6aa2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8cfa1f3c-e1c6-4d51-a0fd-88ba8737fba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16aee936-b6b7-49d0-b723-7b92965e4408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3f50e6d-4807-43a4-a35a-b777646a6aa2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16aee936-b6b7-49d0-b723-7b92965e4408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2268392f-8c71-44e6-8c7f-cd44d8905d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3f50e6d-4807-43a4-a35a-b777646a6aa2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2268392f-8c71-44e6-8c7f-cd44d8905d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e6335cbc-0fb7-4797-b6f3-be60810dbadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3f50e6d-4807-43a4-a35a-b777646a6aa2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e6335cbc-0fb7-4797-b6f3-be60810dbadb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c58cb76a-cee7-463e-88c8-a7e2fc4aeb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3f50e6d-4807-43a4-a35a-b777646a6aa2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c58cb76a-cee7-463e-88c8-a7e2fc4aeb6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7647680b-f4ec-49f4-8ce1-08ecd8ba194a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3f50e6d-4807-43a4-a35a-b777646a6aa2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7647680b-f4ec-49f4-8ce1-08ecd8ba194a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_f180e8f9-3efa-4c3b-9f2d-2578d33f49e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_f180e8f9-3efa-4c3b-9f2d-2578d33f49e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_4da0ba46-8404-4a0c-86d2-327d97948273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_4da0ba46-8404-4a0c-86d2-327d97948273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_671e44ec-98d5-4c24-a9b3-bfa5019d2ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_671e44ec-98d5-4c24-a9b3-bfa5019d2ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_38b0473d-c63f-41dd-ace8-4f0637938ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_38b0473d-c63f-41dd-ace8-4f0637938ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8fd9b297-0ad2-4fd9-a81a-8dfd1c806ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8fd9b297-0ad2-4fd9-a81a-8dfd1c806ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_61e7a86d-24ef-49be-8fa6-2d49dc0eadd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_61e7a86d-24ef-49be-8fa6-2d49dc0eadd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_7fb6a901-6c3c-4337-aecd-1ee2bd67a5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_7fb6a901-6c3c-4337-aecd-1ee2bd67a5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_c8cd2f46-8cb2-4aab-a25d-9acabec996bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_016f1476-e5fd-4d96-a00b-c0ead9c36dac" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_c8cd2f46-8cb2-4aab-a25d-9acabec996bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eb11a964-39a9-4ba2-bee1-e48b21754287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_ba342747-0530-474c-b92f-87993f288d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eb11a964-39a9-4ba2-bee1-e48b21754287" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_ba342747-0530-474c-b92f-87993f288d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_f33dc6c4-6fb2-447c-b0b1-d08d8f215414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eb11a964-39a9-4ba2-bee1-e48b21754287" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_f33dc6c4-6fb2-447c-b0b1-d08d8f215414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b1d78905-f31e-4e5a-b391-df245742fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eb11a964-39a9-4ba2-bee1-e48b21754287" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_b1d78905-f31e-4e5a-b391-df245742fac8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_90cbe01f-c57a-40a6-b5d0-d55d2671e6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_21d6123f-6c3f-4e72-a20b-75380f72e34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_90cbe01f-c57a-40a6-b5d0-d55d2671e6e0" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_21d6123f-6c3f-4e72-a20b-75380f72e34f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_99ebdb47-7552-4dd9-8fcf-fc453110ed98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_90cbe01f-c57a-40a6-b5d0-d55d2671e6e0" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_99ebdb47-7552-4dd9-8fcf-fc453110ed98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_5a42571e-d092-4d55-a186-09bf43dae732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_667064ff-1c3f-4f35-9c6a-1ab18ba34b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_5a42571e-d092-4d55-a186-09bf43dae732" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_667064ff-1c3f-4f35-9c6a-1ab18ba34b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c1a0e3e4-2707-4c23-a6bb-4a4e9da4e325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_5a42571e-d092-4d55-a186-09bf43dae732" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_c1a0e3e4-2707-4c23-a6bb-4a4e9da4e325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_69e849f5-7771-43c9-8d1d-8b3618775dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_b57ee34f-813f-4cb1-83fd-ad86010b8229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_69e849f5-7771-43c9-8d1d-8b3618775dd4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_b57ee34f-813f-4cb1-83fd-ad86010b8229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_3988a81b-472d-46bf-8f3e-675384ad37f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_69e849f5-7771-43c9-8d1d-8b3618775dd4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_3988a81b-472d-46bf-8f3e-675384ad37f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_a8935f79-0700-4a8c-a13f-e711fbd5dd7b" xlink:href="mrk-20221231.xsd#mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_69e849f5-7771-43c9-8d1d-8b3618775dd4" xlink:to="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_a8935f79-0700-4a8c-a13f-e711fbd5dd7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5c8f6cd9-ed2e-4f40-bb98-0206e1d70858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_43de3359-82e8-41d7-9430-a9a7c82c2c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5c8f6cd9-ed2e-4f40-bb98-0206e1d70858" xlink:to="loc_us-gaap_InvestmentIncomeInterest_43de3359-82e8-41d7-9430-a9a7c82c2c41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8448670d-37a8-4b93-ac16-986f27d0fc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5c8f6cd9-ed2e-4f40-bb98-0206e1d70858" xlink:to="loc_us-gaap_InterestExpense_8448670d-37a8-4b93-ac16-986f27d0fc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_63cb2771-900c-4329-b99b-694693a41608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5c8f6cd9-ed2e-4f40-bb98-0206e1d70858" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_63cb2771-900c-4329-b99b-694693a41608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6e11c8cb-26e7-4e00-9288-193e13b2db77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5c8f6cd9-ed2e-4f40-bb98-0206e1d70858" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6e11c8cb-26e7-4e00-9288-193e13b2db77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_78e97084-7a65-4890-a557-8f9911a2d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5c8f6cd9-ed2e-4f40-bb98-0206e1d70858" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_78e97084-7a65-4890-a557-8f9911a2d0e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_dd9367bb-472a-4532-8cd5-36814ed8c81a" xlink:href="mrk-20221231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5c8f6cd9-ed2e-4f40-bb98-0206e1d70858" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_dd9367bb-472a-4532-8cd5-36814ed8c81a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c9276d93-68dc-4edb-a6e6-79c1ea0f37e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c9276d93-68dc-4edb-a6e6-79c1ea0f37e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_57d9526a-a1cc-415d-add1-4b213115268f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_57d9526a-a1cc-415d-add1-4b213115268f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9a5b3582-664e-4786-8512-97866216cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9a5b3582-664e-4786-8512-97866216cc35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_68ec6f17-08ef-4228-a8fd-f53266bb7ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_68ec6f17-08ef-4228-a8fd-f53266bb7ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_63b81786-c76e-47a5-a4e1-e9274bdaeb03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_63b81786-c76e-47a5-a4e1-e9274bdaeb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_7a3741c1-230e-425f-a543-9af6e6d8df31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_7a3741c1-230e-425f-a543-9af6e6d8df31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_cce32de5-f27e-48f0-8c79-81ebd79aeb77" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_cce32de5-f27e-48f0-8c79-81ebd79aeb77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_683ecd0e-b454-4f5e-9c5a-20d5112d1061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_683ecd0e-b454-4f5e-9c5a-20d5112d1061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3ad436d6-e6d9-4f6e-90d4-763be69bb763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3ad436d6-e6d9-4f6e-90d4-763be69bb763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_802d0435-0ea7-40ca-bd07-0dc82be38c7c" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_802d0435-0ea7-40ca-bd07-0dc82be38c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent_0259ac0e-75b3-40b1-81b9-5ad76fdf6037" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent_0259ac0e-75b3-40b1-81b9-5ad76fdf6037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_51b0dbd6-2a43-4bea-b6da-f3207dcefa8a" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7e7c126-0531-4581-a6fe-c7591151e398" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_51b0dbd6-2a43-4bea-b6da-f3207dcefa8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_50929b9b-885f-4653-a29f-c8df29b1a18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_50929b9b-885f-4653-a29f-c8df29b1a18a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0475c8bf-7f54-4121-b469-52ba67616945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0475c8bf-7f54-4121-b469-52ba67616945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_aafc551a-8eb6-4571-8f8d-32182abc4827" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_aafc551a-8eb6-4571-8f8d-32182abc4827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c94a2f84-a3c2-4ec0-984d-2a87150a3572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c94a2f84-a3c2-4ec0-984d-2a87150a3572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ad44cec5-85b5-4ca8-ab19-b13499b0e790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ad44cec5-85b5-4ca8-ab19-b13499b0e790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ae1461e7-3ad5-4d5d-9617-33f998882af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ae1461e7-3ad5-4d5d-9617-33f998882af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5206d8cf-cb22-4e4c-accd-0c936243d605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5206d8cf-cb22-4e4c-accd-0c936243d605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_6821ab55-aecb-45af-9174-fe30eb31a297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_6821ab55-aecb-45af-9174-fe30eb31a297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_cde7afea-074d-4a00-9064-d3874ec978c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_cde7afea-074d-4a00-9064-d3874ec978c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxRateReconciliationAssetAcquisition_95755bf1-6794-4408-9ec5-3ee0f9fee7de" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxRateReconciliationAssetAcquisition"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_mrk_IncomeTaxRateReconciliationAssetAcquisition_95755bf1-6794-4408-9ec5-3ee0f9fee7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_e564fd33-d61d-48cf-a535-9bea2ad15d11" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_e564fd33-d61d-48cf-a535-9bea2ad15d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_9928f442-2868-4026-aa67-a3bdcbb22dcd" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cf47d53c-768b-4aa3-83fc-8eb64d4243b1" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_9928f442-2868-4026-aa67-a3bdcbb22dcd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f634169-1a8c-43b9-9430-1e0b44a9aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c0a540ab-807b-4a66-bf3c-469401ed438b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f634169-1a8c-43b9-9430-1e0b44a9aec0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c0a540ab-807b-4a66-bf3c-469401ed438b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_767841fc-eb19-434f-a387-88ae58d5c525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f634169-1a8c-43b9-9430-1e0b44a9aec0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_767841fc-eb19-434f-a387-88ae58d5c525" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeTaxesonIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3af81547-61fe-43dc-bdfe-3d030b90c54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_77cfa7c4-9a19-42fe-a4b5-1c355d41cade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3af81547-61fe-43dc-bdfe-3d030b90c54a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_77cfa7c4-9a19-42fe-a4b5-1c355d41cade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_68502c18-817c-414f-91b2-708578fb7d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3af81547-61fe-43dc-bdfe-3d030b90c54a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_68502c18-817c-414f-91b2-708578fb7d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3ed98572-1ba1-4b72-92b9-be562a109c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3af81547-61fe-43dc-bdfe-3d030b90c54a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3ed98572-1ba1-4b72-92b9-be562a109c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2f4484fd-1507-4a27-8953-6acd5ecd98f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_03d5505b-ea37-45b6-8795-7e188e7f3907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2f4484fd-1507-4a27-8953-6acd5ecd98f2" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_03d5505b-ea37-45b6-8795-7e188e7f3907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0e65dbb-6beb-40fd-b80a-375918064894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2f4484fd-1507-4a27-8953-6acd5ecd98f2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c0e65dbb-6beb-40fd-b80a-375918064894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e1aab738-3c23-4d2d-9f46-f1dab13a9931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_47453091-0cfb-43ea-b4ed-09b97032abe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e1aab738-3c23-4d2d-9f46-f1dab13a9931" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_47453091-0cfb-43ea-b4ed-09b97032abe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_10aadd12-c7dd-4f72-bdc9-8ab5aca2ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e1aab738-3c23-4d2d-9f46-f1dab13a9931" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_10aadd12-c7dd-4f72-bdc9-8ab5aca2ef8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_19d21edb-d3f0-4c07-bbbc-bf26618de194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e1aab738-3c23-4d2d-9f46-f1dab13a9931" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_19d21edb-d3f0-4c07-bbbc-bf26618de194" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b83e7640-cc2c-4164-81ff-fdfada42f2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_aaa978e9-0af5-471c-81f1-9867bf73e160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b83e7640-cc2c-4164-81ff-fdfada42f2ef" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_aaa978e9-0af5-471c-81f1-9867bf73e160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a5c2e7a0-abde-4b99-bcb8-3c9a54269fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b83e7640-cc2c-4164-81ff-fdfada42f2ef" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a5c2e7a0-abde-4b99-bcb8-3c9a54269fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_466722e2-5728-4d05-b308-5d8baec16e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6c60e047-2b52-46c7-b8ca-89b649bfb599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_466722e2-5728-4d05-b308-5d8baec16e89" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6c60e047-2b52-46c7-b8ca-89b649bfb599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_3f5fbcbc-0465-4eb6-8827-1cb7a4a2e18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_466722e2-5728-4d05-b308-5d8baec16e89" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_3f5fbcbc-0465-4eb6-8827-1cb7a4a2e18c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7b907006-4822-4f99-8a29-c405c4e16f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_466722e2-5728-4d05-b308-5d8baec16e89" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7b907006-4822-4f99-8a29-c405c4e16f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_3e506c94-196f-433b-acaa-ed72ac3ded87" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_466722e2-5728-4d05-b308-5d8baec16e89" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_3e506c94-196f-433b-acaa-ed72ac3ded87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_be040350-3534-4b6e-bf26-f83e895723bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_466722e2-5728-4d05-b308-5d8baec16e89" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_be040350-3534-4b6e-bf26-f83e895723bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_59582c00-15ef-42bc-8043-4fd8f62181d7" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_466722e2-5728-4d05-b308-5d8baec16e89" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_59582c00-15ef-42bc-8043-4fd8f62181d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4cc52b0e-e51c-4991-91d5-e99646306d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_176a242b-449f-44c6-a552-f8a5e600206a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_4cc52b0e-e51c-4991-91d5-e99646306d92" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_176a242b-449f-44c6-a552-f8a5e600206a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1172bb06-8b55-41c4-9069-ec2e360ef521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_4cc52b0e-e51c-4991-91d5-e99646306d92" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1172bb06-8b55-41c4-9069-ec2e360ef521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_0c79c7dc-d37a-4748-9ca0-f0edc285de0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_0c79c7dc-d37a-4748-9ca0-f0edc285de0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_fe117a46-b1e2-4ffd-aac0-c4a80a45992d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_fe117a46-b1e2-4ffd-aac0-c4a80a45992d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38a59dfc-e2d7-4a0f-9a44-03b3ab79e138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38a59dfc-e2d7-4a0f-9a44-03b3ab79e138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_e61d76f2-b3b7-4480-b797-8fd1eabe6ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_e61d76f2-b3b7-4480-b797-8fd1eabe6ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_c978a9ae-5440-4ea5-93d1-c2f484b173bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_c978a9ae-5440-4ea5-93d1-c2f484b173bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_afca9d80-5be4-40ac-b864-f332b8f47648" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_afca9d80-5be4-40ac-b864-f332b8f47648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_321d178a-208f-4086-b713-82186dab266c" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_321d178a-208f-4086-b713-82186dab266c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e8c0aaf8-76f3-4aeb-b80a-6c01d2ec2ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e8c0aaf8-76f3-4aeb-b80a-6c01d2ec2ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_cabe4c90-126c-46e1-99d7-97b18ab133ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_cabe4c90-126c-46e1-99d7-97b18ab133ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_eeb0f4c7-0987-477c-8811-0d5df2658bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2104e0bc-0c6d-4fe4-ab57-25e02df1a15d" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_eeb0f4c7-0987-477c-8811-0d5df2658bc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7819e8e2-f7b2-402f-b603-63f082d1fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_946e0509-d626-469c-bb73-ef77136bc060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7819e8e2-f7b2-402f-b603-63f082d1fbd2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_946e0509-d626-469c-bb73-ef77136bc060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_96a9b021-1a9a-4ed2-93d5-87c6a4baec8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7819e8e2-f7b2-402f-b603-63f082d1fbd2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_96a9b021-1a9a-4ed2-93d5-87c6a4baec8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da4c6ee3-4aab-4a57-b2e9-5147ba11f89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_fe535604-9789-4b9c-b183-25e7e254cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da4c6ee3-4aab-4a57-b2e9-5147ba11f89b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_fe535604-9789-4b9c-b183-25e7e254cc39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_f215dd76-9666-431d-a272-4f2fd5535df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da4c6ee3-4aab-4a57-b2e9-5147ba11f89b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_f215dd76-9666-431d-a272-4f2fd5535df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6406e5eb-2e5e-49b6-9e45-2a6a2b9dfe86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7575a3f3-d06e-43fb-aee8-e8f2f321cb03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6406e5eb-2e5e-49b6-9e45-2a6a2b9dfe86" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7575a3f3-d06e-43fb-aee8-e8f2f321cb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bb1f2a6c-fe62-490b-a022-2103004ae1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6406e5eb-2e5e-49b6-9e45-2a6a2b9dfe86" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bb1f2a6c-fe62-490b-a022-2103004ae1d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1a088b07-7088-4876-9756-12f4a267d0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_7a6c4b5e-1d3f-47bb-af0b-a73b91a57112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1a088b07-7088-4876-9756-12f4a267d0f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_7a6c4b5e-1d3f-47bb-af0b-a73b91a57112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_8e1bc4ab-b073-47a4-8af4-e256e5fd8e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1a088b07-7088-4876-9756-12f4a267d0f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_8e1bc4ab-b073-47a4-8af4-e256e5fd8e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_80113c50-da6c-405a-88ec-dd09b99bd275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_aee18fb0-8097-4c18-af9a-5505485b31d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_80113c50-da6c-405a-88ec-dd09b99bd275" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_aee18fb0-8097-4c18-af9a-5505485b31d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_4f92ec71-64c2-44e9-8864-07a4ec8c58c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_80113c50-da6c-405a-88ec-dd09b99bd275" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_4f92ec71-64c2-44e9-8864-07a4ec8c58c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e15bd1c2-c976-4622-ab40-4e1222d0690d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8125c24d-0716-4bfc-a1f5-0c828d9d790b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e15bd1c2-c976-4622-ab40-4e1222d0690d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8125c24d-0716-4bfc-a1f5-0c828d9d790b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e8d74cc0-e6ea-49e2-9bcd-9516dc3f5f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e15bd1c2-c976-4622-ab40-4e1222d0690d" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e8d74cc0-e6ea-49e2-9bcd-9516dc3f5f8d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>mrk-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6a80835e-3d33-418a-be61-33ea02b302af,g:f2b57eeb-4f2d-41ff-83c8-1b4e9f7a4523-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20221231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended" id="ie05f30a819b74503991a93ca82832942_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d6374c12-795c-40fd-9508-7b651f834084" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentType_d6374c12-795c-40fd-9508-7b651f834084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ab33d850-b5cb-4730-8527-6707755af848" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentAnnualReport_ab33d850-b5cb-4730-8527-6707755af848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6669ed2f-15e3-48ad-8d92-989fe780d843" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentPeriodEndDate_6669ed2f-15e3-48ad-8d92-989fe780d843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_004f0606-7d9b-4fa1-abd5-2b9257f92566" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_CurrentFiscalYearEndDate_004f0606-7d9b-4fa1-abd5-2b9257f92566" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4245f171-bd1c-4242-b893-26a445ee45eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentTransitionReport_4245f171-bd1c-4242-b893-26a445ee45eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cfa6fa9c-21f7-4a73-a72b-6f83af58433b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityFileNumber_cfa6fa9c-21f7-4a73-a72b-6f83af58433b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2d46a3f0-6e36-4f26-830e-8999be9dfb14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityRegistrantName_2d46a3f0-6e36-4f26-830e-8999be9dfb14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_54a96d86-de3f-4aa4-8a1d-3104efc4f440" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressAddressLine1_54a96d86-de3f-4aa4-8a1d-3104efc4f440" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eaf7e57a-d052-4467-9d55-a67104edebb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressCityOrTown_eaf7e57a-d052-4467-9d55-a67104edebb2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0f10f8d4-6885-4aa9-841e-d0e451db4318" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressStateOrProvince_0f10f8d4-6885-4aa9-841e-d0e451db4318" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_480d718c-635e-4ffe-a3bf-1bcbc919960e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressPostalZipCode_480d718c-635e-4ffe-a3bf-1bcbc919960e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_84e5d2cc-3646-424a-994e-4eeadb9b1f83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_CityAreaCode_84e5d2cc-3646-424a-994e-4eeadb9b1f83" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4a6ea60c-32f2-4110-b65a-df619613c6d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_LocalPhoneNumber_4a6ea60c-32f2-4110-b65a-df619613c6d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_795ceabb-2b3d-4abf-9a9a-f5b64e764ab8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_795ceabb-2b3d-4abf-9a9a-f5b64e764ab8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5dad80e1-683a-4250-ae63-30ce1ab980c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityTaxIdentificationNumber_5dad80e1-683a-4250-ae63-30ce1ab980c8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_29e5ef4e-585a-4ac9-89ea-169dcbcc113c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_Security12bTitle_29e5ef4e-585a-4ac9-89ea-169dcbcc113c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cc3777cc-6d02-4bb5-b824-1c1ac9ba649c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_TradingSymbol_cc3777cc-6d02-4bb5-b824-1c1ac9ba649c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f5d86d67-d503-4e04-80bc-29d3e8d2edbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_SecurityExchangeName_f5d86d67-d503-4e04-80bc-29d3e8d2edbe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_36c06dfc-9177-4895-bf52-03b86b7b4a46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_36c06dfc-9177-4895-bf52-03b86b7b4a46" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_19fab279-9336-4e00-bb4b-b3e786cf4dd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityPublicFloat_19fab279-9336-4e00-bb4b-b3e786cf4dd1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e045ac8a-43f9-41ed-be91-963ce97bb7d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e045ac8a-43f9-41ed-be91-963ce97bb7d2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_27966c05-2fc5-4586-9c87-f53f9e48f344" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityVoluntaryFilers_27966c05-2fc5-4586-9c87-f53f9e48f344" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d1f4c630-1af6-4c15-a5c6-8672131c629b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityCurrentReportingStatus_d1f4c630-1af6-4c15-a5c6-8672131c629b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6a1745ee-f84c-4f9f-a478-d1c06415689f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityInteractiveDataCurrent_6a1745ee-f84c-4f9f-a478-d1c06415689f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c574b886-6d00-492e-a59d-59f00b49961c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityFilerCategory_c574b886-6d00-492e-a59d-59f00b49961c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a2323c9c-066e-47c7-9134-07a0b696c72d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntitySmallBusiness_a2323c9c-066e-47c7-9134-07a0b696c72d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8d15552f-cfe9-45a6-bb3c-32fc68fde3f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityEmergingGrowthCompany_8d15552f-cfe9-45a6-bb3c-32fc68fde3f3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4d8a4a7b-e672-4403-818f-d7e43f57c750" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4d8a4a7b-e672-4403-818f-d7e43f57c750" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_34bef415-7cf1-4034-9c51-7fdf1edfbe7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityShellCompany_34bef415-7cf1-4034-9c51-7fdf1edfbe7b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fb05caa2-0d58-4ae7-96e4-7e1ed3a5d887" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_AmendmentFlag_fb05caa2-0d58-4ae7-96e4-7e1ed3a5d887" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c0e109f2-f5b2-4ec0-9340-bfce5730376a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentFiscalYearFocus_c0e109f2-f5b2-4ec0-9340-bfce5730376a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6e3cb1ff-019d-49a7-b12b-0bd2bb689fb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6e3cb1ff-019d-49a7-b12b-0bd2bb689fb2" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6261b5a1-afc4-4b8f-a1dc-409b56e77e71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityCentralIndexKey_6261b5a1-afc4-4b8f-a1dc-409b56e77e71" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c203cd6d-b9e9-437e-b976-75b9727b848c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c203cd6d-b9e9-437e-b976-75b9727b848c" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_d384bf74-8d6d-4dc7-93ee-34be6a74c57c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentInformationTable_d384bf74-8d6d-4dc7-93ee-34be6a74c57c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_d384bf74-8d6d-4dc7-93ee-34be6a74c57c" xlink:to="loc_us-gaap_DebtInstrumentAxis_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_a48abba0-d1d3-431d-98b7-33a4ed2d79f2" xlink:href="mrk-20221231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A0.500Notesdue2024Member_a48abba0-d1d3-431d-98b7-33a4ed2d79f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_46abe05d-1603-4444-b89f-7cc7b2d27388" xlink:href="mrk-20221231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A1.875Notesdue2026Member_46abe05d-1603-4444-b89f-7cc7b2d27388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_e2b41ada-981f-480a-a952-303fed13f641" xlink:href="mrk-20221231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A2.500Notesdue2034Member_e2b41ada-981f-480a-a952-303fed13f641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_c8afc2dc-8ea7-4185-a658-59d90ff257b5" xlink:href="mrk-20221231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A1.375Notesdue2036Member_c8afc2dc-8ea7-4185-a658-59d90ff257b5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="extended" id="i27d7a4f2c3ac4588b6b794b0566dccec_ConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_43cac79f-bbee-4ce0-8bd3-13d52828b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_43cac79f-bbee-4ce0-8bd3-13d52828b7e0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a23ab70-8f4b-4864-82ae-25b36b7c114a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a23ab70-8f4b-4864-82ae-25b36b7c114a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3eb9056e-5ac7-4292-a3bf-74c73fdf15de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_NetIncomeLoss_3eb9056e-5ac7-4292-a3bf-74c73fdf15de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e997e7b-1cd2-4b16-8193-c3361da7125b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e997e7b-1cd2-4b16-8193-c3361da7125b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_b3a65a58-7fa1-4bf7-b294-bdced5917150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_DividendsCommonStockCash_b3a65a58-7fa1-4bf7-b294-bdced5917150" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6334136-d37a-44b5-bb62-aff0927436ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6334136-d37a-44b5-bb62-aff0927436ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_d0436059-98cb-436d-a69c-0da02669bffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_d0436059-98cb-436d-a69c-0da02669bffc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a575434-d94d-4448-8d66-3c4a5cb0404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a575434-d94d-4448-8d66-3c4a5cb0404a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1a75df8e-9b60-40eb-a528-807b87540fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1a75df8e-9b60-40eb-a528-807b87540fa9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e38cda66-ad4c-40aa-8923-ad72481e8a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_StockholdersEquityOther_e38cda66-ad4c-40aa-8923-ad72481e8a12" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d39dce5-ef0b-4f31-a499-4ef46f19ed1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6ccfa879-b4e5-4a6c-9922-7d90f755c57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_43cac79f-bbee-4ce0-8bd3-13d52828b7e0" xlink:to="loc_us-gaap_StatementTable_6ccfa879-b4e5-4a6c-9922-7d90f755c57f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0460052-bf0d-4e3f-b22a-8d17061074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6ccfa879-b4e5-4a6c-9922-7d90f755c57f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0460052-bf0d-4e3f-b22a-8d17061074a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f0460052-bf0d-4e3f-b22a-8d17061074a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0460052-bf0d-4e3f-b22a-8d17061074a2" xlink:to="loc_us-gaap_EquityComponentDomain_f0460052-bf0d-4e3f-b22a-8d17061074a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0460052-bf0d-4e3f-b22a-8d17061074a2" xlink:to="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c79ca69d-5dd8-4ad3-a289-f39f55fbd274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_CommonStockMember_c79ca69d-5dd8-4ad3-a289-f39f55fbd274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c77e7a86-afb1-4fcc-9409-7610b8385897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c77e7a86-afb1-4fcc-9409-7610b8385897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4453d0ba-f9ca-43b2-849d-384fc6e05fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_RetainedEarningsMember_4453d0ba-f9ca-43b2-849d-384fc6e05fda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c2a52bd-6006-4050-8c89-5464c20854f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c2a52bd-6006-4050-8c89-5464c20854f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5e1ebff4-4279-46aa-b93b-6492cb7be323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5e1ebff4-4279-46aa-b93b-6492cb7be323" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b4028b77-7c04-4dc9-a50f-0c5e72996f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b4028b77-7c04-4dc9-a50f-0c5e72996f21" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SummaryofAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="extended" id="ib0461d5f24b94b40abe60e0b1a3dc495_SummaryofAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:href="mrk-20221231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_b91c920c-31d4-46ec-ac0b-32289308834f" xlink:href="mrk-20221231.xsd#mrk_SalesDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_SalesDiscounts_b91c920c-31d4-46ec-ac0b-32289308834f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks_30977e31-2970-4657-a686-743dd7029cde" xlink:href="mrk-20221231.xsd#mrk_AccrualForChargebacks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_AccrualForChargebacks_30977e31-2970-4657-a686-743dd7029cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates_c0a67f22-f077-4570-b476-b7c99ac7e654" xlink:href="mrk-20221231.xsd#mrk_AccrualForRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_AccrualForRebates_c0a67f22-f077-4570-b476-b7c99ac7e654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_3151544b-e188-4717-a4d4-fe1f21b7e40e" xlink:href="mrk-20221231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_3151544b-e188-4717-a4d4-fe1f21b7e40e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_591aceaa-2abd-416a-ba0f-900b386e549c" xlink:href="mrk-20221231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_591aceaa-2abd-416a-ba0f-900b386e549c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms_4503927d-78d2-4353-90d3-e26b2da31932" xlink:href="mrk-20221231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_RevenuePerformanceObligationPaymentTerms_4503927d-78d2-4353-90d3-e26b2da31932" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_31fb7de3-34fd-407d-9c57-52a1c3bd79bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_31fb7de3-34fd-407d-9c57-52a1c3bd79bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ee10593c-37db-4198-b904-94370cdfc146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_Depreciation_ee10593c-37db-4198-b904-94370cdfc146" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_c7933761-7ad0-4964-a66e-884507f86d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_AdvertisingExpense_c7933761-7ad0-4964-a66e-884507f86d2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_80510259-373a-4d66-bc93-2e822ae5e960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_80510259-373a-4d66-bc93-2e822ae5e960" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3c18771-b6e5-4dd1-ae1b-24f524450be9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_srt_RangeAxis_f3c18771-b6e5-4dd1-ae1b-24f524450be9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3c18771-b6e5-4dd1-ae1b-24f524450be9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f3c18771-b6e5-4dd1-ae1b-24f524450be9" xlink:to="loc_srt_RangeMember_f3c18771-b6e5-4dd1-ae1b-24f524450be9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f3c18771-b6e5-4dd1-ae1b-24f524450be9" xlink:to="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cf5e959f-b264-4158-af51-e1d76677283a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:to="loc_srt_MinimumMember_cf5e959f-b264-4158-af51-e1d76677283a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9497f4b0-fb70-4fc6-ae25-44bf5343d8b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:to="loc_srt_MaximumMember_9497f4b0-fb70-4fc6-ae25-44bf5343d8b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5793dcc3-a0c4-4e37-a46e-05582193d999" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_srt_StatementGeographicalAxis_5793dcc3-a0c4-4e37-a46e-05582193d999" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5793dcc3-a0c4-4e37-a46e-05582193d999_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5793dcc3-a0c4-4e37-a46e-05582193d999" xlink:to="loc_srt_SegmentGeographicalDomain_5793dcc3-a0c4-4e37-a46e-05582193d999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5793dcc3-a0c4-4e37-a46e-05582193d999" xlink:to="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2c0933ec-7fe3-4007-999c-1360b9718d1d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:to="loc_country_US_2c0933ec-7fe3-4007-999c-1360b9718d1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_29b493b1-fd43-4db2-a9c5-33a44b6a0877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:to="loc_us-gaap_NonUsMember_29b493b1-fd43-4db2-a9c5-33a44b6a0877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4" xlink:to="loc_us-gaap_SegmentDomain_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4" xlink:to="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_7c804031-90b2-4967-9d66-69047c2867cf" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:to="loc_mrk_PharmaceuticalsegmentMember_7c804031-90b2-4967-9d66-69047c2867cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_40e7fd47-9419-4509-bf8e-5759b97e0b0c" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:to="loc_mrk_AnimalHealthsegmentMember_40e7fd47-9419-4509-bf8e-5759b97e0b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022bafe4-a790-48d9-8dce-2fdfaee9b053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022bafe4-a790-48d9-8dce-2fdfaee9b053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_022bafe4-a790-48d9-8dce-2fdfaee9b053_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022bafe4-a790-48d9-8dce-2fdfaee9b053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_022bafe4-a790-48d9-8dce-2fdfaee9b053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022bafe4-a790-48d9-8dce-2fdfaee9b053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f0a1c414-80c5-441a-a2ef-0f5fc4fab43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:to="loc_us-gaap_BuildingMember_f0a1c414-80c5-441a-a2ef-0f5fc4fab43b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_aa861573-e28a-4e44-9bbf-026e1d4eb6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_aa861573-e28a-4e44-9bbf-026e1d4eb6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_09e923c7-0e50-484f-98e2-05faaa7b0f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_09e923c7-0e50-484f-98e2-05faaa7b0f7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09e923c7-0e50-484f-98e2-05faaa7b0f7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_09e923c7-0e50-484f-98e2-05faaa7b0f7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09e923c7-0e50-484f-98e2-05faaa7b0f7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5204188-2fcf-45b1-82a0-d6daee8728cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_09e923c7-0e50-484f-98e2-05faaa7b0f7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5204188-2fcf-45b1-82a0-d6daee8728cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1857bdc8-f913-4b16-bc6d-072b12919d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5204188-2fcf-45b1-82a0-d6daee8728cb" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1857bdc8-f913-4b16-bc6d-072b12919d7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SpinOffofOrganonCoNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="extended" id="ic8173d91c74a4e759b14b2b3051eac1f_SpinOffofOrganonCoNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_311801c5-a2a6-49e6-aab9-5cd249865242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_311801c5-a2a6-49e6-aab9-5cd249865242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9486416f-140e-436f-8982-a070c05143a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9486416f-140e-436f-8982-a070c05143a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_39cc324e-0634-4713-b38d-c8e3e680016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_39cc324e-0634-4713-b38d-c8e3e680016f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_eebfbf61-90d2-4322-892a-f5f42b720d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_eebfbf61-90d2-4322-892a-f5f42b720d8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_43d16b07-2449-46cf-8f2e-ff0baf4ca120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_RevenueFromRelatedParties_43d16b07-2449-46cf-8f2e-ff0baf4ca120" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_f8c1492e-1998-4951-87d2-199c914b2f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_f8c1492e-1998-4951-87d2-199c914b2f61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_d2d34081-dde0-4fa6-b9d3-db92408ce130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_d2d34081-dde0-4fa6-b9d3-db92408ce130" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_bac20f8c-98a2-481b-adbd-dc418ac6fde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_bac20f8c-98a2-481b-adbd-dc418ac6fde6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_906dfb9a-22f5-4709-96aa-4dee8df1a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_906dfb9a-22f5-4709-96aa-4dee8df1a84b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7a2f6600-fb99-4454-88e9-f32fc3a66668" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_dei_LegalEntityAxis_7a2f6600-fb99-4454-88e9-f32fc3a66668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a2f6600-fb99-4454-88e9-f32fc3a66668_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7a2f6600-fb99-4454-88e9-f32fc3a66668" xlink:to="loc_dei_EntityDomain_7a2f6600-fb99-4454-88e9-f32fc3a66668_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b6091f28-9760-48da-9399-72a10fc1d287" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7a2f6600-fb99-4454-88e9-f32fc3a66668" xlink:to="loc_dei_EntityDomain_b6091f28-9760-48da-9399-72a10fc1d287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_b25ef7d5-8394-4b97-b1ac-4a9963bf49e4" xlink:href="mrk-20221231.xsd#mrk_OrganonCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b6091f28-9760-48da-9399-72a10fc1d287" xlink:to="loc_mrk_OrganonCoMember_b25ef7d5-8394-4b97-b1ac-4a9963bf49e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_srt_RangeAxis_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717" xlink:to="loc_srt_RangeMember_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717" xlink:to="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48640bf2-69a5-4c9c-9f77-53f758e07eb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:to="loc_srt_MinimumMember_48640bf2-69a5-4c9c-9f77-53f758e07eb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6657183d-849e-40c0-839c-1d4fa964450c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:to="loc_srt_MaximumMember_6657183d-849e-40c0-839c-1d4fa964450c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ca961e10-cb94-414b-9ca8-739a8d280e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ca961e10-cb94-414b-9ca8-739a8d280e65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ca961e10-cb94-414b-9ca8-739a8d280e65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ca961e10-cb94-414b-9ca8-739a8d280e65" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ca961e10-cb94-414b-9ca8-739a8d280e65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ca961e10-cb94-414b-9ca8-739a8d280e65" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_7557d88d-3a1a-429d-8408-d48ae808d28f" xlink:href="mrk-20221231.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:to="loc_mrk_TransitionServicesAgreementMember_7557d88d-3a1a-429d-8408-d48ae808d28f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_56709f8c-78b8-4ae8-b2d3-edb1290ca415" xlink:href="mrk-20221231.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_56709f8c-78b8-4ae8-b2d3-edb1290ca415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6445d134-b82a-4fb7-b774-c1e9b6b1c94a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_srt_CounterpartyNameAxis_6445d134-b82a-4fb7-b774-c1e9b6b1c94a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6445d134-b82a-4fb7-b774-c1e9b6b1c94a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6445d134-b82a-4fb7-b774-c1e9b6b1c94a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6445d134-b82a-4fb7-b774-c1e9b6b1c94a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc0f084-cbb4-4415-a415-85e1c937801b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6445d134-b82a-4fb7-b774-c1e9b6b1c94a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc0f084-cbb4-4415-a415-85e1c937801b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_28499184-cc4f-4294-897e-a75eda81e686" xlink:href="mrk-20221231.xsd#mrk_OrganonCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc0f084-cbb4-4415-a415-85e1c937801b" xlink:to="loc_mrk_OrganonCoMember_28499184-cc4f-4294-897e-a75eda81e686" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" xlink:type="extended" id="i4a1534616f3448f489a024b53013795c_AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f58ce7d4-b7e3-4fab-b42b-80365bf8252a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f58ce7d4-b7e3-4fab-b42b-80365bf8252a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_7422d98b-614a-4c4f-a30e-fee2f44c0352" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_7422d98b-614a-4c4f-a30e-fee2f44c0352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_874626fa-fcc2-402f-aeb6-ba96d0cfd958" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_874626fa-fcc2-402f-aeb6-ba96d0cfd958" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_f4032dc2-0ecf-49c0-9219-9f1d4a1b3a2d" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_f4032dc2-0ecf-49c0-9219-9f1d4a1b3a2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_590723d5-9fe5-4daf-9d22-9227ade42b5f" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_590723d5-9fe5-4daf-9d22-9227ade42b5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4cc2ea55-a78b-4e0d-b6ed-16285ed5f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4cc2ea55-a78b-4e0d-b6ed-16285ed5f14e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_f030bb1e-c8c1-469b-b961-41e073176d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_f030bb1e-c8c1-469b-b961-41e073176d98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_629dde61-2917-454f-af7c-90883fa973ee" xlink:href="mrk-20221231.xsd#mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_629dde61-2917-454f-af7c-90883fa973ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2c1428ed-ef79-4744-a50b-1c7f47dbd251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2c1428ed-ef79-4744-a50b-1c7f47dbd251" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_799ecf2d-e466-41e1-a80c-8fa58e10b996" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_799ecf2d-e466-41e1-a80c-8fa58e10b996" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_6fdd5672-0628-479d-90e9-82160a553fa3" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_6fdd5672-0628-479d-90e9-82160a553fa3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e87b59a5-c0bd-47d0-9ea3-50cffab80524" xlink:href="mrk-20221231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e87b59a5-c0bd-47d0-9ea3-50cffab80524" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_189e8f3d-2922-4b02-a1d3-b9526de324d4" xlink:href="mrk-20221231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_189e8f3d-2922-4b02-a1d3-b9526de324d4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_be5ca6fd-a5a4-4a4f-8ce3-505e31341d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_be5ca6fd-a5a4-4a4f-8ce3-505e31341d44" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_e0af7dea-369a-45fe-a913-42dae24478fb" xlink:href="mrk-20221231.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_e0af7dea-369a-45fe-a913-42dae24478fb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentToBeMadeToCollaborativePartner_31d65b37-877c-4164-99bc-5a25540768f0" xlink:href="mrk-20221231.xsd#mrk_MilestonePaymentToBeMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_MilestonePaymentToBeMadeToCollaborativePartner_31d65b37-877c-4164-99bc-5a25540768f0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners_5292fede-7a57-48c9-97cc-bb90933f95e6" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners_5292fede-7a57-48c9-97cc-bb90933f95e6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner_e14a33f8-f365-4331-876c-f2316e66048f" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner_e14a33f8-f365-4331-876c-f2316e66048f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c3d332a3-ff91-4e55-8e3d-cc8990bae4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c3d332a3-ff91-4e55-8e3d-cc8990bae4d6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_be0c90e4-540d-45a9-8fb5-c03e9d47f794" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_RoyaltyRatePercentage_be0c90e4-540d-45a9-8fb5-c03e9d47f794" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_bc4d2fb3-7c0e-4107-9125-cab14810dac0" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_bc4d2fb3-7c0e-4107-9125-cab14810dac0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_21e60f1a-2322-46f7-b784-268f95532372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_21e60f1a-2322-46f7-b784-268f95532372" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b5f18342-2a30-4e60-86c1-43aabf440f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b5f18342-2a30-4e60-86c1-43aabf440f9b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_9904a560-9e98-450a-ada6-0ce954daaa2c" xlink:href="mrk-20221231.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_9904a560-9e98-450a-ada6-0ce954daaa2c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShareCounterparty_cadfe8f2-d62b-47d6-8c05-e9fd127d4c08" xlink:href="mrk-20221231.xsd#mrk_ProfitShareCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ProfitShareCounterparty_cadfe8f2-d62b-47d6-8c05-e9fd127d4c08" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShare_a4177dca-83ba-497b-bae8-1458e62b0da7" xlink:href="mrk-20221231.xsd#mrk_ProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ProfitShare_a4177dca-83ba-497b-bae8-1458e62b0da7" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesThreshold_f521b990-a2e3-47ee-85b6-1db33bd89916" xlink:href="mrk-20221231.xsd#mrk_SalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_SalesThreshold_f521b990-a2e3-47ee-85b6-1db33bd89916" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_aeda6b0e-fbd6-4527-9a29-3c59b4ddcc2d" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_aeda6b0e-fbd6-4527-9a29-3c59b4ddcc2d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_9d693025-4087-45ff-8c6f-76cedf7e0b57" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementNumberOfCollaborationTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_9d693025-4087-45ff-8c6f-76cedf7e0b57" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d549e8-e227-4b86-a9b0-80a59c389971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d549e8-e227-4b86-a9b0-80a59c389971" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_397026f6-57da-474e-82df-2980e78cfabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_Investments_397026f6-57da-474e-82df-2980e78cfabd" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired_c665e132-031b-4d91-8036-ed1cb9d9c5d3" xlink:href="mrk-20221231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_PremiumOnSharesAcquired_c665e132-031b-4d91-8036-ed1cb9d9c5d3" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_f122c529-1cfc-4a62-8a42-017a588513a1" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_f122c529-1cfc-4a62-8a42-017a588513a1" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_3e1aaef1-2541-4565-9dfa-bde08fcc6339" xlink:href="mrk-20221231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_3e1aaef1-2541-4565-9dfa-bde08fcc6339" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_6c2d38d3-7e25-480a-a7df-6f423b4a8429" xlink:href="mrk-20221231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_6c2d38d3-7e25-480a-a7df-6f423b4a8429" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_4858b3dc-1cdd-4c94-8e2c-1b75b15b6f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_4858b3dc-1cdd-4c94-8e2c-1b75b15b6f34" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ef136c5f-e468-4808-a965-7a046821cfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_SharePrice_ef136c5f-e468-4808-a965-7a046821cfdc" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_efaceb5c-a0dc-448c-84cc-37c6f8e09e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_efaceb5c-a0dc-448c-84cc-37c6f8e09e1c" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_170a7813-7f74-463b-ae66-acefe5e22285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_InventoryNet_170a7813-7f74-463b-ae66-acefe5e22285" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e814d45d-151c-44d4-9e9f-d0624c2e6060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e814d45d-151c-44d4-9e9f-d0624c2e6060" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4c4f410-bb34-4886-8a30-230f1ef40145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4c4f410-bb34-4886-8a30-230f1ef40145" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_160d34b9-9c8f-4e91-bd48-71beb77b7e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_160d34b9-9c8f-4e91-bd48-71beb77b7e9f" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0072725a-271a-4b45-9455-7a1997f59ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0072725a-271a-4b45-9455-7a1997f59ad3" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_dc8456b2-1707-403a-9d52-cac7ce34956e" xlink:href="mrk-20221231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_dc8456b2-1707-403a-9d52-cac7ce34956e" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d85cfc7c-e1e0-42e3-afe8-b8db92069cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_Goodwill_d85cfc7c-e1e0-42e3-afe8-b8db92069cbe" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4297a18d-2326-46e2-9a4c-9c966b42b715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4297a18d-2326-46e2-9a4c-9c966b42b715" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2d1d0f5b-cfda-472c-9b45-95cc17698984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2d1d0f5b-cfda-472c-9b45-95cc17698984" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_fa079b27-507d-4c1e-929b-a4d0af4ddc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_fa079b27-507d-4c1e-929b-a4d0af4ddc80" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_330786c6-2c6e-4eb6-a9ac-0f78ab1e93e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_330786c6-2c6e-4eb6-a9ac-0f78ab1e93e8" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91be13c9-895d-43ac-ada9-f1a8f39bf81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91be13c9-895d-43ac-ada9-f1a8f39bf81b" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_faddc7b0-aff7-45d9-8e1b-d415d768f83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_faddc7b0-aff7-45d9-8e1b-d415d768f83c" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68d2bfa7-5c31-4796-b958-e7de82bc8432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68d2bfa7-5c31-4796-b958-e7de82bc8432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_68d2bfa7-5c31-4796-b958-e7de82bc8432_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68d2bfa7-5c31-4796-b958-e7de82bc8432" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_68d2bfa7-5c31-4796-b958-e7de82bc8432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_476c08f5-f90f-4dd1-a4f4-62907ffdadf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68d2bfa7-5c31-4796-b958-e7de82bc8432" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_476c08f5-f90f-4dd1-a4f4-62907ffdadf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyPharmaMember_8351a1fe-33b4-4eb4-84a0-6d2cd3fd94c7" xlink:href="mrk-20221231.xsd#mrk_RoyaltyPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_476c08f5-f90f-4dd1-a4f4-62907ffdadf6" xlink:to="loc_mrk_RoyaltyPharmaMember_8351a1fe-33b4-4eb4-84a0-6d2cd3fd94c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3fedcaaf-556e-4925-ba8d-8c65915c2004" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_CounterpartyNameAxis_3fedcaaf-556e-4925-ba8d-8c65915c2004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fedcaaf-556e-4925-ba8d-8c65915c2004_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3fedcaaf-556e-4925-ba8d-8c65915c2004" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fedcaaf-556e-4925-ba8d-8c65915c2004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3fedcaaf-556e-4925-ba8d-8c65915c2004" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ModernaMember_9c5ef7d9-3e49-4660-bb95-26724cecb8f5" xlink:href="mrk-20221231.xsd#mrk_ModernaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_ModernaMember_9c5ef7d9-3e49-4660-bb95-26724cecb8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember_8e0985c9-ff0c-424c-8f33-008941e68d65" xlink:href="mrk-20221231.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_OrnaTherapeuticsMember_8e0985c9-ff0c-424c-8f33-008941e68d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrionCorporationMember_c68f52ba-4cf6-4206-bcde-c52acc1f3e51" xlink:href="mrk-20221231.xsd#mrk_OrionCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_OrionCorporationMember_c68f52ba-4cf6-4206-bcde-c52acc1f3e51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_52c5e01a-4432-473e-865e-8474dba941b8" xlink:href="mrk-20221231.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_52c5e01a-4432-473e-865e-8474dba941b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_b1f4546b-87c6-4153-8219-f5db78136c0c" xlink:href="mrk-20221231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_BristolMyersSquibbMember_b1f4546b-87c6-4153-8219-f5db78136c0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GileadSciencesMember_f5433b81-d612-404d-ae11-96faa0068dfc" xlink:href="mrk-20221231.xsd#mrk_GileadSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_GileadSciencesMember_f5433b81-d612-404d-ae11-96faa0068dfc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_e8d4668c-8fe1-4527-a13f-f78e26ab19bd" xlink:href="mrk-20221231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_e8d4668c-8fe1-4527-a13f-f78e26ab19bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_c0b53f63-813d-4e04-b504-046a48c08a11" xlink:href="mrk-20221231.xsd#mrk_SeagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_SeagenMember_c0b53f63-813d-4e04-b504-046a48c08a11" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_2046c151-669a-4ba1-974b-e555904f3467" xlink:href="mrk-20221231.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_SentinelMember_2046c151-669a-4ba1-974b-e555904f3467" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_32944e83-f831-4a06-a53a-e4e7012f5387" xlink:href="mrk-20221231.xsd#mrk_IAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_IAVIMember_32944e83-f831-4a06-a53a-e4e7012f5387" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fae62110-af84-413c-a4d3-a1371b874695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fae62110-af84-413c-a4d3-a1371b874695" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fae62110-af84-413c-a4d3-a1371b874695_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fae62110-af84-413c-a4d3-a1371b874695" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fae62110-af84-413c-a4d3-a1371b874695_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fae62110-af84-413c-a4d3-a1371b874695" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b45192bf-2882-47fd-a52e-da54a5c79fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b45192bf-2882-47fd-a52e-da54a5c79fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9fca9723-670b-4eb6-bf13-07deb4b2bfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:to="loc_us-gaap_LicensingAgreementsMember_9fca9723-670b-4eb6-bf13-07deb4b2bfa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_d305b0f0-2758-45a5-96c0-16657fec7adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_d305b0f0-2758-45a5-96c0-16657fec7adb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_d305b0f0-2758-45a5-96c0-16657fec7adb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d305b0f0-2758-45a5-96c0-16657fec7adb" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_d305b0f0-2758-45a5-96c0-16657fec7adb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d305b0f0-2758-45a5-96c0-16657fec7adb" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_7bcf210c-23bb-4194-8d48-1f5d438e1ecb" xlink:href="mrk-20221231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_DevelopmentMilestonesMember_7bcf210c-23bb-4194-8d48-1f5d438e1ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_0466172d-e535-4928-82b3-f199c8165229" xlink:href="mrk-20221231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_RegulatoryMilestonesMember_0466172d-e535-4928-82b3-f199c8165229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_6095e68e-a3bb-40dd-85d8-2b2eb5cb46f5" xlink:href="mrk-20221231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_SalesBasedMilestonesMember_6095e68e-a3bb-40dd-85d8-2b2eb5cb46f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FirstCommercialSaleMilestonesMember_ee463876-7876-4fb6-8e0d-2d59995a688c" xlink:href="mrk-20221231.xsd#mrk_FirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_FirstCommercialSaleMilestonesMember_ee463876-7876-4fb6-8e0d-2d59995a688c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b0145106-608c-4212-8da7-98f37dc7d68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b0145106-608c-4212-8da7-98f37dc7d68d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b0145106-608c-4212-8da7-98f37dc7d68d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0145106-608c-4212-8da7-98f37dc7d68d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b0145106-608c-4212-8da7-98f37dc7d68d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0145106-608c-4212-8da7-98f37dc7d68d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_b99ddd9b-a9dd-4d6c-bca3-251d63568f38" xlink:href="mrk-20221231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:to="loc_mrk_AcceleronPharmaIncMember_b99ddd9b-a9dd-4d6c-bca3-251d63568f38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_6b8fc6b3-0351-4c7a-a1a1-4838ff7a96c0" xlink:href="mrk-20221231.xsd#mrk_ThemisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:to="loc_mrk_ThemisMember_6b8fc6b3-0351-4c7a-a1a1-4838ff7a96c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_4f2f791a-f55b-4076-8425-d21dee80ec60" xlink:href="mrk-20221231.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:to="loc_mrk_ArQuleMember_4f2f791a-f55b-4076-8425-d21dee80ec60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_01f56955-d7f4-4455-bfd8-ec3c76e3f61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_01f56955-d7f4-4455-bfd8-ec3c76e3f61b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_01f56955-d7f4-4455-bfd8-ec3c76e3f61b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01f56955-d7f4-4455-bfd8-ec3c76e3f61b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_01f56955-d7f4-4455-bfd8-ec3c76e3f61b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5a76fa43-33d5-4e7f-a988-4de80fe36b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01f56955-d7f4-4455-bfd8-ec3c76e3f61b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5a76fa43-33d5-4e7f-a988-4de80fe36b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8eabc748-9f95-44e8-832e-d4ee6bac2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a76fa43-33d5-4e7f-a988-4de80fe36b8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8eabc748-9f95-44e8-832e-d4ee6bac2ab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1452ca9c-9575-463c-a281-5afb9248481d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_RangeAxis_1452ca9c-9575-463c-a281-5afb9248481d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1452ca9c-9575-463c-a281-5afb9248481d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1452ca9c-9575-463c-a281-5afb9248481d" xlink:to="loc_srt_RangeMember_1452ca9c-9575-463c-a281-5afb9248481d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1452ca9c-9575-463c-a281-5afb9248481d" xlink:to="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c3e12fc-a3f9-4661-9323-4f295bf9b883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:to="loc_srt_MinimumMember_2c3e12fc-a3f9-4661-9323-4f295bf9b883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_30ae89f2-077b-4063-b950-674a01f999c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:to="loc_srt_MaximumMember_30ae89f2-077b-4063-b950-674a01f999c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_62812f0b-df58-48a9-8f69-b1356aff8afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_AssetAcquisitionAxis_62812f0b-df58-48a9-8f69-b1356aff8afb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_62812f0b-df58-48a9-8f69-b1356aff8afb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_62812f0b-df58-48a9-8f69-b1356aff8afb" xlink:to="loc_us-gaap_AssetAcquisitionDomain_62812f0b-df58-48a9-8f69-b1356aff8afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_62812f0b-df58-48a9-8f69-b1356aff8afb" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImagoBioSciencesIncMember_e77161f0-ecc0-4638-ae55-a6b7edc09856" xlink:href="mrk-20221231.xsd#mrk_ImagoBioSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_ImagoBioSciencesIncMember_e77161f0-ecc0-4638-ae55-a6b7edc09856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_6c5446c9-e28f-416f-a3cd-7d7c0494a7d9" xlink:href="mrk-20221231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_PandionTherapeuticsMember_6c5446c9-e28f-416f-a3cd-7d7c0494a7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_c300bc9c-d430-487c-ac22-5ea923edd3a0" xlink:href="mrk-20221231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_c300bc9c-d430-487c-ac22-5ea923edd3a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_6d5c0aa2-74bc-43be-9f00-1563b70acbfc" xlink:href="mrk-20221231.xsd#mrk_OncoImmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_OncoImmuneMember_6d5c0aa2-74bc-43be-9f00-1563b70acbfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_2ea65723-7226-4b13-8020-aea9be2c5c61" xlink:href="mrk-20221231.xsd#mrk_VelosBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_VelosBioMember_2ea65723-7226-4b13-8020-aea9be2c5c61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_e58d4d7d-ac12-408f-8a04-e881580dac56" xlink:href="mrk-20221231.xsd#mrk_DunboyneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_DunboyneMember_e58d4d7d-ac12-408f-8a04-e881580dac56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_ProductOrServiceAxis_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5" xlink:to="loc_srt_ProductsAndServicesDomain_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5" xlink:to="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralAndInjectableFormulationsMember_835f2610-9db8-4fa9-a700-25e30a59d68b" xlink:href="mrk-20221231.xsd#mrk_OralAndInjectableFormulationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_OralAndInjectableFormulationsMember_835f2610-9db8-4fa9-a700-25e30a59d68b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralFormulationMember_57e00fab-480f-4c8d-b202-d1b9449f07ce" xlink:href="mrk-20221231.xsd#mrk_OralFormulationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_OralFormulationMember_57e00fab-480f-4c8d-b202-d1b9449f07ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InjectableFormulationMember_7413570d-b8be-4e0e-aa08-7f3bb72f0f82" xlink:href="mrk-20221231.xsd#mrk_InjectableFormulationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_InjectableFormulationMember_7413570d-b8be-4e0e-aa08-7f3bb72f0f82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_222ab14b-604c-42e2-8505-9e45c988d75d" xlink:href="mrk-20221231.xsd#mrk_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_COVID19Member_222ab14b-604c-42e2-8505-9e45c988d75d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_5cc424ed-b358-4404-860d-3cea8e8c1f26" xlink:href="mrk-20221231.xsd#mrk_TukysaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_TukysaMember_5cc424ed-b358-4404-860d-3cea8e8c1f26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_258416a9-f656-43af-bd79-2069a78604a7" xlink:href="mrk-20221231.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_SentinelMember_258416a9-f656-43af-bd79-2069a78604a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_123583ed-d6fd-48dc-92e3-d08f4aac0730" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_123583ed-d6fd-48dc-92e3-d08f4aac0730" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_123583ed-d6fd-48dc-92e3-d08f4aac0730_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_123583ed-d6fd-48dc-92e3-d08f4aac0730" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_123583ed-d6fd-48dc-92e3-d08f4aac0730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c16442d7-1f07-4335-9f68-7a171e5377fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_123583ed-d6fd-48dc-92e3-d08f4aac0730" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c16442d7-1f07-4335-9f68-7a171e5377fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_9da34c34-3e28-47cc-90c5-70e319065e66" xlink:href="mrk-20221231.xsd#mrk_OncoImmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c16442d7-1f07-4335-9f68-7a171e5377fd" xlink:to="loc_mrk_OncoImmuneMember_9da34c34-3e28-47cc-90c5-70e319065e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7f6e793-8adb-4d34-8dc9-b952f020937c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7f6e793-8adb-4d34-8dc9-b952f020937c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f7f6e793-8adb-4d34-8dc9-b952f020937c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7f6e793-8adb-4d34-8dc9-b952f020937c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f7f6e793-8adb-4d34-8dc9-b952f020937c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fba211-ec15-4983-b154-5cb0ea02f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7f6e793-8adb-4d34-8dc9-b952f020937c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fba211-ec15-4983-b154-5cb0ea02f1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b6ba30a4-1106-4f4b-b59b-50f0d1374f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fba211-ec15-4983-b154-5cb0ea02f1df" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b6ba30a4-1106-4f4b-b59b-50f0d1374f83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7aa83008-4da1-4106-be2a-aef9c663fc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7aa83008-4da1-4106-be2a-aef9c663fc47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_73f662fb-f111-449b-a741-bdc2c6d8eeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7aa83008-4da1-4106-be2a-aef9c663fc47" xlink:to="loc_us-gaap_SubsequentEventMember_73f662fb-f111-449b-a741-bdc2c6d8eeae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i01633d80f5eb4300bfe2e0288be51ac3_AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a1f245fe-9bc9-4703-a90f-c6f5425339bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a1f245fe-9bc9-4703-a90f-c6f5425339bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_8f8bce79-76cb-4c78-ba91-23e4920d9051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_8f8bce79-76cb-4c78-ba91-23e4920d9051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5568ce8d-9b59-42ac-ad15-c739099af20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5568ce8d-9b59-42ac-ad15-c739099af20a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a8a49e67-590a-46f5-93a5-ffa41cc300fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a8a49e67-590a-46f5-93a5-ffa41cc300fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f5457740-afd0-474b-bfd2-1c06ec17a979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f5457740-afd0-474b-bfd2-1c06ec17a979" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_065bbba8-d9ce-4e0b-892e-51857eb95e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_065bbba8-d9ce-4e0b-892e-51857eb95e76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c22134-e4aa-4268-a983-dbb539f270cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c22134-e4aa-4268-a983-dbb539f270cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_47a4e0a2-501e-44a4-a81d-1e7af5900d97" xlink:href="mrk-20221231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_47a4e0a2-501e-44a4-a81d-1e7af5900d97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_02bd54b9-cb25-46df-a31b-332063ff320b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_02bd54b9-cb25-46df-a31b-332063ff320b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cafb8d2-a794-479a-8046-b8fdfac549b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_Goodwill_6cafb8d2-a794-479a-8046-b8fdfac549b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_56fdf53f-aad6-420d-8fc5-8f4e3b831911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_56fdf53f-aad6-420d-8fc5-8f4e3b831911" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_dfbbef0f-c8c6-4842-b096-8816858ad3b1" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_dfbbef0f-c8c6-4842-b096-8816858ad3b1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_c486730a-b195-42c4-a95f-5a1049edf527" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetProductsAndProductRightsMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_c486730a-b195-42c4-a95f-5a1049edf527" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01ce31e6-af5b-4d29-80ff-ade18963fb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01ce31e6-af5b-4d29-80ff-ade18963fb2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01ce31e6-af5b-4d29-80ff-ade18963fb2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01ce31e6-af5b-4d29-80ff-ade18963fb2c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01ce31e6-af5b-4d29-80ff-ade18963fb2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01ce31e6-af5b-4d29-80ff-ade18963fb2c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_8d488b43-75fe-4dc0-b09a-0cee0e822a99" xlink:href="mrk-20221231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:to="loc_mrk_AcceleronPharmaIncMember_8d488b43-75fe-4dc0-b09a-0cee0e822a99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_3c885788-a433-4ab6-9929-3edd9d465efc" xlink:href="mrk-20221231.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:to="loc_mrk_ArQuleMember_3c885788-a433-4ab6-9929-3edd9d465efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e727169e-bdc2-4354-9bf5-8d9372b644e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e727169e-bdc2-4354-9bf5-8d9372b644e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e727169e-bdc2-4354-9bf5-8d9372b644e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e727169e-bdc2-4354-9bf5-8d9372b644e4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e727169e-bdc2-4354-9bf5-8d9372b644e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_77ca595f-41d6-4635-831e-e6840dfd7eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e727169e-bdc2-4354-9bf5-8d9372b644e4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_77ca595f-41d6-4635-831e-e6840dfd7eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_461c391a-51bc-45aa-af04-78331bbdb2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_77ca595f-41d6-4635-831e-e6840dfd7eac" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_461c391a-51bc-45aa-af04-78331bbdb2c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended" id="i79889f7bb97146ed809d9432b1fc63e2_CollaborativeArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_61380e2f-89d7-4799-b362-41bf5979a795" xlink:href="mrk-20221231.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_61380e2f-89d7-4799-b362-41bf5979a795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_df3068c3-0481-47fa-b4f5-79bb9c731e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_Liabilities_df3068c3-0481-47fa-b4f5-79bb9c731e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_d3b50d45-152b-495f-81fd-6c9877ff9333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_AdjustmentForAmortization_d3b50d45-152b-495f-81fd-6c9877ff9333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0ac7f8c1-2b2c-4720-9448-c293839fd0ab" xlink:href="mrk-20221231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0ac7f8c1-2b2c-4720-9448-c293839fd0ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_f23bb6f2-628b-43ac-8ade-9d22c03376c3" xlink:href="mrk-20221231.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_f23bb6f2-628b-43ac-8ade-9d22c03376c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_d92a23fc-dcf3-46fa-b224-ada481ff71ff" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_d92a23fc-dcf3-46fa-b224-ada481ff71ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_3c7dbbf4-d7a8-40bc-b93c-2931db94ef11" xlink:href="mrk-20221231.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_3c7dbbf4-d7a8-40bc-b93c-2931db94ef11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c058857-c958-4a5e-bc91-b3fe80ddc2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c058857-c958-4a5e-bc91-b3fe80ddc2f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_ef233b66-2a94-48d4-8d12-852d93f37e60" xlink:href="mrk-20221231.xsd#mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_ef233b66-2a94-48d4-8d12-852d93f37e60" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e407c1df-0678-4b69-bc94-d82c84ff9224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e407c1df-0678-4b69-bc94-d82c84ff9224" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_5cc35129-e425-4ebc-b586-4e761009d2a6" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_RoyaltyRatePercentage_5cc35129-e425-4ebc-b586-4e761009d2a6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_081e9f23-d214-4daa-bc88-a07dc49fefcc" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_081e9f23-d214-4daa-bc88-a07dc49fefcc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_c81979f7-21e0-41d3-bf0e-7998ca2fb8b2" xlink:href="mrk-20221231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_c81979f7-21e0-41d3-bf0e-7998ca2fb8b2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_00b011ef-9253-4829-adfe-c71d5a30c618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_Revenues_00b011ef-9253-4829-adfe-c71d5a30c618" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_44c6bfd4-2877-45d3-b4a6-7d8296f596b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_44c6bfd4-2877-45d3-b4a6-7d8296f596b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_CounterpartyNameAxis_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_f8603d3f-c31d-4dbe-bfc9-6d0216a98fc6" xlink:href="mrk-20221231.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_AstraZenecaMember_f8603d3f-c31d-4dbe-bfc9-6d0216a98fc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_fda104dd-4dcd-4531-9772-f8a6abdd7d2a" xlink:href="mrk-20221231.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_EisaiMember_fda104dd-4dcd-4531-9772-f8a6abdd7d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_3ad97907-61b3-4ea3-b58f-335198692809" xlink:href="mrk-20221231.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_BayerAGMember_3ad97907-61b3-4ea3-b58f-335198692809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_a66c49ae-6dae-4998-83ec-3f395af6e280" xlink:href="mrk-20221231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_a66c49ae-6dae-4998-83ec-3f395af6e280" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_087bf560-980e-4d08-acf8-8d0e3cbd7f21" xlink:href="mrk-20221231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_BristolMyersSquibbMember_087bf560-980e-4d08-acf8-8d0e3cbd7f21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90df9ed8-9ba5-400c-8602-6a258ce5493a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_ProductOrServiceAxis_90df9ed8-9ba5-400c-8602-6a258ce5493a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90df9ed8-9ba5-400c-8602-6a258ce5493a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_90df9ed8-9ba5-400c-8602-6a258ce5493a" xlink:to="loc_srt_ProductsAndServicesDomain_90df9ed8-9ba5-400c-8602-6a258ce5493a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_90df9ed8-9ba5-400c-8602-6a258ce5493a" xlink:to="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_5e2bb631-b1ad-4cd3-971a-f1aff6a939ba" xlink:href="mrk-20221231.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_LynparzaMember_5e2bb631-b1ad-4cd3-971a-f1aff6a939ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_d86aaa73-ecb6-487c-b033-6f58150b3cea" xlink:href="mrk-20221231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_LenvimaMember_d86aaa73-ecb6-487c-b033-6f58150b3cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_8aeab151-6de9-4d83-b670-77da5d39039d" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_AdempasMember_8aeab151-6de9-4d83-b670-77da5d39039d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_58ca3614-addf-49c5-9f58-a29de82e1b7e" xlink:href="mrk-20221231.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_VerquvoMember_58ca3614-addf-49c5-9f58-a29de82e1b7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_9724924f-7974-42ec-bd18-8b021d8c2cd6" xlink:href="mrk-20221231.xsd#mrk_ReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_ReblozylMember_9724924f-7974-42ec-bd18-8b021d8c2cd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_414976b0-56d3-4eaa-97c9-07c21f68a851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_414976b0-56d3-4eaa-97c9-07c21f68a851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_414976b0-56d3-4eaa-97c9-07c21f68a851_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_414976b0-56d3-4eaa-97c9-07c21f68a851" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_414976b0-56d3-4eaa-97c9-07c21f68a851_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_414976b0-56d3-4eaa-97c9-07c21f68a851" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_a408d57f-e737-4e48-9fba-6b21c333b283" xlink:href="mrk-20221231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_mrk_SalesBasedMilestonesMember_a408d57f-e737-4e48-9fba-6b21c333b283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fcc7bcbd-be70-4474-a2b1-3448d8446a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fcc7bcbd-be70-4474-a2b1-3448d8446a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_a304ffd7-f37f-47c7-a751-4718199b24d3" xlink:href="mrk-20221231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_mrk_RegulatoryMilestonesMember_a304ffd7-f37f-47c7-a751-4718199b24d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5ffb3423-a324-4522-82b0-2f228e223287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5ffb3423-a324-4522-82b0-2f228e223287" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_0a68dc0f-d62b-490a-9982-fcbbfdaed7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_us-gaap_LicensingAgreementsMember_0a68dc0f-d62b-490a-9982-fcbbfdaed7c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adb708e7-627c-4b25-82dc-92c20ec2c3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adb708e7-627c-4b25-82dc-92c20ec2c3f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_adb708e7-627c-4b25-82dc-92c20ec2c3f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adb708e7-627c-4b25-82dc-92c20ec2c3f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_adb708e7-627c-4b25-82dc-92c20ec2c3f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f90c1ee-4d7f-41df-a492-03bb84e92efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adb708e7-627c-4b25-82dc-92c20ec2c3f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f90c1ee-4d7f-41df-a492-03bb84e92efe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_13ed0613-3eb5-4057-b2ab-51e8c4c28f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f90c1ee-4d7f-41df-a492-03bb84e92efe" xlink:to="loc_us-gaap_LicenseMember_13ed0613-3eb5-4057-b2ab-51e8c4c28f50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_710c7716-666d-42fe-8f5b-a8caab649333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_710c7716-666d-42fe-8f5b-a8caab649333" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_710c7716-666d-42fe-8f5b-a8caab649333_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_710c7716-666d-42fe-8f5b-a8caab649333" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_710c7716-666d-42fe-8f5b-a8caab649333_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6aac3d55-5568-412d-b4d9-9192f1e1eafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_710c7716-666d-42fe-8f5b-a8caab649333" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6aac3d55-5568-412d-b4d9-9192f1e1eafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1bc3491c-5323-40c8-9940-f15c08dc3790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6aac3d55-5568-412d-b4d9-9192f1e1eafa" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1bc3491c-5323-40c8-9940-f15c08dc3790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_aac5f99b-237f-422c-a0b8-47e7d4c554c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_aac5f99b-237f-422c-a0b8-47e7d4c554c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_aac5f99b-237f-422c-a0b8-47e7d4c554c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_aac5f99b-237f-422c-a0b8-47e7d4c554c4" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_aac5f99b-237f-422c-a0b8-47e7d4c554c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_aac5f99b-237f-422c-a0b8-47e7d4c554c4" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_f062c1f6-1457-45e3-8947-8e89addb4839" xlink:href="mrk-20221231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:to="loc_mrk_RegulatoryMilestonesMember_f062c1f6-1457-45e3-8947-8e89addb4839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_daa4b5b5-9f57-4ad9-b584-0a50346234db" xlink:href="mrk-20221231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:to="loc_mrk_SalesBasedMilestonesMember_daa4b5b5-9f57-4ad9-b584-0a50346234db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a50445a-24ac-4e15-825f-06690dca7078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_RangeAxis_3a50445a-24ac-4e15-825f-06690dca7078" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a50445a-24ac-4e15-825f-06690dca7078_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3a50445a-24ac-4e15-825f-06690dca7078" xlink:to="loc_srt_RangeMember_3a50445a-24ac-4e15-825f-06690dca7078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3a50445a-24ac-4e15-825f-06690dca7078" xlink:to="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65fde2ef-f8ea-400a-a1ba-169fcf631396" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:to="loc_srt_MinimumMember_65fde2ef-f8ea-400a-a1ba-169fcf631396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f831f47-3998-4b3d-af4d-8d5509c55f3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:to="loc_srt_MaximumMember_1f831f47-3998-4b3d-af4d-8d5509c55f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f504c856-00d6-4567-86a8-45cd6d55b359" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_ConsolidationItemsAxis_f504c856-00d6-4567-86a8-45cd6d55b359" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f504c856-00d6-4567-86a8-45cd6d55b359_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f504c856-00d6-4567-86a8-45cd6d55b359" xlink:to="loc_srt_ConsolidationItemsDomain_f504c856-00d6-4567-86a8-45cd6d55b359_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c7ad58a2-efc7-456d-84fc-f004082e11c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f504c856-00d6-4567-86a8-45cd6d55b359" xlink:to="loc_srt_ConsolidationItemsDomain_c7ad58a2-efc7-456d-84fc-f004082e11c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_30209b76-a5ab-4196-b590-f94e3bbd82c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c7ad58a2-efc7-456d-84fc-f004082e11c4" xlink:to="loc_us-gaap_OperatingSegmentsMember_30209b76-a5ab-4196-b590-f94e3bbd82c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2" xlink:to="loc_us-gaap_SegmentDomain_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_affef2e8-6546-4bf5-8299-c4d0b6e0d6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2" xlink:to="loc_us-gaap_SegmentDomain_affef2e8-6546-4bf5-8299-c4d0b6e0d6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_db273938-2448-46a9-9a16-d4062c326d50" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_affef2e8-6546-4bf5-8299-c4d0b6e0d6ca" xlink:to="loc_mrk_PharmaceuticalsegmentMember_db273938-2448-46a9-9a16-d4062c326d50" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended" id="i1aa53ec9cc554f9c9a5ff1c48d8374b4_CollaborativeArrangementsFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_d5083c5e-dcea-4de7-9e02-f278a4ec2a84" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_d5083c5e-dcea-4de7-9e02-f278a4ec2a84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_ebf81b09-192c-44c4-ae5f-ab288c8eac79" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_ebf81b09-192c-44c4-ae5f-ab288c8eac79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_66061c1a-1a25-4539-9a4e-10d94f30d286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_Revenues_66061c1a-1a25-4539-9a4e-10d94f30d286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f1ed26d5-dc81-402d-9dfc-125583ef13ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f1ed26d5-dc81-402d-9dfc-125583ef13ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9324fde-4e0f-4527-a890-e99eef9c0059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9324fde-4e0f-4527-a890-e99eef9c0059" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_65724553-4e34-4576-bfa5-cfa095bb4c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_65724553-4e34-4576-bfa5-cfa095bb4c20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_bbd2edc9-6432-4f0a-a3c3-31e809f295e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_ReceivablesNetCurrent_bbd2edc9-6432-4f0a-a3c3-31e809f295e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_21bf5a41-325d-4fd2-bf07-ad5c4b1f874f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_21bf5a41-325d-4fd2-bf07-ad5c4b1f874f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fa71de90-e756-44d5-b37f-06b48c496355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_fa71de90-e756-44d5-b37f-06b48c496355" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_7097908c-f266-4724-9746-7f7fe58428fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_AdjustmentForAmortization_7097908c-f266-4724-9746-7f7fe58428fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f310f710-4c58-4a7d-a684-429d32b9666b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f310f710-4c58-4a7d-a684-429d32b9666b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a1ebcdbf-12a0-44ac-a11a-a86f1a060975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a1ebcdbf-12a0-44ac-a11a-a86f1a060975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a1ebcdbf-12a0-44ac-a11a-a86f1a060975_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a1ebcdbf-12a0-44ac-a11a-a86f1a060975" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a1ebcdbf-12a0-44ac-a11a-a86f1a060975_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a1ebcdbf-12a0-44ac-a11a-a86f1a060975" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_59abb019-4c3d-474e-8acb-4a975614d46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_SalesMember_59abb019-4c3d-474e-8acb-4a975614d46c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bd78464f-7d8c-472f-9e94-526baad42d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_CostOfSalesMember_bd78464f-7d8c-472f-9e94-526baad42d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_183cd1cd-0ac1-49f0-a677-8e4e8a8b3e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_183cd1cd-0ac1-49f0-a677-8e4e8a8b3e7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b80109da-ce63-43a7-9609-6e4fcd414895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b80109da-ce63-43a7-9609-6e4fcd414895" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_728c675f-d4f8-48e7-a7d4-dec703817258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_728c675f-d4f8-48e7-a7d4-dec703817258" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_728c675f-d4f8-48e7-a7d4-dec703817258_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_728c675f-d4f8-48e7-a7d4-dec703817258" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_728c675f-d4f8-48e7-a7d4-dec703817258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_728c675f-d4f8-48e7-a7d4-dec703817258" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_166e48f8-841d-4f00-9821-b250df813f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_166e48f8-841d-4f00-9821-b250df813f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3790c2a4-b20d-48d7-84ef-c387e660a501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3790c2a4-b20d-48d7-84ef-c387e660a501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4e358e7-0ade-43ad-bf36-7df53c37efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4e358e7-0ade-43ad-bf36-7df53c37efe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_57126c53-ac80-4a7d-8f3f-2ea0339bd254" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_srt_CounterpartyNameAxis_57126c53-ac80-4a7d-8f3f-2ea0339bd254" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57126c53-ac80-4a7d-8f3f-2ea0339bd254_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_57126c53-ac80-4a7d-8f3f-2ea0339bd254" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57126c53-ac80-4a7d-8f3f-2ea0339bd254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_57126c53-ac80-4a7d-8f3f-2ea0339bd254" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_29122307-9905-4d8e-87f3-619419384954" xlink:href="mrk-20221231.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_AstraZenecaMember_29122307-9905-4d8e-87f3-619419384954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_014ebeb6-7f86-413b-8865-306d81c6df24" xlink:href="mrk-20221231.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_EisaiMember_014ebeb6-7f86-413b-8865-306d81c6df24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_36b7a3da-d75d-46af-8044-170090086882" xlink:href="mrk-20221231.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_BayerAGMember_36b7a3da-d75d-46af-8044-170090086882" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_f534fd7f-37fc-4a06-8a89-d0f279fa82fb" xlink:href="mrk-20221231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_f534fd7f-37fc-4a06-8a89-d0f279fa82fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894811a5-dd22-46a7-b956-b8c506bb354c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894811a5-dd22-46a7-b956-b8c506bb354c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_323b10c0-1864-45b7-8f4b-97b9697bad7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894811a5-dd22-46a7-b956-b8c506bb354c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_323b10c0-1864-45b7-8f4b-97b9697bad7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_883bb316-2961-4cea-9e65-1296e5ace9a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_srt_ProductOrServiceAxis_883bb316-2961-4cea-9e65-1296e5ace9a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_883bb316-2961-4cea-9e65-1296e5ace9a3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_883bb316-2961-4cea-9e65-1296e5ace9a3" xlink:to="loc_srt_ProductsAndServicesDomain_883bb316-2961-4cea-9e65-1296e5ace9a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_883bb316-2961-4cea-9e65-1296e5ace9a3" xlink:to="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_c58cb237-3c73-45d1-b962-20eae1426afe" xlink:href="mrk-20221231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_c58cb237-3c73-45d1-b962-20eae1426afe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_f6b44ae4-81e1-400c-a3b9-b2c03422afb5" xlink:href="mrk-20221231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_f6b44ae4-81e1-400c-a3b9-b2c03422afb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_8ad455f1-161c-4ad9-9343-b28ee8473537" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_AdempasMember_8ad455f1-161c-4ad9-9343-b28ee8473537" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_09bc330b-9f98-46e3-8d97-b5338933db99" xlink:href="mrk-20221231.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_VerquvoMember_09bc330b-9f98-46e3-8d97-b5338933db99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_0893978c-3992-41f4-b993-79dfe80f3f92" xlink:href="mrk-20221231.xsd#mrk_LagevrioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_LagevrioMember_0893978c-3992-41f4-b993-79dfe80f3f92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_0d1d9414-b4c9-47d6-a31d-a3b1ea05e109" xlink:href="mrk-20221231.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_LynparzaMember_0d1d9414-b4c9-47d6-a31d-a3b1ea05e109" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i0645242754de4af3877ab2f307fcafa2_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_594435b0-7e97-4464-981d-086dac73d4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_594435b0-7e97-4464-981d-086dac73d4dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_0f9144fd-e65f-4243-bf6a-f4a38bbc16cb" xlink:href="mrk-20221231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_0f9144fd-e65f-4243-bf6a-f4a38bbc16cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_3fa5f01a-8d3e-4606-a8fa-8a9c9c872078" xlink:href="mrk-20221231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_3fa5f01a-8d3e-4606-a8fa-8a9c9c872078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_b20ae504-02d4-4d7b-ae81-f162725ef85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_b20ae504-02d4-4d7b-ae81-f162725ef85e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_95e6d31a-c479-43aa-a921-339f0aa73908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_95e6d31a-c479-43aa-a921-339f0aa73908" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_203b3836-2086-42e2-9a96-e796c3cc0f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_203b3836-2086-42e2-9a96-e796c3cc0f35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1735fee2-d15a-40c4-8499-06e3945537dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_203b3836-2086-42e2-9a96-e796c3cc0f35" xlink:to="loc_srt_StatementScenarioAxis_1735fee2-d15a-40c4-8499-06e3945537dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1735fee2-d15a-40c4-8499-06e3945537dc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1735fee2-d15a-40c4-8499-06e3945537dc" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1735fee2-d15a-40c4-8499-06e3945537dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_20a6a28c-29c0-45a1-8078-1cb55d10cc45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1735fee2-d15a-40c4-8499-06e3945537dc" xlink:to="loc_srt_ScenarioUnspecifiedDomain_20a6a28c-29c0-45a1-8078-1cb55d10cc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6b05eb53-d06d-4ad0-9fa5-935a9acd5669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_20a6a28c-29c0-45a1-8078-1cb55d10cc45" xlink:to="loc_srt_ScenarioForecastMember_6b05eb53-d06d-4ad0-9fa5-935a9acd5669" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended" id="ib730beee3d2643e3aa1f437e8ce4f397_RestructuringChargesActivitiesbyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3d6fe308-0f44-4ae7-ab73-b03275b03f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3d6fe308-0f44-4ae7-ab73-b03275b03f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_24ffa9da-3813-43d5-985d-138ed02ccc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_24ffa9da-3813-43d5-985d-138ed02ccc19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d8af96c1-3e91-459d-9f6d-37952c9cd061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d8af96c1-3e91-459d-9f6d-37952c9cd061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d8af96c1-3e91-459d-9f6d-37952c9cd061_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d8af96c1-3e91-459d-9f6d-37952c9cd061" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d8af96c1-3e91-459d-9f6d-37952c9cd061_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d8af96c1-3e91-459d-9f6d-37952c9cd061" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_dd1393ff-0c9c-42c1-b889-d7eecf5b2945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_dd1393ff-0c9c-42c1-b889-d7eecf5b2945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_3e22420d-b9c7-4931-8418-cc714d1d2b97" xlink:href="mrk-20221231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:to="loc_mrk_AcceleratedDepreciationMember_3e22420d-b9c7-4931-8418-cc714d1d2b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_0428e092-5b98-46bd-837f-b083b0806b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:to="loc_us-gaap_OtherRestructuringMember_0428e092-5b98-46bd-837f-b083b0806b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1f720cc4-c1e0-4a6e-ac12-ce530a32989a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1f720cc4-c1e0-4a6e-ac12-ce530a32989a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1f720cc4-c1e0-4a6e-ac12-ce530a32989a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1f720cc4-c1e0-4a6e-ac12-ce530a32989a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1f720cc4-c1e0-4a6e-ac12-ce530a32989a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1f720cc4-c1e0-4a6e-ac12-ce530a32989a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_69df47f0-22df-40c8-b2a2-0ed921003eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_CostOfSalesMember_69df47f0-22df-40c8-b2a2-0ed921003eb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d6f35451-72df-4e12-98dc-a3fe2668508e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d6f35451-72df-4e12-98dc-a3fe2668508e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f349f4cc-7acf-4df9-acc7-6ee81e6754ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f349f4cc-7acf-4df9-acc7-6ee81e6754ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8c0e1277-ebda-48fe-bf0c-8d27db30e2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_RestructuringChargesMember_8c0e1277-ebda-48fe-bf0c-8d27db30e2e0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended" id="ice357c60721c4f11961daaa42996f0db_RestructuringActivitiesbyProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ffbe1a70-ede3-4fe8-811c-0acc950e2189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ffbe1a70-ede3-4fe8-811c-0acc950e2189" xlink:to="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f604b194-05c2-4da8-a818-c1d1eb6bc95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_us-gaap_RestructuringReserve_f604b194-05c2-4da8-a818-c1d1eb6bc95a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c9f7db7d-9841-4af0-a537-3fca0c424a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c9f7db7d-9841-4af0-a537-3fca0c424a0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_3e2bf075-0d96-4db6-9081-e7300aeaafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_us-gaap_PaymentsForRestructuring_3e2bf075-0d96-4db6-9081-e7300aeaafa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_b18d90b6-0f64-4c9d-8156-28523502ccc2" xlink:href="mrk-20221231.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_b18d90b6-0f64-4c9d-8156-28523502ccc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_338ad846-58f4-478f-a34f-2b5592b7f949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af2a3f45-d668-4e4c-8901-61d15e0dd9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ffbe1a70-ede3-4fe8-811c-0acc950e2189" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af2a3f45-d668-4e4c-8901-61d15e0dd9f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_427fef8b-0bfe-457c-9601-71e390536ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af2a3f45-d668-4e4c-8901-61d15e0dd9f8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_427fef8b-0bfe-457c-9601-71e390536ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_427fef8b-0bfe-457c-9601-71e390536ad8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_427fef8b-0bfe-457c-9601-71e390536ad8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_427fef8b-0bfe-457c-9601-71e390536ad8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_427fef8b-0bfe-457c-9601-71e390536ad8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_f2756fbf-8f63-42e1-9d47-661a44780cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_f2756fbf-8f63-42e1-9d47-661a44780cdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_d811dc4e-4308-4947-8b03-2ef317fe6d63" xlink:href="mrk-20221231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:to="loc_mrk_AcceleratedDepreciationMember_d811dc4e-4308-4947-8b03-2ef317fe6d63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_a23c3c67-20dd-4e8a-b0a7-17df27defb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:to="loc_us-gaap_OtherRestructuringMember_a23c3c67-20dd-4e8a-b0a7-17df27defb2d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i661374e5fdeb43d5bfa26edf88d47590_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_b560f081-5cf3-458e-8dbf-6567b0cad0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_b560f081-5cf3-458e-8dbf-6567b0cad0ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NumberOfInterestRateDerivativesMatured_070395cd-83e9-4e51-ad33-1c3580ef791a" xlink:href="mrk-20221231.xsd#mrk_NumberOfInterestRateDerivativesMatured"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_mrk_NumberOfInterestRateDerivativesMatured_070395cd-83e9-4e51-ad33-1c3580ef791a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DerivativeNotionalAmountMatured_b40757fa-bbc4-459d-9d98-6e2fbd200b36" xlink:href="mrk-20221231.xsd#mrk_DerivativeNotionalAmountMatured"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_mrk_DerivativeNotionalAmountMatured_b40757fa-bbc4-459d-9d98-6e2fbd200b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32fa072d-3d22-47a5-b242-47ce65a538f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32fa072d-3d22-47a5-b242-47ce65a538f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7dcab50-ad9c-4525-acd0-9b19cbb5ba85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7dcab50-ad9c-4525-acd0-9b19cbb5ba85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_68017f3f-b3e9-4afa-9f50-3cbf297d5b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_68017f3f-b3e9-4afa-9f50-3cbf297d5b1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_48da61cc-c298-480b-841b-ed6c059b8f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_48da61cc-c298-480b-841b-ed6c059b8f25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_a474d040-f145-41b4-a7dd-685e3ecd1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_a474d040-f145-41b4-a7dd-685e3ecd1ac5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_684d336d-5674-4944-8612-68304062e199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_684d336d-5674-4944-8612-68304062e199" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_39b4395b-e013-4747-b208-6b5d790983b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_39b4395b-e013-4747-b208-6b5d790983b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_4ea5a672-46a9-4069-a45c-f2970ff5095c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_4ea5a672-46a9-4069-a45c-f2970ff5095c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_1dae41f7-4b37-4bdd-9f5a-9a58146cd843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_1dae41f7-4b37-4bdd-9f5a-9a58146cd843" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7b7b891b-7a78-483e-a699-e0c3fefd876c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7b7b891b-7a78-483e-a699-e0c3fefd876c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ed3d01f6-6fd7-4ca9-b57d-fd7b7f5dd351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ed3d01f6-6fd7-4ca9-b57d-fd7b7f5dd351" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6b557c2c-27fd-4d69-8706-5d595f41ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6b557c2c-27fd-4d69-8706-5d595f41ebc3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_02e3a5ac-988c-4f99-8a7d-5776e1ecec82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_02e3a5ac-988c-4f99-8a7d-5776e1ecec82" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_93605c95-3b6f-42ae-a1ee-f907d3ece58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_93605c95-3b6f-42ae-a1ee-f907d3ece58c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_436ac1ce-8ba4-4920-b098-bc90708f55a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_AccountsReceivableSale_436ac1ce-8ba4-4920-b098-bc90708f55a5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7ba7d6e3-2322-46b9-b845-a74523704ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_RestrictedCashCurrent_7ba7d6e3-2322-46b9-b845-a74523704ff9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_b9567e49-62ae-4935-b66c-7ba30338e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_b9567e49-62ae-4935-b66c-7ba30338e0d8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_ffec6652-8944-4c49-afa8-1854cab28209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_ffec6652-8944-4c49-afa8-1854cab28209" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea352d83-ee00-4608-befe-cf2cd57de73c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_srt_RangeAxis_ea352d83-ee00-4608-befe-cf2cd57de73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea352d83-ee00-4608-befe-cf2cd57de73c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ea352d83-ee00-4608-befe-cf2cd57de73c" xlink:to="loc_srt_RangeMember_ea352d83-ee00-4608-befe-cf2cd57de73c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ab70236-f8a5-464b-ace6-c5fe23d35e29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ea352d83-ee00-4608-befe-cf2cd57de73c" xlink:to="loc_srt_RangeMember_0ab70236-f8a5-464b-ace6-c5fe23d35e29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d7f46f57-4f62-4104-b430-1c70dab61697" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0ab70236-f8a5-464b-ace6-c5fe23d35e29" xlink:to="loc_srt_MaximumMember_d7f46f57-4f62-4104-b430-1c70dab61697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_eaac4b8e-f644-44ba-b925-27afdd69d2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_HedgingDesignationAxis_eaac4b8e-f644-44ba-b925-27afdd69d2df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_eaac4b8e-f644-44ba-b925-27afdd69d2df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_eaac4b8e-f644-44ba-b925-27afdd69d2df" xlink:to="loc_us-gaap_HedgingDesignationDomain_eaac4b8e-f644-44ba-b925-27afdd69d2df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_eaac4b8e-f644-44ba-b925-27afdd69d2df" xlink:to="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6bb4627b-9ef3-4838-98b5-da82e6c52371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6bb4627b-9ef3-4838-98b5-da82e6c52371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_23b4d110-0ae0-483a-b86e-da5b1ee22ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:to="loc_us-gaap_NondesignatedMember_23b4d110-0ae0-483a-b86e-da5b1ee22ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bca3ad75-1cb2-4baf-9392-888b1e123a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bca3ad75-1cb2-4baf-9392-888b1e123a73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bca3ad75-1cb2-4baf-9392-888b1e123a73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bca3ad75-1cb2-4baf-9392-888b1e123a73" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bca3ad75-1cb2-4baf-9392-888b1e123a73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f9a1d186-bba8-4a1a-bb95-e8eb8f99382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bca3ad75-1cb2-4baf-9392-888b1e123a73" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f9a1d186-bba8-4a1a-bb95-e8eb8f99382b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_c1a94f69-5621-4db9-ba81-9683c3b5426c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f9a1d186-bba8-4a1a-bb95-e8eb8f99382b" xlink:to="loc_us-gaap_InterestRateSwapMember_c1a94f69-5621-4db9-ba81-9683c3b5426c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2863e64-7bc9-4b05-9980-b04af6ddd673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2863e64-7bc9-4b05-9980-b04af6ddd673" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2863e64-7bc9-4b05-9980-b04af6ddd673_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2863e64-7bc9-4b05-9980-b04af6ddd673" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2863e64-7bc9-4b05-9980-b04af6ddd673_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5647d549-d92c-4cc3-856c-29b0cb37c867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2863e64-7bc9-4b05-9980-b04af6ddd673" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5647d549-d92c-4cc3-856c-29b0cb37c867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5dfd5e5-703a-46be-8df1-5c6b38558565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5647d549-d92c-4cc3-856c-29b0cb37c867" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5dfd5e5-703a-46be-8df1-5c6b38558565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0f18425b-f173-454d-8a2d-194b82a36a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0f18425b-f173-454d-8a2d-194b82a36a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1682af44-0626-4e0d-8ca4-29d2496ddb45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0f18425b-f173-454d-8a2d-194b82a36a6d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1682af44-0626-4e0d-8ca4-29d2496ddb45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a14c8238-f2fc-4cf5-8da7-f98cbc15f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a14c8238-f2fc-4cf5-8da7-f98cbc15f690" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a14c8238-f2fc-4cf5-8da7-f98cbc15f690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a14c8238-f2fc-4cf5-8da7-f98cbc15f690" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a14c8238-f2fc-4cf5-8da7-f98cbc15f690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_57037ab8-15b6-4d04-9ae1-001a7db78208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a14c8238-f2fc-4cf5-8da7-f98cbc15f690" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_57037ab8-15b6-4d04-9ae1-001a7db78208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_de6ae47f-3803-410a-a59b-12233a8b20aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_57037ab8-15b6-4d04-9ae1-001a7db78208" xlink:to="loc_us-gaap_AccountsReceivableMember_de6ae47f-3803-410a-a59b-12233a8b20aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f14b8d73-8156-4d36-a527-4642efc594e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_srt_MajorCustomersAxis_f14b8d73-8156-4d36-a527-4642efc594e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f14b8d73-8156-4d36-a527-4642efc594e6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f14b8d73-8156-4d36-a527-4642efc594e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_f14b8d73-8156-4d36-a527-4642efc594e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f14b8d73-8156-4d36-a527-4642efc594e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationMember_5fb373da-111c-459d-b811-2b6b49ab29c2" xlink:href="mrk-20221231.xsd#mrk_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:to="loc_mrk_McKessonCorporationMember_5fb373da-111c-459d-b811-2b6b49ab29c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmerisourceBergenCorporationMember_b575c5bc-5fa0-426c-abaf-45bd8721ee0b" xlink:href="mrk-20221231.xsd#mrk_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:to="loc_mrk_AmerisourceBergenCorporationMember_b575c5bc-5fa0-426c-abaf-45bd8721ee0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CardinalHealthIncMember_6b45b571-173c-4fed-8641-357b65cac994" xlink:href="mrk-20221231.xsd#mrk_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:to="loc_mrk_CardinalHealthIncMember_6b45b571-173c-4fed-8641-357b65cac994" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb6f5c9c-f50e-4612-b221-153552751d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb6f5c9c-f50e-4612-b221-153552751d70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fb6f5c9c-f50e-4612-b221-153552751d70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb6f5c9c-f50e-4612-b221-153552751d70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fb6f5c9c-f50e-4612-b221-153552751d70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7995229-3026-442a-b402-0624e520cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb6f5c9c-f50e-4612-b221-153552751d70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7995229-3026-442a-b402-0624e520cb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_2867cd50-484f-42ed-b07b-f2fd70fecf98" xlink:href="mrk-20221231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b7995229-3026-442a-b402-0624e520cb39" xlink:to="loc_mrk_A2.35NotesDue2022Member_2867cd50-484f-42ed-b07b-f2fd70fecf98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36a19bd3-ce55-4770-9fe8-498dd8c9506e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_DebtInstrumentAxis_36a19bd3-ce55-4770-9fe8-498dd8c9506e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_36a19bd3-ce55-4770-9fe8-498dd8c9506e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_36a19bd3-ce55-4770-9fe8-498dd8c9506e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_36a19bd3-ce55-4770-9fe8-498dd8c9506e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_36a19bd3-ce55-4770-9fe8-498dd8c9506e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_fc624c72-3941-421c-a4e7-938d282823ba" xlink:href="mrk-20221231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:to="loc_mrk_A2.40NotesDue2022Member_fc624c72-3941-421c-a4e7-938d282823ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_3b33e0a5-1790-4e02-a522-2ae99108a1de" xlink:href="mrk-20221231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:to="loc_mrk_A2.35NotesDue2022Member_3b33e0a5-1790-4e02-a522-2ae99108a1de" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="ie6c8b391c4c947429b51678b33447c4f_FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_be25c786-78b4-4779-99bb-c4109f8e5a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_be25c786-78b4-4779-99bb-c4109f8e5a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_d8b30a1d-42b3-4616-be46-6649a9b04e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_d8b30a1d-42b3-4616-be46-6649a9b04e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_beec25a5-874d-4456-9e88-f414d86ef946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_beec25a5-874d-4456-9e88-f414d86ef946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_beec25a5-874d-4456-9e88-f414d86ef946_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_beec25a5-874d-4456-9e88-f414d86ef946" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_beec25a5-874d-4456-9e88-f414d86ef946_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_beec25a5-874d-4456-9e88-f414d86ef946" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_bd61fb7d-a9d1-4e9b-96b9-60298950e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_bd61fb7d-a9d1-4e9b-96b9-60298950e54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_bd2a7db9-5bd9-4a50-8cd9-047acbac1b17" xlink:href="mrk-20221231.xsd#mrk_EurodominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:to="loc_mrk_EurodominatedNotesMember_bd2a7db9-5bd9-4a50-8cd9-047acbac1b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c4670a7-9f1d-4577-abf2-726a0d791c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c4670a7-9f1d-4577-abf2-726a0d791c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8fd94bbd-1f91-4025-a4aa-59a61f4a9415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c4670a7-9f1d-4577-abf2-726a0d791c1e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8fd94bbd-1f91-4025-a4aa-59a61f4a9415" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsFairValueofHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="extended" id="i9a8dd80e5e8b4d26aa44d586cb35a542_FinancialInstrumentsFairValueofHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_158f02b3-5e56-4513-8e61-82d0f7441ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_158f02b3-5e56-4513-8e61-82d0f7441ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0f0a203a-4dbe-4458-9603-4bf1e43f9e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0f0a203a-4dbe-4458-9603-4bf1e43f9e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_6ae2383b-6833-4bc8-85d2-14f802e8c41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:to="loc_us-gaap_DerivativeTable_6ae2383b-6833-4bc8-85d2-14f802e8c41e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3dd3514c-e434-402a-a14e-b5a19010bc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_6ae2383b-6833-4bc8-85d2-14f802e8c41e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3dd3514c-e434-402a-a14e-b5a19010bc15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3dd3514c-e434-402a-a14e-b5a19010bc15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3dd3514c-e434-402a-a14e-b5a19010bc15" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3dd3514c-e434-402a-a14e-b5a19010bc15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_44dcec15-5a13-4669-98a2-6e2754c0eebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3dd3514c-e434-402a-a14e-b5a19010bc15" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_44dcec15-5a13-4669-98a2-6e2754c0eebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_7f64ed81-8cdb-4d46-bf0a-6f3c8effc177" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44dcec15-5a13-4669-98a2-6e2754c0eebd" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_7f64ed81-8cdb-4d46-bf0a-6f3c8effc177" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="ibfa79966e04b49aeae0c3c63bcc50afb_FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_bc710dd9-5552-471d-8709-3ef1b7c1d5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeAssets_bc710dd9-5552-471d-8709-3ef1b7c1d5ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_c4394cff-46d1-4559-9844-d9ef99265d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_c4394cff-46d1-4559-9844-d9ef99265d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_60699bea-48b8-42b4-9573-789efec0aa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeLiabilities_60699bea-48b8-42b4-9573-789efec0aa9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_779df192-2da4-49cd-a1a6-c14f4f39b190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_779df192-2da4-49cd-a1a6-c14f4f39b190" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_10b18aa4-cb25-4f59-ad06-871fcb852774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_10b18aa4-cb25-4f59-ad06-871fcb852774" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8c47e60c-472e-4213-9ee9-169dcbee3ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8c47e60c-472e-4213-9ee9-169dcbee3ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8c47e60c-472e-4213-9ee9-169dcbee3ea1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c47e60c-472e-4213-9ee9-169dcbee3ea1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8c47e60c-472e-4213-9ee9-169dcbee3ea1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c47e60c-472e-4213-9ee9-169dcbee3ea1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_29286bf6-2ebc-482a-a163-ccfa81880e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:to="loc_us-gaap_InterestRateContractMember_29286bf6-2ebc-482a-a163-ccfa81880e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e716d927-81ed-4ebc-8064-d2ec4e0b8354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e716d927-81ed-4ebc-8064-d2ec4e0b8354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_cbc4fa42-6b9e-45b8-9b55-427a3885d544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:to="loc_us-gaap_HedgingDesignationAxis_cbc4fa42-6b9e-45b8-9b55-427a3885d544" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cbc4fa42-6b9e-45b8-9b55-427a3885d544_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_cbc4fa42-6b9e-45b8-9b55-427a3885d544" xlink:to="loc_us-gaap_HedgingDesignationDomain_cbc4fa42-6b9e-45b8-9b55-427a3885d544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_cbc4fa42-6b9e-45b8-9b55-427a3885d544" xlink:to="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9960347b-aa1b-4b28-b4b0-666d0e630f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9960347b-aa1b-4b28-b4b0-666d0e630f43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9e173e63-5d46-436f-a17c-64a2a528d25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:to="loc_us-gaap_NondesignatedMember_9e173e63-5d46-436f-a17c-64a2a528d25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4e8da032-7a59-4958-b3f6-50b04c90329d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4e8da032-7a59-4958-b3f6-50b04c90329d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4e8da032-7a59-4958-b3f6-50b04c90329d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4e8da032-7a59-4958-b3f6-50b04c90329d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4e8da032-7a59-4958-b3f6-50b04c90329d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4e8da032-7a59-4958-b3f6-50b04c90329d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_ea030813-8ea5-44cc-ace9-2289ddbb9d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_ea030813-8ea5-44cc-ace9-2289ddbb9d1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_8fc346e1-ed6c-4ed1-87fb-8152eeb65379" xlink:href="mrk-20221231.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_8fc346e1-ed6c-4ed1-87fb-8152eeb65379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_bc495503-82ec-4372-ac77-8421e3093feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_bc495503-82ec-4372-ac77-8421e3093feb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75e2ff30-62c7-4859-aa83-37f91c2f0411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75e2ff30-62c7-4859-aa83-37f91c2f0411" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="extended" id="ic6d52ac5c0a94311abb91eb2e1233af5_FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f836c0d0-6216-49fb-ad24-c8e8af12eb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_Revenues_f836c0d0-6216-49fb-ad24-c8e8af12eb59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_78846c8c-376d-4da7-96c6-76f087c884f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_78846c8c-376d-4da7-96c6-76f087c884f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bc7c5155-d324-46f6-816e-d6afc0455ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bc7c5155-d324-46f6-816e-d6afc0455ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_df3b7fef-aa15-4c4e-85ca-38295cc5cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_df3b7fef-aa15-4c4e-85ca-38295cc5cd77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_185b718c-3911-48f9-8dcc-b7db770ebbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_185b718c-3911-48f9-8dcc-b7db770ebbb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_9579eb0c-73c8-4417-83d5-59812bb15a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_9579eb0c-73c8-4417-83d5-59812bb15a3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8a8be9a6-4c6c-4d08-aa53-c915b9987e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8a8be9a6-4c6c-4d08-aa53-c915b9987e29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2a835fd7-8e52-4e99-a88b-aed8d6491b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2a835fd7-8e52-4e99-a88b-aed8d6491b4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_20b67028-300c-4036-b867-0ab84b39350a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_20b67028-300c-4036-b867-0ab84b39350a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1f58b34-3fb3-4f1c-a387-13c66eceae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1f58b34-3fb3-4f1c-a387-13c66eceae20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_e1f58b34-3fb3-4f1c-a387-13c66eceae20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1f58b34-3fb3-4f1c-a387-13c66eceae20" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_e1f58b34-3fb3-4f1c-a387-13c66eceae20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eaf7a790-4a25-4317-a9a2-0ccf691fc73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1f58b34-3fb3-4f1c-a387-13c66eceae20" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eaf7a790-4a25-4317-a9a2-0ccf691fc73e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5ad5be1a-f995-4626-9ebf-740389f755d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eaf7a790-4a25-4317-a9a2-0ccf691fc73e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5ad5be1a-f995-4626-9ebf-740389f755d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8d2afc6-3074-4f6e-beab-e32e8909c1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8d2afc6-3074-4f6e-beab-e32e8909c1d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8d2afc6-3074-4f6e-beab-e32e8909c1d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8d2afc6-3074-4f6e-beab-e32e8909c1d9" xlink:to="loc_us-gaap_EquityComponentDomain_d8d2afc6-3074-4f6e-beab-e32e8909c1d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51a3b89e-85ec-4f2d-9430-daebf14c963d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8d2afc6-3074-4f6e-beab-e32e8909c1d9" xlink:to="loc_us-gaap_EquityComponentDomain_51a3b89e-85ec-4f2d-9430-daebf14c963d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_0b22af47-a285-47a3-841b-3458dcd2ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_51a3b89e-85ec-4f2d-9430-daebf14c963d" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_0b22af47-a285-47a3-841b-3458dcd2ca9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f19a3652-7344-4efe-8abe-92cfd41b71f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f19a3652-7344-4efe-8abe-92cfd41b71f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_f3f551c8-d02b-4a25-9816-d78c3030ab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f19a3652-7344-4efe-8abe-92cfd41b71f9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_f3f551c8-d02b-4a25-9816-d78c3030ab17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6b34e4fd-0276-4601-a4f3-dded10a5f2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6b34e4fd-0276-4601-a4f3-dded10a5f2cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6b34e4fd-0276-4601-a4f3-dded10a5f2cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6b34e4fd-0276-4601-a4f3-dded10a5f2cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6b34e4fd-0276-4601-a4f3-dded10a5f2cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6b34e4fd-0276-4601-a4f3-dded10a5f2cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fbd59672-0775-4dae-89ca-7e99981b0040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:to="loc_us-gaap_InterestRateSwapMember_fbd59672-0775-4dae-89ca-7e99981b0040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b27572aa-6e38-46f5-a915-c03929c00b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b27572aa-6e38-46f5-a915-c03929c00b2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="ie6efe285a9a84a3d98c31b13fe362233_FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c8114581-ba57-4505-9d46-82f2442af1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_51b5b1e9-aa7f-44a8-aa45-9742d2041b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c8114581-ba57-4505-9d46-82f2442af1bf" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_51b5b1e9-aa7f-44a8-aa45-9742d2041b39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_c8114581-ba57-4505-9d46-82f2442af1bf" xlink:to="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_69c1d213-f5f5-4c1e-9d10-2bce43958605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_69c1d213-f5f5-4c1e-9d10-2bce43958605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_69c1d213-f5f5-4c1e-9d10-2bce43958605_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_69c1d213-f5f5-4c1e-9d10-2bce43958605" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_69c1d213-f5f5-4c1e-9d10-2bce43958605_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_69c1d213-f5f5-4c1e-9d10-2bce43958605" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_685047fa-e7d0-49c4-8386-e010ac1e4682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_685047fa-e7d0-49c4-8386-e010ac1e4682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_5bca7773-efcd-4f50-967b-4d1f514d51f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:to="loc_us-gaap_InterestRateContractMember_5bca7773-efcd-4f50-967b-4d1f514d51f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_931d9c06-dc15-42ae-854d-5fdc172be79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:to="loc_us-gaap_ForwardContractsMember_931d9c06-dc15-42ae-854d-5fdc172be79b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b020aed-6605-47c8-8c92-a327d1e1aafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b020aed-6605-47c8-8c92-a327d1e1aafc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b020aed-6605-47c8-8c92-a327d1e1aafc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b020aed-6605-47c8-8c92-a327d1e1aafc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b020aed-6605-47c8-8c92-a327d1e1aafc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b020aed-6605-47c8-8c92-a327d1e1aafc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_edca251d-3376-4d07-a932-57ded444928b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_edca251d-3376-4d07-a932-57ded444928b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_7c2b88c6-de6d-4d2d-8b37-e1fe23d37e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:to="loc_us-gaap_SalesMember_7c2b88c6-de6d-4d2d-8b37-e1fe23d37e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632c217e-86a4-4b79-9ebf-9b1840ae2b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632c217e-86a4-4b79-9ebf-9b1840ae2b4b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended" id="ia719fe5a865d4c4b9d4286cc15659ef6_FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dd3657bb-cc27-42fc-ab1d-9b51de88cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dd3657bb-cc27-42fc-ab1d-9b51de88cbb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c14c2000-c278-465c-8a31-772b1d8e0aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c14c2000-c278-465c-8a31-772b1d8e0aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cdecffdb-7ebb-4a30-9b59-97b09214a63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cdecffdb-7ebb-4a30-9b59-97b09214a63e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16a9e893-dcbd-4da1-804b-536e1a350325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16a9e893-dcbd-4da1-804b-536e1a350325" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cf8a8d23-810b-4196-b1af-659cd62d7c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cf8a8d23-810b-4196-b1af-659cd62d7c4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_2a74b300-1ea9-4b97-a76d-f5e6bd79ca9d" xlink:href="mrk-20221231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_2a74b300-1ea9-4b97-a76d-f5e6bd79ca9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d2a95d72-143a-4dc3-a00a-be0d42518f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d2a95d72-143a-4dc3-a00a-be0d42518f61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d086356-8636-4b2c-aff6-5972e9186bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d2a95d72-143a-4dc3-a00a-be0d42518f61" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d086356-8636-4b2c-aff6-5972e9186bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d086356-8636-4b2c-aff6-5972e9186bc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d086356-8636-4b2c-aff6-5972e9186bc2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d086356-8636-4b2c-aff6-5972e9186bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d086356-8636-4b2c-aff6-5972e9186bc2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7d7303ac-4070-49ea-9b02-87193eb9a927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_CommercialPaperMember_7d7303ac-4070-49ea-9b02-87193eb9a927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c7dc25-46fe-4b64-8657-c4ec6715fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c7dc25-46fe-4b64-8657-c4ec6715fb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4273976e-5c29-4af1-b76d-d1ef49e4b170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4273976e-5c29-4af1-b76d-d1ef49e4b170" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d0d18a9c-3298-4bd7-b1cc-161bad0560a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d0d18a9c-3298-4bd7-b1cc-161bad0560a5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="iac25277c65d84c508368dd938df637f3_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33d69161-a13e-41c2-8dbb-40e8279be846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33d69161-a13e-41c2-8dbb-40e8279be846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_073ccfe6-f5ce-4bed-9a5a-78b789753801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_073ccfe6-f5ce-4bed-9a5a-78b789753801" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_5e189964-96e0-4f43-b361-f35a7e891d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_TradingSecurities_5e189964-96e0-4f43-b361-f35a7e891d1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_118aae56-8323-4cec-8694-e649cceafc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_118aae56-8323-4cec-8694-e649cceafc94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_29fe6147-5780-46e9-9ae4-8bda6f61ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_DerivativeAssets_29fe6147-5780-46e9-9ae4-8bda6f61ae93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2a2d36e5-0af9-4976-92e2-966387888c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2a2d36e5-0af9-4976-92e2-966387888c4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7115a0b5-a5c0-43f6-b6b3-1b66fcf01dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7115a0b5-a5c0-43f6-b6b3-1b66fcf01dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_dd3695fe-20c9-44f7-88bd-1e4ca6e4a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:to="loc_us-gaap_DerivativeLiabilities_dd3695fe-20c9-44f7-88bd-1e4ca6e4a362" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4c6a370f-0f3f-44f7-adfa-f516088671a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4c6a370f-0f3f-44f7-adfa-f516088671a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_56e2fd48-a04b-423a-a4ed-010e98af1a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_56e2fd48-a04b-423a-a4ed-010e98af1a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_56e2fd48-a04b-423a-a4ed-010e98af1a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_56e2fd48-a04b-423a-a4ed-010e98af1a33" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_56e2fd48-a04b-423a-a4ed-010e98af1a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d877face-3d98-45e9-9f78-b5d5fdd84951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_56e2fd48-a04b-423a-a4ed-010e98af1a33" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d877face-3d98-45e9-9f78-b5d5fdd84951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6a37ba7e-9abc-4740-877a-179c266a612e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d877face-3d98-45e9-9f78-b5d5fdd84951" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6a37ba7e-9abc-4740-877a-179c266a612e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4340cf9-cc88-4f4d-ae87-4d44767e371c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4340cf9-cc88-4f4d-ae87-4d44767e371c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d2b49857-3531-426f-ad6e-cba63e74ad30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d2b49857-3531-426f-ad6e-cba63e74ad30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2610e1e9-dc8f-43d7-9fe1-e3795ca3fd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2610e1e9-dc8f-43d7-9fe1-e3795ca3fd06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b17dda1b-2152-44b0-b125-2cae5f74e8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b17dda1b-2152-44b0-b125-2cae5f74e8c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b17dda1b-2152-44b0-b125-2cae5f74e8c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b17dda1b-2152-44b0-b125-2cae5f74e8c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b17dda1b-2152-44b0-b125-2cae5f74e8c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b17dda1b-2152-44b0-b125-2cae5f74e8c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_426d8072-3cd1-4674-9ef9-ad5a543f9bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_CommercialPaperMember_426d8072-3cd1-4674-9ef9-ad5a543f9bcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_fc34c916-667b-471a-b576-7e30b14bdb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_fc34c916-667b-471a-b576-7e30b14bdb0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_34d07d81-f31a-436b-b39a-e0b30a9b6153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_34d07d81-f31a-436b-b39a-e0b30a9b6153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_10e0e580-791a-4cdb-8e46-ee1cfb33c237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_10e0e580-791a-4cdb-8e46-ee1cfb33c237" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_17ddab6f-9694-4a28-b6f0-62ce761838ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_EquitySecuritiesMember_17ddab6f-9694-4a28-b6f0-62ce761838ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1be9a33a-9b03-444c-af80-f40e0cd2ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1be9a33a-9b03-444c-af80-f40e0cd2ac4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_bbb32e39-5ae5-4de2-8efd-c5e54d317b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_bbb32e39-5ae5-4de2-8efd-c5e54d317b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_40df16e0-7815-4904-b7ad-deb96c23aba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:to="loc_us-gaap_InterestRateContractMember_40df16e0-7815-4904-b7ad-deb96c23aba5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended" id="i3ade21dfa0eb4af290681f9bb1150553_FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_401be273-4db9-4af6-9f94-0ba2bafdb7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_401be273-4db9-4af6-9f94-0ba2bafdb7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f11c5cb-0eb7-431d-9082-f433bf313dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f11c5cb-0eb7-431d-9082-f433bf313dca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1a372100-01e5-46a0-995d-8bfdd51acd92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1a372100-01e5-46a0-995d-8bfdd51acd92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_8d600295-8bc3-4e24-bb51-447d1842c0bb" xlink:href="mrk-20221231.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_8d600295-8bc3-4e24-bb51-447d1842c0bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0c6d834b-c0df-4a8e-b15b-93971b42db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b7fb229e-4563-4e5d-b65e-8b1ff802fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b7fb229e-4563-4e5d-b65e-8b1ff802fd90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_21db98b6-05e5-42d7-9ab8-48426379bcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_21db98b6-05e5-42d7-9ab8-48426379bcc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5ccdcf81-a1e1-4614-9468-baf22956ab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5ccdcf81-a1e1-4614-9468-baf22956ab3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5ccdcf81-a1e1-4614-9468-baf22956ab3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5ccdcf81-a1e1-4614-9468-baf22956ab3a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5ccdcf81-a1e1-4614-9468-baf22956ab3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3d673208-e2ad-4016-b42c-84738823606a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5ccdcf81-a1e1-4614-9468-baf22956ab3a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3d673208-e2ad-4016-b42c-84738823606a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_73034132-6183-4f5f-b4a7-6fbd4c48fc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3d673208-e2ad-4016-b42c-84738823606a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_73034132-6183-4f5f-b4a7-6fbd4c48fc51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e87cdb0d-02e6-4587-8ca0-4a7b38908288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e87cdb0d-02e6-4587-8ca0-4a7b38908288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_e87cdb0d-02e6-4587-8ca0-4a7b38908288_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e87cdb0d-02e6-4587-8ca0-4a7b38908288" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_e87cdb0d-02e6-4587-8ca0-4a7b38908288_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_176a615d-15d8-4814-ae24-eab351286542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e87cdb0d-02e6-4587-8ca0-4a7b38908288" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_176a615d-15d8-4814-ae24-eab351286542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_58663ddb-2c68-4407-83e5-02f8c883b1f0" xlink:href="mrk-20221231.xsd#mrk_SanofiPasteurMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_176a615d-15d8-4814-ae24-eab351286542" xlink:to="loc_mrk_SanofiPasteurMember_58663ddb-2c68-4407-83e5-02f8c883b1f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i006308ff0fc94cd1a8a8ca7b4c53574f_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_de961a9a-9b40-418c-bb65-a60e5e9f3c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:to="loc_us-gaap_LIFOInventoryAmount_de961a9a-9b40-418c-bb65-a60e5e9f3c3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8ec7dca3-3017-4d7c-b4ec-d567ef30671b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:to="loc_us-gaap_InventoryNoncurrent_8ec7dca3-3017-4d7c-b4ec-d567ef30671b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_08ba5ce7-ad97-428b-947e-793c41cfcc63" xlink:href="mrk-20221231.xsd#mrk_InventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:to="loc_mrk_InventoryTable_08ba5ce7-ad97-428b-947e-793c41cfcc63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_a8c38dbf-c34a-49d7-91ee-e06816c3d680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_InventoryTable_08ba5ce7-ad97-428b-947e-793c41cfcc63" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_a8c38dbf-c34a-49d7-91ee-e06816c3d680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a8c38dbf-c34a-49d7-91ee-e06816c3d680_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_a8c38dbf-c34a-49d7-91ee-e06816c3d680" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a8c38dbf-c34a-49d7-91ee-e06816c3d680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_a8c38dbf-c34a-49d7-91ee-e06816c3d680" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ae526020-1be8-4d18-b217-0ee4a979bf56" xlink:href="mrk-20221231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ae526020-1be8-4d18-b217-0ee4a979bf56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02b72f5d-d042-4b44-9866-13483f598b30" xlink:href="mrk-20221231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02b72f5d-d042-4b44-9866-13483f598b30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="extended" id="i145e52573e0845bf8fe9157606ec24c0_GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:to="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9a1cad1-3942-491d-84a6-2919f7f9aff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:to="loc_us-gaap_Goodwill_f9a1cad1-3942-491d-84a6-2919f7f9aff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_e85c3ac8-6cd9-4643-9155-19483267b5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_e85c3ac8-6cd9-4643-9155-19483267b5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_c184159e-9543-46c2-b2e8-5c667ae7db7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_c184159e-9543-46c2-b2e8-5c667ae7db7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_28600b6c-098a-4c71-900c-ca3d53993a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e67582d4-03f5-49fc-b94e-d98691be2229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e67582d4-03f5-49fc-b94e-d98691be2229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6fc3f69e-3bbe-49ac-8d74-d9ffecd11dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6fc3f69e-3bbe-49ac-8d74-d9ffecd11dc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6fc3f69e-3bbe-49ac-8d74-d9ffecd11dc9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830" xlink:to="loc_us-gaap_SegmentDomain_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830" xlink:to="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_0103491f-96ea-431a-a811-ab3758eda7a1" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:to="loc_mrk_PharmaceuticalsegmentMember_0103491f-96ea-431a-a811-ab3758eda7a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_c9784f97-c766-4c69-aaa9-4fcd32e2a2d7" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:to="loc_mrk_AnimalHealthsegmentMember_c9784f97-c766-4c69-aaa9-4fcd32e2a2d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended" id="ia6aa484f61a244d9a10115db35bc0fb6_GoodwillandOtherIntangiblesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8e2b3fe1-f503-471e-969d-3914c8e1a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8e2b3fe1-f503-471e-969d-3914c8e1a537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_262525be-2ddb-4c26-8626-06d28c8f7e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_262525be-2ddb-4c26-8626-06d28c8f7e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1f44f43-0f3c-4a35-8e68-e04b8d56fdda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1f44f43-0f3c-4a35-8e68-e04b8d56fdda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3954b6ff-1ee8-4e8d-8911-79b3fcd720c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3954b6ff-1ee8-4e8d-8911-79b3fcd720c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_30a7a527-3e15-48db-afe0-acc630efea80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_InventoryWriteDown_30a7a527-3e15-48db-afe0-acc630efea80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_82697fb6-9259-4b96-b4ef-af646b411a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_82697fb6-9259-4b96-b4ef-af646b411a7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b0c92d40-6647-4832-aaa6-94bc13d0a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b0c92d40-6647-4832-aaa6-94bc13d0a3a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6363a2c3-3297-4c10-bc1b-352d9e2148a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6363a2c3-3297-4c10-bc1b-352d9e2148a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_503abaf9-d62b-412d-9bcc-001212550e7d" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_503abaf9-d62b-412d-9bcc-001212550e7d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f790a693-df64-4ff3-8b77-e75ae3481d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f790a693-df64-4ff3-8b77-e75ae3481d32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9a99a80b-f057-48b0-be53-cb81b2c59a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9a99a80b-f057-48b0-be53-cb81b2c59a86" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dfbb051c-f628-4774-9c26-dbe1f2376965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dfbb051c-f628-4774-9c26-dbe1f2376965" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8e0af329-0797-496b-bff6-f3e95e7233e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8e0af329-0797-496b-bff6-f3e95e7233e3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_37b649c2-25ed-4d27-9640-7eb9ce10cc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_37b649c2-25ed-4d27-9640-7eb9ce10cc64" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_188cc83a-49f6-4e48-aa5b-3a852f934b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_188cc83a-49f6-4e48-aa5b-3a852f934b31" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1e259a30-08c0-4a3a-8d05-d47fb108b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1e259a30-08c0-4a3a-8d05-d47fb108b3bd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:href="mrk-20221231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fe23510-becc-4ac1-a596-86d026f9fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fe23510-becc-4ac1-a596-86d026f9fcc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fe23510-becc-4ac1-a596-86d026f9fcc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fe23510-becc-4ac1-a596-86d026f9fcc7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7fe23510-becc-4ac1-a596-86d026f9fcc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fe23510-becc-4ac1-a596-86d026f9fcc7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0228eb62-1c22-47bc-87dd-082e78d95a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0228eb62-1c22-47bc-87dd-082e78d95a6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e1b9932d-a929-454f-be90-21a9158cdd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:to="loc_us-gaap_TradeNamesMember_e1b9932d-a929-454f-be90-21a9158cdd9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_56f35b53-3259-464b-8527-ad83a623d8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:to="loc_us-gaap_LicenseMember_56f35b53-3259-464b-8527-ad83a623d8fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4b447c77-5581-4f8d-8bf3-a5de82d4e734" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_srt_ProductOrServiceAxis_4b447c77-5581-4f8d-8bf3-a5de82d4e734" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b447c77-5581-4f8d-8bf3-a5de82d4e734_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4b447c77-5581-4f8d-8bf3-a5de82d4e734" xlink:to="loc_srt_ProductsAndServicesDomain_4b447c77-5581-4f8d-8bf3-a5de82d4e734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4b447c77-5581-4f8d-8bf3-a5de82d4e734" xlink:to="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_07f21459-33fb-4d9c-9509-ba6a8a249eb7" xlink:href="mrk-20221231.xsd#mrk_ReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_ReblozylMember_07f21459-33fb-4d9c-9509-ba6a8a249eb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_c2124652-f558-42e9-8a8c-e75e7c4492f7" xlink:href="mrk-20221231.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_ZerbaxaMember_c2124652-f558-42e9-8a8c-e75e7c4492f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_257833fc-d269-455b-87e9-45268ca15cf4" xlink:href="mrk-20221231.xsd#mrk_SivextroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_SivextroMember_257833fc-d269-455b-87e9-45268ca15cf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_d808315b-f06b-425d-b39c-3cd4c6327e58" xlink:href="mrk-20221231.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_GardasilGardasil9Member_d808315b-f06b-425d-b39c-3cd4c6327e58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_e4cfcf7f-4b84-4772-b4cd-84f3f37f0edc" xlink:href="mrk-20221231.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_BridionMember_e4cfcf7f-4b84-4772-b4cd-84f3f37f0edc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember_91782941-08d1-4cc4-8f92-8de12dbdc782" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_AnimalHealthMember_91782941-08d1-4cc4-8f92-8de12dbdc782" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_d8db7ced-7d86-44af-b7e2-7bd4049a2c40" xlink:href="mrk-20221231.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_LynparzaMember_d8db7ced-7d86-44af-b7e2-7bd4049a2c40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_a87a8ba7-6ebe-4dd0-b69a-577d3b84a29d" xlink:href="mrk-20221231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_LenvimaMember_a87a8ba7-6ebe-4dd0-b69a-577d3b84a29d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_df1fe082-5624-4109-b27a-331136c67ec9" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_AdempasMember_df1fe082-5624-4109-b27a-331136c67ec9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_e68a1ba7-fe28-4504-80be-4cc3dd732ff3" xlink:href="mrk-20221231.xsd#mrk_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_COVID19Member_e68a1ba7-fe28-4504-80be-4cc3dd732ff3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SotaterceptMember_b41b45e4-989b-4fa6-91fa-b62bd88ca282" xlink:href="mrk-20221231.xsd#mrk_SotaterceptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_SotaterceptMember_b41b45e4-989b-4fa6-91fa-b62bd88ca282" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_0e780d1f-e861-45c6-a20e-e3d4497618eb" xlink:href="mrk-20221231.xsd#mrk_NemtabrutinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_NemtabrutinibMember_0e780d1f-e861-45c6-a20e-e3d4497618eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GefapixantMember_9395dd90-5567-4924-8b77-9d37f282695d" xlink:href="mrk-20221231.xsd#mrk_GefapixantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_GefapixantMember_9395dd90-5567-4924-8b77-9d37f282695d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DerazantinibMember_82f9dcf7-cab6-4f4d-adc5-4886a2d6e22c" xlink:href="mrk-20221231.xsd#mrk_DerazantinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_DerazantinibMember_82f9dcf7-cab6-4f4d-adc5-4886a2d6e22c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3c217f25-c06d-4d8c-9022-c82356475cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3c217f25-c06d-4d8c-9022-c82356475cc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c217f25-c06d-4d8c-9022-c82356475cc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c217f25-c06d-4d8c-9022-c82356475cc1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c217f25-c06d-4d8c-9022-c82356475cc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f3203561-e92a-4c40-bc25-a4a316f1a2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c217f25-c06d-4d8c-9022-c82356475cc1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f3203561-e92a-4c40-bc25-a4a316f1a2d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_24252713-1785-4745-a022-b31d23f801e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f3203561-e92a-4c40-bc25-a4a316f1a2d0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_24252713-1785-4745-a022-b31d23f801e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_68144daa-caed-4840-9f84-96e9d5f848c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_68144daa-caed-4840-9f84-96e9d5f848c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_68144daa-caed-4840-9f84-96e9d5f848c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_68144daa-caed-4840-9f84-96e9d5f848c1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_68144daa-caed-4840-9f84-96e9d5f848c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8bb9a174-b603-436a-887c-069658de63c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_68144daa-caed-4840-9f84-96e9d5f848c1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8bb9a174-b603-436a-887c-069658de63c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_25e11216-1fb8-4482-86b7-aa178f2e857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8bb9a174-b603-436a-887c-069658de63c5" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_25e11216-1fb8-4482-86b7-aa178f2e857f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_16047a39-e988-4f88-8939-618a5fa21119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_ValuationTechniqueAxis_16047a39-e988-4f88-8939-618a5fa21119" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_16047a39-e988-4f88-8939-618a5fa21119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_16047a39-e988-4f88-8939-618a5fa21119" xlink:to="loc_us-gaap_ValuationTechniqueDomain_16047a39-e988-4f88-8939-618a5fa21119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_3203382d-7f92-463c-86a2-0a5fc986d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_16047a39-e988-4f88-8939-618a5fa21119" xlink:to="loc_us-gaap_ValuationTechniqueDomain_3203382d-7f92-463c-86a2-0a5fc986d48b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_5b0bd21d-e8d6-4f68-a168-91bb29b3b02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_3203382d-7f92-463c-86a2-0a5fc986d48b" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_5b0bd21d-e8d6-4f68-a168-91bb29b3b02d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21400930-89b8-4e8f-8868-edd6e95e6e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21400930-89b8-4e8f-8868-edd6e95e6e4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21400930-89b8-4e8f-8868-edd6e95e6e4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21400930-89b8-4e8f-8868-edd6e95e6e4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21400930-89b8-4e8f-8868-edd6e95e6e4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d20e092-e640-4a75-bfc1-0ac7d84acc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21400930-89b8-4e8f-8868-edd6e95e6e4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d20e092-e640-4a75-bfc1-0ac7d84acc4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_41d774e7-3b15-44cf-98e2-7e544093e3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d20e092-e640-4a75-bfc1-0ac7d84acc4a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_41d774e7-3b15-44cf-98e2-7e544093e3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6e94ad2a-2985-45bc-b32a-387b6f240ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6e94ad2a-2985-45bc-b32a-387b6f240ab4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6e94ad2a-2985-45bc-b32a-387b6f240ab4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6e94ad2a-2985-45bc-b32a-387b6f240ab4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6e94ad2a-2985-45bc-b32a-387b6f240ab4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_481d898c-b761-42cc-9022-bcac3e627857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6e94ad2a-2985-45bc-b32a-387b6f240ab4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_481d898c-b761-42cc-9022-bcac3e627857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bb429787-00df-450d-b030-0f45ea9ddeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_481d898c-b761-42cc-9022-bcac3e627857" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bb429787-00df-450d-b030-0f45ea9ddeb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended" id="iaeae5c5a70da4fe9a32181be956d0467_GoodwillandOtherIntangiblesOtherIntangiblesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_81e29f12-af35-49d7-a435-f9b2c747602d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_81e29f12-af35-49d7-a435-f9b2c747602d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02ae90be-2429-43ea-9ea0-5ceb7d7ed74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02ae90be-2429-43ea-9ea0-5ceb7d7ed74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_831ad375-f5c5-4a29-85a3-02a59f8897c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_831ad375-f5c5-4a29-85a3-02a59f8897c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4e92575b-a4bb-4105-a25e-60f7ac755093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4e92575b-a4bb-4105-a25e-60f7ac755093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e92575b-a4bb-4105-a25e-60f7ac755093_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4e92575b-a4bb-4105-a25e-60f7ac755093" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e92575b-a4bb-4105-a25e-60f7ac755093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4e92575b-a4bb-4105-a25e-60f7ac755093" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6ebb9dce-4992-413c-9c50-e6908154f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6ebb9dce-4992-413c-9c50-e6908154f7da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_579bcbd9-3215-43c7-8a9d-c07909deafae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_TradeNamesMember_579bcbd9-3215-43c7-8a9d-c07909deafae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_df7ebc95-bf98-4337-8ac6-8f6f4229c69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_df7ebc95-bf98-4337-8ac6-8f6f4229c69d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_14e80f31-e404-4f31-87e7-05c2bd78e390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_LicenseMember_14e80f31-e404-4f31-87e7-05c2bd78e390" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_07d51620-bd1c-40ef-a23e-aaf31c770a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_07d51620-bd1c-40ef-a23e-aaf31c770a27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07d51620-bd1c-40ef-a23e-aaf31c770a27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_07d51620-bd1c-40ef-a23e-aaf31c770a27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_07d51620-bd1c-40ef-a23e-aaf31c770a27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3897a9f7-8ab0-4dc1-b1b4-13d4aa0920ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_07d51620-bd1c-40ef-a23e-aaf31c770a27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3897a9f7-8ab0-4dc1-b1b4-13d4aa0920ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_57751378-8ac7-4ef2-b8b7-3b0933e90914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3897a9f7-8ab0-4dc1-b1b4-13d4aa0920ff" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_57751378-8ac7-4ef2-b8b7-3b0933e90914" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="extended" id="i9c7a2f58687f4750a3690e0913313699_LoansPayableLongTermDebtandLeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cf018298-a318-4499-9510-b56c013cbc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtCurrent_cf018298-a318-4499-9510-b56c013cbc17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_a66e6cee-4757-40d6-af4c-b101e9a7fd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_DebtCurrent_a66e6cee-4757-40d6-af4c-b101e9a7fd8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_bfd64cf9-6d44-4001-b249-b143e5e961e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_bfd64cf9-6d44-4001-b249-b143e5e961e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_f98c508f-27f2-4d5f-9865-d61e4cc775fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_f98c508f-27f2-4d5f-9865-d61e4cc775fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69b2e80c-8e86-4c69-9163-d83ac5613ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69b2e80c-8e86-4c69-9163-d83ac5613ef1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_341041e2-beb7-4da5-8ee4-dd27d9770451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_341041e2-beb7-4da5-8ee4-dd27d9770451" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_49006496-840b-4988-a42e-ef43d155469c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_49006496-840b-4988-a42e-ef43d155469c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce14a72d-ceff-4d73-81aa-7c047ced88c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce14a72d-ceff-4d73-81aa-7c047ced88c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_872bc98d-5453-41f6-9b36-b036c3e514b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_872bc98d-5453-41f6-9b36-b036c3e514b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_777cfb76-1f5e-4e17-be4d-2b19f9c014a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_777cfb76-1f5e-4e17-be4d-2b19f9c014a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearOne_614ec4c6-c2ac-4bad-b838-dd95dd21ef78" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearOne_614ec4c6-c2ac-4bad-b838-dd95dd21ef78" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearTwo_facf6faa-d469-421b-bfe6-139f039582bf" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearTwo_facf6faa-d469-421b-bfe6-139f039582bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearThree_8b7c5207-1e78-4dac-b8fb-2dcb24598939" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearThree_8b7c5207-1e78-4dac-b8fb-2dcb24598939" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFour_526181c3-e142-4d79-8157-8d190261ec77" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFour_526181c3-e142-4d79-8157-8d190261ec77" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFive_ecf32233-8a3b-48a5-a515-3f894bb46b97" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFive_ecf32233-8a3b-48a5-a515-3f894bb46b97" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efb7b920-c789-4946-ab30-7d26106c17ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efb7b920-c789-4946-ab30-7d26106c17ea" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c88057cb-9ba2-4735-ab40-4ffaefa93ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c88057cb-9ba2-4735-ab40-4ffaefa93ab2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0e2d9833-cf9b-441d-a860-7d67f2aa9357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0e2d9833-cf9b-441d-a860-7d67f2aa9357" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c4ef106e-6037-45bf-a908-65d25b1352c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_OperatingLeaseCost_c4ef106e-6037-45bf-a908-65d25b1352c8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2100b9cd-905a-4c11-b3f4-683cc4cbf965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_OperatingLeasePayments_2100b9cd-905a-4c11-b3f4-683cc4cbf965" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3bbdbf42-b9e3-431e-aacd-3e24414a6ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3bbdbf42-b9e3-431e-aacd-3e24414a6ea9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_587df8d3-5fe8-4f28-a89e-39a40454018c" xlink:href="mrk-20221231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_587df8d3-5fe8-4f28-a89e-39a40454018c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d69a1958-dd69-4ffe-ac3d-de4fc50fabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d69a1958-dd69-4ffe-ac3d-de4fc50fabdc" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1068bd7-9763-43b7-bc71-1b2f2d2dd889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1068bd7-9763-43b7-bc71-1b2f2d2dd889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1068bd7-9763-43b7-bc71-1b2f2d2dd889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1068bd7-9763-43b7-bc71-1b2f2d2dd889" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1068bd7-9763-43b7-bc71-1b2f2d2dd889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1068bd7-9763-43b7-bc71-1b2f2d2dd889" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f8aefe01-4d81-4324-b5d7-5b161d7a0a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:to="loc_us-gaap_BuildingMember_f8aefe01-4d81-4324-b5d7-5b161d7a0a06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_24f5c317-fc60-4e28-a495-26b39e73aed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:to="loc_us-gaap_VehiclesMember_24f5c317-fc60-4e28-a495-26b39e73aed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_875cdd40-a493-4373-ab6d-34ba80a8f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_875cdd40-a493-4373-ab6d-34ba80a8f2b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_875cdd40-a493-4373-ab6d-34ba80a8f2b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_875cdd40-a493-4373-ab6d-34ba80a8f2b8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_875cdd40-a493-4373-ab6d-34ba80a8f2b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_875cdd40-a493-4373-ab6d-34ba80a8f2b8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b9bb4e18-f63a-405a-911a-47f2caaad357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:to="loc_us-gaap_CommercialPaperMember_b9bb4e18-f63a-405a-911a-47f2caaad357" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_1c036656-32f5-4fe3-b139-6d3aa53971c4" xlink:href="mrk-20221231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:to="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_1c036656-32f5-4fe3-b139-6d3aa53971c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d07bba3-1545-4d62-95e9-cc875b705d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d07bba3-1545-4d62-95e9-cc875b705d2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d07bba3-1545-4d62-95e9-cc875b705d2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d07bba3-1545-4d62-95e9-cc875b705d2a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d07bba3-1545-4d62-95e9-cc875b705d2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d07bba3-1545-4d62-95e9-cc875b705d2a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember_fc35c2ae-967a-4020-8843-f9667b24daaf" xlink:href="mrk-20221231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_OtherVariableRateDebtMember_fc35c2ae-967a-4020-8843-f9667b24daaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_65ebd8bd-e58e-4dde-b637-e19ef7863198" xlink:href="mrk-20221231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A63DebenturesDue2026Member_65ebd8bd-e58e-4dde-b637-e19ef7863198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_c272b745-2f66-4883-befd-70acb418f960" xlink:href="mrk-20221231.xsd#mrk_A170NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A170NotesDue2027Member_c272b745-2f66-4883-befd-70acb418f960" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_407d49e6-cdb0-4002-9e7c-238d1a6b7783" xlink:href="mrk-20221231.xsd#mrk_A190NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A190NotesDue2028Member_407d49e6-cdb0-4002-9e7c-238d1a6b7783" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_94b3229f-cc44-4aeb-8520-5a934d68a1af" xlink:href="mrk-20221231.xsd#mrk_A215NotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A215NotesDue2031Member_94b3229f-cc44-4aeb-8520-5a934d68a1af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_4112927f-1aee-4354-825d-dbf2dc4eec49" xlink:href="mrk-20221231.xsd#mrk_A275NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A275NotesDue2051Member_4112927f-1aee-4354-825d-dbf2dc4eec49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_e8d27bd6-672f-45f8-aa9a-13cc0942af4c" xlink:href="mrk-20221231.xsd#mrk_A290NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A290NotesDue2061Member_e8d27bd6-672f-45f8-aa9a-13cc0942af4c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="extended" id="i976d42d46bdc489e98232e946bda6625_LoansPayableLongTermDebtandLeasesLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eaf290d3-c944-4e97-ba7e-faad0800b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eaf290d3-c944-4e97-ba7e-faad0800b9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_95fa4f5d-873c-482a-8e61-b3d817fe4d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_95fa4f5d-873c-482a-8e61-b3d817fe4d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9e1da8ac-d0c0-4147-bdee-5fd8d8a860e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:to="loc_us-gaap_DebtInstrumentTable_9e1da8ac-d0c0-4147-bdee-5fd8d8a860e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b215f657-0df8-49b8-a903-6f9b9ba38ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9e1da8ac-d0c0-4147-bdee-5fd8d8a860e3" xlink:to="loc_us-gaap_DebtInstrumentAxis_b215f657-0df8-49b8-a903-6f9b9ba38ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b215f657-0df8-49b8-a903-6f9b9ba38ef6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b215f657-0df8-49b8-a903-6f9b9ba38ef6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b215f657-0df8-49b8-a903-6f9b9ba38ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b215f657-0df8-49b8-a903-6f9b9ba38ef6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member_7c25df6c-3286-458a-8635-623618aa784e" xlink:href="mrk-20221231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A2.75NotesDue2025Member_7c25df6c-3286-458a-8635-623618aa784e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_47e835f3-4711-4648-bb57-8ff6b417e286" xlink:href="mrk-20221231.xsd#mrk_A215NotesDue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A215NotesDue2031Member_47e835f3-4711-4648-bb57-8ff6b417e286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_2f2a2277-5bb2-4f1c-8463-ea8bb009c4d1" xlink:href="mrk-20221231.xsd#mrk_A275NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A275NotesDue2051Member_2f2a2277-5bb2-4f1c-8463-ea8bb009c4d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member_de92bc4e-4686-4a6a-9a9c-f66cec5125af" xlink:href="mrk-20221231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A3.70NotesDue2045Member_de92bc4e-4686-4a6a-9a9c-f66cec5125af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member_5fcfb824-90f7-4488-b1f7-deba86dd9ea8" xlink:href="mrk-20221231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A3.40NotesDue2029Member_5fcfb824-90f7-4488-b1f7-deba86dd9ea8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_29f6c2a8-804d-4cb4-b61f-c5c67a2c4883" xlink:href="mrk-20221231.xsd#mrk_A170NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A170NotesDue2027Member_29f6c2a8-804d-4cb4-b61f-c5c67a2c4883" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_dcdd9f08-9823-4ac8-adec-eef55bf04e25" xlink:href="mrk-20221231.xsd#mrk_A290NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A290NotesDue2061Member_dcdd9f08-9823-4ac8-adec-eef55bf04e25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member_b098a8b1-3a2c-4410-b804-8838ea1cc463" xlink:href="mrk-20221231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A4.00NotesDue2049Member_b098a8b1-3a2c-4410-b804-8838ea1cc463" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member_b47ea4eb-4c1b-4807-a9c5-7ead5506bf3a" xlink:href="mrk-20221231.xsd#mrk_A415NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A415NotesDue2043Member_b47ea4eb-4c1b-4807-a9c5-7ead5506bf3a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member_781d2fa6-cbf7-4e9b-88eb-c479411417b0" xlink:href="mrk-20221231.xsd#mrk_A145NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A145NotesDue2030Member_781d2fa6-cbf7-4e9b-88eb-c479411417b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member_04e53b79-10cd-4024-b28e-2762848b04c8" xlink:href="mrk-20221231.xsd#mrk_A245NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A245NotesDue2050Member_04e53b79-10cd-4024-b28e-2762848b04c8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member_754f7718-a589-4aa4-8caa-61586df301f0" xlink:href="mrk-20221231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A1.875EuroNotesDue2026Member_754f7718-a589-4aa4-8caa-61586df301f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member_4db37f42-80ea-4983-8df5-170f6cbbbd03" xlink:href="mrk-20221231.xsd#mrk_A075NotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A075NotesDue2026Member_4db37f42-80ea-4983-8df5-170f6cbbbd03" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_1d0a86e4-7e3e-4a55-89cc-2b9ce49abcc9" xlink:href="mrk-20221231.xsd#mrk_A190NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A190NotesDue2028Member_1d0a86e4-7e3e-4a55-89cc-2b9ce49abcc9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member_030d216c-98ec-428d-a463-edab783f26e7" xlink:href="mrk-20221231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A3.90NotesDue2039Member_030d216c-98ec-428d-a463-edab783f26e7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member_f2643fe9-8ed1-4aeb-a3e3-0ee245563fa3" xlink:href="mrk-20221231.xsd#mrk_A235NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A235NotesDue2040Member_f2643fe9-8ed1-4aeb-a3e3-0ee245563fa3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member_5bb490f3-7563-4d18-b31f-47aa0cb8deb6" xlink:href="mrk-20221231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A2.90NotesDue2024Member_5bb490f3-7563-4d18-b31f-47aa0cb8deb6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_668a7f56-57a3-4d53-be72-4b43b3674908" xlink:href="mrk-20221231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_668a7f56-57a3-4d53-be72-4b43b3674908" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member_f3ce675d-2744-45ed-82e6-4a31a2a34266" xlink:href="mrk-20221231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A0.50eurodenominatednotesdue2024Member_f3ce675d-2744-45ed-82e6-4a31a2a34266" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member_27d471cd-ccb9-4b35-9989-a1edeb09435a" xlink:href="mrk-20221231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A1.375eurodenominatednotesdue2036Member_27d471cd-ccb9-4b35-9989-a1edeb09435a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member_9568eec4-c3fb-48d3-b2e9-62ed4f275fd5" xlink:href="mrk-20221231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A2.5EuroNotesDue2034Member_9568eec4-c3fb-48d3-b2e9-62ed4f275fd5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_9f2d503d-bae6-4dd1-8fe8-9cd0d9a81c84" xlink:href="mrk-20221231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_9f2d503d-bae6-4dd1-8fe8-9cd0d9a81c84" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_10b9fa0b-4c5f-4f20-b119-dad309523e56" xlink:href="mrk-20221231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_10b9fa0b-4c5f-4f20-b119-dad309523e56" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_d432c494-0ff3-4a08-b31f-b5da2da798df" xlink:href="mrk-20221231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_d432c494-0ff3-4a08-b31f-b5da2da798df" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_be57009e-bf67-40f8-a0c4-88ea833a4322" xlink:href="mrk-20221231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_be57009e-bf67-40f8-a0c4-88ea833a4322" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_cd5e9ec0-ea5a-48b6-aeed-83debb08e923" xlink:href="mrk-20221231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_cd5e9ec0-ea5a-48b6-aeed-83debb08e923" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_7caf6626-e5b6-4733-b9b7-f89b9a97d902" xlink:href="mrk-20221231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_7caf6626-e5b6-4733-b9b7-f89b9a97d902" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_d4e0cd99-c537-4d27-bcea-d770b89a8ee2" xlink:href="mrk-20221231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A63DebenturesDue2026Member_d4e0cd99-c537-4d27-bcea-d770b89a8ee2" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member_745d73fb-0c4a-402d-ad58-3236ed075084" xlink:href="mrk-20221231.xsd#mrk_A280NotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A280NotesDue2023Member_745d73fb-0c4a-402d-ad58-3236ed075084" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember_46ad70dd-4439-4b2f-8200-4141aa07eec3" xlink:href="mrk-20221231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_OtherLongTermDebtMember_46ad70dd-4439-4b2f-8200-4141aa07eec3" xlink:type="arc" order="29"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ContingenciesandEnvironmentalLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="extended" id="if68f298c94db41209b9a556b5392a9bc_ContingenciesandEnvironmentalLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_c22dfa31-5e68-4b2c-a201-62871224738d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_c22dfa31-5e68-4b2c-a201-62871224738d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_052ca824-d8b4-4156-8f54-fc78c81ad284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_052ca824-d8b4-4156-8f54-fc78c81ad284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dabee509-91c5-4c15-b37b-adbf83dbd8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dabee509-91c5-4c15-b37b-adbf83dbd8ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_e4320a84-9180-486f-a860-9bc19545fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_e4320a84-9180-486f-a860-9bc19545fbe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod_37491d60-0420-4497-917a-fdbf4041ec3f" xlink:href="mrk-20221231.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_mrk_LossContingencyTrialPeriod_37491d60-0420-4497-917a-fdbf4041ec3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_33f2e6fd-b2db-48a7-a831-cb3e0c743c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_33f2e6fd-b2db-48a7-a831-cb3e0c743c4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_b4bccc9f-33f0-4ad2-8797-a46cde88c5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LitigationReserve_b4bccc9f-33f0-4ad2-8797-a46cde88c5e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_d8f5dacc-45bb-41bc-842a-ebb3b1e1cc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_d8f5dacc-45bb-41bc-842a-ebb3b1e1cc3a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_66a995d3-5a65-4b01-ab82-81318c36ed1f" xlink:href="mrk-20221231.xsd#mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_66a995d3-5a65-4b01-ab82-81318c36ed1f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities_e0b99acb-7769-4518-ac8b-ce762bf1ef01" xlink:href="mrk-20221231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_mrk_TermForPayingOffEnvironmentalLiabilities_e0b99acb-7769-4518-ac8b-ce762bf1ef01" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_e1793f12-6886-4b1d-8c87-dce067288a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_e1793f12-6886-4b1d-8c87-dce067288a61" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31babfd9-0d25-4afa-bba0-0c6e32b381b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_srt_ProductOrServiceAxis_31babfd9-0d25-4afa-bba0-0c6e32b381b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31babfd9-0d25-4afa-bba0-0c6e32b381b8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_31babfd9-0d25-4afa-bba0-0c6e32b381b8" xlink:to="loc_srt_ProductsAndServicesDomain_31babfd9-0d25-4afa-bba0-0c6e32b381b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_31babfd9-0d25-4afa-bba0-0c6e32b381b8" xlink:to="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_62f5feb3-775c-46e0-92f6-60c8c1f1c2bc" xlink:href="mrk-20221231.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:to="loc_mrk_GardasilGardasil9Member_62f5feb3-775c-46e0-92f6-60c8c1f1c2bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_e5616561-3344-474f-b17d-61d7661676a7" xlink:href="mrk-20221231.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:to="loc_mrk_BridionMember_e5616561-3344-474f-b17d-61d7661676a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_950584e7-7289-45da-95a7-a96cc7115152" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_srt_LitigationCaseAxis_950584e7-7289-45da-95a7-a96cc7115152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_950584e7-7289-45da-95a7-a96cc7115152_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_950584e7-7289-45da-95a7-a96cc7115152" xlink:to="loc_srt_LitigationCaseTypeDomain_950584e7-7289-45da-95a7-a96cc7115152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_950584e7-7289-45da-95a7-a96cc7115152" xlink:to="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_d44ca854-9af8-472a-88ab-55407eddabd3" xlink:href="mrk-20221231.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_d44ca854-9af8-472a-88ab-55407eddabd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_059fbb7f-b69d-4565-af81-e11ffa12fd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:to="loc_us-gaap_PatentsMember_059fbb7f-b69d-4565-af81-e11ffa12fd3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b831b447-12a0-48ba-9513-9cc6b5fdb4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b831b447-12a0-48ba-9513-9cc6b5fdb4c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b831b447-12a0-48ba-9513-9cc6b5fdb4c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b831b447-12a0-48ba-9513-9cc6b5fdb4c9" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b831b447-12a0-48ba-9513-9cc6b5fdb4c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b831b447-12a0-48ba-9513-9cc6b5fdb4c9" xlink:to="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember_14cb37c5-c545-4b65-977c-2022b097ba9e" xlink:href="mrk-20221231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:to="loc_mrk_CommercialandOtherLitigationMember_14cb37c5-c545-4b65-977c-2022b097ba9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_c123f966-134a-4fb8-b11d-9a1e75f946e6" xlink:href="mrk-20221231.xsd#mrk_PatentlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:to="loc_mrk_PatentlitigationMember_c123f966-134a-4fb8-b11d-9a1e75f946e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5ad2b7b1-53bf-44e8-9ca0-03376e454580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5ad2b7b1-53bf-44e8-9ca0-03376e454580" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5ad2b7b1-53bf-44e8-9ca0-03376e454580_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5ad2b7b1-53bf-44e8-9ca0-03376e454580" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5ad2b7b1-53bf-44e8-9ca0-03376e454580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2505fe0f-5ca5-4a5d-8412-40e193823f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5ad2b7b1-53bf-44e8-9ca0-03376e454580" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2505fe0f-5ca5-4a5d-8412-40e193823f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_6f5f7239-96ba-4092-bf68-3d6a4448254a" xlink:href="mrk-20221231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2505fe0f-5ca5-4a5d-8412-40e193823f4a" xlink:to="loc_mrk_LegalDefenseCostsMember_6f5f7239-96ba-4092-bf68-3d6a4448254a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dcafa351-dad5-44ad-b28d-6aed99b9850b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_srt_StatementGeographicalAxis_dcafa351-dad5-44ad-b28d-6aed99b9850b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dcafa351-dad5-44ad-b28d-6aed99b9850b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dcafa351-dad5-44ad-b28d-6aed99b9850b" xlink:to="loc_srt_SegmentGeographicalDomain_dcafa351-dad5-44ad-b28d-6aed99b9850b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dcafa351-dad5-44ad-b28d-6aed99b9850b" xlink:to="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c13371cc-d953-461a-9cda-42717353af32" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:to="loc_country_US_c13371cc-d953-461a-9cda-42717353af32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a698a546-5948-4b3c-9a04-2d4ce4eebb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:to="loc_us-gaap_NonUsMember_a698a546-5948-4b3c-9a04-2d4ce4eebb8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO_3c68e27a-269a-447c-b9a0-0e84be0edd32" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:to="loc_country_CO_3c68e27a-269a-447c-b9a0-0e84be0edd32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_744e575e-f70d-424b-9a5c-665fd58917bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_us-gaap_LitigationStatusAxis_744e575e-f70d-424b-9a5c-665fd58917bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_744e575e-f70d-424b-9a5c-665fd58917bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_744e575e-f70d-424b-9a5c-665fd58917bd" xlink:to="loc_us-gaap_LitigationStatusDomain_744e575e-f70d-424b-9a5c-665fd58917bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3bd4122a-cf11-4115-80d9-02555507a545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_744e575e-f70d-424b-9a5c-665fd58917bd" xlink:to="loc_us-gaap_LitigationStatusDomain_3bd4122a-cf11-4115-80d9-02555507a545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f501a3d5-ab30-41d6-8883-fdad62df539e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3bd4122a-cf11-4115-80d9-02555507a545" xlink:to="loc_us-gaap_PendingLitigationMember_f501a3d5-ab30-41d6-8883-fdad62df539e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#EquityShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="extended" id="id4f5a9dbb98443f8b2fc20ea9b22cf2e_EquityShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0dc992a-91a7-41d1-848d-8d72563a4c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:href="mrk-20221231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0dc992a-91a7-41d1-848d-8d72563a4c19" xlink:to="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a1e3b064-aa72-4f08-9097-c1e9443ee252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:to="loc_us-gaap_CommonStockSharesIssued_a1e3b064-aa72-4f08-9097-c1e9443ee252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d7d44fa8-99c3-466c-9245-491ec833c1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d7d44fa8-99c3-466c-9245-491ec833c1dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_24eff856-f8ea-46d7-a29c-f9453f7112f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_24eff856-f8ea-46d7-a29c-f9453f7112f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cc29a80e-f88d-43d9-9229-3e44855e8724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2251816d-e963-4760-8969-5dc13a8a3697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0dc992a-91a7-41d1-848d-8d72563a4c19" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2251816d-e963-4760-8969-5dc13a8a3697" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2251816d-e963-4760-8969-5dc13a8a3697" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc" xlink:to="loc_us-gaap_EquityComponentDomain_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc" xlink:to="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c503c338-0ece-4751-9011-967d448a2ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:to="loc_us-gaap_CommonStockMember_c503c338-0ece-4751-9011-967d448a2ab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_71c5d2e3-2295-40b2-b6a4-c409b9368dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_71c5d2e3-2295-40b2-b6a4-c409b9368dd4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended" id="i46c28e05df7544329fa10dc42aa89833_ShareBasedCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ab93171-4fbe-4b96-93ce-a201311a9ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ab93171-4fbe-4b96-93ce-a201311a9ab2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d213f08f-351f-4910-9f48-b2b16dbf8506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d213f08f-351f-4910-9f48-b2b16dbf8506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_272de05c-6cf2-4295-979b-2a2656502a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_272de05c-6cf2-4295-979b-2a2656502a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_992e0505-d64c-4e84-9fab-aeccab399d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_992e0505-d64c-4e84-9fab-aeccab399d69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c672f130-641f-4e89-bed0-f605130fc8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c672f130-641f-4e89-bed0-f605130fc8d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d6d8b4de-3ca7-410f-b3b9-7e11a0850087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensation_d6d8b4de-3ca7-410f-b3b9-7e11a0850087" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d056a429-375f-46d7-acb9-7b5000300f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d056a429-375f-46d7-acb9-7b5000300f1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a435fceb-52f9-43f4-8a7b-b7f0d87a7e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a435fceb-52f9-43f4-8a7b-b7f0d87a7e04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d2108df-2c9d-4388-ac04-2f5cf61a4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d2108df-2c9d-4388-ac04-2f5cf61a4b14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_03f8e331-5d8a-4016-9450-42c51e106f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_03f8e331-5d8a-4016-9450-42c51e106f6a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6b43c32-1175-440c-81ca-59df7e3af641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6b43c32-1175-440c-81ca-59df7e3af641" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de9d0df7-05bf-4afa-a846-e197924f10eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6b43c32-1175-440c-81ca-59df7e3af641" xlink:to="loc_srt_RangeAxis_de9d0df7-05bf-4afa-a846-e197924f10eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de9d0df7-05bf-4afa-a846-e197924f10eb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_de9d0df7-05bf-4afa-a846-e197924f10eb" xlink:to="loc_srt_RangeMember_de9d0df7-05bf-4afa-a846-e197924f10eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_de9d0df7-05bf-4afa-a846-e197924f10eb" xlink:to="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62f263f6-7a9a-45d4-af07-44cf7884e782" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:to="loc_srt_MinimumMember_62f263f6-7a9a-45d4-af07-44cf7884e782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_146ed60b-6d25-467a-8597-1b140b0e3de1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:to="loc_srt_MaximumMember_146ed60b-6d25-467a-8597-1b140b0e3de1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="extended" id="i1ed638678f0a4c75b13eef3511e8a78b_ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4a92bf7-30d4-4776-8c4e-29b3884537a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4a92bf7-30d4-4776-8c4e-29b3884537a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5081d50f-1591-4146-9646-b6cdf2bb6662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5081d50f-1591-4146-9646-b6cdf2bb6662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0bf85d25-94ff-45e2-99d3-7764f92a5870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0bf85d25-94ff-45e2-99d3-7764f92a5870" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f228200e-9549-400b-bfc1-8182ee68d7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f228200e-9549-400b-bfc1-8182ee68d7ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee601850-bb89-4813-94a0-8dc9934f2539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_09a5fcf6-1a73-4208-bfbf-82aa678145e5" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_09a5fcf6-1a73-4208-bfbf-82aa678145e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30d29203-0ce2-4ef3-bc49-bd68f040bc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30d29203-0ce2-4ef3-bc49-bd68f040bc5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91b777eb-50fc-4759-ac85-3a7091f33896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91b777eb-50fc-4759-ac85-3a7091f33896" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1a15e6ee-dc96-4e95-8b20-cbc208b6c649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1a15e6ee-dc96-4e95-8b20-cbc208b6c649" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb7e1665-8f12-43af-8e2e-a633b6f76a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb7e1665-8f12-43af-8e2e-a633b6f76a73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5d1a5a27-9a21-4b0e-9b66-7f23f662f055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_93f2b65c-1caf-44aa-a965-c5c247bbcfd2" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_93f2b65c-1caf-44aa-a965-c5c247bbcfd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_755a3b65-19f4-46d9-84de-15404cbb290c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_755a3b65-19f4-46d9-84de-15404cbb290c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7683d23e-671d-4c2c-b329-722a0675a423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_755a3b65-19f4-46d9-84de-15404cbb290c" xlink:to="loc_us-gaap_AwardTypeAxis_7683d23e-671d-4c2c-b329-722a0675a423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7683d23e-671d-4c2c-b329-722a0675a423_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7683d23e-671d-4c2c-b329-722a0675a423" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7683d23e-671d-4c2c-b329-722a0675a423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7683d23e-671d-4c2c-b329-722a0675a423" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62dd52af-e046-49df-9f6a-69c6aecdc293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62dd52af-e046-49df-9f6a-69c6aecdc293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7d73fe8c-94b7-437b-9953-bd86803d9097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:to="loc_us-gaap_PerformanceSharesMember_7d73fe8c-94b7-437b-9953-bd86803d9097" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended" id="ib90ef89826db489fac5734def4064862_PensionandOtherPostretirementBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_2ef9e073-4030-4492-bb7f-6e45e733eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_2ef9e073-4030-4492-bb7f-6e45e733eec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_58ceb5c4-fcd3-42f8-b7dd-b523597cc228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_58ceb5c4-fcd3-42f8-b7dd-b523597cc228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_7260c911-e533-4cc9-9aca-6a3527a77ff3" xlink:href="mrk-20221231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_7260c911-e533-4cc9-9aca-6a3527a77ff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_953f045e-b62e-46a9-8021-e8472c64ca11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_953f045e-b62e-46a9-8021-e8472c64ca11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_9cb85db6-b592-4249-8826-92d6466e4626" xlink:href="mrk-20221231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_9cb85db6-b592-4249-8826-92d6466e4626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_a84309bb-027a-42d4-ad3f-f89a7d2b60bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_a84309bb-027a-42d4-ad3f-f89a7d2b60bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_eed60f3e-9058-49ba-85b4-06cff192f6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_eed60f3e-9058-49ba-85b4-06cff192f6b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_e0fd1d63-e230-4e88-ac64-b8a1bbc4a21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_e0fd1d63-e230-4e88-ac64-b8a1bbc4a21e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_d38fc936-6226-4041-a9c2-453cfb70412a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_d38fc936-6226-4041-a9c2-453cfb70412a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_d38fc936-6226-4041-a9c2-453cfb70412a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d38fc936-6226-4041-a9c2-453cfb70412a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_d38fc936-6226-4041-a9c2-453cfb70412a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d38fc936-6226-4041-a9c2-453cfb70412a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_99343e67-d867-4bd0-8560-573430f32050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:to="loc_us-gaap_DomesticPlanMember_99343e67-d867-4bd0-8560-573430f32050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2f654d46-4a0f-4f86-be7f-8047af1c1f5f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_99343e67-d867-4bd0-8560-573430f32050" xlink:to="loc_country_US_2f654d46-4a0f-4f86-be7f-8047af1c1f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_caa85333-4a98-4285-9d4a-9fac3cc4810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:to="loc_us-gaap_ForeignPlanMember_caa85333-4a98-4285-9d4a-9fac3cc4810a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e551de9a-e8b5-4843-896b-8da9d0799aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e551de9a-e8b5-4843-896b-8da9d0799aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e551de9a-e8b5-4843-896b-8da9d0799aa4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e551de9a-e8b5-4843-896b-8da9d0799aa4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e551de9a-e8b5-4843-896b-8da9d0799aa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e551de9a-e8b5-4843-896b-8da9d0799aa4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cdeaa778-20f3-4619-bb19-ac08a2c70dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cdeaa778-20f3-4619-bb19-ac08a2c70dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_013fe1a6-17a4-4f85-964a-659e852763e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_013fe1a6-17a4-4f85-964a-659e852763e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95dbfb87-a651-4b5f-ac7e-2886c5e7397c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95dbfb87-a651-4b5f-ac7e-2886c5e7397c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95dbfb87-a651-4b5f-ac7e-2886c5e7397c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95dbfb87-a651-4b5f-ac7e-2886c5e7397c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95dbfb87-a651-4b5f-ac7e-2886c5e7397c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c18bfb8d-e341-483f-bb2b-06727432c37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95dbfb87-a651-4b5f-ac7e-2886c5e7397c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c18bfb8d-e341-483f-bb2b-06727432c37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a08a0b76-47b1-4a9c-9741-4612bc6154cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c18bfb8d-e341-483f-bb2b-06727432c37e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a08a0b76-47b1-4a9c-9741-4612bc6154cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_9779fb72-4442-4bfc-8c98-5c7d5b3eb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_9779fb72-4442-4bfc-8c98-5c7d5b3eb85f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_d7109c51-0882-4f30-bd58-ad456ef1b8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_d7109c51-0882-4f30-bd58-ad456ef1b8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember_680d67a6-7767-4ed0-a5e1-610e035922b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_us-gaap_FixedIncomeInvestmentsMember_680d67a6-7767-4ed0-a5e1-610e035922b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_6ddf399c-9128-490b-9191-1182e3296008" xlink:href="mrk-20221231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_6ddf399c-9128-490b-9191-1182e3296008" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7da4b27e-2dde-4070-b334-49a3ea3efdb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_srt_RangeAxis_7da4b27e-2dde-4070-b334-49a3ea3efdb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7da4b27e-2dde-4070-b334-49a3ea3efdb2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7da4b27e-2dde-4070-b334-49a3ea3efdb2" xlink:to="loc_srt_RangeMember_7da4b27e-2dde-4070-b334-49a3ea3efdb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7da4b27e-2dde-4070-b334-49a3ea3efdb2" xlink:to="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b9acb0f-0336-4bb4-b362-5172fd1c5cd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:to="loc_srt_MinimumMember_7b9acb0f-0336-4bb4-b362-5172fd1c5cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d357853-1e72-409d-b9bb-fa3b39015c5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:to="loc_srt_MaximumMember_1d357853-1e72-409d-b9bb-fa3b39015c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6865d026-cf8a-47f2-b054-a50edd281c2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_srt_StatementScenarioAxis_6865d026-cf8a-47f2-b054-a50edd281c2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6865d026-cf8a-47f2-b054-a50edd281c2f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6865d026-cf8a-47f2-b054-a50edd281c2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6865d026-cf8a-47f2-b054-a50edd281c2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e450aff2-3c39-40d0-96e7-30e7ab834ade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6865d026-cf8a-47f2-b054-a50edd281c2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e450aff2-3c39-40d0-96e7-30e7ab834ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0bd5e971-a12c-4d1e-b524-227bb6441d0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e450aff2-3c39-40d0-96e7-30e7ab834ade" xlink:to="loc_srt_ScenarioForecastMember_0bd5e971-a12c-4d1e-b524-227bb6441d0f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="id4e2f1ee7d63423c9283d509cbc9f881_PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_bbbee1c2-8c13-40a3-a057-784e9c1346cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_bbbee1c2-8c13-40a3-a057-784e9c1346cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1723d1dc-0450-4e94-8abe-3da4aafb7c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1723d1dc-0450-4e94-8abe-3da4aafb7c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_986a49e0-e78c-46fb-afe2-5f2850c05cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_986a49e0-e78c-46fb-afe2-5f2850c05cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ff4a85d3-db81-4810-826a-52d9b1046f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ff4a85d3-db81-4810-826a-52d9b1046f06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a7cfa31d-7ba1-4a6f-81c2-f15bbb515b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a7cfa31d-7ba1-4a6f-81c2-f15bbb515b64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_e8605fc6-8e2e-4c10-81bd-075e80e2d498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_e8605fc6-8e2e-4c10-81bd-075e80e2d498" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_ea62f3da-fd44-4978-bcd5-373364ab4541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_ea62f3da-fd44-4978-bcd5-373364ab4541" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6ade02cc-8706-4f16-a5e2-ac22cf2f591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6ade02cc-8706-4f16-a5e2-ac22cf2f591f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f20f7dd-ca86-442c-860e-3617b2af9e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f20f7dd-ca86-442c-860e-3617b2af9e4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b7441bae-edcf-493a-9e83-1250be062fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b7441bae-edcf-493a-9e83-1250be062fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b7441bae-edcf-493a-9e83-1250be062fa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b7441bae-edcf-493a-9e83-1250be062fa1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b7441bae-edcf-493a-9e83-1250be062fa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b7441bae-edcf-493a-9e83-1250be062fa1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f12d0753-ee9a-47f7-b978-23e09cc4c704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:to="loc_us-gaap_DomesticPlanMember_f12d0753-ee9a-47f7-b978-23e09cc4c704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a44e19f6-7cdb-4315-ba86-da60c8e2288c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f12d0753-ee9a-47f7-b978-23e09cc4c704" xlink:to="loc_country_US_a44e19f6-7cdb-4315-ba86-da60c8e2288c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8c730ec7-dfe5-4303-8e43-a527a54eff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:to="loc_us-gaap_ForeignPlanMember_8c730ec7-dfe5-4303-8e43-a527a54eff9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8bf59a88-c206-4966-b13c-e9874447d541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8bf59a88-c206-4966-b13c-e9874447d541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8bf59a88-c206-4966-b13c-e9874447d541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8bf59a88-c206-4966-b13c-e9874447d541" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8bf59a88-c206-4966-b13c-e9874447d541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8bf59a88-c206-4966-b13c-e9874447d541" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0141d68a-dc28-415d-bc60-8fdb3bd11700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0141d68a-dc28-415d-bc60-8fdb3bd11700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_10df99fd-a67b-427a-8c35-7a4ebb1edacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_10df99fd-a67b-427a-8c35-7a4ebb1edacb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended" id="id48a7ebc80c347adb91934196cf86332_PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0bef6f87-7557-40ae-97c9-fe2185d0a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0bef6f87-7557-40ae-97c9-fe2185d0a8ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fc33bc4d-f7c8-4df4-9c6f-6a4e2926e317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fc33bc4d-f7c8-4df4-9c6f-6a4e2926e317" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ff966934-fa54-48fb-b55a-9883113c8e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ff966934-fa54-48fb-b55a-9883113c8e60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_623681fa-3849-4f99-a36c-a01cdc580186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_623681fa-3849-4f99-a36c-a01cdc580186" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_96c9351e-51f2-4ce1-8393-95f7e7078e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_96c9351e-51f2-4ce1-8393-95f7e7078e40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_8abd15f8-a589-4406-90ab-5fe3814339ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_8abd15f8-a589-4406-90ab-5fe3814339ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_48aea7b6-ebde-448a-bf4a-56cfc7fa64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_48aea7b6-ebde-448a-bf4a-56cfc7fa64ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_a304b6e3-e603-4394-aa7e-13e965ea57ed" xlink:href="mrk-20221231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_a304b6e3-e603-4394-aa7e-13e965ea57ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4866c6ff-f5b7-4bff-8852-1c253e21464f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_47d31ef0-ada7-4772-a75a-c6dd0622b6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_47d31ef0-ada7-4772-a75a-c6dd0622b6eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_09a99f4e-d3ef-46af-9779-9dabcc2a51f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_09a99f4e-d3ef-46af-9779-9dabcc2a51f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_90dbdf9f-ead2-42c8-8fa1-f8ec6a0c642c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_90dbdf9f-ead2-42c8-8fa1-f8ec6a0c642c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b07aa4c0-dc1b-46ab-956b-1eed08dfe252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b07aa4c0-dc1b-46ab-956b-1eed08dfe252" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_b91d8a4e-a0e5-4f91-ad43-80b18d64b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_b91d8a4e-a0e5-4f91-ad43-80b18d64b3a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_ceba279c-21a3-496c-b8d2-7d17741f4b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_ceba279c-21a3-496c-b8d2-7d17741f4b7f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_be79b84b-8598-40c3-904a-4adfa0b2c1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_be79b84b-8598-40c3-904a-4adfa0b2c1e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_6f13e01a-88f2-4136-9cff-416a4654270c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_6f13e01a-88f2-4136-9cff-416a4654270c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_082090d1-ad05-44d3-b0db-ae99a00431ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_082090d1-ad05-44d3-b0db-ae99a00431ef" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_aac78605-de60-4b7c-8d8c-bfe8806e8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_aac78605-de60-4b7c-8d8c-bfe8806e8adf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_333af41a-7ca4-459e-ba02-6ab961107573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_333af41a-7ca4-459e-ba02-6ab961107573" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges_bacdb8b0-cecd-4906-aebf-dbbd9129e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherChanges_bacdb8b0-cecd-4906-aebf-dbbd9129e9b9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9434ece2-c148-46ee-b84e-389282726c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ac48292c-4e60-45bb-afbd-df7bf1371caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ac48292c-4e60-45bb-afbd-df7bf1371caf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_99499492-fcec-4c26-85fa-a1a95f047b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_99499492-fcec-4c26-85fa-a1a95f047b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4b762f6e-361e-4b03-b624-10ae18dfc7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4b762f6e-361e-4b03-b624-10ae18dfc7e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1376977a-92ad-4d8d-93c2-3406da458b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1376977a-92ad-4d8d-93c2-3406da458b53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_53fe7f14-2940-4b6f-82ac-a20b3bbf3723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_53fe7f14-2940-4b6f-82ac-a20b3bbf3723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_53fe7f14-2940-4b6f-82ac-a20b3bbf3723_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_53fe7f14-2940-4b6f-82ac-a20b3bbf3723" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_53fe7f14-2940-4b6f-82ac-a20b3bbf3723_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_53fe7f14-2940-4b6f-82ac-a20b3bbf3723" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_cc4f04c6-8dad-4f63-b689-42e45a95e25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:to="loc_us-gaap_DomesticPlanMember_cc4f04c6-8dad-4f63-b689-42e45a95e25b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_38a4ae86-fa5f-4b7f-9b93-e8dba5924342" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_cc4f04c6-8dad-4f63-b689-42e45a95e25b" xlink:to="loc_country_US_38a4ae86-fa5f-4b7f-9b93-e8dba5924342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f580bb86-24c6-4569-a91a-f6204a941878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:to="loc_us-gaap_ForeignPlanMember_f580bb86-24c6-4569-a91a-f6204a941878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4171dd64-634c-46ef-8652-92875f4ad88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4171dd64-634c-46ef-8652-92875f4ad88a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4171dd64-634c-46ef-8652-92875f4ad88a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4171dd64-634c-46ef-8652-92875f4ad88a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4171dd64-634c-46ef-8652-92875f4ad88a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4171dd64-634c-46ef-8652-92875f4ad88a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ec339464-1475-432c-bbf3-e66dc849ac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ec339464-1475-432c-bbf3-e66dc849ac36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_de7d8caa-9630-49af-aac5-1f82e68453bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_de7d8caa-9630-49af-aac5-1f82e68453bb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="extended" id="i472a4b6e9aa44a7e8e8608ad82960d74_PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_83e1e2e3-cedf-4cd3-9329-350da71c6ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_83e1e2e3-cedf-4cd3-9329-350da71c6ce2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_b8151aee-f0cc-42a2-a674-72b92ad58357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_b8151aee-f0cc-42a2-a674-72b92ad58357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_eef13f16-cc61-4ea5-846a-09c6cb1f630d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_eef13f16-cc61-4ea5-846a-09c6cb1f630d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_cf13b0ed-60dd-4ebe-87a3-982ebc0bc0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_cf13b0ed-60dd-4ebe-87a3-982ebc0bc0e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_58dc492f-c053-4442-ba04-878efd07b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_58dc492f-c053-4442-ba04-878efd07b1ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_58dc492f-c053-4442-ba04-878efd07b1ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_58dc492f-c053-4442-ba04-878efd07b1ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_58dc492f-c053-4442-ba04-878efd07b1ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_58dc492f-c053-4442-ba04-878efd07b1ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_523d9326-5f3f-4445-bb61-041c0ce85632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:to="loc_us-gaap_DomesticPlanMember_523d9326-5f3f-4445-bb61-041c0ce85632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_da778408-fa92-4114-9171-52d915c748aa" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_523d9326-5f3f-4445-bb61-041c0ce85632" xlink:to="loc_country_US_da778408-fa92-4114-9171-52d915c748aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1103c9ea-ba18-40e1-a805-8fef9d3caaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:to="loc_us-gaap_ForeignPlanMember_1103c9ea-ba18-40e1-a805-8fef9d3caaba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_221f7762-f867-4f21-a2a3-707270964ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_221f7762-f867-4f21-a2a3-707270964ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_667ac5e5-5f54-4a2f-bca2-fce632bb31c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_221f7762-f867-4f21-a2a3-707270964ca6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_667ac5e5-5f54-4a2f-bca2-fce632bb31c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="extended" id="i5965b996bc9e4296adcdbb658b57bc89_PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56249f73-b4d0-461f-929e-5237bcdc4b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_df0a5234-6cdb-42f7-8cdb-6e555b2750b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56249f73-b4d0-461f-929e-5237bcdc4b2c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_df0a5234-6cdb-42f7-8cdb-6e555b2750b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56249f73-b4d0-461f-929e-5237bcdc4b2c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_307067f3-e924-4152-b5a0-a8a9ee1578d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_307067f3-e924-4152-b5a0-a8a9ee1578d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_307067f3-e924-4152-b5a0-a8a9ee1578d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_307067f3-e924-4152-b5a0-a8a9ee1578d3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_307067f3-e924-4152-b5a0-a8a9ee1578d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_307067f3-e924-4152-b5a0-a8a9ee1578d3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0a8b052-dd41-418b-8293-94f8ea65875b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:to="loc_us-gaap_DomesticPlanMember_e0a8b052-dd41-418b-8293-94f8ea65875b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f2d04a96-cc06-49ce-8815-6512ac3ba0b6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_e0a8b052-dd41-418b-8293-94f8ea65875b" xlink:to="loc_country_US_f2d04a96-cc06-49ce-8815-6512ac3ba0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f51415d6-52c7-491e-8d66-5cb6b51bbee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:to="loc_us-gaap_ForeignPlanMember_f51415d6-52c7-491e-8d66-5cb6b51bbee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a03ed3e3-b263-40fa-9171-5db1140724eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a03ed3e3-b263-40fa-9171-5db1140724eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a03ed3e3-b263-40fa-9171-5db1140724eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a03ed3e3-b263-40fa-9171-5db1140724eb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a03ed3e3-b263-40fa-9171-5db1140724eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b0447e55-e264-4dea-8baa-e4a0199622c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a03ed3e3-b263-40fa-9171-5db1140724eb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b0447e55-e264-4dea-8baa-e4a0199622c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1c7d3cbe-13b9-4d73-b96f-f82ff1d18b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b0447e55-e264-4dea-8baa-e4a0199622c7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1c7d3cbe-13b9-4d73-b96f-f82ff1d18b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3d7cf8c-9182-4db2-9075-8f38074af86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3d7cf8c-9182-4db2-9075-8f38074af86f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e3d7cf8c-9182-4db2-9075-8f38074af86f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3d7cf8c-9182-4db2-9075-8f38074af86f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e3d7cf8c-9182-4db2-9075-8f38074af86f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3d7cf8c-9182-4db2-9075-8f38074af86f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_304b6375-a9de-4c60-a6c2-505358125431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_304b6375-a9de-4c60-a6c2-505358125431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2a1cc875-7fa3-4b59-ab63-5b839853a62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2a1cc875-7fa3-4b59-ab63-5b839853a62e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_173d2214-e3f2-474e-b53d-3b39f6e08ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_173d2214-e3f2-474e-b53d-3b39f6e08ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_abb43f00-9d98-4d5d-b273-497696b940a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_abb43f00-9d98-4d5d-b273-497696b940a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_34dc72f2-8b87-424d-91bb-97cc4e846f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_34dc72f2-8b87-424d-91bb-97cc4e846f31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_1cf09d31-5ec1-4332-a84d-281b40038fd2" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_1cf09d31-5ec1-4332-a84d-281b40038fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_39d128ec-2b26-442f-9f1a-6f1e0e661ef5" xlink:href="mrk-20221231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_39d128ec-2b26-442f-9f1a-6f1e0e661ef5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_c58a662e-62ae-4414-a551-745b2f6fbd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_c58a662e-62ae-4414-a551-745b2f6fbd9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e51762c2-619a-4d6a-a26d-4755b03e6c5a" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e51762c2-619a-4d6a-a26d-4755b03e6c5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_13215550-0757-4842-ac9c-e4fc75ea85b2" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_13215550-0757-4842-ac9c-e4fc75ea85b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_71f06ff4-d0b8-4580-b6fd-b7915ebacd25" xlink:href="mrk-20221231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_71f06ff4-d0b8-4580-b6fd-b7915ebacd25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_4d9dca88-7a2d-453b-8067-9b154ac3dece" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_4d9dca88-7a2d-453b-8067-9b154ac3dece" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_b107d8e8-1e8a-4fbc-b9bf-93b4c78763c6" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_b107d8e8-1e8a-4fbc-b9bf-93b4c78763c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_ae895c43-8608-4ff7-82b8-8a3cae9b936e" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_ae895c43-8608-4ff7-82b8-8a3cae9b936e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_a2c2a539-8f43-4368-9cb9-c82a151d6503" xlink:href="mrk-20221231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_a2c2a539-8f43-4368-9cb9-c82a151d6503" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDerivativeMember_b616939e-6a8e-4f8c-bfb6-460d6677a125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_DefinedBenefitPlanDerivativeMember_b616939e-6a8e-4f8c-bfb6-460d6677a125" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_093d4fad-5d26-426d-acb8-b269cc9ea1e2" xlink:href="mrk-20221231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_093d4fad-5d26-426d-acb8-b269cc9ea1e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_5faa53a0-270b-4c26-bb2e-cfead2037e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_OtherInvestmentsMember_5faa53a0-270b-4c26-bb2e-cfead2037e14" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="extended" id="id26805eb687d4a69a4c38e4e4b07bfd6_PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_422a0d87-1016-45a3-ae53-fb5ddc966785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_422a0d87-1016-45a3-ae53-fb5ddc966785" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b8cf3dfd-ead1-48fe-a5a6-de7ab167acfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b8cf3dfd-ead1-48fe-a5a6-de7ab167acfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_396712bf-374c-43c0-995b-d1d22ec6650a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_396712bf-374c-43c0-995b-d1d22ec6650a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_0fe352d8-b573-4f10-8f81-d25f28d0b0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_0fe352d8-b573-4f10-8f81-d25f28d0b0bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_a0d9d2c7-bc8a-4073-aed0-432f5e7d5300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_a0d9d2c7-bc8a-4073-aed0-432f5e7d5300" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_a5b4cbd8-9e96-491d-b237-1113041d44f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_a5b4cbd8-9e96-491d-b237-1113041d44f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_10018534-d82f-4cf2-8697-e0408ebec43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_422a0d87-1016-45a3-ae53-fb5ddc966785" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_eb2eccdc-5e80-487d-94cc-b41d5f753720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_eb2eccdc-5e80-487d-94cc-b41d5f753720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_eb2eccdc-5e80-487d-94cc-b41d5f753720_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_eb2eccdc-5e80-487d-94cc-b41d5f753720" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_eb2eccdc-5e80-487d-94cc-b41d5f753720_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_eb2eccdc-5e80-487d-94cc-b41d5f753720" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_53cdadc9-2879-4a4e-8c44-f12acb05fb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:to="loc_us-gaap_DomesticPlanMember_53cdadc9-2879-4a4e-8c44-f12acb05fb6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6cfd1412-8ada-4c3c-bb69-9224f5b69df4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_53cdadc9-2879-4a4e-8c44-f12acb05fb6b" xlink:to="loc_country_US_6cfd1412-8ada-4c3c-bb69-9224f5b69df4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ad3a5df7-45a4-49ed-bc25-01657a8c9174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:to="loc_us-gaap_ForeignPlanMember_ad3a5df7-45a4-49ed-bc25-01657a8c9174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cd100c10-f324-48dd-861f-c78abedd0323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cd100c10-f324-48dd-861f-c78abedd0323" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_cd100c10-f324-48dd-861f-c78abedd0323_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cd100c10-f324-48dd-861f-c78abedd0323" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_cd100c10-f324-48dd-861f-c78abedd0323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_aaeff9ad-ee30-4701-ac09-629de5ae5a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cd100c10-f324-48dd-861f-c78abedd0323" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_aaeff9ad-ee30-4701-ac09-629de5ae5a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6e4a1324-6e59-4af6-949f-268359d05fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_aaeff9ad-ee30-4701-ac09-629de5ae5a0e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6e4a1324-6e59-4af6-949f-268359d05fd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54075c31-f1ac-4a46-b1a4-6a60c095bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54075c31-f1ac-4a46-b1a4-6a60c095bb05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54075c31-f1ac-4a46-b1a4-6a60c095bb05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54075c31-f1ac-4a46-b1a4-6a60c095bb05" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54075c31-f1ac-4a46-b1a4-6a60c095bb05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa385b73-1275-4c34-b374-c2b5c174939b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54075c31-f1ac-4a46-b1a4-6a60c095bb05" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa385b73-1275-4c34-b374-c2b5c174939b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0d55d67a-001c-44ca-bd98-1de1d2d76789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa385b73-1275-4c34-b374-c2b5c174939b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0d55d67a-001c-44ca-bd98-1de1d2d76789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a88dd9b9-0181-44ea-8228-c18c9df3be70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a88dd9b9-0181-44ea-8228-c18c9df3be70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a88dd9b9-0181-44ea-8228-c18c9df3be70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a88dd9b9-0181-44ea-8228-c18c9df3be70" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a88dd9b9-0181-44ea-8228-c18c9df3be70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a88dd9b9-0181-44ea-8228-c18c9df3be70" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_0dec382f-0bba-495d-8f2a-d3df14a25ab9" xlink:href="mrk-20221231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_0dec382f-0bba-495d-8f2a-d3df14a25ab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_fff75a55-9ec3-479d-9501-b7c4ad650463" xlink:href="mrk-20221231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_fff75a55-9ec3-479d-9501-b7c4ad650463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_84b237ce-23a1-4e39-a60b-b3095828beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:to="loc_us-gaap_OtherInvestmentsMember_84b237ce-23a1-4e39-a60b-b3095828beaf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="extended" id="i4fe161900c714a4bbcd71c2385ca9a23_PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5f6cf72b-d1ff-4d43-8cf2-055942871ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_482bbee9-a1ff-4298-9e24-69a00637fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5f6cf72b-d1ff-4d43-8cf2-055942871ac1" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_482bbee9-a1ff-4298-9e24-69a00637fc6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5f6cf72b-d1ff-4d43-8cf2-055942871ac1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c69c2793-accd-401c-90cf-05130a583ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c69c2793-accd-401c-90cf-05130a583ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c69c2793-accd-401c-90cf-05130a583ba5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c69c2793-accd-401c-90cf-05130a583ba5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c69c2793-accd-401c-90cf-05130a583ba5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_670533d1-8e3a-4f8e-ae2d-014a54839f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c69c2793-accd-401c-90cf-05130a583ba5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_670533d1-8e3a-4f8e-ae2d-014a54839f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_190d9dd8-c2ef-47da-b920-54672b1e60e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_670533d1-8e3a-4f8e-ae2d-014a54839f4d" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_190d9dd8-c2ef-47da-b920-54672b1e60e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_07aa790a-2125-4942-8f8f-3d2b2f76254c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_07aa790a-2125-4942-8f8f-3d2b2f76254c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07aa790a-2125-4942-8f8f-3d2b2f76254c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_07aa790a-2125-4942-8f8f-3d2b2f76254c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07aa790a-2125-4942-8f8f-3d2b2f76254c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_07aa790a-2125-4942-8f8f-3d2b2f76254c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4f0a84ea-ec0f-4a3d-ba9e-808ad63f9e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4f0a84ea-ec0f-4a3d-ba9e-808ad63f9e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97f95799-6bd5-4a09-8dc2-1f41873b82af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97f95799-6bd5-4a09-8dc2-1f41873b82af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f93a2821-4f97-4715-8cad-c957819a64c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f93a2821-4f97-4715-8cad-c957819a64c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1532be3b-b2eb-4833-8c90-98f25b73fc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1532be3b-b2eb-4833-8c90-98f25b73fc47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_77a17012-296b-4a7d-adf7-20efce750f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_77a17012-296b-4a7d-adf7-20efce750f8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_77a17012-296b-4a7d-adf7-20efce750f8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_77a17012-296b-4a7d-adf7-20efce750f8a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_77a17012-296b-4a7d-adf7-20efce750f8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_77a17012-296b-4a7d-adf7-20efce750f8a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_fdfff5ca-a8d3-4d3e-98fd-7559b0cad478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_fdfff5ca-a8d3-4d3e-98fd-7559b0cad478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_cc012be2-2204-4d9f-910a-8d9317a47d26" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_cc012be2-2204-4d9f-910a-8d9317a47d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_5e601482-fc3e-4468-9271-b6ed8e19242c" xlink:href="mrk-20221231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_5e601482-fc3e-4468-9271-b6ed8e19242c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7ede4cea-2991-4b56-b4c6-da9647185220" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7ede4cea-2991-4b56-b4c6-da9647185220" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_e6ed70eb-5aa8-49ad-be24-1359891b990e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_e6ed70eb-5aa8-49ad-be24-1359891b990e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_33b9bf96-42bf-45a9-9bb8-bebae81522bc" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_33b9bf96-42bf-45a9-9bb8-bebae81522bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4369dfe1-e994-4f1d-9283-526dae3ace7c" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4369dfe1-e994-4f1d-9283-526dae3ace7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_6aac18a6-7d7e-44e4-8079-f99569937b7d" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_6aac18a6-7d7e-44e4-8079-f99569937b7d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8b5aee6b-2f29-49e1-ac41-f7bf5e615479" xlink:href="mrk-20221231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8b5aee6b-2f29-49e1-ac41-f7bf5e615479" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDerivativeMember_9a57042d-25e8-4179-bb48-4e195396fd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_us-gaap_DefinedBenefitPlanDerivativeMember_9a57042d-25e8-4179-bb48-4e195396fd16" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="extended" id="i70a5fc843e1740e3be02c88fb7a75320_PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_6013a832-7b75-4e5e-861d-456e21e6b7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_6013a832-7b75-4e5e-861d-456e21e6b7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_93d903d8-6f98-445f-aacc-e435e4ac8bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_93d903d8-6f98-445f-aacc-e435e4ac8bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_2b762a1a-a48c-44ab-b4f6-4156d2e99308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_2b762a1a-a48c-44ab-b4f6-4156d2e99308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_1ce2addc-70e8-4609-a652-7c55da549b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_1ce2addc-70e8-4609-a652-7c55da549b88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fc3a6d73-e406-485e-b908-f659445316fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fc3a6d73-e406-485e-b908-f659445316fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b2adcd5e-34bb-445f-8077-f9c00d2b2df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b2adcd5e-34bb-445f-8077-f9c00d2b2df6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_542f40f3-96db-482b-b94c-b62c970be16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_542f40f3-96db-482b-b94c-b62c970be16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_542f40f3-96db-482b-b94c-b62c970be16a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_542f40f3-96db-482b-b94c-b62c970be16a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_542f40f3-96db-482b-b94c-b62c970be16a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_542f40f3-96db-482b-b94c-b62c970be16a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_60cfb909-b32b-4549-a1ed-8e3a330b20a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:to="loc_us-gaap_DomesticPlanMember_60cfb909-b32b-4549-a1ed-8e3a330b20a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bec0223e-59d9-4455-8e0d-c122c7fc0b0a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_60cfb909-b32b-4549-a1ed-8e3a330b20a2" xlink:to="loc_country_US_bec0223e-59d9-4455-8e0d-c122c7fc0b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4d17c7b7-032b-4db6-a543-1300b95927c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:to="loc_us-gaap_ForeignPlanMember_4d17c7b7-032b-4db6-a543-1300b95927c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3768ca39-299a-4e1c-8d87-624146e9b899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3768ca39-299a-4e1c-8d87-624146e9b899" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3768ca39-299a-4e1c-8d87-624146e9b899_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3768ca39-299a-4e1c-8d87-624146e9b899" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3768ca39-299a-4e1c-8d87-624146e9b899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3768ca39-299a-4e1c-8d87-624146e9b899" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f0762728-12d6-4988-ba62-1925fd0271ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f0762728-12d6-4988-ba62-1925fd0271ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c21368eb-249b-4d94-b294-0afb0bfe0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c21368eb-249b-4d94-b294-0afb0bfe0d89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended" id="i2ec4a65b0ae548a29180a903f342adaf_PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c675e617-ca21-4c9b-8522-306e187b5ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c675e617-ca21-4c9b-8522-306e187b5ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_81e84a59-c3df-44e1-8ac2-c14b0c00114f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_81e84a59-c3df-44e1-8ac2-c14b0c00114f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_202a3196-132d-479a-bafe-bfca9669e543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_202a3196-132d-479a-bafe-bfca9669e543" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f036c432-e10a-42b6-a9d7-8e6d5ddb1262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f036c432-e10a-42b6-a9d7-8e6d5ddb1262" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_b45d714f-d300-47a1-96eb-7742003edeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_b45d714f-d300-47a1-96eb-7742003edeae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_292c54e7-fc72-4d52-84ab-42307f8a9391" xlink:href="mrk-20221231.xsd#mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_292c54e7-fc72-4d52-84ab-42307f8a9391" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_74166707-6eac-44e2-89bf-2cf2fa15de13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_74166707-6eac-44e2-89bf-2cf2fa15de13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5f7e0bba-58a1-4590-81c8-23cf3cf5e419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5f7e0bba-58a1-4590-81c8-23cf3cf5e419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f7e0bba-58a1-4590-81c8-23cf3cf5e419_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5f7e0bba-58a1-4590-81c8-23cf3cf5e419" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f7e0bba-58a1-4590-81c8-23cf3cf5e419_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5f7e0bba-58a1-4590-81c8-23cf3cf5e419" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_14b81b03-86b8-4653-bb06-3716549eaadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:to="loc_us-gaap_DomesticPlanMember_14b81b03-86b8-4653-bb06-3716549eaadf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9d851903-a957-4292-b3ac-87261b83be92" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_14b81b03-86b8-4653-bb06-3716549eaadf" xlink:to="loc_country_US_9d851903-a957-4292-b3ac-87261b83be92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9053c623-2403-42ee-82de-5a79c4a0954a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:to="loc_us-gaap_ForeignPlanMember_9053c623-2403-42ee-82de-5a79c4a0954a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_627343cf-382c-4153-bb63-6174db512f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_627343cf-382c-4153-bb63-6174db512f34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_627343cf-382c-4153-bb63-6174db512f34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_627343cf-382c-4153-bb63-6174db512f34" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_627343cf-382c-4153-bb63-6174db512f34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_627343cf-382c-4153-bb63-6174db512f34" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c237cea0-4c22-4c50-8885-5d8802dfd724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c237cea0-4c22-4c50-8885-5d8802dfd724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9d20dd62-0d45-4d3b-8205-d0f6ffab2182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9d20dd62-0d45-4d3b-8205-d0f6ffab2182" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="extended" id="ib5003f61e76c4d49a313dd8a9736a4ff_PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_e7a5a727-4388-4af6-82c7-ffa81649f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_e7a5a727-4388-4af6-82c7-ffa81649f72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_4a95c2f6-46d9-40f2-8838-1e07828b04dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_4a95c2f6-46d9-40f2-8838-1e07828b04dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_b57f98a4-2811-4eff-a33b-e6b00b61349d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_b57f98a4-2811-4eff-a33b-e6b00b61349d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_9b1daec7-38c6-4647-9147-7af79b43e290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_9b1daec7-38c6-4647-9147-7af79b43e290" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3d6b3492-c6ad-4547-8a6e-75517f063362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3d6b3492-c6ad-4547-8a6e-75517f063362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2dafef07-98e7-4894-855b-a3b5dbdd4405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2dafef07-98e7-4894-855b-a3b5dbdd4405" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_3e602233-c8bd-431a-87c2-9dab53596ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_3e602233-c8bd-431a-87c2-9dab53596ea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_24170e31-53dd-45e4-97a4-bdd55a595b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_24170e31-53dd-45e4-97a4-bdd55a595b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_24170e31-53dd-45e4-97a4-bdd55a595b5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_24170e31-53dd-45e4-97a4-bdd55a595b5c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_24170e31-53dd-45e4-97a4-bdd55a595b5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_24170e31-53dd-45e4-97a4-bdd55a595b5c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_53c2f674-1fa2-4818-9fe8-69d16018e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:to="loc_us-gaap_DomesticPlanMember_53c2f674-1fa2-4818-9fe8-69d16018e426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7b00c3bc-e66e-444d-8aec-bff170f9bfc0" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_53c2f674-1fa2-4818-9fe8-69d16018e426" xlink:to="loc_country_US_7b00c3bc-e66e-444d-8aec-bff170f9bfc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d5bdcb7e-ee47-4e2c-994f-df3e47a41e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:to="loc_us-gaap_ForeignPlanMember_d5bdcb7e-ee47-4e2c-994f-df3e47a41e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e516b013-b988-40d1-a8e2-1302fcea3eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e516b013-b988-40d1-a8e2-1302fcea3eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4fe16f19-cdbe-4e76-a690-d68245369fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e516b013-b988-40d1-a8e2-1302fcea3eb4" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4fe16f19-cdbe-4e76-a690-d68245369fdc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="extended" id="i1051dc83c8b2443ab1e79f34cda756c8_PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_5d4b3c81-c96a-4308-a1a8-f83198fe0dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_5d4b3c81-c96a-4308-a1a8-f83198fe0dd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_187603ee-d689-4581-ad8f-8f87e9204fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_187603ee-d689-4581-ad8f-8f87e9204fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b1f72153-f6b2-443d-944b-30e792d66175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b1f72153-f6b2-443d-944b-30e792d66175" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c67aaf56-e9d7-46df-b3fe-7a699ee85b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b1f72153-f6b2-443d-944b-30e792d66175" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c67aaf56-e9d7-46df-b3fe-7a699ee85b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c67aaf56-e9d7-46df-b3fe-7a699ee85b96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c67aaf56-e9d7-46df-b3fe-7a699ee85b96" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c67aaf56-e9d7-46df-b3fe-7a699ee85b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c34999c6-06e5-4b0d-aea6-e59306d612c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c67aaf56-e9d7-46df-b3fe-7a699ee85b96" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c34999c6-06e5-4b0d-aea6-e59306d612c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6312089b-9949-4041-b93a-1859d7091a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c34999c6-06e5-4b0d-aea6-e59306d612c5" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6312089b-9949-4041-b93a-1859d7091a68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended" id="iffe2713a896a4b2da668207a572c08e1_OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:href="mrk-20221231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c3bb0084-e073-4993-8a58-52f7c2c2b82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c3bb0084-e073-4993-8a58-52f7c2c2b82b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1753da94-b734-4246-86f3-0a993beab09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_InterestExpense_1753da94-b734-4246-86f3-0a993beab09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_469cdf50-887c-44c7-a22d-bd9e0c14bb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_469cdf50-887c-44c7-a22d-bd9e0c14bb68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6bb0c2fc-20fc-45f0-9883-6e5e139ccea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6bb0c2fc-20fc-45f0-9883-6e5e139ccea1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7f66fc64-3ecd-4af8-bcaa-c090551f714e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7f66fc64-3ecd-4af8-bcaa-c090551f714e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_f9994430-b58f-4e1d-95b9-d4ad51cbd7f8" xlink:href="mrk-20221231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_f9994430-b58f-4e1d-95b9-d4ad51cbd7f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_93800ef9-694a-4aaa-adad-73e98a77e45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_93800ef9-694a-4aaa-adad-73e98a77e45d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3d14b2f4-31bf-4309-844a-1ee3fcfd4cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3d14b2f4-31bf-4309-844a-1ee3fcfd4cea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:href="mrk-20221231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_dba666cb-7f37-41b4-aa10-088344ca6d2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:to="loc_srt_StatementScenarioAxis_dba666cb-7f37-41b4-aa10-088344ca6d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dba666cb-7f37-41b4-aa10-088344ca6d2f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_dba666cb-7f37-41b4-aa10-088344ca6d2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_dba666cb-7f37-41b4-aa10-088344ca6d2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fb4bb794-f04b-47b4-ba83-2f7239b38194" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_dba666cb-7f37-41b4-aa10-088344ca6d2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fb4bb794-f04b-47b4-ba83-2f7239b38194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d506540a-5cda-40d8-8513-35436ee3f83c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fb4bb794-f04b-47b4-ba83-2f7239b38194" xlink:to="loc_srt_ScenarioForecastMember_d506540a-5cda-40d8-8513-35436ee3f83c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8242a9a8-e884-48c5-b35c-ea789baea0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8242a9a8-e884-48c5-b35c-ea789baea0d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_877eeb95-e116-4922-8dce-52c8a2cfcd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8242a9a8-e884-48c5-b35c-ea789baea0d2" xlink:to="loc_us-gaap_SubsequentEventMember_877eeb95-e116-4922-8dce-52c8a2cfcd35" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="extended" id="id3db816a4401479dae16350bb13ce410_TaxesonIncomeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_8d373fcf-d244-4dc0-bb16-787268424f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_8d373fcf-d244-4dc0-bb16-787268424f41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0215b8eb-417e-4b20-9a40-9802311f94f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0215b8eb-417e-4b20-9a40-9802311f94f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_05606cb6-94cb-4954-8b56-b26d91c84e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_05606cb6-94cb-4954-8b56-b26d91c84e53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_a7e16a1c-0ef4-4d23-9a11-58197730da86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_a7e16a1c-0ef4-4d23-9a11-58197730da86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_2b89ebbf-6ecf-462b-a522-29fd5dd61383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_2b89ebbf-6ecf-462b-a522-29fd5dd61383" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_ca24c010-3855-445e-876e-e5e9f4d944b1" xlink:href="mrk-20221231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_ca24c010-3855-445e-876e-e5e9f4d944b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_dd6fdc8e-2326-4c19-a4ac-13ba15700eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_IncomeTaxesPaid_dd6fdc8e-2326-4c19-a4ac-13ba15700eff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_97c31835-693c-4729-ac98-6f1048e03598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_97c31835-693c-4729-ac98-6f1048e03598" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a5bb836e-5375-4e7b-8367-c90253d52340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a5bb836e-5375-4e7b-8367-c90253d52340" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77c0ebd2-12b5-4714-94ce-3d68034d6e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77c0ebd2-12b5-4714-94ce-3d68034d6e6d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2dee0108-74ed-45c0-80e6-0987121a1993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2dee0108-74ed-45c0-80e6-0987121a1993" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_112aff26-d41e-4fe1-8f1d-c78cd91bebb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_112aff26-d41e-4fe1-8f1d-c78cd91bebb8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_65cb8f6a-09a4-46bf-930d-c64a018e18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_65cb8f6a-09a4-46bf-930d-c64a018e18e8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_621de120-4360-4602-97f4-2134a0d6865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_621de120-4360-4602-97f4-2134a0d6865c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_46d4e12d-9f48-45eb-a5d5-640fc0362028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_46d4e12d-9f48-45eb-a5d5-640fc0362028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_46d4e12d-9f48-45eb-a5d5-640fc0362028_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46d4e12d-9f48-45eb-a5d5-640fc0362028" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_46d4e12d-9f48-45eb-a5d5-640fc0362028_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46d4e12d-9f48-45eb-a5d5-640fc0362028" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e0fd8c6c-b501-49f9-b7ce-78f38669f65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:to="loc_us-gaap_ForeignCountryMember_e0fd8c6c-b501-49f9-b7ce-78f38669f65a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_af7f5050-f85f-4c8c-8088-ddd2d3a80403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:to="loc_us-gaap_DomesticCountryMember_af7f5050-f85f-4c8c-8088-ddd2d3a80403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_a2dfdfe6-b70a-449a-ab27-ba7662a3956c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_a2dfdfe6-b70a-449a-ab27-ba7662a3956c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_aa39fece-3ee9-4743-b3fa-8a9dcf61f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a2dfdfe6-b70a-449a-ab27-ba7662a3956c" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_aa39fece-3ee9-4743-b3fa-8a9dcf61f7cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_3ebce888-0e64-4bbd-b23f-02077e6081c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_3ebce888-0e64-4bbd-b23f-02077e6081c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_3ebce888-0e64-4bbd-b23f-02077e6081c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_3ebce888-0e64-4bbd-b23f-02077e6081c3" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_3ebce888-0e64-4bbd-b23f-02077e6081c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_3ebce888-0e64-4bbd-b23f-02077e6081c3" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_d47b14c2-b89d-4e04-bdbb-da01957ebf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_d47b14c2-b89d-4e04-bdbb-da01957ebf6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_87925e34-6a3e-4594-8baa-f64506ba9d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_87925e34-6a3e-4594-8baa-f64506ba9d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_042b361e-7b27-45bf-8fa7-078286a270dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_042b361e-7b27-45bf-8fa7-078286a270dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_042b361e-7b27-45bf-8fa7-078286a270dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_042b361e-7b27-45bf-8fa7-078286a270dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_042b361e-7b27-45bf-8fa7-078286a270dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_042b361e-7b27-45bf-8fa7-078286a270dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember_18414c8e-8e26-4d52-90c2-049712c21316" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:to="loc_mrk_IncomeTaxesPayableMember_18414c8e-8e26-4d52-90c2-049712c21316" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1e4b1f95-caf1-4d55-a7f9-d1c662219653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1e4b1f95-caf1-4d55-a7f9-d1c662219653" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended" id="i73f3648476bb46fea887fffad40c087f_TaxesonIncomeDeferredIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_714537bc-8525-4caf-89fd-db3e3e5e6d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_714537bc-8525-4caf-89fd-db3e3e5e6d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_16e3984a-6cdf-4c01-9876-bcc246952126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_16e3984a-6cdf-4c01-9876-bcc246952126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_aceb4461-160d-4e3d-9653-ff8fd353e371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_aceb4461-160d-4e3d-9653-ff8fd353e371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_865259c0-7060-4d4f-be4e-2875a8f27dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_865259c0-7060-4d4f-be4e-2875a8f27dc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_4ec73736-b351-4574-8a90-0d7608b5c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_4ec73736-b351-4574-8a90-0d7608b5c89b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_e4d4ae07-4634-4ccc-b60a-3aa53b09b893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_e4d4ae07-4634-4ccc-b60a-3aa53b09b893" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_997cb00f-aed5-402a-bee0-168d30254401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_997cb00f-aed5-402a-bee0-168d30254401" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_f0b09208-19bc-43f1-9cf1-9f27eb081993" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_f0b09208-19bc-43f1-9cf1-9f27eb081993" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_3d15359f-23a8-451c-a937-e98c6cef43a7" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_3d15359f-23a8-451c-a937-e98c6cef43a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f6a79533-a50b-4d79-a080-dc70df02cfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f6a79533-a50b-4d79-a080-dc70df02cfbc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2c4d4dd8-309e-418a-b3d1-1d4ef34b9dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2c4d4dd8-309e-418a-b3d1-1d4ef34b9dac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5f341477-a913-41f0-8337-8e7b7d47314b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5f341477-a913-41f0-8337-8e7b7d47314b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4292dda8-80fd-4ae4-b041-67e72e786b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4292dda8-80fd-4ae4-b041-67e72e786b9c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7147e1e5-0cd5-4689-91c3-3c7833ad9192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7147e1e5-0cd5-4689-91c3-3c7833ad9192" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_941b7127-478e-482c-8161-f68fb6b3ef1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_941b7127-478e-482c-8161-f68fb6b3ef1a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_af4ae06e-1e6f-48f8-a091-e25acc63daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_af4ae06e-1e6f-48f8-a091-e25acc63daf9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_57331cf9-6cf4-43b9-a02b-832c870bf35f" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_57331cf9-6cf4-43b9-a02b-832c870bf35f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_76f50129-d4a5-448e-8fdc-b4f93f9a8136" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_76f50129-d4a5-448e-8fdc-b4f93f9a8136" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_79affc51-00cf-4484-882d-a5524b210785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_79affc51-00cf-4484-882d-a5524b210785" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fe3389bb-c222-416e-a9e1-e6c0f6f52e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_fe3389bb-c222-416e-a9e1-e6c0f6f52e64" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_33bcafa8-a672-481f-b6fd-9abdef023080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilities_33bcafa8-a672-481f-b6fd-9abdef023080" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_37965362-c340-4588-9957-76b6c5d6bc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_37965362-c340-4588-9957-76b6c5d6bc1a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_ad7ebf73-2425-4839-87ee-743d5a115b8d" xlink:href="mrk-20221231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_ad7ebf73-2425-4839-87ee-743d5a115b8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_67acebf9-54ca-47b0-b537-89050188a0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_ad7ebf73-2425-4839-87ee-743d5a115b8d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_67acebf9-54ca-47b0-b537-89050188a0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_67acebf9-54ca-47b0-b537-89050188a0b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_67acebf9-54ca-47b0-b537-89050188a0b0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_67acebf9-54ca-47b0-b537-89050188a0b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_37e36c59-76ae-4ba3-9a4a-9e4a95a98442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_67acebf9-54ca-47b0-b537-89050188a0b0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_37e36c59-76ae-4ba3-9a4a-9e4a95a98442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_98f6e920-043f-43cd-a6f1-c4b80a65a1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_37e36c59-76ae-4ba3-9a4a-9e4a95a98442" xlink:to="loc_us-gaap_OtherAssetsMember_98f6e920-043f-43cd-a6f1-c4b80a65a1f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeIncomeTaxAuthorityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails" xlink:type="extended" id="i82994ebb9fa745dcaca44b7b97974e4c_TaxesonIncomeIncomeTaxAuthorityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_bf0754fc-53e7-4421-a3ec-9f889bab7268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_f4cb3f6d-a33f-470f-90ca-4c2c6b70b530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_bf0754fc-53e7-4421-a3ec-9f889bab7268" xlink:to="loc_us-gaap_IncomeTaxesPaid_f4cb3f6d-a33f-470f-90ca-4c2c6b70b530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_abde9997-6976-4f86-b7a1-817177d00059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_bf0754fc-53e7-4421-a3ec-9f889bab7268" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_abde9997-6976-4f86-b7a1-817177d00059" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_307b2951-1b2a-440c-9bbc-1095e76efb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_abde9997-6976-4f86-b7a1-817177d00059" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_307b2951-1b2a-440c-9bbc-1095e76efb3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_307b2951-1b2a-440c-9bbc-1095e76efb3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_307b2951-1b2a-440c-9bbc-1095e76efb3f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_307b2951-1b2a-440c-9bbc-1095e76efb3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_307b2951-1b2a-440c-9bbc-1095e76efb3f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_68bc5c6d-37e2-4156-afaa-7c013b91b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:to="loc_us-gaap_DomesticCountryMember_68bc5c6d-37e2-4156-afaa-7c013b91b5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_77174a8f-042d-43e7-bbcd-5797a977e757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:to="loc_us-gaap_ForeignCountryMember_77174a8f-042d-43e7-bbcd-5797a977e757" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i1fcc3783a8804bc1a18f4f7e2df86c6d_OtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7be32586-497b-49db-85a2-c64937d5d113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7be32586-497b-49db-85a2-c64937d5d113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_fb01580a-af79-4e5f-b65d-7c3a8c5d8708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_fb01580a-af79-4e5f-b65d-7c3a8c5d8708" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f598ad0d-441c-4834-83f8-dc6e844804e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f598ad0d-441c-4834-83f8-dc6e844804e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b3f26f31-b392-4184-b2cc-752d9d4a09be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b3f26f31-b392-4184-b2cc-752d9d4a09be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fbb73004-b166-48a7-8f6c-cd1e179c5169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fbb73004-b166-48a7-8f6c-cd1e179c5169" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_878f2ab1-69a3-4c4a-b7f0-ca2315c95b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_878f2ab1-69a3-4c4a-b7f0-ca2315c95b2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_27ecd9fb-ef65-49c4-92fe-c2a0f6736f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_27ecd9fb-ef65-49c4-92fe-c2a0f6736f72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e442bcec-35a5-4dee-bb24-a61af595b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e442bcec-35a5-4dee-bb24-a61af595b4fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_599e7e48-f75c-4bcf-8be4-45291fb10c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_599e7e48-f75c-4bcf-8be4-45291fb10c65" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb7c807c-974b-4eae-ae91-463593b63b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_38dff1cb-79b0-47b0-8331-b5f56b74211c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_38dff1cb-79b0-47b0-8331-b5f56b74211c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_984343f9-82f2-4533-886c-7167f9b0fd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_984343f9-82f2-4533-886c-7167f9b0fd0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_984343f9-82f2-4533-886c-7167f9b0fd0c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7" xlink:to="loc_us-gaap_EquityComponentDomain_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7" xlink:to="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_479b764e-d6d8-4898-a983-3e76fd0dced0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_479b764e-d6d8-4898-a983-3e76fd0dced0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d5a7d92e-154f-4c83-8bd5-90155574b526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d5a7d92e-154f-4c83-8bd5-90155574b526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember_5f333d00-3e86-41e3-a177-5ab4f93a4719" xlink:href="mrk-20221231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_PensionPlanNetLossMember_5f333d00-3e86-41e3-a177-5ab4f93a4719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_a9d41b45-8b0b-45c9-b8d6-2e2b46f6650d" xlink:href="mrk-20221231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_a9d41b45-8b0b-45c9-b8d6-2e2b46f6650d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember_2257cfd7-2b47-44e8-a718-3d51b05964de" xlink:href="mrk-20221231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_PensionPlanPriorServiceCostMember_2257cfd7-2b47-44e8-a718-3d51b05964de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_e9bc9b4d-8a45-4dc8-9eeb-0e0c5ecd12cb" xlink:href="mrk-20221231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_e9bc9b4d-8a45-4dc8-9eeb-0e0c5ecd12cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_17e12789-4b2a-421c-a2da-7d526d6557fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_17e12789-4b2a-421c-a2da-7d526d6557fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30904ab8-af40-4932-ac61-352498a2761d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30904ab8-af40-4932-ac61-352498a2761d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended" id="i425770d441584ac09d6559deeddda4f3_SegmentReportingSalesofCompanysProductsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_28049d95-182a-46eb-a0f2-f4958f3310e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:to="loc_us-gaap_Revenues_28049d95-182a-46eb-a0f2-f4958f3310e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncreaseDecreaseInHedgeRevenue_fd13faa9-50d5-404c-92ae-fc045e6ba283" xlink:href="mrk-20221231.xsd#mrk_IncreaseDecreaseInHedgeRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:to="loc_mrk_IncreaseDecreaseInHedgeRevenue_fd13faa9-50d5-404c-92ae-fc045e6ba283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_088ffd87-1393-41b2-88df-a9f69438c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_088ffd87-1393-41b2-88df-a9f69438c0d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_50744f8f-b202-46cb-9c3c-b59dd07533ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_srt_StatementGeographicalAxis_50744f8f-b202-46cb-9c3c-b59dd07533ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_50744f8f-b202-46cb-9c3c-b59dd07533ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_50744f8f-b202-46cb-9c3c-b59dd07533ef" xlink:to="loc_srt_SegmentGeographicalDomain_50744f8f-b202-46cb-9c3c-b59dd07533ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_50744f8f-b202-46cb-9c3c-b59dd07533ef" xlink:to="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4ffec673-0259-466c-a700-8161180c2b86" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:to="loc_country_US_4ffec673-0259-466c-a700-8161180c2b86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_290e9fe3-2bff-42fd-bcaa-5130c46950ef" xlink:href="mrk-20221231.xsd#mrk_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:to="loc_mrk_InternationalMember_290e9fe3-2bff-42fd-bcaa-5130c46950ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b6fdb6b2-de41-435f-8b0a-df27450bf589" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_srt_ConsolidationItemsAxis_b6fdb6b2-de41-435f-8b0a-df27450bf589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b6fdb6b2-de41-435f-8b0a-df27450bf589_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b6fdb6b2-de41-435f-8b0a-df27450bf589" xlink:to="loc_srt_ConsolidationItemsDomain_b6fdb6b2-de41-435f-8b0a-df27450bf589_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b6fdb6b2-de41-435f-8b0a-df27450bf589" xlink:to="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_43ca778c-e570-4895-b3f9-1cc2d41675d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:to="loc_us-gaap_OperatingSegmentsMember_43ca778c-e570-4895-b3f9-1cc2d41675d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b40be9d4-fc13-4d0a-91df-80ee044fa877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b40be9d4-fc13-4d0a-91df-80ee044fa877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6059c11f-f5d9-4220-bd9d-7c593d16bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6059c11f-f5d9-4220-bd9d-7c593d16bb05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6059c11f-f5d9-4220-bd9d-7c593d16bb05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6059c11f-f5d9-4220-bd9d-7c593d16bb05" xlink:to="loc_us-gaap_SegmentDomain_6059c11f-f5d9-4220-bd9d-7c593d16bb05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6059c11f-f5d9-4220-bd9d-7c593d16bb05" xlink:to="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_6ebe9413-fbb0-4f2e-a081-d498a076eff1" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:to="loc_mrk_PharmaceuticalsegmentMember_6ebe9413-fbb0-4f2e-a081-d498a076eff1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_2f243816-a20e-4b96-bb6b-fc25dc5b5bfc" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:to="loc_mrk_AnimalHealthsegmentMember_2f243816-a20e-4b96-bb6b-fc25dc5b5bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_60a1afe6-2e5f-4396-9d96-c8ccdb3aa4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:to="loc_us-gaap_AllOtherSegmentsMember_60a1afe6-2e5f-4396-9d96-c8ccdb3aa4ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2bdd641d-7328-4619-8e8a-805240da798d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_srt_ProductOrServiceAxis_2bdd641d-7328-4619-8e8a-805240da798d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2bdd641d-7328-4619-8e8a-805240da798d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2bdd641d-7328-4619-8e8a-805240da798d" xlink:to="loc_srt_ProductsAndServicesDomain_2bdd641d-7328-4619-8e8a-805240da798d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2bdd641d-7328-4619-8e8a-805240da798d" xlink:to="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_429dbd9b-a9f9-4fc0-8270-3e1d298265c3" xlink:href="mrk-20221231.xsd#mrk_KeytrudaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_KeytrudaMember_429dbd9b-a9f9-4fc0-8270-3e1d298265c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_a4f5b02a-3227-4ee7-b91f-683e0181e5c8" xlink:href="mrk-20221231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_a4f5b02a-3227-4ee7-b91f-683e0181e5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_5e582ab2-bddc-48c9-8251-8dd033f9f484" xlink:href="mrk-20221231.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_LenvimaMember_5e582ab2-bddc-48c9-8251-8dd033f9f484" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_2ead744c-6e6e-49d5-9ea8-de076f1de144" xlink:href="mrk-20221231.xsd#mrk_ReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_ReblozylMember_2ead744c-6e6e-49d5-9ea8-de076f1de144" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_91ede841-6ad5-493d-87b1-d61c018ef2af" xlink:href="mrk-20221231.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_GardasilGardasil9Member_91ede841-6ad5-493d-87b1-d61c018ef2af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_5466f780-0926-448a-838e-bd2741576c69" xlink:href="mrk-20221231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_5466f780-0926-448a-838e-bd2741576c69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_97133650-3013-465b-8ea6-4c9c20885a96" xlink:href="mrk-20221231.xsd#mrk_RotateqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_RotateqMember_97133650-3013-465b-8ea6-4c9c20885a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_aaf62bac-a802-4ea7-8030-c1fef64834a7" xlink:href="mrk-20221231.xsd#mrk_Pneumovax23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_Pneumovax23Member_aaf62bac-a802-4ea7-8030-c1fef64834a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_7ccf820c-be54-4a04-8f8e-11f60826483a" xlink:href="mrk-20221231.xsd#mrk_VaqtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_VaqtaMember_7ccf820c-be54-4a04-8f8e-11f60826483a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_e7acf20f-5c5c-41e2-85de-87c5cce31aba" xlink:href="mrk-20221231.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_BridionMember_e7acf20f-5c5c-41e2-85de-87c5cce31aba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_12762f13-9e54-4c67-b7c1-7b175eaf386e" xlink:href="mrk-20221231.xsd#mrk_PrevymisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_PrevymisMember_12762f13-9e54-4c67-b7c1-7b175eaf386e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_f1bdfa48-5455-43f9-a7c5-aa76e0b9c464" xlink:href="mrk-20221231.xsd#mrk_DificidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_DificidMember_f1bdfa48-5455-43f9-a7c5-aa76e0b9c464" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_3f132792-9f4a-4271-8d52-e7c500683e35" xlink:href="mrk-20221231.xsd#mrk_PrimaxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_PrimaxinMember_3f132792-9f4a-4271-8d52-e7c500683e35" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_c89a3ed6-9b1d-4990-8610-d1d321d3d0ee" xlink:href="mrk-20221231.xsd#mrk_NoxafilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_NoxafilMember_c89a3ed6-9b1d-4990-8610-d1d321d3d0ee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_ebc8a004-2954-4749-8d67-bdaf02540a60" xlink:href="mrk-20221231.xsd#mrk_InvanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_InvanzMember_ebc8a004-2954-4749-8d67-bdaf02540a60" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_4c1f1069-5b7e-4f2d-8020-6ca738e9a455" xlink:href="mrk-20221231.xsd#mrk_CancidasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_CancidasMember_4c1f1069-5b7e-4f2d-8020-6ca738e9a455" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_69b7599d-eaf7-4709-9d64-348df0270e92" xlink:href="mrk-20221231.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_ZerbaxaMember_69b7599d-eaf7-4709-9d64-348df0270e92" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_4f37ba13-82bd-48f8-9d5a-9a2556321777" xlink:href="mrk-20221231.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_4f37ba13-82bd-48f8-9d5a-9a2556321777" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_fea276bc-4e9c-4527-8f13-54671fae775e" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_AdempasMember_fea276bc-4e9c-4527-8f13-54671fae775e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_f634cc1a-df1b-47c6-88ac-2120207fe5c2" xlink:href="mrk-20221231.xsd#mrk_LagevrioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_LagevrioMember_f634cc1a-df1b-47c6-88ac-2120207fe5c2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_1b4da73f-4359-4873-a381-c1263d48ad6b" xlink:href="mrk-20221231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_IsentressIsentressHDMember_1b4da73f-4359-4873-a381-c1263d48ad6b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_a1aaddaf-074d-4bdd-9a04-b492f4efb7eb" xlink:href="mrk-20221231.xsd#mrk_BelsomraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_BelsomraMember_a1aaddaf-074d-4bdd-9a04-b492f4efb7eb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_bd27cfac-97ef-47de-9e85-3dc301d4fddc" xlink:href="mrk-20221231.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_SimponiMember_bd27cfac-97ef-47de-9e85-3dc301d4fddc" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_e20c1f49-21f9-45ef-be58-32a0dcd56372" xlink:href="mrk-20221231.xsd#mrk_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_RemicadeMember_e20c1f49-21f9-45ef-be58-32a0dcd56372" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_318523c4-3ca0-4e73-b1ca-e58f30af4eb5" xlink:href="mrk-20221231.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_JanuviaMember_318523c4-3ca0-4e73-b1ca-e58f30af4eb5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_b6a0ed19-bf8f-4b96-926d-1794212ca5fa" xlink:href="mrk-20221231.xsd#mrk_JanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_JanumetMember_b6a0ed19-bf8f-4b96-926d-1794212ca5fa" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_e5fc3beb-063a-432c-8253-f30f0c0b6e81" xlink:href="mrk-20221231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_OtherPharmaceuticalMember_e5fc3beb-063a-432c-8253-f30f0c0b6e81" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_2d4cacb9-1d1a-4935-ad64-98707e6ceaba" xlink:href="mrk-20221231.xsd#mrk_LivestockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_LivestockMember_2d4cacb9-1d1a-4935-ad64-98707e6ceaba" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_dbeef3d6-863a-4293-ac0f-2d22f4443cc2" xlink:href="mrk-20221231.xsd#mrk_CompanionAnimalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_CompanionAnimalsMember_dbeef3d6-863a-4293-ac0f-2d22f4443cc2" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="extended" id="ic38c09d61d374542ab790ae8299b75e0_SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_deb0ba1f-74c5-42fc-af58-ce9315344642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0109e27b-2291-4948-a652-b9241355fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_deb0ba1f-74c5-42fc-af58-ce9315344642" xlink:to="loc_us-gaap_Revenues_0109e27b-2291-4948-a652-b9241355fc04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_01ed7a53-81c3-430e-aa11-4f997d32422f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_deb0ba1f-74c5-42fc-af58-ce9315344642" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_01ed7a53-81c3-430e-aa11-4f997d32422f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_30bc9e22-02d4-4296-8ad5-f4def4441066" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_01ed7a53-81c3-430e-aa11-4f997d32422f" xlink:to="loc_srt_StatementGeographicalAxis_30bc9e22-02d4-4296-8ad5-f4def4441066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_30bc9e22-02d4-4296-8ad5-f4def4441066_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_30bc9e22-02d4-4296-8ad5-f4def4441066" xlink:to="loc_srt_SegmentGeographicalDomain_30bc9e22-02d4-4296-8ad5-f4def4441066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_30bc9e22-02d4-4296-8ad5-f4def4441066" xlink:to="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d2bbb1a2-16f8-4d69-b931-36a282498391" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_country_US_d2bbb1a2-16f8-4d69-b931-36a282498391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_4841c682-d51c-4cf4-a449-c94e9d53e826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_us-gaap_EMEAMember_4841c682-d51c-4cf4-a449-c94e9d53e826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_61aabd2b-fc5f-4ce1-b84d-f719c8ba11d6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_country_CN_61aabd2b-fc5f-4ce1-b84d-f719c8ba11d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_396d8290-5bd0-4f9b-b399-f15216ff0e57" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_country_JP_396d8290-5bd0-4f9b-b399-f15216ff0e57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_1164ada4-ad5f-4b1d-a46b-e2f4ffb3e1e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_srt_AsiaPacificMember_1164ada4-ad5f-4b1d-a46b-e2f4ffb3e1e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_438f1aa3-30ca-4036-af47-e90f395b44cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_srt_LatinAmericaMember_438f1aa3-30ca-4036-af47-e90f395b44cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_01b0b32b-8ad9-462c-bfb3-af859deae3ba" xlink:href="mrk-20221231.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_mrk_OtherCountriesMember_01b0b32b-8ad9-462c-bfb3-af859deae3ba" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="extended" id="icb49025915bd43ceb35f6d3fade4946a_SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0ec4a613-99fa-484f-9fdc-840f62b69edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0ec4a613-99fa-484f-9fdc-840f62b69edd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ebdaa140-ebaa-4e20-a9c9-a59b38f9c190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_InterestExpense_ebdaa140-ebaa-4e20-a9c9-a59b38f9c190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_cd1298e5-7911-4592-8e01-243dfbc84ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_AdjustmentForAmortization_cd1298e5-7911-4592-8e01-243dfbc84ead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0e317efc-08d6-4048-bc28-1e22fc9e4fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_Depreciation_0e317efc-08d6-4048-bc28-1e22fc9e4fc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d97f0992-5a2a-49f6-b2e3-89e3c7ccb389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d97f0992-5a2a-49f6-b2e3-89e3c7ccb389" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_84fb9fd0-c997-4395-b492-98457c40cd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_RestructuringCharges_84fb9fd0-c997-4395-b492-98457c40cd05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6c21ccc2-bb60-4886-b1c1-59afa29d9b79" xlink:href="mrk-20221231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6c21ccc2-bb60-4886-b1c1-59afa29d9b79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6723464a-d8f8-4415-ad93-0874a5e3b1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6723464a-d8f8-4415-ad93-0874a5e3b1bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7b1b683-51e6-4c93-836e-d3008269cf10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:to="loc_srt_ConsolidationItemsAxis_c7b1b683-51e6-4c93-836e-d3008269cf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c7b1b683-51e6-4c93-836e-d3008269cf10_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c7b1b683-51e6-4c93-836e-d3008269cf10" xlink:to="loc_srt_ConsolidationItemsDomain_c7b1b683-51e6-4c93-836e-d3008269cf10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c7b1b683-51e6-4c93-836e-d3008269cf10" xlink:to="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_cf904498-e003-47f4-85e1-c47df095f532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:to="loc_us-gaap_OperatingSegmentsMember_cf904498-e003-47f4-85e1-c47df095f532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d4f6d596-dfa7-4c33-aa81-b645a74f102a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d4f6d596-dfa7-4c33-aa81-b645a74f102a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_dae91035-9e8f-4838-94c1-0cc685ec96c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_dae91035-9e8f-4838-94c1-0cc685ec96c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30aca2d4-79dd-48e2-aa56-226aebd7f836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30aca2d4-79dd-48e2-aa56-226aebd7f836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30aca2d4-79dd-48e2-aa56-226aebd7f836_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30aca2d4-79dd-48e2-aa56-226aebd7f836" xlink:to="loc_us-gaap_SegmentDomain_30aca2d4-79dd-48e2-aa56-226aebd7f836_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30aca2d4-79dd-48e2-aa56-226aebd7f836" xlink:to="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_ebc505e9-7ccf-41e3-8005-d40331c4c0ff" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:to="loc_mrk_PharmaceuticalsegmentMember_ebc505e9-7ccf-41e3-8005-d40331c4c0ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_b4346690-1789-476d-bc11-3fd8858cae3d" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:to="loc_mrk_AnimalHealthsegmentMember_b4346690-1789-476d-bc11-3fd8858cae3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_20344c55-3f14-4859-b6f8-a042f42b44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_20344c55-3f14-4859-b6f8-a042f42b44b7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="extended" id="i30542087c9444066b9f470770214c693_SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0fb82c6e-cbce-48eb-ab87-a343412847c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0fb82c6e-cbce-48eb-ab87-a343412847c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a6abaaf9-f1c0-447a-9c72-afedf1a56da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a6abaaf9-f1c0-447a-9c72-afedf1a56da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_acc238d2-b0df-4ba1-a49e-97617169d9fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:to="loc_srt_ConsolidationItemsAxis_acc238d2-b0df-4ba1-a49e-97617169d9fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_acc238d2-b0df-4ba1-a49e-97617169d9fb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_acc238d2-b0df-4ba1-a49e-97617169d9fb" xlink:to="loc_srt_ConsolidationItemsDomain_acc238d2-b0df-4ba1-a49e-97617169d9fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c387b68d-8022-4ec3-8789-9b09a23a5121" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_acc238d2-b0df-4ba1-a49e-97617169d9fb" xlink:to="loc_srt_ConsolidationItemsDomain_c387b68d-8022-4ec3-8789-9b09a23a5121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ec2bb853-ca2d-4f3e-862b-6806b4a2a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c387b68d-8022-4ec3-8789-9b09a23a5121" xlink:to="loc_us-gaap_OperatingSegmentsMember_ec2bb853-ca2d-4f3e-862b-6806b4a2a13b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_82c022a8-df78-4f61-a771-f068231d664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_82c022a8-df78-4f61-a771-f068231d664d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_82c022a8-df78-4f61-a771-f068231d664d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_82c022a8-df78-4f61-a771-f068231d664d" xlink:to="loc_us-gaap_SegmentDomain_82c022a8-df78-4f61-a771-f068231d664d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_82c022a8-df78-4f61-a771-f068231d664d" xlink:to="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_8207f329-8581-4e53-b4d9-ef47bcad0867" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:to="loc_mrk_PharmaceuticalsegmentMember_8207f329-8581-4e53-b4d9-ef47bcad0867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_70b1cf06-f058-4358-a82c-2a166befda07" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:to="loc_mrk_AnimalHealthsegmentMember_70b1cf06-f058-4358-a82c-2a166befda07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_8e25c114-bcb9-491f-a23d-4489513d6fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:to="loc_us-gaap_AllOtherSegmentsMember_8e25c114-bcb9-491f-a23d-4489513d6fef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="extended" id="i21c7fbb5820445f48242fde7f79e58f3_SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bd9088e0-fe4e-45e2-a070-2e723c41b87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2fee98f6-f19d-4c35-8c54-86900dc1b317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bd9088e0-fe4e-45e2-a070-2e723c41b87c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2fee98f6-f19d-4c35-8c54-86900dc1b317" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_33166161-623f-4033-8d47-5de02ba29b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bd9088e0-fe4e-45e2-a070-2e723c41b87c" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_33166161-623f-4033-8d47-5de02ba29b71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_003d2bb2-fdf4-422e-a9ab-0c52219f1734" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_33166161-623f-4033-8d47-5de02ba29b71" xlink:to="loc_srt_StatementGeographicalAxis_003d2bb2-fdf4-422e-a9ab-0c52219f1734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_003d2bb2-fdf4-422e-a9ab-0c52219f1734_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_003d2bb2-fdf4-422e-a9ab-0c52219f1734" xlink:to="loc_srt_SegmentGeographicalDomain_003d2bb2-fdf4-422e-a9ab-0c52219f1734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_003d2bb2-fdf4-422e-a9ab-0c52219f1734" xlink:to="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1444a28a-ee3c-42a9-8299-34d5a5df42c5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_country_US_1444a28a-ee3c-42a9-8299-34d5a5df42c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_295be1f5-19da-4eda-8f77-55c5d26e7cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_us-gaap_EMEAMember_295be1f5-19da-4eda-8f77-55c5d26e7cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_c21bdc53-9673-43a2-9c89-3ae82bf5594d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_srt_AsiaPacificMember_c21bdc53-9673-43a2-9c89-3ae82bf5594d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_bc401122-fda8-4203-a7dd-4ce063ce7076" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_srt_LatinAmericaMember_bc401122-fda8-4203-a7dd-4ce063ce7076" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ba1ec92c-b0a3-4791-975b-2acda6f45eab" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_country_CN_ba1ec92c-b0a3-4791-975b-2acda6f45eab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_cfc952fe-1f2a-49e7-a269-740710a36a39" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_country_JP_cfc952fe-1f2a-49e7-a269-740710a36a39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_65198d89-398f-41c5-b239-a076807fe802" xlink:href="mrk-20221231.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_mrk_OtherCountriesMember_65198d89-398f-41c5-b239-a076807fe802" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_RestructuringCharges" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>mrk-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6a80835e-3d33-418a-be61-33ea02b302af,g:f2b57eeb-4f2d-41ff-83c8-1b4e9f7a4523-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_3728d0a5-bbe7-4d3d-a73d-07939c5711b6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_d399ce17-aeec-4ec1-860e-6b26072baec8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRealEstateMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:to="lab_us-gaap_DefinedBenefitPlanRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_4e4c1443-bfea-418e-a479-da529d9e2238_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_fc8a9587-81cb-47b2-b1c2-e18a52a7aea8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8eedb9d5-c307-4cf9-b1a2-3845ebf1f2ec_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_443691ce-eda4-49cc-96a6-e62249c738a1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A170NotesDue2027Member_3dd142dd-70bb-4eaf-a71e-b9dd703d298d_terseLabel_en-US" xlink:label="lab_mrk_A170NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% notes due 2027</link:label>
    <link:label id="lab_mrk_A170NotesDue2027Member_label_en-US" xlink:label="lab_mrk_A170NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% notes due 2027 [Member]</link:label>
    <link:label id="lab_mrk_A170NotesDue2027Member_documentation_en-US" xlink:label="lab_mrk_A170NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.70% notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member" xlink:href="mrk-20221231.xsd#mrk_A170NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A170NotesDue2027Member" xlink:to="lab_mrk_A170NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_5056050d-993c-4c9f-b7ef-1de2cc99d68c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation earned on arragement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A235NotesDue2040Member_d2e77477-27fe-47f0-ab18-302e48b9ed27_terseLabel_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040</link:label>
    <link:label id="lab_mrk_A235NotesDue2040Member_label_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2040 [Member]</link:label>
    <link:label id="lab_mrk_A235NotesDue2040Member_documentation_en-US" xlink:label="lab_mrk_A235NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member" xlink:href="mrk-20221231.xsd#mrk_A235NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A235NotesDue2040Member" xlink:to="lab_mrk_A235NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_2cb6b7ac-d61a-45aa-a518-64316077b6d8_totalLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_f5004aae-8bde-4572-9627-9d6935fcca73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock and Treasury Stock Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_19ea37b9-5583-4b7c-a92a-6a9ac819f43d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_b7f13253-27e4-4f06-b4cd-8a5ada3514a1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3a5d97b8-5177-436a-ae11-28d971816c79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_8abe763d-7570-4ca1-ae09-ae65101b2ee7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_49bedf78-42a7-40fa-acbd-1f6da065c18e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to stockholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_74b74153-0da7-49b4-bded-7e6a70b44a6b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment (at cost)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_85c2b4b4-7ca6-481d-af7e-e722b92d5d6d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of loans payable and long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_2d4bed7b-3d76-4a8e-aded-f60f8cdb2466_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_9a37098b-c88b-4184-ba25-4fa1d7beddc3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_c2a962a5-e4cb-445b-b7de-7ac063d779e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_21c6ea73-4f85-4e6e-baab-ab10b4682819_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LagevrioMember_fff6378c-5d64-4991-8758-dc47d5a55f15_terseLabel_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio</link:label>
    <link:label id="lab_mrk_LagevrioMember_label_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio [Member]</link:label>
    <link:label id="lab_mrk_LagevrioMember_documentation_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember" xlink:href="mrk-20221231.xsd#mrk_LagevrioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LagevrioMember" xlink:to="lab_mrk_LagevrioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104fed5-c88c-4e5b-b439-affd44a02861_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_2b043839-1fb8-469c-b7a0-f4d1d7bf02f0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d9a6d229-4ee3-4b88-a3d1-29e3cc263448_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_3c1d1de3-d877-4ea0-a35f-8ab6d59ea7d3_negatedLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1fce6c73-f528-4eaf-9fa5-db75b47a6626_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4e910dcc-bd7c-43d3-8413-da068e7dfba6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7e25a14c-be87-44fb-bde8-8e2af2085fb0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f55abd73-922b-48b5-837d-dbd5387b328e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_f650012f-fcd8-4dde-878e-d42fc53ffda3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5131d4aa-7fc6-4e06-a2f4-b4131e6937a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Location and Pretax Gain or Loss Amounts for Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_0b98dc9e-9b8d-40aa-a727-ee9e4347e346_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6e566369-18e6-4062-a1f0-70439a5bf91d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_82088731-aa4e-4e0f-b919-f7a3c13f7a44_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_cd92ce42-0184-44ae-9031-0ef0be3be025_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_96a01967-55ec-42cc-b292-e9bfe5b2ffa9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e1283c15-e43e-466f-9111-c9a8430c9b31_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_b902e6fa-bfda-4113-894c-8ffc603e98cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b80ca5b4-959e-46dc-9aad-03ce3e5ea164_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_f9f9c865-813c-4411-9cff-186a0b420363_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash and cash equivalents related to discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_126b16f4-466e-402b-be78-26d6f9bb6501_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1eb533e0-12e6-4e72-9a66-78b8c3745ced_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_d06951dd-c6f0-4c4c-b2e9-f51d7ee20e81_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_dc5781fa-3d4f-4912-9707-4d11be0f64a8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_16ca598e-e071-47f4-9598-c1c8e77bb0ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_8b3d573d-6e6c-4417-8705-7df7f2938181_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_789dac90-8b15-477f-a8fd-45d091cf04c1_terseLabel_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:href="mrk-20221231.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:to="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_28a003a3-f3f7-47dd-88b2-d825af759424_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_24d16947-272e-45b8-812d-548467ac7ae4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_260c1e4d-3030-414f-a957-c3b9a443e811_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_73cf0ffd-406f-4eef-9788-4974e3b12851_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9efed013-cc8e-4d98-8432-1ac0cd33ed76_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_011f0a8f-5125-4528-8075-6f8dcc0cdc17_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_248ee4f6-bd6b-4c26-bf86-adb92a75843d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_a733ddbb-a865-4e7c-a5c4-2fad1b801c13_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax&#160;Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_20e07ecd-cd78-4469-a8e7-cb8774d4aec6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3fb55bbb-c878-41ee-8d8f-c7c0fbcf5db4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_263c6899-b789-4bc2-b1d2-8e93812d095c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_9f89b7f1-723a-4e52-964d-df296d269be8_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_70933a77-1730-426f-a149-c3b6a8552412_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c1a77ddc-a3f7-4797-8672-dd4eb3f51e03_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets January&#160;1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_bc67a908-1e05-4236-9fb6-d31b61f770d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_00cd9e55-edcf-4a43-844a-d10c709fb803_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e79f5337-1470-453d-a527-0c43773a4fd3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bd1be3d3-f398-4009-a36f-e75a9e59b2a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_6680cf91-4763-4e1b-b450-7f4c37348eaa_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_label_en-US" xlink:label="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Products and Product rights, Measurement Input</link:label>
    <link:label id="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Products and Product rights, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetProductsAndProductRightsMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:to="lab_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_7060d09c-c221-4ca0-b484-81a3ddf5a52d_terseLabel_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets equities</link:label>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets Equities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets equities investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:href="mrk-20221231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:to="lab_mrk_EmergingMarketsEquitiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_7eeee3f2-bb5d-4a8d-a52d-edd514a886ab_terseLabel_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Credit</link:label>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_label_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Cost [Member]</link:label>
    <link:label id="lab_mrk_PensionPlanPriorServiceCostMember_documentation_en-US" xlink:label="lab_mrk_PensionPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember" xlink:href="mrk-20221231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PensionPlanPriorServiceCostMember" xlink:to="lab_mrk_PensionPlanPriorServiceCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_05f06a34-2cab-4492-ac52-3376252f65b3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cd82c6b4-db7d-4826-8d19-1c1e200ee42d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_12fe065d-6357-43a4-a83e-036ce5289039_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average interest rate of commercial paper</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_27c02f5d-e4cb-4bfb-9caf-c6f504f1be69_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Income Net of Taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a3194983-9efb-47f9-a07d-f02e26fab902_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_feca9602-39bf-4a3d-85c5-fb3771ec9a1b_terseLabel_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_6cb3a648-5fa4-4bc1-b43f-d0adfb18b605_verboseLabel_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_label_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts Other Investments [Member]</link:label>
    <link:label id="lab_mrk_InsuranceContractsOtherInvestmentsMember_documentation_en-US" xlink:label="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember" xlink:href="mrk-20221231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InsuranceContractsOtherInvestmentsMember" xlink:to="lab_mrk_InsuranceContractsOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_2bf2f8b7-3d1b-45cf-b30f-4e0692e0d5dd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_a39570af-dd1d-44a0-8257-7d2bac4df3c4_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_53b38d82-2a7c-4da9-90a0-36a2c24d7b60_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_9183ab02-0921-4fa8-9989-8679cd01e41c_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains) losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_4c27d5ff-dfee-4582-af30-9ca87f9f82bc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits from adjustments related to examination</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_79cfbd05-3ab2-47b2-a55e-e6ccfa2bedc5_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_f80757e3-d589-444d-917f-4669ba73d814_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b1326285-2f60-4a47-ab48-9a73ef3a4c5a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4d37127d-76fc-4862-9c51-5a11e6f26061_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_bad7f7a0-1994-4e13-b47f-9b5173727068_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_a56d90ae-defd-4141-be63-e0491fb5a24b_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DerazantinibMember_c6460da7-0a68-4ae0-9f36-cbaa8beb956f_terseLabel_en-US" xlink:label="lab_mrk_DerazantinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derazantinib</link:label>
    <link:label id="lab_mrk_DerazantinibMember_label_en-US" xlink:label="lab_mrk_DerazantinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derazantinib [Member]</link:label>
    <link:label id="lab_mrk_DerazantinibMember_documentation_en-US" xlink:label="lab_mrk_DerazantinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derazantinib</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DerazantinibMember" xlink:href="mrk-20221231.xsd#mrk_DerazantinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DerazantinibMember" xlink:to="lab_mrk_DerazantinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_452c3bcd-994e-4007-a764-9b4bbaa1a78b_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_label_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthsegmentMember" xlink:to="lab_mrk_AnimalHealthsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_81ff77cb-e741-44e5-ae59-d4c643e5733f_terseLabel_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other fixed income obligations</link:label>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_FixedIncomeObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:href="mrk-20221231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:to="lab_mrk_FixedIncomeObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_44f6b8b2-51ed-4125-b1e0-a6396f03f56a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners_4a0a6fe1-42eb-4639-91a9-eeea52dc8bbf_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development payments to be made to a collaborative partners</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Payments To Be Made to a Collaborative Partners</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Payments To Be Made to a Collaborative Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" xlink:to="lab_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d68a9cf6-6143-49b7-bf9f-d98e74da6a56_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_98be8559-95ce-4d42-8bf8-5e05569df2ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_782eb07d-011d-4d77-b859-134a15d4c28f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f240e-0638-4e16-89e7-cf5ef1036544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f2ddd71d-e45a-4db2-8c43-66be8c1e7327_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_a5cb2b54-c8af-4265-9cd9-66aa45c30820_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_7b1aba7f-a3c0-489b-903a-199768881f5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service (cost) credit arising during the period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1a00feba-60ad-4fa1-a7c2-d863d4ad5eac_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09d91440-e190-482f-8e79-397c96b0c830_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_fd98e499-897c-4367-871e-a2302ce29b1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e0993d4b-ccfb-4d1a-ab67-baf028e24f58_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c5610b5f-67e4-44c5-9c4a-d540124e05e3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9daef9ca-47f5-45a7-97f9-79643386dd0b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_774fe7d2-8b00-4efb-91c2-890fab02481b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0187bf42-c93b-4e45-8c3b-342b6b18dbd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3ab8ee30-4a44-44fa-a9b5-66746d271c01_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_f93b510a-f8b0-434f-8393-854a8095be14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Acceleron Pharma Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_89a9aab1-1c9e-4432-931e-ea2c4d3fee14_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_105a1146-3ebd-4fd9-b7b6-be2f0e2f58d0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6aea7ba9-848c-4f3d-8485-5c11b20d2da7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3b0585e-adc0-4034-8f04-722e060ce75d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_85d05dc3-3821-47d2-af10-98f5bea70c88_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_29efcca0-c545-4911-a99a-db2094d179eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_d7ae16dc-a48f-440c-9e37-7b581acd6ee7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7dc0cdaf-6fc5-469e-a393-710187ff2ff0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_75f4363c-c7bf-4fcf-82e6-7c7f87710453_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_6c91f345-5a48-4424-938c-953e7f2640d4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_95fa9025-8045-4994-887f-c273748526fb_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and product rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c8f631fd-5007-46ee-859b-01c6f907596d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain (loss) recognized in OCI on derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SanofiPasteurMember_a65f7691-f8d7-41c2-b956-3aebd521c028_terseLabel_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_label_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_documentation_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember" xlink:href="mrk-20221231.xsd#mrk_SanofiPasteurMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SanofiPasteurMember" xlink:to="lab_mrk_SanofiPasteurMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaMember_c51f57f6-268f-445a-a739-ec82324ff725_terseLabel_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia</link:label>
    <link:label id="lab_mrk_JanuviaMember_label_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member]</link:label>
    <link:label id="lab_mrk_JanuviaMember_documentation_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember" xlink:href="mrk-20221231.xsd#mrk_JanuviaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaMember" xlink:to="lab_mrk_JanuviaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_38f83115-4619-4c50-9ece-cfb971381166_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_202bf39b-82e5-4921-84b8-674dba8e0c92_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_52696583-6ff4-4122-b868-3ed520891038_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payments accrued</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Regulatory Milestone Payments Accrued</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Regulatory Milestone Payments Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:to="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_e1ab7085-5b0c-4ad0-846b-50f658a8b890_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differential arising from:</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_78f8bfd6-e2c3-4275-bae3-362b2eb67ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_33c28b1b-b388-47ef-a865-2ad022d367e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bbda597c-a463-4f10-a88e-bc7840fbd382_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OralFormulationMember_87131a93-e029-4a98-ab69-5b85e91e9390_terseLabel_en-US" xlink:label="lab_mrk_OralFormulationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation</link:label>
    <link:label id="lab_mrk_OralFormulationMember_label_en-US" xlink:label="lab_mrk_OralFormulationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral formulation [Member]</link:label>
    <link:label id="lab_mrk_OralFormulationMember_documentation_en-US" xlink:label="lab_mrk_OralFormulationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral formulation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralFormulationMember" xlink:href="mrk-20221231.xsd#mrk_OralFormulationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OralFormulationMember" xlink:to="lab_mrk_OralFormulationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3fe9ebac-a406-4f53-a0b3-62a34ce0996b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5f1db120-c251-4112-9883-6285359f97ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b1e18d24-a90a-4fad-8684-8fb0c254876e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_5943a533-067b-482d-8b72-b4ca3f7aac99_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_98a0caee-0fee-41ce-9b40-65fc6daa7753_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Options</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeOptionMember" xlink:to="lab_us-gaap_ForeignExchangeOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_cae83f57-0c32-4592-b88c-ee9014d6facc_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible future contingent development-related payments (up to)</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:to="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f211a654-245c-49ab-95d5-bec59f294929_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_76ab6eab-cbbc-4f83-a948-5e26673759f4_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5625e007-9b0d-4524-9180-a4eccbe06fa6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_075952e1-3c8d-40df-bded-9bbce411846b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e0a81c5f-28a0-49fc-a8e4-d312952a4dfd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RotateqMember_17bb6eb0-2fb0-4c00-9a76-7ddd1663afba_terseLabel_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq</link:label>
    <link:label id="lab_mrk_RotateqMember_label_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rotateq [Member]</link:label>
    <link:label id="lab_mrk_RotateqMember_documentation_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember" xlink:href="mrk-20221231.xsd#mrk_RotateqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RotateqMember" xlink:to="lab_mrk_RotateqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ac3c8077-9afd-4706-82e2-c9e1536d3d8b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_97879d6f-0f0f-4a7a-8278-5ea440a1fce4_terseLabel_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_label_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement [Member]</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_documentation_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember" xlink:href="mrk-20221231.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TransitionServicesAgreementMember" xlink:to="lab_mrk_TransitionServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_40f09215-859e-4362-984e-03db786b26a6_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_207a9a54-d0ed-42b1-bffb-95e8e2082d88_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NumberOfInterestRateDerivativesMatured_0b79f2ec-ee06-4360-80aa-e2deaeb15dc7_terseLabel_en-US" xlink:label="lab_mrk_NumberOfInterestRateDerivativesMatured" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate derivatives matured</link:label>
    <link:label id="lab_mrk_NumberOfInterestRateDerivativesMatured_label_en-US" xlink:label="lab_mrk_NumberOfInterestRateDerivativesMatured" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Matured</link:label>
    <link:label id="lab_mrk_NumberOfInterestRateDerivativesMatured_documentation_en-US" xlink:label="lab_mrk_NumberOfInterestRateDerivativesMatured" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate derivatives that matured during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NumberOfInterestRateDerivativesMatured" xlink:href="mrk-20221231.xsd#mrk_NumberOfInterestRateDerivativesMatured"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NumberOfInterestRateDerivativesMatured" xlink:to="lab_mrk_NumberOfInterestRateDerivativesMatured" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_227b8155-bfeb-4d40-bcab-ab7821c364c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c1c2e8a7-2e86-4866-83c2-b48b4256bd11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_38396862-eff4-4f74-ac1e-2aaf64990469_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims settled (in cases)</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4bac4dc2-e350-492f-b530-7f2df2f9038a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_59329620-0ffe-4ca5-93f1-4a043426d64a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_d416bf96-f136-404c-b1ea-e239ca10e0df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleronPharmaIncMember_098bce24-e8f5-48a7-ab1f-08dfe96aa085_terseLabel_en-US" xlink:label="lab_mrk_AcceleronPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleron Pharma Inc.</link:label>
    <link:label id="lab_mrk_AcceleronPharmaIncMember_label_en-US" xlink:label="lab_mrk_AcceleronPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleron Pharma Inc. [Member]</link:label>
    <link:label id="lab_mrk_AcceleronPharmaIncMember_documentation_en-US" xlink:label="lab_mrk_AcceleronPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleron Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember" xlink:href="mrk-20221231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleronPharmaIncMember" xlink:to="lab_mrk_AcceleronPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_61c02287-764d-4e27-b2dc-0b0a97beb46e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_14729423-6aaa-4210-9d0e-f384dafc795a_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8ee958eb-2cdb-4528-99de-089717baaed2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1473de9d-a4aa-4967-a589-1be84b44b5fd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_200b9a34-a646-42d1-9e30-9305133ae8b3_terseLabel_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_label_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pharmaceutical [Member]</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_documentation_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember" xlink:href="mrk-20221231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPharmaceuticalMember" xlink:to="lab_mrk_OtherPharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_27ee0da7-f817-439d-a433-1be7feffbf50_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_3a2a448a-8d8a-4d44-b505-62ac9e1d29e5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition of business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_8c038545-3079-4e03-8455-10d76f06dd8d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_f7562d11-00ed-48fe-bebb-5e4e7768712b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_06c0c1cb-e463-4b59-8787-e87e540a8482_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_8b61bd04-40fc-41e3-85fc-c47f331ce7dc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_8a7d8646-d7ec-419a-b76a-bf2a285753af_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_be3a83e0-1315-4b8f-904f-b1558e986683_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_b7e8c0d0-f1aa-4622-8236-1e66205fcdc4_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_17b830f5-6df1-4800-92d4-f0a619f3f178_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3054bc94-a0de-4e76-81ae-200ae3ddb862_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Pneumovax23Member_8b33f5cb-b96c-48fb-b70e-e7e49314a950_terseLabel_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_label_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23 [Member]</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_documentation_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member" xlink:href="mrk-20221231.xsd#mrk_Pneumovax23Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Pneumovax23Member" xlink:to="lab_mrk_Pneumovax23Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_9a7f46bf-9031-43bf-bb34-c3037d7c146e_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b4566b6-e871-45a2-a7ce-324b1225eeb5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c31e373-3476-4862-b0a0-957b81e62879_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7a277dbe-7eca-4c18-8b27-1fccbd5a57bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9711cbd0-af08-49fa-970f-d0db1d448741_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6651f92b-d5eb-4994-871d-0688357ef048_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_edb40095-48da-4b62-a113-0bbd9e134a73_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ad82653e-15aa-4d67-aefc-8e7540b53722_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_da687f14-6550-4d59-b133-84dcd69ed711_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5a81d7be-4de3-41c8-a65a-29bc3cb35353_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_7a206646-7cda-48db-b908-d54f419f9960_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d8b303e-485a-4187-a72f-000bce2a052d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6caa5aee-84f5-4dd2-90ab-20f24d823c42_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_ebdd5bdc-5c1a-4c49-a993-71cfb8140699_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance on foreign NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5b3075f4-289e-4cb1-b230-f9b5a9967d00_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0725acb6-85b6-48b1-b72c-5980da5f1ae0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b1b0d99f-839c-4432-aa5b-0b234e80d0fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_69953ddb-c855-4d91-8d21-5b0e60777e73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bf9c9a37-92f8-4593-886c-e41a5492a9a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e4730ea1-a25d-487b-a755-fb8249dfc5de_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1530a6f4-0b94-46d7-93c9-41bf7a466342_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_3aa5ad64-95b8-49a1-a67d-382816e07e5d_terseLabel_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable contingent payments</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20221231.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7907aeb-c337-43b3-863a-85fb6cd51f3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ebb884ca-bd79-48b8-90ba-9835a81e716e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Tax Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c3d88570-32dc-4d85-b439-9b89b43ce992_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_97315169-4cd7-4607-ae07-b59d19ed989d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_9d0ceabd-8ba9-48ae-ad1d-e60090992b4b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_2dd821f2-869a-423a-a316-1bbb66c06d20_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties, current</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IsentressIsentressHDMember_773c7dad-b93a-4472-a816-3d19daf4e046_terseLabel_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_label_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member]</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_documentation_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember" xlink:href="mrk-20221231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IsentressIsentressHDMember" xlink:to="lab_mrk_IsentressIsentressHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_3ac19fc4-55ed-4936-b11f-290f77142bb3_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c0579b3a-d440-4b6c-ac82-cdf3fae65d09_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearThree_c4e2db82-9103-4fa7-8414-36d96697168a_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2025</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearThree_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Three</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearThree_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearThree" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearThree" xlink:to="lab_mrk_LongTermDebtInterestPayableYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2ed35601-49a7-4243-a6f8-379ee9e09e0d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of accounts receivable represented by customers with largest balances (as percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_355c4c66-a099-4ba0-8489-305dda90afce_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative costs since program inception</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_ea90c43f-8329-4553-830c-0206adccb563_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_b9430c8a-f779-4160-a65c-de66908cfd4b_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI and the foreign-derived intangible income deduction</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1914e731-e24e-4d52-869c-76feb7433f8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_f2a1611c-850b-461b-ac2a-f618178aad5d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_d06d47c4-3e60-4f40-9a98-89b1108e6b56_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ae8999bf-d842-4807-abc2-34db3f9e904c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_0b7e322c-1860-4e40-9a02-eff78b785b45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_97adf3fd-dfe0-49cc-a9d1-71a41fda6f29_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_9759b213-ee12-4e66-b7af-ed10e85d57cc_terseLabel_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards</link:label>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_label_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</link:label>
    <link:label id="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_documentation_en-US" xlink:label="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:href="mrk-20221231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:to="lab_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4d711401-1b22-4960-834e-9e6a0b332c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which share-based payment awards vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_5775555c-e1ff-42c1-a141-4b0e8e0992c5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c8010951-b15d-4992-8757-60bad3ee4303_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_2ee37b39-1487-436d-abd7-344225eb60a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_62a00592-589a-4334-b6ea-3152f3c7699e_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:href="mrk-20221231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_7c59bc9d-a8c5-47ae-ab75-c9dc8b0c2205_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_c5a42994-3d8b-4498-8a78-3f0d1fca202e_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other profits</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_7c96b664-7c6e-44bf-a380-bc2eba9ff1ad_negatedTerseLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio Inc., net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:href="mrk-20221231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_330ce6c5-b498-4019-8d98-d5aa6d5b6357_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2b06f3a-bcd0-440b-ad6b-b630c3cca9f5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_47d45888-3ff7-42b8-b5ad-17314670b21b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_222b0569-5dc8-4723-a79c-ddb7f0d47448_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_97d5e101-5d45-4a2f-9d84-7c0a9e422c0b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_1953f635-a69c-4111-b76f-ea6d01732f75_terseLabel_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% notes due 2045</link:label>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_label_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes Due 2045 [Member]</link:label>
    <link:label id="lab_mrk_A3.70NotesDue2045Member_documentation_en-US" xlink:label="lab_mrk_A3.70NotesDue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes Due 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member" xlink:href="mrk-20221231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.70NotesDue2045Member" xlink:to="lab_mrk_A3.70NotesDue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_872dbe18-f7ba-43a1-8bd9-df86d51efb02_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_d469cd30-84e4-4f74-9824-9c08718be9e6_terseLabel_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember" xlink:href="mrk-20221231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopmentMilestonesMember" xlink:to="lab_mrk_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_13d14fc4-afbf-4e02-b0de-78c4c3794bf7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_c2dabe26-11d7-43eb-a8eb-0710dfa72a7f_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future sales-based milestone payments</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:href="mrk-20221231.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_db170b9d-e643-40ff-9710-3b2aa2d53e27_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes Assets And Liabilities Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:href="mrk-20221231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:to="lab_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_572db7b2-4ba0-43f7-81da-3f4707f3d6be_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b88d4587-040e-4b12-b1e8-f673008ece37_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e3c1e972-d49f-4688-8f5d-2bd7e8456207_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_104dbc24-d02c-4c5b-9d9e-a278a7d00c9c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ff01a683-7f97-4000-8dad-be92d787065d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_488dc824-6053-45eb-9440-d02e1a73fa09_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxRateReconciliationAssetAcquisition_2034e862-d814-4524-aefe-47e4f289a7d2_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxRateReconciliationAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio</link:label>
    <link:label id="lab_mrk_IncomeTaxRateReconciliationAssetAcquisition_label_en-US" xlink:label="lab_mrk_IncomeTaxRateReconciliationAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Rate Reconciliation, Asset Acquisition</link:label>
    <link:label id="lab_mrk_IncomeTaxRateReconciliationAssetAcquisition_documentation_en-US" xlink:label="lab_mrk_IncomeTaxRateReconciliationAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Rate Reconciliation, Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxRateReconciliationAssetAcquisition" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxRateReconciliationAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxRateReconciliationAssetAcquisition" xlink:to="lab_mrk_IncomeTaxRateReconciliationAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_d45b668b-9c99-4a35-b926-43836aaabc83_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_c4f020ca-3610-4f3c-bcf0-c3848a29a924_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in Other current assets</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_1166dad9-22d5-4844-a9c2-b1be8a72ad18_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_2ff699b0-43a9-4f31-a680-16f7bc86f045_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relating to assets sold during the year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_370d979a-42aa-4af0-8834-ed6e587bfeaf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1b240207-9661-481b-bf04-692f03cc920d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties associated with uncertain tax positions, expense (benefit)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_30e2c4ab-dfc9-4f2a-9282-336c4bbf0cb7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_129c1107-68ac-443a-8fad-e13ad6949dfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains) losses for equity securities held through ownership interests in investment funds</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CardinalHealthIncMember_6afd11d1-32ca-4f81-aa60-d5986e0aebcd_terseLabel_en-US" xlink:label="lab_mrk_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_mrk_CardinalHealthIncMember_label_en-US" xlink:label="lab_mrk_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_mrk_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_mrk_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CardinalHealthIncMember" xlink:href="mrk-20221231.xsd#mrk_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CardinalHealthIncMember" xlink:to="lab_mrk_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1fc6b3c8-e0a1-4c86-be77-3e1dc7698657_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_ff75f3ec-00ba-4976-95f9-a4c8717bb9ff_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_3bf30cf6-254c-41bb-8eaf-de2a0651bb2d_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Expected to Vest (in shares)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_e36ec03c-d18d-45b4-9a59-8e81735d30c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SivextroMember_b05115c0-555b-49a8-9408-32f6f1fd30af_terseLabel_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro</link:label>
    <link:label id="lab_mrk_SivextroMember_label_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:label id="lab_mrk_SivextroMember_documentation_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember" xlink:href="mrk-20221231.xsd#mrk_SivextroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SivextroMember" xlink:to="lab_mrk_SivextroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_cb462b6e-cbff-45d4-a2c2-a77410257a96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_d52d4205-ee9a-4060-b85f-5006b565bdd5_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7dc028cd-6232-45fb-affa-7cdd91557bdd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GileadSciencesMember_0073c17c-ae46-4581-8f96-717801e1bc96_terseLabel_en-US" xlink:label="lab_mrk_GileadSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences</link:label>
    <link:label id="lab_mrk_GileadSciencesMember_label_en-US" xlink:label="lab_mrk_GileadSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences [Member]</link:label>
    <link:label id="lab_mrk_GileadSciencesMember_documentation_en-US" xlink:label="lab_mrk_GileadSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GileadSciencesMember" xlink:href="mrk-20221231.xsd#mrk_GileadSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GileadSciencesMember" xlink:to="lab_mrk_GileadSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62e7dcd9-1ed0-4d35-80b2-51c123748fe1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_710eeb5c-b614-40fe-8772-70f9e8470732_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_15e2e934-755e-4661-b0f0-347988bfcde1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_afd9f74b-aed6-4276-ae94-650a60f73165_negatedTerseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_15f0e584-4247-44e2-8203-fa121e14e458_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_0235b820-291c-4b17-b193-ff07cf669bf5_terseLabel_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% notes due 2049</link:label>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_label_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_mrk_A4.00NotesDue2049Member_documentation_en-US" xlink:label="lab_mrk_A4.00NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Notes Due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member" xlink:href="mrk-20221231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A4.00NotesDue2049Member" xlink:to="lab_mrk_A4.00NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_f25f8e05-4e2f-483d-81e0-864dd30f268c_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Be Noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:href="mrk-20221231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62fac2d4-347d-425b-95be-2f15c86ce89c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SimponiMember_b38d83ed-f163-434d-918a-3d7f715400d2_terseLabel_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi</link:label>
    <link:label id="lab_mrk_SimponiMember_label_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member]</link:label>
    <link:label id="lab_mrk_SimponiMember_documentation_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember" xlink:href="mrk-20221231.xsd#mrk_SimponiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SimponiMember" xlink:to="lab_mrk_SimponiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_9e46d55e-dc2a-4c90-b945-6500e22fb2b4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1e023805-9d4a-42ff-8de3-56c78e5baba7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D capitalization, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c87829ed-cbf1-4871-b415-a28909a16e30_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A415NotesDue2043Member_8a16e6cb-5897-4089-861a-3a4f32d2282e_terseLabel_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% notes due 2043</link:label>
    <link:label id="lab_mrk_A415NotesDue2043Member_label_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2043 [Member]</link:label>
    <link:label id="lab_mrk_A415NotesDue2043Member_documentation_en-US" xlink:label="lab_mrk_A415NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member" xlink:href="mrk-20221231.xsd#mrk_A415NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A415NotesDue2043Member" xlink:to="lab_mrk_A415NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f3802197-1a92-44fd-b19b-e83e3ee5827e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6b244d55-5643-4f38-a121-9c2dba965493_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_dd33ea7a-0e28-4717-82ed-a3f6a00348bf_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_c9be7961-b124-4d02-9cae-7a5266009f67_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative downward price adjustment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_4765dad3-a6e2-451b-bc7e-bf4b0d97161c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c667d74a-f589-483e-87f5-4210d3fef10a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_dadd7762-48f7-49bc-87eb-5df9646669ae_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_67fa2ea3-b25b-4a46-a91b-7cdc573d1d3d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire productive assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_b1d1602a-04ca-48bb-9646-5c088e5cc11b_negatedLabel_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_label_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense, Other</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_documentation_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income and expense items not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:href="mrk-20221231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:to="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_8758f24b-14b5-4ced-ad6c-c3b1f817344a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Nonvested RSU and PSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_37fd294f-a90a-42ad-ab9e-954be502a36c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_8a2665ac-8521-44c2-8812-84a53e7b0429_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_f1f49094-c4d9-4806-9e44-fdf3b5fba1b5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_KeytrudaMember_b99752f8-b1c8-4030-8246-50218f8ee225_terseLabel_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda</link:label>
    <link:label id="lab_mrk_KeytrudaMember_label_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:label id="lab_mrk_KeytrudaMember_documentation_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember" xlink:href="mrk-20221231.xsd#mrk_KeytrudaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_KeytrudaMember" xlink:to="lab_mrk_KeytrudaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ad7e77ff-7997-439d-a79d-58d7f11de45c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_87cabc9b-ff30-4420-8abb-d46f002575d9_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_a2841ad9-83a4-477f-8565-8868f8da4f33_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, trial period</link:label>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_label_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Trial Period</link:label>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_documentation_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Trial Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod" xlink:href="mrk-20221231.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyTrialPeriod" xlink:to="lab_mrk_LossContingencyTrialPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_4e7fb852-e93a-498a-b8fc-9fbea8e53a05_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates current cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b605ef9d-b5ca-42fb-acdb-6ed43c047ff2_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_1f2a594e-5d0e-4ef3-8c2a-2093bc3bfe25_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_c8e333ac-ec95-4c3a-ba12-446ff55fdf8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_11588a2a-d740-474c-9138-cb4ad10489ac_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_574d92d8-45da-45be-8f81-d04475646237_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_b2d8baa1-0e0b-47a3-8dc4-814032248c35_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_7fe7906a-9c25-49b2-88b6-7f556f4a8b25_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:href="mrk-20221231.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:to="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e04e5c4d-1d68-4e3d-b429-3ac84f8fd1cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ec95f6eb-75ef-43e8-a548-09441a3499c9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0c503567-6871-4e40-a4fa-0e39d40fcd6f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8025ff5b-9fed-44f8-a5bf-7b1c143e907a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_81fd8ed3-64ad-416c-b6c0-a32bc1e54238_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_92a7c86d-4977-468e-8dd0-0f475b809fa6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_7d94ec13-761a-4030-ad09-374b5eec755d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_084f7993-aaf7-4dcc-a403-5162ca1db13c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_d0d809f2-646d-45cc-a846-026a017f5d12_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_21b6bbb4-7835-40bb-8773-118109bd97b8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_6f99bb59-73a3-4a83-a80a-c576e49d6f85_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_d84fc2f9-122c-4d26-b536-25a3f06bd398_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_bdd322de-c20c-4b7e-968d-02de9c69f48c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_189c8af0-911d-49a9-bd62-084c9ab0ea0a_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7292fd4f-d5b8-495d-8621-4250666ccc3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_0ab573f4-0016-49d2-88c5-96c3ed7ad0c5_terseLabel_en-US" xlink:label="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made To License or Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made to partner as part of a licensing or collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:href="mrk-20221231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:to="lab_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyPharmaMember_fd08ffd0-5217-4185-aeeb-d006d75f0a24_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma</link:label>
    <link:label id="lab_mrk_RoyaltyPharmaMember_label_en-US" xlink:label="lab_mrk_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma [Member]</link:label>
    <link:label id="lab_mrk_RoyaltyPharmaMember_documentation_en-US" xlink:label="lab_mrk_RoyaltyPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyPharmaMember" xlink:href="mrk-20221231.xsd#mrk_RoyaltyPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyPharmaMember" xlink:to="lab_mrk_RoyaltyPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_253eafcd-7bc9-40b9-ae50-ba390c81b683_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_f135c757-1a7a-45a8-bb84-b22a349b6c45_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Capitalization</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_dbb4d7f0-4014-43be-9396-b9163f07096a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2265360f-1c80-4742-a77e-e8d11fb7dc21_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b89dbad4-7a74-4ddb-8de9-d35f3f91aaef_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses recognized on investments in equity securities without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_44ed753a-ce75-4f6c-8c67-423a849f33cb_terseLabel_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_label_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Markets Equity Securities [Member]</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitySecuritiesMember_documentation_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:to="lab_mrk_DevelopedMarketsEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_289e503c-e483-489c-b323-2ac5e51a0aa1_terseLabel_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_label_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements [Member]</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:href="mrk-20221231.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:to="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_9d8f305b-1c73-41c6-8771-a7712ec703be_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_2b48df84-0f19-4243-82b0-2f27cd14cf2e_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4d80cddc-5c10-462f-9c9d-f145a41def53_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_ab1ed76d-89f1-4bc8-b2bf-1491b6fe7ce6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_dda951d6-c34d-4a4c-b7cd-3fd5e1c9b4ec_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party amount in cost of sales</link:label>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_label_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties Amount in Cost of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:to="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_cb2d6cba-9d58-4d56-aa26-b4bbe79626bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6b7ba137-264f-4dec-83b3-46b3f6d3888b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b6bdd571-0f00-4ff4-b8c9-d769cc8d0078_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_d6635a42-90fb-41a3-a05e-b897c8041a7a_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differential arising from:</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_5b281c33-04e2-432f-aad8-1e92934e072e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Legal Defense Costs</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_f1583500-45a3-4e91-9bd4-9b6a4d17db86_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_6b8db482-4f44-4004-a14e-57ed3d35ef15_terseLabel_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, lease not yet commenced, amount</link:label>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_label_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:label id="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_documentation_en-US" xlink:label="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:href="mrk-20221231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:to="lab_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_5ff59ed7-1973-4aa2-bbeb-5e3d1cc9a220_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_71f199fa-b99a-402d-907a-34157caba07c_totalLabel_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current and noncurrent inventories</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of current and noncurrent inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:href="mrk-20221231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:to="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A275NotesDue2051Member_5badfb99-3d62-4fb9-a126-62c8847ceb0a_terseLabel_en-US" xlink:label="lab_mrk_A275NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2051</link:label>
    <link:label id="lab_mrk_A275NotesDue2051Member_label_en-US" xlink:label="lab_mrk_A275NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2051 [Member]</link:label>
    <link:label id="lab_mrk_A275NotesDue2051Member_documentation_en-US" xlink:label="lab_mrk_A275NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member" xlink:href="mrk-20221231.xsd#mrk_A275NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A275NotesDue2051Member" xlink:to="lab_mrk_A275NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7a97acc-ae4d-494b-af49-53fb1f35c81e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_974d1e03-dc6d-47ba-95a6-18a417f07193_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32ce8b59-7985-4b52-bac6-c8090e1b2055_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f8a69a0c-7637-47d4-93f3-013c32600048_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_47a25670-a1ae-4507-be59-9849943d2d4b_terseLabel_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder</link:label>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_label_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder [Member]</link:label>
    <link:label id="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_documentation_en-US" xlink:label="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Subject To Repayment At Option Of Holder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:href="mrk-20221231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:to="lab_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_ac4e2a9a-ffd3-4be3-b637-ccc64743d625_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_380798bb-f811-4fce-9c7c-82b6c0af387c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2d79150e-a736-4f1e-98b4-c3f88348e14c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_a10bef1a-a357-4de4-8e6d-28a6c86385d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_d9fadbb2-9f1d-48f9-a90c-ad054beec719_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_fc472e67-7894-4d88-8464-37310f612b43_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bda60dbd-0462-4824-96a3-7487d3b81b76_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A280NotesDue2023Member_b7a488b2-99ef-42d7-8dda-8a8ccea77aab_terseLabel_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% notes due 2023</link:label>
    <link:label id="lab_mrk_A280NotesDue2023Member_label_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Notes Due 2023 [Member]</link:label>
    <link:label id="lab_mrk_A280NotesDue2023Member_documentation_en-US" xlink:label="lab_mrk_A280NotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member" xlink:href="mrk-20221231.xsd#mrk_A280NotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A280NotesDue2023Member" xlink:to="lab_mrk_A280NotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_8cde891f-af1f-488a-bbd0-70e88b866c70_terseLabel_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member" xlink:href="mrk-20221231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375Notesdue2036Member" xlink:to="lab_mrk_A1.375Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_9d26c8e4-3ef3-4946-bc57-c69ce9e66f2c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_a0e2de29-29cb-4189-bb57-657bf3f3cef0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e2472411-8066-4110-bf7c-5c8d3f1bada4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7f671b81-05ab-4999-b514-27a170f0dafb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3837a33b-2ac0-4014-9fac-12010aaec992_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7199f927-4ad8-4508-a1b6-998b32019c25_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_fe2dfca9-f83b-46e4-9a7a-1b16f74f79fc_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_d39a81d0-0fc7-47cd-a2a8-d56b1563b677_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations before taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7a7f1ae8-db36-488d-bfc9-8d0cef72db9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CancidasMember_17d78de0-c87d-4cd5-9c81-abc8cc2b7c34_terseLabel_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas</link:label>
    <link:label id="lab_mrk_CancidasMember_label_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member]</link:label>
    <link:label id="lab_mrk_CancidasMember_documentation_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember" xlink:href="mrk-20221231.xsd#mrk_CancidasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CancidasMember" xlink:to="lab_mrk_CancidasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_d1386a59-7673-4ca5-a088-42fe714cc82d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3d624b03-4459-4673-bddb-8dd7806675ab_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_922842aa-97c5-4289-84b6-91baa26c913b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39e8c6e2-e43d-4906-a67e-31431a7afc61_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_519a81b1-03e8-4508-98bf-37e87c354e2e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7b0356b0-1c34-4325-b12b-af1c2661ebc0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_62984477-f59d-424d-9c16-13c50752dbf4_terseLabel_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equities</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Markets Equities Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed markets equities investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:to="lab_mrk_DevelopedMarketsEquitiesInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_d62fb6d1-a926-42c9-b0ae-e34954ba30e4_terseLabel_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_label_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP [Member]</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_documentation_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:href="mrk-20221231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:to="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FirstCommercialSaleMilestonesMember_6fec0ec7-2dd9-45ac-85d4-1e2be7293020_terseLabel_en-US" xlink:label="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestones</link:label>
    <link:label id="lab_mrk_FirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_mrk_FirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FirstCommercialSaleMilestonesMember" xlink:href="mrk-20221231.xsd#mrk_FirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FirstCommercialSaleMilestonesMember" xlink:to="lab_mrk_FirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b4765513-2cd9-4089-9ee9-4a3621756bcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6685d41c-0edf-4f1a-a068-1efc7d926312_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CostsExpensesAndOther_0544f8ed-977b-4c33-b1cb-99db5df32747_totalLabel_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs, expenses and other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_label_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Expenses And Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_documentation_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of cost of sales, operating expenses and nonoperating income or expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther" xlink:href="mrk-20221231.xsd#mrk_CostsExpensesAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CostsExpensesAndOther" xlink:to="lab_mrk_CostsExpensesAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BristolMyersSquibbMember_d0b85301-581e-4fd0-9ad6-45125ac3e5ea_terseLabel_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_label_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember" xlink:href="mrk-20221231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BristolMyersSquibbMember" xlink:to="lab_mrk_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_5bffcf7a-0544-4159-a9a6-57c2972a7747_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_eb6da93c-4e38-4173-8c30-6590cd7e031f_terseLabel_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember" xlink:href="mrk-20221231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RegulatoryMilestonesMember" xlink:to="lab_mrk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_f20499a5-b35b-4c68-ae10-ade868a39de4_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Information Pertaining to Stock Option Plans</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional information pertaining to stock option plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRatePercentage_aa3a0bb7-5a8a-4da6-804e-ec0eb5e15370_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRatePercentage" xlink:to="lab_mrk_RoyaltyRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_5d3bf98e-37c9-4f79-a5cf-44ebaff63567_verboseLabel_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_RealEstateInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_RealEstateInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember" xlink:href="mrk-20221231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RealEstateInvestmentFundsMember" xlink:to="lab_mrk_RealEstateInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0e766b5f-ebe1-483e-9415-bb491c1425cb_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_12620d99-ff8e-46a3-82bf-3538b44f1b64_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DunboyneMember_05dc2fb6-8130-4324-a0d9-d8972a754827_terseLabel_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:label id="lab_mrk_DunboyneMember_label_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne [Member]</link:label>
    <link:label id="lab_mrk_DunboyneMember_documentation_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember" xlink:href="mrk-20221231.xsd#mrk_DunboyneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DunboyneMember" xlink:to="lab_mrk_DunboyneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_79ba9290-964e-4e1e-9ba0-59fe7b6a6926_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and product rights - Reblozyl (12 year useful life)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4a47ee86-9f02-422d-b870-789c7a947cf0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxLineItems_f29c994e-206a-4244-a8a9-9119dbb4109f_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_mrk_IncomeTaxLineItems_label_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_mrk_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_mrk_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxLineItems" xlink:to="lab_mrk_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InjectableFormulationMember_1770512b-e065-418a-abc4-a7c977f63d9c_terseLabel_en-US" xlink:label="lab_mrk_InjectableFormulationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation</link:label>
    <link:label id="lab_mrk_InjectableFormulationMember_label_en-US" xlink:label="lab_mrk_InjectableFormulationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">injectable formulation [Member]</link:label>
    <link:label id="lab_mrk_InjectableFormulationMember_documentation_en-US" xlink:label="lab_mrk_InjectableFormulationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">injectable formulation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InjectableFormulationMember" xlink:href="mrk-20221231.xsd#mrk_InjectableFormulationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InjectableFormulationMember" xlink:to="lab_mrk_InjectableFormulationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_015a9059-21f3-48c5-bdfb-4d7aaf71b642_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_bd4bd980-ca97-4018-969a-a2e1baf7b634_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_011ad43f-bc0f-426d-a047-e119fc793480_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_5d88e382-7bd6-4949-a33b-4a0726ee4eb6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_ccba4d4c-9575-4850-b32c-b0e94168bda4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan net gain (loss) and prior service credit (cost), net of amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7b31a498-9f83-4818-80a7-3c0d1401995b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_6c99a3b5-fb10-4d4f-81c0-3a46c49bdcd9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_bbe8a29e-8f70-4b88-8a3a-0fb6a0acc5da_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b205d16d-2971-4b61-99cd-1c9abec625aa_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f727091a-1d7a-402f-bbe4-dc7462d226cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on investments, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_85572cef-071f-45a7-8849-c277dfe6fca1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_1c8ff2bf-0376-4505-ba96-5308afbf6a75_terseLabel_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% notes due 2033</link:label>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_label_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member]</link:label>
    <link:label id="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_documentation_en-US" xlink:label="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point five zero percentage notes due on two thousand and thirty three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:href="mrk-20221231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:to="lab_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_80d64e7f-4a27-42f7-8662-841e6477b21a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_8c07aaf0-d1df-4855-a60c-b69aa3825976_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ca4b78fe-5059-45ba-bcff-9b84faab343d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProfitShare_69b5ac8c-a013-4ca9-8fe6-8167a80bff11_terseLabel_en-US" xlink:label="lab_mrk_ProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit share</link:label>
    <link:label id="lab_mrk_ProfitShare_label_en-US" xlink:label="lab_mrk_ProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share</link:label>
    <link:label id="lab_mrk_ProfitShare_documentation_en-US" xlink:label="lab_mrk_ProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShare" xlink:href="mrk-20221231.xsd#mrk_ProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProfitShare" xlink:to="lab_mrk_ProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_351c74b3-c2ec-4cfa-9bd0-7d994381402b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_7b95b8f2-6a46-4cb0-8471-3e9fa43a63f3_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f070404f-fad4-4480-9152-1e667200db01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_d372fc65-26e8-46bc-85c4-15c882a95aab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_981ceb82-25a6-452b-8410-b94630535567_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_2fbf5ef0-dd9d-4a9c-b0b3-bb72c8f113c2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Flows Provided by Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_0fb5c62d-c490-4045-9c32-09496ede048a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (income) from investments in equity securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_87069d1d-4250-44ed-b6d7-54567afe988e_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_McKessonCorporationMember_55ff9cd8-ff40-46f5-bda3-c49068a63751_terseLabel_en-US" xlink:label="lab_mrk_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson</link:label>
    <link:label id="lab_mrk_McKessonCorporationMember_label_en-US" xlink:label="lab_mrk_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_mrk_McKessonCorporationMember_documentation_en-US" xlink:label="lab_mrk_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationMember" xlink:href="mrk-20221231.xsd#mrk_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_McKessonCorporationMember" xlink:to="lab_mrk_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_7839a66b-f609-4eb8-b4da-b387b30ad8b6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_06de774d-eddd-4de4-a324-8e7a2f4b5703_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_0e92d280-d603-44b2-acc9-1dd1332bd47c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_759b970c-6c5a-4b83-b208-447d710f74d6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5365c813-5aed-4487-8e9d-33f9b129e30d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_88c3d4d2-233f-48cf-b604-492cd4ac37f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_2025860e-5ac3-49f3-b0cd-f0c3588143e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AccrualForChargebacks_d10dd678-02c1-44d3-bcda-9377773b8288_terseLabel_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for chargebacks reflected as direct reduction to accounts receivable</link:label>
    <link:label id="lab_mrk_AccrualForChargebacks_label_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Chargebacks</link:label>
    <link:label id="lab_mrk_AccrualForChargebacks_documentation_en-US" xlink:label="lab_mrk_AccrualForChargebacks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for chargebacks reflected as a direction reduction to accounts receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks" xlink:href="mrk-20221231.xsd#mrk_AccrualForChargebacks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AccrualForChargebacks" xlink:to="lab_mrk_AccrualForChargebacks" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8d3c8673-0183-4bee-bcad-8c2b9150170f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8d69878d-471e-4d8a-a76f-08670875ccbc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_f1ec8144-01cc-4ebb-b64a-4d6fcd3e8a1c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrevymisMember_cfe6b5eb-5843-4bbb-84e3-cb9abec6dcfe_terseLabel_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:label id="lab_mrk_PrevymisMember_label_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:label id="lab_mrk_PrevymisMember_documentation_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember" xlink:href="mrk-20221231.xsd#mrk_PrevymisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrevymisMember" xlink:to="lab_mrk_PrevymisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_15799d98-8da2-4897-948d-d31ed80dcdc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_074ce1b4-c314-4d0a-816d-8f3e830d36d1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefits related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e1310b5a-9f3a-453d-b060-5247b12e1748_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f386fffe-2031-4809-b115-d09c936825bc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_3089ea6e-0603-4129-8db4-fd6b455dfead_terseLabel_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_label_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member" xlink:href="mrk-20221231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.500Notesdue2034Member" xlink:to="lab_mrk_A2.500Notesdue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2b53e9b8-68d9-4bb7-9fc8-6755a3eadea9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_d3b6ae52-763b-4b61-9c2f-f676262483fc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and sales, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:to="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_c81ab05e-e255-408c-adb4-7f14200e0fbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8592bc1d-31c1-4d73-a1fd-4b331faa724f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_933659a9-84a5-4839-87f9-68c77034bbc8_terseLabel_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% notes due 2036</link:label>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_label_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member]</link:label>
    <link:label id="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_documentation_en-US" xlink:label="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point seven five percentage notes due on two thousand and thirty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:href="mrk-20221231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:to="lab_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_d9be5757-48c3-41ed-8743-c57f6b4581fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_23d67828-7f98-447a-9634-912a1dbd6a66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_1b14ae9b-4c7c-4ef1-a497-bbc9fb1fd863_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Restructuring Costs</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_72a9209b-4bcd-4cf7-99b4-65ca4b1301a3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_a28a89e2-0468-462d-b300-b8310c235c6a_terseLabel_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:href="mrk-20221231.xsd#mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:to="lab_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_8a4f3cd4-d511-462f-bd66-9212cae3c03c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory related, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_79c4d1f8-a5bc-43da-8a1a-ad07e04bbd36_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6462741a-e13e-4e2d-96fc-3916c94595a8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_a7cf08e8-52a2-4280-9afd-df2bb9c3a9a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_d0976ed5-ee0c-4db4-a5f8-7f13f91e9674_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_64b384d8-bbfa-4af1-9cc9-74e81bf79d65_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI and the foreign-derived intangible income deduction</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0e51254-bd3e-4909-b8b7-e9cdcc4d6de7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_441ea1a4-a2c6-4e94-85a2-b426ed3c872b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_14641a60-8306-44ac-9a50-3ead2524e135_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestones payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_31a3002a-5cfc-4976-8e82-a8bcad940a98_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5f799670-7ae6-4f56-9637-bc42032ba09b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_eeff08e2-362c-4040-89ea-54a2d3d081de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_a1cab04c-3f01-4877-9e8f-fe401aa41278_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_e698d237-eabe-408f-ae55-fabf0fbbc76c_terseLabel_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product return period and expiration</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_label_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period After to Expiration Date</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_documentation_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period After to Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:href="mrk-20221231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:to="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0b304cc2-b7ca-4542-9dcd-2f6dd04d3792_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_88b657bc-2e92-416b-950b-977715d5a795_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5cf7333b-a21d-4cff-9f39-f675919a6ec6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_9d25b55f-ed4e-4c1f-9ed4-933e92cef4c3_terseLabel_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_label_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:label id="lab_mrk_RevenuePerformanceObligationPaymentTerms_documentation_en-US" xlink:label="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms" xlink:href="mrk-20221231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenuePerformanceObligationPaymentTerms" xlink:to="lab_mrk_RevenuePerformanceObligationPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32e2910e-232c-4007-a105-27127589a44f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f636d06e-ff3b-4aa1-afbe-a8c3dc331629_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_d286bb4b-51a6-4110-9a8b-5af37dd50e39_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_44163fae-2c13-4f9c-8d83-9f92506d6b44_negatedTerseLabel_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net liabilities</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_99c5ce20-95b7-4c5f-aaeb-f03380310b1b_terseLabel_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:href="mrk-20221231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:to="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_4489c559-fdf4-4da8-b99f-0f8f9557b620_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_ecbf431a-43be-4b33-8112-f7b5289c593a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_45aa466f-8091-4e49-af2f-df4b93cdff9e_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_68161c6c-14a6-4c5c-a235-20f763692760_terseLabel_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests</link:label>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_label_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests</link:label>
    <link:label id="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_documentation_en-US" xlink:label="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:href="mrk-20221231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:to="lab_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_3c71d160-04ef-4ba6-bfdb-ff8b7f8c511f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_b7f5522c-2f6b-4677-87fe-a0c5afdd1ce8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_e220912b-6a95-4753-aba8-f521261a3390_terseLabel_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share)</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lab_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_0d6e00c8-1e9a-4861-8861-88abb4398544_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds collected from factoring of receivable, held in restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_a28c27fc-82a5-4c31-ba2e-dac5af0749ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_147be182-2552-4aac-a0f3-2a622c9853ac_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AmerisourceBergenCorporationMember_a01ac775-cb33-409c-9325-70d4490b9438_terseLabel_en-US" xlink:label="lab_mrk_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_mrk_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_mrk_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_mrk_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_mrk_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmerisourceBergenCorporationMember" xlink:href="mrk-20221231.xsd#mrk_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AmerisourceBergenCorporationMember" xlink:to="lab_mrk_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_b2cadbd7-6297-49bd-9af7-a5ca97a699d4_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_cf2a86cf-1e15-4a2d-85e7-95d0bb991f59_terseLabel_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Gain</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_label_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Loss [Member]</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanNetLossMember_documentation_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Net Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:href="mrk-20221231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:to="lab_mrk_OtherPostretirementBenefitPlanNetLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_eac97e3d-cbba-43d6-82ef-3810706bc61e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_d2c176c8-a0c5-4e11-be0b-175143175ad6_terseLabel_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And Agency Obligations Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:to="lab_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets_d947b4a1-df13-4044-ae79-016172963ece_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaboration targets</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Collaboration Targets</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Collaboration Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementNumberOfCollaborationTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:to="lab_mrk_CollaborativeArrangementNumberOfCollaborationTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_a419659c-3da3-4755-afa0-83d17e9d1ff1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_31d31d50-c3cd-463e-aae9-35e93158826a_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c23b0d48-02b3-48e8-83f2-158d44c935bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_aadf238d-62bb-448a-b00a-b4ea544fe55a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f7292d59-985d-49b9-8d51-a36d65e87415_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_365ec045-5d34-4167-a68b-11e5b4dd0472_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_ffc160cb-c280-4eb3-92dc-159a4478f480_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_b90118a5-08a0-462b-9f37-a181dccba342_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes And Other Assets, Noncurrent [Member]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes And Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:href="mrk-20221231.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:to="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_62e146fa-371f-4bf1-904b-fad6609b292e_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Pandion</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_dbc13aa4-fbc8-4bdc-8692-f14b6bb3987a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_d6e7f16b-03ff-45ec-8a19-c854d25bd7f1_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pretax restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_01e50807-1a17-4388-a3ee-dbfb36c3329d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A145NotesDue2030Member_809de357-a91e-49ba-bb03-fd1f34584c68_terseLabel_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030</link:label>
    <link:label id="lab_mrk_A145NotesDue2030Member_label_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% Notes Due 2030 [Member]</link:label>
    <link:label id="lab_mrk_A145NotesDue2030Member_documentation_en-US" xlink:label="lab_mrk_A145NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member" xlink:href="mrk-20221231.xsd#mrk_A145NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A145NotesDue2030Member" xlink:to="lab_mrk_A145NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4f7b029a-83aa-4141-a2bc-f523e373a4e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ae58ef3e-0971-4fa8-8a6c-337554a076c0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_15818c59-3177-4484-919d-8b9fd99cad63_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_147f382a-fa38-4f52-aed4-ee064803992a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_9058ab42-fcba-44a5-a9d2-11f338e5f475_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent_3e388c41-fdad-49f1-a585-14f993e3c03d_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of VelosBio</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_1c36d1ce-c8ce-4eee-aaa5-82b62d902f10_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_58a0db59-8890-4516-ba8d-099812a8e6d1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_96c8c319-9e24-487a-bb0a-8df73bd76d20_terseLabel_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_label_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_documentation_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:href="mrk-20221231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:to="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e82c744-5f6f-4500-b0bf-f1ec9edde17b_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5fbe84e9-39ac-4b52-9e51-db845a354136_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b6bb403b-da80-4e27-b997-6f3fc92542fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_418e3b7a-1b66-488d-a108-65a5b75387b6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_4173517a-ece3-4216-a240-d49c37ec6b8a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e6688e84-1813-41ff-a09f-b815b4ecbe50_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_62991425-ed43-444e-a796-c9b75075c192_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1ba9bcb3-3fcc-405c-9b08-c83817b19212_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_883ef4c3-0f33-4c53-9707-d39b64e7a4bc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_3d20a678-aa7c-4016-be89-a184bf126e04_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon &amp; Co.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a3c72242-98a7-48db-af29-269a24ed0b06_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_acdf2ddb-22ae-4512-a0c3-72a9b671f111_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1e3dda64-0f6e-447d-994e-5ede8c0c206f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_ff0ec688-7f70-42f4-8d34-6afc75fbe49b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_204900c4-7b6c-4a48-8495-424f52276b45_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_95cde817-bf7f-4bdc-aa89-4bad6bf09c72_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_4b26ae18-19e0-466b-9c7d-491a77298b38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8233b46f-995e-4824-80e8-ac2a39275dd9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_bb036b09-1ec7-41dc-8f44-78dcf8b4fe85_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_84829c5a-d311-41b1-8aaa-500b3a73c8a8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-Off of Organon &amp; Co.</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8ca6c11f-dce9-46bc-8925-7d0156d45bbe_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable net impact to income tax provision if unrecognized tax benefits were recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanumetMember_e0425fc8-5f9c-4dc0-ab7e-42aa9bab83d1_terseLabel_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet</link:label>
    <link:label id="lab_mrk_JanumetMember_label_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanumetMember_documentation_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember" xlink:href="mrk-20221231.xsd#mrk_JanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanumetMember" xlink:to="lab_mrk_JanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d74589a8-a2ab-440b-92c3-2bafebdecda6_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_9cbd401d-9ed9-4058-90d3-c29f128e9fe0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_25d105df-0ef6-4014-96a5-3b70d09d1184_terseLabel_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments to be made</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments to be Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments to be Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:href="mrk-20221231.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:to="lab_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_f243be5f-59eb-4248-80dc-8a3dfc61e89c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c73f6ac0-5ce8-4076-acd6-28a33468a406_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_21416e51-d921-4c40-99cb-b79550a6def5_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_050224a2-74a4-4740-b55b-113c1fa4d493_terseLabel_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for paying off environmental liabilities</link:label>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_label_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term For Paying Off Environmental Liabilities</link:label>
    <link:label id="lab_mrk_TermForPayingOffEnvironmentalLiabilities_documentation_en-US" xlink:label="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for paying off environmental liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:href="mrk-20221231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:to="lab_mrk_TermForPayingOffEnvironmentalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_a9aa9dbe-315b-4b76-bb77-5fb4bf163e51_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_e6d1528d-b684-434c-a2d1-9b7c0aece561_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received from counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_a0f4fd64-15f5-41e5-87a1-e499beb547e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_6e443fef-715e-49c0-a962-b0b82aa50664_terseLabel_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_label_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:label id="lab_mrk_ScheduleOfOtherIntangiblesTable_documentation_en-US" xlink:label="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangibles [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable" xlink:href="mrk-20221231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable" xlink:to="lab_mrk_ScheduleOfOtherIntangiblesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f3952fe-04c3-49cc-86ec-67910d5aaff6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_ad47d40f-6b0f-4bbe-860c-e022319d4dbf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_b48d397d-d43c-4eb0-9364-39b6d228e142_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_37e9ce92-7682-4dcb-af16-4b170f4b5125_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AdempasMember_538b40ec-515a-454d-8c84-d306e4887c86_terseLabel_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:label id="lab_mrk_AdempasMember_label_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas [Member]</link:label>
    <link:label id="lab_mrk_AdempasMember_documentation_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AdempasMember" xlink:to="lab_mrk_AdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_edf17024-3326-4428-84b3-df0000ed6fe4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2d012e7c-fa2f-4a79-956c-b3aea6062783_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ff20b696-5043-48b6-b3e4-817a76e21ee8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_3f64ffc2-1133-4820-ae3a-22c1981dea98_terseLabel_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_label_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_documentation_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember" xlink:href="mrk-20221231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AlliancerevenueLynparzaMember" xlink:to="lab_mrk_AlliancerevenueLynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_ef368f9a-ab64-4df6-b282-eab9218f5df7_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NemtabrutinibMember_aec6f961-6656-4cc7-a41a-6949606b8921_terseLabel_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib</link:label>
    <link:label id="lab_mrk_NemtabrutinibMember_label_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib [Member]</link:label>
    <link:label id="lab_mrk_NemtabrutinibMember_documentation_en-US" xlink:label="lab_mrk_NemtabrutinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nemtabrutinib</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember" xlink:href="mrk-20221231.xsd#mrk_NemtabrutinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NemtabrutinibMember" xlink:to="lab_mrk_NemtabrutinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_90f01912-9079-46e9-914a-2aabf3ae7453_negatedLabel_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other unallocated, net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_label_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Other Expenses Net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_documentation_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net expenses not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:href="mrk-20221231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:to="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_315ff9c9-77dc-4d4c-8947-90e365ffb72b_terseLabel_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_label_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_documentation_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:href="mrk-20221231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:to="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_bddfed08-c0b0-4454-80de-96ec05179e88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Between Effective Tax Rate and U.S. Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f0828a8-0fd5-48a9-87f6-7e669d6bf5a0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ad7f1438-f9d0-48e8-9349-e524aa11ebec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_8ac0ccd2-5892-4657-a30a-d7fa3c200fa4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges Related to Restructuring Program Activities by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b691a906-33a2-422b-a0f8-b61cd561f548_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_30a4330b-be91-4079-9f5b-82de91765bcf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_04b2b7c3-d5c8-435e-9ad8-ebfe55f3c9ff_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2222d595-d197-4d14-8575-d83e84c5f410_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_32c098af-0a2c-49cd-8dcd-1d773b10fcb6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_3f13b68e-0ee1-4bcd-a508-ef2d5c180666_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrnaTherapeuticsMember_e7b0b3d0-5299-4c85-bdb7-abc260035cc9_terseLabel_en-US" xlink:label="lab_mrk_OrnaTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orna Therapeutics</link:label>
    <link:label id="lab_mrk_OrnaTherapeuticsMember_label_en-US" xlink:label="lab_mrk_OrnaTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orna Therapeutics [Member]</link:label>
    <link:label id="lab_mrk_OrnaTherapeuticsMember_documentation_en-US" xlink:label="lab_mrk_OrnaTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orna Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember" xlink:href="mrk-20221231.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrnaTherapeuticsMember" xlink:to="lab_mrk_OrnaTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bbd28589-3712-4a6a-ac5d-91d34986bfdc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c362256-ff1f-4661-a52d-f485c3c0a798_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_6a3b5706-4391-4b55-9dd5-f62205321f2f_terseLabel_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375eurodenominatednotesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% euro-denominated notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member" xlink:href="mrk-20221231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375eurodenominatednotesdue2036Member" xlink:to="lab_mrk_A1.375eurodenominatednotesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFive_f5e291bc-f334-4250-adf5-08f6f09388b6_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2027</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFive_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Five</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFive_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFive" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearFive" xlink:to="lab_mrk_LongTermDebtInterestPayableYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7607caf5-100a-4367-818f-5d1d001cef15_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_37339268-3fff-479d-8ac0-6e6d48df86db_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PandionTherapeuticsMember_7e815628-9b5c-494a-baff-ce804d51fbc8_terseLabel_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics</link:label>
    <link:label id="lab_mrk_PandionTherapeuticsMember_label_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics [Member]</link:label>
    <link:label id="lab_mrk_PandionTherapeuticsMember_documentation_en-US" xlink:label="lab_mrk_PandionTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pandion Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember" xlink:href="mrk-20221231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PandionTherapeuticsMember" xlink:to="lab_mrk_PandionTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ed110afc-1103-44bf-bec8-36a28ef85aa6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_cc8241dc-3c9b-40f9-8e24-1a899e4b8d48_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDerivativeMember_65f3f054-2122-41e4-8e69-1a1b3a8c714b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDerivativeMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDerivativeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDerivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDerivativeMember" xlink:to="lab_us-gaap_DefinedBenefitPlanDerivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9e46dc3f-dfe8-483b-8390-384894246ae2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_0b1d54d9-f314-4e81-96c5-3f7ad81669a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_533d70e5-719f-4f5b-b100-47f8d2bebb68_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_0cd33a63-b16f-4821-b033-052f7c0f201f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_e8d215ed-7932-46e0-a271-c7ac67838c58_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation payments to settle equity awards attributable to precombination service</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_b596fca1-a3bb-49e6-b0f1-569f982adfa8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax settlements</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_3a839c6f-3b63-49d4-a2f4-756232b3ae8f_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Research and Development Expenses</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_6c83844c-31d5-4627-973e-57138e6146f6_terseLabel_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Company's pension investments categorized as level 3 assets</link:label>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_label_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Pension Investments Which Are Categorized As Level Three Assets Percentage</link:label>
    <link:label id="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_documentation_en-US" xlink:label="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company pension investments which are categorized as level three assets percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:href="mrk-20221231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:to="lab_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_15096ff3-13f0-4bce-93a2-d027163128ea_negatedTerseLabel_en-US" xlink:label="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of Organon</link:label>
    <link:label id="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_label_en-US" xlink:label="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction</link:label>
    <link:label id="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_documentation_en-US" xlink:label="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:href="mrk-20221231.xsd#mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:to="lab_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4f22cd86-fb0d-4c4e-a42b-08e9d2202ebe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6ae5787e-79a4-44e2-8f64-24dc93c4413f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0f09ce1a-63fd-4d1e-ae9a-50a13221ee7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax share-based compensation cost recorded, related to continuing operations</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InvanzMember_2049736d-2881-412b-acc7-433ef7ae5b57_terseLabel_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz</link:label>
    <link:label id="lab_mrk_InvanzMember_label_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member]</link:label>
    <link:label id="lab_mrk_InvanzMember_documentation_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember" xlink:href="mrk-20221231.xsd#mrk_InvanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InvanzMember" xlink:to="lab_mrk_InvanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55b8385d-23f4-4546-a474-c1da11358173_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_5485f19a-01b9-4a5a-949d-30e080d5df79_terseLabel_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_label_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:label id="lab_mrk_ChargesRelatedToProgramDiscontinuation_documentation_en-US" xlink:label="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges related to program discontinuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:href="mrk-20221231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ChargesRelatedToProgramDiscontinuation" xlink:to="lab_mrk_ChargesRelatedToProgramDiscontinuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_882ffbc8-8804-44e5-8b47-f8d43e593396_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_dccab843-7aea-4810-a5f9-18f1f53703fa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity income (loss) from affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_8cd3e208-69bf-4318-932e-607d741134f0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OralAndInjectableFormulationsMember_6c009bce-e302-4fc4-a8e9-897d96868c31_terseLabel_en-US" xlink:label="lab_mrk_OralAndInjectableFormulationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral and Injectable Formulations</link:label>
    <link:label id="lab_mrk_OralAndInjectableFormulationsMember_label_en-US" xlink:label="lab_mrk_OralAndInjectableFormulationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral and injectable formulations [Member]</link:label>
    <link:label id="lab_mrk_OralAndInjectableFormulationsMember_documentation_en-US" xlink:label="lab_mrk_OralAndInjectableFormulationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">oral and injectable formulations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralAndInjectableFormulationsMember" xlink:href="mrk-20221231.xsd#mrk_OralAndInjectableFormulationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OralAndInjectableFormulationsMember" xlink:to="lab_mrk_OralAndInjectableFormulationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_bbf1bd9a-ab61-42c6-b799-5d08547dc6c7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_91e28a62-e19c-4dd2-8ec5-c7640ca87472_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_6f2ae7dc-e3b5-4e8a-8b0b-a8871b51ef9e_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, equipment and office furnishings</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_67b82c31-fcfa-499a-934a-83c54f4a8b98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_d5fd1738-8430-4b5c-8860-d576511e8cd8_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation January&#160;1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_833a850f-e643-4df4-bc9c-a7203a7b6330_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3febb6b2-5c0c-4d61-95b1-7376f1f2a8c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculations of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7998ef90-1023-4ea8-9f69-b368f347895a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_7e023ecc-f295-484e-987b-39f35876d0cd_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, Assets</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Unrecognized Tax Benefits</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets unrecognized tax benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:to="lab_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_39c4495c-d94e-4ac5-a1f4-d865a9bd99c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_29654c92-8cfc-4fae-8c7f-554289a4b7fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8b56be6f-76fa-4df2-828c-7fbdae808fbd_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_61e4f6c0-5db1-4590-a602-58518ca1121f_terseLabel_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product return period</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_label_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</link:label>
    <link:label id="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_documentation_en-US" xlink:label="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:href="mrk-20221231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:to="lab_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_6adf5a03-5a4d-48d2-a152-f4ab7a6e7ad9_negatedTerseLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of ArQule, Inc., net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Five, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Five, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:href="mrk-20221231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_131f44ec-56bd-42a9-a5cd-77f24f9e603b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a882e698-4d90-40fb-ac80-6757b31d327e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_fdcf14af-e069-474b-a046-174a816b5288_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary growth rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d13d4206-6345-4651-aa85-554fe1431e02_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ea363e7b-d7d7-4cf7-b02b-b8a3e0d0f88a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_d55a06e1-389a-4ddf-9635-d48fde5187dd_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementsAbstract" xlink:to="lab_mrk_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_59306c96-0033-4de4-a46e-b4464d0b6e1f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c93cd8f0-99af-405e-a33a-32576daabb2f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_e3dd4b94-cbb4-4442-ae14-e689deb6444f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_038a62c0-c699-4228-9704-305f92f151e8_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other segments</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_32a59f6a-dd18-44f7-88b5-0d44e14dc5ba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d518fa55-1ebd-42b7-84ff-35d565406ba8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available borrowing capacity under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_09dd8f64-abe1-49a4-ad6c-abb53db8ca20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ab2b030e-85e2-4dd9-aafe-f5b41681cdd8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_72667a5c-01db-4841-9414-e6896054bf21_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_33c4f335-900c-40dd-8f41-a0ac0d27ed90_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_e76fc2be-03e6-4ea1-8e2c-6ebe293017da_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.&#160;equities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_fadea25b-10bd-41e0-a10d-949f688b1408_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_8a628c46-c6b8-472b-82f9-63d2cde2a23a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to the sale of the marketing rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_de0bfb44-ab1c-462f-92b5-5a39b1807550_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearTwo_30233dc3-0fc5-45d7-b1b2-b8f13da52064_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2024</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearTwo_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Two</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearTwo_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearTwo" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearTwo" xlink:to="lab_mrk_LongTermDebtInterestPayableYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_090db731-23d7-4ac6-9dca-f0ece8558e68_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ReblozylMember_e9c46926-2fe0-4d55-9ac4-4729bed7e596_terseLabel_en-US" xlink:label="lab_mrk_ReblozylMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reblozyl</link:label>
    <link:label id="lab_mrk_ReblozylMember_b210d0c5-618e-4f8d-8853-e15a4ed68d0a_verboseLabel_en-US" xlink:label="lab_mrk_ReblozylMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Reblozyl</link:label>
    <link:label id="lab_mrk_ReblozylMember_label_en-US" xlink:label="lab_mrk_ReblozylMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reblozyl [Member]</link:label>
    <link:label id="lab_mrk_ReblozylMember_documentation_en-US" xlink:label="lab_mrk_ReblozylMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reblozyl</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember" xlink:href="mrk-20221231.xsd#mrk_ReblozylMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ReblozylMember" xlink:to="lab_mrk_ReblozylMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_eb70d63d-f6ad-44b9-bc7f-0107e2018101_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_25110e95-9e95-47f4-b307-a38a8c079fef_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_2287ce22-1d02-45ac-8632-ed19ab9658e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_97971544-616e-41f6-8ee5-b6338e8a4e71_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_7d096cda-3433-4988-a6e1-4bda5d974510_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_66313148-3d87-4b82-a1b7-e6535fdc1861_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9f1fde95-1b2a-4bf3-baa0-9c9eefc9e0ac_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BayerAGMember_7a6b929a-5db0-4768-9c2d-88f4959a42e1_terseLabel_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:label id="lab_mrk_BayerAGMember_label_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:label id="lab_mrk_BayerAGMember_documentation_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember" xlink:href="mrk-20221231.xsd#mrk_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BayerAGMember" xlink:to="lab_mrk_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8f70e3d8-90a0-4904-bfc4-c2890deab30d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a1455324-ee05-445e-a0ee-777c5f3af037_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck &amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f1c73cf2-8546-4967-85ec-1e59bf5660e9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck &amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4e767185-82a4-4bc0-88c3-fb0b50163777_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_6226256c-435b-4868-82c4-549b0cc07122_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses and other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_bd498631-8a2b-419a-95eb-40c61bd4445e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of unrecognized prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0be53b93-1175-43c8-8614-dfbb93d3cb68_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFour_09147599-a384-41c0-a466-af637465ea84_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2026</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFour_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Four</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearFour_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFour" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearFour" xlink:to="lab_mrk_LongTermDebtInterestPayableYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_41263306-0094-44bb-88af-ae7fd9b9e52c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary growth rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArQuleMember_f9e62c09-cf23-46e2-beef-946bc468cf0c_terseLabel_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule</link:label>
    <link:label id="lab_mrk_ArQuleMember_label_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:label id="lab_mrk_ArQuleMember_documentation_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember" xlink:href="mrk-20221231.xsd#mrk_ArQuleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArQuleMember" xlink:to="lab_mrk_ArQuleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_5964ad27-71f4-450a-9be0-4b590ef19536_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e890c7c0-8a13-43b9-b8ab-791bbc96e7fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9bab2836-a835-4f37-9a02-22287419c58e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e35a4fa2-5d4f-4a03-b8e6-620072c3425a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantity of stock options that vest per year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LegalDefenseCostsMember_8a119be6-3840-451e-b578-a33ed74e0570_terseLabel_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_label_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_documentation_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember" xlink:href="mrk-20221231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LegalDefenseCostsMember" xlink:to="lab_mrk_LegalDefenseCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_5a4c2318-fcee-4f87-b1af-4b6e4e4c9e89_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_afa87608-47d2-4171-a418-0d34107631cb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax settlements</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f2705526-d331-4666-84fc-0e471890252d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_846879f2-a020-46f8-a11c-9f7132417e7e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9f102068-2f67-47eb-8576-84550e0d930e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesDiscounts_a7af4f8f-cb2f-4b57-a0e9-961b7b1c1cb2_terseLabel_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_label_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_documentation_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts" xlink:href="mrk-20221231.xsd#mrk_SalesDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesDiscounts" xlink:to="lab_mrk_SalesDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_198dfd3e-2895-40a5-913d-bd985c9d0ce1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AstraZenecaMember_7ba164fd-8c01-4615-b4b4-5feea0aa88a6_terseLabel_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_label_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember" xlink:href="mrk-20221231.xsd#mrk_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AstraZenecaMember" xlink:to="lab_mrk_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_971fcafe-b2f0-4feb-bb5a-580d896674e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AuditInformationAbstract_label_en-US" xlink:label="lab_mrk_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mrk_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mrk_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AuditInformationAbstract" xlink:href="mrk-20221231.xsd#mrk_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AuditInformationAbstract" xlink:to="lab_mrk_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_529519a1-69a1-437c-a414-32179f65e400_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_8109ca5d-25a2-4fa7-893b-eb9b053cac9b_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_395dc7a9-af8a-4f42-98ad-492080f1b6c9_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_10ee029b-f11b-47cb-ab9d-3a21c3334e27_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_912ec733-47d9-4941-8089-39013abdce65_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_5eb4b810-b7d0-4bbb-8527-e20bfb1a9965_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_da2d1873-6eaa-4400-8324-c37b4c1ce114_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_217ec589-fe64-440b-8a81-4223f1c6d4bf_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding by others, development costs subject to funding</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:to="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_446c2ffb-f4e3-49f9-940f-154d1b8213c5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_d0b09bb9-44ae-4f7f-a990-ff7d2b82ce6c_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic defined benefit plan (credit) cost other than service cost</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_c4e30225-d358-4ed3-8682-550f848bab8e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected restructuring and related cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d5d706a0-681d-4332-b627-d599775511d5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_059ebaaa-4c2e-49e9-90d5-37445da73232_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_18a82a7a-9ec9-4bff-bedb-c80d63f34799_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_fde4a9ab-d3e3-4d53-a260-a00690812875_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_b64f125a-4e8c-494a-9912-f2b524228ac7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_096cca99-bcb6-46a7-b209-505a465309e6_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember" xlink:href="mrk-20221231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueKoselugoMember" xlink:to="lab_mrk_AllianceRevenueKoselugoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bb4c4fb6-4517-4b98-9a69-5e6ddbf88c9e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_cf922b00-f76d-4b8b-a374-db5bc102965f_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9a772b5c-fd85-482d-932c-3df93377e794_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_cf122f1f-1295-41ac-8ab4-1bf3c8295adc_verboseLabel_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset-backed securities</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Asset Backed Securities Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset backed securities fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:href="mrk-20221231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:to="lab_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_06bdc467-ccf2-449c-989b-0909375af8f4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_e48c42be-c675-455e-b582-c7b86be1c43c_terseLabel_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% notes due 2029</link:label>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_label_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_mrk_A3.40NotesDue2029Member_documentation_en-US" xlink:label="lab_mrk_A3.40NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member" xlink:href="mrk-20221231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.40NotesDue2029Member" xlink:to="lab_mrk_A3.40NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities_36c38e8b-c5f3-49b0-b038-a604f443c1a9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral advanced to counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d955999e-5c20-4353-865a-ae633d0f5a15_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_b7d44c03-999c-4b8b-beab-6d6dd40214b5_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableSale_9f295aca-0262-420b-88e1-5f7f5b71d469_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Factored accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableSale_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableSale" xlink:to="lab_us-gaap_AccountsReceivableSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fbe5dce9-569f-4695-a1a0-e3d79ffe60ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_4d0580c6-dc47-452b-a451-a9b173744a45_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_925c1325-d4ea-4abb-a896-6774b1331e81_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_78befbad-b032-40f3-bd23-ecd7d632ab28_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_cb50ff38-6e0c-421e-91e1-34abfbb07bcc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b24d835a-bbd0-4990-8703-d09ad5698da3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Long-Term Debt and Leases</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DerivativeNotionalAmountMatured_6d889b98-1486-4ad2-aab4-0a94bda6e79d_terseLabel_en-US" xlink:label="lab_mrk_DerivativeNotionalAmountMatured" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total notional amount of Interest rate derivatives matured</link:label>
    <link:label id="lab_mrk_DerivativeNotionalAmountMatured_label_en-US" xlink:label="lab_mrk_DerivativeNotionalAmountMatured" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Notional Amount Matured</link:label>
    <link:label id="lab_mrk_DerivativeNotionalAmountMatured_documentation_en-US" xlink:label="lab_mrk_DerivativeNotionalAmountMatured" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Notional Amount Matured</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DerivativeNotionalAmountMatured" xlink:href="mrk-20221231.xsd#mrk_DerivativeNotionalAmountMatured"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DerivativeNotionalAmountMatured" xlink:to="lab_mrk_DerivativeNotionalAmountMatured" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e24a7ad5-a214-4406-a057-dd77b9dd9954_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_157c3d73-2373-4444-92c8-34ede56ef177_terseLabel_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from Organon &amp; Co.</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_label_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operations Distribution Received</link:label>
    <link:label id="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_documentation_en-US" xlink:label="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operations Distribution Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:to="lab_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6335546e-de6c-4ef7-9c72-2d963e8ef42b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_fe73f8d2-f2cc-4db2-8903-15d724c2d5f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c20e19ad-95e2-4ed8-9f75-2027b8f297ff_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeInvestmentsMember_cf35383e-84b0-4a44-8183-89345e4995c1_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Investments</link:label>
    <link:label id="lab_us-gaap_FixedIncomeInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeInvestmentsMember" xlink:to="lab_us-gaap_FixedIncomeInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_91cf8e56-ff00-497f-901a-bbb9f2392aa0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_332058c0-3eb4-4169-a5ce-cfdf390e4cdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_5bf2eb47-820e-4c97-aa45-f92417952e50_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract indexed to issuer's equity, indexed shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_label_en-US" xlink:label="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contract Indexed to Issuer's Equity, Indexed Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:to="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_055f7a04-e9a5-44ac-8718-f73363a54b1f_terseLabel_en-US" xlink:label="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate possible expenditure on environmental matters in excess of amounts accrued</link:label>
    <link:label id="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_label_en-US" xlink:label="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Exit Costs, Reasonably Possible Additional Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:to="lab_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A215NotesDue2031Member_58c98d8c-c07d-4567-aa20-f32edf5db95e_terseLabel_en-US" xlink:label="lab_mrk_A215NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15% notes due 2031</link:label>
    <link:label id="lab_mrk_A215NotesDue2031Member_label_en-US" xlink:label="lab_mrk_A215NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15% notes due 2031 [Member]</link:label>
    <link:label id="lab_mrk_A215NotesDue2031Member_documentation_en-US" xlink:label="lab_mrk_A215NotesDue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15% notes due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member" xlink:href="mrk-20221231.xsd#mrk_A215NotesDue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A215NotesDue2031Member" xlink:to="lab_mrk_A215NotesDue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d17a3feb-9856-421b-89b5-88f82a9f2eb6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_b14807c5-1804-425e-90ba-3c2e01ef005a_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments made to collaborative partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:href="mrk-20221231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:to="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d646c1e9-caa4-4092-b49e-3ed7a6f3059a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_88e99927-05bf-4142-82c1-190b28df3492_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_5872e1d4-e9d6-4327-bffa-db68da86d535_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_4c0b30f4-c2fb-4469-9c93-42e9ab9ddcb8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_90fd64fa-22a7-48c8-9abc-71f4563afb2e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_7166ded2-4620-4321-837d-c5da1b7cfd47_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_bb55a239-6008-4a59-b70d-b859a96d3c92_verboseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetMeasurementInput" xlink:to="lab_mrk_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_d4854fc2-0660-4dda-a850-bf6e63304212_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b9a2bd68-3c8b-4554-a7b7-84d07274584b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f710ee3e-fbf8-4f88-998d-09d014828c1a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_ead4c61d-187a-4733-bec6-baf8f81c4247_terseLabel_en-US" xlink:label="lab_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements and curtailments</link:label>
    <link:label id="lab_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_label_en-US" xlink:label="lab_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax</link:label>
    <link:label id="lab_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_documentation_en-US" xlink:label="lab_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" xlink:href="mrk-20221231.xsd#mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" xlink:to="lab_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SentinelMember_b4ccf757-ee35-4ac6-8302-c5fd163b20c2_terseLabel_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel</link:label>
    <link:label id="lab_mrk_SentinelMember_label_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:label id="lab_mrk_SentinelMember_documentation_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember" xlink:href="mrk-20221231.xsd#mrk_SentinelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SentinelMember" xlink:to="lab_mrk_SentinelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_e28bf545-0769-4bce-96b2-cb0bd26b6765_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - profit sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementProfitSharing" xlink:to="lab_mrk_CollaborativeArrangementProfitSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_3cc31e5a-fa9e-4835-9763-54d61d52a5e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service credit amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_20e636dd-641b-46d5-9a56-f7bc1a2ab33d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in AOCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2f989e07-6c70-4881-9257-b591b075d8aa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ba8b3a44-6d35-4ca9-8939-0be593c5d029_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash (Used in) Provided by Financing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_569ec478-e16d-4479-b0e5-74e5908b10ba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2149dd67-470f-4afb-abc6-bf230afd6118_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_412c3e84-1ecf-468b-83e1-2b5bb1965c77_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_97c7b1a1-d2fb-458c-a271-e1551b04bf56_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_60eb7c80-0317-4c3c-9892-f1e2d92cda32_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_a9d2cbee-0025-4559-9c03-5440899e370b_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1270d574-13bf-402b-9c63-bcb99cd0dd41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_a861ec77-ce22-4897-a965-0fe73b2f0c61_terseLabel_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc.</link:label>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_label_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc. [Member]</link:label>
    <link:label id="lab_mrk_ArtivaBiotherapeuticsIncMember_documentation_en-US" xlink:label="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Artiva Biotherapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember" xlink:href="mrk-20221231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArtivaBiotherapeuticsIncMember" xlink:to="lab_mrk_ArtivaBiotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_80602b27-9803-4096-be15-35a54dbcfe7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_56f034b2-f25d-4ba8-b0a1-c4da2c7be9c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_b9e4d78d-23be-462b-836b-6f47b094b04a_terseLabel_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member" xlink:href="mrk-20221231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.40NotesDue2022Member" xlink:to="lab_mrk_A2.40NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_41544142-9a54-4c4f-9420-432f9b7b6549_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Continuing Operations Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc110fec-da85-4191-be3b-4569a7efd261_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_3e3f4a56-155f-4a92-97d3-0ab072633c47_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum planning cycle of hedges (less than)</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_d22674a6-997b-4037-a1e9-0e981a93afad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_30236907-3002-47d4-89db-3abb8b733d70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_86d9b287-a11c-4202-a64b-7aff74aceb8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_1285e11e-e166-46f4-a87d-c1f98039150c_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net assets (liabilities)</link:label>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_label_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets and Liabilities Recognized, Net</link:label>
    <link:label id="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets and Liabilities Recognized, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:href="mrk-20221231.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:to="lab_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e1cc0662-5839-43cf-8504-2d73c6f76bdb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_b5848aca-4a36-4001-8e89-e917d699d676_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_4c16b366-b0c3-4c1f-8f7f-18cd5917354a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_d401590a-b151-4243-8a34-92dcdc2dae88_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_5791c98a-9d89-415f-9d76-8d919cc1e1e8_terseLabel_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% euro-denominated notes due 2034</link:label>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_label_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Euro Notes Due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.5EuroNotesDue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.5EuroNotesDue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.5% Euro Notes Due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member" xlink:href="mrk-20221231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.5EuroNotesDue2034Member" xlink:to="lab_mrk_A2.5EuroNotesDue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3e260246-d575-4b67-a7c7-53f2f4f19b14_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc9bbc1c-4de8-4f75-8902-cda2cac06a42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ebc6e322-8b7a-485e-92e1-ba976a7f09e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_6bb061dd-6be6-4287-a103-17c5dc7ba807_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_873719a0-398b-4a7f-af45-c3abfff419db_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_daefa1ac-d43e-4551-a553-e655040fc382_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8d5b4d76-d5a2-4f71-99ce-64984ef7ad9d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms_ab2d6ef6-0a76-4bc3-b3cb-062284e9f697_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Research Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:to="lab_mrk_CollaborativeArrangementNumberOfResearchPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CO_b04086b5-88e8-427f-8697-7ec0a6848a83_terseLabel_en-US" xlink:label="lab_country_CO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLOMBIA</link:label>
    <link:label id="lab_country_CO_label_en-US" xlink:label="lab_country_CO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLOMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CO" xlink:to="lab_country_CO" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_89f560d9-4d79-4caf-b461-b76ce7d9da0b_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_e01fcee8-2254-41b8-aa3f-f00fb941b24d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_8fc4670e-8233-4ca2-ab53-ff60873b1bc4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_784362fa-2be2-4fd0-8612-9c0f1f97459c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_ab8a639d-d0b9-40c5-b0b8-6cb7e8c142db_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f0510da9-2d67-47a9-8168-4a2a5e36b5e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BelsomraMember_59c7b974-ea3c-46a8-935c-05ab4c5800bb_terseLabel_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra</link:label>
    <link:label id="lab_mrk_BelsomraMember_label_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:label id="lab_mrk_BelsomraMember_documentation_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember" xlink:href="mrk-20221231.xsd#mrk_BelsomraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BelsomraMember" xlink:to="lab_mrk_BelsomraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9095d7fa-4959-413c-8a3e-2d6599bf6e6d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_6afd2bb7-cac7-4653-9fe2-883494391003_terseLabel_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member" xlink:href="mrk-20221231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.500Notesdue2024Member" xlink:to="lab_mrk_A0.500Notesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_ba7c2bb8-3310-4e00-95f4-159d6eed4b27_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of exchange rate changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LenvimaMember_5e7e74c0-f1ad-4782-8c79-1a02e98fc412_verboseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_d03f7ee4-cb2e-4e6f-a4cf-de0d2682320a_terseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_label_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:label id="lab_mrk_LenvimaMember_documentation_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember" xlink:href="mrk-20221231.xsd#mrk_LenvimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LenvimaMember" xlink:to="lab_mrk_LenvimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_6988417f-7df2-4834-97f8-97dbb4d0bce8_terseLabel_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="mrk-20221231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_mrk_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_2fb1ac63-89fd-4455-9eed-3bbf94c06a6a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028&#160;&#8212;&#160;2032</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_aab69536-936c-49d9-893a-7e0b539f79c6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0918d282-1c77-4f7d-b5f4-46454dbd01e3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_8167ff49-c4b0-43b7-bda5-bf34a0d31a9d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets on NOL carryforwards relating to foreign jurisdictions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_692e2e0e-1573-4637-b2e9-c436e1083a8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_af8c3661-2b95-4829-a9bd-d87bd16e0499_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_9936a75a-f509-4564-873d-48fd66edb704_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_eee38d04-a680-4374-bd01-afaaeb947b01_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefits</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_c50bca48-5900-4187-9492-c5c7d9c446c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_12baca50-6230-467b-9b01-4bcf73e5b780_terseLabel_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_label_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member" xlink:href="mrk-20221231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875Notesdue2026Member" xlink:to="lab_mrk_A1.875Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_62b6c373-e333-4494-973e-a7d6890da74d_terseLabel_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% debentures due 2028</link:label>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_label_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member]</link:label>
    <link:label id="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_documentation_en-US" xlink:label="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point nine five percentage debentures due on two thousand and twenty eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:href="mrk-20221231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:to="lab_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_c0f15a55-09d6-46d8-aab2-249924708656_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_1be05c17-2869-45a3-9b97-ba2a6bf1cbdc_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_b2a830f2-a205-4ee7-b13d-2de387fba7fd_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_cd0f3bf3-5a6a-40b9-a4f5-918c7e0b85f2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_bf276d4d-463b-464f-b658-bdee5706859e_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_aa37d7b5-bc75-4731-a842-77e779c29034_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_61e236da-bc49-4257-bcb2-23a45d94691d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_656b7a31-90f7-4074-9cfc-fcff11b97d4a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_7989d155-57bb-4079-bf81-ae1278084d90_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_61d2c463-730b-4720-ba31-64a894884cbf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_5b9ac179-8da9-4a55-9c2e-5b40d4cba97c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relating to assets still held at December 31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_484a1f29-aafe-48b8-ab4c-d0fd796878a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_706f4ac6-ad8f-4c6b-ad34-133b8df0ddae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_8f8a0a30-16e3-431f-9fe7-81dee3af604d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_COVID19Member_792f788f-2e65-4c89-aa97-9ffc9eaebbb7_terseLabel_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_mrk_COVID19Member_label_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_mrk_COVID19Member_documentation_en-US" xlink:label="lab_mrk_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member" xlink:href="mrk-20221231.xsd#mrk_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_COVID19Member" xlink:to="lab_mrk_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_69b08faf-e3dc-4ce0-853f-f19c911be57f_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_33a199d0-1930-4f93-8367-9d22d51a6118_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_258bc5f5-57b6-4a0b-9211-606f07d1ad60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on derivatives, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryTable_c3ed3661-f550-4b55-9e3e-a567976c89be_terseLabel_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_label_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_documentation_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable" xlink:href="mrk-20221231.xsd#mrk_InventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryTable" xlink:to="lab_mrk_InventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_c06b400a-ab14-4c8f-a135-b3f4fd6b560c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_001307af-a326-4e17-95b1-6e2aed87c405_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_43f11f5c-781c-4547-a181-2bae057bafcf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_483c78a6-fc68-41f5-a65d-b7db9fe9fe35_terseLabel_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_label_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Other Changes Plan Assets</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets_documentation_en-US" xlink:label="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in plan assets, not otherwise separately disclosed in the financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:href="mrk-20221231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:to="lab_mrk_DefinedBenefitPlanOtherChangesPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7b36ca5d-ea72-44ed-917b-6dd514416e99_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_e2ca580a-af8a-4801-95ae-cb8191b44ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-off related to contract termination</link:label>
    <link:label id="lab_us-gaap_ProductionRelatedImpairmentsOrCharges_label_en-US" xlink:label="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments or Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="lab_us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8159a138-1384-44e8-8aee-6becefe9c145_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_8701e97e-aeb7-471c-8360-e0e060f82046_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Activity by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_d3876fa3-2e17-45ac-bd34-436de17e06e3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International equities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7bd99c1b-1d01-49f4-b585-f4ac4ede72e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_96baf379-d158-4159-98db-96bed294d1a1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3c525e59-6dac-45f4-9e50-5eebaccf0650_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_9ce87450-a9dc-4ab2-9c80-d2fb33ed668d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RecognizedAsAbstract_b78c9194-c8d6-48da-beae-51c4c6713652_terseLabel_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_label_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized As [Abstract]</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_documentation_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract" xlink:href="mrk-20221231.xsd#mrk_RecognizedAsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RecognizedAsAbstract" xlink:to="lab_mrk_RecognizedAsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentToBeMadeToCollaborativePartner_270ec9dd-120a-431f-8ed0-dea6b022053b_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment to be made to collaborative partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentToBeMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment To Be Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentToBeMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentToBeMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment To Be Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentToBeMadeToCollaborativePartner" xlink:href="mrk-20221231.xsd#mrk_MilestonePaymentToBeMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentToBeMadeToCollaborativePartner" xlink:to="lab_mrk_MilestonePaymentToBeMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ImagoBioSciencesIncMember_95d9590e-bdf9-440f-8de4-bcd77b02cda9_terseLabel_en-US" xlink:label="lab_mrk_ImagoBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imago BioSciences, Inc.</link:label>
    <link:label id="lab_mrk_ImagoBioSciencesIncMember_label_en-US" xlink:label="lab_mrk_ImagoBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imago BioSciences, Inc. [Member]</link:label>
    <link:label id="lab_mrk_ImagoBioSciencesIncMember_documentation_en-US" xlink:label="lab_mrk_ImagoBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imago BioSciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImagoBioSciencesIncMember" xlink:href="mrk-20221231.xsd#mrk_ImagoBioSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ImagoBioSciencesIncMember" xlink:to="lab_mrk_ImagoBioSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProfitShareCounterparty_508b0442-9ab5-4c45-89ee-b0abaa5cc5b9_terseLabel_en-US" xlink:label="lab_mrk_ProfitShareCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit share by counterparty</link:label>
    <link:label id="lab_mrk_ProfitShareCounterparty_label_en-US" xlink:label="lab_mrk_ProfitShareCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share Counterparty</link:label>
    <link:label id="lab_mrk_ProfitShareCounterparty_documentation_en-US" xlink:label="lab_mrk_ProfitShareCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Share Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShareCounterparty" xlink:href="mrk-20221231.xsd#mrk_ProfitShareCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProfitShareCounterparty" xlink:to="lab_mrk_ProfitShareCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_edc05b76-1a55-46bb-ae70-74a6a4bc0f78_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_5136b219-1e9b-41a5-81a8-65615c29a621_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrimaxinMember_2d803e25-962f-4a81-903c-ad4079952bc0_terseLabel_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin</link:label>
    <link:label id="lab_mrk_PrimaxinMember_label_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member]</link:label>
    <link:label id="lab_mrk_PrimaxinMember_documentation_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember" xlink:href="mrk-20221231.xsd#mrk_PrimaxinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrimaxinMember" xlink:to="lab_mrk_PrimaxinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_d8c5f1c0-3f48-443d-bf5f-963b600e92e1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8355bc9a-448f-448d-a2bb-fb64abfdd7b7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4f64978a-bb1e-471e-a949-24230e8fdfc4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_1040a6a3-02df-426d-b750-3c527cdecebb_terseLabel_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="mrk-20221231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_43f1a697-7b2f-4295-bc65-c12b1720b894_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a5a63e69-e183-438c-a776-4ed669310e47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_a61d47bf-6ed4-4672-b9ab-d678a3fb4770_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_label_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:label id="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:to="lab_mrk_IntangibleAssetsExcludingGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_0ba144f0-8ed8-4be6-8c9a-c635a39657e3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_a7e75bb4-26ad-4633-8847-cd0c4c7e47b1_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:href="mrk-20221231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_fcc06b8a-7d03-4e62-a087-1a2d5f93a4b0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VaqtaMember_00712328-ca7b-4990-b921-8dbe5898d42f_terseLabel_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta</link:label>
    <link:label id="lab_mrk_VaqtaMember_label_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:label id="lab_mrk_VaqtaMember_documentation_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember" xlink:href="mrk-20221231.xsd#mrk_VaqtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VaqtaMember" xlink:to="lab_mrk_VaqtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0422592e-e182-499c-9c5d-e73c2e8547d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_d797457a-1eac-43c3-8dcb-21777f9f86bc_negatedTerseLabel_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_label_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_documentation_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:href="mrk-20221231.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:to="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e5cadb5e-7b18-44e6-a4e8-3b469e993691_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6c9ca5ed-e384-4fd0-ab90-81f7d95d8671_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about the Changes in Liabilities for Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_119d0903-318d-4c26-a39a-694872edd181_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_cac372fe-3b0b-4af1-ba6a-c624e57592ad_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_90a0b3a7-5ce7-4c32-9083-847516136bda_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_8131198e-58c3-4a43-8205-17c10188301a_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NoxafilMember_ebccc1da-9b4d-4b4f-b384-9f045873aa2f_terseLabel_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil</link:label>
    <link:label id="lab_mrk_NoxafilMember_label_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member]</link:label>
    <link:label id="lab_mrk_NoxafilMember_documentation_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember" xlink:href="mrk-20221231.xsd#mrk_NoxafilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NoxafilMember" xlink:to="lab_mrk_NoxafilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ca2c6844-7fd4-4e78-985b-20358e8b77fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_0cc4b3d4-d58a-47d4-a664-c32a7c28ecb3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d2fb0ad6-a198-42de-bc43-ff9554d07af3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares collectively authorized for future grants under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_11bf7179-c87d-47f6-a572-c1c6d47b6372_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d33200ff-6633-4af9-8b44-0b7bba53f725_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a52f76f4-ceb4-430d-b5b9-f19123dd79ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d2b2a5f0-9ffa-4722-add5-bc277472fc7f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_f7d6de83-fec4-434e-beb6-0dd0fd83d2bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60f70985-1ad1-4b2b-be52-ebbc3b177002_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b12e598d-4ed9-46aa-bc9e-c017140e4cf3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_63280056-4d53-44d6-96ff-571720bd3d71_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions to defined contribution savings plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_acfdd5db-c745-4329-a470-fa904c7aa516_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_d3d8e0d6-87ea-4955-90e7-7c1ab16bc456_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of Pandion Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_403f09f8-9159-4767-9dfc-9b8a2a280a55_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_8662da21-8b74-4d40-8ad5-036981275d88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income of discontinued operations attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_baf5ef2e-a7ea-4989-8a35-68b056c4cf82_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_551b2291-070f-4f4b-bcdd-4ab4d6e19c7c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_99d1998a-0a5b-41e7-84c3-915e1550609a_terseLabel_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_label_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad MMR II Varivax [Member]</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_documentation_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:href="mrk-20221231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:to="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_4e075e9f-a72e-4a7a-9a8f-4c0ab79a1f97_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of OncoImmune</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_450fffb3-9800-49ba-86f7-735f35f26c98_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_45c42750-d591-4866-a4f5-59f9ad58882d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of securities and other investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4e23b77c-12c5-470b-9837-531ba6a037c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_8772238d-85fa-4967-88ca-b7e78c70fc0d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_559f3bb3-88ae-4a02-a9dc-b2b561131e30_terseLabel_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Other Investments</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_label_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Other Investments [Member]</link:label>
    <link:label id="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_documentation_en-US" xlink:label="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:href="mrk-20221231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:to="lab_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_913896b8-11de-4c09-a61a-167f284a9945_terseLabel_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:href="mrk-20221231.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_40de8dc8-e2b7-43c4-9901-7e717302c00c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_2a2f70e6-1aac-4415-b622-391861220b05_totalLabel_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and publicly traded equity securities, fair value</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_label_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:href="mrk-20221231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:to="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e85c4a5-6898-498d-8125-a9705fa71ab6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Nonvested January 1 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a08d4123-f893-4417-9348-499ecf034b5f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Nonvested December 31 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_9f720757-5bbc-4528-83aa-21e623a10976_terseLabel_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Litigation</link:label>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_label_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Other Litigation [Member]</link:label>
    <link:label id="lab_mrk_CommercialandOtherLitigationMember_documentation_en-US" xlink:label="lab_mrk_CommercialandOtherLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and Other Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember" xlink:href="mrk-20221231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CommercialandOtherLitigationMember" xlink:to="lab_mrk_CommercialandOtherLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6d2f508e-e130-4992-9cef-e5b6ff891f25_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_989095a0-388e-49e1-9491-0daee513afd5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_766400af-d0c9-4e37-bb4e-723536aed2f3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4779c91-2cd9-4440-a213-9f45ad3d09f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e56d343d-3b18-499d-b94f-f28c24417eb9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aebeb4a6-05ae-4d16-b88b-f9936fe5dcdd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_f5d44510-4ad9-4a68-a732-6388b4043b03_terseLabel_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% notes due 2039</link:label>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_label_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% Notes Due 2039 [Member]</link:label>
    <link:label id="lab_mrk_A3.90NotesDue2039Member_documentation_en-US" xlink:label="lab_mrk_A3.90NotesDue2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.90% Notes Due 2039</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member" xlink:href="mrk-20221231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.90NotesDue2039Member" xlink:to="lab_mrk_A3.90NotesDue2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679ae268-87cf-4738-b976-d803b3788046_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_20cd9e09-7ac9-4915-a8f7-ea2f6bf5832c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_cf492aa9-3081-42bc-a250-cc9cd4104a06_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_b022cc20-600e-4ce3-aeeb-b3ed6d429c29_terseLabel_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_label_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Increase (Decrease) Noncash Activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_documentation_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash activity affecting the restructuring reserve, including accelerated depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:href="mrk-20221231.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:to="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A190NotesDue2028Member_a89674c2-c3e7-44da-9238-fe20c95fa7d4_terseLabel_en-US" xlink:label="lab_mrk_A190NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2028</link:label>
    <link:label id="lab_mrk_A190NotesDue2028Member_label_en-US" xlink:label="lab_mrk_A190NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2028 [Member]</link:label>
    <link:label id="lab_mrk_A190NotesDue2028Member_documentation_en-US" xlink:label="lab_mrk_A190NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.90% notes due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member" xlink:href="mrk-20221231.xsd#mrk_A190NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A190NotesDue2028Member" xlink:to="lab_mrk_A190NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_dd68054f-27a2-4cb6-84ad-d9f1c5d68d27_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_fb060a24-708e-4fb8-8de7-0768eff9d2c6_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_545558ac-0766-4fca-b087-7b1e57e004a6_terseLabel_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.55% notes due 2037</link:label>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_label_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member]</link:label>
    <link:label id="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_documentation_en-US" xlink:label="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point five five percentage notes due on two thousand and thirty seven.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:href="mrk-20221231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:to="lab_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_a03bcca8-bdef-47c4-a1eb-8b2e3718fb24_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_98d323fa-4d8f-4a6e-8e8b-bd36d5246fa8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_f6c47eb7-aa16-4112-8d7d-b34c308926d7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_c3cf56d8-2c39-4be8-a825-10131ac22a21_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e475a3f5-f06f-4574-a45d-ee9c23b0fb3a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_953815c4-7339-4fff-adc5-14e55c944894_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information Relative to Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_ee5be698-d504-4768-bba2-0c412904442f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory related, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2ac0dac0-3cb9-46c8-baa9-c042236369f7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A290NotesDue2061Member_6d0f7b49-695d-47c0-b769-78998a90f083_terseLabel_en-US" xlink:label="lab_mrk_A290NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2061</link:label>
    <link:label id="lab_mrk_A290NotesDue2061Member_label_en-US" xlink:label="lab_mrk_A290NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2061 [Member]</link:label>
    <link:label id="lab_mrk_A290NotesDue2061Member_documentation_en-US" xlink:label="lab_mrk_A290NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member" xlink:href="mrk-20221231.xsd#mrk_A290NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A290NotesDue2061Member" xlink:to="lab_mrk_A290NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_142b35d4-7e04-478d-8d23-6a284f074361_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_043f87e3-c1c3-4f54-8ec0-8d8ef8532ea5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_0780b309-4e6c-4ff6-aa0f-301e2fe16c88_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion, and Amortization [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_3d5e2b85-bc2e-4348-8fa6-0b3d41743ea5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PensionPlanNetLossMember_57279f88-6d04-43bd-8cdb-cc5e073675b2_terseLabel_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss</link:label>
    <link:label id="lab_mrk_PensionPlanNetLossMember_label_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss [Member]</link:label>
    <link:label id="lab_mrk_PensionPlanNetLossMember_documentation_en-US" xlink:label="lab_mrk_PensionPlanNetLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan Net Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember" xlink:href="mrk-20221231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PensionPlanNetLossMember" xlink:to="lab_mrk_PensionPlanNetLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_850f2ce5-bff4-4bf9-b059-cae9fad78346_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization included in benefit cost</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_e09024af-d3bc-4546-873b-4c795e5c8737_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_144f02e9-03c2-4183-a2cd-5535a23b7fd9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bebfa173-1b70-41dc-ad5b-e1072ad94a2c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_a2b2bd9a-8f69-412b-a1bc-f157420dab64_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_61acc21f-387c-4dd2-a5e8-23c3e1d1a989_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d962d44-5676-4afe-a115-b816303f4ec5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5f0df1ab-9d9f-44c2-bba7-91cd1bf86bb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4f06e84a-8c02-4bfa-8cde-30dd0bd5bd31_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9fec1d3e-f3f1-4162-9501-88ccc03e174c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_fe22deb9-b22a-4853-bddd-be93860cc56d_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c55ff37e-7a7e-409b-a0f2-30363d1c8ecb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_99d2cac3-b201-435d-b83f-f247c5f50d99_terseLabel_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember" xlink:href="mrk-20221231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesBasedMilestonesMember" xlink:to="lab_mrk_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4062527e-7807-42fc-aced-9ae32ce0c160_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7c5a2134-3502-48fe-be8c-e38b065eebb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SotaterceptMember_40cf3d0c-bd1e-4675-be70-6cf43d4a2bd0_terseLabel_en-US" xlink:label="lab_mrk_SotaterceptMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">sotatercept</link:label>
    <link:label id="lab_mrk_SotaterceptMember_label_en-US" xlink:label="lab_mrk_SotaterceptMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">sotatercept [Member]</link:label>
    <link:label id="lab_mrk_SotaterceptMember_documentation_en-US" xlink:label="lab_mrk_SotaterceptMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">sotatercept</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SotaterceptMember" xlink:href="mrk-20221231.xsd#mrk_SotaterceptMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SotaterceptMember" xlink:to="lab_mrk_SotaterceptMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b1dee35-1dc2-42aa-9a5b-340f74104483_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding assuming dilution (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_e7122a80-7627-45f0-9e92-e6d291c16ab5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_4b9732b1-e17f-4001-957b-b07fecde8e06_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_e2693020-79fa-467a-b025-2a6a001325d2_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock investment in counterparty</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Preferred Stock Investment In Counterparty</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Preferred Stock Investment In Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:to="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_97af3e66-607d-4954-9537-65d7dfc1c4e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a700428d-4298-4d64-83b7-51508357e1cf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PatentlitigationMember_76dc1336-e774-45ac-846c-1ee432fc1a86_terseLabel_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation</link:label>
    <link:label id="lab_mrk_PatentlitigationMember_label_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation [Member]</link:label>
    <link:label id="lab_mrk_PatentlitigationMember_documentation_en-US" xlink:label="lab_mrk_PatentlitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember" xlink:href="mrk-20221231.xsd#mrk_PatentlitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PatentlitigationMember" xlink:to="lab_mrk_PatentlitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_45c94474-0a34-4ad0-9545-348f6ee9f51f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities held through ownership interests in investment funds</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_5587f055-668d-4644-bc3a-7125b3af5fc0_terseLabel_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable</link:label>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_label_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_mrk_IncomeTaxesPayableMember_documentation_en-US" xlink:label="lab_mrk_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncomeTaxesPayableMember" xlink:to="lab_mrk_IncomeTaxesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_7fa166be-bb34-4bb3-90ee-8e4ead396718_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b0c38c9a-8d9a-4a1f-8e8b-64671e44c897_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ThemisMember_30d4a832-4522-4ba9-af9c-53d98543766b_terseLabel_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis</link:label>
    <link:label id="lab_mrk_ThemisMember_label_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:label id="lab_mrk_ThemisMember_documentation_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember" xlink:href="mrk-20221231.xsd#mrk_ThemisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ThemisMember" xlink:to="lab_mrk_ThemisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dbba0470-19b8-485b-8b8a-1ba09a23aa80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1eefde58-693a-4668-bf85-63e99eeb887f_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_0b1110fa-d108-4b16-96de-7a7a39d9c7ea_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IAVIMember_50890e19-c3ef-4018-9672-18dfc8a746a0_terseLabel_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI</link:label>
    <link:label id="lab_mrk_IAVIMember_label_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:label id="lab_mrk_IAVIMember_documentation_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember" xlink:href="mrk-20221231.xsd#mrk_IAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IAVIMember" xlink:to="lab_mrk_IAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesThreshold_9cf5b095-76a9-4155-899c-1d181e3a5b43_terseLabel_en-US" xlink:label="lab_mrk_SalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales threshold</link:label>
    <link:label id="lab_mrk_SalesThreshold_label_en-US" xlink:label="lab_mrk_SalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales threshold</link:label>
    <link:label id="lab_mrk_SalesThreshold_documentation_en-US" xlink:label="lab_mrk_SalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesThreshold" xlink:href="mrk-20221231.xsd#mrk_SalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesThreshold" xlink:to="lab_mrk_SalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LynparzaMember_d596cf7b-5c2f-4ee7-b135-baa58c006e67_terseLabel_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza</link:label>
    <link:label id="lab_mrk_LynparzaMember_label_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:label id="lab_mrk_LynparzaMember_documentation_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember" xlink:href="mrk-20221231.xsd#mrk_LynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LynparzaMember" xlink:to="lab_mrk_LynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_56c26c55-ad67-4b9e-9a99-544a7457b7ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_c3cf25a1-4e00-4d49-a1e5-a936c161f2bb_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific (other than China and Japan)</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_01f4816b-186d-4209-bb10-e30a0f03e77f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_12475b75-8987-40e4-a8b6-d26ec642b48c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_de7e9364-7528-41f5-b5e6-fb049727386e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total segment profits</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_785050dd-e94c-4b87-a308-5cb84273da19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b7d16d8f-0610-4cd7-861e-8b8260eb5a0f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_00283fb6-2365-4942-8ac3-33bb13b28cdb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_901e0660-e48c-4dee-ad6c-152238b36d62_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ef9c2aa6-8b2e-47d7-a85f-f648146b62c7_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charge related to marketed product</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_65ead4ac-210b-4614-8294-e3177d236af7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6df2f9d1-45b4-4ee3-926f-d8cc9982e473_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_eac49a10-09e3-419a-a936-fd22c04208fe_terseLabel_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_label_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_documentation_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember" xlink:href="mrk-20221231.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZetiaantitrustlitigationMember" xlink:to="lab_mrk_ZetiaantitrustlitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_cfd5bbc3-f72f-4aea-9db1-3b821233c614_terseLabel_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt</link:label>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_label_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt [Member]</link:label>
    <link:label id="lab_mrk_OtherVariableRateDebtMember_documentation_en-US" xlink:label="lab_mrk_OtherVariableRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember" xlink:href="mrk-20221231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherVariableRateDebtMember" xlink:to="lab_mrk_OtherVariableRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_915041b3-a446-443f-919c-337c987f55e6_terseLabel_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Research Collaborations and Licensing Agreements</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Research Collaborations And License Agreements [Text Block]</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to acquisitions, research collaborations and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:href="mrk-20221231.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:to="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0aac5331-5c72-4e48-8e8f-cdda64190976_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9a454b4a-d6a1-4811-a564-3a492ef392f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Environmental Liabilities</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2d0462b9-03f3-4fa9-b85a-113838d5644d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_6bb03cd1-4aeb-4e2c-8e13-e791aff772fc_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding by others, percentage of development costs</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:to="lab_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e54cbb59-8b93-424d-8a7a-8d2f9ea9cc8c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e62b5b0b-7d45-4724-a7db-dfb2efac34bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_096e4e30-0314-4715-86f7-deed2441763c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b7d98040-2900-4ee9-9f87-54a4a1a1aac8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance January&#160;1 (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_22cb3c85-d21a-48e6-8caf-f6ac3ff8fdf4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance December&#160;31 (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d7e227ce-c591-4645-9d0e-b2da7d7658de_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_693334fb-b3b5-4911-8cf6-feed8aec60c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_e294dd95-e2b1-4e31-ad3f-4812eeea0242_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other postretirement benefits, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_88709141-173b-480b-b026-04d7652a4308_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_b48ec47a-b3cb-4a88-bff2-4de4ce7bec8a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_2590b5c0-5069-4ff0-b724-46b7b4df02de_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_021f85e3-50a4-4f60-b6f8-8ce9668c4229_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, new claims filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_3e877a0b-2b80-4b90-8f80-33eba175b4f6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4fd099f9-c4c6-4379-924f-eef67959efc8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6f77fffa-3382-4418-9251-39dcf5db44f2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_c66d63b3-51da-4294-854f-a8dfc2d17060_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other postretirement benefits, Liabilities</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_label_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_documentation_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:to="lab_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_0aa43856-bac8-4b61-a58f-093c145fe6c1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Investing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_20246aa6-a9de-4e50-aee5-01c74337542b_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future regulatory milestone payments</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:href="mrk-20221231.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7689e70f-ed2a-4ef3-9648-8f5695f1f0e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Loss from Affiliates and Depreciation Included in Segment Profits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2c13859a-734b-4792-80d3-2b8bf8142b14_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ff0141f1-ede5-4a39-ad3d-e41c5b8c8ae3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GefapixantMember_25cd5dc2-2e22-4a7f-8fcc-f00962b4cd16_terseLabel_en-US" xlink:label="lab_mrk_GefapixantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">gefapixant</link:label>
    <link:label id="lab_mrk_GefapixantMember_label_en-US" xlink:label="lab_mrk_GefapixantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">gefapixant [Member]</link:label>
    <link:label id="lab_mrk_GefapixantMember_documentation_en-US" xlink:label="lab_mrk_GefapixantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">gefapixant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GefapixantMember" xlink:href="mrk-20221231.xsd#mrk_GefapixantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GefapixantMember" xlink:to="lab_mrk_GefapixantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_311fd0b0-d44f-437d-9f4b-83bb4033810a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bac6c186-7045-45b8-8c84-074e6326a919_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of taxes attributable to parent</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_74638ab3-05ed-460a-8773-d2f70d941f52_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9984e77f-2011-4353-b87f-41c9be202469_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate applied to income from continuing operations before taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_b984db1c-fa62-4ab4-8b17-e0ff59674f13_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_aa904b9f-c58c-4e7a-a6ad-c88f394df9fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_51d99b8a-0847-433e-8c1c-19b6f6fd71db_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_ce5df0a9-c6c7-4048-9098-b7d440cd5b6e_terseLabel_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% notes due 2024</link:label>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_label_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A2.90NotesDue2024Member_documentation_en-US" xlink:label="lab_mrk_A2.90NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member" xlink:href="mrk-20221231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.90NotesDue2024Member" xlink:to="lab_mrk_A2.90NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b044ad2b-a50d-463c-864e-79fcaf1cd4b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, January 1 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c6d4dca4-d70b-426c-9c95-88a23e7572d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Outstanding, December 31 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d9c9cb58-b0d3-41d8-b6cb-abbb5d472eab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_8044a77f-8e3f-4ef8-bd45-54a916b64cd1_terseLabel_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Credit</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_label_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Cost [Member]</link:label>
    <link:label id="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_documentation_en-US" xlink:label="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plan Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:href="mrk-20221231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:to="lab_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_298ec589-266d-44c5-b67c-5e54ed70896c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_e097160a-0bed-4f4a-b31c-37a302b589a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a18c5a2f-9329-4c4c-96e4-eb94978cbfd0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60c309d2-0595-4686-be35-5abd21cb6e27_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ca65ea83-5275-489b-b3b5-6b1493f4816a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_92687c9a-3f50-4794-a5b6-e46bcafc8cc6_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_c844fa67-c8ad-450c-b0ca-111f78a6adba_terseLabel_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO inventory amount</link:label>
    <link:label id="lab_us-gaap_LIFOInventoryAmount_label_en-US" xlink:label="lab_us-gaap_LIFOInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIFO Inventory Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LIFOInventoryAmount" xlink:to="lab_us-gaap_LIFOInventoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_593b45fd-544b-441f-8872-556d66e48ed8_terseLabel_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.40% debentures due 2028</link:label>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_label_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member]</link:label>
    <link:label id="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_documentation_en-US" xlink:label="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point four percentage debentures due on two thousand and twenty eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:href="mrk-20221231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:to="lab_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherCountriesMember_3563dd57-7d79-480c-a3dc-ffd5cc43bd77_terseLabel_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_label_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_documentation_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember" xlink:href="mrk-20221231.xsd#mrk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherCountriesMember" xlink:to="lab_mrk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60d5073f-4df0-4337-ac91-837251d59ec7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_507d7ff7-e870-4b01-a894-34318ff72a37_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1ac29390-0de9-4b70-bbe1-ad741b552d7d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8315d77e-d7cf-4325-8526-80b743092df5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b62c9cb0-e4f4-4db0-8c05-86f4a71c19c7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ModernaMember_6a565c3d-043a-4feb-8121-673f8bbd809b_terseLabel_en-US" xlink:label="lab_mrk_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderna</link:label>
    <link:label id="lab_mrk_ModernaMember_label_en-US" xlink:label="lab_mrk_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderna [Member]</link:label>
    <link:label id="lab_mrk_ModernaMember_documentation_en-US" xlink:label="lab_mrk_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderna</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ModernaMember" xlink:href="mrk-20221231.xsd#mrk_ModernaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ModernaMember" xlink:to="lab_mrk_ModernaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4379d8ec-f549-4af7-bf02-3eb7957101d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Derivative Pretax (Gain) Loss Recognized in Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_d72730d7-f308-4ef6-94f5-b81a71192fff_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Pandion</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_f77bd354-4d7b-4e2b-943d-f71a754df606_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses and other tax credit carryforwards, Assets</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_label_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards</link:label>
    <link:label id="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets operating loss carryforwards and other tax credit carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:to="lab_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_6e76ec83-f4a4-421b-8742-8d6948a81bb8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_878878c9-6d0a-43ea-b358-181fd1294317_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of Company's Products</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd50ccb4-9a77-49b3-b579-69455c986e5e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_78f039f9-bb0a-412b-b282-6bf4701ab3f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_5ceed045-89d9-4c72-b3e9-06ebe568d905_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Revenues by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_46d6cdf5-668b-4bb3-877d-85bc8441bfae_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_6d8c8321-6427-45c3-b18a-e17622b5e6d1_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_1b11326e-7f88-45cb-825c-a040d65022f6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9170fc79-b8b6-4a66-941d-cd44025d3a93_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VelosBioMember_92339953-3032-4791-947a-160850fe82ba_terseLabel_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio</link:label>
    <link:label id="lab_mrk_VelosBioMember_label_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio [Member]</link:label>
    <link:label id="lab_mrk_VelosBioMember_documentation_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember" xlink:href="mrk-20221231.xsd#mrk_VelosBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VelosBioMember" xlink:to="lab_mrk_VelosBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_4c4aab71-3fc4-4f8a-b094-f09c374448a7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_201c64be-ff63-45c2-a780-04ea5669dc6d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_1dbf0097-be68-4acd-9e1e-59731a390f55_terseLabel_en-US" xlink:label="lab_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="mrk-20221231.xsd#mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6d779f5c-a4d8-4ea9-ba58-7ab2179d9feb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_af019de0-cd79-4fae-b890-ebb39fd46e1d_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation and Funded Status</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_dc308e51-53d6-45cd-a3e8-6749bf6bc7d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_c89d1c20-cc6c-455b-a088-c3878c1e591a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_e01bff8f-8d80-4270-8c26-40325b45cbe8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5c73c0e2-d124-49db-99be-2bac12f3c009_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_738da015-d12e-4024-8798-646c969d2021_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_d2982947-dca0-4854-af83-75f5b4a33082_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits relating to stock option exercises</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b490861e-666e-49d3-9a9f-3f890d0dce9e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a76fd33e-a3d8-41cc-9fee-09ff44cc08fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of&#160;Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VerquvoMember_54b7b616-d962-483e-8715-bb8463f3b06b_terseLabel_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:label id="lab_mrk_VerquvoMember_label_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo [Member]</link:label>
    <link:label id="lab_mrk_VerquvoMember_documentation_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember" xlink:href="mrk-20221231.xsd#mrk_VerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VerquvoMember" xlink:to="lab_mrk_VerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_260b53d5-84b4-40e4-b4e0-e60c0d28108f_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:to="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_6bc6b695-3845-4f2b-b1cb-e8745418a89f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17a99391-6299-4622-9813-35042d315a14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherLongTermDebtMember_1c89fcb2-6543-4101-ace0-670a77ead669_terseLabel_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherLongTermDebtMember_label_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_mrk_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_mrk_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember" xlink:href="mrk-20221231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherLongTermDebtMember" xlink:to="lab_mrk_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fe791875-3b6f-4eb2-a3f5-a2f86a762f68_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_b59c0218-dc65-451f-930a-2e95e1c24a9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_690ccf98-84b1-4469-a3ba-622467964f1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of securities and other investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_e2dcd1d0-1e30-4ae5-b9c9-225bfeebdea3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_f3ebf589-43fc-4ab2-897d-08f6ba2555a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_cd7b1d35-d4f8-49da-b556-a03a13a62bd1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax for accumulated foreign earnings, liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d666a572-dfbb-467f-9105-782f60e07fdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d0ddc2a5-eae2-42ce-92e1-6cee43674de0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ba0fbeda-5490-4cb2-ba6a-b1f8a4a3481f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a1905879-57d3-4e1d-9021-f8a6cba146ee_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_b106f7c5-8c7e-453d-8655-6d57514ce868_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</link:label>
    <link:label id="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="mrk-20221231.xsd#mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0399c5c1-547a-4541-b239-1f2ed8df3bf0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8dadc27e-b0bc-414c-ac3b-cd2c7d1044ed_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_96f1c9f7-4bcf-49a8-8048-533551b57889_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_267fd0e7-1d6d-46bc-9dfb-dcfc7e9d173b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_aa794cbc-485f-40c0-ac24-934860191956_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_aa6b8ad8-db1a-4cb0-ba1d-e362cce83088_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_62a14849-da0f-4a12-acd9-8956a282914d_terseLabel_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And Agency Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:to="lab_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner_0d4db653-996b-4caf-8da9-1c3c7e3683b6_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development payments made to a collaborative partner</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Payments Made To a Collaborative Partner</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Payments Made To a Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" xlink:to="lab_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_575abd05-9e28-43d0-b401-52e4ec6663b7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_fad23611-767b-4660-9ac2-408d7db71437_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain recognized in Other (income) expense, net on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_89db105c-269c-479e-a598-2a87e82f2c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ed8ddeeb-f2cc-4e76-beb1-7a033c05c9fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_d2250f85-1a7f-4e4d-9d63-16b88e3bc435_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_13888916-4441-45e0-a088-18cafade4c58_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_26576c96-6d92-4909-afba-9d3d1350858c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upward price adjustment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EurodominatedNotesMember_0071c0ba-d6b0-4dfe-9925-9322e2b5a7b5_terseLabel_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-denominated notes</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_label_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_documentation_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember" xlink:href="mrk-20221231.xsd#mrk_EurodominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EurodominatedNotesMember" xlink:to="lab_mrk_EurodominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_fbc25b61-41b5-41b0-b619-21b2870b4513_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_3c2abfe3-d3ca-410b-982a-609fcf1ee8d1_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_76e247bc-3b2e-4d8d-a0b1-ab55c9473208_terseLabel_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations</link:label>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Obligations Fixed Income Securities [Member]</link:label>
    <link:label id="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations fixed income securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:to="lab_mrk_CorporateObligationsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_ac9b898d-6793-424f-b3ab-6d5688991b6d_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of continuing involvement after disposal</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Period of Continuing Involvement after Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:to="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_a9e3577e-825d-464a-b169-5a9ef9de82ba_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, deduction, percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRateDeductionPercentage" xlink:to="lab_mrk_RoyaltyRateDeductionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForEnvironmentalLossContingencies_a5397602-cfc5-473e-a838-ae63fbf7a6db_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities for environmental matters</link:label>
    <link:label id="lab_us-gaap_AccrualForEnvironmentalLossContingencies_label_en-US" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for Environmental Loss Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:to="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c1dc005a-1d50-4701-ae61-0455af7d3e47_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, maturities, repayments of principal in 2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_2f874b70-8421-41c9-9e94-92c42c9eaa69_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_55a9c6a5-cb71-4d54-8883-84f95c5a40a7_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_c6c8247d-0477-4682-b6bd-16b4cde27fd6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_272a323b-dff8-4ac4-aa01-827e5d1fe194_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_b9a44b2f-b5c3-4121-af12-961f9baacfe1_terseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of VelosBio Inc.</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_a5b29e10-526b-479d-9b45-ddd5a8cb201c_verboseLabel_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_label_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two</link:label>
    <link:label id="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_documentation_en-US" xlink:label="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:to="lab_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c605e072-0df3-4558-8226-1d869ac3ef63_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BridionMember_5d153209-9865-4fde-beb0-b4bfeb5f9b95_terseLabel_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion</link:label>
    <link:label id="lab_mrk_BridionMember_label_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member]</link:label>
    <link:label id="lab_mrk_BridionMember_documentation_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember" xlink:href="mrk-20221231.xsd#mrk_BridionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BridionMember" xlink:to="lab_mrk_BridionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_46a6c3b0-84a3-40c7-a164-ad10529ed52a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e43a131f-b409-4081-90d0-26d0c1b4a470_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0634c211-2107-4e84-9390-010a984e3357_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EisaiMember_7ec5b7a8-dc77-4831-b075-9ffcdf3d0fbf_terseLabel_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_mrk_EisaiMember_label_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_mrk_EisaiMember_documentation_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember" xlink:href="mrk-20221231.xsd#mrk_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EisaiMember" xlink:to="lab_mrk_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_2904279a-15ca-4796-b055-c60e827220bb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_78d19a81-76e7-435b-88ce-638faa9b7a5a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax share-based compensation cost recorded</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7b7db373-2b85-4744-a9a9-479230113788_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_512f2d3d-fe2b-4004-9102-a329c75fd3fb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4ab8234c-3012-4601-a95d-fac79fec1e5a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_19575ab7-7821-44e7-ba44-1a81721f5e0d_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_597c8d25-84ad-4269-ac60-aa5ac9855aa8_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets, acquired</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SeagenMember_994c2ac0-1121-4650-b258-15a9ce147e3a_terseLabel_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:label id="lab_mrk_SeagenMember_label_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen [Member]</link:label>
    <link:label id="lab_mrk_SeagenMember_documentation_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember" xlink:href="mrk-20221231.xsd#mrk_SeagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SeagenMember" xlink:to="lab_mrk_SeagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InternationalMember_22013b09-40cd-47be-9d46-704248b5dd97_terseLabel_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Int&#8217;l</link:label>
    <link:label id="lab_mrk_InternationalMember_label_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_mrk_InternationalMember_documentation_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember" xlink:href="mrk-20221231.xsd#mrk_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InternationalMember" xlink:to="lab_mrk_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_ee49c92b-04b3-436a-935e-c4246bad9bb8_terseLabel_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of OncoImmune</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_label_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two</link:label>
    <link:label id="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_documentation_en-US" xlink:label="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Business Combination Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:to="lab_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e5b99856-33e7-48b9-afb2-bd129ffddfeb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in Sales as a result of AOCL reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_69c314c9-18ac-4c4a-afd4-6f88edb8038b_verboseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_7ec9341a-375e-4ede-8291-6995e2d4f276_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_adcfb6d0-2192-4abf-8e0e-800c6d8c1234_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_98fa165f-b578-4bc3-99eb-e258b8355011_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity before deduction for treasury stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_a101d656-0afa-4d70-b763-c2a2da23d97b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_478a9799-eaa6-4dca-b90e-634456f4efeb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d2ce11b3-dbeb-446d-b68f-ace6bc114598_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_a917ef3f-9c59-4c1a-a590-66990bbf0ab0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_1bf1fcbd-1cc1-42f2-9681-557028a5d8d7_terseLabel_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_label_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_mrk_MovementinCommonStockandTreasuryStockRollForward_documentation_en-US" xlink:label="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Common Stock and Treasury Stock [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:href="mrk-20221231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:to="lab_mrk_MovementinCommonStockandTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_3901d68c-1b26-48ba-83ad-b7637e525df9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment (at cost)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ce428027-8bc1-48fa-a3dd-d19f658ce63b_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_9cfb2897-c43f-4981-be12-45982ca15288_terseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_85cf9874-933f-4018-8fb7-82f01b46e793_verboseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_label_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment [Member]</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_documentation_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PharmaceuticalsegmentMember" xlink:to="lab_mrk_PharmaceuticalsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_34e8ea65-250c-47f4-9371-f6a8f21d79b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_f62449d9-78ac-49be-b134-ffe4491636e3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_42bb6463-0786-46fe-9b6a-e8277e6c64b9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherChanges_acef3d02-f0bd-4a41-8b5d-f0a7de08920d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherChanges_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanOtherChanges" xlink:to="lab_us-gaap_DefinedBenefitPlanOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_67a9ae8f-cf21-41c1-8a68-1640746c674f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c153a2fc-f01f-47d0-b683-3a0f2ce764fd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_da957193-031c-46b9-b3a1-29cfac1b42c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AccrualForRebates_5236ee48-361b-46cc-80a5-e5e567c33783_terseLabel_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for rebates included in accrued and other current liabilities</link:label>
    <link:label id="lab_mrk_AccrualForRebates_label_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual For Rebates</link:label>
    <link:label id="lab_mrk_AccrualForRebates_documentation_en-US" xlink:label="lab_mrk_AccrualForRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for rebates recorded as current liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates" xlink:href="mrk-20221231.xsd#mrk_AccrualForRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AccrualForRebates" xlink:to="lab_mrk_AccrualForRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock_f88f6a9f-71e6-49fd-b611-fd432e262337_terseLabel_en-US" xlink:label="lab_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock_label_en-US" xlink:label="lab_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Taxes Paid [Table Text Block]</link:label>
    <link:label id="lab_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock_documentation_en-US" xlink:label="lab_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock" xlink:href="mrk-20221231.xsd#mrk_ScheduleOfIncomeTaxesPaidTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock" xlink:to="lab_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_b112c0c6-d383-4225-b8ec-1b1fa0ef0ae0_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_73435a51-f561-4220-a990-62985ff8204a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9d60dea1-2a37-474e-8e06-abf5136a9661_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) amortization</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_816e605f-bd07-4018-97e1-439860bc7e70_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A075NotesDue2026Member_c7d16aa1-30e0-46ee-9c81-f5f27ccbdbf9_terseLabel_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026</link:label>
    <link:label id="lab_mrk_A075NotesDue2026Member_label_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A075NotesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A075NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Notes due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member" xlink:href="mrk-20221231.xsd#mrk_A075NotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A075NotesDue2026Member" xlink:to="lab_mrk_A075NotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_acbe7dc0-7a26-476d-9e7a-90e1b3c208f8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_0fa07611-9353-441c-b549-32aca8dfc3d2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product intangibles and licenses, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A63DebenturesDue2026Member_1392ecff-ff8c-4517-8999-80a5641a09e1_terseLabel_en-US" xlink:label="lab_mrk_A63DebenturesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.30% debentures due 2026</link:label>
    <link:label id="lab_mrk_A63DebenturesDue2026Member_label_en-US" xlink:label="lab_mrk_A63DebenturesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.3% Debentures Due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A63DebenturesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A63DebenturesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six point three percentage debentures due on two thousand and twenty six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member" xlink:href="mrk-20221231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A63DebenturesDue2026Member" xlink:to="lab_mrk_A63DebenturesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_dbbd5a3f-0d71-4f49-bc7a-d6aff25c26f3_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_61cbbd81-6351-4c16-bf30-9c2d933b41ed_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_51c858b1-3bfa-4795-8933-7e83c659af4f_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of the United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ff32596c-4fe0-401d-a499-af28e0601a87_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal, Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_1a514f05-4d74-4c9d-bda6-0aac1abc42f8_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4442ac3d-e068-49fc-bf8e-a5bbee0791ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthMember_26a58d8e-5a9b-4c36-86b0-24b45df7daa2_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthMember_label_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthMember" xlink:to="lab_mrk_AnimalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_61d01f73-aaef-4b1e-b207-54ed8123007b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Profits to Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_e9cf4829-fcaa-4b47-b622-ed2e4b0d6da9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_92e28a74-45cf-467d-9114-883431f91a73_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_722b68db-b569-49bd-b931-6e71962bf2c3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities for accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b0d63051-d87c-484e-8d98-98e4df9849c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_289a67e7-329b-4905-b324-7a46353f91ec_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_90c72bf1-0a03-47f7-8c7d-446ed1230a77_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c1c40b61-bc36-4e58-9a35-b24b5bcace87_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_038c1b35-fa46-4efa-ac51-9fbd6265c2c1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fa87c811-70ed-486e-8bdd-6e5f5492b448_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GardasilGardasil9Member_442e3e22-51e0-4d29-8562-f0f2181dfbed_terseLabel_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_label_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member]</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_documentation_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member" xlink:href="mrk-20221231.xsd#mrk_GardasilGardasil9Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GardasilGardasil9Member" xlink:to="lab_mrk_GardasilGardasil9Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_ad2a2075-22c4-4462-babb-61d627e2cbf9_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_868fe78d-bf81-4aaa-989f-7cb50c038d99_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_4e924a4c-1df2-46d6-b3a3-dff38a75ccff_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains recognized on investments in equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_80331ba6-2715-4437-af5d-ed7c1df8fe14_terseLabel_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, Liabilities</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_label_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Equity Method Investment</link:label>
    <link:label id="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_documentation_en-US" xlink:label="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:to="lab_mrk_DeferredTaxLiabilitiesEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_19c8d6f2-ee49-4ad2-9d93-18f076afa885_terseLabel_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% notes due 2025</link:label>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_label_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_mrk_A2.75NotesDue2025Member_documentation_en-US" xlink:label="lab_mrk_A2.75NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.75% Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member" xlink:href="mrk-20221231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.75NotesDue2025Member" xlink:to="lab_mrk_A2.75NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_61506876-b6a1-49ff-afd6-2297d4e47988_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_97f541a1-d8b5-48f7-aa69-b34233fb4f95_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RemicadeMember_a539195e-b36b-489b-a141-760e2a29b3f5_terseLabel_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_mrk_RemicadeMember_label_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_mrk_RemicadeMember_documentation_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember" xlink:href="mrk-20221231.xsd#mrk_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RemicadeMember" xlink:to="lab_mrk_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_dbb09755-5694-4196-9ef0-1d6dbe6fe5d3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2811597b-ebe0-4f64-9e3f-76ea52a28b00_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c280e049-3c0c-416a-b3e9-7333edbc0fe0_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance January&#160;1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3328c510-bb2d-4d6e-a6ee-19308a77835e_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance December&#160;31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7b660d1f-eaa4-4272-9f83-500407a85219_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product intangibles and licenses, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OncoImmuneMember_a6514bef-2aef-4df0-a722-7fc21294f813_terseLabel_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune</link:label>
    <link:label id="lab_mrk_OncoImmuneMember_label_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune [Member]</link:label>
    <link:label id="lab_mrk_OncoImmuneMember_documentation_en-US" xlink:label="lab_mrk_OncoImmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OncoImmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember" xlink:href="mrk-20221231.xsd#mrk_OncoImmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OncoImmuneMember" xlink:to="lab_mrk_OncoImmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_5b025409-a200-4132-8e31-2ba7b5f315ad_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_cbadcff3-65b3-49c6-b96f-248fcfa7d8be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_3ec32107-5af8-4337-96a9-c5005edc1cfb_terseLabel_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% notes due 2039</link:label>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_label_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member]</link:label>
    <link:label id="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_documentation_en-US" xlink:label="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five point eight five percentage notes due on two thousand and thirty nine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:href="mrk-20221231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:to="lab_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9e7cee70-618d-49fb-b7c9-0edd705ac797_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_617d061a-38b7-4d3c-97db-4b009b123ffe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_d9d9b8d6-608e-4ce9-af34-a1196cef62c3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_1ead3440-c852-4a00-8864-69a8cd1bb963_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e8cdf9f1-8323-4d01-86d2-df396dc59b55_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_92c73df0-4afe-4bb2-bbdc-7862c1c6c4f7_terseLabel_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% euro-denominated notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_label_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Euro Notes Due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875EuroNotesDue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875EuroNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Euro Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member" xlink:href="mrk-20221231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875EuroNotesDue2026Member" xlink:to="lab_mrk_A1.875EuroNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_b085e29c-6877-4e5e-8392-f00c272dc929_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_6485281a-39bf-4ff5-9bf0-984983a5bd25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dfab3fb5-2c94-4aee-8d69-09f219b017f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ccb2aea7-1c77-4d80-8305-6cb5d27d81d2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZerbaxaMember_cb606932-3f70-49f0-a4ed-94835a2cacf0_terseLabel_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_label_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_documentation_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember" xlink:href="mrk-20221231.xsd#mrk_ZerbaxaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZerbaxaMember" xlink:to="lab_mrk_ZerbaxaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_328b3902-7479-451d-8d69-3fb1e2c255cc_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DificidMember_83ebf0f0-18bb-4e49-9f2a-3cba4d835c3f_terseLabel_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid</link:label>
    <link:label id="lab_mrk_DificidMember_label_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:label id="lab_mrk_DificidMember_documentation_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember" xlink:href="mrk-20221231.xsd#mrk_DificidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DificidMember" xlink:to="lab_mrk_DificidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_b212a8cd-be9b-4cda-b168-3b6152563b22_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:href="mrk-20221231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_20b52230-cb2c-4de3-a172-27b353d6bc65_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_d5a06d95-3102-494c-aac1-b4b1264f6c03_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_97588d3b-005b-42bc-a275-04058fab6b52_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_b1bfda09-c73b-44e9-b4e1-e4392c559855_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_5d4530e0-fa41-4ca7-8614-c793f2a9e5b6_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TukysaMember_a15caacf-a556-4f02-8446-6d8209da7389_terseLabel_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:label id="lab_mrk_TukysaMember_label_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa [Member]</link:label>
    <link:label id="lab_mrk_TukysaMember_documentation_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember" xlink:href="mrk-20221231.xsd#mrk_TukysaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TukysaMember" xlink:to="lab_mrk_TukysaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_2f8ed1a3-59c8-455b-8302-dd5e5e63a61f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Three, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_0a27f9b4-7359-48b5-b69c-fa05cc278757_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_31694dc4-58e0-4192-80fc-cf355514a350_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory classified in Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_01152e7b-1899-4881-8b7b-2bd2030e18e8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncreaseDecreaseInHedgeRevenue_c7bbda82-20c8-49cf-8480-9753db07e66e_terseLabel_en-US" xlink:label="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in revenue hedging activities</link:label>
    <link:label id="lab_mrk_IncreaseDecreaseInHedgeRevenue_label_en-US" xlink:label="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Hedge Revenue</link:label>
    <link:label id="lab_mrk_IncreaseDecreaseInHedgeRevenue_documentation_en-US" xlink:label="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Hedge Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncreaseDecreaseInHedgeRevenue" xlink:href="mrk-20221231.xsd#mrk_IncreaseDecreaseInHedgeRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncreaseDecreaseInHedgeRevenue" xlink:to="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_2c0bd7ad-69f4-42f4-a7d2-349f8d04d64c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_34422e3b-ed1c-4e96-8515-14a2d8f73371_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_723939f3-2dba-4bfa-bdcb-566db8324a13_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_label_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_documentation_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember" xlink:href="mrk-20221231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedDepreciationMember" xlink:to="lab_mrk_AcceleratedDepreciationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_8dcf3844-191d-4988-8426-b8f3e2f993f4_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, equipment and office furnishings</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_000f6e1e-f5e8-49ac-9cfb-315a67e6a6df_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_4272862c-a349-4fcf-966e-c85c1b34f3d1_terseLabel_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.60% notes due 2042</link:label>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_label_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]</link:label>
    <link:label id="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_documentation_en-US" xlink:label="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:href="mrk-20221231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:to="lab_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_06afa7e5-2577-4fc4-b118-a3781e2ef615_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_5a5c90e4-492f-4c7c-8784-15befb7a9bb7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group, other expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_1fa9a2ca-14c2-4a32-94ae-00b453e30775_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status December&#160;31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_e4b78ade-0ab9-43c0-b58e-e13cee17d3c3_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LivestockMember_18853fd1-be7c-44fa-83d2-70773bd94e7e_terseLabel_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock</link:label>
    <link:label id="lab_mrk_LivestockMember_label_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:label id="lab_mrk_LivestockMember_documentation_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember" xlink:href="mrk-20221231.xsd#mrk_LivestockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LivestockMember" xlink:to="lab_mrk_LivestockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_631169f5-35aa-42b0-a148-60de06cc4104_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_01f53121-3dd4-4977-ae4d-3a57d6be3b16_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition tax liability, current</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A245NotesDue2050Member_3a477189-3a3f-4d90-bf2d-4e672e4b7099_terseLabel_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050</link:label>
    <link:label id="lab_mrk_A245NotesDue2050Member_label_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes Due 2050 [Member]</link:label>
    <link:label id="lab_mrk_A245NotesDue2050Member_documentation_en-US" xlink:label="lab_mrk_A245NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member" xlink:href="mrk-20221231.xsd#mrk_A245NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A245NotesDue2050Member" xlink:to="lab_mrk_A245NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_f70c3a69-22a4-4b16-b8f7-bb42f8be4557_terseLabel_en-US" xlink:label="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:href="mrk-20221231.xsd#mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:to="lab_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a5548456-07f8-4bac-ae52-12a19d4fbb05_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_fa009992-c9e6-4e88-91e1-7fc24d0d793f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_a019da62-3000-41be-a508-cce5bdb44c82_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and promotion costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e78a4d58-8d26-42d0-8aa5-3fa2955cef8b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal, Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_6c8d8765-5dba-4823-b41b-e394f6b29043_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Seagen Inc. common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_64565732-ba10-4795-8411-278544d70e21_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8e7be1e3-82af-414b-a810-1ddcba8868b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_24a6f17d-69e9-4c34-b87a-e12214dc36f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges and Spending Relating to Restructuring Activities by Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d915a03e-010a-48b5-a08e-14e2408b7fae_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_77964d94-5f9a-41cd-8e76-e6839ce9e081_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_9cda119c-a87e-4fb9-91c5-84d0e4ac0351_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_db792f71-9bdf-439e-a86b-8c59db5a18c4_terseLabel_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_mrk_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discussion of the accounting policy for contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentConsiderationPolicyTextBlock" xlink:href="mrk-20221231.xsd#mrk_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentConsiderationPolicyTextBlock" xlink:to="lab_mrk_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_92aaa36f-a747-498b-a909-ccd8e2b6f4b3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense, 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_e77badb6-2e27-4d77-9c7b-d010ad7c5acf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a244f7e2-a429-496a-ada9-8732c895930a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_211dbc6d-ee43-4c2c-911b-62b60519a9f9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a26b9110-7e28-4217-bc25-a81a37b0a97f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_5087c85a-4f3c-46d7-9a84-d21a87c973ea_terseLabel_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:href="mrk-20221231.xsd#mrk_AssetsandLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:to="lab_mrk_AssetsandLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_784d2242-9b33-434a-bbde-f1aa814abe29_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal defense costs reserve</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_075bfa87-712b-4861-9aae-669ae6a16ffd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_c46fd478-2549-4707-9953-feac3944b4ba_terseLabel_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member" xlink:href="mrk-20221231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.35NotesDue2022Member" xlink:to="lab_mrk_A2.35NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_5e4f8ddc-7cd0-4064-9204-896877b38a7f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_cd8e299e-c6c4-473b-9f86-9e9bcf7f0c27_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_0a56ee79-11bf-40d2-815f-08fdc5745ede_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_db8714c0-c966-4018-8704-71d21d6b8292_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers into Level 3</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:to="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9a05682f-4799-4880-a2b1-b71395420dce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearOne_4ad5d1a3-bf90-422c-aa46-eb04e25e8ec6_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, interest payments in 2023</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearOne_label_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year One</link:label>
    <link:label id="lab_mrk_LongTermDebtInterestPayableYearOne_documentation_en-US" xlink:label="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Interest Payable, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearOne" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtInterestPayableYearOne" xlink:to="lab_mrk_LongTermDebtInterestPayableYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanionAnimalsMember_ba46c3e5-9174-401c-83ad-3e9287d0aa7c_terseLabel_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_label_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_documentation_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember" xlink:href="mrk-20221231.xsd#mrk_CompanionAnimalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanionAnimalsMember" xlink:to="lab_mrk_CompanionAnimalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b64a71ab-2642-42c1-aaa8-50bf2bbe4fcd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate applied to income from continuing operations before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_71bcd5b7-ca9c-483f-b699-f4276e41afc0_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_ecea5a96-95d9-4ebf-aa8c-3ea78aa1355b_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Promotion Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_a832c04e-bf1c-4bc6-9cc4-d2ec5128ff90_terseLabel_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations</link:label>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_label_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Obligations Investment Funds [Member]</link:label>
    <link:label id="lab_mrk_CorporateObligationsInvestmentFundsMember_documentation_en-US" xlink:label="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate obligations investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CorporateObligationsInvestmentFundsMember" xlink:to="lab_mrk_CorporateObligationsInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_2280131e-9cd5-44c1-8609-229a3b77c2e7_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties, current</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2b979bf0-fca0-4360-ab57-a00ce433ab95_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities of Continuing Operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_7b1f1430-aadc-4d2f-8a00-6a972a3c28e5_terseLabel_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024</link:label>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.50eurodenominatednotesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.50% euro-denominated notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member" xlink:href="mrk-20221231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.50eurodenominatednotesdue2024Member" xlink:to="lab_mrk_A0.50eurodenominatednotesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_951d406f-b41e-4a3f-8452-cf493ee60503_terseLabel_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments collaborative arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20221231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_7127af96-55ee-4dab-8bf9-503c26268548_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrionCorporationMember_be751b9b-fcc1-4197-af2f-721a004f93ba_terseLabel_en-US" xlink:label="lab_mrk_OrionCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orion Corporation</link:label>
    <link:label id="lab_mrk_OrionCorporationMember_label_en-US" xlink:label="lab_mrk_OrionCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orion Corporation [Member]</link:label>
    <link:label id="lab_mrk_OrionCorporationMember_documentation_en-US" xlink:label="lab_mrk_OrionCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orion Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrionCorporationMember" xlink:href="mrk-20221231.xsd#mrk_OrionCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrionCorporationMember" xlink:to="lab_mrk_OrionCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_a5f9c825-0eb2-4ca4-b2e7-eeb17e23354e_terseLabel_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_label_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:label id="lab_mrk_PremiumOnSharesAcquired_documentation_en-US" xlink:label="lab_mrk_PremiumOnSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on shares acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired" xlink:href="mrk-20221231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PremiumOnSharesAcquired" xlink:to="lab_mrk_PremiumOnSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_00210550-8c75-4c74-8bd7-279f549f7165_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrganonCoMember_b09af29b-a87e-4903-8e10-2076236c608b_terseLabel_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:label id="lab_mrk_OrganonCoMember_label_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co. [Member]</link:label>
    <link:label id="lab_mrk_OrganonCoMember_documentation_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember" xlink:href="mrk-20221231.xsd#mrk_OrganonCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrganonCoMember" xlink:to="lab_mrk_OrganonCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_ac74d867-2183-4407-930c-7aa58c2feb12_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_6e920f3f-0aa0-4ceb-91c1-c97679bd5a37_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_67f44aa0-c4c5-43a5-8d2d-4467e8b997b6_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales by Merck</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementSalesNet" xlink:to="lab_mrk_CollaborativeArrangementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_f488730d-5f99-43a4-83ad-606f923fd493_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net Income Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>mrk-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6a80835e-3d33-418a-be61-33ea02b302af,g:f2b57eeb-4f2d-41ff-83c8-1b4e9f7a4523-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1d5197c1-003f-440b-8335-da4c92c811aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_d384bf74-8d6d-4dc7-93ee-34be6a74c57c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d5197c1-003f-440b-8335-da4c92c811aa" xlink:to="loc_dei_DocumentInformationTable_d384bf74-8d6d-4dc7-93ee-34be6a74c57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_d384bf74-8d6d-4dc7-93ee-34be6a74c57c" xlink:to="loc_us-gaap_DebtInstrumentAxis_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f2dc5d76-fd9c-4b9d-ba51-1162e3a44943" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_a48abba0-d1d3-431d-98b7-33a4ed2d79f2" xlink:href="mrk-20221231.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A0.500Notesdue2024Member_a48abba0-d1d3-431d-98b7-33a4ed2d79f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_46abe05d-1603-4444-b89f-7cc7b2d27388" xlink:href="mrk-20221231.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A1.875Notesdue2026Member_46abe05d-1603-4444-b89f-7cc7b2d27388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_e2b41ada-981f-480a-a952-303fed13f641" xlink:href="mrk-20221231.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A2.500Notesdue2034Member_e2b41ada-981f-480a-a952-303fed13f641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_c8afc2dc-8ea7-4185-a658-59d90ff257b5" xlink:href="mrk-20221231.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_af77c425-b77b-49df-a67d-870f16d16c04" xlink:to="loc_mrk_A1.375Notesdue2036Member_c8afc2dc-8ea7-4185-a658-59d90ff257b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_d384bf74-8d6d-4dc7-93ee-34be6a74c57c" xlink:to="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d6374c12-795c-40fd-9508-7b651f834084" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentType_d6374c12-795c-40fd-9508-7b651f834084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ab33d850-b5cb-4730-8527-6707755af848" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentAnnualReport_ab33d850-b5cb-4730-8527-6707755af848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6669ed2f-15e3-48ad-8d92-989fe780d843" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentPeriodEndDate_6669ed2f-15e3-48ad-8d92-989fe780d843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_004f0606-7d9b-4fa1-abd5-2b9257f92566" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_CurrentFiscalYearEndDate_004f0606-7d9b-4fa1-abd5-2b9257f92566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4245f171-bd1c-4242-b893-26a445ee45eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentTransitionReport_4245f171-bd1c-4242-b893-26a445ee45eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cfa6fa9c-21f7-4a73-a72b-6f83af58433b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityFileNumber_cfa6fa9c-21f7-4a73-a72b-6f83af58433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2d46a3f0-6e36-4f26-830e-8999be9dfb14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityRegistrantName_2d46a3f0-6e36-4f26-830e-8999be9dfb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_54a96d86-de3f-4aa4-8a1d-3104efc4f440" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressAddressLine1_54a96d86-de3f-4aa4-8a1d-3104efc4f440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eaf7e57a-d052-4467-9d55-a67104edebb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressCityOrTown_eaf7e57a-d052-4467-9d55-a67104edebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0f10f8d4-6885-4aa9-841e-d0e451db4318" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressStateOrProvince_0f10f8d4-6885-4aa9-841e-d0e451db4318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_480d718c-635e-4ffe-a3bf-1bcbc919960e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityAddressPostalZipCode_480d718c-635e-4ffe-a3bf-1bcbc919960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_84e5d2cc-3646-424a-994e-4eeadb9b1f83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_CityAreaCode_84e5d2cc-3646-424a-994e-4eeadb9b1f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4a6ea60c-32f2-4110-b65a-df619613c6d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_LocalPhoneNumber_4a6ea60c-32f2-4110-b65a-df619613c6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_795ceabb-2b3d-4abf-9a9a-f5b64e764ab8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_795ceabb-2b3d-4abf-9a9a-f5b64e764ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5dad80e1-683a-4250-ae63-30ce1ab980c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityTaxIdentificationNumber_5dad80e1-683a-4250-ae63-30ce1ab980c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_29e5ef4e-585a-4ac9-89ea-169dcbcc113c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_Security12bTitle_29e5ef4e-585a-4ac9-89ea-169dcbcc113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cc3777cc-6d02-4bb5-b824-1c1ac9ba649c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_TradingSymbol_cc3777cc-6d02-4bb5-b824-1c1ac9ba649c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f5d86d67-d503-4e04-80bc-29d3e8d2edbe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_SecurityExchangeName_f5d86d67-d503-4e04-80bc-29d3e8d2edbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_36c06dfc-9177-4895-bf52-03b86b7b4a46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_36c06dfc-9177-4895-bf52-03b86b7b4a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_19fab279-9336-4e00-bb4b-b3e786cf4dd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityPublicFloat_19fab279-9336-4e00-bb4b-b3e786cf4dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e045ac8a-43f9-41ed-be91-963ce97bb7d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e045ac8a-43f9-41ed-be91-963ce97bb7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_27966c05-2fc5-4586-9c87-f53f9e48f344" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityVoluntaryFilers_27966c05-2fc5-4586-9c87-f53f9e48f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d1f4c630-1af6-4c15-a5c6-8672131c629b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityCurrentReportingStatus_d1f4c630-1af6-4c15-a5c6-8672131c629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6a1745ee-f84c-4f9f-a478-d1c06415689f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityInteractiveDataCurrent_6a1745ee-f84c-4f9f-a478-d1c06415689f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c574b886-6d00-492e-a59d-59f00b49961c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityFilerCategory_c574b886-6d00-492e-a59d-59f00b49961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a2323c9c-066e-47c7-9134-07a0b696c72d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntitySmallBusiness_a2323c9c-066e-47c7-9134-07a0b696c72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8d15552f-cfe9-45a6-bb3c-32fc68fde3f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityEmergingGrowthCompany_8d15552f-cfe9-45a6-bb3c-32fc68fde3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4d8a4a7b-e672-4403-818f-d7e43f57c750" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4d8a4a7b-e672-4403-818f-d7e43f57c750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_34bef415-7cf1-4034-9c51-7fdf1edfbe7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityShellCompany_34bef415-7cf1-4034-9c51-7fdf1edfbe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fb05caa2-0d58-4ae7-96e4-7e1ed3a5d887" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_AmendmentFlag_fb05caa2-0d58-4ae7-96e4-7e1ed3a5d887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c0e109f2-f5b2-4ec0-9340-bfce5730376a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentFiscalYearFocus_c0e109f2-f5b2-4ec0-9340-bfce5730376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6e3cb1ff-019d-49a7-b12b-0bd2bb689fb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6e3cb1ff-019d-49a7-b12b-0bd2bb689fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6261b5a1-afc4-4b8f-a1dc-409b56e77e71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_EntityCentralIndexKey_6261b5a1-afc4-4b8f-a1dc-409b56e77e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c203cd6d-b9e9-437e-b976-75b9727b848c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_332d1e12-d2ea-4bfb-81b6-9bec511e129e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_c203cd6d-b9e9-437e-b976-75b9727b848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AuditInformation" xlink:type="simple" xlink:href="mrk-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AuditInformationAbstract_ad770c2d-212d-483c-a1d7-2bc2e86a909b" xlink:href="mrk-20221231.xsd#mrk_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_73d5b146-83ac-4b19-a2c2-8614cfe6ae9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_AuditInformationAbstract_ad770c2d-212d-483c-a1d7-2bc2e86a909b" xlink:to="loc_dei_AuditorName_73d5b146-83ac-4b19-a2c2-8614cfe6ae9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_c28678d9-43b9-4ed4-a6ba-7cc4dbb31a58" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_AuditInformationAbstract_ad770c2d-212d-483c-a1d7-2bc2e86a909b" xlink:to="loc_dei_AuditorLocation_c28678d9-43b9-4ed4-a6ba-7cc4dbb31a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_e2017c70-0a8e-4fbf-9694-0958682ddb5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_AuditInformationAbstract_ad770c2d-212d-483c-a1d7-2bc2e86a909b" xlink:to="loc_dei_AuditorFirmId_e2017c70-0a8e-4fbf-9694-0958682ddb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6fd4c2ab-af6f-456b-9cd5-d773776fc401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_Revenues_6fd4c2ab-af6f-456b-9cd5-d773776fc401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2c6f61ce-88b0-4d5d-8143-76f65ba99b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2c6f61ce-88b0-4d5d-8143-76f65ba99b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3e96fc81-5559-4d2d-bc8a-2289d96e68a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3e96fc81-5559-4d2d-bc8a-2289d96e68a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b27904b5-053e-490c-9355-302426cdcaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b27904b5-053e-490c-9355-302426cdcaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_37ae568e-f146-45f4-8005-d2dc2b35a25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:to="loc_us-gaap_RestructuringCharges_37ae568e-f146-45f4-8005-d2dc2b35a25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bfa5e326-4056-4aad-8022-13cb764e72d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bfa5e326-4056-4aad-8022-13cb764e72d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_55083d78-d1cf-4f88-9dd3-26b9e0d2a507" xlink:href="mrk-20221231.xsd#mrk_CostsExpensesAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_61e88dbc-b587-4ac5-9516-7a2d5b9cf7f1" xlink:to="loc_mrk_CostsExpensesAndOther_55083d78-d1cf-4f88-9dd3-26b9e0d2a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aac43db8-69bc-410f-aba7-a542711a8e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aac43db8-69bc-410f-aba7-a542711a8e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6e74aabe-c33d-42b3-92b8-458b2dd440e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6e74aabe-c33d-42b3-92b8-458b2dd440e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b3cdf8b2-4adc-48aa-b9c2-df74300bab4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b3cdf8b2-4adc-48aa-b9c2-df74300bab4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_61daf591-840f-466d-976e-07f122b291f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_61daf591-840f-466d-976e-07f122b291f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_b222f2ee-83a3-4781-aa20-d7fc5f5ae00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_b222f2ee-83a3-4781-aa20-d7fc5f5ae00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bead3a4b-59e8-45d2-9cac-ade7ea315170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bead3a4b-59e8-45d2-9cac-ade7ea315170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55a76988-e164-445b-b991-274d18c7971d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_NetIncomeLoss_55a76988-e164-445b-b991-274d18c7971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_38aea6f5-d5f4-4e44-9303-e594ba2e1ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_38aea6f5-d5f4-4e44-9303-e594ba2e1ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_34215131-ff3f-4d57-97c6-3de4bd7eac24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_38aea6f5-d5f4-4e44-9303-e594ba2e1ed4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_34215131-ff3f-4d57-97c6-3de4bd7eac24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_dec8fb8a-ee96-4a90-b2ba-51efa3275606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_38aea6f5-d5f4-4e44-9303-e594ba2e1ed4" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_dec8fb8a-ee96-4a90-b2ba-51efa3275606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_86df0ebe-eeed-4c07-ae3f-11ce8c87e299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_38aea6f5-d5f4-4e44-9303-e594ba2e1ed4" xlink:to="loc_us-gaap_EarningsPerShareBasic_86df0ebe-eeed-4c07-ae3f-11ce8c87e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_d0bd5042-da01-4027-a3a6-83c2a5d0080f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18eb0af1-cf53-42d3-a57b-4a4ecf1cd6c7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_d0bd5042-da01-4027-a3a6-83c2a5d0080f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1be4c465-50fc-45e1-8745-1b48eaf73d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d0bd5042-da01-4027-a3a6-83c2a5d0080f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1be4c465-50fc-45e1-8745-1b48eaf73d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_f2cee7b7-9eaa-4ce1-9d25-176f41faacb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d0bd5042-da01-4027-a3a6-83c2a5d0080f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_f2cee7b7-9eaa-4ce1-9d25-176f41faacb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_054b3208-9a9d-4e7a-b6a4-15b7601e19be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d0bd5042-da01-4027-a3a6-83c2a5d0080f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_054b3208-9a9d-4e7a-b6a4-15b7601e19be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3147922b-785f-4d0d-89d9-31b39ff2a953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64e553a7-c1df-41fc-8575-83e29cd24090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3147922b-785f-4d0d-89d9-31b39ff2a953" xlink:to="loc_us-gaap_NetIncomeLoss_64e553a7-c1df-41fc-8575-83e29cd24090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fcd614e2-4923-49b9-a93f-b7bc290a5836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3147922b-785f-4d0d-89d9-31b39ff2a953" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fcd614e2-4923-49b9-a93f-b7bc290a5836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6501e775-967b-4d7e-ae68-d3f3e17d3b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fcd614e2-4923-49b9-a93f-b7bc290a5836" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6501e775-967b-4d7e-ae68-d3f3e17d3b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5dae7e82-a5ac-4b52-8322-47416e42b23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fcd614e2-4923-49b9-a93f-b7bc290a5836" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5dae7e82-a5ac-4b52-8322-47416e42b23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3ec0026c-460e-4f1f-808d-5596f7345ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fcd614e2-4923-49b9-a93f-b7bc290a5836" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3ec0026c-460e-4f1f-808d-5596f7345ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0d131e11-fec0-4f3c-a064-6434ccc21e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fcd614e2-4923-49b9-a93f-b7bc290a5836" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0d131e11-fec0-4f3c-a064-6434ccc21e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58814b01-4a43-49d3-b4b2-d87382c5dbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fcd614e2-4923-49b9-a93f-b7bc290a5836" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58814b01-4a43-49d3-b4b2-d87382c5dbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5e324a3f-7cee-4272-8fdd-dbc6af27ee04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3147922b-785f-4d0d-89d9-31b39ff2a953" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5e324a3f-7cee-4272-8fdd-dbc6af27ee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedBalanceSheet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0b960657-b96a-4ac1-89d0-f39f81083edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0b960657-b96a-4ac1-89d0-f39f81083edb" xlink:to="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04f03c1d-f409-496f-b226-cf8013702e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04f03c1d-f409-496f-b226-cf8013702e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_da886643-3ff8-42ae-bfa8-f739336d05bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:to="loc_us-gaap_ShortTermInvestments_da886643-3ff8-42ae-bfa8-f739336d05bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_08edcd0f-b426-4b2f-8dff-e600a8adcf01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_08edcd0f-b426-4b2f-8dff-e600a8adcf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_56c756c8-02c1-4bdb-813c-64d3f9ebe3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:to="loc_us-gaap_InventoryNet_56c756c8-02c1-4bdb-813c-64d3f9ebe3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_418b96a4-270e-4f57-acfb-c66875f14d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:to="loc_us-gaap_OtherAssetsCurrent_418b96a4-270e-4f57-acfb-c66875f14d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f2c56b6-03a5-436c-b7b6-220e53975948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_406916cb-3b94-46d9-b5f7-598c4cfb0496" xlink:to="loc_us-gaap_AssetsCurrent_1f2c56b6-03a5-436c-b7b6-220e53975948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_213f21ef-38f0-4940-bdb3-ba359b7ca022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_213f21ef-38f0-4940-bdb3-ba359b7ca022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_b1f7482d-9278-4347-84ab-165c8afa08d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_b1f7482d-9278-4347-84ab-165c8afa08d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_50924742-bcde-431d-89c3-a2b8f70a1b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_b1f7482d-9278-4347-84ab-165c8afa08d1" xlink:to="loc_us-gaap_Land_50924742-bcde-431d-89c3-a2b8f70a1b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_780b9073-5243-42c2-b163-3b55a65ef032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_b1f7482d-9278-4347-84ab-165c8afa08d1" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_780b9073-5243-42c2-b163-3b55a65ef032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_74ab3258-7552-4480-894d-23009b1877b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_b1f7482d-9278-4347-84ab-165c8afa08d1" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_74ab3258-7552-4480-894d-23009b1877b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_7a3d438f-aba6-43fa-b777-3e910654cff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_b1f7482d-9278-4347-84ab-165c8afa08d1" xlink:to="loc_us-gaap_ConstructionInProgressGross_7a3d438f-aba6-43fa-b777-3e910654cff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5b54967e-845a-4aee-a269-5c03bdebaaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_b1f7482d-9278-4347-84ab-165c8afa08d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5b54967e-845a-4aee-a269-5c03bdebaaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b7242de8-8858-489a-b487-9f5642509c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b7242de8-8858-489a-b487-9f5642509c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2d7aedb5-f435-40bc-ae9a-f6650acfef7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2d7aedb5-f435-40bc-ae9a-f6650acfef7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7c52cd93-3eec-44a4-b791-cefc2eee1c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_Goodwill_7c52cd93-3eec-44a4-b791-cefc2eee1c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b166fbd-a22e-4e04-936b-90c40db9321c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b166fbd-a22e-4e04-936b-90c40db9321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_bd54a5b0-570c-4984-8514-e3045119dd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_bd54a5b0-570c-4984-8514-e3045119dd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2cf9d4ef-feac-4a16-8812-6339cde1fa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0dff4295-6615-45e3-9d05-04ccf88c434b" xlink:to="loc_us-gaap_Assets_2cf9d4ef-feac-4a16-8812-6339cde1fa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0b960657-b96a-4ac1-89d0-f39f81083edb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_69dfc447-46d5-4264-b882-b5d7ee4bfc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:to="loc_us-gaap_DebtCurrent_69dfc447-46d5-4264-b882-b5d7ee4bfc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f2e83264-0713-4778-b160-097a2a473f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:to="loc_us-gaap_AccountsPayableCurrent_f2e83264-0713-4778-b160-097a2a473f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c68c8a99-b8f6-41b5-87c7-eaf0bd185dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c68c8a99-b8f6-41b5-87c7-eaf0bd185dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_5e283f6d-6d51-4ec6-9adf-e0a57df252b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_5e283f6d-6d51-4ec6-9adf-e0a57df252b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1bac97b2-838e-42e0-842b-933f341bf1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:to="loc_us-gaap_DividendsPayableCurrent_1bac97b2-838e-42e0-842b-933f341bf1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4222ccb7-ffe8-406b-a409-a57d84dc5066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eb9b355f-d7c7-483c-84b0-475776e47d6d" xlink:to="loc_us-gaap_LiabilitiesCurrent_4222ccb7-ffe8-406b-a409-a57d84dc5066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1a39810d-1e0c-4672-8a59-913e471776a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1a39810d-1e0c-4672-8a59-913e471776a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8aadcd4d-d2f2-4a95-a57a-ca622276e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8aadcd4d-d2f2-4a95-a57a-ca622276e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_34311a0a-6c4d-4474-99a1-c6efb138db28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_34311a0a-6c4d-4474-99a1-c6efb138db28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_79e95ef9-e163-485a-aa17-2d112bcd3d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:to="loc_us-gaap_CommonStockValue_79e95ef9-e163-485a-aa17-2d112bcd3d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9ed02d8c-1bdd-4c6e-983a-c20045763fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9ed02d8c-1bdd-4c6e-983a-c20045763fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b9506ca-90f4-4d5a-a71c-1d1ea0e12760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b9506ca-90f4-4d5a-a71c-1d1ea0e12760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ad8e45d-c15d-4b5f-a6d7-12210cbd658c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ad8e45d-c15d-4b5f-a6d7-12210cbd658c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_e0ad526b-c08b-400b-8ea0-e48ebf4cd9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_e0ad526b-c08b-400b-8ea0-e48ebf4cd9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_948625fa-5c99-4961-a0b1-869d19c7348d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:to="loc_us-gaap_TreasuryStockCommonValue_948625fa-5c99-4961-a0b1-869d19c7348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9cee66b-ac98-4e82-b218-5c2f08adf87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20333392-7bc9-47c4-a3ee-930ef4bde9b7" xlink:to="loc_us-gaap_StockholdersEquity_a9cee66b-ac98-4e82-b218-5c2f08adf87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6d213280-1904-43d9-8fc8-239d23a9d342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_MinorityInterest_6d213280-1904-43d9-8fc8-239d23a9d342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_810e1e67-4b3d-4865-b53d-d1050f8e380f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_810e1e67-4b3d-4865-b53d-d1050f8e380f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_526694f5-e053-493c-8871-06744584b3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_390cde8a-bcbd-4d9b-84f3-6bde5787ae58" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_526694f5-e053-493c-8871-06744584b3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedBalanceSheetParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_59793fb1-57b4-4615-9bf5-dae7bae473a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d11c5bb7-229c-4577-b62e-05a936338a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59793fb1-57b4-4615-9bf5-dae7bae473a3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d11c5bb7-229c-4577-b62e-05a936338a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_2f68d0ea-206d-4567-b946-5d7fa08e43c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59793fb1-57b4-4615-9bf5-dae7bae473a3" xlink:to="loc_us-gaap_InventoryNoncurrent_2f68d0ea-206d-4567-b946-5d7fa08e43c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e95dba67-35eb-4728-9797-c1315059d589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59793fb1-57b4-4615-9bf5-dae7bae473a3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e95dba67-35eb-4728-9797-c1315059d589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d5e034f9-4b5a-4821-9f70-002a8984d966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59793fb1-57b4-4615-9bf5-dae7bae473a3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d5e034f9-4b5a-4821-9f70-002a8984d966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_06947382-70d1-4984-bc6d-d3bc42ed42d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59793fb1-57b4-4615-9bf5-dae7bae473a3" xlink:to="loc_us-gaap_CommonStockSharesIssued_06947382-70d1-4984-bc6d-d3bc42ed42d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b71f0b85-bee6-40c5-aad9-4530997faca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59793fb1-57b4-4615-9bf5-dae7bae473a3" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b71f0b85-bee6-40c5-aad9-4530997faca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3475e8f8-059d-431a-93a1-515cfff0c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6ccfa879-b4e5-4a6c-9922-7d90f755c57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3475e8f8-059d-431a-93a1-515cfff0c228" xlink:to="loc_us-gaap_StatementTable_6ccfa879-b4e5-4a6c-9922-7d90f755c57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0460052-bf0d-4e3f-b22a-8d17061074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ccfa879-b4e5-4a6c-9922-7d90f755c57f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0460052-bf0d-4e3f-b22a-8d17061074a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0460052-bf0d-4e3f-b22a-8d17061074a2" xlink:to="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c79ca69d-5dd8-4ad3-a289-f39f55fbd274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_CommonStockMember_c79ca69d-5dd8-4ad3-a289-f39f55fbd274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c77e7a86-afb1-4fcc-9409-7610b8385897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c77e7a86-afb1-4fcc-9409-7610b8385897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4453d0ba-f9ca-43b2-849d-384fc6e05fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_RetainedEarningsMember_4453d0ba-f9ca-43b2-849d-384fc6e05fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c2a52bd-6006-4050-8c89-5464c20854f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c2a52bd-6006-4050-8c89-5464c20854f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5e1ebff4-4279-46aa-b93b-6492cb7be323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5e1ebff4-4279-46aa-b93b-6492cb7be323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b4028b77-7c04-4dc9-a50f-0c5e72996f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3df01aa0-19cf-4483-bb82-d1fea3f65e10" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b4028b77-7c04-4dc9-a50f-0c5e72996f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_43cac79f-bbee-4ce0-8bd3-13d52828b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ccfa879-b4e5-4a6c-9922-7d90f755c57f" xlink:to="loc_us-gaap_StatementLineItems_43cac79f-bbee-4ce0-8bd3-13d52828b7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_43cac79f-bbee-4ce0-8bd3-13d52828b7e0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a23ab70-8f4b-4864-82ae-25b36b7c114a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a23ab70-8f4b-4864-82ae-25b36b7c114a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3eb9056e-5ac7-4292-a3bf-74c73fdf15de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_NetIncomeLoss_3eb9056e-5ac7-4292-a3bf-74c73fdf15de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e997e7b-1cd2-4b16-8193-c3361da7125b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1e997e7b-1cd2-4b16-8193-c3361da7125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_b3a65a58-7fa1-4bf7-b294-bdced5917150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_DividendsCommonStockCash_b3a65a58-7fa1-4bf7-b294-bdced5917150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6334136-d37a-44b5-bb62-aff0927436ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b6334136-d37a-44b5-bb62-aff0927436ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_d0436059-98cb-436d-a69c-0da02669bffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_d0436059-98cb-436d-a69c-0da02669bffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a575434-d94d-4448-8d66-3c4a5cb0404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a575434-d94d-4448-8d66-3c4a5cb0404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1a75df8e-9b60-40eb-a528-807b87540fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1a75df8e-9b60-40eb-a528-807b87540fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e38cda66-ad4c-40aa-8923-ad72481e8a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_StockholdersEquityOther_e38cda66-ad4c-40aa-8923-ad72481e8a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d39dce5-ef0b-4f31-a499-4ef46f19ed1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_eeb0bcc0-d1af-4dc3-807d-1a5d6d412649" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d39dce5-ef0b-4f31-a499-4ef46f19ed1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0a9b02eb-3258-499b-8d62-bdca70d6e5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_f6e8ba9c-ebcf-42b7-ba86-e1cec902c1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0a9b02eb-3258-499b-8d62-bdca70d6e5b1" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_f6e8ba9c-ebcf-42b7-ba86-e1cec902c1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2df80991-4b77-4837-b2da-a6735dcbcd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2df80991-4b77-4837-b2da-a6735dcbcd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bc61742b-5eae-4850-8ca9-d015511c2b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2df80991-4b77-4837-b2da-a6735dcbcd25" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bc61742b-5eae-4850-8ca9-d015511c2b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2df80991-4b77-4837-b2da-a6735dcbcd25" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_e91d42c3-9d50-4153-9c8e-ef2fa8d83d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_AdjustmentForAmortization_e91d42c3-9d50-4153-9c8e-ef2fa8d83d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f9068af1-bdca-47a7-a6d9-151aaec07730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_Depreciation_f9068af1-bdca-47a7-a6d9-151aaec07730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_cc5b0595-532d-4de7-8fb3-e1ec143f82b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_cc5b0595-532d-4de7-8fb3-e1ec143f82b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_54e7945b-ee15-4a1c-9619-1ea1f61d6923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_54e7945b-ee15-4a1c-9619-1ea1f61d6923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_77bb88e2-1091-46a2-aebf-1f83168b3ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_77bb88e2-1091-46a2-aebf-1f83168b3ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_ee69cefc-b38f-4cf8-9e85-d081ee02838f" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_ee69cefc-b38f-4cf8-9e85-d081ee02838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d8cf3fce-7759-4802-abbc-1d6c2e73a7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d8cf3fce-7759-4802-abbc-1d6c2e73a7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6a49bc48-42a5-417a-b336-338c60633b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_ShareBasedCompensation_6a49bc48-42a5-417a-b336-338c60633b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7060a9ad-6013-4686-b807-ca43e6d3678b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7060a9ad-6013-4686-b807-ca43e6d3678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_265e43b2-6f41-4e96-b9de-14d897a6be63" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34b08a59-d990-4067-ab47-cd0a88e9cdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34b08a59-d990-4067-ab47-cd0a88e9cdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c43200be-3254-4dd1-b9c7-14860855b0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c43200be-3254-4dd1-b9c7-14860855b0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_287d7867-a466-45d8-a490-264e78f5b671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_287d7867-a466-45d8-a490-264e78f5b671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a18a4db3-12a0-48c4-8937-35baadeae82e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a18a4db3-12a0-48c4-8937-35baadeae82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_76c6b8d5-ddf3-4124-be1e-cf4d8572bbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_76c6b8d5-ddf3-4124-be1e-cf4d8572bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_dcd0711d-31b2-424f-acb4-ed3d17814082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_dcd0711d-31b2-424f-acb4-ed3d17814082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_09badd6c-70ff-41cf-a21a-d3c1b0cfae8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7779854e-c99f-4761-b852-11d98c56bdd5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_09badd6c-70ff-41cf-a21a-d3c1b0cfae8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_50e3e2b3-0de8-43c3-8bfe-f51abcba9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2df80991-4b77-4837-b2da-a6735dcbcd25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_50e3e2b3-0de8-43c3-8bfe-f51abcba9ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_26b32ff8-afd1-49be-9ded-c40881c2f890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_26b32ff8-afd1-49be-9ded-c40881c2f890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_82c6087b-1674-43d2-b64b-20a4b54440f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_82c6087b-1674-43d2-b64b-20a4b54440f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_62e1b41a-8a0b-47be-a593-edf30824fe99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_62e1b41a-8a0b-47be-a593-edf30824fe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_74545afa-d9fd-4d18-bc93-58f534fd5a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_74545afa-d9fd-4d18-bc93-58f534fd5a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_08bfaa8e-53bb-49c2-8b7d-b66fd0190dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_08bfaa8e-53bb-49c2-8b7d-b66fd0190dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_a02d7434-9053-4d77-a64d-2c885146eb53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_a02d7434-9053-4d77-a64d-2c885146eb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_1dcc1679-9c56-4341-94b4-4438e0308f58" xlink:href="mrk-20221231.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_1dcc1679-9c56-4341-94b4-4438e0308f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_6e54b890-e9fd-45e0-9cad-87453c40111c" xlink:href="mrk-20221231.xsd#mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired_6e54b890-e9fd-45e0-9cad-87453c40111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3d59831c-d9ca-4770-b1e8-2cea1f6ebc54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3d59831c-d9ca-4770-b1e8-2cea1f6ebc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d4862380-4da5-4614-adf2-f2373a7a7979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d4862380-4da5-4614-adf2-f2373a7a7979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7507db21-065c-4f12-99eb-5271e01bb9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5ff51d41-5baa-4dba-9c4f-cc2265090615" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_7507db21-065c-4f12-99eb-5271e01bb9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_001adbac-2f28-4471-8c03-e6d05e984103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_001adbac-2f28-4471-8c03-e6d05e984103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1ca25efc-ba62-4d8d-9282-24837a3fa9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1ca25efc-ba62-4d8d-9282-24837a3fa9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4702693-29a0-489c-938f-22c294919bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4702693-29a0-489c-938f-22c294919bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_26e8b1e3-1af6-4c0c-a5ca-d2e0eb746ace" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived_26e8b1e3-1af6-4c0c-a5ca-d2e0eb746ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5203e91-c3a3-4843-8a81-57e337fcfff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5203e91-c3a3-4843-8a81-57e337fcfff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_1de01734-8e9e-41ca-bae8-4875145324a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_1de01734-8e9e-41ca-bae8-4875145324a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8109b1d9-ad0e-43f6-a76c-daec6fe524b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8109b1d9-ad0e-43f6-a76c-daec6fe524b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a7e31cac-d404-4b20-a681-dc1f01284c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a7e31cac-d404-4b20-a681-dc1f01284c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_97a4925b-17c7-4b88-a9c9-97596d54d4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3303082d-82bd-44bb-a2e7-c44e3001e597" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_97a4925b-17c7-4b88-a9c9-97596d54d4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_379d8958-619d-4f03-acb5-6954e6657fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_379d8958-619d-4f03-acb5-6954e6657fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_e7b0e03f-8640-4d75-b8c6-4c8c2bfac48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_379d8958-619d-4f03-acb5-6954e6657fc2" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_e7b0e03f-8640-4d75-b8c6-4c8c2bfac48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_81b58bf2-c833-4768-9241-21e94b332f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_379d8958-619d-4f03-acb5-6954e6657fc2" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_81b58bf2-c833-4768-9241-21e94b332f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_86bc9837-22f9-49c3-8b4d-08e7f25cd884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_379d8958-619d-4f03-acb5-6954e6657fc2" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_86bc9837-22f9-49c3-8b4d-08e7f25cd884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_546dbf93-8f6d-491c-a144-b6ef38230e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_379d8958-619d-4f03-acb5-6954e6657fc2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_546dbf93-8f6d-491c-a144-b6ef38230e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d185ba4-63f2-44a1-991a-fa868ff95032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d185ba4-63f2-44a1-991a-fa868ff95032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2ffa36e-2d0e-4df2-b579-709027b98bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2ffa36e-2d0e-4df2-b579-709027b98bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e9c3332-e1b8-4780-9a30-16bd57091006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e9c3332-e1b8-4780-9a30-16bd57091006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_042eb61d-aa9e-4a27-8dbf-a9574ad5759b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_042eb61d-aa9e-4a27-8dbf-a9574ad5759b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580dca1a-d43e-49a2-b8d5-d55f76696eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_002cade0-e529-4046-a093-1143837b87d8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_580dca1a-d43e-49a2-b8d5-d55f76696eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="simple" xlink:href="mrk-20221231.xsd#ConsolidatedStatementofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_50233956-ed8a-4b0f-9ac8-34173cf7d704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bf77c463-3560-4591-b4b1-187d9246fce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50233956-ed8a-4b0f-9ac8-34173cf7d704" xlink:to="loc_us-gaap_RestrictedCash_bf77c463-3560-4591-b4b1-187d9246fce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperations" xlink:type="simple" xlink:href="mrk-20221231.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_156e221d-446d-43d1-811c-7b38c4164f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_220b4496-4be7-46a7-9931-1da5de819aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_156e221d-446d-43d1-811c-7b38c4164f05" xlink:to="loc_us-gaap_NatureOfOperations_220b4496-4be7-46a7-9931-1da5de819aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="simple" xlink:href="mrk-20221231.xsd#SummaryofAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa0cdbb6-7d2b-4a86-ad08-1284a498c4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ffa6825e-156a-4a9d-9ac3-aeb0968d512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa0cdbb6-7d2b-4a86-ad08-1284a498c4d8" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ffa6825e-156a-4a9d-9ac3-aeb0968d512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="simple" xlink:href="mrk-20221231.xsd#SpinOffofOrganonCo"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c7d4d2a1-6dae-40e6-9d2b-2da2e493f2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_59470b5b-acef-46ab-ba74-4cb6f6db3e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c7d4d2a1-6dae-40e6-9d2b-2da2e493f2ae" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_59470b5b-acef-46ab-ba74-4cb6f6db3e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements" xlink:type="simple" xlink:href="mrk-20221231.xsd#AcquisitionsResearchCollaborationsandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_82333702-76ad-451b-b7b0-e15ee48e514e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_d5ba5691-9b4a-455a-a2e9-58c9cc89fbc8" xlink:href="mrk-20221231.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_82333702-76ad-451b-b7b0-e15ee48e514e" xlink:to="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_d5ba5691-9b4a-455a-a2e9-58c9cc89fbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20221231.xsd#CollaborativeArrangements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_2b52c592-9302-40b9-ad53-ceda66746731" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd7256a0-e47b-4779-936a-acb5d2703a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_2b52c592-9302-40b9-ad53-ceda66746731" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd7256a0-e47b-4779-936a-acb5d2703a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20221231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_23432248-ee94-434c-9093-cbb1d028fcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_e8d8886c-e3a6-495a-aef1-cf43e0c63d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_23432248-ee94-434c-9093-cbb1d028fcde" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_e8d8886c-e3a6-495a-aef1-cf43e0c63d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d6b8304c-9aae-4e81-ba22-bece58c46833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_984a1203-80f0-4fa0-ab5e-9dddb5fd2dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d6b8304c-9aae-4e81-ba22-bece58c46833" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_984a1203-80f0-4fa0-ab5e-9dddb5fd2dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20221231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e932910b-3f86-4507-9ae6-4841f54f2d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ec6edead-00f8-4c2b-8dd8-f3e5ac4f044c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e932910b-3f86-4507-9ae6-4841f54f2d2f" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ec6edead-00f8-4c2b-8dd8-f3e5ac4f044c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bdae8db-7767-4d02-a603-d5c13223db46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_76c9f192-a3a3-40b0-9edf-8dee8c33386b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bdae8db-7767-4d02-a603-d5c13223db46" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_76c9f192-a3a3-40b0-9edf-8dee8c33386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeases"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_91924d27-8392-470a-9d56-aa8d8b967602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_68491f41-b648-49fd-8964-f3f3f6a68265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_91924d27-8392-470a-9d56-aa8d8b967602" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_68491f41-b648-49fd-8964-f3f3f6a68265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="simple" xlink:href="mrk-20221231.xsd#ContingenciesandEnvironmentalLiabilities"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d9d65fec-c147-44f7-ac0d-c2734a3b5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1bb85951-69c8-4a2e-b9dd-ecc587fed2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d9d65fec-c147-44f7-ac0d-c2734a3b5d45" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1bb85951-69c8-4a2e-b9dd-ecc587fed2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20221231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0b60fd35-d95a-4724-92ea-3911dde37f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0f00c6d6-f461-4aae-a871-82ca27927f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0b60fd35-d95a-4724-92ea-3911dde37f99" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0f00c6d6-f461-4aae-a871-82ca27927f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_918f9698-b84e-44a2-ae64-94a0a9dd2cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b09996e1-42b0-49a4-8f88-b3d654fd4ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_918f9698-b84e-44a2-ae64-94a0a9dd2cd3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b09996e1-42b0-49a4-8f88-b3d654fd4ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e543f1d3-2744-45d8-a8b3-a63cb69521f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_826c684e-ff09-4677-b62d-f5fee27b4fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e543f1d3-2744-45d8-a8b3-a63cb69521f4" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_826c684e-ff09-4677-b62d-f5fee27b4fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherIncomeExpenseNet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_76fe5c55-5a48-4d08-9cc9-5962395cc5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0bbfd7f1-6a22-4ce4-b637-61502482db43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_76fe5c55-5a48-4d08-9cc9-5962395cc5a4" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0bbfd7f1-6a22-4ce4-b637-61502482db43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1a177a47-0621-48cf-a965-e1e429201ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_97e54be5-e3d3-4373-ae7a-af90701ee1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a177a47-0621-48cf-a965-e1e429201ce1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_97e54be5-e3d3-4373-ae7a-af90701ee1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShare" xlink:type="simple" xlink:href="mrk-20221231.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5ca66160-9946-4964-b17e-630a20e10ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_778aa95a-ee4a-414c-b369-2a66b32a05ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5ca66160-9946-4964-b17e-630a20e10ea9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_778aa95a-ee4a-414c-b369-2a66b32a05ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_46e432cf-9de5-42f5-8fb5-584cf420c888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_ebc3aae8-0a49-4701-9360-5e00456cb85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_46e432cf-9de5-42f5-8fb5-584cf420c888" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_ebc3aae8-0a49-4701-9360-5e00456cb85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d09d9b12-ed80-4ab3-adb4-c99652ddf27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_04b7f01f-f613-4e2c-b9a8-2c64582eeca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d09d9b12-ed80-4ab3-adb4-c99652ddf27a" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_04b7f01f-f613-4e2c-b9a8-2c64582eeca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrk-20221231.xsd#SummaryofAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9888dd21-b62f-40a5-9edc-21ad90e84517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9888dd21-b62f-40a5-9edc-21ad90e84517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_ba88900b-f95b-455e-be67-4a10f02f5500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_ba88900b-f95b-455e-be67-4a10f02f5500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d047c107-aaa2-45ab-a3ab-a491cb198abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d047c107-aaa2-45ab-a3ab-a491cb198abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ebe3e448-e960-4e1c-b821-7480c71ee5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ebe3e448-e960-4e1c-b821-7480c71ee5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_95f4e1a6-858c-481b-b722-067b2340c351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_95f4e1a6-858c-481b-b722-067b2340c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_30a515f4-435e-48a6-99ae-ebc28510437b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_30a515f4-435e-48a6-99ae-ebc28510437b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_16abc5a3-988f-4ba3-bf25-7ef708e6f50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_16abc5a3-988f-4ba3-bf25-7ef708e6f50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_b3a7aa2c-1e62-4583-807f-6683d440e0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_b3a7aa2c-1e62-4583-807f-6683d440e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_49fa521b-48f0-4a03-8145-3f4e596ef2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_49fa521b-48f0-4a03-8145-3f4e596ef2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_323c2ead-f89d-43d3-b38e-5be3db0440ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_323c2ead-f89d-43d3-b38e-5be3db0440ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4b0c18eb-42eb-490c-970e-624d43fcade4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4b0c18eb-42eb-490c-970e-624d43fcade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_ebd26835-16df-448f-8169-e1b255d50f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_ebd26835-16df-448f-8169-e1b255d50f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_9dfcbc1f-b577-48e6-8ad0-1774664309ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_9dfcbc1f-b577-48e6-8ad0-1774664309ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentConsiderationPolicyTextBlock_af5ee006-b787-4cb0-b30f-6bdb3674e4a4" xlink:href="mrk-20221231.xsd#mrk_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_mrk_ContingentConsiderationPolicyTextBlock_af5ee006-b787-4cb0-b30f-6bdb3674e4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f0e5ef19-eb36-425f-8a9b-0dec31f97db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f0e5ef19-eb36-425f-8a9b-0dec31f97db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_41b8a8e0-9479-4cbd-87ef-d0243ec35670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_41b8a8e0-9479-4cbd-87ef-d0243ec35670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_70cfdd32-1640-4bac-88d1-ac6a6e34c2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_70cfdd32-1640-4bac-88d1-ac6a6e34c2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d0707da9-0eaf-4257-b83c-9f0c12c4b2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d0707da9-0eaf-4257-b83c-9f0c12c4b2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e006a4de-6a6b-428d-ab8c-9ea4cff41166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e006a4de-6a6b-428d-ab8c-9ea4cff41166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0bf8fa2c-da71-4a01-a30d-76576f21b717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0bf8fa2c-da71-4a01-a30d-76576f21b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_36831aa8-cd5e-46c0-b1fc-435beb24ce4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_36831aa8-cd5e-46c0-b1fc-435beb24ce4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8dac6a9b-34e1-4c8c-8e70-d20892de6f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_UseOfEstimates_8dac6a9b-34e1-4c8c-8e70-d20892de6f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04609ea7-b348-4493-b5a0-ef6c5c2338c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92a45039-7f43-48d0-b9f1-f842c10f6947" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04609ea7-b348-4493-b5a0-ef6c5c2338c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#SpinOffofOrganonCoTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8431e29b-6ee3-4f09-9f25-5df8c00b9c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ee4454b8-3ad0-4e43-bcb5-b7d904fd4c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8431e29b-6ee3-4f09-9f25-5df8c00b9c80" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ee4454b8-3ad0-4e43-bcb5-b7d904fd4c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#AcquisitionsResearchCollaborationsandLicensingAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b5c13f6d-ac52-48a9-b477-695d980e72d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_005972fe-fa88-4edd-a97d-38fb896c77a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b5c13f6d-ac52-48a9-b477-695d980e72d3" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_005972fe-fa88-4edd-a97d-38fb896c77a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#CollaborativeArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_cbb6f8d6-5199-480b-bae4-dcfac52be970" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_bf265381-4645-4f96-b4fc-90fbab6e5637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_cbb6f8d6-5199-480b-bae4-dcfac52be970" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_bf265381-4645-4f96-b4fc-90fbab6e5637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a9f69471-0ec5-49e8-a6a8-534c147586a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_58810bde-35a3-4366-8ff8-a75806335645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a9f69471-0ec5-49e8-a6a8-534c147586a6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_58810bde-35a3-4366-8ff8-a75806335645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_21a540fc-4051-42b4-b6b8-ce2b36e72cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a9f69471-0ec5-49e8-a6a8-534c147586a6" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_21a540fc-4051-42b4-b6b8-ce2b36e72cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6f9e0239-7559-4ce1-ac06-10bb2213dc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6f9e0239-7559-4ce1-ac06-10bb2213dc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_674971bc-b1e1-4c7d-b850-cdd90e5bc2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_674971bc-b1e1-4c7d-b850-cdd90e5bc2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_34759dfe-bec8-4ed3-8e8b-7d06cce7842d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_34759dfe-bec8-4ed3-8e8b-7d06cce7842d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_085e750d-8f1a-4c25-91b5-b85c9004813c" xlink:href="mrk-20221231.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_085e750d-8f1a-4c25-91b5-b85c9004813c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_270e8b14-8232-486f-bb80-71d828f928fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_270e8b14-8232-486f-bb80-71d828f928fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1278270b-6338-4c13-8b33-acc5215082c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1278270b-6338-4c13-8b33-acc5215082c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_83835c2e-15ed-4153-a747-1a0113d8f682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_83835c2e-15ed-4153-a747-1a0113d8f682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d51ab632-6e97-4d60-aee9-5202c65eef94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d51ab632-6e97-4d60-aee9-5202c65eef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_88d9629b-d12f-4e2d-9d48-44e64c5921e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_19314871-d52c-4953-82bc-c7249bb8200b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_88d9629b-d12f-4e2d-9d48-44e64c5921e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e23b6c7a-8e72-4476-bd65-6b241070ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b4ee3b3e-2706-4745-8fda-e075177b6cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e23b6c7a-8e72-4476-bd65-6b241070ed4a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b4ee3b3e-2706-4745-8fda-e075177b6cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72dd5fe7-a08b-4ea8-9405-5434d8fb853f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6ac4a742-9a81-4563-8011-f5409e12ea89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72dd5fe7-a08b-4ea8-9405-5434d8fb853f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_6ac4a742-9a81-4563-8011-f5409e12ea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_8bce92f2-0e4d-469c-83f0-b9860069dffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_72dd5fe7-a08b-4ea8-9405-5434d8fb853f" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_8bce92f2-0e4d-469c-83f0-b9860069dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_515acdc1-b0e6-4deb-864b-2762e72b2c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9435119c-d308-4169-a398-757a394499c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_515acdc1-b0e6-4deb-864b-2762e72b2c88" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9435119c-d308-4169-a398-757a394499c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock_3eb48cc7-d8df-41e2-8f8d-a505840052cf" xlink:href="mrk-20221231.xsd#mrk_AssetsandLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_515acdc1-b0e6-4deb-864b-2762e72b2c88" xlink:to="loc_mrk_AssetsandLiabilitiesLesseeTableTextBlock_3eb48cc7-d8df-41e2-8f8d-a505840052cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3d168abd-3f3a-42fd-a099-040b4c62e421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_515acdc1-b0e6-4deb-864b-2762e72b2c88" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3d168abd-3f3a-42fd-a099-040b4c62e421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f078d62b-97b8-4f3a-8bf6-8d76a5803dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_25f3c6c7-82e9-48ee-840e-572d369d5d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f078d62b-97b8-4f3a-8bf6-8d76a5803dfb" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_25f3c6c7-82e9-48ee-840e-572d369d5d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a76bda4-87e0-4413-b51d-e5b73bc856bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_948c3b66-9fdb-4cf8-bd86-48702488fdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a76bda4-87e0-4413-b51d-e5b73bc856bf" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_948c3b66-9fdb-4cf8-bd86-48702488fdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5972b0d7-49e7-4647-8a51-7d4a609c457c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a76bda4-87e0-4413-b51d-e5b73bc856bf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5972b0d7-49e7-4647-8a51-7d4a609c457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_d44a65e3-f876-42bc-8e36-55f9e5807948" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a76bda4-87e0-4413-b51d-e5b73bc856bf" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock_d44a65e3-f876-42bc-8e36-55f9e5807948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_7733ff95-a9e5-4641-9ee2-0f320cf49fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5a76bda4-87e0-4413-b51d-e5b73bc856bf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_7733ff95-a9e5-4641-9ee2-0f320cf49fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_f97ce338-3f7d-4a24-bcde-399946bc0638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_f97ce338-3f7d-4a24-bcde-399946bc0638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_b8598ff7-1fed-4df8-a495-1eec66030619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_b8598ff7-1fed-4df8-a495-1eec66030619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_fb8299b6-6d89-4e57-9bb4-7d1e0483d5f5" xlink:href="mrk-20221231.xsd#mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock_fb8299b6-6d89-4e57-9bb4-7d1e0483d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_c67253df-234e-450f-9a0c-c136b5a5664a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_c67253df-234e-450f-9a0c-c136b5a5664a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_a78cd273-4383-4472-b826-84e90de78e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_a78cd273-4383-4472-b826-84e90de78e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_52e669c6-f2b5-47fe-956e-3efe38eab50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_52e669c6-f2b5-47fe-956e-3efe38eab50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_133acbcc-1398-4d8d-981b-4c62418a6241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_133acbcc-1398-4d8d-981b-4c62418a6241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_06d5daf6-d84a-4cb0-abc9-11f7b73ea765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_06d5daf6-d84a-4cb0-abc9-11f7b73ea765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_cd11435a-254f-4935-be3c-3f377c1745dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_87550fe8-1c5f-49e6-a5e9-ab298c55aa12" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_cd11435a-254f-4935-be3c-3f377c1745dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherIncomeExpenseNetTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_17986d1e-4f72-4ab1-a555-ac018f590954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_4188bb33-f1eb-4426-997a-8cf461d59727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_17986d1e-4f72-4ab1-a555-ac018f590954" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_4188bb33-f1eb-4426-997a-8cf461d59727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9358c8e2-8d00-4b8b-92e4-dc8c33869dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_75253ca7-9b16-4c97-ad5a-05382002427d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9358c8e2-8d00-4b8b-92e4-dc8c33869dbb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_75253ca7-9b16-4c97-ad5a-05382002427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a8f04f58-8050-497f-9d36-54de17df7b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9358c8e2-8d00-4b8b-92e4-dc8c33869dbb" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a8f04f58-8050-497f-9d36-54de17df7b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_16abae9a-41c9-4d01-afa0-0b835c7157d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9358c8e2-8d00-4b8b-92e4-dc8c33869dbb" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_16abae9a-41c9-4d01-afa0-0b835c7157d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_766868a9-030c-479b-82fb-d66f8fea2423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9358c8e2-8d00-4b8b-92e4-dc8c33869dbb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_766868a9-030c-479b-82fb-d66f8fea2423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock_f119e58a-3396-49c6-9fe2-95fcec8d4d82" xlink:href="mrk-20221231.xsd#mrk_ScheduleOfIncomeTaxesPaidTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9358c8e2-8d00-4b8b-92e4-dc8c33869dbb" xlink:to="loc_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock_f119e58a-3396-49c6-9fe2-95fcec8d4d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_98c780cc-8880-48b5-9c79-c6c89e151f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9358c8e2-8d00-4b8b-92e4-dc8c33869dbb" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_98c780cc-8880-48b5-9c79-c6c89e151f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f760ae86-5b2f-4561-9ec7-ce30c5554e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a6ab8b87-c416-49c7-ac1a-0043411995f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f760ae86-5b2f-4561-9ec7-ce30c5554e24" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a6ab8b87-c416-49c7-ac1a-0043411995f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ccd385a1-d692-4db9-a4ef-933469ebdf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f249f694-7110-4180-825c-6f5e6d3b4877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ccd385a1-d692-4db9-a4ef-933469ebdf9b" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f249f694-7110-4180-825c-6f5e6d3b4877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_36e7d5d2-b293-4d72-a8e1-0bba56c37b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_653d484b-c7cd-41df-8791-571ff184b20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36e7d5d2-b293-4d72-a8e1-0bba56c37b94" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_653d484b-c7cd-41df-8791-571ff184b20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_2531665c-f0f3-464b-b777-70c63d9e32dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36e7d5d2-b293-4d72-a8e1-0bba56c37b94" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_2531665c-f0f3-464b-b777-70c63d9e32dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_459c255d-f2fa-4a4b-a680-5bbf232fa893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36e7d5d2-b293-4d72-a8e1-0bba56c37b94" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_459c255d-f2fa-4a4b-a680-5bbf232fa893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_36cf9b3f-5edb-4211-bc9d-b53f07c2478d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36e7d5d2-b293-4d72-a8e1-0bba56c37b94" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_36cf9b3f-5edb-4211-bc9d-b53f07c2478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_00af3791-0edc-4447-9926-614f3d9b83fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36e7d5d2-b293-4d72-a8e1-0bba56c37b94" xlink:to="loc_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_00af3791-0edc-4447-9926-614f3d9b83fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#NatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/NatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3085c12-a3f0-40f4-80a1-cef8abdd8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0af67a7f-1ec3-4c0f-b1d2-d2abf23c3e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3085c12-a3f0-40f4-80a1-cef8abdd8dab" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0af67a7f-1ec3-4c0f-b1d2-d2abf23c3e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SummaryofAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SummaryofAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3b7a5a4-a3ac-447b-b336-c321bb4cb814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3b7a5a4-a3ac-447b-b336-c321bb4cb814" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3c18771-b6e5-4dd1-ae1b-24f524450be9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_srt_RangeAxis_f3c18771-b6e5-4dd1-ae1b-24f524450be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f3c18771-b6e5-4dd1-ae1b-24f524450be9" xlink:to="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cf5e959f-b264-4158-af51-e1d76677283a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:to="loc_srt_MinimumMember_cf5e959f-b264-4158-af51-e1d76677283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9497f4b0-fb70-4fc6-ae25-44bf5343d8b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_450cd457-5152-4560-bb3b-a0468030cac1" xlink:to="loc_srt_MaximumMember_9497f4b0-fb70-4fc6-ae25-44bf5343d8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5793dcc3-a0c4-4e37-a46e-05582193d999" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_srt_StatementGeographicalAxis_5793dcc3-a0c4-4e37-a46e-05582193d999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5793dcc3-a0c4-4e37-a46e-05582193d999" xlink:to="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2c0933ec-7fe3-4007-999c-1360b9718d1d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:to="loc_country_US_2c0933ec-7fe3-4007-999c-1360b9718d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_29b493b1-fd43-4db2-a9c5-33a44b6a0877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c076d5b4-a7eb-43b1-9786-224e21af2c67" xlink:to="loc_us-gaap_NonUsMember_29b493b1-fd43-4db2-a9c5-33a44b6a0877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1cf20ae6-f30c-47f1-b5c5-c227cfc0b1a4" xlink:to="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_7c804031-90b2-4967-9d66-69047c2867cf" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:to="loc_mrk_PharmaceuticalsegmentMember_7c804031-90b2-4967-9d66-69047c2867cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_40e7fd47-9419-4509-bf8e-5759b97e0b0c" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_35592cd7-34f2-4da9-b5f5-3643377cf8ed" xlink:to="loc_mrk_AnimalHealthsegmentMember_40e7fd47-9419-4509-bf8e-5759b97e0b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022bafe4-a790-48d9-8dce-2fdfaee9b053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022bafe4-a790-48d9-8dce-2fdfaee9b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_022bafe4-a790-48d9-8dce-2fdfaee9b053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f0a1c414-80c5-441a-a2ef-0f5fc4fab43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:to="loc_us-gaap_BuildingMember_f0a1c414-80c5-441a-a2ef-0f5fc4fab43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_aa861573-e28a-4e44-9bbf-026e1d4eb6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f922359-e7d8-41d7-b446-5244efbced12" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_aa861573-e28a-4e44-9bbf-026e1d4eb6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_09e923c7-0e50-484f-98e2-05faaa7b0f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_09e923c7-0e50-484f-98e2-05faaa7b0f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5204188-2fcf-45b1-82a0-d6daee8728cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_09e923c7-0e50-484f-98e2-05faaa7b0f7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5204188-2fcf-45b1-82a0-d6daee8728cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1857bdc8-f913-4b16-bc6d-072b12919d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5204188-2fcf-45b1-82a0-d6daee8728cb" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1857bdc8-f913-4b16-bc6d-072b12919d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:href="mrk-20221231.xsd#mrk_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6d3bee4f-324a-4cb9-954b-df94224ac07a" xlink:to="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_b91c920c-31d4-46ec-ac0b-32289308834f" xlink:href="mrk-20221231.xsd#mrk_SalesDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_SalesDiscounts_b91c920c-31d4-46ec-ac0b-32289308834f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForChargebacks_30977e31-2970-4657-a686-743dd7029cde" xlink:href="mrk-20221231.xsd#mrk_AccrualForChargebacks"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_AccrualForChargebacks_30977e31-2970-4657-a686-743dd7029cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AccrualForRebates_c0a67f22-f077-4570-b476-b7c99ac7e654" xlink:href="mrk-20221231.xsd#mrk_AccrualForRebates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_AccrualForRebates_c0a67f22-f077-4570-b476-b7c99ac7e654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_3151544b-e188-4717-a4d4-fe1f21b7e40e" xlink:href="mrk-20221231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate_3151544b-e188-4717-a4d4-fe1f21b7e40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_591aceaa-2abd-416a-ba0f-900b386e549c" xlink:href="mrk-20221231.xsd#mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate_591aceaa-2abd-416a-ba0f-900b386e549c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RevenuePerformanceObligationPaymentTerms_4503927d-78d2-4353-90d3-e26b2da31932" xlink:href="mrk-20221231.xsd#mrk_RevenuePerformanceObligationPaymentTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_mrk_RevenuePerformanceObligationPaymentTerms_4503927d-78d2-4353-90d3-e26b2da31932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_31fb7de3-34fd-407d-9c57-52a1c3bd79bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_31fb7de3-34fd-407d-9c57-52a1c3bd79bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ee10593c-37db-4198-b904-94370cdfc146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_Depreciation_ee10593c-37db-4198-b904-94370cdfc146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_c7933761-7ad0-4964-a66e-884507f86d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_AdvertisingExpense_c7933761-7ad0-4964-a66e-884507f86d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_80510259-373a-4d66-bc93-2e822ae5e960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_SummaryOfSignificantAccountingPoliciesLineItems_60359f5b-acec-4d97-b6c0-0164931dc8f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_80510259-373a-4d66-bc93-2e822ae5e960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SpinOffofOrganonCoNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ab7d62ac-99b8-4ef2-b0cf-91d548d154df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ab7d62ac-99b8-4ef2-b0cf-91d548d154df" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7a2f6600-fb99-4454-88e9-f32fc3a66668" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_dei_LegalEntityAxis_7a2f6600-fb99-4454-88e9-f32fc3a66668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b6091f28-9760-48da-9399-72a10fc1d287" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7a2f6600-fb99-4454-88e9-f32fc3a66668" xlink:to="loc_dei_EntityDomain_b6091f28-9760-48da-9399-72a10fc1d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_b25ef7d5-8394-4b97-b1ac-4a9963bf49e4" xlink:href="mrk-20221231.xsd#mrk_OrganonCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b6091f28-9760-48da-9399-72a10fc1d287" xlink:to="loc_mrk_OrganonCoMember_b25ef7d5-8394-4b97-b1ac-4a9963bf49e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_srt_RangeAxis_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6df92dc3-4ffe-4b7e-8d85-bd16f7bad717" xlink:to="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_48640bf2-69a5-4c9c-9f77-53f758e07eb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:to="loc_srt_MinimumMember_48640bf2-69a5-4c9c-9f77-53f758e07eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6657183d-849e-40c0-839c-1d4fa964450c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8274935-b355-4037-ac90-1f78294f032e" xlink:to="loc_srt_MaximumMember_6657183d-849e-40c0-839c-1d4fa964450c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ca961e10-cb94-414b-9ca8-739a8d280e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ca961e10-cb94-414b-9ca8-739a8d280e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ca961e10-cb94-414b-9ca8-739a8d280e65" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_7557d88d-3a1a-429d-8408-d48ae808d28f" xlink:href="mrk-20221231.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:to="loc_mrk_TransitionServicesAgreementMember_7557d88d-3a1a-429d-8408-d48ae808d28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_56709f8c-78b8-4ae8-b2d3-edb1290ca415" xlink:href="mrk-20221231.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_8d6f9b95-9eb1-4578-b631-7f4f322b092e" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_56709f8c-78b8-4ae8-b2d3-edb1290ca415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6445d134-b82a-4fb7-b774-c1e9b6b1c94a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_srt_CounterpartyNameAxis_6445d134-b82a-4fb7-b774-c1e9b6b1c94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc0f084-cbb4-4415-a415-85e1c937801b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6445d134-b82a-4fb7-b774-c1e9b6b1c94a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc0f084-cbb4-4415-a415-85e1c937801b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_28499184-cc4f-4294-897e-a75eda81e686" xlink:href="mrk-20221231.xsd#mrk_OrganonCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcc0f084-cbb4-4415-a415-85e1c937801b" xlink:to="loc_mrk_OrganonCoMember_28499184-cc4f-4294-897e-a75eda81e686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b5f6e41d-67d1-4185-a74e-64af80beedd6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_311801c5-a2a6-49e6-aab9-5cd249865242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_311801c5-a2a6-49e6-aab9-5cd249865242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9486416f-140e-436f-8982-a070c05143a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9486416f-140e-436f-8982-a070c05143a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_39cc324e-0634-4713-b38d-c8e3e680016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_39cc324e-0634-4713-b38d-c8e3e680016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_eebfbf61-90d2-4322-892a-f5f42b720d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_eebfbf61-90d2-4322-892a-f5f42b720d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_43d16b07-2449-46cf-8f2e-ff0baf4ca120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_RevenueFromRelatedParties_43d16b07-2449-46cf-8f2e-ff0baf4ca120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_f8c1492e-1998-4951-87d2-199c914b2f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_f8c1492e-1998-4951-87d2-199c914b2f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_d2d34081-dde0-4fa6-b9d3-db92408ce130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_d2d34081-dde0-4fa6-b9d3-db92408ce130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_bac20f8c-98a2-481b-adbd-dc418ac6fde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_bac20f8c-98a2-481b-adbd-dc418ac6fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_906dfb9a-22f5-4709-96aa-4dee8df1a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7710c1cf-07c0-4ecd-8309-9a5a8c0d7ed1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_906dfb9a-22f5-4709-96aa-4dee8df1a84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_83c0075b-313a-4c9e-9c96-04e0e73c35f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_83c0075b-313a-4c9e-9c96-04e0e73c35f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_88637638-4be6-4220-a973-6ff62172123c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_88637638-4be6-4220-a973-6ff62172123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_d51cc874-0321-4bb0-9e69-82f59e9a65e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_d51cc874-0321-4bb0-9e69-82f59e9a65e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_abd37510-d129-4d07-bd0a-fed522f37c2b" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses_abd37510-d129-4d07-bd0a-fed522f37c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_028b0331-be6e-4abb-a84d-a1e58f11c71a" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts_028b0331-be6e-4abb-a84d-a1e58f11c71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_bea658e3-7ef0-4ccf-ae41-48ea4925a5fc" xlink:href="mrk-20221231.xsd#mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:to="loc_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet_bea658e3-7ef0-4ccf-ae41-48ea4925a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_7404b268-473b-40aa-8004-f2dcce064b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_1495f21d-6fdd-466a-94c0-3b08dbdc9f23" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_7404b268-473b-40aa-8004-f2dcce064b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_322e594b-6faa-4d43-adb7-afcb0c3112bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_322e594b-6faa-4d43-adb7-afcb0c3112bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_822ab485-000f-4b79-81b4-63a06711e790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_822ab485-000f-4b79-81b4-63a06711e790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aa9a025f-ab10-4396-9117-1581face2c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aa9a025f-ab10-4396-9117-1581face2c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_2b80e950-06d4-4c02-a3c3-cfc314cb8fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_2b80e950-06d4-4c02-a3c3-cfc314cb8fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_3fd74d1c-0483-4366-83d7-616c72bd5452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b36e8168-ee0c-410d-b307-05db72b5c4f2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_3fd74d1c-0483-4366-83d7-616c72bd5452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5fd19404-dd53-446d-9ee7-dcc7cbef73f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5fd19404-dd53-446d-9ee7-dcc7cbef73f8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68d2bfa7-5c31-4796-b958-e7de82bc8432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68d2bfa7-5c31-4796-b958-e7de82bc8432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_476c08f5-f90f-4dd1-a4f4-62907ffdadf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_68d2bfa7-5c31-4796-b958-e7de82bc8432" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_476c08f5-f90f-4dd1-a4f4-62907ffdadf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyPharmaMember_8351a1fe-33b4-4eb4-84a0-6d2cd3fd94c7" xlink:href="mrk-20221231.xsd#mrk_RoyaltyPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_476c08f5-f90f-4dd1-a4f4-62907ffdadf6" xlink:to="loc_mrk_RoyaltyPharmaMember_8351a1fe-33b4-4eb4-84a0-6d2cd3fd94c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3fedcaaf-556e-4925-ba8d-8c65915c2004" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_CounterpartyNameAxis_3fedcaaf-556e-4925-ba8d-8c65915c2004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3fedcaaf-556e-4925-ba8d-8c65915c2004" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ModernaMember_9c5ef7d9-3e49-4660-bb95-26724cecb8f5" xlink:href="mrk-20221231.xsd#mrk_ModernaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_ModernaMember_9c5ef7d9-3e49-4660-bb95-26724cecb8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrnaTherapeuticsMember_8e0985c9-ff0c-424c-8f33-008941e68d65" xlink:href="mrk-20221231.xsd#mrk_OrnaTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_OrnaTherapeuticsMember_8e0985c9-ff0c-424c-8f33-008941e68d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrionCorporationMember_c68f52ba-4cf6-4206-bcde-c52acc1f3e51" xlink:href="mrk-20221231.xsd#mrk_OrionCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_OrionCorporationMember_c68f52ba-4cf6-4206-bcde-c52acc1f3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_52c5e01a-4432-473e-865e-8474dba941b8" xlink:href="mrk-20221231.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_52c5e01a-4432-473e-865e-8474dba941b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_b1f4546b-87c6-4153-8219-f5db78136c0c" xlink:href="mrk-20221231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_BristolMyersSquibbMember_b1f4546b-87c6-4153-8219-f5db78136c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GileadSciencesMember_f5433b81-d612-404d-ae11-96faa0068dfc" xlink:href="mrk-20221231.xsd#mrk_GileadSciencesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_GileadSciencesMember_f5433b81-d612-404d-ae11-96faa0068dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_e8d4668c-8fe1-4527-a13f-f78e26ab19bd" xlink:href="mrk-20221231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_e8d4668c-8fe1-4527-a13f-f78e26ab19bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_c0b53f63-813d-4e04-b504-046a48c08a11" xlink:href="mrk-20221231.xsd#mrk_SeagenMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_SeagenMember_c0b53f63-813d-4e04-b504-046a48c08a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_2046c151-669a-4ba1-974b-e555904f3467" xlink:href="mrk-20221231.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_SentinelMember_2046c151-669a-4ba1-974b-e555904f3467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_32944e83-f831-4a06-a53a-e4e7012f5387" xlink:href="mrk-20221231.xsd#mrk_IAVIMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_184dc843-8e5a-4844-9e86-3b240a2a1b0e" xlink:to="loc_mrk_IAVIMember_32944e83-f831-4a06-a53a-e4e7012f5387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fae62110-af84-413c-a4d3-a1371b874695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fae62110-af84-413c-a4d3-a1371b874695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fae62110-af84-413c-a4d3-a1371b874695" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b45192bf-2882-47fd-a52e-da54a5c79fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_b45192bf-2882-47fd-a52e-da54a5c79fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9fca9723-670b-4eb6-bf13-07deb4b2bfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f688148-38ad-49d4-9b10-b3bb646ea6ed" xlink:to="loc_us-gaap_LicensingAgreementsMember_9fca9723-670b-4eb6-bf13-07deb4b2bfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_d305b0f0-2758-45a5-96c0-16657fec7adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_d305b0f0-2758-45a5-96c0-16657fec7adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d305b0f0-2758-45a5-96c0-16657fec7adb" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_7bcf210c-23bb-4194-8d48-1f5d438e1ecb" xlink:href="mrk-20221231.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_DevelopmentMilestonesMember_7bcf210c-23bb-4194-8d48-1f5d438e1ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_0466172d-e535-4928-82b3-f199c8165229" xlink:href="mrk-20221231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_RegulatoryMilestonesMember_0466172d-e535-4928-82b3-f199c8165229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_6095e68e-a3bb-40dd-85d8-2b2eb5cb46f5" xlink:href="mrk-20221231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_SalesBasedMilestonesMember_6095e68e-a3bb-40dd-85d8-2b2eb5cb46f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FirstCommercialSaleMilestonesMember_ee463876-7876-4fb6-8e0d-2d59995a688c" xlink:href="mrk-20221231.xsd#mrk_FirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_ea8b120d-5f76-41f0-825c-ea4666ff0f6a" xlink:to="loc_mrk_FirstCommercialSaleMilestonesMember_ee463876-7876-4fb6-8e0d-2d59995a688c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b0145106-608c-4212-8da7-98f37dc7d68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b0145106-608c-4212-8da7-98f37dc7d68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0145106-608c-4212-8da7-98f37dc7d68d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_b99ddd9b-a9dd-4d6c-bca3-251d63568f38" xlink:href="mrk-20221231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:to="loc_mrk_AcceleronPharmaIncMember_b99ddd9b-a9dd-4d6c-bca3-251d63568f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_6b8fc6b3-0351-4c7a-a1a1-4838ff7a96c0" xlink:href="mrk-20221231.xsd#mrk_ThemisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:to="loc_mrk_ThemisMember_6b8fc6b3-0351-4c7a-a1a1-4838ff7a96c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_4f2f791a-f55b-4076-8425-d21dee80ec60" xlink:href="mrk-20221231.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4dd0ae2-8f26-43e0-8bad-d46809a066fa" xlink:to="loc_mrk_ArQuleMember_4f2f791a-f55b-4076-8425-d21dee80ec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_01f56955-d7f4-4455-bfd8-ec3c76e3f61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_01f56955-d7f4-4455-bfd8-ec3c76e3f61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5a76fa43-33d5-4e7f-a988-4de80fe36b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01f56955-d7f4-4455-bfd8-ec3c76e3f61b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5a76fa43-33d5-4e7f-a988-4de80fe36b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8eabc748-9f95-44e8-832e-d4ee6bac2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5a76fa43-33d5-4e7f-a988-4de80fe36b8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8eabc748-9f95-44e8-832e-d4ee6bac2ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1452ca9c-9575-463c-a281-5afb9248481d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_RangeAxis_1452ca9c-9575-463c-a281-5afb9248481d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1452ca9c-9575-463c-a281-5afb9248481d" xlink:to="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c3e12fc-a3f9-4661-9323-4f295bf9b883" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:to="loc_srt_MinimumMember_2c3e12fc-a3f9-4661-9323-4f295bf9b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_30ae89f2-077b-4063-b950-674a01f999c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7fae97f0-f3d9-4051-8901-e12d14bca6e7" xlink:to="loc_srt_MaximumMember_30ae89f2-077b-4063-b950-674a01f999c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_62812f0b-df58-48a9-8f69-b1356aff8afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_AssetAcquisitionAxis_62812f0b-df58-48a9-8f69-b1356aff8afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_62812f0b-df58-48a9-8f69-b1356aff8afb" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImagoBioSciencesIncMember_e77161f0-ecc0-4638-ae55-a6b7edc09856" xlink:href="mrk-20221231.xsd#mrk_ImagoBioSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_ImagoBioSciencesIncMember_e77161f0-ecc0-4638-ae55-a6b7edc09856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PandionTherapeuticsMember_6c5446c9-e28f-416f-a3cd-7d7c0494a7d9" xlink:href="mrk-20221231.xsd#mrk_PandionTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_PandionTherapeuticsMember_6c5446c9-e28f-416f-a3cd-7d7c0494a7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArtivaBiotherapeuticsIncMember_c300bc9c-d430-487c-ac22-5ea923edd3a0" xlink:href="mrk-20221231.xsd#mrk_ArtivaBiotherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_ArtivaBiotherapeuticsIncMember_c300bc9c-d430-487c-ac22-5ea923edd3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_6d5c0aa2-74bc-43be-9f00-1563b70acbfc" xlink:href="mrk-20221231.xsd#mrk_OncoImmuneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_OncoImmuneMember_6d5c0aa2-74bc-43be-9f00-1563b70acbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_2ea65723-7226-4b13-8020-aea9be2c5c61" xlink:href="mrk-20221231.xsd#mrk_VelosBioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_VelosBioMember_2ea65723-7226-4b13-8020-aea9be2c5c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_e58d4d7d-ac12-408f-8a04-e881580dac56" xlink:href="mrk-20221231.xsd#mrk_DunboyneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c27f09ec-c777-4805-9037-7cbb4e8f2a63" xlink:to="loc_mrk_DunboyneMember_e58d4d7d-ac12-408f-8a04-e881580dac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_ProductOrServiceAxis_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_30f6f4fb-29b2-4dd2-94fd-cc9fac7485b5" xlink:to="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralAndInjectableFormulationsMember_835f2610-9db8-4fa9-a700-25e30a59d68b" xlink:href="mrk-20221231.xsd#mrk_OralAndInjectableFormulationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_OralAndInjectableFormulationsMember_835f2610-9db8-4fa9-a700-25e30a59d68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OralFormulationMember_57e00fab-480f-4c8d-b202-d1b9449f07ce" xlink:href="mrk-20221231.xsd#mrk_OralFormulationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_OralFormulationMember_57e00fab-480f-4c8d-b202-d1b9449f07ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InjectableFormulationMember_7413570d-b8be-4e0e-aa08-7f3bb72f0f82" xlink:href="mrk-20221231.xsd#mrk_InjectableFormulationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_InjectableFormulationMember_7413570d-b8be-4e0e-aa08-7f3bb72f0f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_222ab14b-604c-42e2-8505-9e45c988d75d" xlink:href="mrk-20221231.xsd#mrk_COVID19Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_COVID19Member_222ab14b-604c-42e2-8505-9e45c988d75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_5cc424ed-b358-4404-860d-3cea8e8c1f26" xlink:href="mrk-20221231.xsd#mrk_TukysaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_TukysaMember_5cc424ed-b358-4404-860d-3cea8e8c1f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_258416a9-f656-43af-bd79-2069a78604a7" xlink:href="mrk-20221231.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5a3e7b9-cbe7-482b-81bb-1f3e066cecd9" xlink:to="loc_mrk_SentinelMember_258416a9-f656-43af-bd79-2069a78604a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_123583ed-d6fd-48dc-92e3-d08f4aac0730" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_123583ed-d6fd-48dc-92e3-d08f4aac0730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c16442d7-1f07-4335-9f68-7a171e5377fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_123583ed-d6fd-48dc-92e3-d08f4aac0730" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c16442d7-1f07-4335-9f68-7a171e5377fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OncoImmuneMember_9da34c34-3e28-47cc-90c5-70e319065e66" xlink:href="mrk-20221231.xsd#mrk_OncoImmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c16442d7-1f07-4335-9f68-7a171e5377fd" xlink:to="loc_mrk_OncoImmuneMember_9da34c34-3e28-47cc-90c5-70e319065e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7f6e793-8adb-4d34-8dc9-b952f020937c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7f6e793-8adb-4d34-8dc9-b952f020937c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fba211-ec15-4983-b154-5cb0ea02f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7f6e793-8adb-4d34-8dc9-b952f020937c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fba211-ec15-4983-b154-5cb0ea02f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b6ba30a4-1106-4f4b-b59b-50f0d1374f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40fba211-ec15-4983-b154-5cb0ea02f1df" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b6ba30a4-1106-4f4b-b59b-50f0d1374f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7aa83008-4da1-4106-be2a-aef9c663fc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d05fa34f-8c1a-4f39-a6f1-be1938c8f1de" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7aa83008-4da1-4106-be2a-aef9c663fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_73f662fb-f111-449b-a741-bdc2c6d8eeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7aa83008-4da1-4106-be2a-aef9c663fc47" xlink:to="loc_us-gaap_SubsequentEventMember_73f662fb-f111-449b-a741-bdc2c6d8eeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a863085-6d12-441f-b497-925507900567" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f58ce7d4-b7e3-4fab-b42b-80365bf8252a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f58ce7d4-b7e3-4fab-b42b-80365bf8252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_7422d98b-614a-4c4f-a30e-fee2f44c0352" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_7422d98b-614a-4c4f-a30e-fee2f44c0352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_874626fa-fcc2-402f-aeb6-ba96d0cfd958" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_874626fa-fcc2-402f-aeb6-ba96d0cfd958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_f4032dc2-0ecf-49c0-9219-9f1d4a1b3a2d" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_f4032dc2-0ecf-49c0-9219-9f1d4a1b3a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_590723d5-9fe5-4daf-9d22-9227ade42b5f" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_590723d5-9fe5-4daf-9d22-9227ade42b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_4cc2ea55-a78b-4e0d-b6ed-16285ed5f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_4cc2ea55-a78b-4e0d-b6ed-16285ed5f14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_f030bb1e-c8c1-469b-b961-41e073176d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_f030bb1e-c8c1-469b-b961-41e073176d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_629dde61-2917-454f-af7c-90883fa973ee" xlink:href="mrk-20221231.xsd#mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_629dde61-2917-454f-af7c-90883fa973ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2c1428ed-ef79-4744-a50b-1c7f47dbd251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2c1428ed-ef79-4744-a50b-1c7f47dbd251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_799ecf2d-e466-41e1-a80c-8fa58e10b996" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts_799ecf2d-e466-41e1-a80c-8fa58e10b996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_6fdd5672-0628-479d-90e9-82160a553fa3" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding_6fdd5672-0628-479d-90e9-82160a553fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e87b59a5-c0bd-47d0-9ea3-50cffab80524" xlink:href="mrk-20221231.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_e87b59a5-c0bd-47d0-9ea3-50cffab80524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_189e8f3d-2922-4b02-a1d3-b9526de324d4" xlink:href="mrk-20221231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_189e8f3d-2922-4b02-a1d3-b9526de324d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_be5ca6fd-a5a4-4a4f-8ce3-505e31341d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_be5ca6fd-a5a4-4a4f-8ce3-505e31341d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_e0af7dea-369a-45fe-a913-42dae24478fb" xlink:href="mrk-20221231.xsd#mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner_e0af7dea-369a-45fe-a913-42dae24478fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentToBeMadeToCollaborativePartner_31d65b37-877c-4164-99bc-5a25540768f0" xlink:href="mrk-20221231.xsd#mrk_MilestonePaymentToBeMadeToCollaborativePartner"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_MilestonePaymentToBeMadeToCollaborativePartner_31d65b37-877c-4164-99bc-5a25540768f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners_5292fede-7a57-48c9-97cc-bb90933f95e6" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners_5292fede-7a57-48c9-97cc-bb90933f95e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner_e14a33f8-f365-4331-876c-f2316e66048f" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner_e14a33f8-f365-4331-876c-f2316e66048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c3d332a3-ff91-4e55-8e3d-cc8990bae4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c3d332a3-ff91-4e55-8e3d-cc8990bae4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_be0c90e4-540d-45a9-8fb5-c03e9d47f794" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_RoyaltyRatePercentage_be0c90e4-540d-45a9-8fb5-c03e9d47f794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_bc4d2fb3-7c0e-4107-9125-cab14810dac0" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_bc4d2fb3-7c0e-4107-9125-cab14810dac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_21e60f1a-2322-46f7-b784-268f95532372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_21e60f1a-2322-46f7-b784-268f95532372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b5f18342-2a30-4e60-86c1-43aabf440f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_b5f18342-2a30-4e60-86c1-43aabf440f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_9904a560-9e98-450a-ada6-0ce954daaa2c" xlink:href="mrk-20221231.xsd#mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet_9904a560-9e98-450a-ada6-0ce954daaa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShareCounterparty_cadfe8f2-d62b-47d6-8c05-e9fd127d4c08" xlink:href="mrk-20221231.xsd#mrk_ProfitShareCounterparty"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ProfitShareCounterparty_cadfe8f2-d62b-47d6-8c05-e9fd127d4c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProfitShare_a4177dca-83ba-497b-bae8-1458e62b0da7" xlink:href="mrk-20221231.xsd#mrk_ProfitShare"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ProfitShare_a4177dca-83ba-497b-bae8-1458e62b0da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesThreshold_f521b990-a2e3-47ee-85b6-1db33bd89916" xlink:href="mrk-20221231.xsd#mrk_SalesThreshold"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_SalesThreshold_f521b990-a2e3-47ee-85b6-1db33bd89916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_aeda6b0e-fbd6-4527-9a29-3c59b4ddcc2d" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementNumberOfResearchPrograms"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementNumberOfResearchPrograms_aeda6b0e-fbd6-4527-9a29-3c59b4ddcc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_9d693025-4087-45ff-8c6f-76cedf7e0b57" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementNumberOfCollaborationTargets"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_CollaborativeArrangementNumberOfCollaborationTargets_9d693025-4087-45ff-8c6f-76cedf7e0b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d549e8-e227-4b86-a9b0-80a59c389971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e0d549e8-e227-4b86-a9b0-80a59c389971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_397026f6-57da-474e-82df-2980e78cfabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_Investments_397026f6-57da-474e-82df-2980e78cfabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PremiumOnSharesAcquired_c665e132-031b-4d91-8036-ed1cb9d9c5d3" xlink:href="mrk-20221231.xsd#mrk_PremiumOnSharesAcquired"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_PremiumOnSharesAcquired_c665e132-031b-4d91-8036-ed1cb9d9c5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_f122c529-1cfc-4a62-8a42-017a588513a1" xlink:href="mrk-20221231.xsd#mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo_f122c529-1cfc-4a62-8a42-017a588513a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ChargesRelatedToProgramDiscontinuation_3e1aaef1-2541-4565-9dfa-bde08fcc6339" xlink:href="mrk-20221231.xsd#mrk_ChargesRelatedToProgramDiscontinuation"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_ChargesRelatedToProgramDiscontinuation_3e1aaef1-2541-4565-9dfa-bde08fcc6339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_6c2d38d3-7e25-480a-a7df-6f423b4a8429" xlink:href="mrk-20221231.xsd#mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner_6c2d38d3-7e25-480a-a7df-6f423b4a8429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_4858b3dc-1cdd-4c94-8e2c-1b75b15b6f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_4858b3dc-1cdd-4c94-8e2c-1b75b15b6f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ef136c5f-e468-4808-a965-7a046821cfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_SharePrice_ef136c5f-e468-4808-a965-7a046821cfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_efaceb5c-a0dc-448c-84cc-37c6f8e09e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_efaceb5c-a0dc-448c-84cc-37c6f8e09e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_170a7813-7f74-463b-ae66-acefe5e22285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_InventoryNet_170a7813-7f74-463b-ae66-acefe5e22285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e814d45d-151c-44d4-9e9f-d0624c2e6060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e814d45d-151c-44d4-9e9f-d0624c2e6060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4c4f410-bb34-4886-8a30-230f1ef40145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4c4f410-bb34-4886-8a30-230f1ef40145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_160d34b9-9c8f-4e91-bd48-71beb77b7e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_160d34b9-9c8f-4e91-bd48-71beb77b7e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0072725a-271a-4b45-9455-7a1997f59ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_0072725a-271a-4b45-9455-7a1997f59ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_dc8456b2-1707-403a-9d52-cac7ce34956e" xlink:href="mrk-20221231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_dc8456b2-1707-403a-9d52-cac7ce34956e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d85cfc7c-e1e0-42e3-afe8-b8db92069cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_Goodwill_d85cfc7c-e1e0-42e3-afe8-b8db92069cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4297a18d-2326-46e2-9a4c-9c966b42b715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4297a18d-2326-46e2-9a4c-9c966b42b715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2d1d0f5b-cfda-472c-9b45-95cc17698984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2d1d0f5b-cfda-472c-9b45-95cc17698984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_fa079b27-507d-4c1e-929b-a4d0af4ddc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_ProductionRelatedImpairmentsOrCharges_fa079b27-507d-4c1e-929b-a4d0af4ddc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_330786c6-2c6e-4eb6-a9ac-0f78ab1e93e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_330786c6-2c6e-4eb6-a9ac-0f78ab1e93e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91be13c9-895d-43ac-ada9-f1a8f39bf81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_91be13c9-895d-43ac-ada9-f1a8f39bf81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_faddc7b0-aff7-45d9-8e1b-d415d768f83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f8a3f4c4-09b1-4196-a502-b1aad226d3c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_faddc7b0-aff7-45d9-8e1b-d415d768f83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2b9d3d5e-9be4-4fe2-acfa-0ed616a4e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2b9d3d5e-9be4-4fe2-acfa-0ed616a4e8b9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01ce31e6-af5b-4d29-80ff-ade18963fb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01ce31e6-af5b-4d29-80ff-ade18963fb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01ce31e6-af5b-4d29-80ff-ade18963fb2c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleronPharmaIncMember_8d488b43-75fe-4dc0-b09a-0cee0e822a99" xlink:href="mrk-20221231.xsd#mrk_AcceleronPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:to="loc_mrk_AcceleronPharmaIncMember_8d488b43-75fe-4dc0-b09a-0cee0e822a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_3c885788-a433-4ab6-9929-3edd9d465efc" xlink:href="mrk-20221231.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48746f90-6795-4acb-9138-63e7caeec54e" xlink:to="loc_mrk_ArQuleMember_3c885788-a433-4ab6-9929-3edd9d465efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e727169e-bdc2-4354-9bf5-8d9372b644e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e727169e-bdc2-4354-9bf5-8d9372b644e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_77ca595f-41d6-4635-831e-e6840dfd7eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e727169e-bdc2-4354-9bf5-8d9372b644e4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_77ca595f-41d6-4635-831e-e6840dfd7eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_461c391a-51bc-45aa-af04-78331bbdb2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_77ca595f-41d6-4635-831e-e6840dfd7eac" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_461c391a-51bc-45aa-af04-78331bbdb2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_03f4b6b6-003b-4092-b4c3-3e43337dac5e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a1f245fe-9bc9-4703-a90f-c6f5425339bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a1f245fe-9bc9-4703-a90f-c6f5425339bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_8f8bce79-76cb-4c78-ba91-23e4920d9051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_8f8bce79-76cb-4c78-ba91-23e4920d9051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5568ce8d-9b59-42ac-ad15-c739099af20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_5568ce8d-9b59-42ac-ad15-c739099af20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a8a49e67-590a-46f5-93a5-ffa41cc300fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a8a49e67-590a-46f5-93a5-ffa41cc300fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f5457740-afd0-474b-bfd2-1c06ec17a979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f5457740-afd0-474b-bfd2-1c06ec17a979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_065bbba8-d9ce-4e0b-892e-51857eb95e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_065bbba8-d9ce-4e0b-892e-51857eb95e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c22134-e4aa-4268-a983-dbb539f270cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_37c22134-e4aa-4268-a983-dbb539f270cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_47a4e0a2-501e-44a4-a81d-1e7af5900d97" xlink:href="mrk-20221231.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_47a4e0a2-501e-44a4-a81d-1e7af5900d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_02bd54b9-cb25-46df-a31b-332063ff320b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_02bd54b9-cb25-46df-a31b-332063ff320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cafb8d2-a794-479a-8046-b8fdfac549b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_Goodwill_6cafb8d2-a794-479a-8046-b8fdfac549b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_56fdf53f-aad6-420d-8fc5-8f4e3b831911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_56fdf53f-aad6-420d-8fc5-8f4e3b831911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_dfbbef0f-c8c6-4842-b096-8816858ad3b1" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_dfbbef0f-c8c6-4842-b096-8816858ad3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_c486730a-b195-42c4-a95f-5a1049edf527" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetProductsAndProductRightsMeasurementInput"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_52f9be58-b9d3-4935-9620-bfd12312e0cf" xlink:to="loc_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput_c486730a-b195-42c4-a95f-5a1049edf527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_75512bc0-ba5b-412b-bc07-f84c8a8a76ae" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_75512bc0-ba5b-412b-bc07-f84c8a8a76ae" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_CounterpartyNameAxis_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4c2f259a-5f92-4aaf-8faf-a7ef99a75c3b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_f8603d3f-c31d-4dbe-bfc9-6d0216a98fc6" xlink:href="mrk-20221231.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_AstraZenecaMember_f8603d3f-c31d-4dbe-bfc9-6d0216a98fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_fda104dd-4dcd-4531-9772-f8a6abdd7d2a" xlink:href="mrk-20221231.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_EisaiMember_fda104dd-4dcd-4531-9772-f8a6abdd7d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_3ad97907-61b3-4ea3-b58f-335198692809" xlink:href="mrk-20221231.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_BayerAGMember_3ad97907-61b3-4ea3-b58f-335198692809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_a66c49ae-6dae-4998-83ec-3f395af6e280" xlink:href="mrk-20221231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_a66c49ae-6dae-4998-83ec-3f395af6e280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_087bf560-980e-4d08-acf8-8d0e3cbd7f21" xlink:href="mrk-20221231.xsd#mrk_BristolMyersSquibbMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5856ee65-0e04-4d94-a0d5-024ec6b36622" xlink:to="loc_mrk_BristolMyersSquibbMember_087bf560-980e-4d08-acf8-8d0e3cbd7f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90df9ed8-9ba5-400c-8602-6a258ce5493a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_ProductOrServiceAxis_90df9ed8-9ba5-400c-8602-6a258ce5493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_90df9ed8-9ba5-400c-8602-6a258ce5493a" xlink:to="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_5e2bb631-b1ad-4cd3-971a-f1aff6a939ba" xlink:href="mrk-20221231.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_LynparzaMember_5e2bb631-b1ad-4cd3-971a-f1aff6a939ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_d86aaa73-ecb6-487c-b033-6f58150b3cea" xlink:href="mrk-20221231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_LenvimaMember_d86aaa73-ecb6-487c-b033-6f58150b3cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_8aeab151-6de9-4d83-b670-77da5d39039d" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_AdempasMember_8aeab151-6de9-4d83-b670-77da5d39039d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_58ca3614-addf-49c5-9f58-a29de82e1b7e" xlink:href="mrk-20221231.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_VerquvoMember_58ca3614-addf-49c5-9f58-a29de82e1b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_9724924f-7974-42ec-bd18-8b021d8c2cd6" xlink:href="mrk-20221231.xsd#mrk_ReblozylMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b149e84-e3cc-4c5b-94a6-1f4d2b8dfd84" xlink:to="loc_mrk_ReblozylMember_9724924f-7974-42ec-bd18-8b021d8c2cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_414976b0-56d3-4eaa-97c9-07c21f68a851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_414976b0-56d3-4eaa-97c9-07c21f68a851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_414976b0-56d3-4eaa-97c9-07c21f68a851" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_a408d57f-e737-4e48-9fba-6b21c333b283" xlink:href="mrk-20221231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_mrk_SalesBasedMilestonesMember_a408d57f-e737-4e48-9fba-6b21c333b283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fcc7bcbd-be70-4474-a2b1-3448d8446a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_fcc7bcbd-be70-4474-a2b1-3448d8446a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_a304ffd7-f37f-47c7-a751-4718199b24d3" xlink:href="mrk-20221231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_mrk_RegulatoryMilestonesMember_a304ffd7-f37f-47c7-a751-4718199b24d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5ffb3423-a324-4522-82b0-2f228e223287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5ffb3423-a324-4522-82b0-2f228e223287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_0a68dc0f-d62b-490a-9982-fcbbfdaed7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d509537-738f-439f-9b7d-cbb8df108c21" xlink:to="loc_us-gaap_LicensingAgreementsMember_0a68dc0f-d62b-490a-9982-fcbbfdaed7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adb708e7-627c-4b25-82dc-92c20ec2c3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adb708e7-627c-4b25-82dc-92c20ec2c3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f90c1ee-4d7f-41df-a492-03bb84e92efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_adb708e7-627c-4b25-82dc-92c20ec2c3f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f90c1ee-4d7f-41df-a492-03bb84e92efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_13ed0613-3eb5-4057-b2ab-51e8c4c28f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f90c1ee-4d7f-41df-a492-03bb84e92efe" xlink:to="loc_us-gaap_LicenseMember_13ed0613-3eb5-4057-b2ab-51e8c4c28f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_710c7716-666d-42fe-8f5b-a8caab649333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_710c7716-666d-42fe-8f5b-a8caab649333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6aac3d55-5568-412d-b4d9-9192f1e1eafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_710c7716-666d-42fe-8f5b-a8caab649333" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6aac3d55-5568-412d-b4d9-9192f1e1eafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1bc3491c-5323-40c8-9940-f15c08dc3790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6aac3d55-5568-412d-b4d9-9192f1e1eafa" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1bc3491c-5323-40c8-9940-f15c08dc3790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_aac5f99b-237f-422c-a0b8-47e7d4c554c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_aac5f99b-237f-422c-a0b8-47e7d4c554c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_aac5f99b-237f-422c-a0b8-47e7d4c554c4" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_f062c1f6-1457-45e3-8947-8e89addb4839" xlink:href="mrk-20221231.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:to="loc_mrk_RegulatoryMilestonesMember_f062c1f6-1457-45e3-8947-8e89addb4839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_daa4b5b5-9f57-4ad9-b584-0a50346234db" xlink:href="mrk-20221231.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5f4589d4-1bf7-427f-9117-7e1beaf9679f" xlink:to="loc_mrk_SalesBasedMilestonesMember_daa4b5b5-9f57-4ad9-b584-0a50346234db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a50445a-24ac-4e15-825f-06690dca7078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_RangeAxis_3a50445a-24ac-4e15-825f-06690dca7078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3a50445a-24ac-4e15-825f-06690dca7078" xlink:to="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65fde2ef-f8ea-400a-a1ba-169fcf631396" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:to="loc_srt_MinimumMember_65fde2ef-f8ea-400a-a1ba-169fcf631396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f831f47-3998-4b3d-af4d-8d5509c55f3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39453383-5dd9-4292-ab7b-7fe546181e1e" xlink:to="loc_srt_MaximumMember_1f831f47-3998-4b3d-af4d-8d5509c55f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f504c856-00d6-4567-86a8-45cd6d55b359" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_srt_ConsolidationItemsAxis_f504c856-00d6-4567-86a8-45cd6d55b359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c7ad58a2-efc7-456d-84fc-f004082e11c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f504c856-00d6-4567-86a8-45cd6d55b359" xlink:to="loc_srt_ConsolidationItemsDomain_c7ad58a2-efc7-456d-84fc-f004082e11c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_30209b76-a5ab-4196-b590-f94e3bbd82c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c7ad58a2-efc7-456d-84fc-f004082e11c4" xlink:to="loc_us-gaap_OperatingSegmentsMember_30209b76-a5ab-4196-b590-f94e3bbd82c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_affef2e8-6546-4bf5-8299-c4d0b6e0d6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7209e0d7-d5c4-4e82-96fe-797c48c0c9e2" xlink:to="loc_us-gaap_SegmentDomain_affef2e8-6546-4bf5-8299-c4d0b6e0d6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_db273938-2448-46a9-9a16-d4062c326d50" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_affef2e8-6546-4bf5-8299-c4d0b6e0d6ca" xlink:to="loc_mrk_PharmaceuticalsegmentMember_db273938-2448-46a9-9a16-d4062c326d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_edca8f7a-454a-414f-8d94-35e22f6f318f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_61380e2f-89d7-4799-b362-41bf5979a795" xlink:href="mrk-20221231.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_61380e2f-89d7-4799-b362-41bf5979a795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_df3068c3-0481-47fa-b4f5-79bb9c731e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_Liabilities_df3068c3-0481-47fa-b4f5-79bb9c731e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_d3b50d45-152b-495f-81fd-6c9877ff9333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_AdjustmentForAmortization_d3b50d45-152b-495f-81fd-6c9877ff9333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0ac7f8c1-2b2c-4720-9448-c293839fd0ab" xlink:href="mrk-20221231.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_0ac7f8c1-2b2c-4720-9448-c293839fd0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_f23bb6f2-628b-43ac-8ade-9d22c03376c3" xlink:href="mrk-20221231.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_f23bb6f2-628b-43ac-8ade-9d22c03376c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_d92a23fc-dcf3-46fa-b224-ada481ff71ff" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_d92a23fc-dcf3-46fa-b224-ada481ff71ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_3c7dbbf4-d7a8-40bc-b93c-2931db94ef11" xlink:href="mrk-20221231.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_3c7dbbf4-d7a8-40bc-b93c-2931db94ef11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c058857-c958-4a5e-bc91-b3fe80ddc2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c058857-c958-4a5e-bc91-b3fe80ddc2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_ef233b66-2a94-48d4-8d12-852d93f37e60" xlink:href="mrk-20221231.xsd#mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement_ef233b66-2a94-48d4-8d12-852d93f37e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e407c1df-0678-4b69-bc94-d82c84ff9224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e407c1df-0678-4b69-bc94-d82c84ff9224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_5cc35129-e425-4ebc-b586-4e761009d2a6" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_RoyaltyRatePercentage_5cc35129-e425-4ebc-b586-4e761009d2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_081e9f23-d214-4daa-bc88-a07dc49fefcc" xlink:href="mrk-20221231.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_081e9f23-d214-4daa-bc88-a07dc49fefcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_c81979f7-21e0-41d3-bf0e-7998ca2fb8b2" xlink:href="mrk-20221231.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_c81979f7-21e0-41d3-bf0e-7998ca2fb8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_00b011ef-9253-4829-adfe-c71d5a30c618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_Revenues_00b011ef-9253-4829-adfe-c71d5a30c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_44c6bfd4-2877-45d3-b4a6-7d8296f596b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c808e443-8c9a-4036-a4d1-df86f19b0b12" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_44c6bfd4-2877-45d3-b4a6-7d8296f596b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_6a968a14-881a-4166-a96d-b2472601f40a" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_6a968a14-881a-4166-a96d-b2472601f40a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a1ebcdbf-12a0-44ac-a11a-a86f1a060975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a1ebcdbf-12a0-44ac-a11a-a86f1a060975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a1ebcdbf-12a0-44ac-a11a-a86f1a060975" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_59abb019-4c3d-474e-8acb-4a975614d46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_SalesMember_59abb019-4c3d-474e-8acb-4a975614d46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bd78464f-7d8c-472f-9e94-526baad42d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_CostOfSalesMember_bd78464f-7d8c-472f-9e94-526baad42d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_183cd1cd-0ac1-49f0-a677-8e4e8a8b3e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_183cd1cd-0ac1-49f0-a677-8e4e8a8b3e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b80109da-ce63-43a7-9609-6e4fcd414895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a60e74f5-ba82-4937-9e3f-176bb5bf9d9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b80109da-ce63-43a7-9609-6e4fcd414895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_728c675f-d4f8-48e7-a7d4-dec703817258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_728c675f-d4f8-48e7-a7d4-dec703817258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_728c675f-d4f8-48e7-a7d4-dec703817258" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_166e48f8-841d-4f00-9821-b250df813f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_166e48f8-841d-4f00-9821-b250df813f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3790c2a4-b20d-48d7-84ef-c387e660a501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3790c2a4-b20d-48d7-84ef-c387e660a501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4e358e7-0ade-43ad-bf36-7df53c37efe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_296c4153-a4df-4a6e-8cc0-81cfebcd914a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4e358e7-0ade-43ad-bf36-7df53c37efe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_57126c53-ac80-4a7d-8f3f-2ea0339bd254" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_srt_CounterpartyNameAxis_57126c53-ac80-4a7d-8f3f-2ea0339bd254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_57126c53-ac80-4a7d-8f3f-2ea0339bd254" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_29122307-9905-4d8e-87f3-619419384954" xlink:href="mrk-20221231.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_AstraZenecaMember_29122307-9905-4d8e-87f3-619419384954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_014ebeb6-7f86-413b-8865-306d81c6df24" xlink:href="mrk-20221231.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_EisaiMember_014ebeb6-7f86-413b-8865-306d81c6df24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_36b7a3da-d75d-46af-8044-170090086882" xlink:href="mrk-20221231.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_BayerAGMember_36b7a3da-d75d-46af-8044-170090086882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_f534fd7f-37fc-4a06-8a89-d0f279fa82fb" xlink:href="mrk-20221231.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6782fb7-c6b3-46ba-95ae-271015e792da" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_f534fd7f-37fc-4a06-8a89-d0f279fa82fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894811a5-dd22-46a7-b956-b8c506bb354c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70dfe9a2-d497-44c3-bf9d-9ccf5cde8e16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894811a5-dd22-46a7-b956-b8c506bb354c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_323b10c0-1864-45b7-8f4b-97b9697bad7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_894811a5-dd22-46a7-b956-b8c506bb354c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_323b10c0-1864-45b7-8f4b-97b9697bad7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_883bb316-2961-4cea-9e65-1296e5ace9a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_srt_ProductOrServiceAxis_883bb316-2961-4cea-9e65-1296e5ace9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_883bb316-2961-4cea-9e65-1296e5ace9a3" xlink:to="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_c58cb237-3c73-45d1-b962-20eae1426afe" xlink:href="mrk-20221231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_c58cb237-3c73-45d1-b962-20eae1426afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_f6b44ae4-81e1-400c-a3b9-b2c03422afb5" xlink:href="mrk-20221231.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_f6b44ae4-81e1-400c-a3b9-b2c03422afb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_8ad455f1-161c-4ad9-9343-b28ee8473537" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_AdempasMember_8ad455f1-161c-4ad9-9343-b28ee8473537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_09bc330b-9f98-46e3-8d97-b5338933db99" xlink:href="mrk-20221231.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_VerquvoMember_09bc330b-9f98-46e3-8d97-b5338933db99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_0893978c-3992-41f4-b993-79dfe80f3f92" xlink:href="mrk-20221231.xsd#mrk_LagevrioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_LagevrioMember_0893978c-3992-41f4-b993-79dfe80f3f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_0d1d9414-b4c9-47d6-a31d-a3b1ea05e109" xlink:href="mrk-20221231.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d57a4f67-8aec-4b0b-bf4c-d0fbf453fd31" xlink:to="loc_mrk_LynparzaMember_0d1d9414-b4c9-47d6-a31d-a3b1ea05e109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e0696675-57b3-4270-8011-37db5475cea8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_d5083c5e-dcea-4de7-9e02-f278a4ec2a84" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_d5083c5e-dcea-4de7-9e02-f278a4ec2a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_ebf81b09-192c-44c4-ae5f-ab288c8eac79" xlink:href="mrk-20221231.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_ebf81b09-192c-44c4-ae5f-ab288c8eac79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_66061c1a-1a25-4539-9a4e-10d94f30d286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_Revenues_66061c1a-1a25-4539-9a4e-10d94f30d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f1ed26d5-dc81-402d-9dfc-125583ef13ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f1ed26d5-dc81-402d-9dfc-125583ef13ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9324fde-4e0f-4527-a890-e99eef9c0059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a9324fde-4e0f-4527-a890-e99eef9c0059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_65724553-4e34-4576-bfa5-cfa095bb4c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_65724553-4e34-4576-bfa5-cfa095bb4c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_bbd2edc9-6432-4f0a-a3c3-31e809f295e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_ReceivablesNetCurrent_bbd2edc9-6432-4f0a-a3c3-31e809f295e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_21bf5a41-325d-4fd2-bf07-ad5c4b1f874f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_21bf5a41-325d-4fd2-bf07-ad5c4b1f874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_fa71de90-e756-44d5-b37f-06b48c496355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_fa71de90-e756-44d5-b37f-06b48c496355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_7097908c-f266-4724-9746-7f7fe58428fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_AdjustmentForAmortization_7097908c-f266-4724-9746-7f7fe58428fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f310f710-4c58-4a7d-a684-429d32b9666b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_83eaafa3-402a-4514-8624-5972c1c81f1c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f310f710-4c58-4a7d-a684-429d32b9666b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d354c77f-2cac-4ab7-a865-b3a6ed12af65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_203b3836-2086-42e2-9a96-e796c3cc0f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d354c77f-2cac-4ab7-a865-b3a6ed12af65" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_203b3836-2086-42e2-9a96-e796c3cc0f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1735fee2-d15a-40c4-8499-06e3945537dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_203b3836-2086-42e2-9a96-e796c3cc0f35" xlink:to="loc_srt_StatementScenarioAxis_1735fee2-d15a-40c4-8499-06e3945537dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_20a6a28c-29c0-45a1-8078-1cb55d10cc45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1735fee2-d15a-40c4-8499-06e3945537dc" xlink:to="loc_srt_ScenarioUnspecifiedDomain_20a6a28c-29c0-45a1-8078-1cb55d10cc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6b05eb53-d06d-4ad0-9fa5-935a9acd5669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_20a6a28c-29c0-45a1-8078-1cb55d10cc45" xlink:to="loc_srt_ScenarioForecastMember_6b05eb53-d06d-4ad0-9fa5-935a9acd5669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_203b3836-2086-42e2-9a96-e796c3cc0f35" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_594435b0-7e97-4464-981d-086dac73d4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_594435b0-7e97-4464-981d-086dac73d4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_0f9144fd-e65f-4243-bf6a-f4a38bbc16cb" xlink:href="mrk-20221231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_0f9144fd-e65f-4243-bf6a-f4a38bbc16cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_3fa5f01a-8d3e-4606-a8fa-8a9c9c872078" xlink:href="mrk-20221231.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_3fa5f01a-8d3e-4606-a8fa-8a9c9c872078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_b20ae504-02d4-4d7b-ae81-f162725ef85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_b20ae504-02d4-4d7b-ae81-f162725ef85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_95e6d31a-c479-43aa-a921-339f0aa73908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_836aa344-bbc8-4db6-84a4-d6cac12cd15a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_95e6d31a-c479-43aa-a921-339f0aa73908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_df881059-1a12-4a23-a7cc-50045593714d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_df881059-1a12-4a23-a7cc-50045593714d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d8af96c1-3e91-459d-9f6d-37952c9cd061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d8af96c1-3e91-459d-9f6d-37952c9cd061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d8af96c1-3e91-459d-9f6d-37952c9cd061" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_dd1393ff-0c9c-42c1-b889-d7eecf5b2945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_dd1393ff-0c9c-42c1-b889-d7eecf5b2945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_3e22420d-b9c7-4931-8418-cc714d1d2b97" xlink:href="mrk-20221231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:to="loc_mrk_AcceleratedDepreciationMember_3e22420d-b9c7-4931-8418-cc714d1d2b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_0428e092-5b98-46bd-837f-b083b0806b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4409c274-e909-450b-8e3d-496767719fa5" xlink:to="loc_us-gaap_OtherRestructuringMember_0428e092-5b98-46bd-837f-b083b0806b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1f720cc4-c1e0-4a6e-ac12-ce530a32989a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1f720cc4-c1e0-4a6e-ac12-ce530a32989a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1f720cc4-c1e0-4a6e-ac12-ce530a32989a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_69df47f0-22df-40c8-b2a2-0ed921003eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_CostOfSalesMember_69df47f0-22df-40c8-b2a2-0ed921003eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d6f35451-72df-4e12-98dc-a3fe2668508e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d6f35451-72df-4e12-98dc-a3fe2668508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f349f4cc-7acf-4df9-acc7-6ee81e6754ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f349f4cc-7acf-4df9-acc7-6ee81e6754ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8c0e1277-ebda-48fe-bf0c-8d27db30e2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_037fba47-aa25-4895-92a1-17fa00904b45" xlink:to="loc_us-gaap_RestructuringChargesMember_8c0e1277-ebda-48fe-bf0c-8d27db30e2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a13fd7b5-b8fd-419c-85d8-6a0745a11806" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3d6fe308-0f44-4ae7-ab73-b03275b03f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_3d6fe308-0f44-4ae7-ab73-b03275b03f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_24ffa9da-3813-43d5-985d-138ed02ccc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ebc12957-e5ef-4a15-8100-8be5aac10c1b" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_24ffa9da-3813-43d5-985d-138ed02ccc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9fdb33a8-5ee1-45f0-a072-df51e29234ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af2a3f45-d668-4e4c-8901-61d15e0dd9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9fdb33a8-5ee1-45f0-a072-df51e29234ee" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af2a3f45-d668-4e4c-8901-61d15e0dd9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_427fef8b-0bfe-457c-9601-71e390536ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af2a3f45-d668-4e4c-8901-61d15e0dd9f8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_427fef8b-0bfe-457c-9601-71e390536ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_427fef8b-0bfe-457c-9601-71e390536ad8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_f2756fbf-8f63-42e1-9d47-661a44780cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_f2756fbf-8f63-42e1-9d47-661a44780cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_d811dc4e-4308-4947-8b03-2ef317fe6d63" xlink:href="mrk-20221231.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:to="loc_mrk_AcceleratedDepreciationMember_d811dc4e-4308-4947-8b03-2ef317fe6d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_a23c3c67-20dd-4e8a-b0a7-17df27defb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_01db962d-8b7f-459b-b297-a78ab91d040f" xlink:to="loc_us-gaap_OtherRestructuringMember_a23c3c67-20dd-4e8a-b0a7-17df27defb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ffbe1a70-ede3-4fe8-811c-0acc950e2189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_af2a3f45-d668-4e4c-8901-61d15e0dd9f8" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_ffbe1a70-ede3-4fe8-811c-0acc950e2189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ffbe1a70-ede3-4fe8-811c-0acc950e2189" xlink:to="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f604b194-05c2-4da8-a818-c1d1eb6bc95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_us-gaap_RestructuringReserve_f604b194-05c2-4da8-a818-c1d1eb6bc95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c9f7db7d-9841-4af0-a537-3fca0c424a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c9f7db7d-9841-4af0-a537-3fca0c424a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_3e2bf075-0d96-4db6-9081-e7300aeaafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_us-gaap_PaymentsForRestructuring_3e2bf075-0d96-4db6-9081-e7300aeaafa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_b18d90b6-0f64-4c9d-8156-28523502ccc2" xlink:href="mrk-20221231.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_b18d90b6-0f64-4c9d-8156-28523502ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_338ad846-58f4-478f-a34f-2b5592b7f949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_37c95f91-b06a-4484-8a52-c55a1ee47ca1" xlink:to="loc_us-gaap_RestructuringReserve_338ad846-58f4-478f-a34f-2b5592b7f949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_946a4777-3a08-4c1b-822c-87e5788927e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_946a4777-3a08-4c1b-822c-87e5788927e7" xlink:to="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea352d83-ee00-4608-befe-cf2cd57de73c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_srt_RangeAxis_ea352d83-ee00-4608-befe-cf2cd57de73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ab70236-f8a5-464b-ace6-c5fe23d35e29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ea352d83-ee00-4608-befe-cf2cd57de73c" xlink:to="loc_srt_RangeMember_0ab70236-f8a5-464b-ace6-c5fe23d35e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d7f46f57-4f62-4104-b430-1c70dab61697" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0ab70236-f8a5-464b-ace6-c5fe23d35e29" xlink:to="loc_srt_MaximumMember_d7f46f57-4f62-4104-b430-1c70dab61697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_eaac4b8e-f644-44ba-b925-27afdd69d2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_HedgingDesignationAxis_eaac4b8e-f644-44ba-b925-27afdd69d2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_eaac4b8e-f644-44ba-b925-27afdd69d2df" xlink:to="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6bb4627b-9ef3-4838-98b5-da82e6c52371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6bb4627b-9ef3-4838-98b5-da82e6c52371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_23b4d110-0ae0-483a-b86e-da5b1ee22ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_07edac6e-1b2e-4e4e-b2a2-7366f5b7fdb5" xlink:to="loc_us-gaap_NondesignatedMember_23b4d110-0ae0-483a-b86e-da5b1ee22ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bca3ad75-1cb2-4baf-9392-888b1e123a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bca3ad75-1cb2-4baf-9392-888b1e123a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f9a1d186-bba8-4a1a-bb95-e8eb8f99382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bca3ad75-1cb2-4baf-9392-888b1e123a73" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f9a1d186-bba8-4a1a-bb95-e8eb8f99382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_c1a94f69-5621-4db9-ba81-9683c3b5426c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f9a1d186-bba8-4a1a-bb95-e8eb8f99382b" xlink:to="loc_us-gaap_InterestRateSwapMember_c1a94f69-5621-4db9-ba81-9683c3b5426c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2863e64-7bc9-4b05-9980-b04af6ddd673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2863e64-7bc9-4b05-9980-b04af6ddd673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5647d549-d92c-4cc3-856c-29b0cb37c867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2863e64-7bc9-4b05-9980-b04af6ddd673" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5647d549-d92c-4cc3-856c-29b0cb37c867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5dfd5e5-703a-46be-8df1-5c6b38558565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5647d549-d92c-4cc3-856c-29b0cb37c867" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5dfd5e5-703a-46be-8df1-5c6b38558565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0f18425b-f173-454d-8a2d-194b82a36a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_eeb822b4-0ea2-4d1e-80ca-ca68d172d1e2" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0f18425b-f173-454d-8a2d-194b82a36a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1682af44-0626-4e0d-8ca4-29d2496ddb45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0f18425b-f173-454d-8a2d-194b82a36a6d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1682af44-0626-4e0d-8ca4-29d2496ddb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a14c8238-f2fc-4cf5-8da7-f98cbc15f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a14c8238-f2fc-4cf5-8da7-f98cbc15f690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_57037ab8-15b6-4d04-9ae1-001a7db78208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a14c8238-f2fc-4cf5-8da7-f98cbc15f690" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_57037ab8-15b6-4d04-9ae1-001a7db78208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_de6ae47f-3803-410a-a59b-12233a8b20aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_57037ab8-15b6-4d04-9ae1-001a7db78208" xlink:to="loc_us-gaap_AccountsReceivableMember_de6ae47f-3803-410a-a59b-12233a8b20aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f14b8d73-8156-4d36-a527-4642efc594e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_srt_MajorCustomersAxis_f14b8d73-8156-4d36-a527-4642efc594e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f14b8d73-8156-4d36-a527-4642efc594e6" xlink:to="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_McKessonCorporationMember_5fb373da-111c-459d-b811-2b6b49ab29c2" xlink:href="mrk-20221231.xsd#mrk_McKessonCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:to="loc_mrk_McKessonCorporationMember_5fb373da-111c-459d-b811-2b6b49ab29c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmerisourceBergenCorporationMember_b575c5bc-5fa0-426c-abaf-45bd8721ee0b" xlink:href="mrk-20221231.xsd#mrk_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:to="loc_mrk_AmerisourceBergenCorporationMember_b575c5bc-5fa0-426c-abaf-45bd8721ee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CardinalHealthIncMember_6b45b571-173c-4fed-8641-357b65cac994" xlink:href="mrk-20221231.xsd#mrk_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_99eb9b1f-4e51-4c2c-961a-79ca396c36ad" xlink:to="loc_mrk_CardinalHealthIncMember_6b45b571-173c-4fed-8641-357b65cac994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb6f5c9c-f50e-4612-b221-153552751d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb6f5c9c-f50e-4612-b221-153552751d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7995229-3026-442a-b402-0624e520cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb6f5c9c-f50e-4612-b221-153552751d70" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7995229-3026-442a-b402-0624e520cb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_2867cd50-484f-42ed-b07b-f2fd70fecf98" xlink:href="mrk-20221231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b7995229-3026-442a-b402-0624e520cb39" xlink:to="loc_mrk_A2.35NotesDue2022Member_2867cd50-484f-42ed-b07b-f2fd70fecf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36a19bd3-ce55-4770-9fe8-498dd8c9506e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_DebtInstrumentAxis_36a19bd3-ce55-4770-9fe8-498dd8c9506e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_36a19bd3-ce55-4770-9fe8-498dd8c9506e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_fc624c72-3941-421c-a4e7-938d282823ba" xlink:href="mrk-20221231.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:to="loc_mrk_A2.40NotesDue2022Member_fc624c72-3941-421c-a4e7-938d282823ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_3b33e0a5-1790-4e02-a522-2ae99108a1de" xlink:href="mrk-20221231.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23a27785-6dfc-49fc-9faf-2d483673ef8e" xlink:to="loc_mrk_A2.35NotesDue2022Member_3b33e0a5-1790-4e02-a522-2ae99108a1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4dce629-8bb1-4f02-adf1-abd123259960" xlink:to="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_b560f081-5cf3-458e-8dbf-6567b0cad0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_b560f081-5cf3-458e-8dbf-6567b0cad0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NumberOfInterestRateDerivativesMatured_070395cd-83e9-4e51-ad33-1c3580ef791a" xlink:href="mrk-20221231.xsd#mrk_NumberOfInterestRateDerivativesMatured"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_mrk_NumberOfInterestRateDerivativesMatured_070395cd-83e9-4e51-ad33-1c3580ef791a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DerivativeNotionalAmountMatured_b40757fa-bbc4-459d-9d98-6e2fbd200b36" xlink:href="mrk-20221231.xsd#mrk_DerivativeNotionalAmountMatured"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_mrk_DerivativeNotionalAmountMatured_b40757fa-bbc4-459d-9d98-6e2fbd200b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32fa072d-3d22-47a5-b242-47ce65a538f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32fa072d-3d22-47a5-b242-47ce65a538f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7dcab50-ad9c-4525-acd0-9b19cbb5ba85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f7dcab50-ad9c-4525-acd0-9b19cbb5ba85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_68017f3f-b3e9-4afa-9f50-3cbf297d5b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_68017f3f-b3e9-4afa-9f50-3cbf297d5b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_48da61cc-c298-480b-841b-ed6c059b8f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_48da61cc-c298-480b-841b-ed6c059b8f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_a474d040-f145-41b4-a7dd-685e3ecd1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_a474d040-f145-41b4-a7dd-685e3ecd1ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_684d336d-5674-4944-8612-68304062e199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_684d336d-5674-4944-8612-68304062e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_39b4395b-e013-4747-b208-6b5d790983b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_39b4395b-e013-4747-b208-6b5d790983b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_4ea5a672-46a9-4069-a45c-f2970ff5095c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_4ea5a672-46a9-4069-a45c-f2970ff5095c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_1dae41f7-4b37-4bdd-9f5a-9a58146cd843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_1dae41f7-4b37-4bdd-9f5a-9a58146cd843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7b7b891b-7a78-483e-a699-e0c3fefd876c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7b7b891b-7a78-483e-a699-e0c3fefd876c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ed3d01f6-6fd7-4ca9-b57d-fd7b7f5dd351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ed3d01f6-6fd7-4ca9-b57d-fd7b7f5dd351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6b557c2c-27fd-4d69-8706-5d595f41ebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6b557c2c-27fd-4d69-8706-5d595f41ebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_02e3a5ac-988c-4f99-8a7d-5776e1ecec82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_02e3a5ac-988c-4f99-8a7d-5776e1ecec82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_93605c95-3b6f-42ae-a1ee-f907d3ece58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_93605c95-3b6f-42ae-a1ee-f907d3ece58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_436ac1ce-8ba4-4920-b098-bc90708f55a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_AccountsReceivableSale_436ac1ce-8ba4-4920-b098-bc90708f55a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7ba7d6e3-2322-46b9-b845-a74523704ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_RestrictedCashCurrent_7ba7d6e3-2322-46b9-b845-a74523704ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_b9567e49-62ae-4935-b66c-7ba30338e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimSecurities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_b9567e49-62ae-4935-b66c-7ba30338e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_ffec6652-8944-4c49-afa8-1854cab28209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_78734812-cfb2-4f67-a2bf-584466ef6fd1" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_ffec6652-8944-4c49-afa8-1854cab28209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_45fc50e4-e340-449c-bd8d-70b8d4be13d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_45fc50e4-e340-449c-bd8d-70b8d4be13d6" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_beec25a5-874d-4456-9e88-f414d86ef946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_beec25a5-874d-4456-9e88-f414d86ef946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_beec25a5-874d-4456-9e88-f414d86ef946" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_bd61fb7d-a9d1-4e9b-96b9-60298950e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_bd61fb7d-a9d1-4e9b-96b9-60298950e54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_bd2a7db9-5bd9-4a50-8cd9-047acbac1b17" xlink:href="mrk-20221231.xsd#mrk_EurodominatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6cf6da6-89ab-4870-ac23-d1c21538bf5e" xlink:to="loc_mrk_EurodominatedNotesMember_bd2a7db9-5bd9-4a50-8cd9-047acbac1b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c4670a7-9f1d-4577-abf2-726a0d791c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a2d52e11-b3fe-47fe-a1bd-4b1ae539be0f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c4670a7-9f1d-4577-abf2-726a0d791c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8fd94bbd-1f91-4025-a4aa-59a61f4a9415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c4670a7-9f1d-4577-abf2-726a0d791c1e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8fd94bbd-1f91-4025-a4aa-59a61f4a9415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_86cc4c3c-80f1-4b33-b159-10cc3fba510d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_be25c786-78b4-4779-99bb-c4109f8e5a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_be25c786-78b4-4779-99bb-c4109f8e5a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_d8b30a1d-42b3-4616-be46-6649a9b04e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_58f65d1d-3b11-426c-b9fb-6bdf21dc1405" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_d8b30a1d-42b3-4616-be46-6649a9b04e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsFairValueofHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bf88a5be-3933-43cb-9e99-73cb0213e08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_6ae2383b-6833-4bc8-85d2-14f802e8c41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bf88a5be-3933-43cb-9e99-73cb0213e08c" xlink:to="loc_us-gaap_DerivativeTable_6ae2383b-6833-4bc8-85d2-14f802e8c41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3dd3514c-e434-402a-a14e-b5a19010bc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6ae2383b-6833-4bc8-85d2-14f802e8c41e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3dd3514c-e434-402a-a14e-b5a19010bc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_44dcec15-5a13-4669-98a2-6e2754c0eebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3dd3514c-e434-402a-a14e-b5a19010bc15" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_44dcec15-5a13-4669-98a2-6e2754c0eebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_7f64ed81-8cdb-4d46-bf0a-6f3c8effc177" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44dcec15-5a13-4669-98a2-6e2754c0eebd" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_7f64ed81-8cdb-4d46-bf0a-6f3c8effc177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6ae2383b-6833-4bc8-85d2-14f802e8c41e" xlink:to="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_158f02b3-5e56-4513-8e61-82d0f7441ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_158f02b3-5e56-4513-8e61-82d0f7441ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0f0a203a-4dbe-4458-9603-4bf1e43f9e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a3735cfe-fa77-4f78-9dea-b474ba1c45eb" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_0f0a203a-4dbe-4458-9603-4bf1e43f9e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bf6441e3-ea98-42ee-aac5-1d4fb901908f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bf6441e3-ea98-42ee-aac5-1d4fb901908f" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8c47e60c-472e-4213-9ee9-169dcbee3ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8c47e60c-472e-4213-9ee9-169dcbee3ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c47e60c-472e-4213-9ee9-169dcbee3ea1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_29286bf6-2ebc-482a-a163-ccfa81880e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:to="loc_us-gaap_InterestRateContractMember_29286bf6-2ebc-482a-a163-ccfa81880e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e716d927-81ed-4ebc-8064-d2ec4e0b8354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e43952a6-460e-4460-a307-c2353be0183b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e716d927-81ed-4ebc-8064-d2ec4e0b8354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_cbc4fa42-6b9e-45b8-9b55-427a3885d544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:to="loc_us-gaap_HedgingDesignationAxis_cbc4fa42-6b9e-45b8-9b55-427a3885d544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_cbc4fa42-6b9e-45b8-9b55-427a3885d544" xlink:to="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9960347b-aa1b-4b28-b4b0-666d0e630f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9960347b-aa1b-4b28-b4b0-666d0e630f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9e173e63-5d46-436f-a17c-64a2a528d25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9a4e1d2a-e4c9-49cd-8a3d-53d60cb2c1f4" xlink:to="loc_us-gaap_NondesignatedMember_9e173e63-5d46-436f-a17c-64a2a528d25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4e8da032-7a59-4958-b3f6-50b04c90329d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4e8da032-7a59-4958-b3f6-50b04c90329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4e8da032-7a59-4958-b3f6-50b04c90329d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_ea030813-8ea5-44cc-ace9-2289ddbb9d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_ea030813-8ea5-44cc-ace9-2289ddbb9d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_8fc346e1-ed6c-4ed1-87fb-8152eeb65379" xlink:href="mrk-20221231.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_8fc346e1-ed6c-4ed1-87fb-8152eeb65379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_bc495503-82ec-4372-ac77-8421e3093feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_bc495503-82ec-4372-ac77-8421e3093feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75e2ff30-62c7-4859-aa83-37f91c2f0411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b7ef49ea-5c20-4f4e-a72d-0894011a7769" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_75e2ff30-62c7-4859-aa83-37f91c2f0411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aafc884c-3c88-4e27-9e4b-20b29d7686c3" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_bc710dd9-5552-471d-8709-3ef1b7c1d5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeAssets_bc710dd9-5552-471d-8709-3ef1b7c1d5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_c4394cff-46d1-4559-9844-d9ef99265d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_c4394cff-46d1-4559-9844-d9ef99265d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_60699bea-48b8-42b4-9573-789efec0aa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeLiabilities_60699bea-48b8-42b4-9573-789efec0aa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_779df192-2da4-49cd-a1a6-c14f4f39b190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeNotionalAmount_779df192-2da4-49cd-a1a6-c14f4f39b190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_10b18aa4-cb25-4f59-ad06-871fcb852774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d50689d6-3b30-4674-b236-31a5e5c358d1" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_10b18aa4-cb25-4f59-ad06-871fcb852774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_4fe20e90-37ed-4247-a756-083173341dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeAssets_4fe20e90-37ed-4247-a756-083173341dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_d3c59fe0-6e06-4f8d-9ec5-4b60b81a905d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_d3c59fe0-6e06-4f8d-9ec5-4b60b81a905d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7b7e97b8-4eca-4057-8af9-5a7074dd3b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7b7e97b8-4eca-4057-8af9-5a7074dd3b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_04b77adc-93aa-47fe-bc8c-1aa285a5d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_04b77adc-93aa-47fe-bc8c-1aa285a5d99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_a6537a55-b10a-4bc1-96db-605d1ec36031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeLiabilities_a6537a55-b10a-4bc1-96db-605d1ec36031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_bc776171-5cee-4fda-afe4-206da9776c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_bc776171-5cee-4fda-afe4-206da9776c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_ad24bced-a2c4-446d-8a1f-10e53d22b7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_ad24bced-a2c4-446d-8a1f-10e53d22b7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_f07c321c-4bc1-4448-93d2-aa9dee0879ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22054580-a31f-456b-9591-eecb56d33473" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_f07c321c-4bc1-4448-93d2-aa9dee0879ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ab05253-155f-4e4b-a53c-c67abc469198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6ab05253-155f-4e4b-a53c-c67abc469198" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1f58b34-3fb3-4f1c-a387-13c66eceae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1f58b34-3fb3-4f1c-a387-13c66eceae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eaf7a790-4a25-4317-a9a2-0ccf691fc73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_e1f58b34-3fb3-4f1c-a387-13c66eceae20" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eaf7a790-4a25-4317-a9a2-0ccf691fc73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5ad5be1a-f995-4626-9ebf-740389f755d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_eaf7a790-4a25-4317-a9a2-0ccf691fc73e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5ad5be1a-f995-4626-9ebf-740389f755d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8d2afc6-3074-4f6e-beab-e32e8909c1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8d2afc6-3074-4f6e-beab-e32e8909c1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51a3b89e-85ec-4f2d-9430-daebf14c963d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8d2afc6-3074-4f6e-beab-e32e8909c1d9" xlink:to="loc_us-gaap_EquityComponentDomain_51a3b89e-85ec-4f2d-9430-daebf14c963d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_0b22af47-a285-47a3-841b-3458dcd2ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_51a3b89e-85ec-4f2d-9430-daebf14c963d" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_0b22af47-a285-47a3-841b-3458dcd2ca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f19a3652-7344-4efe-8abe-92cfd41b71f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd8a73e2-2b08-4b16-96fc-cf25fd111dc0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f19a3652-7344-4efe-8abe-92cfd41b71f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_f3f551c8-d02b-4a25-9816-d78c3030ab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f19a3652-7344-4efe-8abe-92cfd41b71f9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_f3f551c8-d02b-4a25-9816-d78c3030ab17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6b34e4fd-0276-4601-a4f3-dded10a5f2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6b34e4fd-0276-4601-a4f3-dded10a5f2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6b34e4fd-0276-4601-a4f3-dded10a5f2cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fbd59672-0775-4dae-89ca-7e99981b0040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:to="loc_us-gaap_InterestRateSwapMember_fbd59672-0775-4dae-89ca-7e99981b0040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b27572aa-6e38-46f5-a915-c03929c00b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a5674ae4-28b7-447f-9a75-89a2ef741f6b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b27572aa-6e38-46f5-a915-c03929c00b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_36bf0b81-6570-423b-ac11-bb327743b26d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f836c0d0-6216-49fb-ad24-c8e8af12eb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_Revenues_f836c0d0-6216-49fb-ad24-c8e8af12eb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_78846c8c-376d-4da7-96c6-76f087c884f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_78846c8c-376d-4da7-96c6-76f087c884f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bc7c5155-d324-46f6-816e-d6afc0455ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bc7c5155-d324-46f6-816e-d6afc0455ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_df3b7fef-aa15-4c4e-85ca-38295cc5cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_df3b7fef-aa15-4c4e-85ca-38295cc5cd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_185b718c-3911-48f9-8dcc-b7db770ebbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_185b718c-3911-48f9-8dcc-b7db770ebbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_9579eb0c-73c8-4417-83d5-59812bb15a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_9579eb0c-73c8-4417-83d5-59812bb15a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8a8be9a6-4c6c-4d08-aa53-c915b9987e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8a8be9a6-4c6c-4d08-aa53-c915b9987e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2a835fd7-8e52-4e99-a88b-aed8d6491b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2a835fd7-8e52-4e99-a88b-aed8d6491b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_20b67028-300c-4036-b867-0ab84b39350a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_084463b8-3332-44ec-9c50-ea4c54d42c4f" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_20b67028-300c-4036-b867-0ab84b39350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a1c93ff-ad4a-487c-a95d-1db518ada1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a1c93ff-ad4a-487c-a95d-1db518ada1db" xlink:to="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_69c1d213-f5f5-4c1e-9d10-2bce43958605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_69c1d213-f5f5-4c1e-9d10-2bce43958605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_69c1d213-f5f5-4c1e-9d10-2bce43958605" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_685047fa-e7d0-49c4-8386-e010ac1e4682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_685047fa-e7d0-49c4-8386-e010ac1e4682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_5bca7773-efcd-4f50-967b-4d1f514d51f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:to="loc_us-gaap_InterestRateContractMember_5bca7773-efcd-4f50-967b-4d1f514d51f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_931d9c06-dc15-42ae-854d-5fdc172be79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_17549218-151b-40a6-9727-85de5ff4b81f" xlink:to="loc_us-gaap_ForwardContractsMember_931d9c06-dc15-42ae-854d-5fdc172be79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b020aed-6605-47c8-8c92-a327d1e1aafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b020aed-6605-47c8-8c92-a327d1e1aafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b020aed-6605-47c8-8c92-a327d1e1aafc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_edca251d-3376-4d07-a932-57ded444928b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_edca251d-3376-4d07-a932-57ded444928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_7c2b88c6-de6d-4d2d-8b37-e1fe23d37e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:to="loc_us-gaap_SalesMember_7c2b88c6-de6d-4d2d-8b37-e1fe23d37e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632c217e-86a4-4b79-9ebf-9b1840ae2b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_822323ea-7cbb-49ff-9c48-65fa8c00ef94" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632c217e-86a4-4b79-9ebf-9b1840ae2b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c8114581-ba57-4505-9d46-82f2442af1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_08999c53-6bad-478e-b613-49671d082cf4" xlink:to="loc_us-gaap_DerivativeLineItems_c8114581-ba57-4505-9d46-82f2442af1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_51b5b1e9-aa7f-44a8-aa45-9742d2041b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c8114581-ba57-4505-9d46-82f2442af1bf" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_51b5b1e9-aa7f-44a8-aa45-9742d2041b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_810220e8-dcaa-4119-a057-b69fe07e5c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d2a95d72-143a-4dc3-a00a-be0d42518f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_810220e8-dcaa-4119-a057-b69fe07e5c21" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d2a95d72-143a-4dc3-a00a-be0d42518f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d086356-8636-4b2c-aff6-5972e9186bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d2a95d72-143a-4dc3-a00a-be0d42518f61" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d086356-8636-4b2c-aff6-5972e9186bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d086356-8636-4b2c-aff6-5972e9186bc2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7d7303ac-4070-49ea-9b02-87193eb9a927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_CommercialPaperMember_7d7303ac-4070-49ea-9b02-87193eb9a927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c7dc25-46fe-4b64-8657-c4ec6715fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_73c7dc25-46fe-4b64-8657-c4ec6715fb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4273976e-5c29-4af1-b76d-d1ef49e4b170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4273976e-5c29-4af1-b76d-d1ef49e4b170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d0d18a9c-3298-4bd7-b1cc-161bad0560a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efb39233-03ef-44ed-8aa0-d7fe1154ca47" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_d0d18a9c-3298-4bd7-b1cc-161bad0560a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d2a95d72-143a-4dc3-a00a-be0d42518f61" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dd3657bb-cc27-42fc-ab1d-9b51de88cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dd3657bb-cc27-42fc-ab1d-9b51de88cbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c14c2000-c278-465c-8a31-772b1d8e0aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c14c2000-c278-465c-8a31-772b1d8e0aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cdecffdb-7ebb-4a30-9b59-97b09214a63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cdecffdb-7ebb-4a30-9b59-97b09214a63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16a9e893-dcbd-4da1-804b-536e1a350325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_16a9e893-dcbd-4da1-804b-536e1a350325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_cf8a8d23-810b-4196-b1af-659cd62d7c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_cf8a8d23-810b-4196-b1af-659cd62d7c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_2a74b300-1ea9-4b97-a76d-f5e6bd79ca9d" xlink:href="mrk-20221231.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1d878c4-eb68-4650-a97a-9d9fee15bce2" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_2a74b300-1ea9-4b97-a76d-f5e6bd79ca9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_30187c3c-696a-4d95-85b3-e3eb820e4dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_30187c3c-696a-4d95-85b3-e3eb820e4dea" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_56e2fd48-a04b-423a-a4ed-010e98af1a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_56e2fd48-a04b-423a-a4ed-010e98af1a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d877face-3d98-45e9-9f78-b5d5fdd84951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_56e2fd48-a04b-423a-a4ed-010e98af1a33" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d877face-3d98-45e9-9f78-b5d5fdd84951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6a37ba7e-9abc-4740-877a-179c266a612e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d877face-3d98-45e9-9f78-b5d5fdd84951" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6a37ba7e-9abc-4740-877a-179c266a612e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b094750f-7be6-4bc2-8ab0-e625b8c7ff4c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4340cf9-cc88-4f4d-ae87-4d44767e371c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4340cf9-cc88-4f4d-ae87-4d44767e371c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d2b49857-3531-426f-ad6e-cba63e74ad30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d2b49857-3531-426f-ad6e-cba63e74ad30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2610e1e9-dc8f-43d7-9fe1-e3795ca3fd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c3863d-0a6b-4e18-89cb-0c14607edc50" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2610e1e9-dc8f-43d7-9fe1-e3795ca3fd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b17dda1b-2152-44b0-b125-2cae5f74e8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b17dda1b-2152-44b0-b125-2cae5f74e8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b17dda1b-2152-44b0-b125-2cae5f74e8c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_426d8072-3cd1-4674-9ef9-ad5a543f9bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_CommercialPaperMember_426d8072-3cd1-4674-9ef9-ad5a543f9bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_fc34c916-667b-471a-b576-7e30b14bdb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_fc34c916-667b-471a-b576-7e30b14bdb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_34d07d81-f31a-436b-b39a-e0b30a9b6153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_34d07d81-f31a-436b-b39a-e0b30a9b6153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_10e0e580-791a-4cdb-8e46-ee1cfb33c237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_10e0e580-791a-4cdb-8e46-ee1cfb33c237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_17ddab6f-9694-4a28-b6f0-62ce761838ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3df3013-8269-4122-8e1a-934bfbb8d360" xlink:to="loc_us-gaap_EquitySecuritiesMember_17ddab6f-9694-4a28-b6f0-62ce761838ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bfb6861d-7d3e-4bf3-b1ae-6219e9c00464" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1be9a33a-9b03-444c-af80-f40e0cd2ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1be9a33a-9b03-444c-af80-f40e0cd2ac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_bbb32e39-5ae5-4de2-8efd-c5e54d317b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_bbb32e39-5ae5-4de2-8efd-c5e54d317b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_40df16e0-7815-4904-b7ad-deb96c23aba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9d43cc78-5e50-45a1-9fb0-c0e9b163c6c5" xlink:to="loc_us-gaap_InterestRateContractMember_40df16e0-7815-4904-b7ad-deb96c23aba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c54ee1c-8e36-480a-b82a-7bdece952da0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33d69161-a13e-41c2-8dbb-40e8279be846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_33d69161-a13e-41c2-8dbb-40e8279be846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_073ccfe6-f5ce-4bed-9a5a-78b789753801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_073ccfe6-f5ce-4bed-9a5a-78b789753801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_5e189964-96e0-4f43-b361-f35a7e891d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_TradingSecurities_5e189964-96e0-4f43-b361-f35a7e891d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_118aae56-8323-4cec-8694-e649cceafc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_118aae56-8323-4cec-8694-e649cceafc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_29fe6147-5780-46e9-9ae4-8bda6f61ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_DerivativeAssets_29fe6147-5780-46e9-9ae4-8bda6f61ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2a2d36e5-0af9-4976-92e2-966387888c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9103570c-c271-4030-89e4-c997e847bdb6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2a2d36e5-0af9-4976-92e2-966387888c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f44e546-9562-4b65-bd56-1187ff178ce3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7115a0b5-a5c0-43f6-b6b3-1b66fcf01dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7115a0b5-a5c0-43f6-b6b3-1b66fcf01dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_dd3695fe-20c9-44f7-88bd-1e4ca6e4a362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:to="loc_us-gaap_DerivativeLiabilities_dd3695fe-20c9-44f7-88bd-1e4ca6e4a362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4c6a370f-0f3f-44f7-adfa-f516088671a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_dcbc5383-e7ab-4902-ae0d-9d49cf1614f4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4c6a370f-0f3f-44f7-adfa-f516088671a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0833413c-1fee-424f-a51e-8f6062d3e1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0833413c-1fee-424f-a51e-8f6062d3e1eb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5ccdcf81-a1e1-4614-9468-baf22956ab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5ccdcf81-a1e1-4614-9468-baf22956ab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3d673208-e2ad-4016-b42c-84738823606a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5ccdcf81-a1e1-4614-9468-baf22956ab3a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3d673208-e2ad-4016-b42c-84738823606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_73034132-6183-4f5f-b4a7-6fbd4c48fc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3d673208-e2ad-4016-b42c-84738823606a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_73034132-6183-4f5f-b4a7-6fbd4c48fc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e87cdb0d-02e6-4587-8ca0-4a7b38908288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e87cdb0d-02e6-4587-8ca0-4a7b38908288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_176a615d-15d8-4814-ae24-eab351286542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e87cdb0d-02e6-4587-8ca0-4a7b38908288" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_176a615d-15d8-4814-ae24-eab351286542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_58663ddb-2c68-4407-83e5-02f8c883b1f0" xlink:href="mrk-20221231.xsd#mrk_SanofiPasteurMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_176a615d-15d8-4814-ae24-eab351286542" xlink:to="loc_mrk_SanofiPasteurMember_58663ddb-2c68-4407-83e5-02f8c883b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_af1bc6e3-8221-4b14-a90a-d7e569a40211" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_401be273-4db9-4af6-9f94-0ba2bafdb7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_401be273-4db9-4af6-9f94-0ba2bafdb7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f11c5cb-0eb7-431d-9082-f433bf313dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f11c5cb-0eb7-431d-9082-f433bf313dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1a372100-01e5-46a0-995d-8bfdd51acd92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1a372100-01e5-46a0-995d-8bfdd51acd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_8d600295-8bc3-4e24-bb51-447d1842c0bb" xlink:href="mrk-20221231.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_8d600295-8bc3-4e24-bb51-447d1842c0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0c6d834b-c0df-4a8e-b15b-93971b42db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9e9f5171-0f30-48ea-95ee-6e30e57cef8d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0c6d834b-c0df-4a8e-b15b-93971b42db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b7fb229e-4563-4e5d-b65e-8b1ff802fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b7fb229e-4563-4e5d-b65e-8b1ff802fd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_21db98b6-05e5-42d7-9ab8-48426379bcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6a64fe5d-89e1-4287-9c9d-bd441e005c38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_21db98b6-05e5-42d7-9ab8-48426379bcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#InventoriesInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_071bcbe1-7ec7-42ba-a021-80a85b7893a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:to="loc_us-gaap_InventoryFinishedGoods_071bcbe1-7ec7-42ba-a021-80a85b7893a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_85693e00-a0de-4f2a-ad9e-7e2e7d70ce65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_85693e00-a0de-4f2a-ad9e-7e2e7d70ce65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_92a112da-e44a-4654-8a76-1eb639c59611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:to="loc_us-gaap_OtherInventorySupplies_92a112da-e44a-4654-8a76-1eb639c59611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_dd8a7d9d-5d52-49f8-9ad3-22662b8488a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:to="loc_us-gaap_InventoryGross_dd8a7d9d-5d52-49f8-9ad3-22662b8488a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_d8af9fb5-280e-4bea-ba89-9b6ea65e41d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:to="loc_us-gaap_InventoryLIFOReserve_d8af9fb5-280e-4bea-ba89-9b6ea65e41d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_9f5d22e6-d86a-491d-833e-e9d52ec01577" xlink:href="mrk-20221231.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:to="loc_mrk_InventoryNetAndInventoryNoncurrent_9f5d22e6-d86a-491d-833e-e9d52ec01577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract_de18525c-3da1-4163-9ccd-53d0c61fceb2" xlink:href="mrk-20221231.xsd#mrk_RecognizedAsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3562bd90-5394-4fab-a44b-14fa1710e4e3" xlink:to="loc_mrk_RecognizedAsAbstract_de18525c-3da1-4163-9ccd-53d0c61fceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f6df5d99-d323-4c0a-ab6f-0cdc1f3b0b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_de18525c-3da1-4163-9ccd-53d0c61fceb2" xlink:to="loc_us-gaap_InventoryNet_f6df5d99-d323-4c0a-ab6f-0cdc1f3b0b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_15f360a9-fb95-4544-adfd-944f709b0e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_de18525c-3da1-4163-9ccd-53d0c61fceb2" xlink:to="loc_us-gaap_InventoryNoncurrent_15f360a9-fb95-4544-adfd-944f709b0e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20221231.xsd#InventoriesInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_aa41751e-1d00-4aee-9f2d-ff603736a8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_08ba5ce7-ad97-428b-947e-793c41cfcc63" xlink:href="mrk-20221231.xsd#mrk_InventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa41751e-1d00-4aee-9f2d-ff603736a8e5" xlink:to="loc_mrk_InventoryTable_08ba5ce7-ad97-428b-947e-793c41cfcc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_a8c38dbf-c34a-49d7-91ee-e06816c3d680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_08ba5ce7-ad97-428b-947e-793c41cfcc63" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_a8c38dbf-c34a-49d7-91ee-e06816c3d680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_a8c38dbf-c34a-49d7-91ee-e06816c3d680" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ae526020-1be8-4d18-b217-0ee4a979bf56" xlink:href="mrk-20221231.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ae526020-1be8-4d18-b217-0ee4a979bf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02b72f5d-d042-4b44-9866-13483f598b30" xlink:href="mrk-20221231.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_3859918f-51ea-4c16-ab18-af89494b1d4d" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02b72f5d-d042-4b44-9866-13483f598b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_08ba5ce7-ad97-428b-947e-793c41cfcc63" xlink:to="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LIFOInventoryAmount_de961a9a-9b40-418c-bb65-a60e5e9f3c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LIFOInventoryAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:to="loc_us-gaap_LIFOInventoryAmount_de961a9a-9b40-418c-bb65-a60e5e9f3c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8ec7dca3-3017-4d7c-b4ec-d567ef30671b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_03fc1bba-893f-420e-b197-e8e5504aa8be" xlink:to="loc_us-gaap_InventoryNoncurrent_8ec7dca3-3017-4d7c-b4ec-d567ef30671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7472beca-81f1-4212-bc3c-e24239c7fdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6fc3f69e-3bbe-49ac-8d74-d9ffecd11dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7472beca-81f1-4212-bc3c-e24239c7fdb6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6fc3f69e-3bbe-49ac-8d74-d9ffecd11dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6fc3f69e-3bbe-49ac-8d74-d9ffecd11dc9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_33eb3d3e-54b3-4fd2-a7d6-1ab53ca7b830" xlink:to="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_0103491f-96ea-431a-a811-ab3758eda7a1" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:to="loc_mrk_PharmaceuticalsegmentMember_0103491f-96ea-431a-a811-ab3758eda7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_c9784f97-c766-4c69-aaa9-4fcd32e2a2d7" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_029aeaf0-010d-4c29-8ddd-1ce215f76a28" xlink:to="loc_mrk_AnimalHealthsegmentMember_c9784f97-c766-4c69-aaa9-4fcd32e2a2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6fc3f69e-3bbe-49ac-8d74-d9ffecd11dc9" xlink:to="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:to="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9a1cad1-3942-491d-84a6-2919f7f9aff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:to="loc_us-gaap_Goodwill_f9a1cad1-3942-491d-84a6-2919f7f9aff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_e85c3ac8-6cd9-4643-9155-19483267b5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_e85c3ac8-6cd9-4643-9155-19483267b5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_c184159e-9543-46c2-b2e8-5c667ae7db7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_c184159e-9543-46c2-b2e8-5c667ae7db7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_28600b6c-098a-4c71-900c-ca3d53993a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b39b1686-d4ff-4c04-8f7a-557fc13db896" xlink:to="loc_us-gaap_Goodwill_28600b6c-098a-4c71-900c-ca3d53993a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e67582d4-03f5-49fc-b94e-d98691be2229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_307018e5-3ba0-40e4-a78a-0a3e3c3b4673" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e67582d4-03f5-49fc-b94e-d98691be2229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301f3a31-570a-4a4b-afec-3039649c323a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:href="mrk-20221231.xsd#mrk_ScheduleOfOtherIntangiblesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301f3a31-570a-4a4b-afec-3039649c323a" xlink:to="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fe23510-becc-4ac1-a596-86d026f9fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fe23510-becc-4ac1-a596-86d026f9fcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7fe23510-becc-4ac1-a596-86d026f9fcc7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0228eb62-1c22-47bc-87dd-082e78d95a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0228eb62-1c22-47bc-87dd-082e78d95a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_e1b9932d-a929-454f-be90-21a9158cdd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:to="loc_us-gaap_TradeNamesMember_e1b9932d-a929-454f-be90-21a9158cdd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_56f35b53-3259-464b-8527-ad83a623d8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_27f6e856-b2e2-4023-b3be-e926ec852728" xlink:to="loc_us-gaap_LicenseMember_56f35b53-3259-464b-8527-ad83a623d8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4b447c77-5581-4f8d-8bf3-a5de82d4e734" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_srt_ProductOrServiceAxis_4b447c77-5581-4f8d-8bf3-a5de82d4e734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4b447c77-5581-4f8d-8bf3-a5de82d4e734" xlink:to="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_07f21459-33fb-4d9c-9509-ba6a8a249eb7" xlink:href="mrk-20221231.xsd#mrk_ReblozylMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_ReblozylMember_07f21459-33fb-4d9c-9509-ba6a8a249eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_c2124652-f558-42e9-8a8c-e75e7c4492f7" xlink:href="mrk-20221231.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_ZerbaxaMember_c2124652-f558-42e9-8a8c-e75e7c4492f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_257833fc-d269-455b-87e9-45268ca15cf4" xlink:href="mrk-20221231.xsd#mrk_SivextroMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_SivextroMember_257833fc-d269-455b-87e9-45268ca15cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_d808315b-f06b-425d-b39c-3cd4c6327e58" xlink:href="mrk-20221231.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_GardasilGardasil9Member_d808315b-f06b-425d-b39c-3cd4c6327e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_e4cfcf7f-4b84-4772-b4cd-84f3f37f0edc" xlink:href="mrk-20221231.xsd#mrk_BridionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_BridionMember_e4cfcf7f-4b84-4772-b4cd-84f3f37f0edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthMember_91782941-08d1-4cc4-8f92-8de12dbdc782" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_AnimalHealthMember_91782941-08d1-4cc4-8f92-8de12dbdc782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_d8db7ced-7d86-44af-b7e2-7bd4049a2c40" xlink:href="mrk-20221231.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_LynparzaMember_d8db7ced-7d86-44af-b7e2-7bd4049a2c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_a87a8ba7-6ebe-4dd0-b69a-577d3b84a29d" xlink:href="mrk-20221231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_LenvimaMember_a87a8ba7-6ebe-4dd0-b69a-577d3b84a29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_df1fe082-5624-4109-b27a-331136c67ec9" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_AdempasMember_df1fe082-5624-4109-b27a-331136c67ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_COVID19Member_e68a1ba7-fe28-4504-80be-4cc3dd732ff3" xlink:href="mrk-20221231.xsd#mrk_COVID19Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_COVID19Member_e68a1ba7-fe28-4504-80be-4cc3dd732ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SotaterceptMember_b41b45e4-989b-4fa6-91fa-b62bd88ca282" xlink:href="mrk-20221231.xsd#mrk_SotaterceptMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_SotaterceptMember_b41b45e4-989b-4fa6-91fa-b62bd88ca282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NemtabrutinibMember_0e780d1f-e861-45c6-a20e-e3d4497618eb" xlink:href="mrk-20221231.xsd#mrk_NemtabrutinibMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_NemtabrutinibMember_0e780d1f-e861-45c6-a20e-e3d4497618eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GefapixantMember_9395dd90-5567-4924-8b77-9d37f282695d" xlink:href="mrk-20221231.xsd#mrk_GefapixantMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_GefapixantMember_9395dd90-5567-4924-8b77-9d37f282695d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DerazantinibMember_82f9dcf7-cab6-4f4d-adc5-4886a2d6e22c" xlink:href="mrk-20221231.xsd#mrk_DerazantinibMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_58628a8b-32fd-4d76-acbe-6b39c005763b" xlink:to="loc_mrk_DerazantinibMember_82f9dcf7-cab6-4f4d-adc5-4886a2d6e22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3c217f25-c06d-4d8c-9022-c82356475cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3c217f25-c06d-4d8c-9022-c82356475cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f3203561-e92a-4c40-bc25-a4a316f1a2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c217f25-c06d-4d8c-9022-c82356475cc1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f3203561-e92a-4c40-bc25-a4a316f1a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_24252713-1785-4745-a022-b31d23f801e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f3203561-e92a-4c40-bc25-a4a316f1a2d0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_24252713-1785-4745-a022-b31d23f801e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_68144daa-caed-4840-9f84-96e9d5f848c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_68144daa-caed-4840-9f84-96e9d5f848c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8bb9a174-b603-436a-887c-069658de63c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_68144daa-caed-4840-9f84-96e9d5f848c1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8bb9a174-b603-436a-887c-069658de63c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_25e11216-1fb8-4482-86b7-aa178f2e857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8bb9a174-b603-436a-887c-069658de63c5" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_25e11216-1fb8-4482-86b7-aa178f2e857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_16047a39-e988-4f88-8939-618a5fa21119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_ValuationTechniqueAxis_16047a39-e988-4f88-8939-618a5fa21119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_3203382d-7f92-463c-86a2-0a5fc986d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_16047a39-e988-4f88-8939-618a5fa21119" xlink:to="loc_us-gaap_ValuationTechniqueDomain_3203382d-7f92-463c-86a2-0a5fc986d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_5b0bd21d-e8d6-4f68-a168-91bb29b3b02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_3203382d-7f92-463c-86a2-0a5fc986d48b" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_5b0bd21d-e8d6-4f68-a168-91bb29b3b02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21400930-89b8-4e8f-8868-edd6e95e6e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21400930-89b8-4e8f-8868-edd6e95e6e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d20e092-e640-4a75-bfc1-0ac7d84acc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21400930-89b8-4e8f-8868-edd6e95e6e4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d20e092-e640-4a75-bfc1-0ac7d84acc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_41d774e7-3b15-44cf-98e2-7e544093e3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d20e092-e640-4a75-bfc1-0ac7d84acc4a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_41d774e7-3b15-44cf-98e2-7e544093e3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6e94ad2a-2985-45bc-b32a-387b6f240ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6e94ad2a-2985-45bc-b32a-387b6f240ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_481d898c-b761-42cc-9022-bcac3e627857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6e94ad2a-2985-45bc-b32a-387b6f240ab4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_481d898c-b761-42cc-9022-bcac3e627857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_bb429787-00df-450d-b030-0f45ea9ddeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_481d898c-b761-42cc-9022-bcac3e627857" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_bb429787-00df-450d-b030-0f45ea9ddeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetsExcludingGoodwillLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ScheduleOfOtherIntangiblesTable_bc183b43-f781-4936-aea5-0e00debca3de" xlink:to="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8e2b3fe1-f503-471e-969d-3914c8e1a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8e2b3fe1-f503-471e-969d-3914c8e1a537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_262525be-2ddb-4c26-8626-06d28c8f7e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_262525be-2ddb-4c26-8626-06d28c8f7e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1f44f43-0f3c-4a35-8e68-e04b8d56fdda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1f44f43-0f3c-4a35-8e68-e04b8d56fdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3954b6ff-1ee8-4e8d-8911-79b3fcd720c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3954b6ff-1ee8-4e8d-8911-79b3fcd720c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_30a7a527-3e15-48db-afe0-acc630efea80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_InventoryWriteDown_30a7a527-3e15-48db-afe0-acc630efea80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_82697fb6-9259-4b96-b4ef-af646b411a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_82697fb6-9259-4b96-b4ef-af646b411a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b0c92d40-6647-4832-aaa6-94bc13d0a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b0c92d40-6647-4832-aaa6-94bc13d0a3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6363a2c3-3297-4c10-bc1b-352d9e2148a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6363a2c3-3297-4c10-bc1b-352d9e2148a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_503abaf9-d62b-412d-9bcc-001212550e7d" xlink:href="mrk-20221231.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_503abaf9-d62b-412d-9bcc-001212550e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f790a693-df64-4ff3-8b77-e75ae3481d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f790a693-df64-4ff3-8b77-e75ae3481d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9a99a80b-f057-48b0-be53-cb81b2c59a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9a99a80b-f057-48b0-be53-cb81b2c59a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dfbb051c-f628-4774-9c26-dbe1f2376965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dfbb051c-f628-4774-9c26-dbe1f2376965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8e0af329-0797-496b-bff6-f3e95e7233e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8e0af329-0797-496b-bff6-f3e95e7233e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_37b649c2-25ed-4d27-9640-7eb9ce10cc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_37b649c2-25ed-4d27-9640-7eb9ce10cc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_188cc83a-49f6-4e48-aa5b-3a852f934b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_188cc83a-49f6-4e48-aa5b-3a852f934b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1e259a30-08c0-4a3a-8d05-d47fb108b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IntangibleAssetsExcludingGoodwillLineItems_08543f23-e2bb-436a-af3d-9af2f3675810" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1e259a30-08c0-4a3a-8d05-d47fb108b3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#GoodwillandOtherIntangiblesOtherIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ee65d0d0-d201-4df3-a398-ecee076161ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ee65d0d0-d201-4df3-a398-ecee076161ee" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4e92575b-a4bb-4105-a25e-60f7ac755093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4e92575b-a4bb-4105-a25e-60f7ac755093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4e92575b-a4bb-4105-a25e-60f7ac755093" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6ebb9dce-4992-413c-9c50-e6908154f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6ebb9dce-4992-413c-9c50-e6908154f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_579bcbd9-3215-43c7-8a9d-c07909deafae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_TradeNamesMember_579bcbd9-3215-43c7-8a9d-c07909deafae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_df7ebc95-bf98-4337-8ac6-8f6f4229c69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_df7ebc95-bf98-4337-8ac6-8f6f4229c69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_14e80f31-e404-4f31-87e7-05c2bd78e390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8e60886-3b2b-46d6-ad62-ad2fa02d4ba6" xlink:to="loc_us-gaap_LicenseMember_14e80f31-e404-4f31-87e7-05c2bd78e390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_07d51620-bd1c-40ef-a23e-aaf31c770a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_07d51620-bd1c-40ef-a23e-aaf31c770a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3897a9f7-8ab0-4dc1-b1b4-13d4aa0920ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_07d51620-bd1c-40ef-a23e-aaf31c770a27" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3897a9f7-8ab0-4dc1-b1b4-13d4aa0920ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_57751378-8ac7-4ef2-b8b7-3b0933e90914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3897a9f7-8ab0-4dc1-b1b4-13d4aa0920ff" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_57751378-8ac7-4ef2-b8b7-3b0933e90914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fc0920de-dd59-47f4-9d19-8282c3f7c2f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_81e29f12-af35-49d7-a435-f9b2c747602d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_81e29f12-af35-49d7-a435-f9b2c747602d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02ae90be-2429-43ea-9ea0-5ceb7d7ed74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_02ae90be-2429-43ea-9ea0-5ceb7d7ed74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_831ad375-f5c5-4a29-85a3-02a59f8897c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eed2d071-7a83-46a3-8597-c9adb54082ce" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_831ad375-f5c5-4a29-85a3-02a59f8897c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_97b91a31-4a4b-4b7c-820e-02772a7c90f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97b91a31-4a4b-4b7c-820e-02772a7c90f3" xlink:to="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1068bd7-9763-43b7-bc71-1b2f2d2dd889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1068bd7-9763-43b7-bc71-1b2f2d2dd889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1068bd7-9763-43b7-bc71-1b2f2d2dd889" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_f8aefe01-4d81-4324-b5d7-5b161d7a0a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:to="loc_us-gaap_BuildingMember_f8aefe01-4d81-4324-b5d7-5b161d7a0a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_24f5c317-fc60-4e28-a495-26b39e73aed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_668a8c32-35bc-4615-bad9-a86de9fb6620" xlink:to="loc_us-gaap_VehiclesMember_24f5c317-fc60-4e28-a495-26b39e73aed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_875cdd40-a493-4373-ab6d-34ba80a8f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_875cdd40-a493-4373-ab6d-34ba80a8f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_875cdd40-a493-4373-ab6d-34ba80a8f2b8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b9bb4e18-f63a-405a-911a-47f2caaad357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:to="loc_us-gaap_CommercialPaperMember_b9bb4e18-f63a-405a-911a-47f2caaad357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_1c036656-32f5-4fe3-b139-6d3aa53971c4" xlink:href="mrk-20221231.xsd#mrk_NotesSubjectToRepaymentAtOptionOfHolderMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_615f91ce-aef5-4e21-b39b-12ce40f18449" xlink:to="loc_mrk_NotesSubjectToRepaymentAtOptionOfHolderMember_1c036656-32f5-4fe3-b139-6d3aa53971c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d07bba3-1545-4d62-95e9-cc875b705d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d07bba3-1545-4d62-95e9-cc875b705d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d07bba3-1545-4d62-95e9-cc875b705d2a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherVariableRateDebtMember_fc35c2ae-967a-4020-8843-f9667b24daaf" xlink:href="mrk-20221231.xsd#mrk_OtherVariableRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_OtherVariableRateDebtMember_fc35c2ae-967a-4020-8843-f9667b24daaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_65ebd8bd-e58e-4dde-b637-e19ef7863198" xlink:href="mrk-20221231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A63DebenturesDue2026Member_65ebd8bd-e58e-4dde-b637-e19ef7863198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_c272b745-2f66-4883-befd-70acb418f960" xlink:href="mrk-20221231.xsd#mrk_A170NotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A170NotesDue2027Member_c272b745-2f66-4883-befd-70acb418f960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_407d49e6-cdb0-4002-9e7c-238d1a6b7783" xlink:href="mrk-20221231.xsd#mrk_A190NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A190NotesDue2028Member_407d49e6-cdb0-4002-9e7c-238d1a6b7783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_94b3229f-cc44-4aeb-8520-5a934d68a1af" xlink:href="mrk-20221231.xsd#mrk_A215NotesDue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A215NotesDue2031Member_94b3229f-cc44-4aeb-8520-5a934d68a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_4112927f-1aee-4354-825d-dbf2dc4eec49" xlink:href="mrk-20221231.xsd#mrk_A275NotesDue2051Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A275NotesDue2051Member_4112927f-1aee-4354-825d-dbf2dc4eec49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_e8d27bd6-672f-45f8-aa9a-13cc0942af4c" xlink:href="mrk-20221231.xsd#mrk_A290NotesDue2061Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cfcfac8-11dd-4f19-9b75-a1f93cf0cda8" xlink:to="loc_mrk_A290NotesDue2061Member_e8d27bd6-672f-45f8-aa9a-13cc0942af4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_443eb018-6f0b-4359-a099-ce8d2994bb2e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cf018298-a318-4499-9510-b56c013cbc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtCurrent_cf018298-a318-4499-9510-b56c013cbc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_a66e6cee-4757-40d6-af4c-b101e9a7fd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_DebtCurrent_a66e6cee-4757-40d6-af4c-b101e9a7fd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_bfd64cf9-6d44-4001-b249-b143e5e961e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_bfd64cf9-6d44-4001-b249-b143e5e961e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_f98c508f-27f2-4d5f-9865-d61e4cc775fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_f98c508f-27f2-4d5f-9865-d61e4cc775fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69b2e80c-8e86-4c69-9163-d83ac5613ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69b2e80c-8e86-4c69-9163-d83ac5613ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_341041e2-beb7-4da5-8ee4-dd27d9770451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_341041e2-beb7-4da5-8ee4-dd27d9770451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_49006496-840b-4988-a42e-ef43d155469c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_49006496-840b-4988-a42e-ef43d155469c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce14a72d-ceff-4d73-81aa-7c047ced88c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce14a72d-ceff-4d73-81aa-7c047ced88c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_872bc98d-5453-41f6-9b36-b036c3e514b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_872bc98d-5453-41f6-9b36-b036c3e514b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_777cfb76-1f5e-4e17-be4d-2b19f9c014a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_777cfb76-1f5e-4e17-be4d-2b19f9c014a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearOne_614ec4c6-c2ac-4bad-b838-dd95dd21ef78" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearOne_614ec4c6-c2ac-4bad-b838-dd95dd21ef78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearTwo_facf6faa-d469-421b-bfe6-139f039582bf" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearTwo_facf6faa-d469-421b-bfe6-139f039582bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearThree_8b7c5207-1e78-4dac-b8fb-2dcb24598939" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearThree"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearThree_8b7c5207-1e78-4dac-b8fb-2dcb24598939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFour_526181c3-e142-4d79-8157-8d190261ec77" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearFour"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFour_526181c3-e142-4d79-8157-8d190261ec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtInterestPayableYearFive_ecf32233-8a3b-48a5-a515-3f894bb46b97" xlink:href="mrk-20221231.xsd#mrk_LongTermDebtInterestPayableYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LongTermDebtInterestPayableYearFive_ecf32233-8a3b-48a5-a515-3f894bb46b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efb7b920-c789-4946-ab30-7d26106c17ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efb7b920-c789-4946-ab30-7d26106c17ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c88057cb-9ba2-4735-ab40-4ffaefa93ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c88057cb-9ba2-4735-ab40-4ffaefa93ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0e2d9833-cf9b-441d-a860-7d67f2aa9357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0e2d9833-cf9b-441d-a860-7d67f2aa9357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c4ef106e-6037-45bf-a908-65d25b1352c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_OperatingLeaseCost_c4ef106e-6037-45bf-a908-65d25b1352c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2100b9cd-905a-4c11-b3f4-683cc4cbf965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_OperatingLeasePayments_2100b9cd-905a-4c11-b3f4-683cc4cbf965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3bbdbf42-b9e3-431e-aacd-3e24414a6ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3bbdbf42-b9e3-431e-aacd-3e24414a6ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_587df8d3-5fe8-4f28-a89e-39a40454018c" xlink:href="mrk-20221231.xsd#mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount_587df8d3-5fe8-4f28-a89e-39a40454018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d69a1958-dd69-4ffe-ac3d-de4fc50fabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_454a2124-3263-4c7e-b3f6-8763da3a6a4e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d69a1958-dd69-4ffe-ac3d-de4fc50fabdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ac91423f-0465-4c8e-81ff-8300f7dcad29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9e1da8ac-d0c0-4147-bdee-5fd8d8a860e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ac91423f-0465-4c8e-81ff-8300f7dcad29" xlink:to="loc_us-gaap_DebtInstrumentTable_9e1da8ac-d0c0-4147-bdee-5fd8d8a860e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b215f657-0df8-49b8-a903-6f9b9ba38ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9e1da8ac-d0c0-4147-bdee-5fd8d8a860e3" xlink:to="loc_us-gaap_DebtInstrumentAxis_b215f657-0df8-49b8-a903-6f9b9ba38ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b215f657-0df8-49b8-a903-6f9b9ba38ef6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.75NotesDue2025Member_7c25df6c-3286-458a-8635-623618aa784e" xlink:href="mrk-20221231.xsd#mrk_A2.75NotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A2.75NotesDue2025Member_7c25df6c-3286-458a-8635-623618aa784e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A215NotesDue2031Member_47e835f3-4711-4648-bb57-8ff6b417e286" xlink:href="mrk-20221231.xsd#mrk_A215NotesDue2031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A215NotesDue2031Member_47e835f3-4711-4648-bb57-8ff6b417e286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A275NotesDue2051Member_2f2a2277-5bb2-4f1c-8463-ea8bb009c4d1" xlink:href="mrk-20221231.xsd#mrk_A275NotesDue2051Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A275NotesDue2051Member_2f2a2277-5bb2-4f1c-8463-ea8bb009c4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.70NotesDue2045Member_de92bc4e-4686-4a6a-9a9c-f66cec5125af" xlink:href="mrk-20221231.xsd#mrk_A3.70NotesDue2045Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A3.70NotesDue2045Member_de92bc4e-4686-4a6a-9a9c-f66cec5125af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.40NotesDue2029Member_5fcfb824-90f7-4488-b1f7-deba86dd9ea8" xlink:href="mrk-20221231.xsd#mrk_A3.40NotesDue2029Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A3.40NotesDue2029Member_5fcfb824-90f7-4488-b1f7-deba86dd9ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A170NotesDue2027Member_29f6c2a8-804d-4cb4-b61f-c5c67a2c4883" xlink:href="mrk-20221231.xsd#mrk_A170NotesDue2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A170NotesDue2027Member_29f6c2a8-804d-4cb4-b61f-c5c67a2c4883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A290NotesDue2061Member_dcdd9f08-9823-4ac8-adec-eef55bf04e25" xlink:href="mrk-20221231.xsd#mrk_A290NotesDue2061Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A290NotesDue2061Member_dcdd9f08-9823-4ac8-adec-eef55bf04e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A4.00NotesDue2049Member_b098a8b1-3a2c-4410-b804-8838ea1cc463" xlink:href="mrk-20221231.xsd#mrk_A4.00NotesDue2049Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A4.00NotesDue2049Member_b098a8b1-3a2c-4410-b804-8838ea1cc463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A415NotesDue2043Member_b47ea4eb-4c1b-4807-a9c5-7ead5506bf3a" xlink:href="mrk-20221231.xsd#mrk_A415NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A415NotesDue2043Member_b47ea4eb-4c1b-4807-a9c5-7ead5506bf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A145NotesDue2030Member_781d2fa6-cbf7-4e9b-88eb-c479411417b0" xlink:href="mrk-20221231.xsd#mrk_A145NotesDue2030Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A145NotesDue2030Member_781d2fa6-cbf7-4e9b-88eb-c479411417b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A245NotesDue2050Member_04e53b79-10cd-4024-b28e-2762848b04c8" xlink:href="mrk-20221231.xsd#mrk_A245NotesDue2050Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A245NotesDue2050Member_04e53b79-10cd-4024-b28e-2762848b04c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875EuroNotesDue2026Member_754f7718-a589-4aa4-8caa-61586df301f0" xlink:href="mrk-20221231.xsd#mrk_A1.875EuroNotesDue2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A1.875EuroNotesDue2026Member_754f7718-a589-4aa4-8caa-61586df301f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A075NotesDue2026Member_4db37f42-80ea-4983-8df5-170f6cbbbd03" xlink:href="mrk-20221231.xsd#mrk_A075NotesDue2026Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A075NotesDue2026Member_4db37f42-80ea-4983-8df5-170f6cbbbd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A190NotesDue2028Member_1d0a86e4-7e3e-4a55-89cc-2b9ce49abcc9" xlink:href="mrk-20221231.xsd#mrk_A190NotesDue2028Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A190NotesDue2028Member_1d0a86e4-7e3e-4a55-89cc-2b9ce49abcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.90NotesDue2039Member_030d216c-98ec-428d-a463-edab783f26e7" xlink:href="mrk-20221231.xsd#mrk_A3.90NotesDue2039Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A3.90NotesDue2039Member_030d216c-98ec-428d-a463-edab783f26e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A235NotesDue2040Member_f2643fe9-8ed1-4aeb-a3e3-0ee245563fa3" xlink:href="mrk-20221231.xsd#mrk_A235NotesDue2040Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A235NotesDue2040Member_f2643fe9-8ed1-4aeb-a3e3-0ee245563fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.90NotesDue2024Member_5bb490f3-7563-4d18-b31f-47aa0cb8deb6" xlink:href="mrk-20221231.xsd#mrk_A2.90NotesDue2024Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A2.90NotesDue2024Member_5bb490f3-7563-4d18-b31f-47aa0cb8deb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_668a7f56-57a3-4d53-be72-4b43b3674908" xlink:href="mrk-20221231.xsd#mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember_668a7f56-57a3-4d53-be72-4b43b3674908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.50eurodenominatednotesdue2024Member_f3ce675d-2744-45ed-82e6-4a31a2a34266" xlink:href="mrk-20221231.xsd#mrk_A0.50eurodenominatednotesdue2024Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A0.50eurodenominatednotesdue2024Member_f3ce675d-2744-45ed-82e6-4a31a2a34266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375eurodenominatednotesdue2036Member_27d471cd-ccb9-4b35-9989-a1edeb09435a" xlink:href="mrk-20221231.xsd#mrk_A1.375eurodenominatednotesdue2036Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A1.375eurodenominatednotesdue2036Member_27d471cd-ccb9-4b35-9989-a1edeb09435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.5EuroNotesDue2034Member_9568eec4-c3fb-48d3-b2e9-62ed4f275fd5" xlink:href="mrk-20221231.xsd#mrk_A2.5EuroNotesDue2034Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A2.5EuroNotesDue2034Member_9568eec4-c3fb-48d3-b2e9-62ed4f275fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_9f2d503d-bae6-4dd1-8fe8-9cd0d9a81c84" xlink:href="mrk-20221231.xsd#mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember_9f2d503d-bae6-4dd1-8fe8-9cd0d9a81c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_10b9fa0b-4c5f-4f20-b119-dad309523e56" xlink:href="mrk-20221231.xsd#mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember_10b9fa0b-4c5f-4f20-b119-dad309523e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_d432c494-0ff3-4a08-b31f-b5da2da798df" xlink:href="mrk-20221231.xsd#mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember_d432c494-0ff3-4a08-b31f-b5da2da798df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_be57009e-bf67-40f8-a0c4-88ea833a4322" xlink:href="mrk-20221231.xsd#mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember_be57009e-bf67-40f8-a0c4-88ea833a4322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_cd5e9ec0-ea5a-48b6-aeed-83debb08e923" xlink:href="mrk-20221231.xsd#mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember_cd5e9ec0-ea5a-48b6-aeed-83debb08e923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_7caf6626-e5b6-4733-b9b7-f89b9a97d902" xlink:href="mrk-20221231.xsd#mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember_7caf6626-e5b6-4733-b9b7-f89b9a97d902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A63DebenturesDue2026Member_d4e0cd99-c537-4d27-bcea-d770b89a8ee2" xlink:href="mrk-20221231.xsd#mrk_A63DebenturesDue2026Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A63DebenturesDue2026Member_d4e0cd99-c537-4d27-bcea-d770b89a8ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A280NotesDue2023Member_745d73fb-0c4a-402d-ad58-3236ed075084" xlink:href="mrk-20221231.xsd#mrk_A280NotesDue2023Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_A280NotesDue2023Member_745d73fb-0c4a-402d-ad58-3236ed075084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherLongTermDebtMember_46ad70dd-4439-4b2f-8200-4141aa07eec3" xlink:href="mrk-20221231.xsd#mrk_OtherLongTermDebtMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_568f4d8b-81ea-4b23-9862-df56106834ae" xlink:to="loc_mrk_OtherLongTermDebtMember_46ad70dd-4439-4b2f-8200-4141aa07eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9e1da8ac-d0c0-4147-bdee-5fd8d8a860e3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eaf290d3-c944-4e97-ba7e-faad0800b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eaf290d3-c944-4e97-ba7e-faad0800b9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_95fa4f5d-873c-482a-8e61-b3d817fe4d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba5385e-33b0-439f-a9ab-58d9f994d784" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_95fa4f5d-873c-482a-8e61-b3d817fe4d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe97b9ee-f7d3-4ae2-b7b1-ac27ee3ad735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe97b9ee-f7d3-4ae2-b7b1-ac27ee3ad735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a40bc4ae-e5a2-4dec-b6d1-7b33dadb18e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a40bc4ae-e5a2-4dec-b6d1-7b33dadb18e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4eee4b16-aff4-4486-b311-6544c8c67ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4eee4b16-aff4-4486-b311-6544c8c67ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8eb6e549-e031-49a7-9526-22ad6e56b5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8eb6e549-e031-49a7-9526-22ad6e56b5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_71e21dc2-3e96-4dc3-904b-a7c257e6a6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_71e21dc2-3e96-4dc3-904b-a7c257e6a6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c10262d2-4ae9-439d-93e8-ceb44f9ae978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c10262d2-4ae9-439d-93e8-ceb44f9ae978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eb4902cd-d50b-4432-a030-ff36850432e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseLiability_eb4902cd-d50b-4432-a030-ff36850432e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_374b2346-7aad-466b-871e-a51450edddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_374b2346-7aad-466b-871e-a51450edddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_51fbc5ad-0b6c-4bda-b9c0-7e7f0350bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12576265-3cdb-4ba8-b59e-65864cf79330" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_51fbc5ad-0b6c-4bda-b9c0-7e7f0350bd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ebab3bc8-e41a-495e-8bf0-b1474a27e0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ebab3bc8-e41a-495e-8bf0-b1474a27e0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fde92def-41e1-46ac-a37a-b9ac9e131a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fde92def-41e1-46ac-a37a-b9ac9e131a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d41a5ff9-4439-4f1f-94ba-4beaf09ac621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d41a5ff9-4439-4f1f-94ba-4beaf09ac621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b1e175eb-56b2-496f-b678-57bf2b15f914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b1e175eb-56b2-496f-b678-57bf2b15f914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6586ae61-f99d-4d48-87d8-8330cb6c2da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6586ae61-f99d-4d48-87d8-8330cb6c2da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c726d101-adae-4769-9538-33931f604b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c726d101-adae-4769-9538-33931f604b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6abb06c9-35a3-4d79-a51b-4823d9f64cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6abb06c9-35a3-4d79-a51b-4823d9f64cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3927264b-ff95-4f40-a09e-2f3170817c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3927264b-ff95-4f40-a09e-2f3170817c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ac4fd580-5cc8-4c75-afbd-ac4aa10bc5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a68c560a-8b22-4a2f-a34e-fd411ca4274f" xlink:to="loc_us-gaap_OperatingLeaseLiability_ac4fd580-5cc8-4c75-afbd-ac4aa10bc5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="simple" xlink:href="mrk-20221231.xsd#LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ContingenciesandEnvironmentalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20908f25-fde3-4ba9-ada8-e01db9bf462a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20908f25-fde3-4ba9-ada8-e01db9bf462a" xlink:to="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31babfd9-0d25-4afa-bba0-0c6e32b381b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_srt_ProductOrServiceAxis_31babfd9-0d25-4afa-bba0-0c6e32b381b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_31babfd9-0d25-4afa-bba0-0c6e32b381b8" xlink:to="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_62f5feb3-775c-46e0-92f6-60c8c1f1c2bc" xlink:href="mrk-20221231.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:to="loc_mrk_GardasilGardasil9Member_62f5feb3-775c-46e0-92f6-60c8c1f1c2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_e5616561-3344-474f-b17d-61d7661676a7" xlink:href="mrk-20221231.xsd#mrk_BridionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9d3182bf-8801-4584-b485-e32a12af9ac4" xlink:to="loc_mrk_BridionMember_e5616561-3344-474f-b17d-61d7661676a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_950584e7-7289-45da-95a7-a96cc7115152" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_srt_LitigationCaseAxis_950584e7-7289-45da-95a7-a96cc7115152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_950584e7-7289-45da-95a7-a96cc7115152" xlink:to="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_d44ca854-9af8-472a-88ab-55407eddabd3" xlink:href="mrk-20221231.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_d44ca854-9af8-472a-88ab-55407eddabd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_059fbb7f-b69d-4565-af81-e11ffa12fd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4f99ed80-868a-4c83-877c-76776ada1837" xlink:to="loc_us-gaap_PatentsMember_059fbb7f-b69d-4565-af81-e11ffa12fd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b831b447-12a0-48ba-9513-9cc6b5fdb4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b831b447-12a0-48ba-9513-9cc6b5fdb4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b831b447-12a0-48ba-9513-9cc6b5fdb4c9" xlink:to="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialandOtherLitigationMember_14cb37c5-c545-4b65-977c-2022b097ba9e" xlink:href="mrk-20221231.xsd#mrk_CommercialandOtherLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:to="loc_mrk_CommercialandOtherLitigationMember_14cb37c5-c545-4b65-977c-2022b097ba9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PatentlitigationMember_c123f966-134a-4fb8-b11d-9a1e75f946e6" xlink:href="mrk-20221231.xsd#mrk_PatentlitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_cdc3be4a-d48b-429f-8e0e-a79e4f647e69" xlink:to="loc_mrk_PatentlitigationMember_c123f966-134a-4fb8-b11d-9a1e75f946e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5ad2b7b1-53bf-44e8-9ca0-03376e454580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5ad2b7b1-53bf-44e8-9ca0-03376e454580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2505fe0f-5ca5-4a5d-8412-40e193823f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5ad2b7b1-53bf-44e8-9ca0-03376e454580" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2505fe0f-5ca5-4a5d-8412-40e193823f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_6f5f7239-96ba-4092-bf68-3d6a4448254a" xlink:href="mrk-20221231.xsd#mrk_LegalDefenseCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2505fe0f-5ca5-4a5d-8412-40e193823f4a" xlink:to="loc_mrk_LegalDefenseCostsMember_6f5f7239-96ba-4092-bf68-3d6a4448254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dcafa351-dad5-44ad-b28d-6aed99b9850b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_srt_StatementGeographicalAxis_dcafa351-dad5-44ad-b28d-6aed99b9850b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dcafa351-dad5-44ad-b28d-6aed99b9850b" xlink:to="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c13371cc-d953-461a-9cda-42717353af32" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:to="loc_country_US_c13371cc-d953-461a-9cda-42717353af32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a698a546-5948-4b3c-9a04-2d4ce4eebb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:to="loc_us-gaap_NonUsMember_a698a546-5948-4b3c-9a04-2d4ce4eebb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO_3c68e27a-269a-447c-b9a0-0e84be0edd32" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dd3f4e4c-dca1-45a9-831c-de06430a77bd" xlink:to="loc_country_CO_3c68e27a-269a-447c-b9a0-0e84be0edd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_744e575e-f70d-424b-9a5c-665fd58917bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_us-gaap_LitigationStatusAxis_744e575e-f70d-424b-9a5c-665fd58917bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3bd4122a-cf11-4115-80d9-02555507a545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_744e575e-f70d-424b-9a5c-665fd58917bd" xlink:to="loc_us-gaap_LitigationStatusDomain_3bd4122a-cf11-4115-80d9-02555507a545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f501a3d5-ab30-41d6-8883-fdad62df539e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3bd4122a-cf11-4115-80d9-02555507a545" xlink:to="loc_us-gaap_PendingLitigationMember_f501a3d5-ab30-41d6-8883-fdad62df539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b65062f9-7792-4d9b-b33a-52911edfb756" xlink:to="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_c22dfa31-5e68-4b2c-a201-62871224738d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_c22dfa31-5e68-4b2c-a201-62871224738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_052ca824-d8b4-4156-8f54-fc78c81ad284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_052ca824-d8b4-4156-8f54-fc78c81ad284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dabee509-91c5-4c15-b37b-adbf83dbd8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_dabee509-91c5-4c15-b37b-adbf83dbd8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_e4320a84-9180-486f-a860-9bc19545fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_e4320a84-9180-486f-a860-9bc19545fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod_37491d60-0420-4497-917a-fdbf4041ec3f" xlink:href="mrk-20221231.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_mrk_LossContingencyTrialPeriod_37491d60-0420-4497-917a-fdbf4041ec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_33f2e6fd-b2db-48a7-a831-cb3e0c743c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_33f2e6fd-b2db-48a7-a831-cb3e0c743c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_b4bccc9f-33f0-4ad2-8797-a46cde88c5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_LitigationReserve_b4bccc9f-33f0-4ad2-8797-a46cde88c5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_d8f5dacc-45bb-41bc-842a-ebb3b1e1cc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_d8f5dacc-45bb-41bc-842a-ebb3b1e1cc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_66a995d3-5a65-4b01-ab82-81318c36ed1f" xlink:href="mrk-20221231.xsd#mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_66a995d3-5a65-4b01-ab82-81318c36ed1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TermForPayingOffEnvironmentalLiabilities_e0b99acb-7769-4518-ac8b-ce762bf1ef01" xlink:href="mrk-20221231.xsd#mrk_TermForPayingOffEnvironmentalLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_mrk_TermForPayingOffEnvironmentalLiabilities_e0b99acb-7769-4518-ac8b-ce762bf1ef01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_e1793f12-6886-4b1d-8c87-dce067288a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_aab5c3c9-c7d5-4072-82cb-48f2a3005306" xlink:to="loc_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss_e1793f12-6886-4b1d-8c87-dce067288a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a06c0b0a-ded0-43c3-b539-686f2d6a646c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_87c42538-0be7-47b2-b3a9-0538359c7681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a06c0b0a-ded0-43c3-b539-686f2d6a646c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_87c42538-0be7-47b2-b3a9-0538359c7681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c829abb2-2f34-443a-8148-5a8b6d60d1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a06c0b0a-ded0-43c3-b539-686f2d6a646c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c829abb2-2f34-443a-8148-5a8b6d60d1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#EquityShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1beec9c6-bc51-4a81-a5ba-498dc7d2d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2251816d-e963-4760-8969-5dc13a8a3697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1beec9c6-bc51-4a81-a5ba-498dc7d2d56e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2251816d-e963-4760-8969-5dc13a8a3697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2251816d-e963-4760-8969-5dc13a8a3697" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f6f3ee4-fcd7-4e7c-a6bb-229ecbbc3ddc" xlink:to="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c503c338-0ece-4751-9011-967d448a2ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:to="loc_us-gaap_CommonStockMember_c503c338-0ece-4751-9011-967d448a2ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_71c5d2e3-2295-40b2-b6a4-c409b9368dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_19fc0406-0a56-4de5-a45a-08b5ad5b68d6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_71c5d2e3-2295-40b2-b6a4-c409b9368dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0dc992a-91a7-41d1-848d-8d72563a4c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2251816d-e963-4760-8969-5dc13a8a3697" xlink:to="loc_us-gaap_ClassOfStockLineItems_f0dc992a-91a7-41d1-848d-8d72563a4c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:href="mrk-20221231.xsd#mrk_MovementinCommonStockandTreasuryStockRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0dc992a-91a7-41d1-848d-8d72563a4c19" xlink:to="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a1e3b064-aa72-4f08-9097-c1e9443ee252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:to="loc_us-gaap_CommonStockSharesIssued_a1e3b064-aa72-4f08-9097-c1e9443ee252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d7d44fa8-99c3-466c-9245-491ec833c1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d7d44fa8-99c3-466c-9245-491ec833c1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_24eff856-f8ea-46d7-a29c-f9453f7112f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_24eff856-f8ea-46d7-a29c-f9453f7112f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cc29a80e-f88d-43d9-9229-3e44855e8724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_MovementinCommonStockandTreasuryStockRollForward_8bf1e855-c27a-46b4-9b6c-88eeaf7151c2" xlink:to="loc_us-gaap_CommonStockSharesIssued_cc29a80e-f88d-43d9-9229-3e44855e8724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e9ea72e-9be5-45f0-93f9-1c239677dadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6b43c32-1175-440c-81ca-59df7e3af641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e9ea72e-9be5-45f0-93f9-1c239677dadb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6b43c32-1175-440c-81ca-59df7e3af641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de9d0df7-05bf-4afa-a846-e197924f10eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6b43c32-1175-440c-81ca-59df7e3af641" xlink:to="loc_srt_RangeAxis_de9d0df7-05bf-4afa-a846-e197924f10eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_de9d0df7-05bf-4afa-a846-e197924f10eb" xlink:to="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62f263f6-7a9a-45d4-af07-44cf7884e782" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:to="loc_srt_MinimumMember_62f263f6-7a9a-45d4-af07-44cf7884e782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_146ed60b-6d25-467a-8597-1b140b0e3de1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f0fe58c-ea2f-4fba-826b-47be28c532de" xlink:to="loc_srt_MaximumMember_146ed60b-6d25-467a-8597-1b140b0e3de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6b43c32-1175-440c-81ca-59df7e3af641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ab93171-4fbe-4b96-93ce-a201311a9ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ab93171-4fbe-4b96-93ce-a201311a9ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d213f08f-351f-4910-9f48-b2b16dbf8506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d213f08f-351f-4910-9f48-b2b16dbf8506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_272de05c-6cf2-4295-979b-2a2656502a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_272de05c-6cf2-4295-979b-2a2656502a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_992e0505-d64c-4e84-9fab-aeccab399d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_992e0505-d64c-4e84-9fab-aeccab399d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c672f130-641f-4e89-bed0-f605130fc8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c672f130-641f-4e89-bed0-f605130fc8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d6d8b4de-3ca7-410f-b3b9-7e11a0850087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensation_d6d8b4de-3ca7-410f-b3b9-7e11a0850087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d056a429-375f-46d7-acb9-7b5000300f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d056a429-375f-46d7-acb9-7b5000300f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a435fceb-52f9-43f4-8a7b-b7f0d87a7e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a435fceb-52f9-43f4-8a7b-b7f0d87a7e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d2108df-2c9d-4388-ac04-2f5cf61a4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9d2108df-2c9d-4388-ac04-2f5cf61a4b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_03f8e331-5d8a-4016-9450-42c51e106f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50a8707b-2771-45ef-874a-788187143f48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_03f8e331-5d8a-4016-9450-42c51e106f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0788572-e266-4045-af35-b58dfa890034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed19f1d6-6824-4523-b32c-08420ccfee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0788572-e266-4045-af35-b58dfa890034" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed19f1d6-6824-4523-b32c-08420ccfee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_62c49ce4-cc00-48de-805a-76aab1290bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0788572-e266-4045-af35-b58dfa890034" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_62c49ce4-cc00-48de-805a-76aab1290bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fe321e82-824d-41b5-a178-ed714ba9f421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0788572-e266-4045-af35-b58dfa890034" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fe321e82-824d-41b5-a178-ed714ba9f421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b3493cb1-b3e1-4617-9e81-c949dbe0b8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0788572-e266-4045-af35-b58dfa890034" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b3493cb1-b3e1-4617-9e81-c949dbe0b8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3e657767-d7aa-4ae8-8fbd-4a9918b68b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b0788572-e266-4045-af35-b58dfa890034" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3e657767-d7aa-4ae8-8fbd-4a9918b68b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9eb5a883-16b5-4ef1-b772-b136f5a31fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9eb5a883-16b5-4ef1-b772-b136f5a31fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1464d80-af34-4b3a-993e-f5b5543ec793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9eb5a883-16b5-4ef1-b772-b136f5a31fed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1464d80-af34-4b3a-993e-f5b5543ec793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_afa035c3-2e41-452d-8889-f1cb585085b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9eb5a883-16b5-4ef1-b772-b136f5a31fed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_afa035c3-2e41-452d-8889-f1cb585085b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eec93137-02bd-4364-9ac6-7d71e6d05c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9eb5a883-16b5-4ef1-b772-b136f5a31fed" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eec93137-02bd-4364-9ac6-7d71e6d05c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ecc7d944-cf8c-4f8e-9b7a-c5ab1a235c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9eb5a883-16b5-4ef1-b772-b136f5a31fed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ecc7d944-cf8c-4f8e-9b7a-c5ab1a235c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6e04e5b2-1684-4e3c-a6cb-1de5962709a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9eb5a883-16b5-4ef1-b772-b136f5a31fed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6e04e5b2-1684-4e3c-a6cb-1de5962709a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f61033ee-3ab0-436a-8acf-b2a82098a12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f61033ee-3ab0-436a-8acf-b2a82098a12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bc682a44-38bc-4bff-9b84-3e37233aaa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bc682a44-38bc-4bff-9b84-3e37233aaa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8bcf8edf-d9fa-4c8d-8889-e36544388055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8bcf8edf-d9fa-4c8d-8889-e36544388055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0617428-d268-4e1f-ae02-a80eb09e6482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8bcf8edf-d9fa-4c8d-8889-e36544388055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0617428-d268-4e1f-ae02-a80eb09e6482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_778df18a-94eb-4166-a77f-73d4ace8e7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8bcf8edf-d9fa-4c8d-8889-e36544388055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_778df18a-94eb-4166-a77f-73d4ace8e7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_469e79a5-c766-4574-8fa9-881ff0201d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8bcf8edf-d9fa-4c8d-8889-e36544388055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_469e79a5-c766-4574-8fa9-881ff0201d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e0b83ebd-d14f-42b1-baa6-5dee47c05eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8bcf8edf-d9fa-4c8d-8889-e36544388055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e0b83ebd-d14f-42b1-baa6-5dee47c05eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eed9d888-76a1-4443-a5a1-a8d7843392a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8bcf8edf-d9fa-4c8d-8889-e36544388055" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eed9d888-76a1-4443-a5a1-a8d7843392a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_275533d1-22bd-47f4-b92f-a282e144db19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_275533d1-22bd-47f4-b92f-a282e144db19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6ddca4a5-370b-4dcb-abfa-30ae8bf2aed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6ddca4a5-370b-4dcb-abfa-30ae8bf2aed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33a37ae4-fd3a-4d1f-985a-bbf1e90a7177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33a37ae4-fd3a-4d1f-985a-bbf1e90a7177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1e56ee1b-6547-46b6-912d-95fc257ea531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1e56ee1b-6547-46b6-912d-95fc257ea531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ea3e35a0-da34-4976-88ce-aa842a04a332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ea3e35a0-da34-4976-88ce-aa842a04a332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3db19406-dba8-4764-9d32-3f2b99d2ec09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3db19406-dba8-4764-9d32-3f2b99d2ec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_232bc781-c4ab-4ee9-9067-6f29d7bd676f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_232bc781-c4ab-4ee9-9067-6f29d7bd676f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_217ba02c-0035-4f57-a674-485f043fb8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd23f3bf-12c0-46f5-b74b-b412c0e647d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_217ba02c-0035-4f57-a674-485f043fb8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62729cf8-13df-484a-8bcb-7f5de3486884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd6c7414-5c0b-4dfe-a3e4-6ebc7e299b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62729cf8-13df-484a-8bcb-7f5de3486884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd6c7414-5c0b-4dfe-a3e4-6ebc7e299b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_99a75f27-ab25-42d6-b9b0-8c28cf2147fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62729cf8-13df-484a-8bcb-7f5de3486884" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_99a75f27-ab25-42d6-b9b0-8c28cf2147fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1d15d7a6-42e8-49d4-ab76-6cb9e7d1f77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62729cf8-13df-484a-8bcb-7f5de3486884" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1d15d7a6-42e8-49d4-ab76-6cb9e7d1f77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27967b1b-bfaf-4964-bc1e-5522fec2e332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_755a3b65-19f4-46d9-84de-15404cbb290c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27967b1b-bfaf-4964-bc1e-5522fec2e332" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_755a3b65-19f4-46d9-84de-15404cbb290c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7683d23e-671d-4c2c-b329-722a0675a423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_755a3b65-19f4-46d9-84de-15404cbb290c" xlink:to="loc_us-gaap_AwardTypeAxis_7683d23e-671d-4c2c-b329-722a0675a423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7683d23e-671d-4c2c-b329-722a0675a423" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62dd52af-e046-49df-9f6a-69c6aecdc293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62dd52af-e046-49df-9f6a-69c6aecdc293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7d73fe8c-94b7-437b-9953-bd86803d9097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66656b15-75bf-454f-a329-908c18ce8b58" xlink:to="loc_us-gaap_PerformanceSharesMember_7d73fe8c-94b7-437b-9953-bd86803d9097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_755a3b65-19f4-46d9-84de-15404cbb290c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4a92bf7-30d4-4776-8c4e-29b3884537a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c4a92bf7-30d4-4776-8c4e-29b3884537a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5081d50f-1591-4146-9646-b6cdf2bb6662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5081d50f-1591-4146-9646-b6cdf2bb6662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0bf85d25-94ff-45e2-99d3-7764f92a5870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0bf85d25-94ff-45e2-99d3-7764f92a5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f228200e-9549-400b-bfc1-8182ee68d7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f228200e-9549-400b-bfc1-8182ee68d7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee601850-bb89-4813-94a0-8dc9934f2539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15dda087-f9f5-4d18-81e0-cb187f08d3d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee601850-bb89-4813-94a0-8dc9934f2539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_09a5fcf6-1a73-4208-bfbf-82aa678145e5" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber_09a5fcf6-1a73-4208-bfbf-82aa678145e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30d29203-0ce2-4ef3-bc49-bd68f040bc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30d29203-0ce2-4ef3-bc49-bd68f040bc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91b777eb-50fc-4759-ac85-3a7091f33896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91b777eb-50fc-4759-ac85-3a7091f33896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1a15e6ee-dc96-4e95-8b20-cbc208b6c649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1a15e6ee-dc96-4e95-8b20-cbc208b6c649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb7e1665-8f12-43af-8e2e-a633b6f76a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb7e1665-8f12-43af-8e2e-a633b6f76a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5d1a5a27-9a21-4b0e-9b66-7f23f662f055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_634fe1d3-482d-4e69-b4fb-7b023d6eb683" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5d1a5a27-9a21-4b0e-9b66-7f23f662f055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_93f2b65c-1caf-44aa-a965-c5c247bbcfd2" xlink:href="mrk-20221231.xsd#mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7047492e-4058-4c3c-8fe9-ab73b4398b69" xlink:to="loc_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue_93f2b65c-1caf-44aa-a965-c5c247bbcfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_48a507a3-1cbf-4830-bfc8-6720b2910601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_48a507a3-1cbf-4830-bfc8-6720b2910601" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_d38fc936-6226-4041-a9c2-453cfb70412a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_d38fc936-6226-4041-a9c2-453cfb70412a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_d38fc936-6226-4041-a9c2-453cfb70412a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_99343e67-d867-4bd0-8560-573430f32050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:to="loc_us-gaap_DomesticPlanMember_99343e67-d867-4bd0-8560-573430f32050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2f654d46-4a0f-4f86-be7f-8047af1c1f5f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_99343e67-d867-4bd0-8560-573430f32050" xlink:to="loc_country_US_2f654d46-4a0f-4f86-be7f-8047af1c1f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_caa85333-4a98-4285-9d4a-9fac3cc4810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7e7cd4ba-5748-4adc-aa2e-62e6edfede6c" xlink:to="loc_us-gaap_ForeignPlanMember_caa85333-4a98-4285-9d4a-9fac3cc4810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e551de9a-e8b5-4843-896b-8da9d0799aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e551de9a-e8b5-4843-896b-8da9d0799aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e551de9a-e8b5-4843-896b-8da9d0799aa4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_cdeaa778-20f3-4619-bb19-ac08a2c70dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_cdeaa778-20f3-4619-bb19-ac08a2c70dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_013fe1a6-17a4-4f85-964a-659e852763e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_843057ed-c2c8-4b01-8319-9a8f4988e09e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_013fe1a6-17a4-4f85-964a-659e852763e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95dbfb87-a651-4b5f-ac7e-2886c5e7397c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95dbfb87-a651-4b5f-ac7e-2886c5e7397c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c18bfb8d-e341-483f-bb2b-06727432c37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95dbfb87-a651-4b5f-ac7e-2886c5e7397c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c18bfb8d-e341-483f-bb2b-06727432c37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a08a0b76-47b1-4a9c-9741-4612bc6154cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c18bfb8d-e341-483f-bb2b-06727432c37e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a08a0b76-47b1-4a9c-9741-4612bc6154cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_5dc1d4a7-6f91-4034-b41b-6b9ea2fe1175" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_9779fb72-4442-4bfc-8c98-5c7d5b3eb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_9779fb72-4442-4bfc-8c98-5c7d5b3eb85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_d7109c51-0882-4f30-bd58-ad456ef1b8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_d7109c51-0882-4f30-bd58-ad456ef1b8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeInvestmentsMember_680d67a6-7767-4ed0-a5e1-610e035922b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_us-gaap_FixedIncomeInvestmentsMember_680d67a6-7767-4ed0-a5e1-610e035922b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_6ddf399c-9128-490b-9191-1182e3296008" xlink:href="mrk-20221231.xsd#mrk_DefinedBenefitPlanCashandOtherInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a80d3203-fb4e-429f-af35-9886d1990b26" xlink:to="loc_mrk_DefinedBenefitPlanCashandOtherInvestmentsMember_6ddf399c-9128-490b-9191-1182e3296008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7da4b27e-2dde-4070-b334-49a3ea3efdb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_srt_RangeAxis_7da4b27e-2dde-4070-b334-49a3ea3efdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7da4b27e-2dde-4070-b334-49a3ea3efdb2" xlink:to="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b9acb0f-0336-4bb4-b362-5172fd1c5cd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:to="loc_srt_MinimumMember_7b9acb0f-0336-4bb4-b362-5172fd1c5cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d357853-1e72-409d-b9bb-fa3b39015c5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5c30a3e-d39d-4545-955f-f76fc27cc0a2" xlink:to="loc_srt_MaximumMember_1d357853-1e72-409d-b9bb-fa3b39015c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6865d026-cf8a-47f2-b054-a50edd281c2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_srt_StatementScenarioAxis_6865d026-cf8a-47f2-b054-a50edd281c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e450aff2-3c39-40d0-96e7-30e7ab834ade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6865d026-cf8a-47f2-b054-a50edd281c2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e450aff2-3c39-40d0-96e7-30e7ab834ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0bd5e971-a12c-4d1e-b524-227bb6441d0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e450aff2-3c39-40d0-96e7-30e7ab834ade" xlink:to="loc_srt_ScenarioForecastMember_0bd5e971-a12c-4d1e-b524-227bb6441d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_a62398a1-9f04-4d0d-afc9-e11e4af97b01" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_2ef9e073-4030-4492-bb7f-6e45e733eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_2ef9e073-4030-4492-bb7f-6e45e733eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_58ceb5c4-fcd3-42f8-b7dd-b523597cc228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_58ceb5c4-fcd3-42f8-b7dd-b523597cc228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_7260c911-e533-4cc9-9aca-6a3527a77ff3" xlink:href="mrk-20221231.xsd#mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage_7260c911-e533-4cc9-9aca-6a3527a77ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_953f045e-b62e-46a9-8021-e8472c64ca11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_953f045e-b62e-46a9-8021-e8472c64ca11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_9cb85db6-b592-4249-8826-92d6466e4626" xlink:href="mrk-20221231.xsd#mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests_9cb85db6-b592-4249-8826-92d6466e4626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_a84309bb-027a-42d4-ad3f-f89a7d2b60bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_a84309bb-027a-42d4-ad3f-f89a7d2b60bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_eed60f3e-9058-49ba-85b4-06cff192f6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_eed60f3e-9058-49ba-85b4-06cff192f6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_e0fd1d63-e230-4e88-ac64-b8a1bbc4a21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bc379196-60b6-4dfc-8633-bda1c0c211c6" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_e0fd1d63-e230-4e88-ac64-b8a1bbc4a21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b1a0c1b9-3948-45b2-a7a8-41c57fd600a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b1a0c1b9-3948-45b2-a7a8-41c57fd600a4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b7441bae-edcf-493a-9e83-1250be062fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b7441bae-edcf-493a-9e83-1250be062fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b7441bae-edcf-493a-9e83-1250be062fa1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f12d0753-ee9a-47f7-b978-23e09cc4c704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:to="loc_us-gaap_DomesticPlanMember_f12d0753-ee9a-47f7-b978-23e09cc4c704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a44e19f6-7cdb-4315-ba86-da60c8e2288c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f12d0753-ee9a-47f7-b978-23e09cc4c704" xlink:to="loc_country_US_a44e19f6-7cdb-4315-ba86-da60c8e2288c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8c730ec7-dfe5-4303-8e43-a527a54eff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c8252979-afd3-4879-af62-5ef3812914bd" xlink:to="loc_us-gaap_ForeignPlanMember_8c730ec7-dfe5-4303-8e43-a527a54eff9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8bf59a88-c206-4966-b13c-e9874447d541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8bf59a88-c206-4966-b13c-e9874447d541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8bf59a88-c206-4966-b13c-e9874447d541" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0141d68a-dc28-415d-bc60-8fdb3bd11700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0141d68a-dc28-415d-bc60-8fdb3bd11700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_10df99fd-a67b-427a-8c35-7a4ebb1edacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_db24191b-d688-4e3f-a7e3-86edd0442377" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_10df99fd-a67b-427a-8c35-7a4ebb1edacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2abd9976-c2ec-4d23-a128-c0fcd8516d73" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_bbbee1c2-8c13-40a3-a057-784e9c1346cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_bbbee1c2-8c13-40a3-a057-784e9c1346cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_1723d1dc-0450-4e94-8abe-3da4aafb7c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_1723d1dc-0450-4e94-8abe-3da4aafb7c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_986a49e0-e78c-46fb-afe2-5f2850c05cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_986a49e0-e78c-46fb-afe2-5f2850c05cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ff4a85d3-db81-4810-826a-52d9b1046f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_ff4a85d3-db81-4810-826a-52d9b1046f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a7cfa31d-7ba1-4a6f-81c2-f15bbb515b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_a7cfa31d-7ba1-4a6f-81c2-f15bbb515b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_e8605fc6-8e2e-4c10-81bd-075e80e2d498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_e8605fc6-8e2e-4c10-81bd-075e80e2d498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_ea62f3da-fd44-4978-bcd5-373364ab4541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_ea62f3da-fd44-4978-bcd5-373364ab4541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6ade02cc-8706-4f16-a5e2-ac22cf2f591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6ade02cc-8706-4f16-a5e2-ac22cf2f591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f20f7dd-ca86-442c-860e-3617b2af9e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6802544f-08ff-4920-ac22-c31d888c2384" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f20f7dd-ca86-442c-860e-3617b2af9e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5a11ac49-bd75-4923-ac10-05d9e004804c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5a11ac49-bd75-4923-ac10-05d9e004804c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_53fe7f14-2940-4b6f-82ac-a20b3bbf3723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_53fe7f14-2940-4b6f-82ac-a20b3bbf3723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_53fe7f14-2940-4b6f-82ac-a20b3bbf3723" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_cc4f04c6-8dad-4f63-b689-42e45a95e25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:to="loc_us-gaap_DomesticPlanMember_cc4f04c6-8dad-4f63-b689-42e45a95e25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_38a4ae86-fa5f-4b7f-9b93-e8dba5924342" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_cc4f04c6-8dad-4f63-b689-42e45a95e25b" xlink:to="loc_country_US_38a4ae86-fa5f-4b7f-9b93-e8dba5924342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f580bb86-24c6-4569-a91a-f6204a941878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1f040166-7bed-459b-b870-d60cc5eaf85d" xlink:to="loc_us-gaap_ForeignPlanMember_f580bb86-24c6-4569-a91a-f6204a941878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4171dd64-634c-46ef-8652-92875f4ad88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4171dd64-634c-46ef-8652-92875f4ad88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4171dd64-634c-46ef-8652-92875f4ad88a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ec339464-1475-432c-bbf3-e66dc849ac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ec339464-1475-432c-bbf3-e66dc849ac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_de7d8caa-9630-49af-aac5-1f82e68453bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c91339ea-f441-4aff-bb1e-8be561d60633" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_de7d8caa-9630-49af-aac5-1f82e68453bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf37a82f-3af9-44ef-afbe-8bec70d8d84b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0bef6f87-7557-40ae-97c9-fe2185d0a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0bef6f87-7557-40ae-97c9-fe2185d0a8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fc33bc4d-f7c8-4df4-9c6f-6a4e2926e317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_fc33bc4d-f7c8-4df4-9c6f-6a4e2926e317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ff966934-fa54-48fb-b55a-9883113c8e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_ff966934-fa54-48fb-b55a-9883113c8e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_623681fa-3849-4f99-a36c-a01cdc580186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_623681fa-3849-4f99-a36c-a01cdc580186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_96c9351e-51f2-4ce1-8393-95f7e7078e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_96c9351e-51f2-4ce1-8393-95f7e7078e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_8abd15f8-a589-4406-90ab-5fe3814339ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_8abd15f8-a589-4406-90ab-5fe3814339ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_48aea7b6-ebde-448a-bf4a-56cfc7fa64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_48aea7b6-ebde-448a-bf4a-56cfc7fa64ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_a304b6e3-e603-4394-aa7e-13e965ea57ed" xlink:href="mrk-20221231.xsd#mrk_DefinedBenefitPlanOtherChangesPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_mrk_DefinedBenefitPlanOtherChangesPlanAssets_a304b6e3-e603-4394-aa7e-13e965ea57ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4866c6ff-f5b7-4bff-8852-1c253e21464f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_2ed0e9b4-40ec-4c4e-8c68-f64646b67867" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4866c6ff-f5b7-4bff-8852-1c253e21464f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_47d31ef0-ada7-4772-a75a-c6dd0622b6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_47d31ef0-ada7-4772-a75a-c6dd0622b6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_09a99f4e-d3ef-46af-9779-9dabcc2a51f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_09a99f4e-d3ef-46af-9779-9dabcc2a51f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_90dbdf9f-ead2-42c8-8fa1-f8ec6a0c642c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_90dbdf9f-ead2-42c8-8fa1-f8ec6a0c642c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b07aa4c0-dc1b-46ab-956b-1eed08dfe252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b07aa4c0-dc1b-46ab-956b-1eed08dfe252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_b91d8a4e-a0e5-4f91-ad43-80b18d64b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_b91d8a4e-a0e5-4f91-ad43-80b18d64b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_ceba279c-21a3-496c-b8d2-7d17741f4b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_ceba279c-21a3-496c-b8d2-7d17741f4b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_be79b84b-8598-40c3-904a-4adfa0b2c1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_be79b84b-8598-40c3-904a-4adfa0b2c1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_6f13e01a-88f2-4136-9cff-416a4654270c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCurtailments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_6f13e01a-88f2-4136-9cff-416a4654270c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_082090d1-ad05-44d3-b0db-ae99a00431ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_082090d1-ad05-44d3-b0db-ae99a00431ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_aac78605-de60-4b7c-8d8c-bfe8806e8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_aac78605-de60-4b7c-8d8c-bfe8806e8adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_333af41a-7ca4-459e-ba02-6ab961107573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_333af41a-7ca4-459e-ba02-6ab961107573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherChanges_bacdb8b0-cecd-4906-aebf-dbbd9129e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanOtherChanges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherChanges_bacdb8b0-cecd-4906-aebf-dbbd9129e9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9434ece2-c148-46ee-b84e-389282726c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_89516b9c-fd0e-410e-806b-941043c42079" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9434ece2-c148-46ee-b84e-389282726c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ac48292c-4e60-45bb-afbd-df7bf1371caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ac48292c-4e60-45bb-afbd-df7bf1371caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_66ab3e8c-fa90-4b38-9416-5b0a3dc0fb56" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_99499492-fcec-4c26-85fa-a1a95f047b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_99499492-fcec-4c26-85fa-a1a95f047b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4b762f6e-361e-4b03-b624-10ae18dfc7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_4b762f6e-361e-4b03-b624-10ae18dfc7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1376977a-92ad-4d8d-93c2-3406da458b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_8911be75-77e2-4282-b874-2fca4c2df758" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_1376977a-92ad-4d8d-93c2-3406da458b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8c4f0db0-f5f9-4b38-abaf-b5f8d425dc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8c4f0db0-f5f9-4b38-abaf-b5f8d425dc01" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_58dc492f-c053-4442-ba04-878efd07b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_58dc492f-c053-4442-ba04-878efd07b1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_58dc492f-c053-4442-ba04-878efd07b1ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_523d9326-5f3f-4445-bb61-041c0ce85632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:to="loc_us-gaap_DomesticPlanMember_523d9326-5f3f-4445-bb61-041c0ce85632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_da778408-fa92-4114-9171-52d915c748aa" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_523d9326-5f3f-4445-bb61-041c0ce85632" xlink:to="loc_country_US_da778408-fa92-4114-9171-52d915c748aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1103c9ea-ba18-40e1-a805-8fef9d3caaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_66ded275-4baf-49aa-85ed-9422ecf7bbd6" xlink:to="loc_us-gaap_ForeignPlanMember_1103c9ea-ba18-40e1-a805-8fef9d3caaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_221f7762-f867-4f21-a2a3-707270964ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_1a6eff9a-991a-4e1d-a3e5-e7e3f8e64984" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_221f7762-f867-4f21-a2a3-707270964ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_667ac5e5-5f54-4a2f-bca2-fce632bb31c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_221f7762-f867-4f21-a2a3-707270964ca6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_667ac5e5-5f54-4a2f-bca2-fce632bb31c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_11d042d1-84b6-4170-80cb-fa70f9e62bf6" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_83e1e2e3-cedf-4cd3-9329-350da71c6ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_83e1e2e3-cedf-4cd3-9329-350da71c6ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_b8151aee-f0cc-42a2-a674-72b92ad58357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_b8151aee-f0cc-42a2-a674-72b92ad58357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_eef13f16-cc61-4ea5-846a-09c6cb1f630d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_eef13f16-cc61-4ea5-846a-09c6cb1f630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_cf13b0ed-60dd-4ebe-87a3-982ebc0bc0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_91d0b0dd-f2c9-4d2b-a266-1fa47a7139a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_cf13b0ed-60dd-4ebe-87a3-982ebc0bc0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_28676c2e-d567-42bc-a925-e763db6c3365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_28676c2e-d567-42bc-a925-e763db6c3365" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_307067f3-e924-4152-b5a0-a8a9ee1578d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_307067f3-e924-4152-b5a0-a8a9ee1578d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_307067f3-e924-4152-b5a0-a8a9ee1578d3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0a8b052-dd41-418b-8293-94f8ea65875b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:to="loc_us-gaap_DomesticPlanMember_e0a8b052-dd41-418b-8293-94f8ea65875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f2d04a96-cc06-49ce-8815-6512ac3ba0b6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_e0a8b052-dd41-418b-8293-94f8ea65875b" xlink:to="loc_country_US_f2d04a96-cc06-49ce-8815-6512ac3ba0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f51415d6-52c7-491e-8d66-5cb6b51bbee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ce733fe-069a-4259-b073-fc840e3e610a" xlink:to="loc_us-gaap_ForeignPlanMember_f51415d6-52c7-491e-8d66-5cb6b51bbee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a03ed3e3-b263-40fa-9171-5db1140724eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a03ed3e3-b263-40fa-9171-5db1140724eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b0447e55-e264-4dea-8baa-e4a0199622c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a03ed3e3-b263-40fa-9171-5db1140724eb" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b0447e55-e264-4dea-8baa-e4a0199622c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1c7d3cbe-13b9-4d73-b96f-f82ff1d18b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b0447e55-e264-4dea-8baa-e4a0199622c7" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1c7d3cbe-13b9-4d73-b96f-f82ff1d18b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3d7cf8c-9182-4db2-9075-8f38074af86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3d7cf8c-9182-4db2-9075-8f38074af86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3d7cf8c-9182-4db2-9075-8f38074af86f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_304b6375-a9de-4c60-a6c2-505358125431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_304b6375-a9de-4c60-a6c2-505358125431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2a1cc875-7fa3-4b59-ab63-5b839853a62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2a1cc875-7fa3-4b59-ab63-5b839853a62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_173d2214-e3f2-474e-b53d-3b39f6e08ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_173d2214-e3f2-474e-b53d-3b39f6e08ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_abb43f00-9d98-4d5d-b273-497696b940a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_03228c9d-99c0-4c6c-b759-8231d4889f5b" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_abb43f00-9d98-4d5d-b273-497696b940a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_4dd6b594-5c66-42a2-8edc-bd8ff2b732c3" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_34dc72f2-8b87-424d-91bb-97cc4e846f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_34dc72f2-8b87-424d-91bb-97cc4e846f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_1cf09d31-5ec1-4332-a84d-281b40038fd2" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_1cf09d31-5ec1-4332-a84d-281b40038fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_39d128ec-2b26-442f-9f1a-6f1e0e661ef5" xlink:href="mrk-20221231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_39d128ec-2b26-442f-9f1a-6f1e0e661ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_c58a662e-62ae-4414-a551-745b2f6fbd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_c58a662e-62ae-4414-a551-745b2f6fbd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e51762c2-619a-4d6a-a26d-4755b03e6c5a" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_e51762c2-619a-4d6a-a26d-4755b03e6c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsInvestmentFundsMember_13215550-0757-4842-ac9c-e4fc75ea85b2" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsInvestmentFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_CorporateObligationsInvestmentFundsMember_13215550-0757-4842-ac9c-e4fc75ea85b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_71f06ff4-d0b8-4580-b6fd-b7915ebacd25" xlink:href="mrk-20221231.xsd#mrk_FixedIncomeObligationsInvestmentFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_FixedIncomeObligationsInvestmentFundsMember_71f06ff4-d0b8-4580-b6fd-b7915ebacd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_4d9dca88-7a2d-453b-8067-9b154ac3dece" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_4d9dca88-7a2d-453b-8067-9b154ac3dece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_b107d8e8-1e8a-4fbc-b9bf-93b4c78763c6" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_b107d8e8-1e8a-4fbc-b9bf-93b4c78763c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_ae895c43-8608-4ff7-82b8-8a3cae9b936e" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_ae895c43-8608-4ff7-82b8-8a3cae9b936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_a2c2a539-8f43-4368-9cb9-c82a151d6503" xlink:href="mrk-20221231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_a2c2a539-8f43-4368-9cb9-c82a151d6503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDerivativeMember_b616939e-6a8e-4f8c-bfb6-460d6677a125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDerivativeMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_DefinedBenefitPlanDerivativeMember_b616939e-6a8e-4f8c-bfb6-460d6677a125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_093d4fad-5d26-426d-acb8-b269cc9ea1e2" xlink:href="mrk-20221231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_093d4fad-5d26-426d-acb8-b269cc9ea1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_5faa53a0-270b-4c26-bb2e-cfead2037e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_87a92af2-42e9-4d90-ac78-27c5fa920bea" xlink:to="loc_us-gaap_OtherInvestmentsMember_5faa53a0-270b-4c26-bb2e-cfead2037e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56249f73-b4d0-461f-929e-5237bcdc4b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bf11c8b2-2b80-4831-898d-204d3b90ec7d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56249f73-b4d0-461f-929e-5237bcdc4b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_df0a5234-6cdb-42f7-8cdb-6e555b2750b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56249f73-b4d0-461f-929e-5237bcdc4b2c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_df0a5234-6cdb-42f7-8cdb-6e555b2750b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7a6d0a9-0c5d-44d6-91ee-9dd912b405d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f7a6d0a9-0c5d-44d6-91ee-9dd912b405d3" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_eb2eccdc-5e80-487d-94cc-b41d5f753720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_eb2eccdc-5e80-487d-94cc-b41d5f753720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_eb2eccdc-5e80-487d-94cc-b41d5f753720" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_53cdadc9-2879-4a4e-8c44-f12acb05fb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:to="loc_us-gaap_DomesticPlanMember_53cdadc9-2879-4a4e-8c44-f12acb05fb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6cfd1412-8ada-4c3c-bb69-9224f5b69df4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_53cdadc9-2879-4a4e-8c44-f12acb05fb6b" xlink:to="loc_country_US_6cfd1412-8ada-4c3c-bb69-9224f5b69df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ad3a5df7-45a4-49ed-bc25-01657a8c9174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9b2f5221-4a26-4100-9e57-0bd4079a2f75" xlink:to="loc_us-gaap_ForeignPlanMember_ad3a5df7-45a4-49ed-bc25-01657a8c9174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_cd100c10-f324-48dd-861f-c78abedd0323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_cd100c10-f324-48dd-861f-c78abedd0323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_aaeff9ad-ee30-4701-ac09-629de5ae5a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_cd100c10-f324-48dd-861f-c78abedd0323" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_aaeff9ad-ee30-4701-ac09-629de5ae5a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6e4a1324-6e59-4af6-949f-268359d05fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_aaeff9ad-ee30-4701-ac09-629de5ae5a0e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6e4a1324-6e59-4af6-949f-268359d05fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54075c31-f1ac-4a46-b1a4-6a60c095bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54075c31-f1ac-4a46-b1a4-6a60c095bb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa385b73-1275-4c34-b374-c2b5c174939b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_54075c31-f1ac-4a46-b1a4-6a60c095bb05" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa385b73-1275-4c34-b374-c2b5c174939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0d55d67a-001c-44ca-bd98-1de1d2d76789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa385b73-1275-4c34-b374-c2b5c174939b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0d55d67a-001c-44ca-bd98-1de1d2d76789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a88dd9b9-0181-44ea-8228-c18c9df3be70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a88dd9b9-0181-44ea-8228-c18c9df3be70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_a88dd9b9-0181-44ea-8228-c18c9df3be70" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InsuranceContractsOtherInvestmentsMember_0dec382f-0bba-495d-8f2a-d3df14a25ab9" xlink:href="mrk-20221231.xsd#mrk_InsuranceContractsOtherInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:to="loc_mrk_InsuranceContractsOtherInvestmentsMember_0dec382f-0bba-495d-8f2a-d3df14a25ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RealEstateInvestmentFundsMember_fff75a55-9ec3-479d-9501-b7c4ad650463" xlink:href="mrk-20221231.xsd#mrk_RealEstateInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:to="loc_mrk_RealEstateInvestmentFundsMember_fff75a55-9ec3-479d-9501-b7c4ad650463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_84b237ce-23a1-4e39-a60b-b3095828beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_a0b3765a-d396-477a-9cf9-7eae853b660d" xlink:to="loc_us-gaap_OtherInvestmentsMember_84b237ce-23a1-4e39-a60b-b3095828beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_422a0d87-1016-45a3-ae53-fb5ddc966785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e4728abc-27e2-4c66-9766-6606ae3e2ecc" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_422a0d87-1016-45a3-ae53-fb5ddc966785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_422a0d87-1016-45a3-ae53-fb5ddc966785" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b8cf3dfd-ead1-48fe-a5a6-de7ab167acfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b8cf3dfd-ead1-48fe-a5a6-de7ab167acfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_396712bf-374c-43c0-995b-d1d22ec6650a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_396712bf-374c-43c0-995b-d1d22ec6650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_0fe352d8-b573-4f10-8f81-d25f28d0b0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_2c492b98-3c97-449f-a3d5-52839258c077" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod_0fe352d8-b573-4f10-8f81-d25f28d0b0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_a0d9d2c7-bc8a-4073-aed0-432f5e7d5300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_a0d9d2c7-bc8a-4073-aed0-432f5e7d5300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_a5b4cbd8-9e96-491d-b237-1113041d44f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_a5b4cbd8-9e96-491d-b237-1113041d44f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_10018534-d82f-4cf2-8697-e0408ebec43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_177e1c00-a832-4d43-bc22-77ddfaf0edfa" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_10018534-d82f-4cf2-8697-e0408ebec43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0315558d-53b0-4458-9641-4ffd6d20ebbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0315558d-53b0-4458-9641-4ffd6d20ebbf" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c69c2793-accd-401c-90cf-05130a583ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c69c2793-accd-401c-90cf-05130a583ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_670533d1-8e3a-4f8e-ae2d-014a54839f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c69c2793-accd-401c-90cf-05130a583ba5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_670533d1-8e3a-4f8e-ae2d-014a54839f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_190d9dd8-c2ef-47da-b920-54672b1e60e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_670533d1-8e3a-4f8e-ae2d-014a54839f4d" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_190d9dd8-c2ef-47da-b920-54672b1e60e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_07aa790a-2125-4942-8f8f-3d2b2f76254c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_07aa790a-2125-4942-8f8f-3d2b2f76254c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_07aa790a-2125-4942-8f8f-3d2b2f76254c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4f0a84ea-ec0f-4a3d-ba9e-808ad63f9e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4f0a84ea-ec0f-4a3d-ba9e-808ad63f9e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97f95799-6bd5-4a09-8dc2-1f41873b82af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97f95799-6bd5-4a09-8dc2-1f41873b82af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f93a2821-4f97-4715-8cad-c957819a64c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f93a2821-4f97-4715-8cad-c957819a64c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1532be3b-b2eb-4833-8c90-98f25b73fc47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46e9c6bd-9362-4ed8-b8ab-ac80a104bb3b" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_1532be3b-b2eb-4833-8c90-98f25b73fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_77a17012-296b-4a7d-adf7-20efce750f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_77a17012-296b-4a7d-adf7-20efce750f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_77a17012-296b-4a7d-adf7-20efce750f8a" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_fdfff5ca-a8d3-4d3e-98fd-7559b0cad478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_fdfff5ca-a8d3-4d3e-98fd-7559b0cad478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_cc012be2-2204-4d9f-910a-8d9317a47d26" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_DevelopedMarketsEquitiesInvestmentFundsMember_cc012be2-2204-4d9f-910a-8d9317a47d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_5e601482-fc3e-4468-9271-b6ed8e19242c" xlink:href="mrk-20221231.xsd#mrk_EmergingMarketsEquitiesInvestmentFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_EmergingMarketsEquitiesInvestmentFundsMember_5e601482-fc3e-4468-9271-b6ed8e19242c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7ede4cea-2991-4b56-b4c6-da9647185220" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsInvestmentFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_GovernmentAndAgencyObligationsInvestmentFundsMember_7ede4cea-2991-4b56-b4c6-da9647185220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRealEstateMember_e6ed70eb-5aa8-49ad-be24-1359891b990e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRealEstateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_us-gaap_DefinedBenefitPlanRealEstateMember_e6ed70eb-5aa8-49ad-be24-1359891b990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopedMarketsEquitySecuritiesMember_33b9bf96-42bf-45a9-9bb8-bebae81522bc" xlink:href="mrk-20221231.xsd#mrk_DevelopedMarketsEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_DevelopedMarketsEquitySecuritiesMember_33b9bf96-42bf-45a9-9bb8-bebae81522bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4369dfe1-e994-4f1d-9283-526dae3ace7c" xlink:href="mrk-20221231.xsd#mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember_4369dfe1-e994-4f1d-9283-526dae3ace7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_6aac18a6-7d7e-44e4-8079-f99569937b7d" xlink:href="mrk-20221231.xsd#mrk_CorporateObligationsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_CorporateObligationsFixedIncomeSecuritiesMember_6aac18a6-7d7e-44e4-8079-f99569937b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8b5aee6b-2f29-49e1-ac41-f7bf5e615479" xlink:href="mrk-20221231.xsd#mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember_8b5aee6b-2f29-49e1-ac41-f7bf5e615479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDerivativeMember_9a57042d-25e8-4179-bb48-4e195396fd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDerivativeMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_eecb2d64-55bc-4469-854e-9ee294b4ecc5" xlink:to="loc_us-gaap_DefinedBenefitPlanDerivativeMember_9a57042d-25e8-4179-bb48-4e195396fd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5f6cf72b-d1ff-4d43-8cf2-055942871ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_12aa4fbb-2e15-4272-a7c3-cd7282edfd4f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5f6cf72b-d1ff-4d43-8cf2-055942871ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_482bbee9-a1ff-4298-9e24-69a00637fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5f6cf72b-d1ff-4d43-8cf2-055942871ac1" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_482bbee9-a1ff-4298-9e24-69a00637fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f0ec647b-a279-4370-b3f7-55fd59d8383f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f0ec647b-a279-4370-b3f7-55fd59d8383f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_542f40f3-96db-482b-b94c-b62c970be16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_542f40f3-96db-482b-b94c-b62c970be16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_542f40f3-96db-482b-b94c-b62c970be16a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_60cfb909-b32b-4549-a1ed-8e3a330b20a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:to="loc_us-gaap_DomesticPlanMember_60cfb909-b32b-4549-a1ed-8e3a330b20a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bec0223e-59d9-4455-8e0d-c122c7fc0b0a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_60cfb909-b32b-4549-a1ed-8e3a330b20a2" xlink:to="loc_country_US_bec0223e-59d9-4455-8e0d-c122c7fc0b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4d17c7b7-032b-4db6-a543-1300b95927c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_164f3fc8-c65e-49b4-874b-a04e44200a32" xlink:to="loc_us-gaap_ForeignPlanMember_4d17c7b7-032b-4db6-a543-1300b95927c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3768ca39-299a-4e1c-8d87-624146e9b899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3768ca39-299a-4e1c-8d87-624146e9b899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3768ca39-299a-4e1c-8d87-624146e9b899" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f0762728-12d6-4988-ba62-1925fd0271ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f0762728-12d6-4988-ba62-1925fd0271ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c21368eb-249b-4d94-b294-0afb0bfe0d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_87e983c2-c681-4e8a-af59-26394950b95b" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c21368eb-249b-4d94-b294-0afb0bfe0d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9c9e5fea-c01c-4832-a6a8-3d6372045ca7" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_6013a832-7b75-4e5e-861d-456e21e6b7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_6013a832-7b75-4e5e-861d-456e21e6b7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_93d903d8-6f98-445f-aacc-e435e4ac8bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_93d903d8-6f98-445f-aacc-e435e4ac8bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_2b762a1a-a48c-44ab-b4f6-4156d2e99308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_2b762a1a-a48c-44ab-b4f6-4156d2e99308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_1ce2addc-70e8-4609-a652-7c55da549b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_1ce2addc-70e8-4609-a652-7c55da549b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fc3a6d73-e406-485e-b908-f659445316fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fc3a6d73-e406-485e-b908-f659445316fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b2adcd5e-34bb-445f-8077-f9c00d2b2df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_40a3fd06-6063-4557-88a9-9c7d23ca78e3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_b2adcd5e-34bb-445f-8077-f9c00d2b2df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_15868a80-bab5-4eb3-97ac-974792f6e61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_15868a80-bab5-4eb3-97ac-974792f6e61b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5f7e0bba-58a1-4590-81c8-23cf3cf5e419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5f7e0bba-58a1-4590-81c8-23cf3cf5e419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5f7e0bba-58a1-4590-81c8-23cf3cf5e419" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_14b81b03-86b8-4653-bb06-3716549eaadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:to="loc_us-gaap_DomesticPlanMember_14b81b03-86b8-4653-bb06-3716549eaadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9d851903-a957-4292-b3ac-87261b83be92" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_14b81b03-86b8-4653-bb06-3716549eaadf" xlink:to="loc_country_US_9d851903-a957-4292-b3ac-87261b83be92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9053c623-2403-42ee-82de-5a79c4a0954a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_acf285da-e667-4192-843b-4274f30b7bec" xlink:to="loc_us-gaap_ForeignPlanMember_9053c623-2403-42ee-82de-5a79c4a0954a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_627343cf-382c-4153-bb63-6174db512f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_627343cf-382c-4153-bb63-6174db512f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_627343cf-382c-4153-bb63-6174db512f34" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c237cea0-4c22-4c50-8885-5d8802dfd724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c237cea0-4c22-4c50-8885-5d8802dfd724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9d20dd62-0d45-4d3b-8205-d0f6ffab2182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_63b6a8e9-6766-4e00-94c6-f4cb38db0b39" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9d20dd62-0d45-4d3b-8205-d0f6ffab2182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f0c806ea-5852-4f27-a39a-50ed835282a9" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c675e617-ca21-4c9b-8522-306e187b5ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_c675e617-ca21-4c9b-8522-306e187b5ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_81e84a59-c3df-44e1-8ac2-c14b0c00114f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_81e84a59-c3df-44e1-8ac2-c14b0c00114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_202a3196-132d-479a-bafe-bfca9669e543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax_202a3196-132d-479a-bafe-bfca9669e543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f036c432-e10a-42b6-a9d7-8e6d5ddb1262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_f036c432-e10a-42b6-a9d7-8e6d5ddb1262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_b45d714f-d300-47a1-96eb-7742003edeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_b45d714f-d300-47a1-96eb-7742003edeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_292c54e7-fc72-4d52-84ab-42307f8a9391" xlink:href="mrk-20221231.xsd#mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax_292c54e7-fc72-4d52-84ab-42307f8a9391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_74166707-6eac-44e2-89bf-2cf2fa15de13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_70ea2d68-ce69-4bf0-9e61-941111cdbbf9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax_74166707-6eac-44e2-89bf-2cf2fa15de13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6160a31a-910b-44e1-b932-82d88438031d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6160a31a-910b-44e1-b932-82d88438031d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_24170e31-53dd-45e4-97a4-bdd55a595b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_24170e31-53dd-45e4-97a4-bdd55a595b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_24170e31-53dd-45e4-97a4-bdd55a595b5c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_53c2f674-1fa2-4818-9fe8-69d16018e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:to="loc_us-gaap_DomesticPlanMember_53c2f674-1fa2-4818-9fe8-69d16018e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7b00c3bc-e66e-444d-8aec-bff170f9bfc0" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_53c2f674-1fa2-4818-9fe8-69d16018e426" xlink:to="loc_country_US_7b00c3bc-e66e-444d-8aec-bff170f9bfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_d5bdcb7e-ee47-4e2c-994f-df3e47a41e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c5a885f8-2465-443d-997e-c618ccc885de" xlink:to="loc_us-gaap_ForeignPlanMember_d5bdcb7e-ee47-4e2c-994f-df3e47a41e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e516b013-b988-40d1-a8e2-1302fcea3eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_6fd6ef04-4b4f-4d0d-9ac9-74c37fccd2b1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e516b013-b988-40d1-a8e2-1302fcea3eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4fe16f19-cdbe-4e76-a690-d68245369fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e516b013-b988-40d1-a8e2-1302fcea3eb4" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4fe16f19-cdbe-4e76-a690-d68245369fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fd47648e-571a-449e-9321-8a503367176a" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_e7a5a727-4388-4af6-82c7-ffa81649f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_e7a5a727-4388-4af6-82c7-ffa81649f72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_4a95c2f6-46d9-40f2-8838-1e07828b04dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_4a95c2f6-46d9-40f2-8838-1e07828b04dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_b57f98a4-2811-4eff-a33b-e6b00b61349d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_b57f98a4-2811-4eff-a33b-e6b00b61349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_9b1daec7-38c6-4647-9147-7af79b43e290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_d31966af-70c5-43b0-ae2d-0c66a4637f1f" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_9b1daec7-38c6-4647-9147-7af79b43e290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ef746e1f-dd08-4e0a-855b-ac196d89668e" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3d6b3492-c6ad-4547-8a6e-75517f063362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3d6b3492-c6ad-4547-8a6e-75517f063362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2dafef07-98e7-4894-855b-a3b5dbdd4405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_2dafef07-98e7-4894-855b-a3b5dbdd4405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_3e602233-c8bd-431a-87c2-9dab53596ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_fc897c97-c016-4bdd-bcc0-6ecbf6c3a556" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_3e602233-c8bd-431a-87c2-9dab53596ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c1575cf-a17f-45ab-9509-77142e614fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b1f72153-f6b2-443d-944b-30e792d66175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c1575cf-a17f-45ab-9509-77142e614fba" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b1f72153-f6b2-443d-944b-30e792d66175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c67aaf56-e9d7-46df-b3fe-7a699ee85b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b1f72153-f6b2-443d-944b-30e792d66175" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c67aaf56-e9d7-46df-b3fe-7a699ee85b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c34999c6-06e5-4b0d-aea6-e59306d612c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c67aaf56-e9d7-46df-b3fe-7a699ee85b96" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c34999c6-06e5-4b0d-aea6-e59306d612c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6312089b-9949-4041-b93a-1859d7091a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_c34999c6-06e5-4b0d-aea6-e59306d612c5" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6312089b-9949-4041-b93a-1859d7091a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b1f72153-f6b2-443d-944b-30e792d66175" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_5d4b3c81-c96a-4308-a1a8-f83198fe0dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_5d4b3c81-c96a-4308-a1a8-f83198fe0dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_187603ee-d689-4581-ad8f-8f87e9204fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2db75351-5597-4f2b-85cc-d8b7e7b94783" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_187603ee-d689-4581-ad8f-8f87e9204fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_356b89a8-ab81-4423-a421-a19c42842a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:href="mrk-20221231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_356b89a8-ab81-4423-a421-a19c42842a06" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_dba666cb-7f37-41b4-aa10-088344ca6d2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:to="loc_srt_StatementScenarioAxis_dba666cb-7f37-41b4-aa10-088344ca6d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fb4bb794-f04b-47b4-ba83-2f7239b38194" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_dba666cb-7f37-41b4-aa10-088344ca6d2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fb4bb794-f04b-47b4-ba83-2f7239b38194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d506540a-5cda-40d8-8513-35436ee3f83c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fb4bb794-f04b-47b4-ba83-2f7239b38194" xlink:to="loc_srt_ScenarioForecastMember_d506540a-5cda-40d8-8513-35436ee3f83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8242a9a8-e884-48c5-b35c-ea789baea0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2b76e6e8-2a0e-4f41-9b1a-f1d1c1f6acba" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8242a9a8-e884-48c5-b35c-ea789baea0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_877eeb95-e116-4922-8dce-52c8a2cfcd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8242a9a8-e884-48c5-b35c-ea789baea0d2" xlink:to="loc_us-gaap_SubsequentEventMember_877eeb95-e116-4922-8dce-52c8a2cfcd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:href="mrk-20221231.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_cd84b54f-1dac-4db8-9cc1-a2f721b463b5" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c3bb0084-e073-4993-8a58-52f7c2c2b82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c3bb0084-e073-4993-8a58-52f7c2c2b82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1753da94-b734-4246-86f3-0a993beab09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_InterestExpense_1753da94-b734-4246-86f3-0a993beab09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_469cdf50-887c-44c7-a22d-bd9e0c14bb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_469cdf50-887c-44c7-a22d-bd9e0c14bb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6bb0c2fc-20fc-45f0-9883-6e5e139ccea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6bb0c2fc-20fc-45f0-9883-6e5e139ccea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7f66fc64-3ecd-4af8-bcaa-c090551f714e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7f66fc64-3ecd-4af8-bcaa-c090551f714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_f9994430-b58f-4e1d-95b9-d4ad51cbd7f8" xlink:href="mrk-20221231.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_f9994430-b58f-4e1d-95b9-d4ad51cbd7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_93800ef9-694a-4aaa-adad-73e98a77e45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_93800ef9-694a-4aaa-adad-73e98a77e45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3d14b2f4-31bf-4309-844a-1ee3fcfd4cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac9235ee-49ee-4d09-8bf4-78d3338c10c7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3d14b2f4-31bf-4309-844a-1ee3fcfd4cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_7123eef2-c52c-445e-a26c-06c55be963bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_3b33b8b2-3133-49f9-8ae8-887bb093474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7123eef2-c52c-445e-a26c-06c55be963bd" xlink:to="loc_us-gaap_InterestPaid_3b33b8b2-3133-49f9-8ae8-887bb093474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_335045fa-6673-4641-80bd-ee8d5859ceab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ae0f3517-b83b-420d-ae00-baa071152824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_335045fa-6673-4641-80bd-ee8d5859ceab" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ae0f3517-b83b-420d-ae00-baa071152824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e35d45e2-8dab-40f6-aa67-c9ea88df7072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ae0f3517-b83b-420d-ae00-baa071152824" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e35d45e2-8dab-40f6-aa67-c9ea88df7072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ae0f3517-b83b-420d-ae00-baa071152824" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1b5cbb6d-a149-4494-a634-aceb91218440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1b5cbb6d-a149-4494-a634-aceb91218440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_eb1d4610-183c-4aed-b9cd-db43b5871143" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount_eb1d4610-183c-4aed-b9cd-db43b5871143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c80d46a3-e9f0-455a-99b1-ea3b6153758d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c80d46a3-e9f0-455a-99b1-ea3b6153758d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_fc2aeb58-6f3b-418a-9137-3e20f8ca6a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_fc2aeb58-6f3b-418a-9137-3e20f8ca6a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c2124b3a-e801-4c4c-8067-3700279f2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c2124b3a-e801-4c4c-8067-3700279f2a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5ac26974-46a1-4a68-84ab-dc3cd421286b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5ac26974-46a1-4a68-84ab-dc3cd421286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_81f40ecd-d2f7-4875-a35b-be9783d53890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_81f40ecd-d2f7-4875-a35b-be9783d53890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxRateReconciliationAssetAcquisition_45f4a727-1f35-4b15-94c0-2c5e562f0a1f" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxRateReconciliationAssetAcquisition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_mrk_IncomeTaxRateReconciliationAssetAcquisition_45f4a727-1f35-4b15-94c0-2c5e562f0a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_c90f49c1-e649-41e1-98e6-ae30ca893a93" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour_c90f49c1-e649-41e1-98e6-ae30ca893a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_ed05ac3b-1173-43e0-9475-8c7e10a6e34c" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo_ed05ac3b-1173-43e0-9475-8c7e10a6e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_3519f268-8753-4d92-ae79-899e48e6f963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract_99d2eddf-5abc-4194-b5ae-74f2e7a1d5f8" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_3519f268-8753-4d92-ae79-899e48e6f963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_61bf6845-b780-4d34-9a0e-c917f0b990bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ae0f3517-b83b-420d-ae00-baa071152824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_61bf6845-b780-4d34-9a0e-c917f0b990bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1fe789b9-0217-462b-acfd-eef26ead6f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_335045fa-6673-4641-80bd-ee8d5859ceab" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1fe789b9-0217-462b-acfd-eef26ead6f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b55e92d4-72ae-4a43-a93c-4860e6815c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1fe789b9-0217-462b-acfd-eef26ead6f36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b55e92d4-72ae-4a43-a93c-4860e6815c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1fe789b9-0217-462b-acfd-eef26ead6f36" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ce05b6b1-ef80-4f34-93fb-aa77138a3595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ce05b6b1-ef80-4f34-93fb-aa77138a3595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_d7ea2b5c-3d9e-4ae7-b104-83ede780ad66" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent_d7ea2b5c-3d9e-4ae7-b104-83ede780ad66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b090df89-56d2-49d2-9507-39262795cfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b090df89-56d2-49d2-9507-39262795cfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8689a6b8-7856-4a0c-b6b6-47490a56c1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8689a6b8-7856-4a0c-b6b6-47490a56c1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_b5a98627-35a0-4e1b-bda8-473c393a71ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_b5a98627-35a0-4e1b-bda8-473c393a71ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_93b7bdae-b4d4-4037-bec3-066fd9731261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_93b7bdae-b4d4-4037-bec3-066fd9731261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_fc2d75bf-6261-4934-aae7-7c70d9d26b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_fc2d75bf-6261-4934-aae7-7c70d9d26b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent_c095b419-3eea-4897-b164-69ac5a7d5d29" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent_c095b419-3eea-4897-b164-69ac5a7d5d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_70afbc01-cbd3-4bf8-8cca-3e243af09806" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent_70afbc01-cbd3-4bf8-8cca-3e243af09806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_03ad3290-d5ed-4875-8963-2be591934ff7" xlink:href="mrk-20221231.xsd#mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent_03ad3290-d5ed-4875-8963-2be591934ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c59acd11-9794-4f3f-8784-b92e5b948e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract_fce0edbc-748e-43f2-a77c-c6e5452d213d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c59acd11-9794-4f3f-8784-b92e5b948e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6a4698c7-04a6-4062-98b6-ae76de943f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1fe789b9-0217-462b-acfd-eef26ead6f36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6a4698c7-04a6-4062-98b6-ae76de943f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2eaeef88-2c48-4216-b4a3-6cdbab6f90fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2eaeef88-2c48-4216-b4a3-6cdbab6f90fb" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_46d4e12d-9f48-45eb-a5d5-640fc0362028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_46d4e12d-9f48-45eb-a5d5-640fc0362028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_46d4e12d-9f48-45eb-a5d5-640fc0362028" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e0fd8c6c-b501-49f9-b7ce-78f38669f65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:to="loc_us-gaap_ForeignCountryMember_e0fd8c6c-b501-49f9-b7ce-78f38669f65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_af7f5050-f85f-4c8c-8088-ddd2d3a80403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41e39b50-8160-4b60-94cb-a3f6a48c1c22" xlink:to="loc_us-gaap_DomesticCountryMember_af7f5050-f85f-4c8c-8088-ddd2d3a80403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_a2dfdfe6-b70a-449a-ab27-ba7662a3956c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_8344b11d-53da-4cf0-95a3-a5f47e3fcc4c" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_a2dfdfe6-b70a-449a-ab27-ba7662a3956c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_aa39fece-3ee9-4743-b3fa-8a9dcf61f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_a2dfdfe6-b70a-449a-ab27-ba7662a3956c" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_aa39fece-3ee9-4743-b3fa-8a9dcf61f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_3ebce888-0e64-4bbd-b23f-02077e6081c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_3ebce888-0e64-4bbd-b23f-02077e6081c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_3ebce888-0e64-4bbd-b23f-02077e6081c3" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_d47b14c2-b89d-4e04-bdbb-da01957ebf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_d47b14c2-b89d-4e04-bdbb-da01957ebf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_87925e34-6a3e-4594-8baa-f64506ba9d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_d87ad169-1321-4088-b6fb-df96f4991bf7" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_87925e34-6a3e-4594-8baa-f64506ba9d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_042b361e-7b27-45bf-8fa7-078286a270dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_042b361e-7b27-45bf-8fa7-078286a270dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_042b361e-7b27-45bf-8fa7-078286a270dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxesPayableMember_18414c8e-8e26-4d52-90c2-049712c21316" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:to="loc_mrk_IncomeTaxesPayableMember_18414c8e-8e26-4d52-90c2-049712c21316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1e4b1f95-caf1-4d55-a7f9-d1c662219653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc7372fa-a846-433c-a0c0-4e1ac2aaee84" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1e4b1f95-caf1-4d55-a7f9-d1c662219653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2fad2685-35fa-49ef-a7e9-663902e7d88b" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_8d373fcf-d244-4dc0-bb16-787268424f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_8d373fcf-d244-4dc0-bb16-787268424f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0215b8eb-417e-4b20-9a40-9802311f94f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent_0215b8eb-417e-4b20-9a40-9802311f94f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_05606cb6-94cb-4954-8b56-b26d91c84e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent_05606cb6-94cb-4954-8b56-b26d91c84e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_a7e16a1c-0ef4-4d23-9a11-58197730da86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_a7e16a1c-0ef4-4d23-9a11-58197730da86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_2b89ebbf-6ecf-462b-a522-29fd5dd61383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_2b89ebbf-6ecf-462b-a522-29fd5dd61383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_ca24c010-3855-445e-876e-e5e9f4d944b1" xlink:href="mrk-20221231.xsd#mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic_ca24c010-3855-445e-876e-e5e9f4d944b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_dd6fdc8e-2326-4c19-a4ac-13ba15700eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_IncomeTaxesPaid_dd6fdc8e-2326-4c19-a4ac-13ba15700eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_97c31835-693c-4729-ac98-6f1048e03598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_97c31835-693c-4729-ac98-6f1048e03598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a5bb836e-5375-4e7b-8367-c90253d52340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a5bb836e-5375-4e7b-8367-c90253d52340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77c0ebd2-12b5-4714-94ce-3d68034d6e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_77c0ebd2-12b5-4714-94ce-3d68034d6e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2dee0108-74ed-45c0-80e6-0987121a1993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2dee0108-74ed-45c0-80e6-0987121a1993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_112aff26-d41e-4fe1-8f1d-c78cd91bebb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_112aff26-d41e-4fe1-8f1d-c78cd91bebb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_65cb8f6a-09a4-46bf-930d-c64a018e18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_65cb8f6a-09a4-46bf-930d-c64a018e18e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_621de120-4360-4602-97f4-2134a0d6865c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_a03adcbe-2f40-4bec-a032-689be16ed4e0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_621de120-4360-4602-97f4-2134a0d6865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ba65468d-ede0-46bb-9a6f-0e2ced50a489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_40177dba-9980-4521-a2f4-5b1b4c58e477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba65468d-ede0-46bb-9a6f-0e2ced50a489" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_40177dba-9980-4521-a2f4-5b1b4c58e477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e08ff638-51c0-4382-839b-a69aded1ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba65468d-ede0-46bb-9a6f-0e2ced50a489" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e08ff638-51c0-4382-839b-a69aded1ea1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_87cd1bb8-2f1f-4430-8366-babadecb85dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba65468d-ede0-46bb-9a6f-0e2ced50a489" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_87cd1bb8-2f1f-4430-8366-babadecb85dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeTaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4ae9a7c6-ecbf-4338-8611-f16ca3b7836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12b5932e-05d5-458b-aff5-66bab942f476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ae9a7c6-ecbf-4338-8611-f16ca3b7836d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12b5932e-05d5-458b-aff5-66bab942f476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7bb81df1-5be8-497a-8f10-37bb2bb12f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12b5932e-05d5-458b-aff5-66bab942f476" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7bb81df1-5be8-497a-8f10-37bb2bb12f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1aea79d7-521a-4e5e-85d3-354a8b1f4c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12b5932e-05d5-458b-aff5-66bab942f476" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1aea79d7-521a-4e5e-85d3-354a8b1f4c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_08e58446-03b0-45ac-9823-f966c3f38fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12b5932e-05d5-458b-aff5-66bab942f476" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_08e58446-03b0-45ac-9823-f966c3f38fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b2b92a3-3794-4845-a5d5-eeccff4bcd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12b5932e-05d5-458b-aff5-66bab942f476" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b2b92a3-3794-4845-a5d5-eeccff4bcd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_aae0370f-12d3-4de2-9afb-2e846c74a5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ae9a7c6-ecbf-4338-8611-f16ca3b7836d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_aae0370f-12d3-4de2-9afb-2e846c74a5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ed8a35cf-77b5-43d1-82fa-0186128e073b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_aae0370f-12d3-4de2-9afb-2e846c74a5b2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ed8a35cf-77b5-43d1-82fa-0186128e073b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cbd07432-d9c3-42c0-9cb3-ffb33fc3676f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_aae0370f-12d3-4de2-9afb-2e846c74a5b2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cbd07432-d9c3-42c0-9cb3-ffb33fc3676f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ebe7d513-7a3c-4656-87a0-33ea9e922a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_aae0370f-12d3-4de2-9afb-2e846c74a5b2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ebe7d513-7a3c-4656-87a0-33ea9e922a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e1b1bae1-0e88-4bbc-a08b-45c8ce684640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_aae0370f-12d3-4de2-9afb-2e846c74a5b2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e1b1bae1-0e88-4bbc-a08b-45c8ce684640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01b8c0d1-bb76-42fe-b640-d9f32dc2a04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ae9a7c6-ecbf-4338-8611-f16ca3b7836d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01b8c0d1-bb76-42fe-b640-d9f32dc2a04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bc91524f-b4a5-4510-9e92-ef0c79985bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_ad7ebf73-2425-4839-87ee-743d5a115b8d" xlink:href="mrk-20221231.xsd#mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc91524f-b4a5-4510-9e92-ef0c79985bb6" xlink:to="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_ad7ebf73-2425-4839-87ee-743d5a115b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_67acebf9-54ca-47b0-b537-89050188a0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_ad7ebf73-2425-4839-87ee-743d5a115b8d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_67acebf9-54ca-47b0-b537-89050188a0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_37e36c59-76ae-4ba3-9a4a-9e4a95a98442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_67acebf9-54ca-47b0-b537-89050188a0b0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_37e36c59-76ae-4ba3-9a4a-9e4a95a98442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_98f6e920-043f-43cd-a6f1-c4b80a65a1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_37e36c59-76ae-4ba3-9a4a-9e4a95a98442" xlink:to="loc_us-gaap_OtherAssetsMember_98f6e920-043f-43cd-a6f1-c4b80a65a1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:href="mrk-20221231.xsd#mrk_IncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable_ad7ebf73-2425-4839-87ee-743d5a115b8d" xlink:to="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_714537bc-8525-4caf-89fd-db3e3e5e6d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_714537bc-8525-4caf-89fd-db3e3e5e6d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_16e3984a-6cdf-4c01-9876-bcc246952126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_16e3984a-6cdf-4c01-9876-bcc246952126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_aceb4461-160d-4e3d-9653-ff8fd353e371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_aceb4461-160d-4e3d-9653-ff8fd353e371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_865259c0-7060-4d4f-be4e-2875a8f27dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_865259c0-7060-4d4f-be4e-2875a8f27dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_4ec73736-b351-4574-8a90-0d7608b5c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_4ec73736-b351-4574-8a90-0d7608b5c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_e4d4ae07-4634-4ccc-b60a-3aa53b09b893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_e4d4ae07-4634-4ccc-b60a-3aa53b09b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_997cb00f-aed5-402a-bee0-168d30254401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_997cb00f-aed5-402a-bee0-168d30254401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_f0b09208-19bc-43f1-9cf1-9f27eb081993" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsUnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits_f0b09208-19bc-43f1-9cf1-9f27eb081993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_3d15359f-23a8-451c-a937-e98c6cef43a7" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards_3d15359f-23a8-451c-a937-e98c6cef43a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f6a79533-a50b-4d79-a080-dc70df02cfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f6a79533-a50b-4d79-a080-dc70df02cfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2c4d4dd8-309e-418a-b3d1-1d4ef34b9dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2c4d4dd8-309e-418a-b3d1-1d4ef34b9dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5f341477-a913-41f0-8337-8e7b7d47314b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5f341477-a913-41f0-8337-8e7b7d47314b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4292dda8-80fd-4ae4-b041-67e72e786b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4292dda8-80fd-4ae4-b041-67e72e786b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7147e1e5-0cd5-4689-91c3-3c7833ad9192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7147e1e5-0cd5-4689-91c3-3c7833ad9192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_941b7127-478e-482c-8161-f68fb6b3ef1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_941b7127-478e-482c-8161-f68fb6b3ef1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_af4ae06e-1e6f-48f8-a091-e25acc63daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_af4ae06e-1e6f-48f8-a091-e25acc63daf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_57331cf9-6cf4-43b9-a02b-832c870bf35f" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesEquityMethodInvestment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxLiabilitiesEquityMethodInvestment_57331cf9-6cf4-43b9-a02b-832c870bf35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_76f50129-d4a5-448e-8fdc-b4f93f9a8136" xlink:href="mrk-20221231.xsd#mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans_76f50129-d4a5-448e-8fdc-b4f93f9a8136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_79affc51-00cf-4484-882d-a5524b210785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_79affc51-00cf-4484-882d-a5524b210785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fe3389bb-c222-416e-a9e1-e6c0f6f52e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_fe3389bb-c222-416e-a9e1-e6c0f6f52e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_33bcafa8-a672-481f-b6fd-9abdef023080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredTaxLiabilities_33bcafa8-a672-481f-b6fd-9abdef023080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_37965362-c340-4588-9957-76b6c5d6bc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_IncomeTaxLineItems_8bb7fa35-3b1e-489d-8eb5-5e18f00c99bb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_37965362-c340-4588-9957-76b6c5d6bc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeIncomeTaxAuthorityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b71ed40-9b7d-4de7-ab3a-0f7e32ebf0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_abde9997-6976-4f86-b7a1-817177d00059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b71ed40-9b7d-4de7-ab3a-0f7e32ebf0c5" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_abde9997-6976-4f86-b7a1-817177d00059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_307b2951-1b2a-440c-9bbc-1095e76efb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_abde9997-6976-4f86-b7a1-817177d00059" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_307b2951-1b2a-440c-9bbc-1095e76efb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_307b2951-1b2a-440c-9bbc-1095e76efb3f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_68bc5c6d-37e2-4156-afaa-7c013b91b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:to="loc_us-gaap_DomesticCountryMember_68bc5c6d-37e2-4156-afaa-7c013b91b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_77174a8f-042d-43e7-bbcd-5797a977e757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7e5ed92-fcbc-4e1e-99e7-639774bab994" xlink:to="loc_us-gaap_ForeignCountryMember_77174a8f-042d-43e7-bbcd-5797a977e757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_bf0754fc-53e7-4421-a3ec-9f889bab7268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_abde9997-6976-4f86-b7a1-817177d00059" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_bf0754fc-53e7-4421-a3ec-9f889bab7268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_f4cb3f6d-a33f-470f-90ca-4c2c6b70b530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_bf0754fc-53e7-4421-a3ec-9f889bab7268" xlink:to="loc_us-gaap_IncomeTaxesPaid_f4cb3f6d-a33f-470f-90ca-4c2c6b70b530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#TaxesonIncomeUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef333f79-2fa2-45c7-b0a0-19d73113c45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef333f79-2fa2-45c7-b0a0-19d73113c45f" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f1a49828-bffe-4ea7-8f8d-e1d6d4e34b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f1a49828-bffe-4ea7-8f8d-e1d6d4e34b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_94d8f63c-cb20-4f12-8aee-e5a89d59c63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_94d8f63c-cb20-4f12-8aee-e5a89d59c63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_682f0ba6-d40f-468e-a1a0-4aade9d9af57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_682f0ba6-d40f-468e-a1a0-4aade9d9af57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2622cacd-6510-4987-b2d2-a6aac56a7dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2622cacd-6510-4987-b2d2-a6aac56a7dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_4b006aa5-28c1-47b2-a6c9-da15afa95b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_4b006aa5-28c1-47b2-a6c9-da15afa95b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_338eeffe-1a41-44a7-b54a-7bf3c4bdeb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_338eeffe-1a41-44a7-b54a-7bf3c4bdeb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_ec160e37-bc47-40f1-b349-51bde9490448" xlink:href="mrk-20221231.xsd#mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction_ec160e37-bc47-40f1-b349-51bde9490448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9c2dc6f4-4c67-445d-a7be-e281e2910507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9b37b6a-4981-4f86-82c6-adc6ea07028d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9c2dc6f4-4c67-445d-a7be-e281e2910507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_cb9ec788-226e-4a2a-9c28-283fd892f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_cb9ec788-226e-4a2a-9c28-283fd892f67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_04298bb2-c873-4a8b-b0af-ff8c908820d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_04298bb2-c873-4a8b-b0af-ff8c908820d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_716bb138-0a77-4336-b6ec-f50c35280704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_716bb138-0a77-4336-b6ec-f50c35280704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_15737890-9d55-4bea-b4ec-0fc3c9838164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_15737890-9d55-4bea-b4ec-0fc3c9838164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2286debe-9494-42c5-a51e-bfd9b1601cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2286debe-9494-42c5-a51e-bfd9b1601cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9df35fc0-b923-4d03-a77a-8b7514b24289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9df35fc0-b923-4d03-a77a-8b7514b24289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6212b35f-ddd5-4cc3-b816-0e526c255978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6212b35f-ddd5-4cc3-b816-0e526c255978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_8e8069e0-9da7-4c6d-b7e3-04d87979c325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_8e8069e0-9da7-4c6d-b7e3-04d87979c325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0fd1838d-83c7-49da-b284-e5007c0059b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8e8069e0-9da7-4c6d-b7e3-04d87979c325" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0fd1838d-83c7-49da-b284-e5007c0059b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c14666cb-0f38-4760-a447-eab5ce564885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8e8069e0-9da7-4c6d-b7e3-04d87979c325" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c14666cb-0f38-4760-a447-eab5ce564885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bffdb42c-7482-4e07-b344-a46ea1dac1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_8e8069e0-9da7-4c6d-b7e3-04d87979c325" xlink:to="loc_us-gaap_EarningsPerShareBasic_bffdb42c-7482-4e07-b344-a46ea1dac1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_6332b650-d6f0-44f7-b578-9c71b0278ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b2aaae92-8e71-494d-81ae-c814cd46b8a6" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_6332b650-d6f0-44f7-b578-9c71b0278ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_89726d99-0c72-4c4f-810a-d148b7dc67ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_6332b650-d6f0-44f7-b578-9c71b0278ae4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_89726d99-0c72-4c4f-810a-d148b7dc67ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_b569eece-f96d-4944-94b9-4339ec6b858f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_6332b650-d6f0-44f7-b578-9c71b0278ae4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_b569eece-f96d-4944-94b9-4339ec6b858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5adcb697-42f7-4679-8e21-2201a8c81d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_6332b650-d6f0-44f7-b578-9c71b0278ae4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5adcb697-42f7-4679-8e21-2201a8c81d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0fb19753-78e8-4b60-ad17-e466ba8397fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0bb3033-b41a-4ec6-bd55-9d9cf012f5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0fb19753-78e8-4b60-ad17-e466ba8397fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0bb3033-b41a-4ec6-bd55-9d9cf012f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2a63308-5959-43c2-9c78-be1799497890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_984343f9-82f2-4533-886c-7167f9b0fd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2a63308-5959-43c2-9c78-be1799497890" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_984343f9-82f2-4533-886c-7167f9b0fd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_984343f9-82f2-4533-886c-7167f9b0fd0c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f09c39cf-1bf4-4535-a7b4-56dd3d779ae7" xlink:to="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_479b764e-d6d8-4898-a983-3e76fd0dced0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_479b764e-d6d8-4898-a983-3e76fd0dced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d5a7d92e-154f-4c83-8bd5-90155574b526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d5a7d92e-154f-4c83-8bd5-90155574b526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanNetLossMember_5f333d00-3e86-41e3-a177-5ab4f93a4719" xlink:href="mrk-20221231.xsd#mrk_PensionPlanNetLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_PensionPlanNetLossMember_5f333d00-3e86-41e3-a177-5ab4f93a4719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_a9d41b45-8b0b-45c9-b8d6-2e2b46f6650d" xlink:href="mrk-20221231.xsd#mrk_OtherPostretirementBenefitPlanNetLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_OtherPostretirementBenefitPlanNetLossMember_a9d41b45-8b0b-45c9-b8d6-2e2b46f6650d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionPlanPriorServiceCostMember_2257cfd7-2b47-44e8-a718-3d51b05964de" xlink:href="mrk-20221231.xsd#mrk_PensionPlanPriorServiceCostMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_PensionPlanPriorServiceCostMember_2257cfd7-2b47-44e8-a718-3d51b05964de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_e9bc9b4d-8a45-4dc8-9eeb-0e0c5ecd12cb" xlink:href="mrk-20221231.xsd#mrk_OtherPostretirementBenefitPlanPriorServiceCostMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_81d1a74e-68fd-4006-919c-879f17d20fca" xlink:to="loc_mrk_OtherPostretirementBenefitPlanPriorServiceCostMember_e9bc9b4d-8a45-4dc8-9eeb-0e0c5ecd12cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_17e12789-4b2a-421c-a2da-7d526d6557fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_17e12789-4b2a-421c-a2da-7d526d6557fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30904ab8-af40-4932-ac61-352498a2761d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e0fd694-129d-4de8-aa6a-8beb87f094dc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_30904ab8-af40-4932-ac61-352498a2761d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_984343f9-82f2-4533-886c-7167f9b0fd0c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7be32586-497b-49db-85a2-c64937d5d113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7be32586-497b-49db-85a2-c64937d5d113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_fb01580a-af79-4e5f-b65d-7c3a8c5d8708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_fb01580a-af79-4e5f-b65d-7c3a8c5d8708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f598ad0d-441c-4834-83f8-dc6e844804e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f598ad0d-441c-4834-83f8-dc6e844804e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b3f26f31-b392-4184-b2cc-752d9d4a09be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b3f26f31-b392-4184-b2cc-752d9d4a09be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fbb73004-b166-48a7-8f6c-cd1e179c5169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_fbb73004-b166-48a7-8f6c-cd1e179c5169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_878f2ab1-69a3-4c4a-b7f0-ca2315c95b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_878f2ab1-69a3-4c4a-b7f0-ca2315c95b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_27ecd9fb-ef65-49c4-92fe-c2a0f6736f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_27ecd9fb-ef65-49c4-92fe-c2a0f6736f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e442bcec-35a5-4dee-bb24-a61af595b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e442bcec-35a5-4dee-bb24-a61af595b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_599e7e48-f75c-4bcf-8be4-45291fb10c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_599e7e48-f75c-4bcf-8be4-45291fb10c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb7c807c-974b-4eae-ae91-463593b63b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_029dd6c5-57de-4028-99b5-396fa7d57f35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb7c807c-974b-4eae-ae91-463593b63b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_38dff1cb-79b0-47b0-8331-b5f56b74211c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_66f662b6-1f0a-47c0-8742-1d06401b95f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_38dff1cb-79b0-47b0-8331-b5f56b74211c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_05e4335d-4ec9-4de2-b5d2-36ead3e6286a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8ef8c7a3-b0b2-4240-949e-5250808da7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_05e4335d-4ec9-4de2-b5d2-36ead3e6286a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8ef8c7a3-b0b2-4240-949e-5250808da7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d88d8e8b-a9b3-4cf5-97d9-32e6cd7755e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d88d8e8b-a9b3-4cf5-97d9-32e6cd7755e5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_50744f8f-b202-46cb-9c3c-b59dd07533ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_srt_StatementGeographicalAxis_50744f8f-b202-46cb-9c3c-b59dd07533ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_50744f8f-b202-46cb-9c3c-b59dd07533ef" xlink:to="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4ffec673-0259-466c-a700-8161180c2b86" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:to="loc_country_US_4ffec673-0259-466c-a700-8161180c2b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_290e9fe3-2bff-42fd-bcaa-5130c46950ef" xlink:href="mrk-20221231.xsd#mrk_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6951d0bf-c993-4162-8805-fa062fb4b13d" xlink:to="loc_mrk_InternationalMember_290e9fe3-2bff-42fd-bcaa-5130c46950ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b6fdb6b2-de41-435f-8b0a-df27450bf589" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_srt_ConsolidationItemsAxis_b6fdb6b2-de41-435f-8b0a-df27450bf589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b6fdb6b2-de41-435f-8b0a-df27450bf589" xlink:to="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_43ca778c-e570-4895-b3f9-1cc2d41675d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:to="loc_us-gaap_OperatingSegmentsMember_43ca778c-e570-4895-b3f9-1cc2d41675d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b40be9d4-fc13-4d0a-91df-80ee044fa877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a6452c9b-84a3-467d-9287-d93727a9d992" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b40be9d4-fc13-4d0a-91df-80ee044fa877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6059c11f-f5d9-4220-bd9d-7c593d16bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6059c11f-f5d9-4220-bd9d-7c593d16bb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6059c11f-f5d9-4220-bd9d-7c593d16bb05" xlink:to="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_6ebe9413-fbb0-4f2e-a081-d498a076eff1" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:to="loc_mrk_PharmaceuticalsegmentMember_6ebe9413-fbb0-4f2e-a081-d498a076eff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_2f243816-a20e-4b96-bb6b-fc25dc5b5bfc" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:to="loc_mrk_AnimalHealthsegmentMember_2f243816-a20e-4b96-bb6b-fc25dc5b5bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_60a1afe6-2e5f-4396-9d96-c8ccdb3aa4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_07e3898d-dd32-4203-a5d8-737d53a4aeae" xlink:to="loc_us-gaap_AllOtherSegmentsMember_60a1afe6-2e5f-4396-9d96-c8ccdb3aa4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2bdd641d-7328-4619-8e8a-805240da798d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_srt_ProductOrServiceAxis_2bdd641d-7328-4619-8e8a-805240da798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2bdd641d-7328-4619-8e8a-805240da798d" xlink:to="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_429dbd9b-a9f9-4fc0-8270-3e1d298265c3" xlink:href="mrk-20221231.xsd#mrk_KeytrudaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_KeytrudaMember_429dbd9b-a9f9-4fc0-8270-3e1d298265c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_a4f5b02a-3227-4ee7-b91f-683e0181e5c8" xlink:href="mrk-20221231.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_a4f5b02a-3227-4ee7-b91f-683e0181e5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_5e582ab2-bddc-48c9-8251-8dd033f9f484" xlink:href="mrk-20221231.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_LenvimaMember_5e582ab2-bddc-48c9-8251-8dd033f9f484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ReblozylMember_2ead744c-6e6e-49d5-9ea8-de076f1de144" xlink:href="mrk-20221231.xsd#mrk_ReblozylMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_ReblozylMember_2ead744c-6e6e-49d5-9ea8-de076f1de144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_91ede841-6ad5-493d-87b1-d61c018ef2af" xlink:href="mrk-20221231.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_GardasilGardasil9Member_91ede841-6ad5-493d-87b1-d61c018ef2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_5466f780-0926-448a-838e-bd2741576c69" xlink:href="mrk-20221231.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_5466f780-0926-448a-838e-bd2741576c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_97133650-3013-465b-8ea6-4c9c20885a96" xlink:href="mrk-20221231.xsd#mrk_RotateqMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_RotateqMember_97133650-3013-465b-8ea6-4c9c20885a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_aaf62bac-a802-4ea7-8030-c1fef64834a7" xlink:href="mrk-20221231.xsd#mrk_Pneumovax23Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_Pneumovax23Member_aaf62bac-a802-4ea7-8030-c1fef64834a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_7ccf820c-be54-4a04-8f8e-11f60826483a" xlink:href="mrk-20221231.xsd#mrk_VaqtaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_VaqtaMember_7ccf820c-be54-4a04-8f8e-11f60826483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_e7acf20f-5c5c-41e2-85de-87c5cce31aba" xlink:href="mrk-20221231.xsd#mrk_BridionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_BridionMember_e7acf20f-5c5c-41e2-85de-87c5cce31aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_12762f13-9e54-4c67-b7c1-7b175eaf386e" xlink:href="mrk-20221231.xsd#mrk_PrevymisMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_PrevymisMember_12762f13-9e54-4c67-b7c1-7b175eaf386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_f1bdfa48-5455-43f9-a7c5-aa76e0b9c464" xlink:href="mrk-20221231.xsd#mrk_DificidMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_DificidMember_f1bdfa48-5455-43f9-a7c5-aa76e0b9c464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_3f132792-9f4a-4271-8d52-e7c500683e35" xlink:href="mrk-20221231.xsd#mrk_PrimaxinMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_PrimaxinMember_3f132792-9f4a-4271-8d52-e7c500683e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_c89a3ed6-9b1d-4990-8610-d1d321d3d0ee" xlink:href="mrk-20221231.xsd#mrk_NoxafilMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_NoxafilMember_c89a3ed6-9b1d-4990-8610-d1d321d3d0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_ebc8a004-2954-4749-8d67-bdaf02540a60" xlink:href="mrk-20221231.xsd#mrk_InvanzMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_InvanzMember_ebc8a004-2954-4749-8d67-bdaf02540a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_4c1f1069-5b7e-4f2d-8020-6ca738e9a455" xlink:href="mrk-20221231.xsd#mrk_CancidasMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_CancidasMember_4c1f1069-5b7e-4f2d-8020-6ca738e9a455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_69b7599d-eaf7-4709-9d64-348df0270e92" xlink:href="mrk-20221231.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_ZerbaxaMember_69b7599d-eaf7-4709-9d64-348df0270e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_4f37ba13-82bd-48f8-9d5a-9a2556321777" xlink:href="mrk-20221231.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_4f37ba13-82bd-48f8-9d5a-9a2556321777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_fea276bc-4e9c-4527-8f13-54671fae775e" xlink:href="mrk-20221231.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_AdempasMember_fea276bc-4e9c-4527-8f13-54671fae775e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_f634cc1a-df1b-47c6-88ac-2120207fe5c2" xlink:href="mrk-20221231.xsd#mrk_LagevrioMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_LagevrioMember_f634cc1a-df1b-47c6-88ac-2120207fe5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_1b4da73f-4359-4873-a381-c1263d48ad6b" xlink:href="mrk-20221231.xsd#mrk_IsentressIsentressHDMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_IsentressIsentressHDMember_1b4da73f-4359-4873-a381-c1263d48ad6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_a1aaddaf-074d-4bdd-9a04-b492f4efb7eb" xlink:href="mrk-20221231.xsd#mrk_BelsomraMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_BelsomraMember_a1aaddaf-074d-4bdd-9a04-b492f4efb7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_bd27cfac-97ef-47de-9e85-3dc301d4fddc" xlink:href="mrk-20221231.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_SimponiMember_bd27cfac-97ef-47de-9e85-3dc301d4fddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_e20c1f49-21f9-45ef-be58-32a0dcd56372" xlink:href="mrk-20221231.xsd#mrk_RemicadeMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_RemicadeMember_e20c1f49-21f9-45ef-be58-32a0dcd56372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_318523c4-3ca0-4e73-b1ca-e58f30af4eb5" xlink:href="mrk-20221231.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_JanuviaMember_318523c4-3ca0-4e73-b1ca-e58f30af4eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_b6a0ed19-bf8f-4b96-926d-1794212ca5fa" xlink:href="mrk-20221231.xsd#mrk_JanumetMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_JanumetMember_b6a0ed19-bf8f-4b96-926d-1794212ca5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_e5fc3beb-063a-432c-8253-f30f0c0b6e81" xlink:href="mrk-20221231.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_OtherPharmaceuticalMember_e5fc3beb-063a-432c-8253-f30f0c0b6e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_2d4cacb9-1d1a-4935-ad64-98707e6ceaba" xlink:href="mrk-20221231.xsd#mrk_LivestockMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_LivestockMember_2d4cacb9-1d1a-4935-ad64-98707e6ceaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_dbeef3d6-863a-4293-ac0f-2d22f4443cc2" xlink:href="mrk-20221231.xsd#mrk_CompanionAnimalsMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d75b291-5db5-4247-b836-56738703cd63" xlink:to="loc_mrk_CompanionAnimalsMember_dbeef3d6-863a-4293-ac0f-2d22f4443cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0a09e849-1a70-41e1-af78-e4e8dbe73374" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_28049d95-182a-46eb-a0f2-f4958f3310e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:to="loc_us-gaap_Revenues_28049d95-182a-46eb-a0f2-f4958f3310e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncreaseDecreaseInHedgeRevenue_fd13faa9-50d5-404c-92ae-fc045e6ba283" xlink:href="mrk-20221231.xsd#mrk_IncreaseDecreaseInHedgeRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:to="loc_mrk_IncreaseDecreaseInHedgeRevenue_fd13faa9-50d5-404c-92ae-fc045e6ba283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_088ffd87-1393-41b2-88df-a9f69438c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_b2f8069f-ee3b-4902-a55b-e3550ca0da54" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_088ffd87-1393-41b2-88df-a9f69438c0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_77bafe24-9655-4bda-9935-e128e3ee8d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_01ed7a53-81c3-430e-aa11-4f997d32422f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_77bafe24-9655-4bda-9935-e128e3ee8d29" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_01ed7a53-81c3-430e-aa11-4f997d32422f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_30bc9e22-02d4-4296-8ad5-f4def4441066" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_01ed7a53-81c3-430e-aa11-4f997d32422f" xlink:to="loc_srt_StatementGeographicalAxis_30bc9e22-02d4-4296-8ad5-f4def4441066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_30bc9e22-02d4-4296-8ad5-f4def4441066" xlink:to="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d2bbb1a2-16f8-4d69-b931-36a282498391" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_country_US_d2bbb1a2-16f8-4d69-b931-36a282498391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_4841c682-d51c-4cf4-a449-c94e9d53e826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_us-gaap_EMEAMember_4841c682-d51c-4cf4-a449-c94e9d53e826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_61aabd2b-fc5f-4ce1-b84d-f719c8ba11d6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_country_CN_61aabd2b-fc5f-4ce1-b84d-f719c8ba11d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_396d8290-5bd0-4f9b-b399-f15216ff0e57" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_country_JP_396d8290-5bd0-4f9b-b399-f15216ff0e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_1164ada4-ad5f-4b1d-a46b-e2f4ffb3e1e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_srt_AsiaPacificMember_1164ada4-ad5f-4b1d-a46b-e2f4ffb3e1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_438f1aa3-30ca-4036-af47-e90f395b44cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_srt_LatinAmericaMember_438f1aa3-30ca-4036-af47-e90f395b44cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_01b0b32b-8ad9-462c-bfb3-af859deae3ba" xlink:href="mrk-20221231.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9c58c368-3d8a-4fca-8675-8267e81611c7" xlink:to="loc_mrk_OtherCountriesMember_01b0b32b-8ad9-462c-bfb3-af859deae3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_deb0ba1f-74c5-42fc-af58-ce9315344642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_01ed7a53-81c3-430e-aa11-4f997d32422f" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_deb0ba1f-74c5-42fc-af58-ce9315344642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0109e27b-2291-4948-a652-b9241355fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_deb0ba1f-74c5-42fc-af58-ce9315344642" xlink:to="loc_us-gaap_Revenues_0109e27b-2291-4948-a652-b9241355fc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_067d5fcf-57ae-4428-a18e-2f1ab9a8613d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_067d5fcf-57ae-4428-a18e-2f1ab9a8613d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7b1b683-51e6-4c93-836e-d3008269cf10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:to="loc_srt_ConsolidationItemsAxis_c7b1b683-51e6-4c93-836e-d3008269cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c7b1b683-51e6-4c93-836e-d3008269cf10" xlink:to="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_cf904498-e003-47f4-85e1-c47df095f532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:to="loc_us-gaap_OperatingSegmentsMember_cf904498-e003-47f4-85e1-c47df095f532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d4f6d596-dfa7-4c33-aa81-b645a74f102a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d4f6d596-dfa7-4c33-aa81-b645a74f102a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_dae91035-9e8f-4838-94c1-0cc685ec96c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d723eaf3-3d55-47a2-beed-c4080e519840" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_dae91035-9e8f-4838-94c1-0cc685ec96c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30aca2d4-79dd-48e2-aa56-226aebd7f836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30aca2d4-79dd-48e2-aa56-226aebd7f836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30aca2d4-79dd-48e2-aa56-226aebd7f836" xlink:to="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_ebc505e9-7ccf-41e3-8005-d40331c4c0ff" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:to="loc_mrk_PharmaceuticalsegmentMember_ebc505e9-7ccf-41e3-8005-d40331c4c0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_b4346690-1789-476d-bc11-3fd8858cae3d" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:to="loc_mrk_AnimalHealthsegmentMember_b4346690-1789-476d-bc11-3fd8858cae3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_20344c55-3f14-4859-b6f8-a042f42b44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4bff0cd4-678d-4ac2-be94-075c4a62110c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_20344c55-3f14-4859-b6f8-a042f42b44b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_189ec658-4153-4d10-8b02-9d62a3dae574" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0ec4a613-99fa-484f-9fdc-840f62b69edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0ec4a613-99fa-484f-9fdc-840f62b69edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ebdaa140-ebaa-4e20-a9c9-a59b38f9c190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_InterestExpense_ebdaa140-ebaa-4e20-a9c9-a59b38f9c190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_cd1298e5-7911-4592-8e01-243dfbc84ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_AdjustmentForAmortization_cd1298e5-7911-4592-8e01-243dfbc84ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0e317efc-08d6-4048-bc28-1e22fc9e4fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_Depreciation_0e317efc-08d6-4048-bc28-1e22fc9e4fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d97f0992-5a2a-49f6-b2e3-89e3c7ccb389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d97f0992-5a2a-49f6-b2e3-89e3c7ccb389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_84fb9fd0-c997-4395-b492-98457c40cd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_RestructuringCharges_84fb9fd0-c997-4395-b492-98457c40cd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6c21ccc2-bb60-4886-b1c1-59afa29d9b79" xlink:href="mrk-20221231.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_6c21ccc2-bb60-4886-b1c1-59afa29d9b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6723464a-d8f8-4415-ad93-0874a5e3b1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30a69a11-70e4-431d-89f0-3e2b8eab6a16" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6723464a-d8f8-4415-ad93-0874a5e3b1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5e7bfa7f-76d2-40be-b65d-313ca05d3c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5e7bfa7f-76d2-40be-b65d-313ca05d3c30" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_acc238d2-b0df-4ba1-a49e-97617169d9fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:to="loc_srt_ConsolidationItemsAxis_acc238d2-b0df-4ba1-a49e-97617169d9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c387b68d-8022-4ec3-8789-9b09a23a5121" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_acc238d2-b0df-4ba1-a49e-97617169d9fb" xlink:to="loc_srt_ConsolidationItemsDomain_c387b68d-8022-4ec3-8789-9b09a23a5121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ec2bb853-ca2d-4f3e-862b-6806b4a2a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c387b68d-8022-4ec3-8789-9b09a23a5121" xlink:to="loc_us-gaap_OperatingSegmentsMember_ec2bb853-ca2d-4f3e-862b-6806b4a2a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_82c022a8-df78-4f61-a771-f068231d664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_82c022a8-df78-4f61-a771-f068231d664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_82c022a8-df78-4f61-a771-f068231d664d" xlink:to="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_8207f329-8581-4e53-b4d9-ef47bcad0867" xlink:href="mrk-20221231.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:to="loc_mrk_PharmaceuticalsegmentMember_8207f329-8581-4e53-b4d9-ef47bcad0867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_70b1cf06-f058-4358-a82c-2a166befda07" xlink:href="mrk-20221231.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:to="loc_mrk_AnimalHealthsegmentMember_70b1cf06-f058-4358-a82c-2a166befda07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_8e25c114-bcb9-491f-a23d-4489513d6fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_17ab2bb7-d51b-4f12-b2bf-cd30cf0fad71" xlink:to="loc_us-gaap_AllOtherSegmentsMember_8e25c114-bcb9-491f-a23d-4489513d6fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ef1ae4b-e7e6-4cba-bcdf-bf934c17bc19" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0fb82c6e-cbce-48eb-ab87-a343412847c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0fb82c6e-cbce-48eb-ab87-a343412847c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a6abaaf9-f1c0-447a-9c72-afedf1a56da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_495a2411-9783-4e33-bad3-8147e3c00279" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a6abaaf9-f1c0-447a-9c72-afedf1a56da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20221231.xsd#SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fa5814fa-e52f-4edd-a236-58fcbf1511ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_33166161-623f-4033-8d47-5de02ba29b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fa5814fa-e52f-4edd-a236-58fcbf1511ac" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_33166161-623f-4033-8d47-5de02ba29b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_003d2bb2-fdf4-422e-a9ab-0c52219f1734" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_33166161-623f-4033-8d47-5de02ba29b71" xlink:to="loc_srt_StatementGeographicalAxis_003d2bb2-fdf4-422e-a9ab-0c52219f1734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_003d2bb2-fdf4-422e-a9ab-0c52219f1734" xlink:to="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1444a28a-ee3c-42a9-8299-34d5a5df42c5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_country_US_1444a28a-ee3c-42a9-8299-34d5a5df42c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_295be1f5-19da-4eda-8f77-55c5d26e7cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_us-gaap_EMEAMember_295be1f5-19da-4eda-8f77-55c5d26e7cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_c21bdc53-9673-43a2-9c89-3ae82bf5594d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_srt_AsiaPacificMember_c21bdc53-9673-43a2-9c89-3ae82bf5594d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_bc401122-fda8-4203-a7dd-4ce063ce7076" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_srt_LatinAmericaMember_bc401122-fda8-4203-a7dd-4ce063ce7076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ba1ec92c-b0a3-4791-975b-2acda6f45eab" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_country_CN_ba1ec92c-b0a3-4791-975b-2acda6f45eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_cfc952fe-1f2a-49e7-a269-740710a36a39" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_country_JP_cfc952fe-1f2a-49e7-a269-740710a36a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_65198d89-398f-41c5-b239-a076807fe802" xlink:href="mrk-20221231.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ac17a3da-9df3-441b-8e8b-9ab07a47d518" xlink:to="loc_mrk_OtherCountriesMember_65198d89-398f-41c5-b239-a076807fe802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bd9088e0-fe4e-45e2-a070-2e723c41b87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_33166161-623f-4033-8d47-5de02ba29b71" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bd9088e0-fe4e-45e2-a070-2e723c41b87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2fee98f6-f19d-4c35-8c54-86900dc1b317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bd9088e0-fe4e-45e2-a070-2e723c41b87c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2fee98f6-f19d-4c35-8c54-86900dc1b317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "6 >H# 2(  A$! Q$!_\0
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M_P!U/YPO^$?U[_H"7G_@,_\ A1_PC^O?] 2\_P# 9_\ "OZ/:*/]:Y?\^?\
MR;_@!_Q+E3_Z&;_\$_\ W4_G"_X1_7O^@)>?^ S_ .%'_"/Z]_T!+S_P&?\
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M)>TG&-_:MVYFE>WL];7/WAU+5M+T:V^V:OJ5O:P[@OFW,RHN3T&6(&:H?\+
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M&7B._P#%OB749;O4=3NY+F]NIF)>65V+,Q/N2:^BX>RV&*JNO45XQV7=_P#
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MAQ/ETN%EGM_W/LO:_+EOR^M_=MWT/RE_X*,?M"M^TA^UGXE\9V5[YVDZ=/\
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MP-^&WP1.MP_#+P]'I5KKVKMJ5Y8VW$*7#(J,8TZ(#L!VCC).,=*_&'_@I_\
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M3K2FJ<N_1_+OZ'[KX8^(O&V$G'*\/AI8VE':.O-!>4]4H^4].B:/V:HKQ?\
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M=7VE6-WZO]&?'9%XA\8<-X!8++L3[.DFW;D@]7OK*+?XGZ1?\1!$O_1KR_\
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ME9IJZ:>Z:>Z/QC_X*/\ _!-W7_V0-<'C[P"USJG@+4[C9;W,@+3:7*Q)$$Q
MP5Q]R3^+H>1S\IU_19\2OAUX0^+?@35/AOX]TB.^TC6+1K>]MI/XE;N#V8'!
M!'((![5^"O[4_P"S_P"(/V8?CMX@^#7B%VE.EW0-C=E,"ZM7 >&4?5",XZ,&
M':OOLBS66-INE5?OQZ]U_GW/XU\7_#NCPGC8YAE\;8:L[<O_ #[GO;_#)7<>
MUFNQY[1117T)^*A7;?LW_"O4_C9\>/"7PMTR!W?6==MX)BJYV0[P97^BQAF_
M"N)K]*_^"('['NH::+S]K?QWI30_:('L?!T<R$,T;96>Z /8X$:GN/,[8SP9
MGC(X+!RJ/?9>O0^OX%X:K\5\3X? P5X74IOM"+O)_/9>;2/T9L[6WL;2*QM(
MPD4,8CB0=%4# 'Y"I* ,#%%?EQ_H0DDK(****!GY'?\ !=W_ ).[T3_L1;7_
M -*KJOBBOM?_ (+N_P#)W>B?]B+:_P#I5=5\45^G9/\ \BREZ'\ >)G_ "7N
M8?\ 7Q_DC]I?^"-W_)@GA7_L(ZI_Z735Y!_P78_9Q/B/X?Z%^TOH%ANN] E7
M2]<9%Y-G*S-%(?9)25_[;>U>O_\ !&[_ ),$\*_]A'5/_2V:OH#XO?#'P[\9
MOAAKWPK\5PA]/U_3);.Y^7)0.I <?[2G##W45\5+%/!9W.JNDW?TOJ?U9AN'
MJ?%/A+ALMEO/#4N5]IJ$7%_>E?RN?SM4HQGFMWXH?#SQ#\)?B)K7PT\66IAU
M'0]2EL[M"/XD8C<,]B,$'N"*@^'_ ()U_P")/CC2?A_X6LVN-1UG4(K.RB49
MW22,%&?89R3V -?HJG%PY[Z;_(_B%X;$1Q/U=Q?/?EY>O->UK=[Z'Z0?\$(_
MV<#I?AOQ#^T]K]AMFU)VT?P^9%Y$"%7GE7V9]J9_Z9L._/O'_!7S_DPCQA_U
MWL/_ $KBKVWX%_"70/@3\(/#WPB\,HHM-!TN*U5PN/-<#YY#[NY9C[M7B7_!
M7S_DPCQA_P!=[#_TKBK\Z6*>-SN%7HYQMZ)JQ_;TN':?"OA-B,N2]Z.'J.;[
MSE!N3^]V7DD?BA7V#_P1"_Y/87_L5+__ -IU\?5]@_\ !$+_ )/87_L5+_\
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MA> L3BZO$;6%JU%&--5&HN44VY./=7Y;V['U_17R!_P^^_8B_P">OB[_ ,$
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MZ9^V%\%HY->NHH_&6@(EMXDM%('FG!"72#CY9 ,G'"MN'IG\X/\ ASO_ ,%
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MX_?L_P#Q-_9K^)-]\+_BIH+V6H6C$Q2A28;N+/RS0N0 Z-V(Z'(.""*XFOZ
M/VEOV4O@O^U?X+/@WXN>%TN?+!.GZG;D1W=BY'WHI,9'NIRIQR#7YE?M)_\
M!%K]I+X47EQJ_P '3#XZT-26C%IM@OXU]&@9L.1TS&S$]=HZ5][EV?X;$P4:
MSY9^>S]'_F?QQQOX-Y_P_B)U\L@\1AGJN57G%=I16KM_-%-=TCXTHK>\7?"S
MXF> =0DTKQQ\/M;T>YC.'AU/2Y8&'X.HX]ZQX=/O[F3RK>RED;.-J1DG/T%>
M]&<9*Z9^/5*%:E-PG%IKHTT_N(:*]1^$7[%G[4WQRNXH/AQ\$=>NH96 %_<V
M1MK4>YFFVI^1K[W_ &/_ /@B-X5\$7UKX\_:FUNVU^^A99(?"^G;OL43#G]]
M*<-/S_" J\<E@<5P8S-<%@H^_*[[+5_UZGV7#/AYQ7Q56C'"8=QIO>I-.,$N
M]W\7I&[\CQ'_ ()6?\$X-7^.7BJR^/\ \9=!>#P3I=P)=,L;N,J=:G0@KP<9
MMU/);HQ7:,C=C];5554*H  &  .E1:?IVGZ180Z7I5C#;6UO&L=O;V\81(T
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3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #P PD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBD+8^M "TAICS!.OXURWCGXG^&_AS8M=^(=3@TU,?(LK
M_/(?15')--*4G:*NS&K6IT(>TJR45W9U#,%;ISUQGFA9%8D=37R!XZ_;P8.\
M/A'P^-HZ7NJL<-](E[=.2WX5XEX@_:B^)?B1Y/-\22V4;'B.PB2#:/0,HW?F
M<UZ5/+:L]7H?"8WCC*L*W&FY5&NRLOO=C]+7?%(CYY[>M?E--\4_&<[[Y/%N
MN.W3+ZE,Q_5JGL/B_P"-].D#P>+M:4@YP;Z1E)]U8D'\JZ?[*GUDCQ%XAX3F
M_@2MZJY^J)F4-@<GT%/1P<X'0XZU^=GAG]L3XE: Z^?J-KK4 _Y8W]JG/_ D
M"G\R:]\^'G[<'AC7WCM?$UE+X<N&P#=!C-:Y]V"Y3_@0Q_M=<<M7 5J:O:Z/
MI,#QCE..:BYN$GTDOU5U][/ID'-+5#2=:L=<L(;W3KN&^LYANCN() \;CU##
M@U<CDWCE2OUKSFFMS[:,HR7-%W0^BFEL=LTJDG.1BD.XM%%% PHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/KYP_< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC(<W+:VK7Y69\??\._\ 4?\ H=+?_P %Q_\ CE'_  [_ -1_Z'2W_P#!<?\
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M>)K"1$/S%\YW(W]T5[\?V#O QVYUSQ!C'&9H/_C5</\ L _-K?C(],06I_\
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MSV.+\1?M&?#SPO'(]SXJL9W0D&"Q8W,F?0K&&(/UQ7@OQ$_;IDN%DM_!FCF
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M'!/RDC\*^Y/V&M1\-R^ ;^RLH/)\11W&_4?-YDD!'R,/]@8(QV.?6OAW(8#
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M*UPVV. ^)/P=\-_%;2C:ZY9B:9%Q!>Q_+/ ?5&_H<CFO@?XT? C7O@[JPBO
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MHEABC7H$48'Z5HKTIJQ[0><GL:<!@5\>W?5G],Q2BN5*R6WH+1112+"BBB@
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MO+5E>74Z+7O/5^K_ ,A#U%?G-^V#_P EWUK_ *XV_P#Z*6OT9/45^<W[8/\
MR7?6O^N-O_Z*6NS+/XWR/G./?^17'_$CQ:@]&^G]110>C?3^HKZAG\]+<^_O
MV&/^2+3?]A:?_P!%Q5[%\3?^2<^*O^P3=_\ HEZ\=_88_P"2+3?]A:?_ -%Q
M5[%\3?\ DG/BK_L$W?\ Z)>OCL1_O4O4_I_)_P#DGZ?_ %[?Y,_)\=3^'\J*
M!U/X?RHK[%;'\Q-78Y>HK]=M"_Y MA_UPC_]!%?D4F.#DGV R?>OO'3/VWO
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M2?\ ,P^IX;_GW'_P%'$_\*2^'O\ T)'A_P#\%L/_ ,31_P *2^'O_0D>'_\
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_1b.jpg
<TEXT>
begin 644 image_1b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #P PD# 2(  A$! Q$!_\0
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M@U<CDWCE2OUKSFFMS[:,HR7-%W0^BFEL=LTJDG.1BD.XM%%% PHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/KYP_< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC(<W+:VK7Y69\??\._\ 4?\ H=+?_P %Q_\ CE'_  [_ -1_Z'2W_P#!<?\
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M>)K"1$/S%\YW(W]T5[\?V#O QVYUSQ!C'&9H/_C5</\ L _-K?C(],06I_\
M'I*^SXEPM?,8[$5J==PC+0_?.%<FR[&953JXB@I2;>K\CY=U3]@SPJUHZZ;X
MBUFWN3]V2Y,4J#ZJ%3^=?-7QD^ ?B7X-W$;ZE''?:5*=L6IVP/EY)P%D'.QC
MZ<CWK].-OO6-XK\+6'B_0[W2-3A6XL;J(QR1N,XS_$/0CJ#[5G1Q]:G)<SNC
MTLTX-R[%T9?5H*G4Z-;?-'Y*XR<$_P"<TX/D\]A@5T/Q"\'3^ _&VL^'[EB\
MEC<M$LC=6CZQL?JA4_C7.$;3CKSUKZOFYXJ7<_GBM2E1G*G4WBVB]H>JW>A:
MK;:E83-!>VDJ3PR+_"RG(_/I]":_4SX9^-(?B!X"T3Q!!M"WULLCHIR$DQAU
MS[,"/PK\I0Q5LJ<?YXK[O_85UY[_ .%FIZ<[;AI^I2>4N?N1NB,!_P!];S^-
M>+F5).FJG8_2N LPE2QTL(_AFK^C1](-+M)SP!ZGI7SG^U;^T.WP]LSX9T"=
M1XBNXMTTZG<;2(YYQC[Y'3TR#Z5Z]\6/B!:?#+P)JWB&\"LMK%^ZC)YDE/"*
M/J<?D:_+_P 1Z]?>*=<O]5U.8S7U[,TTS@]6)Z?0= /0"N#+\+[5^TELC[/C
M+/I9;06$P[M4GN^R_P V4Y9?.8O*3*7)=GD)+.QY))[GFHF8YR?TH[DGG-+M
MW*.1UP?85]3ZG\^;O5B!&<9XP/7O]*T=$\-:EXDO4LM*L[C4KQCQ;VD1D?'J
M0.@]S@>]>F? +]GO4_C-??:9)FTWPW!)MGOE!WRGC,<?J<$9/;/>OOWP!\-=
M ^&VBIIN@Z?#8Q*,-(B_O).!R[=6/%>5B<P5!\D-6??Y#PEB<VBJ]67LZ71V
MU?I_F?$WA?\ 8G\?:Y!%/?R:=HD;]8YYS),O?E4!7\-V:[FV_P""?]Q+#NG\
M<I%)_=32MX_/SA_*OL98%7!ZGUIVP?C7CSS'$2VE8_4:/!&34HI2IN;[N37Y
M-'P_K/[!GB.S7=I/B;3KYO2ZA:W!_$%Z\A\?? 3QW\.\RZWH4[6:];VSVSPA
M>Q)4_+_P("OT_P >]0RV_F;@3D,,'(_G6D<SKQTGJCFQ? F5UXOV%Z<O6Z_'
M_,_(7:$..F2!R.?R[5^FW[-W_)#O!^/^?%?YFO-_CK^R3H_BNWN-7\)QQZ+K
MZJ9#;0KM@NB,D@CHK'U'Y=37J7P#TN\T+X0^&M.U"VDL[VUM?)EAE&&5@3G-
M7C<3#$459:W/-X7R/%9)F=6&(5XN.DEL]5]Q\]?\%!?^/GP'_NWO\[>OD ?<
M7Z5]?_\ !03_ (^? ?\ NWO\[>OD ?<7Z5ZN _@1/SWC+_D<UOE^2"OH_P#8
M._Y+!J__ & IO_1]O7SA7TC^P<O_ !=[5S_U IAC_MO;UKC?]WGZ'!PS_P C
MG#?XD?>4?2DD;# <<CUIOF;#C''K7D?[1_QIA^$O@YY+9HWUZ^!@L83R0QZR
M$?W1U]R!7QT8.I)174_IS%XNE@<//$5G:,5<\8_;+^.9FF?P#HTQ")AM5GB;
M(Z9$.>W8M]<=J^1-X;##'('3MQ4UY<2W=U+/<3-<W$TAEFE<Y:1R>2?<U HR
M3DDGJ2:^TH4(T()(_EG.,UJ9QBYXJIMLEV71"_>K9\(>%-1\:^(++0])A,]_
M?2>5&N.!W+,>P49)/^-9"+D-U./09/\ G_$5][_LE? <?#_PX/$FLP >(M3C
M!6-AS:P$ A/9CU;\!VYC%XCZO3OU9U\/Y+4SG&*CM!:R?EV^9ZK\)_AEIOPJ
M\&V6@Z< 1$ \\Y7YIY3]YSS^'T KM$& ><\]Z:$)0#.#W(%/ P,=:^.E)S?-
M+<_J*C1AAZ<:5-6C%62%HHHJ38B:3! X QWKX4_;;^(#:_\ $*R\-V\F+;18
M-TZCH9Y5R?KA"F/<FONFX^52_P#=['VK\HOB#XD?Q=XWUS66)87UY+.F3G"%
MCM&>^%P/PKV<LIJ=1S?0_+N/<=+#X&&%@[.H]?1'/R8#8IM!YH Q7TUM;GX#
MT"BBBF(*.]%+VI/4!8Y-@(YQ]?S_ ,_7UKZU_9&_:'2R%MX&\1S[8BVW3+V4
M\*?^>+'M_L_EVY^2>,=*6*0PL&!.X'((."*Y\12CB(.$M.Q[N49K6RC%+%4?
MFNZ/U_5B<]Q3T.0>G7BOBS]GO]KLZ-;6OAWQQ*\EJN([;6F^8QCL)N,D=@PS
M[CC)^Q=+U>WU2U2YMIX[FUE^:*>)PRN.Q!'!KY&KAYT7:2/Z6RG.,)G%%5<-
M+7K'JOZ[FA13!(,X[TJN&!/;I7,>Z.HI-P]:* %HI,\TTO@]*5T K-CMFLSQ
M#KMEX=TNYU#4KJ.QLK="\L\S851]:R?'OQ'T+X=:0^I:[?16-N 1&'/SRMC[
MJ#J3_C7P+\>_VAM6^,>H_98HVTSPS ^8+ GYY>P:;U/<+VKNPV%G7=TM#Y//
MN(L-DM)W:=5KW8_Y]OF5?V@/C9<_&/Q=Y\1>#0++='86V[!(Z&1N/O'MZ#%>
M4GKSU]J<S?-G^=-)R:^NITXTHJ,4?S3C,95QU>>(K.\I:O\ KL)1116IPA11
M10 4^+&_!'WN"?;TIE.7H>.G-)C2OH?H#^QIX_?Q7\+QH]S+YE]H4WV7<S99
MX6&Z-CZ?QK_P"OH%#D5\%?L/>)'TWXHWNE-+LM]4T]QL_O2QD,I_!#+^=?>D
M0(3GZ5\ACJ:I5VEU/Z?X3QTL=E-*4W>4;Q?R_P" /HHHKSS[ **** "OF']O
MC_DG/A[_ +"R_P#HF6OIZOF']OC_ ))SX>_["R_^B9:[<'_O$/4^5XI_Y$V)
M_P /ZH^&9.GXT@_A%+)T_&A1G'TK[!WL['\M'9_#CP!+X_\ ^$GAMH_-O--T
M>34K=1U9HY8MP^I1G _^O7&'Y\MZD_SKZ+_843S?BSK"=,Z'+GW'VBWXKSKX
M^_#L_#;XH:SI4<?EV+L+NR & 87)P!]&#+^&>]<L:W^T2I-]-#Z2OEMLHHX^
M*^U*+^_3]3S@C%=E\'O'#_#CXCZ'XA#$06UP%NE'.Z!OEDX_W23]0*XQCR:<
MO&"<#D $GN:ZIP4XN#/#P]6IAJL*U-V<6FOD?KW!,MQ!'+$XDBDPZLIR"IZ$
M54\0ZS;>']$O=4O)!#:64+W,TA'W412S'\@:\A_9*^(7_";_  AT^WEE\R_T
M8_V?.&/S;5 \LG_@.!GN5-8/[:WQ!7P[\-X/#L3[;[7IO+;:>EO&0TA_$E1C
MT)KXU4)>W]BUJ?U-4SBG#*GF:VY;_/M]^A\4^//%%UXU\6:QKMV2+C4+IYF3
M=N"+DA5!] H4?AFL%^6S@ =,"AR=W."1QP:",INR./X>YK[&,>2*4=C^5JE6
M56;J3=W)W?S'1ABXVKN)^48&6)]!_GO76?$[P0_P]\21:+-G[7'9P37/M+(@
M=E'TW;<]\9XSBNV_95^'?_">?%FP>XA$NFZ1_P 3"YW#(8J?W:?B^T_133_V
MO6_XOMK8Q@"*W&/^V2US>T_VCV?D>_'+>3)Y9A/K)17HMSQ=NM(>C?3^HI2<
MTAZ-]/ZBNQGS:W/O[]AC_DBTW_86G_\ 1<5>Q?$W_DG/BK_L$W?_ *)>O'?V
M&/\ DBTW_86G_P#1<5>Q?$W_ ))SXJ_[!-W_ .B7KX[$?[U+U/Z?R?\ Y)^G
M_P!>W^3/R?'4_A_*B@=3^'\J.U?8]#^8GK(<O45^NVA?\@6P_P"N$?\ Z"*_
M(I!\N?3/8GC'/2OT)TC]L/X8VVEVD,NLSI+'$BLHLIS@A1_L5XF8TIU(PY%>
MQ^K<"8W#8*5=XFHH7MNTNY[U17B'_#97PM_Z#=Q_X 3_ /Q%'_#97PM_Z#=Q
M_P" $_\ \17A_5ZW\C^X_6_[=RK_ *"8?^!+_,]OHKQ#_ALKX6_]!NX_\ )_
M_B*ELOVOOAIJ-_;6=MK$\D]Q((T4V4R@L2 .2F.])T*J5W%C6>96W98F'_@2
M_P SVJOB7]O[_D;?"W_7A+_Z,%?:Z2;L\8_&OB?]OTY\6^%O^O"7_P!&"NK+
M_P".CP.-/^1-4]8_F?*S=32#HWTI6ZFD7'S9..*^N/YL/K/_ ()__P#(:\9_
M]>]K_P"A25]H)]T5\7?L <:QXS.1_J+4?^/2_P"%?9T<A*_=-?)9CKB6S^EN
M#4UDU*_>7YDM0SL%!STQW_'/Z4[S?FP1^7-<+\7_ (M:1\)?"L^K:F^Z<J5M
M+,'Y[B3!PH_'J>U>?&#F^5'V%>O3PU*5:J[17<^&?VL[B"X^/?B0P<LGV=)6
M'0N((\_T'U!KQ]^M:.OZW=^(=:O=5U"3SKZ]G:XF;H-S') '8<XQ6<QR<^M?
M<4H\D(I]C^2,QQ*QN+JXB*TE)O[V(> #]:^V/V![=SX,\4.5^1M0C7/J1$"1
M^H_.OBE4!D&T[CW'\J_0C]CGPP_AKX'V-Q(IBEU6XDU':PYVD*BG\516_&N'
M,G:AROJ?8\#4I3S93MHHMOR/&_VYOB$=5\3:=X0M9\PZ?&+NY53C,SC]V&_W
M5Y]]_;'/RTX"L0!@#I75?%?Q4?&OQ(\2:P7\U+J_E,;?],@VV,?@BJ/PKE.I
M( P *Z<-35&E&!\YGF,GF.85J[>EW;T6B$KL?A/\.KSXI^-M/T"S!59GWW,P
M./*@&-[?49  ]37'J-Q [DU]N?L+_#^.P\'ZKXJF3%UJ5P;6!BO_ "PCQDCZ
MN6'_   4L76]C2<T;\.99_:V8PP\OA6K]%_F?1_A3PS8>#]!LM(TR%;>RM(Q
M'&H'7 ZGW/>MA%"K@=*18]HZTX#%?&-N3YGN?U+"$:45""LEL+1112- I#C-
M+2$9[XH 8RJS<^G(]:%7 /.>_2G;,CDYI%7;D9S2;8'QW_P4$_X^? ?^[>_S
MMZ^0!]Q?I7U__P %!?\ CY\!_P"[>_SMZ^0!]Q?I7U^ _@1/YEXR_P"1S6^7
MY(*^D/V#CCXP:M_V YO_ $HMZ^;Z^C_V$25^+FL$=?["F'/?_2+>ML9_ GZ'
M!PQ_R.<-?^8^UO%_BW3_  7H-_K6J3+;V%E$9)7)YQZ >I. /6OS-^*OQ*U#
MXI>,[O7M1+()/DM;<-\L$()VJ/U)/J37K/[6OQQ_X6#XBD\,Z/<9T'2G(ED0
MY%U<CO[JO0>^37SH_P!['..V3SBN/ 850I\\UJSZ7C+/?K]?ZE0E^[@];?:E
M_P  ,[W+$8)Y.*=&-Y YRQP,#K1@;??/X5VWP>^%E[\7?&MKH5L'BML"6\N!
MT@A)Y/\ O'&%Y]:]2<E%.;Z'Y[AJ%3%U8T:*O)Z(]9_9#^!@\::X/%FLPAM!
MTZ8"TCD7BYN!W([HN1]3_N\_>$0!7CC!Q65X9\-6/A70K+2--@2VL;-!%%&J
M\!0/YGJ?<FM=%V@C.>:^,Q->6(J<SV/ZDR+)Z>382-".L]Y/N_\ @"@8I:**
MYCZ(**** .?\<:@^E^#/$%Y'_K+?3[B93TY6-B/Y5^3/RCA1A1T'H.U?K+XX
MT]M2\&>(+53\UQIUQ$.,\M&P_K7Y- @@$="*^ARK:1^(^(G-[7#]K/[[A111
M7OGXZ%%%% !1110 4I^[^-)05)YI:=1K<>DI48VANH.?2N\^&?QN\7_"J=/[
M&U,_8@<MIMR/,MV'LO\ ">.JXK@T1F4%5)R<#W^E=1X(^&WB/XDWWV/P_ILM
M\<@/<%2D,7^](>/RS45>22_>6L>A@YXNG73P5U/^[>__  Q]<^ OVX_#.JQP
M0^)-.N=!N6X:>!3/ /?Y1O'TVGZU[9X<^,'@KQ2J_P!E^)M,NW89$2W $F/4
MH<,/Q%?/7@#]A"V"+=>+]>DFE('^AZ8H15^LK<G\%'UKVS0?V:OAKX>@$4'A
M+3[D 8+7Z&Z)]_WA89KY7$+#*7[IL_H/)ZG$E2">.C3Y?._-_P"2W7WGI,4R
MS(KJP=&Y!4Y!_&H;S4;73HS)=31V\?)W2,%'ZT[3M,M=)LX[2R@BM;6(;8X8
M4"(@] !P!6=XD\%:#XPBCBUS1[#6(H\E$OK5)@I]1N!Q7GZ7\C[:7M.3W$N;
MSV.+\1?M&?#SPO'(]SXJL9W0D&"Q8W,F?0K&&(/UQ7@OQ$_;IDN%DM_!FCF
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M'!/RDC\*^Y/V&M1\-R^ ;^RLH/)\11W&_4?-YDD!'R,/]@8(QV.?6OAW(8#
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M*UPVV. ^)/P=\-_%;2C:ZY9B:9%Q!>Q_+/ ?5&_H<CFO@?XT? C7O@[JPBO
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MHEABC7H$48'Z5HKTIJQ[0><GL:<!@5\>W?5G],Q2BN5*R6WH+1112+"BBB@
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MO+5E>74Z+7O/5^K_ ,A#U%?G-^V#_P EWUK_ *XV_P#Z*6OT9/45^<W[8/\
MR7?6O^N-O_Z*6NS+/XWR/G./?^17'_$CQ:@]&^G]110>C?3^HKZAG\]+<^_O
MV&/^2+3?]A:?_P!%Q5[%\3?^2<^*O^P3=_\ HEZ\=_88_P"2+3?]A:?_ -%Q
M5[%\3?\ DG/BK_L$W?\ Z)>OCL1_O4O4_I_)_P#DGZ?_ %[?Y,_)\=3^'\J*
M!U/X?RHK[%;'\Q-78Y>HK]=M"_Y MA_UPC_]!%?D4F.#DGV R?>OO'3/VWO
M5IIUK ]KK#/'$B,4M@1D ?[5>+F-&I4C#D5['ZGP-F&%P#KO%5%"]K7?J?25
M%?.W_#<W@#_GSUK_ ,!5_P#BJ/\ AN;P!_SYZU_X"K_\57B?5:W\K/UC_6+*
M/^@F'WGT317SM_PW-X _Y\]:_P# 5?\ XJD/[<_P_ /^BZSNZX-J.GK]ZE]6
MK?RL/]8LI_Z"8_>?15?$O[?W_(V^%O\ KPE_]&"OL7PUXA@\4^'M,UBU1EM=
M0MHKJ$/][9(@9<^^"*^.OV_3GQ;X6_Z\)?\ T8*Z,!I72/$XRG&IDDY1=TW%
M_B?*K=32#HWTI6ZFD'1OI7UQ_-[ZGUG_ ,$__P#D->,_^O>U_P#0I*^SE/ K
MXQ_X)_\ _(:\9_\ 7O:_^A25]GJ,K7R68_[TS^E.#=<EI>K_ #(YD$H"M]WZ
M5^>O[5/P5_X5AXS_ +4TVW*^'=8D9XA&ORV\W5HOH>J].K#^')_0T1D?Q?I7
M)_$WX=Z?\3?"-_X?U,?Z-<Q_+(%RT,@Y61?<'^9K/"8AX>IS7T9W<1Y-'.L$
MZ>TXZQ?GV^9^5<BXD*\'!Z@YHX!!/.#VX-;7C'PEJ'@7Q3?Z%J<7E7UG(49>
M@=>H=3W!&#^..U8F<MG'![5]@IJ34EL?S!4A.G-PJ*S6C/=OV5_CB?AEXI72
M-4GQX<U20)(6/%O,>%D'H#\H/X'M7Z"6\H>/<,$8SP<@^]?D*"!NXX((Q7W)
M^Q]\=_\ A*]&'@W6)]^M6"9LY9&YN+< #;G'++S]1CI7AYCA$_WT/F?K_!.?
MJ+_LNN]'\#?1]O\ (Z3]KGX5M\0?A\FJV$ EUC1"US& ,F2$C$J#WP 1]*_/
M@J,Y'3^=?KTZF9 , KW&,Y%? G[57P%?X;>(FU_1X<^&]2E+$*IQ:3$DE#U^
M4\;3QU([9,99B4DZ4GZ&O'.1RE;,Z"OTFEY;/_,^?R,4N<*>H)XR#C_/2G/'
M@XSSZ>E,(QQ7T%[['XMYGVE^S#^T_!JUI;>$O%ETL&H1+Y=C?SOM2=0.(V..
M''KWR/3GZLCD!7H1CUK\@0VW! &X'()KW?X4_M<>*_A_#!8ZFH\2:1$0JI<O
MMN8QQTDP<@>A%>#B\!>7M**WZ'[%P[QI"A36%S/6VTO+LS]# V5I5&.V*\(\
M*?MD?#G741;W4)]"F)P8]0A?'0<[U!7';DCITKNX?CO\/)H]R^-=!P>0&U"-
M3CZ$YKQ94:D79Q9^KT<UP&(CSTJT6O5+\SO:CDDV&O+=<_:A^&>@Q,\OBFTN
M2.BV0:<G_O@&O$_B%^W?"VZW\':(S2$;1?:F1A>O*QKGV^\P^GKI#"5JFBB<
M>-XARO Q<JM>+?9.[_"_^1]*^/\ XD:)\-M"FU?7+M;2U083G+RMV5!W-3?#
MGQ@GQ \%Z7X@CM6LDOXO.6!GWE1VR<#^5?F!XN\=:]X\U:34==U.;4KHG"F0
M_+&,D[44<*.3T'>OT9_9L&WX&^#A_P!."_S-=&*P:PU*+;NSY_(N)9YYF%2G
M"/+3C&Z[[]?^ >"_\%!/^/GP'_NWO\[>OD ?<7Z5]?\ _!07_CY\!_[M[_.W
MKY 'W%^E>W@/X$3\GXR_Y'-;Y?D@KZ/_ &#O^2P:O_V IO\ T?;U\X5]'_L'
M?\E@U?\ [ 4W_H^WK7&_[O/T.#AG_D<8;_$C[TCZ4V;ZX/K3H^E*PS7QG4_J
M?H?#_P"V5\$3X>U=O&^D0@:9>N%U&-1@03=!)_NMP#QP?7=Q\O2\$#!! P01
M@BOUK\2:#9>)M%O=+U*W6ZL;N(Q2Q.N0RGC_ .O7YC_&'X8WWPH\<WNB7*O)
M!GS;.<_\MH23M.?48P?<&OI\!B>=*E+='X#QID+P=?Z]07[N>Z[/_@G%5T7@
M'QMJ/P\\56&NZ3(4N;63<T>?EE3^)"/1A_*N=/#$9SCK2K)LSQGW'45[$HJ4
M6FM#\UHU*E"I&K3=FM4S]6OAYX[TWXC>$M/U[2Y!+:7:9P3\T;?Q(?<'/Z5T
M\1RI]CQ]*_//]E7XVGX:>+!I.I7.WP[JK[9"WW;>;@))[ \ _@>U?H/;2[H^
M /P.>U?&8JC[";70_J'A[.H9UA%5VG'22\^_HRQ13=Y]*3>?[OZUQGU(^FMG
MM3J0C)H @:/)/ICFOD_]H;]D<ZI<W7B+P-'''<R9ENM')VQR>K1>C$\[>Y/;
M-?6VWFD,>>^/PK>C6G0ES09XV9Y5A<VH>QQ,;KH^J?D?D-J&G7&F7<MI=V\U
MK=PG;+#-&4="/4'_ /55;9COD5^H/Q.^!7A#XK6Q76]-7[8!\FH6_P D\?7^
M(=1DG@Y%?*_CW]AWQ1I-Q+)X9U"#7K?[RQ73"WFZGC))4\8YR/IZ_24,PI5%
M:7NL_"\UX+S'!-RPZ]K#RW^:W^ZY\S$8H&2I5022"/T__777:_\ "3QIX9ED
M74O"^JP+']Z5;5GB_P"^P-OZUG^"M.6]\;:!87&(Q/J$$,BR<84N V?H,]:]
M!U(.+DFCXR.$K4ZT:5:#BVTM58_43P!X=3PGX+T/1XP%2QLHH#@8R54 G\3F
MNB7I4$+8C4GTZ#I]:E5P17PLFY2NS^NJ4(T:<::T227W#Z*;N'O^5&X>_P"5
M%C6Z'44W</?\J-P]_P J+!=#J*;N'O\ E1N'O^5%@NAU%-W#W_*C</?\J+!=
M#J*;N'O^5&X>_P"5%@NA2,U\W?MS>&(]2^&%AK*QYN-*OXR9,=(I,HP_%_*_
M*OI#</?\J\J_:CL3J?P*\50JNYQ#'(JXY)25&X]^*Z,-)PK1?F>'GE".)RS$
M4GUB_OW/S2(520*;C!&*M6FGSZI,L5G!/=3$ ".&%G;/I@ UWGAG]GCXA^*Y
M0EGX7OH%/674(S:I^<F,_@*^SE4C!)N21_+>'P6)Q+M1IRD_)-GGFTN._P"5
M='X$^'FN_$/6X],T#3Y;^Y8C>P^6*%<_>D;L/U]J^GOA[^P?'\MQXSUII5!!
M.G::"JMT/SRGKW& HZ?>]/J+PCX(T3P7I0T_0].@TRS7CR[=<9..I/4GIR:\
MJMF4(7C3U/T/*.!L7B&IX]^SAV^TU^AYQ\!?V=-*^$.G?;)I%U3Q).@$]^5&
M$'=(O1>>O4U[*@POI2;.  <8IRC:*^<G.51\TF?N&#P=# 45A\/'EBOZ^\6B
MBBLSN"BBB@ HHHH *^8?V^/^2<^'O^PLO_HF6OIZOF']O;#?#SP^"0H&K*<L
M<#_4RUV8/2O!ON?+<4?\B;$_X?U/AF3I^--;[HI[X)()VXYYIK*-H^85]EMH
M?RW9WL?1_P"P=_R5_5O^P#-_Z/MZ^](_NU\%?L)N(OB_JF#OSH,V<=OW\':O
MO2(Y4\8YKY/,?]X;/Z-X&_Y$T?\ %(?4,\0D!#<JPP1ZU-32.:\V]C[]JZL?
MF+^T%\/#\-/BEJ^EQ1[=/F?[79=OW+G@?\!.Y<_[.>,UM_LK_#T>//BQ8O<1
M;].T?_3YR5RI93^[7\6"GZ*:^AOVW/AX==\#6GBB"-7NM&D*2L!AC;R$!N>X
M4X./<]*Z']C_ .&W_"$_"V/4;A-FH:XXO) PY6(#$2_EEO\ @=?1O%_[)>_O
M;'X=3X:OQ+*BU^Z3Y_EO;[]#W5%P!V["GD84TB+@8SGTI2.,5\X?N2&GJ*_.
M;]L'_DN^M?\ 7&W_ /12U^C+<8K\Y?VP&!^/&MC<N1#;\9_Z9*:];+-*Q^:\
M>_\ (KC_ (D>+T'HWT_J*./[RTN 0>>N!D>__P"JOJ&TC^>TM3[]_88_Y(M-
M_P!A:?\ ]%Q5[%\3?^2<^*O^P3=_^B7KQO\ 8:?;\&9UQR-5F/\ XY'7L'Q/
ME*_#CQ7A=Q_LJZ&,_P#3)J^.K_[U)^9_3V3_ /)/T_\ KV_R9^48ZG\/Y49&
M,=Z<R*K8WCT/X<4G /W@:^RBTU<_F-K5M@K[.P/UI0^1\Q.::<9^\M'']Y:=
M[$Z=1VY?4T;E]33>/[RT<?WEJN8-.P[<OJ:<F#SG@=C_ )_SFH^/[RTY5RK'
MKCG/0=/6I<E:[#0_4_X+J$^$'@@\X_L.QX]/]'2OEG]OW'_"6^%L?\^$O_HP
M5]2?!:7?\'_!!V]-#LAU[^0E?+/[?CX\6^%L_P#/A-T'3Y\C^5?*8-?[4_F?
MT-Q.U_JZDNT/T/EANII!T;Z4_:&7.X#/UIH R1N7'XU]3=/J?SS>]SZR_P""
M?_\ R&O&?_7O:_\ H4E?:"?=%?%_[ 6$UCQF00W[BUX!Y^]+7V?&<H#7R68Z
MXAM']+<&:9-2]7^8^HY$#=3VQ4E(1FO./N#YK_; ^")\;^'%\4:3")=;TJ,^
M:L:?// .H'/)7.<=^:^$-H*J5/RD<'UK]?9H1(-K'Y3UXK\]?VJ_@K_PJ_QF
M=4TZ#9X=U=S)'L'RVTI)W1]> >J_7';)^@RW$_\ +J?R/Q3CG(K/^U*"\I+\
MF>%D8K1\/>(K[PKK5EJNF3-!J%E()X''9AV([@]"*S\;SP1QQS2A3@@$;O49
M.*]V3BU;N?CT)2IR4XNS6I^H'P9^*5A\6?!%GK5ML2YR(KR!7SY,V 2.@X.<
M_C77:[H-CXCTJZTW4[9+NRN8S'+#(,JRGJ*_.#]G_P",=Q\'?&J7DGF2:'=D
M1:A;KT"G@2 8ZJ?S%?I)IE]!K-A!>6\BS6TZB2*1#D,I&017R.*P[P]3W=C^
MF.&\ZIYY@N6KK4CI)=_/T9^??Q^_9NU/X3WLNHZ>LFI>%7;]W<H"TEMG^&4#
ML. &].W'/B##YL9&.H/J/45^O4]C%>0RPSHDT,JE'BD4,K ]B#UKY<^,?[%E
MCJ\MQJG@FX73;QLN^E3'%M(3GA#_  '\"*]+"Y@O@JOYGPG$'!,X2>)RN-T]
MX=O2_P"7W'Q,1CN">X':G*3MQDXST[5T/B[X=>(/ %V;37]*N=,D!VI),G[J
M0_[,GW6_ YKG6CP"3QCL>#7NQDIJ\6?DE6C4H3=.K%Q:Z-6_,,MD<D#VQ1N;
M'3'TI .!G(SVQF@[DXY&?44:[/8A1;Z"[B,''3UH>5I 03VH"$X/)]@*  Y.
MT$XX^7!_KQ3OT0)K84'.> !D<"OTX_9N_P"2&^#O^O!?YFOS;\/^%M8\579M
M-$TN[U6Y.#Y5K"7(^I' 'OG%?IG\$-!O_"OPJ\.:/J<'V;4+.U6*:+<&VMUQ
MD<=Z\+,Y1E323ZGZSX?4JGUNM5Y7R\MKVTO=:7/G3_@H+_Q\^ _]V]_G;U\@
M#[B_2OK[_@H&V;CP'GC_ (_5Y]<V_P#]>OD(C9\I9<CBNS ->P2/F>,?^1S6
M^7Y(2OH_]@[_ )+!J_\ V IO_1]O7SAQ_>6OH[]A%PGQ?U8CYLZ%.#MYQ^_M
MZUQG^[S]#@X9_P"1QAO\2/O6/I3L@&HXW)'3OCK3R,]Z^,W/ZG6PV10V*\B_
M:0^#,7Q9\#RI;*BZ]8 W%A*1@[AU3/HPX]C7K^WWXIDB;F ! P/2M:<W3DI1
MW1RXO"T\=0GAJZO&2L?D)=6LEI-)%+&T4L;E)(V&&1@<$'W!R*A8].0>.U?5
M_P"VA\$!I-]_PGFD0 6UPP74HHEQY;]!+@==W /3D9YS7RI\BN<,I!],XK[&
MC6C7I\Z>I_+.;Y75RC$RP]17ML^Z&J0BL".O%?=?['_QQ'C#0!X2UFXWZ[IT
M>;>61OFN+88 ^K+T/M@U\*# ))93^?\ A6MX4\4:AX+U^RUK2I_*O[*431,#
MP?52.X8<$=\CTK/$T88BG9[G3D.<5,GQBK)WB[*2[K_@'ZSQG(SQSZ&I-IKC
M/A3\3-/^*G@NRU_33\DJ[)X,Y:"4 ;D/N#^A%=?YGLW_ 'R:^/<73?*S^H:5
M2&)A&M3=XR5T3T445)T!1110 F*8R#<,D\5)24 1R GIS7(_%;3FU3X8>+;4
M@%Y=)NT0D;L,86VG'KG%=B%Q5:^MENH)()/FCD4JP(Z@\$?K3BVI)W.>O3=2
ME."ZIH_(@MP"$ W+_DTP\=,'_@-:OB?0I/#7B/5-*G7;/8W<ELX]T8@_RK*<
M98FONXV:375'\@58RI3E!O9V?R8GX+^5'X+^5&!1@5?+'^DCGN'X+^5'X+^5
M&!1@4<L?Z2"X?@OY4?@OY48%&!1RQ_I(+A^"_E1^"_E1@48%'+'^D@N'X+^5
M'X+^5&!2$ =J.5?TD OX+^5>C_L\:<NJ_&;PC;NF^,WZR,@Z.$5GP?;C->;X
M%>^_L5^'6U?XR1W^W]UI5G-<,Q&1N9?+ ^OSD_@:YL1RQI2?D>WDM!XG,J%+
MO)?F?H#''L0+P$'3'3'I3Q'GJW'IBA0-O Q4BKE1GK7Q#UU/ZR2MZB!,#VI5
M7:*4+0*8["T444#"BBB@ HHHH **** "L;Q)X2T;Q;#';ZWI=EJUNAWI#>VZ
MRJK<\@,.O-;-(1DT:]&3*,9IQDKI]SAD^"'P^'_,D^'B>Y&F0C_V6E7X)_#_
M "?^*)\/X_[!D/\ \37;E,XYH"U?M)_S'+]3PV_LX_<CF] ^'/A;PI>/=Z+X
M=TO2;ET,;365FD3LA()4E0#C@?E721C"^U&VE Q2;<M6=$*<::Y::LNR%II]
M*=32N3G-2:&?K>BVGB'2[O3;^%;BRNXFAFB;HRL""/R-7+:V2U@CAB58XHU"
M(BC 50, "I IR>:4#%.[)Y4GS6U[@!BD:G4F,FD-JXW&<5S&M?"_PCXCOWOM
M8\,Z3JM\X"M<WEE'+(0!@#+ G'M74;:-H[U2DULS.=*%5<M2*:\]3B?^%)?#
MW_H2/#__ (+8?_B:/^%)?#_&!X)T >O_ !+8?_B:[;8/2C;Z'%5[2?\ ,S#Z
MGAE_RZC]R,O0/"VE>%;(V>C:;::59E_,,%E L2%B "<* ,X Y]A5RZLX;^"6
MUN(DGMY5*21RJ&5U/!4@\$59P<<FDV\U#;;NSIC",8J,59=CB3\$?A_\V?!/
MA_DYS_9D/_Q-(/@E\/B/^1(\/_\ @MA_^)KN *0(.:KVD_YF<WU/#?\ /N/W
M(XG_ (4E\/?^A(\/_P#@MA_^)H_X4E\/?^A(\/\ _@MA_P#B:[;8/2C8/2G[
M2?\ ,P^IX;_GW'_P%'$_\*2^'O\ T)'A_P#\%L/_ ,31_P *2^'O_0D>'_\
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>mercklogotoprightcornera.jpg
<TEXT>
begin 644 mercklogotoprightcornera.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E 2 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBO)/C!^T=X/^"JQP:U=2WFK2+N32]/ DGQV9LD! ?4GZ548N;M$Y\1B*.%IN
MK7DHQ75GK=%?$=Q_P4=<7W[GP(K6>?\ EIJFV0C\(B*]F^#W[7?@OXNZA%I2
MM/H.N2#]W8Z@5VS-Z1R X8^W!]JWEAZL%>2/%PW$&68NI[*E67-YIJ_I=(]V
MHHHKF/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBO&_C9^T]X3^"L:VMZTNIZY(F^/2[,C>!V,C
M'A ??GVJHQE-VBCFQ.)HX2FZU>2C%=6=-\;/B1'\)?AGK?B5HUFFM8@EM">D
MDSD)&#[;B,^U?D[KFN7WB35KK5-4N)+S4;J4S3W,S9>1CWKZWT/XU7'[9'BA
M/AQX@L8O#F@W6^\CFTV4O=>9"-RH7<;",;B?D[5W?_#NWP1_T,7B#_ON#_XW
M7IT90PNE3<_,,XHXKB=QJY<^:C'35V][J[/RL?G_ ,TZ.1XY%>-FCD1@RNK8
M*D<@@BOO[_AW;X(_Z&+Q!_WW!_\ &Z/^'=O@C_H8O$'_ 'W!_P#&ZZOKE'N?
M.+A#-5KRK_P)'>?LC_&*?XN?"V-M3F,^OZ3)]CO9&ZS<9CE/^\O7W5J]RKX@
M\9:C'^P=?VEAX0)\1_\ "1(UQ>QZVW,(A.U/+,87&[S7SD'[E>L_!/\ ;$\+
M_%J^@T>]@;PWXAFXBMKB0/!<'^[')Q\Q_ND#\:\RI1;O4@O=/TW+<VITE#+\
M=42KQT?GVUVNU;YGT-1117&?7!17R!^V%^V)XK_9V^(6CZ!H6BZ/J5M>:6+Y
MY-267>K&61,#8ZC&$KGOV8?V^-=^,7Q8L?"/BO1M'TNWU&"06=SIWFAOM*#>
M$;>Y&&57Q[[:ODE:Y',KV/N"BFLP1<G@"OSI\??\%-/%6D>.->L/#7A_0+[0
M+6]DM[*ZNEG\R>)3M$AVN!\V,CCI2C%RV'*2CN?HQ17R;\$OVMO%'Q._9^^)
M/CS4-(TFUU3PPL[6UO:K+Y$OEVXE&_<Q;J>QKYZ;_@J1\157<WA?PNH_W;C_
M ..TU"3)<XH_3>BOS$D_X*G_ !"6-F_X1GPI\J[O^7C_ ..U[O\ M,?ME>+/
M@GI?PZNM'T;1[]_$FD?VA<K?++B-L1'";77C]XW6G[.6P>TCN?8E%?F0W_!4
MKXB+][POX77_ (#<_P#QVO1O@W_P4T@USQ!;Z7\1- MM$M;J18DU?2Y7:& D
MX!E1\L%]6#''I0Z<NP>TB?>-%5_M4'V3[3YR?9MGF>=N&S;C.<],8KXR^-O_
M  4F\/>$+^XTCP#I:^*[Z!RDFIW,ACL5(X.S'SR_48'H6J5%RV*<E'<^U:*_
M+?\ X>>_%'[9O.E>%/*_Y]_LTW\_.S7TA\-_VV-3\??L[^/_ !Y_PC5I::[X
M2C&ZW\]GM;ARH8$='4>WZTW"2)4XL^N**^0/V2_VT/$G[1'Q*O?#>K>'M+TF
MUM],DOA-8R2L[,LD:8^;C'SU[=^T1\<M*_9_^&]]XEOU6ZO&_<:?8;MINKAA
M\B_[HZL>P%)Q:=NI2DFK]#U&BOBG]FW]L[XC_M!?$>WT"S\%:+:Z7"!<ZKJ"
MW,Q^S09QQGJ['A1_05]K4.+CHPC)2U04445)04444 %%%% !1110!R'Q3\<0
M_#?X>:_XEF7S!IUJTJ)_?D/RQI^+E1^-?D?X@\07_BK6KS5M4N&O-1O)3-/<
M2=78_P">*_3#]L?3;C5/V>/%*VNYFB$%PZ+WC2>-F_(#/X5^8'->S@8KE<NI
M^-<<8BH\52H/X5&_S;:_0W/!'C#4/ /BS2O$6ER>7?Z;.L\>[HV.&4^S+N!K
M]6/A7\6=!^,'A6WUK0[E2"%6XM&8>=:R=T<=O8]^U?D7S7T[^RW^S?XZ\27%
MMXMM=?NO ^CR_P"JO+-C]IO$!_AC^[L]WR/]EJUQ=.$H\TG9H\_A3,<7AZ[P
M]&FZD9:M+IYW>GJ?HC6#XN\8:1X%T&YUG7;Z'3M-MUR\TS #V '<GL!1I^AZ
MA:Z*+*7Q#?7ESMQ_:$T< F^N%C"?^.U\A?M1?LR_$#6H)O$-EXNU+QM96BF9
MM*OL)+  #EHDC 1N.P4'_>KQZ<(SE:4K'ZUF6-Q.%PSJT*#G*VUUI]SN_D?-
MWQX^*]Q\9OB1J'B)UEALL"WL;:3K# GW0<=R2S'W:O/XY'CD5T9HY$8,KJV"
MI'((--YHYKZ6,5!<J/YRKXBIB*LJ]1WE)W9^I7[+'Q2G^+'PCTW4M0F^T:O9
MR/8WLG&9)$P0YQ_>1D)]S7LE?)__  3STVXMOA?K][*I$%UJI$/OLB0,1^)Q
M^%?6%?-UHJ-1I;']&Y+7J8G+J%6K\37_  +_ #/S'_X*A_\ );?"_P#V+Z_^
ME,U?*EJVN> =6\/ZY LFGWJK#JVF7/\ >"R'9(I]-\;"OJO_ (*A_P#);?"_
M_8OK_P"E,U5_B=\'!XH_83^%_C^RC_XF'ARVDAN]O\=G+=2#/_ )"I^C-6D9
M6BCT9*[9]/\ [0'[3.GP?L@_\)OHLVVZ\5V::?8(K<Q3S*RR@^\867\4K\JU
MTFYBT>/4?)9;!IS:+-V\Q5#%?P4K6M?>.-:U;P7HOA.6Z:;1=*NY[FSLU7[L
ML^S=]?N\?[[?WJ^C_P!J[X1CX+_L\?!3P_+"L.K22WU[J?JUU)' S@G_ &?E
MC^BTXQY-.X-N6O8[']DG_DRGX]?[EW_Z0)7C/[#D>DR_M*>&UUQ;&33?LUYY
MBZAL,.?L[[<[_EZ]*]F_9)_Y,I^/7^Y=_P#I E?*7P?^%&J_&WQ]I_@_19K2
MWU"^266.74&80J(XRYR55CT'I2_FN'\MC]BO[/\ A9_SZ>$/^_=I7Q-_P5*B
MCM_$WPXC@58XEL+L(J<  20X Q7+?\.N_B;_ -!OPC_W_G_^,5T__!4.$VOB
M#X9P'K'IMVAV^S1"HBDI*SN7)MQ=U8]C_P""<^AZ=JG[-O\ INGVMYNUB\4^
M? KY'R<<BOCW]NSP;X8\"_M":CIWA:VMK&TDLH+B[L+-0D,%R^\L HX7<NQL
M#^]6UX1\.?$+2_V0X/'O@/Q9KNDV^EZK>0ZQIFFWLL<;0DIBX55/5,X?VY_A
MK@/V</A/9?M$?%Z'0O$7B9M--RK7<TDSF2ZU J<O%&[9'F$<Y;M_>JHJTG(A
MOF2B>S_&CXZZYHO[&?PC\$Q7$L-]XBTMWOI]WSM80.8XXL]<2#9GV7'\52?L
M-_L@Z/\ %K3IO&_C6%KSP['.]M8:4K,@NW3&^60K@[%/RA1U(.?]JO\ \%)O
M"-MX0\=_#VSTVU6TT2V\._V?9V\?2,0S'@?\!=*^N?V#-9L=6_9;\'QV3+OL
MOM%I<JO\,RSR%L_7<#_P*I;M"ZZE)7G9]#TZ#X*_#ZUTG^S8O!'AZ.PV[/L_
M]EP[,>_RUX9\;O@;X3^"_P"S?\9W\(V;:79:U8"XFL5<F&*1/ES'G)4,#TZ>
ME?55>,_MB_\ )L/Q&_[!+_S%8INZ1K)*S/A7_@F_JUGH/QI\2:EJ-Q':6%GX
M9NKBXN9FPD4:30%G8^@%<'^T;\9M:_:J^-$2:/;3W6G)-_9OA[3$4[W1FQYA
M']^0_,?0;1_#6I^Q;\-[?XO>+/'?A"XNI+&/5/"UQ$MS"Y4QR"YMV0D#[R[@
MN5[BN4^&_BG6OV3_ -H2&[UC28YM0\/W<EEJ%G(N?,B8;7:$GN4.Y&[_ $:N
MK3F;ZG/K9+H?J'^S+\ [#]GKX:6VA1>5=:U<'[1JVHQKM^TSGL,\[4'RK^?5
MC7L%9/A?Q-IOC+P[IVNZ/=QWVEZA"MQ;7$?22-AD&M:N/?5G5MH@HHHH&%%%
M% !1110 4444 9^JZ7;:YI=WI][$L]G=Q/;S1MT>-AM8?B#7Y;_'[]G_ %OX
M'^))HY89[SPY-)_H&JJOR.IY$;D?=D'3GKU%?JQ5#5-+L]:L9K/4+6&]LYEV
MR07$8DC<>A4\&NFA7=%]T?-9UDE+.*2C)\LX[/\ 1^1^4_[._P .8?BI\7-!
MT&[&=/:0W5VO]Z&,;V3_ (%C;_P*OU@@@CM84BB18XD 5508"@<  "OF/]H7
MX<:3\$? E_X\^'&D0>%_$MI+%')>V4656WD<(X\MLH!DKSMKY5_X:_\ B_\
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M(_VP+KPMK<;-IW@FY_M.>5E.+F-6!M,?[Y*-]$:O6?\ @JM_R"?AM_U\W_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>mrk-20221231_g1.jpg
<TEXT>
begin 644 mrk-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BO+/C+^VY\)?V?GDC\7?$#PUI-U#G?9_:A<7BX_Z8
M1;I?_':^7/BI_P '"/PD\)S20^&=!\6>+I5SMF\E+"U?TPTC&3\XA732P=>I
M\$6?/9EQ9DV7MK&8F$6NE[R_\!5W^!][45^0OQ"_X.+_ (A:NSKX7\!^$=#C
M;(!U">?4I$'L5,*Y^JD>U>.>,?\ @MC^T5XL=A#XSL]$A;K%I^C6BCL1AI(W
M<=.S=SG-=\,CQ,M[+Y_Y7/BL9XR</47:ESU/\,;?^E.)^[M%?SNZ]_P4:^/'
MB3=]H^+/CJ/<NT_9=5DM>,YX\HK@^XYQQTKF=0_:]^+.K3^;=?%#XB74N-N^
M7Q)>.V/3)DKHCP_4ZR1X=3QSP"_AX:;]7%?YG])%%?S8?\-4_%#_ **1X]_\
M*"[_ /CE:>D?MN_&;05B6T^+'Q(ACA)*1CQ)>&,9Y/R&3;U)/2C_ %?GTFON
M,X^.F#O[V%E_X$O\D?T>45_/MX7_ ."J_P"T-X0*_9/BEX@FV=/MJ07WKU\Z
M-\]>_P#2O4O _P#P7O\ CUX5D3^T9?"/B9!C<+_2?*9AWYMWBP?P_#M6,LAQ
M"V:?]>AZN%\;,CJ.U6G4A\HM?A*_X'[;T5^6_P -O^#CUMT<7C#X8+M_Y:76
MCZKT^D,J?SEKZ2^$G_!;7X ?%.2*&Y\1:EX1NYB L.NZ>\*Y]Y8C)$N/5G K
MCJ9;B8;P?RU_(^MR[Q"X=QKM2Q44^TKP_P#2DE]Q];45B^!/B3X=^*.B+J7A
MG7M&\0Z<W NM-O8[J$G_ 'HR1^M;5<+33LS[*G4C.*G!W3ZK5!11104%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKP/XKX?,7'!9K:G6>BEM&3_]MD^VS>S6B/T"HHHKPS]D"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBD9#*1P01R".M25\N?TEOJ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 445X)_P4>_;)M_V*?V9]4\1PO
M_B;4LZ=X?MI,-YEVZG$A7ND2@R-V.U5R"XK2G3E4FH1W9QYAF%# X:>+Q+M"
M";;\E^O1+J]#XA_X+O?M]MKFKGX)^%;YOL5BZ3^*9X6XGF&&BL\CJJ<.X_O[
M!P485^9E6=9UBZ\0ZO=:A?W$UY?7TSW%Q<3.7DGD=BS.S'DL6)))ZDU6K[S"
MX:-"DJ<?^'9_$?$_$.(SK,9X^OUTBOY8K9+]>[;?4****Z#Y\**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?@W_P %=OVQ
MI/VLOVJM0@TZZ\[PAX*:32-'5&S'.RM^_N1V)DD7 (ZQQQ]\U^HG_!7#]K%O
MV5?V0=7DTZZ6W\4>+B=$TC:V)(C(I\Z=<<CRXMQ#=G:/U&?P3KZ3(L+O7EZ+
M]?\ +[S^?/&KB9KV>24'VG/_ -MC_P"W-?X6%%%%?2'\]!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?MW_P $2/VQ&_:,_9D'A36+KS?%'PZ$>GR%VS)=V)!^
MS2\]2H5HCU_U:DG+U^(E>[?\$W_VJI?V0?VLO#?B::=H=!O9!I6NKD[6L9F4
M.Y Z^6P24#N8@.YKS\RPOMZ#BMUJC[GP]XF>39Q"K-VI3]V?H]G_ -NNS]+K
MJ?T+44V*99XEDC97C<!E93D,#T(-.KX<_L\**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 =-\&?B;>_!?XM^&?%VG%A>^&]3M]2B .-YBD5]I]F *D'@@FO
MZ6/#7B&U\7>'-/U:QD\ZQU2VCN[>0?QQR*'4_B"#7\P-?OI_P2"^+9^+O_!/
MWP'-+)YEYX?@DT&X&<[/LKF.(?\ ?CR3^.*^?S^C>$:JZ:?>?N_@=FCAB\1E
MTGI**FO6+L_O4E]Q],4445\N?TB%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?K+_P;C?$DW_PO^)/A%V_Y
M!6J6NKQ GK]IB:)\?3[*G_?0K\FJ^]?^#>GQM_8?[87B'1G;$6N^&)MHS]Z6
M&>!U_P#'#+_G->?FM/FPLO+7[C[WPRQKPW$F&?23<7_V]%I?C8_9>BBBOAS^
MRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\
MG\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+
M_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8G
MR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\
M@UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ
M1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\
M=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_
M /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%'
M]N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\
M!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6
M;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\
M$/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\
M/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^
MUE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';
M_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!
M?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'X
MI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/
M^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_
M^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#
M^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\
MG\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8GR^X/^(-\/?W_ /P+
M_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\ @UF_^,5^UE%']N8G
MR^X/^(-\/?W_ /P+_@'XI_\ $/[\=O\ G\\!?^#6;_XQ1_Q#^_';_G\\!?\
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ME3^=>76P]6D[5(M'Z7E6?Y=F4>? 5HU/)/5>JW7S1JT445B>N%%%% !1110
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MJBBBN,[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\,_;R_X*#^!/\
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M*M._^3J_"&BCZM /K,S]WO\ B* ^ ?\ T*/Q@_\ !5IW_P G4?\ $4!\ _\
MH4?C!_X*M._^3J_"&BCZM /K,S]WO^(H#X!_]"C\8/\ P5:=_P#)U'_$4!\
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M_P!"C\8/_!5IW_R=7X0T4?5H!]9F?N]_Q% ? /\ Z%'XP?\ @JT[_P"3J/\
MB* ^ ?\ T*/Q@_\ !5IW_P G5^$-%'U: ?69G[O?\10'P#_Z%'XP?^"K3O\
MY.H_XB@/@'_T*/Q@_P#!5IW_ ,G5^$-%'U: ?69G[O?\10'P#_Z%'XP?^"K3
MO_DZC_B* ^ ?_0H_&#_P5:=_\G5^$-%'U: ?69G]!7P'_P"#ASX*_M#?&?PO
MX%T7PO\ %"UU;Q9J4.EV<U[IMBEO'+*X13(R7C,%!/)"L?8U]Y5_+U_P2_\
M^4B?P5_['#3O_1ZU_4+7-7IJ#5CIH5'-784445@;A7Y]_$K_ (.1/@=\+/B-
MX@\,:AX5^*TVH>'-2N-+N9+?3-/:%Y8)6B<H6O5)4LI() .,9 Z5^@E?RE_M
MC?\ )W?Q4_['#5O_ $MFKHP]-3;N<^(J."5C]EO^(H#X!_\ 0H_&#_P5:=_\
MG4?\10'P#_Z%'XP?^"K3O_DZOPAHKH^K0.?ZS,_=[_B* ^ ?_0H_&#_P5:=_
M\G4?\10'P#_Z%'XP?^"K3O\ Y.K\(:*/JT ^LS/W>_XB@/@'_P!"C\8/_!5I
MW_R=1_Q% ? /_H4?C!_X*M._^3J_"&BCZM /K,S]WO\ B* ^ ?\ T*/Q@_\
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M+$V)(F_V9%4^U=W7/MN=&^P4444 %%%% !1110 4444 %%%% !1110 4444
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M=_\ )U?A#11]6@'UF9^[W_$4!\ _^A1^,'_@JT[_ .3J/^(H#X!_]"C\8/\
MP5:=_P#)U?A#11]6@'UF9^[W_$4!\ _^A1^,'_@JT[_Y.H_XB@/@'_T*/Q@_
M\%6G?_)U?A#11]6@'UF9^[W_ !% ? /_ *%'XP?^"K3O_DZOO;X*?%%?C7\*
M-!\61Z'KWAN'Q!:+>PZ=K4,<-_;QORGFI')(JLRX;;O) 8 X;*C\-?\ @@K_
M ,$S/^&L?C&/B5XPT[SOAWX%NU:""=<Q:YJ2X=(<?Q1195Y >&)1"&#.!^^5
M<M:,8NT3JHRG)<T@HHHK$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=$M;Y1W9X.(9#[(8A]:_2#]G3]L'X;_M7:(U[X%\5:?K3Q('N+/)AO;7_KI
MX$BC/&[&TGH37\WU:7A'QCJW@#Q'::QH6IZAH^K6#B6VO+*=H)X&]5=2"#]#
M7D8K):-36G[K_#[O\C]6X;\7LVP#5+'?OZ?GI->DNO\ V\FWW1_3U17Y+_L5
M?\%]M:\*/::!\9K)]>T[B-/$5A$J7T Z9GA&$F4<?,FUP 3B1C7ZB?"CXO\
MA?XY>"K7Q%X1US3_ !!HMX/W=U9R[USW5AU1QW5@&!X(%?-8K!5<.[5%IWZ'
M]#<-\897GE/FP-3WEO!Z27JNJ\U=>9TE%%%<A]0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YO^V1
M_P FA_%3_L3]7_\ 2*:O2*\W_;(_Y-#^*G_8GZO_ .D4U5'="EL?RET445ZQ
MY 4444 %%%% !1110 4444 %%%% !7H/[*?[06I_LJ_M&^#OB%I&YKSPKJ4=
MXT2MM^TP\K-"3Z21-)&?9S7GU%&^@;:G]<W@'QSI?Q.\#:+XDT2Z2^T?Q!8P
MZC8W"?=G@FC62-Q]58'\:UJ_.7_@VY_:X_X7%^R7J'PVU*Y\S6_AE=;;4.?F
METVX9I(O<^7*)D/95\H=Z_1JO)G'EE8]:$N:-PHHHJ2@HHHH **** "BBB@
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MQ/XFT_P5X;U#6-6O+?3M+TJWDN[RZN'"16T,:EG=F/ 55!)/H*_FQ_X*O_\
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M=VNG19R(8(ND:#T')/+%F))\VKNI8=1U>YPU<0Y:+8****Z#G"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9-5\)O*^2\!):YM%_P!QCYRCDD/-T" 5^M=>74@XRL>I3GS1N%%%%06%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'2G)WJ4_<EZQV?SC9^MPHHHKSS[P**** "BBB@ HHHH **** "BBB@ HHHH
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MVZU*"UGFEB6.X2]L8UDS&ZMD)+(,$X^;ITKX?K]'O^#7_P#Y/Z\7?]D_O/\
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MMM4^-/BQ/#MNX#MH7AYDN+T=#MDNF!BC8<@A%E![,*B52,=RXTY2V/RA52[
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MQA> S/GX[KT:%/E5WN>?7J<SLM@HHHK<YPHHHH **** "BBB@ K[Y_X(3_\
M!,W_ (;'^-O_  GGBVP\WX;^!+I'DBE7]WK>H##QVWHT:?+)*.A!1"")"1\L
M?L9?LF>)/VV?VA]!^'OAE"MSJDOF7EXR%HM,M$P9KF3_ &44\#(W,54'+"OZ
M=/V<OV??#7[+/P4\/^ O"-G]CT/P[;"WA!YDG<DM)-(?XI)'+.Q[LQZ# KGQ
M%7E5EN=&'I<SN]CME4(H51A1P .U%%%>>>@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO]L;_D[OXJ?]CAJW_I;-77A=V<F*V1YO1117:<04444 %%%% !1110!]'_\
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M_P"/D-AXL^,4FH> _",VV:#1T4)K6I)U&]6!%JAX^^#(1GY%R&K[:_X)7_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*?_@X*_:\;4_$FC?!O
M1[IEM]-":OXA$;8WS.N;:!O]U#YI!R#YD1ZK7Z:?&#XHZ7\$_A9X@\7:U)Y>
ME^'+";4+@Y^9EC4MM7_:8@*!W) K^;SXQ_%35?CA\5?$'B_7)FFU3Q%?2WUP
M<Y"%V)"+Z*HPJCLJ@=J]S(\+SU75EM'\S\:\9.)'@\NCEE%^_6W\H+?_ ,"=
MEYI21S5%%%?6'\N!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!^WO_!&G]O9/VIO@@OA#Q#?>9X\\$P)#,97S)JED,+%<\\LR\)(>
M?FVL3^\ 'V?7\U/[.GQ_\0_LP?&/1/&WAFX\G5-%G$GEL3Y5W$>)() .L;KE
M2.O.000"/Z$OV6/VF/#G[6_P4TGQMX9FW6>H)LN;9V!FTZY4#S+>3_:0D<]&
M4JPX8$_'YM@?8S]I#X7^#/ZP\+>-5FN"^H8J7[^DNN\HK1/U6TOD^IZ)1117
MCGZP%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %-GGCM8'DD=8XXU+.[':J@<DD]@*=7YO_P#!
M<7_@HDO@7PY=?!GP??\ _$ZUB$#Q-=0/S8VKC(M,CH\JD%QVC('/F<=&%P\J
M]14X_P##'@\2<08;)<!/'XG:.RZRD]HKU_!7?0^/O^"M'[=K?MF?M -:Z-<,
MW@7P>TEEHX4_+>N2!+=G_KH5 7/1%7@%FKY4HHK[RC1C2@J<-D?Q/FV:8C,L
M94QV*=YS=W^B7DEHO)!1116AYH4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!>\,>)=0\&>)-/UC2KN:PU32[F.[M+F%MLEO+&P9'4]B& (
M^E?T5?L5_M,6/[7/[-?AGQQ:>5'<ZC;B+4K=#_QZ7L?R3QXZ@;P2N>2C(>]?
MSCU^BG_!OK^U*W@WXOZY\*]2N&&G>+HFU+2D9_ECOH4_>*H]9(%))_Z=U'>O
M'SG"^TH^T6\?RZ_YGZOX1\2/+\W^I57^[K^[Z37POYZQ^:['Z\4445\>?UB%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F_[9'_
M ":'\5/^Q/U?_P!(IJ](KS?]LC_DT/XJ?]B?J_\ Z1354=T*6Q_*71117K'D
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?TO?\$?\ ]KO_ (;(
M_84\)Z]>W37/B30$_P"$?UUG;=(]W;*H$K$\EI8FBE)]9&':OIZOP9_X-P/V
MNO\ A2W[7%]\.=4NEBT/XH6PAM][;5BU*W#/ <G@>9&9H\#EG:(=A7[S5YE:
M'+.QZ=&?-&X4445D:A1110 4444 >)?\%%_VI(OV./V-/'/CSS$CU/3[!K72
M%;_EI?S_ +JWX[A9'#L/[J-Z5_+I=74M]=23322333,7DD=BS.Q.223R23SD
MU^K'_!SU^U?_ ,)%\1?!OP;TVY+6OAV+_A(=:16^4W4RM';1L/[T</F/]+I?
M>ORCKT,/"T;]SS\1.\K=@HHHKH.<**** "BBB@ HHHH **** "BBB@ HHHH
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M?-?H-_P<M?\ *12R_P"Q/L/_ $?=5^?->I1^!'EUOC84445H9A1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#\G]>+O^R?WG_IQTVLZWP,TH_&C]WJ***\L]0**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF'3K9>(K:/\ V(UP,]6.6.68D^:UZ=&GR1L>96J<\KA1116ID%%%% !1110
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MR[R_!;+JV4445Z!\*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?=7_! #XT-X#_;#U#PG-)ML_'6CRPHF[&ZZMLSQ
MGWQ$+D8_VOP/[15_-W^QY\5/^%)?M4?#[Q4TGEP:/KUI+<MG'^CF0+,,^\3.
M/Q[U_2)7R>?4N6LIKJOR_I']1^">9.ME%3!R>M*>GE&2NO\ R92"BBBO#/V4
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\W_ &R/^30_
MBI_V)^K_ /I%-7I%>;_MD?\ )H?Q4_[$_5__ $BFJH[H4MC^4NBBBO6/("BB
MB@ HHHH **** "OZ,/V)/@#I/[4O_!$_P3\/M<7_ (EWBKP=]C:0#+6\F]VB
MF7_:CE5''N@K^<^OZ;/^"0O_ "C1^#G_ &+Z?^C'KEQ6B3.G"ZR:\C^;'XH_
M#;5_@Y\2=>\)Z];_ &36O#6H3Z9?0YR$FA<H^#W7*G!Z$8/>L&OU _X.7OV-
MS\/?CAH/QBTBT9=)\<1C3-99$ 2'48$_=N2.\L"X ];9R3S7Y?UT4Y<T;F%2
M/+*P44451(4444 %%%% !7I_[&'[2-]^R+^U'X)^(ECYC'PUJ2374,?WKFT?
M,=S$.V7A>11GH6![5YA10]= 3L[H_KN\+^)K#QIX:T[6-*NHK[2]6MH[VSN8
MCF.XAD4.CJ?1E((]C5ZOSY_X-TOVN_\ A?'[&DG@34KKS?$'PMN!8*'/SRZ;
M+N>U;_@!$L6!T6),GYJ_0:O)G'EE8]:$N:-PHHHJ2@K^;O\ X+:?M9_\-8?M
M\^*)K.X\_P .^"S_ ,(SI.ULQNEN[>=*.QWW#2D,.J"/K@5^XG_!4#]J]?V,
M_P!B3QMXRAN/)UQK7^R]# /S-?W&8XF7U\O+2D?W86[U_,+)(TTC,S,S,<DD
MY)-=F%A]HX\5/[(VBBBNPXPHHHH **** "BBNT_9T^!VL?M+?'7PIX"T%-VJ
M>*M2BL(F()6!6;YY6Q_!&@9V_P!E#0&^A^QW_!M!^R#_ ,*X_9_\0?%W5;79
MJWCZ<Z?I+.OS1:;;N0[*>H\VX#9'<6T9'6OR=_X*$_\ )_7QP_[*!KW_ *<;
MBOZ?/A/\,M)^"_PQ\/\ A'0;?[+HOAG3X-,LH^ZQ1($7)[L0,D]223WK^8/_
M (*$_P#)_7QP_P"R@:]_Z<;BN6A+FFV==>/+!(\?HHHKJ.0**** "BBB@ HH
MHH *_K,_9Z_Y(%X'_P"Q?L/_ $FCK^3.OZS/V>O^2!>!_P#L7[#_ -)HZX\5
MT.O"[L["BBBN,[0KC_VA?^2!>./^Q?O_ /TFDKL*X_\ :%_Y(%XX_P"Q?O\
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MA(%V_:'1!YDQ']Z23>Y]W-=Q7E5)<TKGJTX\L;!1114%A1110 4444 %%%%
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M*>\DCDL3T&<#   [^BBO,WU/3VT04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^6O_!Q_\06:\^%W
MA6-OE1+[5;A<]23%%$?PQ-^?;O\ J57XJ_\ !P!XP/B']N6TT\-^[T'PU9VN
MT'@,\D\Y/4\D2KZ< <=SZN2PYL4GV3?Z?J?F?BYBW1X;J07VY0C^/-_[:?#M
M%%%?9G\AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5V/P,^/WB_]FWQ_:^)O!>N7FAZM:\%X6S'<)WCEC.5
MD0]U8$=#U -<=14RBI*TMC6C7J4:BJT9.,HNZ:=FGW36Q^U_[!O_  6J\$_M
M)0V?AWQXUGX&\;/MB5I9-NEZH^.L4K?ZIB?^6<A[@*[DX'V[7\N=?6W[$_\
MP6%^)7[):V>BZE,?''@N#"#3-1F/VBS3C_CWN,%D QPC!T R JYS7SV,R._O
MX?[O\O\ @G[WPCXR.*CA<]5ULJD5K_V]%;^L=?[KW/W6HKPG]DO_ (*-_"O]
ML>QAC\,Z]'9^(&3=+H.I$6^H1D#)VH3B4#KNB+ #&<'BO=J^>J4YTY<LU9G[
MY@<PPV-HK$82HIP>S3NO^'\MT%%%%9G8%%%% !1110 4444 %%%% !1110 4
M444 %%%% !115/Q%XDT_PAHEUJ>K7]GI>FV2&6XN[N=8(($'5G=B%4>Y.*"9
M245S2V+E<K\9/C?X3_9]\#77B3QEKMAX?T:U'S3W+X,C8R$C09:1SCA$!8]A
M7Q+^V-_P7L\&?#"*ZT;X56:>-]=7='_:EPKQ:3:MTRO22XP>R[$(P0YZ5^6/
M[0'[2_CC]J+QM)K_ (Y\0WVNWQR(5E;;;V:'^"&)<)&OLH&3R<DDU[.#R>K5
M]ZK[J_'^O4_)N*_%K+<N3H9=:O5\O@7K)?%Z1^]'UY_P4#_X+;^)?CVE]X5^
M&/V[PAX/DS#/J.[R]4U5.XW*?W$9_NJ=[#JP!*5\$T45]3A\/3HQY*:L?S7G
MG$&/S?$O%8^HY2Z=DNT5LE^>[NPHHHK8\8**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OZ5/V9?B WQ7_9R\
M!^)F=I)->\/V-_*3U\R2W1G!]PQ(/N*_FKK]]/\ @CUXN/C'_@G1\.9G;=-8
MP75@X_N^3>3QH.@_@5#QZXR3FO!S^%Z49]G^:_X!^W^!N+<<RQ&&_F@I?^ R
M2_\ ;F?3%%%%?*G],A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M60?)#J4>T7:>V_='-D_>:63'W36>%G9\K-,5#3F/S]HHHKN.$**** "BBB@
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M^ELU?U:5_*7^V-_R=W\5/^QPU;_TMFKKPN[.3%;(\WHHHKM.(**** "BBB@
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M-'ZT4445YAZ84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:IR+S/ /BW\5]?\ CG\3-<\7^*-0FU7Q!XANWO;VZE/,CL>@'154855'"JH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'#T[SUZ'=7J6AIU/EVBBBO0//"BBB@ HHHH **** /T _P"#=O\ 9 _X7_\
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M^#F+XP?$3P-^S9X8\.^'[.:W\!^++UX/$FJP,2S21[7M[-_[D<A#N3_&80O
M!#?AK7]9'[0WP$\-_M0?!?Q#X#\669O-!\26K6UPJD"2$\%)8R0=LD;A74X.
M&4<$<5_,1^V5^R?XD_8I_:'\0?#WQ-&S76DS;[.\$92+5+1LF&YCZ_*Z]0"=
MK!D/S*:SPLE;E-,5!I\QY=11174<H4444 %%%% !1110 5_21_P16_9[\ _
MW]@KPA?>![ZVUV3QI:IK&LZRB;9+V\8;7A(ZJMNP:$)Q@QL2-S,3_-O7Z)?\
M$!?^"E/_  R_\9A\+?%M]Y?@/Q]>*MI/-)MCT74VPB2$GA8YL+&_8,(VR ')
MQQ$7*.AOAY*,M3]ZJ***\T]$**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY[?\ @J#_ ,I
M?BI_V&W_ /0$K^A*OP!_X*X:-_87_!1;XGP^5Y/F7UO<;<YSYMG!+N_'?GVS
MVZ5[F0_QY+R_5'XKXX1?]D4)?]/%^,9?Y'SC1117UA_,(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 445<\/>'-0\7:S;Z;I-A>:IJ%VXC@M;2!IIIF/0*B@LQ]@*"HQ<GRQW
M*=%?:W[-_P#P0H^,/QG2"^\4?8/ASH\V#G4_](U!E/=;9#P?597C/M7W9\ _
M^"&?P1^$,<-QKMCJ7C[5(QEI=7G*6H;U6WBVKCVD,GUZ8\W$9MAZ6E[OR_JQ
M^@Y'X7Y_F24_9>R@^M3W?_);.7X6\S\4O!_@77/B'K":=X?T;5=<U"3A+73[
M22ZF?Z(@)/Y5]&_"S_@C=^T%\4Q'(/!+>';23'[_ %R\BL]OUBR9O_(=?NCX
M'^'7A_X8Z(FF^&]#T?P_IT>-MKIMG':PC'^R@ _2MFO)JY_4?\.*7KK_ )'Z
MCEG@=@H)2Q^(E-]HI17WOF;_  /R9^'W_!N)XJOMK>*OB7X?TO!!9-)TZ:_W
M#N TC0X^NT_3M7MWPX_X-]OAOX+NX[N[\>?$:XO8\8DT^ZM]/4G.>T3OU /#
MCD5]\45P5,UQ4]Y?=8^WP7ACPWAK..'YGWE*3_!NWX'@_@'_ ()X^#?AY#''
M:^*/BW-&F,JWC_5H%< <*1!/&, Y/'<GMQ7J&@?"#2?#0_T>[\42=1_I7B74
MKOK_ -=9V_\ K5U%%<4JU26LFSZW"Y3@L.K4*48^B1DR^"K.:)D:;5@K J=N
MJW2GGT(DR/J*Y'Q1^S#X>\6))YVK_$2TD?!#V7CO6K4H<8X"707\",=^M>B4
M5,:DELS>K@\/57+4@FO-)GRI\2O^"0GP[^*$3K>^+OB["K9QCQ=-=;1Z#[2)
M>G/7/4UX%XX_X-P_#%X)#X;^)VO::>2BZGI<5[GI@$QO#[\X[]..?THHKKIY
MCB8?#(^9QW .08QWKX:+?DW'_P!):/QE^)/_  ;X?&'PN))?#^N>#?%$*CY(
MUN9+*Y?_ (#(GEC_ +^5\V_%O]@#XT? U9'\3?#?Q19V\/\ K+JWM?MUJGUF
M@+QC\6K^BRBNVGGM>/QI/\/Z^X^,S'P5R6LKX6<Z3]5)?<U?_P F/Y<Z*_HX
M^-_[$/PF_:-BG_X3#P'X>U2ZN/OWRVWV:^S_ -?$6V7KSC=BOBC]H3_@W:T'
M5XY[SX8^,[S1[DY9--UY?M-J3V59XU$D:C_:20^]>I0SRA/2=X_BOZ^1^;YQ
MX-9SA4YX.4:T?+W9?<]/NDV?D]17M7[2G_!/7XN?LHM--XN\(WRZ1$V!J]C_
M *9I[#L3*F?+SS@2!&XZ5XK7KTZD9KF@[H_*\9@<3@ZKH8JFX2722:?W,***
M*LY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K]AO^#=."1?V6?&TA1A&_BIE5\?*Q%I;D@'U
M&1^8]:_'FOV@_P"#>O3FL?V(=<D9@PO/&-Y,H'\(%I9)C_QPG\:\G.G_ +*_
M5'ZEX/0YN(X/M";_  M^I]V4445\:?UL%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>;_ +9'_)H?Q4_[$_5__2*:O2*\W_;(_P"30_BI
M_P!B?J__ *1354=T*6Q_*71117K'D!1110 4444 %%%% !7]-G_!(7_E&C\'
M/^Q?3_T8]?S)U_39_P $A?\ E&C\'/\ L7T_]&/7+BOA1U87XF?2%%%%<)W'
MQ+_P7I_8W;]JG]AW4M8TNS-SXJ^&KOK^GA$S)-;!<7D([X,(\S:.6>WC'>OY
MW:_KYN+>.\MY(9HTEBE4HZ.NY74\$$'J#Z5_,=_P5-_9 ?\ 8F_;5\7>$+>!
MH?#UU-_:_A]MI"MI]P6:- 3U\I@\)/<PD]Z[<+/[)QXJ'VD?.]%%%=9QA111
M0 4444 %%%% 'Z ?\$[_ /@K#)^RI_P3J^-'P]FU!H?$D</VGP023O26]*V]
MR$/0>02+E1W)D//2OS_HHJ8Q2;:ZE2DVDGT"BBBJ)"BBB@ HHHH *^H/^"/G
M[(0_;*_;I\*Z'?6OVGPSX??_ (2#759=T;VMNRD1,,8(EE:*,C^Z['M7R_7[
MW?\ !N3^R#_PH[]D"Y^(6J6RQZ_\4K@74)=,20:; 62W7D9'F,99<@X97B[B
MLJT^6-S6C#FE8_0ZBBBO,/3"OY8_^"A/_)_7QP_[*!KW_IQN*_J<K^6/_@H3
M_P G]?'#_LH&O?\ IQN*ZL+NSEQ6R/'Z***[CA"BBB@ HHHH **** "OZS/V
M>O\ D@7@?_L7[#_TFCK^3.OZS/V>O^2!>!_^Q?L/_2:.N/%=#KPN[.PHHHKC
M.T*X_P#:%_Y(%XX_[%^__P#2:2NPKC_VA?\ D@7CC_L7[_\ ])I*<=P/Y,Z*
M**]<\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#^E3_@B;_P HN/A'_P!@^Z_]+KFOJBOE?_@B;_RBX^$?_8/NO_2ZYKZH
MKR:GQ,]6G\"] HHHJ2PK^4O]L;_D[OXJ?]CAJW_I;-7]6E?RE_MC?\G=_%3_
M +'#5O\ TMFKKPN[.3%;(\WHHHKM.(**** "BBB@ HHHH ^C_P#@D-_RDM^#
MG_8P1_\ H#U_2+\:_@WX?_:$^%&O>"O%5BFI>'_$EHUG>0-P2IY#*?X75@K*
MPY5E4CD5_-U_P2&_Y26_!S_L8(__ $!Z_IMKAQ7Q([L+\+/Y9?V[?V-_$'["
M?[26N> ->W7$=HPN=+U#85CU6Q<GRIU^N"K 9"NCKDXR?':_I"_X+$_\$Y;?
M]O[]F^;^R((8_B)X062^\/7! #7?RYDLF;^[,%&"2 LBH20-V?YP]3TVYT74
M;BSO+>:TO+21H9X)HS')"ZDAD93RK @@@\@BNBC4YX^9SUJ?)+R(:***V,0H
MHHH **** "BBB@ HHHH **** "BBN]_9O_9E\;_M:?%"S\'^ M!NM<UF\(+"
M,;8;2/(!FFD/RQQKGEF/H!DD FVX;Z(Q/A1\*/$7QR^(ND^$_">DWFN>(M<N
M!;65E;+N>5SSUZ*H +,S$*J@DD $U_1A_P $I?\ @F9HO_!.OX*?9[@VNJ?$
M+Q$B2^(=6C7*@CE;6 D!A!'GOR[98@?*JU?^"7?_  2?\(_\$Z?!3WC20^(_
MB-K$ CU;76CPL*\$VUJ",QP@@$D_-(0&; "HGUI7GUJW-[L=CT*-'EU>X444
M5SG0%>;_ +9'_)H?Q4_[$_5__2*:O2*XG]I;0_\ A)_V<OB!INV9_P"T/#>H
MVVV$9D;?:R+A1@_-SQP>:J.XGL?R<T445ZQY 4444 %%%% !1110 5_5/^PG
MI;:'^Q!\&[%F61K/P-HD#,!PQ6P@7(_*OY6*_J:_X)Y:DNK?L#?!.=9OM!;P
M)HBNY.276PA5\GU# @^XKEQ6R.K"[L]BHHHKA.X**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YO^V1_R:'\5/\
ML3]7_P#2*:O2*\W_ &R/^30_BI_V)^K_ /I%-51W0I;'\I=%%%>L>0%%%% !
M1110 4444 %?TV?\$A?^4:/P<_[%]/\ T8]?S)U_39_P2%_Y1H_!S_L7T_\
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M>0?%K5?#?_"=Z+X.&AVJ7T\4UN]SJ%["6VLUO$-J,$.P.6D4KYJ$*W./V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME@B6.-52- %55& H'0 4ZBBO!/VT**** "BBB@ HHHH **** "BBB@ HHHH
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M_P#TFDIQW _DSHHHKUSQPHHHH **** "BBB@ K]'O^#7_P#Y/Z\7?]D_O/\
MTXZ;7YPU^CW_  :__P#)_7B[_LG]Y_Z<=-K.M\#-*/QH_=ZBBBO+/4"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "D=%E1E90RL,$$9!%+10!_-[^V)\$V_9S_:B
M\<^"]C)!H>K2QVF003:N?,MS^,+QG\>]>:U^D7_!P_\ L\-X?^)OA'XG6=OB
MU\0VQT74G4?*MS#EX68_WGB+*/:WK\W:^^P5;VM",_+7UZG\.<89,\KSC$8*
MUHQDW'_"]8_@TO4****ZCYH**** "BBB@ HHHH **** "BBB@ HHHH ****
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M6U]/1']P<%Y/_9>2X?!R5I*-Y?XI>]+[F[?(****Y#Z@**** "BBB@ HHHH
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M+'?8 Y>(820G.8PIX$1S^+]>G3J*<;GF5*;A*P4445H9A1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >'_\ !1;]FA?V
MK_V0_%OA6&#SM9CM_P"TM&PN6%[ "\:KZ>9\T1/82FOYY71HG965E93@@C!!
MK^HJOPK_ ."S/[)A_9H_:YO]4T^W:/PSX_WZU8L%/EPSLW^E0 ],K(=X Z),
M@KZ+(<39N@^NJ_4_ _&SAUSITLYI+X?<GZ-WB_D[KYH^1Z***^F/YS"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T433RK'&K.[D
M*JJ,EB>@ K]MO^"0/_!."+]D[X<)XT\56:GXB>*+92T<J_-H=JV&%N/25N#(
M>Q 0?=);Y3_X(:_\$_T^+?C;_A;GBRP\SPWX9N=F@V\R?)J%^A!,^#]Z.#C'
M8R$<_NV!_8"OF<ZQ]W]7I_/_ "_S/Z*\(>"%&"SW&QU?\-/HNL_5[1\M>J84
M445\Z?OP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!7U?2+7Q!I-U87UM!>6-]"]O<6\Z"2.>-
MP59&4\,I!((/!!K\*O\ @JU_P3SN?V)_B\-2T6&:;X>>*97DTF;EO[/E^\]G
M(WJO)0G[R=R4?'[NUP?[2W[//A_]J;X*ZYX(\20^9I^L0[4F5<R64PYBGC]'
M1L$=B,J<@D'OR_&O#U+_ &7N?$<=\'TL_P O=)65:%W"7G_*_*6S[.SZ'\U]
M%=M^T7\!->_9C^,VO>"/$D/EZGH=P8O,4'R[J(_-'-&>Z.A5AW&<'!! XFOM
MXR4ES1V/XTQ%"I0JRHUDXRBVFGNFM&F%%%%48A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7U-_P1Z_9E;]I#]M/09+JW\W0?!>/$&HDC
MY6,+#R(SG@[IC'D=U5_2OEFOW(_X(H?LH_\ #.W[(]KKVH6[0^)/B(4U>ZWK
MAH;7!%I%_P!^V,GJ#.1V%>=FF)]C0=MWHC[_ ,->'7FV=TU-?NZ7OR^3T7SE
M96[7['V)1117Q!_9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %>;_MD?\FA_%3_ +$_5_\ TBFKTBO-_P!LC_DT/XJ?]B?J_P#Z
M1354=T*6Q_*71117K'D!1110 4444 %%%% !7]-G_!(7_E&C\'/^Q?3_ -&/
M7\R=?TV?\$A?^4:/P<_[%]/_ $8]<N*^%'5A?B9](4445PG<%%%% !1110!^
M%?\ P<E_L;GX2?M*Z7\5M)M&CT/XC1>3J)1 (X-3@0*<XX'FPA'&>2T<QR>W
MYKU_4%_P4Q_9#A_;<_8U\7>"%AA;6S!_:6@RR#_4:A "T.#_  [_ )HF/9)F
MK^8&\LYM.O);>XAD@N(',<L4BE7C8'!4@\@@\$&O0P\^:-NQY^(ARROW(Z**
M*Z#G"BBB@ HHHH **** "BBO</\ @G'^RA-^VE^V-X+\">7(VDW=V+S677CR
MM/A_>3\Y&TLH\M3_ 'I%I-V5V-*[LC]JO^" O[(7_#,_["^G>(-0MUB\2?%!
MT\071*X>.T*XLHB>X\HF7V-PP[5]Q5%86,.EV,-K;Q1P6]NBQ11HNU8T48"@
M=@ ,8J6O*E)R=V>K&/*K!1114E!1110 5_+'_P %"?\ D_KXX?\ 90->_P#3
MC<5_4Y7\L?\ P4)_Y/Z^.'_90->_].-Q75A=V<N*V1X_1117<<(4444 %%%%
M !1110 5_69^SU_R0+P/_P!B_8?^DT=?R9U_69^SU_R0+P/_ -B_8?\ I-'7
M'BNAUX7=G84445QG:%<?^T+_ ,D"\<?]B_?_ /I-)785Q_[0O_) O''_ &+]
M_P#^DTE..X'\F=%%%>N>.%%%% !1110 4444 %?H]_P:_P#_ "?UXN_[)_>?
M^G'3:_.&OT>_X-?_ /D_KQ=_V3^\_P#3CIM9UO@9I1^-'[O4445Y9Z@4444
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M4T4BE7B=3AE8'D$$$$5#7J'EA1110 4444 %%%% !7] _P#P04_X*&K^UO\
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MP;,_LA?\(%\#O$7QBU2UVZEXXF;2M'9ARFG6\G[UP?26X4J01_RZJ>]?CI\
M?@QJW[17QL\+>!=#0MJOBK4H=.@;;N6'S& :1A_=1=SL>RJ37]5/P>^%>D_
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M0!-I^HW&D:A!=VD\UK=6LBRPS1.4DB=3E65AR&! ((Y!%?T<?\$<?^"D%O\
MM^_LZ1QZS<1)\1O!ZQV?B"#A3> C$5ZBC^&4 [@,;9%<8"E"?YP:]<_8?_;
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M2\.K+LF6*J+]Y7]Y_P"'["^[WO\ MX****\D_4@HHHH **** "BBB@ HHHH
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M )26_!S_ +&"/_T!Z_IMKAQ7Q([L+\+"BBBN4Z@HHHH **** "BBB@#\%_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^?/\ P6-_X)<M\=M,N_BE\/\ 3U;QEI\&[6=-A4 ZW!&I_>H
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MM=QX6Z4>9;L?]V9(V_"OYNY8F@E:.161T)5E88*D=017UV1U^>@Z;^R_P?\
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M* "BBB@ HHHH **** "BBB@ HHHH *\W_;(_Y-#^*G_8GZO_ .D4U>D5YO\
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MLO\ L3[#_P!'W5?GS7J4?@1Y=;XV%%%%:&84444 %%%% !7ZS?\ !JQ_R/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** /=_^"7__ "D3^"O_ &.&G?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_0;_P;E?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /I%-51W0I;'\I=%%%>L>0%%%% !1110 4444 %?TV?\$A?^4:/P<_[%]/\
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M44 %%%% !1110 4444 >[_\ !+__ )2)_!7_ +'#3O\ T>M?U"U_+U_P2_\
M^4B?P5_['#3O_1ZU_4+7#BMT=V%^%A1117*=05_*7^V-_P G=_%3_L<-6_\
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M74<H4444 %%%% !1110!]'_\$O/V_M5_X)\?M,6/B16N;KPGJ^VP\2Z;&?\
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M=\R:SIBX53D_>E@^5&[E#&WS'>1QXFG]M'9AJGV&?HY1117&=@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH_X?A?LY_P#0VZI_X(KS_P"-T?4<1_(_N8?ZY9#_ -!M+_P./^9]<45\C_\
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M:;H]I:W,6X-Y<B0HK+E20<,",@D&N7%23M9G3A8M-W1TE%%%<AV!7'_M"_\
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MPX5_:P_Z)3_Y<VC_ /R71[2'=![.?9GR!17U_P#\.%?VL/\ HE/_ )<VC_\
MR71_PX5_:P_Z)3_Y<VC_ /R71[2'=![.?9GR!17U_P#\.%?VL/\ HE/_ )<V
MC_\ R71_PX5_:P_Z)3_Y<VC_ /R71[2'=![.?9GR!17U_P#\.%?VL/\ HE/_
M )<VC_\ R71_PX5_:P_Z)3_Y<VC_ /R71[2'=![.?9GR!17U_P#\.%?VL/\
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M_:P_Z)3_ .7-H_\ \ET?\.%?VL/^B4_^7-H__P EU?M(=T1[.?9GR!17U_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGWKZS(7^X:\_T1_+OC?3:SJC/O27X3G_ )H****]P_&0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *]J_P""<=G)??MW_"9(EWLOB:SD(_V5D#,?
MP )_"O%:^CO^"1N@_P#"2?\ !1?X86^,^7?7%U][;_J;.>;_ -DZ=ZQQ3M1F
M_)_D>UPW3=3-L+376I!??)'[_4445^>G]W!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/N^5.NWIVQGGU-7]:CU1'U67<_FIHK^CW_APK^R?_P!$I_\ +FUC_P"2Z/\
MAPK^R?\ ]$I_\N;6/_DNG]:AYB^JS\C^<*BOZ8M&_P""-?[,6@S-)!\'_#<C
M,02+B6XN5X]I)&'^->A>#OV#_@E\/W5]%^$7PUT^93D31>&[/SNN?]9Y>[]>
M*7UJ/1#^JRZL_EP\)^!M;\>ZA]DT+1]5UJZ) \FPM)+F3)S@;4!/.#^5>]_"
MO_@D-^TG\8)(?[+^$/BRRCF/$NLPKHZ*/[Q^U-&<=^ 2>V:_IDTK2+70K&.U
ML;6WL[6/A(8(Q'&GT4  58J'BGT1HL*NK/PW^#7_  ; _%?Q6T,WC;QMX/\
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M\C!S!,\9_P#0:^EX?GI.'HS^=_'7"/GPF*7:<7\N5K\V<[1117T9_/X4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G3_P '
M!G[+;>-/A-H/Q5TVWW7WA!QIFK,H^9K&:3]TY]HYVP!_T\,>U?D37].7Q)^'
MNE?%GX?ZUX8URV%WH^OV4MA>1'JT<BE6P>S#.0>H(!'(K^<?]ICX":O^S%\=
M/$G@;6E;[9H-XT*3%-JW<)^:*=1_=DC*L/3=CJ#7U>1XKFINB]X[>A_,7C-P
MV\-CXYM27N5=)>4TO_;H_BFSA:***]T_% HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD4JT; X((/((/&#4=?7'\JA1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9<PRW%8"N\-C(.$X[IK^KKLUH^@4445H<(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 445:T71;SQ'JUO8:?:75_?7D@B@MK:)I9IW/ 5
M54$LQ[ #- XQ;=D5:^E/V _^"97C;]N7Q%'>0QR>'O MK+MOM?N(B4<@\Q6R
MG'G2^N#M3^(@[5;ZB_8 _P""$EUK#V/BSXV))9V@*S6WA:&7$TPZC[7(OW%/
M_/-#N_O,I!6OU*\.^'-/\(:%9Z7I-C9Z9INGQ+!;6EK"L,-O&HPJ(B@!5 Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>mrk-20221231_g2.jpg
<TEXT>
begin 644 mrk-20221231_g2.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML_A]=:1I_@[2[4M)<I/?7$,3EF+0R"#HYA7;E]BG]L: /-?VH?VQ/V7?V*_
M"_$_]JOXY^'O VB22F*UNM=OA&]W*!DQP1#,EPX'.R-6;'.,5XI^S1_P77_X
M)+?M>?$>T^$?P%_;4\.ZCXDU&X$&F:1J^G7^CRWTQ.%B@_M&W@$\C'A4C+,W
M8&OFK]C;X9^"O^"CW_!;[]IW]I?]I;PY:>*-._9TU;3/ 'PA\,ZW MS9:-+L
MF>^OU@D!3[0TT)9)""0)CCF.,KZC_P %=O%W_!&;]J?P#XA_8L_;2_;#^&7@
M?QKHTEM)IVJ7FO64&O\ A&] BN89[<R$/"S(R$KD!XY,'@T ?3'[87[??[(7
M[ GAC1_&7[7WQKL?!.F:_?O9:1=WUC=3BYG1-[(!;Q2$$+SD@"O#M _X.)?^
M"+'B758M&T[]O[PE'-,P5'U"PU"TB!) ^:6>V1$'/5F '7M7R[_P74^._P %
M?AAIG_!/S]HKQ1\8&\5^ ="^->D:S?>.XX?M[:OIL5I#(VH;;5#YYEC!EQ$A
MW%OE7D"NI_:*_P""]W_!$[]HOX3^(O@1X+\"Z[\;_$?B'0[JTTCX7:/\&-4E
MO=9E>)@L<8N+- GS8/F [DQN4$J!0!^GWASQ'X>\8>'['Q;X2UZRU32M3M([
MK3=3TZZ2>WNX)%#QRQ2(2LB,I#!E)!!!!KY#^,/_  <%_P#!&_X$?$>X^$_Q
M&_;L\,IK=I<FWNXM$TO4=6MX)0=K))<V-M- C*<A@SC:00<$5\&?&31?VT_^
M"=?_  :^_"G]DKQYKM]X7^)GQ+\8V7@2>3[23=>'K#6=2O+O[*75OE<6:F!U
M!_=B5D&"@-?K1^RU^Q9^S3^QO\ ]-_9L^ GPGT?1_"]AIR6EU;)81E]4(3:\
M]X^W-S+)R7=\EBQ[<4 =7\&/CA\'OVB_ASIWQ>^ _P 3=$\7^&-6C+Z?KGA_
M48[JVFP<,H="0&4Y5D.&4@A@""*R?V=?VI/@'^UGX4U7QQ^SQ\1K;Q-I6A^)
M+O0-5O+6VFB6WU&VV^?;D3(A)3>N2 5.>":_/K]F7P-X=_X)Q_\ !P_XH_8Y
M^ -A'HWPI^/_ ,&/^$^_X0C3QY=AHGB*UO);>6:UA'RP1RQ6\I94 !,J*,+"
MBCH_^#8G_DSOXQ?]G2>,OYVE 'W%XX_:D^ ?PV^/7@C]F'QO\1K;3_'GQ'@U
M";P3X=DMIFDU1+& SW3(ZH8T\N)2QWLN<<9/%>(?M ?\%PO^"5?[+/Q@UOX!
M?'W]L#1O#GB_PY-'%K6B7.C:C*]J[Q),@+16SH<QR(W#'[WK7AG_  4 _P"5
MBS]@/_L7_B1_Z8)J\0_9Y_;-_8/_ &1/^"XG[>S_ +;?Q>\(>%%\0:QX%'AH
M^*X0_P!J,&D7'VCRLHV-OG0;NGWUH _1;]E#_@J%_P $^_VX]>N/"7[*G[5W
MA+QCK-K:FYFT.RO&AOA ,;I1;3JDK(I(#,%(4L 2"17O5?B]\=OCM^Q7_P %
M"O\ @L'^R9=_\$E+'3O$/B_X<^-+G6?BU\0? _AF6RL=/\,;$$UK>77DQK/Y
MR^?&@RP#3% <S%3^T- !1110 4444 %%<_-\6/A9;S/;W'Q+\/QR(Q5T?68
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M;0[5[.YO;W49% +BWM+2*6XF"[EW,D9"[UW$;AGX[_91^,__  1[_P""HO\
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M%F'Q3\2O$_C7XA^-M>FT:RU!9+J^=W2PTZ]1[W4%CAC0'8J RB15S@L?:?\
M@I-^TM^SE_P4%_8[_8P^&O[,1BM_@Y^T)^TEX>TWQ-H5K8I8[M*MKB62]TF>
M"+Y8G%RHWJ,KOA#*64AB ?=?[+/_  5?_P""='[:_P 0+OX4_LO?M;^%/%OB
M6SBDE?0[6>6"YFC3[\D,<Z(;A%'):+> .2<<UU7[6W[>/['W["/A:P\8_M<_
MM ^'_ UEJL[0Z4NK3LUQ?.H!?R;>)7EE"[EW%$(7<NXC(S\:?\'$O@[P?\!?
MV<_@S^VC\,?"FG:+XP^"/QL\,2>%]2TNS2"2'3)IS;7&F H!BUE1T#0CY2$
MQC(-G]F'2-*_:,_X.-OVG_B+\1M/AU2;X!?#KP;X7^'JWT8D72EU:S?4;N>!
M6R(Y6D$B&1<-L=ESAB* /M[]FS]J?]G7]L+X90_&/]F'XQ:'XV\-3SM!_:FA
M7@E6*90"T,JG#PR@,I,<BJP#*<8(SW]?G%^SSI&D?LT_\'*'Q=^!'PQTN#2/
M#'Q?_9NTWXB:[H^GQ".V.NVFK_V:;E8UPJ/)$\S2, "[MN;).:_1V@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_$'_@]Y_P"36?@?_P!E U'_ -(17[?5^(/_  >\
M_P#)K/P/_P"R@:C_ .D(H \__P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9
M^UW_ -O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC6=.9ECB65G59'C5'?RVS\A9F0@DFOU#HH _,C_@D_XF_:!_X)G_ +5NN?\
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MM%?0_P!FY=_SYA_X"O\ (_(/]=.,?^AEB/\ P=4_^2/"O^'9/[!'_1KGA?\
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M@G_#@[_JZ[_RQ?\ [NH_X<'?]77?^6+_ /=U?S5_Q#'C[VGM/JFM[_'2W_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %97CCQQX0^&GA#4?'WC[Q%::1HVD6CW.I:E?2A(H(E&
M2S$_D!U)( R2!1XX\<>$/AIX0U'Q]X^\16FD:-I%H]SJ6I7TH2*")1DLQ/Y
M=22 ,D@5^%W_  5)_P""I/B_]N'Q>_@#P!-=Z1\,M(N]VFZ:Q*2ZM*IP+NY
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MH_\ I"*_;ZOQ!_X/>?\ DUGX'_\ 90-1_P#2$4 >?_\ !IM_RE,_:[_[>/\
MT^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[U
MG_TI- 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?>+]IW1WNIE3F.W. R0 \\'. )'^MO$7PP^'?BSX=W'PD\0^"M,N?#%UIO\
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M'X(=$N[[R?5_):'N\'<'8#A+ >SI^]6E\<^K?9=HKHOF]0HHHKY$^P"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MO'OVN?VR_ '[*/A^QL[G2[OQ+XU\12_9O!G@+11OU#6;DG"A5 )CB!^]*1A1
MT#-A3TX3"8G'8B-"A%RG+9+^M$MVWHEJ]#FQ>,PV P\J^(DHPCNW_6K;T26K
M>BU-_P#:8_:?^$7[)WPUF^)GQ=UXP0;_ "-,TVU3S+S5+H_<MK:+.9)&/;@
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M _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !1110 4444 %%%%
M!1110 5X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI-
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M@V?A;PKHMKINFZ?;);V%A8P+%#;Q(,*B(H 50   .!5N...*-8HD"JH 55&
M .PI:RS',YX[EI0CR48?#!;+NV_M2?VI/5[*R22URW*X8#FJSDZE:?QS>[[)
M+[,5]F*T6[NVVRBBBO+/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OQ!_X/>?\ DUGX'_\ 90-1_P#2$5^WU?B#_P 'O/\ R:S\#_\
MLH&H_P#I"* //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?
M)Z_?Z@ HHHH **** "BBB@#Q+]O3]OS]G_\ X)W?!4_&'XZ:I=SS7UXNG>$_
M">AVWVG5O$VIOQ%8V-N.996.!GA5!RQ KYW_ ."?/[&O[4/QM_:IG_X*X?\
M!2?2+?0?B#=^'Y-&^$7PALKCS;?X<Z%,27\^3CSM2G5B)7 &T.ZG&X10:'_!
M13_@B_JO[?/[6W@G]KS3/VY_'WPUUOX>:"VG^#[/PMIUK)'IDTCRM/>1-+DI
M/*LB(S@9VPQ@'Y16O^RQ_P $OOVIOV??CUH'Q?\ B'_P5Z^-OQ-T;1WN&O?
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M*2?_ !58G_!/&Q\>+\#=26?7;%I!XTU42L+4X:038<CG@%MQ [ BOH^O"_\
M@GO_ ,D3U;_L>]9_]*30!ZY]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XU
ML44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_
M ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR
M_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&
M_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+
MQO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q
M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\
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M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
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M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
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M[>#P>&R_#QH8>/+%=/S;>[;>K;NV]6[A1117,=04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7X@_\ ![S_ ,FL_ __ +*!
MJ/\ Z0BOV^K\0?\ @]Y_Y-9^!_\ V4#4?_2$4 >?_P#!IM_RE,_:[_[>/_3Y
M/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4
M444 %%%% !1110 5X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
M2DT >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%9?C+QOX.^'?AZ?Q9X\\4Z?HVF6PS/?ZG=I#$GL6<@9/8=3
MVJ9SA2@YS=DMV]$A-I*[-2JNM:YHOAK2I]=\1:Q:Z?8VL9DN;R]N%BBA0=69
MV("CW)KYWO?VWOB%\;[N7PY^PW\%+KQ6BR&*3QWXF233]!MF!P65F ENB#U1
M IZ$9%2Z+^P9?_$[58/&?[:_Q>U'XC:A#();;PU 6LM!L7[!+:,@S$=-[XW#
M[RFOGGGT\<^7*J3K?WV^6DO^W[-S_P"X<9+HVCE^LNII1CS>>T?OZ_*X[7_V
M^!\0M8G\#_L8?"C4_B;JL,ABN=<CS::%8OZRWD@ D(Z[4^\!\K9JM;?L5?%+
MX\W$>O?MQ_&RX\06V\2)\/O"$DFGZ'"<Y"R%2)KK!Z,Q4CIDBOHCP_X=T#PG
MH]OX=\+:'9Z;I]I&$M;&PMEAAA7^ZJ( JCV JY0LAJ8Y\V:U?;?W$N6DO6%V
MY_\ <24EU44/ZLZFM:7-Y;1^[K\V_0R/ _@#P1\,_#L'A'X>^$M.T73+<?N;
M'3+1(8U/<X4#)/<GD]S7-?'C]F;X)_M,Z38:#\;?!\FM66F7+7%E;#5[NU1)
M67:7(MY8]YQD MG&6QC)SWE%>S5P."KX5X:K2C*FU;E<4XV6RY6K67H;RITY
M0Y&DUVZ'SM_PZ@_8"_Z()_Y=.J__ "51_P .H/V O^B"?^73JO\ \E5]$T5Y
M/^J?"O\ T 4?_!4/_D3#ZE@_^?<?N7^1\_Z/_P $M_V%?#^K6NO:)\$I+6]L
MKE+BTN8?%>JAXI48,CJ?M7!! (/M7T!117HX'*LKRM26#H0I*6_)&,;VVORI
M7L;4Z-&C?V<4K]E8*\V^-?[(?[.O[06;KXG?"_3[K41@Q:W:*;:_B8?=(N(B
MLAP0" 25]J])K)\=>._!OPQ\'ZAX_P#B%XEL]'T72;9KC4=2OYA'%!&.I8G\
M !U)( !) KHQ& P^94_J]:DJBEIRM*5WTT=]>PJRH^S;JVY5J[[6\[GS[?\
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M?_!/?_DB>K?]CWK/_I2: /=**** "BBB@ HHHH **** "BBB@ HHHH ****
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M\,S<#Q]\1+;%S*A_CM-/&2?56DRC \[370_#/]@+X3>'?$B?$KXS:QJ?Q/\
M&0P3X@\:2?:(X#G.+>U.8H5!Y488KV85X7]LXW,-,KH\T?\ GY4O"GZQ5N>?
ME9*+Z3.;V]2K_!CIW>B^75_EYG/-^UI^T)^T<QT[]B[X)O!HTOR_\+)^(,3V
M>G[?[]M;8\VYXY#8 !&&7%:G@W_@G]X3UGQ!!\1?VK/'VJ?%CQ-$V^+_ (2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !15#Q-XJ\+^"M$G\2^,O$EAI&FVJ
M[KG4-3O$MX(E]6D<A5'U-?-_B_\ X*N_L^7.O3>!/V:O"_BOXS>)(CM;3_AU
MHDES:PL>AFO'"PI'_P!-%+@5WX+*\QS&_P!6I.26[2]U>LGHO5M'GX[-<MRV
MWUFJHM[)OWG_ (8KWI>B3/I^L7Q[\1_A[\+/#\GBSXF>.=(\/:7#_K=0UK48
MK6%3C.-\C 9]LYKYF_LW_@K)^TGSJ>L>#/V??#T_6WL47Q%X@"'JK.<6J9'
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M_P#DK] ]KQ/2WI4:GI.<']SA-?\ DR]3ZDHKY5_X=L_$WPE\WP=_X*0?''2
MO^JM_$6O0ZU;Q>@6.:-?E]LT?\**_P""LG@<?\4E^W1X$\:*G^KB\:_#9;#(
M[!FL7)/IGJ>M']DY;4_@XZGZ2C4B_P#TB4?_ "8/[7S*E_&P%3UA*G)?C.,O
M_)3ZJHKY5_X6E_P6 \#<>*/V6/A)XZ"=3X,\;W&F&3Z?V@IQ^-'_  \*_:+\
M'G'QC_X)@_%VPV_ZT^#'M/$(7UP8'3<*/]7<?/\ @SIS_P -6FW_ . N2E^
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M/JOB ;/AK^P9\>M9S]RYNO!*V-L_TEEE_I7TW!;P6L*V]K D<:#"1QJ JCT
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M>&?@Q\,]<^*OC&X\O3="TZ2[N<$!I-H^6-<]6=MJ*.[,!7X/_%OXG>)OC/\
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M_P#90-1_](17[?5^(/\ P>\_\FL_ _\ [*!J/_I"* //_P#@TV_Y2F?M=_\
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MQ)^Q]H37'P;TW]HN+Q1\(;#2XC_9]Q;:9?6\VKW%BHX^QB% R%!LVV^T8VG
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M_P#!>MW%W#::C 89Y+&Y:&95)!RCKRIXZB@#6KPO_@GO_P D3U;_ +'O6?\
MTI-'_#O?X)_]#;X[_P#"RN?\:Q/^">/@+1H/@;J5NEU?%8O&FJQ*3>,20DVP
M9/<X49/<Y- 'T?16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"
M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:O-_B?^T1^R5\&O,C^(_Q[TK3YXL^98IK1N+I<?\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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MI'_/S>_^!;5:TK0++1Y'DM99V+K@^;,6'ZT 7J_$'_@]Y_Y-9^!__90-1_\
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MG\.=.\-P^+/%=YXE\1QZ<A47^K76S[1>29)S))Y:9(P/E'%=E10!\Y_M-_\
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MEN_-O9!C.4M8@TSCW"$<BO&/^&^?VE_CW_HG[$O[$?B'4+&;B'QS\3Y!H>E
M=IHX23/=1_[FUNO'%>>?\$2OV,=0^'OP&7XL_M!? 'PQ:>)=6O\ [;X9UK4=
M,\W6Q9NN0\S2[O(R>4";6*\N,XK[VK\?S"GD>0XVIA:5/ZS.#MSRE:FVNT(.
M[^=1KNC]FRZIGO$&!IXJK4^K0FK\D8WJ)/O.:LK^5-/M(^3?^&&/VM/C_P#Z
M5^VC^V[K"Z?-S-X&^$D']C:<!WBDNF!N+F,]PX!]_3U_X!_L3?LJ?LQQ(WP4
M^"&AZ/>*N&U=K<W%^^>NZZF+S$'GC=CGI7J=%>5BL]S/%4G1<^6G_)!*$/G&
M*2?J[OS/6PN0Y7A*RK*'/47VYMSG\I2;:]%9>04445Y![ 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<1
M\3?VD_@#\&E<?%#XP^'M%E09-I>:I&+@_P"[""9&_!36.(Q.'PM-U*\U"*ZR
M:2^]DRG""O)V1V]%?.;_ /!1SP;XT<VO[.'P,^(7Q(<G$5_H_AV2UT[/^W<W
M.W8/<H:3^V_^"FOQ6_Y!G@SX??"JPDZMJU^^M:E$.Q40@6Y/J&Q7B?ZS9;5T
MPBG7?_3N#E'_ ,#TI_?,Y_K=)_!>7HK_ ([?B?1M<!\3_P!JC]G'X,^9'\3?
MC3X=TJ>+.^QEU)'N>/2",M(?P6O,?^&!?$OQ _??M*?M=?$+QF'_ -?I6FWB
M:-ILOJ&MK;.?P85W_P ,/V,/V5O@YY<OP^^!7AZTN(L>7?7-D+JY4^TT^^0?
M]]4?6N),5_"P\**[U)\TO_ *=X_^50Y\7/X8J/J[O[E_F< ?^"B6E^.CY'[-
M7[./Q#^(1?\ U&IVNB-I^F/Z9NKG&W/NG2CS_P#@IQ\5O]58_#SX46$G7SI'
MUS4X<^FW%LV/?'-?1H  P!11_8V88G_?,;-_W::5*/WKFJ?^5 ]A5G_$J/Y:
M+_/\3YR_X=[R>/?WW[2O[47Q#\>[_P#7Z6NJ_P!EZ9)Z_P"BVW3\'Z5Z1\,/
MV1OV9?@UY<GPW^!_AW3IXL>7?'3UFNAC_IO+ND_\>KT6BNC#</Y+A*OM84(N
M?\TO?G_X'*\OQ+AA</!\RCKW>K^]ZG._%OXG>&?@Q\,]<^*OC&X\O3="TZ2[
MN<$!I-H^6-<]6=MJ*.[,!7X/_%OXG>)OC/\ $S7/BKXQN/,U+7=1DN[G!)6/
M<?EC7/147:BCLJ@5_0%17S'''!.)XS]C#ZW[*G3N^7DYKR?5OGCLM$K:7>NI
MQYCE\\?RKGY4NEKZ_>C^=NNB^$GQ.\3?!CXF:'\5?!UQY>I:%J,=W;9)"R;3
M\T;8ZJZ[D8=U8BOTH_X;Y_XW&?\ #.?]M?\ %,?\(Q_PCFSS/W7]LX^V^;_O
M9_T7']ZOMJOS?+O!Z-:K*KALRM*E.UU2U4HV=U^]^X]'B#PWS7A>6$>+J6>(
MHPKP]W[,[VZ[JVJZ'._"3XG>&?C/\,]#^*O@ZX\S3==TZ.[MLD%H]P^:-L=&
M1MR,.S*17157U;5])T'39M8UW4[>RL[="]Q=7<ZQQQ*.K,S$!1[FOGWQ[_P5
M"_9=T#7G\$?"J_UKXH^)1D)H/PTT>35')Z F9,0[<]2')'I7[Y+%4L%1BL54
M7-97>W,^MHW;U?17^9[&4</YYGDG# X>=5Q^)QB^6/G*7PQ7G)I+N?155M8U
MK1_#NF3:UX@U:VL;.V3?<7=Y.L442^K,Q 4>Y-?,?_"7_P#!4?\ :#^7P?\
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MF:U^SQ?>,;GPQK0O;76?!7BZQ4F;0=<LY!+:7B $$A7!1@""4D<*5;#  ?\
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M_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4F@#W2BBB@ HHHH ****
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MVO7_ +6P#^&3?^&,I?DF>C_J!Q5#^+1C2_Z^5:-+_P!.5(V/IVBOF+_A=O\
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M7&K>(=1NF<^I$EP5_2CVV:RVHQ7K-_I!_F']G<"4?XF8UY_X,-&WWSQ$&O\
MP%^AZ-XU_:L_92T73;K3/%'[4/@C2FEA:-F_X32SAGC)&,I^\W!AU&!QBORS
M_;0_;&_:7^#GQ!:'X"?\%)Y?'WABY=FLIM-N[<7EE_TRN D2K)QTD3(."2J$
M@']/?#O[!?[%7A;:='_95\ AD'R277A>VN''N&E1CGWS7@/_  5XT?P]\/\
M]EBT^"'P$^$.GIXG^(_B"WT?3--\,Z#&ES);QG[1-Y:PH"1^[CC;'\,ISQFO
M%S[#YC5P$JLYJ#@KKD<[M]%ND[NRU3\C]+\*LWX.P'%E#!8?#3Q*KR49+$1H
M<D8[RJ:QJ2CR1O)\LXW2M*Z/Q_\ ^%E^/O\ A9'_  M__A++W_A)_P"VO[7_
M +<\W_2/MWF^=]HW?W_,^;/K7W_^Q-H?_!8[]KK2D\<V'[3^L>%/"$S?NO$/
MB&))#> '!-K!Y>Z4 _Q$HAP0')4@<A_PX1_:=_X4)_PL#_A*]'_X3;_7?\()
MN'^IVY\O[7N\O[1G^#'E_P#36OLW_@C#XZ\67?[*MS\#/B3H][I?B7X:>(;C
M2+_2]3@:*YA@D/VB$NK8('[R1%]HACC%?+9!E&-AF*I8SGIQFG)6;7,UT;3W
MM=M:,_=O%CQ#X9Q7!U3'<-K"XNIAZD:4W.G&HZ4'=*4(SC9QYE&*DDZ;OI>Q
MMZ#_ ,$MOAKXGNK;7?VL/C%XW^,6I6Q5HXO%6N2Q:;"X_BBLX6 0>JL[@]\U
M]"^ OAK\//A9H*>%_AGX%TCP_IT?W;'1M.CMHL^NV-0"?<\UMT5^EX? X3"N
M]*"3[[M^K>K^;/XJS?B?/\]BH8W$2G!;0^&G'_#3C:$?^W8H****ZCP0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<^$OVAO"?B+4O#W@;P_-J>H2V5G)/-,R0Q D\ +EL*&902,T </X<_X(B?\
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M]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI- 'NE%%% !1110
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M2?>!\W_\*<_X*1?M<_O_ (]?%VT^!O@^X^]X-^&]RMUKLT1_@N-3;Y(6P>L
M((X*UZ_^SG^P_P#LQ?LL1M=?"'X76=OJ\P)O?$NHDW>J73-]]GNI=TGS$DE5
M*KD_=%>LT5SXK/,=B*+H0M2I/[$%RQ?^+K/UFY/S.G"9%@<-66(J7JU5]NH^
M:2_P_9AZ045Y!1117CGLA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 456U;6-)T'3Y-6UW5+:RM85S-<W<ZQQH/4LQ 'XUXK\2/^
M"EG[#7PMF:RU_P#:-T&]NPVU;+P[(^J2L_9,6BR8;/&"1COBL*^*PV&5ZTU%
M>;2_,]3+,DSG.JGL\OPU2M+M"$IO_P E3/<Z*^2/&O\ P52O(=&?7?A;^Q[X
M_P!0T\<1:]XV>V\,:5,>VRZO'(8?\!!]J\4N/^"BO_!1O]H'59/#O[.?PX\,
MP ED>;PMHEUK,ME)V6:[N/*LPO\ MC</K7A8WBS),#)0E-RD]HQBW)_X5;7Y
M7/8K<'X_ :YG7HX7RJ58<_\ X)INI6_\IGUO^V;\9_VH_@+X._X6+\!?@7IG
MC[3K.$MK6F#4)HM0MP,GS8HT1A.F.JK\Z]0K#)7\MOVM_P#@H=\5_P!N'2-"
MM/&?A*P\.Z;H\DLT.EZ;/(ZSS/A?-D+]2J@JHQP';^]Q[?\ M%? _P#X*!^&
M/@9JWQQ_;)_;%U;3+:*-(K7PGH^L%7O[N0X2!HK+R;=5)RQ(,NU$<X..?B D
ML2S$DD\DGK7XCXG\7X_$067PA4I0J)2E&?*FXIZ>ZO>BFU>TK/3:Q\_Q;GO#
MM'AN&382A&IB.=2EB5&I"\$G[BC.6MY6?,Z5-VC:SNV>Z_L>?\%!OBG^Q/I^
MN:;X0\.Z7K>EZS)%//8:Q<R11V\R @S(R="RD*P(YVIR-O/T3'_P6 _;'^(=
MEL^&7[+@C,B@>=9^%M6U63!_CC$:HC''0,<$U\$Z5JFHZ'JEMK6D7CV]W9W"
M3VMQ$<-%(C!E8'L00#^%?N?^Q]^T+IG[3_[/N@?%JT:-;VYMOL^MVT?_ "[W
MT>%F3'8$_.H_N.I[U7A=C<RSFE/*?K\Z2IKFC&*CK%OWO>:YE9M:)]?(\WA/
M.,F6">#Q^'E4<6W%PJ1IW3W4FZ<Y-)[<LH/7J?$)\=?MP_&?]Y\2? '[3.JP
MR\G1M%T&Q\&VVT_\LW??(\B^N[!Q74?#OX)_&3PM<C4O G_!''P]'>,V\ZY\
M1/BO9ZI/(_\ ?,<BN4;O\N/:OT#HK]BH\'8"%15*DY3FOM349R^4JBG)?)H^
MPCG'"]!WI9)0D^]6IB:C_"O!?A;R/EVSO_\ @KIJ=JEAX>^'?P \)VJ*%CAU
M"_U2Z:)?11;@)D?E4O\ PIW_ (*J^)/^0U^V1\/O#6[K_P ([\//MFWV'VIQ
MG\:^G:*]Q99"UI59O_M]K_TGE.C_ %SJTO\ =\#A8?\ <"%3_P!/>T_$^8O^
M&*/VP=>_Y'[_ (*=^-;G=R__  COA'3]*R?;R]V*3_AV)HNL?-X^_;1^/WB#
M=]^"\^([1P9]HXXAM_.OIZBC^R<"_BBY?XI2E^;8?Z_\4Q_A584_^O=&A2_]
M-TXV/F2'_@D)^PM<RK<^+_A[KGB293D3:]XTU*8[O[Q"SJ"?P[UUGAW_ ()L
M_L'^%]O]F_LL>$9=HX_M'3OMGY^>7S^->WT5<,KRRF[QH0O_ (5_D<^(XZXU
MQ4>6KF>(:[>VJ6^[FM^!Q?AW]F_]G?PAM_X1/X"^"]+VC"_V=X6M(,?39&*[
M"UL[2Q@6UL;6.&)!A(XD"JH]@.E245V0ITZ:M!)>A\]B,9C,9+FKU)3?]YM_
MF%%%%6<P4444 %%%% !1110 55FT31KG5[?Q!<:5;27]I!)#:WKP*988Y"AD
M1'(RJL8T+ <'8N<[1BU12:3W*C*4'>+M_P '<*JPZ)HUMJ]QX@M]*MH[^[@C
MANKU(%$LT<9<QH[@995,CE0>!O;&-QS:HH:3!2E%-)[[A1113)"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,5:,5Y)(]+ 95E^6I_5Z:BWN]Y2\Y2=Y2?FVPHHHK@/0"BBB@ HHHH ****
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M?>*+K4)6]=R;UB;/NE?0/BKQAX2\"Z-)XB\;>*-.T?3X?];?:I>QV\*?5W(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^(/\ P>\_\FL_ _\
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MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+1_96%>[F_6I4?\ [<'^O>?1_APP\/\
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MD_L$_L[^!/C+\*/B[XZO/&GA_2M?\?CP_>^"-;OE3[8DHDAD6\L2Z(R1Q%'
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M>[YE:6K>]NA]GE52C6PJG%)2V?>__!"BBBOT$],**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X@_\'O/_ ":S\#_^
MR@:C_P"D(K]OJ_$'_@]Y_P"36?@?_P!E U'_ -(10!Y__P &FW_*4S]KO_MX
M_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110
M4444 %%%% !1110 5X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_[
M'O6?_2DT >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7X@_\ ![S_ ,FL_ __ +*!J/\ Z0BOV^K\0?\ @]Y_Y-9^
M!_\ V4#4?_2$4 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\
M[>/_ $^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 5X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DT >Z4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X@_P#![S_R:S\#
M_P#LH&H_^D(K]OJ_$'_@]Y_Y-9^!_P#V4#4?_2$4 >?_ /!IM_RE,_:[_P"W
MC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%%
M!17X)_&?XV?\$OOCG_P4R_:H\??\%-_V]_&?@+3/#_Q'T_P9\-O"OA+QQJUH
MT(TS3TM]1G:VTY)6$;W*KB1U5=ZR@$G<!]=_'_XQ? ?_ ()5_P#!"7XC_M'?
M\$U/C?JWCNPUV6.X\"^+-9\8/XA<:IJ4]II8EBFF+8^SX\WR&&%DA=67)9:
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MU[U10!X+_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/7O5% '@O\
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M '@O_#NKX'_]#=X[_P#"OGH_X=U? _\ Z&[QW_X5\]>]44 >"_\ #NKX'_\
M0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7SU[U10!X+_ ,.ZO@?_ -#=X[_\*^>C
M_AW5\#_^AN\=_P#A7SU[U10!X+_P[J^!_P#T-WCO_P *^>C_ (=U? __ *&[
MQW_X5\]>]44 >"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7SU[U10!X+
M_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/7O5% '@O\ P[J^!_\
MT-WCO_PKYZ/^'=7P/_Z&[QW_ .%?/7O5% '@O_#NKX'_ /0W>.__  KYZ/\
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M5\]'_#NKX'_]#=X[_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\
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M*^>O>J* /!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO_P *^>O>J* /!?\
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M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ]ZHH \%_X=U? __H;O'?\
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MNKX'_P#0W>.__"OGKWJB@#P7_AW5\#_^AN\=_P#A7ST?\.ZO@?\ ]#=X[_\
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M HHHH **** "BBB@ HHHH **** "BBB@ KPO]KO_ (*8_L&?L&WNGZ1^UO\
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M?[9?[(7PSTR'2_ NJZ?X6\?Z5X=LHQ':Z;J5W9K'J#PQKA4\^1E=@!C]V@&
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M&Z\-BVO(I)=5C\H V%K%;PS1-,-JD.W5$E* 'WY^T_\ M=_LS?L6_#<_%O\
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M"*_;ZOQ!_P"#WG_DUGX'_P#90-1_](10!Y__ ,&FW_*4S]KO_MX_]/D]?O\
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MXD1[QW"+''$TB,R$!^0:_5;QW')-X(UF*)"S-I5P%51DDF)L "M6B@#\\/\
M@@W\'?B'JW_!O-X ^!U_%J/A+Q)JW@_Q=ID+ZE:2VUQIL]SK&K)%,R, ZE?,
M20<9Q@CJ*\8_X)K_ /!3/X$_\$P_V"= _P"">_[9'[-GQ,\)_%[X;VU_I$OP
M\T;X7:CJ:^-)FN9I5N=-N;:![6Y2Y$H)>21%+,V"RX8_KM10!\5_\$ /V7?C
M9^R5_P $U_#GP_\ CWX0D\+ZWK'B+6/$5OX)EDW-X9L[Z\>>#3R/X&5&#LF
M4:5E(#!A7VI110 4444 %%%% !1110 4444 %%%% !1110 4444 ?,'_  5^
M_;J\>_\ !/3]B#Q!\=_A!\)M1\:^-KJ[AT;P9H=CI<]W&=1N%<K/<) "_D11
MQRRL!C>46/<I<,/S;_X)N_\ !1;]@O\ 8_O-5_:0_:!^%W[2_P 4OVBO'ENL
MGQ%^*NM?!6[>0$@$Z=IR%@+2PC("K&@7>$4L%58XX_W#HH _-3]LCQ3K'[$/
M_!5CX=_\%?;_ .&'BW6/@YX^^!S_  _^)E_X=\.SW]WX3?[:FI66I75I K3>
M4WR0.45O+\M@069%=/V;?%US_P %3/\ @LGH'_!0'X2^ _$UE\#_ (&_"[4-
M \(^,?$_AVZTK_A*O$&IR%;A[*"[2.9K:*U)5I&12)% Q\PQ^EE% 'P'_P '
M.'A#Q9XZ_P""./Q%\->"/"^HZSJ,VN^&VAT_2K*2XGD"ZW9,Q5(P6("@DX'
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MMU+=Q(CWCN$6..)I$9D(#\@UQ_\ P6S_ ."AGB#XI?MM-_P3A^(&C?&;PO\
ML\^'=/AG^+GB#X5^!KR]U3QQ<RQ1S+HD%P@"V]CY<JK-(I)=A+'@@#/[-T4
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M(/\ Q&\_LL_]&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\
M$;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_
M -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&
M/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\
M**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_
M  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\
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M]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ
M_P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\ 1CWQ _\
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M%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^%
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M_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>mrk-20221231_g3.jpg
<TEXT>
begin 644 mrk-20221231_g3.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@
MJ9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?
M])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27
M;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\
MJ&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AK
MG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\
M>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_
M?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^H
MH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /
MP!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?
M^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$
MV_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^
M"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9
M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /Y/?^"PO_  2[_P""
M@?\ P1[^&W@[XD?$C_@HIKGC&#QCKD^FVUMH>OZK ]N\4(E+L99L$$'&!17Z
M"?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_
M '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@
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MG6_PZBO9?WU[I>MRQVL[MTY.EQ6SM@8)E/8YK[9\:?M6_M.?\$L_V-/V+O\
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M'P1)IFJK<R2V)OM6F!F4 >4VR\A^4YY+#M0!\B?\$]_VCO#_ .R!_P %)/\
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M8_[0^P:/I$UQ;P2*;4PF[E12EK SJ%:64JBC<20 :_62B@#\1?VE/''[3?\
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MB?X=^.?A/X<.J^<[S7+Q6MT<@1,5N51PS"1'B=ECE216KAO!?_!.S]MW3_\
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M /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%%
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MH_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\
M5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% !7R_P#\
M%<?V5?VNOVL_V2Y?!_["_P"T_K7PK^)FA:[;:UH&K:7KUSIT&J>2LBOIUW);
MY;R)!)NP59?,BCW#:6KZ@HH _"?_ ()F_P#!.;_@I#^VU^UGX>^.G[<NB>"?
M!/@_X%?M-^,/&>HVFB+(VIZYXPGOH);F&#+.B:<ES:PLKAL.@8#S=P>/Z:^.
M?PJ_X.-_V:/VI_BOKG[&OC/P7\:OAM\39GN/!T'Q(\0_9KCX=R.TK".&)GB5
MHHC,5 4R^8D,)8*RL&_3ZB@#\J/@I_P1N_X*)?\ !/;_ ((ZV/[-'_!/K]J+
M1-(^.3>.F\8^-;B>R@ETGQ$\T"6\^DQR7=N[11B*&U"R[4,C0-N\M9CLL?L8
M_P#!-C_@H?\ M%_\%+_"'_!3+_@J!X"^''PYA^$OA*71?AG\*_AQ=_:(%N95
MN%DO)BKR1HN;J>0 2,Q?RLA1%F3]3Z* /CK0?AE_P5>^/&E_M0_"'X__ !0\
M/_#G1=:OY+7]FCQO\/Y<:IIEH9[XQW-[M?)<(NG;E&TL&F ()R/@CXP_\$T?
M^#A?_@HC\$_ ?_!-C]N[5?AAIOPQ\(^)[:]\3_&JR\02:CK?B2WMA(D3;'<O
M)-LE?!DA@+NJ&1AA]_[>44 4O#>@:9X4\.V'A;18FCL]-LHK6T1G+%8HT"*"
M3R> .:NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"*
M*/\ @]Y_Y-9^!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P
M:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%% !1110 5^&G_!T/?>,-8_X* _ _
MX=Z9\3O%>A:5>_#/5[F[M_#?B.XL/.ECO%VLWDN-Q ..:_<NOPT_X.:?^4G'
MP%_[)1K?_I8M=."C&>+A&2NFT?.<7XG$8/A?&5Z$G&<:<FFM&FEHTSX*_P"%
M/ZK_ -'!?%?_ ,./J'_QRC_A3^J_]'!?%?\ \./J'_QRNTHK[3ZA@O\ GVON
M/Y#_ ->.,/\ H/J_^!O_ #.+_P"%/ZK_ -'!?%?_ ,./J'_QRC_A3^J_]'!?
M%?\ \./J'_QRNTHH^H8+_GVON#_7CC#_ *#ZO_@;_P SB_\ A3^J_P#1P7Q7
M_P##CZA_\<H_X4_JO_1P7Q7_ /#CZA_\<KM**/J&"_Y]K[@_UXXP_P"@^K_X
M&_\ ,XO_ (4_JO\ T<%\5_\ PX^H?_'*/^%/ZK_T<%\5_P#PX^H?_'*[2BCZ
MA@O^?:^X/]>.,/\ H/J_^!O_ #.+_P"%/ZK_ -'!?%?_ ,./J'_QRC_A3^J_
M]'!?%?\ \./J'_QRNTHH^H8+_GVON#_7CC#_ *#ZO_@;_P SVG_@@PWC/P3_
M ,%HO!?@9?B]XVU?2=1^&?B"YNM/\1>++J^B:5%C"MLE<KD=N*_HCK^>/_@B
M=_RG.^'G_9*/$G\HZ_H<KX_,80IXV<8*R7^2/ZNX QF*S#@_"8C$S<YR3O)N
M[?O26K] HHHKB/L0HHHH **** "BBB@ HHHH **** /RE_X*(?\ !R3XN_9Y
M_:BO?V;?V+_V,M8^*X\ ^/K#P_\ %'Q#([QVQNIK:[G;1]/$66-\1:S%99 R
M@VDZ"&3Y9!]]?L&_MI_"W_@H/^ROX6_:P^$&G:I8:1XFMI"VEZW;"*[L+B*1
MHIH)5!()5T.&4E74JPX85^,W_!3W]BWXF_!7]ONW_;/_ ."2?[8?@7QMJGCO
M]IG1?^$D^#,NM6UY'I7C]+/59+=[IHYBL08+J(,<QA=&N7&649CZW]JK_@Y<
M^(?C_P#X(U:)XZT_PO%\,OC#\3/'FJ?#;7-:M1<2:?X5>SCMGU+58-@DN,K;
MWUOY<:AY(Y)'*M(81Y@!]R_L[?\ !='X(_M4?\%8/%W_  3%^"OP]EU>U\':
M%>W6H?$N+75-K<7UH\,=S:0VPA)=$DE,?G>: 6B?:I7:[><_M*_\'&VE_#+X
M]_%3X0?LR?\ !/[XF_&G1O@7+)#\7_&WAB5(+'098C(+A0#'(9!$89PQ8QY-
MO,1E$,E?F9_P2?\ VGO^"6'[(G_!=/P6G[-/QAN[[X9WOP=LO VD^*[GPIJ$
M-SKWBJ\GMDDDFA> 2QM-<ESO91$BE5#!56NZTGX3_MO_ +:G[0/_  4$^*7_
M  2#^+6F?"+X8WVM:AI?Q+\.^)[F*\F\:ZI&E]]MGLV>T=M,^T!KEP=ZE3=*
M-X'$(!^['[&G[6OPB_;K_9C\(?M8_ J]NYO"_C+3FN=/74(!%<6[QRO!/;S*
M"P62*:*6)MK,NZ,[688)^8?V[O\ @LS\6/V,?VB]1^ _A/\ X)4?'SXK65A8
M6ERGC+P#X9GNM-N#-$)#&DB0."R$[6&>"#4W_!N#\6O@9\6/^"0'PK;]G_X=
M7OA31_#L%[HNH:+J&H_;)$U**ZD>[G,^Q!)Y\LK7'"*%\_8  M:'_!P)^W=X
MH_8!_P""9WB_XB?#*_FM_'7B^Z@\(> IK;/G0ZE?!P9X\<^;%;1W,R8!_>1)
MV- $7_!)+_@M%H/_  5A\4_$/PUX:_90\<?#T?#B2WMM9NO%;(4-[(\J-9':
MH,<\?E$O&WS+D9 K[;KYS_X)0_L*>%_^"='["/@3]F?1[")=8L]+34/&VH(
M7U'7;A5DO9W;J^)/W:$DD111KG"BOHR@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$
M'_@]Y_Y-9^!__90-1_\ 2$44?\'O/_)K/P/_ .R@:C_Z0BB@#S__ (--O^4I
MG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH
M*_#3_@YI_P"4G'P%_P"R4:W_ .EBU^Y=?AI_P<T_\I./@+_V2C6__2Q:Z\!_
MOM/U1\KQQ_R1^/\ ^O4_R/CZBBBOO3^(0HHHH **** "BBB@ HHHH ]P_P""
M)W_*<[X>?]DH\2?RCK^AROYX_P#@B=_RG.^'G_9*/$G\HZ_H<KX?-?\ D83^
M7Y(_L[PT_P"2'P7^&7_I<@HHHKSS[H**** "BBB@ HHHH ***I^(?$&C>$]
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MO-"5VP3>9]U-H=<KSB0USG_#_C_@C;_TD)^'_P#X%S?_ !NC_A_Q_P $;?\
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MZM9]0L+^9/#%M*+IHX(FO9DD(=D\IW<_NH_-&]D ;']8(((R#D'H10 4444
M%%%% !1110 4444 %%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/>?\ DUGX
M'_\ 90-1_P#2$44 >?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\ P:;?\I3/
MVN_^WC_T^3U^_P!0 4444 %%%% !1110 5^&G_!S3_RDX^ O_9*-;_\ 2Q:_
M<NOPT_X.:?\ E)Q\!?\ LE&M_P#I8M=> _WVGZH^5XX_Y(_'_P#7J?Y'Q]11
M17WI_$(4444 %%%% !1110 4444 >X?\$3O^4YWP\_[)1XD_E'7]#E?SQ_\
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M//\ LE'B3^4=?T.5\/FO_(PG\OR1_9WAI_R0^"_PR_\ 2Y!1117GGW04444
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M7/\ ^CAOA1_X;@?_ !=>(45Z7]C8#^7\6?GW_$6^.?\ G_'_ ,%P_P CV_\
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M &3_ %G_ -(9J /Y;OV2?^3;O!__ &"%_P#0FKT6O.OV2?\ DV[P?_V"%_\
M0FKT6OT'"_[M#T7Y'\'\1?\ )08S_K[4_P#2V%%%%;GCA1110 4444 %%%%
M&1\0/^1#UO\ [!%S_P"BFK]Y/^"!'_*&W]GO_LG\/_HZ6OP;^('_ "(>M_\
M8(N?_135^\G_  0(_P"4-O[/?_9/X?\ T=+7S/$'QT_G^A_1G@5_NF._Q4_R
MD?7]%%%?.G[X%%%% !1110 4444 %%%% 'X:?\'-/_*3CX"_]DHUO_TL6OCZ
MOL'_ (.:?^4G'P%_[)1K?_I8M?'U?7Y%_N3]7^A_*/C1_P EA'_KU#\Y!111
M7LGY*%%%% !1110 4444 %>X?\$3O^4YWP\_[)1XD_E'7A]>X?\ !$[_ )3G
M?#S_ +)1XD_E'7EYS_R+Y?+\S]*\)/\ DN*'^&I_Z0S^ARBBBOBS^O@HHHH
M**** "BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\'O/_ ":S\#_^R@:C_P"D
M(HH \_\ ^#3;_E*9^UW_ -O'_I\GK]_J_ '_ (--O^4IG[7?_;Q_Z?)Z_?Z@
M HHHH **** "BBB@ K\-/^#FG_E)Q\!?^R4:W_Z6+7[EU^&G_!S3_P I./@+
M_P!DHUO_ -+%KKP'^^T_5'RO''_)'X__ *]3_(^/J***^]/XA"BBB@ HHHH
M**** "BBB@#W#_@B=_RG.^'G_9*/$G\HZ_H<K^>/_@B=_P ISOAY_P!DH\2?
MRCK^AROA\U_Y&$_E^2/[.\-/^2'P7^&7_I<@HHHKSS[H**** "BBB@ HHHH
M*\__ &LO^36/B7_V3_6?_2&:O0*\_P#VLO\ DUCXE_\ 9/\ 6?\ TAFH _EN
M_9)_Y-N\'_\ 8(7_ -":O1:\Z_9)_P"3;O!__8(7_P!":O1:_0<+_NT/1?D?
MP?Q%_P E!C/^OM3_ -+84445N>.%%%% !1110 4444 9'Q _Y$/6_P#L$7/_
M **:OWD_X($?\H;?V>_^R?P_^CI:_!OX@?\ (AZW_P!@BY_]%-7[R?\ ! C_
M )0V_L]_]D_A_P#1TM?,\0?'3^?Z']&>!7^Z8[_%3_*1]?T445\Z?O@4444
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M]9_](9J] KS_ /:R_P"36/B7_P!D_P!9_P#2&:@#^6[]DG_DV[P?_P!@A?\
MT)J]%KSK]DG_ )-N\'_]@A?_ $)J]%K]!PO^[0]%^1_!_$7_ "4&,_Z^U/\
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MU#\Y!1117LGY*%%%% !1110 4444 %>X?\$3O^4YWP\_[)1XD_E'7A]>X?\
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MB@ HHHH *\__ &LO^36/B7_V3_6?_2&:O0*\_P#VLO\ DUCXE_\ 9/\ 6?\
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MW_X65S_C1_P[W^"?_0V^._\ PLKG_&K_ -8?^G7_ )-_P#C_ .(#_P#4Q_\
M*/\ ]U/YYZ*_H8_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\
M&C_6'_IU_P"3?\ /^(#_ /4Q_P#*/_W4_GGHK^AC_AWO\$_^AM\=_P#A97/^
M-'_#O?X)_P#0V^.__"RN?\:/]8?^G7_DW_ #_B __4Q_\H__ '4_GGHK^AC_
M (=[_!/_ *&WQW_X65S_ (T?\.]_@G_T-OCO_P +*Y_QH_UA_P"G7_DW_ #_
M (@/_P!3'_RC_P#=3^=#X@?\B'K?_8(N?_135^\G_! C_E#;^SW_ -D_A_\
M1TM>E_\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XUYF88_Z
M^XOEM:_6_P"B/T;@3@?_ %*HUX?6/:^U<7\'+;EO_>E>]_(]THKPO_AWO\$_
M^AM\=_\ A97/^-'_  [W^"?_ $-OCO\ \+*Y_P :\X^^/=**\+_X=[_!/_H;
M?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &@#W2BO"_P#AWO\ !/\ Z&WQ
MW_X65S_C1_P[W^"?_0V^._\ PLKG_&@#W2BO"_\ AWO\$_\ H;?'?_A97/\
MC1_P[W^"?_0V^.__  LKG_&@#W2BO"_^'>_P3_Z&WQW_ .%E<_XT?\.]_@G_
M -#;X[_\+*Y_QH _*C_@YI_Y2<? 7_LE&M_^EBU\?5_0Q_P[W^"?_0V^._\
MPLKG_&C_ (=[_!/_ *&WQW_X65S_ (U[&!S7ZE1]GR7UOO;]&?E'&GAA_K?G
M"QWUOV5HJ/+[/FV;=[\\>^UC^>>BOZ&/^'>_P3_Z&WQW_P"%E<_XT?\ #O?X
M)_\ 0V^._P#PLKG_ !KL_P!8?^G7_DW_  #Y+_B _P#U,?\ RC_]U/YYZ*_H
M8_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&C_6'_IU_Y-_P _X@
M/_U,?_*/_P!U/YYZ*_H8_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%>8_M4?MG?LL?L1> 8OB=^U?\
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M* //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J
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M%IX%T[X3Q>5]FGCD1%@,8E=8X%@!"JJ@ @"@#[;HHHH **** "BBB@ HHHH
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MX-:'9:GXO@\/7LGA33M3N/)MKK4A YMHII/X(VEV!F[*2:_!_P#8\_X)<?\
M!R=^QG^T-XW_ &MO"_PL^ _C+XH>/KAY=;\>?$/7SJ.HQ*Y)DCMG26-;='RH
M944?+&B#"*% !U_[47P.U/4/^"TW_!-[_@FS^U'-:^,]$^'OP)L[C7++4T^T
MV6IZO;6-^D\KI(")E>71;8X<'<H ;.3GIO\ @G]\'/!GAC_@X3_;T_X)W?#I
M+KPC\-O'7PF6]O=.\(.EE_9T]Q;Z6&EM JE+>1?[9O#&0N$)&!@ 5[1_P4,_
MX)P?\%)?C;XK_9@_X*<_ 2#P%+^T[\&/#UO!X\\&:A=M!H^N/+%NNK>VFWX5
M%EFO(PK2+NCN21(K1@.?\$^O^"=7_!27X)^*/VH/^"G7Q^T;P0/VG/C1H,MI
MX$\%Z1J@?2M"\N(?9HKBX8LK+YL5F"H9P([09=FD(0 ^0/\ @LG^R#_P3L_9
M<_97\"_\$+/^"?\ \"K?XB?M$>+_ !A:WFF:G)I]G=>(M)ADN7N7N=1U"&",
MH7A;R5C8*J6BF23:L:L_I/Q[^$<7Q+_X.3/V.OV)OVF#:>.O#OPQ_9UCEN-/
MURW%U9ZKJT.G:J9;UXY00Y>:SM)#N')MDSTKSO\ 8:_X)>_\')?[ _Q2\;?'
MOX;?"3X">*?B'\0+U[CQ)\0/B#K[:GJ\H=M\D4<PFC$4;R?.X5078+N)"(%^
MO/\ @H3_ ,$Y?^"D'C#]IC]G7_@K=^R-IW@34_V@?AEX$AT+XB^ ];OC:Z7K
M'FVTXN5MIMX7:KW]^F'D4[&B97)CVL >=_\ !#33]*^ /_!=3]NK]DWX5Z5#
MI/@1=1M-<L/#]A&([/3[@7&=L$2_+"N+UU"J  L:+C"*!^P]?GS_ ,$3O^";
M/[4'[,WQ.^-_[=G[>EWX=3XP_'OQ(E]J/A_PM<&>S\/6,<DLBVRRY(9F>4#:
M&D"I;P_O&8O7Z#4 %%%% !1110 4444 %%%% !1110!^(/\ P>\_\FL_ _\
M[*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\ *4S]KO\ [>/_
M $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B#_P>\_\
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M71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\
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;_A75)=0TE=#\/)9.LTD?EL696.X;>U% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>mrk-20221231_g4.jpg
<TEXT>
begin 644 mrk-20221231_g4.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MQY;Z3JWCG4O[/\*6<L$KG4+GS(8_+4HC!3NGB&6*CYQSP<=K0 4444 %%%%
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M,,V&=U81;U4'C8%\U%RQ#..K_9:_9A_:IO\ ]I'2OBK\8OV9O@E\+?"V@6!
MT3PAX5TVYOM1OL.%N(KI8FDM0"P)Q(" @4*2S...\/?LE?\ !2']B'QU\2?#
M'[%.A^#/$_@OXAZM+J.EW>NZC]GN_#T\FX;MI= Y16 R/,#>5&V%.Y" <O\
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MOVKOV[?A1XQ\=^(;S]I[X.?#'2?#OFR>#O!.H7-MJ&K^(8$5F0LGSR1R2 *
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MFHH _;__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!_[-?C7PO\'_  -\*]?^(_COQA9?;M%\+>&5 =K/YL3NY#$ ^7(1A&XB<MM
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ME_\ 90-9_P#2Z:BC]K#_ ).F^)?_ &4#6?\ TNFHH _;_P#X--O^4IG[7?\
MV\?^GR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** /QC_X
M*]?\%>O^"E_[.O\ P4O\2?LH?LH?$CP3H?AK0_!.D:LJ^(O"*WTKRW*MYG[S
M<#C(&!VKY^_X?8_\%S_^CAOA1_X;@?\ Q='_  6Q_P"4Y_Q#_P"R4>&_Y25X
MA7TN6Y;A,3A%4J*[UZON?SMX@^(7%.0<4U<%@JJC3BH-)PB]XIO5J^Y[?_P^
MQ_X+G_\ 1PWPH_\ #<#_ .+H_P"'V/\ P7/_ .CAOA1_X;@?_%UXA17?_8V
M_E_%GQ7_ !%OCG_G_'_P7#_(]O\ ^'V/_!<__HX;X4?^&X'_ ,71_P /L?\
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MT3^VW\.=5^*/@N#X76FBMXATOPZM[;6FLI"%N)S;$".-GF\Z0*0ORW.4R8R
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M=(_\%L7_ ,31_P *_P# ?_0DZ1_X+8O_ (FM>BCDAV#ZWB_^?DOO9D?\*_\
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M$O\ [)_K/_I#-7\MW[)/_)MW@_\ [!"_^A-7NY!_O,O3]4?B?CC_ ,D_AO\
MK[_[9(]%HHHKZL_F,**** "BBB@ K(^('_(AZW_V"+G_ -%-6O61\0/^1#UO
M_L$7/_HIJF?P,Z,'_O=/_$OS/WD_X($?\H;?V>_^R?P_^CI:^OZ^0/\ @@1_
MRAM_9[_[)_#_ .CI:^OZ_.3_ $ "BBB@ HHHH **** /X0OVL/\ DZ;XE_\
M90-9_P#2Z:BC]K#_ ).F^)?_ &4#6?\ TNFHH _;_P#X--O^4IG[7?\ V\?^
MGR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** /YXO^"V/_
M "G/^(?_ &2CPW_*2O$*]O\ ^"V/_*<_XA_]DH\-_P I*\0K[3)O]PCZO\S^
M0?%O_DN:_P#AI_\ I""BBBO4/S4**** "BBB@ K["_X-EO\ E)O\>O\ LE&A
M_P#I8U?'M?87_!LM_P I-_CU_P!DHT/_ -+&KQ\\_P!R^:_4_6_!?_DL)?\
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M_P#9*/#?\I*\0KV__@MC_P IS_B'_P!DH\-_RDKQ"OM,F_W"/J_S/Y!\6_\
MDN:_^&G_ .D(****]0_-0HHHH **** "OL+_ (-EO^4F_P >O^R4:'_Z6-7Q
M[7V%_P &RW_*3?X]?]DHT/\ ]+&KQ\\_W+YK]3];\%_^2PE_UZG^<#]RJ***
M^//ZM"BBB@ HHHH **** /S7_P"#K+_E%2/^RK^&/_2LU^3=?K)_P=9?\HJ1
M_P!E7\,?^E9K\FZ^GX?^"IZK]3^<_'7_ 'O _P"&I^< HHHKZ$_ PHHHH **
M** "N,^+_P#R%OA[_P!E7\-_^G"*NSKC/B__ ,A;X>_]E7\-_P#IPBKDQ_\
MN53T9]3P1_R6& _Z^P_-']7]%%%?!']OA1110 4444 %%%% 'G_[67_)K'Q+
M_P"R?ZS_ .D,U?RW?LD_\FW>#_\ L$+_ .A-7]2/[67_ ":Q\2_^R?ZS_P"D
M,U?RW?LD_P#)MW@__L$+_P"A-7NY!_O,O3]4?B?CC_R3^&_Z^_\ MDCT6BBB
MOJS^8PHHHH **** "LCX@?\ (AZW_P!@BY_]%-6O61\0/^1#UO\ [!%S_P"B
MFJ9_ SHP?^]T_P#$OS/WD_X($?\ *&W]GO\ [)_#_P"CI:^OZ^0/^"!'_*&W
M]GO_ +)_#_Z.EKZ_K\Y/]  HHHH **** "BBB@#^$+]K#_DZ;XE_]E UG_TN
MFHH_:P_Y.F^)?_90-9_]+IJ* /V__P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3;
M_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH **** /YXO^"V/_*<_P"(?_9*/#?\
MI*\0KV__ (+8_P#*<_XA_P#9*/#?\I*\0K[3)O\ <(^K_,_D'Q;_ .2YK_X:
M?_I""BBBO4/S4**** "BBB@ K["_X-EO^4F_QZ_[)1H?_I8U?'M?87_!LM_R
MDW^/7_9*-#_]+&KQ\\_W+YK]3];\%_\ DL)?]>I_G _<JBBBOCS^K0HHHH *
M*** "BBB@#\U_P#@ZR_Y14C_ +*OX8_]*S7Y-U^LG_!UE_RBI'_95_#'_I6:
M_)NOI^'_ (*GJOU/YS\=?][P/^&I^< HHHKZ$_ PHHHH **** "N,^+_ /R%
MOA[_ -E7\-_^G"*NSKC/B_\ \A;X>_\ 95_#?_IPBKDQ_P#N53T9]3P1_P E
MA@/^OL/S1_5_1117P1_;X4444 %%%% !1110!Y_^UE_R:Q\2_P#LG^L_^D,U
M?RW?LD_\FW>#_P#L$+_Z$U?U(_M9?\FL?$O_ +)_K/\ Z0S5_+=^R3_R;=X/
M_P"P0O\ Z$U>[D'^\R]/U1^)^./_ "3^&_Z^_P#MDCT6BBBOJS^8PHHHH **
M** "LCX@?\B'K?\ V"+G_P!%-6O61\0/^1#UO_L$7/\ Z*:IG\#.C!_[W3_Q
M+\S]Y/\ @@1_RAM_9[_[)_#_ .CI:^OZ^0/^"!'_ "AM_9[_ .R?P_\ HZ6O
MK^OSD_T "BBB@ HHHH **** /X0OVL/^3IOB7_V4#6?_ $NFHH_:P_Y.F^)?
M_90-9_\ 2Z:B@#]O_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V
M\?\ I\GK]_J "BBB@ HHHH **** /YXO^"V/_*<_XA_]DH\-_P I*\0KV_\
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M_5_1117P1_;X4444 %%%% !1110!Y_\ M9?\FL?$O_LG^L_^D,U?RW?LD_\
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M>J_4_G/QU_WO _X:GYP"BBBOH3\#"BBB@ HHHH *XSXO_P#(6^'O_95_#?\
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M]GO_ +)_#_Z.EKZ_KY _X($?\H;?V>_^R?P_^CI:^OZ_.3_0 **** "BBB@
MHHHH _A"_:P_Y.F^)?\ V4#6?_2Z:BC]K#_DZ;XE_P#90-9_]+IJ* /V_P#^
M#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H *S_ !7X
MK\.>!O#EWXM\6ZO#8:;80F6\O)SA(DZ;CCMS6A45]86.J6DFGZG917%O*NV6
M">,.CCT*G@B@#RW_ (;G_9'_ .B]:#_W^?\ ^)H_X;G_ &1_^B]:#_W^?_XF
MNZ_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XF@#A?\ AN?]D?\
MZ+UH/_?Y_P#XFC_AN?\ 9'_Z+UH/_?Y__B:[K_A5WPS_ .B=Z%_X*(?_ (FC
M_A5WPS_Z)WH7_@HA_P#B: /PO_X*B? OX@_M%_\ !5OQE^TI\&_[!UCP5JWP
M^T33=/UK_A+M-M_-NK</YL?DSW"3+MR/F*!3V)KRO_AD3XZ_] ;0?_"WTG_Y
M*K^B3_A5WPS_ .B=Z%_X*(?_ (FC_A5WPS_Z)WH7_@HA_P#B:]/#9MB,+15.
M"5EWO_F?G'$7A?D'$V:SS#%5:L9R234902T22WA)].Y_.W_PR)\=?^@-H/\
MX6^D_P#R51_PR)\=?^@-H/\ X6^D_P#R57]$G_"KOAG_ -$[T+_P40__ !-'
M_"KOAG_T3O0O_!1#_P#$UT?V]C/Y8_<_\SP_^((<*?\ /ZO_ .!4_P#Y6?SM
M_P##(GQU_P"@-H/_ (6^D_\ R51_PR)\=?\ H#:#_P"%OI/_ ,E5_1)_PJ[X
M9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 31_;V,_EC]S_S#_B"'"G_
M #^K_P#@5/\ ^5G\[?\ PR)\=?\ H#:#_P"%OI/_ ,E4?\,B?'7_ * V@_\
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ML$FH)._>_P#FCXKBS@3*.,:E*>-G4BZ::7(XKXK7OS1EV\C^=O\ X9$^.O\
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MH_M[&?RQ^Y_YA_Q!#A3_ )_5_P#P*G_\K/YV_P#AD3XZ_P#0&T'_ ,+?2?\
MY*KF?B/^Q'^T;KVH^#I])\-:#*FE?$'1-3OS_P )WHZ^5:V]Y')-)\UV-VU%
M)VC+'& ">*_I*_X5=\,_^B=Z%_X*(?\ XFC_ (5=\,_^B=Z%_P""B'_XFLZV
M<XJM2=.2C9Z=?\SORKPBX;RC,J.-HU:SG3DI).4+73OK:FG;T:.%_P"&Y_V1
M_P#HO6@_]_G_ /B:/^&Y_P!D?_HO6@_]_G_^)KNO^%7?#/\ Z)WH7_@HA_\
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MTU['\[?_  R)\=?^@-H/_A;Z3_\ )5'_  R)\=?^@-H/_A;Z3_\ )5?T2?\
M"KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q->A_;V,_EC]S_ ,SX
M3_B"'"G_ #^K_P#@5/\ ^5G\[?\ PR)\=?\ H#:#_P"%OI/_ ,E4?\,B?'7_
M * V@_\ A;Z3_P#)5?T2?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1
M#_\ $T?V]C/Y8_<_\P_X@API_P _J_\ X%3_ /E9_.W_ ,,B?'7_ * V@_\
MA;Z3_P#)5'_#(GQU_P"@-H/_ (6^D_\ R57]$G_"KOAG_P!$[T+_ ,%$/_Q-
M'_"KOAG_ -$[T+_P40__ !-']O8S^6/W/_,/^((<*?\ /ZO_ .!4_P#Y6?SM
M_P##(GQU_P"@-H/_ (6^D_\ R56=XP_8U_: U3PEJFF6&@Z#)/<Z=/%"G_"<
MZ0-SM&P R;K Y(ZU_1K_ ,*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1
M#_\ $TGGN+:MRQ^Y_P"9=/P4X5I5(S5:M=-/XH=/^X9\:_\ !(;XV?!_]E[_
M ()H_!S]G[XZ?$_0=#\7>%?!\5CK^D?VI%<_99Q)(Q3S;=I(GX8<H[#GK7TA
M_P -S_LC_P#1>M!_[_/_ /$UW7_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[
MT+_P40__ !->*?L!PO\ PW/^R/\ ]%ZT'_O\_P#\31_PW/\ LC_]%ZT'_O\
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MVD_'+X637/\ 9>J!T:VO8PD]I/&Q62&502 RL.Q(((()!!H ] HHHH ****
M"BBB@ HHHH **** "BBB@ HKY.^/?_!4VU^'GQRUS]G[X#_LR>,?BKKOA.U$
M_BU_#2[8--!4-LW!)&=QN (V@;OE!)! Z;P?_P %._V;O%O[&&H_MMB?4K7P
M_HTC6FJZ1+"AOH=0!C46:J&V.[F6(J0VW;(&8J VT ^BZ*^3?V9O^"JFA_&S
MXT:)\#?BK^SQXJ^&FK>+])_M+P1/XA8/!K-OM9P5;8A0LBL5X93M(W E0U3X
MV?\ !62Q\%?&'Q5\'O@3^R[XS^*$_@)3_P )OJ?A\;+;3&7.],A)"Y4JZG(7
MYHW W!2: /KVBO*OV>_VR?@?^T5^SK!^TWX>\2)H_AO9+_:LGB":.V.ERQ'$
ML<[%MB[>#NW$%64@\UP_[%__  4;^'_[;WQ9^(?@+X8^$9XM&\$26PL?$DU[
MD:Q'*\J>:L!C4PKF(D;F8E6!(4Y% 'T;1110 4444 %%%% !1110 4444 %%
M%% !17@G[:/[?/@W]D'4O#7@2U^'6N^-_&WC&9T\-^$/#D8,]P%(!=VP=BY.
M!A6)(;C"L1G_ +(7_!17PA^TWXU\4_!_QK\+==^''COP?:?;-:\+^)R-R6F5
M!G63"_*OF1EMRKQ*C L#D 'T717PXW_!<3X9#6?^$N'[.7C<_"D>)?[$/Q4\
MD?9/M'][RMN=F/GQOW[?X-WR5ZY^U[_P4/\ !?[,/BCPK\+?"/PTUSXB^./&
M=N;KP_X6\+[2\MKSB=GPV$;:^W:K9$;D[0N: /H>BOG;]D?_ (*+_#W]IJ?Q
MCX5\7> M9^'?BSP#$9_%?AKQ1@/:6P!W3A\+E%Q\VY5(RIP0P)\GT3_@N!\-
M=0UW3O$^M_LY>-M)^%NK^(VT73?BE>QJ+-[@$C<T>WY4X9CAV<*K?*2K* #[
MAHI%964,I!!&01WI: "BBB@ HHHH **** "BBB@#^$+]K#_DZ;XE_P#90-9_
M]+IJ*/VL/^3IOB7_ -E UG_TNFHH _;_ /X--O\ E*9^UW_V\?\ I\GK]_J_
M '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ KE/C5IOP7O?AQJ6H
M_M Z)X=O?"NEP-?:G_PE%A#<6<"1J2962967(!.#C/.!UKJZ\A_;;_9-M?VT
M_@DWP-U;XE:IX9TZYU6"[U&?2H$D>[CBW%8'#\;/,,<GKF): /DOX=OXZ_X*
MT_MD>#OVA--\(3^'O@9\&=8>X\)7E[!Y5QX@U!)(GW(O9/,@A)'(1(]I.]V"
MV?\ @G,ULW[>/[99\7;/-_X2)A^_Z_8_M6H^O\/E^5[8Q78_!C_@CG?_  3\
M4^&=8\._MS?%!]*\-:M:WD'AO[<8[&>.&993;M$LFT1O@JP P0QXKI_VF?\
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M /:$_P""D_[0/AX^'_&'Q%^%FK67A'PM"K+)IVG"QS$9 1D.PM[95! ;",S
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M3?$O_LH&L_\ I=-11^UA_P G3?$O_LH&L_\ I=-10!^W_P#P:;?\I3/VN_\
MMX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\
M': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O
M:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /
M[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A
M"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*
M_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:
MP_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_
MX:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F
M_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_
M:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"C
ME?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z
M.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!
M_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^(
M'_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%
ME??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A9
M7W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_
M !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_Q
MVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC
M_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_A
MK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#
M]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J
M;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_
M *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY
M7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5
M^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?
M^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_
M (65]_\ ': #]K#_ ).F^)?_ &4#6?\ TNFHKA+N[NK^ZEOKZYDFGFD:2::9
/RSR.3DLQ/)))R2:* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>mrk-20221231_g5.jpg
<TEXT>
begin 644 mrk-20221231_g5.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MN+2K>=49RRLEN3$&>,F$8.^3S#D;4R.V\9?\%+OVD/C=\7OB/'\#OVF/@_\
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M%_:D_P""?7C;7]'N_#C)XL\3^%(;F#Q'X9U$;X[B+["8US;M+&DB-,2A5R0
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M8M?'U>YEV5T<9A_:2DT[VT/QCC[Q*S7A//%@<-1A.+A&5Y<U[MM=&NQ^B?\
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MFHGEV-IP<Y0LEZ'3@^/^#\PQ4,-A\6I3FTHJTM6]EK&Q_1'1117$?8A1110
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MO_95_#?_ *<(JY,?_N53T9]3P1_R6& _Z^P_-']7]%%%?!']OA1110 4444
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M*N3'_P"Y5/1GU/!'_)88#_K[#\T?U?T445\$?V^%%%% !1110 4444 %%%%
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M0!^W_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U
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M?\-3\X!1117T)^!A1110 4444 %<9\7_ /D+?#W_ +*OX;_].$5=G7&?%_\
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M!^W_ /P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\
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M #__ !-=U_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \30!PO\
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M%_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\
MHG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\
MXFOY[_AO^Q'^T;H&H>,9]6\-:#$NJ_$'6]2L#_PG>CMYMK<7CR12?+=G;N0@
M[3AAG! /%?TE?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $UTX
M3%5,'5]I!)NUM3YWB?AG <69:L%BY2C!24KP:3NDUUC)6U['\[?_  R)\=?^
M@-H/_A;Z3_\ )5'_  R)\=?^@-H/_A;Z3_\ )5?T2?\ "KOAG_T3O0O_  40
M_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q->E_;V,_EC]S_ ,S\^_X@API_S^K_ /@5
M/_Y6?SM_\,B?'7_H#:#_ .%OI/\ \E4?\,B?'7_H#:#_ .%OI/\ \E5_1)_P
MJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-']O8S^6/W/_,/^((<*
M?\_J_P#X%3_^5G\[?_#(GQU_Z V@_P#A;Z3_ /)5'_#(GQU_Z V@_P#A;Z3_
M /)5?T2?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\%$/_ ,31_;V,_EC]
MS_S#_B"'"G_/ZO\ ^!4__E9_.W_PR)\=?^@-H/\ X6^D_P#R51_PR)\=?^@-
MH/\ X6^D_P#R57]$G_"KOAG_ -$[T+_P40__ !-'_"KOAG_T3O0O_!1#_P#$
MT?V]C/Y8_<_\P_X@API_S^K_ /@5/_Y6?G/_ ,&_7BGP?^Q%_P $_O\ A2/[
M3_C?0?#'BC_A8.NZE_9G]N6U[_HMQ<!X9/,M'EC^9>=N[<.X%?;W_#<_[(__
M $7K0?\ O\__ ,37=?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$
M/_Q->*W=W/V"G35*G&"V22^XX7_AN?\ 9'_Z+UH/_?Y__B:/^&Y_V1_^B]:#
M_P!_G_\ B:[K_A5WPS_Z)WH7_@HA_P#B:/\ A5WPS_Z)WH7_ (*(?_B:19RO
MA3]KO]FGQSXCM/"/A'XQZ/?ZE?R^59V<$K%Y7QG:,KUXKT>L>Q^'W@'2[R/4
M-,\$:/;W$3;HIX-,B1T/J&"Y!K8H **** /X0OVL/^3IOB7_ -E UG_TNFHH
M_:P_Y.F^)?\ V4#6?_2Z:B@#]O\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3
M;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBO/OVHOVEOAM^R/\%M5^
M./Q4GN?[,TS8B6MC&'N+N>1@L<,2D@%F)[D  %B0 30!Z#17Q[\'/^"MMAXN
M^+_A'X3_ !U_9:\:?#$?$$JO@?6?$ WV^INY41J<QH4+EXU&W?AI4W8#!JT?
MVFO^"J6A_!'XSZU\#/A7^SSXJ^)>K^$=(_M/QM+X>8)!HUML5R6;8Y=E1U9N
M%4;@-Q(8* ?6-%?/'B7_ (*:?LV^'/V+[']MY[K49_#FILMMI^DQ0(+Z6_+.
MALBA;:LBM'(6.[;M0L"PQGD/@9_P57M/'?QQ\/? 3X\_LP>,OA7JOC&W\WPA
M<>)%W0ZB<$JA)CC:-FQ@<,-Q"DJ2,@'UM17QY\9?^"N&G>$/BOXO^&/P+_9;
M\:?$V/X>LZ>.=;T$!+73'0L)%R$D+;"D@);9DQ/C(4M7T'^R_P#M*?#?]K;X
M+:3\<OA9-<_V7J@=&MKV,)/:3QL5DAE4$@,K#L2""""00: /0**** "BBB@
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M\-=0UW3O$^M_LY>-M)^%NK^(VT73?BE>QJ+-[@$C<T>WY4X9CAV<*K?*2K*
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M_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110
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M/VIO^CE?B!_X65]_\=H_X:P_:F_Z.5^('_A97W_QV@#^[VBOX0O^&L/VIO\
MHY7X@?\ A97W_P =H_X:P_:F_P"CE?B!_P"%E??_ !V@#^[VBOX0O^&L/VIO
M^CE?B!_X65]_\=H_X:P_:F_Z.5^('_A97W_QV@#^[VBOX0O^&L/VIO\ HY7X
M@?\ A97W_P =H_X:P_:F_P"CE?B!_P"%E??_ !V@#^[VBOX0O^&L/VIO^CE?
MB!_X65]_\=H_X:P_:F_Z.5^('_A97W_QV@#^[VBOX0O^&L/VIO\ HY7X@?\
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2FFF<L\CDY+,3R22<DFB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>mrk-20221231_g6.jpg
<TEXT>
begin 644 mrk-20221231_g6.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M\=_B5IWAO3IIO*MI+UF:2XD R4BBC#22L!R0BD@<F@#MZ*\?_9[_ &^_V/\
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MWX.>(TN/&D;:PA5(([RT</$0/WI:.!FP,$$@4 ,_:E_:@_X*0?L.?!;P/?\
MQ6\:>"_%?C'Q-\3&L6BT72]EK-II@C:.V#/'&4D,OF#S-G *_>QFM*3]J/\
MX*!?LU?MS?#+X*_M0>+_  1XE\._%61X8K3PSI#VXTF;.S9%(X$CA'>+F0OO
M4MPIP:])_P""GG[)GQ?_ &JK+X7P?"2RL)F\*>/H=6U?[=?"#;;*!DKD?,WM
M2?ME?LE_&#XV_MI? 3XX^!;*PDT'X>ZO-<>(Y+F^$<J(TT#CRT(RYQ&W2@#A
MO@G\??$$G[>G[3WAFQ\#>#["3P?X9-Y8:SIOA>W@U&\D6)'7[7<HHDN0#CAR
M>@]*\D\$?MK_ /!4_P",G[#6J?MF^%_''@'1=+\&O<F_M9-"\R[UU89 97PP
M:."-$=455P[&-R6&5KWGX7_L7?&_PI^V'^T5\:=7L--70_B5X;>R\+R1Z@K2
M22F)5 D3'[L9!Y-97[/W[#'Q[^'7_!)WQ;^R#XET_2T\9ZQ9:O%900ZDKVY:
MX;,>9<8'OQQ0!C_'/_@IS\;'_9=^ ]]\#_"FCP?$SX\3Q66G-?(SV6G3+)#!
M-(JL3P9IH]F_<%4L6W%>:?BG]J'_ (*,?LV_M;?!?]F;X\>,_!/B#3?'6N;+
MOQ)HFBF&2^@:2)'MV1@HBDB))#H,.LRY&5-<1^U)^RQ=?!W]C+]G72_&WQN\
M+> /BS\+=2DF\*S:]=N=-O;@3QSR0F=(V56!CMG4N-IVLIP"67F?BIJ_[4GQ
M!_X*5?LU:A^TIXL\"7>OG6C+;>%?AY,\]OI-I'(DC3RN[NQDFVR,<$J$MUP3
M\V #I_B]_P %*_VDM=_:H^)7P<TO]IKP)\%XO!6M3:=X8T?QCX8DG&OB)G43
M2WCHT=NLFU'!)4;)EP&VEC]X?LL^,OBC\0/@-X=\7_&5O"\GB&]M"U[=>#-4
M%YIMR Q"2PRC((90"0"P#9 8C%?)/[3O[+G[<OC;XG>+;?Q=^SO\)OCKX8UE
MV_X0W5?$<5KI6I^&X"6VPM+$D4L@7< 2LC%O+#!D)*CW7_@F5^R1XU_8M_97
ML/@]\0_%-OJ>L2ZI<ZE>K92,]O9M-L'V>)F +* @8G !=WQQR0#Y(_X*]^-_
MAO\ #?\ X*3?!'QS\7O!,GB/PUIOAR275]#BTN*]:\B^T7 V""4A).2#ACCC
M/:N1TAO ?[9__!1;X.^/_P!A+]DK6_A_HG@S5H+WQMK\GA>'2;>>"*=)65TM
MR8@3$LD0).^0S;<;4!KZW_:=_9"^,OQ4_P""C?P:_:8\)66GOX6\$V3Q:[+/
M?A)D8O.1LC(R_$BU]84 ?G'\1/\ @H_^T1\:/VA_B-X&^!7[2_PA^$OAWX<:
M@^FV ^(^H6T5SXHO(WDC?8;@_+%OA8;D V*\>2Q8[9OB-_P5N^,6N_\ !+_2
M?VN?AII^D:1XR@\>Q>&_$EN]I]HM!*L,DKM$KL2%=# X!)*[BN6QDGC;_@GA
M^TM\!OV@_B3XZ^ G[.?PG^+'AOXCZA)J5A'X_M;9KKPW>2/)(VP7"X:(/*WR
MJQWJD>=I4[MW]HO_ ()T?M+_ !%_X)N:/^SIIMMX%N?'TGC.#7->7PWI%IH>
MF\0RQD*MO#$DCJIB4R%%+8[!5% 'T+^Q</VX-7MM9\>_M?>)O";V7B"WL[[P
MEX=\,VS!]&CD$CRV\\C1J790T*YS)R'.[I7B/_!6?]E;]H7XC_$[X9_M._ [
MX9:7\1(_A]).-3^'^LHLL5RKNCB58791-G;M90=V4B(5P"!]L:'9RZ?HEG83
M@!X+6.-PIR 54 _RKY7_ &^OV3/VIO&GQH\$_M<?L:>/[.V\8>#+=K6Y\+Z[
M>2)8:I;DR8^4'9O(FEC8-MW(RD.AC7(!\X_!'X]?LB_%W]N?P#??M!?LD>*O
M@)\6=-N([;P\EDBV>G:G<,Q6..Y0V\4FZ3<T2DJ0P?87^[4GAVS_ &GM;_X+
M)_'WPQ^RQK_AS0]9O?#]I_:'B+Q+:/<1Z?;+!IYS%"O$DK2%%&_*A=Y() KO
M$_9(_P""B'[:O[3GPW^+?[<&@>!_!?AKX8:J-2L-)\+71FGOIQ+#-MR)9N'>
MWA#%I%"JIVJ6)->L_ #]DOXP?#O_ (*8_%_]J3Q)96"^$_&>A6UKHDT-\'G:
M1%LPV^/&4'[E^?IZT <Q^P9^V?\ M7?&OX;_ !I^'OQ T'PYKOQ.^$NM3:59
MW,+_ &&QU.XS<1IYQX"*LMM(2RA,H5X4@D^ ^/?^"DW[:O[-GB'P=XF^)/[4
MWP?\=3:QKT5MXG^&?A*."XGTB%R2P-Q;DX90-N3(V'9>)%R:]0\+_P#!-[]I
M5O!'[6_A&;6M,T.Y^,WB<W_@R_AU(N)(!?WEP8I]@W1++'*D3<' E;@XP?*/
M&?\ P3=_;T^)/[,W@SX+6'[-_P )_!9\":I9W-Q/IFJ1C4/%%Q#&\7VJ::-2
MJ_*[LX=BSN^0% P #VC]I_\ :W_;IF_X*(2_L1_LL:GX4M!JO@^&\L=1\1V!
M9-+DV&66Y=U5R_RQE%0HPW2*2"!7/_'3]O#]JGPK\;O#/[$5O^T%\,/ OBS1
MO!]OJ7Q,^)OB\PP6#7\D2R?9;1)]L9&V2/&5#/N) C"-GV*#]D[XQ2?\%7E_
M;#ETRQC\'-\/QI1=K]3<K=;,;?+';/&X'%<+^V5^P/\ &6Y_;*B_;4^ ?PH\
M!?$@:KH::9XJ\!>/XHC%*Z(L<=S TRF-6"1Q#)(92AQN$C!0#M/^"9G[<GCC
M]IR_\>_!GXOZSX7UGQ3\.]2CA/BGP9<K+IFO6<ID5+F$J2IYC.2N 1(GRJ0P
MKZOKYO\ ^">W[//QO^$6F^)_&W[0/@WX<>'M7\1Z@&TSP[\/O"ME9)I-DK.P
M@EN+>)&N3E@ &+[1&#O9G;'TA0 4444 %%%% !1110 4444 %%%% '\(7[6'
M_)TWQ+_[*!K/_I=-11^UA_R=-\2_^R@:S_Z7344 ?M__ ,&FW_*4S]KO_MX_
M]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445YO^UY\?=,_9?\ V:O&/QTU%HR^@:-))I\4
MOW9[Q\1VT1]FF>-3[$GM0!Z)#>6ES(\5O=1R-&<2*C@E3[XZ5)7X\?\ !.E_
MBG^PQ^U7\)?B)\8M8E?0_P!I7PS*;R>YR-EY-=,ULS$_><EK1RQQA;]QVR?O
M?]LS]OZ]_9J^*W@_]GGX8_!IO'/CWQK;R7&F:5<>([?2+6*!"XW/<W *;F,<
M@5.,[#R"5# 'TA17SW\"OVU_B%XI\-^/]2_:;_92\5?"VZ^'>G3:AJLMTQU#
M3[VVBB:60VMXD:1SNJKDHI(PRX8\[?(O /\ P5?_ &COB/X5L/C9X,_X)T>(
M-=^'&HZM]BAU;PQXQMM2U5%$C1EVTV"(RJV5;Y6VKT^?!5B ?<-%> _&+]N9
M/A1^US\+?V6H_A;+?K\2[.2X77)]5:V?30H<[6MF@8N?DY!=""<$<5+-^VYY
M7_!0.+]A7_A66?,\)?VW_P )3_;73Y2WD_9O)]OO>;^% 'O-%? VA_\ !:#X
ML>/OAIXQ^(_PM_8*U;6;7P!J5R/%UXOC2)+.RL8D#"<2M;AY)#B4M"D;>6D:
MN6(;"S>)O^"UWB73_A?H_P"TEX<_8D\3W7PKN;R"QU;Q?>^(+>W>&\;B6*WM
MPKM.D;AT$I*([J5RAH ^[Y+JUBF2WEN8UD?[D;. S?0=ZDKXN_:;^(WP-U7_
M (*,?LY3:I\+-0UK6M>TN6Z\*^*(/$S6D.GPN'<%[3R&^T;@<\R)C/M5C4O^
M"IGQ3U[X_?$C]F?X(?L4ZMXS\4>!-1\FV^Q>*X8+:[MD9EEN)Y)H56V(/EA(
MP9&D,A (V\@'V317RM\!?^"J_P *_BE^R)XS_:J^(/@?4?"?_"O[U[+Q/X>>
M<7,JW/[L11PN5CWF5Y4C =4P^0V -Q\P\4?\%E_C9\.O@5%^T9\2?^">FNZ7
MX5UXP_\ "%ZJ?&4+0ZCYC KY^+<R6H:$/(CF-EDV@+P0U 'WQ5:76-(@D,,V
MJ6R.IPRM.H(/TS5+P#XI_P"$Y\":+XU^P_9?[8TBVOOLWF[_ "?-B639NP-V
M-V,X&<=!7Y=_!?\ 8H^!'[:G_!3?]I'PU\==)U"ZMM$UQKC3CIVI/;-'(]PR
ML25^]P!P: /TI^-?P$^#'[2?@@^ /C9X T[Q+HSS+<1VUZI_=R $"2.1"'C;
M#$;D8'#$9P37"?L^?L"?L3_LO>)YO'?P*^#.E:1J\<3Q/JLNI7-[/;JPPP22
MZFD,.1D':5R"0>":^3?V:?#^N?\ !.3_ (*K6'[#O@GQWK&J_#7XC>%WU32-
M)UF[\XZ9.(KJ0.I  #;[.:,E0-R2INW% U9'A;Q3\'_$?[)G[;$'PM^$M_X8
MN++4M1BU^XO?%!U$:G<[[K,Z*8(OLZY#'R\O]X#=QR ?IG%-%<1B:"571AE7
M1L@_C3J^ _@1^VY_PQI_P3X_9KB_X5E_PDG_  G5TFB9_MK[']AW7#_OO]3)
MYN-WW?EZ=:^@_P!HC]MS_A0G[4WPJ_9H_P"%9?VM_P +-N98O[:_MKR/[-V.
MJY\GR7\[.[/WTZ4 >\U'!=VMR6%M<QR%#APC@[3Z''2OS<_9:_:Z_:X\:?\
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MOV/_ -H;]E^^^&?B]-';4]*AD\11:E%=0 !MI>.-5!V98,I=3L=3M*X/U30
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ME_\ 90-9_P#2Z:BC]K#_ ).F^)?_ &4#6?\ TNFHH _;_P#X--O^4IG[7?\
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M6Q?_ !-'^K\_^?GX?\$/^(ZX3_H!E_X,7_R)^\G_  _X_P""-O\ TD)^'_\
MX%S?_&ZN>'?^"[/_  2&\6>(+'PKX<_;X\!WFHZG>16EA:17<N^>:1PB(O[O
MJ6( ^M?@?_PK_P !_P#0DZ1_X+8O_B:Y/XG>$_"VCZ_\/;W2?#6GVLP^*WAP
M"6VLT1L'4(LC*@&L:^22H495.>]E?;_@GIY+XQX;.<VH8%8-Q=62C?G3M=VO
M;E5S^L^BBBO#/VD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _A"_:P_Y.F^)?_90-9_\ 2Z:BC]K#_DZ;XE_]E UG
M_P!+IJ* /V__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"G
MR>OW^H **** "BBB@ HHHH _#3_@YI_Y2<? 7_LE&M_^EBU\?5]@_P#!S3_R
MDX^ O_9*-;_]+%KX^KZ_(O\ <GZO]#^4?&C_ )+"/_7J'YR"BBBO9/R4****
M "BBB@ KW#_@B=_RG.^'G_9*/$G\HZ\/KW#_ ((G?\ISOAY_V2CQ)_*.O+SG
M_D7R^7YGZ5X2?\EQ0_PU/_2&?T.4445\6?U\%%%% !1110 4444 ?FO_ ,'6
M7_**D?\ 95_#'_I6:_)NOUD_X.LO^45(_P"RK^&/_2LU^3=?3\/_  5/5?J?
MSGXZ_P"]X'_#4_. 4445]"?@84444 %%%% !7&?%_P#Y"WP]_P"RK^&__3A%
M79UQGQ?_ .0M\/?^RK^&_P#TX15R8_\ W*IZ,^IX(_Y+# ?]?8?FC^K^BBBO
M@C^WPHHHH **** "BBB@ HHHH K:UK6C>&]&N_$7B+5K:PT^PMI+F^OKV=8H
M;:%%+/)([$*B*H+%B0  2:?IVHZ?K&GP:OI%_#=6EU"LUK=6TH>.:-@&5U92
M0RD$$$<$&OS5_P""[_BOQ'8?$KP9X3^)NM>(K'X5WO@S69(ET1V6&\\1K;S_
M &2.XV\,@D%IPV<(\I&/F(];_P"";GP5OO!7[+OBF^_94_; M?%MOXE\/0OX
M9T75)!<6_@W6FM#O5W1Y&QYKAFB,:G$:\$Y9@#[5HK\C_P!LK]DKQ9^P;^SS
MX=_:!\2_M:^+[W]H;4O%B""XTWQ/-<0:F6E8LD44D:RNB1>5N+Y4NVP@AU%?
MJWX&N_$E_P""='OO&-FEMJ\VE6\FJV\8PL5R8U,JCV#EA^% &K17Y%^'O .K
M_ML?#C]HS]L+XU_M'>+?#_CCX;:UJ/\ PBNEZ?KYM;;0H[6)IH(O*^\JNZF
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M_0Y1117Q9_7P4444 %%%% !1110!^:__  =9?\HJ1_V5?PQ_Z5FOR;K]9/\
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M^H **** "BBB@ HHHH _#3_@YI_Y2<? 7_LE&M_^EBU\?5]@_P#!S3_RDX^
MO_9*-;_]+%KX^KZ_(O\ <GZO]#^4?&C_ )+"/_7J'YR"BBBO9/R4**** "BB
MB@ KW#_@B=_RG.^'G_9*/$G\HZ\/KW#_ ((G?\ISOAY_V2CQ)_*.O+SG_D7R
M^7YGZ5X2?\EQ0_PU/_2&?T.4445\6?U\%%%% !1110 4444 ?FO_ ,'67_**
MD?\ 95_#'_I6:_)NOUD_X.LO^45(_P"RK^&/_2LU^3=?3\/_  5/5?J?SGXZ
M_P"]X'_#4_. 4445]"?@84444 %%%% !7&?%_P#Y"WP]_P"RK^&__3A%79UQ
MGQ?_ .0M\/?^RK^&_P#TX15R8_\ W*IZ,^IX(_Y+# ?]?8?FC^K^BBBO@C^W
MPHHHH **** "BBB@ K^3_P"#_P#R%?B#_P!E7\2?^G"6OZP*_D_^#_\ R%?B
M#_V5?Q)_Z<):]G(O]]?H_P!#\D\:/^2/C_U]A^4CM****^O/Y2"BBB@ HHHH
M **** /UE_X-3?\ E%3_ -U7\3_^E8K])Z_-C_@U-_Y14_\ =5_$_P#Z5BOT
MGK\YG\;/[_P?^Z4_\*_(****DZ0HHHH **** /X0OVL/^3IOB7_V4#6?_2Z:
MBC]K#_DZ;XE_]E UG_TNFHH _;__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^
M4IG[7?\ V\?^GR>OW^H *S_%?BOPYX&\.7?BWQ;J\-AIMA"9;R\G.$B3IN..
MW-:%17UA8ZI:2:?J=E%<6\J[98)XPZ./0J>"* /+?^&Y_P!D?_HO6@_]_G_^
M)H_X;G_9'_Z+UH/_ '^?_P")KNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>
MA?\ @HA_^)H X7_AN?\ 9'_Z+UH/_?Y__B:/^&Y_V1_^B]:#_P!_G_\ B:[K
M_A5WPS_Z)WH7_@HA_P#B:/\ A5WPS_Z)WH7_ (*(?_B: /QL_P""Y_P_US]L
M;]NKX2?&3]G#4M!\1^&_#'P^U33-<U+_ (2BPL_LUU-<J\<?EW4T<CY4$[D5
ME'<BOF[_ (9$^.O_ $!M!_\ "WTG_P"2J_HD_P"%7?#/_HG>A?\ @HA_^)H_
MX5=\,_\ HG>A?^"B'_XFO2PF:8C!TO9P2:O?6_\ F?GW$_AMD?%F9+&XNI4C
M-14;0<4K)M]82=]>Y_.W_P ,B?'7_H#:#_X6^D__ "51_P ,B?'7_H#:#_X6
M^D__ "57]$G_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\373_
M &]C/Y8_<_\ ,^=_X@API_S^K_\ @5/_ .5G\[?_  R)\=?^@-H/_A;Z3_\
M)5'_  R)\=?^@-H/_A;Z3_\ )5?T2?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG
M_P!$[T+_ ,%$/_Q-']O8S^6/W/\ S#_B"'"G_/ZO_P"!4_\ Y6?SM_\ #(GQ
MU_Z V@_^%OI/_P E4?\ #(GQU_Z V@_^%OI/_P E5_1)_P *N^&?_1.]"_\
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M_P#HG>A?^"B'_P")KQ6[NY^P4Z:I4XP6R27W'"_\-S_LC_\ 1>M!_P"_S_\
MQ-'_  W/^R/_ -%ZT'_O\_\ \37=?\*N^&?_ $3O0O\ P40__$T?\*N^&?\
MT3O0O_!1#_\ $TBSE?"G[7?[-/CGQ':>$?"/QCT>_P!2OY?*L[."5B\KXSM&
M5Z\5Z/6/8_#[P#I=Y'J&F>"-'M[B)MT4\&F1(Z'U#!<@UL4 %%%% '\(7[6'
M_)TWQ+_[*!K/_I=-11^UA_R=-\2_^R@:S_Z7344 ?M__ ,&FW_*4S]KO_MX_
M]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%>
M??M1?M+?#;]D?X+:K\<?BI/<_P!F:9L1+6QC#W%W/(P6.&)20"S$]R  "Q(
M)H ]!HKX]^#G_!6VP\7?%_PC\)_CK^RUXT^&(^()5? ^L^(!OM]3=RHC4YC0
MH7+QJ-N_#2INP&#5H_M-?\%4M#^"/QGUKX&?"O\ 9Y\5?$O5_".D?VGXVE\/
M,$@T:VV*Y+-L<NRHZLW"J-P&XD,% /K&BOGCQ+_P4T_9M\.?L7V/[;SW6HS^
M'-39;;3])B@07TM^6=#9%"VU9%:.0L=VW:A8%AC/(? S_@JO:>._CCX>^ GQ
MY_9@\9?"O5?&-OYOA"X\2+NAU$X)5"3'&T;-C X8;B%)4D9 /K:BOCSXR_\
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M^UA_R=-\2_\ LH&L_P#I=-11^UA_R=-\2_\ LH&L_P#I=-10!^W_ /P:;?\
M*4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !1110
M 4444 %<I\:M-^"][\.-2U']H'1/#M[X5TN!K[4_^$HL(;BS@2-23*R3*RY
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M*?QK^,OB_P"(6F>*-4-\=:\0WY>^T]PD(C\B1B^W8\(D .5)=@00Q! /!O\
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M$G[67C_XA6E_H,^F2Z!XOOVGM )9(F,NQG8%@(RO3I(WK0!\41_V'_Q#>O\
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M8;\LS$ ^M_@8-4'P3\'#6]_VW_A%M/\ MGF?>\W[-'OS[[LUU-  4!5   X
MHH **** "BBB@ HHHH **** /X0OVL/^3IOB7_V4#6?_ $NFHH_:P_Y.F^)?
M_90-9_\ 2Z:B@#]O_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V
M\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /X0OVL/^
M3IOB7_V4#6?_ $NFHH_:P_Y.F^)?_90-9_\ 2Z:B@#]O_P#@TV_Y2F?M=_\
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M[_X[1_PUA^U-_P!'*_$#_P +*^_^.T ?W>T5_"%_PUA^U-_T<K\0/_"ROO\
MX[1_PUA^U-_T<K\0/_"ROO\ X[0!_=[17\(7_#6'[4W_ $<K\0/_  LK[_X[
M1_PUA^U-_P!'*_$#_P +*^_^.T ?W>T5_"%_PUA^U-_T<K\0/_"ROO\ X[1_
MPUA^U-_T<K\0/_"ROO\ X[0!_=[17\(7_#6'[4W_ $<K\0/_  LK[_X[1_PU
MA^U-_P!'*_$#_P +*^_^.T ?W>T5_"%_PUA^U-_T<K\0/_"ROO\ X[1_PUA^
MU-_T<K\0/_"ROO\ X[0!_=[17\(7_#6'[4W_ $<K\0/_  LK[_X[1_PUA^U-
M_P!'*_$#_P +*^_^.T ?W>T5_"%_PUA^U-_T<K\0/_"ROO\ X[1_PUA^U-_T
M<K\0/_"ROO\ X[0!_=[17\(7_#6'[4W_ $<K\0/_  LK[_X[1_PUA^U-_P!'
M*_$#_P +*^_^.T ?W>T5_"%_PUA^U-_T<K\0/_"ROO\ X[1_PUA^U-_T<K\0
M/_"ROO\ X[0!_=[17\(7_#6'[4W_ $<K\0/_  LK[_X[1_PUA^U-_P!'*_$#
M_P +*^_^.T ?W>T5_"%_PUA^U-_T<K\0/_"ROO\ X[1_PUA^U-_T<K\0/_"R
MOO\ X[0!_=[17\(7_#6'[4W_ $<K\0/_  LK[_X[1_PUA^U-_P!'*_$#_P +
M*^_^.T ?W>T5_"%_PUA^U-_T<K\0/_"ROO\ X[1_PUA^U-_T<K\0/_"ROO\
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CTU%<)=W=U?W4M]?7,DT\TC2333.6>1R<EF)Y)).2310!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>mrk-20221231_g7.gif
<TEXT>
begin 644 mrk-20221231_g7.gif
M1TE&.#EA>@%  '   "'Y! D  /\ +     !Z 4  A____^_W]^_OY@ ("
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MP@I%^^1 %7HV6,($!2!!O@$(IT "!CRDJ5ZQGE*/ @BN>E&$<Z[2;KXLKUA
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M !5XRE#D*1 #3* >)/I/A (@C#R4H![]R)@J(-,N]?@#BI&#&\<T0O^3=!U
M+8E9:][J<0 ]! M:.:F0JQ2R2PNIKGM81:N:=K;( /421/HJA12!.*&2*9%3
M>@3 O'"K"F'0R287H$TXPW2339DQ!@;HYF1U>UHUS1,G-$.MZ@JP"MI(1@'G
MVI2:DG.3M3VM*,/1@S2%,UN8.F@W9B2B[SH3H4) !@%3-<4O2P"Q;H5$ *5
M0 E"Q0":I,]9MA5C%3ERP8NH<#@EL-1KEVN1@TD&05$A+@'I1.$MK5<@!!I
M4R=PX>\6(C1U2 A?3RNL=ZT($*9 A<\.$+E%RL1K$\2N*1D@3W\$()4E"+%!
M]',DF$4W)PY6KW,$+ S9$@ 537V;(?PTOXW_V,B0IH2(;74SD=(>Y',J;*!
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MK" RC^44_N!\H0-'5&@@A\5&<5,C]6 ;B%$<O@-"2"89+W, \(%K(D$4PKB
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MLWZ+@<$;XC&ED"]M!C(S)#T)(Q,:E ?"1!?N62E*)"OL-P (0##=(6XZ<"_
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ME\+4-)LR*=^*8;;DAF/"&E*_(A2Y#51]X7*=01>]E!Q14:O]$=W]R*04T!;
M=RFO8UL28*.V\3=<(2IF,TJ39: I(3576 \=;=:DQ8B>!6DG,Y2!HXG!K-L.
M4A-T$AZ\')W]P8+&H<);01[ZXDY?0RCX'3S=C6>:K2"$3=0%0]IGP@H-T$R@
M(MT\ <SL;1)OMYO0:=Y=,E9]01=?O!-XO!6_X4D>DBZ)@R BE^$68LQC%12:
M$D'\#3J-!.&;<7?U\.!\Z.+-P<083A(3DAY![A-4@>.906\HT-%%[N,[D=I.
9?MX% !8"$![E5AXGH]?D5[[E7/XA 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>mrk-20221231_g8.jpg
<TEXT>
begin 644 mrk-20221231_g8.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X19,17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    F    <@$R  (    4    F(=I  0    !    K    -@ +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$P+C @5VEN9&]W
M<P R,#$T.C W.C(U(#$Q.C$Q.C0Y   #H $  P    '__P  H ( !     $
M  + H , !     $   #9          8! P #     0 &   !&@ %     0
M 28!&P %     0   2X!*  #     0 "   " 0 $     0   38" @ $
M 0  %0X         2     $   !(     ?_8_^  $$I&248  0(  $@ 2
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(                  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
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MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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M_2G]NOY+_MS_;?___^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _0      !( -0    $ +0    8       $X0DE-
M _<      !P  /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M X<    &              #9   "P    "D 4@ @ $0 80!V &D <P @ &4
M; !E &, = !R &\ ;@!I &, ( !S &D 9P!N &$ = !U '( 90 @ "T ( !W
M &@ ;P!L &4 ( !N &$ ;0!E     0                         !
M          +     V0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    V0    !29VAT;&]N9P   L     &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -D
M    4F=H=&QO;F<   +      W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3004       $
M 3A"24T$#      5*@    $   "@    ,0   >   %O@   5#@ 8  '_V/_@
M !!*1DE&  $"  !( $@  /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M                  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M  Q!9&]B95]#30 !_^X
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M^K?3NN.QCFFT#&?NVUOVMM8XL?;B9+2'>KB7/HH=;5_P2U4DDE+ !H#6B -
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MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0      >P
M  $!    & !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $4 ; !E
M &T 90!N '0 <P   !T 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !% &P 90!M &4 ;@!T ', (  Q #  +@ P     0 X0DE-! 8       <
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M4D%96%E:( ?/  8  P       &%C<W!-4T94     &YO;F4
M       !  #VU@ !     -,M041"10
M                                !6-P<G0   #     3&1E<V,   $,
M    :7=T<'0   %X    %&)K<'0   &,    %&M44D,   &@    #G1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DY($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A
M=&5D+B!!;&P@4FEG:'1S(%)E<V5R=F5D+@!D97-C          ]'<F%Y($=A
M;6UA(#(N,@
M                                                          !8
M65H@        \U0  0    $6SUA96B                      8W5R=@
M       ! C,  /_N  Y!9&]B90!D      #_VP!#  8$! 0%! 8%!08)!@4&
M"0L(!@8("PP*"@L*"@P0# P,# P,$ P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  +" #9 L ! 1$ _]T ! !8_\0 T@    <! 0$! 0
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MD=U;A\/+[/J+]K.+_P#.%'E@1:5YA\S.M#=31:?;$BA"P*)I:5)^%FEB_P"
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MR" "C*'D+GCRWV"?\,V3BS_(3R/%IT5C<12W*0@A"7*E>7@PH1]!PSB_)?\
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MGVO'U& Y.SN0JHB=6=F;M@#R!^9WDSSY:75SY:OOK:63K'=1NCQ2(9 2A9'
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M;GB?4FM>%S 7%*\02DB@_*3##5/^<S?RRMN2V.GZI?OQJKB*&)">M"S2\_\
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M4\E>5Y+O3[*QN/JL5OIBL+VYEC6C.9(.4O%ZMPCC9/W7#U5Y9RS6/RN_-O\
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MB_)S2KM+I=$:\FC*M$;RXFF52N]2A<1-O_,C9U*"WA@C2*!!%"@ 2- %4 ;
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M%[JRW_ERV?U19/&1,Y'V8W/V"JO1N?'XOY,])P6\-O$L4$:Q0H J1HO%0H%
M !X8&U;1-)U>V^KZG90WD0K\$Z+(NXH=B#U&1;RG^3'Y<>5;M[O1M%ABNGJ/
M7DK*ZJQJ54N6XBO\N>1_S2$WY;?\Y SZMIJ%8X+N'4XHS5!(DX#S)R[JY]1*
MC^;/85UKVF^:/R^N[[2+F.:#4K"8P25Y EHB&!!Z%6-",X__ ,X87Z-Y:\R6
M!=/5M]265D&S<98@H-/#E%GH[-FS9LV;-FS9CT/;WSR-_P Y127$?Y[>4C""
M#)9V"AAUY#4IR,];*11:=-B!]&/S9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;
M-FS_T?5.;-FS9PG_ )S#M7E_*6*1& 6VU.VE8'>J^G+%Q'TR\LYO_P X2Z19
M3>9_,>JR?[VV-K!;6ZG_ 'W<R.TK4\0UO$O^RSU]F/3$)?K!:+@$X\OW_(&O
M *>GOSX_['.$?\YC>7;G4?RWM-6@BB8:)>I+=3/02I#<CT*(?Y6F:$2+_J/^
MQGG2\_.74+K\FH/RYE@=S!<J_P"D&E++]41_5C@],J#\,Q#*W/[**G'^3TI_
MSB-Y*O- _+R35KU/2N/,4PNX8B*,+6->,)/?X^3R+_Q7)'G=<V;,>F,5%!)"
M\:FK4%-_$[[X_-FS9L3>-74HZ\U8<2KT*D>XSC'GC_G%'\N/,EZU_I_K>7KJ
M4\KA;$)]7>O7]PPX1M7_ 'SZ:?Y&0J#_ )P@TY+X23>;IGL0U6A2R5)N/@)3
M,ZU]_2SOWDCR-Y=\EZ%;Z)H-K]7M8?[R1J-+*]-Y)7 '-V^7_ _9R19LV;-F
MS9LV;-FS9LYA^=?Y*:7^8^CJJLEEKMKO:7W'E6BG]TYV/ G/+M_^1/Y^>6[N
M6TT^UNY;:)32XT^Y_<LCBK #G&V_[2^GDZ_YPYL)M.\Z>9K._BEM]0@@BB:%
MR5XLLC>H& -&:H^';/6^;-FS9LV;-FS'H>_RSRC^:M]J/F7_ )RO\J>7[:,2
M)H-SIY,)8 <59=1N9"7X[_5Z? "W+TUC3XVSU8 0?\_OQV;-FS9LV;-FS9LV
M;-FS9LV;-FS9LV;-FS9LV?_2]4YLV;,>A[^V1_SQY*T7SGY:N_+NM([V%W0E
MHB%D1T8.CHQ!HRL/#(U^4?Y+^7ORTM[Z/3)9;RYU"13/>W 7U/3CY>G& H"J
M!S/+B/B_:_R.BYLQPI\S^7-.\R>7M0T'4D+V6HP/;S<=F 8;.I(-'1OC0_S9
MP3R[_P X7>7;'S&M[K&MRZKHL+!X=-$ @:2C5"32AV^#LWI)&S_\5YZ(L[.W
MM((K6UB6"V@18H((U"1QQQCBJHB@*JJH554!57]C!.;-FS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FS93=.@/SSS!K,L_DC_G*6RF1GBTS7(V9P]4B/KU,IY'X6*L
MI=OY.6>GE8$ KN#OCLV;-FS9LV;$+Z]M+*RN;RZD6*VM8GFN)&Z)'&I9F/R4
M5SR=^05O>^?O^<@M<_,)VG^H6#W-Q!)**L1=*]M:V[G[/[NV9N/_ ##KGKBH
M\<W)?$;=<KDOB,LD#J<U1FJ/'IUS5'CTZYJC-FJ"*@[9LQ( J30#KFS9LV;-
MFS9LV;-FS9LV;-FS9__3]4YLV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV
M;-FS9LV;-FS'IG"?^<JO(]QJOEG3O-6G$C4/+<X=@-B]M<,B2;_Y#!6_U/4R
M>_D_YPL/-'DVSNK6Y^LR6];>=B1S_=L57F.VPR<U&;-FS9LV;-G!?^<L?S,M
MO+_DMO*EG(/TSY@3A(JM1H;(-221A_Q<4:WCK]I?7_WVV2'_ )QL_+R7R;^6
MUJ;V$Q:SK!^OWZ-LRAQ2&,@_9*0A"RG[,CR9PG_G(?\ .C\R+3\RM0T?3M1N
M]"L-):.*V@MG:(S4 8S.:!G64G[']TT:Q_!]MG@VG>?/^<@O-4RQ:3J_F'46
MKQII\ER%'^MZ'%?^"P[L/R-_YR-UQF>>TOHDYGG)J%\L9YD5)XR2>HU>7VN'
M^RPQ3_G$#\WI8 [R:;$YD93"]TY/2OJ_!$PXM]G[7J?S+QQD?_.+7YZ6TS7%
MJMO'.G((\5\$8@%NC?"0&]ROVO\ 6PU7\I?^<M[.&)[;4M19I:+)$FMCD@44
M!<O,J4'[/!GQMLG_ #F)H-XLK1ZO=?5N1,;M#?HP(^+]J82;?9_:QR?G+_SE
M7HMIPU+1KV50P47=[H\JGK4+RBCB0U^STQ>+_G,/\R=.E$&M>7;#ZP#R93'<
MVS\">A#O)_P5/]CASIG_ #FY-5!J/E-'Y-\4MM?<>*$T^S)"=_G(F2>U_P"<
MT/R^:)3>:+JT4C&E(EM95_X(SQ_\1P_M_P#G*_\ )Z2&*2:[O+0R4YI+9S5C
MJ:5<QAUV_P AFPZTG_G(C\F]3Y>CYFMH"G7ZTDMK6K4^%KA(U8>/'[.3#3/.
M?E#5)&33==T^^D4<F6VNH96 I6I5&)&QPY#H:$$&NX]QE\E\1FJ,U1TKOFJ,
MV:H\<U1FS5%*UVS9LP(/3-49LV;-G__4]4YLV;-FS9LV;-FS9LV;-FS9LV;-
MFS9LV;-FS9LV;-FS9LV;-FS8&O;*VOK2:TNHEFMKA&CEC=00R,*%2#\\\J:5
M<+^0?YFZI!J44K^5-5'JV3QU>L"\J( :*TB=^7[2+_/GJG2]1L=2T^UU"RE6
M:TO(HY[>5&#!HY%Y*PXDKN/Y<%U&;-FS9LV%OF3S#I?EW0;_ %S5)?1T_3X7
MGN)-J\4%>*@TY.Q^"-/VWXIGCOR)HVO?GM^<4_F76HJ^7M-F22\B8CC';(6:
MULE_F]0J1(W_ !FE;XF7/::K0444'84I\LC/F+\M/(GF;4[/4]>T.VU"_L&5
M[>YF3XZ(25C>A'JQ GEZ,OJ0\N7P?%DDAMXH42**,1Q1@"-% 55'2B@ <0,5
MS9LV8]#M7VQO'P%/[,;+$DB&-U#(PHRL.0(]_;"34_(?DK4XS'J/E_3KU3T$
M]K#)0GN"RDK_ +'(Q??\X]_DW?($F\JVB**T-N9K<[CN87C;\<)+_P#YQ1_)
MFZ</'IMS:@#^[BO+@C;_ (S/*<C.K?\ .&'D:17;2=:U2QE;F4]8PW$25^R
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MG'_.O_.&VN1ZM$/)]\DVFR@!_P!(O22)_=HDHZ#_ %.7^MGHK\J_RXTO\O\
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>;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>mrk-20221231_g9.jpg
<TEXT>
begin 644 mrk-20221231_g9.jpg
M_]C_X  02D9)1@ ! 0 !+ $L  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        $L     0   2P    !  .@ 0 #     0 !  "@
M @ $     0   C>@ P $     0   *      _^T .%!H;W1O<VAO<" S+C
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MW0 $ "3_V@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]#]_**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'V'3'T[Q!IT,&D)-;;H(SB2>RNKX %!=))+$KE8P0#^EZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KG_%/BSPKX&T*Z\4^-=9T_P_HMEY?VG4=4NHK*
MS@\UUBC\R>9DC3?(ZHNYAEF ') KH*_G1_X+@^-=*O\ Q]\+/AS#%<#4M#T?
M5=;N)651;M;ZS/#;P+&P<N9%?39C("BJ%9-K,2P4 _HNHKX@_P"";WBG7?&'
M[$OPMU;Q'=?:[NWT^]TN.3RTCVV>D:A=6%G'B-54^5:V\4>XC<VW<Y9B6/V_
M0 4444 ?_]+]_**** "O'_CI\=/AQ^SI\.-1^*'Q0U'[#I5CB*&&(![S4+QP
MQBL[.(LOFW$NT[5RJJJM)(R1([K\X?MQ_MQ^#?V0O!JVMJMOKGQ%URW9]!T%
MV)2-"2GV^_V,KQV<;J0J@K)<R*8XRH6::#\P/V7OV#OBY^VAJNF_M/?MD>*-
M8NM"U"X2YT[2+UI/M^MZ6S37($;AXQI6ER3RY@CMXP9(6D,"VZ-!.X!T'BW_
M (*E?M+_ +1WB$_"W]B_X<7&F:E<7$@34Y(TUK5!9?:[>.WNGA>(:?ID9W".
M[>Z-U!&)AB:,H)6S['_@F7^VK^TS>1>*OVL_BI_8V[^T+RVL+RYD\1WFG7EU
M<*)(HK*&:#3+.WG2,2 6=R515BC\I<$1?N=\+_@I\(_@KI1T?X4>$-'\+6\E
MO:VUP^FVD<-Q>)9*R0&[N //NI$#O^\G>20L[,6+,Q/J% '\T/QF_P""6/QQ
M_9>\*W?QU^"/Q0_M>[\':??ZIJ,UG'-X8UBSLX8@)Y+&6*ZN%EQ:M<-.K3P-
MY:%(Q,T@2OT?_P""7W[7GCO]J'X<>*=(^*US_:?B_P %:A;^?JD=G!9Q7FG:
MJ)7M=ZVY6,W$4EO<(^R"%/*$/WY#(U?=_P ;KWP;IWP7\?:A\1K"XU3PG:^%
M]9FUZQM&*W%UI<=G*UW#$PEA(DD@#JI$L9#$?.OWA^ /_!$?3/&4OQH^(6L6
M+W \)VOA>&VU1%N0MN=4N;R)].,EOO!DD$$-]Y<@1A$I=2R^: X!_2=1110
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MUXOU.Z;='X@T_1-1MQY%Q%MBCT^"R(WSPQ1S?O+5SOMVFB&=AD$R2Q1^H?\
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MX:^ ?#7PYT*6XGTWPKH]AHEG+=LKW$EOIT"6\32LB1HTC)&"Q5%4MG"@<5^
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MX:XUF\EMYUD8N4,:IIL)C 16#,^YF!4+_2=7\P7_  6K_P"3IO"W_9/]._\
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MP-)MD:WDW1[T /[?*X_XA>-=*^&O@'Q+\1M=BN)]-\*Z/?ZW>16BJ]Q);Z=
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M0U--"BBU&SO]8O$CM]+M[*Y@\R2YN(HYKA7CMR8RUPB$O,C)#X!\;H?VR?\
M@I!>2_'30OA%Y?A;PMI]U#IDFEVD<,MQIRW%U)Y<=Y=-'=:W<0M$\31V@9$E
M!\NVADG82\__ ,$U/B%^RI\/?C)'J'[1NE[M:DU#3&\':_>9;1]#O(UNA-/?
M SI&F^1[;R)Y()EMI%$Q> (90 ?TG?LA?"&Y^!'[-'P]^%NH1W$&I:3H\<VJ
M07,T-P]OJFHN]]?PB2W'E-'#=W$L<94L/+5?G<Y=OH^L_2=6TK7]*L]=T*\M
M]1TW4;>*[L[RTE6>WN;>=0\4L4J%DDCD1@RLI*LI!!(-:% ''_$+P5I7Q*\
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M)]GFE%S(SV*LB'8C&3RE_HNHH _G!_X67_P6T_MC^POL?B#[3_?_ .$<\/\
MV7_D(_V7_P ?7V/[/_Q\?/\ ZS_CT_TW_CS_ ']=A^S)_P $]OVJ/'7[4</[
M1/[7]Q<:-/H6L67B8S-?V&H7^MZI:2K+:P1BSEN(+6SMS"@D4A L(2WMXU4F
M2#^@ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]?]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838992704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-6571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merck&#160;& Co., Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">126 East Lincoln Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rahway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">740-4000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1918501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock ($0.50&#160;par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,538,592,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,820,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000310158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023, to be filed with the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member', window );">0.500% Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member', window );">1.875% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.875% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member', window );">2.500% Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.500% Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member', window );">1.375% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 36A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.500Notesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.875Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.500Notesdue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.375Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838580800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842309264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 59,283<span></span>
</td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">17,411<span></span>
</td>
<td class="nump">13,626<span></span>
</td>
<td class="nump">13,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">10,042<span></span>
</td>
<td class="nump">9,634<span></span>
</td>
<td class="nump">8,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,548<span></span>
</td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">13,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">1,501<span></span>
</td>
<td class="num">(1,341)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CostsExpensesAndOther', window );">Total costs, expenses and other</a></td>
<td class="nump">42,839<span></span>
</td>
<td class="nump">34,825<span></span>
</td>
<td class="nump">35,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from Continuing Operations Before Taxes</a></td>
<td class="nump">16,444<span></span>
</td>
<td class="nump">13,879<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on Income from Continuing Operations</a></td>
<td class="nump">1,918<span></span>
</td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net Income from Continuing Operations</a></td>
<td class="nump">14,526<span></span>
</td>
<td class="nump">12,358<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net Income Attributable to Noncontrolling Interests</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">14,519<span></span>
</td>
<td class="nump">12,345<span></span>
</td>
<td class="nump">4,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">$ 14,519<span></span>
</td>
<td class="nump">$ 13,049<span></span>
</td>
<td class="nump">$ 7,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.01<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (in dollars per share)</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">5.71<span></span>
</td>
<td class="nump">4.86<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (in dollars per share)</a></td>
<td class="nump">$ 5.71<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CostsExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of cost of sales, operating expenses and nonoperating income or expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CostsExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072841914560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">$ 14,519<span></span>
</td>
<td class="nump">$ 13,049<span></span>
</td>
<td class="nump">$ 7,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive (Loss) Income Net of Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized (loss) gain on derivatives, net of reclassifications</a></td>
<td class="num">(71)<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on investments, net of reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Benefit plan net gain (loss) and prior service credit (cost), net of amortization</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="num">(603)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(339)<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="num">(441)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 14,180<span></span>
</td>
<td class="nump">$ 14,805<span></span>
</td>
<td class="nump">$ 6,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072848481600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,694<span></span>
</td>
<td class="nump">$ 8,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021)</a></td>
<td class="nump">9,450<span></span>
</td>
<td class="nump">9,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note&#160;8)</a></td>
<td class="nump">5,911<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,169<span></span>
</td>
<td class="nump">6,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">35,722<span></span>
</td>
<td class="nump">30,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property, Plant and Equipment (at cost)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">13,166<span></span>
</td>
<td class="nump">12,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery, equipment and office furnishings</a></td>
<td class="nump">16,760<span></span>
</td>
<td class="nump">16,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">9,186<span></span>
</td>
<td class="nump">8,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment (at cost)</a></td>
<td class="nump">39,407<span></span>
</td>
<td class="nump">37,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="nump">17,985<span></span>
</td>
<td class="nump">18,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">21,422<span></span>
</td>
<td class="nump">19,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other Intangibles, Net</a></td>
<td class="nump">20,269<span></span>
</td>
<td class="nump">22,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">9,528<span></span>
</td>
<td class="nump">11,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">109,160<span></span>
</td>
<td class="nump">105,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="nump">4,264<span></span>
</td>
<td class="nump">4,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">14,159<span></span>
</td>
<td class="nump">13,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,986<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,239<span></span>
</td>
<td class="nump">23,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">28,745<span></span>
</td>
<td class="nump">30,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Taxes</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">3,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">8,323<span></span>
</td>
<td class="nump">9,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Other paid-in capital</a></td>
<td class="nump">44,379<span></span>
</td>
<td class="nump">44,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">61,081<span></span>
</td>
<td class="nump">53,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,768)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' equity before deduction for treasury stock</a></td>
<td class="nump">102,480<span></span>
</td>
<td class="nump">95,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021</a></td>
<td class="nump">56,489<span></span>
</td>
<td class="nump">57,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</a></td>
<td class="nump">45,991<span></span>
</td>
<td class="nump">38,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interests</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">46,058<span></span>
</td>
<td class="nump">38,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 109,160<span></span>
</td>
<td class="nump">$ 105,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072841903152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">$ 2,938<span></span>
</td>
<td class="nump">$ 2,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">1,039,269,638<span></span>
</td>
<td class="nump">1,049,499,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072850398368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Other Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 26,001<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 39,660<span></span>
</td>
<td class="nump">$ 46,602<span></span>
</td>
<td class="num">$ (6,193)<span></span>
</td>
<td class="num">$ (55,950)<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">7,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(6,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">25,404<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">39,588<span></span>
</td>
<td class="nump">47,362<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
<td class="num">(56,787)<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">13,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(6,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">5,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">38,257<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">44,238<span></span>
</td>
<td class="nump">53,696<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
<td class="num">(57,109)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">14,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(7,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 46,058<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 44,379<span></span>
</td>
<td class="nump">$ 61,081<span></span>
</td>
<td class="num">$ (4,768)<span></span>
</td>
<td class="num">$ (56,489)<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072848564192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072850466048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">$ 14,526<span></span>
</td>
<td class="nump">$ 12,358<span></span>
</td>
<td class="nump">$ 4,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible asset impairment charges</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss (income) from investments in equity securities, net</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="num">(1,940)<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge for the acquisition of Pandion Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo', window );">Charge for the acquisition of VelosBio Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(1,568)<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(644)<span></span>
</td>
<td class="num">(2,033)<span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(674)<span></span>
</td>
<td class="num">(895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="num">(289)<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">380<span></span>
</td>
<td class="num">(540)<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Noncurrent liabilities</a></td>
<td class="num">(545)<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="num">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="num">(1,473)<span></span>
</td>
<td class="num">(1,758)<span></span>
</td>
<td class="num">(2,433)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Provided by Operating Activities of Continuing Operations</a></td>
<td class="nump">19,095<span></span>
</td>
<td class="nump">13,122<span></span>
</td>
<td class="nump">7,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(4,388)<span></span>
</td>
<td class="num">(4,448)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of Seagen Inc. common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of securities and other investments</a></td>
<td class="num">(1,204)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales of securities and other investments</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of Acceleron Pharma Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,174)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired', window );">Acquisition of Pandion Therapeutics, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,554)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired', window );">Acquisition of VelosBio Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired', window );">Acquisition of ArQule, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Other acquisitions, net of cash acquired</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
<td class="num">(1,365)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">32<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net Cash Used in Investing Activities of Continuing Operations</a></td>
<td class="num">(4,960)<span></span>
</td>
<td class="num">(16,421)<span></span>
</td>
<td class="num">(9,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities of Continuing Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,986)<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on debt</a></td>
<td class="num">(2,251)<span></span>
</td>
<td class="num">(2,319)<span></span>
</td>
<td class="num">(1,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,936<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived', window );">Distribution from Organon &amp; Co.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(840)<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid to stockholders</a></td>
<td class="num">(7,012)<span></span>
</td>
<td class="num">(6,610)<span></span>
</td>
<td class="num">(6,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net Cash (Used in) Provided by Financing Activities of Continuing Operations</a></td>
<td class="num">(9,119)<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
<td class="num">(2,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Cash Flows from Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations', window );">Net Cash Flows Provided by Discontinued Operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">2,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(410)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">4,606<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets)</a></td>
<td class="nump">8,167<span></span>
</td>
<td class="nump">8,153<span></span>
</td>
<td class="nump">9,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Less: Cash and cash equivalents related to discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets)</a></td>
<td class="nump">$ 12,773<span></span>
</td>
<td class="nump">$ 8,167<span></span>
</td>
<td class="nump">$ 8,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operations Distribution Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Five, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Four, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash associated with the entity's discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845783232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843084336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#160;&amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company&#8217;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners. </span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#8217;s consolidated financial statements through the date of the spin-off (see Note&#160;3).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842418656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Accounting Policies</a></td>
<td class="text">Summary of Accounting Policies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#8217;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $178 million and $2.7 billion, respectively, at December&#160;31, 2022 and were $207 million and $2.6 billion, respectively, at December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note&#160;19 for disaggregated revenue disclosures.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40&#160;years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and from 3 to 15&#160;years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Depreciation expense was $1.8 billion in 2022, $1.6 billion in 2021 and $1.7 billion in 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion Costs &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.2 billion in 2022, $2.0 billion in 2021 and $1.8 billion in 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company&#8217;s policy for releasing disproportionate income tax effects from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is to utilize the item-by-item approach.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#8217;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard&#160;Not Yet Adopted &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842418784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Spin-Off of Organon &amp; Co.</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon&#8217;s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0&#160;billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts included in the consolidated statement of income for the above MSAs include sales of $383&#160;million and $219&#160;million in 2022 and 2021, respectively, and related cost of sales of $404&#160;million and $195&#160;million in 2022 and 2021, respectively. Amounts included in the consolidated statement of income for the TSAs were immaterial in 2022 and 2021. The amounts due from Organon under all of the above agreements were $511&#160;million and $964&#160;million at December&#160;31, 2022 and 2021, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $345&#160;million and $400&#160;million at December&#160;31, 2022 and 2021, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The results of the women&#8217;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#8217;s consolidated statement of income as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556&#160;million in 2021 and $743&#160;million in 2020 related to the spin-off of Organon, which are also included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845485216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock', window );">Acquisitions, Research Collaborations and Licensing Agreements</a></td>
<td class="text">Acquisitions, Research Collaborations and Licensing Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recently Completed Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $175&#160;million, which will be recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0&#160;billion, $2.8&#160;billion in regulatory milestones, and $5.5&#160;billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100&#160;million in Kelun-Biotech&#8217;s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60&#160;million of transaction costs. Imago&#8217;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $200 million and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.2 billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck&#8217;s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. As Royalty Pharma is sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received is being recognized by Merck as a reduction to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses ratably over the estimated Phase 2b research period. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375&#160;million. Royalty Pharma is eligible to receive royalties on future sales. If Royalty Pharma elects to provide the additional funding noted above, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as a higher royalty rate. Merck will record the milestone payments as an expense within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> upon receipt of the related approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440&#160;million, $675&#160;million in regulatory milestones, and $2.4&#160;billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100&#160;million in Orna&#8217;s Series B preferred shares in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion&#8217;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of MK-5684. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of MK-5684, as well as tiered double-digit royalties on sales if the product is approved. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82&#160;million in developmental milestones, $334&#160;million in regulatory milestones, and $485&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech&#8217;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for advanced solid tumors. Upon option </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">exercise, Merck made a payment of $30&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022, and agreed to make additional payments of $30&#160;million upon completion of specified project activities and $25&#160;million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $111&#160;million to fund Kelun-Biotech&#8217;s ongoing research and development activities, of which $51&#160;million was paid in 2022. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90&#160;million in developmental milestones, $290&#160;million in first commercial sale milestones, and $780&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron&#8217;s development work focused on evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron&#8217;s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to sotatercept, Acceleron&#8217;s portfolio includes Reblozyl (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. Reblozyl is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck received a contingent regulatory milestone payment of $20&#160;million in 2022 and remains eligible to receive up to $80&#160;million in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The transaction was accounted for as a business combination. The Company incurred $280&#160;million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs in 2021. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights - Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12 year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion&#8217;s development work focused on advancing a pipeline of precision immune modulators targeting </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">critical immune control nodes. Total consideration paid of $1.9 billion included $147&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.7 billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead&#8217;s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $2.0&#160;billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold. Upon passing $3.5&#160;billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced the Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP). The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#8217;s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30&#160;million, which was included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5&#160;million in developmental milestones, $570&#160;million in regulatory milestones, and $1.05&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. OncoImmune&#8217;s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50&#160;million for a 20% ownership interest in the new entity, which was valued at $33&#160;million resulting in a $17&#160;million premium. Merck also recognized other net liabilities of $22&#160;million. The Company recorded </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $462&#160;million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#8217;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207&#160;million in 2021, which are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio&#8217;s lead investigational candidate, zilovertamab vedotin (MK-2140), is an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180&#160;million (primarily cash) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $2.7 billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $43&#160;million, an increase to total consideration paid of $47&#160;million, and an increase to net assets recorded of $90&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational ADC targeting LIV-1, which is currently in Phase 2 clinical trials. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $616&#160;million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and is receiving tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products are being amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational oral antiviral COVID-19 medicine. See Note&#160;5 for additional information related to this collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $85&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;D of $113&#160;million, cash of $59&#160;million, deferred tax assets of $72&#160;million and other net liabilities of $32&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $239&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;D impairment charge of $90&#160;million within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. The Company also recorded a reduction in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses resulting from a decrease in the related liability for contingent consideration of $45&#160;million. In 2022, the Company wrote off the remaining IPR&amp;D intangible asset and related contingent consideration liability; the net impact to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses was immaterial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#8217;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305&#160;million in 2020, of which $260&#160;million was reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The remaining $45&#160;million of costs were reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95&#160;million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020. ArQule&#8217;s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing arrangement for derazantinib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(361)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck recorded intangible asset impairment charges in 2022 and 2021 related to nemtabrutinib and in 2022 related to derazantinib (see Note&#160;9).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to acquisitions, research collaborations and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072847821392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text">Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600&#160;million liability (which remained accrued at December&#160;31, 2022) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Merck made sales-based milestone payments to AstraZeneca aggregating $400 million and $550 million in 2022 and 2020, respectively. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022 and 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $250&#160;million and $160 million, respectively, from Merck to AstraZeneca. A regulatory milestone of $105&#160;million that was accrued at December&#160;31, 2022 was paid in January 2023. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.6 billion at December&#160;31, 2022 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250&#160;million and $106&#160;million, respectively, of cumulative amortization catch-up expense.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck made sales-based milestone payments to Eisai aggregating $600&#160;million, $200 million and $500 million&#160;in 2022, 2021 and 2020, respectively. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $50&#160;million, $75&#160;million and $10&#160;million, respectively, from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $814 million at December&#160;31, 2022 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">136</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made sales-based milestone payments to Bayer of $400&#160;million and $375&#160;million in 2022 and 2020, respectively. There are no sales-based milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $633 million and $57 million, respectively, at December&#160;31, 2022 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,038</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses in all periods now include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalty and milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#8217;s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80&#160;million. Merck recorded alliance revenue of $166 million in 2022, which includes royalties of $146&#160;million and the receipt of a regulatory approval milestone payment of $20&#160;million, compared with alliance revenue of $17 million in 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072847771696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RestructuringIn 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $666 million in 2022, $868 million in 2021 and $880 million in 2020 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2022, Merck has recorded total pretax accumulated costs of approximately $3.3 billion. The Company expects to record charges of approximately $400 million in 2023 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">337</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other activity in 2022, 2021 and 2020 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;14) and share-based compensation. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be largely completed by the end of 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843233728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:5pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(162)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022,&#160;nine interest rate swap contracts with a total notional amount of&#160;$2.25&#160;billion&#160;matured. These swaps effectively converted the Company&#8217;s&#160;$1.0&#160;billion,&#160;2.4%&#160;fixed-rate notes and $1.25&#160;billion, 2.35% fixed-rate notes due 2022 to variable rate debt. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:45.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a">Other current assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,824</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597">Other Assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,691</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786">Other Noncurrent Liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,540</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,926</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">19,466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">28,681</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">32,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">773</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges against rising treasury rates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company estimates $104 million of pretax net unrealized gains on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $462 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2022 on equity securities still held at December&#160;31, 2022. Unrealized net losses of $232 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2021 on equity securities still held at December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company also had $832 million and $596 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During 2022, the Company recorded unrealized gains of $56 million and unrealized losses of $12 million related to certain of these equity investments still held at December&#160;31, 2022. During 2021, the Company recorded unrealized gains of $110 million and unrealized losses of $1 million related to certain of these investments still held at December&#160;31, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December&#160;31, 2022 were $289 million and $19 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022, 2021 and 2020, the Company also had $598&#160;million, $1.7&#160;billion and $800&#160;million, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $1.0&#160;billion, $(1.4)&#160;billion and $(583)&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $11.3 billion and $6.8&#160;billion of cash equivalents, respectively, (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December&#160;31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above. </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion and at December&#160;31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 21%, 20% and 13%, respectively, of total accounts receivable at December&#160;31, 2022. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.5 billion and $2.8 billion of accounts receivable as of December&#160;31, 2022 and 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2022 and 2021, the Company had collected $67 million and $62&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in January 2023 and 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to various counterparties was $19 million at December&#160;31, 2022. Cash collateral received by the Company from various counterparties was $66 million and $164 million at December&#160;31, 2022 and 2021, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072847816720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,841</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,142</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,911</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,938</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.3 billion at December&#160;31, 2022 and 2021, respectively. Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2022 and 2021, these amounts included $2.4 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $516 million and $256 million at December&#160;31, 2022 and 2021, respectively, of inventories produced in preparation for product launches.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843439184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangibles</a></td>
<td class="text">Goodwill and Other Intangibles<div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31, 2021 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December&#160;31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,268</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,204</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2022 and 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron (see Note&#160;4). </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,810</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,879</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">635</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,651</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,477</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the more significant acquired intangibles included in products and product rights, on a net basis, related to human health marketed products at December&#160;31, 2022 were Reblozyl, $3.5 billion; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $406 million;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Sivextro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $122 million; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, $120 million; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $97 million. Additionally, the Company had $4.6 billion of net acquired intangibles related to animal health at December&#160;31, 2022, of which $2.3&#160;billion related to products and product rights and $2.2&#160;billion was attributable to trade names, primarily related to Allflex. At December&#160;31, 2022, IPR&amp;D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note&#160;4); MK-7264 (gefapixant), $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016; and MK-1026 (nemtabrutinib), $418 million, obtained through the acquisition of ArQule in </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 (see below and Note&#160;4). Some of the more significant net intangible assets included in licenses and other above at December&#160;31, 2022 include Lynparza, $1.6 billion, related to a collaboration with AstraZeneca; Lenvima, $814 million, related to a collaboration with Eisai; and Adempas, $633 million, related to a collaboration with Bayer. See Note&#160;5 for additional information related to the intangible assets associated with these collaborations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, the Company recorded an impairment charge of $1.6&#160;billion within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjg_e7b500cc-8996-45e1-8231-cde2ddbd2b59">Cost of sales</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> intangible asset for impairment. The Company revised its cash flow forecasts for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120&#160;million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in 2020 related to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> recall. A phased resupply of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was initiated in the fourth quarter of 2021 and completed during 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, the Company recorded $1.7 billion of intangible impairment charges within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjk_b1192ef4-ec86-4241-a5a3-3f1beac17af0">Research and development</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses, of which $1.6&#160;billion represents IPR&amp;D impairment charges related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies that was obtained through the 2020 acquisition of ArQule (see Note&#160;4). Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807&#160;million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which is expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated current fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780&#160;million impairment charge. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80&#160;million intangible asset impairment charge related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, the Company recorded a $275&#160;million IPR&amp;D impairment charge related to nemtabrutinib. As part of Merck&#8217;s annual impairment assessment of IPR&amp;D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to 8.5% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, the Company recorded a $90&#160;million IPR&amp;D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#8217;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was $2.1 billion in 2022, $1.6 billion in 2021 and $1.8 billion in 2020. The estimated aggregate amortization expense for each of the next five years is as follows: 2023, $1.8 billion; 2024, $1.7 billion; 2025, $1.6 billion; 2026, $1.5 billion; 2027, $1.3 billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843207792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans Payable, Long-Term Debt and Leases</a></td>
<td class="text">Loans Payable, Long-Term Debt and Leases<div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loans payable at December&#160;31, 2022 included $1.7 billion of notes due in 2023 and $197 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2021 included $2.3 billion of notes due in 2022 and $149 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.65% and 0.08% for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,496</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,738</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,494</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,483</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,060</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">749</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">527</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">526</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 1.40% and zero for 2022 and 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#8217;s option at any time, at varying redemption prices. Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s borrowings require that Merck comply with covenants and, at December&#160;31, 2022, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2023, $1.7 billion; 2024, $1.3 billion; 2025, $2.5 billion; 2026, $2.2 billion; 2027, $1.5 billion. Interest payments related to these debt obligations are as follows: 2023, $882 million; 2024, $845 million; 2025, $778 million; 2026, $751 million; 2027, $720 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of seven years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#8217;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#8217;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost was $334&#160;million in 2022, $343&#160;million in 2021 and $340&#160;million in 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $335 million in 2022, $340&#160;million in 2021 and $334&#160;million in 2020. Operating lease assets obtained in exchange for lease obligations were $57 million in 2022, $117 million in 2021 and $473 million in 2020. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,013</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $232 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843207792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Environmental Liabilities</a></td>
<td class="text">Contingencies and Environmental Liabilities <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December&#160;31, 2022, approximately 70 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#8217;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#8217;s information request by seeking information relating to Merck&#8217;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#8217;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#8217;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#8217;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#8217;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#8217;s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#8217;s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company&#8217;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#8217; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other Zetia MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 10, 2023, the district court denied the Merck Defendants&#8217; and Glenmark defendants&#8217; motions for summary judgment. In the cases filed by direct purchaser plaintiffs, retailer plaintiffs, and indirect purchaser plaintiffs, plaintiffs seek up to a maximum of $12.7&#160;billion in damages after trebling. The court has scheduled trial for these plaintiffs (all plaintiffs other than the Insurer Plaintiffs) for April 17, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">340B Program Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck&#8217;s 340B Program integrity initiative. HRSA&#8217;s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA&#8217;s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck&#8217;s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company&#8217;s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit&#8217;s ruling in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharmaceuticals Corp. v. Johnson </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> United Therapeutics Corp. v. Johnson</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#8217;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name &#8220;Merck&#8221; in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties&#8217; coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments on February 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCl), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Court for the Northern District of West Virginia issued a decision in the Company&#8217;s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company&#8217;s favor, upholding the USPTO&#8217;s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity toward the end of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in Europe, for which there will be an oral hearing on March 8, 2023. In first instance decisions, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPC has been found invalid in Germany and Romania, and has been upheld in Czech Republic and Sweden. Appeals are pending in Germany, Czech Republic and Sweden. The Company has filed for injunctive relief in Belgium, Czech Republic, Finland, France, Greece, Hungary, Ireland, Portugal, Switzerland and Slovakia. An </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> preliminary injunction was granted in Finland, which has been subsequently maintained in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter-partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> proceedings, Czech Republic and Switzerland, and an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter-partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> preliminary injunction has been granted in Ireland. A preliminary injunction was granted in France and the validity of the SPC and the associated patent were held to be </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">prima facie</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> valid. Preliminary injunctions have been refused in Portugal, Greece, Belgium and Hungary. In Belgium, the Company has filed a main infringement action against generic companies and a request for preliminary measures in that action has been refused.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2022 and 2021 of approximately $230 million represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#8217;s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December&#160;31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#8217;s financial condition, results of operations or liquidity for any year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072847820240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes 6,500,000,000&#160;shares of common stock and 20,000,000&#160;shares of preferred stock.</span></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capital Stock</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072847816720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation Plans</a></td>
<td class="text">Share-Based Compensation PlansThe Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees <div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#8217;s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, 87 million shares collectively were authorized for future grants under the Company&#8217;s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#8217;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#8217;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#8217;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2022, 2021 and 2020 was $541 million, $498&#160;million and $475&#160;million, respectively. The amounts in 2021 and 2020 include $479 million and $441 million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2022, 2021 and 2020 were $78 million, $69 million and $65 million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#8217;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2022, 2021 and 2020 was $87.10, $75.99 and $77.67 per option, respectively. The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,326</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">60.77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73.11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.55</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.09</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">539</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,730</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">384</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonvested January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">951</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">77.58</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nonvested December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected to vest December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80.96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,895</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $813 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843039792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefit Plans</a></td>
<td class="text">Pension and Other Postretirement Benefit Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Periodic Benefit Cost</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;6), termination charges were recorded in 2022, 2021 and 2020 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2022 and 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note&#160;15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obligations and Funded Status</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,999</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,458&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,854</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(760)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(210)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,052</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(315)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Actuarial (gains) losses primarily reflect changes in discount rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the accumulated benefit obligation was $17.2 billion and $24.9 billion, respectively, for all pension plans, of which $9.7 billion and $13.8 billion, respectively, related to U.S. pension plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,445</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,081</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,226</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Plan Assets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2022 and 2021, $765 million and $943 million, respectively, or approximately 4% of the Company&#8217;s pension investments were categorized as Level&#160;3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,443</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,654</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,495</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,067&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,957</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">943</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">436</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">231</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#8217;s U.S.&#160;pension and other postretirement benefit plans is allocated 25% to 40% in U.S.&#160;equities, 10% to 20% in international equities, 35% to 45% in fixed-income investments, and up to 8% in cash and other investments. The portfolio&#8217;s equity weighting is consistent with the long-term nature of the plans&#8217; benefit obligations. The expected annual standard deviation of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">returns of the target portfolio, which approximates 10%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contributions during 2023 are expected to be approximately $270 million for U.S. pension plans, approximately $150 million for international pension plans and approximately $20 million for other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Benefit Payments</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028&#160;&#8212;&#160;2032</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Other Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements and curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Actuarial Assumptions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#8217;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company&#8217;s U.S. pension and other postretirement benefit plans will be 7.00%, as compared to 6.70% in 2022. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2022, 2021 and 2020 were $175 million, $158 million and $158 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140073016952672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">962</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140&#160;million will be recorded in the first quarter of 2023 from ownership interests in investment funds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid was $937 million in 2022, $779 million in 2021 and $822 million in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843039792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text">Taxes on Income<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the utilization of foreign tax credits, was $2.2 billion at December&#160;31, 2022, of which $732 million is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the remainder of $1.5 billion is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,011</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">912</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,006</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,795</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2022, $349 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $345 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $563 million of deferred tax assets relating to various U.S. tax credit carryforwards and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NOL carryforwards. Valuation allowances of $247&#160;million have been established on these U.S. tax credit carryforwards and NOL carryforwards. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid in 2022, 2021 and 2020 (including amounts attributable to discontinued operations in 2021 and 2020) were $3.2 billion, $2.4 billion and $2.7 billion, respectively. Income taxes paid consisted of:</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes TCJA transition tax payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits relating to stock option exercises were $45 million in 2022, $21 million in 2021 and $12 million in 2020. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2021 reflects a settlement with the IRS discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $1.8 billion at December&#160;31, 2022, the income tax provision would reflect a favorable net impact of $1.8 billion.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2022 could decrease by up to approximately $31 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#8217;s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $54 million in 2022, $(37) million in 2021 and $16 million in 2020. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $256 million and $192 million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&#160;million (of which $172&#160;million related to continuing operations and $18&#160;million related to discontinued operations). The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236&#160;million net tax benefit in 2021 (of which $207&#160;million related to continuing operations and $29&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IRS is currently conducting examinations of the Company&#8217;s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#8217;s income tax returns are open for examination for the period 2003 through 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072846041904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,542</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.14&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, 2 million, 9 million and 5 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072847707344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note&#160;3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(584)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(612)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(359)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836973504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,686</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">579</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,065</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,832</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,897</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,523</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">633</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,813</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">969</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,989</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,016</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">710</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,590</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,550</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30,744</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">395</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,077</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165&#160;million, $218&#160;million and $54&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,493</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,582</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,568</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">38,815</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity income/loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,993</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">966</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838679520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#8217; interests are shown as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#8217;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no </span>goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#8217;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#8217;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#8217;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company&#8217;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#8217;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $178 million and $2.7 billion, respectively, at December&#160;31, 2022 and were $207 million and $2.6 billion, respectively, at December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#8217;s total unbudgeted spending and the Company&#8217;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck&#8217;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note&#160;19 for disaggregated revenue disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock', window );">Depreciation</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40&#160;years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and from 3 to 15&#160;years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Promotion Costs</a></td>
<td class="text">Advertising and Promotion Costs &#8212; Advertising and promotion costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Software Capitalization</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Acquired Intangibles</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>Certain of the Company&#8217;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are </span>expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Costs</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies and Legal Defense Costs</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on Income</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company&#8217;s policy for releasing disproportionate income tax effects from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is to utilize the item-by-item approach.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span>Certain reclassifications have been made to prior year amounts to conform to the current year presentation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#8217;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards&#160;&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#8217;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#8217;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard&#160;Not Yet Adopted &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discussion of the accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843246976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843125824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights - Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12 year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing arrangement for derazantinib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(361)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838646768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250&#160;million and $106&#160;million, respectively, of cumulative amortization catch-up expense.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">136</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,038</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses in all periods now include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalty and milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843123344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to Restructuring Program Activities by Type of Cost</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">337</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and Spending Relating to Restructuring Activities by Program</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December&#160;31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be largely completed by the end of 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837036640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Effect of Net Investment Hedges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(162)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:45.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a">Other current assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,824</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597">Other Assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,691</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786">Other Noncurrent Liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,540</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,926</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">19,466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">28,681</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">32,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock', window );">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</a></td>
<td class="text">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Location and Pretax Gain or Loss Amounts for Derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">773</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges against rising treasury rates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Information on Investments in Debt and Equity Securities</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December&#160;31 is as follows:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $462 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2022 on equity securities still held at December&#160;31, 2022. Unrealized net losses of $232 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2021 on equity securities still held at December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summarized Information about the Changes in Liabilities for Contingent Consideration</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December&#160;31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OffsettingAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843070912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,841</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,142</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,911</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,938</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072848479824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill Activity by Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31, 2021 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December&#160;31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,268</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,204</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div>(2)&#160;&#160;&#160;&#160;Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2022 and 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Other Intangibles</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangibles at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,810</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,879</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">635</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,651</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,477</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842973776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,496</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,738</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,494</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,483</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,060</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">749</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">527</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">526</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetsandLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,013</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetsandLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetsandLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072850478224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Summary of Common Stock and Treasury Stock Transactions</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)  &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072844056848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</a></td>
<td class="text">The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information Relative to Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,326</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">60.77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73.11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.55</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.09</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">539</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,730</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock', window );">Additional Information Pertaining to Stock Option Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">384</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Nonvested RSU and PSU Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonvested January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">951</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">77.58</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nonvested December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected to vest December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80.96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,895</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional information pertaining to stock option plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838793728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other&#160;Postretirement&#160;Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Obligation and Funded Status</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation January&#160;1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,999</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,458&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation December&#160;31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,854</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status December&#160;31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(760)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(210)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,052</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(315)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Actuarial (gains) losses primarily reflect changes in discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock', window );">Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,445</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,081</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,226</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s pension plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,443</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,654</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,495</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,067&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,957</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">943</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">436</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The plans&#8217; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">231</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock', window );">Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#8217;s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Summary of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028&#160;&#8212;&#160;2032</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Other Comprehensive Income</a></td>
<td class="text">The following amounts were reflected as components of <span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements and curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.&#160;Pension&#160;and&#160;Other<br/>Postretirement&#160;Benefit&#160;Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843125824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">962</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140&#160;million will be recorded in the first quarter of 2023 from ownership interests in investment funds.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845819744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Effective Tax Rate and U.S. Statutory Rate</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax&#160;Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Income Before Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,011</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Taxes on Income</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Income Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">912</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,006</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,795</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock', window );">Income Taxes Paid</a></td>
<td class="text">Income taxes paid consisted of:<div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes TCJA transition tax payments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January&#160;1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December&#160;31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;Amount in 2021 reflects a settlement with the IRS discussed below.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ScheduleOfIncomeTaxesPaidTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Income Taxes Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ScheduleOfIncomeTaxesPaidTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072850489088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculations of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,542</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.14&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843310624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in AOCI by Component</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note&#160;3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(584)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(612)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(359)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072841922944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Sales of Company's Products</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,686</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">579</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,065</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,832</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,897</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,523</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">633</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,813</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">969</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,989</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,016</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">710</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,590</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,550</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30,744</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">395</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,077</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div>(6)&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165&#160;million, $218&#160;million and $54&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Consolidated Revenues by Geographic Area</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,493</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,582</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,568</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Segment Profits to Income Before Taxes</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">38,815</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Equity Loss from Affiliates and Depreciation Included in Segment Profits</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity income/loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock', window );">Property, Plant and Equipment, Net by Geographic Area</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,993</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">966</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072850478224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837277952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SalesDiscounts', window );">Customer discounts</a></td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AccrualForChargebacks', window );">Accrual for chargebacks reflected as direct reduction to accounts receivable</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AccrualForRebates', window );">Accrual for rebates included in accrued and other current liabilities</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate', window );">Product return period and expiration</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,824<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising and promotion costs</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate', window );">Product return period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Capitalized Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery, equipment and office furnishings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">36 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate', window );">Product return period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Capitalized Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery, equipment and office furnishings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AccrualForChargebacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual for chargebacks reflected as a direction reduction to accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AccrualForChargebacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AccrualForRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrual for rebates recorded as current liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AccrualForRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenuePerformanceObligationPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenuePerformanceObligationPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Goods, Goods Return Period After to Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837197264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration received</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Disposal group, other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember', window );">Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartiesAmountInCostOfSales', window );">Related party amount in cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">35 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mrk_OrganonCoMember', window );">Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartiesAmountInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartiesAmountInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrganonCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mrk_OrganonCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mrk_OrganonCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838632992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,512<span></span>
</td>
<td class="nump">$ 6,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax', window );">Income from discontinued operations before taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod', window );">Tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Income of discontinued operations attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations, net of taxes attributable to parent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 2,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Research and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Restructuring Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072811046080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)<br> $ / shares in Units, &#8364; in Millions, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="19">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>research_program </div>
<div>collaboration_target</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,548.0<span></span>
</td>
<td class="nump">$ 12,245.0<span></span>
</td>
<td class="nump">$ 13,397.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388.0<span></span>
</td>
<td class="nump">4,448.0<span></span>
</td>
<td class="nump">4,429.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2,660.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,953.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,911.0<span></span>
</td>
<td class="nump">$ 5,911.0<span></span>
</td>
<td class="nump">5,911.0<span></span>
</td>
<td class="nump">5,953.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 841.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456.0<span></span>
</td>
<td class="nump">456.0<span></span>
</td>
<td class="nump">456.0<span></span>
</td>
<td class="nump">777.0<span></span>
</td>
<td class="nump">841.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,264.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,882.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,204.0<span></span>
</td>
<td class="nump">21,204.0<span></span>
</td>
<td class="nump">21,204.0<span></span>
</td>
<td class="nump">21,264.0<span></span>
</td>
<td class="nump">$ 18,882.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146.0<span></span>
</td>
<td class="num">(57.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mrk_OncoImmuneMember', window );">OncoImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ChargesRelatedToProgramDiscontinuation', window );">Charges related to program discontinuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207.0<span></span>
</td>
<td class="nump">305.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Inventory write-off related to contract termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SentinelMember', window );">Sentinel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SentinelMember', window );">Sentinel | Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember', window );">Imago BioSciences, Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember', window );">Pandion Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_OncoImmuneMember', window );">OncoImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PremiumOnSharesAcquired', window );">Premium on shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_VelosBioMember', window );">VelosBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_DunboyneMember', window );">Dunboyne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.0<span></span>
</td>
<td class="nump">&#8364; 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet', window );">Other net assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PremiumOnSharesAcquired', window );">Premium on shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember', window );">Acceleron Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets, acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other net liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,411.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember', window );">Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other net liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember', window );">Themis | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination, contingent consideration arrangements, change in amount of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,280.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other net liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed', window );">Share-based compensation payments to settle equity awards attributable to precombination service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ModernaMember', window );">Moderna | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember', window );">Orna Therapeutics | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrionCorporationMember', window );">Orion Corporation | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments', window );">Eligible future contingent development-related payments (up to)</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Regulatory milestones payments</a></td>
<td class="nump">2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments', window );">Sales milestone payments</a></td>
<td class="nump">$ 5,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty', window );">Preferred stock investment in counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner', window );">Upfront and milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentToBeMadeToCollaborativePartner', window );">Milestone payment to be made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners', window );">Research and development payments to be made to a collaborative partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner', window );">Research and development payments made to a collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.0<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485.0<span></span>
</td>
<td class="nump">780.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRateDeductionPercentage', window );">Royalty rate, deduction, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember', window );">Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Oral and Injectable Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProfitShareCounterparty', window );">Profit share by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProfitShare', window );">Profit share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember', window );">Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Oral Formulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProfitShareCounterparty', window );">Profit share by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProfitShare', window );">Profit share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SalesThreshold', window );">Sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember', window );">Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Injectable Formulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProfitShareCounterparty', window );">Profit share by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProfitShare', window );">Profit share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SalesThreshold', window );">Sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner', window );">Upfront and milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementNumberOfResearchPrograms', window );">Number of research programs | research_program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementNumberOfCollaborationTargets', window );">Number of collaboration targets | collaboration_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember', window );">Artiva Biotherapeutics, Inc. | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 616.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares', window );">Forward contract indexed to issuer's equity, indexed shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Minimum | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Maximum | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Regulatory Milestones | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SentinelMember', window );">Sentinel | Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets, acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_IAVIMember', window );">IAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrk_RoyaltyPharmaMember', window );">Royalty Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Compensation earned on arragement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts', window );">Additional funding by others, percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding', window );">Additional funding by others, development costs subject to funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Assets and Liabilities Recognized, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ChargesRelatedToProgramDiscontinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Charges related to program discontinuation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ChargesRelatedToProgramDiscontinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementNumberOfCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Collaboration Targets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementNumberOfCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementNumberOfResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Research Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementNumberOfResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Preferred Stock Investment In Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentToBeMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment To Be Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentToBeMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PremiumOnSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium on shares acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PremiumOnSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProfitShareCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit Share Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProfitShareCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Payments Made To a Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Payments To Be Made to a Collaborative Partners</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRateDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Deduction, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRateDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and Milestone Payments to be Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made to partner as part of a licensing or collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the forward contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mrk_OncoImmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mrk_OncoImmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_OncoImmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_OncoImmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_VelosBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_VelosBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_DunboyneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_DunboyneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_ModernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_ModernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrnaTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_FirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_FirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_GileadSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_GileadSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OralAndInjectableFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OralAndInjectableFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OralFormulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OralFormulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_InjectableFormulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_InjectableFormulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SeagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SeagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_TukysaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_TukysaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_IAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_IAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrk_RoyaltyPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrk_RoyaltyPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842382192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,204<span></span>
</td>
<td class="nump">$ 21,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember', window );">Acceleron Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Products and product rights - Reblozyl (12 year useful life)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible assets, acquired</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember', window );">Acceleron Pharma Inc. | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetProductsAndProductRightsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Products and Product rights, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetProductsAndProductRightsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AcceleronPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836614256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">$ 1,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
<td class="nump">22,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,283<span></span>
</td>
<td class="nump">48,704<span></span>
</td>
<td class="nump">41,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,555<span></span>
</td>
<td class="nump">48,322<span></span>
</td>
<td class="nump">41,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,005<span></span>
</td>
<td class="nump">42,754<span></span>
</td>
<td class="nump">36,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Licenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_VerquvoMember', window );">Verquvo | Licenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_ReblozylMember', window );">Reblozyl | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential future sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued', window );">Regulatory milestone payments accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsRegulatory', window );">Potential future regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Lynparza | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement', window );">License option payment related to collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential future sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Lenvima | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Adempas | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRateDeductionPercentage', window );">Royalty rate, deduction, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Regulatory Milestone Payments Accrued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License option payment related to collaborative arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsMadetoCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsMadetoCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Regulatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Sales-Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProbableContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probable Contingent Payments Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProbableContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRateDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Deduction, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRateDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836110688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 59,283<span></span>
</td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">17,411<span></span>
</td>
<td class="nump">13,626<span></span>
</td>
<td class="nump">13,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">10,042<span></span>
</td>
<td class="nump">9,634<span></span>
</td>
<td class="nump">8,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,548<span></span>
</td>
<td class="nump">12,245<span></span>
</td>
<td class="nump">13,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other current liabilities</a></td>
<td class="nump">24,239<span></span>
</td>
<td class="nump">23,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other current liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other current liabilities</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other current liabilities</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Payables included in Other Noncurrent Liabilities</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Bayer AG | Collaborative Arrangement | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Bayer AG | Collaborative Arrangement | Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Total sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,684<span></span>
</td>
<td class="nump">952<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,038<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit Sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Sales, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LagevrioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LagevrioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837172896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays', window );">Estimate of cumulative pre tax costs that will result in cash outlays</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash', window );">Estimate of cumulative pre tax costs that will be noncash</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 666<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative costs since program inception</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will be noncash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072804990784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Charges Activities by Type of Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 666<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">Selling, general and administrative<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
<td class="text">Restructuring costs<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837238848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Activities by Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(449)<span></span>
</td>
<td class="num">(608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(341)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash activity affecting the restructuring reserve, including accelerated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RestructuringReserveIncreaseDecreaseNoncashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837415328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">$ 832,000,000<span></span>
</td>
<td class="nump">$ 596,000,000<span></span>
</td>
<td class="nump">832,000,000<span></span>
</td>
<td class="nump">$ 596,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Unrealized gains recognized on investments in equity securities without readily determinable fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Unrealized losses recognized on investments in equity securities without readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative upward price adjustment</a></td>
<td class="nump">289,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative downward price adjustment</a></td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities held through ownership interests in investment funds</a></td>
<td class="nump">598,000,000<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="nump">598,000,000<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">(Gains) losses for equity securities held through ownership interests in investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="num">(1,400,000,000)<span></span>
</td>
<td class="num">$ (583,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of loans payable and long-term debt, including current portion</a></td>
<td class="nump">26,700,000,000<span></span>
</td>
<td class="nump">35,700,000,000<span></span>
</td>
<td class="nump">26,700,000,000<span></span>
</td>
<td class="nump">35,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, carrying amount</a></td>
<td class="nump">30,700,000,000<span></span>
</td>
<td class="nump">33,100,000,000<span></span>
</td>
<td class="nump">30,700,000,000<span></span>
</td>
<td class="nump">33,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Factored accounts receivable</a></td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="nump">2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Funds collected from factoring of receivable, held in restricted cash</a></td>
<td class="nump">67,000,000<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">67,000,000<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimSecurities', window );">Cash collateral advanced to counterparties</a></td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received from counterparties</a></td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">164,000,000<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="nump">164,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member', window );">2.40% Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member', window );">2.35% notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | McKesson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of accounts receivable represented by customers with largest balances (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of accounts receivable represented by customers with largest balances (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of accounts receivable represented by customers with largest balances (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 11,300,000,000<span></span>
</td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="nump">$ 11,300,000,000<span></span>
</td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_NumberOfInterestRateDerivativesMatured', window );">Number of interest rate derivatives matured | interest_rate_swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DerivativeNotionalAmountMatured', window );">Total notional amount of Interest rate derivatives matured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum planning cycle of hedges (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum planning cycle of hedges (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DerivativeNotionalAmountMatured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Notional Amount Matured</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DerivativeNotionalAmountMatured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_NumberOfInterestRateDerivativesMatured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivatives that matured during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_NumberOfInterestRateDerivativesMatured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrk_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrk_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrk_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrk_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrk_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrk_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072846026976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (49)<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843409632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Hedges (Details) - Loans payable and current portion of long-term debt - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837220000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">28,681<span></span>
</td>
<td class="nump">32,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">9,215<span></span>
</td>
<td class="nump">12,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">19,466<span></span>
</td>
<td class="nump">20,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 4,824<span></span>
</td>
<td class="nump">$ 6,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets<span></span>
</td>
<td class="text">Other Assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 1,609<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 2,691<span></span>
</td>
<td class="nump">$ 1,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 8,540<span></span>
</td>
<td class="nump">$ 10,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of derivative</a></td>
<td class="nump">$ 10,926<span></span>
</td>
<td class="nump">$ 10,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845241664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Gross amounts recognized in the consolidated balance sheet, asset</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received, asset</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, asset</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Gross amounts recognized in the consolidated balance sheet, liability</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received, liability</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, liability</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838763264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 59,283<span></span>
</td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">1,501<span></span>
</td>
<td class="num">(1,341)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (339)<span></span>
</td>
<td class="nump">$ 1,756<span></span>
</td>
<td class="num">$ (441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other (income) expense, net<span></span>
</td>
<td class="text">Other (income) expense, net<span></span>
</td>
<td class="text">Other (income) expense, net<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of gain recognized in Other (income) expense, net on derivatives</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Increase (decrease) in Sales as a result of AOCL reclassifications</a></td>
<td class="num">(773)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (income) expense, net | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged items</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Derivatives designated as hedging instruments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 773<span></span>
</td>
<td class="num">$ (194)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836928032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836940848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information on Debt and Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI', window );">Total debt and publicly traded equity securities, fair value</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities and Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DebtSecuritiesandEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072803948944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,286<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">865<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Currency Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Foreign government bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845234064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, beginning balance</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="num">(146)<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther', window );">Other</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, ending balance</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration, liability, current</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember', window );">Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, beginning balance</a></td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, ending balance</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input, discount rate</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072844399856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 1,841<span></span>
</td>
<td class="nump">$ 1,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work in process</a></td>
<td class="nump">7,063<span></span>
</td>
<td class="nump">6,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Supplies</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates current cost)</a></td>
<td class="nump">9,142<span></span>
</td>
<td class="nump">8,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Decrease to LIFO cost</a></td>
<td class="num">(293)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_InventoryNetAndInventoryNoncurrent', window );">Total current and noncurrent inventories</a></td>
<td class="nump">8,849<span></span>
</td>
<td class="nump">8,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RecognizedAsAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">5,911<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other Assets</a></td>
<td class="nump">$ 2,938<span></span>
</td>
<td class="nump">$ 2,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of current and noncurrent inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RecognizedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized as.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RecognizedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845346480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LIFOInventoryAmount', window );">LIFO inventory amount</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">2,938<span></span>
</td>
<td class="nump">2,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember', window );">Inventory Not Expected to be Sold Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember', window );">Inventories Produced in Preparation for Product Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory classified in Other assets</a></td>
<td class="nump">$ 516<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LIFOInventoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LIFOInventoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845273120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 21,264<span></span>
</td>
<td class="nump">$ 18,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">21,204<span></span>
</td>
<td class="nump">21,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">17,997<span></span>
</td>
<td class="nump">15,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">17,936<span></span>
</td>
<td class="nump">17,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">3,267<span></span>
</td>
<td class="nump">3,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 3,268<span></span>
</td>
<td class="nump">$ 3,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072804103584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 20,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,269<span></span>
</td>
<td class="nump">$ 22,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Cost of sales<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration liability, changes in estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (146)<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense, 2023</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense, 2024</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense, 2025</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense, 2026</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated aggregate amortization expense, 2027</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">7,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,661<span></span>
</td>
<td class="nump">9,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember', window );">Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge related to marketed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AnimalHealthMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Licenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration liability, changes in estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SotaterceptMember', window );">sotatercept | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember', window );">nemtabrutinib | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">IPR&amp;D impairment charges</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember', window );">nemtabrutinib | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GefapixantMember', window );">gefapixant | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">6,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,810<span></span>
</td>
<td class="nump">$ 7,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Reblozyl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Sivextro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">3,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License | Derazantinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IntangibleAssetsExcludingGoodwillLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetsExcludingGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Excluding Goodwill [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetsExcludingGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AnimalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AnimalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SotaterceptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SotaterceptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NemtabrutinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NemtabrutinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GefapixantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GefapixantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SivextroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SivextroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_DerazantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_DerazantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845101376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangibles - Other Intangibles (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 41,746<span></span>
</td>
<td class="nump">$ 42,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">21,477<span></span>
</td>
<td class="nump">19,505<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">20,269<span></span>
</td>
<td class="nump">22,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">7,661<span></span>
</td>
<td class="nump">9,281<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">7,661<span></span>
</td>
<td class="nump">9,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Products and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">23,555<span></span>
</td>
<td class="nump">23,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">16,745<span></span>
</td>
<td class="nump">15,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">6,810<span></span>
</td>
<td class="nump">7,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets Excluding Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">7,651<span></span>
</td>
<td class="nump">6,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">4,097<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">$ 3,554<span></span>
</td>
<td class="nump">$ 3,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072807947536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current maturities</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">$ 2,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-term debt, maturities, repayments of principal in 2023</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-term debt, maturities, repayments of principal in 2024</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-term debt, maturities, repayments of principal in 2025</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-term debt, maturities, repayments of principal in 2026</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-term debt, maturities, repayments of principal in 2027</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearOne', window );">Long-term debt, interest payments in 2023</a></td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearTwo', window );">Long-term debt, interest payments in 2024</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearThree', window );">Long-term debt, interest payments in 2025</a></td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearFour', window );">Long-term debt, interest payments in 2026</a></td>
<td class="nump">751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LongTermDebtInterestPayableYearFive', window );">Long-term debt, interest payments in 2027</a></td>
<td class="nump">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Available borrowing capacity under credit facility</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount', window );">Lessee, operating lease, lease not yet commenced, amount</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember', window );">Other Variable Rate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Effective interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member', window );">6.30% debentures due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member', window );">1.70% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member', window );">1.90% notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member', window );">2.15% notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member', window );">2.75% notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member', window );">2.90% notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted-average interest rate of commercial paper</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember', window );">Notes Subject To Repayment At Option Of Holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LongTermDebtInterestPayableYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Interest Payable, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LongTermDebtInterestPayableYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_OtherVariableRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=mrk_NotesSubjectToRepaymentAtOptionOfHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072807822560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 28,745<span></span>
</td>
<td class="nump">$ 30,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member', window );">2.75% notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 2,496<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member', window );">2.15% notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">1,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member', window );">2.75% notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,979<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member', window );">3.70% notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member', window );">3.40% notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,738<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member', window );">1.70% notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member', window );">2.90% notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,483<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member', window );">4.00% notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,471<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member', window );">4.15% notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,239<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member', window );">1.45% notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member', window );">2.45% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member', window );">1.875% euro-denominated notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member', window );">0.75% notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 995<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member', window );">1.90% notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member', window );">3.90% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member', window );">2.35% notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member', window );">2.90% notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember', window );">6.50% notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 711<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member', window );">0.50% euro-denominated notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member', window );">1.375% euro-denominated notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member', window );">2.50% euro-denominated notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 526<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember', window );">3.60% notes due 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember', window );">6.55% notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember', window );">5.75% notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember', window );">5.95% debentures due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember', window );">5.85% notes due 2039</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember', window );">6.40% debentures due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member', window );">6.30% debentures due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member', window );">2.80% notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.75NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A215NotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A275NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.70NotesDue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.40NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A170NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A290NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A4.00NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A415NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A145NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A245NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.875EuroNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A075NotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A190NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A3.90NotesDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A235NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.90NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.50eurodenominatednotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.375eurodenominatednotesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.5EuroNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A63DebenturesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A280NotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845346352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other Assets</a></td>
<td class="nump">$ 1,346<span></span>
</td>
<td class="nump">$ 1,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets<span></span>
</td>
<td class="text">Other Assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,294<span></span>
</td>
<td class="nump">$ 1,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845215040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,294<span></span>
</td>
<td class="nump">$ 1,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072807944384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Environmental Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 19, 2022</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>case </div>
<div>Plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForEnvironmentalLossContingencies', window );">Accrued liabilities for environmental matters | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_TermForPayingOffEnvironmentalLiabilities', window );">Term for paying off environmental liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss', window );">Aggregate possible expenditure on environmental matters in excess of amounts accrued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember', window );">Legal Defense Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Legal defense costs reserve | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember', window );">Commercial Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | Plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember', window );">Patent litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled (in cases)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | Outside of the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | COLOMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_BridionMember', window );">Bridion | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled (in cases)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_BridionMember', window );">Bridion | Patents | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LossContingencyTrialPeriod', window );">Loss contingency, trial period</a></td>
<td class="text">1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyTrialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Trial Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyTrialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_TermForPayingOffEnvironmentalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term for paying off environmental liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_TermForPayingOffEnvironmentalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForEnvironmentalLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs accrued as of the balance sheet date for environmental loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13207-110859<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 55<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=6571209&amp;loc=d3e13703-110860<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForEnvironmentalLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14362-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CommercialandOtherLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_PatentlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837168368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Narrative (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072844299376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Shareholders' Equity (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MovementinCommonStockandTreasuryStockRollForward', window );"><strong>Movement in Common Stock and Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance January&#160;1 (in shares)</a></td>
<td class="nump">1,049,000,000<span></span>
</td>
<td class="nump">1,047,000,000<span></span>
</td>
<td class="nump">1,038,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances (in shares)</a></td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="num">(9,000,000)<span></span>
</td>
<td class="num">(7,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance December&#160;31 (in shares)</a></td>
<td class="nump">1,039,000,000<span></span>
</td>
<td class="nump">1,049,000,000<span></span>
</td>
<td class="nump">1,047,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MovementinCommonStockandTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Movement in Common Stock and Treasury Stock [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MovementinCommonStockandTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072844299664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares collectively authorized for future grants under share-based compensation plans (in shares)</a></td>
<td class="nump">87,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Quantity of stock options that vest per year</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period over which share-based payment awards vest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pretax share-based compensation cost recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Pretax share-based compensation cost recorded, related to continuing operations</a></td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefits related to share-based compensation</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of options granted (in dollars per share)</a></td>
<td class="nump">$ 87.10<span></span>
</td>
<td class="nump">$ 75.99<span></span>
</td>
<td class="nump">$ 77.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Contractual term of options</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Contractual term of options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842416016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 15.45<span></span>
</td>
<td class="nump">$ 9.80<span></span>
</td>
<td class="nump">$ 9.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">22.50%<span></span>
</td>
<td class="nump">20.90%<span></span>
</td>
<td class="nump">22.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072844283968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of&#160;Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, January 1 (in shares)</a></td>
<td class="nump">18,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted (in shares)</a></td>
<td class="nump">2,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised (in shares)</a></td>
<td class="num">(6,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited (in shares)</a></td>
<td class="num">(862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, December 31 (in shares)</a></td>
<td class="nump">13,719<span></span>
</td>
<td class="nump">18,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">13,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable (in shares)</a></td>
<td class="nump">8,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)</a></td>
<td class="nump">$ 65.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">87.10<span></span>
</td>
<td class="nump">$ 75.99<span></span>
</td>
<td class="nump">$ 77.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">60.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited (in dollars per share)</a></td>
<td class="nump">73.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)</a></td>
<td class="nump">70.55<span></span>
</td>
<td class="nump">$ 65.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">70.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 65.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838889984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845203984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested January 1 (in shares) | shares</a></td>
<td class="nump">11,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted (in shares) | shares</a></td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested (in shares) | shares</a></td>
<td class="num">(5,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited (in shares) | shares</a></td>
<td class="num">(1,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested December 31 (in shares) | shares</a></td>
<td class="nump">12,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber', window );">Number of Shares, Expected to Vest (in shares) | shares</a></td>
<td class="nump">11,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 74.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">87.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">75.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">78.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares</a></td>
<td class="nump">81.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 80.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested January 1 (in shares) | shares</a></td>
<td class="nump">1,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted (in shares) | shares</a></td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested (in shares) | shares</a></td>
<td class="num">(725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited (in shares) | shares</a></td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested December 31 (in shares) | shares</a></td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber', window );">Number of Shares, Expected to Vest (in shares) | shares</a></td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 77.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">88.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">87.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">77.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares</a></td>
<td class="nump">78.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 78.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072810998752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions to defined contribution savings plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage', window );">Percentage of Company's pension investments categorized as level 3 assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests', window );">Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | U.S.&#160;equities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | U.S.&#160;equities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | International equities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | International equities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Fixed Income Investments | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Fixed Income Investments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Cash And Other Investments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,094<span></span>
</td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">$ 12,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,473<span></span>
</td>
<td class="nump">$ 12,195<span></span>
</td>
<td class="nump">$ 12,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company pension investments which are categorized as level three assets percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DefinedBenefitPlanCashandOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DefinedBenefitPlanCashandOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072804001200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(753)<span></span>
</td>
<td class="num">(755)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(383)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service cost</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss (gain) amortization</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838122832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(306)<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(392)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(3,129)<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(918)<span></span>
</td>
<td class="num">(941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">9,094<span></span>
</td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">13,999<span></span>
</td>
<td class="nump">14,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(3,851)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(918)<span></span>
</td>
<td class="num">(941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">9,854<span></span>
</td>
<td class="nump">13,999<span></span>
</td>
<td class="nump">14,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="num">(760)<span></span>
</td>
<td class="num">(932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">(706)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(2,793)<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate changes</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(671)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets', window );">Other</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">8,473<span></span>
</td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation January&#160;1</a></td>
<td class="nump">11,575<span></span>
</td>
<td class="nump">12,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses</a></td>
<td class="num">(3,283)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effects of exchange rate changes</a></td>
<td class="num">(732)<span></span>
</td>
<td class="num">(678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherChanges', window );">Other</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation December&#160;31</a></td>
<td class="nump">7,755<span></span>
</td>
<td class="nump">11,575<span></span>
</td>
<td class="nump">$ 12,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status December&#160;31</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other Assets</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="num">$ (315)<span></span>
</td>
<td class="num">$ (753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DefinedBenefitPlanOtherChangesPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in plan assets, not otherwise separately disclosed in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DefinedBenefitPlanOtherChangesPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(9)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDivestituresBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDivestituresPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838825552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</a></td>
<td class="nump">$ 9,186<span></span>
</td>
<td class="nump">$ 13,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">8,421<span></span>
</td>
<td class="nump">12,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</a></td>
<td class="nump">9,081<span></span>
</td>
<td class="nump">12,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">8,421<span></span>
</td>
<td class="nump">12,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation</a></td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets</a></td>
<td class="nump">$ 948<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072809341312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 765<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">9,094<span></span>
</td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">$ 12,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">4,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">2,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,934<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">3,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">2,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 1 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">4,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,934<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 2 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,379<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">3,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | NAV | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8,473<span></span>
</td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,422<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,963<span></span>
</td>
<td class="nump">4,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 1 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6,333<span></span>
</td>
<td class="nump">9,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,957<span></span>
</td>
<td class="nump">4,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,656<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 2 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Other fixed income obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Insurance contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | NAV | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_FixedIncomeObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838061664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) - Pension Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">$ 943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">13,067<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">9,094<span></span>
</td>
<td class="nump">13,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod', window );">Relating to assets sold during the year</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">12,195<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">8,473<span></span>
</td>
<td class="nump">12,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers into Level 3</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Insurance Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">937<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers into Level 3</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets January&#160;1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Relating to assets still held at December 31</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases and sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfers into Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets December&#160;31</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_InsuranceContractsOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_RealEstateInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836190896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) - Other Postretirement Benefits - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 1 | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 2 | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Level 3 | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Developed markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Emerging markets equities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Developed markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Government and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Corporate obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">NAV | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_EmergingMarketsEquitiesInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_DevelopedMarketsEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_CorporateObligationsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072837097808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028&#160;&#8212;&#160;2032</a></td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028&#160;&#8212;&#160;2032</a></td>
<td class="nump">3,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028&#160;&#8212;&#160;2032</a></td>
<td class="nump">$ 1,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836507184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax', window );">Settlements and curtailments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="num">(472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="num">(472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax', window );">Settlements and curtailments</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="num">(424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service (cost) credit arising during the period</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax', window );">Total</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Net loss (gain) amortization included in benefit cost</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Prior service credit amortization included in benefit cost</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax', window );">Settlements and curtailments</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax', window );">Total</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845104496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Salary growth rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838853120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) - Other Postretirement Benefits<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Health care cost trend rate assumed for next year</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845104832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (157)<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss (income) from investments in equity securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
<td class="num">(1,940)<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic defined benefit plan (credit) cost other than service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OtherNonoperatingIncomeExpenseOther', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(681)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
<td class="num">(1,341)<span></span>
</td>
<td class="num">$ (890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (462)<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income and expense items not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845451856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072810959408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate applied to income from continuing operations before taxes</a></td>
<td class="nump">$ 3,453<span></span>
</td>
<td class="nump">$ 2,915<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract', window );"><strong>Differential arising from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(1,835)<span></span>
</td>
<td class="num">(1,446)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount', window );">GILTI and the foreign-derived intangible income deduction</a></td>
<td class="nump">462<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(110)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D tax credit</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Tax settlements</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Restructuring</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IncomeTaxRateReconciliationAssetAcquisition', window );">Acquisition of VelosBio</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour', window );">Acquisition of Pandion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo', window );">Acquisition of OncoImmune</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">$ 1,918<span></span>
</td>
<td class="nump">$ 1,521<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Tax&#160;Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate applied to income from continuing operations before taxes</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract', window );"><strong>Differential arising from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings</a></td>
<td class="num">(11.10%)<span></span>
</td>
<td class="num">(10.40%)<span></span>
</td>
<td class="num">(16.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent', window );">GILTI and the foreign-derived intangible income deduction</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credit</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax settlements</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges', window );">Restructuring</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent', window );">Acquisition of VelosBio</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent', window );">Acquisition of Pandion</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent', window );">Acquisition of OncoImmune</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total, Tax Rate</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">22.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Four, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Business Combination Two, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxRateReconciliationAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Rate Reconciliation, Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxRateReconciliationAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842396128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Transition tax for accumulated foreign earnings, liability</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets on NOL carryforwards relating to foreign jurisdictions</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic', window );">Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards</a></td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="nump">$ 2,412<span></span>
</td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefits relating to stock option exercises</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Favorable net impact to income tax provision if unrecognized tax benefits were recognized</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties associated with uncertain tax positions, expense (benefit)</a></td>
<td class="nump">54<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Liabilities for accrued interest and penalties</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember', window );">Income Taxes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent', window );">Transition tax liability, current</a></td>
<td class="nump">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent', window );">Transition tax liability, noncurrent</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowance on foreign NOL carryforwards</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="nump">1,201<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowance on foreign NOL carryforwards</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="nump">$ 977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service (IRS) | Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service (IRS) | Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Unrecognized tax benefits from adjustments related to examination</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets credit loss carryforwards and NOL carryforwards domestic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845475024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Income Before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="num">$ (3,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">15,433<span></span>
</td>
<td class="nump">12,025<span></span>
</td>
<td class="nump">9,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from Continuing Operations Before Taxes</a></td>
<td class="nump">$ 16,444<span></span>
</td>
<td class="nump">$ 13,879<span></span>
</td>
<td class="nump">$ 5,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836927872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 2,265<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,164<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">57<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">3,486<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,510)<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="num">(605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">71<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(129)<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision</a></td>
<td class="num">(1,568)<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="num">(566)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">$ 1,918<span></span>
</td>
<td class="nump">$ 1,521<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845173936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income - Deferred Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Product intangibles and licenses, Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D capitalization, Assets</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory related, Assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Accelerated depreciation, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Equity Method Investments, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Pensions and other postretirement benefits, Assets</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Compensation related, Assets</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits', window );">Unrecognized tax benefits, Assets</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards', window );">Net operating losses and other tax credit carryforwards, Assets</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, Assets</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal, Assets</a></td>
<td class="nump">3,605<span></span>
</td>
<td class="nump">2,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, Assets</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes</a></td>
<td class="nump">3,006<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Product intangibles and licenses, Liabilities</a></td>
<td class="nump">2,575<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventory related, Liabilities</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Accelerated depreciation, Liabilities</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DeferredTaxLiabilitiesEquityMethodInvestment', window );">Equity method investments, Liabilities</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans', window );">Pensions and other postretirement benefits, Liabilities</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other, Liabilities</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Subtotal, Liabilities</a></td>
<td class="nump">4,298<span></span>
</td>
<td class="nump">5,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, Liabilities</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Taxes</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">3,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards and other tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxAssetsUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxAssetsUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxLiabilitiesEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxLiabilitiesEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838467840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Income Tax Authority (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 3,239<span></span>
</td>
<td class="nump">$ 2,412<span></span>
</td>
<td class="nump">$ 2,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 1,348<span></span>
</td>
<td class="nump">$ 1,201<span></span>
</td>
<td class="nump">$ 1,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072838038496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance January&#160;1</a></td>
<td class="nump">$ 1,529<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions related to current year positions</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions related to prior year positions</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction', window );">Spin-off of Organon</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance December&#160;31</a></td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="nump">$ 1,529<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072842354192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Income from Continuing Operations Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 14,519<span></span>
</td>
<td class="nump">$ 12,345<span></span>
</td>
<td class="nump">$ 4,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Merck &amp; Co., Inc., basic</a></td>
<td class="nump">14,519<span></span>
</td>
<td class="nump">13,049<span></span>
</td>
<td class="nump">7,067<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Merck &amp; Co., Inc., diluted</a></td>
<td class="nump">$ 14,519<span></span>
</td>
<td class="nump">$ 13,049<span></span>
</td>
<td class="nump">$ 7,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average common shares outstanding (in shares)</a></td>
<td class="nump">2,532<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common shares issuable (in shares)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average common shares outstanding assuming dilution (in shares)</a></td>
<td class="nump">2,542<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.01<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (in dollars per share)</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from Continuing Operations (in dollars per share)</a></td>
<td class="nump">5.71<span></span>
</td>
<td class="nump">4.86<span></span>
</td>
<td class="nump">1.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Income from Discontinued Operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (in dollars per share)</a></td>
<td class="nump">$ 5.71<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845988288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072804141232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 38,257<span></span>
</td>
<td class="nump">$ 25,404<span></span>
</td>
<td class="nump">$ 26,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="num">(949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="num">(656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(446)<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">87<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(359)<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(339)<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="num">(441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">46,058<span></span>
</td>
<td class="nump">38,257<span></span>
</td>
<td class="nump">25,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">144<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(775)<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">163<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(612)<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(71)<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(2,743)<span></span>
</td>
<td class="num">(4,540)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
<td class="num">(633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,408)<span></span>
</td>
<td class="num">(2,743)<span></span>
</td>
<td class="num">(4,540)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember', window );">Pension Plan Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember', window );">Other Postretirement Benefit Plan Net Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="num">(446)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember', window );">Pension Plan Prior Service Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember', window );">Other Postretirement Benefit Plan Prior Service Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,830)<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
<td class="num">(1,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(584)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(603)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(603)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(2,433)<span></span>
</td>
<td class="num">(1,830)<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4,429)<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin-off of Organon &amp; Co.</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (4,768)<span></span>
</td>
<td class="num">$ (4,429)<span></span>
</td>
<td class="num">$ (6,634)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanNetLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanNetLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_PensionPlanPriorServiceCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrk_OtherPostretirementBenefitPlanPriorServiceCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843193280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072809849456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Sales of Company's Products (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 59,283<span></span>
</td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IncreaseDecreaseInHedgeRevenue', window );">Increase (decrease) in revenue hedging activities</a></td>
<td class="nump">810<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Revenue related to the sale of the marketing rights</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">57,555<span></span>
</td>
<td class="nump">48,322<span></span>
</td>
<td class="nump">41,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">52,005<span></span>
</td>
<td class="nump">42,754<span></span>
</td>
<td class="nump">36,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">20,937<span></span>
</td>
<td class="nump">17,186<span></span>
</td>
<td class="nump">14,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Reblozyl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,897<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">3,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,135<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Dificid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">169<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,684<span></span>
</td>
<td class="nump">952<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,813<span></span>
</td>
<td class="nump">3,324<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,964<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">2,118<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">5,568<span></span>
</td>
<td class="nump">4,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">2,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,728<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">27,206<span></span>
</td>
<td class="nump">22,425<span></span>
</td>
<td class="nump">19,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">26,811<span></span>
</td>
<td class="nump">22,159<span></span>
</td>
<td class="nump">19,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">24,989<span></span>
</td>
<td class="nump">20,401<span></span>
</td>
<td class="nump">18,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12,686<span></span>
</td>
<td class="nump">9,765<span></span>
</td>
<td class="nump">8,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Reblozyl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Dificid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,822<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">32,077<span></span>
</td>
<td class="nump">26,279<span></span>
</td>
<td class="nump">21,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">30,744<span></span>
</td>
<td class="nump">26,163<span></span>
</td>
<td class="nump">21,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">27,016<span></span>
</td>
<td class="nump">22,353<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">8,251<span></span>
</td>
<td class="nump">7,421<span></span>
</td>
<td class="nump">6,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Reblozyl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">3,792<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Dificid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">79<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Pharmaceutical segment | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,728<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">2,628<span></span>
</td>
<td class="nump">2,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Animal Health | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Operating Segments | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncreaseDecreaseInHedgeRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Hedge Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncreaseDecreaseInHedgeRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_KeytrudaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_KeytrudaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RotateqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RotateqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_Pneumovax23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_Pneumovax23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VaqtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VaqtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrevymisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrevymisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_DificidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_DificidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrimaxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrimaxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NoxafilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NoxafilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_InvanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_InvanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CancidasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CancidasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LagevrioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LagevrioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BelsomraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BelsomraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LivestockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LivestockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072845207296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Consolidated Revenues by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 59,283<span></span>
</td>
<td class="nump">$ 48,704<span></span>
</td>
<td class="nump">$ 41,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">27,206<span></span>
</td>
<td class="nump">22,425<span></span>
</td>
<td class="nump">19,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">14,493<span></span>
</td>
<td class="nump">13,341<span></span>
</td>
<td class="nump">11,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,191<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">2,726<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,614<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,582<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 2,568<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836173648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(962)<span></span>
</td>
<td class="num">(806)<span></span>
</td>
<td class="num">(831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(2,085)<span></span>
</td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(1,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="num">(1,824)<span></span>
</td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(1,669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(13,548)<span></span>
</td>
<td class="num">(12,245)<span></span>
</td>
<td class="num">(13,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(337)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">16,444<span></span>
</td>
<td class="nump">13,879<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">38,815<span></span>
</td>
<td class="nump">32,927<span></span>
</td>
<td class="nump">27,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">36,852<span></span>
</td>
<td class="nump">30,977<span></span>
</td>
<td class="nump">26,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">1,963<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before taxes</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(962)<span></span>
</td>
<td class="num">(806)<span></span>
</td>
<td class="num">(831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(2,085)<span></span>
</td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(1,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="num">(1,642)<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
<td class="num">(1,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(13,011)<span></span>
</td>
<td class="num">(11,692)<span></span>
</td>
<td class="num">(12,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(337)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SegmentReportingUnallocatedOtherExpensesNet', window );">Other unallocated, net</a></td>
<td class="num">$ (5,651)<span></span>
</td>
<td class="num">$ (3,031)<span></span>
</td>
<td class="num">$ (4,394)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SegmentReportingUnallocatedOtherExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other net expenses not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SegmentReportingUnallocatedOtherExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072836550992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details) - Operating Segments - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity income (loss) from affiliates</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity income (loss) from affiliates</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Animal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity income (loss) from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Other segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity income (loss) from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140072843930752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 21,422<span></span>
</td>
<td class="nump">$ 19,279<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">12,891<span></span>
</td>
<td class="nump">11,759<span></span>
</td>
<td class="nump">10,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">6,993<span></span>
</td>
<td class="nump">6,081<span></span>
</td>
<td class="nump">5,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">857<span></span>
</td>
<td class="nump">737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>mrk-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrk="http://www.merck.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrk-20221231.xsd" xlink:type="simple"/>
    <context id="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic48140e5f2c345cd8c115278efdfc4d5_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i988d9636bde7433d8e2793b8bbe786ff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0af637dd40e445c8087ffbd9b3638e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e30d57aa7714c7c991d4956adf482da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i870984a7a0814cf9a460c7a4b331c37f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i34c3eef0e8e84d89b879da53d7b2eea5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8390537a2d14419183a1bd3184b81223_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief9bf241be3f43c8aac25c903996f2e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3278c06a03cc4b83ad0c695bac71a99b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibfa7328e43b745528acea4fb982c4641_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50a206ace8ff4b2b880a7d891b6470c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia197d01df12640948153fd9f84a852ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7bb557eb99a549468966b5c77bdf145c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i757e7f21bc85496da119ddd7169fc883_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieca83e510fb04e31bb09eba119b9f8c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76fa2929d2f845298f21dbaee7f2ef16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e85ab6516bc49b78971f2a3b5bdf41b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8308747617614e9eab0ac29c4014c53b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06a03badfaf044d5abe8434be9cfeda8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07bd86cfed75419480323eb478cad36f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f49f49133634761b181692557d66dda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77dda1a9a6f4400c931bc6647f046197_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e06bfa03d5c48d190290cd1a81579c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21cb44e6556045cc99f6b8f0af62b975_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5efd7e6396194280b6782fba989ef826_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33db89af09b04ff88b03f0b7993e3646_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32922e48a4134ee0925f14bd1c083d4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i542103e76e6741a6805402bb88262b54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i170384be3a654d119874ff6b7ed2eb92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d8637c5e12649be98c7fe608718e069_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba91acdcb37e4a5d8335bd645c29a624_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7edbd57c4cf745c49a7f15beff700c5b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i15342adbb5e246fdaf6be1f7d6f161e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i074f335e3eb646d3a641ffed1cc54d29_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i326e10191d3348dd83075e847b9e3840_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e37f8c9ec504794ac6b72298c935735_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb5bb04f307f47dcb79f92a26d5a4eb1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f1e6ddf39c24d7f843d5f7b097b9c69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if945586aba2d4519bdf8f10667672306_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf11a2d764284028938a06f7df969c24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e6bbb5f87c44047960024c6b0517fd6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2af1368f91147fab0b3d00e67b4afa4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i152d7547c40c49cfa09fdd72d4292d05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a2d859521db4ed99e9f6f0c3c55169a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i90ed8021173448b0b3372bcb951af216_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6acc5aab0ca4602b1c723258ab0abe5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3dd256716df46d1b2aef36eb21dc58a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88b53a8f47684df2aa5a27b6be330095_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0248176f895b46cfac11e4d46217846a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie24801838a2c42948246ef5a5409d8e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id9b39a79d65a4ca691a37dcfe4922939_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cc952f1b2f2496fb3e7cb831f0dbcc7_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="i05ee48b166b44fbaa88adeaa6cccbcca_I20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="i91a08ec51d834fb4b5ee3a778a3ddf08_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="if7b56448c76a44d38b534e9b53205ce6_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i3eb2867b2dcb413caf68f19d0cff8a38_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="ibe247952fa8f40f48f9d542a2f0c75b2_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="id0e03ea81b4d43bc833a87aaff997b7c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id47f3aaa34b04200b41ca2809b9e4542_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic18668b15f364b13be1b1dcc95030f0c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idfa6366e1ebc4503ba80ecd66a39f955_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8d0002590484feda2fc8325dc655c8b_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="ie7668e0129294bdcbf2855d7d0ee191d_D20230201-20230224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-24</endDate>
        </period>
    </context>
    <context id="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="ib17138b844f348b1a50f35c8ae1978e5_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i74aa3e82c01b42c6a7419c59ba514f25_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrk:RoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i44db6d09190041e18d6b1b29eb14bb9b_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5db175a81b9f43c1b0e8d6bbfc9cad3d_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ie53196e6917242ea85419903828dbab2_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="if640c54f5da1491792d044ba5742c097_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i4fffd33d73024f8cae603f326b7f1104_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="iad647dc2d4aa4b91a0013d32ad01912d_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrnaTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id70dba7305144817a9064998df5667d1_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i0a30e3c742444082976808cee5c16655_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ic774cbcb70554e169b26550e484a0585_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i6296f4bad6634365be938b368f535a4e_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="id8672dcf41ce4577b1f1b821640eae58_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i82b90cfcdde044b7a79d4c12ce3af129_D20220501-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic68d62a9a6db4df3bf89fc5ddf7583e1_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="ic0cf91de3d1d4c32ad48e6066885e0f2_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:FirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="ifb1eeae45b61446697e00a09ff97862e_D20220501-20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="i7073d5a9d7f24a98995d80fe479f8283_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ifcf26d356d3946f4a878afd16a2a4024_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i785539df716f4bce95f1ef45066b0e36_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ic1f1de3723354ed1af5631e0fd919013_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="if030a4536a8047a1a585275c17092ed8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic10f48c8ad804e3ab3fb873838f81931_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd86187433f44eaeacfe4a3eb6a5201f_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="ibfdc0787087a47d68adfea5ef5195bef_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i53d43b0dc8d742539a81797aad2c7dac_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AcceleronPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i49e02de6be3a44268b77d9db477d3905_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ifb1df4caa295436598a3f45d73add47c_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="icaad804e1a1445199d9e01dd42edfc61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PandionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7dd421f3e24b48ab92de4b4ccbc4ffe1_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralAndInjectableFormulationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OralFormulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:GileadSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InjectableFormulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i8d99c64b435b4e87a51ff910dece08c8_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="id251d0d82d7944d495c9d8d8fce4e269_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i88f4e389e77641b6b46442285a84c3f4_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i3f065c4f1db344d4862bd79ea44a07a9_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i12a517b30e874a00bab97ff6980aab5c_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied63ffc9cee949b990458159c3946f6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabf1056dbb7047808e6072640db0a6d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if24d4378188a4e47a19056c597f67512_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:OncoImmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d7e45260eac48ce932cb909af8a62bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a3283ebb19c47db98e2743d3caf9d25_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7357cac30444434ad7267d089052bf5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a994069745948e3b6a58225dd2dcb81_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cb16d00cf524ce297989b91888f968a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib083b0720a7641e5b2ed5b897cb5a1da_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if015b711a0c1463280f53a5f53f0095c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i283a4724505a457e8167cdc1100bb0e8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4da143af2cbc4550b7cd444b2d54ff99_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie84d4260b7474298a9608482089dbef7_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic456a004e9b54fa88ffab861b40c8472_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31c7604e87594ef485dd05502812fe51_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c949b3574474579a0c233dda2bb577b_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic69078b53a814524aeaac691b26539ee_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9049cb40e504958ac9e397e60d37fb6_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ef894740f0b49e788276233080a4067_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0b6e4139824b4eefae9cfeae92fb9040_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ic59c3148ee024ea4afbac1489fd25b72_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="if6e2e88bfbbc44c8886ee11658c63510_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i81bb7eeadd574ca5b21e9826619b23af_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="icad0f525031d46d9be68d02f33cb1b6e_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id02a0b579904410ba96e69084e79c5b6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i803562aa74fa4ea3891ea730ee3b8ff2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b0c88b077dc43d395324479284c52e5_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i58fae9f157404c948f717699cc8b6041_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd2616ccfb4c414f9da26e3832020bb2_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ia4b8f860929044a7877bf8a6ed4c2c2c_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ie44bffe9a3144afd88ce155275642a73_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="ifa5431df1071454ba96911ea2466090d_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="i611105bf33cb4418b7e1bae1d7e7ea5f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8bdf7308172b42feb5eb31dfaf5c1b15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9cd932eaa95a4c7e99fe3e6f21d65b0c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i259bbbafc4fc42dcac9e345225999d94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i101468e37b9d4cf382b7335393246678_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c7aac3504dc4b288b6ecdf3ff0688b9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8deae556e5124fc0a386203ac8730e23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46a9b57f7713451ab3d958cb0b3c227c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id4bb57af17fa46da951221280cae2d61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd326598790045f6bcc0f44c24e3b67f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if29b92e874b140df8ddfc7bb19c76d76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf71a18afeee4bdfa2f728eb5087abcb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic0a13a1700a349c494acb5ee8a7c314a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i01cb97bb488247dca17be49d7a0fb045_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38b3ed6377c5412fbd503a5deff1c930_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ebd2bf240ad4502a0f8eb75120c4db4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8026cfa395c34fc78f7ffb4639e7cfd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89fa20a8d8c344b79257be206a940dc8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3721b0ead6be47bd8aaa1248657e3dc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife46a1fcf6064f56a383f3b0d9487ba3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56a887176a9241c998829941def3e75f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i36c243b4cafd413ba234033925c3b3cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ce2f27604dc40d8b3dc414670f4a61f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23c8a34670be4d2f852e82ad0329e859_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99ab1b65fec2429e9e9fb8b77ca7676c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8073582f227c469789fa05dbe73664e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0cbe6f30ebf448ca8dd317840d491e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f186ca6621243c0b67606ff25b17513_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a6baf80c0d6487ba768a3bf8d2eb9d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i477ac519583c49c4a85dfaec2d9aeeb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11a011afad64440c8c568e59dfd355ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9171e04635a4e7ca60a79f50cda5a90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2370a20f6b9477d9190b59f039b3caf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie86f8b6b06284e30a88d0cfda2123b04_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia743de15853e41f3b910d4cf1122df64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i35980e373bed42f38371f148fe8ecf3e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09d51996c5b14f1cb72dad54b7d4d76b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1775ff52a4f4c97a6d68baca5ddf177_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ab1b0334084476e98316729e3a8c112_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibfc3245aba5546e0b11f27c281841fce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4c7f305f94d485faf5c727853db7751_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9c533dce277413ebf7c86906b5c8f94_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46a865d1c00d4bf6b87ba7cfb8872940_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ccee6352d064f868e634387f9b6defb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e2ef9288be849db9f064efef46fecd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaaba9c09c27c48bab00412147d7b1bd5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7660095e034c4216aa9276e5feedb36c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76b2184ceafa474a9e19170e8fb42f5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a750360d1484fdfbcaf406737a1903c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i164d9fadd4974909b666bfa2279e3149_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia28b73d8d0524599afa19cadb0b0e70a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6ca606083fe4ddabb3985078aa79999_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic5ab13a91e6d41409f02aa3644bb33d5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09bd2e76e1e742df96a5837cbb96ed58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e3ec7d905d742d7a5ff17c57e5fcbf2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30cb0bc5ac844767be8fb1d138e6664b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i846e3e5062424fcb9eb3c09ff655d70c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7065d7527cac47058269d8ba6fac070e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie657eb0222df4887b09402876cce71d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3416ec93d1a492fa1f433c26d04679c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5de854d06ac4eeca3f033f63ac8cf18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bd89ab9867a451bb7d8f5e7dd23cfa9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5bfe141a54941c1ae25d64fbabae891_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i855e5afb6533435a88463827fb0e2179_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d25852fad3a41db9c665d20c687a9bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98f6db34c320474f93fc442eab2cae85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib730f07be57a4e6abbd8c475c9858a84_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ba49d74de774a7da3dd6fe57759ddd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia83aee4fe2eb49e79b304d069fa8ad26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i732d1a8cd545457bb9404f007a3ddbbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8bafd4db40a4019a8844632901e67e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3a3942c4b5040c183b0a32bce8ccfc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i379f2e061e03444ab72ac31156ba6076_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i890188202bc349308f5fddb70d1ac474_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6d323bb0936465fa024e1457a0783f9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9134617e9894461384c3736c75213497_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8cca313b49524b8880414378a9bd58a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i465e0e2b26a34a65a2ceff807a69c161_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i45ceb7081ad348a5b332291f5eac99f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d83c83f0aaa41bab160e17f7828a23c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4211db3a27fa41ce9ef8afb548f9103d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1754d2b50304b08aa2cc44626f808d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2440fcb0b354debb320abddbe888325_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i864756958f464b8baebe379049606e29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i601ee311bfa347d0b5dcc37af824a720_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd816c120f854e69b9a2159aeed10f3e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie947e36c8b7f43249d8241cd508c5350_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43ac66950463401192d572c40841d4cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f9b197fc4714188b0f988ab63603db4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i157fad50a46146f7862f955f23ac964b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70782495edd949faa59537a7ff4fad68_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32e2939d44e74e1299e632f622332de7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c327eb0afa44aaa8b041180a9931985_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice4c5d96e848446187e39b06993aa908_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb42b703c354447eacb3e957b27d7ec1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67875c460a8c4de69af3791511d877db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2d4b8387cc44522a4d608929cf3f19d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e2f8008c6984b9c8973be53aa0971ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac7e27beb28f433687f6a328ad49420e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4e6787b2f43c4435bb7b7e0c9b5c5a48_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1d8391ce634476c8543dbb3f18f43dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc3969c4d6864a2da3a1f1ed7fc44512_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic4460340464041e0b1e1151e1bdec68e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb510662b9e944c6a56938d27b6835b2_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="id85c300cf38349adb26180577979e5c2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3592e3674e13431aaf91bd67cef2a754_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7552297483f94fa5b4160dc0db014d06_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4eb748e33a7a454fac71c562342ce760_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic45c2b8530f9432f800bd21578f8e217_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b231d9fdbfd40ae8d6fe71ed37de345_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i30469f7c418b4bd2a85fcc554df58178_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia817beebd6444eea99db772afc066555_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i864a963e97a44b5f8189640f9cb94d43_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib79c6477e2f646dd83409e81121b5a29_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e1e5bec9c0340748f3a3782a3f7fd23_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i804346c2237043e084b1afb341655a9f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3b44b6cfd4f4a8b99ef33bcc3c06df7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib7d722d97d3e436e80d290bc86ab1496_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2335ada88a2240b6bd6252e8fa8510a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib615d69119594f11b401cf972b449c5d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i706e14a3fa394260932acb94f50053ee_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i015fe5f90bbd4e93a29ffe724e90bfd0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3c3521eff5d4d78bed2d56d42e3789f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc8bfe07436149a2b63950679699d1df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c693f6dd72a403f89d6d2355a3b1c83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7cd884e75e9428f87dc9ff260d2f3ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibaa6d39939da4e91b837b366cdef3966_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i975b430806c14e4dac19b89356167bc0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba21ed671f2448ceb380d10aa9f40bd6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc1ca9c45f2f4c0d8e7d64701e4cb36d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0562404e8e0e4465a752940a1235ee59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16a86b0a2eb94ae1872813f8188edae8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54629a1dafcf430fb0b2f74327fdd6df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d9a9c572051413cbcbfc3a23280168d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice7363f8460840bb83ffb6ca99594560_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1decc07eadc24124bed0dd2deaff444a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibedf7a5f7ef7456586ec0f021a1d0f3d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3327a1e7655544f3a7d9953a5234e2fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b6eb5443eb44c5f83120bd0907e38cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e08ad749ea24620a73bf3de13d4ba83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97f4ba5c710647b8a25a7267abdd6754_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51f9f13e5ade4b49abc89a6dd9a5b2b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia78f45a1853841d69480601600ad30b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b6c21a42378451b9dab85a8423576f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98c6fc33bcf040b88cd4cce4a3bd53e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i720ba97855924cd9b21a8b29de3ba988_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94d6a7f93e314fc384e0b1149d0ae9eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bdcd5cba5f543dbb50dea0289f3ab2c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4983cbf854e94eceae83083147be86a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i972eba5067f8445596ed5ff359126657_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88144043844d4f7eb9f8cde0124c59f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8a80bcbbfa39470ab7a14b86c6fa70a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8adcbd8025954472931113ef2fd8a95c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0aa3f0a78454591b3695e1829428150_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i074bc4aaa1734fa79f0b7f5045ab90d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90b319f5a70d43988516fed4f52eb15d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c66f3b052f74fd3a26dc81f448660a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3861723ccf964ba380c10a13117f1a30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i235bd559e79d45cebeb01c3aa68198fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5164087f50654464a6032ddfbb33b657_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a75ee9f06394ac58129ef3c07183626_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id196364c06404f1e93dce678dce64cec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i446658f48ca64a5595891b7cc6692950_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6bca802b14ca406fa68447bf048b3c14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37f49dfec5954846bc22018691bd0081_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5838f63c0490478eae7fa5bddaafa36d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieead02c0663c47e4a289f16813bc7306_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5160bc069bcb4a1386bf4185147cc88d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i140d4ac54a9b4fafb92531ca8b76c69e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2dfc74fe5a384595a4c97c4a0eabb454_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i702a5a6064884c78964fb0c841f02433_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37bec909d9be4e24b3a7a85153c4ce18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4af38eda5034b1d8ed205026267630f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf14eee6b5fa4782a433bc13f07577f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c95ec70187e405ba677c24678202bd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia218fcd1db1141ed905f718a91fc9422_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa89acddce894ac08beedd53e127e143_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07e7539f63d64ce1a5c2568c9999a584_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20cd4c7fd5f14851a86d5a655db5663c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50be94d522084d82a3e96d121db4b2c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1afdd113c40545adb3ae03acc9c4e126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i782b995c5324440982290223b2cdddac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2677274a350445afa69443c36f4a89da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2c912a0937747a8a1ae5182d756b260_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i350a79055507478fabc61583f11e2080_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc29185c1fed4990966cf824e4597298_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdbb1216db6a47e88141c7169ea7875f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6226dc468d5e40ba93e5e688a3b0e650_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0a0380fe0b24b768f534f7027ad8b63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90271718d0194ea79773a039096567de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie96270cdbd7b4606af8ee569a6ed934f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91b986dd8de2458386abddf2a2a64bfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19c9b82f66ad4f6498c0bd7bc43fd253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8101d6016e644c484984a91964cd5fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79f69e11c219486faa68b50184be96c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c1579987fd245a6b9ae265038125773_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i948c5f8c4b584db887310340bf216160_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib90fcefa805241de9e12f2aebc441fc2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i51bfda27ae2b4cc3b94f9a7440352c5e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98a279e868ca477a849941852602f9df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c7a1215a0c049cab8f08a9594ad42b1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i68492993011c48bbab8080844004db56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3510a74c551e449094abce6bec887425_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id60f9472b85e42f18f616225451c542f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i917d2ebe84824a7586c16f24fea495cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28fc358415004cc2a37dd74e64f8d2aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i581c1be0a6984114bfd52dffb52aa7b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5eb0ff4d140346c8963217923368c0ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35cfc0da81f545a398181fa07b3382da_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22c40b5faace4195ac18bb1e51000e7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i759f47c95ce6483d905aaf752e1639ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9644f4dc6e546f19f3bdc2c69c7d465_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b9830a106f140a087b9c78bbfbfeec5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idedfb451ef964827840ce24bbd35a732_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i486c2ecbdf8a41108c15e0a511be9082_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5aa72455647c4823a7fc65aabb141a7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ceb209deb764a8782b3ad355afef10c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3107fb4932bc4642aad4cb642bf31a32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7649d0b0708041d7bd6500bc0db7bc79_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2236bd4b78d4c168553c865384cc010_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79e23e28964b402e8ac69b9bf7d33084_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if90327fad224463b8fddba51b5516717_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a3fb85e46d14551bb0ef34fe80bda15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c48d4b8b6ca4bb9aaba77abc6391c4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bc33cb4b50d4093aaf63905d920b1dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie43420ce5f064a3fa05fa2e2380d5539_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6b0d4e6828342e7a26da27a695dcde1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57a4692f6adb46a1a2793a6f353cad90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09ac1d9076f34481aea8771778d0d812_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4aa8f87dfa5498d867f4797c0697444_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i74466407315d4f298256e0ad5a5af77f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb3b3087926f41c1a474ada3d5d72501_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i459db40bfb714e7ca275d3cd836dbbbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic518fb07b7674674ba2208e212142086_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3452cdca4b2f46d194438c26b62c02fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieccc452488d6486c8350f571676063d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05de9c17c11d43bf908b28fd7f8aa30d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie80636fc2f0a4f8a946fb3e439e28f9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86dc918aa0f64dcebee5f10eb3e80c7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa3f2dea94cb406697c29216f2be9c81_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i193fc51da4a7485394ab28fa7fa5e658_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08c7da7d4a5749148765d47894aacd5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4015a3ff1e184474b72f68389cc87127_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e96a196d04943a1ab350c5e9d0cae4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic62406c431da439e8e81a3791303ddb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f4177637bb44c09bd64388d2df9d922_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0220a923758c4bbd97582689f870643e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba235620efd64c3b8e1fc94776a989c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52ccb5ece8414e37a06261c0cde991d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5e340eeaa5d4f1181e43e1abda96454_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2601263e66d45e19c1438f48a9f0aee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44d8e82b21924b988d762ffa1a17dd8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7899bb44630417a973d878c81948748_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60e8c59227254e75bd6682c05eec4d10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifae7d7fb2e5a4743961396935e496534_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8bc30062b2684131ae471612e9872ee9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5dad97abcda4f9fb9cdfaae3938ec50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85d91b9f5ded401face6465d1b7b9508_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i440ab66872cb40a6b47d2221be7afb0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i563ada8aba96419d844e481095ea53b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i445a31ac64064f36b804f06383d1bfe0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i746270f61b8f444fbc5e79bbfa2f5d0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2dd8a5476f7e4f6bb0e3488f27974234_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc25519774c84d2b8046b1745b6979f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78bb2725e97d486ba1ea5b683ff9e12a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1027036535d44087b6a7e473c3fdfc32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85671c3d685a45d797f772c5f3312b8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9a21b3709dd42128d8264f2a5257c18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83d6a9e2a4e04b1bb46f7d1cbcc4e416_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i150ff06d48a9497eafdf58dc03d8e518_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b040b0e94924f0291cc48a435447245_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifae251a0ecc04d6b9054f018ef917ce8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief83301bd6734273beb742bcd0fd8b21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10131b7117eb4770b663e21fa15b98c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a0a0f8c7fc64e1ab6f955a741b7f056_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd64d4dc46a44fca8aa2e2d65f22ec14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94a54e6f42254f4a80ac3cbfedbeda25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1291079726f54d9482e915764e3a28f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9feab63c1b64ebb859b0a44c8c0fe14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4cdff6731374404ac0a075ce6ab9b79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a379c20670240a9b25634d9750efe8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibaaa3375ce0c4bcfa1287f588b3077dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34968f94170b4606b1bd3134b883f9fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac658e91c1524deea0992c47f1872ea4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1db832513f3d41efa179eca26a0e6899_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b330f981b284955bf6356724ac55d7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c20eb419e3840d885552c3057349c91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19edb02be5e746299724e213abfcaada_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd18b2833711484dbc7ffca9c326cd7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib24345a0ff484deb98e10e4105afa5bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36627656f09a4021bfe46b0d8181fb2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4296dad71f474d0fa88ccb38226b4f44_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd71198dffc74a99b2e0c368d96a14ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa8b5a245d4f455da78fcffb96a7508c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ba9f35c12c54ef98f07fea573c78bd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6da2f157b824f52851dd9e978b0eeff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c08e07575e9490cb5a8f9cf49bbd641_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib444129703be4af2a20054714bf0ecec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrk:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie56c0f796a90447b8097ae8d7be632fe_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i567c0acaaf20420daa3260e2b7668e47_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i022aa53b13d84e14a5eedc763cefd54e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i925bfec8ab2743348c69f615eb5a44fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if61807d83368439782aa2842af89525a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99ba9b9962fd485ea74e2d2c10d17307_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cc9093833ea43efa72b1bc502bed4da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66a4d286567e47718bed1dc0ec61c06d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9a53de261014635b46dff37511f8a28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8ab8ac0847f4ea2aec591d7ec276bb9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70c3ea6a6aab40a686a75e01c429aed9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34571e3bf0a24f04a885f828cb94cfd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5bf7773e95f40eeb049ba5fec44f5e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0140812b0eab469a965b4b15301949bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94cf60618c5e4aaca021c753bff1b8a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id57473094cd042cca3f71ebfab8a12ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f2e09c593c942af8e3407a887af82d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5be0c233ffc9447ebd088af22f69de87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie233154d86a14b82a3feeae38dd79d18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6138bf37696649a6bd6e971b74356d51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i213276daa7804281bc7394485ab71d33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i460644d8e3e54a79b686e69c684cec5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibace400774984c3dbc9f9ea52b1e0e6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie47add64e2cd40f998158d2c98eb4042_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5fbb5dd4448e485981b74dc5719bdbc0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7debb2fba50146bebb232e6e8e26d1e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i323a82a0676e447aa0ee30bbd32c0379_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4629f93a6cb342d7a2adcf465132267d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice62906f5f13486296cfddb3eecc61f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a998c05c25e45d897132264cd7393b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AnimalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2eb0aca1931486da121627e2b099a6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SotaterceptMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf54a72af67e45fda2e3769dc2ee1bbb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GefapixantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0ae54ef35294062adb30816c2eba9da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie57ef40fb83d43d0b204010eab10ace2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3518262d4c349ecb316b3c7dec9767f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibc70591306cb403fbd97773b449e9870_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc9e424e32fb43b8855afaaf0a1576b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DerazantinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d0e372671334e94bc77b2dfc17299c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21861da46868461288c97e4ab76ae0fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NemtabrutinibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fda3b4d09eb4fa583ba37378f5415c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bb0b8ac7a6746a7b99550c3290a6912_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">mrk:NotesSubjectToRepaymentAtOptionOfHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a963f7bb7df4286b00142ee3a4b4163_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b81622562e043619ce4097e5de6538d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedd526ebaff749a5b3eafa6e57a81046_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84a1b935714646a28acc02e8da2af399_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.75NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78f6217a86d54e6b955c5c6727e00fbc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i233cd0a66f3a4e1293ee7180976a6a9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A215NotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33401fab91ba450bad968abb1f3afcb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff1742d1bcca4273b22d4c2ec6e6d4d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A275NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaaf0e9d91b9c4abf8d628b3c4bebc216_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic09e345560f6497791f50eb94308c444_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.70NotesDue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fb3e5f968ec4dd8825fd0c8bb6ad4aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9dcfc6075c6a4565a9f8554b61999abe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.40NotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i739a3710a3de4d7ebb81ef763fccbdea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib470cd6f92154bc78779d5a55eb10d70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A170NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1c794da2c364cef883126c44ac0eadf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i822efa59fe3745939a910b1611d44288_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A290NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92399f31232247e0b6bbcf5a6a089235_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5b551b1b91d472893ca0398491a7cce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A4.00NotesDue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5713c49e1e844949024ca754f258c89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3ac8327b23a4313b04a011b58ea1d2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A415NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49a36c48450a4259b629f674ef5433a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ff19b2f06b94d72a4c24b4eea59c7d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A145NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11f4a58945df459196d4289980f7f9f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e0bcb5b5a434f51bab2f5d76da43e3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A245NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2a8b5ffe89f474aaa717071531eb373_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i298d3bf22286484c845cea75b0818c0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.875EuroNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77ca7a1f2cbc41178098a0d44729387d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i400c4310ee744a12bbb7413c21f7cac2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A075NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58e87abb2aae4b75ba3cbbada4ba4c18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e5590941b574c9c837595f0aace5727_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A190NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f7aac49ddf54d1c84c0298cedae4e0d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bfb5c52b3d044d7b880a56872ae93e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A3.90NotesDue2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i224209bee44647d1890dfbfe59b6f186_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fa89611a5164af6b8cccaea01b34c43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A235NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd075f7f4f1d41c190d492328b684c9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3f2e241750c47b19940f1f7920f4c9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.90NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i620b959fd9e146b0bd7d17c8f78e14de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6eac77276524db589b7a8df253bdb8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97601a3d96de4a38be031a08c94ba40b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if24293f6fd55415d9560fd27185731e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.50eurodenominatednotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie629738e7a1a43b4844c99c144e93473_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if83a7f94ec0b4f15a760d11fa20711ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.375eurodenominatednotesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82da477c35664e5e9a498ca0e106941a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebb2ca9915d3447a9524c55e37e9fef7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.5EuroNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c0f5eccf7f542f78f0a069e1e0441a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29ba76bbfef44f90b331caf152aedf4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92331b59f2ca4a2cb806ae55ee55125f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8c58e35b90f44c7b85f122be398e01b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d334e27c8974586a1e136fdef62aea3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icded3aad9e2b4fa5bcc6bbe73f7bd27d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c09fe213ba245e79cdc9b37441d663c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8bccfb63cc84447d9f2fdc7082467dbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45478d0ad35e4c2d8be4c0a65f047423_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75f8a178ed8f450eabe1b16459124dcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8dfca1e518a440e79e02408f4fe0efb6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8f6b68af8b9428d91b0377f34290f43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3af20c7a3814238b67e841a07acf4cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85a75657caa24185aa254c6f8bac7779_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A63DebenturesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91242e71ad3045608d2523c26d489ee5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f1e9b9048084ef786463cd80bb97477_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A280NotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5179a79bc0fb422a93c77860d39e3e5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e4ff66345424bd1af13776a97cc3571_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18dfd3b19f344509849614fd0c8c7ae6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i047a9aa409af47a39aec099d05eb850f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:OtherVariableRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31d717109e794d52a04995b9284f4213_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f477cad38324ad7a03c8f6e78a1056c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbd61b5e13024c6d821da5de889797bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2746565f1354a23af85f4f99207c98b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i894c84a8a53146d0996d343ee95c4d6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b1982ad1e3245b8821c7a9045cfbf7f_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ib81588e6e7c24f96af260cda2030da9b_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic3d2016a9f564132a989caf8220b8a3d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic39a2a021f974911b1ac6fafab48dfb4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id7972a4598aa47ccbf40c79991ea05ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CommercialandOtherLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a61ea22950f47828b95fed44e6413c2_D20221219-20221219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="i706bfb75e173464c95cb81cf1f960b6b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i225a64a3f7814a45b055a29ef0ca80d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b134a981f8749cfa64471811826b386_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:PatentlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8fa23748b8b24ab09e6d4660601d9eb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02fa96876a7745d29042dd0d714d3299_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i591ce0aef96f4308b1211d94ac08b222_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac458cf9779e41db953d53fb8f7b2fb3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i619a10076fc241c5bba81067acbe0104_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied7d80ed2ab14e968047a6b71fb4fea8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if85a36eaa81c4367aeafea1a95984d7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05aa65f0a24d4c608a963845531c19d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35f05e64cc234f2facc385938bb0d4e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29556b6857e2444296df1ce227fcb0df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cb6182a68904c0fa3a216d4c959472b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i047b115329a54c42a89e9abfb277e348_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1539f9d21d0436d90ee19b2d83cb5bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieac41e3734b14c5880a3e1babce1d967_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a159c6ddc2b4e71b751463a5bd906db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26d66e8191e3489da8b88251530ce552_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebb1a8351aa841838361b44de4c7bef0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1c3c2b238964beeb4fe2cc7ee98547f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i574b9cef0b2d4bfba6872a7e1206e397_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a26a46ae4f5482dab104697c724f404_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d9eb5934f114a0ea5d847b51acea3e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01435fa53a734b81a8a042035680737d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e3d2094305840f097c63ebbc04cedc4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d52da3a5a0c45c3bc80f202edf4ac2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2db1b4d2bd9c40969669b8308c8c2bfc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8022a250b1054e89b99021d780f54e3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b6232b3f5be49b195d9d3ebc647e54f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic44da905f6234e16bc83498f4aa76788_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1df1024a4cf24b4aaee26f266a7f5311_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56ae559c54a246ed8624ac3c291db4ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i848f3f6ab9414064b3b30f280304bf53_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2c0a82ed5be4adf90a87892aa7ff607_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55f277519eb246b7ad1d130d25ceadd5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic872792688f1452c879827ccb8b53f29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i828d9b689a9a4998aeab58dcb22c19af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied44e32a46c642a681ff4b0c0b6653d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71639f6c7cbe47e6a0f521ccb6b05b3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf01f0ea26c74696a3c2fc263ac75d7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82fec81188f1404dad80d2b60480bcf3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd533fe7f6474d57ac75249e0844aeff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97b6b2c158a945fbbbdf1d5fa0e98e1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fc462ae433d483c8e93d9298f863a55_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac89e1f592aa4c2dbd20dfdbdfc094c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica85b54a9c6148748a002d6f700af7b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1299e9fb62e24c01a38fa23973dc4b86_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i780a5fe64af9456ea212e3e1f7b5e699_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i413442eca9f64a4e80a2e82ca894c2d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbc781fa4b494ad0a981a37fc93215ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58ee2b762b6b42f9bcb9883b482b84e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79ab820615b2409ca822a8463ecc1b8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b8e535c106149f6a29ce6dfa87a1b16_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb5a0ac36a4541debd3bd1591b829d44_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae76956543ea4116b33a51d411999395_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00f688bf2c244f1f8c8c8453882fdc19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a283bca60094770a190b7b2501d36af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80e040b356d6468cacda7ff0c18e4591_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied6e50be712242db98c4f2730d77ff37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i219e6bd79d244a7aa455084fdf94ea31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13af1fe3667346629b41c84114948a2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e5ed95b785743b59085bf03f11a8494_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i581419defa34403898493f6ba2fb9935_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a561dd7e3cd44c686766ee939d51f32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia697527e9ee9479b91cf4b0aa0f597a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68566a927ade4b2496958500664255bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54e4c057f83442c6859610dc3378cae9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9e5e29c38c04370a51a4e41907f7cb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i094e594db1c34ab39387886a26d20ef2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie604b32af7dc41e2a7c47c6f522d23cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i973d00b66e0c460bb172e8acfe0e30e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf57448d49a348f296cd544807eec041_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1def8f4c268e4881aac2d1b076b727ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic55010634a68440fbcb5037b4995212f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a80b04cb6e043ad80ede6971d9cb2fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacbcb5d3d18240d6abf33c438338c41e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbdefef8716e469f866e5bdb3ad97823_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i368338736b594e6d8a76278bb806f294_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b2074c0c51149d29db8c27132c778b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb2d07ba578d453a9b330ea183531e7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e296686a26b46e991479d3824a63f4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i884f9a28b2df4b68bb8abbdc76ca1ecf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff3c3527b06a4e589f09f08ceb1e72ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f4a61f86932408aa31104c0df81ca3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3d036d559f54833a22c6bca2390859a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84db46bf07e44ef4b3a8a839cbf0f428_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1df28cf4387a4d8783f18cf6ddeef882_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8ab2d575b2449d08e6ad76e2f9283f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ef55351ff9e48e89c15fd31549ae893_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e42ced466d047bf95c8e1543dc8863a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24f0c6fe869446d9a36fa7dbefe7fb88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i572499192bfe479396365f275d94e763_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e9fc972b25f4585bf6789b43ca0f28a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i408e755f4b8346248d1b01996e6dda61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68d015a29c7d47dfa305d0b880483f37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d5d96ce993e4d57bafec31c8f3709be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ea35cf15d4343148d21525946bb5556_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id02a5d1a28e148448be5e2748d591f32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf0d465701b24fabb785a43c5d0b22a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie35e62b283ac416e801a76b2e9fcba1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7da8f4d50a2c49a585bbb716acb0701e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia02763a738b84f0f957e97e34d95f28c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6945f7ef76e445392d96e1e24babbc7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e222b032b0148bbbecabb38a15019c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b6676439afb4baa89166d48a1c80d4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9bb0806cf1747e39ed7c1afcb91fcab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ab187b6caab4fde8baaa89614f937d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifcdb915e70724220b3edab3c2cf16e13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if18d5994096f4b6e8384cad8cc87790b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d94212fbb084b18a3e0d07785229801_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c5eb30d21af404795b2b73f609cadb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib14271cdd75a40bd9db2047fa6eebb56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b45cf02542b4df1a1557fc79ecf4d7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icac839fbba234105bdce0c3639ea1f65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2884cebbeb4349cbbd54902567b98f99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c3419a800d84e95847c4ea6b6573ef9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec63912400cc4143bca10be161105b2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c9d46acf005430da76b238da3400312_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d1b3faf898a4df1b8da83fc0342315d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7dc3922262e347318e148317d58cd00a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibeea740fa5b6439494e7da959619e151_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i222c3f84c00f4528b3b117910de864f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6b957e5e1bb40e48f22b7266013e6b5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8117fc38d2c448f4957b803029d27a29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5e3be79b32040aea41c8fa4c833cfe8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i157a12054ba44b08a715faa3db64912a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bf31aaab8564b709a2447727d50c0f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18725820f3894e1888c310bc183d1281_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75548de2a3824999a1caa66dd0cbddd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2f0d1c8a7964938a5f4ca7b0fa2b293_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3d7c3d7dc05473f9e300744f303a60c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib326ce09514b4493be47a196b35b9582_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8dd8330fb14d4d3c81eb6e836222ed54_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8077994810984b39938b2aa1928d7cf5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1de47dc04136455bbae3a9a127f6e0b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1375d29c86944eb696207a9446cdb738_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64de9cd521724bc0abcd5e2f16a38d97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1c7dcf2922c4017968e8f899598a7fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b426282e3524c13bbfad8775bd40381_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia564f2a19eab4fd992df2ff0405138c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6582d2efd0054414b352812e2b962b7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63145f7e3f1b41fdb8abebc2998c2d19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9f04d31c0704d299ee261c7b15963d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i607173f7a74747529e546f2f09ffa3eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1211698fdc9d4fe4b5bfb05d555dd4dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d81a32ba3204600bc00f943bd7244b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee60ebe97eef4e579466f9b404815248_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i690c9d1b13044a0b8c56110bdcdd1656_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d8bff79d9b44c1e809568cd8f8ea9dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9495ef8ea329494482b31a7316e5c091_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc0b8c867d2b407bb7a590e2865c3daa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5630976df72c476e8f334a3899a205aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b0851bdc7b8443086939d63202a6a2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7986a9f3720e473ab5b5f32f521a73ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if44e31b11f2140fcab839b2f25edc3a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0de70c29ff2e41c3a2cc1406100028c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57d0ac7c4da141c8a4d4240d67ebfa08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i674529c9196143a7a4d48e89efa7d6dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1146171a1f32494fb878dd8a8dd84f7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf091cd60ecc46999362e8ca49e4429a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaad887cf23134b0d82635fe324756cb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdcb20a992b94779aab076cc55de3e6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e76f4f8aabc405e8b026bc6b713eaf3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9208e7f8ceab4fdda68258420c992acd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0892e4eb2bf447490676f226fec365b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i847b880d005a4f7e86c4d63096d9f2fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11fc421c59ce461fa247d668f9e0221e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie69d7f997d164052a95715c97dc7fc49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4ea705e6e4e4f58ab5537473f2b8015_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23786efd39504e7cbf7f9927055b6962_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7821d4f79dda401db43e25763b2a2bff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5325b943b7c84934a25bbb141bac26e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i27c2a54b17b24f0c93b411c2e4ad8e00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4438b86aa5244c2818db9db11a86fec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i874116ca095e4632ac107ccefe0dd09d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide1a603e4a3f4ea6a050c80f3be11e9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2570383925d24316b345fb6a6f82400b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i632724ebfd9a4a49807cc6f4c47e6534_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35977504bb0a4d55a4b76850394ec55d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14e90de4ed4f463996171254297798a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia29673509c9a4010bcd22958c0959847_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i665dd2b6cb854b829b803fff15542e78_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42e54cf9d54b4adc809169913679112d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9246f8fd405044e7a1e70d29a4549ea1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i15e5ad8e04634fc58a8bf8264d2ef413_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccd5163788694a7393d6ef6c3f78716e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i358c1248155b4206a0b0e8e6b96f4f5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43019cb2131f4efb95c47d2d7a4beaa4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb68c4cc84fa49ccb20a1ed79caa36ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84b4b0f9f50a40e5b9e1a1acbbae1af0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:FixedIncomeObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32bef4bc7a3846e78b7f7ec8d18a4c04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie22d02a4139c468ab28d1f7187278f7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifef6b8011f814ceea9fcdf1de32c0ce4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7a0ffc04beb4fbfb3aa513e65b14e42_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if02aeb26424c437e890d0d17de1ecffc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i468fbb9f8f4c4000adb9871b4f1e127f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b3000327cc74724b46322105f078001_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbd903913036435f9d3f677c2aead426_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d1fe0dac3c04016a05d83b48841886b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i105aa835a75742bf940d91e90318d5cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6533c9582744312a8b885531846a690_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8d3e011897140d2a236f7bbd70e8013_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i069baeccce9b4520a111bdee9431129f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb99c5b079ae4247a981dba6a8503c3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee39b49b33a847d487e04603c75762fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad821c2d4149482a8d9a5902ea95e485_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4018090676e1474786e1971f3ec5c780_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7809219dc2c546249334a05ed0fb7c04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib828317235f34a7c933d9c8403e3746e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51d036f34012427e97ebac833cef5892_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i537bba5b6e244ca494ec109af70bb702_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5679535497fa4788b52666e4cf70d170_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib56d072311c84277b36632d5a803fd7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i512bb771659642bd8da429add2af7ece_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia60b0d81c82b44b2a9fb4a6fbdc1f05f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80f4a71103804c5c990a5e460fe9febc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8491a5785cf2462fa234d89c89950509_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69c94abeafb1473a8d323ca363297440_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i980c20ea27d44058855c0549523b629e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f51ec0ea3d34dddab95685e90d307b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia486b0610beb4dedb992b7d0a70d8173_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b084b871a324422ae5462c19f697ce4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01600af18ed54eaa90e40505a5ebe18a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7727910cc59d4a4d84eb330b2e6c98e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3255f205337471b9de00d03043da0b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d3cfd0494654287bce631815c2f48fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38cc140712f549368583bb21f0c9ad6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5af5903c6944bc8992989ed8fe54eb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id85d88e511504c9f8addf47ea0c5c8c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd750cc2ed934cf198a8e5af0722e734_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bab51d3da9c40bd9dab9219b12b6477_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18fab0cd3eb5497c95c9598936cc5f60_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d226b317f604d05847b7f6e28dc4596_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1f30f26103a4bb09be1f8df2ba5a0cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61ce603ee97843dab7cd57610eefcff7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ff8b9d77acb419cadc79b2388cf8aea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia49b3ac0859944108a2886b9ffe70668_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91e7988a858549c6831c3fc177094480_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6082ce67ffaf4296a00a661b69d5e2fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b08b0d47a644db7b10259546dfb010c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85a15f6641e7489e8bec87d0c0d09275_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6bf55b6630574907879c5690efda4aac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e9d5863fab44dbe8edafd532df689cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i274a84d55dbe43f0909b3b9ea5a73369_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8144400fac414d76bbf83fa31a181ee9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d7e9a4146a347b6b61274dd7dc190a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib416e715279d4c49acf44bd176c0e993_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2279fdb171bf475ea5bbaf850cf969d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide944573e70e4c3a941f811b9ae4fc69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a3d2cafcaf747a081a5bb4742d24ffd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc86d76a34274e1c9ffa42afa18a0501_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia73a0658e8094bba8381b0c5aa3afa6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibeb05cb659f145bc9934cb7f8611cab9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69eb54ad43994b288d84c18edf6e95b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6da8c122d974d1f937fe4c99ef076c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5733f7bba54d42aaa43b121a730f82fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccf522bd9fa148caa6b5eed555edc571_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d449dd9dde74791bf4aaeb9a684a535_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ca87f79abc048f6a89896b3f649a822_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72d655338ad14d529fd86da3f800ac76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if41b6862ec6b49808939615624817c34_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a8c892d473c4518b1b24faf48003494_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1567e8cd88db4e33937d223c023e86a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ffff716f5884ae9a3c95e17da117a8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica01a70e35a14ac7b9ab80bb54bbcd37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dcf8778d6694d0b8a4abf0e7cf5ab5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16e73b7ddb0346da916527922a567950_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f078b74a4254907b6f6bfa3674d200b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f3f57f040b7479f99574732ff1ae8b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b52200a65f14226a303e0b59890c740_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4975d29336746c9aa345d496769bdb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2c66956557e4be194a774c381c9da86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0551986dd6aa44a8a13162962abcebe3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i740356c629584008ad4233ee4ddba3e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i391d62977ce249c595df8b51fff32129_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icedae49afe70492a8921f596e854194f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia8a215a4d92941e58289c363ae043414_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i196e5beea93a4b41b938b075dbb6919f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22de86a0013c4258b4c507ce158eb4e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75398dcffd9046fa9a38d8247cf75272_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25e5ffd30d9c4ef599c56ecbaaf44659_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88d52c4001584a19bb8951cddf85e6d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43740d47c36d4df0968fd590a094a8dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f395a8003a04bc1bc87026e0744fb1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icdb33c38937d499487bba962e0672886_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:InsuranceContractsOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if954f770736b43af9be4de4254082a5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9eec32cd86894cbcbc60de256176e451_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:RealEstateInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8d8c9312ccf47048b5a4a7d309afce1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbbf0cf596c64dd0988a11364164dcad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0855ec477af54d6c9e617a29197d7847_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9dcc62c4863b4fd5965bad472ce89f84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44f98c489cc64681a483c72df528f6e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7203e778ea74a408a9fa5899876be16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i723ef648281046feb09a5a0b71329ea6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0c611c813754eab88e05244b68c044b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07ab2616ba0d4b4cb6674640617b0f57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9381a63fc854eb5922d6264e132c65f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic78ebf602989410196340e3c5dcc143f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb96f837754f4435950d58e7ac6948d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77861343b2ad4e85b03f9edee1fd484a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82a9cf06ce114e07b7471b2af3056851_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37d33c007f854d6686e954a4cfa0d98e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43b3b5be37054468ab22fe27ee8df713_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3aeeacc677f42a5a7d9c47033789337_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e4352166d754870a7bd84cb271c20c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic779d812947244a493bd0e236b71c768_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8c0625b0b6345e8a53a2d538fa4f71c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac6e499506a74f4eb80bc1d6dcb6eb92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea9249f1c9bb4890a527687499ad8b1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97fba52804d74a09b2d6f5991fe15088_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a9f1e2ac854460d80e3d43cf0117001_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib24ff29c998a499e98829ddd938859af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i880f66c107f0451ab68cb5731877e3f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b0e0627cafe4467a18c0746b1b2cb31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5d48bd88a7544ca9f12cbe3c8d542e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i581fc4c408a34c2b823593ff34f1bb45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice88c13053694b56b1bbb9845b06064e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:EmergingMarketsEquitiesInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i018e647cc2bc4aee9902c487f5cc618d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff115c544a4247a9bebf28565714478f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25beda17672d4e7b927a143d69ecbcf9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76b3d9bc36e8470ea10fce95680f1e68_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i480b0e7376cc4bf192c2b8defec32548_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e52fe255fa64668b45ea3f63c0ec370_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a3df3939a70427b944df35cdc081c04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice8b60bea50f4819980218f7402e7751_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id979bf377b1c4fa49c254ea8c1bf378c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1635544067c487894b39dde19771e15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanRealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0194124ad9d04baf9e149becd0219b96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5299a986957347d28938ccdaf51e78fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d3ebf994c704c56a8470a4394936128_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib520139920004af9959a218c4bc47d91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i627a57072a524b84b539c7ae028c9972_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i913b5f5f9ed74e87afbc473b332d0abc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b96c6aee77c4665b7d0f0f1c63ae176_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31b5a437c2054f779c773692231f8df3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc2a4b136e3240bbb703440f5d3e6850_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe65bc4981604870be12a703c9e2575e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4945633529e43d2802b597e5521836b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b67d5c167014b2182a1ef46a48101ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f74ddf524274e6fad860cb8fd17fe7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32c0f7bc74d34dfcab9c341a70dce9ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4cedd5ed62c843f4a46823653d960a3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae98f337e3924c8fb5cf7830c2920bcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c86d54c41ad43afb4205c1d54aaebd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadf0e72b4d76455c823ebeace0a9683c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80b61c9047804b46affa899a8994e404_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife91ab3ff9224a8887d6fc6c9327342e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DevelopedMarketsEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i893c7b0fee694fc39725e06248904f34_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0a6cce590324043bd914a90ea6fc3c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i449c16f5e60d47029b762e1c47644d98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6adae9ebb2144625a68e34d2e532d6d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb26e9094cc24bb49df536a196047854_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic72091fefb0c4f5eba7ad4a943ab6bcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idba55f68908c47baad1db7eed4abbd32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc82d08170a947b081f642de831e03f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5dd78bf53984767890f793f585b726d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4daa1ffee7c443d69903ce6fc8dedd2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45784d2a67054e4aa4806ae5f92c6849_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6f3b6b407264debb979379641cba1b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4fb8860eec2457bbef07d977cc5fbf0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5a1edbf368048fba661bb380d38af5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia405f11b3d1a404a8fbfee06d703b855_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifce1c8735b2e427cbfa6b1c2d907a6d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7a12aafcc6847b89509b7ae957e4d23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i369b80c6e5c64b4488babbdd01f641d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46e297e9db7d4cca8668e1a16be22d72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i924ed285bc1d45b996c203cd7bd05c25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:CorporateObligationsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7383c74280514a6eb812d7f52ac9def8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b3cf34ce5394b47a3b70ab7ba21f07c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie728cd5943f143eda362306c2e64188a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6010bc5ccc09432a9350066c737cebcb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f1c226f8e9b4d3589285259cf838b6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7c81130363941eabcbe047788cc8ac0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad865b817d2e4f2eb417e13f1b94cdea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0623f98779b4a1f9deb8c5985cebccc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99f2b5e073ef435584f2836b3a9c7e62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief8502a68f6c4572816d41762470ddad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i795f5a645a9b4b7ca40fb6b7556a8459_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a45fefd7c93443aae003ae9986384cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i766d1fb2733a4f39a4b6c0c5a672f068_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibbd9a236b87e45e38116d6ad65882768_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba509df50d7d4c6a8ad7c22884e1628a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02f69b3633a347ecb320f84b5f266212_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9604e1478cf43bf91e60a2fe7f8e4e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a749daf21de4a6f862d6f87b5c3ec41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd49f7a962454bec93ed6ef6e39f5d9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f4de48dbad544b2ac8a8ad5bfb3ffa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic252bec7fec546e7af106a451f9b665f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c314bb744ef4c0dbbd31c567c5f81af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if944cd16f6074744b8d053e0926af6bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c1f9774a89a4460b8b9fcf596fab680_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if50e936239a449409453997e9da0fdbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i675b5277bd1b4865ac978e2a5444457b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d27b886acce4aba86858f24529ae547_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cc364573597419f9c326fddd7d8610d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b12891dbba4474da8538f68cfe990b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iec2ece4e28dc4d3a8d51b0b78cbadf8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a61546d8dd040dfa6713efca302e7de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1cb9718cd4a44578e0ac990325f2f60_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6da749426fbb44f2999732f3b38a24f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i351c42adbb0a4ccdb08af0c3e1a68785_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0352f2158524b81942eb49ff2876ee1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">mrk:DefinedBenefitPlanCashandOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5495cc09a654440a149148e4e68ccd3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00c54d6e8143424db472e467e5653785_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia358ddcd5cd64c81874827bf799c7cbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69c9e567da174a86ad13d7332a5ceace_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd3d23b42991496e8be8317108cbd31b_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="ie41dca853a9a42358f40da6cbd07030c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6e60950b557f4677846291e08c9270f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44fa248a36c14567824971ef9f972e05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f5705ed276147c49ca285310c722e6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf27171f8c7f483b8f695370dd8fed99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i540b17b98c5447ca8f7d0de2174e6403_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i799b8472304c4a24aa87481dc87bcefb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia09a86e8c1434a81b69233805423f1e7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e0b703f3bba444fa6d4622ccfa960f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74765aa20bbc4bdd99d6913c1418a345_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45f82e1279454361b6876985ee31a5f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4630f56a7e0a427882ad898683404c6e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5ce7859bb6640678ff3056905b8d464_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f36c5d17d7f4ad793c7d79ff96b69c6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1fc09dc5008b41e08065acb6f23ea811_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia160115328384ec0a210cc9247afaacf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i712fa8b98e5e4ccab42eee70db45d412_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1639bac565704b8db1b75f669f2f8d20_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35687940c55f4162a974c6fba1256951_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98d2ea2a866e477993f83cbe1be3386e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if78fe5701f56444a87f6705cef245749_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i780c56afcbfb4d95a44ba74fad92b717_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10df6e4d4fef4be191cf9f09fe3b0e69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b4f7ce11e074645a9ba948f88f64501_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2100c8d9763e4e2aa3d44e5ab5e6f3ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb4671bf8a444d7784d46176642a8000_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia053f4e630254ab8bd394403714172dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i913f7d5516324116a41cb3fd560183ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49e9678f0bde4535890e00b607c39661_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief7889eac2c64545bb3064c36a62e54c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3213007d978d4f60ad986031900fb73a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i633b278a9073462da9b159814994a35a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5f13a2378f44c6bac00f3c347b5d737_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3fec19785aa54818a2736cc335cd0740_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaaee5000881d4ca39ed66d7be4ecd22b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98661ac7371d4fd4b9c2f6c95474a731_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0f4a1d4687e4f92b7cea51e261e5084_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanNetLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9544cabffb54d55968d75c6c7d1efed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01173ed3d18241a0a998253f0b59e277_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:PensionPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i376ce6e940de4569b4fddf8c906fe3c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6758445e91bf414bb1e7540b3c5e6998_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrk:OtherPostretirementBenefitPlanPriorServiceCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia91e2c24c996468b982a1dc76e03f861_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9731d40c6ab449cb60589aa31b26a73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i055b33b897694fecaa100eb09d061cc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0ceb00afac54256a4f7d60880c98740_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08a3ddbfa55a431d93af3aa9f262e6f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i021a82cd1a4140339a5639441d8b47f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i469a9a4b8f4d4ca3ac6924d254ddf426_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd610e2349614dcfb3c65f5ed1df8bd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c1932046958463fad5e8a483638872c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d05e5c857ab4caf84ea5087f3cb2a5f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5745637e84f64e87b8c42fd884e6b4cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i85cca07e668f4fb582cffbfc5b2aa7b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4ad82bfee384b30ac43e9a17ca1089e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b4d358834924f50a81f5fafd726b128_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4823df2547cf46b8875abd9cf558f5ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c17734546b947998281488d9a6ec98a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2afc6a3ad1a4eacbe19b964577a66dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cae1b53fac2493694141969a8253308_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c7db9326a224e2ba5066b84103c543a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida28401748b24f92b416cd0833611fd1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0bd8d6774e74f7bb3b1974282e31ba0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i386ded0f805747da8de2d6ff8fb385c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc73f7080d9b496c8de0c1ab17b2c074_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7022852951b641658ce5d9c243dac44c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i962d004cfae84806a1690091e3ae9d53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20b05e5faabb4aa8822babd60bc90181_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32e8b2707de1407695f9bbb06e69dc0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a5c22c83dbc43948fa3d2fcba8c2036_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i983e74feb34f4218b9743956866ea60b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe79fe1f7c2f4216adf7ef2d4c9e7785_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6630bb637394adca02acfc9eeedf615_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibec24a942c8b4c0a8fc6fdaf544a83e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i110ea0b902704bc5be59e310b57c93a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie88453b113924c5589f84f11706642fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76d1c52b6d904599af1561feb5d9d169_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i07fa681a6a3f4803ac978bc4430cb16f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i644651c9869647669ec353da52f990d9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3ab722f2e32a4c6683c5a3c36bc74c42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcbfd454bf4b4f66a38aeb71bd572837_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0da2a3204d4e412fb81a43cc22c0763a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia6e0f2f8901b420ea1bc6e4977b34b1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23153be3d78a4b25841635d342d31f02_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5df9cf0c885b47bb915bcac974671884_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82f7b5010d8b4521aba879ed86a464bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia33e8904188b4076969981d84d6398e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaeb0222df25c4f04995c870d2c8857d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4e74080b44234734ace0dedce547e587_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibda8cdb993f6413fba844f94a33ca058_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea178521e12f47089370df87334ff7b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7077f41ca14446182bb6e9b4d27b1b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b007cc3680b447fb3c5201bf94aad44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c0c7519eadd4f2cb22aa9f1248dd720_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28b4a4a5f68b41c48bd3a0fcfc84a504_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibf6fa89df609474b9bb96eaafe8ebbf1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia7e07e4f949d474eb749d0ba3fb1b4d7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94ba2d46833f40a295ab92101c6ea29e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i30c671ce13ae432fba6dcaad37ca8570_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd6d0c174afc46489b7ddef3c33543ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib169bea2441d4f30ae99b18bf17d4fde_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a8c832c3c4b4e4eb34256d6efbbd10f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16e6f28f13f14ac490531d72573bcbaf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56cb5b6040ce4ad9ac372cec6d2cca04_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17ef3a8f82f04dfe83a51cfd751ae411_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia04f7472ddd5484b8c9216a9fffd29ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22ac39abc88b48dfae3f97f17cd94587_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd57f79d2d0e41c3b93e0ea8a1fa225d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87a2e2a2eb9c43d4b2d533d346a44334_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if80ca468315e4aae943a5b9df597243d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99df6a07597644d285a92793c5d8e7ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a49a4371bb94327920efa9b894769ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8d68a994755427bbfccdd19f9ad6ee0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74ee8738806c47fdbfa08983e60c6b39_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if74b581cfc6d488fba45c7674c3dfe6d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7f1f993fee094825a8fff330454f6f81_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i380654ff24e1418b9128e9fb90b05595_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2d28f16c5374e7f83b2e84bbe26110e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83690f4cdc6b473bbc907e1481854b3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id86b5383dbf64f898217d2bc2c3fa325_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c50b2fa3e364cbb801d4ba254d494c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54e206a2ffcc45d1bb510c4187e62a29_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb1603f10ef8494fa56655543909b4c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i045d0c50e54f4c0db0bce141309e9adf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4b4d13befb54158b149f2d9f6063ff9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id11490c3b30c40b1a23a28951f1e180a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c1c6fb66e744cdbac35155a426b3d6c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c68bc52927041289397d599a9612eff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f47bdad3162408c9b0f25ac776b4bfa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86224d1130564bcd9c3939e4e0d87dda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66955337b2e7472982d44f7d7785e83f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66f7da2549bc46508c0eb51f336b6e15_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa717dbb9c014d55a5428a202d0f8635_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1348a3599a104ba6a35f574703cd74e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4bea3c67785843179ba5a14d3faedac4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i696096e4ab134aecb6a7f9a41513fb2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc1a741e5ac843f0b62b174581b00278_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44f9720b066543308e337df0f16afce7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i438e2ece521548b282bf2388b2b7bb93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f274e7070274a88949b99aeff4a315a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84c33f54fbf848d3b95f8a9426848007_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6aaafda79ee404ba309fdcef5eb6abb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic44ad729c19c4e508c4d35a83785a3b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b5118866f4f4421a29aecc0b9d07410_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic25c060bf8b740dabb223a13c1a73ff6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i502953fc972e41468a767f66ce4c9cba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d9a656842a84362b57aeb885a898b92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98f5e15ad16b4a99a824425bbe60d470_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2b71549b3e14a12b8973697db00d8a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5077564ac8bc42e3a13c994eadfd523e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i265d917b453a46658f7507d16b56613e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i849cac43efbf4becaea56c79b6c78fd9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f1370ce5e87458b818b4352ac61a828_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefb64688266941e4a497a73d06448942_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i296b1fd777794c17891e11e10a141300_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09f99ef9d1b74fcabeb55184c85dc86f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if880d0df286f426ebb17d41d1f490635_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22e66e074cc0484bb09293c2d0e5387e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i51deec1b5b1a4ffbadb9e0abc2bf9307_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7480c05016014e139e36eb2b979873e3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2a12590988ac4caeaf1fbdb0caf12c50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b87c87bafd747c68f3308bdf2b646b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b5634d11ca74ea5af6b94a23678fe55_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7a1ed4e577d4643b2128afb0f146b35_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i197589a15f2e48f3bd5253b3634b8a2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6db360f0cd94810bf55adb667501e93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8953ddf05c074e5f87682037915661be_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77531b3a80ec4e3db6cebfc5913221da_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i681c4e2421fb4a899d60ff0568080be8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i57ec68701cc14e0f8f6ef79be8cba10e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia30d45a724314df6954c76e688a98335_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie54a4ca20a1f484298d307aee478cb00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida70ce761b0a4a9abdcb51468b1da149_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03261902b5dc4073ae6a6577c04bb346_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37ed6b5c044b44be8ffdeed43f3cb411_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e744f26fdbd4b499f10d72b19177ab2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i24d4ad8a15ed48bcb33632d14c4c6264_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0be72db3712d4da0b435716421f1fbf7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idbe4fcb8c9074698941c54291c494471_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic80bf4c2fae84eec92800503e7eb93b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26309d6272d64a7fba7afe8b3b07827b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c1515bf37fb46d2b516dba8cd589e89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c291d86eea247ea9a5865cade31456c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccbfca06b90041849cfc691d6f2cdcdd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebeaf99e4a1d4bceb36a747c6b3e139b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9bcd1287d5c2475cb24e77ab4fa0658a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0c448b7df4944588d513ed2e91cc958_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea1073cf01244476bfda2869a55121f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7698a3afbd87428f86f0f8054fe5e279_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i617770866c9d4c829c27635c3e97c236_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i505e0a1800cb4556b5eb673f1dfc4a33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b8af54e95f4451d8430cc22433b5edf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9a9406845944bb7a2fd7d973f3a9d1f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bd312c6ba714cecbedcc9a7366b852d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i31f649bf31fa46b39e37b5bbdb7840aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60682002d9fe4c8a8fd6083bda3281ed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice356b14a6ad46418365ea9bb55cb102_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8f6d8c5bfbe43ea902f7cce7547af44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f8ca3795ab84ff48b77c6fa70f7cffc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if482bee327734fda9fa6f722e7d953b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2e22a11988949b88c13fe1e17f2b78a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0794dfa269ce44c7890d47b9989dd683_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15b258a143a242c6b252146d74dbac1d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i90a98ae870914b948c565659e918f453_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iefba66a377874ba2b44b702df3e1d749_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3ec35638b37649b895fe6f1af825d879_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f1ca9ec329841abb944f3c69f76e638_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife5efa30ffc24b3ca056dde5eb034cf2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a448ec43a2749f1bb446aa74a3bed8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie10456cbffc5448993342502159c294a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bdaeae1c70b40aaa1e3b158b17ef808_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedbc88ea95514451917cf053f720e3ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6f58bf19d1640f8a24c1ab656bd7e18_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ae8c44fbfd54215a8cb3d32bf50788d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibfc958ec611e402d89f8dba65cf34f21_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide81cf5396514fa28192d55d76c92ed8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibeda3b83cc1345dab64a83c66a84ee67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d25683f4f6841718c7e93350d0d5a67_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i629bc23e5a69421a92ee3560e059c642_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71e77126574f42bb96d0bb8e53774cd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i613d1486fc28474c8acbd3dda55239ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8fe4630cc947444b83450d5ccf9a3062_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i293647d3e306407ebf8717a4faa018af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bc9b30cdb6f46cf84ff8676fca96daf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia49136d6485e4f27b3b68f218f591205_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d3c8d57174c4ba09a7ae459144cccc8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifdd8810addb24069affe76f94ec0a5be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1c464d5e9ce4a76ba55304fc35bee88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e30185203174bacaee8e9bba03bd862_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib909438afce24a8780c7df58861bb88f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib609b96d8c4c45d1a0af8c7f1afebe6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie99e22750ba14129b0cd8b6a97dad49c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9f10dba5ec404300bd6208a5fc3914aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ec7cb4b83004d9a983d8127e07e2b2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb5eeb8fa10948649d5874f868693a1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9bd6baf002c54d9a9da34f801bd78e3b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i338443af5bd847189e38c92ac1ec921e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5884d63fe366495081e710da8a78d315_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d6da244d9d94c518f93764d97f2d35a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e9b9cf8c9aa4481bb00fc5b21378b37_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc50a7e8a028404c9337837900c373c8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id51698f086f24b71b9570d9313720f9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc622e652dab409a966bb1005b97fb12_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8283275c2880459b937b5ba98b866084_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2cf47d7044f4adba5964039483ad7f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39f0ead2a04c463ebca54852c312306b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4466289ff2147e2b0ad5ba8dad1504d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3e907a5d5f345568c0c95ad777ef996_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08fdb9e60bb54154be013bfb3b99ed37_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i552cf9a2dba34015bca9ef712e555836_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc13214640dd49aea3a6f573732950f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i183853257a9744bda89e18492b5adce3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52ff9b6d884c4cd4ad827974b7a04cac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib38ff4e18c854e00bd319922ef36c8fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04e83011764347d1b6364b08e35f618b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c361862132d4c12a3df559d1247ce11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieaa9b80b3f7d4f2ca54fe62d484ad6ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic322d64f24e846d9afd0e3dba16e24cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42ae64bb8a33446faaac7873a35016cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i91629c66e76841e49ac8fdbce3d95883_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idea2621b38e949de95e267f3fa6822d5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8aa77411ccf241218037cc5cd351cba4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf36505cfcb544e6bc2016ef576a5a96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie40150bacb004b09aa1761eea6e209fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5fcc4830492c4d41b40fdd59f5359d79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib79561000ee344c4bc43f4af90649a06_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if0761d7789524bce842b332f0db014bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iab8bed311c094329b4d745c12c4a5cc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a1ca67f428141cebc70732cebff9521_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54e6f6f6fd524dd69fe636e2947bdfa1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42c259a7a44a4b05a2c75e4dbb68b616_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d6f7b78017c4b1aae8ad926d48e6a38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i990a4dc4b81240de8e34aeaaf52eb1ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a3d395096a04f008b6ad61b7397f8a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide4387d3b03f47fb943aef0ec03b900b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b7753d0b2864abf84b4f0352e03b254_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i51a96ab2adc74657a7fc0400faed593c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f891fe0d78a4c3bbd5bda2518e4ea4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cfe13e7da014c61bc807c8e56ec5f0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45b3d413326442638d0877fd2e9e29a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2bed06c5b34b488ea2f844c3779949d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86879f1d260a48b2b3fc2ba0929452ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebe4eeaab037443a9c7ca2df4c70ad71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebc3747831fa47ea8edcca64589a2d04_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b0483a589fe4ef9a10b6defdb741d26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i180972d620b04773bac120852a0a31db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20844159d5914e56aaeb01e98bfffaad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic398861a5e604978a3c98fc5841e68cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i531ac966525143049c09ffd864bcbafa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d8ac6036c8646999d891c258acab031_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacbc57c3e1584457acadc54ca8ee0f09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a777627607f4c4abb9584a4411dbf0d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i890f308e305745e993afb171875461d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56526eb7b6df403d980ccad23c43f766_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i29d93056d1c2487eb95a4a49fc8d01a3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4894c9df276a4645b9f3fd98b62ebacb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3c8a2d41e93427ab955bd22bcf78ae0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2119c2582b0b42a289d1ca7e693a7795_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74dc6f5dabd64668b9cecba5fe18fa39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6688637b104f45498e4d1adcc1dff8f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73d257fa44324b53a1ef7ca1720ac517_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2554a55ac3e445b4b77f581e924fa49e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e5f83c1f72f44e1be95132b049ae22c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i963120dbdfdb4d71a1491aa18697e865_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0c6c6b918224b0b9941f8fdd4403701_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18e5c6c625744b5397f0c31a5173824d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb094efcfafa4c4b90bf422d01d01cf6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i218fada0b11b421db5b8600c0019d4f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c439560c469498ca75bab3229912fed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id26f89beeaae4c7f931c5d4d81ab0bc1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i337d955832ba4199a0df850ea23b5676_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c0fa7b9aa8d4e40bc457315bc042e44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd8a7e5fe48142d5a2a4a1449d7e5fd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42a2c421146a4685b24d4d63dc874137_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31df7669833c47408aded7bcb0d91766_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa2ea2b06d674eb997a7ca0ea9ee4f84_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2ff1d1758224e68b457056f4c1aa244_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71007b7779374d738c052de5ee0be00c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95ada1ec00a9474b86440d7e3fe85a61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if194957d47c14626990ac7579d8a2860_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if379b668eb4a408d857cc08dbfb7cda2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i343efbd897d7479798adb44173aabdef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba066b9bf1844c0e995daa549acba43e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4556e60ce4f74c22ad0cb51ba398629d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb44034bd361427c89ea4308da4aa6cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4158ddf9b78a40c0b069dad583f960ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie51d2c4b860046aaae61f55468059f18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d7f372308b340f7ba087719099057d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e4aab7a7520412f993065e092f416c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9f3e56752d724c438792f86d2f774c4c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f295cd4f0de410cbcd6deb71260cc77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96716f25cfcd4ea78877e455aa3addec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fb33bfd647d4010a30f8e7417dfba4c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec693e2b56e5450795dee9a8f5b1fd7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icdd89273ea4c4e4086ce9cefe2ab8a36_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4713191775b44625bd8480c87097307a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7771fa9d00e456f945808f5b1350a86_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i840fe2106741497387f3e41d6c0fbd82_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idad74c169614459ebd6a2feba9923acc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i923e47ae0d0a44b59c583a5e9fa3fa54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d0e54bbc4e1406baa90d17d42691c90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2b2e025a9ae49f6b693fe2b2b301a7f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5bcd741098644d6bdebda5470bbbf63_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia689dc2ff1e4458792332eba5e96c16b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i884402da04444fdfa741b60ec14e6df6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia22a7046c70e4bfb87b82cb904893496_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i886f7113739342fe9e0a88000b89520c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9dc938ddcd1a435c9cf8105a8ddbd1d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i998005d150c24a6bb8ccdcd6c0251302_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92b79a3305ac435cb2d4da9934529da6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0045db94c49d4a67a671551c92f63b4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied160c449f26454885073f7135732aeb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8284319e3a8f41c5bf0824118bcb2446_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife1e166e6f2f4a579b637ff0e714bbbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id876bec63a044a438106d7fc364c0be2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i047342a7dd6a464e8f2c160368b133c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8cb013593b44a96a79cd5ac26f510cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3e683e533014f74b1427b3564e847c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ad4d8d7f0ad4e40bc7dda4d86aae1fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i50c971a16db240a29a2f4b213472c027_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3f1ccd890df4f68b103d447a8e62b07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0427bb4042474443a828a8f3595154f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i269ce30010de4d15b4e17a5aedff6cd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8211b4d2d96b4d6e924cc16fb296c131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fcf7b65ffe347b797e561991df21993_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81ccffe7157345caa23575cf77dbeed0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1820461e7a084ed6a964f1b3b8d8d802_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0faa095bd4a45aba5e98f155fde2079_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a5bba0a77af4a8783702f2047952acc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4fae4d6107f488b8909bcca3be91c69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c06014407b8411a91506d49df92a824_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic251c7f3bb4e47e08296afcc17172e83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86e3b8649d7640388a5c9c721c08642e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9d9802536b44e179a60195bfc87b3da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i123ba3f4a40d493d9ae8d39e4a5ef78f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c691cc03ca947218df95a3a774da470_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccd56b99f7e44e7ab521fd0a98e8b8c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a6d999cecc9424eaed8887c265ddf14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ee703bcc3304d2199a268dbca3b2a98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id490c58a5ad24c1ea00c4115bb016c7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67a8eb31fe5a4c7e8d7672a9f0861b87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i525155431d7c4ed0a672cb8897ee553b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fa316713ea647e5a80b2ef8e8cc5435_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mrk:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="research_program">
        <measure>mrk:research_program</measure>
    </unit>
    <unit id="collaboration_target">
        <measure>mrk:collaboration_target</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>mrk:interest_rate_swap</measure>
    </unit>
    <unit id="case">
        <measure>mrk:case</measure>
    </unit>
    <unit id="claim">
        <measure>mrk:claim</measure>
    </unit>
    <unit id="plaintiff">
        <measure>mrk:Plaintiff</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF80LTEtMS0xLTcxMzMw_45baff7f-969e-433d-9ded-5bb4f99af31a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF81LTEtMS0xLTcxMzMw_992b99c9-a253-4e99-bede-e9f5952deb60">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF82LTEtMS0xLTcxMzMw_ccff7cf2-82ee-4f3b-b73f-e745d43c5777">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl80L2ZyYWc6NmYxNmVlYzA4YmMwNDlkNjg0ZTQ3YzlkMDA2NWIyYWEvdGFibGU6NTY2ZWU5YzdlNjYwNGY3ZDliNzM0NmZmMTA0ODc0ZjAvdGFibGVyYW5nZTo1NjZlZTljN2U2NjA0ZjdkOWI3MzQ2ZmYxMDQ4NzRmMF85LTEtMS0xLTcxMzMw_ae9ecd62-dce1-4a07-86f2-26e93039780c">0000310158</dei:EntityCentralIndexKey>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate
      contextRef="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b">P3M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ib8d0002590484feda2fc8325dc655c8b_D20210602-20210602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTQvZnJhZzo0ZTg0Yjg5MTUzZGM0ZTJmYjIzNTY1MmEzNDIxMTUwMi90ZXh0cmVnaW9uOjRlODRiODkxNTNkYzRlMmZiMjM1NjUyYTM0MjExNTAyXzI3_ecf67a0f-fd01-4e2d-821d-cdcd958e21f9"
      unitRef="number">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="id85c300cf38349adb26180577979e5c2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i3592e3674e13431aaf91bd67cef2a754_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i7552297483f94fa5b4160dc0db014d06_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i4eb748e33a7a454fac71c562342ce760_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ic45c2b8530f9432f800bd21578f8e217_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i0b231d9fdbfd40ae8d6fe71ed37de345_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i30469f7c418b4bd2a85fcc554df58178_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ia817beebd6444eea99db772afc066555_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i864a963e97a44b5f8189640f9cb94d43_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ib79c6477e2f646dd83409e81121b5a29_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i3e1e5bec9c0340748f3a3782a3f7fd23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i804346c2237043e084b1afb341655a9f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="id3b44b6cfd4f4a8b99ef33bcc3c06df7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ib7d722d97d3e436e80d290bc86ab1496_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i2335ada88a2240b6bd6252e8fa8510a4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i015fe5f90bbd4e93a29ffe724e90bfd0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ib3c3521eff5d4d78bed2d56d42e3789f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ibc8bfe07436149a2b63950679699d1df_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i2c693f6dd72a403f89d6d2355a3b1c83_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ia7cd884e75e9428f87dc9ff260d2f3ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ibaa6d39939da4e91b837b366cdef3966_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i975b430806c14e4dac19b89356167bc0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="iba21ed671f2448ceb380d10aa9f40bd6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ibc1ca9c45f2f4c0d8e7d64701e4cb36d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i0562404e8e0e4465a752940a1235ee59_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i16a86b0a2eb94ae1872813f8188edae8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i54629a1dafcf430fb0b2f74327fdd6df_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i8d9a9c572051413cbcbfc3a23280168d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ice7363f8460840bb83ffb6ca99594560_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i1decc07eadc24124bed0dd2deaff444a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ibedf7a5f7ef7456586ec0f021a1d0f3d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i3327a1e7655544f3a7d9953a5234e2fb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i1b6eb5443eb44c5f83120bd0907e38cb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i1e08ad749ea24620a73bf3de13d4ba83_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i97f4ba5c710647b8a25a7267abdd6754_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i51f9f13e5ade4b49abc89a6dd9a5b2b4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ia78f45a1853841d69480601600ad30b6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i1b6c21a42378451b9dab85a8423576f3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i98c6fc33bcf040b88cd4cce4a3bd53e4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e">http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i720ba97855924cd9b21a8b29de3ba988_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i94d6a7f93e314fc384e0b1149d0ae9eb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i8bdcd5cba5f543dbb50dea0289f3ab2c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i4983cbf854e94eceae83083147be86a2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i972eba5067f8445596ed5ff359126657_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i88144043844d4f7eb9f8cde0124c59f9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i8a80bcbbfa39470ab7a14b86c6fa70a3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505">http://fasb.org/us-gaap/2022#RestructuringCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i20cd4c7fd5f14851a86d5a655db5663c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i50be94d522084d82a3e96d121db4b2c5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i1afdd113c40545adb3ae03acc9c4e126_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i782b995c5324440982290223b2cdddac_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i2677274a350445afa69443c36f4a89da_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ia2c912a0937747a8a1ae5182d756b260_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i350a79055507478fabc61583f11e2080_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ifc29185c1fed4990966cf824e4597298_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="icdbb1216db6a47e88141c7169ea7875f_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i6226dc468d5e40ba93e5e688a3b0e650_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjg_e7b500cc-8996-45e1-8231-cde2ddbd2b59">http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjk_b1192ef4-ec86-4241-a5a3-3f1beac17af0">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODcvZnJhZzo1ZTcwOTY4YzFiOWY0N2E1ODM1MWJlYTUyMjQ3MWQzYS90YWJsZTpjODQyYzdhNmM4MmU0ZjU2YWRjNzdhOTIyNjhlYWI2OS90YWJsZXJhbmdlOmM4NDJjN2E2YzgyZTRmNTZhZGM3N2E5MjI2OGVhYjY5XzEtMS0xLTEtNzEzMzA_c5ccadad-0faf-40c3-a645-e49b5ec24cc5"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjUz_61990af7-6ce9-40f4-9474-7a19cc6c4ea6">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6YTcyMTIyNTdlZTFjNDk2MDhlMDcxZWZiMjdkNzBkNGMvdGFibGVyYW5nZTphNzIxMjI1N2VlMWM0OTYwOGUwNzFlZmIyN2Q3MGQ0Y18wLTEtMS0xLTcxMzMw_382b9996-bccd-4ed8-ba68-e733b9972af2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yMjU_2bd1c9d4-fb35-4bed-b58e-8dd1c218e01b">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yMjU_fc375326-af69-454b-81d5-a36e72fe6826">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6MzY0YzNkYzc1MzBjNDUwYWEzMzAxZTQ1MzNmOTA1YjAvdGFibGVyYW5nZTozNjRjM2RjNzUzMGM0NTBhYTMzMDFlNDUzM2Y5MDViMF8wLTEtMS0xLTcxMzMw_c229c0f3-90a2-4f63-af33-49e3aad47512">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU0_f490895b-a474-445b-bb8d-e530e902a82a">1-6571</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU5_bc0a1e2e-ea8c-4f6e-9856-7242d97447ab">Merck&#160;&amp; Co., Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18wLTAtMS0xLTcxMzMw_e98dfca4-1fa5-4399-b4d8-6837193636c4">126 East Lincoln Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18xLTAtMS0xLTcxMzMw_59afaf19-02dc-40a1-a56b-555715dd0306">Rahway</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18xLTItMS0xLTcxMzMw_63c11685-461f-48cd-aed9-53be48546ef3">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6ZGM4YzNkYTBiN2UyNGE1N2JmM2ZjMzIyYjA2YzIwOGMvdGFibGVyYW5nZTpkYzhjM2RhMGI3ZTI0YTU3YmYzZmMzMjJiMDZjMjA4Y18xLTMtMS0xLTcxMzMw_194a4b3d-82a1-4b27-ae7d-f21f76cf4dc3">07065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU1_416a8c5c-2f29-4fd1-a39c-ded74b3e418e">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjYw_12d3ce63-76cd-4d39-9be5-28bda02fe93e">740-4000</dei:LocalPhoneNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6MmUwMzVhNDBkM2E2NGZhYTg3NmIwZWJlN2I1NTIzNzYvdGFibGVyYW5nZToyZTAzNWE0MGQzYTY0ZmFhODc2YjBlYmU3YjU1MjM3Nl8wLTAtMS0xLTcxMzMw_3718d436-3b8c-448e-862a-731ffb9f7077">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6MmUwMzVhNDBkM2E2NGZhYTg3NmIwZWJlN2I1NTIzNzYvdGFibGVyYW5nZToyZTAzNWE0MGQzYTY0ZmFhODc2YjBlYmU3YjU1MjM3Nl8wLTEtMS0xLTcxMzMw_2b232619-6695-4ff5-9325-2819add2e7db">22-1918501</dei:EntityTaxIdentificationNumber>
    <dei:Security12bTitle
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8yLTAtMS0xLTcxMzMw_f637ec7a-955b-4477-a642-adcffae15c7f">Common Stock ($0.50&#160;par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8yLTEtMS0xLTcxMzMw_3d25a962-c133-4f7f-b70e-504937bcbe27">MRK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8yLTItMS0xLTcxMzMw_f5dd7a6e-196b-4357-8536-5489c508e5c6">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8zLTAtMS0xLTcxMzMw_45617156-244b-4516-bd1f-cc4dcaf17be4">0.500% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8zLTEtMS0xLTcxMzMw_daeb3fcf-3b18-4761-931a-dcb2585749c2">MRK 24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie82a087054d940a28d8f6c499bf8c1e4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF8zLTItMS0xLTcxMzMw_bf0ffb16-0eb8-4e50-acad-ac0670073763">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF80LTAtMS0xLTcxMzMw_11aa1a32-83c0-4d79-a637-fd4db052f90c">1.875% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF80LTEtMS0xLTcxMzMw_e0d3933d-687c-49f6-a869-e0cec883eb74">MRK/26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i73ee053772e3412998ad8c7c00c4e213_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF80LTItMS0xLTcxMzMw_0e1512be-be9d-4789-8a50-d90884bad251">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF81LTAtMS0xLTcxMzMw_4b553c17-09ad-47f7-a4b1-2257e3fff758">2.500% Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF81LTEtMS0xLTcxMzMw_37f6bf8f-ea20-4a76-ad12-cd800b4c4629">MRK/34</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2b92c98fe9194b0096c6b0f53c277381_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF81LTItMS0xLTcxMzMw_d21df653-9c7a-421a-b28e-49167db7dfdd">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF82LTAtMS0xLTcxMzMw_782671a8-3db7-40b1-b8de-e7794b0e84d7">1.375% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF82LTEtMS0xLTcxMzMw_56fe9c65-49ae-4fcf-8b3e-7c49e0cf5ee0">MRK 36A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie1255237aaf84f9ba5054406bb772722_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWJkYWI2YTY2NjkwNGM0NDlkNTY0YWRiOWU2NzQ5MjgvdGFibGVyYW5nZTo5YmRhYjZhNjY2OTA0YzQ0OWQ1NjRhZGI5ZTY3NDkyOF82LTItMS0xLTcxMzMw_0a5f6490-6015-4d43-99a6-eb5b9f3644b8">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU4_16ac8bb4-c48f-4968-bbb4-c45a26a78b63">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjU2_e80dac77-5ed7-460b-9ab7-778eb40fc8ad">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjUx_cea1903a-69c4-44c5-91d2-28eaf71fbcff">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjYx_fce71f24-cf96-4f78-b9bc-2d6b8d2f2464">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWE0Njc1ZjJlYzE3NDE4YzlkNTA5NTgwMTVmODdjOWIvdGFibGVyYW5nZTo5YTQ2NzVmMmVjMTc0MThjOWQ1MDk1ODAxNWY4N2M5Yl8wLTAtMS0xLTcxMzMw_66f40c1b-cc09-4ba6-9f04-41f232345725">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWE0Njc1ZjJlYzE3NDE4YzlkNTA5NTgwMTVmODdjOWIvdGFibGVyYW5nZTo5YTQ2NzVmMmVjMTc0MThjOWQ1MDk1ODAxNWY4N2M5Yl8xLTMtMS0xLTcxMzMw_00d3fd55-fb4b-42bf-8e38-535d6e8727db">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6OWE0Njc1ZjJlYzE3NDE4YzlkNTA5NTgwMTVmODdjOWIvdGFibGVyYW5nZTo5YTQ2NzVmMmVjMTc0MThjOWQ1MDk1ODAxNWY4N2M5Yl8yLTMtMS0xLTcxMzMw_aac6ec11-642c-4ffe-9846-11090b176293">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjYy_ab8eca54-9136-48be-863d-046eb3d29044">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8yNjUy_6ed5301b-f4e2-4377-aa96-9f68c3ab6e49">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic48140e5f2c345cd8c115278efdfc4d5_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8xMDk5NTExNjM5NTg1_5089beba-9fde-4d7b-bd99-04a8d19704d9"
      unitRef="shares">2538592467</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat
      contextRef="i988d9636bde7433d8e2793b8bbe786ff_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGV4dHJlZ2lvbjpmYTIzNDg3NjQ3M2M0NDlhYTRmNGIyN2U1Y2RlNTM3Zl8xMDk5NTExNjM5NzA5_35ce4d2b-4c9b-4481-bb48-0351c220ba7a"
      unitRef="usd">230820000000</dei:EntityPublicFloat>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xL2ZyYWc6ZmEyMzQ4NzY0NzNjNDQ5YWE0ZjRiMjdlNWNkZTUzN2YvdGFibGU6YzliZjVhYjcxNGNiNDM3ZTg5NWFhOGEzNDY0MDJlZDAvdGFibGVyYW5nZTpjOWJmNWFiNzE0Y2I0MzdlODk1YWE4YTM0NjQwMmVkMF8yLTAtMS0xLTcxMzMw_a22d0a7c-2a21-4d19-bc55-dc70698eae23">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Proxy Statement for the Annual Meeting of Shareholders to be held May&#160;23, 2023, to be filed with the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Securities and Exchange Commission within 120&#160;days after the close of the fiscal year covered by this report&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:Revenues
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEtMS0xLTEtNzEzMzA_84464a4e-99d7-4fb7-bfcd-260e14260db9"
      unitRef="usd">59283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEtMy0xLTEtNzEzMzA_c2ae8312-81e5-4d6b-ab5a-28c547f0a482"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEtNS0xLTEtNzEzMzA_94c2f89f-559a-4b42-9c66-233f6b193f69"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzMtMS0xLTEtNzEzMzA_b5bba2b5-f4be-47d5-a3b6-eaf3d6b55c8f"
      unitRef="usd">17411000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzMtMy0xLTEtNzEzMzA_0f8adcb4-d621-47b5-80f2-937536b4fcdc"
      unitRef="usd">13626000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzMtNS0xLTEtNzEzMzA_b62b4008-7a0e-4d20-b101-140783d14111"
      unitRef="usd">13618000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzQtMS0xLTEtNzEzMzA_e1d12365-bbcf-44d9-8568-d158ea4bcd2c"
      unitRef="usd">10042000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzQtMy0xLTEtNzEzMzA_75658cbe-d604-42b0-a0f1-4da9350b1f76"
      unitRef="usd">9634000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzQtNS0xLTEtNzEzMzA_6457cf1e-d4f8-4343-823e-fbf96f07bb1d"
      unitRef="usd">8955000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzUtMS0xLTEtNzEzMzA_5dc4b231-9603-4413-b8a6-b770c4fef5f0"
      unitRef="usd">13548000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzUtMy0xLTEtNzEzMzA_52cbf22a-ac41-420b-abf0-6e6cbdcb0697"
      unitRef="usd">12245000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzUtNS0xLTEtNzEzMzA_cd258fff-3c7c-41ed-a706-22d42e0c1ec9"
      unitRef="usd">13397000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzYtMS0xLTEtNzEzMzA_aaff87b2-59b1-421f-a88f-e5335f59fbbd"
      unitRef="usd">337000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzYtMy0xLTEtNzEzMzA_bd675427-a67e-46b4-85b9-7fcdb8b1b74b"
      unitRef="usd">661000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzYtNS0xLTEtNzEzMzA_9aac8d86-755a-48c4-9af5-6e842d96bfc4"
      unitRef="usd">575000000</us-gaap:RestructuringCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzctMS0xLTEtNzEzMzA_1feb55b5-e7c3-4801-b9f2-d049d6984574"
      unitRef="usd">-1501000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzctMy0xLTEtNzEzMzA_7c94603c-737d-4eb3-aeef-d3f050dd8271"
      unitRef="usd">1341000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzctNS0xLTEtNzEzMzA_084e8321-b481-419f-a636-9b21ab0bc7f4"
      unitRef="usd">890000000</us-gaap:OtherNonoperatingIncomeExpense>
    <mrk:CostsExpensesAndOther
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzgtMS0xLTEtNzEzMzA_e14760fb-3df6-466c-8126-f7b2bd39c499"
      unitRef="usd">42839000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzgtMy0xLTEtNzEzMzA_517b89db-095c-4d06-823d-4910e8cd5367"
      unitRef="usd">34825000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzgtNS0xLTEtNzEzMzA_c99dae0f-04d7-4c10-9c61-e6e615db9b7c"
      unitRef="usd">35655000000</mrk:CostsExpensesAndOther>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzktMS0xLTEtNzEzMzA_75051f30-cfe0-48a8-a47f-d39f65070c03"
      unitRef="usd">16444000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzktMy0xLTEtNzEzMzA_0161d1cf-01e0-4e19-b3c0-e02aca24f352"
      unitRef="usd">13879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzktNS0xLTEtNzEzMzA_3459bdf5-e0e5-4916-b159-d56497145bb3"
      unitRef="usd">5863000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEwLTEtMS0xLTcxMzMw_0f89ea8c-8f18-4b7e-9ebb-00a1e5829098"
      unitRef="usd">1918000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEwLTMtMS0xLTcxMzMw_471e445d-6a88-4eb9-b71b-2ca14c46a6fd"
      unitRef="usd">1521000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEwLTUtMS0xLTcxMzMw_88363dd4-65d8-4d1d-81ec-dc534b12d45e"
      unitRef="usd">1340000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzExLTEtMS0xLTcxMzMw_255e78f3-0bd4-40c4-b60e-945b0dab26be"
      unitRef="usd">14526000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzExLTMtMS0xLTcxMzMw_34b3f821-efcd-4020-ac28-3037cf20a156"
      unitRef="usd">12358000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzExLTUtMS0xLTcxMzMw_68ae5589-d783-40c4-8294-e5779c69ab0c"
      unitRef="usd">4523000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEyLTEtMS0xLTcxMzMw_36653a2a-76d7-420e-9083-02c0b93470b4"
      unitRef="usd">7000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEyLTMtMS0xLTcxMzMw_f2eedd16-7c2f-4b23-b26f-05bbf13eccac"
      unitRef="usd">13000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEyLTUtMS0xLTcxMzMw_c0a2e39a-c686-4489-ba38-24674be9f660"
      unitRef="usd">4000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEzLTEtMS0xLTcxMzMw_1b70d929-1a3b-4655-aa36-d2dc61d7f4ea"
      unitRef="usd">14519000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEzLTMtMS0xLTcxMzMw_da45f28c-7db8-446b-aa65-9d41b3b012b2"
      unitRef="usd">12345000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzEzLTUtMS0xLTcxMzMw_ebcd046a-ba15-4265-af90-1c19504ca184"
      unitRef="usd">4519000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE0LTEtMS0xLTcxMzMw_3a6516d5-f5bf-4b31-b8a1-54e37bbf7965"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE0LTMtMS0xLTcxMzMw_5bd776a4-030d-4d30-bead-0f3ee7a39088"
      unitRef="usd">704000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE0LTUtMS0xLTcxMzMw_c5f88b80-0016-495d-a0b1-e249d45a32f3"
      unitRef="usd">2548000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE1LTEtMS0xLTcxMzMw_0e2a22e7-f670-43d8-8085-38d9f0d82f2d"
      unitRef="usd">14519000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE1LTMtMS0xLTcxMzMw_e421d46a-979c-432d-8e8e-1b5c77818a7a"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE1LTUtMS0xLTcxMzMw_30175bd6-90bf-4acd-ba56-8a742c300bec"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE3LTEtMS0xLTcxMzMw_2d41252d-e082-4224-a958-d648991530c7"
      unitRef="usdPerShare">5.73</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE3LTMtMS0xLTcxMzMw_b0a1f449-66c3-427f-90cf-f4986ed111a5"
      unitRef="usdPerShare">4.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE3LTUtMS0xLTcxMzMw_b9a2a8c9-91c7-43c6-8b5c-c52f54a95885"
      unitRef="usdPerShare">1.79</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE4LTEtMS0xLTcxMzMw_c6a48c20-f624-448b-b54b-e28d092e5f45"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE4LTMtMS0xLTcxMzMw_b7e2a7de-4f33-4d5c-9b38-d2b3614f1202"
      unitRef="usdPerShare">0.28</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE4LTUtMS0xLTcxMzMw_f3cbc6b6-a1d3-4735-ba91-254c4e6b5c71"
      unitRef="usdPerShare">1.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE5LTEtMS0xLTcxMzMw_1d901e36-21cf-4d8f-8104-5bb253a70a0a"
      unitRef="usdPerShare">5.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE5LTMtMS0xLTcxMzMw_5d231a59-bec9-4487-908d-322055d6cf7f"
      unitRef="usdPerShare">5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzE5LTUtMS0xLTcxMzMw_c9db3706-a7b3-4ffe-87cd-52f5e3f29227"
      unitRef="usdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIxLTEtMS0xLTcxMzMw_28d7a2df-d855-46f8-86d1-69b7434b0cad"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIxLTMtMS0xLTcxMzMw_5dfa1e8d-4d12-40e1-b0e8-8faaeb3328aa"
      unitRef="usdPerShare">4.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIxLTUtMS0xLTcxMzMw_5fe6be47-2d66-4577-8580-ab64270cc042"
      unitRef="usdPerShare">1.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIyLTEtMS0xLTcxMzMw_d1ba3229-2983-4e8f-b2c8-ebf61c4e254c"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIyLTMtMS0xLTcxMzMw_dde1c795-da31-4679-829a-380b374aa0bf"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIyLTUtMS0xLTcxMzMw_f4aab314-7632-4a8d-94f9-4933d657f04a"
      unitRef="usdPerShare">1.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIzLTEtMS0xLTcxMzMw_5a1c9517-7cc1-4c30-9fa4-40477d23948d"
      unitRef="usdPerShare">5.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIzLTMtMS0xLTcxMzMw_3b5d8d6e-9c5b-4fde-95d5-5edc898bf576"
      unitRef="usdPerShare">5.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpkNzJmYzU1NjUxODI0NDg3YTM3NDc1MTc0ZWUwNDJmMS90YWJsZXJhbmdlOmQ3MmZjNTU2NTE4MjQ0ODdhMzc0NzUxNzRlZTA0MmYxXzIzLTUtMS0xLTcxMzMw_e391ba98-f6a1-4135-90bd-f884053cf687"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzEtMS0xLTEtNzEzMzA_234f6839-404f-499e-8929-a6e87d510f4e"
      unitRef="usd">14519000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzEtMy0xLTEtNzEzMzA_ade326cf-0e42-41e1-a50f-6df857c63027"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzEtNS0xLTEtNzEzMzA_68c89a68-e8e3-46f3-9a83-4aa8fe3eb3e7"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzMtMS0xLTEtNzEzMzA_1a5b821d-536c-4d15-b47c-d2650479338d"
      unitRef="usd">-71000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzMtMy0xLTEtNzEzMzA_98a02523-59d6-47ed-8692-15f0d2e97468"
      unitRef="usd">410000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzMtNS0xLTEtNzEzMzA_45b7ae06-6ed2-4c24-8c29-1c02c3d469f7"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzQtMS0xLTEtNzEzMzA_6c2f8bf0-6a77-4218-9214-a332f7072d52"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzQtMy0xLTEtNzEzMzA_1c868bf2-7dee-4396-a47b-5665e0d33aac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzQtNS0xLTEtNzEzMzA_02fde83b-ea46-4652-98ab-507266766a42"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzUtMS0xLTEtNzEzMzA_e18515c7-ac8c-4aef-9c47-273110e5e6bc"
      unitRef="usd">-335000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzUtMy0xLTEtNzEzMzA_6e194b3b-54d9-437f-abee-e2558a82ed53"
      unitRef="usd">-1769000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzUtNS0xLTEtNzEzMzA_74c45fa8-4600-47ea-9fca-4f2bfb570605"
      unitRef="usd">279000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzYtMS0xLTEtNzEzMzA_e30a78af-9fe6-4aa1-a090-b57629337918"
      unitRef="usd">-603000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzYtMy0xLTEtNzEzMzA_3a3e28f6-6b6d-49af-be53-582803e981bd"
      unitRef="usd">-423000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzYtNS0xLTEtNzEzMzA_4cc1bc32-1157-41ce-9fff-cd1c7016d764"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzctMS0xLTEtNzEzMzA_26ecb0ca-cb51-4963-aeb6-69b7c3584930"
      unitRef="usd">-339000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzctMy0xLTEtNzEzMzA_79fa0c07-4e1a-431e-93bc-13f36b6f4e63"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzctNS0xLTEtNzEzMzA_fd44bafd-a38a-46c3-9555-e6c8d917cbac"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzgtMS0xLTEtNzEzMzA_8d8c9982-6fde-4e17-9f66-bd1a614e9896"
      unitRef="usd">14180000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzgtMy0xLTEtNzEzMzA_7759562d-820c-4877-beef-d9508dac73f3"
      unitRef="usd">14805000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzAvZnJhZzphMWIyNDdjYWExNmI0MjAyOTJmMmJiMjQyZTMzMmVkYi90YWJsZTpmYWRhNWZmOGRhNDc0NmMyYmQwNTIwNTZlZGU0NjI3NS90YWJsZXJhbmdlOmZhZGE1ZmY4ZGE0NzQ2YzJiZDA1MjA1NmVkZTQ2Mjc1XzgtNS0xLTEtNzEzMzA_d0b15607-632d-42fa-98cd-e41e800dfabe"
      unitRef="usd">6626000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMtMS0xLTEtNzEzMzA_6790cb0b-f271-4728-ac24-77e0697fc375"
      unitRef="usd">12694000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMtMy0xLTEtNzEzMzA_ffa09e1d-969a-4567-be68-5cf7cb8cb970"
      unitRef="usd">8096000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMS0xLTEtMTIxNzg3_99e6a31e-97df-4002-977f-042bfa5804ba"
      unitRef="usd">498000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMy0xLTEtMTIxNzg3_87e88920-0573-42d9-8358-8f46b82148b8"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo1MmQ2MGY4ZTdhYzU0YmM1YjhkNWY3MWVhNGUxNTE5NF82Nw_650e1333-87af-43e9-b123-e63973eae7b0"
      unitRef="usd">72000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo1MmQ2MGY4ZTdhYzU0YmM1YjhkNWY3MWVhNGUxNTE5NF84MQ_48510082-e8a2-4723-89d7-9688186fdffc"
      unitRef="usd">62000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMS0xLTEtNzEzMzA_cc41fb1b-877d-495f-8afb-d562f4fc34dc"
      unitRef="usd">9450000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQtMy0xLTEtNzEzMzA_8c6c2923-6fec-47af-9aa9-7b0d943d9c59"
      unitRef="usd">9230000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo2MjdmYzg1NTRjMmE0NDNjODIxMGU3ZDM5YjFjOWU1MV80MQ_5ba6612c-0333-4ea7-8a5b-bb3bb4870dca"
      unitRef="usd">2938000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo2MjdmYzg1NTRjMmE0NDNjODIxMGU3ZDM5YjFjOWU1MV81NA_f59f2822-0803-4a15-b7fb-b1ddb1a62188"
      unitRef="usd">2194000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMS0xLTEtNzEzMzA_7bd1f409-e49e-4776-b820-5c9667624279"
      unitRef="usd">5911000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzUtMy0xLTEtNzEzMzA_9dcb14d7-811c-4c4d-a21d-89d75d6f1afa"
      unitRef="usd">5953000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzYtMS0xLTEtNzEzMzA_2b510771-ddf0-40bf-b78d-93debc2cf550"
      unitRef="usd">7169000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzYtMy0xLTEtNzEzMzA_ea2010ff-2c60-4bcf-9539-eb397699f7ee"
      unitRef="usd">6987000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzgtMS0xLTEtNzEzMzA_2f364fbf-99f0-4f63-9f80-e7038f8b9207"
      unitRef="usd">35722000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzgtMy0xLTEtNzEzMzA_13cccb2c-17a4-45b2-af3e-46c98fbdf124"
      unitRef="usd">30266000000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzktMS0xLTEtNzEzMzA_255ac470-494b-4f5e-9a70-c33b669678e8"
      unitRef="usd">1015000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzktMy0xLTEtNzEzMzA_5d9017e9-7a94-4e75-89ba-fbd2515a67f9"
      unitRef="usd">370000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:Land
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzExLTEtMS0xLTcxMzMw_8805c834-7708-49e4-bfea-bc8666fd55fa"
      unitRef="usd">295000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzExLTMtMS0xLTcxMzMw_f674d695-d9f9-4f1a-91c7-f00b2c5353c6"
      unitRef="usd">326000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEyLTEtMS0xLTcxMzMw_019dcc75-23ca-485c-97fe-30d2bfddfbf8"
      unitRef="usd">13166000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEyLTMtMS0xLTcxMzMw_d78c9ac8-39fe-4d4c-b695-2fc4cb95338c"
      unitRef="usd">12529000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEzLTEtMS0xLTcxMzMw_6c56ed53-2a3b-432f-8efb-f1d9a342e58d"
      unitRef="usd">16760000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzEzLTMtMS0xLTcxMzMw_7e078623-3e21-4f24-87e6-8b184edb8082"
      unitRef="usd">16303000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE0LTEtMS0xLTcxMzMw_c6874fa5-d752-42b2-8020-c166e4e706b2"
      unitRef="usd">9186000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE0LTMtMS0xLTcxMzMw_1de3b35e-e160-4cf8-b52f-8c89f055006b"
      unitRef="usd">8313000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE1LTEtMS0xLTcxMzMw_e64cdd76-7c31-4465-b3a1-f8c29b4f8791"
      unitRef="usd">39407000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE1LTMtMS0xLTcxMzMw_74d3bd62-7e0d-434d-bf70-f45b379565ba"
      unitRef="usd">37471000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE2LTEtMS0xLTcxMzMw_0904f36b-2e3f-43f8-ba88-e2c818c6f4a9"
      unitRef="usd">17985000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE2LTMtMS0xLTcxMzMw_0081df0d-8e9d-4ce4-a11c-0f3f961199ef"
      unitRef="usd">18192000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE3LTEtMS0xLTcxMzMw_8045b332-9491-47ad-8946-8406bc396e99"
      unitRef="usd">21422000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE3LTMtMS0xLTcxMzMw_f8ab8f28-7de9-460e-b4e6-b19671b4704a"
      unitRef="usd">19279000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE4LTEtMS0xLTcxMzMw_7b05b389-faa3-428f-bbd1-21c69cbde30c"
      unitRef="usd">21204000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE4LTMtMS0xLTcxMzMw_1b86838a-6f7d-4fb3-82c0-950ec10a7919"
      unitRef="usd">21264000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE5LTEtMS0xLTcxMzMw_f3767371-dc08-41db-a6fd-f6d90443cdb6"
      unitRef="usd">20269000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzE5LTMtMS0xLTcxMzMw_67192ac1-0a1c-49eb-870f-ed1ab0eb9af4"
      unitRef="usd">22933000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIwLTEtMS0xLTcxMzMw_57afa5b9-2759-4ed0-bc08-ba0444459acc"
      unitRef="usd">9528000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIwLTMtMS0xLTcxMzMw_c40c8d14-83e5-4f06-9207-3fd8209fb3d3"
      unitRef="usd">11582000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIyLTEtMS0xLTcxMzMw_2bee8908-a557-4011-8e38-0cffb7c5927a"
      unitRef="usd">109160000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzIyLTMtMS0xLTcxMzMw_6695dcc2-0d0f-4891-9ac2-fa6fb6e8cc45"
      unitRef="usd">105694000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI1LTEtMS0xLTcxMzMw_36ff02ec-de56-407e-890e-fb0f06a8e19c"
      unitRef="usd">1946000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI1LTMtMS0xLTcxMzMw_0e938f20-8eb9-4d72-a9a3-e8719a255ea0"
      unitRef="usd">2412000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI2LTEtMS0xLTcxMzMw_505f09a7-adbe-4b49-8565-56ea4fb4c5c6"
      unitRef="usd">4264000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI2LTMtMS0xLTcxMzMw_eee9484b-f844-4a29-8cac-7a88d7f3acd9"
      unitRef="usd">4609000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI3LTEtMS0xLTcxMzMw_738c31c6-af1a-46d1-aa60-c05542f0aa7d"
      unitRef="usd">14159000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI3LTMtMS0xLTcxMzMw_4edc2ce7-b88e-49b2-9a00-da1aeada57ec"
      unitRef="usd">13859000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI4LTEtMS0xLTcxMzMw_dfe2f4e0-26f3-49fa-8f23-6700c63d3e91"
      unitRef="usd">1986000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI4LTMtMS0xLTcxMzMw_9bc60d08-aac9-4e3f-824c-e990600f1cfe"
      unitRef="usd">1224000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI5LTEtMS0xLTcxMzMw_d9e24dbe-f330-4556-90d9-70b72e82334e"
      unitRef="usd">1884000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzI5LTMtMS0xLTcxMzMw_6012abe8-ace3-4116-9381-83af6278662b"
      unitRef="usd">1768000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMxLTEtMS0xLTcxMzMw_2b4501e2-8c5b-4121-b129-1da9c4d8a447"
      unitRef="usd">24239000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMxLTMtMS0xLTcxMzMw_545ed769-b0ec-41ed-9be9-e3aadc1e294d"
      unitRef="usd">23872000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMyLTEtMS0xLTcxMzMw_44f0f4e8-6fbb-433c-9985-5f884a817cdd"
      unitRef="usd">28745000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMyLTMtMS0xLTcxMzMw_cc4a6c7a-a4cc-4167-8579-b4f66139329b"
      unitRef="usd">30690000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMzLTEtMS0xLTcxMzMw_3943c167-a587-4fde-bef3-0ca280414442"
      unitRef="usd">1795000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzMzLTMtMS0xLTcxMzMw_0f1ef707-d0c6-4e89-a1c7-9d2314b5ff5c"
      unitRef="usd">3441000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM0LTEtMS0xLTcxMzMw_b5bc24f5-dab3-4ca7-8ba7-c427f5eb1f4b"
      unitRef="usd">8323000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM0LTMtMS0xLTcxMzMw_d42bcf5c-0975-40af-bf30-da4a28e641a0"
      unitRef="usd">9434000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfMTk_2eecb14e-ee56-421a-86ea-8980278c747d"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfMTk_c0992fe8-b8db-4b69-ac04-b5075db5a030"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNDU_c41ecf73-1b37-4a70-af1a-465d95d38e0c"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNDU_f7627945-fb21-4674-a7dc-ab2f93d75c6e"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNjQ_2aec779b-4ca2-4f50-9a3e-c1e2daf1b023"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDU2ODllYzNlYzdkNDA0Yzk2NDVmMmE3NjIxYjNlNzJfNjQ_b9512a8b-4948-49ab-be2d-e887e5c048d4"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTEtMS0xLTcxMzMw_19c35809-b44c-42bf-ac9d-1c805187702a"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM3LTMtMS0xLTcxMzMw_1093e3b6-3ffb-47fd-878e-5dd48375cffa"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM4LTEtMS0xLTcxMzMw_bd9cceb2-8cd5-487b-9caa-881e63e2f63c"
      unitRef="usd">44379000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM4LTMtMS0xLTcxMzMw_cf5c2ed3-09a3-44be-99d4-84d43360bd72"
      unitRef="usd">44238000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM5LTEtMS0xLTcxMzMw_180772c0-a57a-45d2-836f-0bd95caf3a38"
      unitRef="usd">61081000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzM5LTMtMS0xLTcxMzMw_3bcd84d4-f560-48b8-85e2-00d901333b46"
      unitRef="usd">53696000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQwLTEtMS0xLTcxMzMw_1a3ff7c0-de93-42a3-9315-90c9fcae2790"
      unitRef="usd">-4768000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQwLTMtMS0xLTcxMzMw_afb1581c-fd08-4c18-bc4e-943130ca69bd"
      unitRef="usd">-4429000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQxLTEtMS0xLTcxMzMw_11b8fd32-48f7-42a5-b5f6-72472d9c5648"
      unitRef="usd">102480000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQxLTMtMS0xLTcxMzMw_d191f150-a679-4912-bc0c-80cbc4c6c329"
      unitRef="usd">95293000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDMzZGM3ODhmNTZjNGQzNDhhYjUwOWQ1YWZiZDgxNjVfMzU_c72e5feb-8134-467a-8d39-f00fc4287053"
      unitRef="shares">1039269638</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDMzZGM3ODhmNTZjNGQzNDhhYjUwOWQ1YWZiZDgxNjVfNTU_9bebb2e7-b4d2-466a-9e3a-45011f95454c"
      unitRef="shares">1049499023</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTEtMS0xLTcxMzMw_bee83ad0-9a10-4122-8958-ce7550b70ffd"
      unitRef="usd">56489000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQyLTMtMS0xLTcxMzMw_bfcb72a1-1eda-41aa-bae5-869e10a13768"
      unitRef="usd">57109000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQzLTEtMS0xLTcxMzMw_de47589e-d3d1-46b0-87dc-735b806129a3"
      unitRef="usd">45991000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQzLTMtMS0xLTcxMzMw_a9ddb402-d39d-4e03-a72f-9b502f2e9254"
      unitRef="usd">38184000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ0LTEtMS0xLTcxMzMw_94aaa095-a91a-4401-8d1c-fdde5231b505"
      unitRef="usd">67000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ0LTMtMS0xLTcxMzMw_c14a07b2-ae57-466b-aa7c-5fbfa52806a9"
      unitRef="usd">73000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ1LTEtMS0xLTcxMzMw_0ffc5bfc-1674-4a40-b254-4015fa496e88"
      unitRef="usd">46058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ1LTMtMS0xLTcxMzMw_a81b8719-0088-4ffd-9be1-f29251197360"
      unitRef="usd">38257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ2LTEtMS0xLTcxMzMw_6cb3ed93-4a8d-4162-b119-e0672da378a5"
      unitRef="usd">109160000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzMvZnJhZzo1YzNlYTFhNzNmNDI0M2Y1OWVhM2IxZDRjYmZlNTA2Yy90YWJsZTo2OGYwOTg1NTMwNjc0OTcyOTdiZjliMjA2NGVmYzZmZS90YWJsZXJhbmdlOjY4ZjA5ODU1MzA2NzQ5NzI5N2JmOWIyMDY0ZWZjNmZlXzQ2LTMtMS0xLTcxMzMw_5bb1257c-312e-435c-b9dd-36f60ac888aa"
      unitRef="usd">105694000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i870984a7a0814cf9a460c7a4b331c37f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMS0xLTEtNzEzMzA_f35e2045-d86b-415f-bfb9-88270bced672"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34c3eef0e8e84d89b879da53d7b2eea5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMy0xLTEtNzEzMzA_4a85bdd7-0cae-4a99-b1c9-51dddb048feb"
      unitRef="usd">39660000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8390537a2d14419183a1bd3184b81223_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtNS0xLTEtNzEzMzA_6996d4f2-e9a6-4a86-a0c2-d8f561ac137c"
      unitRef="usd">46602000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief9bf241be3f43c8aac25c903996f2e3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtNy0xLTEtNzEzMzA_f3a68377-4a71-43b0-add6-aae3d19b25ac"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3278c06a03cc4b83ad0c695bac71a99b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtOS0xLTEtNzEzMzA_e048aefa-5f0d-4687-b807-f6f523c3368b"
      unitRef="usd">-55950000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfa7328e43b745528acea4fb982c4641_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMTEtMS0xLTcxMzMw_0fea4c1d-20f2-4485-bb50-9f9ff6530ed4"
      unitRef="usd">94000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEtMTMtMS0xLTcxMzMw_460c69c4-84a6-438e-8cb2-a2da6b346594"
      unitRef="usd">26001000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia197d01df12640948153fd9f84a852ed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzItNS0xLTEtNzEzMzA_2c0da7df-58ad-4441-9a50-a7e2d04eeaad"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzItMTMtMS0xLTcxMzMw_8c9f035f-6e03-4b58-a3f9-c56420de853b"
      unitRef="usd">7067000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7bb557eb99a549468966b5c77bdf145c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzMtNy0xLTEtNzEzMzA_f8502dbc-4293-4700-b5c0-5c2e34049bdc"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzMtMTMtMS0xLTcxMzMw_afd90809-b2ac-414c-8311-28158855a0c5"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo1YTc3ZGFmZTM0M2E0OTc1OGU0NjRkZWVhZWM4NzRhM180NQ_5d71f305-c6f4-4163-a015-3dcb3707dcbd"
      unitRef="usdPerShare">2.48</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia197d01df12640948153fd9f84a852ed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzQtNS0xLTEtNzEzMzA_70d7d1b4-7ebf-4832-9980-b938bfbbce49"
      unitRef="usd">6307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzQtMTMtMS0xLTcxMzMw_23cf0669-ab30-43cc-8ca8-17d5886e93fd"
      unitRef="usd">6307000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzUtOS0xLTEtNzEzMzA_a40e43ff-4e59-409e-842a-c66bc6a7e0ac"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzUtMTMtMS0xLTcxMzMw_98949b63-480b-4c21-aac8-da41d4bf84b1"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i757e7f21bc85496da119ddd7169fc883_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzYtMTEtMS0xLTcxMzMw_b29a008b-c8a9-40b6-97ed-293f11c83309"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzYtMTMtMS0xLTcxMzMw_122cd331-8e3e-4e42-a5c2-34bb904b1250"
      unitRef="usd">15000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i757e7f21bc85496da119ddd7169fc883_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzctMTEtMS0xLTcxMzMw_d83b976b-9079-4f2d-8d59-ec69657fa2dd"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzctMTMtMS0xLTcxMzMw_2f69b250-c190-498f-a7dd-e9ef030a99c8"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="ieca83e510fb04e31bb09eba119b9f8c4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzgtMy0xLTEtNzEzMzA_baf9bd80-848b-46dd-9014-9776d03ad856"
      unitRef="usd">72000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzgtOS0xLTEtNzEzMzA_53a7d5b4-6ae2-49d5-95f5-8beac00b1210"
      unitRef="usd">-444000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzgtMTMtMS0xLTcxMzMw_262ef44e-2440-4cd0-aebf-653b8424c6a9"
      unitRef="usd">-372000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMS0xLTEtNzEzMzA_cc303c93-c8a9-41ea-99d9-dd269e04f44c"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76fa2929d2f845298f21dbaee7f2ef16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMy0xLTEtNzEzMzA_c91645d1-2cc2-44b8-8a4a-ceeb1f996058"
      unitRef="usd">39588000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e85ab6516bc49b78971f2a3b5bdf41b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktNS0xLTEtNzEzMzA_24b335de-d832-4ba6-a267-096375d07b94"
      unitRef="usd">47362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8308747617614e9eab0ac29c4014c53b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktNy0xLTEtNzEzMzA_cd0b14c9-b4cc-49b8-a362-ed51313d8ee2"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06a03badfaf044d5abe8434be9cfeda8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktOS0xLTEtNzEzMzA_84996f0d-f630-4483-ad00-546022de7c2a"
      unitRef="usd">-56787000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07bd86cfed75419480323eb478cad36f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMTEtMS0xLTcxMzMw_f194f57e-b01c-4ce1-a887-59c9da47584e"
      unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzktMTMtMS0xLTcxMzMw_e24fd1e2-eac5-4270-b0b8-407b92f0239c"
      unitRef="usd">25404000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i77dda1a9a6f4400c931bc6647f046197_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEwLTUtMS0xLTcxMzMw_ebe9ad6e-98db-43b7-850a-c23746f03585"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEwLTEzLTEtMS03MTMzMA_5eddfbd3-e5a5-4031-a715-f20040b117f4"
      unitRef="usd">13049000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e06bfa03d5c48d190290cd1a81579c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzExLTctMS0xLTcxMzMw_128be2e8-d2c8-42e9-854b-7fa77a95600e"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzExLTEzLTEtMS03MTMzMA_e217a2ff-7280-43f6-8135-887f8af8e9a4"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246NmM3YjM5MDNkYjAwNDhiNWI0Y2Q2OTZmNWY0OGIxZWJfNDU_5dee3389-92f2-4505-b322-34c5f800ab3a"
      unitRef="usdPerShare">2.64</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i77dda1a9a6f4400c931bc6647f046197_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEyLTUtMS0xLTcxMzMw_cd0a86c1-3409-4faa-8c46-dfcf6d5f68ef"
      unitRef="usd">6715000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEyLTEzLTEtMS03MTMzMA_a09c2647-7ac1-4bca-9978-e966a59f141d"
      unitRef="usd">6715000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEzLTktMS0xLTcxMzMw_55da466c-745a-48a3-a373-ef8c642aee43"
      unitRef="usd">840000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzEzLTEzLTEtMS03MTMzMA_d2ed3bf9-1d24-473e-8e0f-0eb300091282"
      unitRef="usd">840000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i21cb44e6556045cc99f6b8f0af62b975_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTMtMS0xLTcyMzA5_6b8d72a0-2080-43fd-8546-f8e06c261fa1"
      unitRef="usd">4643000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i0e06bfa03d5c48d190290cd1a81579c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTctMS0xLTcyMzA5_38db9289-b5a2-426f-9127-b1880fed9e1d"
      unitRef="usd">449000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i5efd7e6396194280b6782fba989ef826_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTExLTEtMS03MjMwOQ_4922572a-74f7-4b4b-bf0d-d2c916eff1e0"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTEzLTEtMS03MjMwOQ_1181fd55-1fa5-4caa-a7d7-e9c9bd86d35e"
      unitRef="usd">5091000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5efd7e6396194280b6782fba989ef826_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTExLTEtMS03MTMzMA_8676382f-54fd-485d-900b-aa08c9151d12"
      unitRef="usd">16000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE0LTEzLTEtMS03MTMzMA_06e71a17-5ba1-4815-a868-2bb6d34448ca"
      unitRef="usd">16000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5efd7e6396194280b6782fba989ef826_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE1LTExLTEtMS03MTMzMA_7c6e0c55-ba52-4b50-9366-b11318852d16"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE1LTEzLTEtMS03MTMzMA_0f8ecfb3-32ef-4527-8880-5db70f4f9e61"
      unitRef="usd">29000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i21cb44e6556045cc99f6b8f0af62b975_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE2LTMtMS0xLTcxMzMw_9c012ec8-734b-4789-a2e3-6fe70b77f8c2"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE2LTktMS0xLTcxMzMw_b724e3a1-e4ca-447b-90df-8db703725379"
      unitRef="usd">-518000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE2LTEzLTEtMS03MTMzMA_48a9ca44-eb9b-4922-beed-29bb199af029"
      unitRef="usd">-525000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTEtMS0xLTcxMzMw_0c354e54-e47a-4dec-a0eb-86127d2d6944"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33db89af09b04ff88b03f0b7993e3646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTMtMS0xLTcxMzMw_4361f733-9375-49de-ba43-41e65f78e8b0"
      unitRef="usd">44238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32922e48a4134ee0925f14bd1c083d4c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTUtMS0xLTcxMzMw_b9fb08d0-d70e-40a3-8f1e-5b537946aa93"
      unitRef="usd">53696000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i542103e76e6741a6805402bb88262b54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTctMS0xLTcxMzMw_59195142-2c1a-406e-ba62-ed84aff196bb"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i170384be3a654d119874ff6b7ed2eb92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTktMS0xLTcxMzMw_7d9ad4ab-e36b-440b-9242-028d95bf445e"
      unitRef="usd">-57109000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d8637c5e12649be98c7fe608718e069_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTExLTEtMS03MTMzMA_455317a9-c26d-4405-ad45-89b014112d3c"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE3LTEzLTEtMS03MTMzMA_41a5bfae-745a-423e-95c4-9d66fcb03c51"
      unitRef="usd">38257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iba91acdcb37e4a5d8335bd645c29a624_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE4LTUtMS0xLTcxMzMw_66e28ecb-539f-4810-8f1e-660600559037"
      unitRef="usd">14519000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE4LTEzLTEtMS03MTMzMA_e1c033a1-ea85-45df-89df-f73ed522dbca"
      unitRef="usd">14519000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7edbd57c4cf745c49a7f15beff700c5b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE5LTctMS0xLTcxMzMw_b2401fdb-f313-46ec-ba17-27434779deff"
      unitRef="usd">-339000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzE5LTEzLTEtMS03MTMzMA_118111f5-f2a6-4a57-bf74-ddc7fb223e5a"
      unitRef="usd">-339000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIwLTAtMS0xLTcxMzMwL3RleHRyZWdpb246YzI0ZjVlN2MzYWQ0NGE2OGI0YjRmMWRiNmRlMzZkMDdfNDU_30b19d4d-243e-456c-bbb3-5b32a1300e33"
      unitRef="usdPerShare">2.80</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="iba91acdcb37e4a5d8335bd645c29a624_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIwLTUtMS0xLTcxMzMw_0135a64c-2199-421b-864d-205d207336fd"
      unitRef="usd">7134000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIwLTEzLTEtMS03MTMzMA_0ec32e82-6fdd-437a-a593-4cb2a6ff8d27"
      unitRef="usd">7134000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i15342adbb5e246fdaf6be1f7d6f161e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIzLTExLTEtMS03MTMzMA_426fdbda-05af-46bc-894e-1ba0c0b24bcb"
      unitRef="usd">7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzIzLTEzLTEtMS03MTMzMA_e139f137-2e9e-4b71-86e2-e7a874b649dd"
      unitRef="usd">7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i15342adbb5e246fdaf6be1f7d6f161e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI0LTExLTEtMS03MTMzMA_383a4f31-3685-44bd-9f4d-59f3cf96eec0"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI0LTEzLTEtMS03MTMzMA_940f89b8-f37e-47c5-95b3-273fed7a280b"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i074f335e3eb646d3a641ffed1cc54d29_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI1LTMtMS0xLTcxMzMw_03d4ade1-b6f7-421a-8110-0125c5ecdda7"
      unitRef="usd">-141000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI1LTktMS0xLTcxMzMw_15981058-25ba-4481-a961-a6f76d658ab1"
      unitRef="usd">-620000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI1LTEzLTEtMS03MTMzMA_94331761-5a0b-43d5-acb9-38cb18532da5"
      unitRef="usd">-761000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i326e10191d3348dd83075e847b9e3840_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTEtMS0xLTcxMzMw_efdadf20-4589-47ba-963e-ef6116c614f3"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e37f8c9ec504794ac6b72298c935735_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTMtMS0xLTcxMzMw_b7953fe5-24bc-47e2-8d8e-ff41e1db9183"
      unitRef="usd">44379000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb5bb04f307f47dcb79f92a26d5a4eb1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTUtMS0xLTcxMzMw_5223e722-cafc-4b63-adfe-b50f777a91ac"
      unitRef="usd">61081000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f1e6ddf39c24d7f843d5f7b097b9c69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTctMS0xLTcxMzMw_c6df57c8-1d02-40fe-a985-8f8866102c30"
      unitRef="usd">-4768000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if945586aba2d4519bdf8f10667672306_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTktMS0xLTcxMzMw_c87f7e39-0771-4c72-ba3d-07558845a7f2"
      unitRef="usd">-56489000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf11a2d764284028938a06f7df969c24_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTExLTEtMS03MTMzMA_49b76dae-7c91-45f2-8fea-682464dff27c"
      unitRef="usd">67000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzYvZnJhZzphNDZlNDJlMzI3OWY0OTQ1ODdiMTRlNzVhZTczMDdjMS90YWJsZTpiZmNhOGIyNmM4OTE0MmQxYjZmNDMxNGZlZDE1YjM1MC90YWJsZXJhbmdlOmJmY2E4YjI2Yzg5MTQyZDFiNmY0MzE0ZmVkMTViMzUwXzI2LTEzLTEtMS03MTMzMA_89e6de8a-ed92-4fd6-b3d2-b894d20e845a"
      unitRef="usd">46058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzItMS0xLTEtNzEzMzA_b278bfee-1b78-408d-aba1-01a966321c63"
      unitRef="usd">14526000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzItMy0xLTEtNzEzMzA_23e78cfc-02b5-498f-806c-acb4a01dd09f"
      unitRef="usd">12358000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzItNS0xLTEtNzEzMzA_4bf122c6-5199-4d9b-9a52-ea66cb0b2dc4"
      unitRef="usd">4523000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentForAmortization
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQtMS0xLTEtNzEzMzA_eceb3848-a26f-41fe-889d-55b0ee12e0d2"
      unitRef="usd">2085000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQtMy0xLTEtNzEzMzA_bdfab4e7-e909-48c0-b07f-532126ca6f06"
      unitRef="usd">1636000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQtNS0xLTEtNzEzMzA_439d3535-4850-46a6-88c4-819a696ae17e"
      unitRef="usd">1817000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUtMS0xLTEtNzEzMzA_5ad71459-c7ca-4dab-ab24-d8954739169e"
      unitRef="usd">1824000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUtMy0xLTEtNzEzMzA_8dff6263-26e3-48e1-8b0b-11fdea8b1264"
      unitRef="usd">1578000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUtNS0xLTEtNzEzMzA_89ba8277-4c74-416c-a859-88b67e16c1b2"
      unitRef="usd">1669000000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzYtMS0xLTEtNzEzMzA_eae46e82-29de-4552-8f1f-569668fab962"
      unitRef="usd">1749000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzYtMy0xLTEtNzEzMzA_4527ffe8-6319-4f82-a226-aa3ccc0fdd6e"
      unitRef="usd">302000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzYtNS0xLTEtNzEzMzA_6fdc451b-6908-4f9c-bfbf-c9cf068b9b9b"
      unitRef="usd">1718000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzctMS0xLTEtNzEzMzA_5b8691ec-3637-481d-8b1b-c7711cbacb79"
      unitRef="usd">-1419000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzctMy0xLTEtNzEzMzA_fe8c30b4-6cb9-43f9-81b2-4b258596bbb8"
      unitRef="usd">1940000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzctNS0xLTEtNzEzMzA_74ae74db-6238-452b-9b3d-8a361c965535"
      unitRef="usd">1338000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzgtMS0xLTEtNzEzMzA_c5291fb5-00bb-4388-883e-8dd977a1af73"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzgtMy0xLTEtNzEzMzA_aa923c9f-965e-4c9a-ac1a-83b772cde24a"
      unitRef="usd">1556000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzgtNS0xLTEtNzEzMzA_7634a9b0-6571-425f-8160-894733ab4238"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzktMS0xLTEtNzEzMzA_c614d138-c3ed-4ae7-a3fc-3b3352fec2eb"
      unitRef="usd">0</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzktMy0xLTEtNzEzMzA_eb33de6b-8b30-4c96-8a6b-2ade40d29bff"
      unitRef="usd">0</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzktNS0xLTEtNzEzMzA_712ea38b-9c86-4b36-8d8b-52346269f3e7"
      unitRef="usd">2660000000</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzExLTEtMS0xLTcxMzMw_afd58960-4548-47ed-a2ff-d1dccb619dec"
      unitRef="usd">-1568000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzExLTMtMS0xLTcxMzMw_65a7fbd3-0a8b-453e-8510-bba13f7cb00c"
      unitRef="usd">187000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzExLTUtMS0xLTcxMzMw_198aa43e-b9dd-4446-ae6e-e3cd21b92eab"
      unitRef="usd">-566000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEyLTEtMS0xLTcxMzMw_e3e628be-02d5-4cbd-8476-0c3aab4727e2"
      unitRef="usd">541000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEyLTMtMS0xLTcxMzMw_76552702-adff-4385-9fef-e10c52db738b"
      unitRef="usd">479000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEyLTUtMS0xLTcxMzMw_1126f63a-9050-467c-939c-6e3d726a8de6"
      unitRef="usd">441000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEzLTEtMS0xLTcxMzMw_8b303f01-5077-4e06-987e-c7d0a186f8df"
      unitRef="usd">-1301000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEzLTMtMS0xLTcxMzMw_a8c42328-fcb9-45fe-ba45-3f38fbda5103"
      unitRef="usd">-805000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzEzLTUtMS0xLTcxMzMw_afd64402-4394-46a1-9da9-a03db27272b7"
      unitRef="usd">-1294000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE1LTEtMS0xLTcxMzMw_0320923b-a11f-486c-8067-b49e860af06c"
      unitRef="usd">644000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE1LTMtMS0xLTcxMzMw_29398d8d-fa01-4e6b-8182-26fbc71b557d"
      unitRef="usd">2033000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE1LTUtMS0xLTcxMzMw_b7fda32e-e758-40c2-910a-236c740b22df"
      unitRef="usd">1002000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE2LTEtMS0xLTcxMzMw_d590fc16-f04e-4d6f-9816-7f6f832112ef"
      unitRef="usd">161000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE2LTMtMS0xLTcxMzMw_ce807011-c38b-47bf-8633-8437a550bb7b"
      unitRef="usd">674000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE2LTUtMS0xLTcxMzMw_6bde3779-1a9a-4a05-bb77-c91bfe728376"
      unitRef="usd">895000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE3LTEtMS0xLTcxMzMw_83a1c416-df20-4efe-abfe-16b5cfaa9fd9"
      unitRef="usd">-289000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE3LTMtMS0xLTcxMzMw_901aa08b-86d9-4340-a85d-4c717452a1dc"
      unitRef="usd">405000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE3LTUtMS0xLTcxMzMw_e9ed3862-97fd-4248-865c-b3ad4f0fab91"
      unitRef="usd">684000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE4LTEtMS0xLTcxMzMw_2c636e56-a627-42c2-8a10-48912a2a392a"
      unitRef="usd">-50000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE4LTMtMS0xLTcxMzMw_e25ff4d6-95dc-4b53-bf2a-67ea4b569475"
      unitRef="usd">277000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE4LTUtMS0xLTcxMzMw_8b6fe7bd-3887-495d-842a-3109f82dbbdb"
      unitRef="usd">-1152000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE5LTEtMS0xLTcxMzMw_b4faeac3-254f-410a-97b4-951d857cf7b8"
      unitRef="usd">380000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE5LTMtMS0xLTcxMzMw_329e9c3d-26b5-4fda-8af2-bc2127c61630"
      unitRef="usd">-540000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzE5LTUtMS0xLTcxMzMw_a2b527d2-bad0-46ef-9538-80c01fd80c1c"
      unitRef="usd">814000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIwLTEtMS0xLTcxMzMw_b91944d7-e1af-4c84-8fbb-e43633fa23df"
      unitRef="usd">-545000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIwLTMtMS0xLTcxMzMw_2c4d0fc8-2382-4428-8bf5-e357b4a3672d"
      unitRef="usd">484000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIwLTUtMS0xLTcxMzMw_118b3060-8267-4d1c-b9fc-7c7f61fec907"
      unitRef="usd">-617000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIxLTEtMS0xLTcxMzMw_68a765a0-4710-4570-bac1-57ea83423636"
      unitRef="usd">1473000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIxLTMtMS0xLTcxMzMw_437ac6c5-8284-4963-90c4-d19638c7837c"
      unitRef="usd">1758000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIxLTUtMS0xLTcxMzMw_005105b9-1077-4060-80f8-b81e6be07515"
      unitRef="usd">2433000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIyLTEtMS0xLTcxMzMw_27b8d3a9-7d74-483c-a973-ec6033fc6726"
      unitRef="usd">19095000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIyLTMtMS0xLTcxMzMw_69eff714-055b-48a0-87b7-ebca0f1d2f52"
      unitRef="usd">13122000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzIyLTUtMS0xLTcxMzMw_41964ca1-5d46-4707-94a4-f711fb40e010"
      unitRef="usd">7617000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI0LTEtMS0xLTcxMzMw_0bf5f681-2f9e-43eb-b798-ceedceb33226"
      unitRef="usd">4388000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI0LTMtMS0xLTcxMzMw_77338c3e-871c-484e-9d5b-b205a0d11a5f"
      unitRef="usd">4448000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI0LTUtMS0xLTcxMzMw_a64937f6-19ab-41a1-ab96-234c4d5741fa"
      unitRef="usd">4429000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI1LTEtMS0xLTcxMzMw_a602afb2-fada-412f-b305-1a6256ebc66c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI1LTMtMS0xLTcxMzMw_641e775e-d991-4e4f-9e22-f0564fe8d5de"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI1LTUtMS0xLTcxMzMw_753bd690-d0ca-464b-8a39-ae6db346d4ce"
      unitRef="usd">1000000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI2LTEtMS0xLTcxMzMw_b2dce2f5-2ed0-421e-9a41-81e052d2751d"
      unitRef="usd">1204000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI2LTMtMS0xLTcxMzMw_7cdfde1a-9551-41e2-9fa7-79c9ce88e220"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI2LTUtMS0xLTcxMzMw_63e6f359-bf94-4718-ae57-505f5cf8e5a7"
      unitRef="usd">95000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI3LTEtMS0xLTcxMzMw_69d7eee5-73c0-40a3-9317-08e26fc42417"
      unitRef="usd">721000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI3LTMtMS0xLTcxMzMw_9e76bf7d-547c-40cb-b1c7-29c06e5c3574"
      unitRef="usd">1026000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI3LTUtMS0xLTcxMzMw_25a27a1e-29d3-4cb3-b044-d68c80df50df"
      unitRef="usd">2812000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI4LTEtMS0xLTcxMzMw_4a8c27e3-96c6-43d6-b42e-f9db769ed6dc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI4LTMtMS0xLTcxMzMw_c4c1762c-a52c-4617-ab6e-451ddda4f517"
      unitRef="usd">11174000000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI4LTUtMS0xLTcxMzMw_cfc18851-e86a-4659-a446-5416d4c72701"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI5LTEtMS0xLTcxMzMw_b21c9a7b-4aec-47e6-bff3-fb844d80598c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI5LTMtMS0xLTcxMzMw_0971585e-eddd-425f-b392-cd2d55408313"
      unitRef="usd">1554000000</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzI5LTUtMS0xLTcxMzMw_61b00852-0923-4dac-9b16-3209cd1b747f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMwLTEtMS0xLTcxMzMw_cee32440-2180-4474-996a-2417b252d444"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMwLTMtMS0xLTcxMzMw_64c0cd47-a71c-4ecc-ad25-25446a90cfc5"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMwLTUtMS0xLTcxMzMw_0dd0b5c6-0d98-4e16-8d98-d7ff0d0c77ef"
      unitRef="usd">2696000000</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMxLTEtMS0xLTcxMzMw_383e617b-3f9f-4fd6-bdeb-dc3755c1892d"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMxLTMtMS0xLTcxMzMw_db44b39d-237f-4384-931d-3c05bdce4067"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzMxLTUtMS0xLTcxMzMw_fd03f093-5c8b-4464-aa33-d0f1f6b8f6da"
      unitRef="usd">2545000000</mrk:PaymentsToAcquireBusinessFiveNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM0LTEtMS0xLTcxMzMw_9ec82f21-016c-4f0c-b9f6-f59f82e0c10f"
      unitRef="usd">121000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM0LTMtMS0xLTcxMzMw_3240032f-2803-42f5-b80f-7ad4ec6a9973"
      unitRef="usd">179000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM0LTUtMS0xLTcxMzMw_7ce666ef-335d-4d91-947a-163d244c618a"
      unitRef="usd">1365000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM1LTEtMS0xLTcxMzMw_9f9cba4e-981b-496f-a460-fbf0e8175519"
      unitRef="usd">-32000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM1LTMtMS0xLTcxMzMw_4439b58e-479d-498b-a130-46542ddd934f"
      unitRef="usd">91000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM1LTUtMS0xLTcxMzMw_008bac54-d8cc-4c21-922b-e0624e8dfedc"
      unitRef="usd">-125000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM2LTEtMS0xLTcxMzMw_b53ad816-1f07-4e0e-9529-c395ed7bc377"
      unitRef="usd">-4960000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM2LTMtMS0xLTcxMzMw_387b323f-9f51-434b-82b7-fc2996aad78d"
      unitRef="usd">-16421000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM2LTUtMS0xLTcxMzMw_64ab559c-d808-46c2-aed8-1063d69838a7"
      unitRef="usd">-9193000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM4LTEtMS0xLTcxMzMw_f5c90ece-82a4-4b7d-bf01-004f43cd66f5"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM4LTMtMS0xLTcxMzMw_14c97b67-6bff-4ce5-a67e-6b7f123a9edd"
      unitRef="usd">-3986000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM4LTUtMS0xLTcxMzMw_c0a54419-399f-4c25-9bf2-6cb3f3b8cc92"
      unitRef="usd">2549000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM5LTEtMS0xLTcxMzMw_b84a61a7-c3ec-4e93-a5c3-fead6fd5dc5f"
      unitRef="usd">2251000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM5LTMtMS0xLTcxMzMw_812bfc17-83cb-42ea-b4d2-82042abc425a"
      unitRef="usd">2319000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzM5LTUtMS0xLTcxMzMw_8db2987d-0b48-41d3-9f68-36ae88ee8597"
      unitRef="usd">1957000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQwLTEtMS0xLTcxMzMw_8a3bafc7-4ff3-4cb4-aaf9-3816cf5ce98e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQwLTMtMS0xLTcxMzMw_88b42412-24eb-4129-a708-60fa72e863b4"
      unitRef="usd">7936000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQwLTUtMS0xLTcxMzMw_e106a46c-1095-4417-9aa4-74c076228c28"
      unitRef="usd">4419000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQxLTEtMS0xLTcxMzMw_c78c31a1-0c06-493e-9d37-62789ddc259c"
      unitRef="usd">0</mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQxLTMtMS0xLTcxMzMw_b0bee3cd-fabb-4899-8e5f-4e80fe3ea713"
      unitRef="usd">9000000000</mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQxLTUtMS0xLTcxMzMw_9d580f20-31fd-421f-9fac-4c8def2eb697"
      unitRef="usd">0</mrk:DisposalGroupIncludingDiscontinuedOperationsDistributionReceived>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQyLTEtMS0xLTcxMzMw_51095e79-970d-4d6a-888f-596d725ac6f2"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQyLTMtMS0xLTcxMzMw_87a205ab-370c-4e4a-827a-d7c4ab510665"
      unitRef="usd">840000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQyLTUtMS0xLTcxMzMw_f3bc2e2f-c04b-4499-bce0-6e6171b008f4"
      unitRef="usd">1281000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQzLTEtMS0xLTcxMzMw_c1552533-892a-48b7-bdcf-700d5de6845d"
      unitRef="usd">7012000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQzLTMtMS0xLTcxMzMw_0c4e936b-06a0-4999-b2cd-fe1c9b51375d"
      unitRef="usd">6610000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQzLTUtMS0xLTcxMzMw_8230424a-d6bd-4f72-a94e-808c5ac5e985"
      unitRef="usd">6215000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ0LTEtMS0xLTcxMzMw_c4d13e19-f4bc-4b4a-a2ae-fbd972396926"
      unitRef="usd">384000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ0LTMtMS0xLTcxMzMw_4c2cc0c8-86ef-4c93-9e80-256d97dece83"
      unitRef="usd">202000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ0LTUtMS0xLTcxMzMw_bdb46407-b97b-4161-868f-7ad38f066a58"
      unitRef="usd">89000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ1LTEtMS0xLTcxMzMw_89576a58-8923-4241-bff0-b3593bc82813"
      unitRef="usd">-240000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ1LTMtMS0xLTcxMzMw_aefc0b1d-8899-416e-91c2-c391ba82d024"
      unitRef="usd">-286000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ1LTUtMS0xLTcxMzMw_1fb9717b-74e7-4e94-b572-7c48ae40c298"
      unitRef="usd">-436000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ2LTEtMS0xLTcxMzMw_474dab5a-e3ac-4ecc-8c8d-471d282229d7"
      unitRef="usd">-9119000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ2LTMtMS0xLTcxMzMw_cf5685ab-2a63-41e6-bd1d-11fcc964172b"
      unitRef="usd">3097000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ2LTUtMS0xLTcxMzMw_45ef4892-0fcd-402f-ab72-ae8c06f9db6d"
      unitRef="usd">-2832000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ4LTEtMS0xLTcxMzMw_ca7674d9-adf2-4e1b-88a8-4fd8f55eb796"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ4LTMtMS0xLTcxMzMw_03ef6fdd-99ed-4dc1-beea-5c789ae01588"
      unitRef="usd">987000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ4LTUtMS0xLTcxMzMw_fa394b36-13b1-4e6b-a098-53dcbb68cfb3"
      unitRef="usd">2636000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ5LTEtMS0xLTcxMzMw_eb5878d1-2d3c-4fe9-bdc3-1df1b2ac45ba"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ5LTMtMS0xLTcxMzMw_4db03dae-5cca-4061-b4f0-af2a370092cf"
      unitRef="usd">-134000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzQ5LTUtMS0xLTcxMzMw_7c99c49f-8b7f-4f89-82dd-78c65c6f3de6"
      unitRef="usd">-250000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUwLTEtMS0xLTcxMzMw_7d5342fb-7792-4226-841c-767ff8b9e405"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUwLTMtMS0xLTcxMzMw_8ca9d1b1-42d0-488c-af69-13f1981456f7"
      unitRef="usd">-504000000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUwLTUtMS0xLTcxMzMw_0a8de96c-4af9-4802-ba76-5a61e49b0f1c"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUxLTEtMS0xLTcxMzMw_931cb971-0a50-45ea-a261-5961fe099659"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUxLTMtMS0xLTcxMzMw_372142e8-411d-4924-a2af-dbbfa04daf2a"
      unitRef="usd">349000000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUxLTUtMS0xLTcxMzMw_570e77e9-1366-44a1-89a6-01716f79bddd"
      unitRef="usd">2386000000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUyLTEtMS0xLTcxMzMw_8e14ba4b-b478-4789-b220-ad391cfcbf6b"
      unitRef="usd">-410000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUyLTMtMS0xLTcxMzMw_66bc7c85-138a-4cc1-a83b-df15330574e9"
      unitRef="usd">-133000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUyLTUtMS0xLTcxMzMw_2bfffbda-cbd5-467b-a451-19567ba91b75"
      unitRef="usd">253000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUzLTEtMS0xLTcxMzMw_34f990c5-532b-4f55-b24c-29841e16a828"
      unitRef="usd">4606000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUzLTMtMS0xLTcxMzMw_dba9976b-de7c-4878-9bb7-3463cde825e8"
      unitRef="usd">14000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzUzLTUtMS0xLTcxMzMw_6aacb0ed-dd1e-41e0-aad2-808332fb1c53"
      unitRef="usd">-1769000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:RestrictedCash
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246OWQyOTJmMTQ2NGFjNDc0NmE2ODc1YWQ5NzhhNDIzMDFfMzg0ODI5MDY5NzYwMg_86a1f5ed-5322-4903-8d45-773c0306d1f4"
      unitRef="usd">71000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246OWQyOTJmMTQ2NGFjNDc0NmE2ODc1YWQ5NzhhNDIzMDFfMzg0ODI5MDY5NzcwOQ_569a1b03-4818-4ba5-b532-c8c15bdb956b"
      unitRef="usd">103000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246OWQyOTJmMTQ2NGFjNDc0NmE2ODc1YWQ5NzhhNDIzMDFfMzg0ODI5MDY5NzYxNg_8327f452-20ad-48b6-b09d-c4b982e79eeb"
      unitRef="usd">258000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTEtMS0xLTcxMzMw_5d20d430-72ce-4337-8527-9717cbe7957f"
      unitRef="usd">8167000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTMtMS0xLTcxMzMw_98aaae91-583d-4cdb-a99f-f5bc84903730"
      unitRef="usd">8153000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU0LTUtMS0xLTcxMzMw_8f5e6a51-b0aa-4e9e-baab-36870a41bc4c"
      unitRef="usd">9934000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU1LTEtMS0xLTcxMzMw_fab9a20c-0d01-437c-844a-eb8b4702e91a"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU1LTMtMS0xLTcxMzMw_6e2edd84-f0c3-4582-a4b0-e7285d957246"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU1LTUtMS0xLTcxMzMw_1482b103-39dc-4cdf-aa7b-05cf89612fa8"
      unitRef="usd">12000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:RestrictedCash
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzE1MDIyMWVjZWJjNGZlOGJhYjA5NWUxMTgxZWNmMzdfMTA5OTUxMTYyODU3OA_a56d9069-c45e-44f9-96a1-7eb4df9bf514"
      unitRef="usd">79000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzE1MDIyMWVjZWJjNGZlOGJhYjA5NWUxMTgxZWNmMzdfMzg0ODI5MDY5NzY5MQ_6751b4c8-35cb-4704-94e9-c04ef027506d"
      unitRef="usd">71000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzE1MDIyMWVjZWJjNGZlOGJhYjA5NWUxMTgxZWNmMzdfMzg0ODI5MDY5NzU5OQ_60b7a4e6-10a1-4118-a176-1e99fad957e3"
      unitRef="usd">103000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTEtMS0xLTcxMzMw_793ea5f2-3fce-4484-b318-e7d8992a81f3"
      unitRef="usd">12773000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTMtMS0xLTcxMzMw_803fcb0b-5c0c-4d01-9a83-bcb5e84908cf"
      unitRef="usd">8167000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xMzkvZnJhZzo4MTM1NGE2ZDE1NDI0M2ZmOWIwNGI0MmI2NDJhNzg0NS90YWJsZTpmZjAxZTljZGE0M2E0MzBiYjlhYTQ5MmVmOTYxZGVlMy90YWJsZXJhbmdlOmZmMDFlOWNkYTQzYTQzMGJiOWFhNDkyZWY5NjFkZWUzXzU2LTUtMS0xLTcxMzMw_6f1f22d2-1f7d-4096-a5b1-54c59168fa2b"
      unitRef="usd">8153000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDUvZnJhZzpjZGVmYmJkNzllMWM0ZTA5YjQyNDFlMmNkMGYzNGZjNS90ZXh0cmVnaW9uOmNkZWZiYmQ3OWUxYzRlMDliNDI0MWUyY2QwZjM0ZmM1XzI5ODk_a4957c21-f8eb-4b56-b110-fe20c4608997">Nature of Operations&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company&#x2019;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spin-Off of Organon &amp;amp; Co. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, Merck completed the spin-off of products from its women&#x2019;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp;amp; Co. (Organon) through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck&#x2019;s diversified brands franchise. Merck&#x2019;s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company&#x2019;s consolidated financial statements through the date of the spin-off (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDUvZnJhZzpjZGVmYmJkNzllMWM0ZTA5YjQyNDFlMmNkMGYzNGZjNS90ZXh0cmVnaW9uOmNkZWZiYmQ3OWUxYzRlMDliNDI0MWUyY2QwZjM0ZmM1XzMyMQ_b6a0c045-b597-4b96-91d0-2f31c820f1bc"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTE1_8f8d0703-c6e1-476d-a2e3-18c9106711e0">Summary of Accounting Policies&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#x2019; interests are shown as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#x2019;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Comprehensive Income (OCI)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Equivalents&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#x2019;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for debt securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for equity securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#x2019;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Commission Guidance Regarding Accounting for Sales of Vaccines &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#x2019;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The nature of the Company&#x2019;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#x2019;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; were $178 million and $2.7 billion, respectively, at December&#160;31, 2022 and were $207 million and $2.6 billion, respectively, at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#x2019;s total unbudgeted spending and the Company&#x2019;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b"&gt;three&lt;/span&gt; to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck&#x2019;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note&#160;19 for disaggregated revenue disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Depreciation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and from 3 to 15&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Machinery, equipment and office furnishings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Depreciation expense was $1.8 billion in 2022, $1.6 billion in 2021 and $1.7 billion in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advertising and Promotion Costs &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.2 billion in 2022, $2.0 billion in 2021 and $1.8 billion in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired Intangibles&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired In-Process Research and Development&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; over its remaining useful life, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Compensation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Costs&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Legal Defense Costs&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income from Continuing Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company&#x2019;s policy for releasing disproportionate income tax effects from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is to utilize the item-by-item approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#x2019;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#x2019;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#x2019;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standard&#160;Not Yet Adopted &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjY1_2656ed77-2f5f-4e5f-98d1-6c605f1aaaa5">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders&#x2019; interests are shown as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjMy_0febcc3c-cb07-4024-a989-2048739e2682">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company&#x2019;s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no &lt;/span&gt;goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjUy_9b4f0653-c9be-4ec1-a4a4-437741a17745">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S.&#160;dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S.&#160;dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Comprehensive Income (OCI)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S.&#160;dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S.&#160;dollar effects of rate changes included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMDk4_44a64358-de43-4197-98ae-6b3320af7c34">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Equivalents&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTIw_8281d274-7ee3-458e-9354-29caeb420ea6">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.&lt;/span&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTk0_5417136f-28f5-41f4-aef4-34eea0a26f5b">&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company&#x2019;s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for debt securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Realized gains and losses for equity securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTUx_f1c7d18a-7115-417f-8c23-9f44c37892d7">&lt;div style="margin-top:8pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company&#x2019;s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Commission Guidance Regarding Accounting for Sales of Vaccines &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company&#x2019;s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The nature of the Company&#x2019;s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company&#x2019;s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part&#160;D)&#160;benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; were $178 million and $2.7 billion, respectively, at December&#160;31, 2022 and were $207 million and $2.6 billion, respectively, at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates.&#160;In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government&#x2019;s total unbudgeted spending and the Company&#x2019;s specific payback obligation.&#160;Rebates may also be required based on specific product sales thresholds.&#160;The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b"&gt;three&lt;/span&gt; to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck&#x2019;s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note&#160;19 for disaggregated revenue disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <mrk:SalesDiscounts
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwNTQx_7a784aee-38c9-4272-b7e8-e3e2a057c2de"
      unitRef="usd">12300000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwNTUx_9456667a-d292-4a65-bbc6-e0120a136eb3"
      unitRef="usd">12300000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwNTY0_44631ac5-946d-42d1-a02e-2bd1f651bcb8"
      unitRef="usd">11400000000</mrk:SalesDiscounts>
    <mrk:AccrualForChargebacks
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMjk1_e768f80c-19e2-43fc-8123-f21544edd94f"
      unitRef="usd">178000000</mrk:AccrualForChargebacks>
    <mrk:AccrualForRebates
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMzAy_f27f36eb-ada4-477b-90be-e67bd7d23d98"
      unitRef="usd">2700000000</mrk:AccrualForRebates>
    <mrk:AccrualForChargebacks
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMzM1_0eb5a902-3feb-4aef-954b-b474b50b8443"
      unitRef="usd">207000000</mrk:AccrualForChargebacks>
    <mrk:AccrualForRebates
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEyMzQy_2c9677ff-9b48-4c41-a726-6c447e0cb8d6"
      unitRef="usd">2600000000</mrk:AccrualForRebates>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate
      contextRef="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjU4_f90662af-f5a4-4512-b3a9-c75b586bfb0a">P6M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate>
    <mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjcy_0ce8b2b0-cd6c-4426-9482-ae555d57c303">P12M</mrk:RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i6e6bbb5f87c44047960024c6b0517fd6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzODc4_c73efcc4-8cef-4cac-ac27-8af4592d84b0">P36D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="ia2af1368f91147fab0b3d00e67b4afa4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzOTYx_b53a0846-941c-4ca2-ac33-2ec35ccf3214">P30D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i152d7547c40c49cfa09fdd72d4292d05_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0MDky_cf4c8517-df91-4aec-94ef-46531966a839">P90D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i7a2d859521db4ed99e9f6f0c3c55169a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0MTUw_6f70c856-9a00-4084-8c73-288bc8e0367e">P30D</mrk:RevenuePerformanceObligationPaymentTerms>
    <mrk:RevenuePerformanceObligationPaymentTerms
      contextRef="i90ed8021173448b0b3372bcb951af216_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0MTYx_fc3e3ee2-6d45-46e0-9599-270300414faa">P90D</mrk:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTM4_966b1887-f832-4c31-8203-f241efaa9b13">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Depreciation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and from 3 to 15&#160;years for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Machinery, equipment and office furnishings&lt;/span&gt;.</us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib6acc5aab0ca4602b1c723258ab0abe5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTA0_27251059-574b-436f-b5e9-d8d5d5177864">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie3dd256716df46d1b2aef36eb21dc58a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTEw_75b841fd-256b-4e1e-abb6-327cf8999376">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i88b53a8f47684df2aa5a27b6be330095_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTQz_5a056703-4ff1-4247-ba7e-52e2ecc797a4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0248176f895b46cfac11e4d46217846a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NTQ5_d32ba6e9-81ec-4fab-8d4e-4a23e0332d86">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NjMy_39082eb7-0fb6-440b-bdf3-095ff099a9e1"
      unitRef="usd">1800000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NjQy_6d277e5e-04d7-4f8d-bceb-c261f34fe44f"
      unitRef="usd">1600000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0NjU1_f48146d6-a712-4282-91d3-ba9623d64de3"
      unitRef="usd">1700000000</us-gaap:Depreciation>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTg5_11cb5bfc-cf40-4c88-b7c3-f03715375983">Advertising and Promotion Costs &#x2014; Advertising and promotion costs are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0ODE2_08a04ea2-e09c-4be8-b31a-5693dfdb1709"
      unitRef="usd">2200000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0ODI2_77c5aff6-2373-4f47-a3c1-13edaf3269e7"
      unitRef="usd">2000000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE0ODM5_8cdafd75-21f6-4df1-8cb4-bc9bb9bd443c"
      unitRef="usd">1800000000</us-gaap:AdvertisingExpense>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjA2_daa4b95a-3fe0-4cc1-b1f8-8cb3ff4e94c8">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Capitalization&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Capitalized software costs are being amortized over periods ranging from 3 to 10&#160;years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie24801838a2c42948246ef5a5409d8e6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE1NDM3_29e775e0-d853-428a-8762-049d77aea97e">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id9b39a79d65a4ca691a37dcfe4922939_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE1NDQz_de675f3a-3d9c-4540-85f3-0d36fad3b2c3">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTU0_10f04039-a272-4757-b215-398f3f6fad6f">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).&lt;/span&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjYw_5662fa03-c12d-471e-afc4-9fd55a2c6ca4">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired Intangibles&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24&#160;years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.&lt;/span&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE2ODA1_81f0bd68-2b28-430d-b9d6-94a066fef03d">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzE2ODEx_0aa706fe-16a4-4c40-a81d-412f594351bb">P24Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTc3_1c9fb9ac-5ce7-4b23-ad99-778bf8b2e80a">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired In-Process Research and Development&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <mrk:ContingentConsiderationPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTUy_cc686c0a-8377-4827-90e4-14abd165fe0a">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;Certain of the Company&#x2019;s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.</mrk:ContingentConsiderationPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjE1_cea5cd28-2733-4e75-9f14-6eef63406456">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are &lt;/span&gt;expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTIz_2d6886ef-42dc-479a-8b0b-3491ad81c322">&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized.&#160;Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; over its remaining useful life, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjY2_1560f27a-832e-4217-be83-408903c9e317">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Compensation&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjY0_c2ba03f8-60e9-4efc-be9a-513a7ea8d008">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Costs&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.&lt;/span&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjE0_b3de152a-fa78-4e6c-8cce-95553a6e15fe">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Legal Defense Costs&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTg2_104ca5db-3e5c-4381-a119-3a4ecd9d11c9">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes on Income from Continuing Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company&#x2019;s policy for releasing disproportionate income tax effects from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is to utilize the item-by-item approach.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEwOTk1MTE2Nzg3NjE_0de94d7b-bc0c-40ea-a8b1-617e5db1975e">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMjg4_50943af9-d229-4b83-bd39-506848cd6e58">&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management&#x2019;s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzMyMTYw_73c6dcc4-94bc-401f-87fa-46222d2e8af4">&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&#160;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity&#x2019;s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company&#x2019;s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standard&#160;Not Yet Adopted &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzU4NDc_544d0054-54da-41e9-8fb5-d13c96158c11">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon&#x2019;s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5&#160;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0&#160;billion were distributed by Organon to Merck in connection with the spin-off. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The amounts included in the consolidated statement of income for the above MSAs include sales of $383&#160;million and $219&#160;million in 2022 and 2021, respectively, and related cost of sales of $404&#160;million and $195&#160;million in 2022 and 2021, respectively. Amounts included in the consolidated statement of income for the TSAs were immaterial in 2022 and 2021. The amounts due from Organon under all of the above agreements were $511&#160;million and $964&#160;million at December&#160;31, 2022 and 2021, respectively, and are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amounts due to Organon under these agreements were $345&#160;million and $400&#160;million at December&#160;31, 2022 and 2021, respectively, and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The results of the women&#x2019;s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company&#x2019;s consolidated statement of income as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556&#160;million in 2021 and $743&#160;million in 2020 related to the spin-off of Organon, which are also included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Details of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Costs, Expenses and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Income of discontinued operations attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reflects amounts through the June 2, 2021 spin-off date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4cc952f1b2f2496fb3e7cb831f0dbcc7_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzUwOQ_de4479fa-b562-427e-8b99-de151b5423a9"
      unitRef="usd">9500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i05ee48b166b44fbaa88adeaa6cccbcca_I20210602"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzc0Mw_232957d5-3b52-4675-82bc-607d890b0cf6"
      unitRef="usd">9000000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i91a08ec51d834fb4b5ee3a778a3ddf08_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzE1NDA_7bb494a6-5378-4eb6-915a-7b33a094613c">P25M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="if7b56448c76a44d38b534e9b53205ce6_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzkzNDU4NDg4NDQ3MjI_a43ae40f-89ac-45a5-b840-cf84cb35053e">P35M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i3eb2867b2dcb413caf68f19d0cff8a38_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzI4OTk_6af422c6-a75b-4350-9ca9-e43155fc0117">P4Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="ibe247952fa8f40f48f9d542a2f0c75b2_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzI5MDU_43065d33-ef53-4208-89d4-0d7afd9ab5a7">P10Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:RevenueFromRelatedParties
      contextRef="id0e03ea81b4d43bc833a87aaff997b7c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzQwMjc_8bd3a764-c7ad-489a-9b0b-12952a14e5d2"
      unitRef="usd">383000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="id47f3aaa34b04200b41ca2809b9e4542_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMwMDI_8b54e55c-7e85-4f04-816f-b61ddefef32b"
      unitRef="usd">219000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="id0e03ea81b4d43bc833a87aaff997b7c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzQxMTg_e6edfe34-679e-42db-9386-17958dfc7a4a"
      unitRef="usd">404000000</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="id47f3aaa34b04200b41ca2809b9e4542_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMwMzQ_19593666-8f83-4182-9686-b75f59212401"
      unitRef="usd">195000000</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ic18668b15f364b13be1b1dcc95030f0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzM2ODE_2b210b63-cffc-4cfa-bde7-aee39c293776"
      unitRef="usd">511000000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="idfa6366e1ebc4503ba80ecd66a39f955_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMxOTk_5de9ca8f-d095-4273-832a-f6d40b5ae1dd"
      unitRef="usd">964000000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ic18668b15f364b13be1b1dcc95030f0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzEwOTk1MTE2MzM3NTU_86d3772c-3762-4309-a751-029a85880de5"
      unitRef="usd">345000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="idfa6366e1ebc4503ba80ecd66a39f955_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzMzMDM_0fbd6e37-7016-41a8-b02b-11e5d73cdc17"
      unitRef="usd">400000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzQwMDY_76621ae6-0a5d-42b2-9032-ecbf1ca41b88"
      unitRef="usd">556000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzQwMjE_9e2bae43-e8c5-48aa-9a87-692a06d067f9"
      unitRef="usd">743000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90ZXh0cmVnaW9uOjkyMjRlZGRhYTZkNjQ0NWY5OTFhNWUwN2FiNWRkZTVmXzU4NDg_32673393-2142-4551-8225-604820a2bc81">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Details of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Costs, Expenses and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Income of discontinued operations attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reflects amounts through the June 2, 2021 spin-off date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEtMS0xLTEtNzEzMzA_9f16c735-8cc8-4545-8beb-d9e553f7a93a"
      unitRef="usd">2512000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEtMy0xLTEtNzEzMzA_872eea21-0801-4dbf-8831-e5e1ad76156c"
      unitRef="usd">6476000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzMtMS0xLTEtNzEzMzA_7b2cbbb8-4028-4ef1-ab98-23db784d8e44"
      unitRef="usd">789000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzMtMy0xLTEtNzEzMzA_59a554e4-e25a-40eb-bff7-188153edc58c"
      unitRef="usd">1867000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzQtMS0xLTEtNzEzMzA_9267543d-30f4-45b6-ba64-97089255cf1f"
      unitRef="usd">877000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzQtMy0xLTEtNzEzMzA_d7704efb-1246-4dff-ac4e-dd53a9849b44"
      unitRef="usd">1513000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzUtMS0xLTEtNzEzMzA_b660a826-9710-4527-ad65-bdc283144616"
      unitRef="usd">103000000</mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzUtMy0xLTEtNzEzMzA_0b59d5d6-5302-445e-9563-3f637a5ac566"
      unitRef="usd">161000000</mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzYtMS0xLTEtNzEzMzA_b8e819e0-443f-43e8-9131-597e1dc614eb"
      unitRef="usd">1000000</mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts>
    <mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzYtMy0xLTEtNzEzMzA_20518a49-b0d2-4f62-afeb-a32bbe97d825"
      unitRef="usd">3000000</mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts>
    <mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzctMS0xLTEtNzEzMzA_47955967-f74c-4311-b13a-a14647568f6e"
      unitRef="usd">15000000</mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzctMy0xLTEtNzEzMzA_45369cf2-100c-481e-891b-2965b2c4fcf7"
      unitRef="usd">-4000000</mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzgtMS0xLTEtNzEzMzA_a74d6740-6009-4373-88ef-c76f81f14f59"
      unitRef="usd">1755000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzgtMy0xLTEtNzEzMzA_9f706bcb-b87e-4d66-87c4-34b6f8d3a9c6"
      unitRef="usd">3548000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzktMS0xLTEtNzEzMzA_a2b0a4db-16ad-4459-b565-1c735fd9e9c9"
      unitRef="usd">757000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzktMy0xLTEtNzEzMzA_96ce65b9-30a8-496d-863b-01a9345b5ce5"
      unitRef="usd">2928000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEwLTEtMS0xLTcxMzMw_1d5a3b10-ad1a-439c-9a4f-e0a5dd006339"
      unitRef="usd">50000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEwLTMtMS0xLTcxMzMw_8449757b-e46d-4806-a087-091088ff1c72"
      unitRef="usd">369000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzExLTEtMS0xLTcxMzMw_e88903a8-a78c-4ede-8811-e42cbd32006d"
      unitRef="usd">707000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzExLTMtMS0xLTcxMzMw_717a22d4-2d0d-42fe-a84b-4ed6c1898057"
      unitRef="usd">2559000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEyLTEtMS0xLTcxMzMw_b17d1242-db34-49c4-8f37-c8e1a726dd3a"
      unitRef="usd">3000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEyLTMtMS0xLTcxMzMw_65e1666a-ff9b-4b9f-9296-ec8f4369b641"
      unitRef="usd">11000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEzLTEtMS0xLTcxMzMw_ff49adaf-5ae7-4d3a-8ed8-e5582122dfa2"
      unitRef="usd">704000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTEvZnJhZzo5MjI0ZWRkYWE2ZDY0NDVmOTkxYTVlMDdhYjVkZGU1Zi90YWJsZTo3Nzg3OTYzOTQ3ZDA0MmEyOTdlNTc3NDIwYzA1ZDI5OC90YWJsZXJhbmdlOjc3ODc5NjM5NDdkMDQyYTI5N2U1Nzc0MjBjMDVkMjk4XzEzLTMtMS0xLTcxMzMw_f4088dfa-5fe9-4b32-8dc2-d3468d7d0cdf"
      unitRef="usd">2548000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI0MjE3_89334139-61f3-464e-b3e4-7428fd3b14cf">Acquisitions, Research Collaborations and Licensing Agreements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#x2019;s financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recently Completed Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In February 2023, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $175&#160;million, which will be recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0&#160;billion, $2.8&#160;billion in regulatory milestones, and $5.5&#160;billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100&#160;million in Kelun-Biotech&#x2019;s Series B preferred shares in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60&#160;million of transaction costs. Imago&#x2019;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $200 million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses of $1.2 billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck&#x2019;s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. As Royalty Pharma is sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received is being recognized by Merck as a reduction to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses ratably over the estimated Phase 2b research period. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375&#160;million. Royalty Pharma is eligible to receive royalties on future sales. If Royalty Pharma elects to provide the additional funding noted above, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as a higher royalty rate. Merck will record the milestone payments as an expense within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; upon receipt of the related approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (pembrolizumab), Merck&#x2019;s anti-PD-1 therapy, as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440&#160;million, $675&#160;million in regulatory milestones, and $2.4&#160;billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100&#160;million in Orna&#x2019;s Series B preferred shares in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion&#x2019;s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of MK-5684. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of MK-5684, as well as tiered double-digit royalties on sales if the product is approved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82&#160;million in developmental milestones, $334&#160;million in regulatory milestones, and $485&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech&#x2019;s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;for advanced solid tumors. Upon option &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;exercise, Merck made a payment of $30&#160;million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2022, and agreed to make additional payments of $30&#160;million upon completion of specified project activities and $25&#160;million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $111&#160;million to fund Kelun-Biotech&#x2019;s ongoing research and development activities, of which $51&#160;million was paid in 2022. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90&#160;million in developmental milestones, $290&#160;million in first commercial sale milestones, and $780&#160;million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron&#x2019;s development work focused on evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron&#x2019;s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition to sotatercept, Acceleron&#x2019;s portfolio includes Reblozyl (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. Reblozyl is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck received a contingent regulatory milestone payment of $20&#160;million in 2022 and remains eligible to receive up to $80&#160;million in sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The transaction was accounted for as a business combination. The Company incurred $280&#160;million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; costs in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 19, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - sotatercept &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products and product rights - Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12 year useful life)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion&#x2019;s development work focused on advancing a pipeline of precision immune modulators targeting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;critical immune control nodes. Total consideration paid of $1.9 billion included $147&#160;million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses of $1.7 billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck&#x2019;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead&#x2019;s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $2.0&#160;billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold. Upon passing $3.5&#160;billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck&#x2019;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#x2019;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced the Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP). The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva&#x2019;s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30&#160;million, which was included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15&#160;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5&#160;million in developmental milestones, $570&#160;million in regulatory milestones, and $1.05&#160;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020 Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. OncoImmune&#x2019;s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50&#160;million for a 20% ownership interest in the new entity, which was valued at $33&#160;million resulting in a $17&#160;million premium. Merck also recognized other net liabilities of $22&#160;million. The Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses of $462&#160;million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck&#x2019;s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207&#160;million in 2021, which are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio&#x2019;s lead investigational candidate, zilovertamab vedotin (MK-2140), is an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180&#160;million (primarily cash) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses of $2.7 billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses of $43&#160;million, an increase to total consideration paid of $47&#160;million, and an increase to net assets recorded of $90&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen&#x2019;s ladiratuzumab vedotin (MK-6440), an investigational ADC targeting LIV-1, which is currently in Phase 2 clinical trials. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $616&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16&#160;million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and is receiving tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#x2019;s territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Also in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#x20ac;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410&#160;million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products are being amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (molnupiravir), an investigational oral antiviral COVID-19 medicine. See Note&#160;5 for additional information related to this collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $85&#160;million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;amp;D of $113&#160;million, cash of $59&#160;million, deferred tax assets of $72&#160;million and other net liabilities of $32&#160;million. The excess of the consideration transferred over the fair value of net assets acquired of $239&#160;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;amp;D were determined using an income approach. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;amp;D impairment charge of $90&#160;million within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. The Company also recorded a reduction in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;expenses resulting from a decrease in the related liability for contingent consideration of $45&#160;million. In 2022, the Company wrote off the remaining IPR&amp;amp;D intangible asset and related contingent consideration liability; the net impact to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;expenses was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5&#160;million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck&#x2019;s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305&#160;million in 2020, of which $260&#160;million was reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The remaining $45&#160;million of costs were reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138&#160;million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95&#160;million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in 2020. ArQule&#x2019;s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton&#x2019;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - nemtabrutinib &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,280&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for derazantinib&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck recorded intangible asset impairment charges in 2022 and 2021 related to nemtabrutinib and in 2022 related to derazantinib (see Note&#160;9).&lt;/span&gt;&lt;/div&gt;</mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie7668e0129294bdcbf2855d7d0ee191d_D20230201-20230224"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4NjI_975b0570-f236-4b26-bc4f-c6cc531c1148"
      unitRef="usd">175000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments
      contextRef="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4Njk_bdabb8ff-a833-4789-8887-c71dd6a74c6a"
      unitRef="usd">1000000000</mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments>
    <mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4NzY_b5dcb250-f295-4c07-8fd4-1a3955f022d0"
      unitRef="usd">2800000000</mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments
      contextRef="i4ecb745f4a134e08907fced6b1d5b0d4_I20230224"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA4ODM_87d43ccb-2df5-4057-850b-6bc25dea109f"
      unitRef="usd">5500000000</mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments>
    <mrk:CollaborativeArrangementPreferredStockInvestmentInCounterparty
      contextRef="ib17138b844f348b1a50f35c8ae1978e5_I20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NjA5MDY_cb728e24-5475-4ccd-b350-43015e354694"
      unitRef="usd">100000000</mrk:CollaborativeArrangementPreferredStockInvestmentInCounterparty>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTE4ODA_929254e3-c307-4dfa-93bd-ce6174aac9b2"
      unitRef="usd">1350000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTE5NTU_08baeb18-bca2-4b53-9254-80c39f3e237c"
      unitRef="usd">60000000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <mrk:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i74aa3e82c01b42c6a7419c59ba514f25_I20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTI0MTg_26bbfaef-7505-4fc0-b235-f9ff201dbc13"
      unitRef="usd">200000000</mrk:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if05ec124e0fc419380a7f93cbfa3839f_D20230101-20230131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwOTk1MTE3MTI0NjM_f98ae9b7-5931-4eac-b5e4-58cb31416c94"
      unitRef="usd">1200000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExOTI_30f72b08-4dcb-401a-804c-77348293157d"
      unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts
      contextRef="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExNjI_7ad1ae55-67da-421a-afa3-b0dce45a088b"
      unitRef="number">0.50</mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts>
    <mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding
      contextRef="i3b5be1547b584d67b71dd3da0bcdcc7d_D20221001-20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExNjc_e780fca8-f862-4802-ba22-3bce4f322d3d"
      unitRef="usd">375000000</mrk:ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i44db6d09190041e18d6b1b29eb14bb9b_D20220901-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyMDc_8e89a628-18d0-48bf-a0b2-59435742eb6a"
      unitRef="usd">250000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i5db175a81b9f43c1b0e8d6bbfc9cad3d_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyMjQ_e55dc7e2-c6f9-42de-b415-8c7c96849ab0"
      unitRef="usd">150000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ie53196e6917242ea85419903828dbab2_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyNDI_d6145411-8b8c-4868-923f-216d50f050d5"
      unitRef="usd">440000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="if640c54f5da1491792d044ba5742c097_D20220801-20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyNjA_c79e0189-e872-4a8d-96b9-462ea5444f99"
      unitRef="usd">675000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i4fffd33d73024f8cae603f326b7f1104_D20220801-20220831"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyNzg_983e478e-3afd-4fda-b918-5428a18403b2"
      unitRef="usd">2400000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="iad647dc2d4aa4b91a0013d32ad01912d_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEyOTY_4493b622-5b7b-43e9-9f1e-647869e5136f"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireInvestments>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="id70dba7305144817a9064998df5667d1_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzMTQ_bbfc181a-84b2-4bd7-a671-b873f933ba25"
      unitRef="usd">290000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i0a30e3c742444082976808cee5c16655_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzMzE_215aaa61-d39f-4c17-a9dc-b41426acc4e6"
      unitRef="usd">35000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic774cbcb70554e169b26550e484a0585_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzNDg_d3a4109e-12f7-4314-8877-41fa41a1a334"
      unitRef="usd">82000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i6296f4bad6634365be938b368f535a4e_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzNjY_362b01fd-a3a7-4c94-a04f-9e2392044813"
      unitRef="usd">334000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="id8672dcf41ce4577b1f1b821640eae58_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEzODQ_4de33cbd-0af1-40d4-bdf8-a7f3279cb697"
      unitRef="usd">485000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0MzA_7f3d7aad-df23-4a35-95eb-bd1a7e0452bc"
      unitRef="usd">30000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner
      contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1MDE_8c06b9c4-4d0e-4191-ad40-af75e99d9b19"
      unitRef="usd">30000000</mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner>
    <mrk:MilestonePaymentToBeMadeToCollaborativePartner
      contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1MTg_b191530c-5884-42a8-baff-1576f6eb146f"
      unitRef="usd">25000000</mrk:MilestonePaymentToBeMadeToCollaborativePartner>
    <mrk:ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners
      contextRef="i7529d9de4caa4074a4a14350c9c06713_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1MzU_5a2e8712-742a-4bde-9bf6-1cb981002d3f"
      unitRef="usd">111000000</mrk:ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners>
    <mrk:ResearchAndDevelopmentPaymentsMadeToACollaborativePartner
      contextRef="i82b90cfcdde044b7a79d4c12ce3af129_D20220501-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE1NTM_1990f16c-e943-48c5-bf3f-c6c4a4131286"
      unitRef="usd">51000000</mrk:ResearchAndDevelopmentPaymentsMadeToACollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic68d62a9a6db4df3bf89fc5ddf7583e1_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0NDg_ef91ca38-5881-41c3-95a0-d67576638620"
      unitRef="usd">90000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic0cf91de3d1d4c32ad48e6066885e0f2_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0NjY_4a227e19-e92b-41d7-b330-d5d734f4ca0d"
      unitRef="usd">290000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ifb1eeae45b61446697e00a09ff97862e_D20220501-20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTE0ODQ_a0221355-db54-440a-b458-06f7410f3f44"
      unitRef="usd">780000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7073d5a9d7f24a98995d80fe479f8283_D20211101-20211130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEwMzE_41b1e151-2514-4f80-99ff-89fdbe499c97"
      unitRef="usd">11500000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <mrk:RoyaltyRatePercentage
      contextRef="ifcf26d356d3946f4a878afd16a2a4024_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzIwODA_0871d8d0-1f92-44f1-8de6-dd26b66239f4"
      unitRef="number">0.22</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i785539df716f4bce95f1ef45066b0e36_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI2ODA_214e0637-e693-43cb-a50d-a1eab0bee7db"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="ic1f1de3723354ed1af5631e0fd919013_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI3NDM_1474cca9-7c07-4f91-b33e-cd901f7a59f2"
      unitRef="number">0.24</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRateDeductionPercentage
      contextRef="ifcf26d356d3946f4a878afd16a2a4024_D20211101-20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI4MDE_fa2433b3-ca8b-4fb5-9040-47907afa23eb"
      unitRef="number">0.50</mrk:RoyaltyRateDeductionPercentage>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="if030a4536a8047a1a585275c17092ed8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI5OTA_794cbd6a-db33-4816-a1fc-2afba993e16c"
      unitRef="usd">20000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic10f48c8ad804e3ab3fb873838f81931_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzMwMjg_21590007-882b-4f97-892f-2b1caa0bc89b"
      unitRef="usd">80000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="ifd86187433f44eaeacfe4a3eb6a5201f_I20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzMxNDE_7773e197-8918-4a13-b712-6b932ed93ebd"
      unitRef="usd">280000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzI0MjI4_b7166421-3a8e-428d-b313-6a4760fdf1f1">&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 19, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - sotatercept &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products and product rights - Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12 year useful life)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - nemtabrutinib &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,280&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for derazantinib&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzEtMi0xLTEtNzEzMzA_5ac1345d-5d83-426d-b434-8b915d1d18e1"
      unitRef="usd">340000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzItMi0xLTEtNzEzMzA_5bffd854-84d6-4454-83ef-32980a4aa4d9"
      unitRef="usd">285000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzQtMi0xLTEtNzEzMzA_395fb031-8138-4fc7-8c8c-054534881eb8"
      unitRef="usd">6380000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7073d5a9d7f24a98995d80fe479f8283_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzUtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpiYzZkOTMwMThiOGY0MjQyYjRhZDZjZGU0NzU0NmFlMV80NA_097b80ec-4dcf-4418-8741-23400de8cfdd">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzUtMi0xLTEtNzEzMzA_15aed1d9-f0bb-41ac-b988-c19638d507af"
      unitRef="usd">3830000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzYtMi0xLTEtNzEzMzA_54a9a664-dbd0-43bd-b989-43fe7b91b95d"
      unitRef="usd">1814000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzctMi0xLTEtNzEzMzA_2633eff1-71cf-454e-a535-f217502a9618"
      unitRef="usd">82000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzgtMi0xLTEtNzEzMzA_81cdefdc-2228-4721-9364-6e7add4c12cb"
      unitRef="usd">9103000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzktMi0xLTEtNzEzMzA_bd8d8381-2790-4d1f-b98c-332738000826"
      unitRef="usd">2411000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ibfdc0787087a47d68adfea5ef5195bef_I20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjE3M2FjMjk3NDU0MzZkYTJlYWMxYmUzNzc5NTY4OS90YWJsZXJhbmdlOjZmMTczYWMyOTc0NTQzNmRhMmVhYzFiZTM3Nzk1Njg5XzEwLTItMS0xLTcxMzMw_c7554ca4-09e0-4237-9a35-a6d81cd1857a"
      unitRef="usd">11514000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="i53d43b0dc8d742539a81797aad2c7dac_I20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM5MjI_74446c4d-ab53-45e0-b381-249e812343f9"
      unitRef="number">0.075</mrk:IntangibleAssetMeasurementInput>
    <mrk:IntangibleAssetProductsAndProductRightsMeasurementInput
      contextRef="i53d43b0dc8d742539a81797aad2c7dac_I20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM5NDU_bf5fa0c2-eafc-43f6-bb83-ae5aadaa2768"
      unitRef="number">0.060</mrk:IntangibleAssetProductsAndProductRightsMeasurementInput>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i49e02de6be3a44268b77d9db477d3905_D20210401-20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ1OTM_457e51fa-f127-45e3-ad6d-28fb9cf4805b"
      unitRef="usd">1900000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="i49e02de6be3a44268b77d9db477d3905_D20210401-20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ2MDU_d1714b5a-d97c-4139-bbb3-023b061bcd2c"
      unitRef="usd">147000000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="ifb1df4caa295436598a3f45d73add47c_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ3OTM_e971c4e3-b32f-4645-8585-6ef5c6299d49"
      unitRef="usd">156000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icaad804e1a1445199d9e01dd42edfc61_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzQ4NTQ_9426da76-4ba6-4251-9202-79f7ff9f91d4"
      unitRef="usd">1700000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:ProfitShareCounterparty
      contextRef="i7dd421f3e24b48ab92de4b4ccbc4ffe1_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzU4MzQ_e1e2a32e-d9b1-4f22-bc55-e352738189ae"
      unitRef="number">0.60</mrk:ProfitShareCounterparty>
    <mrk:ProfitShare
      contextRef="i7dd421f3e24b48ab92de4b4ccbc4ffe1_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzU4NDg_9d587cc2-bd6a-4cb9-86c7-bc1fa3bd33d4"
      unitRef="number">0.40</mrk:ProfitShare>
    <mrk:SalesThreshold
      contextRef="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY0NTQ_d4ba32aa-c7be-4b08-af7a-148ae84194fe"
      unitRef="usd">2000000000</mrk:SalesThreshold>
    <mrk:ProfitShareCounterparty
      contextRef="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY1NDQ_2d5e25cf-2fcd-42fe-b161-4ac60bcf44ec"
      unitRef="number">0.65</mrk:ProfitShareCounterparty>
    <mrk:ProfitShare
      contextRef="i2a46666657da4ffa9cf57b60c07a85c3_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY1NTg_9091a568-d9c6-41fa-abba-5e817a4337c7"
      unitRef="number">0.35</mrk:ProfitShare>
    <mrk:SalesThreshold
      contextRef="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY2MTg_04d30ef3-9dfe-41a3-81e9-d7ef6462326c"
      unitRef="usd">3500000000</mrk:SalesThreshold>
    <mrk:ProfitShareCounterparty
      contextRef="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY3MTQ_0d6d804e-319f-408c-b638-312e674c67ca"
      unitRef="number">0.65</mrk:ProfitShareCounterparty>
    <mrk:ProfitShare
      contextRef="i297b2f9f8014468ba7c22c358f3e0c2a_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzY3Mjg_2a836f27-0dcd-4dd9-b4ca-290bd8e4fa9e"
      unitRef="number">0.35</mrk:ProfitShare>
    <mrk:CollaborativeArrangementNumberOfResearchPrograms
      contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwNDQ1MzYwNTE0NzE3_e036430c-e1f7-48ba-94e4-daa47e19e605"
      unitRef="research_program">3</mrk:CollaborativeArrangementNumberOfResearchPrograms>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEwNTg_3031c0a1-d3f9-48e9-8c45-9168486eac57"
      unitRef="usd">30000000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner
      contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzkwOTI_0c56e650-1d5c-43cc-9597-9d22f4966d63"
      unitRef="usd">15000000</mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner>
    <mrk:CollaborativeArrangementNumberOfCollaborationTargets
      contextRef="i72a0f472a73e490b94f7550a5f05b610_D20210101-20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwNDQ1MzYwNTE0NzI3_0507797c-3675-45e0-8ca3-e9f81c590c01"
      unitRef="collaboration_target">3</mrk:CollaborativeArrangementNumberOfCollaborationTargets>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i8d99c64b435b4e87a51ff910dece08c8_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTEwOTM_084ca266-59d7-4e51-b75c-f51af4d9b20f"
      unitRef="usd">217500000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="id251d0d82d7944d495c9d8d8fce4e269_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMDE_fd03ef6b-f200-4ebd-952a-10436d111cfd"
      unitRef="usd">570000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i88f4e389e77641b6b46442285a84c3f4_D20210101-20210131"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMDg_961eb1ab-807d-49c2-b8fe-b53a55355c7d"
      unitRef="usd">1050000000.00</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:RoyaltyRatePercentage
      contextRef="i3f065c4f1db344d4862bd79ea44a07a9_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzk1MjY_880997e6-93b3-4adf-8e99-e6a2c718d6b8"
      unitRef="number">0.07</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i3f065c4f1db344d4862bd79ea44a07a9_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzk1MjY_96744b31-cde9-4fb3-9ec9-ba55fc372537"
      unitRef="number">0.07</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i12a517b30e874a00bab97ff6980aab5c_D20210101-20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzk1MzI_00cab969-7da1-4700-9620-bf68f1f29940"
      unitRef="number">0.14</mrk:RoyaltyRatePercentage>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMTQ_ee346759-f359-4a67-91d0-dee28b4eb0a4"
      unitRef="usd">423000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMTc0_be70d6ea-1e1b-4e3d-bfb9-75a55215708c"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ied63ffc9cee949b990458159c3946f6c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMTgz_6d79e8b7-5e67-480d-bbfa-df99bdf288c1"
      unitRef="number">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:Investments
      contextRef="iabf1056dbb7047808e6072640db0a6d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMjQ0_35b1d478-54e0-46c3-858a-8edbd8a1cfe1"
      unitRef="usd">33000000</us-gaap:Investments>
    <mrk:PremiumOnSharesAcquired
      contextRef="id37f85cd6edd4351b13c577cc1c32ed4_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMjYy_58b28f17-1b6c-469a-adc7-d547a0254386"
      unitRef="usd">17000000</mrk:PremiumOnSharesAcquired>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="iabf1056dbb7047808e6072640db0a6d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEwMzIx_fd679417-0fac-47c5-9e47-304f62329311"
      unitRef="usd">-22000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo
      contextRef="if24d4378188a4e47a19056c597f67512_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzM4NDgyOTA3NTExMjA_cfcffa45-0047-4272-96f9-d2f9e629eae2"
      unitRef="usd">462000000</mrk:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo>
    <mrk:ChargesRelatedToProgramDiscontinuation
      contextRef="i0d7e45260eac48ce932cb909af8a62bd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExMTIx_e91e0b01-1f92-4b8f-8bb3-7f9e7a960063"
      unitRef="usd">207000000</mrk:ChargesRelatedToProgramDiscontinuation>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i1a3283ebb19c47db98e2743d3caf9d25_D20201201-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExNDIw_a773f560-7ace-4a34-9ecc-5026d79627c3"
      unitRef="usd">2800000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="ic7357cac30444434ad7267d089052bf5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExNzk5_64b832fe-8e3a-4e4a-9ff4-13193d2f41fd"
      unitRef="usd">180000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3a994069745948e3b6a58225dd2dcb81_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzExODYw_3b970efb-a951-4b66-aca7-a5624191f328"
      unitRef="usd">2700000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0cb16d00cf524ce297989b91888f968a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyMDMy_0d523682-d5cb-4cef-b454-335244d73f80"
      unitRef="usd">43000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="ib083b0720a7641e5b2ed5b897cb5a1da_D20211201-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyMDc5_3bb90bce-7d27-44f4-bd9c-fb7ff542d725"
      unitRef="usd">47000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="if015b711a0c1463280f53a5f53f0095c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyMTI1_0cbc4801-f541-4fe4-b072-10e72f546bb5"
      unitRef="usd">90000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyNzk4_b247aada-3355-4a1f-b0eb-9e0a8c90966b"
      unitRef="usd">600000000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyODA3_123c96b7-4d57-40fe-84fe-e7c5a98a1e90"
      unitRef="usd">1000000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares
      contextRef="i283a4724505a457e8167cdc1100bb0e8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyODMx_8e59ce35-0453-4845-868a-f94d7b41dbfc"
      unitRef="shares">5000000</us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares>
    <us-gaap:SharePrice
      contextRef="i283a4724505a457e8167cdc1100bb0e8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyODc4_f3677ee4-bcc7-4302-99fe-92fb9d370f4c"
      unitRef="usdPerShare">200</us-gaap:SharePrice>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4da143af2cbc4550b7cd444b2d54ff99_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEyOTA3_d78f1479-5ab0-4aae-8cd5-0355a8ad2cb1"
      unitRef="usd">616000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:PremiumOnSharesAcquired
      contextRef="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMDI3_7cf1fd43-7faa-4054-bf59-119ad6c27e54"
      unitRef="usd">16000000</mrk:PremiumOnSharesAcquired>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i11c5c47bf737423c852cf902aeae420a_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMjEy_85b15842-98d9-4dc6-9898-f88a608bf6ec"
      unitRef="usd">2600000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ie84d4260b7474298a9608482089dbef7_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMjI2_85d6ab70-33ec-412c-b2e9-431d51bfde2c"
      unitRef="usd">850000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic456a004e9b54fa88ffab861b40c8472_D20200901-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzEzMjU5_136c1987-d202-4edd-bf1e-bff6e3a629ad"
      unitRef="usd">1750000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="i31c7604e87594ef485dd05502812fe51_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0Mjc4_7442f0cb-3ea9-49f5-9a2c-a4cc67f162b5"
      unitRef="usd">210000000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i6c949b3574474579a0c233dda2bb577b_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NDQx_3c347c7a-c2fa-4615-9695-79383d35d6c9"
      unitRef="usd">65000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:RoyaltyRatePercentage
      contextRef="ic69078b53a814524aeaac691b26539ee_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NDkx_8ecdb2ff-20e5-45d2-9939-956a7ab3265c"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="id9049cb40e504958ac9e397e60d37fb6_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NDk3_239752f6-f128-4f89-a5b8-5aa56c219456"
      unitRef="number">0.33</mrk:RoyaltyRatePercentage>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NzIx_77f149b4-4fbe-4b93-be73-957ff6d1283d"
      unitRef="eur">256000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0NzI1_3b9b87ca-34a0-4ec4-ab0e-7b2a7ee84ac0"
      unitRef="usd">302000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i4306e22f73b84fb4b2c09310e8bdbb18_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0ODQz_1a3d7c40-ca42-4157-93ce-0fe0a0060dfe"
      unitRef="usd">289000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
      contextRef="i4ef894740f0b49e788276233080a4067_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE0ODcw_a2898ce2-73c9-42e2-b31e-4c434e0971df"
      unitRef="usd">13000000</mrk:AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i0b6e4139824b4eefae9cfeae92fb9040_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1MDcy_db62b686-6e1b-4f2d-8851-3a7db2a3714b"
      unitRef="usd">410000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ic59c3148ee024ea4afbac1489fd25b72_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1MjUw_15940d99-3fad-4eb6-ae18-d9be05db4820"
      unitRef="usd">401000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:InventoryNet
      contextRef="if6e2e88bfbbc44c8886ee11658c63510_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1MzA5_0027437d-6fa3-4e24-941c-0fa133ccfe9e"
      unitRef="usd">9000000</us-gaap:InventoryNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i81bb7eeadd574ca5b21e9826619b23af_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE1NjYz_2f591c49-7b49-4664-9075-68e9ee4a3a34">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icad0f525031d46d9be68d02f33cb1b6e_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2MzIx_e7d8fd9c-4ce3-42cc-aa11-9b99b20cdf75"
      unitRef="usd">366000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2NTU4_f0f7ebbe-f2ba-4341-b162-fa4ada7d6f35"
      unitRef="usd">85000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2Nzkw_de9f6b9b-b365-4c1c-83dc-4e20793bb703"
      unitRef="usd">113000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2ODAy_e10c7b3d-0127-406c-bacc-1262f14b386a"
      unitRef="usd">59000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2ODI5_802b596f-3de5-4828-b5e0-21cc4f861848"
      unitRef="usd">72000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2ODYx_9ed682d5-7fb2-4fce-bf4e-22549f457d85"
      unitRef="usd">-32000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:Goodwill
      contextRef="id02a0b579904410ba96e69084e79c5b6_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE2OTU1_5c043e87-c645-4c3d-93cf-0f5115413073"
      unitRef="usd">239000000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i803562aa74fa4ea3891ea730ee3b8ff2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE3NDIz_52e7e32e-5801-46d0-99f7-0b6bb88b403c"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i803562aa74fa4ea3891ea730ee3b8ff2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE3NjI2_3349ffb4-38db-48ca-b93a-10dce63ebc45"
      unitRef="usd">-45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner
      contextRef="i0b0c88b077dc43d395324479284c52e5_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE4MjI3_8b88b744-9349-48db-bfe2-528eafd0689f"
      unitRef="usd">6500000</mrk:UpfrontPaymentsMadeToLicenseOrCollaborativePartner>
    <mrk:ChargesRelatedToProgramDiscontinuation
      contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5MTk5_08d36057-1d54-41a0-8bff-8389e72c3f33"
      unitRef="usd">305000000</mrk:ChargesRelatedToProgramDiscontinuation>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5MjIw_58461052-90ab-499d-a364-43e579e8ec49"
      unitRef="usd">260000000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5Mzkx_3bdd1542-0dec-49d4-a522-ffc260bce812"
      unitRef="usd">45000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icd2616ccfb4c414f9da26e3832020bb2_D20200101-20200131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5ODgz_84aa0c42-bc9e-48e8-8cb1-770aff84b984"
      unitRef="usd">2700000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed
      contextRef="ia4b8f860929044a7877bf8a6ed4c2c2c_I20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzE5ODk1_3bc5780d-6814-4367-91eb-65dbb43ce0d7"
      unitRef="usd">138000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="ia4b8f860929044a7877bf8a6ed4c2c2c_I20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzIwMDc2_a8668243-fd63-4258-9af4-723cf38dba28"
      unitRef="usd">95000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzEtMS0xLTEtNzEzMzA_e0b53380-a163-4e33-af53-5d89c286cb0e"
      unitRef="usd">145000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzItMS0xLTEtNzEzMzA_3ce02ca2-944c-45aa-8a42-aab5c0a03575"
      unitRef="usd">2280000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzMtMS0xLTEtNzEzMzA_fc42f3eb-07e2-4371-a92c-3a420020a2c1"
      unitRef="usd">80000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzQtMS0xLTEtNzEzMzA_6b39d2b5-0b61-47c9-a8a3-870184ab240f"
      unitRef="usd">361000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzUtMS0xLTEtNzEzMzA_3e544fe0-bbb8-4d4f-8672-0c063c2dda6f"
      unitRef="usd">34000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzYtMS0xLTEtNzEzMzA_a3ec3948-5fa3-471c-ade3-a069556bd7ca"
      unitRef="usd">2178000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzctMS0xLTEtNzEzMzA_0dd1f82f-cb7a-4ca9-aab0-19f4a270a9a1"
      unitRef="usd">512000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ie44bffe9a3144afd88ce155275642a73_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90YWJsZTo2ZjM1MTk1MThiZjg0OTc0ODk0NDgxOWFkYjQ1Zjc1MS90YWJsZXJhbmdlOjZmMzUxOTUxOGJmODQ5NzQ4OTQ0ODE5YWRiNDVmNzUxXzgtMS0xLTEtNzEzMzA_b89bb522-744d-47a9-bd0f-7f742538a212"
      unitRef="usd">2690000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="ifa5431df1071454ba96911ea2466090d_I20200116"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNTcvZnJhZzowNjI1MWYxNThkMDY0OGEwOTgwYzllOTA3ZjQ4ODk3Yi90ZXh0cmVnaW9uOjA2MjUxZjE1OGQwNjQ4YTA5ODBjOWU5MDdmNDg4OTdiXzIwOTA0_75bafcb7-c174-4ba7-91f7-652880d217f0"
      unitRef="number">0.125</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEyMjkw_84679e68-cab3-4e36-9aaa-b3b894b963f2">Collaborative Arrangements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#x2019;s more significant collaborative arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#x2019;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#x2019;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600&#160;million liability (which remained accrued at December&#160;31, 2022) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Merck made sales-based milestone payments to AstraZeneca aggregating $400 million and $550 million in 2022 and 2020, respectively. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022 and 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $250&#160;million and $160 million, respectively, from Merck to AstraZeneca. A regulatory milestone of $105&#160;million that was accrued at December&#160;31, 2022 was paid in January 2023. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.6 billion at December&#160;31, 2022 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amount is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trade &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;ccounts payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250&#160;million and $106&#160;million, respectively, of cumulative amortization catch-up expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Eisai&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and Lenvima.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck made sales-based milestone payments to Eisai aggregating $600&#160;million, $200 million and $500 million&#160;in 2022, 2021 and 2020, respectively. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022, 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $50&#160;million, $75&#160;million and $10&#160;million, respectively, from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $814 million at December&#160;31, 2022 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bayer AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#x2019;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#x2019;s Verquvo (vericiguat), which was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#x2019;s share of profits from sales of Adempas and Verquvo in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made sales-based milestone payments to Bayer of $400&#160;million and $375&#160;million in 2022 and 2020, respectively. There are no sales-based milestone payments remaining under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $633 million and $57 million, respectively, at December&#160;31, 2022 and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; Accrued and other current Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount as of December 31, 2021 includes accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Ridgeback Biotherapeutics LP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; has since received multiple additional authorizations worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#x2019;s share of profits) are reflected as decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expenses in all periods now include an allocation for overhead charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount in 2020 includes upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued royalty and milestone payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bristol Myers Squibb&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck&#x2019;s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80&#160;million. Merck recorded alliance revenue of $166 million in 2022, which includes royalties of $146&#160;million and the receipt of a regulatory approval milestone payment of $20&#160;million, compared with alliance revenue of $17 million in 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="i611105bf33cb4418b7e1bae1d7e7ea5f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDg4NjY_26a1eeeb-98c9-4d62-9ee5-bb65f1409516"
      unitRef="usd">600000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="i8bdf7308172b42feb5eb31dfaf5c1b15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDg4ODA_3b6ebf31-8bc2-4fbe-94fb-29e16f5c770a"
      unitRef="usd">600000000</us-gaap:Liabilities>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9cd932eaa95a4c7e99fe3e6f21d65b0c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDg4OTQ_04c61994-1ac2-4632-92be-e6a3730ba73b"
      unitRef="usd">250000000</us-gaap:AdjustmentForAmortization>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i611105bf33cb4418b7e1bae1d7e7ea5f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzIxNDk_fb5039d7-8181-4d77-a432-ff3c9b92de81"
      unitRef="usd">400000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i259bbbafc4fc42dcac9e345225999d94_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzIxNTY_7dd41480-ac11-4727-9abd-51a68d76489e"
      unitRef="usd">550000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="i101468e37b9d4cf382b7335393246678_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzIzMjA_f15a8031-c11d-4112-9cc8-d2d0b024a86b"
      unitRef="usd">2100000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i4c7aac3504dc4b288b6ecdf3ff0688b9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI1MTg_3f2bb204-0ed9-4404-abe7-b8c85202077e"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i8deae556e5124fc0a386203ac8730e23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI1MjU_c0a8646c-5697-4c23-a74e-359ccd87122b"
      unitRef="usd">160000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:CollaborativeArrangementRegulatoryMilestonePaymentsAccrued
      contextRef="i101468e37b9d4cf382b7335393246678_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzM4NDgyOTA3MjA5MDQ_6b9af8a4-1629-44da-a948-63023e7dfec7"
      unitRef="usd">105000000</mrk:CollaborativeArrangementRegulatoryMilestonePaymentsAccrued>
    <mrk:PotentialFutureMilestonePaymentsRegulatory
      contextRef="i101468e37b9d4cf382b7335393246678_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI2Mzc_677993fc-a40b-463b-93b0-c452b1d17abb"
      unitRef="usd">1100000000</mrk:PotentialFutureMilestonePaymentsRegulatory>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i46a9b57f7713451ab3d958cb0b3c227c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzI3OTY_ed8d6e65-0d76-476e-83a4-8bbaa4d21fa0"
      unitRef="usd">1600000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEyMzAw_3eae4646-0e9f-476c-93bd-2c223120e7e3">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trade &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;ccounts payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250&#160;million and $106&#160;million, respectively, of cumulative amortization catch-up expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;153&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; Accrued and other current Liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount as of December 31, 2021 includes accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expenses in all periods now include an allocation for overhead charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount in 2020 includes upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued royalty and milestone payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="id4bb57af17fa46da951221280cae2d61_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEtMS0xLTEtNzEzMzA_51a8172e-d40d-422f-8e92-a34f1f5d0610"
      unitRef="usd">1116000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="idd326598790045f6bcc0f44c24e3b67f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEtMy0xLTEtNzEzMzA_d09e3307-728d-4163-ad7b-fb25b6a011f4"
      unitRef="usd">989000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="if29b92e874b140df8ddfc7bb19c76d76_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEtNS0xLTEtNzEzMzA_ee65aacb-a415-4526-80d1-2f331d23984c"
      unitRef="usd">725000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="idf71a18afeee4bdfa2f728eb5087abcb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzItMS0xLTEtNzEzMzA_e7f2bd24-3389-4e2a-9cfe-57676a82965a"
      unitRef="usd">54000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ic0a13a1700a349c494acb5ee8a7c314a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzItMy0xLTEtNzEzMzA_8c9c1980-64c2-43c4-b4de-d49b5b2e5784"
      unitRef="usd">29000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i01cb97bb488247dca17be49d7a0fb045_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzItNS0xLTEtNzEzMzA_20ebfbeb-644f-4621-a78a-6378d0766d14"
      unitRef="usd">8000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i38b3ed6377c5412fbd503a5deff1c930_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzMtMS0xLTEtNzEzMzA_84d92fcf-3880-4195-b245-eeda382ab073"
      unitRef="usd">1170000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i1ebd2bf240ad4502a0f8eb75120c4db4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzMtMy0xLTEtNzEzMzA_3db0b0c5-2448-41ac-8d5f-4f93ff615ee4"
      unitRef="usd">1018000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i8026cfa395c34fc78f7ffb4639e7cfd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzMtNS0xLTEtNzEzMzA_9e0267c2-4c2d-4282-8302-71953ae13b9f"
      unitRef="usd">733000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i89fa20a8d8c344b79257be206a940dc8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzUtMS0xLTEtNzEzMzA_2c2a93c2-ed31-44bf-a696-77d66f1d69ef"
      unitRef="usd">492000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3721b0ead6be47bd8aaa1248657e3dc6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzUtMy0xLTEtNzEzMzA_770f15dc-61bd-4e85-87ec-c6d11b93b518"
      unitRef="usd">167000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ife46a1fcf6064f56a383f3b0d9487ba3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzUtNS0xLTEtNzEzMzA_775249b8-3e34-44ca-b6cd-e9d51628fc5d"
      unitRef="usd">247000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i56a887176a9241c998829941def3e75f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzYtMS0xLTEtNzEzMzA_f2b67647-5617-4a35-8226-75cc5176856f"
      unitRef="usd">185000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i36c243b4cafd413ba234033925c3b3cb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzYtMy0xLTEtNzEzMzA_7574e9dc-9f50-48e9-a807-4a98d350f34e"
      unitRef="usd">178000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9ce2f27604dc40d8b3dc414670f4a61f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzYtNS0xLTEtNzEzMzA_9d250213-8b6d-4cff-a80f-db84ca6a49c1"
      unitRef="usd">160000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i23c8a34670be4d2f852e82ad0329e859_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzctMS0xLTEtNzEzMzA_d1bf56ba-126d-4e9d-9886-3da62cc39d71"
      unitRef="usd">106000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i99ab1b65fec2429e9e9fb8b77ca7676c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzctMy0xLTEtNzEzMzA_729e4267-1ab3-4921-8e3a-fd17f716f55d"
      unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8073582f227c469789fa05dbe73664e4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzctNS0xLTEtNzEzMzA_10e5f15f-94ad-44d3-8d92-65c51aeb3ceb"
      unitRef="usd">133000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie0cbe6f30ebf448ca8dd317840d491e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEwLTEtMS0xLTcxMzMw_296b7db1-1fc6-4201-8fb7-f0a74ad39e32"
      unitRef="usd">303000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i8f186ca6621243c0b67606ff25b17513_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEwLTMtMS0xLTcxMzMw_aa65e547-f904-4c12-8a30-21078924c0f0"
      unitRef="usd">271000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6a6baf80c0d6487ba768a3bf8d2eb9d1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzExLTEtMS0xLTcxMzMw_c940bd43-7815-4f4e-883c-a927f1143eb1"
      unitRef="usd">123000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i477ac519583c49c4a85dfaec2d9aeeb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzExLTMtMS0xLTcxMzMw_f2074e62-a3f2-4055-8caf-a535971dce05"
      unitRef="usd">415000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i11a011afad64440c8c568e59dfd355ce_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEyLTEtMS0xLTExMDA0Nw_4c259a33-480d-4420-bf4c-008e1937be7a"
      unitRef="usd">600000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ib9171e04635a4e7ca60a79f50cda5a90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTozZGQ4NzliYWM0YjM0NDQ3YWFiNDZiNjUyMDg5MzMwYy90YWJsZXJhbmdlOjNkZDg3OWJhYzRiMzQ0NDdhYWI0NmI2NTIwODkzMzBjXzEyLTMtMS0xLTExMDA0Nw_e288dbe7-784f-4f2f-a6ae-bc40f527d426"
      unitRef="usd">0</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9cd932eaa95a4c7e99fe3e6f21d65b0c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDkyMTQ_04c61994-1ac2-4632-92be-e6a3730ba73b"
      unitRef="usd">250000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="if2370a20f6b9477d9190b59f039b3caf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NTk5NDg_45ee1c72-8ce4-4ad2-9287-f1d22979c7df"
      unitRef="usd">106000000</us-gaap:AdjustmentForAmortization>
    <mrk:LicenseOptionPaymentRelatedToCollaborativeArrangement
      contextRef="ie86f8b6b06284e30a88d0cfda2123b04_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQzODk_8bc4df59-fff1-425e-90f0-cae00ad4cc96"
      unitRef="usd">125000000</mrk:LicenseOptionPaymentRelatedToCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="ia743de15853e41f3b910d4cf1122df64_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ2NTU_eeeb4ab6-23dc-445e-b38b-8d5addaf5543"
      unitRef="usd">600000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i35980e373bed42f38371f148fe8ecf3e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ2NTk_203ea3c9-5926-4d01-8b21-749b458fb431"
      unitRef="usd">200000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i09d51996c5b14f1cb72dad54b7d4d76b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ2NjY_b8e44d53-ae92-4de1-bdf4-9d457a3b0262"
      unitRef="usd">500000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="ib1775ff52a4f4c97a6d68baca5ddf177_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzQ4MzY_13261e19-eb91-4b5c-90aa-f27ee529b2e6"
      unitRef="usd">2600000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i3ab1b0334084476e98316729e3a8c112_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDAxNzE_dd32d3bd-cf3f-40a3-9584-5e13dce9cf69"
      unitRef="usd">50000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="ibfc3245aba5546e0b11f27c281841fce_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzUwMzM_22ad2899-ad0e-4455-a0a9-c3f6772cee18"
      unitRef="usd">75000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="if4c7f305f94d485faf5c727853db7751_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzUwNDA_da673d78-a0d4-4578-8be8-1a71aec7b2bc"
      unitRef="usd">10000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia9c533dce277413ebf7c86906b5c8f94_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzUzNzM_07976841-cdde-4cf6-b77a-14ee077c3d30"
      unitRef="usd">814000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i46a865d1c00d4bf6b87ba7cfb8872940_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzEtMS0xLTEtNzEzMzA_7d4f45b7-24eb-4da7-a2a8-2969a73d9321"
      unitRef="usd">876000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i9ccee6352d064f868e634387f9b6defb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzEtMy0xLTEtNzEzMzA_d668c9e7-db8a-4dcb-a156-ced7deafd7fb"
      unitRef="usd">704000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i4e2ef9288be849db9f064efef46fecd2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzEtNS0xLTEtNzEzMzA_49edc0a5-995f-4247-8b1a-93748d47eef1"
      unitRef="usd">580000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaaba9c09c27c48bab00412147d7b1bd5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzMtMS0xLTEtNzEzMzA_306f16b6-3fbb-4f0f-b4db-7741d0889fda"
      unitRef="usd">212000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7660095e034c4216aa9276e5feedb36c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzMtMy0xLTEtNzEzMzA_deda6fe2-0162-464f-a480-d59bf2b17ff7"
      unitRef="usd">195000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i76b2184ceafa474a9e19170e8fb42f5c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzMtNS0xLTEtNzEzMzA_6bd95b59-5488-4997-b6b0-3376bcb0f506"
      unitRef="usd">271000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6a750360d1484fdfbcaf406737a1903c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzQtMS0xLTEtNzEzMzA_7453fbb5-9d0a-496f-91c0-a43dfd555c4c"
      unitRef="usd">158000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i164d9fadd4974909b666bfa2279e3149_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzQtMy0xLTEtNzEzMzA_9e705935-72a8-4545-a852-7dc84d6c4012"
      unitRef="usd">127000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia28b73d8d0524599afa19cadb0b0e70a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzQtNS0xLTEtNzEzMzA_0c581a1d-d659-45a1-92bb-07ec352c1c96"
      unitRef="usd">73000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id6ca606083fe4ddabb3985078aa79999_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzUtMS0xLTEtNzEzMzA_6779202e-63a6-4e72-8bcb-3ac975fb60a1"
      unitRef="usd">136000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic5ab13a91e6d41409f02aa3644bb33d5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzUtMy0xLTEtNzEzMzA_18bb6d7a-1fa8-4abe-ac0f-c6036bd58e6e"
      unitRef="usd">173000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i09bd2e76e1e742df96a5837cbb96ed58_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzUtNS0xLTEtNzEzMzA_012042af-c45a-47c1-8571-a8f7c0b9dc25"
      unitRef="usd">185000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9e3ec7d905d742d7a5ff17c57e5fcbf2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzgtMS0xLTEtNzEzMzA_e2b61035-5630-4787-8c26-b2aee67115d4"
      unitRef="usd">214000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i30cb0bc5ac844767be8fb1d138e6664b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzgtMy0xLTEtNzEzMzA_8b82314e-f293-4def-8c5b-b2b0c9c5889f"
      unitRef="usd">200000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i846e3e5062424fcb9eb3c09ff655d70c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzktMS0xLTEtNzEzMzA_bc99c52d-de94-4b9c-9c42-cdaba15be97c"
      unitRef="usd">0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7065d7527cac47058269d8ba6fac070e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo2ZWY5Nzg4MjRlMWE0MTVlYWFjNmE1OWUwNmI3YmE5MC90YWJsZXJhbmdlOjZlZjk3ODgyNGUxYTQxNWVhYWM2YTU5ZTA2YjdiYTkwXzktMy0xLTEtNzEzMzA_ecee86c7-cc76-4527-aadb-241a6ea309b5"
      unitRef="usd">625000000</us-gaap:LiabilitiesCurrent>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="ie657eb0222df4887b09402876cce71d3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDExNjE_0e84159e-bf40-4212-ac53-b8deb359ebbe"
      unitRef="usd">400000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="id3416ec93d1a492fa1f433c26d04679c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzcxNjk_54af91a4-b729-4478-811f-1982a446d614"
      unitRef="usd">375000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id5de854d06ac4eeca3f033f63ac8cf18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzgwNDQ_c9e9026b-b5b2-474f-864f-86f018ef51d5"
      unitRef="usd">633000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0bd89ab9867a451bb7d8f5e7dd23cfa9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzgwNTE_1c6d12f6-5d84-4f30-9bca-74bb750dd76b"
      unitRef="usd">57000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ib5bfe141a54941c1ae25d64fbabae891_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEtMS0xLTEtNzEzMzA_376667f9-e389-471c-b416-8ebe3c95fe93"
      unitRef="usd">341000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i855e5afb6533435a88463827fb0e2179_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEtMy0xLTEtNzEzMzA_4568caaa-9234-4375-b1ad-25ef5fc3b7f5"
      unitRef="usd">342000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i6d25852fad3a41db9c665d20c687a9bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEtNS0xLTEtNzEzMzA_96d637f7-86eb-4b83-9b89-1bbbc8f164de"
      unitRef="usd">281000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i98f6db34c320474f93fc442eab2cae85_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzItMS0xLTEtNzEzMzA_2b60b64f-457b-4791-afa2-b05109564bd2"
      unitRef="usd">238000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ib730f07be57a4e6abbd8c475c9858a84_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzItMy0xLTEtNzEzMzA_a968463f-721a-4cfc-ab51-39d283a4b0bb"
      unitRef="usd">252000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i0ba49d74de774a7da3dd6fe57759ddd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzItNS0xLTEtNzEzMzA_6328400b-1555-4bd6-a006-d3b4ce8e8580"
      unitRef="usd">220000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ia83aee4fe2eb49e79b304d069fa8ad26_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzMtMS0xLTEtNzEzMzA_b8306aeb-2b21-4691-9d3b-2362316abc22"
      unitRef="usd">22000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i732d1a8cd545457bb9404f007a3ddbbb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzMtMy0xLTEtNzEzMzA_0a33c465-6df3-490d-8aa6-77fa0ae3fe68"
      unitRef="usd">7000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ib8bafd4db40a4019a8844632901e67e2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzMtNS0xLTEtNzEzMzA_e9db287d-91a9-4881-83af-465d03fa1c1f"
      unitRef="usd">0</mrk:CollaborativeArrangementSalesNet>
    <us-gaap:Revenues
      contextRef="ib5bfe141a54941c1ae25d64fbabae891_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzQtMS0xLTEtNzEzMzA_fc92c8ac-71bf-4a80-b48f-526af4b71054"
      unitRef="usd">601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i855e5afb6533435a88463827fb0e2179_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzQtMy0xLTEtNzEzMzA_a9370b3b-1b46-4a2b-bdd7-591046c93977"
      unitRef="usd">601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d25852fad3a41db9c665d20c687a9bd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzQtNS0xLTEtNzEzMzA_8ee3af4d-0f6a-409c-a531-9c90d00bfb25"
      unitRef="usd">501000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie3a3942c4b5040c183b0a32bce8ccfc0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzYtMS0xLTEtNzEzMzA_9be8f615-dc88-4f79-9f2b-1c20c34edb33"
      unitRef="usd">210000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i379f2e061e03444ab72ac31156ba6076_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzYtMy0xLTEtNzEzMzA_35488a7b-f321-487b-9c6f-3a9d2d347995"
      unitRef="usd">424000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i890188202bc349308f5fddb70d1ac474_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzYtNS0xLTEtNzEzMzA_115557ef-cba6-4d78-aba5-c2f5d4bfd790"
      unitRef="usd">196000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if6d323bb0936465fa024e1457a0783f9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzctMS0xLTEtNzEzMzA_604f180a-add5-43ab-86ec-ebeba760a89e"
      unitRef="usd">153000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9134617e9894461384c3736c75213497_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzctMy0xLTEtNzEzMzA_dad3cf64-f6f7-461a-ad0e-b277b1ba394e"
      unitRef="usd">126000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8cca313b49524b8880414378a9bd58a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzctNS0xLTEtNzEzMzA_aa614336-7a87-4ea2-9f2a-de9ef7fc5079"
      unitRef="usd">47000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i465e0e2b26a34a65a2ceff807a69c161_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzgtMS0xLTEtNzEzMzA_e2a8edb6-4304-4f95-92c0-cb11d1a565af"
      unitRef="usd">75000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i45ceb7081ad348a5b332291f5eac99f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzgtMy0xLTEtNzEzMzA_41a71d89-94ee-48ac-be47-2602e2ed1b61"
      unitRef="usd">53000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9d83c83f0aaa41bab160e17f7828a23c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzgtNS0xLTEtNzEzMzA_5f376929-a7b5-492f-a009-3bb1531214b3"
      unitRef="usd">63000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i4211db3a27fa41ce9ef8afb548f9103d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzExLTEtMS0xLTcxMzMw_94a60a6b-757e-4165-bc3f-8c533e2bd6f7"
      unitRef="usd">143000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if1754d2b50304b08aa2cc44626f808d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzExLTMtMS0xLTcxMzMw_e7ecbdb1-ab8d-444c-94f3-4d049c0b9db1"
      unitRef="usd">114000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id2440fcb0b354debb320abddbe888325_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEyLTEtMS0xLTcxMzMw_3d94bde3-e78a-4361-aea1-7b8f6cf2c880"
      unitRef="usd">80000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i864756958f464b8baebe379049606e29_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZToxMDY5MzU2OWU4YjM0OWQ3OWJlMDg2NjM3MmIwMTAxMy90YWJsZXJhbmdlOjEwNjkzNTY5ZThiMzQ5ZDc5YmUwODY2MzcyYjAxMDEzXzEyLTMtMS0xLTcxMzMw_9416433f-745f-4692-8620-497b469f6b60"
      unitRef="usd">472000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i379f2e061e03444ab72ac31156ba6076_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0Xzg0Njk_42f64e73-c5e4-4b22-8381-ed775347309c"
      unitRef="usd">153000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Revenues
      contextRef="i601ee311bfa347d0b5dcc37af824a720_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzEtMS0xLTEtNzEzMzA_73e5e142-ffb3-470e-8899-3e805e982adc"
      unitRef="usd">5684000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd816c120f854e69b9a2159aeed10f3e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzEtMy0xLTEtNzEzMzA_f4ed3727-d1b7-4725-a3b8-028b0e5e8a91"
      unitRef="usd">952000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie947e36c8b7f43249d8241cd508c5350_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzEtNS0xLTEtODU5OTQ_99782429-55ee-4875-830a-ed0f459bfe1b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i43ac66950463401192d572c40841d4cf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzMtMS0xLTEtNzEzMzA_b074b6e2-56ac-43bb-8d83-ce1324be2324"
      unitRef="usd">3038000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4f9b197fc4714188b0f988ab63603db4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzMtMy0xLTEtNzEzMzA_1d8b23d5-07f3-4816-a9ce-fd831753d3d7"
      unitRef="usd">502000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i157fad50a46146f7862f955f23ac964b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzMtNS0xLTEtODU5NzE_7c6f14cf-c120-4afe-a900-c41250c01a01"
      unitRef="usd">17000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i70782495edd949faa59537a7ff4fad68_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzQtMS0xLTEtNzEzMzA_be6a87b2-77a5-4534-91f9-ad43fa73f8fc"
      unitRef="usd">147000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i32e2939d44e74e1299e632f622332de7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzQtMy0xLTEtNzEzMzA_e1acae2a-e524-40d9-bec2-c18e424408c7"
      unitRef="usd">37000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5c327eb0afa44aaa8b041180a9931985_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzQtNS0xLTEtODU5NzE_bfe2a38b-173f-4aa9-bf0c-b4a9e0bcfc69"
      unitRef="usd">6000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ice4c5d96e848446187e39b06993aa908_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzUtMS0xLTEtNzEzMzA_29293f6d-6440-4f20-872c-71f1778107e0"
      unitRef="usd">88000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibb42b703c354447eacb3e957b27d7ec1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzUtMy0xLTEtNzEzMzA_b274d4eb-bedc-407c-b9c1-82b9d83ec083"
      unitRef="usd">137000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i67875c460a8c4de69af3791511d877db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzUtNS0xLTEtODU5NzE_c5874c78-7f58-48a2-9261-8bb8f2894a2d"
      unitRef="usd">349000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie2d4b8387cc44522a4d608929cf3f19d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzgtMS0xLTEtNzEzMzA_c20e5b9b-c5b5-4fc7-9f40-3750e400a4a1"
      unitRef="usd">348000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7e2f8008c6984b9c8973be53aa0971ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90YWJsZTo4OTc4NjQ4YThiNDg0NDE1YjliM2Y4YzZkMmNkM2QxNS90YWJsZXJhbmdlOjg5Nzg2NDhhOGI0ODQ0MTViOWIzZjhjNmQyY2QzZDE1XzgtMy0xLTEtNzEzMzA_9d28d853-67c6-41e0-8a8f-8a1bd9abb863"
      unitRef="usd">283000000</us-gaap:LiabilitiesCurrent>
    <mrk:RoyaltyRatePercentage
      contextRef="iac7e27beb28f433687f6a328ad49420e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzODI_6a6e52f6-a8b8-43ac-b377-903c323c7a79"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i4e6787b2f43c4435bb7b7e0c9b5c5a48_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzODc_ed94036f-6e14-45f3-b607-ec10acf10a0e"
      unitRef="number">0.24</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRateDeductionPercentage
      contextRef="ib1d8391ce634476c8543dbb3f18f43dd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzOTI_e40cffbe-c3e1-4645-be78-17b741e5756f"
      unitRef="number">0.50</mrk:RoyaltyRateDeductionPercentage>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ic10f48c8ad804e3ab3fb873838f81931_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDUzOTc_3fb85fac-ea67-427f-abd5-f429e3aa8dae"
      unitRef="usd">80000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:Revenues
      contextRef="ifc3969c4d6864a2da3a1f1ed7fc44512_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDk2Mzc_1882bef5-18fe-40ab-9a14-0e9ccda4fdd3"
      unitRef="usd">166000000</us-gaap:Revenues>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="ib1d8391ce634476c8543dbb3f18f43dd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDgyOTM_b744e5b8-1b3b-4dd2-aed9-e2509c3b196d"
      unitRef="usd">146000000</us-gaap:RoyaltyIncomeNonoperating>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="if030a4536a8047a1a585275c17092ed8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NDgyNTg_ce26075a-fc3b-4115-b59b-4f0c9e7460bf"
      unitRef="usd">20000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:Revenues
      contextRef="ic4460340464041e0b1e1151e1bdec68e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjAvZnJhZzo0MDdlNGY2NmNkMmQ0NDFjYWNhZTlhZTY2YzkwMjQ1NC90ZXh0cmVnaW9uOjQwN2U0ZjY2Y2QyZDQ0MWNhY2FlOWFlNjZjOTAyNDU0XzEwOTk1MTE2NTE5NTg_baaf28fa-81ce-4fe7-aa41-af612a5239d7"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzMyMTY_5ae2c0ac-6035-42fe-bd71-b58cf444e7c1">RestructuringIn 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#x2019;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#x2019;s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. &lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recorded total pretax costs of $666 million in 2022, $868 million in 2021 and $880 million in 2020 related to restructuring program activities. Since inception of the Restructuring Program through December&#160;31, 2022, Merck has recorded total pretax accumulated costs of approximately $3.3 billion. The Company expects to record charges of approximately $400 million in 2023 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e"&gt;Selling, general and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00"&gt;Restructuring costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;337&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9"&gt;Selling, general and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96"&gt;Restructuring costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e"&gt;Selling, general and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505"&gt;Restructuring costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other activity in 2022, 2021 and 2020 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;14) and share-based compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring reserves December&#160;31, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be largely completed by the end of 2025.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzYzMg_90486846-2dc5-4946-983c-d6d44a7750da"
      unitRef="usd">3700000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzY3Nw_a4e32772-9c46-4bc8-9d7b-18a495222c4e"
      unitRef="number">0.70</mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzgzMw_d07dfc72-bc24-46b2-8909-ce8e3afa6b86"
      unitRef="number">0.30</mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEwMjA_9304c229-cc3c-4c1d-9217-25bd5d1e7b3e"
      unitRef="usd">666000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEwMzA_e1cb969c-0bfc-4347-aca9-b66286521256"
      unitRef="usd">868000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEwNDM_efac51bf-8578-4b85-b375-8135f6c09041"
      unitRef="usd">880000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEyMjE_f9c17b4e-8fc3-4686-9d8d-530b4f05b69e"
      unitRef="usd">3300000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="idb510662b9e944c6a56938d27b6835b2_I20231231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzEyODA_f2c19d7c-d55f-4545-8af3-02ab067d9a24"
      unitRef="usd">400000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzMyMTk_19f8cba3-38b4-4608-a835-b734e34193db">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e"&gt;Selling, general and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00"&gt;Restructuring costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;337&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9"&gt;Selling, general and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96"&gt;Restructuring costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e"&gt;Selling, general and administrative&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505"&gt;Restructuring costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7552297483f94fa5b4160dc0db014d06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMS0xLTEtNzEzMzA_96a86990-8951-49bc-8027-c6c76a0b4266"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id85c300cf38349adb26180577979e5c2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMy0xLTEtNzEzMzA_eacee259-baa7-48a8-8684-27d2e56e7387"
      unitRef="usd">72000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3592e3674e13431aaf91bd67cef2a754_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItNS0xLTEtNzEzMzA_777ab1a6-133d-46ae-a82d-7f90f6e36c57"
      unitRef="usd">133000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItNy0xLTEtNzEzMzA_32a06521-c64a-4828-a38b-bfc39c3318dd"
      unitRef="usd">205000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i30469f7c418b4bd2a85fcc554df58178_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMS0xLTEtNzEzMzA_fbd9e6c1-49fa-413d-8c4a-38e6f5bebdb2"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic45c2b8530f9432f800bd21578f8e217_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMy0xLTEtNzEzMzA_edbf6ba3-aef0-454d-aacb-0e243a970410"
      unitRef="usd">19000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4eb748e33a7a454fac71c562342ce760_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtNS0xLTEtNzEzMzA_7a4d5707-8db2-4257-a42a-a86163939f35"
      unitRef="usd">75000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0b231d9fdbfd40ae8d6fe71ed37de345_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtNy0xLTEtNzEzMzA_12fbaed8-7a34-40ea-9c37-6f60e1f5394e"
      unitRef="usd">94000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib79c6477e2f646dd83409e81121b5a29_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMS0xLTEtNzEzMzA_d1dc663e-652d-4d6c-b9ed-9860614ce070"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i864a963e97a44b5f8189640f9cb94d43_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMy0xLTEtNzEzMzA_5b2dec5b-3a70-4d8f-bf6f-df4f237f0d1c"
      unitRef="usd">29000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia817beebd6444eea99db772afc066555_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtNS0xLTEtNzEzMzA_3734034d-a25a-4684-8ea5-2675df2db61e"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3e1e5bec9c0340748f3a3782a3f7fd23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtNy0xLTEtNzEzMzA_b1af5a79-c8fa-4144-bc9f-a6d1ecd70d93"
      unitRef="usd">30000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib7d722d97d3e436e80d290bc86ab1496_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMS0xLTEtNzEzMzA_ca19a99f-8995-4d80-9cba-29926e0842c7"
      unitRef="usd">212000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2335ada88a2240b6bd6252e8fa8510a4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMy0xLTEtNzEzMzA_c1ba1409-8bdf-4cf5-a428-40a674294f62"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id3b44b6cfd4f4a8b99ef33bcc3c06df7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtNS0xLTEtNzEzMzA_b12466f5-e75e-4b57-88bd-aeb056ba20fe"
      unitRef="usd">125000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i804346c2237043e084b1afb341655a9f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtNy0xLTEtNzEzMzA_0da363fc-0009-4556-ba09-2e70d24bb0be"
      unitRef="usd">337000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtMS0xLTEtNzEzMzA_227ffed7-7417-41b1-9449-c7701e239b12"
      unitRef="usd">212000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtMy0xLTEtNzEzMzA_fe15cad1-ae77-4f8a-83bf-3fcddb8a541e"
      unitRef="usd">120000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtNS0xLTEtNzEzMzA_be86a6e4-5adc-4cad-bdd5-a082af3ff21b"
      unitRef="usd">334000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzYtNy0xLTEtNzEzMzA_7e3f717f-0522-4279-9c90-e02299f4be6f"
      unitRef="usd">666000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2c693f6dd72a403f89d6d2355a3b1c83_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMS0xLTEtNzEzMzA_847fa464-601a-47ae-92ac-bdf5b42928a5"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib3c3521eff5d4d78bed2d56d42e3789f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMy0xLTEtNzEzMzA_e4c69143-c438-460c-abd0-0fab2d8237d0"
      unitRef="usd">52000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i015fe5f90bbd4e93a29ffe724e90bfd0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtNS0xLTEtNzEzMzA_067a1411-4a1e-4834-9c94-5d3676f44e6b"
      unitRef="usd">108000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibc8bfe07436149a2b63950679699d1df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtNy0xLTEtNzEzMzA_301b50eb-1324-495d-9721-9f97ba51b894"
      unitRef="usd">160000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iba21ed671f2448ceb380d10aa9f40bd6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMS0xLTEtNzEzMzA_5163a037-61a4-4d1d-b956-1def12694801"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia7cd884e75e9428f87dc9ff260d2f3ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMy0xLTEtNzEzMzA_993b3066-f923-4477-8967-38b5640d695e"
      unitRef="usd">12000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibaa6d39939da4e91b837b366cdef3966_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktNS0xLTEtNzEzMzA_16644881-8cbd-4e74-9d2c-3479fb8ce2fe"
      unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i975b430806c14e4dac19b89356167bc0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktNy0xLTEtNzEzMzA_09c7beb7-ba79-4b88-8cd8-cc59f512a435"
      unitRef="usd">19000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i16a86b0a2eb94ae1872813f8188edae8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTEtMS0xLTcxMzMw_3bcf136d-fb85-46bf-a990-9b814e2c0ace"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibc1ca9c45f2f4c0d8e7d64701e4cb36d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTMtMS0xLTcxMzMw_ef6d5120-24ac-46a3-8267-1641ff3e82e5"
      unitRef="usd">27000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i54629a1dafcf430fb0b2f74327fdd6df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTUtMS0xLTcxMzMw_597db157-5e66-4167-8ee8-b242f48ed435"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0562404e8e0e4465a752940a1235ee59_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTctMS0xLTcxMzMw_af50fc17-73f0-4407-a512-bf2315fc5ab2"
      unitRef="usd">28000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8d9a9c572051413cbcbfc3a23280168d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTEtMS0xLTcxMzMw_9affa3f9-25da-4bc7-8f26-b9b0133dee85"
      unitRef="usd">451000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1decc07eadc24124bed0dd2deaff444a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTMtMS0xLTcxMzMw_9ced923c-f35c-46f0-89a3-ee2dce0b04b4"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ice7363f8460840bb83ffb6ca99594560_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTUtMS0xLTcxMzMw_be730f5b-73da-4ef3-a6cc-19792df8f5d9"
      unitRef="usd">210000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibedf7a5f7ef7456586ec0f021a1d0f3d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTctMS0xLTcxMzMw_72aa172a-a6be-4aad-8462-94f852403c2c"
      unitRef="usd">661000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTEtMS0xLTcxMzMw_767b651a-c4b4-4436-81d9-b4f3c0a31456"
      unitRef="usd">451000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTMtMS0xLTcxMzMw_8a064a81-42fd-433d-b05b-ec726b58e365"
      unitRef="usd">91000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTUtMS0xLTcxMzMw_344f0d32-690a-41bc-9f51-d5aec27209d2"
      unitRef="usd">326000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEyLTctMS0xLTcxMzMw_2f61f43d-6675-48ca-b7d3-1e323d95d106"
      unitRef="usd">868000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1e08ad749ea24620a73bf3de13d4ba83_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTEtMS0xLTcxMzMw_047f047e-7b83-463f-95c0-7346d3aed6bd"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i97f4ba5c710647b8a25a7267abdd6754_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTMtMS0xLTcxMzMw_79f7fbf1-09df-498e-950d-1f1e76485698"
      unitRef="usd">143000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1b6eb5443eb44c5f83120bd0907e38cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTUtMS0xLTcxMzMw_d2e258cd-199d-42c5-bde3-0c9eff33cf4a"
      unitRef="usd">32000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3327a1e7655544f3a7d9953a5234e2fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTctMS0xLTcxMzMw_b806ffba-b53d-4a07-9238-0a4daf83b831"
      unitRef="usd">175000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i51f9f13e5ade4b49abc89a6dd9a5b2b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTEtMS0xLTcxMzMw_f7f6dea6-0d2f-48d9-ba32-cd454345a7c4"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia78f45a1853841d69480601600ad30b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTMtMS0xLTcxMzMw_ad092adc-6814-425f-b3a5-6561e8e67591"
      unitRef="usd">44000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1b6c21a42378451b9dab85a8423576f3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTUtMS0xLTcxMzMw_5ba817f3-b78d-467d-b4ad-33b507b3fc8e"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i98c6fc33bcf040b88cd4cce4a3bd53e4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTctMS0xLTcxMzMw_6c68a1e9-e771-414c-aa02-dacc5420d935"
      unitRef="usd">47000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i720ba97855924cd9b21a8b29de3ba988_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTEtMS0xLTcxMzMw_19d908d0-89a5-4ce0-911d-9f31e7790e8c"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8bdcd5cba5f543dbb50dea0289f3ab2c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTMtMS0xLTcxMzMw_d4032432-a464-4c9f-bfea-1254419bafae"
      unitRef="usd">81000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i94d6a7f93e314fc384e0b1149d0ae9eb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTUtMS0xLTcxMzMw_9b1987b5-bf5d-44b9-bcf3-0dd50abe712a"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id440eb7ab1ed4b159153de0ed8b94de7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTctMS0xLTcxMzMw_07af9678-0b02-483b-aafb-c691d8512ca4"
      unitRef="usd">83000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i88144043844d4f7eb9f8cde0124c59f9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTEtMS0xLTcxMzMw_c237d98e-9d9b-4223-98b4-a216edcafe72"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4983cbf854e94eceae83083147be86a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTMtMS0xLTcxMzMw_6d8d550f-3545-48a6-96bc-995ddda7093c"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i972eba5067f8445596ed5ff359126657_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTUtMS0xLTcxMzMw_71d3229f-deb8-49d0-a8ad-fba667b87afb"
      unitRef="usd">190000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8a80bcbbfa39470ab7a14b86c6fa70a3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTctMS0xLTcxMzMw_82de2388-3fe1-47e2-af41-1f0cb5def7fc"
      unitRef="usd">575000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8adcbd8025954472931113ef2fd8a95c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTEtMS0xLTcxMzMw_0fffd6a8-050a-48d3-ace3-eb241e764c95"
      unitRef="usd">385000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie0aa3f0a78454591b3695e1829428150_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTMtMS0xLTcxMzMw_ad910ff7-b7f8-4319-a90f-2fbc352c607b"
      unitRef="usd">268000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i074bc4aaa1734fa79f0b7f5045ab90d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTUtMS0xLTcxMzMw_c1142f73-2cf2-43cb-afef-bbd3aa8909cd"
      unitRef="usd">227000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE4LTctMS0xLTcxMzMw_b6f01712-76b8-4e1d-9006-82a8b578459d"
      unitRef="usd">880000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90ZXh0cmVnaW9uOjFhM2JiZjhkNDc3ZjRmNjlhMjI1MTQ3MTBlY2RkZjY3XzMyMzY_98dc61cf-c061-448e-bc66-255c59fc3e51">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;334&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restructuring reserves December&#160;31, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;The remaining cash outlays are expected to be largely completed by the end of 2025.</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i90b319f5a70d43988516fed4f52eb15d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtMS0xLTEtNzEzMzA_a91ae273-c5fc-45a1-99e4-89585b8398ba"
      unitRef="usd">567000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9c66f3b052f74fd3a26dc81f448660a5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtMy0xLTEtNzEzMzA_2d976227-9b39-4256-84fa-a52b2eccc8c4"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i3861723ccf964ba380c10a13117f1a30_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtNS0xLTEtNzEzMzA_b01ccd38-0e65-49af-9a23-97a54b63ef76"
      unitRef="usd">19000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzEtNy0xLTEtNzEzMzA_ce74f481-de13-412b-be65-f90b43663751"
      unitRef="usd">586000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItMS0xLTEtNzEzMzA_632ca6c2-4513-46e6-a12b-5467747791cc"
      unitRef="usd">451000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItMy0xLTEtNzEzMzA_0b317749-2427-4345-a11f-f5006b1d179b"
      unitRef="usd">91000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItNS0xLTEtNzEzMzA_b64bc58f-8fd3-4257-8465-727228448ba5"
      unitRef="usd">326000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzItNy0xLTEtNzEzMzA_6e976700-750f-44e4-9eb5-a927c592d176"
      unitRef="usd">868000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtMS0xLTEtNzEzMzA_2b4718e6-f035-4ba3-84b0-6e0e4c9f6400"
      unitRef="usd">422000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtMy0xLTEtNzEzMzA_1cae39b6-a379-4cc5-a03a-2015ff453375"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtNS0xLTEtNzEzMzA_17e1bc79-996e-4f88-b31b-32ff34fe6501"
      unitRef="usd">186000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzMtNy0xLTEtNzEzMzA_0480fe91-f88a-4796-b3e9-771736d808f2"
      unitRef="usd">608000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="ia2eddab20b4440a2a3f97b371aeac605_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtMS0xLTEtNzEzMzA_d944a834-1aa4-464a-96de-b0f1a9ce4b24"
      unitRef="usd">0</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i8d092ac36ee54eabb4dae88a97285ba0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtMy0xLTEtNzEzMzA_45ef82c5-7f07-4854-b010-fc49d838086c"
      unitRef="usd">-91000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i4b95ef363df7471fb0622091cb2dd84f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtNS0xLTEtNzEzMzA_be3c766a-d3d2-48c3-97b4-52beca44634c"
      unitRef="usd">-118000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzQtNy0xLTEtNzEzMzA_0e606b37-4862-4e98-8a3e-ec329465f743"
      unitRef="usd">-209000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="i235bd559e79d45cebeb01c3aa68198fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtMS0xLTEtNzEzMzA_a2767141-ef05-439b-89d9-99757ff4d147"
      unitRef="usd">596000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5164087f50654464a6032ddfbb33b657_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtMy0xLTEtNzEzMzA_1bce874b-7ec8-483d-bae9-d05ee710d5a9"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9a75ee9f06394ac58129ef3c07183626_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtNS0xLTEtNzEzMzA_b6bf2e5f-9acb-4680-8141-c900056751a9"
      unitRef="usd">41000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzUtNy0xLTEtNzEzMzA_ae3accfb-8127-4c4f-8780-0d85fe819645"
      unitRef="usd">637000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtMS0xLTEtNzEzMzA_b1870c6c-2e64-4acc-b3ad-c46898adf8be"
      unitRef="usd">212000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtMy0xLTEtNzEzMzA_aaf71ba8-a338-4425-9f46-75ecbfbbf92d"
      unitRef="usd">120000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtNS0xLTEtNzEzMzA_90a81f5b-0387-43a5-914a-6260815d6690"
      unitRef="usd">334000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzYtNy0xLTEtNzEzMzA_3a15e887-f587-4be3-8600-d18473d1bea3"
      unitRef="usd">666000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctMS0xLTEtNzEzMzA_c9ca4b7e-0a9f-4be7-8cd2-0ca07f998b61"
      unitRef="usd">329000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctMy0xLTEtNzEzMzA_6de40079-6045-4034-aa9a-d1e0218d0a71"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctNS0xLTEtNzEzMzA_9e7228b0-2de1-4546-a5be-76af5c2fd3c6"
      unitRef="usd">120000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzctNy0xLTEtNzEzMzA_4786b3f2-e7a3-49e3-86de-384c228acf4e"
      unitRef="usd">449000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="ib615d69119594f11b401cf972b449c5d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtMS0xLTEtNzEzMzA_abcd26f4-74d9-4730-947e-5ac4dcc2505c"
      unitRef="usd">0</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i706e14a3fa394260932acb94f50053ee_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtMy0xLTEtNzEzMzA_383dbc0e-3f3f-4024-9597-3f981ac79e0c"
      unitRef="usd">-120000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i46f740e3e5b44edabfcbfe5a2357fcf8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtNS0xLTEtNzEzMzA_23e40735-793f-4b47-a4a8-241ef9242f17"
      unitRef="usd">-221000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzgtNy0xLTEtNzEzMzA_82e4ce66-0ba1-4632-9539-4280c5b0210e"
      unitRef="usd">-341000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="id196364c06404f1e93dce678dce64cec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktMS0xLTEtNzEzMzA_aa3ef4ca-8d3e-4c30-a6cc-961ff0a6dd58"
      unitRef="usd">479000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i446658f48ca64a5595891b7cc6692950_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktMy0xLTEtNzEzMzA_167894be-d46d-4096-bd37-766c0bb016e3"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i6bca802b14ca406fa68447bf048b3c14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktNS0xLTEtNzEzMzA_18918b1c-f3e2-43b7-95b0-d22a93b55a07"
      unitRef="usd">34000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpiZmYyNzRhMjI3ZjY0NjQ2YmUyNTQ2ZDRjOWU1NGU0OC90YWJsZXJhbmdlOmJmZjI3NGEyMjdmNjQ2NDZiZTI1NDZkNGM5ZTU0ZTQ4XzktNy0xLTEtNzEzMzA_44dc569c-d6b0-4b0c-9111-45d2af547ba6"
      unitRef="usd">513000000</us-gaap:RestructuringReserve>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTY0_c0b31242-8ccc-477f-b5bd-d39f0fc1922b">Financial Instruments&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A significant portion of the Company&#x2019;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#x2019;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S.&#160;dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and reclassified into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#x2019;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022,&#160;nine interest rate swap contracts with a total notional amount of&#160;$2.25&#160;billion&#160;matured. These swaps effectively converted the Company&#x2019;s&#160;$1.0&#160;billion,&#160;2.4%&#160;fixed-rate notes and $1.25&#160;billion, 2.35% fixed-rate notes due 2022 to variable rate debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,824&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,691&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,926&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;19,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;28,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;32,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; below). The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received/posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;59,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain (loss) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;773&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges against rising treasury rates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company estimates $104 million of pretax net unrealized gains on derivatives maturing within the next 12&#160;months that hedge foreign currency denominated sales over that same period will be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amount ultimately reclassified to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Investments in Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net losses of $462 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in 2022 on equity securities still held at December&#160;31, 2022. Unrealized net losses of $232 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in 2021 on equity securities still held at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, the Company also had $832 million and $596 million, respectively, of equity investments without readily determinable fair values included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. During 2022, the Company recorded unrealized gains of $56 million and unrealized losses of $12 million related to certain of these equity investments still held at December&#160;31, 2022. During 2021, the Company recorded unrealized gains of $110 million and unrealized losses of $1 million related to certain of these investments still held at December&#160;31, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December&#160;31, 2022 were $289 million and $19 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, 2021 and 2020, the Company also had $598&#160;million, $1.7&#160;billion and $800&#160;million, respectively, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for equity securities held through ownership interests in investment funds. Losses (gains) recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; relating to these investment funds were $1.0&#160;billion, $(1.4)&#160;billion and $(583)&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;340&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;340&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;931&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;865&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included $11.3 billion and $6.8&#160;billion of cash equivalents, respectively, (which would be considered Level 2 in the fair value hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Cost of sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December&#160;31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimated fair value of loans payable and long-term debt (including current portion) at December&#160;31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion and at December&#160;31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company&#x2019;s investment policy guidelines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 21%, 20% and 13%, respectively, of total accounts receivable at December&#160;31, 2022. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.5 billion and $2.8 billion of accounts receivable as of December&#160;31, 2022 and 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December&#160;31, 2022 and 2021, the Company had collected $67 million and $62&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and the related obligation to remit the cash within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company remitted the cash to the financial institutions in January 2023 and 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#x2019;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#x2019;s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to various counterparties was $19 million at December&#160;31, 2022. Cash collateral received by the Company from various counterparties was $66 million and $164 million at December&#160;31, 2022 and 2021, respectively. The obligation to return such collateral is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i37f49dfec5954846bc22018691bd0081_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0ODg_abccdb68-64c1-479b-8368-6ec6d4d2f402">P2Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i5838f63c0490478eae7fa5bddaafa36d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzQ5ODY_a9ed1c17-8c38-49ec-a2a5-8b2f877cb035">P6M</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTcx_e8207759-201e-4fa7-bcaa-3c88125f20cd">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtMS0xLTEtNzEzMzA_b611d852-59ec-4a08-ba25-b4cad93ece28"
      unitRef="usd">48000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtMy0xLTEtNzEzMzA_e4b036fc-bd9e-451a-a501-1364be01ed0a"
      unitRef="usd">49000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtNS0xLTEtNzEzMzA_25eccb06-d795-4578-900a-32c0f56abc3d"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ieead02c0663c47e4a289f16813bc7306_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtNy0xLTEtNzEzMzA_65ff30d2-8d8c-4913-b548-497c971c5574"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i5160bc069bcb4a1386bf4185147cc88d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtOS0xLTEtNzEzMzA_adb980bf-1154-4ec4-9024-d385aaa14779"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i140d4ac54a9b4fafb92531ca8b76c69e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzMtMTEtMS0xLTcxMzMw_ba95c7f5-c764-4356-b26f-eebe6e7d26e7"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2dfc74fe5a384595a4c97c4a0eabb454_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtMS0xLTEtNzEzMzA_7d0746af-7967-4cde-9ffd-d169543e554d"
      unitRef="usd">162000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i702a5a6064884c78964fb0c841f02433_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtMy0xLTEtNzEzMzA_2d5906b0-2781-4529-8f97-cf129da17d0e"
      unitRef="usd">296000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i37bec909d9be4e24b3a7a85153c4ce18_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtNS0xLTEtNzEzMzA_8f398536-f872-477c-a3ce-bdbbc03b1249"
      unitRef="usd">-385000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="if4af38eda5034b1d8ed205026267630f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtNy0xLTEtNzEzMzA_2d4bc24d-a6b7-4699-b5e2-6588fb073978"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="icf14eee6b5fa4782a433bc13f07577f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtOS0xLTEtNzEzMzA_f62f5d00-9e00-4e9d-9f27-9f1001909848"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i9c95ec70187e405ba677c24678202bd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo4MWZkNTFlNjk1MTY0MjkxOGQ5MjdmMGI4MzY0NDk3ZC90YWJsZXJhbmdlOjgxZmQ1MWU2OTUxNjQyOTE4ZDkyN2YwYjgzNjQ0OTdkXzQtMTEtMS0xLTcxMzMw_9aa5458f-9c85-49f6-bc8d-11c8b0fefe8d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <mrk:NumberOfInterestRateDerivativesMatured
      contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcwNTM_232a44ae-514c-4f1b-8b4a-a3b3bd0a8395"
      unitRef="interest_rate_swap">9</mrk:NumberOfInterestRateDerivativesMatured>
    <mrk:DerivativeNotionalAmountMatured
      contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcxMDg_bd7203e9-13b7-4fc4-81aa-ddf30bc53337"
      unitRef="usd">2250000000</mrk:DerivativeNotionalAmountMatured>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia218fcd1db1141ed905f718a91fc9422_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcxNjg_d0a11a17-6d52-41cf-b160-7552506b1c7b"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia218fcd1db1141ed905f718a91fc9422_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzcxNzI_182320e2-0de8-43fb-ba4f-3f62fdbcca45"
      unitRef="number">0.024</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifa89acddce894ac08beedd53e127e143_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDc2MzE_a3ab79fc-461f-4946-af36-64d1ee6e177b"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifa89acddce894ac08beedd53e127e143_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDc2NDY_c779cd7d-9d8b-4c20-8dbf-5263d2f9e743"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTUw_63a4da67-273e-4f81-828e-632f312d59ae">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtMS0xLTEtNzEzMzA_b00213b4-bb72-439d-8a46-c05a11380ace"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i07e7539f63d64ce1a5c2568c9999a584_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtMy0xLTEtNzEzMzA_3db19cf6-69be-479e-bc75-2da31c0fcaef"
      unitRef="usd">2263000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtNS0xLTEtNzEzMzA_1cf2093d-5eda-44c4-b519-ebb0bdf71360"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i07e7539f63d64ce1a5c2568c9999a584_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmNDFjMGRmMTA2NjA0ZjVlOGY5YzYzMjllNTAyMjhiYy90YWJsZXJhbmdlOmY0MWMwZGYxMDY2MDRmNWU4ZjljNjMyOWU1MDIyOGJjXzMtNy0xLTEtNzEzMzA_be640a9e-d97c-4d4c-ba9c-0a1c12fb0c29"
      unitRef="usd">13000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTQz_1fc99f2b-47c9-4da4-8ff6-49ebba74847f">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value of&lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4,824&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,691&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;9,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;8,540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;10,926&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;19,466&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;28,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;32,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i20cd4c7fd5f14851a86d5a655db5663c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMy0xLTEtNzEzMzA_cf5af43e-0390-4839-a396-f8c747ba7515"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i20cd4c7fd5f14851a86d5a655db5663c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtNy0xLTEtNzEzMzA_c52edef4-44f7-4587-8b4c-5d41aab2bc05"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i50be94d522084d82a3e96d121db4b2c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtOS0xLTEtNzEzMzA_b88a8d16-c732-4ab9-a3b9-a8e7568efdad"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i50be94d522084d82a3e96d121db4b2c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMTMtMS0xLTcxMzMw_3847e608-95fe-47f4-acc8-f14e8ccf3ee3"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i782b995c5324440982290223b2cdddac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMy0xLTEtNzEzMzA_408c8d3b-2f87-4657-b975-93ee43cfdac9"
      unitRef="usd">220000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i782b995c5324440982290223b2cdddac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtNy0xLTEtNzEzMzA_2d9ac8b4-5974-43c1-8126-6e5ec38197aa"
      unitRef="usd">4824000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i1afdd113c40545adb3ae03acc9c4e126_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtOS0xLTEtNzEzMzA_44fec3c0-cb7e-418a-ac29-13e07da57515"
      unitRef="usd">271000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1afdd113c40545adb3ae03acc9c4e126_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMTMtMS0xLTcxMzMw_fe496814-a12e-464a-8411-2f56dffb4772"
      unitRef="usd">6778000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ia2c912a0937747a8a1ae5182d756b260_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMy0xLTEtNzEzMzA_6c89a4a1-3097-4952-8f1a-dfaac99dbcea"
      unitRef="usd">27000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia2c912a0937747a8a1ae5182d756b260_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctNy0xLTEtNzEzMzA_450415a6-bf65-47e3-bd19-068bb3671810"
      unitRef="usd">1609000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i2677274a350445afa69443c36f4a89da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctOS0xLTEtNzEzMzA_f53cc746-ac17-49f9-96b3-b39627522359"
      unitRef="usd">43000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2677274a350445afa69443c36f4a89da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMTMtMS0xLTcxMzMw_2ff709b9-1221-48fc-a312-c3eeb4088cf5"
      unitRef="usd">1551000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i350a79055507478fabc61583f11e2080_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtNS0xLTEtNzEzMzA_e330bd73-4cb6-427b-ab8f-2521617dd801"
      unitRef="usd">101000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i350a79055507478fabc61583f11e2080_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtNy0xLTEtNzEzMzA_3e8c8ed1-350f-4401-8dc3-820abb372586"
      unitRef="usd">2691000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ifc29185c1fed4990966cf824e4597298_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMTEtMS0xLTcxMzMw_cb4f5b55-8305-48cc-8515-642264b29b5b"
      unitRef="usd">24000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifc29185c1fed4990966cf824e4597298_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMTMtMS0xLTcxMzMw_48083bb7-5434-4274-bd58-6a0caaee8e37"
      unitRef="usd">1623000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="icdbb1216db6a47e88141c7169ea7875f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktNS0xLTEtNzEzMzA_ea5aefe3-262a-4635-a2bf-0ed50b230744"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icdbb1216db6a47e88141c7169ea7875f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktNy0xLTEtNzEzMzA_918f8972-d1d1-4ddd-b36e-7bfe6bbf6787"
      unitRef="usd">91000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i6226dc468d5e40ba93e5e688a3b0e650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMTEtMS0xLTcxMzMw_20a4ede1-3a76-449f-9126-86c10ffaab85"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6226dc468d5e40ba93e5e688a3b0e650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMTMtMS0xLTcxMzMw_ead6aa2f-34d3-43ce-9b43-f77102a03068"
      unitRef="usd">43000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ic0a0380fe0b24b768f534f7027ad8b63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTMtMS0xLTcxMzMw_18f9a254-92e3-4a00-978e-7f792d7a9aff"
      unitRef="usd">247000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ic0a0380fe0b24b768f534f7027ad8b63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTUtMS0xLTcxMzMw_83ec15cf-a581-4656-9880-5a13d89ac07f"
      unitRef="usd">102000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic0a0380fe0b24b768f534f7027ad8b63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTctMS0xLTcxMzMw_db59d710-599f-4370-b89d-fb6ec390a217"
      unitRef="usd">9215000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i90271718d0194ea79773a039096567de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTktMS0xLTcxMzMw_eef692af-73e7-46b3-b54a-12af28b328db"
      unitRef="usd">328000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i90271718d0194ea79773a039096567de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTExLTEtMS03MTMzMA_699dd8da-451a-4f1d-8a3a-c25a773f437c"
      unitRef="usd">25000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i90271718d0194ea79773a039096567de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEwLTEzLTEtMS03MTMzMA_ce9c9fb4-7f4c-4ff5-b5e7-6d81f16333f1"
      unitRef="usd">12245000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTMtMS0xLTcxMzMw_66fbc809-3a45-4960-94f1-91e7ea0c0bef"
      unitRef="usd">186000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i91b986dd8de2458386abddf2a2a64bfe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTctMS0xLTcxMzMw_301ae8bc-5327-4d23-9111-e76a585d840c"
      unitRef="usd">8540000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTktMS0xLTcxMzMw_8e7d1c27-5999-4448-8afd-01b44b802ad4"
      unitRef="usd">221000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i19c9b82f66ad4f6498c0bd7bc43fd253_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEzLTEtMS03MTMzMA_424c7eea-b727-45a3-a0cf-5170f8bbc0cc"
      unitRef="usd">10073000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i6bec1b5f2fdb4081a1d75b4744ea8243_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTUtMS0xLTcxMzMw_2a53e0b3-e7dd-40bb-83c5-a6523602383a"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if8101d6016e644c484984a91964cd5fa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTctMS0xLTcxMzMw_29e60cd7-7c66-4aba-99b2-47c1fc385a43"
      unitRef="usd">10926000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ie96270cdbd7b4606af8ee569a6ed934f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTExLTEtMS03MTMzMA_8b1958dd-092e-424e-9fcf-9c76e94993b7"
      unitRef="usd">96000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i79f69e11c219486faa68b50184be96c3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEzLTEtMS03MTMzMA_750b4035-28f0-47b0-84e1-16d11f0951c9"
      unitRef="usd">10640000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i8c1579987fd245a6b9ae265038125773_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTMtMS0xLTcxMzMw_969c26ca-dcf0-46ab-b292-8b14cef83eac"
      unitRef="usd">186000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i8c1579987fd245a6b9ae265038125773_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTUtMS0xLTcxMzMw_f4bacc03-456b-4da4-968e-79a1f774bd64"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8c1579987fd245a6b9ae265038125773_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTctMS0xLTcxMzMw_56fb387e-8355-4ed1-be1b-20158ecbabb7"
      unitRef="usd">19466000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i948c5f8c4b584db887310340bf216160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTktMS0xLTcxMzMw_542c9b58-51d3-438f-8c1a-be0d43ad9734"
      unitRef="usd">221000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i948c5f8c4b584db887310340bf216160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTExLTEtMS03MTMzMA_5edacb51-0297-4dfc-949e-ebb4b6c1cb5e"
      unitRef="usd">96000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i948c5f8c4b584db887310340bf216160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE0LTEzLTEtMS03MTMzMA_d8ff3ad9-bfd7-4fef-9b21-d74af421cd3e"
      unitRef="usd">20713000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTMtMS0xLTcxMzMw_638f1bdd-4e11-41d1-8bd5-1d2a7d6e04e6"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTUtMS0xLTcxMzMw_e4f66911-1262-4adc-9bc4-cef170cd8612"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTctMS0xLTcxMzMw_76d9c859-a7dd-4da1-8212-339915565af3"
      unitRef="usd">28681000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTktMS0xLTcxMzMw_6e73fcb8-277d-48c6-9c08-86a4ed7f7e22"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTExLTEtMS03MTMzMA_cfb8d5bd-aa01-40b8-93c2-ded85e4310b0"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzE1LTEzLTEtMS03MTMzMA_f20871d9-e105-4f49-8750-6a22466eb3f4"
      unitRef="usd">32958000000</us-gaap:DerivativeNotionalAmount>
    <mrk:OffsettingAssetsAndLiabilitiesTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTgz_e31dfc28-626f-42cc-95eb-ee1efcea37e8">The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received/posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mrk:OffsettingAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItMS0xLTEtNzEzMzA_da56418c-31f9-4bc8-be5e-335e0f2693f1"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItMy0xLTEtNzEzMzA_6d55e846-9bc4-4ed1-ad4e-7541fe90fa06"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItNS0xLTEtNzEzMzA_7f531f8a-5a76-4565-a6d1-09951e7b9895"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzItNy0xLTEtNzEzMzA_65840b34-467d-4203-ab41-ee5fcd6b63e4"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtMS0xLTEtNzEzMzA_1fa929b6-0e67-4d02-b1c7-5222aabb0bd5"
      unitRef="usd">220000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtMy0xLTEtNzEzMzA_f78372d4-85b1-444e-bd2e-9123174230f9"
      unitRef="usd">220000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtNS0xLTEtNzEzMzA_987d0337-7779-43ec-8ff8-56ea58f180df"
      unitRef="usd">110000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzMtNy0xLTEtNzEzMzA_507095fb-920b-42ae-8136-8c93a0dbf95b"
      unitRef="usd">110000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtMS0xLTEtNzEzMzA_8f86f105-cc8e-4d80-896b-06df2bb41ccd"
      unitRef="usd">66000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtMy0xLTEtNzEzMzA_06597588-be38-460a-884b-ea19f28c4d88"
      unitRef="usd">19000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtNS0xLTEtNzEzMzA_d0e3e97a-c132-4f4e-8139-0312798e0574"
      unitRef="usd">164000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzQtNy0xLTEtNzEzMzA_d051c4b0-cc46-471c-9aa5-e5720207d2c5"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtMS0xLTEtNzEzMzA_9656a18f-0031-41b4-b24d-28a87dfa119b"
      unitRef="usd">147000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtMy0xLTEtNzEzMzA_64db48d4-7d5a-4cd0-8572-baffd259eee9"
      unitRef="usd">170000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtNS0xLTEtNzEzMzA_25fde904-8ce6-4cf5-88d7-919b81356346"
      unitRef="usd">275000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmYzM0MTE0ZDRiMzk0MjM1OGVjZjQ4YzI2ODA0MmUzMC90YWJsZXJhbmdlOmZjMzQxMTRkNGIzOTQyMzU4ZWNmNDhjMjY4MDQyZTMwXzUtNy0xLTEtNzEzMzA_ce84603f-5183-4322-96d6-4eb2c2ae7dea"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTI5_31c27e70-782d-424c-8d2b-b3725070fe39">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;59,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain (loss) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;773&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:Revenues
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMS0xLTEtNzEzMzA_84464a4e-99d7-4fb7-bfcd-260e14260db9"
      unitRef="usd">59283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMy0xLTEtNzEzMzA_c2ae8312-81e5-4d6b-ab5a-28c547f0a482"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItNS0xLTEtNzEzMzA_94c2f89f-559a-4b42-9c66-233f6b193f69"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItNy0xLTEtNzEzMzA_1feb55b5-e7c3-4801-b9f2-d049d6984574"
      unitRef="usd">-1501000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItOS0xLTEtNzEzMzA_7c94603c-737d-4eb3-aeef-d3f050dd8271"
      unitRef="usd">1341000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTEtMS0xLTcxMzMw_084e8321-b481-419f-a636-9b21ab0bc7f4"
      unitRef="usd">890000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTMtMS0xLTcxMzMw_b40f965e-c1a4-4f28-b1d5-9004387293b4"
      unitRef="usd">-339000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTUtMS0xLTcxMzMw_d7e4638b-5cd0-418c-9537-3a6288705151"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzItMTctMS0xLTcxMzMw_76662fec-5bac-4adc-830d-0f3c49a771ce"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ib90fcefa805241de9e12f2aebc441fc2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzUtNy0xLTEtNzEzMzA_3ee9a354-a510-45eb-8c3d-8192c2ebdbe9"
      unitRef="usd">13000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i51bfda27ae2b4cc3b94f9a7440352c5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzUtOS0xLTEtNzEzMzA_da270f93-989c-4dd2-901b-dae378eb4e75"
      unitRef="usd">40000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i98a279e868ca477a849941852602f9df_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzUtMTEtMS0xLTcxMzMw_281896ce-6a92-4d68-a182-87832815426d"
      unitRef="usd">-40000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ib90fcefa805241de9e12f2aebc441fc2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzYtNy0xLTEtNzEzMzA_80182dc6-36af-48d0-b2fe-878dde8f226f"
      unitRef="usd">-4000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i51bfda27ae2b4cc3b94f9a7440352c5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzYtOS0xLTEtNzEzMzA_92862ba1-a694-4bed-b00f-74a7f49b27c1"
      unitRef="usd">-1000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i98a279e868ca477a849941852602f9df_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzYtMTEtMS0xLTcxMzMw_033ad2a3-5ca1-4192-969c-7ff71ce8f4b9"
      unitRef="usd">76000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzktMTMtMS0xLTcxMzMw_4c31411e-9ff7-48c9-af2f-dff79a703f14"
      unitRef="usd">684000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzktMTUtMS0xLTcxMzMw_b28eb147-967e-4eca-9c56-db8a994dbebe"
      unitRef="usd">333000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzktMTctMS0xLTcxMzMw_015f6175-55bb-46a8-bf07-4f8ec5286d84"
      unitRef="usd">-383000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:Revenues
      contextRef="i6c7a1215a0c049cab8f08a9594ad42b1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTEtMS0xLTcxMzMw_f0779d09-6622-4078-b960-cb51e6777a6b"
      unitRef="usd">773000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68492993011c48bbab8080844004db56_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTMtMS0xLTcxMzMw_d8f1beff-614a-416e-9166-e8c5cd9bb049"
      unitRef="usd">-194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3510a74c551e449094abce6bec887425_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTUtMS0xLTcxMzMw_a3df18e5-936a-4b8b-9b87-1fee80fdcf3a"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i966c0574579842adb1aad8f47b86bae5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTEzLTEtMS03MTMzMA_9d90c131-69d5-4158-878a-a382021103be"
      unitRef="usd">-773000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ib4279b466c2f455680947cdc1b006c76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTE1LTEtMS03MTMzMA_a55a206d-c530-4929-b9ad-6d29bc8c80c6"
      unitRef="usd">194000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i3bd8de7403ce41cd8cd98f100015cc67_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEwLTE3LTEtMS03MTMzMA_9cfc6dab-e480-44a8-84ea-7bb3dc34d59a"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTctMS0xLTcxMzMw_52533e3d-b5a3-4344-9695-37c5c1b0bb34"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="id60f9472b85e42f18f616225451c542f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTktMS0xLTcxMzMw_fa9ac6d7-99b6-48d2-bcde-9ed4c524d9c6"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i917d2ebe84824a7586c16f24fea495cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTExLTEtMS03MTMzMA_7a5c0eae-6132-4902-a648-aad36e5a4b55"
      unitRef="usd">-4000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i926eff1a8ec14b039e29169742609ad8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEzLTEzLTEtMS03MTMzMA_43c143b1-39e1-400c-b8fd-ae228e1a0f4d"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id60f9472b85e42f18f616225451c542f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEzLTE1LTEtMS03MTMzMA_35a6a8b1-2e15-4fbc-af3d-0248130962c7"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i917d2ebe84824a7586c16f24fea495cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEzLTE3LTEtMS03MTMzMA_d39f73aa-fe91-44c1-8a97-5f8879f85fc1"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTcy_a387dc8d-e64a-4731-80e3-a0f39b173062">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;These derivative contracts serve as economic hedges against rising treasury rates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ieead02c0663c47e4a289f16813bc7306_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzMtMy0xLTEtNzEzMzA_b66c459f-3692-4ac7-b9b0-ebe90e80db00"
      unitRef="usd">49000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i5160bc069bcb4a1386bf4185147cc88d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzMtNS0xLTEtNzEzMzA_2e213b1d-f87d-4834-9459-3a96b68b71b5"
      unitRef="usd">-313000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i140d4ac54a9b4fafb92531ca8b76c69e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzMtNy0xLTEtNzEzMzA_b5b0c652-8a2d-4ce8-8d7c-1e4b5e809dc2"
      unitRef="usd">12000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i28fc358415004cc2a37dd74e64f8d2aa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzQtMy0xLTEtNzEzMzA_303c13aa-f802-435e-ac49-af5624dc90a1"
      unitRef="usd">37000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i581c1be0a6984114bfd52dffb52aa7b6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzQtNS0xLTEtNzEzMzA_2dbdf6ff-b6bf-443a-8e01-539d4a14f0e6"
      unitRef="usd">-9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i5eb0ff4d140346c8963217923368c0ef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzQtNy0xLTEtNzEzMzA_ab522ecc-d18b-4efc-a2dc-0527a7282c94"
      unitRef="usd">-13000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i35cfc0da81f545a398181fa07b3382da_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzUtMy0xLTEtNzEzMzA_e873e3f1-60f8-437e-8348-47a92f700e01"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i22c40b5faace4195ac18bb1e51000e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzUtNS0xLTEtNzEzMzA_34b6cf14-5d81-4897-bdac-8896682aaa44"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i759f47c95ce6483d905aaf752e1639ce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzUtNy0xLTEtNzEzMzA_fdcf99a1-ca0f-4894-b32f-ce7acbc868ee"
      unitRef="usd">-9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic9644f4dc6e546f19f3bdc2c69c7d465_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzYtMy0xLTEtNzEzMzA_76dc16b2-8858-4c72-b699-2ca2abcdcde6"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0b9830a106f140a087b9c78bbfbfeec5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzYtNS0xLTEtNzEzMzA_d79f664d-a236-4fc3-925c-36bf2ed0659a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="idedfb451ef964827840ce24bbd35a732_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2ZlNjI1NzQyZDQ0YmQwOTQ5MzBkNDVjMjFlYjA2ZC90YWJsZXJhbmdlOmIzZmU2MjU3NDJkNDRiZDA5NDkzMGQ0NWMyMWViMDZkXzYtNy0xLTEtNzEzMzA_d7e9dc0e-b90e-4f53-87e7-fa8aee116a53"
      unitRef="usd">-15000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzk5NjA_5995ee88-f7dd-41dd-a1c9-fdb6d4e1fb3d"
      unitRef="usd">104000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTc2_534867dc-a03c-4481-9ad7-409dbbd1b033">&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net losses of $462 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in 2022 on equity securities still held at December&#160;31, 2022. Unrealized net losses of $232 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in 2021 on equity securities still held at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMS0xLTEtMTE3NDk5_06d5fbe7-b895-4e78-af14-9cb31cc2549a"
      unitRef="usd">498000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMy0xLTEtMTE3NDk5_e0774d93-9cae-4711-af1c-671859024762"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNS0xLTEtMTE3NDk5_67000ec2-7df8-47f3-9498-f3610eb5d27b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i486c2ecbdf8a41108c15e0a511be9082_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNy0xLTEtMTE3NDk5_3c5ad3a0-bf9f-465b-8a2d-c030056c886b"
      unitRef="usd">498000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtOS0xLTEtMTE3NDk5_18c21859-d64b-4e1a-8c1d-8a70abc6dc95"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTEtMS0xLTExNzQ5OQ_e881d671-92d8-4e32-87bc-ff941b714df1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTMtMS0xLTExNzQ5OQ_c507ebe6-77f8-49af-9f0b-f8c2fd2f2fe8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5aa72455647c4823a7fc65aabb141a7e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTUtMS0xLTExNzQ5OQ_a2a1cc7d-b33f-44de-a76b-c65c34b6a9ab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMS0xLTEtNzEzMzA_62be3cd2-d3ce-47ad-a6f8-e32d4cb06e69"
      unitRef="usd">68000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMy0xLTEtNzEzMzA_598a3426-bb39-4ebe-ac21-ebfb49908f58"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNS0xLTEtNzEzMzA_99c3f790-1cc3-4bb3-910b-1c4cd7d97c52"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ceb209deb764a8782b3ad355afef10c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtNy0xLTEtNzEzMzA_7a948c3b-92ab-4308-b1e1-f8f6f84b3d1e"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtOS0xLTEtNzEzMzA_57322ed3-4492-477b-a94b-924c2fe49259"
      unitRef="usd">80000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTEtMS0xLTcxMzMw_29ea27b8-664d-4819-a0d8-bb30775a99a0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTMtMS0xLTcxMzMw_681c59cc-01b2-42c5-bfbe-6283d0581685"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3107fb4932bc4642aad4cb642bf31a32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzMtMTUtMS0xLTcxMzMw_7cde3cc1-de94-4c85-a250-47f86559c573"
      unitRef="usd">80000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMS0xLTEtMTI4NjM1_826147b1-9766-485c-8e55-6caaed2bb580"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMy0xLTEtMTI4NjM1_b64b52c1-d9cc-4f79-bff3-adcc89cb30f6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtNS0xLTEtMTI4NjM1_c008c06f-8ce8-4eaf-9f81-228f3be61e8f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i348d9bf9cbff4f95a6b034fdb2b718a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtNy0xLTEtMTI4NjM1_bb1831a5-70ae-4bae-b7ca-76a6c776babf"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtOS0xLTEtMTI4NjM1_561f9802-cd6d-4205-ba1a-884b86428d9c"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMTEtMS0xLTEyODYzNQ_e292a791-76e7-4ff2-a521-d2ba6839663e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMTMtMS0xLTEyODYzNQ_45300913-181a-409b-8da1-4c04aef0350f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8cea6c6da66465ab0c24ec9637d4acc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzUtMTUtMS0xLTEyODYzNQ_1876fcc7-c86e-40d2-b234-13f8179acc80"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMS0xLTEtNzEzMzA_8ce47a02-1bf6-408b-b6ed-0db4dfd4122a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMy0xLTEtNzEzMzA_f4ad4a6a-8fbf-473f-87c0-54ee9dae0e6c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtNS0xLTEtNzEzMzA_10766b0b-3cff-4f98-be33-53fcea8cf0de"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7649d0b0708041d7bd6500bc0db7bc79_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtNy0xLTEtNzEzMzA_c1b224ba-4727-4c8d-8d88-15a2aa963837"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtOS0xLTEtNzEzMzA_3f3e2982-081a-4710-9353-bbb90fc65649"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMTEtMS0xLTcxMzMw_613f8d19-03db-464e-93c4-13ad0405b61c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMTMtMS0xLTcxMzMw_8adea116-dadd-44a2-b59e-b4957c61ec43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2236bd4b78d4c168553c865384cc010_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzQtMTUtMS0xLTcxMzMw_3479efee-f58c-43c3-a78b-1e03a91b92ae"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMS0xLTEtNzEzMzA_ae90183f-be21-4358-8c1b-7ce034105ed5"
      unitRef="usd">569000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMy0xLTEtNzEzMzA_cacbed65-8e39-45e1-8a1e-a5532d30c36e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtNS0xLTEtNzEzMzA_7be9667a-fc18-4b37-a5eb-ce3ee5d9a1fa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtNy0xLTEtNzEzMzA_422d7adb-ef6e-4573-81df-8e556e59cbf3"
      unitRef="usd">569000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtOS0xLTEtNzEzMzA_9353bbc9-c100-4234-ba72-8dbdc00fc834"
      unitRef="usd">86000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMTEtMS0xLTcxMzMw_d6382d7a-9ee0-486c-96a3-d9340aea90c2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMTMtMS0xLTcxMzMw_4754cdcc-e21f-43ec-a59b-86f2021ce5e4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzYtMTUtMS0xLTcxMzMw_54fb0d21-cd4b-4195-add4-30a701c6ee19"
      unitRef="usd">86000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzctNy0xLTEtNzEzMzA_8fbaa6f8-e532-4b32-9110-e5d5a8002013"
      unitRef="usd">1284000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzctMTUtMS0xLTcxMzMw_687101c9-cc18-4d9e-8f54-662bd346fd41"
      unitRef="usd">1647000000</us-gaap:EquitySecuritiesFvNi>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzgtNy0xLTEtNzEzMzA_73ec5d48-da66-4f20-822c-638b3f32810c"
      unitRef="usd">1853000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphNmE0MjBlNzJjNzk0ZWQ1OWI5MTcxMzk5YjViNWRiMi90YWJsZXJhbmdlOmE2YTQyMGU3MmM3OTRlZDU5YjkxNzEzOTliNWI1ZGIyXzgtMTUtMS0xLTcxMzMw_1eef2cd4-f06c-49d2-8fd9-449302d6db77"
      unitRef="usd">1733000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDk4NDI_32470d64-2f1d-4aba-920d-65c02e922c0c"
      unitRef="usd">-462000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDk4ODU_d129bf50-7257-48d6-9b66-42586341fe48"
      unitRef="usd">-232000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwNzQz_2e6dc1f1-2a43-47a5-86f9-e3fde411a264"
      unitRef="usd">832000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwNzUw_e47bed94-0206-43d3-ad95-ca195a2f0700"
      unitRef="usd">596000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMjE1_365b6e1b-cea3-40f3-a6da-2785dfc51fb9"
      unitRef="usd">56000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMjQz_00c53152-ad31-48b5-98d7-08688b2b8969"
      unitRef="usd">12000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMzYz_d4483e37-5442-4f1c-bf0e-ec37dd22500f"
      unitRef="usd">110000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExMzkx_2dc84668-552a-4aef-bf1e-7ba209d9ac99"
      unitRef="usd">1000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNjQ4_5492c48f-9b05-4b5d-9950-dd40c1070b8b"
      unitRef="usd">289000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNjU1_45bed4ef-954f-42b1-b564-dadafccd2c21"
      unitRef="usd">19000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNzI1_3fcd1192-f338-4540-97d6-b5a48c03a14e"
      unitRef="usd">598000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExNzMy_10422c5e-89c8-4c97-912a-31a13e8b1be2"
      unitRef="usd">1700000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzM4NDgyOTA3MjIyOTc_78af1c4c-f53c-44f2-81f1-78f366081905"
      unitRef="usd">800000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExOTQ2_b5b64a63-97a8-42b6-99f6-f4d9865f595f"
      unitRef="usd">-1000000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExOTUw_7560a943-d111-4ef1-bb97-17a95654038c"
      unitRef="usd">1400000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzExOTU3_33e84c7c-2d68-4094-8907-7fbf09b8b53d"
      unitRef="usd">583000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTYy_19af6c58-3f6f-46b5-bd64-196b75b30626">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis at December&#160;31 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;340&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;340&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;931&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;409&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;865&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79e23e28964b402e8ac69b9bf7d33084_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMS0xLTEtMTE3MjMy_12ef1936-489a-4f69-8e32-5e6821dd1a0d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if90327fad224463b8fddba51b5516717_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMy0xLTEtMTE3MjMy_6d45c3d6-9e88-44a7-bfc3-21d0bbe40ec7"
      unitRef="usd">498000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a3fb85e46d14551bb0ef34fe80bda15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNS0xLTEtMTE3MjMy_cf40bb9f-6d49-413a-b7c9-e24a8acde8fd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c48d4b8b6ca4bb9aaba77abc6391c4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNy0xLTEtMTE3MjMy_129a2066-84a7-418c-8732-4938b9bcdc62"
      unitRef="usd">498000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bc33cb4b50d4093aaf63905d920b1dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtOS0xLTEtMTE3MjMy_d5e6f200-f4e5-430c-95c7-1f86ce801e58"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie43420ce5f064a3fa05fa2e2380d5539_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTEtMS0xLTExNzIzMg_a3e2a513-ec19-4dbb-9e61-7c458807d746"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6b0d4e6828342e7a26da27a695dcde1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTMtMS0xLTExNzIzMg_373bd1c9-d0d4-4ca2-85b5-86c7918057cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57a4692f6adb46a1a2793a6f353cad90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTUtMS0xLTExNzIzMg_f2e97177-c7b7-424d-b300-1e164005655d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09ac1d9076f34481aea8771778d0d812_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMS0xLTEtNzEzMzA_e97c9082-86f6-4a18-9d37-af6d0dd3dd12"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4aa8f87dfa5498d867f4797c0697444_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMy0xLTEtNzEzMzA_26ca397c-08b0-4442-892b-c804409b31c3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74466407315d4f298256e0ad5a5af77f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNS0xLTEtNzEzMzA_ff826398-1f51-43b2-93b1-72fe770d264b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb3b3087926f41c1a474ada3d5d72501_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtNy0xLTEtNzEzMzA_7ca108a7-5446-44cb-95ca-20ef9e570fc5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i459db40bfb714e7ca275d3cd836dbbbe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtOS0xLTEtNzEzMzA_d215b074-6696-43d1-9758-22be8f8ee726"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic518fb07b7674674ba2208e212142086_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTEtMS0xLTcxMzMw_d35e8313-bfd9-4f61-a90e-e0652037e6a0"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3452cdca4b2f46d194438c26b62c02fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTMtMS0xLTcxMzMw_9f11e9dd-a411-491f-aa5b-0d472ccc14a1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieccc452488d6486c8350f571676063d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzUtMTUtMS0xLTcxMzMw_bb9e84d0-225c-440b-80f4-2b334e8a3057"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i05de9c17c11d43bf908b28fd7f8aa30d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMS0xLTEtNzEzMzA_37356123-5e9d-4d8a-b3f9-04f8fa7d2d46"
      unitRef="usd">1015000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie80636fc2f0a4f8a946fb3e439e28f9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMy0xLTEtNzEzMzA_a3ff721f-a16d-45b5-866a-831c7958d055"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i86dc918aa0f64dcebee5f10eb3e80c7b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtNS0xLTEtNzEzMzA_1fb56100-1a6a-44b2-b553-ecb918de4172"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifa3f2dea94cb406697c29216f2be9c81_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtNy0xLTEtNzEzMzA_3dbb1712-41b3-4986-b1b1-145a0ab7ba97"
      unitRef="usd">1015000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i193fc51da4a7485394ab28fa7fa5e658_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtOS0xLTEtNzEzMzA_09b79a71-e97c-4115-9ac4-0e63dcbd057b"
      unitRef="usd">368000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i08c7da7d4a5749148765d47894aacd5d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMTEtMS0xLTcxMzMw_9a723451-20c8-40bc-bc88-fe3ce0f8ee5a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4015a3ff1e184474b72f68389cc87127_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMTMtMS0xLTcxMzMw_e6377287-840d-43e7-8428-8e5503018a6b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7e96a196d04943a1ab350c5e9d0cae4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzYtMTUtMS0xLTcxMzMw_5ffdb69a-0896-4bfa-a7dd-51b3f0901c07"
      unitRef="usd">368000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:TradingSecurities
      contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMS0xLTEtNzEzMzA_bef0357c-221b-4903-8684-439000725f61"
      unitRef="usd">1015000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMy0xLTEtNzEzMzA_53a023e5-acd8-4c02-a957-755190b069a3"
      unitRef="usd">498000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0220a923758c4bbd97582689f870643e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctNS0xLTEtNzEzMzA_928b32b6-286d-4f83-bb0c-85f51c262d0e"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctNy0xLTEtNzEzMzA_be9d3889-c82b-4937-b85a-0785eb30e334"
      unitRef="usd">1513000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctOS0xLTEtNzEzMzA_fccb4417-0eb6-4713-b450-1e3991056497"
      unitRef="usd">368000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMTEtMS0xLTcxMzMw_3348d036-d29d-493d-bd24-8b171aa6f00c"
      unitRef="usd">2000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMTMtMS0xLTcxMzMw_a0951172-2a73-4143-95e7-d117c7d6d4d9"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzctMTUtMS0xLTcxMzMw_1ab2b5d8-21a3-44a8-b799-3cb6fe5c627f"
      unitRef="usd">370000000</us-gaap:TradingSecurities>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i44d8e82b21924b988d762ffa1a17dd8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMS0xLTEtNzEzMzA_35f70306-7ad4-4ccb-985d-e99e43304c4e"
      unitRef="usd">68000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if7899bb44630417a973d878c81948748_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMy0xLTEtNzEzMzA_8a11d7ad-82c3-4df2-917c-a974d1b8051f"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i60e8c59227254e75bd6682c05eec4d10_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktNS0xLTEtNzEzMzA_e360461d-7e4f-45ad-b701-3bea5be72493"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifae7d7fb2e5a4743961396935e496534_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktNy0xLTEtNzEzMzA_1fd178c7-a912-42fd-ae3f-c4eb2d3aa471"
      unitRef="usd">68000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8bc30062b2684131ae471612e9872ee9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktOS0xLTEtNzEzMzA_0e8671b3-5886-48fe-968d-8f8ab27ab272"
      unitRef="usd">80000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id5dad97abcda4f9fb9cdfaae3938ec50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMTEtMS0xLTcxMzMw_cbb63a2b-d84f-414b-8ee7-58be67fa45c6"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i85d91b9f5ded401face6465d1b7b9508_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMTMtMS0xLTcxMzMw_e40fdf7f-b0ff-4315-8d9b-ec8350291355"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i440ab66872cb40a6b47d2221be7afb0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzktMTUtMS0xLTcxMzMw_02c7260d-371e-4fd5-9dfa-36c47d102280"
      unitRef="usd">80000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i563ada8aba96419d844e481095ea53b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTEtMS0xLTcxMzMw_613b789e-f490-4a27-9d0f-5df99280947b"
      unitRef="usd">3000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i445a31ac64064f36b804f06383d1bfe0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTMtMS0xLTcxMzMw_d72130fc-ccb0-476b-8647-5e8703aa2a54"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i746270f61b8f444fbc5e79bbfa2f5d0a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTUtMS0xLTcxMzMw_fe8a82d6-c50b-42d4-9645-41fdeadacbb7"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2dd8a5476f7e4f6bb0e3488f27974234_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTctMS0xLTcxMzMw_deb4758c-4212-49a7-a606-f0fb7c094b7b"
      unitRef="usd">3000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idc25519774c84d2b8046b1745b6979f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTktMS0xLTcxMzMw_ff55b379-eb95-4742-83b2-ff108c8155bc"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i78bb2725e97d486ba1ea5b683ff9e12a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTExLTEtMS03MTMzMA_c8da6363-9def-4021-9ae3-f48cccca11e0"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1027036535d44087b6a7e473c3fdfc32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTEzLTEtMS03MTMzMA_381f5066-6af8-4ee0-8ae1-d3e75cde226b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i85671c3d685a45d797f772c5f3312b8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEwLTE1LTEtMS03MTMzMA_87efbf60-2dfb-42fc-8701-80655b5dbd58"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i05de9c17c11d43bf908b28fd7f8aa30d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTEtMS0xLTcxMzMw_bed0cbbe-e44d-4e37-9375-7cba3fe92c18"
      unitRef="usd">269000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie80636fc2f0a4f8a946fb3e439e28f9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTMtMS0xLTcxMzMw_0a29160f-3d66-4ced-a09c-cf50d7589b68"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i86dc918aa0f64dcebee5f10eb3e80c7b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTUtMS0xLTcxMzMw_83d51c27-8776-4884-bf79-b59336ff7679"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifa3f2dea94cb406697c29216f2be9c81_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTctMS0xLTcxMzMw_96b88659-e481-461a-84d9-e6f24fcb52b6"
      unitRef="usd">269000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i193fc51da4a7485394ab28fa7fa5e658_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTktMS0xLTcxMzMw_65e95fea-7988-483e-8ace-ab6352ab31db"
      unitRef="usd">1279000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i08c7da7d4a5749148765d47894aacd5d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTExLTEtMS03MTMzMA_9d5fba30-c9c2-43f1-b0be-1bad909d5e37"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4015a3ff1e184474b72f68389cc87127_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTEzLTEtMS03MTMzMA_d5334e4c-ce33-4e65-94dd-ae998115218e"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7e96a196d04943a1ab350c5e9d0cae4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzExLTE1LTEtMS03MTMzMA_a8d305df-7055-45bb-897d-095ac6aab6fc"
      unitRef="usd">1279000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTEtMS0xLTcxMzMw_286c95ee-fde0-4c91-a0ca-a980fb665b28"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTMtMS0xLTcxMzMw_7b68208b-b481-4866-973d-caee2eb915fd"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0220a923758c4bbd97582689f870643e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTUtMS0xLTcxMzMw_ea2ad6a0-9eae-4bc9-9fac-803439570126"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTctMS0xLTcxMzMw_2ae159f9-a0c9-4ac6-8857-00342dca1efb"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTktMS0xLTcxMzMw_f288337c-2fe0-4b2e-9853-235e4a166b39"
      unitRef="usd">1363000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTExLTEtMS03MTMzMA_52ec84b7-f08e-4793-a154-4add995b6f0f"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTEzLTEtMS03MTMzMA_cf93aedf-0b77-4878-acbb-e69bb7085040"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzEyLTE1LTEtMS03MTMzMA_05f242f1-0ac6-4518-ab53-582d29cffa74"
      unitRef="usd">1363000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="if9a21b3709dd42128d8264f2a5257c18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTEtMS0xLTcxMzMw_6c69a050-64dc-451e-a312-7fe6b9e62c59"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i83d6a9e2a4e04b1bb46f7d1cbcc4e416_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTMtMS0xLTcxMzMw_96fa9249-2eca-417b-a3d5-520b513414ce"
      unitRef="usd">218000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i150ff06d48a9497eafdf58dc03d8e518_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTUtMS0xLTcxMzMw_68507e4d-d091-497c-9b33-f1acb956ab60"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8b040b0e94924f0291cc48a435447245_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTctMS0xLTcxMzMw_31378fe9-3d35-4139-bc6f-86e9658bae77"
      unitRef="usd">218000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ifae251a0ecc04d6b9054f018ef917ce8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTktMS0xLTcxMzMw_53addd25-f798-45c7-9931-34477afcb0e3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ief83301bd6734273beb742bcd0fd8b21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTExLTEtMS03MTMzMA_ad8dea12-b9ff-4a5c-b49c-f9630dab1453"
      unitRef="usd">351000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i10131b7117eb4770b663e21fa15b98c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTEzLTEtMS03MTMzMA_81975ef6-974e-4494-81ac-54c44496efc3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2a0a0f8c7fc64e1ab6f955a741b7f056_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE0LTE1LTEtMS03MTMzMA_2926ee8b-02cc-40cf-b7d4-f3d217c265c7"
      unitRef="usd">351000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idd64d4dc46a44fca8aa2e2d65f22ec14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTEtMS0xLTcxMzMw_46ac279a-18be-4a20-b5c6-a4b6b70d4665"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i94a54e6f42254f4a80ac3cbfedbeda25_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTMtMS0xLTcxMzMw_a82c5b74-9aec-4dd4-b636-d343a358b0f0"
      unitRef="usd">215000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1291079726f54d9482e915764e3a28f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTUtMS0xLTcxMzMw_ca1dbca0-f13d-43c3-8844-cfdd64065176"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if9feab63c1b64ebb859b0a44c8c0fe14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTctMS0xLTcxMzMw_97e83962-2e82-40ae-94e9-23b16ac39d0e"
      unitRef="usd">215000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if4cdff6731374404ac0a075ce6ab9b79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTktMS0xLTcxMzMw_2308d764-ed8e-4cee-b074-0c5f1d2afa77"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5a379c20670240a9b25634d9750efe8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTExLTEtMS03MTMzMA_bc8a49c1-8aec-498c-b119-7d92690076a2"
      unitRef="usd">184000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibaaa3375ce0c4bcfa1287f588b3077dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTEzLTEtMS03MTMzMA_c8570663-d8a5-441d-9b10-2368fd5db6f4"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i34968f94170b4606b1bd3134b883f9fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE1LTE1LTEtMS03MTMzMA_a8e2c1c4-2631-4826-be75-1e08efe69d31"
      unitRef="usd">184000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iac658e91c1524deea0992c47f1872ea4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTEtMS0xLTcxMzMw_7fdaea26-4358-4c64-af8e-c74eba7c55e9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1db832513f3d41efa179eca26a0e6899_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTMtMS0xLTcxMzMw_ad95ed7e-c9f8-4500-8ecb-414400ba7933"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1b330f981b284955bf6356724ac55d7b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTUtMS0xLTcxMzMw_c5384f57-5b62-483d-bc4d-66760974b294"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4c20eb419e3840d885552c3057349c91_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTctMS0xLTcxMzMw_aee98b5a-7a40-4b17-996e-09ebedc442e3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i19edb02be5e746299724e213abfcaada_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTktMS0xLTcxMzMw_31a75fb3-4a93-4b19-a4f2-4ccc2611f2cf"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idd18b2833711484dbc7ffca9c326cd7d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTExLTEtMS03MTMzMA_eb57787d-6a54-409b-9da4-f911f23efe8e"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib24345a0ff484deb98e10e4105afa5bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTEzLTEtMS03MTMzMA_c33f6b3a-5ce0-457b-82f3-5c8d1d6fe3f2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i36627656f09a4021bfe46b0d8181fb2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE2LTE1LTEtMS03MTMzMA_dd3f260b-bade-4259-9c5c-32ade1b89c2b"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTEtMS0xLTcxMzMw_7e79266e-d6fc-4d1a-82f0-15febd8f2a1e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTMtMS0xLTcxMzMw_8a089dec-c0ef-4d59-bfea-d5f0081c2b29"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0220a923758c4bbd97582689f870643e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTUtMS0xLTcxMzMw_d9761468-bb1c-4cec-aad7-8bab6045b017"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTctMS0xLTcxMzMw_e15668dd-943a-48a3-8020-db5fd334e9e0"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTktMS0xLTcxMzMw_b6f5b873-8a00-4d9e-99ef-81d323097237"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTExLTEtMS03MTMzMA_f99588b6-fca7-4486-8c69-e00ae2ae2229"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTEzLTEtMS03MTMzMA_6d41b5dd-dda9-4e5a-b663-1eef5f903d87"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE3LTE1LTEtMS03MTMzMA_0e96a975-b1a9-4069-83dc-b165df4929dd"
      unitRef="usd">549000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTEtMS0xLTcxMzMw_fc799e74-89d8-437b-b1ea-456d4dc681e7"
      unitRef="usd">1355000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTMtMS0xLTcxMzMw_ff25605b-d7c3-4926-adf7-a3383aa5aa80"
      unitRef="usd">931000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0220a923758c4bbd97582689f870643e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTUtMS0xLTcxMzMw_f7f5a5da-d3b9-4395-9089-4d187c19ad41"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTctMS0xLTcxMzMw_f596650f-de73-4a81-891b-6d88d20d4af0"
      unitRef="usd">2286000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTktMS0xLTcxMzMw_92bd9c43-f18d-4303-ad61-6f6854028e04"
      unitRef="usd">1731000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTExLTEtMS03MTMzMA_4f49e35a-005e-4586-8b0c-6220e5735e12"
      unitRef="usd">551000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTEzLTEtMS03MTMzMA_c53a0145-d9c4-4814-8507-367c248bbb2d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzE4LTE1LTEtMS03MTMzMA_19b12dd1-6ed2-4aa6-a5c7-4510e12e48a9"
      unitRef="usd">2282000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTEtMS0xLTcxMzMw_3969ab56-e42b-4139-a6cc-85821bdcd4b5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTMtMS0xLTcxMzMw_bfdec829-24ca-4e10-9457-70913bc79f95"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0220a923758c4bbd97582689f870643e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTUtMS0xLTcxMzMw_f57d0244-1da1-47cf-9587-9afbbbef323d"
      unitRef="usd">456000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTctMS0xLTcxMzMw_47898a7d-43f6-4607-a002-314d61764771"
      unitRef="usd">456000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTktMS0xLTcxMzMw_56c89434-70fa-4209-95cf-bf87385588c7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTExLTEtMS03MTMzMA_a67d9a27-b14f-4f07-80cc-8ac7d39e1d80"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTEzLTEtMS03MTMzMA_2e91b108-df64-4ec1-9c4b-5f1f8e4e1d4c"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIxLTE1LTEtMS03MTMzMA_d5823a19-3e8d-4d7c-a3b9-34bf8e34daa7"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="if9a21b3709dd42128d8264f2a5257c18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTEtMS0xLTcxMzMw_2e00fab2-172b-44df-92e6-3094a57847c3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i83d6a9e2a4e04b1bb46f7d1cbcc4e416_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTMtMS0xLTcxMzMw_c12108d2-d728-4947-91ca-65e9202e0e61"
      unitRef="usd">402000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i150ff06d48a9497eafdf58dc03d8e518_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTUtMS0xLTcxMzMw_ce874b88-f123-4246-8072-3fe2624ae40e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8b040b0e94924f0291cc48a435447245_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTctMS0xLTcxMzMw_a8332920-e193-4f6a-9a87-ebb2acef6cdf"
      unitRef="usd">402000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifae251a0ecc04d6b9054f018ef917ce8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTktMS0xLTcxMzMw_6ad62bea-3458-4f17-a10a-d186ec917752"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ief83301bd6734273beb742bcd0fd8b21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTExLTEtMS03MTMzMA_c03c7ebb-c6d1-46b7-90b5-ef8c8ea90c6b"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i10131b7117eb4770b663e21fa15b98c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTEzLTEtMS03MTMzMA_fdb290f1-64c3-4620-8320-c1534675af32"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2a0a0f8c7fc64e1ab6f955a741b7f056_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzIzLTE1LTEtMS03MTMzMA_2f6fd26b-3f90-44ac-8888-193a3ac18203"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idd64d4dc46a44fca8aa2e2d65f22ec14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTEtMS0xLTcxMzMw_454fcd4e-e61f-456e-8fa1-7f92606d089b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i94a54e6f42254f4a80ac3cbfedbeda25_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTMtMS0xLTcxMzMw_d07934f9-ef76-4ba7-9f6d-75dae1b66237"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1291079726f54d9482e915764e3a28f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTUtMS0xLTcxMzMw_51a0ca91-70f3-4a76-9aed-740c15d3ae4d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if9feab63c1b64ebb859b0a44c8c0fe14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTctMS0xLTcxMzMw_7c13e69e-1eab-48c1-91ad-e3b81bffb85d"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if4cdff6731374404ac0a075ce6ab9b79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTktMS0xLTcxMzMw_6936742b-2f72-42e0-a375-0965b26b396e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5a379c20670240a9b25634d9750efe8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTExLTEtMS03MTMzMA_3a0e35f1-0df8-4750-8b9e-954f9b822613"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ibaaa3375ce0c4bcfa1287f588b3077dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTEzLTEtMS03MTMzMA_6d9edbc8-5248-4de9-a4c8-a297a3c2704e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i34968f94170b4606b1bd3134b883f9fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI0LTE1LTEtMS03MTMzMA_a838e484-2c2d-439c-a6cd-36973f0c7a7e"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTEtMS0xLTcxMzMw_ddc09f00-f8bc-4998-afd5-4a52fce2cc86"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTMtMS0xLTcxMzMw_b89df21a-2e03-45e5-9a8d-bec8521b4540"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0220a923758c4bbd97582689f870643e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTUtMS0xLTcxMzMw_20ff773c-efec-417a-8d9b-ac45fcb27716"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTctMS0xLTcxMzMw_84b2ab7a-2b4f-4f6f-a832-be781d7d74fe"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTktMS0xLTcxMzMw_3c43061c-4a01-4aa0-9782-837595db5991"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTExLTEtMS03MTMzMA_01d30acb-fcca-4f34-adc0-c5c98df30e03"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTEzLTEtMS03MTMzMA_045e2344-fe40-44ec-820b-204e9878bea3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI1LTE1LTEtMS03MTMzMA_1aeec72d-7138-4e84-a22e-ab07917c9a6f"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic62406c431da439e8e81a3791303ddb8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTEtMS0xLTcxMzMw_294c6d14-b56e-49fe-a6f3-1924ee3e84ec"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6f4177637bb44c09bd64388d2df9d922_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTMtMS0xLTcxMzMw_5190d102-b55d-40b9-bf96-6501d4013c9c"
      unitRef="usd">409000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0220a923758c4bbd97582689f870643e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTUtMS0xLTcxMzMw_9e1ead78-83b1-4764-a7c7-150994f5657d"
      unitRef="usd">456000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iba235620efd64c3b8e1fc94776a989c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTctMS0xLTcxMzMw_91149dbf-b420-4220-8f71-d5789bce840c"
      unitRef="usd">865000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i52ccb5ece8414e37a06261c0cde991d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTktMS0xLTcxMzMw_17ad03a9-681a-444b-b4c3-b3d7e775f5ed"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib5e340eeaa5d4f1181e43e1abda96454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTExLTEtMS03MTMzMA_1ac3713b-4f4e-4e9c-acb0-3447442e99f4"
      unitRef="usd">121000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie2601263e66d45e19c1438f48a9f0aee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTEzLTEtMS03MTMzMA_651a65df-be80-4b52-914e-c76354f15d5c"
      unitRef="usd">777000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i248730dfeb3e4bd78ca07fbeb3668fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTphOGFjNzYyMzkxMTI0ZjI5YmM4Y2NkM2Q2NTBjOGYzYi90YWJsZXJhbmdlOmE4YWM3NjIzOTExMjRmMjliYzhjY2QzZDY1MGM4ZjNiXzI2LTE1LTEtMS03MTMzMA_845fe781-ef64-4ab0-b89d-4ffaee7d16c8"
      unitRef="usd">898000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i4296dad71f474d0fa88ccb38226b4f44_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0MTg3_9bff5fcf-b8e1-4dd7-a0b9-0c146f757e3c"
      unitRef="usd">11300000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ifd71198dffc74a99b2e0c368d96a14ab_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDc1MTQ_a2e44749-61cf-4b92-b079-fef9a186f768"
      unitRef="usd">6800000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE5NTYz_9c364c8f-f9b2-4a5d-8ce4-72f19e9239df">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Cost of sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December&#160;31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzEtMS0xLTEtNzEzMzA_d6b42505-f8e6-4d0e-99da-03b9a9920c6e"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzEtMy0xLTEtNzEzMzA_848a6b3e-8cee-4641-8082-537be9693cb1"
      unitRef="usd">841000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzMtMS0xLTEtNzEzMzA_9a9b031b-d1b2-4a42-b84b-9707f07de34f"
      unitRef="usd">-146000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzMtMy0xLTEtNzEzMzA_113bb28d-dccf-408f-9dd7-f58fd17f38f4"
      unitRef="usd">57000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzQtMS0xLTEtNzEzMzA_1e51e344-f4bf-4581-ad9d-71c7bce0d005"
      unitRef="usd">119000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzQtMy0xLTEtNzEzMzA_e76a1187-493d-41b5-ab1e-cbb7d04cd34b"
      unitRef="usd">109000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzUtMS0xLTEtNzEzMzA_a36e6ebe-1c1e-4945-a095-71d3ecbe6a3e"
      unitRef="usd">56000000</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzUtMy0xLTEtNzEzMzA_2b1ae038-0c2c-4708-b411-ed8b507c442d"
      unitRef="usd">12000000</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzYtMS0xLTEtNzEzMzA_cd218c1d-914b-40ec-b55d-d88a46e008ef"
      unitRef="usd">456000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpmMjNiODA0NTQ1YTM0MzYwYjlmMzFlNGM4OTk3NGVjZS90YWJsZXJhbmdlOmYyM2I4MDQ1NDVhMzQzNjBiOWYzMWU0Yzg5OTc0ZWNlXzYtMy0xLTEtNzEzMzA_dec6f6db-7b3a-400b-9e6f-d3cfc0e17048"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iaa8b5a245d4f455da78fcffb96a7508c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0NzIz_a77a100c-d672-403b-a75e-37952509de7a"
      unitRef="usd">368000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1ba9f35c12c54ef98f07fea573c78bd3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0NzMw_b44fcba7-e538-4412-8ba5-f5c2fe070cf2"
      unitRef="usd">620000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iaa8b5a245d4f455da78fcffb96a7508c_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE0OTM5_9743ae2c-b85a-48f4-829d-bd37185fa1c6"
      unitRef="number">0.115</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NTAxMzE_d65ab4cc-a8f0-43da-a0fd-8ba7d4952d61"
      unitRef="usd">122000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1ODEw_050bd8c5-ca9b-4d29-9b8b-762705483d5c"
      unitRef="usd">26700000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1ODQ3_565af5e7-d397-4b72-8748-89f741095cdf"
      unitRef="usd">30700000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1ODY1_5626a560-0428-4b0e-a683-4935276c8ecd"
      unitRef="usd">35700000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE1OTAy_a0fdb662-55a9-426c-a288-be8643498031"
      unitRef="usd">33100000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6da2f157b824f52851dd9e978b0eeff_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3MzI0_ab3a10f7-3e37-40e5-8ab9-d53a676cfa5e"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9c08e07575e9490cb5a8f9cf49bbd641_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3MzI4_a3307ee1-9e77-4813-8d64-ba1236ae5eef"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib444129703be4af2a20054714bf0ecec_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3MzM1_e54e6f71-2767-4129-a4f3-155414ca9e1f"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableSale
      contextRef="ie56c0f796a90447b8097ae8d7be632fe_D20221001-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3Nzkx_4a467e19-706a-4a73-95ae-4320d64bf108"
      unitRef="usd">2500000000</us-gaap:AccountsReceivableSale>
    <us-gaap:AccountsReceivableSale
      contextRef="i567c0acaaf20420daa3260e2b7668e47_D20211001-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE3Nzk4_8d253155-c4ff-49f7-b37e-bb8a2586c945"
      unitRef="usd">2800000000</us-gaap:AccountsReceivableSale>
    <us-gaap:RestrictedCashCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE4MzE3_ee756dab-e776-4a2e-b163-384ceff1f54c"
      unitRef="usd">67000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzE4MzI0_1bd0d35c-24c7-4284-94c3-1851f021cc0f"
      unitRef="usd">62000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DerivativeCollateralRightToReclaimSecurities
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzM4NDgyOTA3MjIzNzk_604e659c-8b85-46d0-8a27-42059acc3c8b"
      unitRef="usd">19000000</us-gaap:DerivativeCollateralRightToReclaimSecurities>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDgzMTE_97d36d09-2d65-428d-882a-75d5b010a01e"
      unitRef="usd">66000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90ZXh0cmVnaW9uOjY3NTc0OTBjMDkzZTRiZTBiOTVmYzI3MzY5YjA4OWZmXzEwOTk1MTE2NDgzMDQ_9b9886fc-656b-4177-8dd6-437eb89ae322"
      unitRef="usd">164000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzU0OQ_59f42800-5d82-4efa-97e0-01307aa95f66">Inventories&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9,142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,911&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.3 billion at December&#160;31, 2022 and 2021, respectively. Amounts recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; are comprised almost entirely of raw materials and work in process inventories. At December&#160;31, 2022 and 2021, these amounts included $2.4 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $516 million and $256 million at December&#160;31, 2022 and 2021, respectively, of inventories produced in preparation for product launches.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzUzNg_4c068fed-2d02-4555-a6c1-ca2b3d3b0149">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9,142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,911&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzEtMS0xLTEtNzEzMzA_32ed038c-6e65-4bee-8a80-8f55818633fc"
      unitRef="usd">1841000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzEtMy0xLTEtNzEzMzA_c8dd097d-38b6-4f84-a8a4-f0fe6d5f196d"
      unitRef="usd">1747000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzItMS0xLTEtNzEzMzA_94a5e92e-b8c3-4cbe-b3c2-aa13b2db5d13"
      unitRef="usd">7063000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzItMy0xLTEtNzEzMzA_6a82c151-2b79-47eb-bcc3-f0202a4f23d5"
      unitRef="usd">6220000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:OtherInventorySupplies
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzMtMS0xLTEtNzEzMzA_63231493-52e1-4515-bb0e-20bd699098c8"
      unitRef="usd">238000000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzMtMy0xLTEtNzEzMzA_cd00f1fd-b52a-48c8-bc7f-e3715aa351d5"
      unitRef="usd">196000000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryGross
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzQtMS0xLTEtNzEzMzA_26052e10-7fd6-462b-a6ea-8377ba800b06"
      unitRef="usd">9142000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzQtMy0xLTEtNzEzMzA_0f5fb99f-b611-419a-afbb-3cdb8d88bc33"
      unitRef="usd">8163000000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzUtMS0xLTEtNzEzMzA_f3764028-ed7f-4223-83db-77e493dd12f1"
      unitRef="usd">293000000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzUtMy0xLTEtNzEzMzA_cd462540-4800-440b-a6b0-f1858f81b900"
      unitRef="usd">16000000</us-gaap:InventoryLIFOReserve>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzYtMS0xLTEtNzEzMzA_87ed1445-8c18-4cf4-943e-46d690a9e4d5"
      unitRef="usd">8849000000</mrk:InventoryNetAndInventoryNoncurrent>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzYtMy0xLTEtNzEzMzA_0d1ad7fa-adaf-4a89-bff3-ad937944d8b0"
      unitRef="usd">8147000000</mrk:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzgtMS0xLTEtNzEzMzA_081187c5-b9f0-44e5-b554-0b47a9027156"
      unitRef="usd">5911000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzgtMy0xLTEtNzEzMzA_808e26f8-2d16-425c-b1b3-37d7f46ab646"
      unitRef="usd">5953000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzktMS0xLTEtNzEzMzA_6c414cc9-713f-492b-8bc0-2a3bff16fa9e"
      unitRef="usd">2938000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90YWJsZTpkMjhlNjliMGFhNjk0N2M1ODQyMmRhNDMwZTY4MjQ1Mi90YWJsZXJhbmdlOmQyOGU2OWIwYWE2OTQ3YzU4NDIyZGE0MzBlNjgyNDUyXzktMy0xLTEtNzEzMzA_98a177a1-e357-46b8-83f0-897d6fcd01c1"
      unitRef="usd">2194000000</us-gaap:InventoryNoncurrent>
    <us-gaap:LIFOInventoryAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzEzMQ_65d019fc-91db-40d5-a3af-7e4a25e73b26"
      unitRef="usd">3400000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:LIFOInventoryAmount
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzEzOA_7503762b-c445-4f79-9ffc-6de9ea53e228"
      unitRef="usd">3300000000</us-gaap:LIFOInventoryAmount>
    <us-gaap:InventoryNoncurrent
      contextRef="i022aa53b13d84e14a5eedc763cefd54e_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzMyMQ_45d5d139-49ce-458f-8f40-64c037dc6a15"
      unitRef="usd">2400000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i925bfec8ab2743348c69f615eb5a44fa_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzMyOA_47fdf36c-2fa0-4110-8d81-4499cb678a42"
      unitRef="usd">1900000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if61807d83368439782aa2842af89525a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzQzOA_a26d5b96-c713-49e2-b2c3-540f173fc545"
      unitRef="usd">516000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i99ba9b9962fd485ea74e2d2c10d17307_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjkvZnJhZzoxM2E4NGIzMjNkNzk0NGIxYmM5YzA5OTBmYmU0MGM2YS90ZXh0cmVnaW9uOjEzYTg0YjMyM2Q3OTQ0YjFiYzljMDk5MGZiZTQwYzZhXzQ0NQ_4d83e8c0-b2f4-4a06-ae46-a1a23f9e2f29"
      unitRef="usd">256000000</us-gaap:InventoryNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyNTQ_e5e5881e-b21e-4df9-9a50-b4adb759022f">Goodwill and Other Intangibles&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes goodwill activity by segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;17,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments on goodwill balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron (see Note&#160;4). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other acquired intangibles at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products and product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,244&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,097&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;41,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Some of the more significant acquired intangibles included in products and product rights, on a net basis, related to human health marketed products at December&#160;31, 2022 were Reblozyl, $3.5 billion; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, $406 million;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, $122 million; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; 9, $120 million; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, $97 million. Additionally, the Company had $4.6 billion of net acquired intangibles related to animal health at December&#160;31, 2022, of which $2.3&#160;billion related to products and product rights and $2.2&#160;billion was attributable to trade names, primarily related to Allflex. At December&#160;31, 2022, IPR&amp;amp;D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note&#160;4); MK-7264 (gefapixant), $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016; and MK-1026 (nemtabrutinib), $418 million, obtained through the acquisition of ArQule in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2020 (see below and Note&#160;4). Some of the more significant net intangible assets included in licenses and other above at December&#160;31, 2022 include Lynparza, $1.6 billion, related to a collaboration with AstraZeneca; Lenvima, $814 million, related to a collaboration with Eisai; and Adempas, $633 million, related to a collaboration with Bayer. See Note&#160;5 for additional information related to the intangible assets associated with these collaborations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2020, the Company recorded an impairment charge of $1.6&#160;billion within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjg_e7b500cc-8996-45e1-8231-cde2ddbd2b59"&gt;Cost of sales&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; intangible asset for impairment. The Company revised its cash flow forecasts for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120&#160;million to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in 2020 related to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; recall. A phased resupply of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zerbaxa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; was initiated in the fourth quarter of 2021 and completed during 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022, the Company recorded $1.7 billion of intangible impairment charges within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjk_b1192ef4-ec86-4241-a5a3-3f1beac17af0"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses, of which $1.6&#160;billion represents IPR&amp;amp;D impairment charges related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies that was obtained through the 2020 acquisition of ArQule (see Note&#160;4). Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807&#160;million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which is expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated current fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780&#160;million impairment charge. The remaining IPR&amp;amp;D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80&#160;million intangible asset impairment charge related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2021, the Company recorded a $275&#160;million IPR&amp;amp;D impairment charge related to nemtabrutinib. As part of Merck&#x2019;s annual impairment assessment of IPR&amp;amp;D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to 8.5% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;amp;D impairment charge noted above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2020, the Company recorded a $90&#160;million IPR&amp;amp;D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck&#x2019;s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The IPR&amp;amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;amp;D programs and profitably commercialize the underlying product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense primarily recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; was $2.1 billion in 2022, $1.6 billion in 2021 and $1.8 billion in 2020. The estimated aggregate amortization expense for each of the next five years is as follows: 2023, $1.8 billion; 2024, $1.7 billion; 2025, $1.6 billion; 2026, $1.5 billion; 2027, $1.3 billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyNDM_b20eaeae-40c5-455b-8b65-f8746e029f45">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes goodwill activity by segment:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;17,936&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes cumulative translation adjustments on goodwill balances.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Accumulated goodwill impairment losses were $531 million at both December&#160;31, 2022 and 2021.</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i7cc9093833ea43efa72b1bc502bed4da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzEtMS0xLTEtNzEzMzA_22cd6dfa-d489-48c6-a27b-a2aa556475ed"
      unitRef="usd">15614000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i66a4d286567e47718bed1dc0ec61c06d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzEtMy0xLTEtNzEzMzA_af40e233-7649-4b91-b7b9-9193475fb78c"
      unitRef="usd">3268000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzEtNy0xLTEtNzEzMzA_8db9a4e4-be6f-4879-a892-6a563c6f867f"
      unitRef="usd">18882000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id9a53de261014635b46dff37511f8a28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzItMS0xLTEtNzEzMzA_10376b3d-4bb3-4ac5-a491-fadfd8e6054e"
      unitRef="usd">2431000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie8ab8ac0847f4ea2aec591d7ec276bb9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzItMy0xLTEtNzEzMzA_b551ac51-0f67-48d4-8684-9670cd59b53a"
      unitRef="usd">5000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzItNy0xLTEtNzEzMzA_10f44543-6146-4023-ad5f-f24ce76f69c9"
      unitRef="usd">2436000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id9a53de261014635b46dff37511f8a28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzQtMS0xLTEtNzEzMzA_905b02a7-644e-41ac-9ae0-f245d365e69f"
      unitRef="usd">-48000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ie8ab8ac0847f4ea2aec591d7ec276bb9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzQtMy0xLTEtNzEzMzA_8f08f1d0-31a3-4b98-a9ae-da16dac9fa83"
      unitRef="usd">-6000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzQtNy0xLTEtNzEzMzA_d5ee9880-41e2-4df1-9bd3-ba8f1686a520"
      unitRef="usd">-54000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i70c3ea6a6aab40a686a75e01c429aed9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzUtMS0xLTEtNzEzMzA_07b213f0-b7e6-4766-81c3-bf2ad8ad3276"
      unitRef="usd">17997000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i34571e3bf0a24f04a885f828cb94cfd0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzUtMy0xLTEtNzEzMzA_c2f8ecb4-642b-44f7-b933-06d337a36ea6"
      unitRef="usd">3267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzUtNy0xLTEtNzEzMzA_f0618509-2a1c-418c-8f7b-cb5e876d7a13"
      unitRef="usd">21264000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id5bf7773e95f40eeb049ba5fec44f5e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzctMS0xLTEtNzEzMzA_87614e31-1129-41ae-90e6-44a9a4a0e3d9"
      unitRef="usd">-61000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0140812b0eab469a965b4b15301949bf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzctMy0xLTEtNzEzMzA_de6ce1c2-d3d3-471f-9f13-7ea6c9f2f112"
      unitRef="usd">1000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzctNy0xLTEtNzEzMzA_c84d44c8-f009-4405-bb7f-461cf3b62518"
      unitRef="usd">-60000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i94cf60618c5e4aaca021c753bff1b8a8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzgtMS0xLTEtNzEzMzA_4ca0a345-7625-4d72-abb9-d394456bb0df"
      unitRef="usd">17936000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id57473094cd042cca3f71ebfab8a12ed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzgtMy0xLTEtNzEzMzA_3d300668-b58a-49f0-893b-631928c24258"
      unitRef="usd">3268000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTplZTVjMjJlYjgxNDU0ZDMzYmM4OWE4NzcxYTg2MTk1Zi90YWJsZXJhbmdlOmVlNWMyMmViODE0NTRkMzNiYzg5YTg3NzFhODYxOTVmXzgtNy0xLTEtNzEzMzA_ba37ae4e-62d5-41ea-8121-4b6a8f105314"
      unitRef="usd">21204000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzIyNQ_0d7703f1-a41a-49d6-ad3a-d4a4404ef671"
      unitRef="usd">531000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzIyNQ_7dca2832-8a03-44d1-80dd-b8848c9cdddd"
      unitRef="usd">531000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyNTI_3cbd8f2c-8781-4006-a7ca-b5bd41987682">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other acquired intangibles at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products and product rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;23,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;635&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,244&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Licenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,097&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;41,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;20,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItMS0xLTEtNzEzMzA_28c59d94-f087-4acd-b340-0a1f7dce65db"
      unitRef="usd">23555000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItMy0xLTEtNzEzMzA_19132fa4-5f28-4fcc-ba6f-ca87fa63cc63"
      unitRef="usd">16745000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0e7ceda63f90469d8b2e44cf3cb91250_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItNS0xLTEtNzEzMzA_443632f3-555d-4f92-9c28-f02aadc02576"
      unitRef="usd">6810000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5f2e09c593c942af8e3407a887af82d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItNy0xLTEtNzEzMzA_fa2320e6-29a5-4f01-a17d-4b3aa0f78bd3"
      unitRef="usd">23671000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5f2e09c593c942af8e3407a887af82d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItOS0xLTEtNzEzMzA_6fb5438b-1731-4d93-8df4-5653fa027983"
      unitRef="usd">15776000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5f2e09c593c942af8e3407a887af82d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzItMTEtMS0xLTcxMzMw_abf211e6-27a9-4a8d-8259-b7d33c094856"
      unitRef="usd">7895000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5be0c233ffc9447ebd088af22f69de87_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtMS0xLTEtNzEzMzA_9ca3a4aa-dcdd-4edc-930f-76ba87217e69"
      unitRef="usd">7661000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5be0c233ffc9447ebd088af22f69de87_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtNS0xLTEtNzEzMzA_e026f9d3-2ec3-4df3-92f7-4532560850e3"
      unitRef="usd">7661000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie233154d86a14b82a3feeae38dd79d18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtNy0xLTEtNzEzMzA_9c047f62-a4ef-4fb7-9486-7aa53f1901e6"
      unitRef="usd">9281000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie233154d86a14b82a3feeae38dd79d18_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzMtMTEtMS0xLTcxMzMw_6a06191f-c63d-4d99-8a34-574948e29eaf"
      unitRef="usd">9281000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i6138bf37696649a6bd6e971b74356d51_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtMS0xLTEtNzEzMzA_d0aedef2-1471-4e38-ab25-c796405f73f9"
      unitRef="usd">2879000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6138bf37696649a6bd6e971b74356d51_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtMy0xLTEtNzEzMzA_13c37a17-a6be-46c2-84af-ed272ff98fbb"
      unitRef="usd">635000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6138bf37696649a6bd6e971b74356d51_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtNS0xLTEtNzEzMzA_5e30d6cb-6d8c-40a7-af34-5613e1267e64"
      unitRef="usd">2244000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i213276daa7804281bc7394485ab71d33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtNy0xLTEtNzEzMzA_6ddcee28-fd22-42e5-a00e-cb14384c66d2"
      unitRef="usd">2882000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i213276daa7804281bc7394485ab71d33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtOS0xLTEtNzEzMzA_7a11865a-2ca3-4eeb-8e67-761c796d0a2b"
      unitRef="usd">493000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i213276daa7804281bc7394485ab71d33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzQtMTEtMS0xLTcxMzMw_c6bcc8fd-6af9-4ae8-b8be-aab1829fbe27"
      unitRef="usd">2389000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtMS0xLTEtNzEzMzA_bf95f5f4-e2b0-45d7-ac12-5470d072340c"
      unitRef="usd">7651000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtMy0xLTEtNzEzMzA_761b5fef-08fd-4c0f-aa00-4d07102eb636"
      unitRef="usd">4097000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7cf9b5e58a254a0e84c12a99fea0b071_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtNS0xLTEtNzEzMzA_54309a62-f00b-453c-9b4d-1c908cc1088d"
      unitRef="usd">3554000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i460644d8e3e54a79b686e69c684cec5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtNy0xLTEtNzEzMzA_b776c86d-6ff1-4dd8-9d8a-77a2f4f2e5ac"
      unitRef="usd">6604000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i460644d8e3e54a79b686e69c684cec5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtOS0xLTEtNzEzMzA_bae69dd1-aa16-48b1-be1d-cc33b1533e60"
      unitRef="usd">3236000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i460644d8e3e54a79b686e69c684cec5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzUtMTEtMS0xLTcxMzMw_b233aadf-b7f3-4eed-8f72-351e74e30ec1"
      unitRef="usd">3368000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtMS0xLTEtNzEzMzA_59079f7a-b4df-4573-a2e2-91316e0fd95f"
      unitRef="usd">41746000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtMy0xLTEtNzEzMzA_3517190e-81bb-4d62-a9d2-86ebdd35020a"
      unitRef="usd">21477000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtNS0xLTEtNzEzMzA_ddd9c76a-3a18-4402-9f0e-073e3861c550"
      unitRef="usd">20269000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtNy0xLTEtNzEzMzA_1547eb34-541e-44b9-b283-4e105168e0a2"
      unitRef="usd">42438000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtOS0xLTEtNzEzMzA_23e12afb-7bef-4ca7-a596-87b74f264504"
      unitRef="usd">19505000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90YWJsZTo0ZDUyYjE3Njk2ZWM0ZDM5YmI5NTgzY2VmMGE4Mzc2NS90YWJsZXJhbmdlOjRkNTJiMTc2OTZlYzRkMzliYjk1ODNjZWYwYTgzNzY1XzYtMTEtMS0xLTcxMzMw_ace62c5d-6a15-458e-882d-00911b5943f4"
      unitRef="usd">22933000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibace400774984c3dbc9f9ea52b1e0e6a_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwNjY_4d9cbf3c-4850-4b2f-8046-7ff6aef82d37"
      unitRef="usd">3500000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie47add64e2cd40f998158d2c98eb4042_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwNzk_2d4fb32c-cd6a-4092-a6b0-d946d91a879e"
      unitRef="usd">406000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5fbb5dd4448e485981b74dc5719bdbc0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NTE5MzY_d3596946-979d-4d28-9261-c7a936f63274"
      unitRef="usd">122000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7debb2fba50146bebb232e6e8e26d1e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzExMDQ_b594f44d-0e4f-483b-b409-3a6ea12f64a6"
      unitRef="usd">120000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i323a82a0676e447aa0ee30bbd32c0379_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzExMTc_184c7f4f-5b99-44f2-9ea6-1a88a4abb0f2"
      unitRef="usd">97000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4629f93a6cb342d7a2adcf465132267d_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzExOTU_8d3959c8-42a8-46e0-853d-d8f4b4ef26ef"
      unitRef="usd">4600000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ice62906f5f13486296cfddb3eecc61f6_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE2NDkyNjc0NjcyMDI_27c12087-9a54-4f1c-a5b4-ddca0825c8d8"
      unitRef="usd">2300000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4a998c05c25e45d897132264cd7393b5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE2NDkyNjc0NjcyMTY_c33a5426-6e63-40bd-9b49-f31e4f6fe08f"
      unitRef="usd">2200000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id2eb0aca1931486da121627e2b099a6e_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE0NDE_15d3b7c0-8a25-4104-84e5-5190445c96fc"
      unitRef="usd">6400000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibf54a72af67e45fda2e3769dc2ee1bbb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE2NDI_75858ffe-e586-434c-8df2-29d69dd418b7"
      unitRef="usd">832000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id0ae54ef35294062adb30816c2eba9da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDMxNjM_178533cd-eace-4cc4-89d5-fb4017c7db5b"
      unitRef="usd">418000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i46a9b57f7713451ab3d958cb0b3c227c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE4Mjg_ed8d6e65-0d76-476e-83a4-8bbaa4d21fa0"
      unitRef="usd">1600000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia9c533dce277413ebf7c86906b5c8f94_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE4ODY_07976841-cdde-4cf6-b77a-14ee077c3d30"
      unitRef="usd">814000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id5de854d06ac4eeca3f033f63ac8cf18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzE5Mzg_c9e9026b-b5b2-474f-864f-86f018ef51d5"
      unitRef="usd">633000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzIyMDU_d12f0a3e-03fd-4853-ae6e-0f9626a511c2"
      unitRef="usd">1600000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:InventoryWriteDown
      contextRef="i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzMyODM_264c4faa-8de3-43fc-a358-c0bdddd7cc53"
      unitRef="usd">120000000</us-gaap:InventoryWriteDown>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2Mzk2Mjk_02660e96-e096-4101-80a8-dad645c49fd1"
      unitRef="usd">1700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ie57ef40fb83d43d0b204010eab10ace2_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2Mzk2OTY_c8a144e9-9cec-408a-9cd8-91021a988ffd"
      unitRef="usd">1600000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="if3518262d4c349ecb316b3c7dec9767f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDU1NzI_71530e35-1809-440b-92e7-4c9c6d5da6dc"
      unitRef="usd">807000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ibc70591306cb403fbd97773b449e9870_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDU1NTg_5598233b-554a-4671-a68e-23743a3585d6"
      unitRef="usd">780000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id0ae54ef35294062adb30816c2eba9da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2Mzk3MDQ_178533cd-eace-4cc4-89d5-fb4017c7db5b"
      unitRef="usd">418000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="icc9e424e32fb43b8855afaaf0a1576b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2NDE5MTI_c3207acb-f45d-48db-89e3-1f7ce7c6d63d"
      unitRef="usd">80000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i0d0e372671334e94bc77b2dfc17299c3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2MzYxNjM_6bced37d-0e16-48f4-bd96-ccdc0c816089"
      unitRef="usd">275000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="i21861da46868461288c97e4ab76ae0fc_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzU4Nzc_4834c83d-2fc9-4385-9de6-3cb9d85d0180"
      unitRef="number">0.085</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzEwOTk1MTE2MzYxNzM_2c74fb19-e8db-4617-af9b-cd5dc34f0d4d"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i58fae9f157404c948f717699cc8b6041_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzcwMzE_aa684689-f975-423d-b21a-325c74147ecf"
      unitRef="usd">-45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgwNjQ_0575a875-f430-428b-a743-61fa2d9ec1d7"
      unitRef="usd">2100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgwNzQ_b04f481c-c128-408f-882e-ab1b28de4283"
      unitRef="usd">1600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgwODc_d4a78d66-eed6-48c2-a6ea-6de8a9c1a1c6"
      unitRef="usd">1800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgxOTM_bb6157fb-cdaf-4130-9acc-4b2ba7e2744d"
      unitRef="usd">1800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMDE_8a04903f-ee7f-4fd1-b7b9-101c8df89ec0"
      unitRef="usd">1700000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMDk_146829a1-85d1-4ef1-9f24-adde32827207"
      unitRef="usd">1600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMTc_ed183d65-8382-4e20-840f-1a9ce0d8ce26"
      unitRef="usd">1500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzgyMjU_0c4186b7-8647-4964-ad1a-5defa1e86e69"
      unitRef="usd">1300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNjA_71647304-a3f3-4d00-a2f1-17beef4baa5e">Loans Payable, Long-Term Debt and Leases&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Loans Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Loans payable at December&#160;31, 2022 included $1.7 billion of notes due in 2023 and $197 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December&#160;31, 2021 included $2.3 billion of notes due in 2022 and $149 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.65% and 0.08% for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term debt at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,496&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.15% notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.70% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.40% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,738&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.70% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.00% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,471&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.15% notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.45% notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.875% euro-denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,060&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.75% notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.90% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.50% notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.50% euro-denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.375% euro-denominated notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;527&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.50% euro-denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.60% notes due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.95% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.85% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.40% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.30% debentures due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;28,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 1.40% and zero for 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck&#x2019;s option at any time, at varying redemption prices. Effective as of November&#160;3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp&#160;&amp;amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s borrowings require that Merck comply with covenants and, at December&#160;31, 2022, the Company was in compliance with these covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The aggregate maturities of long-term debt for each of the next five years are as follows: 2023, $1.7 billion; 2024, $1.3 billion; 2025, $2.5 billion; 2026, $2.2 billion; 2027, $1.5 billion. Interest payments related to these debt obligations are as follows: 2023, $882 million; 2024, $845 million; 2025, $778 million; 2026, $751 million; 2027, $720 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#x2019;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of seven years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company&#x2019;s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company&#x2019;s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost was $334&#160;million in 2022, $343&#160;million in 2021 and $340&#160;million in 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $335 million in 2022, $340&#160;million in 2021 and $334&#160;million in 2020. Operating lease assets obtained in exchange for lease obligations were $57 million in 2022, $117 million in 2021 and $473 million in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes prepaid leases that have no related lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Maturities of operating leases liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $232 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0Xzk2_c156dd29-4881-4dee-b15f-9e9a96ed0c7c"
      unitRef="usd">1700000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i7fda3b4d09eb4fa583ba37378f5415c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzEyMg_43220df5-7ea3-4ef7-bb20-8368b02b6ac0"
      unitRef="usd">197000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNA_0ccaa489-ccd4-4d5d-99d5-b133d0156f62"
      unitRef="usd">2300000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i2bb0b8ac7a6746a7b99550c3290a6912_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI5NQ_f8c56615-3c9a-4853-8764-6b7e862b4bbc"
      unitRef="usd">149000000</us-gaap:DebtCurrent>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="i8a963f7bb7df4286b00142ee3a4b4163_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzQ0OA_2e97ffb6-bf46-4370-8a09-94f1b533fe07"
      unitRef="number">0.0065</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="i9b81622562e043619ce4097e5de6538d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzQ1NQ_b5821c25-02b4-4077-8c77-31de8482be5b"
      unitRef="number">0.0008</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNTY_1949e94c-0b76-4134-9920-09f9ff33a3d4">&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term debt at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,496&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.15% notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75% notes due 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.70% notes due 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.40% notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,738&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.70% notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,494&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2061&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.00% notes due 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,471&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.15% notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.45% notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.45% notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.875% euro-denominated notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,060&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.75% notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.90% notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.90% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.90% notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;749&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.50% notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.50% euro-denominated notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.375% euro-denominated notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;527&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.50% euro-denominated notes due 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.60% notes due 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.55% notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.95% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.85% notes due 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;271&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.40% debentures due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.30% debentures due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80% notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;167&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;28,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iedd526ebaff749a5b3eafa6e57a81046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo3OGNlMzU0OGU4Zjc0NmFiYTc1MWYxYjI2Nzg3NzZjNV80_5618ff97-e307-48e9-896c-f715f27c93c9"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iedd526ebaff749a5b3eafa6e57a81046_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEtMS0xLTEtNzEzMzA_3d6a5d6d-4ab7-4e92-ac8b-4609a8ec3b72"
      unitRef="usd">2496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i84a1b935714646a28acc02e8da2af399_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEtMy0xLTEtNzEzMzA_0349b57a-9f07-4969-a35c-f9e02a08def2"
      unitRef="usd">2495000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i78f6217a86d54e6b955c5c6727e00fbc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzItMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpkNjU2MDllZWE4MWQ0ZDVhYjViOTlhOWI1MDgzNTgwZF80_67d3857b-4d4c-4872-b019-62d38faad99c"
      unitRef="number">0.0215</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i78f6217a86d54e6b955c5c6727e00fbc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzItMS0xLTEtNzEzMzA_76203d8c-1359-4065-bf83-b6bc18139fcc"
      unitRef="usd">1986000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i233cd0a66f3a4e1293ee7180976a6a9c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzItMy0xLTEtNzEzMzA_66407772-ac69-4736-8cf3-da89c17d1747"
      unitRef="usd">1986000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i33401fab91ba450bad968abb1f3afcb4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo5ZDY2MDBhYmI2NDU0N2JhOTQ4OGVjNmFlOTkwNTk2Ml80_058b2d66-daf2-4648-b795-20ac60dda642"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i33401fab91ba450bad968abb1f3afcb4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMtMS0xLTEtNzEzMzA_ef25031e-5423-47ea-9dce-c81b336f0ac9"
      unitRef="usd">1979000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iff1742d1bcca4273b22d4c2ec6e6d4d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMtMy0xLTEtNzEzMzA_45692c95-2f6f-4bf9-8bc7-d55da8245301"
      unitRef="usd">1979000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaaf0e9d91b9c4abf8d628b3c4bebc216_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzQtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo5ZjU5NGI3ZmNhNzg0MmQwOWUyMjQyMWZmMTUwNTBjNV80_46a7f87b-31ae-4439-9cc8-747bd33eafa9"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaaf0e9d91b9c4abf8d628b3c4bebc216_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzQtMS0xLTEtNzEzMzA_d2609527-bd0c-4b89-b9e7-a91a55308e2b"
      unitRef="usd">1978000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic09e345560f6497791f50eb94308c444_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzQtMy0xLTEtNzEzMzA_6829825b-c19a-46d7-8f22-aed4a5e2216f"
      unitRef="usd">1977000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7fb3e5f968ec4dd8825fd0c8bb6ad4aa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzYtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjo0MTljNWUxMjFjMDA0YzNkYjVjNDljYzhmYmViN2FhOF80_85d9ef4d-d298-4b8c-8eab-748001f25215"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7fb3e5f968ec4dd8825fd0c8bb6ad4aa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzYtMS0xLTEtNzEzMzA_4e5d15f7-7539-4f6f-a9d9-c379ec7acc72"
      unitRef="usd">1738000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9dcfc6075c6a4565a9f8554b61999abe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzYtMy0xLTEtNzEzMzA_af02951b-8138-48cb-ad30-a57689305586"
      unitRef="usd">1736000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i739a3710a3de4d7ebb81ef763fccbdea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzctMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjplN2EwNzM0NDg1MTA0MmQ1YjY4ZTFlYjBlYmVjOGI5M180_1f286601-ef90-465a-b2dc-abb60f6308c4"
      unitRef="number">0.0170</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i739a3710a3de4d7ebb81ef763fccbdea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzctMS0xLTEtNzEzMzA_8b962f50-2399-4732-adfa-56e473f36193"
      unitRef="usd">1494000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib470cd6f92154bc78779d5a55eb10d70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzctMy0xLTEtNzEzMzA_2bf07b8e-55a3-4745-b4bf-2cb3c1e4423e"
      unitRef="usd">1493000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie1c794da2c364cef883126c44ac0eadf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzgtMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpjNWZkOTExNTA5Y2Y0M2I5YTMwYmFjYzc5ZGIzMzg0N180_5bef9f9a-8c33-41b1-add7-ea6acf5c98ba"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie1c794da2c364cef883126c44ac0eadf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzgtMS0xLTEtNzEzMzA_cedceaf0-1664-4a08-9b72-d15b8aa160db"
      unitRef="usd">1483000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i822efa59fe3745939a910b1611d44288_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzgtMy0xLTEtNzEzMzA_21c24260-e4b6-4200-baec-109184096aba"
      unitRef="usd">1484000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92399f31232247e0b6bbcf5a6a089235_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzktMC0xLTEtNzEzMzAvdGV4dHJlZ2lvbjpkN2FmNzExZTViMDk0M2Y4YTIxY2IxNDYwZDFiYzBmYl80_9247307f-7348-4f1b-a51e-866bd0e7a55a"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i92399f31232247e0b6bbcf5a6a089235_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzktMS0xLTEtNzEzMzA_9f60fe9b-85da-4a32-a70e-4e0a4370b7c2"
      unitRef="usd">1471000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id5b551b1b91d472893ca0398491a7cce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzktMy0xLTEtNzEzMzA_ad0e3409-d70d-4e39-b608-44991ee7e967"
      unitRef="usd">1470000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia5713c49e1e844949024ca754f258c89_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEwLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MWYxMmNjMjA3ZDkxNDlhYjk4ZDRhOTUzOTgxN2E3N2JfNA_eff6eef1-7a92-41d3-be13-f8efb0a64918"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia5713c49e1e844949024ca754f258c89_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEwLTEtMS0xLTcxMzMw_14640b08-4d84-4a74-b6d4-d78d78839cf3"
      unitRef="usd">1239000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic3ac8327b23a4313b04a011b58ea1d2d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEwLTMtMS0xLTcxMzMw_cdbf300e-76b4-4fcb-9e3d-c0aba953d687"
      unitRef="usd">1239000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i49a36c48450a4259b629f674ef5433a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzExLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MmIwZjVhYmM0MDk3NDY3ODk5NzM1NjZlMmNlMzI0NDVfNA_6574fc48-c2f9-41b2-a1ab-cc2cd4071b95"
      unitRef="number">0.0145</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i49a36c48450a4259b629f674ef5433a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzExLTEtMS0xLTcxMzMw_847b275f-1b9c-4158-b830-6ba7b0c27558"
      unitRef="usd">1237000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5ff19b2f06b94d72a4c24b4eea59c7d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzExLTMtMS0xLTcxMzMw_caa04319-10d9-435e-ba33-d6f28f9de552"
      unitRef="usd">1235000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i11f4a58945df459196d4289980f7f9f6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246OTQ4YTQyNzhjYzZjNGUzYWI5YjNjN2M4OWFlM2MxMmVfNA_7d1bb9b4-2817-44e0-a761-35f1136cbf58"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i11f4a58945df459196d4289980f7f9f6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEyLTEtMS0xLTcxMzMw_4e38608c-4c8c-4087-8c9e-dbd28a229219"
      unitRef="usd">1213000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e0bcb5b5a434f51bab2f5d76da43e3e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEyLTMtMS0xLTcxMzMw_75aa32de-cb65-45c7-810e-789530859cee"
      unitRef="usd">1212000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia2a8b5ffe89f474aaa717071531eb373_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MTJhYjk2MDk0ZjA1NGUxZDllYTg2OGRkYzJiOTk2OGJfNA_92794d72-172d-4473-85ae-5863dde111dc"
      unitRef="number">0.01875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia2a8b5ffe89f474aaa717071531eb373_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTEtMS0xLTcxMzMw_2b5da613-dab3-40b6-8bd2-94ae2f9cbc59"
      unitRef="usd">1060000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i298d3bf22286484c845cea75b0818c0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTMtMS0xLTcxMzMw_17d91df4-9ea0-4090-9ad9-b276fc0a0782"
      unitRef="usd">1123000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i77ca7a1f2cbc41178098a0d44729387d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTAtMS0xLTExNzU1MS90ZXh0cmVnaW9uOjVhNzM4NGZjMDhmYjRmN2VhZjQzYTgyOTI0OWQyODU1XzQ_0a65176a-8dc6-4fe7-8b2d-868f3d410e61"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i77ca7a1f2cbc41178098a0d44729387d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTEtMS0xLTExNzU1MQ_a8a10c70-79b3-402d-9d76-a57b7cfbe39f"
      unitRef="usd">995000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i400c4310ee744a12bbb7413c21f7cac2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzEzLTMtMS0xLTExNzU1MQ_17536860-3ec3-408f-95eb-df91533ce6f4"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i58e87abb2aae4b75ba3cbbada4ba4c18_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246YmEyNjJmZmE2ODYyNDU3MDg4Y2M1MWU2NDc0NDdjN2NfNA_44b613a7-10d5-42e1-91f1-b4e664c4abcc"
      unitRef="number">0.0190</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i58e87abb2aae4b75ba3cbbada4ba4c18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE0LTEtMS0xLTcxMzMw_0ad60f1e-0298-4043-87cb-1d34446cd798"
      unitRef="usd">994000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9e5590941b574c9c837595f0aace5727_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE0LTMtMS0xLTcxMzMw_8b55a35e-3ec9-4918-b5cd-a6da191a7bde"
      unitRef="usd">994000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f7aac49ddf54d1c84c0298cedae4e0d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246Mzk0Mzc0NzBkMGZlNDIwM2ExYmMzYTE2MThiYjFhMWJfNA_a549fda5-468f-45e5-9145-b014a69a1d15"
      unitRef="number">0.0390</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5f7aac49ddf54d1c84c0298cedae4e0d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE2LTEtMS0xLTcxMzMw_a07d99d8-9202-4f7a-bd38-6cfe1163b9ad"
      unitRef="usd">985000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2bfb5c52b3d044d7b880a56872ae93e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE2LTMtMS0xLTcxMzMw_7c52ab4f-6c6a-43c1-8762-31fdad7f5399"
      unitRef="usd">984000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i224209bee44647d1890dfbfe59b6f186_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MDA1YzYwYzNkNjM4NDQ1Y2JkZGE1YjMyMjBmOGQyYTJfNA_41877166-afc3-4b8c-b815-4bd66f47897e"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i224209bee44647d1890dfbfe59b6f186_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE3LTEtMS0xLTcxMzMw_023c48af-0ffd-4bc5-823a-7c0f0863dfc3"
      unitRef="usd">984000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6fa89611a5164af6b8cccaea01b34c43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE3LTMtMS0xLTcxMzMw_fb2e50cc-f324-4d9f-ac20-b0722878dff8"
      unitRef="usd">983000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd075f7f4f1d41c190d492328b684c9b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE4LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NTdjOTdhNTBjYWJjNGZmZWEzNjdmY2RjZGViNGU4YTdfNA_d94d6ee9-24a2-4122-ab3f-c32fd4640732"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idd075f7f4f1d41c190d492328b684c9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE4LTEtMS0xLTcxMzMw_04078aa5-29de-48b6-8ae0-dc9cae472fcd"
      unitRef="usd">749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id3f2e241750c47b19940f1f7920f4c9d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE4LTMtMS0xLTcxMzMw_24014270-da14-4f90-9a9c-8e69b913ef32"
      unitRef="usd">748000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i620b959fd9e146b0bd7d17c8f78e14de_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE5LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NmViOWFjNjVkNDY3NGQxZWExZGI4ZmUwZGZlMWZiNTRfNA_6fff636e-c6af-4660-a69e-77eab11d5173"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i620b959fd9e146b0bd7d17c8f78e14de_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE5LTEtMS0xLTcxMzMw_d2d60b81-a517-4ecb-a44c-028d740730f0"
      unitRef="usd">711000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic6eac77276524db589b7a8df253bdb8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzE5LTMtMS0xLTcxMzMw_bfb0c23f-8acc-4ea3-9dcf-a7d99654fc74"
      unitRef="usd">715000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i97601a3d96de4a38be031a08c94ba40b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIwLTAtMS0xLTcxMzMwL3RleHRyZWdpb246ODUxODdkOGQzZjllNDQzZmIxN2VjYjkwNDNhMGIxMmJfNA_a6602f32-ed50-4ca1-ab69-26e6c4bfbb01"
      unitRef="number">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i97601a3d96de4a38be031a08c94ba40b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIwLTEtMS0xLTcxMzMw_eea3070a-55c3-41a7-969d-cfd3fb065867"
      unitRef="usd">531000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if24293f6fd55415d9560fd27185731e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIwLTMtMS0xLTcxMzMw_36e7f894-3c74-4699-8c03-442c3e545cb2"
      unitRef="usd">563000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie629738e7a1a43b4844c99c144e93473_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIxLTAtMS0xLTcxMzMwL3RleHRyZWdpb246OTRjOWY0ZmFhZDA5NGRlZjllMmMyYzkwN2Q2OWNlYmFfNA_2a6a5294-8a64-435d-9bce-6da11ec3928b"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie629738e7a1a43b4844c99c144e93473_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIxLTEtMS0xLTcxMzMw_82e14e09-8982-42bd-952f-0a16daa034db"
      unitRef="usd">527000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if83a7f94ec0b4f15a760d11fa20711ed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIxLTMtMS0xLTcxMzMw_35aa582b-b1dc-48aa-8f6c-7d1eda5bfa78"
      unitRef="usd">559000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i82da477c35664e5e9a498ca0e106941a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIyLTAtMS0xLTcxMzMwL3RleHRyZWdpb246NjM0YTU1ZTM0Mzk0NGZmN2FmYzJkZjZhOTllMzMzYmZfNA_07b8e0cc-02cf-47be-9f02-f3e223971dac"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i82da477c35664e5e9a498ca0e106941a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIyLTEtMS0xLTcxMzMw_574f8ebe-f240-4c53-a01c-be5a3e19f245"
      unitRef="usd">526000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iebb2ca9915d3447a9524c55e37e9fef7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIyLTMtMS0xLTcxMzMw_56a97e51-f30d-477a-88b8-d86d8500fab1"
      unitRef="usd">558000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8c0f5eccf7f542f78f0a069e1e0441a0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIzLTAtMS0xLTcxMzMwL3RleHRyZWdpb246MWU4MDBmNmMwNDFmNGM5NGFlMzdjOWZlMzM5NTk3ODFfNA_75cd355b-620d-4a54-83e1-ea72952c1cf1"
      unitRef="number">0.0360</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8c0f5eccf7f542f78f0a069e1e0441a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIzLTEtMS0xLTcxMzMw_eb2ac65a-1b68-4f79-a4ff-3b782a602653"
      unitRef="usd">492000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i29ba76bbfef44f90b331caf152aedf4f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzIzLTMtMS0xLTcxMzMw_6ee21873-e4cb-4f23-8e2a-fdbacabccdfa"
      unitRef="usd">491000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92331b59f2ca4a2cb806ae55ee55125f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI0LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MGNiZmMyZWQ5MWUzNDE3NmI1NzU1MDJkMzY1MjhjZThfNA_86cb5562-13f2-4b59-8d67-23bfa3824da3"
      unitRef="number">0.0655</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i92331b59f2ca4a2cb806ae55ee55125f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI0LTEtMS0xLTcxMzMw_5e68cf6a-ca1c-4efc-b884-aade243c7872"
      unitRef="usd">408000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if8c58e35b90f44c7b85f122be398e01b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI0LTMtMS0xLTcxMzMw_a32c8ccf-0376-4c25-98ec-23f8a78ada24"
      unitRef="usd">409000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7d334e27c8974586a1e136fdef62aea3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI1LTAtMS0xLTcxMzMwL3RleHRyZWdpb246ZDgzZWI5ZGNmY2UwNDlkNjkzMGNkMzk2ZTFiY2U4ZGRfNA_1551e53a-9270-4b7a-b939-8d9b0e7a4d19"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7d334e27c8974586a1e136fdef62aea3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI1LTEtMS0xLTcxMzMw_dbe86c36-f239-4192-b99b-39924507a7db"
      unitRef="usd">339000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="icded3aad9e2b4fa5bcc6bbe73f7bd27d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI1LTMtMS0xLTcxMzMw_acd99ac6-124d-447d-a760-cf412c933abf"
      unitRef="usd">338000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3c09fe213ba245e79cdc9b37441d663c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI2LTAtMS0xLTcxMzMwL3RleHRyZWdpb246ZTI3ODY1NGU3NDQwNDNjNzk2MDQ0OTNmNGUwZmI0NGNfNA_2d1ad4e4-bf07-451d-b3f0-8bec62464575"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3c09fe213ba245e79cdc9b37441d663c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI2LTEtMS0xLTcxMzMw_6bf70f50-4dda-49d7-ad2b-eb57cb20ee4e"
      unitRef="usd">307000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8bccfb63cc84447d9f2fdc7082467dbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI2LTMtMS0xLTcxMzMw_5472d6b7-8bf1-4cd3-af9c-ef206a7afd2e"
      unitRef="usd">306000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i45478d0ad35e4c2d8be4c0a65f047423_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI3LTAtMS0xLTcxMzMwL3RleHRyZWdpb246YjIyMjE1NjM4ZGRlNDFiMWFiMzVhNjE2YTljZDExMDBfNA_a8859656-ad5b-4201-bac9-cae9e6c80a0d"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i45478d0ad35e4c2d8be4c0a65f047423_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI3LTEtMS0xLTcxMzMw_48c0ddab-5722-4199-b6e9-c4a826a8876f"
      unitRef="usd">271000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i75f8a178ed8f450eabe1b16459124dcf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI3LTMtMS0xLTcxMzMw_be7737bd-ce4d-43a7-8131-ee3010c34e2b"
      unitRef="usd">271000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8dfca1e518a440e79e02408f4fe0efb6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI4LTAtMS0xLTcxMzMwL3RleHRyZWdpb246MWQyYTI4OGU2ZWVkNGU5ZWE4NWJiNTJiZWMzOGI4OGJfNA_dfa5210c-9a12-48f4-a695-6a344f7d0cdb"
      unitRef="number">0.0640</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8dfca1e518a440e79e02408f4fe0efb6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI4LTEtMS0xLTcxMzMw_d98467c7-b326-4269-bc56-5477c238f917"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib8f6b68af8b9428d91b0377f34290f43_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI4LTMtMS0xLTcxMzMw_002ba80d-64c3-4a4a-bb86-3b01007a48ca"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3af20c7a3814238b67e841a07acf4cf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI5LTAtMS0xLTcxMzMwL3RleHRyZWdpb246NzM4M2IyOWVmZjhmNDIwZDhlYWNiNTg0YjU2YTEwYTVfNA_e7074fb4-9da1-4948-a452-909677437ab6"
      unitRef="number">0.0630</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if3af20c7a3814238b67e841a07acf4cf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI5LTEtMS0xLTcxMzMw_b1dad3d0-df70-4dee-a9f5-a2e8105dc2c6"
      unitRef="usd">135000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i85a75657caa24185aa254c6f8bac7779_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzI5LTMtMS0xLTcxMzMw_31611d9b-b85a-40f7-8766-c3ec45060f88"
      unitRef="usd">135000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i91242e71ad3045608d2523c26d489ee5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMwLTAtMS0xLTg0MjY2L3RleHRyZWdpb246YWJiNjYzMTA0OTk4NDRiYzg5MDRkNDU4NThkZTJmYTNfNA_d3081c1e-9e08-4598-b05d-f6e45138104e"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i91242e71ad3045608d2523c26d489ee5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMwLTEtMS0xLTg0MjY2_b7de78d3-57c8-4b15-89f4-e57228f61e8a"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6f1e9b9048084ef786463cd80bb97477_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMwLTMtMS0xLTg0MjY2_09b6813f-effd-4ff7-8afb-a99c2e653c71"
      unitRef="usd">1749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5179a79bc0fb422a93c77860d39e3e5c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMyLTEtMS0xLTcxMzMw_7d522791-b659-47eb-a245-0222bcd18fa5"
      unitRef="usd">167000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3e4ff66345424bd1af13776a97cc3571_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMyLTMtMS0xLTcxMzMw_7e0c68e8-0d6e-4dc2-af4e-86f30c1225ab"
      unitRef="usd">215000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMzLTEtMS0xLTcxMzMw_e33046c2-a3c8-4263-9136-6856a66f0f1b"
      unitRef="usd">28745000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTozYjMxMGUyNjlmODc0M2Y3OTU3NjA5YzlkYmJlMjJhMy90YWJsZXJhbmdlOjNiMzEwZTI2OWY4NzQzZjc5NTc2MDljOWRiYmUyMmEzXzMzLTMtMS0xLTcxMzMw_3924ca31-beb4-4568-a8ff-1e1b17fed912"
      unitRef="usd">30690000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i18dfd3b19f344509849614fd0c8c7ae6_I20221231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzY4OQ_b9127c79-fea8-4087-af61-a56b36d3292d"
      unitRef="number">0.0140</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="i047a9aa409af47a39aec099d05eb850f_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzY5Ng_2cadef57-82f6-4f94-99bf-9f1ed66411ec"
      unitRef="number">0</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3af20c7a3814238b67e841a07acf4cf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0Xzc1NQ_1fe74492-5a45-4c00-b4c2-d78c37ff3e32"
      unitRef="number">0.0630</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNTY_624c506c-4ccf-428f-9605-0eef3afa201e"
      unitRef="usd">1700000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNjQ_a47b80c9-b05e-48f9-ba49-f765f0ab48f7"
      unitRef="usd">1300000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzNzI_2ae85acf-587e-4e2c-affd-89921ce5a688"
      unitRef="usd">2500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzODA_80933a22-5eab-4e08-bcf7-92d1122f100f"
      unitRef="usd">2200000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzIzODg_1759c0f8-6d37-4b74-b38f-591aefcc1da7"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <mrk:LongTermDebtInterestPayableYearOne
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0NjQ_7cc6ee6a-311d-4ac6-8942-464add49d450"
      unitRef="usd">882000000</mrk:LongTermDebtInterestPayableYearOne>
    <mrk:LongTermDebtInterestPayableYearTwo
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0NzI_d69c9b11-72cc-4875-b3a7-d8552b3c0602"
      unitRef="usd">845000000</mrk:LongTermDebtInterestPayableYearTwo>
    <mrk:LongTermDebtInterestPayableYearThree
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0ODA_e0e2f468-9cae-4e82-8159-5c52968b64a7"
      unitRef="usd">778000000</mrk:LongTermDebtInterestPayableYearThree>
    <mrk:LongTermDebtInterestPayableYearFour
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0ODg_65d68940-2a26-4913-a372-f1339f3d3371"
      unitRef="usd">751000000</mrk:LongTermDebtInterestPayableYearFour>
    <mrk:LongTermDebtInterestPayableYearFive
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI0OTY_73ee2751-671d-40a4-9456-42050ef3ef9e"
      unitRef="usd">720000000</mrk:LongTermDebtInterestPayableYearFive>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzI1MTg_d70e979d-e364-436c-9e9b-43b31ec46105"
      unitRef="usd">6000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i31d717109e794d52a04995b9284f4213_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzM1MjM_bf47c9da-e8cb-461a-8c2b-19049c52e36b">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i31d717109e794d52a04995b9284f4213_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzM1ODA_635f91bb-6132-4595-bd49-9846c3473043">P4Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3f477cad38324ad7a03c8f6e78a1056c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzM2NDQ_acfc4736-5244-464c-9bf0-472f33a60f4b">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseCost
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU1MTk_fd0a1a4c-304b-4070-b309-9a3ecfe44d38"
      unitRef="usd">334000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU1Mjk_8019e1a6-e6ed-4069-a2c0-efb77453c765"
      unitRef="usd">343000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU1NDI_d52a2774-871d-40f9-a672-d488ca7b8a64"
      unitRef="usd">340000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU2Mzc_44680aca-f84c-4c61-baed-0391066f64cc"
      unitRef="usd">335000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU2NDc_34655c34-1025-47f8-8ebe-91224729a792"
      unitRef="usd">340000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU2NjA_d0ece100-732f-4ad2-948b-03795b53f7fc"
      unitRef="usd">334000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU3NDE_e57210cf-60da-4643-bb74-31653f5a07e6"
      unitRef="usd">57000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU3NTE_6b1e5a05-19b4-437f-aa8f-8737e454ac48"
      unitRef="usd">117000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzU3NjQ_a0e7cb84-27f8-4acb-bf70-dbb44640e810"
      unitRef="usd">473000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mrk:AssetsandLiabilitiesLesseeTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNDY_ecbe6d35-9de7-4efe-b9c6-3b473ba0f186">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes prepaid leases that have no related lease liability.&lt;/span&gt;&lt;/div&gt;</mrk:AssetsandLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMS0xLTEtNzEzMzA_2e678756-ded3-44eb-8a67-d5f34e905908"
      unitRef="usd">1346000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMy0xLTEtNzEzMzA_5b7bd4b5-9872-4699-9753-6af28115f336"
      unitRef="usd">1586000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMS0xLTEtNzEzMzA_cfa7409e-dfbe-4ff2-ac46-c7f7d129c9d4"
      unitRef="usd">281000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMy0xLTEtNzEzMzA_6f195d42-9dd4-4450-802a-bfbd608147ea"
      unitRef="usd">304000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMS0xLTEtNzEzMzA_68bec5df-ac44-40bd-9024-e257dda2cc95"
      unitRef="usd">1013000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMy0xLTEtNzEzMzA_9d1d4aee-89de-4fdd-9231-c0bd02daa689"
      unitRef="usd">1225000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzYtMS0xLTEtNzEzMzA_4de5df65-5da2-4146-a1f0-dfecf9e56fac"
      unitRef="usd">1294000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzYtMy0xLTEtNzEzMzA_d5fc55b7-d3ed-4492-b005-25e794c18f9b"
      unitRef="usd">1529000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzctMS0xLTEtNzEzMzA_32c13533-f673-41fd-b399-949ba4bbc185">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzctMy0xLTEtNzEzMzA_02c71627-0f98-4c06-b409-ab06a6d768c8">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzgtMS0xLTEtNzEzMzA_bc4156b3-aead-45fb-8b58-c311119a5385"
      unitRef="number">0.031</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzgtMy0xLTEtNzEzMzA_ee32d3dd-3c40-4de8-8175-437c02ac6fc7"
      unitRef="number">0.026</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNTc_72fbca43-9220-4662-a77a-6965c6fc9dea">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Maturities of operating leases liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzAtMS0xLTEtNzEzMzA_155868e6-12d5-4873-ae6b-5384669c6fb4"
      unitRef="usd">323000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzEtMS0xLTEtNzEzMzA_ce5e6ded-e155-4d55-8b43-c1287b532a16"
      unitRef="usd">258000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzItMS0xLTEtNzEzMzA_191500ce-cb47-410c-bcf7-915d606a89da"
      unitRef="usd">224000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzMtMS0xLTEtNzEzMzA_70a09504-ed48-4e08-bcd6-f57114364a6e"
      unitRef="usd">157000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzQtMS0xLTEtNzEzMzA_1d6cde87-87ff-4560-91e1-e40d71409d4b"
      unitRef="usd">126000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzUtMS0xLTEtNzEzMzA_cc293797-828d-4995-94e1-9b45db4cd858"
      unitRef="usd">404000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzYtMS0xLTEtNzEzMzA_1920fadd-9327-41d4-881d-0590aa973481"
      unitRef="usd">1492000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzctMS0xLTEtNzEzMzA_ff4ebe90-ae36-448b-bf24-3849f1ac2083"
      unitRef="usd">198000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo3YWEwOTM0Y2Y0ZDU0NDdmODdiNjRmZmVjMTIyMDkwMS90YWJsZXJhbmdlOjdhYTA5MzRjZjRkNTQ0N2Y4N2I2NGZmZWMxMjIwOTAxXzgtMS0xLTEtNzEzMzA_f2d77c58-fd62-40b9-a819-0aaecf0cc302"
      unitRef="usd">1294000000</us-gaap:OperatingLeaseLiability>
    <mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90ZXh0cmVnaW9uOmUzYjc5MzRkMTU5YzQyNjhhNTZhNWNkMjJhZjQ4M2Q0XzYxNDM_13784c16-6332-4833-bbd7-eeaa13a4d0ba"
      unitRef="usd">232000000</mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMzMTg3_0d4ea578-5892-4be6-a684-aee11f6b2ef5">Contingencies and Environmental Liabilities &lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil 9&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December&#160;31, 2022, approximately 70 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Governmental Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney&#x2019;s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government&#x2019;s information request by seeking information relating to Merck&#x2019;s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company&#x2019;s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General&#x2019;s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck&#x2019;s development of an insulin glargine product, and its subsequent termination, as well as Merck&#x2019;s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government&#x2019;s investigation and intends to produce information and/or documents as necessary in response to the CID.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company&#x2019;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#x2019;s policy is to cooperate with these authorities and to provide responses as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S.&#160;These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings.&#160;Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Commercial and Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#x2019; motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#x2019;s class certification order and remanded for further proceedings consistent with the court&#x2019;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs&#x2019; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#x2019; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other Zetia MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On February 10, 2023, the district court denied the Merck Defendants&#x2019; and Glenmark defendants&#x2019; motions for summary judgment. In the cases filed by direct purchaser plaintiffs, retailer plaintiffs, and indirect purchaser plaintiffs, plaintiffs seek up to a maximum of $12.7&#160;billion in damages after trebling. The court has scheduled trial for these plaintiffs (all plaintiffs other than the Insurer Plaintiffs) for April 17, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;340B Program Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck&#x2019;s 340B Program integrity initiative. HRSA&#x2019;s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA&#x2019;s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck&#x2019;s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company&#x2019;s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit&#x2019;s ruling in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis Pharmaceuticals Corp. v. Johnson &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; United Therapeutics Corp. v. Johnson&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;M-M-R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;M&#x2011;M&#x2011;R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;II vaccine, which charge that the Company misrepresented the efficacy of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;M-M-R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck&#x2019;s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merck KGaA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name &#x201c;Merck&#x201d; in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties&#x2019; coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#x2019;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#x2019;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments on February 3, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has settled with five generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia, Janumet, Janumet XR&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; As previously disclosed, the FDA granted pediatric exclusivity with respect to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(sitagliptin), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(sitagliptin/metformin HCl), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#x2019;s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#x2019;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#x2019;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Court for the Northern District of West Virginia issued a decision in the Company&#x2019;s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to the market in May 2026 or earlier under certain circumstances, and their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to the market in July 2026 or earlier under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additionally, in 2019, Mylan filed a petition for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company&#x2019;s favor, upholding the USPTO&#x2019;s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#x2019;s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity toward the end of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; SPCs in Europe, for which there will be an oral hearing on March 8, 2023. In first instance decisions, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; SPC has been found invalid in Germany and Romania, and has been upheld in Czech Republic and Sweden. Appeals are pending in Germany, Czech Republic and Sweden. The Company has filed for injunctive relief in Belgium, Czech Republic, Finland, France, Greece, Hungary, Ireland, Portugal, Switzerland and Slovakia. An &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex-parte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; preliminary injunction was granted in Finland, which has been subsequently maintained in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter-partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; proceedings, Czech Republic and Switzerland, and an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter-partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; preliminary injunction has been granted in Ireland. A preliminary injunction was granted in France and the validity of the SPC and the associated patent were held to be &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;prima facie&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; valid. Preliminary injunctions have been refused in Portugal, Greece, Belgium and Hungary. In Belgium, the Company has filed a main infringement action against generic companies and a request for preliminary measures in that action has been refused.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lynparza&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#x2019;s financial condition, results of operations or cash flows either individually or in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Legal Defense Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#x2019;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December&#160;31, 2022 and 2021 of approximately $230 million represents the Company&#x2019;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company&#x2019;s potential liability varies greatly from site to site. For some sites the potential liability is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In management&#x2019;s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December&#160;31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15&#160;years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company&#x2019;s financial condition, results of operations or liquidity for any year.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="icbd61b5e13024c6d821da5de889797bd_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzEwOTk1MTE2ODk0ODE_9f02ffbd-7ec0-4edf-b5f6-0e3f171da95e"
      unitRef="case">70</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie2746565f1354a23af85f4f99207c98b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzEwOTk1MTE2ODk0ODU_1f8a3ead-72dc-4c98-81ca-b755b5d72305"
      unitRef="case">15</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i894c84a8a53146d0996d343ee95c4d6e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzEwOTk1MTE2ODk0OTM_d2753c35-f6e2-453a-93dd-b1fc98cb2e16"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i2b1982ad1e3245b8821c7a9045cfbf7f_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3MjI_5cde3972-b069-443b-9f46-5c4947d89813"
      unitRef="claim">35</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ib81588e6e7c24f96af260cda2030da9b_D20220630-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzM4NDgyOTA3NTg5OTA_b0a9e942-6e0a-4efb-b7e7-db79880e8679"
      unitRef="claim">23</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ic3d2016a9f564132a989caf8220b8a3d_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzM4NDgyOTA3NzA1ODQ_6ee485f1-fbed-40c9-9d89-d55cc723cc84"
      unitRef="usd">12700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ic39a2a021f974911b1ac6fafab48dfb4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzE4ODEy_dbcf58ec-fb92-4a33-b292-c18a3815e3ce"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ic39a2a021f974911b1ac6fafab48dfb4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzE5MjY0_dbcf58ec-fb92-4a33-b292-c18a3815e3ce"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id7972a4598aa47ccbf40c79991ea05ad_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzE5Mzk1_5657ba60-64b9-4f01-9d9f-f903cfc8da3a"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <mrk:LossContingencyTrialPeriod
      contextRef="i7a61ea22950f47828b95fed44e6413c2_D20221219-20221219"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3NTQ_1ce19472-2a54-4a12-a2a2-83227c294f3c">P1D</mrk:LossContingencyTrialPeriod>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i706bfb75e173464c95cb81cf1f960b6b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3Mzc_b6a2b854-c2ef-40ce-96ca-540c8ab2c4fd"
      unitRef="case">5</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i225a64a3f7814a45b055a29ef0ca80d6_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc3NDY_bd78aa22-24d7-4d49-acc4-4296e5216dfe"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i3b134a981f8749cfa64471811826b386_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzI2NTk2_6076f529-5855-4436-9d3e-f54386603dde"
      unitRef="case">22</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LitigationReserve
      contextRef="i8fa23748b8b24ab09e6d4660601d9eb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzI5ODc5_194b3e4a-0204-4bb2-9575-aec039e4a3d7"
      unitRef="usd">230000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i02fa96876a7745d29042dd0d714d3299_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzI5ODc5_7b1a648c-4ab7-444d-af47-e20e6edc61ef"
      unitRef="usd">230000000</us-gaap:LitigationReserve>
    <mrk:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzkzNDU4NDg4OTc4NjU_63f4c92f-06f1-4c0d-b1a3-1b23f298527b">liabilities</mrk:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:AccrualForEnvironmentalLossContingencies
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyNDI1_1d4c4cca-2723-4b6c-aba1-d610fe5e5eb9"
      unitRef="usd">39000000</us-gaap:AccrualForEnvironmentalLossContingencies>
    <us-gaap:AccrualForEnvironmentalLossContingencies
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyNDMy_401e583c-fe78-440e-8d3f-16de0acb7609"
      unitRef="usd">40000000</us-gaap:AccrualForEnvironmentalLossContingencies>
    <mrk:TermForPayingOffEnvironmentalLiabilities
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyNjg2_91d891fe-d49b-4d8a-8496-584c6c99a8c9">P15Y</mrk:TermForPayingOffEnvironmentalLiabilities>
    <us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzgvZnJhZzphMjFkY2EzMDUzMDk0MTM1Yjc5ZTI5YzNhMjZkNTkxOS90ZXh0cmVnaW9uOmEyMWRjYTMwNTMwOTQxMzViNzllMjljM2EyNmQ1OTE5XzMyOTc0_486c1f3b-d66a-45f9-8249-9de3e0857cdf"
      unitRef="usd">35000000</us-gaap:EnvironmentalExitCostsReasonablyPossibleAdditionalLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1XzMzMQ_c3bc3a4f-e234-49eb-8160-4cb54038e792">Equity&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Merck certificate of incorporation authorizes 6,500,000,000&#160;shares of common stock and 20,000,000&#160;shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Capital Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of common stock and treasury stock transactions (shares in millions) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances primarily reflect activity under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1XzY5_75b3b34b-433a-4cc3-b579-2d4d63af5575"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1Xzk5_6c939479-063c-4f84-816a-9e862f14e0a1"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90ZXh0cmVnaW9uOmE4YTM1ODIxNjM4NTRkNGE4Y2Q3ZjA3ZGU0NzIzNmM1XzMzNw_d1bc4147-fa3f-479c-ae66-00617db7f219">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of common stock and treasury stock transactions (shares in millions) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury&lt;br/&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issuances &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,577&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances primarily reflect activity under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItMS0xLTEtNzEzMzA_e11e080f-a086-4ec2-ba5d-824868123964"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i170384be3a654d119874ff6b7ed2eb92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItMy0xLTEtNzEzMzA_6eb027e9-d0b8-4f09-b0de-33c6c273daec"
      unitRef="shares">1049000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItNS0xLTEtNzEzMzA_1648b27b-b470-4f45-943c-6e28ace61ce5"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i06a03badfaf044d5abe8434be9cfeda8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItNy0xLTEtNzEzMzA_28368bbf-a139-4bca-b441-f90594e738d6"
      unitRef="shares">1047000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i870984a7a0814cf9a460c7a4b331c37f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItOS0xLTEtNzEzMzA_76745deb-52c6-40fe-8c9c-99f5844c149e"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3278c06a03cc4b83ad0c695bac71a99b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzItMTEtMS0xLTcxMzMw_d12f3f9e-3adb-4222-94a8-0d7686cd8d9d"
      unitRef="shares">1038000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i591ce0aef96f4308b1211d94ac08b222_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtMS0xLTEtNzEzMzA_0f802255-a8be-44e8-99c4-67b0863491e7"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtMy0xLTEtNzEzMzA_941de4d3-a6bf-4e74-88f6-e6080daeccbf"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iac458cf9779e41db953d53fb8f7b2fb3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtNS0xLTEtNzEzMzA_0cfeca5d-ae64-46e1-bbcc-948bc8d63527"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtNy0xLTEtNzEzMzA_b9571697-1b26-473f-aa88-96b523383abc"
      unitRef="shares">11000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i619a10076fc241c5bba81067acbe0104_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtOS0xLTEtNzEzMzA_6e3774c0-928f-42b2-875c-82b42a74ed73"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzMtMTEtMS0xLTcxMzMw_e955a040-e951-4fe8-b8f1-ca81947d995f"
      unitRef="shares">16000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i591ce0aef96f4308b1211d94ac08b222_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtMS0xLTEtNzEzMzA_a80cdd68-eed8-42cf-9893-9bae8ff9ecba"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie90446cef0114e448d1f5ea50f1ac821_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtMy0xLTEtNzEzMzA_0304a366-ead3-4c7b-91c6-cf515297a973"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iac458cf9779e41db953d53fb8f7b2fb3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtNS0xLTEtNzEzMzA_cac5650e-be6e-402b-afa7-da727fbc5192"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i34f61170574e41f09c19f203e15a0ab8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtNy0xLTEtNzEzMzA_3e2ab652-9f3a-47eb-96ab-e9c2f0900d7a"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i619a10076fc241c5bba81067acbe0104_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtOS0xLTEtNzEzMzA_991c771f-389a-456b-ad61-a5a3e5c54f38"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i89f19930240d4b37b41c6c852e0be5cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzQtMTEtMS0xLTcxMzMw_e2fe839d-0d05-4548-bac7-888a1e65c744"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:CommonStockSharesIssued
      contextRef="i326e10191d3348dd83075e847b9e3840_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtMS0xLTEtNzEzMzA_5fdae441-c930-450f-af0b-d7755454f0c8"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if945586aba2d4519bdf8f10667672306_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtMy0xLTEtNzEzMzA_7e89c224-9624-4bf2-a15f-a6f7e1adf183"
      unitRef="shares">1039000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic59a136debcc4ba2a73b6a4b7428d94e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtNS0xLTEtNzEzMzA_6296af43-9514-46af-b659-344c797cb0cd"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i170384be3a654d119874ff6b7ed2eb92_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtNy0xLTEtNzEzMzA_e0c841f9-38cd-4f5f-865e-d5e8a9b116ce"
      unitRef="shares">1049000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1e79f2b9eb7c4893a91d0b13ab6b1d36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtOS0xLTEtNzEzMzA_9115d0e9-5b3c-40b7-a4be-00024e667226"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i06a03badfaf044d5abe8434be9cfeda8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODEvZnJhZzphOGEzNTgyMTYzODU0ZDRhOGNkN2YwN2RlNDcyMzZjNS90YWJsZTpkNjA0MjczYjMwN2U0N2Y5YjgyYmUzZTUyNWNlZGJjNy90YWJsZXJhbmdlOmQ2MDQyNzNiMzA3ZTQ3ZjliODJiZTNlNTI1Y2VkYmM3XzUtMTEtMS0xLTcxMzMw_65657038-5e84-4209-b174-dafbf20a9f44"
      unitRef="shares">1047000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMjM_f52cae6c-6d8d-411c-a855-72826296b8b1">Share-Based Compensation PlansThe Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees &lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company&#x2019;s shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, 87 million shares collectively were authorized for future grants under the Company&#x2019;s share-based compensation plans. These awards are settled with treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10&#160;years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company&#x2019;s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company&#x2019;s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company&#x2019;s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total pretax share-based compensation cost recorded in 2022, 2021 and 2020 was $541 million, $498&#160;million and $475&#160;million, respectively. The amounts in 2021 and 2020 include $479 million and $441 million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2022, 2021 and 2020 were $78 million, $69 million and $65 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company&#x2019;s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price of options granted in 2022, 2021 and 2020 was $87.10, $75.99 and $77.67 per option, respectively. The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information relative to stock option plan activity (options in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(6,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;60.77&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;73.11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;70.55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;70.09&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;539&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercisable December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additional information pertaining to stock option plans is provided in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of stock options vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;384&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nonvested January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;88.52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(5,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;75.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;77.58&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nonvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected to vest December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;80.96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,895&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, there was $813 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzQ1Mg_27d05d9f-e19c-434c-85cc-185c5b5fdf02"
      unitRef="shares">87000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwODQ_9e0bc1fb-f16c-46d6-92e2-f1b19f5731fe">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id2bcbaf072504345ad85a02b400ea1db_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzgyNA_15b68497-b833-46db-99fc-71dbccef2c27">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i51f0f999fd774659b9c3a27f1aa22863_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzgyNw_b758c9aa-2583-4cf8-a41f-62d4f0fb40d9">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMDk_a50eec56-4780-425d-abf3-1b52be40053e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMTA_c18399d4-da25-448f-b780-c78808bd8d71">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzEwOTk1MTE2MzUwNDE_11474f9d-7d52-4934-bc4f-aaeec4c09665"
      unitRef="usd">541000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIwODA_1b09a12c-fefd-4bc9-b0f2-e5055bb89de2"
      unitRef="usd">498000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIwODc_c4c3872b-1e7a-4759-9682-1641660f9424"
      unitRef="usd">475000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIxMTk_3a4a606f-05d9-4851-bed3-b169b31dd9d2"
      unitRef="usd">479000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIxMjY_b89d799f-e424-4f18-a4d0-693f6e643cdf"
      unitRef="usd">441000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIyNjg_9ac8fc3c-0e1f-4112-b3c7-728a1f979f60"
      unitRef="usd">78000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIyNzI_cc4d0ff0-269b-44c6-9151-f08d9d8c7f5e"
      unitRef="usd">69000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzIyNzk_c09db61e-1bb0-48c3-be4a-33f3c36618dc"
      unitRef="usd">65000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzMzODc_40c6de3a-0b0c-4a13-ba79-8b0b35c0216a"
      unitRef="usdPerShare">87.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzMzOTE_feb84944-5beb-499e-b4d4-e3c88d24ce94"
      unitRef="usdPerShare">75.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzMzOTg_d2649ba4-fa06-49c6-b7c7-4bb25ca0f3f0"
      unitRef="usdPerShare">77.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwODY_631eb90a-ba2f-4ba5-8ea7-fa10b75cb7ae">The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzM0OTk_ded7bb7e-9148-4c26-b0b2-805b099cff5c"
      unitRef="usdPerShare">15.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzM1MDM_29cf4a3b-65e1-441d-b011-5872d830de9e"
      unitRef="usdPerShare">9.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzM1MTA_33d0e732-af7a-45c2-8953-8116d73c53a3"
      unitRef="usdPerShare">9.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzEtMS0xLTEtNzEzMzA_e96bde16-00d8-4e02-9935-5b9d8c9df96f"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzEtMy0xLTEtNzEzMzA_33a77a4b-82c4-4053-8cd5-cf068f762374"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzEtNS0xLTEtNzEzMzA_a0e2a53d-c495-47dc-af40-9d6af709aed5"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzItMS0xLTEtNzEzMzA_5000f161-8972-4015-b081-85ad7a2b7673"
      unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzItMy0xLTEtNzEzMzA_3aa1d18b-933d-4c48-9a45-e60ecb9448e3"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzItNS0xLTEtNzEzMzA_d754fc9a-e9de-4ea9-ae3a-937e0cfab25a"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzMtMS0xLTEtNzEzMzA_d57fe01a-4397-4b7c-a7d0-d83d139afa43"
      unitRef="number">0.225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzMtMy0xLTEtNzEzMzA_2727d3ee-28f5-42cd-b186-42c401635cad"
      unitRef="number">0.209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzMtNS0xLTEtNzEzMzA_21acc4d6-310b-45db-8130-de0e68b9851b"
      unitRef="number">0.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzQtMS0xLTEtNzEzMzA_a17c150a-d959-4b29-9605-24351b6b7545">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzQtMy0xLTEtNzEzMzA_0a9ebe4b-8cc9-4c28-961f-234e36c23de5">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTplYzZkYzliNmYyMmU0ZTM5YWEzN2ZmZmI0OWFjNjdlNi90YWJsZXJhbmdlOmVjNmRjOWI2ZjIyZTRlMzlhYTM3ZmZmYjQ5YWM2N2U2XzQtNS0xLTEtNzEzMzA_f251f31a-53f9-4142-bd95-44693f812856">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUxMDU_2666522a-c988-4ec4-a03b-ace4351d1efa">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information relative to stock option plan activity (options in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(6,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;60.77&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;73.11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,719&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;70.55&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;13,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;70.09&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;539&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercisable December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzEtMS0xLTEtNzEzMzA_793dd456-be58-450d-a736-16b40606f8de"
      unitRef="shares">18572000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzEtMy0xLTEtNzEzMzA_a31fcb3b-77d9-4cf6-bd7b-bd23bc615764"
      unitRef="usdPerShare">65.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzItMS0xLTEtNzEzMzA_70038516-08a8-4dca-9e9e-73004fc46a06"
      unitRef="shares">2326000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzItMy0xLTEtNzEzMzA_965ef1ae-6968-4100-b220-2e46b8a96e70"
      unitRef="usdPerShare">87.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzMtMS0xLTEtNzEzMzA_9bf47b74-9d15-46d8-aecf-404992fe64ed"
      unitRef="shares">6317000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzMtMy0xLTEtNzEzMzA_ec7b45ca-310d-41ea-b406-0b4b93714635"
      unitRef="usdPerShare">60.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzQtMS0xLTEtNzEzMzA_d5499a1a-e6dc-4874-953a-d7f60df02c26"
      unitRef="shares">862000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzQtMy0xLTEtNzEzMzA_58beffdc-0ee2-4553-9f21-4ac11176caef"
      unitRef="usdPerShare">73.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctMS0xLTEtNzEzMzA_f89635bf-041f-4c32-beda-f5aaeaf9c3f6"
      unitRef="shares">13719000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctMy0xLTEtNzEzMzA_e4ce61b5-3a3f-4480-9b8a-0221507b8e0c"
      unitRef="usdPerShare">70.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctNS0xLTEtNzEzMzA_91f73d66-f160-40dc-8d47-c0c2b4e99151">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzctNy0xLTEtNzEzMzA_d38012c7-9f0a-4748-b4b8-d7ccee90ccfe"
      unitRef="usd">554000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtMS0xLTEtNzEzMzA_bd6c7830-ad03-473a-8d7c-1ddc663bd8da"
      unitRef="shares">13199000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtMy0xLTEtNzEzMzA_eb81a693-a754-4062-8b45-d011db54aa67"
      unitRef="usdPerShare">70.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtNS0xLTEtNzEzMzA_284bc489-2de0-4983-bd1d-4fb087eae603">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzgtNy0xLTEtNzEzMzA_6db9fc09-9905-42f2-8e3b-6c4cc36ef859"
      unitRef="usd">539000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktMS0xLTEtNzEzMzA_fe518bba-31db-4581-a09e-dd6e5b0b7330"
      unitRef="shares">8730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktMy0xLTEtNzEzMzA_c60c4735-e16e-4e01-ba9c-74590f3d87a2"
      unitRef="usdPerShare">65.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktNS0xLTEtNzEzMzA_1df8aa50-f6a7-4bb3-9449-ba270e8efcb9">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpjYmU5NjI1ZWU3NTA0NzFiYTBkYTMzNzgxOWMyZDIwYy90YWJsZXJhbmdlOmNiZTk2MjVlZTc1MDQ3MWJhMGRhMzM3ODE5YzJkMjBjXzktNy0xLTEtNzEzMzA_a7b01bd2-a971-4934-85c6-543af2365674"
      unitRef="usd">399000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwODk_aa81b7de-0146-4f1c-baca-386ec5b87115">&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additional information pertaining to stock option plans is provided in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of stock options vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;384&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzEtMS0xLTEtNzEzMzA_cbf7aa4a-5d42-4adb-a03a-8a8797b3b3f8"
      unitRef="usd">225000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzEtMy0xLTEtNzEzMzA_e7d4d1d3-ff70-4cf3-86c2-91114861dc81"
      unitRef="usd">106000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzEtNS0xLTEtNzEzMzA_b7d2fb38-2d24-40e5-b447-d94c9117ddcc"
      unitRef="usd">51000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzItMS0xLTEtNzEzMzA_5282a629-f1f8-4efe-b1ee-edb20debd0ea"
      unitRef="usd">30000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzItMy0xLTEtNzEzMzA_23398896-66bb-47f9-8190-71ecf0127534"
      unitRef="usd">27000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzItNS0xLTEtNzEzMzA_37fb3617-c5b6-4709-875b-0c5f97f34451"
      unitRef="usd">25000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzMtMS0xLTEtNzEzMzA_1dd1578f-35d0-4d2c-b63f-200325be05a0"
      unitRef="usd">384000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzMtMy0xLTEtNzEzMzA_e94ed1e8-ef95-4eff-857b-022a5aba5e9c"
      unitRef="usd">202000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTpiYWYwODA2YzkxNmM0NmNjYjEzZGFlNjE1YzhiZDAzZS90YWJsZXJhbmdlOmJhZjA4MDZjOTE2YzQ2Y2NiMTNkYWU2MTVjOGJkMDNlXzMtNS0xLTEtNzEzMzA_18df39cc-0141-4759-ad1c-4b900c466a40"
      unitRef="usd">89000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzUwOTA_28663f6d-724b-41bb-9b54-87e17723f008">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nonvested January 1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;88.52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(5,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;75.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(725)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;87.87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;77.58&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nonvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;81.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected to vest December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;80.96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,895&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;78.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ied7d80ed2ab14e968047a6b71fb4fea8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItMi0xLTEtNzEzMzA_af3e041f-1338-45b2-8fc6-5c097bd895cc"
      unitRef="shares">11790000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ied7d80ed2ab14e968047a6b71fb4fea8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItNC0xLTEtNzEzMzA_2d5cf224-11e5-4316-9261-3bc4edfc6c66"
      unitRef="usdPerShare">74.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if85a36eaa81c4367aeafea1a95984d7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItNi0xLTEtNzEzMzA_41bf4976-ddab-4d11-a5f2-939439e972cb"
      unitRef="shares">1966000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if85a36eaa81c4367aeafea1a95984d7c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzItOC0xLTEtNzEzMzA_b00c799e-2385-4405-94e2-52c6a54ce062"
      unitRef="usdPerShare">77.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtMi0xLTEtNzEzMzA_1e009671-494e-40a9-aa8b-5deaa74d3ac6"
      unitRef="shares">7170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtNC0xLTEtNzEzMzA_fb2b9b96-42c1-4880-a3f8-4e526da92d63"
      unitRef="usdPerShare">87.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtNi0xLTEtNzEzMzA_d2890675-7d58-469a-ae74-90a13611d2cc"
      unitRef="shares">951000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzMtOC0xLTEtNzEzMzA_3591c04f-79cf-4b8a-85b5-49786bcc7fdd"
      unitRef="usdPerShare">88.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtMi0xLTEtNzEzMzA_8da7925d-d1c4-40ab-ac98-3bec7d731d98"
      unitRef="shares">5150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtNC0xLTEtNzEzMzA_deb49693-2f64-4c3e-a3a0-1f865133941b"
      unitRef="usdPerShare">75.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtNi0xLTEtNzEzMzA_a736fe22-833c-4888-a242-a0fca3f9953b"
      unitRef="shares">725000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzQtOC0xLTEtNzEzMzA_e0a8afde-fb7a-464d-b0ec-be314a11d030"
      unitRef="usdPerShare">87.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtMi0xLTEtNzEzMzA_f50b4868-ed78-43f7-ba80-017b01c61911"
      unitRef="shares">1110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iae6da6d8b8f94ee2a827e3307e608fcc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtNC0xLTEtNzEzMzA_ccbfae23-d1a0-4ad5-b435-4a23706a1c24"
      unitRef="usdPerShare">78.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtNi0xLTEtNzEzMzA_9fba08eb-7a80-42eb-9efe-15915d471156"
      unitRef="shares">171000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if3dca2b7d25444aba66bbd3630da9252_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzUtOC0xLTEtNzEzMzA_2882a042-a3dc-4a12-8827-ca6d37bd7405"
      unitRef="usdPerShare">77.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtMi0xLTEtNzEzMzA_df12cf21-d884-4444-a146-a722c105ae10"
      unitRef="shares">12700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtNC0xLTEtNzEzMzA_95e580c5-552d-49c3-903e-9538d220688d"
      unitRef="usdPerShare">81.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtNi0xLTEtNzEzMzA_2c921a98-fb95-4442-b657-be092812c470"
      unitRef="shares">2021000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzgtOC0xLTEtNzEzMzA_9b5e9384-2330-4eb7-9e87-7e36ddedbf29"
      unitRef="usdPerShare">78.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber
      contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktMi0xLTEtNzEzMzA_e62e86b9-ad26-4b35-af9b-86a44ec38acc"
      unitRef="shares">11254000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="i05aa65f0a24d4c608a963845531c19d3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktNC0xLTEtNzEzMzA_03a75c40-bdf0-4dab-997b-6ece74cf5b92"
      unitRef="usdPerShare">80.96</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber
      contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktNi0xLTEtNzEzMzA_56775421-abf7-4c27-8c9e-804b43fc59d0"
      unitRef="shares">1895000</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber>
    <mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="i35f05e64cc234f2facc385938bb0d4e8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90YWJsZTo4OGFmNGNjYWJkYWU0OWZlOGU3OGQyMjk0MzVmMzQ0OS90YWJsZXJhbmdlOjg4YWY0Y2NhYmRhZTQ5ZmU4ZTc4ZDIyOTQzNWYzNDQ5XzktOC0xLTEtNzEzMzA_e68609f8-873d-4e35-b659-a3cda59ac0e9"
      unitRef="usdPerShare">78.26</mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzQ4MjE_f3819b0f-ee4a-40bf-87f0-47764c2741f8"
      unitRef="usd">813000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xODQvZnJhZzpjNjQwYzZiYjE1Yzg0ZmMyYWE4Njc1OWRiZWE4Njg0Ni90ZXh0cmVnaW9uOmM2NDBjNmJiMTVjODRmYzJhYTg2NzU5ZGJlYTg2ODQ2XzQ5ODg_e599ccf9-c4e3-4319-b4e1-371fddcc903e">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzk0MTA_91f5b8d3-d4ad-4972-ba5c-5d649813cec6">Pension and Other Postretirement Benefit Plans&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S.&#160;retirees and their dependents, through its other postretirement benefit plans. The Company uses December&#160;31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&#160;Postretirement&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with restructuring actions (see Note&#160;6), termination charges were recorded in 2022, 2021 and 2020 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (see Note&#160;15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; if related to the spin-off of Organon (each as noted above).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Obligations and Funded Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Actuarial (gains) losses primarily reflect changes in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, the accumulated benefit obligation was $17.2 billion and $24.9 billion, respectively, for all pension plans, of which $9.7 billion and $13.8 billion, respectively, related to U.S. pension plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Information related to the funded status of selected pension plans at December 31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension plans with a projected benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension plans with an accumulated benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;948&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December&#160;31, 2022 and 2021, $765 million and $943 million, respectively, or approximately 4% of the Company&#x2019;s pension investments were categorized as Level&#160;3 assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s pension plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,443&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,422&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other fixed income obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The plans&#x2019; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#x2019;s pension plan assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets sold during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;257&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has established investment guidelines for its U.S.&#160;pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company&#x2019;s U.S.&#160;pension and other postretirement benefit plans is allocated 25% to 40% in U.S.&#160;equities, 10% to 20% in international equities, 35% to 45% in fixed-income investments, and up to 8% in cash and other investments. The portfolio&#x2019;s equity weighting is consistent with the long-term nature of the plans&#x2019; benefit obligations. The expected annual standard deviation of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;returns of the target portfolio, which approximates 10%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international&#160;pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S.&#160;equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expected Contributions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contributions during 2023 are expected to be approximately $270 million for U.S. pension plans, approximately $150 million for international pension plans and approximately $20 million for other postretirement benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expected Benefit Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&#160;&#x2014;&#160;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amounts Recognized in Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Postretirement&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (loss) gain arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (cost) credit arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service credit amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements and curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Actuarial Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Pension&#160;and&#160;Other&lt;br/&gt;Postretirement&#160;Benefit&#160;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan&#x2019;s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company&#x2019;s U.S. pension and other postretirement benefit plans will be 7.00%, as compared to 6.70% in 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The health care cost trend rate assumptions for other postretirement benefit plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year that the trend rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Savings Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee&#x2019;s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2022, 2021 and 2020 were $175 million, $158 million and $158 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNjI_1fa5578b-528e-43d8-84d3-7b7ad0268586">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the&#160;following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&#160;Postretirement&#160;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMS0xLTEtNzEzMzA_2be52c05-07ef-4d14-8aa0-0c3df83bd460"
      unitRef="usd">372000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMy0xLTEtNzEzMzA_77941cb8-e5cf-47bb-8560-fff0ebdc5d61"
      unitRef="usd">403000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtNS0xLTEtNzEzMzA_a0af8945-fdfa-41a8-888c-c26d13891e66"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtNy0xLTEtNzEzMzA_921890dd-5811-4df2-bc86-6739ca75f14f"
      unitRef="usd">283000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtOS0xLTEtNzEzMzA_f55dce62-bf95-4292-b846-0cd88994187b"
      unitRef="usd">328000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTEtMS0xLTcxMzMw_fddb3fdb-74cb-4ec4-9df5-6ad15e858290"
      unitRef="usd">297000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTMtMS0xLTcxMzMw_b17993b2-a4f9-4643-b23a-004f6101250c"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTUtMS0xLTcxMzMw_acb5c3ec-97f0-4c96-aefe-abf95adf35c6"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzMtMTctMS0xLTcxMzMw_0576b0b5-4a52-41f6-9000-f09b92f7cf56"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMS0xLTEtNzEzMzA_02c633aa-e079-4a68-b906-757ad23b2069"
      unitRef="usd">457000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMy0xLTEtNzEzMzA_c68eb6ee-5849-4f60-9b29-58fdd82af6db"
      unitRef="usd">404000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtNS0xLTEtNzEzMzA_4edba5fc-5e53-46cf-b897-e6ac25b5f805"
      unitRef="usd">431000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtNy0xLTEtNzEzMzA_fd6dc5bf-d9d5-45fd-ab28-4e12c4312d1a"
      unitRef="usd">145000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtOS0xLTEtNzEzMzA_22346e5c-2862-40b3-b19a-7339f61b549f"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTEtMS0xLTcxMzMw_ca4216d6-c276-4cb3-a5aa-067e26b574ec"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTMtMS0xLTcxMzMw_5f67eb89-0ef8-4d59-94c3-b889696ab062"
      unitRef="usd">46000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTUtMS0xLTcxMzMw_c44e4753-3a54-4f66-a6c6-a23cc348173a"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzQtMTctMS0xLTcxMzMw_90d4ef4d-e3db-4bb0-931a-881fb840197b"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMS0xLTEtNzEzMzA_34ca24c5-1d17-49df-83fd-605e5da74d34"
      unitRef="usd">753000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMy0xLTEtNzEzMzA_1b8aef5b-3a88-49da-b1bb-bc5f3c5d6962"
      unitRef="usd">755000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtNS0xLTEtNzEzMzA_c0e57edc-8782-489e-9123-bc5c62101ad6"
      unitRef="usd">774000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtNy0xLTEtNzEzMzA_80e11aab-0ae6-4a42-aaa7-3852b5681953"
      unitRef="usd">383000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtOS0xLTEtNzEzMzA_31633eb2-ce0b-4c49-b9f9-ad861d08afbf"
      unitRef="usd">416000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTEtMS0xLTcxMzMw_f478cb27-1bfd-45ec-800b-d6a72e3bc4d1"
      unitRef="usd">414000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTMtMS0xLTcxMzMw_8fb236b8-c1c5-4a90-955f-e6c9531edfed"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTUtMS0xLTcxMzMw_9aa8b645-53c7-436e-b495-553030450219"
      unitRef="usd">79000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzUtMTctMS0xLTcxMzMw_d357d8c1-6860-41f2-9598-9fed8676f327"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMS0xLTEtNzEzMzA_a477c02b-4eb6-46ad-b978-5513c53609dd"
      unitRef="usd">-32000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMy0xLTEtNzEzMzA_15129830-89c1-474b-b0c8-b366c169c18d"
      unitRef="usd">-38000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtNS0xLTEtNzEzMzA_2f9d638b-34ac-449d-b3a9-ad3b533f094a"
      unitRef="usd">-49000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtNy0xLTEtNzEzMzA_0e0fa606-769a-45b0-a3dd-d579a9c3f230"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtOS0xLTEtNzEzMzA_9f7f4411-bfb8-4ad9-a985-3bcc8c1874af"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTEtMS0xLTcxMzMw_5a1f5219-dc76-406a-8d39-5dfbd4602c30"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTMtMS0xLTcxMzMw_979214d5-e21f-4146-b3b1-db6d67c029dd"
      unitRef="usd">-57000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTUtMS0xLTcxMzMw_b4042ad5-808a-4f17-93be-da6066ae1a5a"
      unitRef="usd">-63000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzYtMTctMS0xLTcxMzMw_bdd8165c-8012-4437-b565-0ce26ebc7dac"
      unitRef="usd">-73000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMS0xLTEtNzEzMzA_d26c777d-d45e-4fac-a057-b85a116f94b7"
      unitRef="usd">-128000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMy0xLTEtNzEzMzA_62808269-fe11-4850-9adc-6040e942bb3f"
      unitRef="usd">-298000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctNS0xLTEtNzEzMzA_2d51042a-3fc2-41d5-9650-6f9c9797fd83"
      unitRef="usd">-303000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctNy0xLTEtNzEzMzA_75bb3f35-404e-4fbd-9fac-c5a07477a435"
      unitRef="usd">-96000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctOS0xLTEtNzEzMzA_cdd85c21-249e-4a7f-8f00-39a3f31ae7bc"
      unitRef="usd">-142000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTEtMS0xLTcxMzMw_79ff4027-b853-4308-b494-5241c4e538c1"
      unitRef="usd">-127000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTMtMS0xLTcxMzMw_2a2b49f6-bc1f-4080-9dc9-2b28b540ce06"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTUtMS0xLTcxMzMw_7b0fd182-64d3-4137-851e-763398a3640d"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzctMTctMS0xLTcxMzMw_b51dfd16-f945-4978-ab60-979e09623a68"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMS0xLTEtNzEzMzA_71e2b92c-10e1-489f-aaf3-438f671d0c33"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMy0xLTEtNzEzMzA_6e4f3906-1e51-4e98-b15c-e9aec547d483"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtNS0xLTEtNzEzMzA_bea5a9a1-16e9-4d72-9803-2920b2bd9faa"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtNy0xLTEtNzEzMzA_b98c366c-a857-4839-9d19-fba1cb19caea"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtOS0xLTEtNzEzMzA_466ff940-ddf9-4dac-ba06-b7cf509e9aab"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTEtMS0xLTcxMzMw_f78f9a74-ce2c-47bf-8315-9ffcfe9dbe0e"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTMtMS0xLTcxMzMw_6b48ac4c-f03c-40a0-bcb4-04c9a8aabcc8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTUtMS0xLTcxMzMw_cf54d69d-a03c-45e3-b87e-a620f9e3a400"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzgtMTctMS0xLTcxMzMw_1ed5e225-2c1b-4f1d-a92f-f39329e06f9c"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMS0xLTEtNzEzMzA_a81c61e7-495b-43db-8373-789889fe816e"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMy0xLTEtNzEzMzA_7b229305-b571-4665-bb43-334c49e00e86"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktNS0xLTEtNzEzMzA_66bccd26-29b8-4eda-92b9-a17580732568"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktNy0xLTEtNzEzMzA_91405f57-e53d-478a-b0f7-6f774ea19302"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktOS0xLTEtNzEzMzA_f9e0bb2a-4b13-4f6a-968b-e03e19c9b7e9"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTEtMS0xLTcxMzMw_8d31c4ed-9b22-441d-898d-b617f8555fd6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTMtMS0xLTcxMzMw_3c4e2ebc-f5ee-4ba0-bf9f-3f9d845447d5"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTUtMS0xLTcxMzMw_e3b4a4ee-537a-45d3-ac94-915a215669b9"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzktMTctMS0xLTcxMzMw_91271b80-f21d-4584-b9da-b254b6b647b0"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTEtMS0xLTcxMzMw_c9adfcef-5b6f-4e52-8c29-65c072f6b42d"
      unitRef="usd">-239000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTMtMS0xLTcxMzMw_a25c39a7-dcae-423a-86b2-ebebe46b0cbd"
      unitRef="usd">-216000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTUtMS0xLTcxMzMw_8e472a46-a087-48c8-992c-a5614b10522f"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTctMS0xLTcxMzMw_ad7a5875-b4f9-448d-8f10-a856c05ce480"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTktMS0xLTcxMzMw_6f9480a3-502b-4561-9a69-1654a88d5c7f"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTExLTEtMS03MTMzMA_f0eb6b2f-bcb9-4757-81e3-eb3ec5c033ad"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTEzLTEtMS03MTMzMA_08a545c5-82bd-460c-8d6c-80ada50d4380"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTE1LTEtMS03MTMzMA_e167698e-8e95-4fe7-8485-8186ef9e2ccc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzEwLTE3LTEtMS03MTMzMA_238ca565-1bb7-4e41-a376-79502761c3a7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTEtMS0xLTcxMzMw_b50dc571-9545-487e-ad93-bd2dc6a3d88c"
      unitRef="usd">425000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTMtMS0xLTcxMzMw_b2dc2722-f84b-46c5-b13d-c52e10096f5f"
      unitRef="usd">600000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTUtMS0xLTcxMzMw_6d4ecc5c-0148-4c6a-be93-6197114b1e7d"
      unitRef="usd">304000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTctMS0xLTcxMzMw_1b7c1d29-8130-4e7e-91cb-9728cd9e819d"
      unitRef="usd">129000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTktMS0xLTcxMzMw_962f01d9-1879-4335-8ff6-f95e734560a2"
      unitRef="usd">148000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTExLTEtMS03MTMzMA_88688c76-62d6-4977-a163-0b46e067d590"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTEzLTEtMS03MTMzMA_dd3ba924-619f-46e2-925a-835b1b9897b2"
      unitRef="usd">-93000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTE1LTEtMS03MTMzMA_195bbddf-4bff-4f00-b146-315bcc346318"
      unitRef="usd">-83000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTplYjYwNWMyODBiMjE0OWQ5OTJmZWNkYjNmYjE3MWQ0NC90YWJsZXJhbmdlOmViNjA1YzI4MGIyMTQ5ZDk5MmZlY2RiM2ZiMTcxZDQ0XzExLTE3LTEtMS03MTMzMA_84d1b144-7c44-4e09-8abb-99af19c78eb2"
      unitRef="usd">-59000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNDk_6be1fbdf-f6ee-4615-b7c8-6d81f918be17">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December&#160;31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effects of exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,052&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Actuarial (gains) losses primarily reflect changes in discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtMS0xLTEtNzEzMzA_9957a551-908c-4f8a-8616-377ca374a1aa"
      unitRef="usd">13067000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8cb6182a68904c0fa3a216d4c959472b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtMy0xLTEtNzEzMzA_45127265-af47-453c-a3e3-df71b21bffa7"
      unitRef="usd">12672000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtNS0xLTEtNzEzMzA_e5bc78db-f4a4-482b-bfcf-b0ca0c8fdc9d"
      unitRef="usd">12195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtNy0xLTEtNzEzMzA_f70a29a2-88c2-423d-967a-81cb002dd816"
      unitRef="usd">12009000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtOS0xLTEtNzEzMzA_ea8b5084-aef2-4683-8a32-b72c41caa022"
      unitRef="usd">1292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id1539f9d21d0436d90ee19b2d83cb5bf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzMtMTEtMS0xLTcxMzMw_9435488e-cf71-4385-a55d-69093121afaf"
      unitRef="usd">1221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtMS0xLTEtNzEzMzA_2163fa9e-ff0a-451a-b00f-ee09119fd90b"
      unitRef="usd">-3129000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtMy0xLTEtNzEzMzA_cbd4fa89-96de-4a75-b6ad-f28860aecb15"
      unitRef="usd">1250000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtNS0xLTEtNzEzMzA_78053e4f-e642-4625-b6b5-ec6b9f17cf58"
      unitRef="usd">-2793000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtNy0xLTEtNzEzMzA_9a522687-0b9c-46d8-b2b8-1bbc2b38cabf"
      unitRef="usd">891000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtOS0xLTEtNzEzMzA_fbafd2d0-af19-4d2d-8004-72b88cf40528"
      unitRef="usd">-306000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzQtMTEtMS0xLTcxMzMw_fa26d348-0244-4387-9cbe-21d32f1ef282"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtMS0xLTEtNzEzMzA_8411c0b5-acd1-4bb7-8b1a-65cc7fbb5add"
      unitRef="usd">293000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtMy0xLTEtNzEzMzA_d6b7aa64-18e8-4cb5-be75-4903e157cd71"
      unitRef="usd">305000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtNS0xLTEtNzEzMzA_5e48b8ef-d823-4ce0-b4ca-b8c71304e838"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtNy0xLTEtNzEzMzA_54585e32-24c5-4e27-8d14-ceb6f674a3f0"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtOS0xLTEtNzEzMzA_55389831-fc9b-42e7-9b78-481d61c92c42"
      unitRef="usd">46000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzUtMTEtMS0xLTcxMzMw_bfe86202-9a7c-4ae5-8975-1e0c9bf24632"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtMS0xLTEtNzEzMzA_fab97af9-8772-4332-8781-dc6f13175a3b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtMy0xLTEtNzEzMzA_03fab23e-0583-48b9-8770-16549cb80afd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtNS0xLTEtNzEzMzA_893d00a5-88ae-4369-82c7-844c6613241e"
      unitRef="usd">-848000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtNy0xLTEtNzEzMzA_7e594469-aaf1-4565-bcd3-5044d8e4e74e"
      unitRef="usd">-671000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtOS0xLTEtNzEzMzA_0ce28b5b-0bd3-49cd-8a66-006211b88854"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzYtMTEtMS0xLTcxMzMw_1bba62a2-df59-49d7-aaca-c6fce7d3753d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctMS0xLTEtNzEzMzA_4e8b87ea-710a-4a87-be65-c031a2db83c7"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctMy0xLTEtNzEzMzA_2ecbfdc8-92b8-48af-8637-9b44bd5c66b4"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctNS0xLTEtNzEzMzA_84c29e59-2eec-4517-b19e-346145bb87a0"
      unitRef="usd">250000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctNy0xLTEtNzEzMzA_dbb4e5c7-140b-4135-831a-651667e82873"
      unitRef="usd">233000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctOS0xLTEtNzEzMzA_3961136a-393c-48bd-9ebe-1fc38cc16790"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzctMTEtMS0xLTcxMzMw_7052e4c1-6219-4433-ac33-a4de5b529eba"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtMS0xLTEtNzEzMzA_942b2c3d-bace-41cf-8d26-0f56d4030e48"
      unitRef="usd">918000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtMy0xLTEtNzEzMzA_f4cbecde-c157-4ffa-b6db-31b62adcb9a9"
      unitRef="usd">941000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtNS0xLTEtNzEzMzA_55c0cf4f-f948-4139-97aa-90cac28acd85"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtNy0xLTEtNzEzMzA_51b250b7-50e1-4f25-9158-b4dc1f0a713f"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtOS0xLTEtNzEzMzA_45bef811-3156-45ae-ab04-e8f0bb37930a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzgtMTEtMS0xLTcxMzMw_2b3d0367-3039-4839-92af-605218e6fdb8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktMS0xLTEtNzEzMzA_e786ff96-9d65-440c-97d3-4bd61d976cde"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktMy0xLTEtNzEzMzA_2897498c-9abb-4db7-a400-884a8bd4fcf2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktNS0xLTEtNzEzMzA_b8671166-aa98-4ce9-9bc7-081ab99049c9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktNy0xLTEtNzEzMzA_f58c3702-ec6c-446e-8949-82e8a8023abe"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktOS0xLTEtNzEzMzA_c99c500c-2af8-45d5-bcf5-90b6726862f7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzktMTEtMS0xLTcxMzMw_7636ecd5-66d1-4785-a7fd-76615c7e5d58"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTEtMS0xLTcxMzMw_8fb485b3-ef70-4600-a704-aa9969770b41"
      unitRef="usd">0</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTMtMS0xLTcxMzMw_432fe325-b03c-4c33-b282-b726ad737ca3"
      unitRef="usd">0</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTUtMS0xLTcxMzMw_20d282c5-321c-4d4d-9c1b-3b3d435f472d"
      unitRef="usd">30000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTctMS0xLTcxMzMw_f25d536c-2942-43ab-a9cd-3113be68ba61"
      unitRef="usd">120000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTktMS0xLTcxMzMw_4b32c5e0-675b-4ddc-a164-e56cb5052a3c"
      unitRef="usd">5000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <mrk:DefinedBenefitPlanOtherChangesPlanAssets
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEwLTExLTEtMS03MTMzMA_5f51c5ea-5399-435a-a791-09ffb6dddce7"
      unitRef="usd">6000000</mrk:DefinedBenefitPlanOtherChangesPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTEtMS0xLTcxMzMw_7676cb40-4767-4ffd-a4c6-5ac6363665a3"
      unitRef="usd">9094000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTMtMS0xLTcxMzMw_e2a7c87e-2e0a-419e-a922-2c1811cc6900"
      unitRef="usd">13067000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTUtMS0xLTcxMzMw_3da60748-38b2-45fe-8a9c-c0556ae95fc4"
      unitRef="usd">8473000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTctMS0xLTcxMzMw_090c75c9-7caa-456b-95a9-70e98d9ecf31"
      unitRef="usd">12195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTktMS0xLTcxMzMw_06e84b3c-c51a-45a0-aa9a-139c98e52bb1"
      unitRef="usd">947000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzExLTExLTEtMS03MTMzMA_00262865-d24f-4b17-bfe2-1a220c258656"
      unitRef="usd">1292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTEtMS0xLTcxMzMw_be466ec3-4852-4aeb-b108-80c134a93613"
      unitRef="usd">13999000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i8cb6182a68904c0fa3a216d4c959472b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTMtMS0xLTcxMzMw_6f3aa9a8-b85a-47a7-8184-726ca45f76bd"
      unitRef="usd">14613000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTUtMS0xLTcxMzMw_44d65e06-0da8-4169-92f6-a43c06518530"
      unitRef="usd">11575000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTctMS0xLTcxMzMw_938dc850-8d43-404f-a388-9e4359c2af25"
      unitRef="usd">12458000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTktMS0xLTcxMzMw_0f522619-5f51-4846-9bc9-864d10ba5d5f"
      unitRef="usd">1541000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="id1539f9d21d0436d90ee19b2d83cb5bf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEyLTExLTEtMS03MTMzMA_bb3e2303-1883-4a4a-9685-1409db6bac52"
      unitRef="usd">1607000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTEtMS0xLTcxMzMw_b0eeeb16-f820-4f3c-9dc8-8a7843755d1b"
      unitRef="usd">372000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTMtMS0xLTcxMzMw_c1c0c224-1b07-4a33-960d-4e9046626b00"
      unitRef="usd">403000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTUtMS0xLTcxMzMw_e2d9ddb3-1573-4fa6-b5ad-898656bf9d53"
      unitRef="usd">283000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTctMS0xLTcxMzMw_b55fb00f-d20c-40fa-ab4a-f299e583b656"
      unitRef="usd">328000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTktMS0xLTcxMzMw_d6c08c62-36de-4601-8d3a-7054f739bd98"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzEzLTExLTEtMS03MTMzMA_e53ab960-23e1-48a2-92b9-b4ab3e0075f4"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTEtMS0xLTcxMzMw_430f55df-b3f8-4f8e-bb2d-9278db777416"
      unitRef="usd">457000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTMtMS0xLTcxMzMw_a3348644-c8f7-4cfc-9b78-3d2b7af25973"
      unitRef="usd">404000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTUtMS0xLTcxMzMw_d158f123-9d99-4338-aef9-b34cbb5c8109"
      unitRef="usd">145000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTctMS0xLTcxMzMw_45de84df-935f-4db6-ad13-88ec258dd80b"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTktMS0xLTcxMzMw_ba873bf4-9075-4dbb-9430-1eda96f2eb12"
      unitRef="usd">46000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE0LTExLTEtMS03MTMzMA_f32fab1b-e150-4b80-8276-5a9f46dd7dd3"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTEtMS0xLTcxMzMw_2da189b9-a810-48a0-aab3-e5b24fe5341d"
      unitRef="usd">3851000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTMtMS0xLTcxMzMw_1b014fce-4c90-4c55-b280-999f228f708c"
      unitRef="usd">332000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTUtMS0xLTcxMzMw_29c91a60-d00c-4a3c-b1d2-8cbfa2c3e535"
      unitRef="usd">3283000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTctMS0xLTcxMzMw_eed92ea1-4d55-4f81-92df-933c249f5028"
      unitRef="usd">240000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTktMS0xLTcxMzMw_3da90748-5330-45fd-a33c-426ce987f8b3"
      unitRef="usd">392000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE1LTExLTEtMS03MTMzMA_c72102ef-3962-41f5-bbd0-0fc8d29ee4c2"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTEtMS0xLTcxMzMw_3c15f740-8619-462f-846e-faa84f1349d3"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTMtMS0xLTcxMzMw_16abfcfb-d188-4a20-9e19-f972fef56388"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTUtMS0xLTcxMzMw_751e4ffa-0842-4f64-bbe8-5bf608046951"
      unitRef="usd">250000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTctMS0xLTcxMzMw_aee7b597-6be0-4d5d-aef8-81cdbc2cde10"
      unitRef="usd">233000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTktMS0xLTcxMzMw_6f67d07b-840a-4f94-b6f9-970962cee613"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE2LTExLTEtMS03MTMzMA_168fe9b7-1dd0-4599-b902-50f78a2f2ed5"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTEtMS0xLTcxMzMw_c5bc5043-ffe0-4013-874c-50cc4372115a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTMtMS0xLTcxMzMw_2d1fd7ed-4e55-4440-bb77-0c700c31d4c8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTUtMS0xLTcxMzMw_0e49ab55-e2be-4e8e-a62e-96b56f53096a"
      unitRef="usd">-732000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTctMS0xLTcxMzMw_22b34944-e980-4e92-b69a-bc80ee9bde7a"
      unitRef="usd">-678000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTktMS0xLTcxMzMw_532c966f-2f8b-490d-9445-db7904c444e5"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE3LTExLTEtMS03MTMzMA_d138993f-f4bb-4225-afad-12195ddc67b4"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTEtMS0xLTcxMzMw_c3245b6d-d9c9-42fc-b646-0d4f98f38599"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTMtMS0xLTcxMzMw_5505bdb8-da3e-4139-94b7-fc0e86492ac3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTUtMS0xLTcxMzMw_13c393be-f80f-4477-b08e-166f9e36055c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTctMS0xLTcxMzMw_d501d9c1-4c9b-43ad-9976-66ee5098e14e"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTktMS0xLTcxMzMw_76e5fbef-f70e-4f6a-81e9-06e3b52fb3d5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE4LTExLTEtMS03MTMzMA_5b34764d-b970-4db3-8a5a-0c5010cbce20"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTEtMS0xLTcxMzMw_ca0dd1f3-623c-4c75-87d6-4ee4225d77da"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTMtMS0xLTcxMzMw_9163215d-fe08-4e72-ade0-b396318e517e"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTUtMS0xLTcxMzMw_6ceb475f-a5c5-4ebd-8c00-773c947ff162"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTctMS0xLTcxMzMw_cfc3fcb7-25c1-4e2b-be8b-2382915e5882"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTktMS0xLTcxMzMw_7dfa2c96-45d7-47fd-97ae-78f370a0533f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzE5LTExLTEtMS03MTMzMA_1467b4ba-4778-4256-9926-d5fa3a6b4831"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTEtMS0xLTcxMzMw_e3f82055-0f79-4786-bd0c-8546d4f513f9"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTMtMS0xLTcxMzMw_ca543329-0de3-4d95-8f2b-62c602ef59fd"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTUtMS0xLTcxMzMw_405c1079-5984-4ce7-8326-5a7049dc6929"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTctMS0xLTcxMzMw_2fbf674c-2445-40d1-8f25-364d6fb98309"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTktMS0xLTcxMzMw_71b61770-beb3-4086-98e8-2094d8ff0326"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIwLTExLTEtMS03MTMzMA_2d292f8d-2f38-4f85-a43f-dd6737e48c96"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTEtMS0xLTcxMzMw_ff1dae80-825d-4392-961e-459f22e50b8e"
      unitRef="usd">918000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTMtMS0xLTcxMzMw_8bccffc1-5adc-44c8-b4c5-c6b7f978a4b6"
      unitRef="usd">941000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTUtMS0xLTcxMzMw_736edc51-7e73-4eb4-87be-445d48f435d6"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTctMS0xLTcxMzMw_32aba912-3720-4845-88dd-394d1fc582d5"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTktMS0xLTcxMzMw_d548b7bb-e0c9-4059-b4ff-d207ab268418"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIxLTExLTEtMS03MTMzMA_16ba2687-2c16-4014-84fe-ecca92853c25"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTEtMS0xLTcxMzMw_8fa0f0a1-96a1-4fe7-9f4c-14b6718d4e75"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTMtMS0xLTcxMzMw_62805226-2f61-4db0-93e5-b47de599f0b3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTUtMS0xLTcxMzMw_154a90d7-e14e-4ea3-a21d-ec33a5ebcafa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTctMS0xLTcxMzMw_ab8350af-999b-4eae-ad5b-68206e4a1d9f"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTktMS0xLTcxMzMw_83cd71ec-c48e-4f3e-a8c1-912329f33b9f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIyLTExLTEtMS03MTMzMA_7f91b570-c44f-479b-86a7-7866ea98b825"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTEtMS0xLTcxMzMw_8afd656d-cd08-48fe-9d8b-4fc5aa59ce88"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTMtMS0xLTcxMzMw_ab57df4f-c517-4c00-9c1a-ca6f5bb9938e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTUtMS0xLTcxMzMw_c231eb07-e32c-4733-ba8d-becc34488f21"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTctMS0xLTcxMzMw_4e6c4b1f-bc97-45a7-9523-f43dd95657aa"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTktMS0xLTcxMzMw_77f5cf63-a3c9-4a97-b8d9-382b516ca992"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanOtherChanges
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzIzLTExLTEtMS03MTMzMA_1a84a0c6-9299-43ef-bd34-f2c1f9f0ea65"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanOtherChanges>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTEtMS0xLTcxMzMw_f275f865-0004-4e95-87b6-efe82210597d"
      unitRef="usd">9854000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTMtMS0xLTcxMzMw_701c2312-0441-454c-b728-fc056a8066ac"
      unitRef="usd">13999000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTUtMS0xLTcxMzMw_2a9bd0a9-8238-43e7-8de2-cc0d04ae7ee9"
      unitRef="usd">7755000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTctMS0xLTcxMzMw_93984e12-fca3-4a19-aac9-a958bf87604d"
      unitRef="usd">11575000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTktMS0xLTcxMzMw_3d31e20e-3fca-4f75-8a36-9e72dedc5753"
      unitRef="usd">1157000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI0LTExLTEtMS03MTMzMA_205f10bb-b619-442f-bd50-165c8a23ab2c"
      unitRef="usd">1541000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTEtMS0xLTcxMzMw_66957e31-3d61-41f5-a657-523cfec2c8a2"
      unitRef="usd">-760000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTMtMS0xLTcxMzMw_ed1258ae-06e6-440d-a519-52773f0a089c"
      unitRef="usd">-932000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTUtMS0xLTcxMzMw_67cc71fc-30ce-4bee-8614-98582ed19438"
      unitRef="usd">718000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTctMS0xLTcxMzMw_db9e9228-c566-4756-be3e-5153a41de866"
      unitRef="usd">620000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTktMS0xLTcxMzMw_6ed40216-b6d2-41df-927f-a9381ba426d3"
      unitRef="usd">-210000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI1LTExLTEtMS03MTMzMA_598c5e11-f3d6-4591-a983-d029c942c920"
      unitRef="usd">-249000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTEtMS0xLTcxMzMw_a4ae4dfe-197c-45af-851f-0d65144ecdae"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTMtMS0xLTcxMzMw_312f9d12-1c1a-4122-bd3c-eb6fa7790ac0"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTUtMS0xLTcxMzMw_0a3171ed-2a4f-4b46-9231-b99fb736c362"
      unitRef="usd">1052000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTctMS0xLTcxMzMw_1a750a33-7994-4a98-985d-37a18b95d47f"
      unitRef="usd">1395000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTktMS0xLTcxMzMw_4e068e06-ad6b-4ea1-ad0a-d61012ffc1f9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI3LTExLTEtMS03MTMzMA_a44b642b-1fb1-40c6-b577-bc211929d736"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTEtMS0xLTcxMzMw_0a20f050-e78e-4b3c-9ced-f3946fde123f"
      unitRef="usd">59000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTMtMS0xLTcxMzMw_3625e945-b4c7-4c73-8a4c-f5c9de4a1eab"
      unitRef="usd">64000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTUtMS0xLTcxMzMw_e40032f5-3212-428f-b031-fe7f19d34bfd"
      unitRef="usd">19000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTctMS0xLTcxMzMw_75009d9a-25d0-481e-9e51-59daef551271"
      unitRef="usd">22000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTktMS0xLTcxMzMw_52d3d213-0557-4834-8841-3cbc245accda"
      unitRef="usd">8000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI4LTExLTEtMS03MTMzMA_28761a73-a977-4ee7-8c0e-727ebf59112c"
      unitRef="usd">8000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTEtMS0xLTcxMzMw_15ab90c5-6aee-4415-9b64-1efb83d88d6e"
      unitRef="usd">706000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTMtMS0xLTcxMzMw_100f1d36-1b71-464d-acc5-258036d4cb35"
      unitRef="usd">877000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTUtMS0xLTcxMzMw_e60603de-6085-4216-bb33-5cde88301920"
      unitRef="usd">315000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTctMS0xLTcxMzMw_1c5c8563-bf9b-4247-ad96-e1ca9f0eb0b3"
      unitRef="usd">753000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTktMS0xLTcxMzMw_9dc2caf1-9b4c-48d6-8726-36713a022072"
      unitRef="usd">202000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToyNWI0YTViN2QzZDg0YmZlYTBhNDZkOWE0MjkzNDRlOS90YWJsZXJhbmdlOjI1YjRhNWI3ZDNkODRiZmVhMGE0NmQ5YTQyOTM0NGU5XzI5LTExLTEtMS03MTMzMA_e606e376-0a08-480c-86fa-267e1dc57f63"
      unitRef="usd">241000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzMjE_380cf9e1-0df0-4b8e-a650-b73128bab2a5"
      unitRef="usd">17200000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzMjg_8a45a749-7cb5-41e4-b7b6-26f3e6dc6e4a"
      unitRef="usd">24900000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzNzg_664b1e4e-6497-4a1e-b2e8-2c0fa593ee1e"
      unitRef="usd">9700000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzIzODU_062faa8e-7f2c-42b4-a97e-1a9296e398fc"
      unitRef="usd">13800000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMzA_15b35339-da5c-436d-9cdb-6ae9ce0733ef">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Information related to the funded status of selected pension plans at December 31 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension plans with a projected benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension plans with an accumulated benefit obligation in excess of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;948&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtMS0xLTEtNzEzMzA_7ed9d6c8-4da4-4147-97a1-b1fb3f9e09e5"
      unitRef="usd">9186000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtMy0xLTEtNzEzMzA_39b1d065-4016-4866-82df-8dcf6f1279dd"
      unitRef="usd">13013000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtNS0xLTEtNzEzMzA_dcb6df0e-e3b2-4e14-9963-bfce2bb6be54"
      unitRef="usd">2779000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzMtNy0xLTEtNzEzMzA_61742318-3dca-49ba-9d6d-fd1adb2940e2"
      unitRef="usd">2507000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtMS0xLTEtNzEzMzA_28d5b32c-e11a-4ff0-baf3-82d011c84188"
      unitRef="usd">8421000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtMy0xLTEtNzEzMzA_8e10f35a-c428-4b60-8602-7db800390568"
      unitRef="usd">12072000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtNS0xLTEtNzEzMzA_a2c66be3-0f21-45c3-b178-9a5e92d6bcea"
      unitRef="usd">2445000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzQtNy0xLTEtNzEzMzA_a83fb6f4-72d7-48a4-9d4b-c77bfc4e4cbf"
      unitRef="usd">1731000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtMS0xLTEtNzEzMzA_69d532de-976b-49eb-bf68-ae11ef89fa84"
      unitRef="usd">9081000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtMy0xLTEtNzEzMzA_9f2e9ecb-98b2-4ebc-916d-563f95e84b4b"
      unitRef="usd">12916000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtNS0xLTEtNzEzMzA_4e184796-0ce6-45d6-9d46-0e5d68410cc6"
      unitRef="usd">1226000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzYtNy0xLTEtNzEzMzA_5a32afde-1c8c-40b4-884a-3a74b78cc5cd"
      unitRef="usd">2462000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctMS0xLTEtNzEzMzA_7ddee3a6-82a1-42d6-8fd1-b5f8eb75aefd"
      unitRef="usd">8421000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctMy0xLTEtNzEzMzA_3565f4a6-07d7-456e-b045-7ebdf1aef705"
      unitRef="usd">12072000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctNS0xLTEtNzEzMzA_e9d077bd-83a3-46f3-94aa-41b8d45aa141"
      unitRef="usd">948000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo3NjU4MWNkZGFlODg0ZmNjOGFiMzQ5NGZjMDEzNmE4Ni90YWJsZXJhbmdlOjc2NTgxY2RkYWU4ODRmY2M4YWIzNDk0ZmMwMTM2YTg2XzctNy0xLTEtNzEzMzA_b7551cb4-9408-4e3a-b0ed-9947b1f937ad"
      unitRef="usd">1723000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebb1a8351aa841838361b44de4c7bef0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM1ODA_4b10bf70-5d95-4cb9-ac0d-9b1b05bacb48"
      unitRef="usd">765000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1c3c2b238964beeb4fe2cc7ee98547f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM1ODc_eed9a2e2-cba9-4461-925d-a743cf70c88d"
      unitRef="usd">943000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage
      contextRef="i574b9cef0b2d4bfba6872a7e1206e397_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM2MjI_ba8ddf3c-c251-4952-9f2b-a552916bb1db"
      unitRef="number">0.04</mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage>
    <mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage
      contextRef="i6a26a46ae4f5482dab104697c724f404_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzM2MjI_f1d117a5-1ea2-4bd2-9435-0ad6f8ef821f"
      unitRef="number">0.04</mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNTY_cd0566ad-e268-401e-9903-f708ec9afaa6">&lt;div style="margin-bottom:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s pension plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;147&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,443&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,422&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other fixed income obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The plans&#x2019; Level&#160;3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s other postretirement benefit plan assets at December&#160;31 by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;NAV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;257&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Emerging markets equities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d9eb5934f114a0ea5d847b51acea3e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMS0xLTEtNzEzMzA_915fed4a-4917-42b4-a413-f3cf74e56928"
      unitRef="usd">49000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01435fa53a734b81a8a042035680737d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMy0xLTEtNzEzMzA_7c0ce4bc-f6a3-4645-b381-370543596ed5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7e3d2094305840f097c63ebbc04cedc4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtNS0xLTEtNzEzMzA_b4a15646-dac9-480c-85cf-1458e7b71e61"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3d52da3a5a0c45c3bc80f202edf4ac2b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtNy0xLTEtNzEzMzA_c51d9f8b-83cc-4c88-8a75-f9c48741e45d"
      unitRef="usd">98000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2db1b4d2bd9c40969669b8308c8c2bfc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtOS0xLTEtNzEzMzA_a16e0e93-322c-48e8-9731-df7d34e690c3"
      unitRef="usd">147000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8022a250b1054e89b99021d780f54e3a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTEtMS0xLTcxMzMw_3efa3263-5cb9-4b7a-b804-51e557e20776"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5b6232b3f5be49b195d9d3ebc647e54f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTMtMS0xLTcxMzMw_bf19c3c2-04aa-427b-8eef-1bea9c8b0825"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic44da905f6234e16bc83498f4aa76788_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTUtMS0xLTcxMzMw_075da3a8-0c88-4b1e-baf3-65d3bd5aae38"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1df1024a4cf24b4aaee26f266a7f5311_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTctMS0xLTcxMzMw_84cac3ed-1a47-4ac3-97e4-6ab2b07472aa"
      unitRef="usd">289000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i56ae559c54a246ed8624ac3c291db4ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzQtMTktMS0xLTcxMzMw_56099d35-f326-4cad-a0be-f161e71c4b1a"
      unitRef="usd">292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i848f3f6ab9414064b3b30f280304bf53_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMS0xLTEtNzEzMzA_13d969d7-1705-4c7a-8413-afab588f2886"
      unitRef="usd">211000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2c0a82ed5be4adf90a87892aa7ff607_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMy0xLTEtNzEzMzA_a88ac49d-ada3-4e24-a284-f241432fbde7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i55f277519eb246b7ad1d130d25ceadd5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtNS0xLTEtNzEzMzA_ca702dd6-f341-4b11-8051-df0153b2c535"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic872792688f1452c879827ccb8b53f29_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtNy0xLTEtNzEzMzA_ea16fd30-9ebf-4c2b-8864-8a768484c64a"
      unitRef="usd">2443000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i828d9b689a9a4998aeab58dcb22c19af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtOS0xLTEtNzEzMzA_aa7fd9d8-1d4a-4895-bc85-9bdcb141b537"
      unitRef="usd">2654000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied44e32a46c642a681ff4b0c0b6653d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTEtMS0xLTcxMzMw_0c683bb0-248e-42de-8bb7-1043cbfdbf94"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i71639f6c7cbe47e6a0f521ccb6b05b3f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTMtMS0xLTcxMzMw_959765b6-5630-4f9b-b9dd-03f76bb1746e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibf01f0ea26c74696a3c2fc263ac75d7a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTUtMS0xLTcxMzMw_afdb7436-1f6c-4cad-a43b-04fc51454116"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i82fec81188f1404dad80d2b60480bcf3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTctMS0xLTcxMzMw_f759f687-af5f-4ae9-a371-58e725dad9e9"
      unitRef="usd">3799000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icd533fe7f6474d57ac75249e0844aeff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzYtMTktMS0xLTcxMzMw_dc679a7f-7e2e-4116-bf97-2bf020c9c9b8"
      unitRef="usd">4035000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97b6b2c158a945fbbbdf1d5fa0e98e1c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMS0xLTEtNzEzMzA_6a8fb172-6457-4b0f-bbba-b6f2956003aa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0fc462ae433d483c8e93d9298f863a55_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMy0xLTEtNzEzMzA_665d2366-ac83-44ff-9fd3-e6506cf4e915"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac89e1f592aa4c2dbd20dfdbdfc094c3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctNS0xLTEtNzEzMzA_f711b172-1a5b-460a-a1ff-ecf06c04dddc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica85b54a9c6148748a002d6f700af7b9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctNy0xLTEtNzEzMzA_80c1edc6-19ec-4af7-a356-fae18ec6608b"
      unitRef="usd">707000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1299e9fb62e24c01a38fa23973dc4b86_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctOS0xLTEtNzEzMzA_34f18318-4084-4da4-ba92-ad7d2cd056ee"
      unitRef="usd">707000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i780a5fe64af9456ea212e3e1f7b5e699_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTEtMS0xLTcxMzMw_7367c52c-29e4-453c-ba1d-805f43e540a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i413442eca9f64a4e80a2e82ca894c2d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTMtMS0xLTcxMzMw_a510baf7-a085-4b91-9282-e202aebe97a7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibbc781fa4b494ad0a981a37fc93215ec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTUtMS0xLTcxMzMw_d9b19f44-cbf1-421e-b074-3787bc608bec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i58ee2b762b6b42f9bcb9883b482b84e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTctMS0xLTcxMzMw_f7858f54-cf8f-4cc9-9cf4-e8ace29a5551"
      unitRef="usd">919000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i79ab820615b2409ca822a8463ecc1b8a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzctMTktMS0xLTcxMzMw_718aac0e-14be-400f-a142-8f209e135e5d"
      unitRef="usd">919000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b8e535c106149f6a29ce6dfa87a1b16_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMS0xLTEtNzEzMzA_bb9e8a57-71eb-458b-93a0-5a642acfd300"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieb5a0ac36a4541debd3bd1591b829d44_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMy0xLTEtNzEzMzA_77664087-0b29-4d97-9b9d-55a9b1c77d1c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae76956543ea4116b33a51d411999395_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtNS0xLTEtNzEzMzA_c0b3df81-4b09-4def-9f0f-d3266d520915"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i00f688bf2c244f1f8c8c8453882fdc19_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtNy0xLTEtNzEzMzA_d7d51c2e-f6e6-4c2f-93d8-f61896128f08"
      unitRef="usd">131000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a283bca60094770a190b7b2501d36af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtOS0xLTEtNzEzMzA_b7d16f1f-fff1-4263-92e5-ce283cef1ee4"
      unitRef="usd">131000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80e040b356d6468cacda7ff0c18e4591_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTEtMS0xLTcxMzMw_784f4662-e889-40cb-968e-4bf5ebd79402"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ied6e50be712242db98c4f2730d77ff37_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTMtMS0xLTcxMzMw_7002a31f-96a6-4207-9917-9f87689667ec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i219e6bd79d244a7aa455084fdf94ea31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTUtMS0xLTcxMzMw_2c30a843-6c8d-4876-8329-1f08332f91fe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i13af1fe3667346629b41c84114948a2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTctMS0xLTcxMzMw_57dbabff-fcb4-48e4-a4d3-d1cf816ce85b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e5ed95b785743b59085bf03f11a8494_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzgtMTktMS0xLTcxMzMw_ca6e83b6-edd5-43a4-a4e7-78c39a60da57"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i581419defa34403898493f6ba2fb9935_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTEtMS0xLTcxMzMw_df4c8300-97fd-4221-9bce-dc4593382d76"
      unitRef="usd">1956000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8a561dd7e3cd44c686766ee939d51f32_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTMtMS0xLTcxMzMw_3616ab3c-e1ee-4941-8cac-e1b0be5af88a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia697527e9ee9479b91cf4b0aa0f597a3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTUtMS0xLTcxMzMw_ea565ced-319f-49e2-b6d1-945c02e053e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i68566a927ade4b2496958500664255bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTctMS0xLTcxMzMw_1c99f163-5315-48f0-93b7-5cacb7865850"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54e4c057f83442c6859610dc3378cae9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTktMS0xLTcxMzMw_1f4499aa-31e0-4024-b43a-271fef223da5"
      unitRef="usd">1956000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if9e5e29c38c04370a51a4e41907f7cb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTExLTEtMS03MTMzMA_866ca418-39d5-494b-a520-7296d0a48289"
      unitRef="usd">2915000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i094e594db1c34ab39387886a26d20ef2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTEzLTEtMS03MTMzMA_155e7ecb-3bac-44b6-9b47-dacaf4d24c4c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie604b32af7dc41e2a7c47c6f522d23cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTE1LTEtMS03MTMzMA_a391c21c-09b1-426c-8e97-5300fdf50b57"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i973d00b66e0c460bb172e8acfe0e30e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTE3LTEtMS03MTMzMA_b97cac9f-e5d8-494e-9cdb-84e9080658c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idf57448d49a348f296cd544807eec041_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzExLTE5LTEtMS03MTMzMA_201dd42c-93ab-4928-977d-4159dc659488"
      unitRef="usd">2915000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1def8f4c268e4881aac2d1b076b727ae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTEtMS0xLTcxMzMw_7567cdd5-dbfd-4e8b-963c-1ecbe0a99714"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic55010634a68440fbcb5037b4995212f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTMtMS0xLTcxMzMw_225a06d9-7653-4c24-8b6c-da6727485903"
      unitRef="usd">1934000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a80b04cb6e043ad80ede6971d9cb2fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTUtMS0xLTcxMzMw_08064791-53ad-46b8-8dda-378d10e91416"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iacbcb5d3d18240d6abf33c438338c41e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTctMS0xLTcxMzMw_54d24585-0a3c-46b0-bf2c-79bdbffcfe27"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icbdefef8716e469f866e5bdb3ad97823_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTktMS0xLTcxMzMw_55145d9b-14f5-4527-b160-08bd5eac5e1d"
      unitRef="usd">1934000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i368338736b594e6d8a76278bb806f294_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTExLTEtMS03MTMzMA_b1dea009-4b5c-4c05-ab3c-b3833718f74c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5b2074c0c51149d29db8c27132c778b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTEzLTEtMS03MTMzMA_c6c18deb-e2e3-48d8-a32b-94b652f05895"
      unitRef="usd">2870000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifb2d07ba578d453a9b330ea183531e7d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTE1LTEtMS03MTMzMA_2a7b2c4b-e2d9-40cb-bbf5-a6df3e9bed5b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3e296686a26b46e991479d3824a63f4c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTE3LTEtMS03MTMzMA_e7e5719b-ffc5-44f0-9803-9d8402ccf0f2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i884f9a28b2df4b68bb8abbdc76ca1ecf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzEzLTE5LTEtMS03MTMzMA_5feb93e3-fed2-4f56-b7ae-e22044203b42"
      unitRef="usd">2870000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iff3c3527b06a4e589f09f08ceb1e72ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTEtMS0xLTcxMzMw_ebd13df8-9daa-43da-a6ba-e3c4e42870c0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f4a61f86932408aa31104c0df81ca3d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTMtMS0xLTcxMzMw_06085c2c-d7af-4dad-86c1-cfc5e6fe5856"
      unitRef="usd">1438000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id3d036d559f54833a22c6bca2390859a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTUtMS0xLTcxMzMw_0ab748a4-5f06-4e88-a5e6-c00b29c8d40d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i84db46bf07e44ef4b3a8a839cbf0f428_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTctMS0xLTcxMzMw_9e6165cd-6bf3-41b2-94e1-4b733c627f8f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1df28cf4387a4d8783f18cf6ddeef882_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTktMS0xLTcxMzMw_8881b048-9873-4e94-8426-d24fa9f1b7ed"
      unitRef="usd">1438000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic8ab2d575b2449d08e6ad76e2f9283f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTExLTEtMS03MTMzMA_f54fad86-35cd-487f-b61f-56757dea4138"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ef55351ff9e48e89c15fd31549ae893_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTEzLTEtMS03MTMzMA_8744247d-43f4-4100-a9c5-ce2cea7e19ab"
      unitRef="usd">2005000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e42ced466d047bf95c8e1543dc8863a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTE1LTEtMS03MTMzMA_85bbd4c9-5779-4f20-8136-0070cb53b4e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i24f0c6fe869446d9a36fa7dbefe7fb88_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTE3LTEtMS03MTMzMA_5872a21f-3750-432a-860b-00c2a9bb3434"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i572499192bfe479396365f275d94e763_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE0LTE5LTEtMS03MTMzMA_8172fc24-d57e-45d9-ac93-47a5ed62e246"
      unitRef="usd">2005000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7e9fc972b25f4585bf6789b43ca0f28a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTEtMS0xLTcxMzMw_96942c0d-b5de-4565-9dca-ccea13dcade7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i408e755f4b8346248d1b01996e6dda61_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTMtMS0xLTcxMzMw_c1c56305-966f-4771-8180-57a848ecd4e4"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i68d015a29c7d47dfa305d0b880483f37_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTUtMS0xLTcxMzMw_fbfd0e21-0a87-419f-9713-0ed6c5a52e8d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d5d96ce993e4d57bafec31c8f3709be_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTctMS0xLTcxMzMw_267bdd5d-a62a-4922-ac4f-f358b372a2e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ea35cf15d4343148d21525946bb5556_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTktMS0xLTcxMzMw_00ca3eed-1cb2-4f71-a469-9ff3da109cf0"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id02a5d1a28e148448be5e2748d591f32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTExLTEtMS03MTMzMA_17436f02-99fc-47d9-afbd-7a426c322eb7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf0d465701b24fabb785a43c5d0b22a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTEzLTEtMS03MTMzMA_1b7ea34e-7afe-4c4b-bc82-191d017f96a3"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie35e62b283ac416e801a76b2e9fcba1f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTE1LTEtMS03MTMzMA_15e11b76-472b-42f8-aba6-58740064cf3f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7da8f4d50a2c49a585bbb716acb0701e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTE3LTEtMS03MTMzMA_df251780-0d7d-4867-8f15-6ac8ee98dc16"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia02763a738b84f0f957e97e34d95f28c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE1LTE5LTEtMS03MTMzMA_07d23d69-9b90-4352-ba0c-07f3b8aa292d"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6945f7ef76e445392d96e1e24babbc7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTEtMS0xLTEyMTQ1Ng_e842821a-a355-4572-b574-701b202394fc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0e222b032b0148bbbecabb38a15019c5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTMtMS0xLTEyMTQ1Ng_eac50e9a-26ea-4492-be83-d18f2dee158d"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0b6676439afb4baa89166d48a1c80d4f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTUtMS0xLTEyMTQ1Ng_51d1b563-bc96-436f-bef0-752683f4087b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib9bb0806cf1747e39ed7c1afcb91fcab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTctMS0xLTEyMTQ1Ng_f968e08c-287a-46d1-b513-dfbf582de387"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ab187b6caab4fde8baaa89614f937d8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTktMS0xLTEyMTQ1Ng_d67f040a-1c4b-4f8b-b1c6-c8e415b3555f"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifcdb915e70724220b3edab3c2cf16e13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTExLTEtMS0xMjY5NTI_0af520cc-cff1-4f15-81db-c4456c8d5bd8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if18d5994096f4b6e8384cad8cc87790b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTEzLTEtMS0xMjY5NTI_658bbdec-af04-4390-bcb8-1bef0c1bfda5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3d94212fbb084b18a3e0d07785229801_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTE1LTEtMS0xMjY5NTI_94d34ae1-6a0b-4293-b4f4-915e3f169551"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3c5eb30d21af404795b2b73f609cadb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTE3LTEtMS0xMjY5NTI_ae7198fb-0458-430e-9324-c4251583974b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib14271cdd75a40bd9db2047fa6eebb56_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE2LTE5LTEtMS0xMjIwOTU_ef37aea3-e99d-4c2e-9a3b-8ccf59670e6a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9b45cf02542b4df1a1557fc79ecf4d7b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEtMS0xLTEyMTQ1Ng_15aa9e18-7b69-44b5-b2b2-1b874da30b00"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icac839fbba234105bdce0c3639ea1f65_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTMtMS0xLTEyMTQ1Ng_c54c607d-6acc-49c5-9c34-3e9df64e9df5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2884cebbeb4349cbbd54902567b98f99_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTUtMS0xLTEyMTQ1Ng_33eee17c-7465-4460-be86-3492a50fb60f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5c3419a800d84e95847c4ea6b6573ef9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTctMS0xLTEyMTQ1Ng_7a9548bc-3f2c-4987-b919-87bf35b7343a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iec63912400cc4143bca10be161105b2d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTktMS0xLTEyMTQ1Ng_5afc3e5f-ac4f-4232-b297-052aa7e76513"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5c9d46acf005430da76b238da3400312_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTExLTEtMS0xMjE0NTY_c618c460-8743-4b29-8d98-92f99fe7b775"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d1b3faf898a4df1b8da83fc0342315d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEzLTEtMS0xMjE0NTY_c56e41aa-c19f-43bf-a4ad-e8c381a38f9f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7dc3922262e347318e148317d58cd00a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE1LTEtMS0xMjE0NTY_31f22945-3ecf-4263-8811-4ff5308ada3b"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibeea740fa5b6439494e7da959619e151_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE3LTEtMS0xMjE0NTY_23fb8b2d-32fe-48f9-b843-3aa85cf2f94a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i222c3f84c00f4528b3b117910de864f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE5LTEtMS0xMjE0NTY_1a132f4c-acbc-4700-9790-8ab7d470446a"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib6b957e5e1bb40e48f22b7266013e6b5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEtMS0xLTcxMzMw_7e6fb2d5-67cc-4c2e-9928-11652eafe070"
      unitRef="usd">2216000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8117fc38d2c448f4957b803029d27a29_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTMtMS0xLTcxMzMw_b05b94aa-28bd-44b7-a925-abcb1009f863"
      unitRef="usd">3495000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic5e3be79b32040aea41c8fa4c833cfe8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTUtMS0xLTcxMzMw_08abddb8-55b0-417d-9ee3-899a0ca4291f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i157a12054ba44b08a715faa3db64912a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTctMS0xLTcxMzMw_6c1617fa-d449-488b-814e-320fea96125c"
      unitRef="usd">3379000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTktMS0xLTcxMzMw_de15b823-099e-4fd9-a3f0-f7a408358d14"
      unitRef="usd">9094000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0bf31aaab8564b709a2447727d50c0f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTExLTEtMS03MTMzMA_7e8c8087-b1aa-4863-9181-e5289924dbac"
      unitRef="usd">3156000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i18725820f3894e1888c310bc183d1281_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTEzLTEtMS03MTMzMA_a7be4a4e-b854-4b73-b07d-f01d63bbbc0e"
      unitRef="usd">4898000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75548de2a3824999a1caa66dd0cbddd4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE1LTEtMS03MTMzMA_8c666a03-7c65-4f6d-ae47-0b47a5b10af9"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia2f0d1c8a7964938a5f4ca7b0fa2b293_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE3LTEtMS03MTMzMA_b048d3b4-6318-43fb-84b1-69ceb603e79a"
      unitRef="usd">5007000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i29556b6857e2444296df1ce227fcb0df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE3LTE5LTEtMS03MTMzMA_45897f2d-3c15-48c2-be35-3c221539bdcd"
      unitRef="usd">13067000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3d7c3d7dc05473f9e300744f303a60c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTEtMS0xLTcxMzMw_c8e763a6-e3ca-4fac-928b-40f2f4efec08"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib326ce09514b4493be47a196b35b9582_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTMtMS0xLTcxMzMw_47e2c210-ca03-4066-918f-5987b3a5f252"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8dd8330fb14d4d3c81eb6e836222ed54_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTUtMS0xLTcxMzMw_1572a3d0-b260-49a9-afb5-0059804f8339"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8077994810984b39938b2aa1928d7cf5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTctMS0xLTcxMzMw_71fb1780-c924-4b7a-a309-d0114218b53a"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1de47dc04136455bbae3a9a127f6e0b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTktMS0xLTcxMzMw_4b79a230-a8e4-4e06-b241-6f0f9d841e9a"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1375d29c86944eb696207a9446cdb738_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTExLTEtMS03MTMzMA_17c64731-eb23-4b21-ae55-f31b7216e0a4"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i64de9cd521724bc0abcd5e2f16a38d97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTEzLTEtMS03MTMzMA_cc434ed1-e0d8-4a00-9b8f-0d1a8cbbe7bb"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1c7dcf2922c4017968e8f899598a7fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTE1LTEtMS03MTMzMA_827b6071-d742-426b-974f-7e3ca6c918ec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0b426282e3524c13bbfad8775bd40381_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTE3LTEtMS03MTMzMA_318b8a2e-d0fa-4b55-a0d5-202f0ccc30e6"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia564f2a19eab4fd992df2ff0405138c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzE5LTE5LTEtMS03MTMzMA_7e98cb72-2bc1-4213-be99-06417cc5a866"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6582d2efd0054414b352812e2b962b7f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTEtMS0xLTcxMzMw_b5e4ba48-c39d-4f4d-83ae-ee6142b50303"
      unitRef="usd">375000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i63145f7e3f1b41fdb8abebc2998c2d19_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTMtMS0xLTcxMzMw_27836e3f-bf95-4fc6-b465-217c49799265"
      unitRef="usd">2957000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia9f04d31c0704d299ee261c7b15963d7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTUtMS0xLTcxMzMw_48b8137c-fbe6-45c5-be45-91720a5ac124"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i607173f7a74747529e546f2f09ffa3eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTctMS0xLTcxMzMw_d44be777-e089-48f5-8f77-a91508034a9c"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1211698fdc9d4fe4b5bfb05d555dd4dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTktMS0xLTcxMzMw_75a1223f-6a86-408a-832d-5802b2d1c794"
      unitRef="usd">3422000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d81a32ba3204600bc00f943bd7244b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTExLTEtMS03MTMzMA_c8c2b09e-3c0d-4b1b-bf3c-4a19fb2c95c1"
      unitRef="usd">531000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee60ebe97eef4e579466f9b404815248_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTEzLTEtMS03MTMzMA_ed015e11-e202-4539-bb4c-bcd128df19b2"
      unitRef="usd">4292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i690c9d1b13044a0b8c56110bdcdd1656_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTE1LTEtMS03MTMzMA_b08e058c-52a2-41f4-b86b-810afe2a3f29"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d8bff79d9b44c1e809568cd8f8ea9dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTE3LTEtMS03MTMzMA_3fb8bf44-3eb9-4a40-843f-c28beb7921c7"
      unitRef="usd">121000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9495ef8ea329494482b31a7316e5c091_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIxLTE5LTEtMS03MTMzMA_2cb26961-91e6-49de-b761-2e1166cab89b"
      unitRef="usd">4944000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc0b8c867d2b407bb7a590e2865c3daa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTEtMS0xLTcxMzMw_d4befd65-9ee7-4244-9acc-74303ca783e4"
      unitRef="usd">177000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5630976df72c476e8f334a3899a205aa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTMtMS0xLTcxMzMw_421aeb0d-0536-44d1-aa42-35260e4f0851"
      unitRef="usd">2656000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b0851bdc7b8443086939d63202a6a2e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTUtMS0xLTcxMzMw_cbd4b42c-09e7-426e-a70f-08f87539d73b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7986a9f3720e473ab5b5f32f521a73ce_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTctMS0xLTcxMzMw_d5f2da6e-28e4-496a-a9d9-7059390f7af3"
      unitRef="usd">130000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if44e31b11f2140fcab839b2f25edc3a6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTktMS0xLTcxMzMw_b46e8d2c-e8a2-45ed-9bb5-2184d8f3d8dd"
      unitRef="usd">2963000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0de70c29ff2e41c3a2cc1406100028c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTExLTEtMS03MTMzMA_0bc4ae67-2073-4b64-b7dd-16439b49c698"
      unitRef="usd">240000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i57d0ac7c4da141c8a4d4240d67ebfa08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTEzLTEtMS03MTMzMA_2c24c6ba-9e40-4cc0-8b05-09b20a269549"
      unitRef="usd">4025000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i674529c9196143a7a4d48e89efa7d6dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTE1LTEtMS03MTMzMA_875fc7e0-451c-4030-8c52-5dd9a3391624"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1146171a1f32494fb878dd8a8dd84f7e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTE3LTEtMS03MTMzMA_fd7ba174-7f41-44c8-a45b-8f3b90707bce"
      unitRef="usd">171000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idf091cd60ecc46999362e8ca49e4429a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIyLTE5LTEtMS03MTMzMA_c0ca064e-19ff-40a1-a962-25b4edd076e4"
      unitRef="usd">4436000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaad887cf23134b0d82635fe324756cb9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTEtMS0xLTcxMzMw_5c75ca9f-6516-41f5-9786-b40bd20dcdb3"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icdcb20a992b94779aab076cc55de3e6f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTMtMS0xLTcxMzMw_c6cce020-f72f-4b4e-a51c-3efc6327eb32"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5e76f4f8aabc405e8b026bc6b713eaf3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTUtMS0xLTcxMzMw_c9a64af3-aa49-43e6-a1ab-7c72ba09dd1b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9208e7f8ceab4fdda68258420c992acd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTctMS0xLTcxMzMw_4a26b636-aedc-443a-8366-e28b59000cdf"
      unitRef="usd">59000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if0892e4eb2bf447490676f226fec365b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTktMS0xLTcxMzMw_3c9ab1ea-85c4-4f75-9b38-4f330ebebd3f"
      unitRef="usd">111000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i847b880d005a4f7e86c4d63096d9f2fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTExLTEtMS03MTMzMA_8fadcef8-7db7-440a-94d7-faa26db1c038"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i11fc421c59ce461fa247d668f9e0221e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTEzLTEtMS03MTMzMA_e4cbc463-06f7-44d2-80c8-37eac1fc0076"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie69d7f997d164052a95715c97dc7fc49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTE1LTEtMS03MTMzMA_c7b46cb0-6ba3-4022-86a9-791dc595574f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if4ea705e6e4e4f58ab5537473f2b8015_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTE3LTEtMS03MTMzMA_20b094bf-e1f2-44f6-8fb2-d2a4b3cbbde1"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i23786efd39504e7cbf7f9927055b6962_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzIzLTE5LTEtMS03MTMzMA_89797728-dda1-4dbe-b524-a13c40c6e927"
      unitRef="usd">209000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7821d4f79dda401db43e25763b2a2bff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTEtMS0xLTcxMzMw_90777d82-9351-4b47-b39a-729f1e9e2e4e"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5325b943b7c84934a25bbb141bac26e9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTMtMS0xLTcxMzMw_89f023aa-9e97-4e86-b7f2-23ee2381a807"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27c2a54b17b24f0c93b411c2e4ad8e00_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTUtMS0xLTcxMzMw_3cfe8dce-fca4-48a2-850b-de700358c99a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia4438b86aa5244c2818db9db11a86fec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTctMS0xLTcxMzMw_53f91e47-1a25-47f0-99d2-fe8b5cdc8ddf"
      unitRef="usd">129000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i874116ca095e4632ac107ccefe0dd09d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTktMS0xLTcxMzMw_2d44914e-f439-473d-9c43-83b93968196e"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ide1a603e4a3f4ea6a050c80f3be11e9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTExLTEtMS03MTMzMA_67f4b613-a31d-41bf-8733-26739b77a244"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2570383925d24316b345fb6a6f82400b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTEzLTEtMS03MTMzMA_3929ba61-b319-47a0-b5d5-1ef059cc2261"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i632724ebfd9a4a49807cc6f4c47e6534_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTE1LTEtMS03MTMzMA_4b10ab55-c6a5-4ab7-888e-a05c4296776c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i35977504bb0a4d55a4b76850394ec55d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTE3LTEtMS03MTMzMA_b6cb90a9-8b9c-40ed-8101-6fba8d14cc32"
      unitRef="usd">171000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i14e90de4ed4f463996171254297798a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI0LTE5LTEtMS03MTMzMA_d2fd88c1-6e82-4b01-995e-11a8147ebbe9"
      unitRef="usd">188000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia29673509c9a4010bcd22958c0959847_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTEtMS0xLTcxMzMw_56372ba8-78a9-4e52-9b82-7f660675b98f"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i665dd2b6cb854b829b803fff15542e78_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTMtMS0xLTcxMzMw_97d46c59-0c14-470a-b162-1c76021f7386"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i42e54cf9d54b4adc809169913679112d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTUtMS0xLTcxMzMw_c7248f11-1fbd-43e9-91dd-b2df96cb2915"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9246f8fd405044e7a1e70d29a4549ea1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTctMS0xLTcxMzMw_a1e74b5e-b4e6-4ada-a8c4-88504197c98f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i15e5ad8e04634fc58a8bf8264d2ef413_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTktMS0xLTcxMzMw_4f4087e8-ce4a-4032-817d-efed44e2b4d6"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccd5163788694a7393d6ef6c3f78716e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTExLTEtMS03MTMzMA_a87e43da-ca03-4a36-8b88-6ab656dbdaf9"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i358c1248155b4206a0b0e8e6b96f4f5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTEzLTEtMS03MTMzMA_5cadd2c9-c945-4e4e-9462-2e5ba0b8d886"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i43019cb2131f4efb95c47d2d7a4beaa4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTE1LTEtMS03MTMzMA_c2c78080-7d29-457e-8b98-61ce6cf6b2e3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icb68c4cc84fa49ccb20a1ed79caa36ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTE3LTEtMS03MTMzMA_e02fc348-ac75-451b-84dc-f699476e58a8"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i84b4b0f9f50a40e5b9e1a1acbbae1af0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI1LTE5LTEtMS03MTMzMA_e98afa11-7991-4ecf-aa9f-94b69c59e00a"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i32bef4bc7a3846e78b7f7ec8d18a4c04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTEtMS0xLTcxMzMw_1f473465-8dd9-40c3-8d81-0dc20d5b844c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie22d02a4139c468ab28d1f7187278f7d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTMtMS0xLTcxMzMw_afd6ab40-e740-4d37-bda8-65126d654edf"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifef6b8011f814ceea9fcdf1de32c0ce4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTUtMS0xLTcxMzMw_209de169-2ff3-41e5-99a9-a5f7377a76ad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if7a0ffc04beb4fbfb3aa513e65b14e42_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTctMS0xLTcxMzMw_fbd3eb9b-3497-4396-93de-326dc967c094"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if02aeb26424c437e890d0d17de1ecffc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTktMS0xLTcxMzMw_1a397fd0-f6a3-4314-9a54-8017a6c194c9"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i468fbb9f8f4c4000adb9871b4f1e127f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTExLTEtMS03MTMzMA_1021f283-c61d-41af-8a5a-1481450bddb8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b3000327cc74724b46322105f078001_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTEzLTEtMS03MTMzMA_4e7e927e-cfe3-40c6-9b92-1ab3f2d31218"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibbd903913036435f9d3f677c2aead426_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTE1LTEtMS03MTMzMA_0a017427-70ea-42c1-b50a-c6c64a5f5be0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d1fe0dac3c04016a05d83b48841886b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTE3LTEtMS03MTMzMA_d61c1045-bcf5-49e7-96ab-5222783ad418"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i105aa835a75742bf940d91e90318d5cc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI2LTE5LTEtMS03MTMzMA_0b467558-1ecb-4d90-b0e4-fe40dffc82a4"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id6533c9582744312a8b885531846a690_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTEtMS0xLTcxMzMw_7fa3e446-073a-4921-aad3-24239625c7cc"
      unitRef="usd">263000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie8d3e011897140d2a236f7bbd70e8013_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTMtMS0xLTcxMzMw_9dfb48ba-abed-4f61-95bc-5534e9a3e3ec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i069baeccce9b4520a111bdee9431129f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTUtMS0xLTcxMzMw_ffb3e58a-e9bc-4fda-93ec-98b63374d526"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icb99c5b079ae4247a981dba6a8503c3c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTctMS0xLTcxMzMw_3e5f788f-c977-4e51-9fec-46e8479ce51d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee39b49b33a847d487e04603c75762fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTktMS0xLTcxMzMw_7eb0aee3-5955-4246-a35b-2407444a0f26"
      unitRef="usd">263000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iad821c2d4149482a8d9a5902ea95e485_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTExLTEtMS03MTMzMA_faa2c671-9bb2-4fc2-b6c6-ee8ae52e09a3"
      unitRef="usd">369000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4018090676e1474786e1971f3ec5c780_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTEzLTEtMS03MTMzMA_05302244-a1dd-4c50-bd96-3788449a3ca2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7809219dc2c546249334a05ed0fb7c04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTE1LTEtMS03MTMzMA_92407385-227a-4731-bb83-43b6d4958a3b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib828317235f34a7c933d9c8403e3746e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTE3LTEtMS03MTMzMA_6f2116a0-af2e-4c29-aeb6-763eca72349b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i51d036f34012427e97ebac833cef5892_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzI4LTE5LTEtMS03MTMzMA_e08c5327-8b96-4e2f-8df0-6af67156ac0b"
      unitRef="usd">369000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i537bba5b6e244ca494ec109af70bb702_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTEtMS0xLTcxMzMw_0958d7d7-2f1c-4def-9701-01a0ccaa5373"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5679535497fa4788b52666e4cf70d170_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTMtMS0xLTcxMzMw_8391881e-579a-40d0-8371-8591f204648d"
      unitRef="usd">448000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib56d072311c84277b36632d5a803fd7b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTUtMS0xLTcxMzMw_47733929-d175-40ed-9df4-7a24a1e5142f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i512bb771659642bd8da429add2af7ece_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTctMS0xLTcxMzMw_e06a3558-3663-465d-8066-68a665bd1574"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia60b0d81c82b44b2a9fb4a6fbdc1f05f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTktMS0xLTcxMzMw_d0faaa3a-d284-43f6-83da-eea30b911765"
      unitRef="usd">448000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80f4a71103804c5c990a5e460fe9febc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTExLTEtMS03MTMzMA_f53952c5-2bf6-4122-9544-6b6afc49dd7e"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8491a5785cf2462fa234d89c89950509_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTEzLTEtMS03MTMzMA_3fd302c1-e052-4630-95ce-6e9af83878c2"
      unitRef="usd">591000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i69c94abeafb1473a8d323ca363297440_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTE1LTEtMS03MTMzMA_ae933184-a11f-42fa-92a2-22cc92733be1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i980c20ea27d44058855c0549523b629e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTE3LTEtMS03MTMzMA_b578d9ab-f54e-4358-9aca-12b0f4b85787"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3f51ec0ea3d34dddab95685e90d307b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMwLTE5LTEtMS03MTMzMA_60ba7d7b-d9b3-414f-a784-13cb5f1c85f3"
      unitRef="usd">597000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia486b0610beb4dedb992b7d0a70d8173_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTEtMS0xLTcxMzMw_e89d5aac-fc6a-4510-a69d-2f3457f3665d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b084b871a324422ae5462c19f697ce4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTMtMS0xLTcxMzMw_621f6584-616f-460e-9539-615c2a1f53b5"
      unitRef="usd">157000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01600af18ed54eaa90e40505a5ebe18a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTUtMS0xLTcxMzMw_0c445be1-689f-4a20-9dea-145cdff95b0d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7727910cc59d4a4d84eb330b2e6c98e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTctMS0xLTcxMzMw_7fdcea46-7326-4811-bf00-3098822504bd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3255f205337471b9de00d03043da0b7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTktMS0xLTcxMzMw_6e471894-b630-415d-be46-51d865539f22"
      unitRef="usd">157000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0d3cfd0494654287bce631815c2f48fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTExLTEtMS03MTMzMA_dcba64fd-d196-4c29-a0ff-ca7cef1644e3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38cc140712f549368583bb21f0c9ad6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTEzLTEtMS03MTMzMA_132fd5f6-ea0b-4f8d-be75-0c730eece276"
      unitRef="usd">223000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if5af5903c6944bc8992989ed8fe54eb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTE1LTEtMS03MTMzMA_5881742e-8f4d-43d6-a798-1969a63dc104"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id85d88e511504c9f8addf47ea0c5c8c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTE3LTEtMS03MTMzMA_3e1f065f-a558-4f62-9558-53718edca9f6"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd750cc2ed934cf198a8e5af0722e734_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMxLTE5LTEtMS03MTMzMA_18f10fd0-0a92-4728-99e6-1c3c5278e540"
      unitRef="usd">225000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5bab51d3da9c40bd9dab9219b12b6477_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTEtMS0xLTcxMzMw_8dd423af-b8d2-4b3e-97d4-0a9a7aa23233"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i18fab0cd3eb5497c95c9598936cc5f60_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTMtMS0xLTcxMzMw_e27996ec-8838-4a52-b081-878cad651680"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d226b317f604d05847b7f6e28dc4596_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTUtMS0xLTcxMzMw_71d8a5a2-c8d9-486e-8c78-e80d421d9574"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1f30f26103a4bb09be1f8df2ba5a0cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTctMS0xLTcxMzMw_3b753777-6911-4af5-a755-aa35a29b2f6b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i61ce603ee97843dab7cd57610eefcff7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTktMS0xLTcxMzMw_1c478bcf-f43c-47ee-ac8d-161d3e5dfe96"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1ff8b9d77acb419cadc79b2388cf8aea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTExLTEtMS03MTMzMA_32955114-072c-4d5e-90c3-839d9e3bd466"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia49b3ac0859944108a2886b9ffe70668_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTEzLTEtMS03MTMzMA_040c0567-6b8d-4ef3-8525-fec6bb5c7f25"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i91e7988a858549c6831c3fc177094480_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTE1LTEtMS03MTMzMA_d4f5add0-30ca-46ec-b7da-38616efedd50"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6082ce67ffaf4296a00a661b69d5e2fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTE3LTEtMS03MTMzMA_b47994cd-30e8-454c-82ac-1abcf8e0e3df"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6b08b0d47a644db7b10259546dfb010c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzMyLTE5LTEtMS03MTMzMA_af4b4252-15b8-49a3-819c-66d640761cf5"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i85a15f6641e7489e8bec87d0c0d09275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTEtMS0xLTcxMzMw_e5223f1e-ec1e-4cbc-9798-3280eca06eb9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6bf55b6630574907879c5690efda4aac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTMtMS0xLTcxMzMw_bb880d82-913f-4c7f-8c63-9792ab05e8d6"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e9d5863fab44dbe8edafd532df689cd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTUtMS0xLTcxMzMw_e008cd30-2bae-4cba-90be-a41d307c4fdb"
      unitRef="usd">761000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i274a84d55dbe43f0909b3b9ea5a73369_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTctMS0xLTcxMzMw_72834b85-e60a-4e3c-a9a6-fdcce3f9122a"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8144400fac414d76bbf83fa31a181ee9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTktMS0xLTcxMzMw_5774c6ca-ef42-4b1a-b9a0-d5cdbc9b4d9b"
      unitRef="usd">780000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9d7e9a4146a347b6b61274dd7dc190a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTExLTEtMS03MTMzMA_6308c07a-e0c5-4d2c-bc53-838964261742"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib416e715279d4c49acf44bd176c0e993_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTEzLTEtMS03MTMzMA_921f5af7-2bce-4d0f-b449-6282f7aa00d8"
      unitRef="usd">44000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2279fdb171bf475ea5bbaf850cf969d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTE1LTEtMS03MTMzMA_18f5afba-d907-4559-97f7-e1cc07195803"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ide944573e70e4c3a941f811b9ae4fc69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTE3LTEtMS03MTMzMA_12d62c52-729a-41ce-b226-19c5935e0f20"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a3d2cafcaf747a081a5bb4742d24ffd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM0LTE5LTEtMS03MTMzMA_40193381-0634-43fc-b0ff-cdb145519cea"
      unitRef="usd">982000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc86d76a34274e1c9ffa42afa18a0501_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTEtMS0xLTcxMzMw_c3a6212d-a414-4ba6-a523-96d501ac66fa"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia73a0658e8094bba8381b0c5aa3afa6c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTMtMS0xLTcxMzMw_b6401f03-11d3-4867-910d-57eef4c74edc"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibeb05cb659f145bc9934cb7f8611cab9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTUtMS0xLTcxMzMw_8f81e8c6-e3c9-4a56-9be0-ba330004219d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i69eb54ad43994b288d84c18edf6e95b8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTctMS0xLTcxMzMw_878d28a4-6288-4ea1-95bc-2d75231a6397"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6da8c122d974d1f937fe4c99ef076c3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTktMS0xLTcxMzMw_2f475638-4516-4eb5-ab0c-423235eb0f5c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5733f7bba54d42aaa43b121a730f82fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTExLTEtMS03MTMzMA_3be0a560-f92d-421f-940d-f989c6153b8f"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccf522bd9fa148caa6b5eed555edc571_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTEzLTEtMS03MTMzMA_1816fd2e-e7e3-4ad7-a2bb-ffb4004336f1"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d449dd9dde74791bf4aaeb9a684a535_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTE1LTEtMS03MTMzMA_eb781eee-6f30-4339-9a88-d801c974d260"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6ca87f79abc048f6a89896b3f649a822_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTE3LTEtMS03MTMzMA_78610e2e-e4ba-4375-8aec-e13b2e9c7cca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i72d655338ad14d529fd86da3f800ac76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM1LTE5LTEtMS03MTMzMA_33deae9a-f194-4b6d-a1b8-e1bab45a1e4b"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if41b6862ec6b49808939615624817c34_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTEtMS0xLTcxMzMw_3466075e-83a0-4095-ae7d-ffe24ad65e04"
      unitRef="usd">943000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a8c892d473c4518b1b24faf48003494_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTMtMS0xLTcxMzMw_fad7d3e1-807a-45f4-b093-ef99bc16b0d2"
      unitRef="usd">6333000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1567e8cd88db4e33937d223c023e86a6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTUtMS0xLTcxMzMw_c2164378-39dc-45f1-9b6c-727202219756"
      unitRef="usd">761000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ffff716f5884ae9a3c95e17da117a8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTctMS0xLTcxMzMw_6c0d604a-af1e-40cd-8476-b45dc0d3434f"
      unitRef="usd">436000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTktMS0xLTcxMzMw_fc86c84c-eda1-4cb2-8c5a-b62f11717ef7"
      unitRef="usd">8473000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica01a70e35a14ac7b9ab80bb54bbcd37_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTExLTEtMS03MTMzMA_b2237613-37bb-4552-a58c-78af965f3310"
      unitRef="usd">1387000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1dcf8778d6694d0b8a4abf0e7cf5ab5e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTEzLTEtMS03MTMzMA_83336d8b-4e6b-4831-8bd8-a8f213383424"
      unitRef="usd">9293000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i16e73b7ddb0346da916527922a567950_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTE1LTEtMS03MTMzMA_8aaa75ec-a3cd-4ee3-9068-1f37e6cd620b"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9f078b74a4254907b6f6bfa3674d200b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTE3LTEtMS03MTMzMA_48eebe99-9f9a-4d7a-8262-2254867737d5"
      unitRef="usd">578000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo5MGI3NWRmZGE5OWU0MWZlYmVjOWNlYjlkMjZhOGQxOS90YWJsZXJhbmdlOjkwYjc1ZGZkYTk5ZTQxZmViZWM5Y2ViOWQyNmE4ZDE5XzM2LTE5LTEtMS03MTMzMA_35df6270-b74e-40f9-a18e-9746cbbfcf82"
      unitRef="usd">12195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzOTI_20291f54-8ee7-449e-ad86-da9ee6287b3b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company&#x2019;s pension plan assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance&lt;br/&gt;Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real&lt;br/&gt;Estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets sold during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Relating to assets still held at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases and sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f3f57f040b7479f99574732ff1ae8b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMS0xLTEtNzEzMzA_7736b8d4-dac4-4cf6-b7fd-10a8551fd320"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b52200a65f14226a303e0b59890c740_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMy0xLTEtNzEzMzA_5fe866b9-34b1-4a61-a878-d1ee5fa10ead"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7dc3922262e347318e148317d58cd00a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtNS0xLTEtNzEzMzA_7b5ba2fc-a2f8-4e1c-bb5e-d30e678cd6f2"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75548de2a3824999a1caa66dd0cbddd4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtNy0xLTEtNzEzMzA_a027b7df-1c46-4403-8cf8-1046218f14bb"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib4975d29336746c9aa345d496769bdb8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtOS0xLTEtNzEzMzA_01066532-7bdd-4d2e-ab71-82ee62a0bce4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if2c66956557e4be194a774c381c9da86_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMTEtMS0xLTcxMzMw_b04daf81-9630-48d2-86ae-abd7ef4b16d9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0551986dd6aa44a8a13162962abcebe3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMTMtMS0xLTcxMzMw_ac58b41f-4118-4895-a4a1-458ce572608e"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i740356c629584008ad4233ee4ddba3e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzMtMTUtMS0xLTcxMzMw_509f0750-6e9c-4df9-9c02-fa5aa00f2447"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMS0xLTEtNzEzMzA_31b974b6-f61d-443e-ae54-df7c875f703b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i391d62977ce249c595df8b51fff32129_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMy0xLTEtNzEzMzA_82151d35-3fec-4318-b0c0-4f7763db0738"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtNS0xLTEtNzEzMzA_61e8e842-e7b3-4f6e-a44d-f6d78ebacbf1"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="icedae49afe70492a8921f596e854194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtNy0xLTEtNzEzMzA_f77ecaf2-502e-4466-bb8a-9bfd4bfabce4"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtOS0xLTEtNzEzMzA_c2b282ee-e600-43b3-836a-f9fc1e56f33d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMTEtMS0xLTcxMzMw_91d2c364-0aae-4ea2-aa7d-d05d943333e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ia8a215a4d92941e58289c363ae043414_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMTMtMS0xLTcxMzMw_21f90245-fe69-45fd-9d8f-d9af98fabb36"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzUtMTUtMS0xLTcxMzMw_840cb681-7d5a-49d5-aa1d-b425695b2658"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMS0xLTEtNzEzMzA_f8fb17d4-4abd-42d0-8fca-8d1e79cfdf92"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i391d62977ce249c595df8b51fff32129_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMy0xLTEtNzEzMzA_2664d890-8145-46e1-a559-017ac6188bea"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtNS0xLTEtNzEzMzA_0f49030f-afd0-46bc-950b-25279eff2cd8"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="icedae49afe70492a8921f596e854194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtNy0xLTEtNzEzMzA_5456bcc9-b87e-4bdc-81e0-47dd9bf82b9d"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtOS0xLTEtNzEzMzA_8571e4ba-5cca-4bac-a79b-f91790eca2e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMTEtMS0xLTcxMzMw_a147b24b-48e1-41dc-bffd-44367cdb4be8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="ia8a215a4d92941e58289c363ae043414_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMTMtMS0xLTcxMzMw_42447a80-da22-49cd-9d39-7be09aef55e6"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod
      contextRef="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzYtMTUtMS0xLTcxMzMw_cbc70176-56c9-476e-9720-cdbfc97d4fa7"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i85404bd90b224b76a677afab0ef660a6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMS0xLTEtNzEzMzA_a51affa8-a45f-4681-8941-2fad8c58e337"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i391d62977ce249c595df8b51fff32129_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMy0xLTEtNzEzMzA_1a66b8d0-c924-4d04-bf58-34ebb41560ec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i3cafc8991b83435e9cd5045f121feaab_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctNS0xLTEtNzEzMzA_b13e3ee5-8e27-41c8-8095-45b99c6cf372"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="icedae49afe70492a8921f596e854194f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctNy0xLTEtNzEzMzA_e835bf1d-f561-453b-b804-8428ae2f1f1a"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i7cabab689f9e4baca6f5432de3d8a0ef_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctOS0xLTEtNzEzMzA_809f160e-edc1-4660-94c2-9328b9e123a0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i26956dcbe4e141b1945b8e6b01b41ef1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMTEtMS0xLTcxMzMw_20da45c0-c919-47b0-80b1-bd70011f73cc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ia8a215a4d92941e58289c363ae043414_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMTMtMS0xLTcxMzMw_d87dfa60-b00a-4f74-a90f-f502ad2ec566"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="if3e4d07e04b646f8971373e341b6dc36_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzctMTUtMS0xLTcxMzMw_fe2b0a79-26c2-46aa-a90d-70cc7050e8ae"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i196e5beea93a4b41b938b075dbb6919f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMS0xLTEtNzEzMzA_895f5af6-3538-4613-910c-10adc8022872"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22de86a0013c4258b4c507ce158eb4e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMy0xLTEtNzEzMzA_8ae58330-9cf3-4f99-b607-ae2177d8ab8d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2884cebbeb4349cbbd54902567b98f99_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtNS0xLTEtNzEzMzA_e1751a40-b9ea-4ed0-a89c-7ef3f428d5cf"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic5e3be79b32040aea41c8fa4c833cfe8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtNy0xLTEtNzEzMzA_0e8255ad-1bf7-4f9f-a4a3-c69e97c7b85e"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f3f57f040b7479f99574732ff1ae8b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtOS0xLTEtNzEzMzA_7f241616-aef4-4ff4-88c5-9c7c04dad791"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b52200a65f14226a303e0b59890c740_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMTEtMS0xLTcxMzMw_546a500e-231e-4270-b3de-c7296ac6a4f7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7dc3922262e347318e148317d58cd00a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMTMtMS0xLTcxMzMw_31a3e334-0328-4a2b-94ae-490172bda6e5"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75548de2a3824999a1caa66dd0cbddd4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzgtMTUtMS0xLTcxMzMw_7eed2470-76e2-4fcc-baf7-85bb9112256e"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2279fdb171bf475ea5bbaf850cf969d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTEtMS0xLTcxMzMw_93b0d36c-051f-4a08-80bc-43e5d185bc41"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75398dcffd9046fa9a38d8247cf75272_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTMtMS0xLTcxMzMw_239f9f1b-0629-4acf-a3db-e6212c03ff57"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d449dd9dde74791bf4aaeb9a684a535_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTUtMS0xLTcxMzMw_fb562051-15ac-4ac1-b48b-5192cca1b6ec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i16e73b7ddb0346da916527922a567950_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTctMS0xLTcxMzMw_f76c96bc-9c4e-49d7-8110-408848f74859"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i25e5ffd30d9c4ef599c56ecbaaf44659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTktMS0xLTcxMzMw_fc0236ab-cfce-44f6-b71a-2ca42c5b3418"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i88d52c4001584a19bb8951cddf85e6d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTExLTEtMS03MTMzMA_f19f896f-f276-4424-9213-2e28e9c00791"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i43740d47c36d4df0968fd590a094a8dd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTEzLTEtMS03MTMzMA_4c4a6661-ca31-42cc-989d-78754f7aad6b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3f395a8003a04bc1bc87026e0744fb1c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEwLTE1LTEtMS03MTMzMA_627db4cd-2a96-429d-a052-e6f24f2decc0"
      unitRef="usd">935000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTEtMS0xLTcxMzMw_8d49db86-c7c9-4d1b-9a36-ce183b2603d7"
      unitRef="usd">-147000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTMtMS0xLTcxMzMw_bae901df-6d82-4b05-9993-0c75ce007218"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="icdb33c38937d499487bba962e0672886_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTUtMS0xLTcxMzMw_d825860e-a7a3-4f4b-9348-55cf33c103b2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTctMS0xLTcxMzMw_9ace524c-5546-444e-a6bd-5954281ed2e2"
      unitRef="usd">-147000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTktMS0xLTcxMzMw_d6ea1a79-0753-4197-bf09-355385f4948f"
      unitRef="usd">-34000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTExLTEtMS03MTMzMA_ad015538-2d38-455d-b9b0-e40763f824da"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTEzLTEtMS03MTMzMA_7890cb33-f83e-4e83-b09b-fe5f7581f400"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="if954f770736b43af9be4de4254082a5f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEyLTE1LTEtMS03MTMzMA_21a7ee11-8284-42d9-b07f-455c6f093b85"
      unitRef="usd">-34000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTEtMS0xLTcxMzMw_9a42e1ae-fbfb-4928-8de0-07b0b490ac7d"
      unitRef="usd">-39000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTMtMS0xLTcxMzMw_c603d8c1-3900-4cc0-bdec-98d7a3a6eef0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="icdb33c38937d499487bba962e0672886_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTUtMS0xLTcxMzMw_2db8ec13-5edd-4031-acdb-a1035c540deb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTctMS0xLTcxMzMw_acdc4834-f71a-4159-967d-45ee003a615c"
      unitRef="usd">-39000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTktMS0xLTcxMzMw_7e9c00d0-e4b2-47d3-9a08-751b9a489785"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTExLTEtMS03MTMzMA_abdae816-606b-4f59-bac4-72e280490ccf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTEzLTEtMS03MTMzMA_6873c377-6fdc-4f58-9c4c-a4b4b97c77e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="if954f770736b43af9be4de4254082a5f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzEzLTE1LTEtMS03MTMzMA_76485a38-b890-40d6-afed-a218dc90a4dd"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i0aa02d6fc8044b2f98cd60594f60b670_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTEtMS0xLTcxMzMw_790314dc-9b45-4ec7-b73b-496627e30cc8"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="ie1050b2238a648f9ab477f88fdb61813_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTMtMS0xLTcxMzMw_f9a738aa-d73b-409f-a9f6-580a7ef976ef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="icdb33c38937d499487bba962e0672886_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTUtMS0xLTcxMzMw_40e45922-1412-4006-ac4f-923dddb29fa3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i0bc2b2deb0aa43b18a8d37676663aa45_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTctMS0xLTcxMzMw_dd7cea92-661e-4ed8-bd91-775413d1c85a"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i48adf3f4cf3e4f2ca1b6b9d2072c34e9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTktMS0xLTcxMzMw_a39673c6-abd9-430c-b633-4064495411ae"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i75f1bba534304140bc9836fd09d56e2c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTExLTEtMS03MTMzMA_077e438f-0c35-45d0-a156-7ca6d3942885"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i45b0c0a32b6b40289ced6bba1bb1cdec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTEzLTEtMS03MTMzMA_2447ceb5-e25b-42a4-ab22-52ea48e2e3ba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="if954f770736b43af9be4de4254082a5f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE0LTE1LTEtMS03MTMzMA_9e3eb6d5-40bf-4064-84f9-5eb28500e038"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e9d5863fab44dbe8edafd532df689cd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTEtMS0xLTcxMzMw_39cca5f6-efc7-4efe-9041-8f342327b1de"
      unitRef="usd">761000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9eec32cd86894cbcbc60de256176e451_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTMtMS0xLTcxMzMw_558e4052-b666-41e4-a83d-cf2e54f10bfb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibeb05cb659f145bc9934cb7f8611cab9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTUtMS0xLTcxMzMw_91afc880-b0c6-49c4-8eeb-386260251de8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1567e8cd88db4e33937d223c023e86a6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTctMS0xLTcxMzMw_4da6959f-7db5-4daa-95a3-8c54ccabb779"
      unitRef="usd">761000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2279fdb171bf475ea5bbaf850cf969d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTktMS0xLTcxMzMw_16e22ab4-ba30-42b5-b3fc-fe71061ea30b"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i75398dcffd9046fa9a38d8247cf75272_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTExLTEtMS03MTMzMA_fffc2226-8d55-4d12-b942-c836014e2d9d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5d449dd9dde74791bf4aaeb9a684a535_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTEzLTEtMS03MTMzMA_7bcbc8ac-3c75-4463-8bec-6f36cb70ebf3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i16e73b7ddb0346da916527922a567950_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpiZjM0NTcxMDM4Y2Y0ZGNkOTZkYWVmMDAxMmFiMzFhYi90YWJsZXJhbmdlOmJmMzQ1NzEwMzhjZjRkY2Q5NmRhZWYwMDEyYWIzMWFiXzE1LTE1LTEtMS03MTMzMA_9254aaf5-184f-4c67-af91-50f30553dc5e"
      unitRef="usd">937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8d8c9312ccf47048b5a4a7d309afce1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMS0xLTEtNzEzMzA_68c90f63-c08c-4ff7-a381-91b9075264aa"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbbf0cf596c64dd0988a11364164dcad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMy0xLTEtNzEzMzA_c947a224-dac5-4abe-9e36-6ff10f941b04"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0855ec477af54d6c9e617a29197d7847_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtNS0xLTEtNzEzMzA_43b1a0c0-90cc-4940-967e-05b2f7b7e0ed"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9dcc62c4863b4fd5965bad472ce89f84_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtNy0xLTEtNzEzMzA_c3f41a41-7ebb-4a6b-a141-ad3c2117814d"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i44f98c489cc64681a483c72df528f6e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtOS0xLTEtNzEzMzA_7fcad72b-2ebe-4e42-8533-286aeafafaf0"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7203e778ea74a408a9fa5899876be16_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTEtMS0xLTcxMzMw_3c0c3c32-a966-46e1-9dea-278beae068b8"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i723ef648281046feb09a5a0b71329ea6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTMtMS0xLTcxMzMw_d9cbdc93-b404-4e76-882e-b202f1f9142d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0c611c813754eab88e05244b68c044b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTUtMS0xLTcxMzMw_4d5b282a-2960-4599-9cce-c423d1c46174"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i07ab2616ba0d4b4cb6674640617b0f57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTctMS0xLTcxMzMw_2943d112-0f7d-476b-b8b9-d4b3948ae358"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id9381a63fc854eb5922d6264e132c65f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzMtMTktMS0xLTcxMzMw_cdfc734a-94fe-462b-8749-b1f50e537bb5"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic78ebf602989410196340e3c5dcc143f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMS0xLTEtNzEzMzA_79b54635-b92a-40e1-b33a-10cc4e9130dd"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifb96f837754f4435950d58e7ac6948d4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMy0xLTEtNzEzMzA_377cb8dd-1d09-419f-a236-31b9095225c7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i77861343b2ad4e85b03f9edee1fd484a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtNS0xLTEtNzEzMzA_f815ea49-6141-42b9-991d-a27ab0698dae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i82a9cf06ce114e07b7471b2af3056851_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtNy0xLTEtNzEzMzA_52966408-ce44-412d-818c-197734df2d8b"
      unitRef="usd">257000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37d33c007f854d6686e954a4cfa0d98e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtOS0xLTEtNzEzMzA_61614e39-05f4-4aeb-a999-aca7c9d82d0b"
      unitRef="usd">279000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i43b3b5be37054468ab22fe27ee8df713_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTEtMS0xLTcxMzMw_bd317b8f-1eb7-4091-adda-6ffa54750ba5"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie3aeeacc677f42a5a7d9c47033789337_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTMtMS0xLTcxMzMw_c7c76384-8358-44c2-b72d-61d6a51bece7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2e4352166d754870a7bd84cb271c20c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTUtMS0xLTcxMzMw_5f214a72-ce3a-4759-856b-15f72c5cc616"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic779d812947244a493bd0e236b71c768_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTctMS0xLTcxMzMw_47ea61ac-dadd-4e85-bf07-700d9f470b0b"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib8c0625b0b6345e8a53a2d538fa4f71c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzUtMTktMS0xLTcxMzMw_67fec2c8-a82e-45c6-97f4-0d385eea6a0f"
      unitRef="usd">402000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac6e499506a74f4eb80bc1d6dcb6eb92_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMS0xLTEtNzEzMzA_55bf4092-8c7a-44fe-bcb1-009c91efc501"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea9249f1c9bb4890a527687499ad8b1e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMy0xLTEtNzEzMzA_e0ac5dd9-e840-46e1-aa48-ab04f968acff"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i97fba52804d74a09b2d6f5991fe15088_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtNS0xLTEtNzEzMzA_19295b02-ba45-47a2-8dc1-91c891636f89"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2a9f1e2ac854460d80e3d43cf0117001_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtNy0xLTEtNzEzMzA_529e813b-31f8-4922-ab7c-d5ee1ca8a904"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib24ff29c998a499e98829ddd938859af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtOS0xLTEtNzEzMzA_a289f6e3-9016-4c20-a397-5151492f7338"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i880f66c107f0451ab68cb5731877e3f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTEtMS0xLTcxMzMw_b7e40467-b52a-4e68-b29e-1d63d86f4b0a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0b0e0627cafe4467a18c0746b1b2cb31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTMtMS0xLTcxMzMw_4d6ada7f-1087-4ce4-b4f3-28d3a4a7bc61"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5d48bd88a7544ca9f12cbe3c8d542e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTUtMS0xLTcxMzMw_387fcaa5-f85f-4fcc-80fc-e5b30af9a71f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i581fc4c408a34c2b823593ff34f1bb45_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTctMS0xLTcxMzMw_925e62e8-54b1-47fa-98d3-27d6de56c5ac"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice88c13053694b56b1bbb9845b06064e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzYtMTktMS0xLTcxMzMw_93382b1d-541f-42b3-985a-d40400fc7a8d"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i018e647cc2bc4aee9902c487f5cc618d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMS0xLTEtMTI5NTEx_eb97558a-22d5-448e-8cf8-be81c7e448ca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iff115c544a4247a9bebf28565714478f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMy0xLTEtMTI5NTEx_dc2d4bab-3a53-409e-b8ff-4f5d002deb6f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i25beda17672d4e7b927a143d69ecbcf9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNS0xLTEtMTI5NTEx_c3dc0b7b-6cc6-4256-bf0f-f6eb19a66728"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i76b3d9bc36e8470ea10fce95680f1e68_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNy0xLTEtMTI5NTEx_9666eeae-2c1d-4a14-a134-4137c0185ad0"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i480b0e7376cc4bf192c2b8defec32548_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctOS0xLTEtMTI5NTEx_bc8d0ff9-6391-4d2c-b3da-0dc4918635b9"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e52fe255fa64668b45ea3f63c0ec370_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTEtMS0xLTEyOTUxMQ_b14ae0e4-2140-43b5-b1ce-089a2e8c6f65"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8a3df3939a70427b944df35cdc081c04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTMtMS0xLTEyOTUxMQ_1b92e8ef-1760-4ad9-8f8b-c83c3693a2e8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice8b60bea50f4819980218f7402e7751_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTUtMS0xLTEyOTUxMQ_af2a87eb-d1ac-42d6-843c-27fbfe10df2c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id979bf377b1c4fa49c254ea8c1bf378c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTctMS0xLTEyOTUxMQ_8f3dd74a-0e80-4138-b09c-97268e6e56a2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie1635544067c487894b39dde19771e15_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTktMS0xLTEyOTUxMQ_b9279f03-b7b1-4151-a7fc-185ab6a532e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0194124ad9d04baf9e149becd0219b96_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMS0xLTEtNzEzMzA_ad3ad392-2d26-42d4-93b5-a83e65250679"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5299a986957347d28938ccdaf51e78fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMy0xLTEtNzEzMzA_b4aa1afb-51c0-4ada-a7f4-ec6eb147ad66"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d3ebf994c704c56a8470a4394936128_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNS0xLTEtNzEzMzA_351dbae5-1d7e-4878-8d6e-dd1acb690924"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib520139920004af9959a218c4bc47d91_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctNy0xLTEtNzEzMzA_1e331647-5360-4338-bdda-de36079851a9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i627a57072a524b84b539c7ae028c9972_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctOS0xLTEtNzEzMzA_28c1b9a1-b009-4976-8074-c1ad93b13377"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i913b5f5f9ed74e87afbc473b332d0abc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTEtMS0xLTcxMzMw_86b86929-a35f-4af2-9497-f3d561644cf1"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b96c6aee77c4665b7d0f0f1c63ae176_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTMtMS0xLTcxMzMw_5d06194a-9dcb-4760-8771-f14b4456898e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i31b5a437c2054f779c773692231f8df3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTUtMS0xLTcxMzMw_65498027-cd32-4e15-a727-399fbbc54526"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibc2a4b136e3240bbb703440f5d3e6850_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTctMS0xLTcxMzMw_0a15b65f-cfc6-444d-b404-325e3254cfac"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe65bc4981604870be12a703c9e2575e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzctMTktMS0xLTcxMzMw_39c89eff-63cf-4fe5-a976-f5670e7be295"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib4945633529e43d2802b597e5521836b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTEtMS0xLTcxMzMw_3e4cf725-5472-452b-847d-694cb2706e46"
      unitRef="usd">206000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9b67d5c167014b2182a1ef46a48101ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTMtMS0xLTcxMzMw_959d056a-b2d2-4178-85e0-ee88f300c2da"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0f74ddf524274e6fad860cb8fd17fe7b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTUtMS0xLTcxMzMw_dff371dd-fe42-43e5-a86d-01dbeb796ef4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i32c0f7bc74d34dfcab9c341a70dce9ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTctMS0xLTcxMzMw_3f7d9e1f-a318-4425-aa4d-2b831b67b026"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4cedd5ed62c843f4a46823653d960a3c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTktMS0xLTcxMzMw_176b68c8-cf47-428a-b56b-88847f88a8fa"
      unitRef="usd">206000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iae98f337e3924c8fb5cf7830c2920bcb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTExLTEtMS03MTMzMA_e06d391f-857b-4c51-bb8a-8305a65724fa"
      unitRef="usd">290000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1c86d54c41ad43afb4205c1d54aaebd6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTEzLTEtMS03MTMzMA_ec9f4e4a-85d8-46d1-bccb-f445896e7fad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iadf0e72b4d76455c823ebeace0a9683c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTE1LTEtMS03MTMzMA_f1d5857e-3073-4db2-aa86-8a01d124f7ed"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80b61c9047804b46affa899a8994e404_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTE3LTEtMS03MTMzMA_ff633afb-c955-4b3b-b888-c7c4dbe4cd14"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ife91ab3ff9224a8887d6fc6c9327342e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEwLTE5LTEtMS03MTMzMA_667b4e5f-9acc-444e-8882-b63adc0a28ef"
      unitRef="usd">290000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i893c7b0fee694fc39725e06248904f34_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTEtMS0xLTcxMzMw_8021c173-6479-462d-abce-41bf684f33df"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0a6cce590324043bd914a90ea6fc3c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTMtMS0xLTcxMzMw_92ff3382-0ed7-49a3-a453-57f9d317113e"
      unitRef="usd">212000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i449c16f5e60d47029b762e1c47644d98_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTUtMS0xLTcxMzMw_28be139e-0a8b-4f14-999a-ad32e611f806"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6adae9ebb2144625a68e34d2e532d6d0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTctMS0xLTcxMzMw_973109dd-bc81-450f-8ca8-cb38add453df"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifb26e9094cc24bb49df536a196047854_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTktMS0xLTcxMzMw_78119c72-93ce-4939-a23e-91ff4025b284"
      unitRef="usd">212000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic72091fefb0c4f5eba7ad4a943ab6bcc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTExLTEtMS03MTMzMA_c6cd731d-79ec-4949-9404-502a213d89c2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idba55f68908c47baad1db7eed4abbd32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTEzLTEtMS03MTMzMA_1625bfe9-d23a-4009-8dd9-65fb161dc33a"
      unitRef="usd">275000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifc82d08170a947b081f642de831e03f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTE1LTEtMS03MTMzMA_bae626f3-d6e7-4804-81f5-20812241d44d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if5dd78bf53984767890f793f585b726d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTE3LTEtMS03MTMzMA_5507bf31-8453-45c6-9190-41312bea1a3a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4daa1ffee7c443d69903ce6fc8dedd2b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEyLTE5LTEtMS03MTMzMA_2d1cb7d6-314d-4215-bfc8-fcd1ef0340c0"
      unitRef="usd">275000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i45784d2a67054e4aa4806ae5f92c6849_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTEtMS0xLTcxMzMw_1f544491-3782-4580-a7d6-60eb396b310b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia6f3b6b407264debb979379641cba1b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTMtMS0xLTcxMzMw_ec0ee2e4-479a-4678-98b4-eef972062302"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie4fb8860eec2457bbef07d977cc5fbf0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTUtMS0xLTcxMzMw_9f0754d7-6baa-490b-a837-0b90e4347265"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie5a1edbf368048fba661bb380d38af5e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTctMS0xLTcxMzMw_9de665eb-fb81-4639-8fde-46cf4c3f49af"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia405f11b3d1a404a8fbfee06d703b855_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTktMS0xLTcxMzMw_e75b2943-5ea4-45ad-aeb3-81040219c69e"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifce1c8735b2e427cbfa6b1c2d907a6d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTExLTEtMS03MTMzMA_a622d7f2-b472-4e27-b7f4-49e92b700680"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia7a12aafcc6847b89509b7ae957e4d23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTEzLTEtMS03MTMzMA_98ef4acb-f8b1-413d-a86f-4e661b71abc6"
      unitRef="usd">191000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i369b80c6e5c64b4488babbdd01f641d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTE1LTEtMS03MTMzMA_c5e33882-87b9-430f-b08c-1f1047d67fbd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i46e297e9db7d4cca8668e1a16be22d72_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTE3LTEtMS03MTMzMA_e0d9eaef-7dd0-4da5-a430-d84e3e8f5d2e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i924ed285bc1d45b996c203cd7bd05c25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzEzLTE5LTEtMS03MTMzMA_78b0bada-11a7-481b-ac35-d20d9893a8a2"
      unitRef="usd">191000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7383c74280514a6eb812d7f52ac9def8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTEtMS0xLTcxMzMw_58e96eb2-1888-481f-8ab1-9b011491a2df"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0b3cf34ce5394b47a3b70ab7ba21f07c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTMtMS0xLTcxMzMw_edac090b-d69e-4c48-9a0d-6c3b64c33ed7"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie728cd5943f143eda362306c2e64188a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTUtMS0xLTcxMzMw_d195ea2b-2cb3-445f-a238-ae378a6f1f2f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6010bc5ccc09432a9350066c737cebcb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTctMS0xLTcxMzMw_1ba62e9e-7b06-47ed-a8e7-26f0fc792960"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8f1c226f8e9b4d3589285259cf838b6d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTktMS0xLTcxMzMw_c72c4757-b667-4c2e-ab84-ad71166ebcb0"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id7c81130363941eabcbe047788cc8ac0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTExLTEtMS03MTMzMA_b03a4b13-cb93-4837-8450-60e4874a3579"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iad865b817d2e4f2eb417e13f1b94cdea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTEzLTEtMS03MTMzMA_f4ae2440-00c2-49e5-b53d-fec707f252d5"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib0623f98779b4a1f9deb8c5985cebccc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTE1LTEtMS03MTMzMA_e13e7b11-0ee2-4bde-ab1e-3c879942ac13"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i99f2b5e073ef435584f2836b3a9c7e62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTE3LTEtMS03MTMzMA_03605438-efbe-48b1-8b39-5ccac511e9e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ief8502a68f6c4572816d41762470ddad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE0LTE5LTEtMS03MTMzMA_d02b464b-ceed-47f7-add4-3baa7e819861"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i795f5a645a9b4b7ca40fb6b7556a8459_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTEtMS0xLTEyMTQ4OA_4d9ec049-e10c-434c-bc34-3933f35147fe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4a45fefd7c93443aae003ae9986384cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTMtMS0xLTEyMTQ4OA_c98d360f-f112-4742-8c92-bb97a32e97e9"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i766d1fb2733a4f39a4b6c0c5a672f068_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTUtMS0xLTEyMTQ4OA_ebfbf428-119a-4ff0-ba45-4e55fc6273a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibbd9a236b87e45e38116d6ad65882768_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTctMS0xLTEyMTQ4OA_5fc124c7-3dbe-4d4a-9420-d286732509cb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iba509df50d7d4c6a8ad7c22884e1628a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTktMS0xLTEyMTQ4OA_39623339-bb80-4494-ae42-1c6f4a24f691"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02f69b3633a347ecb320f84b5f266212_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTExLTEtMS0xMjE0ODg_7c801bd9-a919-44c2-97e9-77165fb4844a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic9604e1478cf43bf91e60a2fe7f8e4e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTEzLTEtMS0xMjE0ODg_9fc97fac-8d86-4103-8e38-49102e7c6ad5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9a749daf21de4a6f862d6f87b5c3ec41_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTE1LTEtMS0xMjE0ODg_7fe34018-3866-45f4-9999-b511395d752b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd49f7a962454bec93ed6ef6e39f5d9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTE3LTEtMS0xMjE0ODg_5ff8942d-f74a-4615-883c-e8b3c13dbca1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f4de48dbad544b2ac8a8ad5bfb3ffa0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE2LTE5LTEtMS0xMjE0ODg_1e24ab70-e99c-44b8-a52a-99a293546cfb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic252bec7fec546e7af106a451f9b665f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTEtMS0xLTcxMzMw_694dd943-ce93-42fa-a543-7747b2d7fba2"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7c314bb744ef4c0dbbd31c567c5f81af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTMtMS0xLTcxMzMw_ba2ffe7f-afb8-4ef5-b3b8-4708e06c3792"
      unitRef="usd">363000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if944cd16f6074744b8d053e0926af6bd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTUtMS0xLTcxMzMw_3ecf1648-d54b-4390-8090-8582588560bc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c1f9774a89a4460b8b9fcf596fab680_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTctMS0xLTcxMzMw_f7eed6bb-db03-4339-ad50-c47569594110"
      unitRef="usd">353000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTktMS0xLTcxMzMw_127228b9-ffbd-4704-be80-8300c9c08893"
      unitRef="usd">947000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if50e936239a449409453997e9da0fdbe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTExLTEtMS03MTMzMA_e5ef828a-5d34-4330-9bc0-672d76f8b1ab"
      unitRef="usd">326000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i675b5277bd1b4865ac978e2a5444457b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTEzLTEtMS03MTMzMA_6a947b0f-7915-44b4-b23a-8eb7563894ef"
      unitRef="usd">468000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9d27b886acce4aba86858f24529ae547_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTE1LTEtMS03MTMzMA_f9f38759-5b73-45d3-a71a-0b3d0f383b90"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9cc364573597419f9c326fddd7d8610d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTE3LTEtMS03MTMzMA_1a8b1d50-990b-41d8-8e47-ea408ef31e13"
      unitRef="usd">498000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NmMyNTg2NGFkMzM0YWYwYmU3MTFjNDQyZGFkNTgzMC90YWJsZXJhbmdlOjg2YzI1ODY0YWQzMzRhZjBiZTcxMWM0NDJkYWQ1ODMwXzE1LTE5LTEtMS03MTMzMA_7fdb46d8-5e6d-4bd5-b72d-c8d411668646"
      unitRef="usd">1292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i6b12891dbba4474da8538f68cfe990b2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU2ODE_e950987a-2a22-4c49-8c61-af5b0c0a5d21"
      unitRef="number">0.25</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iec2ece4e28dc4d3a8d51b0b78cbadf8b_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU2ODc_2c6625ce-0a21-4dfd-98d6-85ca30edf0e9"
      unitRef="number">0.40</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2a61546d8dd040dfa6713efca302e7de_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3MDg_d23f0227-2235-4097-af13-232254c246f5"
      unitRef="number">0.10</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ia1cb9718cd4a44578e0ac990325f2f60_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3MTQ_a68bf9a8-318f-46af-994c-85601ae2e90b"
      unitRef="number">0.20</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i6da749426fbb44f2999732f3b38a24f1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3NDQ_d454ecd6-173b-4407-a074-1c5d41719a12"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i351c42adbb0a4ccdb08af0c3e1a68785_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3NTA_2b255a64-536d-4b03-bc78-b7ddb37cde32"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="id0352f2158524b81942eb49ff2876ee1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzU3OTI_76955b6f-1ac5-4f1d-95c0-b7448efaf606"
      unitRef="number">0.08</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests
      contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzYwMjg_0d5a13fc-e31f-45bc-a8b6-27c07603e0ac"
      unitRef="number">0.10</mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzY1OTQ_0272d5f6-87b7-448a-99ae-b0cccde5f70f"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzY2MzU_3216c463-3a26-4333-9690-81962c9cc88c"
      unitRef="usd">150000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzY2ODg_fd082bec-0a85-4ed3-a1f4-4275c3b6990a"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMzk_99c87649-dc0c-43b8-a170-5065e84cddeb">&lt;div style="margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected benefit payments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Pension Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Postretirement&lt;br/&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&#160;&#x2014;&#160;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzEtMS0xLTEtNzEzMzA_8e866678-00c8-40ca-b292-35549f22ab5b"
      unitRef="usd">627000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzEtMy0xLTEtNzEzMzA_d27d8442-2285-4eda-ab1b-44bd21fba56d"
      unitRef="usd">271000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzEtNS0xLTEtNzEzMzA_adf05dc7-2df2-4447-94da-ad1e14c38862"
      unitRef="usd">84000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzItMS0xLTEtNzEzMzA_d67619ff-5968-4441-b268-fe21236bcead"
      unitRef="usd">634000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzItMy0xLTEtNzEzMzA_34cca3f1-a779-47c1-a210-0be5d8d196f1"
      unitRef="usd">257000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzItNS0xLTEtNzEzMzA_95b1e1ee-5d81-49d2-91bb-42dab5faf4c4"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzMtMS0xLTEtNzEzMzA_d2bc3df6-5391-44d5-b1b6-dd8d5ef1b70b"
      unitRef="usd">650000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzMtMy0xLTEtNzEzMzA_ea1d6772-3e6f-4238-8e8e-26b72e09b2e9"
      unitRef="usd">262000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzMtNS0xLTEtNzEzMzA_d28c9cc8-dc9b-4809-987d-3980ce77b825"
      unitRef="usd">87000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzQtMS0xLTEtNzEzMzA_33b29542-704d-47c1-9afc-562b29ccbb8a"
      unitRef="usd">676000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzQtMy0xLTEtNzEzMzA_b0a99f8a-09d5-4b85-8750-60be5d689f3a"
      unitRef="usd">283000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzQtNS0xLTEtNzEzMzA_561f7ecc-cf91-43d4-b8c6-6ac7b3531158"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzUtMS0xLTEtNzEzMzA_602365cd-774c-4595-ba12-c3b861df9feb"
      unitRef="usd">694000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzUtMy0xLTEtNzEzMzA_0dfd8568-1229-489b-9104-49765397aa88"
      unitRef="usd">297000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzUtNS0xLTEtNzEzMzA_927aa621-180f-4596-bae8-b9d8089e10b4"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="ieac41e3734b14c5880a3e1babce1d967_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzYtMS0xLTEtNzEzMzA_fe5a829b-4588-4b50-ab3b-004d6608a57f"
      unitRef="usd">3948000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzYtMy0xLTEtNzEzMzA_cf84a27c-1cee-4433-be7d-f1a4546f252a"
      unitRef="usd">1704000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTphM2QwODQ0NTI2MWQ0ZTliOTgzM2Q0Y2E5NWMxNzU3NC90YWJsZXJhbmdlOmEzZDA4NDQ1MjYxZDRlOWI5ODMzZDRjYTk1YzE3NTc0XzYtNS0xLTEtNzEzMzA_912380f4-9e7a-4e01-986f-3da14d79b0ff"
      unitRef="usd">474000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNDg_2ef2c5c7-d887-44b0-a2d2-d1da40bc5645">The following amounts were reflected as components of &lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Postretirement&lt;br/&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (loss) gain arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (cost) credit arising during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss (gain) amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service credit amortization included in benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements and curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMS0xLTEtNzEzMzA_7341ab96-8b73-4170-b613-6381acb784e6"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMy0xLTEtNzEzMzA_b73ee734-ac1a-4888-b59f-80ba6c4a0a72"
      unitRef="usd">813000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtNS0xLTEtNzEzMzA_02f0bad9-dc37-446f-81fc-fbf5c687ddca"
      unitRef="usd">-472000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtNy0xLTEtNzEzMzA_30af10ea-38a9-44fc-b6be-1dbd26bb6fde"
      unitRef="usd">116000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtOS0xLTEtNzEzMzA_e16b0b3b-7118-4a4e-8adf-0e9f9ad0ecb4"
      unitRef="usd">772000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTEtMS0xLTcxMzMw_7a2b60ed-1c13-46ac-94a6-78f57343a5db"
      unitRef="usd">-424000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTMtMS0xLTcxMzMw_78a3fb5b-0737-44ce-ae3a-6274349fb86d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTUtMS0xLTcxMzMw_62a6e5fe-d804-4447-b709-d5e68e024e2e"
      unitRef="usd">156000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzMtMTctMS0xLTcxMzMw_65acdce6-768a-4188-a946-da1db77571ec"
      unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMS0xLTEtNzEzMzA_070a6ea9-1f7d-4c5d-9f80-99418b2cfba3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMy0xLTEtNzEzMzA_6cb7a105-68c3-4224-941e-ec8c049c3476"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtNS0xLTEtNzEzMzA_8079b9c4-92e1-40ff-b7d3-60d90194538f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtNy0xLTEtNzEzMzA_9951b6be-6f0c-4415-901d-8254c1915f96"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtOS0xLTEtNzEzMzA_ebf868a2-0437-4b89-b6d5-9768fe88cbec"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTEtMS0xLTcxMzMw_ff625f15-83e8-4d00-8776-7f844d45e968"
      unitRef="usd">-64000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTMtMS0xLTcxMzMw_4dd7ab5a-94e8-4044-883f-33196342733b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTUtMS0xLTcxMzMw_0b7cecca-71c1-45b2-878e-cb615194f39b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzQtMTctMS0xLTcxMzMw_825470b0-c47e-44b1-8685-af11321c883c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMS0xLTEtNzEzMzA_cc397ab9-bc40-4029-a80b-7ef7a09deb01"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMy0xLTEtNzEzMzA_ced7083e-d6c9-4d96-94db-1ce2adec6c90"
      unitRef="usd">-813000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtNS0xLTEtNzEzMzA_da9894cc-67e2-4197-b736-aa8478a684ac"
      unitRef="usd">472000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtNy0xLTEtNzEzMzA_9526d649-7b58-48bf-9bac-807c444900d6"
      unitRef="usd">-112000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtOS0xLTEtNzEzMzA_8fd0db8e-c2bd-4734-b8c9-5ea4011ec2db"
      unitRef="usd">-768000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTEtMS0xLTcxMzMw_bd3030af-543c-4a28-ab51-deb3fa2bc335"
      unitRef="usd">360000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTMtMS0xLTcxMzMw_7aefee40-dcd7-4acd-8f80-94d789e625bd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTUtMS0xLTcxMzMw_b372d697-a87e-422f-a009-2a4c5599a7ec"
      unitRef="usd">-156000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzUtMTctMS0xLTcxMzMw_b096b5d5-6322-4972-bcf2-b475da139dcd"
      unitRef="usd">-199000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMS0xLTEtNzEzMzA_7573dd99-a039-4448-bfda-a7a643b4afb5"
      unitRef="usd">-128000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMy0xLTEtNzEzMzA_ae3dbfbb-81e7-43a1-aad1-366761e574a6"
      unitRef="usd">-298000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtNS0xLTEtNzEzMzA_e9937d38-1193-49db-bc59-692d0d001484"
      unitRef="usd">-303000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtNy0xLTEtNzEzMzA_6702faaa-7dec-4a68-848c-7a265cda3b59"
      unitRef="usd">-96000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtOS0xLTEtNzEzMzA_65f835ec-2d77-4c5c-9d09-a0db8de6282d"
      unitRef="usd">-142000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTEtMS0xLTcxMzMw_c4770866-3fcf-4f08-b848-4246121c2c63"
      unitRef="usd">-127000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTMtMS0xLTcxMzMw_bb9813cb-d113-465b-994c-b05804b59772"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTUtMS0xLTcxMzMw_a5a7263c-1c3e-4e03-9f2d-7b82fd1abcb1"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzYtMTctMS0xLTcxMzMw_60f9cd76-c45b-4f3d-bc2c-dcc0ba919619"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMS0xLTEtNzEzMzA_1c162905-c423-4dd2-ab40-5a9053a0c012"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMy0xLTEtNzEzMzA_d302d759-dac0-4568-be5b-f4644b0ee535"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctNS0xLTEtNzEzMzA_af15ecc7-9233-4422-8add-ab72b2f463ea"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctNy0xLTEtNzEzMzA_6e9ce20f-1731-44ad-8f91-58b903f29baf"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctOS0xLTEtNzEzMzA_ae7e8439-82da-4800-8f84-bcff433b6521"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTEtMS0xLTcxMzMw_9a4c6aaf-0888-4250-bf74-f6393a886ec0"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTMtMS0xLTcxMzMw_f724a25d-f378-4519-a933-f331c16a41f9"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTUtMS0xLTcxMzMw_620dc2ab-c69f-4d9a-b46c-04c320e4f01e"
      unitRef="usd">-63000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzctMTctMS0xLTcxMzMw_be65e6be-4f8e-458c-9515-7af1b79a7f94"
      unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMS0xLTEtMTMwMDAx_505c776b-e36c-401f-a670-edc5ae8e4a4f"
      unitRef="usd">251000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMy0xLTEtMTMwMDAx_61290977-dddc-4536-ade9-5f873e3fca5e"
      unitRef="usd">232000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNS0xLTEtMTMwMDAx_6580cee8-f8cf-4f1c-9db1-d50710830c98"
      unitRef="usd">23000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNy0xLTEtMTMwMDAx_441758a2-a7c5-482c-8038-9d18a89bba2d"
      unitRef="usd">1000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtOS0xLTEtMTMwMDAx_2a7b3fb2-7e02-48fa-9f15-aa6a75be696b"
      unitRef="usd">-18000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTEtMS0xLTEzMDAwMQ_aedcf657-602b-4bb5-ab92-b7ceb6bce926"
      unitRef="usd">15000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTMtMS0xLTEzMDAwMQ_2ab61774-ed63-43e2-8690-16a1b4030fbc"
      unitRef="usd">-1000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTUtMS0xLTEzMDAwMQ_daa0937d-4fa4-4f48-87ab-970d021117c8"
      unitRef="usd">-29000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTctMS0xLTEzMDAwMQ_3ac0c45b-9579-445d-a6c6-c6802376a3df"
      unitRef="usd">-4000000</mrk:OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i3cecc0d2fe9643dd8ea3d62f2dc4a14c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMS0xLTEtNzEzMzA_60173a39-7ab1-4a53-a756-3028e27831e9"
      unitRef="usd">347000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="icc397d7f78cf45cc88b702d552647d00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMy0xLTEtNzEzMzA_bf035354-ed6d-4532-a3cc-deb7fbbee31d"
      unitRef="usd">492000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i7ff8809f1a4b48fda098d14c9c8a80fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNS0xLTEtNzEzMzA_558875f5-bb04-42eb-9755-45d186579cbf"
      unitRef="usd">277000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtNy0xLTEtNzEzMzA_24d22d18-97fb-4ebb-9a4d-82db92b44e71"
      unitRef="usd">83000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtOS0xLTEtNzEzMzA_1d55d243-52eb-48e5-bb20-1ea2ea882d32"
      unitRef="usd">108000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTEtMS0xLTcxMzMw_4f44a063-494c-448e-b7b8-7a3b3734ee34"
      unitRef="usd">124000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="ib96be59679d0488687e1689c7b3d047f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTMtMS0xLTcxMzMw_0e1e6eff-1d6a-4712-9f02-47ae2e666743"
      unitRef="usd">-101000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="i88878659148844a3bc0b4b1b4d2ebbd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTUtMS0xLTcxMzMw_7165e777-2e42-4146-baa9-a8be4e6201dc"
      unitRef="usd">-134000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax
      contextRef="id427c81ebc8146c08a3a06e2c2d15f9a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZToxYzkzNzYxYWZhNDQ0N2U4YTQxMjJjYjZkOWY5NWQ0NC90YWJsZXJhbmdlOjFjOTM3NjFhZmE0NDQ3ZThhNDEyMmNiNmQ5Zjk1ZDQ0XzgtMTctMS0xLTcxMzMw_aa33cea3-afa4-4b38-a27b-6814f4cc46c7"
      unitRef="usd">-95000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNTE_ac6ea9c3-ec7a-43b8-9285-e6ad8bf5ceab">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S.&#160;pension and other postretirement benefit plan and international pension plan information are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Pension&#160;and&#160;Other&lt;br/&gt;Postretirement&#160;Benefit&#160;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salary growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.30&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtMS0xLTEtNzEzMzA_13998342-0f5f-4863-a587-13ca9e77d576"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtMy0xLTEtNzEzMzA_03c40f5a-368b-48be-b827-665aede1bf52"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtNS0xLTEtNzEzMzA_3ac0c61c-18cc-4ad9-9310-8248cbb27710"
      unitRef="number">0.0340</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtNy0xLTEtNzEzMzA_4382ba7d-71f9-4616-abf1-857ed25402ab"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtOS0xLTEtNzEzMzA_300896f4-117a-4149-8c77-d10e0004cc4e"
      unitRef="number">0.0110</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzMtMTEtMS0xLTcxMzMw_58e16abf-fbbe-4f81-8b29-a1adf823bd42"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtMS0xLTEtNzEzMzA_9ff6c1a0-79bb-43bb-9f89-269ae156b532"
      unitRef="number">0.0670</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtMy0xLTEtNzEzMzA_1757b659-daa3-4a52-8b25-2a2c7edc0a0c"
      unitRef="number">0.0670</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtNS0xLTEtNzEzMzA_6196e709-a697-43ff-9f5a-4960b7ad13c4"
      unitRef="number">0.0730</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtNy0xLTEtNzEzMzA_415d9f74-9e91-4b8e-b000-dcb6a42992c5"
      unitRef="number">0.0370</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtOS0xLTEtNzEzMzA_7d3ef875-f055-4979-9519-a78cf2b590d7"
      unitRef="number">0.0380</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzQtMTEtMS0xLTcxMzMw_c640caf0-39af-4344-8405-517ac652bdb3"
      unitRef="number">0.0440</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtMS0xLTEtNzEzMzA_23a69ed7-29fc-4f68-b26c-3e2990e37620"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtMy0xLTEtNzEzMzA_1be9e3f1-49b3-4b2b-8575-cf728d2fe8b8"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtNS0xLTEtNzEzMzA_c3f4bbc4-fe5f-46ac-870d-a4641e8d3210"
      unitRef="number">0.0420</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtNy0xLTEtNzEzMzA_ab21dc96-3d0d-47b0-a90e-c760c799ecef"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtOS0xLTEtNzEzMzA_f8bc60da-9c19-423e-b70b-1b38531df22b"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzUtMTEtMS0xLTcxMzMw_ba0522c1-4528-47a0-8ab7-e15c27c4b439"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtMS0xLTEtNzEzMzA_2b3c3129-492a-4e07-9df5-f578fb3001e9"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i20a580f7ac9949a7a6e60bc124d3ba7c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtMy0xLTEtNzEzMzA_39d4028b-8e4b-4359-a37c-4aa3b8044fa1"
      unitRef="number">0.0470</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i2d7ec56a32fc48bbbae632b458fc3006_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtNS0xLTEtNzEzMzA_f7bf8538-f8aa-4a9a-a02b-2956ef335449"
      unitRef="number">0.0490</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i4d5c45c4555e4c1cb4a1787fb5c43e7b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtNy0xLTEtNzEzMzA_2b974006-ba58-4ea0-bdc2-a0bd2531cd93"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i1511dca0b95f43d38f4964a3f37eac23_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtOS0xLTEtNzEzMzA_94ab29b9-ca79-45f0-b878-c6ee1e016774"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i084d2c9bf3d84a6f9c2bc907b4ee8534_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzYtMTEtMS0xLTcxMzMw_24e03794-bb2a-406c-89d2-59216d6466db"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtMS0xLTEtNzEzMzA_c3696ee9-6fb3-4845-af5e-bac797058243"
      unitRef="number">0.0550</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ia358ddcd5cd64c81874827bf799c7cbb_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtMy0xLTEtNzEzMzA_90067ecc-038a-49a6-a833-ca8afb3402d1"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i69c9e567da174a86ad13d7332a5ceace_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtNS0xLTEtNzEzMzA_cab327fb-214a-4362-b86d-a96b494d7b30"
      unitRef="number">0.0270</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtNy0xLTEtNzEzMzA_369a33e9-34a7-433e-be62-3823a71f29cd"
      unitRef="number">0.0390</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtOS0xLTEtNzEzMzA_34b62e2c-a845-4659-971c-8e2a8c185057"
      unitRef="number">0.0150</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzgtMTEtMS0xLTcxMzMw_7a5fbf36-8993-48ef-add2-849a41c6c8c1"
      unitRef="number">0.0110</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktMS0xLTEtNzEzMzA_9a897332-aaf0-493b-99a9-01440548d06a"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ia358ddcd5cd64c81874827bf799c7cbb_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktMy0xLTEtNzEzMzA_9ecd1145-cd86-4b2a-942c-36fa711f1816"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i69c9e567da174a86ad13d7332a5ceace_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktNS0xLTEtNzEzMzA_14eb529b-9dad-4e51-8727-887287f4a437"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktNy0xLTEtNzEzMzA_6737f2d0-e8fd-442a-84ba-760b9338e04a"
      unitRef="number">0.0320</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktOS0xLTEtNzEzMzA_063e19bd-2e2e-4af0-abbf-f8dbfc789422"
      unitRef="number">0.0290</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzktMTEtMS0xLTcxMzMw_87fb493f-dc26-4bda-be7a-681136e9e2ac"
      unitRef="number">0.0280</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="ic5495cc09a654440a149148e4e68ccd3_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTEtMS0xLTcxMzMw_2c553902-3b82-4aca-84e6-e6f8e0b6df46"
      unitRef="number">0.0530</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="ia358ddcd5cd64c81874827bf799c7cbb_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTMtMS0xLTcxMzMw_48136255-14ea-434c-bbff-5c105df62ac6"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i69c9e567da174a86ad13d7332a5ceace_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTUtMS0xLTcxMzMw_33f0be74-3051-478a-83a7-b91486928276"
      unitRef="number">0.0470</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i5a159c6ddc2b4e71b751463a5bd906db_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTctMS0xLTcxMzMw_e0762e8c-1735-4239-8f7f-773b1322cee9"
      unitRef="number">0.0330</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i53aa5fa16f7c4f5c92ebb8b4686f4e7b_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTktMS0xLTcxMzMw_36c6f252-31b0-4ae8-bbc4-c8667d3915d4"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="iccda8b6f18df44c8b6ab2a65bf31b6a7_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTpkYWRlNjc4Zjg0Y2Y0MWFlYjU0YzE5MzU5MzJkNGJhOC90YWJsZXJhbmdlOmRhZGU2NzhmODRjZjQxYWViNTRjMTkzNTkzMmQ0YmE4XzEwLTExLTEtMS03MTMzMA_756c8366-6cb2-4c36-9a6b-344220dff12f"
      unitRef="number">0.0300</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="icd3d23b42991496e8be8317108cbd31b_D20230101-20231231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzg4NDk_59703844-ec16-4647-b8b0-bc6857a5df02"
      unitRef="number">0.0700</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i00c54d6e8143424db472e467e5653785_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzg4Nzk_dd503120-53af-46d2-a87d-2910a0c3cf74"
      unitRef="number">0.0670</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzNjE_5a5da785-5898-4400-a1ac-0443f8bb9149">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The health care cost trend rate assumptions for other postretirement benefit plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health care cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year that the trend rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzEtMS0xLTEtNzEzMzA_5497411d-1622-4bca-baf2-eb535f551e92"
      unitRef="number">0.078</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzEtMy0xLTEtNzEzMzA_24eb3825-096e-40af-9f6f-fc64afa9caec"
      unitRef="number">0.064</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i26d66e8191e3489da8b88251530ce552_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzItMS0xLTEtNzEzMzA_78efc0fc-11f8-43cd-97f4-dd23758aaa67"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i047b115329a54c42a89e9abfb277e348_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90YWJsZTo4NDNjMDUyMzkxOTg0NmY4YWZhN2ViNTZhMzk3MDU0ZS90YWJsZXJhbmdlOjg0M2MwNTIzOTE5ODQ2ZjhhZmE3ZWI1NmEzOTcwNTRlXzItMy0xLTEtNzEzMzA_fe3c93e2-0950-4b61-8a8e-d41b1ac84f33"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkyOTc_b1ad66e5-d6b2-4c7f-b8f8-b9a639bf003f"
      unitRef="usd">175000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMDE_1ef571af-c980-464e-8e5d-8fbd1cbee6d6"
      unitRef="usd">158000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTAvZnJhZzpjZjZiMTIyMThlNGM0NTViODJmMTE2OTBiY2FhMjc3ZS90ZXh0cmVnaW9uOmNmNmIxMjIxOGU0YzQ1NWI4MmYxMTY5MGJjYWEyNzdlXzkzMDg_e003a200-7745-4cb5-b314-b97e2aef4122"
      unitRef="usd">158000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg5Nw_1d662b78-95af-40a3-b443-9533f3d91c2f">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss (income) from investments in equity securities, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140&#160;million will be recorded in the first quarter of 2023 from ownership interests in investment funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest paid was $937 million in 2022, $779 million in 2021 and $822 million in 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg5OQ_9667e50e-55b1-4c50-a3e5-40baada8aa5c">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss (income) from investments in equity securities, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140&#160;million will be recorded in the first quarter of 2023 from ownership interests in investment funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzEtMS0xLTEtNzEzMzA_3289cd64-0e6c-40d7-ac4e-71e107fffe5f"
      unitRef="usd">157000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzEtMy0xLTEtNzEzMzA_09e4294c-1a84-4375-9cad-df82c7730ba1"
      unitRef="usd">36000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzEtNS0xLTEtNzEzMzA_1243dfe7-de9e-4309-9143-797014d1d190"
      unitRef="usd">59000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzItMS0xLTEtNzEzMzA_3354405d-9ad6-4717-9071-22a5cd75f3e5"
      unitRef="usd">962000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzItMy0xLTEtNzEzMzA_9a070c0a-8625-4d4b-8b93-0e6b207be272"
      unitRef="usd">806000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzItNS0xLTEtNzEzMzA_d20bdd11-1329-4159-9ff3-078265e9960a"
      unitRef="usd">831000000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzMtMS0xLTEtNzEzMzA_64f446cd-be36-4518-8d7e-52108e4f5cd2"
      unitRef="usd">-237000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzMtMy0xLTEtNzEzMzA_82d4fd92-643e-461f-a37e-30b2f6ecabdd"
      unitRef="usd">-297000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzMtNS0xLTEtNzEzMzA_efc6b2d0-61b3-43cd-8847-103e57b0fe28"
      unitRef="usd">-145000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzQtMS0xLTEtNzEzMzA_80372a46-f6aa-49f7-a4fc-2597d3f83af7"
      unitRef="usd">-1419000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzQtMy0xLTEtNzEzMzA_3bc2d4a6-f044-4475-b484-701af3551567"
      unitRef="usd">1940000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzQtNS0xLTEtNzEzMzA_ebf0450e-a91b-461c-b48c-3d0bc1b80fad"
      unitRef="usd">1338000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzUtMS0xLTEtNzEzMzA_c73ab68c-f7b7-46ab-9278-428078ae565a"
      unitRef="usd">-279000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzUtMy0xLTEtNzEzMzA_da851cb9-4f25-4881-8a52-c9caa994e2b7"
      unitRef="usd">-212000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzUtNS0xLTEtNzEzMzA_2a796b00-b376-421b-8e0a-dfb50badabe2"
      unitRef="usd">-339000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzYtMS0xLTEtNzEzMzA_33fbfe20-e0d4-4166-95dd-d0f866c0457a"
      unitRef="usd">681000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzYtMy0xLTEtNzEzMzA_e1a780e2-8782-47e3-b87f-5fe965fa60e9"
      unitRef="usd">256000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzYtNS0xLTEtNzEzMzA_2b68c7ff-d5fd-4800-82c3-79c12bfed5cd"
      unitRef="usd">130000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzctMS0xLTEtNzEzMzA_9b635efd-9654-49d8-ba30-9569211ced22"
      unitRef="usd">-1501000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzctMy0xLTEtNzEzMzA_8d08a3cb-b7b5-4b68-be54-f85c0109d38b"
      unitRef="usd">1341000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90YWJsZTo0ZDZlYWI5NDliOGQ0Y2EzYjc5ZTM0OTBlYTAyNThkNC90YWJsZXJhbmdlOjRkNmVhYjk0OWI4ZDRjYTNiNzllMzQ5MGVhMDI1OGQ0XzctNS0xLTEtNzEzMzA_a35dc228-7605-4ab4-b165-d523b7ce57d3"
      unitRef="usd">890000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie41dca853a9a42358f40da6cbd07030c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzE2NDkyNjc0NDQ4NzA_efd7c1dd-c5f6-4d82-9585-209bd66f41bb"
      unitRef="usd">140000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:InterestPaid
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg2Mg_eae1c7a5-6d0c-4728-a128-0b766a3f0099"
      unitRef="usd">937000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg3Mg_737f5399-d8fd-4457-8c13-ce85bc19a73f"
      unitRef="usd">779000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTMvZnJhZzo0ZGEzZjRlNDZmM2M0YTI5OWEzNjE5NjRhZjg5YjI5Yy90ZXh0cmVnaW9uOjRkYTNmNGU0NmYzYzRhMjk5YTM2MTk2NGFmODliMjljXzg4NQ_0491a4ef-8edd-4345-8be8-8347050e66f7"
      unitRef="usd">822000000</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYzMDM_318d8734-038e-4b80-bdc5-da1d58b26f33">Taxes on Income&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate applied to income from continuing operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Differential arising from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GILTI and the foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of VelosBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of Pandion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of OncoImmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,918&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the utilization of foreign tax credits, was $2.2 billion at December&#160;31, 2022, of which $732 million is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and the remainder of $1.5 billion is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income from continuing operations before taxes consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,011&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15,433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Taxes on income from continuing operations consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,918&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product intangibles and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pensions and other postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses and other tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,006&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,795&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December&#160;31, 2022, $349 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $345 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $563 million of deferred tax assets relating to various U.S. tax credit carryforwards and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;NOL carryforwards. Valuation allowances of $247&#160;million have been established on these U.S. tax credit carryforwards and NOL carryforwards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income taxes paid in 2022, 2021 and 2020 (including amounts attributable to discontinued operations in 2021 and 2020) were $3.2 billion, $2.4 billion and $2.7 billion, respectively. Income taxes paid consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes TCJA transition tax payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax benefits relating to stock option exercises were $45 million in 2022, $21 million in 2021 and $12 million in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amount in 2021 reflects a settlement with the IRS discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If the Company were to recognize the unrecognized tax benefits of $1.8 billion at December&#160;31, 2022, the income tax provision would reflect a favorable net impact of $1.8 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December&#160;31, 2022 could decrease by up to approximately $31 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company&#x2019;s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $54 million in 2022, $(37) million in 2021 and $16 million in 2020. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $256 million and $192 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck&#x2019;s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&#160;million (of which $172&#160;million related to continuing operations and $18&#160;million related to discontinued operations). The Company&#x2019;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236&#160;million net tax benefit in 2021 (of which $207&#160;million related to continuing operations and $29&#160;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The IRS is currently conducting examinations of the Company&#x2019;s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company&#x2019;s income tax returns are open for examination for the period 2003 through 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNzI_2a75b337-693c-401e-81b6-9c0090184e8f">&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&#160;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate applied to income from continuing operations before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Differential arising from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(11.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GILTI and the foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of VelosBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of Pandion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of OncoImmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,918&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItMS0xLTEtNzEzMzA_17e40a1b-85c5-4d27-99ae-7b4fadf3b9fd"
      unitRef="usd">3453000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItMy0xLTEtNzEzMzA_82846773-45fc-43c4-be30-31f752a94d58"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItNS0xLTEtNzEzMzA_c08f8b7d-b202-4d8a-9467-49342b274773"
      unitRef="usd">2915000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItNy0xLTEtNzEzMzA_f941973f-c597-463b-ba9a-6426b0c1e798"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItOS0xLTEtNzEzMzA_ca785e07-5e99-43bf-bee9-bb476022f278"
      unitRef="usd">1231000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzItMTEtMS0xLTcxMzMw_ee4f1c29-b1e0-4dbf-8a08-a420e2fa6b2a"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtMS0xLTEtNzEzMzA_b6682281-30aa-4354-b6ff-3dcd3de0c89d"
      unitRef="usd">-1835000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtMy0xLTEtNzEzMzA_e2488e67-5f36-487e-9f12-a8356c00ac18"
      unitRef="number">-0.111</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtNS0xLTEtNzEzMzA_3302d963-5a87-44f0-a36a-5bcf018da33d"
      unitRef="usd">-1446000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtNy0xLTEtNzEzMzA_73987fe5-bce2-4b64-9865-e22eaf4db002"
      unitRef="number">-0.104</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtOS0xLTEtNzEzMzA_807c1884-ed3e-40ed-bc87-7959734527f8"
      unitRef="usd">-965000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzQtMTEtMS0xLTcxMzMw_dd99e533-e40f-4d91-83d7-75d8f214cc36"
      unitRef="number">-0.165</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtMS0xLTEtNzEzMzA_1be07e88-a2b9-4c0d-9696-f62d8817c6cf"
      unitRef="usd">462000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtMy0xLTEtNzEzMzA_57af7fac-4c5d-4c86-b369-9cb042533ed1"
      unitRef="number">0.028</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtNS0xLTEtNzEzMzA_aec0c509-61cb-44e0-9a0b-8251218f4d79"
      unitRef="usd">-75000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtNy0xLTEtNzEzMzA_8b20ba14-d46b-4280-9dde-70de8e36c041"
      unitRef="number">-0.005</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtOS0xLTEtNzEzMzA_3dbb0b09-57b4-40d9-86eb-9e3d29afc363"
      unitRef="usd">349000000</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount>
    <mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzUtMTEtMS0xLTcxMzMw_444e7c8d-f419-41a9-8f68-015cf5f0377d"
      unitRef="number">0.060</mrk:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMS0xLTEtMTIzNzk3_adc661c8-2d38-475b-9dd1-5511432466cf"
      unitRef="usd">-110000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMy0xLTEtMTIzNzk3_89702a9a-ddaf-4c24-b8f9-bd27c0ebc4dd"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNS0xLTEtMTIzNzk3_b1e89406-ee53-4250-9a30-a8adbe7dd18b"
      unitRef="usd">2000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNy0xLTEtMTIzNzk3_a70b3da2-1576-472f-8f24-5722b86b5eaa"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtOS0xLTEtMTIzNzk3_7983b95b-b95a-4af1-98f7-4392b46e5235"
      unitRef="usd">57000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMTEtMS0xLTEyMzc5Nw_482970d0-2e63-4d09-be0e-5b01b2350d95"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctMS0xLTEtMTIzODA3_36b95bec-7461-4948-bee2-a4dcc425c31b"
      unitRef="usd">81000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctMy0xLTEtMTIzODA3_d38750d7-c595-4966-b75c-34445395a120"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctNS0xLTEtMTIzODA3_a65567d4-dfd9-46b3-86d5-57fbd8629be5"
      unitRef="usd">81000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctNy0xLTEtMTIzODA3_a1e3b209-69a8-4a11-941b-89b1931e9c58"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctOS0xLTEtMTIzODA3_968d9234-7ecb-4851-9b4f-15db5d444a70"
      unitRef="usd">108000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzctMTEtMS0xLTEyMzgwNw_4bdecf03-c286-4930-85a4-40c102d3dce6"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMS0xLTEtNzEzMzA_6cb9cf55-3e92-494a-899f-adba5a78e44c"
      unitRef="usd">-10000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMy0xLTEtNzEzMzA_783ba022-0ad8-4c77-8f23-de428dd3181f"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNS0xLTEtNzEzMzA_6a195574-c748-47f1-92c1-a8a970082bb2"
      unitRef="usd">-275000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtNy0xLTEtNzEzMzA_903bd7bb-5344-47df-9182-7818620c4723"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtOS0xLTEtNzEzMzA_6fdb2136-7738-4362-8f23-62cfb4180766"
      unitRef="usd">-13000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzYtMTEtMS0xLTcxMzMw_d410a99c-1945-4dea-acf2-c2eb3029baee"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTEtMS0xLTcxMzMw_34769b2a-4ffc-48bc-9c31-85f303a85b4f"
      unitRef="usd">108000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTMtMS0xLTcxMzMw_d4b461aa-58cf-46f6-bd67-21ad22c2fa0b"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTUtMS0xLTcxMzMw_1e0d1823-3ed3-41d5-ab17-b57aff7cef19"
      unitRef="usd">102000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTctMS0xLTcxMzMw_d9a2ebce-cb84-46cb-ad55-473103fc44a4"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTktMS0xLTcxMzMw_7b22d6c7-76a3-4de9-9c37-0a3d78589765"
      unitRef="usd">37000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzEwLTExLTEtMS03MTMzMA_409eea46-519b-43c5-b7e2-809dfa2cbe64"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTEtMS0xLTcxMzMw_6987e744-ff0f-47f9-82de-6ade404523d8"
      unitRef="usd">11000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTMtMS0xLTcxMzMw_988ca006-723d-49ea-851c-78eabfe1e1a5"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTUtMS0xLTcxMzMw_0adcb43d-7d18-4488-97c6-9a9610cd7d04"
      unitRef="usd">61000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTctMS0xLTcxMzMw_4f835376-26ab-41f4-9c8c-fca77a3991b7"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTktMS0xLTcxMzMw_aa9f0a3c-5023-46df-8db8-f599e736b4d8"
      unitRef="usd">105000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzExLTExLTEtMS03MTMzMA_ec14c66c-6e5d-46e3-ab64-53c362e64243"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <mrk:IncomeTaxRateReconciliationAssetAcquisition
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTEtMS0xLTEyMzgzNg_04919408-b9ed-4b7f-b406-b3be92d51a70"
      unitRef="usd">0</mrk:IncomeTaxRateReconciliationAssetAcquisition>
    <mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTMtMS0xLTEyMzgzNg_c612e160-13dd-466c-ab73-bc11d02855e6"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent>
    <mrk:IncomeTaxRateReconciliationAssetAcquisition
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTUtMS0xLTEyMzgzNg_12dce822-a57c-4c00-a678-5a08c0518eb2"
      unitRef="usd">-9000000</mrk:IncomeTaxRateReconciliationAssetAcquisition>
    <mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTctMS0xLTEyMzgzNg_a111ba13-eaa0-4ba0-bd23-f6d5c860355f"
      unitRef="number">-0.001</mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent>
    <mrk:IncomeTaxRateReconciliationAssetAcquisition
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTktMS0xLTEyMzgzNg_03aaccff-8905-41d2-bfee-c06a0e61313c"
      unitRef="usd">559000000</mrk:IncomeTaxRateReconciliationAssetAcquisition>
    <mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTExLTEtMS0xMjM4MzY_6f8622f7-71fb-42ef-bd9d-c520281d9186"
      unitRef="number">0.095</mrk:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTEtMS0xLTEyMzgzNg_4a392d4e-e12a-4381-9227-b60087f129b9"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTMtMS0xLTEyMzgzNg_7343733c-ecf1-463b-aea2-e524509c0280"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTUtMS0xLTEyMzgzNg_459a04d6-22b4-4ce0-8aa2-93a2aed3ba04"
      unitRef="usd">356000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTctMS0xLTEyMzgzNg_4fd7374e-39e3-4cc5-a600-a5c9deb7557e"
      unitRef="number">0.026</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTktMS0xLTEyMzgzNg_0446b7c5-b092-4eb1-8490-75fcfc39e955"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFour>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE1LTExLTEtMS0xMjM4MzY_050b7dc4-b8b4-4a89-883e-c6fa1a9dc648"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTEtMS0xLTcxMzMw_0997f7ef-a922-4b1a-99cb-2b9ac1e4f637"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTMtMS0xLTcxMzMw_7a4639cf-f46c-4952-8a01-1f569afb2640"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTUtMS0xLTcxMzMw_8378f853-4dfb-41fe-ac7f-43e2a48167af"
      unitRef="usd">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTctMS0xLTcxMzMw_3d1d8aba-a71a-417a-8388-727fa76538fa"
      unitRef="number">0</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTktMS0xLTcxMzMw_fd6e4266-edcb-4a30-a21d-07ae1cebd616"
      unitRef="usd">97000000</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo>
    <mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE0LTExLTEtMS03MTMzMA_83648576-2a6f-435f-b326-7c6d6b718fd2"
      unitRef="number">0.017</mrk:EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTEtMS0xLTcxMzMw_66e08514-b123-45de-b3ad-19fd3a07e1e7"
      unitRef="usd">-80000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTMtMS0xLTcxMzMw_90f9154d-50c2-409f-a665-316298e19414"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTUtMS0xLTcxMzMw_bdffcf71-211b-4f09-ac95-f4a78eb52cb6"
      unitRef="usd">-29000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTctMS0xLTcxMzMw_2de0c979-bf2a-43bc-a912-6ffaab17b5bf"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTktMS0xLTcxMzMw_bec549aa-0a35-4e18-a4ab-4fd52f86d07e"
      unitRef="usd">-9000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE3LTExLTEtMS03MTMzMA_40bde485-00b2-456c-9c60-6da814e55ba4"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTEtMS0xLTcxMzMw_e5830928-e46a-4d89-97d9-d4e33aa5830f"
      unitRef="usd">1918000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTMtMS0xLTcxMzMw_67e5cfd3-f693-48c7-ba3c-85dd90b67faa"
      unitRef="number">0.117</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTUtMS0xLTcxMzMw_c6a37df6-f1d4-4c6e-bb05-328a281c9bcd"
      unitRef="usd">1521000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTctMS0xLTcxMzMw_789d4054-437b-41a1-be3a-40f5d7882721"
      unitRef="number">0.110</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTktMS0xLTcxMzMw_6603544c-0e26-42b1-bc87-11900bae87aa"
      unitRef="usd">1340000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTc3MmE4ODY3MDg0NDMzYmU0ZTZmMzQ2Njg2ZjljOS90YWJsZXJhbmdlOjJlNzcyYTg4NjcwODQ0MzNiZTRlNmYzNDY2ODZmOWM5XzE4LTExLTEtMS03MTMzMA_b8195201-0f3b-4ef9-88cc-7eb2cdc26cac"
      unitRef="number">0.229</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzczNQ_42d26ca7-6d09-43b2-b9e9-cda2d575b156"
      unitRef="usd">2200000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent
      contextRef="i6e60950b557f4677846291e08c9270f0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5Xzc1NA_f00ccc48-f4f2-4fbb-93c2-aabe47aaa643"
      unitRef="usd">732000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent
      contextRef="i44fa248a36c14567824971ef9f972e05_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzgxNA_dac4cf12-47b2-454b-b91b-4d003780680e"
      unitRef="usd">1500000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNjU_a337858c-55cd-4025-8d62-f6fde591a80a">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income from continuing operations before taxes consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,011&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15,433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzEtMS0xLTEtNzEzMzA_5790d42f-347a-4e4b-922a-d0b83448bd3c"
      unitRef="usd">1011000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzEtMy0xLTEtNzEzMzA_290161cf-49ba-4451-9212-6bc57bbd745f"
      unitRef="usd">1854000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzEtNS0xLTEtNzEzMzA_8b2e1b3d-27c4-4f8a-af88-fe2b30b7e923"
      unitRef="usd">-3814000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzItMS0xLTEtNzEzMzA_464763b0-e7ee-40e6-90c7-93ca5b9443fa"
      unitRef="usd">15433000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzItMy0xLTEtNzEzMzA_43efff40-b55a-40f0-9db4-bcd5a51f469c"
      unitRef="usd">12025000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzItNS0xLTEtNzEzMzA_307f429c-8e9d-4a1c-af8a-53e595291945"
      unitRef="usd">9677000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzMtMS0xLTEtNzEzMzA_3e968f39-76f7-4dc1-bd9b-f5140f0c45d1"
      unitRef="usd">16444000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzMtMy0xLTEtNzEzMzA_dac9b709-c769-46d8-80c8-20940cbc3b49"
      unitRef="usd">13879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTowM2UzN2I4OWQzYmM0YjlmOGYzNDM4ZTQyMDhkMDBkYS90YWJsZXJhbmdlOjAzZTM3Yjg5ZDNiYzRiOWY4ZjM0MzhlNDIwOGQwMGRhXzMtNS0xLTEtNzEzMzA_36972307-1ebb-439a-b04a-29bfc2e3cdb1"
      unitRef="usd">5863000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYzMTg_b227dd8c-f687-478e-a087-d8c9fc7a2036">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Taxes on income from continuing operations consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,918&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzItMS0xLTEtNzEzMzA_2c8faded-ca8d-4b2c-9deb-cbee49459882"
      unitRef="usd">2265000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzItMy0xLTEtNzEzMzA_9c4f99aa-f5d7-4fda-a37e-32a2b14decbf"
      unitRef="usd">74000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzItNS0xLTEtNzEzMzA_7cac91a7-76af-442f-87ca-6140f7d0d023"
      unitRef="usd">893000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzMtMS0xLTEtNzEzMzA_9c9143de-a873-4dc0-8af6-2226bf0e1297"
      unitRef="usd">1164000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzMtMy0xLTEtNzEzMzA_8b5a4642-38f6-4b99-9231-fc91cc6d756f"
      unitRef="usd">1273000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzMtNS0xLTEtNzEzMzA_bf125e95-4cc9-474d-91d4-59eba704f123"
      unitRef="usd">969000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzQtMS0xLTEtNzEzMzA_31026992-c1f3-41c2-b66f-a25b238a611e"
      unitRef="usd">57000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzQtMy0xLTEtNzEzMzA_7086be82-f6a7-4c76-925d-1dc784ff7e75"
      unitRef="usd">-13000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzQtNS0xLTEtNzEzMzA_e306b544-4715-4a30-8477-579241731eb5"
      unitRef="usd">44000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzUtMS0xLTEtNzEzMzA_b410f373-8e5c-40c5-bcd6-b9387edc930f"
      unitRef="usd">3486000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzUtMy0xLTEtNzEzMzA_22f2c00a-5c55-40f7-8783-250eaa3fb016"
      unitRef="usd">1334000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzUtNS0xLTEtNzEzMzA_a1aaee12-b27e-477f-a2d2-c086170ffbea"
      unitRef="usd">1906000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzctMS0xLTEtNzEzMzA_d4ca7519-e933-41e3-9ec9-cd349cf0af2d"
      unitRef="usd">-1510000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzctMy0xLTEtNzEzMzA_00c3942d-f893-4657-a900-c1017515a1c6"
      unitRef="usd">240000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzctNS0xLTEtNzEzMzA_27742abb-48c8-4c30-a7d4-9d765229ed5e"
      unitRef="usd">-605000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzgtMS0xLTEtNzEzMzA_59db07d5-1d5c-4dab-9278-f97cd0135e0b"
      unitRef="usd">71000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzgtMy0xLTEtNzEzMzA_10dcca18-8e56-4844-887c-dc5c7b012368"
      unitRef="usd">-77000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzgtNS0xLTEtNzEzMzA_ed8fa6b8-5751-4469-95fd-bd90bcb01ee8"
      unitRef="usd">64000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzktMS0xLTEtNzEzMzA_762ceb38-f20b-4568-a4a6-341d756e1ddd"
      unitRef="usd">-129000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzktMy0xLTEtNzEzMzA_9fd7cf6d-bade-4385-9cf6-52d4203e3b54"
      unitRef="usd">24000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzktNS0xLTEtNzEzMzA_0193065b-9fc6-4067-83a1-525ceb1f9ec6"
      unitRef="usd">-25000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzEwLTEtMS0xLTcxMzMw_d1330683-0e3e-43fc-ad02-7f4cff09c1b4"
      unitRef="usd">-1568000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzEwLTMtMS0xLTcxMzMw_f0ae5aa2-e413-4d8c-8c8d-ad06af883b95"
      unitRef="usd">187000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzEwLTUtMS0xLTcxMzMw_7a227a4f-ff8f-4f5e-8692-08510506fd9e"
      unitRef="usd">-566000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzExLTEtMS0xLTcxMzMw_bc4c5401-0584-4dba-b3c6-1922209be9eb"
      unitRef="usd">1918000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzExLTMtMS0xLTcxMzMw_8be0a966-795f-4ace-bdd8-08e86072c914"
      unitRef="usd">1521000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NDY2MmQyMzA0NDg0NTg1YWY1MjBjYmZhN2NmODllNC90YWJsZXJhbmdlOjU0NjYyZDIzMDQ0ODQ1ODVhZjUyMGNiZmE3Y2Y4OWU0XzExLTUtMS0xLTcxMzMw_b053ec8b-8929-488b-bf8c-85a3811581f0"
      unitRef="usd">1340000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNzM_b7293eb6-96a5-4d10-9cd3-de9a82326ac8">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31 consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.921%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product intangibles and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,575&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventory related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pensions and other postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;372&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;91&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses and other tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,006&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,795&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItMS0xLTEtNzEzMzA_8467ad79-b102-4b37-afc9-b627755ccdbf"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItMy0xLTEtNzEzMzA_74bf220e-ae8c-480f-9b78-561b4c441288"
      unitRef="usd">2575000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItNS0xLTEtNzEzMzA_bddf9a3d-3212-4f3d-bc67-25f215f7bd19"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzItNy0xLTEtNzEzMzA_21dead6b-3e00-4b2f-ba4f-51bdd795bc41"
      unitRef="usd">3207000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtMS0xLTEtMTI0MDQz_97bf41d9-ea22-48bb-9da3-899b3283989d"
      unitRef="usd">1341000000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtNS0xLTEtMTI0MDQz_61a8befd-9422-4271-907c-5ea822be0e28"
      unitRef="usd">274000000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtMS0xLTEtNzEzMzA_16850aa0-db4e-4e83-9fd0-cc3fb98a226e"
      unitRef="usd">43000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtMy0xLTEtNzEzMzA_031facab-f66d-47b5-8e47-95b181fb33ff"
      unitRef="usd">423000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtNS0xLTEtNzEzMzA_5c3e6516-7a8b-4893-92df-927e8a904848"
      unitRef="usd">119000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzMtNy0xLTEtNzEzMzA_cb235eba-9f43-4c57-949f-cc1879cef6f0"
      unitRef="usd">370000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtMS0xLTEtNzEzMzA_9045aae0-6899-4463-951a-645fc4991c95"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtMy0xLTEtNzEzMzA_65a28b50-7aba-482f-955f-d1b111486eff"
      unitRef="usd">657000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtNS0xLTEtNzEzMzA_7b83526e-ad9d-4b34-b94d-bb6b58d0e9e9"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzQtNy0xLTEtNzEzMzA_f7a0d58b-8771-4726-a284-085e3508031a"
      unitRef="usd">589000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtMS0xLTEtNzEzMzA_678ecccb-8d52-449e-8049-5d08072eb4b2"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <mrk:DeferredTaxLiabilitiesEquityMethodInvestment
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtMy0xLTEtNzEzMzA_c9ca9178-fae2-4b2b-a242-219524858f03"
      unitRef="usd">92000000</mrk:DeferredTaxLiabilitiesEquityMethodInvestment>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtNS0xLTEtNzEzMzA_91d12b1e-8cef-4de8-8bb2-8883d52c72d5"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <mrk:DeferredTaxLiabilitiesEquityMethodInvestment
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzUtNy0xLTEtNzEzMzA_5f7c0966-593c-462c-811d-cf37f4040a61"
      unitRef="usd">335000000</mrk:DeferredTaxLiabilitiesEquityMethodInvestment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtMS0xLTEtNzEzMzA_7051acd5-89be-4ecb-b08e-16fd71e78b16"
      unitRef="usd">372000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtMy0xLTEtNzEzMzA_a8985e36-ba62-49d5-ae0e-fb145f6209db"
      unitRef="usd">284000000</mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtNS0xLTEtNzEzMzA_c4e42e88-2fad-42af-8c25-7c07d39d9a85"
      unitRef="usd">487000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzYtNy0xLTEtNzEzMzA_827eb3e7-09a2-44dc-acfb-4893974d0220"
      unitRef="usd">338000000</mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzctMS0xLTEtNzEzMzA_11ac0d57-3bc5-4d80-acb2-ea16f60e5169"
      unitRef="usd">335000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzctNS0xLTEtNzEzMzA_28d23045-a6c6-4418-80fa-64ca976985db"
      unitRef="usd">301000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <mrk:DeferredTaxAssetsUnrecognizedTaxBenefits
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzgtMS0xLTEtNzEzMzA_f2594d95-c586-4c83-8855-9b64e226309c"
      unitRef="usd">91000000</mrk:DeferredTaxAssetsUnrecognizedTaxBenefits>
    <mrk:DeferredTaxAssetsUnrecognizedTaxBenefits
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzgtNS0xLTEtNzEzMzA_ad625103-33cc-4ac3-9add-81704af9cdd2"
      unitRef="usd">75000000</mrk:DeferredTaxAssetsUnrecognizedTaxBenefits>
    <mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzktMS0xLTEtNzEzMzA_57428060-4d5e-4d06-ba99-a1d9334844fb"
      unitRef="usd">912000000</mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards>
    <mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzktNS0xLTEtNzEzMzA_60fac604-54a9-4818-a493-93acbf1396b3"
      unitRef="usd">867000000</mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTEtMS0xLTcxMzMw_0503ffed-df02-4444-9983-057fa7a513a1"
      unitRef="usd">511000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTMtMS0xLTcxMzMw_99466100-f016-40b5-93c9-4074d4fecede"
      unitRef="usd">267000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTUtMS0xLTcxMzMw_21a7608a-1e96-49a0-8d24-072c9e39c63d"
      unitRef="usd">434000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEwLTctMS0xLTcxMzMw_d8ff38fd-0d3f-479d-92c8-285fbf39ef8d"
      unitRef="usd">180000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTEtMS0xLTcxMzMw_31f594af-3bc7-44d1-917d-684772dab6bb"
      unitRef="usd">3605000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTMtMS0xLTcxMzMw_b366fcb3-4ad7-44a3-8110-8db0fd330bef"
      unitRef="usd">4298000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTUtMS0xLTcxMzMw_a6282203-41c4-4ea2-a6a7-af925d15f040"
      unitRef="usd">2557000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzExLTctMS0xLTcxMzMw_8b3320ca-2f20-4a4e-838a-96a3ed56a3b7"
      unitRef="usd">5019000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEyLTEtMS0xLTcxMzMw_bcb73859-5b7f-4790-b5fc-8b672103cc38"
      unitRef="usd">599000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEyLTUtMS0xLTcxMzMw_99d9ae99-51e6-4138-b697-7b8c9f67d66a"
      unitRef="usd">287000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTEtMS0xLTcxMzMw_a6f17a1b-e54d-4135-9f59-2cc8915833c8"
      unitRef="usd">3006000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTMtMS0xLTcxMzMw_b5767008-8d6b-463a-aad6-a9dbc092f84c"
      unitRef="usd">4298000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTUtMS0xLTcxMzMw_0262b55a-96c3-461f-9274-791f99cfc7b7"
      unitRef="usd">2270000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzEzLTctMS0xLTcxMzMw_c55c2e8e-8bb2-478e-821d-6d8d1bc99dc1"
      unitRef="usd">5019000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE0LTMtMS0xLTcxMzMw_e59a7bfc-5424-47ea-a23b-ea4d8e671c5d"
      unitRef="usd">1292000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE0LTctMS0xLTcxMzMw_ef35db07-e69b-47c8-8ab1-729993f54472"
      unitRef="usd">2749000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i3f5705ed276147c49ca285310c722e6a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE2LTEtMS0xLTcxMzMw_513b94dd-62bd-45ac-861d-eb9e20168966"
      unitRef="usd">503000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iaf27171f8c7f483b8f695370dd8fed99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE2LTUtMS0xLTcxMzMw_3216744d-ef10-472a-8521-030d03ecf5e8"
      unitRef="usd">692000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE3LTMtMS0xLTcxMzMw_d0bd5f2f-e07e-4363-9f73-b6db66292bee"
      unitRef="usd">1795000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTo1NjBjODc5YTlkMGQ0MDdjOGExN2JhOWViNGI0ODViNy90YWJsZXJhbmdlOjU2MGM4NzlhOWQwZDQwN2M4YTE3YmE5ZWI0YjQ4NWI3XzE3LTctMS0xLTcxMzMw_e9469ef1-eb5e-454c-8892-bcdc1e8dbe72"
      unitRef="usd">3441000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzIyNDY_a71d3f19-1ad8-422d-ac7c-159afa2d3724"
      unitRef="usd">349000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i540b17b98c5447ca8f7d0de2174e6403_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzIzNTA_7b9ddafa-0bda-4d8e-a9ed-86457638e55c"
      unitRef="usd">345000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI0Nzg_1684349c-0bfa-44d7-90c9-87b4a6884fba"
      unitRef="usd">563000000</mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i799b8472304c4a24aa87481dc87bcefb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI2MDE_7550a4e7-2809-412c-82d3-c7eaeb1c796d"
      unitRef="usd">247000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:IncomeTaxesPaid
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI3ODk_f242e315-cdb6-432e-ad08-2c2b5b567bd3"
      unitRef="usd">3200000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI3OTM_56f9c994-e3ff-412d-91e9-da71b0c91913"
      unitRef="usd">2400000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4MDA_f24f13b7-3997-4e75-9fb6-5d77700a69f8"
      unitRef="usd">2700000000</us-gaap:IncomeTaxesPaid>
    <mrk:ScheduleOfIncomeTaxesPaidTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzM4NDgyOTA3MDg5MzY_34f1b9df-2f7f-420c-a258-02b32088b9c0">Income taxes paid consisted of:&lt;div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes TCJA transition tax payments.&lt;/span&gt;&lt;/div&gt;</mrk:ScheduleOfIncomeTaxesPaidTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia09a86e8c1434a81b69233805423f1e7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzEtMS0xLTEtMTMwNDQz_0f77a23e-d324-42cf-9c3d-c64ed6d4d090"
      unitRef="usd">1891000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i3e0b703f3bba444fa6d4622ccfa960f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzEtMy0xLTEtMTMwNDQz_eddd1125-67b8-4af1-908d-0d282d171d00"
      unitRef="usd">1211000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i74765aa20bbc4bdd99d6913c1418a345_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzEtNS0xLTEtMTMwNDQz_45351ad4-e002-420e-bfc8-ddf592058737"
      unitRef="usd">977000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i45f82e1279454361b6876985ee31a5f1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzItMS0xLTEtMTMwNDQz_d31f6eb5-4920-4d38-b614-c29b7bd566be"
      unitRef="usd">1348000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4630f56a7e0a427882ad898683404c6e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzItMy0xLTEtMTMwNDQz_df170b38-5a6c-45e5-9003-47b44d6fbd14"
      unitRef="usd">1201000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ic5ce7859bb6640678ff3056905b8d464_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzItNS0xLTEtMTMwNDQz_84bfa761-7ac0-49d6-8ef1-c3cf5e758c0a"
      unitRef="usd">1763000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzMtMS0xLTEtMTMwNDQz_8657f5bf-c22c-4937-a649-ff70b181ed40"
      unitRef="usd">3239000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzMtMy0xLTEtMTMwNDQz_18dccf76-4a62-4ab7-8405-8c402e634c2c"
      unitRef="usd">2412000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZToyZTU3MmM2ZjFhNTU0NmFhYjY3MGVlM2I2MmJhODNiMC90YWJsZXJhbmdlOjJlNTcyYzZmMWE1NTQ2YWFiNjcwZWUzYjYyYmE4M2IwXzMtNS0xLTEtMTMwNDQz_7e884013-dab5-4cd2-bdb8-b31c16163b44"
      unitRef="usd">2740000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4NzE_6ac1cf63-5910-40e6-bd6a-30a539ea456d"
      unitRef="usd">45000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4ODE_1a32c92a-4c10-4fd3-be62-957a2b694e15"
      unitRef="usd">21000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzI4OTQ_cc174fac-651e-4abd-ac3f-95cfe0c05795"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzYyNzk_f792156e-1ec3-4fe1-8418-f7cd876590f0">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Amount in 2021 reflects a settlement with the IRS discussed below.</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzEtMS0xLTEtNzEzMzA_7c0d33ef-d30c-469f-9a5b-cfa06e945839"
      unitRef="usd">1529000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzEtMy0xLTEtNzEzMzA_4051c830-c58b-4d75-a391-616a6e73a355"
      unitRef="usd">1537000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i50a206ace8ff4b2b880a7d891b6470c1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzEtNS0xLTEtNzEzMzA_05336a04-4d72-4ef7-b029-b1c2740b5266"
      unitRef="usd">1225000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzItMS0xLTEtNzEzMzA_dc1c3725-cb22-40b7-9425-9c0a148234f2"
      unitRef="usd">344000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzItMy0xLTEtNzEzMzA_2c8b8de6-1db1-4447-8c83-1027b6b97bc1"
      unitRef="usd">306000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzItNS0xLTEtNzEzMzA_dfc454ca-29b5-4474-89e0-8099dc2da54f"
      unitRef="usd">298000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzMtMS0xLTEtNzEzMzA_c01a0736-7bec-4873-85ef-f4368e89d8f4"
      unitRef="usd">48000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzMtMy0xLTEtNzEzMzA_8cbfaa9e-da22-4f0e-ba47-1d15f24085fe"
      unitRef="usd">63000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzMtNS0xLTEtNzEzMzA_c103b706-0828-4aa0-94d1-458f6d9d070c"
      unitRef="usd">110000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzQtMS0xLTEtNzEzMzA_33308061-d416-4b0d-bda0-df482a4077cc"
      unitRef="usd">40000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzQtMy0xLTEtNzEzMzA_6d930ce9-29b3-4d3a-8460-24361f2e18d6"
      unitRef="usd">230000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzQtNS0xLTEtNzEzMzA_c188dc46-923d-4c1e-9e59-7567f20904af"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzUtMS0xLTEtNzEzMzA_813ef534-9587-41d7-9e87-11491af79262"
      unitRef="usd">6000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzUtMy0xLTEtNzEzMzA_8b9fad93-77d7-475d-8c87-6bb82b3f4a04"
      unitRef="usd">46000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzUtNS0xLTEtNzEzMzA_4f19f31b-b1ea-4b7d-bdb8-17a1c3b85f0c"
      unitRef="usd">70000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzYtMS0xLTEtNzEzMzA_3a999127-4368-49fa-a8d5-18d5fa9a3611"
      unitRef="usd">40000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzYtMy0xLTEtNzEzMzA_30d9893f-dc2c-4108-9b71-843283e45635"
      unitRef="usd">58000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzYtNS0xLTEtNzEzMzA_a45616e7-38a3-46d6-83fe-15e2be01b089"
      unitRef="usd">22000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzctMS0xLTEtNzEzMzA_5814863e-a9a7-4862-a487-2ad430323886"
      unitRef="usd">0</mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction>
    <mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzctMy0xLTEtNzEzMzA_7425dbf6-3dab-46ca-9393-03d167a828fe"
      unitRef="usd">43000000</mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction>
    <mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzctNS0xLTEtNzEzMzA_deac34ca-f59c-40e0-8170-210a198db5a2"
      unitRef="usd">0</mrk:UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzgtMS0xLTEtNzEzMzA_5b1d9050-d514-4a41-b816-6f4bf5c9c944"
      unitRef="usd">1835000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzgtMy0xLTEtNzEzMzA_048f737c-9c32-459d-89de-59a5452384ff"
      unitRef="usd">1529000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90YWJsZTpjMjk2OWJkMjFlMDY0NTNiYjdjYmE5MmMxMjZjODliOS90YWJsZXJhbmdlOmMyOTY5YmQyMWUwNjQ1M2JiN2NiYTkyYzEyNmM4OWI5XzgtNS0xLTEtNzEzMzA_1cf04f33-5906-41be-a9a7-7cf7dce86ace"
      unitRef="usd">1537000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzMyNTE_20475311-8b41-4578-a936-35b6eba5d614"
      unitRef="usd">1800000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzMzMjY_a13fdf16-11cd-4a98-9017-cafcc00ed2f0"
      unitRef="usd">1800000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzM1NzY_27ad9c2e-d827-42c3-99bc-4138b3ae9122"
      unitRef="usd">31000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQxNjI_9f04edb5-481b-45ea-a733-fd2fa886a560"
      unitRef="usd">54000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQxNzI_934cc28a-1c96-4398-88f3-07e11dbe2542"
      unitRef="usd">-37000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQxODU_cc9ace09-96b5-4bf0-80ba-32338a8b82fa"
      unitRef="usd">16000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQzNjM_5233288d-15db-4648-9d8b-601417aeed64"
      unitRef="usd">256000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQzNzA_7cbd996d-e09e-4080-b66a-beee9fe6d60c"
      unitRef="usd">192000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9f36c5d17d7f4ad793c7d79ff96b69c6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ1ODg_96d0a382-9ecc-47f7-a7e1-b9c81581c7ef"
      unitRef="usd">190000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1fc09dc5008b41e08065acb6f23ea811_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ2MDE_a2e01dd2-dc33-412e-9a4e-314942001253"
      unitRef="usd">172000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia160115328384ec0a210cc9247afaacf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ2NDE_eb6d7719-0a96-4bd8-8546-86e9230e0c67"
      unitRef="usd">18000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i9f36c5d17d7f4ad793c7d79ff96b69c6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ4NjQ_317e61ec-b7c8-4775-a94f-3334384147f2"
      unitRef="usd">236000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i1fc09dc5008b41e08065acb6f23ea811_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ5MDE_36d4b521-fbb7-4197-81f8-5c666a497f91"
      unitRef="usd">207000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ia160115328384ec0a210cc9247afaacf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTYvZnJhZzo1N2RiNzY4NzMwZWI0NGZmOTMwMTBhM2QzZDVlODlmOS90ZXh0cmVnaW9uOjU3ZGI3Njg3MzBlYjQ0ZmY5MzAxMGEzZDNkNWU4OWY5XzQ5NDE_68d0393d-21a5-4ea3-8bc3-8fd5b6fba06d"
      unitRef="usd">29000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzQyOA_d4c8754f-e8f3-4a60-a335-ac367f63fb68">Earnings per Share&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share (shares in millions) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income from Continuing Operations Attributable to Merck &amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,542&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2022, 2021 and 2020, 2 million, 9 million and 5 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzQyMQ_bdc7a18b-27db-4c92-925a-3c54e1dc9a5b">&lt;div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share (shares in millions) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income from Continuing Operations Attributable to Merck &amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,542&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Continuing Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from Discontinued Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEtMS0xLTEtNzEzMzA_a0e1b605-d839-4933-b90e-00d9d5b969e7"
      unitRef="usd">14519000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEtMy0xLTEtNzEzMzA_a5ee9495-d8d5-4d24-a6a7-28f60afa32c8"
      unitRef="usd">12345000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEtNS0xLTEtNzEzMzA_1a4098ae-6759-464b-a207-d743e905fc1a"
      unitRef="usd">4519000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzItMS0xLTEtNzEzMzA_e04a69e4-8ca8-4685-9b76-74087c9f0608"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzItMy0xLTEtNzEzMzA_7a55213c-865a-4948-a671-ce8081a1155e"
      unitRef="usd">704000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzItNS0xLTEtNzEzMzA_57081eaf-1f88-44c9-8d01-c2e29d9e4efe"
      unitRef="usd">2548000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMS0xLTEtNzEzMzA_448ecea6-0777-4863-9254-248eda20140b"
      unitRef="usd">14519000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMS0xLTEtNzEzMzA_f4b794d0-b7fe-42b2-812e-8353c5209296"
      unitRef="usd">14519000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMy0xLTEtNzEzMzA_84256e6e-76fa-4c0c-bca0-74b2a323bf1d"
      unitRef="usd">13049000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtMy0xLTEtNzEzMzA_85cb0b66-268d-4eb3-8d7f-37ba5f4c90c5"
      unitRef="usd">13049000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtNS0xLTEtNzEzMzA_c6b2c670-725e-4459-acd5-39b7472be7d9"
      unitRef="usd">7067000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzMtNS0xLTEtNzEzMzA_e60f0af1-905d-4860-8b1c-709c1972f46d"
      unitRef="usd">7067000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzQtMS0xLTEtNzEzMzA_7aa3499b-24b1-42df-a7d2-1fce1c373957"
      unitRef="shares">2532000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzQtMy0xLTEtNzEzMzA_4c4b6fcc-b1e0-4fc8-805f-cb8a85d7f01c"
      unitRef="shares">2530000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzQtNS0xLTEtNzEzMzA_e4cd699b-3f1e-4de3-99c3-9cfa7be4d6c1"
      unitRef="shares">2530000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzUtMS0xLTEtNzEzMzA_1f7d34ab-a9cd-4ede-b206-709163eba3e7"
      unitRef="shares">10000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzUtMy0xLTEtNzEzMzA_f6c0f96a-c22d-43d2-bdec-86b5fe9697f9"
      unitRef="shares">8000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzUtNS0xLTEtNzEzMzA_7a30abd2-41c6-49c8-b29f-325627427bdf"
      unitRef="shares">11000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzYtMS0xLTEtNzEzMzA_9179da2a-e732-41fa-be4a-ed54892b2431"
      unitRef="shares">2542000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzYtMy0xLTEtNzEzMzA_1ba8277a-2a09-4a46-a2c7-c270aeb5e7a6"
      unitRef="shares">2538000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzYtNS0xLTEtNzEzMzA_edda18b7-f23a-4365-a35c-d91588c85c30"
      unitRef="shares">2541000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzgtMS0xLTEtNzEzMzA_38ce9fe3-dddb-4256-acc2-86339f67c1f6"
      unitRef="usdPerShare">5.73</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzgtMy0xLTEtNzEzMzA_d078da01-07b9-4ed6-9a58-23077eba3926"
      unitRef="usdPerShare">4.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzgtNS0xLTEtNzEzMzA_d7df58d8-11cd-4788-a1da-5b8f7fc4b72b"
      unitRef="usdPerShare">1.79</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzktMS0xLTEtNzEzMzA_6c4ab11e-f54d-4ab0-be99-3786bbb7b81b"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzktMy0xLTEtNzEzMzA_f106b890-9ab5-4df2-a214-b9ef2fb03e90"
      unitRef="usdPerShare">0.28</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzktNS0xLTEtNzEzMzA_9130e8d3-b758-48f5-8e37-b45b48199889"
      unitRef="usdPerShare">1.01</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEwLTEtMS0xLTcxMzMw_d31b7fdd-7a87-4a53-8aaf-ca6b6e5c4911"
      unitRef="usdPerShare">5.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEwLTMtMS0xLTcxMzMw_f7cfb750-a75b-4834-ba96-a786bb39cfcf"
      unitRef="usdPerShare">5.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEwLTUtMS0xLTcxMzMw_52af3c19-7df4-4e03-b19f-cec15c73e628"
      unitRef="usdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEyLTEtMS0xLTcxMzMw_d5ae8368-7d57-4990-8905-147235f1815a"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEyLTMtMS0xLTcxMzMw_dd3ecab5-6c29-4dc3-a9bd-a1c450d89ec0"
      unitRef="usdPerShare">4.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEyLTUtMS0xLTcxMzMw_2903af07-4adb-4231-8964-5b2f81489e2e"
      unitRef="usdPerShare">1.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEzLTEtMS0xLTcxMzMw_77f51d89-17cb-4344-a342-2815790145c2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEzLTMtMS0xLTcxMzMw_02072bf6-6a7b-464d-8ebe-3f5e6c8277ba"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzEzLTUtMS0xLTcxMzMw_ec31b9bc-eb9f-4d62-93d2-be8abf61c39c"
      unitRef="usdPerShare">1.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzE0LTEtMS0xLTcxMzMw_85f84639-d65e-464e-85c9-7e4794082f03"
      unitRef="usdPerShare">5.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzE0LTMtMS0xLTcxMzMw_85bf6f2f-cfd5-4e74-82f2-904a1f69d63a"
      unitRef="usdPerShare">5.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90YWJsZTo1ZTM4YTVmMGEwYWE0ZjgwYmFjYjllYWVmOTZkNTcwNi90YWJsZXJhbmdlOjVlMzhhNWYwYTBhYTRmODBiYWNiOWVhZWY5NmQ1NzA2XzE0LTUtMS0xLTcxMzMw_4c03e16c-f89a-4ac9-8853-48d49098720d"
      unitRef="usdPerShare">2.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzE4OQ_03872f21-98c8-4c76-9f03-5c622f001bde"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzE5Mw_76fe2ab9-1921-4ca5-93d3-ab573a7dfb79"
      unitRef="shares">9000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xOTkvZnJhZzowMGYyMjdiZTViMWQ0YTEwODg3MTE4NmY5MDM1NjFmMC90ZXh0cmVnaW9uOjAwZjIyN2JlNWIxZDRhMTA4ODcxMTg2ZjkwMzU2MWYwXzIwMA_f70f8138-269b-4fea-82be-678b5a68bd60"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzkxOQ_cd51e341-b186-4545-86ae-2ec9b9575ec1">Other Comprehensive Income (Loss)&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2020, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon (see Note&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Primarily relates to foreign currency cash flow hedges that were reclassified from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;AOCL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;14).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzkzNDU4NDg4MzcxMzI_b066a821-3fc3-4bcf-a53f-64d08a1c3c93">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2020, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Spin-off of Organon (see Note&#160;3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Primarily relates to foreign currency cash flow hedges that were reclassified from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;AOCL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;14).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i712fa8b98e5e4ccab42eee70db45d412_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtMS0xLTEtNzEzMzA_63c24ad5-32aa-4a98-85bc-cdd59ff8c135"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1639bac565704b8db1b75f669f2f8d20_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtMy0xLTEtNzEzMzA_11d350c6-57d6-4899-bab0-8a86a710d03e"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35687940c55f4162a974c6fba1256951_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtNS0xLTEtNzEzMzA_8048ef14-7af6-4e25-98f8-3bc0393668a1"
      unitRef="usd">-4261000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98d2ea2a866e477993f83cbe1be3386e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtNy0xLTEtNzEzMzA_c6838640-5bff-4650-b99c-4ecbe301bb70"
      unitRef="usd">-1981000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief9bf241be3f43c8aac25c903996f2e3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEtOS0xLTEtNzEzMzA_0a32c639-2360-4ea4-87e8-f8582a3808e8"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItMS0xLTEtNzEzMzA_f8a4a63f-23ac-4100-87f0-f683a0d8c0f2"
      unitRef="usd">-383000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItMy0xLTEtNzEzMzA_f5b55c16-a116-46d3-acab-f2ad3415cd76"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItNS0xLTEtNzEzMzA_cab3ecca-0458-4a39-aceb-2502bc5e9296"
      unitRef="usd">-633000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItNy0xLTEtNzEzMzA_0b914949-b53f-4a12-a921-ca0107641817"
      unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzItOS0xLTEtNzEzMzA_ea464807-a185-4b4c-be40-1ad03a0f212f"
      unitRef="usd">-949000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtMS0xLTEtNzEzMzA_a3291903-2d00-4b3d-99f6-de8fa0e66bd3"
      unitRef="usd">-84000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtMy0xLTEtNzEzMzA_e033edee-0322-4853-8122-42b7b1fc5fad"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtNS0xLTEtNzEzMzA_df971b4d-2291-4658-afa5-ccd56a636da6"
      unitRef="usd">-120000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtNy0xLTEtNzEzMzA_d1bb41f5-344e-4b2b-b89f-5d80b6d0de52"
      unitRef="usd">-89000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzMtOS0xLTEtNzEzMzA_6c517b57-2f0d-4c86-af11-87e36cbdd2e6"
      unitRef="usd">-293000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtMS0xLTEtNzEzMzA_98514cfc-bada-4315-bbab-03876fe84df9"
      unitRef="usd">-299000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtMy0xLTEtNzEzMzA_1c6e48b0-8f5d-4e4d-ae09-d3a0692a4876"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtNS0xLTEtNzEzMzA_7042c2a5-4e16-4bdb-acd9-06002ff59a88"
      unitRef="usd">-513000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtNy0xLTEtNzEzMzA_42e5f49c-7717-47af-a530-aae55214e68b"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzQtOS0xLTEtNzEzMzA_aab453a0-f859-441c-bf0c-82586369ebc6"
      unitRef="usd">-656000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtMS0xLTEtNzEzMzA_0409650c-8bcb-4927-938e-ed7e8426f743"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtMy0xLTEtNzEzMzA_c9c93cae-9006-41f3-8ef5-03bb17ae3114"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtNS0xLTEtNzEzMzA_55eec6f5-4520-4489-bb8f-5b36a01f731d"
      unitRef="usd">-306000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtNy0xLTEtNzEzMzA_446ee64c-78d0-4685-9ecc-6ddffd0d382e"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzUtOS0xLTEtNzEzMzA_6ba3709f-5b07-4e21-b29b-b712cfb056b2"
      unitRef="usd">-287000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtMS0xLTEtNzEzMzA_f8d6c157-3338-4bc2-b6e2-55f8f23f1fe9"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtMy0xLTEtNzEzMzA_de6a6055-1165-44e2-8ad9-a689d53e895c"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtNS0xLTEtNzEzMzA_0aed6829-442f-4ee8-80b5-1879440751bd"
      unitRef="usd">-72000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtNy0xLTEtNzEzMzA_a7455a32-ee89-4daa-ab45-6091f343f037"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzYtOS0xLTEtNzEzMzA_1ffbb2a4-4bdb-4480-9647-6618e866bff8"
      unitRef="usd">-72000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctMS0xLTEtNzEzMzA_b57f1f9a-5e96-4d52-9984-5256e415f2f6"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctMy0xLTEtNzEzMzA_54f12b5f-dd99-4ce8-ae9b-b8172f876f4d"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctNS0xLTEtNzEzMzA_aec196a9-86c9-4fad-a440-f158083a331e"
      unitRef="usd">-234000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctNy0xLTEtNzEzMzA_04859a07-9e5f-40bc-a89c-1c9567c4667c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzctOS0xLTEtNzEzMzA_e11fcf4c-d552-4084-88c8-236bc3eb2ccf"
      unitRef="usd">-215000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if78fe5701f56444a87f6705cef245749_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtMS0xLTEtNzEzMzA_be47cbdb-969d-4d03-b5aa-67228729e6db"
      unitRef="usd">-297000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0fadc7db9690470a90cd38cfc4aa4da6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtMy0xLTEtNzEzMzA_c7c8ae78-62aa-42f5-b635-19ff6644e0a4"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i12eb194f0ceb4ebda4b8e944411f4174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtNS0xLTEtNzEzMzA_5a025a78-0317-459f-92fb-662bff8e3296"
      unitRef="usd">-279000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if8e6859f5a1b43ec83936901b11d70dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtNy0xLTEtNzEzMzA_0257a248-e8f1-47d9-9db2-4da175fca3a6"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzgtOS0xLTEtNzEzMzA_7eefb35f-a972-431c-884a-5a4d1ca6c44d"
      unitRef="usd">-441000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i780c56afcbfb4d95a44ba74fad92b717_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktMS0xLTEtNzEzMzA_0506ad6e-893d-4b4c-a6e3-2f0e4a82c49b"
      unitRef="usd">-266000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10df6e4d4fef4be191cf9f09fe3b0e69_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktMy0xLTEtNzEzMzA_67d51b49-09a1-46bc-a44a-ac7fae511d5d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b4f7ce11e074645a9ba948f88f64501_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktNS0xLTEtNzEzMzA_b36581b2-6f17-418e-92e6-60b5587bca26"
      unitRef="usd">-4540000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2100c8d9763e4e2aa3d44e5ab5e6f3ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktNy0xLTEtNzEzMzA_42e54493-7e5d-42f9-a731-dc4cf1bd302e"
      unitRef="usd">-1828000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8308747617614e9eab0ac29c4014c53b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzktOS0xLTEtNzEzMzA_d8a0965e-d81a-49ba-9b33-81e1938cffc2"
      unitRef="usd">-6634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTEtMS0xLTcxMzMw_ab7817e6-5601-4ff0-be45-f37d44ca08f0"
      unitRef="usd">333000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTMtMS0xLTcxMzMw_f59b17bb-5ea1-4633-ac1c-fc58366bc0f7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTUtMS0xLTcxMzMw_800eba1e-849f-41e2-9711-8320d04b40ee"
      unitRef="usd">1737000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTctMS0xLTcxMzMw_016dcdcb-e91c-41da-ba4f-5fd9ac21da2a"
      unitRef="usd">-304000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEwLTktMS0xLTcxMzMw_e010f1c7-11be-4235-a498-a9b153cf3a7a"
      unitRef="usd">1766000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTEtMS0xLTcxMzMw_5f3e0af8-754b-4005-8e02-bba86cc2b493"
      unitRef="usd">75000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTMtMS0xLTcxMzMw_158783b6-7ecc-455b-8182-7db2c7da32b7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTUtMS0xLTcxMzMw_b67d0a7a-c75b-44b9-a546-2661ec9a0acc"
      unitRef="usd">332000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTctMS0xLTcxMzMw_a9eb7e30-16e7-4f70-a2ad-5e2c58706836"
      unitRef="usd">119000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzExLTktMS0xLTcxMzMw_0aab5586-b367-4b6b-8e7e-33ec2247a935"
      unitRef="usd">526000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTEtMS0xLTcxMzMw_919ac1d3-84e8-4032-97c7-c4b7eec7a4ca"
      unitRef="usd">258000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTMtMS0xLTcxMzMw_b13728f4-3efc-41a9-ae09-6bf761b33d22"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTUtMS0xLTcxMzMw_f8b551e0-2a3b-4bde-a081-3559ad51ae17"
      unitRef="usd">1405000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTctMS0xLTcxMzMw_daa30d38-976e-49d5-9833-b2fed28ec755"
      unitRef="usd">-423000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEyLTktMS0xLTcxMzMw_026e8b33-6f30-4608-b22c-566ba02b793d"
      unitRef="usd">1240000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTEtMS0xLTcxMzMw_31db5481-4162-49f8-aff3-eb1453538d8d"
      unitRef="usd">-192000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTMtMS0xLTcxMzMw_148560cd-320b-47e8-887e-559f95af3c38"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTUtMS0xLTcxMzMw_d172132e-7d31-46fb-863f-0719a1fcccdf"
      unitRef="usd">-466000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTctMS0xLTcxMzMw_69bed09c-963e-4582-b33c-2449859a501d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzEzLTktMS0xLTcxMzMw_71d2cf38-07f5-4b38-acb8-9e3bd783e10f"
      unitRef="usd">-658000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTEtMS0xLTcxMzMw_cd09aaf8-fed9-4ea8-808d-f5a1db40da70"
      unitRef="usd">-40000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTMtMS0xLTcxMzMw_0162d672-58ee-4459-b414-3882837e3574"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTUtMS0xLTcxMzMw_8f322412-1f5e-46e4-99a8-c11e619e78fe"
      unitRef="usd">-102000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTctMS0xLTcxMzMw_b00c9f60-7ec7-431d-90c7-df94518fb20a"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE0LTktMS0xLTcxMzMw_8941f3ec-c073-429b-9cf2-801b29f30b04"
      unitRef="usd">-142000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTEtMS0xLTcxMzMw_1169eae4-074f-40d9-9173-701af417c38c"
      unitRef="usd">-152000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTMtMS0xLTcxMzMw_3b159be6-1961-40f7-af0e-fe6aac197376"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTUtMS0xLTcxMzMw_afb35b8c-e777-4e72-81eb-1f0fd0d376e2"
      unitRef="usd">-364000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTctMS0xLTcxMzMw_542c0272-8c09-4642-afa6-7afe73740bc4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE1LTktMS0xLTcxMzMw_8fbbc6d3-8c78-4879-af83-c8db879c893b"
      unitRef="usd">-516000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7d746b9450624f828ba8f92e9447b0c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTEtMS0xLTcxMzMw_db8a23b4-1cdb-49e8-b4a9-e1656b1a019c"
      unitRef="usd">410000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i38494c87624f4b058457c9dee4ab1d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTMtMS0xLTcxMzMw_73b89f1a-2d91-4452-ab82-bec83250bd67"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i57009dd03e3044b8badb0b07b2c5a766_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTUtMS0xLTcxMzMw_0d9b9615-fe1c-4277-a5e6-e95ac3f4b08d"
      unitRef="usd">1769000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icc3db1a57ea44b098f64061272d21bf7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTctMS0xLTcxMzMw_d9ea8c3b-8a1c-4db7-a570-e35e4285be5c"
      unitRef="usd">-423000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE2LTktMS0xLTcxMzMw_1d957535-0ad7-49c5-a50f-42e7b296b42e"
      unitRef="usd">1756000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTEtMS0xLTg0MTE1_caf6bbee-8596-49b7-baa2-979634de6a58"
      unitRef="usd">0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTMtMS0xLTg0MTE1_b468c05b-2e1c-4191-8552-df1ea83e665e"
      unitRef="usd">0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTUtMS0xLTg0MTE1_2ad00254-4ce0-49c7-9f95-df5ad44a9186"
      unitRef="usd">28000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTctMS0xLTg0MTE1_fc561335-6c69-44a9-bee7-bee35bc6ce3c"
      unitRef="usd">421000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i7edbd57c4cf745c49a7f15beff700c5b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTktMS0xLTg0MTE1_d4424168-0d7f-4147-bfb9-b4e14819f336"
      unitRef="usd">449000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb4671bf8a444d7784d46176642a8000_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTEtMS0xLTcxMzMw_5694b9fd-bbc8-487c-a668-c61f3012eb27"
      unitRef="usd">144000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia053f4e630254ab8bd394403714172dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTMtMS0xLTcxMzMw_7c46900f-2844-4ca5-b939-31d215bf979f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i913f7d5516324116a41cb3fd560183ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTUtMS0xLTcxMzMw_57e3a00b-8f1d-4e20-9b34-1b192df17f44"
      unitRef="usd">-2743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49e9678f0bde4535890e00b607c39661_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTctMS0xLTcxMzMw_ff30ade6-e5ad-4751-93b6-af63f45865c4"
      unitRef="usd">-1830000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i542103e76e6741a6805402bb88262b54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE3LTktMS0xLTcxMzMw_d78e3edd-9408-4ea7-816c-b4d0c4ae7d7c"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTEtMS0xLTcxMzMw_60c30750-ae46-4400-aa18-2f9e6ce7bf8b"
      unitRef="usd">684000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTMtMS0xLTcxMzMw_9c4f5388-f06a-4368-9448-892de5c6f40c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTUtMS0xLTcxMzMw_a642e4b2-0af8-4d11-b22e-0af8d4f9de5e"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTctMS0xLTcxMzMw_fb2d67a0-b330-42fc-84df-17ec06d86948"
      unitRef="usd">-584000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE4LTktMS0xLTcxMzMw_56352165-4ba7-42b0-b0f2-b19054c4dc13"
      unitRef="usd">170000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTEtMS0xLTcxMzMw_30ba7d5d-f479-4dd7-ae59-b3ca51d697ee"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTMtMS0xLTcxMzMw_32fbca85-2884-4f34-81d4-082953fc33ae"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTUtMS0xLTcxMzMw_b7e8176e-83aa-4c72-87f1-e37b94169114"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTctMS0xLTcxMzMw_8b08e043-5657-4dac-8686-26fec9674a9b"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzE5LTktMS0xLTcxMzMw_83b2d5db-a57b-4bfc-a573-43c011c89b13"
      unitRef="usd">150000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTEtMS0xLTcxMzMw_a1ac23ea-a591-473c-9c69-c30db87772db"
      unitRef="usd">541000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTMtMS0xLTcxMzMw_a4421e8e-3347-4f18-a16d-d8b5c758b213"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTUtMS0xLTcxMzMw_9808d9c1-b681-4edd-8141-9a35728e56ce"
      unitRef="usd">82000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTctMS0xLTcxMzMw_6508a604-61d5-4c96-93c8-10f361d48920"
      unitRef="usd">-603000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIwLTktMS0xLTcxMzMw_428b4dab-2fd1-4e70-a14f-8ea4a787e4f0"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTEtMS0xLTcxMzMw_2bba5f19-0ceb-471f-9b06-1431cd5bcccd"
      unitRef="usd">775000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTMtMS0xLTcxMzMw_c996c871-7f7f-4005-8de1-0d63fdba4d30"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTUtMS0xLTcxMzMw_df560e86-82a9-4816-87a0-1515e9c361c9"
      unitRef="usd">-329000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTctMS0xLTcxMzMw_ea933a38-2f58-4d88-ade2-c82175f574d6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIxLTktMS0xLTcxMzMw_a5aad262-9b25-4e6c-9ecb-f69f26a27ea0"
      unitRef="usd">446000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTEtMS0xLTcxMzMw_20eade2b-5919-4104-8f85-9b0797ddfe6a"
      unitRef="usd">163000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTMtMS0xLTcxMzMw_d32a519d-7a5d-44cf-ac4a-53308ded78ed"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTUtMS0xLTcxMzMw_9f521202-8595-498c-b087-b7cf0f872c6e"
      unitRef="usd">-76000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTctMS0xLTcxMzMw_ac13b9ac-3f92-42f1-8799-c79bbd8e106c"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIyLTktMS0xLTcxMzMw_3621b8e8-3146-4a98-b6df-6c85683b6dc8"
      unitRef="usd">87000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTEtMS0xLTcxMzMw_08193909-71e1-4623-b256-ca01dc1d1ede"
      unitRef="usd">612000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTMtMS0xLTcxMzMw_469b0675-6c10-40d2-8dc1-67dfbe88d810"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTUtMS0xLTcxMzMw_17d5086f-d557-48f3-96c0-474f1b91d618"
      unitRef="usd">-253000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTctMS0xLTcxMzMw_8dbe74a5-0897-4078-9146-065e4e94def3"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzIzLTktMS0xLTcxMzMw_9ec12ddf-dac5-4989-822e-b58a8f80170c"
      unitRef="usd">359000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i39abf3d667bf4d80a04d7659ee7a1b6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTEtMS0xLTcxMzMw_ca6c471c-32fc-44bd-a4ec-2ad6adb4a214"
      unitRef="usd">-71000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7b846c36053b46608ae59b4eea81d297_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTMtMS0xLTcxMzMw_65fa7f15-1f56-4db0-9577-0b94977e5886"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie38c40e673014fdd90a23b0ec4cc46f2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTUtMS0xLTcxMzMw_f1b3393a-65dc-4103-8dcd-f4651397b45a"
      unitRef="usd">335000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4084facb02b741ff943be5bec504b2fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTctMS0xLTcxMzMw_0f1e551a-3f78-4ac1-8e54-c1d8442e0e5b"
      unitRef="usd">-603000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI0LTktMS0xLTcxMzMw_14f44918-357e-4300-84d8-42343448a4c7"
      unitRef="usd">-339000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief7889eac2c64545bb3064c36a62e54c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTEtMS0xLTcxMzMw_74fdee56-0358-428c-ad62-9998939c9ad4"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3213007d978d4f60ad986031900fb73a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTMtMS0xLTcxMzMw_84696f9e-f0bd-4df9-a22e-79d077a1e3ee"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i633b278a9073462da9b159814994a35a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTUtMS0xLTcxMzMw_6b99cc8b-c6d6-4044-84f6-0001c1e7ad60"
      unitRef="usd">-2408000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5f13a2378f44c6bac00f3c347b5d737_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTctMS0xLTcxMzMw_794ab04b-4591-4400-9730-af43c35ec0b0"
      unitRef="usd">-2433000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f1e6ddf39c24d7f843d5f7b097b9c69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90YWJsZTo4OTNlODQ4ODE3ZDI0N2VmYmZmMjhlYWM5NzI1ZmJlZS90YWJsZXJhbmdlOjg5M2U4NDg4MTdkMjQ3ZWZiZmYyOGVhYzk3MjVmYmVlXzI2LTktMS0xLTcxMzMw_21c2d271-0740-447e-afea-760296efb156"
      unitRef="usd">-4768000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i3fec19785aa54818a2736cc335cd0740_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzU1MQ_666ca1c2-3b3c-4c7a-82bb-81ea1c3f46e6"
      unitRef="usd">3100000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="iaaee5000881d4ca39ed66d7be4ecd22b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzU1OA_fa768fd2-3180-4f64-a49a-5a80161b7dee"
      unitRef="usd">3600000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i98661ac7371d4fd4b9c2f6c95474a731_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzY1Mg_9ef83800-65eb-42df-9b7e-717689732c82"
      unitRef="usd">-446000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ic0f4a1d4687e4f92b7cea51e261e5084_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzY1OQ_def9d190-fec3-4a53-a754-d00944bec2d4"
      unitRef="usd">-473000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="ib9544cabffb54d55968d75c6c7d1efed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzc1MQ_bb2ed551-a3ed-4ea6-84ef-df9a2a06d424"
      unitRef="usd">-152000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i01173ed3d18241a0a998253f0b59e277_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzc1OA_82222c67-8da9-4b29-98e1-eb691c6e00aa"
      unitRef="usd">-190000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i376ce6e940de4569b4fddf8c906fe3c0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzg2NA_db70edbd-f4b5-4b05-a2e1-cee09974abc5"
      unitRef="usd">-135000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i6758445e91bf414bb1e7540b3c5e6998_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDIvZnJhZzo3NDBlMzE1MjkzMmU0NGFkODRjNjFjMzI0ZmM2ZDY5MC90ZXh0cmVnaW9uOjc0MGUzMTUyOTMyZTQ0YWQ4NGM2MWMzMjRmYzZkNjkwXzg3MQ_d71936e0-6ce5-49a3-a2fa-c63a052c4db7"
      unitRef="usd">-181000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3MTU_cbbc8a29-5ed7-4678-ab0b-2a6796df8db3">Segment Reporting&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S.&#160;government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;579&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;297&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Reblozyl &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,832&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,897&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R II/Varivax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,724&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;602&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;922&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Dificid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,523&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress HD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;179&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,813&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,249&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,550&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30,744&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;57,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;32,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue for Lynparza and Lenvima represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&#160;5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue for Adempas/Verquvo represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(6)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165&#160;million, $218&#160;million and $54&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,568&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;59,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Continuing Operations Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;36,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;38,815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#x2019;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity income/loss from affiliates and depreciation included in segment profits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity income from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity income from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, by geographic area where located is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,422&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzExMg_b6a0c045-b597-4b96-91d0-2f31c820f1bc"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3NDg_059e306b-bab2-4c0d-8557-b137bbe66a4f">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;579&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;297&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Reblozyl &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,832&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,897&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R II/Varivax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,724&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;602&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;922&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Dificid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,523&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress HD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;274&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;179&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,813&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,249&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,550&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30,744&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;57,555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,728&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;32,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue for Lynparza and Lenvima represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&#160;5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Alliance revenue for Adempas/Verquvo represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. &lt;/span&gt;&lt;/div&gt;(6)&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165&#160;million, $218&#160;million and $54&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="ia91e2c24c996468b982a1dc76e03f861_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMS0xLTEtNzEzMzA_611088dc-4271-4092-822b-a5e69e3a7cdc"
      unitRef="usd">12686000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9731d40c6ab449cb60589aa31b26a73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMy0xLTEtNzEzMzA_10c66783-16a4-45b4-af3d-ca87f6699778"
      unitRef="usd">8251000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i055b33b897694fecaa100eb09d061cc0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtNS0xLTEtNzEzMzA_29e5920f-23a4-4c42-bb6d-56ddfafefc40"
      unitRef="usd">20937000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0ceb00afac54256a4f7d60880c98740_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtNy0xLTEtNzEzMzA_225a37c7-853a-4a07-b79a-a8eb5bce7519"
      unitRef="usd">9765000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08a3ddbfa55a431d93af3aa9f262e6f5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtOS0xLTEtNzEzMzA_d5a78258-d75a-4091-815e-fb9d25e108b4"
      unitRef="usd">7421000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i021a82cd1a4140339a5639441d8b47f3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTEtMS0xLTcxMzMw_fec05268-4f0a-4850-bc7a-f093d0556926"
      unitRef="usd">17186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i469a9a4b8f4d4ca3ac6924d254ddf426_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTMtMS0xLTcxMzMw_f4635048-265b-4770-80ee-df5639cb553e"
      unitRef="usd">8352000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd610e2349614dcfb3c65f5ed1df8bd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTUtMS0xLTcxMzMw_f2bcaf8f-1074-471b-99ec-e0fbef2b3886"
      unitRef="usd">6028000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c1932046958463fad5e8a483638872c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQtMTctMS0xLTcxMzMw_d77e5b8f-1fb9-46f2-beaf-96ec8503ea36"
      unitRef="usd">14380000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d05e5c857ab4caf84ea5087f3cb2a5f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMS0xLTEtNzEzMzA_fbf5ea50-ca76-4cb8-93ff-1e5189936313"
      unitRef="usd">584000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5745637e84f64e87b8c42fd884e6b4cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMy0xLTEtNzEzMzA_b84b83a9-eb17-49d1-981d-bf316b3e8c03"
      unitRef="usd">532000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85cca07e668f4fb582cffbfc5b2aa7b5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtNS0xLTEtNzEzMzA_b79847af-c415-4a81-8574-dd9c7c94f4f4"
      unitRef="usd">1116000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4ad82bfee384b30ac43e9a17ca1089e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtNy0xLTEtNzEzMzA_b6af5f62-5cf6-46ee-98bc-2fe249b80146"
      unitRef="usd">515000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b4d358834924f50a81f5fafd726b128_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtOS0xLTEtNzEzMzA_ba0385fe-2680-4451-a60f-be5a50b84181"
      unitRef="usd">473000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4823df2547cf46b8875abd9cf558f5ab_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTEtMS0xLTcxMzMw_1fd6e296-dafd-4230-8875-5777b03fe344"
      unitRef="usd">989000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c17734546b947998281488d9a6ec98a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTMtMS0xLTcxMzMw_5c0286a5-c016-4bf9-9dea-4feaa57fd7a4"
      unitRef="usd">417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2afc6a3ad1a4eacbe19b964577a66dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTUtMS0xLTcxMzMw_00d75e36-7f7d-4ff2-bf53-4105618c7876"
      unitRef="usd">308000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cae1b53fac2493694141969a8253308_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzUtMTctMS0xLTcxMzMw_d3ec8124-9663-4417-8ef5-b9ffdb9e7607"
      unitRef="usd">725000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c7db9326a224e2ba5066b84103c543a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMS0xLTEtNzEzMzA_f747e60b-26b4-4c17-a6c3-9004a2fc4928"
      unitRef="usd">579000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida28401748b24f92b416cd0833611fd1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMy0xLTEtNzEzMzA_c62ffaeb-52e7-444c-ac12-31401bd4917b"
      unitRef="usd">297000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0bd8d6774e74f7bb3b1974282e31ba0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtNS0xLTEtNzEzMzA_50b3dda5-b8c5-4f90-8214-0e839da5d6dd"
      unitRef="usd">876000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i386ded0f805747da8de2d6ff8fb385c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtNy0xLTEtNzEzMzA_16d8192f-c430-4db3-8b84-bc2861e429f0"
      unitRef="usd">417000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc73f7080d9b496c8de0c1ab17b2c074_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtOS0xLTEtNzEzMzA_46c4fbf5-3560-4a5b-b210-b4c15f53da0a"
      unitRef="usd">287000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7022852951b641658ce5d9c243dac44c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTEtMS0xLTcxMzMw_61d0b17c-9c51-43d3-b276-faf4492504e4"
      unitRef="usd">704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i962d004cfae84806a1690091e3ae9d53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTMtMS0xLTcxMzMw_e3657e36-51f8-4725-8cc7-7f2fac1a7417"
      unitRef="usd">359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20b05e5faabb4aa8822babd60bc90181_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTUtMS0xLTcxMzMw_02970148-83f4-4415-9f9f-3af879ed21ce"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32e8b2707de1407695f9bbb06e69dc0f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzYtMTctMS0xLTcxMzMw_293f8063-a3ba-4024-b1c0-a9a51a156bfa"
      unitRef="usd">580000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a5c22c83dbc43948fa3d2fcba8c2036_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMS0xLTEtMTAwNTU2_9b48648e-a495-43ce-a87d-8755f7433001"
      unitRef="usd">123000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i983e74feb34f4218b9743956866ea60b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMy0xLTEtMTAwNTU2_1c41c8d9-4c75-42d7-86a6-4eea09c7c842"
      unitRef="usd">43000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc3969c4d6864a2da3a1f1ed7fc44512_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctNS0xLTEtMTAwNTU2_1882bef5-18fe-40ab-9a14-0e9ccda4fdd3"
      unitRef="usd">166000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe79fe1f7c2f4216adf7ef2d4c9e7785_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctNy0xLTEtMTAwNTU2_a69bb700-c623-4889-b588-77ce62a459de"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6630bb637394adca02acfc9eeedf615_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctOS0xLTEtMTAwNTU2_aa075f98-ae8d-4b53-9913-f572e50940ea"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4460340464041e0b1e1151e1bdec68e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTEtMS0xLTEwMDU1Ng_baaf28fa-81ce-4fe7-aa41-af612a5239d7"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibec24a942c8b4c0a8fc6fdaf544a83e0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTMtMS0xLTEwMDU1Ng_b1fd249c-2118-42dd-8153-732a0db93cf6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i110ea0b902704bc5be59e310b57c93a3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTUtMS0xLTEwMDU1Ng_f20cd35b-268f-4c0c-be61-b3a334d87696"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie88453b113924c5589f84f11706642fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzctMTctMS0xLTEwMDU1Ng_8a2c822a-996b-4b87-8eb8-94c6b48aa30d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76d1c52b6d904599af1561feb5d9d169_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMS0xLTEtNzEzMzA_7aa9d047-0cb2-44da-8c7f-e642f758298a"
      unitRef="usd">2065000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07fa681a6a3f4803ac978bc4430cb16f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMy0xLTEtNzEzMzA_eab868be-5816-493b-bb05-adbda7931f6c"
      unitRef="usd">4832000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i644651c9869647669ec353da52f990d9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtNS0xLTEtNzEzMzA_51bb6287-7320-4a6e-9d08-c60ddccc7549"
      unitRef="usd">6897000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ab722f2e32a4c6683c5a3c36bc74c42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtNy0xLTEtNzEzMzA_d529ba4f-d8b9-4911-bbf7-05d803dbbacd"
      unitRef="usd">1881000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcbfd454bf4b4f66a38aeb71bd572837_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtOS0xLTEtNzEzMzA_cfa81578-ea41-423d-83d2-9d17dcd43455"
      unitRef="usd">3792000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0da2a3204d4e412fb81a43cc22c0763a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTEtMS0xLTcxMzMw_d2916f0e-e456-4b86-8d42-745793dfe591"
      unitRef="usd">5673000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6e0f2f8901b420ea1bc6e4977b34b1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTMtMS0xLTcxMzMw_6ee8aec7-cfb9-4114-8621-ea2689bda6fe"
      unitRef="usd">1755000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23153be3d78a4b25841635d342d31f02_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTUtMS0xLTcxMzMw_035b4fc0-455d-4c00-b166-8616daa79322"
      unitRef="usd">2184000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5df9cf0c885b47bb915bcac974671884_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzgtMTctMS0xLTcxMzMw_a1e71be1-4bad-4c0b-9ef8-fd7e1bd162d9"
      unitRef="usd">3938000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82f7b5010d8b4521aba879ed86a464bd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMS0xLTEtNzEzMzA_073ceeaf-829d-4826-8e6c-74290c99fbad"
      unitRef="usd">1724000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia33e8904188b4076969981d84d6398e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMy0xLTEtNzEzMzA_aafbbfd2-1fce-43e7-85fa-e20570ce0103"
      unitRef="usd">518000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaeb0222df25c4f04995c870d2c8857d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktNS0xLTEtNzEzMzA_f7149e56-9643-444e-8b91-e76fbeed98b6"
      unitRef="usd">2241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e74080b44234734ace0dedce547e587_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktNy0xLTEtNzEzMzA_149b19c9-ef61-4a08-8d37-15675aa43098"
      unitRef="usd">1629000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibda8cdb993f6413fba844f94a33ca058_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktOS0xLTEtNzEzMzA_9b46bd51-4a05-4fc7-8ccb-9818063bf19b"
      unitRef="usd">506000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea178521e12f47089370df87334ff7b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTEtMS0xLTcxMzMw_7dcfc683-c6bf-436d-a8fd-ceb6d8a66952"
      unitRef="usd">2135000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7077f41ca14446182bb6e9b4d27b1b9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTMtMS0xLTcxMzMw_d1c1cf14-6a2b-43b3-8bb6-76b0053b9e51"
      unitRef="usd">1378000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b007cc3680b447fb3c5201bf94aad44_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTUtMS0xLTcxMzMw_c72c7f49-457e-4a4e-95cd-058cbc666566"
      unitRef="usd">500000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c0c7519eadd4f2cb22aa9f1248dd720_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzktMTctMS0xLTcxMzMw_747f6aee-c966-48f9-b9f9-67960232c28b"
      unitRef="usd">1878000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28b4a4a5f68b41c48bd3a0fcfc84a504_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTEtMS0xLTExNjI0Mw_cb113858-2a4f-4119-9e92-2fdeda06a09d"
      unitRef="usd">508000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf6fa89df609474b9bb96eaafe8ebbf1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTMtMS0xLTExNjI0Mw_133e8479-e75b-4f34-863f-5484dafc53a3"
      unitRef="usd">275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7e07e4f949d474eb749d0ba3fb1b4d7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTUtMS0xLTExNjI0Mw_5ea4c678-9e15-4184-a225-9dfa28c0001d"
      unitRef="usd">783000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94ba2d46833f40a295ab92101c6ea29e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTctMS0xLTExNjI0Mw_eda88385-35df-4f19-8537-13c903703b9b"
      unitRef="usd">473000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30c671ce13ae432fba6dcaad37ca8570_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTktMS0xLTExNjI0Mw_61d7cafa-f818-4338-a766-32780079e1e7"
      unitRef="usd">334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd6d0c174afc46489b7ddef3c33543ed_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTExLTEtMS0xMTYyNDM_387a20ab-74ba-4681-8a49-3aed55d03683"
      unitRef="usd">807000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib169bea2441d4f30ae99b18bf17d4fde_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTEzLTEtMS0xMTYyNDM_9f7ebf68-54b7-405b-9d38-0506f96bf8a1"
      unitRef="usd">486000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a8c832c3c4b4e4eb34256d6efbbd10f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTE1LTEtMS0xMTYyNDM_58f16c9c-c328-4d25-b66b-8be5c0eef234"
      unitRef="usd">311000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16e6f28f13f14ac490531d72573bcbaf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzExLTE3LTEtMS0xMTYyNDM_54e7bb50-b2fa-40dc-97e6-1f7d5e4845ce"
      unitRef="usd">797000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56cb5b6040ce4ad9ac372cec6d2cca04_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTEtMS0xLTcxMzMw_0f82926f-e6d7-4756-8797-3c32fb28d0ca"
      unitRef="usd">346000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17ef3a8f82f04dfe83a51cfd751ae411_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTMtMS0xLTcxMzMw_93b8a394-f47f-40af-be7c-864c85d7d6b0"
      unitRef="usd">256000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia04f7472ddd5484b8c9216a9fffd29ef_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTUtMS0xLTcxMzMw_6b178cf3-c1b6-492f-b18e-3b90304eaa5e"
      unitRef="usd">602000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22ac39abc88b48dfae3f97f17cd94587_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTctMS0xLTcxMzMw_f044965b-46fe-40a6-b9a7-1350db91fa86"
      unitRef="usd">547000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd57f79d2d0e41c3b93e0ea8a1fa225d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTktMS0xLTcxMzMw_f5278043-bd91-4571-9991-605e824aaeb8"
      unitRef="usd">346000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87a2e2a2eb9c43d4b2d533d346a44334_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTExLTEtMS03MTMzMA_b9ec3a61-478d-4976-9fce-53745501e746"
      unitRef="usd">893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if80ca468315e4aae943a5b9df597243d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTEzLTEtMS03MTMzMA_0e9eefd9-c2c1-4860-a6f1-08487eefb77d"
      unitRef="usd">727000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99df6a07597644d285a92793c5d8e7ca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTE1LTEtMS03MTMzMA_3da9a22a-0f87-4e10-8c6f-43c96daecc64"
      unitRef="usd">359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a49a4371bb94327920efa9b894769ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEwLTE3LTEtMS03MTMzMA_875be54a-be2c-4bce-87c6-fe770d6de15c"
      unitRef="usd">1087000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8d68a994755427bbfccdd19f9ad6ee0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTEtMS0xLTcxMzMw_99256aac-2fbd-430d-93a1-90c9b6faf267"
      unitRef="usd">95000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74ee8738806c47fdbfa08983e60c6b39_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTMtMS0xLTcxMzMw_f76959b8-31a7-48d9-a394-889e1064910a"
      unitRef="usd">78000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if74b581cfc6d488fba45c7674c3dfe6d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTUtMS0xLTcxMzMw_a1028e64-f55c-4dbc-9e61-b9d555b473e3"
      unitRef="usd">173000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f1f993fee094825a8fff330454f6f81_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTctMS0xLTcxMzMw_3b3e546e-dedc-438d-bbe1-c63e5686f68c"
      unitRef="usd">100000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i380654ff24e1418b9128e9fb90b05595_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTktMS0xLTcxMzMw_df3cf5d5-ded1-41ea-bd51-4c635df9cb08"
      unitRef="usd">79000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2d28f16c5374e7f83b2e84bbe26110e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTExLTEtMS03MTMzMA_67cef9ac-a449-406e-9c48-2884250dd378"
      unitRef="usd">179000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83690f4cdc6b473bbc907e1481854b3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTEzLTEtMS03MTMzMA_c8255a01-bcb6-402e-a960-2d9abe0c8211"
      unitRef="usd">103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id86b5383dbf64f898217d2bc2c3fa325_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTE1LTEtMS03MTMzMA_3cdfb148-4dca-4ab0-b7dd-713b342c76e4"
      unitRef="usd">67000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c50b2fa3e364cbb801d4ba254d494c8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzEyLTE3LTEtMS03MTMzMA_0010a5a2-b948-4cf1-b0b2-f6234d711207"
      unitRef="usd">170000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54e206a2ffcc45d1bb510c4187e62a29_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTEtMS0xLTcxMzMw_79cf21ab-677e-4dbe-95fe-dae3f4fe2947"
      unitRef="usd">922000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb1603f10ef8494fa56655543909b4c7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTMtMS0xLTcxMzMw_b21a8557-99ec-462c-bbee-ed81bccd173b"
      unitRef="usd">762000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i045d0c50e54f4c0db0bce141309e9adf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTUtMS0xLTcxMzMw_ce9083eb-5ec2-47c7-9d98-f612034c70d0"
      unitRef="usd">1685000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4b4d13befb54158b149f2d9f6063ff9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTctMS0xLTcxMzMw_7fba8a80-b4f9-4095-839b-bf0910bb9553"
      unitRef="usd">762000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id11490c3b30c40b1a23a28951f1e180a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTktMS0xLTcxMzMw_75e5f455-c3c8-4f95-9647-0c01853785aa"
      unitRef="usd">770000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c1c6fb66e744cdbac35155a426b3d6c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTExLTEtMS03MTMzMA_4d0ac33f-e69f-4a5e-a816-2f47a377d651"
      unitRef="usd">1532000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c68bc52927041289397d599a9612eff_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTEzLTEtMS03MTMzMA_1a6455e7-87fc-4528-9a85-f34841684ce9"
      unitRef="usd">583000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f47bdad3162408c9b0f25ac776b4bfa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTE1LTEtMS03MTMzMA_6059a63d-174f-4491-956a-a1dcae6d070d"
      unitRef="usd">615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86224d1130564bcd9c3939e4e0d87dda_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE0LTE3LTEtMS03MTMzMA_f6285ac1-6552-43b8-8394-4ca63391fd4e"
      unitRef="usd">1198000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66955337b2e7472982d44f7d7785e83f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTEtMS0xLTcxMzMw_61e05cc1-e7f0-4000-8a77-73df11b6f508"
      unitRef="usd">188000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66f7da2549bc46508c0eb51f336b6e15_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTMtMS0xLTcxMzMw_db2b6164-fe7d-4553-abf4-694cea877781"
      unitRef="usd">240000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa717dbb9c014d55a5428a202d0f8635_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTUtMS0xLTcxMzMw_492cd9ae-a403-4a40-9a44-addf5aba040a"
      unitRef="usd">428000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1348a3599a104ba6a35f574703cd74e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTctMS0xLTcxMzMw_30085d9b-3554-40b6-851d-65147dcb0fa4"
      unitRef="usd">153000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bea3c67785843179ba5a14d3faedac4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTktMS0xLTcxMzMw_b9bdd7f4-58d1-48e2-bed8-9eab889adaf0"
      unitRef="usd">218000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i696096e4ab134aecb6a7f9a41513fb2f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTExLTEtMS03MTMzMA_d4c7bdb1-a746-4938-87c5-d71cbc2b992a"
      unitRef="usd">370000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc1a741e5ac843f0b62b174581b00278_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTEzLTEtMS03MTMzMA_781faf67-7e5e-48e3-9511-cdad23e74937"
      unitRef="usd">119000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44f9720b066543308e337df0f16afce7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTE1LTEtMS03MTMzMA_ffb7fa48-af18-4c0c-a655-a1da8d0ffb71"
      unitRef="usd">162000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i438e2ece521548b282bf2388b2b7bb93_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE1LTE3LTEtMS03MTMzMA_5e36cb39-5bf5-4aa6-b021-51f70d84f9c1"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f274e7070274a88949b99aeff4a315a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEtMS0xLTExNjI3Mw_cc553594-15fa-4b33-89a6-62c3b8f11550"
      unitRef="usd">241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i84c33f54fbf848d3b95f8a9426848007_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTMtMS0xLTExNjI3Mw_d5a69a42-63f2-4868-8406-ec0a734cd669"
      unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6aaafda79ee404ba309fdcef5eb6abb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTUtMS0xLTExNjI3Mw_87fff8e1-3f3c-4dcc-8a34-d2d75464618e"
      unitRef="usd">263000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic44ad729c19c4e508c4d35a83785a3b7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTctMS0xLTExNjI3Mw_29839975-b9ec-43b9-9fbe-2c7554ae73cd"
      unitRef="usd">166000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b5118866f4f4421a29aecc0b9d07410_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTktMS0xLTExNjI3Mw_8f477619-8cdd-4182-bb98-2759f4e476f4"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic25c060bf8b740dabb223a13c1a73ff6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTExLTEtMS0xMTYyNzM_b803a5a9-edd3-4b76-bd58-3a088100c6e4"
      unitRef="usd">175000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i502953fc972e41468a767f66ce4c9cba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEzLTEtMS0xMTYyNzM_03a4a7e8-a96f-4053-b245-989ff6214b80"
      unitRef="usd">102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d9a656842a84362b57aeb885a898b92_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE1LTEtMS0xMTYyNzM_372b1460-cfde-4ed2-bddb-96d778402938"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98f5e15ad16b4a99a824425bbe60d470_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE3LTEtMS0xMTYyNzM_f72001eb-588f-4a88-a0ec-17e8305dc008"
      unitRef="usd">110000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2b71549b3e14a12b8973697db00d8a4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTEtMS0xLTcxMzMw_cc6b8f05-1289-44c5-8ef2-b19cd8880b8f"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5077564ac8bc42e3a13c994eadfd523e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTMtMS0xLTcxMzMw_e44e59a6-a34b-4c20-b378-3e85dd67017b"
      unitRef="usd">238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i265d917b453a46658f7507d16b56613e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTUtMS0xLTcxMzMw_312c2af9-1a7b-4aee-a257-773c86fcec2c"
      unitRef="usd">239000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i849cac43efbf4becaea56c79b6c78fd9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTctMS0xLTcxMzMw_679eed1a-e497-497f-abe2-c9b25a3fc8b4"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f1370ce5e87458b818b4352ac61a828_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTktMS0xLTcxMzMw_d5a02080-5749-4db7-b55b-b6c8bf4c04d7"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefb64688266941e4a497a73d06448942_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTExLTEtMS03MTMzMA_88f9829b-eab4-40dd-9dae-c8ec7402b517"
      unitRef="usd">259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i296b1fd777794c17891e11e10a141300_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTEzLTEtMS03MTMzMA_f07888d4-c3cb-465a-bf41-d01d41795998"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09f99ef9d1b74fcabeb55184c85dc86f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTE1LTEtMS03MTMzMA_0f8d2c56-77f0-4b4d-8449-81b042347360"
      unitRef="usd">248000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if880d0df286f426ebb17d41d1f490635_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE2LTE3LTEtMS03MTMzMA_aea3f526-6879-4294-baf6-794ac6794c8a"
      unitRef="usd">251000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22e66e074cc0484bb09293c2d0e5387e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEtMS0xLTcxMzMw_c3f85816-aadb-45e5-8946-4ed31c6997d7"
      unitRef="usd">51000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51deec1b5b1a4ffbadb9e0abc2bf9307_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTMtMS0xLTcxMzMw_f3912628-ad73-47af-bfbc-99acc23d5301"
      unitRef="usd">187000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7480c05016014e139e36eb2b979873e3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTUtMS0xLTcxMzMw_d87131ab-e950-4cff-af90-60db4ce9fe6c"
      unitRef="usd">238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a12590988ac4caeaf1fbdb0caf12c50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTctMS0xLTcxMzMw_7aae2e6e-a65a-443e-bbb8-483cc795d7e6"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b87c87bafd747c68f3308bdf2b646b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTktMS0xLTcxMzMw_c7710e43-8c68-45cc-8c74-d6804824e585"
      unitRef="usd">199000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b5634d11ca74ea5af6b94a23678fe55_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTExLTEtMS03MTMzMA_2010c707-9e15-480f-a789-bc822e79c281"
      unitRef="usd">259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7a1ed4e577d4643b2128afb0f146b35_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTEzLTEtMS03MTMzMA_2d0819a9-ad7c-457b-9011-5d5fc599ab75"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i197589a15f2e48f3bd5253b3634b8a2b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE1LTEtMS03MTMzMA_a3e2a434-21cd-41d1-8150-78860f18c951"
      unitRef="usd">287000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6db360f0cd94810bf55adb667501e93_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE3LTE3LTEtMS03MTMzMA_03f6a002-489e-492f-8b71-c69d6ce16790"
      unitRef="usd">329000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8953ddf05c074e5f87682037915661be_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEtMS0xLTExNjI4Ng_056f1676-3308-4d55-bc70-6b410ea97153"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77531b3a80ec4e3db6cebfc5913221da_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTMtMS0xLTExNjI4Ng_11043ee6-da72-492d-a5c2-4a347d7a9d22"
      unitRef="usd">185000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i681c4e2421fb4a899d60ff0568080be8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTUtMS0xLTExNjI4Ng_6fe70d59-7f75-4941-87b4-93730e5ea868"
      unitRef="usd">189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57ec68701cc14e0f8f6ef79be8cba10e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTctMS0xLTExNjI4Ng_b5bc201e-838e-4a71-a716-b977ee8835f7"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia30d45a724314df6954c76e688a98335_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTktMS0xLTExNjI4Ng_7e00c54b-9728-4daa-a9ae-c185fd67da07"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie54a4ca20a1f484298d307aee478cb00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTExLTEtMS0xMTYyODY_f2122e14-fc67-465f-83a0-6688dca16e81"
      unitRef="usd">202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida70ce761b0a4a9abdcb51468b1da149_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEzLTEtMS0xMTYyODY_56969d15-d817-4978-a535-7ac94f0fd49b"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03261902b5dc4073ae6a6577c04bb346_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE1LTEtMS0xMTYyODY_91dc638c-0492-4b2a-ad32-4bb72a15d346"
      unitRef="usd">202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37ed6b5c044b44be8ffdeed43f3cb411_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE3LTEtMS0xMTYyODY_b66998a4-c6d8-4917-a7d9-4fae91dab703"
      unitRef="usd">211000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e744f26fdbd4b499f10d72b19177ab2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTEtMS0xLTcxMzMw_89205288-c47e-4a7a-866c-658f7b67f10a"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24d4ad8a15ed48bcb33632d14c4c6264_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTMtMS0xLTcxMzMw_662649b3-f4a1-4933-949c-f2abf5eeb2dd"
      unitRef="usd">168000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0be72db3712d4da0b435716421f1fbf7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTUtMS0xLTcxMzMw_db9675e6-040c-4049-9b96-7ac62477a40d"
      unitRef="usd">174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbe4fcb8c9074698941c54291c494471_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTctMS0xLTcxMzMw_c8e71905-ce14-416f-834c-3f2ecdde2f38"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic80bf4c2fae84eec92800503e7eb93b9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTktMS0xLTcxMzMw_67fb314d-978a-4ec1-b316-453766b9eeb1"
      unitRef="usd">208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26309d6272d64a7fba7afe8b3b07827b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTExLTEtMS03MTMzMA_5873b7e0-597c-4382-807b-21898d98082b"
      unitRef="usd">212000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c1515bf37fb46d2b516dba8cd589e89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTEzLTEtMS03MTMzMA_91143bc2-cb7b-4030-b3ea-7120bf4dfed6"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c291d86eea247ea9a5865cade31456c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTE1LTEtMS03MTMzMA_54d5d894-82cb-44d0-a892-23ce09b9c4d8"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccbfca06b90041849cfc691d6f2cdcdd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzE4LTE3LTEtMS03MTMzMA_f151c163-f2fe-4ac0-b498-7c90164c4db4"
      unitRef="usd">213000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebeaf99e4a1d4bceb36a747c6b3e139b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEtMS0xLTcxMzMw_728eb4d4-4e95-4820-98b7-386088dfc8b7"
      unitRef="usd">89000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9bcd1287d5c2475cb24e77ab4fa0658a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTMtMS0xLTcxMzMw_51451fc6-e936-4367-8b23-0c2fb568de8f"
      unitRef="usd">79000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0c448b7df4944588d513ed2e91cc958_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTUtMS0xLTcxMzMw_88ed2a1a-daaf-446f-bd27-2e3f9615cc15"
      unitRef="usd">169000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea1073cf01244476bfda2869a55121f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTctMS0xLTcxMzMw_4dfe9519-b220-445d-b853-8870cbeac095"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7698a3afbd87428f86f0f8054fe5e279_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTktMS0xLTcxMzMw_85ab6c2f-8000-4191-919e-9194a79c87f3"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i617770866c9d4c829c27635c3e97c236_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTExLTEtMS03MTMzMA_16481992-d6b5-4880-9701-8a77ae33fda5"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i505e0a1800cb4556b5eb673f1dfc4a33_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTEzLTEtMS03MTMzMA_d9b781b3-ad4b-4971-82e1-5a4625ce5c67"
      unitRef="usd">74000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b8af54e95f4451d8430cc22433b5edf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE1LTEtMS03MTMzMA_653ea07d-615e-49e8-9799-99f600e53c67"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9a9406845944bb7a2fd7d973f3a9d1f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIwLTE3LTEtMS03MTMzMA_efd808ec-792b-4660-a23a-7e4f46b1657f"
      unitRef="usd">130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bd312c6ba714cecbedcc9a7366b852d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEtMS0xLTEwMDQ5NA_a2752605-b14e-45a2-92e4-82a0f3e706aa"
      unitRef="usd">329000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31f649bf31fa46b39e37b5bbdb7840aa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTMtMS0xLTEwMDQ5NA_c2c19a3f-7b0e-4c89-887f-fa96ead83109"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60682002d9fe4c8a8fd6083bda3281ed_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTUtMS0xLTEwMDQ5NA_b1845053-0881-45b7-8d10-d7c1b4f5d7da"
      unitRef="usd">341000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice356b14a6ad46418365ea9bb55cb102_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTctMS0xLTEwMDQ5NA_d5af3ece-e6e8-41ce-9f26-fa06c1a018f2"
      unitRef="usd">312000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8f6d8c5bfbe43ea902f7cce7547af44_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTktMS0xLTEwMDQ5NA_0255c776-aeb9-4fa9-a630-fd7e7275e5d7"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f8ca3795ab84ff48b77c6fa70f7cffc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTExLTEtMS0xMDA0OTQ_86502356-3519-45c5-88e1-fee8d3789a86"
      unitRef="usd">342000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if482bee327734fda9fa6f722e7d953b2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEzLTEtMS0xMDA0OTQ_62b46812-7c1d-4997-80a7-ff049fea30f8"
      unitRef="usd">259000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2e22a11988949b88c13fe1e17f2b78a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE1LTEtMS0xMDA0OTQ_999105ff-c39b-4198-b507-d28a1b869043"
      unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0794dfa269ce44c7890d47b9989dd683_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE3LTEtMS0xMDA0OTQ_356ee5ed-4897-4968-9c77-270c11bec6b0"
      unitRef="usd">281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15b258a143a242c6b252146d74dbac1d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTEtMS0xLTEwMDQ5NA_79ae79dc-67a7-434b-a810-ed806832031d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90a98ae870914b948c565659e918f453_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTMtMS0xLTEwMDQ5NA_ea40c51b-2b83-49de-b165-de69279c1887"
      unitRef="usd">238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefba66a377874ba2b44b702df3e1d749_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTUtMS0xLTEwMDQ5NA_4bc3daaf-acce-4f3a-8139-d28a5607cc78"
      unitRef="usd">238000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ec35638b37649b895fe6f1af825d879_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTctMS0xLTEwMDQ5NA_1f184f7a-d9fa-4a6f-961a-00a338e39e31"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f1ca9ec329841abb944f3c69f76e638_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTktMS0xLTEwMDQ5NA_d61e15d5-2faf-4a3a-b5f6-3670b3f6514c"
      unitRef="usd">252000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife5efa30ffc24b3ca056dde5eb034cf2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTExLTEtMS0xMDA0OTQ_1572191f-f349-4be0-8099-ffb15f525e35"
      unitRef="usd">252000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a448ec43a2749f1bb446aa74a3bed8c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTEzLTEtMS0xMDA0OTQ_201fe930-aae3-446f-8a08-376f50964e66"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie10456cbffc5448993342502159c294a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTE1LTEtMS0xMDA0OTQ_24e0f12a-84bd-4245-9e56-103e02308a57"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bdaeae1c70b40aaa1e3b158b17ef808_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI0LTE3LTEtMS0xMDA0OTQ_1325b8c6-cfd9-4286-8ab2-946d4dc61f94"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iedbc88ea95514451917cf053f720e3ff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTEtMS0xLTEwMDUwMw_d671b9f4-2532-4d45-8a66-b9eb71a755dd"
      unitRef="usd">1523000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6f58bf19d1640f8a24c1ab656bd7e18_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTMtMS0xLTEwMDUwMw_518d402b-3dab-4527-b380-3d4fc90d5332"
      unitRef="usd">4161000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ae8c44fbfd54215a8cb3d32bf50788d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTUtMS0xLTEwMDUwMw_ee4f78eb-6d03-4568-9c77-2ca56d5637a3"
      unitRef="usd">5684000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibfc958ec611e402d89f8dba65cf34f21_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTctMS0xLTEwMDUwMw_18a117f5-28ec-499c-b7b4-36b3358b3049"
      unitRef="usd">632000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide81cf5396514fa28192d55d76c92ed8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTktMS0xLTEwMDUwMw_a7e45b72-4e12-46da-9dae-0aa5f3519476"
      unitRef="usd">320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibeda3b83cc1345dab64a83c66a84ee67_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTExLTEtMS0xMDA1MDM_3ac86eb0-ef65-4928-bccd-93846dc2e5ac"
      unitRef="usd">952000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d25683f4f6841718c7e93350d0d5a67_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTEzLTEtMS0xMDA1MDM_8aa14443-ffc8-4406-be65-11fe7eb043a3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i629bc23e5a69421a92ee3560e059c642_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTE1LTEtMS0xMDA1MDM_8d9f2701-893e-4832-ad80-3356a7735d78"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71e77126574f42bb96d0bb8e53774cd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI2LTE3LTEtMS0xMDA1MDM_e095f450-a3b9-480e-8dde-5bdc3967cc95"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i613d1486fc28474c8acbd3dda55239ac_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTEtMS0xLTEwMDUwMw_10d0183f-68a8-4fa3-97b1-38b56784907d"
      unitRef="usd">274000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8fe4630cc947444b83450d5ccf9a3062_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTMtMS0xLTEwMDUwMw_0cb5e6b2-c433-403f-90fa-b9f7c35ba865"
      unitRef="usd">359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i293647d3e306407ebf8717a4faa018af_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTUtMS0xLTEwMDUwMw_f2b07ca3-cbe1-4b45-9556-a5d37f9aacc2"
      unitRef="usd">633000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6bc9b30cdb6f46cf84ff8676fca96daf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTctMS0xLTEwMDUwMw_5f6a3adb-7341-456b-9b3d-b4b293779216"
      unitRef="usd">294000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia49136d6485e4f27b3b68f218f591205_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTktMS0xLTEwMDUwMw_ad7cb621-adcc-4b5e-b0e7-ce2329df2745"
      unitRef="usd">474000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d3c8d57174c4ba09a7ae459144cccc8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTExLTEtMS0xMDA1MDM_4f6b7061-c292-456c-955c-c3843d5d576b"
      unitRef="usd">769000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdd8810addb24069affe76f94ec0a5be_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTEzLTEtMS0xMDA1MDM_aee42ccb-b8d3-4ff7-86ed-6b150cabb267"
      unitRef="usd">326000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1c464d5e9ce4a76ba55304fc35bee88_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTE1LTEtMS0xMDA1MDM_60ca8899-7f7d-4092-963e-19d4acbb9451"
      unitRef="usd">531000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e30185203174bacaee8e9bba03bd862_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI3LTE3LTEtMS0xMDA1MDM_586d596b-df11-4537-8877-b481079aa396"
      unitRef="usd">857000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib909438afce24a8780c7df58861bb88f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTEtMS0xLTEwMDUxOA_e3465769-16ad-4a5f-bf11-b8d8b776cb0f"
      unitRef="usd">79000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib609b96d8c4c45d1a0af8c7f1afebe6c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTMtMS0xLTEwMDUxOA_94b05485-df2f-4d58-8b5c-aae4e2e423a3"
      unitRef="usd">179000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie99e22750ba14129b0cd8b6a97dad49c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTUtMS0xLTEwMDUxOA_11a813f3-b2eb-4962-b1ac-fbc95e7eae71"
      unitRef="usd">258000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f10dba5ec404300bd6208a5fc3914aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTctMS0xLTEwMDUxOA_fb80d7d1-ed75-4197-9298-acb73fd62be6"
      unitRef="usd">78000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ec7cb4b83004d9a983d8127e07e2b2f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTktMS0xLTEwMDUxOA_99e53506-ffaa-463c-bf03-0578cfa25d74"
      unitRef="usd">241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb5eeb8fa10948649d5874f868693a1b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTExLTEtMS0xMDA1MTg_dde34ec4-17cf-459b-80ac-f4c05fdf817c"
      unitRef="usd">318000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9bd6baf002c54d9a9da34f801bd78e3b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTEzLTEtMS0xMDA1MTg_b6807d37-106e-42cf-bda4-020a7b2e7e9e"
      unitRef="usd">81000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i338443af5bd847189e38c92ac1ec921e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTE1LTEtMS0xMDA1MTg_beda8de6-c7aa-4c09-aa0a-47a52ea9ae47"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5884d63fe366495081e710da8a78d315_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzI5LTE3LTEtMS0xMDA1MTg_2dce0e49-c231-4b13-979b-8daccc18f875"
      unitRef="usd">327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d6da244d9d94c518f93764d97f2d35a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTEtMS0xLTcxMzMw_4241bb4c-7ef0-4f33-8a51-d1479799d229"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e9b9cf8c9aa4481bb00fc5b21378b37_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTMtMS0xLTcxMzMw_17af83e7-8940-4dbe-a87b-51473e117b99"
      unitRef="usd">706000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc50a7e8a028404c9337837900c373c8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTUtMS0xLTcxMzMw_9fcf10b3-0487-4142-bc1c-23f32b28b40b"
      unitRef="usd">706000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id51698f086f24b71b9570d9313720f9d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTctMS0xLTcxMzMw_d5efdf40-37d0-483c-b14c-cfd25fd5af65"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc622e652dab409a966bb1005b97fb12_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTktMS0xLTcxMzMw_8d20b7fa-3ff6-4740-beb7-b49c3c099a16"
      unitRef="usd">825000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8283275c2880459b937b5ba98b866084_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTExLTEtMS03MTMzMA_10547a70-dd1e-4a75-b8bb-22b2698be21e"
      unitRef="usd">825000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2cf47d7044f4adba5964039483ad7f8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTEzLTEtMS03MTMzMA_4d6aa718-b0f3-458e-babd-e590edaafd04"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39f0ead2a04c463ebca54852c312306b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTE1LTEtMS03MTMzMA_ba6d990b-3056-4fda-aa31-20a0ef23f3c5"
      unitRef="usd">838000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4466289ff2147e2b0ad5ba8dad1504d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIyLTE3LTEtMS03MTMzMA_14eec417-7636-46bb-ac06-12c6d7d6f4f3"
      unitRef="usd">838000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3e907a5d5f345568c0c95ad777ef996_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEtMS0xLTcxMzMw_9834b705-bf9c-4b71-b12a-71b8d3d5af6f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08fdb9e60bb54154be013bfb3b99ed37_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTMtMS0xLTcxMzMw_82bf0893-4fbf-4f74-8d64-e6fe8eff8579"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i552cf9a2dba34015bca9ef712e555836_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTUtMS0xLTcxMzMw_d6713388-fa96-4975-b1fe-94d38c803691"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc13214640dd49aea3a6f573732950f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTctMS0xLTcxMzMw_48166bdb-1642-4b7c-a63a-9dea7ffe024d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i183853257a9744bda89e18492b5adce3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTktMS0xLTcxMzMw_cde26af1-734b-4f83-be1a-925075ced80b"
      unitRef="usd">299000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52ff9b6d884c4cd4ad827974b7a04cac_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTExLTEtMS03MTMzMA_2d87cc70-0bb0-4025-90b8-45f89394a427"
      unitRef="usd">299000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib38ff4e18c854e00bd319922ef36c8fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTEzLTEtMS03MTMzMA_d75e4e68-0e67-44e7-a2ed-88b75f45662a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04e83011764347d1b6364b08e35f618b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE1LTEtMS03MTMzMA_d287db4d-f57d-4538-994f-bcf80cb508cc"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c361862132d4c12a3df559d1247ce11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzIzLTE3LTEtMS03MTMzMA_15f0abf5-e1c2-4a9a-8da2-5da6c7a17817"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaa9b80b3f7d4f2ca54fe62d484ad6ff_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTEtMS0xLTcxMzMw_af99ed92-2807-4925-94e1-46c44e1c0fac"
      unitRef="usd">1248000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic322d64f24e846d9afd0e3dba16e24cf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTMtMS0xLTcxMzMw_40dc5f78-a7f9-474f-a0a9-3048ae27a43a"
      unitRef="usd">1565000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42ae64bb8a33446faaac7873a35016cb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTUtMS0xLTcxMzMw_356a7a05-d4c4-4301-9182-e8ced5967649"
      unitRef="usd">2813000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91629c66e76841e49ac8fdbce3d95883_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTctMS0xLTcxMzMw_70d77d96-5df8-409c-b989-5152a1f485af"
      unitRef="usd">1404000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idea2621b38e949de95e267f3fa6822d5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTktMS0xLTcxMzMw_61f690c5-ee98-4035-a783-fb4e71a7d87e"
      unitRef="usd">1920000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8aa77411ccf241218037cc5cd351cba4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTExLTEtMS03MTMzMA_29427f2b-55f0-47c5-931b-7bc41c251f44"
      unitRef="usd">3324000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf36505cfcb544e6bc2016ef576a5a96_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTEzLTEtMS03MTMzMA_51eda136-4e71-40f4-8e82-3bfc9d65fccb"
      unitRef="usd">1470000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie40150bacb004b09aa1761eea6e209fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTE1LTEtMS03MTMzMA_00eaa1d3-d598-48fb-8002-7f4ebe809f12"
      unitRef="usd">1836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fcc4830492c4d41b40fdd59f5359d79_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzMzLTE3LTEtMS03MTMzMA_5330473b-c4a7-43e6-85bf-cebd3b9d87ca"
      unitRef="usd">3306000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib79561000ee344c4bc43f4af90649a06_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTEtMS0xLTcxMzMw_b9474f49-5bba-4cef-9029-329640fbd51b"
      unitRef="usd">355000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0761d7789524bce842b332f0db014bd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTMtMS0xLTcxMzMw_cdd13767-c5fa-4c2a-8a09-b4da0baaa81c"
      unitRef="usd">1344000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab8bed311c094329b4d745c12c4a5cc0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTUtMS0xLTcxMzMw_7c602a6a-6c44-40fa-a170-dd140e663b5f"
      unitRef="usd">1700000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a1ca67f428141cebc70732cebff9521_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTctMS0xLTcxMzMw_a620c9cc-6f5d-4a47-8f35-d0d9ca71af7e"
      unitRef="usd">367000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54e6f6f6fd524dd69fe636e2947bdfa1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTktMS0xLTcxMzMw_6cfa7187-563a-46eb-a5d8-2646e5f662db"
      unitRef="usd">1597000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42c259a7a44a4b05a2c75e4dbb68b616_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTExLTEtMS03MTMzMA_3ad8664f-2e6d-4fa2-bc87-8f37d8d83321"
      unitRef="usd">1964000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d6f7b78017c4b1aae8ad926d48e6a38_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTEzLTEtMS03MTMzMA_ed94df26-5029-4234-90d6-5a27a95dbf81"
      unitRef="usd">477000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i990a4dc4b81240de8e34aeaaf52eb1ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTE1LTEtMS03MTMzMA_d58cd1ab-23d2-497d-9683-156f8c330278"
      unitRef="usd">1494000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a3d395096a04f008b6ad61b7397f8a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM0LTE3LTEtMS03MTMzMA_44abf9a6-d343-482c-a6bd-55f6a491fbe0"
      unitRef="usd">1971000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide4387d3b03f47fb943aef0ec03b900b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTEtMS0xLTcxMzMw_034e5154-b4aa-4499-8aeb-5e012ea78eea"
      unitRef="usd">969000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b7753d0b2864abf84b4f0352e03b254_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTMtMS0xLTcxMzMw_27f85c3f-03ec-47e2-8492-987a49742c22"
      unitRef="usd">1282000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51a96ab2adc74657a7fc0400faed593c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTUtMS0xLTcxMzMw_44a3ef9e-e5a7-49b2-8ee6-cc98c988fda6"
      unitRef="usd">2249000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f891fe0d78a4c3bbd5bda2518e4ea4e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTctMS0xLTcxMzMw_28b49930-b938-43d0-892d-c44e0bc97734"
      unitRef="usd">841000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cfe13e7da014c61bc807c8e56ec5f0c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTktMS0xLTcxMzMw_a2ec4aa4-03dc-4769-a46c-e31566a4d899"
      unitRef="usd">1275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45b3d413326442638d0877fd2e9e29a2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTExLTEtMS03MTMzMA_39d2e056-f5e6-403f-bb05-54bf591d8fa2"
      unitRef="usd">2118000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2bed06c5b34b488ea2f844c3779949d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTEzLTEtMS03MTMzMA_7cca13f8-0672-4b31-bc10-fc85c22f9584"
      unitRef="usd">882000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86879f1d260a48b2b3fc2ba0929452ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTE1LTEtMS03MTMzMA_764afca4-abe5-4184-8b6d-874d63e969fb"
      unitRef="usd">1321000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebe4eeaab037443a9c7ca2df4c70ad71_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM1LTE3LTEtMS03MTMzMA_43f76de3-9b42-45d3-a462-b4b08da0c723"
      unitRef="usd">2202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebc3747831fa47ea8edcca64589a2d04_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTEtMS0xLTcxMzMw_f09696b6-6f86-4f47-9e22-b9614183189e"
      unitRef="usd">24989000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b0483a589fe4ef9a10b6defdb741d26_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTMtMS0xLTcxMzMw_0478c6be-48b5-40ce-a3bf-8d36cc2d96b2"
      unitRef="usd">27016000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTUtMS0xLTcxMzMw_90a4dc24-61b6-446c-979e-328cee114c0e"
      unitRef="usd">52005000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20844159d5914e56aaeb01e98bfffaad_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTctMS0xLTcxMzMw_de48b5a6-c198-427f-92ee-728a5e1ee78c"
      unitRef="usd">20401000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic398861a5e604978a3c98fc5841e68cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTktMS0xLTcxMzMw_e455943a-926b-4bf0-a0a8-29ac885db674"
      unitRef="usd">22353000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTExLTEtMS03MTMzMA_52add7d4-d151-44c5-be36-2654be7b2e1e"
      unitRef="usd">42754000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d8ac6036c8646999d891c258acab031_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTEzLTEtMS03MTMzMA_2f48d1fe-4e2c-4cde-a7b3-5d3721891ef2"
      unitRef="usd">18010000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iacbc57c3e1584457acadc54ca8ee0f09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTE1LTEtMS03MTMzMA_1b027687-6b72-4ecc-92d3-09eac14ed171"
      unitRef="usd">18600000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM2LTE3LTEtMS03MTMzMA_eb067c50-51bf-4ae1-80a9-282e00cfb60b"
      unitRef="usd">36610000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a777627607f4c4abb9584a4411dbf0d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTEtMS0xLTcxMzMw_443438a5-3e92-4299-911c-aa2b925b368f"
      unitRef="usd">710000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i890f308e305745e993afb171875461d3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTMtMS0xLTcxMzMw_651032ca-b7e7-48c4-95d2-ce360b9b2ec6"
      unitRef="usd">2590000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56526eb7b6df403d980ccad23c43f766_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTUtMS0xLTcxMzMw_9decf053-8adc-4718-9e62-b1d0d992c8ee"
      unitRef="usd">3300000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29d93056d1c2487eb95a4a49fc8d01a3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTctMS0xLTcxMzMw_2df1142e-197a-4108-934c-cca930a6d8da"
      unitRef="usd">667000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4894c9df276a4645b9f3fd98b62ebacb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTktMS0xLTcxMzMw_03425b74-d1c8-4e0a-983e-0a39db95476f"
      unitRef="usd">2628000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3c8a2d41e93427ab955bd22bcf78ae0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTExLTEtMS03MTMzMA_b3d169d0-c945-4434-848e-8c8d0c0454fa"
      unitRef="usd">3295000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2119c2582b0b42a289d1ca7e693a7795_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTEzLTEtMS03MTMzMA_8cd399e2-c1bb-46a8-a8b0-872e0ea570e1"
      unitRef="usd">612000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74dc6f5dabd64668b9cecba5fe18fa39_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTE1LTEtMS03MTMzMA_0a0d9363-a5ad-404a-8f12-875849d934e2"
      unitRef="usd">2327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6688637b104f45498e4d1adcc1dff8f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM4LTE3LTEtMS03MTMzMA_94c85f5b-45f2-4154-9971-7a1d5d77034f"
      unitRef="usd">2939000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73d257fa44324b53a1ef7ca1720ac517_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTEtMS0xLTcxMzMw_90594ba2-2f6b-4b29-8c68-b2f8bf86b614"
      unitRef="usd">1112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2554a55ac3e445b4b77f581e924fa49e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTMtMS0xLTcxMzMw_067b99de-cb84-47da-8076-eb37f982308c"
      unitRef="usd">1138000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e5f83c1f72f44e1be95132b049ae22c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTUtMS0xLTcxMzMw_244c32f0-4742-41b4-88a4-39ba4a57ebbc"
      unitRef="usd">2250000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i963120dbdfdb4d71a1491aa18697e865_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTctMS0xLTcxMzMw_cf4e98a1-66ef-4f47-a5dc-28a53c261131"
      unitRef="usd">1091000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0c6c6b918224b0b9941f8fdd4403701_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTktMS0xLTcxMzMw_da98a3d8-bf52-4d33-997a-5769453e3abc"
      unitRef="usd">1182000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18e5c6c625744b5397f0c31a5173824d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTExLTEtMS03MTMzMA_9510227d-db66-4694-b920-948ec0afe723"
      unitRef="usd">2273000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb094efcfafa4c4b90bf422d01d01cf6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTEzLTEtMS03MTMzMA_6c409e26-6951-4ee3-b5d6-2f4e4165ebeb"
      unitRef="usd">872000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i218fada0b11b421db5b8600c0019d4f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTE1LTEtMS03MTMzMA_af3fba38-93c9-4fc5-adda-103c31a2cc4b"
      unitRef="usd">892000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c439560c469498ca75bab3229912fed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzM5LTE3LTEtMS03MTMzMA_54bf86ab-4a23-41b3-99ba-3e41c174acaa"
      unitRef="usd">1764000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id26f89beeaae4c7f931c5d4d81ab0bc1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTEtMS0xLTcxMzMw_b20fb9de-5653-4fb0-b626-613487e7943a"
      unitRef="usd">1822000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i337d955832ba4199a0df850ea23b5676_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTMtMS0xLTcxMzMw_af55b3ad-eb0f-41ff-8a70-7d0d7f6bb899"
      unitRef="usd">3728000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTUtMS0xLTcxMzMw_172d18d5-9093-4557-9bb5-fd8f92cc988b"
      unitRef="usd">5550000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c0fa7b9aa8d4e40bc457315bc042e44_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTctMS0xLTcxMzMw_5bc1b703-4b36-43c3-a4b7-895d24cbcae6"
      unitRef="usd">1758000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd8a7e5fe48142d5a2a4a1449d7e5fd3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTktMS0xLTcxMzMw_ac435137-95be-41dc-81a2-f29f812e10fb"
      unitRef="usd">3810000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTExLTEtMS03MTMzMA_427e15e7-b021-4871-8eb3-16d8002b357d"
      unitRef="usd">5568000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42a2c421146a4685b24d4d63dc874137_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTEzLTEtMS03MTMzMA_a425a0fc-ddfa-42e7-9bb6-5926ad443b51"
      unitRef="usd">1484000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31df7669833c47408aded7bcb0d91766_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTE1LTEtMS03MTMzMA_0d44340f-d452-4304-869c-9d7c8539b7a5"
      unitRef="usd">3219000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQwLTE3LTEtMS03MTMzMA_20f19ae9-777d-42a7-8c4e-a03f8306d121"
      unitRef="usd">4703000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa2ea2b06d674eb997a7ca0ea9ee4f84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTEtMS0xLTcxMzMw_46e1d163-898c-4365-b4a7-ba8e46914093"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2ff1d1758224e68b457056f4c1aa244_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTMtMS0xLTcxMzMw_57e5f4a8-d0e8-4396-87e2-9c62b15abfa6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTUtMS0xLTcxMzMw_b01632c9-ba9f-4db8-b38e-85bdedbc9fcc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71007b7779374d738c052de5ee0be00c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTctMS0xLTcxMzMw_4e025eac-26cf-422f-8981-5c1bdd631e2b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95ada1ec00a9474b86440d7e3fe85a61_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTktMS0xLTcxMzMw_db06ddb8-a09d-4068-947e-d398be996c13"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTExLTEtMS03MTMzMA_c79dd211-2f16-45a9-95be-e7db506c9fac"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if379b668eb4a408d857cc08dbfb7cda2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTEzLTEtMS03MTMzMA_797a4cd1-dc01-4416-8eb2-f6dea5f26eef"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i343efbd897d7479798adb44173aabdef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTE1LTEtMS03MTMzMA_33caf423-6b8b-48da-b934-bd702f4aa6c1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQxLTE3LTEtMS03MTMzMA_58c20470-e8bb-44f9-9505-ac414da33f88"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba066b9bf1844c0e995daa549acba43e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTEtMS0xLTcxMzMw_014d4972-8e00-4ecd-b498-3303488c6eeb"
      unitRef="usd">26811000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4556e60ce4f74c22ad0cb51ba398629d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTMtMS0xLTcxMzMw_a818212b-99d4-434b-b8d6-25c80af19317"
      unitRef="usd">30744000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTUtMS0xLTcxMzMw_d5fecd6c-7445-482b-89f0-3d3366d00b18"
      unitRef="usd">57555000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb44034bd361427c89ea4308da4aa6cb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTctMS0xLTcxMzMw_e6ee5e6f-f540-4ed3-af71-27f0995c3891"
      unitRef="usd">22159000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4158ddf9b78a40c0b069dad583f960ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTktMS0xLTcxMzMw_c7cdaf6c-9de7-41c1-8dd3-2a194e965505"
      unitRef="usd">26163000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTExLTEtMS03MTMzMA_a6495dae-aa8f-406a-9cb6-e1c04a08dcd1"
      unitRef="usd">48322000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie51d2c4b860046aaae61f55468059f18_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTEzLTEtMS03MTMzMA_fb078907-e109-4e8c-911b-d19a91f34fa5"
      unitRef="usd">19517000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d7f372308b340f7ba087719099057d4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTE1LTEtMS03MTMzMA_fc3b1ae3-b6a7-42bc-b8f8-25ee0b1542d8"
      unitRef="usd">21819000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQyLTE3LTEtMS03MTMzMA_05799423-57b8-4c1e-bcd9-2d027f32e914"
      unitRef="usd">41336000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e4aab7a7520412f993065e092f416c4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTEtMS0xLTcxMzMw_925358b1-a119-4fa9-a1e9-c8f8592a9030"
      unitRef="usd">395000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f3e56752d724c438792f86d2f774c4c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTMtMS0xLTcxMzMw_c23f6d58-e1f9-49f9-80a1-9726afebfff6"
      unitRef="usd">1333000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f295cd4f0de410cbcd6deb71260cc77_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTUtMS0xLTcxMzMw_b155b3a1-78cc-4fae-9950-62ccacaae1aa"
      unitRef="usd">1728000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96716f25cfcd4ea78877e455aa3addec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTctMS0xLTcxMzMw_9b02127a-137f-4a5e-aedf-4d072a844667"
      unitRef="usd">266000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fb33bfd647d4010a30f8e7417dfba4c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTktMS0xLTcxMzMw_0546f804-5751-4f12-aa1a-59c7735f00d4"
      unitRef="usd">116000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec693e2b56e5450795dee9a8f5b1fd7c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTExLTEtMS03MTMzMA_7c7f1194-55b9-4ff5-87b9-65b79cf0cf4d"
      unitRef="usd">382000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdd89273ea4c4e4086ce9cefe2ab8a36_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTEzLTEtMS03MTMzMA_41949fe1-c48a-460f-85e6-738c08726bac"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4713191775b44625bd8480c87097307a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTE1LTEtMS03MTMzMA_03b91046-d7bb-4006-8992-c5d62da903ce"
      unitRef="usd">111000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7771fa9d00e456f945808f5b1350a86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQzLTE3LTEtMS03MTMzMA_6506430c-a076-4bd9-8171-b15064032015"
      unitRef="usd">182000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i840fe2106741497387f3e41d6c0fbd82_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTEtMS0xLTcxMzMw_7a02a4e8-d0e5-4e26-86ad-ece94b46dd56"
      unitRef="usd">27206000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idad74c169614459ebd6a2feba9923acc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTMtMS0xLTcxMzMw_f3060815-eb5c-4f63-b9bc-d1a3301dbd8f"
      unitRef="usd">32077000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTUtMS0xLTcxMzMw_fc60f346-54fe-4ffd-ac4f-289bb26626d0"
      unitRef="usd">59283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i923e47ae0d0a44b59c583a5e9fa3fa54_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTctMS0xLTcxMzMw_8daad395-4a6e-46ef-a78a-1f77c810cb49"
      unitRef="usd">22425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d0e54bbc4e1406baa90d17d42691c90_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTktMS0xLTcxMzMw_fe1b8b20-c1a5-40a2-9926-77ebd1337cd3"
      unitRef="usd">26279000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTExLTEtMS03MTMzMA_0cca8c22-41fa-41ec-83eb-0c77751b63c6"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2b2e025a9ae49f6b693fe2b2b301a7f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTEzLTEtMS03MTMzMA_afe62413-2cc2-4559-9134-201e4b129058"
      unitRef="usd">19588000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5bcd741098644d6bdebda5470bbbf63_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTE1LTEtMS03MTMzMA_6558ff0e-ab2d-4857-b217-2a46419885b0"
      unitRef="usd">21930000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo4ODAyYjliYWYwNDA0YThmYTJkMTAzNzI2YTAyMDgzOS90YWJsZXJhbmdlOjg4MDJiOWJhZjA0MDRhOGZhMmQxMDM3MjZhMDIwODM5XzQ0LTE3LTEtMS03MTMzMA_f5c1fb57-ffaf-4eb2-97ea-93265da03df5"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <mrk:IncreaseDecreaseInHedgeRevenue
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzIxOTkwMjMyNzAwNzM_e956abe5-9798-47db-8ac1-198a0eb6390c"
      unitRef="usd">810000000</mrk:IncreaseDecreaseInHedgeRevenue>
    <mrk:IncreaseDecreaseInHedgeRevenue
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzIxOTkwMjMyNzAwODA_d7c86e92-1be4-4e8f-9d62-292ff508a882"
      unitRef="usd">-203000000</mrk:IncreaseDecreaseInHedgeRevenue>
    <mrk:IncreaseDecreaseInHedgeRevenue
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzIxOTkwMjMyNzAwODk_de516629-0e41-48a6-a818-8c8f301f4481"
      unitRef="usd">-19000000</mrk:IncreaseDecreaseInHedgeRevenue>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzEwOTk1MTE2MzM5Nzg_9ed5e2f2-8ab8-4c0b-8a13-732891a69ffa"
      unitRef="usd">165000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzMzNTc_7904cc74-78d5-4480-9f90-43d6b3018233"
      unitRef="usd">218000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzEwOTk1MTE2MzQ3MTk_7bf39a9c-1230-41e1-ab84-db4becfb7e2e"
      unitRef="usd">54000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3NTQ_8f885af9-9f0c-42c9-9d5f-5548b62e5e10">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;27,206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;14,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,629&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,568&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;59,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="i840fe2106741497387f3e41d6c0fbd82_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzEtMS0xLTEtNzEzMzA_24f9bd6d-003f-44c0-bdc4-f1fba0d5a11e"
      unitRef="usd">27206000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i923e47ae0d0a44b59c583a5e9fa3fa54_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzEtMy0xLTEtNzEzMzA_31f9105e-b2dd-4f01-9d00-8d91dcb47242"
      unitRef="usd">22425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2b2e025a9ae49f6b693fe2b2b301a7f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzEtNS0xLTEtNzEzMzA_b18f18b2-85e5-4849-917c-746d8e121e2d"
      unitRef="usd">19588000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia689dc2ff1e4458792332eba5e96c16b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzItMS0xLTEtNzEzMzA_7dad17fc-b965-4e9a-b967-60923580ff5b"
      unitRef="usd">14493000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i884402da04444fdfa741b60ec14e6df6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzItMy0xLTEtNzEzMzA_693abc05-6d24-46ec-84fc-a857315383ba"
      unitRef="usd">13341000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia22a7046c70e4bfb87b82cb904893496_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzItNS0xLTEtNzEzMzA_812e1236-47f4-48cc-b547-d84db52892bb"
      unitRef="usd">11547000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i886f7113739342fe9e0a88000b89520c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzMtMS0xLTEtNzEzMzA_92243b43-f80a-4fc2-a934-6e3473f7501b"
      unitRef="usd">5191000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9dc938ddcd1a435c9cf8105a8ddbd1d8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzMtMy0xLTEtNzEzMzA_d754ed2b-4b07-46a3-ac5a-245f59e34a34"
      unitRef="usd">4378000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i998005d150c24a6bb8ccdcd6c0251302_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzMtNS0xLTEtNzEzMzA_9ca17a17-9bdc-4f09-acc6-65fb5da22b9f"
      unitRef="usd">2751000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92b79a3305ac435cb2d4da9934529da6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzQtMS0xLTEtNzEzMzA_c7c8d396-efdc-4850-b89b-d939789e845f"
      unitRef="usd">3629000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0045db94c49d4a67a671551c92f63b4d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzQtMy0xLTEtNzEzMzA_674c5d29-a22b-453c-b375-e88f1954405d"
      unitRef="usd">2726000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied160c449f26454885073f7135732aeb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzQtNS0xLTEtNzEzMzA_25c1f0cc-252b-47f6-b7d7-57099b1624d7"
      unitRef="usd">2602000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8284319e3a8f41c5bf0824118bcb2446_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzUtMS0xLTEtNzEzMzA_c7c354b5-0560-46a2-b86d-fe50b0ff4fb9"
      unitRef="usd">3614000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife1e166e6f2f4a579b637ff0e714bbbd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzUtMy0xLTEtNzEzMzA_d24662d9-6e87-436d-a774-a02f7dec15ed"
      unitRef="usd">2407000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id876bec63a044a438106d7fc364c0be2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzUtNS0xLTEtNzEzMzA_60a88759-aa7b-4abc-a34a-d4f94f3b95b6"
      unitRef="usd">2113000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i047342a7dd6a464e8f2c160368b133c3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzYtMS0xLTEtNzEzMzA_58f12b6e-09e6-4c70-8ac7-ce81dc4a5a6e"
      unitRef="usd">2582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8cb013593b44a96a79cd5ac26f510cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzYtMy0xLTEtNzEzMzA_c5312e16-3373-4f43-93f2-436f3608e19a"
      unitRef="usd">2206000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3e683e533014f74b1427b3564e847c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzYtNS0xLTEtNzEzMzA_4a46efbb-73ac-4b2a-aa96-67cc9f681b0c"
      unitRef="usd">1890000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ad4d8d7f0ad4e40bc7dda4d86aae1fe_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzctMS0xLTEtNzEzMzA_9d4433cf-70cf-44f9-bb84-5b96527cae75"
      unitRef="usd">2568000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50c971a16db240a29a2f4b213472c027_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzctMy0xLTEtNzEzMzA_c7a9e246-7923-4c53-bbe5-35c470c4af26"
      unitRef="usd">1221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3f1ccd890df4f68b103d447a8e62b07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzctNS0xLTEtNzEzMzA_fe26bb0b-9212-4241-a5aa-9cfd8514eebc"
      unitRef="usd">1027000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzgtMS0xLTEtNzEzMzA_3c855f78-8480-4d5c-9989-758cdfff1826"
      unitRef="usd">59283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzgtMy0xLTEtNzEzMzA_248f0f0f-8cb0-4b73-902e-f596215a0383"
      unitRef="usd">48704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTplYjhmOGM5ZjMwZDU0ODc5OWNiMTQ0OGQ4ZTc3YjBlYy90YWJsZXJhbmdlOmViOGY4YzlmMzBkNTQ4Nzk5Y2IxNDQ4ZDhlNzdiMGVjXzgtNS0xLTEtNzEzMzA_ed6b5f36-53e6-4542-b171-21d024f5c2f9"
      unitRef="usd">41518000000</us-gaap:Revenues>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3NDI_975f205d-fcd1-4df2-94e0-cf1615062e45">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Continuing Operations Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Years Ended December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;36,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;38,815&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(13,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;16,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzItMS0xLTEtNzEzMzA_1859d701-3aae-475f-8df3-c7b658c85567"
      unitRef="usd">36852000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzItMy0xLTEtNzEzMzA_049901bd-a981-4c81-baf8-5e40542b7044"
      unitRef="usd">30977000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzItNS0xLTEtNzEzMzA_0742a87d-6554-4469-9fae-86f3ae58ef31"
      unitRef="usd">26106000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzMtMS0xLTEtNzEzMzA_cca83044-aee6-4353-beb8-28fc75b14b05"
      unitRef="usd">1963000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzMtMy0xLTEtNzEzMzA_8516c8d5-49b8-4d57-9225-090fc884e30d"
      unitRef="usd">1950000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzMtNS0xLTEtNzEzMzA_2e35d218-2484-447e-b39e-7300902c7356"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzQtMS0xLTEtNzEzMzA_f9653a3a-e215-41c7-b5cd-74daf36de111"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzQtMy0xLTEtNzEzMzA_38fddafb-8dc1-4e48-88ba-29c053d9b901"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzQtNS0xLTEtNzEzMzA_2c9709e0-ec28-4f5c-b472-d4d159794684"
      unitRef="usd">1000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzUtMS0xLTEtNzEzMzA_66b47840-5c10-4b46-9ff5-a04de37847d8"
      unitRef="usd">38815000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzUtMy0xLTEtNzEzMzA_2f2c58cd-79a8-4cb7-9789-9beb890694c6"
      unitRef="usd">32927000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzUtNS0xLTEtNzEzMzA_fd7af41b-e289-4408-9be2-dc828e00b1c8"
      unitRef="usd">27776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0f295cd4f0de410cbcd6deb71260cc77_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzYtMS0xLTEtNzEzMzA_8ff40155-a1de-481a-a126-5d440dc91a3a"
      unitRef="usd">1160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iec693e2b56e5450795dee9a8f5b1fd7c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzYtMy0xLTEtNzEzMzA_9a49e1ef-6807-49be-863b-679633b7da9e"
      unitRef="usd">156000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie7771fa9d00e456f945808f5b1350a86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzYtNS0xLTEtNzEzMzA_2110bae9-12c1-4e1f-bca8-5e2fa3401153"
      unitRef="usd">75000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzgtMS0xLTEtNzEzMzA_1313c1c6-ec9c-40e3-85f0-e507c6df036e"
      unitRef="usd">157000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzgtMy0xLTEtNzEzMzA_8dd26018-872c-415b-b51b-d7d1a5dc6908"
      unitRef="usd">36000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzgtNS0xLTEtNzEzMzA_34eee3cb-84f8-4fee-bdb0-2457dec6f0a9"
      unitRef="usd">59000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzktMS0xLTEtNzEzMzA_184a20c2-19c8-4d24-a253-8c7caaee09fa"
      unitRef="usd">962000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzktMy0xLTEtNzEzMzA_f4827c92-b8dc-48a3-976d-da5847b8df40"
      unitRef="usd">806000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzktNS0xLTEtNzEzMzA_9bfc5acd-3635-4c4f-8d1d-e8b52b378b5c"
      unitRef="usd">831000000</us-gaap:InterestExpense>
    <us-gaap:AdjustmentForAmortization
      contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEwLTEtMS0xLTcxMzMw_550b558c-e282-4c58-bd07-836490ebb334"
      unitRef="usd">2085000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEwLTMtMS0xLTcxMzMw_ebca5307-8d9b-4f01-8c4f-7589ac9c6059"
      unitRef="usd">1636000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEwLTUtMS0xLTcxMzMw_4fa8e2e4-1cd0-4d10-b434-a4541e32b91e"
      unitRef="usd">1817000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzExLTEtMS0xLTcxMzMw_438c85d4-9955-44e5-9db5-7105ac83bf56"
      unitRef="usd">1642000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzExLTMtMS0xLTcxMzMw_b037b902-ce2c-48c6-bddd-1dd3ddf126ac"
      unitRef="usd">1414000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzExLTUtMS0xLTcxMzMw_7e3c8e2a-5aea-4b76-81c0-1d3401ff2e1a"
      unitRef="usd">1519000000</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEyLTEtMS0xLTcxMzMw_aee09390-b36c-4d55-9a81-8e82a7f64579"
      unitRef="usd">13011000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEyLTMtMS0xLTcxMzMw_c8e21266-c973-436d-9b76-4edcbff60106"
      unitRef="usd">11692000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEyLTUtMS0xLTcxMzMw_e65f80af-676a-4d6b-9f6b-60405292bb11"
      unitRef="usd">12911000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEzLTEtMS0xLTcxMzMw_39911ce1-ad6f-40c5-967e-3908fc0124c9"
      unitRef="usd">337000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEzLTMtMS0xLTcxMzMw_55754650-cc98-4d60-9342-c4fbeaa60629"
      unitRef="usd">661000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzEzLTUtMS0xLTcxMzMw_b9d358f2-df02-4753-9dcc-9e91fef96ba9"
      unitRef="usd">575000000</us-gaap:RestructuringCharges>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i1c6c1e02431c4cb4b4191b9bb860ce83_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE0LTEtMS0xLTcxMzMw_445c97b7-dac9-4e6f-a224-9f615f56970f"
      unitRef="usd">5651000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i0427bb4042474443a828a8f3595154f1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE0LTMtMS0xLTcxMzMw_10aa8cc3-925d-4e2f-88a4-08cfb9557cd7"
      unitRef="usd">3031000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i6037a50067e242ee86f1a7bdb60d98f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE0LTUtMS0xLTcxMzMw_be40de60-34d6-472c-ae07-b2d7df866fa0"
      unitRef="usd">4394000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE1LTEtMS0xLTcxMzMw_1c3c41db-9f4a-41c4-9484-d8b92d2554dd"
      unitRef="usd">16444000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE1LTMtMS0xLTcxMzMw_bdb1feca-7c3a-44f1-b418-c2aba50fbcef"
      unitRef="usd">13879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7ba993a20994af0b61525dc0a0a0128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTozMjI4MGMyMjAwM2U0MTNjODc3YjMyOWYxZmYwNjc1MC90YWJsZXJhbmdlOjMyMjgwYzIyMDAzZTQxM2M4NzdiMzI5ZjFmZjA2NzUwXzE1LTUtMS0xLTcxMzMw_b575d78f-62b9-49a7-9aef-100d0641bb4f"
      unitRef="usd">5863000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3MDQ_c4fb149c-072d-4c47-a46e-f7f323f6dfe1">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity income/loss from affiliates and depreciation included in segment profits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Equity income from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity income from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity loss from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtMS0xLTEtNzEzMzA_fa49ddec-4171-4b68-b0f5-33fcc37c713d"
      unitRef="usd">39000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtMy0xLTEtNzEzMzA_776264c9-3c7f-4d8d-9ecc-9619374add47"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtNS0xLTEtNzEzMzA_7b53dd83-dd93-472d-9aaa-e956604ac7de"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzMtNy0xLTEtNzEzMzA_2c30a4ce-fdcf-4ade-8fa2-b966444a0c88"
      unitRef="usd">39000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i180972d620b04773bac120852a0a31db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtMS0xLTEtNzEzMzA_c7502af9-de4f-4b4b-8830-893432349286"
      unitRef="usd">5000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idfe42f12e42e411eac8fc6d800ef37a4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtMy0xLTEtNzEzMzA_f538abc0-846c-4d82-824e-d9d253146294"
      unitRef="usd">177000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4295c0f8bfbf4139a7a4af7fc7f8d01f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtNS0xLTEtNzEzMzA_53265f88-f1ef-4aa3-a1e8-f372c1edd4a0"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzQtNy0xLTEtNzEzMzA_a0c6c9b8-f0ca-40df-b2ca-b478414f79ad"
      unitRef="usd">182000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctMS0xLTEtNzEzMzA_33c9e78d-1f28-48b5-acc3-8f3e48de2821"
      unitRef="usd">11000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctMy0xLTEtNzEzMzA_47066e6f-d758-4126-8a43-e3432545b171"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctNS0xLTEtNzEzMzA_daa1267e-90c8-4f7a-aaa0-5600116f46a9"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzctNy0xLTEtNzEzMzA_0c4893ff-c19f-407c-a4d1-dd491915b625"
      unitRef="usd">11000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i531ac966525143049c09ffd864bcbafa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtMS0xLTEtNzEzMzA_de5b1fb9-b89d-41bb-a1e4-650438b273a3"
      unitRef="usd">6000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0ad5342a7cd145c18ac1fd15efb41f00_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtMy0xLTEtNzEzMzA_fcfff96b-ba16-4f28-a20f-148fa09d6ad2"
      unitRef="usd">158000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if194957d47c14626990ac7579d8a2860_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtNS0xLTEtNzEzMzA_3773e63e-aa5a-4199-ab20-2ef467838048"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i53d3ae952fba495ca80864f70865b07c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzgtNy0xLTEtNzEzMzA_57f96b9b-e679-4f73-a9e7-439e67443b5d"
      unitRef="usd">164000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTEtMS0xLTcxMzMw_e6dbaa5f-c5d5-4b87-b9ca-55aea75d7a3d"
      unitRef="usd">-6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTMtMS0xLTcxMzMw_cefff989-cd7e-4f87-a457-d79147e4aa53"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTUtMS0xLTcxMzMw_91bb981b-4140-4017-b865-7445cfc1919d"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzExLTctMS0xLTcxMzMw_f84977b2-57ad-43fb-87b5-a0637c860f71"
      unitRef="usd">-6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iad1bbad6c18f474694d530a069bf116c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTEtMS0xLTcxMzMw_379ff501-3315-4e6c-8999-92b7997ac968"
      unitRef="usd">6000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i36bebb09bb104f88be4f5da0ed06d5c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTMtMS0xLTcxMzMw_0f2370f1-0917-4054-a2b7-56d98a65e553"
      unitRef="usd">143000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i14dd97be84c0481aabef6f54515338f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTUtMS0xLTcxMzMw_0d2e94f4-7bb6-47ab-950c-2ff87ca1e943"
      unitRef="usd">1000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia9830555a2164c03b1790e1d89154c54_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTowZjhiODhjOWYzYTk0OGVkYmU5ZTRlNGU1MzZiZjRlYi90YWJsZXJhbmdlOjBmOGI4OGM5ZjNhOTQ4ZWRiZTllNGU0ZTUzNmJmNGViXzEyLTctMS0xLTcxMzMw_7c75af75-b5f8-4e81-afc8-8643c67dfda1"
      unitRef="usd">150000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90ZXh0cmVnaW9uOjE0NmQ4NTAzNWQ3MzQ5NGM5ZTdlMDc5NDJkZGM5OGE0XzU3Mjc_78707551-a0e4-4909-a48b-38d4697714bd">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, by geographic area where located is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,891&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,422&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i269ce30010de4d15b4e17a5aedff6cd6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzEtMS0xLTEtNzEzMzA_166f3185-b737-4109-8a19-669a7fb73a57"
      unitRef="usd">12891000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8211b4d2d96b4d6e924cc16fb296c131_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzEtMy0xLTEtNzEzMzA_31d2abcc-88d1-4766-8829-90fc98727426"
      unitRef="usd">11759000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9fcf7b65ffe347b797e561991df21993_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzEtNS0xLTEtNzEzMzA_a85801a7-cfdd-4d2c-89f4-8d466db998b5"
      unitRef="usd">10394000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i81ccffe7157345caa23575cf77dbeed0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzItMS0xLTEtNzEzMzA_fd61f973-6b05-4b95-8434-6e6873646d67"
      unitRef="usd">6993000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1820461e7a084ed6a964f1b3b8d8d802_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzItMy0xLTEtNzEzMzA_29c37957-c9bb-4173-b4c5-3abf8d1d4269"
      unitRef="usd">6081000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie0faa095bd4a45aba5e98f155fde2079_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzItNS0xLTEtNzEzMzA_4c0486a7-8f37-4e32-8892-7ef961afa15a"
      unitRef="usd">5314000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7a5bba0a77af4a8783702f2047952acc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzMtMS0xLTEtNzEzMzA_5770afce-70cb-44f0-8b35-60bfb44815d7"
      unitRef="usd">966000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie4fae4d6107f488b8909bcca3be91c69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzMtMy0xLTEtNzEzMzA_48726817-4dfa-42f7-b932-7ffd15442cb2"
      unitRef="usd">857000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4c06014407b8411a91506d49df92a824_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzMtNS0xLTEtNzEzMzA_e2cc08fb-62a7-4777-ae19-0a7b6316216b"
      unitRef="usd">737000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic251c7f3bb4e47e08296afcc17172e83_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMS0xLTEtMTI3NjAy_51cad966-f707-48a8-9311-fdf676813e04"
      unitRef="usd">225000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i86e3b8649d7640388a5c9c721c08642e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMy0xLTEtMTI3NjAy_361c3acf-2f1c-4974-9d3e-4d7d7bea5ec0"
      unitRef="usd">199000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if9d9802536b44e179a60195bfc87b3da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtNS0xLTEtMTI3NjAy_cf5b4461-7535-4099-b986-27ad1e275c84"
      unitRef="usd">169000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i123ba3f4a40d493d9ae8d39e4a5ef78f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMS0xLTEtNzEzMzA_cf5bbbc0-b323-429a-8a97-4eab4e6e47eb"
      unitRef="usd">207000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1c691cc03ca947218df95a3a774da470_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtMy0xLTEtNzEzMzA_4aaa20bc-3d6d-4c8f-87ef-27204dea59a6"
      unitRef="usd">220000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iccd56b99f7e44e7ab521fd0a98e8b8c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzQtNS0xLTEtNzEzMzA_fe645393-5aa2-4c14-a7f0-43791c2d4bd6"
      unitRef="usd">216000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a6d999cecc9424eaed8887c265ddf14_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzYtMS0xLTEtNzEzMzA_aee67e7b-96b6-4611-915f-05663e49b0c1"
      unitRef="usd">135000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ee703bcc3304d2199a268dbca3b2a98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzYtMy0xLTEtNzEzMzA_706940f2-8e21-4e4b-a920-27f9400883fe"
      unitRef="usd">159000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id490c58a5ad24c1ea00c4115bb016c7d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzYtNS0xLTEtNzEzMzA_6806fc6d-065a-4f86-b5f7-32d909ef5629"
      unitRef="usd">166000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i67a8eb31fe5a4c7e8d7672a9f0861b87_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzctMS0xLTEtNzEzMzA_3e4e2215-42d3-4d54-af3a-5167547c897d"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i525155431d7c4ed0a672cb8897ee553b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzctMy0xLTEtNzEzMzA_df4e8f80-cd75-4cac-87d5-f212d6b8e83c"
      unitRef="usd">4000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2fa316713ea647e5a80b2ef8e8cc5435_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzctNS0xLTEtNzEzMzA_012b3e70-190f-436e-ab68-062886f221a7"
      unitRef="usd">4000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if0af637dd40e445c8087ffbd9b3638e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzgtMS0xLTEtNzEzMzA_bf9bf4a3-e39f-4293-acfe-6c507d963795"
      unitRef="usd">21422000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5e30d57aa7714c7c991d4956adf482da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzgtMy0xLTEtNzEzMzA_2313a4df-fa74-4ab8-b66f-3f1e553a28ad"
      unitRef="usd">19279000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2f49f49133634761b181692557d66dda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDUvZnJhZzoxNDZkODUwMzVkNzM0OTRjOWU3ZTA3OTQyZGRjOThhNC90YWJsZTo3ZDM5NmJlODk4NGY0M2ZhOGU3ODIwMTdiYWI4YTYzNi90YWJsZXJhbmdlOjdkMzk2YmU4OTg0ZjQzZmE4ZTc4MjAxN2JhYjhhNjM2XzgtNS0xLTEtNzEzMzA_113b7406-9d64-4969-98ca-6cc141b75c0f"
      unitRef="usd">17000000000</us-gaap:PropertyPlantAndEquipmentNet>
    <dei:AuditorName
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDgvZnJhZzpkNmI5MGY1YWRmZTc0N2I1OGMxODRiODc0NjkwYWIxOS90ZXh0cmVnaW9uOmQ2YjkwZjVhZGZlNzQ3YjU4YzE4NGI4NzQ2OTBhYjE5Xzk0NzE_3dd32aa7-bac4-47ed-8029-4218a75b3e4a">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yMDgvZnJhZzpkNmI5MGY1YWRmZTc0N2I1OGMxODRiODc0NjkwYWIxOS90ZXh0cmVnaW9uOmQ2YjkwZjVhZGZlNzQ3YjU4YzE4NGI4NzQ2OTBhYjE5Xzk0NzI_dc95c1d7-5540-4860-8d9e-826fc3681946">Florham Park, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8yNTMvZnJhZzo1MzMyM2UxMzI0YjM0MjkyYjljY2JlNWYyNjRiZjFhZi90ZXh0cmVnaW9uOjUzMzIzZTEzMjRiMzQyOTJiOWNjYmU1ZjI2NGJmMWFmXzUwMA_58faedc5-88d7-45e2-ba81-06f9543e182f">238</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>160
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG3.C)-!, $73):E4X-J;^2]4-K:S)2UL'4@+9!PX)X'C.$9;H&$ BJ;;4G'
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MTJP@)<]H"1C97,PNX7F, F50(?[(R!/O?0>*R@.E/]3#Y_1BYJ@9D9PD0KG
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M%O10"C- KZH.4Z(X>FA,B*GB+2#45QK#P'1:!TZ+G8DU4)4!.*8"(N.$8:T
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M@@O,-#/XQ"!"&\!\RKEZZ>A;K/UHB?X"4$L#!!0    ( ,F"6%89?^KL"@@
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M"7-M;Z*<!4--V%#@U*V#+LSUL351YZ8?Y]M[CL&=GZ$^IS=+0+U94-H,E!:
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M2 (IW7&]$H=O4/LS,'JQX,I^R:&R'8T<$N^4%GD-XPER5E0M?:OC< +X_0M
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M8+#10R'3L(LVG97L1D!5H\8 XOFWCD@>I1Z=MBEYP (B?BS.WP):"G% \LR
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MI-(P5X.:%&&@--PX^/4DGQB689E@YYI9?;#N[H*8P?NL+Y299FDNE;77Y*+
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M$^8PM(I&"E;2A,Q2(*0X^2;/4K5VWS?=P5'^1FKZJ*B:N\QRZ.ZFU5]3C8F
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MCU>CN&1V'X*M^27]VH9@*_X3#0U=F0[@>6YMZ#Z0@OZ_-A?_ U!+ P04
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MY GHV8HNKM02T#SW\5>W<3UDV)]HX\XZ;=R6?6^U<:]KRHY<<:VC41Z$28^
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MX5^7I;E3\QXUC'!*N(A;O/4$E)8\N:[*8WG$7C5.A%(3TRNS !TXE3%6;UD
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MCRK+Z<?6(1ZMLH3^"?DDT(L/P/?+# C5?^ $> <'D??C_P%02P,$%     @
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M[M$ 8/&\7-!#TI.&C^O,UC!:)EWUQ7O>:V$6@%JA6;*D3NUFCC50D$ITW@(
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ME5"/-5(;%GLC5@J<P(<!3<N"I4&4HMG5CN4H (1&B*IDB!SC-SR:-F53!+O
M/[Q\Q$8'XH)(73&\7D9+!<UJ$H_D['FB(Q%8=2GWF-B;'GD(F"Z2Z[E8Z:*
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M]MH,^Q$!O', ?+[;PY P4KS),]"'J2&HV#.[CD%[Y[".4K"UZ^ "!"G@?E8
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M&6]2-G_4ZDC__F:C:K T=+F7,7 7O@#/MTK5Y@\<P/X_I!__%U!+ P04
M" #)@EA6C4' YX0#   )"   &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6R-56UOXS8,_BN$5PPM8,2QG*1)E@1(KRNNP Y7M'OY,.R#8C.Q<++D27+3
M[->/DI/4V=KTOE@613Y\2%'D;*O--ULB.GBII++SJ'2NGB:)S4NLN.WI&A6=
MK+6IN*.MV22V-LB+8%3)A/7[HZ3B0D6+69 ]F,5,-TX*A0\&;%-5W.QN4.KM
M/$JC@^!1;$KG!<EB5O,-/J'[K7XPM$N.*(6H4%FA%1A<SZ-E.KT9>/V@\+O
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M3+9)EIO2PFRH[CNQBS3+W3?U4P>V@Z60$[U\R& 5 R2-D@9%%.( !43K:ZI
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MA7HM:MU"7MXI#*&A"2]S&2WG"/!A5$E(<ME"@)O0;K&,A)MLM_H#.2U:#58
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MKNA6A2E:,X#<94?+OK(]O=YB\37%T!4U,6DY.@+1N04-6S8CWL0@U5@.1:/
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MBA&@U(-+.@4# ,+00, LBX\"%T1.7F'7^J&ZUHFK>@O! JQA<4\&F 4S )+
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M#1"9$R92J2JIJ!_[VA12L9^@2;_5BZ)6Y']$%Q1KLH!4EB5ZXJPA&149=N"
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M52B>3H:_61 /:3**9K$DDU7#3(:;/L:BKALF3UG2OB2<"VAS9<^MVQ4..8=
M(*42?JAK$%'HZ:]N%PA0GA_,]L_J4W Q">#_*US\ZHQ#RZO_ A#T$)X3P)?0
M":!!ZR)754[+9"6"ST7>& 3+UBB;]-GQCK%<R:V<$C<TC]@31U?@<K."'WY6
M*'Y:^^U,D70A:GE,[X[ IT_L]8ZHZF6E,L]4I.-5=F3^*WH4DJXN$)"SJ9P6
M96&W9!%X%M!I%FSZ>N".E6:.K#C65=A,!Q)#JU?8N.UZ$&T]KUC"#E;\3W0*
M'=\=] ">BM&T<<K3VBZJ\V(SLQY-I*O=4FV"M#F);]TPR]ID$8]JDOJRR-HD
MU@V8YK8&[Y@S^M2N#BGJJ,O_0<S ?FT!.?:*E2_GA3[3,$S0&[1TA).K.?@;
M,:;XT!<;B-'%:!BU=2@0%\-)NJM*-.YBF(SVKX'TJBU0;A_*I6ZH%KD5.K:+
M*BN;7)&!R2N+W06[%NE;*3UQG8@TG"V$SE%QLX PB8(OR'^E9M1N4&4\"T1+
MQPX-SZ%!0G>1I!TTQJ]<'[^)14O IE9.Y!]+F7VY?LY0%(BB3LE)7"BJI<[1
M!Y'OK6*U,G*H;7Z:J_FN6P(CMVXP]([M! <-'#LPU2AZ&("."?0M204E1Y$U
MQM"^]B68GU--J_U^/':!0/9%WT5Z&)B+Q*C?FH*V8@WA +M1Z7!L]*V"8P/Y
MO!.G5DK%ME E-I\IZB_7,]HP!<HL-9\"65>!6&N0@I4I8/_;TDU^'GAUQC05
MA9WR= !920M3%6O';L;*'2^\Q3,^'5@D-_@AU+=3=V'T=V7T=:99Y#^'SS#9
M-E8_:JOJMBWA>  >=26^2NP$_"A4-&/MRSTNY$^;OAS9)YRE@&(YY>O$3/@5
MJ$'%P7P7;&<8[2"H$F(Y@]V2#HS0+ZZ4 FT?RKW'[-@\&=%3.@=0&VOT\H!Z
M9RHQ.K5\W]N_2G!9S&A'\X&-U,?NE(C1HCZ2JV';J;:MVXGJJ!M;6\ "S(*3
MH7*9TY /R553O2B3%1"4J5K(=:&-<VW#=PFT!)%_KO;C'$2[C;QWYBU13I,P
MZD. DE$XF3CM29)PG% 5\(9.*="1%Z>DY(]Y$(W"X0@>3,*T[QR8A)/!V?7=
MUF0)[31@CHHL*#C:Z T3<R\+[\0_J#:Z>X?N$8G=<EZQ1Q_.[.Q!&(F_'/S]
M=&;'#L(^WD;\MQ\.\??4/HKC<(17<3^<T'\QF_QPP+I++N=7 HGQ_U+QS-=C
MOK:X6S=W 4:&UZYOZ#;S= ISEUNTZ*7>B22@TDT-)+$ -HVL/6Y ZD?7)?W2
M9GCWX6$^-VI.,?ZTI[+XFZP:":7QITT1I<$HB<6%&(_".!'?>0;$P2 >"V8;
MXG2,S<7E.!A$R948]\,DH39XI@H:?9F.XRN1 .GH8+&CPZV(!D$23;!<T@]'
M(S$&K!=B-!J*GQ7O(CXV=38B]T$GS403;Z8_@9DAF1E,6E^Y*SN>E@;)H.]C
M'2)#-&L .P_^F@&[NINGE;ND8*J>R!2?MNBX7_A6BGM#7GI*-Z1_F,6N<P,O
M<6"HBVR_+P^/U6J7APM0D("+^F.*.Q(?#[;SX;2U0Q:!([^8]E[6"^IZ5+%N
M9=?5%J]+1P8&Z9#\%"F :F]\:52E*V^[VY#OZ=MV[6^QEX]1?,!\S>.C[[O5
MCB@<!<F$TIH,PS3%X\F88($N1H,=H9,@2OI,Z%A,@%B:AJ.X9=WE*(A&?3 8
ME.B+RR0>7='0](#C41!%-"8-T>U=1DET14N,THYG)X@:!TF??$NC$-C' 27]
M@HUTU.L-HD=!/"*:II">,6)+)R,W']OS]/61Y8.YJQ8 H.U3J?YU3PA-U>E\
MSW3&NZ9[G^H#:@2'F6\O!NC>\,0ISQ]=CFJ1/Q7#P0BZZ4]%'_F(/^>#)@JZ
M-I8+\9OG&G=+T6 ;ESJ3KBAS*'5XZLKVIG/5OE0XNM(/"G39AG;!W;KOGNY^
MLWAP5_7[X>X'CQ]P\L7>%:6:82K4<=1#C\@_(K@O5J_XXA[-M]5+_KA0:&0,
M#<#[F4;GY[_0 KM?<N[_#5!+ P04    " #)@EA69Z%8IG87  "@30  &0
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M[&"A6NATF*P4'6PV->==Y2%[:TY:\ 27I 34;K-23V>9I0Z8R&IIE)LEKYP
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M($J1 6PZ3#]9:R?VIW$O'U.,D^C?G!_'[BUQE?M)W4C')A$3$$3>4PE(X8:
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MXK*;->._T09JR=(A+<@VLEP^V(4I>RY_G'(.KWI.$B\F,*"K;ZMZSP[N!/3
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MZH%6ECG(_ C0OR[M5/)5$KRCGM2^12PSK:E&:%:9M)>1(_J&)O"Q;-:RYD>
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M*?)$9UIR*"R5?5 J%W:CA%JM%$>&L%"0D58)A+K0;NO*%%N!O5;GE<[7 LG
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MY$GLDY#KF<:W3N$;RE?>MT-GI7" =F2:<K#" =^!8?Y U.'W.I5/Q&A/.RX
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MU\39 ;_/J,,/9U^JCK]U\%ZOH-,:G_ACEV]I&]>F<]<;,$SAJ0>E; ?$&:]
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M'/'/2MR-+7;\4XYE86VQY8\;A5IF: '>KXK"-C=T0/O;GC?_ U!+ P04
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M&.1$&H#GB[;MQQM:8'JO]>W_ E!+ P04    " #)@EA6U_+]85(D  ";>P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6S=/?MOVT::_PJ1?< &9,=6
MFK:[;0,X[F-SUS9!TN[B<+@?1N1(FH8BM1S2CO:OO^\Y#XIB[%QQ.!RPV]@6
M.?/-]WZ.OKYON_=^:VU??-C5C?_FR;;O]W]]^M276[LS_K+=VP8^6;?=SO3P
M:[=YZO>=-16]M*N?+J^N/G^Z,ZYY\N)K^MN;[L77[=#7KK%ONL(/NYWI#B]M
MW=Y_\^3ZB?[AK=ML>_S#TQ=?[\W&OK/]K_LW'?SV-*Q2N9UMO&N;HK/K;Y[<
M7/_UY?)S?(&>^+NS]S[YN<"CK-KV/?[RJOKFR15"9&M;]KB$@7_N[*VM:UP)
MX/BG+/HD[(DOIC_KZM_3X>$P*^/M;5O_PU7]]ILG7SXI*KLV0]V_;>__9N5
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MW#7%_=:5V\+@9GW7UC42Q#6]!1SVA?,%:I<>_F^KR^(5_KV4=5>F!H!@$=P
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MN*)7FRXK:I@U&[I;Q>!%1-  \-H 57,@OO=!E/9#!R3R2J$S-!6@XSOA:J$
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MU%L3^^!X^K>VAD;UX7\->LS2WD<CH1U:,G8?4>#7Z=NNP;P0]<W9#PZ;@"
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M;1G6)HB[#<.P#[1T)1&52(VDXNS?[Y)25*>(LWV1^+CW\-P'#U<'J;[H&M'
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M\:N([S&?01+Y$(=Q_ I>,D6>.+SD%![7.3'DHL<";CM4S+:)!B8*H+U.:M;
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M@=P&QSN]U8LHB<?PHS'%2BI*+3V$-)HDQ!Y-!C+J9@10^VO79_8,DB2:)I-
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M[IOAL:(+/EH^0/NE,7Z]X ";?QD6_P%02P,$%     @ R8)85B@ID]%A!0
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MG0!^GRAEVP=G8'V\'_X-4$L#!!0    ( ,F"6%992J2L& 0  "L+   9
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M[V*"^:W:T:P]&-G8<6@A#0Y7=KO&:58H,L#G2RG-[D !^OEX_B]02P,$%
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MBN^8>N7'8L5CN&]S S=7;*H;9"=RL\5EZ<NV[=.VZ<:4VR0=Z9=R <I]&L
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MT!T-/*(JCZL&1A;.5];2H$NY,,/? BB[ =<W4IIZ8 LT/YKX-U!+ P04
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M/H-/)VV)/!)=>0 EQR+@49U22I\H.X"ITU#DCK7/#3%@ H\Q$%%D8(4GK"=
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M=U7=Z^;G:3]&M 1<BE1OT-2Z]MT+49A??)DO57[@7UFM\JK*]_R(N5SK@EY
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MF++^IK_>4=FR^LK]+E,J2ZK-!6<1EV4#?7Z69>IYI^Q@_<L*D_\!4$L#!!0
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M5P;X?L68/-RH!LK#LME_4$L#!!0    ( ,F"6%8G@5*P2%$  .-(!P 9
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;,W=>6_;:)ZNX:]"U!G,Z09259:\
M]U0'>"O<]WT[.!@P,F-KVI;<DIRJ /WAC^18%K6$M#BW!Z?_Z%(<\:(<1?X]
MX4L^_.V/Z>P?\[NZ7DA_/MQ/YG__Z6ZQ>/S;K[_.1W?U0S7_9?I83Y:_\V4Z
M>Z@6RU_.;G^=/\[JZN9YHX?[7X<G)Q>_/E3CR4\??WO^FC_[^-OT:7$_GM3^
M3)H_/3Q4LV^_U_?3/_[^T^"G]1?"\>W=8O6%7S_^]EC=UE&]2![]V?)7O[XJ
M-^.'>C(?3R?2K/[R]Y_$X&]"#(?GJTV>GY..ZS_FC<?2ZIOY/)W^8_4+X^;O
M/YVL7E-]7X\6*Z1:_N=K_:F^OU]9RU?RSQ?VI]>]KC9L/E[KZO.WO_QV/E?S
M^M/T/AO?+.[^_M/53])-_:5ZNE^$TS_T^N5;>GZ!H^G]_/G_I3]>GGORDS1Z
MFB^F#R\;+U_!PWCR_;_5GR]_%(T-AL,?;#!\V6#XU@U.7S8X?>L&9R\;G+UU
M@_.7#<[?NL'%RP87;]W@\F6#R]T-!C_8X.IE@ZNW[N'Z98/KMVXP.%F_<R=O
MWN3US7[SNSU8O]V#W??[XH=_H]9O^.#-[_A@_98/=M_SLQ_N9?VF#][\K@_6
M;_O@S>_[8/W&#_;>^1]NLG[K!WOO_8_^L@S6;_[@S>_^</WN#]_\[@_7[_[P
M[9_UUP_[FS_MP_6[/WSSNS]<O_O#-W_BA^MW?_CF=W^X?O>';W[WA^MW?_C\
M[O_Z_:?J\X]DN5I4'W^;3?^09JOG+[W5@^>?Z\_;+W\2CR>K(10M9LO?'2^W
M6WP4HW\^C>?CU3B8?Y#">EY7L]&=M/R)?E]]GLZJY]^0JLF-9(]'J]DSN97$
M[:RNEX-H,9=^EMQJMGK6UUKZBUPOJO']_*_2OTF_2O.[:E;/I?%$2B;CQ=+^
M]_]U=7IQ]A^KKSCC^_OO.]P\:_.U?VO^\K=?%\OO<O5:?QV]?$>_?_^.AC_X
MC@:2,YTL[N:2,KFI;PYLG[1O?]JU?=J^_577]EG'ZQ^V +\NW][7]WBX?H]_
M'[:*:OWY%VEX]D$:G@Q/I222I;_\VU\/O+!/[8Q937Z13@>=C-S.>*/%*S-L
M891V)JH?E\Q))Z.V,^+I]DVO1NOXLWFZ?Q.CMS-.]>TMBM&NR/7H]<4,6ABS
MG7&G7U__A-L8J^-/^''V)L;N^J.9O>F;<M[^E_B56:;I[S_W_O-Q-KV=50_2
MJ/GS[S\7U>RV7AS8F?OV-^*DY35[;_^K_LHT?\A^_\\!V#\&5I)0^LO+3^E#
MKS)X^T>@[9L-NYC)_C=[@(G>_$EJ4^*W_VUI8Y*W_SUH^URG#),Q3,[\E"F8
MSTCYAA]6@^O.5[/\]W+W.SZX:'LY6S/X]#5GG3Z[IS]P?W]:1J=Z/I<:@4OZ
M/_;R:Y*QJ!_F__=0T/E.GATF5X<G_C9_K$;UWW]Z7/T FWVM?_KX[_]K<''R
M'X>&.XG))*:0F$IB&HGI)&:0F$EB%HG9).:0F$MB'HGY)!:06$AB$8G%)):0
M6$IB&8GE)%:06$EB0D#:5FPX>XT-9VWZQ]<#,JLC,#?UU_I^^K@Z\G(H+;1*
MQZ8%$I-)3"$QE<0T$M-)S" QD\0L$K-)S"$QE\0\$O-)+""QD,0B$HM)+"&Q
ME,2R[]C%,[9:S/[Z<7!Z?G;UVZ]?FS'@P+.&P[/S[6<5AZS3Z\OM9Y7DRQ?M
MH[7GX#Y_'=SGK8/;K[Y]7R%93*5J]4_^62T]SJ8W3\]+[E(UG]>+@XL;K>RQ
M4YS$9!)32$PE,8W$=!(S2,PD,8O$;!)S2,PE,8_$?!(+2"PDL8C$8A)+2"PE
ML>P[=MZ8O&>G5[M#_,"3SG8G?7'H2</KG1%.OG;1/F1[CO"+UQ%^T>O?WE+]
MYV,]F1]<</N]E3QV?).83&(*B:DDII&83F(&B9DD9I&836(.B;DDYI&83V(!
MB84D%I%83&()B:4DEEWL#=V3G=G=^8QB_QG#BXN=)Y7DJQ;MH[7GX+Y\'=R7
MK8/;F'Q=CNGI;'QX1+=N?.R()C&9Q!024TE,(S&=Q(S+O:-4Y]?GI]L?%)/<
MHT5B-HDY).:2F$=B/HD%)!:26$1B,8DEASYS@\'V9RY]RY.RR[TQM_^D_-"3
M=C_B!?D-EB0FVD=?S\%Z]3I8KUH'ZZ?I9#&>W*[^#3R:3N;CF_K[";*'IFRK
M=.R4)3&9Q!024TE,(S&=Q(RKO8_@Y>7.2I!)[M B,9O$'!)SK_9^2%Z=[?SX
M\\@=^B06D%A(8A&)Q226['^2SLXO=D;G&YZ3O>$Y^1L^M<7^<_;^!I;D'X!H
M'U@]Q^'UZSB\;AV'VG1Z\\?X_O[0^&O=\MCQ1V(RB2DDII*81F(ZB1G7^T=C
M!L.+LYT!2.[2(C&;Q!P2<Z_W3S*YNKH:[HQ <I<^B04D%I)81&(QB24'/TTG
M.Y^F]$W/RM[TK/Q-G]_B37\72_*/0K2/JY[#<'#R.@U7]0YMAUW]\-^KA\?_
MD*7QPV,UGCVOE8[N5M=.'KZ,NY4[=D:BFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ
M#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):]:,UQ/;@\V5U#1?=9H%J):J)CBO=-
M"8V^F4%K2GB]$'HT??@\GCP?/_ZP.IQ\\,BRM&J767[]^5SJ#ZLTL?S%JA^F
M>I@^+9\\_?+C3>_'U>?Q_7CQ[6#X:'V51X</4I-134$U%=4T5--1S4 U$]4L
M5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-6R%VWK*,#9[H'UER<U$\K/Y[M'
MUM'75:*:Z!CY?2/%<!,IAJV1PIN,IL;#P].D/CCI6S<^>M*3FHQJ"JJIJ*:A
MFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5J"8Z
M9GO?[+"I91N\0R_; "UF0S49U1144U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?
MU0)4"U$M0K48U1)42U$M0[4<U0I4*U%-"(K;CA2;RK;5K2%:#D<HRR"Q^"8]
MU(N[Z<T':?K'I)[-[\:/TF,]&]63175[^#A%JWITJ" U&=445%-134,U'=4,
M5#-1S4(U&]4<5'-?M-4RZNOQVI-?=D\R1/?IHUJ :B&J1:@6HUJ":BFJ9:B6
MHUKQID],B>Y3= SIOB%@4_\V:.]_^^2EAOSSX/K@I$<[WE!-1C4%U514TU!-
M1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4$QV3
MO6]RV+3.#2[>844"[9U#-1G5%%1344U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5
M E0+42U"M1C5$E1+42U#M1S5"E0K44T(BMN.%)L^O$%[(5Y8O_TN,NW4T4D"
M[<=#-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M0354E3+
M4"U'M6*P7S:X>SN;$MVCZ)C???/!IM9OT-'K][VD09K5]]6BOEG=LV9](^R;
M\?S[!99//VSZ:\>/3@QHUQ^J*:BFHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ
M!:@6HEJ$:C&J):B6HEJ&:OE@OZEP>+)WS>7^DTY/]I( VV=(<=M)8--H.&BO
M-#RZPPGM.40U&=445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U
M&-425$M1+4.U'-6*P7X=Y/7NK770/8J.&=XS(PPW/8_#]I['_T\:G-I?Y;'1
M ]5D5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46U
M#-5R5"N&^]66>PL5Z!Y%1S3H&STVY9'#]O+(]9W]ODE_S,:+^N?IER_-18M5
MD)A5HX6TJ&</+\GD8'1 RQ]1348U!=545--034<U ]5,5+-0S48U!]5<5/-0
MS4>U -5"5(M0+4:U!-525,M0+4>U8KC?.3G<NR,PNDO1,=O[9H?A)CNTMT1&
M]>HH0WWP;DWMFQX="-".2%134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+
M4"U$M0C58E1+4"U%M0S5<E0K4*U$-=$QV?LFATU'Y/ =.B*':$<DJLFHIJ":
MBFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9JN6H5J!:
MB6I"4-QVI-AT1"X?MAV,^+1UGL-C-;XYF"%:D:,S!*G)J*:@FHIJ&JKIJ&:@
MFHEJ%JK9J.:@FHMJ'JKYJ!:\:%O7Q@UVCAN'Z"XC5(M1+4&U%-4R5,M1K4"U
M$M5$Q^CN&PTVS9'#]N;(]3D.X\-77+1O?70F0,LC44U!-175-%334<U -1/5
M+%2S4<U!-1?5/%3S42UXT;;.@-]-!&@C)*K%J):@6HIJ&:KEJ%:@6HEJHF-B
M]TT$FT;(86L]U.N9"]*_)'\VO7D:+>;/34Z/WW\AS<:W=XO#80&MA40U&=44
M5%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*
M5"M1373,_;ZY8E,+.;Q\A_,:T'Y(5)-134$U%=4T5--1S4 U$]4L5+-1S4$U
M%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K4"U$M6$H+CM2+%IDARV-TFJX\GJ
MNLS[\=?Z1AI/%M7D=OSYOI:J^;Q>';58!8U9??AD![1&$M5D5%-0344U#=5T
M5#-0S40U"]5L5'-0S44U#]5\5 M>M*V3'4X&NTL;:#LDJL6HEJ!:BFH9JN6H
M5J!:B6JB8Y[WS0N;OLEA1]_D0W4[E7X?3Z/1N)Z,ZOD'R9B,?I'^)45/G^?U
M/Y]6I5#*UQ_<JZ(=/SHRH.V3J*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKY
MJ!:@6HAJ$:K%J):@6HIJ&:KEJ%:@6HEJHF/V]\P6IYN>RM,3?GGC%&V51#49
MU1144U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U$M0[4<
MU0I4*U%-"(K;CA2;_LG3]O[)L'[[C33;J:.3Q&#O6.1@>+)SY96,[E-!-175
M-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!M135,E3+4:U M1+5
M1,<$[YL0AIN$T-XRZ5??GN]TL:JC?CG;87V=QOCK^CR(@W$!K:!\T9K79 U.
MS_?B EHMB6HJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHI
MJF6HEJ-:@6HEJHF.<=XW+FRJ)4];>Z8^QK-J,J]&STL3H^G\!]$ K9)\T9K1
M8+?Y6T;WJ*":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:
MBFH9JN6H5J!:B6JB8W#W#0:;@LCEP[9@X-:+MUPTT:X<'0W.]J+!@34&<I<*
MJJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6HEJ%:CFH%
MJI6H)CIF=]]LL&F(/&UOB/2KR<WJ@$%\5\^JQ_II,1X=/FZ 5D6BFHQJ"JJI
MJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5
MJ"8ZIGS?%+%IE3S]WB[%7AZ!%DJBFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJY
MJ.:AFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5J"8$Q6U'BDVAY&EKN]1QET>@
M/9*H)J.:@FHJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHI
MJF6HEK]H6V?57^XND!?H/DM4$QT3O&]"V/1#GK;W0[[M?$>T"1+59%134$U%
M-0W5=%0S4,U$->MTOS5P<':Y_3/"1G?IH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*
M:AFJY:A6H%J):J)C<O=-!ILFR-/V)LBWW1&['3DZ&J"-CZBFH)J*:AJJZ:AF
MH)J):M:+MO7OA^O=?S_8Z#X=5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*
M5"M1373,[I[9X&S3Y'C66NOTT5O<U3-ILKDDXB_WX^KS^'Z\&-?SOQ[*">W@
ML3D!U6144U!-134-U714,U#-1#7K1=LZA'!^L1,3T%TZJ.:BFH=J/JH%J!:B
M6H1J,:HEJ):B6H9J.:H5J%:BFN@8XWUCPJ:=\:R]G=&;C*;&P\/3I#X8"= ^
M1E2344U!-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!M135
M,E3+4:U M1+51,=L[YL=AIOL\+WH";T:X@SM;$0U&=445%-134,U'=4,5#-1
MS4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M130B*VXX4FV['
ML_9NQT-5T./)UWJ^^-$U$>W@T7F"U&144U!-134-U714,U#-1#4+U6Q4<U#-
M?=&:ZS.[W>H>ND<?U0)4"U$M0K48U1)42U$M0[4<U0I4*U%-=$SQOBEA4_2X
M?-B6$MYVWF,[<G0R(#49U1144U%-0S4=U0Q4,U'-0C4;U1Q4<U^TYAF>9\/3
MW6A [M)'M0#50E2+4"U&M0354E3+4"U'M0+52E03':.[;S38]#R>M?<\]CCM
M$6U\1#49U1144U%-0S4=U0Q4,U'-0C4;U1Q4<U^T9DSX>3C<C0EHD2.J!:@6
MHEJ$:C&J):B6HEJ&:CFJ%6_YP)3H+D7'=.X[_3?]C&>M94T?C=>E@H,E">U;
M'SWJT29&5%-0344U#=5T5#-0S40U"]5L5'-0S7W1FC^Y3O<."*#]BJ@6H%J(
M:A&JQ:B6H%J*:AFJY:A6O.'S4J)[%!V#N.^@W[0FGK6W)OJS^F'\]"!-)]+\
MKEKNH?6.3^W8T7,?[4U$-0755%334$U'-0/53%2S4,U&-0?5W+-#77&[<Q]M
M0T2U -5"5(M0+4:U!-525,M0+4>U M5*5!,=$[QO0MBT)IZUMR:&]>%>9:G^
M\[&>S.O#!PC0%D54DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40
MU2)4BU$M0;44U3)4RU&M>-&V3L:YV%LT8%L4*6X[*6Q:%,_:6Q339328_SZ>
M'@P$:'<BJLFHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6H
MEJ!:BFH9JN6H5J!:B6JB8[+W3 [GFX[%\^_E3&@!PCE:LXAJ,JHIJ*:BFH9J
M.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5J%:BFA 4
MMQTI-GV,Y^U]C#]:MCB8)-!V1E2344U!-175-%334<U -1/5+%2S4<U!-1?5
M/%3S42U M1#5(E2+42U!M135,E3+7[2M]86=4Q6+ \\9[MTRLD1?E^B8RWWG
M_G S]UN+E=Y8:=".'#WQT?)$5%-0344U#=5T5#->M*W/U\XI=":Z1PO5;%1S
M4,T]\&<[O-K]N>2A^_11+4"U$-4B5(M1+4&U%-4R5,M1K4"U$M5$QT3N._$W
M58?G[56'QS<5M(-'3W^TZA#5%%1344U#-1W5C//]DKWKD]WICQ88HIJ-:@ZJ
MN0?^; =7>\,?;3!$M0#50E2+4"U&M0354E3+4"U_PX^/XN4YYVT?@Q)]6:)C
MDO:=U)NZP>7#MDDM/TT^3[\=OD-2^Z9'SV12DU%-0345U314TU'-0#43U2Q4
MLU'-0347U3Q4\U$M0+40U2)4BU$M0;44U3)4RU&M0+42U43'9.^;'#9MA.??
M^X[8$P310D)4DU%-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4
MBU$M0;44U3)4RU&M0+42U82@N.U(L:DX/&^O.'SCB0)HTR&JR:BFH)J*:AJJ
MZ:AFH)J):A:JV:CFH)J+:MZ+UCQ^>WJR<_&V__*DP:!Y&L/YQ?:S O2%A:@6
MH5J,:@FJI:B6H5J.:@6JE:@F.D9RWY&_*3L\;R\[['&F %IXB&HRJBFHIJ*:
MAFHZJAFH9J*:A6HVJCFHYJ*:=WZ@/O%T=_JCA8>H%J):A&HQJB6HEJ):AFHY
MJA6H5J*:Z)CB?5/"IO#PO+WPT)]-'^O9XML'Z?&^FBR>+R"L__DT_O'E@VC9
M(:K)J*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJWOE^P=OPZGHW): =AJ@6HEJ$
M:C&J):B6HEJ&:CFJ%:A6HIKHF.)]4\*F[/"\O>PPK(_H%T#+#U%-1C4%U514
MTU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4
M$QV3OF>2N-B4'UZ\0_GA!5I^B&HRJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:
MAVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H5J*:$!2W'2DVY8<7[>6'_E%W=6S'
MCLX2:/TAJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6H
MEJ):AFHYJA47^T6)@YT3>4MTCZ)C@O=-",--0FBO212C47U?SY8!P5\&A(=*
M,B:C7PZ& [0I$=5D5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U
M"-5B5$M0+46U#-5R5"M0K40UT3'F^\:(3??BQ>D[K%V@]8NH)J.:@FHJJFFH
MIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF6HEJ-:@6HEJ@E!
M<=N18E,2N7S8=F3B4S6_>ZYCD+Y,9]_7+5YRQ?2+]/DE;QR,%:WNT;&"U&14
M4U!-134-U714,U#-?-&V>HP'Y[NW,;#0G=JHYJ":BVH>JOFH%J!:B&H1JL6H
MEJ!:BFH9JN6H5J!:B6JB8Y[WS0N;:LB+UIZHC_&LFLRKT7-"&$WGB\/9 *V"
M1#49U1144U%-0S4=U0Q4,U^T9C88[I:[6^@N;51S4,U%-0_5?%0+4"U$M0C5
M8E1+4"U%M0S5<E0K4*U$-=$QN?LF@TW#XT5[PZ,R7XP?JD5](SW-ZR]/]]+]
M^$N].HHPGBRJR>WX\WW]4@3UH?W\2+0#$M5D5%-0344U#=5T5#-0S>SX:ST8
M2M_J:G8HYUKH"[%1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K4"U$M5$
MQ\CO&RDV#9(7[0V2QN3GQ]ETM#KC8<4?*H"0_F+XX;]7#X__(1^LE&S?P]%I
M JV41#4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4
MRU M1[4"U<H7K7FH]>)T]UBKZ!CL?8/#IE3RHKU4<E,]W:B</A@/T#))5)-1
M34$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1
MK4"U\F*_IO7GJ^%>.GB/,LF+39GD17N9I#:=WOPQOK\_& C0\DA4DU%-0345
MU314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;44U3)4RU&M0+7R
M1=OJ;3\;#/82P7N40EYN2B$O6QNBOE\%L5I9&*T>K&X_\;6ZKR>'SVYLMXZ-
M"*@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ
M9:B6HUJ!:N6+MG7[U[.]%05JG]L)8=/Q>-G>\1C?U0_CPW$ [7-$-1G5%%13
M44U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+42U#M1S5"E0K
M44UTS/6^N6&XR0W?*Z'0RJ9+M 42U6144U!-134-U714,U#-1#4+U6Q4<U#-
M134/U7Q4"U M1+4(U6)42U M1;4,U7)4*U"M1#4A*&X[4FQ:("];*Z'Z5S:U
MNT?'"K0)$M445%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M?M*T#R1<[
M-Q:(T%W&J):@6HIJ&:KEJ%:@6HEJHF.:]TT+FX+'Y</6M#"=+,:3V]6EDJ/I
M9#Z^J6?5*BP<# BMU-$!@=1D5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5\
M5 M0+7S1FB>C79WOY@-RCS&J):B6HEJ&:CFJ%:A6HIKHF-]]\\&FT/&RO= 1
MZ%AHW\/1L0&M>T0U!=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -7"%VWK
M?H6#T]W<@-8]HEJ":BFJ9:B6HUJ!:B6JB8ZYWC<W;.H>+]M[\>3Z2SV;U3?2
MHOKSI=?Q8#9 VQQ1348U!=545--034<U ]5,5+-0S48U!]5<5/-0S4>U -7"
M%ZV9#2Z'N]$ K6U$M0354E3+4"U'M0+52E03':.[;S38U#9>MM<VOKE]J=TY
M.AR@Y8RHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:^*(UP\'I7CA
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M]6K(H+"]HE3Q]"&ZCP7AI0-V1'AE@;6*Q)ZFTEK;U>G*'MI9$4@:@])\*"U
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MI)&&IB1:9S)I)UI-,<\)_?8T55/,#0)[<B352N=A&\^?I^_CF4@+H>U<J*V
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M+E"]_IAEY=<'=0//6?YQ^W&F_P=02P,$%     @ R8)85E&9XW8T#   07P
M !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULQ5UMC]LV$OXK@J\XM$ ;
M2]1[;G>!W65[%US2!INV!]SA/FAMKBU$EEQ)WDV*^_&5;,<TR='8DJ>G+XGM
M'3XD'W'(>?@B7KT4Y<=J*41M?5IE>74]6=;U^O5T6LV68I54KXJUR)N_/!7E
M*JF;K^5B6JU+D<RWB5;9E-EV,%TE:3ZYN=K^]KZ\N2HV=9;FXGUI59O5*BD_
MWXFL>+F>.),O/SRDBV7=_C"]N5HG"_%!U+^LWY?-M^D!99ZN1%ZE16Z5XNEZ
M<NN\YG'<)MA:_)J*E^KHL]56Y;$H/K9?WLRO)W9;(I&)6=U"),U_S^)>9%F+
MU)3CMSWHY)!GF_#X\Q?T'[:5;RKSF%3BOLC^E<[KY?4DFEAS\91LLOJA>/F'
MV%?(;_%F159M_[5>]K;VQ)IMJKI8[1,W)5BE^>[_Y-.>B*,$3M"1@.T3,#V!
MUY' W2=PSTW@[1-X6V9V5=GRP),ZN;DJBQ>K;*T;M/;#ELQMZJ;Z:=X^]P]U
MV?PU;=+5-PU?6?)8E$E+OW5;EDF^$,USK2OK.^N'-$_R69IDUIM\U\3:1_4U
M%W629M4WC<4O'[CU]5??6%]9:6Z]2[.L,:BNIG53LA9_.MN7XFY7"M91"H=9
M[XJ\7E;6]_E<S%6 :5.E0[W8EWK=,121B]DKRW6^M9C-&%"@^_.3.T!R?GYR
M&ZF->WA*[A;/[?N4K"2?*]]_JI>BM.IEDEMJHO^\;3"M-[585?^%'M"N !Y<
M@+;W>5VMDYFXGC3=2R7*9S&Y^>M?G,#^&T0N)1@G E.(]P[$>QCZS8<D$V![
MWB4+MLG:OO7YQH]9Y%Y-GX]Y,*V\*+0]U8H#5H[O1 <KI>3^H>0^6O+[HJJM
MXLFJNFJP2^X?Y>J$GN-H-0"LW( %6@U JZX:!(<:!#CWS6"0YHMOK87(1=ET
M0FU;3^9-)YA6]:Y50_4*S++8ML>T>IE6<>#J#\8TBF+?AVL5'FH5HK5Z:-IH
M4LZ6V]K,Q7,S\JY;SX6J$@*T^EZD506P8LSSM;I 6&X<PI6)#I6)T,J\3SXG
MCTW[:GK_6;9I>NYV&+B=S<I-\[&M8+'MCF:;LFP[IRQ-'M,LK5.X149&$9G'
MW%BK+F#E1J'V?#E:[H&=1GQ@)499N5T599W^OATMH7K&9@WL2'M>]Z:1$[BZ
MWP%&D=/Q3!U;A@3VV>6WQ*<FQ*R$U8S_S<.MFX$F;9ZXE525J.&1WC:KUWB@
M5CW JF%?L^*0571DI5;P*.9QT J^_9ROD_+W!"P^FK3O0$B*QJG05-J8I(V-
M'87L2T#%/B4:IT)3V9<AH(,&.B=[E7URQ>]\P^U((S,@2\<..KQ3AEP.'G/]
MI(P9NX[&^I]UVP[Z_VY"@5G2?.MLBR U:(:]6Q4E&J="4\F64:+CC^[3:*#:
MFWU*-$Z%IK(O(UP'#W$?Q$RDSV8(!;D 2*T9H;JV+D( (Q8Z^DB+%G0H$3(H
M=O"HN,/GOT^K).WM[6A6O=L;)1JG0E-IEN&Z$XWN[421]YY]2C1.A::R+V6!
M@^N"B[T=$ Z.IWL[I"Z,N!HMZ$ BF!08#!<8'=Y^EWQN?K[]>U^'QW/KV^1(
MT3@5FLJT5#K,&=OA&:E@(D7C5&@J^U(P,5027.SP>W@EOO;TX1TRTGL%CA=T
M*!%2N[ 3VF4V*S;MFL)^PFC7^O;S1&_EK-!E83Y>B-XMD50J4:&I#T!J*N:-
MW@^0BBQ2-$Z%IK(O11;#Y^)IITD9,-O.C%[!-/(<?4X8+_906J3Z8;CZZ=$K
M#!(">/:]6R0E&J="4ZF7>HN%H_<'I#*,%(U3H:GL2QG&_I_+)LQ<$=&G_0"3
M@!F]P9^ACIA41^S$JLGYO<%@H4 D>_:D4J)Q*C1U?X&49*X]=H?@DLHT4C1.
MA::R+V6:BR](T78(^\R4=6N]1P!L/&,1%2_U4%:D?')Q^=2C1WA(YPOQF,P^
M6G?IEJMD+39U.JNLM^_[]A)XJ7JW4](U*"HT]8D<;4,:?Q\2[48DVIU(?X:(
M<Z6(<_&%,>)>PC/7#HR])8"1L<N)X\4>2HM45RZNKG9-[<<B_U)QL@D%/./>
M;9%TY8H*325=:C<W&+TG()5OI&B<"DUE7\HW%U\N WL"S ] ?LTM8<8.G'O
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MT%2JI:*)1S^*'9/*&E(T3H6FLB]E38POT/1R6N $MGXQTSUD%.JK4I!1U'$
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M%TESQ_%$TURY7&&Q+9E$E&R $K:)L/L2S2U&TU"\-L?T.Z[@T&\>"X)S(O0
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M>CEJC/-;,XN)QK#05&9!>U"S]NCBY7:02MAFT9*7TQ@Y;MG+:8SL<9V7 R%
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MX_!_%/U!R\10-%W_QM?R[+[6>Z+_C+!YG)$$?:8D$:N/Z#Z+SHQ:@YIAH+0
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M=EKX[SD[:5:@,#[L2V/']U[?N_-=TI72]Z9$M/!0"6G&06EM?12&)B^Q8N9
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M8?8HX$(Q::!FCVPF$)@L2*W6A(9::5\AP@DE%_L6=469G5E"W=Y,87=G#W:
M2[CD0E"@24-+3IR>,.]4G[2JDS=43S$_@$'\!9(H2;; )Q^'Q\_A(>6O3V+2
M)S'Q?(,W^31?,G<?X><%G<&YQ<K\VN:K)1IN)W(M>V1JEN,XH)XTJ)<89)\_
MQ:/H^S:7_XGLF>=![WGP'GLV85H_<KF XTHU5/7U+2G@@K,9%]QRW%K9EG;D
M:=V,6691&BXW;;V.2)+1H ]Z)G?8RQV^+[>I&M&6Z*_@C4ONM'LWQ6]J.M<%
MU! YS46#;B&:@IS1G;4EP@OKVTP._VGR=43\TF*XT=9NI%XR31H-")P3*#KX
M>AB ;L=4N[&J]IT^4Y;FAE^6--E1NP ZGRMEUQLW//IO1?8$4$L#!!0    (
M ,F"6%8@5 NYI@8  !PS   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM
M;,6;:V_;-A2&_PKA%4,+9+%XD2^=8R!Q&C1 V@5-VWTH]H&Q&5NH+'D2':?
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MY@K[X0]>.VV0!91H =MA"^@4+ERIJ4F0> &=\T6A6+V6\.KS6P^!I&%R2[Z
M=L"0YK;>3L =%_,WFZR9=WE9?QNG0;YA\NW=$\^V7^Y#!MY%8EJ+92$^-X^J
M_>!_\05+P'2=)-GA:'9\TPJ9O%A&O6J6.(,<XTRA9QM%0PA"OF<>1R11!ME1
MYBI.F"@]@#U-%S2:L^-+E(C?<UPN[)X.WB!H WU098^DI4T2M[LD;: /DNB#
MG*,/TG=!$-)FO2&HWX ^2*(/LJ-/N\5KQ\'W+5XOEE&3(S$+.<:L0D_9\AH@
M4A])/:K7[S=<YB()6<@.62W4K_/FNN64N%RIJ9F3Q(7:(2[DE+A<J:E)D,2%
MG!,7TG$*U:]_##&DX7H"2>1"OQ*Y=AQ\Q]*8'-U<W9>7B(4=(Q;6^4G,HOI>
MMRG*]QM..%A2%OZ)E'4^G2;K+"":@5@Y"X3%A7O C.7+;O+0E>M*34VIQ"[<
M#G9AI]CE2DU-0N7VU+'89=W#P89=)Z]^,\40A!HN&[$D+VRGEL.7+=&K;6^H
M>=6C8 \U5%PL40C;4:A2<<M\NJVZ.PP<N]0G[G75%$H^PS^=SS[&T;/;FQT%
MSRFON5)3,REY#;?#:]@IK[E24Y,@>0T?RVOV@F?8 JN7$%N(ZE82&[93S^'5
M;JB9T&N='M/$ED3B%+'C5/N5;H>! Y?VQ)F<FC!)=,01T1U]?]!NX-!UZTI-
M39>D-=(.K1&GM.9*34V"I#7B?).,Z/M?^OU!0U#C_4%2^4'1K]PDVW'P?3?)
M7BRC)D>2(;$#U+$_M](WP?2;IX:@IING1'(8V?=73*T5>+N!HU'6O:Z:0@E@
MQ,HVCDO^ ;=+[+X.+H)M$!R1!$<&[9P)K&!X<!(<J:E)D&!('(,AT:%OX)/Z
MW1)#%/2\?@,=^I(.?3M-.9_Y1V]AV8T>.@M<J:EIE0SIPU:6@N^4#%VIJ4F0
M9.A;H>N(GP(CPR0?HCH4&<-ZI'[#O%MY="%[;N0#3<1\34'('D0[[[0O3L;)
M]E&,[1L>K_*G&>YCSN-E_G+!J+"<!8CO'^*8/[_)'I H'X@9_P]02P,$%
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MU,PN:S)>3G[@;1 CR1W5!A3Y#,8P,2.72E$Q@R(8U81-B9G#,UF#P@ *-&Y
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M<Z]I&E95]=7@65F\:-2/*[P+@G8!^'ZAE-TWW&VCO5WF_P%02P,$%     @
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MI*M*GQ>-6#&1+,M[F3F3JC/*A[%J7H%K [6_8$QN)[H]JMKAX!]02P,$%
M  @ R8)85C"#HOCP P  G!$  !D   !X;"]W;W)K<VAE971S+W-H965T-S N
M>&ULK5A=C]HX%/TK5EI5K=29Q 8"3 %IAFFW?1CM:$;=/JSVP22&6'5L:INA
M\^_7^2!?. '4O)"O>T_.\;7OP9GMA?RI(D(T^!TSKN9.I/7VQG55$)$8JVNQ
M)=P\60L98VTNY<956TEPF";%S$6>Y[LQIMQ9S-)[CW(Q$SO-*">/$JA='&/Y
M>D>8V,\=Z!QN/-%-I),;[F*VQ1OR3/3W[:,T5VZ!$M*8<$4%!Y*LY\XMO%DB
M+TE((_ZA9*\JYR"1LA+B9W+Q+9P[7L*(,!+H! *;PPM9$L82),/C5P[J%.],
M$JOG!_0OJ7@C9H4560KV@X8ZFCL3!X1DC7=,/XG]5Y(+&B5X@6 J_07[/-9S
M0+!36L1YLF$04YX=\>]\("H)T&])0'D":B8,6Q(&><(@%9HQ2V7=8XT7,RGV
M0";1!BTY2<<FS39J*$_*^*RE>4I-GE[\)42XIXP!S$/PMXZ(!-^XQGQ#5XPH
M< 6*@-MDP*E^!:M7\$PVII0:O+\G&E.F/IC [\_WX/W;#^ MH!P\F Q3)35S
MM2&9O,H-<D)W&2'40@@B\""XCA3XS$,2U@%<HZZ0B X2[U GXCT)KL$ ?@3(
M0\A":'E^.NR@,RA&?)#B#4Z-^+]/POR:R;C',OS/-E(9T- .E"SP&[7% 9D[
M9@4K(E^(LWCW!OK>)YO*GL!JFH>%YF$7>J'Y(UB1#>6<\HU9? SS@-AT9V!^
M"I;TH9<%@L@?SMR7JJ#C*#B93% 156,Z*IB..IG>!K]V5%'=-GD[LR\M208V
MJNH<#GR[ +\0X'<*2->PC;E_]+(KWVL,J25F-+3S&1=\QF>6GO#P1-W'Q^,!
MD=>LNS7*;Z$Y*6A.3M0]V,4[AC4)P>:P0FF\Q52FG8X)I8AU1DR.Z(P&L$&Y
M.Z9&>%H0GG82?HRP<;& [#0-,+,1Z\R_=*KV!%:3"KW2I+R^>F:.U)/LOM#J
MNBOF#/OLFSE:=9[!\70Z;LQ&6]C(ARTK"**2+?JCWMF=?G%ID*U[MJPJ6+HS
M[#3"]OZ9Y]4;:'.AVX*&DQ9.I7O"<^WS= _-H1ISH.(J.5%K6&6JU*F6]@E/
M^">G,6;@*\%,1U9^O3IH7VAUM:770K^WOM1IVQ?K[@FMKKOT='BNJ9_7EXXM
M>X#\H[9DC6I;/*6QPU/.?J(K=:9?7!B+U;<H*)T>=EM]>TN:'B_BYJ >AURU
M_,-$I1VC3MN[J!_E4'Y;5?,MF#6JV8W<RCXW)G*3;O\5",2.ZVP_6-PM/C'<
MIAOKQOT[>+/,/A24,-EWBP<LS816@)&U@?2NQV;D9/8I(+O08IONIE="F[UY
M>AH1'!*9!)CG:R'TX2)Y0?%!9O$_4$L#!!0    ( ,F"6%;8(_@8'0T  !&8
M   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;+V=_V_;-AK&_Q7"-PPM
MD-;6=Z=+ K0FN05H;T6R]8 ;[@?&9FRALN1)<I(6_>./LAW3E!1&NGOB_;#:
MCOAY:3[D*^DQ29W=9_G78B%E21Z625J<#Q9EN7HW'!;3A5R*XFVVDJGZRVV6
M+T6IWN;S8;'*I9AM"BV3H3L:A<.EB-/!Q=GFL\_YQ5FV+I,XE9]S4JR72Y%_
M^R"3[/Y\X P>/[B*YXNR^F!X<;82<WDMRS]7GW/U;KBGS.*E3(LX2TDN;\\'
M[YUW?.Q5!39'?(GE?7'PFE1?Y2;+OE9O+F?G@U%5(YG(:5DAA/KG3DYDDE0D
M58^_=]#!/F95\/#U(YUOOKSZ,C>BD),L^5<\*Q?G@_& S.2M6"?E57;_F]Q]
MH:#B3;.DV/R?W.^.'0W(=%V4V7)76-5@&:?;?\7#KB$."KCN$P7<70&W:P%O
M5\"K%PB>*.#O"OA=(P2[ D'7 N&N0+AI^VUC;5J:BE)<G.79/<FKHQ6M>K&1
M:U-:-7"<5CWKNLS57V-5KKSX-<MF]W&2$)'.R._E0N;D,BU%.H]O$EF0-^2?
M(L]%I3YY164IXJ1X37XB<4H^J5*J;Q1GPU+5HZ(-I[N8'[8QW2=B.N13EI:+
M@K!T)F<MY2?V\MYSY>DS\5T+8*@:<-^*[F,K?G"M1"JG;XGGG!!WY+KDSVM*
M7OWTNNV+V3'7<J4PHV<Q%%,;UAWC6#"\.V;4CC':W-OW7&_#]9[@ZFY*WA>%
M+)6:#]-D/8O3.=GWZK\^JE+DLI3+XC]M'74;PF\/467U=\5*3.7Y0*7M0N9W
M<G#Q\S^<</1+F[A(&$7"&!+&03!#='\ONF^C7VPS5*PSU E)9=FF[)83;CC5
MZ?7N0O6_\/1L>'<HF35:7\DZA60M1[FGGF<>Q4$5,QHYV#=R8&WDR^5*Q+FZ
M?"A/2'V4G1 >IW$IWWQ4IX39";DNA1I<ZE"2W:J#I]E2DBPGDVRI*K:HKD#4
MF6/W^5_LH:P^J6 L72]E=6+)TM:!::UAWX&)A%$DC"%AW*[J)"LV(A5"#1M+
M+PGWO22T]Y+/5S^+Y>H72N)]?R'3A<CG=?Q642NMKZ)(& T;(]*)1J/:L$5&
MY""8H5NTURWZ/T;WI;HBNCT8X>15\ZSZ^N6&O;7J?3L)$D;MC7JE "*?+C:7
MT3-YI^[85E7SM(UY9+4X"&;TI/&^)XV?R2AIJ?K%9MRK&X%XME.6)+&XB9.X
M_'92)01U1%'=,,BBC-6MH.I3MZH#DCN1K&5;'[ &[=L'D# Z;B2*-XX?UA+%
M]J#@X* @JIW<094R1#O=BW9J%>W],LO+^/M6*/FP4B-3DMOL\***B,WU=)LV
M5G9?;9 P>MIH=M=I)/'F00I7.XB?-D\'XX.#C%9W1OH^>V1M=[;O_6(^S^5<
MO22B18O-?9+7>E,]:M9^7*_]Q%Z-OJW:*2:#QN0HFBG4@2'BX(3R6X5RFHW6
MN*"8V*O16Z@N,1DT)D?13*%<+92+$RIH%<KMD \F]FKT%JI+3 :-R5$T4RAM
MU#A62Z"?4&&K4%ZST8*F4% #IE-,!HW)4313*&VN.'9WI9=04:M0?K/1O*90
M4-NE4TP&C<E1-%,H;= XSS@TC_?>K1I O1,HC4)I#$KC*)JIJ;93G/#E_6P'
MZK) :11*8U :1]%,[;4EX]CM@^ZV]@YTF.RB,'3J"19J?72*R5J..G7'M:,X
MJF9F0VO'PK%;%O^6^8UX$*TM"_4=H#0*I3$HC:-HIJ+:SG!.CY VH;X&E$:A
M- :E<13-_-%=>RJNW5.YK%E6S5\B2"Z3S05MF9&ER+_*ZO4JSV;K:6MZM0?L
MVQ&@- JE,2B-NRT^4?B4:>9J+\:U>S&7Z9W2,LN_D?N\^DEBEMVGK;(A?8T)
ME$:A- :E<;?%-7*?4DT;,Z[=F'F?JKO(A/PF15(N6N5"NAL3*(U":0Q*XRB:
MJ:OV<=PCS+AQH5-NH#0*I3$HC:-HIO;:&G)1$V_<IAWC-TU5>[C>PG6)R: Q
M.8IF"J(M(-=N ;V?276Q4Y ?Y&,\K4RY8O/;<U;IU"H+U!6"TBB4QJ TCJ*9
M,FM7R#V"*^1"72$HC4)I#$KC*)JIO7:%W&=FZG3Y1=YMVBYA?3;AQ!ZHMV0=
M0C)H2(ZBF4IHV\A]9J;+[U\NZ1OGM%4 J&\$I5$HC4%I'$4S)=6^D7L$W\B%
M^D90&H72&)3&431SX8#VC;QG?*.>4U?MN-[+!*"N$)3&H#3N-5VATR?<!4][
M0I[=$WJA68?VJ+TUAEI(4!J#TOB.9DR*](,G1-86DF>WD(JLFF"<3^6J5'<X
MUI^[[:3>PD'-)"B-06D<13,5/EB]=8SE6]CU6]@%7-@57-@E7"]A)GG:3/)0
M9I+7-'9"OV$FV</U%JY+3 :-R5$T4Q!M)GEV,RF5RU+<Y&MU8HUOGDVX4"<)
M2J-0&H/2.(IF:JR=).\(3I('=9*@- JE,2B-HVBF]MI)\E#SB[RFM^,[XWJ^
MA=I)74(R:$B.HIER:#O)L]M)O>\_FVN*HG'C)-A<G30>U58>T192R^SS%I0;
M!;697/;O^+^VH?9O//LZIOHIZY,4Q3K?KDF\3%?K\H30N)AF:_7^JIK(_(-\
M4?=^VUO%/^1TD<9_KZ4^2-T@3D2Q(#Q1-?E!>'6S6!50AQR@U<"YDM-UGJNL
MV:H4U!""TBB4QJ TCJ*9FPIH0\@?O?RYT8>Z1% :A=(8E,91-%-[[2?Y=C]I
MGR5RE25:=84Z0U :A=+8CN9X!XE_]'8T#D:'_]6G]*+J8.JGK2+?;A7-Y:U8
MQ0\B?=8ILH-Z"PEUBJ T!J5Q%,T46#M%_A&<(A_J%$%I%$IC4!I'T4SM#[;[
M03E%?M.U&7MN?;L?J%'4)22#AN0HFBF']HE\NT_T>3MS>CO5:#>-FN35YGVM
M]RUV6N]!!W6*H#0&I7$4S519.T7^$9PB'^H406D42F-0&D?13.VU4^2CG"*_
M91;0V*F[$O9PO87K$I/MCCJT+Z+Q:=V_0-7,;&CM ?EV#\B22M5U[)6\2;+O
MWY+6AH=..(+2*)3&H#2.HIF":\/*/\*$(Q_J+T%I%$IC4!I'T<S]%+6_%-@G
M''7/JD%SRHS7W.G"'JZO<)UB,FA,CJ*9@FC3)[";/O;L:UDE;.?V'8!0&H72
M&)3&4313;VT2!>[+)]\ ZA]!:11*8U :1]%,[;5_%-BW'^J1?)M;_OBCL)Y[
MH=Y/EY ,&I*C:*8<VM()[):./?5>QW?RH<RS5GF05LH$2J-0&H/2.(IF"GZP
MFW1PA-R+W1 :NR,T=DMH[)[0+V$E!=I*"NR;1/?(O6%S9H);]V_MT7KKUB$D
M@X;D*)HIAW9W KN[8\^]OXI\)HHX&3Z^(*T+GNPQ>@]%J$$$I3$HC:-HIO;:
M< K&1TC#4.\)2J-0&H/2.(IF:J^]I\ ^6:I'&F[9(MEMV ]0WZA+2 8-R5$T
M\\$)V@X*[7:0/0U_R.-9G+7N<V/G]AU^4!J%TAB4QE$T4V_M-H7.RZ?>$.H\
M06D42F-0&D?13.VU\Q3:IR=U3[UA<V?HT]K\W8D]6&_9GH_(H!$YBF:*H:V@
MT&X%V1/OL_M6V>F]AR#42(+2&)3&4313=>TXA?X1TB_4?(+2*)3&H#2.HIG:
M:_,IM,]8ZI%^@T8R=)M;E]O#]1:N2TP&C<E1-%.0@Z>&V1VA/W(QDR05RR>>
M$H9]3!CV.6'0:4-0&D?13%6UL11&1TBQ4&,)2J-0&H/2.(IF:J^-I= ^DZE'
MBFVN/G-=WZ^G6*@KU"DF:SO*&]<>W<E1-3,;6KLXH=W%.4B=G:Y6H7.%H#0*
MI3$HC:-HYM,9M3D4'6$M6@0UBJ T"J4Q*(VC:*;VVBB*[-.2NJ?2J+ESL^LV
MKE;MX7H+UR4F@\;D*)HIB'9O(KM[L]M;M54!Z&P@*(U":0Q*XRB:J:BV@*(C
MK":+H$80E$:A- :E<13-U%X;09%]ZE&/].HW4IT7!/4K57NXWL)UB<EV1QTN
M;O"\L+9=!D?5S&QH[;I$=M=EES:KS:F_I2N1?V^=2VN']!Y%4&<&2F-0&D?1
M3'&U@Q,=87E8!/5YH#0*I3$HC:-HIO8'SXY'+0^+FDNUG.9C .SA>@O7)2:#
MQN0HFBF(-E\BN_ERD&EE>A<OVQ,M=-8.E$:A- :E<13-U%;[/=$15HQ%4!<(
M2J-0&H/2.(IF:#_6+M 8M6)L!S+V_7+J5ZKV:'UU&S<7C#5",FA(CJ*9<FAC
M9FPW9G2:I3(7WT6ZV7:L50[H-!THC4)I#$KC*)HIL#9ZQD=8(#:&6D)0&H72
M&)3&4313>VT)C>VS@BR/D6Q5&6K^0&ET1S,W@:PG9JBE@Z)MM1L6"RE+*DIQ
M<;:4^5Q.9)(49+-!V_F@&LW[3TDN;ZO'P[Y[[PZ&C<^I\XX[U>=#C;DX6XFY
M_"3R>9P6))&W"CEZ6]U-;Z: /;XIL]7Y0&6CFZPLL^7FY4**F<RK ]3?;[.L
M?'Q3!;C/\J^;:E_\%U!+ P04    " #)@EA6-],P["<$  !$%0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970W,BYX;6R]6%&3FS80_BL:FLDD,^V!! BXV)ZY
M^-KT9I+6<]>T#YT^Z$"VF0!R)?E\Z:^OA#DP()CS#<F+0;#[\>UZEV_1[,#X
M%[&E5(+'/"O$W-I*N;NT;1%O:4[$!=O10MU9,YX3J99\8XL=IR0IG?+,1HZ#
M[9RDA;68E==6?#%C>YFE!5UQ(/9Y3OC7]S1CA[D%K:<+M^EF*_4%>S';D0V]
MH_+S;L75RJY1DC2GA4A9 3A=SZTK>+E$GG8H+?Y,Z4&<G ,=RCUC7_3B)IE;
MCF9$,QI+#4'4X8$N:99I),7CWPK4JI^I'4_/G]!_*8-7P=P309<L^RM-Y'9N
MA19(Z)KL,WG+#K_2*B!?X\4L$^4O.%2VC@7BO9 LKYP5@SPMCD?R6"7BQ %Z
M PZH<D#/=7 K![<,],BL#.N:2+*8<78 7%LK-'U2YJ;T5M&DA?X;[R17=U/E
M)Q<?&$L.:98!4B3@=[FE'-P4DA2;]#ZC OQDN/;FFDJ29N*MNOOY[AJ\>?46
MO )I 3XI'/77B)DM%3.-;\<5B_='%FB Q36-+X +?P3(0<C@OGR^.VR[VRH?
M=5)0G114XKD#>$VTX$H(*@7X^3'.]DE:;$"=L+\_*B]P(VDN_C%%?'R$9WZ$
M[LY+L2,QG5NJ_03E#]1:O/X!8N>=*?Z)P%K9<.MLN&/HBP^<"0&6A/.O.@%7
M.=L7TA3Q$0:7,/KU\;#P8.#AF?UP&HK!"GEN6%NU.'HU1V^4XU4<[_-]1B1-
M-$$NT_^(?DV8:!Z1_!,""'I!T*'9MX*1[_AFFGY-TQ^E^1LU)L[O,W(0CCJ,
M#%8H<ETS(UPSPJ.,;E:WKTF^>W=MXC7J>FX)3P36BC*HHPR^?4,'4V9C(K!6
M-L(Z&^$T#1WV*B[ &';*LF\4H1":JS*J&48OZ9/H.7SZ1L-\H-/(I#/*:,59
MLH]5X6B=W!T7@.L9P2QWHVCG%LM4:.W83T8$^.V[IWK&5!F9"*V=D68^@*."
M^_P.JG!:+VW7]_U.S1K-<#!4M8URPW'I/D<6*ZB6XN' ZU$UF/E!@ >H-@(.
MQQ5\H.5A7X=Q")TNJ;Y5$$8#8@T;M8;C<OT')PD%!<FIN<E'O<\NZ8G0VK$V
M<P#$WZ'))YT8ID)K9Z29&>"H")_1Y$&_>\.@.[X9K4(T4*.-EL-Q,3^KQ?M:
MC=U>@_>-O&A@RH2-H,,7*3KLJS5"GM>E9+!RP\C,"36:CL8U_6,:TT)0X\?;
MI/H]%5H[SD:_T7?0;S2I?D^%UL[(R??]1/J-^L(<8+\[<AJL,':\@?ILU!M-
MI]ZH+\N>$W4_:@U6KAHT!H@VVHU>I-V5U^FGOII]NLUMLG)Q=S_ /MGBTON+
MGPC?I(4 &5TK-^<B4#'QXY;=<2'9KMSUNF=2LKP\W5(EYUP;J/MKQN330F^D
MU1NGB_\!4$L#!!0    ( ,F"6%:=J-O@>0@  !Q$   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<S+GAM;+6<77/:.!2&_XJ&[>ZT,PG8\A=D$V8:W)UV)FTR
M23\N=O9"V *\-19KB]#\^Y6-@Y M%)PYW+3!2*^EQSKR>67ARPW+?Q8+2CGZ
MM4RSXJJWX'QU,1@4T8(N2=%G*YJ);V8L7Q(N/N;S0;'**8FK2LMT@"W+'RQ)
MDO7&E]6QNWQ\R=8\33)ZEZ-BO5R2_.F:IFQSU;-[SP?ND_F"EP<&X\L5F=,'
MRK^M[G+Q:;!3B9,ES8J$92BGLZO>>_LB]+RR0E7B>T(WQ=[?J.S*E+&?Y8=/
M\57/*EM$4QKQ4H*(_Q[IA*9IJ23:\5\MVMN=LZRX__>S^E]5YT5GIJ2@$Y;^
M2&*^N.H->RBF,[).^3W;?*1UAZH&1BPMJG_1IBYK]5"T+CA;UI5%"Y9)MOV?
M_*I![%6P_0,5<%T!-RNX!RHX=07GV IN7<&MR&R[4G$("2?CRYQM4%Z6%FKE
M'Q7,JK;H?I*5U_V!Y^+;1-3CXQM&L@+=D2<R3>D9NF'9_/PKS9<HI%..2!:C
M&RJP%N@<?2%Y3LJKA-Z&E),D+=Z)H]\>0O3VS3OT!B49^IRDJ;B:Q>6 B[:5
M9QA$=3NNM^W !]IA8_2997Q1H ]93&-58" ZM>L9?N[9-38JAC3J(\<^0]C"
M6-.@R?'5;4WU\/CJEJ$WSNXZ.96><U!/7(Y/6<'SM8@ZCOZ^$070)TZ7Q3\Z
MVELU5Z]63B87Q8I$]*HG9HN"YH^T-_[C-]NW_M21@A0+@<04BNZ.HFM2'U?#
MFY?#.Q8\ST2 Y7E)4\P?ZSSA"=6.W*VF7VF6\^CCV XL<5$?]QFU"V&G62@T
MMNZ5??=V??=>Z'L9Z:MMI%>1_=S[%<NK.9C-4*H TL'8GL3;AS%R_08,KPW#
MM7$#AK&YKX3A[V#XG0:"' !GXFXF()5!5I1$5GF21<F*I.7\)H+9T4'QVU#:
M(\38HJY1!"2FP MV\((3P7-U\((VO%;D3(PMZ@H/2$R!-]S!&YX(GJ>#-VS!
MPUX+GK%%7>$!B2GP1CMXHQ/!\W7P1FUXN 7/V**N\(#$%'BV)7,]ZT3X FU&
M9[4CMSWXS&WJ"A!*326XERW;G0@FF?A "XYV\ QWB5I[G]=PB)NXC WHC M(
M3<6%)2X,@DM[7ZBU%5RNU\1E;$!G7$!J*BZ9X]O&Y/=H7-H[0:V]CRL(ADU<
MH*D\E)J*2R;S=K=L_A N[=Q?:RNX/+N)"RAAKW&=(OVW9?YOOV0 CL.EG^O;
M>7^ 6U,]4$I?XSJ%0;"E0[#-%N'](TG2RBM-62YJ)]D<142<,.%/:)W%-$=1
M3N.$HYDXEHJC6FY^RPKY5OL>">H-H-14<-(=V&9[<+NBY3J1P)662T=G:%,M
MOM$8D4?QS9R*7*-<D=R50.6@U,(SGRA 3Y3D.LL^>77-T%SSM?"D.[#-]J %
M+V*%UH?7.OL#RW'<YKC2%'*=A@_7%I(C5.V(S-1M<ZK>ZLCS+*/M3#L3=YS6
MK5Y3R&VNL&B57'UGL$R<L3EQKI;#S]GL?"U&*RD*RA&;<C&&Q: 6DR;]%2U(
M)@;VC.6(J1U':4*F!Z<'W$ZAO:#1[[J,LOYD-PJ%FD)NX!SHMTQW\0OI+A5]
M%=>.-2_FMFL9XR*0N!BC2W%I(QJ?(;)DZTP[8.M3J2MDS>S7W)ZN$R&4FDI/
M9K_8G/W>\H6X27PG>5+=1NX)I]6RNI8.9!X[ 54+H=14C#(KQK!+WQAT[1M4
M+8124U'*C!F;,^8/LQFM'K3)Y$_$-=52W"K9[EZ\6GW+;MYBGLM9^^6:D],I
M$E\L$U]L3GS]OF/]7B:]8O2LQ0E0O*8'?8%9J_/H <V(H=14CC(CQCYL($)F
MM1-0M1!*344I<V1L3D ?..%5[O!2% ;:*/2=9A2"KH]#J:EP9 Z,S3FPW0]$
MO(KD0H:JUI.:93J/+]!5<B@U%:',OO$(-E0A5[DGH&HAE)KZW%WF_HXY]S\V
M5&N9U@VSF<Z;3]?Y:?HIUL,=:1 <LT&P^Z-FJ ZU<"#S^@FH6@BEIB*4+L'!
ML#L[0)T"J%H(I::BW-LC8UX_/SI4'7VHCIJA"KOQY12YOR-S?\><^^.^[:FA
MZNCV-5V;93J/+] 5="@U%:$T$HX'&ZJ@7@)4+8124U%*+^&85]>/#E5?&ZK8
M;JX.FL_7F<XI[($C[8%CM@>X'S1BU=/'*F3:/P%5"Z'45(321#A#V%@%-1.@
M:B&4FHI2F@G'O)1_=*R.]+$:M&(5U!] J:D[2J4_<,W^ +=28%\;JV:9K@,,
M5"V$4E,12A?AVJ"QZH*Z"5"U$$I-12G=A&M^YG!LK-8RK5AMIL#FTW6&<PI_
MX$I_X)K]P:1\3I5'"4G1BJQHK@4#^O0 5"V$4E/Q[6V>=V'#%-1)@*J%4&HJ
M2NDD7/,CB1_UEHCSYRT12L"6.S"C8\:JIPUBRV_>< \5M!K[PT)SLU^+1;H"
MU^P*OE1WT8?U]%\:<?25H?OG7:GH/4>WJ^IG"K<S])&E\0$DH,\<0-5"*#45
MKC05;@ ;OJ#F E0MA%)344ISX;ZTB1_DMS1N>^>-/6JN%^L*N:-FW)["(;C2
M(;AFAW"]3M(XR>;ZGT^!/EL 50NAU-1?9$GOX%F@(>F!>@A0M1!*344I/81G
M?A(!M^OPA1,9=AV::W8&>@HGX4DGX;VP=__0WB\QS]&-2$L.\C/KN@9^H&8#
M2DWE)\V&9S8;W^DBB5+]+TK-53O',:C)@%)3L4F3X<&:# _49("JA5!J*LJ]
M'_R:30;@E&@^D2FD01]:0*EM@0[V7IL@O-:\>OU$(9S7.N/;]PSLCNY><?&^
M>K%#X_BU?1%N7U0A9;;OS?A,\GDB4L64SH2DU0]$!_+MJRBV'SA;52]GF#+.
MV;+Z<T&),#=E ?']C E+5'\H3[![(<CX?U!+ P04    " #)@EA67.0$80D+
M   %:@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6RUG5UOV\@5AO\*
MH6Z+76 C<;[(F=0VT,18-$ 6#3;=]J+H!6W1MK"2Z))TO/OO2\J2SGQQ*)*'
M-XEEDR_GI>>8KQX.CZY>B_*WZBG/Z^CWW79?72^>ZOKY_6I5W3_ENZQ:%L_Y
MOOG)0U'NLKIY63ZNJN<RS]:'G7;;%8WC9+7+-OO%S=7A>U_*FZOBI=YN]OF7
M,JI>=KNL_.-#OBU>KQ=D<?K&+YO'I[K]QNKFZCE[S+_F]:_/7\KFU>JLLM[L
M\GVU*?91F3]<+_Y&WG\DE+9['#;YUR9_K;2OH];+75'\UK[XM+Y>Q.V0\FU^
M7[<:6?/?M_QCOMVV4LU _G=479P/VNZH?WU2_^G@OG%SEU7YQV+[[\VZ?KI>
MR$6TSA^REVW]2_'Z]_SH2+1Z]\6V.OP;O1ZWC1?1_4M5%[OCSLT(=IO]V__9
M[\<SH>U >,<.]+@#O70'=MR!'8R^C>Q@ZS:KLYNKLGB-RG;K1JW]XG!N#GLW
M;C;[]O?XM2Z;GVZ:_>J;ST6VKZ(OV1_9W3;_,?I<[!_?_3,O=]%M?E='V7X=
M?<Z;LU1%[^R??7^;U]EF6_W0_.C7K[?1]]_]$'T7;?;1SYOMMOD-55>KNAE@
M>YC5_7$P']X&0SL&<YO?+R-&?HQH3*EG]X^7[T[,W5?-:3F?&WH^-_2@QSKU
M&IN?]E5=OC0SMX[^\[G9(/I4Y[OJOSYS;VK<K]86Y/OJ.;O/KQ=-Q55Y^2U?
MW/SE3R2)_^JSBB1F&&=GXRRD?F/^IGU6W_9/#ONW?RJ^W5"9<G&U^J9[<+=B
M<:+B\U;&X/AY<#PX.+I,Q9^C?5$WDW+]DK>_;.$;8E!EZ&\#2<PP+,Z&!>HT
M%)C&D<0,X\G9>!+\37^MLSI?-W]2ZKP1KZ.R>>DS_*9"N#;/XF5,4WLZ!H\V
MTDMZ]I).+*G4+2FN$LO"VT;"W$CX"TJ>AR9["HI8!<6(;X!!E:'S"DG,,*S.
MAA5J02E,XTABAG$2P]4^1BFIHXQ34\2NJ?#QQOK1T@N96%9' ;VNB))V71VW
M$EU;F<.# $&"EVG/M4IX2RLL,W2*8:F9IB$\$(9:7B081@:;1U(SS4,X(>%T
M<G&!\0LO6N'CC?4#V8,$K_"7%)CP%%BJ;!O"4V#:5N;P("&0<$1@RS0V"XQ[
MPV!89O <FR-)$(@2),4ML& T&6P>2<TT#V&%A-/*Q04FO07&4GMBSI%$"$01
M$KS@7U)?RE=?TK:A?/65^NN+0EZ@X;S EMRJ+ZJ\;WV18L#QO>\<H8)"J* $
M]WU_,*,,-H^D9IK7F$<XLEQ:7T<9I[ZX-3'#AQMK!\((G8HRJ$LI2,KL^CIN
M)<RM.@(BA;A PW&!.-<OFGH'B4HSL-1,TY I*"[0H*A$ TO-- ^)A>) #>JG
M&L2^?H4/-]8.9!$ZE6M0%VP0KIP_$R[9:+9B'?4%:8'VL0UEU5?B?0,6EAD\
MQ>;(%!0R!<7E&Q05<&"IF>0:$@O#(1RL@W#8;US"AQMK![((FPHXF =P<,EL
M&Q[ P27WUQ>#M,#":8$O8_O]ES<?AF6&3C$L-=.T=G<$%W P5,"!I6::A\3"
M< #'4:;E@WI]V7_WPT<;ZP:B")N*-Y@';_"4V#8\>(.G'7>Z&(0%%@X+W$'S
MG'D'B8HWL-1,TQ I&"[>8*AX TO-- ^!A>'@#>;'&]P!].'CC?4#681-Y1O,
MPS<H<R[#'KZA;V7>2H:TP,-I@2RY?>\K]MY,1N4;6&JF:<@4')=O<%2^@:5F
MFH?$PG'X!O?S#>(L<@@?;ZP?""-\*N#@'L!!'0[*/8"#LHY;RUQ;K-&W6L,N
M,.$O,-SE&G.D"@ZI@N,"#HX*.+#43/.063@.X. =RS;< ILCCG"((WPJX> >
MPD&)_0Z,>P@');2CP" P\'!@($O9WF/.7\KBW3K?%[O-_G#^#::8>(>-RCRP
MU,S3 #F#XS(/CLH\L-3,]6&08@0.\SC*$&%=TZ1SUSE\P+&&(*&(J=1#>*A'
MG,2V#0_U:*YJ_IH3D"%$.$/$[A)$;X6%908OQ9LC: @(&@*7>@A4ZH&E9IJ'
M&"-PJ(?P+^N(W0*;946IMJ1T*O<0+O=0RG'A8@_5!>T%) @13A#$@?94>H>(
M2CVPU$S3$#,$+O40J-0#2\TT#R%&X% /X:<>Q*8%X<.-M0-A1$R%'L*%'LJY
M)R9<YJ%O9*ZIAK"0]"WIL*N+>9%]6&;H!,-2,TU#H$APD4>"BCRPU$SS$%<2
M'.21="SIL*LK?+BQ=B"()%.)1^(2#R6=IP%<X*&Z;H@E$!22/M[!;&+OY1UA
MF<$3;(XTD4":2'!Y1X+*.[#43//:0RI(3ZET\ [F3,PY@D@"0229RCL2EW?H
ME7-TX>(.)3NB80)!(1FZGH-R[Q!1V0:6FFD:XD2"RS825+:!I68^-@5Q)<5A
M&^F%ZSG"AQMK!X)(.I5LI"[92+GCP@4;*9?^ZDHA**3AH) LA1T-O;>;PS)#
M)QB6FFD:XD2*RS525*Z!I6::A[B2XG"-U,\U$OO:%3[<6#L01-*I6"-UL49*
M[-4<J8LU4M)Q*RR%H)"&@T)\J*XPJ/=>S,*Z@V?<+(_!:L_!XG*.%)5S8*F9
MYB&^I#B<(_5SCM@IMSF"20K!))W*.5*7<PCFE)O+.432$14E! ?9M[2#]=X8
M8UYL'Q8>_*3S'(%#0N"0N.1#HI(/+#73/ 0:B4,^CC+.C3'F</OP <<:@K B
MI[(/Z;(/0>W%'M)E'T)T+*:2$"9D'_OHO< Q[P4NK#MXSLV1021D$(D+0R0J
M#,%2,\U#QI$X,$1VP!"GW.8(*Q+"BIS*0J3+0@2UNPM(EX4(T?%N36IM.\)A
M@BT3>^V]KVG2A[#,X DV1^20$#DD+@N1J"P$2\UL6P*11N&P$.5G(<R>E^'#
MC;4#T41-92'*92%<4=N%RT*X(O[J4A =5"\+L5<&>Y_,#,L,[@XS1[Q0$"\4
M+@M1J"P$2\TT#_%%X; 0U<5"[(M7^'AC_4 045-AB')A"(_M)Y^5"T-XW)$5
M%00%%0X*PEE"Y7\O%I89/,/FB!,*XH3"91\*E7U@J9GF(:XH'/:A_.Q#.&_%
MPL<;ZT=K(C85?B@7?C#G9KIRX0=C'=F0Q'JCKW!6$$O5%-@ZOVLFVDO9LY*J
M1VQPBQ@L.<N]UA8LQJ4>)SVT$S ']R QU4X #ODXZ3CEYJSUZSGB:$]:7[%X
M*OPX*9@M1YV6/[&+/UC<U>PMUGI_Q>$$(9;2OJAYEU;UZ R?;7,$#1)K3<)B
M7.9QTD,[ 7-0#Q)K;<AB'.YQTG'*S5F>U'/$T9ZT+F/Q5/AQ4C":ECK/1I^V
M$AU;60/4.H'%X421')I377R)0\4@:'*6>ZUQ6(Q+0DYZ:"=@EDZF>BM3K%ZF
M'<U,$WO)4L\!1UO2NYE.;V?J(A$J[.=>B*>?J;Z5-4 M5O0T-$V6S%MRWO=N
M/6*#9]P\?4WUQJ;8G4V16YO.T]M4;VZ*U=VTH[UI8C\4V7/ T9:TZ#*]P:FO
MPZFS:I/X.IQV/3]-] ZG/2U.Z5+:2QZ]B[)Z=(9/MEGRA][E%+O-*7*?TWD:
MG>J=3K%:G7;T.J5.D]!YFIWJW4ZGMSOU]#MU+V^>;B#Z(DFK7;>6*7KZG?ZC
M?LI+[[!P.YRBR5E.M:B!W.24X'8Y19.S3H 697H:G5XP%8\*QA_^Q*$)GJVH
MLUIPI7U$3_L!23]GY>-F7T7;_*'9JWV@>!&5;Q\Y]/:B+IX/G]IS5]1UL3M\
M^91GZ[QL-VA^_E T5X3CB_:#@,Z?_'3S?U!+ P04    " #)@EA6 )Q' (8#
M  !K#   &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6RM5VUOVCH8_2M6
M-DVM!,T;KQU$:F'3G<3N16.]^S#=#R9Y &N.S6P'RK^_MI.F0%W65GPI<?*<
MPWG.<=R'P9:+7W(%H-!]3ID<>BNEUM>^+],5Y%A>\34P_63!18Z57HJE+]<"
M<&9!.?6C(.CX.2;,2P;VWE0D UXH2AA,!9)%GF.QNP7*MT,O]!YN?"/+E3(W
M_&2PQDN8@;I;3X5>^35+1G)@DG"&!"R&WDUX/0HMP%;\2V K]ZZ1:67.^2^S
M^)(-O< H @JI,A18?VQ@!)0:)JWC=T7JU=]I@/O7#^R?;?.ZF3F6,.+T!\G4
M:NCU/)3! A=4?>/;OZ!JJ&WX4DZE_8NV56W@H;20BN<56"O("2L_\7UEQ!X@
M[CT#B"I ]%) 7 %BVVBIS+8UQ@HG \&W2)AJS68NK#<6K;LAS,0X4T(_)1JG
MD@G'3*(IWN$YA0::<+9L?@>1HS',%<(L0Q/0+DG41+>88I8"FMGM]865>\AD
M<3$&A0F5E[KJ;C9&%^\OT7M$&/I**-4%<N KK=5\HY]6NFY+7=$SNL:07J$X
M;* HB"('?/1R>'@(][5#M4U1;5-D^>)G^;0;8R)3RF4A /V\F4LE]![\S]5:
MR=5R<YD7\UJN<0I#3[]Y$L0&O.3#N[ 3?'0U>B:R@[;CNNWX%'ORCUJ!0#=2
M@G)F6*([%FT.C$T2QJW.P-_L-^ H:O<>BPZ$M6IAK=/"UB#TWF/+<GLVD#U_
MFGS1O)-0"FZ@F<(*])&C$%^@SX3IW4LP15,NB=VV/S_=*W,@Z9V//K$BMY2<
M.2/]@YS3/HW>BC[PIEU[TSY)=Y.FHH#,OKS<4J>%$,8&2O"<4-T\.--L/PDJ
MZH5'83ZMB8.6.\M.K;?SNBPGE<Q= XU*Y>?-\K2<M]HW.COM@9O=VLWN"S;3
MWYP]T$].A]Y]^G8&87R4NJ,HBMKNV'NUT-Z;8W^4?][D_Z#H==:-SL5V8%^_
MMJ]_DOX[5]H%7IM(C8GU7MJYNN\[4NRWCJ)V%+6COCOJ,'B<,H*3:G_8<0JR
M)MYHP4O0$Z"9,1^%*S-S7.P "WGIG!9.\W>1A3H'A3<@#[O<FZ7"UW69Z8F!
M%SI['1(XVZJFL]:>W\%5$!\?N\_41<?_1OV]2=",X5^Q6!(]X%%8:%QPU=7G
MMR@GVW*A^-H.AW.N]*AI+U?ZUP (4Z"?+SA7#PLS;]:_+Y+_ 5!+ P04
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M,A[O'9X1S&](P[TBGN-Y)?+AQ^7NH=S&RA3E\8KR>*E?XUT_K,*(J3D7*I%
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M'3#0SE12M \A$60Q8W2'F$)+-G6AS=314GY:J/?^()A\FLHXL?CTI4S%,_J
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M] N!OF8F-T7SX&.)9Q/.=HBKT8"F&II,+0WF1U3Y_45R^!J!G)R];# G7QZ
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M2Z9A^>%'_B#H,CMPF% A:)+=+@@."5,-Y/<9I6+[H 8HCZ &/P!02P,$%
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M=4_*14:4;HJI*PL!9&)%&7-]SXO<C-#<&?;MO9$8]OE<,9K#2" YSS(B_EP
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MM;&U0T_1 .-&39PD\D[VHJE!(?H9:['=;X;M?E,6-QIJMB@AF/^6XNL*>F2
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MA=C_=GQK#),4E*B\J5D#*EF78R6+%):HO*F% ERRQN.EQG6[RX;=7CT&+UD
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M5 $-!#@-#) J7=%UJ3)-KO0\.@ZB'Y[ZE,LQ4A4:'F+1I,I@U"M5(6! B&-
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MZ:D<TE-^2#^V8?2_R$E0QZ,Z[R/HK7L4FEY120#2L&*>%$H$H&B$0M-+*XE
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MF"I\)D\LL(80OR+?C.4X7_#CO&Q-7[D>_P*NVPF*1B@TO;B2.11A=4(%E$I
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M]8)V[_5F0Z+;(C35-G8#J"\Z-H+,<E#KKY#=7PW.+Z3['\_OVT(#R(_Z>1M
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MWF.^IH4 &5DI2O<R5(7DAP/+PXUDV^H([XE)R?+J<D-P2G@)4.]7C,GC3=E
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M3Z02=*/Y-BP5YA<<*VS@@<U!2)95P6H$&<W+__BU2L19 !SW!* J '4#HIZ
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MS4JLA)WI!FO>*;2I!/'4;'S;&!1Y!ZJ4'P7!L5\)67MITJVM39KH+2E9X]J
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M?) C5V%C=95N4C7LKFQ8<*)A(7GD3"TDB5@*J<'_WN[O!Q8!%RG5J((MJKO
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MQP7$*0AM@-]GG*OMBZZ@OL><_ M02P,$%     @ R8)85I-W2KY[ @  E08
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M$U"M"+8;(QLO"U-IK,CX967_&ZB<@SV?26G6&Q>@_Q-E?P%02P,$%     @
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MH&P [D^E-.N)/:#]?Y#^!U!+ P04    " #)@EA6WFNNP'H#  "F#0  &@
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M( 5< ]3S%6/R]49/T!W-XC]02P,$%     @ R8)85DS!'F4%!0  Y14  !H
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M([:0.:%PQ9%8% 7FCQ/(V6ILN=9ZX)K,,JD'[&@TQS.X 7D[O^*J9]<J*2F
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MON?XGFOG9+R3ZD&7 (8\5ESH25 :4X_"4.<E5%1?R1H$KJRDJJC!J5J'NE9
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M"D?=V4EF5A'Q05#*VIZ)A6V;F6;C27:W%YU>,!)LLTN1*DG;R;\O2"F" !R
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M&I.[[='=@1;K8L/P16BSXHJO*TH2*O,"<WTAA'X_R&]0;5)/_P=02P,$%
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M ?+[%>?B[:)\0'L^:?$_4$L#!!0    ( ,F"6%;&W$A@\P,   \4   :
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M]%VBX]3\$59Z%15Z@#47BK 5>H\^_MP0]1M]YE*BI> )NEXN"258@42812@
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M!$'Y'-QY'GGU<\K;_/]Y_!=02P,$%     @ R8)85I>*NQS     $P(   L
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M/NSN$JP08(6\6"?NM2GTQ'W[1-PT$,T'A)DZU-PL".000 [W!7EB%DM+(",
M&>T0\K,L9)DKT584PC<"?*-]\8F#L:2)& /(>%\Y??;/2M.43 !DLD?(NY!
MI@ RW5N=D=5<$,@,0&9[A/12<A"@ICO@Q;R4]<JJ!NMJJ6QWG[)!K3![Y6:U
M6$C[U, =Y[E9E;4SKAB[5,VU\BB190;,FKEQ<<#AU73:IJ&=R=*4XC>Y6/[I
M6O#W%!)99L"LF>/<M3&5;J^_$]>J4M+F<T=8%/+>T!9R@#PS8!=-QR.;R$L<
M6RO+65MOO-Q&IADPJ\8E76U7N:LTKBQ2*&26 ;-:ONC2*4_+PD4V#=Y:BB&C
M#)B5<EX^N#>X.-VOLL@? V:!?#5F\JB+0LAR(J[JN8NFSUT?HIPU'!XE$LB
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M;%!+ 0(4 Q0    ( ,F"6%:L_L<H[@   "L"   1              "  :\
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M2P$"% ,4    " #)@EA6P)R%%?H%  "Q&P  &               @($-%
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ R8)85H0R!CGY
M P  J T  !@              ("!/1H  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( ,F"6%:)3R!DV <  "DA   8              "
M@6P>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #)@EA6
MQ"2&5!$#  # "   &               @(%Z)@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ R8)85AE_ZNP*"   )$0  !@
M     ("!P2D  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M ,F"6%8@KM:<C0(  +T&   8              " @0$R  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #)@EA6IQD!J94*   K-@  &
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M970Q,RYX;6Q02P$"% ,4    " #)@EA69YM4S9(E  ")?P  &0
M    @(':=P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M ,F"6%8) W_I)A$  +@Y   9              " @:.=  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ R8)85@N/][8["   V!4  !D
M             ("! *\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #)@EA6,0MK.&D>   ;:0  &0              @(%RMP  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,F"6%:-0<#GA ,
M  D(   9              " @1+6  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ R8)85@U%LGYC#@  ."D  !D              ("!
MS=D  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #)@EA6
MTJ;RUCH,  "N(   &0              @(%GZ   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,F"6%8^JEJ]:2@  (-\   9
M      " @=CT  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ R8)85LM? 4SS @  T 8  !D              ("!>!T! 'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #)@EA6IIEF_;$)  #5&0
M&0              @(&B( $ >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( ,F"6%9GH5BF=A<  *!-   9              " @8HJ 0!X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ R8)85CJ6%0#4
M P  N @  !D              ("!-T(! 'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #)@EA6S?@:6G4-  #G(P  &0
M@(%"1@$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,F"
M6%9+M-NYX ,   $*   9              " @>Y3 0!X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ R8)85OT4Q"NT!0  51   !D
M         ("!!5@! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #)@EA6?/@9>B$1  #C*@  &0              @('P70$ >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,F"6%;7\OUA4B0  )M[
M   9              " @4AO 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ R8)85L=[4=>' P  CP<  !D              ("!T9,!
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #)@EA6N+TE
ME@T%   ^#   &0              @(&/EP$ >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( ,F"6%8H*9/1804  .H/   9
M  " @=.< 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MR8)85EE*I*P8!   *PL  !D              ("!:Z(! 'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #)@EA68P[PQ+P.   E,0  &0
M            @(&ZI@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( ,F"6%9!I_T.P@(  -8%   9              " @:VU 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ R8)85M6^:]C1 P
M= @  !D              ("!IK@! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #)@EA6WQV4^@P%  "Y#   &0              @(&N
MO $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,F"6%8.
MBHW>S0(  '0&   9              " @?'! 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ R8)85@5LPE(T!0    T  !D
M     ("!]<0! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,F"6%;N,\J'Q04  #<0   9              "
M@1KJ 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ R8)8
M5GDCUQ;."P  I1P  !D              ("!%O ! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #)@EA6?H>13T "  #0!   &0
M        @($;_ $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( ,F"6%; 10[(D@<  &5!   9              " @9+^ 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ R8)85D9(;[KR!0  C2T
M !D              ("!6P8" 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #)@EA6<=9$KIL$   X$P  &0              @(&$# (
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,F"6%8G@5*P
M2%$  .-(!P 9              " @581 @!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ R8)85K'IA(JA!P  [T8  !D
M ("!U6(" 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #)
M@EA6_<$?1L4,  !:G@  &0              @(&M:@( >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,F"6%91F>-V- P  $%\   9
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M970U."YX;6Q02P$"% ,4    " #)@EA65BBTAP,$  #E$P  &0
M    @($YH0( >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M ,F"6%;SDE3ADP(  #<&   9              " @7.E @!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ R8)85B!4"[FF!@  '#,  !D
M             ("!/:@" 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #)@EA6J2'%GFT#   O"P  &0              @($:KP( >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( ,F"6%8ZGZBJ904
M $\;   9              " @;ZR @!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ R8)85B#NID[H P  [1(  !D              ("!
M6K@" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #)@EA6
M&,O;5<L$  #&&P  &0              @(%YO ( >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( ,F"6%:,OKEG'A$  $3+   9
M      " @7O! @!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ R8)85I-5$V#< P  D X  !D              ("!T-(" 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #)@EA6"_< +CL#  !I"@
M&0              @('CU@( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( ,F"6%8D2@NR]@(  !H+   9              " @57: @!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ R8)85C"#HOCP
M P  G!$  !D              ("!@MT" 'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " #)@EA6V"/X&!T-   1F   &0
M@(&IX0( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( ,F"
M6%8WTS#L)P0  $05   9              " @?WN @!X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ R8)85IVHV^!Y"   '$0  !D
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M=#<W+GAM;%!+ 0(4 Q0    ( ,F"6%;;S,U9, (  -T%   9
M  " @5X6 P!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @
MR8)85NF1QQ+3 P  110  !D              ("!Q1@# 'AL+W=O<FMS:&5E
M=',O<VAE970W.2YX;6Q02P$"% ,4    " #)@EA6I79MN"L%  #&&   &0
M            @('/' , >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4
M Q0    ( ,F"6%:@T9)\:@,  +X*   9              " @3$B P!X;"]W
M;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ R8)85BTV(Y5[!0
M92   !D              ("!TB4# 'AL+W=O<FMS:&5E=',O<VAE970X,BYX
M;6Q02P$"% ,4    " #)@EA6&F.QM0$#  ":"   &0              @(&$
M*P, >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( ,F"6%:[
M%BA4"P4  (X:   9              " @;PN P!X;"]W;W)K<VAE971S+W-H
M965T.#0N>&UL4$L! A0#%     @ R8)85H?.K*O6"0  ^V   !D
M     ("!_C,# 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4
M" #)@EA6XQ&F-!L&  #9(0  &0              @($+/@, >&PO=V]R:W-H
M965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( ,F"6%9SGI,2+@L  %)<   9
M              " @5U$ P!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L!
M A0#%     @ R8)85E**US^) P  V@\  !D              ("!PD\# 'AL
M+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4    " #)@EA6N'K:6[L@
M   =V0$ &0              @(&"4P, >&PO=V]R:W-H965T<R]S:&5E=#@Y
M+GAM;%!+ 0(4 Q0    ( ,F"6%:T APFM D  '!5   9              "
M@71T P!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ R8)8
M5CJ8/]MW#P  '<H  !D              ("!7WX# 'AL+W=O<FMS:&5E=',O
M<VAE970Y,2YX;6Q02P$"% ,4    " #)@EA6,SU< J,#  !L#P  &0
M        @($-C@, >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0
M   ( ,F"6%;Q=^W_:@4  $(>   9              " @>>1 P!X;"]W;W)K
M<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @ R8)85LV?B.V&!   ]1<
M !D              ("!B)<# 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q0
M2P$"% ,4    " #)@EA6$G9X6HD"  !T!@  &0              @(%%G ,
M>&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( ,F"6%; =J\#
M? 0  -,4   9              " @06? P!X;"]W;W)K<VAE971S+W-H965T
M.38N>&UL4$L! A0#%     @ R8)85I-W2KY[ @  E08  !D
M ("!N*,# 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4    " #)
M@EA6]JDR%CD&  "['P  &0              @(%JI@, >&PO=V]R:W-H965T
M<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( ,F"6%;<YC&Y* @  *@]   9
M          " @=JL P!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#
M%     @ R8)85@V#P*C4 @  *P@  !H              ("!.;4# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#%     @ R8)85MYKKL!Z P
MI@T  !H              ("!1;@# 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N
M>&UL4$L! A0#%     @ R8)85DS!'F4%!0  Y14  !H              ("!
M][L# 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ R8)8
M5GI*,?L> P  +@T  !H              ("!-,$# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#,N>&UL4$L! A0#%     @ R8)85KQ,D"2H P  7PP  !H
M         ("!BL0# 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L! A0#
M%     @ R8)85A\[[5#%!   )A4  !H              ("!:L@# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%     @ R8)85J527=QJ @
ME08  !H              ("!9\T# 'AL+W=O<FMS:&5E=',O<VAE970Q,#8N
M>&UL4$L! A0#%     @ R8)85HTDITUE"@  ;5$  !H              ("!
M"= # 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%     @ R8)8
M5KEQBD0? @  I@0  !H              ("!IMH# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#@N>&UL4$L! A0#%     @ R8)85J"C)M%['@  BG@! !H
M         ("!_=P# 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL4$L! A0#
M%     @ R8)85IGZ\Z'?!   L!X  !H              ("!L/L# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#%     @ R8)85DYTGP\%!@
MJR0  !H              ("!QP $ 'AL+W=O<FMS:&5E=',O<VAE970Q,3$N
M>&UL4$L! A0#%     @ R8)85L;<2&#S P  #Q0  !H              ("!
M! <$ 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&UL4$L! A0#%     @ R8)8
M5I?XY\6P!   XQX  !H              ("!+PL$ 'AL+W=O<FMS:&5E=',O
M<VAE970Q,3,N>&UL4$L! A0#%     @ R8)85F;74+-L P  C!8   T
M         ( !%Q $ 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #)@EA6EXJ[
M',     3 @  "P              @ &N$P0 7W)E;',O+G)E;'-02P$"% ,4
M    " #)@EA6)SO'4Z8'  !V2@  #P              @ &7% 0 >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ R8)85B)<<!<I P  6$(  !H
M     ( !:AP$ 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ R8)85O\^K5Z" @  Q3\  !,              ( !RQ\$ %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     'D >0!4(0  ?B($

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1424</ContextCount>
  <ElementCount>692</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>247</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statement of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofIncome</Role>
      <ShortName>Consolidated Statement of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statement of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>Consolidated Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofEquity</Role>
      <ShortName>Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statement of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Statement - Consolidated Statement of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statement of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPolicies</Role>
      <ShortName>Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Spin-Off of Organon &amp; Co.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCo</Role>
      <ShortName>Spin-Off of Organon &amp; Co.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements</Role>
      <ShortName>Acquisitions, Research Collaborations and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangements</Role>
      <ShortName>Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Goodwill and Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangibles</Role>
      <ShortName>Goodwill and Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Loans Payable, Long-Term Debt and Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeases</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Contingencies and Environmental Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities</Role>
      <ShortName>Contingencies and Environmental Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Share-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlans</Role>
      <ShortName>Share-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Pension and Other Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Other (Income) Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other (Income) Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.merck.com/role/SummaryofAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Spin-Off of Organon &amp; Co. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoTables</Role>
      <ShortName>Spin-Off of Organon &amp; Co. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SpinOffofOrganonCo</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables</Role>
      <ShortName>Acquisitions, Research Collaborations and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsTables</Role>
      <ShortName>Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/CollaborativeArrangements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Restructuring</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Inventories</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Goodwill and Other Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesTables</Role>
      <ShortName>Goodwill and Other Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/GoodwillandOtherIntangibles</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/LoansPayableLongTermDebtandLeases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Equity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Share-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansTables</Role>
      <ShortName>Share-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/ShareBasedCompensationPlans</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Other (Income) Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other (Income) Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNet</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/TaxesonIncome</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/EarningsperShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SegmentReporting</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/NatureofOperationsDetails</Role>
      <ShortName>Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/NatureofOperations</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Summary of Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SummaryofAccountingPoliciesDetails</Role>
      <ShortName>Summary of Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/SummaryofAccountingPoliciesPolicies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Spin-Off of Organon &amp; Co. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Collaborative Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails</Role>
      <ShortName>Collaborative Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Collaborative Arrangements - Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails</Role>
      <ShortName>Collaborative Arrangements - Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails</Role>
      <ShortName>Restructuring - Charges Activities by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Restructuring - Activities by Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringActivitiesbyProgramDetails</Role>
      <ShortName>Restructuring - Activities by Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Financial Instruments - Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails</Role>
      <ShortName>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails</Role>
      <ShortName>Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Information on Debt and Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails</Role>
      <ShortName>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Inventories - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesInventoriesDetails</Role>
      <ShortName>Inventories - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails</Role>
      <ShortName>Goodwill and Other Intangibles - Other Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails</Role>
      <ShortName>Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Contingencies and Environmental Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails</Role>
      <ShortName>Contingencies and Environmental Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Equity - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityShareholdersEquityDetails</Role>
      <ShortName>Equity - Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails</Role>
      <ShortName>Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails</Role>
      <ShortName>Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails</Role>
      <ShortName>Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails</Role>
      <ShortName>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails</Role>
      <ShortName>Other (Income) Expense, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails</Role>
      <ShortName>Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Taxes on Income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeNarrativeDetails</Role>
      <ShortName>Taxes on Income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Taxes on Income - Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails</Role>
      <ShortName>Taxes on Income - Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Taxes on Income - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income - Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails</Role>
      <ShortName>Taxes on Income - Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Taxes on Income - Income Tax Authority (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails</Role>
      <ShortName>Taxes on Income - Income Tax Authority (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Taxes on Income - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Calculations of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails</Role>
      <ShortName>Segment Reporting - Sales of Company's Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Consolidated Revenues by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails</Role>
      <ShortName>Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="mrk-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  mrk-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="mrk-20221231.htm">mrk-20221231.htm</File>
    <File>ex23-consentofindependentr.htm</File>
    <File>ex241-powerofattorney11.htm</File>
    <File>ex242-certificationofboard.htm</File>
    <File>ex311-rule13ax14a15dx14ace.htm</File>
    <File>ex312-rule13ax14a15dx14ace.htm</File>
    <File>ex321-section1350certifica.htm</File>
    <File>ex322-section1350certifica.htm</File>
    <File>exhibit1013-plansepmrk2019.htm</File>
    <File>exhibit1023-2019annualceon.htm</File>
    <File>exhibit1024-2019annualrsut.htm</File>
    <File>exhibit1025-2020annualnqso.htm</File>
    <File>exhibit1026-2020annualceon.htm</File>
    <File>exhibit1027-2020annualrsut.htm</File>
    <File>exhibit1028-2020psutermsan.htm</File>
    <File>exhibit1029-2020annualceop.htm</File>
    <File>exhibit1030-2021annualceon.htm</File>
    <File>exhibit1031-2021annualpsut.htm</File>
    <File>exhibit1032-2021annualceop.htm</File>
    <File>exhibit1033-2021specialret.htm</File>
    <File>exhibit1034restrictedstock.htm</File>
    <File>exhibit1035-2022annualrsut.htm</File>
    <File>exhibit1036-2022annualpsut.htm</File>
    <File>exhibit1037-mrkchirfiguind.htm</File>
    <File>exhibit107-2017annualnqsot.htm</File>
    <File>exhibit108-2019annualnqsot.htm</File>
    <File>exhibit21-clean2x22x23.htm</File>
    <File>mrk-20221231.xsd</File>
    <File>mrk-20221231_cal.xml</File>
    <File>mrk-20221231_def.xml</File>
    <File>mrk-20221231_lab.xml</File>
    <File>mrk-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrk-20221231_g1.jpg</File>
    <File>mrk-20221231_g2.jpg</File>
    <File>mrk-20221231_g3.jpg</File>
    <File>mrk-20221231_g4.jpg</File>
    <File>mrk-20221231_g5.jpg</File>
    <File>mrk-20221231_g6.jpg</File>
    <File>mrk-20221231_g7.gif</File>
    <File>mrk-20221231_g8.jpg</File>
    <File>mrk-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3171">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="49">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>166
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrk-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 49,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 3171,
    "http://xbrl.sec.gov/dei/2022": 49
   },
   "contextCount": 1424,
   "dts": {
    "calculationLink": {
     "local": [
      "mrk-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrk-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrk-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrk-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrk-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrk-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 1160,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 75,
    "http://www.merck.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 80
   },
   "keyCustom": 96,
   "keyStandard": 596,
   "memberCustom": 146,
   "memberStandard": 94,
   "nsprefix": "mrk",
   "nsuri": "http://www.merck.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.merck.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000010 - Statement - Consolidated Statement of Cash Flows (Parenthetical)",
     "menuCat": "Statements",
     "order": "10",
     "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical",
     "shortName": "Consolidated Statement of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Taxes on Income - Income Before Taxes (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails",
     "shortName": "Taxes on Income - Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Taxes on Income - Taxes on Income (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails",
     "shortName": "Taxes on Income - Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
     "shortName": "Taxes on Income - Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Taxes on Income - Income Tax Authority (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
     "shortName": "Taxes on Income - Income Tax Authority (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails",
     "shortName": "Taxes on Income - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
     "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - Earnings Per Share - Narrative (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - Segment Reporting - Narrative (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - Segment Reporting - Sales of Company's Products (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
     "shortName": "Segment Reporting - Sales of Company's Products (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrk:IncreaseDecreaseInHedgeRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Nature of Operations",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.merck.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Consolidated Revenues by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ia689dc2ff1e4458792332eba5e96c16b_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
     "shortName": "Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i2f49f49133634761b181692557d66dda_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Summary of Accounting Policies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.merck.com/role/SummaryofAccountingPolicies",
     "shortName": "Summary of Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Spin-Off of Organon & Co.",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.merck.com/role/SpinOffofOrganonCo",
     "shortName": "Spin-Off of Organon & Co.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements",
     "shortName": "Acquisitions, Research Collaborations and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Collaborative Arrangements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.merck.com/role/CollaborativeArrangements",
     "shortName": "Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.merck.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.merck.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.merck.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Goodwill and Other Intangibles",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangibles",
     "shortName": "Goodwill and Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.merck.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Loans Payable, Long-Term Debt and Leases",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeases",
     "shortName": "Loans Payable, Long-Term Debt and Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Contingencies and Environmental Liabilities",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities",
     "shortName": "Contingencies and Environmental Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.merck.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Share-Based Compensation Plans",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlans",
     "shortName": "Share-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Pension and Other Postretirement Benefit Plans",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans",
     "shortName": "Pension and Other Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Other (Income) Expense, Net",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNet",
     "shortName": "Other (Income) Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Taxes on Income",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.merck.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Earnings per Share",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.merck.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Other Comprehensive Income (Loss)",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.merck.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statement of Income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.merck.com/role/ConsolidatedStatementofIncome",
     "shortName": "Consolidated Statement of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrk:CostsExpensesAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies",
     "shortName": "Summary of Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Spin-Off of Organon & Co. (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoTables",
     "shortName": "Spin-Off of Organon & Co. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables",
     "shortName": "Acquisitions, Research Collaborations and Licensing Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Collaborative Arrangements (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.merck.com/role/CollaborativeArrangementsTables",
     "shortName": "Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Restructuring (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.merck.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.merck.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.merck.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Goodwill and Other Intangibles (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesTables",
     "shortName": "Goodwill and Other Intangibles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables",
     "shortName": "Loans Payable, Long-Term Debt and Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.merck.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statement of Comprehensive Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
     "shortName": "Consolidated Statement of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Share-Based Compensation Plans (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables",
     "shortName": "Share-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables",
     "shortName": "Pension and Other Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Other (Income) Expense, Net (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables",
     "shortName": "Other (Income) Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Taxes on Income (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.merck.com/role/TaxesonIncomeTables",
     "shortName": "Taxes on Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Earnings per Share (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.merck.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.merck.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Nature of Operations (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.merck.com/role/NatureofOperationsDetails",
     "shortName": "Nature of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "mrk:SalesDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Summary of Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.merck.com/role/SummaryofAccountingPoliciesDetails",
     "shortName": "Summary of Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "mrk:SalesDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i05ee48b166b44fbaa88adeaa6cccbcca_I20210602",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
     "shortName": "Spin-Off of Organon & Co. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i05ee48b166b44fbaa88adeaa6cccbcca_I20210602",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheet",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.merck.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails",
     "shortName": "Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
     "shortName": "Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i58fae9f157404c948f717699cc8b6041_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ibfdc0787087a47d68adfea5ef5195bef_I20211119",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Collaborative Arrangements - Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
     "shortName": "Collaborative Arrangements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i0bd89ab9867a451bb7d8f5e7dd23cfa9_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Collaborative Arrangements - Financial Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
     "shortName": "Collaborative Arrangements - Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ie0cbe6f30ebf448ca8dd317840d491e8_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Restructuring - Narrative (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.merck.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
     "shortName": "Restructuring - Charges Activities by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Restructuring - Activities by Program (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
     "shortName": "Restructuring - Activities by Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Financial Instruments - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i966c0574579842adb1aad8f47b86bae5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
     "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i966c0574579842adb1aad8f47b86bae5_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Balance Sheet (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
     "shortName": "Consolidated Balance Sheet (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
     "shortName": "Financial Instruments - Fair Value of Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
     "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
     "shortName": "Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i926eff1a8ec14b039e29169742609ad8_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ieead02c0663c47e4a289f16813bc7306_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ieead02c0663c47e4a289f16813bc7306_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Information on Debt and Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iba235620efd64c3b8e1fc94776a989c6_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
     "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Inventories - Inventories (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.merck.com/role/InventoriesInventoriesDetails",
     "shortName": "Inventories - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LIFOInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Inventories - Narrative (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.merck.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LIFOInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i50a206ace8ff4b2b880a7d891b6470c1_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statement of Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.merck.com/role/ConsolidatedStatementofEquity",
     "shortName": "Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i870984a7a0814cf9a460c7a4b331c37f_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
     "shortName": "Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
     "shortName": "Goodwill and Other Intangibles - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
     "shortName": "Goodwill and Other Intangibles - Other Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iedd526ebaff749a5b3eafa6e57a81046_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:AssetsandLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:AssetsandLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails",
     "shortName": "Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccrualForEnvironmentalLossContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Contingencies and Environmental Liabilities (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
     "shortName": "Contingencies and Environmental Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccrualForEnvironmentalLossContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.merck.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Equity - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.merck.com/role/EquityShareholdersEquityDetails",
     "shortName": "Equity - Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i870984a7a0814cf9a460c7a4b331c37f_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statement of Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical",
     "shortName": "Consolidated Statement of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Share-Based Compensation Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
     "shortName": "Share-Based Compensation Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails",
     "shortName": "Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails",
     "shortName": "Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails",
     "shortName": "Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ied7d80ed2ab14e968047a6b71fb4fea8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails",
     "shortName": "Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ied7d80ed2ab14e968047a6b71fb4fea8_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i047b115329a54c42a89e9abfb277e348_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ieac41e3734b14c5880a3e1babce1d967_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ieac41e3734b14c5880a3e1babce1d967_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iebb1a8351aa841838361b44de4c7bef0_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i2db1b4d2bd9c40969669b8308c8c2bfc_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statement of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
     "shortName": "Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if1c3c2b238964beeb4fe2cc7ee98547f_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "icedae49afe70492a8921f596e854194f_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i44f98c489cc64681a483c72df528f6e3_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i00c54d6e8143424db472e467e5653785_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i00c54d6e8143424db472e467e5653785_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
     "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Other (Income) Expense, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
     "shortName": "Other (Income) Expense, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails",
     "shortName": "Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Taxes on Income - Narrative (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
     "shortName": "Taxes on Income - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20221231.htm",
      "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 247,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CO": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COLOMBIA",
        "terseLabel": "COLOMBIA"
       }
      }
     },
     "localname": "CO",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r1009"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1000"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1003"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrk_A0.500Notesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2024 [Member]",
        "label": "0.500% Notes due 2024 [Member]",
        "terseLabel": "0.500% Notes due 2024"
       }
      }
     },
     "localname": "A0.500Notesdue2024Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A0.50eurodenominatednotesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.50% euro-denominated notes due 2024 [Member]",
        "label": "0.50% euro-denominated notes due 2024 [Member]",
        "terseLabel": "0.50% euro-denominated notes due 2024"
       }
      }
     },
     "localname": "A0.50eurodenominatednotesdue2024Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A075NotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Notes due 2026",
        "label": "0.75% Notes due 2026 [Member]",
        "terseLabel": "0.75% notes due 2026"
       }
      }
     },
     "localname": "A075NotesDue2026Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2036 [Member]",
        "label": "1.375% Notes due 2036 [Member]",
        "terseLabel": "1.375% Notes due 2036"
       }
      }
     },
     "localname": "A1.375Notesdue2036Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375eurodenominatednotesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% euro-denominated notes due 2036 [Member]",
        "label": "1.375% euro-denominated notes due 2036 [Member]",
        "terseLabel": "1.375% euro-denominated notes due 2036"
       }
      }
     },
     "localname": "A1.375eurodenominatednotesdue2036Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875EuroNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Euro Notes Due 2026 [Member]",
        "label": "1.875% Euro Notes Due 2026 [Member]",
        "terseLabel": "1.875% euro-denominated notes due 2026"
       }
      }
     },
     "localname": "A1.875EuroNotesDue2026Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Notes due 2026 [Member]",
        "label": "1.875% Notes due 2026 [Member]",
        "terseLabel": "1.875% Notes due 2026"
       }
      }
     },
     "localname": "A1.875Notesdue2026Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A145NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.45% Notes Due 2030",
        "label": "1.45% Notes Due 2030 [Member]",
        "terseLabel": "1.45% notes due 2030"
       }
      }
     },
     "localname": "A145NotesDue2030Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A170NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.70% notes due 2027",
        "label": "1.70% notes due 2027 [Member]",
        "terseLabel": "1.70% notes due 2027"
       }
      }
     },
     "localname": "A170NotesDue2027Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A190NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.90% notes due 2028",
        "label": "1.90% notes due 2028 [Member]",
        "terseLabel": "1.90% notes due 2028"
       }
      }
     },
     "localname": "A190NotesDue2028Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.35NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2022 [Member]",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% notes due 2022"
       }
      }
     },
     "localname": "A2.35NotesDue2022Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.40NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.40% Notes Due 2022 [Member]",
        "label": "2.40% Notes Due 2022 [Member]",
        "terseLabel": "2.40% Notes Due 2022"
       }
      }
     },
     "localname": "A2.40NotesDue2022Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.500Notesdue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.500% Notes due 2034 [Member]",
        "label": "2.500% Notes due 2034 [Member]",
        "terseLabel": "2.500% Notes due 2034"
       }
      }
     },
     "localname": "A2.500Notesdue2034Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.5EuroNotesDue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.5% Euro Notes Due 2034 [Member]",
        "label": "2.5% Euro Notes Due 2034 [Member]",
        "terseLabel": "2.50% euro-denominated notes due 2034"
       }
      }
     },
     "localname": "A2.5EuroNotesDue2034Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.75NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% Notes Due 2025 [Member]",
        "label": "2.75% Notes Due 2025 [Member]",
        "terseLabel": "2.75% notes due 2025"
       }
      }
     },
     "localname": "A2.75NotesDue2025Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.90NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% Notes Due 2024",
        "label": "2.90% Notes Due 2024 [Member]",
        "terseLabel": "2.90% notes due 2024"
       }
      }
     },
     "localname": "A2.90NotesDue2024Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A215NotesDue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.15% notes due 2031",
        "label": "2.15% notes due 2031 [Member]",
        "terseLabel": "2.15% notes due 2031"
       }
      }
     },
     "localname": "A215NotesDue2031Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A235NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.35% Notes Due 2040",
        "label": "2.35% Notes Due 2040 [Member]",
        "terseLabel": "2.35% notes due 2040"
       }
      }
     },
     "localname": "A235NotesDue2040Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A245NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes Due 2050",
        "label": "2.45% Notes Due 2050 [Member]",
        "terseLabel": "2.45% notes due 2050"
       }
      }
     },
     "localname": "A245NotesDue2050Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A275NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.75% notes due 2051",
        "label": "2.75% notes due 2051 [Member]",
        "terseLabel": "2.75% notes due 2051"
       }
      }
     },
     "localname": "A275NotesDue2051Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A280NotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Notes Due 2023 [Member]",
        "label": "2.80% Notes Due 2023 [Member]",
        "terseLabel": "2.80% notes due 2023"
       }
      }
     },
     "localname": "A280NotesDue2023Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A290NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.90% notes due 2061",
        "label": "2.90% notes due 2061 [Member]",
        "terseLabel": "2.90% notes due 2061"
       }
      }
     },
     "localname": "A290NotesDue2061Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.40NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.40% Notes Due 2029",
        "label": "3.40% Notes Due 2029 [Member]",
        "terseLabel": "3.40% notes due 2029"
       }
      }
     },
     "localname": "A3.40NotesDue2029Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.70NotesDue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes Due 2045 [Member]",
        "label": "3.70% Notes Due 2045 [Member]",
        "terseLabel": "3.70% notes due 2045"
       }
      }
     },
     "localname": "A3.70NotesDue2045Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.90NotesDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.90% Notes Due 2039",
        "label": "3.90% Notes Due 2039 [Member]",
        "terseLabel": "3.90% notes due 2039"
       }
      }
     },
     "localname": "A3.90NotesDue2039Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A4.00NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.00% Notes Due 2049",
        "label": "4.00% Notes Due 2049 [Member]",
        "terseLabel": "4.00% notes due 2049"
       }
      }
     },
     "localname": "A4.00NotesDue2049Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A415NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2043 [Member]",
        "label": "4.15% Notes Due 2043 [Member]",
        "terseLabel": "4.15% notes due 2043"
       }
      }
     },
     "localname": "A415NotesDue2043Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A63DebenturesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point three percentage debentures due on two thousand and twenty six.",
        "label": "6.3% Debentures Due 2026 [Member]",
        "terseLabel": "6.30% debentures due 2026"
       }
      }
     },
     "localname": "A63DebenturesDue2026Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedDepreciationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Depreciation [Member]",
        "label": "Accelerated Depreciation [Member]",
        "terseLabel": "Accelerated Depreciation"
       }
      }
     },
     "localname": "AcceleratedDepreciationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleronPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acceleron Pharma Inc.",
        "label": "Acceleron Pharma Inc. [Member]",
        "terseLabel": "Acceleron Pharma Inc."
       }
      }
     },
     "localname": "AcceleronPharmaIncMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AccrualForChargebacks": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for chargebacks reflected as a direction reduction to accounts receivable.",
        "label": "Accrual For Chargebacks",
        "terseLabel": "Accrual for chargebacks reflected as direct reduction to accounts receivable"
       }
      }
     },
     "localname": "AccrualForChargebacks",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AccrualForRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for rebates recorded as current liability.",
        "label": "Accrual For Rebates",
        "terseLabel": "Accrual for rebates included in accrued and other current liabilities"
       }
      }
     },
     "localname": "AccrualForRebates",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to acquisitions, research collaborations and license agreements.",
        "label": "Acquisitions Research Collaborations And License Agreements [Text Block]",
        "terseLabel": "Acquisitions, Research Collaborations and Licensing Agreements"
       }
      }
     },
     "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adempas",
        "label": "Adempas [Member]",
        "terseLabel": "Adempas"
       }
      }
     },
     "localname": "AdempasMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueAdempasVerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Adempas/Verquvo",
        "label": "Alliance revenue - Adempas/Verquvo [Member]",
        "terseLabel": "Alliance revenue - Adempas/Verquvo"
       }
      }
     },
     "localname": "AllianceRevenueAdempasVerquvoMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueKoselugoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Koselugo",
        "label": "Alliance revenue - Koselugo [Member]",
        "terseLabel": "Alliance revenue - Koselugo"
       }
      }
     },
     "localname": "AllianceRevenueKoselugoMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AlliancerevenueLynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Lynparza [Member]",
        "label": "Alliance revenue - Lynparza [Member]",
        "terseLabel": "Alliance revenue - Lynparza"
       }
      }
     },
     "localname": "AlliancerevenueLynparzaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corporation",
        "label": "AmerisourceBergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AnimalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health [Member]",
        "label": "Animal Health [Member]",
        "terseLabel": "Animal Health"
       }
      }
     },
     "localname": "AnimalHealthMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AnimalHealthsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health segment [Member]",
        "label": "Animal Health segment [Member]",
        "terseLabel": "Animal Health"
       }
      }
     },
     "localname": "AnimalHealthsegmentMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArQuleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ArQule [Member]",
        "label": "ArQule [Member]",
        "terseLabel": "ArQule"
       }
      }
     },
     "localname": "ArQuleMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArtivaBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Artiva Biotherapeutics, Inc.",
        "label": "Artiva Biotherapeutics, Inc. [Member]",
        "terseLabel": "Artiva Biotherapeutics, Inc."
       }
      }
     },
     "localname": "ArtivaBiotherapeuticsIncMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net",
        "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net",
        "terseLabel": "Net assets acquired"
       }
      }
     },
     "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Other Assets and Liabilities Recognized, Net",
        "label": "Asset Acquisition, Other Assets and Liabilities Recognized, Net",
        "terseLabel": "Other net assets (liabilities)"
       }
      }
     },
     "localname": "AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AssetsandLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee [Table Text Block]",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsandLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.merck.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mrk_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG [Member]",
        "label": "Bayer AG [Member]",
        "terseLabel": "Bayer AG"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BelsomraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Belsomra [Member]",
        "label": "Belsomra [Member]",
        "terseLabel": "Belsomra"
       }
      }
     },
     "localname": "BelsomraMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BridionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridion [Member].",
        "label": "Bridion [Member]",
        "terseLabel": "Bridion"
       }
      }
     },
     "localname": "BridionMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb",
        "label": "Bristol Myers Squibb [Member]",
        "terseLabel": "Bristol Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "negatedTerseLabel": "Other net liabilities",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CancidasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancidas [Member].",
        "label": "Cancidas [Member]",
        "terseLabel": "Cancidas"
       }
      }
     },
     "localname": "CancidasMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health, Inc.",
        "label": "Cardinal Health, Inc. [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ChargesRelatedToProgramDiscontinuation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to program discontinuation",
        "label": "Charges related to program discontinuation",
        "terseLabel": "Charges related to program discontinuation"
       }
      }
     },
     "localname": "ChargesRelatedToProgramDiscontinuation",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementNumberOfCollaborationTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Collaboration Targets",
        "label": "Collaborative Arrangement, Number Of Collaboration Targets",
        "terseLabel": "Number of collaboration targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfCollaborationTargets",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_CollaborativeArrangementNumberOfResearchPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Research Programs",
        "label": "Collaborative Arrangement, Number Of Research Programs",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfResearchPrograms",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Preferred Stock Investment In Counterparty",
        "label": "Collaborative Arrangement, Preferred Stock Investment In Counterparty",
        "terseLabel": "Preferred stock investment in counterparty"
       }
      }
     },
     "localname": "CollaborativeArrangementPreferredStockInvestmentInCounterparty",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementProfitSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Profit Sharing",
        "label": "Collaborative Arrangement, Profit Sharing",
        "terseLabel": "Alliance revenue - profit sharing"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitSharing",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Regulatory Milestone Payments Accrued",
        "label": "Collaborative Arrangement, Regulatory Milestone Payments Accrued",
        "terseLabel": "Regulatory milestone payments accrued"
       }
      }
     },
     "localname": "CollaborativeArrangementRegulatoryMilestonePaymentsAccrued",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments",
        "terseLabel": "Eligible future contingent development-related payments (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Regulatory milestones payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Sales, Net",
        "label": "Collaborative Arrangement, Sales, Net",
        "terseLabel": "Net sales by Merck"
       }
      }
     },
     "localname": "CollaborativeArrangementSalesNet",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Abstract]",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.merck.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mrk_CommercialandOtherLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial and Other Litigation [Member]",
        "label": "Commercial and Other Litigation [Member]",
        "terseLabel": "Commercial Litigation"
       }
      }
     },
     "localname": "CommercialandOtherLitigationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CompanionAnimalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Companion Animals [Member]",
        "label": "Companion Animals [Member]",
        "terseLabel": "Companion Animals"
       }
      }
     },
     "localname": "CompanionAnimalsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company pension investments which are categorized as level three assets percentage.",
        "label": "Company Pension Investments Which Are Categorized As Level Three Assets Percentage",
        "terseLabel": "Percentage of Company's pension investments categorized as level 3 assets"
       }
      }
     },
     "localname": "CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Line Items]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Table]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discussion of the accounting policy for contingent consideration.",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_ContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.",
        "label": "Contingent Payments Collaborative Arrangement",
        "terseLabel": "Contingent payments collaborative arrangement"
       }
      }
     },
     "localname": "ContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CorporateObligationsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate obligations fixed income securities.",
        "label": "Corporate Obligations Fixed Income Securities [Member]",
        "terseLabel": "Corporate obligations"
       }
      }
     },
     "localname": "CorporateObligationsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CorporateObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate obligations investment funds.",
        "label": "Corporate Obligations Investment Funds [Member]",
        "terseLabel": "Corporate obligations"
       }
      }
     },
     "localname": "CorporateObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CostsExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.",
        "label": "Costs Expenses And Other",
        "totalLabel": "Total costs, expenses and other"
       }
      }
     },
     "localname": "CostsExpensesAndOther",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DebtSecuritiesandEquitySecuritiesFVNI": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities and Equity Securities, FV-NI",
        "label": "Debt Securities and Equity Securities, FV-NI",
        "totalLabel": "Total debt and publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesandEquitySecuritiesFVNI",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes And Other Assets, Noncurrent",
        "label": "Deferred Income Taxes And Other Assets, Noncurrent [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes Assets And Liabilities Net [Table]",
        "label": "Deferred Income Taxes Assets And Liabilities Net [Table]",
        "terseLabel": "Deferred Income Taxes Assets And Liabilities Net [Table]"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAssetsAndLiabilitiesNetTable",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards and other tax credit carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards",
        "terseLabel": "Net operating losses and other tax credit carryforwards, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxAssetsUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets unrecognized tax benefits.",
        "label": "Deferred Tax Assets Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrecognizedTaxBenefits",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxLiabilitiesEquityMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Equity Method Investment",
        "label": "Deferred Tax Liabilities, Equity Method Investment",
        "terseLabel": "Equity method investments, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesEquityMethodInvestment",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.",
        "label": "Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans",
        "terseLabel": "Pensions and other postretirement benefits, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic",
        "label": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic",
        "terseLabel": "Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards"
       }
      }
     },
     "localname": "DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DefinedBenefitPlanCashandOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Cash and Other Investments [Member]",
        "label": "Defined Benefit Plan, Cash and Other Investments [Member]",
        "terseLabel": "Cash And Other Investments"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashandOtherInvestmentsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DefinedBenefitPlanOtherChangesPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in plan assets, not otherwise separately disclosed in the financial statements.",
        "label": "Defined Benefit Plan Other Changes Plan Assets",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherChangesPlanAssets",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DerazantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derazantinib",
        "label": "Derazantinib [Member]",
        "terseLabel": "Derazantinib"
       }
      }
     },
     "localname": "DerazantinibMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DerivativeNotionalAmountMatured": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Notional Amount Matured",
        "label": "Derivative Notional Amount Matured",
        "terseLabel": "Total notional amount of Interest rate derivatives matured"
       }
      }
     },
     "localname": "DerivativeNotionalAmountMatured",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DevelopedMarketsEquitiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed markets equities investment funds.",
        "label": "Developed Markets Equities Investment Funds [Member]",
        "terseLabel": "Developed markets equities"
       }
      }
     },
     "localname": "DevelopedMarketsEquitiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DevelopedMarketsEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed markets equity securities.",
        "label": "Developed Markets Equity Securities [Member]",
        "terseLabel": "Developed markets"
       }
      }
     },
     "localname": "DevelopedMarketsEquitySecuritiesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DificidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dificid [Member]",
        "label": "Dificid [Member]",
        "terseLabel": "Dificid"
       }
      }
     },
     "localname": "DificidMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Including Discontinued Operations Distribution Received",
        "label": "Disposal Group Including Discontinued Operations Distribution Received",
        "terseLabel": "Distribution from Organon &amp; Co."
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsDistributionReceived",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Research and Development Expenses",
        "label": "Disposal Group, Including Discontinued Operations, Research and Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Restructuring Costs",
        "label": "Disposal Group, Including Discontinued Operations, Restructuring Costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DunboyneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dunboyne",
        "label": "Dunboyne [Member]",
        "terseLabel": "Dunboyne"
       }
      }
     },
     "localname": "DunboyneMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent",
        "terseLabel": "Acquisition of VelosBio"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Four",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Four",
        "terseLabel": "Acquisition of Pandion"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationFour",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Four, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Four, Percent",
        "terseLabel": "Acquisition of Pandion"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Two",
        "terseLabel": "Acquisition of OncoImmune"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent",
        "terseLabel": "Acquisition of OncoImmune"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]",
        "terseLabel": "Differential arising from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]",
        "terseLabel": "Differential arising from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount",
        "terseLabel": "GILTI and the foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent",
        "terseLabel": "GILTI and the foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EmergingMarketsEquitiesInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging markets equities investment funds.",
        "label": "Emerging Markets Equities Investment Funds [Member]",
        "terseLabel": "Emerging markets equities"
       }
      }
     },
     "localname": "EmergingMarketsEquitiesInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "label": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "terseLabel": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will be noncash.",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash",
        "terseLabel": "Estimate of cumulative pre tax costs that will be noncash"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays",
        "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EurodominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro-dominated Notes [Member]",
        "label": "Euro-dominated Notes [Member]",
        "terseLabel": "Euro-denominated notes"
       }
      }
     },
     "localname": "EurodominatedNotesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.",
        "label": "Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests",
        "terseLabel": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests"
       }
      }
     },
     "localname": "ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_FirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Commercial Sale Milestones",
        "label": "First Commercial Sale Milestones [Member]",
        "terseLabel": "First Commercial Sale Milestones"
       }
      }
     },
     "localname": "FirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point eight five percentage notes due on two thousand and thirty nine.",
        "label": "Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member]",
        "terseLabel": "5.85% notes due 2039"
       }
      }
     },
     "localname": "FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point nine five percentage debentures due on two thousand and twenty eight.",
        "label": "Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member]",
        "terseLabel": "5.95% debentures due 2028"
       }
      }
     },
     "localname": "FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point seven five percentage notes due on two thousand and thirty six.",
        "label": "Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member]",
        "terseLabel": "5.75% notes due 2036"
       }
      }
     },
     "localname": "FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FixedIncomeObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed income obligations investment funds.",
        "label": "Fixed Income Obligations Investment Funds [Member]",
        "terseLabel": "Other fixed income obligations"
       }
      }
     },
     "localname": "FixedIncomeObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GardasilGardasil9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gardasil/Gardasil 9 [Member].",
        "label": "Gardasil/Gardasil 9 [Member]",
        "terseLabel": "Gardasil/Gardasil 9"
       }
      }
     },
     "localname": "GardasilGardasil9Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GefapixantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "gefapixant",
        "label": "gefapixant [Member]",
        "terseLabel": "gefapixant"
       }
      }
     },
     "localname": "GefapixantMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GileadSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences",
        "label": "Gilead Sciences [Member]",
        "terseLabel": "Gilead Sciences"
       }
      }
     },
     "localname": "GileadSciencesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and agency obligations fixed income securities.",
        "label": "Government And Agency Obligations Fixed Income Securities [Member]",
        "terseLabel": "Government and agency obligations"
       }
      }
     },
     "localname": "GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GovernmentAndAgencyObligationsInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and agency obligations investment funds.",
        "label": "Government And Agency Obligations Investment Funds [Member]",
        "terseLabel": "Government and agency obligations"
       }
      }
     },
     "localname": "GovernmentAndAgencyObligationsInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IAVI [Member]",
        "label": "IAVI [Member]",
        "terseLabel": "IAVI"
       }
      }
     },
     "localname": "IAVIMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ImagoBioSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imago BioSciences, Inc.",
        "label": "Imago BioSciences, Inc. [Member]",
        "terseLabel": "Imago BioSciences, Inc."
       }
      }
     },
     "localname": "ImagoBioSciencesIncMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IncomeTaxRateReconciliationAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Rate Reconciliation, Asset Acquisition",
        "label": "Income Tax Rate Reconciliation, Asset Acquisition",
        "terseLabel": "Acquisition of VelosBio"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationAssetAcquisition",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_IncomeTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Payable [Member]",
        "label": "Income Taxes Payable [Member]",
        "terseLabel": "Income Taxes Payable"
       }
      }
     },
     "localname": "IncomeTaxesPayableMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IncreaseDecreaseInHedgeRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Hedge Revenue",
        "label": "Increase (Decrease) In Hedge Revenue",
        "terseLabel": "Increase (decrease) in revenue hedging activities"
       }
      }
     },
     "localname": "IncreaseDecreaseInHedgeRevenue",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InjectableFormulationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "injectable formulation",
        "label": "injectable formulation [Member]",
        "terseLabel": "Injectable Formulation"
       }
      }
     },
     "localname": "InjectableFormulationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InsuranceContractsOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance contracts other investments.",
        "label": "Insurance Contracts Other Investments [Member]",
        "terseLabel": "Insurance contracts",
        "verboseLabel": "Insurance Contracts"
       }
      }
     },
     "localname": "InsuranceContractsOtherInvestmentsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input",
        "label": "Intangible Asset, Measurement Input",
        "terseLabel": "Present value discount rate",
        "verboseLabel": "Discount rate"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInput",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mrk_IntangibleAssetProductsAndProductRightsMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Products and Product rights, Measurement Input",
        "label": "Intangible Asset, Products and Product rights, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "IntangibleAssetProductsAndProductRightsMeasurementInput",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mrk_IntangibleAssetsExcludingGoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Excluding Goodwill [Line Items]",
        "label": "Intangible Assets Excluding Goodwill [Line Items]",
        "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillLineItems",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International [Member]",
        "label": "International [Member]",
        "terseLabel": "Int\u2019l"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InvanzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invanz [Member].",
        "label": "Invanz [Member]",
        "terseLabel": "Invanz"
       }
      }
     },
     "localname": "InvanzMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoriesProducedinPreparationforProductLaunchesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories Produced in Preparation for Product Launches [Member]",
        "label": "Inventories Produced in Preparation for Product Launches [Member]",
        "terseLabel": "Inventories Produced in Preparation for Product Launches"
       }
      }
     },
     "localname": "InventoriesProducedinPreparationforProductLaunchesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of current and noncurrent inventories.",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total current and noncurrent inventories"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Not Expected to be Sold Within One Year [Member]",
        "label": "Inventory Not Expected to be Sold Within One Year [Member]",
        "terseLabel": "Inventory Not Expected to be Sold Within One Year"
       }
      }
     },
     "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory [Table]",
        "label": "Inventory [Table]",
        "terseLabel": "Inventory [Table]"
       }
      }
     },
     "localname": "InventoryTable",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IsentressIsentressHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Isentress/Isentress HD [Member].",
        "label": "Isentress/Isentress HD [Member]",
        "terseLabel": "Isentress/Isentress HD"
       }
      }
     },
     "localname": "IsentressIsentressHDMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janumet [Member].",
        "label": "Janumet [Member]",
        "terseLabel": "Janumet"
       }
      }
     },
     "localname": "JanumetMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Januvia [Member] .",
        "label": "Januvia [Member]",
        "terseLabel": "Januvia"
       }
      }
     },
     "localname": "JanuviaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_KeytrudaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Keytruda [Member]",
        "label": "Keytruda [Member]",
        "terseLabel": "Keytruda"
       }
      }
     },
     "localname": "KeytrudaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LagevrioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lagevrio",
        "label": "Lagevrio [Member]",
        "terseLabel": "Lagevrio"
       }
      }
     },
     "localname": "LagevrioMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LegalDefenseCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Defense Costs [Member]",
        "label": "Legal Defense Costs [Member]",
        "terseLabel": "Legal Defense Costs"
       }
      }
     },
     "localname": "LegalDefenseCostsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LenvimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lenvima [Member]",
        "label": "Lenvima [Member]",
        "terseLabel": "Alliance revenue - Lenvima",
        "verboseLabel": "Lenvima"
       }
      }
     },
     "localname": "LenvimaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "terseLabel": "Lessee, operating lease, lease not yet commenced, amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotyetCommencedAmount",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License option payment related to collaborative arrangement",
        "label": "License option payment related to collaborative arrangement",
        "terseLabel": "License option payment related to collaborative arrangement"
       }
      }
     },
     "localname": "LicenseOptionPaymentRelatedToCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LivestockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Livestock [Member]",
        "label": "Livestock [Member]",
        "terseLabel": "Livestock"
       }
      }
     },
     "localname": "LivestockMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Current Maturities [Member]",
        "label": "Long Term Debt, Current Maturities [Member]",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtInterestPayableYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Five",
        "label": "Long-term Debt, Interest Payable, Year Five",
        "terseLabel": "Long-term debt, interest payments in 2027"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearFive",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Four",
        "label": "Long-term Debt, Interest Payable, Year Four",
        "terseLabel": "Long-term debt, interest payments in 2026"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearFour",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year One",
        "label": "Long-term Debt, Interest Payable, Year One",
        "terseLabel": "Long-term debt, interest payments in 2023"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearOne",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Three",
        "label": "Long-term Debt, Interest Payable, Year Three",
        "terseLabel": "Long-term debt, interest payments in 2025"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearThree",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LongTermDebtInterestPayableYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Interest Payable, Year Two",
        "label": "Long-term Debt, Interest Payable, Year Two",
        "terseLabel": "Long-term debt, interest payments in 2024"
       }
      }
     },
     "localname": "LongTermDebtInterestPayableYearTwo",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LossContingencyTrialPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Trial Period",
        "label": "Loss Contingency, Trial Period",
        "terseLabel": "Loss contingency, trial period"
       }
      }
     },
     "localname": "LossContingencyTrialPeriod",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_LynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lynparza [Member]",
        "label": "Lynparza [Member]",
        "terseLabel": "Lynparza"
       }
      }
     },
     "localname": "LynparzaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ManufacturingAndSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and supply agreements",
        "label": "Manufacturing and supply agreements [Member]",
        "terseLabel": "Manufacturing and supply agreements"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MilestonePaymentToBeMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment To Be Made to Collaborative Partner",
        "label": "Milestone Payment To Be Made to Collaborative Partner",
        "terseLabel": "Milestone payment to be made to collaborative partner"
       }
      }
     },
     "localname": "MilestonePaymentToBeMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsMadetoCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Made to Collaborative Partner",
        "label": "Milestone Payments Made to Collaborative Partner",
        "terseLabel": "Milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "MilestonePaymentsMadetoCollaborativePartner",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ModernaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Moderna",
        "label": "Moderna [Member]",
        "terseLabel": "Moderna"
       }
      }
     },
     "localname": "ModernaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and asset backed securities fixed income securities.",
        "label": "Mortgage And Asset Backed Securities Fixed Income Securities [Member]",
        "verboseLabel": "Mortgage and asset-backed securities"
       }
      }
     },
     "localname": "MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MovementinCommonStockandTreasuryStockRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in Common Stock and Treasury Stock [Roll Forward]",
        "label": "Movement in Common Stock and Treasury Stock [Roll Forward]",
        "terseLabel": "Movement in Common Stock and Treasury Stock [Roll Forward]"
       }
      }
     },
     "localname": "MovementinCommonStockandTreasuryStockRollForward",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_NemtabrutinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "nemtabrutinib",
        "label": "nemtabrutinib [Member]",
        "terseLabel": "nemtabrutinib"
       }
      }
     },
     "localname": "NemtabrutinibMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NotesSubjectToRepaymentAtOptionOfHolderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Subject To Repayment At Option Of Holder [Member]",
        "label": "Notes Subject To Repayment At Option Of Holder [Member]",
        "terseLabel": "Notes Subject To Repayment At Option Of Holder"
       }
      }
     },
     "localname": "NotesSubjectToRepaymentAtOptionOfHolderMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NoxafilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noxafil [Member].",
        "label": "Noxafil [Member]",
        "terseLabel": "Noxafil"
       }
      }
     },
     "localname": "NoxafilMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NumberOfInterestRateDerivativesMatured": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivatives that matured during the period.",
        "label": "Number of Interest Rate Derivatives Matured",
        "terseLabel": "Number of interest rate derivatives matured"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesMatured",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.",
        "label": "Offsetting Assets And Liabilities [Table Text Block]",
        "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis"
       }
      }
     },
     "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_OncoImmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OncoImmune",
        "label": "OncoImmune [Member]",
        "terseLabel": "OncoImmune"
       }
      }
     },
     "localname": "OncoImmuneMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OralAndInjectableFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "oral and injectable formulations",
        "label": "oral and injectable formulations [Member]",
        "terseLabel": "Oral and Injectable Formulations"
       }
      }
     },
     "localname": "OralAndInjectableFormulationsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OralFormulationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "oral formulation",
        "label": "oral formulation [Member]",
        "terseLabel": "Oral Formulation"
       }
      }
     },
     "localname": "OralFormulationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OrganonCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organon &amp; Co.",
        "label": "Organon &amp; Co. [Member]",
        "terseLabel": "Organon &amp; Co."
       }
      }
     },
     "localname": "OrganonCoMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OrionCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orion Corporation",
        "label": "Orion Corporation [Member]",
        "terseLabel": "Orion Corporation"
       }
      }
     },
     "localname": "OrionCorporationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OrnaTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orna Therapeutics",
        "label": "Orna Therapeutics [Member]",
        "terseLabel": "Orna Therapeutics"
       }
      }
     },
     "localname": "OrnaTherapeuticsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax",
        "terseLabel": "Settlements and curtailments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other long term debt.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income and expense items not separately disclosed.",
        "label": "Other Nonoperating Income Expense, Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherPharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other pharmaceutical.",
        "label": "Other Pharmaceutical [Member]",
        "terseLabel": "Other pharmaceutical"
       }
      }
     },
     "localname": "OtherPharmaceuticalMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherPostretirementBenefitPlanNetLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Postretirement Benefit Plan Net Loss [Member]",
        "label": "Other Postretirement Benefit Plan Net Loss [Member]",
        "terseLabel": "Other Postretirement Benefit Plan Net Gain"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlanNetLossMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherPostretirementBenefitPlanPriorServiceCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Postretirement Benefit Plan Prior Service Cost [Member]",
        "label": "Other Postretirement Benefit Plan Prior Service Cost [Member]",
        "terseLabel": "Other Postretirement Benefit Plan Prior Service Credit"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlanPriorServiceCostMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherVariableRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Variable Rate Debt [Member]",
        "label": "Other Variable Rate Debt [Member]",
        "terseLabel": "Other Variable Rate Debt"
       }
      }
     },
     "localname": "OtherVariableRateDebtMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PandionTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pandion Therapeutics",
        "label": "Pandion Therapeutics [Member]",
        "terseLabel": "Pandion Therapeutics"
       }
      }
     },
     "localname": "PandionTherapeuticsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PatentlitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent litigation [Member]",
        "label": "Patent litigation [Member]",
        "terseLabel": "Patent litigation"
       }
      }
     },
     "localname": "PatentlitigationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Five, Net of Cash Acquired",
        "label": "Payments to Acquire Business Five, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of ArQule, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessFiveNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Business Four, Net of Cash Acquired",
        "label": "Payments to Acquire Business Four, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of VelosBio Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessFourNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PensionPlanNetLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension Plan Net Loss [Member]",
        "label": "Pension Plan Net Loss [Member]",
        "terseLabel": "Pension Plan Net Loss"
       }
      }
     },
     "localname": "PensionPlanNetLossMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PensionPlanPriorServiceCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension Plan Prior Service Cost [Member]",
        "label": "Pension Plan Prior Service Cost [Member]",
        "terseLabel": "Pension Plan Prior Service Credit"
       }
      }
     },
     "localname": "PensionPlanPriorServiceCostMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PharmaceuticalsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical segment.",
        "label": "Pharmaceutical segment [Member]",
        "terseLabel": "Pharmaceutical segment",
        "verboseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalsegmentMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Pneumovax23Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumovax 23[Member].",
        "label": "Pneumovax 23 [Member]",
        "terseLabel": "Pneumovax 23"
       }
      }
     },
     "localname": "Pneumovax23Member",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Regulatory",
        "label": "Potential Future Milestone Payments Regulatory",
        "terseLabel": "Potential future regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsRegulatory",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Sales-Based",
        "label": "Potential Future Milestone Payments Sales-Based",
        "terseLabel": "Potential future sales-based milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsSalesBased",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PremiumOnSharesAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on shares acquired",
        "label": "Premium on shares acquired",
        "terseLabel": "Premium on shares acquired"
       }
      }
     },
     "localname": "PremiumOnSharesAcquired",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PrevymisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevymis",
        "label": "Prevymis [Member]",
        "terseLabel": "Prevymis"
       }
      }
     },
     "localname": "PrevymisMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PrimaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primaxin [Member].",
        "label": "Primaxin [Member]",
        "terseLabel": "Primaxin"
       }
      }
     },
     "localname": "PrimaxinMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProQuadMMRIIVarivaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQuad/M-M-R II/Varivax [Member].",
        "label": "ProQuad MMR II Varivax [Member]",
        "terseLabel": "ProQuad/M-M-R II/Varivax"
       }
      }
     },
     "localname": "ProQuadMMRIIVarivaxMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProbableContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable Contingent Payments Collaborative Arrangement",
        "label": "Probable Contingent Payments Collaborative Arrangement",
        "terseLabel": "Probable contingent payments"
       }
      }
     },
     "localname": "ProbableContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ProfitShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Share",
        "label": "Profit Share",
        "terseLabel": "Profit share"
       }
      }
     },
     "localname": "ProfitShare",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_ProfitShareCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Share Counterparty",
        "label": "Profit Share Counterparty",
        "terseLabel": "Profit share by counterparty"
       }
      }
     },
     "localname": "ProfitShareCounterparty",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_RealEstateInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate investment funds.",
        "label": "Real Estate Investment Funds [Member]",
        "verboseLabel": "Real Estate"
       }
      }
     },
     "localname": "RealEstateInvestmentFundsMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ReblozylMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reblozyl",
        "label": "Reblozyl [Member]",
        "terseLabel": "Reblozyl",
        "verboseLabel": "Alliance revenue - Reblozyl"
       }
      }
     },
     "localname": "ReblozylMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RecognizedAsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized as.",
        "label": "Recognized As [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "RecognizedAsAbstract",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member].",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding",
        "terseLabel": "Additional funding by others, development costs subject to funding"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs",
        "terseLabel": "Additional funding by others, percentage of development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two",
        "terseLabel": "Charge for the acquisition of VelosBio Inc.",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Payments Made To a Collaborative Partner",
        "label": "Research and Development Payments Made To a Collaborative Partner",
        "terseLabel": "Research and development payments made to a collaborative partner"
       }
      }
     },
     "localname": "ResearchAndDevelopmentPaymentsMadeToACollaborativePartner",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Payments To Be Made to a Collaborative Partners",
        "label": "Research and Development Payments To Be Made to a Collaborative Partners",
        "terseLabel": "Research and development payments to be made to a collaborative partners"
       }
      }
     },
     "localname": "ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.",
        "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity",
        "terseLabel": "Non-cash activity"
       }
      }
     },
     "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RevenuePerformanceObligationPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms",
        "label": "Revenue, Performance Obligation, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTerms",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date",
        "label": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date",
        "terseLabel": "Product return period and expiration"
       }
      }
     },
     "localname": "RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date",
        "label": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date",
        "terseLabel": "Product return period"
       }
      }
     },
     "localname": "RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_RidgebackBiotherapeuticsLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ridgeback Biotherapeutics LP",
        "label": "Ridgeback Biotherapeutics LP [Member]",
        "terseLabel": "Ridgeback Biotherapeutics LP"
       }
      }
     },
     "localname": "RidgebackBiotherapeuticsLPMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RotateqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RotaTeq [Member]",
        "label": "Rotateq [Member]",
        "terseLabel": "RotaTeq"
       }
      }
     },
     "localname": "RotateqMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RoyaltyPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma",
        "label": "Royalty Pharma [Member]",
        "terseLabel": "Royalty Pharma"
       }
      }
     },
     "localname": "RoyaltyPharmaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RoyaltyRateDeductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Deduction, Percentage",
        "label": "Royalty Rate, Deduction, Percentage",
        "terseLabel": "Royalty rate, deduction, percentage"
       }
      }
     },
     "localname": "RoyaltyRateDeductionPercentage",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_RoyaltyRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Percentage",
        "label": "Royalty Rate, Percentage",
        "terseLabel": "Royalty rate, percentage"
       }
      }
     },
     "localname": "RoyaltyRatePercentage",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestones [Member]",
        "label": "Sales-Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SalesDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Discounts",
        "label": "Sales Discounts",
        "terseLabel": "Customer discounts"
       }
      }
     },
     "localname": "SalesDiscounts",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales threshold",
        "label": "Sales threshold",
        "terseLabel": "Sales threshold"
       }
      }
     },
     "localname": "SalesThreshold",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SanofiPasteurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Pasteur [Member]",
        "label": "Sanofi Pasteur [Member]",
        "terseLabel": "Sanofi Pasteur"
       }
      }
     },
     "localname": "SanofiPasteurMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ScheduleOfIncomeTaxesPaidTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Income Taxes Paid",
        "label": "Schedule of Income Taxes Paid [Table Text Block]",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "ScheduleOfIncomeTaxesPaidTableTextBlock",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_ScheduleOfOtherIntangiblesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Intangibles [Table]",
        "label": "Schedule Of Other Intangibles [Table]",
        "terseLabel": "Schedule Of Other Intangibles [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIntangiblesTable",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.",
        "label": "Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_SeagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seagen",
        "label": "Seagen [Member]",
        "terseLabel": "Seagen"
       }
      }
     },
     "localname": "SeagenMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SegmentReportingUnallocatedOtherExpensesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other net expenses not allocated to segments.",
        "label": "Segment Reporting Unallocated Other Expenses Net",
        "negatedLabel": "Other unallocated, net"
       }
      }
     },
     "localname": "SegmentReportingUnallocatedOtherExpensesNet",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SentinelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sentinel [Member]",
        "label": "Sentinel [Member]",
        "terseLabel": "Sentinel"
       }
      }
     },
     "localname": "SentinelMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number",
        "terseLabel": "Number of Shares, Expected to Vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional information pertaining to stock option plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]",
        "terseLabel": "Additional Information Pertaining to Stock Option Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",
        "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SimponiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi [Member].",
        "label": "Simponi [Member]",
        "terseLabel": "Simponi"
       }
      }
     },
     "localname": "SimponiMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SivextroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sivextro [Member]",
        "label": "Sivextro [Member]",
        "terseLabel": "Sivextro"
       }
      }
     },
     "localname": "SivextroMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point five five percentage notes due on two thousand and thirty seven.",
        "label": "Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member]",
        "terseLabel": "6.55% notes due 2037"
       }
      }
     },
     "localname": "SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point five zero percentage notes due on two thousand and thirty three.",
        "label": "Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member]",
        "terseLabel": "6.50% notes due 2033"
       }
      }
     },
     "localname": "SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six point four percentage debentures due on two thousand and twenty eight.",
        "label": "Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member]",
        "terseLabel": "6.40% debentures due 2028"
       }
      }
     },
     "localname": "SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SotaterceptMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "sotatercept",
        "label": "sotatercept [Member]",
        "terseLabel": "sotatercept"
       }
      }
     },
     "localname": "SotaterceptMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_TermForPayingOffEnvironmentalLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term for paying off environmental liabilities.",
        "label": "Term For Paying Off Environmental Liabilities",
        "terseLabel": "Term for paying off environmental liabilities"
       }
      }
     },
     "localname": "TermForPayingOffEnvironmentalLiabilities",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_ThemisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Themis [Member]",
        "label": "Themis [Member]",
        "terseLabel": "Themis"
       }
      }
     },
     "localname": "ThemisMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]",
        "label": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]",
        "terseLabel": "3.60% notes due 2042"
       }
      }
     },
     "localname": "ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_TransitionServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition services agreement",
        "label": "Transition services agreement [Member]",
        "terseLabel": "Transition services agreement"
       }
      }
     },
     "localname": "TransitionServicesAgreementMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_TukysaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tukysa",
        "label": "Tukysa [Member]",
        "terseLabel": "Tukysa"
       }
      }
     },
     "localname": "TukysaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction",
        "negatedTerseLabel": "Spin-off of Organon"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and Milestone Payments Made to Collaborative Partner",
        "label": "Upfront and Milestone Payments Made to Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and Milestone Payments to be Made to Collaborative Partner",
        "label": "Upfront and Milestone Payments to be Made to Collaborative Partner",
        "terseLabel": "Upfront and milestone payments to be made"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments made to partner as part of a licensing or collaborative arrangement.",
        "label": "Upfront Payments Made To License or Collaborative Partner",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontPaymentsMadeToLicenseOrCollaborativePartner",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_VaqtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaqta [Member]",
        "label": "Vaqta [Member]",
        "terseLabel": "Vaqta"
       }
      }
     },
     "localname": "VaqtaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VelosBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VelosBio",
        "label": "VelosBio [Member]",
        "terseLabel": "VelosBio"
       }
      }
     },
     "localname": "VelosBioMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verquvo",
        "label": "Verquvo [Member]",
        "terseLabel": "Verquvo"
       }
      }
     },
     "localname": "VerquvoMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZerbaxaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zerbaxa [Member]",
        "label": "Zerbaxa [Member]",
        "terseLabel": "Zerbaxa"
       }
      }
     },
     "localname": "ZerbaxaMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZetiaantitrustlitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zetia antitrust litigation [Member]",
        "label": "Zetia antitrust litigation [Member]",
        "terseLabel": "Zetia antitrust litigation"
       }
      }
     },
     "localname": "ZetiaantitrustlitigationMember",
     "nsuri": "http://www.merck.com/20221231",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific (other than China and Japan)"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r405",
      "r457",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r479",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r571",
      "r573",
      "r574",
      "r1079",
      "r1080"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r405",
      "r457",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r479",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r571",
      "r573",
      "r574",
      "r1079",
      "r1080"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r403",
      "r404",
      "r579",
      "r605",
      "r946",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r485",
      "r975",
      "r1082",
      "r1138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r558",
      "r559",
      "r561",
      "r562",
      "r708",
      "r897",
      "r918",
      "r939",
      "r940",
      "r972",
      "r986",
      "r996",
      "r1081",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r558",
      "r559",
      "r561",
      "r562",
      "r708",
      "r897",
      "r918",
      "r939",
      "r940",
      "r972",
      "r986",
      "r996",
      "r1081",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r485",
      "r975",
      "r1082",
      "r1138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r481",
      "r902",
      "r973",
      "r994",
      "r1076",
      "r1077",
      "r1082",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r481",
      "r902",
      "r973",
      "r994",
      "r1076",
      "r1077",
      "r1082",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r558",
      "r559",
      "r561",
      "r562",
      "r654",
      "r708",
      "r740",
      "r741",
      "r742",
      "r873",
      "r897",
      "r918",
      "r939",
      "r940",
      "r972",
      "r986",
      "r996",
      "r1070",
      "r1081",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r558",
      "r559",
      "r561",
      "r562",
      "r654",
      "r708",
      "r740",
      "r741",
      "r742",
      "r873",
      "r897",
      "r918",
      "r939",
      "r940",
      "r972",
      "r986",
      "r996",
      "r1070",
      "r1081",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r403",
      "r404",
      "r579",
      "r605",
      "r948",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r709",
      "r1049"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r424",
      "r709",
      "r1015",
      "r1049"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r482",
      "r483",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r974",
      "r995",
      "r1082"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r482",
      "r483",
      "r926",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r974",
      "r995",
      "r1082"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r424",
      "r709",
      "r1015",
      "r1016",
      "r1049"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r993"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableSale": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease from sale of accounts receivable.",
        "label": "Accounts Receivable, Sale",
        "terseLabel": "Factored accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForEnvironmentalLossContingencies": {
     "auth_ref": [
      "r560",
      "r962",
      "r1011",
      "r1012",
      "r1071",
      "r1073"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.",
        "label": "Accrual for Environmental Loss Contingencies",
        "terseLabel": "Accrued liabilities for environmental matters"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r33",
      "r303",
      "r324"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r71",
      "r78",
      "r261",
      "r1027",
      "r1028",
      "r1029"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r160",
      "r350"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r377",
      "r386",
      "r807",
      "r1028",
      "r1029"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r377",
      "r387",
      "r388",
      "r807",
      "r950",
      "r1027"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377",
      "r387",
      "r388",
      "r1027"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": {
     "auth_ref": [
      "r72",
      "r78",
      "r1087"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax",
        "terseLabel": "Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r75",
      "r77",
      "r78",
      "r362",
      "r912",
      "r923",
      "r924"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r386",
      "r387",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r74",
      "r78",
      "r261",
      "r863",
      "r919",
      "r920",
      "r1027",
      "r1028",
      "r1029",
      "r1046",
      "r1047",
      "r1048"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r69",
      "r78",
      "r261",
      "r387",
      "r388",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848",
      "r1027"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of intangible assets, acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Other paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r1046",
      "r1047",
      "r1048",
      "r1116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Other Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r110",
      "r151"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Promotion Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising and promotion costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r453",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other segments"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r744"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Pretax share-based compensation cost recorded"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r363",
      "r489",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r110",
      "r143",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r1105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r989",
      "r1106",
      "r1107",
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Consideration paid"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r989",
      "r1106",
      "r1107",
      "r1108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r1105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r301",
      "r323",
      "r354",
      "r399",
      "r465",
      "r471",
      "r477",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r805",
      "r808",
      "r836",
      "r993",
      "r1079",
      "r1080",
      "r1124"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r345",
      "r367",
      "r399",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r805",
      "r808",
      "r836",
      "r993",
      "r1079",
      "r1080",
      "r1124"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r491",
      "r510"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r135",
      "r490",
      "r510",
      "r906"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Foreign government bonds",
        "verboseLabel": "Debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r270",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r796",
      "r980",
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r796",
      "r980",
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r799",
      "r1036"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Business combination, contingent consideration arrangements, change in amount of contingent consideration liability",
        "terseLabel": "Contingent consideration liability, changes in estimated fair value",
        "verboseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r249",
      "r250",
      "r798"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Contingent consideration, ending balance",
        "periodStartLabel": "Contingent consideration, beginning balance",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r249",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration, liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "verboseLabel": "In-process research and development (IPR&amp;D)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Products and product rights - Reblozyl (12 year useful life)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed",
        "terseLabel": "Share-based compensation payments to settle equity awards attributable to precombination service"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r112",
      "r348",
      "r941"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r106",
      "r112",
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets)",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r106",
      "r294"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1018"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r106"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r106"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Hedged items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Obligation and Funded Status"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r800",
      "r801",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r175",
      "r554",
      "r555",
      "r928",
      "r1078"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Environmental Liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies and Legal Defense Costs"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r1046",
      "r1047",
      "r1116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance December\u00a031 (in shares)",
        "periodStartLabel": "Balance January\u00a01 (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40",
      "r993"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r80",
      "r382",
      "r384",
      "r392",
      "r908",
      "r914"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r97",
      "r391",
      "r907",
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r292",
      "r293",
      "r485",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r118",
      "r119",
      "r292",
      "r293",
      "r485",
      "r925",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r118",
      "r119",
      "r292",
      "r293",
      "r485",
      "r927",
      "r1140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r118",
      "r119",
      "r292",
      "r293",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of accounts receivable represented by customers with largest balances (as percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r292",
      "r293",
      "r485",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r258",
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r976",
      "r978",
      "r1139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r128",
      "r470",
      "r471",
      "r472",
      "r473",
      "r479",
      "r1052"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other profits"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r92",
      "r902"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r1043",
      "r1099",
      "r1101"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r1043",
      "r1099"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r238",
      "r779",
      "r787",
      "r1043"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r1043",
      "r1099",
      "r1101"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r117",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r397",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r592",
      "r599",
      "r600",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Loans Payable, Long-Term Debt and Leases"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r302",
      "r305",
      "r319",
      "r405",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r852",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1041"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r296",
      "r298",
      "r576",
      "r852",
      "r968",
      "r969"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount of debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r590",
      "r835",
      "r968",
      "r969"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of loans payable and long-term debt, including current portion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r57",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r58",
      "r405",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r852",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1041"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r58",
      "r187",
      "r190",
      "r191",
      "r192",
      "r295",
      "r296",
      "r298",
      "r317",
      "r405",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r852",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1041"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Debt, carrying amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r1043",
      "r1100",
      "r1101"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r238",
      "r1043",
      "r1100"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r238",
      "r780",
      "r786",
      "r787",
      "r1043"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Total deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r37",
      "r38",
      "r304",
      "r318",
      "r774"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Subtotal, Liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r760",
      "r761"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred Income Taxes",
        "verboseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r1043",
      "r1100",
      "r1101"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Equity Method Investments, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Product intangibles and licenses, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r775"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "R&amp;D capitalization, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory related, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1097"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred tax assets on NOL carryforwards relating to foreign jurisdictions"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Accelerated depreciation, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Pensions and other postretirement benefits, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Compensation related, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r776"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance, Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r226",
      "r1097"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred income taxes, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "terseLabel": "Inventory related, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Product intangibles and licenses, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r235",
      "r1098"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Accelerated depreciation, Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r645",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]",
        "terseLabel": "Actual return on plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod": {
     "auth_ref": [
      "r659",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold",
        "terseLabel": "Relating to assets sold during the year"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": {
     "auth_ref": [
      "r659",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held",
        "terseLabel": "Relating to assets still held at December 31"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r638"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedLabel": "Actuarial (gains) losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r631",
      "r670",
      "r696",
      "r978",
      "r979"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Net loss (gain) amortization"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r631",
      "r671",
      "r697",
      "r978",
      "r979"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of unrecognized prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r300",
      "r322",
      "r629",
      "r630",
      "r653",
      "r978"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Salary growth rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r679",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "terseLabel": "Expected rate of return on plan assets",
        "verboseLabel": "Expected rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Salary growth rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r633"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation December\u00a031",
        "periodStartLabel": "Benefit obligation January\u00a01"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r640",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r682",
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r647",
      "r657",
      "r700",
      "r976",
      "r977",
      "r978",
      "r979"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCurtailments": {
     "auth_ref": [
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDerivativeMember": {
     "auth_ref": [
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or other contract with one or more underlyings, notional amount or payment provision or both; can be settled net by means outside contract or delivery of asset; and with minimal or no initial net investment, in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Derivative [Member]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DefinedBenefitPlanDerivativeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDivestituresBenefitObligation": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale.",
        "label": "Defined Benefit Plan, Benefit Obligation, Divestiture",
        "negatedTerseLabel": "Spin-off of Organon"
       }
      }
     },
     "localname": "DefinedBenefitPlanDivestituresBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDivestituresPlanAssets": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale.",
        "label": "Defined Benefit Plan, Plan Assets, Divestiture",
        "negatedTerseLabel": "Spin-off of Organon"
       }
      }
     },
     "localname": "DefinedBenefitPlanDivestituresPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "auth_ref": [
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "terseLabel": "International equities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "auth_ref": [
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "terseLabel": "U.S.\u00a0equities"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2028\u00a0\u2014\u00a02032"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r665",
      "r979"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r631",
      "r669",
      "r695",
      "r978",
      "r979"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r644",
      "r655",
      "r657",
      "r658",
      "r976",
      "r977",
      "r978"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value of plan assets December\u00a031",
        "periodStartLabel": "Fair value of plan assets January\u00a01",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Plan assets at fair value"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r639"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effects of exchange rate changes"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r629",
      "r653",
      "r978"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status December\u00a031"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Health care cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r631",
      "r636",
      "r668",
      "r694",
      "r978",
      "r979"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r666",
      "r692",
      "r978",
      "r979"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanOtherChanges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherChanges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "auth_ref": [
      "r689",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r689",
      "r690",
      "r978"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r689",
      "r690",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r1088"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Plan amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r649",
      "r1089"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r646"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effects of exchange rate changes"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r654",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": {
     "auth_ref": [
      "r660",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement",
        "terseLabel": "Purchases and sales, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRealEstateMember": {
     "auth_ref": [
      "r976",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Real Estate [Member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "DefinedBenefitPlanRealEstateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r632",
      "r673",
      "r699"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r632",
      "r673",
      "r699"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r634",
      "r667",
      "r693",
      "r978",
      "r979"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": {
     "auth_ref": [
      "r661",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3",
        "terseLabel": "Transfers into Level 3"
       }
      }
     },
     "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r705"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer contributions to defined contribution savings plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r110",
      "r158"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "negatedLabel": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r110",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": {
     "auth_ref": [
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.",
        "label": "Depreciation, Depletion, and Amortization [Policy Text Block]",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, asset"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r65",
      "r67",
      "r369"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset.",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r368",
      "r371",
      "r835",
      "r949"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "netLabel": "Derivative assets",
        "terseLabel": "Gross amounts recognized in the consolidated balance sheet, asset",
        "verboseLabel": "Fair Value of Derivative, Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAverageRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Average Remaining Maturity",
        "terseLabel": "Maximum planning cycle of hedges (less than)"
       }
      }
     },
     "localname": "DerivativeAverageRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r67",
      "r281",
      "r370",
      "r947"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
        "negatedTerseLabel": "Cash collateral received, asset",
        "terseLabel": "Cash collateral received from counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r67",
      "r281",
      "r370",
      "r947"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset",
        "negatedLabel": "Cash collateral received, liability"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimSecurities": {
     "auth_ref": [
      "r67",
      "r370",
      "r947"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset",
        "terseLabel": "Cash collateral advanced to counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r1112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r1112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.",
        "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r277",
      "r279",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r268",
      "r271",
      "r277",
      "r279",
      "r283",
      "r285",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r819"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r276",
      "r1113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r368",
      "r371",
      "r835",
      "r949"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Derivative liabilities",
        "terseLabel": "Gross amounts recognized in the consolidated balance sheet, liability",
        "verboseLabel": "Fair Value of Derivative, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r65",
      "r67",
      "r369"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r1110",
      "r1111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount of derivative"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r274",
      "r277",
      "r280",
      "r282",
      "r285",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Products and product rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r714",
      "r745",
      "r746",
      "r748",
      "r754",
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r18"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax",
        "totalLabel": "Income from discontinued operations before taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "terseLabel": "Income from Discontinued Operations (in dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Discontinued Operation, Period of Continuing Involvement after Disposal",
        "terseLabel": "Period of continuing involvement after disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": {
     "auth_ref": [
      "r7",
      "r23",
      "r1103"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period",
        "terseLabel": "Tax provision"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Less: Cash and cash equivalents related to discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r19",
      "r344"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Disposal group, other expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r19",
      "r344"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r27",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Spin-Off of Organon &amp; Co."
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCo"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r1090",
      "r1091",
      "r1092"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r361",
      "r565",
      "r566",
      "r567",
      "r573",
      "r574",
      "r575",
      "r865",
      "r943",
      "r1044"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from related parties, current"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r49",
      "r565",
      "r566",
      "r567",
      "r573",
      "r574",
      "r575",
      "r865",
      "r1044"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties, current"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r393",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r425",
      "r428",
      "r436",
      "r437",
      "r438",
      "r442",
      "r823",
      "r824",
      "r909",
      "r915",
      "r957"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net Income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic Earnings per Common Share Attributable to Merck\u00a0&amp; Co., Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r393",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r428",
      "r436",
      "r437",
      "r438",
      "r442",
      "r823",
      "r824",
      "r909",
      "r915",
      "r957"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net Income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r841"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r763"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total, Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Tax\u00a0Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r401",
      "r763",
      "r789"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory rate applied to income from continuing operations before taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r1095",
      "r1102"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowances"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r1095",
      "r1102"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r1095",
      "r1102"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1095",
      "r1102"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1095",
      "r1102"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r1095",
      "r1102"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "R&amp;D tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r1095",
      "r1102"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Tax settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r747"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r744"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Income tax benefits related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r749"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefits relating to stock option exercises"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss": {
     "auth_ref": [
      "r557",
      "r561",
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets.",
        "label": "Environmental Exit Costs, Reasonably Possible Additional Loss",
        "terseLabel": "Aggregate possible expenditure on environmental matters in excess of amounts accrued"
       }
      }
     },
     "localname": "EnvironmentalExitCostsReasonablyPossibleAdditionalLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r186",
      "r341",
      "r386",
      "r387",
      "r388",
      "r411",
      "r412",
      "r413",
      "r415",
      "r421",
      "r423",
      "r445",
      "r502",
      "r619",
      "r750",
      "r751",
      "r752",
      "r782",
      "r783",
      "r822",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848",
      "r863",
      "r919",
      "r920",
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r834"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities held through ownership interests in investment funds"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r355",
      "r834",
      "r944"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r1056"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Loss (income) from investments in equity securities, net"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r916",
      "r1056"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "(Gains) losses for equity securities held through ownership interests in investment funds"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r916",
      "r1056"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r138",
      "r320",
      "r997",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative downward price adjustment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative upward price adjustment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r826",
      "r827",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r590",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r827",
      "r870",
      "r871",
      "r872",
      "r968",
      "r969",
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r826",
      "r827",
      "r829",
      "r830",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r590",
      "r657",
      "r662",
      "r827",
      "r870",
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r590",
      "r657",
      "r662",
      "r827",
      "r871",
      "r968",
      "r969",
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r590",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r827",
      "r872",
      "r968",
      "r969",
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summarized Information about the Changes in Liabilities for Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r657",
      "r825",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "NAV"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r590",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r870",
      "r871",
      "r872",
      "r968",
      "r969",
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r831",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r270",
      "r274",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r492",
      "r493",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513",
      "r601",
      "r616",
      "r820",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r960",
      "r1053",
      "r1054",
      "r1055",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r352",
      "r535"
     ],
     "calculation": {
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Estimated aggregate amortization expense, 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated aggregate amortization expense, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated aggregate amortization expense, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated aggregate amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r531",
      "r534",
      "r535",
      "r537",
      "r903",
      "r904"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r144",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r150",
      "r903"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments that regularly generate a fixed amount of interest income. Examples include, but are not limited to, bonds, certificates of deposit, notes and debt securities.",
        "label": "Fixed Income Investments [Member]",
        "terseLabel": "Fixed Income Investments"
       }
      }
     },
     "localname": "FixedIncomeInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Jurisdiction"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Exchange losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r949",
      "r976",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).",
        "label": "Foreign Exchange Option [Member]",
        "terseLabel": "Currency Options"
       }
      }
     },
     "localname": "ForeignExchangeOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r1084",
      "r1139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Foreign government bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r1090",
      "r1091",
      "r1092"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of issuer's shares to which the forward contract is indexed.",
        "label": "Forward Contract Indexed to Issuer's Equity, Indexed Shares",
        "terseLabel": "Forward contract indexed to issuer's equity, indexed shares (in shares)"
       }
      }
     },
     "localname": "ForwardContractIndexedToIssuersEquityIndexedShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r1115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contracts"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r351",
      "r518",
      "r905",
      "r961",
      "r993",
      "r1058",
      "r1065"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r520",
      "r961"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangibles"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r529",
      "r530",
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r519",
      "r526",
      "r961"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r816"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r817"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r268",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill.",
        "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r1037",
      "r1069"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Intangible asset impairment charge related to marketed product"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r1037",
      "r1069"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "verboseLabel": "IPR&amp;D impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r90",
      "r111",
      "r255",
      "r416",
      "r417",
      "r418",
      "r419",
      "r434",
      "r438"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0&amp; Co., Inc.",
        "totalLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r253",
      "r256"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net Income Attributable to Noncontrolling Interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r400",
      "r788"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r299",
      "r313",
      "r336",
      "r465",
      "r470",
      "r476",
      "r479",
      "r910",
      "r959"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before taxes",
        "totalLabel": "Income from Continuing Operations Before Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r400",
      "r788"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r256",
      "r399",
      "r414",
      "r465",
      "r470",
      "r476",
      "r479",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r824",
      "r836",
      "r959",
      "r1079"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income from continuing operations",
        "totalLabel": "Net Income from Continuing Operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r82",
      "r311",
      "r314",
      "r332",
      "r393",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r428",
      "r436",
      "r437",
      "r824",
      "r909"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from Continuing Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r82",
      "r332",
      "r335",
      "r393",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r428",
      "r436",
      "r437",
      "r438",
      "r824",
      "r909",
      "r915"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from Continuing Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r23",
      "r333",
      "r344",
      "r792"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Income from discontinued operations, net of taxes"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r18",
      "r23",
      "r253",
      "r256"
     ],
     "calculation": {
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Income of discontinued operations attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r18",
      "r23",
      "r256"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests",
        "totalLabel": "Income from discontinued operations, net of taxes attributable to parent"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r264",
      "r429",
      "r436",
      "r437"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Income from Discontinued Operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r85",
      "r110",
      "r139",
      "r312",
      "r331",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "verboseLabel": "Equity income (loss) from affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r11",
      "r12",
      "r13",
      "r14",
      "r16",
      "r17",
      "r22",
      "r24",
      "r25",
      "r26",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r539",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r401",
      "r764",
      "r772",
      "r778",
      "r784",
      "r790",
      "r793",
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r402",
      "r422",
      "r423",
      "r463",
      "r762",
      "r785",
      "r791",
      "r917"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on Income from Continuing Operations",
        "totalLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails",
      "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r385",
      "r758",
      "r759",
      "r772",
      "r773",
      "r777",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r1095"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowances"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r1095"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign earnings"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r763"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. statutory rate applied to income from continuing operations before taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r1095"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1095"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r1095"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r1095"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "R&amp;D tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "auth_ref": [
      "r1095"
     ],
     "calculation": {
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "terseLabel": "Tax settlements"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r107",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r146",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r149",
      "r899",
      "r900",
      "r901",
      "r903",
      "r953"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Acquired Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r142",
      "r148"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other Intangibles, Net",
        "totalLabel": "Net",
        "verboseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r297",
      "r316",
      "r389",
      "r459",
      "r851"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r1038"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r949",
      "r976",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap",
        "verboseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Software Capitalization"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r1021"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r1025"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates current cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r1024"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedLabel": "Decrease to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r365",
      "r942",
      "r993"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note\u00a08)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r1020"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory classified in Other assets",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical",
      "http://www.merck.com/role/InventoriesInventoriesDetails",
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r347",
      "r364",
      "r444",
      "r514",
      "r516",
      "r517",
      "r898",
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r1025"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "terseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r94",
      "r458"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r500",
      "r1136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LIFOInventoryAmount": {
     "auth_ref": [
      "r945"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.",
        "label": "LIFO Inventory Amount",
        "terseLabel": "LIFO inventory amount"
       }
      }
     },
     "localname": "LIFOInventoryAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r1019"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r862"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r1121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r54",
      "r399",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r806",
      "r808",
      "r809",
      "r836",
      "r958",
      "r1079",
      "r1124",
      "r1125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r45",
      "r307",
      "r327",
      "r993",
      "r1042",
      "r1057",
      "r1118"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r56",
      "r346",
      "r399",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r806",
      "r808",
      "r809",
      "r836",
      "r993",
      "r1079",
      "r1124",
      "r1125"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Payables included in Accrued and other current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r34",
      "r35",
      "r399",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r806",
      "r808",
      "r809",
      "r836",
      "r1079",
      "r1124",
      "r1125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Payables included in Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r1083"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Available borrowing capacity under credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r60",
      "r1073"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Legal defense costs reserve"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r1073"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r1073"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Long-term debt, current maturities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r180",
      "r405",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r180",
      "r405",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r180",
      "r405",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r180",
      "r405",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r180",
      "r405",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "Long-term debt, maturities, repayments of principal in 2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r58",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r556",
      "r558",
      "r559",
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r176",
      "r177",
      "r556",
      "r558",
      "r559",
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss contingency, claims settled (in cases)"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r1073",
      "r1074",
      "r1075"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r556",
      "r558",
      "r559",
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, new claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss contingency, number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss contingency, pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery, equipment and office furnishings"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery, equipment and office furnishings"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "verboseLabel": "Unallocated"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r1117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r64",
      "r306",
      "r326",
      "r399",
      "r501",
      "r563",
      "r566",
      "r567",
      "r568",
      "r574",
      "r575",
      "r836"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r447",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.",
        "label": "Net Cash Provided by (Used in) Discontinued Operations",
        "totalLabel": "Net Cash Flows Provided by Discontinued Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]",
        "terseLabel": "Cash Flows from Discontinued Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r1035"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net Cash (Used in) Provided by Financing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r1035"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net Cash Used in Investing Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r106",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net Cash Provided by Operating Activities of Continuing Operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r87",
      "r111",
      "r315",
      "r334",
      "r344",
      "r380",
      "r383",
      "r388",
      "r399",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r423",
      "r434",
      "r465",
      "r470",
      "r476",
      "r479",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r824",
      "r836",
      "r959",
      "r1079"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income Attributable to Merck &amp; Co., Inc.",
        "totalLabel": "Net Income Attributable to Merck &amp; Co., Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r259",
      "r263",
      "r380",
      "r383",
      "r422",
      "r423",
      "r1029"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r419",
      "r425",
      "r426",
      "r435",
      "r438",
      "r465",
      "r470",
      "r476",
      "r479",
      "r959"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Merck &amp; Co., Inc., basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r438"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Merck &amp; Co., Inc., diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r631"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside of the United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r253",
      "r619",
      "r1046",
      "r1047",
      "r1048"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/NatureofOperationsDetails",
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r963",
      "r964",
      "r965",
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "Separation Costs"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r857",
      "r992"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r854"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liability",
        "verboseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r854"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r854"
     ],
     "calculation": {
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r856",
      "r858"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r853"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r861",
      "r992"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r860",
      "r992"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term",
        "verboseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails",
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Valuation allowance on foreign NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "verboseLabel": "Total segment profits"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r366",
      "r993"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r270",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r73",
      "r75",
      "r674"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Prior service (cost) credit arising during the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r75",
      "r79",
      "r379",
      "r674"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Prior service credit amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r373",
      "r374",
      "r376"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized loss on investments, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": {
     "auth_ref": [
      "r78",
      "r387",
      "r842",
      "r844",
      "r848",
      "r1027"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r387",
      "r842",
      "r844",
      "r848",
      "r1027"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r76",
      "r386"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedTerseLabel": "Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r372",
      "r376"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized (loss) gain on derivatives, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r372",
      "r376",
      "r811",
      "r812",
      "r818"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r376",
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "Increase (decrease) in Sales as a result of AOCL reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r813"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r814"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r81",
      "r186",
      "r381",
      "r384",
      "r391",
      "r842",
      "r847",
      "r848",
      "r907",
      "r913",
      "r1027",
      "r1028"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other Comprehensive (Loss) Income Net of Taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r256",
      "r257",
      "r260",
      "r381",
      "r384"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax": {
     "auth_ref": [
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Benefit plan net gain (loss) and prior service credit (cost), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r70",
      "r75",
      "r206"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Net loss (gain) amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax": {
     "auth_ref": [
      "r75",
      "r79",
      "r379",
      "r1086"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r75",
      "r79",
      "r379",
      "r674"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedTerseLabel": "Net loss (gain) amortization included in benefit cost"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r270",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "verboseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Licenses and other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r1022"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other investments.",
        "label": "Other Investments [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r55",
      "r993"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 5.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "negatedTotalLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r201",
      "r629",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r679",
      "r680",
      "r682",
      "r685",
      "r688",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r705",
      "r706",
      "r707",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Postretirement Benefits"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r963",
      "r964",
      "r965",
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r1030",
      "r1031"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r543",
      "r1034"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "(Payments) receipts, net"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid to stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired": {
     "auth_ref": [
      "r1031"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Three, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Pandion Therapeutics, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessThreeNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r1031"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Acceleron Pharma Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r100",
      "r797"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisition of business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Other acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r395",
      "r495"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedTerseLabel": "Purchase of Seagen Inc. common stock"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Payments to acquire investment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of securities and other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r394",
      "r1106",
      "r1107",
      "r1108"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures",
        "terseLabel": "Payments to acquire productive assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r1073"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r654",
      "r656",
      "r662",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r702",
      "r703",
      "r705",
      "r711",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r33",
      "r629",
      "r630",
      "r653",
      "r978"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36",
      "r629",
      "r630",
      "r653",
      "r978"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r200",
      "r629",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r679",
      "r680",
      "r682",
      "r685",
      "r688",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r705",
      "r706",
      "r710",
      "r978",
      "r979",
      "r983",
      "r984",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefits"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r682",
      "r976",
      "r977",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r1032",
      "r1033"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-Term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales of securities and other investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Revenue related to the sale of the marketing rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r102",
      "r220"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Cash received from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductionRelatedImpairmentsOrCharges": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.",
        "label": "Production Related Impairments or Charges",
        "terseLabel": "Inventory write-off related to contract termination"
       }
      }
     },
     "localname": "ProductionRelatedImpairmentsOrCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r159",
      "r349"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment (at cost)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross [Abstract]",
        "terseLabel": "Property, Plant and Equipment (at cost)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r161",
      "r329",
      "r911",
      "r993"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r1023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r1023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r328",
      "r337",
      "r993"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "verboseLabel": "Receivables included in Other current assets"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r78",
      "r387",
      "r842",
      "r846",
      "r848",
      "r1027"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "negatedTerseLabel": "Reclassification adjustments, pretax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r387",
      "r842",
      "r846",
      "r848",
      "r1027"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTotalLabel": "Reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r76",
      "r379",
      "r386"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r125",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Profits to Income Before Taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartiesAmountInCostOfSales": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.",
        "label": "Related Parties Amount in Cost of Sales",
        "terseLabel": "Related party amount in cost of sales"
       }
      }
     },
     "localname": "RelatedPartiesAmountInCostOfSales",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r340",
      "r864",
      "r865",
      "r1123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Payments on debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r223",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Compensation earned on arragement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "verboseLabel": "Charge for the acquisition of Pandion Therapeutics, Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r222",
      "r339",
      "r1132"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 3.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r1018",
      "r1039",
      "r1133",
      "r1135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1018",
      "r1039"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Funds collected from factoring of receivable, held in restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r541",
      "r543",
      "r546",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r542",
      "r545",
      "r549",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative costs since program inception"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r542",
      "r545",
      "r549",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring and related cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r542",
      "r545",
      "r549",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Expenses",
        "verboseLabel": "Total pretax restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r110",
      "r547",
      "r549",
      "r1072"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 4.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Restructuring costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r169",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r542",
      "r543",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r1013",
      "r1014"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs.",
        "label": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r543",
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r42",
      "r193",
      "r325",
      "r922",
      "r924",
      "r993"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r341",
      "r411",
      "r412",
      "r413",
      "r415",
      "r421",
      "r423",
      "r502",
      "r750",
      "r751",
      "r752",
      "r782",
      "r783",
      "r822",
      "r919",
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r685",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r1090",
      "r1091",
      "r1092"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r685",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r1090",
      "r1091",
      "r1092"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r629",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r679",
      "r680",
      "r682",
      "r685",
      "r688",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r705",
      "r706",
      "r707",
      "r710",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r200",
      "r201",
      "r629",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r679",
      "r680",
      "r682",
      "r685",
      "r688",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r705",
      "r706",
      "r707",
      "r710",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r955"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r88",
      "r338",
      "r565",
      "r566",
      "r567",
      "r573",
      "r574",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r390",
      "r399",
      "r456",
      "r457",
      "r469",
      "r474",
      "r475",
      "r481",
      "r482",
      "r485",
      "r501",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r570",
      "r572",
      "r574",
      "r575",
      "r836",
      "r910",
      "r1079"
     ],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales",
        "totalLabel": "Sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r859",
      "r992"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales",
        "verboseLabel": "Total sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r78",
      "r1119",
      "r1120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in AOCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Information on Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r241",
      "r242",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r58",
      "r187",
      "r190",
      "r191",
      "r192",
      "r295",
      "r296",
      "r298",
      "r317",
      "r968",
      "r970",
      "r1045"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r271",
      "r277",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Location and Pretax Gain or Loss Amounts for Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r11",
      "r12",
      "r13",
      "r14",
      "r16",
      "r17",
      "r22",
      "r24",
      "r25",
      "r26",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r1050"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculations of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r1085"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.",
        "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Effective Tax Rate and U.S. Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.",
        "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Sales of Company's Products"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Summary of Expected Benefit Payments"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r826",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r144",
      "r149",
      "r903"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r961",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Goodwill Activity by Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Income Before Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Other Intangibles"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r28",
      "r46",
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r1114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Effect of Net Investment Hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r276",
      "r1113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r166",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r89",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Consolidated Revenues by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r83",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r123",
      "r124",
      "r126",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r126",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Equity Loss from Affiliates and Depreciation Included in Segment Profits"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Nonvested RSU and PSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r712",
      "r713",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r213",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summarized Information Relative to Stock Option Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r358",
      "r359",
      "r360",
      "r446",
      "r603",
      "r604",
      "r605",
      "r607",
      "r611",
      "r616",
      "r618",
      "r972",
      "r1010",
      "r1040"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Summary of Common Stock and Treasury Stock Transactions"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r988",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r485",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r545",
      "r551",
      "r961",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r465",
      "r468",
      "r473",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofIncome": {
       "order": 2.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/ConsolidatedStatementofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Pretax share-based compensation cost recorded, related to continuing operations",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofCashFlows",
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Period over which share-based payment awards vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Contractual term of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Nonvested December 31 (in shares)",
        "periodStartLabel": "Number of Shares, Nonvested January 1 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares collectively authorized for future grants under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r734"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r1094"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Number of Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, December 31 (in shares)",
        "periodStartLabel": "Number of Options, Outstanding, January 1 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of\u00a0Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of options granted (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r718",
      "r737",
      "r738",
      "r739",
      "r740",
      "r743",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r1093"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Quantity of stock options that vest per year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted-average interest rate of commercial paper"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r308",
      "r309",
      "r321",
      "r1026"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r116",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r343",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r485",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r540",
      "r545",
      "r551",
      "r961",
      "r1137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails",
      "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
      "http://www.merck.com/role/SummaryofAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r61",
      "r186",
      "r341",
      "r386",
      "r387",
      "r388",
      "r411",
      "r412",
      "r413",
      "r415",
      "r421",
      "r423",
      "r445",
      "r502",
      "r619",
      "r750",
      "r751",
      "r752",
      "r782",
      "r783",
      "r822",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848",
      "r863",
      "r919",
      "r920",
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r445",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r186",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "negatedTerseLabel": "Issuances (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r186",
      "r193",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r133",
      "r993",
      "r1042",
      "r1057",
      "r1118"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Merck\u00a0&amp; Co., Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Merck\u00a0&amp; Co., Inc. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' equity before deduction for treasury stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r253",
      "r254",
      "r262",
      "r341",
      "r342",
      "r387",
      "r411",
      "r412",
      "r413",
      "r415",
      "r421",
      "r502",
      "r619",
      "r750",
      "r751",
      "r752",
      "r782",
      "r783",
      "r822",
      "r842",
      "r843",
      "r848",
      "r863",
      "r920",
      "r921",
      "r1042",
      "r1057",
      "r1118"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet",
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r398",
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r617",
      "r619",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "terseLabel": "Spin-off of Organon &amp; Co."
       }
      }
     },
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Share-based compensation plans and other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r849",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r849",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r849",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r1104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Transition tax for accumulated foreign earnings, liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent": {
     "auth_ref": [
      "r1104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current",
        "terseLabel": "Transition tax liability, current"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent": {
     "auth_ref": [
      "r1104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent",
        "terseLabel": "Transition tax liability, noncurrent"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails",
      "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r310",
      "r355",
      "r944"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "totalLabel": "Investments"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r492",
      "r493",
      "r601",
      "r616",
      "r820",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r1053",
      "r1054",
      "r1055",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity",
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r63",
      "r195",
      "r196"
     ],
     "calculation": {
      "http://www.merck.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "terseLabel": "Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r40",
      "r186",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchases of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r186",
      "r193",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Treasury stock shares purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r542",
      "r543",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r956",
      "r976",
      "r1134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r757",
      "r766"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance December\u00a031",
        "periodStartLabel": "Balance January\u00a01",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r767"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r769"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements",
        "terseLabel": "Unrecognized tax benefits from adjustments related to examination"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails",
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r765"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Liabilities for accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r765"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties associated with uncertain tax positions, expense (benefit)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r768"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions related to current year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r767"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions related to prior year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r770"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r771"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Favorable net impact to income tax provision if unrecognized tax benefits were recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r1117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r1050"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Common shares issuable (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r427",
      "r438"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Average common shares outstanding assuming dilution (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r425",
      "r438"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1001": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1002": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1003": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1004": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1005": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1006": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1007": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1008": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1009": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(1)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(3)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1074": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1075": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1076": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1077": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1078": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1079": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1080": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1081": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1082": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1083": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1084": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1085": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1086": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1087": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1088": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1089": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1090": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1091": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1092": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1093": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1094": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1095": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1096": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1097": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1098": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1099": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1141": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1142": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1143": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1144": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1145": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1146": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1147": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "60",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(ii)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14362-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6571209&loc=d3e13703-110860",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>167
<FILENAME>0001628280-23-005061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-005061-xbrl.zip
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M4T]-OO.HMF?SOM=?&N._ %!+ P04    " #)@EA6J"W2-=,&   S.0  &P
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MNH1HJB:[//,,W^@U>YS0/-BX\Q]02P,$%     @ R8)85B=NB,KX!@  *QH
M !X   !E>#(T,BUC97)T:69I8V%T:6]N;V9B;V%R9"YH=&WM65ESVS80?N^O
M0)1ICAF)%"59ED3%,XVM-%>=CNW4T[YT0&)EHJ$(%@ MJ[^^BP4I*;82IYV<
MG?I!)@'LO=\N $[O'+TZ//OUYQG+[")G/[]^_/+9(6MUPO"\?QB&1V='[.G9
M3R_9(.A&[$SSPD@K5<'S,)P=MU@KL[:<A.%RN0R6_4#IB_#L)'2L!F&NE(%
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M$[I3O$ERR[>+^M=_1J$/.@=_ U!+ P04    " #)@EA6\^:;$< '   \'P
M'@   &5X,S$Q+7)U;&4Q,V%X,31A,35D>#$T86-E+FAT;=59VW+;.!)]WZ_
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M@.2#J6NMB*?,N\J@HC0%\&1]%8QC;817P#<E$YFCN&6 %49D07BE*6BX G2
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MA(]-,[EQ^;IRLJ>8]FH)'\/3I=N]9-?EYLZ;W.HWW"O[&^[S_P%02P,$%
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ME9)6&D9+BPGG@&I4YQ]!5B7BJFR.<E:0(M7?T6!F.KKQB:MJ;EF(DDKCL]J
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M7$CX<ZDS*">5#TTL@\M&J93'X 18@4&I+V ?IOY:*C'I +KJL(MT@&YG!_D
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M [2I)T:F\M8G0L<Y'NA=TO0V2@R3"=4MD9>B!""H;G!GN?C3$EWP]?P9G!L
M2B=W2Y4V_[>C-6(U?6]+U(4@EQDG,3$OSYV[PIUE6P^P[M#VT-TO<6E"N-02
M;0*HAS#]LR7<S*4&+::)$Q.TL6MP%.?$JAC&K.^V*J]'&W"9#B8XU3?"%VB1
MIIJZY32Y3E_3V&]V4$-5/(J;5P3V8CT+[H_J;,3QM%2>2WXL2@;^H.'K/FHQ
M1Z'L4-7V6J26X#A8.BCA(YX$.!'5EADV'CSU('[R _\,/^(%41(RO-6?8F@
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MX8*"EUE%<)]9%WN2\;TFQ5&:%_);C3][B28TU(A9#8G&FRN[";5ODMHW;-1
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M&WEG5(FC ZT)RYFPW/&!=O?)4P:TJW*CC)9V&-B7R3FCI>T4QI>&<QA5XNA
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M?AN,VL/A1>7/@)B5OZUZ[;#;[@UZ&[UVG?_!GGQY" ,@KC.!C6R$_^_%<K)
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MJ,J=-%:05:B2;;0UL:\8H '[#QB@VRTXXB\8 XAU&!2IM#MBT0<;,(K5W+5
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MH( 7/B7[O<YJM2=?<F_Z+Z9I*[<KWT%BD/ZG(:W_^7-OF^P%^!-=G$-Z,*'
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MLVNBNOIA/D]1"J>^J_#>25,NJ8@C<L4/%C&-4WN"915<$;;L!L#4\(D!/M0
M.7QV5I0"+(F-2'$!I-. Y!CQ37_AQX H6Y.LZD&YW!K6$^GO,"AN'$)U>0\&
MPHH&%7S<F,>%,NQT9K-YSI8V\=F.#<^WS!<"(;4.9GJHXAN9^%DEN-#8OKUX
MKK^%1I)QD&\(?8B<@7N-7TW3SB1:]1FC0T2#BSV'_6[->]9;;OKH&F)6KCMQ
M=_GIZL./FRME>?84N;$\@MJQXV?=C^@8]X#8]/'PC-KG6N+AFM[Y>+@@IC"?
M9H^G;UR:EV \_0#S2H6;EK8P8Y.\S?X#%R;BP3HO&#&,M7&F,;6H01L:@8G!
M)K3,WW)CCY'0<S^=)B]-;2[ITF03[T#!3ELJ!A?.MHC+YXA-][QTGCSP@SA2
M&A&+1"]O&A)/J'MZBA>C.#U/#.WVDVELP0F]MFWGF9JE'\&O46YN+GM>M,"+
M3Y^_*3_)NR@>,47)9264'HFO](>B#49<W_SXS _#'8<G'M1S#I(]^)WA2&AY
M2^-(NER'<^2KN75\T$??P8,R=B9P9.7EWA(DFA2OBD>LPF18+^>Y''DB >H9
MQ<##;[XW,36;!..O+!!S/9+TZ&4B3R:N@GD("5[SK#_-\,\H1X+L<JP6 ,<F
MQ.+9JG*5&+.0__XT0(F;B*(63(&)E,,\/0ZCEX5JLK#<N=:6X]\. F'X$\%1
M&6>%F8RT/$0_DI']:% FYL-(:JB7B>/T0W* 2B 5[ >C0#)BZ9.$0/!9?!&A
MB+[]L# <4PAR:,"9J)Q@3">%)09P+MJ0(''[1'K\IGS@1R'$E A'],!L3IT;
M#7(QO9-308U@<H@V!"N7C;OD=5]4D.L;K5@ZA#*J%,O5ITU,6"PF-;_GC39O
M6@'F#%=4&IRNF"#^B#5<G!+;2@Q@3*]9K%@E[:3-<49]JJ%DJF%<3ZIATOE4
M@ZY-J8$:9T;P<E>&L,2&\FCO->7[+0(.O^$I.P,R9F=0QYR=\41-ITS9BUW9
M_5%3=LJTF'>E,K?#0.J=&Z4SZ&?IG+,\GO$LG5YF^D$ZW1ZDDP7DT@MHOH#V
M4W3:%LI^A$Z71^@4KMTZ_0NR'Y?3]#GOA^ <FH#S%9O5'3N,)Y[04!MA!U[&
MF3]?^-X,1I_XF!J^'4$%4,WS9W3M9.;.U#%F+&O@3#]=YL2FR]15!-\M5)Y^
MX$P_<*8?.-/HP)EN;-%,;#%EJ+:]ZD/)<PVNR7E3V?.ZY_!H\\ZGI#/,^RY9
M]T6GY#ST4W+Z*3EO:TI.MU 9.^!F]U-R^BDY_92<\QIJTD_)J9%R*0/_G*A1
MPDP\'[+T,X-.<&:02E[O9P9UP<O09_W,H.9F!LWZF4']S*"SGAETR!/HXHB2
M-S>CIT;_HR5^]6UH)=O0ZID HVLG&O/O5JRQY*UUT,WMI)(\AT%4K4YCZ6?Y
M]+-\^ED^9SO+IQ_<T_[@G@K3;:K-_.B2=0);[4PT:DA3__UPG$Y/3,D:C@.V
M:S\^IA\?DS$^QHC-CV'^PN@BQ\\Y;1G0.BH#)!?$IHN4VB5Y +'2/:8"&"1J
M!')1UY5WUH5(LE+<I3)86+3LJ'3I4P5<A+\R9(N*E@7KL/.,<F6U130W?*=U
M02UT_\4A\/1 .7@F$'MGKJ@&B\C4C)H'"8C8#Y:WVCK>WL4=^SXU&?$-RT?7
MI #/N"RR*=I8\HCWPCH".!'@"^HD'XD2!$?HD5FI=QO#W;%6E _.YLFD.-$#
MI*SQ9+ G*G?[>W9\R==E-[T<0__1(I?^./,&01#8$2/-+E&R.BB0+Q9\ )].
MVD.]@P+CJ<IQ,Z?Z(&+)(&(]8S/T<?>#B">1/NE'IO4CT_J1:?6/3*NEG&0>
M@D2TC+0K=UJ:J.0A66+",*O?+O@OP@KF@?^VAT*6C?X[TL#I8.B_GPUWM:$F
M9@_]VT/_"J%_3XHQ/;AO#^Y[,N"^^JSS#I$VF=!45 +XEK^<8DA7 )(2:+]Z
M*;3?L:;.!!+(7NT*WFUS:+^C--3Q2(ASW!5NUPK]R_"K9[*<_@Z#N_6POC5C
MD 6RUJE"]4[(VEE"]O;RT,/QRH/C#:1OTBF(IDZ(7P^VV[#"ZT7NE*%T.\K'
M'B>W.9Q<?:&.>IS<MXJ3&QSH;K70= "NAY=M8M##^N/JRUO!Q0TW5#<,[O#,
M87!!4_8PN&<)@QMH4;U+5E&/>=MCWO:8MSWFK4S,V_%<74Q/!?-V-*PC4SM5
M]7%MF=JL>Z93UGH1R7U(ZI247=W)$T=:"Q[/%YU7GZM:C\Y[HNB\@;I(%G&<
MO7/?8_'V6+P]%N]Y@87V6+P]%F]-U$BZ80)C]ISHT6,3]]C$;QJ;N)X\:H\_
M?+KXPX$K->Y4X4./-=QC#1^QB=7%"<+SUFS&G\@>3P05M(AIW,65%[=A.[G\
MSN%1UH!F6@G,]% ^:K)09XWEH_A'NM*_F(,*+3._U1F;2DRU'@^WQ\/M\7 ;
MP,,MCYTZFD0RW3U"[DD@Y*:3CUU2[KB-'FZVT^B:/=QL#S=[/-QL#S7;0\WV
M4+,]U&PAJ%F6PAQ?Y,:M>J5146D<!>-;&X5['-0>![7'03UVA$W"%6=8GV\:
M\_1P6AN\7$J'B (4.^#[W9I#1%3O6!NENQ&U*/ALF4(%;:@NTL4*P<L=P ++
M0,>^_'3UX<?-E;)LL!V^:PAQ8E+<6!Y!R-GQ0^]'E(U[0+#.,2^2 W3?D;Z?
MJ@@KVEPFF.D2#* ?8"*I<%M2$ ,$L[#9?^#2VX+)X+Q@4#W6/IX&C*-^1&C(
M4>\*]22M,B,=,I8;>TS3V!C38?+Z VK+N?YTG=?^3%MJHQ M(7$%C=0YQ<@
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MQE5$5P:Q=F6,IE')$C5J[%.?TP5P3GAT>=9?'_6W)IS?J.]3+J%U=MZ]Z-Z
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MC@7\7XHX'<-"9R(<BF2D!)SW&"Y/)C".'/AP(:3K5RI.(NVB_+U.0O>;^!*
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MJ(I>"]7^?M,1VUG89XS4?.JQMW$;UO[T?I:&^>%F^M.Q#4_'4VX82?1)#](
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M.22DQUK<0_0V$5"Q@\;Z'@@=%"'\6;YU#CFVK,,9RS&.'HV1NN#"3(AIF(+
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M[?1JL>U]NK;DN-XKB&YW=W'56)!V>DY1;7'Q0?3/+C]?_''6/[]93()UGD>
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MT$S$5&*@Q*OB$IB[SC\;?&)_:W+?A'*\CAJ0S4'HS> _HV3LO_M_4$L#!!0
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M>L0_9_K?:O\-3)@^37D%K^#F2,?*K8B7T;\=ZZ'.16^KN[U;G^<="SSPIAW
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M+EVB'YMKCHI+"%4/M=0U4&L4KFXERLR+)SML?VG_$2F<EF-E^B?HND:LKO9
ML#B01)A4H"LLM^,S%ZLTO^HI,5SSM9^JB%)H"^N@7'U0=8L<9B8J\L6W?$OI
M%/]WG%9:[EIM#$$D?-D@%MZ7T53.LL:#'J:6:Y$M\,3<PJ/5Z^E=PCF>Q#?
M0'&.,O2JDER/U$-L'&&GV]SG4JQD+ 7I*/KR>"HQK%:NN ,?@J@(G3"N5!:I
MKSPM@KQ(\5<0%K^;(4I3-U9'H+>C;MW]:&XG*@49.Z'XELLYA44.\MU3P^C;
M9B+2I"DYT%QYK^(=/NH8+DU-<3T6'QZ_.]ON;99F3HN27C@9IJGO0;($MS&
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M'KRD8<WBQU\^HSYRY:)8-V4X0^>)_,,*0&)%?MG=ML7+H#B.EZEA*4?.DX-
M6L,:GOT]P\2/HVAJY9)@>Z^[2^N^NC@<7+[O7QR^._EX<O7;4RV]O&_5N3W4
M[A26\32,:[*)!F8.2@Y.@51Q47='2L89]@+H6/UH(Z8!GY8.\C%8;T&!,$M&
M^B*SXVCX-QMDH8-J6R, ?NQMUP*CLBS1[NUABAB4/(@8B\G\"_3YIX$^GZ8
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MKM,Q._MEL;\% @T5"+JX I,?@Q]*97/\,JS>3L?"K:EJSZ%F.S;^@L!368_
M'(+'G_NQ&R0?%\Q:X.;\7%5\#=*;S%H?-826BM0E8@9!2&!<@U];)-C%)5-4
M,EDN&#SL!0-9 +V%]"*\1IPZT"YS=25G.!;O]3B&^Y1,@S$&+,#'-PFCGX"*
MQ4C:9@N,>>+>8: [OG!HS^].FAJ<2E95\P[7&SS%49S009())K-PD@%B\D)Q
MZ6$2/DC$(S>2^@3)002]C8E09_,1Q<9+D"J-S0GZ&O.3^>=[) TVQQ@(!NPL
M$"H(;&AF5F(<;&2GM76.737'_8#FZJ:UL_RCD7['2#:]7!/-X0E6C1#J/3P6
M9ZZ C+NI6NGJ=RSV6BLQ1V(?,CX#PK5*P>BEE=L>*-+6@5AF;XO+@O_-,@?1
MXJF"L^>BZC:"R/#4(DVM[VY3;"R+2QE,\#R*N<4;_&&!5"9IW"$@.5>A<(1$
M3X9%FJE2VK>-OS&4&1W'Q0.ST&]*=(I-FRRGV&&<1S.Z,U*$5YV3]!UJD!7@
M-U%$5(PB3HAYI5#2TF'CQH+R;;6U6UYX]PAQ[1Z6965]G8=14#<:$43Y5$4W
M:H-[398S574RPI1BKXZ;J$'A!S=-3WG.$YW%+\=9;)BUI>5$8^*DX0BK3*#8
M;UH&E1:,UFD&O-\3L 5,R$!:CR=SDU,SLZ::9]U>:CC77-2"7_F1PG^FL%?,
M,S;__A50J%6+KNU'([H.G6FX4!VWR#(7)^0;RI;E?,@:/<N_J\7QA+9\Y_%L
M>>SV?,Y8]?;:/YM^YWO8DC$\03%":TVOM]NEOEF:W6&5LMV(70XU#&>M8KB%
M4..IH""MM8I-.JL2T BUQU!NW8"F=P(1F@*$A\YM(M=-RPK#.^WJKYG_$^+"
MEX^&"RT+-HW\9O=.'Y@<X_LPT(C0( 5P+VNYC]*JQR1R'.!&8>Z>A8_;2-*A
M29%_S;[U[AM27'370X4PW/N=_K+AOX$?:QYBA\QP2I??-Q+ & 8'RE"I[W^2
ML42MBK%<JQ%-*7$;G+8SMK^0YR,TL 0.#5<.WVDF:QC5+BOO I_:$AIJ5$;)
M^I/*J ZB<26>.R^\4\'PQUJ-1-^!>,49PV^?D$Q\/,88\J![+\01>'*9BI8$
MHRSE@1$"QGQXD66["V4FN-J?SU@!=0Y" B$A8'A]*$!APLYFID@#"G[-0[P<
M6^")J$)^7TFU(QGI8:H7I9IZ]TLUK:#\AK  56*\BD+9*,^(E,J-5M/YHTD;
M0*Y-EO'+"1LWTVYJ0LGB"(U(%86A[.[SI>QJ\5DN+ZL03Q@N2&,NP2?!@G_+
MD"RG;%%_LNX]&^H_AL/Z>,SHJO+XFW5&LU-#[EYI(<50 K]PAW 0P3BL)WQ;
M-$"=JU@9W2N$3R](PU# G#/0H5X&A)K0-SK$ DV:50DGZ3B--:5^>ARI8@RH
MK3\#T1+C=?/Y@6]."S\&)GP\5O1)[':9.*^VSVTM':N0=BV,O:QUH1>D! :W
M[_+4:5!,$"T55&_58Z1[@5@:*RI+')+5::Z&L/DBOF=FB!_SF_OL43LE?[2L
M?#RR+WKSCO.QA0[?TVY_>'ZOZR1;'N'>3UB&JA=8@M@MSQ#S.61.^69#B3#0
M>:;CY)$L\K%);4N:)79UN\5L*6I%I<X]"-"<H*M>,8$X-*^4S*Y@CEU;K_%>
M43'WILGR 9ZA7BM9HXLOJZ:EY5N/#CEFT7NS\[+KLQ)+>/!E39K/FR0DN&?^
M:\ ]DK0D:Y,BS0H95]U#PY*%G]O9!/$8F<R^2/@)'D)F)VY$-,$:8JX(1]^S
M0FAZ[6\C.9TK@O"+,3RFPZM*QB-FR@A<&58TLUW(7&&7.U)E#6<MSE\:LZZ&
M#*:9&=O!V+X:;!CI:UL=UG'% 0()C0/(R']VV1%$EB^\=^FPZG5A51,L%"HZ
MMSE83[K0,EM[9'G/TJ5S/*26B:[XO7&LR=C!FCC,W=AF%,_LP&!K5Q5%,E:F
M>+1G8V P:W7=2/M;(4EE&?4"9<F%,92[:B1@.;/:6[=Q9)?-I<BBUR,M=RH'
MF4;#P8NI4Y!7L=. I[3$VC'JO=U 2K0]J[ F?!G_]&SYMD<M M=X:=,<C&Q%
M_5>HA8*>J#((O[-H1I2,64832OLI/Q&]1IX %HPR'AY-Q/5O2$_?F9UV2Z\$
M4=43HYEAM"WKN*'+K"H%:\J(Y1GXKA!+N0Y4<R0#5>>[DA4M Q*A8;"A1.QT
M]=K>_LDYOT4X$Y\P%>Q'R2^P]"TO,\#ORVCWA8UQ>_GB1>.?7W[*.,G\-2,_
MZ4KZS:$)9_"_<3Z)?OI_4$L#!!0    ( ,F"6%9Z+2/K_AP  !*<   >
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MC^6O9H--CXSY^+B.6^B1NW(EFC<2!@1W(+%4L<Y-5$OH^O75%,^APL'<JG-
MC!@>$QQY9GH,-!3YPH\4NX]</FP"6)YDW]&='B<HKPMA1'GR>06:C\C2M72(
MQ7JJ3PX/Q;BS\!7"PT@$4D .-ASC<%$9:$%:ETR;/$F%8>(T@ <Y2Z4P70H+
M&I)G7<J18Q)3R%&4H8]NA2I'!@UQ^:;0VD.Z3R?*.(]C+)@"P:SI)32?813
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M11^WKRY!>;6?[&;Z'-5UO"K5=1FER)MY=#96-M8)1&F*5,JL [(M4,#?,5Z
MF_$I)UK!LCGWM)PK9,&1G5=SQ_.C/(23 L%BZ@NL+4H9H.@IPWMCT!NE**QC
MK/URE[,UV[FJX!N2+!5#H6*QV?>1Q%71B^U,B5-+(M[48,D@4W:*K#.BV$HP
M HLJ/\F78,/M\-GA;N157#A+24[S@0+P2 O#GGJSQ0UN[&IL4G=C.34[FA3A
MVS$Z%VX<##E\%(*DXU(?CMD9.9$/(1!FQ_IC40CMZ:#/(@(_J!^^NFQI'"^*
M*\P4Q)6U!'ZSL-#*-=%LYH5T&KMCWC R$7TBE54$;FG5'\@-C.F<=8A:2QI@
MP[WD*L-R?=;'7A=W 2B9U=M<+2L0&&Y16L(W_!G+HN&JVNM6+_0CJ-MMQ& Z
MG+6R71>(IQ!_+D;YF?NS.A*\G8:>^.'-X=Z9^/F&X#8R6*.-6;; >MGB^+^A
M/4O+_^5R@C32,8:C9X;B[_YH:_0742ZMZ^O.Y7GWWZ+UEUC.3:=]]>F:;%RP
M>-M7%["Z6XK2X*\5T!<?NQB0%7?=JX]TX?;/6OAS$L<']:/7+^RE';N^^MAM
M=SNWHG5Y+JYOKMJ=\T\WG24WI;&+1O\<HQP]54&Z @_MFBIPUQWWU4UMPP=3
M,>S4P2]1LHZWSA>J/UZ7SM'U<MC#0(&,T4\U[D7XAX+Z)AE>>"<1F._J\TQU
M,_H._2C,*%I!G5YRVSUWG\I> H%1T&7!@FVV2&4H6A3B@H\=$R?@<!G&*&VE
M&P>"R$Y$U\_@@OH*%&%8 ")GJBD;S9K!$X)=F"^*G#ORYK(@E>7H7 L,Y]2-
MZ^'N<;FIW.([YN:JPGM09>0=N8A\-'"ESA$^,HE"<-&F8-K#Y!]PXV'E*E_P
M,%HTD &!XFSYHA07""M&HF2R+TK).?/B-.F YY2,O2$&LQY4$)G"?MC%; #N
M9193\"N1@>*&!V!;?.:HKUL,'T<XE83+G)$^^ULS),41/E\E!;TMGJ2'$#U?
MW#K0BI\E6,BSV 2"$"%$U,3+J(O.@#(A]M<FF(_8YRW1/GD-KF,[0^88'\-@
MK@%N>9X)VTUSJ(:)^CG(D+GX(<>$8<_5PZ,=C9Z,KC@":6U$ZCEN-7</6FYA
M6"!_5@K8[1VNK"%/8U75O3.AM!-3@V3D<R% C8#F!BM,U$!.)M9"A$@1<,1[
M#DQ\.8=9&JRTX9>JL#]X]RRV-D%NQ0K8U^9L3(": :]9')L@DLG)LCC/Q3@A
M$BFD&V[SAP6"G01Z36SVMPQ2FT-U>M3/XD3E"J-J_.V^3(BC%P_,>F-6*5#J
M(TI2"DV':3"E)P-%"-@Y90&3\[;@A?!-$- N!@%G4)U*"VGV8=OV,.(F:/GR
M_*='"$O/L#C,JUX<G(9ZT(BE2B<J>%#;!-<H9JK*VPA3HL&3H<2V-[0;% AS
M6BU9_3N_Z2S!.>)GHOA^@19#V5\Q<5*2A'XFF.U7+0,)>'.P13/@\QZ!.1&1
M^5*BR30"K[C"4F#S(%>2MNC4P)OYE<)]IS!WS!,V7U]21#\EC==?_.VMF?AK
M60-UH550(0]MT)L?R!OU,*/.=.KY4PV?[X9LFNM&-J&EFSF[VZ$75T: 8'J/
M<N=P=Q>/=0AO4(R6V]1;U2:V:V$G3QC8; +#P)L:AC,&/CQ"@/U84-K"&/A1
M/"U@%MAP!),;95^ ^FH2# B$F$X-7,%.RPCE)UV$Y\S_&3;J-T[*^VM&RH:.
M9YT>2\:,:2OCS4/L.X<6D09QA 11RBCF7@X"+D(/)X\P%Y:"EAK((!AGZ5>4
M:Z\BBF.[I7Z]Q[&BE@=KXF[L[=8;%,<N^<,U\A@(.+)LW(/1/!:>I&+7VR:[
M;B@?N%9M)G:4(Y@XU1V!C/M<=F=F4#46Z9D/7YO-?G(I@BP<(7QK11QLIBQ,
MEM^4Q[ 0/"V1JYQ@5E$[,=1J@-V3&',MKA@MO:38W#^H-P]F2;+Y58F%M9*E
MZV9-(G7_I$(0=@$0;18F*G@DJ&?.%$C,8UR5TX31G&^.RRA._@[SY-<@BA!V
M!9;CSQEH:VQ-&V6Q1T'$>12E)3CD-2=T2I"5 K]1A+E,&&E 4OI!J\D\-]#,
MR/%)$FZ[/1?,Q6)J EWC"#.A,(ISF6WA6]D18_;);RO@=AA,B+%% <%DS-_2
M)WO&XBX1<YDP6X(KAOT+OF_V6#>KN2BA_FKY7T3+\X!NK/AG@OL2")%($L4I
M#NL(T@II7B975BQ+)1^H93!&(.9L_YJ@/ GUM'O0/I;"TJQR.%7-:I\)3MX$
MR!C8; H @9E#O&\^L_&=$_.ZV<W=T%(+47")7F:)JQS4+P7R:XMD5ZT48P5&
M,:WS=>QE(T0=>D6_:J[LR!"49F1YCN<SVL@6@\ZVN%ZZ&G$],P'4 =LPZ 4Y
MK7G!:MOT47:$P+F!T2^VXI\H!=R?SY T_GQ\WC*E$Z90R/8$SV/P"^Q&[,(5
M$5E:L%O>35PB?'J>'#FQ)K-T&,48C,40Z&(KO-J^-KMOA+%.'53=G"AEX+>%
M>CIU@F8%<X1<>0^!Q1=T=\]?X)CUI7I$NAF^R6*.D>1-[UH<!&F<-/?K+MFQ
M#@&_-HK3>6N*5,/4_8499TNLN'<:@X^S.,EDF.8UQWY.[HL<YM?E/A!W0928
MW^%X23:;A[RLKL.!6WMH>A*-L!"<R_K1%RU0SDE!*X&<S%4'N1!8AZSPKIRT
MB%P20BC[Q?Z:)D.VB-$R35Z"6TI1Y):VK9>DW[+@-ERVVV4_T/>F$K)FRV8$
M[C@.( /WW7E[%)G_6I+-Y!7](.W;6&SHU&2@'?E!RYRUWKB(L7B7SIWE/G>N
M-AT,9AB7#":L_\2TDVD=LEB1?:< PQ5(!.QGJ8) ABK*7I+Y3U98XS$T_HFK
MX5C.$WJ]7$ ON2:.\HHSR7'.>C>V3&S=9MHI4&I_A08%O=6:R!4:)$M(?:&<
M8KT9]%%%_@$S 7LS0)BJ=V7&S\G#N8[#4_6J1=@I)Z6=PDDJ:@=$C3[T2.6)
MB>:B&5&2Z[$]H92L<D$"F^0N8?4W%\V@_;OU%="!)Y$#=NF%I"TZM\QF?SE_
MPN @-2V*0&>%X./HB+IXE.C N BDI\IDEU.BH3_:9_.;*#;3@K/L=*_Y)TD2
M\0FS]&[,'W_;"&9HD_,?\MC]C8G8.ZG\1>-?WWY*./__G)%?S@7Y&XC^8CTF
MEX>=KQJ S3\(8O'D[]=[GC>=V]Y-M]WKWG5$^^JN<XGEDL^>\@H<\&K]B"TJ
M3'L)"L8]*MEJPB=TP]._#N>B=L,<).G\ZA:*4=L %"0D_\P2!O^H1Z';)M3%
M(-N?;X,971/J)L<BYPWPP#@N2JZ+OC58[ QKROMPN)CGFDE^P_(HXQ-,62G9
M3T4II4QLDQM[;P1_]2GB/2)\<(W;=Z%)#EI)C[%>'8;&,+^/U?@:;'A\!K0
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M,0J'/-YD:7=="Z=: TF41^A'2@(?7ZO;)H[6%*TF#K;=VM1;"W?2J"C^3'2
M355W3G0L))CAI13..M&!D#Y(*3P)AQX-84$:F7Q(<(2S&(?H%J'3[P:-]3V\
M%I#9\&?YU@6'UW".42S'.'HTQK. "S,Q-2F()BO40:70^D;29SO,B7<<$#=
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MFIP;C2;>UC>$H<6C<6BW]UQVY,7RU5"B;8#E^@EG=5A5MGXXU-X4#U(=J+]
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M!1TL\F@L3SMN-PQZ4$=DO(G-NE]87KU=RP[*ZLVZRFVY]E>=;V'WCZ:CNHF
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M72;,Y661&8>[SM%A^S' C-:1T]E?/R(8FMT]Z*R]V?:AT]S?7S?0>)?L=\M
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M4\!]C'B0E#;>O=$5]\[X^B(RGQC,>HA37;8WV@& :DV.-K4DZN2^,$+BHJ3
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MMQ'F;7"!6(6,]$YTG)"T4FE0+.9[C*<1Q3 _"^05Y([FAC"OIR^!>:T,-Z[
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M@?+L, HS0EG]\E/GX-AD@/%#Y&2H$+OVV&1=@5AFW59Z<\BZHY',Y*7%ZSE
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MUXJ .OI@1?,[$NVVK&%Y9E0E)Y]$24K8NA"3:Y!=2. ,S!\4T#EW&SX(5X*
M)E%&87,;SL?5-.P0* ,>PK&D,S,\[_X6PL([DA5B:SGT3R+*Q8V/F+[T5@0W
M8D>954Q717$>H4^AE76)IH,RQNI^6H?O_*S;Z'N#0S3X1F3\%3VG$Y)R0U'^
MEA7'41P&&>1'VU9F/H3F1"2[%&@RC3"_Y[R8(&4#<T)JIX$*C)O_I+:PS=.U
MO/],R5)>G+L]!V+Y2=RMJX7/A2=^!;NCE(LF,^R-G6V%ESWCSRK4O'#ZY*/'
M:!]/I)AV[2@FU"0S)TY;I&+O?AN/@8F#X0N",',,;>N5DK,M."?WR,U2LD5X
MD0_-*;D=7K'R%&NY/8IG=!"AE$C9?A%"6Q3Q@1"Q#"M27@2RDT+@ZFXI=GNO
MY/^0_C]/NMWF8\!*3Z353MUH5?N 2LJ*IE,)EBU&GH7BFLRMB&WCN.)A)9(G
MA_0CXE5R.+W<=)9/L_1%,KQOQOZ#4HD'Q_-BO>)>.]\C,D#\:*I%0?%MD'8@
M?;(K&C@D%D8GN"0<AE&K288C/QV5%"H:B2@9,HB J2XGJN+=<M6E@&5.3,85
MTWRC'/\I,Q[S7.G!KU88O$K9H7D)-:V-50BJYK@-+:N5D7Q/QKX863$ZYS)@
MXED8Z28(M792(A*J3HY[ EIH(H(EACBU/$ MKHSAM+P0:JE,O8)\$;^BT_L"
M6 JZ?T$B_#V#HQBSVD59[*KBJ.;LUMG]%>U(]ZXQ=\8"$YF3B)J*V#)-*=./
M+-E&T:9SA$T](WTE27RIHY4-L"JAOVRA9+XBVY2:%OFHU)_D3C"/)2:\&FT
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MKC\.T5 /Q>_M,/)F\+]Q.@E^^_]02P,$%     @ R8)85MC+_.KL'   J9D
M !X   !E>&AI8FET,3 S,"TR,#(Q86YN=6%L8V5O;BYH=&WM7>MSXL:6_[Y_
M15_/WER["F-C_/9DJAC,3,B.'V4SSLVGK49J3&>$Q.IAAOO7[WET2RT0-IXX
MADF22B482:U^G/?YG</;?YQ?M7N_7G?$,!T%XOKS^T_=MMC8WMGYI=G>V3GO
MG8N?>A>?Q'Y]MR%ZL0P3G>HHE,'.3N=R0VP,TW1\NK,SF4SJDV8]BN]W>C<[
M.-3^3A!%B:K[J;_Q[BU^ _]5TG_W7V__L;TMSB,O&ZDP%5ZL9*I\D24ZO!>_
M^"KY(K:WS5WM:#R-]?TP%7N[>TWQ2Q1_T0^2KZ<Z#=0[.\[;'?[[[0Z]Y&T_
M\J?OWOKZ06C_QPU]T/=/&L='^R?'!_U]*9NRV1P<'WK'\OC V]L[V/W?!DQR
M!V[G9Y)T&J@?-T8ZW!XJ?/_IT=XX/9MH/QV>-G9W_[E!][U[.XC"%%X6P\/\
MD<>8&RE57]-M&>C[\)36L\&/VLM>%$3QZ9M=^N<,KVP/Y$@'T]-_M6(M@W_5
M$MCY[43%>L"7$_T?=7H"<Z*_)F:2\'"@0V4GS3/M?!WJODY%8[?>W"W/\^D9
M5BS.>6@L?1^.;3M0@_3T<+^^?P0SLE_2,/FWSO@>G)>*7V8+&KM+[4&O<W-Q
M*SY<W2Q<RDC&]W#<:30^W:TW#IQUT.(:>\?UH_G5Y5^O;'F-(U@><$=#W/:N
MVO\CKJY[W:M+T>Y<B8\WK<O>GW/!GR_/.S>B]U-'?.OZB*'+:Z.O5KNNB\X-
MG.$/;YK'9Z)]5:^)[F6[#L*O<8*?.I>][EW''/3UI];E:RW^<2DP][*7WC(:
MYU2G,#-OB4WL#74BX%\IDFP$DYN*:"#2H1*PH!%\/1[#.+(?P!<1?9^DD?=%
M1&/4;"(9*T\/-*@D'<)5&,<W.J8NSO5@H&)46SS42$YIN"F.),.I&,<ZB@7\
M.\C2+"Z/7'_V!CY_VU-:EKFA'\6^BK=A^P,Y3M2I_7#FZV0<R.FI#FGSZ*$S
M,UP_2M-H=(HD\Z#B%#8J,!1!Q,&7"TU8WV5MF,)$4]^^V5RNTZ6=U*^XAF*D
ML? R+&CQHW\/^\2P)_7]QN%2P^[0N?'9 7DD8QG^N-'<F*$@5@AC8.@HT+Y
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M+T ]#0F: 4),IR9_;*=EA/*3+L)SYO\,&_4[)^7]-2-E0\>S3H\E8\89E6'
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M=ED0K]$)7K#/%FRS%1#7*NOGHRRYV237YIERT?JCL PS3;J[ZT^HO$$'VO8
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MJ4:"^5)K67$<BJE,QZFOXTZT_TM[=BHR!>:HE1R_:3R981I?/C@\MYM?0N$
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MWN\I'+>P[G&81BX9\.+L?-89[1712+>;,5M& M-PD_R9B,@R,2D3SI"8,<6
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M%79^M+@W"EB1JF^E2I,QQE5+I:GZU"QXD>4'3H!&T9HEYP"#;XP#H#FK1^1
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MO:(QKJ&TMM=-'MUO.?N'C:<DCV*WMT9S_5F>+>?XZ&@;LSR?E^S8/I!1_46
M;[=>/@)]00_*^;INOT<\>'3^PX/'N[Z4R6=FFQYA:DG99&?GZ"D#RO'+IZ L
MZ* A2?&ED;,6U>S];F!^WW:CO5J&+Z:>?S;2^W_O T'Y8:$:6-U\(T[UXROW
MX:R^B/K/WST4UU]>FJT^.P)=MC,8@^:$P1^[WPD82VC;DH2UYGX.@=\?[!UM
MHD0"P=Z!LX^P1Y[O[P7P?D#ZB4"\>0I*B:EMDHRV-"\5X/7X</4J!FL"T,;*
MS<FVBB8V]NM/(8K/JGKPNG3ST&ENIK3,?Q\ZK0.V<YW&(G7'CR:<ZSCB_P2F
M7J\"X-4ZWJW<<VU[+$KI.(ZRFS%U5*"PET6]G-]L36^VIC=;T\8OX,W6]/HP
MOQ6VIF;=.3CX8<%ZZY6E;5"5OEMC$\'NF[7IS=JT$>!K.H?U-W/3QBGHF[EI
M17-3L^W4#U[=WO1=T\8WJ]/+69V:^TZ[^69VVEJS4U5-PO8\*SBF,H4;*?9<
M5@@3 )<80S8CF>Z;1H5XKZ%([P1&M-Y%6*S !;@3,KTYT<DQTKJD(T&QR&$\
MC2AQ]T7Z:8%^W=A0V.'I:X0=5N;85H0=5B8\>0++D,@L5=TN#2V'=SHJ^7H*
MD'HQ&K'(=;,XT0_I1=,C'&M5ROI5NFQ5-,J-CSM<5P0P/ZFD0)UWAT4#SL5=
MX5WY]]R+UJI.J7<-K ?FMHI?ZH)\_;];O3/"*'UDWXR%@/2T,,050N&W-:<F
M/^R\GR6:GVLKFI4?V.UW>FZ+#HTOS"O -)(R!L@$@&6)B(G,]]FYWY4Q]05Z
MO*Q0"QOTSWK7I1QU^=O!@7-PJ /W91_$F>R#6!6H.L<"EHS<:CFMEMRN&OY9
MJ28_*I ,EP))@?0MAQ"8IG#:Q4MYSMFW0?5>8\[@EB;Y&/;F18*XA.1S\V>.
MB(:A\(K?):^!IONEN]6(.N_[JT;391[!E6=UGD/EGPQ$6R7&];8E>\1I'^,)
MG*DTT,TVIG18)YQA/^&;RE*)NIX#-1K&:N& 7)@KDJ2<%(=Y%#.Y)K'P,E>V
M-;8J0E26+C?UC4T%I?*H6/B<RB]36AO@1!9;B7,V M3D()[JAXB/\YZ-+UIP
MQ9CY-EYPY>N6@'K;.290/^U_[9_VSD]?LHQ*!:UI2K7<OI.7OY)J-#NM;DU8
M,[6XJ/,U0"Z5[=9:-7?=.,LK;E64%?1',CNY@&-Z3-7E$$L9Y>T997_Q4%7^
M+M9(!^:C:X11+FD^D%[1A'N 84@!9)T,T/JQ%@RF5JLP@)HN4XB;4@@HMQR%
MP4QOQ<)MAUT7YS(4A%:.M<+@5F531M6.0#8$P,Q<+(NFV'=D<W"93JM'I($6
M=8><7Y'ZTIR:++9&I=Q,53=Y?*X\/EGZ3 U$S5C+(_IV!1&']4=4,KZ0(PNO
M7%Y_495M*38'SM+'*A'Q2/BI;'PN[J<^]6,(H^6@XP+YU1_)8E:AO%,U)]%]
M>#(K%X6K'.TA6JXE(PU?V+V"IWXRFM$^4WZ?]W9 X$$/)%Y&- 0%7#:Z?U'2
MW) EEHK4>9]^W 2!WA;Z?.BTR24XZ%V=]<]-2:S>V>7GBW^<]<X'KTNO6X]K
M#S4@_@]J%KN*@"C^&#66CIT6'<+O(A0Q3'"5887$C8F'?4N"D@8\JB @3-$M
MI%"IJL@E%A/9H1AAM8%K,4UE"<A6O28U(%+)0FRVR['15*1LDE29(0)A%*L*
MR#*WRO!L92CK*DRD71?HIR9<%O&TJ+.U?"J#N1:(?2LK\*RR AO%_BVI;078
M?TPVEBN!%@;)FD'[)YRX(@39E"_BW6_L85I@" %)+=BCQMH%R9VT$X7JJ,^5
ML!MPV'3B08S%SZBU]SSA,#57%-Y;1C545OTPDVZ%^7+;(1ME\)824U&+!$$;
MT= 8ZW2OCOQ+J@$W7^>D3.7L^KBV^,=)4K=.:LP]LTR0!Q^VSCR:X#R ;ON/
M"P9:*[9M21T/PVM/!4_'6\UD+<3R *X!]CQ<\R)V6R,CIZU5K((=4K['+P#M
M$$]!LR/GW J(HM3%Y=ABKZ6V$%F<$J&!8=%0._8#L5!IDMN+R2R:8-W>W#X%
MRU$T9#&ADD6RD2@E+(!-S)?N3;!V;\QZ9M9$UB65]B^])+)C5:QB%;*TME.&
M@58B2L_UH&[$'+Q6.O0JCOU'T*$S/P$8 4U[DV6$'BOQHWT& 3 +I!E!!#ZP
M:7A4(Z@'5HN(<Q-'2<(F9H.U2M)4$-C]"94R2T4PR^MOEY=%F#&EF4&<4&8:
M0I,T+Q/\HD7AYX'ZD-HV;PBFM\3+82394S_A0S_PT]EW!-.+M%A="%*;N8Q)
M3_5W*0.>P@MT6,31!"1/=116N)6L/XBU-W&S'E!U07X+BPW'$;"'8:XACZC9
MY2S!B#E\!S< __+#D0\SX^A4#S!!8Z%P%5L/>"(=F/ H$/A'XM^;W@RQ],80
M$H-\3,)%S40(P6.4U6&A\*]D3!$DIL<=CNF92P84#L7(3Q.Y8SRDO-.#_=XT
MCH"Q3IXCQ9?+E^&L*3FMEHO;2\3TT)OOT9,WWK%Y,R[VT>J"O<F7B9)K/C)/
M:JVTY]-VT)XFD')2;OX'"UFRKP  &=F>XEM@$!LD0QV6 L0D(UDN_R&1'TL%
M_Y-V<"MW8/6-K6ECF N@C(-10 -Y:S^+&^[.E'^BIR+YT"MCU&]J83O#$4"H
M=L<%BC8N-K"0E"2EGSE0C)L0E'47O:G#+$&Z1[0CN@M%G(S]J7$(D>,":0:V
MC?9!DL:QBG7[K:TB"9EF\31*1#(OUBO_D/7^)$NH:#&VOXENR4]3(]PE%+_)
MHDPAG_4-OF)M5);KEM0".[JIJN^6O-_9ZS$^A.&)@,WF$5BI)+:FXNL;S'U'
MA1O,G2#R#M9  [;'Z_QU6[I\Y%[GZ\%5_^,7[=:8:^VQJCMZ0W+A#]= HKE-
MGHU/QHU0Z:S6AA3!@?84NY\,A>X"[DFQ23)_;K5"46[J4N/OHJ?:%CQ,0PKU
M(0EJROE?Z9@M=*$T#56^UD!81,N%\=2&@I.#_FZ,0J1:X$X8@7C&W:)/W6S.
M3Q*8=]?XY7.9)G\'XP!0S$HB[-*%+GJ@[?@F^3. 7(Y QD3Y4!I@[&KT0;%P
MOW7R+F[.XS&;P:J+_&FA+[U*$+0[++$OY0XSUK=Y5(3LJEY@$6JSVEU=EF53
M?H_6.!^N/\7]DKB[H+.S=G_YJ5Q\&&E-@U:?9ODME/O6OX24^$C;[X_70F0[
MK+Y%":Z 9U%HFOXMD!25BF9;'Z/Y/J(6"!;5I[PB=-'Z6RF4DAG88%(!8VP5
MV*!8$8U(H7HZ%KWAS]8Y3B3^?/4QW4L!GN[;C(RP"T)SB.K(UO@JV2VM546+
M5JZ5F%EU:V?;'#37GUH9,NV0<*F+$*"[;C91W2RKV'A-X:%MZJ3(+VWS,-;0
M_XS U:];TRFPJ8*T!U>=\^M/O:O.Q_[G_N ?+Q@/M5_9!;#Y\MV^%F2, G"3
M5;# ET!+3S(NK1.F,U^_ICM\%$+ 4?T'$-8F#T["($_0B$"DGU(Q?"'_4#E^
M0\4NE$\NX'>)="HDKHHB*"QG5)#A*UGDBEZNNE.OM*8=/@FA&I0&/3]:11#B
MYC!M2U -/06$:KW/O>[@ZN*\WV6=;K=W.4!%_1F&T"==W0,CO2H*#BPA:L)G
M9/-#&W<225,Z9F63"]H3+K 6&140^+="QMIX$3 ?4A8IS"R7[Q!1 9-&&9FD
M9-=.M/-ACL50YP)K#SA]$("N!J@I,%DCCD+?5;UT*<;G7QDJF#/,R$!KG[)=
M3CG&\?A32C@-EP[CL']$&7HZ!#RTABAZO<UNBB.H'<\DS[V)A5@VNTZWPF9/
M5.^08JKST9)9DHH)2;S#P$_&0OH$T*&?\I+** /IX:Q1 D ='N9$EQ 1N'3N
MU1?EX&U)<.8Z16[(WM3_^W;0EN:A<TBB>N?TK'^.YL#.H/^UQRXO_NQ=O60R
MRI8Q<U U=0Z%)@)&@S/L<AK=B;@D!..;TI/0O[XD'\)S4\5RS1')32QNT223
M&EM\)!,CD$2A_#"#Q6AZ%,4U\V^T*4VUA&)9D=[";U<+O]TR^ 1R7/"S^R/@
M/JCQ)UB$A,R&B4SI594K?'=L7&#_S+P;G<12LN9-^#<)7,KB8)M)!AK>2EX=
MF)C[L7$GQ2I5$3[Q8_)OA=*[JSI7<PG#.# ,@V;1%0G]RH6*'ZHJ(YLO;H=8
MN3UT7ZIOW<^=/S]VNG\#BO^YW_T'^W1QA5=]S;Y<7IRSZ_[OY_U/_6[G?,"N
M>M>#SJ"'22^Z*_QYM]_YC ^^?!Y<L\[Y*>OVK@:=_CGK7IQ=?NZ3(^EK_T+V
MDG_=W,9#Y^#-EP1:*@JOUWG5F"YHC$..J8P;;,-7&==FE;8!N3;*IC+L2/E
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M.OSVG?9!Z^<3=.XJ#Z#\8=Y#^&[5P9<[%X\?\FL_ K4 NO[CA?%^J$&7T*D
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M*I"QZT^+:-@.Q>_],/)F\)]Q.@E^^_]02P,$%     @ R8)85LXX\#K7'
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MU,H/=UFTTW<[])#YL>+ZZ:LF&.@G8;7F9_0A"H)H1AN,D\A3/@)%H#F\1(]
M<9 =N?39E0>$)USB2V*FLXD.Q9M]X<MY"H?V0>H 1ZX>J0'J0K3!0I\"%Z0
M[QV-<"[@PSS($*7[$"5CI0G?,JJSN+&N>'[@HWIUL*B2.J^?^N%UUZV2WK3?
MT*8=9/42AHW\QUW8<FE= 7E!=!-=TXH$4#;ZAK.)]B:,[984!G\DY7U(D&!R
M_0NL'238<4%A[=H4O%LQ4B!G4LLM)7!"0ZG0+[Z">1.<( 2MD:0.9NW<DP./
MI2G>!A,H"3(<#$LV+[OH/01*# 8P)? M+.@\$K<1>;WDD*0E!%S=(U\Z3J3'
M\4&13B1JLYD. AA,D !4OK&R)7P(;HJ7!Y*Y$JYUSR2)8$$PZ0^P[3:!D=YO
M"B.=ZEL-A^"+/JBQ6QG >:3KX:539I>LB=Y;PK?K5.4Z2U+RO"2'B]&QP?LG
M48#$NVT<!)#NUC5 -P59Q)@(0 08SK"#,]7%4E<<&(QL #>QEX7.1A2R-P44
M?BGG%+0&IDIS8/-R)+NVJ?15BS1*E*/^ !4$NT.'!C@MA!V#=R-9.^'VK$JI
MR3<A!F,.LABXA:XT#$>\)"A@@OY::D4(*E28Z"Y&.[(EPNC^<_02Y=N;Z!1@
M&MJ6F1,6T<45E)N^=S@8+0<%OW#8H?) VJ DLH_+'C)<AZYB.I[31C-YAPN)
MX)*$#A ?*Y)(- +_F,7$RN:1X[[]9**BMWY1\:+#H@)I<I03):Q#1'R)C5(C
M@I8E%S1I2$U6'3$T7!!:P -$"7YL213!D2Q@&DV ,!$ID2+,IR.@.61JUED6
MHP"SD=@_)3 %:![4FJ'N\AY@R)3!T(F$X4;@(4U1R2XH?+RID7WH5BO2+*Y:
M<. EQ5@SY.3R<?"FICD(%E\%J.KMLBQO@3$MIZ!#L\JG!9R4XO4CU+C@9'J:
M8KQ5;C1W&Z?4-]<36ZH 3E6'7I 3>[IQ<'FG@$>'SI1@3./%##-% 9X!V/Z*
M=V&Y',R&:%JUK2O[;7I&L*#8!*3-[*[,V"[71XMJ (F>F=PXW12Y<;3_IDN/
M/] R]-1:1 >H+73I;BQ;@/N7):B#PBA#,D&?'U=N=*1#:9:AT0DTZMP:S$#%
M7K$MHC9QK<C:%;1G(YL&J//1 +Y2MRK,D15@#&!B9 =0KZ@.61,"&T1M<<TY
M(6 -!_-693$I3^_G[->*5,72R$%B&#B>6PU+V98(E8X))H9%NHMBD,%"I]=%
M^DG?X,'&4!+5$8:)DL#'5^JFC:.U1:>-@^UVMO7.TIVT%A1_(3K MFHZ)SH6
M$LSP4)RSSG0@I ]2"D_"PE]C6)!&)A\3GF MQ[%.4 ;*PLU)]1T\%I#9\+-Z
MZ9+#:W$F#GPOISAZ,L6S@ _F8A;E()J,4 >50NN;2)_M,"O><4#<  DB\F_>
MG"#4@9(>!%N>X/&T6*HOE_]D]<QTJMQ9K5*@0^(_K)>YS.^LT+)&9#^-R=%[
M]O*OOW[YQR[6=>G%7H$MD,><WK4&,?BA$O@!.G^/ALC+_7TR2.0HNE6M1:3"
M6DJN+U[LPO(*"C;R!SR59!(^O-61=>3A4ZO[XPA4\QQO N*-$K^4FXY14L2!
MS-7H)93G9H<KHDKX=:E<Q-=BXA;R;:HRO )F@$F[,9*^OA-=DI!&H@.;$_#!
M)H>><O8>_/NX)L+31IB:Z6'PR"&FQK!!Y10.7K??'."V,:MW<$ZA)7'Q0?3/
M+C]?_'G6/Q\^+_1[8+!FYD(BZ$7Z)Q21K'**I/KWPB(T&"?$VYS3&N<Z,6-F
M.\<.8D#<YIY:K>S0Q2\D^Y&UPT<5J@2-PSQ0:U );=% DJM3((E?)%HT$-%:
M)K &+!BDJ BLEX4$9]=>0_/K)I'Q)&W1-WEX"\/#E4T(%Y/T-NFI<%Y80DT&
MU$Y!^0X*QI/["'<O[A;ANA6.@2QB&Z:R'%/L@32H!1Q  \$I)&IBS=T*E)B(
M/[X:-<N!WE!AE@ZXT>A4T-H9L5MDU\I\"XX+XW0\Y8K,^^K@9V7>C4'/KX'B
MUN+/_F=,:^&G)A@(G0^B)3L8<B)'/Y6#RZ2P\R)R6J0+S1FH3XE[DVJ*4&N1
M_4LN7PB_$I/?P^"E9K/.#>-1Q'YV]6C( <OJK.:V$;*MZP>(GASB AI\=!.6
MBK#B@")H<+US:7'0%&=#$3C.3#*6$U>#A<&,((24XYNZH3ARE*,QNXBT:]C7
MRC/5QZN%]AAZ2]14:@KG_1*,SULP;DRL8!#>1D$>9DB5PU*0K,O 8<BO6=@U
M$+<N5J\QLKVJ,2X1YA&)S&1-N!6VS>-(N49X:B4YQQ*BMFYF-HYOH*C)$7#B
M"$#=*L-5I M!$ )&%2Z9L+?T8844V\!&(8\:Q: -!9/X.'RY*.&6&8CI=\F^
M;FB14NT0M*,9+5S*T0655K1F5#_[!9''C\XF%\'UDF'$W,OXN$B)CI;'.-UB
MY#CB4NSC1 4$DRXM3S9IYOOE+7*4PO:R^BU+Q:#[<Y*4$O%&[8[ &?BV2XKJ
M6 8S.4^KTS]41?W G"N([2>2+2K0]F&W2-NK.T,&813NQBI!^)A@*4L*?IYI
ME18&&'M-J0@T"0?.N2G](O&>,I]/X=HDRF\FXE/!?2F[ZK_4\\^DGC<F)'>E
M,CAOPJ$WQ'MQ[-P1H@EV?0^HW!5Q@U5@@[^H(,H%MS$EE%D"8?79)")FL@D'
M%OCXTKYNMZPZ*3=H-<A42<QZ6U0@SHQL^<L, 79[))RMEY+NV)8[ L2O>/&"
M,44P$@*0+]@)0LSA0H+BBQ#A:(=9#^^@_$/S!6<;<+@J%6JA$L5X>O^&;?$6
M%"S<QU@E:'R0!C@:7+;M\5)>OB@RGQ)U0[9"5%L+9NL6>3[V&.\YJ6H93%5*
M_9*'/Y,\W)@0W:F2V60#1:&)]+/I@&O<% \$%@P4FY'SD4:8D(/QNI1#\BRH
MRD7_\C%XKL((I$.QH@IN5P\\5C0MG4-MIA6;3;F"3=EKB8\HOVKF9,N,,&45
MTR([MMS, PKV*4CIN6<M?%BW2.SLMX^HN\"93K%(!ES131&,-3TN'<_9T$@
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MHH$T=SYRWLRQPDLT\-+ZJS/N?U,& X%5I\L4+AA3@=ZZ43J?A#F:!+72IHE
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MXRB3Y:B+J1#N[I/![LZSVVC7>?TT2A)@3!N9&@,3> (+0,N<Y@DL\?.-G2?
M%Z>?0,MWNM+' SWN^__Z"V]EMI\-]I_A.KPZ.CDZ&_YQ3P/;[5R6X(TJXP_Z
MW!5X[O)X$*S55PI^?+:]O?GBH)A,HWQ.?VV]6 ^NHBJX!.F&DJ@N@GDQ"_#N
M,U7591KCK^<U'*S@70Y<=$U><G;^SKP@NHG*)*BF*D['*=R>YO""M H2+>><
MAX(AWFP>G<[*:@:?Q@_C1[M'SU23(V6GUTJ&<YI%N3<O_$&_>! $%S@$\\4
M_JAFH_^HV'P+N,2D"J(\">(B3TBT5T$QIFOT<KP$?U0JN#"W'MA;W6_3#<['
MW^69JN!M<$MYD\(;$C6&O6JO31C$T32M@5;_B\M/WYE5^D;GVZ4*8)^\U_ P
M!RWZ75XN=S*02?1Q@SG&4Y#[V__S E4!_N$)_]!F,5T:Q*=SI]U;-8M;K]71
M*%-Z!*.B3%2Y ;271=-*/=?_>-$8&CT$\RXO8::CHJZ+R?,](+?F8)'[\649
M]/[^X,G^#@ZZAM'428-I#V@^C^ND?6T7F,9F_^7-P5;OM3MZ[6,:,@\;%J8"
MGO"/1SN/&FM'' Y83U 569H$R,!>R"78N^85X8O/MZ<? [R$_]T9/'VJ10>O
M([ZS^PS=,RO?WH/5>(6L+[B83]6OO^P]>V'.E*Q?_]*4_)+O8VU:TH36!MGG
M1C#,\UF4>0OS^8=GM9=AT1$Y!%OM+H[(:J] ]T%X$\V#G1 MT>VN<Z"'HY_9
M([7PL\_&9L!ZY1<NL/>:'^G$\K@2%1=EA+K*\QFH["7>]>B?[T&M0V\#GN:O
M<)"W=P9[W^;"G!8E_@1Z550'N$K59W \41ZZA<*W=[AN8P8[RY^@A2OS#1ZO
M[J5!(ZQ];!Z3@KFT#OL9UWKT>\].W1Q8&][WQ=VOTOQL?["YL_4Y2O/^76NW
MGTRN=Z+ZW79\>52^J\=?Y\W!YK-/\;P<P(M'9?IE6M#QF].W9Q?#DXO@Y.W%
M\<&1IPM]G8%T$YG8]N2S"$KU_V9I"11,?HLBB,;CM)Q$Z"C(YD$4QPKV(JW!
M)O\+;GCS[OPBR(K+ #XB'H>BO 1;_[R.P&2?!S=J5*4UV-IUL(;^?9KDK[_L
M/N7_0U__A)ZH^(%!7$SH2C6-Z;\?\N(F4\FEHK^ H4272($XRGKN_P8C+C?4
MQY0$\@9Y42JZ@T=M?]R@J?*U=9HD3PO'3Y=@=KU>O 4G9['[[UZ/7/=.OP3>
M4]S0/*=E$:MD5J(KI8K+=*22H,@7;:%=)UQHQQ5TD]97:1[L;P9)-*]@[5Y&
M:89O]E>VSS^T\&W!!(0C',=95J.3YF51CE5:X\O%LV0>;/MM/F_'%HB93C&P
MM[OD_K>><OG6?V9P:L=SWR.\]4DGY$[]GL.5<0<_'>R0V>'X3]=$Z5X/3N']
M1?*P'F+@GIYWE\>$#E*B,_X+* VMA)NK-+YBCV6?*W5LCSC2"EQ4<$)2U"C@
MZC5\9R"?=$@FR^@*4K"C3:*'L[HJ;G+MWQP5'X-H5%RK,% ?B3 CUZD*/.$Z
M3=@=.D01"M\\/@Y&"I@&?/0$/E^0L4/R&FAY.@690(S?G1#?.BZCF,.[,(8(
M)0H-<Z1@2M4,H[13&&VEZCI3Y-5N$C2(BOT7003/@"B/9UG$' ,]M\YRE078
M'#"F?O)O4]GW1ZZ_K1"Y[F_C,ARF>)3@ !^!I+Z.,EBAZH'I])!IT*%*4#;@
MZ,7XJ\@^ZYHBZE-TMO3%!'].X9$DA7_!T9_"6TH=_Z"KW@F6PTI'G(@*I"$H
MM5$>*Q)SP30J(U XIE?!\=K!>A@D>M&4731#-O!PB70SQD_"9ZZ*#/1C$PP"
M,6K"0.F8@RT\,#BC2%_ZY3RJ:03:]&A.-T@$B[@'!8S@ATF1<V (J/DTFFL*
MK6; O^R;]-@F4:)P@G%47077:00Z(1 M?&1>@LH1TFR+&8IPT *(496!BLH<
M%K<*43F$OR,B95858./Q:V B 5<=S<B1(/Q!F G\Y8X2/][F)>R.F.,6PJ:@
M:G*,*P,;)\X)NL]CQF2;P9C@1^'$J!C!:#].42T.@[Q8O$UQ"<=#'J)%1BZ'
MJR;?A$$,<01V31>^#MXVBU5S+W,5JZJ*RKDY#7H/X;X*.&4UGM-$Z^@C#H1X
M/.T"GAHZTB-@9,)2%Y_,]XNTX9Z8]G?.;@]6D-TZE+)V[E&".=SK#\N WZ'
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M_$7T<>-,993Z>%RK217*\N0R.3I%?"[:\M2A0"THZ%Q&94IIE..RF#!5P0R
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M ;+? 7YIH)GN%C#=WI4-&YJO88"PCKW;U&37M '"J\=I"?9'$K'I4Y'TN I
M>L/_C\D_JHW$GD4S:D45@94"_'V"\X0?YL%-,<M0(%\K^*K*^;M74<)&1BD^
M(GPA[B2Z3V#5?-D;C&<E3EU$;[\DMYS:^:H6[[0 _(=V/?4YHSPR(5<4:!O
M"1<X5'4>.W+E:<%9_,]+E$#IM6JEM=L8$?M?[2/1J"HR.*B?F@G/_W]56A9_
MJ39&<+H^;$1CH(7G4783S:M&Q.<N$_!_3.ETM#+2Z=F W>[GUA%X!JK';(K,
MR6H5#[%(C3Q9K1FY+DLS4E^S!@X6J[*.X,?KM- :*CLZINRUR-)XWF6N.QX
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M'U498X&,>VF*I;'<(B"*&ZFM=3"LZYP3\EYEQ0@^?RIGZ2WE687!SMY6<#(
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M1A!<7&@N^,XH94>CHQG@RW\JTRV*7"&2W![L/L6E^'-X##2Y&EOU@,4>+3"
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M</@#3LP&VGO>UA<3A2[/X#J-@O-Y'@>__O)D^T7P^DS^\:;(U5S^W?$&S))
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MH8N-^U_,>E!75]1)4=7DJ\DQM="V$N]B MA8F=%8,EI$%NQ>>_9(EF%#-R3
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M*&+&*1^!CD]1/D%5<QN?^JJIZC/>)^GQ#MPGNK$LLLKMUD?8:S+XU.JC8GH
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M2YE*8+01_E.D\!84EQ@CU;&/W]^;T$>CFABL!%9SR14!CTC9<>+5C8C=4MH
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M+H<M]+R!833;M_O]Y[$ 342V+_I"?R.<R7-U5T]:Y^_O&XF;IH<]\<_6, G
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MC7:D22SM0[LEF@Y"64 )NCNK=46-&F<5/T>\^[0$,N-8 V%FSZ5;;91512N
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MV0%;4&"*- C:N9_+)%)J+&4:\HC6__RMT[]RRTK.?W7?A:/%HDB)HN";0K%
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MK#'X>%0D<_C/53W)_OG_ 5!+ P04    " #)@EA6AY VD.^Y  "BXP0 '@
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MD-]/?N ,<?'E28TDJ*\%5YV(7HNHESP%3+D.,0.2W(CH<42*WACP4)X]M55
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M?B[,D$U\A0]-8TPX,<5Y,GR\ W;)6-@M.U3J>C52U8*;[TEYW*;&7Q4;H4;
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M,"$9[I%@9U-]@LRXHO;/?KL%($!<$EQQQGJQ3\NG>:'' 4P()'B4C\3N1E4
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MOR:Y2>^!8K;01539^G2L,6P87$<J.)\F@^"W7Y_MO@K>G<D?'T"UG,K?+4_
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M^ZS)NT@X:RH6%U>>HO:&XLZU>TOT)6P^UH)U P-.6G,N-E*E:#W(X^3Z5JB
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M%32I!FSTV:X-WKH86ZH9B[LMW;7NOO7]M0VD===>R?9/XA:>B<:^V9C2BDP
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MYCZ$@?3XE=Z[F0*5%*]"'[I$"F!__UU&0<KM<^$B:;W+)@\HMM@-F+97FZ;
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MC)C(91^**%17M#KJ7^45+3Y,BQX*_^3\,59798TB: [^_GV"N0)9\W\,N[J
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M>TU!P2<//"A8IDRM2ZU-*.:E)*[HO%VU 7=D]>_0=Y%7_8YT=)?E TYM9^
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M!-*M97)R[^C7P[LW9O8P^>NCQI!^1 ,C;5\[/&5]YP;M_(J"YE=9$A_R;_\
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MHN)_^YR0R"@ND-.4M>!21!D%]>X8<1AM('*!%>*&.6"O!7;20WMKP?9B,59
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M3+*/T%GE&<$C96P$TLZ>\3);;QW8Y+N3A ?&!3C<G4RI#H>+MPQB3WLT_G[
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M"6;8B/?Q['F(N-"ZQQ-* SQS2&M&WUK&K<\*^1F96/12LS+TY\A1!-1CFU4
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M.-.[]F6=4QPU<9E7RQ!<G+P[/@]JA23RV=XF9Z(DG\*DS=-UCGLWY7'Q^RS
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M,[R?52@""8#M@,8&;!;*=62PB08.AXFJ9C*:%A2D046!^X7.X1B>[*<;ODQ
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M8RQ)\@0<-C0B2)E?.&:1@M& %?C$XN::'-:^EK>L22_&-N@(A3>QN]:"V(1
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M[EXLE1U<*42UNMX-N*&-X^KF(CAI2%LC/JE2.6:Y\)1JF#*NYV.N:3E[F":
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MWX6?P11H!"[-J.WH9Q0=?24]5.IV#</9D72AUH"JX:+1,^I+TZMKX4X7A&I
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M:5J,B9Z4EQ=#U)>)BI%1_1..C]\!AH=WQ776&,@(T/!UR\R]9E+X64$!*;Q
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M8+$]B"AQ@^YU0""%W:J617(L3QXWJ;4)U@HWSM<'*\Z\]@,7+-1R_HR;;P#
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M)"Y9JZAPF0RVC&Q6 ARI-!L+B-% P@@B-X@;_63$M$*$X )OFEU)+09;EN2
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MM^KWN!^\.V&#70?\6^8</-16%S0&WMY\OG@XPNM_UHZNBT3M;YBC-G" -AN
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MI7-TQ\3SB,4\WJQ)-V&)MRFR=I-Q0&_S>XU7.-5T(5)TUQ(BLI'M4.A-^_)
MBS#L9E+OB[?O/KQGE=,5PR%R*./[FS@K$@Y[RI_FHE!+MIPK836"$6)0@NMB
M<7 .[W*1022Z'& Q-#(/ &\WPD;J4@].QPRKGE"'F"Z*[ZS9&DY+F&HI% >!
M.<45&OKNFZ.#$[HELPO/DU(!/'F$5<'@H=W.RZ.CSM&+P\[!BX.7CU<D?U*Y
M25VIA >LL Y,!,1@  "*FS,SQBAZ*III.%6BNWB5&"+^,T3E9?X=V[S3P&0P
M:8!Z1Y.'0M6^$@72(8'UE*7:(%CMJB@Y'+6H ##^TP_$7V,V-BX&'F?,3INH
M=\B1]L&"HBDI*:= O3XS%[K.I1?1H:!;6)](W0!!:RDQ'?0-1AP@MF'N @J(
MA'F\I!WPO1NG;*1%&8KE<M7!R[.%&\FBWR6TIQ%;1(@HKAK!5^II2HHE] TE
MB] V-GDF9,4U2AJ'6V#'L?X72FFL<$(EQ:C*,%4GP=Q]RQDO\"7^0 7(\(LN
MNA?(@<S%Q3Q;5?2N*_#6IB8\#+\9318C31''2$5LW R\J8D76M*/GZD5(\/@
MFG1@JK?1NE1-]LU444$+ N>M+72#+<8Y/BO:"*X8PM#2:E&.&3E]G$7:3D9!
M#8NRRURJ&3EBBK9)6-"UVT%*(MB7H3YE6)*%1GU-6<<+0O R@-9=_-%',#E5
M_V&FK6U4,_+.\59U)W;(M;, WGD4 J'*^VI-H2<JWN'NBK2(G6)J)Q"'55-S
MS;4HFG;?(OG[RP^E8->?A]SUN4P0G16VQ9K'@P]/\HLU^1(I[20A<$R)$D97
M3AO";YHR+N$SAINC.SI3@S4UI"\:@(JA*_R#**Q"NIH?3/Y\Z/@$DO"A%H"K
M&TJ'<+D0)1UD[Q$BHU.7MRVL;KR6/NV?>RK#.\;Z2#F!2J@@D0MR(*]9.%.L
M$5!]C*A,& 7%K;=8F.D2WR2E[]'*O0OB8 Z5L-F+S0B(3#[MJ=&9=PMFINY7
M;>D7:EDY<*E'%7D,3RC;[ETKL:=B6?M:<X\S4%)PS7#!$ZS^3H>(KU]FBW;5
M;T!6\Z@N/59B)8H-X_$&TA/"Z"XT>AKP9Z=H-)K\$9S&VYPP(]+%S80RC\)-
MZ(N+X,O!;)V>GX:K*YP3C]N!'_SW7O%W-GDUG[#%GR[>1>#M@@ZI@XKN.ZB4
M@\USCF.<D!9.%O?86/XMU2TJ3/D$_=GLGR?HSP.%_AP\07^>H#]?7:#("+R=
MLMQHKC%8S')OO&EQO)=B1ZO+=WG/;9]2=-AMVZC43?*T\P\_7BWZDS<6WXX5
M9]=<!;<"5<M+O"!VMX@X5?$1+,AJNKMRZ)*5N@7F0CEKMEWQCR)#"\GW;%ZN
MN,-T^3(*LAW:)AWF,L8+'W1T[U7CD]"NDQDW$E>)[+K;JG\R"&<;+@Z>[JB<
MXU4''B]'X0\BC;5G+NIYL2XRV+J>FF*G73 ZHJEYPU4_WFQM=-$RFO"@]^KM
M(YCDNH.S6 >X'$DV>_&R"#O!:Q:R4-6;BS>&FA2X-/XDK 9G(8[QU<LC@AD0
M>45Y-E8-:^<#1M(:U_F0\Q7QM@D^C=ZS&'?HG8J"KYQ5-V %-)==5 8$"YP8
M'">%5=@=-F\?H=:,W3$G>27M//'UL$LNKS*I;8DWB?CGVE63,1*#F:Z^& MY
MPV!;"L=+R#>'PYPNE=^.)Y6$:MZA<V?](!##^5FI+7\V'1XP<B OC87[%F$-
M@\N*_('.?>'MNLC;S&L?#X^CG:UMCVZ$#D/V(GAAA9,5BQ[(3&8P'5U6=*'=
M"H=)>Y6:Y'6NM'[3&<.VC;#LE^3 OY^M,T#CRZE#1=-!Q')A:N\1YN7+A]\R
M!UFUZI'B"CK>'EWD%58C:>986=74]0A)-KY'NO^ZMF!:\M5OBPN/1<P<_> 6
M4S%N+G><NUK#_E/2I/TR2<?0+5]KUW7K]"^Z6\SD6(N%DW7+Z#[G.28^JK7[
MZA+=F^&1,N>="E,.Q>3:YT_3=F(GOBX/MY\PIZ&".[Z<-@ARF6/T8LRKLH(B
M'RU+?G^3JDF%M-)4]'>)G4WIB$P@L]/%8GU_<O=Q\+<)#Q.5F: ;<Y4'3PY@
M6%WK1EM:N]=;?G-H0!;1R0@>] /97J@HP]PKTJ1"67AFV,2#MA=.=]6ZI!Q'
M1Y[^$,UNA=Q;TTON.C^Z*0IQ%.VS$2X@X#K";DD_VRT?OU8'2VXKIZ>Y.O5M
M".C2X8GVK^3D5-=;%A5@RA'=C\A$)WK;4VG?GMK^#?IK0'7 2[%B4]9>Y&3U
MJ<:!13&J+Z&LAAZ8/H U_%YK!X7!"ADW_G8X8CZ\8#[7^1$<]W4@EU:%\D<P
MS\]JFMII5DZMX33J)HBY6+.=!"]>,['R:A@6-^'\XD40(-GYQX11,G'9B%!2
ME7Z+"^XGT3&5/LZ9N$(NGL=DJ G\5F=#3_F92ND6'+. 5I6"RW$P=*O]6Q\X
M7,;GC&Z6\-\3_W'O81#'\I/80!/&<3>UA/%A))5,7_2=A/"L:5^)075YHM@M
MI2?-@["U#F&AG"G8%/#W]0MO6WO/V&-'/?\R</="Q+5*K)IJA97K'BVEWWYI
MTF"@[5CXBS1)E"Y<48"E4VS]*,!/JQ?HO!UBYWNFZ?J4*5:AJEJ<(KJ?-,(Y
MU&D*^A#B@_QM4_[2#%C,#F$MB4RI7E")1[3 JS J76*!7F/;16^:Y*/HBBJ\
M6L!C.:T>4ZF[=*3PDL=60T$58I</WG QM'1NZ6G'?TIW365L>I!'!2& K=0G
M5I:1H>!U)[YB0$$1Z,N**N3]X4EL]\32;+T5'W1)2MO;%+57\F6=N0(_'A\6
M<J_*ST^W>]E-%KAF?)EDWU)];>1!7.TIS@APFA&VEX0@/K BK'NHVL8T%^?@
M(3L 0##QM[L;A09Q<9?5'!=A\PS#BZ_/<1 4[U[QT7^+X&*T^5E,*??S':!X
MR6HL7N*A?C-WQ9"_T(-A$5QQFBN_Q+<0K[K*T^-5U[E8X_/(U$!V91_S318+
ME3;@5MJ^/_Z0W+)]M]5Z_!5]'E/M4+LH.-$6SBM?-RR446TV"$Y.59<N<=B!
M_;S+BG@C^9B;I6'^I%76_7.68+5FN]E46^\U9_.T\<70!694OA4L;,S+=O<S
ML?LO]<C.@%S.:NMQV)SGM.*,/5Y1[2[_QASYC18(OZSP5L"/\$:>;Y0KD]@@
MC.:D6JS)3$#DZ\+,<I4-U6KA$E0;EW!"Q2[Y4>>YI)LC)5Z0-O0.2V!U*=T(
M9V*)@/6F%5X]KZQ%CX;GK^XJ(TW7N4V,9F^*ST=Y0L8\C#]/R)@'BHPY?$+&
M/"%C_@"D/U4_1S69+(R&R0?N'E*JR'-CQTL5!DCVK#5]R7F.>2)MM=!7+'B8
MRG"K1LB$E0TP(U#?1_<)_)W*PJ4S5+5=%;YM\B=!G)*>\'C5L5^=Q6N;O%F^
M<.H&R[ H*LI]+E %:>=OA8H/BT7ZO)$8X64X.HQN.ZP0BG<90)-]=R\S+7]S
MSQ8GX&(J0UV%:'L*UCKF0%+&+]YW,G<UE<VU-\.=S1:K1\N;=MO.;&;Y+_'B
M'%")YLFRE'MHH[WMU!$$J*2_H:,^B QQ)L$DW:1F_;_-G_MD&]QZ?C<SDU4K
M>@\R>4A3.7<'=-%CU)@PX1(>GPRVA++[DH/]1_SV,(]?6W=>92!L8M]99_C/
M_WZ82L<_:["67_&=4G\ZL:S+.8K(X&NM_KJ_ST"9?'(#/(P_3VZ !^H&./J,
M&V"G;[(Y_#.JQOF;_P-02P,$%     @ R8)85K'&. ,W'   EH@  !X   !E
M>&AI8FET,3 W+3(P,3=A;FYU86QN<7-O="YH=&WM76MSVS;6_O[^"JS[;M>>
MD>6+<G'L-#..+XF[\65M)YU^VH%(R$)#D5R0M*S]]7LN  A2E..VB:WMMM-I
M+9&X'9SK<PZ@UW\Y/#^X_OGB2(S+22(N/K[]<'(@5M8W-GX:'&QL'%X?BO?7
MIQ_$L_[FEK@V,BUTJ;-4)AL;1V<K8F5<EOGNQL9T.NU/!_W,W&Q<7VY@5\\V
MDBPK5#\NXY4WK_$;^*^2\9O_>_V7]75QF$751*6EB(R2I8I%5>CT1OP4J^*S
M6%^W;QUD^<SHFW$IMC>W!^*GS'S6MY*?E[I,U!O7S^L-_OQZ@P9Y/<SBV9O7
ML;X5.OYA12L5;^U$SP:OHF?X7_EJ--@:#0:O=E[M/-]\&<E_;L$D-^!U;E.4
MLT3]L#+1Z?I8X?B[@Q=YN3?5<3G>W=K<_.L*O??F]2A+2QC,0&/^D_N8ZZE4
M=^6Z3/1-NDOK6>&F[G&4)9G9_6Z3_MG#)^LC.=');/=O^T;+Y&^] BB_7BBC
M1_RXT/]6NZ]@3O1IRI-\"8T3G2HW:9[IT=U8#W4IMC;[+YO3[)Y@!.14YNO,
M<&OS05.\/KH\O1+'YY=B22>XO;GU4IR=GZW_X^/^AY/CDZ-#<75]?O!W<7YQ
M?7)^)E;/_G%UOB;>7>Z?75\MZ1H^GAT>78KK]T?B].@2IO[]=X.=/7%PWN^)
MD[.#/HC8UB;^=71V??+IR*[OXL/^V=QZ%O*]?_;55D3][.H2J!8]A)'&NA#P
MKQ1%-9E(,Q/92)1C)8#8$_@ZSZ$?.4S@BXR^+\HL^BRR')6:*'(5Z9$&;:13
M> K]Q%:]],6A'HV408W%74WDC+J;84\RG8G<Z,P(^'=4E95I]MR?Y^O[:.BH
MY_5-?]/K'/<LUD6>R-FN3HD*PP1&V[M5IH3U)9;)RBRW.NO9B_Z+%R]:7>0R
MCD'IKB=J! JN#QH.GI=$'?O&,#.Q,NNPBXG,"[7K_MAKC4Z-]H#>-Z QAUE9
M9I/=Y["%[?D@__-C.Z]7._WG6ULXKQ+H4,:ME?=IU1ME//_LV<O^]F!GX>/-
M_M;"9_=U^WRS__S%]H.ZW: I\[2!,$4NTQ]6!BLMVA%QMW*0B"S1L4!1V+./
M8'O:3^R6[&[G=P(>[04: SOJV.#'M"3OP/Z7XGJ6J^^_>[ZSY_G64FHQ$0QW
M\M]&A6>=5$!5+QIK_^V<L"PK[=[O<U:+%T9'7V7'EV6UW?OZ_R\&_5<O_R<V
ME@7Y$!SO)]A6-@"/N;.G8*N?]]#!^=_8WJ.[7!M)LOM$>_S(HHL;_ PW>+MS
M@]T<7)OG[.G\UDW?1 JL_&Y2-KKY8[(B3R964<;LN%NEL Q\:^7-)U64&/(C
MAWYCYJ3/&H9.;2"_K#2YR Q);3F6I4 "%7\P??4E_;SS1^6$[H4?:U.4I)[%
M8- ?# 9_?9K]?DJ3_.J)M_SQUWX%LI_&OW?;;9C='53]=_/$]N;#>>)>,OQ!
M&.:M3&0:J7DFV2#@Y3&1N8<YH"=]\>[H[.AR_X,X.3L^OSS=1Y3T\7'$AY&7
M0,,&$#@$"9VH0J@[92)=$"2F4Z'^5<D$_BA*F20("Q9BM:B&OZBH)!10F R,
M.3HUN<DB511K@HRY$J&S4T /,?!3Z7!&)60$XP%_S_"=87;7%_-S4NC40V/X
M4\/ +1^_)Z9C'8T1^\0.8Q"EH1IE1EGT,RW'0J:I!EXN EBT#@3[XF0D9EEE
MA)KD23:CY,Q40S-\[X"G1]TK,]$ISK['[W."!M9OJ:48.FU,?JJ3!"8D8L7-
M8>FX9D/$LE LXZI $="/U.CDI/_T++,@P@)-H(<ZT>6L$5T]&L^*8 8"]EG<
MX$X2]AW0F%Q+(NXI;,UG!_EG"/FGD8/\4TQ& &>(*]JR"U VU"4S@D*>&X5<
MT",&!,8O=*RET:K@;^1H!/,A#H?6^,TOF09ZW$+W%;*N'L'D"M"AQ/O#F>]4
MI06SLDQC\5:E:H2MX<E$EZ52.#XMX/OO=K:W7NX5XFTF38Q?'X),1&5F8 IV
MS%@EZ@8&$*O8.[;8WMSS7='GK;VU7XG(/R)K7=4*Y1+44)5S>O.1^8N]D^,&
M%X!HOL4->K&Y21LEA]DM*!Z2=F8="QCN3W%WG,P'&M+X!3G-IY Y<",C,+(2
MOKS564*\0%SG]$X.YCN:82-6&V@.Y[23YP[[-O)P34+7G><U?(Q? ,MB;Y_\
MP#TA@;U5B6_ "##H?@[-8GTG]L6JY-P/+$Q"MS$P\LAD$U'J"2>5X/]K2ZNW
M0*4*3+:>G)%%%N?'XNCTXL/YSZ='9]?+.NE]\"9 )QBPO9=5HOJ/KVP[3&/#
M$A(O(9\:)0M@K0RX$O6N1";/P"*V,HL*&B1)-B5701H)RCL?%SUZDEL,@'1N
MVXX2, !?5NDM>!3*"AF[!L[7B%'YM:<+G%J 3+_:>_@8'2-4:0)>C3?T<>AC
MG*FI^#DSGZTJ.+J+8/DW2D0)$*!H:F/\"@=_BU4?T*/3RO42&NY+ 9)&W[ED
M[EB#?IEDZ-2LVCY_ F4 M+T>&[ 7I_BH[E6.2FL&B39!2ABW#]>\.JQ():69
MU4AU$U4[6K:A2XL +V4Q6!(QMQ[/#S3IU/IF]U$)Z)UFH*- SXB) E:EMR/7
M\=!U_ UYOUOX**W]^!)'/B'P(6W8=*R8+T)R(:F ]C^!I!&7&$M$B!4-.!MY
MQIZX91O)[,(BELBB#/F).8E<)S4!KH;!ARW.DUA3 /8!F (_KJK^#3A19V
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MO^AM_9KY+^UF/_-FMNU@M:\>"JO*4KR0%@V/!IY&DC52,-ZCPOQN&B$]L/"
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MAV*U4% J;E<PQUR=[P37C\[]$H8?('#9&B7I]/)5?<V2O\!ZGR.GK5<#D,V
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MRJK3!7D!CM_._KOEG]'PA R<GB2WEE$C%Z;GF9J*WZ/XFQ'(_3L/EG^CA!?
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M\%W)58?9EI-R#Q9K++?R2#GY]$$A@O*,% @\( N=$)O'Y2Q4JQJP6R0.9)&
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M1_0J3::RXF3/"[PUD%N,)@,&'V:!H$A5!!P_SI?3I%O?6-5B%7F<>U?K\R*
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MP35"K*!3"&Y7UA;BD-).7HX?EJSJ4_E-A2:1@R7%]+%@7-Y2F'^L.=J:$82
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M+MB5343#94('8* C"V!( D,5GECJ6R.-T?"<BCKQ,G\(CNBZX74_D(/P/:)
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MH:K25@ B(1!74RP0;5.1""5)9.B E2 A2R]$VG>6A($$D/"WDJ7'+4=1'EB
M+$&6,9=H)@L0_O:RH% [ 0KM@ZL4\_W@G@Y$K,A;Q(07$NI\.R460,P#B/#R
MEW7]$6OM ('T>F *9"(.[)DLI''L6'AA-;?Q[WG=TF,1O6Z(JM8VSG-V$!X1
ML#0)RY#KP9!+MI]OLEY=O%K4K36Y8H>6QWMD;9/5;A4BC?1ZU2,]4;E'2)%<
M6J%C8_^!L"RO^@]*#D31'KEL$)3MW2C;6T79'LKVX(;-T8@X+T;<L5*P3AD#
M^9/PN 4WEQ49P?U"E))>IPW++R2VM1I%(]RK;PNET.R?BB1(I$W!P:<N4@3)
MJ+$A[*A"[5&S!'BN5'"2/(\1=VL#&*27Y%P$;Q44-+GDE17;(29ESS_^\> F
M44 !)=J_R+I?\0 4J$B"^HED2W_(!W$>V(T6Y8B:B4B#J#D%#T,QDHYM2'.C
MT Z-F0DH QR(X+"1'<,\I)?FH_##:;8@>G>D02(OI-"%P" +&L*T*N<M1APU
M#4-8\E/8!!IRP"8DPD JXS!HGJ(T"!M2;.BU-F*&:W'*\B&W8_;LZ=K;=;9I
MAJ.[=  2S:K3E7Y8_=!$%S#QGZ_Z,3^5K/57Q8M*^<H*ED]B#I]C8G@"0Y%>
MGTZ!=N*-,R&"WQ0WE^ LD= #SE)*"- LG)(L/]@L'*5S\R E;K?&9LFHER,O
M%NKE_H-ZN374RZ%>#CY6 Y:#M8Y8ST_0]HF$+O6977@V;$4U38-AVS>:=Z Q
M(!EEQ$45/!WPT#@/LP0GI'/0$ 7MT%+!X&>-G=BVE<*9B1\BQXF(.#LBZ'+G
M]%D ,4<@8@]E;B5G/2M&LAK=:@MHT!&0A$X[%8\]4> [-4U'+!ZJ.RFC3H*
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M7+/X0KMWK?^.M0<O'U9[\*)ORDGX,/0C]>'_ U!+ P04    " #)@EA6J:=
MYBHP" !L)F0 $    &UR:RTR,#(R,3(S,2YH=&WLO6M[$\?2]_O^_A39[+?/
M)'VH/N7*RG,1(-FL&YD$3%CVFUQ5W=6VC"RQ9!NP/_VNEFU.2; )LJ41 \&Q
M3C.CJ5]7_:L/U3_\WS>'DV]>\?QH/)O^ZX[^5MWYYO_^^,/_TW7_^>G)HV_N
MS_+)(4^/O[DW9SSF\LWK\?'^-\\+'[WXILYGA]\\G\U?C%]AURT^<V_V\G0^
MWML__L8H8S]Z<?Z]QZBB==S98FT'.F)'['5G+:,R9)7!^G_VOJ^&7&"F#JHI
M\K9:NVAS[#0!IQH0G+'_IWR/-H+6L6@7#"A6B6URH"DI-BJJVDZ[?RS?3K[A
M].C[PN-_W=D_/G[Y_7??O:'YY-LCSM_NS5Y])R]\)Y=K[ER\,<].IL?ST[]^
M\\6+'WQ@,IZ^>/ONUZ]??[OXQ&R^)^]2]KOV,N$17[Y]_.;XK]\]GLI;N=WW
M[X[G.#VJL_DA'HM=VME4ITRGWY[SY*C;0WSY]D 5CVAQD(L7/KC P_F'UW?(
M\_SBVSP[7+Q+&ZLOWWDT/_[S(>7)#P[7+GC\B2\\GAX=XS2__<)OCCY\]VM[
M^5[]W7]&CY[F?3[$[N-/C8]F8'3XU'G.WW'Q@;\ZA4XI??>F0?#^M9>/0+@X
MH/_N_,5W=OJ[<VO[GJW>'OE/&'QP$>W5]PCH!*@/WGP)V*<@T*Y3L;NPUO<3
MG.[]ZPY/NV=/[PCIC.7''P[Y&+]I1^WXOR?C5_^Z<V\V/9;VVVV?OI0[F\\?
M_>O.,;\Y_FYQ7[[[\7_^YW]^.!X?3_A'X:2[).*'[\Z?^^&[\R/3K)S^^$,9
MO_KFZ/ATPO^Z4\9'+R=X^OUT-F4Y__C-]^V-/#__=5P*3Q>_RNM;XD/FXWQ^
M^C?'3[C^Z\X8:ZPYENP59LCHR:5J$ P6P$#&_G&_78K22G?O*)WB83LUC[^_
M*VZI--?T\P3W[GQS?IODL&^.OZ_C-URZBI/6YL9%GBSV]U.Z/WOUR#QYM6-'
M)^7@P:O=7]+!X\,'9X_O__9FM+W_8K3]S(X.?GN]NWW7[6Z/W-;V;V]V#E[(
MXX>O']__Z?"1W9KLG+W<'YWMJ='V ]B]_T!OG3U4HU^>O7[\_-G9X^UG:O3\
MH9/'IZ/[>Z]W)U$],KNG.\^SWSK<>;-U^+M\_B[L'(Y>;]V?O-@ZV%.[V[_9
MG;/)B]']NV;K^4-Y[X-7Y9>?Q_3+,[^UO6-VGS]S.V=ELG6P\WKKEQV[>W\R
MWCH;J:W#W</1]EWU^'Y6NP=W+S[SNWS>37>W9WKK8'>RNSTYV#+/S-;!77E/
M>?'X^4,[.OO-[,JUC.[_!EMG3PY'/\LU;C\X'CU5;QYMYS>CL]'K/\ 1UAIJ
MEWSB#JPM72IR0QT1U)2P6HUW?OSY[J.G#W[X[@,#WZ2]+R/1S^.CC),=QOG/
M\LS18."K#*S_9."4#*644X?&21CFE"0,%^XDN+KD3&'RZLZ/S0@KL^^O<OQ9
M&2Q\+0N;/UDX9VG N9HN&I8F7"UU%&SM.( K8+,+(4@3WKE%^SZ82CPYO2<6
MGN/DX;3PF__ET\&V5]G6_<FVR(ES\:8KF74'J$(7O9C:>$Y6V12BRG=^5/+'
MBBU<_!P;%T-9G+\*QBFPX+!$UY0Y*,6H"WW"QJ(=OG_"KWAZPD\XS_:FXR9:
M?IG-RM'BQQ,^/IE/S]OUK_)C?CQ[\.;E>+[0-O<EMU@M"V^V[N^]VIW^>W_W
M;'8VNK\_EL=O=LZR?&9'[1S\-#GGXL6IG/=L9'[>WSW8@\?WDMK]S[[*A[]/
M\7DZ>7PP>OWXEX=B]Y\/ML[D^@Z>C$>__#X6KM3C[8>G6_='9SO/?SY\?'\/
M_G/VX&QT\.ST#_+:9!- ?+#\ /G949+T*$A"4VJ*R@>Z\^.O=O0WAOQYCKG=
MPV].Y)8OS#@].22>W_G0M!2+(&%<4A"A<D$CK=D:)PW:N1S/3:N5ERSC\I<[
MWQ3.XT/14?^Z\W#KYTM+7V08WS\]GN47^[.):+ZC!Z(VCT^W9L>\>/;IR\GX
M6*3G15[YI!E92&F>70Z@5FWJ[=\N32U-?$_,N^?D/&>[OXSD\;\/=PX>GDGS
MUB.YCJW[#^4ZGKT>C3\V]9/)X_M/QH_OOY#C;;W8.7LR&1WNCD<'(VG>STYW
MMD=J=/! 7KM[^I^SA_8/SM4'E*RT%FD]P)+91J-+ETLNR44VNB9IMM_J2S-?
MVO73#3:Z;)7*U48+"0L9KZ,2]YY"8I?-)QKLI1F?\-'Q_"1+ZQQ/]QY.\\E\
MSN7>[.CXZ;&TRA:2'U=Y>G;(C^?W9H<OY[S/TZ/Q*SY_\L&;X_:0)OQ@VJYP
MT9Y7;>"#T:6!W^QL;XUW#G?D<[_9+;,COG;'[;2VN/U ;9T]>+W[?.O%[B\[
M9NLTJ9WG_S[:W7[Y8NOYCM[:WFMM]6#'R/&W1Z]WMG</M@ZW)O+O4#YS(&U[
MLC6^^,Q__KU/AV7R^/ WO7OP3#^^O[6_T]XCWV5T]M/^UN'(R''DW^Y$SG2X
M]<LS(U <C^XUO_[@>*OY@K.[?RA0.F<M+3!8%.4ML5LT>.HD@W06;24?Q+5_
M*N/_?YOA'M>%Q[T[+4]Y_FJ<^>BIM-+/B0/6)</6!V!M0>0^UJ2IR-E90GYP
M,&#5)ZS(A1;13<? KH.HN(N54Z?0!%U<#2;Q[6"5'(5L&&,F<,Y%&Z.*$!.*
M\THT>*M>8562*15C['0N(EPXB+>JJG1:J43*V9KR[6 5G#,F!8AR2JCH"+17
M):M"2D-1?L"J3UC5Y,%I@(ZM4X*5!$$LP;61@I2BO,).W0I6P"1,L;78AAP$
MK!QT=MY8,)F#5P-6ZXO5Z$]8>>LJ)G2=A#SNP,70)5NH"\DDG8POM> 56#WE
MR43L^ M/Q103(>MN.1Q/QV)B,<PKL=9+L19_#F(91*-3=%:)Y[*F1J6H&.U"
MK"TC" -B?4),[!B0;>HH8^Q I=QT5N@XH0_*1:S*WSIBB@2:DFJA6D AQ^+E
MFC07&PI;< -B?4*L((>LV'0@+'6 WG91>>ZL\J2QNH1H;ATQJ\"G&C+H2"#^
M"Z.K.3L'I;JH0QP0ZQ-BU5,EITL7L[(="&Y=U,5T$;WA2"@Z["I9OWS$4#@B
M9BH>0"0AIE0H!(,U*^\EDQP06U_$?OL38BY"-IQ*%Y0*$BC)=Z+L4V>L5R9'
M%2A<A9A8DW&>]P6N^_R*)[.7S8+_@*SH 9.WG$3D [D:=90$1/18I@0%/C6L
M-9"U=F2ASK&":K,_2))'<JY+J$3E$XK'D/"4H=P66112]A "F^K!EQ*M2$*.
M6AM-#DT:R.H365GE(']:CX360I;FC@+J3HB3M"VSL5QOBRS+FAUQ3A*A006(
MU:(-T:"MH99/#L4/9*T=695S]";[SH4D>!5P74R..Q]\#$BVBN>XM6C8AOU]
M-L8&^8U5A)96D 4M*@M3'<A:7[*>_8DLG7(B3;DC*^H*M(VBLU!^H$4#5=N,
M<#59[ZQY;Q_G>WST63-*+(FL\KD6J("14N)J+>5L1;F7.O1P]0HH(\B(%75'
M(FPD$EJ)?R%19VVHVILJ<2C<,% 42C"FI% L@_4<53%)D;A0) UI&.SI%5#"
MC??HH6-M!2C*V"'Z)M^#$I&3=5%7]6=]*5#&6H<%8T1C6BI*Q1MG.%:,3BL<
MYCKT"JBH*J18BK@D$SNPB)TH&-LYQZ*-$SA45XT>?BE02KO*KHI3H@*<)-2F
M6CD8^5U1+>IBIMT%4'H :HV VGL+U$B^^^C@&?RA6HYE%759MRX%SJ%+#%4>
M<A'0."A]U<#A<L:CR6;KC.9:78$2(G$QQ?D"AB7YN]#F U=]X4I'\*1=[DP.
MI8/H)/0YT%V-6F2-5QSY=J;/B':BRBJ(FA(!A8:\34[YT*8>%ET&KOK%%6,6
M)^%"9[WU'7A1ZQ%+[')0472R.+ 4;X4KDWVRU1?1ZR@>M,94?#'6.;2D<[0#
M5[WBJK+(8H#<I4BY34ZFCIQD@0BA0-#&Q.!NA2L,N<0('!PG,+'&4+(H+.,E
M$ZR6>>!J?;EZ\1%7^>P/%=$J5+$KWD$'A7T7H[*=J"Z?M$B; E=U?RY_O)E:
M%FI3LJF@Z'9-T0:RWN?"U2;O!\9ZQ9A.(1J1RN*Q#'70EEBDH')70O%) I(6
M07_KC*7@"*P$99\U,!3,.E%,UGGM ^4A3^P78R':) )>=15U:4//U"55J1/+
M:M0V0:6K.MMOPH^)%BP^Z"JA.V8F&U71"C%54%0&/]8OQDB"(A/&3G2UZ0"+
M$FTOH3-P4<XT)532[3.6=<:4P553(:L26;PJ!"5.-4O,+ -CZ\O8@]>/MN]>
MK"]_\/KQ]D/8NOM'U-6EDE4' 421>2>407:=1A/0"7Y$U^A#7<Z M'+>@ *.
MK!CD4C XDT"A4.2871K@ZAE<Y"NRH]@YL5<K/H(=9C0BQ:P. 8VQUQGQ60Y<
MVF/TI- P)4#6,9BH;9L"&+D@QP&NGL&522EF53H5('5@VOBT+KJS1G*XXB/
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M<^RPDG?6@G48(W@;3:BDV.C0AYD^ ZQ?RW;@OA@7G6C^8A%TH92]=\6H[&/
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M.;9M.8/F8D-A"WW8O'GP+-<4O I\JB&#C@3B4S"ZFK-S4*J+.O1IE.WFE<I
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MK;GUW _@/C#@+K.D3LJX:[1MGG&"537%F&E 4%*77!< [@FL54X&G;-GT5Z
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M9@I3O9A3::ZJY]#)>G;8.2-9>L)E<373T-2UMX[S/Q6 1#'=7L;YH!U ?N!
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MF8NDB(XH&52UXTP;(8]I*EN@*W@7!CGA\@,*ZJ(*(H$Z'9844Y49WG6JX;S
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M$,8??Q/^_NV'!S'N@=3Y _T7O-'GV:/4RD)U[?U-6\>D%;=0"2Z[LVMC=.-
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MP5;5+8.^%[S?Z!JA[DB4T'0H'>-HJ?1.+.MO6^([Z'O(+OZ"@Y8#^F@5<=(
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M%TBH;6W=."1\N=Q'M^/5<XT@<D <1K-DR>K8-2K=[1V]+?1KA80O*/1J8T6
MY*T,2*)E%:BCM*7LY)D7F*Y\#:'OD/#1W:G>%*QVC-Z@F!F5#E!RS![(XP+U
M2=<0^KUV]'NT\%DL!^,@7+$<PY<M:M.E?Y=H@\8=6_ANK_W3: L$!O8^F@3T
MV;@T&T(Q1JO<T6Z8;O@?1ZW^\3?A[]]^Z!.]HIQN% 6^8+K#D.;PBE0JV-)S
MTQH)J,!+A7&!3KZM[7L%?B^G[9($<^9HT @"4R=C<>.<E3+H OOVJ4*J#=J)
MM-V;+WF;+X5WF.EJXAWJLKS30W+OV]>0T[W#NQ<LZ_"8<\3$Y@P]00&Y=1Q]
M"A;M=ZQ?NJ/<SR(G#>'LG:)+ ^>TX4G<BS=IQ=QNF"VXHYQN%-&]7+:B.N,<
MX,L,3.B:!JVL &]]EVK8O..]WM;VJ2.Z%WPS9V8):@:3$,;PY0'"0CV*"G*_
M0''&CNC.!MI9M,W%L+H4("Y@@)JI+'+\!0%7Z,#><KI]1/=R<L^0JM8SI350
M9J:)Z>C2&W5H=[RPNZ/<SR(GENYD)2-0(+T+M7$,HS_>'8/L<,,$P=^^__VG
M5W^(^=%K?_-I7%MA-PKR7O!IO:+H'D/*4>H#W:944"FA:Q/MON6^Y?[XN.\%
MT[\@7C%'8)E I8D1MJ@.*PR$*<_7U?>#ROU4,>IUS,P+]C?IU) P:Q4 VU#D
MZ#!;C-XFSK+EOG?W,T:'+SA@W!J&% 'W!F8@,T='K8)'?F1L?W-9 LZB,*=6
MCG=ZTXK#<A:FI'-9:.AJ:'Z!5/)6V E\SE5N!:?I&(DLA9=K-M59IU'$DKS9
M[&W+?<O]X0'C"V:7G=LL7*FL'9UL?90(;0;W&J7G\[5"[8#Q?&;F!>4^YB2V
MY9&%@9#6-I\D/0</HX9SRWWO[F<,&%^. )BJ-3."'#X\UB.E>^ Z!V;,V>Y8
MT?<D!)Q&88,89E.D,B! %;B@QDAIC@P7>!?J7OO6=PC"?C@&?_KF[>_>O%T_
M\'>2=Y:LB&)V0X.R7 /,,)-E(T@0JIM6NT#F^;8B_Z;0:XO\6U^>0QHSE@AO
M:U<WBRPTA<A]I.4%1/ZT =<6^;<6^= :T[(C%^ T1:QFG<OLK/GE0(Q3B_R4
MNKK5PQ!WU+U"&5FK]5G7AZ!+^BLJ+#BI=.,QMNZWKKY?1CFJ,_5A+:"16RI:
M]3:ED.*\P"-2I]35#O_.E.-0TMI4TX^,!AG+*&*D(8,"9KO J,3;BOS9P[\7
MG >*8EP<8SB" 3#;<0<^RW%'6.<%&JUV^+=%_DW9:HPF%#*-)K@K(W)4K6C1
MVJ0+U'N<4E<[_#NY[J5!S,;#?.WDPT306^D^R689WO8#@5M7WTM7U+D[0>,R
M*BB&<5W;:(ZF+C/R ATH]]#5+]^\??>Q?AS'E??Q<_Y1_3]B?BVGT]<Y7:7#
ML%CW[. QNBR73-J-BAJ9MIJ%+C!Q:PO^%(*_2H]A4&.?0Z!GA1Y3.[9>EGV(
M%14RZ_D%O\/"2]!W%L%CJ<5\N'M9HF\J?92"Z-3)XZLA>*<6_"DU=KL0\<X,
M<%9O#9-##&8?+"MV;$,\N;-]63B]&=@:^WM:K\BYUEXZ+B==0]?6&@6(F-U9
M_0*]*%MCIW#25^DU/.;L#^-*LP5D"X-*49>M-@&?H5OP6_ G"!U?\(&@LD+%
M%"9:+D)KR@QC'\+C,-)7Z"7?H>,EZ#N+X$6RV8A"/1+Z&+RV^>,EK*[B%+AO
M%W?H>'L&(GF4ILB)#H,:5YS+Z& #*G/J!7IN3\G UMB?WSK*R*$(0Y>Q,'*%
MDH9&8Z RC-US>-Y@[(<1_%__13];JOI<W[WZ_"HCOD!A9.0DEP[056/I3T.$
ML3/XOF \;]RUM?U-^S;BK&F->E?(+@J&7GQMY=2RX 6J179 N+7]5Y(=-D7;
M"O:8 D9TKLOXHDX<S(VNH.U3RNE6L=^=Y*ZC'--'RSP*J9?MUN586F.&J-BN
M4!9R2KD_JYQ*2Q3KN(Q!!PJWWDHRV,B&N&2TLP8[HOMQM?URV0H_IC-'!6)/
MZ)92 XNV#$H.B LT5MU6VT\:T;W@C8<2R-1L=08H)F.;Z^]DPWLX7*#]>T=T
M6]M_Q>).D"05;## PJ7'Q$B,+CFF7&!VXBGEM".Z<\H=$]8>SM-T#@!KZGQ$
M=</R>(Y0=SW>EM-W<KUMM+5I4H8/P"#-6E!AU!1#'+D3!*>-Z,Z2%"#O%<P(
M(!*\S.-%ANH#R4=RU2VA\P9.9Y%0"H#/BHF%8 G)>);1HTA#3;0+-#(\;7QR
M%@F!KR.+")1% ; 8FZ3G$$PUY N,1;W7+G23E]Q&"3E::0]1"12!T>7#9!HM
M.>T"[WS?2U47["=!&C8:D<UJP#C4A3B:KN@-COG-6T(WM4<OF+Z=C8Z9W^H>
MH*:,/#@;C"8: ^C\$MKVZ-$2<N^XMIL^A*!*BO>&.>>DR5C+KO=^(GOT@F>;
MU<925\B_[!'!5!Z=$]DS1(JUJYGNW_SNS>O/WKS]Q1O_,//KB[7S-^]?OWO[
MQW_XM]^<)LWX\]^_7U_$KQL"_NWO;GS\[.V[?_BUOO[X2ZB.3W_YZO6K3]]_
M>A&G'MYBG8[1>#K,KCQ'M6+$;CJ3+S</9$OQSZ6H?[B0%)MB'8"3YRQ09BI2
M[9&NO;2@>;G'*ZXJQ7]Y\WIOC*^TN@E5]@EZ!)P<986@4GH;V1(OEQC[P=3X
MO?>=*^C\+&K$>90BP8H]S "RB0CUEMTZ:X.L6XTOH9D_ZQK]Z/7G\=F[XX^[
MM\(^JD/3%:X4!?=IA36+]ZB*3'RYUW6>;2O\7K(^B_AFZ:-E6X(8#8SKV@3#
M0#(;$T;LG>_O[J7_[[_@I_K9;_7U_) :^H$WPDM%*#Y QC$Y4_&XABA:02H<
M9>[(:U_LSZ+%LZQ'*6M%)@97Z-!@&E +0(J!HQ\'T\^.WZZLK^+_V@OS5Q9F
M??'?OOO9VA:^6)KUI2I_6IJO?^Q/7[3Y]4_]+ZOXU8]\G[B_Z."2=(17($J*
M@<6\K@7MIN0?5K%^M8H72K8_:A7KMU_%^G*K."E\H*ZHQ('-3 -[,QB<WDO!
M#ZM8OEK%LE?QFU:Q?/M5+"^VBMH'S^ES^$1PKDS C2Q)Q,GM<K?NCSGA7O"F
M2%S6:493ZU&CA3IKG]1[T^&A_D5.=,/T#>M17LX!SCY;-VBRC)\LYV'!O5(M
M[$?YKGW8Y?I7NUR__\)\*]/_FW=K.SI^I]]XO-;UQ?XZ /CJ>_[IS=MP_>P'
MJ OX+YMJ__:;:G^Q336@3C_N>%44VMIA$\I47(HI5'KQOQ!-Z><3S<NNXK?6
MZ&_>VV?Q^_?K]_SYY^MO_[UZX2]^PIG44_K+J.=PPS**C4&Y8AMBP"8UUHXC
MC4I>X"+B'W5M,!Z_^6W$N_^ZP1SIAR\24_]'_Q"?_4K_J/;)58I< 5(;L';T
M"NN,Y@9"-5)25AA:+I 6_>L+\U^J@_[ES6M___;M^G?_XI7:JT^N-(>_YZ R
M8C;""N0@KFWMQ+4XM19X@4DNWW*1/J3WKK(JFHV6:TKVM:=Q-TZ4T8\1JIPQ
M1<X?9IQG55XNV!A0K)()^X#%BG+2+#/:"CT"H5P@O?FGL^0G[]_]]LW;]4?[
MBYN0Y4]>??SZIU_XVHO LF)O8Z!E#,%AG3BJ1U2^+"63>>0%2K2^:5E^MG[T
MLW>O_%KKHD561![L1_99N1I*ZYW+6!X_:]"%LL\/7Z#'9Z%[%%O16/8/1;G+
MVN%<1KNYIPJ6I MEH<^UF@_)1A,0#M56S!QL+DLQ46I?J-9EV&%<*!M]KM5\
M2%8:1G*+VDA@0,>UTS*A\(CH54?6&^VT/[1#>?Q&"]A+#E2*HM"(N>ED8>0.
MR^!@W&BC_5$7\R'[K \/XB%FN"($),[L9:"48;S.3[C1/ONC+N9#MEG)CCYF
MI;FB<ITDW=>'DBFXO*WCI;?9?]%/_R)W_-'Z3W_[6C_Y=7P>K]_';^+MYZ\\
M/OKU;UXJ>WVND_LAFWU-+S)]E,(&1]*Z')W<AMEZK)#IVB?W R3UISN8?UV+
MH.]>O?[X)_[NU><?,K*_^>(_Z2\N2+[XSI^N17GU^OWZ^5_^PC>O7^S1ORWS
M5UJQU#IZX\X07G09&'=I0)JJGA>2^?=5V,]>?>9?B"SFCZ&QO9\_0NA46RJ;
M<(P =S5H$4%E&HP)7TPRKW()?7_1#O33-Y_^[LWK]>E?U,S_Q/W]I^\_63]W
M_K.^>OV+-Y]]]B]'^?1GO_VG3][\?_\[YL?Q*WW[@UPY?YVLK/)BR<J*74Q]
MX*!RS FS:C024;(ESU;NN'!KP?[M]=O03U[]Y]'_\%4=^U?K>9&5ZP.9!(J/
MD5"QJ= *D].TMA5HC7K'E?OO+0F?_63^O^^_6+^+K)LLK$*;,F( D4A/[FY1
M+7IGC#NNV_]YNU;JDR\N0Z^V7DF<L7;'F@,!0)D2J0R/8V(0@5PHE7'^,^[Q
MR8Z2.IVF"4H!*BK%9V=/!U68>J5Z]0N<C(]?[]K"JD 6#X.PJ<L%A2S0:UW'
M*ETI4WGZ\_3QJYT<R$-R:#7HX=RE+]"KU3J/,J-;K_:/= H_?I6)R]%RE&YI
M,&4H@"G!VMFE&54Z?W?$^4_J'Z2-HI:9RQ5/R$A8EEBJIV21C&XE4.ZX< ^,
M1E]PY9I!DD>M40B^>*-<!3B9<WU6ZAU7[F'1Z$NN6RW%>0IA/Z:]J?8)$$-M
M!&9WO>.Z_>C1Z NN%\V%E\E""ALD-S;EE'8X5K)UZEVH2N+\9]SCZR@Z@X S
M'8L-5@;#()<9Q]SBNJB]]7(_-AI]R'H/*D7F+#UZ.=[M,)U6K) U'TJ(MU[O
M1T:CCZF2\CZMZJ X(I0BAU<J6!NUV:I=JK;XM*?PXU>YBUKVB4B6,+EH@4DX
M)(*T&NH5BP"N<60_YBK<&- [EM$-$ MK##&(HZYI-KE2^\?5CNR'K'=T=BB!
MU$N%G%.*MB-;X> .F.W6Z_W((_LQ5>J%(=6M-".HF0+=8ECX*& M_=:K_8@C
M^R&K;&OGIN7 ^&CYFL=LA0E8E_^&IKP6X_Q]R.<_J7^05F5=IVY"8"]MK!"9
M;78!*)TJU.6J_8X+]\@$\@N^J%-[TARC8F]0*RI4MYYS8*G<,^^X<H]+(+_<
MNH&$'/T]Q6; Z(.E1"F&A;P+8KWCNOWX">276Z](8I90;XXP8)CU@K#B%<46
M _S\4P,N=;2]X,2:5GLI-(5X0F+1*8SKRRNEI%&_P,2::QUM+_A(0^_6B%4*
M=< V5:P.X0HBH'W<<N4>=[2]X(CYD;6O8'Z=;@".IKY0Z]Z!;$SJ=,=U^_&/
MMI><Z15>U_8X5 =P96W4T;WWX;,07& BWC>LUS$6[U=?_)J#J'\Y1DQ=9A=4
MC1CKJ\9<)[AVB8DXR0+"9VL7&"%\OM5YP?"+EU=77[O:6IV<8.(MT64 @5*_
MP',:WV)U_O:;IM?"R4N"KK5"IH \ZAH]=-1H6!=F#+? Z?$+]G*$V6)I[7N6
M:0/F&((\:3@ZS1H9\Q:$_=G^]ZOUE7G[9;/M3]_\$!.<?YBW0VJE'K//R@VJ
M%A7A-GH6&Q*-+O X^(F7Z>5HZH0>& +E2#NAV''UENQ2,*/[/;S>W][^+@H8
MTF" $5(MH8)9#3HFC'8?@0NV6P!VHI5[P<L56?;"&[@(+M]A:V-<#L0)H_1D
MO,+0EF,H_4^/%PT^>34_!+D?K97\BVCX3P,NOIQ@\2+OF_U),_\<;SY^J[_[
M[2O73U[^D;<__3;_^/ZS5Z_CLZ]&<_SYWO];??NI>KQ_=_P1OOS2O<1_XJ_>
MOIGO_=V_?J7LKW_+_RO^^.[M^ZEWO"I.6='1A.*H!B!N6 :+:J_6<$5.&XKS
M*O9O0/G%"P0?!L<<7Q']9!/RO3NJQ[#>C850(,-5:REA16;!ZLNJ;4).2\AS
M*G8>S>"E:*H/: ,5DB86YN+"1R+Y_'79V^C<&(J'E+$7UCZGI8ZAL"R/=,VN
M*MFP!>85.L^>=AM_.J/S&$):56X^JT*%TKOHP*/\L$XVH.R;D/,2\IR*!93C
M[4'CA ]WLNHH#68;,&="N\*PHVUT;@S%0Z;'^,1:HG40K# ]K3N.'#'K3+9)
M&XKS*O;IC,Y#"&E>I;>R3H_!@#UUCF %[MB9J?DFY+R$/*=BRRPCAO,@M65T
MDB%T%%ZFW*WIN,(@]FUT'@'%3S[YY-7QH.?;+X;'_^*/KW^G;__SEEG/0;#B
M50J&1 @F8X>6DQ<KN*"Y0FOKT^[JY_$]3P0,#W<M%(@K?DX;W#S3TL<Z4I1L
M;&#."\P6\%&[ #JY649T!NM%'7J(5G*MA>4*3^YM5_0\C#SFQ5B#V0=S!VF0
MHRC7'*DYJ:'5QIN1\PKXV5W18^X4N/69;0!Y AHS#;4IGF-PK@\W,.<%9@OX
M:(7S2M1A?)BS2T?[!U=@GJ(8+JP[N[E=T8D8><P=6=-TU*Y'L4/H\7R5F" ,
M(D6\Q#L:3[O)/[LK>LPS0ZY1;?14;W"\.0,5JJ#HT5S8"V]@S@O,%O ' 1^/
MHO6&VAI$,QT%E[N'6KH/Z%>88KQ=T2,8^46\_OS5I[?,GTYM#*42L+4/,QB@
MHL_"O6.M.7=#Y(D%>QX7=&- M-CDB400!$EFW:H0-&[1J^EN_3HQ($\IV,XX
M8Y;D,@AH*L]H$S,YK?/PMI.7V^4\D(D'O5)#/:EPF6(@Z(N)XE6M'J\2E2]?
MR-U,G%*PS^9R'G-%O$X@'DU&-5P1P&"/,<4;]*D.X!N0\P+RE((5;+,4\-1@
MX():44J1&EU#YN@[&;E=S@.9>$Q/2[&C12!5S4"5N353FUC,I52NFXGS"O;9
M7,Y# .DMV!H5FE&A$,I(,;."@3*]Y ;DO( \I6";#F_-N4]SZ,=C]-IG2S=E
M;Z7C3CYNE_,_,O'KL$_>_.<?O^FHN&2"4[@?J?BP#@FML@DM-@8R8N@R.QN*
M\RKV/#;GSH18D&34)&\'(:@S*;)-< DBWG.N]K'Q4"@>DC$RQ%[,L-,R4CI=
M2U//143$3*P;BA,K]NF.C<<0$MY !5; 8>!%.1US:@X 79ZK[/!X'QN/A.(Q
M1:.UA!:3TJB ^; 8$DNP-LBEZ[YH.+%BG^[8> @AP0RC6ZU=&O@8+,F0M5(Y
M'IO/W6QV8D*>4[&$L_IHAE,*#!'-.K!FV)@R*\K.(#W,Z/QM4?ZSOIWZV:M/
MOOJGG)S!2V:/"J4B5T7M"5RZNA"; _3B5G$/FGL*Z?[8!NN2J"  CNK"* B$
M*.%]]*FCI4B9^R!Y"E0N*=VN1JUEB]X4')&[#^W>T9S 8;<); ]T#CH>DPIU
MRPD#+,$@<5DAUC"J-@<U[K3I> ;I7LT#/>;)F*E-CU'J$P)J2UNA W0_ZI8*
MX9==]1N5FZ-R2>DJ1LF6+*4:M!):S3% B*R#U3T":'N@<]#QF.+37D>WZ)-8
MP=I@J-C'[-!FKUG:IN,9I'LU#_005,9,\2S./ S(3.HP/_*F@%298:/R#*A<
M4KK<DFPL:1XO/(Y6U91)8C(J(-C<*<Q=]/,_TKE^Y/]^K_.7O_SU1Q_]N[Y]
M];G^X8YY4NT]5H  :QNW#SUC*,)U,DSLPM$V'^<5[WGJ?YX%EK#UKVO'['2'
M+" RG*G,=C@CFK!A.2\L3R_>8\!;X6( K0-U6%_D,F-Z#* 8O'/^VPF=A8_'
MW(E-99\FTA.A]ER! D *+(?D6L9^1N;$XGUF)_006$(K\0JGH[8$*BQ]V:!D
MZAUR!=QEPW)>6)Y>O$F%**&Z5@# RLT,0PQF(ZLF.YVYG=!)^'A,_X"50NX=
M/T0+E-9]+ SL,$,Z8:?[3RS>9W9"#X$%O3B-*J%S0C:WUE0E:P.>D]KN*CXQ
M+$\OWL8&"CH2UP?5@6UV+>GIO+ZW[(3F62N$?OWF^-U_?W((+YDGM<14EIE8
M! A,S 1#-8/#+/>3,3<6[(]ML2X)B%(4BB,U*G,!$D;K@V+:<P7/,&D#<E]
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M@FT#\B3JO9H!>@@M33H"S1X+#2@4EDR5%%*U5-9="?$LM%Q2O6@NMO;Z:9B
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M$8I8BIU,*>$*G ;3EA!M/!?*H59!5E=!EE)@009E6'$A&FE*%!$2\([B+H,
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M>*I8:(.4<N^1XYAJK5? <,Z7B8LYVT;P3#N3I2'7 M$"! J9Y=ZD8?^(=BN
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M%$<>--9 +I('^-YX(+WQ7&?,>P<Q@.:2.Y9A*;'U!/Y)(P\::]$6R0-T?WH
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M_B\YF+33G7?P/O);;YM\^KQ]MG4*T30Y.(.Q75^-@DC\*$351]OOME(8/SJ
MN1WT#LX^]2!N_OQ;OOT:GO%YDU:K49N7HVHGA?5&T0[VBG5H*F5'4RLZF4@Y
M1(59FAD* (1DR1LU'"5 9Q"<?K)Y[/IC]\TH>Z889[>1XI@F?4Q"_ I^W"WW
MBZ_+F:&?JPB?7!-A)I57'LL.(A:\/;C^CF*9[C &H)E9BU*4K;W<4T=?U>G]
MYH4>G[F--=:[Y?NR. 9+<'G-"09O0L>UD1O Y?" )5UQFK<\;UV6YRPU&&<"
MK'&&?8<*8SO*6=EAJ794,)HYGZZ]#&4RO[ERZ&XOT[<ROM^LYEE!B7Y?@,AV
M/^6#5X5=SF!IWN*Z?5E<L:2*ZM1V! '+2S7A(*[<=CS!GF?&4VM 7!%'&?L^
M7IAW(?<MI+&J<GS(!?T@C*532RN /Q6MX[\ISB!,9Z9#/)$0K5OPWZDT'>LL
M!\%R% NW]E(B<55\GCYXBO+W HS@^Z.B_UA3E >@W\2FQF5I!Y39=JA-94=J
MQSI$:*M0.+PT!?9PB@!Z(73[0HEKN9-%% =0]$-[9*C88.D#) GH!A+T81Y[
MNUJ&'Z\"7@06GKU*^N#(80MBX')0+SI%1%QM*SRM+/CJ0N+MWI]?M\\^'NV\
M_N7+-GE#=MY] ML!MJ2W]?737[]U=\@6W@GVY>S@ZMK_*<SA; >>O_WNC[.#
M_0/TJ??V:/>U(0>??^D>] !O@"O8_KP-,YJ1I4@Y%I:F62?5(:%+0[U=1E2'
MI]A[+3U'G#\<)'Y$HKVO3K;J;;@FBO<2^[UYR^R5>A4"-"<9EITLDQ#+><\Z
M,B7!;V()LD8 (^NUEV$_O<2"H1N7]QYX=\85=USOO+RQ.G%.T=^3:%9#"4L1
MMFTGG\=E/K1Y+' )!2OYM E^^IUM'C\?]S:73EL;>QL?DC>]0;<X!3I=5MZP
MC#^+.-\.M989F*5L0]RR$O)."(IO8'[_CTW3C8S=;@EKI@&0R^6]I@K0JC5J
M5SJ;#&XL82-/]'GQVJ89/;\GBS@'@DS($1_S/!_!*\QWM?E;Y4S[^0CT#VCQ
M1IFCY%57#8>-3UW?/Q%*%::3?#CMZ:+[9/CT\9$@5'2<B\%Y%2=8^J]'.7QR
MH58/JBO@_.Z90(M*!=<FZ103'55LB8'N[E^_?3GX:XL 4"4[,(Z==S&Y\V4'
M@.O!7WLYO)/LG/W!MC\?7@6Z[*"W=W3P^=/1SN<#LKN_B0[._D"[?_V!=S[O
M'7UZMP7S.TAW7G\YW7TK3J\%9SY+N3-<=21C&H(SSCLJHZ2CK/%>.<P,]U6%
M(<CIAU%AOB1/_@MM,%29^8$JDV/5';NG2[<XMVCIK0UB90];T;V%Z%[=BVL)
M4S(C'8/#3@+/?4=SY#H,49ER;;0C?.WE]MZUI@L/(9JK9U4G#JJJ0[R:%W-P
M=>E38O,3W2NKQ)Y9RU7F.EAF8'53QCN"I5F'42$-0\(QDU4IL8.B_%+;W0E#
M'BC7T'BY=H(H)#ABU,IP9*VPPF>&2JF],-C1%BW<L]R>74,+E&688Y9U"*4@
MMPQG'6VQ[QA#K5$><^WHVLL #]!_)SO%"()%.W9A$RY]?/C@)^6UQ0=W%=8K
M^, JIU-O?"?56'0HSW!'IEAUK-&$"<:I-"3B@V0^TKEZIK2%"/<HO5<@@O;(
M>PT&%CD-TNL8ZBBC+/R%,HX03WF6MA#ABESSU#G$4LZ)2RDF4@IEA>$FM.QV
M!+<)A?N66W0-(F"L%%8IZ8C4H ZU7'94EO*.M]1JQ(B7R*R]Q!N"LRL0(7M\
M$.$GY;6%"'<5UBL0P2&;RC2UG4QPTZ'29QTE,MEQR#@C1.HTIQ$B/)N/=*Z>
M*6TAPCU*[Q6(@!QFX*I<1SMI > *V1$*<(*52 BJE24,MQ#ABEP3+8F1PCN)
M)=4(R<QD&GF6&L)Y*G +$>Y9;O'U+()F0&[,.TBJ(+>>=Q350&_"N$N]]YR)
MM9?D>A8A?819A)^4UQ8BW%58KZXR<)]!5.P[3A' LXH#1+"8=(P5"&EJ:$9D
M!1'F(YVK9TI;B'"/TGL%(EB"K<]8VI%AC9<2K#J:" =0%V?<:FZ]M2U$N)H=
MPX0QDG*EO*!>:L!4C%*4:0UHF!/20H1[EEMR#2)P03*.E>BD(*0=B@ =:&%=
MQW$>3(T3U/*014BO9A'21YA%^$EY;2'"787U"D1@&;A DS&PJ@I,:UAR$#IU
M'6ZH=,AX!I%TM="09IN/#"/<DRUM,<(]BN_5-()B/J,2=3*$088M!;0@5=9Q
MFFGITXQ2+7X"(WRO5'U&,7[=A++Z*.^'LOCG:19KV><AU''3\%;?AD)\E^C3
MQ!PYF#*,]TN25Q7-Y7F;KB0?)BKYZKK=SI=^\14&Y]2PZ#L+%X9C5ZXG"GR3
M\WG\J)_LC;NNJIVCB,WH[KEI1AL/VXUQ]GR3))E'2\IF=%G["]CU[\"M#S6S
MMB*OEM)Z_-0&;OHWSI016M..H1#D4IF)CJY^98IDB@L=UAD/W/ !.QC>3B._
M*XPW]J'^R=?&PSP:HQP[WVS6^H TH#?W35T=4]XO1O#)?\9YV-TR*N)!E?!!
MZ-<\_,9NE]BP^?)'T]V;@U%?@$UOC,R"^5B8T#:&" _NU3X6W7%_I,K8EK<<
M/CYO1OYV EEE..\P9WF'9DAWI-*\P[EPFB*@L0KYKN*1.[/5,N1?CUS<9WS%
MFC_!=8^9(S4Y<%AUN^?&?-K*:U??  _^R4[\B86K_<-XZZ!TQL5=;YA4SXN'
M^@R3)_!0"&*3X=@<)<,C& \,OVYY/SI2HZM3^:J&U[U2_'(]FZ?K\>#D)V1J
MRAKB8;A)?X8)A2_%^^&;83SUP\*Y%\,XDCC<T"12UCM[K#H=;MR_I?QAS[5Z
MYKH^"ZHZ#"(DX$9J-'Z$5OOD;^,4EBA5G4R:T$C=L([$EG2(<,IS[+7QODDQ
M2#.,=W-\U4,%.H^0O4T,LFYIL^_FG8.' N?4RT<C\&FN"TZJ+/HAB=T]3=RQ
M*T^3K9#;5N"-CUWR6HU4=;K%%;]]\8SIZ.Q:EFW/'8Z[ZL*Q?^CL)T_"C[QF
M-TG)QGE&#@)!\.P#>/W3N?CS:A+G'MH-GVX\GK!EBLV!R[5;?'1^\.#D;V\<
M>#M".\;++.QH%1TMM>D0FVEA"5S):.L'6S_X"-A+7WRW^>1*!*EQ]:@+$W*)
M,@;<8*F"+PM.("P=]6=^FH#J=V9>&/; ?\);RDE0 ?:Z!S,_70]Q+#P.0KY
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MP&U+B4RJ]>"#LV[^Z?/'HX//YF3GW4Z^\QK0Q_XAV_GK[='NNS> 5@[0]FM
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M9E\"OVFZNM:E+5QME'G!!*^]_"-TE\U'<:MU-!7P07?R^U2:.]G4Q3B4U\7
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M%!$$#-[?=R:4V^2!O;D'$DS&"211.N^&PLM(R:*?@X0%7S'3,]6"7;G"6F]
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ME699,/15T2 Q5\;I5X59ODW"X;8>XH><0KSO$%I>K:E*]44!; 5=>2'')37
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MJ=/9",;+QZL1:%YZM">*2\RQX8$&[F3=_K792IS2D' \#PSO8(9KK2#CZ^-
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M]7X&QW^3C]4EV%-XZ)B'L$G03EM'!#5LPCPIE=G: <%*H2'?1R65I/ K9(;
M?&S/^CTBD;0 Y""XA#TI0)V-^V;O\AIHHX))8CR+R"C>/BH!CJ:0RDS8-&JY
M5BX\EG'5O\TN!X)=F82\#;0L/%D_O\%;9%6QG"Y&@:1!PU-LTI;W!:U$7129
M%S>UZ6P,$A8Q?<=O)Z8@RD8#)U'I T)5.V/.P3OS,\[ILN5AJJ-! :09>JY2
M\TEXB>70#'K.&OVZ65K7[$3&!/ LO(>:(X1\&G!:*C732^_(M',X1X0[37.?
M"!OG*X2M@"3!J# PS'X@?2:I.[9?0?3J% [2);0 /<F+09(&I74B:=^)AI6+
M(O!S)-P NQPS?24?K4V)-PGSH!@'1@L]FA!A0[G".I]WJ!YZTMH>1[#U"9?N
M&Q(^&$.-L!%4=WS1S)"X!.&,JCQO:(7FI%HQ38YE$7H$:ZWIW^=R@_=H2<!<
M4DW]A49%;V/2M);O"9Q G\L0NW$T"D,H5$N%CXZRM.+@DT84B_S3!<X%#R2_
M<<:3BLNBZGX 2Q:,8PQG7!')*4>06)@^-.M)EZ*]W1U.F="MZ3;L>EWITL5L
MX/C9?[[S]'\RS[Q$\:F5'AF%/7^0Y/S438FYD ?CZM\RLOK&BXY+)'!-'7V[
MZ#;2-$<XS+6>64^TX@ST()C$\"J8$V ^&!L5G8(5+#X(A9\NN9*(0GDIUS]2
MS"3T:"4@L!2H0MTFT?IQBD0?2+ QU[E @:@<B1[&[!AB])0I_'NLJIH>HP0L
M1 %2*I?*)#L!(Z/PF4E(. <;8[>OS*C8TV)?* #HX1<C<-#XS(*;/'*HR-$&
M*K*!BFR@(H\<*M)]VMVG'D)=GJ4&HXB'A DB$<A:@@)B3WDQ:CH^X)GL8/B_
M:Y\,=.CT,"952MP C].CGA>_-1>_E!.J=>VSK[&"OGN.@%"<H+QGZ%9F4C59
MF7-T562WU,C8Y9#'[&\WHS\%FXMD7 A%%91"VQJ LS?7I?/.R"H-XWT2":+6
MSPU<;^)Z503;@<WP@H8L_N!42+!J<,;.T G0G\#%%',5_,9L0>DS.(BG! Z6
M*)4%^% 6L*FQ8%I2ITA9E,:,]6<$"@93.2.&;KX'C[ HYQ4E#VPR&V0,1:4(
M*&3=U4HPX&$ME*UMM3B;'8[,$':V*#\*O3HXTNF$?4/T:&L.E(#_@\,9-YG
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MQFLWY B1"QCJIY%W;.V[T)SWHIG:QT686_ZH%YP9D*S%O"QJ'7-N#<Z,I&S
M@E1YDF*@N(IH-B/,L>FK,+&PH'^_?C7<B89P:.$=P-$P:4!=S@PJQ2;])'R,
MN8QT3L>N_R0\BA.,*W')=O0>;W&AJ]K8JAB6_G(/M7NA8%THBNU.(8)4D9$\
MK_3/YA\ODK2:9VKQ<YK3A-./7LCMY>@Z7#8OZ('\M5/J.[NLV 4F*T^6KW?H
M*X,&"[X[?+KS[.G!RJ]W=P8KO[ONMOO/=Y[O'=WHMI]!]SZ@0K.GG:BS#R3,
M%\O"? .8WX-_.0<B&N8PDA1W8D*6VO_6JL1HP(G+8V]Y;[^]C,3[@@*I:\&(
M\B7NP[N *=Y;B=%@#R;V[%_]IWM'!]'61(_5//VD\OH.*E'N9[Z^1S'GWM-;
M0#M#%8J>Y_H<KBJKBJ\_85-*M<"AN!\E^E)GQ1QS,8(57#K9-N?5(SJOC%R\
M0I$Y-B*S.:SNZK!:W_/H^=%>M%45B-4N8SVOOU$9Z<V#5S"R+^9[N[O3],<Y
M,->1$^3:UP2I?7;X?#",MA)PZ"X1.:>C_XC2"D2%_KX3KH?;KO+][EPF"/&J
MXM@@L/-Q)[R':U&[;Q398'_W&8C$7XVZ+,!2F:D1R,1<ST8E[."_&_C[_JF+
MOPL!RN$C:/MG3Z^C9P>PZ)?IJ*CJXLY7?8UH;[YRU==JJQ_L/=N%51^K2_VW
MWFSUQ['5!T>'!]%6G.D*@\"/9V,?/::-??!L[YNPP]S*^_CI'V_41%]ZC$=K
MZ K=)<?Y0]X>SWYLAX?$\??^8' $UGZNFUD1%S$,)+I4<1S8^3^H^OO*];U)
MB/SA+KYXN_L'3P^'Z.UY%@Y8/-.%RIJRR-,$8WM5,XJ;6N6Z:+Z.G^DNY^J[
MB,SS6R0- I34\QL@TZY%RSQP6-I#0Z7M[QRXDLI1BF#B-#:U8[W("TIR"2&6
M _MH\\%>M-"JK##(FZA:!46'S1P3_;8DN"M%>QO@X@\N&P\.L6ADXT+'.L62
MPI.9+I$,9!%] &TW;.II4:9_!Z7<A"&QI85UJ55-Q4@@'E-X3+],JX^12IJ,
M2E_K:02O0C6VLP(T'E8S'K_]_?15?_#\9D+R ).*'SJI7WH>RX(%>*I1<:FC
M>*I*)&@I$<\=T,A4.]$)%K!+[E$@.(84AJJ7QTW=E#I ZI0>S ;FO9GCE6-8
M0=FJ5!>=?N(Z$7#:#0AGN?BX%^D47P/QI\04 ;>[FJ8P(AF*NE1IAGI])SJ%
MK2[(H5Z4:!,7+?A-X[2,FUE5(_5%!6]0TK%'O"CY @:':*-23QK8,46Y<$I#
MZJK-O- LEMH\GN;8T.:8N86QRFP$9!EF0%0:'1<-B!UQ9< NU=2;Q51ZV\+9
MBL>5+6Q1[0NZP/T"BS)@^%4#,^(]++JBV_,DL!:DE\A4.I,J<&0PF,$HX>;R
M+J8TU[!NY(H65B;@LS,DH]Z)AEE5]/PK?8U<IZZBW<MDPSUB$&342ZS%TXJF
MW'$%P6^6$^ *%P3+X(L9@K\J7?7H;00CQGP18,_@Y3#3L#!9D4]PQ51%<&<'
M? X&B0P3RJXY,@L-GKZH+$5)A6<2"9RK9,5_T<B]X8&J I6"ZU<V>>7O %)6
MX[2LZ@Z"'BZUR?45;$P]HSF!Q_)N,$P8,!V51IX)N1\R3R!*>XY#)TR QW*!
M*VK/R1L\VAS#","355U35?C'-,UTFR:'WK&EZ$!'EC->*J)UJ+C0)2LJLBPZ
M:!',$1/#OBQQ]P<%KLZ"<?4SL,ER/48:$)31N$!JJT8+QPD</G3$X?+\'&VE
MVXS8(&Z(?HL;@NIEX0&@R2JAQ4H1L#XC3:H#>@D<XJR Q=;PP(*E::;AX$SX
MO?)FK&)_HRO>*_ T>*M4CDY2,/)*+V!T9GAF/&QIH'+C)S:5[OS9=;_+82(S
M7A>V7_C-D-T"-0E^\((^V4HOY3:^18??Q(;7C-2RI3SJ=:T?:<'V*6(!JJ1@
M:] 35T@ 8Y0(T:")=O;YBD2N\A5"4#&VA]5QQ?H8F9=DG+@ 15F)%J\ZE*\,
MWVAF,T$MU8LBF]:LBL"KN^+CTOV^9T^R3'\BSC2ZHQ&,RKL=2A9)^$T%)#BW
M9)BE_JM)2V$\@6M0HY%J(O5<T0K+3U]K-+ZRZ'51@$8G@ K>Y;BH0%;!,ACB
MW)=@-(!B4*B^KWCL<LK0K9;7?5VUE@% 5V27+HLN&FH5,JC447L'M&; 4JT@
M^98OU55/.#EP\]%TPI]@+%<> TV6CN&4>X=GJRR356#PMUS/D#/O%QXIV!S,
MRI24:C$>5_ 2HP6>4N:79O!Y,\/"?[XGGG27VIQHB=$D=)0ZQ[#R4>+(79;.
MR$":&>,6]6&&I"0-;\,Y:(:%R,WM9Z_4AF/'&';VXF!2615;L\7L45+.N1),
M._DD:RR=KV%EQDU);Y_F.#%>\2><GG-Q#3P"HI8%!<)7!<R1@Z%E?+Q _^PU
M:T1#Z8BSNKXTDP]P"?\P];L]4@RRN]N+!8)<P'G*)K><8[1WP+7@<[(N5:)1
M08E3P1YD7L&=2ZX5I@-C B?%!%UK-G7([H =@0MGGA&#IGEO[N;;T,9,JIR=
M;[<GG)5HS^/_@IH YZCKZ/<N@E&@IP9#VXDNZ-]R<J>L;\;I)S2:P)!B(8AA
M.49XCL')1:^3@/;+4W2:UG7E+XJ%RHC4*\:YA G;V]W;(]/%:;:/>7'5GQ97
MH,]!'QL34_0=%XBJ&<XPFYC_XW#_*891,N*$/0-C]R,;// 0!&;",2U/11XR
MOA_]7 R__[&_LPL^!_W>CH@%[-I!I74T!5F\1I$^DMK1_5::KU5FEB;_]=/G
MB];VG_ZT*3A]X%6%FX+3^QGQXRDXO68?/CM\&G_YNRX!]?GXT956);JYH-%?
MN?J4FZ9C'MAI^K[#:AJ!EY:C^XPAS*DJP92%>R-UBM2X@C? YI1X!^@66P,+
MK!#\NZG$!0)'G2.5]@KKT2$+#QHVI3^G7LT/_F12JAFX2C7,=:S)R]IG?K6]
M'L?\/ID@\.!Y;V]W-YKK GEMKS#&K<&1*1;.CFN_J7LP1@3(.N9@B:EHFI=I
M4<+G?]-A7:T>J1[#N]8FWA/3VZ/MY\J:R+Q,D50Z2_4EA;B$!3NBX\G,2@46
M/ ;&<>X:,-_K"(-B&(O)M4[D/I1(G*F/VJ,%EM_,T34S;L0<F6S6UD_S5V*F
M0.K@_S#)ZMQMM(O[E+$!PRQ#!42!?5P$T$)*G!^[:B)/9(ESB)@OIB@U".,"
M;>PK<+O9UF[_RB.TO5*EXP?U!"$0GPXY:XD-INR8Z5E7,.MLC=KH@MQ?0B;L
MF&.,P,2J1NS3+21022&OD2>TG*NYQ7#@BZ(IXP[9=0MAY9=<)36GH"-'%2]3
M"L8TN9J-TDE3-."\P,>S@DOT5()A!K#'*LF%M.54QI.!:5N:L<\4;/!F%EVJ
MK*'GX#:T#*VT-5!9T4\%3>0T3$YES8E-8.%%^)D?D37V/BS"O"FKAE(IF*7U
M=%94S-'):W*..>)VP$"HBQR6:DX14YP4A2H0%E;1TFQ5&)2'OS,=-QFXJR8U
M$0YYF]<7E6^:T2SB>[IK::+%@0]5%.>99FDMO@QX%DUILW28;BDY \=+FSAQ
M+C5N*HIG63^9@M>YO!@.P3(3"&/:HL=A$L5J#@6ELK$*,VX)%WD[S^K\^*\F
MM<%QM]F4.$6<SDSLN-&[3RE1:)XOZC4Q:5%\;,GDTG794(@KH/22?!$,@U,C
M,IZ"2*O[%<JC3:6PLVW'Q#L* _L@,^#.3W-:CO4-?'7I)INUM"MMJ8[#HEQ+
M&9^D%:DGE/4@"AOC0I4]^-\R28M+58'$J])<CTD,#9J@@)7V/DMS2FXB8[W[
M,-=-6<A)6/4H)I>*<G<7^?MG75=$,K"^$D:<1S.#YT^URFJ;?:*I2AHZI>9H
MD\%^H2F88/HN%_T=)!."R#"ET)#['%[=BT"91+-)!B8:C],TMZ%?FWPFDY"
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M[FQHS)E.^!P.RKTT.6TVD!SL,*Y*^?#+K_T!1R'IWWMM-B>*U/Q3Y2;?L><
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M?9/!7/OHO7U+,CP1BF 65R'86"&O<"K0H@F;QPVJE2T"QR]%"NU/V):*?+E
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MJ*8O=5>^9&0K6OI( V&'CYX=?\4TY:.#QX]OGC:EP?2XP-CP_>.#1X]611B
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M?)&72T-WXZ*L\O%%-C8#\7OBCQ\_"S\^#L7_@'X8Y2W.9/*^)?%7)A^R43G
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M4AE4QXYP:"]F)9]ZD*I+Q#10#G^VV7F:XQF!GJ#;M,29YN&4;5.7;078%:W
M>4;R>8$R(Q+_MW%D/]-&O.D>R)Q/1S1_.;N7'HPO,URO.(I;9JR&HK9EYTS4
MLIFAY)!4&.N?=#1CP5C4+>N]4=5F\->@@=#F YX:#FIN4ARD6;:(0D;3$H8&
M3FV]K!OPMF4" 32?S*B%^FQF%<I*Z'1&!G(@H1.Z9] !O-7&O0K#HM%E]+8D
MF^,HT]^FAD,?="DAF?$0IZK%JTQ'55G3B'(2\W1QN+B2M863YY&BME>$WE:I
M.J?70MROW75=Y&^\;=-QIR/9KFW3_0Q@U[9I T?\_;1MZM=K=RF(Q-53FYY&
M8BI$'+VB2DIRQ J->[--7S=PL::@"X7?0)^:PN5J"[*^ZA$[<L,,KJN8_R-Z
M<(9^/V0VY4*NP>^:@4AB"@4Q,C496V\+%UN)8SUM0_[%?WH4+/TT;PL-JM9V
M7.1F6!,N&59X.8*I]$):]H]&IM0V)%-',W)(RA$R;G/@?_E#=G(CJ+@,EB-;
MJ(7H9IXQ?Y4&,R3M3O9K6>;L](HE19.&=G.>U;"MX=2S#D]EECW1+%+0W7C6
ML\'S*)REBA=?0QS)6,7OG>=96A0FKX/H5:\C;K=X1",B54_:T@Q(>R-(0%.M
M967]GL'D97O%.VSA@@2+3;?%5!79*P,Z"_KA3(/6#$SP[Q9#>GO-9@D@):_=
MDF".;['N]<Z$OOZXX_7+[/IIX*X8IUJB:+,LW6!5.QKQU4)LHJPX&S-I&QC:
M65&4YY*JB\S128EV]Q E-ABKY]J$0Z ;X(-PR.#$H9,A^:MHZ2J")0$C6U46
M;*^3(!B2\5Y,^<J88JIAM %[F B!L)@E)_;"5/A#/#QD@. S< A,!J1. K)
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MG,^S1H@I28TTS/;&7%HHCV26CY*."(K1\7&I:);:3-29E]4*#2+S9*$*FE<
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M(]X1\]V=(#HCHVU>MF3I[BTJ<YZ)K0D)_:^R^@@M^(Y]I@>L!UX:,D1>.64
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MIS?:<Q3;1I0:+*>[BT::^WE9<OOC@+=5R-@*!);6YN3Z5\!.<275#EPB":.
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M7R>E:'EYMV&78>< _XSIW2.7@A<N?C/H4WAO9*F$/F:EG X#<8.@ETZK=!X
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M%?'*'5TA50TGP@5OI%I)[I1S9-19<ZC'/F8\":/+AI)W+12(%?A,"CD)BP8
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M=K%VJWY*.EX9.C#WWMM*<Q@)K=%(E72T*>&>>7JX:_1J=H1XR,U47)(KK!"
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MPW<.=-@")]H&_S7T0,*(HV!JE&J.B3L=-)W J4,Q,-$IVR0W*+W80,>Y2XC
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M;::\C[S2=+\*G];1YMY=;^2[WHHOL4(Z"R\+KH27_9MR5=W3D*[1W-0"Q ]
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M6 /@#D)NJ[@ I:[ZSLBT!]3+3/=H,OT=,B"E:YO26RW* D UFMB\RA687(6
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MVC%-M5!+)ZMEJS*H!;LP]DVHB\P%U6ED!CC(?LE4:SJYS:*7J*V;?JF9@HY
MBQ+9"\4M3J]-3>D)4XVZ@GG\+\1A$CX4B\N/"9'-Q$DGEPDQ8]:3OCQ0^TTI
MV]XG?YY67;6J/,XJCW//\S@K ;^P6S$SF\1TCU6_3J0GP97&H-)*&$Z5P&:J
ME=JUVE/)3*("#<0/4%.6.6,8)$W< 5>S&O2<JCKVYZ7&OKD!1KW GLB((E7:
M>._/T_?<Z8E7[%T _QCW\-W[BUJ:*J4;(><S$*KC7X4C6(^DT;EQU$='&K/9
MA%[560AUWC!P:P6$2U//^JYI30TJC@#;C*9RY&PHF7AIX90?>:^\YFG'N<V\
M:1<;=:C41EF+;A(AR8$$&QMR1+3[3.(E9;CBV&>CP,_())3-P%2N#G;[T2GY
M)LNV!V=4 *T%:XQ.7\T',0(BARL(XQS0ZYLNK*7.:*UWC3623&$;IAP86LU&
MLXW[_MVGZ3GW<-; OOI4RR]3&!?!X$E@;AJ#/P7^\LASW-I1Y&EO&7>.&]V6
MS-6@0.@.^XR^%/@80.$>!91&/13<_COA(4U#R(V,Q9F1L9P%]IOP'?<!"R=J
ME*#U*PKWB71EE#>9)NC<E^J(2B#'#&%4T>U(M>@ >I3I9ACL29_)+.Z-$EDZ
M*_LR8BLJ,6O!M$:5"7G+AV">9Q>HZPT$)JOU50/9[)JI1,%#-HX-B5)/KTS:
MAQ-V5$5P'DJS /*677/;B5":9A:!\N+W$5:G__(P]H5MU]B-\/UH[-YSW^$X
MR EDLS."UR@7CNIO 0)>M\2CTH;T/.16Z<FS5O(GBO(;3.W*O^XMZ&U1K$=$
M<:\7.O8 \WMX%'%KF*""&+UE=T$2#]D=H.C/&&O#,;(UN-QU0">@IU!72O?K
M$/[$%_="'GWE[.#<=SS8R >*UQUF]U:T+7@)"N%,UE-^G_2]3W,X?@,\L .O
MQNX>G/@?,!)E,HMQ$N8'ATQ,.LU.R1,9%,\<:Q:PLY&<$$9B.H5[**,ZW0\Z
M((<)O%P'+-.0*N@?V$S$8&S>;4?C A/@,P&[=:R@P3Y/0*9F*NSS@P-RS08>
M?(J*#&G.5ZK0.7[A\(RT+F5D>!Q>^RN'IP&<X4H^HH1"B0SG?:S$J65JAE+?
M+MR&""="G[U/\&F +%BEKJKKU0,\D3[A/ +4WWV.F@Y2RAP+GH2J#!L9_,]2
M,]7Z%)Q((LL:G=C5/0RH.L(4[<BL33E1BE3,"?2<GI*8.5H9.Z<6$9HB: 9,
M=KBUN<\#7@#[5A,<T*DL<VRIW0PYR6GN@^:=.$;PD87('>HY5-E4V&SD518
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M-&KG)@P&X6(AJB7@7HK^D<4 /'@MY;SCRW\]C-4%?E28X;P,*6W!Y[L8ZMS
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M64#1W+<$>W#B(1L(7X3<=<?XBQCAJO&2!+-X!W GP,89N8)6 V]COS?N&NP
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M\!$[P*] ?G I[,'V','50I"9S8%A/RA[VAEHG=9R>40<0/AP5()>:3FAE;C
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MI<SSHZ3G.93+'9594NZ,0@K4)U-F0#@YE$#QJ+6"&(ZIO2[9_A/6SA/4G:&
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M3?3K,X_)O9%'D< 6Q#W5%05%2;9+OIJ]H9+ML>00;\AVHEC06[G]D0U_<K+
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MJMZP%CO GVDT3]!'6.Q[?L5QE5]1Y5=4^155?L43U)UU,*()R86L.2. 4F&
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MZJU#/)>0C\8X@S=F0QZQGA"^.E0YH,X+_$!?A2B$)QF'\""-#A:0"'=\P"+
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M@()$EGH)X ;(;-#I8 EP/7XS+=N)9[(H"0<B'.-$'<:5HE<I>;GS?MS,>O0
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MT2/8L4&09XVS[LGJY[^=-$X[1ZL8 *=@1Q'Z?+O*V8TLYZ6NK7]TSF+IMY?
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MOC^_90=W<6*/V5'SY/"-X1FGK8IG[ W/V"Z30'I/R;W0S524$&/\\HC_)K)
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M":.$3C!0C<ZSO4U&?)SM8@T0K;K&P(L;['=TWDGA(T(OTL5>($L$4,G =_J
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MM"F*X*A#L@L*NA3I(ZZZ%>U1E+/J5E0BT%3=BJJ2[[7&.'*.I05* R:<0;;
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M@O48(5UNQ>O--GD$X"I.)B/45AA_()$7&*H3 K  \;.3LH\.Y:15('M0ZW%
M''<GP%T!>8YX!X!S7RIRBP/]]% RZ91_R"GV-#F4!A:7 -07042D2<>_<3#O
MJD[SBYQU6R::F>B#MC%0U%#H"MOA,2BRN1'<6CE)C:0@!G48^#_(9< Z#Q1F
M@%^->8DW@G_"I"=<EQ.GN@>;QL*_E.5SEAH^J<6C5.V\(IVCVXR>K8PB^/5]
M$@8CL:NH]V<IQ2*U(M@\E[ZZ0O1[&J(14BA<4]C570J[=A2!2LB[5'5-;0O>
MK +D4:X<$.U?A3\*OK$#PXV,(Z8(83(3[V<CS3P[/Q:H2I,>\1%8J,_./=B5
MQ7?6.BLGKS(9:YM'M_91,;^2*#>BA5F!90%]*H=A#027Y9(G^NCH$:S+>HOR
M8E ./88[O@*^6;!.QT^D^S(:.GTT?A] TV:^P =P.W$G%@.W_)4,>"Q2UV<_
M<.%]^%HY^BO2;PP%* %@WMFD!419]R.[H+%=$?DE+N4&:>)T&+C$EF\D). ^
MXR<ZN+B\T'\<LG/[WHEP4#-8Z)X3QT*@[7+E>8GO_"/5CIN0 S@L6-#!^<75
MS6$Z=3GK+ "=': FX:(@C!?2*BMD5<A*?A2%+0WV<0*]I!XEG<9X5>CT$G0;
MPTT(U;T'GD2C#'(AY>XL+[_RV:\)[$/Z<O& ?[X\3SV-L KCS(45@M0B8D1"
M+P$B_,&_ 2K<8U1F\Z@ ]*",?NV+10#=.W8"I,..V8,07XG=\(&0$2,7U #)
MK@#&AA.:V?3H[>U1L $@#&R6RTA-A+R3A?"$P(/EV2 Z@J3GBGH/%F4S1$,,
MU<*F$YN\$5$DH@@Y>,3[(A[#J0:N"'G/<9UX3"MQD+$& P$WXE?E8(E;/4PZ
MO3Y'US$""+1$UPZ%WV#GR :=*2+)2"^&XH@E/O<=3_KI[P/%+S5^[#MT.;J!
MC0*!"#XR;$1J'I*MS#B%F@(DXG08)#'R745R^A* /[JKVVPL>*BICF@MFE9=
MHJ07B;\38+=P6"#\@#QM6)$,WY+FX(0RP*>4'#AM6I!1>"X%JOOH[,9+/@CN
MQD.ZX@/%>N]$>(^J2HV^HYAA-!1&><LB3PE0XSH(>XZM>0/\A3?"7W\" P,
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M.]>GFNMYB\S0(C,<]*)?03EZB\QPR^:TR ROZ2JTR SWN0I-169X3*?9C@K
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MY[><.](/OH9[5]BV"WCXU?8.N=-( 'CLU["^V8.62UI>/5@>N334"0[#V##
M+S\YP"^7]< OAV6"; %I$QQ]_NF_Q6+YX?*=%??4*.5MK[NN&:)F:?J8(#T,
MOZEP,<N\S&-$N-7N*IHO^;,9<P>(=>8#)+9(6<T*0'%+)G3!L%\)KU'_<J<+
M4GLG^%(ZZK41[O2*0Z%JKY#\^YI"\L,BY4UU\<'1[T2^WZ^3[Z!S<B?Y]GIU
M]+N16JM2DP1ME-%$-"\]THUQ'&::R$4A1ED)K#0:@7!5P^F?H)E=+D&:J#9
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M:+MD/>ZF<K@](2P(3"KD0- C2(#&=ABIEP"4-MC_T'09T/8=VL^A$#&T9]/
MLWF>EE O6/DG"? :E/RC?C\<G.W0Y*U5Z_9!?T>]B[ [/&^/I6''T@=+J#=X
MEF-Y8*#K)79=XQQO3A;&W*\H*3$3_K>EU(!9WTD$?0O^$%_E?6-C+Z0UP>.&
MSPZ]-<$&C]=I.!P.#\3<>?9>",_!A^X9X'@A=_AQ8R"'?H<WF$*#\/QL5X]8
M>Z7:*]5>J8T=I\/ST\&!WJCZACV5*H"&UOW=GNJUCC:G'V#D]AC!A!!<9"*R
MNI)_#01MZWEK,>JPDDP-W ENC8G>,:&09R3BV&\]43\IK I<0W&Z>X(_$BI#
M@8!C,>+0"(;'M>  @4*U<*"MYI&<!BG;# 05-V80O87X@IU#&/)DDL+[L;F2
M1A"@WV9R(:)$@PS8;AKXH%M-O[93B$>6C[-HI.'3P_75>DB!O_\<(E[5+<C>
M^G<AO#TSR(.$>\VU?XS6DTNG0MA :D@'5P^75 B&G5@B?M6($240\6*1)A$"
M%"I<']IA.[ BLGK8/;=R>1I]E1/=B0#(FTL_^3!S=R[P$L) S,B.HS]71&=W
M[+ "T9!?U1,*NA\!^%R\"H=&?2+.?1CFS; )> X.\AZ5H$=8MAHAC-IQ!7'#
M[LQV'8%H^,I3RS(;SP4=(^&-T(PFR*\4$/06J-6,$OI<.&C5)CK5(YBD=+P*
M %$!AIAK04<Y3K-E2G2KR- !G"*RYWSEW$$<640Y0=@E,BUSO>#4#$QE^[F/
M$1(5<I&O-V[!2$B_^X%\Q/1W[X.!2<2[')"XJ<%QJ?LACNY/S:Y-;\@1UUS[
M;3HLQZH^YN,K;=.NXF!!4.X0D;-,W@2]"]N"91/2NY)$=6"9]9T+D*[<)@7K
M\K7:I(4;$=3U(;A+KO(J["(<[&#N7K!._[>O13=1J)$B%H!UE_D_$Q+@)F<.
MD0;Y_+"<GKV$!XK]@%@BO/-X.HIK(7Q(1EAHBAD:UV=J79\$.]7K=<XLX>"Q
M]GIK;8?T<+>-MM;S37-GX?3:6$1?'4 )1\3<XSW(.[V&1]5V1_BFAT!3,$[V
M%J+2P4:&%3"0*4[H'YW/';,F+3Y89! $&#8O@WT &AIKS!>U,XB?[6/,]3O*
M95&!$]YUXWJ5C5,77M]8PIV!R2%7H;' _ )=*%M9^%%G2$(O<R$$$6N$3@#U
M QJ& :H9O8O0)>S9L%YNH,((8-*=!RR]0/W:89F,:XI?:CPPZJ#7/?-["E;@
M _V7C&5&RNM43DA3=JX,OW$-%J>W$RZ.K[H4.Y[.QA9>EKL:9/4[$-7Q:R;-
M)/7V[$;D%O1WTDSF_&N:'/]T>?E),6>ZC.:S'SY]OB6F<Z",W*S.X8Z)^HSI
M$)=-J'XQV:_$\*\C>9-O!#65&2%?(RXAW54V51D?]3HB.V,DQZ+,I6L+CV0<
MR6L"THQR#SU;)G,<+%?,,\UR]2[&0R1G A%V_7P89S,/@).,O3<2#+U>K+8:
M"#X4N6[NK:03W+931!O*JC-7G7FN7JF:'&R@ZOI8.(Q9*S:*36D.M^(&;0I[
M!R8>K_*(]IVA*%:TE9I%NOM. V8RF2C<+V-Q\ON.^(;F<T)\1*MF)(TQ)"<J
MQQ#M?'C#._Z&C?8=K,H:N,/0W;R=Q:+>6#:<:"5:OE76A_2:PQ6+@/T+LO,,
M;!'\WJ<:W;PS)YAXRUZ]PS]0.V3[VPV4AQFE2>'XJ?2%T!Q?72STSB2(2>PY
MLL82*0'$Q )F-8]7'KE:HU!?1B)QTZ!7U,QJ(8LL&G>"7^Z\L'K&,3N#J-.J
M/ED4[6/!<*G+$BQ8C1 (MUP-P*C#SN7Q^0@POA1^3 AARF2GF0'M?4P,>#VZ
M"RJ;8AB0PO3UX$(C=+5ET35;X(1U77*? KM 7SO3^_&9V%BR]<FJUNN\5=K/
MQ*]%5TTVH373\O#'H<-X0()K3RTILJJ#.SDKE9<0=$::1M4CAA#_BJ^\=CBO
MTQ;.JX7S:N&\7C&<UV;M8)^,B,$NM:',[5/B<1G;F$,$KQ*9E1:FD0K]-*'(
M#+?FLLHY_/_M9)%2-GU%,[(2%"85@C);<#@+=0+J0@"JI>KN@Z#:)<AIE++X
M+!KESAOQ'2"8&,]S@W"[6Y%3TF6PAKS6--7NH^XEZJHJ[/AD6P+4?U%4W0^L
M'I.6I)4A](P5CEIE8I*=X*\16EOHPD:G@FKOH90:YWG6Z(P*;D,BE8:B<#K'
MW!@$M<LH1EL.F_/LW&#4M'+RW#0:Y=T9QGNC"EZE(]P)IA&WXY(.7,D)=W+*
M-8Z]M7C@?>KFP,'K?A7ZM>2)<TA[O<_%R#=*U%!Z_\C'0MYQO)-90)0^"8Y<
M1U1BFS,YL34/<):O#1A0Y*JG,=YU[CH[4/10R:5XEC)BUS?3,5@[P2>ZACQ^
MSMKB2$KJ)03:-A\A<0G#:[@YB0YT<\3M@;?QN2#N:<,3[&C /' DBQM</.VI
MM2 -'_5<!37?'VUVT;VC9C)XE^(XO<G?;[ECO<."BCSK=@9GVR$/[C1LY_R>
MH^X??/'0YGKZ&#B1+QM6#YFI7!(7YKXAF#11HK^^Q=O;:9FO T"NQ=MK$M[>
M/3C0,Y89U8?W1EQF5%#* 87?4+4W+>%0'7DTR)Y&IE$_-3A?L]*D7T[U4--*
M&9ZD5.% [M!3(YPUZPX]6?5.2](M23>)I!]>/?/$U3$O#KP#]#5LK"F#HXGD
MO]Z1I]'/77B_C15P;]"#=HP]@X,Y'CKU^V-\^/UIYVQ_7DL&CMPV<^<Q&Q2>
M=,Y/[N5+J4D(0'YS/.CT:IR1V(^5H\Q'#F8,Q^1>!+[2!NCM\*Q[*)I]"[7U
MM Z1<'@^;$^F@2<S"$^'_8,'0J-WGY'0:IA:5=,P_C4@I)V>GC:=\[?@7_LX
ME//3\_9<FG@NY\\(3?U(-DYSN?[/:9[;SL-;U1!0QMAKP$?NA8/A>=.%0ZM\
M[N-0CGKA^?EP>V#(]E3V="K]B_ZSG,J+-P=^L\5AK2OU0%RI1$W]\QI:<M,\
MCR]JLA#W2UQ7*BM65\1-HEQE7I@D^JO?_OGQ^^/>13"1US).EQHR8Y:)1=N=
MH=4_7I>DZ_=/VG-IX+D,NL]X+H^I@_0NFJF!O 87Y(%P^M;=M1>;9@<KLSV1
MO9Q(OWN('2$.,16[BK.Q94[V0\R!AV7<-42"]/MA[_3@>X?7T&=C$SE?,(EM
M2-T]"4]VCI"U)W[ )WX1#LZ:>N#W-7T.6#8:P-.[9>-V)4J[Z&H'1M ;.U[W
M&A_/NP>A[D/A?SJ6>9@4MJE=\TE_UV:=[8$?]($/AO=,3VF>C'P9^?D_F%8&
M'M)P4L6V/.CL_/XKRL[OA?W!H=BV;;CE:<-@W38WOXGG<G)R^C+"8(U,Q?FU
M@IIONAWM"HW?!M,:(R_:T,U^Y,59>RX-/!=U25]&7G_OM%YH-"SG[M( 71*4
MI)4G/N[E.$W^528$Y<EXKRAH^MW>27!5CK!Y@=^3*P^QQT?'1?=LD_,:(V5:
M[;>YW*P]F[TD;YR>'51]P$:O8,.C4R9SH]@Z3/4D\:@&$N8FS(G>2;?I\F-7
MHGS6P,331B4:2%B;0A(7@UUQ$MIS/L1S/N_O"J6WEW-^S7F+3B^-1Q9\AYE9
MM"&B<Q%V>X<2TFE,8+Y-7ML-:?1T<,^@1'OBAWCB9^')L*G0LH]:J=5MOJ_Q
M9YGG[X-?G<9219%%H[+07;.2-$'1F*7<J9XZ3TIJ3?_HJ8O-H]]ZH7C6='G8
MAD;V([C:8VG@L>R:=]* 6-6CN1+WO]N[V5-KTD5U:<,#^V^Q6'X(KM(.QZD>
M33.XFW!?6H\.?\4-%*!H579/FBY%=[V<SVI@;&3Q+^C>/'43@P;=F\VF<O^Q
M6QBT9-R2\?[M_WN"L33,'[[NI>\?F#\<>TB+/"\7J*A-HKBD=*('5RP^VHXU
MXL8^5&';>=$-U-E..F>]IFML][B.>XZ/;I[/U@+O(&_00V7>8=V@#8Z)SOFN
M88Z6H%N";BY!]SH[HT[LBZ#W5%&[_SU'?6T23:<RD\E8OH8$;J"RQ@=<V@SA
M?1Q*MW.R*V1#>S#[$02]>\;S&V"U\V U<N@E9+GM:M[?4Y _? \;H=0]KIW_
M")O20'%\UFE^IY4GN.![-*L>-M][FETOY 8_KEEVZ#=X P1$9W#/6NOV0K47
MJKU0Z]@%G8M#O5"D.W]+Z3@:H&H3/EBE[0"6J$?3U5H^Z^-L_+!S<@^<KOYF
MG*Y^9SB\%:?+=M%^A.F?W7/N[GX/.D/"8[M< .%P@[]^M]\/\;\]ZF<.?W0Q
MYPJQTH*WO<Y9,(KB&-8>!F\'W7ZPX'_1L_[7F<R7<HR[$Z]"1*2)DD(DLPBS
MLL!<P%2NQ5)$&6$0C+D%4,?@L*W1R0(>B!(BTP&L_#613?_YR>;-7X(_YC*0
M'IH>GM^8P/00%:("J!?EP406,@.K$#X;K0*Q7,8KM 0)JZ@015FDV2H HU B
M=>"G*7"3*(&MP:=DED7TA/HRT?:F,- 56])+K[_Y[,]/SL;WX-4[;MZEQ<.@
MF_)]A$TUHZ+,Y/'O2 RP15=>C^4[R/\.:A_N#V6Q7X?4CVO4Y\52"YT$BD+H
M-#7M6* JH7A0!7XDD0[ZB(,KDM-+)G8C<QQL5.8P.> N0!I L+DTPVH>AB^'
MS^"N_<=T%ZMR)AZ[^M2RS(!-X9#C,8Z)5.K0(J::8K/4!(B6^J**/+B1<8S_
MNP7K"^F=\NM2)CG>!+V5F2(/&!V>3+!/6J0NG+F,4Q@KN!9Q*8.%%#ELAD8!
MBR,!#)D:M5)[-7;(S.B]L(?11#EE.L%EG*?V#HM,4AG&C+\.@R(#ZA!C_@?.
M5!];2IT!J4$XKBT=1S2EW8_K-AIB'Y,SPRV.T-VX-(X%Z#G"S@3N+6PT'6&6
MX;8R/]GF_IT^-S?Q>[._'K[!1.:<:^9M!%-G'ASE4@(U%9)'."6 H[DD@D?E
MEJ\,R)D$:#4F4<2G_VX3SY"+99RN)$+L+053D:9XY!/CL8SQ'L&P$[D$_A7Q
M(]7K,!5C?1=A2B.849SF\"7<2[X8<@+W<--H>O7P44ZP3=0I44?I8+CB1DKF
M#-[O-$OA5R)WG25P0O!:T#CH\4Q>1SB/,I?3,H:K,342F>Y2&* R M\OE:@7
MP$3&T9+GB/*;1#K(?5@G,+S:E06JN2,VD.;VC9,H7_)34V8IM=,6GAY1%K"#
M_]%:A#OA91;A&U*UHAK"Z 3^Q5$GB%Q%'S0S9S&"V:0)3C+4A[8*\GE9'$_2
MFV2SSJ%H^ZR/"NJ:LG<338JY,N?<7RG+K&M_(D9 J&6Q^2?.-08V!KNSSTM[
M<N9O@/O?>6;MNID\'F52?#D64YCA>Q'?B%7^YEN?/0%O<G=MTX(=-G:K(C^=
M/NYJF3M.4"4ALGQ/Z8BLE_])/.\$@GDFIW]^\U^1&)P/>[WS2>_DK#_LRNZ%
M'%R<#'NCBZ[L=\^[T_\[PWX1(!K_]*TXK%D'!S?C='IP4P8- EA(@DH$S+SF
M:N^B3NR3$:',8/53ZP3$TCW-6XON8^^1("_'<_QZ7*(6&S.K=P!T<6@6.DKX
MJA;%59&.,DH;=3P58.)%)HM(Z> :I7<9"Z5YYC 4<$:2J*#TX B.@-_.HGUV
M%?2CU==^3E%_YWCOQP2%/9M#8!O\ +(>).=G"=M,>L^K4%-!YL6D8.%C96+^
M.0-S21D?SI9%_I9)WK+<;%D@(Z(K4#Q0VP*Z&A?QBK6I+"UG<_HFR^?1TBF<
MCQ)GX& *G&%KVV:'2[T?6KM2EB;WH/^(WJ472$>!9^EXQC4YU+1MPMXUM,_9
M]X"V#! #Z5B!1"> \I_-Y2(@S@1O@QV*)B48.\!V(F"0VO97#T99\.\2E?J"
M-%6:%WP0FW^3)Q>GL%JBBQ(=N@7-A@;*R=7 $ROFHJ#9E4F9EX0['@ /!8,?
M^"N<0S2% 13H+"OJ95R0+T $8%N!75'& K@HS"TEFR%)"UK F*<"#TY+'$XG
ME, *U""=X ?MOJ";E=SI4(!1-&-WK,K[M*"O&IW#[8U.3UP)JG%VX=TK$]L5
MY+TZL=X.YC!;94! XJ%@P8XCB+;R-NS@];L=3?[\YFY-!HR&-[=SA%LLAWMR
MLDU9+-I-(T6&>@9Z?"W1'"H?-NOY%"TI-'&@7!@#&5>@>(EDA?I?!G, @3J'
MVY?#(>$U @XUH8N1J_*S3,Z +7&\0EY'\D;[8/_1^=RA\R71R\HB\T?/^QO@
M'8;]!ILX&,.,D-Y=/M()+HD3X76?QNCQ5AX.-4_"%#[[D.OY(LOCLUBJL\#W
MP,WZ48ZR4F0K==G/*)(WH!EJ1H*LK<Q):XUPR07*#[BL,$N4K>J7G0#?V>]^
M^$ZY:)\B'VM' E08#OL'V^8 V*;[3!O5^Q"(47HMM]*RZN.5C0E1 2<V:[U:
M=YW_;%SGE[-,LJPX4%9 T" Z2Y7=LF"WD41-X9*@;S+!N$^N4EBQ)K5,E L7
M-9VYN&;OYS)%$QH%*(PQR5!5&8'V!N)<9,=*Z4]FQVA3!K,LO2GFG4 KMB!#
M2;3:$ LK>'FY@.TCVV$$Q'8#)#:91,QBT"D*AFNN(C4Z])K<2P?I,$8*.4HQ
M7!\LT@1CKSG]'"S723X62TF*)D^^;B\64A:U3 L,8GC3+!H'8[!IX*#$ VR1
M9Z67CXGAL,180[UQ<+Y_EW&9''\7P?[#O5$.<*$"3:Q]>G&H0.C;@[YNE#A&
M&6>7,9P:&W7!S3R"(?E5:$7*"5L*.9(99>!P=$]IU'1S0U>^A* .)N54C$ES
MYJDL%C!>A+:I47'+)9(,2D%M/D8S)=("=,UKR77Y_95]80$&;F$44J MF74J
MFY$AK>*L:8(X7Q6]\6=Z^RRM5:2VE WL=$FS-U.ZFJ.XD@'>8J3<,/@K7+S@
M[_@??/X7,1:E)G@*5RS$%WP;K![,!M3IQ4HOYVWO3($(+'1:"Y^%CG.XZF\#
M)*0GHB;K*N?^A*4*W^B4HD$'E'O#OL(*?8 > DH,1V^),,82*5L9>D[,&J8'
M1)F"NJ,.B242\* ,SB!+5R(F?H3U!_QC-*=R$:OP-ZE\+DU-D'#0BIN4XX*#
MX&%=X@%%O?1]U;>>KXC$Q*=NUR,3',);HN&%GR4F!P3?X7V:R@RG30Y!VJB_
M ?EKUG+ +-)=AN&0J%[@:C\NQ SV6%@]F-7B490N/7N0G*-X8(J.D3TFH'DO
MY"0:XQVOYT"+%3Z<I1@4S-AGD,AT&8M\D3MNVA$2$>PD2#/4B*7(,04#1WS;
MZPQ.=!I;<,2R%5]N2(YX))KAGB]7>>[$C<@F^3LVG55LL:1S%DN8UE=*V0 1
M^_:T0C(8<;4:@/8&TW89ZHFEF%CK!!8!FR$7*,AAG_]^/#@9#H(C6 00.+SB
MXR\_'9_USR_ D(]R=@3Y/!TD$=@J@;@&38+0TN(5*OO'Z.Y!1PUL_4(6\U6,
M62\]^/D\&J%>X)A-(XE;H_Q.S <7)5S")8SVB;)E^O:D"Z2N#>>&62!*@9IG
MZ6*4CE?HPHI$R$<ZC4992LXKW-EE&J_T P$:;71K-7_!$U*N,^4YHO#O'_1.
MN\4WZ'#A7![M1:-MJG@K1,)Q84]H,.,G]J+R3?!)_X3[W:Z7']D*B#H!06*V
MTS<W3@F,JN/+.3@Z2=00D+^G-6+""H=*N(;8N#W= ^:QG^42E/<1D#@G[#)I
MRJ\HV7)*PLRU:@0;^*\THMNJ3KQ&MUK*+$>>0#(1KP[H^\B'E4877,-%03?#
MXO=?+X^'O9.S;_]Y,>RR;>3X<]&^R=6ED5^CO.!$"T_M-=E7CDCEX_DEG: 3
M12M9[-=EIB+@.IU4.";[;O'5[<W:K'KU.]5#B_+;&3A0QD@'/NE<&K"]?Y>K
M(BLG8O_;B3)A\J_RFJC<2"R4%DO8(F(SM$FLQGS\^/';C_\$)05LCW0AX+D8
M+'>^!0L0B@5;:"R B*[KI:0Z%V!JJ)ER!K6Z'AW'Z%0?L4RR]TRB!NS&*>I-
M/OR4?DEZC)O2!FH7B#+R\$N,! &AL">TF /UW*19/+F)*"7/N=JDXV^TC_54
M19* Q!T3FT&O@4^;*)-GP.IQR=]A]I".<OY!/&D5?"\QC,3SASU!IO/C]Y=&
MIZ@Y*DS=]4YJ#L=[G$7YE^V.:>N0? /%Q&4Y@XEX,@+/XC<\"$H<HQL/'%1L
M=$Z@/PNC8:!E.9;ZN@0Q:I^.B86!U9V5^%#FFA4O)ID9Z(\]V%$RI6TO<ZV7
ML]:>X%;-5IW@'XH.'6%3:YTMQ*36K(?UT/))[ZB(%&/>B[PU[;>7+YYI3YN[
MM47_VG,IS]M<RC:7LLVE?.6YE+N%^Y^"$3D2Q:1*:C/:"V9[3E;4$\GI<8V/
MLQ<5\_4Q_J6R<#@ Y6F)2@]AY]AM+E04)=MY3DD.':Z:]K<R7M4H::RC:W59
M!+,X'9%C]'A=MS^N4>^-#H?:,0UG=K/J"K1.Q=^^_^48Z#DX^N7OQR>GY\-W
MCM=TDI6S/"C0[&;+?E6D8W37R>#3\*0;]'J7O>#HZO_[A']0_A!HF?\!*L*"
MMS0K4#&/<%=EED:&8I@H^&W*4XF>R9"RM=2SE-RDW8^80L3ON-V0W6A<U7H@
M?2-A<?7[IZO.-KJD<A.^[5^TRN0C*),'>HLOF9W57^4'Q(;O"O]:6[P2"-X]
M_%L3(<#H&#("6&/W7?VU8<"(HERD6;Z]=;:^*W4N#"H8$QC+J,N:TH/73/JN
MBXOW=; AM-M>UUVNZUHDE\MT[QG.]52-;<*Z!RST?Q&:4=15NCO^<Z="^2Y'
M?SKB6OK$X1":RZ1E@4G?)#TW)TF$G"%!I/:'B&Y$\@".4A\#_^/WWS[UCZT6
MH4+P:TXC7!I'/%/0'DJ<YN>_?W?</QT23^J?GW7?Z5OK^;1A!]8$OY=M^;A<
M2N>EW,*IJ/S'79N?J>^DC\%4U-HX'WR1)FFA?)^<:-IH__R3S.76-U/<=G(M
M2$>N"",L6%:70]\8WSWH"X16?WNP0% U WB1*'3+R54V;=&$9JF87#G;%;=0
M:0=L2OX+N"$G)%**81C@]4O(!\RQX"GZHQUIX:9G8,'3!N8#+"Y512.U6^B\
M\W%REIRQ8?U4 8B"2V6-;,AH>KC,:VR.,24!)<>?LG0L\WQC5O6!9A1_7!?E
M&N3$Y=MYZ&;*4O&!83'XA8/H0C&1XZ7:+IOXSU<D9R8%-X%S;XMH03]QLAQ"
M&'Y"=50KB94#8CS'M^CK1+)J*D4>$5+,JA-<%G 08\HN8(8XZ(7J<N,K1B)&
M9HMO^?CI=VJI^#TQR;=G+O[7,HLP>QDE(A>)40HU2;>SB]-^<)2GF("<C>6R
M #'^]K0SU#_^0 ^1G)_)J5A&7T5"SYP/#.+8!PXJ@FG2[9\&1XE<%&*4E?"6
M:(2/#GOG^M%.\-F^"B^NT0\&]=):!:G,\5B\"S"O(NI1[$R>3]DI$1%E,4]5
M]:9)?_S)+ 1GH,M*:FM)\!\__*,3_.JNR9OW!KWF0'5AS,NRE&0(F\+#*AT_
MJH2S*3M^1#)"99Y$">8$86E,E'_)5>VMTLST2:#[:NV@(SJ099KGS,OGPLMB
M9XT/;\\(!)GB]GDYQMLX+>/UI!J.'A?5-7&9(.6N46 =AJKDHC*D"?F="2=-
M><><:B25PH97G LD<U?TL".6$NRTXQ4CXVZ5O"51$$UCW)7*3MHM S[PV:G7
MG,A8K&RT5KTJ4&PIU.@NU=1_X&,QRB['--$_Q3K1. 8E*RWC"8^/HRPS3#_W
MCX#6PW74++KAB5+:=>;2.)^!>QEE \NPHNFFH\@D"2-7.:EX"6'/!=)#0I/"
MD'3L\H()K5J]P R+*\;/J4*7@62PZ(HA9SP+"GZ6U%,:B@(-SN-+ G\M1F2H
MO$5&K['FC)/'B/0#^LR4D0_&438N,6\4CALU*'5"8S"APOISW%!S"Q2,IX=7
M8P(SSC'O44PQ@J_2\]WU+<3*X@_50J"QPFW&Q$1*/(E#96P?73C-T.)INIMB
MSM >Z_K.D(AI38];,TA5WRL+3]H_._'A22],.JZ/3EJMD;[8!3'L0$G3<LG-
MEI M<E%J^TB"L2TIZJ=8#(MG):TT7P4%\S;U\H^Y3C4C:#Y'8-8HMSB%B82#
MIE*\F[DD2:8X+C^#G'9$26):&0".B:>E2@N(0*I2GR *XD+G:H,(7$2%DVZ,
MDA,C31L%)[D=E"Q[2-'ZH%E%ZU>@I**=^@->K@DC-1ZH*::7(IVEL*Q[.[2V
MAG5<U'S*&,@U7W0[W@YY*CR_HF]M(><5_<YY_2OZG=/U5[B5Z@P@5.B0^7JM
M@?OSL5JZN2.D*>';CN$_)V'EUW,13_&2Z+3KF"P=\RX#3J.7Z#DR3>VB]0A3
M:%@LQ1@+8O"BZ.R]T.21<Y8I3" .YJ#8%7.KP1TH1_V^#KV0S.+>VJ$C*?36
M3KRWAJ*M22&TIX/E2;6C]3:-5BVMZ(9N;46<JOH8CX;_2 NR+6N6=#M&^"UP
MF"2F^XX,?GO1\P5T__2\7D*':Y4<ZPB/[+-["/KG:\]%O-B<B[B+1#M]TV8P
M-CQ-K<U@;#,8'S>#<<]JZB5H]ZL\(M7^YPC,DPG5WH(0T5H?V*EIF8T/5GNE
M**4+H8$!>BNWR(D8RT F>)5S]&+JN-<F>RYD4). 9#FA%<7H@8O("12""420
M'AAL($ AD\Z)PRP$*(OHM2F78+&AR(U%F8SGDN(/7/1Q'9$:Z**\C45.Z ]E
MQKHK)6S.TQ@H\VX]3\E/[HQ$[6.L9*66-12&7^;RO?[C T)*QV+U/DIH0^E'
M'_SA3M9;;= Q\]=6Y'2Z+'94TT?U9O5UA[ZJ=.#A[TY..L.SS5]W.[V-W]TV
M; \LAV'_7L/>_MUI]WZ_?%F3'6XU[!U=0!^SL?.X/Q@^K3>/R/NSC-E7^[TH
M3&WE+6W0[NPXV_1'[VKD^HC]6)^D2=B.YWOTEA 9V*;*WVUQPO?= ;97GK]W
M*-JFC[7,+8CL<+9K0U\Y,.+;[=IEN[K>=NW<&%HUI3[@QL__FV9?E(</^="N
M[;@/JS?E0]LU[[SH!K9C[O7"X?F@Z0V9[W&QGK0_["[SV;K_ZT'>H8?V=SVL
M.U2_VM-P<#%L*;JEZ!=#T<.=.WSOBYYWULE4I^1FJUTZ)#?B+ ?ZE]O>D=I'
M$@;A1GV^O]L>U%ZUAN@D_?-.K^D:23U9[4K2>]O2;[:Q ^]:Y$8;\"!IKYX,
M!KW.X*600OT*6U+8EA2&G5VEX$&3P@/='2H&T]]*[/>Z-3*XVM/]F87R%0:X
M./;%&'TV0]K)24%@="H(4VT$I&ZG8 0YBO5[W;G[[6\#I4^W<_I^*T_D0[=@
M&R_E2]CF>H+M=H;M-N]CF_N5;2;.^2U%I \N%^$/JJ\:9X3&B( DO@=8IP0R
M8GNF4_0H/Q!+JTPAX*24G%7*0TTX/X"KVFVBJ=,"2:4]6*8*?R"\.:8L<'KL
MW=/JK4^KZT_+R8:<2#VU?)YF!?=K0>9\L(G^#Y10G,!ZL99=6CWLM[W!>@;J
M^A&-'S8;11HZ'P;;8M:3QB.L&I96COG'MDC;Z3ABZK4=\M%($&._:Q*A0W6Z
M:UO(R>4#6Z9B]NV!\_<Z&HUD;4D7T_\JX#0I;JR8<$4AIQFYY5Z)E!.LS\*C
MEE^I$IF.$FCRFB:5JYJ,.\<TU=!N18;;^B@T]]=-W \#ZF$I<;2EB";5;"(N
M-D,Z*_']13K^@N#D8RR757630!H3+N* 3X%X<+=UR95ZI88NR<I8=S4:R;%8
MR$!241M5^&.IH_@:K*2 UXXDW'TJ@.$.G+IP.E UT[W@J )D_P?\]JI4>55_
M2T=Y<#DF_(E^MW<6'/UQ];?+=^]"ATE2*=\"NQ10U8WX*G.O@FSI%&92\K:=
MTX$CX]$MH#9<II_M3GSKI.;.5=G6Z7K1!Y-+G-[ ,9:YY+Y&^?Q^DUB3?CSN
MV"R-"HF\YFO4!Y4PM]/I%$LZX?XC9C5VE]8D37@9MDFP+?)U)>DX+9>Q7BJ_
MEPIVX2YS10AWQMEBJ,,6?YJ$5/KD+B1TM^1;$VF[O86 9S:)3L6H*G2$Z)H&
M_)Q>/XE ($:CDID7UX-/C/Y#1_U;-A.)J@ZJ:6Z4+^$,@=RJ]1.#7=K%^L1%
M5?DYMH=@44"NZWJ=+$FY+MD,X*')*-JO$0#(YK4 ,#^INSX)(5\8D8T4;_4[
M$-09@;_?+D7,W$DN3"+&U*"BZ8-'+_R86,G%Q<JNA,%31(S6\T[7*[)%HDRP
M&#YV!%0NDPA86ID03Y&T2S*O@("\[75._*'@PU[GK/N->AR9)4SDC$J;NC6/
M7E0?/:?RNO5'^YW>B?\HBN8-CYY5'CTQ553KT^VOS>&TIW$'2RVXD?#6KP40
M)C??5F6TN%(>*53_'O3\?Y^H?YNB>GR;^HC:,LJ$6]>FV9*!R8!NEREUM;+%
M>EQDZV!>(29<H>KW+!@%7*$E]<@R]\)I@W7;8S7,Q<]CK[16NN1:L311O:9-
MTR9@%7*":J+>4$3(P3>;(EVXX%BY1NB.BOBH4X7F5][&JVVN;KL].[Z_YY[R
MBW6_ZA\APW"F,7T<)<1C0J<$&6$]X",X ^S9:-2Q&IT;@6%6@4RN(U@V@T*%
M =6V,3C4#)$?> 9'/WS^Z1UW1CA4#8ZPC1.IR@[K>,JP>K,>PE/6KW1W[4KW
M3XFG].OXS[#**;H;^$^_,Z@\.NR:>LLZ5E$=^:2[*ZO8PRW?< 4/E_8L:%7U
M)M(Y6; J]SPKL"7N3[H5C DX5R,"%J(H,X4[/49,#[K#6L&*,@4U23UWL$(<
M3RB:$,;<FL1UW]ESICGHG)_=.4_X8W Z_-"SQD\(I-WKGSS.3+M;;6BO<^Y-
M].V9TPQO&J?D5C@F$G[0I Z4-MW*_CGA?+X]=8Q5,/TG41%,Q9@P,U2G)&&P
M!C1//64SP3RGS) \0-=ZN0QB4QHWW0#0M)D=V%')0:M=2<9FW<R+?. "7!XJ
MRI-,W"3D#Z+!F;]%N7G-:R^_/NWZ&]"V@CF :MFVD+HMI-Y'*YC&""OTR8^Y
MRX#,I>2NP5X!MO;>9ZH 6\-'&7!>!':31: ;^]DVH3H82'_@CZY%;!!Q'=P]
M?@"4B!NE)UMWFH<(?)>J&Z>@@E0]0-&4@AURHO7SD8PC>:W# 8A)K@K+*;QA
M?'T:+$M,T PMR-6[D))_H>#SW)WPA*01QQKQ3E=..SLG,C"<V:?/MFNV(.E;
M9NRB-H$5ZRE4F"SOFZLD;5_.J#!V1D7PVRA6O1[X&#]2'\.\"#YI]QYM9__#
M/O-#&9+NL^<[[76W=IZ21C4M,^ZR(PL"D9S6:FSD1DTK>Z"@?Y4ES)<47\5T
MYYC4%&M7^Z7=H4WV6NY((!A<^]E)BE:4L']4^AH<:&IFDHBQZ9Q"T<"KOUU6
M'2,6< _(!PX)K(,4T0P0]Y4BI:K)N?BJ$3.K6-*ZJEO]GL!$A<*,)0+!F:H(
MIN;#" Q&..K $-G+ICN^\BRKR*K5=[JYZ%-RUABLSPD%3$=@,&!'6:_%@Z9%
M\J#![L0,O%ZY2-NC.'D7*4HH(X##]1R:)_^(TU'<;*7J2[WE&E[0E?G-!/E_
MEA3F>+8[4\<][\,Y\TVL,Z8TE-UX)__&L,H7<^Q7J>E0\(M);WE^";KF&"%W
M4(:N8GTYV9DAW!X+MW94<!-TJFV.B3%?YL *_A_<[+% A-',_A)G,)(2P<>!
MV@BZ>T0JKPJ^ZIF.2HU4GE=QR<5XCNJCR_/U?&IG7>5])[NQ/@?-VN5^7@X*
M2)CZ5[\8XOZD8K:>KOAL-&UFXW&>#+4!.*$Q&U$D?N2,XM:CB)UD[O/4<-[-
M_IBEB/]._40P"6M,GD$M5X&;18MR02D<"><\P3PS4#[R\);6)VAG32AY%DV-
MSH:9<Z<[,BTTE[3OL7.L*@A>^*XF4JB3YX#N,,>&G)V@=-!B;^M'8=\Q4=GT
MR[II8X3H=,V#[^)JGOEQ&^SPDC-"\$39K< 7Z+!T5X<M(:P0<^K9K]#=[<B0
M)-:#_P@SALT*G12A3,XPX819BV% 5LNE++3/?DK1#U]5,LL5DD&>XT^//O]P
M]<Y1,T4)NP6CCH-\+N.I_Q[= 45<@XC7C1CP3O>[']#B/_Z2I#<P'9#7!+E/
M <8LIR=Z'VR;L$HFWSP#=DN:<(/9WZUG]X-9$$/__PKJOG-7\*IT+_PSE5_A
M< BB/\ >%KI;1IH8X3$K!:C'A31=!ZA;@?'5L!$Z97=(.<JC281YG^PQ^3P7
MV9+?3NF5P??I?($OSY:=X.B7S]]S2UGXX_$FXJ[NB'K?U48[W[G&![%4)R6H
MWDPF1PWP$C,1,,%3BF@@BEZBTL8QM8DCVK@=8+^I]K"<*X3-%PZ4NER%S+C"
MHH):!Q:D\) FAC)(\*VJ8A2NX5B3J"KR^NQ_2K)$;%_E+Z3(%_K1, M,!\8P
MT0,508IJBVS"?C_;/PP'*7)GW& )JM-X!8<8320N,K?'JC]AP1:#)5!4<F[5
M6\$T2'/5S80P\!.IN(R_Q$DJ.>1%F6CLM*2X)N'F3X]U R5@<MBOPW9WI!FG
M,654TRVP"I^Y9)'V1*I8G^."1'+6?03C%4_7R_WF#B^FXX0]*4=.'BJ=@@33
MC,]MOVMLO^]2H!-2)2+8 %!5\DJ*-=!45F#O'9-H&&(Y2"P88;KF>U(INIVS
M 3H7.!M=-ZVM6I[5# R2FYA=J..RTRC+"_T.S@;O#_B@*?L3,QXQ\"N2$ADM
M]Y3ZZ'_ /+YFH;P,XK)/NPK0$8!UKRW#49LN@<G&:OJ'2VF_P;XRH?7.MR T
MU1 ,G4B>"E\N\4:^[=G /_9'\T9;VV;D:SI#5?6#JL]7-6]E]8G#\-P\BGD<
MI5*HJ 5UP^2>0_A A&TS97(,!_%%5LLS1C&^QO\,IX[G/56M9TG5"W6R7!9=
M<Z.!1,[2@E'<W=]7V*?*K+4+@0^)+G.M<MRZ*[K9$N5J:^62"KZH0XDR*5@_
MV<*N,$=A>YWP)<GDAJVNUA[XRW.;R2T$%:PMT@GZ0*O#YC6SMPWE/*&J?H$Y
MNL.N#ZKO]@NHVSZ[6Q;-OXJ^S_-PR'AM!W3[EQKQL2UN_$6S.J'\:*3C1T<?
M^85OQ.]1_@4N>(ZMW ^X18I+0PN14+,<2MN'C[@H">.\,%MSIP/*]%FDUSHJ
MZ0:4*M^EK(6!;86WA@J[3-P6?V=;F]'%IO9E^9H?7L<G3) 73F0AA7'>\K<X
M:U6K<PT2.RUS1[UQ%$I7_P>:CI32ZCQQJ K0I8>\C5#>ZL;7\S+50H]0@]0!
M48F,.F\QQ4:7Q*309B95DDL<B0R\9SW:4,P\)2<H>G+H:!/J"X+Z-#>/\RKB
MUIK-J7&YH3=H[=C24=$G*_/,;+Q@/^O[+B%6?^54XR#SFL#M+?.<VEH!2;[Z
M]+->FW[6II^UZ6>O//WL\96L'4,W/RKF?Z69/ZE:OQ@V_@(T+<K0R!$*),JQ
M%;<2Q@'\#2N8A8'O(*K(,:Z4PF(1Q[VE?FJ[,&+F1X:=ZD'NS=!-5P37*8HL
M\IM183X%;M9D;45'<\6][40[%I0&/EIMH0X<J#KE*3$V<NN=E#7*5"-F1(R@
M!U$'U='J'39+.7RH_RVWT37Q%+90)QB]=OH!JU-T#HV46G3N86+DVNG"5F+[
M%AM^=ONT4X)2F:5A\#<!VXS>T95D*_)J'M&_813X^2C"#G$ZM,WVJ=DK/])
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MO%>3J0Q6TPB5165WZZD2M98JTLOSOC\\6*_?+'BP*[SXF,EV:7&-?E"9YB\
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M=E79X&*)61,K.\_#]3ORK4$4A7"]-A/A?/*\U)DQ?$USO>?$88[3Z3'^S@9
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M,F]V>" G#U7/Q<\%LE+*F;LN5U^IER(+&IEZ>EV!GMZ89!%RLJA,!K=+.19
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M>PV0P0(5!E#<V3K>Z] T/S2H E0,2H6@1/=4,(%8,=0P*J&J/BZ;9AAYQ'?
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MSCOQ].OK5>ULSNOZCBHY.&J8\2B-"Y8E,<YG6O7=2$EZ<1KW==U-MFV4/((
M0=UDO=;1\G-6EDN39:FKUF\IAR\>4>./WB_Y_%\G92HO]W0V3N4BY[5),I?T
M'-+/5DN395>7!<QK17+Q2KI.E?\?]&"R:'&4]WL>P[(_86X13&L3O?VE>5NY
MU@/5#[+H)?:?H;9OP0N;<_+J@8.FN\;9V/EA#6JY'XB)Z-DN"<C>Z]I?UN1L
MZ)E>:[.Q&%@:?X2UIA?9*&I(YRD(%R_>Q&7BH7]Q5LW@W-^3YW P?0M"*H7(
M+8:2,RI]L=_JAS9.1W\5=)F_F/W;4>1['P=^Z)J*@;HHII684B]:'&"N%XI
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M76VIT5!B-1I]TM>S.5)1=OG:UE@#D40^9M[D>I]Q&X43\%= GEKJ+!J39$/
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M;:C?6YGVAU'6AN-I[DFF3>I!=U35>21AWF5\7VZB7L>\LV1&.<H+E/L&S[M
MY3<7C+ZU[M*R<:OVR374_337OYZU2+Y;4]>>V 8+!VW<%'/8/%JW-PX7MTT+
M]F2DAQ]SKG'H+>[\8U-'D#_SQR(-Z/DB#:B^]?;7\>#?9O*O@Z\\O"W@Y>'M
MFT <W2M!\8Y'/DM0O 3%MQ 4[Z*B(A]83^'[#*7'7IQL+UH^DGBTO;@X/Z]B
MT\G\/-0S72N5=_?SR]55\1EUE:RJJQFWEW8!%O>["[[5WSWT#J@TU4T[8&?=
MWRM1#:.'=9/*1&X?M;2:OS?ON93$'V%DOY\RH?<K5\Z%B0;9H&( UUFO^VSW
MZH;0?,'@TQI R_N0^])7J<>9/N\LVI&GB5[TG6^_T3"FCW(CME;UV+Q119,*
M<YIZHU:QW^4L"C]*0=XK6H@VMO7X\S&@]O-E+T+UT9^\F5Q$8*A#2K1?\1C'
MH?V6JDS?)V]5M'.G_L=QRON-1OBOO_5SC5!B%,GLZ/YUXK9/!L+YA1D.;#MX
M%0:3LXJJ5J<'3_'EZ?=?# \$?@8>^#U'H]J3_J)MVU^2DG^/(O09 7G1$I [
M'N8-RQI>9D%XNG'K=VNDWWZ376P5Y_@TEUR>YPR@NDZ[+KO[[G,@7!MN^1C_
M=Y4[/S?I)E&I O&YAOI\ZK]O?ODA6M;G0_WQ^\$H#RM_Z8?ERR7UZ)V?9#+P
M&MHSI%=O+VR=?5C9.[-)_+]K[ER_O9_?^M?,K;_'U3X3Y-*WX3ZZ]+VK+BOW
M"6-?=-6KW^/PR[[Y6,8J]@6ZWEC_E7="M1OBADM[]__ND;T5)?Q[V*LV;'.]
M*SZ*SS^D#_^PYFY8W:#5WMR.IB$_!^%YVZ>C="Z?GW^277OH->!J'AI]C0\-
MEQ[Z,_O<:/LVE>^/'*C'9:WWT8RN03GI&_%1>UD#Z#6#OF(BDK:^ALCC\_N<
M@Q=MZL(5(+C]\\+>-9_Z_L7\F[M[Z/;#3M(M'_YI_SWX\/UH//II4A&PYF+J
M/Y)+YF+J]G+>3QQR?F&@@PQ6.LNAMM1J;I@*6%.L'=7"8/+/84)(B" "Z1>$
M"=I+-#6#,SV<_M\]P/=Z(WWFTZ7!:ZW/O_\C%2E>^.E>KXH@Q'M\F'T_NC@#
M;IS]1>F;4<CB_,1OQ:]GW=^1OSZ:P_&[7_$?[UZ2HPOWYNF[5S^K-\_/GGYZ
M?OC[AZ.3T[=')W^2HS>_OW]U\H2].CEBQR>_?WCYYFW\^]G[YX?_.?N5' ]?
M?CH_/?KT&AZ=/*6O#I^BXT_/X-'/?[Y__O>?GYZ?_ F/_G[&XM\?CPY?OW\U
ME!^./CUY]VKTR^FK]+V_GWT\/G1O7O[]],/Q6?S>FR<?GY_\<G9T]LL@WO=C
MO.>GH[._WKX<*/CR[U^FKT[.WQY_^N7LY:<_T?&;/S\\/WP&CP]?DY<G1^3X
MT**C$PM?_?WG^^/#>(T7]7?^YY=3<^:&S\]^)T=GK]X<G_R)C^-8X_7A\T,7
MQV[A\:<_/QQ_^F,8GQ,>G;W\\#^?GLZ.7L /OYX\G1U_>OHICOD?22FGFGJ@
ME!. !B. "=8!S*%'-/YT1NT=,-7'DOS[7\O;X6"+[HKKP<Z*5VC;(IC>O:$H
M7G&4W6X\JV?EXP+7S<O[6,%U\]/> %Q%A#N'XF6LY-0:9KR'!F*FK(94T)#!
M%37@B@JX/A"X?EP&5XNUEP1A()%G@#IN@#9, RPMHR) 327>.Z"R+R!= ]>"
M=07KOD:L"\)HI8C&4"FJ S0<,<R<A3K^%V&9L0XV6 <+UCT,UAVO*)**6ARD
M"H QI0$U% -E.0>8D, -4O%G5"0IZC,D=P7K;FS8A_R?73;L?ZQZ0#UM4^%G
M+LAKN'EN-Q_7< Z5&]SG#;[4K;5)\L2^8)W<ZVM].-;F%M_LB3>J',6=\WV:
M[.<AL6!/GXS<BZH'X_3%>.C*N;R]<_EHS<$3C46CL6$@4.,!%8X!30P'7@<2
M#1+&K Q[!TCT*4*[ZN!Y +OFLY"\D[#1/4=%@8U[@HT5UP4,4CMK*' <HP@;
M$4 D#%&G)X(1;FBPSD;8('V.^9;4^2+%79'BK9O@18KO1XI7C7+#L8F[00*A
M83S\'8; I%6+""TDB4"-$*JD>&M&^4/:W3MC>=R@_=V-(&G#/'0#DKIGC]1+
M4/-[1U1ZLC3]M0.DP-/VX.GW-=O$(Q<7BC-@C V 4J> 9%P"AYCTFAKK<%(R
M8!]2O'.VR168=%=:S<HMOTBKZ2R$=,\V*1#R !"R8J<(QIFTQD<[!5) L8%
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MB8[S/ACIR<?4 &]Z/!ZE44[&N0CO66KVX*>S I7;@\JW:S:<8)"A0""PP4-
MI99 4Y'\ORIP!@6TD.P=(-ZG=+U^MNLVW&.B1'[$<-8=&Z[ V:[!V2IK&>+(
M(1LU/Y3@S",%#+$0>(BUU9@&PG#.UY=BW255T*6@RWV$R@JZ[ BZK-J5A#)E
M7& 13E([!X4X,(@IX!BG2B#*C(G*$NM+OMXJIZ/@LJ5*H8Y9CEEF>E&L/VM"
MEJJA^S ,XWK4'K#_^)$/@X)3VVS%\#YA5&78V3CFH_>)O%5Y+2V0 4E C?!
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M0EK(-2361BTR<4A;KEB<&X&B:68*5#X"J'R^HEOZ:&5K'S1@ 3I N13 2"A
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M$9LA @>JXO\0(5$[C4:+01)QA1D3CG/G='%Z[#)^K 26/:;!(1\M$VT9H%C
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M:H\B<N-HWR*;X+F^LX/W]GRR]\]5A@1N7-[KR[9IB7%-L40NV:.4MKM'C8B
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M\62C]0Q1P1/BN3C0*,?!P"!!"^5!Z>B] Z8W[?]Z&KU&+>^E;NBZ1DR%C2W
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MFKO!.3-.Z(BX,F":&.V0)0SG\[&<AA ,XVGOP-PD2% %MW/9Q"TX&U7CWY,
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MXQ<G/]*73SUY_>>OXL7'8[CN\X]PSY3WY^53V(>G<(^/K]\?'KW1TI(D $?
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M(#Y9Z/_WGW:W5MW;N16/TLXMN?<DVSW#'$NW!Q<!0OEQH<!IH?R7/]1&W+2
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MZ<QH:V:6@_@Y]1W#Q4=@9GB[O)KV:%RQ,,&/.[5M^#,_]NPD_\""P7T<YV&
M. ^5-H69R[G2QDJ?US3D:(3+-VTRO$?9=1QE$_HTG[NU@Q(+CIG.BV!"C@KD
M($6;\"_1F"];\&I&?[;H)HL[Z+^-@_[Q:!2:QRI'*,_B/%K=+#OG64O XW@>
M3VX<K-0N=1:T:8$;GO\H%I+/C?V<>CY;Y/';);8G@)J+;&Q+KPU^?T:;W;XV
M:A1Q54>'K][B-X(319A,B.HDP#!-'-D(/QB/T6)+91)N0QW=U.*X9W766F*W
MKLZNH+S6JG(;K"LH$Z*;]B;1SZQ##ZC>'NC+%1+O;'^0/X< (U 1WT53B<W:
MKF>KM3(7%^]<=27Y1AMH_]^S4;[OK$XI%_0T=<9-)=SL2'E&M.;4=#DVWH97
MQ[.OM]_+GVJ/N2Y]9J9V3L^F2[ ]<OGL> /,XURVEH'.C\: UCF+VJ#YTH?:
M%08[M<U]5N)(#28"6N;'F]?1S)>P%!IYU'LR#V@L5TW-%Y8S;7W8X_ZX9/9F
ML+I"IFP;Y)O8#\UU.F!4O7SR_.[C'BMGXA<Z;<[EH$XSU_@2G%M2K:>CG.;.
M]LMBIR>S0Q]7YNCE]D)-Y6"^:E;[355\6BDS7/AHV2;*@;1&.=K2@V#TOC37
MR)SEP93H3TOXN*E$:_+ *^:+#?F<;JX4]:451>$>7ZH4;8F?E04U]YZ%,^?K
MSC5URRR6(XPCWU2BM?65BWJO46R2O\UQCJ;*S2_*ZF 7FWYO8 1^C$TM7-ON
MJ+WO)?MWOEE:-KM54P^8;Y7;')3/-*O-!6;+E]AO3VG/$M2PBM:8.6]VNEQM
MNI1U7Q0PSB^]<D7X5(Z7+MM>YS.^N.@AV]+6TNYN]L KPKNH;@4&M.-L^Y6C
M,!U,]G0CEEE$I2UW;H_D%P^CE$HO'^Y>$I,&!YKD4"/>X^5 _@5H"M]OU,),
M@-9*D;M!EGN!U-^*SPF;< 2[V4;VRPFN DX7*?4:F;]"9'ZW6@&MV9?K/3G:
MHU)K?'"Q%?DP;+[+S+;*_Y^!DS^&X\L!I32M66*U.:4"J&F?HSAMQY!5UZ$-
MF<5F)&^CJV=AJ%-89XX/_73AS3:/RQ:"+M:0$ZJA27.V#?<VJLQ;YF]C8DO+
MWU^5@M(!<C2,N07-.-?9#^S1QGG*34G*T9 <[X)M"[DQV>RY"T<N'UY8J1HI
MYE\V*T\'9T4"X!MGS0%FN$7I2+?@Z^;<Q"*Q>M$1DG7Y6Q*SE4=N[K-D1C_J
M_5[.<8:,8R?S;$?WM&NGQ.336O=BO*VX<U6]NQXRO-U@X6]-^/09 $XYS0\"
M]2<(]1.0!]B9<8T@PG-\>).(5X%HBQ0A.8*H$M*>,F02YYXI;6C8Z,>2L$HX
MR<1%3%P2J;U1SO!$(^?64/J0(HXM%P$R%."L):I+.S/?D68L<;-1\Q.[\Z!/
MR9'Y5@3W%YD86%T^.==^/T=!)TV6(8;9B;Y2%C;[P$JH+V>RP,@H39++3< T
M/K+MH=RVBUFN7VJ/DRX.>0)*;UZIC2WX%AL UTO;S%9O-IT\FB-IK:Z?S)^W
MV!='XQPF:GH6%"]X.0UXR:' LAV395]XNMF(=Z,9\;S=<%/::WO9EL_&Q(5[
MT4.S%,])KI1=/AF;#T-D*P&LL-/2 &*RG$/KG^1CFN-^LV'3IK-+ELS9 Y5\
MV&!PX98UYR+LB<UV38Z[CII3H^66Y7IY$?W&QAS#C[)GLR-_DZ45Y<A1B#$?
MH(8G;5)K<?4<],4/OJL>WZL2+YQ,5QBH9;76>&X$9;GKY)IAEXWWWNFH7[I^
M]*;]DYBCG,/ESJN9@BTU)LM'=6=<.*/J_B6=19:\@/ZDN?JT/YV=&.]/WLXJ
MP-_;+"LYYSHW^><<N':O><><V8UR"\EAN6Q9UZD]+X.>5J+-\\=>".0\.SK?
MJ'F?X?:.S]JVD4M=@TNN=@!RU[:]+F>KFXZXI?/E:7\P\XZS^!=N*_G4WY>,
M05C_C[,:=E@@B-PDR^ WO__XY-NF$=%I[@Z=^;,#:F-_>8T_Y;+;_%"_Q2-;
M3I\O]WK+N_/[;#?_,]O-3QMW]6#N@9+U8&X]F%L/YG[=!W,_>]!VO3TGELJ2
M*)WC-'?'!(N1<1U48,F$9/1EYU\_ZY5=SPS:,E!>4SEE7?I#?_0*K))1/@"5
M0W_C14N353W^TZH>_V55CQ>K>C:X8*:]>K_/M/IL-,[OTVQ;YM$T+V:'[.:?
MN9>4>K]MP3:W&9H$]636$S].9FG@8@ M[)\<(]PP?>:'^):MGB73)G\Y'XEI
M&R5/9N;325[5:C>1><N??*>%V[?P!INN(DWP?ZF7TU%K8X#3D0^PS>R^V2'%
M_F" @.PH-PI<=<#FA6NMU9?C=(MG_<075].)*T;PS J=;)BA:SNQ>&.>&3^/
MTV;-S42*7!Q7@H23I6QGZUX]V;A=8RP??^*!%V>-LB\=)]-%3>/"+E^NW,N<
MTLXR:.J+7!R,FI.-%]G895=L.&^,WMDCS%:X>NFE1E(E%]#&W_,)=I?[_9WG
MR'KN*+A^E]*\<E;>Z?MC?W:2?6X_*X&<?_:X-."9M%TJ2P=!G]MKM6WV9PNQ
M%S<M2M:7FLSF;-CL?K-Y%#/?]4(/>G_.NZMLTE15@->T/' &L*&TP)J77,P<
M^*;4*#=;G-US:81+TU$HRU+SYL*3FW?+:KWL7?97A_.!;!=1:-[FYR@/]NB-
MVSC$))8 0F]Z?CI#JK:YZ5K3@WEM3^D+?S8+R+3=2Y=31(OF4BVS%->W#2TM
MT7)1X#QOCCIKF95S2?NY9<-"_$M'L+::I:TPF>6<\AGH5B!RA"7/7K3GBW7N
M[ 2:Y\/YF<#]5@TL;7Y.>4PF9VWYQQS$VSTO<0<T2J6J,8MZ.W"BF>L\SD/A
M\H'%Q6"?WC=OAVWSUZ8A1AZX/?EV/^OE5GQS?*>)@[CF9/CC$/J-CLX]TIH5
MKC;*.[&A==#MO(ZE--9MKI-YIU53<XP:#9N+3N;J92VYUY;[%=F>S'-S&_MS
M*7/.)U%<P)Y-!Y+VL?9S^==J='3>*;EI?==T 5X=L>&:\KIYC[:,S.?1CI<W
M:/U9RA+F]6GY..D2_\Z67U1=HP5*+[L6L7:5NV=M!1:$;%+*1T?C>%2.NLX5
M_IRHI02MM#M8L&A+Z<*2O?? OO^X=)K@V21L=Y(@TK-LU\GX[7<E-/-TMMB5
MR8%Y:B *H^+]Y._.1P>:KR[A]>/[O.XWRBK-;8R(@8.$.%44.14UBBQ2B_/T
MTA#W#@A]Q#:G![IFU&Z6LTR5_6N17 $) @&>]%IR[P1($W:8"N,MYHJG0G(R
M(SFI)-\.R?_X\,9P(24XU2A00Q&W4B#GO$01 R)8PF1T[&HD)T7HKT/UI)PU
MAEF*C>$V82>)H")X;.$?0G6A.IY1'5>J;X?JK_$;SB4CU@MDN P@Z($@BVE$
MU 62I"#..PU4)X_XYZB.2]G9 O=+9=1,-33-)W+==N/:+5*=N41YIDIFS5(G
M5["(9D?V-J^RL&\6UYLY2/.TQY)I9:=-6G-QJ:;FJ%0GV5)8A\Y.F_LMOM;,
M'0 #9K]5=Y.5M$S>A'D[W-#/4_>:OO)ML]LVW5JJ_?MMCK7TY6U]V.7UM1F?
MN3/5+F_6Q7?UTVL^<+/L526^K)[[)2';5(#-[:1<;XYF)!CDUFV3M?."<\=E
M?N<E(S=;O)MT63W3N'!#EM:^.([7W#3;F&[>=:@=U-X;O<^N?EGTV6ENYM;V
M;7VWV*(\N<&"I=)&.')V%:R6P2SMOA0P@;U\E\V92<RUU<UXP5) .OO+-X=Y
M0G/>Z_Q>\P(6\XL=3YN2@J??-O^=S11=#"9==*Q-Y1P\B$,N,\H6TMJIPC+"
M;GZ! 7#]4A?DBT@XLZ@N)%\>D9$C)&<3>Q17=GU]@V>^P\I0NIR;&\9!F=TZ
MRV"N,&#>W:7L><N#&\^_FH,\RV*XU*)E+JZSN9UP\T$[JK5WTO\P,\ASNMO;
M23:T9T6 .<W9;AQ\L)V#"R*Q?ZWG6QDWF[]?+%<[R+/H%D,[X8W2,?N\B3F5
M]9_/RQ!+5\*6DU=]Y3FYP ]K^1:\D_'9K#3S4W9T\82: T"STLRV+'/0CGR8
MXV.)<H[[D\;_Z0\;79>?<A9<V024/'/WRT?E[L_G"9:9IKD_\WQ8[_[2'-T5
M.%@</)EO0\,=LSV9SYR9I3?GYRE6_<C+/(N.E1<^WG1$[Z<)63?VHI!XF36:
M]DI+)PWO?G?*#,9KV:C8)LE4"!Q'SH776*N47#".2::C>//\0A]4+INF92_L
MX-EHO&0J7<U"E5^?A0K7>DO>1"5UTM@C8B+X)2QYI&&74:)$<!Y#,#R!A:KT
MIH%ZTAJHUW9'OHS4^F)2MS9,=40N)?/'Q^=O$E4I^YC(AMR452F'#'811:E<
M4(&RD).Z])&ZU _97QI+DB.>8-<_!?@]<7'<CBPE950Q+?QP;?D7D>$@E+5*
M$>Z5-X8$;H2T(7%-@RU,L1F0J/)_$\8X)&]P=,(:3!%+P!W<QH2,X XYKKC[
M_^Q]:7,<-Y+V7^G@N[LA11!TH8"J0MF[C* MV<L94Y0E:CSR%P9.LJAF5V\?
MHJA?_V8"J*,/7A(ED5;/A&2*W87"D<@[G\P2)3AG0!C)&L+XU/O_B4>]N?^?
M>LQ_7!ZGNLP+X+*D5%P0KCDELDASDFO."YMH)4R.]S__[/M/'VL8\3!V"HS&
M8X@\71D17 @*+4=>>E;U0F<1C^ET#FJ[]BX)8L \1CC/]O$.]@U-#SL+=G<;
M"$< #[0#N@?Z=>Q8+^3KO6+K2?BP.E?SR33V" ]V>C4-)H /4(U"1Y@FJ-4@
MBK0!J>?S23VV'JA@COVT\>77CQ';Z04[K_4D>"[1V7)M?D)C(;8.CUD-BB\P
M#S4W)QZR"6UZTX)*K7&1($UB@T&T(KU;J)> '=;3>#FP=Q&PDGJA_K^=7S=.
MW.U@(".*WA2S(YK=Z5O=<CP>AJS;A:Y"P=?AR[>"\RM:]6 _UQ6"-,6A,7-F
MC$#^H]FB>>O-:]RE"*[4G/>@]4WT:PVPV+7657#WM/A*&-![I#>QO\4-,:.O
ML.D6.O9E4[%$-.0CX2Z'@-IB[<*"G1QCKDM@4[(Y^I#(7]6-6P+=1B/3+YR,
M5C.<4Q49@6^6]*3UB6X/%G8)UJ])]8&<5@8V\L?O2>Q\]%T!5$Y3C5"%RL)?
M'/XFJF2,%$EI,8\P ?5S:]<C549:Q3V^KB@OHRYQ95DZ4Q0\STI5:B9!N:52
MIJG(KRO*0[TA1M5[=4._89*4_^N5)X^7G@1>(@7,ZN?M23^#@U[0,?!L?S3S
MR056XMC1]Z=8X GS8U<F>9Y*1UR&AD5&4Z*8+(DN,I6)7#F5R*W=:?4A(I$N
MY^@W,"O>G?)EBC'O<NY[Z%2^U;G[Y7R7IZXOCQ-MA4I50K3)->$<-,D2='<B
M;99EH-MKEOAHYLII!R*(OON&$7?\]&GP6RXK"LO>^2 &6N^\CU/TG-\H1T%7
M:>MCHOB-SRVG[JP'0VS08)I.Q-'CW8-=O+S>_=TLSL@6$[,G-X*@Z:"?VCJJ
M7K,,%/HQ*7L;JY F,L)7=5A*OJ(-A0]<EQ;KHE4=Z]%VO[0?B1BT,H\7B;J@
MAX/T63J@AA%XE 1X@VXVV^A6QG@*C@L;MU9%;H[#PVJ,0C&C#R+UDR\;]3'X
MVYMLJ*4&RX]+2_$%GJT:VL0P,*(3G.G7JR,>%O]RC+^%+;N.\^68AJ\R)PJP
MU1)>E'F2I%SG*LEHX4Q^.\[WLBM1/&Q5QY=ATD<XY[5,SLCOKU$TKD?S8UTP
MZ[3F1&CKP&*6FDA098B0CF=E:@17R=8NRU=8'.Q9K)+TX8GQ+#(-5/W;Q@^>
M.&1("8[AHD^A#0F2E[)<N))27CBI$L5,DJ!7CTLG^88V[ITVCMY^.%89DXG@
M*/2H1MH R:=!K4VM9IG6CJ64 VTD=Z*-GP:GP#;?8^Y#PS8[/MRE(#^ F-,_
M[>5L,C?RJX>5MH-XQ,(".UEDN=N#:1U26;M\U_GX)FN"9JDI,@Z<-=&\U$XF
M8%B8(C4\A2N>9)O[<\_W)SF \8ZUXUJ ]")@ U)T.FNX2<AE\XS1,L^E8.76
M;KG^_ERAABP*X-NST$("+\_*+*5&<6O*TI8N=XEF.LMH7LH-"=P["1R]N3C.
M79$ #0 +E4E".'!3$+0%L% AE!8V87EAKV:A-USK,K%&8 RA8)P+%(JL2)56
M94:E2^E&9?H"9PIBT6EFF;4IR0W/X#+;A)1969*T2%B2<,J=E%=>ZU[)2R/^
M&OB_*YG^K4P'_O!,A]?6#E[4,QL\RK0,>)K5M,U;,FU=&%J!P]J7G*Y!LEKJ
MK[J!.RB*#=S!!NY@ W?P?<,=W A?L-R'/#,IU]J:U&E>%+G*DR)/5:I5GN=@
MT5UWWQ]$BZQG&$?$$"!ZK&T$+-L;F;T 5!XTEPW8X-$!/P;S0E$A"N($2\%V
M9Y2(-,&$-TXM*"BEHFR9/G3*69DH(!^:<I>E4H&N*KE.4U P348?4K>M/BEL
M4 )7M@2C!FWR=M>\H(W>SZ?6S8>#H2\47^C>L=T!^"T4<$]G$XDO(_CBMBF5
M;Q/;ZX&U[2$%AC: 2^,GX9O!5,4:[L70Q]),X-7 =BJ/ H#07MZ'=!U343F\
M+Y-2)5KR/$D5U47*TDS ;Z2RUWDV&J;R$G,_)K/+ET,YF@$SP6:.8U2^W_B9
M_5ZY]9$Q+/C][KC+\^3%T5YRG!9I1I.L)%G!%>'8%DEEMB1&F P815&(G&_M
MIMF*"72#16N9,6F6%S0WCN>&JE1:G]"94J/A4#?'>?_'^?SBN,@4Z"C.$-A[
M.$Y++9%*Y82EA7:B+$M6Y%N[?,6B#8P.=R[$@AX [_UY7@W1@?SUBP%"W<J-
M'$L(=*L+QXM<< ,:D,QD6JA<6<:2I-QPK"] XG]\/,YD GP%%"#N'"6@+Q=$
MR<*2++6IU;HH0='9VF5W95A)R@4M<K@DF>*Y=E)3:KGA>4H+P?,-P_H2IYD=
M&Y8JF8/ $=1J.%*IB##<$BY39A/&4B. 8=$5^?, &=:!U*?PR\GEM@>]'[>H
MOK5S&$IU\\FHFI[V6=HR_N=78W'KS= ;S08$IU_VV0T6M-4(G?_ML#W669B;
M7/LK[^#9P>4QG+E(K2I(XD!5X#Q11!G'",@PYY*RE*6%HZ<[:TJJ'@:XQ^;,
M[W;F?UP>YR8M"IM9DG!3 -\5ABAM%=%I3AWCSG)?1G=-?<6W1_?8'/O=COT-
M/7:@Y( YEA-9T!24)Y&2DAH&&E29I\SDW%C,@[RFK*Z%][A-*.OV[L9OZ(#Z
MPJ[./>QW.:O0_?)+/9U--V[-@Z.3[)A2Y/A.$^UX0K@6@JA",^(25M",%5DI
M5MR:5CJ3&T5!+2PY+=,RU<P5VNHRSX%PW;);L[?UGDN!@GY>>_;D3V+0.AJ7
M8=B_LL&Y7AN[<;6[@^4%CML%:K] #QT1-#(3 #]"J]1U:MQRAX#0F^O*%\1A
MO<_QFRIZO3UX'N:TD0%7R8##9\_3XT2 >F5E2FQ2:JQQ@9O'J"197C+C@."*
MI,32RO2AJWN;D[_+R>^GQT6A,^E<3E)6H/^$%T0R30EEUDC'TKRT!9Y\\@B4
MOLWAW^7P#[)CH>&,39&1E (%<.,H$5IQ4/M+I4IE.&?Z5E;>?:M^7U;]\BUD
M1G+X9FI?UVYV 2(Q:&#?'1V XG6VEQX;*;DJ,XD "JAXP?U7U DD!N8<MR7H
M8@\I/MR<VN 7.?8/?=R$BM>7'NMF@T KZPJ90I_8H/<- F;S*&(D^V*S6LUB
M[W'?(_N]'=:ADUB\. 1QZZ?-(71Y_7!)_><1Y#Z^"1&1FR9HOA@Y(KR'F,I8
M7DYJ;(#FO^O;@YZ/A_6E]6C0L6\NEA<,WR_4AC=OC]-K6UI-;4_1?6"@7TTT
M8-LC^ 5/<.L7_@;-,1:PLF=W(YM9C6URA[%1W4 /ZWGH-#@/M8*]/@R^R'VQ
M+YYLH?Q;$,8^RO<#.[?0"W;/IU!\@V-JN1S"+C1TWQ&YLG[#0YI4DQ$2BC.G
M/M7"MQZ[*71I4RX2*IB0J>8I5L+RW+I,9CPIC;#7Y9LW<O57!-FTOU=P44'$
MXHO5T/I=VT2[UNA@%/[-CE-0L(L,Q*X1&4/WFR2BR%.2\-(4A;2R]$4$=XU=
M(A)9*8O2Y)E$-:FDDA5&.\O+-"U9N3G.+W"<?WP\-C8O,L= E3)H2</M(2+#
MP(EAN9.&J52C-_6Z;(OM3LK%@H&0/]6A%B^#I=C0WZB:6G*!147C27UFL1*[
MY= -6SB?#V<5_,YW-/!]=1:8.AQ>DQ(VGE@L<1XAIG(<#[$\3T+]YQB>(^WH
MP4/E/UT D^VCAWKLFTE4*SSSVK[.%[4^&/H8K O$8[@ ZVAOM'QMILU'WZ^U
M ?,XIHE+>,)*(K%I "^R@JB49H25PC&'MR1?<=M^2VNC.;6->;&P'1WPTS0B
M"C4=4R(2= ]KK-\:MTU8=;*:=$U3L)-*2%+%?S7=CA"82@>8JYU!^^;*XT7!
M+0]Z*$P$=1_@*^AM"@!F'3HRFA3 J>!E7AE%\(;98&BQ.;!$2*\1XFIX% </
M+W:.2"YN$M"2T/1P_:>!D51:>E0-^Z&:@M*J+@>NFDS#Y*?>*_Y_,&(U"R#%
M#0;' E1V@YA1>;78OS%V1@)5>>1[Q'B=>767Y-)B\?DA;KM_T(/4@^9]&17"
M.=I$^VX9'L3KUM.O\?;M $R-W8>;[6C'F]FI'R VGL8#CE-M![GVQ6 WR(">
M'M_=C8VO/6F)I3N]@ T]\+]6O2X^:U#XGX3"Z_73:<9^^J@%U;)TZNE[WZ^
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M*N^A\G<F:@XKI![7WDUR13S[F[3@&?-/MBI$;[ %9]J"!M ZTQ:4D4:KF 1
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M&<D3+M)$IDH+^G@K^)_9F:R&TP?2=/1OJDT&[;TI49K^>!M_8*"#L)9659H
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M<"-/?I1\XU%KR*M\8Z,JWR-365*5LU)F&;><V#23P%FL(LJY@E A:,:LT9D
M59ENB[RX)U7Y6RK$CT&I"1YCZT.IVPWV9J@#,>>((36;^*C#)ZDZ:_;A8;"L
M1ZWJ_!8.R2=V](^H3?7=,*D[,*D_5IVI:5YDG!G"$L<)SU1.E,PY*8M$E&F6
M:4?=UJXH5EG40]=\KN%+7TKS67KE)VD^#Y:-/&K-YT8VLE&$[I''+"E"IB@2
ML*D0<(KGA!OGB-3<$NRJ*$O!2X76%=W.Z%4U!]_BTO^=O3M):"XZM;Y7MT>+
MM>_ML!YC0N7&T?-EM)_SR;N[L*QI<S[ M)YUI].X;3=<Z4Y<Z<V*YJ/R/)$B
MS4'5H0EH/FE!I,DSHHQ.!:.<YS0'KI2L\J2'KOEL?#Y_5\UGPT*^+0M94FP2
ME94F,]CN(4D)YYDE998SPES."IE)G>7(0O*K4*,V_ITOH];,)O,&A=P7/V[\
M.0]&H^F.QCNC-RSH3BSH[:H6(ZR@I04%AC-'.+."E)11DI6%I4;GE%L%+.C1
MZ3 ;[\U&A]DPC?MB&DMZ2YID5$A>$I48T%M<GA+IK"*2I4K9LC B1:RUC3/F
MZ]W$ +KX). I/6U0GK8'(_M=^&.>/ +UQ1]1J.Z,%M0+.]OPHCOQ(KVBP& ;
ME:S,"^(*KD&!H90HRB21E.>\R'+A<@L*S"KLX].-/^0[UB6FL$CX:7.5O^55
M7E(K>,;R4KN4 $' 51;4$E%215)$DT@U=]HAE.??P!GR><G(MS @/J]"\8$(
M]4>28G+8]%G<!(/OG4F<K,A[67"3%SPA>9*4(.\1;UU81W21.T$=Y2XK,1A<
M9*LB_Y$X+1Y,]=Z&6SU8_67#K1XFM[I<KC4NDEQI190H+ '.E1-1:$X85\"N
M#).ESK=VV7;&Q3UY2[XX\[AWA(@U$WM@SI4^)--5T-?*PCVR"&OY>:5.CXP7
M/DC-;97KA1/\O9Y.L<W-VJ\\\P[BEZ=R:@_GL]!(]6=_J.'A(_EAPP[OQ [?
MK2IOJ4HD-XK0'#M)\JPD*LLS0A&/P9G2EAJQ@[/'ERW\V( 7/EMU>YSLZD&J
M;E^.76U4NWOD9<NJ7:YMGJF2L$0*PLO<$)$S11(J2\8SE6EL.)1NE^EGJW9?
MB[G<4V[/ ]/>X"8@4OG["H'*-ZD\WT#[@A-X[IS5LT/WB9QMPZWNAKMR@9PJ
M:%_ZP\''@XMC:C+)%$V(-%02SDI-2LD=L=CLPR1)SABH7MEJFZR'KGEM,GV^
M2Q5IPU.^ 4\Y6.0I@O,2C#5%+ ?MAXLD)S(1!4E*F@CA')AUZ=8NRZ]J#/^8
M,H$>*\#I+7Q7/DO(=[?[8LZK!\CG'I[N= L^-GUA@>%M7%%W9EX?5A0B*T29
M,##=9"$TX=98(@2EP,M2K0P#"96;K=TB^?OYHAZ4(^K+>J$>(-]Y>/K5W?C.
MQJ=TGTQI2:,J:"'3U'"2F@1;,#I+I. *V5.NJ2A%DA4>FSC[;)WJ0<-CKGLW
M3=8H5_V^,:1<T^#CZVI;O]OI],=!U+E H[HJ6BB7VK2,%MNT5,MM6OX>IN7C
M5KGZK76.ZL7&.DU?G0T'O!L'O%Q1RQ0M#$UY2HQBG/!2<R(<*X@6ELHBS8U!
M=/;'5U2_<5-MU*@-+_G"O&1)F\HS2_,\E\2Y$G0H53I2IF5.K!:.L[Q4.:=;
MN_2SR^L?CGLJ=CI+5\*#M[2_X')W:E9/K;I[9X;/F,F#Z=QPOYUS/G='-JK;
M/;';5W9<3WP*+#PPN]SPV;OQV8\K.IMSO)1&.I))6Q .&AH1U@ABLTRD%.Q9
M)U-TI:V6[CQTK>U>;_#7=;5]KBCX/EG^_3;K>=0L_^^D8:^P_(T7\S[EP9+>
M[7@B!#!]DCE;@M[-4B*,!I.>\5R8PB3:.._%_/RJAP?!H+W2_H,GM5Y#XWNY
ME'PGN[D7ZMK>\%?T0DUW.+]E+]1[F'YQN][07^*-=]HMA/UR0ZMGTX&,G;1G
MIT!H)Z?P7SOXQWQD!^GV #73P71<C4CMW,#(F=U9:AR[T/$^_#LR*1D4'NS9
MZ[F*9()3*@S-BI0G-BDM*S-.59G8-!&).Z;HZK^V/[;O:AL)F*"D_)&*9>,-
M?W.5?!!9H>_1)/#[R'?"#5[]^[\7]F915$@GG 8>D2=2<RUSE94NE3R5ALM"
MI<R+BK01%6D0%5WI_I[^OWD5R+W%+/P%.X/#O0]B86]D?J\T%KSMG4RL11C#
MZ1&\_N=AK=]]<SZO&SY_\>)LGQ[\^19^!^\"/G_XV_.+PZ,3X-7#X>'1'OOK
M[ ]^^.P=>PM\_J]_GR;Z_%\C^6<Y/SS;2P_.WGSXZ^PY/?SM#QCG#_X6Y@AS
M.H/W9B CSE\\.^' _ZM_XWS.GK-C43+&*2M)3ATC/.>6*&8Y*7@JG&&*<NV"
M3/="=@_EI67<"A#G<%J4EZY4N;/,,<&<<J4HBJV!!?$YAH.93>; 3_I'LSUH
M,8,73\=#"(?SP?!'=T2K%ZI_VY8N5SC%FR>XN* 4"$UKQI2F!2]<#H8I$S2U
MMDP*9ZS=NNKVY8N:ZME\.JO<Y<+MX]G5E^^>E3-_^8Z 5_U2G\/K+MM53C&^
M-)Y/IG,[D+W#\'N.S,U.47)5TU/<<0Q:P0+L9(2=+8;#2HXT##&=(\[S=#!I
MSD^OGM^P/3_9GA^^&W2V\=#_<U#!;WQL"T?OQI)CJ:HA3,M.=P:PABG,=#*1
MHY,X2.UF%D[7U[7:P7SL)K"VP5A>^H^W<6(7=CC$_T;@(QB\.E>PZ&:$2?MU
MG!(N>W9:30S\=C*[W/;SAT. K:A'=GLPJ2_E<';I'YO4K@*-X51.%F>U'7?X
M!!<V'P/YX:BUUO/)Q,*FX4YJD+*R&@W<?#:'Q['!)$P SNV=-<T\8&MAAZ<^
M_PK^*:=3"QLUZB-J^TUI#Q:4XQK6][ZR%U._HT"3[^P,1H2YFKF78;"<<37V
M(AW?8S\ B<&/&CZH4&S!AIU6L/7G\C+DQL.^GF/]XGLYG-M6]M7S&>D=Z\CX
MO<8]P^GBNU&M=J!-U7[BTZD_9A@1E[3MA_?3A1L$>]ONAU\DG/7+21TT\8&K
M1D!I0/^P]*";XX6&GP+-3F!U:@ZSL/B6034=C&I\#Y#*"%=>A<T[K>  )ZC7
M] :$+\V'LVZ#F_&L-P4&>*XX&"+"5 Z>A05<G *](=U*_.)%-0MJ0#R!__I_
M(J7%3]/5=RQI ^OY1OEU!?(KB\WFAY=^]D-/)T= Q=.@;T]O,V/V\#C=_FCP
MJU63N9Q<HE;&M@<'=J+?><I_#90]AWG\TP[G(_)S5<\LD#K\=PR7^%QJ._>J
M+VS(SO;@]YG9&3Q9^.K3@1[64]@G&7F:]<,NL+R.QR'+P6L%%P1HI)H,@KX-
M6WM:C?$BAYL6IG<"U(^D]P%8V13NQ,!;%U-/Z$AA#4_<[E]_O$>CN9/:,Y$P
ME7.0ATAYU<<P'2#N^1BO^A29#+P6[UMUXC^$I<)-T;")?ME X)6JS>7 3.8(
M<#LZFY]XEO!D[]DOTZ?M7&83*V>-3- H!R8[2WLZL;.P(#]W7 I.8641UR_
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MC(^$BO+<5Z1)6*XAZ%T86F+@:5@:S (' ..KO@#BFZO%C^K6G8)5:W[G@I_
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MO8 4!H"9D8G21NLBY..D(!UBKGARDR]DO9;7\[TCZ>/$CNJ7=H)*WZ_UQ+>
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MC1(8%?RPA':VTAYFI1;SYSEVRII.[?2W23W=-.J[#8NZP 1?3D&(T PV/J/
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M64^Y*AF(/V"U"N.P-UX:=%#Z3@ &3D)CQ=Y27_->.W+\<NL8V X1D% N.9[
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M>7/RZW&YWA5!?'HL/\ ?@T']XWVZV+(=D=W=RP:S7 .\A<*,L!VZQB)&OV]
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MX(MY!)X#-L0*J<$-]!+Q?'9BG;-(1$V4Y8PIK[9VV;+%K Q/R4EW+R;& Z+
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MWGZ!'<M(G.?]]A?P3CH7K=/8"=M+D#G/9P%0ZS*\[:8R\8XG)(&II(4/,H;
MF2".,"^4\IYX1F.H(G ,CU:\+;R 17)K3*I-VN9&,?C1;\<Q,BZ5,"@Q^,&M
M5,B0@&&N(M6.1X=M;MNEBRQO#9;/SI30C:M-2M7P5-E+RV< UI"!W%\<_#=2
MA."7Y3C4Q1Q?UP5Y4]5;D]*R:9S7T][@O!QM7C88)J_>_K'_&A%S#[A5DQJ
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MY15S9D-L\'8>1.GS@T_[[%AGYU9Q#E%JK@/-FM^E2)&@.MH4L-0F;>W*G9M
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M/ 8>HL;8=8.WH=9*BB24R\88"!V 7BO3V !T"0 ZEV%TP9'D(;,BO:J,'X4
M5 <"T,"CC[H><;B<^N61X]G=0N;;7?VVQ9^SV\P:T%T=G*]PS/!O/)D&#)_8
MQE8L7'AZ2C9RD'K#"Z'#H(^A/^A/^DL]KW<]L2U3,@]^0O [>9<#@K?0_=78
M&[AS2.+ 4%"BN9$@@8(0GX.*W)=B- 4I/%XW)/G7F>)^6D[/MU\O_;]R8A_S
M:-B6V1LMLQ\6XI00/2VF,K&4/3 (/C(?0;*8,*#0(7L;:XC@:-I^6KM8Y7;+
MT$,4(EYW2'<I5%P_!+K[*2AN"&FTM!$C6*Z=-#ZY@*9@Y);GZ_KTER%00YJ;
M(<V<0T]14G8F6A:C-0QHCAAB"DR"0)-1<1_TQI:YA)FW&?U]WZ/S[W_HFD9?
MTI5Z]A567?+.9+] 6<,^2PMP$WR 37T+ST]>[?G)38#/>G[B^]Y4W19_+G&Q
ML[<D'?DU'X[RN",?FE%\3-N+#\L7F/*NQ4946ZY_2W,MUV:N9R'>%^?U.D0K
M,]Z.2R;VJGETVL8E1A7=T_V,)Q2I/OW'=?5RQ5BR>AW#I8 G%Y@\NUWD+C$P
M&?:P=SP<#=)Q/^5>I"M4'3Q?&C['$'#<G^SU3J72^Z[[[?N:="!!?,B3\X7E
M%=&/*BG [A'=M=(.].))')!B][X;_^.7[WO[PS3EV3IE3:J<0-T5.T?>_C3N
M/4V9QCSN?3?J#V.?+C3Y?DHE-#D>TLCJ\Y#O,^4V[>\?#KIN937+T'L_I,>[
M\"!U:/25_3RJK BGF-2=]<B[)]/+7GQ8\KJ&9Y1AYZ]%2'9QH/^71_\]^G/8
M^X[LN#\;Z9/>E'2L$H9-:4.GV9@Z%[]O_K8YG97GOW<C^R=6I9@2_TZY2/<J
MT5&_]HR>LK6>N\*8AE*/ 4\3*5/1CS=[OR_RNSV93=;Y!\]G<IV-YNE^'36.
MNQ'3C$W9YN:^,_LL67OW_/7W3G4V>W\?CDX%\.2SWZU/W3W;I8.Z^@8_TX.>
MF^[Q7B6^HX]?U--QQ2"Z^&'7K6[<J[-;NT!MSL8TJKPG:3Q]L=[A5 KU2Z<3
M2%>MWYW*M"HDV<JH3TK:K]Q9].'C/!C4?W&NH_=F;Z'']^@,&[L1?-*6Z0/0
M"$Z'VFWS?VE<%S7NBA%.5:Y>GJZ=CN)D=MF#W DUGF^/=85)=)+<[%WHI'5F
M!A='\;DGH2%??.Q+A[S9NPZXKB %(6%K]4(F'67C!:.KPOBS7W.O93B:D<WL
M=J^?<C)>Y'2<6L,%:I;<&Q_%F,?CRH&&<:]/*G6*/)?2?'_2\GU,7V0"_W3/
M&S(39Z-M#EQ*F0HX9P/WP*6SAH9J15*-F?CK,1,_I_L_?\>S Z%]9J$ 9T!3
MP#!JQ8)+.2AZ(P3R*>'*_:C;$M(F!<+DZ%42"%X6% 64BM(D#L;ZZ_=U:9JQ
M%,V(=,\/[S1@\30A+%CI&4 EI!6B,.&=1 "3C("-+?5%>N*I6R+/4:2?IZB=
M8Z/] O9\<W2TX_/(_LFAG>.C[:00_WO4GSGFEU[I@O]Q%8/M)2+'R634#T<7
MA_#]!?=B-IY1+@.:UNEX*L7F+&RO?U9"L<'G;T6?P\G4W[UPR]E=OJ?!DX[<
M"%=TRDY#X@8CY!Q1%:Y4,0JCBT6XZ^[5_)U4;I+_1?J:+N'1;2AR.8KL'N\\
M>_4N^NRY-($%'20#"X4YT_TH7+A<M$@U):H63U'U;KN<\)"<Q^"=L0A:A&"3
M*SK;E*2*!7V;]GN>]M?/WXEHDI#%,)T<,"B*,Q\B,@LT'9JG9$W8V-*+;39.
M9WV>R/SSW,G3D&Y5:A96D#RYT]I.3)>R)]-8^Z/+^)/_I.7ENW,,RK:+2L['
MF&=O*M&]^0FO[XUK^7+BSB\1<<X3A/KH=,;$ZR$_U-DIC2A2YLJA]\4TXLXO
M$7=>GEYM7)[KQ8^Y3F-M7)YI815L1^'6X*$;H><#$GJN>!^E2]@\9_[4#S/7
MZ9ZXBE;A_,9]'X!;H<,;=RXUI8BY9 $"-7@046"6.E'L'#!@=EXT/L^K"L#^
MVG[V1F]__%W2]>'-^VW^\H]7ZN4?_QS0]>7.^VVUO?_B>/OUT[^V3^8+P)X?
M[[S_\''G]1MZEKW^]L=7^NVSJ-_LTUB?O9';'^/)F_?TO6?//U[&YZFL,<86
MS[)RGH$5D040AKD<LHI>E^S5QI:"Q:[7JUYF^B!T4(WG;G5.PJT0DMZY9-9I
MG3668+120'&^<V"4D[8$GJ6PU^_6VY#TWI!TKI06M'$1$9F7"A@HJUD0F)C4
MN>@25;!%5R1=)/]IP-: [5L!-I.D=EH63 I!I."C,3I)'HVSZ$-J!)Y?'=CF
MNY5YDXRRQ3)G*N5[<(KY0,ZB""%$5VIC^4Q1LEL6,<J#$'@^,LJ4G3Q9+*B;
M5@!.MS*Z:JG&FG*Q68LK)@4%44E>]WF]*A% 9@PR4KQZ?6K%SV'1;SAM0=!@
MZ$8P]&(A4I7!\% WXD%;@B'K!<."D@6N!??:0$B28$@UKI3&O'#7/)95O' ;
MLK8(V6 (R46P.GJG'3I82O35@.&VP# 7>*$W-3HNS$J!#&*)#(,63/DD'7F9
M@8= P*#O''@U.UTQ.^4!P2=+_J>U@#:A2LD4LEJK?4K)+B68:'9Z2SM=(%A4
MTM&4!R:TUA1'),.0<\.2"A"S(X?+<;)3>>?F08T8Y2;1PFE-['*BA97ML7YW
M(G9:2W*&DF4.X+/U0?%:J>L+.DS2M&CAZX'-(A5[<(H;S(')( 4#0]&")Z!A
M4AF:&'+IHJS10F-B;]P+=^UNHF02Z&+2E9S/AN"!0^'<5F\DA-""A:^*"W/!
M D>E(AC-3"J*@>>).43#K"W(,:N2C=O8NC.98K/2%;/2X *6!"D 1^#"UQU5
M"AJEYR(;F^620X7'W1CMP:QW/H3(/@7I;&)>H&?@G&#DE15:WW7BJJ"(HES=
M&.VKDZ?<A41CK2H&7P\GIX?G;MDA:AWV?>]:&GBS)U[OZ&EII8%G#9Z[6M1Q
MP]0;8>HB!WV)7D:'D5D1"$G1<1; %::EP0+!"JYA8\OP]:L O"F(/F"WN644
MRJP?8-ZU4&:- '-U*@ ;8-X5,!?VFY3E004F A@"3!E82,DR[04'$[WRUEX.
MF V_&GY]*_BUM$*_AE]WQ*_Y(-KE3#$S),:+00;<1X9:">:CYXGS4$)E']5K
M@E_+X"6];NJL76,YUWC0&LR'92:YV$9PK?DVQ!+X-E8ODWSG3 :!I_(@(P3-
M@4?A5."H9(C9Q5@BOW$FHZK,R_*/X3"-GQZDW_+HSW[,X]^&@]26NALM=6\6
M<AN^TH<9H5F*SC$HUC-?R%\7D1P1!3D%I2KAWV+)R9KD-EHMVJKXN\J29F5N
M1.8* #!8B5$)H4U PZVY<;S>8&%YL# 7P2L-SJ$-K*A:'.+H-PI/"E/HDTP*
MK/?D 8-<Y %M5KK>5NH\%\Z1 0:"?Z^X*[JD%"Q/HG+3P(VCTF:E2[/2^3A5
MU#I1FPN+A* ,DG4, VH69=$)0DG6\XTMX<T*6>GCK!?]+0_HQ=TGO=U\T'7B
M[SH8IOW^0;\C%*"8HA6+7L"98I*2*@3NE0&C"W()68"VR*U3Q=\X2)A-P3^F
M$T!0\_2"^)__=9@/QKEASHTP)RX$#(9#$8XC(Y74#!2&>NHULAQR0&LX.D^A
ML="+S5]7/6!H%6DKYHIXH< (F[WS0+\H!U%99:+5DM[Q]L8!0X.(^X&(N> A
M85*Q&&#%%,MHYBI8\,R"M#:(4)-#%2+DG=V29K$K9K$N1E1"!?!:0G#.<1"@
MK*O;69KBR1L'#\UB[\5BYP,)1$/SI RSZ,AB,\J:!<3*KIN++5%SZRG<7Z6B
M[\?9I>+7/,XXJH1-9[QIM6ZZ]:6X@#,4,&2>99 &%:#1*"/IE>,6C8_"W*96
M<BIW0IAG9U)O\'(;>-E=B!FR1)=3,!0N\,H<X#7S,G(6@Q!)H*8)+!M;E[#.
MK'K(T+*7*^: @(XY6.X$N:#@4 >EI/2BZ(RQ,@#<HB:P <,2@6&^(Z! *Y+S
MC"*"S*#66(<,EDG#998YB6#$QM8EN81FI^MMISXY%9TJ'!&!0L) TYF%+=9)
MAU)=GQZNV>E]V.E\?*"+LL9+S] &S2J?7VU,X9D*06@EI("@*N/3"MGI,JK>
M%LOSKDE,WV[P#=Q@N9PDRP\T;U0#M[%U2D+2:_PCMWCH%5F"[X]^Y&[EJ5]J
M7'I)K?,JUJ[^2C;2_[,26\THFZ>LR:M#4\?/:.KBT6C4T=QW/'&7%ZHN;;Y6
MXO#)?1.1+#STFB?1*/Y-0:&TA7SP6%.]#DO0X(H77*7K<FJ>,XJ=//EEJG;-
MY;Y93^G.W9[FS>)?VQ^WC]]Y0,/1!&:UI=A8&,U"5(6YJ)7*,B13[,:6@+7=
M:+_)8O!5._1_SL5\7 AZWWWZ5PM![YS%*,)J2#)HKC@$[A!EC !&FN*X2ZI#
MT&LE&1N"+@-!MR\B:+8YAA0$P^ 2 X#(/-2>5HF#CSQX>H\05-RYB/DQ =K]
MWN".;7YF-+)7!^@K'#O\&T^F@<-DN!@VK$#4T'L:X^B(1E.WGH<70HA_]3'T
M!_U)?]T/[,DE'-B[B2JN1K;^SI%"D@"\Q,"#HO4NAZ DQY!2R,XY)?5U(X5S
M>M06N5LM<B<+88)*'D+*BF7KD($RM-QE%,P&5TPL,KK:,]JM[?F]&R+_ W;X
M^.*0[K+GMWXH<_?B00-6&Z]= 0.U&V4EV+2>?#7#39;^NMYT0YDEH,SV?#)"
M&%"500)T;2;I)7-&<@;>!OJKF&!X+1!<%H/$8[3Z^[I'YU/_,*G.Y:E?0S_F
M\O>LNL&=S79"ZA\DLHL?F>\NLP0T@$U]"U].7NW+R4V +S1?F*K6XL\EKFSV
M5L^TL?5BZMJ/>[@_I ?XB!WX#0NY^A,\V.W37,T2\YN]I_ND"9.Z=U#Q[30J
M&/?^W]<\6_WTW+A?EA>?1OVT&_3%]KT'1_LL#2=L=KVU1]NW_]GC<?__#O /
M?_22QK0C?^=OW]-GY*N3M\]>T7UV]M[(OP]>_O'WP<[[M^]?OGYZLO/L=_X?
M&ANA[#N0Q4"VBD6=@4&0!);*"9:3M5J!5=S'RX](]4@C!S--B4?[1U.#N*A$
M$2=QCQT=]O*TN&6S=S&F.6?[^SC:[1]T\;DB17ZT4"!7&0IFYHT=E<BY3?8G
M<^:.L_";1I+'D^%![AWB22UBVIR+64EGJNWW#XYPYL@OO').!V9CL;(JP()\
MC_MILG?JJIW[UFP%XF=?P4!+T='DZJ\L5  \D)O9"=GS.2&=^[DW.EL+=S,+
MHXP?&!8:X8\X.,:3\<8/%ZV&3.:\U*YZX'/6]5G;*66Y3SLUVU3):+KI_I'\
MB#R:FL+?\.L.H+<WJNO1__11.1#"):&M!)ZYS\IK$,'S++GCY9W=V'I=79:_
M_8#K->K>VHUX6-9NR+U?JG=S4.L6<.LRTYZ#O*FC@5%&D[PQ7#KP/B$D4Y*P
MDJ,RRN+G[/=\\/#^:#SIEY.K3-II&Y>8C>L [-=^VLTU+NC]W.^2KWB8CVBY
M&_?^]>_KKN^+3W!AA0>]K!7^>IC\XJ#WSZ/!25WF^),I85:76_[TJ$]ZV(N#
M(2WC)[V]/$B]0(^>X]X!C6KWA!S<?1KJR9->MYIT:?+)L'[EC%N")AYW1[FC
MEJAY]=F)J:]<A-,]_;]HK?ESU!\^9)JMNS%)E<SAX$]R(OJ[G8QPT"-I#4C*
M^"?V!]@%'V0[?_9KIXI(<])/.,G5I^^1ZO4FM$)..I&2QW)(EZB&V#ON3_9Z
MO[S\OQ?/F/";L_G<1;I_(E>4G)AQ=56/AZ-!HA4S][H(?'Q^5NKDTZ3NTS?I
M(>F)ONEYZL31.6+5Z1L.<CPBQV^S]W=2[^$Q^>DTB>1ZU5XB1Y.]X6CF_X]K
MH!C)%2;)]P@ /E X5E^J$U>&1R.:I/\>X8@LILY>=3&??-MBWB//>TQ>=J[\
M?9ETE*1]-)CT#ZL54$ TLY Y(7_2X\WKH*]9/?3]O2Z\4W/.H_TN^*A_?(++
M)V<X?"88&MO181G1Q4^#CTY+^^,>A5K3K,5D>/KQ7CF:'(UR;[H.[^:S+XW)
MY"DVK<]-UQM.E1/C7I^ X!173E7XW"'76=N<4=ZM@>]P1'AU>#@:_DFO?PJ*
MR$!>GW^,'@[&PU[]5+\&417"ILC4C;._'XY&XWSN4>L'L'=8X^E9F#T;QV2O
M/TKLD"SGY/P3+41CX^D8AR<XZ/9#Z2H'IV213WK'>_VX5^55+W0J<QI=Z=/D
M[>&HFC6%L+&+[(<'IS!*7YA^D/2T?UCQ^F#6'W4R(A689@?H\I6!<O>@_[%>
M9OK^>1")P_&DCJ$"]=P]L0M"SQ'>UP]]]6I5N= /]L'A8;/W[TY2LWK>.@MS
M_@5I^/APT)_T,N%J741#GASG/%7J.LT'>41:^>NILDV5I+O:1;6K-ZGSD>O3
MCJXXZ#V=Q-YW-$='L4[JQ0MUQ$WVIW,7FD[T^/MNH.1ATSI2OX;5!B,MY.-I
MQ<$*3/27SK8_W)(PRYR-YU-GEP<5/CJ=,7&1+:#.3FE$D3)7#NN1TDN#BEG^
MI'KEJ[U,_':T3P.DSY.F]0_PH'IFY$Y,T[M5!J?@0CI$B#&>LPYZ 2OJ5I=E
M_..7ELJ95*9[%]V&Q5F^J=OXZ"Y^.,X_GO[R4^J3\>')C_V#;NS=EWZZ>+E+
M2CXZB4[?/DO?;/)I"F=6?C2[\^SMS>ZMN>VIZ7O&;W(OKWR;;XHKW_O<9=VF
MTOI65_W\>X;?[IM?8ZP ]S-6<ZVK+O< U[WLK=^PANL- >RX]_R@KO"GJ>9I
M(KP=ZEJ+AW[H4UVK_=#\PD-_JX?.+G#1KT"AZ'PHWXZ4/98#$7<N%"7?(V<E
M1"BHP"8>=(I162Q. EIY<^:',TJCQUQP,"OO@I>O(^R\?P5O7N_U=Y[MTG>>
MBS?O!_UM^0;>?'Q+UZ%KR5=_[?PV7]ZUJW<^[LJ=9WM[+__Q@K^L10JO_Z__
M\H\7']^^WWN_L__JY(U\];$^PW\^/E_HSV15UEF 9*4$Q<#RS)SSGJGLN,[>
M24QQ8TL_,6[QJ,2JEY&NV]F,=M+L$0+KG6MC4W+"1 K9B].0C0\>I= ><TZ"
M%Y6_>:[+A\/.N196!7)25EJ61+"$G5(S5,$Q+EW@!*L.O=C8\OK.E;'K!F3W
M@F7?'I ])A3+'FQ6)KI@"R@)/I%?*&+2O!YJU_P.C)?GW</2_RLG]C&/A@W=
M;HANIXV_7C[[7;]\_>J=]Y:F2'JF==>@SVKF%$>6$R^@?66L#]4E<^3+_W3?
M"+=J?<&64?'?KG&-:SPH9TQCP[PU&^;=SM>N;%O\NW?:41B-\9J#4<"%\#)I
M*R-P!R)!+$LEQ&R)DF4MA]L+B9+ +023)=,&(P,5 G/)*1:S('<F9$D_-[;4
M$Z[<NB9*&IG&JGC+4'P0WI8(5H!P%$X6[QP&HPQ7*4#CR_R*P#"7!1#)!:F2
M9MS6!C-.&(8^9E8('835*JED*V/\LK( S4I7Q4J%M@4I@D4P DRQSLCBM2Z2
MUGQO(#2^S*]GI>>C6;+4=S::(LC?8C63R@!+)BOEG$404O/(!?+:$.J;I;EY
MV-#G&IR9ZQT0+:/;T.HAYIVC(<MK3LGKG)('7Q"UU\JB+04(28UKS)^K@)ZO
M%H.?;-#9()FUJ!EH!<R+XADF4 6M*J[48^V7L(2M>NC3Z$%6S*E2,DNO? +(
M%K*0WF>C9#%2*B53;LR?JP(1<V%0%A@Q2V192V# DV<A1TG^ELM0F\BY2&&0
MNK.#U0QVQ0Q61R5M#AP+ B"B"[R>\>;HO1+>Z4;\N1H&.Q\1A4+6JEQ@@M9O
MBHB0#+;PR *@SSS$$HW?V+HS4>_R>7T>XU[050>DUCT*^DZU;:'+0#-FB#IY
MDQVX2G#N;%8^<$.828;(;QX(?1,D: ^$E;\OQ#_2DT]:3&*&'!D&17+FK(S,
MBB*L=8+;7#NMMIV?EE.^(S"$ #)8KJ+2 & SQJ"RUQ1[VV1S%(W%].L"PUS4
M0],""7*@6"=%BGHL^4\^"N9DJ#R7.7*G-K;$W<.>9J@K9JC&.JLC&(XN0LK&
M8U'6"RU$<M:FFV_^-$-=IJ'.1SM1.PO1.F:+=I5N6#(O#1EJ"*Y(YP%EVMA2
MX%?(4!N/:;O!_=[@0;<8O^*YU49P^DB.A:\!P^F5'=S7^#"ZD',L1F?MC5:'
M +4;Y-5,1H,S;HB'C,J[47W]-!X-X]9I/+@BA_=@!K$2I[V6VP]@"4)9[PQH
ME@F"4\Y6VD0M96W8RYV7/A95A+\V!>WCI7QYH%AI=R';&27/.OC H@Z:08F6
M^0*<*:MY)F1!0%%CI;5-=RYSI7[ @[8W'^]=3^$^$NA>[D'==8?N.Z>^;);%
M<>ZB\0Z"C\Y;%;)6B-Q;D;&Q=3T<=,_EHWV2+CFMF+'1,!"9,X>NT \1DL<0
MG%$42+E%_IF&I+=#TJ]X]]NP?UW=?G2=68#6@Q!LVCGZY+0'[;3H?8XD+.)A
M=^&/E]$!C:_5D?QJOJ?'.?DK30$UV[_I^O3C8- [I.L.T[AW,#P^39W4UNOT
MUC!.E:#VBQ[2T^YE)'39HWG-;=XOFW>URO-^@=F/GU%]S?78;Q-[:;YIA2?V
MQ3QIVRFJ5S1?1.PECMC=<L1?))%;56*DGT=]$N:@MWV21^/>;_\]ZH>PIH1(
MO^8P&'X\&?2^&QS132=Y%/,A#1#W)]]WG=1[I3\:U^&Q.,#QN)=')Y.]T9#\
MOWV<'(U.&[+'X7ZHO=HGO7(TKB\=CH:33"@S#),I'P^>$5!T!!.?: -V:%'I
M]L Z[D&,),ZI>=://B4/=9!''5\'3NJ(0J[D$;-2U%E"_0*#3^K5 1[M[M'@
M=P?#4/F$+C2([\@H+IO#WG<_;__V?>5-F FE"J"C^YAN(U1VA=\W?]M\TGM^
M-**;/YG>?,;6,<WJG]+?7$I<A =YOX_GV7)&E2*![C9,O=0?=V[V^)3?I*,1
MF3YN_A,'1UW/^XXLY(PBAM2F'V?\,/6MO4S3,NRXJJ:,7?U**4"/=4T^C^XB
MI\__4V]O>$R"'IU29<4A(VGLT\R.SX3T71WN<7\P./=VYU+,N%CHI<H;<4Z4
M1S,>F/G6_=]7R>P,*U_04YI/>K!S["6?F%-2+YS4)SHE*IE1OU1=O3)7<'!4
M-6PN78#19FE##M(54,HX6PPJZ3"!!\GS%VI=Y6G:8'_TX<=?IV#[*\W1OZL-
M'4QP]ZPXALDU31O<GG;V^?'+UQ\$C4_2W_1L+]X9-%G+8ABZX%CM/\."LI;Y
M6E0H5;1H?=U+7<@ _.],3T\7M(Y^I*KT5#?B\&A0S7/*+-+K^-CV\:_^_M%^
MUYWZ1CH!N=9/!4D*$0&4#L$&FWGT04>-\*7ZYZ83-]&)^"XG#UR9PDP6P$ 7
MQ8+AEN4H.,9"/S@Y7G*QQ>__]JI?ELY ;% 7A(Z)J7^F*1TJA<I!0P@T!8Z;
MJ4,0R2DO8C8*P)KH-*@4@BJB0D9*MU2'9QV3#MV^Z<4E>O'ZQ;L,/)82,HLJ
M"P8&- O9.B;(&D%D;;4IM7?))7KQB=PKXVC0GU+.5<>&5N#\UV%_=-*C%:X[
MWM^/E<:QOG PY2<\74I9.&%G?U5-ZW=Q<D:"F^D"O]E[^FD1'IP\.>/,NAXI
M6:>S;*K"E]!YT9"/#NL5;L*W3B93P$5:OAR'K)"T-#BKG'+%":_$M8]N5&7]
MY=-8_ST;U"]G*_6?^>F(?(;=CE?J<7?W6IY2QW=U/G2A92^CL0RD+0Q#TJR
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M/K?BO-4QV;F4K _".QLT&:JNE1O!,XH*%..) C4,V0I)7NJRRI";Q:Z*Q28
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MTG$:4@:*N>4BG]_WK7/T2MGGUPRWKS;/5D*Q'+.=<PE$Q*Q\, R5]0QB)&^
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M;H2)E^Z#7]^+:.:[:N:[A"B\F>]7,=^%3?&LHC4&65))DOG&6KD?@&D9<D0
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MAYFR?/M]Q]<I8X#/)$P"BWEZDB4N:$D8#DI(&\76=0(D5BL;;^!;_U0Z:Y1
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M9(B^#'*?7E:\9-L?5!P:^ #VY*3;L?[P;KJX!O'GIXO?3=4%YD S[$^EF.N
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MROON:>[]W@Z-SM@I@M:@WWXSEJ,$3SU06 I<UBY0"/:K508+(;#B2B?KO"2
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MXB>LD4:8#/Q2D4(TF"/MHP2-D 32.BADP#_0A G)N-S:H4H\E4ZW!: +0!>
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MF7OF30'4 JCW!M2K@O7*@[_RW;.)^5O,]94']L=3/U2^.O0]GT#?B)7BP3"
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MQFG@TF4.U>-J+_ 5-,QKF/<M8MZZ\O>: W2-@:1^(A\4\%EI9)SKS$#71+[
M(S.2+ )ME<Y";NUHW6"MP5J#M76F+#:/Y / W4H%*:V0"]"LLCD&3@!SFENF
MC(T27 A!IG57D&J0UR!OLR%O75F:S7I]*-SKYW(*'X1,B0S6G"0#1,-01TN$
M3W!B>+GN7DLGH=P4U%M#_2XYV(3.B[WZ?Q]C&.^-%^-\>5NN=<W I2GL[0;M
M!NT&[0;M!K>]P<;VCNPN\W2\H.O':S#,5XO=/!OMW7'3NFY1W':-=HUVC<VX
MQFVY^Z,CX)5X]R-]@D:7)XMJ/L_'M"U@M:#NTI]X$.Z2NV947?1<FYTTM:X3
M5'\[G-,PYO,?I_MA/.FDY;,4_7A6B$YLOZ/F'EZ+F^27/U>.52EO/ 9M6 99
MVW\JS]#$R)QV4H04$P2]N0FK%T/H0YR7O[%/N>'@IN#@N@XY-1Q\3!SL'8L*
MA9;*2<\D1&20!6<>M&66T_X6HO7%-QQL.-AP</W'E&Z%@PWO;HAW_8-*VB8N
M 1B1><' QL*\=I9Y+"&$7)14:6L'].;ESS>L:U@WV -##>L> NMZIX7 .N_0
MUASV8A@8;AER+ID2D(RPAI91-*S[1K'NKFE1@\.ZP9S;:?;M8V)@[S"/-M%Y
M4$ &;2'[5G)/?(](7R"VKIS6SL6U%[!LL-1@:7A':QHL/6KXH7\8!XU-'J5E
M04!A4(B<.5X#$!AM4CZ+5.L1-6!JP#148%K7X9AF&SX( /6/Q\CL11#<L50,
M,,A1,!\A,%U$<1D(@"!N[5AK&_@T\!D<^*SKF$H#GP<!GY4>\MI)A<(SE6N-
MA60CPUHY3 $99L1W$Z(=&O@\4"KOZ4W3^,.CIO1^KK-_-J]WM$;?(&QK?:O!
M_7 PG8^K.#R=Y;UNB#_4G&PFMP$.5F<4Y[E>86OG._G]J>1TTSNH3,EVC7:-
M=HV6G7QW(O7S=/819VF4_XR[2%2FXTYU![W\6,8UNM4,KR?-G>.;Q:,405GN
M4P(II$M.&B@2M=0VBFOG]G[>*\^<VVSNL_40R$\KV;LR<UXP2"9LS=Z%5)B7
MV3#%/:"V#FQ4+6MM?0;S-XX23B6#/DN$S"&($, 4FT0,,4(&<8MVU^=0HJ'!
M#=&@E\,:A13<)<F2E8Z!!\N\B,B,SIX6)O-L:IX#7RUWT)"@(<&-D$!H7@HW
MJ3JYP=N,)17M4JR-$+-N?&$H"-'+^HS960C.L4)+PT""88Y;R53)TDC ##PW
MOM!08EU\(7#@@6>"" F%2]J-(B$&* U@)>C&%QX6#7IYD>B4DL0,6!:>T* 8
M9!Z=93D$B3$7$U-I?*$AP1K"5 6SU )YCI%#,L%S38 @7"Y>6-J5;M[SMO&%
M^T"(7M:@P61DR,@4:+(HBK ,!4>6A#,YTM)9+;_BY)QO7&ESH0V"BY",52"M
M"CE8D"$F7I(+4MQ1:9MRWM3YU\^=(W,K6MJM631),#"!#'X>-*.%BRZCY]&$
MK1TA>5/-KTPU!1=*!"L$+3]8RX,Q*DM14.C@W?%YI+:?/K[*]K/-2@K2\R)8
M/49&*DOLVRGZ$8568*S&HMJ.^M6JK42.G,#9EFB@YJZ;XK5&"Z3+A>N[JFU3
MSYNJ9S\?2Q93DC2!J>(Y \#('/V/D8&,"J-PDJNA[:@;6UKQ2JWZSVR\6.3)
M*![.9GD2CT;3@SK/MPO<7_#$PT"4.[O84C*0($4P"% B.D2993*Z2)FC@.:(
M'P#2\)7 /6A:K 2992,* VTR<T3>F"U>&FX2=SYLKB/^8H!YB#X/=^(=7R]*
MU&P0R*: E"1X@(YC5#&4G$).*)LC_H'1H!>X3]QZ!<63X6X-@X!DQQ>3F-4)
MLR#;3JJ:!=YPH.' '=T&T@N2-2M-T9 \N'KX25NR111*5UK8?B#XT O;U\A)
M1"_JX?W:[IA PB/-K@4>A4X*,US1P:FA1$.)&R8#EXS!J$A;#^00G/:!DWD1
M7>0EW]FF:&AP0S3HA>UM%"H;GYF@56+@ZH%5@8EE%9P(I=!ZI<86&@[</6@/
M,95BK!+* G# R)%;';/!X(/U+<@P#'SH!^V],C5.RV2QDH',G*&RFG%O=) F
M*&^N2/)K2KO92JMK2?XHN;%< D<?I#8*:G%6GDMVH848'MCQUP_:*^19Z2(8
M3\4QH'5A+M!N[C44'YR41M000U/,KTPQ R(J5;=/'B'$@D(Z6[1S07%K4VJ[
MZ4 4MA^R-\GG%*)C6@(I;,J>(=E"#*6WJ**T'-I^^M6JK0)O7/$@+ ]@N DB
M)"+$]12%(D.Y[:</K9[]D#TZY3(X8#+*6N+7Q]K!)C%EO%6%1XLV#VL_74,7
MW_/MA=>2;O/EJP]'JP?3RZIMQO>H[6(E;)Y2Y+YPSHH+D8'WM N7I!F@EB5F
M&:,SF^L(OY$B/E B7\.<P?6-:DQB/=C2[P#E?"I2().9*P8ZZWH:+K&0H]-2
M!-# ZVDXWW"EX<J0<&5=?9@:E[E?O.D%]24OQ5H562Z9N(RPR%SR@6$$76*0
MUHK&91KF#!-SUM4/J7&9]6!++T7 09 8"%%DZ(KJF\+0*4E<QCJ1;+)0<N,R
M#5<&YVU=5^^AQF7N%V]Z*0<J@N*T3@R0"_J!G'GK)'-$2KU.0=/BK?M48X.
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M<WZ_\R2<\46L<<_3V^X604I^>9!2;8L+_ /GXMJ]\-DMZC ^?K7%Z['7[VZ
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M\<P43)F2XX5<Y,Z[;;^PT/SICV,X;\>]="T^HZVM JU_8 &Z:AP=<H^E3C&
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M# F.$U$L><$!/,2"I.Y'MU8SQEGCC)$T!:Y%M(I'&J@G., =L:J\\N=?:MP
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MTQ>K\,(* '>V/J:EC.:::-18 8"+";)$Y3:HS%J<E':!%>$%J9[<^+0"P H
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MCH[M'[6ZQ7#8-(J=G ^&K719OM3JAM@%W1(%S"Y#:VG6VC][G5CKI=KP.-:
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MHXY4!A*KH\'+4(>+^LZ'P^P4)<[!18H\ 05B#H$A-HA9&2VA27(KLPK@[ZA
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M]LQP5XM5,"9H9& =$(?50BXPC:1/D1#)G+$!#):N(J]5Y/6I>04N 1<2U+&
M.0_*:8VMD%I1&PV+3VX>44'! Z%@-HT6UL8ZGD#WI46<>0)NK*2($3"0027!
MC,E04!7*74/N2BFGV+@8.9=<!:(-#LFEF(][)Z*KXV-KH'+L3NZZ\X8TKYK?
M<A?@QDF=-W8^D";]_?3@_5L"8[RLG_S:V7O_X;*Y7W!73K121$ID4]XHR?V
MG29 95V0,G&EC8KY^-B" Y\S)<.JP@D+#=:C=*HR6"^F/;-Q5\H\US8AG%(
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M@Y@D+*)4I](7&#A-MNFJA*V-\_66'I>O.E@;J?7#CM B>B#/:)**E/ H3,"
M2T"!%6#/Q5@F(HPRG0<I2*T5%3C678'=.%_73('EF4YXDC&=\9R&F<P#[D=I
MJB,:(A9VTU'VOEG!@@+K^R%GF2])0K$N-*.,<)XE).*@O_HI UN7K68%&^?K
M@RNP.F(Z]$7*HBR@P+=YDJH,TZ)3)C05FZRM-3AR-W?ENMRC,/[9P<=_AI]/
M3X;[NV\N/N^>##Y]W <%]MC_=(KS>'D!<T$%5J5^2C6G))<L(#2G&6$T#DGN
MYTF:TBAE/$$%-KJ= KN!OZ[,U_BJ@[616C_L""THL#R03$;2)U(C_%LJ15BN
M8\)"E05^+$4HX! $T7( 8MT5V(T'=LT4V"QF:9S$J6 LI '\QL*8B@3T6>S8
ME>8;!?:>6<%B_=<@"0*9<\)A;PCU=4JR-$F(B)2@L9_X.LM6LX*-!_;!%5B,
M8H0J#8"9^S1._$R&<1B),)$TRY6*-PKL@Q^YO4YKKF,<5[B$'D!/Z^FGR[W#
M'?_@\(SN[\+]E\?QWNZ[L_W=#W0?UN_SX9_#3X<&_@I;G04B4"17?D9HG&>$
M@\@F.E$T#D#A\A'Y%VYG-Y7,"K^EK>S:>ER^O>S 5YVIVPLL759#-H$7?9G\
MKHLO2I)+594;07;G4_6R=ZJ.>"I5FLF(@*X!YX(',<ER38E"E$&FDT!E#-7)
M#/;NCT>GUVX<LVNFUR8Z4#G/?9KY&54ZS1*:1$)F/N=Y2M-O+@7;91,@^XDL
M)\0]9\,K[LPK]OJ\PL]YD@61)D"<DE"-2B_3'(S@7(0JB2.1!J#T;J7TEZU8
M<&]G[F!RHJK%Y7S<1O,WZR!QD.8LS;GP-:=AR'(@2. POHQR%:EXDWUSK_QC
MN>1\*N,P3/. \"3."4T5L(Z0Q@0V)>1"!IEF,?"/Y/%EWVS\9VNF9T0*Q%.2
M1#2F(>4R8#J(TA3KG L1Q6FP\9_=,RM8\)^ERA=)IC+BRT01*D5(F*:*9(F.
M?!&$8<P0P?A3M+;G92551>S#8 03KRX'A?2:4^*^!P7B]V#IR_760KY.J_MN
M"[*26:U:EOM76_[KX1;E<2MQVF<ZB5(IJ:\HC048BJG67.8\2J+L^SJ2-A;B
M-['U%879H\BG"3+S"+U)81*1/(@2DF1QPI)$^SI MIZ!B?CX@J0_@)W?AR?J
MNXQW4;W\M5C\:O+Y55G\-ROGL8I\&:>,I6E 12KR/) T!PXA-<6V<1LGX#JQ
M^,7(=QY2P2(PXA6GA,9)1EBF-0DP12S52N9!B'GS6TG^O=";#\YQC>;_VX3Q
M@6K#?G9F^],AG!9AXMW-/(:L.BY&9CA1GV^=3NM)H6?VHV(D@5I_I[%AK/=Q
M3L/6<>@]9;4WKE0-(U#2*T8>?.J9"7J,E^?J&7PF!E.I:@]6MRHO8 EKCTV\
M<P8CP,LJAC'1R0E\!L^9#MQS8+\4[/6Y@E]L.-Q=66KO;E'Z()-:1CS(=01Z
MH)]G-$\"JJ4O,I$R=44Z1WP=DYC'X_^E8!ZCXW_<;+JA^\<?JO_\GQ-?#/\9
ML8_Y]&#X 7B%B/<NW^$8@3?\#3SCY&3_\//)_L?],^01GT__IGOAW_Y_+C_1
M@[^/.)S@5*0YT8J!$@?Z-]CF24!8G( .+J,P#^63Y\'J9"4VDG?<9Q\[ C)&
M_9QI^#'*F1)^GDL_5CR+_2N23>EWV.<;8LJ_XO['^\='H6!2Z3@E6:@30G5.
M29YS37(=*)DD- B4>/(<EVII_W%)$2,1&CK ?=M"[C"V+&$PV_;ZX(G57#-9
M/Z[YL9B<&!ZIO@@U-E0-# T_V&#GUYB>1;#_]U&@54II'I*8T9A0X?N$4[!1
M99J)*-4Z4E%X%^SZEMEWBPD:%/5J >JQ"F2DDDH-S8=PQ<5)"3_  8&?QZR:
M;*$\W8-].C/PBO0/$)*6M.!S-IIYDV*HMIS0G0$7,\\;VDO&H'6H>MM[V<I;
M9F3L/KP;Z<YJ6M$6C-C/[8A?E,,Q/E9]46**HV:>G@X&YJA.1T"FLL!'LX%W
M/&45 Y)2#9'#'Q#M7V"R. Q8DPE^4TQJKY[RNI %#-!.Q7M_PJJQ??O_8</Q
M']YN>3+$EU?C;>_IWOO=9^:%\,/W&TAW=D_AA(+B@E^+<@C:F8"S#^L]5M6S
M+:?5X)?(J<9LAJ?'+!PLZ$@48V:'T2@OV][A"6A)\X$ &92X]S"(B8(+)Z4=
M15'74Y@)+H?ZGRD\%+\QVI&$X[C]2-G>"]"*63%:6..67#NJ806S+BIEIVPI
M 99_/)AY%\@Z!9#EB.%2P^H:FMY5HDNHP9:1&WU*O0":AK>;!Q5L))1]V,1L
M2?O(Q[JX0%D>.SZNU#%0B >:R+0"NK>J\@"T&0(D.+34A<2JF#AI-F($P_8T
MGOH9*#BU83:P5KH<#,J+^G<#4]SR_NO'NUVSZ]2PO79*[U1SU [TV^:@O1GM
MP^L/+]3@7.W!6$[JVYGN^2\GQMY<[A]^.DJP:[:?"!!A0A,:9J"2)7Y,?#"2
M0:U@H1\HU,N7P^<>+P8#^.$/) SZ" CC$U#UX46YH8<KZ>'T[R-&4Y[Y(D<@
ML\*B$O 3HV"VI5BSBW'X)$5ZB*ZGA_BQT,-)I=2&(JZDB,LW1R%360R&!(FS
M%"A"A0(L=RU)EN=A(%3,$LQ*";>78R\]BD@>"46\*J?5AB"N(HB#W9VCS,=*
M_"&8/HIQ( @_(USHE.2A#((PU('O8\VX[>5&R3V"2!\+08!&M"&(JPGB^"A(
MXUSX.B.)C%+L8$0)CT"1B/. *2U$()F1&5=SB&VO<3;,S:=*#=#G8$T>U,VM
M8<9!U69X\P,JJ&W0:%B=]0BJF<5;-D,#'<GG8'1+ZGFLP:-OH!X?-8Y4B$2I
MA)$H""2AV/XCRVE(:$(9;$PN:>P_>9YE*]C)\-XUT+OL_*UUS5]RYT&SD$DN
M<AX$) T%&"!9&@/?8"F161R'/!)^XH>P\RM0';V=OQ]=\TX[?WNM\E?<>U0B
ME*]"39.,Y(*A5IF%) OBG,0B#O,DXW#X06:DZ7*KG][>WX]6>9>]O[W^^&MN
M_?%1$LL$.+Q/0H8EV_(@(BQ*0Z*#*,IU)*,(,W[2>+G0:&_K[T=_O-/6WUI3
M_"6W_O#341HI%<+.DB1%6>\S2G(:8]T^/_:5CI3.%6Q]N!PT:;;^,?ME&P_T
M"2BM[&&,'QC7@7Y1*5E,7C%1#(K);(]]*8;3X;\:M_L+-H9O)K.-S7,%)0=[
MA\=',O55GN:2J"BAA$:)(+G*P1R.>!0H09/ CS'^MX*2G<WC";,-GG;[8*,<
MQF.O3(3BS^G(Q@9-O&A^W;@JSPL#HF'B;#KV!L7_3 N)WZ!'?U5(93%F-8^Q
MS)]J E0U6EM<>=,:#"]\VK$:J0IN$V4U+A%SXXVG\%.-4<)%DL8 EJS8Q<C3
MTY$-AU7E$ 8$CVU>LW!\<6V0T(O1E%FX;N= N_.3AG# X)4F?/>[L0J!S_YQ
M4<C)20,3[-SE %W^_!;&ZW(PG5Q]2X=58'A;5??)& )_L?9#Y^^3JAG#F!TK
MPBO%S@C3,,3?V>""S>HGO_5Y(## [K)=->,.K\ROXX-:?]_I6A8,/ 1I"?<&
M"$55>!6,@3WL #Q0VH'7_J^"11D-@DP&<1H"O_5S%>4Q#7@.*JN?^?H(%--#
ME/G_]S?VN$;M/;H1E_K1#1EX(O"0T:0V(U]QM!=XGI6?<13X29Q1'6A)!<@6
M/\DR(9(HRL)<Z-PJ!'"/DCLHDN.,ZSA+_#BG">69GVO!6<I#!19U&J7^E><]
MN?J\9W$JOF.2CF%O?RD&PN(V2ML:PEH7)5P)LI,9D,C 3 OQ'3 #>)L1ED,V
MFH*@0Y_R7+(6JC9P-; /Q(F1LE*=JT$Y1B]G[Z*YC"VU1B#.EJ>&XT$Y4\H[
M*:<U/'3+.U<GA1@H WGPA$-2($S"/*\OE*7"8#_,"M0)#3=XK*K8Z%B9-Q>H
M@YII('"B&#D$VK;WT:!ASME@:J>*=(>Z2VT! T.NI 3MP*[ $@@(M Q<F-.I
M/!XZP$H[#!P% H65>3E";L:# E1- U\:NI\+W.E"%XC@J6LU:6!0S3"LHJ);
M. A\6@YJ<PEH+1;+@% GO'?;>[DXW/F.P14EJ$3H8G9H$O>"_C:6U3$;%9?6
MY;QE?,[%$+0TA=1EU]NNH@%6M !G"[HR^I0#]:!N9M8!=WC2WG:!RUV8_0#I
M7I<CD"RS=F<[R)<+4!O;%;9?E&[+WBE0T< 6Q2<[RL2]FA,74"^"N8 "SH&"
MCQ%$-H3'MY1L!S]'4SL$^D+Z<R#3( V Z:4YE7'(?)KG,<]#X%HT#'J]G/IF
MQT%S;@PW^&B.&/ Q.Y9WS5#,EVA>!SW3 \ZN^%U.JXNRDK4:_7+VQEZP=[IW
MQ#5-12X949D *R,)&,E$R$F0PRZ(. 0SA#]Y7@-K&5GXSF(RP1906@$<R%'H
M"@)M:=)2#U@6\-V/(8B_%!Q/U2>+=V!J7+ !$L!F_WO[C_[2)(IU'G!.DB *
ML=1<3+BD.<'V!R*B:>33Z,ES74ZKU=N/? ;#96-DLZB\;GO_6%'2[#ER-F?N
M 0-JLRX,+5Q+!1I;+3 995%(F4R9'XE,)RK-&-C B=BPA1]#%N'^[M]'3&@!
MFY^0.*040V:"Y%S[A*:ACB*6^)KRZ\BBKS"H 6RX#;E:P*ORZI.RFEC0H*.3
MI^Y?(S1!I, F3="ST(B0(/2&!GB'$@\TE?I9XP=H1)Z1S5:#&12,-S*JM(*>
MLX%!9=8G"B3X(W7W>89J4<-1(_@7S]""\C@/=!O)+\ICT#)@[1&I#4.L&#Z-
MX)-A16JXIH1S8>'*;J';!=WV#A:>?<4*6_AX^RIXKGTA/LDE;GFH^!DU:F&4
M[>OG"L.V]Q[UQI4N)T<D#M=LU0]4<"2J7HU&:$'LC>8GBUJ4TY'-[>HKEE-\
M%B+#X7V5T5^!X.9.+*,T ]$*-A#30:-?W30C/G,:IAC O["(N/+_,V45# X&
M:59]"RE\.I;, O*O?#GL3ZOF+BSL32J7@>!V!F)V;=62PGPF[ LPW]K@TUL,
MKU$%:^"L;E/P1#=#MFER+=*W]YI&',!EXZJ<Y]/@2H(H=ENX8%*4RCKZ:C5F
M5:MO&C1U.3++^E1M'V_/5QG?C1FT: 3-M528B+-ABE$]K<R!QXDUS )8%+GB
MR>C,A&]A^,S#%9T@8'M^NS,74!&:V*4QFW!<*6OWH.R"NQ!G/CG9=KIU)R_1
MI>2X<P0#7#D4 _1WGE#<C(;R<'OQ=I/_24I-ILUI-,]J,"WV><W1G'E/"P?!
M7O4NW"B32?9LVWL%[SU?D-OPW&4[L7MZ["ZCO0?VY427@Z+$SZH220(VFPE[
M[AKW\2*G6LU-'BMKOB']P$VYH9>Z(9AYDNH"&['F)AXFB=/#TP3C*B4F_CK'
M0#'2 ^OK0:L,_J!U"8=AOM"-H)A44T6F8^.RAP/6V*9P:HJAH1PVQ*VJ_X"=
MO@ :K[8<.,I]OF2?OI]R.UX@\7)H*1H#$>=(=AV(5<T&]DMS-4868"RPR#9H
ML?S<?HK1TJ(YOM^L'5)A<R\Z0PJ)T[>,N9,%8WPH\ZLFH*&8+*1Y5L9C3?5;
M%-"&B6,FREVB@$QG6F12)#X35+"$Q[D.&0V9I.CZBXYV4=/V S\@MRMGTU?
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MW7I7N_5Q<X0UM?DV'.%;.<*"79?H((\E#4D.O)M@7U62^2$C')AWXF<!35%
M1OY5\.7U.:!K8=5M]/B?[LQ\6%(J?<IEF.01B;(\)30%4<J5ID2Q. (&E_-8
M^ILE_ZY+'G$?C"3L.1MA_F;*.<FX4B0(!&?,#X*8BR8<.._\[JWR:GR]^K[B
MR*^'L%YW]7V^(QLG[7<])0OJ?0)G0L12HU(/PMSGDN1^"(PIC&%O62A$'J.3
MU@^6D=WKKN!?(V]_E()_6U_BH^09ZZ[@;WC&#^(9"P9 +F';&(C2+)?H$I#
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MTT;^%V\C?W-;^!]37O>ZSKYM$'2/85/MR6Q3;?=0'*6AYH+1B.2PI(0F24C
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M))YWSJJBG-:>&+!B:)=]H(YAN<=5"6H),@F38</@W$S@*. JU84T G.$0F$
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M#N%5;]D8E,%RR, 4 W/S[RF350%,"#G@_WLX&X/\2K:\(( _B>%$0?;_>?^
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M/ %]"NP10Q/UD:68FC. 4-AC=-VC%%)#LV>("%1?!!PJBVQ!H-KDI*@DP;&
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M#B-JS?ZY;6;?L@J>-^?P:Y*S]U"D:D17$T6[,)@X5Z1TZ(U!(-GH[THI96"
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M!# SKBQ0!K2YQFHI&ZT_<PGPN+.ZJ$P%+]>=KU.C8[/,+TQPQ?9$,@F1S@N
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MFS9RAPWHKQVO 3_#?#"(5;AFYM8=5MJNAB?L$G0P]&E>8*-ZQ%F#+8U%VIC
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M/#SN#TYC'&U6SX^JC%-Y8(^^O5[- <C+5G\RV8IFS)NQ2F>]Y__?QH6K)EP
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MHP)'UPZYL> MS86D!.?<.INK)@0F&<[")FB'65$A/M=#FA;Q"50;+)5 *@C
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M3P#??I3%=A@M?!6\VS\Y/*Y&)X?5L3UM;@3/]GKSU>:%Z^#=#!@]>.3\U?
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M1PO6ZNRX]G'Q5B1'8'.W/8"&PEC'Y_DJ^?S7QS]^)Y_]RQ\T-6]U*:JT9H1
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MWYRTTQ:KC63O-F%D4.ZF<E$O*3=KG\4Z)25V2^TY[%$16J\HERQ; UL*;N_
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M2IV4+@N)(EFG%2462F4=1+2"4:'IAC6!X9Y:&(=78%#J2&2\GYH]%WVU6%)
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M%HP''S#Y6'.M8_/)YDZQN?;Z<:6D=_> EQ;$.E<P.\UH//F0>F9NV4JQ'Z
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MORQ[;-M26[#&,ZU#!S)H60R!&]U@*O3&1\<Y;;;>FVR8;+C=-IL,5*#%J%R
MT"U:Y, H%"F'D'"R8==L6%;:]26,/F!&DB4#$JHAI&1ZTX<T='3>DX8-DPR3
M#'><B'  >F<[57#0<F+N14.(X,@5)S+)L',R+ SQ,6>HJ9*1#F/OOB/#2-:T
M6!M79&@XHH:RN=HWV?!QL>'NYKR6!34:A40!,B=.3@.)UG*K#BVEZ>G95V9L
M..)3T%S#9J6&K=% \]5PC<,17S"!3Z,4X/3T/%0A,[@DV46?L4$%I-H!N+F<
MJA7$V79T]X)=.N+1NU%L-1O/552PMAL&0)-\\3T36=O*T3' U.H#TZI7D?;&
M+COND*.FZ,S42[2U8\*V_4%W:O6V6ETZWUT94F4R#6TV$",:S"I=<57'7(>Q
MV'!TC&&?6@1/L6ZEC*X@0,Q!LA6H@1!<+\YI0B;0ZZMYM2G678IUZ6YWOB5?
MHS?9(QEP.KJR]\DXK!%#%-N]O6EF;4KUL*4:*6C60UW_RY#)%C=&5M"\IWGH
MO4VI[ERJ2U\[6(<A%&=L"F @=$U:UXUA-#S24585*Z3C:KESS>O],[9?:\[N
MPN'^RW[V]RJ+N[<%NN\\A5YK22V/.3*?06,^[)W 4R=7R$:[_?:6DRRW(8O;
M\.QIH);T?K2QTJY<84J&H@\&4]/;136E?I"+:[-T_YZ1@7(@FV*18A$TC2\Z
MF+&MD2@H'M)TZ^V<#$NW7M*8H]M@G&MA5+',!IUM)F8-$* JWEL].M[L:S7)
M,,EPNQEY81LKIXA=0UFN.'I[<.XE.5>)M[_L/I?6MD2,A8FO].*DU&0D5!RE
MLI-!%FN80M!'#+S#V1)[<F-K_G\<-?2I04"-*'PIK4 =[9]Z$HQ<)C?VE1L+
M@U_)I?E",!;TB@$A9_3^5>-;UE3$40J8)S<F-[8U1Y$:E>J\;YBAN8XA=P$-
M.Z3;G&J8F<BN^;"P^?FQ^)M&]XWHDO*!HQD]5 R,YCQ1H\<>-1/97/Z?9/BX
MR'#W=9$<0L_,%*&!)R(([+RC'&POOLM<%]DU&3;+VVJ"H8F&-1U]4R*X;A!L
MTT\+UN1BX-*WL(0YI;IG4JVU1^^Y82<'I1(ECB(MQBBMQKS][MM3JK>5ZM+&
MYXI+O7DQDB483=RR(<]L>F=]'""$U-V4ZL.3:FP V)K^)QDR#B\?D3!2*D Q
M;+^_]LS3MR7AI;M/.(^=4&)2#]:H9-$@:<[>BG5U9%,^;:^N[13RG@DY52JY
M9R2N%DI/5#3(2AQZ GT*O)]"WELA+YU_N8P^/V,L!B85<HZFD%0C+K 7K+E6
MFD)^J$+.OJ480RC4'+3HL;>2&H5>K*6:IZ]^]X)=^O]":$*"9+K#X=-)S9#C
MHH)E8HCD5,A'QW=V_VU1JN];Q)#/+YI<F.N#Z1E<K2[/3T_:ZD?9O/K^*+GG
M-KYY(-;!H8T5K<6QHJM55]6LOANRN:U-<VL7ZT:RW72E[G]J___=W44Y[(6.
M#HY327XTC@$LMF# Y&+R4%RN >9"QTXQ[S?,F %2LCF**8$TO;(8#4ENIG?Q
M,)J-BX6C8X3#,UU]*+9_X/TC6SG?9? YF3Z9_MY,MU1J0=\@APK1%7;L8?29
MT= ] &Z?Z:_GX&<OGIEV?F5>'7@"_]; 7WAL.[7<@CA31CT*B!T,6PQ&.B)7
ME]@V?W2</@EA(G\B?R+_HT2^1NQ92FVE- 8) 4-NWH=J?9"27I4>FF'\#JF^
M\$%7[Q*$7$S 5@?5G4%.U62?UW<*<TP'7<QT,GTR?3+]+DR',<V:7>JQ%!CS
MNJ%B%)<;.9<UQ)],WS73%Q[U5&U+%LC0:' !MC93("?#$)M^*T" ?G0,(4VF
M3Z9/IG^,3!]MC+"FUJK7.#T[SM%!"A2YH4V-Y]3,7@-_L>F@UY)J@6I$Q^31
MD<";4B,93K[K&.VR]'QT7#Z!/*=F)O(/!?DW/SX?*_+O[D(GZRA;"<I^H)H9
MB8MECL!<6\@?U!$WD7_GY=?E;A+V/N3D@@F9>52O](9BJ287ZIAB#\&-@GB?
MA+*M^I63P9/!D\%WFAYOM9><2TL)H5DN!,3=2JX]$L?M;]J;#-XJ@Y?;A$H(
M(;6B^)6D?Y7@3.%6#)7N70@E@!\FF$\\;@;>D\&3P9/!.V!PDAPXM\8V0&J$
M+HT&"]Y33!FCG8;RG6-VN96K$%&.4@V%VI2U$@S:5(SK(4NJ+7G+VRS4/B$[
M(3LA>Z<65-WFPAD(?!S]KCGUQ)U"&OLNK>4)V9U#=KG-#HH("Z+!/@KLMTRF
M^.2-USM84LXAMWAT'/-FR^L)V0G9"=D=%"L(1+&32WTTG8X5O3 7AE12!\G;
MA^R<3=@J@3?V3<;6D\_6Z, Y?!L=#;DB!C.DRMQK+_[HV/E/',:' N'USLO?
M7!&?BO[;3KX[_A?]Z\?S?O4*9H#J,?X<7G]_<7EUTE]>?^GDK,G9U6.#:[IN
M0:SP*,8?];H^TN.3*WW=^G8%>_O_??K\_/)DW)''%W)*5R??R:?CZAG_".#Y
MYL6@2QE'.#K^E?OU]2W<_/M#+-'>ZCT='?]>3YM.SE8G9]_)Y=4SO=:7JZNG
M=+7Z7BYD]4SH\L6%M+$_]$RNKG>+7F\27?WJR]_^UZ]7S^5B=?F4]&?/+U8G
M^LOROR].] ?T0*NG])VLSLZO5BQRMJJG^MLG_42/IJ]W]51>VW&Z>GHB%W11
MG[Y\M/JS?D</O:)G^ECK 9]?R*4>[<=?.]'S&P_5:KSFB7Y='Y"VNCH?9_+L
MY&IU(8K2>G)Z0FO*GO<WOM3XI<7W]*>?_WQ7[&=2Y1G+Q?4-"^Z3U?!/K.BL
MC0_<HY]TN7S"G]'%-R=G:X$%O3<?TP/O]_F!'X_7N,>7Z[H2^=/5O\MW<OKJ
M]OY,!FM5Z.-/9U76X_,@\N7ZN?M&1]0+.CU]>?W<M-6+2[VY*UI5%8M>,_WX
M@J[D6DGT_/G%^3]T++V2RY4^%M_*>$JO7ER<7:Z?H^O7'"^G&)>+TY?CUR^E
MOKC0(^FO?/_T_%)^_,7UZUV?Q(NS<]:K\MVU&O1 3:Z&!LY^.I_G%R=U_/OL
MO,GIY2>K=G)9AZCT!RI=/EWUT_/O5>-73\^;WH1O],4^&3*^/-'+3Q>K*ZE/
MST[^5U]O\9B_&J*^?/%,;TJ]_GQ<H).S%W3M/7E-"*^N?O9#!1M/U/<G[>KI
MCQ'2:[_U:N"R__P58AVD7ER]^5=>4U0=P+C8CG[PEZ*[]6/E7%Q<H]?^?GKQ
MSW'O&S%\(?2MH:ZG^)A.OZ>7ET>_^3D[%!RO7[8WO>/7&/-67/2^W;=[32H-
M$,\OUO?[\?6#NU;_O]!N3V#U]&+$T/_/"84"SI7F8O9@Q:($C. 8K7A;;/^?
MK# 8VOF7W]!AG?7JX,[XO!_<*:]^/S(R'0?69WZ#M!?,NTZ.T#9Q/C7?:H38
M F*K23KWKFF<A'J=Z.GO2/OMR+? ^JRI7@8O!<069&ZV5@QN5,:Q]%/:^(JU
MBW8VO?1:]!4L5:BC^B1V/UI=-:#,/OS/9R-8L<XZ\T_7Y\]3Q#_5I])>G&H^
M^'GO4J^^ZG]2@&J85NGLZB^OC3!?G#U_<77Y^Z=T]HU<?G'VS^QQK:$_ZSG]
M[O2\?GN@2>+?_ONIK<_^ZXS^BB^^>O:E_OGB'T_^_L4_OOK7O]BO?_A/]^5?
MOX GS[[6\_Y:7^_?_O[U7S]_^>4/[?2_?_A6S^.+_]'+BZY',$4D&P 40ZTD
MTPA%DB^9 Q^M1%/IYV.DNG@A;R1Y^N7@$.*V@L-W&]Q&S'0==+.,D$'CF>].
MV@A#5I<OGNFYO_PQSJ[7S\<(9OX95G^BG];3%R/^76D0=7;9Y6+](QJT_$;C
MC?,75Y^, VA M>HG9QIOZ0G_&(._GH*\%JE?!SB7_WQ6?QX.G:R?UM6OUL'=
M*OQZS'"L3_#WY\_TJKU\%?QI=B%GET.]KX7]CW\IIG\5FUQ/^%U?EY^BEG56
MK3?CE)Y?RN,?/_A4(R]]A9>/3\[65W?]2Y_^_'!Q,Z9>W_/K;[^* 1 ?E8 C
M#'A5U.C5"[^*$!ZM(X3%','U]WQ\E&U\X[?M(_?&[[WML.51PC?_YMN.^O;O
M)>NW?J[YD8<TS_4C/]?LRX&<:WJ4T_LI=A?GFBP<R+GJ\QK?[;K^0OFXQ3SI
M?:[ E#MLR?AGX4GW+F_E.IF^SS=S\RZH$<*^\:ULWI0WE]O<TW=]\RT<LXP_
M>]</XYG\A2?SM67;6RQ4[.-3^\6/4XC_PA>_.?[]C].(VWKG;WS*'\X5_*/0
MZ?KB?7YY15<;U2GGE7OCE7M[<_!YO9;7Z\_G5_JH;6&(.<1+<C.M)[[N>@4G
MOM[WRDU\W>YZ;>+KCN6O;WTE/FA5ZW=C^%\>_>G1ZC]>S>J-6>IW8M6=+L2[
M/%KS!>8+S!>8+S!?X%8O<.L![%7OB(,8P&X>Q7]'IVO'T;_1V0NZ>'D]4>+>
MV?]YVPNP$__XNPWE[^X?O_6;OE=_^+N]VUOXPWT//>9NP?)H9M<1H_X;?.^.
MI/!L9G<K:_CSD[_]??Q<_<>3SY[ U_YK^[=__?+;K_[\MV^__NM_/7ORV6__
M\>39'TZ>_/"'IU^?+*SAS_2XPQWPP^??/_GAJ;[V'[_]VO]G_/+9'Y_^[:]?
M?__DL\]??OW7+WYX\M<_G/SW#S^6W?[\2G_^AR<__/9_<@Z)2P/3J(*!VI/A
MW)MQEDJ,KK?@W]+);HMFRKNL)FP3Q??1CFN[VWDF;A\^;H&C]]92BMV!]XF"
M#6(Y8D%;,VQ_8_G$[79P^_+GN(U=2DJ,)@ [ Y2<H9*+:4YD;+>R0FWB=N)V
MXG:GN,VM!O3*62]!HUI7Q(T"/+G%4IMB>&XQWRU6OUQ&L1R9?*]&_RH&Q%7#
M',6T8"5EO6>IC_XQ$Z@3J!.H.P%JC%":> K% R*2JT0IM68KM]9@ G7'0%W$
MJ61]YMRZ<162 ;#!E*IH=1:2=T63$.8)U G4#WU['RI0[UR?@P%S;![#*'N4
M*A(%B TPY83<N*R!:N>$P+Z!]JM%Y&J=32D&;[*.@P::%T.<G2E^;-HBRU7@
MS1,"DWZ3?A\C_;JO*6%,,68!%H= .4,-Q55L5-*DWW[2[\FRTS=;:-2+,YB"
M-9HB>%,2#0:V+!W8I883?Q-_$W^OX\_&Z+!H]IR( *B0"RYYU'A!PP66L'7\
M3<S=$G.+_M948V%PW8R:#XHYC(9@M%.*I4K,/MDB1\=W+C$\ 3<!]R  E\&&
MF*HR+18]6*$&/@01:(TI"$[ [1IPBU;/T8ZJS-&:)%@UC>UHL%JO3T\DLK9[
M@'Q @'O?30O[;>O\;;UZ0:>O"K^MWE1QY#U,M=LPYLYCS&/,8^S!,=[7[WX3
M=QW> ,%EC=$=4_&/ZSJ0HR[4^8\%GRZO3DY/5T_EM+U>?W45-BSP/UT??[OK
M<V-,>GBKNB6"A='5E[T'SHE2SM2)K?24+*4;B[_=+EZ['K/^N!ZROGJMY-N?
MQBWZ/WJ'YMS<5F*ZOVPXPX-CS,#)].2: 0AB2"*8UG,M.?9L Q^\57$'V? O
M%X?Y*%D2T#7-]W*NX@%KQ-AZX>CT[09]PG"RY)!8LK"3*".B:R&:T$73P^"*
M85NM@9YS"HUM#F6R9++D;2SYU6U@4JG7@NBX! A1L+9H(7;G71<B?@>8C+J>
M^M%6J#+I<2MZ+-V]R4F1 MY(YJ#,2!J) #0-3%HNH@\V=W=TO-D%]==3P0>K
MX"J-!)"Z9 OHJ:!*-V(2S3D<0I\*WFL%+\9_'>9%D>Q-M%XTETC),!<RR+T!
M=[IV.4T%[X^"[[Z$4XF)4\&. OK&*?4(P3<)K9"5:P&['P7\7M;O&<_?EYZ7
MKL7JV0^'HI%D-8H/.BR7D,AT[-5)3#V$MVQCG.'U84O;#^M=JRP@#ASK<!RY
M2&+K&)QT-Z5]0-+>L.2A:[Z&!,82Z5@MY U1;J;9V!""_D_\U/9!:?LV@3<5
M\BX2-/2H:H[%%]3'(9!8".#@'<0] ^\=JGGA/-.L":V':+HD-!![,]A*-TU3
M*RP:>7-(1\>;+3]GY'VX$NY!H-FL@N4$J1?,+N0@JE[683ND*>']EO#"6U7
M5DVDG,DMD@%L40=DUPR#CQJ)L4^Q[(V$M^2<.FCWP/EI6[47%^NO/I752Z$W
MEQ!^&Z)NN#3[@:B#-@[HW?EL?7/^0]_E^4PDML.MKS?\ [UT=KF! >)FP#=K
M2J]D2G.2L?;6\2UYQ+ZO^;T%6Q\JZGE7X]?'B91=^@<F4CX04A;+"#XE: 45
M)$XS&DCB#,6(QKI,-;E26&@B92)E6TBYNXM@>TB9Z+@5.I8> ML!;;#=4-=
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M -M;WB[K(7!,7N-:XR+5P5MG& J;Z-#72H[3(9<+GKR=O'T0O'5)<N#<&ML
MJ1&Z-%H2>T\Q98S;]YQ-KMZ2JW7!U9PJKOM'5QA6BY9-<<X:L*5 Z1E*Q#EG
M,)DZ?1Z[V\40)?;>@FU#HSTBUJC1#A-U@!2O]]G:R=3=,?7;!5.K]2$1F]JK
M,A5Z,IP=&5\)?(T<P)7!U'@H3H^)N(FX#XJX4EKT50_CHN;E#ID+1E=;ZR5*
M:G;KB)MI^K:6H/[Q:ADJ//FSPN^W_],=]H*IF^YS4OAY,.A=,%Y\$:S6SKU:
M$X 3@,N]6B&#;9!K2 U:MYA*;Q$M600JK4T [BT ?U@ $"I02LF92L$9#?@T
MMR[83"XY0L]$+?$$X 3@!.#K  P]8*1B;2 +7!W7DJU/8K/F3^SJ3')W#CJW
M %WRN3'49CRA1GI>&4<V>B.I>^A>[U*U!Y7F/LQVU=<-VE<7ZP[M*U7A<U7!
MBM8R>'R770O;\.K.8\QCS&/LP3'>UP)_$W<=W@#!]><G9TW.KAZ;\0.[I>(?
MY92N],175^>O6*@O>W)ZNGHJIVU%5S\5]E]MUO3_Z?J\K<O(#==G/[J,W+T;
MIR6ROJ5>BP5@W['4EFQ$Z,ERRG:;W3BO1Z\_K@>OK\[^&<#]:=RL_Z/W:D9R
MMXOD7F[8QDL#;%R2J;FB@>;8( 7]5%P)[),-+1\=.]A< G[W9B-OH<4'3D7O
MU"KHP$1\"PV+L]&R]Z%0@M*1&'+NI?3&R147WD'#6Y#NG(7:DJ07[F0F0>M:
M-ZD5;X!M-(@8C*TY5K$V^[$">>!NN0F3?8%);1Q"#05#UK$$H61FPN3%INQ+
M21,F!P63ORP;"?I81J-?RC3:,8#&!P&*B;%VO>W.:I P83)ALK7T@JMGWX0U
MSX# KE!I(:><4@KZE3C3B_W&Q\)ABE0E>JC*"QB& %"0)&XF8@1?G#0O?J87
M^R7BNW<BA4)MM)6HHR5I]^L=&HS-:^A9 PANLQ/I%/'V1;RP-+8DY$8[4INC
MQ@ .L^%NT8080XD=-.;K1\=AL];]U/!^:?A6>Y6[TS@^!@@6'.BPC"6DWBRV
MF,37=Y#PC.KW1]$;3CUJU@WY&M]&5\L8FV%D:P1L3J$7#XVV;529ZMX7=4-D
M6RT%K^,R6%^P2DLJ=Y6\JZKBJ>[#4O?2AI9'E7<.P?02Q("48-@BFRZQYUA<
MUR=HJON@U'V;^+OC,!MFFX/*.U!'%F@"/H(MGF*?\?>>ZWGIMO(:?HLX9XHO
M8, W5#WG/L;MFC04#USB_D3@#]-*]1\O+NI3NI3+%9WI==1'^O*3U9E<O9=!
MX(9WO!_P.2R#P$_WY$_C=OSVK/U)KJY.Y9F<39?G;;GSPV9).0(OCL1T[FP
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M=9#LT;@"W4!-V5!'9Z+MP<886HWRH*89UD;PWUP1GXK^VTZ^^ZDZPY<OGJE
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M1>,=CZ X<][8GIN!G-AP831Z]P)"(0E1\UN_N0@S"3<)]S$2KF$HCE+HM6B
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M8I6!3!325D8#4A(88Q28T>=8@BZRH<&O>M,Z&KXM-%S9T<YFADDVD?'2 KB
M2>M*VA.%4KTRW=%^RWL1PZ,RJ1CE4ZA"4?("9&PGN0NVI$1HP5N9T#(;8$V.
M]BZI8Y%4,DB$.3OO*VBTZ$O,X*4Q/D3^T6.>QRK!@R,?V6?O3  1C T"(&N1
M/&O_3A6'5B7*](7MQ"[&FRW&FL!8K9PKWD+P$GTJ 7+27F4M,W0Q'JL8#XXN
MV*H5H-=LOQL4O/)&$:Q+0MGJ=;8,:N6Z&-]5,<[>LR&F= 2O@4WI:%*1I(U+
M+,?>A:XWW[:X#D+PP1,ZA5D4GHRB^55$JM(++V6)+>]U:C8UZU)=5.^8J*:0
MI=.6Q]<9L!30&M3%FE 1V,3-751O6U0'L>3.5\HZ!X'M)#38[$1DFT?(8H)E
M&\BAK%O;(%=#=&Y/5-<4+[XQX8$/]FCV@AN^GNC ,SIC'/"Y\M8[9D<0HY4.
M/52@%&3*;.B5G!REJ+LS?XQ0>K82-6AMJB"C%B%[UO;;(9>4DQ)2QAP5U6RE
MVEQG_A=@=%TZRWGCM;]-;!!&#;&J'%."$"5:S4:%9Y)@"4FMWV/7L;$>; R<
M_"0QVU*BH !RF=@*$5BS21)J= %SK1T;'1OKRLWL:V)4! G% \J8=''5QJ@J
M*2M#Z-@8)S:&H8,JZL@&JQ8)P8I6A42$DEN)IQRB<L;5$#LV.C;6A V-K&J0
MQG;8'IPL09(I8'*52O'%>^C@;>-A-720@C))&%6#@*@U*Q0^BV*)5,: L14F
M\JLQ )T,G0P7VSO54*MF$S<&9..#8@@ZEM+2<P0;L1]NO&4R#",'48?8<L:+
M*)43D+44:*(75EG%G*C>F-#)T,EP=:]*"+(ZEY7T58)5V%(O)NN-"MZ3J:K'
M,8R3&*L!A9Y @O,BV78>FEP0B?4+H8HS);@*2>+:XABZ&(],C&62))WV&2NQ
M[N]1A2P]N*22SLET,1ZM&#\:9E)U6-!7H63PO/(3B 2U524III7S3ME]P4'1
MQ7BSQ3C9 B&5$-"S"9^;/<_B2R:'8D%3#PX>K1@/H@I-:.6%T(H:;!50<Q:L
M:&5!-AF)-:)77W 8=#'>;#&V0=4,N56L,6R\I:"-C:96 U6E!+:'*MVVN ZB
M"J.VY#0%82$I ;ZBB+S@"NV+*V1=MIBWMN.5(Y6ZI(Y,4C.%D)61UK@(R39]
M.:48P";II /JDGK;DCH(*HS&!)U484E5M67C,"RI%D5AXU?R"NLQE)%)ZK>6
M<O!7PMT)S0_QD'J.P=-6N@KDP&=6"3(@48RR56#V=7',))3NUQ\CA?*'*$)N
M'S_W@[?/*45O;4"A=;$"() (N0:1**CLB5_(7]AL&_LF?3_Z,#)NU*J4S;8=
M4-+@,29*50?KK%< /JS??=>YL1YNO!MPHV1=(&$2!JUII_Y)I%#;!H$M4NI"
MR6UP'&'GQLBXH6VB@LH[S]..?(K:HP)37*2<<HV=&^/DQN.AOI%-R3+Y)!PK
MBFSU6-=./591'245T?$ A\Z-SHUUI2YUR928LG$4P$M"Q98U1>N"K(K<^N./
M.Q\NQH>A7A&=<T1(0F=5!##D!2K3TA$:G]GJM%CDUK;:O'BACH:1H0%""S7P
MQO-*!*FJJ)M_HU"E;+2%CH9;1L.3H>J0<BBRUBB<B4I T5DPW%'(DB&JX(Q-
ML:.AHV$-.0C)MIR#UE9TX%Q(8 E-=29+AH.7/7AAG,CX&$KXX!T_Q]M'OSQ/
M"I D@="JG7<TR8JD,@D9(FH*V55G>U*DNRK( 4VI)IJ(7H+V*0+PWVUF&S2H
M+'MNL]$*\J.A(*L465ZI"N5;878L480:DLC!L'4739/F+LAW59 SA>1D(K2R
M0E Q!I;;4#U(3=[;'A4\6D'^;2C(6#4&3TF4EOP,='$B@,E"^YHJ*5FJSEV0
M[ZH@E^ACJL9[UL*@(L3,MC9AR*J]&M:?^ZP+\IH$.0\%.5136E8'(2G(MD$7
M1)(QB^BU"^3(.M1=D.^J()-RQEH Z7P+_ D1DHFE4*L6HTBM/S*X"_*:!/GE
MBHT<M8]5&I%\BQE65@GT-8NVVYX<6J-I?2=U>HK#2TOG/P[X_OM[W)H)[I<)
MOJ#]_&YRD+@MV(:BISH<!BE&4+J9BD5"PAI)04R4"X,IINCZ#O\X@A$_Y HH
MAO^+6NBB6VQ  1';AAT&0\YJRTM-V^#?N/W]?E9B9&"P.D:,P47K#?BB0S0A
MYX+5*O*AYAY--%)@#-(.)4!46).P*B_V!+$I+B HMV@B\%C<%RH>=&QT;%S,
M+5@,I1HC9"\ALWG;0HH03(1HG-(]F>%(L3%,9FBL*@G)"E4\B6:\BE <B=)V
M)).+,FKHV.C86%?*,JNE,C%J;@:P%1)M1*U"AI19^8CK3V;8L;'6V,0/.5#)
M&.7 "VN:!]*T_<Y6Z+ 0_]W'8!7V'*@=&^O"AM,>K9=>H]60 B1K8O9(4H<<
MHU]_H8:.ATO%)Y[@03<?5D0EDI110/1.!.E!9(4EFJ2,\;[O7G0P7-GS$I5)
MMMH:J7B@X-D 9D7")&-TD9AZ^:C;WJ48)C0,+@47=11H6@HEK%JPR>A%-<4Z
MUB@@5W46&;J@;K:@FA1==DCD?0;G;/)%5EE5=@9)>===I&,5X$$J0UND4Q%0
MQ)*3@!: &+Q7HBI( -:%&*CG0+NS8JR213 ^:VFA>L]:N#?,<]V2W9=JNAB/
M58P'J0R=A18WZD4N1@L@905Z_JN)L::4+5B]O@+)78Q')L8I:P0VPQP9#3*E
MY*4!D-460R[8?JAGM&(\2'$H4=GD6)/.M:40 "@B@01AM*5V<C-77%\ <1?C
ML8DQL2*=&>0\C!"\3*0TLBCG2-IZV_,<WKJX#O(<FIA#I%J%,[GE!R)>==OF
M6+7.2_*)=+3CLG[7E.9P)9SPVJ,'%Y?Y87K(U\_GD+H'K4+RN\F<\M'LRZ62
MUQ$FW:_1K]&OT:]QF]>X0T<UCO7;.Q)]+V]CN?QB__Y$KVGWX!65R1[.7K(F
MV(/K3^OA$,$Z8UKI1S!%!ZF3C9ZLU2H8E[I[^C;U\ =O_F?HA3+$EK'75ECP
M6H#5203P1;@(.6DO'8';VM;2=0_U-VZC7[WJ=W*^V*S8P%.0F <:%55P"$%)
M_JU'O(V5&0/'5[2Q2.M0)%V8&:I%REJ2@BB$:J3,NFQP=O#.C9%Q0U8/I52K
M07L@5[$$)W,*M2A?R:]?I^C<6!,W!IZV4JOQJA11"9@;INWY!5>$5"51\M'Q
M:M"YT;FQ)FX8G1D=*3,]#)2:,<5L0*&7)5.L7=\8+3<&KCU3?8FDJD"C@@!@
M:P41BM I&,5*99)?\M!W;G1N7.Q 7Z92+!6G<P!3 <$%;9PU)3J)9OWG@#L?
M+LB'@2]1>=?*N@>1*W@!.K!E8ET2(03P-00,%?L>1F?#&N(,D"*;N,:3B1IR
MJ,GFZH-ADS=JF7+J<0:WS88';X_W./G:?*?[STFZ8B)K#\'Z)"!;)5)B1/"H
M6736:UC0(<H1Q1IT85V'L*K,UJ6%S#I_ 8,U@98V*WX)D5+ID?;C%>+W0R'.
ML0(!2ZTM; *XPD*<<Q(5P(;HR%<L/;KOK@HREBK)ZP3%.[ VLSI.B3"3Q.B"
MZ>E!QRO(:B#(E?'+"S$)([T14))F6SXX$5"JHG@M]M0%^<X*<I#)J1PE^" A
M@<-:,<38_C#=>^;]$0NR&0IR=:;I5")':P4DDT1B@UMDGUFJ"7)17]C,[X*\
MV8)<*2I,IM:H-2"/NR^N9I>CT=Z [O'VMR^P=B"PSOD$9*N(F',[($-M@TR+
MY R6+%$'JF.S@[^5F/N?V](TF>[G@SWJD??]&OT:_1K]&I^_1L_QWG.\?]'.
MC";[)"N1BU"SB5Y;DDY#8-NS&NBA'Z-46]^MA*>W@EY9>2,<^"C Z2(P91*@
M4G6!A]*4VD,_NEF[)FZ01,?KCHVR98, DTI4@%$2LG5K\OJYT?EP03X,0]%U
M90:P%2NI> $1C4"P1EA?8S'**V6(C5JE.QLZ&ZX8%@8Q*U<M.5G 2QV3=YI4
M!N\ 2NQYWD?+C$$8N@Z)E(DD)(8DH"H0,4846(PFIU0-LH>3=FZL+6,S%J1(
M*6D%K,!:=($,%$W6Z.**[-P8*S<&8>C1&R5C*2+EH 18647(&$1.)O"T9;6C
MVR*=&VOC1DW:4901<M:0$L12K7&HHFON<]MMD5OGPR ,W0>E8O9:1--V***)
M K4A$56M(+5-.D"W13H;UE'XWFO)TXIJDAG8)$GHL0!&,)A<RCT@;K3,6 E/
MSRX75BR*\)$R4P.BB"UOI94:M3(EQ+R^>ME=D$<FR"6AM=6%*$,&GQ"+*LD3
ML3"GQ/9HCZ.Y=8$=AJ(KMN%2I2B*-BB@E74)I43A;$W*J9*-:>=)O.W">L>$
MM>:@BPS*2UYI?>+?J@-=*!A%TM2>*WJ\0CP,0T](3KMJ1''D!01><'DTK= \
MJ%J#*@ ]#/WN"K(MQ8?$]G0,X)WGY;?Z:*H--GGM2A?DT0KR, S=6NE3-4J$
MYO8#FQW;VU$*4$;I1*C0?"$751?DS19D*(BJ5B*? 4QQ,4J3R?%"7:@4W8]C
MW[[ #L/0=5$Y^>*$45 $:&5%XO$2-1=%51J068Y-?5Y3&/K&A!O^>#![=3##
M0[IRB.%HTR=?/1S ^@!%H_/2MI/)R$JD0[(UZNP"Q.[6&R62WJ^$&++:#P!1
M">-#RX ;I,#&)R<IF>B243)MKEMOC:F]>]KU=7 #V>I,+H%D0P,*I139\O#1
M 2^+J-+ZPP$Z'R[(AT&((65)I D$^(@"V%H4,200/$&CU])I(_76MC*^LZ&S
MX8KAQU!3"+SP4-:L7Z3$"K$OT?N<;4VUAPJ-EAF#$,/(XV:A>.$2,C.B3 *#
M\4*F* D,,/MMURDZ-];%#8N*2JK&!0FA)G1.I62"+"9@/:Y^U[DQ0FX,0PP+
M.6<I"5X'%.L:)HI0"_%ON4(V%2)N<(AAY\;(N($@;54JF:+X5T!&1Z66+]%+
MDX*UW1:Y;3X,0@S)VZ0C&&$)V2"Q6 12,B(H"5*KF%VD;HMT-JPEV(%4#M[P
MA"/0/J>*+JFL2Y0>75'=1SI69JR$&*+3NOBJ15K4^"+M1?*5^1$IZL2K"*N-
M:_.1=D$>F2"C1Z41:VYN"9]"M#(FCQ2M)RC:=!_IK0OL,,0P!JJ +;UM2*J%
M,I16**>RZ#;#SBM,V?$R'Z]<'KL+Z\B$U;B8@LR.;':0 $)(+1"XR!9JJ$I/
MD#E>(1Z&&&9+QK0$>\&G*,#(*I(,6:C*RKHOSM>TOA##+L@C$V1PI*.G6)(O
MD#/CVP52J%RBIHRM/["_"_*Z!'D88DBR1$*JPC.'!12T EF<10E AD*U15,7
MY+LJR%$#%1ULRKS\VA2CRUJ:7'PJTF9MN_I\ZP([##'T(<F$!852V(+[51*8
MC15%LR2':#"@'IOZ_*UE-'QT,#M\@2]HF<^P37W1GI'*>=+?;F2P\Y5WZ[T)
M)GO005H%Z"@%U;9UK,8<"]6>@&B<A)(K$8<V4.3ATT*UA/G,IRH"LJ$?DU0*
MHD+=$XGT0Q+KJY^=3*X&,ED3(8%'D[S$Y!-J5:7O]2QOG0_#B,."6;:8H>(B
M"<@01$19A,LF.<C&4/%;VSV-2"?#5>.&O ZYV BF*N!9A:9%L[*!0PYX;<*N
M48R5&(-XPZ*B)=1)Z)R, +"UI1X* LGX@*ZJJKM&T;FQMI2&4LF4;<Z\3('1
M&(V5TKGLC<]T4@6W<V.$W!C$&ZJ$3A,K&3Y))\!3<S22%]I56;./.KHO1 9T
M;G1N7*PL0U59\]QB^S=!,39$':RV,==@0CK.N] MD5ODPR#>,'N=P5LODG.>
M+1%- E, @<4KY5QCO>R62"?#U?.@^1R4,M(X$T$1\L0B"=Z'D'-@:[B[2\=*
MC)5HPR0-0E)&Y!39%FG'G@)8V<Y30_" QOK8,[+<54'&$IQ-0?FB":JF!,J3
M,E6E"+D0=G?IK0OL,-JP I(&D$+*K%M0L!7)FB(J92]]U587>]8BWT5ULT4U
MM;/K-0;O61M'56.A%+*-P38COB<1'K$(#V,-F;#DDU*BI2H0D$K3TQ4)DX./
M$31F9?J:>U<%.<:JDR7I#54PU@9>>(-QR6#,GER/-1RO( ]C#=D DA9,$%03
ML?*<E C)1&%SQFR5HD@]&_B=%62JH:5]=Z&Z#-;KH%QA_=EI\+(47']>TBZP
M%Q788:QAD3J!@R0R,0;!5R]:+2!A$J*GH&)P:ES*\YJ2&:X$&%Y[/.'B,C],
M#_GZ^1QR]^1PAV:3A_NO:7[8*B=_/IQPTZMA]VOT:_1K]&M<]AK?6NSY3_RM
MUW@X?=U#S(<AYM%6BPXLQ@3)9P19DTO>6H<!;$]J.T[%5'\,,7_ [?L%GMQ_
M#B52EA %*9D%&,@B9<.*:32F&JM85?W"J;7NP/VV3->KI\-&L)5J\3D: (-(
M4AJDR/:/"9![D/FM$^+1D! YAF*<K*(JI=ET!2U"CEJTE,1H-+7CRUO;O5QE
MA\.5U0KGBJI)>V,0JHD(R6696=/PNDK73ZZ-%AJ_#:%!J:8*.@BE6C;L6J5(
MC'X!9&W-CH<8-SBS;2?'R,B14HFHC4O!$U@R02E7'!9G0]"^DV.\Y,A#<C >
ME(;LA2G-M54 100M1='!>:.MC'F#ZVQT<HR-',@SJE0K2TO XS @VR9:AP"D
MG+Z&LVV=$!<DQ,LA(4QTVA@3V0()4@!$$$ALE:CL*J"&ZJ+J!DF'P]4=[5+S
M7$K&L3UBP%-.1LL:(-FJG6,H](B9L4+C0[CYVT=_/I!/?GKQW.<@%:N) J.*
M3(VL1=NY$-ZK5I(; D"O 'IG)3E')WE%!Q]R!9-J5.0DZDJ^!@+J"3/'*\GO
MAY(<:XZ^8A:A!"= 22,"FWP"HI*:/"MQY0M["UV2-UN2(WJ(!:M6A0!=#4X7
M_NF3S88R](3SXY5DM;(F5S(@51 F.)9D6T%$_D<DJY2)MGBKOV#K=TG>;$E.
M!6+UR-8<6$B4HZ'BJ#HRL=H2UU^5NTORNB39#"79UAHBZ"*JAU;]4ED1@LF"
M0C)9F9(RJB[)=U62705>C$-)K'D!)(TYM(TTFVHRM6(_ECU>2;9#25:D 9.7
M@F+,;">G(-!JY(49=32VE9@;Y9I\V7CU=# K-!/+BW$+#B?S@]UIF9Q(U?'[
MAP>O?E K;]YZL/L7);A)S#)I[GR"AY/*LC1YW83IHIF+U]9'9_+NK)ZZ>9_!
M_[F]3MEL#TK6K*539ET^,QW(8U72(5A58W+.UNY!N57(JY6\PBY"*:TZ8*:6
M>4-79,+S7[T'GUJJZ-3RGO-X;9P#Y1J0?A,E%=;2WJ%*VIG>F7[Y2+QL%*3D
M :A"EB6E8E2VSF=;@\+.]%MG^B 7-".[-F>&P,H*.X^:%<FTW[P,)%TV/C+3
MC3.=Z9WIG>G?(M-K!,A%N>HD*WK-L"_2&I)1.ZPNK3^K9M^D61/K!UF\#>6J
M' 11+"0!)DH19/MA@[8A6"=3WMP(R<[[SOO.^W4<M<NJ1K;I,40$8"B$%&NN
M-KJ*R079=?C;YOH@RWKU1,6E)$J2AKENHL!BI6BIE5VT$922K,/;KL-WIG>F
M?Y-,UZXXU])%*3(08L&0 BM]RAJ9R5K=F7[;3!]DQE?::\T+KZ@UM;Q?$D2B
MP+JZD3+'+$.(9FL[@N],[TS?$*:?/7V^5:9?.7BF6DFQ551K:GH$&<&:N*@)
MC[*61#V;XVTS?:5V 5FJ00<4MAAHFKH4,64IG-?%NQJ2PL2:NG9KJAS=(=LA
MVR%[I0A%;Y/5WJ>B$@1G,4<?2*,%_L?Z]<<:=\A>%++#>A,.62U.L@H?E6V!
MB*PZ:X,B4/+6F1"!ZM8VN- AVR';(3L"R,:B?0K!(?<+8,+@@@U5@]41R8+O
M8>"CA>^P4DB-U01OH[#)&P&LYPKT"H5,IDA^RZ3XA8J?'< =P!W MP#@G(UC
M==;8Z$'%&C/;H+64XDMP2O;"$+</VF$E%X4AJ>;EBU$F :H$5G#!"T*0@:I1
MU$HR0>Q:;H=LA^P8("NAE5"SAI5:"QDTAD@14\M;ZIM7[EJUW/VC/5$.#L7Q
MA3N!+T[@86D>7TL"Q]RUY$HKBF=%\IIG?RC0JE<'!VYK6WVGXY7+\XR%P8NS
MDM\?8MHE_G^9OM[^._\X:??Q'43CU ^#.@U_'LT/I_7=2JF&]<@JW+/VXF5\
MM/S/O[TZF$_;B/PPH]U%R8:_M=X3^A[ :AV)A'-J5]C:_HOZZW((5W]>A__U
M0L^TM?TC-QNG^Y/IQ^)$D\,=/)R\H1E-]@CG1S,J[6CG/ATN#WHNSW=._O+X
M_O_^=?**9I/Y#O)G#V:3*7^9_M_1E#_ %YKLX&N:[!\<3A+1_B3O\K>G=<I7
MX_L=[M GAT4G.U.:X2SOO+LW><KO\*4GN,?3FB_X:D9SOMK)UZ;<OC:I)NV>
M4WZ=)TB9'!ZTENQ-#R<S8I+FZ>X4%Y ]J)^]5?O2X#W^]*O3!UI_HDQ[B6;+
M 3/JNTF+?IC@?FF_J'L?Y'(QPYOL-I!/]X]PZ6'_9,[OX>S%='\A<N[K,Q[L
MNF9\_-KJM)@(K=M_/-CCV[WC@>-QG+=NGLYW%AU_,CDF+XZF93&QYVW-6(SX
M;_?^=6_9/:]H?]XZO?7.P:+F%<O,X8P.IS-:?+MU[KSU>YX1'O(8'G?U!'=W
M#_)RQ!:SCT>9WKZB?+@<VW9+%K )3F;M:SQ,?-&C&??,4:W3/&W7YH_M$5^J
M#>GN ;/ED"?$Y("?X<6'J4"8=Q:-^&[R@B^XOV@ $_/5<DKMTFO:75Q].G^Y
MG(F'/&A\T4]ZX-7![+ R+@].YM9QKRTV*OS?+M0?:;DP'_<+/_1Q/_!3?U9;
MX.69Y^/0]Y"4#E&5E!# 0\%@3:@NY$I-Z?],T([^NK[P44EXNNB)^Q\&ZI\T
MR_P,^((^: A";ZB*\,>_=V3>^]]]_#T>/=E[S/\^?/OHSX=OG_SC-_GL_2_J
M\>\/X='>,V[W,[[??__Y[/<'[QZ_+[O_?O^;?O+3@^<4K8S!H]"HM6"-+8J0
MG1)8;9)9HBVZE=ZS*XO[?[9I>[&AIJR924 ZE S%8"A6)9E\R E+#:D/]34.
M=7ZNLW/:9A(2M1)0:A$Q%">"S6@DE2I;J0J09PPUKU\?V=#6R<,IS;^[X/!K
M=,HV7;(4";)4=%X9JNWFFGRA/OS7-?R&[_V\:%.Y?[W0VE@!,GH6<F6$-EJS
MJ:;!5<N:_%G#?V%)1Y53]"KD M@\R($D9L:YT;;JZCX37=^'>AU#_?27Y^A"
MJA&#,"I4 0ZKB!&R:*>?%)(F7E@9ZI^1]*::SO87G8J[D\M*NRLM%2%H5U,"
MJ#K&Z(VN)IG0LE"K/@6N;0H\_NF7YP4L4&:Z*V^2 ) L[=*#4-FV:L@JHFI'
MGM>RKANKVDX/JW 2(>>29, JLR'%$]$'VX?Z^H;ZZ?WG.FG;Z@T*:Q9;--*(
ME'T0R9>2C,^%# \UG#74+.U+S_!T/Q_LT:>V]'<+W?_HU<6G0Y'&ZJJ5#59#
M"HHA0 EBK3IX1]0E__JFPY.G#Y][%ZU-K@J%F=?YJEC-LUF*EJ\B4$5>?MW6
M]JK'9#$;,LYW/C'Z/ID/2Z/R@PGYP69<K _O)DL+?;K_HMF"/!WFT_EALQ/?
M3 ]W!H8M+RU',SJQ01<&Y/'5/EB5'VW?X_M^,*EQ?_^(5R4V\?<+S@I/H-<?
M]TLNL*5QO(/@]:O#,[;'WDS+X<[)YO<GWSK>E)0?OX)I?K![=/CYKWRR6=*F
M*$O+#6Z-*.4&??+)SYW9QSW-%R32C/ EJX3<Q!]P]PV^FV]]?WH7:+HO/NVV
MSSWQ)[M%7]S[K'6]C[O<A&*B',P6X_W#T7ZAV7(K\^]XNPV8[,P:&_]CBB:
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MGBFR,6BC\[%(",$%STI(B"V+.;_@Z^;L$WR:\ZE.W[+\OZ?972E&>Y,X?33
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M24)ETL@#SZ_*GH"V(_2.(_2&$]!V=&X@.H=1B 5CB)"S<)ZT !7;<5KC!&(
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M<T,8X?,@0*J0,38BY7BR(3%G4MC:82^X8!M>D52WI/<'JOY[-*M:#*SKCE^
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M% 7E AL/C&B#PYL%7&KF 5E:%<7"?*7PDCFA8RH<P86!30L24>HXXCYBI"U
M1[:3;0QY,@S?VF%BX6+R(L7U\X@LJX!B612A4(%YY7DJ),%34$R!G<%,9"#/
M7B K<XQ1>!.B4T*HF =*%'G>;'E><5RB>!'J(-W3\0O.I5.YX0O.\Q:C(TAS
M@Y$2R2</(F^$N)OH%PG?) FO10RC&/5K\QA.A3BPP$X%SY'3F9I;;9#6+"(O
MDR76!"^YKJ.PE\J* Q"H-V=G%YU8:BMJ%^DX_-(M%&7II1;C=@S&J*1B0M90
M("B.6&2,=X@Z8SV)/$FF-M<36;(Z2IAC-J(40K2R<HMQ5UO+)3,^H<2E1]P(
MBC107D22D,8F1R7?X!A'09::>5/J$.,H3&45E1@C/-%,Z:1%;I"=JNXR$5FO
M$N(L@OK01"J;EF9=%?&NGRNE!L&/0AQ66:8Q'J872-#666056".<*(LTTQHI
MJI)54C"=;!'TIR'H]8R*5'J\Z.L'%F^,Q#@%&3F5$L7@05];AI&E)""L;"0^
MNB!)3O@N4RTV6X+K&O6XJ:J+2GYP_<:X8Y1FDFN1>SM:F3FW2,@Q*I'R,DBG
MB$Z!YHY1=1+G9UB^<3 XB;WG4*TQ3QN&)00Q)FJY?]"FLMJ%5^'THC\X@[-1
MVE'."4!L>GR%C%@+PI$CN1VE"!'@QP9$3 K,8A5)5%L[&B]0MUVR)QY7;E<4
M++A#<N_#*NX4XT(D[BW'DZ,C<#)$\( $]A1Q;!*R4@K$B*1&1V(XJ49A35>!
M%D&NET'PN'V0B@)>M>!.>-]=2,DG!1M$"%CS"1MDO1$H 0[KZ 3U#JQYND@;
MI"*WSZ$-4E' ZY7C"><Z#1%[HPQRJ2IK=AY90RB2*=D\(AYV>.$.2$60ZZ:
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M<MQ@+-^!CP(3\\'$!$61PE+M! 8; W@*D$LP+X1(*!!'".%:QNQQD&(ZQ:I
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M>%&- 8,<1=$2F22.@D@SVXU:=P.DA%A*F[ER&)XJ@2WJI!;J9-(BI3I0AKE
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M@IM%P;E*<@ZH-2X1I:4M-[<\P<W5)&H0R5*9 W,[^XNY9T=!<$U]AZ?H1!?
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MB#1P\L!]E*J4W*.4O/QX\.QMUC0;)@SARGH".3ETCGTB2ALOG3(^*HK.\5>
M!,7@+(6R0X.+W=XPMQJP]B\M]&WL<N]C&J5>FNWO-"MM<MST=+W<Y?*&=/6*
MX]77S;=X[?D4W/DX-8]).>-(>Q^'YX/8.W9_)/PT%4'_(F4+F,'L;-5-0[N%
M&S2"XH0!QDQD4G.@B=HDK 3F+4V<&IK?HHCO+&"*5Q@%*Y3B&G-DIDT=R[_,
M*,7^W_WH;_O7!WCEP3-FH'EYZ!S;^]B/D^-+K^S*MV9LFG[YBO/(G-%%NO$K
M5TA0P#&FT28I#^.\M457_CP>?>'C[U#,1LE]("[C$+]S@X_N8KSSM^M[@1MQ
M==ENFO&5/?LJE<]YO=.=B@)"U7!ZJ/]=HT139OYW][ #Z!V/"NC_GV\K@M[9
M/RH0\/>_N>T:=6_K1CS,6S?DYI8MPLBX&?D"U5X+=LXMB)$ZK/$X>(I-9F^!
MFWS-N5R#YW6=(A4"-$K':$<1Y:<9"X?#23K"=_PP&(8/#TMK\+\O+VF-.'S^
MP^#@TPMV\/[#IX.37^GAO_[YX=7SG]\CE7E_@,]Y<W+ WSQ'>C-':T)YQR<<
MW\6KHX.+-T=(B7[_"0[_=8!4YN#3P?N?3UY_>O/A$,?ZGT\?_D3_*$3)D@!&
M/#.*@ 1)C'*)\!2LMU++%-B4O#994\\*.>3>&"=\]HXY\#$:I*K.>I]5 D@J
M[/02<L6S8@!'YPC KY!2-!46OJS_+&6D]Y>2FO77N;C"->%N,8OI-GUS#/OW
M+$Z_A.,4SP?I57X6POG).;*'%)N9+A"T,LL&V9^PM'TZ?/XK'#Y_!P>?2EST
MY5M/E7(&72Z1@R#@0R9.BDP41&H<"R)8T1:E!1@WXV4"@><*ZJGNQ:#^<>Q.
MWQ6B?XJ\/!PW7'UXBB,I3'W8Z$BXIB/]F8X,BH[TIJP=7;3!8/CQ2EV1&Z!_
MMBQLX3K@M*>E3#YSVR8@C-,?N+-Q^N[RA^]C?XS^QL5W_=-F/LV7OK_^A@59
M:,T+IQ]_88I[=,H69[EULS?//MYK/FK%MZ>?";VG#+_Q8[K';OSL:X\U>U3
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MA%2HDTYZXG$GB$=O768IHJ,.V;FI.OG8=%(C S:26\F\0F=9FI!DM($#[GE
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M.6BMKU9FY+1J8-^.RYRLX%ILL:#KWABO=1^=%;XZ,_0P>V?,=I\R9A[,ZSU
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MZ]^&KJOLA? Y:FFB1)4&0;--1C(32_!+U?5;U/6UR#:JI,Z62J*,8FA*,$X
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M4A.7LR) 94P"KYAH'ST5MF^9NG>$Z1HG-6[#_WRS\P /#\ZV$,<8!22G>/:
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M57#&&Q(A."(3VO+ N2R. J:RTL[0C&#4UZHC+H+JZ.N6(5_5^4[5><WP9Q3
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M$;N??U&OBD"_CL/=YT&]>O[/]V_Q[[V?7]#_?BY]"'\::ZA1"J65)DFDHXZ
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M)]-7_EZ"%('N&/A5^C0#H@#5H+PHO\.C\GSGBTKA2;5J.%J>M E5DHD,3Y:
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MV8E2!Y8OPH,=4MW"VRCP?%P[([O7=5"_DQA6#EY9=J\2'7'/PCNTY1;PCH^
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M'=)S#5GYX8OE4^<+,?+@LG%B'40G,F%T1H(Z+6]I9T,_TR!&.TW#*/B/,$H
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MB&B2'T]@9!F(Z:4/9[?>,_'M2R0O3C;#Z'.,EZ Y-QERY*5?-\S<JX]]GV8
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M-@CCW-#H_;91Z7.H,";\+ +&3@'&N N&RE7Y KTJLMH!T/"M_M#WGGP,2(O
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MGL&WC_#['3AD_QB._6#,JO\MR4?_&:-@1#@"L'QT'2@*@LCER$?6B$@"B2X
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MC994QQ+=N+UL7.^.C_\0!B]$>H%(;Z@N:M<<%M-5<@4H88*2)DCRZ>'O76N
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M=Q3)S--(D3L,[:9;Q><LFG2P?F,WV24+A3VEY'1U? 8(;R:A(:YE30VV#MZ
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M\"VQOO- !BSKTRD66O/3A.O8DEA6'(J[KS-06C8W-+=@<+SW(IME3["O%MP
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M0+F8U?U'>#%YO\Z7R^>\GGF&5]/9.3_GY4=:K.73'KAYUOJY$Y2Z&/X'$&,
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M)%&M<R7%JOIS\0:*,1UK/ +^'2+#8W-N<\_A6J?*UB#=\50(-*5U-<ELL]4
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MR389A\X\P).M'S:F_6POZ5X//_:?WBZQ\_M@M;+.ZX F.F\SI@Q5",>(JH1
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M-ALV;6H<*@MB2XAC<F"/3+4^8NN2 W\/P(OFZ\N'NZ]/-%GA<C0@HZM@M$Z
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M+5[6S9#73LORY?EJN<)98;@39X0C2PD4_PLF)H9+QH)"ARK%4BFXSK3:$>)
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M FE^7BR=K7 -[A0GZD4!KC'5W!\VU5>Z5H):G&U5@8X"/Z1"^&Q,E%R18$Q
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MEA"WCZK= G#<&K._K"N:OBLP[V:G,"EQ*A,X+2<PG^$:&P)]ES_Y+P,&SAE
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M!T!]5[3-BE:3SQ[N6GY>]Q:\FD\F*-5!XDE(:AE)"4H:*7I0P25!4G </X_
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MI9*GDJFKA"U87 06"X(B/QR\H359CM(S+0U]=S\S=0]BPHZ9NKMH9-Q$S '
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M7VE+_$B4K)]5_11"_226W_E)U(:5&M74J=3Q+74D>*:5&FUL9"ED%EK7" R
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M/X^6NB S:)G)!HLB\=)_;SFB*3HF%W:1=1>W9)UB\.)NBL'% 5C;<4ME(X3
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MM^7%5WI<=:_(2Z[;V-6;KNX% \_.NJ0 HZE)-YK1F64#^$QK1*YCPM8!RYT
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ME\DBU294[\-RG;HL-'(NN %>H@.EG !GHH5 L%T1Z+0MG3EQ%]7X!D4K'3Y
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ML7(,/%YR[6[@ITK%W;?;LQ=E[SO+MY%;_-;&=4T41+$(!@G"-NJ_UMH-@W%
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MIA2Z]]O8'-WT[DTGE;Y<G]!#'Y-X-@^1_CR??0%;O!0Q<S @0F"P50M(Q0;
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M=>!S26"TM)":KU[0B1Q(*7;EGM'U43)@#Y+Z8P;L(2*;A $[9*\%90^EDF5
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M*K9RCW:O$U$(IWW-#SD&7U-!_ZX6LVWM_A"MC'!\-.SP0RI$4U,"1=(R6*\
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M5[SF19CE90+O_BF* -79R"NTEJZ.?[VS$=1OQK:=UD9@<1T(NT'^D26'%VT
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MW18^\&^M=L689$'B;5"'W":_\1 EOWBL/B:C2<7>U?W3C.S;+#E@2YJD]\0
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MFA(A%V^*\I['TGI<X\MHS7.-%LY!:?J0,9RRK*SL+0%<(YU.YIO>0LI&KI*
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MVN*]MV"\-:"*JVUM P?'+;<V,\9TZRO5,Q] U83VH^1\+N'MCG$JDMDHO.;
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M^5%()V!G>M??1U?VW_6W(&2 L]/[WR;]^QB70I_D!QFUP8080JE5GHF!4C:
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MG,]VKG-=Z"/T2>"(OHZ>#L# P  \![\ ^A2@HNWOX@@ AH: %   !P%&XR,
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M38K7EZP!VHE0V%=V^"ZB\42]#"H:@S?",G2=R728#Y],U/S(U]U36AUWD@[
MU1))N'H$-,=?IV A[P=\;=+7>2JZV:$O4%_*;4BV9\T$YK79 HHGB[CR9XJW
MQQY_.HB+B,JVYD2"'_$3*1XG=[X[W)C /E7I>8O++ [2H:!),M]4)L!:H7BT
M!B\IN9GY;?@;&U=FZ&8';^(W.N#W;7A#^DR16I%H3/>JP?ES[7<#$]Q^?H1G
MEJ&RH0"A__C@&7%.'^_$'='DN58P3]YLV_A@K,T-_%F8+\E1!&()HEB*'"EQ
MZICG#I-KTJ?:2YD8E\CLX!"-#M3V-W1[ 7F8QKY J")"5L)P0GSCG&[UQ].<
M>WXD\4WZT(&V0YAYQ?FY\IT/I>O#JQK;36?<FKS$^383O1#$34M8+'(T4#(;
M#.T[__EAVQY[_'74=&FL>C@821MZNR?ZF-5+-2S[A,7,!^N=I1D[%.S\\47O
MQUT(-47R%)C^)V(2K]&!)^X4@P2U>\Z;I#@=N/E D3%&1Y$$@5D\;]N6AR.R
MH:_4[K__X7DYV56/NIY W1<EB;Y/N?6GWE=9]"2=6HNT:D+AC7N XI4/BP8(
M)]GS7]SX.C:AV)M+J3N.=?TTEN1".G"7AD6P.HIK8F#/.":VJ'-VE'IX2-GP
M&V]<3N!16Z-U]1_'WB\X7=3/*&BD S-?:,_ ^BD4VM(_>U3VV.,_@I8AD<EN
M%&GJJSL(DF&M1_;/;5<&WGTWO((;8I[(X-AE.;8KIW\4''F!/6,ZVA/5>KWI
MAD_)^>M1$^VY]=M9BS?-YWI:?VUE+6NRU$P8GYI_[&/H>NVF[9(?FP-KYM<2
MW3G5_&WGKN T@A^-[0Z!#N#2.H70D>[!(DXGH3]W>9Y<OK02:;\A!@F-VOPY
M,Y*R."R7O]/M@IOGN#T>J]Q12,/UKR5+D=.@/O?NV94]GDW]+4JR=<[/HR!G
M(-'6;AHU[CU)!YH<'8;J)?R%6YUIFY#QLWH7Z4"E:PL=T*<%:IP,MB?XM13V
ME/L7M@B?(HB.?@FY89RZ\IBX<7P:7WROCC]8H_X[;2987*E-/W:<Y:E!MPEF
M,H$R2A[$&9'.#"]/3U6=0T5<WKU^WZQ'M_Z57:9?@*HJ(DA=.FH ,UF/8'"W
M4'M+>#.W/-.4*SFZA3U%2T$W%TAG*_,*W<-BZ0"PL_A#T:D?/G.ZK4^>:M\S
M!!DSI[$R3F))4FV/'$GL^#8#@CHZ1LW&6[#R6.!L+>^G>S+G V2W]7+CO04/
M,Z]V6S$^\H9!$<U0C!!F?J,!1E),HP,QYBE@5K VTX^9S$$=LH^E5+K5?(QL
MF+5MG3KNO7@<V8J!NR&/V=YBD5*XX+J[5(S-VOHNES#U$<NA-JQ64\@2I/AE
MQUQ*W\! W5,"G47*HP-':!1?.H#J84!,#GG2SNE2M,B$<1I"C8D.A%I@2"WP
M(6-KS/@KE-S'74]2:+ ZE0Y0V&@,?V-17>*<1.<JQU[!O8)[!?<*_K6"EC\8
MP3#0@F)$#:WUR:+8$W)(KFN?,8<5V4*\;X;K8US6')Z<OODA4EA!QWOD_+MM
M'K(,3(,.--[<.KC90Y*H:CDM.E%1'G^D875#)W3KCKG1A6;3U#QIRVOC?LKG
M:+PS ;[\;^]HH3)?6$\'V-B>;K>Q,GWHWXVB \P'*.QUH<&I1LT&.MT7#-Z,
M\^Y2DL] +1<4Y$BR5<O;A1YDG6J<C-R#?*AKK[A'[A9S!\>7M3CU\[!GF^8%
MZVKGU[91K_H):1$B!*D'6]%44>1/D<]0O"EJ=+YU.;L'E_3X\"K*,RX$.HP>
M$[GZ4#VD3B<DJ '#7RM T#:M/8_#'B)%7+C_L,N$[>ND/1THM!M/I3FZ].I_
MTR_5^1KW5+XTG4<DZT#U?-,FME%B8YB"=&.9SM20HQ:RLR#".J"H<U1M8U@W
MXC-FO']:J=$12>/LB;0]4_;L%*N58?!P$ABPNCMB(335;J80=;P;[3 G*7]R
MZ GDN#^B24.A DFU+\EQJ2I%-$Q/'*&<+.:OYO%?.H":HH;,C\[6*]I7C,7)
M'LTECZ=" X?I@!C4_ATZ!KX/[/>'-!:*M;.'SU*&58/*B_![$Y;8K^6.=,#1
MOPI0GSD(O4KUGNP1<D9Q4J"'BZ96[ R&']8@M\Q30_JL&R5ZO[V$9@3X?-AR
M4;T9K;L08(9(=C2>;S"+-1+=LBWTV= IXC:^E?GQOYJ3FTDT8X0M*-(D+QP'
MMROG]ZX\DJ?AQT%9NRI3ETS)4R[6)^Z^+C$]L>]2M[RNY3A:B5H*G?E&DT*,
MH,!>6^ >F"[\H(Z,0N D.1XA-B4IMT&QS3+H0/L HODZ!* #/XU)8(C_I$B5
M#B06XI]%K>V6<T"7SD/],']S$8TB8/=KS\0:*8IQ$D)EA1X'9TX>8MT'0N!F
M;H#N<L//(B8+P01I9I%R,AM9>$FC[/QV$.W4(Q(S';B,;.6@\+A@*1FZ%&T&
M/ <M#!(#(4GU8W94, >=<Q:_<;S_2OU!!R)>:S#0@6\YA% PW[+THP,2QG2
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M4%\*-R%41=?JXCJ_)Y0N?GI:I0.U/]PLN<GVB%G3.M934(I\]?.M/*(Q69T
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M_$9H^K>BJI6SZV67C7+C%>)13HKS \;UCROSMKHF(8(+B*.U[-FDQ-\^&:Q
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M.P%LZ%L5NQ="7H+.MQW5/_6G/O[S NP]K[5F8V\<]ID&5]Q5 575+EL<="T
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M66&)&\\[=']Y_H?H 21)'$'A[5]97Z QDOK?G;HR[K&YQGNMT;1'VZ#_6V
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M)D5)#^EW?%FWJJGYJWU.*X,ZH7=.V#*#/0QOH@-Z.>B9;LS[GM$EVI5CC^G
M,@STWWW.2TB>;TN?5[L_@][K?+DTDIJ%F'GL/TUK(=,!JGA"#>LT'7"&@?5<
M_%4/'0 KRLT3:J!=_9D=M=4C^/?LG]]&D,3H "77:!)-C>/WHR$M:5EN.[]>
M8 OF>1V_T5C!=&(J#_%S"[W(^]'+*J>&#?_+<KU89*69@$&,YXXJ)@I%O.B*
MW;521)B]_%TT_TN,JV9?-@(ELVNNG?A[EAR*RR81;5!>>!=HVA]BCOM+6]9^
M"];*U9NSFK"JE(=&"AEU$#Y,Q3\V8][//_/S-<>"%HT%=,%,^O@V"K?Y5-P0
M63:<<$PK[%IU5OA4.!NQT#V]]E"S5Z=.L[23Y-J6 T(<!<#5_7.(]J3J;-)T
MXZ<7J481"GS-0QMRIT_\)%RI$U8R,7V!-XU +]R@L6#)_OZ>-%8VLMHM4IOV
M^K)/T(,S6]03]0L*:0VO2W?+#;=S$+@;H<_,33>6>F?]K(3#6+]W]'A/@",R
MK_+["2L]0P=(IY$4GK1?+S4',R.6BO18CDCX*=<CR?W!JH=&G!O)91-GVZ,$
M-WNZQ \:/_I:<;Q:]92#Z,O1%43Y_(K-I-S(]E1&6[3&"?\GPUI]N(Y+L1O?
ML9TQ$:\C@ON4-XT?*=\M8(&$P? F<B19B6:C<4<<N0E^/&&M <9N[X@DJXQY
M5(V5AYP/D,^\N4%^<5*Y*>#I 70*QA4Q-MR&JG1J444?\Z<#UFEF V\[K#Y#
M_=SRM-,C;D?G.JLSBZZWO$H('JO)OS/@$Y2NZ'784N97G!6:_O=,/%HH8O([
M>D<G*9D.V!UX0P>RBD*PL(.(QFK8>JR,'*V5'<PHM2S)];6?L +J^HA]H *5
M*4#W(29GT3M7WB13(XF078U%C(;;I@#ML"48(D=9($908.:;LUJX,5>G#]VG
M!I8$2Y6?_S?]HSK2@5 SZ R"!,ZJVU1I.J!C8S[3!2]#-!9"UJ$4\,\?X"_!
M*F0+^7]M41^ 1B!'726S:_O[?J?+.THT5C##9>(O!Y4EA-;-]=W%V\J0P-9R
MV4#NL*7&\<\CU-GI_"7!$Z&A3:JGIIDB=D6FPUM1AVG=6!8?.B#@7[KS< V,
M]7K79.?42DQ_1D"C=-VEWLVF/!)RVT%2:S#N:$[X!*K\6=7TBG]=K;DAT4/:
M:(.M[8W%28V;;*OR%A&M\W[NAR8]+R>?KQGY7'?-U*%Z9JR[Q \G8[MT?4"V
M6,X3_38H.BUR1MY +:XE90)YYFMS@I%H:I$VS\_,^_\Q<@_1 H/73%"0 %<(
M_CIRS&Q8KSIN#MM0+W@.2\K<52O^(N]K)>*;].!]06!!>+#0*RD3/9N7QRN7
MD668R0DT2=R<V$*!EC/'OH?V>@CA\![I"\U]3TP,+X6.'C:1(U;5'QBP(PO<
M##XWE0%MM!7HWPP1[\9>Z]LL]%\YL^+Q3=3L6VN6,8\N@^DE()"USM9!/^Y!
MC;K*PP$1>S!A=;SU9S[P]W\2\QC:&!VHX@C]M2+S3-XM4^3C,<LBG,H"OX)<
M=(:9<1RS37RQSL[!SZ$34876U#*,NQ$;K05RH)ABBCO-U-+O*"1M$'>IBK^H
M^V*LRI2N>?"1PA[1 E0#=LR3F$PP7W$A!!D3DJ.+AZ:OUS7?;SHR[FFW+['T
M8#+)^$'@3((!UZV$$/<J&?_P'F@87$-W3OB4?ZB1R)LM:[$WD0F]]UYC4G;H
M@-1.G5()V80V")>G?M X;4TJ;+4,'RM..V=IV7S!<N&#_<MGW#0>OL4'7P/N
MZHG7_HB27A;AX>GDL4=(W"TQ+5%T@''^?^^F= ?5.N</;8#TIAN-?834]XFY
M%2;@?WC.HX2$-$3>+#-3XRM*+_SU3Q]ZNVH6."K@#X8+X,T8(3HPE0IUQ3+Z
M]^DZ+V^&&#+M6,\O)X2RMS)[SUXA";\VE[V K,B2@L.06@O^4"7:U^X/I%%5
M'7E]V%1RC5QC)4*7^P\"I<?0CY__Q'3F$$: 5-\VM?UD*R3()+&]_Z'JZ0JV
M:@Y*692HBR"--7=X0XL@W>:'XH:?6OHA/I#FFX43TIDVJ5;N61./S_4<C(6/
M(!KO:T Y0F$?:/DYX]8!EFCDO9S>DZPD+P;J;)/=IU?]G="MD<#AJ:*0:UHZ
M [.F6_VKT%2U>]T\UCZ'/G'H>SV EXX&)V"HM:"2!,U/-?ZUA3 L"J^/)4EW
MS2_O^.0%JY->!FAD3>H):N8M)I3I0</+&LP6;4<"?6(>=L3F$*4-!XJV,E1^
MK'?C! H-W@TY2X0UQW^-83 S$Y1__NMU[NC9N?I=T%3\AFB\.4?-K$B#/J,#
M1RKX1/%"FT_496EV'TEP1\]/;>\J[UY#S*>H/N.N"*:YO,R7L(P:+EA;F(,O
M3*$C39KTE:]Y2/>/'44XE=O3@>0RLBK4;XJ:D)W&W:EF(.J.%GC4T?'@N/!3
M?I_@:JKDW_UJGSDZ4*E+286T&)&/;B&HIU+K3M5BB5_H0*+6KW_8<A>.I@.Y
M-TQU'YYV1YQ^:*P=V/;\K]:URT<'#LS2P @W!^-NA0S??3G\\G6P215O?+B[
MJ.4+ALR)ZH6ZJR6W'W2)PE_NS%L*<Q',LB9A/ NI<XD^8G&%.38M(0[>?$WC
M74?#8X<G+#0A^BEMJ1>DN&9?]BR51FU 1^:)<?UTP,US-+H1P:E !T[?:!YS
M]_[>)+!J9?5F1_9D#_5\BKU12#7Z*EIL(6M)PN?^']ZEF4^DL5')MZI6A,@!
MBZGLL<,94]AGYR <E@7U=FX?_&SUXKKFX3]WHQW0XW1@O(F87D5%0NV1@L&7
M4[*4+'G3L:.]5^!6T:,'HT8/KAXJ3FG3/A1DOMY3N#AL22ST"0GR4AR<74:K
M;72TY*;JB*6\ROR5[>87UY[QF5,^=Z/_!1I,*UV:_VH_[JU;_[M:NOD?;0@<
M;J8#QQ9H$/QJ<DB16^#[;#95@8LQ9=^KYUTE9S(Y]M6%TX009&U$+P\I'M0X
M93!H3+5NOZ?(2U0[%06&[F <L0*V\3=SG"[MX#P=P#G3@7 8K1>VJ0T714S&
M(6CBR?*K&A:^?^5REV0(_JKGV*FA'WH"D^CFTI+\NT<O??0]X?TY3!1U6]YY
MSJ8IR0;)EEW'U@HI-6KQ#(]7R#Q!<B"P:<7J6%1P'/YA^>A<>@(AKB%U8T?$
MV=X!/"Z>B#GB6GQE[(_2GUT1&DLR.=@-BC="CUD9$;1KK&W\[4Q.V^$,SPE$
MC\M__X0V4CF3K-5VHOARC=-\X&D]\?=M? JKR*6<1EN%/IJ(/]2 <" \Q+/
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M^XG8+5Y![G10L33EC;0@8A"# /:@Q\3&$K%R=/\I6/"V-$!_%N3?396#6Y.
M95=,_6[9<"2B'MBW=82U%!U4B ! 8J:0(D;99?,YC15X5LP>T9L:0^ZB*B^4
M)+D%)!J0NLDUP"KB_/Z\%O6W*_EC*PKT8L\?^*45L([6L"%AMS]$_OP!A,@8
M# "0. K 9PM>0J@'EO9<T;.Z?T(Q+971H4*#T*#]D%_FG=_IXQ2&(F@'/&FP
MM/L>[8<P:^_ X56Q*%R+<?[98S>F197P!P(J2K&G5CL%;"\L(QY(H$AH E:;
MU$MH;Q+F(![\.N98*YK_0:_F%1UTXF[*]?KEQDN,3P\S/I6XZ2EHYZ'RYFXD
M<CHJ;*E6@R+<AW 8CQR[0-#(W7 6YNS/>U;Q4:K_?;/(R;?:.Y:@QJ&@IPJ+
MPK_+13$9'"=HKB$+84< COJ6I,AW=KUX7"!]C+>:<0HQ#')DPJW(U$$XH8(#
MN$:4H#5,EA3TB12CK^K)SNZLN)=4\%WF@NR%T"YRVWD[@6PN/K.?M/(O7S7X
MB0<QX6J7,A=+'W4Z9(UH>Q\0B8X6M^O":UFC1;=^U6Y,,H(D94(Y <B.J_ZP
M#$5ZHN9R)V&D3DZ]-&FZ];VG2U>5P@*61>[]E%KDBWQL8@-&!X&O191-P5M1
MA6N44[7@ZHNDJ<F'3P?KB*6BO<4$4$7Y%DO]*YT?,Z,!'3[HN>&JBWVT$66B
M@D8#@(*JV"ZF_NY8?EZ#&R9!Y&E9>ZT"#8*)I8VYC)T:R.3>-E;,JM3YN.X?
M>_E@POL@(\9HT-D7%VTC/[\U,DIXCP?)ZJ![D"0Q"$6@=9(.0KX9]"F:.I$8
M\H(BHCCTJ;O[BHMYM*= ?P#W%Q\R_MMUN-8W9[(+[0@4V'X( ;T,=;"=DA;&
M9I*J)@,/QBF> QR,L-OJ2#!8K;&ZXX#0,>D+XS 3(4OM&T+O\JGV3Q!%7<N-
M>/"0=MU;DMO$6M FAF5!M_A;:0%M;^7=?;6>TH<)1,I=.;#?FGAJ^9K_]\[2
M__"H<S>0QGP0>(LD$O N!P_\>"SE&7Z0L!9U7#+.6JPW]9>%P^#SWZLEFZXB
M8VGW9;EZ+Z$SY[]&)'I?:SN7+;?K3:W X),1''30??;7T$&:?$]'HM%4?D_)
MDI9#[Y:1( 6)C+NLL:D78EU^_BKX*'I)?PI2#V&F_=B?ABA]Q*?W:@&1/63K
MWI"[T[,$P_G%1I:H&J.^8,-O)W%X*(7+FW:X?])M4,RTG&@2K+<66GMB]#NW
MQ/8=G+G()56;2F:-M<M%(*Y04- #!F^#O(RTGQ.YFEBC@CVK_:0&1)M\,8;,
MJR!-9759W?NS:A.LQ92#'20 ,#=FB>  R!^J2O98_Z3\Q#H#'"!LY189]+NS
MD3_+LUNW_Y/:^4C$1)$SN$E[>=_2.RW\S=P9 -ZR"4HPU"==H:@KU4$8%\%$
MQ8%3[%-'R\$?=$U &:]%2!E,SP*+GYN@9 JV'2A<[-LT@"+A4> B]9U0OMR\
M:HN<Q_F$@0^G /FK*KST]L5<VRNAM1_@6-FCN0AYFA(Q+Y<HTJ*2^5IAB1QI
M:#ZPFEY;6YU4IN,A'V$UBLQZH.=ILS"Z(1?/8=P>R_?,0,M;\-1OS::ATYY_
M"_J+II,3(\[$Y.Z%.XW'>:)-;(.,#%H?W "QZ2BPPM&(^BH,X=9G(O+U21)Y
MRA5".Z-RJR.9O3A9+;S]W1EKRDN9PK,';=6G67[R]A7W)89527T4S'CH#Q O
M1H?]EMOU9 9XEX1OWG##^/%J!T%O\^6?<D[$J <%5Q>$GT[[+QQ]VI:%+/B2
M6EVATSJ:_/%!:@Y@,[+$_]DC4/_;+;[7430V9BI:P)!X-I+@IEUI5]9[Q9EV
MBJ-4J6/I@Z, M4_#B>GD[EOA;.AG%*^&^ *"D<;M$]@\W)=L'3_1?J3D:" J
M(4Y!L@0Q_."7@)]O)':K25BBH1%I@FC2)"R-.^M4HL\!U?5_XO$F:/!-^/S7
MBU]5SP<,UW0@CW89]<=U4[I:JA].:@>VI\49P*FNE$]E -!,BD^\JZT .+T!
M</O?]:7_FH>ULD;AR-S>UA_^@'])NMJD-.: 5./\Y:I,[,;9K(<7"RPWVF4)
MT<)PUQS]-1#8 ;=A2%:!(8CLR_5$Y#5B6?!CM21#K8\Z,P4:1C^U0T^^82NH
MG+FQ]%V3\1=(BO20[?9[PMR*&\%0!_BI_:C#E[/M'QSNV_?FW6.7'=/??O.V
MZ_K='.7[^MC90; MQ(D]B,9"RR>411J[O-P+/@_%I%>NB>=R;EGH3N\EAP(+
MBX+G_T/SU8;FH@:8HK5-IR)U50N&OS*)Q@PR>\+=  5V1^!3=?%0-BL8'\&?
M#J+<+GE]F:C0Q]X9F1T1?BL*>?Z-I5=$0%<"]CH/^_DM+F4ZJ%&8_;C[(8$S
M=?K@T&%5J<*880D<P<2?'8G!YX++7.!#J&(&\WD<R]A!PG,=N[0@B.12-&.9
M ZV2ZX!'-Y?/P<3:>ZEAY#9YVYO,'Q6UB1JNB0_D+MC=\CHWYN&-2+76<:Q^
MLU\4-QOT%Y@.3[7,I-75^F31WJW(\ZLNK(:Z%5&K/;/<(V>J"_(?>JJ_OG]X
MSV33B,Q%Z^6&E'0MXR90@N:^!C\7%2<E;XZR4_RLL>OZPBH!U<<KIM-.K4&_
MJ\/#$/6UF!()'Z5)6@4!?;?<)M.G\FQ?<;K#KFUM$,3GJ_K# !TQ6E*?-QI\
MJ8%\4Z/;#=R.WD5ED[2;D-*=M PCVBJF:D&!@$DNV,W#+C4#M$X88?I7%O,_
M6=[]FPO<LT,!W-UV%1T4_(T:I":&MAY5Z J59P3 /<+*P;5'?;3PR_$"M;BX
MLV%W_1_:#-<FH^M1)"6&[4HZ*$B2; F%7>J7BI-DGPS*#QY_[FI:(O&DZT K
MWO=M0EK=3%*J4!!\PR3!7+"H8*$;)?\8D+>'SO\J>#[QE!/0[?3P;65JI)K'
M5)>,2-\F^5!)#Q=F)H-"!U66396;":JRKZ;YF:PO>'I*;O7%Z(G&Z,GQ1&L_
MZ%B^K2.ZKJ,VC5O$4@2WR  9:= B\M1C#FV.1 _4"H73C@LY<=4:>LH6>W7G
MTS:?["(W*Z%^E#3T5?:CUZE=$ [5MM&7?S<77F*O@YJ,F0[P =.: 3=Z-@H3
MH_+'TI \-9.KZ*-5^ST2R[__^&/WP^4_%(9\]&;8E4L-D\"I_2X]$-V]1E*@
M@VCZ2\WCV_IKD,VIS[@YUC^E#D6Y!+F;$'Z(]Y?4L/6N.W_7-/\AXXUJ;K(>
M3[9%M([^&D]N-*:#>H:R@65<DK$0Z9Q/#5M1_BT]9=^/Z+T97X\>#T1M7]2F
M@SZI(_1***V(^E.8F3,8)LCR?20==-F/]L$EA(LH\K?JDW\?B$:-DP [,7$"
MP8;!IQ8N/;F>#8ZJAMAEWS#)3!(F*_)NC3R*\/=VR'/!FU.=Z:# KS#%TEH%
MDD0.K-9N*PYM?_OV\M4S'R*B4.L_-^?RGIM,Y_J]L\(C90N+?RV7_6VQZP'J
M?N!240U@)4=V*)S  @;2.V=OC+'WNLX\\E\X57;#<E/(7*X7>2O*9<1EA@XB
MG5Y-D\K<3RHD717MK,#I)AZ[C&V+]TBEW4RM_80^B^!4=X2)GR\MRC$G>6M7
M]DGGG2HJ* A:E1)+:-!F=,Q(&$S>/S'=_"4'5P<AN(NM^(T7[2S?KSW2L\H"
ML-PLU074N4;MS.M<>2-HXN.PXS)M';1WU]6^?Q.3,AU%16$(=]E'#BUM3U'1
M,*.I,M]@Y(7Q^S\^Q9P<7O@1G<\"KNR*BPUQB%UJF$^M,<V6$&F+<1T%;,>M
MO^4K<IU)^C@<.6V\36A5;UH5"1/O*_K6A!=GB-;!'[@L0 <=IATGA4^AFY+
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MM#QT'\P\Q?!I*)'TM_T)"KA0-;N\01_$]1*P_(YTH(CM*1'-N+??E:\=1-I
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M?0P3+^F@74G81GMFCEMT.OC;RHW\U)0]$7V$(ZSPHEHPXS'->2V$M2?IUXH
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MK,K4J$Z*"<GL+=R9Y)Q'TFX8AIN^>S+%HR/AFF<]J<OS@O=8V\=%KGO9H$
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MLZ+:<T56@3V0_35%'G624@V9+2S"T3'##UU?I1X-;7/;DN**F-S^/J!5E3B
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MAZ'@ORRTW7<V*FAU2/S-M3 L7K\S;&+$@J57945XYY7C,"ON?-;B>T@-ME8
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M: D;H_0S:U2^"E0#PURI#$SWT]=O/^.EY9\XHY*]Z79D@%$/J#S\8=3[H?<
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MA62#&/]Y^Y:\I3Q)*,"I'@;MFH:K[VR[20<=I(-PPM37,(G)7_ V.*+R U+
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M5:-O[>SL,=P62@Z@G#)("9&/RI\2I28]40!_V(TX0+3=UJ#M%WS.2-4-&8$
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MH9BP[3VZ-Z360HU%+[!GM5+ 5!2,G:P]!QVN8R,@(V$2SC&*P0Z/_,>]JI-
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M3VZ+VU T"H=+,I(C[=Z)U];Y.VT=F(L+C0S)!1"IN#Z"J1:RT3R1#JK,V?Y
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M(F*28N(2OP[X/RE)":E?)[]N\O>N:X0%!84E1$5$)?ZG#WX+(".V9JL035!
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MSZ,%YWA:C,E2V[SR+^:165&UGA=>9'JAQ7:=C@C0MEX7/&8MP_; O^$#,N3
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M-PUEC0=X:]>Q=V_I>BVR'-82$('N_Q?UPG^8R.M V@IQU8P(3X!UR S)W:#
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M19I-,>HR"6\1X5J_J-3/*7A8)N^&UHJ)_;>"_ZO=PN30TK_Z\F:7)L@'1/+
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MD"3G<?N,ZI-1;U%\XU U&/&'B.#TK]A+7F\[CAB?V3NFU+J.*EU:RR,FD_6
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M^XW'%;V.X.6ZPRZHB.HUW2NEI)B-T$_5;(!'@<D'WZEFV;@DS,;GO=P5*%7
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M:2\GG83?YQ=68X4.33),3L@UGT,0FPUC!\Q<,H"_0GW]B(#&L)8?@EH-,N$
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M5MCWNYFFR+7?-_6IWMRZ B>[N@U_V_ W\(';O:*SCH\"H7>,5[7BSXH]7,X
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M>.?-O4A*["2O8>*,3*"!\HC&M.=6ZFY::CRE-U(63#\3)$9'>J&(\E\.06_
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MW-P(SFK5H5_*@[FG=3V+FT_<D?JVT-[>JAUCVOD3(K>1Q'D>;"DD*6$$.$N
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M2[-1FZ"42FU"1G$,XC*%EL#^[+V+1;^R1<&>Q7O;:5I".72N7]WY:(9=ZH?
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M;:Q+O]V3(:T+7KUK?@84<TR4,J>>G>TX9QK%@GWQ,L\ S2VS(5[#"QF)W9)
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M#YK8ONQ3&W&X62TJWRW$,!(2^.4-[C4)M?.PRD8V\T$,/RY%FKF=TC2L/Z"
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M' MHN+N[3WH JG[VQ ,5K2-]'[E=V"ZOG#CILJ=5]]#M)?'28X^M'C=W^)D
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M62)]JC'A6<8SC2RG4V_9<AVREU%W!_"8'UAV/^2CE)W5E+#</&VL^$"$9XE
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MZP7C;&5G)V+,JO?OE;VK'G*J32"QP"IQ52X=!L(I4?2=;"AVNSW787[Z&3C
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M41V)3"O23S4W"IY3 U0>E7F !TY\6#"1EVMVF26DKMZFR!VD!DK=%Y$<-!J
M$"ADHW7E0U6PG!UJPMF60A7*8A;W0"XVEA(!^H,M5,DDC%![QT>S*]=TG-^V
MJLN+\,],_;E:,;(KU_M6+3GN -L$2AX;]W\W2LXT3"]>22\$(GA3'UC^8![
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MN>M_//?S_K_O_[W'_VAU7"/FNLYUGM=Y7K_S=UYK(_HD8@&+=]DYV %B"\2
M8^@_0#0&*&P_23SA"7@"Z"$FZ@5L@ 5B\\?\YX+Y0T)\_E-20D)<0DI22NH?
M35I6!FW24E(R\C*R<O,'^K^%\G(+YW^9%_)_#ET@*2XN*2<M)2WW;Q^B-\ 2
M&3'W!:[B8JN !4O$Q)>(B6H +*JCY#_4$P/^KT-L@;B$I)0TJH8\VJ%X,:J^
MN#BJM"2J,?IM&/H](+%$<NG*#=NE%)V/2Z\ZJ[3QRJUT&>T=^0SEO2U<G4TG
MSH7+RJFHJJEKZ*[6TU^SUL34S'SS%@N;/VSM['<Z[-JW_\!!%]=#ASU.>I[R
M\O;Q#3P?="$XY.*EJ]>N1T3>B(I.N'WG;F+2O?O)&9F/'F=E/WGZK*"PJ+BD
M]&79JZKJFMJZ^K<-C:UM[1V=79^Z>]B<_H&OWP:_#_W@34Q.3?-GH-FY>;O$
M '&Q__OXI5U+4+L6S/M >MXNL07!\QV62$BNW""U=+NS]/&SBJLV7I%1VG$K
M/9\AJ[UI+U?YQ+D6.14=$[8N;]ZT?UCV]PP+_R]9]A^&_3]V]0 +Q<50YXDO
M 7  -,/'"B-%0  >,J"--O"8;/LJ2F]YC9:,"+BF7:-Q75"9RUFTV_5QU/26
M=-=,5T_-"_U#<08C&.A:+R)W7P0X7! !C1%E(J#^B0BXZD3_NH9:S!16@$,3
MEX3(0\P;["\[WG"BLYY2IY*(\!,_*GR)#C[YW?5WU]]=?W?]W?5_VZX#,XB\
MO B0*!<!X5=$ $,+T0RQY-C74"#]K+)^-2N//'Q6KYOW)21'O+=B3Y1C?N+I
MQ=OK))7G9$6 =(4(:'@.8T1 P154_)!,QF4K$8 L,A,!=[+(72"?)P*R&X9G
MYN@ R&HCSN[R&@T6 43L'"D-/3>0$:W_[[4RZDVF6J4FN9DJ-ST>2U<C_9EL
M?+UB0U8#2/-M=7-<V^.VHJFQ86GA7>>&GFQQO8=YJ^KY$\);0=AN93K1P#AV
MS@/6/KK1:7N%_\!NP]I7NSO'! O) 7\T>O067F#?W".=U^)NP_7@\X7Q=&]"
M=Z&KD(8L@L^VF39']&%+Z=3#O/UFD_6+'EQP5@](_B/1-/[BV=C!KP/';@X<
M% $C30)GDI0P'UGL2B()DRM75'.H,KZWFQ52\]P.-4L$8Q;F*J4?#&EY>VC)
MG=27C0^T],7I_S"JHI3%''TJ,$8^$M1)%P76\'*HV"LOI)X=RSD,C=N$?^!L
M,;F?.F!K[Z.]GU2T%W/K'HF^:PC9#)^!7 1F\.HNL@6)R+MF(7T--O7DOPX\
M]#+"86GK<D;PW:A#;YO$)IY:?91VL0W$2EEO)&T2II.5O7&:E8N@O.6!57UZ
M;9GTC\4A*Q-,RDO!\A6'E(^(?V_$%)^? IS=CPH.(#U@ 6J9#7NK9CVN&%>;
M@Y/QL5[1E=%R/K2IR3(J\1NR<^#6B@4RG\/WZFU98=S4]?A2+*#DD@C9\-N%
M27"H8'](-E^72ZDMMV1&N\NU9'20G-D2A2\//5\WX.CB<-CNYA]O<K_F5Y7A
M7B\[<_;'?L#9EM0F\ 09QT%6,I.+'U=E<&?XQ<*<\P1Y*)SSQ4CJJA0U]"G3
M5E'8H!M>)3MPW?5<ENV>ZENWMF$=G=T/"5:3>PD%E-$.[@0^FEJ KS=4K)O3
M?=W</1Y@\G2Y9^&]V*HMK+M[_8(-4"\X++L9/6T!Z-.,()K !WF'%4<L("S?
M"\KA^3;;\YIK(F]9*;*'GH]I.>U/KY8(Z?=NDQ !FH;S)CK;_I<:>06ZP,9Q
M$WXX<71:'_KBYG;H9R*8BR+@]B$(*P(\Q9U%0.L26P#]"ZSA+P+6_"G,$P&C
M_2( ?[MK?)H,H..SF!-WFGO&D3[<U.Q6L@C8(V:K]&\U:5W>)%OK*KHV682;
MB 3T1#PKI*TJ.>[ZDX C5R2_%"6.G65^C>^:Q+*(/1X<O2B0%?X*#R]Y537Z
M$*)PL#UL:ZVLB".)3EOS5M+UQ!\L.FB[PYJ^"\GVX\6P";!F$V^R"LL]J_58
M!$@"G47CF%*&&@E\ O7N<IV^;DY\^N6P22/]5.\]ON_&I"]MI\67VP'6IJ^A
M>CUX:39? 44A"LC0?]PUYI%BQQM+)7)_&'2#8:&/A\_5^UF6[MZ=I%Q8(B5[
MA[^%5D+R$1Q$VJA<1]RG-KX1.G('F4&6Y([0M:S7A>QH^]!.<E,LH;+KJ?ZU
MTTUU]+#8CMK>@)55CXL>U8TT%KLA\GHB0(H/DX2O<:S<R@7"'+)BM[<>NZ10
M-?(A]*9T[DWXU^MWV7&</R*Q]/?A5<\VS61J:Z^JC$?/] %D&(,^S3V!_?8,
M6N\D7YR7'6G2'(L5#Y+5:3,!556=+-WS@P]9OYM88:FV9*V_Y8'6;]M.WGQ6
M#%RD,'"0?B2LC.&CN!F>1$+!,OP2ZE<7V)F%N9&L6C>\1?JRM0ZDZF"V]-"/
MM;MB#F4LJ<G+PAMMM*J@%/W!V6'^<-*XNPF1DT8GF(T.CD)ZL468D3:!'FD7
MY,C&+R0I0.^#LW]4ZO'L(V..F,6;.C:Y^5NK=:XYZ/.GV>VW'QBR&QY.:G^9
MO!3)P$!Z7K"2@#^,RDDD;4$_(T&&:\56K@A@(S'<W1^V<P7L[,O3=O30U]NC
MB,5XLUEEI9U[CT3)8PMKT@['CO5EHKG#"QT71&XEY&-'G07'X"/0T./O_#G[
M.DK,>PY6PB'+-R=0IV2UX. ]]3MB7\V:WI+WI3DJM(M-Z,&*3'X<>JX1-/-(
MZJ!2<LCM[OJMC]K754B>"2HS^7[RTTPLT3IK:$&^Q)I;50]/R&@67'))1MIP
M12ZPJCV?@0Y927(05I)-("9;MQ[]_48:-O4DY)8-D=W"\#M;>O>XG:\L>74D
M\?Q=Y7>!#D;?S<ULXG/XJB.SJ-['H-ZGY#9JZ2AS5.E5P'T6MB=.]C1IY;,A
MBX0C7QA*E# DGLO[6@%Z1V][?F87JZOY%0@K6B(*JB(@TB?D-B+##DJ'52/9
M?;>SO[AYTY?>)MR=7G[AS5'3 8O3&T[*D!I*ZMKPR\A')),&C\D#YZGYQ%&A
MP(%<2Y[WO"]L_+J]*!%2Y='9 ]:J7:M2=NT+]J.Q,XN#RCYX'-(I+Q"367'C
M5+V[">Z$,;2YFD.L-8;6$.K'(ZC8QZW^B#3D4IVVH0-1_7'PU<YPOY<DW/J+
M^#3\>&EW_=D-R- >@Q:<+P'2#AXUYA4B,KK<4+XQ]VGK^?$XIE3;M@[2AB"5
M@E7AS/U%%Z*/)1TC9;Y-\SHH+K6S?^BR_7M",1[6=! 0AJG</W'=V:SZ$5:?
M5C%4S>59V?OSM(;@/PQ/5)1T.39<H'K+"Z9O2I;467L/D!\F [7"QR KFUY2
MBO*'55T,3"^1GP,1N#%U&LTU])X_>R _>UYDU?#R7?5.+4M[^&J/H^4?GTER
M#RIFN%V)F'@$G*FAHH 70(3TB;"27S\(*Y<P$5EEU%>U/,)5*_DG(02&#X=X
M@[F8Y)&Y:!M#LUXI9^&>@E<CLH'>]#/E#6=G,ET;_+!<EV9(FUI'I8@ [FY*
M-Y._6AA3E*OQG;2,EWC=M*735+?@D(E@^49.QS>)JY4N%Y7?_G#,?V\K"$'7
MH06*BQE4*?3SN0J.ZT*$=/NNLNCJ?M;:W',A'AQ<];C&#_IQMR=W5T5Y19]X
M^]BJ/'2OW?3Y4,\5NPHV/I%NI'/QF%CZ,NMYK*["EE#KFWO'VK9I&4(7!29'
M?-.V)#&6O"TQ[^SQ+(V\;Y2;X%%FW>)#5$+<L'>_&;Q1?M\S/XS W;?<@Q]2
M,;\J>\C=A(+BQ$@B1]6,6>#?5^PC F2MYG;T">\\4)<<[-EP7UK[O./@,W^#
M)7-$OB4Z9#/"3%N-_HQ&EV01$U::1Y=@#>-15:[F'FY<61!KJVVT:S,I^?SJ
M1IDL+:\D?[_3'Y]_( ?*! 2?A A5(+1J$%9NYI^#S%5'UG#'^?K">)*#OR?'
M*TR3?Y\7?.U\KN/>&,>$D<\61PX3W)S6M2Y^CWVO%+&YM\G.4OON-MQI\%1S
M'%E%F UZ4<7)+7TRX:[G*5HA]KN[IKX;R6RT6?2E*/ Y,<[\25CN6!9=%3Q-
M[_;CH^LQG(@J>MC:&&38D#:@+G_?@O,C1C"5K[G(% QY.'><EY!5"_7.7'+$
MT7>/7M(W^8L>(0>-[^\\B2TA2%4N[X6U(7LVY7HGL_LQ:>O#'I^1.>LHA10?
M;=NEF59F\6+*!9L65.F_V2_MS7+Y.EB+^>2"R*-L5$*(HL=:I /+=0QS8V!5
MK"1YR;"O17,U,UICZNV<+O/^ND^1[UY>.:@_D'9V2?0QJS)2Z8U9[RDQE%Q+
MS<+>J-J>\%[A0VLKDKTPBBP5,LQVJ4OU^#-T?!DLQ[/+7E1Y5Z/>>O\0KU9N
MG;-]H-Z=X R3U=]IB4L2*U3Y[]#1M:C1'O03(D#F!Q9+-B(S"04U6FM?\+QN
M&8_0V=0"/XMK9J#/1+X._\.D7M/DBXNWPD^.N4AMF"*.F*/J!Z(B(J#R?NKH
M&A1#Y5!C]*!]#+H&V0(V:*]09>=:LD?B^(BJJEF\6_VE#X\N<^4MMVL\2LB7
M&9M0#; ^^!$-]&MHG,M3H-74&SA6"A^;7SHRS(Y)\=_#],6J[3L:=S2T[DGR
MC?*(#L^=,57*)9B-@6H3QW;6'(_2$?\,LC*P2HKH0E5)0F13>!E;C4<,.$+
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ME[-?5GLO+/.=VKU[<>-F:X7/,R[CM-$<T(V[3B])JL8NAKU>\LI)GFW@J<E
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M [UZ=X569 5D)P(8E[[4?C9+OBFE/I!?YGWJ@,ZR3-K:D!_ZXH>CN70HF,[
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MG0U[.:K'0]IDE^B:L?2X/UW[BV?_GF.1_Z\\^[MC_X]?O8"\F BZ>6**  Z
MYGA80:P0"':!#*D3;[F#+/O:Y+Y7=5K20B!*ITX]FD\K8"_:?>AQ_.SFAX>R
M#_EHG!OZGF0XCH&B^A#9.T+ \9P0:(IY*00:<X7 %6?ZU]64TD%!%?A]ZJ(
M>8"IQOYAQSAG.O,I92:= .<&4N"+=##WSZY_=OVSZY]=_X_MR@IG$QHIO0Q6
M>AU% ;:@"W+A"V&XV-+FUQL#;Y..D97<(GWC*J^LW:JW7F0VZX40",3,6Q+B
M0=X><XI@;48"(*#_FF"IJ %F?<C>._PC0J"O$:'H4P=' 8.LA%\;50EZ)00D
MU 4)-#%XQT<;%9(G-)WSC;:BO8HZL6A]A,U$+W:C2H9UR>FB>XTK+<0%DUZ&
MSR!E_D'R!TI)Y^/.P6HPL=<BGERK,M#7_6$GCT4;LUZ[9.?>$#%5X/I6ZSU2
M#]H.NUT"_2B10D"%O!*ZR[*X5'6>D LEUA0;>:WJ6%F>ZE'?<V?KR;.R/6L8
M7_4?GRL!7 ^[Q>'\J)&(*M251?Z0J<WM?UU^S=K^Z%SEJLA/4W?6/K"]<X<1
M90 H_';Z'>9-A%VX!V#PW)"9/*'*P?.2VDI-%$@JW'[::]]' 82<@ U]?<U+
M8[X?<,]>N7^O@WR.CDYF:6^KB*W*'A';4+HJ8D3: FERA( KE,-UJVOS6Y"\
MD5*6_=19N;)6RS;>\5#G[:_]]L!L/B++38]!7;#:Q14"D;,GZ&VSKRTU!&L6
MS'P\$R_L<5Q^:9V\F*%8I,A(RE;ULZZ'J0WX:Q0YT)<N<AAV@1K9W\YND?QP
M*.OE1]\81U4M>^DKBOD61EN_#URRS#,<&5P$UAP F9DTHT\/6LV2>],9S:&A
MV@[79LXO*0S6%UO?HK02,3+\)OTXB?C)[X2;_9XWHR%+M:*T9H!1@ZQ+LH8)
M4 ]_)ZPFN#=3L,$3ZAQZ%2'9Y=ZIO+MC545YVK8M'8;K&\3]ZI14[MU;;-D5
MN%5"Q?6O3;6>2. E0"9L(7!U87)\EM6BV==/;&8<]#__W,^?8'"C74U1->3=
M9>F5?K0QY>EDD@?4QF6PW,:Y3$=D%7R2&V6Y)#K(^G1+[N<=N@E4G2#;NH#W
M;X<> V%GW5HREZ,+E2\$:K98'RCP_*;N,N'(FJUX>=U>YG4"^].6.N9)QZR=
M^*='#;_IGDT13ZGP.9;JLUG\8JMHFZT*X+J?Y,0F+(8V,.8RC;CG7OD_\;\8
M5OP9/ZHV)Z>RD6O0;/5*077KEQN!-=8F*()/H%,1B8P&5R)FAR#G;/*$3(Y"
M75=&Q->"XLV;@,/O97>\G:1KS8C,.*O6DUP$68@<:1F7$ 7+<2T:TQ9V%PS=
M=^+C:M-":@SO;Q]Y%X,SWJ4C8943YY.0?"^TIO$?5NR_:-A:M8EC0D#?F6N"
M-$D6"X''':[VOYS9BBT7 AS_<OCQ!AX:=^7) AL7/+T3$A,"DG?!IGVX0#J?
M* 0ZOLSR!7\\S3V:"!3$&6-38+6Q(5PL69\H9<O5HJ@Q7EG%C8=-K-%XL]?5
M]V'N==V\IJ621S66B<3]",B9T.1T5%,*&V'5::9;/-T7+]=#]!IL;#H[J.1W
M4;.RKW?W#><O5O,&H@:&*TT!B4%1FL6)S!QVRSAJM80*= 9]U8,N\WW)338R
MG"7YONS[LAV[2O%JHR$2"@69F3?*4U52BBK26H T'7_K$-,.<HL0>#$YX<^U
MYU6U@T')D(%4(FE=;T[TV>%2#AAEK:M94+ T'DBS"Y;L,$J2_+[LWE.CK'6/
MQ-(A/#=_"(P7 GZXWDD&5HRDR2S0K\_$[*0P/)+N,\?\)LW=A])\IZAZ6[4F
M'AUJ6AURKN3NT\PUZ.87$G],(C(W69AD+*;#I0*BLND*#!;1[&NQDG:G3OK<
MY!??ZYR\HN>G"\+4VE\'\JP$-VW6D98(RFRLX;/<^M2HBU)UFKMEX,UZI9P;
M;K9I)VV.B]S:%#;FA>-0$1E#KE0-GN,Z#!4_/7*HO*8?4V\Q8,1Y?KW\08G'
MXW=[KD?*DR(WNTJ?FBI+28(>+,YOQ*K25A#=$-G''#%F3C)LRBSP=.NT47?$
MQ5GO193+@G99U9=VRF>U?Z/>#9*SMI\+.%/Z>?GDYGK(EW\0C9@=0B H^1I%
M,:REQZK.2Y(S>)F\?(SZ^/N";WQ)XWUXQ_H-3,<UD5PIF8I;JU\X7!E9D?%Z
MQY#%>#KW2@,*L /8:%SI\VB?HP,83G)4<,G$27]"Y&>C*=NG:Z(2EQV[F_MR
MSB;U*P((;M"9#P<+P49L7(;]^)4GD-H1CDG=??]9IRU.]18MRE#(>5^K3+T5
MC[MU#:.5I!0;R/M>.DC%@#4X\)358'<'(D/EGA^JYM197!RG+_%J<6A_WE-%
M*6\)#+J\>N_2+(F4-^)+IGA?SP=KQ7+XB.P!O@-I.93-Z40V(QTX*9H^%,I>
M]5@BICP;PNPIC=A1&[I[CPZNI\\H[H1(HF1+VJBTU:%>R%D(B%^!6L+Y(K"]
M((V\!DIT*N*N*N#*(4HF,J-C(2<CW1*DL^WO:1LOO6Z45QV\>CB8X2U%8.:,
M7^#[C@TJ5<D]@7>A%XH0I1B9*L2^>DM>"LMX+3)=%[GEMJGA]@F"SBE]HNG$
M^@W3I7LOF<-.*+D-@"I"@)F%518"QY-[)NN\%K>?LM[RR /O'CB@W>YQL/W!
MQD\$G34Y"_->GJD',%-Y:;K+9:_PO% <II&"VA!I<FLYI=2&\FC,1A^2RBU]
MU)5AACN9>.#.XY?E2:N 8_:]QG'3JFY?KFN^W$=Q@E;P]>"C'"RLJL9NF<"S
MY:PD.+%7K4T"O;/>JW+\>T\DNQS$+%E_9>/4]/B6P"C(%EV17B@=S"-_&E@*
MU1BGW<^"3W/%#D/[]A2^4E/:&3GIFKGZT55O_X,5Y4%1TS'+-/W$:D!_5(&
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MCGHOM59K BO"J89LV,ZFM<^&RSPK-5P=^_:,>.Y>AS[-.X>NS#YWXB4)<F@
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M.^[-Z;#K0K!CZJKU93=(1YY[%/6,[BD=DH&O8-]QWRZJ*J3P?)<Q,P"HD?=
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M3NY$1+00D&P&FYR1+6"/0:L0F"G,;VS!?:8%SN(\.7C$20;L>HJ<QH7D9B5
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MD!8%R__=N*L070BL(,32T<LLT-60SB_^HQ %^:DN=A$NXN#;8Y>$ /4%W";
MM]FJ<NQYD.O/!_[^VD107)6FPQF-=72^_D(+<OT]OOG\^$TAL*J?*03XXB9(
M5*?  :7>J4 LJI7&*6.XA1WFH/%@D0M\]_P5](P"?4'9[=5UL*JY8]:>3=XD
M!-[B8M )Z?P3R;99"8:C+</K_L8*SY+CL%,KQD">- K&-F>/V12N&+)S"P&I
M4<,MK,[SY6S(ED+F7&"G:=P%'/,R=BIFL&<2>0OC%BP]%A#:5A2]XF"3!NB+
M&HL*X&_? \<6X"]"8.M_M( =2?P#!OM9#/X"P8GUA#GI!?H[9!N7@#AEH+5:
MCA!XI(VNRD><^=\!S)=#%J6A^+X+7_Q9QSY$F<_;K;&4IP9K&*/C6$"S/Z=!
M:]SV!BK66@B$S%,_"@@UX+P1RM)>.?/5@B9TQ*&6T=9_9-]I/+*X"!UU?S)_
M#;(4O;@8?S-LX:T0D'('F];8"U)!>?"[._5MY0(9"ZVY2/V(A'*[!)-BB#KE
M'NHF]2%.[.\6#MF8"($WGJQ)]"K4M>^U:\;'?H7A32SR=5\;95\-=NK04=S8
M.,X,=)MQM24I"FC_6!A>$ (3*.Y7%7)-D+=(,;H@&]RF^OFZ*'#*B3BD!I6J
M#\W!O;A_!<L?7["3ZV<$KA E"3?EPJ*/32(].FU^60D+Q?-7_QXM.FPI..[B
MH"!R+3BS[^#K$R041"D85&2\L&U!$@+NP/+?:H3 ZPXAH 2W#+A VO;PPW(>
M2O1%( 9)2J/1T1+D%R32-^-:_]11_ZBCNGY51N0BL ;-&PFHE/'!,[ +!P.G
M@FF46$0V,W\6=P\.$P+A*#'%Y(R@3AI^<ZFN_9MY%2VH<)E: H7_Y4)PX73"
M*\M?$?BE40B\W#_C^Y%C#Z<MQ2SP,>^QG0(55[PX2(C^AV=XM4"^._CV&<GI
MYY8^0R^5[X3+R6]Q4T$#:!)_L1U-(\[XC\G_&I+A+Z7X[U[C]I/UAY+AFQ!A
M@2\$RAQF/-#T_ SQ_GNLO(%0VEZI52X$CB92!"J=5'>L N[+#E1HCBN&"H&L
MC">@F.4Z</(L*M?H&^9N(M*** D$"3)_9E>TQ,U^3*6.?<'\ 1 _N,S\9S[Q
M0T71K\Q)^",0TCI0#)U.SH=;OF"7H!SXDHJH@PO;T85XO6-ZS]] 3'U!9_80
MYAWIC52^GCH623,GA>./@35%@U,WP60\;Y<93F 4P)UNF3/)$+A\@M50Z-;B
M9T?!>YC/>>CR6B,%_\3V:'W&'#.9MW5 %X?*2A88FL];X)]1.&'I<-8C$&7
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MMMXRO!$>:UBZ[7#<&;Y/H3]$HZY:2[]FG8!Z:*,D9,?\8C)!MOGHAB0RV[C
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M/7?K)RHZV+X:N;LN?*>$7;]]I7/U]N8+O>\Z)X_SXHWA%+F;\Q(IA\+@!8-
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M-E)%=R#?JPM].'%P2$09Y7);0$1]+FXO7JDH>4$T^?XY];HP5'7/0@X]AFQ
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M&,^Y0 .>;>&,)KZ'>+F 0![8>Q@51&1&<(&A3S^9[+]O7I0+M!TADAKN(>!
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M\-TYD"8/IQ?-93/K?]682Z#?#!>8FY[EP)E=W. Z\8L)"H+1:55R3;F >,\
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M^EG=!; ]5);-#9"$@A.H%,M]H&47E- J(XO3I_TLG0QH6BXYR$C?=G/[YK>
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MJ+-(0:S1>ZQ:D$&BP7+.0%AIR>=[NX)/KU\XALKANW?O_?(>W#FP[3%Q*9G
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MT1YW94\VL+/T_!&P'N;G/[WD[HLXHWV9;\,L9;EWA)5)=ZWT_QZ[^LP6_Q_
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M<OZ(:+.SI0,_ME]2#FN/2'PY9F.G??"AJUR4?02T"(L?XIR'W^:N9X8DU&O
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M;RSWQ"P0Y;B[!_*O0X6-6;J;[Y*<NSR.O[I>I!.6-/E<0$:KJV +J?C[9SX
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M)'JFO/Z)[:#'/O1,I7[D V\P_T4:P3Y%KMI<+\S=R[N/H183I'B/S+:!9[[
MXGWU:-^KGC!"T6+!.9>F3I^Z,)<_=Z8Z+"<8]6;UDQ^6!(3I?VN:65ROA"2
MW>_)3 <$SK).;E<N'-:Y46CXC(/C]ER)PV_IV.%E%'LVIMCQ6*+/I@-2Y[.O
M[3,@74'"(7::A]#5E]?>F$4DS_V*C#^&<"T).D&11&K<_X*#M./^9>/D#R'L
MVXVQWH'[<Z3GPRI$MC428@L/^ !E^E>]FG\8AA'_U>Z#V8GD*6J '(1A([8Q
M"DR-PI2))L^C92$BK+ JIH@/G /]79S!O+&/BMGVVQCTU"G7X!\?KPGB<D%F
M!W$M^$4*:8X64( P[PEP/_'/"V7-U9F-!></SQMPY2P0#SD<C-I2$G5HKQ9A
MD0\8XK$*%S<ZM!EMLE?9E1;8;Y?6BG=\O92_>=SZGQBWP?\&A)/_=X%P.PO-
M5N?E!S&L&_N_FBF_]SRD2U^54$0A0H?G@^9*_&;5TWW,?$MKSV_:;>4T <BV
M@K:X?[2"0T%E]TZ</WSOUH7Y[[ 7X01-46I**5/53[GBWM=.6RWMDU\I+L<.
MCR>K&G!-,#.(2K;\OI</D!%-V8)H.:D>CCIR]ZOOP=F?R "-/OT^PC]WP'7O
M\L,F1/==@3L01>!:CN9P$5.,U$-FX26&IU@B"O,!#%+Q]/"?NMK[^X0*_&]R
M)W#/WSX2=,.,FI@/F+J;E=!*1#0'">N^7\U$5/'U6>L XR$Z:S+1_O8,X^/U
MM862VZ,$Z.2"?\QEA6*)1='%C'49P96%[U@82>J.,GTGO5./UFS:Y"JE%9C]
M74G7]P.,8(:69H9(M_<JR.(U49#0G'R*^?T4G/!G1DG]<P](=IQK2MQ2#G&)
M2 1;5M/LEWB(EUI1B'C'GND 6$EV@L03*$=S]>>)\('\/_U.^I+Q#_4$IJJ4
MV(U&2/W._UFW?P=")M];S5"\>#*52&$6@#Y\0.6+V1J6-5=O;<A1^ W\L?(U
M J_J:I1DKF=^-_I-'>-3=<B*^O'?D]X/\C]<)OG:6N*+8X^+CB4I=&HN_M/0
M:U.6R2QDA' ,H>F6X%QI9FK;'C4^<)2<U556%N5HH#NQVPI+DO^RD.K.Y#3L
M.CUY-?8N-5EMG+[QDQS3)TW]X8*DXKJAUO^$S[Y<PSD.A#Z*%-D#C!HEM:,3
M,Q LG_/)D=:_X(ZZ%&*:I+##[:BY7LOB.D!"!M@8L4<D$5JD3G/E*YM;*8I<
M=29Q@C13,6$?JTX7.\$T*Z,+U%..A>BH'[OS_N%EUI,QLI2.?\.9P7S.(;#Q
M>#DF"J.T0(HDBO,!+Z(\WFZ0JXXL,#2*0VVQ,?3U2YPLNW!YYLFWMTU//HK0
M+82!Y;;$I8D6,O.8_4A5,[$T/)51MW@R"58=&/$KYVW47HVS(SB_'Y'3K_!P
M3-G7'OSIB9/"FI[US.VP.,EG@IQBI@:)L:;99UA93:^Q;<9PP/7-IC:U#P<.
MBQW7:%>Q>INT:HW_>MNC5N9FE7GUIE W0DT7^^O6LW"(19,D",/=!$,H!]T\
M%,AZ5_4@XG:-^\.S&R8U8BKE;LJ,;7/#>VPZOXQBXQ"-IP(/483+B2DXB8VO
MX.Y!P7P7US:9:[83;B\M=*+,/<]^N+E72&:EH<"7?_>9*K:3@@0(M:B2C#+;
MZ4LL6VP 1S+:,/)!%+'1!.Y)6/GT"Y\'3_QRHFS>35P4\A,,Z1);%]D?BH'%
M0S@FH57L+0.@7ZG9(U\:3]FJ?# PX:Q%^*H'DN?U!BTNA%S1L[3QJ_60;#7W
M>X"V[,5MA-]0F"<.H2:\VI)EJ0&MN)&)5IR448#B5\RHZTIBBYZ:U#F*[PZ=
ML=4//1QUFS>-6E$/Q!:QRF#Q3G<J*<E,!]K#U&*?9A%;Q;A"A;!LN'WSA&?E
MG>[[7V^F*^J<&)@T>*L26;W)4&"!(3^%*Z,P,I@8=B+O_AG>8^X>^OY>KLE+
M',/9=*]A<+O=;?4$]_LW+IRN6SL6K].U]W,U^($,BYLP^0!['"ICH1IPDGAU
MTY,F41J5"F8:V8OJ3BG83-/!B+;'\F_V)[]I*5ZQ[UXBL&S\[[Z,Q;0?LV8O
M,0-FHHM"?1MNDU=54%2@L;;MNT(#FM14DY1^K+@I47MFYM0]25T9BTLQ;@A=
M>!A VJ3K&!^R,E1(Y0/)!(7OY%6F(52.?:6OJR)KITIZOX[D]XV*4[AMV\8R
M0S/7*(BN$_Q2HTMK0]B-CM^FW,/5;&9?9KV"CIK:\>().F'J,T1O>#&S:O?6
MGQ,$'KFQ=I)TBD<"J0]A"=X=O ,-%U,O#?D\QUNRVI,8;X?CN/JT\$=3%=.R
M9;07R15LAF-'<N>HHJ' _![YGU6_^$E8$;K&.60_@1:':AM.]C23%4)%U#&)
M7"-ZDFAY)?#CGIFB=O52E4Y:YH[UD6;V>6#C13/E;\H_[M/# Y">568PJ[ L
M%>^:@%;=#P/.KQLT_+W9W*+FK<UE,8Y+MHY'!!:EY!*[NI1LUB5%[>Y[_Y__
M.OBIPK82$^KKV>9D.P?>@T#[5>,0UBZ25(&!#NBMKRZ+5#]Z\%F&[F9S+5&E
M:<&2H*!)3"5E)L>7X\.5"8BLJ6HI.=:\*^A=L?!XOEGF"IO%2ZW5SU:ADW//
MIMB?:BD7F,,U5[&&N?*%[ YF"$/L,;0/1.$EH>W/]K1?)QF<F7MNNO>)1IK9
MI&OGY[UBZC<3U/I":H5_/17^['N.5P=>**,S<@.X&@<QX/ ,>'X@'(SKGGM=
MFCA#D 0;56=A,:BP>5=['.@?D(AZ%.KK6%$7W0SZ;_W0H[I=[_&G/&?C>(JP
MDT#4&M9I# .)-Z$BYG0;)6ETN-T@!BQ7O&&F[*NFW\<'RO!^Z+B5WD;%?D^3
ME$(>6GE82G7K^HGZTULC3.W@E;VHQF(0VFB=8'J,<^1+KEH=DQ#-$CTR@.^1
M]RD]?7+,ZG9P])OCF4X!XWU/&<(W=CJD?]A%7L&HUP0;$>GLAY,BC.YJC_YA
M:L(,H7FV=%.%R*E^0Z]#T7=9(_OCDUH\L9U.D>=^*H7GT-NY,LTTKU2,.T6*
MT.HJ#MUX'NK25(\><&1_OF8SD3UQXDY8TDGJBR-CCVYVF ,BQQL$CJ]RH6*X
M,KK'(=0$60(JM.95FVGA? B* W[/US%;6SGZUUG[:#&U^U_Z2:\VSA1<LT=[
M!9DQQK$/M::>JW@"=Q!+K1MY6L>A$9:9<>J1*B8[4W)CYT;KMXSO><^7]MFJ
MD^Y<?'#78_T6C?^GG6L-AS*/XF]%N95+*VVIV69&K22[A);A995+KM6Z9[24
ME%):8IAF+#%#)"S6HQ:A*9='XQ)2I@QF<XG*)>,R->-2F+PO-?LRMWU][NG3
M/D\?]NG#_\O_P^_YG_.<\SOG/.?\CZ@7V?7/W"T6,V.N::6UI!-;%[U<NM9_
M+%:DMG2$V#TRH3FQAFGMTW]=54'-!I^ZM-@.0@?B0$WR25B'<PX4]2&))0BM
MC9O>,UA\N:3<_VE*Z:+:#L&%<9_6^*;'2@\O&,RH#]N)2/VL$# )]R:W DYL
M(^[_X\S1 %2)R*V)KJB4U;+9B!!+[_-KK'J V(#/+7[#449Y]=7LWF%U8L$;
MQAP;HCD-4JS(+JK;KA46A_9=S0O9J[6P)/!XH6B(PS8MT8,.%8549X.H^[Q:
M;),#3'.)YM#/*$N<"2-5SV*TST45;G$^*RYVFJII=-?W1W((%5%CSV]LTM4P
M>"L'K@9"!Z4@GR%<SP>Y7B!7S(G%T,FV=UTC1.G?XI*='0,GG4,GO-0G2VUQ
MN@MW3(AY*-,A.X<2@Z6Y!$^QOB0,Z>++ ;K?J513.W)4M08OK^7E*!X+8NV-
M&H);\<"DTR4%C38-];6HSE?ZKZ-4)E6"W4J81QQ?2AT"F=(*UP\RC%&/J".L
M#PQG<4N>%-8F/[HL-I6A+*FT[Z:W@-&N/6)53:O[,RA+_<<3V.6EY][=UY7U
M,A5HP*;,O]U9]6)CE"9V/[2"0('959C#IPF5^;TI?@U7(DMN(UB,YO5[H?='
M?+4/1S<%W>FNZ+PSZC::9- >,RU3NADL,+I&Q$N+*E?:UIBW+5AX;]EO4=&D
MDMW^3[<<$C],BCP^[A=/U]G/3;54 >:I(;V(WDIZKTAA/\#,Y< SKV*2S0:/
M$F&"6726G>*SXD;SW,JD8VV_'[%6R=.<3G]5_3TJMW?,*?8XFD\F),KZ95I0
M;DK8[7>QX4TGSS'>B3SV7!AIS1XK[Z 7*7H @,HR6^0DO1$%#D>_B>2M_QB8
M-HZ'^VMF%HGI8>WFAH:=-,>AIVJ^+0<7%M;&-E4&#B^*]D"LN26Q+=D=Y;_S
M6W@S.H4;/RJ]G_\@+HCTJ<S'Y[1V='6I=3I8)\1;E7]N#GF3M-;:C-*-J<E(
MY$L9% O$V[YY,/+XX+CVS;I&O8&0QBBROY_C;(O5D\((A=UW@T9/@?KD]8BJ
MV!99&<D7*J.A9I>TB$P@@P)U.DO5-,Q("?'3/IGM]C+I6I#Q:N-M28]J[GQG
MIID?;WP\+D\XB;)96Q_KO#I].P9FI<HL$!K[>4R8J]ER2'Z97QO,,3ET(FO"
M1#=EJZ8^)]2KFM()0F[28-%IA'990-6B#!)!).DTM:CWMG-13(N44;?:%QN\
MM^.28GQ:M5N6>15 /HP1821VL7)@I@5-S975[Y-1NW6DS4Y2<C[^U22VI3Q#
M784S=Q0J$>4A\.LJ P]XH($=@&6S V'#I/J"KA*&_7:N<KY+IH.8L[C5TO/$
MV81C!A=1HXF"[H51H=1=PHV"3(@ATP*%M1!:,@X7%+Y?:JZMQ>R\1"H ,Z)[
M S*$5:B8Y1!/6 Q[VR$%E602K).LP_9S,;/8D%/,/8!EZN.<INV=%'691/L?
M<+82;#S!Y#&UEBI<M6ZN0>Q"&6?5$;.E&8+>U,(-]>Y,)%RITRR[3-7>$G^T
ML]D^,YXV]<N5<,OA'/((GR/:+ <2(R5*V 4T "DK+42DH;4-]Y]F>#[#!.JY
M7+^RS8L0CB;4YS5FN7GI*_62KL3I)=GVS5)DP2/5#N\>JW(.KCA:Y1D[PE-?
M-EM/RDU!GP\B@8R81#=HJE9\ .%Y(@&E,?19O^C6KN&!RJR);+93\Y2;KYO&
M3UZ_LO9TVU@W()M-;2'W)VQ_GHB''*R3 _=)A7$]XGUQB_/-IOU]@(>V#; !
M^-+?3K[@^0^"($1D$3;GN[.-N!Q^CAQ@4^D6TS3& WB*N:V;N[W*M*0S01:D
MG>92%D]X/8B1F-*$KG+ P0!>(P=4#>9EEC:8,:&V9 >5[4/IYWVXR-( H9H6
M.2"H^_1FE73\>6"KSJ<8#E]AO\)^A?T*^[^"7??)=-TQO;&Q 6E_P]"0L2OA
MQ;YL5Y-<DNZ-W" 2/CO+]9M5\N%_ 5!+ P04    " #)@EA6 :K$!I45  #E
M%0  $P   &UR:RTR,#(R,3(S,5]G-RYG:685E0=4D\D6Q[\$ B&R^D$*! $3
M:KZH0&A25)+00@2!$%I$Z<VH"PB(V"BA&I6$("BHH80.2S'8B%)$L&P$1%9=
M90$QEO7YJ2O6Y_+RYOS/;\ZY,_?./?^9<\;7S\?%-38700?2 (#\35,' %:
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MNO&/I?#K+Z+^)2,0@/O_ %!+ P04    " #)@EA6AVSD$?!*  #]>@  $P
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M(?Q#0_B@,E(R?+9(?_> B!  )@.54Y%15(')\T&A*N"?G#( D-^$?*N?2 2
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MR+/E7?AF]Z0 ^>=2R9)W00C2DY1/V\**#QX6'/XM;7=8@C/67H 1G%_W SR
M " "2 (P0!$X AP%= $CP RP NP!9P .> %^0# 0 <0 9X"+0")P#4@'<H "
MH!@H ZJ 6J ): &> "^!+N 5, R, V^!.6 9^ QL ML0"(0:0@]A@>R'\$*$
M(.(0&$0)H@[1A1R#6$#L(2<AGA!_2!@D!G(.D@A)A>1 "B%ED!K( \@32 >D
M'S(*>0=9A& @6V3D9'1DK&3<9(?)I,F4R#3)C,FLR$Z0>9(%D463G2>[2I9%
M=HOL+EDCV1.R+K)ALK=DRV0;X%1-2\Y.?HA<DER)7)O<C-R!W(,\F#R./($\
M@_P6>15Y,WD;^2#Y6_*/Y#@**@H6"CX*28HC% 84UA1PBB"*.(HK%#D4=R@:
M*9Y3#%*\H_A,0:"DISQ(*4ZI0FE(:4?I21E!>9$R@_(V90/E"\IARCG*32HJ
M*G8J82I%*@,J>RIOJE-45ZCRJ*JI'E/U4\U2;5!34^^G%J=6HS:C=J4.I;Y(
MG4U]EQI-/4 ]1_V5AI:&EP9&HT?C0.-/<Y8F@Z:<II5F@&:!9GO/OCU">U3V
MF.UQWQ.U)WE/\9[F/7U[YO9L[V7:*[Q7;:_57N^]9_9F[:W:^V+OQ%XL+2TM
M/ZTRK3DMDO8T;1;M/=IVVG>T.#IF.C$Z;3HGNC"ZJW2E=(_I1NFP]/3TA^F/
MTCO0A])?I2^C?T8_1?^5@85!BL&0P9T!Q9#+T,@PP/")<0^C$*,FHS-C-&,&
M8QUC'^/'?7OV'=ZGO<]U7]R^W'T/]KW>M\'$P@1E,F/R8[K"5,[4P?2!F9KY
M,+,NLSOS>>8BYF?,LRSD+ (LVBQPEG,LQ2PO6.98J5B%60U9O5D362M9>UD_
MLS&SR;'9L$6RY;(]8GO+3LY^F-V0W9<]F;V6?81]BX.;0Y,#P7&9HXIC@.,+
MYP'.HYP(S@3.:LYASJW]?/MU]_OL3]G?M'^2BX)+C,N<*X(KG^L%U\<#K >.
M'( ?2#A0>V#L(-E!L8,6!T\=+#K8?7"#FX=;GSN0.YO[&?=''G:>HSS>/-=Y
M6GD6>5EXU7F1O-=YT;Q+?&Q\FGR^?%E\S_D^'SIXR.!0V*'"0[V'MOF%^:WY
MS_)7\T\*[!50$O 0N"[P5."S(*^@B6",8(7@F- >(24A+Z%,H3:A+X>%#]L>
MCC_<=/B#,*>PH7"T<(7PA B]B(9(D,@MD2%1*E$E41_1/-%78F1B\F)>8KEB
M?>)DX@KB2/$\\7X)2@EE"7^)6Q*O)>DD-27#)2LDWTFQ2QV3.BO5)/5)6E#:
M03I%NDV:(",OXRM3+#,.988:0<]"FZ$8F!@,#LN%#<G2R^K)HF3ORZ[)B<LA
MY/+EWLBSR)O(Q\L_E=]14%0(5JA26%045#RI>$/QM1*KTG&E*TKMRI3*6LHH
MY19EG(J"2JA*K<KJ$<DC/D?*CWQ0%59%J!:KSJKQJ[FJ%:J]5>=3/ZE^4_VM
MQB$-5XU;&C-'!8ZZ'[U]=$%35--;\Z[F)RT9K6"M!JTOVBK:L=J/=<AU]'42
M='IUF76M=7-TI_3X]3SU*O0^Z\OKG])_;$!I8&R08O#:D-L0;EAF^-E(T2C6
MZ+DQG;&E<8[QS#&Q8\''FDW(3(Q,TDPF3(5,_4V;S  S0[,TL\GCPL>#CC\T
MIS(_;IYK/F\!M8BQ:+-DL72Q++?<M-*R2K8:MQ:Q#K-^:L-HXV139O/%5L<V
MU?:MG;1=K%V7/9<]TOZ^ [6#C<-MAPU'7<=TQSDG>:>+3B,GA$]$GNAPYG+V
M=7[DPNCBZE)WDO*D[<GRDWA7,]=;KAMNAFXWW#[#M>&9\&7WH^[7W1<1:HA4
MQ(*'FD>JQP=/-<\TST4O#:\,KX](;60.<LW;P+O ^XN/F4^I#]'7UK?:C\;O
MI-\#?V9_'__G 3P!D0']@>*!%P/?!JD$I0=]#C8.OAT""3D1<C^4%=Q,=8>)
MA%T(>Q>N'IX;_C7")J(NDBG2/[([2BSJ<M1"M%YTR2F*4_!33V,.Q9R)>1>K
M&5L8!XESBWN*$D"=1\V=UC]]Y\S>,SYG>L[*G$T]NW[.]ESS>>[SI\_/7M"_
M4'&1X6+PQ=?Q1^(++E%<0E[JO2Q[.?LR(<$]H3-1)C$C$7\%?J4S"9J4E42\
MZG&U-UDA.?\:U37_:R,I&BEW4IE2HU-GTTS2&J_S74^XOI[NDMZ1(9=1D+DW
M,RSS;=:QK/O9@MG7LO$Y7CG#N5JYU3<.WKA\XTN>>]Y _M'\J@+N@L2"K9O(
MFV\*]0L;;QV^E5%$511>-%]L4]Q6HE12=IOK=N+MG5+_TK=W+.X\+U,L*RL_
M6)Y<05815K%XU^GNJTJ=ROM5DE6%U>S5B?> >V'WEFI.UHS4&M<^K5.JJZH7
MJK_1P-*0T AIC&K\W.35]/:^_?W^!T8/GC8?:6YX*/6PM.502^XCMD?)K7M;
MS[<2T='HC<>!CS\^\7PR^]3EZ?@SNV=#S\V?][XP?M'^4N_ELS;--G2[6GM+
MATK'@TZESJ8NA:[&;OGNAA[YGH9>A=[&/L6^^Z^47S7WJ_:W#F@,/!G4&7PY
M9#C4-6PZW#]B/?+FM=/KMV_<WWP8]1U=&PL?VQX_/4$YD3"Y;S)CZN#4K6G1
MZ>JW"F\?O=-YUSUC.3,^"Y]=?A_R'C]W?IY^/F.!=Z'L ^Q#RZ+>XJLEQZ6Y
MY<#E[8\75YA6;GP2^52_>G2U^[/=Y[FUX#4BY@IV/[9T76[]Z<;QC:E-O\WM
M+PE?]W^]@U/"M6W9;BUL1^"I\5D[HCO-!&/"!-&/2"2N '2DKR87;1/PV^,3
MP$!Z ]Q/[^XFB./ >8".AH9F#PW=GCUT3+1[:9G8&.GH&-DX65C86%@XF>A(
MX?OCKP.$GI:6GH%^'P/#/E8&!@;67<# ^BT+TW]2 /$QP$0#?M#<)(?P V1,
M$'(F"'$2W+OL)3Z':(!24D)(X?M^AQS\;**@I**FV;.7%O*/B>#7&/F/Q'T
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M4Y</T];U[RV74,J+<1=LDZN^U#2HKD\P.VAC?!01^Y-+;"2O/(;'3B_"I(A
ME6!Q;-RRK,IM7I,79:/23S0:8,O(-S1W[*9R+R\]:CWGW[UT0+)BJ!'=[^KB
MEB]ML?4NUKDDC_$ V_2'RB6*AT0 \3E8C @\8<\T60P-7?I(=^K3PT/S$S=R
M+X4UOCGJL7WPU<M3=B.VUM:P9F3%>IA-E6 I[29Z)&&Z\=.9)=DO-2%B=82K
M<)7H4W&U[^$IFU?CA]X,=HV>4#RS<^7@W0I43Z6_8.H-1_6FT 2?#=C^7.T8
MW\?=7D3@R,>'Q]$+T\/J.YJ5A(>22")0ZFBS92BZT/=ZM:R(>Y2Z O[Q9"I$
M"+^RV<\#2EGC,%D^]JD2M,*MCUXA/(-\]4D](6:8-!?=_7*M5Q+&PQ3(QL5J
M"GL"51L^QC3TZ("3]L"&569GF6#I4O'_Z4$<):YP5?UQGBLK)0,H:1F:4 B1
M5O-]_WC6L9M&OO(M;?<L>O?$^<>3E.\P*8WACQP:I[_EHJ#_>2#"0WK?_^=W
M<BSI?<^/?!!2+N%O$NS]>>Y"1N)=)^',@#R)41*$5-\RD5*_D/"# $#\RT#^
MX;M$-#_;"/EV.KH;OZ?Q_'%\0WKG(NU\XG_6]"V,[IY?@T]1P +@ W0 5R <
M0 (A((X ?,$(!T*!8"  \ >I<) : CX]P3=7D!X&IB! FB08(P OD,N7]+Z;
MZ@=B?WG6]"N-5//HWS#\#/O^H/N'^?KNYMUMB%M F+][B)F;-_R/= MX*/1'
MPZU @_ -\/?\4<PQA$?HK^]:H0%^W]])8EAX>GU/)XE&%>*+A"-";'R/[1Z>
M0?Y4#R4I#=CM0P"@)KT8ZOQ2-K5G<$!8X)](5 '!2$^D/\(_S ]\H].UW,UD
M1J*![_2N8:$!^@A_1+!KZ.Y!-BA]5"#B._/>;\R[E-T40S_24=W_V^TG#POV
MM=*UL_JS\O],,0GQ1/R)0N7J&VKEZODG&@,< >9#1(8:AAA8F1QS"PCPW4V@
M^4'^$_,>KX#@:$U?I.</33%^:[S!#_*N=MV_G>+NLH<C@D/_@MWF!_G/[+1N
MGMH!O@'!ORB7Z5L&+?V?";MBF ;X[S[WA 8$FH6%AB!^5=Q>7U"1_T2E<PL(
M!17Z3W1:DK?@'\BD,2GR+1\8R30^ W_064DHR0=$>M_E -C$OJOH)AC!+H:\
M!0#'MR0?$>=OG]!OG]!?A=\^H=\^(>"W3^BW3^BW3^BW3^BW3^BW3^BW3^BW
M3^BW3^BW3^BW3^BW3^BW3^BW3^BW3^BW3^C_@SXATJGI(=+:?6IW_=Y=R#D!
M3< =" #<2$Z*XR2'12@80TA8($C3)3DP=ET7_F#*[N$(]_\X#Q^XXY !I  9
MX(<'B.*;OX7ZVWDN!""^8S[X_0C,/T3*=7??) 4/\)..= V4ADK)2 .J&I&!
MKG ?1"B?&\(3Z:_&O_H0S<^'=%?CMY4WD3$)U$9X(0VB@Q&6T:96\&@?N+([
MOX8ZGVJD2J1?H!\BU)4OTL_7/T0E4HV?5+@*B.^2I?GY2"RA/FK\WWX%86=R
MG$\[(!C!)R\%DX3+R$#Y%&2EH++*<K+*$GPP&:B,].X?3%)&245.7D56AN][
MX =K"W;W4+'0T?M>%_BFQO_+N5Z$K%1 L*<T5%E965H&)@V#28(<DB%1_J&N
MD9+^(0(_2M!!A,"#D8&D Z_==U>W@+!0-7[^'TWP"_Q9[%_JZ@>C._PG7V!8
ML"^I<G>X-.+[CSM 7NA/WL ?OL*_+OIG\I\J "4Q,?E[6?S\?G*'A.J&A_X]
M=\BNGT': A$2$!8,1^B&@V(*_,@>BO3P^.O<NRE_D@L1B?P7K+LI/UD#5;2#
M$:ZA <%6 0&^/[K_W_P(YI=\"!TPJO'O_BI&4D91$B9O!957 :T"!I64D5.1
MD?G&:A+@CO2(^F?6[S^@^1,K:(_NKJ&N_Y;9':[B$1#LYPIJ$^GGZHF0]@Y$
M>/+S_>PD%9+/!JP9+ ;Z*]U06_MX<( 'TA=,T ]VC>+3=_7S<^6#2<%($IB8
MJ!CZAX2Z^N^Z[=3X08H4$NFN(JNE*0.#:LO)Z$#E=.6@4"68GH*VEK:NC)R"
MC*:"GLR/O#H!\+!=C?W(Z[Z;5_D_R_O-X^?J^[\K8]<"=HL ,[KN#AM2LTE$
MNUUC\@W[1I25(05P ,O(_,AE_^\8_DBW]D>"&H=]IYN"-84C=)">B)!=JKR"
M!$Q>$8Q*8%26@"G )&"*<F $:4IR$O*R,F"$@CA(5Y*5@"DK2,C*0"5DH4I@
M5):0AX%1%@;2P'(49< (\BKNOLN#Z6"4E9.%'9%1E-/1T5/6A"K(*&I#H0I*
M\EI:VCI:FKK*<@I:>CJ:_'R[!JYR'!F)\+7308**#"&U2U%&[M<D^U^28%#%
M[TDDH['</>%7XU>0EY>5_T[_<T-E%904Y"3D9)059$@0;((B%/8-PDB4;U 6
MI,A#O_'(2>SF4B1!)5)3Y$@0I,@IR<N0((P$Y4D05(VB+*BX7:A$@LJ[4$F&
M!*$D""-!61*4(T%Y$B3E!94K!Y4#4W>A' E^HRB2H-(N5(:1((E'61Z$BC E
M$E3>A6!WR4&5E>1)4($$%4E0B01W>92523S*4!*$D: L"<J1("GOKB3@2%:0
M +M4 C0#"04)10DE"64)4#50J 04)@&5E8#*28!=##)!%25 >X"!O*"5@$8"
MVH\\:$J@)8!& ]K"$5EY/1E-'65M)5DM)1U-.1U9)1U=F(P<3%M12TM145%Y
M=PGY-J ,D"'@S!;U?4FQ1 1]QWR1?*2)6,45_LWFX:2YS)W_.QGY5Q/ OQV
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M+[J?'2;IQ:5;Y'!_0]=DS_6KQF0)J(?JTG,V?6*X;7U\-W8Z,\RLIT#V7OV
M7S<4:1,2?*7AT?-")DD!<;V+LM+2UKG7IP\0L+.(=6'\N[E[\9@K[=3;@V4G
MC-HF)(((Q4\+<#W<GL?BVU7TDF7"T>@A]3K/Y]?*&VO8TG/;=A9U:0DNN/T4
MX. 2&3H9W^M\<G#*+<WIC6#-LVW)#]WDO!N90PZHM+XCKQ>JY^O1&:WFYZSK
M&Q,V"9A%/TF_V\&)V@?:!_:A6<JC3PWB!G%UV:A>953OT:B'O?FA+1@BD,-%
MFWQ76W(^3P)*<^S8U0N5C\T:.,BZ*X5%H_37C(55U\&I2'=H;ZKH[.5'/;4&
MUUKNU'9U#5RY1S<1]WI?A.JIA22-!;&P;2*@$.>#G#(=5)K@EM#U#*" AZ.'
M]LJ618<1YI3P1C=X-Z=T>]M 6]1&WB$8ZQ8OAG>H%\XY1KH/E'A30QWYVV3>
MJTM/C5=+FVV6)&F\;D_&OT//BT\N?FG5?G0M<_"<"U*0"'2I7E6+K&AZDZ.;
MHL[[Q1?=E9][!S0\:WUFGZ:KD0<(P1'=U96$0!^1VFQ)N6K3IY2"UVX+NIS0
M^XA>U3;&/P#GR 4F%-2_857,">=H?DUM-?,K+?/S$)_]ZJP.L;>W'KZ$+W2]
M2YHQ&W7606.SX^RP%TL9+I3;.79%%=KM@>>+L.7=RG>C21G6C83QWTS;Y'U'
M!,(]V3$%^/?4!?C2]]L!$KB8T3?CFK(]&\/G\KK/ZDOS&[A+,UF8*-\U%KL5
M _-TPC\$^_$&OF-8+M>'%B7:,W_"8O1\1.9G#LB3#]U,>P4+EGDD\Z8Q6#O\
MR^%WJ5]Z<G2K$OWXSR$\Z9*%'I<1@8C@KU87.O+TQC<6L];5'F';6WTO@NLE
MKL/]E464X*OZ_4I..N]9K>M.2I&=(>SD7,YO2I!+8F/2N@7<*:H]D_QME'(-
M^M_7G:\6_N#LW3^N/[*2U'L#HR\PCG&G>.Y='BGS%?GY/A$X\Q7;I9'E;(#5
M?U^=$]H'C=)#E@XL9&4M!!\KIMR92UIE^M"S=(@(Z*<E*WPE I/]%1V+!5TH
M]0^$:$Q)059HXU?A@U*5Y;3C$WP\=Z5--9C9WZ2LO7@"<F:+_<T,XOGC9$Y-
M%OR8O^X<2@28XWRFQYZ_6)%CXW+BX[YRK4[^6=#'J8=RJ*7G#Y9<<"]WJ$X<
MP(1TK?5H2WZ4C#/;AZ8?KR]S7OCB6\!.#V[R1@914C%WMHHG/(>K:+6+1N51
MIV26'*[SBYRAAQ*!?)^U9M"$I6/.S5?WK*J>(.#/J29%52[5XGV8VS<\9DS<
M4RZ+'X03V-ARJ0B14;9F@Z"E,Z:UU)1>W[JA$I?K0Q8DZV2F*K+4^Y@AY-A@
M]1TBT$@$WK]W[)B*P*+F5K/'+0?R[C;8T3I,C3L=*CH].W1V1@%"&(LQ_FQ0
MU=+*WG<,YT((T>B,D+D5E6;P<- _LL#"QYE#AH.U>I^1P4U\\3-Z2T*((J9S
M//7-XE;)]EKY_03.:_GU$@-8(I!J3].*_X#?Q+_AL.'-S!',\<\YD[HTLU]@
M0RG_])39!]V#5S3<>,!U6>J8AIC& FMH'E=D UI5-7J^O--QW4?TE(&[!]W^
M["3_$UZ=L;KKK1JU>(MC*>!>T,KA)4IPP^W.:4VA@MNTL'1>^\OJ@/J@/\<Y
MO*JZ1M,9],*^DLO@_'S+*LSC*F%1\+BFV/.*(.]057O''9M><..KS%$^A<-B
M.\<[Q^!RRVZ?D0J=IQN$TY_D?1V*C8]CW$3=_]K:NV\1-DTPB(NB67W0D)$;
MZ)9^YV!?J5/RA9=#<XNUZ">;B*2B;?LA]((\SQ16&Q.[T_+2B\NXCC6%)[ ]
M39]6X"+OGO);UXF T#B_"_9BOJ//:K?QCM^3K=8D]V?7%I<G90Q :\M'*A,!
M>'[O@^:&A@L+#[+YSJIP9-C0)%IJVK@!T[RL-<9<72QW4^[372V&U>8]H0BC
M/NBC;?KHH>=5#344F%6V0;J;WK+#V39UU:RVYO[679LMMWN/'F3(%RFG,EBL
M13?1S+KOO&:TCO*4&-$01RN  V("EVO_JD&C@B_5L6OYO:L(TR>,49U%W)'8
M,A:!*5LL0\-<GG^?RX"=[JG23I[]/#*+[1<I[1W?\>LRH'LV[R_<B2D!]5<T
MAZM\=ZXG6NU%R3#;X4<UXJI"EPM##EY)U;O^]7Z%D^+6M*=2P==!78SM@E.K
M%\;O<>NKHD>I,U/R26_I?4(U4'Z+!FS#YNZIG#CI[2KENFD5TS+7"N1(3M+Y
MKB!$%+.9G\HU[>($;M,I :K7"G CKO75\^KA6.OX=-6*,ES"=J3<!R[_ ]93
MUZ\*"2.0@J)<F)W2OH/@TD%P;,,E+9@X6F(EA,T'*F]F-^Q!2/ X/GS5&7]M
MHE/96%'CB^,M5\^43_*\'42@STNBP?#TU=X/R*WB"A=3XR,-SK)</$Y*+;:N
M<0.?D]46/]^KAD\,<7%CGVA@4Z;\&[$1\WFO!G*7V:.=S!?#!_A&Q]BCA,2H
M/T8/&)6C4CB$B0#V8ES0U==VPRT5H4L5D8D1'CQGKJ3PP*0%7K\3F4!UQ&PX
MHRO&/XQQ;Y8%6KO6GC6<3ID1Y6)?4K=?T.A8Q74RRD55]VW&N8Q(2!**RN0J
M H1J95(5"E/5$;F)8ORLX;-KBFWY&<VY PT9\ $Y#X'WXODNX)2M6V]BUIL?
M@I7OS&B)4A(?/.DO%"4X_3Q]_]*/J:N-!ES;3S'*XKR)@-80>^/K5[7[@;*K
MIC6=#R\NL-Y 7(U?D8K"$H)J3Q&!PW%N/LY:(USR:<<W>-B.DB4^4LNVAW]X
MX=&@WN)1P"JZ:?LE>Q'_-\<1J.^G^ZXN.6%=L;1=#E4-@5;:M\?,0O'-3'2(
M1=.-4B[/[C<"#X?E.6>HAUM:LOAE<S"IGK??@Q;]R/C@ENQ\M>P'WDQUG32+
MAPAC;IYAOMK&.]JR+V_PG95"L]Z(!.<6-.^HTYJ^M&I<=)SG77_[^8>I);9I
MCHN;8D_L3ZMZU91H=-W/)$BFJ37A8G&HPBB.KE=>*H)"?K/J)2^>QU^OZ];E
MLJ=7[R]]2OVT O]@CK>G(DL"O2!96?7>HL9Q:>S@P+V)VF*;NP:51^BR4+WP
M.&>=1I6(O+OP! &6'6-KJZ/<W<4ML#J ?"UP31F5.)-(J[' 2P3 !4>R9><]
MR]VEEVL;!I]NU]^'FC)9#D R$P(U.$KY>1/SP]58"$&)F!"CA\8E_5P8K\YZ
M/<P,,MUHU>+"<Q,T5L#3XNP4IX#!34U6$<#@%>5QJL< E?B-)D*P]Y1C<@>C
MK*"1?8JD.U^XP>K)" TM<4]J?!9^\QZ&]SVA(2"0K\"N_M'MRZ56\=E5U]FC
MD%U?9*Z_=WRWDQ45$XG&SVBD5&VL*B_QQ TK=^<X&F1@E<MR"(L&Z5VA :8<
M;LN;#R:T#Q_36!#7$)9_%.F(Z^MJO+VT]')B?"DC2&3#@68T[[ NK^]+[N%T
M5-0S<)V)7<B^*XD'-RU("56TA_3&RT%7Q.!=2-3(F&3B>8M(K8*]2?=W+MW:
MN?YLM0O5PZA,L%A^_72L1[O;@MO1L#6I'QUL>#S"WBT]RM!L]&NK8(P9-@0;
M8H]_B84,';YJ3*_&?U4D-"40^[)$?7#GNIEY[\;ZZR/)^!G&^<K3@^\Q#-6A
M%CB/4TF,PP+GGG?29:REJ@_ 6LJ+\<;"SS9EAZC.,PV%"@!/BI R2Y9+UT8=
MV\HF^5^$Q-3P]_'K;UH8'IU?0M?>'7V*6H"J?@ZM%K:/<ANPR,Q9OVB<3SW#
MGK%C==J*L.FIB1ZSSF1 +W"A)5?DDCLKD/*G!#-6NX\%5)U\<%69NK#944"4
MTBC:R=-E;"$0?\\L%[7 H2'6@$,\./OR!/.F0U/E;:7+RBSFV_&V9U!O).P7
MP,]1</T2CG.+\C^2.'E@$,N>R21Q:P@V1?.X6KC1+VMSEB)- \=)CJDF!//V
M:F0:---/WA\*%8_:[WCL_ASK*W;O]GL=FX,S9>_X:X/G/I>J;J*OQPS?PE4<
MK7M=CWR^%8N)3FG2H^]/:;,.=7UQD=NCCQ>T7AQA9K4[(\ZX_D9)?C;SI+=!
M<?61[!=N-MS/98+<B<"558)>A#2NS86_ QR 7=PJ8TM"B99#4=X<2]3/>?QF
MM2(T*-13F;:ENY2^X.=1*54OIM(7'.W(Q[;@ID,EYLWW/2)YCAXQX)Z=1R&9
M-/Q@TA'@"N$Z;Z\A,8MIL?&0C'2DW;\Q*\[N%<G9?2=7Y02,:;O/_#Y:V'J;
MYT8!(4@;$R2E.WU#M:-4L>CQ^ =D<+T-<Z'QY:?,M*)ZZ[/O;Z@K[U?72 07
MNP7;:PT%G>CNT.%UV&8SXOFM5;WF)*\:E7P3ZK"=\=A\%V^-3;OX M0"7PP1
MP)TIT9R[??&((W(4GC_5K7RJE()"RU"Z+0//\6XN$=4+?<)6O6!]GNM"W8X'
M1?,EO:X7M^Y;B461#YZ]F]Z'Q&U%W<2HH^7HGUH-5N4H  TT%^YXJ6'CP<YC
M&Z/ -&4%B'>]'J)P6A*)%4EOY$9-9G_X.2$F'\,TS??4>4UCTP@.PY)S7L*/
M[O<OH$R^CBA_HC__Y(RE1;]6?\=:C'DSN/.)OGFPY>^.B+XY"+F.ORYM#4K&
M==&'GQ#'A&,F>0?]G)>FGJ4S2BX'/KUY9DWR81$1N#8ZE]S.*-XWS]M3+>6H
M6Q^NB+PSD5]_M1W<"[TONM5&Z%([@UO :0?ATN<J8M6GS;<NK%RY/?\Z!W/F
MO?BS*_45@^%%U5*\[6\.8,@Q/@3KMDSW'8$/$U')%H%?L,_%:FZ]'CRKR,=\
MB?:(O+HH+_X2MF*SCPO4"-SN4?6\_^7RK*DCCI4*@HI,YO9SC?>O=[(EKQ0'
M:[9&2/?9K^>A,"SV0]J8VN::IB&)["PR'\&0H]ZTTB\VD6O!O:Y$0$DS),Q,
MT;[!I-[CI?4T(J7UWL7$F67>%T2 $SN$J^.)WQ.S<%,X*Z;H[H>K-UZ6>*K=
MLXC$6^AI<:T:00\LG([)PRDOH.5PY;-=&0XA3\+@T'BK^S?8FAI%O AW$ZV)
M@#E+KC%AZ:NZQ)?7J2T%Q3CM+AL5JLQ]CJ>4AGF.%SHC(\\(8@97C,49_-_$
M!%:;85YGUH_GYCXZ8EQ?^[#E4+64Y-NKPMD7WW:VEP]8-L%&6?!/\5?QC["S
ME2^;3O8O>1=R6-:C]-Z+?.S1,T02 0[!+%I-<&$.QN?WU^/\++OZG>O7:*JD
M K*KA$YJ((UY]M40?-POU/7QYKE@DU46KE6/][0:(TLP.Q65TX*H]3SYV<!.
M[6"8(9?BR[3J57Z7U;B^<BRZ$S2!/.93M'[B?7,K\IRV\8OMLS#'+LW/]34O
MZ5*.,,9_"5+UV\SM[XV?-\-U\'8F"6CE6M>/G!RN8D+ZE3K<VYA+V[0X'[>"
MRC>D9M"8Q*+.J;Z>.\'1/5U0D%OGS56XOMX^>7CH?@;3$]>#IX7NZB7$&G*X
M!\PO'(F;.I4Q19$@=YE5_^!1":];"6RZ !!._NY%"$^\*A$ QSLWV(5;4_[G
M<46=(T5X,QJR3SV1U:]3[R1$R=X2O%:*OV)V#B?310CRQ&SWMAICJBK\YD_!
M3[[.O.7CPQZ:<IUFF,=RL>[FAD@%N*(\_-K*LW\<['/O;4\^[#1^]G;B@G1W
M!:.RRQ),J'[/WFFDEA#BO@S+LR\E\91\_.VM:1B7VN6\8)$1.2OKF4N #C?
M3?WN0JL[9CYS7HT!JSO,OW&W&NY5XCQ3Y*FE621M[8N=SD O,%2NHX^,>W,T
MUT[C@D=WS-W74F13-N$AFWLK^A^L?46GJ0E3MBBL21S7J]$Z+::7^$+KS%&
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M?<->%AT6_NIDEK*5L3L2JU,&&,7,F,Q"QP\Y]-7#*ZX$C%Z1L?A@E% @M6)
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M\>*D$S:WO,[7-QZCK^Y5J3K"!PUWHT'(7[(V2BEQ)IPJ?!LCNIYQ;1F6F59
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M)UGRA5XALDWQ.CK[>#]2M/X'#T/"8'Y%$[Y;J/*7*?VL+19*/\'RMT>I>0P
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MH'A0Z>$" ]"5%=:U$(O3J*^#&5#"LK<3XDY*7;+PE*G=/0U^*)V6)GCM@S2
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MP%'J'>6/EYV&81^T!KZ\67UN6A2Y8WMD^[J?#8N(RB:3@)53[C%;H6I1)WU
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MVRUP>;SKAR\%K64:7+2,8]<$1S_IK<[[)>:?@@RRH7F;#&P<[R:X)YWJ7V,
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M.!=6A_$;/^I31AW2-Q3"K"LD R1^^YL9M#I 8M>L@#\/_WY?>8)F06ML%=K
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MQ"C=QP^<D[8YJ7A6";]L*VL"?K?Q7_SM@JG_'_^>PO_,G*;_-U!+ P04
M" #)@EA69,2J_MQ  @"+B1< %    &UR:RTR,#(R,3(S,5]L86(N>&ULW+UI
M<]RXEB;\O7\%WNJ8'E>$4,4%),';RX2\57O&92ML5]_IJ'@C ZO$KE12EV2J
MK/[U W#)9"HW@ E2[+X55TXI2>"<!^2# ^ L__2_OM\OP:,HRBQ?_?,/_D_>
M#T"L6,ZSU>T___#;M_<0__"__N7O_NZ?_C\(_^_K+Q_!VYRM[\6J F\*02K!
MP9]9=0?^RD7Y!Y!%?@_^FA=_9(\$PG^I;WJ3/SP5V>U=!0(O")]_6_PE)MC#
M821@R,,0(A\32$7LPS 4Q MHZ 5$7MW^108T2H2@$,F J\NDA#AD&/H4B50F
M!$5!6#>ZS%9__$7_H*040"FW*NM?__F'NZIZ^,O//__YYY\_?:?%\J>\N/TY
M\+SPY^[J']K+O^]=_V=87^VG:?IS_>WFTC([=*%JUO_Y__[Z\2N[$_<$9JNR
M(BNF.RBSOY3U'S_FC%0UYF?E D>OT+_![C*H_P3] (;^3]]+_L.__!T #1Q%
MOA1?A 3ZW]^^?#C:9?JSON+GE;C5(WLCBBSG7RM25!\)%4LE?=U:]?0@_OF'
M,KM_6(KN;W>%D(>;71;%3JM:RE1+Z<=:RK\_UMG/%XCO2-YJ7U8'PM7J?G(E
MXRE,/SD3]YOB!S&^P+UN+A:Y>:#>K?A4S^ZFJXM%'U]B5X]%7I'E!(_%MIN>
MR$O]AX_J4]N-;N@$F=;]M-3=$U5\K\2*BX8M=YH&&?_G']2GQ;J$MX0\+%ZO
MRVPERO*:_6V=E9DF[^OO6;D(DP!SCT204I% Q$,.2:)^>$D:IBQ*?)_&BVKS
M:"_$"O[VM9.B[LJHGQ\L]*R.O*^%*/-UP;8SW?WRT/2E9BX]U^&?5^1>E ^D
MO4$)JXV"1OY_Z<0$/3G![UK2__^??M[J-AS7Y51H+><'5,YVQ%EJ8R$OGL.0
M,U,8MN]@J32H,9"DI+42;1,*D"#X62RKLOL+U'^I7\1SO?R\-\K71:<!*=B9
M06BO^)GERD9ZJ.#.>&B;TDK5*K=Z0!J E0@_@+S@HE V\ %U]A[:MT*J5OEK
ML5(?JALUX%\$6;Y3=EXE?A7W5!0+'J8I$WX"B1 ,(L%\B&-/P)@&L9<$E B&
M;7CA?)=SHP@M'Q"U@':48("N&3NXQ6QDHFB%!:VT0(M[!6H0&XG![XW,#GG#
M'"!'%&+0X:1L8@[ <V*QN',8Q]RLZ3)COU794K&6*#^L'M6Z.R^>ZMD1"<1\
MA$)(I2!ZW2P@04D*.8F"E*<B"$(K=CG5V=QX92/<('OC)*QFM.(*K)$)Q1@G
M:]HP < 189SL:E*J,%'Z.4D8W3.,'MZLBT(U]CXO1':[^D:^O_O^(%:E: EI
M(1DF:803B'U&(4IH *G/ BA\K#B")$00*X8XT]_<2**5TXX;SF%J1@\.D1J9
M(5I)02LJ4+*"5ECPJA7W1W>T80B,(^8XU]NDY&&H^G/^,+UM&(6TS3:=L*=O
M!5F5A.DE4GF]XO6ORWJ7NKS)%8T]?1/?J]=*JS\66 A.4QY!%GH)1$RFBEQ(
M $.,(D&E+P/!;,AEL"0SI1W0:0)ZLMMQT?#!,6.I22 ?F;\.H]UJ <B*]^$O
M0:,(^+W]5VL$:I4<FD87P^J(_8;+,2DO7@S7<\:\O,%A7/HQ+\LW^:K*5K>Z
MWQNQTF>H;Y8DNR\_K>L]"[5<BU.?"2@X01"EC,$T)C$4<1"HWY(0$]^&-,]W
M.3=VU!(#MA7Y"CPT0@-62VW'D :0FU&A6R!'YKP:PS=]#%MY02/P%6A$=D=I
MYO XXBZ##B<E*7, GK.1Q9UVM'-?_+&X]A/O4UZ)\NU:* R3=FLTY-Q' ><P
M\:A:^ DB(4E\ 96]QA,OY$&*N0G-'.]B;K3B_Y1X_P.LM)R KX5V-4G,J.0$
MC*>IPPTX(U/%(5S.;R*; L1;5Z!Z-AT9J)V^9O(@&?/H>0@:WE37U5SH!XT+
MS]^?N'$2_CLO>,=W!E<.,ZN^B%*HF^Z4[?96/(IE_J ?@^M"V7&W0G_4[%HH
M ^];?B,*F1?WR@#\7-TIUGF3W^NU<OW(O"/%2O!%Y$6Q%WD<IFG(U+(UE9 F
M0D*?BX"Q-.4QMEJV.I5N;JS:EQ"(6D2@/A&E7:.<G;7F=B3-#+L7&Y^1B;W3
MJU[B]C0#/=6N0*<<J'+0J@?4#] HJ+_O#7"CHSNC<13H'=F7;F6;U!0=!=;G
M5NLXG0PP<(,PVLXHR.L,CT D"4H2&"120)1(#Q+J8QAZ@4"8IH('B;&!>["+
MN5%Q\%,8[=HER+.PWP[#:&#@7@S.R#S8X%*+"-ZVN PQ<(\\9^8&[L5 363@
M'@+,D8%[$H)3!N[A&Z<S<$\*OF/@GKYRF('[K2!Z2^"K8.NB/B->!(S&-"$,
M\M@G$$6$0!(I>HM1Z,=>DM"8XT6U<8H]:P3M]6#%;D=\?%W[*925?OHM-P#W
ML3,S"R]"9&1*>RMH!;:278%6V*O:UGOWMW56/>U\__[?X*</[NRVH]@XLKWV
MVY_4?CJJWG,;Z/B%P]YS'0O$UTOQ67ZM<O;'7;Y4]Y;->'XC="FVYW<R\CQ$
MB("8<F7?1$D TSA(H%J>IF$D&2-):+-*->]Z;G;/U_7]/2F>0"[U8N5>+5-J
M#=J3/4'*M?JR^5/_H,>.12Q&QHQ>QL%[9-[IA-98]\7N*.?W6O)QSDSM 7-$
M1A8=3\I2]H \IZ\!+0SVA!=%(?B'%<OOQ9Z'2G/XL59,^OE!%,W!ZS4MZ]7C
MPD\%"1.:PBC"(40T89"D 8$Q20G#?BI1:'12X4"6N3%?IPIX*/+'K+3V'KED
M6,Q8;B*P1S>W6IP;-0Y[P%V!K39@JP[XO5/(K4?^I;"Z<]4?+,G4/OR70G;
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MS('C#LZ 2N&7H^JL,/@%HDQ<!_QRT/;+?CMH\X)%X">E.BGOFD;;5 H+QM.
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M32-Z&'7F*\@Y9Y T88%I G&<!)!S)&@H(U]XX>*A]GKX6I&B>C'LG\OP B,
M_C=9K4GQU.S[^^,,"&5Q0E(/0X5\I%Z#,(:II#'DH4]C7R:)QY-V0-ZM!F?1
M=30<G00O,1AO!:L]*9O1"$<:#L]C/!51! 5G$B*"0H@1(I#['E.,)2E6[X?5
M&G:$P9AF"7O3 Y]4@Q>PILB;F38CH#GZ.NIL@F/7>=XM01HMH?'A7E\XH?%)
M*,XG-#Y]^S"3Z4A.K'[EQ+-57#]F9;4022JC,%0V%4J4316%')(H2*#'4)@D
M(4&26YWENQ)L;D;7J?QSK7)35<IV-O9F_/D2(SHRP;[,8%J3LFOD';&V,[$F
MI7778#[G?>?M#XQ(UB4]7BL)N#X24NTV#@I%H9[_)JG^ZZ?M-6T.Q>L_2<$_
M/]0.#N_S0HJL6JOW[<.J<6;_J\AN[RK!KY4526[%N^^B8%DI;HJ,B07E/A4A
MUUEC4@R1YZ5JH:A6YB*)B#*+4QH0JT7YU K,;:+I9 6ML*"3%M3B7H%6/W6%
M+M7$\^62%"503U]3MLFR:M/DSXO9I#/GIV#DR:E6"]9Z@;[RH*^]3G_3O[ K
M>%)#H+/EUB!L'A8-@W8Q:8"X F<>,H=1YR\TCJZ"V:<6?]H8^1<:G+W0^Y>2
MPSXMYX=5I832<W6]C+LI<KYF57F]XNW'+[K;\GET[R*.L<=DJE.EQR%$PJ>0
MHLB#B40L3$*$!2&FZ3D'RC"WB6X3G%X8NT=?,@*GYYV)<!UYZMAJT&P478%.
MB=H'L?T%%+4>5V O8\#XHV">H'."T9@H4>=HHV*5M_-"/$_D[QS:\F1Y/"]4
MO9_/\]*F[&><=_>BT(>NOY+B#U&5=41AIN>Y+J;S_7K%RRZ3C!=[W$L99&J,
M(&+$4],,1A#[).1<1B0*C"+_;#N>V]S2R0[N&^'KBN3FV3FM<3\_N8R%YL@S
MR@;(5F[0"0ZVDH-:] '9G:T@-I\YQH)ZHNGBZ+.K%G ;R*56P5%&YR%XG9@.
MK)J;; X8HF2?^ ?=;\_VK8NV/B>ZT1$C7YN D3=Y6744+]3_0AE 2B,.$<'U
M@0V'@O/(5[_B6#5E2/%G>YL;KW<A./59:"TR:&4&;^J(&G/R.8_T>5)WBM_(
M3'X*.B7O /H^CZ Y9SM%<B*BOAA1*Y8V1N@$-9]O8S(^-E:G3\+F-PVL_=2>
MVBAB_Z14:(YN%EXDO9B$" :,4(A0&D#"H@"&81('42#CB%H=D1_L979,2YZT
M/WBY$Z'8Q+QMA08]52S+/!U$VNQLX&+\1F;:GGQ7/; <UFTZ!8"K2DT'^YBV
M-M,I-?>J,9V\V+YJ^+NZL-,UY^K)*.O3V\]%G5Y>B;Y@' <LI@ARFB@;# <Q
MQ-Q/H<]\H305 IDML\]U-#=2:&0%K;"MBX2"%'0"FU<-/XGO:1YPB=K8R^?!
M@%E5#3=!8U#5\),-3U8UW$2]?M5PH^N'NE?D1?5-%/<Z+NK9&=,'7?U-K09U
M?HB%'TCAQ6J%%H=1 E%($"0X%- +8R:B *=>F-JY19AU/#?*Z$2%I#UISEIA
MZV,?[5K%\OM[?3A'EN"!/-C6SC4>$%._ _<PC^XOH$2&6F:@A3YPN-\)7F?
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M?+T4GV676^195I%OA"Z%C@*K@\ 6)&(TH!&"#!,)41!',&4\531)"(I8Z.'
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MF[/H<SW.S2YK!+8\=SX+J^%!LTNPQCY9KF7=<=W?RCO*HMD8'5?GPV?[F_9
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M8VF85<@"?3-.=HOIR#Q;P_FF#V<C+V@%O@*-R"Y3$IC"XRQ#P=D.)TY88 K
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M_Q6*N+BMWW)YZ1:]\Y UI9L4/>MXNFQU*U9,$?0V/.2:EG68W<+CF(9>J!8
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ME?!QF!ASH\=W997=UZ\HN;TMZO4S(#WQ@6CDOP+V%8,'#I09,8X/_\CTV"@
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MKH#>Y7 MJZ)^EK=!II^;^K>_J":J\L/JIDX-O9!)ZB5$4,C",-'%(4*(XY!
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MR 1BGQ,82I1XB0QY3(VJ7'4/,[<EX2 EJ,0$?U:"6H8%7@#5S ]Q/50C4_D
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M@)/2E3D +QG)XL[!0:65>^!KOLK8\[ZS^%)*SR<Q#F$BTP0BS_,@YH1#*M*
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M/M]DHJ@C,OQ(>B+":J,:H 0B) *( R^$DOB!+WPD4&35'^CB2',S;7N;12Q
MK<+SP/*,ET$WLX2=0#GV N0216N#N1<A1X;SY7$F-:![U7UI2/??8&]0WZ"?
M/>]SOA4Z9SWP4-H<9 =A1!5UP"#U&4343R#U4T4DTDN8C..42J,@N8XQYD8A
M6LK_!&LM)^ [ ;2DYD;4)2#[#5@'\(Q,"Q4RI8AE90LMY("S[4L0F9N/#J":
MR"H\!YD;XZX'@PZ;[=*=DYEB/:*W+:R^2^V9[D.QS1X4<7Z1[ZH*1]F3^+K1
M=;)U'9?B[CO9_G>V6KT5NB$;*;XO91!)++P(*BM*0H1##K$O/(ACQ'GHR2#&
MS)0";0>?&S<V\NL(?+;7 #QN1-D/@&DE=*[X%OREU !4*!XM%3%G!^OYZ6?6
M,5$?F7+W@'^1X" \4-*7A?Y+^8%6 &@-E,$&/H\.N#E/CPG\1 0^^(UW5-IR
M*(0=_&_]R,D6AJ'*ME>,P<\8M@?7'7_54[YN\J>,"_[V^?=")['L^X3?,"5
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MBV$J$(*2RY!&DA*?&O7IZ!ID=@2[EQ%40@[BT[-PFO'BM2"-S6^V^-BG<W4
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ME&M,;[RFC;5.I_JHA'Z?%:SJV2SXH6/S9Z$&NR,_OHK-^VRU4^+<:L-\R6C
M8T8)3'F$(>)1# G1)0\1I2))XR"F UI=#Y)E;C35[H+=5J35!QN\45\;UX&>
MFP*H?ZUV.Y<;%3N?/E,WR"23,KK;I)R/-UJ/G[JG1>\RU>\><[64E,4LSU]7
M-A;3OU=Z+X#2'-2J@U)WU_VFKYH ISVIATGR"GVKKX+L?&_KZQXY-,6,*L;7
M%J=V57U6+WG=WR>F"25^F, @1E+1KV 0AS2$**:AC'F(,38*F^H;:&[<JN4$
M!T'5AZ@N'IBM<!%<,W)T =G(S#<0K0'Y6]U0.$O,NC#,Q!E7W<J>IE+U7#^P
MO=JNR-:B*&[8_^RRJLM'^>-&-*\QC2GG4>)#3WH>1%(B2#%+(4_BE#',/2^Q
MZL+1.^+<R*(1&+0D7H!&YJ%-UWIQ-Z,/IVB.S"/7 FG?BLT4'%<=V7K'F[8Q
MFZGZ)_W9C&^T#QK\(*5@.B=MW\WUF]J=?A-:IVQ55[O,U$4;17,94?ADNGJ<
M-IFJK>L-521(V';)XSB," I@ZDD*D4]"2+Q(*'9*$X8]I(MLF,85.I-J;N35
M%AJ02NIR\_)?YA%R[J:LF]->;2)&YKV]3NT&TUHM<*S7 AS-5JT:T+HM&O?:
MGXU^%A&.#C\YXR#(5YG'B>(D)YY/J]!*Y[AW1%^Z&VNR $WG\+1C.-T_?'@L
M2;9M\H:/:EQ5%6MT_:"R?- RH@'V61A"#XD HC"0D!".H2_2( V1\!*[N"_S
MH>>V4!Y79=,>O$_B7GVUNOF\KBS\SOY4V6(>S(S]<= =>?5K"5W">B3V-*6M
M['%S&*)B./#DP2MV@)P+:[%\PC R^ZJK1Y=U[\OB%E_59[@16[45T6.?UI<I
MWNTVFE[;G7*D'^$PTLZ+2#<(%*D/4\J1^B,FB/L)ISBV:Q!XO5!&'^BDS0-O
M&-OH\PG]C>9E'1%623V\<9&#N3,CQHGF8Z(BH8=>@^=+:]72N^-'=_ YXDT'
M DW*I^X ?,FS#I]L[ZO178:$J$^GUO>?!%%FF/[C<[Y]%EN]!BC*%[RNXQ%3
MS"G"RHZ4"$'D>0@2'PD8)8*'/(R$(F)3AXS=T',S)BOI%R!OY <K+?NB^@]8
MYUN@E "LT6)1AR&9[^DMIZ;?\3(>X&/398WU7G3PJ<*Z_$_9955C_>Z =4\M
ME&NQ-G>2C(?Y1)X0Y]A;^3J&P=?AT+!\X&1>BV&*MET3 Y_@JJ)MO8J5*Y0N
M*=/J<E5?]86NLOLJ!N+7]8<?3,G[1>KK;Y3@:H]Q?[\IK>"N.Y>1E%$J> +]
M5*>Q$A) 2@6%D0BYSUA*@L"[KA3N-(K,;3FKM0:/6NVR*I7:)1QU'Z2U@9KO
M=2CKDI7JZP@G?2<@)0*+GANO+=8[T;MF&MTQ_S=H].B1<WL8_6?U)K6;)S;7
M?#EZC3[L7Z/RKIOZ->J^<<RRPM/.X6CUB"=2XY4+&4\[6?T5D">6QW[7IY-:
MU^J3>/XL=$O)PU_5#%2[RV7B2_7=2P)IFA*UTPLX3+V$P!#Y4<(()5["EMM\
M2U;].[W^X:R6P_V@XS':G1YC[QW3_K+U7M:R-*>6W]A99@AY_P[.+9 CKPI[
MZ<H8:"4N:/W+7F"G")KOR]PB.=%>K'HKU2+9_V(ZJKEF#E/'GLO@(9/ML\P5
M:N^M+.ZR)^.;((G4'DT4[W<B\"*_SDJ-*.%2D2\,>:S];;KKF!_$, X8QBAA
M@GK&L4_GAYC;'B3X.8G^4WO.1 'X3@ MJ3D]7("QGU2O!V=D(CV'RX J:!<
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M#[$7QXIR?0]2F3 8,<Q#Z5/"";(/0;@PVMP8M?[^]M*"1MR!MELWU#:Q" X
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M*ZEIQ;8BH E:4NDLIZJ%L.ZOJ!6WS2Z;9++-&&U^4S@R2QX4;LPIK3,HE5Z
M2FU0ZPT.BN_+ZNH^NTU1K6T.*OU!#4 [,'<!*@Q  X++W+8I)\U9)MPD0D^<
M-S?E1)QFV4TZ^L"E+2M850!3\'W]R^,"F6<O>5_6W?GZ72VP7W;;*JOT1=7,
M)0]3@GWN04\R7>Z7<4@"@B&/8NI'<4CC)+%:S\:3=6Z+6.U&+LL.\)9.(#^I
M5[O5]4DME[@1)]UP79O'5(Z]F+5G;J_#XKB4?#7)YR\%E;Z@5!CJX]-*Y<5I
ML6*'R]?X<^-JS1I1TFD7JO$A/UF=)AC2?=N2?:.*A"32)T(M)E076L*80RI9
M"C'WF)!)P&EJ=-)B,^CL7"U5HZ>CV(FLII95U:5B75G% ]8(HUDP=,LXQG9L
M1TU_\X^I>WB\0D>.^?77N*9;QI6]+W30\#NR9ADG11W+Y2<\P5QXD.&$0\1X
M!%.&?4@HPXP%-&&A483(Z:/G1C.-=.:A^2^@ZF:)ZP 8F0L:P0;D)[P P3PK
M83@8$^4BG(#BJ(GV><4[L@Y>W#!9KL%Y0=L9!A>N&&80_9+G_*]LM;IA_[/+
M-H+7)EAI>BVY'^*8Z&YL<1(J'B(1)![&$ 52)#YB# ?<QA#J&FQNS%3*6&0#
MBAEV0FIFU;@":F0&:\1<@$;0_::R%-6= 6,"B"/#I7.H20T6$Z5?&BI&]PRC
M"F7GZ"J@7S?Y4\8%?_O\>Z'/N_<G8C>Z.E)5&?=,VYNE;A* J*=X!"E&09I1
M*.=4)Z<G.A(VB71>NKG'[CIQYN:4TU9_66.UT4<7]S@<ZQZ4T7N#LSVF[$CJ
MRLDTH['IIFADHCL[.V^T-FI3_-/9>5I8SI(U);H!UQ%I7BG,I+3J!KB7Q.OH
MJ<.H^>:)9.KO*_$QW]R2E7@OZ/96,,7]>L!6VL,O&[5A_7V]$62E"S+J:HR5
M@TU[7-(@P"@@!*8)BY21AU.(D0XH\BDA0<Q2/[3R>SF1:FYVH58"%'LM%N!>
M"P]V>^E!>?AFQ\9NYL^,E">?E=%/]=6$W+8F9*\@5,)"K>+B*"VLU L<%"OK
MTNY//9SZW9QB[8BJW<@T*6,[A?$E<;M]^)6[\/7+ -)"'Y2L\F*W$8>&,:G
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M41&HBR-8D<D$66)W>HRRZJFR&T0M;/E9E)X9BP3RLWCV[_ZO1FEDYBCE XV
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MP>?V^;=K$??V ZO=?I8E2ZWFQNRD?RS$1^84MV#;%X >@)JK.L\V0T];SGD
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ME,K!!'6STBO /O:1>O8#E.H K0_0"K4Z@X!2):!T E_60&D%&K7 C3;D2L5
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MQ__:Y.MGDT7QQV->E$K5I=DHKT.=8A$%-,TPI#0SMH0) I>8F#)II@!.E,H
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MU]]E:O;)UUI_T *P?5;TH]* X+'X]\3#YJM,^%1B3UM0?.+!>%5Z?.K^W29
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M]F>-H4T,#*S=)E'9YEW=EO+YKF<JD]&UX/DR;W)8F<0J.S\G$T))$6#( Q9
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M+K<-W(N7=^:Y>;^->MN=WFZ?:<94R 2AD+(TA"CB*609(3 1 4Y0)GC*K0*
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ML@,C_!7XVD!M%.@N&0]J^SEI/,@GFH1\0^\TYPQ#[\0DX]C@9+/*,$7[T\C
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M>;I3 .PU\+B][@>=K[VV8^_C;KS[0?-L%]ZSF3XU8MER_<^G97.W2CA.2)C
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MMOEZ\N_N"19U5*5)TO"5RQ4M%FMSYA63!%,1IC -<F5AQHA"PG1^7!83)/.
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M$:9&1?KTO=R+YT8?/4; CEB&Q74RMR'Z#WL==IM:?[34'T=/A-5#@%&IK#]
MQR1W14O7W"CK/"0Z#W>5-V"K-JN?'NJ< 7K#^G:QW&ZD,%O<>1ZF*([#!(HH
M"B!.D@1F..<029P&&4%A' KW"V0'":9&?O7\-(GS]^*#O?S@E3*KQ'JYI$5I
M3A>-L>68/=M]H%RND >"?V"./,Q8='X #">"6HGJE-#W37 / +U>_+KT_P+W
MO#W@.7VMVZ>AO@$=Q>*15EQ<;@IS /%E4?[=^'QE.,E2DH>0HA I$LPS2(.
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MD%G@YHC13Y"I$9/Z#&-7=XN>0V#K>C$\L(.[89Q*9+ K+E/IL?]KI<D,:%6
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M10BISD>#*,%,T$2F1-C&!E[H:VH4\6V]H4L=(VA$!=3(6@4LJ^Z510<*1==
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MQD=EB-.*'4_R,T_UG*=TN:W*>"V7ZQ^*$&2Y3]C>Y)7#'+$(Y1CR,&<0XX1
MPDD$<2@)U=GZ.',JSV#3Z=3F]-=W;T#C/#\#00@1F8&=(F"OB<F8T.C2LY"6
MU:A8$H1GK >FC:%@=B<9!]Q\48]-E^,2D@,(SVC*Y5UO=[KEJ9SD!.4BP<K<
M"$.:0ISQ#"K>XC -<APG$<U9:.7(XMCOU"CLU%6F<UBN'>*];W^OQ?$%;H/+
MX=/$.P(UW'WQR5Y?^OZX"PJ+^^3.U]WOEV]7&_7%&/\\'5'WN]J)J99U1[>K
MA^UFG@9)(J0((4Y"I+=" <RB5$ >"QJPE.<"6^<VO=#7U CHLVI,'VH\JJ5!
M J&3\^E4WCJWO/VEYB5\&8MC&D8$)@AE$-.80)8B 5D6$TH2$7$2SA]EP=8C
M(]SN<SB,WPZ#:C>A>T9J8!+?2UH%-,] 2UA@I/4'G/V]ND< 1[I+OP9(I^MS
M2V@ZKLPOM3#:-;FE*NVK<=M7W//SOUFORO5R(<QW<KN1]\W>4N LQCE7VZ\D
M48N4$!32+$:0Y8E,H@AAA:YM>OYSG4QM=3J0$QA!>V3G/PMI-X/Z FI@ZNR%
MD5-N_DL@7)&:_VS3HV7FOZ1<.S'_Q6=[YI_9LE+^8ZO(X]VC^D]]V,P(#9E(
M,ACQC$$<QQC2E*4PPP*E88KC#%LE+.[L96H3?B\D,%(Z)HXY":3=QO=J>(8^
MA3M"9H!#_$X(?*5S.=G'N%E;NM1\EIRE\V'WS.1O:S.P2G[W;B7>JCW!/$\#
M)&4D8<YRM4'*LPRJ[T% 1 0*<!9F/+!R9#O;P]3F>2-DDS52B0G>6N^.S@/9
M/=>]P#/P/'=&QBE;>:?VO1*6GVYQM)SEG0JUTY9W/^A^IO1))^#6"= +^5W?
MT3_**CF=COM\7M+]J]QLEF9_<+,2;[;%ABZ6^E^_*>M!O_%%\B4MRT6^J/(_
MW8C_W58I[G2ZS)M/;VY?RWQ=R&_TYUQ2@7D2"!AD*84XC2+()$\@HWF69P''
MH?UIU8MI,35"VJM676/QO7:6Y_$O^U%</@SZEQCJ@<G58  .0&C2?+[26OVB
MDQP;*$"-A4FR-P-[.(#" [0  1J1W=O'L( ]+D # S0R,U!AHW,E_RM\6_;G
M9?\2W]A()W'_0M^:T\'?BX]QQY'BR\DVVF'EB\/?/@9]>6'<#;>O4E>?DLOF
MF 5SGJ=Q"M7^*X:8*D,JBU (>9R+((E8B+C5L>KSIJ=GXE32V2\Y1U!=MC'Z
M S#TZ4DM6(\,&4<@V"^&_<$8:86R!\5I@3BM=P=K'[TP&I6>%K3-;V>><">=
M@YC)FZ)0PV"(\'.Q5N2HL[$M5G=S&68LCW$,49H0B!F7D"1,<1%#3(0)2]+$
MRB7;NL>I4=3-<KG0;FF@D(]RM94 @@<CK\D+J02VG[9VB%^F-.\X#GX=U(Z8
M;@D\ Y7(X.LP4-H3HW=(1^++ZZ%UXE$GF#KHU:Z=T5C72:TV&;N]V#.TLL.@
MO;E?%YO%/\^8II_UX^H/*V':^+PN-X7<+"JG@)817+Y?%Q_EQE3 J:M[ZUQR
M;PHI%IO]GCOB/ ID3&%.B80X4[8I29,(QE@D@8A#&DNG<C5346QJ*TY5NZJL
M:]IS(ZQ.H[D#!"Q,Y5JU2U=;;U9OU+E2S#%<<R+XV\9Z3D3<"2VLI\YS7E6H
M_&*2?)X[SZD^L5I'DS04O*K4O'"(D^\/<9C'0YRICK&O8-2IJ#5N).M4M#YS
MCSXY^:XN%<65S;E=ZB*97;H=U2H*D4RB1 B8X(!!G BUK%-=2BIE/* A95$D
M>M:.ZB//U%;C-]^U46>26NNA!^S)$.YZY>X*=.5 V2V3(\(_] %9N\K47A=P
M\19CK,I3U^#KOQ15+VE>JC;5-=!U%*NZJME^]%L5Q)J'.<F(1"E,>(K4YB@+
M( GC%+*8! REL<@HG6_6&[JT8]&J62<RW#4^W)3\IOOH54"OALF.P]R5'YB*
M+FCL3"*'"GKB@KK14:?TH2+',_/HK_TFF#*@WM#R^^=B_;A0>][73W^4NNIF
M':*WNKOAF\6CR7&ERXPL5EOUNSK#B:Z8S6C&(EU:-Q'Z,HU3HNOK$HB8C$G$
M8X%"XC(QKQ-G:A-::0.T.N"55D,9.;^ 1C-MZ>RT GNU]'*\5PWL=7,CA"N'
MU8Y(QANL@0EH-T[MT=F/V:EQFCF.DC.)^0'7$_E=*<RHI.D'N&.R]=1J/Y)^
MO2T7*ZGVS?P?VT65**KJY4YMDW2,BA*IZNF#>L[$J<SCA$B.TPS*(!$0XY1
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MGQK?-[*"6EC02 N,N+/=OP5XM5@!H:,UBQ(\R,($;\M?' W7<;\52]MWLE_
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M[>I1_?:PO(+_G%!MQ#QG@C)-OTC^I[92Y[(^'3S3;W*_7Q<ZWO%-D]BL"9C
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M -(XCJ!,XAAAE/,H<SK)[2W)U+AV+R^@Y?]Q]NCM.1QVA#H*R .3::T#J)4
M6HL9J/4 ^;H.50*O=EFF?VE%*>G%;Q>U?92<H [0!G\V6GLT*J]&WI_C<4\Y
MQG9+O@ZN$T[+5S;8=]_[J#ZT=?&DOK-%^5T*'>:KK%41,ZR=G41,0WT/%D!"
MN(0))AF6>4H%<4IE=;J;J5%C(QRXT]*Y[G!/ FF[O;T6GL'WMK6 ,[ #R<@X
M [\5Z]*K*W,7%-ZVMB<[&7E?VZ7H\TUMY]/NCH]O="4KMBZJ_'C[X[>/6^TG
M9*I/2M6@MOSN"GI?SBD+12+S!"*J> $S'D$6<091$H:*$TB>$*MSL#Z=3XTH
M*CGU\ES4DH*'6E1[;S_G$>CFDJ%Q'7H/VA:]?3<Q S7:GTR-VPKMS\.C;>]Q
M.23J(_EA>D;?R3FS+WP=+IO.38[FR-E7V;9[9^\VW%8)KNW/XFG^YM.<J1US
MEK 89IEVBPK3'&:*[F$J.:*)#I#-(AONWS<Y-49_\^G#I]]?W][8$4H+FFY2
M[J?PT%1[25?KZ?M<O1,&6BGYKW?KQ_^L'Z[LL_H?>].LU=0HD_&YZ,T4._&7
MGA/GXSPC>9P@0:#:3*G_<)I#AI, LC3A,E6;*(JL3OWW34YNXGQ?K*CCK/EH
M.VN<M!UZUOS7[4>?4^:CORGS<>0I\_'LE/G8<\HTVYPFR=C-2MPJHV=UMV!+
M6:6%:?Y4>1'/)0IR+M5J%(:Z\D_ ,DAIE,,<H9P1]>\0.YU06/<\M0G82.=V
M7&$/M-T)QB#P#3RC=_D$JP#M1NHZE=1LEV]PG+@#9P0]G878]SOJ\8@S',<G
M)NX-]*,L96UOBBW7!056=]KT+A[E%V6AUZ&J\RSG.$F1A%D8Z3P1-(24Q1',
M\P1E:<0"QIVBH2[T-S5Z.A 7U/*"/[7$H!;9T9?H$N!VA.41QH%IZBH$G6G(
M$A=/Y'.IMU$IQU+U8Z*Q?:T?O=QPOKW?+G40]C>UTR^7E;^D^-]MN=&;_CH^
M.,UPE(0YA2&3^L)&(+5##T)(.,J#G*0X)E;I4=VZG1K9*,CEXFX%WFR+PCC?
MM60'>^'=^,9R!.QHQS^N [-/2V#P#-Z]W.!FLRD6;+LQ.?$W:_"9%OK7_C-C
MN"'HB:<L.QV5KMR .&8MQ[?[D==GU?QJE_Z%LHPF$1%0($8@1CR&#*E]6\)9
M*C,>X-#-!?*@]:E142V<&]4<XF7'*+U1&)@X:KD&8("3&GN:Z(=MCSJ?3ZIU
M/&U//^0V.X5<S-^M-HO-TXT0:LC+-^K'3\6W]8_5/$=Q@ 0E,!1)"G&J?LJ"
M)(.8AC264<)B:>4VU]''U&9J)2:HY9P!+:G"$6A9[:9O%Z#=D]@33 -/Y5X(
M64]K"PPZCDC5V]6\5C_LIW-7FZ-,:@NEFJEM\ZB[?\=KN2S7]P5MDED1GC*U
M#8"21ASBA&:01#&'**8,\SA#B%FMO<^;GMIT;J2S=PTX@JI[QEX'P, 3M1&L
M1^ZI(Q#LO1_Z@S&2;X,]*$YN"Z?U[G!*.'IA-)>#TX*V'0K./''U@<5O=+'2
M]:,_RHT.(GB_7/_0-:IDM3>LOS2"2"S2G$),8IUF3]%31B.I#9"8$)8G,G&Z
MR''L?VKTM2]:Z[AW<,7=^;S"-YHC'EQHT<$K+?POI@S(K,HMI54P!0+E;)3S
M"A<$_1]<6/7^4B<8+M!T'&4X-=,C6RCZ-4;(I-43.JU>V*1G3&@N0L92R"E7
MVZ8DCB#)90BS+,($1R10Z%CG"CW3R=28RHCY[W7BQBHS:.B2&?0<EI?M+Q\(
M#<P^)\'IDQ+T'$H."4$]H#62J=83-;=<H!?@Z,H$>N[5\?* 7A#^( OHI6=]
MA636UP+-K<"[G_R[=DG]H@CYC?FIK!_^Q):+N^J#933EBC S&$4!@E@B!$F<
M8QC$1"12"LQ"IZP:7J2:&L.^RW/)JQK%LA8?%$I^4/WL7H[%P\#9F8VC#\?
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M<X'RB.41C&E"(=9EFRC.8TB"C.N XRS.K:K!6/4V->IIA#6G*&(OKG.UR@Z
M61ZFB<!"._LS';R90Y;$&61"RCA%2183.5_).YW;>BR(205QN]=_;9!MF=[3
MMSDXO;<0:TD*:E&]E@*]C(B_0J =?8U=!O2RVB>*@%J\U(^C_U@5DJ_O5HM_
MFOBEQA7M=L6UE2I+U?=VJ5WS]1KQ6:T+Q6YU:.) RSFE42I2%D/&4V50IE$
M:89#F*8R30D/"8J<RA#[$&IJC'\C1"58%8*I0S77VL=G78 GG2+FH1'<C9V\
MC)\=B8T]*@-S75L=$ZC9*#0#C4I@IU)EYQJE:OO6O/+YXJ Y$Z-/E#WQIQ>1
M1J59GR >L['7MON1]J?-=UG<KA[5*K NGKYN'QZ6"UG.DT"&42*HHF%,( YC
MM:_G^OHCHC@6!"<D<-K7G^YF:L3:R.7&FV<@M&/"ZX$9F-N,@& GX0PT,L[
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M(DDQQ%QY4UX28R%ER@-F%#X]>O+4Z*,6#FCIP.U',[(XQJN;%:Y"8>CM%D,
MC#_PL\J>^)(+P7Y]7/WX-W5/]1&K'W;?[O&31OE(SRK0?(WG+[!?PWS/?MZO
MLN7ZL_J@]3]UTU+R*!I7XD[W,GUX6FUTP;2;)7]XRG)=,^V':(H>1"B*(DR8
M_CIC];'JSC@>3F!"?1$EPO,0,=[K<"#/U#[Q^-<H.L@B2LR=?Q<&NKR4&AGV
M@3E%:0-*=8#6I?K73J-6#LY=V949-&J5]= KQ4"I68_%F@M[F:_L1K;;2,M
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M:$@AIT:[+1WUJ<Z\T1(L=?I9Q0&E4ZG^7FFTT7GOJY=Z,[6\15]8=I-YJ5$
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MUXDR-=K92EUO'&1;N770F+4D-X^37&FLRR&F\4PP,'N=+=DP SO#E,J G39
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M?.F]P)<X$J'B%Z)81<:*7V*)(68BC6/,4!!8E5XP&'-J'*-%!FPG\PPLQ9^
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M1T'5#YN\//URMWSX<_7PM-H4BND5M3S\J7[W^BE[?&HR8J(TI"B2'$9(-]Q
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M!?#'(#78KP'1$6?U$F%4/KL&I$.NN^I9]AM8OZ_4=4M2[S;$)(HC%G+HH9!
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M(4$:8!]QTT/? >//C1E_/>DDRO=:F!\^#IF-RX>_(V,\,OMU'48ZZK>&MZ-
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M%4PO_4;7/6RH:[W(OE<4_"O)UKJX^.UZ_SL=&"T)#\+8]V$2)[IB3>Q!3%@
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MU\!T5![ZJH<-(\F_"'ZO"/>=*+/[IF7YCZQ<!C)-$$T\F*) QP$P#+' ".*
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MT4O<S>W;WW1PZX%BEIF'[J;8S*7Z*A,W\J)8EW [4*HEX)^T"C\O@%8-:-U
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ME8'/$TRM-L83RCZW];!)(-SIO@"-]J!2O]H:[@'H)'Q4J1HM!J &H<IAK&$
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M[/7/UM 3K@GFX%7.OWK+Y)V*S]G-XNL5P3-"_!7JW/7+-=M2=D9P7E.MSFP
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M5NU_<9/[AU @0A$$,/)U"1\>8)A&<0"E)P,_];FD9I7O>L:8&_VVXOUG^P/
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M]6%*U3\#R@,O](2?BG3Y710TGPC:[ECC@5N#>.&8RAA$4V?R5<",[E!NI%N
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M.)]FGM[<L^3Y"W%"$^CDF:N:W+07^97^N#&=Q:DEY:9!?5(EN0M-^@4"<M.
M>%HW;J)[GR/U_O/T4?WTQV_=;]0_C);BC]_^#U!+ P04    " #)@EA6!!^0
M"3UT 0!^(1$ %    &UR:RTR,#(R,3(S,5]P<F4N>&ULW+U;<UO'DB[X?GZ%
M9\_KI%WW2T=WG]#5K3C>ED*2>Y^9%T1=LBBT04 -@+*T?_UD 2 )DB ( K6X
M%D]W;,NFI%5Y^2HK;Y7UK__S^_GDIV\X7XQGTW_[&_^9_>TGG*99'D_/_NUO
M?WQ^"^YO__/?_\?_^-?_"^!_O_SXVT^O9^GB'*?+GU[-,2PQ__37>/GEIW]D
M7/SY4YG/SG_ZQVS^Y_A; /CWU5]Z-?OZ8SX^^[+\23 A;__N_%],<,Q)C2"S
ME*"X"Q#1<) 2 Q-1,A'*_W/V+T5$;1$CJ"(R_;%2P,GD@$>%OMB@M)"KCT[&
MTS__I?XCA@7^1,Q-%ZO__+>_?5DNO_[++[_\]==?/W^/\\G/L_G9+X(Q^<OE
MG_[;YH]_O_/G_Y*K/\V]][^L?O?JCR[&N_X@?9;_\K___MNG] 7/ XRGBV68
MIKK 8OPOB]4/?YNEL%S)_$&Z?KKW3]3_@LL_!O5'P 5(_O/W1?[;O_^/GWY:
MBV,^F^!'+#_57__X^.[&DN<X3W_^G&;GO]3?_>75C+#P(9Q56E=_=_GC*_[;
MWQ;C\Z^3JY]]F6/YM[^=S_^D)87@8KW@_WW]=W^Y7OOK'!<$EQ6OO]$/-I^H
MBQU!!WY?XC3CFKG+)2:S=.,/3:IH9_/+OSD)$2>KGXXRCD>K+[^(B^4\I.6(
M9\V]31Q(=@648I%P)37DH)(7R7$>PDVV*\T+(GJEB06FG\]FWWZA#_]295'_
M9264E4#N++<6S'%T7VZ\=],RFY^OY/DYQ F.LG0J%JO 94-;(R<+7B)M*$4;
M*5B5M$TGL7#?RC>YV5;TBWGZ:3;/.">+<KETF*<[2K^)YLV?^.5KF-.'('T9
M3_+EWZZFI84.E[/&$EVKCDC_VT\D@8+S.>;?UIJ[E]$5ETNRN;CZD\>BXF(!
M9R%\';W&2#R0,%;<O/@^7HS(2":=K8&2?0(5?888- ?.C4 9E/)*[L%$"8NX
M(G>SQ!H8.%DN+G]RC9#[J>@/'VTT.VLJYL$!Y?=PCJ]GYV$\'85B;5)"0[26
MCEB?"P1C,SC+"C>9F\14IW"YIJ4?T+32\5[('"GP'H%#1_SH!?M9,_;[;(F+
M?(&D1_5W/(\X'P7E0HR!0>:9/#?),W@7+7EN06$6V?HB'O 8]GU_2$ X5G.S
MQF+L&PK\9V?U%@]FPX,R] >9SL -N:"*_@^B\P5L2C:*+*QT[A HW//]@Z @
MG@\46HBQ;RB(FW"6EW!&$14/.1"(.3ECC@4(7E-00KX99BZ+4?P0*-SS_8.@
M()\/%%J(L6\H\)_E-ISE)9R3"R71Z0D.@ZVAO2:A: ?:9\]*$=I&?9A5V/G]
M@Z"@G@\46HBQ1RC<XW=3S(_OEGB^&$DI,D<N( L,Y$@5"M-X-. C)LWK[WC<
MXV0>%:=>K=[/$=(\%FDJY(& Y3/]V5$VDC@FNJW7Y&6S0EZ09@YL-)H7)Q5S
M^R*0P\%15QM48'JD[G8 XM&"' @ 7DRG%V'R$;_.YLM1B%)FIQE$G<A\6LG
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M7X=EV+ U,H';V@\'Q:D$JO@"05D'F9/3I;@VSI<FJ===JQ^&F.>7<SU9TH-
MS,HVO@I+/)O-?XR2MBHZ,HP4XS-07B !WF?0OC 6E?>&GY8OV;'H8?AX;HG5
MX^4Z"%A\.@^3R<N+!4ECL1@%(85,/@$S!D'9>GF,2P7,!A:--\F*W  6-Q8]
M#!;/)ZEZJEP' 8LWYS@_H_/QU_GLK^47"NB_ANF/D<M<:RT*I(+D=>M@*%23
MJ[IE,J[4=KK3&@#V+'X83)Y/SK65G'N&R[M4YB\N\IC^Q(OE$A=KE;R=A+.1
MRBZH8",@>5%U@)(DR;@"V2)%;9HV@3ZMD_7^M0\#R_/)QC:2\B!,RZ<O%--?
M(KW>2B[D+H%-A0,1KRA4TQQLR86"^A+1M@AQMM<\#!O/+>=ZM%1[QL0+DD>N
M,EF!N42F4P@"6-8.5$ Z)PTJL$ADRZ"S<_8D.-Q8[K!+F,\GMWJ\+ =RL>[Z
M=N!;^LEBE!ARYHNH+2QDVS Q\%(QB"6AMI)):TX;HWC/PH<!X_GD4EO(=U 0
M6=\S7C-A4*98)[<R3H&6\L%"Y"("BUG$6./P$Z]"W+OT83!Y/MG4-C(>A)/Q
MBMB8A\F[:<;O_PM_C(PP/.IZM[@D12(A!RGP7"=9^*@-6HNV1>'NUK*' >39
MY5!/D.U K,CBNI,2\\L?'RLE.$WX&;\O7](?_G.4!).I3M")OH9@TB+]FS5@
M-?TB;'3*M1E_^R IAX'H^:15N]%!,V#]ZR]WY$P\_WG4V.M5R+8EO)O$'C3]
M^LXG3A^"O9^J$V=AKV:.W5K@:J1RR-:R)#(0?W2,.)FJI; @8A+H3/#L=D%K
M]^BV>[Y_4ARRCJY7;4Y69AVYJK>'0YW-RCT$D00XPU4J: *>.%)L:[%^AD8U
MT]*-\.-($?8=@:[)_FTS.9^LCC/6Y6IP(OT#LX)@8JCC,E6.4?*@3^L^O[5@
M/U.BND3 4:(<!@K>CN?G[_((!>,V608LN'I#KUZE,%X!\]H9)W*.^K0ZZHWE
M^AD&U24"CA#C( _P5[/I8C89Y^JBK.[;5,=E5JKG<G[<6Q;[OM?B?8N#Z3WQ
MG+\<6+K^]-5:UZ\G.(PL% ZI: E*9 E!U\FE06$JG-RZM"^3=\SL]WM(.76\
M_4?\AM,+I""X9)5$B!3GF )*FP@^90VT5:2UAH(?MB^&/(:ER[7[G5K>0L>W
M9]@?)=4!/';P:K98+EY,\YOO7W&ZP,65, Q'YW),$+6K4XF2!J\Y!2M!D"OD
M4[&E-3KNHZ7?P>9=H*6)U >"GO?EU]DL5VX^X?S;..'BTVR21R*98GA"<"XR
M4%EG"J>5!-H"1L?@?=P[JN-8_.RFIE][TT;;.R#40/0# -$GG$QJRP!.<1XF
MQ,R+?#Z>K@9AU2ZUC=1&$CU93\=!:TW.=R8_+M:.:2&<S]Z@<:'UZRN'4=:O
M>>H$7!VH9 ! ^TB:(0*^$#^OZ;B>S+Y6@W[)3+VSP534P+0DY]ZS!%YJ#9()
M)4S**81]UZ>.<X?V$-3O&PZ=P*J= H:!IN7\(BTOYK137GT)\S/R_J0-J T%
MAZ4FBY0N]48A(^]/Y"2BU$'H?:FV(T%TAXY^'WWH"CNGB7L D'F__(+SWV?3
MV5>LAG1ZMO8MKS9 "1JE($:8-G7F%IW;I&W@,D5;1UZ(O;?QC@'/?HKZ&<?;
M*8P:JN#Q@/)K0$WQK"8T3H)4S7:M!'0EG6E>\3;2FCF9UZW[%( 6Y\#G7&<+
M1X\LBZ#9K4S%SJ+$SH_W,XJW$T"T$>#Q1F6V#),F1F4-X-]FB\5;DMBKV910
M?4' ?K]&^&RZ>(EE-L?UG_L<OB.Q3'(C;8VG8?YC5?VD'9'H;Q)ID]6>()M'
M]G840E(R1P?&DW059P5"#)8"724LY\&AW]>+<GS6JQ-V^O6HNL@C#$7W@]D&
MQ.)F/[^DV*6,R3:@)3,>$9*L4Z3(*P OB"NE710Y*\70=P+A.Z3TZY1U![_3
M9#X M^SA741_8G)1QSU\J-<L26'+Y7P<+Y;UA:K/LWLV4)0I%U<;$4/M'G(A
M )U% G*Q2C(60U3[BF[=&,]C..G7#>S';G:N\<&8S'U2V,?UNGF.?*\<BO8<
MG*(30AF3P5N#P,CG$B(*SYO7"5K0W:\GVP^F&VOS65CN411"%(%8.W=(I-9Q
M"$$PR+8D771 VI=/CL]^7J_H%WV/TL3@K./K\2*MF<)\S=/ON'Q?R/^YN;.N
MIC%L-E7$D&50$;3'Z@1E 3Z%!"&CQ2"YYG;?Q<'3(7@"\?T\HO%T2'TJO0[
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MF P4+4B3:J[4@! ,M?16>]6ZK/EX?'0V_J>#T^9HZ0X@)?SW,/\35TGMZXZ
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M[SM=14,X6;<8VC+@JS3\#B&. EEJVDG$CV(*5!0,@B$+GA,OC M778D.$7@
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MN(><4\W.CD]OG<+)8,:0@;'B0"41P>7LH$C4(:G"E&I] 7$?/?T:F%:8N&U
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M^1>)=I/$D4(F48=7%>=7;WF1P98.05- DR.K&Z1U">Q>8@[+Q+)G!J4VLA\
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M#>F'>,O 2HS*I60AN_KN D=! 4N=$:B9=HHQ+5)YP! ]9KV^.P&;P:8S(0_
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MB $]1>B<@G.5&;DP)3!@L4Z"M5S;W-ULWT>3VV\]O7NX=JN_04'U]88 8O"
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M(#Q;(]ODXD6NE**E( EM*=;-M*O%S$VQ,63+6["7[$: =^1&]^,\)O:WRQC
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MC !JGR[B$O]U49W6[Y6+]XJTDNE"OD4!EVK7M2(]!%,X1.1>NN1(18,Z[>X
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M@W-:<"9!(6@9-(8I-R2)8F\!AN'N9;WHG,8:8XP$MNK$Y5\6\^7R+,DLI:"
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MD>;GE]^^H;3EMB#A5FWG,M3%5C-Y*1YX]66!EP'#K\O5Y+RZ:K^1H_:W,+W
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M,<#J_LI[C;/T]3PL+N]C E?)">F@B%(=@:+IP X6BG<I)JXI*&Z=*_:<3(.
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M'2Z W_[Q]O<ZZZH.Y2-N> ZH>+&@HJQ_D>%&CC1YTT$[KDS*3K5NM_8T1<.
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M1X%=@7%'?C765JXBD#MDZKAR^AN"9!:2D%I&9)P<^?]7\K*WUO<I>=E'!1W
MZ?;\FGNE%L(+9^@$ 8&1Y.0V464C(:42''>.H6B=:/0X-;U Z5B-/\@1;B+^
M#H#T=-D.6FZRISW;<<RT>\>:.F@49(%)(8M.:M7:'CRZ=FJ:&IECX-1."1T@
MZJ$EL-FY4TRJ!"7 1$_RT=&!CW5VNK!!.J>S5JVAM)N2:3'4J:G50&E=0N]J
M<?J@D&?:BE$E#\K7 :5!9M RDS$11>)E?/#U8%RUT/-/H7. T#L STWHZ\7#
MT-?55EPG<TME([GC/(**PD%4D8$Q)C,TDI7F;=H'D-4;I [1_P-;O:TR.L#7
MV\4\7W.U90&YE40JZ'KOKJ0I9"S:!$8%$;1P6>C0&$\[R)CV1!P%/\<*NP.\
M/)HVI-#EP*0 &W25BW:US-& 9I&1I.@3?XK4JL&VU&B%4)W:4DT4URD KY9F
MM%B4QP Z"0:J*(10!S0SYQ7C/%AK6C?X>W;9?7MI>WAVWSZB[P!$E[4BE[EG
M+U8K7&_SSI!DP]PF^R.0H:E2@I#0@Q#.YQRCS[SUG=UCM/0'H$-TO;-(YTC!
M3YP>^NO5*R_+BSZ%/['>H&TXNV3I9H3/==ETDLH@WPQYI7T[<W"V1'!<"\1H
MM+3W-J:=R:)[OWA:$ZHQA,87?6<;TS9=Z"8KEOQAKS6C12*0F)%6T"*Q%IP2
M'"7SLC1/*7V2H&D-K1-L4<>IX& \?<=E7#3NM9$>X\AJ%*5(\E!%LJ <F04A
M. G2%L^3*$SQUG?./Z-I$*Y&&YDT)JY:*:*#K>J6=W/M\KRYSI;,FADZN0W(
M2!RI.@DW"DG?\J!1)ZE='B^380=!TT*J4Y^PG0J[PN.E*4!;M>4L9P]::P'*
M\EQG2GF06'BTB6>-XY7<7M+0RT7ST>I]%#@'R+J+8_$>!]<=E=Z5ZW37]XO5
MK*KJ=4TE7<UHL;V>7WS%RZ% 9TE)KU(I)+G:.U+K6OVD%&2/Q7MA=':M$QJ.
MI;F7>^J1T3BN+KO:Z6X9$6>&&>\CV2;*Q9J>&15X;2581UQ@8B'X\;:[6X3T
MTH9J/)0=*O7.-KZWBZJ4<'XU'<]:GPOW D3>3*A*&0(/!A(G.[=('[D?;T.[
M2\NTQMHI('2$[+O<@'[LO^ER%KD+Q&Z*0I,O5=V=S S9#;RDZ+2PMG7V0PNZ
M!V'S!/-8Q]_>1M;ILZE7^WU>%LNOF^<NYC=BVDIB]?$B_C>F]7KQM[ BVM[B
MNK;/?+%<UJRYRXJFU:R0]__C#USB^TLR,=/RIU]]29\UKD([';WCU)9-).\.
M*L:$8%II5W,T.1FCVD0R)CP'Q!2UR5(JVSZ1IX,F45=.I"HH&'H&TM:44J$L
M!*L-,">Y)>9Y'G$^4U\.^[C8^:D[OX\FNK)'-O23<?6N%/KB_>)\EGZ\/J?=
MHL9P,5]LOCC+,FE?D(%!.IQ4<1D\)CJPHF'1\>"9'F_ U2 2>W'5)\5A4SUV
MT:WT=G#W)V,1;;3H;?4I,9%WR;0%%XH''2RS*F<91\1HDVF5/;6:;@S/IMH[
M%IF?QMI'KSV,RU7XXG.8D;QO>"=SZEVA17IED'UZU""[NW[/F(K6AIS RQ N
MYR#$Y!+P$(3306?O6^>7GH:S7N(6D^[:/:#F<)MDL0[G(P9I0TTX"5I#Y"S4
M!E@<O,D1#)U4'),T3(YW+;IOD/8$48RID'JH3KHR=J\#-3\UE&*RUG#+02=$
M,I1R@%!0$5A,#IX^2_>'A(T1:VMB])I_?U"VU6>WAN_=$?0;LRED0>N/7,X@
MDJKEJK6X@B3*&6J9A8@VC!< >8JR0="T_[[0;*:USM#XL"5;8ZNE,)NDX.GR
M7%%*.;)?LH 0?$9DSOHP7N?SL;D;M"K<O^^JZ H]S6S>L>]3MKEN89[?+W$=
M_JRS.%:+91W'<7D?NBJ+Y:V;KK;7(P>_?IS;CC;2Z.#RPH3(M- 2N-:TI&H.
M8M R03(VQ*2,Y]Z-MM-->'EQZ]77(Y:VV9H?\'RCW-67V;>7/QX9WG<[Y_-N
M<Z'+#$]I8JGA3##:,E!"DF!3G2(99;U/E5&8\2*!8W/W?"]<]L'[H+%UTZ.G
M ^_V_CRF=Q=T<KY(Z;)'+N;'ICQMBAN1%^VB5"!+'=E4Z. ,TEG@,AF#"4/[
M)E/'T-LA]CO X&(B0#QC\&^;/85B@_4DX5"S;R2W$'P0P%(JM!V59&5K7^,X
MBJ== *=#5B-('Z#F9PSJJZHH';*.R ,4[XE;(PQXC 6L8M+Y8K7.O>SI/=1M
MGQ);C6!]@*([@/7U(?CZGQ>S]8_*UV*^,1_K]I!=%J$D Y)91=N#08@8(J 4
MZ#SSB>?6K2B>)*C#?)+^3(UV*NT G_=XN%K?F@<9G4=PNI8O%Y'!*\D@!UIJ
M7"5O9&M?<B<ATVZ2#16]:"WU#J!S:\_>+M(:Y__M?/''9F )+<WSBTPKME8S
MUR+5Q?GYIA7:9?O9J_V<14%BK)F#PM%^;H,$IW@$J;3+*8L4?&MKM GATT*S
M 8 64VNS P@_<GI<KN_L IDQ D1D#E3D9&B8DB 5H4OFG.?4OA7UH^1TF$K7
MW\G<2IW](O-JH1?N@S1:@)6*SAXB$1P] [Q()=-ZL[RTMAN?)&C:S;"9VH?!
MZ0 == "H;5^1Q;=-%5;=N2MWK__\1D[6UKDJLFC-DX/,1+QT[KPCD67KDF22
MA=@\ 6@(75W"ZQ 8/-+KI9E..L#9DQ,P3)0*5<G A-TTF^<05)&0,V;.@BXB
MC3<KY,#!-:=-Q.WO4&VFT*[ N6,(0M#&JE#3XURTH)0MX(/5X'P06*SBQ?R_
M03;[:WV?03;[J* #.-V>I/+QC_!MNV/'K+VQ I@EVA5Y7\1 "F#1>]JZ(V-J
MS"$V-Y3T J%C-?W$ )L#Q=Y%CXVG)Z=$8;45(8!!29:K*1J"YQH2DU[XQ,C5
M;AT8>:[C:XX!4SLE=+ A/6E2O+EN ,&<4D9&!U)*0?+"!#YI!AA4TBHKD=1)
M1HX^H*S#>I/G89 =J>0.H/L!O^/\ E=GQ4F36*[]+<G+4;Z0:+)0D!RZ4+C
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MV0%$GZ[_)<>-H78,K*_,I!Q)8LI M=I+E#()V;Z3Q;%%V\^D1/:H8[N5TCI
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M:MI-J!T"!D+K0'5,7+A\RPQ=O_[S&Z8UYO4BXL?%>:XID;/YNSG^)X9M,6Y
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M0])*0TW+ 5\W^0J)R+R-P?_L:FC8FWK"S1$*78PFW8FQ<GEB/S#J$JFY>&.
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MW#:W*]>:,01K'>FZD'\UQ$J,O)98,1=$LBQCZW3J.9IZ ],^FK\W$ZZA&CJ
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ML9SA:F.A.B>>5:CK@.L(+B95W<$:P42/05!PP6WKRL,!Y$U<-G2T W<LC74
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M%+^W_"96_">2\>8^_E/">5C.%ANW9YS1F0D#J;@ RA8!D6E%P3##G(7C2;0
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MCBQ.<8#N($4_/T!WB-3[&* ;E$+NBP&;<@0EN888G($<#$L.A7#NJ2%,)S]
M=Y#&[@_0'2*^#AS%_6&N+EG),%G(!34QP"0X5'1JU]==K; 4WWP*S>D-T#W$
M31PF\PY \\A 3Q>+]L%1;">8H3/8&(A<)D#OZ'16-FLU;JA\B@-TV\7'>^FA
M2S1M;2Q'H;CG$;(A9A3*0EDKDFD8S)DI):2UH^.IO_!W/SWO.D!WB- [ ,^S
MDUL95YQ8"9!3;:?F.D-,AH$K.<J8.;>L]=Z($QV@.TCS0P?H#E%#![#:9R8K
M9[EX7S($8RGRJ\_ +DD--BB,D6,.S<?WO9P!NH> ;VQE=8#'W1[3C&-"*U6
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M)PL+V1N:!T =G )](VQ*9%- +E]E96;E\@M]P/77OX.K67*,V L2T!<&2NL
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MN=9T.SG#T#BNDVG=*-V [&G+(2>!VR#(CZ?["PBR]CAA;W&9\(X75A(RS.2
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MS)?&-N\!"=/,6AK?K)TBZ0Z \NKCI^O%%]S5"K[[0.+\*:PPOUQ\K*.>=C,
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M1*,#Y6VH:5P&DGX@8N2B-*^2_ Y)TR+N7,AX&I!-U-01ZC8.\6-V>,!@?;9
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MH%FDB,SZ6L+&("?+<F$BE3AZ)GE-R43#E<]Q61XNZ1[Q\N<E'9"92.22YNQ
M,D^"X8ZN[MJ8P+/"(E7T.8S_\E IF6C>\5D>&0Z6= ?%I8^X>&)#D2:ZN;*6
M#"67Q%*I VQJA0#::+.RDJO1TR1'+H]J/Y'X'$@Z40>'P\IO8#7']W6-WSC
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M!\=M76/$&-.C[=UZ2$R_DR(.0</>(34GR;X#U_GQX5QWITMFH_ 4 / H @4
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M&0  97@S,3(M<G5L93$S87@Q-&$Q-61X,31A8V4N:'1M4$L! A0#%     @
MR8)85J+*V(])!   G0\  !X              ( !GR$  &5X,S(Q+7-E8W1I
M;VXQ,S4P8V5R=&EF:6-A+FAT;5!+ 0(4 Q0    ( ,F"6%95.0-?600  !(.
M   >              "  20F  !E>#,R,BUS96-T:6]N,3,U,&-E<G1I9FEC
M82YH=&U02P$"% ,4    " #)@EA6^="EI2JA  !5K@< '@
M@ &Y*@  97AH:6)I=#$P,3,M<&QA;G-E<&UR:S(P,3DN:'1M4$L! A0#%
M  @ R8)85E'W C/U'   8IL  !X              ( !'\P  &5X:&EB:70Q
M,#(S+3(P,3EA;FYU86QC96]N+FAT;5!+ 0(4 Q0    ( ,F"6%:9BC5H@A\
M )^Q   >              "  5#I  !E>&AI8FET,3 R-"TR,#$Y86YN=6%L
M<G-U="YH=&U02P$"% ,4    " #)@EA6'S5!HXX=   &H   '@
M    @ $."0$ 97AH:6)I=#$P,C4M,C R,&%N;G5A;&YQ<V\N:'1M4$L! A0#
M%     @ R8)85GHM(^O^'   $IP  !X              ( !V"8! &5X:&EB
M:70Q,#(V+3(P,C!A;FYU86QC96]N+FAT;5!+ 0(4 Q0    ( ,F"6%:PC?MK
M3AT  #:B   >              "  1)$ 0!E>&AI8FET,3 R-RTR,#(P86YN
M=6%L<G-U="YH=&U02P$"% ,4    " #)@EA6'@\ 6Y,M   '/@$ '@
M        @ &<80$ 97AH:6)I=#$P,C@M,C R,'!S=71E<FUS86XN:'1M4$L!
M A0#%     @ R8)85D8]H0^\+@  74 ! !X              ( !:X\! &5X
M:&EB:70Q,#(Y+3(P,C!A;FYU86QC96]P+FAT;5!+ 0(4 Q0    ( ,F"6%;8
MR_SJ[!P  *F9   >              "  6.^ 0!E>&AI8FET,3 S,"TR,#(Q
M86YN=6%L8V5O;BYH=&U02P$"% ,4    " #)@EA68*HQ";LM  "2.@$ '@
M            @ &+VP$ 97AH:6)I=#$P,S$M,C R,6%N;G5A;'!S=70N:'1M
M4$L! A0#%     @ R8)85J9T%]>F+@  RST! !X              ( !@@D"
M &5X:&EB:70Q,#,R+3(P,C%A;FYU86QC96]P+FAT;5!+ 0(4 Q0    ( ,F"
M6%;../ ZUQP  *^<   >              "  60X @!E>&AI8FET,3 S,RTR
M,#(Q<W!E8VEA;')E="YH=&U02P$"% ,4    " #)@EA6X:+DL^!@   -(P(
M'@              @ %W50( 97AH:6)I=#$P,S1R97-T<FEC=&5D<W1O8VLN
M:'1M4$L! A0#%     @ R8)85H>0-I#ON0  HN,$ !X              ( !
MD[8" &5X:&EB:70Q,#,U+3(P,C)A;FYU86QR<W5T+FAT;5!+ 0(4 Q0    (
M ,F"6%981H#9!W<  $C^ @ >              "  ;YP P!E>&AI8FET,3 S
M-BTR,#(R86YN=6%L<'-U="YH=&U02P$"% ,4    " #)@EA6 BCU;4<E  "#
MNP  '@              @ $!Z , 97AH:6)I=#$P,S<M;7)K8VAI<F9I9W5I
M;F0N:'1M4$L! A0#%     @ R8)85K'&. ,W'   EH@  !X
M ( !A T$ &5X:&EB:70Q,#<M,C Q-V%N;G5A;&YQ<V]T+FAT;5!+ 0(4 Q0
M   ( ,F"6%;':6/(VA\  &^K   >              "  ?<I! !E>&AI8FET
M,3 X+3(P,3EA;FYU86QN<7-O="YH=&U02P$"% ,4    " #)@EA6C!=KHF,E
M  !#,04 &@              @ $-2@0 97AH:6)I=#(Q+6-L96%N,G@R,G@R
M,RYH=&U02P$"% ,4    " #)@EA6J:= YBHP" !L)F0 $
M@ &H;P0 ;7)K+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( ,F"6%;$VR/#Y"8
M !/4 0 0              "  0"@# !M<FLM,C R,C$R,S$N>'-D4$L! A0#
M%     @ R8)85L6J,Q5^0@  OLT" !0              ( !$L<, &UR:RTR
M,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ R8)85DOY]EI/& $ _UL, !0
M             ( !P@D- &UR:RTR,#(R,3(S,5]D968N>&UL4$L! A0#%
M  @ R8)85@8MMVH/_@  )QH" !,              ( !0R(. &UR:RTR,#(R
M,3(S,5]G,2YJ<&=02P$"% ,4    " #)@EA6>N+XJD7C  !Z2@$ $P
M        @ &#( \ ;7)K+3(P,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( ,F"
M6%:?.VN!$$(  '%M   3              "  ?D#$ !M<FLM,C R,C$R,S%?
M9S,N:G!G4$L! A0#%     @ R8)85DKDC2$,/@  SEX  !,
M ( !.D80 &UR:RTR,#(R,3(S,5]G-"YJ<&=02P$"% ,4    " #)@EA6"9MA
MMDA$  "38   $P              @ %WA!  ;7)K+3(P,C(Q,C,Q7V<U+FIP
M9U!+ 0(4 Q0    ( ,F"6%8J_ZA4X4@  &-E   3              "  ?#(
M$ !M<FLM,C R,C$R,S%?9S8N:G!G4$L! A0#%     @ R8)85@&JQ :5%0
MY14  !,              ( ! A(1 &UR:RTR,#(R,3(S,5]G-RYG:6902P$"
M% ,4    " #)@EA6AVSD$?!*  #]>@  $P              @ '()Q$ ;7)K
M+3(P,C(Q,C,Q7V<X+FIP9U!+ 0(4 Q0    ( ,F"6%9<[]G^54   +5%   3
M              "  >ER$0!M<FLM,C R,C$R,S%?9SDN:G!G4$L! A0#%
M  @ R8)85F3$JO[<0 ( BXD7 !0              ( !;[,1 &UR:RTR,#(R
M,3(S,5]L86(N>&UL4$L! A0#%     @ R8)85@0?D D]= $ ?B$1 !0
M         ( !??03 &UR:RTR,#(R,3(S,5]P<F4N>&UL4$L%!@     I "D
*?@L  .QH%0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
